PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	ELLIS, JA; KIERULF, JC; KLASSEN, TP				ELLIS, JA; KIERULF, JC; KLASSEN, TP			INJURIES ASSOCIATED WITH IN-LINE SKATING FROM THE CANADIAN HOSPITALS INJURY REPORTING AND PREVENTION PROGRAM DATABASE	CANADIAN JOURNAL OF PUBLIC HEALTH-REVUE CANADIENNE DE SANTE PUBLIQUE			English	Article								In-line skating, also known as rollerblading, is an increasingly popular recreational activity that carries with it the potential for injury. As reported in the Canadian Hospitals Injury Reporting and Prevention Program database (CHIRPP), 194 children were injured while in-line skating. Fractures to the radius and ulna were the most common type of injury sustained (57.5%), followed by lacerations and abrasions (14.9%). Five children had concussions and very few children reported wearing protective gear such as a helmet or wrist, elbow and knee protectors. Compared to the database overall, in-line skaters suffered more severe injuries and were more likely to require follow-up treatment. Safety implications in relation to protective gear and learning the sport of in-line skating are discussed.	UNIV OTTAWA,DEPT EPIDEMIOL & COMMUNITY MED,OTTAWA,ON,CANADA; UNIV OTTAWA,CHILDRENS HOSP EASTERN ONTARIO,OTTAWA,ON K1N 6N5,CANADA	ELLIS, JA (corresponding author), UNIV OTTAWA,SCH NURSING,451 SMYTH RD,OTTAWA,ON K1H 8M5,CANADA.						ALTER B, 1993, INLINE SKATERS R OCT; Banas M P, 1992, J Orthop Trauma, V6, P301, DOI 10.1097/00005131-199209000-00006; *CAN HLTH WELF, 1991, 2 CAN HOSP INJ REP P; ELLISON LF, 1993, CHRONIC DIS CANADA, V14, P96; GUYER B, 1985, PEDIATR CLIN N AM, V32, P5; LAJOIE M, 1993, STUDY IN LINE SKATIN; MENZIES D, 1992, LIVING SAFETY    SPR, P16; *NAT INJ INF CLEAR, 1993, EST REP; RODGERS E, 1993, INLINE SKATERS M SEP, P11; *US CONS PROD SAF, 1992, NEISS EST REP EST CA; 1993, INLINE SKATERS  0714	11	33	33	0	1	CANADIAN PUBL HEALTH ASSN	OTTAWA	1565 CARLING AVE, SUITE 400, OTTAWA ON K1Z 8R1, CANADA	0008-4263			CAN J PUBLIC HEALTH	Can. J. Public Health-Rev. Can. Sante Publ.	MAR-APR	1995	86	2					133	136					4	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	QX063	WOS:A1995QX06300015	7757893				2021-06-18	
J	GENUARDI, FJ; KING, WD				GENUARDI, FJ; KING, WD			INAPPROPRIATE DISCHARGE INSTRUCTIONS FOR YOUTH ATHLETES HOSPITALIZED FOR CONCUSSION	PEDIATRICS			English	Article						CONCUSSION; CLOSED HEAD INJURY; YOUTH ATHLETES	CONTACT-SPORTS; 2ND IMPACT; GUIDELINES; INJURIES	Objective. To evaluate the medical care, especially the discharge instructions regarding return to participation, received by youth athletes hospitalized for a closed head injury. Methods. We examined the records of all patients admitted over a 5-year period (1987 through 1991) to The Children's Hospital of Alabama for a sports-related closed head injury. Descriptive information was recorded and discharge instructions reviewed. Injury severity was graded according to guidelines current during the study period, as well as those outlined most recently by the Colorado Medical Society, which have been endorsed by a number of organizations including the American Academy of pediatrics. Discharge instructions recorded for each patient were then compared with those recommended in the guidelines. Results. We identified 33 patients with sports-related closed head injuries. Grade 1 concussions (least severe) occurred in 8 patients (24.2%), grade 2 in 10 (30.3%), and grade 3 (most severe) in 15 (45.4%). Overall, discharge instructions were appropriate for only 10 patients (30.3%), including all with grade I concussions, but only 2 with a grade 2 (20.0%) and none with a grade 3 concussion. Conclusion. All who care for youth athletes must become familiar with the guidelines for management of concussion to provide appropriate care and counseling and to avoid a tragic outcome.	UNIV ALABAMA,DEPT PEDIAT,DIV ADOLESCENT MED,BIRMINGHAM,AL; UNIV ALABAMA,SE CHILD SAFETY INST,BIRMINGHAM,AL							CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; CANTU RC, 1992, PHYSICIAN SPORTSMED, V20, P55, DOI 10.1080/00913847.1992.11947483; CANTU RC, 1988, CLIN SPORT MED, V7, P459; CANTU RC, 1991, ADOLESC MED, V2, P141; DYMENT PG, 1991, SPORT MED HLTH CARE, P250; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; HUGENHOLTZ H, 1982, CAN MED ASSOC J, V127, P827; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; LEHMAN LB, 1990, CLIN SPORT MED, V9, P247; Ryan A J, 1991, Br J Sports Med, V25, P81; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; WILBERGER JE, 1991, YOUR PATIENT FITNESS, V3, P4; WOODWARD GA, 1992, PEDIATRICS, V89, P849; 1991, GUIDELINES MANAGEMEN	15	33	33	0	5	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD, ELK GROVE VILLAGE, IL 60007-1098	0031-4005			PEDIATRICS	Pediatrics	FEB	1995	95	2					216	218					3	Pediatrics	Pediatrics	QE313	WOS:A1995QE31300011	7838638				2021-06-18	
J	LEE, ST; LIU, TN; WONG, CW; YEH, YS; TZAAN, WC				LEE, ST; LIU, TN; WONG, CW; YEH, YS; TZAAN, WC			RELATIVE RISK OF DETERIORATION AFTER MILD CLOSED-HEAD INJURY	ACTA NEUROCHIRURGICA			English	Article						MILD HEAD INJURY; RISK OF DETERIORATION	INTRACRANIAL HEMATOMA; SKULL RADIOGRAPHY; EARLY SEIZURES; ADMISSION; TRAUMA	In this prospective study, a series of 1812 consecutive mild head injured adult patients who visited the hospital emergency department were assessed. Twenty-eight patients (1.5%) deteriorated after head injury; 23 of these (1.3% of the series) required surgical intervention. Five patients (0.3%) deteriorated due to non-surgical causes [post-traumatic seizure 2, syndrome of inapproapriate secretion of antidiuretic hormone (SIADH) 3]. Most of the deterioration occurred within the first 24 hours (57%). Post-traumatic headache was found in 280 patients (15.5%) and 84 patients (4.6%) suffered post-traumatic vomiting. The relative risk is calculated. Age over 60, presence of drowsiness, focal motor weakness, post-traumatic headache and vomiting has increased risk of deterioration (p < 0.001). This study suggests that post-traumatic headache and vomiting deserve more clinical attention rather than being considered as post-traumatic syndrome only.	CHANG GUNG MED COLL,DEPT NEUROSURG,TAIPEI,TAIWAN; CHANG GUNG MEM HOSP,TAIPEI 10591,TAIWAN							ANDO S, 1992, ACTA NEUROCHIR WIEN, V1119, P97; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; CAVENESS WF, 1961, EPILEPSIA, V2, P123; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DELACEY G, 1990, BRIT J RADIOL, V63, P14, DOI 10.1259/0007-1285-63-745-14; DESAI BT, 1983, EPILEPSIA, V24, P289, DOI 10.1111/j.1528-1157.1983.tb04892.x; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; FEUERMAN T, 1988, NEUROSURGERY, V22, P449, DOI 10.1227/00006123-198803000-00001; FISCHER RP, 1981, J TRAUMA, V21, P920, DOI 10.1097/00005373-198111000-00002; GOLDSTEIN J, 1991, MED CLIN N AM, V75, P641, DOI 10.1016/S0025-7125(16)30439-4; HUGENHOLTZ H, 1987, CHILD NERV SYST, V3, P266, DOI 10.1007/BF00271820; JENNETT B, 1974, ARCH NEUROL-CHICAGO, V30, P294; JONES JJ, 1981, LANCET, V2, P850; KLAUBER MR, 1980, NEUROSURGERY, V24, P31; LEE ST, 1990, J TRAUMA, V30, P194, DOI 10.1097/00005373-199002000-00010; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; LIVINGSTON DH, 1991, AM SURGEON, V57, P14; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; MENDELOW AD, 1983, BRIT MED J, V287, P1173, DOI 10.1136/bmj.287.6400.1173; MENDELOW AD, 1982, BRIT MED J, V285, P1530, DOI 10.1136/bmj.285.6354.1530; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RISH BL, 1973, J NEUROSURG, V38, P155, DOI 10.3171/jns.1973.38.2.0155; SAINSBURY CPQ, 1984, ARCH DIS CHILD, V59, P856, DOI 10.1136/adc.59.9.856; SNOKE JW, 1984, BRAIN, V107, P15; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; TEASDALE G, 1974, LANCET, V2, P81; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006; YAMAGUCHI M, 1992, HEADACHE, V32, P427, DOI 10.1111/j.1526-4610.1992.hed3209427.x	30	33	35	0	1	SPRINGER-VERLAG WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.		1995	135	3-4					136	140		10.1007/BF02187757			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	RN606	WOS:A1995RN60600005	8748803				2021-06-18	
J	MENON, VK; LANDERHOLM, TE				MENON, VK; LANDERHOLM, TE			INTRALESION INJECTION OF BASIC FIBROBLAST GROWTH-FACTOR ALTERS GLIAL REACTIVITY TO NEURAL TRAUMA	EXPERIMENTAL NEUROLOGY			English	Article							FIBRILLARY ACIDIC PROTEIN; COLONY-STIMULATING FACTOR; FACTOR MESSENGER-RNA; RAT-BRAIN; GENE-EXPRESSION; ENDOTHELIAL-CELLS; MICROGLIAL CELLS; CEREBRAL INJURY; STAB WOUNDS; FACTOR BFGF	A traumatic injury to the rat brain is known to induce astrocyte proliferation and hypertrophy leading to astrogliosis. In addition, trauma also induces microglial proliferation in the brain. Since basic fibroblast growth factor (bFGF) is believed to play a role in mediating glial responses to brain injury, we examined the effects of bFGF administration on astrocyte and microglial proliferation and astrocyte hypertrophy resulting from a traumatic injury to the rat brain. Intracerebroventricular infusion of bFGF for 2 days prior to and following injury failed to alter glial reactivity. In contrast, a single intralesion injection of bFGF immediately after injury increased total cell. division 2 and 5 days later, with an exclusive effect on glial fibrillary acidic protein-negative glia which consisted mostly of cells of macrophage-microglial phenotype. In addition, bFGF also enhanced injury-induced astrocyte hypertrophy. These results support a role for bFGF in macrophage-microglia proliferation and astrocyte hypertrophy following brain injury. They also suggest that alteration of injury responses of nonneuronal cells of the brain may be a potential side effect of intracerebral administration of bFGF. (C) 1994 Academic Press, Inc.		MENON, VK (corresponding author), UNIV CALIF DAVIS,SCH MED,DEPT CELL BIOL & HUMAN ANAT,DAVIS,CA 95616, USA.				NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG06159] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG006159] Funding Source: NIH RePORTER		ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; ARAUJO DM, 1992, J NEUROSCI, V12, P1668; ARENANDER AT, 1989, J NEUROSCI RES, V23, P257, DOI 10.1002/jnr.490230303; BAIRD A, 1989, BRIT MED BULL, V45, P438, DOI 10.1093/oxfordjournals.bmb.a072333; BAROTTE C, 1989, NEUROSCI LETT, V101, P197, DOI 10.1016/0304-3940(89)90530-2; BENHARROCH D, 1990, ISRAEL J MED SCI, V26, P212; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CANCILLA PA, 1992, J NEUROPATH EXP NEUR, V51, P560, DOI 10.1097/00005072-199209000-00011; DAMORE PA, 1990, CANCER METAST REV, V9, P227, DOI 10.1007/BF00046362; ECLANCHER F, 1990, GLIA, V3, P502, DOI 10.1002/glia.440030609; EGAN RA, 1991, BRAIN RES, V568, P330, DOI 10.1016/0006-8993(91)91421-V; EISEMANN A, 1991, ONCOGENE, V6, P1195; Emoto N, 1989, GROWTH FACTORS, V2, P21, DOI 10.3109/08977198909069078; FALKENBURG JHF, 1990, J IMMUNOL, V144, P4657; FERRARA N, 1988, BRAIN RES, V462, P223, DOI 10.1016/0006-8993(88)90550-1; FLOTTRAHMEL B, 1992, NEUROREPORT, V3, P1077, DOI 10.1097/00001756-199212000-00011; FRAUTSCHY SA, 1991, BRAIN RES, V553, P291, DOI 10.1016/0006-8993(91)90837-L; GALL C, 1979, J COMP NEUROL, V183, P539, DOI 10.1002/cne.901830306; GANTER S, 1992, J NEUROSCI RES, V33, P218, DOI 10.1002/jnr.490330205; GASSON JC, 1990, PROG CLIN BIOL RES, V338, P27; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1988, J NEUROSCI, V8, P4707; GOMEZPINILLA F, 1992, J NEUROSCI, V12, P345; GONZALEZ AM, 1991, ANN NY ACAD SCI, V638, P416, DOI 10.1111/j.1749-6632.1991.tb49057.x; GOSPODAROWICZ D, 1986, CELL DIFFER DEV, V19, P1, DOI 10.1016/0045-6039(86)90021-7; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; HOZUMI I, 1990, BRAIN RES, V524, P64, DOI 10.1016/0006-8993(90)90492-T; HOZUMI I, 1990, BRAIN RES, V534, P291, DOI 10.1016/0006-8993(90)90142-X; ITOH A, 1990, AM J RESP CELL MOL, V3, P245, DOI 10.1165/ajrcmb/3.3.245; JANECZKO K, 1989, BRAIN RES, V485, P236, DOI 10.1016/0006-8993(89)90566-0; KITAMURA T, 1978, ACTA NEUROPATHOL, V44, P31, DOI 10.1007/BF00691636; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; KNISS DA, 1988, BRAIN RES, V439, P281, DOI 10.1016/0006-8993(88)91485-0; LEWIS GP, 1992, J NEUROSCI, V12, P3968; LOGAN A, 1988, MOL CELL ENDOCRINOL, V58, P275, DOI 10.1016/0303-7207(88)90164-5; LOGAN A, 1992, J NEUROSCI, V12, P3828; LOGAN A, 1992, BRAIN RES, V587, P216, DOI 10.1016/0006-8993(92)91000-5; MATUO Y, 1988, IN VITRO CELL DEV B, V24, P477, DOI 10.1007/BF02628502; MCNEIL PL, 1989, J CELL BIOL, V109, P811, DOI 10.1083/jcb.109.2.811; MILLER MW, 1988, BRAIN RES, V457, P44, DOI 10.1016/0006-8993(88)90055-8; MIYAKE T, 1989, BRAIN RES, V489, P31, DOI 10.1016/0006-8993(89)90005-X; MORRISON RS, 1985, J NEUROSCI RES, V14, P167, DOI 10.1002/jnr.490140202; MORRISON RS, 1986, P NATL ACAD SCI USA, V83, P7537, DOI 10.1073/pnas.83.19.7537; MURABE Y, 1982, CELL TISSUE RES, V222, P223; MURRAY HM, 1973, EXP NEUROL, V41, P290, DOI 10.1016/0014-4886(73)90270-7; OHNO K, 1990, BIOCHEM BIOPH RES CO, V169, P719, DOI 10.1016/0006-291X(90)90390-9; PERRAUD F, 1988, GLIA, V1, P124, DOI 10.1002/glia.440010204; PERRAUD F, 1990, DEV NEUROSCI-BASEL, V12, P11, DOI 10.1159/000111831; PUUMALA M, 1990, BRAIN RES, V534, P283, DOI 10.1016/0006-8993(90)90140-7; RAIVICH G, 1991, J NEUROSCI RES, V30, P682, DOI 10.1002/jnr.490300412; SHIMOJO M, 1991, NEUROSCI LETT, V123, P229, DOI 10.1016/0304-3940(91)90937-O; STREIT WJ, 1990, J HISTOCHEM CYTOCHEM, V38, P1683, DOI 10.1177/38.11.2212623; SWEETNAM PM, 1991, J NEUROCHEM, V57, P237, DOI 10.1111/j.1471-4159.1991.tb02121.x; TOPP KS, 1989, GLIA, V2, P201, DOI 10.1002/glia.440020309; VIJAYAN VK, 1990, MOL CHEM NEUROPATHOL, V13, P107, DOI 10.1007/BF03159912; WALICKE P, 1986, P NATL ACAD SCI USA, V83, P3012, DOI 10.1073/pnas.83.9.3012; WALICKE PA, 1991, J NEUROSCI, V11, P2249; WEICH HA, 1991, J CELL BIOCHEM, V47, P158, DOI 10.1002/jcb.240470209	58	33	33	0	0	ACADEMIC PRESS INC JNL-COMP SUBSCRIPTIONS	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495	0014-4886			EXP NEUROL	Exp. Neurol.	SEP	1994	129	1					142	154		10.1006/exnr.1994.1155			13	Neurosciences	Neurosciences & Neurology	PM769	WOS:A1994PM76900015	7925836				2021-06-18	
J	EWINGCOBBS, L; THOMPSON, NM; MINER, ME; FLETCHER, JM				EWINGCOBBS, L; THOMPSON, NM; MINER, ME; FLETCHER, JM			GUNSHOT WOUNDS TO THE BRAIN IN CHILDREN AND ADOLESCENTS - AGE AND NEUROBEHAVIORAL DEVELOPMENT	NEUROSURGERY			English	Article						ADOLESCENTS; BRAIN INJURY; CHILDREN; GUNSHOT WOUNDS; NEUROPSYCHOLOGICAL ASSESSMENT; OUTCOME	CLOSED HEAD-INJURY; CIVILIAN PRACTICE; EXPERIENCE; MANAGEMENT; MEMORY; SCALE; COMA	NEUROBEHAVIORAL OUTCOME AFTER craniocerebral gunshot wounds was evaluated in a prospective, 3-year, longitudinal follow-up of a consecutive case series of 13 children and adolescents. The younger group was composed of seven children, ages 1.5 to 4 years, and the older group contained six children, ages 5 to 14. Outcome measures included the Glasgow Outcome Scale and neuropsychological assessment of intelligence, language, motor, memory, attention, academic achievement, and adaptive behavior. Glasgow Outcome Scale scores at baseline indicated moderate and severe disabilities in 69 and 23%, respectively. At the 3-year follow-up, 85% had moderate disabilities but only 8% were severely disabled. Significant and persistent neurobehavioral deficits varied with developmental level at the time of cerebral insult. Intellectual functioning was clearly more impaired in children younger than 5 years of age at the time of injury than in older children. Cognitive and motor factors were most closely related to deficits in the younger group. Disability in older children and adolescents was associated with impaired attention, adaptive behavior, and behavioral disturbance. Disabilities appear to be at least as severe in our sample after cerebral gunshot wounds as in our studies of severe pediatric closed-head injury. At the time of follow-up, younger children sustaining gunshot wounds had slightly lower intelligence quotient scores and similar receptive language, expressive language, and gross motor scores compared with children with severe closed-head injury. The older gunshot wound patients were significantly more impaired than patients with severe closed-head injuries on measures of adaptive behavior and attention. Our findings suggest that early brain injury may not be associated with a more favorable prognosis than comparable injuries in older children and that the type of deficits observed vary with developmental level at the time of injury.	UNIV TEXAS,HLTH SCI CTR,DEPT PSYCHIAT,SAN ANTONIO,TX 78284; OHIO STATE UNIV,COLL MED,DIV NEUROL SURG,COLUMBUS,OH 43210	EWINGCOBBS, L (corresponding author), UNIV TEXAS,HLTH SCI CTR,DEPT PEDIAT,6431 FANNIN,MSB 7142,HOUSTON,TX 77030, USA.		fletcher, jack/Q-5975-2019; Fletcher, Jack/AAX-2931-2020		PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [21889, 27597] Funding Source: Medline		BARLOW B, 1982, J PEDIATR SURG, V17, P927, DOI 10.1016/S0022-3468(82)80469-7; BASTIA HC, 1898, TREATISE APHASIA OTH; Bayley N., 1969, MANUAL BAYLEY SCALES; BEERY KE, 1989, REVISED ADM SCORING; BUSCHKE H, 1974, J EXP CHILD PSYCHOL, V18, P488, DOI 10.1016/0022-0965(74)90126-X; Dunn L., 1981, PEABODY PICTURE VOCA; DUNN LM, 1970, PEABODY INDIVIDUAL A; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FLETCHER JM, 1985, J EXP CHILD PSYCHOL, V40, P244, DOI 10.1016/0022-0965(85)90088-8; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; HANNAY HJ, 1979, CORTEX, V15, P269, DOI 10.1016/S0010-9452(79)80031-3; HECAEN H, 1976, BRAIN LANG, V3, P114, DOI 10.1016/0093-934X(76)90009-2; HEDRICK DL, 1974, SEQUENCED INVENTORY; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P199, DOI 10.1007/BF01808959; Hollingshead A. B., 1958, SOCIAL CLASS MENTAL; HUBSCHMANN O, 1979, J TRAUMA, V19, P6, DOI 10.1097/00005373-197901000-00002; Jastak J., 1978, WIDE RANGE ACHIEVEME; JENNETT B, 1975, LANCET, V1, P480; KAUFMAN HH, 1983, ACTA NEUROCHIR, V67, P115, DOI 10.1007/BF01401671; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LILLARD PL, 1978, SURG NEUROL, V9, P79; McCarthy D., 1972, MCCARTHY SCALES CHIL; MINER ME, 1990, NEUROSURGERY, V26, P20, DOI 10.1227/00006123-199001000-00002; MINER ME, 1986, NEUROSURGERY, V19, P952, DOI 10.1227/00006123-198612000-00009; NAGIB MG, 1986, NEUROSURGERY, V18, P533, DOI 10.1227/00006123-198605000-00003; RAIMONDI AJ, 1984, CHILD BRAIN, V11, P12; RAIMONDI AJ, 1970, J NEUROSURG, V32, P647, DOI 10.3171/jns.1970.32.6.0647; SAINTJAMESROBER.I, 1979, ADV CHILD DEV BEHAV, V14, P253; SARNAIK AP, 1989, J TRAUMA, V29, P1434, DOI 10.1097/00005373-198910000-00023; SHERMAN WD, 1980, WESTERN J MED, V132, P99; SMITH A, 1984, EARLY BRAIN DAMAGE, V1, P299; Sparrow S., 1984, VINELAND ADAPTIVE BE; Spreen O, 1969, NEUROSENSORY CTR COM; TEASDALE G, 1974, LANCET, V2, P81; Terman L. M., 1972, STANFORD BINET INTEL; TEUBER H, 1962, Dev Med Child Neurol, V4, P3; Wechsler D., 1974, MANUAL WECHSLER INTE	39	33	34	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0148-396X			NEUROSURGERY	Neurosurgery	AUG	1994	35	2					225	233		10.1227/00006123-199408000-00007			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	PA207	WOS:A1994PA20700021	7969829				2021-06-18	
J	LEE, MW; DEPPE, SA; SIPPERLY, ME; BARRETTE, RR; THOMPSON, DR				LEE, MW; DEPPE, SA; SIPPERLY, ME; BARRETTE, RR; THOMPSON, DR			THE EFFICACY OF BARBITURATE COMA IN THE MANAGEMENT OF UNCONTROLLED INTRACRANIAL HYPERTENSION FOLLOWING NEUROSURGICAL TRAUMA	JOURNAL OF NEUROTRAUMA			English	Article							SEVERE HEAD-INJURY; PRESSURE; THERAPY	The purpose of this study was to evaluate the role of barbiturate therapy as an adjunctive treatment for control of intracranial hypertension when conventional methods failed. To this end, a retrospective chart review was conducted on 21 neurosurgical trauma patients with uncontrolled intracranial pressure (ICP) admitted to a trauma/intensive care unit. In this patient population, the overall mortality was 48%. Control of ICP was achieved in 67% of patients. The survival of patients experiencing ICP control with barbiturate coma was better than those patients who failed therapy (71% vs 14%,p = 0.021). Thus, in a subgroup of neurosurgical trauma patients who are refractory to conventional management of elevated ICP, barbiturates appear to improve survival, suggesting that this therapy has an important role in the management of neurotrauma patients.	MERCY HOSP, DEPT MED, DIV CRIT CARE MED, TRAUMA INTENS CARE UNIT, PITTSBURGH, PA 15219 USA; MERCY HOSP, DEPT SURG, DIV GEN SURG, PITTSBURGH, PA USA; MERCY HOSP, DEPT SURG, DIV TRAUMA SERV, PITTSBURGH, PA USA							BOWERS SA, 1980, NEUROSURGERY, V6, P237; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; HOFF JT, 1977, ACTA NEUROL SCAND, V56, P158; JENNETT B, 1975, LANCET, V1, P480; KASSELL NF, 1980, NEUROSURGERY, V7, P593, DOI 10.1227/00006123-198012000-00010; MARSHALL LF, 1979, J NEUROSURG, V50, P26, DOI 10.3171/jns.1979.50.1.0026; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; PAPPAS TN, 1981, AM J HOSP PHARM, V38, P494, DOI 10.1093/ajhp/38.4.494; REA GL, 1983, NEUROSURGERY, V12, P401, DOI 10.1227/00006123-198304000-00005; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; SMITH AL, 1977, ANESTHESIOLOGY, V47, P285, DOI 10.1097/00000542-197709000-00010; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; WILBERGER JE, 1990, J TRAUMA, V30, P733, DOI 10.1097/00005373-199006000-00014	14	33	33	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	1994	11	3					325	331		10.1089/neu.1994.11.325			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	PF221	WOS:A1994PF22100008	7996586				2021-06-18	
J	BRISS, PA; SACKS, JJ; ADDISS, DG; KRESNOW, MJ; ONEIL, J				BRISS, PA; SACKS, JJ; ADDISS, DG; KRESNOW, MJ; ONEIL, J			A NATIONWIDE STUDY OF THE RISK OF INJURY ASSOCIATED WITH DAY-CARE-CENTER ATTENDANCE	PEDIATRICS			English	Article						CHILD CARE; CHILDREN; DAY CAVE CENTERS; EPIDEMIOLOGY; INJURY; PEDIATRIC; PLAYGROUND; PREVENTION	CHILD-CARE; HOME CARE; EPIDEMIOLOGY; ILLNESS	Objective. Because an increasing proportion of US children spends time in day care center environments, a national estimate of injury risks in day care centers is needed. Methods. We interviewed directors of 1797 day care centers from every state and the District of Columbia from October to December 1990 and analyzed medically attended injuries and center characteristics reported by the directors. Results. The centers were attended by 138404 children. In the 2 months before the center directors were interviewed, 556 children sustained injuries requiring medical attention while attending the centers. The injury rate was 1.5 injuries per 100000 child hours in day care. The most common injuries were cuts or lacerations (31%), bumps or bruises (15%), fractures (10%), and dental injuries (8%). Most injuries (51%) occurred on the playground. Many injuries (18%), and more than half of fractures and concussions (53%) were due to falls from climbing equipment. Conclusions. Day care center injury rates estimated by this study were relatively low. Many injuries that occur in this setting are probably minor. However, lowering the height of playground equipment and providing more resilient playground surfaces could further reduce injury risks in day care centers.	CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,ATLANTA,GA; CTR DIS CONTROL & PREVENT,PREVENT MED RESIDENCY PROGRAM,ATLANTA,GA; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,ATLANTA,GA							ARONSON SS, 1988, EXCHANGE         MAY, P35; CHANG A, 1989, PEDIATRICS, V83, P272; DAWSON DA, 1990, US DHHS ADV DATA, V187; GUNN WJ, 1991, AM J DIS CHILD, V145, P779; GUYER B, 1990, AM J DIS CHILD, V144, P649, DOI 10.1001/archpedi.1990.02150300047016; HASKINS R, 1986, PEDIATRICS, V77, P951; HURWITZ ES, 1991, PEDIATRICS, V87, P62; LANDMAN PF, 1987, AM J DIS CHILD, V141, P292, DOI 10.1001/archpedi.1987.04460030070027; ORYAN M, 1990, SEMIN PEDIATR INFECT, V1, P252; OSTERHOLM MT, 1990, SEMIN PEDIATR INFECT, V1, P222; PHILLIPS DA, 1987, EXCHANGE         SEP, P9; PICKERING LK, 1986, REV INFECT DIS, V8, P539; PICKERING LK, 1990, SEMIN PEDIATR INFECT, V1, P263; RIVARA FP, 1989, PEDIATRICS, V84, P1011; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P327; SACKS JJ, 1990, AM J PUBLIC HEALTH, V80, P986, DOI 10.2105/AJPH.80.8.986; SACKS JJ, 1989, JAMA-J AM MED ASSOC, V262, P1641, DOI 10.1001/jama.262.12.1641; SHAH BV, 1989, SOFTWARE SURVEY DATA; SOLOMONS HC, 1982, CHILD HEALTH CARE, V10, P90; THACKER SB, 1992, JAMA-J AM MED ASSOC, V268, P1720, DOI 10.1001/jama.268.13.1720; WHITE AA, 1983, P AM STAT ASS SECT S, P277; 1988, MMWR, V37, P629; 1992, CARING OUR CHILDREN; 1985, DHHS PHS851320 PUB 1	24	33	33	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD, ELK GROVE VILLAGE, IL 60007-1098	0031-4005			PEDIATRICS	Pediatrics	MAR	1994	93	3					364	368					5	Pediatrics	Pediatrics	MY687	WOS:A1994MY68700002	8115192				2021-06-18	
J	DONDERS, J				DONDERS, J			ACADEMIC PLACEMENT AFTER TRAUMATIC BRAIN INJURY	JOURNAL OF SCHOOL PSYCHOLOGY			English	Article							HEAD-INJURY; CHILDREN; INTELLIGENCE; PERFORMANCE; ADOLESCENTS; SEQUELAE	The academic placement of 87 children 6 years 6 months to 16 years 6 months old who had sustained traumatic brain injuries was determined within 1 year after injury. Forty-five children had returned full-time to regular academic programs, 21 children were receiving special education support for less than 50% of their classes, and 21 children were enrolled in special education classes for more than 50% of their time. The predictive power of various patient history variables with regard to school reentry was evaluated by means of stepwise discriminant analysis. Verbal IQ at initial postinjury assessment appeared to be the most important factor with regard to school placement within the first year after injury. Theoretical and research implications are discussed.		DONDERS, J (corresponding author), MARY FREE BED HOSP,235 WEALTHY SE,GRAND RAPIDS,MI 49503, USA.						BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; Cohen S. B., 1986, J HEAD TRAUMA REHAB, V1, P22; COOLEY E, 1991, J HEAD TRAUMA REHAB, V6, P47; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; DENNIS M, 1985, J CLIN EXP NEUROPSYC, V7, P526, DOI 10.1080/01688638508401283; DONDERS J, 1990, CHILD NERV SYST, V6, P148, DOI 10.1007/BF00308492; EWINGCOBBS L, 1986, J HEAD TRAUMA REHAB, V1, P57; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; GOLDSTEIN FC, 1987, J LEARN DISABIL, V20, P518, DOI 10.1177/002221948702000903; Goldstein FC, 1985, DEV NEUROPSYCHOL, V1, P195, DOI 10.1080/87565648509540310; Hollingshead A. B., 1958, SOCIAL CLASS MENTAL; KLONOFF H, 1977, J NEUROL NEUROSUR PS, V40, P1211, DOI 10.1136/jnnp.40.12.1211; Lehr E, 1990, PSYCHOL MANAGEMENT T; Levin H., 1979, J PEDIATR PSYCHOL, V4, P389, DOI DOI 10.1093/JPEPSY/4.4.389; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; Luria A. R, 1973, WORKING BRAIN; *MI STAT BOARD ED, 1987, REV ADM RUL SPEC ED; Reitan R, 1974, CLIN NEUROPSYCHOLOGY; ROURKE BP, 1988, CLIN NEUROPSYCHOL, V2, P293, DOI DOI 10.1080/13854048808403271; Rourke BP, 1983, CHILD NEUROPSYCHOLOG; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SATZ P, 1981, J CONSULT CLIN PSYCH, V49, P851, DOI 10.1037/0022-006X.49.6.851; SAVAGE RC, 1991, J HEAD TRAUMA REHAB, V6, P1; SHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592, DOI 10.1016/S0002-7138(09)60964-X; TEASDALE G, 1974, LANCET, V2, P81; TELZROW CF, 1987, J LEARN DISABIL, V20, P536, DOI 10.1177/002221948702000905; Wechsler D., 1974, MANUAL WECHSLER INTE; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; YLVISAKER M, 1985, HEAD INJURY REHABILI	32	33	33	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0022-4405			J SCHOOL PSYCHOL	J. Sch. Psychol.	SPR	1994	32	1					53	65		10.1016/0022-4405(94)90028-0			13	Psychology, Educational	Psychology	MY571	WOS:A1994MY57100004					2021-06-18	
J	LEVIN, HS; CULHANE, KA; FLETCHER, JM; MENDELSOHN, DB; LILLY, MA; HARWARD, H; CHAPMAN, SB; BRUCE, DA; BERTOLINOKUSNERIK, L; EISENBERG, HM				LEVIN, HS; CULHANE, KA; FLETCHER, JM; MENDELSOHN, DB; LILLY, MA; HARWARD, H; CHAPMAN, SB; BRUCE, DA; BERTOLINOKUSNERIK, L; EISENBERG, HM			DISSOCIATION BETWEEN DELAYED ALTERNATION AND MEMORY AFTER PEDIATRIC HEAD-INJURY - RELATIONSHIP TO MRI FINDINGS	JOURNAL OF CHILD NEUROLOGY			English	Article							PREFRONTAL CORTEX; RHESUS-MONKEY; BRAIN-DAMAGE; LESIONS; PERFORMANCE; DOPAMINE; COMA	This study investigated the usefulness of a delayed alternation task in characterizing the cognitive sequelae of closed head injury in children and adolescents. Verbal learning and memory (California Verbal Learning Test) were also studied for comparison. Sixty-two closed head injury patients (mean age, 9.6 years), who were studied after an average postinjury interval of 20 months, were divided according to both their lowest postresuscitation Glasgow Coma Scale score (3 to 8 versus 9 to 15) and age range (5 to 7 years versus 8 to 16 years) at the time of testing. Magnetic resonance imaging was performed to evaluate the relationship of focal brain lesions to cognitive and memory performance. Fifty-six neurologically normal children (mean age, 9.9 years) were tested on the same measures. The results disclosed no relationship between delayed alternation performance and severity of injury. In contrast, verbal memory was impaired in the severely-injured patients, relative to both controls and less severely-injured patients. Frontal lobe (but not extrafrontal) lesion size incremented the Glasgow Coma Scale score in predicting verbal memory, but there was no relationship between focal brain lesions and delayed alternation performance. In contrast to the tendency for more efficient delayed alternation performance in the 5- to 7-year-old subjects than in the 8- to 16-year-old subjects, verbal memory significantly improved with age in the closed head injury and control groups. Notwithstanding our essentially negative findings for delayed alternation, it is possible that this task may be useful for assessing frontal lobe injury in younger children or infants. Our results indicate limitations in extrapolating from nonhuman primate studies of delayed alternation to frontal lobe function in children and adolescents.	UNIV TEXAS,SCH MED,DEPT PEDIAT,HOUSTON,TX; UNIV TEXAS,SW MED SCH,MARY NELL & RALPH ROGERS MRI CTR,DALLAS,TX; UNIV TEXAS,SW MED SCH,DEPT NEUROSURG,DALLAS,TX; UNIV TEXAS,CALLIER CTR COMMUN DISORDERS,DALLAS,TX 75235; UNIV BALTIMORE,DIV NEUROL SURG,BALTIMORE,MD	LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG,D73,GALVESTON,TX 77550, USA.		Fletcher, Jack/AAX-2931-2020; fletcher, jack/Q-5975-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-21889] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; BROZOSKI TJ, 1979, SCIENCE, V205, P929, DOI 10.1126/science.112679; BUTTERS N, 1969, SCIENCE, V156, P1271; CHOROVER SL, 1966, NEUROPSYCHOLOGIA, V4, P1, DOI 10.1016/0028-3932(66)90016-9; DAMASIO HC, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P92; DELIS DC, 1986, CALIFORNIA VERBAL LE; DIAMOND A, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P339; FREEDMAN M, 1986, BEHAV NEUROSCI, V100, P337, DOI 10.1037/0735-7044.100.3.337; FUSTER JM, 1984, TRENDS NEUROSCI, V7, P408, DOI 10.1016/S0166-2236(84)80144-7; GOLDMAN PS, 1971, EXP NEUROL, V32, P366, DOI 10.1016/0014-4886(71)90005-7; GOLDMAN PS, 1971, J COMP PHYSIOL PSYCH, V77, P212, DOI 10.1037/h0031649; HIRST W, 1988, BRAIN COGNITION, V8, P379, DOI 10.1016/0278-2626(88)90060-7; Hollingshead A. B., 1958, SOCIAL CLASS MENTAL; IRLE E, 1984, BEHAV NEUROSCI, V98, P884, DOI 10.1037/0735-7044.98.5.884; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; MARKOWITSCH HJ, 1981, BRAIN BEHAV EVOLUT, V18, P96, DOI 10.1159/000121779; OSCARBERMAN M, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P230; SAWAGUCHI T, 1991, SCIENCE, V251, P947, DOI 10.1126/science.1825731; STAMM JS, 1971, EXP NEUROL, V33, P263, DOI 10.1016/0014-4886(71)90020-3; TEASDALE G, 1974, LANCET, V2, P81; THOMAS GJ, 1980, J COMP PHYSIOL PSYCH, V94, P808, DOI 10.1037/h0077834; Wechsler D., 1974, WECHSLER ADULT INTEL; WILCOTT RC, 1990, BEHAV NEURAL BIOL, V53, P393, DOI 10.1016/0163-1047(90)90268-B	26	33	33	0	1	DECKER PERIODICALS INC	HAMILTON	4 HUGHSON STREET SOUTH PO BOX 620, LCD 1, HAMILTON ON L8N 3K7, CANADA	0883-0738			J CHILD NEUROL	J. Child Neurol.	JAN	1994	9	1					81	89		10.1177/088307389400900121			9	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	MP947	WOS:A1994MP94700021	8151091				2021-06-18	
J	MCLAUGHLIN, RM; TILLSON, DM				MCLAUGHLIN, RM; TILLSON, DM			FLEXIBLE EXTERNAL FIXATION FOR CRANIODORSAL COXOFEMORAL LUXATIONS IN DOGS	VETERINARY SURGERY			English	Article							SKELETAL FIXATION; STABILIZATION; REPAIR; JOINT; CAT	An external fixator consisting of two Ellis pins connected by a flexible band was developed and evaluated as a treatment for craniodorsal coxofemoral luxations in dogs. The technique for closed application of the fixator without injury to the coxofemoral joint or sciatic nerve was developed in six dog cadavers. The coxofemoral joints were then surgically destabilized and the limbs were manipulated through a full range of motion to assess the efficacy of the fixator in maintaining joint reduction. The fixator maintained joint reduction and stability after a surgically created craniodorsal luxation except when the femur was externally rotated 90 degrees. A flexible external fixator was then applied unilaterally in four healthy dogs. The dogs tolerated the fixator well and were bearing weight on the limb within 2 days after surgery; the range of motion was not limited by the fixator. The efficacy of a flexible external fixator in maintaining joint reduction after craniodorsal coxofemoral luxation was then evaluated in eight large dogs. The right coxofemoral joint in each dog was luxated surgically by removal of the dorsal joint capsule and transection of the ligament of the head of the femur and deep gluteal muscle. The joint was reduced and the fixator pins were applied in a closed fashion. In four dogs, a flexible external band was applied to the pins. Luxation did not reccur in these four dogs. The bands were not applied initially in four control dogs. Luxation occurred in three of the four control dogs within 24 hours of surgery. The joints that luxated were reduced and the flexible bands applied. Luxation did not recur after the bands were in place. The dogs tolerated the external fixators well, were bearing weight within 2 days of surgery, and walking with only minimal lameness 5 days after surgery. Luxation of the coxofemoral joints did not occur during the 2-week period in which the fixators were in place. The joints remained stable 1 week after removal of the fixators, at which time the dogs were euthanatized. Necropsy evaluation identified inflammation surrounding the pins and fibrous thickening of the dorsal joint capsule. The flexible external fixators were applied closed, maintained reduction of the coxofemoral joint after replacement of a craniodorsal luxation, and allowed weight bearing and limb usage soon after surgery. The flexible external fixator has several advantages over other methods of treating craniodorsal coxofemoral luxations. Complications noted in this study included pin tract drainage, pin loosening, and disruption of the flexible bands. (C) Copyright 1994 by The American College of Veterinary Surgeons		MCLAUGHLIN, RM (corresponding author), KANSAS STATE UNIV,COLL VET MED,DEPT CLIN SCI,MANHATTAN,KS 66506, USA.						ALLEN SW, 1986, COMP CONT EDUC PRACT, V8, P457; ARON DN, 1986, J AM ANIM HOSP ASSOC, V22, P659; ARON DN, 1984, COMP CONT EDUC PRACT, V6, P845; BASHER AWP, 1986, VET SURG, V15, P356, DOI 10.1111/j.1532-950X.1986.tb00243.x; BENNETT RA, 1987, VET SURG, V16, P207, DOI 10.1111/j.1532-950X.1987.tb00940.x; BONE DL, 1984, VET SURG, V13, P263, DOI 10.1111/j.1532-950X.1984.tb00807.x; Braden T. D., 1988, Veterinary and Comparative Orthopaedics and Traumatology, V1, P26; CAMPBELL JR, 1965, VET REC, V77, P1173, DOI 10.1136/vr.77.40.1173; DANGELIS M, 1973, J AM ANIM HOSP ASSOC, V9, P175; DEVITA J, 1952, 89TH P ANN M AM VET, P191; FOX SM, 1991, COMP CONT EDUC PRACT, V13, P381; GREENE JE, 1953, N AM VET, V34, P50; GRILL F, 1989, CLIN ORTHOP RELAT R, V241, P166; HAMMER DL, 1980, J AM VET MED ASSOC, V177, P1018; HUNT CA, 1985, J AM VET MED ASSOC, V187, P828; JOHNSON ME, 1987, VET SURG, V16, P346, DOI 10.1111/j.1532-950X.1987.tb00965.x; Leeds E. B., 1979, Journal of Veterinary Orthopedics, V1, P35; LUBBE AM, 1990, J SMALL ANIM PRACT, V31, P234, DOI 10.1111/j.1748-5827.1990.tb00791.x; MEIJ BP, 1992, J SMALL ANIM PRACT, V33, P320, DOI 10.1111/j.1748-5827.1992.tb01157.x; SALTER RB, 1961, J BONE JOINT SURG BR, V43, P518; SALTER RB, 1960, J BONE JOINT SURG AM, V42, P31, DOI 10.2106/00004623-196042010-00004; SALTER RB, 1980, J BONE JOINT SURG AM, V62, P1232, DOI 10.2106/00004623-198062080-00002; SLOCUM B, 1986, J AM ANIM HOSP ASSOC, V22, P331; SMITH WS, 1963, J BONE JOINT SURG AM, V45, P491, DOI 10.2106/00004623-196345030-00005; STADER O, 1955, N AM VET, V36, P1026; STEAD AC, 1970, J SMALL ANIM PRACT, V11, P591, DOI 10.1111/j.1748-5827.1970.tb05620.x	26	33	33	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0161-3499			VET SURG	Vet. Surg.	JAN-FEB	1994	23	1					21	30		10.1111/j.1532-950X.1994.tb00438.x			10	Veterinary Sciences	Veterinary Sciences	MR756	WOS:A1994MR75600003	8140735				2021-06-18	
J	ARCIA, E; GUALTIERI, CT				ARCIA, E; GUALTIERI, CT			ASSOCIATION BETWEEN PATIENT REPORT OF SYMPTOMS AFTER MILD HEAD-INJURY AND NEUROBEHAVIORAL PERFORMANCE	BRAIN INJURY			English	Article							EVALUATION SYSTEM; RECOVERY; SEQUELAE	Patients with closed-head injuries may have physical, affective, behavioural and memory problems that persist for weeks, months or years. Even patients with minor head trauma have been found to exhibit deficits in neurobehavioural performance. However, very little research has been done to examine the association between patient symptoms after minor head injury and neurobehavioural performance. The associations between five sets of symptoms (memory problems, neurological problems, confusion, neurasthenia and co-ordination) and five neuro-behavioural areas (simple motor speed, response speed and attention, complex perceptual motor performance, visual memory, and learning) were examined in a group of 32 adults who had suffered mild to moderate head injury. Patients reported their symptoms with a four-point rating scale. Neurobehavioural functioning was assessed using computerized tests. Memory difficulties were the problems most frequently experienced by the patients and most closely associated with performance deficits.	UNIV N CAROLINA, CHAPEL HILL, NC 27514 USA							Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; ARCIA E, 1991, J SCHOOL PSYCHOL, V29, P337, DOI 10.1016/0022-4405(91)90021-I; ARCIA E, 1992, NEUROTOXICOL TERATOL, V14, P103, DOI 10.1016/0892-0362(92)90058-I; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; COONLEYHOGANSON R, 1984, NEUROSURGERY, V14, P315, DOI 10.1227/00006123-198403000-00009; DIKMEN S, 1977, ANN NEUROL, V2, P492, DOI 10.1002/ana.410020608; DIKMEN SS, 1989, MILD HEAD INJURY, P229; GRONWALL D, 1974, LANCET, V2, P605; HOOISMA J, 1990, ADVANCES IN NEUROBEHAVIORAL TOXICOLOGY : APPLICATIONS IN ENVIRONMENTAL AND OCCUPATIONAL HEALTH, P245; LETZ R, 1990, ADVANCES IN NEUROBEHAVIORAL TOXICOLOGY : APPLICATIONS IN ENVIRONMENTAL AND OCCUPATIONAL HEALTH, P189; LETZ R, 1986, NEUROBEHAVIORAL EVAL; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; OSHAUGHNESSY EJ, 1984, J FAM PRACTICE, V18, P391; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RIMEL RW, 1985, NEUROSURGERY, V2, P1608; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; RUTHERFORD WH, 1989, MILD HEAD INJURY, P218; Strub R, 1985, MENTAL STATUS EXAMIN; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742	24	33	33	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV-DEC	1993	7	6					481	489		10.3109/02699059309008175			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	MA173	WOS:A1993MA17300002	8260952				2021-06-18	
J	SHAPIRA, Y; LAM, AM; ARTRU, AA; ENG, C; SOLTOW, L				SHAPIRA, Y; LAM, AM; ARTRU, AA; ENG, C; SOLTOW, L			KETAMINE ALTERS CALCIUM AND MAGNESIUM IN BRAIN-TISSUE FOLLOWING EXPERIMENTAL HEAD TRAUMA IN RATS	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						ANESTHETICS, INTRAVENOUS; KETAMINE; BRAIN; HEAD INJURY; EXCITATORY AMINO ACIDS; GLUTAMATE; ASPARTATE; GLYCINE; IONS; CALCIUM; MAGNESIUM; RECEPTORS; N-METHYL-D-ASPARTATE	PROTECTS HIPPOCAMPAL-NEURONS; CEREBRAL-ARTERY OCCLUSION; EXCITATORY AMINO-ACIDS; SPINAL-CORD NEURONS; NMDA-RECEPTOR; ISCHEMIC-INJURY; DAMAGE; GLUTAMATE; ANTAGONISTS; INVITRO	We previously reported that the N-methyl-D-aspartate receptor antagonists dizocilpine maleate and ketamine improved the neurological severity score (NSS) after head trauma in rats. Other investigators have reported increased calcium and decreased magnesium following head trauma in untreated rats. The present study was designed to determine whether ketamine influences the concentrations of calcium and magnesium in brain tissue following head trauma. Eighty-six male Sprague-Dawley rats (180 +/- 15 g) were divided into eight groups. Groups A (no head injury) and C (head injury) received no treatment. Groups B (no head injury) and D-H (head injury) received ketamine. In groups D, E, and F, ketamine, 180 mg/kg i.p., was given 1, 2, and 4 h after head trauma, respectively. In groups G and H, ketamine, 120 and 60 mg/kg, respectively. was given 1 h after head trauma. After we killed the rats at 48 h, cortical slices were taken to measure tissue calcium and magnesium content by the inductively coupled plasma atomic emission spectroscopy method. In the contused hemispheres, calcium increased and magnesium decreased (p < 0.0001). Among the head-injured groups, the increase in brain tissue calcium was smaller in groups receiving 60 mg/kg of ketamine at 1 h or 180 mg/kg of ketamine at 1, 2, or 4 h than in the group not receiving ketamine. The decrease in brain tissue magnesium was smaller in the groups receiving 180 mg/kg of ketamine at 1 and 2 h than in the group not receiving ketamine. Temporalis muscle and rectal temperatures at 1, 2, 4, 24, and 48 h after head trauma were not significantly different between treated and untreated groups. It is concluded that, in this model of closed cranial impact, 180 mg/kg of ketamine given 1 or 2 h after injury reduced both the increase in brain tissue calcium and the decrease in brain tissue magnesium at 48 h following head trauma.	UNIV WASHINGTON,SCH MED,DEPT ANESTHESIOL,SEATTLE,WA 98195	SHAPIRA, Y (corresponding author), BEN GURION UNIV NEGEV,SOROKA MED CTR,DEPT ANESTHESIOL,DIV ANESTHESIOL,IL-84105 BEER SHEVA,ISRAEL.						Aikawa J.W., 1981, MAGNESIUM ITS BIOL S, P21; ALBERS GW, 1989, ANN NEUROL, V25, P398, DOI 10.1002/ana.410250412; BENEVISTE H, 1984, J NEUROCHEM, V43, P1369; CHAN PH, 1989, BRAIN RES, V487, P380, DOI 10.1016/0006-8993(89)90845-7; CHEUNG JY, 1986, NEW ENGL J MED, V314, P1670; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1988, TRENDS NEUROSCI, V11, P456; CORKEY BE, 1986, J BIOL CHEM, V261, P2567; COTMAN CW, 1987, TRENDS NEUROSCI, V10, P263, DOI 10.1016/0166-2236(87)90170-6; COURSEN G, 1990, STATUS KETAMINE ANES, P1; DESHPANDE JK, 1987, J CEREBR BLOOD F MET, V7, P89, DOI 10.1038/jcbfm.1987.13; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GARFINKEL L, 1985, Magnesium, V4, P60; GLOBUS MYT, 1991, NEUROSCI LETT, V127, P389; GRAHAM SH, 1993, J CEREBR BLOOD F MET, V13, P88, DOI 10.1038/jcbfm.1993.11; HAPPEL RD, 1981, BRAIN RES, V211, P476, DOI 10.1016/0006-8993(81)90976-8; HILLERED L, 1989, J CEREBR BLOOD F MET, V9, P607, DOI 10.1038/jcbfm.1989.87; KASS IS, 1982, J PHYSIOL-LONDON, V332, P459, DOI 10.1113/jphysiol.1982.sp014424; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIM JP, 1987, BRAIN RES, V437, P103, DOI 10.1016/0006-8993(87)91531-9; KINOUCHI H, 1993, J CEREBR BLOOD F MET, V13, P105, DOI 10.1038/jcbfm.1993.13; KOHMURA E, 1990, J CEREBR BLOOD F MET, V10, P877, DOI 10.1038/jcbfm.1990.144; KWO S, 1989, Journal of Neurotrauma, V6, P13, DOI 10.1089/neu.1989.6.13; LEMKE M, 1987, BIOCHEM BIOPH RES CO, V147, P1170, DOI 10.1016/S0006-291X(87)80192-4; Lemke M, 1990, J NEUROTRAUM, V7, P41, DOI 10.1089/neu.1990.7.41; LODGE D, 1986, J PHYSIOL-LONDON, V377, pP28; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MATSUMOTO K, 1991, BRAIN RES, V543, P236, DOI 10.1016/0006-8993(91)90033-R; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1987, J CEREB BLOOD FLOW M, V7, pS620; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; MELDRUM BS, 1987, MED BIOL, V65, P153; MEYER FB, 1989, BRAIN RES REV, V14, P227, DOI 10.1016/0165-0173(89)90002-7; NIGAM S, 1986, PROSTAG LEUKOTR ESS, V23, P1, DOI 10.1016/0262-1746(86)90070-3; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; Olney J, 1978, KAINIC ACID TOOL NEU, P95; OLNEY JW, 1989, SCIENCE, V244, P1360, DOI 10.1126/science.2660263; OLNEY JW, 1986, NEUROSCI LETT, V68, P29, DOI 10.1016/0304-3940(86)90224-7; RAPPAPORT ZH, 1987, STROKE, V18, P760, DOI 10.1161/01.STR.18.4.760; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; ROTHMAN SM, 1987, NEUROSCIENCE, V21, P673, DOI 10.1016/0306-4522(87)90028-5; RUBIN H, 1976, J CELL PHYSIOL, V89, P613, DOI 10.1002/jcp.1040890418; SADEE W, 1982, J NEUROCHEM, V39, P659, DOI 10.1111/j.1471-4159.1982.tb07943.x; SHAPIRA Y, 1992, J NEUROSURG ANESTH, V4, P231, DOI 10.1097/00008506-199210000-00001; SHAPIRA Y, 1992, ANESTHESIOLOGY, V77, P79, DOI 10.1097/00000542-199207000-00012; SHAPIRA Y, 1989, Neurological Research, V11, P169; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHAPIRA Y, 1992, ANESTH ANALG, V75, P238; SHARP FR, 1991, ANN NEUROL, V30, P801, DOI 10.1002/ana.410300609; SHIMADA N, 1990, STROKE, V21, P1445, DOI 10.1161/01.STR.21.10.1445; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMON RP, 1984, SCIENCE, V226, P850, DOI 10.1126/science.6093256; STEVENS MK, 1990, J CEREBR BLOOD F MET, V10, P77, DOI 10.1038/jcbfm.1990.10; TANNO H, 1993, J CEREBR BLOOD F MET, V13, P116, DOI 10.1038/jcbfm.1993.14; VACANTI FX, 1984, STROKE, V15, P695, DOI 10.1161/01.STR.15.4.695; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1988, J BIOL CHEM, V263, P757; WEISS J, 1986, BRAIN RES, V380, P186, DOI 10.1016/0006-8993(86)91447-2; WIELOCH T, 1982, J CEREB BLLOD FLOW M, V2, P305; WONG EHF, 1986, P NATL ACAD SCI USA, V83, P7104, DOI 10.1073/pnas.83.18.7104; WROBLEWSKI JT, 1987, P NATL ACAD SCI USA, V84, P5068, DOI 10.1073/pnas.84.14.5068; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1; Young W, 1987, Cent Nerv Syst Trauma, V4, P27	68	33	33	0	2	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	NOV	1993	13	6					962	968		10.1038/jcbfm.1993.120			7	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	MC445	WOS:A1993MC44500008	8408321	Bronze			2021-06-18	
J	BOHNEN, N; TWIJNSTRA, A; JOLLES, J				BOHNEN, N; TWIJNSTRA, A; JOLLES, J			PERSISTENCE OF POSTCONCUSSIONAL SYMPTOMS IN UNCOMPLICATED, MILDLY HEAD-INJURED PATIENTS - A PROSPECTIVE COHORT STUDY	NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY			English	Article						MHI; POSTCONCUSSIONAL SYMPTOMS; STROOP COLOR WORD TEST; LIGHT, SOUND	SEQUELAE; CONCUSSION	We report the follow-up of 41 nonhospitalized subjects with uncomplicated mild head injury (MHI) and no premorbid compromising condition. At 3 months after the trauma 22 patients still complained of at least 1 postconcussional symptom (PCS) and 10 patients had 3 or more PCS. At 6 months 12 patients complained of at least 1 PCS, whereas 9 patients still had 3 symptoms or more. Patients with persistent PCS complained more of emotional symptoms. Results obtained with objective tests indicated that this group was characterized by a decreased performance on the Stroop Color Word Interference Test and a reduced tolerance to light and sound stimuli in comparison with patients with only few or no PCS. Persistent neurobehavioral deficits were correlated with scores on a postconcussive/cognitive rating scale, but not with scores on an emotional/vegetative scale. Although most patients may substantially recover after MHI, about 1 in 4 patients may persist with a residue of neurobehavioral deficits. Patients with persistent PCS should be evaluated in a multidiagnostic and objective way in order to gain a better understanding of the nature and origin of the subjective symptoms.	UNIV LIMBURG,DEPT NEUROPSYCHOL & PSYCHOBIOL,6200 MD MAASTRICHT,NETHERLANDS; UNIV LIMBURG HOSP,DEPT NEUROL,MAASTRICHT,NETHERLANDS			Bohnen, Nicolaas/A-1312-2007				Acker MB, 1989, NEUROPSYCHOLOGY, V3, P123, DOI 10.1037//0894-4105.3.3.123; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BOFF K, 1986, HDB PERCEPTION HUMAN, V1; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1992, J NEUROL NEUROSUR PS, V55, P222, DOI 10.1136/jnnp.55.3.222; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; DIKMEN SS, 1989, MILD HEAD INJURY, P229; GRONWALL D, 1987, NEUROBEHAVIORAL RECO, P355; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JAKOBSEN J, 1987, ACTA NEUROL SCAND, V75, P341, DOI 10.1111/j.1600-0404.1987.tb05456.x; JONSSON CO, 1967, ACTA NEUROL SCAND, V43, P158, DOI 10.1111/j.1600-0404.1967.tb05725.x; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; MCLEAN A, 1983, J CLIN NEUROPSYCHOL, V5, P361, DOI 10.1080/01688638308401185; NOVICK MR, 1966, J MATH PSYCHOL, V3, P1, DOI 10.1016/0022-2496(66)90002-2; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTHERFORD WH, 1977, LANCET, V1, P1; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; VERHAGE R, 1964, THESIS NETHERLANDS; 1985, SAS USERS GUIDE STAT	24	33	33	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0894-878X			NEUROPSY NEUROPSY BE	Neuropsychiatr. Neuropsychol. Behav. Neurol.	JUL	1993	6	3					193	200					8	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	LK298	WOS:A1993LK29800010					2021-06-18	
J	MACNIVEN, E; FINLAYSON, MAJ				MACNIVEN, E; FINLAYSON, MAJ			THE INTERPLAY BETWEEN EMOTIONAL AND COGNITIVE RECOVERY AFTER CLOSED-HEAD INJURY	BRAIN INJURY			English	Article							TRAUMA PATIENTS; FOLLOW-UP	This study examined 59 patients who had suffered closed head injuries with respect to their MMPI scores and Category Test scores as assessed shortly post-injury and on subsequent assessment. The number of MMPI scales elevated above t=70 on the first assessment was negatively correlated with the magnitude of improvement made on the Category Test. Multiple regression analyses showed that the extent of cognitive deficit, as indicated by the Category Test, could be predicted from the degree of psychopathology, with MMPI scales 2 (depression), 7 (psychasthenia) and 8 (schizophrenia) being highly predictive of Category Test performance. These results suggest that patients with better psychological functioning perform at a higher level and make a greater post-traumatic recovery on neurocognitive tests. Although we cannot determine if the emotional impairment is due to neuropathology or is reactive in nature, there are clear implications for rehabilitation.	CHEDOKE MCMASTER HOSP,DEPT PSYCHOL,HAMILTON L8N 3Z5,ONTARIO,CANADA							ALFANO DP, IN PRESS CLIN NEUROP; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BORNSTEIN RA, 1988, NEUROSURGERY, V23, P622, DOI 10.1227/00006123-198811000-00013; Burke J M, 1989, Brain Inj, V3, P35, DOI 10.3109/02699058909008071; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; DIAMOND R, 1988, INT J CLIN NEUROPSYC, V10, P35; FARR SP, 1988, MMPI USE SPECIFIC PO, P214; FORDYCE DJ, 1983, J NEUROL NEUROSUR PS, V46, P620, DOI 10.1136/jnnp.46.7.620; Goldstein K, 1952, PSYCHIATR, V15, P245, DOI 10.1080/00332747.1952.11022878; Hathaway S.R., 1943, MINNESOTA MULTIPHASI; KWENTUS JA, 1985, PSYCHOSOMATICS, V26, P8, DOI 10.1016/S0033-3182(85)72900-3; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; MACK JL, 1979, MMPI CLIN RES TRENDS, P53; NOCKLEBY DM, 1987, INT J CLIN NEUROPSYC, V9, P145; Prigatano GP, 1986, CLIN NEUROPSYCHOLOGY, P135; Reitan Ralph M, 1986, HALSTEAD REITAN NEUR; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; VANWOERKOM TCAM, 1977, LANCET, V1, P812; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019	21	33	33	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	MAY-JUN	1993	7	3					241	246		10.3109/02699059309029676			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	MA170	WOS:A1993MA17000005	8508180				2021-06-18	
J	HURVITZ, EA; MANDAC, BR; DAVIDOFF, G; JOHNSON, JH; NELSON, VS				HURVITZ, EA; MANDAC, BR; DAVIDOFF, G; JOHNSON, JH; NELSON, VS			RISK-FACTORS FOR HETEROTOPIC OSSIFICATION IN CHILDREN AND ADOLESCENTS WITH SEVERE TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						BRAIN INJURIES; HETEROTOPIC; OSSIFICATION	BONE-FORMATION; HEAD-INJURY; PATIENT	Previous reports on the incidence of heterotopic ossification (HO) in children and adolescents with traumatic brain injury (TBI) have ranged from 3% to 20%. These studies mention HO briefly or address patient cohorts with coma more than three months. We reviewed the medical records of 90 children younger than 19 years old, who were comatose more than 24 hours after TBI. Mean followup was 33.1 months (range = 2 to 128 months). Incidence of HO was 14.4% (n = 13). One to five sites were involved, with hip and knee most frequent, followed by shoulder, elbow, and nonjoint sites. Children with HO were older than 11 years (relative risk [RR] = 18.85, confidence interval [CI] = 3.7, 95.7), had a greater length of coma (RR = 7.22, CI = 1.4, 37.1), and had a greater associated risk for poor functional outcome (RR = 2.89, CI = 1.02, 7.9) compared to those without RO. Multiple limb fractures showed a trend toward association with increased incidence of HO. Other factors, including gender, history of skull fracture, brain CAT scan findings, and presence of spasticity, were not predictive of HO. Eleven children were treated with etidronate, four with nonsteroidal antiinflammatory drugs, and one with surgery. Only three children had residual functional impairments attributed to the presence of HO.	UNIV MICHIGAN,MED CTR,DEPT PHYS MED & REHABIL,ANN ARBOR,MI 48109	HURVITZ, EA (corresponding author), VET AFFAIRS MED CTR,REHABIL MED SERV,2215 FULLER RD,ANN ARBOR,MI 48105, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS001120] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS-01120-03] Funding Source: Medline		ALEXANDER MA, 1990, ARCH PHYS MED REHAB, V71, P769; BRINK JD, 1978, ORTHOP CLIN N AM, V9, P451; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BURING K, 1975, CLIN ORTHOP RELAT R, V110, P293; CHIODO AE, 1987, ARCH PHYS MED REHAB, V68, P645; DOCZI T, 1982, NEUROSURGERY, V10, P685, DOI 10.1227/00006123-198206010-00001; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; EVANS EB, 1968, J AMER MED ASSOC, V204, P843, DOI 10.1001/jama.204.10.843; FREED JH, 1982, PARAPLEGIA, V20, P208, DOI 10.1038/sc.1982.39; GARCIAMORTEO O, 1983, J BONE JOINT SURG AM, V65, P812, DOI 10.2106/00004623-198365060-00013; GARLAND DE, 1984, ARCH PHYS MED REHAB, V65, P531; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; GARLAND DE, 1988, CLIN ORTHOP RELAT R, V233, P86; HOFFER MM, 1975, CLIN ORTHOPAEDICS, V110, P244; MIELANTS H, 1975, ACTA ORTHOP SCAND, V46, P190, DOI 10.3109/17453677508989207; MINAIRE P, 1980, ARCH PHYS MED REHAB, V61, P214; MITAL MA, 1987, J PEDIATR ORTHOPED, V7, P83, DOI 10.1097/01241398-198701000-00017; Ommaya A K, 1966, Ann R Coll Surg Engl, V39, P317; RITTER MA, 1987, ORTHOPEDICS, V10, P1379; SAZBON L, 1981, J BONE JOINT SURG BR, V63, P120; SAZBON L, 1982, SCAND J REHABIL MED, V15, P43; SHAPIRO K, 1983, PEDIATRIC HEAD TRAUM; SHAUL PW, 1985, AM J DIS CHILD, V139, P467, DOI 10.1001/archpedi.1985.02140070041029; 1985, SAS USERS GUIDE STAT, P403	24	33	36	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	1992	73	5					459	462					4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	HU709	WOS:A1992HU70900011	1580774				2021-06-18	
J	YUAN, XQ; WADE, CE; CLIFFORD, CB				YUAN, XQ; WADE, CE; CLIFFORD, CB			SUPPRESSION BY TRAUMATIC BRAIN INJURY OF SPONTANEOUS HEMODYNAMIC RECOVERY FROM HEMORRHAGIC-SHOCK IN RATS	JOURNAL OF NEUROSURGERY			English	Article						BRAIN INJURY; FLUID-PERCUSSION INJURY; HEMORRHAGIC SHOCK; CATECHOLAMINE; ALDOSTERONE; RAT	FLUID-PERCUSSION MODEL; HEAD-INJURY; LACTIC-ACIDOSIS; ANGIOTENSIN-II; MORTALITY; ACTH; TRH	The effects of brain trauma on cardiovascular and endocrine responses to hemorrhage were investigated. Forty anesthetized rats were randomly assigned to one of four groups of 10 rats each: a control group (Group C); a group with induction of hemorrhage at 16.2 ml/kg/10 min (Group H); a group with fluid-percussion brain injury at a peak pressure of 1.7 atm and an impulse duration of 25 msec (Group T); and a group receiving hemorrhagic shock following brain trauma (Group TH). Group C and T rats showed no significant alterations in cardiovascular function. At the end of hemorrhage there were no significant differences between Groups TH and H in the nadirs of mean arterial blood pressure (MABP) (mean values +/- standard error of the mean: 42 +/- 2 vs. 40 +/- 4 mm Hg) and stroke volume index (SVI) (0.61 +/- 0.11 vs. 0.66 +/- 0.10 ml/bt/kg); however, 1 hour post-hemorrhage recovery was blunted in Group TH compared to Group H (MABP 56 +/- 4 vs. 65 +/- 3 mm Hg; cardiac index 182 +/- 15 vs. 220 +/- 15 ml/min/kg; and SVI 0.71 +/- 0.06 vs. 0.81 +/- 0.06 ml/bt/kg). Since the two groups showed no significant differences in heart rate, preload (central venous pressure), and afterload (systemic vascular resistance), the reduced cardiac index recovery in Group TH is believed due to the attenuation of cardiac contractile performance. The Group TH preparation potentiated hormonal responses to hemorrhage with significantly higher epinephrine and aldosterone levels than in Group H. Brain trauma enhanced the norepinephrine response to hemorrhage, even at an injury level that by itself did not result in an increase in this hormone. Group TH rats also had significantly lower blood pH and HCO3 levels. The data suggest that brain trauma suppresses MABP and cardiac index recovery after hemorrhage mainly by inhibiting cardiac contractile performance, probably due to high catecholamine levels and severe metabolic acidosis.	LETTERMAN ARMY INST RES,DIV MIL TRAUMA RES,SAN FRANCISCO,CA 94129							Altman PL, 1974, BIOL DATA BOOK, VIII; BERNTON EW, 1985, ANN EMERG MED, V14, P729, DOI 10.1016/S0196-0644(85)80047-0; CHEN V, 1990, AM J PHYSIOL, V258, pH101; CLIFTON GL, 1981, NEUROSURGERY, V8, P309, DOI 10.1227/00006123-198103000-00002; CRUICKSHANK JM, 1988, POSTGRAD MED, P140; DAVIES AO, 1984, J CLIN ENDOCR METAB, V59, P398, DOI 10.1210/jcem-59-3-398; DAVIS RA, 1984, SURG GYNECOL OBSTET, V159, P597; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EISENBERG H, 1983, INTRACRANIAL PRESSUR, P549; GUYTON AC, 1986, TXB MED PHYSL, P206; HINDMAN BJ, 1990, ANESTHESIOLOGY, V72, P1064, DOI 10.1097/00000542-199006000-00018; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; MACKENZIE ET, 1979, STROKE, V10, P711, DOI 10.1161/01.STR.10.6.711; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1986, ANN EMERG MED, V15, P1462, DOI 10.1016/S0196-0644(86)80944-1; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MCINTOSH TK, 1986, CIRC SHOCK, V18, P241; MCLEOD AA, 1982, BRIT HEART J, V47, P221; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; NEWFIELD P, 1980, CRIT CARE MED, V8, P254, DOI 10.1097/00003246-198004000-00123; PILATI CF, 1990, P SOC EXP BIOL MED, V193, P225; POPP AJ, 1982, J SURG RES, V32, P416, DOI 10.1016/0022-4804(82)90121-4; PROCTOR HJ, 1988, J TRAUMA, V28, P347, DOI 10.1097/00005373-198803000-00010; RAFF H, 1985, AM J PHYSIOL, V249, pR611; RAFF H, 1986, AM J PHYSIOL, V250, pR240; REICHENBACH DD, 1970, HUM PATHOL, V1, P125; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; SALTER G, 1977, ANN SURG, V181, P1; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; STENING WA, 1986, AUST NZ J SURG, V56, P549, DOI 10.1111/j.1445-2197.1986.tb07098.x; WADE CE, 1986, AM J PHYSIOL, V250, pR287; WADE CE, 1980, J APPL PHYSIOL, V49, P930; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	34	33	34	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	SEP	1991	75	3					408	414		10.3171/jns.1991.75.3.0408			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GC311	WOS:A1991GC31100013	1651379				2021-06-18	
J	GALLETTI, P; DEROSA, M; COTTICELLI, MG; MORANA, A; VACCARO, R; ZAPPIA, V				GALLETTI, P; DEROSA, M; COTTICELLI, MG; MORANA, A; VACCARO, R; ZAPPIA, V			BIOCHEMICAL RATIONALE FOR THE USE OF CDPCHOLINE IN TRAUMATIC BRAIN INJURY - PHARMACOKINETICS OF THE ORALLY-ADMINISTERED DRUG	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article; Proceedings Paper	MEETING ON PHARMACOLOGY OF TRAUMATIC BRAIN INJURY	JUN 22-23, 1990	TOLEDO, SPAIN	WORLD FEDERAT NEUROL			CDP-CHOLINE; ISCHEMIA; BIOSYNTHESIS; METABOLISM	A pharmacokinetic analysis of CDPcholine has been carried out treating either rats or dogs by oral administration with the double labelled molecule. [methyl-C-14, 5-H-3]CDPcholine represents a useful tool to test the structural integrity of this compound during the transmembrane transport and to follow the metabolic fate of cytidine and choline fragments. Furthermore, the identification of the labelled metabolites of the exogenously administered CDPcholine in the various organs allows us to draw interferences about its pharmacological mechanism(s). These studies appear of great interest in view of the extensive therapeutic use of the molecule in the treatment of several CNS pathologies including traumatic brain injury. The results of this work can be summarized as follows. (a) The molecule is rapidly cleaved at the level of the pyrophosphate bridge and a fast uptake of the hydrolytic products occurs. (b) The metabolism of the molecule is characterized by a differential utilization of the two moieties by the various organs. Liver is the most active organ in utilizing CDPcholine with a preferential uptake of the choline fragment. (c) The [H-3]cytidine moiety, in all the organs examined, appears to be incorporated into the nucleic acid fraction via the cytidine nucleotide pool. The [C-14]choline moiety is in part converted into betaine, which in turn acts as methyl donor to homocysteine, yielding [C-14]methionine, subsequently incorporated into proteins. The time-dependent increase in the labelling of phospholipids is indicative of a recycling of choline methyl groups via CDPcholine and/or S-adenosylmethionine. (d) The uptake of CDPcholine by the brain is relatively low; however, a good metabolic utilization of the drug can be observed. The salvage of the choline moiety in de novo phospholipid biosynthesis is indeed highly operative in this organ.		GALLETTI, P (corresponding author), NAPLES UNIV,SCH MED 1,DEPT BIOCHEM MACROMOLECULES,VIA COSTANTINOPOLI 16,I-80138 NAPLES,ITALY.		Morana, Alessandra/AAX-8200-2020	De Rosa, Mario/0000-0002-2976-0818; MORANA, ALESSANDRA/0000-0003-3189-2526			ALBERGHINA M, 1981, J NEUROSCI RES, V6, P421, DOI 10.1002/jnr.490060316; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BOISMARE F, 1978, PHARMACOLOGY, V17, P15, DOI 10.1159/000136830; DEROSA M, 1985, NOVEL BIOCH PHARM CL, P139; DORMAN RV, 1982, PHOSPHOLIPIDS NERVOU, P132; FINKELSTEIN JD, 1980, TRANSMETHYLATION, P49; FIORAVANTI M, 1983, CEREBRAL PATHOLOGY O, P343; GALLETTI P, 1985, BIOCHEM PHARMACOL, V34, P4121, DOI 10.1016/0006-2952(85)90204-7; KAKIHANA M, 1988, STROKE, V19, P917; KENNEDY EP, 1957, FED PROC, V16, P847; KHORANA HG, 1954, J AM CHEM SOC, V76, P3617; LOEB C, 1985, NOVEL BIOCH PHARM CL, P339; MCMURRAY WC, 1972, ANNU REV BIOCHEM, V41, P129, DOI 10.1146/annurev.bi.41.070172.001021; MILLER LL, 1951, J EXP MED, V94, P431, DOI 10.1084/jem.94.5.431; PECKER J, 1980, LOUEST MED, V33, P1075; RIGOULET M, 1979, J NEUROCHEM, V32, P535, DOI 10.1111/j.1471-4159.1979.tb00381.x; ROMEO G, 1981, B SOC ITAL BIOL SPER, V62, P1175; TROVARELLI G, 1981, NEUROCHEM RES, V6, P821, DOI 10.1007/BF00965041; VANCE DE, 1979, TRENDS BIOCHEM SCI, V4, P145, DOI 10.1016/0968-0004(79)90001-X	19	33	33	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	JUL	1991	103			S			S19	S25					7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	GF379	WOS:A1991GF37900004	1940961				2021-06-18	
J	PFENNINGER, EG; LINDNER, KH				PFENNINGER, EG; LINDNER, KH			ARTERIAL BLOOD-GASES IN PATIENTS WITH ACUTE HEAD-INJURY AT THE ACCIDENT SITE AND UPON HOSPITAL ADMISSION	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						ACIDOSIS; GLASGOW-COMA-SCALE; HEAD INJURY; HYPERCAPNIA; HYPOXIA	TRAUMA; MODEL; FLOW	Prior to the start of supportive therapy at the site of the accident, arterial blood samples from 47 patients with acute head injury were taken for blood gas analysis. At the same time, the degree of unconsciousness was assessed using the Glasgow-Coma-Scale. After transport to the hospital, arterial blood gases and the level of unconsciousness were again determined. A very close correlation was found between the initial depth of unconsciousness and the degree of hypercapnia (R = -0.90). Patients with head injury and other multiple injuries did not differ in this respect (R = -0.95) from those with isolated head injury. The correlation between Pao2 and the degree of unconsciousness was less well defined, and the results showed a greater degree of scatter (R = 0.54). The acidosis observed resulted mainly from the rise in Paco2. The absence of any correlation between the base excess and the Glasgow-Coma-Scale levels (R = 0.27) makes a common metabolic derangement unlikely. As a result of intubation and controlled ventilation, the hypercapnia of the comatose patients had been corrected, and a correlation could no longer be found between the Glasgow-Coma-Scale level and the Paco2. In order to avoid hypoventilation, which carries with it the danger of a rise in intracranial pressure, all patients with severe head injury should be intubated and ventilated as soon as possible after the accident.	UNIV ULM,ANAESTHESIOL CLIN,W-7900 ULM,GERMANY							Brown F. D., 1982, HEAD INJURY BASIC CL, P151; CROCKARD HA, 1977, J NEUROSURG, V46, P776, DOI 10.3171/jns.1977.46.6.0776; CROCKARD HA, 1977, J NEUROSURG, V46, P783; FROMAN C, 1968, BRIT J ANAESTH, V40, P354, DOI 10.1093/bja/40.5.354; FROST EAM, 1979, J NEUROSURG, V50, P768, DOI 10.3171/jns.1979.50.6.0768; GENTLEMAN D, 1990, LANCET, V335, P330, DOI 10.1016/0140-6736(90)90615-C; GRUBB RL, 1974, STROKE, V5, P630, DOI 10.1161/01.STR.5.5.630; HEMMER M, 1985, B EUR PHYSIOPATH RES, V21, P287; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; KATSURADA K, 1973, SURGERY, V73, P191; KOHI YM, 1984, INJURY, V16, P25, DOI 10.1016/0020-1383(84)90110-4; LASSEN NA, 1976, BRIT J ANAESTH, V48, P719, DOI 10.1093/bja/48.8.719; MACIVER IN, 1958, LANCET, V1, P390; MILLEN JE, 1985, J NEUROSURG, V62, P587, DOI 10.3171/jns.1985.62.4.0587; NAERAA N, 1983, ACTA ANAESTH SCAND, V7, P191; NILSSON B, 1977, J NEUROSURG, V47, P241, DOI 10.3171/jns.1977.47.2.0241; NORTH JB, 1974, ARCH NEUROL-CHICAGO, V13, P338; Pfenninger E, 1986, Aktuelle Traumatol, V16, P1; RIMMEL R, 1979, JACEP, V8, P64; SCHMITZ JE, 1982, NOTFALLMEDIZIN, V8, P892; TEASDALE G, 1976, BRIT J ANAESTH, V48, P761, DOI 10.1093/bja/48.8.761; VICARIO SJ, 1983, ANN EMERG MED, V12, P145, DOI 10.1016/S0196-0644(83)80554-X	22	33	33	0	0	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	FEB	1991	35	2					148	152		10.1111/j.1399-6576.1991.tb03263.x			5	Anesthesiology	Anesthesiology	EY354	WOS:A1991EY35400010	2024564				2021-06-18	
J	LEVIN, HS; HIGH, WM; WILLIAMS, DH; EISENBERG, HM; AMPARO, EG; GUINTO, FC; EWERT, J				LEVIN, HS; HIGH, WM; WILLIAMS, DH; EISENBERG, HM; AMPARO, EG; GUINTO, FC; EWERT, J			DICHOTIC-LISTENING AND MANUAL PERFORMANCE IN RELATION TO MAGNETIC-RESONANCE IMAGING AFTER CLOSED HEAD-INJURY	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article									UNIV TEXAS,MED BRANCH,DEPT RADIOL,GALVESTON,TX 77550; UNIV HOUSTON,DEPT PSYCHOL,HOUSTON,TX 77004	LEVIN, HS (corresponding author), UNIV TEXAS,MED BRANCH,DIV NEUROSURG,D-73,GALVESTON,TX 77550, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 21889] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS021889] Funding Source: NIH RePORTER		ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ALEXANDER MP, 1988, NEUROLOGY, V38, P802, DOI 10.1212/WNL.38.5.802; BENTIN S, 1984, NEUROPSYCHOLOGIA, V22, P601, DOI 10.1016/0028-3932(84)90024-1; CHESTER CS, 1987, ANN NEUROL, V22, P77; DAMASIO H, 1979, NEUROLOGY, V29, P644, DOI 10.1212/WNL.29.5.644; DIMOND SJ, 1977, BRAIN, V100, P543, DOI 10.1093/brain/100.3.543; GEFFEN G, 1984, PSYCHOL BULL, V96, P273, DOI 10.1037/0033-2909.96.2.273; JACOBSON JT, 1983, EAR HEARING, V4, P311, DOI 10.1097/00003446-198311000-00009; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVIN HS, 1981, BRAIN LANG, V12, P360, DOI 10.1016/0093-934X(81)90025-0; LHERMITTE J, 1929, REV NEUROL PARIS, V2, P703; LINDENBERG R, 1955, AM J PATHOL, V31, P297; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PANDYA DN, 1971, BRAIN RES, V32, P31, DOI 10.1016/0006-8993(71)90153-3; RUBENS AB, 1977, ARCH NEUROL-CHICAGO, V34, P750, DOI 10.1001/archneur.1977.00500240038006; RUBENS AB, 1985, ANN NEUROL, V18, P459, DOI 10.1002/ana.410180408; Sparks R., 1968, CORTEX, V4, P3, DOI DOI 10.1016/S0010-9452(68)80009-7; Spreen O, 1969, NEUROSENSORY CTR COM; SPRINGER SP, 1975, NEUROPSYCHOLOGIA, V13, P341, DOI 10.1016/0028-3932(75)90011-1; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1970, PATHOLOGY TRAUMA, P166; TEASDALE G, 1974, LANCET, V2, P81; WALE J, 1986, NEUROPSYCHOLOGIA, V24, P483, DOI 10.1016/0028-3932(86)90093-X; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	28	33	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	OCT	1989	52	10					1162	1169		10.1136/jnnp.52.10.1162			8	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	AV315	WOS:A1989AV31500007	2795042	Bronze, Green Published			2021-06-18	
J	STEWART, JT; HEMSATH, RH				STEWART, JT; HEMSATH, RH			BIPOLAR ILLNESS FOLLOWING TRAUMATIC BRAIN INJURY - TREATMENT WITH LITHIUM AND CARBAMAZEPINE	JOURNAL OF CLINICAL PSYCHIATRY			English	Article									UNIV FLORIDA,GAINESVILLE,FL 32611	STEWART, JT (corresponding author), VET ADM MED CTR,PSYCHIAT SERV 116A,GAINESVILLE,FL 32602, USA.						BUNNEY WE, 1978, PSYCHOPHARMACOLOGY G, P1249; COHN CK, 1977, DIS NERV SYST, V38, P630; CUMMINGS JL, 1984, AM J PSYCHIAT, V141, P1084; FORREST DV, 1982, ARCH GEN PSYCHIAT, V39, P817; HALE MS, 1982, J NERV MENT DIS, V170, P362, DOI 10.1097/00005053-198206000-00006; JAMPALA VC, 1983, AM J PSYCHIAT, V140, P1197; KRAUTHAMMER C, 1978, ARCH GEN PSYCHIAT, V35, P1333; REISS H, 1987, J CLIN PSYCHIAT, V48, P29; ROSENTHAL M, 1984, REHABILITATION HEAD, P3; SHUKLA S, 1987, AM J PSYCHIAT, V144, P93	10	33	34	0	0	PHYSICIANS POSTGRADUATE PRESS	MEMPHIS	P O BOX 240008, MEMPHIS, TN 38124	0160-6689			J CLIN PSYCHIAT	J. Clin. Psychiatry	FEB	1988	49	2					74	75					2	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	M1311	WOS:A1988M131100009	3123468				2021-06-18	
J	FULD, PA; FISHER, P				FULD, PA; FISHER, P			RECOVERY OF INTELLECTUAL ABILITY AFTER CLOSED HEAD-INJURY	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article									JACOBI HOSP,BRONX,NY 10461							BLACK P, 1971, APR P INT S HEAD INJ; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; COSTA LOUIS D., 1964, PERCEPT MOT SKILLS, V18, P748; DENCKER SJ, 1958, ACTA PSYCHIATRI S122, V33; DILLON H, 1961, JAMA-J AM MED ASSOC, V175, P86, DOI 10.1001/jama.1961.03040020012003; FORD FR, 1973, DISEASES NERVOUS SYS; GRONWALL, 1974, LANCET, V2, P605; HJERN B, 1964, ACTA PEDIATRICA S152; Jacobson SA, 1963, POSTTRAUMATIC SYNDRO; LEWIN W, 1966, MANAGEMENT HEAD INJU; MACGINITIE W, 1973, PROBLEMS ASSESSMENT, P35; MEALEY J, 1968, PEDIATRIC HEAD INJUR; NAUGHTON JAL, 1971, 1970 P INT S HEAD IN; RICHARDSON F, 1963, DEV MED CHILD NEUROL, V5, P471; Ruesch J, 1944, AM J PSYCHIAT, V100, P480, DOI 10.1176/ajp.100.4.480; SHAFFER D, 1975, OUTCOME SEVERE DAMAG; SYMONDS C, 1962, LANCET, V1, P1	17	33	33	0	0	CAMBRIDGE UNIV PRESS	NEW YORK	40 WEST 20TH STREET, NEW YORK, NY 10011-4211	0012-1622			DEV MED CHILD NEUROL	Dev. Med. Child Neurol.		1977	19	4					495	502					8	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	DR293	WOS:A1977DR29300009	892246				2021-06-18	
J	KERR, A; EICH, RH				KERR, A; EICH, RH			CEREBRAL CONCUSSION AS A CAUSE OF COUGH SYNCOPE	ARCHIVES OF INTERNAL MEDICINE			English	Article																Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; ENGEL GS, 1950, PPC; GURDJIAN ES, 1958, NEUROLOGY, V8, P819; Hamilton WF, 1944, AM J PHYSIOL, V141, P0042; KERR A, 1953, ANN INTERN MED, V39, P1240, DOI 10.7326/0003-4819-39-6-1240; LARSSON LE, 1954, ACTA PSYCHIAT SC S95, P1; MCINTOSH HD, 1956, AM HEART J, V52, P70, DOI 10.1016/0002-8703(56)90119-3; MEYER JS, 1955, ELECTROEN CLIN NEURO, V7, P529, DOI 10.1016/0013-4694(55)90078-X; Rossen R, 1943, ARCH NEURO PSYCHIATR, V50, P510; Scott WW, 1940, ARCH NEURO PSYCHIATR, V43, P270, DOI 10.1001/archneurpsyc.1940.02280020078006; SHARPEYSCHAFER EP, 1953, BRIT MED J, V2, P860, DOI 10.1136/bmj.2.4841.860	11	33	34	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0003-9926			ARCH INTERN MED	Arch. Intern. Med.		1961	108	2					248	&		10.1001/archinte.1961.03620080080008			0	Medicine, General & Internal	General & Internal Medicine	5561A	WOS:A19615561A00007	13752173				2021-06-18	
J	Groat, RA; Magoun, HW; Dey, FL; Windle, WF				Groat, RA; Magoun, HW; Dey, FL; Windle, WF			Functional alterations in motor and supranuclear mechanisms in experimental concussion	AMERICAN JOURNAL OF PHYSIOLOGY			English	Article									NW Univ, Med Sch, Inst Neurol, Chicago, IL USA; NW Univ, Med Sch, Dept Anat, Chicago, IL USA							CLARK SL, 1943, COMMUNICATION; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DURET H, 1920, TRAUMATISMES CRANI 1, V2, P161; GURDJIAN ES, 1943, SURG GYNECOL OBSTET, V76, P623; Scott WW, 1940, ARCH NEURO PSYCHIATR, V43, P270, DOI 10.1001/archneurpsyc.1940.02280020078006; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223; WILLIAMS DJ, 1941, NEUROL PSYCHIAT, V4, P107	7	33	33	0	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0002-9513			AM J PHYSIOL	Am. J. Physiol.	MAR	1944	141	1					0117	0127					11	Physiology	Physiology	V37QQ	WOS:000202544400019					2021-06-18	
J	Schaller, WF				Schaller, WF			After-effects of head injury - The post-traumatic concussioin state (concussion traumatic encephalopathy) and the post-traumatic psychoneurotic state (psychoneurosis, hysteria) A study in differential diagnosis	JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																Aring CD, 1937, J AMER MED ASSOC, V109, P1092, DOI 10.1001/jama.1937.02780400008003; Cassasa CB, 1924, P NEW YORK PATH SOC, P101; CLAUDE H, 1927, ANN MED LEG, V4, P393; DURET H, 1877, GAZ MED PARIS, P598; GUSSENBAUER C, 1880, DTSCH Z CHIR, V15, P47; Hall GW, 1934, J AMER MED ASSOC, V102, P510, DOI 10.1001/jama.1934.02750070008002; HALL GW, 1934, JAMA-J AM MED ASSOC, V102, P513; HUDDLESON JH, 1932, ACCIDENTS NEUROSES C; JAKOB A, 1913, HISTOLOGISCHE HISTOP, V5, P182; JONES A, 1917, MALINGERING PHILADEL; KOCH W, 1874, ARCH KLIN CHIR, V17, P231; KOCH W, 1874, ARCH KLIN CHIR, V17, P190; KOCHER T, 1901, SPEZIELLE PATHOLOG 3, V9; KOCHER T, 1892, DTSCH Z CHIR, V35, P433; KOLLMANN M, 1926, DTSCH MED WCHNSCHR, V52, P1814; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; Martland HS, 1929, ARCH NEURO PSYCHIATR, V22, P1001, DOI 10.1001/archneurpsyc.1929.02220050139008; MUINIO D, 1939, OXFORD LOOSE LEAF ME, V6, P136; OPPENHEIM H, 1889, TRAUNIATISCHEN NEURO; OSNATO M, 1927, PHENOMENA ARCH NEURO, V18, P181; RAND CARL W., 1932, ARCH NEUROL AND PSYCHIATR, V27, P605; RAND CW, 1932, ARCH NEUROL PSYCHIAT, V27, P1342; RAND CW, 1932, ARCH NEUROL PSYCHIAT, V27, P644; Ricker G, 1919, VIRCHOWS ARCH A, V226, P180, DOI 10.1007/BF02039959; Rosanoff A J, 1929, Cal West Med, V30, P197; Scagliosi G., 1898, VIRCHOWS ARCH, V152, P487; Schaller WF, 1918, J AMER MED ASSOC, V71, P338, DOI 10.1001/jama.1918.02600310016006; SCHALLER WF, 1929, JAMA-J AM MED ASSOC, V93, P971; SCHALLER WF, 1937, ARCH NEUROL PSYCHIAT, V37, P1076; SCHALLER WF, 1929, JAMA-J AM MED ASSOC, V93, P967; Schaller WT, 1937, ARCH NEURO PSYCHIATR, V37, P1048, DOI 10.1001/archneurpsyc.1937.02260170076004; SCHMAUS H, 1890, VIRCHOWS ARCH PATH A, V122, P470; Schwab SI, 1919, ARCH NEURO PSYCHIATR, V1, P579, DOI 10.1001/archneurpsyc.1919.02180050064007; Smith SK, 1933, AM J PSYCHIAT, V13, P57; Wechsler IS, 1935, J AMER MED ASSOC, V104, P519, DOI 10.1001/jama.1935.02760070001001	35	33	33	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0002-9955			J AMER MED ASSOC	J. Am. Med. Assoc.	OCT-DEC	1939	113						1779	1785					7	Medicine, General & Internal	General & Internal Medicine	V24LH	WOS:000201651700128					2021-06-18	
J	Donnelly, J; Czosnyka, M; Adams, H; Cardim, D; Kolias, AG; Zeiler, FA; Lavinio, A; Aries, M; Robba, C; Smielewski, P; Hutchinson, PJA; Menon, DK; Pickard, JD; Budohoski, KP				Donnelly, Joseph; Czosnyka, Marek; Adams, Hadie; Cardim, Danilo; Kolias, Angelos G.; Zeiler, Frederick A.; Lavinio, Andrea; Aries, Marcel; Robba, Chiara; Smielewski, Peter; Hutchinson, Peter J. A.; Menon, David K.; Pickard, John D.; Budohoski, Karol P.			Twenty-Five Years of Intracranial Pressure Monitoring After Severe Traumatic Brain Injury: A Retrospective, Single-Center Analysis	NEUROSURGERY			English	Article						Traumatic brain injury; Intracranial pressure; Cerebral hemodynamics; Autoregulation; Outcome	CEREBRAL PERFUSION-PRESSURE; CEREBROVASCULAR REACTIVITY; DECOMPRESSIVE CRANIECTOMY; HEAD-INJURY; MANAGEMENT; AUTOREGULATION; BEDSIDE; CARE; THRESHOLDS; TRIAL	BACKGROUND Intracranial pressure (ICP) is a clinically important variable after severe traumatic brain injury (TBI) and has been monitored, along with clinical outcome, for over 25 yr in Addenbrooke's hospital, Cambridge, United Kingdom. This time period has also seen changes in management strategies with the implementation of protocolled specialist neurocritical care, expansion of neuromonitoring techniques, and adjustments of clinical treatment targets. OBJECTIVE To describe the changes in intracranial monitoring variables over the past 25 yr. METHODS Data from 1146 TBI patients requiring ICP monitoring were analyzed. Monitored variables included ICP, cerebral perfusion pressure (CPP), and the cerebral pressure reactivity index (PRx). Data were stratified into 5-yr epochs spanning the 25 yr from 1992 to 2017. RESULTS CPP increased sharply with specialist neurocritical care management (P<0.0001) (introduction of a specific TBI management algorithm) before stabilizing from 2000 onwards. ICP decreased significantly over the 25 yr of monitoring from an average of 19 to 12 mmHg (P<0.0001) but PRx remained unchanged. The mean number of ICP plateau waves and the number of patients developing refractory intracranial hypertension both decreased significantly. Mortality did not significantly change in the cohort (22%). CONCLUSION We demonstrate the evolving trends in neurophysiological monitoring over the past 25 yr from a single, academic neurocritical care unit. ICP and CPP were responsive to the introduction of an ICP/CPP protocol while PRx has remained unchanged.	[Donnelly, Joseph; Czosnyka, Marek; Adams, Hadie; Cardim, Danilo; Kolias, Angelos G.; Aries, Marcel; Smielewski, Peter; Hutchinson, Peter J. A.; Pickard, John D.; Budohoski, Karol P.] Univ Cambridge, Brain Phys Lab, Div Neurosurg, Dept Clin Neurosci,Addenbrookes Hosp, Cambridge, England; [Donnelly, Joseph] Univ Auckland, Dept Anaesthesiol, Auckland, New Zealand; [Czosnyka, Marek] Warsaw Univ Technol, Inst Elect Syst, Warsaw, Poland; [Cardim, Danilo] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver Gen Hosp, Vancouver, BC, Canada; [Kolias, Angelos G.; Hutchinson, Peter J. A.; Menon, David K.; Budohoski, Karol P.] Univ Cambridge Cambridge, NIHR Global Hlth Res Grp Neurotrauma, Cambridge, England; [Zeiler, Frederick A.; Lavinio, Andrea; Robba, Chiara; Menon, David K.] Univ Cambridge, Div Anaesthesia, Dept Med, Cambridge, England; [Zeiler, Frederick A.] Univ Manitoba, Rady Fac Hlth Sci, Dept Surg, Winnipeg, MB, Canada; [Zeiler, Frederick A.] Univ Manitoba, Rady Fac Hlth Sci, Clinician Investigator Program, Winnipeg, MB, Canada; [Aries, Marcel] Maastricht Univ, Med Ctr, Dept Intens Care, Univ Maastricht, Maastricht, Netherlands; [Robba, Chiara] Univ Genoa, IRCCS Oncol, Policlin San Martino, Dept Anaesthesia & Intens Care, Genoa, Italy; [Hutchinson, Peter J. A.; Pickard, John D.; Budohoski, Karol P.] Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Addenbrookes Hosp, Cambridge, England	Donnelly, J (corresponding author), Univ Auckland, Dept Anaesthesiol, Auckland City Hosp, Level 12 Auckland Support Bldg,2 Pk Rd, Auckland, New Zealand.	donnellyj87@gmail.com	Cardim, Danilo Augusto/B-8447-2012; Donnelly, Joseph/N-6803-2019; Robba, Chiara/AAS-7421-2020	Cardim, Danilo Augusto/0000-0002-9261-1321; Donnelly, Joseph/0000-0002-6502-8069; Zeiler, Frederick/0000-0003-1737-0510; Hutchinson, Peter/0000-0002-2796-1835; Kolias, Angelos/0000-0003-3992-0587	National Institute for Healthcare Research (NIHR, UK) through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre, an NIHR Senior Investigator Award; NIHR Research Professorship; Woolf Fisher Scholarship (New Zealand); European Union Framework Program 7 grant (CENTER-TBI) [602150]; National Institute of Health Research Medtech; In vitro diagnostics co-operatives in Cambridge	These studies were supported by National Institute for Healthcare Research (NIHR, UK) through the Acute Brain Injury and Repair theme of the Cambridge NIHR Biomedical Research Centre, an NIHR Senior Investigator Award to Dr Menon, and an NIHR Research Professorship to Dr Hutchinson. Dr Donnelly is supported by a Woolf Fisher Scholarship (New Zealand). Dr Zeiler has received salary support for dedicated research time from the Cambridge Commonwealth Trust Scholarship, the University of Manitoba Clinician Investigator Program, and the Royal College of Surgeons of Canada-Harry S. Morton Travelling Fellowship in Surgery, during which this project was completed. Dr Hutchinson andDrMenon were also supported by a European Union Framework Program 7 grant (CENTER-TBI; Grant Agreement No. 602150). Dr Zeiler and Dr Cardim have received PhD funding from the Cambridge Commonwealth Trust. Dr Kolias, Dr Hutchinson, Dr Menon, and Dr Budohoski declare funding from the NIHR Global Health Research Group on Neurotrauma, which was commissioned by the NIHR using Official Development Assistance (ODA) funding (project 16/137/105). The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, National Institute for Health Research or the Department of Health. The authors have the following potential conflicts of interest: Dr Czosnyka receives part of licensing fees for ICM+, owned and distributed by Cambridge Enterprise Ltd; paid lectures for Integra Lifescience Speakers' Bureau; and is partially supported by National Institute of Health Research Medtech and In vitro diagnostics co-operatives in Cambridge. Dr Smielewski receives part of the licensing fees for the software ICM (Cambridge Enterprise Ltd, Cambridge UK), used in this project for data collection and data preprocessing. The other authors have no personal, financial, or institutional interest in any of the drugs, materials, or devices described in this article. Dr Menon has had consultancy, research collaboration, or trial data monitoring interactions with Solvay Ltd; GlaxoSmithKline Ltd; Brainscope Ltd; Ornim Medical; Shire Medical, and Neurovive Ltd; Calico Inc; Pfizer Ltd; Pressura Ltd; Glide Pharma Ltd; and NeuroPro Ltd.	Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Beck B, 2018, J NEUROTRAUM, V35, P1021, DOI 10.1089/neu.2017.5287; Brady KM, 2008, STROKE, V39, P2531, DOI 10.1161/STROKEAHA.108.514877; Brady KM, 2009, PEDIATRICS, V124, pE1205, DOI 10.1542/peds.2009-0550; Bratton S, 2007, J NEUROTRAUM, V24, P59, DOI DOI 10.1089/neu.2007.9987; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Bullock R., 1996, EUR J EMERG MED, V3, P109, DOI 10.1097/00063110-199606000-00010; BUXTON RL, 1970, LANCET, V2, P498; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; CZOSNYKA M, 1994, INT J CLIN MONIT COM, V11, P223, DOI 10.1007/BF01139874; Czosnyka M, 1997, J NEUROL NEUROSUR PS, V63, P721, DOI 10.1136/jnnp.63.6.721; Dias C, 2015, NEUROCRIT CARE, V23, P92, DOI 10.1007/s12028-014-0103-8; Donnelly J, 2017, J CEREBR BLOOD F MET, V37, P694, DOI 10.1177/0271678X16639060; Donnelly J, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1293-6; Donnelly J, 2015, NEUROCRIT CARE, V22, P20, DOI 10.1007/s12028-014-0042-4; Donnelly J, 2015, EXPERT REV NEUROTHER, V15, P169, DOI 10.1586/14737175.2015.996552; Fuller G, 2011, BRIT J NEUROSURG, V25, P414, DOI 10.3109/02688697.2011.570882; Gerber LM, 2013, J NEUROSURG, V119, P1583, DOI 10.3171/2013.8.JNS13276; GUILLAUME J, 1951, PRESSE MED, V59, P953; Guiza F, 2015, INTENS CARE MED, V41, P1067, DOI 10.1007/s00134-015-3806-1; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Lavinio A, 2007, BRIT J ANAESTH, V99, P237, DOI 10.1093/bja/aem118; Lawrence T, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-012197; Lazaridis C, 2014, J NEUROSURG, V120, P893, DOI 10.3171/2014.1.JNS131292; Le Roux P, 2014, INTENS CARE MED, V40, P1189, DOI 10.1007/s00134-014-3369-6; Lewis PM, 2015, PEDIATR CRIT CARE ME, V16, P739, DOI 10.1097/PCC.0000000000000471; Lundberg N., 1959, ACTA PSYCHIAT SCAND, V36, P1; McCullough AL, 2014, BRIT J ANAESTH, V113, P202, DOI 10.1093/bja/aeu204; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; PRICE DJ, 2012, INTRACRANIAL PRESSUR, V14, P1; R Core Team, 2017, R LANG ENV STAT COMP; Rao V, 2013, SCAND J TRAUMA RESUS, V21, DOI 10.1186/1757-7241-21-78; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; ROSNER MJ, 1984, J NEUROSURG, V60, P312, DOI 10.3171/jns.1984.60.2.0312; Sekhon MS, 2015, NEUROCRIT CARE, V23, P210, DOI 10.1007/s12028-015-0141-x; Smirl JD, 2014, J APPL PHYSIOL, V116, P1614, DOI 10.1152/japplphysiol.01266.2013; Sorrentino E, 2012, NEUROCRIT CARE, V16, P258, DOI 10.1007/s12028-011-9630-8; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steiner LA, 2004, CRIT CARE MED, V32, P1049, DOI 10.1097/01.CCM.0000120054.32845.A6; Steiner LA, 2002, CRIT CARE MED, V30, P733, DOI 10.1097/00003246-200204000-00002; Stocchetti N, 2014, NEW ENGL J MED, V370, P2121, DOI 10.1056/NEJMra1208708; Thomas E, 2015, BRIT J ANAESTH, V115, P487, DOI 10.1093/bja/aev233; Timofeev I, 2011, BRAIN, V134, P484, DOI 10.1093/brain/awq353; Tseng MY, 2005, STROKE, V36, P1627, DOI 10.1161/01.STR.0000176743.67564.5d; Venables W.N., 2002, MODERN APPL STAT S; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Young AMH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148817; Yuan Q, 2015, CRIT CARE MED, V43, P1405, DOI 10.1097/CCM.0000000000000965	53	32	32	0	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUL	2019	85	1					E75	E82		10.1093/neuros/nyy468			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	IV6CO	WOS:000484356700018	30476233				2021-06-18	
J	Henry, RJ; Doran, SJ; Barrett, JP; Meadows, VE; Sabirzhanov, B; Stoica, BA; Loane, DJ; Faden, AI				Henry, Rebecca J.; Doran, Sarah J.; Barrett, James P.; Meadows, Victoria E.; Sabirzhanov, Boris; Stoica, Bogdan A.; Loane, David J.; Faden, Alan I.			Inhibition of miR-155 Limits Neuroinflammation and Improves Functional Recovery After Experimental Traumatic Brain Injury in Mice	NEUROTHERAPEUTICS			English	Article						Traumatic brain injury; miR-155; microglial activation; neuroinflammation; neuroprotection	PROGRESSIVE NEURODEGENERATION; MICRORNA-155; ACTIVATION; EXPRESSION; MICROGLIA; POLARIZATION; HIPPOCAMPUS; CYTOKINE; IMMUNITY; MODELS	Micro-RNAs (miRs) are short, noncoding RNAs that negatively regulate gene expression at the post-transcriptional level and have been implicated in the pathophysiology of secondary damage after traumatic brain injury (TBI). Among miRs linked to inflammation, miR-155 has been implicated as a pro-inflammatory factor in a variety of organ systems. We examined the expression profile of miR-155, following experimental TBI (controlled cortical impact) in adult male C57Bl/6 mice, as well as the effects of acute or delayed administration of a miR-155 antagomir on post-traumatic neuroinflammatory responses and neurological recovery. Trauma robustly increased miR-155 expression in the injured cortex over 7days. Similar TBI-induced miR-155 expression changes were also found in microglia/macrophages isolated from the injured cortex at 7days post-injury. A miR-155 hairpin inhibitor (antagomir; 0.5nmol), administered intracerebroventricularly (ICV) immediately after injury, attenuated neuroinflammatory markers at both 1day and 7days post-injury and reduced impairments in spatial working memory. Delayed ICV infusion of the miR-155 antagomir (0.5nmol/day), beginning 24h post-injury and continuing for 6days, attenuated neuroinflammatory markers at 7days post-injury and improved motor, but not cognitive, function through 28days. The latter treatment limited NADPH oxidase 2 expression changes in microglia/macrophages in the injured cortex and reduced cortical lesion volume. In summary, TBI causes a robust and persistent neuroinflammatory response that is associated with increased miR-155 expression in microglia/macrophages, and miR-155 inhibition reduces post-traumatic neuroinflammatory responses and improves neurological recovery. Thus, miR-155 may be a therapeutic target for TBI-related neuroinflammation.	[Henry, Rebecca J.; Doran, Sarah J.; Barrett, James P.; Meadows, Victoria E.; Sabirzhanov, Boris; Stoica, Bogdan A.; Loane, David J.; Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; [Henry, Rebecca J.; Doran, Sarah J.; Barrett, James P.; Meadows, Victoria E.; Sabirzhanov, Boris; Stoica, Bogdan A.; Loane, David J.; Faden, Alan I.] Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Baltimore, MD 21201 USA; [Loane, David J.] Univ Maryland, Sch Med, Dept Anesthesiol, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA; [Faden, Alan I.] Univ Maryland, Sch Med, Dept Anesthesiol, 685 West Baltimore St,MSTF 6-02, Baltimore, MD 21201 USA	Loane, DJ; Faden, AI (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA.; Loane, DJ; Faden, AI (corresponding author), Univ Maryland, Sch Med, Shock Trauma & Anesthesiol Res STAR Ctr, Baltimore, MD 21201 USA.; Loane, DJ (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA.; Faden, AI (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, 685 West Baltimore St,MSTF 6-02, Baltimore, MD 21201 USA.	rhenry@som.umaryland.edu; sarah.doran@som.umaryland.edu; jbarrett@som.umaryland.edu; vmeadows@som.umaryland.edu; bsabirzhanov@som.umaryland.edu; bstoica@som.umaryland.edu; dloane@som.umaryland.edu; afaden@som.umaryland.edu		Henry, Rebecca/0000-0001-8548-1170; Faden, Alan I./0000-0003-0128-2348; Loane, David/0000-0003-0393-3503; Barrett, James/0000-0002-0924-9449	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS037313, R01 NS082308, T32 AI095190]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [T32AI095190] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313, R01NS082308] Funding Source: NIH RePORTER	This work was supported by NIH R01 NS037313 (AIF), R01 NS082308 (DJL), and T32 AI095190 (SJD).	Al-Haidari AA, 2017, ONCOTARGET, V8, P14887, DOI 10.18632/oncotarget.14841; Barrett JP, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0843-4; Butovsky O, 2015, ANN NEUROL, V77, P75, DOI 10.1002/ana.24304; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; Caballero-Garrido E, 2015, J NEUROSCI, V35, P12446, DOI 10.1523/JNEUROSCI.1641-15.2015; Cardoso AL, 2012, IMMUNOLOGY, V135, P73, DOI 10.1111/j.1365-2567.2011.03514.x; Pena-Philippides JC, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0753-x; Dickey LL, 2017, J NEUROIMMUNOL, V308, P17, DOI 10.1016/j.jneuroim.2017.01.016; Elmesmari A, 2016, RHEUMATOLOGY, V55, P2056, DOI 10.1093/rheumatology/kew272; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Freilich RW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079416; Gaudet AD, 2018, NEUROSCIENTIST, V24, P221, DOI 10.1177/1073858417721150; Gaudet AD, 2016, J NEUROSCI, V36, P8516, DOI 10.1523/JNEUROSCI.0735-16.2016; Griffiths-Jones Sam, 2006, V342, P129, DOI 10.1385/1-59745-123-1:129; Harmon JL, 2017, J NEUROTRAUM, V34, P487, DOI 10.1089/neu.2015.4395; Harrison EB, 2017, FRONT MOL NEUROSCI, V10, DOI 10.3389/fnmol.2017.00228; Hu RZ, 2014, IMMUNITY, V41, P605, DOI 10.1016/j.immuni.2014.09.015; Israelsson C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104754; Jablonski KA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159724; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Keck-Wherley J, 2011, DEV NEUROSCI-BASEL, V33, P451, DOI 10.1159/000330884; Kerr WG, 2011, ANN NY ACAD SCI, V1217, P1, DOI 10.1111/j.1749-6632.2010.05869.x; Koval ED, 2013, HUM MOL GENET, V22, P4127, DOI 10.1093/hmg/ddt261; Kumar A, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0819-4; Kumar A, 2016, BRAIN BEHAV IMMUN, V58, P291, DOI 10.1016/j.bbi.2016.07.158; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; LaPlaca M. C, 2018, CLIN BIOMECH BRISTOL; Levine J, 2016, GLIA, V64, P668, DOI 10.1002/glia.22953; Lippai D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070945; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lumpkins K, 2008, J TRAUMA, V64, P358, DOI 10.1097/TA.0b013e318160df9b; Matsukura S, 2016, ALLERGOL INT, V65, pS17, DOI 10.1016/j.alit.2016.04.018; McCoy CE, 2010, J BIOL CHEM, V285, P20492, DOI 10.1074/jbc.M110.102111; Moore CS, 2013, ANN NEUROL, V74, P709, DOI 10.1002/ana.23967; Morganti JM, 2015, J NEUROSCI, V35, P748, DOI 10.1523/JNEUROSCI.2405-14.2015; Morris G, 2018, EPILEPSIA, V59, P1518, DOI 10.1111/epi.14475; Murugaiyan G, 2011, J IMMUNOL, V187, P2213, DOI 10.4049/jimmunol.1003952; Nazari-Jahantigh M, 2012, J CLIN INVEST, V122, P4190, DOI 10.1172/JCI61716; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; O'Connell RM, 2009, P NATL ACAD SCI USA, V106, P7113, DOI 10.1073/pnas.0902636106; Ponomarev ED, 2013, GLIA, V61, P91, DOI 10.1002/glia.22363; Quinn SR, 2011, INT IMMUNOL, V23, P421, DOI 10.1093/intimm/dxr034; Rajasekhar M, 2017, J AUTOIMMUN, V79, P53, DOI 10.1016/j.jaut.2017.01.002; Reschke CR, 2017, MOL THER-NUCL ACIDS, V6, P45, DOI 10.1016/j.omtn.2016.11.002; Sandhir R, 2004, NEUROSCI LETT, V369, P28, DOI 10.1016/j.neulet.2004.07.032; Simon DW, 2017, NAT REV NEUROL, V13, P572, DOI 10.1038/nrneurol.2017.116; Stefini R, 2008, J NEUROSURG, V108, P958, DOI 10.3171/JNS/2008/108/5/0958; Stein CA, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp841; Stenvang Jan, 2012, Silence, V3, P1, DOI 10.1186/1758-907X-3-1; Sun YX, 2012, IMMUNOL LETT, V146, P25, DOI 10.1016/j.imlet.2012.04.007; Tan Y, 2015, NEUROCHEM RES, V40, P550, DOI 10.1007/s11064-014-1500-2; Thome AD, 2016, J NEUROSCI, V36, P2383, DOI 10.1523/JNEUROSCI.3900-15.2016; Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082; Torres Adrian G, 2011, Artif DNA PNA XNA, V2, P71; Vermeulen A, 2007, RNA, V13, P723, DOI 10.1261/rna.448107; Wang P, 2010, J IMMUNOL, V185, P6226, DOI 10.4049/jimmunol.1000491; Wang WX, 2015, EXP NEUROL, V265, P84, DOI 10.1016/j.expneurol.2014.12.018; Woodbury ME, 2015, J NEUROSCI, V35, P9764, DOI 10.1523/JNEUROSCI.4790-14.2015; Yuan ZH, 2016, AM J PHYSIOL-LUNG C, V310, pL426, DOI 10.1152/ajplung.00195.2015	62	32	34	0	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1933-7213	1878-7479		NEUROTHERAPEUTICS	Neurotherapeutics	JAN	2019	16	1					216	230		10.1007/s13311-018-0665-9			15	Clinical Neurology; Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	HJ8PD	WOS:000457460900022	30225790	Bronze, Green Published			2021-06-18	
J	Ritzel, RM; Doran, SJ; Barrett, JP; Henry, RJ; Ma, EL; Faden, AI; Loane, DJ				Ritzel, Rodney M.; Doran, Sarah J.; Barrett, James P.; Henry, Rebecca J.; Ma, Elise L.; Faden, Alan I.; Loane, David J.			Chronic Alterations in Systemic Immune Function after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						chronic inflammation; immunosuppression; systemic immunity; traumatic brain injury	PROGRESSIVE NEURODEGENERATION; EXPERIMENTAL STROKE; INTERFERON-GAMMA; T-LYMPHOCYTES; ACTIVATION; INFECTION; IMMUNODEPRESSION; INFLAMMATION; CONSEQUENCES; MONOCYTES	There is a compelling link between severe brain trauma and immunosuppression in patients with traumatic brain injury (TBI). Although acute changes in the systemic immune compartment have been linked to outcome severity, the long-term consequences of TBI on systemic immune function are unknown. Here, adult male C57Bl/6 mice underwent moderate-level controlled cortical impact (CCI) or sham surgery, and systemic immune function was evaluated at 1, 3, 7, 14, and 60 days post-injury. Bone marrow, blood, thymus, and spleen were examined by flow cytometry to assess changes in immune composition, reactive oxygen species (ROS) production, phagocytic activity, and cytokine production. Bone marrow derived macrophages (BMDMs) from sham and 60-day CCI mice were cultured for immune challenge studies using lipopolysaccharide (LPS) and interleukin-4 (IL-4) models. Acutely, TBI caused robust bone marrow activation and neutrophilia. Neutrophils and monocytes exhibited impairments in respiratory burst, cytokine production, and phagocytosis; in contrast, ROS levels and pro-inflammatory cytokine production were chronically elevated at 60 days post-injury. Cultures of BMDMs from chronic CCI mice demonstrated defects in LPS- and IL-4-induced polarization when compared with stimulated BMDMs from sham mice. TBI also caused thymic involution, inverted CD4:CD8 ratios, chronic T lymphopenia, greater memory conversion, increased T cell activation, impaired interferon induction, and chronically elevated Th1 cytokine and ROS production. Collectively, our in-depth phenotypic and functional analyses demonstrate that TBI induces widespread suppression of innate and adaptive immune responses after TBI. Moreover, at chronic time points, TBI mice exhibit hallmarks of accelerated immune aging, displaying chronic deficits in systemic immune function.	[Loane, David J.] Univ Maryland, Sch Med, Dept Anesthesiol, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA	Loane, DJ (corresponding author), Univ Maryland, Sch Med, Dept Anesthesiol, 655 West Baltimore St,6-011, Baltimore, MD 21201 USA.	dloane@som.umaryland.edu		Barrett, James/0000-0002-0924-9449; Ritzel, Rodney/0000-0002-0160-2930; Henry, Rebecca/0000-0001-8548-1170; Faden, Alan I./0000-0003-0128-2348; Loane, David/0000-0003-0393-3503	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS082308, R01NS037313, F32NS105355]; National Institute on Aging (NIA) Claude D. Pepper Older Americans Independence Center [P30-AG028747]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [T32AI095190] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS037313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG028747] Funding Source: NIH RePORTER	We would like to acknowledge Ethan Glaser, B.Sc., for his technical assistance, and Dr. Xiaoxuan Fan, Ph.D., and Karen Underwood, B.Sc., of the University of Maryland Greenebaum Comprehensive Cancer Center Flow Cytometry Facility for support with flow cytometry studies. We would also like to thank Dr. Nevil Singh, Ph.D., for helpful discussion. This work was supported by National Institutes of Health grants R01NS082308 (D.J. Loane), R01NS037313 (A.I. Faden), and F32NS105355 (R.M. Ritzel), and The National Institute on Aging (NIA) Claude D. Pepper Older Americans Independence Center P30-AG028747 (D.J. Loane).	Alharfi IM, 2014, J NEUROTRAUM, V31, P452, DOI [10.1089/NEU.2013.2904, 10.1089/neu.2013.2904]; Amit I, 2016, NAT IMMUNOL, V17, P18, DOI 10.1038/ni.3325; Bai RJ, 2017, MED SCI MONITOR, V23, P1707, DOI 10.12659/MSM.901124; Barrett JP, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0843-4; Bosmann M, 2013, TRENDS IMMUNOL, V34, P129, DOI 10.1016/j.it.2012.09.004; Brubaker AL, 2011, AGING DIS, V2, P346; Byrnes KR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-43; CHEADLE WG, 1991, AM J SURG, V161, P639, DOI 10.1016/0002-9610(91)91247-G; Chen Y, 2012, METHODS MOL BIOL, V844, P115, DOI 10.1007/978-1-61779-527-5_8; Cole JH, 2015, ANN NEUROL, V77, P571, DOI 10.1002/ana.24367; Correa BL, 2014, NEUROIMMUNOMODULAT, V21, P206, DOI 10.1159/000356827; Courties G, 2015, CIRC RES, V116, P407, DOI 10.1161/CIRCRESAHA.116.305207; Denes A, 2011, J CEREBR BLOOD F MET, V31, P1036, DOI 10.1038/jcbfm.2010.198; El-Benna J, 2016, IMMUNOL REV, V273, P180, DOI 10.1111/imr.12447; Emsley Hedley C. A., 2010, Infectious Disorders - Drug Targets, V10, P91; Franceschi C, 2000, ANN NY ACAD SCI, V908, P244; Gennery Andrew, 2017, F1000Res, V6, P1427, DOI 10.12688/f1000research.11789.1; Hazeldine J, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00235; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Junger WG, 2013, SHOCK, V40, P366, DOI 10.1097/SHK.0000000000000038; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kesinger MR, 2015, J TRAUMA ACUTE CARE, V78, P396, DOI 10.1097/TA.0000000000000526; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068963; Liesz A, 2009, STROKE, V40, P2849, DOI 10.1161/STROKEAHA.109.549618; Linehan E, 2015, EUR J MICROBIOL IMMU, V5, P14, DOI [10.1556/EuJMI-D-14-00035, 10.1556/EUJMI-D-14-00035]; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Ma EL, 2017, BRAIN BEHAV IMMUN, V66, P56, DOI 10.1016/j.bbi.2017.06.018; Marks W, 2013, CENT EUR J IMMUNOL, V38, P494, DOI 10.5114/ceji.2013.39767; Mazzeo AT, 2006, J NEUROTRAUM, V23, P962, DOI 10.1089/neu.2006.23.962; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Meisel C, 2004, STROKE, V35, P2, DOI 10.1161/01.STR.0000109041.89959.4C; Mouzon BC, 2014, ANN NEUROL, V75, P241, DOI 10.1002/ana.24064; Nikolich-Zugich J, 2014, J IMMUNOL, V193, P2622, DOI 10.4049/jimmunol.1401174; Offner H, 2006, J IMMUNOL, V176, P6523, DOI 10.4049/jimmunol.176.11.6523; Perkins DJ, 2016, J INTERF CYTOK RES, V36, P454, DOI 10.1089/jir.2016.0003; Rhind SG, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-5; Ritzel RM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0329-1; Schwulst SJ, 2013, J TRAUMA ACUTE CARE, V75, P780, DOI 10.1097/TA.0b013e318299616a; Scott BNV, 2013, SYST REV-LONDON, V2, DOI 10.1186/2046-4053-2-68; Seifert HA, 2012, METAB BRAIN DIS, V27, P131, DOI 10.1007/s11011-012-9283-0; Selassie AW, 2011, J TRAUMA, V71, P1226, DOI 10.1097/TA.0b013e318226ecfc; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Smith C, 2013, NEUROPATH APPL NEURO, V39, P35, DOI 10.1111/nan.12006; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Smrcka M, 2005, Bratisl Lek Listy, V106, P144; Spellberg B, 2001, CLIN INFECT DIS, V32, P76, DOI 10.1086/317537; Suz P, 2006, J NEUROSURG ANESTH, V18, P5, DOI 10.1097/01.ana.0000189079.26212.37; Vernon PJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0146105; Winkler MS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182427; Wolach B, 2001, J NEUROSURG, V94, P706, DOI 10.3171/jns.2001.94.5.0706; Wood RL, 2017, BRAIN INJURY, V31, P1270, DOI 10.1080/02699052.2017.1332387; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yang YH, 2013, INT REV IMMUNOL, V32, P249, DOI 10.3109/08830185.2012.755176; Yilmaz G, 2006, CIRCULATION, V113, P2105, DOI 10.1161/CIRCULATIONAHA.105.593046	59	32	32	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2018	35	13					1419	1436		10.1089/neu.2017.5399		MAY 2018	18	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GJ4CQ	WOS:000431466600001	29421977	Green Published			2021-06-18	
J	Mettang, M; Reichel, SN; Lattke, M; Palmer, A; Abaei, A; Rasche, V; Huber-Lang, M; Baumann, B; Wirth, T				Mettang, Melanie; Reichel, Stephanie Nadine; Lattke, Michael; Palmer, Annette; Abaei, Alireza; Rasche, Volker; Huber-Lang, Markus; Baumann, Bernd; Wirth, Thomas			IKK2/NF-kappa B signaling protects neurons after traumatic brain injury	FASEB JOURNAL			English	Article						neuroinflammation; apoptosis neurological outcome; neurodegeneration; conditional mouse model	NF-KAPPA-B; CLOSED-HEAD INJURY; SPINAL-CORD-INJURY; NERVOUS-SYSTEM; REDUCES INFLAMMATION; FUNCTIONAL RECOVERY; ACTIVATION; EXPRESSION; EPIDEMIOLOGY; MICE	Traumatic brain injury (TBI) is the leading cause of death in young adults. After the initial injury, a poorly understood secondary phase, including a strong inflammatory response determines the final outcome of TBI. The inhibitor of NF-kappa B kinase (IKK)/NF-kappa B signaling system is the key regulator of inflammation and also critically involved in regulation of neuronal survival and synaptic plasticity. We addressed the neuron-specific function of IKK2/NF-kappa B signaling pathway in TBI using an experimental model of closed-head injury (CHI) in combination with mouse models allowing conditional regulation of IKK/NF-kappa B signaling in excitatory forebrain neurons. We found that repression of IKK2/NF-kappa B signaling in neurons increases the acute posttraumatic mortality rate, worsens the neurological outcome, and promotes neuronal cell death by apoptosis, thus resulting in enhanced proinflammatory gene expression. As a potential mechanism, we identified elevated levels of the proapoptotic mediators Bax and Bad and enhanced expression of stress response genes. This phenotype is also observed when neuronal IKK/NF-kappa B activity is inhibited just before CHI. In contrast, neuron-specific activation of IKK/NF-kappa B signaling does not alter the TBI outcome. Thus, this study demonstrates that physiological neuronal IKK/NF-kappa B signaling is necessary and sufficient to protect neurons from trauma consequences.	[Mettang, Melanie; Reichel, Stephanie Nadine; Lattke, Michael; Baumann, Bernd; Wirth, Thomas] Ulm Univ, Inst Physiol Chem, Albert Einstein Allee 11, D-89081 Ulm, Germany; [Abaei, Alireza; Rasche, Volker] Ulm Univ, Core Facil Small Anim Magnet Resonance Imaging, Ulm, Germany; [Lattke, Michael] Francis Crick Inst, Neural Stem Cell Biol Lab, London, England; [Palmer, Annette; Huber-Lang, Markus] Univ Hosp Ulm, Inst Clin & Expt Trauma Immunol, Ulm, Germany	Wirth, T (corresponding author), Ulm Univ, Inst Physiol Chem, Albert Einstein Allee 11, D-89081 Ulm, Germany.	thomas.wirth@uni-ulm.de	Rasche, Volker/P-6523-2016; Huber-Lang, Markus/AAJ-2209-2020; Lattke, Michael/AAE-5079-2020; Wirth, Thomas/X-7172-2019	Lattke, Michael/0000-0001-5533-8592; 	German research foundationGerman Research Foundation (DFG) [CRC1149]	The authors thank Petra Weihrich, Melanie Gerstenlauer, Annika Gnann, Ute Leschik (all from the Institute of Physiological Chemistry, Ulm University), and Sonja Braumuller (Institute of Clinical and Experimental Trauma-Immunology, University Hospital Ulm) for excellent technical assistance. This work was supported by the German research foundation (CRC1149/Project A03 to T.W. and CRC1149/Project Z03). Melanie Mettang and Stephanie N. Reichel are members of the International Graduate School in Molecular Medicine Ulm (IGradU). The authors declare no conflicts of interest.	Acarin L, 2000, J NEUROPATH EXP NEUR, V59, P151, DOI 10.1093/jnen/59.2.151; Acarin L, 1998, NEUROREPORT, V9, P2869, DOI 10.1097/00001756-199808240-00035; Bales KR, 1998, MOL BRAIN RES, V57, P63, DOI 10.1016/S0169-328X(98)00066-7; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Braunstein KE, 2010, HUM MOL GENET, V19, P4385, DOI 10.1093/hmg/ddq361; Chen J, 2005, J BIOL CHEM, V280, P40364, DOI 10.1074/jbc.M509329200; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cucchiara B, 2001, J NEUROL SCI, V187, P81, DOI 10.1016/S0022-510X(01)00529-9; Duckworth EAM, 2006, BRAIN RES, V1088, P167, DOI 10.1016/j.brainres.2006.02.103; Engelmann C, 2014, NEURAL REGEN RES, V9, P707, DOI 10.4103/1673-5374.131572; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gabriel C, 1999, MOL BRAIN RES, V65, P61, DOI 10.1016/S0169-328X(98)00330-1; Gyoneva S, 2015, TRENDS PHARMACOL SCI, V36, P471, DOI 10.1016/j.tips.2015.04.003; Hang CH, 2006, BRAIN RES, V1109, P14, DOI 10.1016/j.brainres.2006.06.045; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Helmy A, 2011, PROG NEUROBIOL, V95, P352, DOI 10.1016/j.pneurobio.2011.09.003; Herrmann O, 2005, NAT MED, V11, P1322, DOI 10.1038/nm1323; Jayakumar AR, 2014, J NEUROTRAUM, V31, P1249, DOI 10.1089/neu.2013.3169; Kabadi SV, 2014, INT J MOL SCI, V15, P1216, DOI 10.3390/ijms15011216; Kaltschmidt B, 2005, BBA-MOL CELL RES, V1745, P287, DOI 10.1016/j.bbamcr.2005.05.009; Kaltschmidt B., 2015, BRAIN FRONT MOL NEUR, V8, P69, DOI DOI 10.3389/FNM0L.2015.00069; Kaltschmidt B, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001271; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; Khorooshi R, 2008, J IMMUNOL, V181, P7284, DOI 10.4049/jimmunol.181.10.7284; Kirkley KS, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0871-0; Lagraoui M, 2017, BRAIN BEHAV IMMUN, V61, P96, DOI 10.1016/j.bbi.2016.12.005; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lattke M, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0157-0; Lattke M, 2012, J NEUROSCI, V32, P11511, DOI 10.1523/JNEUROSCI.0182-12.2012; Ledoux AC, 2014, BIOCHEM SOC T, V42, P76, DOI 10.1042/BST20130156; Lian H, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-47; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lothian C, 1997, EUR J NEUROSCI, V9, P452, DOI 10.1111/j.1460-9568.1997.tb01622.x; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Maqbool A, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-40; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; Mattson MP, 2005, NEUROCHEM RES, V30, P883, DOI 10.1007/s11064-005-6961-x; Mattson MP, 2000, J NEUROCHEM, V74, P443, DOI 10.1046/j.1471-4159.2000.740443.x; Memet S, 2006, BIOCHEM PHARMACOL, V72, P1180, DOI 10.1016/j.bcp.2006.09.003; Menon DK, 2017, HAND CLINIC, V140, P239, DOI 10.1016/B978-0-444-63600-3.00014-3; Mincheva-Tasheva S, 2013, NEUROSCIENTIST, V19, P175, DOI 10.1177/1073858412444007; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Nenci A, 2007, NATURE, V446, P557, DOI 10.1038/nature05698; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Pennypacker KR, 2001, EXP NEUROL, V172, P307, DOI 10.1006/exnr.2001.7817; Pennypacker KR, 2000, ACTA NEUROBIOL EXP, V60, P515; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Pizzi M, 2006, EUR J PHARMACOL, V545, P22, DOI 10.1016/j.ejphar.2006.06.027; Qin ZH, 2007, ACTA PHARMACOL SIN, V28, P1859, DOI 10.1111/j.1745-7254.2007.00741.x; Quillinan Nidia, 2016, Anesthesiol Clin, V34, P453, DOI 10.1016/j.anclin.2016.04.011; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; Schmeisser MJ, 2012, J NEUROSCI, V32, P5688, DOI 10.1523/JNEUROSCI.0111-12.2012; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schmidt-Strassburger U, 2012, FASEB J, V26, P4990, DOI 10.1096/fj.12-208587; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Turner MD, 2014, BBA-MOL CELL RES, V1843, P2563, DOI 10.1016/j.bbamcr.2014.05.014; Villasana LE, 2014, EXP NEUROL, V261, P156, DOI 10.1016/j.expneurol.2014.05.016; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wang DB, 2014, BBA-MOL BASIS DIS, V1842, P1186, DOI 10.1016/j.bbadis.2013.12.015; Widera D, 2016, NEUROPHOTONICS, V3, DOI 10.1117/1.NPh.3.4.041804; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; YANG KY, 1995, NEUROSCI LETT, V197, P101, DOI 10.1016/0304-3940(95)11919-N; Yang Li, 2007, Neurosci Bull, V23, P307, DOI 10.1007/s12264-007-0046-6; Yuan YM, 2015, BRAIN BEHAV IMMUN, V48, P287, DOI 10.1016/j.bbi.2015.04.008	77	32	34	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2018	32	4					1916	1932		10.1096/fj.201700826R			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GB4SP	WOS:000429051400015	29187362	Green Published			2021-06-18	
J	Swanson, RL; Hampton, S; Green-McKenzie, J; Diaz-Arrastia, R; Grady, MS; Verma, R; Biester, R; Duda, D; Wolf, RL; Smith, DH				Swanson, Randel L., II; Hampton, Stephen; Green-McKenzie, Judith; Diaz-Arrastia, Ramon; Grady, M. Sean; Verma, Ragini; Biester, Rosette; Duda, Diana; Wolf, Ronald L.; Smith, Douglas H.			Neurological Manifestations Among US Government Personnel Reporting Directional Audible and Sensory Phenomena in Havana, Cuba	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TRAUMATIC BRAIN-INJURY; BALANCE; VALIDITY; CONSISTENCY; DISORDERS; INVENTORY; ILLNESS	IMPORTANCE From late 2016 through August 2017, US government personnel serving on diplomatic assignment in Havana, Cuba, reported neurological symptoms associated with exposure to auditory and sensory phenomena. OBJECTIVE To describe the neurological manifestations that followed exposure to an unknown energy source associated with auditory and sensory phenomena. DESIGN, SETTING, AND PARTICIPANTS Preliminary results from a retrospective case series of US government personnel in Havana, Cuba. Following reported exposure to auditory and sensory phenomena in their homes or hotel rooms, the individuals reported a similar constellation of neurological symptoms resembling brain injury. These individuals were referred to an academic brain injury center for multidisciplinary evaluation and treatment. EXPOSURES Report of experiencing audible and sensory phenomena emanating from a distinct direction (directional phenomena) associated with an undetermined source, while serving on US government assignments in Havana, Cuba, since 2016. MAIN OUTCOMES AND MEASURES Descriptions of the exposures and symptoms were obtained from medical record review of multidisciplinary clinical interviews and examinations. Additional objective assessments included clinical tests of vestibular (dynamic and static balance, vestibulo-ocular reflex testing, caloric testing), oculomotor (measurement of convergence, saccadic, and smooth pursuit eye movements), cognitive (comprehensive neuropsychological battery), and audiometric (pure tone and speech audiometry) functioning. Neuroimaging was also obtained. RESULTS Of 24 individuals with suspected exposure identified by the US Department of State, 21 completed multidisciplinary evaluation an average of 203 days after exposure. Persistent symptoms (>3 months after exposure) were reported by these individuals including cognitive (n = 17, 81%), balance (n = 15, 71%), visual (n = 18, 86%), and auditory (n = 15, 68%) dysfunction, sleep impairment (n = 18, 86%), and headaches (n = 16, 76%). Objective findings included cognitive (n = 16, 76%), vestibular (n = 17, 81%), and oculomotor (n = 15, 71%) abnormalities. Moderate to severe sensorineural hearing loss was identified in 3 individuals. Pharmacologic intervention was required for persistent sleep dysfunction (n = 15, 71%) and headache (n = 12, 57%). Fourteen individuals (67%) were held from work at the time of multidisciplinary evaluation. Of those, 7 began graduated return to work with restrictions in place, home exercise programs, and higher-level work-focused cognitive rehabilitation. CONCLUSIONS AND RELEVANCE In this preliminary report of a retrospective case series, persistent cognitive, vestibular, and oculomotor dysfunction, as well as sleep impairment and headaches, were observed among US government personnel in Havana, Cuba, associated with reports of directional audible and/or sensory phenomena of unclear origin. These individuals appeared to have sustained injury to widespread brain networks without an associated history of head trauma.	[Grady, M. Sean; Smith, Douglas H.] Univ Penn, Perelman Sch Med, Dept Neurosurg, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA; [Swanson, Randel L., II; Hampton, Stephen; Biester, Rosette] Univ Penn, Dept Phys Med & Rehabil, Perelman Sch Med, Philadelphia, PA 19104 USA; [Swanson, Randel L., II; Hampton, Stephen; Green-McKenzie, Judith; Diaz-Arrastia, Ramon; Grady, M. Sean; Verma, Ragini; Biester, Rosette; Duda, Diana; Wolf, Ronald L.; Smith, Douglas H.] Univ Penn, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Green-McKenzie, Judith] Univ Penn, Div Occupat & Environm Med, Dept Emergency Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Diaz-Arrastia, Ramon] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Verma, Ragini; Wolf, Ronald L.] Univ Penn, Dept Radiol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Duda, Diana] Univ Penn, Penn Therapy & Fitness, Good Shepherd Penn Partners, Philadelphia, PA 19104 USA	Smith, DH (corresponding author), Univ Penn, Perelman Sch Med, Dept Neurosurg, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.; Smith, DH (corresponding author), Univ Penn, Perelman Sch Med, Ctr Brain Injury & Repair, 3320 Smith Walk,105 Hayden Hall, Philadelphia, PA 19104 USA.	smithdou@upenn.edu			Health Resources and Services AdministrationUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA); National Institute for Occupational Safety and HealthUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)	All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Green-McKenzie reported receiving grants from Health Resources and Services Administration and the National Institute for Occupational Safety and Health. No other disclosures were reported.	Alahmari KA, 2014, ARCH PHYS MED REHAB, V95, P65, DOI 10.1016/j.apmr.2013.09.011; Alderfer BS, 2005, J HEAD TRAUMA REHAB, V20, P544, DOI 10.1097/00001199-200511000-00006; Barin K, 2008, BALANCE FUNCTION ASS, P229; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Beck A.T., 1993; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Brown SG, 2004, BRAIN COGNITION, V55, P283, DOI 10.1016/j.bandc.2004.02.010; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Chlebowski C, 2011, WECHSLER MEMORY SCAL; Delis DC, 2000, CALIFORNIA VERBAL LE; Gallaway M, 2017, OPTOMETRY VISION SCI, V94, P68, DOI 10.1097/OPX.0000000000000935; Garzia R P, 1990, J Am Optom Assoc, V61, P124; Goodglass H., 2001, BOSTON DIAGNOSTIC AP; Grace J, 2002, FRONTAL SYSTEMS BEHA; Horn Linda B, 2015, Arch Phys Med Rehabil, V96, P1747; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jones TF, 2000, NEW ENGL J MED, V342, P96, DOI 10.1056/NEJM200001133420206; Jorge RE, 2014, PSYCHIAT CLIN N AM, V37, P13, DOI 10.1016/j.psc.2013.11.005; McCutchan PK, 2016, MIL MED, V181, P1002, DOI 10.7205/MILMED-D-15-00444; McInnes K, 2017, PLOS ONE, V12; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Nashner LM., 1993, HDB BALANCE FUNCTION, P280; POWELL LE, 1995, J GERONTOL A-BIOL, V50, pM28, DOI 10.1093/gerona/50A.1.M28; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rouse M, 2009, OPTOMETRY VISION SCI, V86, P357, DOI 10.1097/OPX.0b013e3181989252; Scheiman M., 2014, CLIN MANAGEMENT BINO, V4th; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shepard NT, 1996, PRACTICAL MANAGEMENT; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Tombaugh TN, 1996, TEST MEMORY MALINGER; Weathers FW, 1991, PCL C FOR DSM 4; Wechsler D., 2008, WAIS 4 TECHNICAL MAN; Weir E, 2005, CAN MED ASSOC J, V172, P36, DOI 10.1503/cmaj.045027; Wrisley DM, 2004, PHYS THER, V84, P906, DOI 10.1093/ptj/84.10.906	37	32	33	1	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 20	2018	319	11					1125	1133		10.1001/jama.2018.1742			9	Medicine, General & Internal	General & Internal Medicine	FZ8LL	WOS:000427860200017	29450484	Green Published, Bronze			2021-06-18	
J	Lamond, LC; Caccese, JB; Buckley, TA; Glutting, J; Kaminski, TW				Lamond, Lindsey C.; Caccese, Jaclyn B.; Buckley, Thomas A.; Glutting, Joseph; Kaminski, Thomas W.			Linear Acceleration in Direct Head Contact Across Impact Type, Player Position, and Playing Scenario in Collegiate Women's Soccer Players	JOURNAL OF ATHLETIC TRAINING			English	Article						repetitive head impacts; subconcussive head impacts; impact exposure; concussions	AMERICAN FOOTBALL; YOUTH SOCCER; EXPOSURE; SEASON	Context: Heading, an integral component of soccer, exposes athletes to a large number of head impacts over a career. The literature has begun to indicate that cumulative exposure may lead to long-term functional and psychological deficits. Quantifying an athlete's exposure over a season is a first step in understanding cumulative exposure. Objective: To measure the frequency and magnitude of direct head impacts in collegiate women's soccer players across impact type, player position, and game or practice scenario. Design: Cross-sectional study. Setting: National Collegiate Athletic Association Division I institution. Patients or Other Participants: Twenty-three collegiate women's soccer athletes. Main Outcome Measure(s): Athletes wore Smart Impact Monitor accelerometers during all games and practices. Impacts were classified during visual, on-field monitoring of athletic events. All direct head impacts that exceeded the 10g threshold were included in the final data analysis. The dependent variable was linear acceleration, and the fixed effects were (1) type of impact: clear, pass, shot, unintentional deflection, or head-to-head contact; (2) field position: goalkeeper, defense, forward, or midfielder; (3) playing scenario: game or practice. Results: Shots (32.94g +/- 12.91g, n = 38; P = .02) and clears (31.09g +/- 13.43g, n = 101; P = .008) resulted in higher mean linear accelerations than passes (26.11g +/- 15.48g, n = 451). Head-to-head impacts (51.26g +/- 36.61g, n = 13; P <. 001) and unintentional deflections (37.40g +/- 34.41g, n = 24; P = .002) resulted in higher mean linear accelerations than purposeful headers (ie, shots, clears, and passes). No differences were seen in linear acceleration across player position or playing scenario. Conclusions: Nonheader impacts, including head-to-head impacts and unintentional deflections, resulted in higher mean linear accelerations than purposeful headers, including shots, clears, and passes, but occurred infrequently on the field. Therefore, these unanticipated impacts may not add substantially to an athlete's cumulative exposure, which is a function of both frequency and magnitude of impact.	[Lamond, Lindsey C.; Caccese, Jaclyn B.; Buckley, Thomas A.; Kaminski, Thomas W.] Univ Delaware, Dept Kinesiol & Appl Physiol, 540 South Coll Ave, Newark, DE 19716 USA; [Glutting, Joseph] Univ Delaware, Sch Educ, Newark, DE USA	Caccese, JB (corresponding author), Univ Delaware, Dept Kinesiol & Appl Physiol, 540 South Coll Ave, Newark, DE 19716 USA.	jcaccese@udel.edu	Buckley, Thomas A/B-7525-2016; Caccese, Jaclyn B./AAH-4571-2020	Buckley, Thomas A/0000-0002-0515-0150; Caccese, Jaclyn B./0000-0003-2329-3603			Ahmadisoleymani SS, 2015, PROCEDIA MANUF, V3, P3796, DOI 10.1016/j.promfg.2015.07.882; Caccese JB, 2016, RES SPORTS MED, V24, P407, DOI 10.1080/15438627.2016.1230549; Caccese JB, 2016, SPORTS MED, V46, P1591, DOI 10.1007/s40279-016-0544-7; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Chrisman SPD, 2016, J CHILD NEUROL, V31, P971, DOI 10.1177/0883073816634857; Cummiskey B, 2017, P I MECH ENG P-J SPO, V231, P144, DOI 10.1177/1754337116658395; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Hox J.J., 2010, MULTILEVEL ANAL TECH, V2nd ed.; Hwang S, 2017, J NEUROTRAUM, V34, P8, DOI 10.1089/neu.2015.4238; Kaminski TW, 2007, J CLIN EXP NEUROPSYC, V29, P742, DOI 10.1080/13825580600976911; Karton C, 2016, 34 INT C BIOM SPORTS; Kawata K, 2016, INT J SPORTS MED, V37, P405, DOI 10.1055/s-0035-1569290; Kawata K, 2016, JAMA OPHTHALMOL, V134, P763, DOI 10.1001/jamaophthalmol.2016.1085; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Lynall RC, 2016, MED SCI SPORT EXER, V48, P1772, DOI 10.1249/MSS.0000000000000951; Maher ME, 2014, BRAIN INJURY, V28, P271, DOI 10.3109/02699052.2013.865269; McCuen E, 2015, J BIOMECH, V48, P3720, DOI 10.1016/j.jbiomech.2015.08.003; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Oeur RA, 2016, 34 INT C BIOM SPORTS, P79; Press JN, 2017, CLIN J SPORT MED, V27, P104, DOI 10.1097/JSM.0000000000000313; Raudenbush SW., 2002, HIERARCHICAL LINEAR, V2nd ed; Shewchenko N, 2005, BRIT J SPORT MED, V39, pI10, DOI 10.1136/bjsm.2005.019034; Tarnutzer AA, 2017, BRIT J SPORT MED, V51, P1592, DOI 10.1136/bjsports-2016-096593; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182; Wu LC, 2016, ANN BIOMED ENG, V44, P1234, DOI 10.1007/s10439-015-1423-3	26	32	32	1	4	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	FEB	2018	53	2					115	121		10.4085/1062-6050-90-17			7	Sport Sciences	Sport Sciences	FY8CL	WOS:000427090400002	29373056	Green Published, Bronze			2021-06-18	
J	Levitch, CF; Zimmerman, ME; Lubin, N; Kim, N; Lipton, RB; Stewart, WF; Kim, M; Lipton, ML				Levitch, Cara F.; Zimmerman, Molly E.; Lubin, Naomi; Kim, Namhee; Lipton, Richard B.; Stewart, Walter F.; Kim, Mimi; Lipton, Michael L.			Recent and Long-Term Soccer Heading Exposure Is Differentially Associated With Neuropsychological Function in Amateur Players	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Brain injury; Sport; Cognitive impairment; Soccer; Heading; Repetitive head trauma	TRAUMATIC BRAIN-INJURY; FOOTBALL SOCCER; COGNITIVE IMPAIRMENT; CONSEQUENCE; CONCUSSIONS; FREQUENCY; SPORTS; IMPACT	Objectives: The present study examined the relative contribution of recent or long-term heading to neuropsychological function in amateur adult soccer players. Participants and Methods: Soccer players completed a baseline questionnaire (HeadCount-12m) to ascertain heading during the prior 12 months (long-term heading, LTH) and an online questionnaire (HeadCount-2w) every 3 months to ascertain heading during the prior 2 weeks (recent heading, RH). Cogstate, a battery of six neuropsychological tests, was administered to assess neuropsychological function. Generalized estimating equations were used to test if LTH or RH was associated with neuropsychological function while accounting for the role of recognized concussion. Results: A total of 311 soccer players completed 630 HeadCount-2w. Participants had an average age of 26 years. Participants headed the ball a median of 611 times/year (mean = 1,384.03) and 9.50 times/2 weeks (mean = 34.17). High levels of RH were significantly associated with reduced performance on a task of psychomotor speed (p = .02), while high levels of LTH were significantly associated with poorer performance on tasks of verbal learning (p = .03) and verbal memory (p = .04). Significantly better attention (p = .02) was detectable at moderately high levels of RH, but not at the highest level of RH. One hundred and seven (34.4%) participants reported a lifetime history of concussion, but this was not related to neuropsychological function and did not modify the association of RH or LTH with neuropsychological function. Conclusion: High levels of both RH and LTH were associated with poorer neuropsychological function, but on different domains. The clinical manifestations following repetitive exposure to heading could change with chronicity of exposure.	[Levitch, Cara F.; Zimmerman, Molly E.] Fordham Univ, Dept Psychol, Bronx, NY 10458 USA; [Zimmerman, Molly E.; Lubin, Naomi; Kim, Namhee; Lipton, Richard B.; Kim, Mimi; Lipton, Michael L.] Albert Einstein Coll Med, Bronx, NY 10461 USA; [Zimmerman, Molly E.; Lubin, Naomi; Kim, Namhee; Lipton, Michael L.] Montefiore Med Ctr, Dept Radiol, 111 E 210th St, Bronx, NY 10467 USA; [Lubin, Naomi; Kim, Namhee; Lipton, Michael L.] Montefiore Med Ctr, Gruss Magnet Resonance Res Ctr, 111 E 210th St, Bronx, NY 10467 USA; [Lipton, Richard B.] Montefiore Med Ctr, Dept Neurol, 111 E 210th St, Bronx, NY 10467 USA; [Lipton, Richard B.; Kim, Mimi] Montefiore Med Ctr, Dept Epidemiol & Populat Hlth, 111 E 210th St, Bronx, NY 10467 USA; [Stewart, Walter F.] Sutter Hlth Res, Walnut Creek, CA USA; [Lipton, Michael L.] Montefiore Med Ctr, Dept Psychiat & Behav Sci, 111 E 210th St, Bronx, NY 10467 USA; [Lipton, Michael L.] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA; [Lipton, Michael L.] Montefiore Med Ctr, 111 E 210th St, Bronx, NY 10467 USA	Lipton, ML (corresponding author), Albert Einstein Coll Med, MRRC, 1300 Morris Pk Ave,Room 219C, Bronx, NY 10461 USA.	Michael.lipton@einstein.yu.edu	Lipton, Richard B/B-5060-2011		National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS082432]; Dana Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS082432] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (Grant R01NS082432; Principal Investigator: M.L.L) and The Dana Foundation. The authors report no disclosures relevant to the manuscript.	Adams J, 2007, CLIN J SPORT MED, V17, P304, DOI 10.1097/JSM.0b013e31803202c8; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Catenaccio E, 2016, RES SPORTS MED, V24, P416, DOI 10.1080/15438627.2016.1234472; Comstock RD, 2015, JAMA PEDIATR, V169, P830, DOI 10.1001/jamapediatrics.2015.1062; Davidson PSR, 2006, J INT NEUROPSYCH SOC, V12, P210, DOI 10.1017/S1355617706060334; Di Virgilio TG, 2016, EBIOMEDICINE, V13, P66, DOI 10.1016/j.ebiom.2016.10.029; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Federation Internationale de Football Association-FIFA, 2007, FIFA BIG COUNT 2006; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Hardin J.W., 2005, GEN ESTIMATING EQUAT; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kaminski TW, 2008, RES Q EXERCISE SPORT, V79, P235; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lingsma H, 2017, NEUROLOGY, V88, P822, DOI 10.1212/WNL.0000000000003679; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Maher ME, 2014, BRAIN INJURY, V28, P271, DOI 10.3109/02699052.2013.865269; Maruff P, 2009, ARCH CLIN NEUROPSYCH, V24, P165, DOI 10.1093/arclin/acp010; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; Orme DR, 2004, REHABIL PSYCHOL, V49, P250, DOI 10.1037/0090-5550.49.3.250; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Rodrigues AC, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00038; Rutherford A, 2005, J CLIN EXP NEUROPSYC, V27, P299, DOI 10.1080/13803390490515504; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Rutherford A, 2009, J CLIN EXP NEUROPSYC, V31, P664, DOI 10.1080/13803390802484755; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Spiotta AM, 2012, NEUROSURGERY, V70, P1, DOI 10.1227/NEU.0b013e31823021b2; Stephens R, 2005, CHILD NEUROPSYCHOL, V11, P513, DOI 10.1080/092970490959629; Stephens R, 2010, J NEUROPSYCH CLIN N, V22, P295, DOI 10.1176/appi.neuropsych.22.3.295; Stewart WF, 2017, NEUROLOGY, V88, P901, DOI 10.1212/WNL.0000000000003657; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; Wilkinson GS, 2006, WIDE RANGE ACHIEVEME, V4th; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8	40	32	32	1	16	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	FEB	2018	24	2					147	155		10.1017/S1355617717000790			9	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	FT3XL	WOS:000423081900004	28829004	Green Accepted			2021-06-18	
J	Zheng, XX; Huang, HB; Liu, JJ; Li, MH; Liu, M; Luo, T				Zheng, Xinxun; Huang, Hongbing; Liu, Jianjun; Li, Minghua; Liu, Min; Luo, Tao			Propofol Attenuates Inflammatory Response in LPS-Activated Microglia by Regulating the miR-155/SOCS1 Pathway	INFLAMMATION			English	Article						propofol; microglia; miR-155; SOCS1	PANCREATIC-CANCER CELLS; ISCHEMIA-REPERFUSION; MODEL; BRAIN; LIPOPOLYSACCHARIDE; ANESTHESIA; INHIBITION; EXPRESSION; SYSTEM; NEUROINFLAMMATION	Propofol is a widely used intravenous anesthetic agent with potential neuroprotective effect in diverse models of neuronal injury, including ischemic stroke and traumatic brain injury. However, few studies have been carried out to determine the effects and molecular mechanisms of propofol in classic microglial activation (M1 activation) related to neuronal injury. This study explored the anti-inflammatory effects of propofol in LPS-activated BV2 microglia. Propofol potently decreased the pro-inflammatory mediators, such as nitric oxide, TNF-alpha, and IL-6, at both the transcriptional and translational levels. Furthermore, propofol suppressed the expression of miR-155 in LPS-activated cells. Knockdown of miR-155 attenuated the anti-inflammatory effect of propofol in cells after LPS exposure. miR-155 was also confirmed as a negative regulator of SOCS1 expression. The inhibitory effect of propofol on LPS-induced inflammation involved the upregulation of SOCS1. Overall, these results suggest that propofol can suppress the neuroinflammatory response of microglia to LPS through the regulation of the miR-155/SOCS1 pathway.	[Zheng, Xinxun; Luo, Tao] Peking Univ, Shenzhen Hosp, Dept Anesthesiol, Shenzhen, Peoples R China; [Huang, Hongbing] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Liu, Jianjun] Shenzhen Ctr Dis Control & Prevent, Key Lab Modern Toxicol Shenzhen, Shenzhen, Peoples R China; [Li, Minghua] Peking Univ, Shenzhen Hosp, Cent Lab, Shenzhen, Peoples R China; [Liu, Min] Hlth & Family Planning Capac Bldg & Continuing Ed, Shenzhen, Peoples R China	Luo, T (corresponding author), Peking Univ, Shenzhen Hosp, Dept Anesthesiol, Shenzhen, Peoples R China.	luotao_wh@yahoo.com			Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81271205]; Natural Science Foundation of Guangdong provinceNational Natural Science Foundation of Guangdong Province [2015A030313781]	This study was supported by Natural Science Foundation of China (grant no. 81271205) and Natural Science Foundation of Guangdong province (grant no. 2015A030313781).	Adachi YU, 2005, ACTA ANAESTH SCAND, V49, P331, DOI 10.1111/j.1399-6576.2005.00564.x; Adembri C, 2006, ANESTHESIOLOGY, V104, P80, DOI 10.1097/00000542-200601000-00014; Androulidaki A, 2009, IMMUNITY, V31, P220, DOI 10.1016/j.immuni.2009.06.024; Bickler PE, 2012, ANESTHESIOLOGY, V117, P280, DOI 10.1097/ALN.0b013e318260a7b9; Butovsky O, 2015, ANN NEUROL, V77, P75, DOI 10.1002/ana.24304; Caballero-Garrido E, 2015, J NEUROSCI, V35, P12446, DOI 10.1523/JNEUROSCI.1641-15.2015; Chen Y, 2014, CURR MED CHEM, V21, P2146, DOI 10.2174/0929867321666131228203906; Cunningham C, 2013, GLIA, V61, P71, DOI 10.1002/glia.22350; Fan K, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0268-x; Franks NP, 2015, ANESTHESIOLOGY, V122, P787, DOI 10.1097/ALN.0000000000000588; Gaudet AD, 2016, J NEUROSCI, V36, P8516, DOI 10.1523/JNEUROSCI.0735-16.2016; Goto G, 2014, MOL MED REP, V9, P1715, DOI 10.3892/mmr.2014.2038; Graeber MB, 2011, FEBS LETT, V585, P3798, DOI 10.1016/j.febslet.2011.08.033; Guedes JR, 2014, HUM MOL GENET, V23, P6286, DOI 10.1093/hmg/ddu348; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Henn A, 2009, ALTEX-ALTERN TIEREXP, V26, P83; Huang X, 2016, BRAZ J MED BIOL RES, V49, DOI [10.1590/1414-431X20165717, 10.1590/1414-431x20165717]; Ishikawa M, 2012, ANESTHESIOLOGY, V117, P1245, DOI 10.1097/ALN.0b013e3182746676; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Liu ZM, 2016, AM J TRANSL RES, V8, P4120; Luo T, 2015, INFLAMM RES, V64, P205, DOI 10.1007/s00011-015-0798-9; Luo T, 2013, ANESTHESIOLOGY, V119, P1370, DOI 10.1097/ALN.0000000000000020; Marik PE, 2005, PHARMACOTHERAPY, V25, p28S, DOI 10.1592/phco.2005.25.5_Part_2.28S; Mayer AMS, 1998, MEDICINA-BUENOS AIRE, V58, P377; Moore CS, 2013, ANN NEUROL, V74, P709, DOI 10.1002/ana.23967; Murphy PG, 1996, BRIT J ANAESTH, V76, P536; Mycko MP, 2015, J NEUROSCI, V35, P16504, DOI 10.1523/JNEUROSCI.2830-15.2015; Nelson LE, 2002, NAT NEUROSCI, V5, P979, DOI 10.1038/nn913; Suk Kyoungho, 2012, Inflammopharmacology, V20, P151, DOI 10.1007/s10787-011-0108-2; Twaroski DM, 2014, ANESTHESIOLOGY, V121, P786, DOI 10.1097/ALN.0000000000000345; Velly LJ, 2003, ANESTHESIOLOGY, V99, P368, DOI 10.1097/00000542-200308000-00018; Vigorito E, 2013, IMMUNOL REV, V253, P146, DOI 10.1111/imr.12057; Wang DM, 2014, EUR J PHARMACOL, V728, P59, DOI 10.1016/j.ejphar.2014.01.057; Wang ZT, 2015, GENET MOL RES, V14, P7529, DOI 10.4238/2015.July.3.28; Wen Y, 2015, MOL MED, V21, P197, DOI 10.2119/molmed.2014.00199; Woodbury ME, 2015, J NEUROSCI, V35, P9764, DOI 10.1523/JNEUROSCI.4790-14.2015; Young Y, 1997, EUR J ANAESTH, V14, P320, DOI 10.1046/j.1365-2346.1997.00130.x; Zheng YY, 2008, ANESTH ANALG, V107, P2009, DOI 10.1213/ane.0b013e318187c313	38	32	36	3	23	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0360-3997	1573-2576		INFLAMMATION	Inflammation	FEB	2018	41	1					11	19		10.1007/s10753-017-0658-6			9	Cell Biology; Immunology	Cell Biology; Immunology	FS6GP	WOS:000419896200002	28875362				2021-06-18	
J	Baniqued, PL; Gallen, CL; Voss, MW; Burzynska, AZ; Wong, CN; Cooke, GE; Duffy, K; Fanning, J; Ehlers, DK; Salerno, EA; Aguinaga, S; McAuley, E; Kramer, AF; D'Esposito, M				Baniqued, Pauline L.; Gallen, Courtney L.; Voss, Michelle W.; Burzynska, Agnieszka Z.; Wong, Chelsea N.; Cooke, Gillian E.; Duffy, Kristin; Fanning, Jason; Ehlers, Diane K.; Salerno, Elizabeth A.; Aguinaga, Susan; McAuley, Edward; Kramer, Arthur F.; D'Esposito, Mark			Brain Network Modularity Predicts Exercise-Related Executive Function Gains in Older Adults	FRONTIERS IN AGING NEUROSCIENCE			English	Article						executive function; cognitive control; functional connectivity; exercise; brain network modularity	WORKING-MEMORY CAPACITY; WHITE-MATTER INTEGRITY; RESTING-STATE NETWORKS; AGE-RELATED-CHANGES; INDIVIDUAL-DIFFERENCES; AEROBIC FITNESS; CARDIORESPIRATORY FITNESS; COMMUNITY STRUCTURE; COGNITIVE DECLINE; OXYGEN-CONSUMPTION	Recent work suggests that the brain can be conceptualized as a network comprised of groups of sub-networks or modules. The extent of segregation between modules can be quantified with a modularity metric, where networks with high modularity have dense connections within modules and sparser connections between modules. Previous work has shown that higher modularity predicts greater improvements after cognitive training in patients with traumatic brain injury and in healthy older and young adults. It is not known, however, whether modularity can also predict cognitive gains after a physical exercise intervention. Here, we quantified modularity in older adults (N = 128, mean age = 64.74) who underwent one of the following interventions for 6 months (NCT01472744 on ClinicalTrials.gov): (1) aerobic exercise in the form of brisk walking (Walk), (2) aerobic exercise in the form of brisk walking plus nutritional supplement (Walk), (3) stretching, strengthening and stability (SSS), or (4) dance instruction. After the intervention, the Walk, Walk+ and SSS groups showed gains in cardiorespiratory fitness (CRF), with larger effects in both walking groups compared to the SSS and Dance groups. The Walk, Walk+ and SSS groups also improved in executive function (EF) as measured by reasoning, working memory, and task-switching tests. In the Walk, Walk+, and SSS groups that improved in EF, higher baseline modularity was positively related to EF gains, even after controlling for age, in-scanner motion and baseline EF. No relationship between modularity and EF gains was observed in the Dance group, which did not show training-related gains in CRF or EF control. These results are consistent with previous studies demonstrating that individuals with a more modular brain network organization are more responsive to cognitive training. These findings suggest that the predictive power of modularity may be generalizable across interventions aimed to enhance aspects of cognition and that, especially in low-performing individuals, global network properties can capture individual differences in neuroplasticity.	[Baniqued, Pauline L.; Gallen, Courtney L.; D'Esposito, Mark] Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA; [Baniqued, Pauline L.; Wong, Chelsea N.; Cooke, Gillian E.; Duffy, Kristin; McAuley, Edward; Kramer, Arthur F.] Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA; [Voss, Michelle W.] Univ Iowa, Dept Psychol & Brain Sci, Iowa City, IA USA; [Burzynska, Agnieszka Z.] Colorado State Univ, Dept Human Dev & Family Studies, Ft Collins, CO 80523 USA; [Cooke, Gillian E.] Univ Illinois, Interdisciplinary Hlth Sci Inst, Urbana, IL USA; [Fanning, Jason; Ehlers, Diane K.; Salerno, Elizabeth A.; Aguinaga, Susan; McAuley, Edward] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL USA; [Fanning, Jason] Wake Forest Sch Med, Dept Internal Med Gerontol, Winston Salem, NC USA; [Kramer, Arthur F.] Northeastern Univ, Dept Psychol, Boston, MA 02115 USA; [Kramer, Arthur F.] Northeastern Univ, Mech & Ind Engn Dept, Boston, MA 02115 USA	Baniqued, PL (corresponding author), Univ Calif Berkeley, Helen Wills Neurosci Inst, Berkeley, CA 94720 USA.; Baniqued, PL (corresponding author), Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA.	paulineb@berkeley.edu	Kramer, Arthur/AAB-2937-2019; Salerno, Elizabeth/N-1317-2019; Ehlers, Diane/AAK-4945-2021	Salerno, Elizabeth/0000-0001-5152-3168; Kramer, Arthur/0000-0001-5870-2724	National Science Foundation (IGERT)National Science Foundation (NSF) [0903622]; Beckman Institute for Advanced Science and Technology; Department of Defense (NDSEG)United States Department of Defense; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R37 AG025667, NS079698]; Center for Nutrition Learning and Memory, UIUC [2012-04673]; American Cancer SocietyAmerican Cancer Society [PF-16-021-01-CPPB]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS079698] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG025667, R37AG025667] Funding Source: NIH RePORTER	This work was supported by the National Science Foundation (IGERT Grant 0903622 to PB), Beckman Institute for Advanced Science and Technology (Graduate Fellowship to PB), Department of Defense (NDSEG to CG), National Institutes of Health (Grant R37 AG025667 to AK and EM, Grant NS079698 to MD), Center for Nutrition Learning and Memory, UIUC (Grant 2012-04673 to AK and EM), and the American Cancer Society (Postdoctoral Fellowship Grant PF-16-021-01-CPPB to DE). We thank Anya Knecht and Susan Houseworth for coordinating the intervention, Nancy Dodge and Holly Tracy for assistance in MRI data collection, Kathleen Kramer and Kishan Patel for assistance with Freesurfer processing, and members of the Lifelong Brain and Cognition Laboratory and Exercise Psychology Laboratory for assistance in data collection.	Andrews-Hanna JR, 2007, NEURON, V56, P924, DOI 10.1016/j.neuron.2007.10.038; Arnemann KL, 2015, NEUROLOGY, V84, P1568, DOI 10.1212/WNL.0000000000001476; Avants BB, 2011, NEUROIMAGE, V54, P2033, DOI 10.1016/j.neuroimage.2010.09.025; Avants BB, 2010, NEUROIMAGE, V49, P2457, DOI 10.1016/j.neuroimage.2009.09.062; Awick EA, 2015, QUAL LIFE RES, V24, P455, DOI 10.1007/s11136-014-0762-0; Balke B, 1959, PRESENT STATUS PHYS; Ball K, 2002, JAMA-J AM MED ASSOC, V288, P2271, DOI 10.1001/jama.288.18.2271; Baniqued P. L., 2015, SOC NEUR ANN M CHIC; Basak C, 2011, BRAIN COGNITION, V76, P407, DOI 10.1016/j.bandc.2011.03.017; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Bennett G., 1997, DIFFERENTIAL APTITUD; Berchtold NC, 2010, NEUROSCIENCE, V167, P588, DOI 10.1016/j.neuroscience.2010.02.050; Bertolero MA, 2015, P NATL ACAD SCI USA, V112, pE6798, DOI 10.1073/pnas.1510619112; Betzel RF, 2014, NEUROIMAGE, V102, P345, DOI 10.1016/j.neuroimage.2014.07.067; Bherer Louis, 2013, J Aging Res, V2013, P657508, DOI 10.1155/2013/657508; Birn RM, 2013, NEUROIMAGE, V83, P550, DOI 10.1016/j.neuroimage.2013.05.099; Bouchard C, 2001, MED SCI SPORT EXER, V33, pS446, DOI 10.1097/00005768-200106001-00013; Brown AD, 2010, NEUROBIOL AGING, V31, P2047, DOI 10.1016/j.neurobiolaging.2008.11.002; Buckley RF, 2017, NEUROLOGY, V89, P29, DOI 10.1212/WNL.0000000000004059; Buckner RL, 2004, NEUROIMAGE, V23, P724, DOI 10.1016/j.neuroimage.2004.06.018; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Burzynska AZ, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00059; Burzynska AZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120315; Cao H, 2014, NEUROIMAGE, V84, P888, DOI 10.1016/j.neuroimage.2013.09.013; Chaddock L, 2010, BRAIN RES, V1358, P172, DOI 10.1016/j.brainres.2010.08.049; Chadick JZ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5223; Chan MY, 2014, P NATL ACAD SCI USA, V111, pE4997, DOI 10.1073/pnas.1415122111; Chen ZJ, 2008, CEREB CORTEX, V18, P2374, DOI 10.1093/cercor/bhn003; Chen ZJ, 2011, NEUROIMAGE, V56, P235, DOI 10.1016/j.neuroimage.2011.01.010; Clune J, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2012.2863; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Cotman CW, 2007, TRENDS NEUROSCI, V30, P464, DOI 10.1016/j.tins.2007.06.011; D'Esposito M, 2003, NAT REV NEUROSCI, V4, P863, DOI 10.1038/nrn1246; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Damoiseaux JS, 2008, CEREB CORTEX, V18, P1856, DOI 10.1093/cercor/bhm207; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Draheim C, 2016, PERSPECT PSYCHOL SCI, V11, P133, DOI 10.1177/1745691615596990; Duncan ES, 2016, BRAIN CONNECT, V6, P524, DOI 10.1089/brain.2016.0437; DUSTMAN RE, 1984, NEUROBIOL AGING, V5, P35, DOI 10.1016/0197-4580(84)90083-6; Ehlers DK, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00110; Ehlers DK, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8570960; Ehlers DK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164246; Ekstrom R.B., 1976, MANUAL KIT FACTOR RE; Erickson KI, 2011, P NATL ACAD SCI USA, V108, P3017, DOI 10.1073/pnas.1015950108; Erickson KI, 2010, CEREB CORTEX, V20, P2522, DOI 10.1093/cercor/bhp293; Ericsson A, 2008, I S BIOMED IMAGING, P480, DOI 10.1109/ISBI.2008.4541037; Etnier JL, 2006, BRAIN RES REV, V52, P119, DOI 10.1016/j.brainresrev.2006.01.002; Fabiani M, 2012, PSYCHOPHYSIOLOGY, V49, P283, DOI 10.1111/j.1469-8986.2011.01331.x; Fanning J, 2017, J BEHAV MED, V40, P332, DOI 10.1007/s10865-016-9788-9; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fornito A, 2015, NAT REV NEUROSCI, V16, P159, DOI 10.1038/nrn3901; Fortunato S, 2010, PHYS REP, V486, P75, DOI 10.1016/j.physrep.2009.11.002; Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312; FROELICHER VF, 1975, CHEST, V68, P331, DOI 10.1378/chest.68.3.331; Gabrieli JDE, 2015, NEURON, V85, P11, DOI 10.1016/j.neuron.2014.10.047; Gallen CL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0169015; Geerligs L, 2015, CEREB CORTEX, V25, P1987, DOI 10.1093/cercor/bhu012; Giavasis S., 2015, C PAC CPAC VERSION 0; Gordon EM, 2017, NEURON, V95, P791, DOI 10.1016/j.neuron.2017.07.011; Grady C, 2012, NAT REV NEUROSCI, V13, P491, DOI 10.1038/nrn3256; Gratton C, 2012, J COGNITIVE NEUROSCI, V24, P1275, DOI 10.1162/jocn_a_00222; Guiney H, 2013, PSYCHON B REV, V20, P73, DOI 10.3758/s13423-012-0345-4; Hagberg A.A., 2008, P 7 PYTHON SCI C, P11, DOI DOI 10.1016/J.JELECTROCARD.2010.09.003; HAWKINS HL, 1992, PSYCHOL AGING, V7, P643, DOI 10.1037/0882-7974.7.4.643; Heckemann R. A., 2003, P 2 UK E SCI ALL HAN; Hedden T, 2012, J NEUROSCI, V32, P16233, DOI 10.1523/JNEUROSCI.2462-12.2012; Hillman CH, 2008, NAT REV NEUROSCI, V9, P58, DOI 10.1038/nrn2298; HUBERTY CJ, 1989, PSYCHOL BULL, V105, P302, DOI 10.1037/0033-2909.105.2.302; JACK CR, 1989, RADIOLOGY, V172, P549, DOI 10.1148/radiology.172.2.2748838; Jain V, 2010, J CEREBR BLOOD F MET, V30, P1598, DOI 10.1038/jcbfm.2010.49; Kane MJ, 2005, PSYCHOL BULL, V131, P66, DOI 10.1037/0033-2909.131.1.66; Kashtan N, 2005, P NATL ACAD SCI USA, V102, P13773, DOI 10.1073/pnas.0503610102; Kawagoe T, 2017, SCI REP-UK, V7, DOI 10.1038/srep40107; Kelly ME, 2014, AGEING RES REV, V16, P12, DOI 10.1016/j.arr.2014.05.002; Kennedy KM, 2009, NEUROPSYCHOLOGIA, V47, P916, DOI 10.1016/j.neuropsychologia.2009.01.001; King AC, 1997, JAMA-J AM MED ASSOC, V277, P32, DOI 10.1001/jama.277.1.32; Kitzbichler MG, 2011, J NEUROSCI, V31, P8259, DOI 10.1523/JNEUROSCI.0440-11.2011; Kramer AF, 1999, ACTA PSYCHOL, V101, P339, DOI 10.1016/S0001-6918(99)00011-6; Kramer AF, 2001, HUMAN FACTORS INTERVENTIONS FOR THE HEALTH CARE OF OLDER ADULTS, P91; Kramer AF, 2006, J APPL PHYSIOL, V101, P1237, DOI 10.1152/japplphysiol.00500.2006; Landman BA, 2011, NEUROIMAGE, V54, P2854, DOI 10.1016/j.neuroimage.2010.11.047; Laumann TO, 2015, NEURON, V87, P657, DOI 10.1016/j.neuron.2015.06.037; Leckie RL, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00985; Liu-Ambrose T, 2012, NEUROBIOL AGING, V33, P1690, DOI 10.1016/j.neurobiolaging.2011.05.010; Liu-Ambrose T, 2010, ARCH INTERN MED, V170, P170, DOI 10.1001/archinternmed.2009.494; Lustig C, 2009, NEUROPSYCHOL REV, V19, P504, DOI 10.1007/s11065-009-9119-9; Madden DJ, 2012, BBA-MOL BASIS DIS, V1822, P386, DOI 10.1016/j.bbadis.2011.08.003; Madden DJ, 2009, NEUROPSYCHOL REV, V19, P415, DOI 10.1007/s11065-009-9113-2; Mathewson KE, 2012, PSYCHOPHYSIOLOGY, V49, P1558, DOI 10.1111/j.1469-8986.2012.01474.x; McKinstry, 2009, NEUROIMAGE, V47, pS102, DOI DOI 10.1016/S1053-8119(09)70884-5; Meunier D, 2014, NEUROBIOL AGING, V35, P42, DOI 10.1016/j.neurobiolaging.2013.07.003; Meunier D, 2010, FRONT NEUROSCI-SWITZ, V4, DOI 10.3389/fnins.2010.00200; Meunier D, 2009, NEUROIMAGE, V44, P715, DOI 10.1016/j.neuroimage.2008.09.062; Monti JM, 2012, HIPPOCAMPUS, V22, P1876, DOI 10.1002/hipo.22023; Muschelli J, 2014, NEUROIMAGE, V96, P22, DOI 10.1016/j.neuroimage.2014.03.028; Newman MEJ, 2006, PHYS REV E, V74, DOI 10.1103/PhysRevE.74.036104; Newman MEJ, 2006, P NATL ACAD SCI USA, V103, P8577, DOI 10.1073/pnas.0601602103; Newman MEJ, 2004, PHYS REV E, V69, DOI [10.1103/PhysRevE.69.026113, 10.1103/PhysRevE.69.066133]; Nomura EM, 2010, P NATL ACAD SCI USA, V107, P12017, DOI 10.1073/pnas.1002431107; O'Bryant SE, 2008, ARCH NEUROL-CHICAGO, V65, P963, DOI 10.1001/archneur.65.7.963; Onoda K, 2013, NEUROSCI LETT, V556, P104, DOI 10.1016/j.neulet.2013.10.023; Persson J, 2006, CEREB CORTEX, V16, P907, DOI 10.1093/cercor/bhj036; Power JD, 2013, CURR OPIN NEUROBIOL, V23, P223, DOI 10.1016/j.conb.2012.12.009; Power JD, 2012, NEUROIMAGE, V59, P2142, DOI 10.1016/j.neuroimage.2011.10.018; Power JD, 2011, NEURON, V72, P665, DOI 10.1016/j.neuron.2011.09.006; Pudas S, 2018, CEREB CORTEX, V28, P936, DOI 10.1093/cercor/bhw418; Ravens J. C., 1962, ADV PROGR MATRICES; Raz N, 2005, CEREB CORTEX, V15, P1676, DOI 10.1093/cercor/bhi044; Raz N, 2006, NEUROSCI BIOBEHAV R, V30, P730, DOI 10.1016/j.neubiorev.2006.07.001; Ross R, 2016, CIRCULATION, V134, pE653, DOI 10.1161/CIR.0000000000000461; Rosvall M, 2008, P NATL ACAD SCI USA, V105, P1118, DOI 10.1073/pnas.0706851105; Sadaghiani S, 2015, P NATL ACAD SCI USA, V112, P8463, DOI 10.1073/pnas.1420687112; Salat DH, 2004, CEREB CORTEX, V14, P721, DOI 10.1093/cercor/bhh032; Salthouse TA, 2005, NEUROPSYCHOLOGY, V19, P532, DOI 10.1037/0894-4105.19.4.532; Salthouse TA, 2004, INTELLIGENCE, V32, P541, DOI 10.1016/j.intell.2004.07.003; Salthouse TA, 1996, NEUROPSYCHOLOGY, V10, P272, DOI 10.1037/0894-4105.10.2.272; Salthouse TA, 2003, PSYCHOL AGING, V18, P91, DOI 10.1037/0882-7974.18.1.91; SALTHOUSE TA, 1991, DEV PSYCHOL, V27, P763, DOI 10.1037/0012-1649.27.5.763; SALTHOUSE TA, 1993, J GERONTOL, V48, pP29, DOI 10.1093/geronj/48.1.P29; Salthouse TA, 2017, J GERONTOL B-PSYCHOL, V72, P7, DOI 10.1093/geronb/gbw069; Salthouse TA, 2010, NEUROPSYCHOLOGY, V24, P563, DOI 10.1037/a0019026; Samanez-Larkin GR, 2008, SOC COGN AFFECT NEUR, V3, P290, DOI 10.1093/scan/nsn029; Satterthwaite TD, 2012, NEUROIMAGE, V60, P623, DOI 10.1016/j.neuroimage.2011.12.063; Schultz DH, 2016, J NEUROSCI, V36, P8551, DOI 10.1523/JNEUROSCI.0358-16.2016; Siegel JS, 2017, CEREB CORTEX, V27, P4492, DOI 10.1093/cercor/bhw253; Soman S, 2016, HUM BRAIN MAPP, V37, P2185, DOI 10.1002/hbm.23166; Song J, 2014, BRAIN CONNECT, V4, P662, DOI 10.1089/brain.2014.0286; Stanley ML, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00954; Stevens AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030468; Stroth S, 2009, NEUROPSYCHOL REHABIL, V19, P223, DOI 10.1080/09602010802091183; Tosh CR, 2015, P ROY SOC B-BIOL SCI, V282, DOI 10.1098/rspb.2014.2568; TUKEY JW, 1962, ANN MATH STAT, V33, P1, DOI 10.1214/aoms/1177704711; Vo LTK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016093; Voss MW, 2016, NEUROIMAGE, V131, P113, DOI 10.1016/j.neuroimage.2015.10.044; Voss MW, 2013, HUM BRAIN MAPP, V34, P2972, DOI 10.1002/hbm.22119; Voss MW, 2013, TRENDS COGN SCI, V17, P525, DOI 10.1016/j.tics.2013.08.001; Voss MW, 2013, BRAIN BEHAV IMMUN, V28, P90, DOI 10.1016/j.bbi.2012.10.021; Voss MW, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00032; Voss MW, 2010, NEUROPSYCHOLOGIA, V48, P1394, DOI 10.1016/j.neuropsychologia.2010.01.005; Warren DE, 2014, P NATL ACAD SCI USA, V111, P14247, DOI 10.1073/pnas.1322173111; Wechsler D., 1997, WAIS 3 ADM SCORING M; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; WENGER HA, 1986, SPORTS MED, V3, P346, DOI 10.2165/00007256-198603050-00004; Wilcox R. R., 2005, OUTLIER DETECTION; Willis SL, 2006, JAMA-J AM MED ASSOC, V296, P2805, DOI 10.1001/jama.296.23.2805; Wilson RS, 2002, PSYCHOL AGING, V17, P179, DOI 10.1037/0882-7974.17.2.179; Woodcock R. W., 1989, WOODCOCK JOHNSON PSY; Zachary R., 1986, SHIPLEY I LIVING SCA; Zhang YY, 2001, IEEE T MED IMAGING, V20, P45, DOI 10.1109/42.906424; Zimmerman B, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00059	152	32	32	0	22	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1663-4365			FRONT AGING NEUROSCI	Front. Aging Neurosci.	JAN 4	2018	9								426	10.3389/fnagi.2017.00426			17	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	FR8WO	WOS:000419355600001	29354050	DOAJ Gold, Green Published			2021-06-18	
J	He, HF; Liu, WF; Zhou, YY; Liu, YB; Weng, PQ; Li, YS; Fu, HG				He, Hefan; Liu, Weifeng; Zhou, Yingying; Liu, Yibin; Weng, Peiqing; Li, Yasong; Fu, Huangde			Sevoflurane post-conditioning attenuates traumatic brain injury-induced neuronal apoptosis by promoting autophagy via the PI3K/AKT signaling pathway	DRUG DESIGN DEVELOPMENT AND THERAPY			English	Article						traumatic brain injury; sevoflurane post-conditioning; cell apoptosis; autophagy; PI3K/AKT signaling pathway	GLOBAL CEREBRAL-ISCHEMIA; PROVIDES NEUROPROTECTION; HYPOXIA-ISCHEMIA; ACTIVATION; RATS; MODEL; MICE; AKT; EXPRESSION; INHIBITOR	Background: Sevoflurane post-conditioning exerts nerve-protective effects through inhibiting caspase-dependent neuronal apoptosis after a traumatic brain injury (TBI). Autophagy that is induced by the endoplasmic reticulum stress plays an important role in the secondary neurological dysfunction after a TBI. However, the relationship between autophagy and caspase-dependent apoptosis as well as the underlying nerve protection mechanism that occurs with sevoflurane post-conditioning following a TBI remains unclear. Methods: The Feeney TBI model was used to induce brain injury in rats. Evaluation of the modified neurological severity scores, measurement of brain water content, Nissl staining, and terminal deoxynucleotidyl transferase dUTP nick end labeling assay were used to determine the neuroprotective effects of the sevoflurane post-conditioning. Both immunofluorescence and Western blot analyses were used to detect the expression of autophagy-related proteins microtubule-associated protein 1 light chain 3-II and Beclin-1, pro-apoptotic factors, as well as the activation of the phosphatidylinositide 3-kinase/protein kinase B (PI3K/AKT) signaling pathway within the lesioned cortex. Results: Autophagy and neuronal apoptosis were activated in the lesioned cortex following the TBI. Sevoflurane post-conditioning enhanced early autophagy, suppressed neuronal apoptosis, and alleviated brain edema, which improved nerve function after a TBI (all P<0.05). Sevoflurane post-conditioning induced the activation of PI3K/AKT signaling after the TBI (P<0.05). The neuroprotective effects of sevoflurane post-conditioning were reversed through the autophagy inhibitor 3-methyladenine treatment. Conclusion: Neuronal apoptosis and the activation of autophagy were involved in the secondary neurological injury following a TBI. Sevoflurane post-conditioning weakened the TBI-induced neuronal apoptosis by regulating autophagy via PI3K/AKT signaling.	[He, Hefan; Liu, Weifeng; Zhou, Yingying; Liu, Yibin; Weng, Peiqing] Fujian Med Univ, Affiliated Hosp 2, Dept Anesthesia, 34 Zhongshan Rd, Quanzhou 362000, Fujian, Peoples R China; [Li, Yasong] Fujian Med Univ, Affiliated Hosp 2, Dept Neurosurg, Quanzhou, Fujian, Peoples R China; [Fu, Huangde] Youjiang Med Univ Nationalities, Affiliated Hosp, Dept Neurosurg, Baise 533000, Guangxi Provinc, Peoples R China	Liu, WF (corresponding author), Fujian Med Univ, Affiliated Hosp 2, Dept Anesthesia, 34 Zhongshan Rd, Quanzhou 362000, Fujian, Peoples R China.; Fu, HG (corresponding author), Youjiang Med Univ Nationalities, Affiliated Hosp, Dept Neurosurg, Baise 533000, Guangxi Provinc, Peoples R China.	rong281@126.com; xiangrong_chen281@126.com			Fujian Province Natural Science FoundationNatural Science Foundation of Fujian Province [2016J01520]	This work was supported by grants from the Fujian Province Natural Science Foundation (no 2016J01520 for Professor Hefan He).	Abdul-Muneer PM, 2017, BRAIN BEHAV IMMUN, V59, P190, DOI 10.1016/j.bbi.2016.09.002; Chen XR, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0917-3; Chen Y, 2015, BRIT J ANAESTH, V114, P327, DOI 10.1093/bja/aeu271; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Deegan S, 2013, CELL MOL LIFE SCI, V70, P2425, DOI 10.1007/s00018-012-1173-4; Delbary-Gossart S, 2016, BRAIN, V139, P1762, DOI 10.1093/brain/aww074; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; Du GL, 2016, NEUROL RES, V38, P1012, DOI 10.1080/01616412.2016.1240393; Feng Y, 2017, CELL MOL NEUROBIOL, V37, P155, DOI 10.1007/s10571-016-0356-1; Gao YY, 2016, J SURG RES, V206, P67, DOI 10.1016/j.jss.2016.07.014; Harvey LD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415618969; He RN, 2015, AUTOPHAGY, V11, P740, DOI 10.1080/15548627.2015.1034404; Jin YC, 2016, WORLD NEUROSURG, V88, P433, DOI 10.1016/j.wneu.2015.10.055; Kim HC, 2017, J NEUROSURG ANESTH, V29, P37, DOI 10.1097/ANA.0000000000000331; Lai ZM, 2016, BRAIN RES, V1630, P25, DOI 10.1016/j.brainres.2015.10.050; Lee H, 2015, BRIT J ANAESTH, V114, P307, DOI 10.1093/bja/aeu268; Li L, 2017, ONCOTARGET, V8, P28544, DOI 10.18632/oncotarget.15325; Lin C, 2016, J PINEAL RES, V61, P177, DOI 10.1111/jpi.12337; Logsdon AE, 2016, BRAIN RES, V1643, P140, DOI 10.1016/j.brainres.2016.04.063; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Miao JY, 2016, NEUROCHEM RES, V41, P2300, DOI 10.1007/s11064-016-1944-7; Ren XY, 2014, NEUROL SCI, V35, P1401, DOI 10.1007/s10072-014-1726-4; Ryter Stefan W, 2013, J Biochem Pharmacol Res, V1, P176; Schmitz KJ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0946-x; Sun DD, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00193; Thal SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050752; Wang HL, 2016, ACTA NEUROCHIR SUPPL, V121, P55, DOI 10.1007/978-3-319-18497-5_10; Yang ZC, 2014, MOL MED REP, V9, P843, DOI 10.3892/mmr.2014.1912; Zhang L, 2016, CELL MOL NEUROBIOL, V36, P131, DOI 10.1007/s10571-015-0227-1; Zhu YM, 2017, NEUROSCIENCE, V356, P125, DOI 10.1016/j.neuroscience.2017.05.004	30	32	35	1	2	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1177-8881			DRUG DES DEV THER	Drug Des. Dev. Ther.		2018	12						629	638		10.2147/DDDT.S158313			10	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	GB1HG	WOS:000428801300001	29606856	DOAJ Gold, Green Published			2021-06-18	
J	Kong, ZH; Chen, X; Hua, HP; Liang, L; Liu, LJ				Kong, Zhong-Hong; Chen, Xin; Hua, Hui-Po; Liang, Liang; Liu, Long-Juan			The Oral Pretreatment of Glycyrrhizin Prevents Surgery-Induced Cognitive Impairment in Aged Mice by Reducing Neuroinflammation and Alzheimer's-Related Pathology via HMGB1 Inhibition	JOURNAL OF MOLECULAR NEUROSCIENCE			English	Article						Postoperative cognitive dysfunction; Glycyrrhizin; High-mobility group box 1; Neuroinflammation	MOBILITY GROUP BOX-1; TRAUMATIC BRAIN-INJURY; SIGNALING PATHWAY; DYSFUNCTION; RATS; ACTIVATION; DISEASE; RAGE; INFLAMMATION; ANESTHESIA	Neuroinflammation and Alzheimer's-related pathology play essential roles in postoperative cognitive dysfunction (POCD). High-mobility group box 1 (HMGB1) is well known as a pivotal mediator in neuroinflammation, and its associations with Alzheimer's-related pathology and POCD have been also revealed. Glycyrrhizin is a nature inhibitor of HMGB1 and is reported with neuroprotective effects through oral administration. Therefore, the present study aims to test the hypothesis that the oral pretreatment of glycyrrhizin prevents POCD by inhibiting HMGB1-induced neuroinflammation and Alzheimer's-related pathology in aged mice. Aged male C57BL/6 mice were subjected to the splenectomy surgery under general anesthesia and the oral pretreatment of glycyrrhizin. The postoperative cognitive changes were evaluated by using Morris water maze (MWM) test. The protein expressions of HMGB1, TLR4, NF-kappa B, p-Tau, and pro-inflammatory cytokines were determined by Western blot assay. The hippocampal level of beta-amyloid (A beta) was assessed by ELISA assay. We found that the oral pretreatment of glycyrrhizin inhibited HMGB1 cytosolic expression, increased the PSD-95 protein expression, and attenuated the severity of postoperative memory impairment, as indicated by the shorter swimming latency and distance in MWM trials when compared with the mice subjected to the surgery alone. Additionally, the pretreatment of glycyrrhizin reduced the postoperative neuroinflammation (production of pro-inflammatory cytokines including IL-1 beta, TNF-alpha, and IL-6 as well as NF-kappa B nuclear expression) and Alzheimer's-related pathology (Tau phosphorylation at the site of AT-8 and Ser396 as well as A beta 40 and 42 concentrations) in the hippocampus of the aged mice undergoing splenectomy surgery. In conclusion, our results suggest that the oral pretreatment of glycyrrhizin can prevent the postoperative cognitive impairment by reducing neuroinflammation and Alzheimer's-related pathology in the hippocampus of aged mice via HMGB1 inhibition.	[Kong, Zhong-Hong; Hua, Hui-Po; Liang, Liang; Liu, Long-Juan] Tongchuan Min Bur, Cent Hosp, Dept Anesthesiol, Tongchuan 727000, Shaanxi, Peoples R China; [Chen, Xin] Shaanxi Prov Peoples Hosp, Dept Anesthesiol, Xian 710068, Shaanxi, Peoples R China	Liu, LJ (corresponding author), Tongchuan Min Bur, Cent Hosp, Dept Anesthesiol, Tongchuan 727000, Shaanxi, Peoples R China.	liulongjuan2015@sina.com					Arora SS, 2014, INT J NEUROSCI, V124, P236, DOI 10.3109/00207454.2013.833919; Cao XZ, 2010, PROG NEURO-PSYCHOPH, V34, P1426, DOI 10.1016/j.pnpbp.2010.07.027; Chavan SS, 2012, MOL MED, V18, P930, DOI 10.2119/molmed.2012.00195; Deane R, 2012, J CLIN INVEST, V122, P1377, DOI 10.1172/JCI58642; Deiner S, 2009, Br J Anaesth, V103 Suppl 1, pi41, DOI 10.1093/bja/aep291; Fang P, 2012, MOL NEUROBIOL, V45, P499, DOI 10.1007/s12035-012-8264-y; Fodale V, 2010, ANAESTHESIA, V65, P388, DOI 10.1111/j.1365-2044.2010.06244.x; Fonken LK, 2016, J NEUROSCI, V36, P7946, DOI 10.1523/JNEUROSCI.1161-16.2016; Fujita K, 2016, SCI REP-UK, V6, DOI 10.1038/srep31895; Gravina SA, 1995, J BIOL CHEM, V270, P7013; He HJ, 2012, CNS NEUROSCI THER, V18, P994, DOI 10.1111/cns.12018; Hovens IB, 2015, NEUROBIOL LEARN MEM, V118, P74, DOI 10.1016/j.nlm.2014.11.009; Hovens IB, 2014, BRAIN BEHAV IMMUN, V38, P202, DOI 10.1016/j.bbi.2014.02.002; Hu ZH, 2010, MED HYPOTHESES, V74, P722, DOI 10.1016/j.mehy.2009.10.040; Jin WJ, 2014, NEUROREPORT, V25, P1, DOI 10.1097/WNR.0000000000000082; Kamer AR, 2012, EUR J ANAESTH, V29, P332, DOI 10.1097/EJA.0b013e3283534f56; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Le Freche H, 2012, ANESTHESIOLOGY, V116, P779, DOI 10.1097/ALN.0b013e31824be8c7; Li RL, 2013, J SURG RES, V185, P815, DOI 10.1016/j.jss.2013.06.043; Li YC, 2012, ACTA ANAESTH SCAND, V56, P595, DOI 10.1111/j.1399-6576.2011.02616.x; Li ZQ, 2013, BIOCHEM BIOPH RES CO, V438, P628, DOI 10.1016/j.bbrc.2013.08.003; Liu WR, 2012, NEUROL RES, V34, P3, DOI 10.1179/1743132811Y.0000000047; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Moller JT, 1998, LANCET, V351, P857, DOI 10.1016/S0140-6736(97)07382-0; Mollica L, 2007, CHEM BIOL, V14, P431, DOI 10.1016/j.chembiol.2007.03.007; Monk TG, 2008, ANESTHESIOLOGY, V108, P18, DOI 10.1097/01.anes.0000296071.19434.1e; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Robinson AP, 2013, J AUTOIMMUN, V43, P32, DOI 10.1016/j.jaut.2013.02.005; Sanders RD, 2010, EUR J ANAESTH, V27, P3, DOI 10.1097/EJA.0b013e3283318ef9; Seymour DG, 2009, AGE AGEING, V38, P147, DOI 10.1093/ageing/afn289; Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603; Song JH, 2013, MOLECULES, V18, P15788, DOI 10.3390/molecules181215788; Stahel PF, 2012, J TRAUMA ACUTE CARE, V73, P782, DOI 10.1097/TA.0b013e31825e898e; Tabuchi M, 2012, CELL MOL NEUROBIOL, V32, P1139, DOI 10.1007/s10571-012-9839-x; Tang JXX, 2011, ANESTHESIOLOGY, V115, P727, DOI 10.1097/ALN.0b013e31822e9306; Terrando N, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00441; Tian A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141596; Tian XD, 2017, BRAIN RES, V1670, P135, DOI 10.1016/j.brainres.2017.06.001; Vacas S, 2013, BRIT MED BULL, V106, P161, DOI 10.1093/bmb/ldt006; van Praag H, 2005, J NEUROSCI, V25, P8680, DOI 10.1523/JNEUROSCI.1731-05.2005; Venereau E, 2013, MOL IMMUNOL, V55, P76, DOI 10.1016/j.molimm.2012.10.037; Wang LN, 2010, NEUROSCI LETT, V471, P152, DOI 10.1016/j.neulet.2010.01.030; Wang W, 2016, NEUROSCIENCE, V316, P328, DOI 10.1016/j.neuroscience.2015.11.001; Wang Y, 2013, MOL MED REP, V7, P1137, DOI 10.3892/mmr.2013.1322; Xie ZC, 2006, EXP GERONTOL, V41, P346, DOI 10.1016/j.exger.2006.01.014; Xu ZP, 2014, SCI REP-UK, V4, DOI 10.1038/srep03766; Yan RQ, 2014, LANCET NEUROL, V13, P319, DOI 10.1016/S1474-4422(13)70276-X; Yang GD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078355; Yang H, 2013, J LEUKOCYTE BIOL, V93, P865, DOI 10.1189/jlb.1212662; Yang H, 2010, BBA-GENE REGUL MECH, V1799, P149, DOI 10.1016/j.bbagrm.2009.11.019; Yang Qing-Wu, 2010, Front Biosci (Schol Ed), V2, P1081; Zhang JC, 2014, BRAIN RES, V1582, P176, DOI 10.1016/j.brainres.2014.07.002; Zhu YJ, 2016, BRAIN RES, V1644, P1, DOI 10.1016/j.brainres.2016.04.074	54	32	33	0	17	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0895-8696	1559-1166		J MOL NEUROSCI	J. Mol. Neurosci.	DEC	2017	63	3-4					385	395		10.1007/s12031-017-0989-7			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	FN4NM	WOS:000415983800013	29034441				2021-06-18	
J	Wang, TW; Chang, KC; Chen, LH; Liao, SY; Yeh, CW; Chuang, YJ				Wang, Tzu-Wei; Chang, Kai-Chieh; Chen, Liang-Hsin; Liao, Shih-Yung; Yeh, Chia-Wei; Chuang, Yung-Jen			Effects of an injectable functionalized selfassembling nanopeptide hydrogel on angiogenesis and neurogenesis for regeneration of the central nervous system	NANOSCALE			English	Article							TRAUMATIC BRAIN-INJURY; ASSEMBLING PEPTIDE HYDROGEL; NEURAL PROGENITOR CELLS; ANIMAL-MODEL; IN-VIVO; ZEBRAFISH; SVVYGLR; REPAIR; OSTEOPONTIN; SCAFFOLDS	Brain injury is a devastating medical condition and represents a major health problem. Tissue and organ reconstruction have been regarded as promising therapeutic strategies. Here, we propose a regenerative methodology focusing on the provision of functionalized nanopeptide scaffolds to facilitate angiogenesis and neurogenesis at the brain injury site. The peptide RADA16-SVVYGLR undergoes self-assembly to construct an interconnected network with intertwining nanofibers, and can be controlled to display various physicochemical properties by the adjustment of microenvironmental factors such as pH and ion concentration. Such scaffolds can support endothelial cells to form tube-like structures and neural stem cells to survive and proliferate. In an in vivo zebrafish brain injury model, sprouting angiogenesis and developmental neurogenesis were achieved, and functional recovery of the severed optic tectum was enhanced in RADA16-SVVYGLR hydrogel-implanted zebrafish. This nanopeptide hydrogel was non-toxic to zebrafish embryos during early developmental stages. This angiogenic self-assembling peptide hydrogel had programmable physical properties, good biocompatibility, and regenerative ability for functional recovery in the injured brain. We suggest that functionalized self-assembling peptides encapsulated with neural stem cells or used alone could be an attractive and effective therapeutic modality for brain injury and diseases (e.g., trauma, stroke, tumor, degenerative neurological disorders, etc.).	[Wang, Tzu-Wei; Chang, Kai-Chieh; Chen, Liang-Hsin; Yeh, Chia-Wei] Natl Tsing Hua Univ, Dept Mat Sci & Engn, Hsinchu, Taiwan; [Liao, Shih-Yung] Natl Tsing Hua Univ, Dept Biomed Engn & Environm Sci, Hsinchu, Taiwan; [Chuang, Yung-Jen] Natl Tsing Hua Univ, Dept Med Sci, Hsinchu, Taiwan; [Chuang, Yung-Jen] Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Hsinchu, Taiwan	Wang, TW (corresponding author), Natl Tsing Hua Univ, Dept Mat Sci & Engn, Hsinchu, Taiwan.	twwang@mx.nthu.edu.tw		Chuang, Yung-Jen/0000-0002-6022-0107; Wang, Tzu-Wei/0000-0003-0669-6240	 [MOST 104-2628-E-007-002-MY3];  [MOST 104-2221-E-007-140-MY2];  [MOST 104-2622-E-007-018-CC2]	The authors are greatly thankful for advice and valuable suggestions from Professor Jia-Cherng Horng (Department of Chemistry, National Tsing Hua University) and Shu-Wei Chang (Department of Civil Engineering, National Taiwan University). We also thank Professor Chi-Shiun Chiang (Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University) for help in cryostat microtome analyses. The authors also thank the funding support from MOST 104-2628-E-007-002-MY3, MOST 104-2221-E-007-140-MY2 and MOST 104-2622-E-007-018-CC2.	Ahmadi F, 2015, RES PHARM SCI, V10, P1; Alunni A, 2016, DEVELOPMENT, V143, P741, DOI 10.1242/dev.122796; Alvarez XA, 2013, FUTUR NEUROL, V8, P175, DOI 10.2217/FNL.12.95; Aramvash A, 2015, J CLUST SCI, V26, P631, DOI 10.1007/s10876-014-0836-8; Arosio P, 2012, BIOPHYS J, V102, P1617, DOI 10.1016/j.bpj.2012.03.012; Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Barbolt TA, 2001, NEUROL RES, V23, P813, DOI 10.1179/016164101101199405; Chan LY, 2011, BLOOD, V118, P6709, DOI 10.1182/blood-2011-06-359141; Cheng TY, 2013, NANOSCALE, V5, P2734, DOI 10.1039/c3nr33710c; Cheng TY, 2013, BIOMATERIALS, V34, P2005, DOI 10.1016/j.biomaterials.2012.11.043; Delov V, 2014, AQUAT TOXICOL, V150, P189, DOI 10.1016/j.aquatox.2014.03.010; Eskandari S, 2017, ADV DRUG DELIVER REV, V110, P169, DOI 10.1016/j.addr.2016.06.013; Estroff LA, 2004, CHEM REV, V104, P1201, DOI 10.1021/cr0302049; Font MA, 2010, CURR CARDIOL REV, V6, P238, DOI 10.2174/157340310791658802; Francis NL, 2016, ACS BIOMATER SCI ENG, V2, P1030, DOI 10.1021/acsbiomaterials.6b00156; Hamada Y, 2004, DENT MATER J, V23, P650, DOI 10.4012/dmj.23.650; Hamada Y, 2003, BIOCHEM BIOPH RES CO, V310, P153, DOI 10.1016/j.bbrc.2003.09.001; Ito K, 2009, MATRIX BIOL, V28, P11, DOI 10.1016/j.matbio.2008.10.002; Kim JH, 2002, NATURE, V418, P50, DOI 10.1038/nature00900; Kojima T, 2010, STEM CELLS, V28, P545, DOI 10.1002/stem.306; Loo Y, 2012, BIOTECHNOL ADV, V30, P593, DOI 10.1016/j.biotechadv.2011.10.004; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Maaswinkel H, 2003, VISION RES, V43, P21, DOI 10.1016/S0042-6989(02)00395-4; Marz M, 2011, DEV DYNAM, V240, P2221, DOI 10.1002/dvdy.22710; Meng FW, 2014, REGEN MED, V9, P367, DOI [10.2217/RME.14.9, 10.2217/rme.14.9]; Orive G, 2009, NAT REV NEUROSCI, V10, P682, DOI 10.1038/nrn2685; Owczarz M, 2015, BIOMACROMOLECULES, V16, P3792, DOI 10.1021/acs.biomac.5b01092; Reddy DS, 2010, PROG BRAIN RES, V186, P113, DOI 10.1016/B978-0-444-53630-3.00008-7; Rodriguez AL, 2014, J MATER CHEM B, V2, P7771, DOI 10.1039/c4tb01391c; Servadei F, 2007, CURR OPIN CRIT CARE, V13, P163, DOI 10.1097/MCC.0b013e32807f2a94; Shen XP, 2016, GREEN CHEM, V18, P53, DOI 10.1039/c5gc02396c; Somaa FA, 2017, CELL REP, V20, P1964, DOI 10.1016/j.celrep.2017.07.069; SPRINGER AD, 1977, BRAIN RES, V128, P393, DOI 10.1016/0006-8993(77)90166-4; Stendahl JC, 2006, ADV FUNCT MATER, V16, P499, DOI 10.1002/adfm.200500161; Tal TL, 2014, REPROD TOXICOL, V48, P51, DOI 10.1016/j.reprotox.2014.05.014; Tam RY, 2014, NEUROPSYCHOPHARMACOL, V39, P169, DOI 10.1038/npp.2013.237; Uchinaka A, 2013, CARDIOVASC RES, V99, P102, DOI 10.1093/cvr/cvt088; Wang TW, 2017, ACTA BIOMATER, V58, P54, DOI 10.1016/j.actbio.2017.06.008; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Ye ZY, 2008, J PEPT SCI, V14, P152, DOI 10.1002/psc.988; Yokoi H, 2005, P NATL ACAD SCI USA, V102, P8414, DOI 10.1073/pnas.0407843102; Yokosaki Y, 1999, J BIOL CHEM, V274, P36328, DOI 10.1074/jbc.274.51.36328; Zhou A, 2016, DRUG DES DEV THER, V10, P3043, DOI 10.2147/DDDT.S109545; Zweckberger K, 2016, ACTA BIOMATER, V42, P77, DOI 10.1016/j.actbio.2016.06.016	44	32	34	7	60	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	2040-3364	2040-3372		NANOSCALE	Nanoscale	NOV 14	2017	9	42					16281	16292		10.1039/c7nr06528k			12	Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied	Chemistry; Science & Technology - Other Topics; Materials Science; Physics	FL6IT	WOS:000414349100022	29046917				2021-06-18	
J	Liu, YL; Xu, ZM; Yang, GY; Yang, DX; Ding, J; Chen, H; Yuan, F; Tian, HL				Liu, Ying-liang; Xu, Zhi-ming; Yang, Guo-yuan; Yang, Dian-xu; Ding, Jun; Chen, Hao; Yuan, Fang; Tian, Heng-li			Sesamin alleviates blood-brain barrier disruption in mice with experimental traumatic brain injury	ACTA PHARMACOLOGICA SINICA			English	Article						sesamin; traumatic brain injury; CCI injury; bEnd.3 cells; oxidative stress; apoptosis; BBB; tight junction proteins	OXIDATIVE STRESS; IN-VITRO; SIGNAL-TRANSDUCTION; PARKINSONS-DISEASE; CELL-DEATH; APOPTOSIS; INFLAMMATION; ACTIVATION; INHIBITION; AUTOPHAGY	Sesamin, a major lignan of sesame oil, was reported to have neuroprotective effects in several brain injury models. However, its protective action in maintaining blood-brain barrier (BBB) integrity has not been studied. In this study we investigated the effects of sesamin on the BBB in a mouse model of traumatic brain injury (TBI) and explored the underlying mechanisms. Adult male C57BL/6 mice were subjected to a controlled cortical impact (CCI) injury and then received sesamin (30 mg.kg(-1).d(-1), ip). The mice were euthanized on the 1st and 3rd days after CCI injury and samples were collected for analysis. Sesamin treatment significantly attenuated CCI-induced brain edema on the 1st and 3rd days after the injury, evidenced by the decreases in water content, tissue hemoglobin levels, Evans blue extravasation and AQP4 expression levels in the ipsilateral cortical tissue compared with the vehicle-treated group. Furthermore, sesamin treatment significantly alleviated CCI-induced loss of the tight junction proteins ZO-1 and occludin in the brain tissues. The neuroprotective mechanisms of sesamin were further explored in cultured mouse brain microvascular bEnd. 3 cells subjected to biaxial stretch injury (SI). Pretreatment with sesamin (50 mu mol/L) significantly alleviated SI-induced loss of ZO-1 in bEnd. 3 cells. Furthermore, we revealed that pretreatment with sesamin significantly attenuated SI-induced oxidative stress and early-stage apoptosis in bEnd. 3 cells by decreasing the activation of ERK, p38 and caspase-3. In conclusion, sesamin alleviates BBB disruption at least partly through its anti-oxidative and anti-apoptotic effects on endothelial cells in CCI injury. These findings suggest that sesamin may be a promising potential therapeutic intervention for preventing disruption of the BBB after TBI.	[Liu, Ying-liang; Xu, Zhi-ming; Yang, Dian-xu; Ding, Jun; Chen, Hao; Yuan, Fang; Tian, Heng-li] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Sch Med, Dept Neurosurg, Shanghai 200233, Peoples R China; [Yang, Guo-yuan] Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai 200233, Peoples R China; [Yang, Guo-yuan] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai 200233, Peoples R China	Yuan, F; Tian, HL (corresponding author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Sch Med, Dept Neurosurg, Shanghai 200233, Peoples R China.	yf021025@126.com; tianhlsh@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81471245, 81671207, 81501657]; Shanghai Jiao Tong University Medicine-Engineering Research Fund [YG2016QN20]	This work was supported by grants from National Natural Science Foundation of China (No 81471245, 81671207, and 81501657), and Shanghai Jiao Tong University Medicine-Engineering Research Fund (YG2016QN20).	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Abu-Qare AW, 2001, J TOXICOL ENV HEAL B, V4, P313, DOI 10.1080/109374001301419737; Ahmad S, 2014, NEUROTOXICOLOGY, V45, P100, DOI 10.1016/j.neuro.2014.10.002; Ahmad S, 2013, J NEUROIMMUNOL, V264, P54, DOI 10.1016/j.jneuroim.2013.09.015; Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nrn1434; Angeloni C, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/370312; Balazy M, 2003, AGEING RES REV, V2, P191, DOI 10.1016/S1568-1637(02)00065-X; Benga O, 2012, MOL ASPECTS MED, V33, P562, DOI 10.1016/j.mam.2012.03.008; Butterfield DA, 2016, PROTEOM CLIN APPL, V10, P1191, DOI 10.1002/prca.201600003; Cao JL, 2015, AQUAT TOXICOL, V167, P180, DOI 10.1016/j.aquatox.2015.08.004; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Fujikawa T, 2005, J ETHNOPHARMACOL, V97, P375, DOI 10.1016/j.jep.2004.11.031; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; Han J, 1999, NAT CELL BIOL, V1, pE39, DOI 10.1038/10032; Hirt L, 2009, J CEREBR BLOOD F MET, V29, P423, DOI 10.1038/jcbfm.2008.133; Hou RCW, 2004, NEUROSCI LETT, V367, P10, DOI 10.1016/j.neulet.2004.05.073; Hou RCW, 2003, J NEUROSCI RES, V74, P123, DOI 10.1002/jnr.10749; Hsieh PF, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-57; Kang R, 2011, AUTOPHAGY, V7, P442, DOI 10.4161/auto.7.4.14681; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011; Lee CC, 2004, J HYPERTENS, V22, P2329, DOI 10.1097/00004872-200412000-00015; Lopez-Garcia I, 2018, BRIT J PHARMACOL, V175, P284, DOI 10.1111/bph.13642; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Mayr M, 2000, FASEB J, V14, P261; Mori T, 2002, J CEREBR BLOOD F MET, V22, P444, DOI 10.1097/00004647-200204000-00008; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nathan C, 2010, CELL, V140, DOI 10.1016/j.cell.2010.03.008; Otani N, 2002, J CEREBR BLOOD F MET, V22, P327, DOI 10.1097/00004647-200203000-00010; Park HJ, 2015, NEUROCHEM INT, V83-84, P19, DOI 10.1016/j.neuint.2015.01.003; Saadoun S, 2010, NEUROSCIENCE, V168, P1036, DOI 10.1016/j.neuroscience.2009.08.019; Salvador E, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00323; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Serbest G, 2006, FASEB J, V20, P308, DOI 10.1096/fj.05-4024fje; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; Shi YG, 2004, PROTEIN SCI, V13, P1979, DOI 10.1110/ps.04789804; Son Y, 2013, METHOD ENZYMOL, V528, P27, DOI 10.1016/B978-0-12-405881-1.00002-1; Tian RF, 2016, BRAIN RES, V1637, P1, DOI 10.1016/j.brainres.2016.01.029; Toklu H.Z., 2015, BRAIN NEUROTRAUMA MO; Warth A, 2004, ACTA NEUROPATHOL, V107, P311, DOI 10.1007/s00401-003-0812-0; Weber DJ, 2014, SCI TRANSL MED, V6, P252; Wu WH, 2010, MOL NUTR FOOD RES, V54, P1340, DOI 10.1002/mnfr.200900271; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu ZM, 2017, J NEUROTRAUM, V34, P925, DOI 10.1089/neu.2016.4491; Yang T, 2014, CELL MOL NEUROBIOL, V34, P797, DOI 10.1007/s10571-014-0070-9; Yin Q, 2015, BRIT J PHARMACOL, V172, P5573, DOI 10.1111/bph.13133; Yin YX, 1998, NATURE, V391, P707; Yuan F, 2016, J NEUROCHEM, V136, P581, DOI 10.1111/jnc.13423; ZHANG J, 2016, OXID MED CELL LONGEV, V2016, DOI DOI 10.1155/2016/4350965; Zhao L, 2015, J PINEAL RES, V59, P230, DOI 10.1111/jpi.12254; Zhao Z, 2015, CELL, V163, P1064, DOI 10.1016/j.cell.2015.10.067	54	32	33	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1671-4083	1745-7254		ACTA PHARMACOL SIN	Acta Pharmacol. Sin.	NOV	2017	38	11					1445	1455		10.1038/aps.2017.103			11	Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Chemistry; Pharmacology & Pharmacy	FL5CL	WOS:000414248600003	28770828	Green Published, Bronze			2021-06-18	
J	Hicks, SD; Johnson, J; Carney, MC; Bramley, H; Olympia, RP; Loeffert, AC; Thomas, NJ				Hicks, Steven D.; Johnson, Jeremiah; Carney, Molly C.; Bramley, Harry; Olympia, Robert P.; Loeffert, Andrea C.; Thomas, Neal J.			Overlapping MicroRNA Expression in Saliva and Cerebrospinal Fluid Accurately Identifies Pediatric Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarker; concussion; microRNA; pediatrics; saliva	BIOMARKERS; CONCUSSION; DIAGNOSIS; SPECTRUM; SPORT; RNAS	To assess the accuracy and physiological relevance of circulating microRNA (miRNA) as a biomarker of pediatric concussion, we compared changes in salivary miRNA and cerebrospinal fluid (CSF) miRNA concentrations after childhood traumatic brain injury (TBI). A case-cohort design was used to compare longitudinal miRNA concentrations in CSF of seven children with severe TBI against three controls without TBI. The miRNAs "altered" in CSF were interrogated in saliva of 60 children with mild TBI and compared with 18 age- and sex-matched controls. The miRNAs with parallel changes (Wilcoxon rank sum test) in CSF and saliva were interrogated for predictive accuracy of TBI status using a multivariate regression technique. Spearman rank correlation identified relationships between miRNAs of interest and clinical features. Functional analysis with DIANA mirPath identified related mRNA pathways. There were 214 miRNAs detected in CSF, and 135 (63%) were also present in saliva. Six miRNAs had parallel changes in both CSF and saliva (miR-182-5p, miR-221-3p, mir-26b-5p, miR-320c, miR-29c-3p, miR-30e-5p). These miRNAs demonstrated an area under the curve of 0.852 for identifying mild TBI status. Three of the miRNAs exhibited longitudinal trends in CSF and/or saliva after TBI, and all three targeted mRNAs related to neuronal development. Concentrations of miR-320c were directly correlated with child and parent reports of attention difficulty. Salivary miRNA represents an easily measured, physiologically relevant, and accurate potential biomarker for TBI. Further studies assessing the influence of orthopedic injury and exercise on peripheral miRNA patterns are needed.	[Hicks, Steven D.; Johnson, Jeremiah; Carney, Molly C.; Bramley, Harry; Olympia, Robert P.; Loeffert, Andrea C.; Thomas, Neal J.] Penn State Coll Med, Dept Pediat, Hershey, PA USA; [Olympia, Robert P.] Penn State Coll Med, Dept Emergency Med, Hershey, PA USA; [Thomas, Neal J.] Penn State Coll Med, Dept Publ Hlth Sci, Hershey, PA USA	Hicks, SD (corresponding author), Penn State Coll Med, Mail Code HS83,500 Univ Dr,POB 850, Hershey, PA 17033 USA.	shicks1@hmc.psu.edu		Hicks, Steven/0000-0002-9579-6798	Children's Miracle Network [417-51HY-4BFB]; Quadrant Biosciences Inc.; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR002014, KL2TR002015] Funding Source: NIH RePORTER	Supported by the Children's Miracle Network (Grant# 417-51HY-4BFB to SDH) and Quadrant Biosciences Inc. (Research agreement with AL and SDH).	Bahn JH, 2015, CLIN CHEM, V61, P221, DOI 10.1373/clinchem.2014.230433; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Bhomia M, 2016, SCI REP-UK, V6, DOI 10.1038/srep28148; Gilad S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003148; Hicks SD, 2016, BMC PEDIATR, V16, DOI 10.1186/s12887-016-0586-x; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lopez JP, 2014, INT J NEUROPSYCHOPH, V17, P23, DOI 10.1017/S1461145713000941; Majem B, 2015, INT J MOL SCI, V16, P8676, DOI 10.3390/ijms16048676; McCarthy MT, 2015, ANN NY ACAD SCI, V1345, P89, DOI 10.1111/nyas.12736; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Mitra B, 2017, J CLIN NEUROSCI, V38, P37, DOI 10.1016/j.jocn.2016.12.009; Pasinetti Giulio M, 2012, Am J Neurodegener Dis, V1, P88; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Redell JB, 2010, J NEUROTRAUM, V27, P2147, DOI 10.1089/neu.2010.1481; Rogelj B, 2004, REV NEUROSCIENCE, V15, P185; Savaskan NE, 2004, EUR J NEUROSCI, V19, P212, DOI 10.1046/j.1460-9568.2003.03078.x; Szklarczyk D, 2015, NUCLEIC ACIDS RES, V43, pD447, DOI 10.1093/nar/gku1003; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Vlachos IS, 2015, NUCLEIC ACIDS RES, V43, pW460, DOI 10.1093/nar/gkv403; Weber JA, 2010, CLIN CHEM, V56, P1733, DOI 10.1373/clinchem.2010.147405; Xia J., 2016, CURR PROTOC BIOINFOR, V55, P1014; Yan WH, 2009, PROTEOM CLIN APPL, V3, P116, DOI 10.1002/prca.200800140; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zaits MN, 2014, MOL PSYCHIATR, V19, P848, DOI 10.1038/mp.2013.93; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	28	32	32	2	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2018	35	1					64	72		10.1089/neu.2017.5111		OCT 2017	9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FS1WO	WOS:000414454100001	28762893	Green Published			2021-06-18	
J	Neuberger, EJ; Swietek, B; Corrubia, L; Prasanna, A; Santhakumar, V				Neuberger, Eric J.; Swietek, Bogumila; Corrubia, Lucas; Prasanna, Anagha; Santhakumar, Vijayalakshmi			Enhanced Dentate Neurogenesis after Brain Injury Undermines Long-Term Neurogenic Potential and Promotes Seizure Susceptibility	STEM CELL REPORTS			English	Article							ENDOTHELIAL GROWTH-FACTOR; NEURAL STEM-CELLS; POSTTRAUMATIC EPILEPSY; COGNITIVE RECOVERY; PROGENITOR CELLS; INHIBITION; HIPPOCAMPUS; CONTRIBUTES; GYRUS; HYPEREXCITABILITY	Hippocampal dentate gyrus is a focus of enhanced neurogenesis and excitability after traumatic brain injury. Increased neurogenesis has been proposed to aid repair of the injured network. Our data show that an early increase in neurogenesis after fluid percussion concussive brain injury is transient and is followed by a persistent decrease compared with age-matched controls. Post-injury changes in neurogenesis paralleled changes in neural precursor cell proliferation and resulted in a long-term decline in neurogenic capacity. Targeted pharmacology to restore post-injury neurogenesis to control levels reversed the long-term decline in neurogenic capacity. Limiting post-injury neurogenesis reduced early increases in dentate excitability and seizure susceptibility. Our results challenge the assumption that increased neurogenesis after brain injury is beneficial and show that early post-traumatic increases in neurogenesis adversely affect long-term outcomes by exhausting neurogenic potential and enhancing epileptogenesis. Treatments aimed at limiting excessive neurogenesis can potentially restore neuroproliferative capacity and limit epilepsy after brain injury.	[Neuberger, Eric J.; Swietek, Bogumila; Corrubia, Lucas; Prasanna, Anagha; Santhakumar, Vijayalakshmi] Rutgers New Jersey Med Sch, Rutgers Biomed & Hlth Sci, Dept Pharmacol Physiol & Neurosci, MSB H-512,185 S Orange Ave, Newark, NJ 07103 USA	Santhakumar, V (corresponding author), Rutgers New Jersey Med Sch, Rutgers Biomed & Hlth Sci, Dept Pharmacol Physiol & Neurosci, MSB H-512,185 S Orange Ave, Newark, NJ 07103 USA.	santhavi@njms.rutgers.edu	Santhakumar, Viji/K-4856-2019	Santhakumar, Viji/0000-0001-6278-4187	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS097750, R01NS069861]; NJCBIR [CBIR16IRG017, CBIR11PJT003]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [S10RR026495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS097750, R01NS069861] Funding Source: NIH RePORTER	We thank Jenieve Guevarra, Dipika Sekhar, and Ying Li for their helpful comments and technical assistance and Dr. Steve Levison for helpful discussions. We extend a special thanks to Dr. Deepak Subramanian for original artwork and design of schematics and graphical representations. The project was supported by NIH R01NS097750 and R01NS069861, and NJCBIR CBIR16IRG017 and CBIR11PJT003 to V.S.	Artegiani B, 2012, AGING-US, V4, P176, DOI 10.18632/aging.100446; Atkins CM, 2011, TRANSL STROKE RES, V2, P546, DOI 10.1007/s12975-011-0123-z; Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; Blaiss CA, 2011, J NEUROSCI, V31, P4906, DOI 10.1523/JNEUROSCI.5265-10.2011; Bull ND, 2005, J NEUROSCI, V25, P10815, DOI 10.1523/JNEUROSCI.3249-05.2005; Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395; Cha BH, 2004, BRAIN DEV-JPN, V26, P394, DOI 10.1016/j.braindev.2003.12.006; Chancey JH, 2014, J NEUROSCI, V34, P2349, DOI 10.1523/JNEUROSCI.3620-13.2014; Cho KO, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7606; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Connor B., 2012, COMPENSATORY NEUROGE; Danzer SC, 2008, NEUROSCIENTIST, V14, P446, DOI 10.1177/1073858408317008; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Echegoyen J, 2009, EPILEPSY RES, V85, P123, DOI 10.1016/j.eplepsyres.2009.02.019; Encinas JM, 2011, CELL STEM CELL, V8, P566, DOI 10.1016/j.stem.2011.03.010; Guo DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064078; Gupta A, 2012, J NEUROSCI, V32, P2523, DOI 10.1523/JNEUROSCI.4141-11.2012; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Hunt RF, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00089; Jacob B, 2009, J CELL BIOCHEM, V107, P393, DOI 10.1002/jcb.22150; Kempermann G, 2015, COLD SPRING HARB PER, V5, DOI DOI 10.1101/CSHPE; Kernie SG, 2010, NEUROBIOL DIS, V37, P267, DOI 10.1016/j.nbd.2009.11.002; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kirby ED, 2015, P NATL ACAD SCI USA, V112, P4128, DOI 10.1073/pnas.1422448112; Lee C, 2009, EXP NEUROL, V220, P400, DOI 10.1016/j.expneurol.2009.08.019; Li Y, 2015, NEUROBIOL DIS, V74, P240, DOI 10.1016/j.nbd.2014.11.021; Louissaint A, 2002, NEURON, V34, P945, DOI 10.1016/S0896-6273(02)00722-5; Lu KT, 2011, J NEUROTRAUM, V28, P441, DOI 10.1089/neu.2010.1473; Marti HH, 2000, AM J PATHOL, V156, P965, DOI 10.1016/S0002-9440(10)64964-4; McCloskey DP, 2005, J NEUROSCI, V25, P8889, DOI 10.1523/JNEUROSCI.2577-05.2005; Neuberger EJ, 2014, J NEUROSCI RES, V92, P1350, DOI 10.1002/jnr.23401; Parent JM, 1997, J NEUROSCI, V17, P3727; Pitkanen A, 2014, EPILEPSY BEHAV, V38, P19, DOI 10.1016/j.yebeh.2014.01.013; Rosen LS, 2001, CANCER J, V7, pS120; Santhakumar V, 2000, J PHYSIOL-LONDON, V524, P117, DOI 10.1111/j.1469-7793.2000.00117.x; Segi-Nishida E, 2008, P NATL ACAD SCI USA, V105, P11352, DOI 10.1073/pnas.0710858105; Shen Q, 2004, SCIENCE, V304, P1338, DOI 10.1126/science.1095505; Shore PM, 2004, NEUROSURGERY, V54, P605, DOI 10.1227/01.NEU.0000108642.88724.DB; Sierra A, 2015, CELL STEM CELL, V16, P488, DOI 10.1016/j.stem.2015.04.003; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; Sun D, 2015, J NEUROTRAUM, V32, P495, DOI 10.1089/neu.2014.3545; Sun D, 2014, NEURAL REGEN RES, V9, P688, DOI 10.4103/1673-5374.131567; Sun GC, 2013, BIOL PHARM BULL, V36, P548; Toth Z, 1997, J NEUROSCI, V17, P8106; Villasana LE, 2015, ENEURO, V2, DOI 10.1523/ENEURO.0056-15.2015; Walker TL, 2008, J NEUROSCI, V28, P5240, DOI 10.1523/JNEUROSCI.0344-08.2008; Whiting M. D., 2006, ANIMAL MODELS COGNIT; Winocur G, 2006, HIPPOCAMPUS, V16, P296, DOI 10.1002/hipo.20163; Yu JD, 2016, CEREB CORTEX, V26, P4299, DOI 10.1093/cercor/bhv199; Yu TS, 2016, NEUROSCIENTIST, V22, P61, DOI 10.1177/1073858414563616; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008	51	32	33	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	2213-6711			STEM CELL REP	Stem Cell Rep.	SEP 12	2017	9	3					972	984		10.1016/j.stemcr.2017.07.015			13	Cell & Tissue Engineering; Cell Biology	Cell Biology	FG4WO	WOS:000410279200020	28826852	DOAJ Gold, Green Published			2021-06-18	
J	Bogner, JA; Whiteneck, GG; MacDonald, J; Juengst, SB; Brown, AW; Philippus, AM; Marwitz, JH; Lengenfelder, J; Mellick, D; Arenth, P; Corrigan, JD				Bogner, Jennifer A.; Whiteneck, Gale G.; MacDonald, Jessica; Juengst, Shannon B.; Brown, Allen W.; Philippus, Angela M.; Marwitz, Jennifer H.; Lengenfelder, Jeannie; Mellick, Dave; Arenth, Patricia; Corrigan, John D.			Test-Retest Reliability of Traumatic Brain Injury Outcome Measures: A Traumatic Brain Injury Model Systems Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injuries; psychometrics; test-retest reliability	FUNCTIONAL INDEPENDENCE MEASURE; DISABILITY RATING-SCALE; INTRACLASS CORRELATION-COEFFICIENT; FACTOR SURVEILLANCE SYSTEM; TBI IDENTIFICATION METHOD; SAMPLE-SIZE REQUIREMENTS; LIFE SCALE; STRUCTURED INTERVIEWS; VALIDITY; KAPPA	Objective: Evaluate the test-retest reliability of measures that comprise the Traumatic Brain Injury Model Systems follow-up data set. Participants: A total of 224 persons with a moderate-severe traumatic brain injury (TBI) enrolled in the Traumatic Brain Injury Model Systems National Database. Design: Following standard administration of the follow-up interview, a second interview was administered 14 to 28 days later using the same interviewer and the same mode of administration. Main Measures: Traumatic Brain Injury Model Systems follow-up interview that includes 66 variables comprised (a) single item measures of demographics; employment; general health as well as specific health conditions; rehospitalization; tobacco, alcohol, and other drug use; transportation; and mental health and (b) multi-item instruments: FIM; Participation Assessment With Recombined Tools-Objective; Disability Rating Scale; Glasgow Outcome Scale-Extended; Supervision Rating Scale; Satisfaction With Life Scale; TBI Quality of Life Anxiety and Depression items; and The Ohio State University TBI Identification Method. Results: Intraclass correlation coefficient values ranged from 0.65 to 0.99, weighted kappa values ranged from 0.54 to 0.99, and kappa values ranged from 0.43 to 1.00. Four kappa/weighted kappa estimates fell below 0.60: arrested, psychiatric hospitalization, number of days not in good physical health, and rating of general emotional health. Conclusions: With few exceptions, good to excellent test-retest reliability estimates were obtained. The findings support the use of these measures in prior and future studies and indicate that persons with moderate-severe TBI can provide reliable self-report.	[Bogner, Jennifer A.; MacDonald, Jessica; Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Whiteneck, Gale G.; Philippus, Angela M.; Mellick, Dave] Craig Hosp Res Dept, Englewood, CO USA; [Juengst, Shannon B.; Arenth, Patricia] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA USA; [Brown, Allen W.] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA; [Lengenfelder, Jeannie] Kessler Fdn, E Hanover, NJ USA; [Marwitz, Jennifer H.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23284 USA	Bogner, JA (corresponding author), Ohio State Univ, Dept Phys Med & Rehabil, Div Rehabil Psychol, Med Ctr 480, Columbus, OH 43210 USA.	bogner.1@osu.edu	Corrigan, John D./E-2921-2011; Juengst, Shannon B/AAC-5891-2019	Philippus, Angela/0000-0001-7427-8660; Brown, Allen W./0000-0001-7228-3351; Juengst, Shannon/0000-0003-4709-545X	National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR)United States Department of Health & Human Services [90DP0084, 90DP0040, 90DP0034, 90DP0041, 90DP0033, 90DP0030, 90DP0032]	The contents of this report were developed under a grant from the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR grant numbers 90DP0084, 90DP0040, 90DP0034, 90DP0041, 90DP0033, 90DP0030, 90DP0032). NIDILRR is a Center within the Administration for Community Living (ACL), Department of Health & Human Services (HHS). The contents of this report do not necessarily represent the policy of NIDILRR, ACL, HHS, and endorsement by the Federal Government should not be assumed.	Andresen EM, 2003, J EPIDEMIOL COMMUN H, V57, P339, DOI 10.1136/jech.57.5.339; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Bogner J, 2009, J HEAD TRAUMA REHAB, V24, P279, DOI 10.1097/HTR.0b013e3181a66356; Bonevski B, 2010, ADDICT BEHAV, V35, P492, DOI 10.1016/j.addbeh.2009.12.030; BROWNSON RC, 1994, EPIDEMIOLOGY, V5, P545; Cantor AB, 1996, PSYCHOL METHODS, V1, P150, DOI 10.1037/1082-989X.1.2.150; Centers for Disease Control and Prevention, 2000, MEAS HLTH DAYS; Cham PMH, 2007, BRIT J DERMATOL, V156, P922, DOI 10.1111/j.1365-2133.2006.07740.x; Cicchetti DV, 2001, J CLIN EXP NEUROPSYC, V23, P695, DOI 10.1076/jcen.23.5.695.1249; CICCHETTI DV, 1990, J CLIN EPIDEMIOL, V43, P551, DOI 10.1016/0895-4356(90)90159-M; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Cuthbert JP, 2016, J HEAD TRAUMA REHAB, V31, pE36, DOI 10.1097/HTR.0000000000000075; Dal Grande E, 2012, BMC MED RES METHODOL, V12, DOI 10.1186/1471-2288-12-108; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; FLEISS JL, 1973, EDUC PSYCHOL MEAS, V33, P613, DOI 10.1177/001316447303300309; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Granger CV, 1986, TOP GERIATR REHABIL, V1, P59, DOI 10.1097/00013614-198604000-00007; Green J, 2001, DISABIL REHABIL, V23, P670, DOI 10.1080/09638280110045382; Hadzi-Pavlovic D, 2010, ACTA NEUROPSYCHIATR, V22, P199, DOI 10.1111/j.1601-5215.2010.00479.x; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Hopkins WG, 2000, SPORTS MED, V30, P1, DOI 10.2165/00007256-200030010-00001; JACOBSON NS, 1984, BEHAV THER, V15, P336, DOI 10.1016/S0005-7894(84)80002-7; KROSNICK JA, 1991, APPL COGNITIVE PSYCH, V5, P213, DOI 10.1002/acp.2350050305; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Malec JF, 2012, ARCH PHYS MED REHAB, V93, P1603, DOI 10.1016/j.apmr.2012.04.003; Masedo AI, 2005, AM J PHYS MED REHAB, V84, P167, DOI 10.1097/01.PHM.0000154898.25609.4A; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; PAVOT W, 1991, J PERS ASSESS, V57, P149, DOI 10.1207/s15327752jpa5701_17; Perdices M, 2009, NEUROPSYCHOL REHABIL, V19, P904, DOI 10.1080/09602010903040691; Petrunoff NA, 2013, J ENVIRON PUBLIC HEA, V2013, DOI 10.1155/2013/423035; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosengren L, 2015, ACTA NEUROL SCAND, V132, P164, DOI 10.1111/ane.12380; Sim J, 2005, PHYS THER, V85, P257; STEIN AD, 1993, AM J PUBLIC HEALTH, V83, P1768, DOI 10.2105/AJPH.83.12.1768; Substance Abuse and Mental Health Services Administration, 2010, OFFICE APPL STUDIE M; Tourangeau R., 2000, PSYCHOL SURVEY RESPO; Tulsky DS, 2016, J HEAD TRAUMA REHAB, V31, P40, DOI 10.1097/HTR.0000000000000131; Weir JP, 2005, J STRENGTH COND RES, V19, P231, DOI 10.1519/15184.1; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; Wright A, 2012, J MAN MANIP THER, V20, P160, DOI 10.1179/2042618612Y.0000000001; Zou GY, 2012, STAT MED, V31, P3972, DOI 10.1002/sim.5466	45	32	32	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2017	32	5					E1	E16		10.1097/HTR.0000000000000291			16	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FG2DW	WOS:000409893800001	28195954				2021-06-18	
J	Schallmo, MS; Weiner, JA; Hsu, WK				Schallmo, Michael S.; Weiner, Joseph A.; Hsu, Wellington K.			Sport and Sex-Specific Reporting Trends in the Epidemiology of Concussions Sustained by High School Athletes	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							DIAGNOSIS; EDUCATION; RECOVERY; GENDER; AGE	Background: Approximately 300,000 U.S. adolescents sustain concussions annually while participating in organized athletics. This study aimed to track sex and sport-specific trends among high school sports-related concussions over time, to identify whether a particular sport predisposes athletes to a higher risk, and to assess whether traumatic brain injury law enactments have been successful in improving recognition. Methods: Injury data for academic years 2005 to 2014 were collected from annual reports generated by High School RIO (Reporting Information Online). The relative proportions of total estimated concussions to total estimated injuries were compared using an injury proportion ratio. The concussion rate was defined as the number of concussions per 10,000 athlete exposures (1 athlete participating in 1 practice or competition), with rates compared using a rate ratio. To evaluate the impact of legislation on sports-related concussions in this population, trends in concussion rates and proportions were analyzed before enactment (academic years 2005-2009) and after enactment (academic years 2010-2014). Results: Between 2005-2006 and 2014-2015, a significant increase (p < 0.0001) in the overall number of concussions for all sports combined, the overall concussion rate (rate ratio, 2.30 [95% confidence interval, 2.04 to 2.59]), and the overall proportion of concussions (injury proportion ratio, 2.68 [95% confidence interval, 2.66 to 2.70]) was seen. Based on the injury proportion ratio, during the 2014-2015 academic year, concussions were more common in girls' soccer than in any other sport (p < 0.0001). Conclusions: Because of potentially devastating consequences, concussion prevention and recognition measures continue to be emphasized in high school contact sports. The data in our study suggest that significant increases in the overall rate and proportion of reported concussions during the past decade could have been affected by traumatic brain injury legislation. To our knowledge, this is the first study to show that girls' soccer players may have an even greater risk of sustaining a concussion than all other sports.	[Schallmo, Michael S.; Weiner, Joseph A.; Hsu, Wellington K.] Northwestern Univ, Feinberg Sch Med, Dept Orthopaed Surg, Chicago, IL 60611 USA; [Schallmo, Michael S.] Wake Forest Sch Med, Dept Orthopaed Surg, Winston Salem, NC USA	Hsu, WK (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Orthopaed Surg, Chicago, IL 60611 USA.	wkhsu@yahoo.com					Bodin D, 2012, PEDIATRIC AND ADOLESCENT CONCUSSION: DIAGNOSIS, MANAGEMENT AND OUTCOMES, P9, DOI 10.1007/978-0-387-89545-1_2; Comstock D, 2016, HIGH SCH RIO REPORTI; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Dick RW, 2009, BRIT J SPORT MED, V43, pI46, DOI 10.1136/bjsm.2009.058172; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harvey H., 2015, YOUTH SPORTS TRAUMAT; Harvey Hosea H, 2014, Yale J Health Policy Law Ethics, V14, P66; Knowles SB, 2010, J ATHL TRAINING, V45, P475, DOI 10.4085/1062-6050-45.5.475; Kroshus E, 2015, HEALTH EDUC BEHAV, V42, P153, DOI 10.1177/1090198114543011; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Madden C, 2009, NETTERS SPORTS MED, P317; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McCrory P, 2013, BRIT J SPORT MED, V47, P268, DOI 10.1136/bjsports-2013-092247; National Federation of State High School Association, 2015, 2014 2015 HIGH SCH A; Noble JM, 2013, NEUROPSYCHOL REV, V23, P273, DOI 10.1007/s11065-013-9239-0; Ono KE, 2016, AM J SPORT MED, V44, P748, DOI 10.1177/0363546515617746; Rivara FP, 2014, AM J SPORT MED, V42, P1197, DOI 10.1177/0363546514521774; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Snyder TD, 2014, US DEP ED DIGEST ED; The Centers for Disease Control and Prevention (CDC), 2006, JAMA-J AM MED ASSOC, V296, P2673	23	32	32	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0021-9355	1535-1386		J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	AUG 2	2017	99	15					1314	1320		10.2106/JBJS.16.01573			7	Orthopedics; Surgery	Orthopedics; Surgery	FC3ST	WOS:000406760100014	28763417				2021-06-18	
J	Aiolfi, A; Benjamin, E; Khor, D; Inaba, K; Lam, L; Demetriades, D				Aiolfi, Alberto; Benjamin, Elizabeth; Khor, Desmond; Inaba, Kenji; Lam, Lydia; Demetriades, Demetrios			Brain Trauma Foundation Guidelines for Intracranial Pressure Monitoring: Compliance and Effect on Outcome	WORLD JOURNAL OF SURGERY			English	Article							SEVERE HEAD-INJURY; MORTALITY	Background Brain Trauma Foundation (BTF) guidelines recommend intracranial pressure (ICP) monitoring in patients who sustained severe traumatic brain injury (TBI). Compliance to BTF guidelines is variable, and the effect of ICP monitoring on outcomes remains a controversial issue. The purpose of this study was to assess guidelines compliance in patients who sustain a severe TBI and to analyze the effect of ICP monitoring on outcomes. Methods Trauma Quality Improvement Program database study, which included patients with isolated severe blunt head trauma (head Abbreviated Injury Scale >= 3 with Glasgow Coma Scale < 9). Patients with severe extracranial injuries excluded. Analyzed variables were demographics, comorbidities, mechanism of injuries, head injury specifics, AIS for each body area, Injury Severity Score, admission vital signs, placement of ICP catheter and craniectomy. Multivariate analysis was used to identify independent predictors for outcomes, overall and in the groups of patients with head AIS 3, 4 or 5. Results During the study period 13,188 patients with isolated severe TBI met the BTF guidelines for ICP monitoring. An ICP catheter was placed in 1519 (11.5%) patients. Stepwise logistic regression analysis identified age >= 65 years, hypotension on admission, AIS 4 and AIS 5 as independent predictors for mortality. ICP monitoring was not an independent protective variable in terms of mortality (OR 1.12; 95% CI, 0.983-1.275; p = 0.088). Overall, ICP monitor placement was independently associated with increased overall complications (OR 2.089; 95% CI, 1.85-2.358; p < 0.001), infectious complications (OR 2.282; 95% CI, 2.015-2.584; p < 0.001) and poor functional independence (OR 1.889; 95% CI, 1.575-2.264; p < 0.001). Sub analysis of the groups of patients with head AIS 3, 4, and 5 failed to show any protective effect of ICP monitors against mortality. In the group of patients with head AIS 4, ICP placement was an independent predictor of mortality (OR 2206; 95% CI, 1652-2948; p < 0.001). Conclusions Compliance with the BTF guidelines for ICP monitoring is poor. ICP monitoring does not have any survival benefit in patients with isolated severe blunt TBI and is associated with more complications and increased utilization of hospital resources.	[Aiolfi, Alberto; Benjamin, Elizabeth; Khor, Desmond; Inaba, Kenji; Lam, Lydia; Demetriades, Demetrios] Univ Southern Calif, Div Acute Care Surg, 2051 Marengo St,Inpatient Tower C,Rm C5L100, Los Angeles, CA 90033 USA	Demetriades, D (corresponding author), Univ Southern Calif, Div Acute Care Surg, 2051 Marengo St,Inpatient Tower C,Rm C5L100, Los Angeles, CA 90033 USA.	demetria@usc.edu	Aiolfi, Alberto/ABA-7242-2020; INABA, KENJI/AAC-8532-2020; Benjamin, Elizabeth/AAD-2457-2020	Aiolfi, Alberto/0000-0002-7764-6075			Agrawal D, 2016, J NEUROTRAUM, V33, P853, DOI 10.1089/neu.2015.4015; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Dawes AJ, 2015, JAMA SURG, V150, P965, DOI 10.1001/jamasurg.2015.1678; Dawes AJ, 2015, J TRAUMA ACUTE CARE, V78, P492, DOI 10.1097/TA.0000000000000559; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Haddad S, 2011, ANAESTH INTENS CARE, V39, P1043, DOI 10.1177/0310057X1103900610; Lane PL, 2000, CAN J SURG, V43, P442; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; Mendelson AA, 2012, CAN J NEUROL SCI, V39, P571, DOI 10.1017/S0317167100015286; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Shafi S, 2008, J TRAUMA, V64, P335, DOI 10.1097/TA.0b013e31815dd017; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Talving P, 2013, J NEUROSURG, V119, P1248, DOI 10.3171/2013.7.JNS122255; You WD, 2016, BMC ANESTHESIOL, V16, DOI 10.1186/s12871-016-0199-9	16	32	35	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-2313	1432-2323		WORLD J SURG	World J.Surg.	JUN	2017	41	6					1543	1549		10.1007/s00268-017-3898-6			7	Surgery	Surgery	EU4AS	WOS:000400972800021	28188356				2021-06-18	
J	Li, X; Pan, YP; Chen, G; Yu, HY				Li, Xiang; Pan, Yongping; Chen, Gong; Yu, Haoyong			Multi-modal control scheme for rehabilitation robotic exoskeletons	INTERNATIONAL JOURNAL OF ROBOTICS RESEARCH			English	Article						Rehabilitation robotic exoskeleton; robot control; series elastic actuator; singular perturbation approach	FLEXIBLE-JOINT ROBOTS; IMPEDANCE CONTROL; ADAPTIVE-CONTROL; AIDED NEUROREHABILITATION; GAIT REHABILITATION; MECHANICAL DESIGN; MANIPULATORS; COMPLIANT; COMPENSATION; ASSISTANCE	In the past few decades, a variety of rehabilitation robotic exoskeletons have been developed for patients with stroke and traumatic brain injury, which can assist therapists and potentially improve the functional outcomes. Many robotic exoskeleton systems adopted series elastic actuators, which are known to offer a number of advantages over rigid actuators, such as high force/torque fidelity, low output impedance, intrinsic compliance, and tolerance to shocks. While several control schemes have been proposed for robotic exoskeletons driven by series elastic actuators, existing methods are limited at high level, by assuming a perfect inner control loop. Due to the nonlinearity in robot dynamics, changing interaction forces, etc., the stability of the overall system consisting of both the robot dynamics and the actuator dynamics may not be guaranteed. This paper presents a multi-modal control scheme for rehabilitation robotic exoskeletons. Three control modes are smoothly integrated into the controller, where the robot-assisted mode allows the human to exert voluntary efforts within a desired region, the robot-dominant mode is activated to correct the movement of the human when the robot is outside the region, and the safety-stop mode is to stop the robot whenever the interaction force is too large which may result in injuries. By using the regional position and force feedback, the proposed controller achieves the paradigm of "assist-as-needed" and also guarantees the safety of the human. The development of the proposed controller follows the singular perturbation approach, and the stability of the overall system is rigorously proved by using Tikhonov's theorem. Experimental results in both upper-limb and lower-limb exoskeleton systems are presented to demonstrate the effectiveness of the proposed control method.	[Li, Xiang] Chinese Univ Hong Kong, Dept Mech & Automat Engn, Hong Kong, Hong Kong, Peoples R China; [Pan, Yongping; Chen, Gong; Yu, Haoyong] Natl Univ Singapore, Dept Biomed Engn, Singapore, Singapore	Yu, HY (corresponding author), EA 02-02,9 Engn Dr 1, Singapore 117575, Singapore.	bieyhy@nus.edu.sg	Pan, Yongping/B-3511-2012	Pan, Yongping/0000-0002-8587-6065	Engineering Design and Innovation Center, National University of Singapore, Singapore [R-261-503-002-133]; Science and Engineering Research Council, Agency for Science, Technology and Research (A*STAR), SingaporeAgency for Science Technology & Research (ASTAR) [1421480015]	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by the Seed Fund of the Engineering Design and Innovation Center, National University of Singapore, Singapore under Grant no. R-261-503-002-133, and in part by the Science and Engineering Research Council, Agency for Science, Technology and Research (A*STAR), Singapore under Grant no. 1421480015.	Agarwal P, 2015, ASME 2015 DYN SYST C; Agarwal P, 2015, INT J ROBOT RES, V34, P1747, DOI 10.1177/0278364915598388; Aguirre-Ollinger G, 2012, IEEE T NEUR SYS REH, V20, P68, DOI 10.1109/TNSRE.2011.2176960; Albu-Schaffer A, 2007, INT J ROBOT RES, V26, P23, DOI 10.1177/0278364907073776; Arimoto S., 1996, CONTROL THEORY NONLI; Asbeck AT, 2015, INT J ROBOT RES, V34, P744, DOI 10.1177/0278364914562476; Banala SK, 2009, IEEE T NEUR SYS REH, V17, P2, DOI 10.1109/TNSRE.2008.2008280; Blaya JA, 2004, IEEE T NEUR SYS REH, V12, P24, DOI 10.1109/TNSRE.2003.823266; Cai LL, 2006, IEEE INT CONF ROBOT, P3504, DOI 10.1109/ROBOT.2006.1642237; Cheah CC, 2007, IEEE T ROBOT, V23, P1260, DOI 10.1109/TRO.2007.909808; Cheah C. C., 2015, TASK SPACE SENSORY F; Cheah CC, 1998, IEEE T ROBOTIC AUTOM, V14, P452, DOI 10.1109/70.678454; Chen G, 2016, MECH MACH THEORY, V103, P51, DOI 10.1016/j.mechmachtheory.2016.04.012; Chen WH, 2000, IEEE T IND ELECTRON, V47, P932, DOI 10.1109/41.857974; De Luca A, 2005, AUTOMATICA, V41, P1809, DOI 10.1016/j.automatica.2005.05.009; Dollar AM, 2008, IEEE T ROBOT, V24, P144, DOI 10.1109/TRO.2008.915453; Duschau-Wicke A, 2010, IEEE T NEUR SYS REH, V18, P38, DOI 10.1109/TNSRE.2009.2033061; Fleerkotte BM, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-26; Haddadin S, 2008, 2008 IEEE/RSJ INTERNATIONAL CONFERENCE ON ROBOTS AND INTELLIGENT SYSTEMS, VOLS 1-3, CONFERENCE PROCEEDINGS, P3356, DOI 10.1109/IROS.2008.4650764; Haddadin S, 2010, INT J SOC ROBOT, V2, P235, DOI 10.1007/s12369-010-0053-z; Haghighi R, 2012, AUTOMATICA, V48, P2526, DOI 10.1016/j.automatica.2012.03.028; HOGAN N, 1985, J DYN SYST-T ASME, V107, P1, DOI 10.1115/1.3140702; Hogan N, 2001, ROBOTICS AUTOMATION; Huang J, 2015, IEEE T AUTOM SCI ENG, V12, P1257, DOI 10.1109/TASE.2015.2466634; Kazerooni H, 2005, IEEE INT CONF ROBOT, P4353; Keller U., 2013, REH ROB ICORR 2013 I, P1; Khalil H., 1992, NONLINEAR SYSTEMS; Kong KC, 2006, IEEE-ASME T MECH, V11, P428, DOI 10.1109/TMECH.2006.878550; Krebs HI, 2007, IEEE T NEUR SYS REH, V15, P327, DOI 10.1109/TNSRE.2007.903899; Lewis F. L., 1993, CONTROL ROBOT END EF; Li X, 2014, IEEE T CONTR SYST T, V22, P1032, DOI 10.1109/TCST.2013.2293498; Li X, 2013, AUTOMATICA, V49, P1614, DOI 10.1016/j.automatica.2013.02.067; Liu C, 2008, AUTOMATICA, V44, P1806, DOI 10.1016/j.automatica.2007.10.039; LOZANO R, 1992, IEEE T AUTOMAT CONTR, V37, P174, DOI 10.1109/9.121619; Meng XL, 2014, IEEE T BIO-MED ENG, V61, P892, DOI 10.1109/TBME.2013.2291910; Michmizos KP, 2012, P IEEE RAS-EMBS INT, P1081, DOI 10.1109/BioRob.2012.6290705; NICOSIA S, 1992, IEEE INT C ROB AUT, P701; Ott C, 2008, IEEE T ROBOT, V24, P416, DOI 10.1109/TRO.2008.915438; Park JH, 2001, IEEE T ROBOTIC AUTOM, V17, P870, DOI 10.1109/70.976014; ParraVega V, 1995, INT J SYST SCI, V26, P2263, DOI 10.1080/00207729508929166; Patel RV, 2009, IEEE-ASME T MECH, V14, P575, DOI 10.1109/TMECH.2008.2009637; Pehlivan AU, 2016, IEEE T ROBOT, V32, P113, DOI 10.1109/TRO.2015.2503726; Petit F, 2015, IEEE ROBOT AUTOM MAG, V22, P37, DOI 10.1109/MRA.2015.2476576; PRATT GA, 1995, IROS '95 - 1995 IEEE/RSJ INTERNATIONAL CONFERENCE ON INTELLIGENT ROBOTS AND SYSTEMS: HUMAN ROBOT INTERACTION AND COOPERATIVE ROBOTS, PROCEEDINGS, VOL 1, P399, DOI 10.1109/IROS.1995.525827; Ronsse R, 2011, IEEE T BIO-MED ENG, V58, P1001, DOI 10.1109/TBME.2010.2089629; Roy A, 2009, IEEE T ROBOT, V25, P569, DOI 10.1109/TRO.2009.2019783; Slotine JJE., 1991, APPL NONLINEAR CONTR; SPONG MW, 1995, AUTOMATICA, V31, P585, DOI 10.1016/0005-1098(95)98487-Q; Sulzer JS, 2009, IEEE T ROBOT, V25, P539, DOI 10.1109/TRO.2009.2019788; Vanderborght B, 2009, INT J ROBOT RES, V28, P90, DOI 10.1177/0278364908095333; Veneman JF, 2007, IEEE T NEUR SYS REH, V15, P379, DOI 10.1109/TNSRE.2007.903919; Whittle M. W., 2003, GAIT ANAL INTRO; Wolbrecht ET, 2008, IEEE T NEUR SYS REH, V16, P286, DOI 10.1109/TNSRE.2008.918389; Yamada Y, 1997, IEEE-ASME T MECH, V2, P230, DOI 10.1109/3516.653047; Yu HY, 2015, IEEE T ROBOT, V31, P1089, DOI 10.1109/TRO.2015.2457314; Yu HY, 2013, MECHATRONICS, V23, P1072, DOI 10.1016/j.mechatronics.2013.08.004; Yu HY, 2003, AUTON ROBOT, V15, P53, DOI 10.1023/A:1024488717009; Zhang JJ, 2015, IEEE T ROBOT, V31, P233, DOI 10.1109/TRO.2015.2392451	58	32	33	16	107	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0278-3649	1741-3176		INT J ROBOT RES	Int. J. Robot. Res.	JUN	2017	36	5-7					759	777		10.1177/0278364917691111			19	Robotics	Robotics	EZ4IV	WOS:000404677700016					2021-06-18	
J	Taylor, DJ; Peterson, AL; Pruiksma, KE; Young-McCaughan, S; Nicholson, K; Mintz, J				Taylor, Daniel J.; Peterson, Alan L.; Pruiksma, Kristi E.; Young-McCaughan, Stacey; Nicholson, Karin; Mintz, Jim		STRONG STAR Consortium	Internet and In-Person Cognitive Behavioral Therapy for Insomnia in Military Personnel: A Randomized Clinical Trial	SLEEP			English	Article						Insomnia; cognitive behavior therapy; military; unguided Internet intervention; randomized clinical trial	TRAUMATIC BRAIN-INJURY; SLEEP DISTURBANCE; PSYCHIATRIC-DISORDERS; OLDER-ADULTS; POSTTRAUMATIC-STRESS; METAANALYSIS; EFFICACY; DEPRESSION; VALIDATION; SYMPTOMS	Study Objectives: Compare in-person and unguided Internet-delivered cognitive behavioral therapy for insomnia (CBTi) with a minimal contact control condition in military personnel. Methods: A three-arm parallel randomized clinical trial of 100 active duty US Army personnel at Fort Hood, Texas. Internet and in-person CBTi were comparable, except for the delivery format. The control condition consisted of phone call assessments. Results: Internet and in-person CBTi performed significantly better than the control condition on diary-assessed sleep efficiency (d = 0.89 and 0.53, respectively), sleep onset latency (d = -0.68 and -0.53), number of awakenings (d = -0.42 and -0.54), wake time after sleep onset (d = -0.88 and -0.50), the Insomnia Severity Index (d = -0.98 and -0.51), and the Dysfunctional Beliefs and Attitudes About Sleep Scale (d = -1.12 and -0.54). In-person treatment was better than Internet treatment on self-reported sleep quality (d = 0.80) and dysfunctional beliefs and attitudes about sleep (d = -0.58). There were no differences on self-reported daytime sleepiness or actigraphy-assessed sleep parameters (except total sleep time; d = -0.55 to -0.60). There were technical difficulties with the Internet treatment which prevented tailored sleep restriction upward titration for some participants. Conclusions: Despite the unique, sleep-disrupting occupational demands of military personnel, in-person and Internet CBTi are efficacious treatments for this population. The effect sizes for in-person were consistently better than Internet and both were similar to those found in civilians. Dissemination of CBTi should be considered for maximum individual and population benefits, possibly in a stepped-care model.	[Taylor, Daniel J.] Univ North Texas, Dept Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA; [Peterson, Alan L.; Pruiksma, Kristi E.; Young-McCaughan, Stacey; Mintz, Jim] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA; [Peterson, Alan L.] South Texas Vet Hlth Care Syst, Res & Dev Serv, San Antonio, TX USA; [Peterson, Alan L.] Univ Texas San Antonio, Dept Psychol, San Antonio, TX USA; [Nicholson, Karin] Carl R Darnall Army Med Ctr, Dept Med, Ft Hood, TX USA; [Mintz, Jim] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA	Taylor, DJ (corresponding author), Univ North Texas, Dept Psychol, 1155 Union Circle 311280, Denton, TX 76203 USA.	Daniel.Taylor@unt.edu	Mintz, Jim/N-7385-2014	Mintz, Jim/0000-0002-8299-5851; Roache, John/0000-0002-7010-8119; Taylor, Daniel/0000-0003-3433-2516	US Department of Defense through the US Army Medical Research and Materiel Command; Congressionally Directed Medical Research ProgramsUnited States Department of Defense; Psychological Health and Traumatic Brain Injury Research Program [W81XWH-10-1-0828]	This study was conducted with support from the US Department of Defense through the US Army Medical Research and Materiel Command, Congressionally Directed Medical Research Programs, Psychological Health and Traumatic Brain Injury Research Program award W81XWH-10-1-0828 (PI: Dr Taylor). There was no other financial support for this research.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Andersson G, 2016, ANNU REV CLIN PSYCHO, V12, P157, DOI 10.1146/annurev-clinpsy-021815-093006; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Beck AT., 1996, BECK DEPRESSION INVE, V2; Blom K, 2015, BEHAV RES THER, V70, P47, DOI 10.1016/j.brat.2015.05.002; Blom K, 2015, SLEEP, V38, P267, DOI 10.5665/sleep.4412; Bootzin R R, 1972, P AM PSYCHOL ASS, V7, P395, DOI DOI 10.1037/E465522008-198; Breslau N, 1996, BIOL PSYCHIAT, V39, P411, DOI 10.1016/0006-3223(95)00188-3; Bryan CJ, 2013, SLEEP, V36, P941, DOI 10.5665/sleep.2730; Carney CE, 2012, SLEEP, V35; CHAMBERS MJ, 1994, SLEEP, V17, P405, DOI 10.1093/sleep/17.5.405; Chang PP, 1997, AM J EPIDEMIOL, V146, P105; Cheng SK, 2012, PSYCHOTHER PSYCHOSOM, V81, P206, DOI 10.1159/000335379; Chervin RD, 1997, J PSYCHOSOM RES, V42, P145, DOI 10.1016/S0022-3999(96)00239-5; Clum GA, 2001, J NERV MENT DIS, V189, P618, DOI 10.1097/00005053-200109000-00008; Collen J, 2012, CHEST, V142, P622, DOI 10.1378/chest.11-1603; COURSEY RD, 1980, BIOFEEDBACK SELF-REG, V5, P57, DOI 10.1007/BF00999064; de Bruin EJ, 2014, BEHAV SLEEP MED, V12, P235, DOI 10.1080/15402002.2013.784703; DRYMAN A, 1991, ACTA PSYCHIAT SCAND, V84, P1, DOI 10.1111/j.1600-0447.1991.tb01410.x; Edinger JD, 2009, SLEEP, V32, P499, DOI 10.1093/sleep/32.4.499; Epstein DR, 2012, SLEEP, V35, P797, DOI 10.5665/sleep.1878; Espie CA, 2001, BEHAV RES THER, V39, P45, DOI 10.1016/S0005-7967(99)00157-6; Espie CA, 2007, SLEEP, V30, P574, DOI 10.1093/sleep/30.5.574; Espie CA, 2009, SLEEP, V32, P1549, DOI 10.1093/sleep/32.12.1549; Espie CA, 2012, SLEEP, V35, P769, DOI 10.5665/sleep.1872; FAWCETT J, 1990, AM J PSYCHIAT, V147, P1189; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; Geiger-Brown JM, 2015, SLEEP MED REV, V23, P54, DOI 10.1016/j.smrv.2014.11.007; Gellis LA., 2011, J AGGRESS MALTREAT T, V20, P904, DOI DOI 10.1080/10926771.2011.613448; Godet-Cayre V, 2006, SLEEP, V29, P179, DOI 10.1093/sleep/29.2.179; Hall RCW, 1999, PSYCHOSOMATICS, V40, P18, DOI 10.1016/S0033-3182(99)71267-3; Ho FYY, 2015, SLEEP MED REV, V19, P17, DOI 10.1016/j.smrv.2014.06.010; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HUEDOMEDINA TB, 2012, BMJ-BRIT MED J, V345, DOI DOI 10.1136/BMJ.E8343; Irwin MR, 2006, HEALTH PSYCHOL, V25, P3, DOI 10.1037/0278-6133.25.1.3; Jacobs GD, 2004, ARCH INTERN MED, V164, P1888, DOI 10.1001/archinte.164.17.1888; JOHNS MW, 1994, SLEEP, V17, P703, DOI 10.1093/sleep/17.8.703; JOHNSON LC, 1983, MIL MED, V148, P727; Koffel EA, 2015, SLEEP MED REV, V19, P6, DOI 10.1016/j.smrv.2014.05.001; Koren D, 2002, AM J PSYCHIAT, V159, P855, DOI 10.1176/appi.ajp.159.5.855; Lancee J, 2016, SLEEP, V39, P183, DOI 10.5665/sleep.5344; Lancee J, 2013, BEHAV RES THER, V51, P797, DOI 10.1016/j.brat.2013.09.004; Leger D, 2006, SLEEP, V29, P171; Lichstein KL, 2006, SLEEP, V29, P232; Margolies SO, 2013, J CLIN PSYCHOL, V69, P1026, DOI 10.1002/jclp.21970; MATSUKAWA Y, 1994, LUPUS, V3, P31, DOI 10.1177/096120339400300107; McLay RN, 2010, MIL MED, V175, P759, DOI 10.7205/MILMED-D-10-00193; MELLMAN TA, 1995, AM J PSYCHIAT, V152, P1659; Mitchell MD, 2012, BMC FAM PRACT, V13, DOI 10.1186/1471-2296-13-40; Morgenthaler T, 2006, SLEEP, V29, P1415; Morin CM, 2007, SLEEP, V30, P1547, DOI 10.1093/sleep/30.11.1547; MORIN CM, 1994, AM J PSYCHIAT, V151, P1172; Morin CM, 1999, JAMA-J AM MED ASSOC, V281, P991, DOI 10.1001/jama.281.11.991; Morin CM, 1999, SLEEP, V22, P1134, DOI 10.1093/sleep/22.8.1134; Morin CM., 1993, INSOMNIA PSYCHOL ASS; Morrow CE, 2013, MIL PSYCHOL, V25, P568, DOI 10.1037/mil0000021; MURTAGH DRR, 1995, J CONSULT CLIN PSYCH, V63, P79, DOI 10.1037/0022-006X.63.1.79; Mysliwiec V, 2013, SLEEP, V36, P167, DOI 10.5665/sleep.2364; Okajima I, 2011, SLEEP BIOL RHYTHMS, V9, P24, DOI 10.1111/j.1479-8425.2010.00481.x; Ozminkowski RJ, 2007, SLEEP, V30, P263, DOI 10.1093/sleep/30.3.263; PAFFENBARGER RS, 1994, ACTA PSYCHIAT SCAND, V89, P16, DOI 10.1111/j.1600-0447.1994.tb05796.x; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Peterson AL, 2013, CONTEMP CLIN TRIALS, V34, P152, DOI 10.1016/j.cct.2012.10.009; Pruiksma KE, 2016, HDB PSYCHOSOCIAL INT, P113; Respironics, 2005, ACT INSTR MAN SOFTW; Riemann D, 2009, SLEEP MED REV, V13, P205, DOI 10.1016/j.smrv.2008.06.001; Ritterband LM, 2012, PSYCHO-ONCOLOGY, V21, P695, DOI 10.1002/pon.1969; Ritterband LM, 2009, ARCH GEN PSYCHIAT, V66, P692, DOI 10.1001/archgenpsychiatry.2009.66; Roberts RE, 2000, AM J PSYCHIAT, V157, P81, DOI 10.1176/ajp.157.1.81; Rybarczyk B, 2002, PSYCHOL AGING, V17, P288, DOI 10.1037/0882-7974.17.2.288; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Sivertsen B, 2006, JAMA-J AM MED ASSOC, V295, P2851, DOI 10.1001/jama.295.24.2851; Smith MT, 2005, CLIN PSYCHOL REV, V25, P559, DOI 10.1016/j.cpr.2005.04.004; SPIELMAN AJ, 1987, SLEEP, V10, P45; Strom L, 2004, J CONSULT CLIN PSYCH, V72, P113, DOI 10.1037/0022-006X.72.1.113; Taylor Daniel J, 2003, Behav Sleep Med, V1, P227, DOI 10.1207/S15402010BSM0104_5; Taylor DJ, 2016, SLEEP, V39, P1795, DOI 10.5665/sleep.6156; Taylor DJ, 2014, INT REV PSYCHIATR, V26, P205, DOI 10.3109/09540261.2014.902808; Trauer JM, 2015, ANN INTERN MED, V163, P191, DOI 10.7326/M14-2841; van Straten A, 2014, PSYCHOL MED, V44, P1521, DOI 10.1017/S0033291713002249; Walsh JK, 1999, SLEEP, V22, pS386; Weathers F. W., 1993, 9 ANN M INT SOC TRAU; Weissman MM, 1997, GEN HOSP PSYCHIAT, V19, P245, DOI 10.1016/S0163-8343(97)00056-X; Wilson SJ, 2010, J PSYCHOPHARMACOL, V24, P1577, DOI 10.1177/0269881110379307; Young- McCaughan S, 2011, RTOMPHFM205; Zachariae R, 2016, SLEEP MED REV, V30, P1, DOI 10.1016/j.smrv.2015.10.004	89	32	33	1	12	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0161-8105	1550-9109		SLEEP	Sleep	JUN	2017	40	6							zsx075	10.1093/sleep/zsx075			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FA6VR	WOS:000405583100016	28472528	Bronze			2021-06-18	
J	Welch, RD; Ellis, M; Lewis, LM; Ayaz, SI; Mika, VH; Millis, S; Papa, L				Welch, Robert D.; Ellis, Morgan; Lewis, Lawrence M.; Ayaz, Syed I.; Mika, Valerie H.; Millis, Scott; Papa, Linda			Modeling the Kinetics of Serum Glial Fibrillary Acidic Protein, Ubiquitin Carboxyl-Terminal Hydrolase-L1, and S100B Concentrations in Patients with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						biomarkers; glia cell response to injury; neural injury; traumatic brain injury	COMPUTED-TOMOGRAPHY FINDINGS; MILD; BIOMARKERS; MANAGEMENT; DIAGNOSIS; GFAP	Glial fibrillary acidic protein (GFAP), ubiquitin carboxyl-terminal hydrolase-L1 (UCH-L1), and S100B have been shown to be predictive of patients with brain injury. Kinetics of these biomarkers in injured humans have not been extensively examined. This prospective multi-center study included patients with mild-to-moderate traumatic brain injury. Blood samples obtained at enrollment and every 6 h up to 24 h post-injury were assayed for GFAP, UCH-L1, and S100B. Random effects models examined changes in the biomarkers' level over time. A total of 167 patients were enrolled; mean age was 46.0 +/- 17.8, 61.1% were male, 143 (85.6%) had a Glasgow Coma Scale score of 15, and 33 (19.8%) had a positive head computed tomography (CT) scan. Baseline median biomarker concentrations for all three were higher among CT-positive patients (p < 0.0001) but GFAP was the only biomarker that significantly increased over time among CT-positive patients relative to CT-negative patients (log transformed values 0.037; 95% confidence interval 0.02, 0.05; p < 0.001), indicating a 3.7% per hour rise in GFAP concentration. There was no significant increase in either UCH-L1 or S100B in CT-positive patients (p = 0.15 and p = 0.47, respectively). GFAP concentrations increased 3.7% per hour among CT-positive patients whereas neither UCH-L1 nor S100B increased, compared with CT-negative patients. The kinetics and temporal profile of GFAP suggest it may be a more robust biomarker to detect patients with positive CT findings, particularly at later post-injury times. Further study is needed to determine if GFAP is a useful test to follow throughout a patient's clinical course.	[Welch, Robert D.; Ellis, Morgan; Ayaz, Syed I.; Mika, Valerie H.; Millis, Scott] Wayne State Univ, Sch Med, Dept Emergency Med, 4201 St Antoine,UHC 6G, Detroit, MI 48201 USA; [Welch, Robert D.] Wayne State Univ, Sch Med, Cardiovasc Res Inst, 4201 St Antoine,UHC 6G, Detroit, MI 48201 USA; [Millis, Scott] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA; [Lewis, Lawrence M.] Washington Univ, Dept Emergency Med, Sch Med, St Louis, MO USA; [Papa, Linda] Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL USA	Welch, RD (corresponding author), Wayne State Univ, Sch Med, Dept Emergency Med, 4201 St Antoine,UHC 6G, Detroit, MI 48201 USA.; Welch, RD (corresponding author), Wayne State Univ, Sch Med, Cardiovasc Res Inst, 4201 St Antoine,UHC 6G, Detroit, MI 48201 USA.	rwelch@med.wayne.edu	Mika, Valerie H./AAO-2816-2020		U.S. Army Medical Research and Material CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-06-1-0517, W81XWH-10-C-0251]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS057676] Funding Source: NIH RePORTER	This work is supported by the U.S. Army Medical Research and Material Command under Contract N. W81XWH-06-1-0517 and Contract N. W81XWH-10-C-0251. The views, opinions, and/or findings contained in this report are those of the authors and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation. The authors would also like to acknowledge the support of Banyan Biomarkers, Inc. personnel Ronald Hayes and Art Weber.	Barbosa RR, 2012, J TRAUMA ACUTE CARE, V73, pS307, DOI 10.1097/TA.0b013e3182701885; Bazarian JJ, 2013, J NEUROTRAUM, V30, P1747, DOI 10.1089/neu.2013.2853; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Centers for Disease Control and Prevention, 2015, REP C ONTR BRAIN INJ; Ercole A, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0614-3; Gillespie BW, 2010, EPIDEMIOLOGY, V21, pS64, DOI 10.1097/EDE.0b013e3181ce9f08; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Huang XJ, 2015, J NEUROTRAUM, V32, P1179, DOI 10.1089/neu.2015.3873; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Keizer RJ, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.131; Korley FK, 2013, ACAD EMERG MED, V20, P463, DOI 10.1111/acem.12136; Lang TA, 2015, INT J NURS STUD, V52, P5, DOI 10.1016/j.ijnurstu.2014.09.006; Lei J, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-1081-8; McCollough CH, 2016, HEALTH PHYS, V110, P287, DOI 10.1097/HP.0000000000000391; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Papa L, 2016, JAMA NEUROL, V73, P551, DOI 10.1001/jamaneurol.2016.0039; Papa L, 2015, J NEUROTRAUM, V32, P661, DOI 10.1089/neu.2014.3655; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Succop PA, 2004, J OCCUP ENVIRON HYG, V1, P436, DOI 10.1080/15459620490462797; Unden J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-50; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; Xie XH, 2012, STAT MED, V31, P2275, DOI 10.1002/sim.5371; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	30	32	33	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN 1	2017	34	11					1957	1971		10.1089/neu.2016.4772			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EV4KD	WOS:000401727500006	28031000	Green Published			2021-06-18	
J	Zarcone, D; Corbetta, S				Zarcone, Davide; Corbetta, Simona			Shared mechanisms of epilepsy, migraine and affective disorders	NEUROLOGICAL SCIENCES			English	Article; Proceedings Paper	International Multidisciplinary Seminar (STRESA HEADACHE)	MAY 25-27, 2017	Stresa, ITALY			Epilepsy; Migraine; Affective disorders; Common mechanisms	HEADACHES	Since the nineteenth century several clinical features have been observed in common between migraine and epilepsy (such as episodic attacks, triggering factors, presence of aura, frequent familiarity), but only in recent years researchers have really engaged in finding a common pathogenic mechanism. From studies of disease incidence, we understand how either migraine among patients with epilepsy or epilepsy among migraine patients are more frequent than in the general population. This association may result from a direct causality, by the same environmental risk factors and/or by a common genetic susceptibility. Ischemic events are the most frequent direct causes, especially among women and elderly people: migraine can lead to silent or clinically considerable strokes, and these ones could explain the increased risk of developing epilepsy in people with a history of migraine. Head injuries can lead headache, often with migraine characteristics, and seizures. But there are also many idiopathic cases. The comorbidity migraine-epilepsy might be explained in these cases by a neuronal hyperexcitability, which increases the risk of both diseases: a higher concentration of extracellular glutamate, the main excitatory neurotransmitter, leads in fact as a result a Cortical Spreading Depression (the pathophysiological mechanism at the base of aura) and convulsions; antiepileptic drugs such as topiramate are, therefore, used also in migraine prophylaxis. A genetic link between these two diseases is particularly evident in familial hemiplegic migraine: mutations of ATP1A2, SCN1A and CACNA1A genes, identified in this disease, have also been involved in different types of epilepsy and febrile seizures. The channelopathies, especially engaging sodium and potassium ions, can be the common pathogenic mechanism of migraine and epilepsy. Both migraine and epilepsy also have, compared to the general population, a higher prevalence and incidence of affective disorders such as anxiety, depression and suicidal ideation. Anxiety and depression can be part of symptoms that accompany migraine or seizures. Female patients with a long history of illness and frequent attacks are the most at risk. The impact of these diseases on the quality of life is the most obvious cause of these disorders, furthermore some antiepileptic drugs can have depressive effects on mood; the anxious-depressive disorders often result from the interaction between iatrogenic and psychosocial factor with common neurobiological pathogenesis. A chronic lowering of 5-HT (serotonin) levels has been demonstrated both in migraineurs and in depressed patients; amitriptyline and venlafaxine are the most indicated drugs in the treatment of migraine with comorbid depression currently. Likewise imbalance in dopamine levels has been also demonstrated: a D2 receptor genotype has been directly related to comorbidity migraine-depression. In women, hormonal fluctuations are also crucial, especially in the post-partum and late luteal phase, when the estrogenic reduction, associated with up-regulation of SNPs and down-regulation of serotonergic and GABAergic systems, increases the risk of migraine and depression. Furthermore, central sensitization phenomena have been highlighted in both diseases, and result in a progressive increase in the frequency of attacks up to chronicity and the consequent development of drug resistance and overuse. Further studies will be necessary to deepen the close relationship between these three diseases.	[Zarcone, Davide; Corbetta, Simona] Gallarate Hosp, UO Neurol & Stroke Unit, ASST Valle Olona, Gallarate, Italy	Zarcone, D (corresponding author), Gallarate Hosp, UO Neurol & Stroke Unit, ASST Valle Olona, Gallarate, Italy.	davide.zarcone@asst-valleolona.it					Bussone G, 2013, NEUROL SCI, V34, pS29, DOI 10.1007/s10072-013-1362-4; Castelnuovo G, 2016, FRONT PSYCHOL, V7, DOI 10.3389/fpsyg.2016.00468; Hesdorffer DC, 2016, CNS SPECTRUMS, V21, P230, DOI 10.1017/S1092852915000929; Kramer DR, 2017, STEREOT FUNCT NEUROS, V95, P1, DOI 10.1159/000452841; Lampl C, 2016, J HEADACHE PAIN, V17, DOI 10.1186/s10194-016-0649-2; Nye BL, 2015, HEADACHE, V55, P359, DOI 10.1111/head.12536; Seo JH, 2016, EPILEPSY BEHAV, V60, P204, DOI 10.1016/j.yebeh.2016.03.028; Winawer MR, 2013, EPILEPSIA, V54, P288, DOI 10.1111/epi.12072	8	32	33	0	17	SPRINGER-VERLAG ITALIA SRL	MILAN	VIA DECEMBRIO, 28, MILAN, 20137, ITALY	1590-1874	1590-3478		NEUROL SCI	Neurol. Sci.	MAY	2017	38			1			S73	S76		10.1007/s10072-017-2902-0			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	EV6FJ	WOS:000401865000015	28527083				2021-06-18	
J	Jennings, RM; Burtner, JJ; Pellicer, JF; Nair, DK; Bradford, MC; Shaffer, M; Uspal, NG; Tieder, JS				Jennings, Rebecca M.; Burtner, Jennifer J.; Pellicer, Joseph F.; Nair, Deepthi K.; Bradford, Miranda C.; Shaffer, Michele; Uspal, Neil G.; Tieder, Joel S.			Reducing Head CT Use for Children With Head Injuries in a Community Emergency Department	PEDIATRICS			English	Article							CLINICAL DECISION-SUPPORT; COMPUTED-TOMOGRAPHY; TRAUMA; IMPLEMENTATION; CERTIFICATION; MAINTENANCE; CARE; IMPROVEMENT; MODEL; RULE	BACKGROUND AND OBJECTIVE: Clinical decision rules have reduced use of computed tomography (CT) to evaluate minor pediatric head injury in pediatric emergency departments (EDs). CT use remains high in community EDs, where the majority of children seek medical care. We sought to reduce the rate of CT scans used to evaluate pediatric head injury from 29% to 20% in a community ED. METHODS: We evaluated a quality improvement (QI) project in a community ED aimed at decreasing the use of head CT scans in children by implementing a validated head trauma prediction rule for traumatic brain injury. A multidisciplinary team identified key drivers of CT use and implemented decision aids to improve the use of prediction rules. The team identified and mitigated barriers. An affiliated children's hospital offered Maintenance of Certification credit and QI coaching to participants. We used statistical process control charts to evaluate the effect of the intervention on monthly CT scan rates and performed a Wald test of equivalence to compare preintervention and postintervention CT scan proportions. RESULTS: The baseline period (February 2013-July 2014) included 695 patients with a CT scan rate of 29.2% (95% confidence interval, 25.8%32.6%). The postintervention period (August 2014-October 2015) included 651 patients with a CT scan rate of 17.4% (95% confidence interval, 14.5%-20.2%, P <.01). Barriers included targeting providers with variable pediatric experience and parental imaging expectations. CONCLUSIONS: We demonstrate that a Maintenance of Certification QI project sponsored by a children's hospital can facilitate evidence-based pediatric care and decrease the rate of unnecessary CT use in a community setting.	[Jennings, Rebecca M.; Tieder, Joel S.] Seattle Childrens Hosp, Div Gen Pediat & Hosp Med, Seattle, WA USA; [Jennings, Rebecca M.; Nair, Deepthi K.; Bradford, Miranda C.; Shaffer, Michele; Tieder, Joel S.] Seattle Childrens Hosp, Div Emergency Med, Seattle, WA USA; [Burtner, Jennifer J.; Pellicer, Joseph F.] Seattle Childrens Res Inst, Ctr Clin & Translat Res, Seattle, WA USA; [Uspal, Neil G.] Providence St Peter Hosp, Emergency Dept, Olympia, WA USA	Jennings, RM (corresponding author), M-S FA 2-115,POB 5371, Seattle, WA 98145 USA.	rebecca.jennings@seattlechildrens.org			Seattle Children's Hospital Academic Enrichment Fund	All phases of this study were supported by Seattle Children's Hospital Academic Enrichment Fund.	Ambroggio L, 2013, PEDIATRICS, V131, pE1623, DOI 10.1542/peds.2012-2635; [Anonymous], SPEC MAN NAT HOSP IN; Ballard DW, 2013, ACAD EMERG MED, V20, P352, DOI 10.1111/acem.12109; Benneyan JC, 2003, QUAL SAF HEALTH CARE, V12, P458, DOI 10.1136/qhc.12.6.458; Benneyan JC, 1998, INT J QUAL HEALTH C, V10, P69, DOI 10.1093/intqhc/10.1.69; Blackwell CD, 2007, ANN EMERG MED, V49, P320, DOI 10.1016/j.annemergmed.2006.09.025; Boucher Nathan A, 2015, Perm J, V19, P90, DOI 10.7812/TPP/14-095; Box G.E.P., 2008, TIME SERIES ANAL FOR; Bressan S, 2012, ACAD EMERG MED, V19, P801, DOI 10.1111/j.1553-2712.2012.01384.x; Cook DA, 2015, JAMA INTERN MED, V175, P35, DOI 10.1001/jamainternmed.2014.5437; Gausche-Hill M, 2007, PEDIATRICS, V120, P1229, DOI 10.1542/peds.2006-3780; Gorzkowski JA, 2014, PEDIATRICS, V134, P747, DOI 10.1542/peds.2014-0316; Grol R, 2003, LANCET, V362, P1225, DOI 10.1016/S0140-6736(03)14546-1; Hennelly KE, 2013, J PEDIATR-US, V162, P392, DOI 10.1016/j.jpeds.2012.07.018; Huber P.J., 1967, P 5 BERK S MATH STAT, V1; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; Jerardi E, 2013, PEDIATRICS, V132, pE749, DOI 10.1542/peds.2013-0720; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Kuppermann N, 2008, PEDIATR RADIOL, V38, pS670, DOI 10.1007/s00247-008-0996-5; Kurowski EM, 2015, PEDIATRICS, V135, pE1052, DOI 10.1542/peds.2014-2077; Levinson W, 2010, NEW ENGL J MED, V362, P948, DOI 10.1056/NEJMclde0911205; Li J, 2015, ACAD MED, V90, P303, DOI 10.1097/ACM.0000000000000547; Mannix R, 2010, ACAD EMERG MED, V17, P694, DOI 10.1111/j.1553-2712.2010.00797.x; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Nigrovic LE, 2015, PEDIATRICS, V136, pE227, DOI 10.1542/peds.2014-3588; Nishijima DK, 2015, ANN EMERG MED, V65, P72, DOI 10.1016/j.annemergmed.2014.08.019; Rogers AJ, 2013, PEDIATRICS, V132, pE356, DOI 10.1542/peds.2013-0299; Sheehan B, 2013, J BIOMED INFORM, V46, P905, DOI 10.1016/j.jbi.2013.07.005; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Trochim W, 2011, CTS-CLIN TRANSL SCI, V4, P153, DOI 10.1111/j.1752-8062.2011.00291.x; WA State Hospital Association, 100K CHILD CAMP; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; Wylie MC, 2014, PEDIATR EMERG CARE, V30, P680, DOI 10.1097/PEC.0000000000000227	33	32	32	0	3	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	APR	2017	139	4							e20161349	10.1542/peds.2016-1349			9	Pediatrics	Pediatrics	ER2CU	WOS:000398602400003	28255067	Bronze			2021-06-18	
J	Ji, XR; Peng, DY; Zhang, YL; Zhang, J; Wang, YN; Gao, Y; Lu, N; Tang, PF				Ji, Xinran; Peng, Dayong; Zhang, Yiling; Zhang, Jun; Wang, Yuning; Gao, Yuan; Lu, Ning; Tang, Peifu			Astaxanthin improves cognitive performance in mice following mild traumatic brain injury	BRAIN RESEARCH			English	Article						Traumatic brain injury; Astaxanthin; NSS; Rotarod test; Y-maze; Object recognition test; Growth-associated protein; Synaptic protein	CLOSED-HEAD INJURY; EXPERIMENTAL SUBARACHNOID HEMORRHAGE; OXIDATIVE STRESS; IN-VITRO; RATS; PATHOPHYSIOLOGY; DEFICITS; PATHWAY; MOTOR; NEUROINFLAMMATION	Background: Traumatic brain injury (TBI) produces lasting neurological deficits that plague patients and physicians. To date, there is no effective method to combat the source of this problem. Here, we utilized a mild, closed head TBI model to determine the modulatory effects of a natural dietary compound, astaxanthin (AST). AST is centrally active following oral administration and is neuroprotective in experimental brain ischemia/stroke and subarachnoid hemorrhage (SAH) models. We examined the effects of oral AST on the long-term neurological functional recovery and histological outcomes following moderate TBI in a mice model. Methods: Male adult ICR mice were divided into 3 groups: (1) Sham + olive oil vehicle treated, (2) TBI + olive oil vehicle treated, and (3) TBI + AST. The olive oil vehicle or AST were administered via oral gavage at scheduled time points. Closed head brain injury was applied using M.A. Flierl weight-drop method. NSS, Rotarod, ORT, and Y-maze were performed to test the behavioral or neurological outcome. The brain sections from the mice were stained with H&E and cresyl-violet to test the injured lesion volume and neuronal loss. Western blot analysis was performed to investigate the mechanisms of neuronal cell survival and neurological function improvement. Results: AST administration improved the sensorimotor performance on the Neurological Severity Score (NSS) and rotarod test and enhanced cognitive function recovery in the object recognition test (ORT) and Y-maze test. Moreover, AST treatment reduced the lesion size and neuronal loss in the cortex compared with the vehicle-treated TBI group. AST also restored the levels of brain-derived neurotropic factor (BDNF), growth-associated protein-43 (GAP-43), synapsin, and synaptophysin (SYP) in the cerebral cortex, which indicates the promotion of neuronal survival and plasticity. Conclusion: To the best of our knowledge, this is the first study to demonstrate the protective role and the underlining mechanism of AST in TBI. Based on these neuroprotective actions and considering its long-standing clinical use, AST should be considered for the clinical treatment of TBI. (C) 2017 Elsevier B.V. All rights reserved.	[Ji, Xinran; Zhang, Yiling; Zhang, Jun; Wang, Yuning; Gao, Yuan; Lu, Ning; Tang, Peifu] Chinese Peoples Liberat Army Gen Hosp 301 Hosp, Dept Orthopaed Surg, 28 Fuxing Rd, Beijing 100000, Peoples R China; [Peng, Dayong] Shandong Univ, Shandong Qianfoshan Hosp, Dept Orthoped, Jing Shi Rd, Jinan 250014, Shandong, Peoples R China	Lu, N; Tang, PF (corresponding author), Chinese Peoples Liberat Army Gen Hosp 301 Hosp, Dept Orthopaed Surg, 28 Fuxing Rd, Beijing 100000, Peoples R China.	luning301@126.com; tangpeifu301@126.com					Algattas H, 2014, INT J MOL SCI, V15, P309, DOI 10.3390/ijms15010309; Ambati RR, 2014, MAR DRUGS, V12, P128, DOI 10.3390/md12010128; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chew BP, 2004, J NUTR, V134, p257S; Conrad CD, 1996, BEHAV NEUROSCI, V110, P1321, DOI 10.1037/0735-7044.110.6.1321; DELLU F, 1992, BRAIN RES, V588, P132, DOI 10.1016/0006-8993(92)91352-F; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Ennaceur A, 2005, BEHAV BRAIN RES, V159, P247, DOI 10.1016/j.bbr.2004.11.006; Fassett RG, 2009, FUTUR CARDIOL, V5, P333, DOI 10.2217/FCA.09.19; Fernandez-Gajardo R, 2014, CNS DRUGS, V28, P229, DOI 10.1007/s40263-013-0138-y; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Guerin M, 2003, TRENDS BIOTECHNOL, V21, P210, DOI 10.1016/S0167-7799(03)00078-7; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kidd PM, 2009, ALTERN MED REV, V14, P14; Kuzelova K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092560; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; Leker RR, 2002, ACTA NEUROCHIR SUPPL, V83, P49; Lin TY, 2010, J AGR FOOD CHEM, V58, P8271, DOI 10.1021/jf101689t; Loane David J, 2015, Handb Clin Neurol, V127, P343, DOI 10.1016/B978-0-444-52892-6.00022-2; Loane DJ, 2009, NAT MED, V15, P377, DOI 10.1038/nm.1940; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Lu YP, 2010, BRAIN RES, V1360, P40, DOI 10.1016/j.brainres.2010.09.016; Ozen LJ, 2012, ARCH CLIN NEUROPSYCH, V27, P85, DOI 10.1093/arclin/acr087; Parchani A, 2014, WORLD NEUROSURG, V82, pE639, DOI 10.1016/j.wneu.2014.06.022; Rachmany L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079837; Shen H, 2009, FASEB J, V23, P1958, DOI 10.1096/fj.08-123281; Siedler DG, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00429; Stoica BA, 2014, J NEUROTRAUM, V31, P758, DOI 10.1089/neu.2013.3194; Thau-Zuchman O, 2012, NEUROSCIENCE, V202, P334, DOI 10.1016/j.neuroscience.2011.11.071; Tripathi DN, 2010, MUTAT RES-GEN TOX EN, V696, P69, DOI 10.1016/j.mrgentox.2009.12.014; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Wang HQ, 2010, BRAIN RES, V1360, P159, DOI 10.1016/j.brainres.2010.08.100; Wang MR, 2013, FOOD CHEM TOXICOL, V56, P450, DOI 10.1016/j.fct.2013.03.004; Weng SM, 2011, NEUROSCIENCE, V180, P314, DOI 10.1016/j.neuroscience.2011.01.061; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wu Q, 2014, MAR DRUGS, V12, P6125, DOI 10.3390/md12126125; Zhang XS, 2014, J SURG RES, V192, P206, DOI 10.1016/j.jss.2014.05.029; Zhang XS, 2014, MAR DRUGS, V12, P4291, DOI 10.3390/md12084291; Zhang XS, 2014, J NEUROSURG, V121, P42, DOI 10.3171/2014.2.JNS13730; Zhao ZR, 2013, J CEREBR BLOOD F MET, V33, P1897, DOI 10.1038/jcbfm.2013.144	45	32	33	1	21	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 15	2017	1659						88	95		10.1016/j.brainres.2016.12.031			8	Neurosciences	Neurosciences & Neurology	EM8ZH	WOS:000395600000010	28048972				2021-06-18	
J	Staton, CA; Msilanga, D; Kiwango, G; Vissoci, JR; de Andrade, L; Lester, R; Hocker, M; Gerardo, CJ; Mvungi, M				Staton, Catherine A.; Msilanga, Daniel; Kiwango, George; Vissoci, Joao Ricardo; de Andrade, Luciano; Lester, Rebecca; Hocker, Michael; Gerardo, Charles J.; Mvungi, Mark			A prospective registry evaluating the epidemiology and clinical care of traumatic brain injury patients presenting to a regional referral hospital in Moshi, Tanzania: challenges and the way forward	INTERNATIONAL JOURNAL OF INJURY CONTROL AND SAFETY PROMOTION			English	Article						traumatic brain injury; epidemiology; Tanzania; quality of care	URBAN; AREA; QCA	Traumatic brain injury (TBI) is the most common cause of death and disability globally disproportionately affecting low- and middle-income countries where increasing injury rates are compounded by limited quality care. The objective of this study is to describe quality of care for TBI patients who presented to Kilimanjaro Christian Medical Center, Moshi, Tanzania. We evaluated a prospective quality improvement TBI registry that enrolled consecutive patients with acute TBI. Descriptive statistics and qualitative comparative analysis was performed. Overall, 893 TBI patients were enrolled during the study period, with a mean age of 32.1 years and who were mostly (80%) male. 12.9% suffered severe TBI (GCS < 9). Most injuries were road traffic (66%) especially motorcyclists (49%) and 26.8% were alcohol related. One intubation occurred, and 22.9% of hypoxic patients received oxygen. Severe TBI mortality was 47%. TBI affects men 15-45 years old in traffic crashes with high mortality for severe TBI (47%) patients. Care addressing secondary injury, hypoxemia, and hypotension is limited.	[Staton, Catherine A.; Hocker, Michael; Gerardo, Charles J.] Duke Univ, Med Ctr, Duke Div Emergency Med, Durham, NC 27710 USA; [Staton, Catherine A.; Hocker, Michael; Gerardo, Charles J.] Duke Univ, Duke Global Hlth Inst, Durham, NC 27710 USA; [Msilanga, Daniel; Kiwango, George; Mvungi, Mark] Kilimanjaro Christian Med Ctr, Moshi, Tanzania; [Vissoci, Joao Ricardo] Fac INGA, Fac Med, Maringa, Parana, Brazil; [de Andrade, Luciano] State Univ West Parana Unioeste, Foz Do Iguacu, Brazil; [Lester, Rebecca] London Sch Hyg & Trop Med, London, England	Staton, CA (corresponding author), Duke Univ, Med Ctr, Duke Div Emergency Med, Durham, NC 27710 USA.; Staton, CA (corresponding author), Duke Univ, Duke Global Hlth Inst, Durham, NC 27710 USA.	catherine.staton@duke.edu		Staton, Catherine/0000-0002-6468-2894	HRSAUnited States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA) [T84HA21123-02]; U.S. National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Duke Division of Emergency Medicine	This project was made possible by the Mentored Research Training Programme in collaboration with the HRSA-funded KCMC MEPI [grant number T84HA21123-02]; U.S. National Institutes of Health and the Duke Division of Emergency Medicine.	Alexander T, 2009, S AFR J SURG, V47, P120; [Anonymous], 2015, R PROJECT STAT COMPU; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Casey ER, 2012, INT J EMERG MED, V5, DOI 10.1186/1865-1380-5-28; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Chandran A, 2010, EPIDEMIOL REV, V32, P110, DOI 10.1093/epirev/mxq009; Constant A, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000228; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; Dusa A, 2010, QUAL QUANT, V44, P99, DOI 10.1007/s11135-008-9183-x; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Georgoff P, 2010, WORLD NEUROSURG, V74, P331, DOI 10.1016/j.wneu.2010.03.025; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Kesinger MR, 2014, INJURY, V45, P1350, DOI 10.1016/j.injury.2014.04.037; Kolaczyk E. D., 2014, STAT ANAL NETWORK R; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Maier D, 2014, WORLD NEUROSURG, V81, P478, DOI 10.1016/j.wneu.2013.08.014; Marx A., 2011, METHODOLOGICAL INNOV, V6, P103, DOI DOI 10.4256/MIO.2010.0037; Mortality in the KCMC Intensive Care Unit, 2012, GRAND ROUND C MOSH; Moshiro C, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-11; MUNIU E, 1994, E AFR MED J, V71, P346; Murgio A, 1999, CHILD NERV SYST, V15, P318, DOI 10.1007/s003810050401; Muyembe VM, 1999, E AFR MED J, V76, P200; Peden M., 2007, ALCOHOL INJURY EMERG; Ragin C. C., 2008, REDESIGNING SOCIAL I; Ragin C. C., 1987, COMP METHOD MOVING Q; Rihoux B, 2006, INT SOCIOL, V21, P679, DOI 10.1177/0268580906067836; Sumner SA, 2014, INJURY, V45, P1681, DOI 10.1016/j.injury.2014.04.034; Thiem A, 2013, R J, V5, P87; van Pelt ED, 2011, EUR J PAEDIATR NEURO, V15, P519, DOI 10.1016/j.ejpn.2011.05.005; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Winkler AS, 2010, WORLD NEUROSURG, V73, P264, DOI 10.1016/j.wneu.2010.03.037; World Health Organization, 2010, VIOL INJ DIS BIENN R	34	32	32	0	11	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1745-7300	1745-7319		INT J INJ CONTROL SA	Int. J. Inj. Control Saf. Promot.	MAR	2017	24	1					69	77		10.1080/17457300.2015.1061562			9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	EK1TG	WOS:000393708100008	26239625				2021-06-18	
J	Zieman, G; Bridwell, A; Cardenas, JF				Zieman, Glynnis; Bridwell, Ashley; Cardenas, Javier F.			Traumatic Brain Injury in Domestic Violence Victims: A Retrospective Study at the Barrow Neurological Institute	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; head trauma; traumatic brain injury	INTIMATE PARTNER VIOLENCE; BATTERED WOMEN	Domestic violence is a national health crisis, which affects people of all ages, races, and socioeconomic classes. Traumatic brain injury is common in victims because of the high frequency of head and neck injuries inflicted through abuse. These recurrent injuries can lead to chronic symptoms with high morbidity. We conducted a retrospective chart review of 115 patients with a history of head trauma as a result of domestic violence. All patients were seen in a subspecialty traumatic brain injury clinic, at which time information regarding their histories and self-reported symptoms were recorded. In total, 109 females and 6 males were included in our study, with an age range of 4-68 years. Overall, 88% reported more than one injury and 81% reported a history of loss of consciousness associated with their injuries. Only 21% sought medical help at the time of injury. Whereas 85% had a history of abuse in adulthood, 22% had experienced abuse in both childhood and adulthood, and 60% of the patients abused as children went on to be abused as adults. Headache was the most common chief complaint, but on a self-reported symptom severity scale, behavioral symptoms were the most severe. Psychiatric disease was present in 84% of patients. Traumatic brain injury is a frequent sequela of domestic violence, from which many victims sustain multiple injuries without seeking medical care. Brain injuries are often sustained over many years and lead to lasting physical, behavioral, and cognitive consequences. Better understanding of these injuries will lead to improved care for this population.	[Zieman, Glynnis; Cardenas, Javier F.] Barrow Concuss & Brain Injury Ctr, 222 W Thomas Rd,Suite 304, Phoenix, AZ 85013 USA; [Bridwell, Ashley] Barrow Neurol Inst, Adult Neurol Program Outpatient Neurol Rehabil, Phoenix, AZ USA	Zieman, G (corresponding author), Barrow Concuss & Brain Injury Ctr, 222 W Thomas Rd,Suite 304, Phoenix, AZ 85013 USA.	Glynnis.Zieman@dignityhealth.org	Zieman, Glynnis/AAQ-3409-2020				Anxiety and Depression Association of America, 2014, FACTS AND STAT; Campbel J., 2015, ED MANAG, V27, P19; Centers for Disease Control and Prevention, 2015, C TRAUM BRAIN INJ US; Davis A, 2014, J TRAUMA NURS, V21, P300, DOI 10.1097/JTN.0000000000000086; Jackson H, 2002, PROF PSYCHOL-RES PR, V33, P39, DOI 10.1037//0735-7028.33.1.39; Kwako LE, 2011, TRAUMA VIOLENCE ABUS, V12, P115, DOI 10.1177/1524838011404251; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Monahan K, 1999, HEALTH SOC WORK, V24, P269, DOI 10.1093/hsw/24.4.269; Morgan CD, 2015, J NEUROSURG-PEDIATR, V15, P589, DOI 10.3171/2014.10.PEDS14356; Murray CE, 2016, TRAUMA VIOLENCE ABUS, V17, P298, DOI 10.1177/1524838015584364; National Coalition Against Domestic Violence, 2015, DOM VIOL NAT STAT; National Coalition Against Domestic Violence, 2015, FACTS DOM VIOL PHYS; Picard M, 1991, HELPS BRAIN INJURY S; United States Department of Health & Human Services Administration for Children and Families Administration on Children Youth and Families Children's Bureau, 2016, CHILDR MALTR 2014; Valera EM, 2003, J CONSULT CLIN PSYCH, V71, P797, DOI 10.1037/0022-006X.71.4.797; Wong JYH, 2014, TRAUMA VIOLENCE ABUS, V15, P22, DOI 10.1177/1524838013496333; Wong J, 2014, CONTEMP NURSE, V46, P170, DOI 10.5172/conu.2014.46.2.170	17	32	32	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2017	34	4					876	880		10.1089/neu.2016.4579			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EL0XD	WOS:000394344200015	27312572				2021-06-18	
J	Ritter, AC; Wagner, AK; Fabio, A; Pugh, MJ; Walker, WC; Szaflarski, JP; Zafonte, RD; Brown, AW; Hammond, FM; Bushnik, T; Johnson-Greene, D; Shea, T; Krellman, JW; Rosenthal, JA; Dreer, LE				Ritter, Anne C.; Wagner, Amy K.; Fabio, Anthony; Pugh, Mary Jo; Walker, William C.; Szaflarski, Jerzy P.; Zafonte, Ross D.; Brown, Allen W.; Hammond, Flora M.; Bushnik, Tamara; Johnson-Greene, Douglas; Shea, Timothy; Krellman, Jason W.; Rosenthal, Joseph A.; Dreer, Laura E.			Incidence and risk factors of posttraumatic seizures following traumatic brain injury: A Traumatic Brain Injury Model Systems Study	EPILEPSIA			English	Article						Epilepsy; Prophylaxis; Relative risk; TBI Model Systems; Epidemiology	HEAD-INJURY; EPILEPSY DEVELOPMENT; GENETIC-VARIATION; EPIDEMIOLOGY; REHABILITATION; ASSOCIATIONS; HOSPITALIZATION; MULTICENTER; DEFINITION; MECHANISMS	ObjectiveDetermine incidence of posttraumatic seizure (PTS) following traumatic brain injury (TBI) among individuals with moderate-to-severe TBI requiring rehabilitation and surviving at least 5 years. MethodsUsing the prospective TBI Model Systems National Database, we calculated PTS incidence during acute hospitalization, and at years 1, 2, and 5 postinjury in a continuously followed cohort enrolled from 1989 to 2000 (n = 795). Incidence rates were stratified by risk factors, and adjusted relative risk (RR) was calculated. Late PTS associations with immediate (<24 h), early (24 h-7 day), or late seizures (>7 day) versus no seizure prior to discharge from acute hospitalization was also examined. ResultsPTS incidence during acute hospitalization was highest immediately (<24 h) post-TBI (8.9%). New onset PTS incidence was greatest between discharge from inpatient rehabilitation and year 1 (9.2%). Late PTS cumulative incidence from injury to year 1 was 11.9%, and reached 20.5% by year 5. Immediate/early PTS RR (2.04) was increased for those undergoing surgical evacuation procedures. Late PTS RR was significantly greater for individuals who self-identified as a race other than black/white (year 1 RR = 2.22), and for black individuals (year 5 RR = 3.02) versus white individuals. Late PTS was greater for individuals with subarachnoid hemorrhage (year 1 RR = 2.06) and individuals age 23-32 (year 5 RR = 2.43) and 33-44 (year 5 RR = 3.02). Late PTS RR years 1 and 5 was significantly higher for those undergoing surgical evacuation procedures (RR: 3.05 and 2.72, respectively). SignificanceIn this prospective, longitudinal, observational study, PTS incidence was similar to that in studies published previously. Individuals with immediate/late seizures during acute hospitalization have increased late PTS risk. Race, intracranial pathologies, and neurosurgical procedures also influenced PTS RR. Further studies are needed to examine the impact of seizure prophylaxis in high-risk subgroups and to delineate contributors to race/age associations on long-term seizure outcomes.	[Ritter, Anne C.; Fabio, Anthony] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Ritter, Anne C.; Wagner, Amy K.] Univ Pittsburgh, Phys Med & Rehabil, Pittsburgh, PA USA; [Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Wagner, Amy K.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA USA; [Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA; [Pugh, Mary Jo] South Texas Vet Hlth Care Syst Polytrauma Rehabi, San Antonio, TX USA; [Pugh, Mary Jo] Univ Texas Hlth Sci Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA; [Walker, William C.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Szaflarski, Jerzy P.] Univ Alabama Birmingham, Dept Neurol, UAB Epilepsy Ctr, UAB Stn, Birmingham, AL 35294 USA; [Zafonte, Ross D.] Harvard Med Sch, Spaulding Rehabil Hosp, Boston, MA USA; [Brown, Allen W.] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA; [Hammond, Flora M.] Carolinas Rehabil, Charlotte, NC USA; [Hammond, Flora M.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA; [Bushnik, Tamara] NYU, Sch Med, Rusk Rehabil, New York, NY USA; [Johnson-Greene, Douglas] Univ Miami, Miller Sch Med, Miami, FL 33136 USA; [Shea, Timothy; Rosenthal, Joseph A.; Dreer, Laura E.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Krellman, Jason W.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Dreer, Laura E.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Pugh, Mary Jo/K-5336-2019	Pugh, Mary Jo/0000-0003-4196-7763; Bushnik, Tamara/0000-0003-3328-257X; Brown, Allen W./0000-0001-7228-3351; Fabio, Anthony/0000-0002-6808-4939	NIDILRRUnited States Department of Health & Human Services [90DP0041, 90DP0038, 90DP0036, 90DP0033]; Polytrauma Rehabilitation Center Traumatic Brain Injury Model System; Department of Veterans Affairs (VA)US Department of Veterans Affairs; NIDILRRUnited States Department of Health & Human Services	The National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR) supported the collection of original data for this manuscript. The contents of this manuscript were developed under grants NIDILRR Grants 90DP0041 (AKW, ACR), NIDILRR 90DP0038 (JWK), 90DP0036 (FH), 90DP0033 (WCW), and the Polytrauma Rehabilitation Center Traumatic Brain Injury Model System (MJP). The Polytrauma Rehabilitation Center TBI Model System is a funded collaboration between the Department of Veterans Affairs (VA) and NIDILRR. NIDILRR is a Center within the Administration for Community Living (ACL), Department of Health and Human Services (HHS). The contents of this manuscript do not necessarily represent the policy of the VA, NIDILRR, ACL, or HHS, and endorsement of this content by the Federal Government should not be assumed.	Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Andriessen TMJC, 2010, J CELL MOL MED, V14, P2381, DOI 10.1111/j.1582-4934.2010.01164.x; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; [Anonymous], 2013, R LANG ENV STAT COMP; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Beghi E, 2010, EPILEPSIA, V51, P671, DOI 10.1111/j.1528-1167.2009.02285.x; Bonita R., 2006, BASIC EPIDEMIOLOGY; Brasure M, 2012, COMP EFFECTIVENESS R; Centers for Disease Control and Prevention, 2014, REP C TRAUM BRAIN IN; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; DESAI BT, 1983, ANN EMERG MED, V12, P543, DOI 10.1016/S0196-0644(83)80294-7; Diamond ML, 2015, EPILEPSIA, V56, P1198, DOI 10.1111/epi.13044; Diamond ML, 2014, EPILEPSIA, V55, P1109, DOI 10.1111/epi.12628; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; Englander J, 2009, J NEUROTRAUM, V26, P1471, DOI 10.1089/neu.2008.0729; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550; Fisher RS, 2012, EPILEPSY BEHAV, V24, P304, DOI 10.1016/j.yebeh.2012.04.128; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; Harrison-Felix C, 2015, J NEUROTRAUM, V32, P1893, DOI 10.1089/neu.2014.3353; Hauser WA, 1996, MAYO CLIN PROC, V71, P576, DOI 10.4065/71.6.576; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Hunt RF, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00089; JENNETT B, 1974, ARCH NEUROL-CHICAGO, V30, P394, DOI 10.1001/archneur.1974.00490350052008; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; Krellman JW, 2014, ARCH PHYS MED REHAB, V95, P633, DOI 10.1016/j.apmr.2013.10.016; Kumar RG, 2016, J HEAD TRAU IN PRESS; Langley J, 2010, BRAIN INJURY, V24, P939, DOI 10.3109/02699052.2010.491494; LEE ST, 1992, J NEUROSURG, V76, P435, DOI 10.3171/jns.1992.76.3.0435; Liu SS, 2016, NEUROPSYCH DIS TREAT, V12, P1425, DOI 10.2147/NDT.S107905; Najafi Mohammad Reza, 2015, Adv Biomed Res, V4, P82, DOI 10.4103/2277-9175.156640; Oluwole OSA, 2011, BRAIN INJURY, V25, P980, DOI 10.3109/02699052.2011.589798; Pretz CR, 2015, ARCH PHYS MED REHAB, V96, P746, DOI 10.1016/j.apmr.2014.09.025; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Ritter AC, 2016, EPILEPSIA, V57, P1503, DOI 10.1111/epi.13470; Ritter AC, 2016, EPILEPSIA, V57, P984, DOI 10.1111/epi.13397; Saunders LL, 2009, BRAIN INJURY, V23, P866, DOI 10.1080/02699050903283213; Szaflarski M, 2006, EPILEPSY BEHAV, V9, P243, DOI 10.1016/j.yebeh.2006.05.011; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Wagner AK, 2000, J TRAUMA, V49, P404, DOI 10.1097/00005373-200009000-00004; Wagner AK, 2010, EPILEPSY RES, V90, P259, DOI 10.1016/j.eplepsyres.2010.06.001; Walker WC, 2015, J HEAD TRAUMA REHAB, V30, P231, DOI 10.1097/HTR.0000000000000127; Yablon SA, 1998, ARCH PHYS MED REHAB, V79, P594; Zhao YQ, 2012, SEIZURE-EUR J EPILEP, V21, P322, DOI 10.1016/j.seizure.2012.02.007	50	32	35	0	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	DEC	2016	57	12					1968	1977		10.1111/epi.13582			10	Clinical Neurology	Neurosciences & Neurology	EF5EI	WOS:000390353100004	27739577				2021-06-18	
J	Gilbert, FC; Burdette, GT; Joyner, AB; Llewellyn, TA; Buckley, TA				Gilbert, Frances C.; Burdette, G. Trey; Joyner, A. Barry; Llewellyn, Tracy A.; Buckley, Thomas A.			Association Between Concussion and Lower Extremity Injuries in Collegiate Athletes	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						injury risk; ankle sprain; anterior cruciate ligament injury; muscle strain; mild traumatic brain injury	PROFESSIONAL FOOTBALL PLAYERS; MANAGEMENT PRACTICE PATTERNS; SPORT-RELATED CONCUSSION; ERROR SCORING SYSTEM; RECURRENT CONCUSSION; MUSCULOSKELETAL INJURY; POSTURAL CONTROL; NCAA CONCUSSION; BALANCE; RECOVERY	Background: Concussions have been associated with elevated musculoskeletal injury risk; however, the influence of unreported and unrecognized concussions has not been investigated. Hypothesis: The purpose of this study was to examine the association between concussion and lower extremity musculoskeletal injury rates across a diverse array of sports among collegiate student-athletes at the conclusion of their athletic career. The hypothesis was that there will be a positive association between athletes who reported a history of concussions and higher rates of lower extremity injuries. Study Design: Cross-sectional study. Level of Evidence: Level 3. Methods: Student-athletes (N = 335; 62.1% women; mean age, 21.2 +/- 1.4 years) from 13 sports completed a reliable injury history questionnaire. Respondents indicated the total number of reported, unreported, and potentially unrecognized concussions as well as lower extremity injuries including ankle sprains, knee injuries, and muscle strains. Chi-square analyses were performed to identify the association between concussion and lower extremity injuries. Results: There were significant associations between concussion and lateral ankle sprain (P = 0.012), knee injury (P = 0.002), and lower extremity muscle strain (P = 0.031). There were also significant associations between reported concussions and knee injury (P = 0.003), unreported concussions and knee injury (P = 0.002), and unrecognized concussions and lateral ankle sprain (P = 0.001) and lower extremity muscle strains (P = 0.006), with odds ratios ranging from 1.6 to 2.9. Conclusion: There was a positive association between concussion history and lower extremity injuries (odds ratios, 1.6-2.9 elevated risk) among student-athletes at the conclusion of their intercollegiate athletic careers. Clinical Relevance: Clinicians should be aware of these elevated risks when making return-to-participation decisions and should incorporate injury prevention protocols.	[Gilbert, Frances C.] Univ North Georgia, Dept Intercollegiate Athlet, Dahlonega, GA USA; [Burdette, G. Trey] Georgia Southern Univ, Sch Hlth & Kinesiol, Statesboro, GA USA; [Joyner, A. Barry] Georgia Southern Univ, Coll Hlth & Human Sci, Statesboro, GA USA; [Llewellyn, Tracy A.] Carolinas Healthcare Syst, Charlotte, NC USA; [Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, 541 South Coll Ave, Newark, DE 19716 USA; [Buckley, Thomas A.] Univ Delaware, Interdisciplinary Program Biomech & Movement Sci, Newark, DE USA	Buckley, TA (corresponding author), Univ Delaware, Dept Kinesiol & Appl Physiol, 541 South Coll Ave, Newark, DE 19716 USA.	tbuckley@udel.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150; Llewellyn, Tracy/0000-0002-6483-2776			Baugh CM, 2014, J LAW MED ETHICS, V42, P314, DOI 10.1111/jlme.12148; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Buckley TA, 2015, CURR RES CONCUSSION, V2, P59; Buckley TA, 2016, J SPORT HEALTH SCI, V5, P61, DOI 10.1016/j.jshs.2016.01.007; Buckley TA, 2015, J ATHL TRAINING, V50, P879, DOI 10.4085/1062-6050-50.7.04; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Burk JM, 2013, CLIN J SPORT MED, V23, P312, DOI 10.1097/JSM.0b013e318285633f; Burman E., 2016, BMJ OPEN SPORT EXERC, V2; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Cross M, 2016, BRIT J SPORT MED, V50, P926, DOI 10.1136/bjsports-2015-094982; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; Finnoff JT, 2009, PM&R, V1, P50, DOI 10.1016/j.pmrj.2008.06.002; Gao JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024446; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Herman DC, 2015, CURR SPORT MED REP, V14, P194, DOI 10.1249/JSR.0000000000000157; Hewett TE, 2012, CLIN ORTHOP RELAT R, V470, P2930, DOI 10.1007/s11999-012-2440-2; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Jaffee MS, 2015, BRAIN INJURY, V29, P221, DOI 10.3109/02699052.2014.983978; Kelly KC, 2014, J ATHL TRAINING, V49, P665, DOI 10.4085/1062-6050-49.3.25; Kerr ZY, 2016, AM J SPORT MED, V44, P220, DOI 10.1177/0363546515612082; Kerr ZY, 2015, AM J SPORT MED, V43, P606, DOI 10.1177/0363546514562180; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Mainwaring LM, 2004, J SPORT EXERCISE PSY, V26, P119, DOI 10.1123/jsep.26.1.119; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; Moreau M. S., 2014, INT J EXERCISE SCI, V7, P62; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Oldham JR, 2016, GAIT POSTURE, V49, P437, DOI 10.1016/j.gaitpost.2016.07.327; Onate JA, 2016, CLIN J SPORT MED, V26, P435, DOI 10.1097/JSM.0000000000000284; Pietrosimone B, 2015, MED SCI SPORT EXER, V47, P2366, DOI 10.1249/MSS.0000000000000684; Pietrosimone BG, 2015, J ATHL TRAINING, V50, P665, DOI 10.4085/1062-6050-50.1.11; Pietrosimone BG, 2012, J ATHL TRAINING, V47, P621, DOI 10.4085/1062-6050-47.6.11; Rahn C, 2015, CLIN J SPORT MED, V25, P248, DOI 10.1097/JSM.0000000000000141; Shumway-Cook A., 2012, MOTOR CONTROL TRANSL; Slobounov S, 2012, CLIN NEUROPHYSIOL, V123, P1755, DOI 10.1016/j.clinph.2011.12.022; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Swanik CB, 2007, AM J SPORT MED, V35, P943, DOI 10.1177/0363546507299532; McLeod TCV, 2008, CLIN J SPORT MED, V18, P235, DOI 10.1097/JSM.0b013e3181705756; Wilkerson GB, 2012, INT J ATHL THER TRAI, V17, P4, DOI 10.1123/ijatt.17.6.4; Williams JM, 2016, J SPORT HEALTH SCI, V5, P197, DOI 10.1016/j.jshs.2015.01.009	48	32	32	0	16	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	NOV-DEC	2016	8	6					661	667		10.1177/1941738116666509			7	Sport Sciences	Sport Sciences	EG8DN	WOS:000391286000011	27587598	Green Published			2021-06-18	
J	Vieira, RDA; Paiva, WS; de Oliveira, DV; Teixeira, MJ; de Andrade, AF; de Sousa, RMC				Almeida Vieira, Rita de Cassia; Paiva, Wellingson Silva; de Oliveira, Daniel Vieira; Teixeira, Manoel Jacobsen; de Andrade, Almir Ferreira; Cardoso de Sousa, Regina Marcia			Diffuse Axonal Injury: Epidemiology, Outcome and Associated Risk Factors	FRONTIERS IN NEUROLOGY			English	Article						head trauma; diffuse axonal injury; Glasgow Outcome Scale; recovery; severe traumatic brain inju cohort study	TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; QUALITY-OF-LIFE; SEVERITY SCORE; INTRACRANIAL-PRESSURE; MAGNETIC-RESONANCE; MODERATE; PREDICTORS; MRI; HYPOTENSION	Diffuse axonal injury (DAI), a type of traumatic injury, is known for its severe consequences. However, there are few studies describing the outcomes of DAI and the risk factors associated with it. This study aimed to describe the outcome for patients with a primary diagnosis of DAI 6 months after trauma and to identify sociodemographic and clinical factors associated with mortality and dependence at this time point. Seventy-eight patients with DAI were recruited from July 2013 to February 2014 in a prospective cohort study. Patient outcome was analyzed using the Extended Glasgow Outcome Scale (GOS-E) within 6 months of the traumatic injury. The mean Injury Severity Score was 35.0 (SD = 11.9), and the mean New Injury Severity Score (NISS) was 46.2 (SD = 15.9). Mild DAI was observed in 44.9% of the patients and severe DAI in 35.9%. Six months after trauma, 30.8% of the patients had died, and 45.1% had shown full recovery according to the GOS-E. In the logistic regression model, the severity variables - DAI with hypoxia, as measured by peripheral oxygen saturation, and hypotension with NISS value - had a statistically significant association with patient mortality; on the other hand, severity of DAI and length of hospital stay were the only significant predictors for dependence. Therefore, severity of DAI emerged as a risk factor for both mortality and dependence.	[Almeida Vieira, Rita de Cassia; Cardoso de Sousa, Regina Marcia] Univ Sao Paulo, Sch Nursing, Sao Paulo, Brazil; [Paiva, Wellingson Silva; de Oliveira, Daniel Vieira; Teixeira, Manoel Jacobsen; de Andrade, Almir Ferreira] Univ Sao Paulo, Sch Med, Dept Neurol, Sao Paulo, Brazil	Vieira, RDA (corresponding author), Univ Sao Paulo, Sch Nursing, Sao Paulo, Brazil.	ritavieira@usp.br	de Oliveira, Daniel Vieira/AAH-1071-2019; Paiva, Wellingson S/G-5517-2013; Sousa, Regina M/H-1108-2012; Almeida Vieira, Rita de Cassia/E-3262-2013	de Oliveira, Daniel Vieira/0000-0002-6768-3286; Paiva, Wellingson S/0000-0002-5165-7040; Sousa, Regina M/0000-0002-2575-7937; Almeida Vieira, Rita de Cassia/0000-0002-7981-9822; Vieira, Rita de Cassia/0000-0001-9210-4445	Sao Paulo Research Foundation (FAPESP)Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [2013/21804-0]; Conselho Nacional de Desenvolvimento Cientifico and Tecnologico Universal MCTI-CNPq [444855/214-9]	This project was supported by Sao Paulo Research Foundation (FAPESP) 2013/21804-0 and Conselho Nacional de Desenvolvimento Cientifico and Tecnologico Universal MCTI-CNPq (444855/214-9).	Association for the Advancement of Automotive Medicine (AAAM), 2008, ABBR INJ SCAL AIS 20; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bennet L, 2013, CLIN EXP PHARMACOL P, V40, P774, DOI 10.1111/1440-1681.12135; Bilotta F, 2009, J NEUROSURG ANESTH, V21, P2, DOI 10.1097/ANA.0b013e31818f8a5c; Brenner M, 2012, J TRAUMA ACUTE CARE, V72, P1135, DOI 10.1097/TA.0b013e31824af90b; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Chabok SY, 2012, J TRAUMA ACUTE CARE, V72, P1654, DOI 10.1097/TA.0b013e318246887e; Chelly H, 2011, J TRAUMA, V71, P838, DOI 10.1097/TA.0b013e3182127baa; Dantas VP, 2004, ARQ NEURO-PSIQUIAT, V62, P313, DOI 10.1590/S0004-282X2004000200022; de la Plata CM, 2007, J NEUROTRAUM, V24, P591, DOI 10.1089/neu.2006.0214; Esbjornsson E, 2013, J REHABIL MED, V45, P771, DOI 10.2340/16501977-1170; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P567, DOI 10.1136/jnnp.2007.120162; Gennarelli T. A., 1987, HEAD INJURY, P108; Gennarelli TA, 1993, HEAD INJURY, P137; Griesdale DEG, 2009, NEUROCRIT CARE, V11, P311, DOI 10.1007/s12028-009-9249-1; Haddad SH, 2012, SCAND J TRAUMA RESUS, V20, DOI 10.1186/1757-7241-20-12; Ham TE, 2012, CURR OPIN NEUROL, V25, P662, DOI 10.1097/WCO.0b013e328359488f; IWADATE Y, 1990, Neurological Surgery, V18, P915; Jeong JH, 2010, J NEUROSURG, V113, P532, DOI 10.3171/2009.10.JNS091152; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Lagares A, 2006, NEUROCIRUGIA, V17, P105; Lane PL, 2000, CAN J SURG, V43, P442; Ley EJ, 2013, J TRAUMA ACUTE CARE, V75, P682, DOI 10.1097/TA.0b013e31829d024f; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Liew B S, 2009, Med J Malaysia, V64, P280; Liu J, 2014, NEURAL REGEN RES, V9, P1222, DOI 10.4103/1673-5374.135330; Liu-DeRyke X, 2009, NEUROCRIT CARE, V11, P151, DOI 10.1007/s12028-009-9228-6; Ljungqvist J, 2011, BRAIN INJURY, V25, P370, DOI 10.3109/02699052.2011.558038; Lorente L, 2014, THROMB RES, V134, P832, DOI 10.1016/j.thromres.2014.07.034; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; Mata-Mbemba D, 2015, J NEUROTRAUM, V32, P359, DOI 10.1089/neu.2014.3453; Matsukawa H, 2013, BRAIN INJURY, V27, P1409, DOI 10.3109/02699052.2013.823655; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Nogueira LD, 2008, REV LAT-AM ENFERM, V16, P314, DOI 10.1590/S0104-11692008000200022; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Parchani A, 2014, WORLD NEUROSURG, V82, pE639, DOI 10.1016/j.wneu.2014.06.022; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Rosa CM, 2011, J TRAUMA, V70, P447, DOI 10.1097/TA.0b013e3182095e14; Sanchez-Olmedo JI, 2005, TRANSPL P, V37, P1990, DOI 10.1016/j.transproceed.2005.03.048; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Scholten AC, 2015, INJURY, V46, P616, DOI 10.1016/j.injury.2014.10.064; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Sobuwa S, 2014, SAMJ S AFR MED J, V104, P492, DOI [10.7196/samj.7720, 10.7196/SAMJ.7720]; Sousa Regina Márcia Cardoso de, 2005, Acta paul. enferm., V18, P354, DOI 10.1590/S0103-21002005000400003; Sousa RMC, 2006, REV ESC ENFERM USP, V40, P203, DOI DOI 10.1590/S0080-62342006000200008; Stein DM, 2011, J TRAUMA, V71, P364, DOI 10.1097/TA.0b013e31822820da; Taw BBT, 2012, ASIAN J SURG, V35, P117, DOI 10.1016/j.asjsur.2012.04.027; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tomei G, 1991, J Neurosurg Sci, V35, P61; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Warner MA, 2010, ARCH NEUROL-CHICAGO, V67, P1336, DOI 10.1001/archneurol.2010.149; Yanagawa Y, 2009, J TRAUMA, V66, P162, DOI 10.1097/TA.0b013e3181469857	54	32	33	0	9	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	OCT 20	2016	7								178	10.3389/fneur.2016.00178			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DZ3WM	WOS:000385780300002	27812349	DOAJ Gold, Green Published			2021-06-18	
J	Herman, DC; Barth, JT				Herman, Daniel C.; Barth, Jeffrey T.			Drop-Jump Landing Varies With Baseline Neurocognition: Implications for Anterior Cruciate Ligament Injury Risk and Prevention	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article; Proceedings Paper	41st Annual Meeting of the American-Orthopaedic-Society-for-Sports-Medicine (AOSSM)	JUL, 2015	Orlando, FL	Amer Orthopaed Soc Sports Med		ACL; biomechanics; motion analysis; injury prevention	NEUROPSYCHOLOGICAL TEST PROTOCOL; LOWER-EXTREMITY BIOMECHANICS; SPORTS-RELATED CONCUSSION; TASK; COHORT; RETURN; PLAY; TOOL	Background: Neurocognitive status may be a risk factor for anterior cruciate ligament (ACL) injury. Neurocognitive domains such as visual attention, processing speed/reaction time, and dual-tasking may influence ACL injury risk via alterations to neuromuscular performance during athletic tasks. However, the relationship between neurocognition and performance during athletic tasks is not yet established. Hypothesis: Athletes with low baseline neurocognitive scores will demonstrate poorer jump landing performance compared with athletes with high baseline neurocognitive score. Study Design: Controlled laboratory study. Methods: Neurocognitive performance was measured using the Concussion Resolution Index (CRI). Three-dimensional kinematic and kinetic data of the dominant limb were collected for 37 recreational athletes while performing an unanticipated jump-landing task. Healthy, nonconcussed subjects were screened using a computer-based neurocognitive test into a high performers (HP; n = 20; average CRI percentile, 78th) and a low performers (LP; n = 17; average CRI percentile, 41st) group. The task consisted of a forward jump onto a force plate with an immediate rebound to a second target that was assigned 250 milliseconds before landing on the force plate. Kinematic and kinetic data were obtained during the first jump landing. Results: The LP group demonstrated significantly altered neuromuscular performance during the landing phase while completing the jump-landing task, including significantly increased peak vertical ground-reaction force (mean SD of LP vs HP: 1.81 0.53 vs 1.38 +/- 0.37 body weight [BW]; P < .01), peak anterior tibial shear force (0.91 +/- 0.17 vs 0.72 +/- 0.22 BW; P < .01), knee abduction moment (0.47 +/- 0.56 vs 0.03 +/- 0.64 BW x body height; P = .03), and knee abduction angle (6.1 degrees +/- 4.7 degrees vs 1.3 degrees +/- 5.6 degrees; P = .03), as well as decreased trunk flexion angle (9.6 degrees +/- 9.6 degrees vs 16.4 degrees +/- 11.2 degrees; P < .01). Conclusion: Healthy athletes with lower baseline neurocognitive performance generate knee kinematic and kinetic patterns that are linked to ACL injury. Clinical Relevance: Neurocognitive testing using the CRI may be useful for identification of athletes at elevated risk for future ACL injury.	[Herman, Daniel C.; Barth, Jeffrey T.] Univ Virginia, Charlottesville, VA USA; [Herman, Daniel C.] Univ Florida, Dept Orthopaed & Rehabil, Gainesville, FL USA; [Barth, Jeffrey T.] Univ Virginia, Dept Psychiat & Neurobehav Sci, Charlottesville, VA USA	Herman, DC (corresponding author), Univ Florida, Dept Orthopaed & Rehabil, Div Phys Med & Rehabil, POB 112727, Gainesville, FL 32608 USA.	hermadc@ortho.ufl.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12 HD001097] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER		Beynnon BD, 2014, AM J SPORT MED, V42, P1806, DOI 10.1177/0363546514540862; Brown TN, 2009, BRIT J SPORT MED, V43, P1049, DOI 10.1136/bjsm.2008.055954; Chappell JD, 2005, AM J SPORT MED, V33, P1022, DOI 10.1177/0363546504273047; Dai BY, 2012, RES SPORTS MED, V20, P180, DOI 10.1080/15438627.2012.680990; Erlanger D, 2003, ARCH CLIN NEUROPSYCH, V18, P293, DOI 10.1016/S0887-6177(02)00138-5; Erlanger D, 2001, J ATHL TRAINING, V36, P280; Goetschius J, 2012, AM J SPORT MED, V40, P1978, DOI 10.1177/0363546512456972; Herman DC, 2008, AM J SPORT MED, V36, P733, DOI 10.1177/0363546507311602; Herman DC, 2015, CURR SPORT MED REP, V14, P194, DOI 10.1249/JSR.0000000000000157; Herman DC, 2009, AM J SPORT MED, V37, P1301, DOI 10.1177/0363546509332253; Herman DC, SPORTS MED IN PRESS; Hewett TE, 2005, AM J SPORT MED, V33, P492, DOI 10.1177/0363546504269591; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Joseph AM, 2013, J ATHL TRAINING, V48, P810, DOI 10.4085/1062-6050-48.6.03; Joy EA, 2013, J STRENGTH COND RES, V27, P2263, DOI 10.1519/JSC.0b013e31827ef12e; Kamath GV, 2014, AM J SPORT MED, V42, P1638, DOI 10.1177/0363546514524164; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Mall NA, 2014, AM J SPORT MED, V42, P2363, DOI 10.1177/0363546514542796; Miranda DL, 2013, J BIOMECH, V46, P567, DOI 10.1016/j.jbiomech.2012.09.023; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Saunders N, 2010, BRIT J SPORT MED, V44, P1128, DOI 10.1136/bjsm.2009.069039; Shultz SJ, 2012, J ELECTROMYOGR KINES, V22, P124, DOI 10.1016/j.jelekin.2011.11.001; Smith HC, 2012, SPORTS HEALTH, V4, P69, DOI 10.1177/1941738111428281; Smith HC, 2012, AM J SPORT MED, V40, P521, DOI 10.1177/0363546511429776; Swanik CB, 2007, AM J SPORT MED, V35, P943, DOI 10.1177/0363546507299532; Weinhandl JT, 2010, J APPL BIOMECH, V26, P444, DOI 10.1123/jab.26.4.444; Wilkerson GB, 2012, INT J ATHL THER TRAI, V17, P4, DOI 10.1123/ijatt.17.6.4	30	32	32	0	33	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	SEP	2016	44	9					2347	2353		10.1177/0363546516657338			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DV6CU	WOS:000383019300025	27474381	Green Accepted			2021-06-18	
J	Cnossen, MC; Polinder, S; Lingsma, HF; Maas, AIR; Menon, D; Steyerberg, EW				Cnossen, Maryse C.; Polinder, Suzanne; Lingsma, Hester F.; Maas, Andrew I. R.; Menon, David; Steyerberg, Ewout W.		CENTER-Tbi Invest Participants	Variation in Structure and Process of Care in Traumatic Brain Injury: Provider Profiles of European Neurotrauma Centers Participating in the CENTER-TBI Study	PLOS ONE			English	Article							QUESTIONNAIRE; MANAGEMENT; QUALITY; LENGTH	Introduction The strength of evidence underpinning care and treatment recommendations in traumatic brain injury (TBI) is low. Comparative effectiveness research (CER) has been proposed as a framework to provide evidence for optimal care for TBI patients. The first step in CER is to map the existing variation. The aim of current study is to quantify variation in general structural and process characteristics among centers participating in the Collaborative European NeuroTrauma Effectiveness Research in Traumatic Brain Injury (CENTER-TBI) study. Methods We designed a set of 11 provider profiling questionnaires with 321 questions about various aspects of TBI care, chosen based on literature and expert opinion. After pilot testing, questionnaires were disseminated to 71 centers from 20 countries participating in the CENTER-TBI study. Reliability of questionnaires was estimated by calculating a concordance rate among 5% duplicate questions. Results All 71 centers completed the questionnaires. Median concordance rate among duplicate questions was 0.85. The majority of centers were academic hospitals (n = 65, 92%), designated as a level I trauma center (n = 48, 68%) and situated in an urban location (n = 70, 99%). The availability of facilities for neuro-trauma care varied across centers; e.g. 40 (57%) had a dedicated neuro-intensive care unit (ICU), 36 (51%) had an in-hospital rehabilitation unit and the organization of the ICU was closed in 64% (n = 45) of the centers. In addition, we found wide variation in processes of care, such as the ICU admission policy and intracranial pressure monitoring policy among centers. Conclusion Even among high-volume, specialized neurotrauma centers there is substantial variation in structures and processes of TBI care. This variation provides an opportunity to study effectiveness of specific aspects of TBI care and to identify best practices with CER approaches.	[Cnossen, Maryse C.; Polinder, Suzanne; Lingsma, Hester F.; Steyerberg, Ewout W.] Erasmus MC, Ctr Med Decis Sci, Dept Publ Hlth, Rotterdam, Netherlands; [Maas, Andrew I. R.] Antwerp Univ Hosp, Dept Neurosurg, Edegem, Belgium; [Maas, Andrew I. R.] Univ Antwerp, Edegem, Belgium; [Menon, David] Univ Cambridge, Addenbrookes Hosp, Div Anaesthesia, Cambridge, England	Lingsma, HF (corresponding author), Erasmus MC, Ctr Med Decis Sci, Dept Publ Hlth, Rotterdam, Netherlands.	h.lingsma@erasmusmc.nl	Ercole, Ari/B-6288-2009; Sahakian, Barbara/AAW-1198-2020; Oresic, Matej/K-7673-2016; Castano-Leon, Ana M/ABF-6322-2020; Gomez, Pedro/N-5051-2019; Cooper, D. James/G-7961-2013; Lagares, Alfonso/B-2969-2011; Laureys, Steven/AAN-2097-2021; Viani, Rafael/V-1196-2018; Badenes, Rafael/K-6628-2019; Majdan, Marek/K-5017-2012; Stocchetti, Nino/O-7444-2017	Ercole, Ari/0000-0001-8350-8093; Sahakian, Barbara/0000-0001-7352-1745; Oresic, Matej/0000-0002-2856-9165; Castano-Leon, Ana M/0000-0002-7918-5049; Gomez, Pedro/0000-0002-4185-5238; Cooper, D. James/0000-0002-5872-9051; Lagares, Alfonso/0000-0003-3996-0554; Laureys, Steven/0000-0002-3096-3807; Badenes, Rafael/0000-0001-7017-0150; Della Corte, Francesco/0000-0003-1736-2318; Andelic, Nada/0000-0002-3719-4406; Morganti-Kossmann, Cristina/0000-0002-0807-2063; Sanchez-Porras, Renan/0000-0002-9084-8114; Wang, Kevin/0000-0002-9343-6473; Bragge, Peter/0000-0003-0745-5131; CAUSIN, Francesco/0000-0001-6491-7027; Ortolano, Fabrizio/0000-0003-1996-948X; Santos, Edgar/0000-0002-8976-5549; Rossi, Sandra/0000-0002-9963-8121; Smielewski, Peter/0000-0001-5096-3938; Majdan, Marek/0000-0001-8037-742X; Ledig, Christian/0000-0003-4862-3138; Stocchetti, Nino/0000-0003-3250-6834; Lanyon, Linda/0000-0002-0885-1825; Parizel, Paul M./0000-0002-0221-2854; Synnot, Anneliese/0000-0002-4008-4208; MARTIN, Didier/0000-0001-7325-4958; Pomposo Gaztelu, Inigo/0000-0002-3095-2649; Newcombe, Virginia/0000-0001-6044-9035; Cameron, Peter/0000-0002-1443-557X; Wade, Derick/0000-0002-1188-8442; Te Ao, Braden/0000-0002-1050-200X; persona, paolo/0000-0003-1584-5148; Feigin, Valery L./0000-0002-6372-1740; Kondziella, Daniel/0000-0001-5562-9808	European Commission 7th Framework program [602150]; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0512-10090] Funding Source: researchfish	Data used in preparation of this manuscript were obtained in the context of CENTER-TBI, a large collaborative project with the support of the European Commission 7th Framework program (602150). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	*AD HOC COMM HLTH, 1996, TDRGEN961 WHO AD HOC; Alali AS, 2013, J NEUROTRAUM, V30, P1737, DOI 10.1089/neu.2012.2802; Brazinova A, 2021, J NEUROTRAUM, V38, P1411, DOI 10.1089/neu.2015.4126; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Checkley W, 2014, CRIT CARE MED, V42, P344, DOI 10.1097/CCM.0b013e3182a275d7; Cnossen MC, 2015, J NEUROTRAUMA; Enblad P, 2004, INTENS CARE MED, V30, P1058, DOI 10.1007/s00134-004-2206-8; European Brain Injury Consortium, EBIC CTR SURV; European Comission, 2007, REM RES PUBL PRIV SE; Galesic M, 2009, PUBLIC OPIN QUART, V73, P349, DOI 10.1093/poq/nfp031; I. o. Medicine, 2009, IN NAT PRIOR COMP EF; Kalantar JS, 1999, J CLIN EPIDEMIOL, V52, P1117, DOI 10.1016/S0895-4356(99)00051-7; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7	15	32	33	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	AUG 29	2016	11	8							e0161367	10.1371/journal.pone.0161367			21	Multidisciplinary Sciences	Science & Technology - Other Topics	DV4DZ	WOS:000382876700016	27571205	DOAJ Gold, Green Accepted, Green Published			2021-06-18	
J	Sen, T; Sen, N				Sen, Tanusree; Sen, Nilkantha			Treatment with an activator of hypoxia-indutible factor 1, DMOG provides neuroprotection after traumatic brain injury	NEUROPHARMACOLOGY			English	Article						DMOG; HIF-1 alpha; Angiogenesis; Traumatic brain injury; Cell death; Lesion volume	CELL-DEATH MECHANISMS; CEREBRAL EDEMA; INDUCIBLE FACTOR-1; UP-REGULATION; NEUROGENESIS; CREB; INHIBITION; PLASTICITY; RECOVERY; PATHWAY	Traumatic brain injury (TBI) is one of the major cause of morbidity and mortality and it affects more than 1.7 million people in the USA. A couple of regenerative pathways including activation of hypoxia-inducible transcription factor 1 alpha (HIF-1 alpha) are initiated to reduce cellular damage following TBI; however endogenous activation of these pathways is not enough to provide neuroprotection after TBI. Thus we aimed to see whether sustained activation of HIF-1 alpha can provide neuroprotection and neuro-repair following TBI. We found that chronic treatment with dimethyloxaloylglycine (DMOG) markedly increases the expression level of HIF-1 alpha and mRNA levels of its downstream proteins such as Vascular endothelial growth factor (VEGF), Phosphoinositide-dependent kinase-1 and 4 (PDK1, PDK4) and Erythropoietin (EPO). Treatment of DMOG activates a major cell survival protein kinase Akt and reduces both cell death and lesion volume following TBI. Moreover, administration of DMOG augments cluster of differentiation 31 (CD31) staining in pericontusional cortex after TBI, which suggests that DMOG stimulates angiogenesis after TBI. Treatment with DMOG also improves both memory and motor functions after TBI. Taken together our results suggest that sustained activation of HIF-1 alpha provides significant neuroprotection following TBI. Published by Elsevier Ltd.	[Sen, Tanusree; Sen, Nilkantha] Augusta Univ, Dept Neurosci & Regenerat Med, 1120 15th St,CA2018, Augusta, GA 30912 USA; [Sen, Tanusree] Univ Georgia, Coll Vet Med, Dept Vet Biosci & Diagnost Imaging, Athens, GA 30602 USA	Sen, N (corresponding author), Augusta Univ, Dept Neurosci & Regenerat Med, 1120 15th St,CA2018, Augusta, GA 30912 USA.	nsen@gru.edu	Sen, Nilkantha/AAW-9788-2020		National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [EY025622]; Augusta University, GA; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY025622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS094516] Funding Source: NIH RePORTER	This work is supported by the grant from the National Institute of Health (EY025622) and the startup funding provided by the Augusta University, GA.	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Arai K, 2009, FEBS J, V276, P4644, DOI 10.1111/j.1742-4658.2009.07176.x; Bachevalier J, 1996, HIPPOCAMPUS, V6, P553, DOI 10.1002/(SICI)1098-1063(1996)6:5<553::AID-HIPO8>3.0.CO;2-J; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Brunson KL, 2001, P NATL ACAD SCI USA, V98, P8856, DOI 10.1073/pnas.151224898; Cao D, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-432; Caravatta L, 2008, J CELL PHYSIOL, V214, P192, DOI 10.1002/jcp.21186; Chen YH, 2011, STROKE, V42, P2733, DOI 10.1161/STROKEAHA.111.620112; Chopp M, 2008, J NEUROL SCI, V265, P97, DOI 10.1016/j.jns.2007.06.013; del Puerto A, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00197; Dery MAC, 2005, INT J BIOCHEM CELL B, V37, P535, DOI 10.1016/j.biocel.2004.08.012; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Farook JM, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.280; Fenn AM, 2015, J NEUROTRAUM, V32, P127, DOI 10.1089/neu.2014.3514; Ge XT, 2014, SCI REP-UK, V4, DOI 10.1038/srep06718; Hewitson KS, 2004, DRUG DISCOV TODAY, V9, P704, DOI 10.1016/S1359-6446(04)03202-7; Hirjak D, 2013, NEUROPSYCHOBIOLOGY, V68, P91, DOI 10.1159/000350999; Humphreys I, 2013, CLINICOECONOMIC OUTC, V5, P281, DOI 10.2147/CEOR.S44625; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kabadi SV, 2015, J CEREBR BLOOD F MET, V35, P2010, DOI 10.1038/jcbfm.2015.165; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kapoor S, 2013, J NEUROSCI, V33, P17398, DOI 10.1523/JNEUROSCI.2756-13.2013; Kayani NA, 2009, PUBLIC HEALTH REP, V124, P551, DOI 10.1177/003335490912400412; Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Laird MD, 2010, J NEUROCHEM, V113, P637, DOI 10.1111/j.1471-4159.2010.06630.x; Li AH, 2013, J MOL NEUROSCI, V51, P1052, DOI 10.1007/s12031-013-0084-7; Li Y, 2009, NEUROSCI LETT, V456, P120, DOI 10.1016/j.neulet.2008.03.096; Liu SJ, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-66; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Mahmood A, 2001, NEUROSURGERY, V49, P1196, DOI 10.1097/00006123-200111000-00031; Merz K, 2011, EUR J NEUROSCI, V33, P1078, DOI 10.1111/j.1460-9568.2011.07606.x; Mir S, 2014, MOL CELL, V56, P786, DOI 10.1016/j.molcel.2014.10.019; Navarro X, 2007, PROG NEUROBIOL, V82, P163, DOI 10.1016/j.pneurobio.2007.06.005; Ockaili R, 2005, AM J PHYSIOL-HEART C, V289, pH542, DOI 10.1152/ajpheart.00089.2005; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rondina C, 2005, J HEAD TRAUMA REHAB, V20, P368, DOI 10.1097/00001199-200507000-00008; Sen N, 2008, NAT CELL BIOL, V10, P866, DOI 10.1038/ncb1747; Sen N, 2012, MOL CELL, V45, P13, DOI 10.1016/j.molcel.2011.10.021; Sen N, 2011, P NATL ACAD SCI USA, V108, P20178, DOI 10.1073/pnas.1117820108; Shein NA, 2007, J NEUROCHEM, V103, P1523, DOI 10.1111/j.1471-4159.2007.04862.x; Sheldon RA, 2009, DEV NEUROSCI-BASEL, V31, P452, DOI 10.1159/000232563; Shenaq M, 2012, J NEUROL SCI, V323, P134, DOI 10.1016/j.jns.2012.08.036; Shi HL, 2009, CURR MED CHEM, V16, P4593, DOI 10.2174/092986709789760779; Siddiq A, 2009, J NEUROSCI, V29, P8828, DOI 10.1523/JNEUROSCI.1779-09.2009; Stoica BA, 2010, NEUROTHERAPEUTICS, V7, P3, DOI 10.1016/j.nurt.2009.10.023; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tian SF, 2013, J BIOL CHEM, V288, P15988, DOI 10.1074/jbc.M112.428789; Trollmann R, 2009, BRAIN DEV-JPN, V31, P503, DOI 10.1016/j.braindev.2009.03.007; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vorhees CV, 2006, NAT PROTOC, V1, P848, DOI 10.1038/nprot.2006.116; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhao ZR, 2013, J CEREBR BLOOD F MET, V33, P1897, DOI 10.1038/jcbfm.2013.144	60	32	33	0	21	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	AUG	2016	107						79	88		10.1016/j.neuropharm.2016.03.009			10	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	DQ1HZ	WOS:000378953400009	26970014	Green Accepted			2021-06-18	
J	Clark, KC; Josephson, A; Benusa, SD; Hartley, RK; Baer, M; Thummala, S; Joslyn, M; Sword, BA; Elford, H; Oh, U; Dilsizoglu-Senol, A; Lubetzki, C; Davenne, M; DeVries, GH; Dupree, JL				Clark, Kareem C.; Josephson, Anna; Benusa, Savannah D.; Hartley, Rebecca K.; Baer, Matthew; Thummala, Suneel; Joslyn, Martha; Sword, Brooke A.; Elford, Howard; Oh, Unsong; Dilsizoglu-Senol, Aysegul; Lubetzki, Catherine; Davenne, Marc; DeVries, George H.; Dupree, Jeffrey L.			Compromised Axon Initial Segment Integrity in EAE Is Preceded by Microglial Reactivity and Contact	GLIA			English	Article						multiple sclerosis; demyelination; axonal domain; inflammation; axonal pathology	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; RIBONUCLEOTIDE REDUCTASE INHIBITORS; ACTIVITY-DEPENDENT RELOCATION; CHRONIC MULTIPLE-SCLEROSIS; TRAUMATIC BRAIN-INJURY; SODIUM-CHANNEL; WHITE-MATTER; MOUSE MODEL; CORTICAL DEMYELINATION; MOLECULAR DOMAINS	Axonal pathology is a key contributor to long-term disability in multiple sclerosis (MS), an inflammatory demyelinating disease of the central nervous system (CNS), but the mechanisms that underlie axonal pathology in MS remain elusive. Evidence suggests that axonal pathology is a direct consequence of demyelination, as we and others have shown that the node of Ranvier disassembles following loss of myelin. In contrast to the node of Ranvier, we now show that the axon initial segment (AIS), the axonal domain responsible for action potential initiation, remains intact following cuprizone-induced cortical demyelination. Instead, we find that the AIS is disrupted in the neocortex of mice that develop experimental autoimmune encephalomyelitis (EAE) independent of local demyelination. EAE-induced mice demonstrate profound compromise of AIS integrity with a progressive disruption that corresponds to EAE clinical disease severity and duration, in addition to cortical microglial reactivity. Furthermore, treatment with the drug didox results in attenuation of AIS pathology concomitantly with microglial reversion to a less reactive state. Together, our findings suggest that inflammation, but not demyelination, disrupts AIS integrity and that therapeutic intervention may protect and reverse this pathology.	[Clark, Kareem C.; Josephson, Anna; Benusa, Savannah D.; Hartley, Rebecca K.; Baer, Matthew; Thummala, Suneel; DeVries, George H.; Dupree, Jeffrey L.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, POB 980709,1101 East Marshall St, Richmond, VA 23298 USA; [Clark, Kareem C.; Benusa, Savannah D.] VCU, Neurosci Curriculum, Richmond, VA USA; [Joslyn, Martha; Sword, Brooke A.; DeVries, George H.; Dupree, Jeffrey L.] Hunter Holmes McGuire VA Med Ctr, Dept Res, Richmond, VA USA; [Elford, Howard] Mol Hlth Inc, Richmond, VA USA; [Oh, Unsong] VCU, Dept Neurol, Richmond, VA USA; [Dilsizoglu-Senol, Aysegul; Lubetzki, Catherine; Davenne, Marc] Univ Paris 04, Univ Paris 06, UMR S 1127,CNRS UMR 7225, Inst Cerveau & Moelle Epiniere,ICM,INSERM,U 1127, F-75013 Paris, France; [Lubetzki, Catherine] Hop La Pitie Salpetriere, AP HP, F-75013 Paris, France	Dupree, JL (corresponding author), Virginia Commonwealth Univ, Dept Anat & Neurobiol, POB 980709,1101 East Marshall St, Richmond, VA 23298 USA.	jldupree@vcu.edu		Benusa, Savannah/0000-0002-1430-9928	National Multiple Sclerosis Society pilot grant; Veterans Affairs MeritUS Department of Veterans Affairs [5IO1BX002565, 101BX001759]; VAUS Department of Veterans Affairs; NIH-NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [5P30NS047463]	Grant sponsors: National Multiple Sclerosis Society pilot grant and Veterans Affairs Merit; Grant number: 5IO1BX002565 (to J.L.D.) and 101BX001759 (to G.H.D.V.); Grant sponsor: VA provided salary support (to J.L.D.; G.H.D.V.).; Grant sponsor: NIH-NINDS; Grant number: 5P30NS047463	Arnett HA, 2001, NAT NEUROSCI, V4, P1116, DOI 10.1038/nn738; Arnett HA, 2002, J IMMUNOL, V168, P427, DOI 10.4049/jimmunol.168.1.427; Baalman K, 2015, J NEUROSCI, V35, P2283, DOI 10.1523/JNEUROSCI.3751-14.2015; Baalman KL, 2013, J NEUROTRAUM, V30, P741, DOI 10.1089/neu.2012.2478; Bhasin M, 2007, BMC IMMUNOL, V8, DOI 10.1186/1471-2172-8-10; Bhat MA, 2001, NEURON, V30, P369, DOI 10.1016/S0896-6273(01)00294-X; Bhave S, 2013, ANTIVIR RES, V100, P151, DOI 10.1016/j.antiviral.2013.07.016; Bjartmar C, 2001, NEUROLOGY, V57, P1248, DOI 10.1212/WNL.57.7.1248; Black JA, 2007, J NEUROPATH EXP NEUR, V66, P828, DOI 10.1097/nen.0b013e3181462841; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Buffington SA, 2011, EUR J NEUROSCI, V34, P1609, DOI 10.1111/j.1460-9568.2011.07875.x; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Burns T, 2014, J NEUROPATH EXP NEUR, V73, P335, DOI 10.1097/NEN.0000000000000058; Buttermore ED, 2013, J NEUROSCI RES, V91, P603, DOI 10.1002/jnr.23197; Calabrese M, 2015, NAT REV NEUROSCI, V16, P147, DOI 10.1038/nrn3900; Coman I, 2006, BRAIN, V129, P3186, DOI 10.1093/brain/awl144; Criste G, 2014, HAND CLINIC, V122, P101, DOI 10.1016/B978-0-444-52001-2.00005-4; Das A, 2013, J NEUROCHEM, V124, P133, DOI 10.1111/jnc.12064; Das A, 2011, J ENDOCRINOL, V208, P171, DOI 10.1677/JOE-10-0338; DeLuca GC, 2006, BRAIN, V129, P1507, DOI 10.1093/brain/awl074; Desmazieres A, 2012, MULT SCLER J, V18, P133, DOI 10.1177/1352458511434370; DeVries G, 2012, FASEB J, V26, P3414; Doring A, 2015, J NEUROSCI, V35, P1136, DOI [10.1523/JNEUROSCI.1797-14.2015, 10.1523/JNEUROSCI.1797-14]; Dupree JL, 2004, NEURON GLIA BIOL, V1, P179, DOI 10.1017/S1740925X04000304; Dupree JL, 2015, J NEUROCHEM, V134, P302, DOI 10.1111/jnc.13114; Dupree JL, 1999, J CELL BIOL, V147, P1145, DOI 10.1083/jcb.147.6.1145; Dutta R, 2011, PROG NEUROBIOL, V93, P1, DOI 10.1016/j.pneurobio.2010.09.005; Dutta R, 2011, ANN NEUROL, V69, P445, DOI 10.1002/ana.22337; Elford HL, 2013, INT J MS CARE, V15, P54; Elmore MRP, 2014, NEURON, V82, P380, DOI 10.1016/j.neuron.2014.02.040; Evans MD, 2013, J NEUROSCI, V33, P6950, DOI 10.1523/JNEUROSCI.0277-13.2013; Figul M, 2003, CANCER CHEMOTH PHARM, V52, P41, DOI 10.1007/s00280-003-0611-2; Fjaer S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084162; Furukawa K, 1998, J NEUROCHEM, V70, P1876; Galiano MR, 2012, CELL, V149, P1125, DOI 10.1016/j.cell.2012.03.039; Glass CK, 2010, CELL, V140, P918, DOI 10.1016/j.cell.2010.02.016; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Greer JE, 2012, J NEUROSCI, V32, P6682, DOI 10.1523/JNEUROSCI.0881-12.2012; Greer JM, 2013, MULT SCLER INT, V2013, DOI 10.1155/2013/151427; Grubb MS, 2010, NATURE, V465, P1070, DOI 10.1038/nature09160; Gudi V, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00073; Guemez-Gamboa A, 2011, J NEUROPATH EXP NEUR, V70, P1020, DOI 10.1097/NEN.0b013e3182358e4e; Gutzmann A, 2014, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00011; Guyton MK, 2009, J NEUROCHEM, V110, P1895, DOI 10.1111/j.1471-4159.2009.06287.x; Guyton MK, 2005, J NEUROSCI RES, V81, P53, DOI 10.1002/jnr.20470; Haji N, 2012, EXP NEUROL, V237, P296, DOI 10.1016/j.expneurol.2012.07.010; Hamada MS, 2015, J NEUROSCI, V35, P7272, DOI 10.1523/JNEUROSCI.4747-14.2015; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Hedstrom KL, 2008, J CELL BIOL, V183, P635, DOI 10.1083/jcb.200806112; Hendrickx DAE, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-64; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Hinman JD, 2013, STROKE, V44, P182, DOI 10.1161/STROKEAHA.112.668749; Howell OW, 2010, J NEUROPATH EXP NEUR, V69, P1017, DOI 10.1097/NEN.0b013e3181f3a5b1; Huizinga R, 2012, GLIA, V60, P422, DOI 10.1002/glia.22276; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; Inayat MS, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-43; Inayat MS, 2002, CANCER BIOL THER, V1, P539, DOI 10.4161/cbt.1.5.174; Ishibashi T, 2002, J NEUROSCI, V22, P6507; Janssens K, 2015, GLIA, V63, P1729, DOI 10.1002/glia.22840; Jenkins SM, 2001, J CELL BIOL, V155, P739, DOI 10.1083/jcb.200109026; Kole MHP, 2008, NAT NEUROSCI, V11, P178, DOI 10.1038/nn2040; Kornek B, 1999, BRAIN PATHOL, V9, P651; Kuba Hiroshi, 2010, Commun Integr Biol, V3, P597, DOI 10.4161/cib.3.6.13242; Kutzelnigg A, 2005, BRAIN, V128, P2705, DOI 10.1093/brain/awh641; Lassmann H, 2001, TRENDS MOL MED, V7, P115, DOI 10.1016/S1471-4914(00)01909-2; Lassmann H, 1999, ACTA NEUROL BELG, V99, P6; Lewis ND, 2014, J NEUROIMMUNOL, V277, P26, DOI 10.1016/j.jneuroim.2014.09.014; Liu JL, 1998, NAT MED, V4, P78, DOI 10.1038/nm0198-078; Mangiardi M, 2011, BRAIN PATHOL, V21, P263, DOI 10.1111/j.1750-3639.2010.00444.x; Marik C, 2007, BRAIN, V130, P2800, DOI 10.1093/brain/awm236; Matsebatlela TM, 2015, CHEM-BIOL INTERACT, V233, P95, DOI 10.1016/j.cbi.2015.03.027; Mayhew CN, 2002, ANTIVIR RES, V56, P167, DOI 10.1016/S0166-3542(02)00108-0; McMahon EJ, 2002, J NEUROIMMUNOL, V130, P32, DOI 10.1016/S0165-5728(02)00205-9; McVoy JRS, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0247-2; Miron VE, 2013, NAT NEUROSCI, V16, P1211, DOI 10.1038/nn.3469; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nikic I, 2011, NAT MED, V17, P495, DOI 10.1038/nm.2324; Noor NA, 2015, INT J CLIN EXP PATHO, V8, P6269; Peles E, 2000, CURR OPIN NEUROBIOL, V10, P558, DOI 10.1016/S0959-4388(00)00122-7; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; Pillai AM, 2009, J NEUROSCI RES, V87, P1773, DOI 10.1002/jnr.22015; Pomicter AD, 2010, BRAIN, V133, P389, DOI 10.1093/brain/awp341; Popescu Bogdan F Gh, 2013, Continuum (Minneap Minn), V19, P901, DOI 10.1212/01.CON.0000433291.23091.65; Povlishock JT, 1999, ACT NEUR S, V73, P15; Rasband MN, 1999, J NEUROSCI, V19, P7516, DOI 10.1523/JNEUROSCI.19-17-07516.1999; Rawji KS, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/948976; Recks MS, 2013, CLIN IMMUNOL, V149, P32, DOI 10.1016/j.clim.2013.06.004; Reeves TM, 2010, BRAIN PATHOL, V20, P1055, DOI 10.1111/j.1750-3639.2010.00412.x; Rosenbluth J, 2003, GLIA, V41, P318, DOI 10.1002/glia.10179; Sama DM, 2013, AGEING RES REV, V12, P982, DOI 10.1016/j.arr.2013.05.008; Schafer DP, 2009, J NEUROSCI, V29, P13242, DOI 10.1523/JNEUROSCI.3376-09.2009; Shepherd MN, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2010.08.001; Skripuletz T, 2008, AM J PATHOL, V172, P1053, DOI 10.2353/ajpath.2008.070850; Spence RD, 2014, NEUROIMAGE, V101, P625, DOI 10.1016/j.neuroimage.2014.07.017; Stanley ER, 1997, MOL REPROD DEV, V46, P4, DOI 10.1002/(SICI)1098-2795(199701)46:1<4::AID-MRD2>3.0.CO;2-V; Sun JJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep14235; Susuki K, 2008, CURR OPIN CELL BIOL, V20, P616, DOI 10.1016/j.ceb.2008.09.007; Suzuki A, 2004, GLIA, V46, P274, DOI 10.1002/glia.20008; Taetzsch T, 2015, GLIA, V63, P423, DOI 10.1002/glia.22762; Trager N, 2014, J NEUROCHEM, V130, P268, DOI 10.1111/jnc.12659; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Turchan J, 2003, NEUROLOGY, V60, P307, DOI 10.1212/01.WNL.0000042048.85204.3D; Vogel PA, 2015, HYPERTENSION, V66, P374, DOI 10.1161/HYPERTENSIONAHA.115.05274; Waxman SG, 2008, ANN NEUROL, V63, P411, DOI 10.1002/ana.21361; Yamasaki R, 2014, J EXP MED, V211, P1533, DOI 10.1084/jem.20132477; Zhou DX, 1998, J CELL BIOL, V143, P1295, DOI 10.1083/jcb.143.5.1295; Zoupi L, 2013, GLIA, V61, P1236, DOI 10.1002/glia.22511	108	32	32	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0894-1491	1098-1136		GLIA	Glia	JUL	2016	64	7					1190	1209		10.1002/glia.22991			20	Neurosciences	Neurosciences & Neurology	DX9WW	WOS:000384748700006	27100937				2021-06-18	
J	Erdodi, LA; Tyson, BT; Abeare, CA; Lichtenstein, JD; Pelletier, CL; Rai, JK; Roth, RM				Erdodi, Laszlo A.; Tyson, Bradley T.; Abeare, Christopher A.; Lichtenstein, Jonathan D.; Pelletier, Chantalle L.; Rai, Jaspreet K.; Roth, Robert M.			The BDAE Complex Ideational Material-a Measure of Receptive Language or Performance Validity?	PSYCHOLOGICAL INJURY & LAW			English	Article						Complex Ideational Material; Performance validity assessment; Embedded validity indicators; Psychogenic interference	TRAUMATIC BRAIN-INJURY; PSYCHOGENIC NONEPILEPTIC SEIZURES; CARD SORTING TEST; LEARNING TEST-II; NEUROPSYCHOLOGICAL TESTS; CLASSIFICATION ACCURACY; INVALID PERFORMANCE; RESPONSE BIAS; DIGIT SPAN; INDICATORS	Scores on the Complex Ideational Material (CIM) were examined in reference to various performance validity tests (PVTs) in 106 adults clinically referred for neuropsychological assessment. The main diagnostic categories, reflecting a continuum between neurological and psychiatric disorders, were epilepsy, psychiatric disorders, postconcussive disorder, and psychogenic non-epileptic seizures. Cross-validation analyses suggest that in the absence of bona fide aphasia, a raw score <= 9 or T score <= 29 on the CIM is more likely to reflect non-credible presentation than impaired receptive language skills. However, these cutoffs may be associated with unacceptably high false positive rates in patients with longstanding, documented neurological deficits. Therefore, more conservative cutoffs (<= 8/23) are recommended in such populations. Contrary to the widely accepted assumption that psychiatric disorders are unrelated to performance validity, results were consistent with the psychogenic interference hypothesis, suggesting that emotional distress increases the likelihood of PVT failures even in the absence of apparent external incentives to underperform on cognitive testing.	[Erdodi, Laszlo A.; Tyson, Bradley T.; Abeare, Christopher A.; Rai, Jaspreet K.] Univ Windsor, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada; [Erdodi, Laszlo A.; Lichtenstein, Jonathan D.; Pelletier, Chantalle L.; Roth, Robert M.] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH 03755 USA; [Tyson, Bradley T.] Western Washington Med Grp, Everett, WA USA	Erdodi, LA (corresponding author), Univ Windsor, Dept Psychol, 168 Chrysler Hall South,401 Sunset Ave, Windsor, ON N9B 3P4, Canada.; Erdodi, LA (corresponding author), Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH 03755 USA.	lerdodi@gmail.com		Abeare, Christopher/0000-0002-7163-7434			American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; Benbadis SR, 2000, SEIZURE-EUR J EPILEP, V9, P280, DOI 10.1053/seiz.2000.0409; Boone, 2007, ASSESSMENT FEIGNED C; Boone K. B., 2013, CLIN PRACTICE FORENS; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Borod JC, 1980, J CLIN NEUROPSYCHOLO, V2, P209, DOI DOI 10.1080/01688638008403793; Bortnik KE, 2010, CLIN NEUROPSYCHOL, V24, P344, DOI 10.1080/13854040903307268; Christensen H, 1997, J Int Neuropsychol Soc, V3, P631; Considine CM, 2011, ARCH CLIN NEUROPSYCH, V26, P445, DOI 10.1093/arclin/acr041; Cragar DE, 2006, CLIN NEUROPSYCHOL, V20, P552, DOI 10.1080/13854040590947380; Dodrill CB, 2008, EPILEPSIA, V49, P691, DOI 10.1111/j.1528-1167.2007.01457.x; Egeland J, 2005, ACTA PSYCHIAT SCAND, V112, P434, DOI 10.1111/j.1600-0447.2005.00599.x; Erdodi L. A., 2016, PSYCHOL ASSESSMENT; Erdodi L. A., 2016, APPL NEUROPSYCHOLOGY; Erdodi LA, 2014, ARCH CLIN NEUROPSYCH, V29, P456, DOI 10.1093/arclin/acu026; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2004, ARCH CLIN NEUROPSYCH, V19, P533, DOI 10.1016/j.acn.2003.08.002; Heaton RK, 2004, REVISED COMPREHENSIV; Heinly MT, 2005, ASSESSMENT, V12, P429, DOI 10.1177/1073191105281099; Jones A, 2013, CLIN NEUROPSYCHOL, V27, P1043, DOI 10.1080/13854046.2013.804949; King JH, 2002, CLIN NEUROPSYCHOL, V16, P506, DOI 10.1076/clin.16.4.506.13912; Langenecker SA, 2005, J CLIN EXP NEUROPSYC, V27, P320, DOI 10.1080/13803390490490515720; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Martin PK, 2015, CLIN NEUROPSYCHOL, V29, P741, DOI 10.1080/13854046.2015.1087597; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; Myers L., 2014, PSYCHOGENIC NONEPILE; Pearson, 2009, ADV CLIN SOL WAIS 4; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Rohling ML, 2002, ARCH CLIN NEUROPSYCH, V17, P205, DOI 10.1016/S0887-6177(01)00109-3; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Stenclik JH, 2013, APPL NEUROPSYCH-ADUL, V20, P243, DOI 10.1080/09084282.2012.704603; Suhr J, 1997, J CLIN EXP NEUROPSYC, V19, P500, DOI 10.1080/01688639708403740; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791; World Health Organization, 2014, ICD10 WHO	37	32	32	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1938-971X	1938-9728		PSYCHOL INJ LAW	Psychol. Inj. Law	JUN	2016	9	2					112	120		10.1007/s12207-016-9254-6			9	Psychology, Clinical	Psychology	FG6MZ	WOS:000410496200004					2021-06-18	
J	Yan, CX; Gao, N; Sun, HJ; Yin, J; Lee, P; Zhou, L; Fan, XQ; Yu, FS				Yan, Chenxi; Gao, Nan; Sun, Haijing; Yin, Jia; Lee, Patrick; Zhou, Li; Fan, Xianqun; Yu, Fu-Shin			Targeting Imbalance between IL-1 beta and IL-1 Receptor Antagonist Ameliorates Delayed Epithelium Wound Healing in Diabetic Mouse Corneas	AMERICAN JOURNAL OF PATHOLOGY			English	Article							INFLAMMATORY CELL INFILTRATION; TRAUMATIC BRAIN-INJURY; HUMAN MONOCYTES; INTERLEUKIN-1; EXPRESSION; RATS; NEUTRALIZATION; MELLITUS; IMPROVES; PROMOTES	Patients with diabetes mellitus often develop corneal complications and delayed wound healing. How diabetes might alter acute inflammatory responses to tissue injury, leading to delayed wound healing, remains mostly elusive. Using a streptozotocin-induced type I diabetes mellitus mice and corneal epithelium-debridement wound model, we discovered that although wounding induced marked expression of IL-1 beta and the secreted form of IL-1 receptor antagonist (sIL-1Ra), diabetes suppressed the expressions of sIL-1Ra but not IL-1 beta in healing epithelia and both in whole cornea. In normoglycemic mice, IL-1 beta or sIL-1Ra blockade delayed wound healing and influenced each other's expression. In diabetic mice, in addition to delayed reepithelization, diabetes weakened phosphatidylinositol 3-kinase-Akt signaling, caused cell apoptosis, diminished cell proliferation, suppressed neutrophil and natural killer cell infiltrations, and impaired sensory nerve reinnervation in heating mouse corneas. Local administration of recombinant IL-1Ra partially, but significantly, reversed these pathological changes in the diabetic corneas. CXCL10 was a downstream chemokine of IL-1 beta-IL-1Ra, and exogenous CXCL10 alleviated delayed wound healing in the diabetic, but attenuated it in the normal corneas. In conclusion, the suppressed early innate/inflammatory responses instigated by the imbalance between IL-1 beta and IL-1Ra is an underlying cause for delayed wound healing in the diabetic corneas. Local application of IL-1Ra accelerates reepithelialization and may be used to treat chronic corneal and potential skin wounds of diabetic patients.	[Yan, Chenxi; Fan, Xianqun] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Ophthalmol,Grad Program, Shanghai 200011, Peoples R China; [Yan, Chenxi; Gao, Nan; Sun, Haijing; Yin, Jia; Lee, Patrick; Yu, Fu-Shin] Wayne State Univ, Sch Med, Kresge Eye Inst, Dept Ophthalmol, Detroit, MI 48201 USA; [Yan, Chenxi; Gao, Nan; Sun, Haijing; Yin, Jia; Lee, Patrick; Yu, Fu-Shin] Wayne State Univ, Sch Med, Dept Anat & Cell Biol, Detroit, MI 48201 USA; [Zhou, Li] Henry Ford Hlth Syst, Henry Ford Immunol Program, Dept Dermatol, Detroit, MI USA	Yu, FS (corresponding author), Wayne State Univ, Dept Ophthalmol, Sch Med, 4717 St Antoine,Room K417, Detroit, MI 48201 USA.; Fan, XQ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Ophthalmol, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.	fanxq@sh163.net; fyu@med.wayne.edu		Fan, Xianqun/0000-0002-9394-3969; Yan, Chenxi/0000-0002-1637-0597	NIH/National Eye Institute (NEI)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY10869, EY17960, p30 EY04078]; Research to Prevent Blindness unrestricted grant; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [R01EY010869, R01EY017960, P30EY004068] Funding Source: NIH RePORTER	Supported by NIH/National Eye Institute (NEI) grants R01EY10869, EY17960 (F.-S.Y.), and p30 EY04078 (NEI core to Wayne State University; F.-S.Y.) and Research to Prevent Blindness unrestricted grant (to Kresge Eye Institute; F.-S.Y.).	Amin A, 2012, J PATHOL, V227, P165, DOI 10.1002/path.3960; Amparo F, 2013, JAMA OPHTHALMOL, V131, P715, DOI 10.1001/jamaophthalmol.2013.195; Arend WP, 1998, ANNU REV IMMUNOL, V16, P27, DOI 10.1146/annurev.immunol.16.1.27; Arend WR, 2002, CYTOKINE GROWTH F R, V13, P323, DOI 10.1016/S1359-6101(02)00020-5; Banda NK, 2005, J IMMUNOL, V174, P3608, DOI 10.4049/jimmunol.174.6.3608; Banerjee M, 2012, CLIN CHIM ACTA, V413, P1163, DOI 10.1016/j.cca.2012.03.021; Bettahi I, 2014, DIABETES, V63, P715, DOI 10.2337/db13-1260; Bikbova G, 2012, CURR DIABETES REV, V8, P294, DOI 10.2174/157339912800840479; Carpintero R, 2010, P NATL ACAD SCI USA, V107, P17692, DOI 10.1073/pnas.1009443107; Cavalli G, 2015, RHEUMATOLOGY, V54, P2134, DOI 10.1093/rheumatology/kev269; Chavey C, 2009, AGING-US, V1, P674, DOI 10.18632/aging.100064; Chikama T, 2007, CORNEA, V26, pS75, DOI 10.1097/ICO.0b013e31812f6d8e; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Dinarello CA, 2011, EUR J IMMUNOL, V41, P1203, DOI 10.1002/eji.201141550; Dinarello CA, 2010, CURR OPIN ENDOCRINOL, V17, P314, DOI 10.1097/MED.0b013e32833bf6dc; Donath MY, 2013, DIABETES OBES METAB, V15, P193, DOI 10.1111/dom.12172; Donath MY, 2013, CELL METAB, V17, P860, DOI 10.1016/j.cmet.2013.05.001; Doz E, 2008, J IMMUNOL, V180, P1169, DOI 10.4049/jimmunol.180.2.1169; Ebaid H, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-235; Esser N, 2014, DIABETES RES CLIN PR, V105, P141, DOI 10.1016/j.diabres.2014.04.006; Evans I, 2006, CYTOKINE, V33, P274, DOI 10.1016/j.cyto.2006.02.003; Gabay C, 1999, CYTOKINE, V11, P561, DOI 10.1006/cyto.1998.0451; Gagen D, 2010, EXP EYE RES, V91, P676, DOI 10.1016/j.exer.2010.08.007; Gao D, 2014, AM J PHYSIOL-ENDOC M, V307, pE289, DOI 10.1152/ajpendo.00430.2013; Gao N, 2015, INFECT IMMUN, V83, P4154, DOI 10.1128/IAI.00980-15; Garcia C, 2010, DIABETES METAB, V36, P327, DOI 10.1016/j.diabet.2010.07.001; Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010; Goldbach-Mansky R, 2012, CLIN EXP IMMUNOL, V167, P391, DOI 10.1111/j.1365-2249.2011.04533.x; Goncalves NP, 2015, J NEUROPATH EXP NEUR, V74, P203, DOI 10.1097/NEN.0000000000000164; Harikumar KB, 2014, NAT IMMUNOL, V15, P231, DOI 10.1038/ni.2810; Hasegawa M, 2013, J DERMATOL SCI, V70, P34, DOI 10.1016/j.jdermsci.2013.01.007; Hedberg-Buenz A, 2016, EXP EYE RES, V146, P386, DOI 10.1016/j.exer.2015.07.020; HELQVIST S, 1994, DAN MED BULL, V41, P151; Hong JW, 2001, INVEST OPHTH VIS SCI, V42, P2795; Huang HY, 2001, J CLIN ENDOCR METAB, V86, P1387, DOI 10.1210/jc.86.3.1387; Hwang MW, 2001, J AM COLL CARDIOL, V38, P1546, DOI 10.1016/S0735-1097(01)01591-1; Ishida Y, 2006, J IMMUNOL, V176, P5598, DOI 10.4049/jimmunol.176.9.5598; Ishida Y, 2012, J CLIN INVEST, V122, P711, DOI 10.1172/JCI43027; Kaji Y, 2005, BRIT J OPHTHALMOL, V89, P254, DOI 10.1136/bjo.2004.055541; Kandhare AD, 2014, CHEM-BIOL INTERACT, V219, P101, DOI 10.1016/j.cbi.2014.05.012; Li GL, 2013, BRAIN RES BULL, V90, P79, DOI 10.1016/j.brainresbull.2012.10.002; Lin M, 2013, KIDNEY INT, V83, P887, DOI 10.1038/ki.2013.11; Liu Q, 2012, AM J PATHOL, V181, P452, DOI 10.1016/j.ajpath.2012.04.010; Ljubimov AV, 2015, PROG RETIN EYE RES, V49, P17, DOI 10.1016/j.preteyeres.2015.07.002; MANDRUPPOULSEN T, 1993, CYTOKINE, V5, P185, DOI 10.1016/1043-4666(93)90003-N; Merhi-Soussi F, 2005, CYTOKINE, V32, P163, DOI 10.1016/j.cyto.2005.09.004; Molnarfi N, 2007, J IMMUNOL, V178, P446, DOI 10.4049/jimmunol.178.1.446; Palmer G, 2007, J INVEST DERMATOL, V127, P1938, DOI 10.1038/sj.jid.5700803; Pflugfelder SC, 2006, AM J OPHTHALMOL, V142, P316, DOI 10.1016/j.ajo.2006.05.002; Saha B, 2010, CYTOKINE, V50, P1, DOI 10.1016/j.cyto.2009.11.021; Schmidt MI, 1999, LANCET, V353, P1649, DOI 10.1016/S0140-6736(99)01046-6; Schwartzman ML, 2010, DIABETES, V59, P1780, DOI 10.2337/db10-0110; Shi LQ, 2012, J NEUROSCI RES, V90, P816, DOI 10.1002/jnr.22798; Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691; Stapleton WM, 2008, EXP EYE RES, V86, P753, DOI 10.1016/j.exer.2008.02.001; Sun HJ, 2015, INVEST OPHTH VIS SCI, V56, P3383, DOI 10.1167/iovs.15-16606; Thomay AA, 2009, AM J PATHOL, V174, P2129, DOI 10.2353/ajpath.2009.080765; Wang F, 2012, AM J PATHOL, V181, P2058, DOI 10.1016/j.ajpath.2012.08.029; WEBER A, 2010, SCI SIGNAL, V3; Wilson SE, 2001, PROG RETIN EYE RES, V20, P625, DOI 10.1016/S1350-9462(01)00008-8; Xu KP, 2011, INVEST OPHTH VIS SCI, V52, P3301, DOI 10.1167/iovs.10-5670; Xu KP, 2004, INVEST OPHTH VIS SCI, V45, P813, DOI 10.1167/iovs.03-0851; Yin J, 2011, INVEST OPHTH VIS SCI, V52, P6589, DOI 10.1167/iovs.11-7709	64	32	34	2	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JUN	2016	186	6					1466	1480		10.1016/j.ajpath.2016.01.019			15	Pathology	Pathology	DN7DZ	WOS:000377236800007	27109611	Green Published, Bronze			2021-06-18	
J	Dash, PK; Hergenroeder, GW; Jeter, CB; Choi, HA; Kobori, N; Moore, AN				Dash, Pramod K.; Hergenroeder, Georgene W.; Jeter, Cameron B.; Choi, H. Alex; Kobori, Nobuhide; Moore, Anthony N.			Traumatic Brain Injury Alters Methionine Metabolism: Implications for Pathophysiology	FRONTIERS IN SYSTEMS NEUROSCIENCE			English	Article						concussion; epigenetic changes; metabolomics; protein methylation; S-adenosylmethionine; transsulfuration	S-ADENOSYLMETHIONINE; AMINO-ACIDS; PLASMA; METHYLATION; INCREASES; DISEASE; SYSTEM; MODEL	Methionine is an essential proteinogenic amino acid that is obtained from the diet. In addition to its requirement for protein biosynthesis, methionine is metabolized to generate metabolites that play key roles in a number of cellular functions. Metabolism of methionine via the transmethylation pathway generates S-adenosylmethionine (SAM) that serves as the principal methyl (CH3) donor for DNA and histone methyltransferases (MTs) to regulate epigenetic changes in gene expression. SAM is also required for methylation of other cellular proteins that serve various functions and phosphatidylcholine synthesis that participate in cellular signaling. Under conditions of oxidative stress, homocysteine (which is derived from SAM) enters the transsulfuration pathway to generate glutathione, an important cytoprotective molecule against oxidative damage. As both experimental and clinical studies have shown that traumatic brain injury (TBI) alters DNA and histone methylation and causes oxidative stress, we examined if TBI alters the plasma levels of methionine and its metabolites in human patients. Blood samples were collected from healthy volunteers (HV; n = 20) and patients with mild TBI (mTBI; GCS > 12; n = 20) or severe TBI (sTBI; GCS < 8; n = 20) within the first 24 h of injury. The levels of methionine and its metabolites in the plasma samples were analyzed by either liquid chromatography-mass spectrometry or gas chromatography-mass spectrometry (LC-MS or GC-MS). sTBI decreased the levels of methionine, SAM, betaine and 2-methylglycine as compared to HV, indicating a decrease in metabolism through the transmethylation cycle. In addition, precursors for the generation of glutathione, cysteine and glycine were also found to be decreased as were intermediate metabolites of the gamma-glutamyl cycle (gamma-glutamyl amino acids and 5-oxoproline). mTBI also decreased the levels of methionine, a-ketobutyrate, 2 hydroxybutyrate and glycine, albeit to lesser degrees than detected in the sTBI group. Taken together, these results suggest that decreased levels of methionine and its metabolic products are likely to alter cellular function in multiple organs at a systems level.	[Dash, Pramod K.; Kobori, Nobuhide; Moore, Anthony N.] UTHlth McGovern Med Sch, Dept Neurobiol & Anat, Houston, TX USA; [Dash, Pramod K.; Hergenroeder, Georgene W.; Choi, H. Alex] UTHlth McGovern Med Sch, Vivian L Smith Dept Neurosurg, Houston, TX USA; [Jeter, Cameron B.] Univ Texas Houston, Sch Dent, Dept Diagnost & Biomed Sci, Houston, TX USA	Dash, PK (corresponding author), UTHlth McGovern Med Sch, Dept Neurobiol & Anat, Houston, TX USA.; Dash, PK (corresponding author), UTHlth McGovern Med Sch, Vivian L Smith Dept Neurosurg, Houston, TX USA.	p.dash@uth.tmc.edu	Jeter, Cameron B./AAO-1797-2021	Jeter, Cameron B./0000-0001-5303-5897	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS087149]; Mission Connect/TIRR Foundation; Gilson-Longenbaug Foundation	This study was supported by Grants from NIH (NS087149), Mission Connect/TIRR Foundation, and the Gilson-Longenbaug Foundation.	Akkaya H, 2014, J BIOCHEM MOL TOXIC, V28, P373, DOI 10.1002/jbt.21573; Aquilani R, 2000, ARCH PHYS MED REHAB, V81, P176, DOI 10.1016/S0003-9993(00)90137-0; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bhaumik SR, 2007, NAT STRUCT MOL BIOL, V14, P1008, DOI 10.1038/nsmb1337; Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913; Bistrian BR, 1998, CRIT CARE MED, V26, P1476, DOI 10.1097/00003246-199809000-00006; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; CLIFTON GL, 1985, J NEUROSURG, V62, P186, DOI 10.3171/jns.1985.62.2.0186; Fernstrom JD, 2005, J NUTR, V135, p1539S, DOI 10.1093/jn/135.6.1539S; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Grillo MA, 2008, AMINO ACIDS, V34, P187, DOI 10.1007/s00726-007-0500-9; Haber M, 2013, EXP NEUROL, V249, P169, DOI 10.1016/j.expneurol.2013.09.002; HIRATA F, 1980, SCIENCE, V209, P1082, DOI 10.1126/science.6157192; Jeter CB, 2013, J NEUROTRAUM, V30, P671, DOI 10.1089/neu.2012.2491; Jeter CB, 2012, J NEUROTRAUM, V29, P119, DOI 10.1089/neu.2011.2029; LAJTHA A, 1961, J NEUROCHEM, V7, P210, DOI 10.1111/j.1471-4159.1961.tb13505.x; Lamont LS, 2003, J APPL PHYSIOL, V95, P1259, DOI 10.1152/japplphysiol.01028.2002; Lardenoije R, 2015, PROG NEUROBIOL, V131, P21, DOI 10.1016/j.pneurobio.2015.05.002; Lee S, 2012, J ALZHEIMERS DIS, V28, P423, DOI 10.3233/JAD-2011-111025; Lim MM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007092; Lu SC, 2009, HEPATOLOGY, V50, P462, DOI 10.1002/hep.22990; Montgomery SE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107756; Nageli M, 2014, CRIT CARE, V18, DOI 10.1186/cc13962; ORLOWSKI M, 1970, P NATL ACAD SCI USA, V67, P1248, DOI 10.1073/pnas.67.3.1248; OTT LG, 1988, DRUG INTEL CLIN PHAR, V22, P763, DOI 10.1177/106002808802201004; Papakostas GI, 2009, J CLIN PSYCHIAT, V70, P18, DOI 10.4088/JCP.8157su1c.04; Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685; Povlishock J T, 1992, Hum Cell, V5, P345; Purohit V, 2007, AM J CLIN NUTR, V86, P14; Singh IN, 2006, J CEREBR BLOOD F MET, V26, P1407, DOI 10.1038/sj.jcbfm.9600297; Smith CJ, 2015, FRONT NEUROL, V6, DOI [10.3389/fneur.2015.00240, 10.3389/fneur.2015.00073]; Vuille-Dit-Bille RN, 2012, AMINO ACIDS, V43, P1287, DOI 10.1007/s00726-011-1202-x; WENDEL A, 1980, FEBS LETT, V120, P209, DOI 10.1016/0014-5793(80)80299-7; Yi P, 2000, J BIOL CHEM, V275, P29318, DOI 10.1074/jbc.M002725200; Zhang ZY, 2007, NEUROSCI LETT, V429, P1, DOI 10.1016/j.neulet.2007.09.061	36	32	32	0	8	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-5137		FRONT SYST NEUROSCI	Front. Syst. Neurosci.	APR 29	2016	10								36	10.3389/fnsys.2016.00036			10	Neurosciences	Neurosciences & Neurology	DK7IV	WOS:000375099300001	27199685	DOAJ Gold, Green Published			2021-06-18	
J	Bramlett, HM; Dietrich, WD; Dixon, CE; Shear, DA; Schmid, KE; Mondello, S; Wang, KKW; Hayes, RL; Povlishock, JT; Tortella, FC; Kochanek, PM				Bramlett, Helen M.; Dietrich, W. Dalton; Dixon, C. Edward; Shear, Deborah A.; Schmid, Kara E.; Mondello, Stefania; Wang, Kevin K. W.; Hayes, Ronald L.; Povlishock, John T.; Tortella, Frank C.; Kochanek, Patrick M.			Erythropoietin Treatment in Traumatic Brain Injury: Operation Brain Trauma Therapy	JOURNAL OF NEUROTRAUMA			English	Article						penetrating ballistic-like brain injury; fluid percussion; biomarker; neuroprotection; rat; controlled cortical impact; therapy	RECOMBINANT-HUMAN-ERYTHROPOIETIN; CORTICAL IMPACT INJURY; FUNCTIONAL RECOVERY; MODEL; MICE; GENE; RATS; NEUROPROTECTION; HYPOTHERMIA; EXPRESSION	Experimental studies targeting traumatic brain injury (TBI) have reported that erythropoietin (EPO) is an endogenous neuroprotectant in multiple models. In addition to its neuroprotective effects, it has also been shown to enhance reparative processes including angiogenesis and neurogenesis. Based on compelling pre-clinical data, EPO was tested by the Operation Brain Trauma Therapy (OBTT) consortium to evaluate therapeutic potential in multiple TBI models along with biomarker assessments. Based on the pre-clinical TBI literature, two doses of EPO (5000 and 10,000 IU/kg) were tested given at 15 min after moderate fluid percussion brain injury (FPI), controlled cortical impact (CCI), or penetrating ballistic-like brain injury (PBBI) with subsequent behavioral, histopathological, and biomarker outcome assessments. There was a significant benefit on beam walk with the 5000 IU dose in CCI, but no benefit on any other motor task across models in OBTT. Also, no benefit of EPO treatment across the three TBI models was noted using the Morris water maze to assess cognitive deficits. Lesion volume analysis showed no treatment effects after either FPI or CCI; however, with the 5000 IU/kg dose of EPO, a paradoxical increase in lesion volume and percent hemispheric tissue loss was seen after PBBI. Biomarker assessments included measurements of glial fibrillary acidic protein (GFAP) and ubiquitin C-terminal hydrolase-L1 (UCH-L1) in blood at 4 or 24 h after injury. No treatment effects were seen on biomarker levels after FPI, whereas treatment at either dose exacerbated the increase in GFAP at 24 h in PBBI but attenuated 24-4 h delta UCH-L1 levels at high dose in CCI. Our data indicate a surprising lack of efficacy of EPO across three established TBI models in terms of behavioral, histopathological, and biomarker assessments. Although we cannot rule out the possibility that other doses or more prolonged treatment could show different effects, the lack of efficacy of EPO reduced enthusiasm for its further investigation in OBTT.	[Bramlett, Helen M.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA; [Bramlett, Helen M.] Vet Affairs Med Ctr, Bruce W Carter Dept, Miami, FL 33125 USA; [Dixon, C. Edward] Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Shear, Deborah A.; Schmid, Kara E.; Tortella, Frank C.] Walter Reed Army Inst Res, Ctr Mil Psychiat & Neurosci, Brain Trauma Neuroprotect Neurorestorat, Silver Spring, MD USA; [Mondello, Stefania] Univ Messina, Dept Neurosci, Messina, Italy; [Wang, Kevin K. W.] Univ Florida, Dept Psychiat & Neurosci, Ctr Neuroprote & Biomarkers Res, Gainesville, FL USA; [Hayes, Ronald L.] Banyan Biomarkers Inc, Ctr Neuroprote & Biomarkers Res, Ctr Innovat Res, Alachua, FL USA; [Povlishock, John T.] Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA; [Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 Fifth Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Mondello, Stefania/A-1813-2012	Mondello, Stefania/0000-0002-8587-3614; Wang, Kevin/0000-0002-9343-6473			Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; Atkins CM, 2010, EUR J NEUROSCI, V32, P1912, DOI 10.1111/j.1460-9568.2010.07467.x; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Bian XX, 2010, NEUROL MED-CHIR, V50, P361, DOI 10.2176/nmc.50.361; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; Brines M, 2008, P NATL ACAD SCI USA, V105, P10925, DOI 10.1073/pnas.0805594105; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Corwin HL, 2007, NEW ENGL J MED, V357, P965, DOI 10.1056/NEJMoa071533; Dixon CE, 1998, J NEUROTRAUM, V15, P95, DOI 10.1089/neu.1998.15.95; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Ehrenreich H, 2009, STROKE, V40, pE647, DOI 10.1161/STROKEAHA.109.564872; Hartley CE, 2008, J NEUROSURG, V109, P708, DOI 10.3171/JNS/2008/109/10/0708; Jin W, 2011, J TRAUMA, V71, P680, DOI 10.1097/TA.0b013e3181f6b984; Jin W, 2011, ANN CLIN LAB SCI, V41, P25; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Liao ZB, 2009, NEUROL INDIA, V57, P722, DOI 10.4103/0028-3886.59466; Lieutaud T, 2008, J NEUROTRAUM, V25, P1179, DOI 10.1089/neu.2008.0591; LIN FK, 1985, P NATL ACAD SCI USA, V82, P7580, DOI 10.1073/pnas.82.22.7580; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Marti HH, 1996, EUR J NEUROSCI, V8, P666, DOI 10.1111/j.1460-9568.1996.tb01252.x; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Mondello S, 2016, J NEUROTRAUM, V33, P595, DOI 10.1089/neu.2015.4132; Ning RZ, 2011, BRAIN RES, V1384, P140, DOI 10.1016/j.brainres.2011.01.099; Nirula R, 2010, CRIT CARE RES PRACT, V2010, DOI 10.1155/2010/209848; Ozisik PA, 2007, SURG NEUROL, V68, P547, DOI 10.1016/j.surneu.2007.01.030; Ozturk E, 2008, PROG NEURO-PSYCHOPH, V32, P81, DOI 10.1016/j.pnpbp.2007.07.016; Ponce Lucido L, 2013, Pathophysiology, V20, P31, DOI 10.1016/j.pathophys.2012.02.005; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Robertson CS, 2013, J NEUROTRAUM, V30, P765, DOI 10.1089/neu.2012.2431; Robertson CS, 2012, J NEUROTRAUM, V29, P1156, DOI 10.1089/neu.2011.1827; Shear DA, 2016, J NEUROTRAUM, V33, P523, DOI 10.1089/neu.2015.4115; Shear DA, 2010, J NEUROTRAUM, V27, P1911, DOI 10.1089/neu.2010.1399; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Valable S, 2010, J CEREBR BLOOD F MET, V30, P361, DOI 10.1038/jcbfm.2009.222; Verdonck O, 2007, J CEREBR BLOOD F MET, V27, P1369, DOI 10.1038/sj.jcbfm.9600443; Warnecke C, 2004, FASEB J, V18, P1462, DOI 10.1096/fj.04-1640fje; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2011, TRANSL STROKE RES, V2, P619, DOI 10.1007/s12975-011-0120-2; Xiong Y, 2011, J NEUROSURG, V114, P549, DOI 10.3171/2010.10.JNS10925; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Xiong Y, 2010, J NEUROTRAUM, V27, P205, DOI 10.1089/neu.2009.1001; Yatsiv I, 2005, FASEB J, V19, P1701, DOI 10.1096/fj.05-3907fje	48	32	33	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR 15	2016	33	6					538	552		10.1089/neu.2015.4116			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DG6HN	WOS:000372184800004	26670694				2021-06-18	
J	Hehar, H; Mychasiuk, R				Hehar, Harleen; Mychasiuk, Richelle			The use of telomere length as a predictive biomarker for injury prognosis in juvenile rats following a concussion/mild traumatic brain injury	NEUROBIOLOGY OF DISEASE			English	Article						Programming; Caloric restriction; Exercise; High fat diet; Recovery	OXIDATIVE STRESS; CALORIC RESTRICTION; PROFESSIONAL FOOTBALL; GENE-EXPRESSION; OBESITY; EXERCISE; DISEASE; GENERATION; CORTEX; DAMAGE	Telomeres were originally believed to be passive players in cellular replication, but recent research has highlighted their more active role in epigenetic patterning and promotion of cellular growth and survival. Furthermore, literature demonstrates that telomere length (TL) is responsive to environmental manipulations such as prenatal stress and dietary programming. As the search for a prognostic biomarker of concussion has had limited success, this study sought to examine whether or not telomere length (TL) could be an efficacious predictor of symptom severity in juvenile rats following concussion. Rats from four distinct experimental groups (caloric restriction (CR), high fat diet (HFD), exercise (EX), and standard controls (STD)) received a mild traumatic brain injury (mTBI)/concussion and were then subjected to a behavioural test battery. The test battery was scored and the animals were categorized as poor, average, or good, based on their performance on the 6 tests examined. Skin cells (from ear notch samples) were taken 17 days post-injury and DNA was extracted for telomere length analysis. Ear notch skin cell TL was highly correlated with brain tissue TL for a given individual. Animals in the CR and EX cohorts had significantly longer telomeres, while animals in the HFD cohort had significantly shorter telomeres, when compared to controls. The mTBI/concussion reduced TL in all cohorts except the EX group. A significant linear relationship was found between TL and performance on the behavioural test battery, whereby shorter telomeres were associated with poorer performance and longer telomeres with better performance. As performance on the test battery is linked to symptom severity, this study found TL to be a reasonable tool for concussion prognosis. Future studies with human populations should examine the validity of TL in peripheral cells, as a predictor of concussion pathology. (C) 2015 Elsevier Inc. All rights reserved.	[Hehar, Harleen; Mychasiuk, Richelle] Univ Calgary, Fac Med, Alberta Childrens Hosp Res Fdn, Heritage Med Res Bldg,Room 274,3330 Hosp Dr NW, Calgary, AB, Canada	Mychasiuk, R (corresponding author), Univ Calgary, Fac Med, Alberta Childrens Hosp Res Fdn, Heritage Med Res Bldg,Room 274,3330 Hosp Dr NW, Calgary, AB, Canada.	rmmychas@ucalgary.ca			Canadian Institute for Health ResearchCanadian Institutes of Health Research (CIHR); Alberta Children's Hospital Research Institute; Markin USRP for Health and Wellness	The authors would like to thank Irene Ma, Rose Tobias, Dr. Michael Esser, and Dr. Cam Teskey for their organizational and research support. They would also like to thank the Canadian Institute for Health Research, the Alberta Children's Hospital Research Institute, and the Markin USRP for Health and Wellness for their financial contributions.	Abdullah AI, 2012, MOL NEUROBIOL, V45, P586, DOI 10.1007/s12035-012-8277-6; Bale TL, 2010, BIOL PSYCHIAT, V68, P314, DOI 10.1016/j.biopsych.2010.05.028; Barker DJP, 2004, J AM COLL NUTR, V23, p588S, DOI 10.1080/07315724.2004.10719428; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Blasco MA, 2004, CARCINOGENESIS, V25, P1083, DOI 10.1093/carcin/bgh185; Blasco MA, 2007, NAT REV GENET, V8, P299, DOI 10.1038/nrg2047; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Colman RJ, 2009, SCIENCE, V325, P201, DOI 10.1126/science.1173635; Eitan E, 2014, TRENDS NEUROSCI, V37, P256, DOI 10.1016/j.tins.2014.02.010; Elias MF, 2003, INT J OBESITY, V27, P260, DOI 10.1038/sj.ijo.802225; Entringer S, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003580; Entringer S, 2011, P NATL ACAD SCI USA, V108, pE513, DOI 10.1073/pnas.1107759108; Ferezou-Viala J, 2007, AM J PHYSIOL-REG I, V293, pR1056, DOI 10.1152/ajpregu.00117.2007; Gaillard R, 2014, HYPERTENSION, V63, P683, DOI 10.1161/HYPERTENSIONAHA.113.02671; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Giacoppo S, 2012, NEUROCRIT CARE, V16, P470, DOI 10.1007/s12028-012-9707-z; Gilley D, 2008, MECH AGEING DEV, V129, P27, DOI 10.1016/j.mad.2007.10.010; Godfrey KM, 2000, AM J CLIN NUTR, V71, p1344S, DOI 10.1093/ajcn/71.5.1344s; Gonzalo S, 2006, NAT CELL BIOL, V8, P416, DOI 10.1038/ncb1386; Guan JZ, 2008, J GERONTOL A-BIOL, V63, P467, DOI 10.1093/gerona/63.5.467; Hemann MT, 2001, CELL, V107, P67, DOI 10.1016/S0092-8674(01)00504-9; Holloszy JO, 2007, EXP GERONTOL, V42, P709, DOI 10.1016/j.exger.2007.03.009; Jennings BJ, 1999, FEBS LETT, V448, P4, DOI 10.1016/S0014-5793(99)00336-1; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kang HJ, 2004, J NEUROSCI, V24, P1280, DOI 10.1523/JNEUROSCI.4082-03.2004; Klapper W, 2001, MECH AGEING DEV, V122, P695, DOI 10.1016/S0047-6374(01)00223-8; LaRocca TJ, 2010, MECH AGEING DEV, V131, P165, DOI 10.1016/j.mad.2009.12.009; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Liu L, 2004, GENE, V340, P1, DOI 10.1016/j.gene.2004.06.011; Lukens JN, 2009, ALZHEIMERS DEMENT, V5, P463, DOI 10.1016/j.jalz.2009.05.666; Mychasiuk R, 2015, NEUROSCIENCE, V288, P145, DOI 10.1016/j.neuroscience.2014.12.034; Mychasiuk R, 2014, JOVE, V8; Mychasiuk R, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00017; Mychasiuk R, 2014, J NEUROTRAUM, V31, P749, DOI 10.1089/neu.2013.3132; Navarro A, 2004, AM J PHYSIOL-REG I, V286, pR505, DOI 10.1152/ajpregu.00208.2003; Noeman SA, 2011, DIABETOL METAB SYNDR, V3, DOI 10.1186/1758-5996-3-17; O'Sullivan RJ, 2010, NAT STRUCT MOL BIOL, V17, P1218, DOI 10.1038/nsmb.1897; Pedram M, 2006, MOL CELL BIOL, V26, P1865, DOI 10.1128/MCB.26.5.1865-1878.2006; Proctor CJ, 2002, MECH AGEING DEV, V123, P351, DOI 10.1016/S0047-6374(01)00380-3; Puterman E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010837; Qiu XL, 2010, CELL METAB, V12, P662, DOI 10.1016/j.cmet.2010.11.015; Roberts CK, 2002, CIRCULATION, V106, P2530, DOI 10.1161/01.CIR.0000040584.91836.0D; Robin JD, 2014, GENE DEV, V28, P2464, DOI 10.1101/gad.251041.114; Schallert T., 2002, PHARM CEREBRAL ISCHE, P201; Seckl JR, 2007, NAT CLIN PRACT ENDOC, V3, P479, DOI 10.1038/ncpendmet0515; Sitte N, 1998, FREE RADICAL BIO MED, V24, P885, DOI 10.1016/S0891-5849(97)00363-8; Smith JA, 2013, NEUROCHEM INT, V62, P764, DOI 10.1016/j.neuint.2013.02.013; Spanswick SC, 2010, LEARN MEMORY, V17, P241, DOI 10.1101/lm.1746710; Suk SH, 2003, STROKE, V34, P1586, DOI 10.1161/01.STR.0000075294.98582.2F; SUTHERLAND RJ, 1988, J NEUROSCI, V8, P1863; Tarry-Adkins JL, 2009, FASEB J, V23, P1521, DOI 10.1096/fj.08-122796; Tzanetakou IP, 2012, AGEING RES REV, V11, P220, DOI 10.1016/j.arr.2011.12.003; Valdes AM, 2005, LANCET, V366, P662, DOI 10.1016/S0140-6736(05)66630-5; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2009, NEUROSURGERY, V64, P1162, DOI 10.1227/01.NEU.0000345863.99099.C7; Weindruch R, 1996, TOXICOL PATHOL, V24, P742, DOI 10.1177/019262339602400618; Weindruch R, 1997, NEW ENGL J MED, V337, P986, DOI 10.1056/NEJM199710023371407; Yadid G, 2001, BRAIN RES, V896, P43, DOI 10.1016/S0006-8993(00)03248-0; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang Z., 2010, METHOD MOL BIOL, V662	63	32	33	3	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0969-9961	1095-953X		NEUROBIOL DIS	Neurobiol. Dis.	MAR	2016	87						11	18		10.1016/j.nbd.2015.12.007			8	Neurosciences	Neurosciences & Neurology	DC1HP	WOS:000368967700002	26709201				2021-06-18	
J	Przekwas, A; Somayaji, MR; Gupta, RK				Przekwas, Andrzej; Somayaji, Mahadevabharath R.; Gupta, Raj K.			Synaptic Mechanisms of Blast-Induced Brain Injury	FRONTIERS IN NEUROLOGY			English	Article						synapse; TBI; neuro-axonal; blast wave injury; mechanobiology; DAI	IN-VITRO; ADHESION; DEFORMATION; STRESS; BIOMECHANICS; SYNAPSES; PROTEINS; NEUREXIN; MODELS; DISPLACEMENT	Blast wave-induced traumatic brain injury (TBI) is one of the most common injuries to military personnel. Brain tissue compression/tension due to blast-induced cranial deformations and shear waves due to head rotation may generate diffuse micro-damage to neuro-axonal structures and trigger a cascade of neurobiological events culminating in cognitive and neurodegenerative disorders. Although diffuse axonal injury is regarded as a signature wound of mild TBI (mTBI), blast loads may also cause synaptic injury wherein neuronal synapses are stretched and sheared. This synaptic injury may result in temporary disconnect of the neural circuitry and transient loss in neuronal communication. We hypothesize that mTBI symptoms such as loss of consciousness or dizziness, which start immediately after the insult, could be attributed to synaptic injury. Although empirical evidence is beginning to emerge; the detailed mechanisms underlying synaptic injury are still elusive. Coordinated in vitro-in vivo experiments and mathematical modeling studies can shed light into the synaptic injury mechanisms and their role in the potentiation of mTBI symptoms.	[Przekwas, Andrzej; Somayaji, Mahadevabharath R.] CFD Res Corp, Computat Med & Biol Div, Huntsville, AL USA; [Gupta, Raj K.] US Army Med Res & Mat Command, Dept Def Blast Injury Res Program Coordinating Of, Ft Detrick, MD USA	Przekwas, A (corresponding author), CFD Res Corp, Computat Med & Biol Div, Huntsville, AL USA.	andrzej.przekwas@cfdrc.com	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146	Department of Defense Congressionally Directed Medical Research Programs (CDMRP)United States Department of Defense [W81XWH-11-2-0057]	The authors (AJP and MRS) would like to express their appreciation to the Department of Defense Congressionally Directed Medical Research Programs (CDMRP) under contract W81XWH-11-2-0057 for supporting this work. The authors acknowledge Dr. Vincent Harrand, CFDRC and Prof. Beverly Rzigalinski, Virginia Tech, for reviewing the manuscript.	Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Berezin V, 2014, CELL ADHESION MOL IM; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Bourgeron T, 2015, NAT REV NEUROSCI, V16, P551, DOI 10.1038/nrn3992; Brennaman LH, 2010, ADV EXP MED BIOL, V663, P299, DOI 10.1007/978-1-4419-1170-4_19; Brockett AT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124859; Calabrese B, 2006, PHYSIOLOGY, V21, P38, DOI 10.1152/physiol.00042.2005; Castaneda P, 2015, J NEUROSCI RES, V93, P1476, DOI 10.1002/jnr.23602; Cernak I, 1999, J TRAUMA, V47, P96, DOI 10.1097/00005373-199907000-00021; Chavko M, 2011, J NEUROSCI METH, V195, P61, DOI 10.1016/j.jneumeth.2010.11.019; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Cotman CW, 2002, TRENDS NEUROSCI, V25, P295, DOI 10.1016/S0166-2236(02)02143-4; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Effgen GB, 2014, J NEUROTRAUM, V31, P1202, DOI 10.1089/neu.2013.3227; Elder GA, 2009, MT SINAI J MED, V76, P111, DOI 10.1002/msj.20098; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Ferenc MT, 2009, SHOCKWAVES CAUSE SYN; Fiala JC, 2002, BRAIN RES REV, V39, P29, DOI 10.1016/S0165-0173(02)00158-3; Fields RD, 2015, NAT REV NEUROSCI, V16, P756, DOI 10.1038/nrn4023; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Froemke RC, 2015, ANNU REV NEUROSCI, V38, P195, DOI 10.1146/annurev-neuro-071714-034002; Fujita Y, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00338; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; Goldstein LE, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0064-3; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Gupta RK, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00059; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hemphill MA, 2015, NEURON, V85, P1177, DOI 10.1016/j.neuron.2015.02.041; Hemphill MA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022899; Herculano-Houzel S, 2009, FRONT HUM NEUROSCI, V3, DOI 10.3389/neuro.09.031.2009; High Brigit, 2015, Front Synaptic Neurosci, V7, P9, DOI 10.3389/fnsyn.2015.00009; Ho VM, 2011, SCIENCE, V334, P623, DOI 10.1126/science.1209236; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kandel E.R., 2000, PRINCIPLES NEURAL SC; Katzenberger RJ, 2015, JOVE-J VIS EXP, DOI 10.3791/52905; Kay KR, 2013, NAT PROTOC, V8, P1366, DOI 10.1038/nprot.2013.078; King A. I, 2003, IS HEAD INJURY CAUSE; Kleiven Svein, 2013, Front Bioeng Biotechnol, V1, P15; LaPlaca MC, 2010, J BIOMECH, V43, P71, DOI 10.1016/j.jbiomech.2009.09.011; Leckband D, 2010, ANNU REV CHEM BIOMOL, V1, P365, DOI 10.1146/annurev-chembioeng-073009-100931; Levinson JN, 2005, NEURON, V48, P171, DOI 10.1016/j.neuron.2005.09.017; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Manibog K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4941; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Maruthamuthu V, 2009, BIOPHYS J, V96, P3005, DOI 10.1016/j.bpj.2008.12.3936; McEwen BS, 2015, NAT NEUROSCI, V18, P1353, DOI 10.1038/nn.4086; Merlo L, 2014, J NEUROTRAUM, V31, P1375, DOI 10.1089/neu.2014.3385; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mikulska K, 2012, CHEM PHYS LETT, V521, P134, DOI 10.1016/j.cplett.2011.11.033; Monnerie H, 2010, EXP NEUROL, V224, P415, DOI 10.1016/j.expneurol.2010.05.001; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Mueller JK, 2014, PHYS BIOL, V11, DOI 10.1088/1478-3975/11/5/051001; Nakagawa A, 2011, J NEUROTRAUM, V28, P1101, DOI 10.1089/neu.2010.1442; Nguyen T, 1997, J BIOL CHEM, V272, P26032, DOI 10.1074/jbc.272.41.26032; Panzer Matthew B, 2012, Front Neurol, V3, P46, DOI 10.3389/fneur.2012.00046; Park K, 2013, FUTUR NEUROL, V8, P555, DOI 10.2217/FNL.13.35; Popoli M., 2014, SYNAPTIC STRESS PATH; Post A, 2014, J NEUROSURG, V120, P453, DOI 10.3171/2013.10.JNS131101; Proctor DT, 2015, GLIA, V63, P2023, DOI 10.1002/glia.22875; Ramakers GJA, 2002, TRENDS NEUROSCI, V25, P191, DOI 10.1016/S0166-2236(00)02118-4; Rashid B, 2014, J MECH BEHAV BIOMED, V33, P43, DOI 10.1016/j.jmbbm.2012.07.015; Risling M, 2011, NEUROIMAGE, V54, pS89, DOI 10.1016/j.neuroimage.2010.05.031; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Sandi C, 2004, NAT REV NEUROSCI, V5, P917, DOI 10.1038/nrn1555; Savtchenko LP, 2007, P NATL ACAD SCI USA, V104, P1823, DOI 10.1073/pnas.0606636104; Sindi IA, 2014, NEUROBIOL AGING, V35, P746, DOI 10.1016/j.neurobiolaging.2013.09.032; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Sotomayor M, 2008, BIOPHYS J, V94, P4621, DOI 10.1529/biophysj.107.125591; Stemper BD, 2014, PROG NEUROL SURG, V28, P14, DOI 10.1159/000358748; Stenfelt S, 2005, J ACOUST SOC AM, V118, P2373, DOI 10.1121/1.2005847; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Taber KH, 2015, J HEAD TRAUMA REHAB, V30, pE15, DOI 10.1097/HTR.0000000000000030; Tan X. G., 2012, ASME 2012 INT MECH E, P829; Tang-Schomer MD, 2012, EXP NEUROL, V233, P364, DOI 10.1016/j.expneurol.2011.10.030; Tao CL, 2012, NEUROSCI BULL, V28, P321, DOI 10.1007/s12264-012-1249-z; Turrigiano G, 2011, ANNU REV NEUROSCI, V34, P89, DOI 10.1146/annurev-neuro-060909-153238; Tyler WJ, 2012, NAT REV NEUROSCI, V13, P867, DOI 10.1038/nrn3383; Uhl GR, 2014, NEUROPSYCHOPHARMACOL, V39, P235, DOI 10.1038/npp.2013.240; Weaver JB, 2012, PHYS MED BIOL, V57, P7275, DOI 10.1088/0031-9155/57/22/7275; Weber JT, 2012, FRONT PHARMACOL, V3, DOI 10.3389/fphar.2012.00060; Xi XF, 2001, J ACOUST SOC AM, V109, P1226, DOI 10.1121/1.1349183; Zander NE, 2015, J NEUROSCI RES, V93, P1353, DOI 10.1002/jnr.23594; Zhu C, 2014, ANN BIOMED ENG, V42, P388, DOI 10.1007/s10439-013-0904-5; Zou H, 2007, J BIOMECH, V40, P1183, DOI 10.1016/j.jbiomech.2006.06.018	90	32	33	0	18	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-2295			FRONT NEUROL	Front. Neurol.	JAN 21	2016	7								2	10.3389/fneur.2016.00002			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DE2BD	WOS:000370430300001	26834697	DOAJ Gold, Green Published			2021-06-18	
J	Richardson, JD; Dalton, SG				Richardson, Jessica D.; Dalton, Sarah Grace			Main concepts for three different discourse tasks in a large non-clinical sample	APHASIOLOGY			English	Article						aphasia; AphasiaBank; discourse analysis; main concept; normative reference	TRAUMATIC BRAIN-INJURY; WORD RETRIEVAL; APHASIC DISCOURSE; YOUNG-ADULTS; STROKE; IMPAIRMENT; RELIABILITY; CINDERELLA; SPEECH; PEOPLE	Background: Semi-spontaneous speech production tasks are commonly elicited to assess discourse ability. When knowledge of a topic, story, or event is shared, it is possible to gauge the informativeness of discourse by evaluating how accurately and completely an individual produces the concepts considered to be essential to the shared topic. This analysis, main concept analysis (MCA), quantifies the degree to which speakers are able to communicate the overall gist of an event. Though MCA is an easy-to-perform, informative, and reliable measure of discourse adequacy, its widespread adoption depends on the development of standardisation and normative reference. Given the large collection of control discourse transcripts available on the AphasiaBank database, it is possible to generate main concept lists based upon a large sample of control speakers and to characterise their performance to establish preliminary normative reference.Aims: The first aim of this study was to develop main concept checklists drawn from a control population for three semi-spontaneous discourse tasks included in the AphasiaBank protocola picture sequence narrative (Broken Window), storytelling (Cinderella), and a procedure (Peanut Butter and Jelly). The second aim was to report MCA results for control speakers to provide a normative reference and to stratify the normative information by age.Methods & Procedures: Ninety-two control transcripts, stratified into four age groups (20-39years; 40-59 years; 60-79 years; 80+ years), were downloaded from the AphasiaBank database. Relevant concepts were identified, and those spoken by at least one-third of the control sample were considered to be main concepts. A multilevel coding system was used to determine the accuracy and completeness of the main concepts produced by control speakers.Outcomes & Results: Main concept checklists for three discourse tasks are provided. Descriptive statistics are reported and examined to assist readers with evaluation of the normative data. No differences between age groups were observed for the Broken Window narrative. For the remaining discourse tasks, the younger half of the sample generally performed differently than the older half of the sample. Additionally, the two younger age groups did not differ significantly from each other, nor did the two older groups.Conclusions: This study provides main concept checklists drawn from a large control sample. Normative information for main concept production is provided for three discourse tasks. The sample distribution is evaluated relative to the normal probability distribution and the sample composition is described, enabling readers to determine the adequacy of normative characteristics of the sample and also the fit between their patient or client and the normative sample. This study also provides information about main concept or event production for four age groups.	[Richardson, Jessica D.; Dalton, Sarah Grace] Univ S Carolina, Dept Commun Sci & Disorders, Columbia, SC 29208 USA	Richardson, JD (corresponding author), Univ New Mexico, Dept Speech & Hearing Sci, Albuquerque, NM 87131 USA.	j.d.richardson@sc.edu		Richardson, Jessica/0000-0003-2769-3014; Dalton, Sarah Grace/0000-0002-1504-8002	Chapman Foundation	This work was supported by the Chapman Foundation.	Andreetta S, 2012, NEUROPSYCHOLOGIA, V50, P1787, DOI 10.1016/j.neuropsychologia.2012.04.003; Armstrong E, 2000, APHASIOLOGY, V14, P875, DOI 10.1080/02687030050127685; Armstrong L, 2007, APHASIOLOGY, V21, P355, DOI 10.1080/02687030600911310; Boyle M, 2014, J SPEECH LANG HEAR R, V57, P966, DOI 10.1044/2014_JSLHR-L-13-0171; Boyle M, 2011, APHASIOLOGY, V25, P1308, DOI 10.1080/02687038.2011.596185; Brandão Lenisa, 2009, Psychol. Neurosci., V2, P147, DOI 10.3922/j.psns.2009.2.006; BUSCH RM, 2005, GERIATRIC NEUROPSYCH, P133; Capilouto G, 2005, J COMMUN DISORD, V38, P431, DOI 10.1016/j.jcomdis.2005.03.005; Capilouto GJ, 2006, APHASIOLOGY, V20, P205, DOI 10.1080/02687030500473122; Carey S., 1988, MIND LANG, V3, P167, DOI DOI 10.1111/J.1468-0017.1988.TB00141.X; Chandler J. D, 1901, BOSTON COOKING SCH M; Code C, 2011, INT J SPEECH-LANG PA, V13, P3, DOI 10.3109/17549507.2010.520090; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; Demir SO, 2006, BRAIN INJURY, V20, P1383, DOI 10.1080/02699050601081844; DEMR SO, 2006, BRAIN INJURY, V20, P1383, DOI DOI 10.1080/02699050601081844; Doyle P.J., 1995, AM J SPEECH-LANG PAT, V4, P130, DOI [10.1044/1058-0360.0404.130, DOI 10.1044/1058-0360.0404.130]; Fabrigar LR, 1999, PSYCHOL METHODS, V4, P272, DOI 10.1037/1082-989X.4.3.272; Fergadiotis G, 2011, APHASIOLOGY, V25, P1414, DOI 10.1080/02687038.2011.603898; Fergadiotis G, 2011, APHASIOLOGY, V25, P1261, DOI 10.1080/02687038.2011.606974; Forbes MM, 2012, SEMIN SPEECH LANG, V33, P217, DOI 10.1055/s-0032-1320041; Frederiksen C.H., 1990, DISCOURSE ABILITY BR, P69, DOI 10.1007/978-1-4612-3262-9_4; Grimes N., 2005, WALT DISNEYS CINDERE; Hankey GJ, 2013, JAMA-J AM MED ASSOC, V309, P1171, DOI 10.1001/jama.2013.2319; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Herbert R, 2008, APHASIOLOGY, V22, P184, DOI 10.1080/02687030701262613; Hilari K, 2012, ARCH PHYS MED REHAB, V93, pS86, DOI 10.1016/j.apmr.2011.05.028; Hilari K, 2011, DISABIL REHABIL, V33, P211, DOI 10.3109/09638288.2010.508829; HOPKINS KD, 1990, EDUC PSYCHOL MEAS, V50, P717, DOI 10.1177/0013164490504001; Hopper T, 2002, APHASIOLOGY, V16, P745, DOI 10.1080/02687030244000059; Kauhanen ML, 2000, CEREBROVASC DIS, V10, P455, DOI 10.1159/000016107; Kazdin A. E., 1982, SINGLE CASE RES DESI; Keppel G, 2004, DESIGN ANAL RES HDB; Kim Hae-Young, 2013, Restor Dent Endod, V38, P52, DOI 10.5395/rde.2013.38.1.52; KINTSCH W, 1978, PSYCHOL REV, V85, P363, DOI 10.1037/0033-295X.85.5.363; Kissela BM, 2012, NEUROLOGY, V79, P1781, DOI 10.1212/WNL.0b013e318270401d; Kong APH, 2011, J SPEECH LANG HEAR R, V54, P148, DOI 10.1044/1092-4388(2010/09-0240); Kong APH, 2009, J COMMUN DISORD, V42, P442, DOI 10.1016/j.jcomdis.2009.06.002; MacWhinney B., 2000, CHILDES PROJECT TOOL CHILDES PROJECT TOOL CHILDES PROJECT TOOL CHILDES PROJECT TOOL CHILDES PROJECT CHILDES PROJECT TOOL CHILDES PROJECT TOOL CHILDES PROJECT TOOL CHILDES PROJECT TOOL; MacWhinney B, 2011, APHASIOLOGY, V25, P1286, DOI 10.1080/02687038.2011.589893; MacWhinney B, 2010, APHASIOLOGY, V24, P856, DOI 10.1080/02687030903452632; Mayer JF, 2003, APHASIOLOGY, V17, P481, DOI 10.1080/02687030344000148; Menn L, 1998, BRAIN LANG, V61, P183, DOI 10.1006/brln.1997.1838; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; Mitrushina M., 2005, HDB NORMATIVE DATA N; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI [10.1161/01.cir.0000441139.02102.80, 10.1161/CIR.0000000000000152, 10.1161/CIR.0b013e31828124ad]; NICHOLAS LE, 1995, J SPEECH HEAR RES, V38, P146, DOI 10.1044/jshr.3801.145; NICHOLAS LE, 1993, CLIN APHASIOL, V21, P87; Olness G. S., 2002, APHASIOLOGY, V16, P623, DOI [10.1080/02687030244000095, DOI 10.1080/02687030244000095]; Prins R, 2004, APHASIOLOGY, V18, P1075, DOI 10.1080/02687030444000534; Ross KB, 1999, APHASIOLOGY, V13, P113, DOI 10.1080/026870399402235; Safaz I, 2008, BRAIN INJURY, V22, P733, DOI 10.1080/02699050802304714; Singhal AB, 2013, NEUROLOGY, V81, P1089, DOI 10.1212/WNL.0b013e3182a4a451; Snyder T. D., 2011, DIGEST ED STAT 2010; Spaccavento S, 2014, NEUROPSYCH DIS TREAT, V10, P27, DOI 10.2147/NDT.S52357; Stark JA, 2010, APHASIOLOGY, V24, P709, DOI 10.1080/02687030903524729; Sullivan M, 2003, STAT INFORM DECISION; ULATOWSKA HK, 1981, BRAIN LANG, V13, P345, DOI 10.1016/0093-934X(81)90100-0; Ulatowska HK, 2003, APHASIOLOGY, V17, P511, DOI 10.1080/0268703034400102; van Dijk TA, 2006, DISCOURSE STUD, V8, P159, DOI 10.1177/1461445606059565; West S.G., 1995, STRUCTURAL EQUATION, P56; Wright HH, 2011, J SPEECH LANG HEAR R, V54, P900, DOI 10.1044/1092-4388(2010/09-0253); Wright HH, 2005, APHASIOLOGY, V19, P263, DOI 10.1080/02687030444000732; YORKSTON KM, 1980, J SPEECH HEAR DISORD, V45, P27, DOI 10.1044/jshd.4501.27	63	32	32	2	29	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology	JAN 2	2016	30	1					45	73		10.1080/02687038.2015.1057891			29	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	CU1TI	WOS:000363303800003					2021-06-18	
J	Brickler, T; Gresham, K; Meza, A; Coutermarsh-Ott, S; Williams, TM; Rothschild, DE; Allen, IC; Theus, MH				Brickler, Thomas; Gresham, Kisha; Meza, Armand; Coutermarsh-Ott, Sheryl; Williams, Tere M.; Rothschild, Daniel E.; Allen, Irving C.; Theus, Michelle H.			Nonessential Role for the NLRP1 Inflammasome Complex in a Murine Model of Traumatic Brain Injury	MEDIATORS OF INFLAMMATION			English	Article							NECROSIS-FACTOR-ALPHA; INTERLEUKIN-1 RECEPTOR ANTAGONIST; CONTROLLED CORTICAL IMPACT; NEURAL PROGENITOR CELLS; NF-KAPPA-B; SUBVENTRICULAR ZONE; NEGATIVE REGULATION; RAT-BRAIN; EXPRESSION; DEATH	Traumatic brain injury (TBI) elicits the immediate production of proinflammatory cytokines which participate in regulating the immune response. While the mechanisms of adaptive immunity in secondary injury are well characterized, the role of the innate response is unclear. Recently, the NLR inflammasome has been shown to become activated following TBI, causing processing and release of interleukin-1 beta (IL-1 beta). The inflammasome is a multiprotein complex consisting of nucleotide-binding domain and leucine-rich repeat containing proteins (NLR), caspase-1, and apoptosis-associated speck-like protein (ASC). ASC is upregulated after TBI and is critical in coupling the proteins during complex formation resulting in IL-1 beta. cleavage. To directly test whether inflammasome activation contributes to acute TBI-induced damage, we assessed IL-1 beta, IL-18, and IL-6 expression, contusion volume, hippocampal cell death, and motor behavior recovery in Nlrp1(-/-), Asc(-/-), and wild type mice after moderate controlled cortical impact (CCI) injury. Although IL-1 beta expression is significantly attenuated in the cortex of Nlrp1(-/-) and Asc(-/-) mice following CCI injury, no difference in motor recovery, cell death, or contusion volume is observed compared to wild type. These findings indicate that inflammasome activation does not significantly contribute to acute neural injury in the murine model of moderate CCI injury.	[Brickler, Thomas; Gresham, Kisha; Meza, Armand; Coutermarsh-Ott, Sheryl; Williams, Tere M.; Rothschild, Daniel E.; Allen, Irving C.; Theus, Michelle H.] Virginia Polytech Inst & State Univ, Virginia Maryland Reg Coll Vet Med, Dept Biomed Sci & Pathobiol, Duck Pond Dr, Blacksburg, VA 24061 USA	Theus, MH (corresponding author), Virginia Polytech Inst & State Univ, Virginia Maryland Reg Coll Vet Med, Dept Biomed Sci & Pathobiol, Duck Pond Dr, Blacksburg, VA 24061 USA.	mtheus@vt.edu		Allen, Irving/0000-0001-9573-5250	VT's OASF; National Institute of Allergy and Infectious Diseases Animal Model Research for Veterinarians (AMRV) [T32-OD010430];  [R01 NS096281];  [R15 NS081623]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS081623, R01NS096281] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32OD010430] Funding Source: NIH RePORTER	The authors would like to thank Dr. Beverly H. Koller (UNC Chapel Hill) for kindly providing the Nlrp1<SUP>-/-</SUP> mice used in this study. The authors would also like to recognize Genetech for providing the Asc<SUP>-/-</SUP> (Pycard<SUP>-/-</SUP>) mice. This work was supported by R01 NS096281, R15 NS081623, and VT's OASF. The authors recognize the VT-PREP and VT-IMSD Programs for student support (Tere M. Williams; Armand Meza) and the Virginia-Maryland College of Veterinary Medicine (Irving C. Allen; Daniel E. Rothschild). Student work (Sheryl Coutermarsh-Ott) on this paper was supported by the National Institute of Allergy and Infectious Diseases Animal Model Research for Veterinarians (AMRV) training grant (T32-OD010430).	Adamczak SE, 2014, J CEREBR BLOOD F MET, V34, P621, DOI 10.1038/jcbfm.2013.236; Alboni S, 2014, BRAIN BEHAV IMMUN, V40, P85, DOI 10.1016/j.bbi.2014.02.015; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Allen IC, 2012, IMMUNITY, V36, P742, DOI 10.1016/j.immuni.2012.03.012; Allen IC, 2011, IMMUNITY, V34, P854, DOI 10.1016/j.immuni.2011.03.026; Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050; Allen IC, 2009, IMMUNITY, V30, P556, DOI 10.1016/j.immuni.2009.02.005; Baumann G, 2013, EXP BIOL MED, V238, P830, DOI 10.1177/1535370213494558; Bergsbaken T, 2009, NAT REV MICROBIOL, V7, P99, DOI 10.1038/nrmicro2070; Boutin H, 2003, MOL NEUROBIOL, V27, P239, DOI 10.1385/MN:27:3:239; Boutin H, 2001, J NEUROSCI, V21, P5528; Brough D, 2011, TRENDS PHARMACOL SCI, V32, P617, DOI 10.1016/j.tips.2011.06.002; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Chen SZ, 2013, PROTEIN CELL, V4, P251, DOI 10.1007/s13238-013-2128-8; CINAT ME, 1994, J AM COLL SURGEONS, V179, P529; Crampton SJ, 2012, J NEUROCHEM, V120, P964, DOI 10.1111/j.1471-4159.2011.07634.x; Emsley HCA, 2005, J NEUROL NEUROSUR PS, V76, P1366, DOI 10.1136/jnnp.2004.054882; FAN L, 1995, MOL BRAIN RES, V30, P125; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Gris D, 2010, J IMMUNOL, V185, P974, DOI 10.4049/jimmunol.0904145; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hensler T, 2002, J TRAUMA, V52, P962, DOI 10.1097/00005373-200205000-00023; Jha S, 2010, J NEUROSCI, V30, P15811, DOI 10.1523/JNEUROSCI.4088-10.2010; Kita T, 1997, INT J LEGAL MED, V110, P305, DOI 10.1007/s004140050093; Kovarova M, 2012, J IMMUNOL, V189, P2006, DOI 10.4049/jimmunol.1201065; Kupershmidt I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013066; LECHAN RM, 1990, BRAIN RES, V514, P135, DOI 10.1016/0006-8993(90)90445-H; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; Liu HD, 2013, NEUROCHEM RES, V38, P2072, DOI 10.1007/s11064-013-1115-z; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; Martin C, 1997, CRIT CARE MED, V25, P1813, DOI 10.1097/00003246-199711000-00018; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Mills CD, 2001, J NEUROTRAUM, V18, P743, DOI 10.1089/089771501316919111; Minkiewicz J, 2013, GLIA, V61, P1113, DOI 10.1002/glia.22499; Miyoshi K, 2008, J NEUROSCI, V28, P12775, DOI 10.1523/JNEUROSCI.3512-08.2008; Namas R, 2009, LIBYAN J MED, V4, P97, DOI 10.4176/090325; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Pedra JHF, 2009, CURR OPIN IMMUNOL, V21, P10, DOI 10.1016/j.coi.2009.01.006; Popovich PG, 2008, NAT REV NEUROSCI, V9, P481, DOI 10.1038/nrn2398; Rathinam VAK, 2012, NAT IMMUNOL, V13, P333, DOI 10.1038/ni.2237; RELTON JK, 1992, BRAIN RES BULL, V29, P243, DOI 10.1016/0361-9230(92)90033-T; Rivest S, 2009, NAT REV IMMUNOL, V9, P429, DOI 10.1038/nri2565; Shechter R, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000113; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Theus MH, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.165; Theus MH, 2010, STEM CELLS, V28, P1231, DOI 10.1002/stem.449; Vaccari JPD, 2009, J CEREBR BLOOD F MET, V29, P1251, DOI 10.1038/jcbfm.2009.46; Walsh JG, 2014, NAT REV NEUROSCI, V15, P84, DOI 10.1038/nrn3638; Williams TM, 2015, J IMMUNOL, V194, P3369, DOI 10.4049/jimmunol.1402098; Williams TM, 2015, AM J PHYSIOL-GASTR L, V308, pG139, DOI 10.1152/ajpgi.00234.2014; YAMASAKI Y, 1995, STROKE, V26, P676, DOI 10.1161/01.STR.26.4.676; Zhang WH, 2003, P NATL ACAD SCI USA, V100, P16012, DOI 10.1073/pnas.2534856100	58	32	33	0	0	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0962-9351	1466-1861		MEDIAT INFLAMM	Mediat. Inflamm.		2016	2016								6373506	10.1155/2016/6373506			11	Cell Biology; Immunology	Cell Biology; Immunology	DL0GP	WOS:000375310700001	27199506	DOAJ Gold, Green Published			2021-06-18	
J	Lant, ND; Gonzalez-Lara, LE; Owen, AM; Fernandez-Espejo, D				Lant, Nicholas D.; Gonzalez-Lara, Laura E.; Owen, Andrian M.; Fernandez-Espejo, Davinia			Relationship between the anterior forebrain mesocircuit and the default mode network in the structural bases of disorders of consciousness	NEUROIMAGE-CLINICAL			English	Article						Disorders of consciousness; Default mode network; Thalamus; Basal ganglia; Anterior forebrain mesocircuit; Precuneus; DTI; Tractography; White matter; Traumatic brain injury; Hypoxic-ischemic brain injury; Vegetative state; Minimally conscious state	DIFFUSE AXONAL INJURY; TRAUMATIC BRAIN-INJURY; BLUNT HEAD-INJURY; MACAQUE MONKEY; PARAHIPPOCAMPAL CORTICES; FUNCTIONAL CONNECTIVITY; VEGETATIVE STATE; DAMAGED PATIENTS; THALAMIC NUCLEI; MULTIMODAL MRI	The specific neural bases of disorders of consciousness (DOC) are still not well understood. Some studies have suggested that functional and structural impairments in the default mode network may play a role in explaining these disorders. In contrast, others have proposed that dysfunctions in the anterior forebrain mesocircuit involving striatum, globus pallidus, and thalamus may be the main underlying mechanism. Here, we provide the first report of structural integrity of fiber tracts connecting the nodes of the mesocircuit and the default mode network in 8 patients with DOC. We found evidence of significant damage to subcortico-cortical and cortico-cortical fibers, which were more severe in vegetative state patients and correlated with clinical severity as determined by Coma Recovery Scale-Revised (CRS-R) scores. In contrast, fiber tracts interconnecting subcortical nodes were not significantly impaired. Lastly, we found significant damage in all fiber tracts connecting the precuneus with cortical and subcortical areas. Our results suggest a strong relationship between the default mode network and most importantly the precuneus - and the anterior forebrain mesocircuit in the neural basis of the DOC. (C) 2015 The Authors. Published by Elsevier Inc.	[Lant, Nicholas D.; Gonzalez-Lara, Laura E.; Owen, Andrian M.; Fernandez-Espejo, Davinia] Univ Western Ontario, Brain & Mind Inst, London, ON N6A 5B7, Canada; [Fernandez-Espejo, Davinia] Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England	Fernandez-Espejo, D (corresponding author), Univ Birmingham, Sch Psychol, Birmingham B15 2TT, W Midlands, England.		Gonzalez-Lara, Laura/S-2209-2018	Gonzalez-Lara, Laura/0000-0002-2688-2721; Fernandez-Espejo, Davinia/0000-0001-5941-7546	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [0000032597]; James S. McDonnell Foundation; Schulich Research Opportunities Program; Canada Excellence Research Chairs ProgramCanada Research Chairs [0000025914]	This research was supported by generous funding from the Canadian Institutes of Health Research (Post-doctoral fellowship: D.F-E.; Operating Grant 0000032597: A.M.O.), James S. McDonnell Foundation (A.M.O.), Schulich Research Opportunities Program (N.D.L.), and the Canada Excellence Research Chairs Program (0000025914; A.M.O., D.F-E.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank Natalie Osborne for assistance in healthy participant data collection.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; ALEXANDER GE, 1986, ANNU REV NEUROSCI, V9, P357, DOI 10.1146/annurev.ne.09.030186.002041; Behrens TEJ, 2003, NAT NEUROSCI, V6, P750, DOI 10.1038/nn1075; Behrens TEJ, 2003, MAGN RESON MED, V50, P1077, DOI 10.1002/mrm.10609; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Boly M, 2009, HUM BRAIN MAPP, V30, P2393, DOI 10.1002/hbm.20672; Cauda F, 2009, J NEUROL NEUROSUR PS, V80, P429, DOI 10.1136/jnnp.2007.142349; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Cherubini A, 2007, NEUROIMAGE, V34, P1331, DOI 10.1016/j.neuroimage.2006.11.024; Cieslik EC, 2013, CEREB CORTEX, V23, P2677, DOI 10.1093/cercor/bhs256; Crone JS, 2015, NEUROIMAGE, V110, P101, DOI 10.1016/j.neuroimage.2015.01.037; Crone JS, 2014, NEUROIMAGE-CLIN, V4, P240, DOI 10.1016/j.nicl.2013.12.005; Cruse D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049933; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; Fernandez-Espejo D., 2015, JAMA NEUROL, P1, DOI [10.1001/jamaneurol.2015.2614, DOI 10.1001/JAMANEUROL.2015.2614]; Fernandez-Espejo D, 2013, NAT REV NEUROSCI, V14, P801, DOI 10.1038/nrn3608; Fernandez-Espejo D, 2012, ANN NEUROL, V72, P335, DOI 10.1002/ana.23635; Fernandez-Espejo D, 2010, J NEUROTRAUM, V27, P1187, DOI 10.1089/neu.2010.1297; Frazier JA, 2005, AM J PSYCHIAT, V162, P1256, DOI 10.1176/appi.ajp.162.7.1256; Fridman EA, 2014, P NATL ACAD SCI USA, V111, P6473, DOI 10.1073/pnas.1320969111; GENTRY LR, 1994, RADIOLOGY, V191, P1; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Gibson RM, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00950; Goldstein JM, 2007, BIOL PSYCHIAT, V61, P935, DOI 10.1016/j.biopsych.2006.06.027; Greicius MD, 2009, CEREB CORTEX, V19, P72, DOI 10.1093/cercor/bhn059; Guillery RW, 2002, NEURON, V33, P163, DOI 10.1016/S0896-6273(01)00582-7; Hannawi Y, 2015, NEUROLOGY, V84, P1272, DOI 10.1212/WNL.0000000000001404; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Jenkinson M, 2002, NEUROIMAGE, V17, P825, DOI 10.1006/nimg.2002.1132; Jenkinson M, 2001, MED IMAGE ANAL, V5, P143, DOI 10.1016/S1361-8415(01)00036-6; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Johansen-Berg H, 2009, ANNU REV NEUROSCI, V32, P75, DOI 10.1146/annurev.neuro.051508.135735; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Klein JC, 2010, NEUROIMAGE, V51, P555, DOI 10.1016/j.neuroimage.2010.02.062; Kobayashi Y, 2003, J COMP NEUROL, V466, P48, DOI 10.1002/cne.10883; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 2006, J CLIN INVEST, V116, P1823, DOI 10.1172/JCI29172; Lavenex P, 2002, J COMP NEUROL, V447, P394, DOI 10.1002/cne.10243; Leh SE, 2007, NEUROSCI LETT, V419, P113, DOI 10.1016/j.neulet.2007.04.049; Lutkenhoff ES, 2015, ANN NEUROL, V78, P68, DOI 10.1002/ana.24423; Lutkenhoff ES, 2013, NEUROIMAGE-CLIN, V3, P396, DOI 10.1016/j.nicl.2013.09.010; Makris N, 2006, SCHIZOPHR RES, V83, P155, DOI 10.1016/j.schres.2005.11.020; Mars RB, 2012, CEREB CORTEX, V22, P1894, DOI 10.1093/cercor/bhr268; Maxwell WL, 2006, J NEUROPATH EXP NEUR, V65, P478, DOI 10.1097/01.jnen.0000229241.28619.75; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; Menzler K, 2011, NEUROIMAGE, V54, P2557, DOI 10.1016/j.neuroimage.2010.11.029; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Morel A, 2007, STEREOTACTIC ATLAS H; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Morris R, 1999, EUR J NEUROSCI, V11, P2506, DOI 10.1046/j.1460-9568.1999.00672.x; Naci L., 2013, JAMA NEUROL, DOI 10.1001/jamaneurol/2013.3686; Naci L, 2014, P NATL ACAD SCI USA, V111, P14277, DOI 10.1073/pnas.1407007111; Palacios EM, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-24; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Patenaude B, 2011, NEUROIMAGE, V56, P907, DOI 10.1016/j.neuroimage.2011.02.046; Saab AS, 2013, CURR OPIN NEUROBIOL, V23, P1065, DOI 10.1016/j.conb.2013.09.008; Sala-Llonch R, 2010, J ALZHEIMERS DIS, V22, P523, DOI 10.3233/JAD-2010-101038; Sallet J, 2013, J NEUROSCI, V33, P12255, DOI 10.1523/JNEUROSCI.5108-12.2013; Schiff ND, 2008, ANN NY ACAD SCI, V1129, P105, DOI 10.1196/annals.1417.029; Schiff ND, 2007, ANN NEUROL, V62, P5, DOI 10.1002/ana.21158; Schiff ND, 2010, TRENDS NEUROSCI, V33, P1, DOI 10.1016/j.tins.2009.11.002; SELEMON LD, 1985, J NEUROSCI, V5, P776; Shirer WR, 2012, CEREB CORTEX, V22, P158, DOI 10.1093/cercor/bhr099; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Soddu A, 2012, HUM BRAIN MAPP, V33, P778, DOI 10.1002/hbm.21249; SUZUKI WA, 1994, J COMP NEUROL, V350, P497, DOI 10.1002/cne.903500402; Thibaut A, 2014, NEUROLOGY, V82, P1112, DOI 10.1212/WNL.0000000000000260; Thibaut A, 2012, J REHABIL MED, V44, P487, DOI 10.2340/16501977-0940; Utevsky AV, 2014, J NEUROSCI, V34, P932, DOI 10.1523/JNEUROSCI.4227-13.2014; Vanhaudenhuyse A, 2011, J COGNITIVE NEUROSCI, V23, P570, DOI 10.1162/jocn.2010.21488; Vanhaudenhuyse A, 2010, BRAIN, V133, P161, DOI 10.1093/brain/awp313; Woolrich MW, 2009, NEUROIMAGE, V45, pS173, DOI 10.1016/j.neuroimage.2008.10.055	78	32	34	0	10	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2016	10						27	35		10.1016/j.nicl.2015.11.004			9	Neuroimaging	Neurosciences & Neurology	DI0LX	WOS:000373189000003	26693399	DOAJ Gold, Green Published			2021-06-18	
J	Samuels, WE; Tournaki, N; Blackman, S; Zilinski, C				Samuels, William Ellery; Tournaki, Nelly; Blackman, Sheldon; Zilinski, Christopher			Executive functioning predicts academic achievement in middle school: A four-year longitudinal study	JOURNAL OF EDUCATIONAL RESEARCH			English	Article						Academic achievement; executive functioning; IEPs; individual education plans; longitudinal research; middle school	LEARNING-DISABLED READERS; LATENT VARIABLE ANALYSIS; TRAUMATIC BRAIN-INJURY; CARD-SORTING-TASK; WORKING-MEMORY; SELF-REGULATION; INDIVIDUAL-DIFFERENCES; READING-COMPREHENSION; PRESCHOOL-CHILDREN; EFFORTFUL CONTROL	Executive functioning (EF) is a strong predictor of children's and adolescents' academic performance. Although research indicates that EF can increase during childhood and adolescence, few studies have tracked the effect of EF on academic performance throughout the middle school grades. EF was measured at the end of Grades 6-9 through 21 teachers' and 22 teacher assistants' assessments of 322 adolescents from disadvantaged backgrounds who attended an urban, chartered middle/high school. Assessment of EF was done through the completion of the Behavior Rating Inventory of Executive Function (BRIEF). BRIEF global executive composite scores (GEC) predicted both current and future English/language arts, mathematics, science, social studies, and Spanish annual grade point averages (GPAs). The effect of BRIEF GEC scores often overshadowed the effects of gender, poverty, and having an individual education plan; the other, non-BRIEF-related effects retained slightly more impact among teacher assistant-derived data than teacher-derived data. The strong relationships between BRIEF GEC scores and these GPAs also remained constant over these 4 years: There was little evidence that EF changed over the measured grades or that the relationship between EF and grades itself regularly changed. The findings indicate that EF scores during early middle grades can well predict academic performance in subsequent secondary-school grades. Although methodological constraints may have impeded the abilities of other factors (i.e., poverty) to be significantly related to GPAs, the effects of EF were strong and robust enough to prompt us to recommend its use to guide long-term, academic interventions.	[Samuels, William Ellery; Tournaki, Nelly] CUNY Coll Staten Isl, Sch Educ, 2800 Victory Blvd,3S-207A, Staten Isl, NY USA; [Blackman, Sheldon; Zilinski, Christopher] John W Lavelle Preparatory Charter Sch, Staten Isl, NY USA	Samuels, WE (corresponding author), CUNY Coll Staten Isl, Sch Educ, 2800 Victory Blvd,3S-207A, Staten Isl, NY USA.	wesamuels@gmail.com					Alloway T. P., 2005, ED CHILD PSYCHOL, V22, P56; Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson V., 2008, EXECUTIVE FUNCTIONS, P123; Baughman FD, 2007, COGN SYST RES, V8, P216, DOI 10.1016/j.cogsys.2007.06.004; Best JR, 2011, LEARN INDIVID DIFFER, V21, P327, DOI 10.1016/j.lindif.2011.01.007; Best JR, 2010, CHILD DEV, V81, P1641, DOI 10.1111/j.1467-8624.2010.01499.x; Bierman KL, 2009, SOC DEV, V18, P305, DOI 10.1111/j.1467-9507.2008.00490.x; Blair C, 2002, AM PSYCHOL, V57, P111, DOI 10.1037//0003-066X.57.2.111; Blair C, 2006, BEHAV BRAIN SCI, V29, P109; Blair C, 2007, CHILD DEV, V78, P647, DOI 10.1111/j.1467-8624.2007.01019.x; Blair C, 2012, DEV PSYCHOL, V48, P647, DOI 10.1037/a0026472; Brocki KC, 2004, DEV NEUROPSYCHOL, V26, P571, DOI 10.1207/s15326942dn2602_3; Buckner JC, 2003, DEV PSYCHOPATHOL, V15, P139, DOI 10.1017/S0954579403000087; Buckner JC, 2009, AM J ORTHOPSYCHIAT, V79, P19, DOI 10.1037/a0014796; Bull R, 1999, DEV NEUROPSYCHOL, V15, P421, DOI 10.1080/87565649909540759; Bull R, 2001, DEV NEUROPSYCHOL, V19, P273, DOI 10.1207/S15326942DN1903_3; Bull R, 2011, DEVELOPMENTAL SCI, V14, P679, DOI 10.1111/j.1467-7687.2010.01012.x; Cantin R. H., 2012, COMMUNIQUE, V41, P20; Cartwright KB, 2012, EARLY EDUC DEV, V23, P24, DOI 10.1080/10409289.2011.615025; Checa Purificacion, 2014, Front Psychol, V5, P326, DOI 10.3389/fpsyg.2014.00326; Checa P, 2011, DEV NEUROPSYCHOL, V36, P1018, DOI 10.1080/87565641.2011.591857; Clark C, 2002, J CHILD PSYCHOL PSYC, V43, P785, DOI 10.1111/1469-7610.00084; Clark CAC, 2010, DEV PSYCHOL, V46, P1176, DOI 10.1037/a0019672; Davidson MC, 2006, NEUROPSYCHOLOGIA, V44, P2037, DOI 10.1016/j.neuropsychologia.2006.02.006; Davis CL, 2011, HEALTH PSYCHOL, V30, P91, DOI 10.1037/a0021766; Dawson P., 2010, EXECUTIVE SKILLS CHI; Diamantopoulou S, 2007, DEV NEUROPSYCHOL, V32, P521, DOI 10.1080/87565640701360981; Diamond A, 2011, SCIENCE, V333, P959, DOI 10.1126/science.1204529; Dilworth-Bart JE, 2012, EARLY CHILD RES Q, V27, P416, DOI 10.1016/j.ecresq.2012.02.002; Duncan GJ, 2007, DEV PSYCHOL, V43, P1428, DOI 10.1037/0012-1649.43.6.1428; Espy KA, 2004, DEV NEUROPSYCHOL, V26, P465, DOI 10.1207/s15326942dn2601_6; Everitt BS., 2010, CAMBRIDGE DICT STAT; Friedman NP, 2011, DEV PSYCHOL, V47, P1410, DOI 10.1037/a0023750; Garner JK, 2009, J PSYCHOL, V143, P405, DOI 10.3200/JRLP.143.4.405-426; Garon N, 2008, PSYCHOL BULL, V134, P31, DOI 10.1037/0033-2909.134.1.31; Geiser S., 2007, CSHE RES OCCASIONAL, V6.07; Ginsburg HP, 1997, J LEARN DISABIL, V30, P20, DOI 10.1177/002221949703000102; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia G. A., 2003, BRIEF P BEHAV RATING; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2002, CHILD NEUROPSYCHOL, V8, P121, DOI 10.1076/chin.8.2.121.8727; Hartman E, 2010, J INTELL DISABIL RES, V54, P468, DOI 10.1111/j.1365-2788.2010.01284.x; Haveman R, 1995, J ECON LIT, V33, P1829; Hintermair M, 2013, J DEAF STUD DEAF EDU, V18, P344, DOI 10.1093/deafed/ent003; Hughes C, 2011, J EXP CHILD PSYCHOL, V108, P663, DOI 10.1016/j.jecp.2010.06.005; Huizinga M, 2007, DEV NEUROPSYCHOL, V31, P193, DOI 10.1080/87565640701190817; Huizinga M, 2006, NEUROPSYCHOLOGIA, V44, P2017, DOI 10.1016/j.neuropsychologia.2006.01.010; Isquith PK, 2013, APPL NEUROPSYCH-CHIL, V2, P125, DOI 10.1080/21622965.2013.748389; Isquith PK, 2004, DEV NEUROPSYCHOL, V26, P403, DOI 10.1207/s15326942dn2601_3; Jansen BRJ, 2013, RES DEV DISABIL, V34, P1815, DOI 10.1016/j.ridd.2013.02.022; Kaufman C., 2010, EXECUTIVE FUNCTIONIN; Kimberg D, 1997, BEHAV NEUROLOGY NEUR, P409; Kotsopoulos D, 2012, J MATH BEHAV, V31, P196, DOI 10.1016/j.jmathb.2011.12.005; Lan XZ, 2011, J EXP CHILD PSYCHOL, V108, P677, DOI 10.1016/j.jecp.2010.11.001; Latzman RD, 2010, J CLIN EXP NEUROPSYC, V32, P455, DOI 10.1080/13803390903164363; Lee K, 2009, J EDUC PSYCHOL, V101, P373, DOI 10.1037/a0013843; Lehto JE, 2003, BRIT J DEV PSYCHOL, V21, P59, DOI 10.1348/026151003321164627; Lehto JH, 1996, Q J EXP PSYCHOL-A, V49, P29, DOI 10.1080/027249896392793; Liew J, 2012, CHILD DEV PERSPECT, V6, P105, DOI 10.1111/j.1750-8606.2011.00196.x; Liew J, 2010, EARLY CHILD RES Q, V25, P51, DOI 10.1016/j.ecresq.2009.07.005; Locascio G, 2010, J LEARN DISABIL-US, V43, P441, DOI 10.1177/0022219409355476; Lohmeier JH, 2012, URBAN EDUC, V47, P612, DOI 10.1177/0042085911434569; Lorsbach TC, 1996, CONTEMP EDUC PSYCHOL, V21, P447, DOI 10.1006/ceps.1996.0030; Luciana M, 2005, CHILD DEV, V76, P697, DOI 10.1111/j.1467-8624.2005.00872.x; Lyon G. R., 2003, CHILD PSYCHOPATHOLOG, P520; Lyons KE, 2011, ADV CHILD DEV BEHAV, V40, P379; Mahone EM, 2002, ARCH CLIN NEUROPSYCH, V17, P643, DOI 10.1016/S0887-6177(01)00168-8; Masten AS, 2012, EDUC RESEARCHER, V41, P363, DOI [10.3102/0013189X12467366, 10.3102/0013189X12459883]; McLean JF, 1999, J EXP CHILD PSYCHOL, V74, P240, DOI 10.1006/jecp.1999.2516; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Monette S, 2011, J EXP CHILD PSYCHOL, V109, P158, DOI 10.1016/j.jecp.2011.01.008; Pennington BF, 1996, J CHILD PSYCHOL PSYC, V37, P51, DOI 10.1111/j.1469-7610.1996.tb01380.x; Pinheiro J., 2020, NLME LINEAR NONLINEA NLME LINEAR NONLINEA NLME LINEAR NONLINEA NLME LINEAR NONLINEA R PACKAGE VERS NLME LINEAR NONLINEA NLME LINEAR NONLINEA NLME LINEAR NONLINEA NLME LINEAR NONLINEA NLME LINEAR NONLINEA NLME LINEAR NONLINEA R PACKAGE VERSION NLME LINEAR NONLINEA R PACKAGE VERSION NLME LINEAR NONLINEA; R Core Team, 2013, R LANG ENV STAT COMP; RACK JP, 1992, READ RES QUART, V27, P28, DOI 10.2307/747832; Revelle W, 2014, PSYCH PROCEDURES PER; Riccio CA, 2013, APPL NEUROPSYCH-CHIL, V2, P133, DOI 10.1080/21622965.2013.748383; Roebers CM, 2012, METACOGN LEARN, V7, P151, DOI 10.1007/s11409-012-9089-9; Romine CB, 2005, APPL NEUROPSYCHOL, V12, P190, DOI 10.1207/s15324826an1204_2; Rosenthal M, 2013, NEUROPSYCHOLOGY, V27, P13, DOI 10.1037/a0031299; Rourke BP, 1997, J LEARN DISABIL, V30, P34, DOI 10.1177/002221949703000103; Russell J, 1996, J CHILD PSYCHOL PSYC, V37, P673, DOI 10.1111/j.1469-7610.1996.tb01459.x; SATTERTHWAITE FE, 1946, BIOMETRICS BULL, V2, P110, DOI 10.2307/3002019; Savage R, 2007, LEARN INDIVID DIFFER, V17, P129, DOI 10.1016/j.lindif.2007.04.001; Sbordone R. J., 1996, ECOLOGICAL VALIDITY, P15; Schuchardt K, 2013, TOP LANG DISORD, V33, P298, DOI 10.1097/01.TLD.0000437943.41140.36; Semrud-Clikeman M, 2014, J AUTISM DEV DISORD, V44, P331, DOI 10.1007/s10803-013-1871-2; Shonkoff JP, 2011, SCIENCE, V333, P982, DOI 10.1126/science.1206014; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Singer JD, 2004, APPL LONGITUDINAL DA; Somsen RJM, 2007, DEVELOPMENTAL SCI, V10, P664, DOI 10.1111/j.1467-7687.2007.00613.x; St Clair-Thompson HL, 2006, Q J EXP PSYCHOL, V59, P745, DOI 10.1080/17470210500162854; SWANSON HL, 1993, J EXP CHILD PSYCHOL, V56, P87, DOI 10.1006/jecp.1993.1027; Swanson HL, 1996, J EXP CHILD PSYCHOL, V61, P242, DOI 10.1006/jecp.1996.0016; Swanson HL, 1999, J EXP CHILD PSYCHOL, V72, P1, DOI 10.1006/jecp.1998.2477; van der Sluis S, 2007, INTELLIGENCE, V35, P427, DOI 10.1016/j.intell.2006.09.001; Van der Ven SHG, 2012, BRIT J EDUC PSYCHOL, V82, P100, DOI 10.1111/j.2044-8279.2011.02035.x; Waber DP, 2006, DEV NEUROPSYCHOL, V29, P459, DOI 10.1207/s15326942dn2903_5; WELCH BL, 1947, BIOMETRIKA, V34, P28, DOI 10.1093/biomet/34.1-2.28; WELSH MC, 1991, COGNITIVE DEV, V6, P59, DOI 10.1016/0885-2014(91)90006-Y; WENTZEL KR, 1993, J EDUC PSYCHOL, V85, P357, DOI 10.1037/0022-0663.85.2.357	101	32	33	5	67	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0022-0671	1940-0675		J EDUC RES	J. Educ. Res.		2016	109	5					478	490		10.1080/00220671.2014.979913			13	Education & Educational Research	Education & Educational Research	DR6BD	WOS:000379985200003					2021-06-18	
J	Cuthbert, JP; Pretz, CR; Bushnik, T; Fraser, RT; Hart, T; Kolakowsky-Hayner, SA; Malec, JF; O'Neil-Pirozzi, TM; Sherer, M				Cuthbert, Jeffrey P.; Pretz, Christopher R.; Bushnik, Tamara; Fraser, Robert T.; Hart, Tessa; Kolakowsky-Hayner, Stephanie A.; Malec, James F.; O'Neil-Pirozzi, Therese M.; Sherer, Mark			Ten-Year Employment Patterns of Working Age Individuals After Moderate to Severe Traumatic Brain Injury: A National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Employment; Rehabilitation	QUALITY-OF-LIFE; GALVESTON ORIENTATION; AMNESIA TEST; OUTCOME 2; UNEMPLOYMENT; RETURN; STABILITY; PREDICTORS; IMPACT; MEN	Objective: To describe the 10-year patterns of employment for individuals of working age discharged from a Traumatic Brain Injury Model Systems (TBIMS) center between 1989 and 2009. Design: Secondary data analysis. Setting: Inpatient rehabilitation centers. Participants: Patients aged 16 to 55 years (N=3618) who were not retired at injury, received inpatient rehabilitation at a TBIMS center, were discharged alive between 1989 and 2009, and had at least 3 completed follow-up interviews at postinjury years 1, 2, 5, and 10. Interventions: Not applicable. Main Outcomes Measure: Employment. Results: Patterns of employment were generated using a generalized linear mixed model, where these patterns were transformed into temporal trajectories of probability of employment via random effects modeling. Covariates demonstrating significant relations to growth parameters that govern the trajectory patterns were similar to those noted in previous cross-sectional research and included age, sex, race/ethnicity, education, preinjury substance misuse, preinjury vocational status, and days of posttraumatic amnesia. The calendar year in which the injury occurred also greatly influenced trajectories. An interactive tool was developed to provide visualization of all postemployment trajectories, with many showing decreasing probabilities of employment between 5 and 10 years postinjury. Conclusions: These results highlight that postinjury employment after moderate to severe traumatic brain injury (TBI) is a dynamic process, with varied patterns of employment for individuals with specific characteristics. The overall decline in trajectories of probability of employment between 5 and 10 years postinjury suggests that moderate to severe TBI may have unfavorable chronic effects and that employment outcome is highly influenced by national labor market forces. Additional research targeting the underlying drivers of the decline between 5 and 10 years postinjury is recommended, as are interventions that target influencing factors. (C) 2015 by the American Congress of Rehabilitation Medicine	[Cuthbert, Jeffrey P.; Pretz, Christopher R.] Craig Hosp, Rocky Mt Reg Brain Injury Syst, Englewood, CO 80132 USA; [Pretz, Christopher R.] Traumat Brain Injury Model Syst Natl Stat & Data, Englewood, CO USA; [Bushnik, Tamara] NYU, Langone Sch Med, Rusk Inst Rehabil Med, New York, NY USA; [Fraser, Robert T.] Univ Washington, Seattle, WA 98195 USA; [Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Kolakowsky-Hayner, Stephanie A.] Santa Clara Valley Med Ctr, Rehabil Res Ctr, San Jose, CA 95128 USA; Indiana Univ, Dept Phys Med & Rehabil, Indianapolis, IN 46204 USA; [O'Neil-Pirozzi, Therese M.] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA USA; [O'Neil-Pirozzi, Therese M.] Northeastern Univ, Dept Speech Language Pathol & Audiol, Boston, MA 02115 USA; [Sherer, Mark] Inst Rehabil & Res Mem Hermann, Houston, TX USA; [Sherer, Mark] Baylor Coll Med, Houston, TX 77030 USA	Cuthbert, JP (corresponding author), Craig Hosp, 3425 S Clarkson St, Englewood, CO 80132 USA.	jcuthbert@craighospital.org	Kolakowsky-Hayner, Stephanie A./I-9858-2019	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Bushnik, Tamara/0000-0003-3328-257X	Traumatic Brain Injury Model Systems (TBIMS) National Data and Statistical Center Grant from the National Institute on Disability and Rehabilitation Research (NIDRR) [H133A110006]; TBIMS Centers grants from NIDRR [H133A120032]; Institute for Rehabilitation and Research Memorial Hermann [H133A120020]; Moss Rehabilitation Research Institute [H133A120037]; Spaulding Rehabilitation Hospital, Harvard Medical School [H133A120085]; Rusk Rehabilitation at New York University School of Medicine [H133A120100]; Indiana University School of Medicine [H133A120035]; TBIMS Follow-up Center subcontract via an NIDRR Prime Award [H133A110006]; NIDRR	Supported by the Traumatic Brain Injury Model Systems (TBIMS) National Data and Statistical Center Grant from the National Institute on Disability and Rehabilitation Research (NIDRR) (grant no. H133A110006); TBIMS Centers grants from NIDRR (grant no. H133A120032); The Institute for Rehabilitation and Research Memorial Hermann (grant no. H133A120020); Moss Rehabilitation Research Institute (grant no. H133A120037); Spaulding Rehabilitation Hospital, Harvard Medical School (grant no. H133A120085); Rusk Rehabilitation at New York University School of Medicine (grant no. H133A120100); Indiana University School of Medicine (grant no. H133A120035), and a TBIMS Follow-up Center subcontract via an NIDRR Prime Award (award no. H133A110006).; The TBIMS National Database is supported by the NIDRR and created and maintained by the TBIMS Centers Program.	Andelic N, 2012, BRAIN INJURY, V26, P261, DOI 10.3109/02699052.2012.654589; Argyle M., 1999, WELL BEING FDN HEDON; Bode RK, 2000, J HEAD TRAUMA REHAB, V15, P637, DOI 10.1097/00001199-200002000-00004; Bornstein M.H., 2003, WELL BEING POSITIVE; BROMAN CL, 1990, AM J COMMUN PSYCHOL, V18, P643, DOI 10.1007/BF00931235; [Bureau of Labor Statistics U.S. Department of Labor], 2012, REC 2007 2009; Carlier BE, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-503; [Centers for Disease Control and Prevention National Center for Injury Prevention and Control], 2013, WHAT AR POT EFF TBI; Corrigan J, 2003, TECHNICAL REPORT PRO; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P1400, DOI 10.1016/j.apmr.2007.08.006; Cuthbert JP, 2015, J HEAD TRAUMA REHAB, V30, P160, DOI 10.1097/HTR.0000000000000090; Dawson DR, 2007, DISABIL REHABIL, V29, P301, DOI 10.1080/09638280600756687; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; Forslund MV, 2014, BRAIN INJURY, V28, P980, DOI 10.3109/02699052.2014.888770; Forslund MV, 2013, J REHABIL MED, V45, P801, DOI 10.2340/16501977-1168; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Fraser R, 2006, J VOCAT REHABIL, V25, P141; Gary KW, 2010, J VOCAT REHABIL, V33, P65, DOI 10.3233/JVR-2010-0516; Gary KW, 2009, ARCH PHYS MED REHAB, V90, P1699, DOI 10.1016/j.apmr.2009.04.014; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; Jackson WT, 1998, ARCH PHYS MED REHAB, V79, P718, DOI 10.1016/S0003-9993(98)90051-X; Ketchum JM, 2012, NEUROREHABILITATION, V30, P13, DOI 10.3233/NRE-2011-0723; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kozlowski AJ, 2013, ARCH PHYS MED REHAB, V94, P589, DOI 10.1016/j.apmr.2012.08.199; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Langdon DS, 2002, MON LABOR REV, V125, P3; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lucas RE, 2004, PSYCHOL SCI, V15, P8, DOI 10.1111/j.0963-7214.2004.01501002.x; Machamer J, 2005, J INT NEUROPSYCH SOC, V11, P807, DOI 10.1017/S135561770505099X; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McKee-Ryan FM, 2005, J APPL PSYCHOL, V90, P53, DOI 10.1037/0021-9010.90.1.53; Montgomery SM, 1999, INT J EPIDEMIOL, V28, P95, DOI 10.1093/ije/28.1.95; [National Institutes of Health National Institute of Neurological Disorders and Stroke], 2013, NINDS TRAUM BRAIN IN; Ponsford JL, 2015, J HEAD TRAUMA REHAB, V30, pE1, DOI 10.1097/HTR.0000000000000033; Pretz CR, 2014, J HEAD TRAUMA REHAB, V29, pE65, DOI 10.1097/HTR.0000000000000025; Pretz CR, 2013, ARCH PHYS MED REHAB, V94, P579, DOI 10.1016/j.apmr.2012.08.197; Rotman D., 2013, MIT TECHNOLOGY REV; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Shigaki CL, 2009, DISABIL REHABIL, V31, P484, DOI 10.1080/09638280802240449; Soares Joaquim J. F., 2008, Cognitive Behaviour Therapy, V37, P50, DOI 10.1080/16506070701628016; The traumatic Brain Injury Model Systems National Data and statistical Center, 2014, TBI MOD SYST PRES; Thompkins A, 2014, APPLY NOT APPLY EMPL; Tsaousides T, 2009, REHABIL PSYCHOL, V54, P299, DOI 10.1037/a0016807; Wagner AK, 2002, ARCH PHYS MED REHAB, V83, P107, DOI 10.1053/apmr.2002.27470; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Walsh F., 2011, RESILIENCE MENTAL HL, P149; Wehman P, 2005, J HEAD TRAUMA REHAB, V20, P115, DOI 10.1097/00001199-200503000-00001; Westman M, 2004, HUM RELAT, V57, P823, DOI 10.1177/0018726704045767; WINEFIELD AH, 1991, BRIT J PSYCHOL, V82, P473, DOI 10.1111/j.2044-8295.1991.tb02414.x	50	32	32	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	DEC	2015	96	12					2128	2136		10.1016/j.apmr.2015.07.020			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	CY6SZ	WOS:000366540400007	26278493				2021-06-18	
J	Phang, I; Papadopoulos, MC				Phang, Isaac; Papadopoulos, Marios C.			Intraspinal Pressure Monitoring in a Patient with Spinal Cord Injury Reveals Different Intradural Compartments: Injured Spinal Cord Pressure Evaluation (ISCoPE) Study	NEUROCRITICAL CARE			English	Article						Intensive care; Intraspinal pressure; Neuromonitoring; Spinal cord injury; Spinal cord perfusion pressure	INTRACRANIAL-PRESSURE; PERFUSION-PRESSURE; ANIMAL-MODEL; DECOMPRESSION	We recently described a technique for monitoring intraspinal pressure (ISP) after traumatic spinal cord injury (TSCI). This is analogous to intracranial pressure monitoring after brain injury. We showed that, after severe TSCI, ISP at the injury site is elevated as the swollen cord is compressed against the dura. In a patient with complete thoracic TSCI, we sequentially monitored subdural ISP above the injury, at the injury site, and below the injury intraoperatively. Postoperatively, we simultaneously monitored subdural ISP and intraparenchymal ISP at the injury site and compared the two ISP signals as well as their Fast Fourier Transform spectra. Subdural ISP recorded from the injury site was higher than subdural ISP recorded from above or below the injury site by more than 10 mmHg. The subdural and intraparenchymal ISP signals recorded from the injury site had comparable amplitudes and Fast Fourier Transform spectra. Intraparenchymal pulse pressure was twofold larger than subdural pulse pressure. After severe TSCI, three intradural compartments form (space above injury, injury site, space below injury) with different ISPs. At the level of maximum spinal cord swelling (injury site), subdural ISP is comparable to intraparenchymal ISP.	[Phang, Isaac; Papadopoulos, Marios C.] Univ London St Georges Hosp, Acad Neurosurg Unit, London SW17 0RE, England	Papadopoulos, MC (corresponding author), Univ London St Georges Hosp, Acad Neurosurg Unit, Room 0-136 Jenner Wing,Cranmer Terrace, London SW17 0RE, England.	mpapadop@sgul.ac.uk		Papadopoulos, Marios/0000-0001-9174-4176	Fletcher Fund; Wings for Life Spinal Cord Research Foundation; Neurosciences Research Foundation; Guthy Jackson Charitable Foundation; London Deanery	MCP was financially supported by Fletcher Fund, Wings for Life Spinal Cord Research Foundation, Neurosciences Research Foundation, and Guthy Jackson Charitable Foundation, and IP was financially supported by Fletcher Fund, Neurosciences Research Foundation and London Deanery. The funders had no input at any stage of this research.	Awwad Waleed, 2014, Eur J Orthop Surg Traumatol, V24 Suppl 1, pS261, DOI 10.1007/s00590-013-1409-5; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Fehlings MG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032037; Jones CF, 2012, SPINE, V37, pE1422, DOI 10.1097/BRS.0b013e31826ba7cd; Jones CF, 2012, J NEUROSURG-SPINE, V16, P624, DOI 10.3171/2012.3.SPINE11970; Kwon BK, 2009, J NEUROSURG-SPINE, V10, P181, DOI 10.3171/2008.10.SPINE08217; Lazaridis C, 2013, NEUROL RES, V35, P138, DOI 10.1179/1743132812Y.0000000150; Phang I, 2015, J NEUROTRAUMA; Sahuquillo J, 1999, J NEUROSURG, V90, P16, DOI 10.3171/jns.1999.90.1.0016; Smith JS, 2010, J BONE JOINT SURG AM, V92A, P1206, DOI 10.2106/JBJS.I.00740; van Middendorp JJ, 2013, J NEUROTRAUM, V30, P1781, DOI 10.1089/neu.2013.2932; Varsos GV, 2015, J NEUROSURG SPINE; Werndle MC, 2014, CRIT CARE MED, V42, P646, DOI 10.1097/CCM.0000000000000028; Werndle MC, 2012, J NEUROTRAUM, V29, P880, DOI 10.1089/neu.2011.2038	14	32	33	1	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2015	23	3					414	418		10.1007/s12028-015-0153-6			5	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	CV8WN	WOS:000364569000017	26136148	Green Accepted			2021-06-18	
J	Sethi, M; Heidenberg, J; Wall, SP; Ayoung-Chee, P; Slaughter, D; Levine, DA; Jacko, S; WilsonA, C; Marshall, G; Pachter, HL; Frangos, SG				Sethi, Monica; Heidenberg, Jessica; Wall, Stephen P.; Ayoung-Chee, Patricia; Slaughter, Dekeya; Levine, Deborah A.; Jacko, Sally; WilsonA, Chad; Marshall, Gary; Pachter, H. Leon; Frangos, Spiros G.			Bicycle helmets are highly protective against traumatic brain injury within a dense urban setting	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Bicycle; Bike share; Helmet; Traumatic brain injury; Trauma; Urban; Head injury	HEAD-INJURY; SAFETY HELMETS; MOTOR-VEHICLES; NEW-YORK; RISK; USERS; COLLISIONS	Background: New York City (NYC) has made significant roadway infrastructure improvements, initiated a bicycle share program, and enacted Vision Zero, an action plan to reduce traffic deaths and serious injuries. The objective of this study was to examine whether bicycle helmets offer a protective advantage against traumatic brain injury (TBI) within a contemporary dense urban setting with a commitment to road safety. Methods: A prospective observational study of injured bicyclists presenting to a Level I trauma centre was performed. All bicyclists arriving within 24 h of injury were included. Data were collected between February, 2012 and August, 2014 and included demographics, imaging studies (e.g. computed tomography (CT)), injury patterns, and outcomes including Glasgow Coma Scale (GCS) and Injury Severity Score. Results: Of 699 patients, 273 (39.1%) were wearing helmets at the time of injury. Helmeted bicyclists were more likely to have a GCS of 15 (96.3% [95% Confidence Interval (CI), 93.3-98.2] vs. 87.6 [95% CI, 84.1-90.6]) at presentation. Helmeted bicyclists underwent fewer head CTs (40.3% [95% CI, 34.4-46.4] vs. 52.8% [95% CI, 48.0-57.6]) and were less likely to sustain intracranial injury (6.3% [95% CI, 2.6-12.5] vs. 19.7% [14.7-25.6]), including skull fracture (0.9% [95% CI, 0.0-4.9] vs. 15.3% [95% CI, 10.8-20.7]) and subdural hematoma (0.0% [95% CI, 0.0-3.2] vs. 8.1% [95% CI, 4.9-12.5]). Helmeted bicyclists were significantly less likely to sustain significant TBI, i.e. Head AIS >= 3 (2.6% [95% CI: 0.7-4.5] vs. 10.6% [7.6-12.5]). Four patients underwent craniotomy while three died; all were un-helmeted. A multivariable logistic regression model showed that helmeted bicyclists were 72% less likely to sustain TBI compared with un-helmeted bicyclists (Adjusted Odds Ratio 0.28, 95% CI 0.12-0.61). Conclusions: Despite substantial road safety measures in NYC, the protective impact of simple bicycle helmets in the event of a crash remains significant. A re-assessment of helmet laws for urban bicyclists is advisable to most effectively translate Vision Zero from a political action plan to public safety reality. (C) 2015 Elsevier Ltd. All rights reserved.	[Sethi, Monica; Heidenberg, Jessica; Ayoung-Chee, Patricia; Slaughter, Dekeya; Jacko, Sally; WilsonA, Chad; Marshall, Gary; Pachter, H. Leon; Frangos, Spiros G.] NYU, Bellevue Hosp Ctr, Sch Med, Dept Surg, New York, NY 10016 USA; [Wall, Stephen P.] NYU, Bellevue Hosp Ctr, Sch Med, Dept Emergency Med, New York, NY 10016 USA; [Levine, Deborah A.] NYU, Bellevue Hosp Ctr, Sch Med, Dept Emergency Med & Pediat, New York, NY 10016 USA	Frangos, SG (corresponding author), NYU, Bellevue Hosp Ctr, Sch Med, Dept Surg, New York, NY 10016 USA.	Spiros.frangos@nyumc.org		Sethi, Monica/0000-0001-7784-0954; Marshall, Gary/0000-0003-1398-5366; Wall, Stephen/0000-0003-3965-5074; Ayoung-Chee, Patricia/0000-0003-1961-4654; Frangos, Spiros/0000-0003-2860-8969	Highway Safety Grant from the State of New York Governor's Traffic Safety Committee	The authors wish to acknowledge injury epidemiologist Dr. Charles DiMaggio, PhD, who advised us on the appropriateness of our statistical methods and analyses. This study was funded by a Highway Safety Grant from the State of New York Governor's Traffic Safety Committee (October, 2011-September, 2014; year 1: $48,000, year 2: $47,705, year 3: $48,206). The sponsor did not participate in the design and conduct of the study, in the collection, management, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.	Al-Habib A, 2012, J TRAUMA ACUTE CARE, V72, P1356, DOI 10.1097/TA.0b013e318250b537; Amoros E, 2012, INJURY PREV, V18, P27, DOI 10.1136/ip.2011.031815; [Anonymous], BIC CRASH DAT 2013 C; [Anonymous], 2014, BIK SAF 2014; Bambach MR, 2013, ACCIDENT ANAL PREV, V53, P78, DOI 10.1016/j.aap.2013.01.005; Basch CH, 2014, J COMMUN HEALTH, V39, P503, DOI 10.1007/s10900-013-9785-7; Belin MA, 2012, INT J INJ CONTROL SA, V19, P171, DOI 10.1080/17457300.2011.635213; Castle SL, 2012, J SURG RES, V173, P327, DOI 10.1016/j.jss.2010.10.031; Centers for Disease Control and Prevention, WEB BAS INJ STAT QUE; Chapman AJ, 2014, AM J SURG, V207, P352, DOI 10.1016/j.amjsurg.2013.12.001; Cripton PA, 2014, ACCIDENT ANAL PREV, V70, P1, DOI 10.1016/j.aap.2014.02.016; Crocker P, 2012, J EMERG MED, V43, P244, DOI 10.1016/j.jemermed.2011.05.029; Davison CM, 2013, INT J EQUITY HEALTH, V12, DOI 10.1186/1475-9276-12-48; DIGUISEPPI CG, 1989, JAMA-J AM MED ASSOC, V262, P2256, DOI 10.1001/jama.262.16.2256; Dultz LA, 2013, J TRAUMA ACUTE CARE, V74, P1138, DOI 10.1097/TA.0b013e31827ab722; Enserink M, 2014, SCIENCE, V345, P1261, DOI 10.1126/science.345.6202.1261; Goodman D. J., 2014, NY TIMES; Graves JM, 2014, AM J PUBLIC HEALTH, V104, pE106, DOI 10.2105/AJPH.2014.302012; Kakefuda I, 2009, ACCIDENT ANAL PREV, V41, P513, DOI 10.1016/j.aap.2009.01.014; Kaplan S, 2015, TRAFFIC INJ PREV, P1; Macpherson A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005401.pub3; MCDERMOTT FT, 1993, J TRAUMA, V34, P834, DOI 10.1097/00005373-199306000-00015; McIntosh AS, 2013, TRAFFIC INJ PREV, V14, P501, DOI 10.1080/15389588.2012.727217; McNally DS, 2013, ACCIDENT ANAL PREV, V60, P15, DOI 10.1016/j.aap.2013.07.011; Meehan WP, 2013, J PEDIATR-US, V163, P726, DOI 10.1016/j.jpeds.2013.03.073; New York City, 2014, VISION ZERO ACTION P; NYC Department of Transportation, 2010, SUST STREETS IND; NYC Department of Transportation, 2012, SUST STREETS IND; Olivier J, 2014, J AUSTRALAS COLL ROA, V25, P10; Olivier J, 2013, ACCIDENT ANAL PREV, V50, P1128, DOI 10.1016/j.aap.2012.09.003; Persaud N, 2012, CAN MED ASSOC J, V184, pE921, DOI 10.1503/cmaj.120988; Povey LJ, 1999, ACCIDENT ANAL PREV, V31, P763, DOI 10.1016/S0001-4575(99)00033-0; Rivara F P, 1997, Inj Prev, V3, P110, DOI 10.1136/ip.3.2.110; Rivara F P, 1999, Inj Prev, V5, P194; RIVARA FP, 1994, PEDIATRICS, V93, P567; THOMPSON DC, 1990, AM J PUBLIC HEALTH, V80, P1471, DOI 10.2105/AJPH.80.12.1471; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1974, DOI 10.1001/jama.276.24.1974; Thompson DC, 1996, JAMA-J AM MED ASSOC, V276, P1968, DOI 10.1001/jama.276.24.1968; Thompson DC, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001855; Thompson J, 2015, TRAFFIC INJ PREV, V16, P147, DOI 10.1080/15389588.2014.914626; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; Tuckel P, 2014, J SAFETY RES, V51, P7, DOI 10.1016/j.jsr.2014.07.003; Webman R, 2013, J TRAUMA ACUTE CARE, V75, P877, DOI 10.1097/TA.0b013e3182a85f97; Winters M, 2010, J URBAN HEALTH, V87, P969, DOI 10.1007/s11524-010-9509-6	44	32	32	0	31	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	DEC	2015	46	12					2483	2490		10.1016/j.injury.2015.07.030			8	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	CX9IW	WOS:000366020000030	26254573				2021-06-18	
J							COUNCIL SPORTS MED FITNESS	Tackling in Youth Football	PEDIATRICS			English	Article							CHRONIC TRAUMATIC ENCEPHALOPATHY; HIGH-SCHOOL FOOTBALL; CERVICAL-SPINE INJURIES; HEAD IMPACT EXPOSURE; BRAIN-INJURY; 2ND IMPACT; RISK-FACTORS; BIOMECHANICAL ANALYSIS; 2ND-IMPACT SYNDROME; POSITION STATEMENT	American football remains one of the most popular sports for young athletes. The injuries sustained during football, especially those to the head and neck, have been a topic of intense interest recently in both the public media and medical literature. The recognition of these injuries and the potential for long-term sequelae have led some physicians to call for a reduction in the number of contact practices, a postponement of tackling until a certain age, and even a ban on high school football. This statement reviews the literature regarding injuries in football, particularly those of the head and neck, the relationship between tackling and football-related injuries, and the potential effects of limiting or delaying tackling on injury risk.						National Football League Players Association	Dr. Meehan participates in research funded, in part, by the National Football League Players Association and receives compensation from ABC-Clio Publishing, Wolters Kluwer, and Springer International Publishing for his authored works. Dr. Landry has indicated he does not have a financial relationship relevant to this article to disclose.	Adickes MS, 2004, SPORTS MED, V34, P201, DOI 10.2165/00007256-200434030-00005; ALVES WM, 1987, CLIN SPORT MED, V6, P211; Badgeley MA, 2013, J PHYS ACT HEALTH, V10, P160, DOI 10.1123/jpah.10.2.160; Banerjee R, 2004, AM J SPORT MED, V32, P1077, DOI 10.1177/0363546504265605; Barbic D, 2005, CLIN J SPORT MED, V15, P294, DOI 10.1097/01.jsm.0000171883.74056.21; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Bjorklund DF, 1998, CHILD DEV, V69, P604, DOI 10.2307/1132190; Boden BP, 2007, AM J SPORT MED, V35, P1075, DOI 10.1177/0363546507299239; Boden BP, 2006, AM J SPORT MED, V34, P1223, DOI 10.1177/0363546506288306; Boden BP, 2005, J AM ACAD ORTHOP SUR, V13, P445, DOI 10.5435/00124635-200511000-00004; Brenner JS, 2014, PEDIATRICS, V133, P1151, DOI 10.1542/peds.2014-0692; Broglio SP, 2013, AM J SPORT MED, V41, P2877, DOI 10.1177/0363546513502458; Cantu R., 2012, CONCUSSIONS OUR KIDS; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2003, NEUROSURGERY, V52, P846, DOI 10.1227/01.NEU.0000053210.76063.E4; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Cantu RC, 2010, J NEUROTRAUM, V27, P1557, DOI 10.1089/neu.2010.1334; Chao S, 2010, SPORTS MED, V40, P59, DOI 10.2165/11319650-000000000-00000; Chomitz VR, 2009, J SCHOOL HEALTH, V79, P30, DOI 10.1111/j.1746-1561.2008.00371.x; Cobb BR, 2013, ANN BIOMED ENG, V41, P2463, DOI 10.1007/s10439-013-0867-6; Collins CL, 2014, J PRIM PREV, V35, P309, DOI 10.1007/s10935-014-0355-2; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; CRITCHLEY M, 1957, BMJ-BRIT MED J, V1, P357, DOI 10.1136/bmj.1.5015.357; Damore DT, 2003, PEDIATR EMERG CARE, V19, P65, DOI 10.1097/00006565-200304000-00001; Daniel RW, 2012, ANN BIOMED ENG, V40, P976, DOI 10.1007/s10439-012-0530-7; Darrow CJ, 2009, AM J SPORT MED, V37, P1798, DOI 10.1177/0363546509333015; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Demorest Rebecca A, 2003, Curr Sports Med Rep, V2, P337; Dompier TP, 2007, J ATHL TRAINING, V42, P395; Donnelly JE, 2011, PREV MED, V52, pS36, DOI 10.1016/j.ypmed.2011.01.021; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Emery CA, 2011, BRIT J SPORT MED, V45, P1289, DOI 10.1136/bjsports-2011-090538; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Erlanger D, 2003, J NEUROSURG, V98, P477, DOI 10.3171/jns.2003.98.3.0477; Fainaru S, 2013, YOUTH FOOTBALL PARTI; Forbes JA, 2014, CHILD NERV SYST, V30, P197, DOI 10.1007/s00381-013-2318-y; Frollo J, 2011, FOOTBALL REMAINS 1 H; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; GOLDBERG B, 1988, PEDIATRICS, V81, P255; Goldstein LB, 2011, CIRCULATION, V123, P816, DOI 10.1161/CIR.0b013e31820a5528; Gorden JA, 2003, J ATHL TRAINING, V38, P209; Graham R., 2014, SPORTS RELATED CONCU; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Harris D, 2012, HIGHSCHOOL FOOTBALL; Haskell WL, 2007, MED SCI SPORT EXER, V39, P1423, DOI 10.1249/mss.0b013e3180616b27; Heck J F, 1996, J Athl Train, V31, P31; Heck JF, 2004, J ATHL TRAINING, V39, P101; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2014, BRIT J SPORT MED, V48, P162, DOI 10.1136/bjsports-2013-092935; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Jordan BD, 1996, PHYSICIAN SPORTSMED, V24, P87, DOI 10.3810/psm.1996.05.1358; Knowles SB, 2009, EPIDEMIOLOGY, V20, P302, DOI 10.1097/EDE.0b013e318193107c; Knowles SB, 2006, AM J EPIDEMIOL, V164, P1209, DOI 10.1093/aje/kwj337; Kontos AP, 2013, J PEDIATR-US, V163, P717, DOI 10.1016/j.jpeds.2013.04.011; LaBella C, 2012, COMPARATIVE ANAL INJ; Levy ML, 2004, NEUROSURGERY, V55, P649, DOI 10.1227/01.NEU.0000134598.06114.89; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; Levy ML, 2004, NEUROSURGERY, V55, P661; LINDER MM, 1995, CLIN J SPORT MED, V5, P167, DOI 10.1097/00042752-199507000-00006; Macpherson A, 2006, PEDIATRICS, V117; Malina RM, 2006, CLIN J SPORT MED, V16, P214, DOI 10.1097/00042752-200605000-00005; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory P, 2012, CURR SPORT MED REP, V11, P21, DOI 10.1249/JSR.0b013e3182423bfd; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McGuine TA, 2014, AM J SPORT MED, V42, P2470, DOI 10.1177/0363546514541926; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Mihalik JP, 2007, DENT TRAUMATOL, V23, P14, DOI 10.1111/j.1600-9657.2006.00488.x; Mihalik JP, 2010, PEDIATRICS, V125; Mueller FO, 1998, CLIN SPORT MED, V17, P169, DOI 10.1016/S0278-5919(05)70071-5; MUELLER FO, 1987, CLIN SPORT MED, V6, P185; Mueller FO, 1977, ANNUAL SURVEY CATAST; Newsome P R, 2001, Int J Paediatr Dent, V11, P396, DOI 10.1046/j.0960-7439.2001.00304.x; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Radelet MA, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.3.e28; Randolph C, 2014, CURR SPORT MED REP, V13, P33, DOI [10.1097/OPX.0000000000000170, 10.1249/JSR.0000000000000022]; Rihn JA, 2009, SPORTS MED, V39, P697, DOI 10.2165/11315190-000000000-00000; Robbins L, 2012, REAL CLEAR SPORTS; ROBERTS GW, 1990, J NEUROL NEUROSUR PS, V53, P373, DOI 10.1136/jnnp.53.5.373; Rowson S, 2007, BIOMED SCI INSTRUM, V43, P200; Rowson S, 2008, CLIN J SPORT MED, V18, P316, DOI 10.1097/JSM.0b013e31817f016a; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schmidt JD, 2014, AM J SPORT MED, V42, P2056, DOI 10.1177/0363546514536685; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; Singh GD, 2009, DENT TRAUMATOL, V25, P515, DOI 10.1111/j.1600-9657.2009.00808.x; Stuart MJ, 2002, MAYO CLIN PROC, V77, P317, DOI 10.4065/77.4.317; Tator CH, 2014, BRIT J SPORT MED, V48, P81, DOI 10.1136/bjsports-2013-093040; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; TOKUDA T, 1991, ACTA NEUROPATHOL, V82, P280, DOI 10.1007/BF00308813; TORG JS, 1979, JAMA-J AM MED ASSOC, V241, P1477, DOI 10.1001/jama.241.14.1477; Trojian TH, 2012, CURR SPORT MED REP, V11, P304, DOI 10.1249/JSR.0b013e31827558c8; Turbeville SD, 2003, AM J SPORT MED, V31, P276, DOI 10.1177/03635465030310022001; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Wetjen NM, 2010, J AM COLL SURGEONS, V211, P553, DOI 10.1016/j.jamcollsurg.2010.05.020; Winters Jackson, 2014, General Dentistry, V62, P34; Wisniewski JF, 2004, DENT TRAUMATOL, V20, P143, DOI 10.1111/j.1600-4469.2004.00259.x; Wong RH, 2014, CLIN NEUROL NEUROSUR, V118, P1, DOI 10.1016/j.clineuro.2013.11.036; Wortzel HS, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/424280; Zemper ED, 2010, BRIT J SPORT MED, V44, P13, DOI 10.1136/bjsm.2009.069096; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44; Zoch T W, 1996, Wis Med J, V95, P570	115	32	32	0	14	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005	1098-4275		PEDIATRICS	Pediatrics	NOV	2015	136	5					E1419	E1430		10.1542/peds.2015-3282			12	Pediatrics	Pediatrics	CV0US	WOS:000363969600033	26498638	Bronze			2021-06-18	
J	Juengst, SB; Adams, LM; Bogner, JA; Arenth, PM; O'Neil-Pirozzi, TM; Dreer, LE; Hart, T; Bergquist, TF; Bombardier, CH; Dijkers, MP; Wagner, AK				Juengst, Shannon B.; Adams, Leah M.; Bogner, Jennifer A.; Arenth, Patricia M.; O'Neil-Pirozzi, Therese M.; Dreer, Laura E.; Hart, Tessa; Bergquist, Thomas F.; Bombardier, Charles H.; Dijkers, Marcel P.; Wagner, Amy K.			Trajectories of Life Satisfaction After Traumatic Brain Injury: Influence of Life Roles, Age, Cognitive Disability, and Depressive Symptoms	REHABILITATION PSYCHOLOGY			English	Article						life satisfaction; life roles; participation; depression; brain injury	QUALITY-OF-LIFE; 1ST 5 YEARS; COMMUNITY INTEGRATION; SOCIAL SUPPORT; SELF-EFFICACY; OUTCOMES; PARTICIPATION; REHABILITATION; INDIVIDUALS; RESILIENCE	Objectives: (a) Identify life satisfaction trajectories after moderate to severe traumatic brain injury (TBI); (b) establish a predictive model for these trajectories across the first 5 years postinjury; and (c) describe differences in these life satisfaction trajectory groups, focusing on age, depressive symptoms, disability, and participation in specific life roles. Research Method: Analysis of the longitudinal TBI Model Systems National Database was performed on data collected prospectively at 1-, 2-, and 5-years post-TBI. Participants (n = 3,012) had a moderate to severe TBI and were 16 years old and older. Results: Four life satisfaction trajectories were identified across the first 5 years postinjury, including: stable satisfaction, initial satisfaction declining, initial dissatisfaction improving, and stable dissatisfaction. Age, depressive symptoms, cognitive disability, and life role participation as a worker, leisure participant, and/ or religious participant at 1-year postinjury significantly predicted trajectory group membership. Life role participation and depressive symptoms were strong predictors of life satisfaction trajectories across the first 5 years post-TBI. Conclusions: The previously documented loss of life roles and prevalence of depression after a moderate to severe TBI make this a vulnerable population for whom low or declining life satisfaction is a particularly high risk. Examining individual life role participation may help to identify relevant foci for community-based rehabilitation interventions or supports.	[Juengst, Shannon B.; Arenth, Patricia M.] Univ Pittsburgh, Med Ctr, Dept Phys Med & Rehabil, Pittsburgh, PA 15260 USA; [Adams, Leah M.; Bombardier, Charles H.] Univ Washington, Sch Med, Dept Rehabil Med, Seattle, WA 98195 USA; [Bogner, Jennifer A.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [O'Neil-Pirozzi, Therese M.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Cambridge, MA 02138 USA; [O'Neil-Pirozzi, Therese M.] Northwestern Univ, Dept Speech Language Pathol & Audiol, Evanston, IL 60208 USA; [Dreer, Laura E.] Univ Alabama Birmingham, Dept Opthalmol, Birmingham, AL USA; [Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Bergquist, Thomas F.] Mayo Clin, Coll Med, Rochester, MI USA; [Dijkers, Marcel P.] Icahn Sch Med Mt Sinai, Dept Rehabil, New York, NY 10029 USA; [Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med Neurosci, Pittsburgh, PA 15260 USA; [Wagner, Amy K.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15260 USA; [Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA	Juengst, SB (corresponding author), Univ Pittsburgh, Kaufmann Med Bldg,Suite 202,3471 Fifth Ave, Pittsburgh, PA 15213 USA.	sbj7@pitt.edu	Juengst, Shannon B/AAC-5891-2019	Juengst, Shannon/0000-0003-4709-545X	National Institute on Disability and Rehabilitation Research through Traumatic Brain Injury Model System (TBIMS) [H133A120887, H133A120084, H133A070029, H133A120037, H133A120026, H133A120096, H133A120085]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [5T32AG027677]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32AG027677] Funding Source: NIH RePORTER	This work was supported by the National Institute on Disability and Rehabilitation Research through Traumatic Brain Injury Model System (TBIMS) Grants H133A120887, H133A120084, H133A070029, H133A120037, H133A120026, H133A120096, H133A120085, and partly supported by the National Institute on Aging (5T32AG027677).	Andersson EE, 2011, J REHABIL MED, V43, P323, DOI 10.2340/16501977-0666; Baird BM, 2010, SOC INDIC RES, V99, P183, DOI 10.1007/s11205-010-9584-9; Beninato M, 2006, ARCH PHYS MED REHAB, V87, P32, DOI 10.1016/j.apmr.2005.08.130; Blanchflower DG, 2008, SOC SCI MED, V66, P1733, DOI 10.1016/j.socscimed.2008.01.030; Bonanno GA, 2012, REHABIL PSYCHOL, V57, P236, DOI 10.1037/a0029256; Bradshaw M., 2014, GERONTOLOGIST; Chmiel M, 2012, SOC INDIC RES, V106, P109, DOI 10.1007/s11205-011-9796-7; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Corrigan JD, 2014, J HEAD TRAUMA REHABI; Corrigan JD, 2013, J HEAD TRAUMA REHAB, V28, P489, DOI 10.1097/HTR.0000000000000004; Darbonne A, 2013, J HAPPINESS STUD, V14, P951, DOI 10.1007/s10902-012-9363-1; Davis LC, 2012, ARCH PHYS MED REHAB, V93, P1324, DOI 10.1016/j.apmr.2012.02.036; DeRoon-Cassini TA, 2010, REHABIL PSYCHOL, V55, P1, DOI 10.1037/a0018601; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Diener E, 2008, HAPPINESS UNLOCKING; Diener E, 1997, ANN REV GERONTOLOGY, V17, P304, DOI DOI 10.1891/0198-8794.17.1.304; Diener E, 2012, AM PSYCHOL, V67, P590, DOI 10.1037/a0029541; Dijkers M, 1997, SPINAL CORD, V35, P829, DOI 10.1038/sj.sc.3100571; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Dorstyn D, 2014, TOP STROKE REHABIL, V21, P40, DOI 10.1310/tsr2101-40; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Fann JR, 2014, J NEUROTRAUMA; Frijters P, 2012, J ECON BEHAV ORGAN, V82, P525, DOI 10.1016/j.jebo.2012.03.008; Fuhrer MJ, 2000, DISABIL REHABIL, V22, P481, DOI 10.1080/096382800413961; Gerstorf D, 2008, DEV PSYCHOL, V44, P1148, DOI 10.1037/0012-1649.44.4.1148; Gignac MAM, 2013, SOC SCI MED, V81, P87, DOI 10.1016/j.socscimed.2012.12.013; Goverover Y., 2013, BRAIN INJURY; Grauwmeijer E, 2014, ARCH PHYS MED REHAB, V95, P1268, DOI 10.1016/j.apmr.2014.02.002; HALLETT JD, 1994, AM J OCCUP THER, V48, P241, DOI 10.5014/ajot.48.3.241; Hart T, 2014, J NEUROTRAUM, V31, P610, DOI 10.1089/neu.2013.3041; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Headey B., 1992, UNDERSTANDING HAPPIN; Hernandez CL, 2014, REHABIL PSYCHOL, V59, P183, DOI 10.1037/a0035887; Huebner RA, 2003, AM J OCCUP THER, V57, P177, DOI 10.5014/ajot.57.2.177; Juengst S, 2014, ARCH PHYS MED REHAB, V95, pE71, DOI [10.1016/j.apmr.2014.07.227, DOI 10.1016/J.APMR.2014.07.227]; Juengst S. B., 2012, SELF AWARENESS COMMU; Kalpakjian CZ, 2004, AM J PHYS MED REHAB, V83, P255, DOI 10.1097/01.PHM.0000118033.07952.8C; Kalpinski RJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/102570; Krause Neal, 2003, J Gerontol B Psychol Sci Soc Sci, V58, pS160; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Mancini A. D., 2015, ASSESSMENT; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; McIntosh CN, 2013, QUAL LIFE RES, V22, P2625, DOI 10.1007/s11136-013-0385-x; McLean A. M., 2013, DISABILITY REHABILIT; Mitchell E. J., 2013, DISABILITY REHABILIT; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Muthen L.K., 1998, MPLUS USERS GUIDE, V8th; Nagin DS, 2010, ANNU REV CLIN PSYCHO, V6, P109, DOI 10.1146/annurev.clinpsy.121208.131413; OAKLEY F, 1986, OCCUP THER J RES, V6, P157, DOI 10.1177/153944928600600303; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Pavot W., 2008, J POSIT PSYCHOL, V3, P137, DOI [10.1080/17439760701756946., DOI 10.1080/17439760701756946, 10.1080/17439760701756946]; Resch JA, 2009, REHABIL PSYCHOL, V54, P51, DOI 10.1037/a0015051; Sander AM, 2011, J HEAD TRAUMA REHAB, V26, P158, DOI 10.1097/HTR.0b013e3181e7537e; Schonberger M, 2011, J INT NEUROPSYCH SOC, V17, P781, DOI 10.1017/S1355617711000701; Stalnacke BM, 2007, BRAIN INJURY, V21, P933, DOI 10.1080/02699050701553189; Temkin NR, 2009, J HEAD TRAUMA REHAB, V24, P460, DOI 10.1097/HTR.0b013e3181c13413; Tsaousides T, 2009, REHABIL PSYCHOL, V54, P299, DOI 10.1037/a0016807; Underhill AT, 2003, BRAIN INJURY, V17, P973, DOI 10.1080/0269905031000110418; Walton David M, 2013, Open Orthop J, V7, P420, DOI 10.2174/1874325001307010420; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002; Williamson M. L. C., J HEAD INJU IN PRESS; Williamson MLC, 2013, BRAIN INJURY, V27, P992, DOI 10.3109/02699052.2013.801512	68	32	33	1	21	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2015	60	4					353	364		10.1037/rep0000056			12	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	CX4YL	WOS:000365706800006	26618215	Bronze, Green Accepted			2021-06-18	
J	Zhu, YJ; Liu, FX; Zou, XC; Torbey, M				Zhu, Yongjin; Liu, Fuxin; Zou, Xunchang; Torbey, Michel			Comparison of unbiased estimation of neuronal number in the rat hippocampus with different staining methods	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Unbiased estimation; Stereological analysis; Hippocampal neuron; Histological study	TRAUMATIC BRAIN-INJURY; AMYOTROPHIC-LATERAL-SCLEROSIS; STEREOLOGICAL ESTIMATION; SUBSTANTIA-NIGRA; SYNAPTIC PLASTICITY; DENTATE GYRUS; CELL NUMBER; SURVIVAL; DISEASE; CORTEX	Background: NeuN and Nissl staining (toluidine blue, cresyl violet staining) are routinely used methods in unbiased stereological estimation of the total number of hippocampal neurons. New method: In the present study, we stained serial frozen coronal sections from 5 normal adult male Sprague-Dawley rat brains with different methods, measured the deformation of hippocampal area in brain sections and estimated the total number of hippocampal neurons using the optical fractionator. Results: The deformation in x, y-axis was not obviously different with different staining protocols, but shrinkage in z-axis was significant after staining (p < 0.001). NeuN staining produced significant higher estimate number than cresyl violet staining by 24% (p = 0.002), however, NeuN and Cresyl Violet staining showed a high degree of correlation in quantification of total neuronal numbers and both methods are suitable for unbiased stereological estimation. Comparison with existing method (s): NeuN is more reliable but if time is limited or the number of animals used in experiments is high, cresyl violet staining may be a feasible method. Conclusions: Compared with previous estimates of the neurons number in rat hippocampus, our present data is reliable and the stereological analysis based on our system is a cost-effective unbiased method for estimation of neuron number. (C) 2015 Elsevier B.V. All rights reserved.	[Zhu, Yongjin; Liu, Fuxin; Zou, Xunchang; Torbey, Michel] Ohio State Univ, Wexner Med Ctr, Dept Neurol, Columbus, OH 43210 USA; [Torbey, Michel] Ohio State Univ, Wexner Med Ctr, Neurosurg, Columbus, OH 43210 USA	Torbey, M (corresponding author), Ohio State Univ, Cerebrovasc & Neurocrit Care Div, Comprehens Stroke & Neurovasc Ctr, Wexner Med Ctr,Dept Neurol & Neurosurg, 395 W 12th Ave,7th Floor, Columbus, OH 43210 USA.	michel.torbey@osumc.edu			Department of Defense, USAUnited States Department of Defense [W81XWH-11-2-0095]	This work was supported by Congressionally Directed Medical Research Programs (NO. W81XWH-11-2-0095), Department of Defense, USA.	Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Aungst SL, 2014, J CEREBR BLOOD F MET, V34, P1223, DOI 10.1038/jcbfm.2014.75; Azcoitia I, 2005, NEUROBIOL AGING, V26, P697, DOI 10.1016/j.neurobiolaging.2004.06.007; Bannerman DM, 2014, NAT REV NEUROSCI, V15, P181, DOI 10.1038/nrn3677; Benes FM, 2001, TRENDS NEUROSCI, V24, P11, DOI 10.1016/S0166-2236(00)01660-X; Bertucco L, 1996, PROCEEDINGS OF THE 1998 IEEE INTERNATIONAL CONFERENCE ON CONTROL APPLICATIONS, VOLS 1 AND 2, P341; Blaya MO, 2014, J NEUROTRAUM, V31, P476, DOI [10.1089/NEU.2013.3135, 10.1089/neu.2013.3135]; BOSS BD, 1987, BRAIN RES, V406, P280, DOI 10.1016/0006-8993(87)90793-1; BOSS BD, 1985, BRAIN RES, V338, P144, DOI 10.1016/0006-8993(85)90257-4; BRAENDGAARD H, 1990, J MICROSC-OXFORD, V157, P285, DOI 10.1111/j.1365-2818.1990.tb02967.x; Burgess N, 2002, NEURON, V35, P625, DOI 10.1016/S0896-6273(02)00830-9; Calhoun ME, 1998, NATURE, V395, P755, DOI 10.1038/27351; Cardoso A, 2011, BEHAV BRAIN RES, V225, P538, DOI 10.1016/j.bbr.2011.07.057; Collins CE, 2010, FRONT NEUROANAT, V4, DOI 10.3389/neuro.05.005.2010; Dorph-Petersen KA, 2001, J MICROSC-OXFORD, V204, P232, DOI 10.1046/j.1365-2818.2001.00958.x; Gittins R, 2004, BRAIN RES BULL, V63, P155, DOI 10.1016/j.brainresbull.2004.02.005; GomezIsla T, 1996, J NEUROSCI, V16, P4491; Grady MS, 2003, J NEUROTRAUM, V20, P929, DOI 10.1089/089771503770195786; Gredal O, 2000, J NEUROSCI METH, V95, P171, DOI 10.1016/S0165-0270(99)00175-2; Hamidi M, 2004, BIOL PSYCHIAT, V55, P563, DOI 10.1016/j.biopsych.2003.11.006; Hatton WJ, 1999, J COMP NEUROL, V409, P169; Heggland I, 2015, EUR J NEUROSCI, V41, P1245, DOI 10.1111/ejn.12876; Hosseini-Sharifabad M, 2007, J NEUROSCI METH, V162, P206, DOI 10.1016/j.jneumeth.2007.01.009; HOWARD CV, 1998, UNBIASED STEREOLOGY; Jinno S, 2007, GLIA, V55, P1334, DOI 10.1002/glia.20552; Jongen-Relo AL, 2002, PHYSIOL BEHAV, V76, P449, DOI 10.1016/S0031-9384(02)00732-1; Kaae SS, 2012, SYNAPSE, V66, P667, DOI 10.1002/syn.21553; Kawagishi K, 2014, NEUROSCIENCE, V272, P29, DOI 10.1016/j.neuroscience.2014.04.050; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kulesza RJ, 2002, HEARING RES, V168, P12, DOI 10.1016/S0378-5955(02)00374-X; Kwon BK, 2002, P NATL ACAD SCI USA, V99, P3246, DOI 10.1073/pnas.052308899; Leutgeb S, 2005, SCIENCE, V309, P619, DOI 10.1126/science.1114037; Li W, 2015, NEUROBIOL DIS, V80, P93, DOI 10.1016/j.nbd.2015.05.002; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Lyck L, 2007, EUR J NEUROSCI, V26, P1749, DOI 10.1111/j.1460-9568.2007.05763.x; Ma SY, 1997, J NEUROL SCI, V151, P83, DOI 10.1016/S0022-510X(97)00100-7; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; McCullers D, 2002, NEUROSCIENCE, V109, P219, DOI 10.1016/S0306-4522(01)00477-8; MCEWEN BS, 1995, CURR OPIN NEUROBIOL, V5, P205, DOI 10.1016/0959-4388(95)80028-X; Miyamoto K., 1994, PARTICLE NUMBER SIZE; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Oberlaender M, 2009, J NEUROSCI METH, V180, P147, DOI 10.1016/j.jneumeth.2009.03.008; Rapp PR, 1996, P NATL ACAD SCI USA, V93, P9926, DOI 10.1073/pnas.93.18.9926; Smith AM, 2008, NEUROTOXICOL TERATOL, V30, P495, DOI 10.1016/j.ntt.2008.05.001; Theoret H, 1999, BRAIN RES, V835, P354, DOI 10.1016/S0006-8993(99)01598-X; von Bartheld CS, 2001, TRENDS NEUROSCI, V24, P504, DOI 10.1016/S0166-2236(00)01960-3; West MJ, 1996, J COMP NEUROL, V370, P11; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Wirenfeldt M, 2003, GLIA, V44, P129, DOI 10.1002/glia.10277; Woeffler-Maucler C, 2014, J NEUROSCI METH, V225, P32, DOI 10.1016/j.jneumeth.2014.01.009; Young NA, 2012, FRONT NEUROANAT, V6, DOI 10.3389/fnana.2012.00027; Zarow C, 2003, ARCH NEUROL-CHICAGO, V60, P337, DOI 10.1001/archneur.60.3.337; Zhu YJ, 2015, DRUG DISCOV TODAY, V20, P65, DOI 10.1016/j.drudis.2014.08.016	55	32	32	0	11	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	OCT 30	2015	254						73	79		10.1016/j.jneumeth.2015.07.022			7	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	CS1XI	WOS:000361861800008	26238727				2021-06-18	
J	Caron, JG; Bloom, GA; Falcao, WR; Sweet, SN				Caron, Jeffrey G.; Bloom, Gordon A.; Falcao, William R.; Sweet, Shane N.			An examination of concussion education programmes: a scoping review methodology	INJURY PREVENTION			English	Article							ASSOCIATION POSITION STATEMENT; FOR-DISEASE-CONTROL; HIGH-SCHOOL; CDC HEADS; KNOWLEDGE; HOCKEY; SPORT; MANAGEMENT; CONSENSUS; COACHES	Objectives The primary purpose was to review the literature on concussion education programmes. The secondary purpose was to inform knowledge translation strategies for concussion researchers and practitioners. Design Research on concussion education programmes is relatively new. As a result, the current study implemented a scoping review methodology, which is a type of literary search used to provide a preliminary assessment of the size and scope of a body of literature, as well as identify strengths, weaknesses and gaps in the research. Methods A five-stage process for conducting a scoping review was followed for this study: (a) identifying the research questions, (b) identifying relevant studies, (c) identifying the study selection criteria, (d) charting the data and (e) reporting the results. Results Concussion education programmes have been developed and implemented with populations ranging in age from 9 to 49 years and have used interactive oral presentations, educational videos and computer-based learning programmes. Although the content of these programmes varied, the topics generally addressed salient aspects of concussion injury and recovery. Quantitative instruments have been the preferred methods for assessment. Conclusions Education programmes aimed at improving participants' long-term concussion knowledge, behaviours and attitudes of concussions are needed. Researchers must consider using a knowledge translation framework to enhance concussion education programmes. The application of such a framework can lead to novel and interesting ways of disseminating information about concussive injury and recovery.	[Caron, Jeffrey G.; Bloom, Gordon A.; Falcao, William R.; Sweet, Shane N.] McGill Univ, Dept Kinesiol & Phys Educ, Montreal, PQ H2W 1S4, Canada	Caron, JG (corresponding author), McGill Univ, Dept Kinesiol & Phys Educ, 475 Pine Ave West, Montreal, PQ H2W 1S4, Canada.	jeffrey.caron@mail.mcgill.ca					Adler RH, 2011, ARCH PHYS MED REHAB, V3, P468; Affoo RH, 2013, J AM GERIATR SOC, V61, P2203, DOI 10.1111/jgs.12553; Ahmed OH, 2012, BRIT J SPORT MED, V46, P675, DOI 10.1136/bjsm.2010.081620; Ahmed OH, 2010, DISABIL REHABIL, V32, P1877, DOI 10.3109/09638281003734409; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Canadian Institutes of Health Research, KNOWL TRANSL COMM; Caron JG, 2013, J SPORT EXERCISE PSY, V35, P168, DOI 10.1123/jsep.35.2.168; Carroll Linda, 2012, CONCUSSION CRISIS AN; Centers for Disease Control and Prevention, CONC SPORT POL; Chrisman SP, 2011, CLIN PEDIATR, V50, P1031, DOI 10.1177/0009922811410970; Cook DJ, 2003, INJURY PREV, V9, P361, DOI 10.1136/ip.9.4.361; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; Creswell J. W., 2017, QUAL INQ; Cusimano MD, 2014, BRIT J SPORT MED, V48, P141, DOI 10.1136/bjsports-2012-091660; Davis GA, 2014, BRIT J SPORT MED, V48, P98, DOI 10.1136/bjsports-2012-092132; DeMatteo C, 2015, DISABIL REHABIL, V37, P1107, DOI 10.3109/09638288.2014.952452; Echlin P. S., 2010, NEUROSURG FOCUS, V29, P1, DOI DOI 10.3171/2010.9FOCUS10187; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Glang A, 2010, INT J SPORTS SCI COA, V5, P1, DOI 10.1260/1747-9541.5.1.1; Goodman D, 2006, J ADOLESCENCE, V29, P351, DOI 10.1016/j.adolescence.2005.07.004; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; Graham ID, 2006, J CONTIN EDUC HEALTH, V26, P13, DOI 10.1002/chp.47; Grant MJ, 2009, HEALTH INFO LIBR J, V26, P91, DOI 10.1111/j.1471-1842.2009.00848.x; Grimshaw JM, 2001, MED CARE, V39, pII2; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Koh JO, 2011, J SPORT MED PHYS FIT, V51, P625; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Krueger R, 2000, FOCUS GROUP PRACTICA, V4; Levac D, 2010, IMPLEMENT SCI, V5, DOI 10.1186/1748-5908-5-69; Manasse-Cohick NJ, 2014, COMMUN DISORD Q, V35, P182, DOI 10.1177/1525740113506605; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; Moore L, 2013, J TRAUMA ACUTE CARE, V74, P1331, DOI 10.1097/TA.0b013e31828c4787; O'Brien K, 2010, AIDS BEHAV, V14, P448, DOI 10.1007/s10461-009-9528-z; O'Malley L., 2005, INT J SOC RES METHOD, V8, P19, DOI [DOI 10.1080/1364557032000119616, 10.1080/1364557032000119616]; Paradis E, 2013, J CRIT CARE, V28, P1062, DOI 10.1016/j.jcrc.2013.05.015; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Provvidenza C, 2013, BRIT J SPORT MED, V47, P332, DOI 10.1136/bjsports-2012-092099; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Register-Mihalik JK, 2013, BRAIN INJURY, V27, P878, DOI 10.3109/02699052.2013.775508; Riekert K.A., 2014, HDB HLTH BEHAV CHANG; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Rubin H.J., 2012, QUALITATIVE INTERVIE, VThird edition; Sarmiento K, 2014, J SAFETY RES, V50, P143, DOI 10.1016/j.jsr.2014.05.003; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Straus SE, 2013, KNOWLEDGE TRANSLATION IN HEALTH CARE: MOVING FROM EVIDENCE TO PRACTICE, 2ND EDITION, P1, DOI 10.1002/9781118413555; Straus SE, 2013, KNOWLEDGE TRANSLATION IN HEALTH CARE: MOVING FROM EVIDENCE TO PRACTICE, 2ND EDITION, P227; Sullivan SJ, 2012, BRIT J SPORT MED, V46, P258, DOI 10.1136/bjsm.2010.080341; Williams D, 2014, BRIT J SPORT MED, V48, P107, DOI 10.1136/bjsports-2012-091853	52	32	32	0	15	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	OCT	2015	21	5					301	308		10.1136/injuryprev-2014-041479			8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	CT4MC	WOS:000362779600003	25825353	Bronze			2021-06-18	
J	Ochs, AL; Ross, DE; Zannoni, MD; Abildskov, TJ; Bigler, ED				Ochs, Alfred L.; Ross, David E.; Zannoni, Megan D.; Abildskov, Tracy J.; Bigler, Erin D.		Alzheimer's Dis Neuroimaging	Comparison of Automated Brain Volume Measures obtained with NeuroQuant (R) and FreeSurfer	JOURNAL OF NEUROIMAGING			English	Article						Brain morphometry; freesurfer; neuroquant((R)); reliability; pallidum	NEUROIMAGING INITIATIVE ADNI; VOXEL-BASED MORPHOMETRY; ALZHEIMERS-DISEASE; HIPPOCAMPAL VOLUME; STRUCTURAL MRI; RELIABILITY; SEGMENTATION; INJURY; ATROPHY; PHANTOM	PURPOSETo examine intermethod reliabilities and differences between FreeSurfer and the FDA-cleared congener, NeuroQuant (R), both fully automated methods for structural brain MRI measurements. MATERIALS AND METHODSMRI scans from 20 normal control subjects, 20 Alzheimer's disease patients, and 20 mild traumatically brain-injured patients were analyzed with NeuroQuant (R) and with FreeSurfer. Intermethod reliability was evaluated. RESULTSPairwise correlation coefficients, intraclass correlation coefficients, and effect size differences were computed. NeuroQuant (R) versus FreeSurfer measures showed excellent to good intermethod reliability for the 21 regions evaluated (r: .63 to .99/ICC: .62 to .99/ES: -.33 to 2.08) except for the pallidum (r/ICC/ES = .31/.29/-2.2) and cerebellar white matter (r/ICC/ES = .31/.31/.08). Volumes reported by NeuroQuant were generally larger than those reported by FreeSurfer with the whole brain parenchyma volume reported by NeuroQuant 6.50% larger than the volume reported by FreeSurfer. There was no systematic difference in results between the 3 subgroups. CONCLUSIONNeuroQuant (R) and FreeSurfer showed good to excellent intermethod reliability in volumetric measurements for all brain regions examined with the only exceptions being the pallidum and cerebellar white matter. This finding was robust for normal individuals, patients with Alzheimer's disease, and patients with mild traumatic brain injury.	[Ochs, Alfred L.; Ross, David E.; Zannoni, Megan D.] Virginia Inst Neuropsychiat, Midlothian, VA 23114 USA; [Ochs, Alfred L.] Virginia Commonwealth Univ, Dept Biomed Engn, Richmond, VA USA; [Ross, David E.] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA USA; [Abildskov, Tracy J.; Bigler, Erin D.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Abildskov, Tracy J.; Bigler, Erin D.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Brain Inst Utah, Salt Lake City, UT USA	Ochs, AL (corresponding author), Virginia Inst Neuropsychiat, 364 Browns Hill Court, Midlothian, VA 23114 USA.	aochs@VaNeuropsychiatry.org		Ochs, Alfred/0000-0003-3932-876X	ADNI (National Institutes of Health)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U01 AG024904]; National Institute on Aging, the National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)NIH National Institute of Biomedical Imaging & Bioengineering (NIBIB); Alzheimer's AssociationAlzheimer's Association; Alzheimer's Drug Discovery Foundation; BioClinica, Inc.; Biogen Idec Inc.Biogen; Bristol-Myers Squibb CompanyBristol-Myers Squibb; Eisai Inc.Eisai Co Ltd; Elan Pharmaceuticals, Inc.; Eli Lilly and CompanyEli Lilly; F. Hoffmann-La Roche Ltd., Genentech, Inc.Hoffmann-La RocheRoche HoldingGenentech; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); GE HealthcareGE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.Johnson & JohnsonJohnson & Johnson USA; Medpace, Inc.; Merck Co., Inc.Merck & Company; Meso Scale Diagnostics, LLC.; NeuroRx Research; Novartis Pharmaceuticals CorporationNovartis; Pfizer Inc.Pfizer; Piramal Imaging; Servier; Synarc Inc.; Takeda Pharmaceutical CompanyTakeda Pharmaceutical Company Ltd; Northern California Institute for Research and Education; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01AG024904] Funding Source: NIH RePORTER	Data collection and sharing for this project was funded by the ADNI (National Institutes of Health Grant U01 AG024904). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer's Association; Alzheimer's Drug Discovery Foundation; BioClinica, Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics, N.V.; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace, Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Synarc Inc.; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. ADNI data are disseminated by the Laboratory for Neuroimaging at the University of Southern California.	Ashburner J, 2000, NEUROIMAGE, V11, P805, DOI 10.1006/nimg.2000.0582; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; Birk S, 2009, INTERN MED NEWS, V9, P12; Brewer JB, 2009, BEHAV NEUROL, V21, P21, DOI [10.3233/BEN-2009-0226, 10.1155/2009/616581]; Brewer JB, 2009, AM J NEURORADIOL, V30, P578, DOI 10.3174/ajnr.A1402; Brezova V, 2014, NEUROIMAGE-CLIN, V5, P128, DOI 10.1016/j.nicl.2014.03.012; Carmichael OT, 2005, NEUROIMAGE, V27, P979, DOI 10.1016/j.neuroimage.2005.05.005; Coe R, 2002, ITS EFFECT SIZE STUP; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Davids M, 2014, MAGN RESON IMAGING, V32, P771, DOI 10.1016/j.mri.2014.01.017; Desikan RS, 2013, AM J NEURORADIOL, V34, P2075, DOI 10.3174/ajnr.A3644; Farid N, 2012, RADIOLOGY, V264, P542, DOI 10.1148/radiol.12112638; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; Fleiss J., 1986, DESIGN ANAL CLIN EXP; Gronenschild EHBM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038234; Han X, 2006, NEUROIMAGE, V32, P180, DOI 10.1016/j.neuroimage.2006.02.051; Heister D, 2011, NEUROLOGY, V77, P1619, DOI 10.1212/WNL.0b013e3182343314; Jack CR, 2008, J MAGN RESON IMAGING, V27, P685, DOI 10.1002/jmri.21049; Jatzko A, 2006, J AFFECT DISORDERS, V94, P121, DOI 10.1016/j.jad.2006.03.010; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Jovicich J, 2006, NEUROIMAGE, V30, P436, DOI 10.1016/j.neuroimage.2005.09.046; Jovicich J, 2009, NEUROIMAGE, V46, P177, DOI 10.1016/j.neuroimage.2009.02.010; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kovacevic S, 2009, ALZ DIS ASSOC DIS, V23, P139, DOI 10.1097/WAD.0b013e318192e745; McEvoy Linda K, 2012, Imaging Med, V4, P343; McEvoy LK, 2010, EXPERT REV NEUROTHER, V10, P1675, DOI [10.1586/ern.10.162, 10.1586/ERN.10.162]; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Morey RA, 2010, HUM BRAIN MAPP, V31, P1751, DOI 10.1002/hbm.20973; Morey RA, 2009, NEUROIMAGE, V45, P855, DOI 10.1016/j.neuroimage.2008.12.033; Mulder ER, 2014, NEUROIMAGE, V92, P169, DOI 10.1016/j.neuroimage.2014.01.058; Olejnik S, 2000, CONTEMP EDUC PSYCHOL, V25, P241, DOI 10.1006/ceps.2000.1040; Petersen RC, 2010, NEUROLOGY, V74, P201, DOI 10.1212/WNL.0b013e3181cb3e25; Ross DE, 2015, J NEUROPSYCH CLIN N, V27, P147, DOI 10.1176/appi.neuropsych.13040088; Ross DE, 2014, NEUROIMAGE, V102, P565, DOI 10.1016/j.neuroimage.2014.07.043; Ross DE, 2013, PSYCHOL INJ LAW, V6, P75, DOI 10.1007/s12207-012-9140-9; Ross DE, 2013, BRAIN INJURY, V27, P634, DOI 10.3109/02699052.2013.767939; Ross DE, 2012, BRAIN INJURY, V26, P1500, DOI 10.3109/02699052.2012.694570; Ross DE, 2013, J NEUROPSYCHIATRY CL, V25, P1, DOI DOI 10.1176/appi.neuropsych.12120401; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Stein JL, 2012, NAT GENET, V44, P552, DOI 10.1038/ng.2250; Testa C, 2004, J MAGN RESON IMAGING, V19, P274, DOI 10.1002/jmri.20001; Voets NL, 2008, NEUROIMAGE, V43, P665, DOI 10.1016/j.neuroimage.2008.08.013; Weiner MW, 2010, ALZHEIMERS DEMENT, V6, P202, DOI 10.1016/j.jalz.2010.03.007; Wonderlick JS, 2009, NEUROIMAGE, V44, P1324, DOI 10.1016/j.neuroimage.2008.10.037	46	32	32	1	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1051-2284	1552-6569		J NEUROIMAGING	J. Neuroimaging	SEP-OCT	2015	25	5					721	727		10.1111/jon.12229			7	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	CP3MO	WOS:000359783900004	25727700				2021-06-18	
J	Pavey, GJ; Qureshi, AT; Hope, DN; Pavlicek, RL; Potter, BK; Forsberg, JA; Davis, TA				Pavey, Gabriel J.; Qureshi, Ammar T.; Hope, Donald N.; Pavlicek, Rebecca L.; Potter, Benjamin K.; Forsberg, Jonathan A.; Davis, Thomas A.			Bioburden Increases Heterotopic Ossification Formation in an Established Rat Model	CLINICAL ORTHOPAEDICS AND RELATED RESEARCH			English	Article							COMBAT-RELATED AMPUTATIONS; TRAUMATIC BRAIN-INJURY; TOLL-LIKE RECEPTORS; ACINETOBACTER-BAUMANNII; OSTEOMYELITIS; EXPRESSION; PERSONNEL; WOUNDS; PREVALENCE; FRACTURES	Background Heterotopic ossification (HO) develops in a majority of combat-related amputations wherein early bacterial colonization has been considered a potential early risk factor. Our group has recently developed a small animal model of trauma-induced HO that incorporates many of the multifaceted injury patterns of combat trauma in the absence of bacterial contamination and subsequent wound colonization. Questions/purposes We sought to determine if (1) the presence of bioburden (Acinetobacter baumannii and methicillin-resistant Staphylococcus aureus [MRSA]) increases the magnitude of ectopic bone formation in traumatized muscle after amputation; and (2) what persistent effects bacterial contamination has on late microbial flora within the amputation site. Methods Using a blast-related HO model, we exposed 48 rats to blast overpressure, femur fracture, crush injury, and subsequent immediate transfemoral amputation through the zone of injury. Control injured rats (n = 8) were inoculated beneath the myodesis with phosphate-buffered saline not containing bacteria (vehicle) and treatment rats were inoculated with 1 x 10(6) colony-forming units of A baumannii (n = 20) or MRSA (n = 20). All animals formed HO. Heterotopic ossification was determined by quantitative volumetric measurements of ectopic bone at 12-weeks postinjury using micro-CT and qualitative histomorphometry for assessment of new bone formation in the residual limb. Bone marrow and muscle tissue biopsies were collected from the residual limb at 12 weeks to quantitatively measure the bioburden load and to qualitatively determine the species-level identification of the bacterial flora. Results At 12 weeks, we observed a greater volume of HO in rats infected with MRSA (68.9 +/- 8.6 mm(3); 95% confidence interval [CI], 50.52-85.55) when compared with A baumannii (20.9 +/- 3.7 mm(3); 95% CI, 13.61-28.14; p < 0.001) or vehicle (16.3 +/- 3.2 mm(3); 95% CI, 10.06-22.47; p < 0.001). Soft tissue and marrow from the residual limb of rats inoculated with A baumannii tested negative for A baumannii infection but were positive for other strains of bacteria (1.33 x 10(2) +/- 0.89 x 10(2); 95% CI,-0.42 x 10(2)-3.08 x 10(2) and 1.25 x 10(6) +/- 0.69 x 10(6); 95% CI,-0.13 x 10(6)-2.60 x 10(6) colony-forming units in bone marrow and muscle tissue, respectively), whereas tissue from MRSA-infected rats contained MRSA only (4.84 x 10(1) +/- 3.22 x 10(1); 95% CI,-1.47 x 10(1)-11.1 x 10(1) and 2.80 x 10(7) +/- 1.73 x 10(7); 95% CI, -0.60 x 10(7)-6.20 x 10(7) in bone marrow and muscle tissue, respectively). Conclusions Our findings demonstrate that persistent infection with MRSA results in a greater volume of ectopic bone formation, which may be the result of chronic soft tissue inflammation, and that early wound colonization may be a key risk factor.	[Pavey, Gabriel J.; Qureshi, Ammar T.; Hope, Donald N.; Potter, Benjamin K.; Forsberg, Jonathan A.; Davis, Thomas A.] Naval Med Res Ctr, Regenerat Med Dept, Silver Spring, MD 20910 USA; [Pavey, Gabriel J.; Hope, Donald N.; Potter, Benjamin K.; Forsberg, Jonathan A.] Walter Reed Natl Mil Med Ctr, Dept Orthopaed, Bethesda, MD USA; [Pavlicek, Rebecca L.] Naval Med Res Ctr, Dept Wound Infect, Silver Spring, MD 20910 USA; [Potter, Benjamin K.; Forsberg, Jonathan A.; Davis, Thomas A.] Uniformed Serv Univ Hlth Sci, Dept Surg, Bethesda, MD 20814 USA	Davis, TA (corresponding author), Naval Med Res Ctr, Regenerat Med Dept, 503 Robert Grant Ave, Silver Spring, MD 20910 USA.	thomas.davis1@med.navy.mil	Potter, Benjamin/U-1769-2019	Potter, MD, Benjamin K./0000-0002-8771-0317; Pavlicek, Rebecca/0000-0002-7109-9576	USAMRAA BAA [10083004]; USAMRAA PRORP-CDMRP [120056]	This work was supported by USAMRAA BAA #10083004 (Principal Investigator JAF) and USAMRAA PRORP-CDMRP #120056 (Principal Investigator JAF).	Ahlers Stephen Thomas, 2012, Front Neurol, V3, P32, DOI 10.3389/fneur.2012.00032; Be NA, 2014, J CLIN MICROBIOL, V52, P2583, DOI 10.1128/JCM.00556-14; Brown KV, 2010, J TRAUMA, V69, pS116, DOI 10.1097/TA.0b013e3181e44cc7; Burns TC, 2012, J TRAUMA ACUTE CARE, V72, P1062, DOI 10.1097/TA.0b013e318241f534; Cadosch D, 2010, J BONE JOINT SURG AM, V92A, P645, DOI 10.2106/JBJS.I.00097; Calhoun JH, 2008, CLIN ORTHOP RELAT R, V466, P1356, DOI 10.1007/s11999-008-0212-9; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; Cipriano CA, 2009, J AM ACAD ORTHOP SUR, V17, P689, DOI 10.5435/00124635-200911000-00003; Collinet-Adler S, 2011, CLIN ORTHOP RELAT R, V469, P274, DOI 10.1007/s11999-010-1488-0; Davis TA, 2013, BONE, V56, P119, DOI 10.1016/j.bone.2013.05.016; Evans KN, 2014, CLIN ORTHOP RELAT R, V472, P396, DOI 10.1007/s11999-013-3325-8; Forsberg JA, 2014, CLIN ORTHOP RELAT R, V472, P1; Forsberg Jonathan Agner, 2010, J Surg Orthop Adv, V19, P54; Forsberg JA, 2009, J BONE JOINT SURG AM, V91A, P1084, DOI 10.2106/JBJS.H.00792; GARLAND DE, 1988, CLIN ORTHOP RELAT R, P86; Hospenthal DR, 2011, J TRAUMA, V71, pS52, DOI 10.1097/TA.0b013e31822118fb; Johnson EN, 2007, CLIN INFECT DIS, V45, P409, DOI 10.1086/520029; Jones Kevin B, 2004, Iowa Orthop J, V24, P123; Mo IFY, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-52; Murray CK, 2005, CURR OPIN INFECT DIS, V18, P502, DOI 10.1097/01.qco.0000185985.64759.41; Murray CK, 2008, J TRAUMA, V64, pS239, DOI 10.1097/TA.0b013e318163cd14; Murray CK, 2008, J TRAUMA, V64, pS221, DOI 10.1097/TA.0b013e318163c40b; Murray CK, 2006, MIL MED, V171, P826, DOI 10.7205/MILMED.171.9.826; Pevsner-Fischer M, 2007, BLOOD, V109, P1422, DOI 10.1182/blood-2006-06-028704; Polfer EM, 2015, BONE JOINT J, P97; Potter BK, 2007, J BONE JOINT SURG AM, V89A, P476, DOI 10.2106/JBJS.F.00412; Salisbury E, 2011, J CELL BIOCHEM, V112, P2748, DOI 10.1002/jcb.23225; Sheppard FR, 2010, AM J SURG, V200, P489, DOI 10.1016/j.amjsurg.2010.03.001; Thompson MG, 2014, ANTIMICROB AGENTS CH, V58, P1332, DOI 10.1128/AAC.01944-13; Tintle SM, 2014, J ORTHOP TRAUMA, V28, P232, DOI 10.1097/BOT.0b013e3182a53130; Uematsu S, 2008, TOLL LIKE RECEPTORS, P240; Yin LY, 2013, MIL MED, V178, P696, DOI 10.7205/MILMED-D-12-00550; Yun HC, 2008, J TRAUMA, V64, pS163, DOI 10.1097/TA.0b013e318160868c	33	32	33	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0009-921X	1528-1132		CLIN ORTHOP RELAT R	Clin. Orthop. Rel. Res.	SEP	2015	473	9					2840	2847		10.1007/s11999-015-4272-3			8	Orthopedics; Surgery	Orthopedics; Surgery	CO1TA	WOS:000358936900017	25822455	Green Published			2021-06-18	
J	Weaver, LC; Bao, F; Dekaban, GA; Hryciw, T; Shultz, SR; Cain, DP; Brown, A				Weaver, Lynne C.; Bao, Feng; Dekaban, Gregory A.; Hryciw, Todd; Shultz, Sandy R.; Cain, Donald P.; Brown, Arthur			CD11d integrin blockade reduces the systemic inflammatory response syndrome after traumatic brain injury in rats	EXPERIMENTAL NEUROLOGY			English	Article						Traumatic brain injury; Systemic inflammatory response; Lung damage; Anti-integrin treatment; Lung	SPINAL-CORD-INJURY; ACUTE LUNG INJURY; ACUTE-PHASE RESPONSE; TRANSCRIPTION FACTOR NRF2; FLUID PERCUSSION INJURY; LEUKOCYTE MOBILIZATION; ORGAN DYSFUNCTION; ALPHA-D; PROTEIN; EXPRESSION	Traumatic CNS injury triggers a systemic inflammatory response syndrome (SIRS), in which circulating inflammatory cells invade body organs causing local inflammation and tissue damage. We have shown that the SIRS caused by spinal cord injury is greatly reduced by acute intravenous treatment with an antibody against the CD11d subunit of the CD11d/CD18 integrin expressed by neutrophils and monocyte/macrophages, a treatment that reduces their efflux from the circulation. Traumatic brain injury (TBI) is a frequently occurring injury after motor vehicle accidents, sporting and military injuries, and falls. Our studies have shown that the anti-CD11d treatment diminishes brain inflammation and oxidative injury after moderate or mild TB!, improving neurological outcomes. Accordingly, we examined the impact of this treatment on the SIRS triggered by TBI. The anti-CD11d treatment was given at 2 h after a single moderate (2.5-3.0 atm) or 2 and 24 h after each of three consecutive mild (1.0-1.5 atm) fluid percussion TBIs. Sham-injured, saline-treated rats served as controls. At 24 h, 72 h, and 4 or 8 weeks after the single TBI and after the third of three TBIs, lungs of rats were examined histochemically, immunocytochemically and biochemically for downstream effects of SIRS including inflammation, tissue damage and expression of oxidative enzymes. Lung sections revealed that both the single moderate and repeated mild TBI caused alveolar disruption, thickening of inter-alveolar tissue, hemorrhage into the parenchyma and increased density of intra-and pen-alveolar macrophages. The anti-CD11d treatment decreased the intrapulmonary influx of neutrophils and the density of activated macrophages and the activity of myeloperoxidase after these TBIs. Moreover, Western blotting studies showed that the treatment decreased lung protein levels of oxidative enzymes gp91(Phox), inducible nitric oxide synthase and cyclooxygenase-2, as well as the apoptotic pathway enzyme caspase-3 and levels of 4-hydroxynonenal-bound proteins (an indicator of lipid peroxidation). Decreased expression of the cytoprotective transcription factor Nrf2 reflected decreased lung oxidative stress. Anti-CD11d treatment also diminished the lung concentration of free radicals and tissue aldehydes. In conclusion, the substantial lung component of the SIRS after single or repeated TBIs is significantly decreased by a simple, minimally invasive and short-lasting anti-inflammatory treatment. (C) 2015 Elsevier Inc. All rights reserved.	[Weaver, Lynne C.; Bao, Feng; Dekaban, Gregory A.; Hryciw, Todd; Brown, Arthur] Univ Western Ontario, Robarts Res Inst, Spinal Cord Injury Team, Mol Med, London, ON N6A 5B7, Canada; [Shultz, Sandy R.; Cain, Donald P.; Brown, Arthur] Univ Western Ontario, Program Neurosci, London, ON N6A 5B7, Canada; [Weaver, Lynne C.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5B7, Canada; [Brown, Arthur] Univ Western Ontario, Dept Anat & Cell Biol, London, ON N6A 5B7, Canada; [Dekaban, Gregory A.] Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 5B7, Canada; [Shultz, Sandy R.; Cain, Donald P.] Univ Western Ontario, Dept Psychol, London, ON N6A 5B7, Canada	Weaver, LC (corresponding author), Univ Western Ontario, Robarts Res Inst, Spinal Cord Injury Team, Mol Med, 1151 Richmond St N, London, ON N6A 5B7, Canada.	lcweaver@robarts.ca	Weaver, Lynne C/K-8491-2013; Brown, Arthur/K-8328-2013; Dekaban, Gregory A./L-1987-2013	Brown, Arthur/0000-0002-8725-3195; Dekaban, Gregory A./0000-0002-3087-4660	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC)	This research was supported by grants from the Canadian Institutes of Health Research (CIHR) (LW and AB) and the Natural Sciences and Engineering Research Council of Canada (NSERC) (DPC). The authors thank Eli Lilly and Company for donating the anti-CD11d mAb (217L) and isotype matched control mAb (1B7) and Dr. Kathy Xu for her contributions to some of the experiments. We appreciate the critical editing of this manuscript by Dr. Canio Polosa.	Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Anthony D, 1998, CURR BIOL, V8, P923, DOI 10.1016/S0960-9822(07)00373-9; BAIGELMAN W, 1981, NEUROSURGERY, V9, P729, DOI 10.1227/00006123-198112000-00021; Bao F, 2005, J NEUROCHEM, V94, P1361, DOI 10.1111/j.1471-4159.2005.03280.x; Bao F, 2004, J NEUROCHEM, V88, P1335, DOI 10.1046/j.1471-4159.2003.02240.x; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Bao F, 2012, J NEUROTRAUM, V29, P1626, DOI 10.1089/neu.2011.2190; Bao F, 2011, EXP NEUROL, V231, P272, DOI 10.1016/j.expneurol.2011.07.001; Baskaran H, 2000, J SURG RES, V93, P88, DOI 10.1006/jsre.2000.5955; Bhatia RK, 2005, INJURY, V36, P956, DOI 10.1016/j.injury.2005.03.009; Campbell SJ, 2003, FASEB J, V17, P1168, DOI 10.1096/fj.02-0757fje; Campbell SJ, 2005, AM J PATHOL, V166, P1487, DOI 10.1016/S0002-9440(10)62365-6; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Cho HY, 2004, FASEB J, V18, P1258; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; Dinkova-Kostova AT, 2005, BIOCHEMISTRY-US, V44, P6889, DOI 10.1021/bi047434h; FAN L, 1995, MOL BRAIN RES, V30, P125; FEUERSTEIN GZ, 1994, CEREBROVAS BRAIN MET, V6, P341; Fleming JC, 2008, EXP NEUROL, V214, P147, DOI 10.1016/j.expneurol.2008.04.024; Gabay C, 1999, NEW ENGL J MED, V340, P448, DOI 10.1056/NEJM199902113400607; Galea J, 2013, J INFLAMM RES, V6, P121, DOI 10.2147/JIR.S35629; Glantz S. A., 2012, PRIMER BIOSTATISTICS; Grayson MH, 1998, J EXP MED, V188, P2187, DOI 10.1084/jem.188.11.2187; Gris D, 2004, J NEUROSCI, V24, P4043, DOI 10.1523/JNEUROSCI.5343-03.2004; Gris D, 2008, EXP NEUROL, V211, P259, DOI 10.1016/j.expneurol.2008.01.033; Gris P, 2009, J NEUROIMMUNOL, V209, P104, DOI 10.1016/j.jneuroim.2009.02.002; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Hopkins RO, 2006, BRAIN INJURY, V20, P263, DOI 10.1080/02699050500488199; Kalsotra A, 2003, J NEUROTRAUM, V20, P1339, DOI 10.1089/089771503322686139; Kalsotra A, 2007, J CEREBR BLOOD F MET, V27, P963, DOI 10.1038/sj.jcbfm.9600396; Kemp CD, 2008, AM SURGEON, V74, P866; Koj A, 1996, BBA-MOL BASIS DIS, V1317, P84, DOI 10.1016/S0925-4439(96)00048-8; KUSHNER I, 1993, PERSPECT BIOL MED, V36, P611; Kyono W, 2002, PEDIATR CLIN N AM, V49, P929, DOI 10.1016/S0031-3955(02)00030-5; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Lou MQ, 2013, CLIN NEUROL NEUROSUR, V115, P904, DOI 10.1016/j.clineuro.2012.09.001; Marzec JM, 2007, FASEB J, V21, P2237, DOI 10.1096/fj.06-7759com; Mochizuki M, 2005, AM J RESP CRIT CARE, V171, P1260, DOI 10.1164/rccm.200406-755OC; Oatway MA, 2005, J NEUROSCI, V25, P637, DOI 10.1523/JNEUROSCI.3960-04.2005; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Pelosi P, 2011, CRIT CARE, V15, DOI 10.1186/cc10259; Pillay NS, 2007, BRAIN RES, V1153, P158, DOI 10.1016/j.brainres.2007.03.056; Rincon F, 2012, NEUROSURGERY, V71, P795, DOI 10.1227/NEU.0b013e3182672ae5; Ryugo M, 2006, SURG TODAY, V36, P321, DOI 10.1007/s00595-005-3160-y; Sauerbeck AD, 2015, J NEUROTRAUM, V32, P159, DOI 10.1089/neu.2014.3497; Shanley TP, 1998, J IMMUNOL, V160, P1014; Shojo H, 2006, BRAIN RES, V1078, P198, DOI 10.1016/j.brainres.2006.01.063; Shultz SR, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-26; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Snedecor G.W., 1989, STAT METHODS, V8th; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Tsitsopoulos PP, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00079; Utagawa A, 2008, BRAIN RES, V1207, P155, DOI 10.1016/j.brainres.2008.02.057; Van der Vieren M, 1999, J IMMUNOL, V163, P1984; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; Vermeij JD, 2013, J NEUROTRAUM, V30, P2073, DOI 10.1089/neu.2013.3060; Wilcockson DC, 2002, J CEREBR BLOOD F MET, V22, P318, DOI 10.1097/00004647-200203000-00009; Yan W, 2008, BRAIN INJURY, V22, P802, DOI 10.1080/02699050802372174	62	32	32	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	SEP	2015	271						409	422		10.1016/j.expneurol.2015.07.003			14	Neurosciences	Neurosciences & Neurology	CT2JG	WOS:000362627200042	26169930	Green Accepted			2021-06-18	
J	Elliott, TR; Hsiao, YY; Kimbrel, NA; Meyer, EC; DeBeer, BB; Gulliver, SB; Kwok, OM; Morissette, SB				Elliott, Timothy R.; Hsiao, Yu-Yu; Kimbrel, Nathan A.; Meyer, Eric C.; DeBeer, Bryann B.; Gulliver, Suzy Bird; Kwok, Oi-Man; Morissette, Sandra B.			Resilience, Traumatic Brain Injury, Depression, and Posttraumatic Stress Among Iraq/Afghanistan War Veterans	REHABILITATION PSYCHOLOGY			English	Article						resilience; PTSD; depression; combat exposure; traumatic brain injury	ACTION QUESTIONNAIRE-II; MENTAL-HEALTH PROBLEMS; POSITIVE EMOTIONS; PSYCHOMETRIC PROPERTIES; PSYCHOLOGICAL RESILIENCE; EXPERIENTIAL AVOIDANCE; DEPLOYMENT RISK; SERVICE MEMBERS; PTSD CHECKLIST; SOCIAL SUPPORT	Objective: We examined the prospective influence of the resilient, undercontrolled, and overcontrolled personality prototypes on depression and posttraumatic stress disorder (PTSD) symptoms among Iraq/Afghanistan war veterans. After accounting for the possible influence of combat exposure, we expected that the resilient prototype would predict lower depression and PTSD over time and would be associated with adaptive coping strategies, higher social support, lower psychological inflexibility, and higher self-reported resilience relative to overcontrolled and undercontrolled prototypes, independent of traumatic brain injury (TBI) status. Method: One hundred twenty-seven veterans (107 men, 20 women; average age = 37) participated in the study. Personality was assessed at baseline, and PTSD and depression symptoms were assessed 8 months later. Path analysis was used to test the direct and indirect effects of personality on distress. Results: No direct effects were observed from personality to distress. The resilient prototype did have significant indirect effects on PTSD and depression through its beneficial effects on social support, coping and psychological inflexibility. TBI also had direct effects on PTSD. Conclusions: A resilient personality prototype appears to influence veteran adjustment through its positive associations with greater social support and psychological flexibility, and lower use of avoidant coping. Low social support, avoidant coping, and psychological inflexibility are related to overcontrolled and undercontrolled personality prototypes, and these behaviors seem to characterize veterans who experience problems with depression and PTSD over time. A positive TBI status is directly and prospectively associated with PTSD symptomology independent of personality prototype. Implications for clinical interventions and future research are discussed.	[Elliott, Timothy R.; Hsiao, Yu-Yu; Kwok, Oi-Man] Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77843 USA; [Kimbrel, Nathan A.] Durham Vet Affairs Med Ctr, Durham, NC USA; [Kimbrel, Nathan A.] Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27706 USA; [Meyer, Eric C.; DeBeer, Bryann B.; Morissette, Sandra B.] Cent Texas Vet HealthCare Syst, VA VISN Ctr Excellence Res Returning War Vet 17, Waco, TX USA; [Meyer, Eric C.; DeBeer, Bryann B.; Gulliver, Suzy Bird; Morissette, Sandra B.] Texas A&M Univ, Coll Med, Dept Psychiat, College Stn, TX 77843 USA; [Gulliver, Suzy Bird] Baylor Scott & White Hlth, Warriors Res Inst, Waco, TX USA	Elliott, TR (corresponding author), Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77843 USA.	telliott@tamu.edu	Elliott, Timothy R./I-5301-2012; Kimbrel, Nathan/P-3109-2016; Gulliver, Suzy/X-9776-2019	Elliott, Timothy R./0000-0002-6608-7714; Kimbrel, Nathan/0000-0001-7218-1005; Gulliver, Suzy Bird/0000-0002-6476-9447; Kwok, Oiman/0000-0002-4617-4562	Veterans Health AdministrationUS Department of Veterans Affairs; Veterans AffairsUS Department of Veterans Affairs [I01RX000304, IK2CX000525] Funding Source: NIH RePORTER	This work was completed with support from the Veterans Health Administration. The views are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.	Aldenderfer M.S., 1984, CLUSTER ANAL; Armed Forces Health Surveillance Center, 2011, DOD NUMB TRAUM BRAIN; Bahraini NH, 2014, PSYCHIAT CLIN N AM, V37, P55, DOI 10.1016/j.psc.2013.11.002; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Belanger HG, 2013, CLIN NEUROPSYCHOL, V27, P159, DOI 10.1080/13854046.2012.758780; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Berking M, 2009, BEHAV RES THER, V47, P663, DOI 10.1016/j.brat.2009.04.011; Berry JW, 2007, J PERS ASSESS, V89, P292, DOI 10.1080/00223890701629813; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Block J., 1993, STUDYING LIVES TIME, P9, DOI DOI 10.1037/10127-018; Block J. H., 1980, MINNESOTA S CHILD PS, V13, P39; Bonanno GA, 2005, CURR DIR PSYCHOL SCI, V14, P135, DOI 10.1111/j.0963-7214.2005.00347.x; Bonanno GA, 2012, BRIT J PSYCHIAT, V200, P317, DOI 10.1192/bjp.bp.111.096552; Bond FW, 2011, BEHAV THER, V42, P676, DOI 10.1016/j.beth.2011.03.007; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Browne M. W., 1992, SOCIOL METHOD RES, V21, P136; Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; CASPI A, 1995, CHILD DEV, V66, P486, DOI 10.1111/j.1467-8624.1995.tb00885.x; Chapman BP, 2011, J PERS SOC PSYCHOL, V101, P593, DOI 10.1037/a0024289; Clarke G N, 2000, Ment Health Serv Res, V2, P155, DOI 10.1023/A:1010141826867; Cohn MA, 2009, EMOTION, V9, P361, DOI 10.1037/a0015952; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Craig T., 2004, J MENTAL HLTH, V13, P59, DOI DOI 10.1080/09638230410001654567; Davydov DM, 2010, CLIN PSYCHOL REV, V30, P479, DOI 10.1016/j.cpr.2010.03.003; DeBeer BB, 2014, PSYCHIAT RES, V216, P357, DOI 10.1016/j.psychres.2014.02.010; Denissen JJA, 2008, J PERS, V76, P67, DOI 10.1111/j.1467-6494.2007.00480.x; Dolan S, 2012, NEUROPSYCHOL REV, V22, P21, DOI 10.1007/s11065-012-9190-5; Fletcher D, 2013, EUR PSYCHOL, V18, P12, DOI 10.1027/1016-9040/a000124; Forbes D, 2001, BEHAV RES THER, V39, P977, DOI 10.1016/S0005-7967(00)00084-X; Fredrickson BL, 2008, J PERS SOC PSYCHOL, V95, P1045, DOI 10.1037/a0013262; Fredrickson BL, 2013, ADV EXP SOC PSYCHOL, V47, P1, DOI 10.1016/B978-0-12-407236-7.00001-2; Fredrickson BL, 2003, J PERS SOC PSYCHOL, V84, P365, DOI 10.1037/0022-3514.84.2.365; Fulton JJ, 2015, J ANXIETY DISORD, V31, P98, DOI 10.1016/j.janxdis.2015.02.003; Grosso JA, 2014, J TRAUMA STRESS, V27, P478, DOI 10.1002/jts.21943; Hayes SA, 2010, BEHAV RES THER, V48, P238, DOI 10.1016/j.brat.2009.11.006; Hayes SC, 2004, PSYCHOL REC, V54, P553, DOI 10.1007/BF03395492; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Holahan CJ, 2005, J CONSULT CLIN PSYCH, V73, P658, DOI 10.1037/0022-006X.73.4.658; Hoyt WT, 2008, REHABIL PSYCHOL, V53, P321, DOI 10.1037/a0013021; Hu LT, 1999, STRUCT EQU MODELING, V6, P1, DOI 10.1080/10705519909540118; Keen SM, 2008, J REHABIL RES DEV, V45, P465, DOI 10.1682/JRRD.2007.09.0138; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Kok BE, 2013, PSYCHOL SCI, V24, P1123, DOI 10.1177/0956797612470827; Kok BE, 2010, BIOL PSYCHOL, V85, P432, DOI 10.1016/j.biopsycho.2010.09.005; Kumpula MJ, 2011, J ABNORM PSYCHOL, V120, P617, DOI 10.1037/a0023927; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Letzring TD, 2005, J RES PERS, V39, P395, DOI 10.1016/j.jrp.2004.06.003; Liverant GI, 2012, J CONSULT CLIN PSYCH, V80, P957, DOI 10.1037/a0030485; Mancini A.D., 2010, HDB ADULT RESILIENCE, P258; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; Meyer EC, 2013, PSYCHOL TRAUMA-US, V5, P521, DOI 10.1037/a0030178; Miller M. W., 2011, RESILIENCE MENTAL HL, P56; Miller MW, 2003, PSYCHOL ASSESSMENT, V15, P205, DOI 10.1037/1040-3590.15.2.205; Min SY, 2007, PSYCHIATR REHABIL J, V30, P207, DOI 10.2975/30.3.2007.207.213; Morissette SB, 2011, REHABIL PSYCHOL, V56, P340, DOI 10.1037/a0025462; Muthen L.K., 1998, MPLUS USERS GUIDE, V8th; Ong AD, 2010, PSYCHOL AGING, V25, P516, DOI 10.1037/a0019384; Ong AD, 2009, J PERS, V77, P1777, DOI 10.1111/j.1467-6494.2009.00600.x; Patrick CJ, 2002, PSYCHOL ASSESSMENT, V14, P150, DOI 10.1037//1040-3590.14.2.150; Pietrzak RH, 2011, J PSYCHIATR RES, V45, P720, DOI 10.1016/j.jpsychires.2010.11.015; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; Rauch SAM, 2009, J TRAUMA STRESS, V22, P60, DOI 10.1002/jts.20380; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Seal KH, 2007, ARCH INTERN MED, V167, P476, DOI 10.1001/archinte.167.5.476; Sharma S., 1996, APPL MULTIVARIATE TE, V1st ed.; Shiner RL, 2003, J PERS, V71, P1145, DOI 10.1111/1467-6494.7106010; Steca P, 2010, PERS INDIV DIFFER, V48, P442, DOI 10.1016/j.paid.2009.11.016; Tellegen A., 2008, SAGE HDB PERSONALITY, V2, P261; Thomas JL, 2010, ARCH GEN PSYCHIAT, V67, P614, DOI 10.1001/archgenpsychiatry.2010.54; Tsai J, 2012, PSYCHIATRY, V75, P135, DOI 10.1521/psyc.2012.75.2.135; Vasterling J. J., 2012, PTSD MILD TRAUMATIC, P3; Vasterling JJ, 2012, J INT NEUROPSYCH SOC, V18, P390, DOI 10.1017/S1355617712000367; Vogt DS, 2008, ASSESSMENT, V15, P381, DOI 10.1177/1073191108316030; Walser RD, 2013, BEHAV RES THER, V51, P555, DOI 10.1016/j.brat.2013.05.009; Weathers F. W., 1993, ANN M INT SOC TRAUM; Windle G, 2012, SOCIAL ECOLOGY OF RESILIENCE: A HANDBOOK OF THEORY AND PRACTICE, P219, DOI 10.1007/978-1-4614-0586-3_18; Windle G, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-8; Wolf EJ, 2012, J ABNORM PSYCHOL, V121, P256, DOI 10.1037/a0023237; Yu C. Y., 2002, EVALUATING CUTOFF CR	83	32	33	0	39	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2015	60	3					263	276		10.1037/rep0000050			14	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	CR0UB	WOS:000361037600007	26214528	Green Accepted			2021-06-18	
J	Sarkaki, A; Farbood, Y; Gharib-Naseri, MK; Badavi, M; Mansouri, MT; Haghparast, A; Mirshekar, MA				Sarkaki, Alireza; Farbood, Yaghoub; Gharib-Naseri, Mohammad Kazem; Badavi, Mohammad; Mansouri, Mohammad Taghi; Haghparast, Abbas; Mirshekar, Mohammad Ali			Gallic acid improved behavior, brain electrophysiology, and inflammation in a rat model of traumatic brain injury	CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY			English	Article						traumatic brain injury; gallic acid; memory; long-term potentiation; cerebral cytokines; rat	LONG-TERM POTENTIATION; NECROSIS-FACTOR-ALPHA; MESSENGER-RNA; PROGESTERONE; EXPRESSION; APOPTOSIS; CYTOKINES; CELLS; CALCIUM; DAMAGE	Traumatic brain injury (TBI) is one of the main causes of intellectual and cognitive disabilities. In the clinic it is essential to limit the development of cognitive impairment after TBI. In this study, the effects of gallic acid (GA; 100 mg/kg, per oral, from 7 days before to 2 days after TBI induction) on neurological score, passive avoidance memory, long-term potentiation (LTP) deficits, and levels of proinflammatory cytokines including interleukin-1 beta (IL-1 beta), interleukin 6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in the brain have been evaluated. Brain injury was induced following Marmarou's method. Data were analyzed by one-way and repeated measures ANOVA followed by Tukey's post-hoc test. The results indicated that memory was significantly impaired (p < 0.001) in the group treated with TBI + vehicle, together with deterioration of the hippocampal LTP and increased brain tissue levels of IL-1 beta, IL-6, and TNF-alpha. GA treatment significantly improved memory and LTP in the TBI rats. The brain tissue levels of IL-1 beta, IL-6, and TNF-alpha were significantly reduced (p < 0.001) in the group treated with GA. The results suggest that GA has neuroprotective properties against TBI-induced behavioral, electrophysiological, and inflammatory disorders, probably via the decrease of cerebral proinflammatory cytokines.	[Sarkaki, Alireza; Farbood, Yaghoub; Gharib-Naseri, Mohammad Kazem; Badavi, Mohammad; Mansouri, Mohammad Taghi; Mirshekar, Mohammad Ali] Ahvaz Jundishapur Univ Med Sci, Ahvaz Physiol Res Ctr, Ahwaz 6135715794, Iran; [Sarkaki, Alireza; Farbood, Yaghoub; Badavi, Mohammad; Mirshekar, Mohammad Ali] Ahvaz Jundishapur Univ Med Sci, Dept Physiol, Sch Med, Ahwaz 6135715794, Iran; [Mansouri, Mohammad Taghi] Ahvaz Jundishapur Univ Med Sci, Dept Pharmacol, Sch Med, Ahwaz 6135715794, Iran; [Haghparast, Abbas] Shahid Beheshti Univ Med Sci, Neurosci Res Ctr, Tehran, Iran	Mirshekar, MA (corresponding author), Ahvaz Jundishapur Univ Med Sci, Dept Physiol, Golestan Blvd,POB 45, Ahwaz 6135715794, Iran.	ma_mib78@yahoo.com	Sarkaki, Alireza/Q-8363-2017; Badavi, Mohammad/C-1452-2013; Mirshekar, Mohammad Ali/S-4167-2017; Farbood, Yaghoob/M-3076-2017; Mansouri, Seyed Mohammad Taghi/F-3847-2014; Haghparast, Abbas/B-3023-2009	Sarkaki, Alireza/0000-0001-9272-6228; Badavi, Mohammad/0000-0003-2290-8565; Mirshekar, Mohammad Ali/0000-0002-0449-6440; Farbood, Yaghoob/0000-0002-6390-0079; Mansouri, Seyed Mohammad Taghi/0000-0002-7549-0708; Haghparast, Abbas/0000-0003-1084-180X	Ahvaz Jundishapur University of Medical Sciences, Physiology Research Center [APRC-146]	This article is part of Mohammad Ali Mirshekar's Ph.D. thesis. This project was supported financially by the Ahvaz Jundishapur University of Medical Sciences, Physiology Research Center (grant No. APRC-146). Conflict of interest: the authors declare that there is no conflict of interest associated with this study.	Albensi BC, 2000, EXP NEUROL, V162, P385, DOI 10.1006/exnr.1999.7338; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Butler MP, 2004, NEUROSCIENCE, V124, P319, DOI 10.1016/j.neuroscience.2003.11.040; Cai YZ, 2004, LIFE SCI, V74, P2157, DOI 10.1016/j.lfs.2003.09.047; Cavaglia M, 2001, BRAIN RES, V910, P81, DOI 10.1016/S0006-8993(01)02637-3; Chen G, 2008, ANN CLIN LAB SCI, V38, P65; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; COLLINGRIDGE GL, 1995, TRENDS NEUROSCI, V18, P54, DOI 10.1016/0166-2236(95)93868-X; Cunningham AJ, 1996, NEUROSCI LETT, V203, P17, DOI 10.1016/0304-3940(95)12252-4; Deadwyler SA, 1996, J NEUROSCI, V16, P354; del Zoppo GJ, 2000, THROMB RES, V98, pV73; DeVries HE, 1997, PHARMACOL REV, V49, P143; Dubal DB, 2001, ENDOCRINOLOGY, V142, P43, DOI 10.1210/en.142.1.43; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Farkas E, 2007, BRAIN RES REV, V54, P162, DOI 10.1016/j.brainresrev.2007.01.003; Faul M, 2010, TRAUMATIC BRAIN INJU, P2; Golan H, 2004, CEREB CORTEX, V14, P97, DOI 10.1093/cercor/bhg108; Greenberg G, 2008, ARCH PHYS MED REHAB, V89, pS45, DOI 10.1016/j.apmr.2008.08.211; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Holmin S, 2004, NEUROSCI LETT, V369, P108, DOI 10.1016/j.neulet.2004.07.044; INOUE M, 1995, BIOL PHARM BULL, V18, P1526; Isuzugawa K, 2001, BIOL PHARM BULL, V24, P1022, DOI 10.1248/bpb.24.1022; Jadon A, 2007, J ETHNOPHARMACOL, V109, P214, DOI 10.1016/j.jep.2006.07.033; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Kim YJ, 2007, BIOL PHARM BULL, V30, P1052, DOI 10.1248/bpb.30.1052; King DR, 2004, SURGERY, V136, P355, DOI 10.1016/j.surg.2004.05.011; Korani MS, 2014, EUR J PHARMACOL, V733, P62, DOI 10.1016/j.ejphar.2014.03.044; Kratz JM, 2008, MEM I OSWALDO CRUZ, V103, P437, DOI 10.1590/S0074-02762008000500005; Lashgari R, 2006, BEHAV BRAIN RES, V171, P324, DOI 10.1016/j.bbr.2006.04.013; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Mansouri MT, 2013, FOOD CHEM, V138, P1028, DOI 10.1016/j.foodchem.2012.11.022; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Montgomery SL, 2012, J NEUROIMMUNE PHARM, V7, P42, DOI 10.1007/s11481-011-9287-2; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Paxinos G., 2006, RAT BRAIN STEREOTAXI, P25; Qi FH, 2009, LETT APPL MICROBIOL, V49, P98, DOI 10.1111/j.1472-765X.2009.02626.x; Roohbakhsh A, 2007, CLIN EXP PHARMACOL P, V34, P223, DOI 10.1111/j.1440-1681.2007.04576.x; Rostworowski M, 1997, J NEUROSCI, V17, P3664; Sakaguchi N, 1998, BIOCHEM PHARMACOL, V55, P1973, DOI 10.1016/S0006-2952(98)00041-0; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Sarkaki AR, 2013, J NEUROTRAUM, V30, P47, DOI 10.1089/neu.2010.1686; Shahrzad S, 2001, J NUTR, V131, P1207; Sirota L, 2001, BIOL NEONATE, V79, P103, DOI 10.1159/000047075; Stein DG, 2008, ANN EMERG MED, V51, P164, DOI 10.1016/j.annemergmed.2007.05.001; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; TANCREDI V, 1992, NEUROSCI LETT, V146, P176, DOI 10.1016/0304-3940(92)90071-E; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; Trivedi MA, 2007, J NEUROTRAUM, V24, P766, DOI 10.1089/neu.2006.0205; Valizadeh Z, 2012, HEALTHMED, V6, P3648; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Williamson G, 2005, AM J CLIN NUTR, V81, p243S, DOI [10.1093/ajcn/81.1.230S, 10.1093/ajcn/81.1.243S]; Yaka R, 2007, FASEB J, V21, P2033, DOI 10.1096/fj.06-7856com; Yang HL, 2006, FOOD CHEM TOXICOL, V44, P1978, DOI 10.1016/j.fct.2006.06.027	58	32	33	0	13	CANADIAN SCIENCE PUBLISHING	OTTAWA	65 AURIGA DR, SUITE 203, OTTAWA, ON K2E 7W6, CANADA	0008-4212	1205-7541		CAN J PHYSIOL PHARM	Can. J. Physiol. Pharmacol.	AUG	2015	93	8					687	694		10.1139/cjpp-2014-0546			8	Pharmacology & Pharmacy; Physiology	Pharmacology & Pharmacy; Physiology	CO4XI	WOS:000359163800011	26222320				2021-06-18	
J	Lillis, KP; Wang, ZM; Mail, M; Zhao, GQ; Berdichevsky, Y; Bacskai, B; Staley, KJ				Lillis, Kyle P.; Wang, Zemin; Mail, Michelle; Zhao, Grace Q.; Berdichevsky, Yevgeny; Bacskai, Brian; Staley, Kevin J.			Evolution of Network Synchronization during Early Epileptogenesis Parallels Synaptic Circuit Alterations	JOURNAL OF NEUROSCIENCE			English	Article						calcium imaging; homeostasis; network; two-photon	EPILEPTIFORM ACTIVITY; PYRAMIDAL CELLS; POSTTRAUMATIC EPILEPTOGENESIS; OPTICAL ELECTROPHYSIOLOGY; FUNCTIONAL CONNECTIVITY; TEMPORAL LOBECTOMY; WEIGHTED NETWORKS; INTERICTAL SPIKES; DENTATE GYRUS; CULTURE MODEL	In secondary epilepsy, a seizure-prone neural network evolves during the latent period between brain injury and the onset of spontaneous seizures. The nature of the evolution is largely unknown, and even its completeness at the onset of seizures has recently been challenged by measures of gradually decreasing intervals between subsequent seizures. Sequential calcium imaging of neuronal activity, in the pyramidal cell layer of mouse hippocampal in vitro preparations, during early post-traumatic epileptogenesis demonstrated rapid increases in the fraction of neurons that participate in interictal activity. This was followed by more gradual increases in the rate at which individual neurons join each developing seizure, the pairwise correlation of neuronal activities as a function of the distance separating the pair, and network-wide measures of functional connectivity. These data support the continued evolution of synaptic connectivity in epileptic networks beyond the latent period: early seizures occur when recurrent excitatory pathways are largely polysynaptic, while ongoing synaptic remodeling after the onset of epilepsy enhances intranetwork connectivity as well as the onset and spread of seizure activity.	[Lillis, Kyle P.; Wang, Zemin; Mail, Michelle; Bacskai, Brian; Staley, Kevin J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA; [Lillis, Kyle P.; Wang, Zemin; Mail, Michelle; Bacskai, Brian; Staley, Kevin J.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Zhao, Grace Q.] Stanford Univ, Dept Neurobiol, Stanford, CA 94305 USA; [Berdichevsky, Yevgeny] Lehigh Univ, Dept Elect & Comp Engn, Bethlehem, PA 18015 USA	Staley, KJ (corresponding author), 114 16th St,2600, Charlestown, MA 02129 USA.	staley.kevin@mgh.harvard.edu	wang, zemin/K-4088-2018; Bacskai, Brian/AAE-9583-2021	wang, zemin/0000-0002-8784-8105; Berdichevsky, Yevgeny/0000-0001-7539-601X; Lillis, Kyle/0000-0003-0219-8113	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS034700, NS074772, NS077908, EB000768]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB000768] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS045776, R01NS077908, R37NS077908, R01NS074772, R29NS034700, R01NS034700] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health grants NS034700, NS074772, and NS077908 (to K.S.), and EB000768 (to B.B.).	Albus K, 2013, J NEUROSCI METH, V217, P1, DOI 10.1016/j.jneumeth.2013.04.014; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Avanzini G, 2014, ADV EXP MED BIOL, V813, P95, DOI 10.1007/978-94-017-8914-1_8; Badea A, 2007, NEUROIMAGE, V37, P683, DOI 10.1016/j.neuroimage.2007.05.046; Bains JS, 1999, NAT NEUROSCI, V2, P720; Bausch SB, 2006, J NEUROPHYSIOL, V96, P2151, DOI 10.1152/jn.00355.2006; Berdichevsky Y, 2013, J NEUROSCI, V33, P9056, DOI 10.1523/JNEUROSCI.3870-12.2013; Berdichevsky Y, 2012, NEUROBIOL DIS, V45, P774, DOI 10.1016/j.nbd.2011.11.001; Berg AT, 2006, ANN NEUROL, V60, P73, DOI 10.1002/ana.20852; Bernhardt BC, 2013, NEUROLOGY, V81, P1840, DOI 10.1212/01.wnl.0000436069.20513.92; Bonifazi P, 2009, SCIENCE, V326, P1419, DOI 10.1126/science.1175509; Buckmaster PS, 1997, J COMP NEUROL, V385, P385; Bushong EA, 2004, INT J DEV NEUROSCI, V22, P73, DOI 10.1016/j.ijdevneu.2003.12.008; Buzsaki G, 2004, TRENDS NEUROSCI, V27, P186, DOI 10.1016/j.tins.2004.02.007; Cao G, 2013, CELL, V154, P904, DOI 10.1016/j.cell.2013.07.027; Clasadonte J, 2012, JASPERS BASIC MECH E, V4; Cohen R, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.058701; Dailey ME, 1996, J NEUROSCI, V16, P2983; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; De Simoni A, 2003, J PHYSIOL-LONDON, V550, P135, DOI 10.1113/jphysiol.2003.039099; DEBANNE D, 1995, J NEUROPHYSIOL, V73, P1282; Dwyer JM, 2013, BIOL PSYCHIAT, V73, P1189, DOI 10.1016/j.biopsych.2012.11.011; Dyhrfjeld-Johnsen J, 2010, J CLIN NEUROPHYSIOL, V27, P418, DOI 10.1097/WNP.0b013e3181fe0709; Dyhrfjeld-Johnsen J, 2007, J NEUROPHYSIOL, V97, P1566, DOI 10.1152/jn.00950.2006; ELWES RDC, 1988, BRIT MED J, V297, P948, DOI 10.1136/bmj.297.6654.948; Fawcett James W, 2012, Handb Clin Neurol, V109, P503, DOI 10.1016/B978-0-444-52137-8.00031-0; Feldt S, 2010, PHYS BIOL, V7, DOI 10.1088/1478-3975/7/4/046004; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Fisher RS, 2014, ADV EXP MED BIOL, V813, P3, DOI 10.1007/978-94-017-8914-1_1; FISHER RS, 1992, J CLIN NEUROPHYSIOL, V9, P441; FREEMAN LC, 1977, SOCIOMETRY, V40, P35, DOI 10.2307/3033543; GAHWILER BH, 1981, J NEUROSCI METH, V4, P329, DOI 10.1016/0165-0270(81)90003-0; GEIGER LR, 1978, ARCH NEUROL-CHICAGO, V35, P276, DOI 10.1001/archneur.1978.00500290022005; Glass HC, 2011, PEDIATR RES, V70, P535, DOI 10.1203/PDR.0b013e31822f24c7; Gleich DF, 2009, THESIS STANFORD U; Goldberg EM, 2013, NAT REV NEUROSCI, V14, P337, DOI 10.1038/nrn3482; GomezDiCesare CM, 1997, J COMP NEUROL, V384, P165, DOI 10.1002/(SICI)1096-9861(19970728)384:2<165::AID-CNE1>3.0.CO;2-#; Gutierrez R, 1999, BRAIN RES, V815, P304, DOI 10.1016/S0006-8993(98)01101-9; Hamilton LS, 2013, NEURON, V80, P1066, DOI 10.1016/j.neuron.2013.08.017; Heinrich C, 2011, NEUROBIOL DIS, V42, P35, DOI 10.1016/j.nbd.2011.01.001; Hellier JL, 2009, NEUROPHARMACOLOGY, V56, P414, DOI 10.1016/j.neuropharm.2008.09.009; Heng K, 2013, EPILEPSIA, V54, P1535, DOI 10.1111/epi.12246; Hochbaum DR, 2014, NAT METHODS, V11, P825, DOI [10.1038/NMETH.3000, 10.1038/nmeth.3000]; Houweling AR, 2005, CEREB CORTEX, V15, P834, DOI 10.1093/cercor/bhh184; Huberfeld G, 2011, NAT NEUROSCI, V14, P627, DOI 10.1038/nn.2790; Hutchison RM, 2013, NEUROIMAGE, V80, P360, DOI 10.1016/j.neuroimage.2013.05.079; Huusko N, 2015, BRAIN STRUCT FUNCT, V220, P153, DOI 10.1007/s00429-013-0644-1; Ikegaya Y, 2004, SCIENCE, V304, P559, DOI 10.1126/science.1093173; Jirsa VK, 2014, BRAIN, V137, P2210, DOI 10.1093/brain/awu133; Johnston MV, 2009, DEV DISABIL RES REV, V15, P94, DOI 10.1002/ddrr.64; Kavoi BM, 2011, INT J MORPHOL, V29, P939, DOI 10.4067/S0717-95022011000300047; Knickmeyer RC, 2008, J NEUROSCI, V28, P12176, DOI 10.1523/JNEUROSCI.3479-08.2008; Kramer MA, 2012, P NATL ACAD SCI USA, V109, P21116, DOI 10.1073/pnas.1210047110; LIEB JP, 1986, EPILEPSIA, V27, P286, DOI 10.1111/j.1528-1157.1986.tb03541.x; Lillis KP, 2008, J NEUROSCI METH, V172, P178, DOI 10.1016/j.jneumeth.2008.04.024; Lillis KP, 2012, NEUROBIOL DIS, V47, P358, DOI 10.1016/j.nbd.2012.05.016; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; Magloczky Z, 2005, TRENDS NEUROSCI, V28, P334, DOI 10.1016/j.tins.2005.04.002; Markov NT, 2013, SCIENCE, V342, P578, DOI 10.1126/science.1238406; MCBAIN CJ, 1989, J NEUROSCI METH, V27, P35, DOI 10.1016/0165-0270(89)90051-4; McIntosh AM, 2004, BRAIN, V127, P2018, DOI 10.1093/brain/awh221; McIntosh AM, 2012, EPILEPSIA, V53, P970, DOI 10.1111/j.1528-1167.2012.03430.x; MILES R, 1986, J PHYSIOL-LONDON, V373, P397, DOI 10.1113/jphysiol.1986.sp016055; Netoff TI, 2004, J NEUROSCI, V24, P8075, DOI 10.1523/JNEUROSCI.1509-04.2004; Newman MEJ, 2001, PHYS REV E, V64, DOI [10.1103/PhysRevE.64.026118, 10.1103/PhysRevE.64.016132]; Opsahl T, 2010, SOC NETWORKS, V32, P245, DOI 10.1016/j.socnet.2010.03.006; Pavlidis P, 1999, J NEUROPHYSIOL, V81, P2787; Perin R, 2011, P NATL ACAD SCI USA, V108, P5419, DOI 10.1073/pnas.1016051108; Pitkanen A, 2014, NEUROTHERAPEUTICS, V11, P286, DOI 10.1007/s13311-014-0260-7; Pozo K, 2010, NEURON, V66, P337, DOI 10.1016/j.neuron.2010.04.028; Prince DA, 2012, JASPERS BASIC MECH E; Raymont V, 2010, NEUROLOGY, V75, P224, DOI 10.1212/WNL.0b013e3181e8e6d0; Rengachary SS, 2005, PRINCIPLES NEUROSURG; Rogawski M., 2012, JASPERS BASIC MECH E; Sabolek HR, 2012, J NEUROSCI, V32, P3009, DOI 10.1523/JNEUROSCI.5853-11.2012; Schreiber T, 1996, PHYS REV LETT, V77, P635, DOI 10.1103/PhysRevLett.77.635; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Snyder AC, 2015, NAT NEUROSCI, V18, P736, DOI 10.1038/nn.3979; Soltesz I, 2006, DIVERSITY NEURONAL M; Steinmetz S, 2013, EPILEPSIA, V54, P580, DOI 10.1111/epi.12071; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; TAJIMA A, 1993, HYPERTENSION, V21, P105, DOI 10.1161/01.HYP.21.1.105; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; Temkin NR, 2009, EPILEPSIA, V50, P10, DOI 10.1111/j.1528-1167.2008.02005.x; Thind KK, 2010, J COMP NEUROL, V518, P647, DOI 10.1002/cne.22235; Trevelyan AJ, 2006, J NEUROSCI, V26, P12447, DOI 10.1523/JNEUROSCI.2787-06.2006; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; Tyzio R, 2003, J NEUROPHYSIOL, V90, P2964, DOI 10.1152/jn.00172.2003; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918; WEINAND ME, 1992, J NEUROSURG, V77, P20, DOI 10.3171/jns.1992.77.1.0020; White A, 2010, EPILEPSIA, V51, P371, DOI 10.1111/j.1528-1167.2009.02339.x; Williams PA, 2009, J NEUROSCI, V29, P2103, DOI 10.1523/JNEUROSCI.0980-08.2009; Yoo JY, 2014, EPILEPSIA, V55, P289, DOI 10.1111/epi.12505; Zhang ZJ, 2012, J NEUROSCI, V32, P2499, DOI 10.1523/JNEUROSCI.4247-11.2012; Zou P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5625	95	32	32	0	18	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	JUL 8	2015	35	27					9920	9934		10.1523/JNEUROSCI.4007-14.2015			15	Neurosciences	Neurosciences & Neurology	CN2LT	WOS:000358253400013	26156993	Green Published, Bronze			2021-06-18	
J	Maneshi, MM; Sachs, F; Hua, SSZ				Maneshi, Mohammad Mehdi; Sachs, Frederick; Hua, Susan Z.			A Threshold Shear Force for Calcium Influx in an Astrocyte Model of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						blast; intracellular Ca2+; mechanosensitive ion channel (MSC); shear stress; traumatic brain injury (TBI)	REACTIVE ASTROCYTES; PEPTIDE INHIBITOR; CA2+ CHANNELS; ION CHANNELS; RELEASE; GLUTAMATE; DYNAMICS; STRAIN; ROLES; CONSEQUENCES	Traumatic brain injury (TBI) refers to brain damage resulting from external mechanical force, such as a blast or crash. Our current understanding of TBI is derived mainly from in vivo studies that show measurable biological effects on neurons sampled after TBI. Little is known about the early responses of brain cells during stimuli and which features of the stimulus are most critical to cell injury. We generated defined shear stress in a microfluidic chamber using a fast pressure servo and examined the intracellular Ca2+ levels in cultured adult astrocytes. Shear stress increased intracellular Ca2+ depending on the magnitude, duration, and rise time of the stimulus. Square pulses with a fast rise time (approximate to 2ms) caused transient increases in intracellular Ca2+, but when the rise time was extended to 20ms, the response was much less. The threshold for a response is a matrix of multiple parameters. Cells can integrate the effect of shear force from repeated challenges: A pulse train of 10 narrow pulses (11.5dyn/cm(2) and 10ms wide) resulted in a 4-fold increase in Ca2+ relative to a single pulse of the same amplitude 100ms wide. The Ca2+ increase was eliminated in Ca2+-free media, but was observed after depleting the intracellular Ca2+ stores with thapsigargin suggesting the need for a Ca2+ influx. The Ca2+ influx was inhibited by extracellular Gd3+, a nonspecific inhibitor of mechanosensitive ion channels, but it was not affected by the more specific inhibitor, GsMTx4. The voltage-gated channel blockers, nifedipine, diltiazem, and verapamil, were also ineffective. The data show that the mechanically induced Ca2+ influx commonly associated with neuron models for TBI is also present in astrocytes, and there is a viscoelastic/plastic coupling of shear stress to the Ca2+ influx. The site of Ca2+ influx has yet to be determined.	[Maneshi, Mohammad Mehdi; Hua, Susan Z.] SUNY Buffalo, Dept Mech & Aerosp Engn, Buffalo, NY 14260 USA; [Sachs, Frederick; Hua, Susan Z.] SUNY Buffalo, Dept Physiol & Biophys, Buffalo, NY 14260 USA	Hua, SSZ (corresponding author), SUNY Buffalo, Dept Mech & Aerosp Engn, 340 Jarvis Hall, Buffalo, NY 14260 USA.	zhua@buffalo.edu			National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS085517]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL054887] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS085517] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health (NIH) grant NS085517. The authors thank Dr. Paul Blank at the NIH for the encouragement and useful discussion at the beginning of the project.	Alford PW, 2011, P NATL ACAD SCI USA, V108, P12705, DOI 10.1073/pnas.1105860108; Besch SR, 2002, PFLUG ARCH EUR J PHY, V445, P161, DOI 10.1007/s00424-002-0903-0; Bowman CL, 2007, TOXICON, V49, P249, DOI 10.1016/j.toxicon.2006.09.030; BRODE HL, 1959, PHYS FLUIDS, V2, P217, DOI 10.1063/1.1705911; Bursac P, 2005, NAT MATER, V4, P557, DOI 10.1038/nmat1404; Butenko O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039959; Caldwell RA, 1998, AM J PHYSIOL-CELL PH, V275, pC619; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; Chung RS, 2005, J NEUROTRAUM, V22, P1081, DOI 10.1089/neu.2005.22.1081; Cullen DK, 2011, J NEUROTRAUM, V28, P2219, DOI 10.1089/neu.2011.1841; Daschil N, 2013, J ALZHEIMERS DIS, V37, P439, DOI 10.3233/JAD-130560; De Bock M, 2014, BBA-MOL CELL RES, V1843, P2211, DOI 10.1016/j.bbamcr.2014.04.016; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Ermakov YA, 2001, BIOPHYS J, V80, P1851, DOI 10.1016/S0006-3495(01)76155-3; Ermakov YuA, 1997, Membr Cell Biol, V11, P539; Gao K, 2013, GLIA, V61, P2063, DOI 10.1002/glia.22577; Gardel ML, 2004, SCIENCE, V304, P1301, DOI 10.1126/science.1095087; Garman RH, 2011, J NEUROTRAUM, V28, P947, DOI 10.1089/neu.2010.1540; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Gu LX, 2012, COMPOS PART B-ENG, V43, P3160, DOI 10.1016/j.compositesb.2012.04.014; Haeberle H, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001750; Hua SZ, 2010, AM J PHYSIOL-CELL PH, V298, pC1424, DOI 10.1152/ajpcell.00503.2009; Jackson JG, 2006, J NEUROPHYSIOL, V96, P1093, DOI 10.1152/jn.00283.2006; Jensen MEJ, 2007, J AM SOC NEPHROL, V18, P2062, DOI 10.1681/ASN.2006070700; Kan EM, 2012, BRAIN RES BULL, V87, P359, DOI 10.1016/j.brainresbull.2012.01.007; KIMELBERG HK, 1995, J CEREBR BLOOD F MET, V15, P409, DOI 10.1038/jcbfm.1995.51; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; LaPlaca MC, 2005, J BIOMECH, V38, P1093, DOI 10.1016/j.jbiomech.2004.05.032; Liao SL, 2001, NEUROREPORT, V12, P3519, DOI 10.1097/00001756-200111160-00029; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Malarkey EB, 2008, GLIA, V56, P821, DOI 10.1002/glia.20656; Meng F., 2011, CARDIAC MECHANO ELEC, P431; Meng FJ, 2012, J CELL SCI, V125, P743, DOI 10.1242/jcs.093104; Meng FJ, 2011, J CELL SCI, V124, P261, DOI 10.1242/jcs.071928; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Niggel J, 2000, J MEMBRANE BIOL, V174, P121, DOI 10.1007/s002320001037; North SH, 2012, ANNU REV ANAL CHEM, V5, P35, DOI 10.1146/annurev-anchem-062011-143105; Ostrow KL, 2003, TOXICON, V42, P263, DOI 10.1016/S0041-0101(03)00141-7; Ostrow LW, 2005, BRAIN RES REV, V48, P488, DOI 10.1016/j.brainresrev.2004.09.005; Ostrow LW, 2011, BIOCHEM BIOPH RES CO, V410, P81, DOI 10.1016/j.bbrc.2011.05.109; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Rahimzadeh J, 2011, AM J PHYSIOL-CELL PH, V301, pC646, DOI 10.1152/ajpcell.00099.2011; Rashid B, 2012, J MECH BEHAV BIOMED, V10, P23, DOI 10.1016/j.jmbbm.2012.01.022; Ravin R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039421; Reinert M, 2000, Neurosurg Focus, V8, pe10; Rzigalinski BA, 1997, J NEUROCHEM, V68, P289; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Saljo A, 2009, J NEUROTRAUM, V26, P1345, DOI [10.1089/neu.2008.0856, 10.1089/neu.2008-0856]; Sanborn B, 2012, J BIOMECH, V45, P434, DOI 10.1016/j.jbiomech.2011.12.017; Suchyna TM, 2009, BIOPHYS J, V97, P738, DOI 10.1016/j.bpj.2009.05.018; Suchyna TM, 2004, NATURE, V430, P235, DOI 10.1038/nature02743; Tamayol A., 2009, P ASME FLUIDS ENG DI; Usachev YM, 1997, J NEUROSCI, V17, P7404; Verkhratsky A, 1996, TRENDS NEUROSCI, V19, P346, DOI 10.1016/0166-2236(96)10048-5; Verkhratsky A, 1996, CELL CALCIUM, V19, P1, DOI 10.1016/S0143-4160(96)90009-3; Verma D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044167; Wang JB, 2010, LAB CHIP, V10, P235, DOI 10.1039/b914874d; Wang Yuexiu, 2011, Commun Integr Biol, V4, P385, DOI 10.4161/cib.4.4.15505; Weber JT, 2001, J BIOL CHEM, V276, P1800, DOI 10.1074/jbc.M009209200; Wilhelmsson U, 2006, P NATL ACAD SCI USA, V103, P17513, DOI 10.1073/pnas.0602841103; Yeung EW, 2005, J PHYSIOL-LONDON, V562, P367, DOI 10.1113/jphysiol.2004.075275; Young JA, 2012, PHARMACOL THERAPEUT, V134, P1, DOI 10.1016/j.pharmthera.2011.08.003; Zhao XR, 2003, GLIA, V44, P140, DOI 10.1002/glia.10283	68	32	34	0	16	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL 1	2015	32	13					1020	1029		10.1089/neu.2014.3677			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV0SU	WOS:000363964200011	25442327	Green Published			2021-06-18	
J	Lopez-Rodriguez, AB; Acaz-Fonseca, E; Viveros, MP; Garcia-Segura, LM				Lopez-Rodriguez, Ana Belen; Acaz-Fonseca, Estefania; Viveros, Maria-Paz; Garcia-Segura, Luis M.			Changes in Cannabinoid Receptors, Aquaporin 4 and Vimentin Expression after Traumatic Brain Injury in Adolescent Male Mice. Association with Edema and Neurological Deficit	PLOS ONE			English	Article							CLOSED-HEAD INJURY; MESSENGER-RNA EXPRESSION; CEREBRAL EDEMA; ENDOCANNABINOID SYSTEM; BARRIER PERMEABILITY; TEMPORAL PROFILE; D-AMPHETAMINE; UP-REGULATION; MURINE MODEL; ASTROCYTES	Traumatic brain injury (TBI) incidence rises during adolescence because during this critical neurodevelopmental period some risky behaviors increase. The purpose of this study was to assess the contribution of cannabinoid receptors (CB1 and CB2), blood brain barrier proteins (AQP4) and astrogliosis markers (vimentin) to neurological deficit and brain edema formation in a TBI weight drop model in adolescent male mice. These molecules were selected since they are known to change shortly after lesion. Here we extended their study in three different timepoints after TBI, including short (24h), early mid-term (72h) and late midterm (two weeks). Our results showed that TBI induced an increase in brain edema up to 72 h after lesion that was directly associated with neurological deficit. Neurological deficit appeared 24 h after TBI and was completely recovered two weeks after trauma. CB1 receptor expression decreased after TBI and was negatively correlated with edema formation and behavioral impairments. CB2 receptor increased after injury and was associated with high neurological deficit whereas no correlation with edema was found. AQP4 increased after TBI and was positively correlated with edema and neurological impairments as occurred with vimentin expression in the same manner. The results suggest that CB1 and CB2 differ in the mechanisms to resolve TBI and also that some of their neuroprotective effects related to the control of reactive astrogliosis may be due to the regulation of AQP4 expression on the end-feet of astrocytes.	[Lopez-Rodriguez, Ana Belen; Acaz-Fonseca, Estefania; Garcia-Segura, Luis M.] Univ Complutense Madrid, Fac Biol, Dept Anim Physiol 2, Madrid, Spain; [Lopez-Rodriguez, Ana Belen; Viveros, Maria-Paz] CSIC, Inst Cajal, E-28002 Madrid, Spain	Lopez-Rodriguez, AB (corresponding author), Univ Complutense Madrid, Fac Biol, Dept Anim Physiol 2, Madrid, Spain.	lranabelen@gmail.com	Garcia-Segura, Luis M/U-3711-2017; Acaz-Fonseca, Estefania/S-5884-2016; Lopez-Rodriguez, Ana Belen/H-3631-2017; Viveros, Maria-Paz/S-6855-2016	Garcia-Segura, Luis M/0000-0002-2450-2916; Acaz-Fonseca, Estefania/0000-0003-2549-6420; Lopez-Rodriguez, Ana Belen/0000-0002-0747-7966; Viveros, Maria-Paz/0000-0002-4119-4636	Ministerio de Economia y Competitividad, Spain [BFU2011-30217-C03-01, BFU2012-38144]; Instituto de Salud Carlos III, Redes tematicas de Investigacion Cooperativa en Salud, Red de Trastornos Adictivos [RD2012/0028/0021]; GRUPO UCM [951579]	Support was provided by the Ministerio de Economia y Competitividad, Spain (BFU2011-30217-C03-01 and BFU2012-38144), Instituto de Salud Carlos III, Redes tematicas de Investigacion Cooperativa en Salud, Red de Trastornos Adictivos (RD2012/0028/0021) and GRUPO UCM (951579). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adelson PD, 1998, ACT NEUR S, V71, P104; Adriani W, 2004, NEUROPSYCHOPHARMACOL, V29, P869, DOI 10.1038/sj.npp.1300366; Adriani W, 2003, BEHAV NEUROSCI, V117, P695, DOI 10.1037/0735-7044.117.4.695; Adriani W, 1998, BEHAV NEUROSCI, V112, P1152, DOI 10.1037/0735-7044.112.5.1152; Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; Badaut T, 2002, J CEREBR BLOOD F MET, V22, P367, DOI 10.1097/00004647-200204000-00001; Bardutzky J, 2007, STROKE, V38, P3084, DOI 10.1161/STROKEAHA.107.490193; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Lopez-Rodriguez AB, 2015, PSYCHONEUROENDOCRINO, V56, P1, DOI 10.1016/j.psyneuen.2015.02.018; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen Y, 2000, CIRC RES, V87, P323, DOI 10.1161/01.RES.87.4.323; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Dardiotis E, 2014, J NEUROTRAUM, V31, P1920, DOI 10.1089/neu.2014.3347; Ding JY, 2009, NEUROSCI LETT, V453, P68, DOI 10.1016/j.neulet.2009.01.077; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Ekmark-Lewen S, 2010, RESTOR NEUROL NEUROS, V28, P311, DOI 10.3233/RNN-2010-0529; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; FRANKE WW, 1982, DIFFERENTIATION, V23, P43, DOI 10.1111/j.1432-0436.1982.tb01266.x; Fukuda AM, 2013, J CEREBR BLOOD F MET, V33, P1621, DOI 10.1038/jcbfm.2013.118; Garcia-Gutierrez MS, 2013, NEUROPHARMACOLOGY, V73, P388, DOI 10.1016/j.neuropharm.2013.05.034; Hellal F, 2004, NEUROSCI LETT, V357, P21, DOI 10.1016/j.neulet.2003.12.036; Hellal F, 2003, J NEUROTRAUM, V20, P841, DOI 10.1089/089771503322385773; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Iring A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053390; Kapoor S, 2013, J NEUROSCI, V33, P17398, DOI 10.1523/JNEUROSCI.2756-13.2013; KENT S, 1992, TRENDS PHARMACOL SCI, V13, P24, DOI 10.1016/0165-6147(92)90012-U; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; KOLB B, 1986, BRAIN RES, V397, P315, DOI 10.1016/0006-8993(86)90633-5; Kreiter KT, 2002, STROKE, V33, P200, DOI 10.1161/hs0102.101080; Larson SJ, 2001, BRAIN BEHAV IMMUN, V15, P371, DOI 10.1006/brbi.2001.0643; Lin Y, 2012, LAB INVEST, V92, P1623, DOI 10.1038/labinvest.2012.118; Litvin Y, 2013, GENES BRAIN BEHAV, V12, P479, DOI 10.1111/gbb.12045; De Jesus ML, 2010, NEUROCHEM INT, V56, P829, DOI 10.1016/j.neuint.2010.03.007; Rodriguez ABL, 2011, CEREB CORTEX, V21, P2046, DOI 10.1093/cercor/bhq277; Lopez-Rodriguez AB, 2015, CEREB CORTEX, V25, P35, DOI 10.1093/cercor/bht202; Marco EM, 2009, MINI-REV MED CHEM, V9, P1407, DOI 10.2174/138955709789957468; Marmarou A, 2003, ACT NEUR S, V86, P7; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; McCarron RM, 2006, J PHYSIOL PHARMACOL, V57, P133; Mechoulam R, 2007, MOL NEUROBIOL, V36, P68, DOI 10.1007/s12035-007-8008-6; O'Connor CA, 2006, ACTA NEUROCHIR SUPPL, V96, P121; Onaivi ES, 2011, CURR NEUROPHARMACOL, V9, P205, DOI 10.2174/157015911795017416; Palazuelos J, 2006, FASEB J, V20, P2405, DOI 10.1096/fj.06-6164fje; Panikashvili D, 2006, NEUROBIOL DIS, V22, P257, DOI 10.1016/j.nbd.2005.11.004; Panikashvili D, 2005, J CEREBR BLOOD F MET, V25, P477, DOI 10.1038/sj.jcbfm.9600047; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Pekny M, 2007, INT REV NEUROBIOL, V82, P95, DOI 10.1016/S0074-7742(07)82005-8; Potokar M, 2013, GLIA, V61, P917, DOI 10.1002/glia.22485; Ren ZG, 2013, J CEREBR BLOOD F MET, V33, P834, DOI 10.1038/jcbfm.2013.30; Rochat L, 2010, NEUROPSYCHOL REHABIL, V20, P778, DOI 10.1080/09602011.2010.495245; Rodriguez JJ, 2001, J NEUROSCI, V21, P823; ROPPER AH, 1984, ARCH NEUROL-CHICAGO, V41, P26, DOI 10.1001/archneur.1984.04050130032017; Schwarzmaier SM, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-32; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Shenaq M, 2012, J NEUROL SCI, V323, P134, DOI 10.1016/j.jns.2012.08.036; Shohami E, 2011, BRIT J PHARMACOL, V163, P1402, DOI 10.1111/j.1476-5381.2011.01343.x; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Siopi E, 2012, J NEUROTRAUM, V29, P354, DOI 10.1089/neu.2011.2055; Siopi E, 2011, J NEUROTRAUM, V28, P2135, DOI 10.1089/neu.2010.1738; Spear LP, 2000, NEUROSCI BIOBEHAV R, V24, P417, DOI 10.1016/S0149-7634(00)00014-2; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stella N, 2010, GLIA, V58, P1017, DOI 10.1002/glia.20983; Straiker A, 2006, AAPS J, V8, pE272; Verkman AS, 2006, BBA-BIOMEMBRANES, V1758, P1085, DOI 10.1016/j.bbamem.2006.02.018; Viveros MP, 2012, J PSYCHOPHARMACOL, V26, P164, DOI 10.1177/0269881111408956; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Zhang M, 2008, NEUROSCIENCE, V152, P753, DOI 10.1016/j.neuroscience.2008.01.022	71	32	39	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUN 3	2015	10	6							e0128782	10.1371/journal.pone.0128782			17	Multidisciplinary Sciences	Science & Technology - Other Topics	CJ7ST	WOS:000355700700120	26039099	DOAJ Gold, Green Published			2021-06-18	
J	Lopez-Rodriguez, AB; Acaz-Fonseca, E; Giatti, S; Caruso, D; Viveros, MP; Melcangi, RC; Garcia-Segura, LM				Belen Lopez-Rodriguez, Ana; Acaz-Fonseca, Estefania; Giatti, Silvia; Caruso, Donatella; Viveros, Maria-Paz; Melcangi, Roberto C.; Garcia-Segura, Luis M.			Correlation of brain levels of progesterone and dehydroepiandrosterone with neurological recovery after traumatic brain injury in female mice	PSYCHONEUROENDOCRINOLOGY			English	Article						Tetrahydroprogesterone; 17 beta-Estradiol; Dehydroepiandrosterone; lsopregnanolone; Progesterone; Testosterone	NEUROACTIVE STEROID-LEVELS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ACUTE REGULATORY PROTEIN; SEX-DIMORPHIC CHANGES; CLOSED-HEAD INJURY; CEREBROSPINAL-FLUID; RAT HIPPOCAMPUS; NERVOUS-SYSTEM; CLINICAL-TRIAL; IN-VIVO	Traumatic brain injury (TBI) is an important cause of disability in humans. Neuroactive steroids, such as progesterone and dehydroepiandrosterone (DHEA), are neuroprotective in TBI models. However in order to design potential neuroprotective strategies based on neuroactive steroids it is important to determine whether its brain levels are altered by TBI. In this study we have used a weight-drop model of TBI in young adult female mice to determine the levels of neuroactive steroids in the brain and plasma at 24h, 72h and 2 weeks after injury. We have also analyzed whether the levels of neuroactive steroids after TBI correlated with the neurological score of the animals. TBI caused neurological deficit detectable at 24 and 72 h, which recovered by 2 weeks after injury. Brain levels of progesterone, tetrahydroprogesterone (THP), isopregnanolone and 17 beta-estradiol were decreased 24 h, 72 h and 2 weeks after TBI. DHEA and brain testosterone levels presented a transient decrease at 24 h after lesion. Brain levels of progesterone and DHEA showed a positive correlation with neurological recovery. Plasma analyses showed that progesterone was decreased 72 h after lesion but, in contrast with brain progesterone, its levels did not correlate with neurological deficit. These findings indicate that TBI alters the levels of neuroactive steroids in the brain with independence of its plasma levels and suggest that the pharmacological increase in the brain of the levels of. progesterone and DHEA may result in the improvement of neurological recovery after TBI. (C) 2015 Elsevier Ltd. All rights reserved.	[Belen Lopez-Rodriguez, Ana; Acaz-Fonseca, Estefania; Garcia-Segura, Luis M.] CSIC, Inst Cajal, E-28002 Madrid, Spain; [Belen Lopez-Rodriguez, Ana; Viveros, Maria-Paz] Univ Complutense Madrid, Fac Biol, Dept Anim Physiol Anim Physiol 2, Madrid, Spain; [Giatti, Silvia; Caruso, Donatella; Melcangi, Roberto C.] Univ Milan, Ctr Excellence Neurodegenerat Dis, Dept Pharmacol & Biomol Sci, I-20133 Milan, Italy	Lopez-Rodriguez, AB (corresponding author), CSIC, Inst Cajal, Avenida Doctor Arce 37, E-28002 Madrid, Spain.	lranabelen@gmail.com	Lopez-Rodriguez, Ana Belen/H-3631-2017; Garcia-Segura, Luis M/U-3711-2017; Giatti, Silvia/G-9334-2016; Acaz-Fonseca, Estefania/S-5884-2016; Viveros, Maria-Paz/S-6855-2016	Lopez-Rodriguez, Ana Belen/0000-0002-0747-7966; Garcia-Segura, Luis M/0000-0002-2450-2916; Giatti, Silvia/0000-0001-7741-826X; Acaz-Fonseca, Estefania/0000-0003-2549-6420; Viveros, Maria-Paz/0000-0002-4119-4636; MELCANGI, COSIMO ROBERTO/0000-0003-0861-8967	Ministerio de Economia y Competitividad, Spain [BFU2011-30217-C03-01, BFU2012-38144]; Institut de Salud Carlos III, Redes tematicas de Investigacion Cooperativa en Salud, Red de Trastornos Adictivos [RD2012/0028/0021]; GRUPO UCM [951579]; Fondazione CariploFondazione Cariplo [2012-0547]	We acknowledge financial support from the Ministerio de Economia y Competitividad, Spain to L.M.G.S. (BFU2011-30217-C03-01) and M.P.V. (BFU2012-38144), Institut de Salud Carlos III, Redes tematicas de Investigacion Cooperativa en Salud, Red de Trastornos Adictivos to M.P.V. (RD2012/0028/0021), GRUPO UCM to M.RV. (951579) and Fondazione Cariplo to R.C.M. (grant number 2012-0547).	Aminmansour Bahram, 2012, Adv Biomed Res, V1, P58, DOI 10.4103/2277-9175.100176; Arevalo MA, 2015, NAT REV NEUROSCI, V16, P17, DOI 10.1038/nrn3856; Azcoitia I, 2001, J NEUROBIOL, V47, P318, DOI 10.1002/neu.1038; Baulieu EE, 2001, INT REV NEUROBIOL, V46, P1; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Borowicz Kinga K, 2011, Front Endocrinol (Lausanne), V2, P50, DOI 10.3389/fendo.2011.00050; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Caruso D, 2014, J NEUROCHEM, V130, P591, DOI 10.1111/jnc.12745; Caruso D, 2013, PSYCHONEUROENDOCRINO, V38, P2278, DOI 10.1016/j.psyneuen.2013.04.016; Caruso D, 2013, NEUROBIOL AGING, V34, P1080, DOI 10.1016/j.neurobiolaging.2012.10.007; Caruso D, 2010, J NEUROCHEM, V114, P921, DOI 10.1111/j.1471-4159.2010.06825.x; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chen MK, 2008, PHARMACOL THERAPEUT, V118, P1, DOI 10.1016/j.pharmthera.2007.12.004; Chodobski A, 2011, TRANSL STROKE RES, V2, P492, DOI 10.1007/s12975-011-0125-x; Ciriza I, 2004, J NEUROENDOCRINOL, V16, P58, DOI 10.1111/j.1365-2826.2004.01121.x; Ciriza I, 2006, J NEUROBIOL, V66, P916, DOI 10.1002/neu.20293; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Giatti S, 2010, NEUROCHEM INT, V56, P118, DOI 10.1016/j.neuint.2009.09.009; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hoffman SW, 2003, J NEUROTRAUM, V20, P859, DOI 10.1089/089771503322385791; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Homsi S, 2009, BRAIN RES, V1291, P122, DOI 10.1016/j.brainres.2009.07.031; Jones NC, 2005, EUR J NEUROSCI, V21, P1547, DOI 10.1111/j.1460-9568.2005.03995.x; Juhasz-Vedres G, 2006, ENDOCRINOLOGY, V147, P683, DOI 10.1210/en.2005-0693; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Lavaque E, 2006, J NEUROBIOL, V66, P308, DOI 10.1002/neu.20221; Li W, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114173; Lin Y, 2012, LAB INVEST, V92, P1623, DOI 10.1038/labinvest.2012.118; Lopez-Rodriguez AB, 2015, CEREB CORTEX, V25, P35, DOI 10.1093/cercor/bht202; Lorenzo Monica, 2005, Pituitary, V8, P233, DOI 10.1007/s11102-006-6046-0; Malik AS, 2003, J NEUROTRAUM, V20, P463, DOI 10.1089/089771503765355531; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Meffre D, 2007, ENDOCRINOLOGY, V148, P2505, DOI 10.1210/en.2006-1678; Melcangi RC, 2008, CELL MOL LIFE SCI, V65, P777, DOI 10.1007/s00018-007-7403-5; Melcangi RC, 2014, PROG NEUROBIOL, V113, P56, DOI 10.1016/j.pneurobio.2013.07.006; Melcangi RC, 2012, J MOL NEUROSCI, V46, P177, DOI 10.1007/s12031-011-9570-y; Milman A, 2008, EUR NEUROPSYCHOPHARM, V18, P181, DOI 10.1016/j.euroneuro.2007.05.007; Mirzatoni A, 2010, J NEUROTRAUM, V27, P1875, DOI 10.1089/neu.2010.1330; Mitro N, 2012, NEUROCHEM INT, V60, P616, DOI 10.1016/j.neuint.2012.02.025; O'Connor CA, 2005, BRAIN RES, V1062, P171, DOI 10.1016/j.brainres.2005.09.011; Papadopoulos V, 2012, BEST PRACT RES CL EN, V26, P771, DOI 10.1016/j.beem.2012.05.002; Pascual JL, 2013, AM J SURG, V206, P840, DOI 10.1016/j.amjsurg.2013.07.016; Pesaresi M, 2010, HORM BEHAV, V57, P46, DOI 10.1016/j.yhbeh.2009.04.008; Popovic Vera, 2005, Pituitary, V8, P239, DOI 10.1007/s11102-006-6047-z; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Shahrokhi N, 2010, CAN J PHYSIOL PHARM, V88, P414, DOI [10.1139/Y09-126, 10.1139/y09-126]; Sierra A, 2003, EUR J NEUROSCI, V18, P1458, DOI 10.1046/j.1460-9568.2003.02872.x; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Siopi E, 2012, J NEUROTRAUM, V29, P354, DOI 10.1089/neu.2011.2055; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Xiong Y, 2007, BRAIN RES, V1185, P301, DOI 10.1016/j.brainres.2007.09.052; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Zhang QG, 2014, MOL CELL ENDOCRINOL, V389, P84, DOI 10.1016/j.mce.2013.12.019	58	32	33	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4530			PSYCHONEUROENDOCRINO	Psychoneuroendocrinology	JUN	2015	56						1	11		10.1016/j.psyneuen.2015.02.018			11	Endocrinology & Metabolism; Neurosciences; Psychiatry	Endocrinology & Metabolism; Neurosciences & Neurology; Psychiatry	CH6JE	WOS:000354142100001	25770855				2021-06-18	
J	Brooks, JC; Shavelle, RM; Strauss, DJ; Hammond, FM; Harrison-Felix, CL				Brooks, Jordan C.; Shavelle, Robert M.; Strauss, David J.; Hammond, Flora M.; Harrison-Felix, Cynthia L.			Long-Term Survival After Traumatic Brain Injury Part II: Life Expectancy	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Life Expectancy; Mortality trends; Prognosis; Rehabilitation; Survival	MORTALITY; REHABILITATION; TRENDS	Objectives: To compute the life expectancy of persons with traumatic brain injury (TBI) based on validated prognostic models from 2 cohorts, to compare mortality and life expectancy of persons with TBI with those of the U.S. general population, and to investigate trends toward improved survival over the last 2 decades. Design: Survival analysis. Setting: Postdischarge from rehabilitation units and long-term follow-up at regional centers. Participants: Two cohorts of long-term survivors of TBI (N=12,481): the Traumatic Brain Injury Model Systems (TBIMS) cohort comprised 7365 persons who were admitted to a TBIMS facility with moderate to severe TBI and were assessed at >= 1 years postinjury, and the California Department of Developmental Services (CDDS) cohort comprised 5116 persons who sustained a TBI and received long-term services from the CDDS. Interventions: Not applicable. Main Outcome Measures: Life expectancy. Results: The estimates of age-, sex-, and disability-specific life expectancy of persons with TBI derived from the CDDS and TBIMS were similar. The estimates of age- and sex-specific life expectancy were lower than those of the U.S. general population. Mortality rates of persons with TBI were higher than those of the U.S. general population. Mortality rates did not improve and the standardized mortality ratio increased over the study period from 1988 to 2010. Conclusions: Life expectancy of persons with TBI is lower than that of the general population and depends on age, sex, and severity of disability. When compared, the survival outcomes in the TBIMS and CDDS cohorts are remarkably similar. Because there have been no marked trends in the last 20 years, the life expectancies presented in this article may remain valid in the future. (C) 2015 by the American Congress of Rehabilitation Medicine	[Brooks, Jordan C.; Shavelle, Robert M.; Strauss, David J.] Life Expectancy Project, San Francisco, CA 94122 USA; [Hammond, Flora M.] Indiana Univ, Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN USA; [Harrison-Felix, Cynthia L.] Univ Colorado, Dept Phys Med & Rehabil, Denver, CO 80202 USA	Brooks, JC (corresponding author), Life Expectancy Project, 1439 17th Ave, San Francisco, CA 94122 USA.	Brooks@LifeExpectancy.org			National Institute on Disability and Rehabilitation Research (NIDRR) of the U.S. Department of Education	Supported by the National Institute on Disability and Rehabilitation Research (NIDRR) of the U.S. Department of Education. However, the contents do not necessarily reflect the opinions or views of the Traumatic Brain Injury Model Systems Centers, NIDRR, or the U.S. Department of Education.	Arias M, 1983, PACIFIC STATE ARCH, P28; Baguley IJ, 2012, MED J AUSTRALIA, V196, P40, DOI 10.5694/mja11.10090; Baguley IJ, 2008, BRAIN INJURY, V22, P919, DOI 10.1080/02699050802448578; Brooks JC, 2015, ARCH PHYS M IN PRESS; Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; California Department of Developmental Services, 1986, CLIENT DEV EV REP CD; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1199, DOI 10.1016/j.apmr.2013.01.023; De Vivo MI, 2012, TOP SPINAL CORD I S1, V18, P214; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Harris C, 1983, INTERRATER RELIABILI; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE45, DOI 10.1097/HTR.0b013e31827340ba; Harrison-Felix C, 2012, J HEAD TRAUMA REHAB, V27, pE69, DOI 10.1097/HTR.0b013e3182738010; Harrison-Felix CL, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P319; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; McMillan TM, 2014, J NEUROL NEUROSUR PS, V85, P1214, DOI 10.1136/jnnp-2013-307279; Middleton JW, 2012, SPINAL CORD, V50, P803, DOI 10.1038/sc.2012.55; Preston DL, 2005, ENCY BIOSTATISTICS, P1; Ratcliff G, 2005, DISABIL REHABIL, V27, P305, DOI 10.1080/09638280400018338; Shavelle R, 2000, J Insur Med, V32, P163; Shavelle RM, 2007, BRAIN INJURY MED PRI, P247; Strauss D, 2004, NEUROREHABILITATION, V19, P257; Strauss D, 1999, J INSUR MED, V31, P104; Strauss DJ, 2006, ARCH PHYS MED REHAB, V87, P1079, DOI 10.1016/j.apmr.2006.04.022; Strauss DJ, 1998, ARCH PHYS MED REHAB, V79, P1095, DOI 10.1016/S0003-9993(98)90177-0; Strauss DJ, 2003, NEUROLOGY, V60, P395, DOI 10.1212/WNL.60.3.395; UB Foundation Activities Inc, IRF PAI TRAIN MAN; World Health Organization, 1992, INT STAT CLASS DIS I	29	32	32	0	6	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2015	96	6					1000	1005		10.1016/j.apmr.2015.02.002			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	CK7FM	WOS:000356398200005	26043195				2021-06-18	
J	Rahn, C; Munkasy, BA; Joyner, AB; Buckley, TA				Rahn, Carrie; Munkasy, Barry A.; Joyner, A. Barry; Buckley, Thomas A.			Sideline Performance of the Balance Error Scoring System during a Live Sporting Event	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; balance testing; environment	COLLEGIATE FOOTBALL PLAYERS; POSTURAL CONTROL; NCAA CONCUSSION; MANAGEMENT; STABILITY; ATTENTION; RECOVERY; AROUSAL; ANXIETY; YOUNG	Objective: The purpose was to examine the influence of a live sporting sideline environment on balance error scoring system (BESS) performance. Design: Prospective longitudinal cohort study. Setting: The BESS was performed by all participants at 3 locations: (1) quiet laboratory, (2) football stadium sidelines, and (3) basketball arena sidelines. Participants: The experimental group had 38 participants (age: 20.1 +/- 1.1 years; height: 170.0 +/- 7.7 cm; mass: 66.7 +/- 9.5 kg) who were female intercollegiate student-athletes (SA). The control group consisted of 38 recreationally active female college students (age: 20.8 +/- 1.1 years; height: 162.6 +/- 6.0 cm; mass: 63.7 +/- 10.6 kg). Interventions: The 2 groups performed the tests at the same locations, the SA group during live sporting events and the control group when no event was occurring. Main Outcome Measures: The dependent variable was the total BESS score. Separate 2 x 3 mixed methods analyses of variance investigated the influence of the environment and practice effect. Results: There was a significant interaction for group by environment (P = 0.004), and the SA group committed more errors at both the football and the basketball settings than the control group. The SA group also committed more errors at football (P = 0.028) than baseline. The control group demonstrated a likely practice effect with fewer errors during each administration. Conclusions: The BESS score deteriorated when performed on the sidelines of a live sporting event potentially challenging the clinical utility of the BESS. Clinicians need to consider the role of the local environment when performing the BESS test and should perform postinjury tests in the same environment as the baseline test.	[Rahn, Carrie] Georgia Southwestern State Univ, Dept Intercoll Athlet, Americus, GA USA; [Munkasy, Barry A.] Georgia So Univ, Dept Hlth & Kinesiol, Statesboro, GA 30460 USA; [Joyner, A. Barry] Georgia So Univ, Coll Hlth & Human Sci, Statesboro, GA 30460 USA; [Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE 19716 USA	Buckley, TA (corresponding author), Univ Delaware, Dept Kinesiol & Appl Physiol, Human Performance Lab 144, Newark, DE 19716 USA.	TBuckley@UDel.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150	National Institutes of Health/National Institute of Neurological Disorders and Stroke Grant [1R15NS070744-01A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R15NS070744] Funding Source: NIH RePORTER	Supported, in part, by a National Institutes of Health/National Institute of Neurological Disorders and Stroke Grant (1R15NS070744-01A1). Dr. Buckley and Dr. Munkasy are the primary investigators on the grant. The funding agency had no role in the development of the manuscript, the interpretation of the results, or the decision where to submit the manuscript.	Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Burk JM, 2013, CLIN J SPORT MED, V23, P312, DOI 10.1097/JSM.0b013e318285633f; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Dewhurst S, 2005, EUR J APPL PHYSIOL, V94, P491, DOI 10.1007/s00421-005-1384-6; Fox ZG, 2008, J ATHL TRAINING, V43, P456, DOI 10.4085/1062-6050-43.5.456; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Horslen BC, 2011, EXP BRAIN RES, V215, P27, DOI 10.1007/s00221-011-2867-9; Hunt TN, 2009, CLIN J SPORT MED, V19, P471, DOI 10.1097/JSM.0b013e3181c12c7b; Kaipust JP, 2013, ANN BIOMED ENG, V41, P1595, DOI 10.1007/s10439-012-0654-9; KAPTEYN TS, 1972, ACTA OTO-LARYNGOL, V73, P104, DOI 10.3109/00016487209138918; Kelly KC, J ATHL TRAI IN PRESS; Littleton A, 2013, J SPORT HEALTH SCI, V2, P227, DOI 10.1016/j.jshs.2013.04.003; MacLellan MJ, 2006, EXP BRAIN RES, V173, P521, DOI 10.1007/s00221-006-0399-5; Maki BE, 1996, J VESTIBUL RES-EQUIL, V6, P53; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McLeod TCV, 2009, J SPORT REHABIL, V18, P465, DOI 10.1123/jsr.18.4.465; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Moreau M. S., 2014, INT J EXERCISE SCI, V7, P62; Ohno H, 2004, NEUROSCI LETT, V364, P37, DOI 10.1016/j.neulet.2004.04.014; Onate JA, 2000, J ATHL TRAINING, V35, P155; Onate JA, 2007, J ATHL TRAINING, V42, P446; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Schneiders AG, 2010, J SCI MED SPORT, V13, P382, DOI 10.1016/j.jsams.2010.01.003; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Wada M, 2001, NEUROSCI LETT, V302, P157, DOI 10.1016/S0304-3940(01)01662-7; Woollacott M, 2002, GAIT POSTURE, V16, P1, DOI 10.1016/S0966-6362(01)00156-4	30	32	32	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2015	25	3					248	253		10.1097/JSM.0000000000000141			6	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	CH3EX	WOS:000353911700009	25098674	Green Accepted			2021-06-18	
J	Gardner, CJ; Mattsson, AF; Daousi, C; Korbonits, M; Koltowska-Haggstrom, M; Cuthbertson, DJ				Gardner, Chris J.; Mattsson, Anders F.; Daousi, Christina; Korbonits, Marta; Koltowska-Haggstrom, Maria; Cuthbertson, Daniel J.			GH deficiency after traumatic brain injury: improvement in quality of life with GH therapy: analysis of the KIMS database	EUROPEAN JOURNAL OF ENDOCRINOLOGY			English	Article							GROWTH-HORMONE DEFICIENCY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; ANTERIOR-PITUITARY DYSFUNCTION; QOL-AGHDA; LONG-TERM; HYPOPITUITARY ADULTS; REPLACEMENT THERAPY; REFERENCE VALUES; LOW-PREVALENCE; MODERATE	Objective: Prevalence of GH deficiency (GHD) caused by traumatic brain injury (TBI) is highly variable. Short-term studies show improvement in quality of life (QoL) during GH replacement (GHR), but long-term data are lacking. The aim of this study was to analyse the clinical characteristics of post-traumatic hypopituitarism and the QoL effects of long-term GHR. Design/methods: Pfizer International Metabolic Database patients with GHD caused by TBI and by non-functioning pituitary adenoma (NFPA) were compared regarding: clinical characteristics at baseline and 1-year of GHR, and QoL response up to 8-years of GHR (QoL-AGHDA total scores and dimensions) in relationship with country-specific norms. Results: TBI patients compared with NFPA patients were younger, diagnosed with GHD 2.4 years later after primary disease onset (P<0.0001), had a higher incidence of isolated GHD, higher GH peak, a more favourable metabolic profile and worse QoL, were shorter by 0.9 cm (1.8 cm when corrected for age and gender; P=0.004) and received higher GH dose (mean difference: 0.04 mg/day P=0.006). In TBI patients, 1-year improvement in QoL was greater than in NFPA (change in QoL-AGHDA score 5.0 vs 3.5, respectively, P=0.04) and was sustained over 8 years. In TBI patients, socialisation normalised after 1 year of GHR, self-confidence and tenseness after 6 years and no normalisation of tiredness and memory was observed. Conclusion: Compared with NFPA, TBI patients presented biochemically with less severe hypopituitarism and worse QoL scores. GHR achieved clinically relevant, long-term benefit in QoL.	[Gardner, Chris J.; Daousi, Christina; Cuthbertson, Daniel J.] Univ Liverpool, Inst Ageing & Chron Dis, Dept Obes & Endocrinol, Liverpool L9 7AL, Merseyside, England; [Mattsson, Anders F.] Pfizer Inc, Pfizer Endocrine Care, Sollentuna, Sweden; [Korbonits, Marta] Queen Mary Univ London, Ctr Endocrinol, Barts & London Sch Med & Dent, William Harvey Res Inst, London, England; [Koltowska-Haggstrom, Maria] Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden	Cuthbertson, DJ (corresponding author), Univ Liverpool, Inst Ageing & Chron Dis, Dept Obes & Endocrinol, Liverpool L9 7AL, Merseyside, England.	daniel.cuthbertson@liverpool.ac.uk		Cuthbertson, Daniel/0000-0002-6128-0822; Korbonits, Marta/0000-0002-4101-9432	Pfizer, Inc.Pfizer	KIMS is sponsored by Pfizer, Inc.	Abs R, 1999, CLIN ENDOCRINOL, V50, P703, DOI 10.1046/j.1365-2265.1999.00695.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Bellone S, 2013, PITUITARY, V16, P499, DOI 10.1007/s11102-012-0446-0; Berg C, 2010, EXP CLIN ENDOCR DIAB, V118, P139, DOI 10.1055/s-0029-1225611; Bhagia V, 2010, BRAIN INJURY, V24, P560, DOI 10.3109/02699051003601705; Brabant G, 2003, HORM RES, V60, P53, DOI 10.1159/000071871; Bushnik T, 2007, BRAIN INJURY, V21, P559, DOI 10.1080/02699050701426915; Busschbach JJV, 2011, EUR J HEALTH ECON, V12, P243, DOI 10.1007/s10198-010-0241-7; Casanueva FF, 2005, ARCH PHYS MED REHAB, V86, P463, DOI 10.1016/j.apmr.2004.05.018; Corneli G, 2005, EUR J ENDOCRINOL, V153, P257, DOI 10.1530/eje.1.01967; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Gardner CJ, 2013, EUR J ENDOCRINOL, V168, P473, DOI 10.1530/EJE-12-0849; Gilet H, 2010, VALUE HEALTH, V13, P495, DOI 10.1111/j.1524-4733.2009.00689.x; Gutierrez LP, 2008, PHARMACOEPIDEM DR S, V17, P90, DOI 10.1002/pds.1510; High WM, 2010, J NEUROTRAUM, V27, P1565, DOI 10.1089/neu.2009.1253; Jeong JH, 2010, J NEUROSURG, V113, P532, DOI 10.3171/2009.10.JNS091152; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Klose M, 2014, J CLIN ENDOCR METAB, V99, P101, DOI 10.1210/jc.2013-2397; Kokshoorn NE, 2011, EUR J ENDOCRINOL, V165, P225, DOI 10.1530/EJE-11-0365; Kokshoorn NE, 2010, EUR J ENDOCRINOL, V162, P11, DOI 10.1530/EJE-09-0601; Koltowska-Haggstrom M, 2006, EUR J ENDOCRINOL, V155, P109, DOI 10.1530/eje.1.02176; Kreitschmann-Andermahr I, 2008, GROWTH HORM IGF RES, V18, P472, DOI 10.1016/j.ghir.2008.08.007; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Maric NP, 2010, J ENDOCRINOL INVEST, V33, P770, DOI [10.1007/BF03350340, 10.3275/7045]; McKenna SP, 1999, QUAL LIFE RES, V8, P373, DOI 10.1023/A:1008987922774; Moock J, 2011, GROWTH HORM IGF RES, V21, P272, DOI 10.1016/j.ghir.2011.07.005; Moreau OK, 2013, J NEUROTRAUM, V30, P998, DOI 10.1089/neu.2012.2705; Moreau OK, 2012, J NEUROTRAUM, V29, P81, DOI 10.1089/neu.2011.2048; Park KD, 2010, BRAIN INJURY, V24, P1330, DOI 10.3109/02699052.2010.506863; Pavlovic D, 2010, EUR J NEUROL, V17, P696, DOI 10.1111/j.1468-1331.2009.02910.x; Schneider HJ, 2011, J NEUROTRAUM, V28, P1693, DOI 10.1089/neu.2011.1887; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Srinivasan L, 2009, BRAIN INJURY, V23, P639, DOI 10.1080/02699050902970778; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tanriverdi F, 2010, PITUITARY, V13, P111, DOI 10.1007/s11102-009-0204-0; Tanriverdi F, 2013, J NEUROTRAUM, V30, P1426, DOI 10.1089/neu.2012.2752; Tritos NA, 2011, J CLIN ENDOCR METAB, V96, P1516, DOI 10.1210/jc.2010-2662; Ulfarsson T, 2013, J NEUROTRAUM, V30, P271, DOI 10.1089/neu.2012.2494; Underwood L, RADIOIMMUNOASSAY BAS, P561, DOI [10.1007/978-3-642-71809-0_23, DOI 10.1007/978-3-642-71809-0_]; Wiren L, 2000, CLIN ENDOCRINOL, V52, P143, DOI 10.1046/j.1365-2265.2000.00899.x	45	32	32	0	8	BIOSCIENTIFICA LTD	BRISTOL	EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND	0804-4643	1479-683X		EUR J ENDOCRINOL	Eur. J. Endocrinol.	APR	2015	172	4					371	381		10.1530/EJE-14-0654			11	Endocrinology & Metabolism	Endocrinology & Metabolism	CC4TO	WOS:000350346900011	25583905	Bronze			2021-06-18	
J	Iverson, KM; Pogoda, TK				Iverson, Katherine M.; Pogoda, Terri K.			Traumatic Brain Injury Among Women Veterans An Invisible Wound of Intimate Partner Violence	MEDICAL CARE			English	Article						Veterans health administration; concussion; abuse; domestic violence; strangulation	HEALTH; STRANGULATION; SCALES	Background: Intimate partner violence (IPV) is prevalent among women Veterans and is known to increase women's risk for traumatic brain injury (TBI). IPV-related TBI has not been examined in the women Veteran population. Objectives: To identify the occurrence of IPV-related TBI in a sample of women Veterans and examine the associations of IPV-related TBI with sociodemographic characteristics, health symptoms, health care utilization, and IPV experiences. Research Design: Cross-sectional mail survey conducted in 2013. Subjects: The sample comprised 176 New England Department of Veterans Affairs (VA) women Veteran patients. Measures: Self-reported IPV-related TBI was assessed with a modified VA TBI screening tool. The survey included validated measures of depression (Center for Epidemiologic Studies Depression Scale) and posttraumatic stress disorder (PTSD; Posttraumatic Disorder Checklist) symptoms, as well as overall mental and physical health (SF-12), and IPV (Conflict Tactics Scales-Revised-2). Questions assessed past-year VA and non-VA health care use. Results: A total of 18.8% (n = 33) met screening criteria for IPV-related TBI history. Women who experienced IPV-related TBI reported significantly higher depression (mean Center for Epidemiologic Studies Depression Scale scores: 26.6 vs. 20.7, P < 0.0001) and PTSD (mean Posttraumatic Disorder Checklist scores: 53.2 vs. 34.1, P < 0.0001) symptoms, and poorer perceptions of physical health (mean SF-12 34.6 vs. 42.3, P < 0.01) than women who experienced IPV to the head without TBI. IPV-related TBI was also associated with poorer perceptions of mental health, as well as more frequent VA health care utilization and overall IPV. Conclusions: IPV-related TBI is associated with poorer mental and physical health in women Veterans. This invisible injury is associated with greater VA health care utilization and IPV exposure. Implications for VA practice and policy are discussed.	[Iverson, Katherine M.] VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, 150 South Huntington Ave 116B-3, Boston, MA 02130 USA; [Iverson, Katherine M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Iverson, Katherine M.; Pogoda, Terri K.] VA Boston Healthcare Syst, Ctr Healthcare Org & Implementat Res, Boston, MA USA; [Pogoda, Terri K.] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA	Iverson, KM (corresponding author), VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, 150 South Huntington Ave 116B-3, Boston, MA 02130 USA.	katherine.iverson@va.gov	Pogoda, Terri/F-6243-2012	Pogoda, Terri/0000-0003-1397-8780	Department of Veterans Affairs, Office of Research and Development, Health Services Research & Development (HSRD) ServiceUS Department of Veterans Affairs [CDA 10-029]	Supported by the Department of Veterans Affairs, Office of Research and Development, Health Services Research & Development (HSR&D) Service as part of KMI's HSR&D Career Development Award (CDA 10-029).	Amara J, 2014, WOMEN HEALTH ISS, V24, pE171, DOI 10.1016/j.whi.2013.12.004; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Banks ME, 2007, TRAUMA VIOLENCE ABUS, V8, P290, DOI 10.1177/1524838007303503; Broomfield J., 2014, SYNERGY, P1; Campbell JC, 2002, LANCET, V359, P1331, DOI 10.1016/S0140-6736(02)08336-8; Dichter M. E., 2013, MILITARY BEHAV HLTH, V1, P107, DOI [DOI 10.1080/21635781.2013.830062, 10.1080/21635781.2013.830062]; Dichter ME, 2011, WOMEN HEALTH ISS, V21, pS190, DOI 10.1016/j.whi.2011.04.008; Dillman D.A., 2011, MAIL INTERNET SURVEY; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Gerber MR, 2014, J WOMENS HEALTH, V23, P302, DOI 10.1089/jwh.2013.4513; Glass N, 2008, J EMERG MED, V35, P329, DOI 10.1016/j.jemermed.2007.02.065; Hendricks AM, 2013, BRAIN INJURY, V27, P125, DOI 10.3109/02699052.2012.729284; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; IOM (Institute of Medicine), 2011, CLIN PREV SERV WOM C; Iverson KM, 2014, RES NURS HEALTH, V37, P302, DOI 10.1002/nur.21602; Iverson KM, 2013, J TRAUMA STRESS, V26, P767, DOI 10.1002/jts.21867; Iverson KM, 2013, J FAM VIOLENCE, V28, P823, DOI 10.1007/s10896-013-9544-7; Iverson KM, 2013, J GEN INTERN MED, V28, P1288, DOI 10.1007/s11606-013-2534-x; Iverson KM, 2013, J WOMENS HEALTH, V22, P267, DOI 10.1089/jwh.2012.3755; Iverson KM, 2013, J TRAUMA STRESS, V26, P102, DOI 10.1002/jts.21781; Iverson KM, 2011, WOMEN HEALTH ISS, V21, pS210, DOI 10.1016/j.whi.2011.04.019; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Kwako LE, 2011, TRAUMA VIOLENCE ABUS, V12, P115, DOI 10.1177/1524838011404251; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moffitt TE, 1997, PSYCHOL ASSESSMENT, V9, P47, DOI 10.1037/1040-3590.9.1.47; National Research Council, 2013, RET HOM IR AFGH ASS; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Plichta SB, 2004, J INTERPERS VIOLENCE, V19, P1296, DOI 10.1177/0886260504269685; Pogoda TK, 2012, J REHABIL RES DEV, V49, P971, DOI 10.1682/JRRD.2011.06.0099; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Sheridan DJ, 2007, TRAUMA VIOLENCE ABUS, V8, P281, DOI 10.1177/1524838007303504; Shore AD, 2005, BRAIN INJURY, V19, P613, DOI 10.1080/02699050400013568; Straus M.A., 2007, ENCY DOMESTIC VIOLEN, P190; Straus MA, 1996, J FAM ISSUES, V17, P283, DOI 10.1177/019251396017003001; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Thomas KA, 2014, PSYCHOL WOMEN QUART, V38, P124, DOI 10.1177/0361684313488354; Thompson RS, 2006, AM J PREV MED, V30, P447, DOI 10.1016/j.amepre.2006.01.016; US Department of Veterans Affairs, 2001, 2001 NAT SURV VET NS; US Preventive Services Task Force, 2013, SCREEN INT PARTN VIO; Varvaro F F, 1993, Orthop Nurs, V12, P37, DOI 10.1097/00006416-199301000-00009; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Weathers F. W., 1993, ANN M INT SOC TRAUM; Widerstrom-Noga EG, 2009, J REHABIL RES DEV, V46, P1, DOI 10.1682/JRRD.2008.03.0038; World Health Organization, 2013, GLOB REG EST VIOL WO	45	32	33	0	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7079	1537-1948		MED CARE	Med. Care	APR	2015	53	4		1			S112	S119		10.1097/MLR.0000000000000263			8	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	DS3BL	WOS:000380657800019	25767964				2021-06-18	
J	Wang, X; Xie, H; Cotton, AS; Tamburrino, MB; Brickman, KR; Lewis, TJ; McLean, SA; Liberzon, I				Wang, Xin; Xie, Hong; Cotton, Andrew S.; Tamburrino, Marijo B.; Brickman, Kristopher R.; Lewis, Terrence J.; McLean, Samuel A.; Liberzon, Israel			Early Cortical Thickness Change after Mild Traumatic Brain Injury following Motor Vehicle Collision	JOURNAL OF NEUROTRAUMA			English	Article						motor vehicle collision; cortical thickness; mild TBI; progression; subacute	TENSOR IMAGING FINDINGS; HUMAN CEREBRAL-CORTEX; WORKING-MEMORY; ANATOMY; ABNORMALITIES; CONCUSSION; ACTIVATION; CHILDREN; OUTCOMES; IMPACT	In a motor vehicle collision (MVC), survivors often receive mild traumatic brain injuries (mTBI). Although there have been some reports of early white matter changes after an mTBI, much less is known about early cortical structural changes. To investigate early cortical changes within a few days after an MVC, we compared cortical thickness of mTBI survivors with non-mTBI survivors, then reexamined cortical thickness in the same survivors 3 months later. MVC survivors were categorized as mTBI or non-mTBI based on concussive symptoms documented in emergency departments (EDs). Cortical thickness was measured from MRI images using FreeSurfer within a few days and again at 3 months after MVC. Post-traumatic stress symptoms and physical conditions were also assessed. Compared with the non-mTBI group (n=23), the mTBI group (n=21) had thicker cortex in the left rostral middle frontal (rMFG) and right precuneus gyri, but thinner cortex in the left posterior middle temporal gyrus at 7.2 +/- 3.1 days after MVC. After 3 months, cortical thickness had decreased in left rMFG in the mTBI group but not in the non-mTBI group. The cortical thickness of the right precuneus region in the initial scans was positively correlated with acute traumatic stress symptoms for all survivors and with the number of reduced activity days for mTBI survivors who completed the follow-up. The preliminary results suggest that alterations in cortical thickness may occur at an early stage of mTBI and that frontal cortex structure may change dynamically over the initial 3 months after mTBI.	[Wang, Xin; Cotton, Andrew S.; Tamburrino, Marijo B.] Univ Toledo, Dept Psychiat, Toledo, OH 43614 USA; [Wang, Xin; Xie, Hong] Univ Toledo, Dept Neurosci, Toledo, OH 43614 USA; [Wang, Xin; Lewis, Terrence J.] Univ Toledo, Dept Radiol, Toledo, OH 43614 USA; [Brickman, Kristopher R.] Univ Toledo, Dept Emergency Med, Toledo, OH 43614 USA; [Wang, Xin; Liberzon, Israel] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA; [McLean, Samuel A.] Univ N Carolina, Dept Anesthesiol, Chapel Hill, NC USA	Wang, X (corresponding author), Univ Toledo, Dept Psychiat, 3120 Glendale Ave, Toledo, OH 43614 USA.	Xin.Wang2@utoledo.edu		McLean, Samuel/0000-0001-9482-3582; Liberzon, Israel/0000-0002-4990-556X	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21MH098198-01]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH098198] Funding Source: NIH RePORTER	The work is funded by NIH R21MH098198-01. We thank Dr. Michael M. Dennis, Cindy Grey, Susan Yeager, Lindsey Katschke, Michelle Haunus, and the Department of Radiology at the University of Toledo for technical support, Drs. Joe Migliori, Jr., and Eric Ferguson for clinical support, Dr. John Wall and Ms. Carol Brikmanis, MA, for editing the manuscript, and Karen Brenner, RN, and Rochelle Armola, RN, of ProMedica Health System for survivor recruitment.	Abu-Judeh H H, 2000, Nucl Med Rev Cent East Eur, V3, P5; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bederson JB, 1998, NEUROSURGERY, V42, P352, DOI 10.1097/00006123-199802000-00091; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2013, NEUROPSYCHOL REV, V23, P169, DOI 10.1007/s11065-013-9237-2; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Caner B, 2012, J NEUROCHEM, V123, P12, DOI 10.1111/j.1471-4159.2012.07939.x; Carlo CN, 2013, P NATL ACAD SCI USA, V110, P1488, DOI 10.1073/pnas.1221398110; Cavanna AE, 2006, BRAIN, V129, P564, DOI 10.1093/brain/awl004; Cruz-Orive LM, 2014, J MICROSC-OXFORD, V253, P119, DOI 10.1111/jmi.12103; Dale WE, 1999, CAN J PHYSIOL PHARM, V77, P763, DOI 10.1139/cjpp-77-10-763; DaSilva AF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003396; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Fischl B, 2012, NEUROIMAGE, V62, P774, DOI 10.1016/j.neuroimage.2012.01.021; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; Fox WC, 2013, NEUROL RES, V35, P223, DOI 10.1179/1743132813Y.0000000162; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; Friedman L, 1998, BRAIN LANG, V64, P231, DOI 10.1006/brln.1998.1953; Gao XA, 2011, J NEUROPATH EXP NEUR, V70, P183, DOI 10.1097/NEN.0b013e31820c6878; Gardner A, 2012, J NEUROTRAUM, V29, P2521, DOI 10.1089/neu.2012.2628; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Goel V, 2007, TRENDS COGN SCI, V11, P435, DOI 10.1016/j.tics.2007.09.003; Hagler DJ, 2006, NEUROIMAGE, V33, P1093, DOI 10.1016/j.neuroimage.2006.07.036; Han X, 2006, NEUROIMAGE, V32, P180, DOI 10.1016/j.neuroimage.2006.02.051; Hayasaka S, 2004, NEUROIMAGE, V22, P676, DOI 10.1016/j.neuroimage.2004.01.041; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; IADECOLA C, 1989, BRAIN RES, V501, P188, DOI 10.1016/0006-8993(89)91042-1; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kan EM, 2012, BRAIN RES BULL, V87, P359, DOI 10.1016/j.brainresbull.2012.01.007; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; Krainin Benjamin M, 2011, J Spec Oper Med, V11, P38; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Lewen A, 1999, ACTA NEUROCHIR, V141, P193, DOI 10.1007/s007010050286; Liberzon I, 2006, ANN NY ACAD SCI, V1071, P87, DOI 10.1196/annals.1364.009; Lillie Elizabeth M, 2013, Biomed Sci Instrum, V49, P297; Lindemer ER, 2013, NEUROIMAGE-CLIN, V2, P601, DOI 10.1016/j.nicl.2013.04.009; Ling JM, 2013, NEUROLOGY, V81, P2121, DOI 10.1212/01.wnl.0000437302.36064.b1; Makris N, 2006, NEUROIMAGE, V33, P139, DOI 10.1016/j.neuroimage.2006.04.220; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McDonald SD, 2010, CLIN PSYCHOL REV, V30, P976, DOI 10.1016/j.cpr.2010.06.012; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Patterson ZR, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00058; Ramnani N, 2004, NAT REV NEUROSCI, V5, P184, DOI 10.1038/nrn1343; Read KM, 2004, J TRAUMA, V57, P815, DOI 10.1097/01.TA.0000136289.15303.44; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Sekiguchi A, 2013, MOL PSYCHIATR, V18, P618, DOI 10.1038/mp.2012.51; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Tate DF, 2014, BRAIN IMAGING BEHAV, V8, P102, DOI 10.1007/s11682-013-9257-9; Tate DF, 2012, BRAIN IMAGING BEHAV, V6, P103, DOI 10.1007/s11682-012-9185-0; Tsai PS, 2009, J NEUROSCI, V29, P14553, DOI 10.1523/JNEUROSCI.3287-09.2009; Tuor UI, 2001, EXP NEUROL, V167, P272, DOI 10.1006/exnr.2000.7565; Urban JE, 2012, J NEUROTRAUM, V29, P2774, DOI 10.1089/neu.2012.2373; Vorobyev VA, 2004, COGNITIVE BRAIN RES, V20, P309, DOI 10.1016/j.cogbrainres.2004.03.011; Wang X, 2008, NEUROSCI LETT, V441, P145, DOI 10.1016/j.neulet.2008.06.013; Wang X, 2010, CEREB CORTEX, V20, P1513, DOI 10.1093/cercor/bhp226; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Wilde EA, 2012, INT J DEV NEUROSCI, V30, P267, DOI 10.1016/j.ijdevneu.2012.01.003; Wilde EA, 2011, INT J PSYCHOPHYSIOL, V82, P86, DOI 10.1016/j.ijpsycho.2011.04.006; Wilkins KC, 2011, DEPRESS ANXIETY, V28, P596, DOI 10.1002/da.20837; Yoganandan N, 2009, J BIOMECH, V42, P1177, DOI 10.1016/j.jbiomech.2009.03.029; Zhang SR, 2009, J REHABIL MED, V41, P1062, DOI 10.2340/16501977-0462; Zhou YX, 2013, RADIOLOGY, V267, P880, DOI 10.1148/radiol.13122542	72	32	33	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 1	2015	32	7					455	463		10.1089/neu.2014.3492			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CE4YV	WOS:000351837400005	25118568	Green Published			2021-06-18	
J	King, S; Green, HJ				King, Summer; Green, Heather Joy			Psychological intervention for improving cognitive function in cancer survivors: a literature review and randomized controlled trial	FRONTIERS IN ONCOLOGY			English	Article						cancer; cognitive function; cognitive rehabilitation; group; randomized controlled trial; survivorship	QUALITY-OF-LIFE; MEMORY SELF-EFFICACY; CHRONIC-FATIGUE-SYNDROME; BREAST-CANCER; ADJUVANT CHEMOTHERAPY; REPEATABLE BATTERY; EXECUTIVE FUNCTION; CLINICAL-TRIALS; IMPAIRMENT; DYSFUNCTION	Although the impact of cancer and associated treatments on cognitive functioning is becoming an increasingly recognized problem, there are few published studies that have investigated psychological interventions to address this issue. A waitlist randomized controlled trial methodology was used to assess the efficacy of a group cognitive rehabilitation intervention ("ReCog") that successfully targeted cancer-related cognitive decline in previously published pilot research. Participants were 29 cancer survivors who were randomly allocated to either the intervention group or a waitlist group who received the intervention at a later date, and 16 demographically matched community volunteers with no history of cancer (trial registration ACTRN12615000009516, available at http://www.ANZCTR.org.au/ACTRN12615000009516.aspx). The study was the first to include an adapted version of the Traumatic Brain Injury Self-Efficacy Scale to assess cognitive self-efficacy (CSE) in people who have experienced cancer. Results revealed participating in the intervention was associated with significantly faster performance on one objective cognitive task that measures processing speed and visual scanning. Significantly larger improvements for the intervention group were also found on measures of perceived cognitive impairments and CSE. There was some evidence to support the roles of CSE and illness perceptions as potential mechanisms of change for the intervention. Overall, the study provided additional evidence of feasibility and efficacy of group psychological intervention for targeting cancer-related cognitive decline.	Griffith Univ, Menzies Hlth Inst Queensland, Gold Coast, Qld, Australia; Griffith Univ, Sch Appl Psychol, Gold Coast, Qld, Australia	Green, HJ (corresponding author), Griffith Univ, Sch Appl Psychol, Parklands Dr,Gold Coast Campus, Southport, Qld 4222, Australia.	h.green@griffith.edu.au	Green, Heather/C-1169-2008	Green, Heather/0000-0003-4254-4076	Griffith University School of Applied Psychology; Griffith University Research Grant [GURG36603]; Psycho-Oncology Cooperative Research Group (PoCoG) Protocol Development Workshop; Cancer Australia; Cancer Institute NSW	This research was funded through Griffith University School of Applied Psychology, Griffith University Research Grant GURG36603 and the Psycho-Oncology Cooperative Research Group (PoCoG) Protocol Development Workshop 2007. PoCoG is jointly funded by Cancer Australia and the Cancer Institute NSW. This paper is based on a Doctor of Psychology (Clinical) dissertation by SK. We would like to thank Dr. Alana Schuurs for assistance with implementation of the intervention; Haley Webb for assistance with random allocation; and Elizabeth Adams, Jessica Davis, Cindy Dimitrievska, Donna Griffiths, Joanne Hughes, Natasha Innes, Claudine Lombard, Collette Morris, Sarah Nash, Britta Walker, and Codi White for assistance with data collection.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Aben L, 2011, CEREBROVASC DIS, V31, P566, DOI 10.1159/000324627; Ahles TA, 2002, J CLIN ONCOL, V20, P485, DOI 10.1200/JCO.2002.20.2.485; Ahles TA, 2007, NAT REV CANCER, V7, P192, DOI 10.1038/nrc2073; Ahn SH, 2007, ANN ONCOL, V18, P173, DOI 10.1093/annonc/mdl333; Antoni MH, 2001, HEALTH PSYCHOL, V20, P20, DOI 10.1037/0278-6133.20.1.20; Bandura A., 1997, SELF EFFICACY EXERCI, Vix; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Bender CM, 2001, J PAIN SYMPTOM MANAG, V21, P407, DOI 10.1016/S0885-3924(01)00268-8; Berger AM, 2012, CANCER-AM CANCER SOC, V118, P2261, DOI 10.1002/cncr.27475; BERRY JM, 1993, INT J BEHAV DEV, V16, P351, DOI 10.1177/016502549301600213; Biringer E, 2005, EUR ARCH PSY CLIN N, V255, P373, DOI 10.1007/s00406-005-0577-7; Bjordal K, 2000, EUR J CANCER, V36, P1796, DOI 10.1016/S0959-8049(00)00186-6; Bower JE, 2005, J CLIN ONCOL, V23, P8280, DOI 10.1200/JCO.2005.08.008; Bowling A., 1991, MEASURING HLTH REV Q; Boykoff N, 2009, J CANCER SURVIV, V3, P223, DOI 10.1007/s11764-009-0098-x; Brezden CB, 2000, J CLIN ONCOL, V18, P2695, DOI 10.1200/JCO.2000.18.14.2695; Broadbent E, 2006, J PSYCHOSOM RES, V60, P631, DOI 10.1016/j.jpsychores.2005.10.020; Campos MPO, 2011, ANN ONCOL, V22, P1273, DOI 10.1093/annonc/mdq458; Carlson MC, 2009, J GERONTOL A-BIOL, V64, P110, DOI 10.1093/gerona/gln008; Carver CS, 2004, HEALTH PSYCHOL, V23, P595, DOI 10.1037/0278-6133.23.6.595; CAVANAUGH JC, 1990, AGING COGNITION MENT, P189, DOI DOI 10.1016/S0166-4115(08)60788-8; Chelune GJ, 1993, NEUROPSYCHOLOGY, V7, P41, DOI DOI 10.1037/0894-4105.7.1.41; Cherrier MM, 2013, LIFE SCI, V93, P617, DOI 10.1016/j.lfs.2013.08.011; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Comijs HC, 2002, J AFFECT DISORDERS, V72, P157, DOI 10.1016/S0165-0327(01)00453-0; Cruess DG, 2000, PSYCHOSOM MED, V62, P304, DOI 10.1097/00006842-200005000-00002; Cruzado JA, 2014, SUPPORT CARE CANCER, V22, P1815, DOI 10.1007/s00520-014-2147-x; Cull A, 1996, BRIT J CANCER, V74, P1674, DOI 10.1038/bjc.1996.608; Curt GA, 2001, BMJ-BRIT MED J, V322, P1560, DOI 10.1136/bmj.322.7302.1560; Dietrich J, 2008, ONCOLOGIST, V13, P1285, DOI 10.1634/theoncologist.2008-0130; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; Duff K, 2005, J CLIN EXP NEUROPSYC, V27, P565, DOI 10.1080/13803390490918363; Ercoli LM, 2013, BRAIN IMAGING BEHAV, V7, P543, DOI 10.1007/s11682-013-9237-0; Fan HGM, 2008, SUPPORT CARE CANCER, V16, P577, DOI 10.1007/s00520-007-0341-9; Fardell JE, 2011, CLIN PHARMACOL THER, V90, P366, DOI 10.1038/clpt.2011.112; Fayers PM., 2001, EORTC QLQ C30 SCORIN; Ferguson RJ, 2007, PSYCHO-ONCOL, V16, P772, DOI 10.1002/pon.1133; Ferguson RJ, 2012, PSYCHO-ONCOLOGY, V21, P176, DOI 10.1002/pon.1878; Fulton C, 1998, Eur J Cancer Care (Engl), V7, P232; Gehring K, 2012, EXPERT REV ANTICANC, V12, P255, DOI [10.1586/era.11.202, 10.1586/ERA.11.202]; Green HJ, 2005, PSYCHOL HEALTH MED, V10, P145, DOI DOI 10.1080/13548500500093308; Green HJ, 2003, CLIN PSYCHOL, V7, P81, DOI [10.1080/13284200410001707533, DOI 10.1080/13284200410001707533]; Greene D, 1994, Cancer Pract, V2, P57; Hagger MS, 2003, PSYCHOL HEALTH, V18, P141, DOI 10.1080/088704403100081321; Helgeson VS, 2006, J CONSULT CLIN PSYCH, V74, P797, DOI 10.1037/0022-006X.74.5.797; Helgeson VS, 2004, HEALTH PSYCHOL, V23, P3, DOI 10.1037/0278-6133.23.1.3; Heritier SR, 2003, MED J AUSTRALIA, V179, P438, DOI 10.5694/j.1326-5377.2003.tb05627.x; Hess LM, 2007, ONCOL NURS FORUM, V34, P981, DOI 10.1188/07.ONF.981-994; Hodgson KD, 2013, CANCER TREAT REV, V39, P297, DOI 10.1016/j.ctrv.2012.11.001; Hofman M, 2007, ONCOLOGIST, V12, P4, DOI 10.1634/theoncologist.12-S1-4; Howell D.C., 2007, STAT METHODS PSYCHOL, V6th ed.; Huckans M, 2010, J REHABIL RES DEV, V47, P43, DOI 10.1682/JRRD.2009.02.0019; Hutchinson AD, 2012, CANCER TREAT REV, V38, P926, DOI 10.1016/j.ctrv.2012.05.002; Jacobs SR, 2007, J PAIN SYMPTOM MANAG, V33, P13, DOI 10.1016/j.jpainsymman.2006.06.011; Janelsins MC, 2011, SEMIN ONCOL, V38, P431, DOI 10.1053/j.seminoncol.2011.03.014; Jenkins V, 2004, PSYCHO-ONCOL, V13, P61, DOI 10.1002/pon.709; Jim HSL, 2012, J CLIN ONCOL, V30, P3578, DOI 10.1200/JCO.2011.39.5640; Jocham HR, 2009, INT J PALLIAT NURS, V15, P336, DOI 10.12968/ijpn.2009.15.7.43424; Kesler S, 2013, CLIN BREAST CANCER, V13, P299, DOI 10.1016/j.clbc.2013.02.004; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; Kohler CL, 2002, HEALTH PSYCHOL, V21, P610, DOI 10.1037/0278-6133.21.6.610; Krupp LB, 2000, NEUROLOGY, V55, P934, DOI 10.1212/WNL.55.7.934; Lemieux J, 2011, JNCI-J NATL CANCER I, V103, P178, DOI 10.1093/jnci/djq508; Leon AC, 2011, J PSYCHIATR RES, V45, P626, DOI 10.1016/j.jpsychires.2010.10.008; Leventhal H, 2004, SAGE HDB HLTH PSYCHO, P197; Man DWK, 2011, NEUROPSYCHOL REHABIL, V21, P884, DOI 10.1080/09602011.2011.627270; McDougall GJ, 2001, GERIATR NURS, V22, P185, DOI 10.1067/mgn.2001.117916; McDougall Graham J, 2001, Clin Gerontol, V23, P127, DOI 10.1300/J018v23n03_11; McDougall GJ, 2011, ARCH PSYCHIAT NURS, V25, P24, DOI 10.1016/j.apnu.2010.05.004; McDougall GJ, 2014, ARCH PSYCHIAT NURS, V28, P180, DOI 10.1016/j.apnu.2013.12.005; McKay C, 2007, ARCH CLIN NEUROPSYCH, V22, P91, DOI 10.1016/j.acn.2006.11.003; Mehnert A, 2008, J PSYCHOSOM RES, V64, P383, DOI 10.1016/j.jpsychores.2007.12.005; Mehnert A, 2007, PATIENT EDUC COUNS, V66, P108, DOI 10.1016/j.pec.2006.11.005; Meyers CA, 2005, CANCER-AM CANCER SOC, V104, P788, DOI 10.1002/cncr.21234; Minton O, 2008, BREAST CANCER RES TR, V112, P5, DOI 10.1007/s10549-007-9831-1; Mols F, 2005, EUR J CANCER, V41, P2613, DOI 10.1016/j.ejca.2005.05.017; Montazeri A, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-102; Montazeri A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-330; Morris SB, 2008, ORGAN RES METHODS, V11, P364, DOI 10.1177/1094428106291059; Paunonen SV, 2010, J PERS, V78, P339, DOI 10.1111/j.1467-6494.2009.00618.x; Petrie KJ, 2007, CURR OPIN PSYCHIATR, V20, P163, DOI 10.1097/YCO.0b013e328014a871; Poppelreuter M, 2004, EUR J CANCER, V40, P43, DOI 10.1016/j.ejca.2003.08.001; Poppelreuter M, 2009, J PSYCHOSOC ONCOL, V27, P274, DOI 10.1080/07347330902776044; Prue G, 2006, EUR J CANCER, V42, P846, DOI 10.1016/j.ejca.2005.11.026; Pullens MJJ, 2010, PSYCHO-ONCOLOGY, V19, P1127, DOI 10.1002/pon.1673; Quinten C, 2009, LANCET ONCOL, V10, P865, DOI 10.1016/S1470-2045(09)70200-1; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; REBOK GW, 1989, DEV PSYCHOL, V25, P714, DOI 10.1037/0012-1649.25.5.714; Reich M, 2008, BREAST CANCER RES TR, V110, P9, DOI 10.1007/s10549-007-9706-5; Reid LM, 2006, DEMENT GERIATR COGN, V22, P471, DOI 10.1159/000096295; Schagen SB, 2009, PSYCHO-ONCOL, V18, P674, DOI 10.1002/pon.1454; Schagen SB, 1999, CANCER, V85, P640, DOI 10.1002/(SICI)1097-0142(19990201)85:3<640::AID-CNCR14>3.0.CO;2-G; Schuurs A, 2009, PARTICIPANTS MANUAL; Schuurs A, 2009, CLINICIANS MANUAL FO; Schuurs A, 2013, PSYCHO-ONCOLOGY, V22, P1043, DOI 10.1002/pon.3102; Schwartz AL, 2000, CANCER INVEST, V18, P11, DOI 10.3109/07357900009023057; Servaes P, 2007, PSYCHO-ONCOL, V16, P787, DOI 10.1002/pon.1120; Silverberg ND, 2007, CLIN NEUROPSYCHOL, V21, P841, DOI 10.1080/13854040600850958; Smith S, 2003, INT J BEHAV MED, V10, P162, DOI 10.1207/S15327558IJBM1002_05; Tannock IF, 2004, J CLIN ONCOL, V22, P2233, DOI 10.1200/JCO.2004.08.094; Tchen N, 2003, J CLIN ONCOL, V21, P4175, DOI 10.1200/JCO.2003.01.119; Valentijn SAM, 2006, PSYCHOL AGING, V21, P165, DOI 10.1037/0882-7974.21.2.165; Valentine AD, 2001, CANCER, V92, P1694, DOI 10.1002/1097-0142(20010915)92:6+<1694::AID-CNCR1499>3.0.CO;2-S; van Dam FSAM, 1998, J NATL CANCER I, V90, P210, DOI 10.1093/jnci/90.3.210; vantSpijker A, 1997, PSYCHOSOM MED, V59, P280, DOI 10.1097/00006842-199705000-00011; Vardy J, 2007, CRIT REV ONCOL HEMAT, V63, P183, DOI 10.1016/j.critrevonc.2007.06.001; Vearncombe KJ, 2009, AUST PSYCHOL, V44, P235, DOI 10.1080/00050060903096652; Von Ah D, 2012, BREAST CANCER RES TR, V135, P799, DOI 10.1007/s10549-012-2210-6; Wagner LI, 2004, ANN BEHAV MED, V27, pS10; Wearden A, 1997, PSYCHOL MED, V27, P81, DOI 10.1017/S0033291796004035; Wefel JS, 2012, CURR NEUROL NEUROSCI, V12, P267, DOI 10.1007/s11910-012-0264-9; Wefel JS, 2004, CANCER-AM CANCER SOC, V100, P2292, DOI 10.1002/cncr.20272; Wefel JS, 2004, BRIT J CANCER, V90, P1691, DOI 10.1038/sj.bjc.6601772; WIENEKE MH, 1995, PSYCHO-ONCOL, V4, P61, DOI 10.1002/pon.2960040108; Wilson BA, 2002, NEUROPSYCHOL REHABIL, V12, P97, DOI 10.1080/09602010244000020	116	32	32	0	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	2234-943X			FRONT ONCOL	Front. Oncol.	MAR 25	2015	5								72	10.3389/fonc.2015.00072			18	Oncology	Oncology	CO3TY	WOS:000359084000001	25859431	DOAJ Gold, Green Published			2021-06-18	
J	Sigurdardottir, S; Andelic, N; Wehling, E; Roe, C; Anke, A; Skandsen, T; Holthe, OO; Jerstad, T; Aslaksen, PM; Schanke, AK				Sigurdardottir, Solrun; Andelic, Nada; Wehling, Eike; Roe, Cecilie; Anke, Audny; Skandsen, Toril; Holthe, Oyvor O.; Jerstad, Tone; Aslaksen, Per M.; Schanke, Anne-Kristine			Neuropsychological Functioning in a National Cohort of Severe Traumatic Brain Injury: Demographic and Acute Injury-Related Predictors	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive impairment; executive functions; memory; outcome prediction; traumatic brain injury	SEVERE HEAD-INJURY; PROGNOSTIC VALUE; MODERATE; REHABILITATION; PRODUCTIVITY; PERFORMANCE; RECOVERY; OUTCOMES; SCORE; CLASSIFICATION	Objectives: To determine the rates of cognitive impairment 1 year after severe traumatic brain injury (TBI) and to examine the influence of demographic, injury severity, rehabilitation, and subacute functional outcomes on cognitive outcomes 1 year after severe TBI. Setting: National multicenter cohort study over 2 years. Participants: Patients (N = 105), aged 16 years or older, with Glasgow Coma Scale score of 3 to 8 and Galveston Orientation and Amnesia Test score of more than 75. Main Measures : Neuropsychological tests representing cognitive domains of Executive Functions, Processing Speed, and Memory. Injury severity included Rotterdam computed tomography score, Glasgow Coma Scale score, and posttraumatic amnesia (PTA) duration, together with length of rehabilitation and Glasgow Outcome Scale-Extended score. Results: In total, 67% of patients with severe TBI had cognitive impairment. Executive Functions, Processing Speed, and Memory were impaired in 41%, 58%, and 57% of patients, respectively. Using multiple regression analysis, Processing Speed was significantly related to PTA duration, Glasgow Outcome Scale-Extended score, and length of inpatient rehabilitation (R-2 = 0.30); Memory was significantly related to Glasgow Outcome Scale-Extended score (R-2 = 0.15); and Executive Functions to PTA duration (R-2 = 0.10). Rotterdam computed tomography and Glasgow Coma Scale scores were not associated with cognitive functioning at 1 year postinjury. Conclusion: Findings highlight cognitive consequences of severe TBI, with nearly two-thirds of patients showing cognitive impairments in at least 1 of 3 cognitive domains. Regarding injury severity predictors, only PTA duration was related to cognitive functioning.	[Sigurdardottir, Solrun; Schanke, Anne-Kristine] Sunnaas Rehabil Hosp, Dept Res, N-1450 Nesoddtangen, Norway; [Sigurdardottir, Solrun; Andelic, Nada] Univ Oslo, Res Ctr Habilitat & Rehabil Models & Serv CHARM, Inst Hlth & Soc, Oslo, Norway; [Roe, Cecilie] Univ Oslo, Fac Med, Oslo, Norway; [Schanke, Anne-Kristine] Univ Oslo, Dept Psychol, Fac Social Sci, Oslo, Norway; [Andelic, Nada; Roe, Cecilie; Holthe, Oyvor O.] Oslo Univ Hosp, Dept Phys Med & Rehabil, Div Surg & Clin Neurosci, Oslo, Norway; [Jerstad, Tone] Oslo Univ Hosp, Dept Neuroradiol, Oslo, Norway; [Wehling, Eike] Haukeland Hosp, Dept Phys Med & Rehabil, N-5021 Bergen, Norway; [Wehling, Eike] Univ Bergen, Dept Biol & Med Psychol, Bergen, Norway; [Anke, Audny; Aslaksen, Per M.] Univ Hosp North Norway, Dept Rehabil, Tromso, Norway; [Anke, Audny] Univ Tromso, Fac Hlth Sci, Dept Clin Med, Tromso, Norway; [Aslaksen, Per M.] Univ Tromso, Fac Hlth Sci, Dept Psychol, Tromso, Norway; [Skandsen, Toril] St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [Skandsen, Toril] Norwegian Univ Sci & Technol NTNU, Fac Med, Dept Neurosci, Trondheim, Norway	Sigurdardottir, S (corresponding author), Sunnaas Rehabil Hosp, Dept Res, N-1450 Nesoddtangen, Norway.	solrun.sigurdardottir@sunnaas.no	Aslaksen, Per/J-6589-2019	Aslaksen, Per/0000-0002-9299-7260; Anke, Audny/0000-0002-2491-2560; Andelic, Nada/0000-0002-3719-4406			Andelic N, 2012, NEUROEPIDEMIOLOGY, V38, P259, DOI 10.1159/000338032; Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; Arango-Lasprilla JC, 2010, ARCH PHYS MED REHAB, V91, P1495, DOI 10.1016/j.apmr.2010.07.010; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL REV 19; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Brown AW, 2010, BRAIN INJURY, V24, P472, DOI 10.3109/02699051003610466; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; Crawford JR, 2007, NEUROPSYCHOLOGY, V21, P419, DOI 10.1037/0894-4105.21.4.419; De Guise E, 2005, BRAIN INJURY, V19, P1087, DOI 10.1080/02699050500149882; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Finnanger TG, 2013, BRAIN INJURY, V27, P1606, DOI 10.3109/02699052.2013.831127; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS51, DOI 10.1016/j.apmr.2008.09.552; GREEN SB, 1991, MULTIVAR BEHAV RES, V26, P499, DOI 10.1207/s15327906mbr2603_7; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hanlon RE, 2005, BRAIN INJURY, V19, P257, DOI 10.1080/02699050400004955; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Iverson GL, 2011, LITTLE BLACK BOOK OF NEUROPSYCHOLOGY: A SYNDROME-BASED APPROACH, P923, DOI 10.1007/978-0-387-76978-3_32; Jackson JC, 2007, J TRAUMA, V62, P80, DOI 10.1097/TA.0b013e31802ce9bd; Kalmar K, 2008, ARCH PHYS MED REHAB, V89, P942, DOI 10.1016/j.apmr.2008.01.008; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Kesler SR, 2000, BRAIN INJURY, V14, P851; Kesler SR, 2003, APPL NEUROPSYCHOL, V10, P153, DOI 10.1207/S15324826AN1003_04; Konigs M, 2012, J NEUROL NEUROSUR PS, V83, P1048, DOI 10.1136/jnnp-2012-302635; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MacCallum RC, 1999, PSYCHOL METHODS, V4, P84, DOI 10.1037/1082-989x.4.1.84; Meyers J., 1995, REY COMPLEX FIGURE T; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; Novack TA, 2001, ARCH PHYS MED REHAB, V82, P300, DOI 10.1053/apmr.2001.18222; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P567, DOI 10.1080/13803390500434466; Thais MERD, 2014, J NEUROPSYCHOL, V8, P125, DOI 10.1111/jnp.12000; Roe C, 2012, J NEUROL RES, V2, P134, DOI DOI 10.4021/JNR133W; Schretlen DJ, 2008, J INT NEUROPSYCH SOC, V14, P436, DOI 10.1017/S1355617708080387; Senathi-Raja D, 2010, NEUROPSYCHOLOGY, V24, P336, DOI 10.1037/a0018239; Sigurdardottir S, 2010, NEUROPSYCHOLOGY, V24, P504, DOI 10.1037/a0018934; Sigurdardottir S, 2009, J INT NEUROPSYCH SOC, V15, P740, DOI 10.1017/S1355617709990452; Skandsen T, 2008, CLIN REHABIL, V22, P653, DOI 10.1177/0269215508089067; Skandsen T, 2011, J NEUROTRAUM, V28, P691, DOI 10.1089/neu.2010.1590; Skandsen T, 2010, ARCH PHYS MED REHAB, V91, P1904, DOI 10.1016/j.apmr.2010.08.021; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; Stuss DT, 2011, CURR OPIN NEUROL, V24, P584, DOI 10.1097/WCO.0b013e32834c7eb9; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Walker WC, 2010, J NEUROL NEUROSUR PS, V81, P87, DOI 10.1136/jnnp.2008.161570; Wechsler D, 1997, WAIS 3 ADM SCORING M; Williams MW, 2013, CLIN NEUROPSYCHOL, V27, P356, DOI 10.1080/13854046.2013.765507; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	55	32	33	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2015	30	2					E1	E12		10.1097/HTR.0000000000000039			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CF1MG	WOS:000352309300001	24695265	Green Accepted			2021-06-18	
J	Briggs, A; Gates, JD; Kaufman, RM; Calahan, C; Gormley, WB; Havens, JM				Briggs, Alexandra; Gates, Jonathan D.; Kaufman, Richard M.; Calahan, Christopher; Gormley, William B.; Havens, Joaquim M.			Platelet dysfunction and platelet transfusion in traumatic brain injury	JOURNAL OF SURGICAL RESEARCH			English	Article						Traumatic brain injury; Aspirin; Platelet transfusion; Multiplate aggregometry	INTRACRANIAL HEMORRHAGE; ANTIPLATELET THERAPY; COAGULOPATHY; CLOPIDOGREL; ACTIVATION; ASPIRIN; REVERSAL; MODEL	Background: Both aspirin therapy and trauma impair platelet function. Platelet dysfunction is associated with worse outcomes in patients with traumatic intracranial hemorrhage (ICH). Platelet transfusion is often used to limit progression of ICH in patients on aspirin, but has not been shown to improve platelet function or outcomes. We hypothesized that platelet transfusion would improve aspirin-induced, but not trauma-induced, platelet dysfunction. Materials and methods: In this prospective trial, blood samples were collected from patients evaluated in our level 1 trauma center with traumatic ICH, at the time of arrival and at the next clinical laboratory draw after admission. Patients on aspirin therapy were transfused one apheresis unit of platelets. Platelet function was assessed using a Multiplate multiple electrode aggregometer. Platelet activation was induced by collagen (COL) and arachidonic acid (AA). Agonist responses are reported as area under the aggregation curve in units (U). Reference ranges for agonist response were provided by the manufacturer, based on studies of healthy controls. Results: Seventeen patients with isolated ICH were enrolled, twelve taking aspirin and five not taking aspirin. All patients on aspirin received platelet transfusion. Median admission platelet function in patients taking aspirin was abnormal in response to both agonists. After transfusion, median platelet function in response to AA improved from 19.0 U to 26.0 U (P = 0.012), whereas there was no improvement in the COL response. In patients not on aspirin, platelet response to COL was abnormal at both time points. Conclusions: Patients with isolated ICH have trauma-induced platelet dysfunction. In addition, patients on aspirin have drug-induced abnormalities in platelet response to AA. Platelet transfusion improves aspirin-induced, but not trauma-induced, platelet dysfunction. (C) 2015 Elsevier Inc. All rights reserved.	[Briggs, Alexandra; Gates, Jonathan D.; Kaufman, Richard M.; Calahan, Christopher; Gormley, William B.; Havens, Joaquim M.] Brigham & Womens Hosp, Boston, MA 02115 USA	Havens, JM (corresponding author), Brigham & Womens Hosp, Div Trauma Burn & Surg Crit Care, 75 Francis St, Boston, MA 02115 USA.	jhavens@partners.org	Kaufman, Richard M/E-8890-2018	Kaufman, Richard M/0000-0003-1520-4535; Calahan, Christopher/0000-0002-9631-8966			Bachelani AM, 2011, SURGERY, V150, P836, DOI 10.1016/j.surg.2011.07.059; Campbell PG, 2010, WORLD NEUROSURG, V74, P279, DOI 10.1016/j.wneu.2010.05.030; Davis PK, 2013, NEUROCRIT CARE, V18, P201, DOI 10.1007/s12028-012-9745-6; Donahue DL, 2014, J NEUROTRAUM, V31, P404, DOI 10.1089/neu.2013.3089; Farndale RW, 2006, BLOOD CELL MOL DIS, V36, P162, DOI 10.1016/j.bcmd.2005.12.016; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Jacoby RC, 2001, J TRAUMA, V51, P639, DOI 10.1097/00005373-200110000-00003; Joseph B, 2013, J TRAUMA ACUTE CARE, V75, P990, DOI 10.1097/TA.0b013e3182a96591; Kutcher ME, 2012, J TRAUMA ACUTE CARE, V73, P13, DOI 10.1097/TA.0b013e318256deab; Nishijima DK, 2012, J TRAUMA ACUTE CARE, V72, P1658, DOI 10.1097/TA.0b013e318256dfc5; Sillesen M, 2013, J TRAUMA ACUTE CARE, V74, P1252, DOI 10.1097/TA.0b013e31828c7a6b; Surin WR, 2008, THROMB RES, V122, P786, DOI 10.1016/j.thromres.2007.10.005; Taylor G, 2013, J TRAUMA ACUTE CARE, V74, P1367, DOI 10.1097/TA.0b013e31828cca61; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234	16	32	34	0	12	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	FEB	2015	193	2					802	806		10.1016/j.jss.2014.08.016			5	Surgery	Surgery	AW4IK	WOS:000346244300039	25218281				2021-06-18	
J	Carlozzi, NE; Kirsch, NL; Kisala, PA; Tulsky, DS				Carlozzi, Noelle E.; Kirsch, Ned L.; Kisala, Pamela A.; Tulsky, David S.			An Examination of the Wechsler Adult Intelligence Scales, Fourth Edition (WAIS-IV) in Individuals with Complicated Mild, Moderate and Severe Traumatic Brain Injury (TBI)	CLINICAL NEUROPSYCHOLOGIST			English	Article						Memory; TBI; WAIS-IV; Wechsler Adult Intelligence Scale-Fourth Edition; Assessment.; Traumatic Brain Injury	CONFIRMATORY FACTOR-ANALYSIS; INDEX SCORE PATTERNS; OF-THE-LITERATURE; COGNITIVE REHABILITATION; MEMORY SCALE; INSUFFICIENT EFFORT; CLINICAL UTILITY; HEAD-INJURY; DIGIT SPAN; WMS-III	This study examined the clinical utility of the Wechsler Adult Intelligence Scales-Fourth Edition (WAIS-IV) in individuals with complicated mild, moderate or severe TBI. One hundred individuals with TBI (n = 35 complicated mild or moderate TBI; n = 65 severe TBI) and 100 control participants matched on key demographic variables from the WAIS-IV normative dataset completed the WAIS-IV. Univariate analyses indicated that participants with severe TBI had poorer performance than matched controls on all index scores and subtests (except Matrix Reasoning). Individuals with complicated mild/moderate TBI performed more poorly than controls on the Working Memory Index (WMI), Processing Speed Index (PSI), and Full Scale IQ (FSIQ), and on four subtests: the two processing speed subtests (SS, CD), two working memory subtests (AR, LN), and a perceptual reasoning subtest (BD). Participants with severe TBI had significantly lower scores than the complicated mild/moderate TBI on PSI, and on three subtests: the two processing speed subtests (SS and CD), and the new visual puzzles test. Effect sizes for index and subtest scores were generally small-to-moderate for the group with complicated mild/moderate and moderate-to-large for the group with severe TBI. PSI also showed good sensitivity and specificity for classifying individuals with severe TBI versus controls. Findings provide support for the clinical utility of the WAIS-IV in individuals with complicated mild, moderate, and severe TBI.	[Carlozzi, Noelle E.; Kirsch, Ned L.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Kisala, Pamela A.; Tulsky, David S.] Univ Delaware, Dept Phys Therapy, Newark, DE 19713 USA; [Tulsky, David S.] Kessler Fdn, Neuropsychol & Neurosci Lab, Spinal Cord Injury Lab, W Orange, NJ 07052 USA	Carlozzi, NE (corresponding author), Univ Michigan, Med Ctr, Dept Phys Med & Rehabil, North Campus Res Complex,Bldg 14,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	carlozzi@med.umich.edu		Tulsky, David/0000-0002-4335-4509	National Institute on Disability and Rehabilitation Research [H133G070138]	This study was supported in part by the National Institute on Disability and Rehabilitation Research (grant # H133G070138). Standardization data derived from the Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV). Copyright (c) NCS Pearson, Inc. Used with permission. All rights reserved.	Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Axelrod BN, 2002, INT J NEUROSCI, V112, P1479, DOI 10.1080/00207450290158377; Axelrod BN, 2001, ARCH CLIN NEUROPSYCH, V16, P293, DOI 10.1016/S0887-6177(00)00048-2; Baxendale S, 2014, J CLIN EXP NEUROPSYC, V36, P137, DOI 10.1080/13803395.2013.870535; Brooks BL, 2011, ASSESSMENT, V18, P156, DOI 10.1177/1073191110385316; Canivez G. L., 2010, 18 MENTAL MEASUREMEN, P684; Canivez GL, 2010, PSYCHOL ASSESSMENT, V22, P827, DOI 10.1037/a0020429; Carlozzi NE, 2013, J CLIN EXP NEUROPSYC, V35, P906, DOI 10.1080/13803395.2013.833178; Cicerone KD, 1996, BRAIN INJURY, V10, P277, DOI 10.1080/026990596124458; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Donders J, 2001, ASSESSMENT, V8, P193, DOI 10.1177/107319110100800207; Donders J, 2002, PSYCHOL ASSESSMENT, V14, P360, DOI 10.1037//1040-3590.14.3.360; Donders J, 2015, ASSESSMENT, V22, P17, DOI 10.1177/1073191114530776; Drozdick LW, 2011, ASSESSMENT, V18, P141, DOI 10.1177/1073191110382843; Esbjornsson E, 2013, BRAIN INJURY, V27, P521, DOI 10.3109/02699052.2012.743179; Fisher D C, 2000, Appl Neuropsychol, V7, P126, DOI 10.1207/S15324826AN0703_2; FLYNN JR, 1987, PSYCHOL BULL, V101, P171, DOI 10.1037/0033-2909.101.2.171; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; Grimes DA, 2005, LANCET, V365, P1500, DOI 10.1016/S0140-6736(05)66422-7; Harman-Smith YE, 2013, J CLIN EXP NEUROPSYC, V35, P785, DOI 10.1080/13803395.2013.824554; Hawkins KA, 1998, CLIN NEUROPSYCHOL, V12, P535, DOI 10.1076/clin.12.4.535.7236; Holdnack J, 2011, ASSESSMENT, V18, P192, DOI 10.1177/1073191110394771; Holdnack JA, 2011, ASSESSMENT, V18, P178, DOI 10.1177/1073191110393106; Kashluba S, 2008, ARCH PHYS MED REHAB, V89, P904, DOI 10.1016/j.apmr.2007.12.029; Langeluddecke PM, 2003, CLIN NEUROPSYCHOL, V17, P273, DOI 10.1076/clin.17.2.273.16499; Langeluddecke PM, 2004, CLIN NEUROPSYCHOL, V18, P423, DOI 10.1080/1385404049052422; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; Michel NM, 2013, ASSESSMENT, V20, P462, DOI 10.1177/1073191113478153; Miller JB, 2011, CLIN NEUROPSYCHOL, V25, P160, DOI 10.1080/13854046.2010.533197; Millis SR, 2001, J CLIN EXP NEUROPSYC, V23, P809, DOI 10.1076/jcen.23.6.809.1017; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Nelson JM, 2013, PSYCHOL ASSESSMENT, V25, P618, DOI 10.1037/a0032086; Palacios EM, 2013, CORTEX, V49, P646, DOI 10.1016/j.cortex.2012.02.011; Pearson, WMS 3 WMS 4 RATIONAL; Psychological Corporation, 1997, WAIS 3 WMS 3 TECHN M; Reese CS, 2012, ARCH CLIN NEUROPSYCH, V27, P176, DOI 10.1093/arclin/acr117; Reynolds MR, 2013, RES DEV DISABIL, V34, P3235, DOI 10.1016/j.ridd.2013.06.029; Ryan JJ, 2005, INT J NEUROSCI, V115, P129, DOI 10.1080/00207450490512704; Ryan JJ, 2012, J CLIN EXP NEUROPSYC, V34, P571, DOI 10.1080/13803395.2012.666229; Spencer RJ, 2013, CLIN NEUROPSYCHOL, V27, P1362, DOI 10.1080/13854046.2013.845248; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; Strauss E, 2000, PSYCHOL ASSESSMENT, V12, P237, DOI 10.1037/1040-3590.12.3.237; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Strong CAH, 2005, J CLIN EXP NEUROPSYC, V27, P746, DOI 10.1081/13803390490919155; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; The Psychological Corporation, 2008, WAIS 4 TECHN INT MAN; Theiling J, 2013, GESUNDHEITSWESEN, V75, P768, DOI 10.1055/s-0033-1357163; Theiling J, 2016, J ATTEN DISORD, V20, P913, DOI 10.1177/1087054713518241; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; Traumatic Brain Injury Model Systems National Data Center, 2006, TRAUM BRAIN INJ MOD; Tulsky D. S., 2000, HDB PSYCHOL ASSESSME; Tulsky D.S., 2003, CLIN INTERPRETATION, P147; Tulsky DS, 2000, PSYCHOL ASSESSMENT, V12, P253, DOI 10.1037//1040-3590.12.3.253; Tulsky DS, 2003, PSYCHOL ASSESSMENT, V15, P149, DOI 10.1037/1040-3590.15.2.149; van der Heijden P, 2003, ASSESSMENT, V10, P115, DOI 10.1177/1073191103010002001; van der Heijden P, 2003, J CLIN EXP NEUROPSYC, V25, P59, DOI 10.1076/jcen.25.1.59.13627; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; West LK, 2011, J NEUROPSYCHOL, V5, P114, DOI 10.1348/174866410X521434; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	68	32	33	1	52	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	JAN 2	2015	29	1					21	37		10.1080/13854046.2015.1005677			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	CC4CS	WOS:000350299000003	25646823				2021-06-18	
J	Dahm, J; Ponsford, J				Dahm, Jane; Ponsford, Jennie			Comparison of long-term outcomes following traumatic injury: What is the unique experience for those with brain injury compared with orthopaedic injury?	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Traumatic brain injury; Outcomes; Orthopaedic trauma; Comparative study	QUALITY-OF-LIFE; POSTTRAUMATIC-STRESS-DISORDER; FATIGUE SEVERITY SCALE; HEAD-INJURY; PSYCHIATRIC-DISORDERS; MULTIPLE INJURIES; DEPRESSION SCALE; HOSPITAL ANXIETY; MAJOR TRAUMA; PSYCHOMETRIC PROPERTIES	Objective: Whilst it has been well-demonstrated that traumatic brain injury (TBI) results in long-term cognitive, behavioural and emotional difficulties, less is understood about how these outcomes differ from those following traumatic orthopaedic injury (TOI). The aim of this study was to compare self-reported outcomes at 5-10 years post-injury for those with TBI, TOI, and uninjured controls. It was hypothesised that participants with TBI would have greater cognitive difficulties; participants with TOI and TBI would have similar functional and physical outcomes, both being poorer than controls; and participants with TBI would have poorer psychosocial outcomes than those with TOI. Participants and methods: Eighty-eight individuals with complicated mild to severe TBI and 96 with TOI recruited during inpatient rehabilitation were followed up 5-10 years post-injury, together with 48 controls followed over a similar period. Self-report measures of global functioning (GOS-E), quality of life (SF-36), psychological wellbeing (SCL-90-R, HADS, PCL-S), psychosocial difficulties (SIP), cognitive difficulties (SF-36 COG), pain (BPI), and fatigue (FSS) were administered. Results: Outcomes for individuals with TBI and TOI differed significantly from controls, with poorer global functioning, and greater psychological distress and interference from pain. Only participants with TBI reported greater cognitive difficulties and anxiety than controls, and were less likely to be employed or in a relationship. Participants with TBI reported greater anxiety, PTSD, psychological distress and psychosocial difficulties than those with TOI. Conclusions: Both TOI and TBI cause long-term disability, interference from pain, and psychological distress. However, cognitive impairments, unemployment, lack of long-term relationships, anxiety and PTSD are more substantial long-term problems following TBI. Findings from this study have implications for managing risks associated with these injury groups and tailoring rehabilitation to improve long-term outcomes. (C) 2014 Elsevier Ltd. All rights reserved.	[Dahm, Jane; Ponsford, Jennie] Monash Univ, Sch Psychol Sci, Clayton, Vic 3800, Australia; [Ponsford, Jennie] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Ponsford, Jennie] Natl Trauma Res Inst, Melbourne, Vic, Australia	Dahm, J (corresponding author), Monash Univ, Sch Psychol Sci, Bldg 17,Wellington Rd, Clayton, Vic 3800, Australia.	jane.dahm@monash.edu			Transport Accident Commission (TAC), through the Institute for Safety, Compensation and Recovery Research (ISCRR)	Information for individuals with traumatic brain injury was accessed from data collected for the Longitudinal Head Injury Study funded by the Transport Accident Commission (TAC), through the Institute for Safety, Compensation and Recovery Research (ISCRR).	Adkins JW, 2008, J ANXIETY DISORD, V22, P1393, DOI 10.1016/j.janxdis.2008.02.002; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Ardolino A, 2012, INJURY, V43, P1662, DOI 10.1016/j.injury.2012.05.008; Australian Bureau of Statistics, 2008, NAT SURV MENT HLTH W; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; Bhandari M, 2008, CAN J SURG, V51, P15; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bouillon B, 2002, RESTOR NEUROL NEUROS, V20, P125; Braden CA, 2012, BRAIN INJURY, V26, P1315, DOI 10.3109/02699052.2012.706351; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; Cameron PA, 2006, INJURY, V37, P1178, DOI 10.1016/j.injury.2006.07.015; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dahm J, 2013, J AFFECT DISORDERS, V151, P392, DOI 10.1016/j.jad.2013.06.011; Derogatis L.R, 1994, SYMPTOM CHECKLIST 90; DIKMEN S, 1993, BRAIN INJURY, V7, P113, DOI 10.3109/02699059309008165; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Ehlers A, 2000, BEHAV RES THER, V38, P319, DOI 10.1016/S0005-7967(99)00123-0; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Frenisy MC, 2006, J TRAUMA, V60, P1018, DOI 10.1097/01-ta.0000215977.00034.c2; Friedland JF, 2001, J NERV MENT DIS, V189, P426, DOI 10.1097/00005053-200107000-00003; Gabbe BJ, 2013, ANN SURG, V257, P166, DOI 10.1097/SLA.0b013e31825d7422; Ghinassi C. W., 2010, ANXIETY; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Gould KR, 2011, J NEUROTRAUM, V28, P1155, DOI 10.1089/neu.2010.1528; Gross T, 2012, ACTA ANAESTH SCAND, V56, P1163, DOI 10.1111/j.1399-6576.2012.02724.x; Haagsma JA, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-236; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Harvey AG, 2003, J INT NEUROPSYCH SOC, V9, P663, DOI 10.1017/S1355617703940069; Helps Y., 2008, INJURY RES STAT SERI, V45; Herrmann C, 1997, J PSYCHOSOM RES, V42, P17, DOI 10.1016/S0022-3999(96)00216-4; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hills A., 2011, FOOLPROOF GUIDE STAT; Holtslag HR, 2007, J TRAUMA, V62, P919, DOI 10.1097/01.ta.0000224124.47646.62; Hoofien D, 2005, APPL NEUROPSYCHOL, V12, P30, DOI 10.1207/s15324826an1201_6; Hoofien D, 2001, BRAIN INJURY, V15, P189; Keller S, 2004, CLIN J PAIN, V20, P309, DOI 10.1097/00002508-200409000-00005; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; MacKenzie EJ, 2002, J TRAUMA, V52, P527, DOI 10.1097/00005373-200203000-00018; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; McCarthy ML, 2003, J BONE JOINT SURG AM, V85A, P1689, DOI 10.2106/00004623-200309000-00006; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ouellet MC, 2009, J REHABIL MED, V41, P179, DOI 10.2340/16501977-0306; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Ponsford J., 2013, TRAUMATIC BRAIN INJU; Ponsford J, 2008, J TRAUMA, V64, P1001, DOI 10.1097/TA.0b013e31809fec16; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Raichle KA, 2006, J PAIN, V7, P179, DOI 10.1016/j.jpain.2005.10.007; Read KM, 2004, J TRAUMA, V57, P815, DOI 10.1097/01.TA.0000136289.15303.44; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Schonberger M, 2010, PSYCHIAT RES, V179, P342, DOI 10.1016/j.psychres.2009.07.003; Steel J, 2010, J TRAUMA, V69, P523, DOI 10.1097/TA.0b013e3181e90c24; Tabachnick BG, 2007, USING MULTIVARIATE S; Tan G, 2004, J PAIN, V5, P133, DOI 10.1016/j.jpain.2003.12.005; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Testa JA, 2005, ARCH PHYS MED REHAB, V86, P1815, DOI 10.1016/j.apmr.2005.03.010; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; The Management of Concussion/mTBl Working Group, 2009, VA DOD CLIN PRACT GU; Valko PO, 2008, SLEEP, V31, P1601, DOI 10.1093/sleep/31.11.1601; Ware JE., 1993, SF 36 HLTH SURVEY MA; Weathers F. W., 1993, 9 ANN C INT SOC TRAU; Westcott MC, 2005, BRAIN INJURY, V19, P1261, DOI 10.1080/02699050500150104; Williams WH, 2002, J TRAUMA STRESS, V15, P397, DOI 10.1023/A:1020185325026; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wood RLI, 2006, J NEUROL NEUROSUR PS, V77, P1180, DOI 10.1136/jnnp.2006.091553; Wood RL, 2008, EUR J ANAESTH, V25, P115, DOI 10.1017/S0265021507003432; Wood RL, 2006, J NEUROL NEUROSUR PS, V77, P71, DOI 10.1136/jnnp.2005.065540; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158; Zeckey C, 2011, BRAIN INJURY, V25, P551, DOI 10.3109/02699052.2011.568036; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472	85	32	32	0	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	JAN	2015	46	1					142	149		10.1016/j.injury.2014.07.012			8	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	AX1YJ	WOS:000346739600027	25123975				2021-06-18	
J	Finnanger, TG; Olsen, A; Skandsen, T; Lydersen, S; Vik, A; Evensen, KAI; Catroppa, C; Haberg, AK; Andersson, S; Indredavik, MS				Finnanger, Torun Gangaune; Olsen, Alexander; Skandsen, Toril; Lydersen, Stian; Vik, Anne; Evensen, Kari Anne I.; Catroppa, Cathy; Haberg, Asta K.; Andersson, Stein; Indredavik, Marit S.			Life after Adolescent and Adult Moderate and Severe Traumatic Brain Injury: Self-Reported Executive, Emotional, and Behavioural Function 2-5 Years after Injury	BEHAVIOURAL NEUROLOGY			English	Article							QUALITY-OF-LIFE; POSTTRAUMATIC-STRESS-DISORDER; COGNITIVE IMPAIRMENT; HEAD-INJURY; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC-DISORDERS; SUBJECTIVE COMPLAINTS; MAJOR DEPRESSION; RATING INVENTORY; MOOD DISORDERS	Survivors of moderate-severe Traumatic Brain Injury (TBI) are at risk for long-term cognitive, emotional, and behavioural problems. This prospective cohort study investigated self-reported executive, emotional, and behavioural problems in the late chronic phase of moderate and severe TBI, if demographic characteristics (i.e., age, years of education), injury characteristics (Glasgow Coma Scale score, MRI findings such as traumatic axonal injury (TAI), or duration of posttraumatic amnesia), symptoms of depression, or neuropsychological variables in the first year after injury predicted long-term self-reported function. Self-reported executive, emotional, and behavioural functioning were assessed among individuals with moderate and severe TBI (N = 67, age range 15-65 years at time of injury) 2-5 years after TBI, compared to a healthy matched control group (N = 72). Results revealed significantly more attentional, emotional regulation, and psychological difficulties in the TBI group than controls. Demographic and early clinical variables were associated with poorer cognitive and emotional outcome. Fewer years of education and depressive symptoms predicted greater executive dysfunction. Younger age at injury predicted more aggressive and rule-breaking behaviour. TAI and depressive symptoms predicted Internalizing problems and greater executive dysfunction. In conclusion, age, education, TAI, and depression appear to elevate risk for poor long-term outcome, emphasising the need for long-term follow-up of patients presenting with risk factors.	[Finnanger, Torun Gangaune; Lydersen, Stian; Indredavik, Marit S.] Norwegian Univ Sci & Technol NTNU, Fac Med, Reg Ctr Child & Youth Mental Hlth & Child Welf Ce, N-7491 Trondheim, Norway; [Finnanger, Torun Gangaune; Indredavik, Marit S.] Univ Trondheim Hosp, St Olavs Hosp, Dept Child & Adolescent Psychiat, Div Mental Healthcare, N-7006 Trondheim, Norway; [Finnanger, Torun Gangaune] Univ Trondheim Hosp, St Olavs Hosp, Childrens Clin, N-7006 Trondheim, Norway; [Olsen, Alexander; Haberg, Asta K.] Norwegian Univ Sci & Technol, MI Lab, N-7491 Trondheim, Norway; [Olsen, Alexander; Haberg, Asta K.] Norwegian Univ Sci & Technol, Dept Circulat & Med Imaging, N-7491 Trondheim, Norway; [Olsen, Alexander; Skandsen, Toril] Univ Trondheim Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, N-7006 Trondheim, Norway; [Skandsen, Toril; Vik, Anne] Norwegian Univ Sci & Technol, Dept Neurosci, Fac Med, N-7491 Trondheim, Norway; [Vik, Anne] Univ Trondheim Hosp, St Olavs Hosp, Dept Neurosurg, Neuroclin, N-7006 Trondheim, Norway; [Evensen, Kari Anne I.] Norwegian Univ Sci & Technol, Dept Lab Med Children & Womens Hlth, Dept Publ Hlth & Gen Practice, N-7491 Trondheim, Norway; [Evensen, Kari Anne I.] Trondheim Municipal, Dept Physiotherapy, Trondheim, Norway; [Catroppa, Cathy] Murdoch Childrens Res Inst, Child Neuropsychol, Melbourne, Vic 3052, Australia; [Catroppa, Cathy] Univ Melbourne, Dept Pediat, Melbourne, Vic 3010, Australia; [Catroppa, Cathy] Univ Melbourne, Sch Psychol Sci, Melbourne, Vic 3010, Australia; [Andersson, Stein] Oslo Univ Hosp, Dept Psychosomat Med, N-0424 Oslo, Norway; [Andersson, Stein] Univ Oslo, Dept Psychol, N-0373 Oslo, Norway	Finnanger, TG (corresponding author), Norwegian Univ Sci & Technol NTNU, Fac Med, Reg Ctr Child & Youth Mental Hlth & Child Welf Ce, N-7491 Trondheim, Norway.	torun.g.finnanger@ntnu.no	Olsen, Alexander/P-5235-2019	Olsen, Alexander/0000-0001-8691-3860; Evensen, Kari Anne I./0000-0002-0129-0164	Norwegian Extra Foundation for Health and Rehabilitation [2010/2/0105]; Liaison Committee [47063700]; SINTEF Unimed Innovation Research Fund [09/9603]; Norwegian research Council, through MI Lab at the Norwegian University of Science and Technology; National Center of Competence Services for functional MRI, Department of Medical imaging, Trondheim University Hospital	The authors thank Brit Bjorklimo and neuropsychologists at the Department of Physical Medicine and Rehabilitation, St. Olavs Hospital, for assistance with collection and preparation of the neuropsychological data and Beate Holmqvist Karlsen, Stine B. Lund, and Otto Aarhaug for research assistance and outcome assessment. The authors would also like to thank Alexandra Maria Costache and Gunnar Gotaas for their contribution in data collection and assistance in the process of preprocessing self-report data in the follow-up phase of the project. This work was supported by the Norwegian Extra Foundation for Health and Rehabilitation (first author, Grant no. 2010/2/0105); the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU) (first author, Grant no. 47063700); and SINTEF Unimed Innovation Research Fund (first author, Grant no. 09/9603). The Norwegian research Council, through MI Lab at the Norwegian University of Science and Technology, and the National Center of Competence Services for functional MRI, Department of Medical imaging, Trondheim University Hospital, also contributed financially to this project.	Achenbach T. M., 2003, MANUAL ASEBA ADULT F; Altman DA, 2000, STAT CONFIDENCE, V2nd; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Beauchamp M, 2011, DEV NEUROPSYCHOL, V36, P578, DOI 10.1080/87565641.2011.555572; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Beck A. T., 1979, COGNITIVE THERAPY DE; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Cicerone K, 2006, J COGNITIVE NEUROSCI, V18, P1212, DOI 10.1162/jocn.2006.18.7.1212; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Conners C., 2000, CONNERS CONTINUOUS P; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; Di Battista A, 2015, BRAIN INJURY, V29, P573, DOI 10.3109/02699052.2014.989905; Di Battista A, 2012, J NEUROTRAUM, V29, P1717, DOI 10.1089/neu.2011.2157; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Donders J., 2015, J HEAD TRAUMA REHABI; Dosenbach NUF, 2007, P NATL ACAD SCI USA, V104, P11073, DOI 10.1073/pnas.0704320104; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Fagerland MW, 2015, STAT METHODS MED RES, V24, P224, DOI 10.1177/0962280211415469; Finnanger TG, 2013, BRAIN INJURY, V27, P1606, DOI 10.3109/02699052.2013.831127; Fletcher JM, 1996, J CHILD NEUROL, V11, P283, DOI 10.1177/088307389601100404; Funderud I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048504; Garcia-Molina A, 2012, BRAIN INJURY, V26, P864, DOI 10.3109/02699052.2012.655362; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Green L, 2012, DEV NEUROREHABIL, V15, P105, DOI 10.3109/17518423.2011.638331; Grissom R. J., 2005, EFFECT SIZES RES BRO; Haberg A. K., 2015, J NEUROSCI RES, V93, P1109; Heaton R., 1993, WISCONSIN CARD SORTI; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Hoofien D, 2001, BRAIN INJURY, V15, P189; Jamora CW, 2012, BRAIN INJURY, V26, P36, DOI 10.3109/02699052.2011.635352; JOHNSTON MV, 1995, BRAIN DEV-JPN, V17, P301, DOI 10.1016/0387-7604(95)00079-Q; Jorge R, 2003, INT REV PSYCHIATR, V15, P317, DOI 10.1080/09540260310001606700; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Lannoo E, 1998, ACTA NEUROCHIR, V140, P245, DOI 10.1007/s007010050091; Lengenfelder J, 2015, APPL NEUROPSYCH-ADUL, V22, P7, DOI 10.1080/23279095.2013.816703; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; Lovstad M, 2012, BRAIN INJURY, V26, P1586, DOI 10.3109/02699052.2012.698787; Lydersen S, 2009, STAT MED, V28, P1159, DOI 10.1002/sim.3531; Malec JF, 2004, REHABIL PSYCHOL, V49, P55, DOI 10.1037/0090-5550.49.1.55; Malloy P, 2005, COGN BEHAV NEUROL, V18, P18, DOI 10.1097/01.wnn.0000152232.47901.88; Meyers J., 1995, REY COMPLEX FIGURE T; Misic-Pavkov G, 2012, EUR REV MED PHARMACO, V16, P1806; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Muscara F, 2008, DEV NEUROPSYCHOL, V33, P623, DOI 10.1080/87565640802171162; Olsen A, 2015, CEREB CORTEX, V25, P2170, DOI 10.1093/cercor/bhu023; Olsen A, 2013, J COGNITIVE NEUROSCI, V25, P903, DOI 10.1162/jocn_a_00358; Ownsworth T, 2004, DISABIL REHABIL, V26, P765, DOI 10.1080/09638280410001696700; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; Prigatano GP, 2005, ACT NEUR S, V93, P39; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; Rabin LA, 2006, ARCH CLIN NEUROPSYCH, V21, P721, DOI 10.1016/j.acn.2006.08.004; Ragsdale KA, 2013, J ANXIETY DISORD, V27, P420, DOI 10.1016/j.janxdis.2013.04.003; Rapoport MJ, 2012, CNS DRUGS, V26, P111, DOI 10.2165/11599560-000000000-00000; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Rosema S, 2015, J NEUROTRAUM, V32, P976, DOI 10.1089/neu.2014.3567; Rotenberg-Shpigelman S., 2008, ISRAELI J OCCUPATION, V17, P77; Roth RM, 2013, ARCH CLIN NEUROPSYCH, V28, P425, DOI 10.1093/arclin/act031; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Schiehser DM, 2011, J CLIN EXP NEUROPSYC, V33, P704, DOI 10.1080/13803395.2011.553587; Seel RT, 2010, J HEAD TRAUMA REHAB, V25, P99, DOI 10.1097/HTR.0b013e3181ce3966; Sigurdardottir S, 2013, J REHABIL MED, V45, P808, DOI 10.2340/16501977-1156; Skandsen T, 2010, ARCH PHYS MED REHAB, V91, P1904, DOI 10.1016/j.apmr.2010.08.021; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smith A., 1982, SYMBOL DIGIT MODALIT; Spitz G, 2012, NEUROPSYCHOLOGY, V26, P604, DOI 10.1037/a0029239; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Stuss DT, 2013, ARCH CLIN NEUROPSYCH, V28, P1, DOI 10.1093/arclin/acs107; Stuss DT, 2011, J INT NEUROPSYCH SOC, V17, P759, DOI 10.1017/S1355617711000695; TEASDALE G, 1974, LANCET, V2, P81; Toglia J, 2010, BRAIN INJURY, V24, P664, DOI 10.3109/02699051003610474; Toplak ME, 2013, J CHILD PSYCHOL PSYC, V54, P131, DOI 10.1111/jcpp.12001; Trahan D. E., 1988, CONTINOUS VISUALMEMO; Vaishnavi S, 2009, PSYCHOSOMATICS, V50, P198, DOI 10.1176/appi.psy.50.3.198; Velikonja D, 2010, J CLIN EXP NEUROPSYC, V32, P610, DOI 10.1080/13803390903401302; Waid-Ebbs JK, 2012, BRAIN INJURY, V26, P1646, DOI 10.3109/02699052.2012.700087; Warriner Erin M, 2006, Curr Psychiatry Rep, V8, P73, DOI 10.1007/s11920-006-0083-2; Wechsler D., 2011, WECHLSER ABBREVIATED; West SL, 2011, NEUROREHABILITATION, V29, P1, DOI 10.3233/NRE-2011-0671; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	93	32	32	0	9	HINDAWI LTD	LONDON	ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND	0953-4180	1875-8584		BEHAV NEUROL	Behav. Neurol.		2015	2015								329241	10.1155/2015/329241			19	Clinical Neurology	Neurosciences & Neurology	CU5MV	WOS:000363577200001	26549936	DOAJ Gold, Green Published			2021-06-18	
J	Doherty, J; Sheehan, AE; Bradshaw, R; Fox, AN; Lu, TY; Freeman, MR				Doherty, Johnna; Sheehan, Amy E.; Bradshaw, Rachel; Fox, A. Nicole; Lu, Tsai-Yi; Freeman, Marc R.			PI3K Signaling and Stat92E Converge to Modulate Glial Responsiveness to Axonal Injury	PLOS BIOLOGY			English	Article							RECEPTOR-MEDIATED PHAGOCYTOSIS; FIBRILLARY ACIDIC PROTEIN; CELL CORPSE ENGULFMENT; TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; JAK/STAT PATHWAY; REACTIVE ASTROCYTES; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; COMPLEMENT RECEPTOR-3	Glial cells are exquisitely sensitive to neuronal injury but mechanisms by which glia establish competence to respond to injury, continuously gauge neuronal health, and rapidly activate reactive responses remain poorly defined. Here, we show glial PI3K signaling in the uninjured brain regulates baseline levels of Draper, a receptor essential for Drosophila glia to sense and respond to axonal injury. After injury, Draper levels are up-regulated through a Stat92E-modulated, injury-responsive enhancer element within the draper gene. Surprisingly, canonical JAK/STAT signaling does not regulate draper expression. Rather, we find injury-induced draper activation is downstream of the Draper/Src42a/Shark/Rac1 engulfment signaling pathway. Thus, PI3K signaling and Stat92E are critical in vivo regulators of glial responsiveness to axonal injury. We provide evidence for a positive auto-regulatory mechanism whereby signaling through the injury-responsive Draper receptor leads to Stat92E-dependent, transcriptional activation of the draper gene. We propose that Drosophila glia use this autoregulatory loop as a mechanism to adjust their reactive state following injury.	[Doherty, Johnna; Sheehan, Amy E.; Bradshaw, Rachel; Fox, A. Nicole; Lu, Tsai-Yi; Freeman, Marc R.] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Dept Neurobiol, Worcester, MA 01605 USA	Doherty, J (corresponding author), Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Dept Neurobiol, Worcester, MA 01605 USA.	marc.freeman@umassmed.edu		Freeman, Marc/0000-0003-3481-3715; Lu, Tsai-Yi/0000-0002-8818-6537	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1 NS053538]; Howard Hughes Medical InstituteHoward Hughes Medical Institute; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS053538] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health (RO1 NS053538) and by the Howard Hughes Medical Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson MA, 2014, NEUROSCI LETT, V565, P23, DOI 10.1016/j.neulet.2013.12.030; [Anonymous], 2010, NAT NEUROSCI, V13, P1441; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Awasaki T, 2006, NEURON, V50, P855, DOI 10.1016/j.neuron.2006.04.027; Bach EA, 2007, GENE EXPR PATTERNS, V7, P323, DOI 10.1016/j.modgep.2006.08.003; Baksa K, 2002, DEV BIOL, V243, P166, DOI 10.1006/dbio.2001.0539; Barres BA, 2008, NEURON, V60, P430, DOI 10.1016/j.neuron.2008.10.013; Beemiller P, 2010, MOL BIOL CELL, V21, P470, DOI 10.1091/mbc.E08-05-0494; Betz A, 2008, P NATL ACAD SCI USA, V105, P13805, DOI 10.1073/pnas.0806291105; BIGNAMI A, 1976, NEUROPATH APPL NEURO, V2, P99, DOI 10.1111/j.1365-2990.1976.tb00488.x; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Brenner M, 2001, NAT GENET, V27, P117; Brown S, 2001, CURR BIOL, V11, P1700, DOI 10.1016/S0960-9822(01)00524-3; Buchon N, 2009, CELL HOST MICROBE, V5, P200, DOI 10.1016/j.chom.2009.01.003; Chen HW, 2002, GENE DEV, V16, P388, DOI 10.1101/gad.955202; Chen J, 1997, P NATL ACAD SCI USA, V94, P2295, DOI 10.1073/pnas.94.6.2295; Chung WS, 2013, NATURE, V504, P394, DOI 10.1038/nature12776; Cohen G, 2006, GLIA, V53, P538, DOI 10.1002/glia.20304; Copf T, 2011, P NATL ACAD SCI USA, V108, P8059, DOI 10.1073/pnas.1012919108; Couto A, 2005, CURR BIOL, V15, P1535, DOI 10.1016/j.cub.2005.07.034; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; Deng Yi Yu, 2011, Front Biosci (Schol Ed), V3, P884; Desai D, 2004, BIOCHEM BIOPH RES CO, V318, P642, DOI 10.1016/j.bbrc.2004.04.073; Doherty J, 2009, J NEUROSCI, V29, P4768, DOI 10.1523/JNEUROSCI.5951-08.2009; Dominguez E, 2008, J NEUROCHEM, V107, P50, DOI 10.1111/j.1471-4159.2008.05566.x; Dostert C, 2005, NAT IMMUNOL, V6, P946, DOI 10.1038/ni1237; Ekas LA, 2010, DEV BIOL, V344, P621, DOI 10.1016/j.ydbio.2010.05.497; Fancy SPJ, 2011, NAT NEUROSCI, V14, P1009, DOI 10.1038/nn.2855; Flaherty MS, 2010, DEV CELL, V18, P556, DOI 10.1016/j.devcel.2010.02.006; Freeman MR, 2003, NEURON, V38, P567, DOI 10.1016/S0896-6273(03)00289-7; Gadea A, 2008, J NEUROSCI, V28, P2394, DOI 10.1523/JNEUROSCI.5652-07.2008; Ghiglione C, 2002, DEVELOPMENT, V129, P5437, DOI 10.1242/dev.00116; Giaume C, 1996, TRENDS NEUROSCI, V19, P319, DOI 10.1016/0166-2236(96)10046-1; Gilbert MM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007083; Gu HH, 2003, J CELL BIOL, V161, P1151, DOI 10.1083/jcb.200212158; Hamby ME, 2010, NEUROTHERAPEUTICS, V7, P494, DOI 10.1016/j.nurt.2010.07.003; Hasselblatt M, 2001, GLIA, V34, P18, DOI 10.1002/glia.1036; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Jones WD, 2007, NATURE, V445, P86, DOI 10.1038/nature05466; Kamen LA, 2007, MOL BIOL CELL, V18, P2463, DOI 10.1091/mbc.E07-01-0061; Karimi M, 2002, TRENDS PLANT SCI, V7, P193, DOI 10.1016/S1360-1385(02)02251-3; Kim LK, 2007, PLOS BIOL, V5, P2064, DOI 10.1371/journal.pbio.0050238; Kim MO, 2002, J NEUROCHEM, V81, P1361, DOI 10.1046/j.1471-4159.2002.00949.x; Lazarini F, 1996, J NEUROCHEM, V66, P459; Lee HK, 2009, J NEUROCHEM, V108, P776, DOI 10.1111/j.1471-4159.2008.05826.x; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Leverrier Y, 2003, J BIOL CHEM, V278, P38437, DOI 10.1074/jbc.M306649200; Logan MA, 2012, NAT NEUROSCI; Logan MA, 2007, NEURON GLIA BIOL, V3, P63, DOI [10.1017/S1740925X0700049X, 10.1017/S1740925X07000646]; Lovegrove B, 2006, CURR BIOL, V16, P2206, DOI 10.1016/j.cub.2006.09.029; Rivas ML, 2008, EMBO REP, V9, P1114, DOI 10.1038/embor.2008.170; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; MacDonald JM, 2013, CELL DEATH DIFFER, V20, P1140, DOI 10.1038/cdd.2013.30; MacDonald JM, 2006, NEURON, V50, P869, DOI 10.1016/j.neuron.2006.04.028; Makki R, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000441; Makranz C, 2004, NEUROBIOL DIS, V15, P279, DOI 10.1016/j.nbd.2003.11.007; Minakhina S, 2011, DEV BIOL, V352, P308, DOI 10.1016/j.ydbio.2011.01.035; Nagai M, 2007, NAT NEUROSCI, V10, P615, DOI 10.1038/nn1876; Napoli I, 2009, NEUROSCIENCE, V158, P1030, DOI 10.1016/j.neuroscience.2008.06.046; Neniskyte U, 2011, J BIOL CHEM, V286, P39904, DOI 10.1074/jbc.M111.267583; Neumann H, 2009, BRAIN, V132, P288, DOI 10.1093/brain/awn109; Neumann J, 2008, J NEUROSCI, V28, P5965, DOI 10.1523/JNEUROSCI.0060-08.2008; Nyga R, 2005, BIOCHEM J, V390, P359, DOI 10.1042/BJ20041523; Okada S, 2006, NAT MED, V12, P829, DOI 10.1038/nm1425; Oliva AA, 2012, J NEUROCHEM, V120, P710, DOI 10.1111/j.1471-4159.2011.07610.x; Qin H, 2007, J IMMUNOL, V179, P5966, DOI 10.4049/jimmunol.179.9.5966; Read RD, 2004, MOL CELL BIOL, V24, P6676, DOI 10.1128/mcb.24.15.6676-6689.2004; Rogers J, 2007, INT REV NEUROBIOL, V82, P235, DOI 10.1016/S0074-7742(07)82012-5; Rogers SD, 2003, GLIA, V41, P180, DOI 10.1002/glia.10173; SawkaVerhelle D, 1997, EUR J BIOCHEM, V250, P411, DOI 10.1111/j.1432-1033.1997.0411a.x; Schwaiger FW, 2000, EUR J NEUROSCI, V12, P1165, DOI 10.1046/j.1460-9568.2000.00005.x; Silver DL, 2005, DEVELOPMENT, V132, P3483, DOI 10.1242/dev.01910; Silver DL, 2001, CELL, V107, P831, DOI 10.1016/S0092-8674(01)00607-9; Sorrentino RP, 2004, GENETICS, V166, P1343, DOI 10.1534/genetics.166.3.1343; Sotillos S, 2013, DEVELOPMENT, V140, P1507, DOI 10.1242/dev.092320; Sotillos S, 2010, DEV BIOL, V340, P571, DOI 10.1016/j.ydbio.2010.02.015; Swanson RA, 2004, CURR MOL MED, V4, P193, DOI 10.2174/1566524043479185; Vidal OM, 2010, J CELL SCI, V123, P3457, DOI 10.1242/jcs.066902; Wang LW, 2008, J CELL BIOL, V180, P721, DOI 10.1083/jcb.200711022; West DA, 2004, NEUROSCIENCE, V127, P333, DOI 10.1016/j.neuroscience.2004.05.022; Wu HH, 2009, NAT NEUROSCI, V12, P1534, DOI 10.1038/nn.2446; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Zhao JB, 2011, CYTOKINE, V56, P343, DOI 10.1016/j.cyto.2011.07.018; Zhou Z, 2001, CELL, V104, P43, DOI 10.1016/S0092-8674(01)00190-8; Ziegenfuss JS, 2008, NATURE, V453, P935, DOI 10.1038/nature06901	87	32	33	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1545-7885			PLOS BIOL	PLoS. Biol.	NOV	2014	12	11							e1001985	10.1371/journal.pbio.1001985			16	Biochemistry & Molecular Biology; Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics	AU5DL	WOS:000345627300002	25369313	DOAJ Gold, Green Published			2021-06-18	
J	Brooks, BL; Khan, S; Daya, H; Mikrogianakis, A; Barlow, KM				Brooks, Brian L.; Khan, Samna; Daya, Hussain; Mikrogianakis, Angelo; Barlow, Karen M.			Neurocognition in the Emergency Department after a Mild Traumatic Brain Injury in Youth	JOURNAL OF NEUROTRAUMA			English	Article						acute; adolescents; children; concussion; neuropsychology	SPORT-RELATED CONCUSSION; STANDARDIZED ASSESSMENT; CHILDREN; ADOLESCENTS; RECOVERY	The early cognitive effects from a mild traumatic brain injury (mTBI) are poorly understood in youth. The aim of this study was to examine acute neurocognitive functioning in children and adolescents who presented to the emergency department (ED) after an mTBI. Youth 8-17 years of age with an mTBI (n = 77; mean age, 13.6 years; 95% confidence interval [CI], 13.0-14.2) and an orthopedic injury control (OIC) group (n = 28; mean age, 13.9 years; 95% CI, 13.1-14.7) underwent a very brief computerized neurocognitive assessment (four subtests from CNS Vital Signs) in a pediatric trauma hospital ED. The mTBI and OIC groups were not significantly different on age, gender, handedness, computer familiarity, race, median family income, pain rating scales, or time from injury to assessment. There were no significant differences between the mTBI and OIC groups for accuracy on immediate memory, delayed memory, and measures of attention and executive functioning. However, the mTBI group performed significantly worse than the OIC on nearly all measures of psychomotor speed and reaction time. Further, cognitive functioning appears to worsen as more time passes since the mTBI. Neurocognitive deficits are detectable in youth with an mTBI who present to the ED, despite having a Glasgow Coma Scale score of 15/15 and normal neuroimaging (or their presentation does not warrant neuroimaging). Their profile appears to include preserved accuracy on cognitive measures, but at the expense of slower psychomotor speed and longer reaction time.	[Brooks, Brian L.; Barlow, Karen M.] Alberta Childrens Prov Gen Hosp, Calgary, AB T3B 6A8, Canada; [Brooks, Brian L.; Mikrogianakis, Angelo] Univ Calgary, Dept Pediat, Fac Med, Calgary, AB T2N 1N4, Canada; [Brooks, Brian L.] Univ Calgary, Fac Med, Dept Clin Neurosci, Calgary, AB, Canada; [Brooks, Brian L.; Barlow, Karen M.] Alberta Childrens Prov Gen Hosp, Res Inst Child & Maternal Hlth, Calgary, AB T3B 6A8, Canada; [Khan, Samna] McGill Univ, Dept Psychol, Montreal, PQ, Canada; [Daya, Hussain] Univ Lethbridge, Dept Psychol, Lethbridge, AB T1K 3M4, Canada; [Mikrogianakis, Angelo] Alberta Childrens Prov Gen Hosp, Sect Emergency Med, Calgary, AB T3B 6A8, Canada; [Barlow, Karen M.] Univ Calgary, Fac Med, Calgary, AB, Canada	Brooks, BL (corresponding author), Alberta Childrens Prov Gen Hosp, Neurosci Program, 2888 Shaganappi Trail Northwest, Calgary, AB T3B 6A8, Canada.	brian.brooks@albertahealthservices.ca	Barlow, Karen/I-6492-2019; Meijer, Anna/K-5118-2016; Barlow, Karen/C-1323-2014	Barlow, Karen/0000-0003-2612-8507	Pediatric Brain Injury Research Program; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); McCarthy Tetrault Award	Funding for this study was provided by the Pediatric Brain Injury Research Program (administered by the Alberta Children's Hospital Research Institute) awarded to Drs. Barlow and Brooks, a summer studentship from the Canadian Institutes of Health Research training program (administered by the Alberta Children's Hospital Research Institute) to Ms. Khan, and the McCarthy Tetrault Award (administered by the Alberta Children's Hospital Research Institute) awarded to Dr. Brooks. None of the funding sources were involved in the design and conduct of the study, the collection, management, analysis, and interpretation of the data, and the preparation, review, or approval of the manuscript.	*AM ASS AUT MED, 1990, ABBR INJ SCAL AIS 19; Andersson EE, 2012, DEV NEUROREHABIL, V15, P26, DOI 10.3109/17518423.2011.633570; Brooks BL, 2012, J CHILD NEUROL, V27, P982, DOI 10.1177/0883073811430863; Brooks BL, 2011, J CHILD NEUROL, V26, P786, DOI 10.1177/0883073810391532; Brooks BL, 2010, APPL NEUROPSYCHOL, V17, P37, DOI 10.1080/09084280903526083; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Centers for Disease Control and Prevention, 2011, NONF TRAUM BRAIN INJ; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Grubenhoff JA, 2010, PEDIATRICS, V126, P688, DOI 10.1542/peds.2009-2804; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; IBM Corp, 2010, IBM SPSS STAT WIND V; Levine Z, 2010, CAN FAM PHYSICIAN, V56, P658; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; Nance ML, 2009, ANN SURG, V249, P859, DOI 10.1097/SLA.0b013e3181a41ae5; Naunheim RS, 2008, J HEAD TRAUMA REHAB, V23, P116, DOI 10.1097/01.HTR.0000314530.30401.70; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Peterson SE, 2009, ANN EMERG MED, V53, P796, DOI 10.1016/j.annemergmed.2008.10.015; Rieger BP, 2013, BRAIN INJURY, V27, P169, DOI 10.3109/02699052.2012.729290; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sroufe NS, 2010, PEDIATRICS, V125, pE1331, DOI 10.1542/peds.2008-2364	25	32	32	0	30	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT 15	2014	31	20					1744	1749		10.1089/neu.2014.3356			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AP8BF	WOS:000342302200008	24849864				2021-06-18	
J	Mackelprang, JL; Harpin, SB; Grubenhoff, JA; Rivara, FP				Mackelprang, Jessica L.; Harpin, Scott B.; Grubenhoff, Joseph A.; Rivara, Frederick P.			Adverse Outcomes Among Homeless Adolescents and Young Adults Who Report a History of Traumatic Brain Injury	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							POSTCONCUSSION SYNDROME; STREET YOUTH; HEALTH; PEOPLE; CARE; INTERVENTION; EXPERIENCES; CHALLENGES; MORTALITY; CHILDREN	Objectives. We examined the prevalence of self-reported traumatic brain injury (TBI) among homeless young people and explored whether sociodemographic characteristics, mental health diagnoses, substance use, exposure to violence, or difficulties with activities of daily living (ADLs) were associated with TBI. Methods. We analyzed data from the Wilder Homelessness Study, in which participants were recruited in 2006 and 2009 from streets, shelters, and locations in Minnesota that provide services to homeless individuals. Participants completed 30-minute interviews to collect information about history of TBI, homelessness, health status, exposure to violence (e. g., childhood abuse, assault), and other aspects of functioning. Results. Of the 2732 participating adolescents and young adults, 43% reported a history of TBI. Participants with TBI became homeless at a younger age and were more likely to report mental health diagnoses, substance use, suicidality, victimization, and difficulties with ADLs. The majority of participants (51%) reported sustaining their first injury prior to becoming homeless or at the same age of their first homeless episode (10%). Conclusions. TBI occurs frequently among homeless young people and is a marker of adverse outcomes such as mental health difficulties, suicidal behavior, substance use, and victimization.	[Mackelprang, Jessica L.; Rivara, Frederick P.] Univ Washington, Sch Med, Harborview Injury Prevent & Res Ctr, Seattle, WA 98104 USA; [Mackelprang, Jessica L.; Rivara, Frederick P.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98104 USA; [Harpin, Scott B.] Univ Colorado, Anschutz Med Ctr, Coll Nursing, Aurora, CO USA; [Grubenhoff, Joseph A.] Univ Colorado, Sch Med, Dept Pediat, Aurora, CO USA; [Grubenhoff, Joseph A.] Childrens Hosp Colorado, Aurora, CO USA	Mackelprang, JL (corresponding author), Univ Washington, Harborview Injury Prevent & Res Ctr, Dept Pediat, 401 Broadway,Suite 4075,Patricia Bracelin Steel, Seattle, WA 98104 USA.	jlmack11@uw.edu	Grubenhoff, Joseph A/H-9994-2019	Grubenhoff, Joseph A/0000-0001-5072-4064; Mackelprang, Jessica/0000-0001-9135-7811	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32-HD057822]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD057822] Funding Source: NIH RePORTER	Jessica L. Mackelprang received fellowship support from the National Institute of Child Health and Human Development (grant T32-HD057822) during the preparation of this article.	[Anonymous], 2013 ANN HOM ASS REP; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Backer Thomas Earl, 2007, J Prim Prev, V28, P375, DOI 10.1007/s10935-007-0100-1; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Barry Paul J, 2002, J Transcult Nurs, V13, P145, DOI 10.1177/104365960201300208; Carlson JL, 2006, J ADOLESCENT HEALTH, V38, P624, DOI 10.1016/j.jadohealth.2005.10.009; Cauce AM, 2000, J EMOT BEHAV DISORD, V8, P230, DOI 10.1177/106342660000800403; Cleverley K, 2011, J ADOLESCENCE, V34, P1049, DOI 10.1016/j.adolescence.2010.11.003; Cochran BN, 2002, AM J PUBLIC HEALTH, V92, P773, DOI 10.2105/AJPH.92.5.773; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Dworsky A, 2013, AM J PUBLIC HEALTH, V103, pS318, DOI 10.2105/AJPH.2013.301455; Edidin JP, 2012, CHILD PSYCHIAT HUM D, V43, P354, DOI 10.1007/s10578-011-0270-1; Ensign J, 2004, QUAL HEALTH RES, V14, P1239, DOI 10.1177/1049732304268795; Ensign J, 1998, SOC SCI MED, V47, P2087, DOI 10.1016/S0277-9536(98)00273-1; Ensign J, 1998, ARCH PEDIAT ADOL MED, V152, P20; Ferguson KM, 2009, J INTERPERS VIOLENCE, V24, P1875, DOI 10.1177/0886260508325490; Hadland SE, 2012, J AFFECT DISORDERS, V136, P377, DOI 10.1016/j.jad.2011.11.019; Hodgson KJ, 2013, AM J PUBLIC HEALTH, V103, pE24, DOI 10.2105/AJPH.2013.301318; Hudson AL, 2010, NURS RES, V59, P212, DOI 10.1097/NNR.0b013e3181d1a8a9; Hux K, 2009, BRAIN INJURY, V23, P8, DOI 10.1080/02699050802590353; Hwang SW, 2008, CAN MED ASSOC J, V179, P779, DOI 10.1503/cmaj.080341; Hwang SW, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b4036; Kidd SA, 2007, J ADOLESCENCE, V30, P283, DOI 10.1016/j.adolescence.2006.03.002; Montauk SL, 2006, AM FAM PHYSICIAN, V74, P1132; Oddy M, 2012, BRAIN INJURY, V26, P1058, DOI 10.3109/02699052.2012.667595; Parks RW, 2007, J ROY SOC MED, V100, P46, DOI 10.1258/jrsm.100.1.46; Roy E, 2004, JAMA-J AM MED ASSOC, V292, P569, DOI 10.1001/jama.292.5.569; Roy E, 2010, J URBAN HEALTH, V87, P95, DOI 10.1007/s11524-009-9397-9; Schofield P, 2011, BRAIN INJURY, V25, P74, DOI 10.3109/02699052.2010.531690; Thompson SJ, 2013, YOUTH SOC; Topolovec-Vranic J, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-1059; Tsai M, 2005, J HEALTH CARE POOR U, V16, P297, DOI 10.1353/hpu.2005.0042; Walls NE, 2011, J SEX RES, V48, P423, DOI 10.1080/00224499.2010.501916; Walton MA, 2010, JAMA-J AM MED ASSOC, V304, P527, DOI 10.1001/jama.2010.1066; Zatzick D, 2014, JAMA PEDIATR, V168, P532, DOI 10.1001/jamapediatrics.2013.4784	35	32	32	0	16	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health	OCT	2014	104	10					1986	1992		10.2105/AJPH.2014.302087			7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	AP1XG	WOS:000341865000046	25122029	Green Published			2021-06-18	
J	Stocker, RPJ; Cieply, MA; Paul, B; Khan, H; Henry, L; Kontos, AP; Germain, A				Stocker, Ryan P. J.; Cieply, Marissa A.; Paul, Benjamin; Khan, Hassen; Henry, Luke; Kontos, Anthony P.; Germain, Anne			Combat-related blast exposure and traumatic brain injury influence brain glucose metabolism during REM sleep in military veterans	NEUROIMAGE			English	Article						Blast exposure; mTBI; Military veterans; Cerebral glucose metabolism; Rapid eye movement sleep	POSTTRAUMATIC-STRESS-DISORDER; MEDIAL PREFRONTAL CORTEX; WHITE-MATTER INTEGRITY; EYE-MOVEMENT SLEEP; FDG-PET; ANXIETY DISORDERS; SPORTS CONCUSSION; FEAR EXTINCTION; AXONAL INJURY; LIVING BRAIN	Traumatic brain injury (TBI), a signature wound of Operations Enduring and Iraqi Freedom, can result from blunt head trauma or exposure to a blast/explosion. While TBI affects sleep, the neurobiological underpinnings between TBI and sleep are largely unknown. To examine the neurobiological underpinnings of this relationship in military veterans, 118 H-fluorodeoxyglucose positron emission tomography (FDG PET) was used to compare mTBI-related changes in relative cerebral metabolic rate of glucose (rCMRglc) during wakefulness, Rapid Eye Movement (REM) sleep, and non-REM (NREM) sleep, after adjusting for the effects of posttraumatic stress (PTS). Fourteen veterans with a history of blast exposure and/or mTBI (B/mTBI) (age 27.5 +/- 3.9) and eleven veterans with no history (No B/mTBI) (age 28.1 +/- 4.3) completed FDG PET studies during wakefulness, REM sleep, and NREM sleep. Whole-brain analyses were conducted using Statistical Parametric Mapping (SPM8). Between group comparisons revealed that B/mTBI was associated with significantly lower rCMRglc during wakefulness and REM sleep in the amygdala, hippocampus, parahippocampal gyrus, thalamus, insula, uncus, culmen, visual association cortices, and midline medial frontal cortices. These results suggest that alterations in neurobiological networks during wakefulness and REM sleep subsequent to B/mTBI exposure may contribute to chronic sleep disturbances and differ in individuals with acute symptoms. (C) 2014 Elsevier Inc. All rights reserved.	[Stocker, Ryan P. J.; Cieply, Marissa A.; Khan, Hassen] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15213 USA; [Stocker, Ryan P. J.] Chatham Univ, Dept Counseling Psychol, Pittsburgh, PA 15213 USA; [Paul, Benjamin] Univ Pittsburgh, Sch Social Work, Pittsburgh, PA 15213 USA; [Henry, Luke; Kontos, Anthony P.] Dept Orthopaed Surg, Pittsburgh, PA USA; [Germain, Anne] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA	Germain, A (corresponding author), Univ Pittsburgh, Sch Med, Mil Sleep Tact & Resilience Res Team, Sterling Plaza 240, Pittsburgh, PA 15213 USA.	germax@upmc.edu		Kontos, Anthony/0000-0002-3749-4310	National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH083035]; Department of DefenseUnited States Department of Defense; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH083035] Funding Source: NIH RePORTER	Participants data were collected from grants funded by the National Institute of Mental Health (MH083035) and the Department of Defense that were reviewed and approved by the Institutional Review Board at the University of Pittsburgh and Human Research Protection Office of the Department of Defense (ClinicalTrials.gov # NCT01637584 and # NCT00871650).	Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2012, NEUROMOL MED, V14, P205, DOI 10.1007/s12017-012-8178-x; Bayly PV, 2005, J NEUROTRAUM, V22, P845, DOI 10.1089/neu.2005.22.845; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bishop SJ, 2007, TRENDS COGN SCI, V11, P307, DOI 10.1016/j.tics.2007.05.008; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bloomfield ILM, 2010, J INT NEUROPSYCH SOC, V16, P17, DOI 10.1017/S1355617709990798; Bogdanova Y, 2012, NEUROPSYCHOL REV, V22, P4, DOI 10.1007/s11065-012-9192-3; Braun AR, 1997, BRAIN, V120, P1173, DOI 10.1093/brain/120.7.1173; Bryant RA, 2009, J INT NEUROPSYCH SOC, V15, P862, DOI 10.1017/S1355617709990671; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Collen J, 2012, CHEST, V142, P622, DOI 10.1378/chest.11-1603; Creamer M, 2005, BEHAV RES THER, V43, P1383, DOI 10.1016/j.brat.2004.11.001; Davis M, 2001, MOL PSYCHIATR, V6, P13, DOI 10.1038/sj.mp.4000812; Davis M, 2010, NEUROPSYCHOPHARMACOL, V35, P105, DOI 10.1038/npp.2009.109; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; Drzezga A, 2003, EUR J NUCL MED MOL I, V30, P1104, DOI 10.1007/s00259-003-1194-1; Edison P, 2013, NEUROPSYCHOPHARMACOL, V38, P938, DOI 10.1038/npp.2012.255; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; First M.B., 1996, STRUCTURED CLIN INTE; French L., 2008, J SPEC OPER MED, V8, P68; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friston K, 2007, STATISTICAL PARAMETRIC MAPPING: THE ANALYSIS OF FUNCTIONAL BRAIN IMAGES, P1; Friston KJ, 1999, NEUROIMAGE, V10, P385, DOI 10.1006/nimg.1999.0484; Germain A, 2004, PSYCHIAT RES-NEUROIM, V130, P259, DOI 10.1016/j.pscychresns.2003.12.003; Germain A, 2004, AM J PSYCHIAT, V161, P1856, DOI 10.1176/appi.ajp.161.10.1856; Germain A, 2008, SLEEP MED REV, V12, P185, DOI 10.1016/j.smrv.2007.09.003; Germain A, 2013, PSYCHIAT RES-NEUROIM, V211, P176, DOI 10.1016/j.pscychresns.2012.05.007; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Giza CC, 2001, J ATHL TRAINING, V36, P228; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Keane T.M., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI DOI 10.1037/1040-3590.1.1.53; Kirov II, 2013, J NEUROL, V260, P242, DOI 10.1007/s00415-012-6626-z; Kontos AP, 2013, J NEUROTRAUM, V30, P680, DOI 10.1089/neu.2012.2506; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; MESULAM MM, 1992, J COMP NEUROL, V318, P316, DOI 10.1002/cne.903180308; Milad MR, 2006, BIOL PSYCHOL, V73, P61, DOI 10.1016/j.biopsycho.2006.01.008; Milad MR, 2002, NATURE, V420, P70, DOI 10.1038/nature01138; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Mosconi L, 2004, NEUROLOGY, V63, P2332, DOI 10.1212/01.WNL.0000147469.18313.3B; Mysliwiec V, 2013, CHEST, V144, P549, DOI 10.1378/chest.13-0088; Nofzinger EA, 1997, BRAIN RES, V770, P192, DOI 10.1016/S0006-8993(97)00807-X; Nofzinger EA, 2004, AM J PSYCHIAT, V161, P2126, DOI 10.1176/appi.ajp.161.11.2126; Nofzinger EA, 2002, BRAIN, V125, P1105, DOI 10.1093/brain/awf103; Nofzinger EA, 1998, BRAIN RES PROTOC, V2, P191, DOI 10.1016/S1385-299X(97)00042-1; Nofzinger EA, 2006, J CLIN SLEEP MED, V2, P316; O'Donovan A, 2013, NEUROSCI BIOBEHAV R, V37, P96, DOI 10.1016/j.neubiorev.2012.10.013; Otis JD, 2011, J CLIN PSYCHOL MED S, V18, P145, DOI 10.1007/s10880-011-9239-2; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Phelps EA, 2004, CURR OPIN NEUROBIOL, V14, P198, DOI 10.1016/j.conb.2004.03.015; Rauch SL, 2000, BIOL PSYCHIAT, V47, P769, DOI 10.1016/S0006-3223(00)00828-3; Rauch SL, 2003, ANN NY ACAD SCI, V985, P389; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Sabet AA, 2008, J BIOMECH, V41, P307, DOI 10.1016/j.jbiomech.2007.09.016; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Shin LM, 2006, ANN NY ACAD SCI, V1071, P67, DOI 10.1196/annals.1364.007; Signoretti S, 2008, J NEUROSURG, V108, P42, DOI 10.3171/JNS/2008/108/01/0042; Signoretti S, 2010, MOL CELL BIOCHEM, V333, P269, DOI 10.1007/s11010-009-0228-9; Stein DJ, 2011, NEUROSCI BIOBEHAV R, V35, P1075, DOI 10.1016/j.neubiorev.2010.11.012; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Tanielian TL, 2008, INVISIBLE WOUNDS WAR, V720; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tsukada H, 2001, SYNAPSE, V42, P242, DOI 10.1002/syn.10011; Viola-Saltzman M, 2012, NEUROL CLIN, V30, P1299, DOI 10.1016/j.ncl.2012.08.008; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004	78	32	32	0	42	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1053-8119	1095-9572		NEUROIMAGE	Neuroimage	OCT 1	2014	99						207	214		10.1016/j.neuroimage.2014.05.067			8	Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	AM4XR	WOS:000339860000022	24893322	Green Accepted			2021-06-18	
J	Perez, AM; Adler, J; Kulkarni, N; Strain, JF; Womack, KB; Diaz-Arrastia, R; de la Plata, CDM				Perez, Alison M.; Adler, Justin; Kulkarni, Nimay; Strain, Jeremy F.; Womack, Kyle B.; Diaz-Arrastia, Ramon; de la Plata, Carlos D. Marquez			Longitudinal White Matter Changes after Traumatic Axonal Injury	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; biomarkers; brain edema; diffusion tensor imaging; traumatic brain injury	TENSOR IMAGING DETECTS; BRAIN-INJURY; VASOGENIC EDEMA; MOUSE MODEL; HEAD-INJURY; MILD; MEMORY; DYSFUNCTION; INTEGRITY; RECOVERY	Diffusion tensor imaging (DTI) has been useful in showing compromise after traumatic axonal injury (TAI) at the chronic stage; however, white matter (WM) compromise from acute stage of TAI to chronic stage is not yet well understood. This study aims to examine changes in WM integrity following TAI by obtaining DTI, on average, 1 d post injury and again approximately seven months post-injury. Sixteen patients with complicated mild to severe brain injuries consistent with TAI were recruited in the intensive care unit of a Level I trauma center. Thirteen of these patients were studied longitudinally over the course of the first seven months post-injury. The first scan occurred, on average, 1 d after injury and the second an average of seven months post-injury. Ten healthy individuals, similar to the cohort of patients, were recruited as controls. Whole brain WM and voxel-based analyses of DTI data were conducted. DTI metrics of interest included: fractional anisotropy (FA), mean diffusivity, axial diffusivity (AD), and radial diffusivity (RD). tract-based spatial statistics were used to examine DTI metrics spatially. Acutely, AD and RD increased and RD positively correlated with injury severity. Longitudinal analysis showed reduction in FA and AD (p<0.01), but no change in RD. Possible explanations for the microstructural changes observed over time are discussed.	[Perez, Alison M.; Adler, Justin; Kulkarni, Nimay; Strain, Jeremy F.; de la Plata, Carlos D. Marquez] Univ Texas Dallas, Ctr BrainHlth, Dallas, TX 75230 USA; [Womack, Kyle B.; de la Plata, Carlos D. Marquez] Univ Texas Dallas, Dallas, TX 75230 USA; [de la Plata, Carlos D. Marquez] Pate Rehabil Ctr, Dallas, TX USA; [Diaz-Arrastia, Ramon] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA	de la Plata, CDM (corresponding author), 2655 Villa Creek Dr 140, Dallas, TX 75234 USA.	cmarquez@paterehab.com	Womack, Kyle/O-5422-2018	Womack, Kyle/0000-0002-6060-9075; Diaz-Arrastia, Ramon/0000-0001-6051-3594	U.S. Department of EducationUS Department of Education [HD133A020526]; National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS060827]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS060827] Funding Source: NIH RePORTER	This work was funded through the U.S. Department of Education HD133A020526 (to Ramon Diaz-Arrastia) and the National Institutes of Health/National Institute of Neurological Disorders and Stroke K23NS060827 (to Carlos Marquez de la Plata). For the other authors, no competing financial interests exist.	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Benson RR, 2007, J NEUROTRAUM, V24, P446, DOI 10.1089/neu.2006.0153; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Chu Z, 2010, AM J NEURORADIOL, V31, P340, DOI 10.3174/ajnr.A1806; Corvol JC, 1998, STROKE, V29, P2649, DOI 10.1161/01.STR.29.12.2649; de la Plata CAM, 2008, ARCH PHYS MED REHAB, V89, P896, DOI 10.1016/j.apmr.2007.12.030; de la Plata CDM, 2011, J INT NEUROPSYCH SOC, V17, P24, DOI 10.1017/S1355617710001189; Delis DC, 2000, CALIFORNIA VERBAL LE; Ding K, 2008, J NEUROTRAUM, V25, P1433, DOI 10.1089/neu.2008.0683; DODRILL CB, 1978, EPILEPSIA, V19, P611, DOI 10.1111/j.1528-1157.1978.tb05041.x; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Farbota KDM, 2012, J INT NEUROPSYCH SOC, V18, P1006, DOI 10.1017/S1355617712000835; Field A. P, 2009, DISCOVERING STAT USI; Gu L, 2013, J TRAUMA ACUTE CARE, V74, P242, DOI 10.1097/TA.0b013e3182684fe8; Hammoud D, 2003, AM J NEURORADIOL, V24, P1237; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kennedy MRT, 2009, J INT NEUROPSYCH SOC, V15, P130, DOI 10.1017/S1355617708090024; Koch S, 2001, AM J NEURORADIOL, V22, P1068; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; Li SX, 2013, INT J LEGAL MED, V127, P159, DOI 10.1007/s00414-012-0712-8; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 2006, J NEUROTRAUM, V23, P1450, DOI 10.1089/neu.2006.23.1450; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Takao H, 2012, HUM BRAIN MAPP, V33, P466, DOI 10.1002/hbm.21225; Tasker RC, 2010, DEV NEUROSCI-BASEL, V32, P374, DOI 10.1159/000316806; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Wang JY, 2011, NEUROLOGY, V77, P818, DOI 10.1212/WNL.0b013e31822c61d7; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P319, DOI 10.1007/s11682-012-9174-3; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Ylvisaker Mark, 1996, Seminars in Speech and Language, V17, P217, DOI 10.1055/s-2008-1064100	56	32	32	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP 1	2014	31	17					1478	1485		10.1089/neu.2013.3216			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AO7GO	WOS:000341520700002	24738754	Green Published			2021-06-18	
J	Cossette, I; Ouellet, MC; McFadyen, BJ				Cossette, Isabelle; Ouellet, Marie-Christine; McFadyen, Bradford J.			A Preliminary Study to Identify Locomotor-Cognitive Dual Tasks That Reveal Persistent Executive Dysfunction After Mild Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Attention; Brain concussion; Gait; Rehabilitation; Walking	CONCUSSION; GAIT; ATTENTION	Objective: To identify different combinations of physical (level, obstacle avoidance, stepping down) and cognitive (visual, mental) demands within a locomotor navigational context that best discriminates between persons with mild traumatic brain injury (MTBI) and control subjects for an eventual clinical tool to assess residual executive dysfunction. Design: Group comparison study. Setting: Rehabilitation facility. Participants: Volunteer sample (N=14) of persons with MTBI (n=7) (6 women; age, 20 +/- 1.6y) and a comparison group (n=7) of subjects without neurologic problems (6 women; age, 22.4 +/- 1.4y). Interventions: Not applicable. Main Outcome Measures: Gait speed (m/s) and dual-task cost calculated as the relative change in gait speed from single (no cognitive task) to dual tasks for the same gait condition. Results: There were significant interactions between groups and cognitive tasks and between groups and cognitive and physical tasks for gait speed. Specifically, the MTBI group walked slower than control subjects in the dual-task conditions when stepping over an obstacle combined with each cognitive task. When gait speed was measured as dual-task costs, group differences were more evident, except for stepping down. Conclusions: These preliminary results suggest that both absolute gait speed and calculated dual-task costs during the combination of stepping over an obstacle with a simultaneous cognitive task are sensitive to revealing executive dysfunction in persons with MTBI. Gait speed can be easily measured in the clinic to provide important information to make diagnoses and decide about return to play or function. Continued work building on these preliminary results is needed toward the development of a clinical tool. (C) 2014 by the American Congress of Rehabilitation Medicine	[Cossette, Isabelle; Ouellet, Marie-Christine; McFadyen, Bradford J.] Ctr Interdisciplinary Res Rehabil & Social Integr, Quebec City, PQ, Canada; [Cossette, Isabelle; McFadyen, Bradford J.] Univ Laval, Fac Med, Dept Rehabil, Quebec City, PQ G1K 7P4, Canada; [Ouellet, Marie-Christine] Univ Laval, Sch Psychol, Fac Social Sci, Quebec City, PQ, Canada	McFadyen, BJ (corresponding author), CIRRIS IRDPQ, 525 Hamel, Quebec City, PQ G1M 2S8, Canada.	brad.mcfadyen@rea.ulaval.ca		Ouellet, Marie-Christine/0000-0003-3477-1893; McFadyen, Bradford/0000-0003-1992-4927	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [CBI-127052] Funding Source: Medline		Bazarian JJ, 2010, J NEUROTRAUM, V27, P527, DOI 10.1089/neu.2009.1068; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2009, EXP BRAIN RES, V194, P67, DOI 10.1007/s00221-008-1669-1; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Goldie PA, 1996, ARCH PHYS MED REHAB, V77, P1074, DOI 10.1016/S0003-9993(96)90072-6; Guskiewicz KM, 2011, PM&R, V3, pS445, DOI 10.1016/j.pmrj.2011.08.009; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Register-Mihalik JK, 2013, NEUROPSYCHOL REV, V23, P300, DOI 10.1007/s11065-013-9238-1; West TA, 2014, J NEUROTRAUM, V31, P159, DOI 10.1089/neu.2013.3031; Yogev-Seligmann G, 2008, MOVEMENT DISORD, V23, P329, DOI 10.1002/mds.21720	11	32	32	0	14	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2014	95	8					1594	1597		10.1016/j.apmr.2014.03.019			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AM2ND	WOS:000339687200025	24726561				2021-06-18	
J	Morkved, N; Hartmann, K; Aarsheim, LM; Holen, D; Milde, AM; Bomyea, J; Thorp, SR				Morkved, N.; Hartmann, K.; Aarsheim, L. M.; Holen, D.; Milde, A. M.; Bomyea, J.; Thorp, S. R.			A comparison of Narrative Exposure Therapy and Prolonged Exposure therapy for PTSD	CLINICAL PSYCHOLOGY REVIEW			English	Article						Posttraumatic Stress Disorder; Trauma; Narrative Exposure Therapy; Prolonged Exposure; Review	POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; AFRICAN REFUGEE SETTLEMENT; FEMALE ASSAULT SURVIVORS; TRAUMATIC BRAIN-INJURY; DEPRESSIVE SYMPTOMS; JAPANESE PATIENTS; BOSNIAN REFUGEES; OLDER VETERANS	The purpose of this review was to compare and contrast Prolonged Exposure (PE) and Narrative Exposure Therapy (NEC). We examined the treatment manuals to describe the theoretical foundation, treatment components, and procedures, including the type, manner, and focus of exposure techniques and recording methods used. We examined extant clinical trials to investigate the range of treatment formats reported, populations studied, and clinical outcome data. Our search resulted in 32 studies on PE and 15 studies on NET. Consistent with prior reviews of PTSD treatment, it is evident that PE has a solid evidence base and its current status as a first line treatment for the populations studied to this date is warranted. We argue that NET may have advantages in treating complex traumatization seen in asylum seekers and refugees, and for this population NET should be considered a recommended treatment. NET and PE have several commonalities, and it is recommended that studies of these treatments include a broader range of populations and trauma types to expand the current knowledge on the treatment of PTSD. Published by Elsevier Ltd.	[Morkved, N.; Hartmann, K.; Aarsheim, L. M.; Holen, D.] Univ Bergen, Fac Psychol, N-5020 Bergen, Norway; [Milde, A. M.] Univ Bergen, Dept Biol & Med Psychol, N-5020 Bergen, Norway; [Milde, A. M.] Hlth Bergen, Reg Resource Ctr Violence Traumat Stress & Suicid, Bergen, Norway; [Bomyea, J.; Thorp, S. R.] SDSU UCSD Joint Doctoral Program Clin Psychol, San Diego, CA 92120 USA; [Bomyea, J.; Thorp, S. R.] VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA 92161 USA; [Thorp, S. R.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA	Thorp, SR (corresponding author), VA San Diego Healthcare Syst, 8810 Rio San Diego Dr,Mail Code 116A4Z, San Diego, CA 92108 USA.	sthorp@ucsd.edu	Thorp, Steven/AAT-7321-2020	Morkved, Nina/0000-0003-2745-8890			Aderka IM, 2013, J CONSULT CLIN PSYCH, V81, P375, DOI 10.1037/a0031523; Aderka IM, 2011, J CONSULT CLIN PSYCH, V79, P421, DOI 10.1037/a0023318; Agger I., 1990, J TRAUMA STRESS, V3, P115, DOI DOI 10.1002/JTS.2490030109; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3rd; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Asukai N, 2008, J TRAUMA STRESS, V21, P340, DOI 10.1002/jts.20337; Asukai N, 2010, J TRAUMA STRESS, V23, P744, DOI 10.1002/jts.20589; Baikie K.A., 2005, ADV PSYCHIAT TREAT, V11, P338, DOI [10.1192/apt.11.5.338, DOI 10.1192/APT.11.5.338]; Bichescu D, 2007, BEHAV RES THER, V45, P2212, DOI 10.1016/j.brat.2006.12.006; Bluett EJ, 2014, J BEHAV THER EXP PSY, V45, P97, DOI 10.1016/j.jbtep.2013.09.003; Bradley R, 2005, AM J PSYCHIAT, V162, P214, DOI 10.1176/appi.ajp.162.2.214; Breedlove S. M., 2007, BIOL PSYCHOL INTRO B; Breslau N, 1999, PSYCHOL MED, V29, P813, DOI 10.1017/S0033291799008612; Breslau N, 2009, TRAUMA VIOLENCE ABUS, V10, P198, DOI 10.1177/1524838009334448; Brewin CR, 2001, BEHAV RES THER, V39, P373, DOI 10.1016/S0005-7967(00)00087-5; Catani C, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-22; CIENFUEGOS AJ, 1983, AM J ORTHOPSYCHIAT, V53, P43, DOI 10.1111/j.1939-0025.1983.tb03348.x; Cloitre M, 2011, J TRAUMA STRESS, V24, P615, DOI 10.1002/jts.20697; Cloitre M, 2009, CNS SPECTRUMS, V14, P32; Courtois CA, 2008, PSYCHOL TRAUMA-US, VS, P86, DOI [DOI 10.1037/1942-9681.S.1.86, 10.1037/1942-9681.S.1.86.]; Craske MG, 2008, BEHAV RES THER, V46, P5, DOI 10.1016/j.brat.2007.10.003; Crumlish N, 2010, J NERV MENT DIS, V198, P237, DOI 10.1097/NMD.0b013e3181d61258; Cukor J, 2010, ANN NY ACAD SCI, V1208, P82, DOI 10.1111/j.1749-6632.2010.05793.x; d'Ardenne P, 2007, BEHAV COGN PSYCHOTH, V35, P293, DOI 10.1017/S1352465807003645; de Bont PAJM, 2013, BEHAV THER, V44, P717, DOI 10.1016/j.beth.2013.07.002; Eftekhari A, 2013, JAMA PSYCHIAT, V70, P949, DOI 10.1001/jamapsychiatry.2013.36; Ertl V, 2011, JAMA-J AM MED ASSOC, V306, P503, DOI 10.1001/jama.2011.1060; Feske U, 2008, J INTERPERS VIOLENCE, V23, P1027, DOI 10.1177/0886260507313967; Foa E. B., 2007, PROLONGED EXPOSURE T, V1; Foa E. B., 2011, PSYCHOL SCI PUBL INT, V14, P65; Foa EB, 2000, J TRAUMA STRESS, V13, P539, DOI 10.1023/A:1007802031411; Foa EB, 1997, ANNU REV PSYCHOL, V48, P449, DOI 10.1146/annurev.psych.48.1.449; FOA EB, 1991, J CONSULT CLIN PSYCH, V59, P715, DOI 10.1037/0022-006X.59.5.715; Foa EB, 1999, J CONSULT CLIN PSYCH, V67, P194, DOI 10.1037/0022-006X.67.2.194; Foa EB, 2004, J CONSULT CLIN PSYCH, V72, P879, DOI 10.1037/0022-006X.72.5.879; Foa EB, 2005, J CONSULT CLIN PSYCH, V73, P953, DOI 10.1037/0022-006X.73.5.953; Foa EB, 2002, J CONSULT CLIN PSYCH, V70, P1022, DOI 10.1037//0022-006X.70.4.1022; FOA EB, 1986, PSYCHOL BULL, V99, P20, DOI 10.1037/0033-2909.99.1.20; Foa EB, 2013, JAMA-J AM MED ASSOC, V310, P2650, DOI 10.1001/jama.2013.282829; Gilboa-Schechtman E, 2010, J AM ACAD CHILD PSY, V49, P1034, DOI 10.1016/j.jaac.2010.07.014; Goodson JT, 2013, J TRAUMA STRESS, V26, P419, DOI 10.1002/jts.21830; Green BL, 2000, J TRAUMA STRESS, V13, P271, DOI 10.1023/A:1007758711939; Grey N, 2001, BEHAV COGN PSYCHOTH, V29, P367, DOI 10.1017/S1352465801003095; Grissom N, 2009, NEUROBIOL LEARN MEM, V92, P215, DOI 10.1016/j.nlm.2008.07.001; GROVES P M, 1970, Psychological Review, V77, P419, DOI 10.1037/h0029810; Gwozdziewycz Nicolas, 2013, Perm J, V17, P70, DOI 10.7812/TPP/12-058; Halvorsen JO, 2010, SCAND J PSYCHOL, V51, P495, DOI 10.1111/j.1467-9450.2010.00821.x; Hembree EA, 2004, J PERS DISORD, V18, P117, DOI 10.1521/pedi.18.1.117.32767; Hensel-Dittmann D, 2011, PSYCHOTHER PSYCHOSOM, V80, P345, DOI 10.1159/000327253; Hijazi A. M., 2013, DISS ABSTR INT B, V74; Institute of Medicine, 2008, TREATM POSTTR STRESS; Ironson G, 2002, J CLIN PSYCHOL, V58, P113, DOI 10.1002/jclp.1132; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048, DOI 10.1001/archpsyc.1995.03950240066012; Lustig Stuart L, 2004, Transcult Psychiatry, V41, P31, DOI 10.1177/1363461504041352; McDonagh A, 2005, J CONSULT CLIN PSYCH, V73, P515, DOI 10.1037/0022-006X.73.3.515; McLean CP, 2011, EXPERT REV NEUROTHER, V11, P1151, DOI [10.1586/ern.11.94, 10.1586/ERN.11.94]; McPherson J., 2011, SAGE J ONLINE, V21; Moser JS, 2010, J NERV MENT DIS, V198, P72, DOI 10.1097/NMD.0b013e3181c81fac; Nacasch N, 2011, J CLIN PSYCHIAT, V72, P1174, DOI 10.4088/JCP.09m05682blu; National Collaborating Centre for Mental Health (NCCMH), 2005, POSTTR STRESS DIS MA; Neuner F, 2004, J CONSULT CLIN PSYCH, V72, P579, DOI 10.1037/0022-006X.72.4.579; Neuner F, 2008, J CONSULT CLIN PSYCH, V76, P686, DOI 10.1037/0022-006X.76.4.686; Neuner F, 2008, CHILD ADOL PSYCH CL, V17, P641, DOI 10.1016/j.chc.2008.03.001; Neuner Frank, 2010, Cognitive Behaviour Therapy, V39, P81, DOI 10.1080/16506070903121042; Neuner F, 2002, BEHAV COGN PSYCHOTH, V30, P205, DOI 10.1017/S1352465802002072; NICE, 2005, POSTTR STREE DIS PTS, V26; Nicholl C., 2004, J MENT HEALTH, V13, P351, DOI [10.1080/09638230410001729807, DOI 10.1080/09638230410001729807]; Nickerson A, 2011, CLIN PSYCHOL REV, V31, P399, DOI 10.1016/j.cpr.2010.10.004; Onyut LP, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-7; Otto MW, 2003, BEHAV RES THER, V41, P1271, DOI 10.1016/S0005-7967(03)00032-9; Pabst A., 2014, CLIN NEUROPSYCHIATRY, V81, P61; Palic S, 2014, J NERV MENT DIS, V202, P111, DOI 10.1097/NMD.0000000000000079; Palic S, 2011, J AFFECT DISORDERS, V131, P8, DOI 10.1016/j.jad.2010.07.005; Paunovic N, 2001, BEHAV RES THER, V39, P1183, DOI 10.1016/S0005-7967(00)00093-0; Powers MB, 2010, CLIN PSYCHOL REV, V30, P635, DOI 10.1016/j.cpr.2010.04.007; Rauch SAM, 2009, J TRAUMA STRESS, V22, P60, DOI 10.1002/jts.20380; Ready DJ, 2012, PSYCHOL TRAUMA-US, V4, P84, DOI 10.1037/a0021997; Resick PA, 2003, CNS SPECTR, V8, P340, DOI 10.1017/S1092852900018605; Resick PA, 2012, J CONSULT CLIN PSYCH, V80, P201, DOI 10.1037/a0026602; Robjant K, 2010, CLIN PSYCHOL REV, V30, P1030, DOI 10.1016/j.cpr.2010.07.004; Rothbaum BO, 2005, J TRAUMA STRESS, V18, P607, DOI 10.1002/jts.20069; Rothbaum BO, 2003, ANN NY ACAD SCI, V1008, P112, DOI 10.1196/annals.1301.012; Rothbaum BO, 2000, EFFECTIVE TREATMENTS FOR PTSD, P320; Ruf M, 2010, J TRAUMA STRESS, V23, P437, DOI 10.1002/jts.20548; Schaal S, 2009, PSYCHOTHER PSYCHOSOM, V78, P298, DOI 10.1159/000229768; Schauer M., 2011, NARRATIVE EXPOSURE T; Schnurr PP, 2007, JAMA-J AM MED ASSOC, V297, P820, DOI 10.1001/jama.297.8.820; Simon NM, 2008, J CLIN PSYCHIAT, V69, P400, DOI 10.4088/JCP.v69n0309; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; Sripada RK, 2013, J TRAUMA STRESS, V26, P369, DOI 10.1002/jts.21813; Stenmark H, 2013, BEHAV RES THER, V51, P641, DOI 10.1016/j.brat.2013.07.002; Thorp SR, 2012, AM J GERIAT PSYCHIAT, V20, P276, DOI 10.1097/JGP.0b013e3182435ee9; Tuerk PW, 2013, PSYCHOL SERV, V10, P401, DOI 10.1037/a0030549; Tuerk PW, 2011, J ANXIETY DISORD, V25, P397, DOI 10.1016/j.janxdis.2010.11.002; Tuerk PW, 2010, J TRAUMA STRESS, V23, P116, DOI 10.1002/jts.20494; Tulving E, 2001, PHILOS T R SOC B, V356, P1505, DOI 10.1098/rstb.2001.0937; Van Dijk Janie A., 2003, American Journal of Psychotherapy, V57, P361; van Minnen A, 2002, BEHAV RES THER, V40, P439, DOI 10.1016/S0005-7967(01)00024-9; Vermetten E, 2014, CURR PSYCHIAT REP, V16, DOI 10.1007/s11920-013-0434-8; Weine SM, 1998, AM J PSYCHIAT, V155, P1720, DOI 10.1176/ajp.155.12.1720; Wolf GK, 2012, J HEAD TRAUMA REHAB, V27, P26, DOI 10.1097/HTR.0b013e31823cd01f; World Health Organization, 1992, ICD 10 CLASS MENT BE; Yoder M, 2012, PSYCHOL SERV, V9, P16, DOI 10.1037/a0026279; Yoder MS, 2013, INT J PSYCHIAT MED, V45, P111, DOI 10.2190/PM.45.2.b; Zang YY, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-41; Zoellner LA, 1999, BEHAV THER, V30, P581, DOI 10.1016/S0005-7894(99)80026-4	107	32	34	2	82	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0272-7358	1873-7811		CLIN PSYCHOL REV	Clin. Psychol. Rev.	AUG	2014	34	6					453	467		10.1016/j.cpr.2014.06.005			15	Psychology, Clinical	Psychology	AP7PL	WOS:000342269100001	25047447				2021-06-18	
J	Barlow, KM; Brooks, BL; MacMaster, FP; Kirton, A; Seeger, T; Esser, M; Crawford, S; Nettel-Aguirre, A; Zemek, R; Angelo, M; Kirk, V; Emery, CA; Johnson, D; Hill, MD; Buchhalter, J; Turley, B; Richer, L; Platt, R; Hutchison, J; Dewey, D				Barlow, Karen M.; Brooks, Brian L.; MacMaster, Frank P.; Kirton, Adam; Seeger, Trevor; Esser, Michael; Crawford, Susan; Nettel-Aguirre, Alberto; Zemek, Roger; Angelo, Mikrogianakis; Kirk, Valerie; Emery, Carolyn A.; Johnson, David; Hill, Michael D.; Buchhalter, Jeff; Turley, Brenda; Richer, Lawrence; Platt, Robert; Hutchison, Jamie; Dewey, Deborah			A double-blind, placebo-controlled intervention trial of 3 and 10 mg sublingual melatonin for post-concussion syndrome in youths (PLAYGAME): study protocol for a randomized controlled trial	TRIALS			English	Article						Concussion; Traumatic brain injury; Melatonin; Placebo; Pediatric; Randomized controlled trial	TRAUMATIC BRAIN-INJURY; IRRITABLE-BOWEL-SYNDROME; QUALITY-OF-LIFE; CENTRAL-NERVOUS-SYSTEM; SPORT-RELATED CONCUSSION; LONG-TERM POTENTIATION; ROUTINE FOLLOW-UP; OXIDATIVE STRESS; HEAD-INJURY; SLEEP DISORDERS	Background: By the age of sixteen, one in five children will sustain a mild traumatic brain injury also known as concussion. Our research found that one in seven school children with mild traumatic brain injury suffer post-concussion syndrome symptoms for three months or longer. Post-concussion syndrome is associated with significant disability in the child and his/her family and yet there are no evidence-based medical treatments available. Melatonin has several potential mechanisms of action that could be useful following mild traumatic brain injury, including neuroprotective effects. The aim of this study is to determine if treatment with melatonin improves post-concussion syndrome in youths following mild traumatic brain injury. Our hypothesis is that treatment of post-concussion syndrome following mild traumatic brain injury with 3 or 10 mg of sublingual melatonin for 28 days will result in a decrease in post-concussion syndrome symptoms compared with placebo. Methods/Design: Ninety-nine youths with mild traumatic brain injury, aged between 13 and 18 years, who are symptomatic at 30 days post-injury will be recruited. This study will be conducted as a randomized, double blind, placebo-controlled superiority trial of melatonin. Three parallel treatment groups will be examined with a 1:1:1 allocation: sublingual melatonin 3 mg, sublingual melatonin 10 mg, and sublingual placebo. Participants will receive treatment for 28 days. The primary outcome is a change on the Post-Concussion Symptom Inventory (Parent and Youth). The secondary outcomes will include neurobehavioral function, health-related quality of life and sleep. Neurophysiological and structural markers of change, using magnetic resonance imaging techniques and transcranial magnetic stimulation, will also be investigated. Discussion: Melatonin is a safe and well-tolerated agent that has many biological properties that may be useful following a traumatic brain injury. This study will determine whether it is a useful treatment for children with post-concussion syndrome. Recruitment commenced on 4 December 2014.	[Barlow, Karen M.; Brooks, Brian L.; MacMaster, Frank P.; Kirton, Adam; Seeger, Trevor; Esser, Michael; Crawford, Susan; Nettel-Aguirre, Alberto; Angelo, Mikrogianakis; Kirk, Valerie; Emery, Carolyn A.; Johnson, David; Buchhalter, Jeff; Turley, Brenda; Dewey, Deborah] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB T2N 4N1, Canada; [Zemek, Roger] Childrens Hosp Eastern Ontario, Ottawa, ON K1H 8L1, Canada; [Emery, Carolyn A.] Fac Kinesiol, Calgary, AB T2N 1N4, Canada; [Hill, Michael D.] Univ Calgary, Hlth Res Innovat Ctr, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada; [Richer, Lawrence] Univ Alberta, Dept Pediat Neurol, Edmonton, AB T6G 2B7, Canada; [Platt, Robert] McGill Univ, Montreal Childrens Hosp, Res Inst, Dept Stat, Montreal, PQ H3H 1P3, Canada; [Hutchison, Jamie] Hosp Sick Children, Dept Crit Care Med, Dept Pediat, Toronto, ON M5G 1X8, Canada; [Barlow, Karen M.] Alberta Childrens Prov Gen Hosp, Calgary, AB T3B 6A8, Canada	Barlow, KM (corresponding author), Univ Calgary, Alberta Childrens Hosp, Res Inst, Room 293,Heritage Med Res Bldg 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	Karen.barlow@albertahealthservices.ca	Hill, Michael D/C-9073-2012; Barlow, Karen/I-6492-2019; Richer, Lawrence/D-3622-2009; Zemek, Roger/H-1039-2018; Kirton, Adam/L-8875-2016; Emery, Carolyn/AAI-2761-2020; Barlow, Karen/C-1323-2014	Hill, Michael D/0000-0002-6269-1543; Richer, Lawrence/0000-0002-6897-8668; Platt, Robert/0000-0002-5981-8443; MacMaster, Frank/0000-0002-7159-7583; Nettel-Aguirre, Alberto/0000-0001-6604-0652; Barlow, Karen/0000-0003-2612-8507; Dewey, Deborah/0000-0002-1323-5832	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [293375]; Faculty of Medicine, University of Calgary	This study is funded by Canadian Institutes of Health Research (grant number: 293375) and Faculty of Medicine, University of Calgary. These funding sources had no role in the design of this study and will not have any role during its execution, analyses, interpretation of the data, or decision to submit results. The design, management, analysis and reporting of the study are entirely independent of any manufacturers of melatonin. Pediatric Emergency Research Teams at Alberta Children's Hospital and Children's Hospital of Eastern Ontario, and Pediatric Emergency Research Consortium, Canada.	Acufla-Castroviejo D, 1995, J PINEAL RES, V19, P57; Castroviejo DA, 2011, CURR TOP MED CHEM, V11, P221; Acuna-Castroviejo D, 2003, ADV EXP MED BIOL, V527, P549; Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Allegra M, 2003, J PINEAL RES, V34, P1, DOI 10.1034/j.1600-079X.2003.02112.x; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Alstadhaug KB, 2010, NEUROLOGY, V75, P1527, DOI 10.1212/WNL.0b013e3181f9618c; Andrews-Zwilling Y, 2010, J NEUROSCI, V30, P13707, DOI 10.1523/JNEUROSCI.4040-10.2010; Antolin I, 2002, BRAIN RES, V943, P163, DOI 10.1016/S0006-8993(02)02551-9; Antonaci F, 2011, CURR NEUROL NEUROSCI, V11, P149, DOI 10.1007/s11910-010-0164-9; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Ayr LK, 2009, J INT NEUROPSYCH SOC, V15, P19, DOI 10.1017/S1355617708090188; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Bayly PV, 2006, J BIOMECH, V39, P1086, DOI 10.1016/j.jbiomech.2005.02.014; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; Borlongan CV, 2000, FASEB J, V14, P1307, DOI 10.1096/fj.14.10.1307; Brooks BL, 2012, J CHILD NEUROL, V27, P982, DOI 10.1177/0883073811430863; Buscemi N, 2006, BMJ-BRIT MED J, V332, P385, DOI 10.1136/bmj.38731.532766.F6; Buscemi N, 2005, J GEN INTERN MED, V20, P1151, DOI 10.1111/j.1525-1497.2005.0243.x; Camins A, 2010, EXPERT OPIN INV DRUG, V19, P587, DOI 10.1517/13543781003781898; Campolo M, 2013, J ENDOCRINOL, V217, P291, DOI 10.1530/JOE-13-0022; Cardinali DP, 2013, HORM BEHAV, V63, P322, DOI 10.1016/j.yhbeh.2012.02.020; Carpentieri A, 2012, PHARMACOL RES, V65, P437, DOI 10.1016/j.phrs.2012.01.003; Cernak I, 2010, DEV NEUROSCI-BASEL, V32, P442, DOI 10.1159/000320085; Citera G, 2000, CLIN RHEUMATOL, V19, P9, DOI 10.1007/s100670050003; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; Dai X, 2007, BEHAV BRAIN RES, V182, P21, DOI 10.1016/j.bbr.2007.04.018; Das A, 2008, J PINEAL RES, V45, P117, DOI 10.1111/j.1600-079X.2008.00582.x; Dehghan F, 2013, ARCH MED RES, V44, P251, DOI 10.1016/j.arcmed.2013.04.002; Dhanaraj E, 2004, PHARMACOL BIOCHEM BE, V79, P733, DOI 10.1016/j.pbb.2004.10.002; Dodge NN, 2001, J CHILD NEUROL, V16, P581, DOI 10.1177/088307380101600808; Donaldson CJ, 2010, OTOLARYNG HEAD NECK, V143, P820, DOI 10.1016/j.otohns.2010.09.024; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Doyle A, 1997, J CLIN CHILD PSYCHOL, V26, P276, DOI 10.1207/s15374424jccp2603_6; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; Erickson JC, 2011, HEADACHE, V51, P932, DOI 10.1111/j.1526-4610.2011.01909.x; Esposito E, 2010, CURR NEUROPHARMACOL, V8, P228, DOI 10.2174/157015910792246155; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; Garcia J, 2001, Semin Pediatr Neurol, V8, P229, DOI 10.1053/spen.2001.29044; Gioia GA, 2011, MANUAL PEDIAT IMMEDI; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza CC, 2006, J NEUROTRAUM, V23, P950, DOI 10.1089/neu.2006.23.950; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Glass KL, 2005, 33 ANN M INT NEUR SO, V2005, P171; Gorgulu AK, 2001, NEUROSURGERY, V49, P1434; Gosselin N, 2010, PHYSICIAN SPORTSMED, V38, P27, DOI 10.3810/psm.2010.10.1805; Gravel J, 2013, SYST REV, V2, DOI 10.1186/2046-4053-2-63; Green LB, 2004, AM J PHYS MED REHAB, V83, P893, DOI 10.1097/01.PHM.0000143400.15346.C8; Green Robin, 2010, Neuropsychol Rehabil, V20, P471, DOI 10.1080/09602011003693298; Gurkanlar D, 2010, TURK NEUROSURG, V20, P442, DOI 10.5137/1019-5149.JTN.3176-10.1; Henninger N, 2007, CRIT CARE MED, V35, P2607, DOI 10.1097/01.CCM.0000286395.79654.8D; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Herrera F, 2001, J PINEAL RES, V31, P356, DOI 10.1034/j.1600-079X.2001.310411.x; Hofstra WA, 2008, EPILEPSY BEHAV, V13, P438, DOI 10.1016/j.yebeh.2008.06.002; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Janusz J.A., 2012, MILD TRAUMATIC BRAIN, P241; Koh JO, 2011, J SPORT MED PHYS FIT, V51, P625; Kotler M, 1998, J PINEAL RES, V24, P83, DOI 10.1111/j.1600-079X.1998.tb00371.x; Kuczynski A, 2011, CAN J NEUR SCI, V38; Kuczynski A, 2013, DEV MED CHILD NEUROL, V55, P636, DOI 10.1111/dmcn.12152; Kumar A, 2009, FUND CLIN PHARMACOL, V23, P439, DOI 10.1111/j.1472-8206.2009.00737.x; LABEL L S, 1991, Neurology, V41, P247; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Len TK, 2011, CLIN PHYSIOL FUNCT I, V31, P85, DOI 10.1111/j.1475-097X.2010.00990.x; Leon J, 2004, LIFE SCI, V75, P765, DOI 10.1016/j.lfs.2004.03.003; Leon J, 2005, J PINEAL RES, V38, P1, DOI 10.1111/j.1600-079X.2004.00181.x; Lima ACP, 2003, NEUROTOX RES, V5, P323, DOI 10.1007/BF03033152; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Louzada PR, 2004, FASEB J, V18, P511, DOI 10.1096/fj.03-0739com; Lu WZ, 2005, ALIMENT PHARM THER, V22, P927, DOI 10.1111/j.1365-2036.2005.02673.x; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Maldonado MD, 2007, J PINEAL RES, V42, P1, DOI 10.1111/j.1600-079X.2006.00376.x; Maldonado MD, 2012, PHYSIOL BEHAV, V105, P1099, DOI 10.1016/j.physbeh.2011.12.015; Manda K, 2007, ACTA NEUROBIOL EXP, V67, P63; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; Meehan WP, 2011, CLIN SPORT MED, V30, P115, DOI 10.1016/j.csm.2010.08.003; Miano S, 2008, NEUROL SCI, V29, P285, DOI 10.1007/s10072-008-0983-5; MITTENBERG W, 1994, BRAIN INJURY, V8, P429, DOI 10.3109/02699059409150994; Moran LM, 2011, J HEAD TRAUMA REHAB, V26, P348, DOI 10.1097/HTR.0b013e3181f8d32e; Mozaffari S, 2010, CURR PHARM DESIGN, V16, P3646, DOI 10.2174/138161210794079254; Nakajima Y, 2010, TOHOKU J EXP MED, V221, P229, DOI 10.1620/tjem.221.229; O'Connell KM, 2013, BIOL RES NURS, V15, P253, DOI 10.1177/1099800411431823; Obermann M, 2010, HEADACHE, V50, P710, DOI 10.1111/j.1526-4610.2010.01644.x; Ochoa JJ, 2011, J PINEAL RES, V51, P373, DOI 10.1111/j.1600-079X.2011.00899.x; Ozdemir D, 2005, NEUROSCI LETT, V385, P234, DOI 10.1016/j.neulet.2005.05.055; Ozdemir D, 2005, PHYSIOL RES, V54, P631; Peres MFP, 2004, NEUROLOGY, V63, P757, DOI 10.1212/01.WNL.0000134653.35587.24; Petersen C, 2008, BRAIN INJURY, V22, P215, DOI 10.1080/02699050801935245; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; REDMAN J, 1983, SCIENCE, V219, P1089, DOI 10.1126/science.6823571; REDMAN JR, 1988, J PINEAL RES, V5, P203, DOI 10.1111/j.1600-079X.1988.tb00782.x; Reiter RJ, 2010, PROG BRAIN RES, V181, P127, DOI 10.1016/S0079-6123(08)81008-4; Reiter Russel J, 2008, Interdiscip Toxicol, V1, P137, DOI 10.2478/v10102-010-0030-2; Reynolds CR, 2002, CLIN GUID BEHAV ASSE; Rodriguez C, 2004, J PINEAL RES, V36, P1, DOI 10.1046/j.1600-079X.2003.00092.x; Rosen J, 2006, J PINEAL RES, V41, P374, DOI 10.1111/j.1600-079X.2006.00379.x; Ryu WHA, 2009, CAN J NEUROL SCI, V36, P429, DOI 10.1017/S0317167100007745; Saha L, 2007, J CLIN GASTROENTEROL, V41, P29, DOI 10.1097/MCG.0b013e31802df84c; Samantaray S, 2008, J PINEAL RES, V44, P348, DOI 10.1111/j.1600-079X.2007.00534.x; Samantaray S, 2009, J PINEAL RES, V47, P134, DOI 10.1111/j.1600-079X.2009.00703.x; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; SARAN A, 1988, INT J PSYCHIAT MED, V18, P75, DOI 10.2190/15AH-JB7Q-U94T-JEAF; Schneider KJ, 2013, BRIT J SPORT MED, V47, P304, DOI 10.1136/bjsports-2013-092190; Shrey DW, 2011, PHYS MED REH CLIN N, V22, P577, DOI 10.1016/j.pmr.2011.08.002; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Solomon GS, 2011, CLIN SPORT MED, V30, P165, DOI 10.1016/j.csm.2010.09.002; Song GH, 2005, GUT, V54, P1402, DOI 10.1136/gut.2004.062034; Tal G, 2013, PEDIATR NEUROL, V48, P424, DOI 10.1016/j.pediatrneurol.2012.11.008; Tan DX, 2000, BIOL SIGNAL RECEPT, V9, P137; Tenovuo O, 2006, CURR OPIN NEUROL, V19, P528, DOI 10.1097/WCO.0b013e328010944f; Thiagarajan P, 2014, NEUROREHABILITATION, V34, P129, DOI 10.3233/NRE-131025; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tsai J, 2012, J CLIN PSYCHIAT, V73, P1110, DOI 10.4088/JCP.11m07587; Tsai MC, 2011, J PINEAL RES, V51, P233, DOI 10.1111/j.1600-079X.2011.00885.x; TYLER GS, 1980, HEADACHE, V20, P213, DOI 10.1111/j.1526-4610.1980.hed2004213.x; UNDERWOOD H, 1987, Journal of Biological Rhythms, V2, P279, DOI 10.1177/074873048700200404; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; van Geijlswijk IM, 2010, PSYCHOPHARMACOLOGY, V212, P379, DOI 10.1007/s00213-010-1962-0; Rios ERV, 2010, INT J NEUROSCI, V120, P583, DOI 10.3109/00207454.2010.492921; Velkov ZA, 2009, EUR J MED CHEM, V44, P2834, DOI 10.1016/j.ejmech.2008.12.017; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wang WZ, 2006, J PINEAL RES, V41, P255, DOI 10.1111/j.1600-079X.2006.00361.x; Watanabe TK, 2012, PM&R, V4, P129, DOI 10.1016/j.pmrj.2011.06.003; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Wilhelmsen M, 2011, J PINEAL RES, V51, P270, DOI 10.1111/j.1600-079X.2011.00895.x; Wilhelmsen Michael, 2011, Ugeskr Laeger, V173, P1424; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Yousaf F, 2010, ANESTHESIOLOGY, V113, P968, DOI 10.1097/ALN.0b013e3181e7d626; Zafonte R, 2009, J NEUROTRAUM, V26, P2207, DOI 10.1089/neu.2009.1015	144	32	32	1	24	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1745-6215			TRIALS	Trials	JUL 7	2014	15								271	10.1186/1745-6215-15-271			10	Medicine, Research & Experimental	Research & Experimental Medicine	AM7SC	WOS:000340067500001	25001947	DOAJ Gold, Green Published			2021-06-18	
J	Carlozzi, NE; Tulsky, DS; Chiaravalloti, ND; Beaumont, JL; Weintraub, S; Conway, K; Gershon, RC				Carlozzi, Noelle E.; Tulsky, David S.; Chiaravalloti, Nancy D.; Beaumont, Jennifer L.; Weintraub, Sandra; Conway, Kevin; Gershon, Richard C.			NIH Toolbox Cognitive Battery (NIHTB-CB): The NIHTB Pattern Comparison Processing Speed Test	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						NIHTB; Processing speed; Pattern Comparison Processing Speed Test; Cognition; Neuropsychological assessment; Mental processes; Outcomes assessment (health care)	TRAUMATIC BRAIN-INJURY; CHRONIC-FATIGUE-SYNDROME; MULTIPLE-SCLEROSIS; WORKING-MEMORY; SEX-DIFFERENCES; GENERAL INTELLIGENCE; AGE-DIFFERENCES; HEAD-INJURY; ADULT AGE; LIFE-SPAN	The NIH Toolbox (NIHTB) Pattern Comparison Processing Speed Test was developed to assess processing speed within the NIHTB for the Assessment of Neurological Behavior and Function Cognition Battery (NIHTB-CB). This study highlights validation data collected in adults ages 18-85 on this measure and reports descriptive data, test-retest reliability, construct validity, and preliminary work creating a composite index of processing speed. Results indicated good test-retest reliability. There was also evidence for both convergent and discriminant validity; the Pattern Comparison Processing Speed Test demonstrated moderate significant correlations with other processing speed tests (i.e., WAIS-IV Coding, Symbol Search and Processing Speed Index), small significant correlations with measures of working memory (i.e., WAIS-IV Letter-Number Sequencing and PASAT), and non-significant correlations with a test of vocabulary comprehension (i.e., PPVT-IV). Finally, analyses comparing and combining scores on the NIHTB Pattern Comparison Processing Speed Test with other measures of simple reaction time from the NIHTB-CB indicated that a Processing Speed Composite score performed better than any test examined in isolation. The NIHTB Pattern Comparison Processing Speed Test exhibits several strengths: it is appropriate for use across the lifespan (ages, 3-85 years), it is short and easy to administer, and it has high construct validity.	[Carlozzi, Noelle E.] Univ Michigan, Dept Phys Med & Rehabil, Ann Arbor, MI 48109 USA; [Tulsky, David S.] NYU, Rusk Inst, Dept Rehabil Med, Dept Orthoped Surg,Dept Gen Med, New York, NY USA; [Tulsky, David S.] Kessler Fdn, Neuropsychol & Neurosci Lab, Spinal Cord Injury Lab, West Orange, NJ USA; [Chiaravalloti, Nancy D.] Kessler Fdn, Traumat Brain Injury Lab, Neuropsychol & Neurosci Lab, W Orange, NJ USA; [Beaumont, Jennifer L.; Gershon, Richard C.] Northwestern Univ, Dept Med Social Sci, Chicago, IL 60611 USA; [Weintraub, Sandra] Northwestern Univ, Dept Psychiat & Cognit Neurol, Chicago, IL 60611 USA; [Weintraub, Sandra] Northwestern Univ, Alzheimers Dis Ctr, Chicago, IL 60611 USA; [Conway, Kevin] NIDA, Washington, DC USA	Carlozzi, NE (corresponding author), Univ Michigan, Dept Phys Med & Rehabil, North Campus Res Complex,Bldg 14,2800 Plymouth Rd, Ann Arbor, MI 48109 USA.	carlozzi@med.umich.edu	Beaumont, Jennifer/AAA-2825-2020	Chiaravalloti, Nancy/0000-0003-2943-7567; Conway, Kevin/0000-0002-7638-339X; Beaumont, Jennifer/0000-0002-1484-260X; Tulsky, David/0000-0002-4335-4509	Blueprint for Neuroscience Research, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HHS-N-260-2006-00007-C]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K23HL085766] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [U01AR057929, U54AR057943] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [U01DK082342] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS077946, R03NS065194, U01NS056975] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013658] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013854, R01AG032088, RC2AG036498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [N44AA002006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC008552] Funding Source: NIH RePORTER	This study is funded in whole or in part with Federal funds from the Blueprint for Neuroscience Research, National Institutes of Health, under Contract No. HHS-N-260-2006-00007-C. The authors do not have any conflicts of interest to report.	Ball K., 2008, INFORM PROCESSING SP; Barker-Collo SL, 2006, ARCH CLIN NEUROPSYCH, V21, P167, DOI 10.1016/j.acn.2005.08.008; Bell NL, 2001, J CLIN PSYCHOL, V57, P417, DOI 10.1002/jclp.1024; Camarata S, 2006, INTELLIGENCE, V34, P231, DOI 10.1016/j.intell.2005.12.001; CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016; Carlozzi NE, 2013, MONOGR SOC RES CHILD, V78, P88, DOI 10.1111/mono.12036; CERELLA J, 1994, ACTA PSYCHOL, V86, P109, DOI 10.1016/0001-6918(94)90002-7; Chaytor N, 2004, J INT NEUROPSYCH SOC, V10, P489, DOI 10.1017/S1355617704104013; Chiaravalloti ND, 2003, J CLIN EXP NEUROPSYC, V25, P489, DOI 10.1076/jcen.25.4.489.13878; Coyle TR, 2011, PSYCHOL SCI, V22, P1265, DOI 10.1177/0956797611418243; Crowe SF, 2000, ASSESSMENT, V7, P113, DOI 10.1177/107319110000700202; DeLuca J, 1998, J CLIN EXP NEUROPSYC, V20, P376, DOI 10.1076/jcen.20.3.376.819; DELUCA J, 1994, J CLIN EXP NEUROPSYC, V16, P183, DOI 10.1080/01688639408402629; DeLuca J, 2004, J CLIN EXP NEUROPSYC, V26, P550, DOI 10.1080/13803390490496641; DeLuca J, 2004, J INT NEUROPSYCH SOC, V10, P101; Demaree HA, 1999, J NEUROL NEUROSUR PS, V67, P661, DOI 10.1136/jnnp.67.5.661; DEMPSTER FN, 1981, PSYCHOL BULL, V89, P63, DOI 10.1037/0033-2909.89.1.63; Denegar C.R., 1993, J SPORT REHABIL, V2, P35, DOI DOI 10.1123/JSR.2.1.35; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Dunn L., 2007, PEABODY PICTURE VOCA, V4th ed.; Finkel SI, 2004, INT J GERIATR PSYCH, V19, P9, DOI 10.1002/gps.998; FLAVELL JH, 1992, DEV PSYCHOL, V28, P998, DOI 10.1037/0012-1649.28.6.998; Forn C, 2013, BRAIN COGNITION, V82, P152, DOI 10.1016/j.bandc.2013.04.003; Gaudino EA, 2001, NEUROPSY NEUROPSY BE, V14, P32; Genova HM, 2009, J INT NEUROPSYCH SOC, V15, P383, DOI 10.1017/S1355617709090535; Gershon RC, 2010, LANCET NEUROL, V9, P138, DOI 10.1016/S1474-4422(09)70335-7; Gold JM, 1997, ARCH GEN PSYCHIAT, V54, P159; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; HALE S, 1990, CHILD DEV, V61, P653, DOI 10.2307/1130951; Han SD, 2012, J INT NEUROPSYCH SOC, V18, P39, DOI 10.1017/S1355617711001299; Haut M W, 2000, Appl Neuropsychol, V7, P237, DOI 10.1207/S15324826AN0704_5; Hawkins KA, 1998, CLIN NEUROPSYCHOL, V12, P535, DOI 10.1076/clin.12.4.535.7236; Hinkley LBN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039804; HUTTENLOCHER PR, 1979, BRAIN RES, V163, P195; Jensen A.R., 1993, CURRENT DIRECTIONS P, V2, P53, DOI [DOI 10.1111/1467-8721.EP10770697, DOI 10.1111/1467-8721.ep10770697]; Jensen Arthur R., 1982, MODEL INTELLIGENCE; KAIL R, 1991, DEV PSYCHOL, V27, P259, DOI 10.1037/0012-1649.27.2.259; KAIL RV, 2008, INFORM PROCESSING SP; Kalmar J. H., 2008, INFORM PROCESSING SP; Kalmar JH, 2008, INFORM PROCESSING SP; Kochunov P, 2010, NEUROIMAGE, V49, P1190, DOI 10.1016/j.neuroimage.2009.09.052; Leavitt VM, 2012, MULT SCLER J, V18, P409, DOI 10.1177/1352458511423651; Lengenfelder J, 2006, ARCH CLIN NEUROPSYCH, V21, P229, DOI 10.1016/j.acn.2005.12.001; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Llorente AM, 1998, J CLIN EXP NEUROPSYC, V20, P60, DOI 10.1076/jcen.20.1.60.1489; Mabbott D.J., 2005, ORG HUM BRAIN MAPP T; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Majeres RL, 1999, MEM COGNITION, V27, P246, DOI 10.3758/BF03211409; Majeres RL, 1997, PERCEPT MOTOR SKILL, V85, P1243, DOI 10.2466/pms.1997.85.3f.1243; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; O'Brien AR, 2008, INFORM PROCESSING SP; Posthuma D., 2008, INFORM PROCESSING SP; Ready RE, 2011, AM J ALZHEIMERS DIS, V26, P463, DOI 10.1177/1533317511421921; Salthouse T. A., 1985, HDB AGING HDB PSYCHO, P400; SALTHOUSE TA, 1991, PSYCHOL AGING, V6, P118, DOI 10.1037/0882-7974.6.1.118; SALTHOUSE TA, 1993, DEV PSYCHOL, V29, P722, DOI 10.1037/0012-1649.29.4.722; SALTHOUSE TA, 1993, J GERONTOL, V48, pP245, DOI 10.1093/geronj/48.5.P245; Salthouse TA, 1990, HDB PSYCHOL AGING, P310; Sasson E, 2012, BRAIN STRUCT FUNCT, V217, P503, DOI 10.1007/s00429-011-0344-7; Sawamoto N, 2002, J NEUROSCI, V22, P5198, DOI 10.1523/JNEUROSCI.22-12-05198.2002; SCHAIE KW, 1994, AM PSYCHOL, V49, P304, DOI 10.1037/0003-066X.49.4.304; SCHAIE KW, 1989, PSYCHOL AGING, V4, P443, DOI 10.1037/0882-7974.4.4.443; Sherman EMS, 1997, CLIN NEUROPSYCHOL, V11, P34, DOI 10.1080/13854049708407027; SIEGEL LS, 1994, INT J BEHAV DEV, P109; SLIWINSKI M, 1997, J GERONTOL B-PSYCHOL, V52, P308; Smith AM, 2012, J NEUROL SCI, V312, P131, DOI 10.1016/j.jns.2011.08.003; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Takeuchi H, 2011, J NEUROSCI, V31, P12139, DOI 10.1523/JNEUROSCI.2948-11.2011; Tiersky LA, 1997, J CLIN EXP NEUROPSYC, V19, P560, DOI 10.1080/01688639708403744; Tulsky D.S., 2003, CLIN INTERPRETATION; van Duinkerken E, 2012, DIABETES, V61, P1814, DOI 10.2337/db11-1358; van Duinkerken E, 2009, DIABETES, V58, P2335, DOI 10.2337/db09-0425; Vernon P.A., 1987, SPEED INFORM PROCESS; VERNON PA, 1983, INTELLIGENCE, V7, P53, DOI 10.1016/0160-2896(83)90006-5; Vichinsky EP, 2010, JAMA-J AM MED ASSOC, V303, P1823, DOI 10.1001/jama.2010.562; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Weintraub S., J INT NEURO IN PRESS; Yakovlev PI, 1967, REGIONAL DEV BRAIN E; Ystad M, 2011, NEUROIMAGE, V55, P24, DOI 10.1016/j.neuroimage.2010.11.016; Zelazo P.D., J INT NEUROPSYCHOLOG; Zimprich D, 2002, PSYCHOL AGING, V17, P690, DOI 10.1037/0882-7974.17.4.690	83	32	33	0	26	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2014	20	6					630	641		10.1017/S1355617714000319			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	AL7PH	WOS:000339326300007	24960594	Green Accepted			2021-06-18	
J	Kinnaman, KA; Mannix, RC; Comstock, RD; Meehan, WP				Kinnaman, Karen A.; Mannix, Rebekah C.; Comstock, R. Dawn; Meehan, William P., III			Management of Pediatric Patients With Concussion by Emergency Medicine Physicians	PEDIATRIC EMERGENCY CARE			English	Article						concussion; management; medication	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; HIGH-SCHOOL; CHILDREN; MILD; PROVIDERS; KNOWLEDGE	Objective: Despite an increase in concussion diagnoses among pediatric patients, little is known about the management of pediatric patients with concussion in emergency departments (EDs). The objective of this study was to assess strategies used by emergency medicine physicians when treating pediatric patients with concussions. Methods: A 17-item questionnaire was e-mailed to members of the American Academy of Pediatrics Section on Emergency Medicine. Two serial e-mails were distributed at 2-week intervals to nonresponders. The survey included multiple-choice and free-text questions that were created by the team of investigators on the basis of prior surveys of family practitioners and physical trainers. We collected demographic information and specific information regarding the use of medications, neuropsychological testing, neuroimaging, return-to-play decision making, and use of published guidelines. Simple descriptive statistics were used. Results: Two hundred sixty-five (29%) physicians completed the questionnaire, of which 52% had been an attending physician for more than 10 years. Ninety-nine percent of the respondents reported managing concussions, with the majority (76%) seeing more than 24 patients with concussion per year. Most clinicians (81%) reported using a published guideline in their management of concussions. The symptoms most likely to prompt head imaging in the ED included a focal neurological deficit (92%), altered mental status (82%), and intractable vomiting (80%). Most (91%) respondents reported using medications to manage the symptoms of patients with concussion, mainly acetaminophen (78%) and nonsteroidal anti-inflammatory medications (77%), whereas 54% of the respondents used ondansetron and 7% of the respondents used narcotics. More than half (56%) of the respondents referred patients with concussion for neuropsychological testing from the ED. Of those, nearly half (49%) of the respondents refer their patients to a sports concussion clinic, whereas 5% of the respondents refer their patients to a neuropsychologist. When discussing discharge instructions, 86% of the clinicians recommended follow-up with a primary care physician, 62% of the clinicians recommended follow-up with a sports concussion clinic, and 11% of the clinicians recommend follow-up with a neurologist. Most respondents (70%) have access to a designated sports concussion clinic. Conclusions: Nearly all emergency medicine physicians surveyed care for pediatric patients with concussion, most by using published guidelines. Emergency medicine physicians routinely use medications to treat the symptoms of concussion and often refer patients to primary care physicians as well as designated sports concussion clinics for follow-up.	[Kinnaman, Karen A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA; [Kinnaman, Karen A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Emergency Med, Boston, MA 02115 USA; [Mannix, Rebekah C.; Meehan, William P., III] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Mannix, Rebekah C.] Harvard Univ, Sch Med, Boston Childrens Hosp, Brain Injury Ctr, Boston, MA USA; [Comstock, R. Dawn] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA; [Meehan, William P., III] Harvard Univ, Sch Med, Boston Childrens Hosp, Div Sports Med, Boston, MA USA; [Meehan, William P., III] Harvard Univ, Sch Med, Boston Childrens Hosp, Sports Concuss Clin, Boston, MA USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA	Kinnaman, KA (corresponding author), 77 Francis St,Neville House,First Floor, Boston, MA 02114 USA.	kkinnaman@partners.org	Mannix, Rebekah/AAD-8702-2020				Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bauer R, 2004, EXP TOXICOL PATHOL, V56, P65, DOI 10.1016/j.etp.2004.04.002; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Collins MW, 2003, AM J SPORT MED, V31, P168, DOI 10.1177/03635465030310020301; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Fung M, 2006, BRAIN INJURY, V20, P889, DOI 10.1080/02699050600831934; Gefen A, 2003, J NEUROTRAUM, V20, P1163, DOI 10.1089/089771503770802853; GENUARDI FJ, 1995, PEDIATRICS, V95, P216; Giebel S, 2011, J EMERG MED, V41, P649, DOI 10.1016/j.jemermed.2011.03.021; Goldsmith W, 2004, AM J FOREN MED PATH, V25, P89, DOI 10.1097/01.paf.0000127407.28071.63; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Lebrun CM, 2013, BRIT J SPORT MED, V47, P54, DOI 10.1136/bjsports-2012-091480; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; Pleacher MD, 2006, BRIT J SPORT MED, V40, DOI 10.1136/bjsm.2005.019067; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Prins ML, 2003, J NEUROTRAUM, V20, P123, DOI 10.1089/08977150360547053; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sturm JJ, 2012, PEDIATR EMERG CARE, V28, P247, DOI 10.1097/PEC.0b013e3182494d87; Thibault KL, 1998, J BIOMECH, V31, P1119, DOI 10.1016/S0021-9290(98)00122-5; Tomei KL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12280; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	27	32	32	0	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0749-5161	1535-1815		PEDIATR EMERG CARE	Pediatr. Emerg. Care	JUL	2014	30	7					458	461		10.1097/PEC.0000000000000161			4	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	AL2GP	WOS:000338944200003	24977993				2021-06-18	
J	Manevich, Y; Hutchens, S; Halushka, PV; Tew, KD; Townsend, DM; Jauch, EC; Borg, K				Manevich, Y.; Hutchens, S.; Halushka, P. V.; Tew, K. D.; Townsend, D. M.; Jauch, E. C.; Borg, K.			Peroxiredoxin VI oxidation in cerebrospinal fluid correlates with traumatic brain injury outcome	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						Peroxiredoxin VI; Traumatic brain injury; CSF; Oxidant stress; Protein thiol; GSH; Lipid peroxidation; Choroid plexus; Epithelial cells; Ependymal cells; Antioxidant protection; Free radicals	1-CYS PEROXIREDOXIN; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; STRESS; PROTEINS; AQUAPORINS; ENZYME; CELLS	Traumatic brain injury (TBI) patients would benefit from the identification of reliable biomarkers to predict outcomes and treatment strategies. In our study, cerebrospinal fluid (CSF) from patients with severe TBI was evaluated for oxidant stress-mediated damage progression after hospital admission and subsequent ventriculostomy placement. Interestingly, substantial levels of peroxiredoxin VI (Prdx6), a major antioxidant enzyme normally found in astrocytes, were detected in CSF from control and TBI patients and were not associated with blood contamination. Functionally, Prdx6 and its associated binding partner glutathione S-transferase Pi (GSTP1-1, also detected in CSF) act in tandem to detoxify lipid peroxidation damage to membranes. We found Prdx6 was fully active in CSF of control patients but becomes significantly inactivated (oxidized) in TBI. Furthermore, significant and progressive oxidation of "buried" protein thiols in CSF of TBI patients (compared to those of nontrauma controls) was detected over a 24-h period after hospital admission, with increased oxidation correlating with severity of trauma. Conversely, recovery of Prdx6 activity after 24 h indicated more favorable patient outcome. Not only is this the first report of an extracellutar form of Prdx6 but also the first report of its detection at a substantial level in CSF. Taken together, our data suggest a meaningful correlation between TBI-initiated oxidation of Prdx6, its specific phospholipid hydroperoxide peroxidase activity, and severity of trauma outcome. Consequently, we propose that Prdx6 redox status detection has the potential to be a biomarker for TBI outcome and a future indicator of therapeutic efficacy. (C) 2014 Elsevier Inc. All rights reserved.	[Manevich, Y.; Hutchens, S.; Halushka, P. V.; Tew, K. D.] Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA; [Townsend, D. M.] Med Univ S Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA; [Jauch, E. C.] Med Univ S Carolina, Dept Med, Div Emergency Med, Charleston, SC 29425 USA; [Borg, K.] Med Univ S Carolina, Dept Pediat, Div Pediat Emergency Med, Charleston, SC 29425 USA	Manevich, Y (corresponding author), Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA.	manevich@musc.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [CA08660, CA117259, NCRR P20RR024485, UL1 TR000062, KL2 RR029880, KL2 TRO]; South Carolina Centers of Excellence Program; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Extramural Research Facilities Program of the National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [COG RR015455]; South Carolina Clinical & Translational Research InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS); Medical University of South Carolina; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R41CA117259] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000062, KL2TR000060] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P20RR024485, UL1RR029882, KL2RR029880, C06RR015455] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM103542] Funding Source: NIH RePORTER	The authors thank P. Darwin Bell, Ph.D., and Ms. S. Steele (Department of Nephrology of the Medical University of South Carolina) for their help with collective duct epithelial cell culture; Ms. R.J. Navarro, MSN/MHA (Division of Emergency Medicine of the Medical University of South Carolina) for CSF and plasma sample collection; and Elizabeth Yeh, Ph.D. (Department of Cell and Molecular Pharmacology and Experimental Therapeutics of the Medical University of South Carolina), for helpful discussions and suggestions before submission of our manuscript. This publication was supported by grants from the NIH (CA08660, CA117259, NCRR P20RR024485-COBRE in Oxidants, Redox Balance and Stress Signaling) and support from the South Carolina Centers of Excellence Program and was conducted in a facility constructed with support from the NIH, Grant COG RR015455 from the Extramural Research Facilities Program of the National Center for Research Resources. This publication was also supported by the South Carolina Clinical & Translational Research Institute, with an academic home at the Medical University of South Carolina, through NIH Grant UL1 TR000062, and Dr. K. Borg was supported through NIH Grants KL2 RR029880 and KL2 TRO.	Basuroy S, 2009, AM J PHYSIOL-CELL PH, V296, pC422, DOI 10.1152/ajpcell.00381.2008; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bayir H, 2006, DEV NEUROSCI-BASEL, V28, P420, DOI 10.1159/000094168; Bienert GP, 2007, J BIOL CHEM, V282, P1183, DOI 10.1074/jbc.M603761200; Chen AS, 2010, J NEUROTRAUM, V27, P263, DOI 10.1089/neu.2009.1051; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; CSERR HF, 1971, PHYSIOL REV, V51, P273; Esposito A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003780; Goetzl L, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.01.034; Greenberg ME, 2008, J BIOL CHEM, V283, P2385, DOI 10.1074/jbc.M707348200; Hansen RE, 2009, P NATL ACAD SCI USA, V106, P422, DOI 10.1073/pnas.0812149106; Hirst RA, 2009, CHILD NERV SYST, V25, P559, DOI 10.1007/s00381-008-0768-4; HUNTER MIS, 1985, NEUROCHEM RES, V10, P1645, DOI 10.1007/BF00988606; Irani DN, 2009, CEREBROSPINAL FLUID; Jeong JH, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.000513; Laterra J. K., 1999, BASIC NEURO CHEM MOL; Leichert LI, 2006, ANTIOXID REDOX SIGN, V8, P763, DOI 10.1089/ars.2006.8.763; Manevich Y, 2005, FREE RADICAL BIO MED, V38, P1422, DOI 10.1016/j.freeradbiomed.2005.02.011; Manevich Y, 2004, P NATL ACAD SCI USA, V101, P3780, DOI 10.1073/pnas.0400181101; Manevich Y, 2013, FREE RADICAL BIO MED, V54, P62, DOI 10.1016/j.freeradbiomed.2012.10.556; Manevich Y, 2002, P NATL ACAD SCI USA, V99, P11599, DOI 10.1073/pnas.182384499; Manevich Y, 2007, J LIPID RES, V48, P2306, DOI 10.1194/jlr.M700299-JLR200; Mokri B, 2001, NEUROLOGY, V56, P1746, DOI 10.1212/WNL.56.12.1746; Power JHT, 2008, ACTA NEUROPATHOL, V115, P611, DOI 10.1007/s00401-008-0373-3; Reed TT, 2011, FREE RADICAL BIO MED, V51, P1302, DOI 10.1016/j.freeradbiomed.2011.06.027; Resnick A, 2007, BIOPHYS J, V93, P1380, DOI 10.1529/biophysj.107.105007; Saigusa T, 2012, AM J PHYSIOL-RENAL, V302, pF801, DOI 10.1152/ajprenal.00253.2011; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Schulte J, 2011, SHOCK, V35, P460, DOI 10.1097/SHK.0b013e3182115f40; Stuhlmeier KM, 2003, EUR J BIOCHEM, V270, P334, DOI 10.1046/j.1432-1033.2003.03393.x; SUBCZYNSKI WK, 1983, BIOPHYS J, V41, P283, DOI 10.1016/S0006-3495(83)84439-7; Sultana R, 2013, FREE RADICAL BIO MED, V62, P157, DOI 10.1016/j.freeradbiomed.2012.09.027; Takata K, 2004, PROG HISTOCHEM CYTO, V39, P1, DOI 10.1016/j.proghi.2004.03.001; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; Uys JD, 2011, NEUROPSYCHOPHARMACOL, V36, P2551, DOI 10.1038/npp.2011.143; Winterbourn CC, 1999, FREE RADICAL BIO MED, V27, P322, DOI 10.1016/S0891-5849(99)00051-9; Winterbourn CC, 2008, FREE RADICAL BIO MED, V45, P549, DOI 10.1016/j.freeradbiomed.2008.05.004; Wood KC, 2005, FASEB J, V19, P989, DOI 10.1096/fj.04-3218fje; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wu Y, 2009, BIOCHEM J, V419, P669, DOI 10.1042/BJ20082061	41	32	32	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	JUL	2014	72						210	221		10.1016/j.freeradbiomed.2014.04.002			12	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	AJ4OS	WOS:000337656300019	24726861	Green Accepted			2021-06-18	
J	Badaut, J; Bix, GJ				Badaut, J.; Bix, G. J.			Vascular Neural Network Phenotypic Transformation After Traumatic Injury: Potential Role in Long-Term Sequelae	TRANSLATIONAL STROKE RESEARCH			English	Article						Traumatic brain injury; Juvenile traumatic injury; Blood-brain barrier; Neurovascular unit; Cerebral blood flow; Smooth muscle cells; Matrix	BLOOD-BRAIN-BARRIER; NITRIC-OXIDE SYNTHASE; CONTROLLED CORTICAL IMPACT; IMPAIRED CEREBRAL AUTOREGULATION; ADVANCE TRANSLATIONAL RESEARCH; CENTRAL-NERVOUS-SYSTEM; P-GLYCOPROTEIN; HEAD-INJURY; EXTRACELLULAR-MATRIX; ALZHEIMERS-DISEASE	The classical neurovascular unit (NVU), composed primarily of endothelium, astrocytes, and neurons, could be expanded to include smooth muscle and perivascular nerves present in both the up- and downstream feeding blood vessels (arteries and veins). The extended NVU, which can be defined as the vascular neural network (VNN), may represent a new physiological unit to consider for therapeutic development in stroke, traumatic brain injury, and other brain disorders (Zhang et al., Nat Rev Neurol 8(12):711-716, 2012). This review is focused on traumatic brain injury and resultant post-traumatic changes in cerebral blood flow, smooth muscle cells, matrix, blood-brain barrier structures and function, and the association of these changes with cognitive outcomes as described in clinical and experimental reports. We suggest that studies characterizing TBI outcomes should increase their focus on changes to the VNN, as this may yield meaningful therapeutic targets to resolve posttraumatic dysfunction.	[Badaut, J.] Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92354 USA; [Badaut, J.] Loma Linda Univ, Sch Med, Dept Physiol, Loma Linda, CA 92354 USA; [Bix, G. J.] Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Bix, G. J.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA; [Bix, G. J.] Univ Kentucky, Dept Neurol, Lexington, KY 40536 USA	Badaut, J (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, Coleman Pavil,Room A1120,11175 Campus St, Loma Linda, CA 92354 USA.	jbadaut@llu.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01HD061946]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD061946] Funding Source: NIH RePORTER	We thank Dane Sorensen for critical review of the manuscript and David Ajao for tissue staining of Cav-1. This study is supported in part by the NIH R01HD061946 (JB).	Abbott NJ, 2010, NEUROBIOL DIS, V37, P13, DOI 10.1016/j.nbd.2009.07.030; Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Abrahamson EE, 2013, J CEREBR BLOOD F MET, V33, P826, DOI 10.1038/jcbfm.2013.24; Alexander MR, 2012, ANNU REV PHYSIOL, V74, P13, DOI 10.1146/annurev-physiol-012110-142315; Alford PW, 2011, P NATL ACAD SCI USA, V108, P12705, DOI 10.1073/pnas.1105860108; Appelberg KS, 2009, J NEUROTRAUM, V26, P497, DOI 10.1089/neu.2008.0664; Armstead WM, 2011, NEUROL RES, V33, P127, DOI 10.1179/016164111X12881719352138; Armstead WM, 1999, EXP TOXICOL PATHOL, V51, P137, DOI 10.1016/S0940-2993(99)80087-6; Armstead WM, 1997, STROKE, V28, P2273, DOI 10.1161/01.STR.28.11.2273; Armstead WM, 1999, J NEUROTRAUM, V16, P391, DOI 10.1089/neu.1999.16.391; Ashwal S, 2000, PEDIATR NEUROL, V23, P114, DOI 10.1016/S0887-8994(00)00176-4; Ashwal S, 2004, J NEUROTRAUM, V21, P1539, DOI 10.1089/neu.2004.21.1539; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Badaut J, 2000, J NEUROENDOCRINOL, V12, P960, DOI 10.1046/j.1365-2826.2000.00539.x; Badaut J, 1997, BRAIN RES, V778, P25, DOI 10.1016/S0006-8993(97)00999-2; Baeten KM, 2011, DEV NEUROBIOL, V71, P1018, DOI 10.1002/dneu.20954; BAETHMANN A, 1988, CRIT CARE MED, V16, P972, DOI 10.1097/00003246-198810000-00008; Bartnik BL, 2005, J NEUROTRAUM, V22, P1052, DOI 10.1089/neu.2005.22.1052; Bauer PM, 2005, P NATL ACAD SCI USA, V102, P204, DOI 10.1073/pnas.0406092102; Beaumont A, 2006, ACTA NEUROCHIR SUPPL, V96, P171; Berardi N, 2004, NEURON, V44, P905, DOI 10.1016/S0896-6273(04)00796-2; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Brown AW, 2004, NEUROREHABILITATION, V19, P37; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Bucci M, 2000, NAT MED, V6, P1362; Casey PA, 2008, J NEUROTRAUM, V25, P603, DOI 10.1089/neu.2007.0481; Cauli Bruno, 2010, Front Neuroenergetics, V2, P9, DOI 10.3389/fnene.2010.00009; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; Cherian L, 2003, J PHARMACOL EXP THER, V304, P617, DOI 10.1124/JPET.102.043430; Cirrito JR, 2005, J CLIN INVEST, V115, P3285, DOI 10.1172/JCI25247; Cohen Z, 1996, PROG NEUROBIOL, V50, P335, DOI 10.1016/S0301-0082(96)00033-0; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; DeKosky ST, 2007, ARCH NEUROL-CHICAGO, V64, P541, DOI 10.1001/archneur.64.4.541; del Zoppo GJ, 2006, ARTERIOSCL THROM VAS, V26, P1966, DOI 10.1161/01.ATV.0000232525.65682.a2; Dityatev A, 2003, NAT REV NEUROSCI, V4, P456, DOI 10.1038/nrn1115; Dore-Duffy P, 2011, NEUROL RES, V33, P176, DOI 10.1179/016164111X12881719352372; Engel DC, 2008, J NEUROTRAUM, V25, P739, DOI 10.1089/neu.2007.0480; Freeman SS, 2008, ANESTHESIOLOGY, V108, P588, DOI 10.1097/ALN.0b013e31816725d7; Fujita M, 2012, J NEUROTRAUM, V29, P2172, DOI 10.1089/neu.2012.2357; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gardner A, 2014, J NEUROTRAUM, V31, P1, DOI 10.1089/neu.2013.3079; Gardner A, 2014, BRIT J SPORT MED, V48, P84, DOI 10.1136/bjsports-2013-092646; Gavett BE, 2010, ALZHEIMERS RES THER, V2, DOI 10.1186/alzrt42; Ge SJ, 2005, J NEUROSCI RES, V79, P421, DOI 10.1002/jnr.20313; Gu Y, 2012, J NEUROCHEM, V120, P147, DOI 10.1111/j.1471-4159.2011.07542.x; Guix FX, 2005, PROG NEUROBIOL, V76, P126, DOI 10.1016/j.pneurobio.2005.06.001; Hall ED, 2012, EXP NEUROL, V238, P176, DOI 10.1016/j.expneurol.2012.08.024; Hamel E, 2006, J APPL PHYSIOL, V100, P1059, DOI 10.1152/japplphysiol.00954.2005; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Himanen L, 2011, BRAIN INJURY, V25, P443, DOI 10.3109/02699052.2011.556580; Hlatky R, 2003, J NEUROTRAUM, V20, P995, DOI 10.1089/089771503770195849; Hubbell MC, 2012, AM J PHYSIOL-CELL PH, V303, pC1090, DOI 10.1152/ajpcell.00408.2011; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jodoin J, 2003, J NEUROCHEM, V87, P1010, DOI 10.1046/j.1471-4159.2003.02081.x; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Kim YS, 2005, J NEUROSCI, V25, P3701, DOI 10.1523/JNEUROSCI.4346-04.2005; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; Kreipke CW, 2009, J CELL MOL MED, V13, P262, DOI 10.1111/j.1582-4934.2008.00508.x; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lajoie P, 2009, J CELL BIOL, V185, P381, DOI 10.1083/jcb.200811059; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; Li DY, 1998, NATURE, V393, P276, DOI 10.1038/30522; Libby P, 2005, CIRCULATION, V111, P3481, DOI 10.1161/CIRCULATIONAHA.105.537878; Lin JL, 2010, J CEREBR BLOOD F MET, V30, P1121, DOI 10.1038/jcbfm.2009.277; Lippert-Gruner M, 2006, BRAIN INJURY, V20, P569, DOI 10.1080/02699050600664467; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Mawuenyega KG, 2010, SCIENCE, V330, P1774, DOI 10.1126/science.1197623; McCaffrey G, 2007, J NEUROCHEM, V103, P2540, DOI 10.1111/j.1471-4159.2007.04943.x; McCaffrey G, 2012, J NEUROCHEM, V122, P962, DOI 10.1111/j.1471-4159.2012.07831.x; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mellergard P, 2010, BRIT J NEUROSURG, V24, P261, DOI 10.3109/02688690903521605; Milner R, 2002, MOL CELL NEUROSCI, V20, P616, DOI 10.1006/mcne.2002.1151; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; MUIZELAAR JP, 1989, NEUROSURGERY, V25, P899; Nag S, 2009, NEUROPATH APPL NEURO, V35, P417, DOI 10.1111/j.1365-2990.2008.01009.x; Nag S, 2007, ACTA NEUROPATHOL, V114, P459, DOI 10.1007/s00401-007-0274-x; Neuwelt E, 2008, LANCET NEUROL, V7, P84, DOI 10.1016/S1474-4422(07)70326-5; Neuwelt EA, 2011, NAT REV NEUROSCI, V12, P169, DOI 10.1038/nrn2995; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; OWENS GK, 1995, PHYSIOL REV, V75, P487; Owens T, 2008, J NEUROPATH EXP NEUR, V67, P1113, DOI 10.1097/NEN.0b013e31818f9ca8; Pierre K, 2005, J NEUROCHEM, V94, P1, DOI 10.1111/j.1471-4159.2005.03168.x; Plesnila N, 2003, NEUROSCI LETT, V345, P85, DOI 10.1016/S0304-3940(03)00396-3; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Pop V, 2011, TRANSL STROKE RES, V2, P533, DOI 10.1007/s12975-011-0126-9; Pop V, 2013, J CEREBR BLOOD F MET, V33, P205, DOI 10.1038/jcbfm.2012.154; PREDESCU D, 1993, AM J PHYSIOL, V265, pH725; Prins ML, 2006, DEV NEUROSCI-BASEL, V28, P447, DOI 10.1159/000094170; Rafols JA, 2007, NEUROL RES, V29, P339, DOI 10.1179/016164107X204648; Ragan DK, 2012, PEDIATR RES, V71, P199, DOI 10.1038/pr.2011.31; Rensen SSM, 2007, NETH HEART J, V15, P100, DOI 10.1007/BF03085963; Roberts DJ, 2013, J NEUROTRAUM, V30, P1717, DOI 10.1089/neu.2012.2841; Ruderisch N, 2011, J CEREBR BLOOD F MET, V31, P1637, DOI 10.1038/jcbfm.2011.21; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sahuquillo J, 1998, ACT NEUR S, V71, P233; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Saubamea B, 2012, J CEREBR BLOOD F MET, V32, P81, DOI 10.1038/jcbfm.2011.109; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Sercombe R, 2002, JPN J PHARMACOL, V88, P227, DOI 10.1254/jjp.88.227; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; Sifringer M, 2007, NEUROBIOL DIS, V25, P526, DOI 10.1016/j.nbd.2006.10.019; Silverberg GD, 2010, J NEUROPATH EXP NEUR, V69, P1034, DOI 10.1097/NEN.0b013e3181f46e25; Silverberg GD, 2010, BRAIN RES, V1317, P286, DOI 10.1016/j.brainres.2009.12.065; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Strbian D, 2008, NEUROSCIENCE, V153, P175, DOI 10.1016/j.neuroscience.2008.02.012; Suehiro E, 2004, J NEUROTRAUM, V21, P1706, DOI 10.1089/0897715042664957; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Ueda Y, 2006, ACTA NEUROPATHOL, V112, P85, DOI 10.1007/s00401-005-0029-5; Vavilala MS, 2006, DEV NEUROSCI-BASEL, V28, P348, DOI 10.1159/000094161; Virgintino D, 2002, NEUROSCIENCE, V115, P145, DOI 10.1016/S0306-4522(02)00374-3; Vogelgesang S, 2004, CURR ALZHEIMER RES, V1, P121, DOI 10.2174/1567205043332225; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Wagenseil JE, 2009, PHYSIOL REV, V89, P957, DOI 10.1152/physrev.00041.2008; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Wei EP, 2009, J NEUROTRAUM, V26, P527, DOI 10.1089/neu.2008.0797; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954; Zhang HQ, 2010, NEUROSCIENTIST, V16, P156, DOI 10.1177/1073858409355830; Zhang JH, 2012, NAT REV NEUROL, V8, P711, DOI 10.1038/nrneurol.2012.210; Zlokovic BV, 2010, NAT MED, V16, P1370, DOI 10.1038/nm1210-1370; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	130	32	33	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	JUN	2014	5	3					394	406		10.1007/s12975-013-0304-z			13	Clinical Neurology; Neurosciences	Neurosciences & Neurology	AH7TD	WOS:000336336200010	24323723	Green Accepted			2021-06-18	
J	Charland-Verville, V; Jourdan, JP; Thonnard, M; Ledoux, D; Donneau, AF; Quertemont, E; Laureys, S				Charland-Verville, Vanessa; Jourdan, Jean-Pierre; Thonnard, Marie; Ledoux, Didier; Donneau, Anne Francoise; Quertemont, Etienne; Laureys, Steven			Near-death experiences in non-life-threatening events and coma of different etiologies	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						Near-death experiences; Greyson NDE scale; coma; cardiac arrest; traumatic brain injury; memory; non-life threatening events	CARDIAC-ARREST SURVIVORS; OF-BODY EXPERIENCE; BRAIN; ANESTHESIA; AWARENESS; FEATURES; AROUSAL; ORIGIN; STATE; MRI	Background: Near death experiences (NDEs) are increasingly being reported as a clearly identifiable physiological and psychological reality of clinical significance. However, the definition and causes of the phenomenon as well as the identification of NDE experiencers is still a matter of debate. To date, the most widely used standardized tool to identify and characterize NDEs in research is the Greyson NDE scale. Using this scale, retrospective and prospective studies have been trying to estimate their incidence in various populations but few studies have attempted to associate the experiences' intensity and content to etiology. Methods: This retrospective investigation assessed the intensity and the most frequently recounted features of self-reported NDEs after a non-life-threatening event (i.e., "NDE-like" experience) or after a pathological coma (i.e., "real NDE") and according to the etiology of the acute brain insult. We also compared our retrospectively acquired data in anoxic coma with historical data from the published literature on prospective post-anoxic studies using the Greyson NDE scale. Results: From our 190 reports who met the criteria for NDE (i.e., Greyson NDE scale total score >7/32), intensity (i.e., Greyson NDE scale total score) and content (i.e., Greyson NDE scale features) did not differ between "NDE-like" (n = 50) and "real NDE" (n = 140) groups, nor within the "real NDE" group depending on the cause of coma (anoxic/traumatic/other). The most frequently reported feature was peacefulness (89-93%). Only 2 patients (1%) recounted a negative experience. The overall NDE core features' frequencies were higher in our retrospective anoxic cohort when compared to historical published prospective data. Conclusions: It appears that "real NDEs" after coma of different etiologies are similar to "NDE-like" experiences occurring after non-life threatening events. Subjects reporting NDEs retrospectively tend to have experienced a different content compared to the prospective experiencers.	[Charland-Verville, Vanessa; Thonnard, Marie; Ledoux, Didier; Laureys, Steven] Univ Hosp Liege, Dept Neurol, Coma Sci Grp, Cyclotron Res Ctr, B-4000 Liege, Belgium; [Jourdan, Jean-Pierre] Int Associat Near Death Studies, Oraison, France; [Donneau, Anne Francoise] Univ Liege, Dept Publ Hlth, Liege, Belgium; [Quertemont, Etienne] Univ Liege, Dept Psychol, Cognit Behav Neurosci Ctr, Liege, Belgium	Laureys, S (corresponding author), Univ Hosp Liege, Dept Neurol, Coma Sci Grp, Cyclotron Res Ctr, B-4000 Liege, Belgium.	steven.laureys@ulg.ac.be	Laureys, Steven/AAN-2097-2021; Laureys, Steven/A-3349-2011	Laureys, Steven/0000-0002-3096-3807; Ledoux, Didier/0000-0002-9314-6564	European CommissionEuropean CommissionEuropean Commission Joint Research Centre [FP7-247919 DECODER]; Belgian National Funds for Scientific Research (FNRS)Fonds de la Recherche Scientifique - FNRS; Tinnitus Prize [FNRS 9.4501.12]; FEDER structural fund [RADIOMED-930549]; Fonds Leon Fredericq; James McDonnell Foundation; French Speaking Community Concerted Research Action; University and University Hospital of Liege	The authors thank Guy Vander Linden from the IANDS Flanders (www.bijnadoodervaring.be) for their help in recruiting NDE testimonies. This research was supported by the European Commission (European ICT Programme Projects FP7-247919 DECODER), the Belgian National Funds for Scientific Research (FNRS), the Tinnitus Prize 2011 (FNRS 9.4501.12), FEDER structural fund RADIOMED-930549, Fonds Leon Fredericq, the James McDonnell Foundation, the French Speaking Community Concerted Research Action and the University and University Hospital of Liege. The funding sources are not liable for any use that may be made of the information contained therein. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Ammermann H, 2007, J NEUROL SCI, V260, P65, DOI 10.1016/j.jns.2007.03.026; Arzy S, 2006, NATURE, V443, P287, DOI 10.1038/443287a; Beauregard M, 2009, RESUSCITATION, V80, P1006, DOI 10.1016/j.resuscitation.2009.05.006; Blackmore S., 1993, DYING LIVE SCI NEAR; Blanke O, 2005, BRAIN RES REV, V50, P184, DOI 10.1016/j.brainresrev.2005.05.008; Blanke O, 2002, NATURE, V419, P269, DOI 10.1038/419269a; Blanke O, 2004, BRAIN, V127, P243, DOI 10.1093/brain/awh040; Britton WB, 2004, PSYCHOL SCI, V15, P254, DOI 10.1111/j.0956-7976.2004.00661.x; Charland-Verville V, 2013, CORTEX, V49, P1997, DOI 10.1016/j.cortex.2013.03.003; COBCROFT MD, 1993, ANAESTH INTENS CARE, V21, P837, DOI 10.1177/0310057X9302100616; Els T, 2004, ACTA NEUROL SCAND, V110, P361, DOI 10.1111/j.1600-0404.2004.00342.x; Facco E, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00490; French CC, 2005, PROG BRAIN RES, V150, P351, DOI 10.1016/S0079-6123(05)50025-6; French CC, 2001, LANCET, V358, P2010, DOI 10.1016/S0140-6736(01)07133-1; Gabbard G., 1991, J NEAR DEATH STUD, V10, P41, DOI [DOI 10.1007/BF01073295, 10.1007/BF01073295]; GABBARD GO, 1981, J NERV MENT DIS, V169, P374, DOI 10.1097/00005053-198106000-00006; Gallup G, 1982, ADVENTURES IMMORTALI; Greyson B, 2000, VARIETIES OF ANOMALOUS EXPERIENCE: EXAMINING THE SCIENTIFIC EVIDENCE, P315, DOI 10.1037/10371-010; Greyson B, 2003, PSYCHIAT SERV, V54, P1649, DOI 10.1176/appi.ps.54.12.1649; Greyson B, 2003, GEN HOSP PSYCHIAT, V25, P269, DOI 10.1016/S0163-8343(03)00042-2; Greyson B, 1998, PERSPECT BIOL MED, V42, P14; GREYSON B, 1983, J NERV MENT DIS, V171, P369, DOI 10.1097/00005053-198306000-00007; Greyson B, 1990, J NEAR DEATH STUDIES, V8, P151, DOI DOI 10.1007/BF01074000; Greyson B, 2007, RESUSCITATION, V73, P407, DOI 10.1016/j.resuscitation.2006.10.013; Heim A., 1891, ALPENCLUB, V27, P327; Hoepner R, 2013, J NEUROL, V260, P742, DOI 10.1007/s00415-012-6689-x; Hou YM, 2013, ANN INDIAN ACAD NEUR, V16, P75, DOI 10.4103/0972-2327.107715; Kelly EW, 2001, DEATH STUD, V25, P229, DOI 10.1080/07481180125967; Klemenc-Ketis Z, 2010, CRIT CARE, V14, DOI 10.1186/cc8952; Lai CF, 2007, AM J KIDNEY DIS, V50, P124, DOI 10.1053/j.ajkd.2007.04.021; Lange R, 2004, BRIT J PSYCHOL, V95, P161, DOI 10.1348/000712604773952403; LEMPERT T, 1994, LANCET, V344, P829, DOI 10.1016/S0140-6736(94)92389-2; Lindley J. H., 1981, J NEAR DEATH STUDIES, V1, P104; Lopez U, 2006, PEDIATR ANESTH, V16, P85, DOI 10.1111/j.1460-9592.2005.01607.x; MARTENS PR, 1994, RESUSCITATION, V27, P171, DOI 10.1016/0300-9572(94)90010-8; McKay R, 2007, CONSCIOUS COGN, V16, P349, DOI 10.1016/j.concog.2006.06.001; Mobbs D, 2011, TRENDS COGN SCI, V15, P447, DOI 10.1016/j.tics.2011.07.010; Moody R., 1975, LIFE LIFE; Nelson KR, 2007, NEUROLOGY, V68, P794, DOI 10.1212/01.wnl.0000256784.85952.6f; Nelson KR, 2006, NEUROLOGY, V66, P1003, DOI 10.1212/01.wnl.0000204296.15607.37; Osterman JE, 2001, GEN HOSP PSYCHIAT, V23, P198, DOI 10.1016/S0163-8343(01)00142-6; OWENS JE, 1990, LANCET, V336, P1175, DOI 10.1016/0140-6736(90)92780-L; Parnia S, 2001, RESUSCITATION, V48, P149, DOI 10.1016/S0300-9572(00)00328-2; Plum, 2007, DIAGNOSIS STUPOR COM; Ring K., 1984, HEADING OMEGA SEARCH; Ring K., 1980, LIFE DEATH SCI INVES; RODIN EA, 1980, J NERV MENT DIS, V168, P259, DOI 10.1097/00005053-198005000-00001; Sabom M. B., 1982, RECOLLECTIONS DEATH; Schwaninger J, 2002, J NEAR DEATH STUD, V20, P215, DOI [DOI 10.1023/A:1015258818660, 10.1023/A:1015258818660]; STEVENSON I, 1989, OMEGA-J DEATH DYING, V20, P45, DOI 10.2190/D8Q9-HHKX-5JWC-FD3V; van Lommel P, 2001, LANCET, V358, P2039, DOI 10.1016/S0140-6736(01)07100-8; Woerlee G.M., 2005, MORTAL MINDS BIOL NE	52	32	32	0	20	FRONTIERS RESEARCH FOUNDATION	LAUSANNE	PO BOX 110, LAUSANNE, 1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	MAY 27	2014	8								203	10.3389/fnhum.2014.00203			8	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	AL9XZ	WOS:000339498200001	24904345	DOAJ Gold, Green Published			2021-06-18	
J	Santarsieri, M; Niyonkuru, C; McCullough, EH; Dobos, JA; Dixon, CE; Berga, SL; Wagner, AK				Santarsieri, Martina; Niyonkuru, Christian; McCullough, Emily H.; Dobos, Julie A.; Dixon, C. Edward; Berga, Sarah L.; Wagner, Amy K.			Cerebrospinal Fluid Cortisol and Progesterone Profiles and Outcomes Prognostication after Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cortisol; outcome; group based trajectory analysis; progesterone; traumatic brain injury	SPINAL-CORD-INJURY; P-GLYCOPROTEIN; 11-BETA-HYDROXYSTEROID DEHYDROGENASES; NEUROSTEROID BIOSYNTHESIS; STEROIDOGENIC ENZYMES; GENE-EXPRESSION; NERVOUS-SYSTEM; HORMONE-LEVELS; CSF CORTISOL; RAT-BRAIN	Despite significant advances in the management of head trauma, there remains a lack of pharmacological treatment options for traumatic brain injury (TBI). While progesterone clinical trials have shown promise, corticosteroid trials have failed. The purpose of this study was to (1) characterize endogenous cerebrospinal fluid (CSF) progesterone and cortisol levels after TBI, (2) determine relationships between CSF and serum profiles, and (3) assess the utility of these hormones as predictors of long-term outcomes. We evaluated 130 adults with severe TBI. Serum samples (n=538) and CSF samples (n=746) were collected for 6 days post-injury, analyzed for cortisol and progesterone, and compared with healthy controls (n=13). Hormone data were linked with clinical data, including Glasgow Outcome Scale (GOS) scores at 6 and 12 months. Group based trajectory (TRAJ) analysis was used to develop temporal hormone profiles delineating distinct subpopulations. Compared with controls, CSF cortisol levels were significantly and persistently elevated during the first week after TBI, and high CSF cortisol levels were associated with poor outcome. As a precursor to cortisol, progesterone mediated these effects. Serum and CSF levels for both cortisol and progesterone were strongly correlated after TBI relative to controls, possibly because of blood-brain barrier disruption. Also, differentially impaired hormone transport and metabolism mechanisms after TBI, potential de novo synthesis of steroids within the brain, and the complex interplay of cortisol and pro-inflammatory cytokines may explain these acute hormone profiles and, when taken together, may help shed light on why corticosteroid trials have previously failed and why progesterone treatment after TBI may be beneficial.	[Santarsieri, Martina; Niyonkuru, Christian; McCullough, Emily H.; Dobos, Julie A.; Dixon, C. Edward; Wagner, Amy K.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15213 USA; [Santarsieri, Martina; Niyonkuru, Christian; McCullough, Emily H.; Dixon, C. Edward; Wagner, Amy K.] Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA; [Dixon, C. Edward; Wagner, Amy K.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15213 USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA; [Berga, Sarah L.] Wake Forest Univ, Dept Obstet Gynecol, Winston Salem, NC 27109 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 Fifth Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu			Centers for Disease Control and PreventionUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [R49 CCR323155]; Department of DefenseUnited States Department of Defense [W81XWH-071-0701]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5P01NS030318]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318] Funding Source: NIH RePORTER	The authors would like to thank Tammy Loucks, Ph D., for her assistance with hormone measurements. This work was supported by the Centers for Disease Control and Prevention (R49 CCR323155), the Department of Defense (W81XWH-071-0701), and the National Institutes of Health (5P01NS030318).	Alderson P., 2005, COCHRANE DATABASE SY, V1; Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Baker DG, 2005, AM J PSYCHIAT, V162, P992, DOI 10.1176/appi.ajp.162.5.992; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; BARBER AE, 1993, J IMMUNOL, V150, P1999; Barnes C, 2004, ARCH PHYS MED REHAB, V85, P1602, DOI 10.1016/j.apmr.2004.02.025; Baulieu EE, 2001, INT REV NEUROBIOL, V46, P1; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Boles J. A., 2013, J NEUROTRAUM, V30; Boles JA, 2012, J NEUROTRAUM, V29, pA44; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BRACKEN MB, 1992, J NEUROSURG, V76, P23, DOI 10.3171/jns.1992.76.1.0023; Bracken MB, 1997, JAMA-J AM MED ASSOC, V277, P1597, DOI 10.1001/jama.277.20.1597; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Caso JR, 2007, EUR NEUROPSYCHOPHARM, V17, P600, DOI 10.1016/j.euroneuro.2007.02.009; Chapman K, 2013, PHYSIOL REV, V93, P1139, DOI 10.1152/physrev.00020.2012; Cooke PS, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00108; Czech C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031501; De Kloet ER, 2004, ANN NY ACAD SCI, V1018, P1, DOI 10.1196/annals.1296.001; Dinkel K, 2003, J NEUROCHEM, V84, P705, DOI 10.1046/j.1471-4159.2003.01604.x; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Erkut ZA, 2002, MULT SCLER J, V8, P229, DOI 10.1191/1352458502ms797oa; Farrell RJ, 2002, ALIMENT PHARM THERAP, V16, P1021, DOI 10.1046/j.1365-2036.2002.01238.x; FAUPEL G, 1976, DYNAMICS BRAIN EDEMA, P337; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; GALICICH JH, 1961, AM PRACT DIG TREAT, V12, P169; Garringer JA, 2013, J NEUROTRAUM, V30, P1415, DOI 10.1089/neu.2012.2565; GERNER RH, 1983, AM J PSYCHIAT, V140, P92; Goyal A, 2013, J NEUROTRAUM, V30, P946, DOI 10.1089/neu.2012.2579; Guo WZ, 2013, NEUROSCI LETT, V547, P53, DOI 10.1016/j.neulet.2013.05.014; Hartz AMS, 2006, MOL PHARMACOL, V69, P462, DOI 10.1124/mol.105.017954; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Heffelfinger AK, 2001, DEV PSYCHOPATHOL, V13, P491, DOI 10.1017/S0954579401003054; Ho JT, 2006, J CLIN ENDOCR METAB, V91, P105, DOI 10.1210/jc.2005-0265; Holub M, 2007, CRIT CARE, V11, DOI 10.1186/cc5729; JENNETT B, 1975, LANCET, V1, P480; Johnson JD, 2002, BRAIN BEHAV IMMUN, V16, P461, DOI 10.1006/brbi.2001.0638; Jones BL, 2001, SOCIOL METHOD RES, V29, P374, DOI 10.1177/0049124101029003005; Karssen AM, 2001, ENDOCRINOLOGY, V142, P2686, DOI 10.1210/en.142.6.2686; King SR, 2002, J NEUROSCI, V22, P10613; Lamontagne F, 2013, CAN J ANESTH, V60, P652, DOI 10.1007/s12630-013-9929-3; Lin JH, 2008, CURR DRUG METAB, V9, P46, DOI 10.2174/138920008783331077; Liu XR, 2006, DRUG METAB DISPOS, V34, P1443, DOI 10.1124/dmd.105.008201; Liu XR, 2009, DRUG METAB DISPOS, V37, P787, DOI 10.1124/dmd.108.024125; Loscher Wolfgang, 2005, NeuroRx, V2, P86, DOI 10.1602/neurorx.2.1.86; Lupien SJ, 2007, BRAIN COGNITION, V65, P209, DOI 10.1016/j.bandc.2007.02.007; Lupien SJ, 1997, BRAIN RES REV, V24, P1, DOI 10.1016/S0165-0173(97)00004-0; MacKenzie SM, 2000, J MOL ENDOCRINOL, V24, P321, DOI 10.1677/jme.0.0240321; McEwen BS, 2001, HUM PSYCHOPHARM CLIN, V16, pS7, DOI 10.1002/hup.266; Meffre D, 2013, NEUROSCIENCE, V231, P111, DOI 10.1016/j.neuroscience.2012.11.039; Meffre D, 2007, J STEROID BIOCHEM, V104, P293, DOI 10.1016/j.jsbmb.2007.03.003; MELLON SH, 1993, BRAIN RES, V629, P283, DOI 10.1016/0006-8993(93)91332-M; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Nagin D., 2005, GROUP BASED MODELING; Niyonkuru C, 2013, J NEUROTRAUM, V30, P938, DOI 10.1089/neu.2012.2578; PARDRIDGE WM, 1979, J CLIN INVEST, V64, P145, DOI 10.1172/JCI109433; Patte-Mensah C, 2004, CELL MOL LIFE SCI, V61, P2274, DOI 10.1007/s00018-004-4235-4; Pluchino N, 2013, CLIMACTERIC, V16, P8, DOI 10.3109/13697137.2013.809647; Popoli M, 2012, NAT REV NEUROSCI, V13, P22, DOI 10.1038/nrn3138; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Roberts DJ, 2008, EXPERT OPIN DRUG MET, V4, P1245, DOI [10.1517/17425255.4.10.1245, 10.1517/17425255.4.10.1245 ]; ROOF RL, 1992, RESTOR NEUROL NEUROS, V4, P425, DOI 10.3233/RNN-1992-4608; ROOF RL, 1993, BRAIN RES, V607, P333, DOI 10.1016/0006-8993(93)91526-X; SAPOLSKY RM, 1985, SCIENCE, V229, P1397, DOI 10.1126/science.4035356; Savaridas T, 2004, INTENS CARE MED, V30, P1479, DOI 10.1007/s00134-004-2306-5; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Schinkel AH, 1999, ADV DRUG DELIVER REV, V36, P179, DOI 10.1016/S0169-409X(98)00085-4; Schumacher M, 2000, J NEUROCYTOL, V29, P307, DOI 10.1023/A:1007152904926; Schumacher M, 2012, FRONT NEUROSCI-SWITZ, V6, DOI 10.3389/fnins.2012.00010; Sorrells SF, 2013, J NEUROSCI, V33, P7877, DOI 10.1523/JNEUROSCI.4705-12.2013; Sorrells SF, 2009, NEURON, V64, P33, DOI 10.1016/j.neuron.2009.09.032; Stein DG, 2011, NEUROSCIENCE, V191, P101, DOI 10.1016/j.neuroscience.2011.04.013; Stein Donald G, 2011, Dialogues Clin Neurosci, V13, P352; Stein DG, 2010, EXPERT OPIN INV DRUG, V19, P847, DOI 10.1517/13543784.2010.489549; Stoffel-Wagner B, 2003, ANN NY ACAD SCI, V1007, P64, DOI 10.1196/annals.1286.007; STROMSTEDT M, 1995, MOL BRAIN RES, V34, P75, DOI 10.1016/0169-328X(95)00140-N; Swaab DF, 2005, AGEING RES REV, V4, P141, DOI 10.1016/j.arr.2005.03.003; Torpy DJ, 2007, HORM METAB RES, V39, P439, DOI 10.1055/s-2007-980200; Uhr M, 2002, J NEUROENDOCRINOL, V14, P753, DOI 10.1046/j.1365-2826.2002.00836.x; VANKALKEN CK, 1993, BRIT J CANCER, V67, P284, DOI 10.1038/bjc.1993.54; Wagner AK, 2011, J NEUROTRAUM, V28, P871, DOI 10.1089/neu.2010.1586; Walf AA, 2009, PSYCHONEUROENDOCRINO, V34, P909, DOI [10.1016/j.psyneuen.2009.01.004, 10.1016/j.psyneuen.2009.07.005]; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Wyrwoll CS, 2011, FRONT NEUROENDOCRIN, V32, P265, DOI 10.1016/j.yfrne.2010.12.001; Xiao GM, 2008, CRIT CARE, V12, DOI 10.1186/cc6887; Yu L, 2002, MOL CELL ENDOCRINOL, V190, P9, DOI 10.1016/S0303-7207(02)00041-2; Zafonte R, 2009, J NEUROTRAUM, V26, P2207, DOI 10.1089/neu.2009.1015	89	32	33	0	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR 15	2014	31	8					699	712		10.1089/neu.2013.3177			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AD7PX	WOS:000333457200001	24354775	Green Published			2021-06-18	
J	Liu, SJ; Zou, Y; Belegu, V; Lv, LY; Lin, N; Wang, TY; McDonald, JW; Zhou, X; Xia, QJ; Wang, TH				Liu, Su-Juan; Zou, Yu; Belegu, Visar; Lv, Long-Yun; Lin, Na; Wang, Ting-Yong; McDonald, John W.; Zhou, Xue; Xia, Qing-Jie; Wang, Ting-Hua			Co-grafting of neural stem cells with olfactory en sheathing cells promotes neuronal restoration in traumatic brain injury with an anti-inflammatory mechanism	JOURNAL OF NEUROINFLAMMATION			English	Article						Neural stem cells (NSCs); Olfactory en sheathing cells (OECs); Traumatic brain injury (TBI); Anti-inflammation	SPINAL-CORD; ENSHEATHING CELLS; APOPTOSIS; REPAIR; TRANSPLANTATION; EXPRESSION; RAT; INTERLEUKIN-6; PROTEIN; BAD	Background: We sought to investigate the effects of co-grafting neural stem cells (NSCs) with olfactory ensheathing cells (OECs) on neurological behavior in rats subjected to traumatic brain injury (TBI) and explore underlying molecular mechanisms. Methods: TBI was established by percussion device made through a weight drop (50 g) from a 30 cm height. Cultured NSCs and OECs isolated from rats were labeled by Hoechst 33342 (blue) and chloromethyl-benzamidodialkyl carbocyanine (CM-Dil) (red), respectively. Then, NSCs and/or OECs, separately or combined, were transplanted into the area surrounding the injury site. Fourteen days after transplantation, neurological severity score (NSS) were recorded. The brain tissue was harvested and processed for immunocytochemistry, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL), and reverse transcription-polymerase chain reaction (RT-PCR). Results: Significant neurological function improvement was observed in the three transplant groups, compared to the TBI group, and co-transplantation gave rise to the best improvement. Morphological evaluation showed that the number of neurons in cortex from combination implantation was more than for other groups (P < 0.05); conversely, the number of apoptotic cells showed a significant decrease by TUNEL staining. Transplanted NSCs and OECs could survive and migrate in the brain, and the number of neurons differentiating from NSCs in the co-transplantation group was significantly greater than in the NSCs group. At the molecular level, the expressions of IL-6 and BAD in the co-graft group were found to be down regulated significantly, when compared to either the NSC or OEC alone groups. Conclusion: The present study demonstrates for the first time the optimal effects of co-grafting NSCs and OECs as a new strategy for the treatment of TBI via an anti-inflammation mechanism.	[Liu, Su-Juan; Zhou, Xue; Wang, Ting-Hua] Sichuan Univ, West China Sch Preclin & Forens Med, Dept Histol Embryol & Neurobiol, Chengdu 610041, Sichuan, Peoples R China; [Zou, Yu; Xia, Qing-Jie; Wang, Ting-Hua] Sichuan Univ, West China Hosp, Translat Neurosci Ctr, Inst Neurol Dis, Chengdu 610041, Sichuan, Peoples R China; [Belegu, Visar; McDonald, John W.] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; [Lv, Long-Yun; Lin, Na; Wang, Ting-Yong; Wang, Ting-Hua] Kunming Med Univ, Inst Neurosci, Kunming 650031, Yunnan, Peoples R China	Xia, QJ (corresponding author), Sichuan Univ, West China Hosp, Translat Neurosci Ctr, Inst Neurol Dis, Chengdu 610041, Sichuan, Peoples R China.	193374073@qq.com; tinghua_neuron@263.net	ZHOU, XUE/F-6129-2013	Belegu, Visar/0000-0002-1361-4517	China National Science FoundationNational Natural Science Foundation of China (NSFC) [81271358, 81070991]	This research was supported by a grant from the China National Science Foundation (number: 81271358, 81070991).	Abraham AB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084838; Amaranath JE, 2014, ANZ J SURG, V84, P424, DOI 10.1111/ans.12445; Blumenthal J, 2013, TISSUE ENG PT A, V19, P2284, DOI [10.1089/ten.tea.2012.0090, 10.1089/ten.TEA.2012.0090]; CharriautMarlangue C, 1995, NEUROREPORT, V7, P61, DOI 10.1097/00001756-199512000-00014; Chauhan NB, 2014, RESTOR NEUROL NEUROS, V32, P337, DOI 10.3233/RNN-130354; Farkas G, 1998, NEUROSCI LETT, V242, P147, DOI 10.1016/S0304-3940(98)00060-3; Hirjak D, 2013, NEUROPSYCHOBIOLOGY, V68, P91, DOI 10.1159/000350999; Jia YY, 2014, CHEM PHARM BULL, V62, P45, DOI 10.1248/cpb.c13-00556; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lama D, 2008, PROTEINS, V73, P492, DOI 10.1002/prot.22075; Lang BC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-80; Lepore AC, 2005, EXP NEUROL, V194, P230, DOI 10.1016/j.expneurol.2005.02.020; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Ma HY, 2011, MOL MED REP, V4, P849, DOI 10.3892/mmr.2011.510; Moppett IK, 2007, BRIT J ANAESTH, V99, P18, DOI 10.1093/bja/aem128; Okano H, 2010, P JPN ACAD B-PHYS, V86, P438, DOI 10.2183/pjab.86.438; Oudega M, 2007, ACTA PHYSIOL, V189, P181, DOI 10.1111/j.1748-1716.2006.01658.x; PITUELLO F, 1990, CELL DIFFER DEV, V32, P71, DOI 10.1016/0922-3371(90)90101-2; Quan JH, 2013, EXP PARASITOL, V133, P462, DOI 10.1016/j.exppara.2013.01.005; Richter MW, 2005, J NEUROSCI, V25, P10700, DOI 10.1523/JNEUROSCI.3632-05.2005; Sasaki M, 2011, EXP NEUROL, V229, P88, DOI 10.1016/j.expneurol.2011.01.010; Skardelly M, 2011, J NEUROTRAUM, V28, P401, DOI 10.1089/neu.2010.1526; Sobrado M, 2003, NEUROSCIENCE, V118, P107, DOI 10.1016/S0306-4522(02)00912-0; Son D, 2014, J BIOL CHEM, V289, P6225, DOI 10.1074/jbc.M113.508994; Toft A, 2013, GLIA, V61, P513, DOI 10.1002/glia.22452; Tran LV, 2014, J TRAUMA NURS, V21, P30, DOI 10.1097/JTN.0000000000000026; Wang G, 2010, CELL TRANSPLANT, V19, P1325, DOI 10.3727/096368910X505855; Wang HH, 2012, NEUROIMMUNOMODULAT, V19, P304, DOI 10.1159/000339302; Wang YC, 2014, CYTOTHERAPY, VS1465-3249, P00841; Wewetzer K, 2011, EXP NEUROL, V229, P80, DOI 10.1016/j.expneurol.2010.08.029; Wu X, 2008, J TRAUMA, V64, P1313, DOI 10.1097/TA.0b013e318165c803; Xie F, 2013, TOXICOL APPL PHARM, V272, P598, DOI 10.1016/j.taap.2013.07.020	32	32	38	1	18	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	APR 2	2014	11								66	10.1186/1742-2094-11-66			9	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	AF8FS	WOS:000334951600001	24690089	DOAJ Gold, Green Published			2021-06-18	
J	Mao, WF; Yi, X; Qin, JB; Tian, ML; Jin, GH				Mao, Weifeng; Yi, Xin; Qin, Jianbing; Tian, Meiling; Jin, Guohua			CXCL12 inhibits cortical neuron apoptosis by increasing the ratio of Bcl-2/Bax after traumatic brain injury	INTERNATIONAL JOURNAL OF NEUROSCIENCE			English	Article						CXCL12; apoptosis; traumatic brain injury; caspase-3; Bcl-2: Bax ratio	CHEMOKINE RECEPTOR; CELL-SURVIVAL; STEM-CELLS; MIGRATION; CXCR4; EXPRESSION; PATHWAY; ANGIOGENESIS; SDF-1-ALPHA; CASPASE-3	CXCL12 and its physiologic receptor CXCR4 are involved in controlling cell survival, proliferation and migration in adult tissues. This study aimed to investigate the effects of CXCL12 on cortical neuron apoptosis in rats after traumatic brain injury (TBI) and the potential mechanisms involved. At 3 days after TBI, in situ terminal transferase d-UTP nick-end labeling assay (TUNEL) showed that the apoptotic index (AI) deceased significantly in the CXCL12 treatment group compared with the control group (p < 0.05). Immunofluorescence double-labeled staining revealed that most of the TUNEL positive cells were NeuN positive neurons. The change trends of active caspase-3 expression were similar as those of the AI. The Bcl-2: Bax ratio was upregulated in the CXCL12 group compared with the control group. However, the effect of CXCL12 could be partially reverted by the additional use of AMD3100 (a kind of antagonist of CXCR4) (p < 0.05). Our results indicated that after TBI in rats CXCL12 combing CXCR4 receptors could inhibit the caspase-3 pathway by upregulating Bcl-2: Bax ratio, which protect neurons from apoptosis.	[Mao, Weifeng] Soochow Univ, Coll Med, Dept Anat & Cytoneurobiol, Suzhou, Peoples R China; [Mao, Weifeng; Yi, Xin; Qin, Jianbing; Tian, Meiling; Jin, Guohua] Nantong Univ, Dept Anat & Neurobiol, Jiangsu Key Lab Neuroregenerat, Nantong 226001, Jiangsu, Peoples R China	Jin, GH (corresponding author), Nantong Univ, Dept Anat & Neurobiol, Jiangsu Key Lab Neuroregenerat, 19 Qixiu Rd, Nantong 226001, Jiangsu, Peoples R China.	jguohua@ntu.edu.cn			Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD)	This work was supported by funding from the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD).	Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Dai SJ, 2010, J MOL CELL CARDIOL, V49, P587, DOI 10.1016/j.yjmcc.2010.07.010; Dziembowska M, 2005, GLIA, V50, P258, DOI 10.1002/glia.20170; Fricker SP, 2006, BIOCHEM PHARMACOL, V72, P588, DOI 10.1016/j.bcp.2006.05.010; Gillard SE, 2002, J NEUROIMMUNOL, V124, P16, DOI 10.1016/S0165-5728(02)00005-X; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hernandez-Lopez C, 2002, BLOOD, V99, P546, DOI 10.1182/blood.V99.2.546; Hernandez-Lopez C, 2008, IMMUNOL LETT, V120, P72, DOI 10.1016/j.imlet.2008.07.006; Hesselgesser J, 1998, CURR BIOL, V8, P595, DOI 10.1016/S0960-9822(98)70230-1; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Itoh T, 2009, NEUROL RES, V31, P90, DOI 10.1179/174313208X332995; Jia JX, 2010, MOL CELL BIOCHEM, V335, P127, DOI 10.1007/s11010-009-0249-4; Khan MZ, 2008, CELL DEATH DIFFER, V15, P1663, DOI 10.1038/cdd.2008.95; Kryczek I, 2005, AM J REPROD IMMUNOL, V54, P270, DOI 10.1111/j.1600-0897.2005.00307.x; Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood-2005-04-1417; Li MZ, 2008, PROG NEUROBIOL, V84, P116, DOI 10.1016/j.pneurobio.2007.11.003; Li SH, 2012, BRAIN RES, V1444, P76, DOI 10.1016/j.brainres.2011.12.055; Liu XL, 2011, PROTEIN CELL, V2, P845, DOI 10.1007/s13238-011-1097-z; Lu M, 2002, P NATL ACAD SCI USA, V99, P7090, DOI 10.1073/pnas.092013799; Nakajima Y, 2010, TOHOKU J EXP MED, V221, P229, DOI 10.1620/tjem.221.229; Nicolai J, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.10; Salakou S, 2007, IN VIVO, V21, P123; Shi W, 2011, NEUROCHEM RES, V36, P375, DOI 10.1007/s11064-010-0332-y; Shyu WC, 2008, J PHARMACOL EXP THER, V324, P834, DOI 10.1124/jpet.107.127746; Solaroglu I, 2006, NEUROSCIENCE, V143, P965, DOI 10.1016/j.neuroscience.2006.09.014; Stumm RK, 2003, J NEUROSCI, V23, P5123; Xiao DaLiao, 2008, Int J Med Sci, V5, P295; Zhu B, 2012, STEM CELLS, V30, P2571, DOI 10.1002/stem.1239	28	32	33	0	9	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0020-7454	1563-5279		INT J NEUROSCI	Int. J. Neurosci.	APR	2014	124	4					281	290		10.3109/00207454.2013.838236			10	Neurosciences	Neurosciences & Neurology	AC6ZB	WOS:000332674400007	23984821				2021-06-18	
J	Zhang, C; Zhu, J; Zhang, J; Li, HY; Zhao, ZJ; Liao, YW; Wang, XY; Su, J; Sang, SS; Yuan, XR; Liu, Q				Zhang, Chi; Zhu, Jie; Zhang, Jing; Li, Haoyu; Zhao, Zijin; Liao, Yiwei; Wang, Xiangyu; Su, Jun; Sang, Shushan; Yuan, Xianrui; Liu, Qing			Neuroprotective and anti-apoptotic effects of valproic acid on adult rat cerebral cortex through ERK and Akt signaling pathway at acute phase of traumatic brain injury	BRAIN RESEARCH			English	Article						Valproic acid; Neuroprotective effect; Traumatic brain injury; Extracellular signal-regulated kinase; Akt; Rat	HISTONE DEACETYLASE INHIBITION; CELL-DEATH; REGULATED KINASE; CORTICAL-NEURONS; SODIUM VALPROATE; ACTIVATION; PROTECTS; DAMAGE; PHOSPHORYLATION; ANTICONVULSANTS	Mood stabilizer valproic acid (VPA), a widely used antiepileptic drug that has been demonstrated neuroprotective effect against various insults through multiple signaling pathways. The role of VPA in traumatic brain injury (TBI) remains unclear. In the present study, we investigated the neuroprotective potency of VPA for protection against TBI in adult rats, focusing on studying signaling mediators of two well characterized pro-survival molecules, extracellular signal-regulated protein kinase (ERK) and Akt. We found that treatment of VPA after TBI significantly attenuated brain edema, reduced contusion volume and the rate of neuronal apoptosis. The treatment also partly blocked an increase in capase-3 activity. VPA markedly up-regulated the activity of ERK and Akt expression. Moreover, treatment with either PD98059, an ERIC inhibitor and/or LY294002, an Akt inhibitor, attenuated the neuroprotection of VPA against TBI to varying degrees. Taken together, these results demonstrated that treatment with VPA after TBI could be neuroprotective via activation of ERK and Akt signaling pathways (c) 2014 Elsevier B.V. All rights reserved.	[Zhang, Chi; Li, Haoyu; Zhao, Zijin; Liao, Yiwei; Wang, Xiangyu; Su, Jun; Sang, Shushan; Yuan, Xianrui; Liu, Qing] Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha 410008, Hunan, Peoples R China; [Zhu, Jie] 101th Hosp PLA, Dept Neurosurg, Rescue Ctr Craniocerebral Injuries PLA, Wuxi 214044, Jiangsu, Peoples R China; [Zhang, Jing] Lanzhou Gen Hosp Lanzhou Mil Command, Dept Otorhinolaryngol Head & Neck Surg, Lanzhou 730050, Gansu, Peoples R China	Yuan, XR (corresponding author), Cent S Univ, Xiangya Hosp, Dept Neurosurg, Changsha 410008, Hunan, Peoples R China.	yuanxianruicsu@hotmail.com; liuqcsu@hotmail.com		li, haoyu/0000-0002-0722-6809	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30901539]	This work was supported by the National Natural Science Foundation of China (30901539).	Adachi M, 2002, CELL DEATH DIFFER, V9, P1240, DOI 10.1038/sj.cdd.4401097; Atkins CM, 2007, EUR J NEUROSCI, V26, P810, DOI 10.1111/j.1460-9568.2007.05720.x; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Boeckeler K, 2006, EUR J CELL BIOL, V85, P1047, DOI 10.1016/j.ejcb.2006.04.013; Bowden CL, 2006, AUST NZ J PSYCHIAT, V40, P386, DOI 10.1111/j.1440-1614.2006.01815.x; Brandt C, 2006, NEUROPHARMACOLOGY, V51, P789, DOI 10.1016/j.neuropharm.2006.05.021; Chen T, 2012, INT J MOL MED, V29, P630, DOI 10.3892/ijmm.2011.870; Clausen F, 2004, J NEUROTRAUM, V21, P1168, DOI 10.1089/neu.2004.21.1168; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Dash PK, 2002, NEUROSCIENCE, V114, P755, DOI 10.1016/S0306-4522(02)00277-4; Dash PK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024648; Dash PK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011383; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; De Sarno P, 2002, NEUROPHARMACOLOGY, V43, P1158, DOI 10.1016/S0028-3908(02)00215-0; Faissner A, 2006, ADV EXP MED BIOL, V557, P25; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GOTOH O, 1985, STROKE, V16, P101, DOI 10.1161/01.STR.16.1.101; Guerra B, 2004, J NEUROCHEM, V91, P99, DOI 10.1111/j.1471-4159.2004.02695.x; Guo H, 2013, J NEUROSCI, V33, P6181, DOI 10.1523/JNEUROSCI.4491-12.2013; Hung C, 2012, CURR TREAT OPTION NE, V14, P293, DOI 10.1007/s11940-012-0178-5; Jeong MR, 2003, FEBS LETT, V542, P74, DOI 10.1016/S0014-5793(03)00350-8; Johannessen CU, 2000, NEUROCHEM INT, V37, P103, DOI 10.1016/S0197-0186(00)00013-9; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Kanai H, 2004, PHARMACOGENOMICS J, V4, P336, DOI 10.1038/sj.tpj.6500269; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kuroki Y, 2001, EUR J NEUROSCI, V13, P472, DOI 10.1046/j.0953-816x.2000.01409.x; Li YQ, 2008, SURGERY, V144, P217, DOI 10.1016/j.surg.2008.03.037; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Ma YH, 2011, BRAIN RES BULL, V86, P441, DOI 10.1016/j.brainresbull.2011.07.007; Miller JS, 2009, NEUROPHARMACOLOGY, V56, P1116, DOI 10.1016/j.neuropharm.2009.03.006; Miller Laura C, 2008, Expert Rev Neurother, V8, P1817, DOI 10.1586/14737175.8.12.1817; Park H. J., 2011, J MOL NEUROSCI; Rekling JC, 2003, NEUROSCI LETT, V335, P167, DOI 10.1016/S0304-3940(02)01193-X; Ren M, 2004, J NEUROCHEM, V89, P1358, DOI 10.1111/j.1471-4159.2004.02406.x; Rogawski MA, 2004, NAT REV NEUROSCI, V5, P553, DOI 10.1038/nrn1430; Rosenberg G, 2007, CELL MOL LIFE SCI, V64, P2090, DOI 10.1007/s00018-007-7079-x; Shein NA, 2009, FASEB J, V23, P4266, DOI 10.1096/fj.09-134700; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Tunnicliff G, 1999, J PHYSIOL PHARMACOL, V50, P347; Wang GH, 2013, NEUROTHERAPEUTICS, V10, P124, DOI 10.1007/s13311-012-0157-2; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu XS, 2008, BRAIN RES, V1227, P12, DOI 10.1016/j.brainres.2008.06.018	45	32	35	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAR 25	2014	1555						1	9		10.1016/j.brainres.2014.01.051			9	Neurosciences	Neurosciences & Neurology	AF1LS	WOS:000334476000001	24508577				2021-06-18	
J	Wang, T; Huang, XJ; Van, KC; Went, GT; Nguyen, JT; Lyeth, BG				Wang, Tao; Huang, Xian-Jian; Van, Ken C.; Went, Gregory T.; Nguyen, Jack T.; Lyeth, Bruce G.			Amantadine Improves Cognitive Outcome and Increases Neuronal Survival after Fluid Percussion Traumatic Brain Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						dopamine; hippocampus; traumatic brain injury; Morris water maze; pharmacokinetics	HEAD-INJURY; HIPPOCAMPAL; EXPRESSION	This study evaluated the effects of clinically relevant concentrations of amantadine (AMT) on cognitive outcome and hippocampal cell survival in adult rats after lateral fluid percussion traumatic brain injury (TBI). AMT is an antagonist of the N-methyl-D-aspartate-type glutamate receptor, increases dopamine release, blocks dopamine reuptake, and has an inhibitory effect on microglial activation and neuroinflammation. Currently, AMT is clinically used as an antiparkinsonian drug. Amantadine or saline control was administered intraperitoneally, starting at 1h after TBI followed by dosing three times daily for 16 consecutive days at 15, 45, and 135mg/kg/day. Terminal blood draws were obtained from TBI rats at the time of euthanasia at varying time points after the last amantadine dose. Pharmacokinetics analysis confirmed that the doses of AMT achieved serum concentrations similar to those observed in humans receiving therapeutic doses (100-400mg/day). Acquisition of spatial learning and memory retention was assessed using the Morris water maze (MWM) on days 12-16 after TBI. Brain tissues were collected and stained with Cresyl-violet for long-term cell survival analysis. Treatment with 135mg/kg/day of AMT improved acquisition of learning and terminal cognitive performance on MWM. The 135-mg/kg/day dosing of AMT increased the numbers of surviving CA2-CA3 pyramidal neurons at day 16 post-TBI. Overall, the data showed that clinically relevant dosing schedules of AMT affords neuroprotection and significantly improves cognitive outcome after experimental TBI, suggesting that it has the potential to be developed as a novel treatment of human TBI.	[Wang, Tao; Huang, Xian-Jian; Van, Ken C.; Lyeth, Bruce G.] Univ Calif Davis, Dept Neurol Surg, Davis, CA 95616 USA; [Wang, Tao] Second Mil Med Univ, Changzheng Hosp, Dept Neurosurg, Shanghai, Peoples R China; [Huang, Xian-Jian] Shenzhen Univ, Peoples Hosp Shenzhen 2, Dept Neurosurg, Shenzhen, Peoples R China; [Went, Gregory T.; Nguyen, Jack T.] Adamas Pharmaceut Inc, Emeryville, CA USA	Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1515 Newton Court,One Shields Ave, Davis, CA 95616 USA.	bglyeth@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	Adamas Pharmaceuticals, Inc.	The research was supported by funding from Adamas Pharmaceuticals, Inc.	BAKAY RAE, 1986, NEUROSURGERY, V18, P234, DOI 10.1227/00006123-198602000-00023; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Giacino JT, 2012, NEW ENGL J MED, V366, P819, DOI 10.1056/NEJMoa1102609; GIANUTSOS G, 1985, EUR J PHARMACOL, V110, P357, DOI 10.1016/0014-2999(85)90564-3; GRELAK RP, 1970, SCIENCE, V169, P203, DOI 10.1126/science.169.3941.203; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Hamm RJ, 2001, J NEUROTRAUM, V18, P1207, DOI 10.1089/089771501317095241; Hammond F., 2010, AM NEUR ASS ANN C MA; Kim BT, 2001, J NEUROSURG, V95, P674, DOI 10.3171/jns.2001.95.4.0674; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morrison D, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001305; Nahas Z, 1998, J NEUROPSYCH CLIN N, V10, P453, DOI 10.1176/jnp.10.4.453; Ossola B, 2011, NEUROPHARMACOLOGY, V61, P574, DOI 10.1016/j.neuropharm.2011.04.030; Owen JCE, 2005, BRIT J PHARMACOL, V145, P587, DOI 10.1038/sj.bjp.0706188; Parsons CG, 1996, EUR J NEUROSCI, V8, P446, DOI 10.1111/j.1460-9568.1996.tb01228.x; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Qin ZH, 1999, J NEUROSCI, V19, P4023; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Sydenham E., 2009, COCHRANE DATABASE SY; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; VANWOERKOM TCAM, 1977, LANCET, V1, P812; Von Voigtlander P F, 1971, Science, V174, P408, DOI 10.1126/science.174.4007.408; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; White H, 2006, ANESTH ANALG, V102, P1836, DOI 10.1213/01.ane.0000217208.51017.56; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	30	32	34	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB 15	2014	31	4					370	377		10.1089/neu.2013.2917			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	AA7PY	WOS:000331290600009	23574258				2021-06-18	
J	Irimia, A; Van Horn, JD				Irimia, Andrei; Van Horn, John D.			Systematic network lesioning reveals the core white matter scaffold of the human brain	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						connectomics; traumatic brain injury; brain network; neurotrauma; neuroimaging; MRI; DTI	ORGANIZATION	Brain connectivity loss due to traumatic brain injury, stroke or multiple sclerosis can have serious consequences on life quality and a measurable impact upon neural and cognitive function. Though brain network properties are known to be affected disproportionately by injuries to certain gray matter regions, the manner in which white matter (WM) insults affect such properties remains poorly understood. Here, network-theoretic analysis allows us to identify the existence of a macroscopic neural connectivity core in the adult human brain which is particularly sensitive to network lesioning. The systematic lesion analysis of brain connectivity matrices from diffusion neuroimaging over a large sample (N = 110) reveals that the global vulnerability of brain networks can be predicated upon the extent to which injuries disrupt this connectivity core, which is found to be quite distinct from the set of connections between rich club nodes in the brain. Thus, in addition to connectivity within the rich club, the brain as a network also contains a distinct core scaffold of network edges consisting of WM connections whose damage dramatically lowers the integrative properties of brain networks. This pattern of core WM fasciculi whose injury results in major alterations to overall network integrity presents new avenues for clinical outcome prediction following brain injury by relating lesion locations to connectivity core disruption and implications for recovery. The findings of this study contribute substantially to current understanding of the human WM connectome, its sensitivity to injury, and clarify a long-standing debate regarding the relative prominence of gray vs. WM regions in the context of brain structure and connectomic architecture.	[Irimia, Andrei; Van Horn, John D.] Univ So Calif, Dept Neurol, Keck Sch Med, Inst Neuroimaging & Informat, Los Angeles, CA 90089 USA	Van Horn, JD (corresponding author), Univ So Calif, Dept Neurol, Keck Sch Med, Inst Neuroimaging & Informat, 2001 North Soto St,Room 102,MC 9232, Los Angeles, CA 90089 USA.	jvanhorn@usc.edu	Irimia, Andrei/B-8275-2008	Irimia, Andrei/0000-0002-9254-9388; Van Horn, John/0000-0003-1537-0816	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [2U54EB005149-06, 1RC1MH088194, R41N5081792-01]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015922] Funding Source: NIH RePORTER	This work was supported by NIH grants 2U54EB005149-06 "NAMIC: Traumatic Brain Injury Driving Biological Project" to John D. Van Horn, 1RC1MH088194 "Informatics Meta-Spaces for the Exploration of Human Neuroanatomy" to John D. Van Horn and R41N5081792-01 "Multimodality Image Based Assessment System for Traumatic Brain Injury" to Stephen R. Aylward. We wish to thank S.Y. Matthew Goh, Carinna M. Torgerson and the dedicated staff of the Institute for Neuroimaging and Informatics at the University of Southern California. The authors declare no competing financial interests.	Achard S, 2012, P NATL ACAD SCI USA, V109, P20608, DOI 10.1073/pnas.1208933109; Adolphs R, 2001, CURR OPIN NEUROBIOL, V11, P231, DOI 10.1016/S0959-4388(00)00202-6; Alstott J, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000408; Alvarez JA, 2006, NEUROPSYCHOL REV, V16, P17, DOI 10.1007/s11065-006-9002-x; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Crofts JJ, 2011, NEUROIMAGE, V54, P161, DOI 10.1016/j.neuroimage.2010.08.032; Delac K, 2005, INT J IMAG SYST TECH, V15, P252, DOI 10.1002/ima.20059; Destrieux C, 2010, NEUROIMAGE, V53, P1, DOI 10.1016/j.neuroimage.2010.06.010; Dinov I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013070; Dinov Ivo D, 2009, Front Neuroinform, V3, P22, DOI 10.3389/neuro.11.022.2009; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Fischl B, 1999, HUM BRAIN MAPP, V8, P272, DOI 10.1002/(SICI)1097-0193(1999)8:4<272::AID-HBM10>3.0.CO;2-4; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Gratton C, 2012, J COGNITIVE NEUROSCI, V24, P1275, DOI 10.1162/jocn_a_00222; Hagmann P, 2008, PLOS BIOL, V6, P1479, DOI 10.1371/journal.pbio.0060159; Hagmann P, 2010, J NEUROSCI METH, V194, P34, DOI 10.1016/j.jneumeth.2010.01.014; Honey CJ, 2008, HUM BRAIN MAPP, V29, P802, DOI 10.1002/hbm.20579; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; Irimia A, 2012, NEUROIMAGE-CLIN, V1, P1, DOI 10.1016/j.nicl.2012.08.002; Irimia A, 2012, NEUROIMAGE, V60, P1340, DOI 10.1016/j.neuroimage.2012.01.107; Irimia Andrei, 2012, Front Neurol, V3, P10, DOI 10.3389/fneur.2012.00010; Kaiser M, 2011, NETWORK-COMP NEURAL, V22, P143, DOI 10.3109/0954898X.2011.638968; Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Lu HP, 2008, IEEE T NEURAL NETWOR, V19, P18, DOI 10.1109/TNN.2007.901277; MacKenzie-Graham AJ, 2008, LECT NOTES COMPUT SC, V5272, P208, DOI 10.1007/978-3-540-89965-5_22; Mueller S, 2013, NEURON, V77, P586, DOI 10.1016/j.neuron.2012.12.028; Newman MEJ, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.208701; Paus T, 2001, BRAIN RES BULL, V54, P255, DOI 10.1016/S0361-9230(00)00434-2; Rencher A.C., 2003, METHODS MULTIVARIATE, DOI [10.1002/0471271357, DOI 10.1002/0471271357]; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Semendeferi K, 2002, NAT NEUROSCI, V5, P272, DOI 10.1038/nn814; Smith SM, 2002, HUM BRAIN MAPP, V17, P143, DOI 10.1002/hbm.10062; Sporns O., 2011, NETWORKS BRAIN; Sporns O, 2012, NEUROIMAGE, V62, P881, DOI 10.1016/j.neuroimage.2011.08.085; TONONI G, 1994, P NATL ACAD SCI USA, V91, P5033, DOI 10.1073/pnas.91.11.5033; van den Heuvel MP, 2011, J NEUROSCI, V31, P15775, DOI 10.1523/JNEUROSCI.3539-11.2011; van Horn JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037454; Vargha-Khadem F, 1994, J Child Neurol, V9 Suppl 2, P67; Zalesky A, 2010, NEUROIMAGE, V50, P970, DOI 10.1016/j.neuroimage.2009.12.027; Zhou J, 2010, BRAIN, V133, P1352, DOI 10.1093/brain/awq075	43	32	34	0	12	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	FEB 11	2014	8									10.3389/fnhum.2014.00051			14	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	AB7CD	WOS:000331946000001	24574993	DOAJ Gold, Green Published			2021-06-18	
J	Liao, CC; Chou, YC; Yeh, CC; Hu, CJ; Chiu, WT; Chen, TL				Liao, Chien-Chang; Chou, Yi-Chun; Yeh, Chun-Chieh; Hu, Chaur-Jong; Chiu, Wen-Ta; Chen, Ta-Liang			Stroke Risk and Outcomes in Patients With Traumatic Brain Injury: 2 Nationwide Studies	MAYO CLINIC PROCEEDINGS			English	Article							POSTOPERATIVE ADVERSE OUTCOMES; HEAD-INJURY; SURGICAL-PATIENTS; POPULATION; SCHIZOPHRENIA; MORTALITY; SEVERITY; EPILEPSY; REHABILITATION; COUNTRIES	Objective: To investigate whether patients with traumatic brain injury (TBI) have an increased risk of stroke or poststroke mortality. Participants and Methods: Using Taiwan's National Health Insurance Research Database, we conducted a retrospective cohort study of 30,165 patients with new TBI and 120,660 personswithout TBI between January 1, 2000, and December 31, 2004. The risk of stroke was compared between 2 cohorts throughDecember 31, 2008. To investigate the association between in-hospital mortality after stroke and history of TBI, we conducted a casecontrol study of 7751 patients with newly diagnosed stroke between January 1, 2005, and December 31, 2008. Results: The TBI cohort had an increased stroke risk (hazard ratio [HR], 1.98; 95% CI, 1.86-2.11). Among patients with stroke, those with a history of TBI had a higher risk of poststroke mortality compared with those without TBI (odds ratio, 1.57; 95% CI, 1.13-2.19). In the TBI cohort, factors associated with stroke were history of TBI hospitalization (HR, 3.14; 95% CI, 2.77-3.56), emergency care for TBI (HR, 3.37; 95% CI, 2.88-3.95), brain hemorrhage (HR, 2.69; 95% CI, 2.43-2.99), skull fracture (HR, 3.00; 95% CI, 2.423.71), low income (HR, 2.65; 95% CI, 2.16-3.25), and high medical expenditure for TBI care (HR, 2.26; 95% CI, 2.09-2.43). The severity of TBI was also correlated with poststroke mortality. Conclusions: Traumatic brain injury was associated with risk of stroke and poststroke mortality. The relationship between TBI and poststrokemortality does not seem to transcend all age groups. This research shows the importance of prevention, early recognition, and treatment of stroke in this vulnerable population. (C) 2014 Mayo Foundation for Medical Education and Research	[Liao, Chien-Chang; Chen, Ta-Liang] Taipei Med Univ Hosp, Dept Anesthesiol, Taipei 11031, Taiwan; [Liao, Chien-Chang; Chen, Ta-Liang] Taipei Med Univ Hosp, Ctr Hlth Policy Res, Taipei 11031, Taiwan; [Liao, Chien-Chang; Hu, Chaur-Jong; Chen, Ta-Liang] Taipei Med Univ, Sch Med, Taipei, Taiwan; [Hu, Chaur-Jong] Taipei Med Univ, Dept Neurol, Shuang Ho Hosp, Taipei, Taiwan; [Chiu, Wen-Ta] Taipei Med Univ, Grad Inst Injury Prevent & Control, Taipei, Taiwan; [Chou, Yi-Chun] China Med Univ Hosp, Dept Phys Med & Rehabil, Taichung, Taiwan; [Yeh, Chun-Chieh] China Med Univ, Sch Med, Grad Inst Clin Med Sci, Taichung, Taiwan	Chen, TL (corresponding author), Taipei Med Univ Hosp, Dept Anesthesiol, 252 Wuxing St, Taipei 11031, Taiwan.	tlc@tmu.edu.tw	Yeh, Chun Chieh/Y-3304-2019; Yeh, Chun Chieh/I-4893-2019	Yeh, Chun Chieh/0000-0001-6753-7564			ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Bazarian JJ, 2009, J HEAD TRAUMA REHAB, V24, P439, DOI 10.1097/HTR.0b013e3181c15600; Brown AW, 2011, J NEUROTRAUM, V28, P167, DOI 10.1089/neu.2010.1400; Burke JF, 2013, NEUROLOGY, V81, P33, DOI 10.1212/WNL.0b013e318297eecf; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; CHAN KH, 1992, J NEUROL NEUROSUR PS, V55, P787, DOI 10.1136/jnnp.55.9.787; Chang CC, 2012, EPILEPSIA, V53, P987, DOI 10.1111/j.1528-1167.2012.03448.x; Chen YH, 2011, STROKE, V42, P2733, DOI 10.1161/STROKEAHA.111.620112; Cheng CL, 2011, PHARMACOEPIDEM DR S, V20, P236, DOI 10.1002/pds.2087; Chou YC, 2012, J REHABIL MED, V44, P319, DOI 10.2340/16501977-0935; Christensen J, 2009, LANCET, V373, P1105, DOI 10.1016/S0140-6736(09)60214-2; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; DeKosky ST, 2010, NEW ENGL J MED, V363, P1293, DOI 10.1056/NEJMp1007051; Demetriades D, 2006, J TRAUMA, V61, P868, DOI 10.1097/01.ta.0000219135.33398.f3; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Engberg AW, 2007, J HEAD TRAUMA REHAB, V22, P221, DOI 10.1097/01.HTR.0000281837.62226.54; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feigin VL, 2007, LANCET NEUROL, V6, P94, DOI 10.1016/S1474-4422(07)70007-8; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hu CJ, 2012, WORLD J SURG, V36, P2051, DOI 10.1007/s00268-012-1609-x; Ishibe N, 2009, J HEAD TRAUMA REHAB, V24, P424, DOI 10.1097/HTR.0b013e3181c13426; Kang JH, 2011, PSYCHOSOM MED, V73, P106, DOI 10.1097/PSY.0b013e3181fdc2c9; Kurth T, 2012, LANCET NEUROL, V11, P92, DOI 10.1016/S1474-4422(11)70266-6; Liao CC, 2012, J TRAUMA ACUTE CARE, V73, P1327, DOI 10.1097/TA.0b013e31826fc87f; Liao CC, 2012, J NEUROL NEUROSUR PS, V83, P1186, DOI 10.1136/jnnp-2012-302337; Liao CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031527; Lin HC, 2008, SCHIZOPHR RES, V101, P234, DOI 10.1016/j.schres.2007.12.485; Marino S, 2007, J NEUROL NEUROSUR PS, V78, P501, DOI 10.1136/jnnp.2006.099796; Nishi N, 2007, SOC SCI MED, V65, P822, DOI 10.1016/j.socscimed.2007.04.013; O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3; PAGANINIHILL A, 1988, BMJ-BRIT MED J, V297, P519, DOI 10.1136/bmj.297.6647.519; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Polusny MA, 2011, ARCH GEN PSYCHIAT, V68, P79, DOI 10.1001/archgenpsychiatry.2010.172; Rosenfeld JV, 2012, LANCET, V380, P1088, DOI 10.1016/S0140-6736(12)60864-2; Shih CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032540; Steiner LA, 2003, J NEUROL NEUROSUR PS, V74, P765, DOI 10.1136/jnnp.74.6.765; Strong K, 2007, LANCET NEUROL, V6, P182, DOI 10.1016/S1474-4422(07)70031-5; Tsai KY, 2012, SCHIZOPHR RES, V138, P41, DOI 10.1016/j.schres.2012.02.013; Wang IK, 2011, STROKE, V42, P716, DOI 10.1161/STROKEAHA.110.594523; Yeh CC, 2013, J NEUROL NEUROSUR PS, V84, P441, DOI 10.1136/jnnp-2012-302547	42	32	33	0	10	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0025-6196	1942-5546		MAYO CLIN PROC	Mayo Clin. Proc.	FEB	2014	89	2					163	172		10.1016/j.mayocp.2013.09.019			10	Medicine, General & Internal	General & Internal Medicine	302DJ	WOS:000330581500010	24485130				2021-06-18	
J	Park, KJ; Park, E; Liu, E; Baker, AJ				Park, Katya J.; Park, Eugene; Liu, Elaine; Baker, Andrew J.			Bone marrow-derived endothelial progenitor cells protect postischemic axons after traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						endothelial progenitor cell; fluid percussion injury; ischemia; traumatic brain injury; vasculature; white matter injury	FOCAL CEREBRAL-ISCHEMIA; CYTOCHEMICAL EVIDENCE; CALCIUM INFLUX; CD34(+) CELLS; NERVE-FIBERS; OPTIC-NERVE; ANGIOGENESIS; STROKE; PROTEOGLYCANS; EXPRESSION	White matter sparing after traumatic brain injury (TBI) is an important predictor of survival and outcome. Blood vessels and axons are intimately associated anatomically and developmentally. Neural input is required for appropriate vascular patterning, and vascular signaling is important for neuron development and axon growth. Owing to this codependence between endothelial cells and axons during development and the contribution of endothelial progenitor cells (EPCs) in ischemic injury, we hypothesized that EPCs are important in axonal survival after TBI. We examined the effects of allogenic-cultured EPCs on white matter protection and microvascular maintenance after midline fluid percussion injury in adult Sprague-Dawley rats. We used two in vitro models of injury, mechanical stretch and oxygen-glucose deprivation (OGD), to examine the effects of EPCs on the mechanical and ischemic components of brain trauma, respectively. Our results indicate that EPCs improve the white matter integrity and decrease capillary breakdown after injury. Cultured cortical neurons exposed to OGD had less axon degeneration when treated with EPC-conditioned media, whereas no effect was seen in axons injured by mechanical stretch. The results indicate that EPCs are important for the protection of the white matter after trauma and represent a potential avenue for therapy.	[Park, Katya J.; Park, Eugene; Liu, Elaine; Baker, Andrew J.] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada; [Baker, Andrew J.] St Michaels Hosp, Dept Crit Care, Toronto, ON M5B 1W8, Canada; [Baker, Andrew J.] St Michaels Hosp, Dept Anesthesia, Toronto, ON M5B 1W8, Canada; [Baker, Andrew J.] Univ Toronto, Dept Anesthesia, Toronto, ON, Canada; [Baker, Andrew J.] Univ Toronto, Interdepartmental Div Crit Care, Toronto, ON, Canada	Park, E (corresponding author), St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, 30 Bond St, Toronto, ON M5B 1W8, Canada.	parke@smh.ca			Ministry of Economic Development and Innovation, Government of Ontario	This study was funded by the Ministry of Economic Development and Innovation, Government of Ontario.	Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; Borlongan CV, 2009, STROKE, V40, pS146, DOI 10.1161/STROKEAHA.108.533091; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Burlacu A, 2013, STEM CELLS DEV, V22, P643, DOI 10.1089/scd.2012.0273; Carmeliet P, 2005, NATURE, V436, P193, DOI 10.1038/nature03875; Chen J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050105; Chen X, 2013, ACTA RADIOL, V54, P313, DOI 10.1258/ar.2012.120605; Di Santo S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005643; Fan Y, ANN NEUROL, V67, P488; Farahvar A, 2012, J NEUROSURG, V117, P729, DOI 10.3171/2012.7.JNS111816; Gong DS, 2012, BRAIN INJURY, V26, P291, DOI 10.3109/02699052.2011.648710; He TR, 2004, STROKE, V35, P2378, DOI 10.1161/01.STR.0000141893.33677.5d; He XY, 2011, CYTOTHERAPY, V13, P46, DOI 10.3109/14653249.2010.510505; Honma Y, 2002, NEURON, V35, P267, DOI 10.1016/S0896-6273(02)00774-2; JOHANSSON S, 1985, BIOCHEM J, V232, P161, DOI 10.1042/bj2320161; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Joyce N, 2010, REGEN MED, V5, P933, DOI [10.2217/rme.10.72, 10.2217/RME.10.72]; KALARIA RN, 1993, ANN NY ACAD SCI, V695, P190, DOI 10.1111/j.1749-6632.1993.tb23050.x; Kuruvilla R, 2004, CELL, V118, P243, DOI 10.1016/j.cell.2004.06.021; Ladhoff J, 2010, CARDIOVASC RES, V88, P121, DOI 10.1093/cvr/cvq109; Lee AF, 2004, J NEUROSCI, V24, P9174, DOI 10.1523/JNEUROSCI.1588-04.2004; Maxwell WL, 1995, J NEUROCYTOL, V24, P925, DOI 10.1007/BF01215643; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; Mielke JG, 2005, J NEUROCHEM, V92, P103, DOI 10.1111/j.1471-4159.2004.02841.x; Mukouyama Y, 2002, CELL, V109, P693, DOI 10.1016/S0092-8674(02)00757-2; Ohta T, 2006, NEUROSURGERY, V59, P679, DOI 10.1227/01.NEU.0000229058.08706.88; Park E, 2009, J CEREBR BLOOD F MET, V29, P575, DOI 10.1038/jcbfm.2008.151; Peichev M, 2000, BLOOD, V95, P952, DOI 10.1182/blood.V95.3.952.003k27_952_958; Resch T, 2012, STEM CELL REV REP, V8, P926, DOI 10.1007/s12015-011-9332-9; Siddiq I, 2012, J NEUROTRAUM, V29, P2647, DOI 10.1089/neu.2012.2444; Siebert JR, 2011, J NEUROCHEM, V119, P176, DOI 10.1111/j.1471-4159.2011.07370.x; Sobrino T, 2007, STROKE, V38, P2759, DOI 10.1161/STROKEAHA.107.484386; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; Taguchi A, 2004, J CLIN INVEST, V114, P330, DOI 10.1172/jci200420622; Urbich C, 2004, TRENDS CARDIOVAS MED, V14, P318, DOI 10.1016/j.tcm.2004.10.001; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; YAMAGATA M, 1986, J BIOL CHEM, V261, P3526; Zhang ZG, 2002, CIRC RES, V90, P284, DOI 10.1161/hh0302.104460	40	32	32	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	FEB	2014	34	2					357	366		10.1038/jcbfm.2013.216			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	304LK	WOS:000330748200022	24301295	Bronze, Green Published			2021-06-18	
J	Bruce, J; Echemendia, R; Meeuwisse, W; Comper, P; Sisco, A				Bruce, Jared; Echemendia, Ruben; Meeuwisse, Willem; Comper, Paul; Sisco, Amber			1 year test-retest reliability of ImPACT in professional ice hockey players	CLINICAL NEUROPSYCHOLOGIST			English	Article						Concussion; Neuropsychology; Mild traumatic brain injury; Hockey; Reliability	SPORTS-RELATED CONCUSSION; PERFORMANCE; MANAGEMENT; STATEMENT; UTILITY; INJURY	The Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT) battery is widely used to assess neurocognitive outcomes following sports-related concussion. The purpose of this study was to examine the 1 year test-retest reliability of ImPACT in a multilingual sample of professional hockey players. A total of 305 professional hockey players were tested 1 year apart using ImPACT. Reliable change confidence intervals were calculated and test-retest reliability was measured using Pearson and Intraclass correlation coefficients. Results indicated that the 1-year test-retest reliabilities for the Visual Motor and Reaction Time Composites ranged from low to high (.52 to .81). In contrast, 1-year test-retest reliabilities for the Verbal and Visual Memory Composites were low (.22 to .58). The 1-year test-retest results provided mixed support for the use of Visual Motor and Reaction Time Composites in select samples; in contrast, the Verbal and Visual Memory Composites may not be sensitive to clinical change.	[Bruce, Jared; Echemendia, Ruben; Sisco, Amber] Univ Missouri, Dept Psychol, Kansas City, MO 64110 USA; [Meeuwisse, Willem] Univ Calgary, Sport Injury Prevent Res Ctr, Calgary, AB, Canada; [Comper, Paul] Univ Toronto, Dept Kinesiol & Phys Educ, Toronto, ON, Canada; [Echemendia, Ruben] Psychol & Neurobehav Associates, State Coll, PA 16801 USA	Echemendia, R (corresponding author), Psychol & Neurobehav Associates, 204 East Calder Way,Ste 205, State Coll, PA 16801 USA.	rechemendia@comcast.net	Echemendia, Ruben/R-6939-2019	Echemendia, Ruben/0000-0001-6116-8462			Baumgartner T.A., 2001, MEAS PHYS EDUC EXERC, V5, P179, DOI [10.1207/S15327841MPEE0503_4, DOI 10.1207/S15327841MPEE0503_4]; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Bruce JM, 2003, NEUROPSYCHOLOGY, V17, P622, DOI 10.1037/0894-4105.17.4.622; BURLINGAME GM, 1995, J MENT HEALTH ADMIN, V22, P226, DOI 10.1007/BF02521118; Cole WR, 2013, ARCH CLIN NEUROPSYCH, V28, P732, DOI 10.1093/arclin/act040; Collie A, 2004, BRIT J SPORT MED, V38, P273, DOI 10.1136/bjsm.2003.000293; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Echemendia RJ, 2001, CLIN J SPORT MED, V11, P23, DOI 10.1097/00042752-200101000-00005; Echemendia RJ, 2013, BRIT J SPORT MED, V47, P294, DOI 10.1136/bjsports-2013-092186; Echemendia RJ, 2012, CLIN NEUROPSYCHOL, V26, P1077, DOI 10.1080/13854046.2012.721006; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; Lange RT, 2010, ARCH CLIN NEUROPSYCH, V25, P442, DOI 10.1093/arclin/acq031; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Mayers LB, 2012, J CLIN EXP NEUROPSYC, V34, P235, DOI 10.1080/13803395.2011.630655; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Piland SG, 2010, J ATHL TRAINING, V45, P273, DOI 10.4085/1062-6050-45.3.273; Randolph C, 2005, J ATHL TRAINING, V40, P139; Randolph C, 2011, CURR SPORT MED REP, V10, P21, DOI 10.1249/JSR.0b013e318207831d; Resch J, 2013, J ATHL TRAINING, V48, P506, DOI 10.4085/1062-6050-48.3.09; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Spreen O., 2006, COMPENDIUM NEUROPSYC; Teesson M., 1994, MEASUREMENT CONSUMER; Yi JY, 2013, CURR SPORT MED REP, V12, P28, DOI 10.1249/JSR.0b013e31827ec9e3; Ziegler M, 2009, PSYCHOL SPORT EXERC, V10, P344, DOI 10.1016/j.psychsport.2008.12.004	38	32	32	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	JAN 2	2014	28	1					14	25		10.1080/13854046.2013.866272			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	AA0AF	WOS:000330756800002	24345194				2021-06-18	
J	Sinclair, KL; Ponsford, J; Rajaratnam, SMW				Sinclair, Kelly L.; Ponsford, Jennie; Rajaratnam, Shantha M. W.			Actigraphic Assessment of Sleep Disturbances following Traumatic Brain Injury	BEHAVIORAL SLEEP MEDICINE			English	Article							EXCESSIVE DAYTIME SLEEPINESS; 1ST 2 YEARS; FATIGUE; DISORDERS; PREVALENCE; DEPRESSION; INSOMNIA; QUALITY; REHABILITATION; QUESTIONNAIRE	The current study examined the use of actigraphy in measurement of sleep following traumatic brain injury (TBI). Twenty-one patients with TBI and self-reported sleep and/or fatigue problems and 21 non-injured controls were studied over seven days using actigraphy and sleep diary reports. Although strong associations between diary and actigraphic assessment of sleep duration were observed in both participant groups, agreement between these methods appeared to weaken in patients with TBI. Associations between sleep diary and actigraphic assessments of sleep disturbance, i.e., wake after sleep onset (WASO) and sleep onset latency (SOL) were not apparent in either group, although weaker agreement between methods for WASO was again observed in patients with TBI. Actigraphy may prove useful to supplement self-report measures of sleep following TBI. More work is required to understand the accuracy of these measures in this population.	[Sinclair, Kelly L.; Ponsford, Jennie; Rajaratnam, Shantha M. W.] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia; [Ponsford, Jennie] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Clayton, Vic, Australia	Rajaratnam, SMW (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton Campus, Clayton, Vic 3800, Australia.	shantha.rajaratnam@monash.edu		Rajaratnam, Shantha/0000-0001-7527-8558	Victorian Neurotrauma Initiative; Jack Brockhoff Foundation; NHMRC Centre for Integrated Research and Understanding of Sleep (CIRUS); University of SydneyUniversity of Sydney; RACV Sir Edmund Herring Memorial Scholarship	We thank the Monash Epworth Rehabilitation Research Centre for assistance with participant recruitment. This work was supported by funding from the Victorian Neurotrauma Initiative, Jack Brockhoff Foundation, NHMRC Centre for Integrated Research and Understanding of Sleep (CIRUS), The University of Sydney, and RACV Sir Edmund Herring Memorial Scholarship. Thank you also to Dr. Stuart Baulk, CQ University, Australia, for his assistance in data analysis and interpretation.	Aaronson L S, 1999, Image J Nurs Sch, V31, P45; American Academy of Sleep Medicine, 2005, INT CLASS SLEEP DIS, V2nd; Ancoli-Israel S., 2003, SLEEP, V28, P1017; Ayalon L, 2007, NEUROLOGY, V68, P1136, DOI 10.1212/01.wnl.0000258672.52836.30; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BLAND JM, 1995, LANCET, V346, P1085, DOI 10.1016/S0140-6736(95)91748-9; Bland JM, 1999, STAT METHODS MED RES, V8, P135, DOI 10.1191/096228099673819272; Bushnik T, 2008, J HEAD TRAUMA REHAB, V23, P17, DOI 10.1097/01.HTR.0000308717.80590.22; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cantor JB, 2008, J HEAD TRAUMA REHAB, V23, P41, DOI 10.1097/01.HTR.0000308720.70288.af; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Chaumet G, 2008, NEUROLOGY, V71, P1609, DOI 10.1212/01.wnl.0000334753.49193.48; Englander J, 2010, BRAIN INJURY, V24, P1379, DOI 10.3109/02699052.2010.523041; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; Kaiser PR, 2010, NEUROLOGY, V75, P1780, DOI 10.1212/WNL.0b013e3181fd62a2; Kanady JC, 2011, J SLEEP RES, V20, P214, DOI 10.1111/j.1365-2869.2010.00858.x; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Kushida CA, 2001, SLEEP MED, V2, P389, DOI 10.1016/S1389-9457(00)00098-8; Ludbrook J, 2010, CLIN EXP PHARMACOL P, V37, P143, DOI 10.1111/j.1440-1681.2009.05288.x; Makley MJ, 2008, NEUROREHAB NEURAL RE, V22, P341, DOI 10.1177/1545968308315598; Makley MJ, 2009, NEUROREHAB NEURAL RE, V23, P320, DOI 10.1177/1545968308325268; Manconi M, 2010, J SLEEP RES, V19, P478, DOI 10.1111/j.1365-2869.2009.00801.x; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; Mccall C, 2012, J SLEEP RES, V21, P122, DOI 10.1111/j.1365-2869.2011.00917.x; Morgenthaler T, 2007, SLEEP, V30, P519, DOI 10.1093/sleep/30.4.519; Netzer NC, 1999, ANN INTERN MED, V131, P485, DOI 10.7326/0003-4819-131-7-199910050-00002; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Ouellet MC, 2006, REHABIL PSYCHOL, V51, P140, DOI 10.1037/0090-5550.51.2.140; Pallant J., 2011, SPSS SURVIVAL MANUAL; Parcell DL, 2008, ARCH PHYS MED REHAB, V89, P843, DOI 10.1016/j.apmr.2007.09.057; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Ponsford J., 2008, 17 WORLD C BRAIN INJ; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; Rao V, 2005, TXB TRAUMATIC BRAIN, P369; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Respironics, 2008, ACT SOFTW US GUID; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; Sadeh A, 2011, SLEEP MED REV, V15, P259, DOI 10.1016/j.smrv.2010.10.001; Schreiber S, 2008, SLEEP MED, V9, P481, DOI 10.1016/j.sleep.2007.04.014; Shekleton JA, 2010, NEUROLOGY, V74, P1732, DOI 10.1212/WNL.0b013e3181e0438b; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Spruyt K, 2011, J SLEEP RES, V20, P223, DOI 10.1111/j.1365-2869.2010.00857.x; Tabachnick B., 2001, USING MULTIVARIATE S; Tryon WW, 2004, SLEEP, V27, P158, DOI 10.1093/sleep/27.1.158; Vaishnavi S., 2010, TXB TRAUMATIC BRAIN, P325; Vaishnavi S, 2010, PSYCHIAT ANN, V40, P553, DOI 10.3928/00485713-20101018-06; Verma A, 2007, J CLIN SLEEP MED, V3, P357; WALKER GC, 1991, ARCH PHYS MED REHAB, V72, P469; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Werner H, 2008, ARCH PEDIAT ADOL MED, V162, P350, DOI 10.1001/archpedi.162.4.350; Williams BR, 2008, CLIN NEUROPHYSIOL, V119, P429, DOI 10.1016/j.clinph.2007.11.003; Worthington AD, 2006, BRAIN INJURY, V20, P327, DOI 10.1080/02699050500488249; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383; Zollman FS, 2010, BRAIN INJURY, V24, P748, DOI 10.3109/02699051003692167	67	32	32	0	10	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1540-2002	1540-2010		BEHAV SLEEP MED	Behav. Sleep Med.	JAN 2	2014	12	1					13	27		10.1080/15402002.2012.726203			15	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	268SZ	WOS:000328192100002	23394102				2021-06-18	
J	Broughton, E; Pobereskin, L; Whitfield, PC				Broughton, Ellie; Pobereskin, Louis; Whitfield, Peter C.			Seven years of cranioplasty in a regional neurosurgical centre	BRITISH JOURNAL OF NEUROSURGERY			English	Article						cranioplasty; craniectomy; complications; outcomes; trauma	DECOMPRESSIVE CRANIECTOMY; HEAD-INJURY; MULTICENTER; INFECTION	Introduction. In recent years craniectomy has been widely used in the management of traumatic brain injury and ischaemic stroke. The objective of this study was to evaluate the indications, techniques and outcomes for patients undergoing cranioplasty over a recent 7-year period in a geographically distinct population. Materials and methods. An observational study was performed retrospectively, with review of case records from 2004 to 2011. Demographic, clinical and outcome data were collected, and complications were classified as major and minor. A multi-variant analysis was performed to identify patient and management factors that influenced outcome. Results. Data were collected on a total of 87 cranioplasty patients with a median age of 42 and a mean follow-up time of 3 years and 10 months. The main indications for craniectomy were trauma (46%), infection (19%) intracranial haemorrhage (15%), tumour (13%) and ischaemic stroke (6%). Eight percent of patients had a synchronous craniectomy and cranioplasty, 14% had cranioplasty within 3 months of craniectomy, 21% within 3-6 months, 35% within 6-12 months, 14% over 1 year and 8% over 2 years later. The most frequently implanted cranioplasty material was titanium (53%), followed by autologous bone (26%) and acrylic (15%). Administration of prophylactic antibiotics was recorded in 97% of cases. Major complications occurred in 20% of patients, including 2 deaths (2%), 5 extradural haemorrhages (6%) and 9 infections (10%). A further 10% of cases experienced minor or cosmetic complications. Conclusions. Cranioplasty is often considered as a low-risk procedure following craniectomy. In our cohort, a 20% risk of major complications, including death, was identified. These findings contribute to the literature,emphasising that cranioplasty is a high-risk procedure. Whilst compelling reasons may guide the undertaking of craniectomy, it is essential that consideration is given to the significant subsequent risks of cranioplasty.	[Broughton, Ellie; Pobereskin, Louis; Whitfield, Peter C.] Derriford Hosp, South West Neurosurg Ctr, Plymouth PL6 8DH, Devon, England	Broughton, E (corresponding author), Derriford Hosp, South West Neurosurg Ctr, Plymouth PL6 8DH, Devon, England.	ebroughton@doctors.org.uk	Whitfield, Peter/ABA-4471-2020	Whitfield, Peter/0000-0003-0566-1820			Al-Tamimi YZ, 2012, BRIT J NEUROSURG, V26, P510, DOI 10.3109/02688697.2011.633640; Chang V, 2010, J NEUROSURG, V112, P1120, DOI 10.3171/2009.6.JNS09133; Cheng YK, 2008, J CLIN NEUROSCI, V15, P1115, DOI 10.1016/j.jocn.2007.09.022; Chibbaro S, 2011, WORLD NEUROSURG, V75, P558, DOI 10.1016/j.wneu.2010.10.020; De Bonis P, 2012, J NEUROTRAUM, V29, P1071, DOI 10.1089/neu.2011.2116; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Hofmeijer J, 2009, LANCET NEUROL, V8, P326, DOI 10.1016/S1474-4422(09)70047-X; Honeybul S, 2011, BRIT J NEUROSURG, V25, P343, DOI 10.3109/02688697.2011.568643; Joffe J, 1999, BRIT J NEUROSURG, V13, P576, DOI 10.1080/02688699943088; Lee SC, 2009, J CLIN NEUROSCI, V16, P56, DOI 10.1016/j.jocn.2008.04.001; Morina Arsim, 2011, Surg Neurol Int, V2, P72, DOI 10.4103/2152-7806.81735; National Collaborating Centre for Chronic Conditions, 2008, STROK NAT CLIN GUID; Sobani Zain A, 2011, Surg Neurol Int, V2, P123, DOI 10.4103/2152-7806.85055; Thavarajah D, 2012, BRIT J NEUROSURG, V26, P78, DOI 10.3109/02688697.2011.603850; Yadla S, 2011, NEUROSURGERY, V68, P1124, DOI 10.1227/NEU.0b013e31820a5470	15	32	33	0	9	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.	JAN	2014	28	1					34	39		10.3109/02688697.2013.815319			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	304FB	WOS:000330731400008	23875882				2021-06-18	
J	de Guise, E; Alturki, AY; LeBlanc, J; Champoux, MC; Couturier, C; Lamoureux, J; Desjardins, M; Marcoux, J; Maleki, M; Feyz, M				de Guise, Elaine; Alturki, Abdulrahman Yaqub; LeBlanc, Joanne; Champoux, Marie-Claude; Couturier, Celine; Lamoureux, Julie; Desjardins, Monique; Marcoux, Judith; Maleki, Mohammed; Feyz, Mitra			The Montreal Cognitive Assessment in Persons with Traumatic Brain Injury	APPLIED NEUROPSYCHOLOGY-ADULT			English	Article						Level 1 trauma center; Montreal Cognitive Assessment; outcome; traumatic brain injury	MENTAL-STATE-EXAMINATION; HEAD-INJURY; AXONAL INJURY; STROKE PATIENTS; IMPAIRMENT; REHABILITATION; MOCA; TBI; PREDICTORS; ADMISSION	The objective of this study was to examine the performance of patients with traumatic brain injury (TBI) on the Montreal Cognitive Assessment (MoCA). The MoCA was administered to 214 patients with TBI during their acute care hospitalization in a Level 1 trauma center. The results showed that patients with severe TBI had lower scores on the MoCA compared with patients with mild and moderate TBI, F(2, 211) 10.35, p=.0001. This difference was found for visuospatial/executive, attention, and orientation subtests (p<.05). Linear regression demonstrated that age, education, TBI severity, and the presence of neurological antecedents were the best predictors of cognitive impairments explaining 42% of the total variability of the MoCA. This information can enable clinicians to predict early cognitive impairments and plan cognitive rehabilitation earlier in the recovery process.	[de Guise, Elaine; LeBlanc, Joanne; Champoux, Marie-Claude; Couturier, Celine; Feyz, Mitra] McGill Univ, Traumat Brain Injury Program, Ctr Hlth, Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada; [de Guise, Elaine; Alturki, Abdulrahman Yaqub; Marcoux, Judith; Maleki, Mohammed] McGill Univ, Neurosurg Dept, Ctr Hlth, Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada; [Alturki, Abdulrahman Yaqub] Natl Neurosci Inst, Riyadh, Saudi Arabia; [Lamoureux, Julie] Univ Montreal, Social & Prevent Med Dept, Montreal, PQ, Canada; [Desjardins, Monique] McGill Univ, Dept Psychiat, Ctr Hlth, Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada	de Guise, E (corresponding author), McGill Univ, Traumat Brain Injury Program, Ctr Hlth, Montreal Gen Hosp Site,Room D13-124,1650 Cedar, Montreal, PQ H3G 1A4, Canada.	elainedeguise@hotmail.ca					Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Copersino ML, 2009, EXP CLIN PSYCHOPHARM, V17, P337, DOI 10.1037/a0017260; Dalrymple-Alford JC, 2010, NEUROLOGY, V75, P1717, DOI 10.1212/WNL.0b013e3181fc29c9; Dawson DR, 2004, BRAIN INJURY, V18, P221, DOI 10.1080/02699050310001617406; DIKMEN S, 1986, ARCH PHYS MED REHAB, V67, P507; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Dikmen SS, 2009, J HEAD TRAUMA REHAB, V24, P430, DOI 10.1097/HTR.0b013e3181c133e9; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Freitas S, 2012, ARCH CLIN NEUROPSYCH, V27, P165, DOI 10.1093/arclin/acr116; Godefroy O, 2011, STROKE, V42, P1712, DOI 10.1161/STROKEAHA.110.606277; Heruti RJ, 2002, ARCH PHYS MED REHAB, V83, P742, DOI 10.1053/apmr.2002.32739; Lehtonen S, 2005, BRAIN INJURY, V19, P239, DOI 10.1080/0269905040004310; Leitgeb J, 2012, J NEUROSURG, V117, P324, DOI 10.3171/2012.4.JNS111448; LEVIN HS, 1992, J NEUROTRAUM, V9, pS359; Lezak M. D, 2012, NEUROPSYCHOLOGICAL A, P158; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Marshall SB, 1991, J NEUROSURG S, V75, P14; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; Mazeaux J. M., 1997, ARCH PHYS MED REHAB, V78, P1316; Metting Z, 2009, ANN NEUROL, V66, P809, DOI 10.1002/ana.21785; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Nazem S, 2009, J AM GERIATR SOC, V57, P304, DOI 10.1111/j.1532-5415.2008.02096.x; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Novack TA, 2000, BRAIN INJURY, V14, P987; Pastorek NJ, 2004, J INT NEUROPSYCH SOC, V10, P807, DOI 10.1017/S1355617704106012; Paul R, 2011, ARCH CLIN NEUROPSYCH, V26, P454, DOI 10.1093/arclin/acr017; Rabadi MH, 2008, ARCH PHYS MED REHAB, V89, P441, DOI 10.1016/j.apmr.2007.11.014; Rossetti HC, 2011, NEUROLOGY, V77, P1272, DOI 10.1212/WNL.0b013e318230208a; Sandhaug M, 2010, BRAIN INJURY, V24, P740, DOI 10.3109/02699051003652849; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Silver JM., 2011, TXB TRAUMATIC BRAIN, V2nd ed.; Toglia J, 2011, ARCH PHYS MED REHAB, V92, P792, DOI 10.1016/j.apmr.2010.12.034; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Wallesch CW, 2001, J NEUROTRAUM, V18, P11, DOI 10.1089/089771501750055730; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; West LK, 2011, J NEUROPSYCHOL, V5, P114, DOI 10.1348/174866410X521434; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Zwecker M, 2002, ARCH PHYS MED REHAB, V83, P342, DOI 10.1053/apmr.2002.29641	40	32	32	0	14	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	0908-4282	1532-4826		APPL NEUROPSYCH-ADUL	Appl. Neuropsychol.-Adult		2014	21	2					128	135		10.1080/09084282.2013.778260			8	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	AM9VL	WOS:000340229000007	24826506				2021-06-18	
J	Jones, SAV; Breakey, RW; Evans, PJ				Jones, Simon Andrew Vann; Breakey, Richard William; Evans, Philip John			Heading in football, long-term cognitive decline and dementia: evidence from screening retired professional footballers	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Aging; Concussion; Epidemiology; Neurology; Soccer	TRAUMATIC BRAIN-INJURY; SOCCER PLAYERS; MEMORY TEST; IMPAIRMENT; PREVALENCE; DEFICITS	Background Heading impairs cognition in the short and medium-terms; however, little is known about the long-term consequences. This study aimed to investigate the hypothesis that chronic low-level head trauma is associated with persistent cognitive decline. Methods All members of Former Player Associations (FPAs) from four professional football clubs in the UK were contacted to participate in the study. Participants were required to complete a self-assessed test of cognition, the Test Your Memory questionnaire. Further information was collected from respondents in order to analyse the potential effect of a number of variables on cognition. Results 10 of 92 respondents (10.87%) screened positive for possible mild cognitive impairment (MCI) or dementia. There was no association between low-risk and high-risk playing positions (HR=0.40, p=0.456) or length of playing career (HR=1.051 95% CI 0.879 to 1.257, p=0.586) and a positive screening result. Age was a risk factor (HR=1.137 per additional year, 95% CI 1.030 to 1.255, p<0.05), although this was not significantly different from the population prevalence across age groups. Conclusions These results suggest that once a player ends their playing career, their risk of harm falls in line with the population, suggesting either that changes are reversible or that heading may not be as harmful as commonly thought. Future longitudinal studies of large numbers of professional football players are needed to support the findings from this study.	[Jones, Simon Andrew Vann] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England; [Breakey, Richard William] Newcastle Upon Tyne Hosp, Dept Pathol, Newcastle Upon Tyne, Tyne & Wear, England; [Evans, Philip John] Durham & Darlington NHS Fdn Trust, Dept Gen Med, Durham, England	Jones, SAV (corresponding author), Newcastle Univ, Inst Ageing & Hlth, Campus Ageing & Vital, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England.	simonvj@gmail.com			National Institute for Health Research (NIHR) Academic Foundation Programme; Newcastle upon Tyne Hospitals (NUTH) NHS Foundation Trust; Newcastle University; National Institute for Health ResearchNational Institute for Health Research (NIHR) [ACF-2013-13-017] Funding Source: researchfish	This research was supported by the National Institute for Health Research (NIHR) Academic Foundation Programme and Newcastle upon Tyne Hospitals (NUTH) NHS Foundation Trust and Newcastle University. The views expressed are those of the authors and not necessarily those of the NHS, NUTH, the NIHR or the Department of Health	Brogger J, 2002, AM J EPIDEMIOL, V155, P572, DOI 10.1093/aje/155.6.572; Brown J, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b2030; Crawford FC, 2007, BRAIN RES, V1185, P45, DOI 10.1016/j.brainres.2007.09.042; Fish M, 2008, NEUROEPIDEMIOLOGY, V30, P25, DOI 10.1159/000115439; Gavett BE, 2011, CLIN SPORT MED, V30, P179, DOI 10.1016/j.csm.2010.09.007; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Koekkoek PS, 2013, J NEUROL SCI, V328, P92, DOI 10.1016/j.jns.2013.02.028; Li SH, 2006, NEUROSCI LETT, V409, P182, DOI 10.1016/j.neulet.2006.09.054; Lipton ML, 2013, RADIOLOGY, V268, P850, DOI 10.1148/radiol.13130545; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; Punnoose AR, 2012, JAMA-J AM MED ASSOC, V307, P1012, DOI 10.1001/jama.2012.231; Rutherford A, 2009, J CLIN EXP NEUROPSYC, V31, P664, DOI 10.1080/13803390802484755; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; van Schalkwyk G, 2012, J GERIATR PSYCH NEUR, V25, P85, DOI 10.1177/0891988712447895; Ward A, 2012, ALZHEIMERS DEMENT, V8, P14, DOI 10.1016/j.jalz.2011.01.002; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8; Zetterberg H, 2007, BRIT J SPORT MED, V41, DOI 10.1136/bjsm.2007.037143	20	32	32	0	32	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2014	48	2					159	U170		10.1136/bjsports-2013-092758			4	Sport Sciences	Sport Sciences	276KK	WOS:000328749000020	24026299				2021-06-18	
J	Williams, D; Sullivan, SJ; Schneiders, AG; Ahmed, OH; Lee, H; Balasundaram, AP; McCrory, PR				Williams, David; Sullivan, S. John; Schneiders, Anthony G.; Ahmed, Osman Hassan; Lee, Hopin; Balasundaram, Arun Prasad; McCrory, Paul R.			Big hits on the small screen: an evaluation of concussion-related videos on YouTube	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						Concussion; Head injuries; Injury Prevention	SOCIAL NETWORKING; RUGBY PLAYERS; INFORMATION; QUALITY; COVERAGE	Background YouTube is one of the largest social networking websites, allowing users to upload and view video content that provides entertainment and conveys many messages, including those related to health conditions, such as concussion. However, little is known about the content of videos relating to concussion. Objective To identify and classify the content of concussion-related videos available on YouTube. Study design An observational study using content analysis. Methods YouTube's video database was systematically searched using 10 search terms selected from MeSH and Google Adwords. The 100 videos with the largest view counts were chosen from the identified videos. These videos and their accompanying text were analysed for purpose, source and description of content by a panel of assessors who classified them into data-driven thematic categories. Results 434 videos met the inclusion criteria and the 100 videos with the largest view counts were chosen. The most common categories of the videos were the depiction of a sporting injury (37%) and news reports (25%). News and media organisations were the predominant source (51%) of concussion-related videos on YouTube, with very few being uploaded by professional or academic organisations. The median number of views per video was 26191. Conclusions Although a wide range of concussion-related videos were identified, there is a need for healthcare and educational organisations to explore YouTube as a medium for the dissemination of quality-controlled information on sports concussion.	[Williams, David; Sullivan, S. John; Schneiders, Anthony G.; Ahmed, Osman Hassan; Lee, Hopin; Balasundaram, Arun Prasad] Univ Otago, Ctr Physiotherapy Res, Sch Physiotherapy, Dunedin 9054, New Zealand; [McCrory, Paul R.] Univ Melbourne, Florey Neurosci Inst, Melbourne, Vic, Australia; [McCrory, Paul R.] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic, Australia; [McCrory, Paul R.] Monash Univ, Australian Ctr Res Sports Injury Prevent, Melbourne, Vic 3004, Australia	Sullivan, SJ (corresponding author), Univ Otago, Ctr Physiotherapy Res, Sch Physiotherapy, POB 56, Dunedin 9054, New Zealand.	sjohn.sullivan@otago.ac.nz	Balasundaram, Arun Prasad/D-1270-2017; McCrory, Paul/Q-8688-2019; Schneiders, Anthony/F-4212-2015	Balasundaram, Arun Prasad/0000-0001-8256-857X; Williams, David/0000-0001-8980-6446; McCrory, Paul/0000-0003-4850-0568; Schneiders, Anthony/0000-0002-1583-3879; Lee, Hopin/0000-0001-5692-0314	University of Otago Medical Research Foundation summer student scholarship	University of Otago Medical Research Foundation summer student scholarship.	Ache KA, 2008, AM J PREV MED, V35, P389, DOI 10.1016/j.amepre.2008.06.029; Ahmed OH, 2012, BRIT J SPORT MED, V46, P675, DOI 10.1136/bjsm.2010.081620; Ahmed OH, 2010, DISABIL REHABIL, V32, P1877, DOI 10.3109/09638281003734409; Alexa: the web information company, TOP SIT TOP 500 SIT; Bernstam EV, 2008, CANCER-AM CANCER SOC, V112, P1206, DOI 10.1002/cncr.23308; Briones R, 2012, HEALTH COMMUN, V27, P478, DOI 10.1080/10410236.2011.610258; Cheng X., 2008, 16 INT WORKSH QUAL S; Evans MF, 2012, BRIT J SPORT MED, V46, P461, DOI 10.1136/bjsports-2012-091113; Eysenbach G, 2008, J MED INTERNET RES, V10, DOI 10.2196/jmir.1030; Google, GOOGL ADW; Grossman L, 2012, TIME, V179, P38; Hughes S, 2011, J MED INTERNET RES, V13, DOI 10.2196/jmir.1716; Internet World Stats, INT US STAT INT BIG; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; Oh H, 2005, J MED INTERNET RES, V7; Perotti V, 2011, 44 HAW INT C SYST SC; Pew Internet & American Life Project, UND PART NEWS CONS; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Randeree E, 2009, TELEMED J E-HEALTH, V15, P255, DOI 10.1089/tmj.2008.0093; Reilly T., 2007, COMMUNICATIONS STRAT, V65, P17, DOI [10.1109/KIMAS.2003.1245106., DOI 10.1109/KIMAS.2003.1245106]; Richardson CG, 2011, SUBST USE MISUSE, V46, P893, DOI 10.3109/10826084.2011.570628; Sullivan SJ, 2012, BRIT J SPORT MED, V46, P258, DOI 10.1136/bjsm.2010.080341; Sullivan SJ, 2009, CLIN J SPORT MED, V19, P228, DOI 10.1097/JSM.0b013e3181a41e43; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; van der Marel S, 2009, INFLAMM BOWEL DIS, V15, P1891, DOI 10.1002/ibd.20976; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832; Yoo JH, 2012, HEALTH COMMUN, V27, P86, DOI 10.1080/10410236.2011.569003; YouTube, WHAT SHOULD I PUT MY; YouTube, WHATS DIFF KEYW TAGS; YouTube, DO I OPT MY VID WATC	35	32	33	0	19	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	JAN	2014	48	2					107	111		10.1136/bjsports-2012-091853			5	Sport Sciences	Sport Sciences	276KK	WOS:000328749000011	23446643	Bronze			2021-06-18	
J	Gajawelli, N; Lao, Y; Apuzzo, MLJ; Romano, R; Liu, C; Tsao, S; Hwang, D; Wilkins, B; Lepore, N; Law, M				Gajawelli, Niharika; Lao, Yi; Apuzzo, Michael L. J.; Romano, Russ; Liu, Charles; Tsao, Sinchai; Hwang, Darryl; Wilkins, Bryce; Lepore, Natasha; Law, Meng			Neuroimaging Changes in the Brain in Contact versus Noncontact Sport Athletes Using Diffusion Tensor Imaging	WORLD NEUROSURGERY			English	Article						Diffusion tensor imaging; Magnetic resonance imaging; Traumatic brain injury	WHITE-MATTER; AXONAL INJURY; HEAD-INJURY; CONCUSSION; ABNORMALITIES; ADOLESCENTS	OBJECTIVE: Traumatic brain injury in contact sports has significant impact on short-term neurologic and neurosurgical function as well as longer-term cognitive disability. In this study, we aim to demonstrate that contact sport participants exhibit differences in diffusion tensor imaging (DTI) caused by repeated physical impacts on the brain. We also aim to determine that impact incurred by the contact sports athletes during the season may result in the differences between the pre- and postseason DTI scans. METHODS: DTI data were collected from 10 contact-sport (mean age 20.4 +/- 1.36 years) and 13 age-matched noncontact-sport (mean age 19.5 +/- 1.03 years) male athletes on a 3-Tesla magnetic resonance imaging scanner. A single-shot, echo-planar imaging sequence with b-value of 1000 s/mm(2) and 25 gradient directions was used. Eight of the athletes were again scanned after the end of the season. The b(0) nondiffusion-weighted image was averaged five times. Voxel-wise, two-sample t tests were run for all group comparisons, and in each case, the positive false-discovery rate was computed to assess the whole-map, multiple-comparison corrected significance. RESULTS: There were significant differences in the fractional anisotropy values in the inferior fronto-occipital fasciculus, parts of the superior and posterior coronal radiate, and the splenium of the corpus callosum (CC) as well as smaller clusters in the genu and parts of the body of the CC. In addition, the external capsule also shows some difference between the contact and noncontact athlete brains. In addition, the preseason and postseason showed differences in these regions, however, the postseason P-values show significance in more areas of the CC. CONCLUSIONS: There are significant DTI changes in the CC, the external capsule, the inferior fronto-occipital fasciculus, as well as regions such as the superior/posterior corona radiata the preseason contact versus the noncontact control athletes were compared and also when the postseason contact athletes with the control athletes were compared. There are also differences in the DTI parameters in the post and preseason scans.	[Gajawelli, Niharika; Lao, Yi; Tsao, Sinchai; Wilkins, Bryce; Lepore, Natasha; Law, Meng] Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA; [Apuzzo, Michael L. J.; Liu, Charles] Univ So Calif, Keck Sch Med, Dept Neurosurg, Los Angeles, CA 90033 USA; [Hwang, Darryl; Law, Meng] Univ So Calif, Keck Sch Med, Dept Radiol, Los Angeles, CA 90033 USA; [Romano, Russ] Univ So Calif, Dept Athlet, Los Angeles, CA USA; [Lepore, Natasha] Childrens Hosp, Dept Radiol, Los Angeles, CA 90027 USA	Gajawelli, N (corresponding author), Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA.	gajawell@usc.edu	Meijer, Anna/K-5118-2016; Hwang, Darryl/M-7221-2019	Hwang, Darryl/0000-0002-1111-9176	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21EB013456]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R21EB012177, R21EB013456] Funding Source: NIH RePORTER	Supported by NIH grant R21EB013456.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Assaf Y, 2004, MAGN RESON MED, V52, P965, DOI 10.1002/mrm.20274; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dru F, 2009, INSIGHT J; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Lao Y, 2013, SPIE MED IMAGI UNPUB; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Strich S, 1961, LANCET, V278, P443; Toussaint N, 2007, P MICCAI 7 2007 BRIS; Virji-Babul N, 2013, PEDIATR NEUROL, V48, P24, DOI 10.1016/j.pediatrneurol.2012.09.005; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Zhang H, 2010, LECT NOTES COMPUT SC, V6204, P83, DOI 10.1007/978-3-642-14366-3_8	26	32	32	2	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	DEC	2013	80	6					824	828		10.1016/j.wneu.2013.10.020			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	290DL	WOS:000329733300080	24120614	Green Accepted			2021-06-18	
J	Zhao, ZR; Faden, AI; Loane, DJ; Lipinski, MM; Sabirzhanov, B; Stoica, BA				Zhao, Zaorui; Faden, Alan I.; Loane, David J.; Lipinski, Marta M.; Sabirzhanov, Boris; Stoica, Bogdan A.			Neuroprotective effects of geranylgeranylacetone in experimental traumatic brain injury	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						controlled cortical impact; functional recovery; GGA; HSP70; neuroprotection; traumatic brain injury	HEAT-SHOCK-PROTEIN; CONTROLLED CORTICAL IMPACT; FOCAL CEREBRAL-ISCHEMIA; ACID-INDUCED SEIZURES; RAT HEAT-SHOCK-PROTEIN-70; TRANSIENT ISCHEMIA; GASTRIC-MUCOSA; CELL-DEATH; HSP70; MICE	Geranylgeranylacetone (GGA) is an inducer of heat-shock protein 70 (HSP70) that has been used clinically for many years as an antiulcer treatment. It is centrally active after oral administration and is neuroprotective in experimental brain ischemia/stroke models. We examined the effects of single oral GGA before treatment (800 mg/kg, 48 hours before trauma) or after treatment (800 mg/kg, 3 hours after trauma) on long-term functional recovery and histologic outcomes after moderate-level controlled cortical impact, an experimental traumatic brain injury (TBI) model in mice. The GGA pretreatment increased the number of HSP70(+) cells and attenuated posttraumatic alpha-fodrin cleavage, a marker of apoptotic cell death. It also improved sensorimotor performance on a beam walk task; enhanced recovery of cognitive/affective function in the Morris water maze, novel object recognition, and tail-suspension tests; and improved outcomes using a composite neuroscore. Furthermore, GGA pretreatment reduced the lesion size and neuronal loss in the hippocampus, cortex, and thalamus, and decreased microglial activation in the cortex when compared with vehicle-treated TBI controls. Notably, GGA was also effective in a posttreatment paradigm, showing significant improvements in sensorimotor function, and reducing cortical neuronal loss. Given these neuroprotective actions and considering its longstanding clinical use, GGA should be considered for the clinical treatment of TBI.	Univ Maryland, Sch Med, Dept Anesthesiol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Baltimore, MD 21201 USA	Zhao, ZR (corresponding author), Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, Hlth Sci Facil HSFI 1, 685 W Baltimore St,Room 263, Baltimore, MD 21201 USA.	zzhao@anes.umm.edu	STOICA, BOGDAN/H-9782-2013	STOICA, BOGDAN/0000-0002-2501-6434; Loane, David/0000-0003-0393-3503; Lipinski, Marta/0000-0002-7537-9014; Faden, Alan I./0000-0003-0128-2348	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 (NS052568), R01 (NS061839)]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061839, R01NS052568] Funding Source: NIH RePORTER	This work was supported by NIH grants R01 (NS052568) and R01 (NS061839) to AIF.	Abe E, 2010, BRAIN RES, V1330, P151, DOI 10.1016/j.brainres.2010.02.074; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Byrnes KR, 2009, GLIA, V57, P550, DOI 10.1002/glia.20783; Chen MZ, 1998, J NEUROTRAUM, V15, P171, DOI 10.1089/neu.1998.15.171; Evans CG, 2010, J MED CHEM, V53, P4585, DOI 10.1021/jm100054f; Faden AI, 2003, J CEREBR BLOOD F MET, V23, P355, DOI 10.1097/01.WCB.0000046144.31247.33; Faul M, 2010, TRAUMATIC BRAIN INJU, P13, DOI DOI 10.3171/2009.10.JNS091500; Fujiki M, 2004, BRAIN RES, V1021, P281, DOI 10.1016/j.brainres.2004.06.054; Fujiki M, 2004, BRAIN RES, V1020, P210, DOI 10.1016/j.brainres.2004.06.031; Fujiki M, 2003, BRAIN RES, V991, P254, DOI 10.1016/S0006-8993(03)03540-6; Fujiki M, 2006, J NEUROTRAUM, V23, P1164, DOI 10.1089/neu.2006.23.1164; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Herrero MT, 2002, CHILD NERV SYST, V18, P386, DOI 10.1007/s00381-002-0604-1; IIZUKA H, 1990, STROKE, V21, P790, DOI 10.1161/01.STR.21.5.790; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kawai T, 2000, J LAB CLIN MED, V136, P138, DOI 10.1067/mlc.2000.108157; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lee SH, 2001, STROKE, V32, P2905, DOI 10.1161/hs1201.099604; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Luo FC, 2012, FREE RADICAL BIO MED, V52, P1218, DOI 10.1016/j.freeradbiomed.2012.01.004; Mailer JJ, 2012, HUM BRAIN MAPP, DOI 101002/hbm.22171; Matsumori Y, 2006, STROKE, V37, P507, DOI 10.1161/01.STR.0000199057.00365.20; Matsumori Y, 2005, J CEREBR BLOOD F MET, V25, P899, DOI 10.1038/sj.jcbfm.9600080; Nakamoto T, 2012, AURIS NASUS LARYNX, V39, P270, DOI 10.1016/j.anl.2011.06.001; Otaka M, 2007, BIOCHEM BIOPH RES CO, V353, P399, DOI 10.1016/j.bbrc.2006.12.031; Piao CS, 2012, NEUROBIOL DIS, V46, P745, DOI 10.1016/j.nbd.2012.03.018; Prins ML, 2010, DEV NEUROSCI-BASEL, V32, P510, DOI 10.1159/000316800; Saatman KE, 2010, NEUROTHERAPEUTICS, V7, P31, DOI 10.1016/j.nurt.2009.11.002; Sakamoto C, 2007, DIGESTION, V75, P215, DOI 10.1159/000110654; Sinn DI, 2007, BRAIN RES, V1135, P167, DOI 10.1016/j.brainres.2006.11.098; SUMIGAMA K, 1983, PROG MED, V3, P1053; Sun YJ, 2006, J CEREBR BLOOD F MET, V26, P937, DOI 10.1038/sj.jcbfm.9600246; Tsuchiya D, 2003, NEUROSURGERY, V53, P1179, DOI 10.1227/01.NEU.0000090341.38659.CF; Tsuchiya D, 2003, J CEREBR BLOOD F MET, V23, P718, DOI 10.1097/01.WCB.0000054756.97390.F7; Wang ZY, 2011, KIDNEY INT, V79, P861, DOI 10.1038/ki.2010.527; Yasuda H, 2005, BRAIN RES, V1032, P176, DOI 10.1016/j.brainres.2004.11.009; Yenari MA, 2005, ANN NY ACAD SCI, V1053, P74, DOI 10.1196/annals.1344.007; Yenari MA, 1998, ANN NEUROL, V44, P584, DOI 10.1002/ana.410440403; Zhao ZR, 2012, J NEUROTRAUM, V29, P2475, DOI 10.1089/neu.2012.2511	39	32	34	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	DEC	2013	33	12					1897	1908		10.1038/jcbfm.2013.144			12	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	266DI	WOS:000328002200010	23942364	Green Published, Bronze			2021-06-18	
J	Campolo, M; Esposito, E; Ahmad, A; Di Paola, R; Wallace, JL; Cuzzocrea, S				Campolo, Michela; Esposito, Emanuela; Ahmad, Akbar; Di Paola, Rosanna; Wallace, John L.; Cuzzocrea, Salvatore			A hydrogen sulfide-releasing cyclooxygenase inhibitor markedly accelerates recovery from experimental spinal cord injury	FASEB JOURNAL			English	Article						inflammation; apoptosis; central nervous system; motor recovery; nonsteroidal anti-inflammatory drug	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; NITRIC-OXIDE; INFLAMMATORY RESPONSE; SIGNALING MOLECULE; OXIDATIVE STRESS; MOUSE MODEL; RAT; EXPRESSION; APOPTOSIS	Spinal cord trauma causes loss of motor function that is in part due to the ensuing inflammatory response. Hydrogen sulfide (H2S) is a potent, endogenous anti-inflammatory and neuroprotective substance that has been explored for use in the design of novel nonsteroidal anti-inflammatory drugs. In the current study, we evaluated the potential beneficial effects of ATB-346 [2-(6-methoxynapthalen- 2-yl)-propionic acid 4-thiocarbamoyl-phenyl ester], an H2S-releasing derivative of naproxen, in a murine model of spinal cord injury (SCI). SCI was induced in mice by spinal cord compression, produced through the application of vascular clips to the dura via a T5 to T8 laminectomy. ATB-346, naproxen (both at 30 mol/kg), or vehicle was orally administered to the mice 1 and 6 h after SCI and once daily thereafter for 10 d. Motor function [Basso Mouse Scale (BMS) of locomotion] improved gradually in the mice treated with naproxen. However, those treated with ATB-346 exhibited a significantly more rapid and sustained recovery of motor function, achieving greater than double the increase in locomotion score of the naproxen group by the 10th day of treatment. ATB-346 also significantly reduced the severity of inflammation (proinflammatory cytokines, apoptosis of neural tissue, and nitrosative stress) that characterized the secondary effects of SCI. Again, the effects of ATB-346 were superior to those of naproxen for several parameters. These results showed marked beneficial effects of an H2S-releasing derivative of naproxen in an animal model of SCI, significantly enhancing recovery of motor function, possibly by reducing the secondary inflammation and tissue injury that characterizes this model. The combination of inhibition of cyclooxygenase and delivery of H2S may offer a promising alternative to existing therapies for traumatic injury.Campolo, M., Esposito, E., Ahmad, A., Di Paola, R., Wallace, J. L., Cuzzocrea, A. Hydrogen sulfide-releasing cyclooxygenase inhibitor markedly accelerates recovery from experimental spinal cord injury.	[Campolo, Michela; Esposito, Emanuela; Ahmad, Akbar; Di Paola, Rosanna; Cuzzocrea, Salvatore] Univ Messina, Dept Biol & Environm Sci, Messina, Italy; [Wallace, John L.] Univ Calgary, Inflammat Res Network, Calgary, AB T2N 4N1, Canada; [Cuzzocrea, Salvatore] Univ Manchester, Manchester Royal Infirm, Sch Med, Manchester Biomed Res Ctr, Manchester M13 9WL, Lancs, England	Wallace, JL (corresponding author), Univ Calgary, Dept Physiol & Pharmacol, Calgary, AB T2N 4N1, Canada.	altapharm@hotmail.com	Wallace, John/AAL-3763-2021; Campolo, Michela/K-6432-2016; di paola, rosanna/U-4356-2019	Cuzzocrea, Salvatore/0000-0001-6131-3690; di paola, rosanna/0000-0001-6725-8581; Ahmad, Akbar/0000-0003-1841-9670	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR)	The authors thank Carmelo La Spada for excellent technical assistance during this study, Caterina Cutrona for secretarial assistance, and Valentina Malvagni for editorial assistance with the manuscript. This work was supported by a grant from the Canadian Institutes of Health Research (to J.L.W.). J.L.W. is a founder and shareholder of Antibe Therapeutics, Inc.	Abe K, 1996, J NEUROSCI, V16, P1066; Aimone JB, 2004, EXP NEUROL, V189, P204, DOI 10.1016/j.expneurol.2004.05.042; Bao F, 2003, NEUROSCIENCE, V116, P59, DOI 10.1016/S0306-4522(02)00571-7; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; Basso DM, 2006, J NEUROTRAUM, V23, P635, DOI 10.1089/neu.2006.23.635; Bethea JR, 1998, J NEUROSCI, V18, P3251; Blackler R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035196; BLIGHT AR, 1992, J NEUROTRAUM, V9, pS83; BOUGHTONSMITH NK, 1988, AGENTS ACTIONS, V25, P115, DOI 10.1007/BF01969102; BRACKEN MB, 1990, MED J AUSTRALIA, V153, P368, DOI 10.5694/j.1326-5377.1990.tb136976.x; Carmel JB, 2001, PHYSIOL GENOMICS, V7, P201, DOI 10.1152/physiolgenomics.00074.2001; Chu QJ, 2013, J SURG RES, V183, P330, DOI 10.1016/j.jss.2012.12.003; Chvatal SA, 2008, BIOMATERIALS, V29, P1967, DOI 10.1016/j.biomaterials.2008.01.002; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; Elrod JW, 2007, P NATL ACAD SCI USA, V104, P15560, DOI 10.1073/pnas.0705891104; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; Finnerup NB, 2001, SPINAL CORD, V39, P256, DOI 10.1038/sj.sc.3101161; Fiorucci S, 2007, BRIT J PHARMACOL, V150, P996, DOI 10.1038/sj.bjp.0707193; Fiorucci S, 2005, GASTROENTEROLOGY, V129, P1210, DOI 10.1053/j.gastro.2005.07.060; Geng B, 2004, BIOCHEM BIOPH RES CO, V313, P362, DOI 10.1016/j.bbrc.2003.11.130; Genovese T, 2006, J NEUROSURG-SPINE, V4, P145, DOI 10.3171/spi.2006.4.2.145; Genovese T, 2008, SHOCK, V30, P142, DOI 10.1097/SHK.0b013e31815dd381; Gomes-Leal W, 2005, BRAIN RES, V1066, P57, DOI 10.1016/j.brainres.2005.10.069; Gong QH, 2010, PHARMACOL BIOCHEM BE, V96, P52, DOI 10.1016/j.pbb.2010.04.006; Goubern M, 2007, FASEB J, V21, P1699, DOI 10.1096/fj.06-7407com; Kearney PM, 2006, BMJ-BRIT MED J, V332, P1302, DOI 10.1136/bmj.332.7553.1302; Kimura H, 2005, ANTIOXID REDOX SIGN, V7, P778, DOI 10.1089/ars.2005.7.778; Kimura H, 2012, ANTIOXID REDOX SIGN, V17, P45, DOI 10.1089/ars.2011.4345; Kimura Y, 2004, FASEB J, V18, P1165, DOI 10.1096/fj.04-1815fje; Kimura Y, 2010, ANTIOXID REDOX SIGN, V12, P1, DOI 10.1089/ars.2008.2282; Kruman II, 1999, J NEUROCHEM, V72, P529, DOI 10.1046/j.1471-4159.1999.0720529.x; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; La Rosa G, 2004, J NEUROSURG-SPINE, V1, P311, DOI 10.3171/spi.2004.1.3.0311; Li L, 2005, FASEB J, V19, P1196, DOI 10.1096/fj.04-3583fje; Li L, 2009, FREE RADICAL BIO MED, V47, P103, DOI 10.1016/j.freeradbiomed.2009.04.014; Lin H, 2006, ANN NEUROL, V60, P399, DOI 10.1002/ana.20965; Liu KL, 2006, J AGR FOOD CHEM, V54, P3472, DOI 10.1021/jf060043k; Malaspina A, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-500; Matsuyama Y, 1998, J SPINAL DISORD, V11, P248; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; Mor-Vaknin N, 2003, NAT CELL BIOL, V5, P59, DOI 10.1038/ncb898; Pedersen MO, 2009, BIOFACTORS, V35, P315, DOI 10.1002/biof.44; Resnick DK, 2004, NEUROREPORT, V15, P837, DOI 10.1097/00001756-200404090-00020; Schmitt Caroline, 2006, Spine J, V6, P113, DOI 10.1016/j.spinee.2005.05.379; Scott GS, 2005, P NATL ACAD SCI USA, V102, P3483, DOI 10.1073/pnas.0500307102; Siddall PJ, 2003, PAIN, V103, P249, DOI 10.1016/S0304-3959(02)00452-9; TAKAHASHI H, 1981, J NEUROSURG, V55, P708, DOI 10.3171/jns.1981.55.5.0708; Tan BH, 2010, NEUROCHEM INT, V56, P3, DOI 10.1016/j.neuint.2009.08.008; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; Verma IM, 2004, ANN RHEUM DIS, V63, P57, DOI 10.1136/ard.2004.028266; Wallace JL, 2008, Patent Application, Patent No. [WO/2008/009127, 2008009127]; Wallace JL, 2007, FASEB J, V21, P4070, DOI 10.1096/fj.07-8669com; Wallace JL, 2007, TRENDS PHARMACOL SCI, V28, P501, DOI 10.1016/j.tips.2007.09.003; Wallace JL, 2007, GASTROENTEROLOGY, V132, P261, DOI 10.1053/j.gastro.2006.11.042; Wallace JL, 2010, BRIT J PHARMACOL, V159, P1236, DOI 10.1111/j.1476-5381.2009.00611.x; Whiteman M, 2004, J NEUROCHEM, V90, P765, DOI 10.1111/j.1471-4159.2004.02617.x; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yip PK, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-6; Zanardo RCO, 2006, FASEB J, V20, P2118, DOI 10.1096/fj.06-6270fje; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008	61	32	35	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2013	27	11					4489	4499		10.1096/fj.13-234716			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	292YB	WOS:000329937500016	23901068				2021-06-18	
J	Galetto, V; Andreetta, S; Zettin, M; Marini, A				Galetto, Valentina; Andreetta, Sara; Zettin, Marina; Marini, Andrea			Patterns of impairment of narrative language in mild traumatic brain injury	JOURNAL OF NEUROLINGUISTICS			English	Article						Mild traumatic brain injury; Narrative analysis; Neurolinguistics; Neuropsychology	CLOSED-HEAD-INJURY; DISCOURSE PRODUCTION; COMMUNICATION DISORDERS; MEASURING GOODNESS; STORY NARRATIVES; APHASIC ADULTS; ABILITIES; AGREEMENT; COHERENCE; SPEECH	Mild traumatic brain injury (mTBI) represents a condition whose cognitive and behavioral sequelae are often underestimated, even when it exerts a profound impact on the patients' every-day life. The present study aimed to analyze the features of narrative discourse impairment in a group of adults with mTBI. 10 mTBI non-aphasic speakers (GCS>13) and 13 neurologically intact participants were recruited for the experiment. Their cognitive, linguistic and narrative skills were thoroughly assessed. The group of mTBIs exhibited normal phonological, lexical and grammatical skills. However, their narratives were characterized by the presence of frequent interruptions of ongoing utterances, derailments and extraneous utterances that at times made their discourse vague and ambiguous. They produced more errors of global coherence [F (1; 21)=24.242; p=.000; eta(2)(p)=0. 536] and fewer Lexical Information Units [F (1; 21)=7.068; p=.015; eta(2)(p)=.252]. The errors of global coherence correlated negatively with non-perseverative errors on the WCST (r=.755; p <.012). The macrolinguistic problems made their narrative samples less informative than those produced by the group of control participants. These disturbances may reflect a deficit at the interface between cognitive and linguistic processing rather than a specific linguistic disturbance. These findings suggest that also persons with mild forms of TBI may experience linguistic disturbances that may hamper the quality of their every-day life. (C) 2013 Elsevier Ltd. All rights reserved.	[Galetto, Valentina] Ctr Puzzle, Turin, Italy; [Galetto, Valentina; Zettin, Marina] Univ Turin, Dipartimento Psicol, I-10124 Turin, Italy; [Andreetta, Sara; Marini, Andrea] Univ Udine, Dipartimento Sci Umane, I-33100 Udine, Italy; [Marini, Andrea] IRCCS E Medea Nostra Famiglia, San Vito Al Tagliamento, Pn, Italy	Marini, A (corresponding author), Univ Udine, Via Margreth 3, I-33100 Udine, Italy.	andrea.marini@uniud.it	Andreetta, Sara/AAL-5932-2021; Marini, Andrea/A-1206-2012	Andreetta, Sara/0000-0002-8067-2629; Marini, Andrea/0000-0002-6058-3864	IRCCS "E. Medea"	Funding for this study was provided by IRCCS "E. Medea". The IRCCS "E. Medea" had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.	Adamovich B. L. B., 1997, APHASIA RELATED NEUR, P93; Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Blyth T, 2012, BRAIN INJURY, V26, P234, DOI 10.3109/02699052.2012.654587; Body R, 2004, BRAIN INJURY, V18, P707, DOI 10.1080/02699050310001596914; Body R., 1999, COMMUNICATION TRAUMA; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Cannizzaro MS, 2002, BRAIN INJURY, V16, P1065, DOI 10.1080/02699050210155230; Carletta J, 1996, COMPUT LINGUIST, V22, P249; Carlomagno S, 2011, BRAIN INJURY, V25, P1010, DOI 10.3109/02699052.2011.605097; CHRISTIANSEN JA, 1995, BRAIN LANG, V51, P291, DOI 10.1006/brln.1995.1062; COELHO C A, 1991, Brain Injury, V5, P381, DOI 10.3109/02699059109008111; Coelho C. A., 1994, STUDIES ADULT CLIN P, P96; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Coelho C, 2012, NEUROPSYCHOLOGIA, V50, P3564, DOI 10.1016/j.neuropsychologia.2012.09.005; Davis GA, 2004, BRAIN LANG, V89, P508, DOI 10.1016/j.bandl.2004.01.003; DAVIS GA, 2000, APHASIOLOGY DISORDER; Erez ABH, 2009, AM J OCCUP THER, V63, P634; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; GLOSSER G, 1991, BRAIN LANG, V40, P67, DOI 10.1016/0093-934X(91)90117-J; GRAHAM DI, 1999, REHABILITATION ADULT, P19; Groher M. E., 1997, DYSPHAGIA DIAGNOSIS; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Heaton R., 1993, WISCONSIN CARD SORTI; Hinchliffe FJ, 1998, BRAIN INJURY, V12, P109, DOI 10.1080/026990598122746; HUBER W, 1982, BRAIN LANG, V16, P1, DOI 10.1016/0093-934X(82)90069-4; Kertesz A., 1982, W APHASIA BATTERY; Kraus J. F., 1996, NEUROLOGY TRAUMA; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Le K, 2011, APHASIOLOGY, V25, P748, DOI 10.1080/02687038.2010.539696; Le K, 2011, J SPEECH LANG HEAR R, V54, P118, DOI 10.1044/1092-4388(2010/09-0022); Levelt WJM, 1999, BEHAV BRAIN SCI, V22, P1; Luzzatti C., 1991, AACHENER APHASIE TES; Marini A, 2005, BRAIN LANG, V93, P46, DOI 10.1016/j.bandl.2004.08.002; Marini A, 2008, SCHIZOPHR RES, V105, P144, DOI 10.1016/j.schres.2008.07.011; Marini A, 2011, APHASIOLOGY, V25, P1372, DOI 10.1080/02687038.2011.584690; Marini A, 2012, J COGNITIVE NEUROSCI, V24, P2211, DOI 10.1162/jocn_a_00283; Marini A, 2011, NEUROPSYCHOLOGIA, V49, P2904, DOI 10.1016/j.neuropsychologia.2011.06.017; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; McDonald S, 2000, APHASIOLOGY, V14, P339, DOI 10.1080/026870300401397; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Miyake Akira, 2000, Seminars in Speech and Language, V21, P169, DOI 10.1055/s-2000-7563; Monsell S., 1996, UNSOLVED MYSTERIES M, P93; Mozeiko J, 2011, APHASIOLOGY, V25, P826, DOI 10.1080/02687038.2010.543983; NICHOLAS LE, 1993, J SPEECH HEAR RES, V36, P338, DOI 10.1044/jshr.3602.338; Parrish C., 2011, PERSPECTIVES NEUROPH, P47; Raven J. C., 1938, PROGR MATRICES PERCE; Reitan R. M, 1992, TRAIL MAKING TEST; REITAN RM, 1992, CLIN NEUROPSYCHOL, V6, P287; Rey A, 1964, EXAMEN CLIN PSYCHOL; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; SAFFRAN EM, 1989, BRAIN LANG, V37, P440, DOI 10.1016/0093-934X(89)90030-8; SHEWAN CM, 1988, J COMMUN DISORD, V21, P103, DOI 10.1016/0021-9924(88)90001-9; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow PC, 2000, BRAIN INJURY, V14, P397; Spalletta G, 2010, PSYCHIAT RES-NEUROIM, V182, P77, DOI 10.1016/j.pscychresns.2009.11.001; Stierwalt Julie A. G., 2002, Seminars in Speech and Language, V23, P129, DOI 10.1055/s-2002-24989; Stout CE, 2000, J MED SPEECH-LANG PA, V8, P15; Thompson PM, 1996, NEUROIMAGE, V3, P19, DOI 10.1006/nimg.1996.0003; Tucker FM, 1998, BRAIN INJURY, V12, P783, DOI 10.1080/026990598122179; Turkstra LS, 1996, BRAIN INJURY, V10, P329, DOI 10.1080/026990596124359; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Whelan BM, 2006, BRAIN LANG, V99, P183, DOI 10.1016/j.bandl.2006.06.100; Ylvisaker M., 2001, LANGUAGE INTERVENTIO, P745; Youse KM, 2005, BRAIN INJURY, V19, P1001, DOI 10.1080/02699050500109951	66	32	32	0	37	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0911-6044			J NEUROLINGUIST	J. Neurolinguist.	NOV	2013	26	6					649	661		10.1016/j.jneuroling.2013.05.004			13	Linguistics; Neurosciences; Psychology, Experimental	Linguistics; Neurosciences & Neurology; Psychology	213RS	WOS:000324078000005					2021-06-18	
J	Sasse, N; Gibbons, H; Wilson, L; Martinez-Olivera, R; Schmidt, H; Hasselhorn, M; von Wild, K; von Steinbuchel, N				Sasse, Nadine; Gibbons, Henning; Wilson, Lindsay; Martinez-Olivera, Ramon; Schmidt, Holger; Hasselhorn, Marcus; von Wild, Klaus; von Steinbuechel, Nicole			Self-Awareness and Health-Related Quality of Life After Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						health-related quality of life; impaired self-awareness; self-awareness	THERAPEUTIC WORKING ALLIANCE; COMPETENCE RATING-SCALE; IMPAIRED AWARENESS; HOSPITAL ANXIETY; REHABILITATION; DEPRESSION; VALIDITY; DEFICITS; MODERATE; QOLIBRI	Objective: To investigate the relations among self-awareness (SA), impaired SA, and health-related quality of life (HRQOL) after traumatic brain injury (TBI). Participants: One hundred forty-one adults hospitalized with TBI and their significant others from a cross-sectional multicenter study. Using Glasgow Coma Scale classification, 32 participants had severe injuries, 29 moderate, 44 mild, and 25 complicated mild TBI. Measures: Patient Competency Rating Scale for Neurorehabilitation; Short Form-36 Health Survey; Cognitive Quality of Life; Quality Of Life after Brain Injury; Hospital Anxiety and Depression Scale; Profile of Mood States; Glasgow Outcome Scale Extended. Method: Patient Competency Rating Scale for Neurorehabilitation ratings made by participants and their significant others were used to assess SA and discrepancies between the 2 ratings were used to define impaired SA. Results: Significant associations were identified between SA and HRQOL, anxiety, depression, and severity of injury. Participants with and without impaired SA differed in cognitive HRQOL and leisure activities. Using multiple regression, no direct predictors of SA were identified, although interaction effects were observed. Conclusion: After TBI, lower SA is associated with higher estimates of HRQOL, particularly in the cognitive domain. Although the associations are modest, the assessment of SA should play a role in the interpretation of reported HRQOL after TBI.	[Sasse, Nadine; Gibbons, Henning; von Steinbuechel, Nicole] Univ Med Ctr, Dept Med Psychol & Med Sociol, Gottingen, Germany; [Martinez-Olivera, Ramon] Univ Med Ctr, Dept Neurosurg, Gottingen, Germany; [Schmidt, Holger] Univ Med Ctr, Dept Neurol, Gottingen, Germany; [Wilson, Lindsay] Univ Stirling, Dept Psychol, Stirling FK9 4LA, Scotland; [Hasselhorn, Marcus] German Inst Int Educ Res DIPF, Frankfurt, Germany; [von Wild, Klaus] KvW Neurosci Consulting, Munster, Germany	Sasse, N (corresponding author), Univ Med Ctr Gottingen, Dept Med Psychol & Med Sociol, Waldweg 37, D-37073 Gottingen, Germany.	n.sasse@med.uni-goettingen.de	Wilson, Lindsay/O-8883-2019; Wilson, Lindsay/A-3659-2009	Wilson, Lindsay/0000-0003-4113-2328; Wilson, Lindsay/0000-0003-4113-2328	ZNS-Hannelore Kohl Foundation, Germany [2008014]	This study was funded by the ZNS-Hannelore Kohl Foundation, Germany (project number 2008014). Participant recruitment was assisted by Professor K. M. Sturmer and Dr S. Sehmisch, Trauma Surgery, Plastic and Reconstructive Surgery, University Medical Center Gottingen (UMG); Professor V. Rohde, Neurosurgery, UMG; Professor R. Behr, Neurosurgery, Clinical Center Fulda; Professor W. Deinsberger, Neurosurgery, Clinical Center Kassel and Dr W. Puschendorf, Westend Neurological Clinic, Bad Wildungen. The authors thank all these collaborators and individuals after TBI and their significant others who participated in this study.	Acquadro C, 1996, QUALITY LIFE PHARMAC; Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Borgaro SR, 2003, BRAIN INJURY, V17, P847, DOI 10.1080/0269905031000089350; Bullinger M., 1990, Z DIFFERENTIELLE DIA, V11, P53; Bullinger M., 1995, Z GESUNDHEITSWISSENS, V3, P21, DOI [10.1007/BF02959944, DOI 10.1007/BF02959944]; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dirette DK, 2007, BRAIN INJURY, V21, P1131, DOI 10.1080/02699050701687326; Eid M, 2003, ENTWICKLUND VALIDIER; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; Pagulayan KF, 2007, J INT NEUROPSYCH SOC, V13, P561, DOI 10.1017/S1355617707070713; Fischer S, 2004, BRAIN INJURY, V18, P547, DOI 10.1080/02699050310001645793; FLEMING J, 1997, BRIT J OCCUPATIONAL, V60, P295, DOI DOI 10.1177/030802269706000703; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; Fleming JM, 1996, BRAIN INJURY, V10, P1; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Garmoe W, 2005, J HEAD TRAUMA REHAB, V20, P348, DOI 10.1097/00001199-200507000-00006; Goverover Y, 2007, BRAIN INJURY, V21, P913, DOI 10.1080/02699050701553205; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P161, DOI 10.1080/09602010802188393; Herrmann-Lingen Ch, 1995, HOSPITAL ANXIETY DEP; Hoofien D, 2004, J CLIN EXP NEUROPSYC, V26, P278, DOI 10.1076/jcen.26.2.278.28084; JENNETT B, 1975, LANCET, V1, P480; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Malec JF, 2007, J HEAD TRAUMA REHAB, V22, P156, DOI 10.1097/01.HTR.0000271116.12028.af; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; McNair DM, 1971, EITS MANUAL PROFILE; Noe E, 2005, J NEUROL, V252, P168, DOI 10.1007/s00415-005-0625-2; O'Callaghan C, 2006, NEUROPSYCHOL REHABIL, V16, P579, DOI 10.1080/09602010500368834; Prigatano G. P., 1991, AWARENESS DEFICIT BR; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano GP, 2005, ACT NEUR S, V93, P39; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Sawchyn JM, 2005, J HEAD TRAUMA REHAB, V20, P301, DOI 10.1097/00001199-200507000-00003; Schonberger M, 2006, BRAIN INJURY, V20, P445, DOI 10.1080/02699050600664772; Schonberger M, 2006, BRAIN INJURY, V20, P1271, DOI 10.1080/02699050601049395; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 2003, BRAIN INJURY, V17, P25, DOI 10.1080/0269905021000010113; Spilker B, 1996, QUALITY LIFE PHARMAC; Sveen U, 2008, CLIN REHABIL, V22, P45, DOI 10.1177/0269215507080768; Svendsen HA, 2006, BRAIN INJURY, V20, P1295, DOI 10.1080/02699050601082123; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 1998, J NEUROTRAUM, V15, P537; The WHOQOL Group, 1993, QUAL LIFE RES, V2, P153, DOI DOI 10.1007/BF00435734; Trahan E, 2006, J HEAD TRAUMA REHAB, V21, P226, DOI 10.1097/00001199-200605000-00003; Vanderploeg RD, 2007, J REHABIL RES DEV, V44, P937, DOI 10.1682/JRRD.2006.12.0163; von Steinbuechel N, 2005, ACTA NEUROCHIR SUPPL, V93, P43; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1167, DOI 10.1089/neu.2009.1076; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Wise K, 2005, BRAIN INJURY, V19, P765, DOI 10.1080/0269905050019977; Wustenhagen S., 2009, THESIS U MEDICAL CTR; Yeates G, 2007, NEUROPSYCHOL REHABIL, V17, P151, DOI 10.1080/09602010600696423; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	56	32	33	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2013	28	6					464	472		10.1097/HTR.0b013e318263977d			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	299AA	WOS:000330365200011	22935572				2021-06-18	
J	Glushakov, AV; Robbins, SW; Bracy, CL; Narumiya, S; Dore, S				Glushakov, Alexander V.; Robbins, Sean W.; Bracy, Connor L.; Narumiya, Shuh; Dore, Sylvain			Prostaglandin F-2 alpha FP receptor antagonist improves outcomes after experimental traumatic brain injury	JOURNAL OF NEUROINFLAMMATION			English	Article						AL-8810; Controlled cortical impact; Glial fibrillary astrocytic protein; G-protein-coupled receptors; Knockout mice; Prostaglandin F2a receptor; Traumatic brain injury	PGE(2) EP1 RECEPTOR; HUMAN CEREBROSPINAL-FLUID; ACID-INDUCED SEIZURE; FREE FATTY-ACIDS; CEREBRAL-ISCHEMIA; INTRACEREBRAL HEMORRHAGE; PATHOLOGICAL CONDITIONS; CORTICAL CONTUSION; STRAIN DIFFERENCES; BARRIER BREAKDOWN	Background: Injuries to the brain promote upregulation of prostaglandins, notably the proinflammatory PGF(2 alpha), and overactivation of their cognate G-protein-coupled FP receptor, which could exacerbate neuronal damage. Our study is focused on investigation of the FP receptor as a target for novel neuroprotective drugs in a preclinical animal traumatic brain injury (TBI) model. Methods: Accordingly, the effects of acute intraperitoneal post-treatment with selective FP antagonist AL-8810 were studied in wildtype (WT) and FP receptor knockout (FP-/-) mice after controlled cortical impact (CCI). Neurological impairments were evaluated using neurological deficit scores (NDS) and the grip strength test. Cortical lesions and overall brain pathology were assessed using immunohistochemistry. Results: Morphological analyses of cerebral vasculature and anastomoses revealed no differences between WT and FP-/- mice. CCI produced cortical lesions characterized by cavitation, neuronal loss, and hematoma with a volume of 20.0 +/- 1.0 mm(3) and significant hippocampal swelling (146.5 +/- 7.4% of contralateral) compared with sham (P < 0.05). Post-treatment with AL-8810 (1 to 10 mg/kg) had no significant effect on cortical lesions, which suggests the irreversible effect of primary CCI injury, but significantly reduced hippocampal swelling to a size not significantly different from the sham group. Post-treatment with AL-8810 at a dose of 10 mg/kg significantly improved NDS at 24 and 48 hours after CCI (P < 0.001 and P < 0.01, respectively). In the AL-8810 group, CCI-induced decrease in grip strength was three-fold (2.93 +/- 1.71) less and significantly different than in the saline-treated group. The FP-/- mice had significantly less hippocampal swelling, but not NDS, compared with WT mice. In addition, immunohistochemistry showed that pharmacologic blockade and genetic deletion of FP receptor led to attenuation of CCI-induced gliosis and microglial activation in selected brain regions. Conclusion: This study provides, for the first time, demonstration of the unique role of the FP receptor as a potential target for disease-modifying CNS drugs for treatment of acute traumatic injury.	[Glushakov, Alexander V.; Robbins, Sean W.; Bracy, Connor L.; Dore, Sylvain] Univ Florida, Coll Med, Dept Anesthesiol, Gainesville, FL 32610 USA; [Narumiya, Shuh] Kyoto Univ, Fac Med, Dept Pharmacol, Sakyo Ku, Kyoto 606, Japan; [Dore, Sylvain] Univ Florida, Coll Med, Dept Neurosci, Gainesville, FL 32610 USA; [Dore, Sylvain] Univ Florida, Coll Med, Ctr Translat Res Neurodegenerat Dis, Gainesville, FL 32610 USA	Dore, S (corresponding author), Univ Florida, Coll Med, Dept Anesthesiol, POB 100159, Gainesville, FL 32610 USA.	sdore@ufl.edu	Dore, Sylvain/AAG-1470-2020; Glushakov, Alexander V/B-5452-2008	Glushakov, Alexander V/0000-0003-2872-8960; Dore, Sylvain/0000-0003-3771-5109	McKnight Brain Research Foundation; Brain and Spinal Cord Injury Research Trust Fund; National Institute of Heath [NS046400]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS046400] Funding Source: NIH RePORTER	This work was supported by a grant from the McKnight Brain Research Foundation, Brain and Spinal Cord Injury Research Trust Fund, and the National Institute of Heath NS046400. Special thanks to Mr. Gerald R Boley, Jr. for technical assistance with immunohistochemistry, and to all Dorelab members for all their generous assistance.	Ahmad AS, 2008, NEUROTOX RES, V14, P343, DOI 10.1007/BF03033858; Ahmad AS, 2006, J NEUROTRAUM, V23, P1895, DOI 10.1089/neu.2006.23.1895; Ahmad AS, 2005, BRAIN RES, V1066, P71, DOI 10.1016/j.brainres.2005.10.068; Ahmad AS, 2006, TOXICOL SCI, V89, P265, DOI 10.1093/toxsci/kfj022; Ahmad Muzamil, 2010, Exp Transl Stroke Med, V2, P12, DOI 10.1186/2040-7378-2-12; Baik EJ, 1999, BRAIN RES, V843, P118, DOI 10.1016/S0006-8993(99)01797-7; BARONE FC, 1993, J CEREBR BLOOD F MET, V13, P683, DOI 10.1038/jcbfm.1993.87; Baskaya MK, 2000, J NEUROSURG, V92, P448, DOI 10.3171/jns.2000.92.3.0448; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bazan NG, 1995, J NEUROTRAUM, V12, P814; Beaumont A, 2000, ACTA NEUROCHIR SUPPL, V76, P125; BHATTACHARYA SK, 1978, PSYCHOPHARMACOLOGY, V56, P235, DOI 10.1007/BF00431857; BHATTACHARYA SK, 1978, PROSTAG LEUKOTR ESS, V1, P159, DOI 10.1016/0161-4630(78)90042-3; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Carlson NG, 2003, J NEUROSCI RES, V71, P79, DOI 10.1002/jnr.10465; Cendes F, 2004, CURR OPIN NEUROL, V17, P161, DOI 10.1097/00019052-200404000-00013; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Clark W, 1998, STROKE, V29, P2136, DOI 10.1161/01.STR.29.10.2136; CLIMAX J, 1981, ARCH INT PHARMACOD T, V250, P254; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Desjardins P, 2003, NEUROCHEM INT, V42, P299, DOI 10.1016/S0197-0186(02)00101-8; DHILLON HS, 1994, J NEUROTRAUM, V11, P405, DOI 10.1089/neu.1994.11.405; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Doi T, 2001, MOL BRAIN RES, V92, P107, DOI 10.1016/S0169-328X(01)00159-0; Dore S, 2006, TRENDS PHARMACOL SCI, V27, P458, DOI 10.1016/j.tips.2006.07.001; DUVDEVANI R, 1995, J NEUROTRAUM, V12, P65, DOI 10.1089/neu.1995.12.65; EGG D, 1980, J NEUROL, V222, P239, DOI 10.1007/BF00313153; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; Fox GB, 1999, J NEUROTRAUM, V16, P377, DOI 10.1089/neu.1999.16.377; Golge M, 2004, ARCH PHYS MED REHAB, V85, P1435, DOI 10.1016/j.apmr.2003.11.029; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Griffin BW, 1999, J PHARMACOL EXP THER, V290, P1278; HADHAZY P, 1988, PROSTAG LEUKOTR ESS, V32, P175, DOI 10.1016/0952-3278(88)90169-X; HAGEN AA, 1977, STROKE, V8, P672, DOI 10.1161/01.STR.8.6.672; HAYASHI S, 1985, J PHARMACOL EXP THER, V233, P628; Homayoun P, 2000, NEUROCHEM RES, V25, P269, DOI 10.1023/A:1007583806138; Homayoun P, 1997, J NEUROCHEM, V69, P199; Kim HJ, 2008, BRAIN RES, V1193, P153, DOI 10.1016/j.brainres.2007.12.017; Kim YT, 2012, NEUROBIOL DIS, V48, P58, DOI 10.1016/j.nbd.2012.06.003; KITANAKA J, 1991, BIOCHEM BIOPH RES CO, V178, P946, DOI 10.1016/0006-291X(91)90983-E; Kochanek PM, 2011, J TRAUMA, V71, pS15, DOI 10.1097/TA.0b013e31822117fe; KOSTIC VS, 1984, EUR NEUROL, V23, P291; Kuhtz-Buschbeck JP, 2003, ARCH PHYS MED REHAB, V84, P424, DOI 10.1053/apmr.2003.50017; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; LI DY, 1994, BRIT J PHARMACOL, V112, P59, DOI 10.1111/j.1476-5381.1994.tb13029.x; LI DY, 1995, J PHARMACOL EXP THER, V272, P15; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; LYNEHAM RC, 1973, LANCET, V2, P1003; Macleod MR, 2009, STROKE, V40, pE50, DOI 10.1161/STROKEAHA.108.525386; Maeda K, 1999, NEUROBIOL DIS, V6, P101, DOI 10.1006/nbdi.1998.0235; Majid A, 2000, STROKE, V31, P2707, DOI 10.1161/01.STR.31.11.2707; Matsushita Y, 2000, ACTA NEUROCHIR SUPPL, V76, P207; McIntosh TK, 1996, LAB INVEST, V74, P315; Mohan Shekher, 2012, Front Neurol, V3, P145, DOI 10.3389/fneur.2012.00145; Moser VC, 2011, TOXICOL PATHOL, V39, P36, DOI 10.1177/0192623310385255; Muller K, 2000, CARCINOGENESIS, V21, P1063, DOI 10.1093/carcin/21.5.1063; Rantala H, 2001, EPILEPSY RES, V46, P251, DOI 10.1016/S0920-1211(01)00281-9; Reid WM, 2010, J NEUROTRAUM, V27, P1243, DOI 10.1089/neu.2010.1270; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saleem S, 2009, NEUROTOX RES, V15, P62, DOI 10.1007/s12640-009-9007-3; Schauwecker PE, 1997, P NATL ACAD SCI USA, V94, P4103, DOI 10.1073/pnas.94.8.4103; SEDERBERGOLSEN J, 1983, ACTA OBSTET GYN SCAN, V62, P79, DOI 10.3109/00016348309155765; Sharma AK, 2007, TOXICOL PATHOL, V35, P984, DOI 10.1080/01926230701748305; SHEARMAN RP, 1975, BRIT J OBSTET GYNAEC, V82, P314, DOI 10.1111/j.1471-0528.1975.tb00641.x; Singh N, 2013, NEUROTOX RES, V24, P549, DOI 10.1007/s12640-013-9410-7; Steward O, 1999, EXP NEUROL, V157, P19, DOI 10.1006/exnr.1999.7040; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TAMAI I, 1983, BRAIN DEV-JPN, V5, P357, DOI 10.1016/S0387-7604(83)80039-4; Tan AA, 2009, J NEUROTRAUM, V26, P539, DOI 10.1089/neu.2008.0611; TOH H, 1995, FEBS LETT, V361, P17, DOI 10.1016/0014-5793(95)00129-W; Tomimoto H, 2000, ACTA NEUROPATHOL, V99, P26, DOI 10.1007/PL00007402; Tomimoto H, 2002, ACTA NEUROPATHOL, V104, P601, DOI 10.1007/s00401-002-0590-0; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Topol EJ, 2004, NEW ENGL J MED, V351, P1707, DOI 10.1056/NEJMp048286; Toti P., 2001, Journal of Submicroscopic Cytology and Pathology, V33, P245; Wang KKW, 2006, CURR OPIN NEUROL, V19, P514, DOI 10.1097/WCO.0b013e3280102b10; WILLMORE LJ, 1991, INT J DEV NEUROSCI, V9, P175, DOI 10.1016/0736-5748(91)90009-B; WISLICKI L, 1982, INT J BIOL RES PREG, V3, P158; WOLFE LS, 1975, PROSTAGLANDINS, V9, P183, DOI 10.1016/0090-6980(75)90023-4; Woodward DF, 2011, PHARMACOL REV, V63, P471, DOI 10.1124/pr.110.003517; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067	84	32	32	0	1	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	OCT 30	2013	10								132	10.1186/1742-2094-10-132			14	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	282XB	WOS:000329206700001	24172576	DOAJ Gold, Green Published			2021-06-18	
J	Zimmerman, RM; Kalish, LA; Hresko, MT; Waters, PM; Bae, DS				Zimmerman, Ryan M.; Kalish, Leslie A.; Hresko, M. Timothy; Waters, Peter M.; Bae, Donald S.			Surgical Management of Pediatric Radial Neck Fractures	JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME			English	Article							DISPLACED FRACTURES; CHILDREN; HEAD; REDUCTION; FIXATION	Background: Management of pediatric radial neck fractures is controversial regarding acceptable alignment, variable reduction techniques, and suboptimal outcomes. The purpose of this study was to assess the characteristics, management, and results in a surgical cohort, in efforts to identify prognostic factors and offer treatment suggestions. It was hypothesized that less invasive reduction maneuvers would precede open reduction and that worse results would correlate with fracture severity, open reduction, and the presence of associated injuries. Methods: Retrospective analysis of 151 children in whom a radial neck fracture had been surgically treated from 2001 to 2011 was performed. The mean age (and standard deviation) and duration of follow-up were 8.4 +/- 2.9 years and 13.3 +/- 20.0 months, respectively; 40% of the patients were male. A successful clinical result was defined as elbow flexion of >= 120 degrees, flexion contracture of <20 degrees, forearm rotation of >= 90 degrees with >= 45 degrees of supination and pronation, and no complications. Results: An isolated radial neck fracture occurred in 54% of the children. The mean angulation and displacement improved from 43 degrees +/- 19 degrees and 37% +/- 35%, respectively, before treatment to 13 degrees +/- 7 degrees and 0.9% +/- 4% after treatment (p < 0.001). Twenty-two procedural combinations were used to treat these patients, and 67% of the open reductions were not preceded by percutaneous or closed reduction attempts. Among 131 patients with adequate follow-up, 31% had an unsuccessful outcome. An age of ten years or more (odds ratio [OR] = 5.85, p = 0.001), a time to surgery of two days or less (OR = 4.73, p = 0.02), and greater fracture displacement (OR = 1.25 per 10%, p = 0.001) were independent predictors of unsuccessful outcomes. Increased fracture severity and open reduction were associated with poor results, although the presence of concomitant injuries was not. It is predicted that closed manipulation will fail for half of fractures angulated >= 36 degrees, and that half of fractures displaced >= 65% will require open reduction. The predicted frequency of unsuccessful outcomes is 50% with 76% displacement. Conclusions: There continues to be great variation in the approach to treatment of displaced radial neck fractures in children. Suboptimal results occurred in 31% of the patients in this series, with worse results in patients older than ten years, who had increased fracture severity, and who underwent open reduction. Less invasive reduction methods should precede open reduction whenever possible.	[Zimmerman, Ryan M.; Kalish, Leslie A.; Hresko, M. Timothy; Waters, Peter M.; Bae, Donald S.] Boston Childrens Hosp, Dept Orthoped Surg, Boston, MA USA	Zimmerman, RM (corresponding author), Massachusetts Gen Hosp, 55 Fruit St,WHT 535, Boston, MA 02114 USA.	Donald.Bae@childrens.harvard.edu					BLOUNT W P, 1950, J Iowa State Med Soc, V40, P203; Brandao GF, 2010, J PEDIATR ORTHOPED, V30, P110, DOI 10.1097/BPO.0b013e3181cf118a; CHAO EY, 1980, J BIOMECH ENG-T ASME, V102, P301, DOI 10.1115/1.3138227; COOPER JE, 1993, ARCH PHYS MED REHAB, V74, P805, DOI 10.1016/0003-9993(93)90005-U; DSOUZA S, 1993, J PEDIATR ORTHOPED, V13, P232; Eberl R, 2010, EUR J PEDIATR SURG, V20, P250, DOI 10.1055/s-0030-1249104; Endele SM, 2010, J PEDIATR ORTHOP B, V19, P246, DOI 10.1097/BPB.0b013e32833918c0; Evans MC, 1999, J PEDIATR ORTHOP B, V8, P93; FOWLES JV, 1986, J PEDIATR ORTHOPED, V6, P51; Futami T, 1995, J Shoulder Elbow Surg, V4, P162; Garcia-Alvarez F, 2001, Chir Organi Mov, V86, P211; HENRIKSON B, 1969, ACTA ORTHOP SCAND, V40, P246, DOI 10.3109/17453676908989505; JONES E R L, 1971, Journal of Bone and Joint Surgery British Volume, V53, P429; Klitscher D, 2009, J PEDIATR ORTHOPED, V29, P698, DOI 10.1097/BPO.0b013e3181b76895; LANDIN LA, 1983, ACTA ORTHOP SCAND, V54, P1; Magermans DJ, 2005, CLIN BIOMECH, V20, P591, DOI 10.1016/j.clinbiomech.2005.02.006; METAIZEAU JP, 1993, J PEDIATR ORTHOPED, V13, P355, DOI 10.1097/01241398-199305000-00015; MORREY BF, 1981, J BONE JOINT SURG AM, V63, P872, DOI 10.2106/00004623-198163060-00002; Navali AM, 2006, J HAND SURG-BRIT EUR, V31B, P689, DOI 10.1016/j.jhsb.2006.04.020; Neher CG, 2003, J PEDIATR ORTHOPED, V23, P626, DOI 10.1097/01241398-200309000-00009; NEWMAN JH, 1977, INJURY, V9, P114, DOI 10.1016/0020-1383(77)90004-3; O'Brien P I, 1965, Clin Orthop Relat Res, V41, P51; Petuskey K, 2007, GAIT POSTURE, V25, P573, DOI 10.1016/j.gaitpost.2006.06.006; Prathapkumar KR, 2006, J BONE JOINT SURG BR, V88B, P358, DOI 10.1302/0301-620X.88B3.17099; Schmittenbecher PP, 2005, J PEDIATR ORTHOPED, V25, P45; Shukla DR, 2012, J SHOULDER ELB SURG, V21, P789, DOI 10.1016/j.jse.2011.12.001; STEINBERG EL, 1988, J PEDIATR ORTHOPED, V8, P35, DOI 10.1097/01241398-198801000-00009; Tan Bryan Hsi Ming, 2011, J Orthop Surg (Hong Kong), V19, P209; TIBONE JE, 1981, J BONE JOINT SURG AM, V63, P100, DOI 10.2106/00004623-198163010-00013; Ugutmen E, 2010, J PEDIATR ORTHOP B, V19, P289, DOI 10.1097/BPB.0b013e32833918a0; VAHVANEN V, 1978, ACTA ORTHOP SCAND, V49, P32, DOI 10.3109/17453677809005720; Vocke AK, 1998, J PEDIATR ORTHOP B, V7, P217, DOI 10.1097/01202412-199807000-00007	32	32	38	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0021-9355	1535-1386		J BONE JOINT SURG AM	J. Bone Joint Surg.-Am. Vol.	OCT 16	2013	95A	20					1825	1832		10.2106/JBJS.L.01130			8	Orthopedics; Surgery	Orthopedics; Surgery	244DQ	WOS:000326367700002	24132355				2021-06-18	
J	Lyons, MJ; Genderson, M; Grant, MD; Logue, M; Zink, T; McKenzie, R; Franz, CE; Panizzon, M; Lohr, JB; Jerskey, B; Kremen, WS				Lyons, Michael J.; Genderson, Margo; Grant, Michael D.; Logue, Mark; Zink, Tyler; McKenzie, Ruth; Franz, Carol E.; Panizzon, Matthew; Lohr, James B.; Jerskey, Beth; Kremen, William S.			Gene-Environment Interaction of ApoE Genotype and Combat Exposure on PTSD	AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS			English	Article						posttraumatic stress disorder; apoE; genetics; GxE interaction	POSTTRAUMATIC-STRESS-DISORDER; SEROTONIN TRANSPORTER GENOTYPE; APOLIPOPROTEIN-E EPSILON-4; TRAUMATIC BRAIN-INJURY; CHILDHOOD ADVERSITY; 5-HTTLPR GENOTYPE; ENTORHINAL CORTEX; OLDER-ADULTS; ASSOCIATION; RISK	Factors determining who develops PTSD following trauma are not well understood. The Euro4 allele of the apolipoprotein E (apoE) gene is associated with dementia and unfavorable outcome following brain insult. PTSD is also associated with dementia. Given evidence that psychological trauma adversely affects the brain, we hypothesized that the apoE genotype moderates effects of psychological trauma on PTSD pathogenesis. To investigate the moderation of the relationship between PTSD symptoms and combat exposure, we used 172 participants with combat trauma sustained during the Vietnam War. PTSD symptoms were the dependent variable and number of combat experiences, apoE genotype, and the combat experiencesxapoE genotype interaction were predictors. We also examined the outcome of a diagnosis of PTSD (n=39) versus no PTSD diagnosis (n=131). The combatxapoE genotype interaction was significant for both PTSD symptoms (P=.014) and PTSD diagnosis (P=.009). ApoE genotype moderates the relationship between combat exposure and PTSD symptoms. Although the pathophysiology of PTSD is not well understood, the Euro4 allele is related to reduced resilience of the brain to insult. Our results are consistent with the Euro4 allele influencing the effects of psychological trauma on the brain, thereby affecting the risk of PTSD. (c) 2013 Wiley Periodicals, Inc.	[Lyons, Michael J.; Genderson, Margo; Grant, Michael D.; Logue, Mark; Zink, Tyler; McKenzie, Ruth] Boston Univ, Boston, MA 02215 USA; [Franz, Carol E.; Panizzon, Matthew; Lohr, James B.; Kremen, William S.] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; [Lohr, James B.; Kremen, William S.] VA San Diego Healthcare Syst, San Diego, CA USA; [Jerskey, Beth] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA	Lyons, MJ (corresponding author), Boston Univ, Dept Psychol, 64 Cummington Mall, Boston, MA 02215 USA.	mlyons@bu.edu		Franz, Carol/0000-0002-8987-1755; Lyons, Michael/0000-0001-6516-9219; Kremen, William/0000-0002-8629-5609	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 AG018386, R01 AG022982, R01 AG018384, R01 AG022381, K01 MH076100]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K01MH076100] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG018384, R01AG022982, R01AG022381, R01AG018386] Funding Source: NIH RePORTER	Grant sponsor: NIH; Grant numbers: R01 AG018386; R01 AG022982; R01 AG018384; R01 AG022381; K01 MH076100.	Amstadter AB, 2012, TWIN RES HUM GENET, V15, P656, DOI 10.1017/thg.2012.43; Amstadter AB, 2009, PSYCHIATRY, V72, P360, DOI 10.1521/psyc.2009.72.4.360; Binder EB, 2008, JAMA-J AM MED ASSOC, V299, P1291, DOI 10.1001/jama.299.11.1291; Boscarino JA, 2012, NEUROPSYCH DIS TREAT, V8, P131, DOI 10.2147/NDT.S29508; Breslau N, 2009, TRAUMA VIOLENCE ABUS, V10, P198, DOI 10.1177/1524838009334448; Carlin JB, 2005, INT J EPIDEMIOL, V34, P1089, DOI 10.1093/ije/dyi153; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Duncan LE, 2011, AM J PSYCHIAT, V168, P1041, DOI 10.1176/appi.ajp.2011.11020191; EMI M, 1988, GENOMICS, V3, P373, DOI 10.1016/0888-7543(88)90130-9; Fennema-Notestine C, 2011, J ALZHEIMERS DIS, V26, P49, DOI 10.3233/JAD-2011-0002; Freeman T, 2005, J NEUROPSYCH CLIN N, V17, P541, DOI 10.1176/appi.neuropsych.17.4.541; Gilbertson MW, 2002, NAT NEUROSCI, V5, P1242, DOI 10.1038/nn958; GOLDBERG J, 1987, ACTA GENET MED GEMEL, V36, P67, DOI 10.1017/S0001566000004608; HIXSON JE, 1990, J LIPID RES, V31, P545; Ioannidis JPA, 2005, PLOS MED, V2, P696, DOI 10.1371/journal.pmed.0020124; JANES GR, 1991, J CLIN PSYCHOL, V47, P80, DOI 10.1002/1097-4679(199101)47:1<80::AID-JCLP2270470112>3.0.CO;2-9; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Juottonen K, 1998, J NEUROL NEUROSUR PS, V65, P322, DOI 10.1136/jnnp.65.3.322; Kilpatrick DG, 2007, AM J PSYCHIAT, V164, P1693, DOI 10.1176/appi.ajp.2007.06122007; Koenen KC, 2009, AM J EPIDEMIOL, V169, P704, DOI 10.1093/aje/kwn397; Kolassa IT, 2010, J CLIN PSYCHIAT, V71, P543, DOI 10.4088/JCP.08m04787blu; Kolassa IT, 2010, BIOL PSYCHIAT, V67, P304, DOI 10.1016/j.biopsych.2009.10.009; Kremen WS, 2012, NEUROPHARMACOLOGY, V62, P647, DOI 10.1016/j.neuropharm.2011.03.012; Kremen WS, 2010, NEUROIMAGE, V53, P1093, DOI 10.1016/j.neuroimage.2010.02.026; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Lee BK, 2011, ARCH GEN PSYCHIAT, V68, P314, DOI 10.1001/archgenpsychiatry.2011.6; Lupien SJ, 2005, J PSYCHIATR NEUROSCI, V30, P328; Lupien SJ, 1998, NAT NEUROSCI, V1, P69, DOI 10.1038/271; Milad MR, 2009, BIOL PSYCHIAT, V66, P1075, DOI 10.1016/j.biopsych.2009.06.026; Moffitt TE, 2005, ARCH GEN PSYCHIAT, V62, P473, DOI 10.1001/archpsyc.62.5.473; Nelson EC, 2009, MOL PSYCHIATR, V14, P234, DOI 10.1038/mp.2008.81; Nutt DJ, 2004, J CLIN PSYCHIAT, V65, P11; Petkus AJ, 2012, J GERONTOL B-PSYCHOL, V67, P653, DOI 10.1093/geronb/gbr163; ROBINS LN, 1989, PSYCHOL MED, V19, P57, DOI 10.1017/S0033291700011028; SAPOLSKY RM, 1985, J NEUROSCI, V5, P1222; Sartor CE, 2012, ARCH GEN PSYCHIAT, V69, P293, DOI 10.1001/archgenpsychiatry.2011.1385; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Teter B, 1999, J NEUROCHEM, V73, P2613, DOI 10.1046/j.1471-4159.1999.0732613.x; Thambisetty M, 2010, ARCH NEUROL-CHICAGO, V67, P93, DOI 10.1001/archneurol.2009.913; TRUE WR, 1993, ARCH GEN PSYCHIAT, V50, P257, DOI 10.1001/archpsyc.1993.01820160019002; Twisk JWR, 2004, EUR J EPIDEMIOL, V19, P769, DOI 10.1023/B:EJEP.0000036572.00663.f2; Wagle J, 2009, DEMENT GERIATR COGN, V27, P525, DOI 10.1159/000223230; Wang Z, 2010, ARCH GEN PSYCHIAT, V67, P296, DOI 10.1001/archgenpsychiatry.2009.205; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Wishart HA, 2006, NEUROLOGY, V67, P1221, DOI 10.1212/01.wnl.0000238079.00472.3a; Xie PX, 2012, AM J MED GENET B, V159B, P644, DOI 10.1002/ajmg.b.32068; Xie P, 2010, NEUROPSYCHOPHARMACOL, V35, P1684, DOI 10.1038/npp.2010.37; Xie PX, 2009, ARCH GEN PSYCHIAT, V66, P1201, DOI 10.1001/archgenpsychiatry.2009.153; Yaffe K, 2010, ARCH GEN PSYCHIAT, V67, P608, DOI 10.1001/archgenpsychiatry.2010.61	49	32	32	0	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4841	1552-485X		AM J MED GENET B	Am. J. Med. Genet. B	OCT	2013	162	7			SI		762	769		10.1002/ajmg.b.32154			8	Genetics & Heredity; Psychiatry	Genetics & Heredity; Psychiatry	238WN	WOS:000325982500020	24132908	Green Accepted, Bronze			2021-06-18	
J	Moreau, JF; Fink, EL; Hartman, ME; Angus, DC; Bell, MJ; Linde-Zwirble, WT; Watson, RS				Moreau, Jacqueline F.; Fink, Ericka L.; Hartman, Mary E.; Angus, Derek C.; Bell, Michael J.; Linde-Zwirble, Walter T.; Watson, R. Scott			Hospitalizations of Children With Neurologic Disorders in the United States	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						epidemiology; hospitalization; intensive care; neurologic outcome; pediatric; pediatric neurocritical care	PEDIATRIC-INTENSIVE-CARE; STROKE; TRENDS; RISK	Objectives: Although neurologic disorders are among the most serious acute pediatric illnesses, epidemiologic data are scarce. We sought to determine the scope and outcomes of children with these disorders in the United States. Design: Retrospective cohort study. Setting: All nonfederal hospitals in 11 states encompassing 38% of the U. S. pediatric population. Patients: Children 29 days to 19 years old hospitalized in 2005. Interventions: None. Measurements and Main Results: Using International Classification of Diseases, 9th Revision, Clinical Modification, codes, we identified admissions with neurologic diagnoses, analyzed patient and hospitalization characteristics, and generated age-and sex-adjusted national estimates. Of 960,020 admissions in the 11 states, 10.7% (103,140) included a neurologic diagnosis, which yields a national estimate of 273,900 admissions of children with neurologic diagnoses. The most common were seizures (53.9%) and traumatic brain injury (17.3%). Children with neuro-logic diagnoses had nearly three times greater ICU use than other hospitalized children (30.6% vs 10.6%, p < 0.001). Neurologic diagnoses were associated with nearly half of deaths (46.2%, n = 1,790). Among ICU patients, children with neurologic diagnoses had more than three times the mortality of other patients (4.8% vs1.5%, p < 0.001). Children with neurologic diagnoses had a significantly longer median hospital length of stay than other children (3 d [1, 5] vs 2 d [2, 4], p < 0.001) and greater median hospital costs ($4,630 [$2,380, $9,730] vs $2,840 [$1,520, $5,550], p < 0.001). Conclusions: Children with neurologic diagnoses account for a disproportionate amount of ICU stays and deaths compared with children hospitalized for other reasons.	[Moreau, Jacqueline F.; Fink, Ericka L.; Angus, Derek C.; Watson, R. Scott] Univ Pittsburgh, Dept Crit Care Med, CRISMA Ctr Clin Res Invest & Syst Modeling Acute, Pittsburgh, PA 15260 USA; [Fink, Ericka L.; Bell, Michael J.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Safar Ctr Resuscitat Res,Med Ctr, Pittsburgh, PA USA; [Hartman, Mary E.] Washington Univ, Sch Med, Dept Pediat, Div Crit Care Med, St Louis, MO 63110 USA; [Linde-Zwirble, Walter T.] ZD Associates LLC, Perkasie, PA USA	Watson, RS (corresponding author), Univ Pittsburgh, Dept Crit Care Med, CRISMA Ctr Clin Res Invest & Syst Modeling Acute, Pittsburgh, PA 15260 USA.	watsonrs@upmc.edu	Viani, Rafael/V-1196-2018; Angus, Derek C/E-9671-2012	Fink, Ericka/0000-0002-3683-4571; , Jacqueline/0000-0001-9250-3972; Watson, R. Scott/0000-0002-2581-7186	National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5TL1RR024155]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [TL1TR000145] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [TL1RR024155] Funding Source: NIH RePORTER	Ms. Moreau received funding from the National Institutes of Health (NIH) T-35 Start-Up Program (#5TL1RR024155). Dr. Fink received funding from NIH. Dr. Angus received funding from NIH (NIH T-35 Start-up training grant). Dr. Watson received funding from NIH. The remaining authors have disclosed that they do not have any potential conflicts of interest.	American College of Surgeons, 1999, TRAUM PROGR RES OPT; [Anonymous], 2011, INT CLASSIFICATION D; [Anonymous], 2005, PUBL US FIL PUF1 PAT; Au AK, 2011, PEDIATR CRIT CARE ME, V12, P566, DOI 10.1097/PCC.0b013e3181fe3420; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feudtner C, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.6.e99; Fullerton HJ, 2003, NEUROLOGY, V61, P189, DOI 10.1212/01.WNL.0000078894.79866.95; Healthcare Cost and Utilization Project (HCUP), 2005, STAT INP DAT SID; Kochanek PM, 2009, PEDIATR CRIT CARE ME, V10, P517, DOI 10.1097/PCC.0b013e3181ab88cd; Lo W, 2009, J CHILD NEUROL, V24, P194, DOI 10.1177/0883073808322665; Perkins E, 2009, STROKE, V40, P2820, DOI 10.1161/STROKEAHA.109.548156; Ramnarayan P, 2007, J MED ETHICS, V33, P255, DOI 10.1136/jme.2005.015768; Roach ES, 2008, STROKE, V39, P2644, DOI 10.1161/STROKEAHA.108.189696; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; *TX DEP STAT HLTH, 2005, TEX HOSP INP DISCH P; United States Census Bureau, METH SUMM INT POP PR	16	32	32	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	OCT	2013	14	8					801	810		10.1097/PCC.0b013e31828aa71f			10	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	AI0EF	WOS:000336518300014	23842588	Green Accepted			2021-06-18	
J	Moler, FW; Silverstein, FS; Meert, KL; Clark, AE; Holubkov, R; Browning, B; Slomine, BS; Christensen, JR; Dean, JM				Moler, Frank W.; Silverstein, Faye S.; Meert, Kathleen L.; Clark, Amy E.; Holubkov, Richard; Browning, Brittan; Slomine, Beth S.; Christensen, James R.; Dean, J. Michael			Rationale, Timeline, Study Design, and Protocol Overview of the Therapeutic Hypothermia After Pediatric Cardiac Arrest Trials	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						cardiac arrest; in hospital; mortality; multicenter; outcome; out of hospital; pediatric; randomized controlled trial; targeted temperature control; therapeutic hypothermia; therapeutic normothermia	TRAUMATIC BRAIN-INJURY; MODERATE HYPOTHERMIA; MILD HYPOTHERMIA; NEONATAL ENCEPHALOPATHY; CEREBRAL-ISCHEMIA; CRITICAL-CARE; RESUSCITATION; NEUROPROTECTION; CARDIOPULMONARY; HYPERTHERMIA	Objective: To describe the rationale, timeline, study design, and protocol overview of the Therapeutic Hypothermia after Pediatric Cardiac Arrest trials. Design: Multicenter randomized controlled trials. Setting: Pediatric intensive care and cardiac ICUs in the United States and Canada. Patients: Children from 48 hours to 18 years old, who have return of circulation after cardiac arrest, who meet trial eligibility criteria, and whose guardians provide written consent. Interventions: Therapeutic hypothermia or therapeutic normothermia. Measurements and Main Results: From concept inception in 2002 until trial initiation in 2009, 7 years were required to plan and operationalize the Therapeutic Hypothermia after Pediatric Cardiac Arrest trials. Two National Institute of Child Health and Human Development clinical trial planning grants (R21 and R34) supported feasibility assessment and protocol development. Two clinical research networks, Pediatric Emergency Care Applied Research Network and Collaborative Pediatric Critical Care Research Network, provided infrastructure resources. Two National Heart Lung Blood Institute U01 awards provided funding to conduct separate trials of in-hospital and out-of-hospital cardiac arrest. A pilot vanguard phase that included half the clinical sites began on March 9, 2009, and this was followed by full trial funding through 2015. Conclusions: Over a decade will have been required to plan, design, operationalize, and conduct the Therapeutic Hypothermia after Pediatric Cardiac Arrest trials. Details described in this report, such as participation of clinical research networks and clinical trial planning grants utilization, may be of utility for individuals who are planning investigator-initiated, federally supported clinical trials.	[Moler, Frank W.; Silverstein, Faye S.] Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; [Meert, Kathleen L.] Wayne State Univ, Dept Pediat, Detroit, MI 48202 USA; [Clark, Amy E.; Holubkov, Richard; Browning, Brittan; Dean, J. Michael] Univ Utah, Dept Pediat, Salt Lake City, UT USA; [Slomine, Beth S.] Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD USA; [Christensen, James R.] Kennedy Krieger Inst, Dept Pediat Rehabil Med, Baltimore, MD USA	Moler, FW (corresponding author), Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA.	fmoler@umich.edu		Holubkov, Richard/0000-0003-0431-3381	Pediatric Emergency Care Applied Research Network (PECARN) [U03MC00001, U03MC00003, U03MC00006, U03MC00007, U03MC00008]; Collaborative Pediatric Critical Care Research Network (CPCCRN) [U10HD500009, U10HD050096, U10HD049981, U10HD049945, U10HD049983, U10HD050012, U01HD049934]; National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD044955]; NIH, NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD050531]; NIH, National Heart Lung Blood Institute (NHLBI)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL094345]; NIH, NHLBIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL094339]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [UG1HD050096, U10HD050096, U10HD049981, U10HD050012, U01HD049934, U10HD049983] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U10HD049945, R21HD044955, R34HD050531] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL094345, U01HL094339] Funding Source: NIH RePORTER	Supported, in part, by the Pediatric Emergency Care Applied Research Network (PECARN) from cooperative agreements U03MC00001, U03MC00003, U03MC00006, U03MC00007, and U03MC00008 and the Collaborative Pediatric Critical Care Research Network (CPCCRN) from cooperative agreements (U10HD500009, U10HD050096, U10HD049981, U10HD049945, U10HD049983, U10HD050012, and U01HD049934).; Dr. Moler received federal grants HD044955 from the National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); HD050531 from NIH, NICHD; and HL094345 from NIH, National Heart Lung Blood Institute (NHLBI). Dr. Dean received federal grant HL094339 from NIH, NHLBI. Drs. Silverstein, Meert, Clark, Holubkov, Browning, Slomine, and Christensen received funding from NIH.	Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Adelson PD, 2012, J NEUROTRAUM, V29, pA17; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; Biswas AK, 2002, CRIT CARE MED, V30, P2742, DOI 10.1097/00003246-200212000-00020; Clark RSB, 1996, J CEREBR BLOOD F MET, V16, P253, DOI 10.1097/00004647-199603000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Corbett D, 1997, STROKE, V28, P2238, DOI 10.1161/01.STR.28.11.2238; Dietrich WD, 2007, PROG BRAIN RES, V162, P201, DOI 10.1016/S0079-6123(06)62011-6; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; Dumas F, 2011, CIRCULATION, V123, P877, DOI 10.1161/CIRCULATIONAHA.110.987347; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gunn AJ, 1998, PEDIATRICS, V102, P1098, DOI 10.1542/peds.102.5.1098; Holzer M, 2002, NEW ENGL J MED, V346, P549; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Laptook A, 2008, PEDIATRICS, V122, P491, DOI 10.1542/peds.2007-1673; Laptook AR, 1997, PEDIATR RES, V42, P17, DOI 10.1203/00006450-199707000-00004; Maier CM, 1998, STROKE, V29, P2171, DOI 10.1161/01.STR.29.10.2171; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Meert KL, 2009, PEDIATR CRIT CARE ME, V10, P544, DOI 10.1097/PCC.0b013e3181a7045c; Moler FW, 2011, CRIT CARE MED, V39, P141, DOI 10.1097/CCM.0b013e3181fa3c17; Moler FW, 2009, CRIT CARE MED, V37, P2259, DOI 10.1097/CCM.0b013e3181a00a6a; Neumar RW, 2008, CIRCULATION, V118, P2452, DOI 10.1161/CIRCULATIONAHA.108.190652; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; Pediat Emergency Care Applied Res, 2003, ACAD EMERG MED, V10, P661; Pemberton VL, 2013, PEDIATR CRIT CARE ME, V14, P19, DOI 10.1097/PCC.0b013e31825b860b; Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Safar P, 1996, STROKE, V27, P105, DOI 10.1161/01.STR.27.1.105; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; Sparrow S, 2005, VINELAND ADAPTIVE BE; STERZ F, 1991, CRIT CARE MED, V19, P379, DOI 10.1097/00003246-199103000-00017; Willson DF, 2006, PEDIATR CRIT CARE ME, V7, P301, DOI 10.1097/01.PCC.0000227106.66902.4F; Winfree CJ, 1996, NEUROSURGERY, V38, P1216, DOI 10.1097/00006123-199606000-00034; Zeiner A, 2001, ARCH INTERN MED, V161, P2007, DOI 10.1001/archinte.161.16.2007	35	32	32	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	SEP	2013	14	7					E304	E315		10.1097/PCC.0b013e31828a863a			12	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	235GN	WOS:000325705100001	23842585	Green Accepted			2021-06-18	
J	Robson, MJ; Turner, RC; Naser, ZJ; McCurdy, CR; Huber, JD; Matsumoto, RR				Robson, Matthew J.; Turner, Ryan C.; Naser, Zachary J.; McCurdy, Christopher R.; Huber, Jason D.; Matsumoto, Rae R.			SN79, a sigma receptor ligand, blocks methamphetamine-induced microglial activation and cytokine upregulation	EXPERIMENTAL NEUROLOGY			English	Article						Methamphetamine; Sigma receptor; Microglial activation; Cytokine; Neurotoxicity	TRAUMATIC BRAIN-INJURY; INDUCED NEUROTOXICITY; PARKINSONS-DISEASE; DOPAMINE TRANSPORTERS; MOLECULAR-BASES; IN-VIVO; MICE; EXPRESSION; MINOCYCLINE; STRIATUM	Methamphetamine (METH) abuse is associated with several negative side effects including neurotoxicity in specific brain regions such as the striatum. The precise molecular mechanisms by which METH usage results in neurotoxicity remain to be fully elucidated, with recent evidence implicating the importance of microglial activation and neuroinflammation in damaged brain regions. METH interacts with sigma receptors which are found in glial cells in addition to neurons. Moreover, sigma receptor antagonists have been shown to block METH-induced neurotoxicity in rodents although the cellular mechanisms underlying their neuroprotection remain unknown. The purpose of the current study was to determine if the prototypic sigma receptor antagonist, SN79, mitigates METH-induced microglial activation and associated increases in cytokine expression in a rodent model of METH-induced neurotoxicity. METH increased striatal mRNA and protein levels of cluster of differentiation 68 (CD68), indicative of microglial activation. METH also increased ionized calcium binding adapter molecule 1 (IBA-1) protein expression, further confirming the activation of microglia. Along with microglial activation, METH increased striatal mRNA expression levels of IL-6 family pro-inflammatory cytokines, leukemia inhibitory factor (lif), oncostatin m (osm), and interleukin-6 (il-6). Pretreatment with SN79 reduced METH-induced increases in CD68 and IBA-1 expression, demonstrating its ability to prevent microglial activation. SN79 also attenuated METH-induced mRNA increases in IL-6 pro-inflammatory cytokine family members. The ability of a sigma receptor antagonist to block METH-induced microglial activation and cytokine production provides a novel mechanism through which the neurotoxic effects of METH may be mitigated. (C) 2013 Elsevier Inc. All rights reserved.	[Robson, Matthew J.; Huber, Jason D.; Matsumoto, Rae R.] W Virginia Univ, Hlth Sci Ctr, Sch Pharm, Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA; [Turner, Ryan C.; Naser, Zachary J.] W Virginia Univ, Hlth Sci Ctr, Sch Med, Dept Neurosurg, Morgantown, WV 26506 USA; [Turner, Ryan C.; Huber, Jason D.; Matsumoto, Rae R.] W Virginia Univ, Hlth Sci Ctr, Sch Med, Ctr Neurosci, Morgantown, WV 26506 USA; [McCurdy, Christopher R.] Univ Mississippi, Sch Pharm, Dept Med Chem, University, MS 38677 USA; [McCurdy, Christopher R.] Univ Mississippi, Sch Pharm, Dept Pharmacol, University, MS 38677 USA	Matsumoto, RR (corresponding author), W Virginia Univ, Sch Pharm, POB 9500, Morgantown, WV 26506 USA.	rmatsumoto@hsc.wvu.edu	Robson, Matthew/H-3127-2013	Robson, Matthew/0000-0002-3277-3062; Turner, Ryan/0000-0001-5523-0645	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [DA013978, D023205, NS061954, T32 GM081741]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM081741] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R01DA023205, R01DA013978] Funding Source: NIH RePORTER	This research was supported by grants from the National Institutes of Health (DA013978, D023205, and NS061954). Ryan C. Turner was also supported by a grant from the National Institutes of Health (T32 GM081741).	Ajmo CT, 2006, CURR NEUROVASC RES, V3, P89, DOI 10.2174/156720206776875849; Bourrie B, 1996, IMMUNOLOGY, V88, P389, DOI 10.1046/j.1365-2567.1996.d01-657.x; BOWYER JF, 1994, J PHARMACOL EXP THER, V268, P1571; Cadet JL, 2009, INT REV NEUROBIOL, V88, P101, DOI 10.1016/S0074-7742(09)88005-7; Cadet JL, 2003, FASEB J, V17, P1775, DOI 10.1096/fj.03-0073rev; Callaghan RC, 2012, DRUG ALCOHOL DEPEN, V120, P35, DOI 10.1016/j.drugalcdep.2011.06.013; Callaghan RC, 2010, MOVEMENT DISORD, V25, P2333, DOI 10.1002/mds.23263; Cooper ZD, 2012, EXPERT OPIN INV DRUG, V21, P169, DOI 10.1517/13543784.2012.651123; Cruickshank CC, 2009, ADDICTION, V104, P1085, DOI 10.1111/j.1360-0443.2009.02564.x; Cuevas J, 2011, J PHARMACOL EXP THER, V339, P161, DOI 10.1124/jpet.111.182816; Czeh M, 2011, DEV NEUROSCI-BASEL, V33, P199, DOI 10.1159/000328989; DEROCQ JM, 1995, J PHARMACOL EXP THER, V272, P224; Escubedo E, 2005, J PHARMACOL EXP THER, V315, P658, DOI 10.1124/jpet.105.089748; Escubedo E, 1998, BRAIN RES, V814, P120, DOI 10.1016/S0006-8993(98)01065-8; Goncalves J, 2008, ANN NY ACAD SCI, V1139, P103, DOI 10.1196/annals.1432.043; Hall AA, 2009, GLIA, V57, P744, DOI 10.1002/glia.20802; Hashimoto K, 2007, BIOL PSYCHIAT, V61, P577, DOI 10.1016/j.biopsych.2006.03.019; Hayashi T, 2007, CELL, V131, P596, DOI 10.1016/j.cell.2007.08.036; Hebert MA, 2000, ANN NY ACAD SCI, V914, P238, DOI 10.1111/j.1749-6632.2000.tb05200.x; Kaushal N., 2011, 2011 M PLANN SOC NEU; Kaushal N., 2012, EUR NEUROPSYCHOPHARM, DOI DOI 10.1016/JEUR0NEUR0.2012.08.005; Kaushal N, 2012, MOL PHARMACOL, V81, P299, DOI 10.1124/mol.111.074120; Kaushal N, 2011, NEUROPHARMACOLOGY, V61, P992, DOI 10.1016/j.neuropharm.2011.06.028; Kaushal N, 2011, AAPS J, V13, P336, DOI 10.1208/s12248-011-9274-9; Kelly KA, 2012, J NEUROCHEM, V122, P995, DOI 10.1111/j.1471-4159.2012.07864.x; Kita T, 2000, NEUROPHARMACOLOGY, V39, P399, DOI 10.1016/S0028-3908(99)00175-6; Komohara Y, 2011, J CLIN EXP HEMATOP, V51, P93, DOI 10.3960/jslrt.51.93; Krasnova IN, 2009, BRAIN RES REV, V60, P379, DOI 10.1016/j.brainresrev.2009.03.002; Kuhn DM, 2006, ANN NY ACAD SCI, V1074, P31, DOI 10.1196/annals.1369.003; Ladenheim B, 2000, MOL PHARMACOL, V58, P1247; LaVoie MJ, 2004, EXP NEUROL, V187, P47, DOI 10.1016/j.expneurol.2004.01.010; Li B, 2009, NEUROSURGERY, V65, P179, DOI 10.1227/01.NEU.0000346272.76537.DC; Matsumoto RR, 2008, EUR NEUROPSYCHOPHARM, V18, P871, DOI 10.1016/j.euroneuro.2008.07.006; Mizoguchi H, 2008, PSYCHOPHARMACOLOGY, V196, P233, DOI 10.1007/s00213-007-0955-0; Mori T, 2012, J PHARMACOL EXP THER, V341, P663, DOI 10.1124/jpet.111.190868; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nagai A, 2005, J NEUROSCI RES, V81, P342, DOI 10.1002/jnr.20478; Nguyen EC, 2005, NEUROPHARMACOLOGY, V49, P638, DOI 10.1016/j.neuropharm.2005.04.016; Niino D, 2010, PATHOL INT, V60, P278, DOI 10.1111/j.1440-1827.2010.02514.x; O'Callaghan JP, 2008, ANN NY ACAD SCI, V1139, P318, DOI 10.1196/annals.1432.032; Perry VH, 2010, NAT REV NEUROL, V6, P193, DOI 10.1038/nrneurol.2010.17; Robson MJ, 2012, CURR PHARM DESIGN, V18, P902; Rodvelt Kelli R, 2010, Curr Drug Abuse Rev, V3, P156; Romanelli F, 2006, PHARMACOTHERAPY, V26, P1148, DOI 10.1592/phco.26.8.1148; Ruscher K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045118; Saijo K, 2011, NAT REV IMMUNOL, V11, P775, DOI 10.1038/nri3086; Sekine Y, 2008, J NEUROSCI, V28, P5756, DOI 10.1523/JNEUROSCI.1179-08.2008; Seminerio MJ, 2011, PHARMACOL BIOCHEM BE, V98, P12, DOI 10.1016/j.pbb.2010.11.023; Seminerio MJ, 2012, INT J NEUROPSYCHOPH, V29, P1; Smith JA, 2012, BRAIN RES BULL, V87, P10, DOI 10.1016/j.brainresbull.2011.10.004; Smith KJ, 2010, NEUROSCI LETT, V481, P144, DOI 10.1016/j.neulet.2010.06.069; Tanibuchi Y., 2010, GEN HOSP PSYCHIAT, V32, pe551; Thomas DM, 2005, J NEUROCHEM, V92, P790, DOI 10.1111/j.1471-4159.2004.02906.x; Thomas DM, 2004, J PHARMACOL EXP THER, V311, P1, DOI 10.1124/jpet.104.070961; Thomas DM, 2004, NEUROSCI LETT, V367, P349, DOI 10.1016/j.neulet.2004.06.065; Volkow ND, 2001, AM J PSYCHIAT, V158, P377, DOI 10.1176/appi.ajp.158.3.377; Volkow ND, 2001, J NEUROSCI, V21, P9414, DOI 10.1523/JNEUROSCI.21-23-09414.2001; Wang GJ, 2012, MOL PSYCHIATR, V17, P918, DOI 10.1038/mp.2011.86; Yao HH, 2010, BLOOD, V115, P4951, DOI 10.1182/blood-2010-01-266221; Yue X, 2012, J HUAZHONG U SCI-MED, V32, P415, DOI 10.1007/s11596-012-0072-0; Zhang L, 2006, PROG NEURO-PSYCHOPH, V30, P1381, DOI 10.1016/j.pnpbp.2006.05.015; Zhang ZR, 2012, BRAIN RES, V1461, P102, DOI 10.1016/j.brainres.2012.04.038	62	32	34	1	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	SEP	2013	247						134	142		10.1016/j.expneurol.2013.04.009			9	Neurosciences	Neurosciences & Neurology	204VO	WOS:000323399600018	23631864	Green Accepted			2021-06-18	
J	Scherer, MR; Weightman, MM; Radomski, MV; Davidson, LF; McCulloch, KL				Scherer, Matthew R.; Weightman, Margaret M.; Radomski, Mary V.; Davidson, Leslie F.; McCulloch, Karen L.			Returning Service Members to Duty Following Mild Traumatic Brain Injury: Exploring the Use of Dual-Task and Multitask Assessment Methods	PHYSICAL THERAPY			English	Article							NATURALISTIC ACTION; POSTURAL STABILITY; ATTENTION DEFICITS; EXECUTIVE FUNCTION; CONCUSSION; BALANCE; GAIT; PERFORMANCE; SLEEP; RECOVERY	Within the last decade, more than 220,000 service members have sustained traumatic brain injury asp in support of military operations in Iraq and Afghanistan. Mild TBI may result in subtle cognitive and sensorimotor deficits that adversely affect warfighter performance, creating significant challenges for service members, commanders, and clinicians. In recent conflicts, physical therapists and occupational therapists have played an important role in evaluating service member readiness to return to duty (RTD), incorporating research and best practices from the sports concussion literature. Because premorbid (baseline) performance metrics are not typically available for deployed service members as for athletes, clinicians commonly determine duty readiness based upon the absence of postconcussive symptoms and return to "normal" performance on clinical assessments not yet validated in the military population. Although practices described in the sports concussion literature guide "return-to-play" determinations, resolution of symptoms or improvement of isolated impairments may be inadequate to predict readiness in a military operational environment. Existing clinical metrics informing RTD decision making are limited because they fail to emphasize functional, warrior task demands and they lack versatility to assess the effects of comorbid deficits. Recently, a number of complex task-oriented RTD approaches have emerged from Department of Defense laboratory and clinical settings to address this gap. Immersive virtual reality environments, field-based scenario-driven assessment programs, and militarized dual-task and multitask-based approaches have all been proposed for the evaluation of sensorimotor and cognitive function following TBI. There remains a need for clinically feasible assessment methods that can be used to verify functional performance and operational competence in a variety of practice settings. Complex and ecologically valid assessment techniques incorporating dual-task and multitask methods may prove useful in validating return-to-activity requirements in civilian and military populations.	[Scherer, Matthew R.] US Army Res Inst Environm Med, Mil Performance Div, Natick, MA 01760 USA; [Weightman, Margaret M.; Radomski, Mary V.] Sister Kenny Res Ctr, Minneapolis, MN USA; [Davidson, Leslie F.] Shenandoah Univ, Dept Occupat Therapy, Winchester, VA USA; [McCulloch, Karen L.] Univ N Carolina, Chapel Hill, NC USA	Scherer, MR (corresponding author), US Army Res Inst Environm Med, Mil Performance Div, 15 Kansas St, Natick, MA 01760 USA.	matthew.scherer@us.army.mil			US Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-09-2-0149]	The research team's ongoing investigation of dual-task and multitask testing methods in service members with mild traumatic brain injury is funded by the US Army Medical Research and Materiel Command (award number W81XWH-09-2-0149).	ABERNETHY B, 1988, J HUM MOVEMENT STUD, V14, P101; Alderman N, 2003, J INT NEUROPSYCH SOC, V9, P31, DOI 10.1017/S1355617703910046; [Anonymous], 2009, STP; [Anonymous], 649011 DODI US DEP D; [Anonymous], 2008, SYMPTOM MANAGEMENT M; Barlow M, 2011, INT J SPORTS PHYS TH, V6, P150; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Boake C, 2005, J NEUROPSYCH CLIN N, V17, P350, DOI 10.1176/appi.neuropsych.17.3.350; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 2000, PSYCHOL RES-PSYCH FO, V63, P279, DOI 10.1007/s004269900006; Casscells SW, 2007, TRAUMATIC BRAIN INJU; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Catena RD, 2009, EXP BRAIN RES, V194, P67, DOI 10.1007/s00221-008-1669-1; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Defense and Veterans Brain Injury Center, 2006, DEF VET BRAIN INJ CT; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; Fischer SC, 2005, MULTITASKING ASSESSM; French LM, 2012, J HEAD TRAUMA REHAB, V27, P63, DOI 10.1097/HTR.0b013e3182248344; Getchell B., 1979, Physical Fitness: A Way of Life, V2nd; Goss DL, 2009, J SPEC OPER MED, V9, P29; Gottshall KR, 2012, IEEE ENG MED BIO, P6141, DOI 10.1109/EMBC.2012.6347395; Guskiewicz KM, 2011, PM&R, V3, pS445, DOI 10.1016/j.pmrj.2011.08.009; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Hart T, 1998, J HEAD TRAUMA REHAB, V13, P16, DOI 10.1097/00001199-199810000-00004; Hettich Thomas, 2010, J Spec Oper Med, V10, P48; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hyndman D, 2006, DISABIL REHABIL, V28, P849, DOI 10.1080/09638280500534994; Lieberman HR, 2005, BIOL PSYCHIAT, V57, P422, DOI 10.1016/j.biopsych.2004.11.014; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Mancini M, 2012, J BIOENGINEER BIOMED, VS1, P007; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Maylor EA, 2001, BRIT J PSYCHOL, V92, P319, DOI 10.1348/000712601162211; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; McCulloch Karen, 2007, J Neurol Phys Ther, V31, P104; McCulloch KL, 2010, J HEAD TRAUMA REHAB, V25, P155, DOI 10.1097/HTR.0b013e3181dc82e7; McCulloch KL, 2009, J GERIATR PHYS THER, V32, P2, DOI 10.1519/00139143-200932010-00002; Meher I, 2004, J AM GERIATR SOC, V52, P1255, DOI 10.1111/j.1532-5415.2004.52353.x; Melzer I, 2007, J NEUROENG REHABIL, V4, DOI 10.1186/1743-0003-4-16; Miller NL, 2011, BEHAV SLEEP MED, V9, P53, DOI 10.1080/15402002.2011.533994; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Peterson AL, 2008, MIL MED, V173, P230, DOI 10.7205/MILMED.173.3.230; Rabago CA, 2011, J NEUROL PHYS THER, V35, P185, DOI 10.1097/NPT.0b013e318235d7e6; Radomski MV, 2013, MIL MED, V178, P246, DOI 10.7205/MILMED-D-12-00144; Radomski MV, 2009, AM J OCCUP THER, V63, P646, DOI 10.5014/ajot.63.5.646; Reeves DL, 2007, ARCH CLIN NEUROPSYCH, V22, pS15, DOI 10.1016/j.acn.2006.10.013; Rhon DI, 2010, MIL MED, V175, P305, DOI 10.7205/MILMED-D-09-00099; Riemann BL, 1999, J SPORT REHABIL, V8, P71, DOI 10.1123/jsr.8.2.71; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rigg JL, 2011, PM&R, V3, pS380, DOI 10.1016/j.pmrj.2011.08.005; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Scherer MR, 2009, PHYS THER, V89, P980, DOI 10.2522/ptj.20080353; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Schwartz MF, 1998, NEUROPSYCHOLOGY, V12, P13, DOI 10.1037/0894-4105.12.1.13; Schwartz MF, 2002, NEUROPSYCHOL REHABIL, V12, P311, DOI 10.1080/09602010244000084; Seelig AD, 2010, SLEEP, V33, P1615, DOI 10.1093/sleep/33.12.1615; Sen A., 2005, J HUMAN DEV, V6, P151, DOI DOI 10.1080/14649880500120491; ShumwayCook A, 1997, J GERONTOL A-BIOL, V52, pM232, DOI 10.1093/gerona/52A.4.M232; Siu KC, 2009, BRAIN RES, V1248, P59, DOI 10.1016/j.brainres.2008.10.078; Starr B, CPR FOR YOUR BRAIN; Steiner WA, 2002, PHYS THER, V82, P1098, DOI 10.1093/ptj/82.11.1098; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; US Department of Veterans Affairs, MAN CONC MILD TRAUM; Vallee M, 2006, ARCH PHYS MED REHAB, V87, P806, DOI 10.1016/j.apmr.2006.02.031; van Donkelaar P, 2006, EXERC SPORT SCI REV, V34, P77, DOI 10.1249/00003677-200604000-00007; van Donkelaar P, 2005, BRAIN INJURY, V19, P1031, DOI 10.1080/02699050500110363; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; Willer Barry, 2006, Curr Treat Options Neurol, V8, P415, DOI 10.1007/s11940-006-0031-9; Wolf TJ, 2008, WORK, V31, P221; Wolf TJ, 2010, WORK, V36, P405, DOI 10.3233/WOR-2010-1045	79	32	33	0	23	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0031-9023	1538-6724		PHYS THER	Phys. Ther.	SEP	2013	93	9			SI		1254	1267		10.2522/ptj.20120143			14	Orthopedics; Rehabilitation	Orthopedics; Rehabilitation	212OM	WOS:000323992700014	23766395	Bronze			2021-06-18	
J	Ahmed, FA; Kamnaksh, A; Kovesdi, E; Long, JB; Agoston, DV				Ahmed, Farid A.; Kamnaksh, Alaa; Kovesdi, Erzsebet; Long, Joseph B.; Agoston, Denes V.			Long-term consequences of single and multiple mild blast exposure on select physiological parameters and blood-based biomarkers	ELECTROPHORESIS			English	Article						Animal models; Brain trauma; Experimental; Physiology; Proteomics	TRAUMATIC BRAIN-INJURY; CONCUSSION; RATS	Mild traumatic brain injury (mTBI), especially when it is repeated (rmTBI), can lead to progressive degenerative diseases and lasting neuropsychiatric abnormalities. To better understand the long-term pathobiological changes in mTBI and rmTBI, we exposed rats to single or repeated (5 total; administered on consecutive days) mild blast overpressure, monitored changes in physiological parameters, and determined the plasma levels of select biomarkers at 42 days post injury by proteomics. We unexpectedly found comparable changes in arterial oxygen saturation levels and heart rates of single-injured (SI) and multiple-injured (MI) rats throughout the observation period. Our analyses indicated lasting oxidative stress, vascular abnormalities, and neuronal and glial cell loss in both injured groups. However, MI rats exhibited a relatively more pronounced increase in the plasma levels of most of the tested markers-particularly those associated with inflammation-albeit the differences between the two injured groups were not statistically significant. Our findings indicate that the frequency of blast exposures is an important determinant of the resulting cumulative damage in rmTBI.	[Ahmed, Farid A.; Kamnaksh, Alaa; Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Ahmed, Farid A.; Kamnaksh, Alaa; Agoston, Denes V.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Kovesdi, Erzsebet] US Dept Vet Affairs, Vet Affairs Cent Off, Washington, DC USA; [Long, Joseph B.] Walter Reed Army Inst Res, Blast Induced Neurotrauma Branch, Ctr Mil Psychiat & Neurosci, Silver Spring, MD USA	Agoston, DV (corresponding author), Uniformed Serv Univ Hlth Sci, Sch Med, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	vagoston@usuhs.edu			Center for Neuroscience and Regenerative MedicineUnited States Department of Defense [G1703F]	We thank the Neurotrauma Team at the Walter Reed Army Institute of Research for their technical help during the exposures. This work was supported by the Center for Neuroscience and Regenerative Medicine grant number G1703F. The views, opinions, and/or findings contained herein are those of the authors and should not be construed as an official position, policy, or decision of the Department of the Army or the Department of Defense. The authors have no financial disclosures. Animal handling and treatments were conducted in compliance with the Animal Welfare Act and other Federal statutes and regulations related to animals and experiments involving animals, and adhered to principles stated in the Guide to the Care and Use of Laboratory Animals, National Research Council. The facilities are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.	Agoston Denes V, 2012, Front Neurol, V3, P107, DOI 10.3389/fneur.2012.00107; Barone FC, 2000, EXPERT OPIN INV DRUG, V9, P2281, DOI 10.1517/13543784.9.10.2281; Cernak I, 2011, NEUROBIOL DIS, V41, P538, DOI 10.1016/j.nbd.2010.10.025; Dash PK, 2010, J NEUROSCI RES, V88, P1719, DOI 10.1002/jnr.22336; De Oliveira CO, 2007, J NEUROTRAUM, V24, P1331, DOI 10.1089/neu.2006.0159; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Gyorgy AB, 2010, J NEUROSCI METH, V192, P96, DOI 10.1016/j.jneumeth.2010.07.029; Hayes JP, 2012, NEUROCASE, V18, P258, DOI 10.1080/13554794.2011.588181; Kamnaksh A, 2012, ELECTROPHORESIS, V33, P3680, DOI 10.1002/elps.201200319; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Long JB, 2009, J NEUROTRAUM, V26, P827, DOI 10.1089/neu.2008.0748; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Schoknecht K, 2012, EPILEPSIA, V53, P7, DOI 10.1111/j.1528-1167.2012.03697.x; Stern RA, 2011, PM&R, V3, pS460, DOI 10.1016/j.pmrj.2011.08.008; Yeh SH, 2011, BRAIN PATHOL, V21, P249, DOI 10.1111/j.1750-3639.2010.00443.x	18	32	33	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0173-0835	1522-2683		ELECTROPHORESIS	Electrophoresis	AUG	2013	34	15					2229	2233		10.1002/elps.201300077			5	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	261KJ	WOS:000327663600012	23712899				2021-06-18	
J	Jacobs, B; Beems, T; van der Vliet, TM; van Vugt, AB; Hoedemaekers, C; Horn, J; Franschman, G; Haitsma, I; van der Naalt, J; Andriessen, TMJC; Borm, GF; Vos, PE				Jacobs, Bram; Beems, Tjemme; van der Vliet, Ton M.; van Vugt, Arie B.; Hoedemaekers, Cornelia; Horn, Janneke; Franschman, Gaby; Haitsma, Ian; van der Naalt, Joukje; Andriessen, Teuntje M. J. C.; Borm, George F.; Vos, Pieter E.			Outcome Prediction in Moderate and Severe Traumatic Brain Injury: A Focus on Computed Tomography Variables	NEUROCRITICAL CARE			English	Article						Moderate traumatic brain injury; Severe traumatic brain injury; Outcome; Predictionmodel; CT-scan; Head injury	SEVERE HEAD-INJURY; PROGNOSTIC MODELS; CLINICAL-VARIABLES; ADMISSION; VALIDATION; IMPACT; SCAN; CLASSIFICATION; HEMORRHAGE; MORTALITY	With this study we aimed to design validated outcome prediction models in moderate and severe traumatic brain injury (TBI) using demographic, clinical, and radiological parameters. Seven hundred consecutive moderate or severe TBI patients were included in this observational prospective cohort study. After inclusion, clinical data were collected, initial head computed tomography (CT) scans were rated, and at 6 months outcome was determined using the extended Glasgow Outcome Scale. Multivariate binary logistic regression analysis was applied to evaluate the association between potential predictors and three different outcome endpoints. The prognostic models that resulted were externally validated in a national Dutch TBI cohort. In line with previous literature we identified age, pupil responses, Glasgow Coma Scale score and the occurrence of a hypotensive episode post-injury as predictors. Furthermore, several CT characteristics were associated with outcome; the aspect of the ambient cisterns being the most powerful. After external validation using Receiver Operating Characteristic (ROC) analysis our prediction models demonstrated adequate discriminative values, quantified by the area under the ROC curve, of 0.86 for death versus survival and 0.83 for unfavorable versus favorable outcome. Discriminative power was less for unfavorable outcome in survivors: 0.69. Outcome prediction in moderate and severe TBI might be improved using the models that were designed in this study. However, conventional demographic, clinical and CT variables proved insufficient to predict disability in surviving patients. The information that can be derived from our prediction rules is important for the selection and stratification of patients recruited into clinical TBI trials.	[Jacobs, Bram; Andriessen, Teuntje M. J. C.; Vos, Pieter E.] RUNMC, Dept Neurol 935, NL-6500 HB Nijmegen, Netherlands; [Beems, Tjemme] RUNMC, Dept Neurosurg 931, NL-6500 HB Nijmegen, Netherlands; [van der Vliet, Ton M.] RUNMC, Dept Radiol, NL-6500 HB Nijmegen, Netherlands; [van Vugt, Arie B.] RUNMC, Dept Emergency Med, NL-6500 HB Nijmegen, Netherlands; [Hoedemaekers, Cornelia] RUNMC, Dept Intens Care Med 632, NL-6500 HB Nijmegen, Netherlands; [Horn, Janneke] Univ Amsterdam, Acad Med Ctr, Dept Intens Care Med, NL-1105 AZ Amsterdam, Netherlands; [Franschman, Gaby] Vrije Univ Amsterdam Med Ctr, Dept Anesthesiol, NL-1081 HV Amsterdam, Netherlands; [Haitsma, Ian] Erasmus MC, Dept Neurosurg, NL-3000 CA Rotterdam, Netherlands; [van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, NL-9700 RB Groningen, Netherlands; [Borm, George F.] RUNMC, Dept Epidemiol Biostat & HTA 133, NL-6500 HB Nijmegen, Netherlands	Vos, PE (corresponding author), RUNMC, Dept Neurol 935, POB 9101, NL-6500 HB Nijmegen, Netherlands.	B.Jacobs@umcg.nl; R.Bartels@nch.umcn.nl; a.van.der.vliet@umcg.nl; a.vanvugt@mst.nl; C.Hoedemaekers@ic.umcn.nl; J.Horn@amc.uva.nl; G.Franschman@vumc.nl; I.Haitsma@erasmusmc.nl; J.van.der.naalt@umcg.nl; TMJC.Andriessen@neuro.umcn.nl; G.Borm@ebh.umcn.nl; P.Vos@neuro.umcn.nl	Hoedemaekers, C.W.E./L-4375-2015		Dutch Brain Foundation [Hersenstichting - HSN-07-01]	The authors wish to thank Ronald H. M. A. Bartels, MD, PhD of the Department of Neurosurgery, Radboud University Nijmegen Medical Centre, for critically reviewing this manuscript and his suggestions, and Robert Huiskes for the development of the prognostic calculator and the website www.tbi-prognosis.com. The POCON study is funded by the Dutch Brain Foundation (Hersenstichting - HSN-07-01). The authors express their gratitude to Dick Drost, Annemiek Coers, Annelou van der Veen, Joshua Field, Vivian de Ruijter, and Heleen Biersteker for their help with data collection. Amon Heijne is thanked for his help with the development and maintenance of the POCON database.	American College of Surgeons, 1997, ADV TRAUM LIF SUPP D, V6th ed; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; COOPER PR, 1979, NEUROSURGERY, V5, P566, DOI 10.1227/00006123-197911000-00004; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; Franschman G, 2012, INJURY, V43, P1838, DOI 10.1016/j.injury.2012.05.020; Hukkelhoven CWPM, 2006, J CLIN EPIDEMIOL, V59, P132, DOI 10.1016/j.jclinepi.2005.06.009; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Jacobs B, 2011, J NEUROTRAUM, V28, P203, DOI 10.1089/neu.2010.1558; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jacobs B, 2010, J NEUROTRAUM, V27, P331, DOI 10.1089/neu.2009.1105; JENNETT B, 1975, LANCET, V1, P480; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Maas AIR, 2007, J NEUROTRAUM, V24, P232, DOI 10.1089/neu.2006.0024; Marmarou A, 2007, J NEUROTRAUM, V24, P239, DOI 10.1089/neu.2006.0036; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Servadei F, 2000, NEUROSURGERY, V46, P70; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; The Brain Trauma Foundation. The American Association of Neurological Surgeons. The Joint Section on Neurotrauma and Critical Care, 2000, J NEUROTRAUM, V17, P597; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; WYATT JC, 1995, BMJ-BRIT MED J, V311, P1539, DOI 10.1136/bmj.311.7019.1539; Young NH, 2008, PLOS MED, V5, P1186, DOI 10.1371/journal.pmed.0050168; Zhou WD, 2008, J NEUROTRAUM, V25, P279, DOI 10.1089/neu.2007.0489; Zuercher M, 2009, BRAIN INJURY, V23, P371, DOI 10.1080/02699050902926267	44	32	33	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2013	19	1					79	89		10.1007/s12028-012-9795-9			11	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	187SP	WOS:000322140000013	23138545				2021-06-18	
J	Donaldson, L; Asbridge, M; Cusimano, MD				Donaldson, Laura; Asbridge, Mark; Cusimano, Michael D.			Bodychecking Rules and Concussion in Elite Hockey	PLOS ONE			English	Article							ICE HOCKEY; INJURY SURVEILLANCE; BRAIN-INJURY; PLAYERS; NHL; NEWSPAPERS; VIOLENCE; SPORTS; LEAGUE	Athletes participating in contact sports such as ice hockey are exposed to a high risk of suffering a concussion. We determined whether recent rule changes regulating contact to the head introduced in 2010-11 and 2011-12 have been effective in reducing the incidence of concussion in the National Hockey League (NHL). A league with a longstanding ban on hits contacting the head, the Ontario Hockey League (OHL), was also studied. A retrospective study of NHL and OHL games for the 2009-10 to 2011-12 seasons was performed using official game records and team injury reports in addition to other media sources. Concussion incidence over the 3 seasons analyzed was 5.23 per 100 NHL regular season games and 5.05 per 100 OHL regular season games (IRR 1.04; 95% CI 1.01, 1.50). When injuries described as concussion-like or suspicious of concussion were included, incidences rose to 8.8 and 7.1 per 100 games respectively (IRR 1.23; 95% CI 0.81, 1.32). The number of NHL concussions or suspected concussions was lower in 2009-10 than in 2010-11 (IRR 0.61; 95% CI 0.45, 0.83), but did not increase from 2010-11 to 2011-12 (IRR 1.05; 95% CI 0.80, 1.38). 64.2% of NHL concussions were caused by bodychecking, and only 28.4% of concussions and 36.8% of suspected concussions were caused by illegal incidents. We conclude that rules regulating bodychecking to the head did not reduce the number of players suffering concussions during NHL regular season play and that further changes or stricter enforcement of existing rules may be required to minimize the risk of players suffering these injuries.	[Donaldson, Laura; Cusimano, Michael D.] Univ Toronto, St Michaels Hosp, Div Neurosurg, Toronto, ON, Canada; [Donaldson, Laura; Cusimano, Michael D.] Univ Toronto, St Michaels Hosp, Injury Prevent Res Off, Toronto, ON, Canada; [Donaldson, Laura; Cusimano, Michael D.] Univ Toronto, St Michaels Hosp, Canadian Brain Injury & Violence Res Team, Toronto, ON, Canada; [Asbridge, Mark] Dalhousie Univ, Dept Community Hlth & Epidemiol, Clin Res Ctr, Halifax, NS, Canada; [Asbridge, Mark] Dalhousie Univ, Dept Emergency Med, Clin Res Ctr, Halifax, NS, Canada	Cusimano, MD (corresponding author), Univ Toronto, St Michaels Hosp, Div Neurosurg, Toronto, ON, Canada.	injuryprevention@smh.ca	Cusimano, Michael/X-4059-2019	Cusimano, Michael/0000-0002-9989-0650	Canadian Institutes of Health Research Strategic Team Grant in Applied Injury ResearchCanadian Institutes of Health Research (CIHR) [TIR-103946]; Ontario Neurotrauma Foundation; University of Toronto Faculty of Medicine CREMS	This research was supported by the Canadian Institutes of Health Research Strategic Team Grant in Applied Injury Research # TIR-103946, the Ontario Neurotrauma Foundation, as well as University of Toronto Faculty of Medicine CREMS funding to LD. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	[Anonymous], 2011, HOCKEY NEWS; Barss P, 2009, J SCI MED SPORT, V12, P164, DOI 10.1016/j.jsams.2007.08.016; Benson BW, 2009, BRIT J SPORT MED, V43, pI56, DOI 10.1136/bjsm.2009.058271; Benson BW, 2011, CAN MED ASSOC J, V183, P905, DOI 10.1503/cmaj.092190; Cusimano Michael D, 2011, Open Med, V5, pe57; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Drakos MC, 2010, SPORTS HEALTH, V2, P284, DOI 10.1177/1941738109357303; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Hagel BE, 2006, CAN MED ASSOC J, V175, P155, DOI 10.1503/cmaj.051531; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Honey CR, 1998, CLIN J SPORT MED, V8, P43, DOI 10.1097/00042752-199801000-00010; JONES JCH, 1993, AM J ECON SOCIOL, V52, P63, DOI 10.1111/j.1536-7150.1993.tb02742.x; Kennan HT, 1999, ARCH SURG-CHICAGO, V134, P14, DOI 10.1001/archsurg.134.1.14; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; NHL concussions put player insurance in question, 2012, CBC SPORTS; Orchard J., 2001, INT SPORTMED J, V2, P1; Pappachan B, 2006, J ORAL MAXIL SURG, V64, P1023, DOI 10.1016/j.joms.2006.03.021; Paul RJ, 2003, AM J ECON SOCIOL, V62, P345, DOI 10.1111/1536-7150.t01-2-00003; Powell JW, 1998, SAFETY ICE HOCKEY, P19; RAINEY DY, 1992, AM J PUBLIC HEALTH, V82, P745, DOI 10.2105/AJPH.82.5.745; Smith AM, 2011, PM&R, V3, P605, DOI 10.1016/j.pmrj.2011.05.013; [Social Scienced and Humanities Research Council of Canada Natural Sciences and Engineering Research Council of Canada Canadian Institutes of Health Research], 2014, TRIC POL STAT ETH CO; The National Hockey League, 2011, NAT HOCK LEAG OFF RU; The National Hockey League, 2010, NAT HOCK LEAG OFF RU; The Ontario Hockey League, 2011, ONT HOCK LEAG OFF RU; Wennberg RA, 2008, CAN J NEUROL SCI, V35, P647, DOI 10.1017/S031716710000946X	28	32	32	0	23	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JUL 17	2013	8	7							e69122	10.1371/journal.pone.0069122			6	Multidisciplinary Sciences	Science & Technology - Other Topics	185WH	WOS:000322000600041	23874888	DOAJ Gold, Green Published			2021-06-18	
J	Beauchamp, MH; Dooley, JJ; Anderson, V				Beauchamp, M. H.; Dooley, J. J.; Anderson, V.			A preliminary investigation of moral reasoning and empathy after traumatic brain injury in adolescents	BRAIN INJURY			English	Article						Empathy; moral reasoning; social skills; traumatic brain injury	JUVENILE-DELINQUENTS; EXECUTIVE FUNCTION; CONDUCT DISORDER; CHILDREN; BEHAVIOR; EMOTION; CHILDHOOD; DAMAGE; TERM; JUDGMENT	Primary objective: Traumatic brain injury (TBI) sustained during childhood can affect a number of socio-cognitive skills; however, little attention has focused on the integrity of moral reasoning in the assessment of post-TBI social sequelae and the role of empathy and intelligence on moral maturity. Research design: In a quasi-experimental, cross-sectional research design, moral reasoning maturity and empathy in adolescents with mild-to-severe TBI (n = 25) were compared to typically-developing peers (n = 66). Methods and procedures: Participants were administered the So-Moral and So-Mature, tasks of socio-moral reasoning and maturity, the Index of Empathy for Children and Adolescents, the Wechsler Abbreviated Scale of Intelligence and a demographic questionnaire. Main outcomes and results: Participants with TBI had significantly lower levels of moral reasoning maturity. Further, adolescents with moderate-to-severe TBI had lower levels of empathy. Empathy correlated positively with moral reasoning abilities and, together with intellectual function, predicted a small, but significant proportion of moral reasoning outcome. Conclusions: Youth who sustained TBI during childhood have poorer moral reasoning abilities than their non-injured peers, potentially placing them at risk for poor social decision-making and socially maladaptive behaviour. This can have a significant impact on long-term social functioning.	[Beauchamp, M. H.] Univ Montreal, Dept Psychol, Montreal, PQ H3C 3J7, Canada; [Beauchamp, M. H.] Ste Justine Hosp, Res Ctr, Montreal, PQ, Canada; [Dooley, J. J.] Edith Cowan Univ, Sch Law & Justice, Sellenger Ctr Res Law Justice & Social Change, Joondalup, WA, Australia; [Anderson, V.] Murdoch Childrens Res Inst, Melbourne, Vic, Australia; [Anderson, V.] Royal Childrens Hosp, Dept Psychol, Parkville, Vic 3052, Australia; [Anderson, V.] Univ Melbourne, Sch Behav Sci, Melbourne, Vic, Australia	Beauchamp, MH (corresponding author), Univ Montreal, Dept Psychol, CP 6128 Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.	miriam.beauchamp@umontreal.ca			Murdoch Childrens Research Institute; Social Sciences and Humanities Research Council of CanadaSocial Sciences and Humanities Research Council of Canada (SSHRC); Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Quebec Health Research Funds (FRSQ)Fonds de la Recherche en Sante du Quebec	This project was funded by the Murdoch Childrens Research Institute, the Social Sciences and Humanities Research Council of Canada and by fellowships to MB from the Canadian Institutes of Health Research and the Quebec Health Research Funds (FRSQ). The funding sources were not involved in the design, collection, data analysis or interpretation of data. The authors report no conflicts of interest.	Anderson SW, 2006, J INT NEUROPSYCH SOC, V12, P224, DOI 10.1017/S1355617706060346; Anderson SW, 1999, NAT NEUROSCI, V2, P1032; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; [Anonymous], 2009, J HEAD TRAUMA REHAB, V24, P303; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; BRYANT BK, 1982, CHILD DEV, V53, P413, DOI 10.1111/j.1467-8624.1982.tb01331.x; Chudzik L, 2007, PSYCHOL REP, V101, P221, DOI 10.2466/PR0.101.1.221-236; Cohn ES, 2010, LAW HUMAN BEHAV, V34, P295, DOI 10.1007/s10979-009-9185-9; Couper E, 2002, BRAIN IMPAIR, V3, P105, DOI DOI 10.1375/BRIM.3.2.105; de Sousa A, 2011, CORTEX, V47, P526, DOI 10.1016/j.cortex.2010.02.004; Decety J, 2012, CEREB CORTEX, V22, P209, DOI 10.1093/cercor/bhr111; Dooley JJ, 2008, BRAIN INJURY, V22, P836, DOI 10.1080/02699050802425444; Dooley JJ, 2010, BRAIN IMPAIR, V11, P152, DOI 10.1375/brim.11.2.152; Eisenberg N, 2000, ANNU REV PSYCHOL, V51, P665, DOI 10.1146/annurev.psych.51.1.665; EISENBERG N, 1991, DEV PSYCHOL, V27, P849, DOI 10.1037/0012-1649.27.5.849; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Gibbs J. C., 1992, MORAL MATURITY MEASU; GRATTAN LM, 1992, BRAIN COGNITION, V20, P185, DOI 10.1016/0278-2626(92)90068-W; Haidt J, 2001, PSYCHOL REV, V108, P814, DOI 10.1037//0033-295X.108.4.814; Hanten G, 2012, DEV SOCIAL NEUROSCIE; Jolliffe D, 2004, AGGRESS VIOLENT BEH, V9, P441, DOI 10.1016/j.avb.2003.03.001; Kenny DT, 2007, COMTEMPORARY ISSUES, V107, P1; Knobe J, 2005, TRENDS COGN SCI, V9, P357, DOI 10.1016/j.tics.2005.06.011; Koenigs M, 2007, NATURE, V446, P908, DOI 10.1038/nature05631; Kohlberg L., 1984, ESSAYS MORAL DEV, V2; Lane JD, 2010, BRIT J DEV PSYCHOL, V28, P871, DOI 10.1348/026151009X483056; Aristu AL, 2008, SPAN J PSYCHOL, V11, P670, DOI 10.1017/S1138741600004674; Leon-Carrion J, 2003, BRAIN INJURY, V17, P207, DOI 10.1080/0269905021000010249; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Malti T, 2009, CHILD DEV, V80, P442, DOI 10.1111/j.1467-8624.2009.01271.x; MARLOWE WB, 1992, BRAIN COGNITION, V20, P205, DOI 10.1016/0278-2626(92)90070-3; Moll J, 2003, NEUROREPORT, V14, P299, DOI 10.1097/01.wnr.0000057866.05120.28; Muscara F, 2009, NEUROPSYCHOL REHABIL, V19, P541, DOI 10.1080/09602010802365223; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; NELSON JR, 1990, J ABNORM CHILD PSYCH, V18, P231, DOI 10.1007/BF00916562; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; PRIGATANO GP, 1993, NEUROPSYCHOL REHABIL, V3, P411, DOI 10.1080/09602019308401449; Pujol J, 2008, HUM BRAIN MAPP, V29, P910, DOI 10.1002/hbm.20436; Raaijmakers QAW, 2005, INT J BEHAV DEV, V29, P247, DOI 10.1080/01650250544000035; Raine A, 2002, J ABNORM CHILD PSYCH, V30, P311, DOI 10.1023/A:1015754122318; Roberts G, 2008, J PAEDIATR CHILD H, V44, P276, DOI 10.1111/j.1440-1754.2007.01251.x; Ross KA, 2011, BRAIN INJURY, V25, P1206, DOI 10.3109/02699052.2011.609519; Schmidt AT, 2010, NEUROPSYCHOLOGIA, V48, P2869, DOI 10.1016/j.neuropsychologia.2010.05.029; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; Stadler C, 2007, Z KINDER JUG-PSYCH, V35, P169, DOI 10.1024/1422-4917.35.3.169; Stams GJ, 2006, J ABNORM CHILD PSYCH, V34, P697, DOI 10.1007/s10802-006-9056-5; TEASDALE G, 1974, LANCET, V2, P81; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Umile EM, 2002, ARCH PHYS MED REHAB, V83, P1506, DOI 10.1053/apmr.2002.35092; Van Vugt E, 2011, INT J OFFENDER THER, V55, P1234, DOI 10.1177/0306624X11396441; Walz NC, 2010, J NEUROPSYCHOL, V4, P181, DOI 10.1348/174866410X488788; Wechsler D., 2011, WECHLSER ABBREVIATED; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X; Wood RL, 2008, J INT NEUROPSYCH SOC, V14, P289, DOI 10.1017/S1355617708080326; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yeates KO, 2010, J INT NEUROPSYCH SOC, V16, P953, DOI 10.1017/S1355617710000986; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Young L, 2010, NEURON, V65, P845, DOI 10.1016/j.neuron.2010.03.003	62	32	32	0	28	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2013	27	7-8					896	902		10.3109/02699052.2013.775486			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	169UO	WOS:000320806200017	23789866				2021-06-18	
J	Elterman, J; Brasel, K; Brown, S; Bulger, E; Christenson, J; Kerby, JD; Kannas, D; Lin, S; Minei, JP; Rizoli, S; Tisherman, S; Schreiber, MA				Elterman, Joel; Brasel, Karen; Brown, Siobhan; Bulger, Eileen; Christenson, Jim; Kerby, Jeffrey D.; Kannas, Delores; Lin, Steven; Minei, Joseph P.; Rizoli, Sandro; Tisherman, Samuel; Schreiber, Martin A.		Resuscitation Outcomes Consortium	Transfusion of red blood cells in patients with a prehospital Glasgow Coma Scale score of 8 or less and no evidence of shock is associated with worse outcomes	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	26th Annual Scientific Assembly of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 15-19, 2013	Scottsdale, AZ	Eastern Assoc Surg Trauma		Traumatic brain injury; transfusion; resuscitation	TRAUMATIC BRAIN-INJURY; CEREBRAL OXYGENATION; SEVERITY SCORE; RISK; ADMISSION; INSULTS	BACKGROUND: Red blood cell transfusion practices vary, and the optimal hemoglobin for patients with traumatic brain injury has not been established. METHODS: A retrospective review of data collected prospectively as part of a randomized, controlled trial involving emergency medical service agencies within the Resuscitation Outcomes Consortium was conducted. In patients with a Glasgow Coma Scale (GCS) score of 8 or less without evidence of shock (defined by a systolic blood pressure [SBP] G 70 or SBP of 70 to 90 with a heart rate >= 108), the association of red blood cell transfusion with 28-day survival, adult respiratory distress syndrome-free survival, Multiple Organ Dysfunction Score (MODs), and 6-month Extended Glasgow Outcome Scale (GOSE) score was modeled using multivariable logistic regression with robust SEs adjusting for age, sex, injury severity (Injury Severity Score [ISS]), initial GCS score, initial SBP, highest field heart rate, penetrating injury, fluid use, study site, and hemoglobin (Hgb) level. RESULTS: A total of 1,158 patients had a mean age of 40, 76% were male, and 98% experienced blunt trauma. The initial mean GCS score was 5, and the initial mean SBP was 134. The mean head Abbreviated Injury Scale (AIS) score was 3.5. A categorical interaction of red blood cell transfusion stratified by initial Hgb showed that when the first Hgb was greater than 10 g/dL, volume of packed red blood cell was associated with a decreased 28-day survival (odds ratio, 0.83; 95% confidence interval [CI], 0.74-0.93; p < 0.01) and decreased adult respiratory distress syndrome-free survival (odds ratio, 0.82; 95% CI, 0.74-0.92; p < 0.01). When the initial Hgb was greater than 10, each unit of blood transfused increased the MODs by 0.45 (coefficient 95% CI, 0.19-0.70; p < 0.01). CONCLUSION: In patients with a suspected traumatic brain injury and no evidence of shock, transfusion of red blood cells was associated with worse outcomes when the initial Hgb was greater than 10. Copyright (C) 2013 by Lippincott Williams & Wilkins	[Elterman, Joel; Schreiber, Martin A.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA; [Brasel, Karen] Med Coll Wisconsin, Milwaukie, WI USA; [Brown, Siobhan; Bulger, Eileen; Kannas, Delores] Univ Washington, Seattle, WA 98195 USA; [Kerby, Jeffrey D.] Univ Alabama Birmingham, Birmingham, AL USA; [Minei, Joseph P.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Tisherman, Samuel] Univ Pittsburgh, Pittsburgh, PA USA; [Christenson, Jim] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Lin, Steven] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Rizoli, Sandro] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada	Elterman, J (corresponding author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,Mail Code L611, Portland, OR 97239 USA.	joel.b.elterman.mil@mail.mil	Lin, Steve/H-3723-2013; Tisherman, Samuel A./AAK-9377-2020	Lin, Steve/0000-0002-8644-9719; Tisherman, Samuel A./0000-0003-3810-3729; Brown, Siobhan/0000-0002-4774-3122	NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01HL077872, U01HL077863, U01HL077885, U01HL077881, U01HL077873, U01HL077887, U01HL077867, U01HL077871, U01HL077866] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [U01 HL077863, U01 HL077908, U01 HL077873, U01 HL077872, U01 HL077865, U01 HL077867, U01 HL077885, U01 HL077866, U01 HL077871, U01 HL077887, U01 HL077881] Funding Source: Medline		BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BERNARD GR, 1994, INTENS CARE MED, V20, P225, DOI 10.1007/BF01704707; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Carson JL, 1999, TRANSFUSION, V39, P694, DOI 10.1046/j.1537-2995.1999.39070694.x; Claridge JA, 2002, AM SURGEON, V68, P566; Committee on Trauma-American College of Surgeons, 2008, ATLS ADV TRAUM LIF S; Dunne James R, 2004, Surg Infect (Larchmt), V5, P395, DOI 10.1089/sur.2004.5.395; Figaji AA, 2010, PEDIATR CRIT CARE ME, V11, P325, DOI 10.1097/PCC.0b013e3181b80a8e; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; Langois JA, 2004, TRAUMATIC BRAIN INJU; Leal-Noval SR, 2008, CURR OPIN CRIT CARE, V14, P156, DOI 10.1097/MCC.0b013e3282f57577; Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C; Malone DL, 2000, CRIT CARE MED, V28, pA138; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; Moore FA, 1997, ARCH SURG-CHICAGO, V132, P620; Leal-Noval SR, 2008, CRIT CARE MED, V36, P1290, DOI 10.1097/CCM.0b013e3181692dfc; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Rubin DB., 2004, MULTIPLE IMPUTATION; Salim A, 2008, J AM COLL SURGEONS, V207, P398, DOI 10.1016/j.jamcollsurg.2008.03.013; Sena MJ, 2009, INTENS CARE MED, V35, P480, DOI 10.1007/s00134-008-1289-z; The Brain Trauma Foundation, GUID MAN SEV TRAUM B; Utter GH, 2011, J NEUROTRAUM, V28, P155, DOI 10.1089/neu.2010.1451; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	26	32	33	1	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2013	75	1					8	14		10.1097/TA.0b013e318298492e			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	300EV	WOS:000330448100002	23778432	Green Accepted			2021-06-18	
J	Immonen, R; Kharatishvili, I; Grohn, O; Pitkanen, A				Immonen, Riikka; Kharatishvili, Irina; Grohn, Olli; Pitkanen, Asla			MRI Biomarkers for Post-Traumatic Epileptogenesis	JOURNAL OF NEUROTRAUMA			English	Article						epilepsy; magnetic resonance imaging; traumatic brain injury	BRAIN-INJURY; SEIZURE SUSCEPTIBILITY; EPILEPSY; HIPPOCAMPUS; MODELS; RATS	The present study tested a hypothesis that early identification of injury severity with quantitative magnetic resonance imaging (MRI) provides biomarkers for predicting increased seizure susceptibility and epileptogenesis after traumatic brain injury (TBI). TBI was induced by lateral fluid percussion injury (FPI) in adult rats. Quantitative T2, T1 rho, and diffusion were assessed with MRI at 9 days, 23 days, or 2 months post-TBI in the perilesional cortex, thalamus, and hippocampus. Seizure susceptibility was assessed at 12 months after TBI using the pentylenetetrazol seizure-susceptibility test. At 9 and 23 days post-TBI, a change in T1 rho of the perilesional cortex showed the greatest predictive value for increased seizure susceptibility at 12 months post-TBI [area under the curve (AUC), 0.929 and 0.952, respectively; p < 0.01]. At 2 months post-TBI, Dav in the thalamus was the best of the biomarkers analyzed (AUC, 0.988; p < 0.05). The highest predictive value of all biomarkers was achieved by combining the measurement of Dav in the perilesional cortex and the thalamus at 2 months post-TBI (AUC, 1.000; p < 0.01). Our results provide proof-of-concept evidence that clinically relevant MRI biomarkers predict increased seizure susceptibility after experimental TBI.	[Immonen, Riikka; Grohn, Olli; Pitkanen, Asla] Univ Eastern Finland, Dept Neurobiol, AI Virtanen Inst Mol Sci, FI-70211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland; [Kharatishvili, Irina] Univ Queensland, Ctr Adv Imaging, Brisbane, Qld, Australia	Pitkanen, A (corresponding author), Univ Eastern Finland, Dept Neurobiol, AI Virtanen Inst Mol Sci, POB 1627, FI-70211 Kuopio, Finland.	asla.pitkanen@uef.fi			Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation	This study was supported by the Academy of Finland (to R.I., O.G., and A.P.) and the Sigrid Juselius Foundation (to A.P.).	Airaksinen AM, 2012, ISMRM 20 ANN M MELB; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Baulac M., 2009, EPILEPSIA, V50, P571; Blanco MM, 2009, EPILEPSIA, V50, P824, DOI 10.1111/j.1528-1167.2008.01797.x; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Engel J, 2011, BIOMARK MED, V5, P537, DOI [10.2217/BMM.11.62, 10.2217/bmm.11.62]; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; Kelley Melinda S, 2009, Epilepsia, V50, P579, DOI 10.1111/j.1528-1167.2008.01813.x; Kharatishvili I, 2007, BRAIN, V130, P3155, DOI 10.1093/brain/awm268; Pitkanen A, 2012, JASPERS BASIC MECH E; Pitkanen A, 2011, NEUROSCI LETT, V497, P163, DOI 10.1016/j.neulet.2011.02.033; Rattka M, 2011, NEUROPHARMACOLOGY, V60, P505, DOI 10.1016/j.neuropharm.2010.11.005; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; VEZZANI A, 1994, BRAIN RES, V660, P138, DOI 10.1016/0006-8993(94)90847-8; Yue L, 2011, EPILEPSY BEHAV, V22, P692, DOI 10.1016/j.yebeh.2011.08.022	17	32	32	1	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2013	30	14					1305	1309		10.1089/neu.2012.2815			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	183MV	WOS:000321821100011	23469770	Green Published			2021-06-18	
J	Joseph, B; Aziz, H; Sadoun, M; Kulvatunyou, N; Tang, A; O'Keeffe, T; Wynne, J; Gries, L; Green, DJ; Friese, RS; Rhee, P				Joseph, Bellal; Aziz, Hassan; Sadoun, Moutamn; Kulvatunyou, Narong; Tang, Andrew; O'Keeffe, Terence; Wynne, Julie; Gries, Lynn; Green, Donald J.; Friese, Randall S.; Rhee, Peter			The acute care surgery model: Managing traumatic brain injury without an inpatient neurosurgical consultation	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	26th Annual Scientific Assembly of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 15-19, 2013	Scottsdale, AZ	Eastern Assoc Surg Trauma		Acute care surgery model; mild traumatic brain injury; neurosurgical consultation; intracranial hemorrhage	MINIMAL HEAD-INJURY; COMPUTED-TOMOGRAPHY; CT; MANAGEMENT; UTILITY	BACKGROUND: Neurosurgical services are a limited resource and effective use of them would improve the health care system. Acute care surgeons (ACS) are accustomed to treating mild traumatic brain injury (TBI) including those with minor radiographic intracranial injuries. We hypothesized that ACS safely manage mild TBI with intracranial hemorrhage (ICH) on head computed tomographic (CT) scan without neurosurgical consultation (NC). METHODS: We performed a retrospective analysis on all TBI patients with positive findings on head CT scan managed without NC during a 2-year period. Propensity scoring matched NC to no-NC patients on a 1: 2 ratio for Glasgow Coma Scale (GCS) score, head Abbreviated Injury Scale (h-AIS) score, neurological examination, age, Injury Severity Score (ISS), findings of initial head CT scan including type and size of ICH. RESULTS: A total of 270 patients with mild TBI and positive CT scan findings were included (90 with NC and 180 without NC). Sixty-three percent were male, and mean (SD) age was 39 (25) years. The median GCS was 15 (13-15), and the h-AIS score was 2 (1-3). In both groups, there was no neurosurgical intervention, in-hospital mortality, or 30-day readmission. In the no-NC group, 8% of the patients had postdischarge emergency department (ED) visits compared with 4% of the NC group (p = 0.5). All patients with postdischarge ED visits in both groups were discharged home from the ED. CONCLUSION: ACS can manage mild TBI with ICH without obtaining an inpatient NC. Further guidelines should be established to help identify which patients meet criteria to be safely managed without NC. (J Trauma Acute Care Surg. 2013; 75: 102-105. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Joseph, Bellal; Aziz, Hassan; Sadoun, Moutamn; Kulvatunyou, Narong; Tang, Andrew; O'Keeffe, Terence; Wynne, Julie; Gries, Lynn; Green, Donald J.; Friese, Randall S.; Rhee, Peter] Univ Arizona, Dept Surg, Div Trauma, Tucson, AZ 85724 USA	Joseph, B (corresponding author), Univ Arizona, Dept Surg, Div Trauma Crit Care & Emergency Surg, 1501 N Campbell Ave,Room 5411,POB 245063, Tucson, AZ 85724 USA.	bjoseph@surgery.arizona.edu					Barker DE, 2006, AM SURGEON, V72, P1166; Brown CVR, 2004, J TRAUMA, V57, P939, DOI 10.1097/01.TA.0000149492.92558.03; Esposito TJ, 2005, ANN SURG, V242, P364, DOI 10.1097/01.sla.0000179624.50455.db; Harbrecht BG, 2010, J TRAUMA, V68, P1367, DOI 10.1097/TA.0b013e3181d990da; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Huynh T, 2006, AM SURGEON, V72, P1162; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; Levy AS, 2011, J TRAUMA, V71, P1199, DOI 10.1097/TA.0b013e31822067fc; Nishijima DK, 2011, J TRAUMA, V70, pE101, DOI 10.1097/TA.0b013e3181e88bcb; RHODES M, 1993, J TRAUMA, V35, P384, DOI 10.1097/00005373-199309000-00009; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Sifri ZC, 2006, J TRAUMA, V61, P862, DOI 10.1097/01.ta.0000224225.54982.90; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; Stein SC, 2006, J TRAUMA, V61, P558, DOI 10.1097/01.ta.0000233766.60315.5e; Stippler M, 2012, EMERG MED J, V29, P528, DOI 10.1136/emermed-2011-200162; Tang AL, 2010, SCAND J SURG, V99, P61, DOI 10.1177/145749691009900202; Valadka AB, 2001, NEUROSURGERY, V48, P17, DOI 10.1097/00006123-200101000-00004; Valadka AB, 2010, J TRAUMA, V68, P1372; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Washington CW, 2012, J NEUROSURG, V116, P549, DOI 10.3171/2011.11.JNS111092	21	32	32	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2013	75	1					102	105		10.1097/TA.0b013e3182946667			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	300EV	WOS:000330448100027	23778447				2021-06-18	
J	Mathias, JL; Dennington, V; Bowden, SC; Bigler, ED				Mathias, J. L.; Dennington, V.; Bowden, S. C.; Bigler, E. D.			Community versus orthopaedic controls in traumatic brain injury research: How comparable are they?	BRAIN INJURY			English	Article						Community controls; control groups; injury controls; orthopedic controls; research design; TBI; traumatic brain injury; trauma controls	MILD HEAD-INJURY; UNIVERSITY-STUDENTS; SOCIAL SUPPORT; CHILDREN; ADOLESCENTS; PERFORMANCE; SENSITIVITY; SEVERITY; SYMPTOMS; SCALE	Background: Community (CC) or orthopaedic/injury (OC) control groups are typically used to evaluate the consequences of traumatic brain injuries (TBIs). Whereas CCs match for demographic variables and are readily available, OCs may additionally control for other pre- and post-injury variables but are more costly to recruit. Together, they enable an evaluation of brain-vs general-injury effects. However, the comparability of these two groups and the increase in control over confounding variables when OCs are used has rarely been examined. Method: The current study compared samples of CCs (n = 71) and OCs (n = 69), aged between 18-80, on a range of demographic (age, gender, education, socio-economic status), background (medical history, handedness), psychosocial (alcohol use, fatigue, pain, depression, social support, community integration, 'post-concussion' symptoms) and cognitive (motor and processing speed, memory, intellectual ability) variables. Results: The two groups were comparable on all variables, except alcohol use, with the OC group having higher levels of alcohol consumption. However, alcohol use did not correlate with any other variable, including commonly used measures of outcome following TBI. Conclusion: The current findings suggest that an orthopaedic injury control group does not have any clear advantages over a carefully recruited community control group.	[Mathias, J. L.; Dennington, V.] Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia; [Bowden, S. C.] Univ Melbourne, Dept Psychol, Melbourne, Vic, Australia; [Bigler, E. D.] Brigham Young Univ, Dept Psychol & Neurosci, Provo, UT 84602 USA; [Bigler, E. D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA	Mathias, JL (corresponding author), Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia.	jane.mathias@adelaide.edu.au	Mathias, J L/L-6295-2013	Mathias, Jane/0000-0001-8957-8594	National Health and Medical Research Foundation [519220]	This research was funded by Project Grant number 519220 from the National Health and Medical Research Foundation.	Adams C., 2008, ERGONOMICS; Alfano MS, 2000, J CLIN PSYCHOL, V56, P975, DOI 10.1002/1097-4679(200007)56:7<975::AID-JCLP13>3.0.CO;2-Z; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR, P117; [Australian Bureau of Statistics Statistics ABo], 1999, NAT SURV US MED; Australian Bureau of Statistics, 1995, NAT HLTH SURV SF 36; Australian Bureau of Statistics, 2008, AUSTR SOC TRENDS; Australian Bureau of Statistics, 2008, CENS POP HOUS SOC IN; [Australian Bureau of Statistics Statistics ABo], 2001, NAT HLTH SURV INJ, V4384.0; Babor T. F., 1989, AUDIT ALCOHOL DISORD; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BIJUR PE, 1990, PEDIATRICS, V86, P337; Boone KB, 2002, J CLIN EXP NEUROPSYC, V24, P561, DOI 10.1076/jcen.24.5.561.1004; Carroll Linda J., 2004, Journal of Rehabilitation Medicine Supplement, P113; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cook T.D., 1979, QUASIEXPERIMENTAL DE; CURRY LM, 1991, PHILADELPHIA HEAD IN; Day AL, 2003, CAN J BEHAV SCI, V35, P73, DOI 10.1037/h0087190; De Monte VE, 2010, J CLIN EXP NEUROPSYC, V32, P28, DOI 10.1080/13803390902806519; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V8, P30, DOI DOI 10.1097/00001199-199309000-00005; Ettenhofer ML, 2012, J INT NEUROPSYCH SOC, V18, P451, DOI 10.1017/S1355617711001895; Ettenhofer ML, 2009, J CLIN EXP NEUROPSYC, V31, P363, DOI 10.1080/13803390802175270; Fischer S, 2004, J INT NEUROPSYCH SOC, V10, P190, DOI 10.1017/S1355617704102051; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Mathias JL, 2004, APPL NEUROPSYCHOL, V11, P134, DOI 10.1207/s15324826an1103_2; Max JE, 1999, J INT NEUROPSYCH SOC, V5, P58, DOI 10.1017/S1355617799511089; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Milders M, 2006, NEUROPSYCHOLOGY, V20, P400, DOI 10.1037/0894-4105.20.4.400; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Reitan RM, 1979, MANUAL ADM NEUROPSYC; Rieger M, 2002, NEUROPSYCHOLOGIA, V40, P76, DOI 10.1016/S0028-3932(01)00068-9; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 2001, CURR DIR PSYCHOL SCI, V10, P106, DOI 10.1111/1467-8721.00127; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Spreen O., 1998, COMPENDIUM NEUROPSYC; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 2001, WECHSLER TEST ADULT; Weiss DS, 1996, IMPACT EVENTS SCALE, P399; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; WINEFIELD HR, 1992, J PERS ASSESS, V58, P198, DOI 10.1207/s15327752jpa5801_17	45	32	32	0	14	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	JUL	2013	27	7-8					887	895		10.3109/02699052.2013.793398			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	169UO	WOS:000320806200016	23758520				2021-06-18	
J	Sonmez, E; Kabatas, S; Ozen, O; Karabay, G; Turkoglu, S; Ogus, E; Yilmaz, C; Caner, H; Altinors, N				Sonmez, Erkin; Kabatas, Serdar; Ozen, Ozlem; Karabay, Gulten; Turkoglu, Suna; Ogus, Ersin; Yilmaz, Cem; Caner, Hakan; Altinors, Nur			Minocycline Treatment Inhibits Lipid Peroxidation, Preserves Spinal Cord Ultrastructure, and Improves Functional Outcome After Traumatic Spinal Cord Injury in the Rat	SPINE			English	Article						apoptosis; behavioral assessment; lipid peroxidation; minocycline; neuroprotection; traumatic spinal cord injury	NEUROPROTECTIVE AGENT; RECOVERY; BRAIN; ACTIVATION; MEXILETINE	Study design. A prospective, randomized experimental research. Objective. To evaluate the short- and long-term neuroprotective effects of minocycline on the secondary injury process of an experimental traumatic spinal cord injury (SCI) model. Summary of Background Data. Traumatic SCI is a devastating problem of health that results in high morbidity and mortality rates. The loss of function after SCI results from both the primary mechanical insult and the subsequent, multifaceted secondary response. Methods. A total of 80 adult male Spraque-Dawley rats (breeded by the Baskent University Animal Research Center) were randomly divided into 4 groups. A T10 contusion injury was produced by using modified Allen technique in all groups except the control group. No medication was administered to the rats in the trauma group. Minocycline was administered intraperitoneally and intravenously to the treatment groups. Short-term and/or long-term neuroprotective effects of minocycline on the lipid peroxidation (malondialdehyde, glutathione), apoptosis (terminal deoxynucleotidyl transferase mediated deoxyuridine triphosphate-biotin nick end labeling), ultrastructure of spinal cord (tissue electron microscopy), and behavioral assessments (Basso-Beattie-Bresnahan) were evaluated. Results. As compared with the trauma group, tissue malondialdehyde and glutathione levels demonstrated that minocycline significantly diminishes lipid peroxidation. Electromicroscopic study showed that minocycline preserves the ultrastructure of spinal cord tissue in the early post-traumatic period. Minocycline treatment significantly reduced the number of terminal deoxynucleotidyl trans-ferase mediated deoxyuridine triphosphate-biotin nick end labeling positive cells both 1 day and 28 days after SCI. Behavioral assessments showed significant improvement in the hind limb functions of minocycline receiving rats starting 7 days after the SCI. Any statistically significant difference was not found between intraperitoneal or intravenous routes for minocycline injection. Conclusion. Minocycline is neuroprotective and contributes to functional improvement after traumatic SCI by eliminating the destructive process of secondary injury. Having both satisfying antiinfl ammatory and antiapoptotic effects in experimental models, it promises to be of therapeutic use in human SCI.	[Sonmez, Erkin; Yilmaz, Cem; Caner, Hakan; Altinors, Nur] Baskent Univ, Dept Neurosurg, Sch Med, TR-06490 Ankara, Turkey; [Ozen, Ozlem] Baskent Univ, Dept Pathol, Sch Med, TR-06490 Ankara, Turkey; [Karabay, Gulten] Baskent Univ, Dept Histol, Sch Med, TR-06490 Ankara, Turkey; [Turkoglu, Suna] Baskent Univ, Dept Biochem, Sch Med, TR-06490 Ankara, Turkey; [Ogus, Ersin] Baskent Univ, Dept Biostat, Sch Med, TR-06490 Ankara, Turkey; [Kabatas, Serdar] Baskent Univ, Istanbul Training & Res Hosp, Sch Med, Dept Neurosurg, Istanbul, Turkey	Sonmez, E (corresponding author), Baskent Univ, Dept Neurosurg, Sch Med, 10 Sokak,45, TR-06490 Ankara, Turkey.	erkinso@gmail.com	Sonmez, Erkin/AAI-8820-2021; Ozen, Ozlem/AAK-4468-2021; yilmaz, cem/AAK-2948-2021; Turkoglu, Suna/AAJ-2243-2021; Kabatas, Serdar/AAA-3069-2020; Ogus, Ersin/AAJ-1058-2021	Sonmez, Erkin/0000-0002-5693-3542; Ozen, Ozlem/0000-0002-9082-1317; yilmaz, cem/0000-0002-2353-8044; Turkoglu, Suna/0000-0003-4805-1918; Kabatas, Serdar/0000-0003-2691-6861; Ogus, Ersin/0000-0002-9877-421X	Baskent University Research FundsBaskent University	Baskent University Research Funds were received to support this work.	BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Buege J A, 1978, Methods Enzymol, V52, P302; Colovic M, 2003, J CHROMATOGR B, V791, P337, DOI 10.1016/S1570-0232(03)00247-2; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fagan SC, 2004, EXP NEUROL, V186, P248, DOI 10.1016/j.expneurol.2003.12.006; Garrido-Mesa N, 2013, PHARMACOL RES, V67, P18, DOI 10.1016/j.phrs.2012.10.006; Kaptanoglu E, 2005, J NEUROSURG-SPINE, V3, P53, DOI 10.3171/spi.2005.3.1.0053; Kaptanoglu E, 2002, J NEUROSURG, V97, P49, DOI 10.3171/spi.2002.97.1.0049; Kaptanoglu E, 2004, NEUROSURG REV, V27, P113, DOI 10.1007/s10143-003-0300-y; Kaptanoglu E, 1999, J NEUROSURG, V91, P200, DOI 10.3171/spi.1999.91.2.0200; Lee SM, 2003, J NEUROTRAUM, V20, P1017, DOI 10.1089/089771503770195867; Morimoto N, 2005, BRAIN RES, V1044, P8, DOI 10.1016/j.brainres.2005.02.062; Pinzon A, 2008, BRAIN RES, V1243, P146, DOI 10.1016/j.brainres.2008.09.047; Stirling DP, 2005, NEUROSCIENTIST, V11, P308, DOI 10.1177/1073858405275175; Teng YD, 2004, P NATL ACAD SCI USA, V101, P3071, DOI 10.1073/pnas.0306239101; Wells JEA, 2003, BRAIN, V126, P1628, DOI 10.1093/brain/awg178; Xu L, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-7; Yong VW, 2004, LANCET NEUROL, V3, P744, DOI 10.1016/S1474-4422(04)00937-8; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769	19	32	36	0	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436	1528-1159		SPINE	SPINE	JUL 1	2013	38	15					1253	1259		10.1097/BRS.0b013e3182895587			7	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	298XR	WOS:000330358500012	23370685				2021-06-18	
J	Graham, DP; Helmer, DA; Harding, MJ; Kosten, TR; Petersen, NJ; Nielsen, DA				Graham, David P.; Helmer, Drew A.; Harding, Mark J.; Kosten, Thomas R.; Petersen, Nancy J.; Nielsen, David A.			Serotonin transporter genotype and mild traumatic brain injury independently influence resilience and perception of limitations in veterans	JOURNAL OF PSYCHIATRIC RESEARCH			English	Article						Genetic Factors; Polymorphism; Resilience; Serotonin Transporter; Traumatic Brain Injury; Veterans	POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSION SYNDROME; COMMUNITY REINTEGRATION; PROMOTER POLYMORPHISM; 5-HTTLPR GENOTYPE; BIASED ATTENTION; FEMALE VETERANS; PTSD CHECKLIST; GENE; DEPRESSION	Evidence indicates that individuals with the 5-HTTLPR variant short/short genotype have increased sensitivity to both positive and negative perceptions of perceived social support. The aim of this study was to evaluate this association among Veterans in the context of mild traumatic brain injury (TBI). As part of a larger TBI center, we performed a cross-sectional study of 67 OEF/OIF/OND Veterans (41 with TBI and 26 controls without TBI) who completed the questionnaires and consented to genetic testing. The primary measures included the Connor-Davidson Resilience Scale (CDRISC) and the Perceived Limitations in community participation subscale of the Community Reintegration of Service Members Instrument (CRIS-PL). Both 5-HTTLPR genotype and TBI status were independently associated with the CRIS-PL (p = .009 for genotype, p = .001 for TBI) and the CDRISC (p = .015 for genotype, p = .003 for TBI) scores. This study suggests that both the 5-HTTLPR genotype and TBI status independently, in an almost equal but opposite direction, influence resilience and perceived limitations to social participation. Further, resilience appears more sensitive to perceived limitations in Veterans carrying an S'S' genotype than in L' carriers, but only in the context of having sustained a TBI. While having a TBI appeared to increase a Veteran's sensitivity to social stress, the Veteran's who were L' allele carriers with a TBI fared the worst, with lower resilience and more perceived limitations for community participation compared to L' carrier Veterans without a TBI or Veterans with the S'S' genotype regardless of TBI status. Published by Elsevier Ltd.	[Graham, David P.; Helmer, Drew A.; Harding, Mark J.; Kosten, Thomas R.; Petersen, Nancy J.; Nielsen, David A.] Michael E DeBakey Vet Affairs VA Med Ctr, Neurorehabil Neurons Networks Traumat Brain Injur, Houston, TX USA; [Graham, David P.; Harding, Mark J.; Nielsen, David A.] Baylor Coll Med, Menninger Dept Psychiat & Behav Sci, Houston, TX 77030 USA; [Graham, David P.] South Cent Mental Illness Res Educ & Clin Ctr MIR, Dept Vet Affairs, Houston, TX USA; [Helmer, Drew A.] VA New Jersey Healthcare Syst, War Related Injury & Illness Ctr, E Orange, NJ USA; [Helmer, Drew A.] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; [Petersen, Nancy J.] Michael E DeBakey Vet Affairs VA Med Ctr, Houston VA Hlth Serv Res & Dev Ctr Excellence, Houston, TX USA	Graham, DP (corresponding author), Michael E DeBakey VAMC, 2002 Holcombe Blvd 153 TBI,Bldg 100,STE 2B-126A, Houston, TX 77030 USA.	david.graham@va.gov	Nielsen, David A/B-4655-2009; Kosten, Thomas/AAI-5998-2021; Graham, David/J-1158-2014		Department of Veterans AffairsUS Department of Veterans Affairs; Veterans Health AdministrationUS Department of Veterans Affairs; Office of Research and Development; Rehabilitation Research and Development ServiceUS Department of Veterans Affairs; Neurons to Networks TBI Center of Excellence [B6812C]; Office of Research and Development, Rehabilitation Research and Development Service Career Development Award-2 [B7496W]; Houston VA HSR&D Center of Excellence [HFP90-020, DA026120 NIH/NIDA DA026120]; Toomim Family Fund; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [R25DA026120] Funding Source: NIH RePORTER	This material is based upon work supported (or supported in part) by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Rehabilitation Research and Development Service: the Neurorehabilitation: Neurons to Networks TBI Center of Excellence (Grant #B6812C), Office of Research and Development, Rehabilitation Research and Development Service Career Development Award-2 (Grant #B7496W), in part by the Houston VA HSR&D Center of Excellence (HFP90-020); through MD Anderson's Cancer Center Support Grant DA026120 NIH/NIDA DA026120, and the Toomim Family Fund. The funding sources had no role in the study design; in the collection, analysis, or interpretation of the data; in the writing of the manuscript; or in the decision to submit the paper for publication.	Amstadter AB, 2012, J PSYCHIATR RES, V46, P87, DOI 10.1016/j.jpsychires.2011.09.017; Belanger HG, 2009, J HEAD TRAUMA REHAB, V24, P4, DOI 10.1097/HTR.0b013e3181957032; Brody GH, 2009, CHILD DEV, V80, P645, DOI 10.1111/j.1467-8624.2009.01288.x; Brody GH, 2009, J CONSULT CLIN PSYCH, V77, P1, DOI 10.1037/a0012996; Carli V, 2011, EUR PSYCHIAT, V26, P471, DOI 10.1016/j.eurpsy.2011.04.008; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Caspi A, 2006, NAT REV NEUROSCI, V7, P583, DOI 10.1038/nrn1925; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Davidson J, 2008, INT CLIN PSYCHOPHARM, V23, P299, DOI 10.1097/YIC.0b013e32830c202d; Dobie DJ, 2002, GEN HOSP PSYCHIAT, V24, P367, DOI 10.1016/S0163-8343(02)00207-4; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Faul F, 2009, BEHAV RES METHODS, V41, P1149, DOI 10.3758/BRM.41.4.1149; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; Fox E, 2011, BIOL PSYCHIAT, V70, P1049, DOI 10.1016/j.biopsych.2011.07.004; Fox E, 2009, P R SOC B, V276, P1747, DOI 10.1098/rspb.2008.1788; Haddley K, 2012, Curr Top Behav Neurosci, V12, P503; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Hariri AR, 2009, ANNU REV NEUROSCI, V32, P225, DOI 10.1146/annurev.neuro.051508.135335; Herman D., 1993, ANN CONV INT SOC TRA; Hu XZ, 2006, AM J HUM GENET, V78, P815, DOI 10.1086/503850; Hu XZ, 2005, ALCOHOL CLIN EXP RES, V29, P8, DOI 10.1097/01.ALC.0000150008.68473.62; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Kaufman J, 2004, P NATL ACAD SCI USA, V101, P17316, DOI 10.1073/pnas.0404376101; Kilpatrick DG, 2007, AM J PSYCHIAT, V164, P1693, DOI 10.1176/appi.ajp.2007.06122007; Kwang T, 2010, DEPRESS ANXIETY, V27, P746, DOI 10.1002/da.20708; Lang AJ, 2003, J TRAUMA STRESS, V16, P257, DOI 10.1023/A:1023796007788; Lesch KP, 1996, SCIENCE, V274, P1527, DOI 10.1126/science.274.5292.1527; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Luthar SS, 2000, CHILD DEV, V71, P573, DOI 10.1111/1467-8624.00168; Luthar SS, 2000, CHILD DEV, V71, P543, DOI 10.1111/1467-8624.00164; Manuck SB, 2004, PSYCHONEUROENDOCRINO, V29, P651, DOI 10.1016/S0306-4530(03)00094-5; Markus CR, 2011, NEUROPSYCHOPHARMACOL, V36, P819, DOI 10.1038/npp.2010.221; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; O'Hara R, 2012, AM J GERIATRIC PSYCH, V00, P00; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Resnik L, 2011, J REHABIL RES DEV, V48, P89, DOI 10.1682/JRRD.2010.04.0070; Resnik L, 2009, J REHABIL RES DEV, V46, P469, DOI 10.1682/JRRD.2008.07.0082; Resnik LJ, 2007, J REHABIL RES DEV, V44, P991, DOI 10.1682/JRRD.2007.05.0071; ROBERTS RE, 1983, AM J PSYCHIAT, V140, P41; Roy A, 2007, NEUROPSYCHOPHARMACOL, V32, P2046, DOI 10.1038/sj.npp.1301331; Stein MB, 2008, NEUROPSYCHOPHARMACOL, V33, P312, DOI 10.1038/sj.npp.1301422; Stein MB, 2006, PSYCHOPHARMACOLOGY, V187, P68, DOI 10.1007/s00213-006-0349-8; Taylor SE, 2006, BIOL PSYCHIAT, V60, P671, DOI 10.1016/j.biopsych.2006.04.019; Uher R, 2010, MOL PSYCHIATR, V15, P18, DOI 10.1038/mp.2009.123; Uher R, 2009, MOL PSYCHIATR, V14, P1072, DOI 10.1038/mp.2009.85; Verschoor E, 2011, STRESS, V14, P407, DOI 10.3109/10253890.2010.548886; Walker EA, 2002, GEN HOSP PSYCHIAT, V24, P375, DOI 10.1016/S0163-8343(02)00203-7; Way BM, 2010, SOC COGN AFFECT NEUR, V5, P203, DOI 10.1093/scan/nsq059; Way BM, 2010, PSYCHOSOM MED, V72, P107, DOI 10.1097/PSY.0b013e3181ce6a7d; Wermter AK, 2010, EUR CHILD ADOLES PSY, V19, P199, DOI 10.1007/s00787-009-0082-z; Windle G, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-8; Woltman H., 2012, TUTOR QUANT METHODS, V8, P52, DOI [10.20982/tqmp.08.1.p052, DOI 10.20982/TQMP.08.1.P052]; Xie PX, 2009, ARCH GEN PSYCHIAT, V66, P1201, DOI 10.1001/archgenpsychiatry.2009.153	54	32	34	0	25	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3956	1879-1379		J PSYCHIATR RES	J. Psychiatr. Res.	JUN	2013	47	6					835	842		10.1016/j.jpsychires.2013.02.006			8	Psychiatry	Psychiatry	135ZH	WOS:000318328700019	23478049	Green Accepted			2021-06-18	
J	Sim, P; Power, E; Togher, L				Sim, Phoebe; Power, Emma; Togher, Leanne			Describing conversations between individuals with traumatic brain injury (TBI) and communication partners following communication partner training: Using exchange structure analysis	BRAIN INJURY			English	Article						Assessment; discourse analysis; discourse profiles; rehabilitation; social communication skills	QUALITY-OF-LIFE; DISCOURSE ABILITIES; SOCIAL INTEGRATION; PEOPLE; SKILLS; APHASIA; ADULTS; COHESION; OUTCOMES; IMPACT	Primary objective: To describe conversational discourse change after joint communication training for individuals with TBI and their everyday communication partners (ECPs), as compared to untrained controls. Hypothesis: Joint training would lead to significantly greater changes in the discourse behaviour of trained participants. Methods and procedures: In this multi-centre non-randomized controlled trial, 29 participants with severe TBI and their ECPs were allocated to either the JOINT training or CONTROL group. Social communication training aimed to train ECPs to better support their partner with TBI to produce more effective conversations. Pre- and post-training casual conversations were compared using exchange structure analysis (ESA) and productivity analysis. Results: ESA and productivity analysis revealed significant change in the use of testing moves by trained ECPs and significant change in productivity by trained participants with TBI. ESA facilitated development of discourse profiles (excessive or impoverished) for participants with TBI, which distinguished the groups at baseline. Conclusions: This study extends one's understanding of individual discourse styles in people with TBI. The impact of different discourse styles on group outcome studies has been highlighted. These discourse findings may facilitate goal-setting in social skills intervention after TBI, with focus on training ECPs to support people with TBI in conversations.	[Sim, Phoebe; Power, Emma; Togher, Leanne] Univ Sydney, Discipline Speech Pathol, Fac Hlth Sci, Lidcombe, NSW 1825, Australia	Togher, L (corresponding author), Univ Sydney, Discipline Speech Pathol, Fac Hlth Sci, 75 East St,POB 170, Lidcombe, NSW 1825, Australia.	leanne.togher@sydney.edu.au	Togher, Leanne/AAC-7083-2019; Power, Emma/A-9263-2015	Power, Emma/0000-0002-2638-0406; Togher, Leanne/0000-0002-4518-6748	National Health and Medical Research CouncilNational Health and Medical Research Council of Australia	The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper. This study was supported by a National Health and Medical Research Council project grant.	Adamovich B. B., 1992, SCALES COGNITIVE ABI; [Anonymous], 2011, IBM SPSS STAT 20 WIN; Argyrous G, 2005, STAT RES GUIDE SPSS; Auerbach S., 1986, J HEAD TRAUMA REHAB, V3, P1; BELLACK AS, 1983, BEHAV RES THER, V21, P29, DOI 10.1016/0005-7967(83)90123-7; Biddle KR, 1996, J COMMUN DISORD, V29, P447, DOI 10.1016/0021-9924(95)00038-0; Body R, 2005, CLIN LINGUIST PHONET, V19, P379, DOI 10.1080/02699200400027189; Bogart E, 2012, BRAIN INJURY, V26, P221, DOI 10.3109/02699052.2011.648711; Boles L, 1998, APHASIOLOGY, V12, P547, DOI 10.1080/02687039808249557; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; COELHO CA, 1995, APHASIOLOGY, V9, P409, DOI 10.1080/02687039508248707; Coelho CA, 2003, APHASIOLOGY, V17, P499, DOI 10.1080/02687030344000111; COELHO CA, 1999, BRAIN DAM B, P55; Coelho CA, 1991, J HEAD TRAUMA REHAB, V6, P92, DOI DOI 10.1097/00001199-199106000-00011; Coelho Carl A., 2007, Seminars in Speech and Language, V28, P122, DOI 10.1055/s-2007-970570; Cunningham R, 2003, APHASIOLOGY, V17, P687, DOI 10.1080/02687030344000184; Dahlberg C, 2006, BRAIN INJURY, V20, P425, DOI 10.1080/02699050600664574; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; De Silva MJ, 2009, INT J EPIDEMIOL, V38, P452, DOI 10.1093/ije/dyn189; Douglas JM, 2010, J SPEECH LANG HEAR R, V53, P365, DOI 10.1044/1092-4388(2009/08-0205); Eggins S., 1997, ANAL CASUAL CONVERSA; Field A. P, 2009, DISCOVERING STAT USI; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; Goldblum G, 2009, APHASIOLOGY, V23, P87, DOI 10.1080/02687030802024094; Halliday M., 1994, INTRO FUNCTIONAL GRA, V3rd; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; Hopper T, 2002, APHASIOLOGY, V16, P745, DOI 10.1080/02687030244000059; Hough MS, 2003, APHASIOLOGY, V17, P183, DOI 10.1080/02687030244000608; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Isaki E, 2000, BRAIN INJURY, V14, P441; Johnson K, 1998, BEHAV MODIF, V22, P502, DOI 10.1177/01454455980224004; Johnston MV, 2006, BRAIN INJURY, V20, P391, DOI 10.1080/02699050500487795; Jorgensen M, 2009, BRAIN INJURY, V23, P727, DOI 10.1080/02699050903133954; Kagan A, 2001, J SPEECH LANG HEAR R, V44, P624, DOI 10.1044/1092-4388(2001/051); Kilov AM, 2009, APHASIOLOGY, V23, P584, DOI 10.1080/02687030701855382; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Lane-Brown AT, 2011, BRAIN IMPAIR, V12, P43, DOI 10.1375/brim.12.1.43; Larkins B, 1999, ASIA PACIFIC J SPEEC, V4, P183; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; McDonald S, 1999, COMMUNICATION DISORD; McDonald S., 2005, FUNCTIONAL ASSESSMEN; McDonald S., 2002, AWARENESS SOCIAL INF; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; MENTIS M, 1987, J SPEECH HEAR RES, V30, P88, DOI 10.1044/jshr.3001.88; MENTIS M, 1991, J SPEECH HEAR RES, V34, P583, DOI 10.1044/jshr.3403.583; Murdoch BE., 2001, TRAUMATIC BRAIN INJU; OFlaherty CA, 1997, APHASIOLOGY, V11, P889, DOI 10.1080/02687039708250463; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; RIPICH DN, 1994, ALZ DIS ASSOC DIS, V8, P95, DOI 10.1097/00002093-199424004-00011; Rousseaux M, 2010, EUR J NEUROL, V17, P922, DOI 10.1111/j.1468-1331.2009.02945.x; Ruff R, 1991, COGNITIVE REHABILITA, P23; Shelton C, 2007, BRAIN INJURY, V21, P1259, DOI 10.1080/02699050701716935; Simmons-Mackie N, 2010, ARCH PHYS MED REHAB, V91, P1814, DOI 10.1016/j.apmr.2010.08.026; Snow P, 1997, APHASIOLOGY, V11, P947, DOI 10.1080/02687039708249421; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; Snow P, 1997, BRAIN INJURY, V11, P409; Snow PC, 1999, APHASIOLOGY, V13, P529, DOI 10.1080/026870399401993; Snow PC, 1995, TRAUMATIC BRAIN INJU; Tate RL, 1999, CORTEX, V35, P39, DOI 10.1016/S0010-9452(08)70784-6; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1997, APHASIOLOGY, V11, P491, DOI 10.1080/02687039708248486; Togher L, 2000, APHASIOLOGY, V14, P365, DOI 10.1080/026870300401414; Togher L, 2004, APHASIOLOGY, V18, P313, DOI 10.1080/02687030344000535; Togher L, 2001, J COMMUN DISORD, V34, P131, DOI 10.1016/S0021-9924(00)00045-9; TOGHER L, 1999, COMMUNICATION DISORD; Togher L, 2010, ISL OF PALMS SC CLIN; Togher L, 2010, TBI EXPRESS PEOPLE T; TOGHER L, 2006, BRAIN IMPAIR, V7, P190, DOI DOI 10.1375/brim.7.3.190; Togher L., 1998, ANAL INTERPERSONAL M; Togher L, 2010, APHASIOLOGY, V24, P914, DOI 10.1080/02687030903422478; Togher L, 2009, BRAIN IMPAIR, V10, P188, DOI 10.1375/brim.10.2.188; Tu LV, 2011, BRAIN INJURY, V25, P560, DOI 10.3109/02699052.2011.571655; Turkstra L.S., 2006, BRAIN IMPAIR, V7, P234, DOI [DOI 10.1375/BRIM.7.3.234, 10.1375/brim.7.3.234]; Turner S, 2006, APHASIOLOGY, V20, P483, DOI 10.1080/02687030600589991; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; Ventola E., 1987, STRUCTURE SOCIAL INT; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wedcliffe T, 2001, S Afr J Commun Disord, V48, P77; Worrall L, 2002, J COMMUN DISORD, V35, P107, DOI 10.1016/S0021-9924(02)00060-6; YLVISAKER M, 1998, TRAUMATIC BRAIN INJU, P303; Ylvisaker Mark, 2005, Seminars in Speech and Language, V26, P256, DOI 10.1055/s-2005-922104	88	32	33	0	25	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2013	27	6					717	742		10.3109/02699052.2013.775485			26	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	143QO	WOS:000318882500011	23672447				2021-06-18	
J	Snell, DL; Hay-Smith, EJC; Surgenor, LJ; Siegert, RJ				Snell, Deborah L.; Hay-Smith, E. Jean C.; Surgenor, Lois J.; Siegert, Richard J.			Examination of outcome after mild traumatic brain injury: The contribution of injury beliefs and Leventhal's Common Sense Model	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Mild traumatic brain injury; Illness perceptions; Outcome	POST-CONCUSSION SYMPTOMS; ILLNESS PERCEPTIONS; HEAD-INJURY; POSTCONCUSSION SYNDROME; MYOCARDIAL-INFARCTION; MISERABLE MINORITY; DEPRESSION SCALE; HOSPITAL ANXIETY; SELF-REGULATION; QUESTIONNAIRE	Associations between components of Leventhal's common sense model of health behaviour (injury beliefs, coping, distress) and outcome after mild traumatic brain injury (MTBI) were examined. Participants (n=147) were recruited within three months following MTBI and assessed six months later, completing study questionnaires at both visits (Illness Perceptions Questionnaire Revised, Brief COPE, Hospital Anxiety and Depression Scale). Outcome measures included the Rivermead Post-Concussion Symptoms Questionnaire and Rivermead Head Injury Follow-Up Questionnaire. Univariate and multivariate (logistic regression) analyses examined associations between injury beliefs, coping and distress at baseline, and later outcome. Participants endorsing stronger injury identity beliefs (p<.01), expectations of lasting severe consequences (p<.01), and distress (p<.01) at time one, had greater odds of poor outcome at time two. Coping styles were also associated with later outcome although variability in findings limited interpretability. Associations between psychological variables and outcome were examined and 76.5% of cases were correctly classified by the model. Consistent with Leventhal's model, participant beliefs about their injury and recovery had significant associations with outcome over time. Coping also appeared to have important associations with outcome but more research is required to examine these. Current reassurance-based interventions may be improved by targeting variables such as injury beliefs, coping and adjustment soon after injury.	[Snell, Deborah L.; Hay-Smith, E. Jean C.] Univ Otago, Rehabil Teaching & Res Unit, Wellington, New Zealand; [Surgenor, Lois J.] Univ Otago, Dept Psychol Med, Christchurch, New Zealand; [Siegert, Richard J.] AUT Univ, Sch Publ Hlth & Psychosocial Studies, Auckland, New Zealand; [Siegert, Richard J.] AUT Univ, Sch Rehabil & Occupat Studies, Auckland, New Zealand; [Snell, Deborah L.] Canterbury Dist Hlth Board, Burwood Hosp, Concuss Clin, Brain Injury Rehabil Serv, Christchurch, New Zealand	Snell, DL (corresponding author), Burwood Hosp, Brain Injury Rehabil Serv, Private Bag 4708, Christchurch, New Zealand.	deborah.snell@cdhb.govt.nz	Siegert, Richard J./K-2030-2019	Siegert, Richard/0000-0002-3074-0929	Neurological Foundation of New Zealand [0728-SPG]	This research has been support by a Small Project Grant from the Neurological Foundation of New Zealand (Grant no: 0728-SPG).	Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Cameron L., 2003, SELF REGULATION HLTH; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Comper P, 2005, BRAIN INJURY, V19, P863, DOI 10.1080/02699050400025042; Crawford S, 1996, J NEUROL NEUROSUR PS, V60, P510, DOI 10.1136/jnnp.60.5.510; Deary V, 2007, CLIN PSYCHOL REV, V27, P781, DOI 10.1016/j.cpr.2007.07.002; Foster NE, 2008, PAIN, V136, P177, DOI 10.1016/j.pain.2007.12.007; French DP, 2006, J PSYCHOSOM RES, V61, P757, DOI 10.1016/j.jpsychores.2006.07.029; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; Graham JW, 2009, ANNU REV PSYCHOL, V60, P549, DOI 10.1146/annurev.psych.58.110405.085530; Hagger MS, 2005, J APPL SOC PSYCHOL, V35, P2345, DOI 10.1111/j.1559-1816.2005.tb02106.x; Hagger MS, 2003, PSYCHOL HEALTH, V18, P141, DOI 10.1080/088704403100081321; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Kaptein AA, 2006, PSYCHOL HEALTH, V21, P431, DOI 10.1080/14768320500456947; Kashluba S, 2008, CLIN NEUROPSYCHOL, V22, P195, DOI 10.1080/13854040701263655; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Lange RT, 2011, J HEAD TRAUMA REHAB, V26, P127, DOI 10.1097/HTR.0b013e3181e4622a; Leventhal H, 2001, HANDBOOK OF HEALTH PSYCHOLOGY, P19; Leventhal H, 1998, PSYCHOL HEALTH, V13, P717, DOI 10.1080/08870449808407425; Leventhal H, 2008, ANNU REV PSYCHOL, V59, P477, DOI 10.1146/annurev.psych.59.103006.093643; Llewellyn CD, 2007, J PSYCHOSOM RES, V63, P17, DOI 10.1016/j.jpsychores.2007.01.013; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Mackenzie JA, 2005, BRIT J CLIN PSYCHOL, V44, P417, DOI 10.1348/014466505X35696; Macleod AD, 2010, MED HYPOTHESES, V74, P1033, DOI 10.1016/j.mehy.2010.01.002; Maxwell S., 2008, ANNU REV PSYCHOL, V59, P1; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; Meares S, 2006, J INT NEUROPSYCH SOC, V12, P792, DOI 10.1017/S1355617706060978; Mittenberg W., 1992, J NEUROL NEUROSUR PS, V41, P611; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; Moss-Morris R, 2002, PSYCHOL HEALTH, V17, P1, DOI 10.1080/08870440290001494; Mulhern S, 2006, J PSYCHOSOM RES, V61, P439, DOI 10.1016/j.jpsychores.2006.03.004; Munro BH, 2005, STAT METHODS HLTH CA; NZGG, 2006, TRAUM BRAIN INJ DIAG; Panayiotou A, 2010, J CLIN EXP NEUROPSYC, V32, P463, DOI 10.1080/13803390903164371; PETRIE K, 1995, J PSYCHOSOM RES, V39, P31, DOI 10.1016/0022-3999(94)00071-C; Petrie KJ, 2002, PSYCHOSOM MED, V64, P580, DOI 10.1097/00006842-200207000-00007; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Rose JM, 2005, BRAIN INJURY, V19, P29, DOI 10.1080/02699050310001617361; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff R., 2003, YOUMANS NEUROLOGICAL, P5181; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Siegert RJ, 2005, DISABIL REHABIL, V27, P1493, DOI 10.1080/09638280500288401; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Snell DL, 2011, BRAIN INJURY, V25, P1126, DOI 10.3109/02699052.2011.607786; Snell DL, 2011, J HEAD TRAUMA REHAB, V26, P468, DOI 10.1097/HTR.0b013e3181fc5e1e; Snell DL, 2010, BRAIN INJURY, V24, P1595, DOI 10.3109/02699052.2010.523048; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; SNELL DL, 2006, NZ MED J, V119, P1231; Stanton AL, 2007, ANNU REV PSYCHOL, V58, P565, DOI 10.1146/annurev.psych.58.110405.085615; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Taylor SE, 2007, ANNU REV CLIN PSYCHO, V3, P377, DOI 10.1146/annurev.clinpsy.3.022806.091520; TEASDALE G, 1974, LANCET, V2, P81; Van Ittersum MW, 2009, PATIENT EDUC COUNS, V74, P53, DOI 10.1016/j.pec.2008.07.041; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	74	32	32	0	27	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUN 1	2013	23	3					333	362		10.1080/09658211.2012.758419			30	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	145UT	WOS:000319044500003	23336822				2021-06-18	
J	Iverson, GL; Koehle, MS				Iverson, Grant L.; Koehle, Michael S.			Normative data for the modified balance error scoring system in adults	BRAIN INJURY			English	Article						Traumatic brain injury; concussion; balance; postural stability; BESS; military; sports	TRAUMATIC BRAIN-INJURY; POSTURAL STABILITY; MOTOR-PERFORMANCE; HEAD-INJURY; CONCUSSION; DEFICITS; INSTABILITY; SPORT	Primary objective: Head trauma, with or without injury to the brain, can impair balance and postural stability. The Modified Balance Error Scoring System (M-BESS) is a rapid, standardized, objective bedside test that can be helpful for monitoring recovery of balance and postural stability following head trauma. The purpose of this study is to develop preliminary normative data for this test for adults. Methods and procedures: Adults between the ages of 20-69 (n = 1234) were administered the M-BESS as part of a comprehensive preventive health screen. They did not have significant medical, neurological or lower extremity problems that might have an adverse effect on balance. Main outcomes and results: M-BESS performance significantly declined with age. Men and women performed similarly on the M-BESS. There was a small significant difference in M-BESS performance, with obese men performing more poorly than non-obese men and a larger significant difference between obese and non-obese women. Conclusions: The M-BESS normative data are presented for the total sample and by age, sex and age-by-sex. These normative data provide a frame of reference for interpreting M-BESS performance in adults who sustain traumatic brain injuries and adults with diverse neurological problems.	Univ British Columbia, Vancouver, BC V6T 2A1, Canada; Copeman Healthcare Ctr, Vancouver, BC, Canada	Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@mail.ubc.ca	Koehle, Michael S/C-7850-2013	Koehle, Michael S/0000-0001-7026-8422; Iverson, Grant/0000-0001-7348-9570			Akin FW, 2011, OTOLARYNG CLIN N AM, V44, P323, DOI 10.1016/j.otc.2011.01.005; Bressel E, 2007, J ATHL TRAINING, V42, P42; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Campbell M, 2005, BRAIN INJURY, V19, P1095, DOI 10.1080/02699050500188898; Docherty CL, 2006, CLIN J SPORT MED, V16, P203, DOI 10.1097/00042752-200605000-00003; Ernst A, 2005, OTOLARYNG HEAD NECK, V132, P554, DOI 10.1016/j.otohns.2004.09.034; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Greenwald BD, 2001, J HEAD TRAUMA REHAB, V16, P238, DOI 10.1097/00001199-200106000-00003; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Kaufman KR, 2006, MED ENG PHYS, V28, P234, DOI 10.1016/j.medengphy.2005.05.005; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Rinne MB, 2006, J REHABIL MED, V38, P224, DOI 10.1080/16501970600582989; Susco TM, 2004, J ATHL TRAINING, V39, P241; Valovich TC, 2003, J ATHL TRAINING, V38, P51; Weightman MM, 2010, J HEAD TRAUMA REHAB, V25, P206, DOI 10.1097/HTR.0b013e3181dc82d3; Wilkins JC, 2004, J ATHL TRAINING, V39, P156	22	32	32	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	2013	27	5					596	599		10.3109/02699052.2013.772237			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	124UK	WOS:000317493000010	23473405				2021-06-18	
J	Leitgeb, J; Mauritz, W; Brazinova, A; Majdan, M; Wilbacher, I				Leitgeb, Johannes; Mauritz, Walter; Brazinova, Alexandra; Majdan, Marek; Wilbacher, Ingrid			Impact of concomitant injuries on outcomes after traumatic brain injury	ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY			English	Article						Traumatic brain injury; Outcome; Concomitant injuries	HEAD-INJURY; INTRACRANIAL-PRESSURE; EPIDEMIOLOGY; MORTALITY	Patients with traumatic brain injury (TBI) frequently have concomitant injuries; we aimed to investigate their impact on outcomes. Between February 2002 and April 2010, 17 Austrian centers prospectively enrolled 863 patients with moderate and severe TBI into observational studies. Data on accident, treatment, and outcomes were collected. Patients who survived until intensive care unit (ICU) admission and had survivable TBI were selected, and were assigned to "isolated TBI" or "TBI + injury" groups. Six-month outcomes were classified as "favorable" if Glasgow Outcome Scale (GOS) scores were five or four, and were classified as "unfavorable" if GOS scores were three or less. Univariate statistics (Fisher's exact test, t test, chi(2)-test) and logistic regression were used to identify factors associated with hospital mortality and unfavorable outcome. Of the 767 patients, 403 (52.5 %) had isolated TBI, 364 (47.5 %) had concomitant injuries. Patients with isolated TBI had higher mean age (53 vs. 44 years, P = 0.001); hospital mortality (30.0 vs. 27.2 %, P = 0.42) and rate of unfavorable outcome (50.4 vs. 41.8 %, P = 0.02) were higher, too. There were no significant mortality differences for factors like age groups, trauma mechanisms, neurologic status, CT findings, or treatment factors. Concomitant injuries were associated with higher mortality (33.3 vs. 12.5 %, P = 0.05) in patients with moderate TBI, and were significantly associated with more ventilation, ICU, and hospitals days. Logistic regression revealed that age, Glasgow Coma Scale score, pupillary reactivity, severity of TBI and CT score were the main factors that influenced outcomes. Concomitant injuries have a significant effect upon the mortality of patients with moderate TBI. They do not affect the mortality in patients with severe TBI. Evidence level 2; prospective, observational prognostic study.	[Leitgeb, Johannes] Med Univ Vienna, Dept Traumatol, A-1090 Vienna, Austria; [Mauritz, Walter] Trauma Hosp Lorenz Boehler, Anesthesiol & Intens Care Med, Vienna, Austria; [Mauritz, Walter; Brazinova, Alexandra; Majdan, Marek] Int Neurotrauma Res Org, Vienna, Austria; [Brazinova, Alexandra; Majdan, Marek; Wilbacher, Ingrid] Trnava Univ, Fac Hlth & Social Serv, Dept Publ Hlth, Trnava, Slovakia	Leitgeb, J (corresponding author), Med Univ Vienna, Dept Traumatol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	johannes.leitgeb@meduniwien.ac.at; walter.mauritz@auva.at; abrazinova@igeh.org; mmajdan@igeh.org; ingrid.wilbacher@hvb.sozvers.at	Brazinova, Alexandra/C-4265-2016; Majdan, Marek/K-5017-2012	Brazinova, Alexandra/0000-0003-0625-256X; Majdan, Marek/0000-0001-8037-742X; Mauritz, Walter/0000-0001-9043-3712	Austrian Worker's Compensation Board (AUVA) [FK 33/2003]; Austrian National Bank [8987]; Ministry of Health; AUVA [FK 11/2008, FK 11/2010]	The data used for this study were collected for a project funded by the Austrian Worker's Compensation Board (AUVA; FK 33/2003) and by the "Jubilee Fund" of the Austrian National Bank (Project 8987), and for a project funded by the Ministry of Health (Contract Oct. 15, 2008) and the AUVA (FK 11/2008 and FK 11/2010). INRO is supported by an annual grant from Mrs. Ala Auersperg-Isham and Mr. Ralph Isham, and by small donations from various sources.	Biersteker HAR, 2012, CRIT CARE MED, V40, P1914, DOI 10.1097/CCM.0b013e3182474bde; Bullock R., 1996, EUR J EMERG MED, V3, P109, DOI 10.1097/00063110-199606000-00010; GROSWASSER Z, 1990, Brain Injury, V4, P161, DOI 10.3109/02699059009026161; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Heinzelmann M, 1996, INJURY, V27, P345, DOI 10.1016/0020-1383(95)00223-5; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Hukkelhoven CWPM, 2003, J NEUROSURG, V99, P666, DOI 10.3171/jns.2003.99.4.0666; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; JENNETT B, 1975, LANCET, V1, P480; Kemp CD, 2008, AM SURGEON, V74, P866; Lefering R, 2008, J TRAUMA, V65, P1036, DOI 10.1097/TA.0b013e318184ee48; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Marmarou A, 2007, J NEUROTRAUM, V24, P270, DOI 10.1089/neu.2006.0029; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Martin RCG, 2002, AM SURGEON, V68, P477; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; Mauritz W, 2008, INTENS CARE MED, V34, P1208, DOI 10.1007/s00134-008-1079-7; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Rickels E, 2010, BRAIN INJURY, V24, P1491, DOI 10.3109/02699052.2010.498006; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P64, DOI 10.1007/s00508-006-0765-0; Sarrafzadeh AS, 2001, CRIT CARE MED, V29, P1116, DOI 10.1097/00003246-200106000-00004; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y	24	32	32	0	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0936-8051	1434-3916		ARCH ORTHOP TRAUM SU	Arch. Orthop. Trauma Surg.	MAY	2013	133	5					659	668		10.1007/s00402-013-1710-0			10	Orthopedics; Surgery	Orthopedics; Surgery	131DL	WOS:000317972300011	23463257	Green Published, Other Gold			2021-06-18	
J	Crupi, R; Paterniti, I; Campolo, M; Di Paola, R; Cuzzocrea, S; Esposito, E				Crupi, Rosalia; Paterniti, Irene; Campolo, Michela; Di Paola, Rosanna; Cuzzocrea, Salvatore; Esposito, Emanuela			Exogenous T3 administration provides neuroprotection in a murine model of traumatic brain injury	PHARMACOLOGICAL RESEARCH			English	Article						Traumatic brain injury; Neuroinflammation; T3; Cortical impact	ACTIVATED PROTEIN-KINASE; THYROID-HORMONE; NONGENOMIC ACTIONS; SERINE PHOSPHORYLATION; BEHAVIORAL RECOVERY; CEREBRAL-ISCHEMIA; CELL-DEATH; BLOOD; THYROXINE; HYPOTHYROIDISM	Traumatic brain injury (TBI) induces primary and secondary damage in both the endothelium and the brain parenchyma. While neurons die quickly by necrosis, a vicious cycle of secondary injury in endothelial cells exacerbates the initial injury. Thyroid hormones are reported to be decreased in patients with brain injury. Controlled cortical impact injury (CCI) is a widely used, clinically relevant model of TBI. Here, using CCI in adult male mice, we set to determine whether 3,5,3'-triiodothyronine (T3) attenuates posttraumatic neurodegeneration and neuroinflammation in an experimental model of TBI. Treatment with T3 (1.2 mu g/100 g body weight, i.p.) 1 h after TBI resulted in a significant improvement in motor and cognitive recovery after CCI, as well as in marked reduction of lesion volumes. Mouse model for brain injury showed reactive astrocytes with increased glial fibrillary acidic protein, and formation of inducible nitric oxide synthase (iNOS). Western blot analysis revealed the ability of T3 to reduce brain trauma through modulation of cytoplasmic-nuclear shuttling of nuclear factor-kappa B (NF-kappa B). Twenty-four hours after brain trauma, T3-treated mice also showed significantly lower number of TUNEL(+) apoptotic neurons and curtailed induction of Bax, compared to vehicle control. In addition, T3 significantly enhanced the post-TBI expression of the neuroprotective neurotrophins (BDNF and GDNF) compared to vehicle. Our data provide an additional mechanism for the anti-inflammatory effects of thyroid hormone with critical implications in immunopathology at the cross-roads of the immune-endocrine circuits. (C) 2013 Elsevier Ltd. All rights reserved.	[Crupi, Rosalia; Paterniti, Irene; Campolo, Michela; Di Paola, Rosanna; Cuzzocrea, Salvatore; Esposito, Emanuela] Univ Messina, Dept Biol & Environm Sci, I-98166 Messina, Italy	Cuzzocrea, S (corresponding author), Univ Messina, Dept Biol & Environm Sci, Viale Ferdinando Stagno DAlcontres 31, I-98166 Messina, Italy.	salvator@unime.it	Campolo, Michela/K-6432-2016; Crupi, Rosalia/U-4364-2019; di paola, rosanna/U-4356-2019	Cuzzocrea, Salvatore/0000-0001-6131-3690; di paola, rosanna/0000-0001-6725-8581; Crupi, Rosalia/0000-0002-7629-3132			Ahmad A, 2012, BRAIN BEHAV IMMUN, V26, P1310, DOI 10.1016/j.bbi.2012.07.021; Akhoundi FH, 2011, NEUROLOGY, V77, P349, DOI 10.1212/WNL.0b013e3182267ba0; Albensi BC, 2001, J NEUROSCI RES, V65, P279, DOI 10.1002/jnr.1151; Alevizaki M, 2006, CLIN ENDOCRINOL, V65, P369, DOI 10.1111/j.1365-2265.2006.02606.x; Axelband F, 2011, J CELL PHYSIOL, V226, P21, DOI 10.1002/jcp.22325; Baratz R, 2010, J NEUROTRAUM, V27, P555, DOI 10.1089/neu.2009.0891; Barreto-Chaves ML, 2011, CURR OPIN ENDOCRINOL, V18, P300, DOI 10.1097/MED.0b013e32834a785c; Bernal J, 2007, NAT CLIN PRACT ENDOC, V3, P249, DOI 10.1038/ncpendmet0424; Botteri M, 2008, CRIT CARE MED, V36, P3089, DOI 10.1097/CCM.0b013e31818bd7df; Cheng SY, 2010, ENDOCR REV, V31, P139, DOI 10.1210/er.2009-0007; Coles Jonathan P, 2004, Curr Opin Crit Care, V10, P120, DOI 10.1097/00075198-200404000-00008; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; D'Arezzo S, 2004, ENDOCRINOLOGY, V145, P5694, DOI 10.1210/en.2004-0890; Davis PJ, 2011, CURR OPIN ENDOCRINOL, V18, P293, DOI 10.1097/MED.0b013e32834abeb2; Davis PJ, 1996, THYROID, V6, P497, DOI 10.1089/thy.1996.6.497; Davis PJ, 2000, J BIOL CHEM, V275, P38032, DOI 10.1074/jbc.M002560200; De Vito P, 2011, THYROID, V21, P879, DOI 10.1089/thy.2010.0429; DISTEFANO JJ, 1982, ENDOCRINOLOGY, V110, P198, DOI 10.1210/endo-110-1-198; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Esposito E, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-66; Farwell AP, 2006, ENDOCRINOLOGY, V147, P2567, DOI 10.1210/en.2005-1272; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; Genovese T, 2008, J PHARMACOL EXP THER, V326, P12, DOI 10.1124/jpet.108.136903; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Gursoy-Ozdemir Y, 2004, J CLIN INVEST, V113, P1447, DOI 10.1172/JCI200421227; Hall ED, 2010, NEUROTHERAPEUTICS, V7, P51, DOI 10.1016/j.nurt.2009.10.021; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Hoffman AN, 2008, LIFE SCI, V83, P602, DOI 10.1016/j.lfs.2008.08.007; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kawano H, 2012, CELL TISSUE RES, V349, P169, DOI 10.1007/s00441-012-1336-5; Khan M, 2004, J NEUROSCI RES, V76, P519, DOI 10.1002/jnr.20087; Kilburn-Watt E, 2010, J NEUROENDOCRINOL, V22, P960, DOI 10.1111/j.1365-2826.2010.02038.x; KINLAW WB, 1985, J CLIN INVEST, V75, P1238, DOI 10.1172/JCI111821; Kline AE, 2007, BEHAV BRAIN RES, V177, P186, DOI 10.1016/j.bbr.2006.11.036; Kline AE, 2008, NEUROSCI LETT, V448, P263, DOI 10.1016/j.neulet.2008.10.076; Lin HY, 1999, AM J PHYSIOL-CELL PH, V276, pC1014; Losi G, 2008, NEUROSCIENCE, V151, P155, DOI 10.1016/j.neuroscience.2007.09.064; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Malekpour Babak, 2012, Acta Med Iran, V50, P113; Mandai K, 1997, NEUROSCIENCE, V77, P849, DOI 10.1016/S0306-4522(97)00517-4; Mendes-de-Aguiar CBN, 2008, J NEUROSCI RES, V86, P3117, DOI 10.1002/jnr.21755; Okosieme OE, 2011, EXPERT OPIN PHARMACO, V12, P2315, DOI 10.1517/14656566.2011.600307; Orihara Y, 2001, FORENSIC SCI INT, V123, P142, DOI 10.1016/S0379-0738(01)00537-0; Parathath SR, 2006, J CELL SCI, V119, P339, DOI 10.1242/jcs.02734; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; PETITO CK, 1993, INT J DEV NEUROSCI, V11, P239, DOI 10.1016/0736-5748(93)90082-O; Powner DJ, 2006, NEUROCRIT CARE, V5, P61, DOI 10.1385/NCC:5:1:61; RAMI A, 1992, LIFE SCI, V50, P645, DOI 10.1016/0024-3205(92)90251-J; Rastogi L, 2006, EXP NEUROL, V200, P290, DOI 10.1016/j.expneurol.2006.02.013; Sarkozy G, 2007, EUR J PAEDIATR NEURO, V11, P129, DOI 10.1016/j.ejpn.2006.11.009; Schlenker EH, 2008, AM J PHYSIOL-REG I, V294, pR1504, DOI 10.1152/ajpregu.00027.2008; SCHWARTZ HL, 1971, J CLIN INVEST, V50, P1124, DOI 10.1172/JCI106584; Shih A, 2001, BIOCHEMISTRY-US, V40, P2870, DOI 10.1021/bi001978b; SHUAIB A, 1994, EXP NEUROL, V127, P119, DOI 10.1006/exnr.1994.1085; SIEGRISTKAISER CA, 1990, J BIOL CHEM, V265, P5296; Slepkov E, 2004, VITAM HORM, V69, P249, DOI 10.1016/S0083-6729(04)69009-1; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Takano T, 2009, STROKE, V40, pS8, DOI 10.1161/STROKEAHA.108.533166; Tang HY, 2004, ENDOCRINOLOGY, V145, P3265, DOI 10.1210/en.2004-0308; Wagner AK, 2007, BEHAV BRAIN RES, V181, P200, DOI 10.1016/j.bbr.2007.04.006; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Yonkers MA, 2008, J NEUROPHYSIOL, V100, P2719, DOI 10.1152/jn.90801.2008; Zohar O, 2011, ACTA NEUROBIOL EXP, V71, P36	63	32	35	0	9	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	1043-6618			PHARMACOL RES	Pharmacol. Res.	APR	2013	70	1					80	89		10.1016/j.phrs.2012.12.009			10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	117BG	WOS:000316926500011	23313345				2021-06-18	
J	Singh, B; Murad, MH; Prokop, LJ; Erwin, PJ; Wang, Z; Mommer, SK; Mascarenhas, SS; Parsaik, AK				Singh, Balwinder; Murad, M. Hassan; Prokop, Larry J.; Erwin, Patricia J.; Wang, Zhen; Mommer, Shannon K.; Mascarenhas, Sonia S.; Parsaik, Ajay K.			Meta-analysis of Glasgow Coma Scale and Simplified Motor Score in predicting traumatic brain injury outcomes	BRAIN INJURY			English	Article						Emergency tracheal intubation; clinically significant brain injuries; neurosurgical intervention; mortality	INTERRATER RELIABILITY; IMPAIRED CONSCIOUSNESS; VALIDATION; CHILDREN; LEVEL	Objective: To perform a systematic review and meta-analysis to compare the Simplified Motor Score (SMS) and Glasgow Coma Scale (GCS) in predicting outcomes in patients with traumatic brain injury (TBI). Data sources and study selection: Ovid EMBASE, Ovid Medline, Ovid PsycInfo, evidence-based medicine reviews and Scopus and related conference proceedings were searched through 28 February 2012 for studies comparing SMS and GCS in predicting the outcomes [emergency tracheal intubation (ETI), clinically significant brain injuries (CSBI), neurosurgical intervention (NSI) and mortality] in patients with TBI. A random-effects model was used for meta-analysis. Data synthesis: Five retrospective studies were eligible, enrolling a total of 102 132 subjects with TBI (63.4% males), with 14 670 (14.4%) ETI, 16 201 (15.9%) CSBI, 4730 (4.6%) NSI and 6725 (6.6%) mortality. Pooled AUC of the GCS and SMS were as follows: CSBI 0.79 and 0.75 (p = 0.16), NSI 0.83 and 0.81 (p = 0.34), ETI 0.85 and 0.82 (p = 0.31) and mortality 0.90 and 0.87 (p = 0.01). The difference in AUC for mortality was 0.03. Large heterogeneity between the studies was observed in all analyses (I-2 > 50%). Conclusion: In patients with TBI, SMS predicts different outcomes with similar accuracy as GCS except mortality. However, due to heterogeneity and limited numbers of studies, further prospective studies are required.	[Singh, Balwinder] Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN 55905 USA; [Murad, M. Hassan] Mayo Clin, Dept Prevent Med, Rochester, MN 55905 USA; [Murad, M. Hassan; Prokop, Larry J.; Erwin, Patricia J.; Wang, Zhen] Mayo Clin, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA; [Mommer, Shannon K.] Mayo Clin, Dept Gen Surg, Rochester, MN 55905 USA; [Mascarenhas, Sonia S.] London Training Coll, London, England; [Parsaik, Ajay K.] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA	Parsaik, AK (corresponding author), Mayo Clin, Dept Neurol, 200 1st St SW, Rochester, MN 55905 USA.	parsaik.ajay@mayo.edu	Zhen, Wang/S-7244-2019; Singh, Balwinder/H-2016-2011; Wang, Zhen/D-5991-2013	Singh, Balwinder/0000-0001-7062-8192; Wang, Zhen/0000-0002-9368-6149; Murad, Mohammad Hassan/0000-0001-5502-5975			Al-Salamah MA, 2004, ACAD EMERG MED, V11, P834, DOI 10.1197/j.aem.2004.03.008; Altman DG, 2003, BMJ-BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; Bassi S, 1999, BRIT J NEUROSURG, V13, P526; Caterino JM, 2012, EMERG MED J, V29, P492, DOI 10.1136/emj.2010.110437; Centers for Disease Control and Prevention, TRAUM BRAIN INJ US R; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Fischer M, 2010, CRIT CARE, V14, DOI 10.1186/cc8963; Gill M, 2005, ANN EMERG MED, V45, P37, DOI 10.1016/j.annemergmed.2004.07.429; Gill M, 2006, ACAD EMERG MED, V13, P968, DOI 10.1197/j.aem.2006.05.019; Gill MR, 2004, ANN EMERG MED, V43, P215, DOI 10.1016/S0196-0644(03)00814-X; Green SM, 2011, ANN EMERG MED, V58, P427, DOI 10.1016/j.annemergmed.2011.06.009; Haukoos JS, 2007, ANN EMERG MED, V50, P18, DOI 10.1016/j.annemergmed.2006.10.004; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Holdgate Anna, 2006, Emerg Med Australas, V18, P379, DOI 10.1111/j.1742-6723.2006.00867.x; Holmes JF, 2005, ACAD EMERG MED, V12, P814, DOI 10.1197/j.aem.2005.04.019; Jackson D, 2010, STAT MED, V29, P1282, DOI 10.1002/sim.3602; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1977, LANCET, V1, P878; Kester ADM, 2000, MED DECIS MAKING, V20, P430, DOI 10.1177/0272989X0002000407; Liberati A, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2700; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; McNarry AF, 2004, ANAESTHESIA, V59, P34, DOI 10.1111/j.1365-2044.2004.03526.x; MEREDITH W, 1995, J TRAUMA, V38, P129, DOI 10.1097/00005373-199501000-00030; Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b2535, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007]; Riechers RG, 2005, J NEUROTRAUM, V22, P1327, DOI 10.1089/neu.2005.22.1327; Ross SE, 1998, J TRAUMA, V45, P42, DOI 10.1097/00005373-199807000-00008; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; TEASDALE G, 1978, J NEUROL NEUROSUR PS, V41, P603, DOI 10.1136/jnnp.41.7.603; TEASDALE G, 1974, LANCET, V2, P81; Thompson DO, 2011, ANN EMERG MED, V58, P417, DOI 10.1016/j.annemergmed.2011.05.033; Van de Voorde P, 2008, RESUSCITATION, V76, P175, DOI 10.1016/j.resuscitation.2007.07.007; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; Wijdicks EFM, 2005, ANN NEUROL, V58, P585, DOI 10.1002/ana.20611	34	32	35	0	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2013	27	3					293	300		10.3109/02699052.2012.743182			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	096OG	WOS:000315413400006	23252405				2021-06-18	
J	Weinstein, E; Turner, M; Kuzma, BB; Feuer, H				Weinstein, Elizabeth; Turner, Michael; Kuzma, Benjamin B.; Feuer, Henry			Second impact syndrome in football: new imaging and insights into a rare and devastating condition Case report	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						brain concussion; cerebral concussion; trauma; postconcussion syndrome; brain injury; football	SPORTS; TRAUMA; EDEMA	Premature return to play for the concussed pediatric athlete may result in devastating neurological injury. Identification of at-risk patients and ideal management of the concussed athlete remain challenging for the pediatrician. The authors review a case of second impact syndrome in which neuroimaging was obtained between the first and second impacts, a circumstance which to their knowledge has not been previously reported. This case offers new insights into the underlying pathophysiology of this disease process and potential risk factors for its development. (http://thejns.org/doi/abs/10.3171/2012.11.PEDS12343)	[Weinstein, Elizabeth] Indiana Univ Sch Med, Dept Emergency Med, Indianapolis, IN USA; [Turner, Michael; Feuer, Henry] Indiana Univ Sch Med, Dept Neurol Surg, Goodman Campbell Brain & Spine, Indianapolis, IN USA; [Kuzma, Benjamin B.] Northwest Radiol Network, Indianapolis, IN USA	Turner, M (corresponding author), Indiana Univ, Dept Neurol Surg, Goodman Campbell Brain & Spine, 1801 North Senate Blvd,Suite 610, Indianapolis, IN 46202 USA.	mturner@goodmancampbell.com					BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P224; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; McCrory P, 2001, CLIN J SPORT MED, V11, P144, DOI 10.1097/00042752-200107000-00004; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; Pellman Elliot J, 2006, Neurosurg Focus, V21, pE12; Sallis RE, 2000, MED SCI SPORT EXER, V32, P1820, DOI 10.1097/00005768-200011000-00002; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538	11	32	32	0	22	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707			J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	MAR	2013	11	3					331	334		10.3171/2012.11.PEDS12343			4	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	094DV	WOS:000315244100016	23277914	Bronze			2021-06-18	
J	Kahalley, LS; Wilson, SJ; Tyc, VL; Conklin, HM; Hudson, MM; Wu, SJ; Xiong, XP; Stancel, HH; Hinds, PS				Kahalley, Lisa S.; Wilson, Stephanie J.; Tyc, Vida L.; Conklin, Heather M.; Hudson, Melissa M.; Wu, Shengjie; Xiong, Xiaoping; Stancel, Heather H.; Hinds, Pamela S.			Are the psychological needs of adolescent survivors of pediatric cancer adequately identified and treated?	PSYCHO-ONCOLOGY			English	Article						cancer; oncology; psychological; children	ACUTE LYMPHOBLASTIC-LEUKEMIA; LONG-TERM SURVIVORS; TRAUMATIC BRAIN-INJURY; CHILDHOOD-CANCER; EXECUTIVE FUNCTION; CRANIAL RADIATION; ADULT SURVIVORS; NEUROPSYCHOLOGICAL PERFORMANCE; YOUNG ADOLESCENT; SOCIAL OUTCOMES	Objectives To describe the psychological needs of adolescent survivors of acute lymphoblastic leukemia (ALL) or brain tumor (BT), we examined the following: (i) the occurrence of cognitive, behavioral, and emotional concerns identified during a comprehensive psychological evaluation and (ii) the frequency of referrals for psychological follow-up services to address identified concerns. Methods Psychological concerns were identified on measures according to predetermined criteria for 100 adolescent survivors. Referrals for psychological follow-up services were made for concerns previously unidentified in formal assessment or not adequately addressed by current services. Results Most survivors (82%) exhibited at least one concern across domains: behavioral (76%), cognitive (47%), and emotional (19%). Behavioral concerns emerged most often on scales associated with executive dysfunction, inattention, learning, and peer difficulties. Cranial radiation therapy was associated with cognitive concerns, 2(1, N=100)=5.63, p<0.05. Lower income was associated with more cognitive concerns for ALL survivors, t(47)=3.28, p<0.01, and more behavioral concerns for BT survivors, t(48)=2.93, p<0.01. Of the survivors with concerns, 38% were referred for psychological follow-up services. Lower-income ALL survivors received more referrals for follow-up, 2(1, N=41)=8.05, p<0.01. Referred survivors had more concerns across domains than non-referred survivors, ALL: t(39)=2.96, p<0.01; BT: t(39)=3.52, p<0.01. Trends suggest ALL survivors may be at risk for experiencing unaddressed cognitive needs. Conclusions Many adolescent survivors of cancer experience psychological difficulties that are not adequately managed by current services, underscoring the need for long-term surveillance. In addition to prescribing regular psychological evaluations, clinicians should closely monitor whether current support services appropriately meet survivors' needs, particularly for lower-income survivors and those treated with cranial radiation therapy. Copyright (c) 2012 John Wiley & Sons, Ltd.	[Kahalley, Lisa S.; Stancel, Heather H.] Baylor Coll Med, Dept Pediat, Psychol Sect, Houston, TX 77030 USA; [Wilson, Stephanie J.; Tyc, Vida L.; Conklin, Heather M.] St Jude Childrens Res Hosp, Dept Psychol, Memphis, TN 38105 USA; [Hudson, Melissa M.] St Jude Childrens Res Hosp, Div Oncol, Div Canc Survivorship, Memphis, TN 38105 USA; [Wu, Shengjie; Xiong, Xiaoping] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA; [Hinds, Pamela S.] Childrens Natl Med Ctr, Dept Nursing Res & Qual Outcomes, Washington, DC 20010 USA; [Hinds, Pamela S.] George Washington Univ, Dept Pediat, Washington, DC 20052 USA	Kahalley, LS (corresponding author), Texas Childrens Hosp, 1102 Bates,Suite 730, Houston, TX 77030 USA.	lskahall@texaschildrens.org	Conklin, Heather M/N-2696-2018; Hudson, Melissa M/N-4441-2018; Hinds, Pamela/W-8115-2019	Hudson, Melissa M/0000-0001-6984-2407; 	National Institute of Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [F32DA024503]; NIH Cancer Center Support CORE Grant [CA21765]; American Lebanese Syrian Associated Charities (ALSAC)American Lebanese Syrian Associated Charities (ALSAC); NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA021765, R25CA023944, K07CA157923] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [F32DA024503] Funding Source: NIH RePORTER	This work was supported, in part, by the National Institute of Drug Abuse F32DA024503 (Lisa Schum [Kahalley], Principal Investigator), the NIH Cancer Center Support CORE Grant CA21765, and the American Lebanese Syrian Associated Charities (ALSAC).	ACHENBACH TM, 1987, PSYCHOL BULL, V101, P213, DOI 10.1037/0033-2909.101.2.213; American Psychiatric Association, 2000, DIAGN STAT MENT DIS; Anderson V, 1997, Pediatr Rehabil, V1, P63; Anderson VA, 2002, CHILD NEUROPSYCHOL, V8, P231, DOI 10.1076/chin.8.4.231.13509; Armstrong GT, 2009, JNCI-J NATL CANCER I, V101, P946, DOI 10.1093/jnci/djp148; BROWN BB, 1993, CHILD DEV, V64, P467, DOI 10.1111/j.1467-8624.1993.tb02922.x; Cantwell DP, 1997, J AM ACAD CHILD PSY, V36, P610, DOI 10.1097/00004583-199705000-00011; Children's Oncology Group, 2008, LONG TERM FOLL UP GU; Clinton-McHarg T, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-25; Conklin HM, 2008, BRAIN INJURY, V22, P847, DOI 10.1080/02699050802403565; Conners C., 2000, CONNERS CONTINUOUS P; Conners C. K., 2008, CONNERS 3 EDITION MA; Dekovic M, 1997, J YOUTH ADOLESCENCE, V26, P253, DOI 10.1007/s10964-005-0001-7; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Eiser C, 2000, J PEDIATR PSYCHOL, V25, P449, DOI 10.1093/jpepsy/25.6.449; Fossen A, 1998, PEDIATR HEMAT ONCOL, V15, P479, DOI 10.3109/08880019809018309; Fuemmeler BF, 2002, CLIN PSYCHOL REV, V22, P547, DOI 10.1016/S0272-7358(01)00120-9; Gioia G. A., 2000, BRIEF BEHAV RATING I; Gurney JG, 2009, J CLIN ONCOL, V27, P2390, DOI 10.1200/JCO.2008.21.1458; Herjanic, 1997, DIAGNOSTIC INTERVIEW; Hill JM, 1998, CANCER-AM CANCER SOC, V82, P208; Holmquist LA, 2002, J CLIN PSYCHOL MED S, V9, P315, DOI 10.1023/A:1020791018897; Jones BL, 2008, FAM COMMUNITY HEALTH, V31, pS61, DOI 10.1097/01.FCH.0000304019.98007.ae; Kahalley LS, 2011, J CANCER SURVIV, V5, P123, DOI 10.1007/s11764-010-0149-3; Kirchhoff AC, 2010, MED CARE, V48, P1015, DOI 10.1097/MLR.0b013e3181eaf880; Krull KR, 2010, J CANCER SURVIV, V4, P210, DOI 10.1007/s11764-010-0123-0; Langer T, 2002, MED PEDIATR ONCOL, V38, P320, DOI 10.1002/mpo.10055; Lockwood KA, 1999, J PEDIATR PSYCHOL, V24, P55, DOI 10.1093/jpepsy/24.1.55; Lorenzi M, 2009, CANCER-AM CANCER SOC, V115, P2234, DOI 10.1002/cncr.24267; Lund LW, 2011, PEDIATR BLOOD CANCER, V56, P532, DOI 10.1002/pbc.22883; Mackie E, 2000, LANCET, V355, P1310, DOI 10.1016/S0140-6736(00)02112-7; Maddrey AM, 2005, J NEURO-ONCOL, V72, P245, DOI 10.1007/s11060-004-3009-z; Mattson SN, 1999, ALCOHOL CLIN EXP RES, V23, P1808, DOI 10.1097/00000374-199911000-00014; McAuley T, 2010, J INT NEUROPSYCH SOC, V16, P495, DOI 10.1017/S1355617710000093; Merikangas KR, 2010, J AM ACAD CHILD PSY, V49, P980, DOI 10.1016/j.jaac.2010.05.017; Meyer EA, 2002, PSYCHO-ONCOLOGY, V11, P74, DOI 10.1002/pon.553; Mody R, 2008, BLOOD, V111, P5515, DOI 10.1182/blood-2007-10-117150; Moleski M, 2000, ARCH CLIN NEUROPSYCH, V15, P603, DOI 10.1016/S0887-6177(99)00050-5; Mulhern Raymond K, 2004, Pediatr Rehabil, V7, P1, DOI 10.1080/13638490310001655528; Nelson EE, 2005, PSYCHOL MED, V35, P163, DOI 10.1017/S0033291704003915; Newby WL, 2000, PSYCHO-ONCOL, V9, P113; Noll RB, 2007, J PEDIATR PSYCHOL, V32, P1089, DOI 10.1093/jpepsy/jsm049; Patenaude AF, 2005, J PEDIATR PSYCHOL, V30, P9, DOI 10.1093/jpepsy/jsi012; Peterson CC, 2008, PEDIATR BLOOD CANCER, V51, P99, DOI 10.1002/pbc.21544; Radcliffe J, 1996, J PEDIATR PSYCHOL, V21, P529, DOI 10.1093/jpepsy/21.4.529; Rapport MD, 2008, HDB CLIN PSYCHOL, V2, P386; Reddick WE, 2006, CANCER-AM CANCER SOC, V106, P941, DOI 10.1002/cncr.21679; Ries L.A.G., 2007, SEER CANC STAT REV 1; RIS MD, 1994, J CLIN EXP NEUROPSYC, V16, P21, DOI 10.1080/01688639408402615; Rodgers J, 1999, ARCH DIS CHILD, V80, P318, DOI 10.1136/adc.80.4.318; Rogers R, 2001, HDB DIAGNOSTIC STRUC; RUTTER M, 1976, J CHILD PSYCHOL PSYC, V17, P35, DOI 10.1111/j.1469-7610.1976.tb00372.x; Ryan AM, 2001, CHILD DEV, V72, P1135, DOI 10.1111/1467-8624.00338; Schultz KAP, 2007, J CLIN ONCOL, V25, P3649, DOI 10.1200/JCO.2006.09.2486; Servitzoglou M, 2008, SUPPORT CARE CANCER, V16, P29, DOI 10.1007/s00520-007-0278-z; Sisk CL, 2005, FRONT NEUROENDOCRIN, V26, P163, DOI 10.1016/j.yfrne.2005.10.003; Sourander A, 1999, SOC PSYCH PSYCH EPID, V34, P657, DOI 10.1007/s001270050189; Spiegler BJ, 2006, J CLIN ONCOL, V24, P3858, DOI 10.1200/JCO.2006.05.9055; Stam H, 2001, SUPPORT CARE CANCER, V9, P489, DOI 10.1007/s005200100271; STEHBENS J A, 1991, Neuropsychology Review, V2, P147, DOI 10.1007/BF01109052; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Wechsler D., 2003, WECHSLER INTELLIGENC; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D, 1997, WECHSLER ADULT INTEL; Wechsler D, 1997, WAIS 3 ADM SCORING M; WELNER Z, 1987, J AM ACAD CHILD PSY, V26, P649, DOI 10.1097/00004583-198709000-00007; Wodka EL, 2008, ARCH CLIN NEUROPSYCH, V23, P283, DOI 10.1016/j.acn.2007.12.004; Zebrack BJ, 2004, J CLIN ONCOL, V22, P999, DOI 10.1200/JCO.2004.06.148; Zebrack BJ, 2002, PEDIATRICS, V110, P42, DOI 10.1542/peds.110.1.42	69	32	33	0	21	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1057-9249	1099-1611		PSYCHO-ONCOLOGY	Psycho-Oncol.	FEB	2013	22	2					447	458		10.1002/pon.3021			12	Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical	Oncology; Psychology; Biomedical Social Sciences	083VQ	WOS:000314493700027	22278930	Green Accepted			2021-06-18	
J	Parri, N; Crosby, BJ; Glass, C; Mannelli, F; Sforzi, I; Schiavone, R; Ban, KM				Parri, Niccolo; Crosby, Bradley J.; Glass, Casey; Mannelli, Francesco; Sforzi, Idanna; Schiavone, Raffaele; Ban, Kevin Michael			ABILITY OF EMERGENCY ULTRASONOGRAPHY TO DETECT PEDIATRIC SKULL FRACTURES: A PROSPECTIVE, OBSERVATIONAL STUDY	JOURNAL OF EMERGENCY MEDICINE			English	Article						ultrasound; computed tomography; Emergency Physician; skull fractures; pediatric head trauma	MINOR HEAD TRAUMA; INTRACRANIAL INJURY; CHILDREN YOUNGER; COMPUTED-TOMOGRAPHY; BEDSIDE ULTRASOUND; DIAGNOSIS; MANAGEMENT; RADIOGRAPHY; SONOGRAPHY; INFANTS	Background: Blunt head trauma is a common reason for medical evaluation in the pediatric Emergency Department (ED). The diagnostic work-up for skull fracture, as well as for traumatic brain injury, often involves computed tomography (CT) scanning, which may require sedation and exposes children to often-unnecessary ionizing radiation. Objectives: Our objective was to determine if bedside ED ultrasound is an accurate diagnostic tool for identifying skull fractures when compared to head CT. Methods: We present a prospective study of bedside ultrasound for diagnosing skull fractures in head-injured pediatric patients. A consecutive series of children presenting with head trauma requiring CT scan was enrolled. Cranial bedside ultrasound imaging was performed by an emergency physician and compared to the results of the CT scan. The primary outcome was to identify the sensitivity, specificity, and predictive values of ultrasound for skull fractures when compared to head CT. Results: Bedside emergency ultrasound performs with 100% sensitivity (95% confidence interval [CI] 88.2-100%) and 95% specificity (95% CI 75.0-99.9%) when compared to CT scan for the diagnosis of skull fractures. Positive and negative predictive values were 97.2% (95% CI 84.6-99.9%) and 100% (95% CI 80.2-100%), respectively. Conclusions: Compared to CT scan, bedside ultrasound may accurately diagnose pediatric skull fractures. Considering the simplicity of this examination, the minimal experience needed for an Emergency Physician to provide an accurate diagnosis and the lack of ionizing radiation, Emergency Physicians should consider this modality in the evaluation of pediatric head trauma. We believe this may be a useful tool to incorporate in minor head injury prediction rules, and warrants further investigation. (C) 2013 Elsevier Inc.	[Parri, Niccolo; Mannelli, Francesco; Sforzi, Idanna] Anna Meyer Pediat Hosp, Dept Pediat Emergency Med, I-50129 Florence, Italy; [Crosby, Bradley J.; Ban, Kevin Michael] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA; [Glass, Casey] Wake Forest Univ, Dept Emergency Med, Winston Salem, NC 27109 USA; [Schiavone, Raffaele] Anna Meyer Pediat Hosp, Dept Emergency Radiol, I-50129 Florence, Italy; [Ban, Kevin Michael] Harvard Univ, Sch Med, Boston, MA USA	Parri, N (corresponding author), Anna Meyer Pediat Hosp, Dept Pediat Emergency Med, Viale Pieraccini 24, I-50129 Florence, Italy.			Parri, Niccolo/0000-0002-8098-2504			*AM COLL EM PHYS, 2008, POL STAT EM ULTR GUI; American Institute of Ultrasound in Medicine, 2007, OFF STAT PRUD US CLI; Bergman DA, 1999, PEDIATRICS, V104, P1407; Chen L, 2007, PEDIATR EMERG CARE, V23, P528, DOI 10.1097/PEC.0b013e318128f85d; Chung S, 2004, ANN EMERG MED, V43, P718, DOI 10.1016/j.annemergmed.2003.09.020; Cross KP, 2010, ACAD EMERG MED, V17, P687, DOI 10.1111/j.1553-2712.2010.00788.x; Da Dalt L, 2007, J PEDIATR-US, V150, P274, DOI 10.1016/j.jpeds.2006.11.060; Decarie JC, 1999, CHILD NERV SYST, V15, P740, DOI 10.1007/s003810050463; Dunning J, 2004, ARCH DIS CHILD, V89, P653, DOI 10.1136/adc.2003.027722; Greenes DS, 1997, ANN EMERG MED, V30, P253, DOI 10.1016/S0196-0644(97)70158-6; Greenes DS, 2001, PEDIATR EMERG CARE, V17, P88, DOI 10.1097/00006565-200104000-00002; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; Gurkov R, 2008, AM J RHINOL, V22, P613, DOI 10.2500/ajr.2008.22.3239; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; Johnson JN, 2009, WEST J EMERG MED, V10, P303; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; Lee MH, 2009, J ULTRAS MED, V28, P717, DOI 10.7863/jum.2009.28.6.717; Lloyd DA, 1997, LANCET, V349, P821, DOI 10.1016/S0140-6736(96)09356-7; Maguire JL, 2009, PEDIATRICS, V124, pE145, DOI 10.1542/peds.2009-0075; Nezafati S, 2010, DENTOMAXILLOFAC RAD, V39, P11, DOI 10.1259/dmfr/97056817; Osmond MH, 2010, CAN MED ASSOC J, V182, P341, DOI 10.1503/cmaj.091421; Palchak MJ, 2004, PEDIATRICS, V113, pE507, DOI 10.1542/peds.113.6.e507; Quayle KS, 1997, PEDIATRICS, V99, part. no., DOI 10.1542/peds.99.5.e11; Rainer TH, 2004, J TRAUMA, V56, P1211, DOI 10.1097/01.TA.0000075800.65485.48; Ramirez-Schrempp D, 2011, PEDIATR EMERG CARE, V27, P312, DOI 10.1097/PEC.0b013e3182131579; Schnadower D, 2007, CURR OPIN PEDIATR, V19, P258, DOI 10.1097/MOP.0b013e3281084e85; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; Simanovsky N, 2009, J PEDIATR ORTHOPED, V29, P142, DOI 10.1097/BPO.0b013e318198452e; Sun BC, 2007, ANN EMERG MED, V49, P325, DOI 10.1016/j.annemergmed.2006.08.032; Torloni MR, 2009, ULTRASOUND OBST GYN, V33, P599, DOI 10.1002/uog.6328; Trenchs V, 2009, EUR J EMERG MED, V16, P150, DOI 10.1097/MEJ.0b013e328321b7b5; Williams H, 2008, ARCH DIS CHILDHOOD-E, V93, P120, DOI 10.1136/adc.2008.145532; You JS, 2010, J CLIN ULTRASOUND, V38, P135, DOI 10.1002/jcu.20669	35	32	32	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0736-4679	1090-1280		J EMERG MED	J. Emerg. Med.	JAN	2013	44	1					135	141		10.1016/j.jemermed.2012.02.038			7	Emergency Medicine	Emergency Medicine	073PO	WOS:000313755200073	22579023				2021-06-18	
J	Singleton, JAG; Gibb, IE; Hunt, NCA; Bull, AMJ; Clasper, JC				Singleton, James A. G.; Gibb, Iain E.; Hunt, Nicholas C. A.; Bull, Anthony M. J.; Clasper, Jonathan C.			Identifying future 'unexpected' survivors: a retrospective cohort study of fatal injury patterns in victims of improvised explosive devices	BMJ OPEN			English	Article							POSTMORTEM COMPUTED-TOMOGRAPHY; COMBAT CASUALTY CARE; TRAUMA VICTIMS; DEATH; AUTOPSY	Objectives: To identify potentially fatal injury patterns in explosive blast fatalities in order to focus research and mitigation strategies, to further improve survival rates from blast trauma. Design: Retrospective cohort study. Participants: UK military personnel killed by improvised explosive device (IED) blasts in Afghanistan, November 2007-August 2010. Setting: UK military deployment, through NATO, in support of the International Security Assistance Force (ISAF) mission in Afghanistan. Data sources: UK military postmortem CT records, UK Joint Theatre Trauma Registry and associated incident data. Main outcome measures: Potentially fatal injuries attributable to IEDs. Results: We identified 121 cases, 42 mounted (in-vehicle) and 79 dismounted (on foot), at a point of wounding. There were 354 potentially fatal injuries in total. Leading causes of death were traumatic brain injury (50%, 62/124 fatal injuries), followed by intracavity haemorrhage (20.2%, 25/124) in the mounted group, and extremity haemorrhage (42.6%, 98/230 fatal injuries), junctional haemorrhage (22.2%, 51/230 fatal injuries) and traumatic brain injury (18.7%, 43/230 fatal injuries) in the dismounted group. Conclusions: Head trauma severity in both mounted and dismounted IED fatalities indicated prevention and mitigation as the most effective strategies to decrease resultant mortality. Two-thirds of dismounted fatalities had haemorrhage implicated as a cause of death that may have been anatomically amenable to prehospital intervention. One-fifth of the mounted fatalities had haemorrhagic trauma which currently could only be addressed surgically. Maintaining the drive to improve all haemostatic techniques for blast casualties, from point of wounding to definitive surgical proximal vascular control, alongside the development and application of novel haemostatic interventions could yield a significant survival benefit. Prospective studies in this field are indicated.	[Singleton, James A. G.; Bull, Anthony M. J.; Clasper, Jonathan C.] Univ London Imperial Coll Sci Technol & Med, Ctr Blast Injury Studies, London, England; [Gibb, Iain E.] Ft Blockhouse, Def Ctr Imaging, Gosport, Hants, England; [Hunt, Nicholas C. A.] Forens Pathol Serv, Abingdon, Oxon, England; [Singleton, James A. G.; Clasper, Jonathan C.] Royal Ctr Def Med, Acad Dept Mil Surg & Trauma, Birmingham, W Midlands, England	Singleton, JAG (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ctr Blast Injury Studies, London, England.	j.singleton11@ic.ac.uk	Bull, Anthony M J/C-2317-2008	Bull, Anthony M J/0000-0002-4473-8264			BELLAMY RF, 1984, MIL MED, V149, P55; Bolliger SA, 2008, EUR RADIOL, V18, P273, DOI 10.1007/s00330-007-0737-4; Bosker AJ, 2012, IEDS WILL REMAIN WEA; Champion HR, 2010, J TRAUMA, V68, P1139, DOI 10.1097/TA.0b013e3181d86a0d; Champion HR, 2003, J TRAUMA, V54, pS13, DOI 10.1097/01.TA.0000057151.02906.27; DCBI Task Force, 2011, REPORT OF THE ARMY D; Demetriades D, 1996, ARCH SURG-CHICAGO, V131, P133; DONCHIN Y, 1994, J TRAUMA, V37, P552, DOI 10.1097/00005373-199410000-00006; DONCHIN Y, 1994, J TRAUMA, V37, P555; Doyle GS, 2008, PREHOSP EMERG CARE, V12, P241, DOI 10.1080/10903120801907570; Eastridge BJ, 2012, J TRAUMA ACUTE CARE, V73, pS431, DOI 10.1097/TA.0b013e3182755dcc; Eastridge BJ, 2011, J TRAUMA, V71, pS4, DOI 10.1097/TA.0b013e318221147b; Farkash U, 2000, J TRAUMA, V48, P303, DOI 10.1097/00005373-200002000-00018; Grabherr S, 2011, INT J LEGAL MED, V125, P791, DOI 10.1007/s00414-010-0526-5; Griffiths D, 2006, CURR ORTHOPAED, V20, P346, DOI 10.1016/j.cuor.2006.07.007; Holcomb JB, 2007, ANN SURG, V245, P986, DOI 10.1097/01.sla.0000259433.03754.98; Jeffery AJ, 2008, CLIN RADIOL, V63, P1160, DOI 10.1016/j.crad.2008.03.003; Kragh JF, 2009, ANN SURG, V249, P1, DOI 10.1097/SLA.0b013e31818842ba; Mazurek Michael T, 2006, J Am Acad Orthop Surg, V14, pS18; MELLOR SG, 1989, BRIT J SURG, V76, P1006, DOI 10.1002/bjs.1800761006; Morrison JJ, 2013, ANN SURG, V257, P330, DOI 10.1097/SLA.0b013e31827eefcf; Nelson TJ, 2008, J TRAUMA, V65, P212, DOI 10.1097/01.ta.0000196010.50246.9a; O'Donnell C, 2008, CLIN RADIOL, V63, P1189, DOI 10.1016/j.crad.2008.05.008; Osler T, 1997, J TRAUMA, V43, P922, DOI 10.1097/00005373-199712000-00009; Ramasamy A, 2009, J R Army Med Corps, V155, P265; Ramasamy A, 2008, J TRAUMA, V65, P910, DOI 10.1097/TA.0b013e3181848cf6; Russell RJ, 2011, PHILOS T R SOC B, V366, P171, DOI 10.1098/rstb.2010.0232; Scholing M, 2009, EUR RADIOL, V19, P2333, DOI 10.1007/s00330-009-1440-4; Shelton HH, 1998, PUB 3 07 2 JOINT TAC; Wullenweber R, 1977, Z RECHTSMED, V80, P277	30	32	32	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	2044-6055			BMJ OPEN	BMJ Open		2013	3	8							e003130	10.1136/bmjopen-2013-003130			8	Medicine, General & Internal	General & Internal Medicine	301VX	WOS:000330561300084	23906957	DOAJ Gold, Green Published			2021-06-18	
J	Twamley, EW; Baker, LG; Norman, SB; Pittman, JOE; Lohr, JB; Resnick, SG				Twamley, Elizabeth W.; Baker, Leen G.; Norman, Sonya B.; Pittman, James O. E.; Lohr, James B.; Resnick, Sandra G.			Veterans Health Administration vocational services for Operation Iraqi Freedom/Operation Enduring Freedom Veterans with mental health conditions	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						brain injury; compensated work therapy; depression; employment; posttraumatic stress disorder; rehabilitation; service utilization; substance use disorder; supported employment; unemployment	RANDOMIZED CONTROLLED-TRIALS; TRAUMATIC BRAIN-INJURY; SUPPORTED EMPLOYMENT; ILLNESS; AFFAIRS	High rates of mental health conditions and unemployment are significant problems facing Veterans of Operation Iraqi Freedom/Operation Enduring Freedom (OIF/OEF). We examined two national Veterans Health Administration (VHA) databases from fiscal years 2008-2009: a larger database (n = 75,607) of OIF/OEF Veterans with posttraumatic stress disorder, depression, substance use disorder, or traumatic brain injury (TBI) and a smaller subset (n = 1,010) of those Veterans whose employment was tracked during their participation in YHA vocational services. Only 8.4% of Veterans in the larger database accessed any vocational services and retention was low, with most Veterans attending one or two appointments. Veterans with TBI and with more mental health conditions overall were more likely to access vocational services. Only 2.2% of Veterans received evidence-based supported employment. However, supported employment was effective, with 51% of those Veterans receiving it obtaining competitive work. Effect sizes quantifying the effect of supported employment provision on competitive work attainment, number of jobs, job tenure, and retention in vocational services were large. Given the high success rate of supported employment for these Veterans, additional supported employment specialists for this population would be expected to improve work outcomes for post-9/11 Veterans who want assistance returning to work.	[Twamley, Elizabeth W.; Baker, Leen G.; Norman, Sonya B.; Pittman, James O. E.; Lohr, James B.] VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, San Diego, CA 92161 USA; [Twamley, Elizabeth W.; Baker, Leen G.; Norman, Sonya B.; Pittman, James O. E.; Lohr, James B.] VA San Diego Healthcare Syst, Dept Vet Affairs, San Diego, CA 92161 USA; [Twamley, Elizabeth W.; Baker, Leen G.; Norman, Sonya B.; Lohr, James B.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Resnick, Sandra G.] VA Connecticut Healthcare Syst, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT USA; [Resnick, Sandra G.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA	Twamley, EW (corresponding author), VA San Diego Healthcare Syst, Ctr Excellence Stress & Mental Hlth, 3350 Jolla Village Dr 116A, San Diego, CA 92161 USA.	elizabeth.twamley@va.gov	Resnick, Sandra G/F-3883-2014	Resnick, Sandra G/0000-0001-6373-1482	VA Health Services Research and Development Mental Health Quality Enhancement Research Initiative [RRP 10-052]	This material was based on work supported by the VA Health Services Research and Development Mental Health Quality Enhancement Research Initiative (grant RRP 10-052).	Adler DA, 2011, PSYCHIAT SERV, V62, P39, DOI 10.1176/ps.62.1.pss6201_0039; [Anonymous], 2011, CWT PROGR HELPS WOUN; Becker D, 2007, PSYCHIAT SERV, V58, P922, DOI 10.1176/appi.ps.58.7.922; Becker DR., 2003, WORKING LIFE PEOPLE; Bond GR, 2008, PSYCHIATR REHABIL J, V31, P280, DOI 10.2975/31.4.2008.280.290; Bond GR, 2001, PSYCHIATR SERV, V52, P313, DOI 10.1176/appi.ps.52.3.313; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Hoffman SW, 2009, CLIN NEUROPSYCHOL, V23, P1400, DOI 10.1080/13854040903369433; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Kuhn JH, 2011, COMMUNITY HOMELESSNE; O'Connor MK, 2011, J REHABIL RES DEV, V48, P597, DOI 10.1682/JRRD.2010.06.0117; Parker, 1992, DESIGNING CONDUCTING; Resnick SG, 2008, J REHABIL RES DEV, V45, P427, DOI 10.1682/JRRD.2007.06.0093; Resnick SG, 2007, J REHABIL RES DEV, V44, P867, DOI 10.1682/JRRD.2007.02.0043; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Sturm R, 1999, PSYCHIATR SERV, V50, P1407, DOI 10.1176/ps.50.11.1407; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Twamley EW, 2003, J NERV MENT DIS, V191, P515, DOI 10.1097/01.nmd.0000082213.42509.69	18	32	32	0	13	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711			J REHABIL RES DEV	J. Rehabil. Res. Dev.		2013	50	5					663	670		10.1682/JRRD.2012.08.0137			8	Rehabilitation	Rehabilitation	202RO	WOS:000323237500008	24013914	Bronze			2021-06-18	
J	Braden, CA; Cuthbert, JP; Brenner, L; Hawley, L; Morey, C; Newman, J; Staniszewski, K; Harrison-Felix, C				Braden, Cynthia A.; Cuthbert, Jeffrey P.; Brenner, Lisa; Hawley, Lenore; Morey, Clare; Newman, Jody; Staniszewski, Kristi; Harrison-Felix, Cynthia			Health and wellness characteristics of persons with traumatic brain injury	BRAIN INJURY			English	Article						Health promotion; wellness; traumatic brain injury; community dwelling	QUALITY-OF-LIFE; COMMUNITY INTEGRATION; PARTICIPATION ASSESSMENT; HEAD-INJURY; REHABILITATION; SATISFACTION; DISABILITY; OUTCOMES; INDIVIDUALS; RELIABILITY	Objective: To describe health and wellness characteristics of persons with TBI living in the community, compare to other disability populations and evaluate the associations between health-related constructs. Design: Observational. Setting: Outpatient rehabilitation hospital and a Veterans Affairs Medical Centre. Participants: Seventy-four community-dwelling adults with moderate-to-severe TBI. Interventions: None. Main measures: Health Promoting Lifestyle Profile II (HPLP-II), Self Rated Abilities Health Practices Scale (SRAHP), Barriers to Health Promoting Activities for Disabled Scale (BHPAD), Medical Outcomes Study 12-Item Health Status Survey Short Form (SF-12), Personal Resource Questionnaire-adapted (PRQ-a), Perceived Wellness Survey (PWS), Diener Satisfaction with Life Scale (SWLS) and Participation Assessment with Recombined Tools-Objective (PART-O). Results: Health-promoting behaviours, self-efficacy and barriers to health were comparable to other disability populations. Perceived health status, participation and life satisfaction were decreased. Measures of health promotion and self-efficacy were positively associated with perceived mental health status, life satisfaction and participation. Barriers to healthy activities were negatively associated with health promotion, self-efficacy and perceived mental health status. Conclusions: Health and wellness status was below desired levels for the study cohort, and comparable to other disability populations. Better understanding of associations among health-related constructs is needed. Continued research on conceptually-based health and wellness interventions for persons with TBI is recommended.	[Braden, Cynthia A.; Cuthbert, Jeffrey P.; Hawley, Lenore; Morey, Clare; Newman, Jody; Staniszewski, Kristi; Harrison-Felix, Cynthia] Craig Hosp, Res Dept, Englewood, CO 80113 USA; [Brenner, Lisa] Mental Illness Res,Educ & Clin Ctr, Vet Integrated Serv Network 19, Denver, CO USA	Braden, CA (corresponding author), Craig Hosp, Res Dept, 3425 S Clarkson St, Englewood, CO 80113 USA.	cbraden@craighospital.org	Brenner, Lisa A./AAG-2442-2019		US Department of Education, Office of Special Education and Rehabilitation Services, National Institute on Disability and Rehabilitation Research [H133A070022]	This research was supported by an award from the US Department of Education, Office of Special Education and Rehabilitation Services, National Institute on Disability and Rehabilitation Research to the Rocky Mountain Regional Brain Injury System (H133A070022). The opinions expressed in this manuscript are those of the authors and do not necessarily reflect the views of the Department of Education or the Department of Veterans Affairs.	Adams T, 1997, AM J HEALTH PROMOT, V11, P208, DOI 10.4278/0890-1171-11.3.208; Ali R, 2002, ADDICTION, V97, P1183; Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Becker H, 1991, Am J Health Promot, V5, P449; BECKER H, 1993, SELF RATED ABILITIES, V17, P42; Becker MH, 1974, HLTH BELIEF MODEL PE; Bezner JR, 2001, ARCH PHYS MED REHAB, V82, P787, DOI 10.1053/apmr.2001.23269; Bogner JA, 2011, ARCH PHYS MED REHAB, V92, P552, DOI 10.1016/j.apmr.2010.11.014; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Branca B, 2004, J HEAD TRAUMA REHAB, V19, P40, DOI 10.1097/00001199-200401000-00005; Brandt J., 2001, HOPKINS VERBAL LEARN; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Centers for Disease Control and Prevention, 2010, OV OB COL; Centers for Disease Control and Prevention, GET STATS TRAUM BRAI; Centers for Disease Control and Prevention and Department of Health and Human Services, 2006, BMI BOD MASS IND; Cicerone KD, 2004, ARCH PHYS MED REHAB, V85, P943, DOI 10.1016/j.apmr.2003.07.019; Correa J.C.R., 2011, J HEAD TRAUMA REHAB, P1; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Corrigan JD, 2003, PROBLEMATIC SUBSTANC; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Driver S, 2006, BRAIN INJURY, V20, P133, DOI 10.1080/02699050500443822; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; Golden CJ, 2002, STROOP COLOR WORD TE; Hagen C, 1974, RANCHO LOS AMIGOS SC; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hillier SL, 1997, BRAIN INJURY, V11, P661; Kalpakjian CZ, 2004, AM J PHYS MED REHAB, V83, P255, DOI 10.1097/01.PHM.0000118033.07952.8C; Kwon BK, 2010, J NEUROTRAUM, V27, P21, DOI 10.1089/neu.2009.1048; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lynch WJ, 2002, J HEAD TRAUMA REHAB, V17, P66, DOI 10.1097/00001199-200202000-00009; Mathias JL, 2007, NEUROPSYCHOLOGY, V21, P212, DOI 10.1037/0894-4105.21.2.212; McCarthy ML, 2006, ARCH PHYS MED REHAB, V87, P953, DOI 10.1016/j.apmr.2006.03.007; McCullagh S, 2005, TXB TRAUMATIC BRAIN, P321; National Institute of Neurological Disorders and Stroke, 2002, TRAUM BRAIN INJ HOP; Nieuwenhuijsen ER, 2006, DISABIL REHABIL, V28, P245, DOI 10.1080/09638280500197743; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Office of Applied Studies Department of HHS, 2010, AD TABL STAT EST SUB; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Pagulayan KF, 2006, ARCH PHYS MED REHAB, V87, P611, DOI 10.1016/j.apmr.2006.01.018; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Putnam M, 2003, J REHABIL, V69, P37; Reitan R. M., 1993, HALSTED REITAN NEURO; Rimmer JH., 2001, CTR HLTH PROMOTION R; RRTC Health & Wellness Consortium, 2004, HLTH LIF EV BAS CURR; Sendroy-Terrill M, 2010, ARCH PHYS MED REHAB, V91, P489, DOI 10.1016/j.apmr.2009.11.011; Smith A., 1982, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Stuifbergen A K, 1995, Sch Inq Nurs Pract, V9, P31; Stuifbergen A. K., 1995, SCHOLARLY INQUIRY NU, V9, P51; Stuifbergen AK, 2000, NURS RES, V49, P122, DOI 10.1097/00006199-200005000-00002; STUIFBERGEN AK, 1994, RES NURS HEALTH, V17, P3, DOI 10.1002/nur.4770170103; Stuifbergen Alexa K, 2004, J Holist Nurs, V22, P12; Stuijbergen AK, 2003, ARCH PHYS MED REHAB, V84, P467, DOI 10.1053/apmr.2003.50028; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; The Traumatic Brain Injury Model Systems National Data and Statistical Center, POL 101A ID SUBJ; U.S. Department of Health and Human Services, 2000, HLTH PEOPL 2010 UND; U. S. Department of Health and Human Services, 2010, HLTH PEOPL 2020 DIS; [Uniform Data System for Medical Rehabilitation State University of New York at Buffalo], 1993, GUID UN DAT SET MED; Walker SN, 1996, P 1996 SCI SESS AM N, P110; Ware J.E., 1994, SF 36 PHYS MENTAL SU; Weinert C, 1987, West J Nurs Res, V9, P589; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P542, DOI 10.1016/j.apmr.2010.08.002; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P957, DOI 10.1097/01.PHM.0000098504.78524.E2	72	32	32	0	26	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2012	26	11					1315	1327		10.3109/02699052.2012.706351			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	005AQ	WOS:000308723100005	22876980				2021-06-18	
J	Weygandt, PL; Losonczy, LI; Schneider, EB; Kisat, MT; Licatino, LK; Cornwell, EE; Haut, ER; Efron, DT; Haider, AH				Weygandt, Paul Logan; Losonczy, Lia I.; Schneider, Eric B.; Kisat, Mehreen T.; Licatino, Lauren K.; Cornwell, Edward E., III; Haut, Elliot R.; Efron, David T.; Haider, Adil H.			Disparities in mortality after blunt injury: Does insurance type matter?	JOURNAL OF SURGICAL RESEARCH			English	Article						Insurance type; Blunt injury; Disparities; Outcomes	TRAUMATIC BRAIN-INJURY; OUTCOMES; RACE; CARE; ASSOCIATION; DETERMINANT; PREDICTOR; DISEASE; IMPACT	Background: Insurance-related outcomes disparities are well-known, but associations between distinct insurance types and trauma outcomes remain unclear. Prior studies have generally merged various insurance types into broad groups. The purpose of this study is to determine the association of specific insurance types with mortality after blunt injury. Materials and methods: Cases of blunt injury among adults aged 18-64 y with an injury severity score >9 were identified using the 2007-2009 National Trauma Data Bank. Crude mortality was calculated for 10 insurance types. Multivariable logistic regression was employed to determine difference in odds of death between insurance types, controlling for injury severity score, Glasgow Coma Scale motor, mechanism of injury, sex, race, and hypotension. Clustering was used to account for possible inter-facility variations. Results: A total of 312,312 cases met inclusion criteria. Crude mortality ranged from 3.2 to 6.0% by insurance type. Private Insurance, Blue Cross Blue Shield, Workers Compensation, and Medicaid yielded the lowest relative odds of death, while Not Billed and Self Pay yielded the highest. Compared with Private Insurance, odds of death were higher for No Fault (OR 1.25, P = 0.022), Not Billed (OR 1.77, P < 0.001), and Self Pay (OR 1.77, P < 0.001). Odds of death were higher for Medicare (OR 1.52, P < 0.001) and Other Government (OR 1.35, P = 0.049), while odds of death were lower for Medicaid (OR 0.89, P = 0.015). Conclusions: Significant differences in mortality after blunt injury were seen between insurance types, even among those commonly grouped in other studies. Policymakers may use this information to implement programs to monitor and reduce insurance-related disparities. (C) 2012 Elsevier Inc. All rights reserved.	[Haider, Adil H.] Johns Hopkins Univ, Dept Surg, Div Trauma Crit Care, Sch Med, Baltimore, MD 21218 USA; [Weygandt, Paul Logan; Losonczy, Lia I.; Schneider, Eric B.; Kisat, Mehreen T.; Efron, David T.; Haider, Adil H.] Johns Hopkins Ctr Surg Trials & Outcomes Res, Baltimore, MD USA; [Licatino, Lauren K.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA; [Cornwell, Edward E., III] Howard Univ, Coll Med, Washington, DC USA	Haider, AH (corresponding author), Johns Hopkins Univ, Dept Surg, Div Trauma Crit Care, Sch Med, Baltimore, MD 21218 USA.	ahaider1@jhmi.edu	Haut, Elliott R./J-3948-2019	Weygandt, Paul/0000-0001-9394-0613	National Institutes of Health/NIGMSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K23GM093112-01]; American College of Surgeons; Hopkins Center for Health Disparities Solutions from the National Center Research Resources [5TL1RR025007]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [TL1RR025007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [K23GM093112] Funding Source: NIH RePORTER	Financial support for this work was provided by the National Institutes of Health/NIGMS K23GM093112-01; American College of Surgeons C. James Carrico Fellowship for the study of Trauma and Critical Care and Hopkins Center for Health Disparities Solutions (A. H. H.) and grant number 5TL1RR025007 from the National Center Research Resources to the Johns Hopkins University School of Medicine, which funds the Predoctoral Clinical Research Training Program (P.L.W.).	Alban RF, 2010, AM SURGEON, V76, P1108; Bosse MJ, 2002, NEW ENGL J MED, V347, P1924, DOI 10.1056/NEJMoa012604; Chan L, 2001, ARCH PHYS MED REHAB, V82, P1151, DOI 10.1053/apmr.2001.24892; DeNavas-Walt C, 2011, CURRENT POPULATION R, P60; Edelman DA, 2007, SHOCK, V27, P134, DOI 10.1097/01.shk.0000239772.18151.18; Farrell RT, 2010, J BURN CARE RES, V31, P385, DOI 10.1097/BCR.0b013e3181db516b; Fedewa SA, 2011, GYNECOL ONCOL, V122, P63, DOI 10.1016/j.ygyno.2011.03.010; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Greene WR, 2010, AM J SURG, V199, P554, DOI 10.1016/j.amjsurg.2009.11.005; HAAS JS, 1994, AM J PUBLIC HEALTH, V84, P1605, DOI 10.2105/AJPH.84.10.1605; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; Haider AH, 2012, ARCH SURG-CHICAGO, V147, P63, DOI 10.1001/archsurg.2011.254; Haider AH, 2011, JT COMM J QUAL PATIE, V37, P435, DOI 10.1016/S1553-7250(11)37054-7; Haider AH, 2011, JAMA-J AM MED ASSOC, V306, P942, DOI 10.1001/jama.2011.1248; Haider AH, 2009, SURGERY, V146, P308, DOI 10.1016/j.surg.2009.05.006; Haider AH, 2009, J SURG RES, V153, P138, DOI 10.1016/j.jss.2008.04.011; Hakmeh W, 2010, ACAD EMERG MED, V17, P809, DOI 10.1111/j.1553-2712.2010.00819.x; Healey C, 2003, J TRAUMA, V54, P671, DOI 10.1097/01.TA.0000058130.30490.5D; Heffernan DS, 2011, J TRAUMA, V70, P527, DOI 10.1097/TA.0b013e31820d0ed7; Hing Esther, 2008, Vital Health Stat 13, P1; Ioannou GN, 2003, AM J GASTROENTEROL, V98, P2082, DOI 10.1016/S0002-9270(03)00423-4; LaPar DJ, 2011, J AM COLL SURGEONS, V212, P759, DOI 10.1016/j.jamcollsurg.2010.12.050; Maybury RS, 2010, SURGERY, V148, P202, DOI 10.1016/j.surg.2010.05.010; McGwin G, 2004, J TRAUMA, V56, P1291, DOI 10.1097/01.TA.0000089354.02065.D0; McKenna MT, 2005, AM J PREV MED, V28, P415, DOI 10.1016/j.amepre.2005.02.009; MILZMAN DP, 1992, J TRAUMA, V32, P236, DOI 10.1097/00005373-199202000-00021; Rosen H, 2009, ARCH SURG-CHICAGO, V144, P1006, DOI 10.1001/archsurg.2009.195; Rosen H, 2009, J PEDIATR SURG, V44, P1952, DOI 10.1016/j.jpedsurg.2008.12.026; Salim A, 2010, J TRAUMA, V68, P211, DOI 10.1097/TA.0b013e3181a0e659; Segui-Gomez M, 2003, EPIDEMIOL REV, V25, P3, DOI 10.1093/epirev/mxg007; Slatore CG, 2010, AM J RESP CRIT CARE, V182, P1195, DOI 10.1164/rccm.2009-038ST; Tepas JJ, 2011, J AM COLL SURGEONS, V212, P722, DOI 10.1016/j.jamcollsurg.2010.12.016; Ward E, 2008, CA-CANCER J CLIN, V58, P9, DOI 10.3322/CA.2007.0011; Williams DR, 2010, HEALTH AFFAIR, V29, P1481, DOI 10.1377/hlthaff.2010.0071; Zarzaur BL, 2010, J SURG RES, V160, P196, DOI 10.1016/j.jss.2009.06.059	35	32	32	0	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	OCT	2012	177	2					288	294		10.1016/j.jss.2012.07.003			7	Surgery	Surgery	004VD	WOS:000308708400024	22858381	Green Accepted			2021-06-18	
J	Donohue, MM; Cain, K; Zierath, D; Shibata, D; Tanzi, PM; Becker, KJ				Donohue, Megan M.; Cain, Kevin; Zierath, Dannielle; Shibata, Dean; Tanzi, Patricia M.; Becker, Kyra J.			Higher Plasma Fractalkine Is Associated With Better 6-Month Outcome From Ischemic Stroke	STROKE			English	Article						CX3CL1; fractalkine; inflammation; outcome; stroke	INTERCELLULAR-ADHESION MOLECULE-1; SYSTEMIC-LUPUS-ERYTHEMATOSUS; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; MICROGLIAL ACTIVATION; SOLUBLE FRACTALKINE; HIPPOCAMPAL-NEURONS; ALZHEIMERS-DISEASE; RECEPTOR CX(3)CR1	Background and Purpose-Fractalkine (CX3CL1) is a unique chemokine that is constitutively expressed on neurons where it serves as an adhesion molecule for lymphocytes and monocytes. CX3CL1 may also be cleaved from the surface of these cells and enter the circulation to act as a traditional chemokine. CX3CL1 could thus influence the inflammatory response after stroke. We hypothesized that patients with higher plasma CX3CL1 after stroke would have a more robust inflammatory response and experience worse outcome. Methods-Plasma CX3CL1 concentrations were assessed in 85 patients who were part of a larger study evaluating immune responses after ischemic stroke; CX3CL1 values were available from Day 1 to Day 180 after stroke onset. CX3CL1 was correlated to measures of inflammation and its effect on outcome assessed. Results-At 1 day after stroke, CX3CL1 was lower in patients with severe strokes. At 180 days after stroke, CX3CL1 concentrations were lower in patients with poor outcome. The association of CX3CL1 and outcome at 180 days was independent of initial stroke severity. Plasma CX3CL1 at 180 days was inversely associated with systemic markers of inflammation, including white blood cell counts and high-sensitivity C-reactive protein. Conclusions-In contrast to our original hypothesis, lower concentrations of CX3CL1 are associated with worse stroke outcome. In light of recent studies suggesting an immunomodulatory and neuroprotective role for CX3CL1 in a variety of neurodegenerative diseases, a therapeutic role for CX3CL1 in stroke recovery should be considered. (Stroke. 2012; 43: 2300-2306.)	[Donohue, Megan M.; Zierath, Dannielle; Tanzi, Patricia M.; Becker, Kyra J.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA; [Cain, Kevin] Univ Washington, Sch Med, Dept Biostat, Seattle, WA USA; [Shibata, Dean] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA	Becker, KJ (corresponding author), Box 359775 HMC,325 9th Ave, Seattle, WA 98104 USA.	kjb@uw.edu	Becker, Kyra/L-1420-2019	Becker, Kyra/0000-0002-8310-4846	National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049197]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049197] Funding Source: NIH RePORTER	This work was funded by National Institute of Neurological Disorders and Stroke R01NS049197.	Bachstetter AD, 2011, NEUROBIOL AGING, V32, P2030, DOI 10.1016/j.neurobiolaging.2009.11.022; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Blann A, 1999, BLOOD COAGUL FIBRIN, V10, P277, DOI 10.1097/00001721-199907000-00009; Chapman GA, 2000, J NEUROSCI, V20; Cho SH, 2011, J BIOL CHEM, V286, P32713, DOI 10.1074/jbc.M111.254268; Cipriani R, 2011, J NEUROSCI, V31, P16327, DOI 10.1523/JNEUROSCI.3611-11.2011; Corona AW, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-93; Deiva K, 2004, EUR J NEUROSCI, V20, P3222, DOI 10.1111/j.1460-9568.2004.03800.x; Denes A, 2008, J CEREBR BLOOD F MET, V28, P1707, DOI 10.1038/jcbfm.2008.64; Duan RS, 2008, NEUROCHEM RES, V33, P1085, DOI 10.1007/s11064-007-9554-z; FASSBENDER K, 1995, STROKE, V26, P1361, DOI 10.1161/01.STR.26.8.1361; Fong SM, 1997, IMMUNOL RES, V16, P299, DOI 10.1007/BF02786396; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Hatori K, 2002, J NEUROSCI RES, V69, P418, DOI 10.1002/jnr.10304; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Kasama T, 2008, FRONT BIOSCI-LANDMRK, V13, P2527, DOI 10.2741/2864; Kastenbauer S, 2003, J NEUROIMMUNOL, V137, P210, DOI 10.1016/S0165-5728(03)00085-7; Kim TS, 2008, NEUROSCI LETT, V436, P196, DOI 10.1016/j.neulet.2008.03.019; Krathwohl MD, 2004, STEM CELLS, V22, P109, DOI 10.1634/stemcells.22-1-109; Lauro C, 2010, NEUROPSYCHOPHARMACOL, V35, P1550, DOI 10.1038/npp.2010.26; Lee S, 2010, AM J PATHOL, V177, P2549, DOI 10.2353/ajpath.2010.100265; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Limatola C, 2005, J NEUROIMMUNOL, V166, P19, DOI 10.1016/j.jneuroim.2005.03.023; Lyden P, 1999, STROKE, V30, P2347, DOI 10.1161/01.STR.30.11.2347; Lyons A, 2009, J NEUROCHEM, V110, P1547, DOI 10.1111/j.1471-4159.2009.06253.x; Maggi L, 2011, FRONT CELL NEUROSCI, V5, DOI 10.3389/fncel.2011.00022; Meucci O, 2000, P NATL ACAD SCI USA, V97, P8075, DOI 10.1073/pnas.090017497; Mizuno T, 2003, BRAIN RES, V979, P65, DOI 10.1016/S0006-8993(03)02867-1; Pabon MM, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-9; Rancan M, 2004, J CEREBR BLOOD F MET, V24, P1110, DOI 10.1097/01.WCB.0000133470.91843.72; Ruitenberg MJ, 2008, J NEUROIMMUNOL, V205, P80, DOI 10.1016/j.jneuroim.2008.09.010; Shan S, 2011, NEUROBIOL AGING, V32, P443, DOI 10.1016/j.neurobiolaging.2009.03.004; Shyu KG, 1997, J NEUROL, V244, P90, DOI 10.1007/s004150050055; Sims JR, 2009, NEUROLOGY, V72, P2104, DOI 10.1212/WNL.0b013e3181aa5329; Simundic AM, 2004, CLIN INVEST MED, V27, P86; Soriano SG, 2002, J NEUROIMMUNOL, V125, P59, DOI 10.1016/S0165-5728(02)00033-4; Tanzi P, 2011, NEUROCRIT CARE, V14, P244, DOI 10.1007/s12028-010-9490-7; Tarozzo G, 2002, EUR J NEUROSCI, V15, P1663, DOI 10.1046/j.1460-9568.2002.02007.x; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; Yajima N, 2005, ARTHRITIS RHEUM-US, V52, P1670, DOI 10.1002/art.21042; Zierath D, 2011, STROKE, V42, P3415, DOI 10.1161/STROKEAHA.111.627331; Zujovic V, 2000, GLIA, V29, P305, DOI 10.1002/(SICI)1098-1136(20000215)29:4<305::AID-GLIA2>3.0.CO;2-V	42	32	33	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0039-2499			STROKE	Stroke	SEP	2012	43	9					2300	+		10.1161/STROKEAHA.112.657411			9	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	000UX	WOS:000308416300021	22798324	Green Accepted, Bronze			2021-06-18	
J	Zhong, Q; Zhou, YF; Ye, WBA; Cai, T; Zhang, XQ; Deng, DYB				Zhong, Qian; Zhou, Yanfang; Ye, Weibiao; Cai, Tuo; Zhang, Xiuquan; Deng, David Y. B.			Hypoxia-Inducible Factor 1-alpha-AA-Modified Bone Marrow Stem Cells Protect PC12 Cells from Hypoxia-Induced Apoptosis, Partially Through VEGF/PI3K/Akt/FoxO1 Pathway	STEM CELLS AND DEVELOPMENT			English	Article							VASCULAR ENDOTHELIAL-CELLS; FOXO TRANSCRIPTION FACTORS; CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; STROMAL CELLS; FUNCTIONAL RECOVERY; PROLYL HYDROXYLATION; TUMOR SUPPRESSION; MULTIPLE-MYELOMA; ISCHEMIC BRAIN	Bone marrow stem cells (BMSCs) have been shown to improve neurological function recovery in cerebral ischemia. Hypoxia-inducible factor-1 (HIF-1) alpha-AA is a more stable mutant form of HIF-1 alpha, which is a crucial oxygen- sensitive regulator. To investigate the protective effects of HIF-1 alpha-AA-modified BMSCs on neuron survival in cerebral ischemia models, we co-cultured HIF-1 alpha-AA-modified BMSCs with neuron-like cells (PC12 cells) and observed a significant increase in the release of vascular endothelial growth factor (VEGF) from BMSCs, the decreased PC12 cell apoptosis, and the upregulation of Survivin expression reduced by hypoxia in PC12 cells compared to enhanced green fluorescent protein (EGFP) BMSCs. In addition, to explore whether VEGF secreted by HIF-1 alpha-AA-modified BMSCs plays an important role in preventing hypoxia-induced apoptosis and the possible mechanism involved, exogenous VEGF were applied and the similar protective effects on PC12 cells were observed in vitro. Furthermore, hypoxia reduced the expression of phosphorylated Akt and phosphorylated FoxO1, whereas the administration of VEGF reversed these changes. Transfection of FoxO1 H215R, a DNA-binding mutant, abrogated the inhibitory ability on Survivin promoter activity, whereas FoxO1 AAA, the active form of FoxO1, presented further repression on Survivin promoter, indicating that FoxO1 directly binds on Survivin promoter as a transcriptional repressor and that phosphorylation status of FoxO1 affects its inhibition on the Survivin promoter. Transplantation of HIF-1a-AA-modified BMSCs after cerebral ischemia in vivo sufficiently reduced neurons apoptosis, decreased cerebral infarction volume, and induced a significant improvement on the modified neurological severity score compared to the EGFP BMSCs group. In conclusion, HIF-1 alpha-AA-modified MSCs showed an obvious protective effect on neuron-like cells or neuron after ischemia in vitro and in vivo, at least in part, through the VEGF/PI3K/Akt/FoxO1 pathway.	[Zhong, Qian; Zhou, Yanfang; Ye, Weibiao; Cai, Tuo; Deng, David Y. B.] Sun Yat Sen Univ, Dept Pathophysiol, Zhongshan Sch Med, Guangzhou 510089, Guangdong, Peoples R China; [Zhong, Qian] Sun Yat Sen Univ, Dept Res Lab, Ctr Canc, Guangzhou 510089, Guangdong, Peoples R China; [Zhou, Yanfang] Guangdong Med Coll, Dept Pathophysiol, Dongguan, Peoples R China; [Zhang, Xiuquan] Univ Utah, Sch Med, Dept Surg, Salt Lake City, UT USA; [Deng, David Y. B.] Sun Yat Sen Univ, Translat Med Lab, Affiliated Hosp 1, Guangzhou 510089, Guangdong, Peoples R China	Deng, DYB (corresponding author), Sun Yat Sen Univ, Dept Pathophysiol, Zhongshan Sch Med, Guangzhou 510089, Guangdong, Peoples R China.	dengyub@mail.sysu.edu.cn			National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [30901547, 30973093, 81171711]; Doctoral Fund of Ministry of Education [20090171110048]; Guangdong Province Natural Science FundNational Natural Science Foundation of Guangdong Province [C030307, 2009B050200010]; Yixian Innovators' Training Project by Outstanding Mentor(s) at Sun Yat-sen University [50000-3126203]; Graduates' internationally cooperated research project of Sun Yatsen University	We are thankful to Helge Chrisopher Leukel for correcting the English of this article. This work was supported by the National Natural Science Foundation of China (NSFC) Grants (30901547, 30973093, and 81171711), Doctoral Fund of Ministry of Education 20090171110048, Guangdong Province Natural Science Fund (C030307 and 2009B050200010), Yixian Innovators' Training Project by Outstanding Mentor(s) at Sun Yat-sen University (50000-3126203), and the Graduates' internationally cooperated research project of Sun Yatsen University (2008-2009).	Alsayed Y, 2007, BLOOD, V109, P2708, DOI 10.1182/blood-2006-07-035857; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; An WG, 1998, NATURE, V392, P405; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Chen JL, 2003, J NEUROSCI RES, V73, P778, DOI 10.1002/jnr.10691; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2008, J NEUROL SCI, V265, P97, DOI 10.1016/j.jns.2007.06.013; Colter DC, 2001, P NATL ACAD SCI USA, V98, P7841, DOI 10.1073/pnas.141221698; Conway EM, 2003, AM J PATHOL, V163, P935, DOI 10.1016/S0002-9440(10)63453-0; Dai Y, 2007, J MOL CELL CARDIOL, V42, P1036, DOI 10.1016/j.yjmcc.2007.04.001; Deng YB, 2005, CHINESE MED J-PEKING, V118, P1533; Deng YB, 2008, NEUROL RES, V32, P148; Dharmasaroja P, 2009, J CLIN NEUROSCI, V16, P12, DOI 10.1016/j.jocn.2008.05.006; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; Donnan GA, 2008, LANCET, V371, P1612, DOI 10.1016/S0140-6736(08)60694-7; Dormond O, 2007, J BIOL CHEM, V282, P23679, DOI 10.1074/jbc.M700563200; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Giaccia A, 2003, NAT REV DRUG DISCOV, V2, P803, DOI 10.1038/nrd1199; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Guha M, 2009, CANCER RES, V69, P4954, DOI 10.1158/0008-5472.CAN-09-0584; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Ikeda N, 2005, STROKE, V36, P2725, DOI 10.1161/01.STR.0000190006.88896.d3; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENOMICS, V52, P159, DOI 10.1006/geno.1998.5416; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Johnson EA, 2004, J NEUROTRAUM, V21, P1183, DOI 10.1089/neu.2004.21.1183; Kurozumi K, 2004, MOL THER, V9, P189, DOI 10.1016/j.ymthe.2003.10.012; Li Y, 2011, NEUROL RES, V33, P583, DOI 10.1179/1743132810Y.0000000013; Longa EZ, 1989, STROKE, V21, P89; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Neufeld G, 1999, FASEB J, V13, P9; Obsil T, 2008, ONCOGENE, V27, P2263, DOI 10.1038/onc.2008.20; Oosthuyse B, 2001, NAT GENET, V28, P131, DOI 10.1038/88842; Perasso L, 2010, NEURAL PLAST, V2010, DOI 10.1155/2010/534925; Podar K, 2001, BLOOD, V98, P428, DOI 10.1182/blood.V98.2.428; POLAK M, 1993, P NATL ACAD SCI USA, V90, P5781, DOI 10.1073/pnas.90.12.5781; Puurunen K, 2001, EXP NEUROL, V167, P348, DOI 10.1006/exnr.2000.7563; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Sharp FR, 2004, NAT REV NEUROSCI, V5, P437, DOI 10.1038/nrn1408; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Solaroglu I, 2003, CHILD NERV SYST, V19, P19, DOI 10.1007/s00381-002-0680-2; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tang XQ, 2005, BRAIN RES, V1057, P57, DOI 10.1016/j.brainres.2005.07.072; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; Vangeison G, 2008, J NEUROSCI, V28, P1988, DOI 10.1523/JNEUROSCI.5323-07.2008; Wang XB, 2008, BIOCHEM BIOPH RES CO, V371, P283, DOI 10.1016/j.bbrc.2008.04.055; Wang Y, 2008, BRAIN RES, V1195, P104, DOI 10.1016/j.brainres.2007.11.068; Wang ZS, 2001, CANCER RES, V61, P7171; World Health Organization, 2004, ANN TABL 2 DEATHS CA; Yilmaz Gokhan, 2010, Exp Transl Stroke Med, V2, P11, DOI 10.1186/2040-7378-2-11; Zhao MZ, 2006, J CEREBR BLOOD F MET, V26, P1176, DOI 10.1038/sj.jcbfm.9600273	54	32	38	0	20	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1547-3287			STEM CELLS DEV	Stem Cells Dev.	SEP	2012	21	14					2703	2717		10.1089/scd.2011.0604			15	Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation	Cell Biology; Hematology; Research & Experimental Medicine; Transplantation	005JW	WOS:000308747700015	22468883	Green Published			2021-06-18	
J	Hemerka, JN; Wu, XR; Dixon, CE; Garman, RH; Exo, JL; Shellington, DK; Blasiole, B; Vagni, VA; Janesko-Feldman, K; Xu, M; Wisniewski, SR; Bayir, H; Jenkins, LW; Clark, RSB; Tisherman, SA; Kochanek, PM				Hemerka, Joseph N.; Wu, Xianren; Dixon, C. Edward; Garman, Robert H.; Exo, Jennifer L.; Shellington, David K.; Blasiole, Brian; Vagni, Vincent A.; Janesko-Feldman, Keri; Xu, Mu; Wisniewski, Stephen R.; Bayir, Huelya; Jenkins, Larry W.; Clark, Robert S. B.; Tisherman, Samuel A.; Kochanek, Patrick M.			Severe Brief Pressure-Controlled Hemorrhagic Shock after Traumatic Brain Injury Exacerbates Functional Deficits and Long-Term Neuropathological Damage in Mice	JOURNAL OF NEUROTRAUMA			English	Article						blast injury; controlled cortical impact; head injury; head trauma; Morris water maze; polytrauma; secondary insult	CONTROLLED CORTICAL IMPACT; NITRIC-OXIDE SYNTHASE; CEREBRAL-BLOOD-FLOW; HIPPOCAMPAL NEUROGENESIS; SECONDARY ISCHEMIA; MOTOR DEFICITS; RESUSCITATION; HYPOTENSION; MODEL; ISOFLURANE	Hypotension after traumatic brain injury (TBI) worsens outcome. We published the first report of TBI plus hemorrhagic shock (HS) in mice using a volume-controlled approach and noted increased neuronal death. To rigorously control blood pressure during HS, a pressure-controlled HS model is required. Our hypothesis was that a brief, severe period of pressure-controlled HS after TBI in mice will exacerbate functional deficits and neuropathology versus TBI or HS alone. C57BL6 male mice were randomized into four groups (n = 10/group): sham, HS, controlled cortical impact (CCI), and CCI + HS. We used a pressure-controlled shock phase (mean arterial pressure [MAP] = 25-27 ram Hg for 35 min) and its treatment after mild to moderate CCI including, a 90 min pre-hospital phase, during which lactated Ringer's solution was given to maintain MAP > 70 mm Hg, and a hospital phase, when the shed blood was re-infused. On days 14-20, the mice were evaluated in the Morris water maze (MWM, hidden platform paradigm). On day 21, the lesion and hemispheric volumes were quantified. Neuropathology and hippocampal neuron counts (hematoxylin and eosin [H&E], Fluoro-Jade B, and NeuN) were evaluated in the mice (n=60) at 24 h, 7 days, or 21 days (n = 5/group/time point). HS reduced MAP during the shock phase in the HS and CCI+HS groups (p < 0.05). Fluid requirements during the pre-hospital phase were greatest in the CCI + HS group (p < 0.05), and were increased in HS versus sham and CCI animals (p < 0.05). MWM latency was increased on days 14 and 15 after CCI + HS (p < 0.05). Swim speed and visible platform latency were impaired in the CCI + HS group (p < 0.05). CCI+HS animals had increased contusion volume versus the CCI group ( p < 0.05). Hemispheric volume loss was increased 33.3% in the CCI + HS versus CCI group (p < 0.05). CA1 cell loss was seen in CCI + HS and CCI animals at 24 h and 7 days (p < 0.05). CA3 cell loss was seen after CCI+HS (p < 0.05 at 24h and 7 days). CA1 cell loss at 21 days was seen only in CCI+HS animals (p < 0.05). Brief, severe, pressure-controlled HS after CCI produces robust functional deficits and exacerbates neuropathology versus CCI or HS alone.	[Hemerka, Joseph N.; Wu, Xianren; Dixon, C. Edward; Garman, Robert H.; Exo, Jennifer L.; Shellington, David K.; Blasiole, Brian; Vagni, Vincent A.; Janesko-Feldman, Keri; Xu, Mu; Bayir, Huelya; Jenkins, Larry W.; Clark, Robert S. B.; Tisherman, Samuel A.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Wu, Xianren; Blasiole, Brian; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15260 USA; [Exo, Jennifer L.; Shellington, David K.; Vagni, Vincent A.; Janesko-Feldman, Keri; Xu, Mu; Bayir, Huelya; Clark, Robert S. B.; Tisherman, Samuel A.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Dixon, C. Edward; Jenkins, Larry W.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Garman, Robert H.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15260 USA; [Exo, Jennifer L.; Shellington, David K.; Bayir, Huelya; Clark, Robert S. B.; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15260 USA; [Tisherman, Samuel A.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15260 USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015; Tisherman, Samuel A./AAK-9377-2020	Kochanek, Patrick M/0000-0002-2627-913X; Tisherman, Samuel A./0000-0003-3810-3729; Wisniewski, Stephen/0000-0002-3877-9860; Shellington, David/0000-0001-6708-6978	Defense Advanced Research Projects Agency (DARPA) Prevent ProgramUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66001-10-C2124]; United States ArmyUnited States Department of Defense [W81XWH-06-1-0247, W81XWH-09-2-0187, T32 HD040686, NS 30218, NS30318]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS030318, R01NS030218, P50NS030318, P20NS030318] Funding Source: NIH RePORTER	We thank the Defense Advanced Research Projects Agency (DARPA) Prevent Program (N66001-10-C2124 to P.M.K.), the United States Army (W81XWH-06-1-0247 and W81XWH-09-2-0187 to P.M.K.; T32 HD040686 to J.L.E.; NS 30218 and NS30318 to C.E.D.) for support. The views, opinions, and findings contained in this article are those of the authors and should not be interpreted as representing the official views or policies, either expressed or implied, of DARPA or the U.S. Department of Defense.	Abrahamson EE, 2009, ANN NEUROL, V66, P407, DOI 10.1002/ana.21731; Ahmad M, 2008, J NEUROSCI RES, V86, P3605, DOI 10.1002/jnr.21809; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Carrillo P, 1998, J TRAUMA, V45, P239, DOI 10.1097/00005373-199808000-00007; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Crookes BA, 2004, J TRAUMA, V57, P547, DOI 10.1097/01.TA.0000135162.85859.4C; Dennis AM, 2006, CRIT CARE MED, V34, pA5, DOI 10.1097/00003246-200612002-00017; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; Dong HX, 2003, J NEUROSCI, V23, P1742; Elsersy H, 2004, ANESTHESIOLOGY, V100, P1160, DOI 10.1097/00000542-200405000-00018; Exo JL, 2009, J NEUROTRAUM, V26, P2403, DOI 10.1089/neu.2009.0980; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; Garner J, 2010, ANN SURG, V251, P1131, DOI 10.1097/SLA.0b013e3181e00fcb; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Giri BK, 2000, STROKE, V31, P961, DOI 10.1161/01.STR.31.4.961; Glass TF, 1999, J NEUROTRAUM, V16, P771, DOI 10.1089/neu.1999.16.771; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Lacombe P, 2005, STROKE, V36, P1053, DOI 10.1161/01.STR.0000163080.82766.eb; Lammie GA, 1999, J NEUROTRAUM, V16, P603, DOI 10.1089/neu.1999.16.603; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Liu F, 2009, J NEUROSCI METH, V179, P1, DOI 10.1016/j.jneumeth.2008.12.028; Lok J, 2007, J NEUROTRAUM, V24, P1817, DOI 10.1089/neu.2007.0372; Luo CX, 2007, J NEUROCHEM, V103, P1872, DOI 10.1111/j.1471-4159.2007.04915.x; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nelson TJ, 2006, J AM COLL SURGEONS, V202, P418, DOI 10.1016/j.jamcollsurg.2005.11.011; Paxinos G., 2001, MOUSE BRAIN STEREOTA; RICHES AC, 1973, J PHYSIOL-LONDON, V228, P279, DOI 10.1113/jphysiol.1973.sp010086; Robertson CS, 2012, J NEUROTRAUM, V29, P1156, DOI 10.1089/neu.2011.1827; Schmued LC, 2005, BRAIN RES, V1035, P24, DOI 10.1016/j.brainres.2004.11.054; Schutz C, 2006, CRIT CARE MED, V34, P492, DOI 10.1097/01.CCM.0000198326.32049.7F; Sell SL, 2008, ANESTHESIOLOGY, V108, P873, DOI 10.1097/ALN.0b013e31816c8a15; Shellington DK, 2011, CRIT CARE MED, V39, P494, DOI 10.1097/CCM.0b013e318206b1fa; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; Stern S, 2009, SHOCK, V31, P64, DOI 10.1097/SHK.0b013e3181778dc3; Stiefel MF, 2005, J NEUROSURG, V103, P707, DOI 10.3171/jns.2005.103.4.0707; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; Tehranian R, 2008, J NEUROTRAUM, V25, P755, DOI 10.1089/neu.2007.0441; Tehranian R, 2006, BRAIN RES, V1101, P126, DOI 10.1016/j.brainres.2006.05.049; Teranishi K, 2012, INJURY, V43, P585, DOI 10.1016/j.injury.2010.09.042; Trabold R, 2006, BRAIN RES, V1071, P237, DOI 10.1016/j.brainres.2005.11.095; Unal-Cevik I, 2004, BRAIN RES, V1015, P169, DOI 10.1016/j.brainres.2004.04.032; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; You ZR, 2008, J CEREBR BLOOD F MET, V28, P1564, DOI 10.1038/jcbfm.2008.44	57	32	32	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2012	29	12					2192	2208		10.1089/neu.2011.2303			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	993KZ	WOS:000307859900007	22738159	Green Published			2021-06-18	
J	Li, L; Zhang, W; Cheng, SW; Cao, DF; Parent, M				Li, Ling; Zhang, Wei; Cheng, Shaowu; Cao, Dongfeng; Parent, Marc			Isoprenoids and Related Pharmacological Interventions: Potential Application in Alzheimer's Disease	MOLECULAR NEUROBIOLOGY			English	Article						Isoprenoids; Protein prenylation; Statins; Bisphosphonates; Prenyltransferase inhibitors; Alzheimer's disease	HMG-COA REDUCTASE; AMYLOID PRECURSOR PROTEIN; TRAUMATIC BRAIN-INJURY; GERANYLGERANYLTRANSFERASE-I INHIBITOR; NITROGEN-CONTAINING BISPHOSPHONATES; BIPOLAR SPINDLE FORMATION; LONG-TERM POTENTIATION; NITRIC-OXIDE SYNTHASE; FARNESYLTRANSFERASE INHIBITOR; MOUSE MODEL	Two major isoprenoids, farnesyl pyrophosphate and geranylgeranyl pyrophosphate, serve as lipid donors for the posttranslational modification (known as prenylation) of proteins that possess a characteristic C-terminal motif. The prenylation reaction is catalyzed by prenyltransferases. The lipid prenyl group facilitates to anchor the proteins in cell membranes and mediates protein-protein interactions. A variety of important intracellular proteins undergo prenylation, including almost all members of small GTPase superfamilies as well as heterotrimeric G protein subunits and nuclear lamins. These prenylated proteins are involved in regulating a wide range of cellular processes and functions, such as cell growth, differentiation, cytoskeletal organization, and vesicle trafficking. Prenylated proteins are also implicated in the pathogenesis of different types of diseases. Consequently, isoprenoids and/or prenyltransferases have emerged as attractive therapeutic targets for combating various disorders. This review attempts to summarize the pharmacological agents currently available or under development that control isoprenoid availability and/or the process of prenylation, mainly focusing on statins, bisphosphonates, and prenyltransferase inhibitors. Whereas statins and bisphosphonates deplete the production of isoprenoids by inhibiting the activity of upstream enzymes, prenyltransferase inhibitors directly block the prenylation of proteins. As the importance of isoprenoids and prenylated proteins in health and disease continues to emerge, the therapeutic potential of these pharmacological agents has expanded across multiple disciplines. This review mainly discusses their potential application in Alzheimer's disease.	[Li, Ling; Zhang, Wei; Cheng, Shaowu; Cao, Dongfeng; Parent, Marc] Univ Minnesota, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA	Li, L (corresponding author), Univ Minnesota, Dept Expt & Clin Pharmacol, 2001 6th St SE,MTRF 4-208, Minneapolis, MN 55455 USA.	lil@umn.edu	cheng, shaowu/C-1622-2013	cheng, shaowu/0000-0001-6148-9565; Li, Ling/0000-0002-9245-7387	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AG031846]; Alzheimer's AssociationAlzheimer's Association [IIRG-09-131791]; American Health Assistance FoundationBrightFocus Foundation [A2010328]; Academic Health Center of the University of MinnesotaUniversity of Minnesota System; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG031846] Funding Source: NIH RePORTER	This work was supported in part by grants from the National Institutes of Health (AG031846), the Alzheimer's Association (IIRG-09-131791, the American Health Assistance Foundation (A2010328), and the Academic Health Center of the University of Minnesota.	ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; Balduini W, 2003, STROKE, V34, P2007, DOI 10.1161/01.STR.0000080677.24419.88; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; BAUER J, 1991, FEBS LETT, V285, P111, DOI 10.1016/0014-5793(91)80737-N; Berndt N, 2011, NAT REV CANCER, V11, P775, DOI 10.1038/nrc3151; Bordier BB, 2003, J CLIN INVEST, V112, P407, DOI 10.1172/JCI200317704; Bosel J, 2005, J NEUROCHEM, V92, P1386, DOI 10.1111/j.1471-4159.2004.02980.x; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Cameron B, 2010, NEUROBIOL DIS, V37, P503, DOI 10.1016/j.nbd.2009.10.006; Capell BC, 2008, P NATL ACAD SCI USA, V105, P15902, DOI 10.1073/pnas.0807840105; Carrico D, 2004, BIOORGAN MED CHEM, V12, P6517, DOI 10.1016/j.bmc.2004.09.020; Cespedes-Rubio A, 2010, J NEUROSCI RES, V88, P3621, DOI 10.1002/jnr.22511; Chan LN, 2009, ELECTROPHORESIS, V30, P3598, DOI 10.1002/elps.200900259; Chen JL, 2003, ANN NEUROL, V53, P743, DOI 10.1002/ana.10555; Cibickova L, 2007, PHYSIOL RES, V56, P765; Clarke R, 2007, SIGHT SOUND, V17, P52; Clezardin P, 2005, CANCER RES, V65, P4971, DOI 10.1158/0008-5472.CAN-05-0264; Cohen-Jonathan E, 2001, CANCER RES, V61, P2289; Cole SL, 2005, J BIOL CHEM, V280, P18755, DOI 10.1074/jbc.M413895200; Collins R, 2002, LANCET, V360, P7, DOI 10.1016/s0140-6736(02)09327-3; Cordle A, 2005, J BIOL CHEM, V280, P34202, DOI 10.1074/jbc.M505268200; Cordle A, 2005, J NEUROSCI, V25, P299, DOI 10.1523/JNEUROSCI.2544-04.2005; CORIA F, 1988, LAB INVEST, V58, P454; Costa RM, 2002, NATURE, V415, P526, DOI 10.1038/nature711; Coxon FP, 2000, J BONE MINER RES, V15, P1467, DOI 10.1359/jbmr.2000.15.8.1467; Cremers S, 2011, BONE, V49, P42, DOI 10.1016/j.bone.2011.01.014; Crespo NC, 2001, J BIOL CHEM, V276, P16161, DOI 10.1074/jbc.M006213200; Crespo NC, 2002, CELL DEATH DIFFER, V9, P702, DOI 10.1038/sj.cdd.4401023; Dechat T, 2007, P NATL ACAD SCI USA, V104, P4955, DOI 10.1073/pnas.0700854104; DeGraw AJ, 2010, CHEM BIOL DRUG DES, V76, P460, DOI 10.1111/j.1747-0285.2010.01037.x; Douma TN, 2011, PSYCHOPHARMACOLOGY, V216, P537, DOI 10.1007/s00213-011-2245-0; Dunford JE, 2001, J PHARMACOL EXP THER, V296, P235; Eastman RT, 2006, J LIPID RES, V47, P233, DOI 10.1194/jlr.R500016-JLR200; Eckert GP, 2009, NEUROBIOL DIS, V35, P251, DOI 10.1016/j.nbd.2009.05.005; Eikelenboom P, 2011, CURR ALZHEIMER RES, V8, P142, DOI 10.2174/156720511795256080; EIKELENBOOM P, 1982, ACTA NEUROPATHOL, V57, P239, DOI 10.1007/BF00685397; Essig M, 1998, CIRC RES, V83, P683, DOI 10.1161/01.RES.83.7.683; Famer D, 2004, NEUROSCI LETT, V371, P209, DOI 10.1016/j.neulet.2004.08.069; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Fawcett JR, 2002, BRAIN RES, V950, P10, DOI 10.1016/S0006-8993(02)02981-5; Martinez MF, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-39; Finder JD, 1997, J BIOL CHEM, V272, P13484, DOI 10.1074/jbc.272.21.13484; Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133; FLEISCH H, 1969, SCIENCE, V165, P1262, DOI 10.1126/science.165.3899.1262; FLEISCH H, 1969, NATURE, V223, P211, DOI 10.1038/223211a0; FLEISCH H, 1966, NATURE, V212, P901, DOI 10.1038/212901a0; Fong LG, 2006, SCIENCE, V311, P1621, DOI 10.1126/science.1124875; Franke C, 2007, NEUROBIOL DIS, V25, P438, DOI 10.1016/j.nbd.2006.10.004; Fuller S, 2010, MUTAT RES-FUND MOL M, V690, P40, DOI 10.1016/j.mrfmmm.2009.08.016; Ghosh A, 2009, J NEUROSCI, V29, P13543, DOI 10.1523/JNEUROSCI.4144-09.2009; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Govek EE, 2011, DEV NEUROBIOL, V71, P528, DOI 10.1002/dneu.20850; Holmberg E, 2006, J NEUROTRAUM, V23, P1366, DOI 10.1089/neu.2006.23.1366; Hooff GP, 2010, MOL NEUROBIOL, V41, P341, DOI 10.1007/s12035-010-8117-5; Horwood JM, 2006, EUR J NEUROSCI, V23, P3375, DOI 10.1111/j.1460-9568.2006.04859.x; Istvan ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/science.1059344; Jahnke W, 2010, NAT CHEM BIOL, V6, P660, DOI [10.1038/NCHEMBIO.421, 10.1038/nchembio.421]; JARVIK GP, 1995, NEUROLOGY, V45, P1092, DOI 10.1212/WNL.45.6.1092; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Johnson-Anuna LN, 2005, J PHARMACOL EXP THER, V312, P786, DOI 10.1124/jpet.104.075028; Jones PH, 2003, CLIN CARDIOL, V26, pI15; Kannan M, 2010, NEUROBIOL AGING, V31, P1543, DOI 10.1016/j.neurobiolaging.2008.09.004; Kavanagh KL, 2006, P NATL ACAD SCI USA, V103, P7829, DOI 10.1073/pnas.0601643103; Kho Y, 2004, P NATL ACAD SCI USA, V101, P12479, DOI 10.1073/pnas.0403413101; Kieran MW, 2007, PEDIATRICS, V120, P834, DOI 10.1542/peds.2007-1356; Kim CK, 2010, MOL PHARMACOL, V78, P142, DOI 10.1124/mol.110.063586; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Kotti T, 2008, P NATL ACAD SCI USA, V105, P11394, DOI 10.1073/pnas.0805556105; Kotti TJ, 2006, P NATL ACAD SCI USA, V103, P3869, DOI 10.1073/pnas.0600316103; Kou JH, 2010, BRAIN RES, V1356, P102, DOI 10.1016/j.brainres.2010.07.102; Kretz A, 2006, NEUROBIOL DIS, V21, P421, DOI 10.1016/j.nbd.2005.08.003; Lane KT, 2006, J LIPID RES, V47, P681, DOI 10.1194/jlr.R600002-JLR200; Lapchak PA, 2010, BRAIN RES, V1344, P217, DOI 10.1016/j.brainres.2010.05.035; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Leu CT, 2006, BONE, V38, P628, DOI 10.1016/j.bone.2005.07.023; Leung KF, 2006, J LIPID RES, V47, P467, DOI 10.1194/jlr.R500017-JLR200; Li L, 2006, ANN NEUROL, V60, P729, DOI 10.1002/ana.21053; Li WD, 2005, CURR BIOL, V15, P1961, DOI 10.1016/j.cub.2005.09.043; Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421; Lin CH, 2001, NEURON, V31, P841, DOI 10.1016/S0896-6273(01)00433-0; Lindberg C, 2005, J NEUROSCI RES, V82, P10, DOI 10.1002/jnr.20615; Liu M, 2010, P NATL ACAD SCI USA, V107, P6471, DOI 10.1073/pnas.0908396107; Liu ZH, 2009, P NATL ACAD SCI USA, V106, P4635, DOI 10.1073/pnas.0806474106; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; Luckman SP, 1998, J BONE MINER RES, V13, P1668, DOI 10.1359/jbmr.1998.13.11.1668; Magrane J, 2005, J NEUROSCI, V25, P10960, DOI 10.1523/JNEUROSCI.1723-05.2005; Manabe T, 2000, J NEUROSCI, V20, P2504; Mans RA, 2012, NEUROSCIENCE, V202, P1, DOI 10.1016/j.neuroscience.2011.12.007; Mans RA, 2010, NEUROSCIENCE, V166, P435, DOI 10.1016/j.neuroscience.2009.12.062; Maurer-Stroh S, 2007, PLOS COMPUT BIOL, V3, P634, DOI 10.1371/journal.pcbi.0030066; McGaugh JL, 2000, SCIENCE, V287, P248, DOI 10.1126/science.287.5451.248; McTaggart SJ, 2006, CELL MOL LIFE SCI, V63, P255, DOI 10.1007/s00018-005-5298-6; Mehta IS, 2010, BIOCHEM SOC T, V38, P287, DOI 10.1042/BST0380287; Meier CR, 2000, JAMA-J AM MED ASSOC, V283, P3205, DOI 10.1001/jama.283.24.3205; Menge T, 2005, NAT REV NEUROSCI, V6, P325, DOI 10.1038/nrn1652; Meske V, 2003, EUR J NEUROSCI, V17, P93, DOI 10.1046/j.1460-9568.2003.02433.x; Morgan K, 2011, NEUROPATH APPL NEURO, V37, P353, DOI 10.1111/j.1365-2990.2011.01181.x; Nallan L, 2005, J MED CHEM, V48, P3704, DOI 10.1021/jm0491039; Newey SE, 2005, J NEUROBIOL, V64, P58, DOI 10.1002/neu.20153; Nguyen UTT, 2009, NAT CHEM BIOL, V5, P227, DOI 10.1038/nchembio.149; O'Dwyer PJ, 2010, ANN ONCOL, V21, P42; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; Onono FO, 2010, MOL CELL PROTEOMICS, V9, P742, DOI 10.1074/mcp.M900597-MCP200; Ostrowski SM, 2007, J BIOL CHEM, V282, P26832, DOI 10.1074/jbc.M702640200; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Paintlia AS, 2008, MOL PHARMACOL, V73, P1381, DOI 10.1124/mol.107.044230; Pang PT, 2004, SCIENCE, V306, P487, DOI 10.1126/science.1100135; Pappolla MA, 2003, NEUROLOGY, V61, P199, DOI 10.1212/01.WNL.0000070182.02537.84; PEDERSEN TR, 1994, LANCET, V344, P1383; Pedrini S, 2005, PLOS MED, V2, P69, DOI 10.1371/journal.pmed.0020018; Perez-Sala D, 2007, FRONT BIOSCI-LANDMRK, V12, P4456, DOI 10.2741/2401; Pooler AM, 2006, J NEUROCHEM, V97, P716, DOI 10.1111/j.1471-4159.2006.03763.x; Ramirez C, 2011, J ALZHEIMERS DIS, V24, P161, DOI 10.3233/JAD-2010-101653; Reid TS, 2004, J MOL BIOL, V343, P417, DOI 10.1016/j.jmb.2004.08.056; Reuveni H, 2003, EUR J BIOCHEM, V270, P2759, DOI 10.1046/j.1432-1033.2003.03647.x; Rodriguez-Vita J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003959; Roelofs AJ, 2010, CURR PHARM DESIGN, V16, P2950; Rogers Maurice, 2011, Scottish Forestry, V65, P34; Rondeau JM, 2006, CHEMMEDCHEM, V1, P267, DOI 10.1002/cmdc.200500059; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Russell RGG, 2011, BONE, V49, P2, DOI 10.1016/j.bone.2011.04.022; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; Salins P, 2007, NEUROSCI LETT, V412, P211, DOI 10.1016/j.neulet.2006.07.045; Schachter M, 2005, FUND CLIN PHARMACOL, V19, P117, DOI 10.1111/j.1472-8206.2004.00299.x; Schulz JG, 2004, J NEUROCHEM, V89, P24, DOI 10.1046/j.1471-4159.2003.02305.x; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Shepardson NE, 2011, ARCH NEUROL-CHICAGO, V68, P1385, DOI 10.1001/archneurol.2011.242; Shepardson NE, 2011, ARCH NEUROL-CHICAGO, V68, P1239, DOI 10.1001/archneurol.2011.203; Shepherd J, 2002, LANCET, V360, P1623, DOI 10.1016/S0140-6736(02)11600-X; Shinohara M, 2010, J BIOL CHEM, V285, P22091, DOI 10.1074/jbc.M110.102277; Shitara Y, 2006, PHARMACOL THERAPEUT, V112, P71, DOI 10.1016/j.pharmthera.2006.03.003; Simons M, 2002, ANN NEUROL, V52, P346, DOI 10.1002/ana.10292; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Snyder EM, 2005, NAT NEUROSCI, V8, P1051, DOI 10.1038/nn1503; Sparks DL, 2005, ARCH NEUROL-CHICAGO, V62, P753, DOI 10.1001/archneur.62.5.753; Sun YX, 2003, PHARMACOL RES, V47, P119, DOI 10.1016/S1043-6618(02)00288-8; Sweatt JD, 2004, CURR OPIN NEUROBIOL, V14, P311, DOI 10.1016/j.conb.2004.04.001; Thinakaran G, 2008, J BIOL CHEM, V283, P29615, DOI 10.1074/jbc.R800019200; Thornton C, 2003, J BIOL CHEM, V278, P23823, DOI 10.1074/jbc.M302389200; Tolias KF, 2011, PROG NEUROBIOL, V94, P133, DOI 10.1016/j.pneurobio.2011.04.011; Townsend KP, 2004, J NEUROSCI RES, V78, P167, DOI 10.1002/jnr.20234; Tsimberidou AM, 2010, EXPERT OPIN INV DRUG, V19, P1569, DOI 10.1517/13543784.2010.535516; Varela I, 2008, NAT MED, V14, P767, DOI 10.1038/nm1786; Vaughan CJ, 2003, AM J CARDIOL, V91, p23B, DOI 10.1016/S0002-9149(02)03270-8; Vollmer T, 2004, LANCET, V363, P1607, DOI 10.1016/S0140-6736(04)16205-3; Vural K, 2011, EUR REV MED PHARMACO, V15, P985; Wagstaff LR, 2003, PHARMACOTHERAPY, V23, P871, DOI 10.1592/phco.23.7.871.32720; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Wolazin B, 2006, ACTA NEUROL SCAND, V114, P63; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Wu HT, 2008, J NEUROTRAUM, V25, P130, DOI 10.1089/neu.2007.0369; Xu RX, 2008, J CELL BIOCHEM, V103, P256, DOI 10.1002/jcb.21402; Yaka R, 2002, P NATL ACAD SCI USA, V99, P5710, DOI 10.1073/pnas.062046299; Yang SH, 2006, J CLIN INVEST, V116, P2115, DOI 10.1172/JCI28968; Ye XJ, 2010, NEURON, V68, P340, DOI 10.1016/j.neuron.2010.09.013; Yee LL, 2011, CLIN THER, V33, P1023, DOI 10.1016/j.clinthera.2011.07.011; Young SG, 2006, J BIOL CHEM, V281, P39741, DOI 10.1074/jbc.R600033200; Zacco A, 2003, J NEUROSCI, V23, P11104; Zhang B, 2002, CANCER RES, V62, P450; Zhou Y, 2008, FASEB J, V22, P47, DOI 10.1096/fj.07-8175com; Zuckerbraun BS, 2005, J SURG RES, V124, P256, DOI 10.1016/j.jss.2004.10.022	163	32	32	0	15	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	AUG	2012	46	1			SI		64	77		10.1007/s12035-012-8253-1			14	Neurosciences	Neurosciences & Neurology	007FE	WOS:000308873400008	22418893	Green Accepted			2021-06-18	
J	Williams, G; Willmott, C				Williams, G.; Willmott, C.			Higher levels of mobility are associated with greater societal participation and better quality-of-life	BRAIN INJURY			English	Article						Mobility limitation; activities of daily living; social participation; quality-of-life	TRAUMATIC BRAIN-INJURY; ASSESSMENT-TOOL HIMAT; COMMUNITY INTEGRATION; AEROBIC CAPACITY; WHOQOL-BREF; POPULATION; REHABILITATION; RELIABILITY; EXERCISE; SATISFACTION	Introduction: Participation rates and quality-of-life (QoL) have been a major focus of rehabilitation programmes and outcome studies following traumatic brain injury (TBI). The extent to which mobility limitations impact on participation rates and QoL has not been thoroughly explored. The main aim of this study was to investigate the relationship between mobility limitations, participation rates and QoL following TBI. Methods: Thirty-nine people who had sustained an extremely severe TBI were recruited from a major rehabilitation facility. Mobility was quantified using the high-level mobility assessment tool (HiMAT). The Brain Injury Community Rehabilitation Outcome (BICRO-39) and Community Integration Questionnaire (CIQ) were used to measure participation rates and the shorter version of the World Health Organization Quality of Life (WHOQoL-BREF) and Assessment of Quality-of-Life (AQoL-2) were used to measure QoL. Results: Mobility was most strongly correlated with the total BICRO-39 score (r = -0.60, p<0.001) and the mobility domain (r = -0.59, p<0.001) of the BICRO-39. Although mobility had a significant relationship with health-related QoL, AQoL-2 (r = 0.60, p<0.001), it was most strongly related to the AQoL-2 independent living domain (r = 0.79, p<0.001). Conclusion: Greater capacity to mobilize was associated with higher participation rates and better QoL.	[Williams, G.] Epworth Med Fdn, Physiotherapy Dept, Richmond, Vic 3121, Australia; [Willmott, C.] Monash Univ, Sch Psychol & Psychiat, Clayton, Vic 3800, Australia	Williams, G (corresponding author), Epworth Med Fdn, Physiotherapy Dept, 89 Bridge Rd, Richmond, Vic 3121, Australia.	gavin.williams@epworth.org.au	Willmott, Catherine/AAA-5105-2019	Willmott, Catherine/0000-0001-8517-9035; Williams, Gavin/0000-0003-2758-7473			Alzahrani MA, 2009, AUST J PHYSIOTHER, V55, P277, DOI 10.1016/S0004-9514(09)70008-X; [Anonymous], 1998, PSYCHOL MED, V28, P551; Bateman A, 2001, ARCH PHYS MED REHAB, V82, P174, DOI 10.1053/apmr.2001.19744; BECKER E, 1978, SCAND J REHABIL MED, V10, P47; Chiu WT, 2006, J NEUROTRAUM, V23, P1609, DOI 10.1089/neu.2006.23.1609; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Eriksson Gunilla, 2005, Scand J Occup Ther, V12, P40, DOI 10.1080/11038120510027630; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; Hawthorne G, 2005, AUST NZ J PUBL HEAL, V29, P136, DOI 10.1111/j.1467-842X.2005.tb00063.x; Hawthorne G, 2009, J NEUROTRAUM, V26, P1623, DOI [10.1089/neu.2008.0735, 10.1089/neu.2008-0735]; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; HUNTER M, 1990, PHYS THER, V70, P363, DOI 10.1093/ptj/70.6.363; JANKOWSKI LW, 1990, ARCH PHYS MED REHAB, V71, P500; Johnston MV, 2005, ARCH PHYS MED REHAB, V86, P735, DOI 10.1016/j.apmr.2004.10.031; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; Kreuter M, 1998, SPINAL CORD, V36, P252, DOI 10.1038/sj.sc.3100592; Lin MR, 2010, ARCH PHYS MED REHAB, V91, P474, DOI 10.1016/j.apmr.2009.10.031; Morris S, 2009, ADV PHYSIOTHERAPY, V11, P218; Mossberg KA, 2008, PHYS THER, V88, P77, DOI 10.2522/ptj.20070022; Mossberg KA, 2007, ARCH PHYS MED REHAB, V88, P315, DOI 10.1016/j.apmr.2006.12.006; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; PERRY J, 1995, STROKE, V26, P982, DOI 10.1161/01.STR.26.6.982; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Reavenall S, 2010, INT J THER REHABIL, V17, P360, DOI 10.12968/ijtr.2010.17.7.48893; Richardson J, 2003, ASSESSMENT QUALITY L, DOI http://www.psychiatry.unimelb.edu.au/centres-units/cpro/aqol/index.html; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; SULLIVAN S J, 1990, Brain Injury, V4, P407, DOI 10.3109/02699059009026194; Thurman DJ, 1999, TRAUMATIC BRAIN INJU; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; Vitale AE, 1997, BRAIN INJURY, V11, P67, DOI 10.1080/026990597123827; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Whittle M, 2007, GAIT ANAL INTRO; *WHO, 2001, ICF INT CLASS FUNCT; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; Williams G, 2006, ARCH PHYS MED REHAB, V87, P437, DOI 10.1016/j.apmr.2005.10.028; Williams G, 2009, INT J THER REHABIL, V16, P2; Williams G, 2010, J HEAD TRAUMA REHAB, V25, P366, DOI 10.1097/HTR.0b013e3181cd3600; Williams GP, 2009, BRAIN INJURY, V23, P307, DOI 10.1080/02699050902774170; Williams GP, 2006, PHYS THER, V86, P395, DOI 10.1093/ptj/86.3.395; Williams GP, 2005, BRAIN INJURY, V19, P833, DOI 10.1080/02699050500058711; Wolman RL, 1994, CLIN REHABIL, V8, P253	44	32	32	0	23	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2012	26	9					1065	1071		10.3109/02699052.2012.667586			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	971GI	WOS:000306191400003	22571773				2021-06-18	
J	Bosco, FM; Angeleri, R; Zuffranieri, M; Bara, BG; Sacco, K				Bosco, Francesca M.; Angeleri, Romina; Zuffranieri, Marco; Bara, Bruno G.; Sacco, Katiuscia			Assessment Battery for Communication: Development of two equivalent forms	JOURNAL OF COMMUNICATION DISORDERS			English	Article							HEMISPHERE BRAIN-DAMAGE; CLOSED-HEAD INJURY; LANGUAGE DISORDERS; PRAGMATICS; SCHIZOPHRENIA; DISCOURSE; REQUESTS; NEUROPRAGMATICS; COMPREHENSION; SENSITIVITY	The aim of this paper was to develop and test two equivalent forms of the Assessment Battery for Communication (ABaCo), a tool for evaluating pragmatic abilities in patients with neuropsychological and psychiatric disorders. The equivalent forms were created using the data from a sample of 390 children, then tested in a sample of 30 patients with traumatic brain injury. Equivalent forms of the same test are useful in clinical practice and intervention research, when performance needs to be tested on two separate occasions, for example before and after a rehabilitation program. The present results provide additional evidence on the psychometric functioning of the equivalent forms of the ABaCo and their usability in a clinical context. Learning outcomes: The reader will be able to discuss the evidence of the psychometric propriety of the equivalent forms of the ABaCo and describe its potential usefulness. (C) 2012 Elsevier Inc. All rights reserved.	[Bosco, Francesca M.; Bara, Bruno G.] Univ Turin, Dept Psychol, Ctr Cognit Sci, Neurosci Inst Turin, I-10123 Turin, Italy; [Sacco, Katiuscia] Univ Turin, Dept Psychol, Ctr Cognit Sci, Neurosci Inst Turin,CCS fMRI Neuroradiol,Koellike, I-10123 Turin, Italy	Bosco, FM (corresponding author), Univ Turin, Dept Psychol, Ctr Cognit Sci, Neurosci Inst Turin, Via Po 14, I-10123 Turin, Italy.	francesca.bosco@unito.it	Sacco, Katiuscia/J-2133-2012; bosco, francesca marina/B-6746-2013	Sacco, Katiuscia/0000-0002-9660-5236; bosco, francesca marina/0000-0001-6101-8587	Regione PiemonteRegione Piemonte; project "Institutions, Behaviour and Markets in Local and Global Settings (IIINBEMA)"; project "The Invisible Grammar of Social Relations"	This research was supported by Regione Piemonte, in particular Francesca Bosco and Bruno Bara were supported by the project "Institutions, Behaviour and Markets in Local and Global Settings (IIINBEMA)", and Romina Angeleri and Katiuscia Sacco by the project "The Invisible Grammar of Social Relations". We thank Silvia Testa for her help with the revision of the manuscript. Special thanks go to Marco Del Giudice for his helpful suggestions and for his critical reading of the manuscript.	Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Angeleri R, 2012, BEHAV RES METHODS, V44, P845, DOI 10.3758/s13428-011-0174-9; Bara BG, 1999, BRAIN LANG, V68, P507, DOI 10.1006/brln.1999.2125; Bara BG, 1997, BRAIN LANG, V59, P7, DOI 10.1006/brln.1997.1812; Bara BG, 2001, BRAIN LANG, V77, P72, DOI 10.1006/brln.2000.2430; Bara BG., 2010, COGNITIVE PRAGMATICS; Bazin N, 2005, SCHIZOPHR RES, V77, P75, DOI 10.1016/j.schres.2005.01.020; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Bosco FM, 2004, J PRAGMATICS, V36, P467, DOI 10.1016/S0378-2166(03)00055-9; Bosco FM, 2008, J PRAGMATICS, V40, P583, DOI 10.1016/j.pragma.2007.05.004; Bosco FM, 2006, J PRAGMATICS, V38, P1398, DOI 10.1016/j.pragma.2005.06.011; Bosco FM, 2012, J COGN PSYCHOL, V24, P525, DOI 10.1080/20445911.2012.658156; Bosco FM, 2009, J COGN SCI, V10, P245; Bosco FM, 2012, J COMMUN DISORD, V45, P181, DOI 10.1016/j.jcomdis.2012.01.005; Brownell H, 1997, BRAIN LANG, V57, P60, DOI 10.1006/brln.1997.1834; Brownell H, 1999, BRAIN LANG, V68, P442, DOI 10.1006/brln.1999.2122; BROWNELL HH, 1990, NEUROPSYCHOLOGIA, V28, P375, DOI 10.1016/0028-3932(90)90063-T; Bryan KL., 1995, RIGHT HEMISPHERE LAN; Corcoran Rhiannon, 2003, Cogn Neuropsychiatry, V8, P223, DOI 10.1080/13546800244000319; Cummings Louise, 2007, Seminars in Speech and Language, V28, P96, DOI 10.1055/s-2007-970568; Davis G. Albyn, 2007, Seminars in Speech and Language, V28, P111, DOI 10.1055/s-2007-970569; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; DeVellis R.F, 1991, SCALE DEV THEORY APP; Docking K, 2000, BRAIN INJURY, V14, P89, DOI 10.1080/026990500120952; Dollaghan CA, 2004, J COMMUN DISORD, V37, P391, DOI 10.1016/j.jcomdis.2004.04.002; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frattali CM, 1995, AM SPEECH LANGUAGE H; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; GARDNER H, 1986, RIGHT HEMISPHERE COM; Grice H.P, 1989, STUDIES WAY WORDS; Holland A., 1998, COMMUNICATION ACTIVI; Holland A, 1980, COMMUNICATIVE ABILIT; Hollingshead A. B., 1975, 4 FACTORS INDEX INDE; KAPLAN JA, 1990, BRAIN LANG, V38, P315, DOI 10.1016/0093-934X(90)90117-Y; Kasher Asa, 1991, CHOMSKYAN TURN, P122; Lakoff R., 1973, 9 REG M CHIC LING SO; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Langdon R, 2002, PSYCHOL MED, V32, P1273, DOI 10.1017/S0033291702006396; Leroy F, 2005, PSYCHIAT RES, V133, P159, DOI 10.1016/j.psychres.2004.07.009; Levinson F. C., 1983, PRAGMATICS; Marquardt TP, 2001, APHASIOLOGY, V15, P1091, DOI 10.1080/02687040143000429; MCDONALD S, 1993, COGNITIVE NEUROPSYCH, V10, P297, DOI 10.1080/02643299308253466; MCDONALD S, 1993, APHASIOLOGY, V7, P535, DOI 10.1080/02687039308248629; McDonald S, 2003, J HEAD TRAUMA REHAB, V18, P219, DOI 10.1097/00001199-200305000-00001; Meilijson SR, 2004, J SPEECH LANG HEAR R, V47, P695, DOI 10.1044/1092-4388(2004/053); Nunnaly J., 1978, PSYCHOMETRIC THEORY; Pell MD, 2007, BRAIN LANG, V101, P64, DOI 10.1016/j.bandl.2006.10.003; Penn C, 1985, S Afr J Commun Disord, V32, P18; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Raykow T., 2009, INTRO PSYCHOMETRIC T; Rousseaux M, 2010, EUR J NEUROL, V17, P922, DOI 10.1111/j.1468-1331.2009.02945.x; Sacco K, 2008, J COGN SCI, V9, P111; Sarno M, 1969, FUNCTIONAL COMMUNICA; Sohlberg M. M., 2001, COGNITIVE REHABILITA; STEMMER B, 1994, BRAIN LANG, V47, P1, DOI 10.1006/brln.1994.1040; van der Meulen I, 2010, INT J LANG COMM DIS, V45, P424, DOI 10.3109/13682820903111952; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889	57	32	32	0	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0021-9924	1873-7994		J COMMUN DISORD	J. Commun. Disord.	JUL-AUG	2012	45	4					290	303		10.1016/j.jcomdis.2012.03.002			14	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	966PA	WOS:000305848700004	22483360				2021-06-18	
J	Lok, J; Zhao, S; Leung, W; Seo, JH; Navaratna, D; Wang, X; Whalen, MJ; Lo, EH				Lok, Josephine; Zhao, Song; Leung, Wendy; Seo, Ji Hae; Navaratna, Deepti; Wang, Xiaoying; Whalen, Michael J.; Lo, Eng H.			Neuregulin-1 Effects on Endothelial and Blood-Brain Barrier Permeability After Experimental Injury	TRANSLATIONAL STROKE RESEARCH			English	Article						Neuregulin-1; Endothelial; Blood-brain barrier; Brain trauma; IL-1 beta; Permeability	TISSUE-DAMAGE; UNITED-STATES; MICE; DISRUPTION; HEALTH; IMPACT	Blood brain barrier (BBB) disruption occurs with a high incidence after traumatic brain injury, and is an important contributor to many pathological processes, including brain edema, inflammation, and neuronal cell death. Therefore, BBB integrity is an important potential therapeutic target in the treatment of the acute phase of brain trauma. In this short communication, we report our data showing that neuregulin-1 (NRG1), a growth factor with diverse functions in the central nervous system (CNS), ameliorates pathological increases in endothelial permeability and in BBB permeability in experimental models of injury. For in vitro studies, rat brain endothelial cells were incubated with the inflammatory cytokine IL-1 beta, which caused an increase in permeability of the cell layer. Co-incubation with NRG1 ameliorated this permeability increase. For in vivo studies, C57B1/6 mice were subjected to controlled cortical impact (CCI) under anesthesia, and BBB permeability was assessed by measuring the amount of Evans blue dye extravasation at 2 h. NRG1 administered by tail-vein injection 10 min after CCI resulted in a decrease in Evans blue dye extravasation by 35 %. Since Evans blue extravasation may result from an increase in BBB permeability or from bleeding due to trauma, hemoglobin ELISA was also performed at the same time point. There was a trend toward lower levels of hemoglobin extravasation in the NRG1 group, but the results did not reach statistical significance. MMP-9 activity was not different between groups at 2 h. These data suggest that NRG1 has beneficial effects on endothelial permeability and BBB permeability following experimental trauma, and may have neuroprotective potential during CNS injury.	[Lok, Josephine; Leung, Wendy; Whalen, Michael J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat, Boston, MA 02114 USA; [Lok, Josephine; Zhao, Song; Leung, Wendy; Seo, Ji Hae; Navaratna, Deepti; Wang, Xiaoying; Lo, Eng H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuroprotect Res Lab, Charlestown, MA USA; [Zhao, Song] Jilin Univ, First Hosp, Dept Orthoped, Spine Div, Changchun 130023, Jilin, Peoples R China; [Lo, Eng H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02114 USA; [Lo, Eng H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA 02114 USA; [Whalen, Michael J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Neurosci, Charlestown, MA USA	Lok, J (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pediat, Boston, MA 02114 USA.	jlok1@partners.org			National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08NS057339, R01NS53560, RO1NSO61255, R01-NS76694]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K08NS057339] Funding Source: NIH RePORTER	This study was supported by National Institute of Health grants (K08NS057339 to JL, R01NS53560, RO1NSO61255 to MW, and R01-NS76694 to EHL). The authors declare no conflicts of interest.	Anton ES, 1997, DEVELOPMENT, V124, P3501; Asahi M, 2001, J NEUROSCI, V21, P7724; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Cacheaux LP, 2009, J NEUROSCI, V29, P8927, DOI 10.1523/JNEUROSCI.0430-09.2009; Ferrari CC, 2004, AM J PATHOL, V165, P1827, DOI 10.1016/S0002-9440(10)63438-4; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lok J, 2007, J NEUROTRAUM, V24, P1817, DOI 10.1089/neu.2007.0372; Lok J, 2009, J CEREBR BLOOD F MET, V29, P39, DOI 10.1038/jcbfm.2008.94; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Talmage D.A., 2008, NOVART FDN SYMP, V289, P93; Talmage David A, 2008, Novartis Found Symp, V289, P74; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tomkins O, 2007, NEUROBIOL DIS, V25, P367, DOI 10.1016/j.nbd.2006.10.006; Vezzani Annamaria, 2007, Epilepsy Curr, V7, P45, DOI 10.1111/j.1535-7511.2007.00165.x; Viviani B, 2003, J NEUROSCI, V23, P8692; You ZR, 2007, J CEREBR BLOOD F MET, V27, P1954, DOI 10.1038/sj.jcbfm.9600497; Zlokovic BV, 2008, NEURON, V57, P178, DOI 10.1016/j.neuron.2008.01.003	19	32	33	0	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483			TRANSL STROKE RES	Transl. Stroke Res.	JUL	2012	3			1	SI		S119	S124		10.1007/s12975-012-0157-x			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	961AT	WOS:000305436500015	22773936	Green Accepted			2021-06-18	
J	Moore, MM; Pasquale, MD; Badellino, M				Moore, Margaret M.; Pasquale, Michael D.; Badellino, Michael			Impact of age and anticoagulation: Need for neurosurgical intervention in trauma patients with mild traumatic brain injury	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	Annual Scientific Meeting of the Keystone Chapter of the American-College-of-Surgeons	NOV 04, 2011	Allentown, PA	Amer Coll Surg		Anticoagulation; head injury; computed tomography; intervention	MINOR HEAD TRAUMA; PREINJURY WARFARIN; SUBDURAL-HEMATOMA; RISK	BACKGROUND: Of the 500,000 brain injuries in the United States annually, 80% are considered mild (mild traumatic brain injury). Unfortunately, 2% to 3% of them will subsequently deteriorate and result in severe neurologic dysfunction. Intracerebral changes in the elderly, chronic oral anticoagulation, and platelet inhibition may contribute to the development of intracranial bleeding after minor head injury. We sought to investigate the association of age and the use of anticoagulation and antiplatelet therapy with neurologic deterioration and the need for neurosurgical intervention in patients presenting with mild traumatic brain injury. METHODS: A retrospective review of all adult (>14 years) patients admitted to our Level I trauma service with a Glasgow Coma Scale (GCS) score of 14 to 15 who underwent neurosurgical intervention during their hospital stay was performed. Patients were stratified into two groups, age <65 years and age >= 65 years. Each group was then further stratified by the use of anticoagulants: warfarin, aspirin, clopidogrel, or a combination. Mechanism of injury, prehospital complaints, admission GCS, type of neurosurgical intervention, intensive care unit length of stay, hospital length of stay, and discharge disposition were evaluated. Z test and logistic regression were used to compare proportions or percentages from different groups. RESULTS: Of the 7,678 patients evaluated during the study period, 101 (1.3%) required neurosurgical intervention. The >= 65 years population underwent significantly more interventions as did those patients on anticoagulants. CONCLUSION: All patients aged 65 years or older who present with a GCS score of >13 after head trauma should undergo a screening computed tomography of the head regardless of prehospital use of anticoagulation. Patients younger than 65 years can be selectively screened based on presenting complaints and mechanism of injury provided they are not on anticoagulation. (J Trauma Acute Care Surg. 2012; 73: 126-130. Copyright (C) 2012 by Lippincott Williams & Wilkins)	[Moore, Margaret M.; Pasquale, Michael D.; Badellino, Michael] Lehigh Valley Hlth Network, Dept Surg, Allentown, PA 18103 USA	Moore, MM (corresponding author), Lehigh Valley Hlth Network, Dept Surg, 1240 S Cedar Crest Blvd,Suite 210, Allentown, PA 18103 USA.	Margaret_M.Moore@lvhn.org					Ahmed N, 2009, SOUTH MED J, V102, P476, DOI 10.1097/SMJ.0b013e31819f97a3; CDC, 1999, WISQARS LEAD CAUS DE; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Garra G, 1999, ACAD EMERG MED, V6, P121, DOI 10.1111/j.1553-2712.1999.tb01048.x; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; HIRSH J, 1995, CHEST, V108, pS231, DOI 10.1378/chest.108.4_Supplement.231S; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; Kirsch T, 2004, EMERGENCY MED COMPRE; Li J, 2001, LANCET, V357, P771, DOI 10.1016/S0140-6736(00)04163-5; Mack LR, 2003, J EMERG MED, V24, P157, DOI 10.1016/S0736-4679(02)00714-X; PERLMUTTER I, 1961, JAMA-J AM MED ASSOC, V176, P212, DOI 10.1001/jama.1961.63040160001006; Ramenofsky ML., 2004, CURRENT SURG THERAPY; Schulman CI, 2008, TRAUMA; STEIN J, 1995, ARCH PHYS MED REHAB, V76, P840, DOI 10.1016/S0003-9993(95)80549-4; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Viola L, 2000, ACTA NEUROCHIR, V142, P1281, DOI 10.1007/s007010070026; Wahl WL, 2001, J TRAUMA, V51, P1151; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	20	32	35	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	2163-0755			J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JUL	2012	73	1					126	130		10.1097/TA.0b013e31824b01af			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	979JU	WOS:000306814100018	22710784				2021-06-18	
J	Cole, JT; Sweatt, AJ; Hutson, SM				Cole, Jeffrey T.; Sweatt, Andrew J.; Hutson, Susan M.			Expression of mitochondrial branched-chain aminotransferase and alpha-keto-acid dehydrogenase in rat brain: implications for neurotransmitter metabolism	FRONTIERS IN NEUROANATOMY			English	Article						glutamate; gamma-amino butyric acid; MSUD; branched chain aminotransferase; traumatic brain injury; branched chain amino acid	SYRUP-URINE-DISEASE; AMINO-ACIDS; GLUTAMATE SYNTHESIS; GLIAL-CELLS; ACUTE STAGE; LEUCINE; ISOENZYMES; ACTIVATION; RECOVERY; PATHWAY	In the brain, metabolism of the essential branched chain amino acids (BCAAs) leucine, isoleucine, and valine, is regulated in part by protein synthesis requirements. Excess BCAAs are catabolized or excreted. The first step in BCAA catabolism is catalyzed by the branched chain aminotransferase (BCAT) isozymes, mitochondrial BCATm and cytosolic BCATc. A product of this reaction, glutamate, is the major excitatory neurotransmitter and precursor of the major inhibitory neurotransmitter gamma-aminobutyric acid (GABA). The BCATs are thought to participate in a alpha-keto-acid nitrogen shuttle that provides nitrogen for synthesis of glutamate from alpha-ketoglutarate. The branched-chain alpha-keto acid dehydrogenase enzyme complex (BCKDC) catalyzes the second, irreversible step in BCAA metabolism, which is oxidative decarboxylation of the branched-chain alpha-keto acid (BCKA) products of the BCAT reaction. Maple Syrup Urine Disease (MSUD) results from genetic defects in BCKDC, which leads to accumulation of toxic levels of BCAAs and BCKAs that result in brain swelling. Immunolocalization of BCATm and BCKDC in rats revealed that BCATm is present in astrocytes in white matter and in neuropil, while BCKDC is expressed only in neurons. BCATm appears uniformly distributed in astrocyte cell bodies throughout the brain. The segregation of BCATm to astrocytes and BCKDC to neurons provides further support for the existence of a BCAA-dependent glial-neuronal nitrogen shuttle since the data show that BCKAs produced by glial BCATm must be exported to neurons. Additionally, the neuronal localization of BCKDC suggests that MSUD is a neuronal defect involving insufficient oxidation of BCKAs, with secondary effects extending beyond the neuron.	[Cole, Jeffrey T.] Uniformed Serv Univ Hlth Sci, USUHS, Dept Neurol, Bethesda, MD 20814 USA; [Sweatt, Andrew J.] Wake Forest Univ Hlth Sci, Dept Physiol & Pharmacol, Winston Salem, NC USA; [Hutson, Susan M.] Virginia Tech, Human Nutr Foods & Exercise, Blacksburg, VA USA	Cole, JT (corresponding author), Uniformed Serv Univ Hlth Sci, USUHS, Dept Neurol, 4301 Jones Bridge Rd,B-3012, Bethesda, MD 20814 USA.	jeffrey.cole@usuhs.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-38641]; National Institutes of Health/National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 38641]	Jeffrey T. Cole and Andrew J. Sweatt conducted the experiments, collected the data and prepared the images. Jeffrey T. Cole, Andrew J. Sweatt, and Susan M. Hutson designed the experiments, interpreted the results, and prepared the manuscript. This work was supported by NIH NS-38641 (Susan M. Hutson). Grant sponsor: National Institutes of Health/National Institute of Neurological Disorders and Stroke; Grant Number NS 38641 (Susan M. Hutson).	Aquilani R, 2005, ARCH PHYS MED REHAB, V86, P1729, DOI 10.1016/j.apmr.2005.03.022; Aquilani R, 2008, ARCH PHYS MED REHAB, V89, P1642, DOI 10.1016/j.apmr.2008.02.023; Berl SCD, 1983, GLUTAMINE GLUTAMATE, P205; BIXEL MG, 1995, J NEUROCHEM, V65, P2450; Bixel MG, 2001, J HISTOCHEM CYTOCHEM, V49, P407, DOI 10.1177/002215540104900314; Bixel MG, 1997, J HISTOCHEM CYTOCHEM, V45, P685, DOI 10.1177/002215549704500506; Blouet C, 2009, J NEUROSCI, V29, P8302, DOI 10.1523/JNEUROSCI.1668-09.2009; CHUANG DI, 2001, METABOLIC BASIS INHE, P1239; Cole JT, 2010, P NATL ACAD SCI USA, V107, P366, DOI 10.1073/pnas.0910280107; COOPER AJL, 1987, PHYSIOL REV, V67, P440; Cota D, 2006, SCIENCE, V312, P927, DOI 10.1126/science.1124147; Gamberino WC, 1997, J NEUROCHEM, V69, P2312; Garcia-Espinosa MA, 2007, J NEUROCHEM, V100, P1458, DOI 10.1111/j.1471-4159.2006.04332.x; Ha JS, 2004, PEDIATR RADIOL, V34, P163, DOI 10.1007/s00247-003-1058-7; HALL TR, 1993, J BIOL CHEM, V268, P3092; HARRIS RA, 1990, ADV ENZYME REGUL, V30, P245; Hutson SM, 2005, J NUTR, V135, p1557S, DOI 10.1093/jn/135.6.1557S; Hutson SM, 2001, J NUTR, V131, p846S; Hutson SM, 1998, J NEUROCHEM, V71, P863; Ichihara A, 1985, TRANSAMINASES, P430; Jan W, 2003, NEURORADIOLOGY, V45, P393, DOI 10.1007/s00234-003-0955-7; Kanamori K, 1998, J NEUROCHEM, V70, P1304; LaNoue KF, 2001, J NEUROSCI RES, V66, P914, DOI 10.1002/jnr.10064; LANOUE KF, 2007, HDB NEUROCHEMISTRY M, P589; LEWANDOWSKI ED, 1990, AM J PHYSIOL, V258, pH1357; Lieth E, 2001, J NEUROCHEM, V76, P1712, DOI 10.1046/j.1471-4159.2001.00156.x; McKenna MC, 1998, DEV NEUROSCI-BASEL, V20, P300, DOI 10.1159/000017325; Parmar H, 2004, J COMPUT ASSIST TOMO, V28, P93, DOI 10.1097/00004728-200401000-00015; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Righini A, 2003, J NEUROIMAGING, V13, P162, DOI 10.1177/1051228403251084; RIVIELLO JJ, 1991, J PEDIATR-US, V119, P42, DOI 10.1016/S0022-3476(05)81036-4; Sakai R, 2004, J NEUROCHEM, V88, P612, DOI 10.1111/j.1471-4159.2004.02179.x; Sener RN, 2002, J NEUROIMAGING, V12, P368, DOI 10.1111/j.1552-6569.2002.tb00146.x; She P, 2007, CELL METAB, V6, P181, DOI 10.1016/j.cmet.2007.08.003; Suryawan A, 1998, AM J CLIN NUTR, V68, P72; Sweatt AJ, 2004, J COMP NEUROL, V477, P360, DOI 10.1002/cne.20200; Sweatt AJ, 2004, AM J PHYSIOL-ENDOC M, V286, pE64, DOI 10.1152/ajpendo.00276.2003; Waagepetersen HS, 2001, GLIA, V35, P246, DOI 10.1002/glia.1089; Yudkoff M, 2005, J NUTR, V135, p1531S, DOI 10.1093/jn/135.6.1531S; Yudkoff M, 1996, J NEUROCHEM, V66, P378; YUDKOFF M, 1993, DEV NEUROSCI-BASEL, V15, P343, DOI 10.1159/000111354; Yudkoff M, 1997, GLIA, V21, P92, DOI 10.1002/(SICI)1098-1136(199709)21:1<92::AID-GLIA10>3.0.CO;2-W; Yudkoff M, 1996, J NEUROCHEM, V66, P2136; YUDKOFF M, 1983, BIOCHEM BIOPH RES CO, V115, P174, DOI 10.1016/0006-291X(83)90985-3; YUDKOFF M, 1994, J NEUROCHEM, V62, P1192	45	32	32	0	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5129			FRONT NEUROANAT	Front. Neuroanat.	MAY 28	2012	6								18	10.3389/fnana.2012.00018			11	Anatomy & Morphology; Neurosciences	Anatomy & Morphology; Neurosciences & Neurology	948EO	WOS:000304486600001	22654736	DOAJ Gold, Green Published			2021-06-18	
J	Cimolin, V; Beretta, E; Piccinini, L; Turconi, AC; Locatelli, F; Galli, M; Strazzer, S				Cimolin, Veronica; Beretta, Elena; Piccinini, Luigi; Turconi, Anna Carla; Locatelli, Federica; Galli, Manuela; Strazzer, Sandra			Constraint-Induced Movement Therapy for Children With Hemiplegia After Traumatic Brain Injury: A Quantitative Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						children; CIMT; kinematics; rehabilitation; traumatic brain injury; upper limbs	UPPER EXTREMITY KINEMATICS; MOTOR FUNCTION MEASURE; CEREBRAL-PALSY; UPPER-LIMB; 3-DIMENSIONAL KINEMATICS; EXCITE TRIAL; STROKE; ADOLESCENTS; RELIABILITY; EVALUATE	Objective: The aims of this study are to quantify the movement limitation of upper limbs in hemiplegic children with traumatic brain injury (TBI) by using a clinical-functional scale and upper limb kinematics and to evaluate the effectiveness of constraint-induced movement therapy (CIMT) on upper limbs. Design: Pre-post study. Setting: Clinical rehabilitation research laboratory. Participants: Ten children with TBI. Main Outcome Measures: The participants were evaluated by clinical examinations (Gross Motor Function Measure, Besta scale, Quality of Upper Extremities Skills Test, and Manual Ability Classification System) and 3D kinematic movement analysis of the upper limb before the CIMT program (pretest: 0.7 years after the injury) and at the end of the program (posttest: 10 weeks later). Results: After the CIMT, most of the clinical measures improved significantly. Some significant improvements were present in terms of kinematics, in particular, in the movement duration and the velocity of movement execution of both tasks; the index of curvature and the average jerk improved, respectively, during reaching and hand-to-mouth task, while the adjusting sway parameter decreased during the 2 movements. Significant improvements were found in upper limb joint excursion after the rehabilitative programme too. Conclusions: Our results suggest that the CIMT program can improve movement efficiency and upper limb function in children after TBI. The integration of the clinical outcomes and upper limb kinematics revealed to be crucial in detecting the effects of the CIMT programme.	[Cimolin, Veronica; Galli, Manuela] Politecn Milan, Dept Bioengn, I-20133 Milan, Italy; [Beretta, Elena; Piccinini, Luigi; Turconi, Anna Carla; Locatelli, Federica; Strazzer, Sandra] IRCCS E Medea La Nostra Famiglia, Bosisio Parini, LC, Italy; [Galli, Manuela] IRCCS San Raffaele Pisana Tosinvest Sanita, Rome, Italy	Cimolin, V (corresponding author), Politecn Milan, Dept Bioengn, Pzza Leonardo da Vinci 32, I-20133 Milan, Italy.	veronica.cimolin@biomed.polimi.it	Beretta, Elena/AAH-5369-2019; Turconi, Anna Carla/AAX-6521-2020; Strazzer, Sandra/AAH-5712-2019; piccinini, luigi/AAH-5470-2019; Cimolin, Veronica/AAF-6414-2019; Turconi, Anna Carla/ABE-6747-2020; FEDERICA, LOCATELLI/AAA-5601-2020; Cimolin, Veronica/AAA-3326-2021; Galli, Manuela/AAH-8783-2019	Beretta, Elena/0000-0002-8036-7624; Strazzer, Sandra/0000-0001-8414-6565; piccinini, luigi/0000-0001-7027-6676; Cimolin, Veronica/0000-0001-6299-7254; Turconi, Anna Carla/0000-0002-5482-924X; FEDERICA, LOCATELLI/0000-0002-8243-5483; Cimolin, Veronica/0000-0001-6299-7254; Galli, Manuela/0000-0003-2772-4837			ACHENBACH TM, 1981, MONOGR SOC RES CHILD, V46, P1, DOI 10.2307/1165983; Boyd R, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-4; Brady K, 2009, DEV DISABIL RES REV, V15, P102, DOI 10.1002/ddrr.59; Caimmi M, 2008, NEUROREHAB NEURAL RE, V22, P31, DOI 10.1177/1545968307302923; Chang JJ, 2005, CLIN BIOMECH, V20, P381, DOI 10.1016/j.clinbiomech.2004.11.015; Chevignard A., 2008, Annales de Readaptation et de Medecine Physique, V51, P238, DOI 10.1016/j.annrmp.2008.01.013; Coker P, 2010, DISABIL REHABIL, V32, P402, DOI 10.3109/09638280903171592; Coluccini M, 2007, GAIT POSTURE, V25, P493, DOI 10.1016/j.gaitpost.2006.12.015; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; Cope SM, 2008, AM J OCCUP THER, V62, P430, DOI 10.5014/ajot.62.4.430; Cope SM, 2010, DEV NEUROREHABIL, V13, P19, DOI 10.3109/17518420903236247; Deluca SC, 2006, J CHILD NEUROL, V21, P931, DOI 10.1177/08830738060210110401; DeMatteo C, 1993, PHYS OCCUP THER PEDI, V13, P833, DOI DOI 10.1080/J006V13N02_01; Eliasson AC, 2006, DEV MED CHILD NEUROL, V48, P549, DOI 10.1017/S0012162206001162; Emanuelson IM, 1997, DEV MED CHILD NEUROL, V39, P502; Facchin P, 2009, AM J PHYS MED REHAB, V88, P216, DOI 10.1097/PHM.0b013e3181951382; Fedrizzi E, 1994, MOTOR DEV CHILDHOOD, P51; Feng C J, 1997, IEEE Trans Rehabil Eng, V5, P253, DOI 10.1109/86.623017; Gordon A, 2007, DEV MED CHILD NEUROL, V49, P23, DOI 10.1017/S0012162207000072; Hoare B, 2007, CLIN REHABIL, V21, P675, DOI 10.1177/0269215507080783; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Karman N, 2003, J HEAD TRAUMA REHAB, V18, P259, DOI 10.1097/00001199-200305000-00004; Linder-Lucht M, 2007, PEDIATRICS, V120, P880, DOI 10.1542/peds.2006-2258; Mackey AH, 2006, ARCH PHYS MED REHAB, V87, P207, DOI 10.1016/j.apmr.2005.10.023; Mackey AH, 2005, GAIT POSTURE, V22, P1, DOI 10.1016/j.gaitpost.2004.06.002; Massie C, 2009, ARCH PHYS MED REHAB, V90, P571, DOI 10.1016/j.apmr.2008.09.574; Menegoni F, 2009, EUR J NEUROL, V16, P232, DOI 10.1111/j.1468-1331.2008.02396.x; Park SW, 2008, NEUROREHAB NEURAL RE, V22, P486, DOI 10.1177/1545968308316906; Petuskey K, 2007, GAIT POSTURE, V25, P573, DOI 10.1016/j.gaitpost.2006.06.006; Pidcock FS, 2009, TOP STROKE REHABIL, V16, P339, DOI 10.1310/tsr1605-339; Poggi G, 2000, BRAIN INJURY, V14, P833, DOI 10.1080/026990500421930; Rab G, 2002, GAIT POSTURE, V15, P113, DOI 10.1016/S0966-6362(01)00155-2; Ramos E, 1997, ARCH PHYS MED REHAB, V78, P491, DOI 10.1016/S0003-9993(97)90162-3; RUSSELL DJ, 1989, DEV MED CHILD NEUROL, V31, P341; Schweighofer N, 2009, PHYS THER, V89, P1327, DOI 10.2522/ptj.20080402; Smania N, 2009, EUR J PHYS REHAB MED, V45, P493; Taub E, 1976, Exerc Sport Sci Rev, V4, P335; Wallen M, 2008, DEV NEUROREHABIL, V11, P124, DOI 10.1080/17518420701640897; Wechsler D., 1974, MANUAL WECHSLER INTE; Wolf SL, 2007, RESTOR NEUROL NEUROS, V25, P549; Wolf SL, 2006, JAMA-J AM MED ASSOC, V296, P2095, DOI 10.1001/jama.296.17.2095; Wu CY, 2007, ARCH PHYS MED REHAB, V88, P964, DOI 10.1016/j.apmr.2007.05.012	42	32	33	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2012	27	3					177	187		10.1097/HTR.0b013e3182172276			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	941CV	WOS:000303941500006	21522025				2021-06-18	
J	Shiroma, EJ; Ferguson, PL; Pickelsimer, EE				Shiroma, Eric J.; Ferguson, Pamela L.; Pickelsimer, E. Elisabeth			Prevalence of Traumatic Brain Injury in an Offender Population: A Meta-Analysis	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						traumatic brain injury; inmates; prevalence; head injury; correctional health care	HEAD-INJURY; SEXUAL OFFENSES; HISTORY; HOSPITALIZATION; DELINQUENTS; EPILEPSY; ABUSE; RISK; TBI	Traumatic brain injury (TBI) can create challenges to managing offenders and to their successful community reentry upon release. In this study, the researchers reviewed relevant articles in Pubmed, PsycInfo, Medline, and EmBase (1983 to 2009) and communicated with other researchers to identify 20 epidemiologic studies that met preestablished inclusion criteria. Random-effects meta-and subgroup analyses were conducted to calculate the prevalence of TBI and the effects of gender, offender type, and definition and method of identifying TBI. The estimated prevalence of TBI in the overall offender population was 60.25 (95% confidence interval: 48.08 to 72.41). A truer estimate of TBI prevalence in offending populations could lead to more appropriate resource allocation, screening, and management of offenders.	[Shiroma, Eric J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Shiroma, Eric J.; Ferguson, Pamela L.; Pickelsimer, E. Elisabeth] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA	Shiroma, EJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave,Kresge Bldg, Boston, MA 02115 USA.	eshiroma@hsph.harvard.edu					Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P201; Barnfield TV, 1998, BRAIN INJURY, V12, P455, DOI 10.1080/026990598122421; BAX L, 2008, MIX COMPREHENSIVE FR; Bax Leon, 2006, BMC Med Res Methodol, V6, P50, DOI 10.1186/1471-2288-6-50; BLAKE PY, 1995, NEUROLOGY, V45, P1641, DOI 10.1212/WNL.45.9.1641; Brain Injury Association of Wyoming, 2008, STUD UND BRAIN UNPUB; Brewer-Smyth K, 2004, BIOL PSYCHIAT, V55, P21, DOI 10.1016/S0006-3223(03)00705-4; Bureau of Justice Statistics, 2008, 221944 NCJ US DEP JU; Carswell K, 2004, J ADOLESCENCE, V27, P415, DOI 10.1016/j.adolescence.2004.04.003; Corrigan JD, 2008, FINAL PROGRAMMATIC R; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P315, DOI 10.1097/01.HTR.0000300226.67748.3e; DelBello MP, 1999, PSYCHIAT RES, V89, P281, DOI 10.1016/S0165-1781(99)00112-2; Diamond PM, 2007, J HEAD TRAUMA REHAB, V22, P330, DOI 10.1097/01.HTR.0000300228.05867.5c; Ferguson PL, 2010, EPILEPSIA, V51, P891, DOI 10.1111/j.1528-1167.2009.02384.x; Finkelstein EA., 2006, INCIDENCE EC BURDEN; Freedman D, 2000, SOC SCI MED, V50, P1757, DOI 10.1016/S0277-9536(99)00417-7; GOODMAN LA, 1970, J AM STAT ASSOC, V65, P226, DOI 10.2307/2283589; Hawley CA, 2003, BRAIN INJURY, V17, P743, DOI 10.1080/0269905031000089341; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Langevin R, 2006, BRAIN COGNITION, V60, P206; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LEWIS DO, 1987, J AM ACAD CHILD PSY, V26, P744, DOI 10.1097/00004583-198709000-00022; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; MARTELL DA, 1992, J FORENSIC SCI, V37, P878; Merbitz C., 1995, J OFFENDER REHABILIT, V22, P11, DOI DOI 10.1300/J076V22N03_02; Minnesota Department of Corrections, 2008, ANN C MINN BRAIN INJ; Miura H, 2005, PSYCHIAT CLIN NEUROS, V59, P661, DOI 10.1111/j.1440-1819.2005.01434.x; Morrell RF, 1998, J OFFENDER REHABIL, V27, P1, DOI DOI 10.1300/J076V27N03_01; Perron Brian E, 2008, Crim Behav Ment Health, V18, P243, DOI 10.1002/cbm.702; Sarapatta M, 1998, BRAIN INJURY, V12, P821, DOI 10.1080/026990598122061; Schofield PW, 2006, BRAIN INJURY, V20, P1409, DOI 10.1080/02699050601130443; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Slaughter B, 2003, BRAIN INJURY, V17, P731, DOI 10.1080/0269905031000088649; TEMPLER DI, 1992, PERCEPT MOTOR SKILL, V75, P195, DOI 10.2466/PMS.75.4.195-202; Turkstra L, 2003, BRAIN INJURY, V17, P39, DOI 10.1080/0269905021000010122; Walker R, 2003, J PSYCHOACTIVE DRUGS, V35, P343, DOI 10.1080/02791072.2003.10400017; Walker R, 2001, SUBST USE MISUSE, V36, P757, DOI 10.1081/JA-100104089	41	32	32	1	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2012	27	3					E1	E10		10.1097/HTR.0b013e3182571c14			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	941CV	WOS:000303941500001	22573043				2021-06-18	
J	Weber, JT; Lamont, M; Chibrikova, L; Fekkes, D; Vlug, AS; Lorenz, P; Kreutzmann, P; Slemmer, JE				Weber, John T.; Lamont, Matthew; Chibrikova, Lyudmila; Fekkes, Durk; Vlug, Angela S.; Lorenz, Peter; Kreutzmann, Peter; Slemmer, Jennifer E.			Potential neuroprotective effects of oxyresveratrol against traumatic injury	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Gliosis; Glutamate; In vitro; Neuron; Oxyresveratrol; Trauma	FOCAL CEREBRAL-ISCHEMIA; SMILACIS-CHINAE RHIZOME; FREE-RADICAL SCAVENGERS; BRAIN-INJURY; CELL-DEATH; NORMOBARIC HYPEROXIA; HIPPOCAMPAL CELLS; OXIDATIVE STRESS; RESVERATROL; DAMAGE	Oxyresveratrol is a potent antioxidant and free-radical scavenger found in mulberry wood (Morus alba L.) with demonstrated protective effects against cerebral ischemia. We analyzed the neuroprotective ability of oxyresveratrol using an in vitro model of stretch-induced trauma in co-cultures of neurons and glia, or by exposing cultures to high levels of glutamate. Cultures were treated with 25 mu M, 50 mu M or 100 mu M oxyresveratrol at the time of injury. Trauma produced marked neuronal death when measured 24 h post-injury, and oxyresveratrol significantly inhibited this death. Microscopic examination of glia suggested signs of toxicity in cultures treated with 100 mu M oxyresveratrol, as demonstrated by elevated S-100B protein release and a high proportion of cells with condensed nuclei. Cultures exposed to glutamate (100 mu M) for 24 h exhibited similar to 37% neuronal loss, which was not inhibited by oxyresveratrol. These results show that the two pathologies of high glutamate exposure and trauma are differentially affected by oxyresveratrol treatment in vitro. Further studies using oxyresveratrol in trauma models are warranted, as toxicity to glia could be beneficial by inhibiting reactive gliosis, which often occurs after trauma. Crown Copyright (C) 2012 Published by Elsevier B. V. All rights reserved.	[Weber, John T.; Chibrikova, Lyudmila] Mem Univ Newfoundland, Sch Pharm, Hlth Sci Ctr, St John, NF A1B 3V6, Canada; [Weber, John T.; Lamont, Matthew] Mem Univ Newfoundland, Hlth Sci Ctr, Fac Med, Div Biomed Sci, St John, NF A1B 3V6, Canada; [Weber, John T.; Fekkes, Durk; Slemmer, Jennifer E.] Erasmus MC, Dept Neurosci, NL-3015 GE Rotterdam, Netherlands; [Fekkes, Durk] Erasmus MC, Dept Psychiat, NL-3015 GE Rotterdam, Netherlands; [Vlug, Angela S.; Lorenz, Peter; Kreutzmann, Peter] Univ Magdeburg, Inst Med Neurobiol, D-39120 Magdeburg, Germany; [Slemmer, Jennifer E.] Univ Prince Edward Isl, Dept Biol, Charlottetown, PE C1A 4P3, Canada	Weber, JT (corresponding author), Mem Univ Newfoundland, Sch Pharm, Hlth Sci Ctr, 300 Prince Philip Dr, St John, NF A1B 3V6, Canada.	jweber@mun.ca; mgl080@mun.ca; lc3147@mun.ca; d.fekkes@erasmusmc.nl; Angela.Vlug@sanofi-aventis.com; Peter.Lorenz@wala.de; Peter.Kreutzmann@med.ovgu.de; jeslemmer@hollandcollege.com		Lamont, Matthew/0000-0003-4365-9078	Research Council for Earth and Life Sciences (ALW)Netherlands Organization for Scientific Research (NWO); Research Council for Medical Sciences (MW); Netherlands Organization for Scientific Research (NWO)Netherlands Organization for Scientific Research (NWO); Hersenstichting Nederland; Natural Sciences and Engineering Research Council (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); Canada Foundation for InnovationCanada Foundation for InnovationCGIAR; Erasmus Medical Centre	Work conducted at the Erasmus Medical Centre was supported by grants from the Research Council for Earth and Life Sciences (ALW) and Research Council for Medical Sciences (MW) with financial aid from the Netherlands Organization for Scientific Research (NWO), a Breedtestrategie subsidie from Erasmus Medical Centre, and funding from Hersenstichting Nederland. The authors thank Robert De Jonge, Doortje Engel and Ans Voskuilen-Kooijman for their technical assistance with lactate, pyurvate and glucose measurements. Work conducted at Memorial University was supported by grants from the Natural Sciences and Engineering Research Council (NSERC) and the Canada Foundation for Innovation. We thank Erica Kelly, Stephanie Hewitt, Catherine Orr and Breanna Skye Fisher for assistance with dissections, immunohistochemistry and cell counting.	Ahmed SM, 2002, J NEUROTRAUM, V19, P1619, DOI 10.1089/089771502762300274; Andrabi SA, 2004, BRAIN RES, V1017, P98, DOI 10.1016/j.brainres.2004.05.038; Ban JY, 2008, J PHARMACOL SCI, V106, P68, DOI 10.1254/jphs.FP0071206; Ban JY, 2006, BIOL PHARM BULL, V29, P2419, DOI 10.1248/bpb.29.2419; Breuer C, 2006, NEUROSCI LETT, V393, P113, DOI 10.1016/j.neulet.2005.09.081; Chao JF, 2008, FREE RADICAL BIO MED, V45, P1019, DOI 10.1016/j.freeradbiomed.2008.07.002; Dore S, 2005, NEUROSIGNALS, V14, P61, DOI 10.1159/000085386; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Engel DC, 2005, NEUROPHARMACOLOGY, V49, P985, DOI 10.1016/j.neuropharm.2005.05.021; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; FEKKES D, 1995, J CHROMATOGR B, V669, P177, DOI 10.1016/0378-4347(95)00111-U; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; Geeraerts T, 2006, J NEUROTRAUM, V23, P1059, DOI 10.1089/neu.2006.23.1059; Huang SS, 2001, LIFE SCI, V69, P1057, DOI 10.1016/S0024-3205(01)01195-X; Inoue H, 2003, NEUROSCI LETT, V352, P203, DOI 10.1016/j.neulet.2003.09.001; Kleindienst A, 2007, PROG BRAIN RES, V161, P317, DOI 10.1016/S0079-6123(06)61022-4; Lorenz P, 2003, NITRIC OXIDE-BIOL CH, V9, P64, DOI 10.1016/j.niox.2003.09.005; Lyons MM, 2003, J AGR FOOD CHEM, V51, P5867, DOI 10.1021/jf034150f; Rimando AM, 2004, J AGR FOOD CHEM, V52, P4713, DOI 10.1021/jf040095e; Sinha K, 2002, LIFE SCI, V71, P655, DOI 10.1016/S0024-3205(02)01691-0; Slemmer JE, 2008, CURR MED CHEM, V15, P404, DOI 10.2174/092986708783497337; Slemmer JE, 2005, NEUROBIOL DIS, V18, P421, DOI 10.1016/j.nbd.2004.09.022; Slemmer JE, 2004, NEUROBIOL DIS, V15, P563, DOI 10.1016/j.nbd.2003.11.027; Slemmer JE, 2002, BRAIN, V125, P2699, DOI 10.1093/brain/awf271; Slemmer JE, 2008, AM J PATHOL, V173, P1795, DOI 10.2353/ajpath.2008.080168; Soleas GJ, 1997, J CLIN LAB ANAL, V11, P287, DOI 10.1002/(SICI)1098-2825(1997)11:5<287::AID-JCLA6>3.0.CO;2-4; Tisdall MM, 2008, J NEUROSURG, V109, P424, DOI 10.3171/JNS/2008/109/9/0424; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Weber JT, 2004, CURR NEUROVASC RES, V1, P151, DOI 10.2174/1567202043480134; Wolf HK, 1996, J HISTOCHEM CYTOCHEM, V44, P1167, DOI 10.1177/44.10.8813082	32	32	35	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	APR 5	2012	680	1-3					55	62		10.1016/j.ejphar.2012.01.036			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	901SE	WOS:000300986300009	22489319				2021-06-18	
J	Weckbach, S; Neher, M; Losacco, JT; Bolden, AL; Kulik, L; Flierl, MA; Bell, SE; Holers, VM; Stahel, PF				Weckbach, Sebastian; Neher, Miriam; Losacco, Justin T.; Bolden, Ashley L.; Kulik, Liudmila; Flierl, Michael A.; Bell, Scott E.; Holers, V. Michael; Stahel, Philip F.			Challenging the Role of Adaptive Immunity in Neurotrauma: Rag1(-/-) Mice Lacking Mature B and T Cells Do Not Show Neuroprotection after Closed Head Injury	JOURNAL OF NEUROTRAUMA			English	Article						adaptive immunity; closed head injury; complement system; natural antibodies; Rag1	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; ISCHEMIA-REPERFUSION INJURY; NATURAL ANTIBODY REPERTOIRE; COMPLEMENT-SYSTEM; BARRIER DYSFUNCTION; INNATE IMMUNITY; TISSUE-INJURY; RAT-BRAIN; ACTIVATION	The role of adaptive immunity in contributing to post-traumatic neuroinflammation and neuropathology after head injury remains largely unexplored. The present study was designed to investigate the pathophysiological sequelae of closed head injury in Rag1(-/-) mice devoid of mature B and T lymphocytes. C57BL/6 wild-type and Rag1(-/-) mice were subjected to experimental closed head injury, using a standardized weight-drop device. Outcome parameters consisted of neurological scoring, quantification of blood-brain barrier (BBB) function, measurement of inflammatory markers and mediators of apoptosis in serum and brain tissue, and assessment of neuronal cell death, astrogliosis, and tissue destruction. There was no difference between wild-type and Rag1(-/-) mice with regard to injury severity and neurological impairment for up to 7 days after head injury. The extent of BBB dysfunction was in a similar range for both groups. Quantification of complement activation fragments in serum revealed significantly attenuated C3a levels in Rag1(-/-) mice compared to wild-type animals. In contrast, the levels of pro- and anti-inflammatory cytokines and pro-apoptotic and anti-apoptotic mediators remained in a similar range for both groups, and the histological analysis of brain sections did not reveal a difference in reactive astrogliosis, tissue destruction, and neuronal cell death in Rag1(-/-) compared to wild-type mice. These findings suggest that adaptive immunity is not of crucial importance for initiating and sustaining the inflammatory neuropathology after closed head injury. The attenuated extent of post-traumatic complement activation seen in Rag1(-/-) mice implies a cross-talk between innate and adaptive immune responses, which requires further investigation in future studies.	[Weckbach, Sebastian; Neher, Miriam; Losacco, Justin T.; Bolden, Ashley L.; Flierl, Michael A.; Stahel, Philip F.] Univ Colorado, Dept Orthopaed, Denver Hlth Med Ctr, Sch Med, Denver, CO 80204 USA; [Bell, Scott E.; Stahel, Philip F.] Univ Colorado, Dept Neurosurg, Sch Med, Denver, CO 80204 USA; [Kulik, Liudmila; Holers, V. Michael] Univ Colorado Denver, Dept Med, Aurora, CO USA; [Kulik, Liudmila; Holers, V. Michael] Univ Colorado Denver, Dept Immunol, Aurora, CO USA	Stahel, PF (corresponding author), Univ Colorado, Dept Orthopaed, Denver Hlth Med Ctr, Sch Med, 777 Bannock St, Denver, CO 80204 USA.	philip.stahel@dhha.org		Losacco, Justin/0000-0001-7867-1152	Colorado TBI Trust Fund (COTBITF); German Research Foundation (DFG)German Research Foundation (DFG); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AR051749]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [R01AR051749] Funding Source: NIH RePORTER	This study was supported by a project grant from the Colorado TBI Trust Fund (COTBITF) to P.F.S. and M.A.F. S.W. was supported by a research fellowship from the German Research Foundation (DFG). V.M.H. was supported by an R01 grant from the NIH (no. AR051749).	Alexander JJ, 2008, J NEUROCHEM, V107, P1169, DOI 10.1111/j.1471-4159.2008.05668.x; Ankeny DP, 2009, J CLIN INVEST, V119, P2990, DOI 10.1172/JCI39780; Austen WG, 2004, SURGERY, V136, P401, DOI 10.1016/j.surg.2004.05.016; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Bechmann I, 2007, TRENDS IMMUNOL, V28, P5, DOI 10.1016/j.it.2006.11.007; Bellander BM, 2011, ACTA NEUROCHIR, V153, P90, DOI 10.1007/s00701-010-0737-z; Bellander BM, 2010, EXP BRAIN RES, V205, P103, DOI 10.1007/s00221-010-2342-z; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Czigner A, 2007, ACTA NEUROCHIR, V149, P281, DOI 10.1007/s00701-006-1095-8; Dimayuga PC, 2009, AM J PHYSIOL-REG I, V297, pR1593, DOI 10.1152/ajpregu.00114.2009; Elward K, 2003, MOL IMMUNOL, V40, P85, DOI 10.1016/S0161-5890(03)00109-3; Engelhardt B, 2011, FLUIDS BARRIERS CNS, V8, DOI 10.1186/2045-8118-8-4; Farkas IG, 2003, ACTA HISTOCHEM, V105, P115, DOI 10.1078/0065-1281-00696; Fee D, 2003, J NEUROIMMUNOL, V136, P54, DOI 10.1016/S0165-5728(03)00008-0; Finsen B., 2011, FEBS LETT; Fleming SD, 2004, J IMMUNOL, V173, P7055, DOI 10.4049/jimmunol.173.11.7055; Fleming SD, 2002, J IMMUNOL, V169, P2126, DOI 10.4049/jimmunol.169.4.2126; Fleming SD, 2006, AUTOIMMUNITY, V39, P379, DOI 10.1080/08916930600739381; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Francis Karen, 2003, Expert Reviews in Molecular Medicine, V5, P1, DOI 10.1017/S1462399403006252; Galea I, 2007, J EXP MED, V204, P2023, DOI 10.1084/jem.20070064; Galea I, 2007, TRENDS IMMUNOL, V28, P12, DOI 10.1016/j.it.2006.11.004; Gasque P, 2004, MOL IMMUNOL, V41, P1089, DOI 10.1016/j.molimm.2004.06.011; Gong N, 2011, J NEUROIMMUNOL, V230, P33, DOI 10.1016/j.jneuroim.2010.08.014; Griffiths MR, 2010, INT J INFLAMM, V2010, DOI 10.4061/2010/151097; Ha GK, 2006, J NEUROIMMUNOL, V172, P1, DOI 10.1016/j.jneuroim.2005.10.012; Harhausen D, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-15; Hazlett LD, 2010, OCUL IMMUNOL INFLAMM, V18, P237, DOI 10.3109/09273948.2010.501946; Hendrix S, 2007, J NEUROIMMUNOL, V184, P100, DOI 10.1016/j.jneuroim.2006.11.019; Hickey WF, 1999, SEMIN IMMUNOL, V11, P125, DOI 10.1006/smim.1999.0168; Hickey WF, 1991, BRAIN PATHOL, V1, P97, DOI 10.1111/j.1750-3639.1991.tb00646.x; Holers VM, 2007, MOL IMMUNOL, V44, P64, DOI 10.1016/j.molimm.2006.07.003; Holers VM, 2005, SPRINGER SEMIN IMMUN, V26, P405, DOI 10.1007/s00281-004-0186-y; Hu ZY, 2009, CURR MED CHEM, V16, P1418, DOI 10.2174/092986709787846523; Kipnis J, 2003, J NEUROTRAUM, V20, P559, DOI 10.1089/089771503767168483; Kulik L, 2009, J IMMUNOL, V182, P5363, DOI 10.4049/jimmunol.0803980; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; Liesz A, 2009, NAT MED, V15, P192, DOI 10.1038/nm.1927; LINDNER V, 1982, ATHEROSCLEROSIS, V43, P417, DOI 10.1016/0021-9150(82)90040-5; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Mombaerts P, 1995, Int Rev Immunol, V13, P43, DOI 10.3109/08830189509061737; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Morgan BP, 2005, IMMUNOL LETT, V97, P171, DOI 10.1016/j.imlet.2004.11.010; Morganti-Kossmann MC, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2010.03.032; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Pachter JS, 2003, J NEUROPATH EXP NEUR, V62, P593, DOI 10.1093/jnen/62.6.593; Perry VH, 1998, J NEUROIMMUNOL, V90, P113; Qiao F, 2006, AM J PATHOL, V169, P1039, DOI 10.2353/ajpath.2006.060248; Ramlackhansingh A.F., 2011, ANN NEUROL; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Reid RR, 2002, J IMMUNOL, V169, P5433, DOI 10.4049/jimmunol.169.10.5433; Rhodes J, 2011, CURR OPIN CRIT CARE, V17, P122, DOI 10.1097/MCC.0b013e3283447948; Sayed BA, 2010, J IMMUNOL, V184, P6891, DOI 10.4049/jimmunol.1000126; Schwartz M, 2001, TRENDS MOL MED, V7, P252, DOI 10.1016/S1471-4914(01)01993-1; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; Stahel PF, 2001, J NEUROTRAUM, V18, P773, DOI 10.1089/089771501316919139; Stahel Philip F, 2006, Expert Rev Clin Immunol, V2, P445, DOI 10.1586/1744666X.2.3.445; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; Szmydynger-Chodobska J., 2011, J CEREB BLOOD FLOW M; Toapanta FR, 2006, IMMUNOL RES, V36, P197, DOI 10.1385/IR:36:1:197; Van Beek J, 2003, ANN NY ACAD SCI, V992, P56; Volanakis JE, 2002, CURR TOP MICROBIOL, V266, P41; Wise PM, 2002, TRENDS ENDOCRIN MET, V13, P229, DOI 10.1016/S1043-2760(02)00611-2; Zhang M, 2006, J MOL CELL CARDIOL, V41, P62, DOI 10.1016/j.yjmcc.2006.02.006	72	32	33	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1233	1242		10.1089/neu.2011.2169			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100023	22335783	Green Published			2021-06-18	
J	Larson, MJ; Clayson, PE; Farrer, TJ				Larson, Michael J.; Clayson, Peter E.; Farrer, Thomas J.			Performance Monitoring and Cognitive Control in Individuals with Mild Traumatic Brain Injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						Cognitive control; Performance monitoring; Traumatic brain injury; Concussion; Stroop; ERN	EVENT-RELATED POTENTIALS; MAJOR DEPRESSIVE DISORDER; ERROR-DETECTION; CONFLICT ADAPTATION; ANTERIOR CINGULATE; ERP COMPONENTS; STROOP TASK; ELECTROENCEPHALOGRAPHIC RECORDINGS; FUNCTIONAL-SIGNIFICANCE; RELEVANT INFORMATION	Literature suggests that individuals with mild traumatic brain injury (mTBI) show subtle abnormalities in the cognitive control process of performance monitoring. The neural bases of performance monitoring can be measured using the error-related negaitivity (ERN) and post-error positivity (Pe) components of the scalp-recorded event-related potential (ERP). Thirty-six individuals with mTBI and 46 demographically similar controls completed a modified color-naming Stroop task while ERPs were recorded. Separate repeated-measures analyses of variance were used to examine the behavioral (response times [RT] and error rates) and ERP (ERN and Pe amplitudes) indices of performance monitoring. Both groups showed slower RTs and increased error rates on incongruent trials relative to congruent trials. Likewise, both groups showed more negative ERN and more positive Pe amplitude to error trials relative to correct trials. Notably, there were no significant main effects or interactions of group for behavioral and ERP measures. Subgroup and correlational analyses with post-concussive symptoms and indices of injury severity were also not significant. Findings suggest comparable performance to non-injured individuals in some aspects of cognitive control in this sample. Neuropsychological implications and comparison with other cognitive control component processes in individuals with TBI are provided. (JINS, 2012, 18, 323-333)	[Larson, Michael J.; Clayson, Peter E.; Farrer, Thomas J.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Larson, Michael J.] Brigham Young Univ, Ctr Neurosci, Provo, UT 84602 USA; [Clayson, Peter E.] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90024 USA	Larson, MJ (corresponding author), Brigham Young Univ, Dept Psychol, 244 TLRB, Provo, UT 84602 USA.	michael_larson@byu.edu	Clayson, Peter/AAC-9207-2019; Clayson, Peter E/F-5438-2011; Larson, Michael J/C-8543-2012	Clayson, Peter/0000-0003-4437-6598; Clayson, Peter E/0000-0003-4437-6598; Larson, Michael J/0000-0002-8199-8065; Farrer, Thomas J./0000-0001-8092-6214	Brigham Young University College of Family, Home, and Social Sciences	This study has not been published or submitted elsewhere and was supported by funds from the Brigham Young University College of Family, Home, and Social Sciences. The authors report no conflicts of interest.	Beck A. T., 1996, BECK DEPRESSION INVE, VII; Benton A., 1976, MULTILINGUAL APHASIA; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1992, NEUROSURGERY, V30, P692; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Carroll JFX., 2001, MENTAL HLTH SCREENIN; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carter CS, 2007, COGN AFFECT BEHAV NE, V7, P367, DOI 10.3758/CABN.7.4.367; Chiu PH, 2007, AM J PSYCHIAT, V164, P608, DOI 10.1176/appi.ajp.164.4.608; Clayson PE, 2011, NEUROPSYCHOLOGIA, V49, P1953, DOI 10.1016/j.neuropsychologia.2011.03.023; Cohen JD, 2000, NAT NEUROSCI, V3, P421, DOI 10.1038/74783; Compton RJ, 2008, EMOTION, V8, P58, DOI 10.1037/1528-3542.8.1.58; Compton RJ, 2007, BRAIN COGNITION, V64, P247, DOI 10.1016/j.bandc.2007.03.006; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.neuro.18.1.193; Dien J, 2005, CLIN NEUROPHYSIOL, V116, P1808, DOI 10.1016/j.clinph.2004.11.025; Dien J, 2004, PSYCHOPHYSIOLOGY, V41, P665, DOI 10.1111/j.1469-8986.2004.00193.x; DIEN J, 2005, EVENT RELATED POTENT; Dien J, 2007, HUM BRAIN MAPP, V28, P742, DOI 10.1002/hbm.20304; Dien J, 2010, BRAIN RES, V1355, P126, DOI 10.1016/j.brainres.2010.07.099; Dien J, 2010, J NEUROSCI METH, V187, P138, DOI 10.1016/j.jneumeth.2009.12.009; Dien J, 2010, PSYCHOPHYSIOLOGY, V47, P170, DOI 10.1111/j.1469-8986.2009.00885.x; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Egner T, 2005, NAT NEUROSCI, V8, P1784, DOI 10.1038/nn1594; Egner T, 2005, NEUROIMAGE, V24, P539, DOI 10.1016/j.neuroimage.2004.09.007; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; FALKENSTEIN M, 1991, ELECTROEN CLIN NEURO, V78, P447, DOI 10.1016/0013-4694(91)90062-9; Falkenstein M, 2000, BIOL PSYCHOL, V51, P87, DOI 10.1016/S0301-0511(99)00031-9; Foti D, 2011, HUM BRAIN MAPP, V32, P2207, DOI 10.1002/hbm.21182; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; GEHRING WJ, 1993, PSYCHOL SCI, V4, P385, DOI 10.1111/j.1467-9280.1993.tb00586.x; Hanslmayr S, 2008, J COGNITIVE NEUROSCI, V20, P215, DOI 10.1162/jocn.2008.20020; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hester R, 2005, NEUROIMAGE, V27, P602, DOI 10.1016/j.neuroimage.2005.04.035; Hiekkanen H, 2009, BRAIN INJURY, V23, P396, DOI 10.1080/02699050902926259; Holmes AJ, 2008, ARCH GEN PSYCHIAT, V65, P179, DOI 10.1001/archgenpsychiatry.2007.19; HORN JL, 1965, PSYCHOMETRIKA, V30, P179, DOI 10.1007/BF02289447; Jung TP, 2000, CLIN NEUROPHYSIOL, V111, P1745, DOI 10.1016/S1388-2457(00)00386-2; Jung TP, 2000, PSYCHOPHYSIOLOGY, V37, P163, DOI 10.1017/S0048577200980259; Jung TP, 1998, ADV NEUR IN, V10, P894; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kerns JG, 2004, SCIENCE, V303, P1023, DOI 10.1126/science.1089910; Kim MS, 2006, PSYCHIAT CLIN NEUROS, V60, P303, DOI 10.1111/j.1440-1819.2006.01506.x; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lagerlund TD, 1997, J CLIN NEUROPHYSIOL, V14, P73, DOI 10.1097/00004691-199701000-00007; Larson MJ, 2007, J INT NEUROPSYCH SOC, V13, P961, DOI 10.1017/S1355617707071305; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; Larson MJ, 2011, INT J PSYCHOPHYSIOL, V82, P69, DOI 10.1016/j.ijpsycho.2011.02.018; Larson MJ, 2009, J INT NEUROPSYCH SOC, V15, P927, DOI 10.1017/S1355617709990701; Larson MJ, 2009, NEUROREPORT, V20, P1486, DOI 10.1097/WNR.0b013e32833283fe; Larson MJ, 2009, NEUROPSYCHOLOGY, V23, P433, DOI 10.1037/a0015723; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Luck S.J., 2005, **DROPPED REF**; Morris SE, 2006, J ABNORM PSYCHOL, V115, P239, DOI 10.1037/0021-843X.115.2.239; Nieuwenhuis S, 2001, PSYCHOPHYSIOLOGY, V38, P752, DOI 10.1017/S0048577201001111; Olvet DM, 2009, PSYCHOPHYSIOLOGY, V46, P957, DOI 10.1111/j.1469-8986.2009.00848.x; Overbeek TJM, 2005, J PSYCHOPHYSIOL, V19, P319, DOI 10.1027/0269-8803.19.4.319; Ownsworth T, 2006, J INT NEUROPSYCH SOC, V12, P54, DOI 10.1017/S135561770606005X; Ownsworth T, 2010, NEUROPSYCHOL REHABIL, V20, P59, DOI 10.1080/09602010902949223; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Pertab JL, 2009, BRAIN INJURY, V23, P498, DOI 10.1080/02699050902927984; Pontifex MB, 2009, NEUROPSYCHOLOGIA, V47, P3210, DOI 10.1016/j.neuropsychologia.2009.07.021; Rainer G, 1998, NATURE, V393, P577, DOI 10.1038/31235; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A, 1964, EXAMEN CLIN PSYCHOL; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Scheibel RS, 2009, J NEUROTRAUM, V26, P1447, DOI 10.1089/neu.2008.0736; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Speilberger CD., 1970, MANUAL STATE TRAIT A; Theriault M, 2009, BRAIN INJURY, V23, P899, DOI 10.1080/02699050903283189; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 1997, WAIS 3 ADM SCORING M; Yeung N, 2004, PSYCHOL REV, V111, P931, DOI [10.1037/0033-295X.111.4.931, 10.1037/0033-295x.111.4.931]	75	32	33	0	9	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAR	2012	18	2					323	333		10.1017/S1355617711001779			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	899DI	WOS:000300794600016	22272692				2021-06-18	
J	Novitski, J; Steele, S; Karantzoulis, S; Randolph, C				Novitski, Julia; Steele, Shelly; Karantzoulis, Stella; Randolph, Christopher			The Repeatable Battery for the Assessment of Neuropsychological Status Effort Scale	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Malingering; symptom validity testing; Assessment; Test construction	STATUS EFFORT INDEX; ALZHEIMERS-DISEASE; GERIATRIC SAMPLE; STATUS RBANS; DIGIT SPAN; TESTS	The measurement of effort is now considered to be an important component of neuropsychological assessment. In addition to stand-alone measures, built-in, or embedded measures of effort have been derived for a limited number of standard neurocognitive tests. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) is a widely used brief battery, employed as a core diagnostic tool in dementia and as a neurocognitive screening battery or tracking/outcome measure in a variety of other disorders. An effort index (EI) for the RBANS has been published previously (Silverberg, N. D., Wertheimer, J. C., Fichtenberg, N. L. 2007. An EI for the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Clinical Neuropsychology, 21 (5), 841854), but it has been reported to result in high false positive rates when applied to patients with true amnesia (e.g., Alzheimers disease). We created a new effort scale (ES) for the RBANS based on the observation of patterns of free recall and recognition performance in amnesia versus inadequate effort. The RBANS ES was validated on a sample of patients with amnestic disorders and a sample of mild traumatic brain injury participants who failed a separate measure of effort. The sensitivity and specificity of the new ES was compared with the previously published EI. Receiver-operating characteristic analyses demonstrated much better sensitivity and specificity of the ES, with a marked reduction in false positive errors. Application and limitations of the RBANS ES, including indications for its use, are discussed.	[Novitski, Julia; Steele, Shelly; Randolph, Christopher] Chicago Neuropsychol Serv, Chicago, IL 60611 USA; [Novitski, Julia] Rosalind Franklin Univ Med & Sci, Dept Psychol, N Chicago, IL USA; [Karantzoulis, Stella] NYU, Med Ctr, Dept Neurol, New York, NY 10016 USA; [Randolph, Christopher] Loyola Univ, Med Ctr, Dept Neurol, Maywood, IL 60153 USA	Randolph, C (corresponding author), Chicago Neuropsychol Serv, 1 E Erie,Suite 353, Chicago, IL 60611 USA.	crandol@lumc.edu					Armistead-Jehle P, 2011, ARCH CLIN NEUROPSYCH, V26, P592, DOI 10.1093/arclin/acr049; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Barker MD, 2010, CLIN NEUROPSYCHOL, V24, P1064, DOI 10.1080/13854046.2010.486009; BERNARD LC, 1990, J CLIN EXP NEUROPSYC, V12, P715, DOI 10.1080/01688639008401014; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Delis DC, 1987, CALIFORNIA VERBAL LE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Green, 2004, GREENS MED SYMPTOM V; Green P., 2003, GREENS WORD MEMORY T; Green P., 2008, MANUAL NONVERBAL MED; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; HODGES JR, 1993, NEUROPSYCHOLOGIA, V31, P775, DOI 10.1016/0028-3932(93)90128-M; Hook JN, 2009, ARCH CLIN NEUROPSYCH, V24, P231, DOI 10.1093/arclin/acp026; IVERSON GL, 1994, ARCH CLIN NEUROPSYCH, V9, P437, DOI 10.1016/0887-6177(94)90006-X; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Randolph C, 1998, REPEATABLE BATTERY A; Silverberg ND, 2007, CLIN NEUROPSYCHOL, V21, P841, DOI 10.1080/13854040600850958; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; WELSH K, 1991, ARCH NEUROL-CHICAGO, V48, P278, DOI 10.1001/archneur.1991.00530150046016; WELSH KA, 1992, ARCH NEUROL-CHICAGO, V49, P448, DOI 10.1001/archneur.1992.00530290030008; Wolfe PL, 2010, CLIN NEUROPSYCHOL, V24, P153, DOI 10.1080/13854040903107791	24	32	32	0	17	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAR	2012	27	2					190	195		10.1093/arclin/acr119			6	Psychology, Clinical; Psychology	Psychology	895HL	WOS:000300486900008	22277124	Bronze			2021-06-18	
J	Rosen, RC; Marx, BP; Maserejian, NN; Holowka, DW; Gates, MA; Sleeper, LA; Vasterling, JJ; Kang, HK; Keane, TM				Rosen, Raymond C.; Marx, Brian P.; Maserejian, Nancy N.; Holowka, Darren W.; Gates, Margaret A.; Sleeper, Lynn A.; Vasterling, Jennifer J.; Kang, Han K.; Keane, Terence M.			Project VALOR: design and methods of a longitudinal registry of post-traumatic stress disorder (PTSD) in combat-exposed Veterans in the Afghanistan and Iraqi military theaters of operations	INTERNATIONAL JOURNAL OF METHODS IN PSYCHIATRIC RESEARCH			English	Article						post-traumatic stress disorder (PTSD); study design; disease registry; combat-exposed Veterans; psychosocial outcomes	STRUCTURED CLINICAL INTERVIEW; TRAUMATIC BRAIN-INJURY; MENTAL-HEALTH PROBLEMS; WAR VETERANS; DEPLOYMENT; SYMPTOMS; THERAPY; ASSOCIATION; VALIDATION; PREDICTORS	Few studies have investigated the natural history of post-traumatic stress disorder (PTSD). Project VALOR (Veterans' After-discharge Longitudinal Registry) was designed as a longitudinal patient registry assessing the course of combat-related PTSD among 1600 male and female Veterans who served in Operation Enduring Freedom (OEF) in Afghanistan or Operation Iraqi Freedom (OIF). Aims of the study include investigating patterns and predictors of progression or remission of PTSD and treatment utilization. The study design was based on recommendations from the Agency for Healthcare Quality and Research for longitudinal disease registries and used a pre-specified theoretical model to select the measurement domains for data collection and interpretation of forthcoming results. The registry will include 1200 male and female Veterans with a recent diagnosis of PTSD in the Department of Veteran Affairs (VA) electronic medical record and a comparison group of 400 Veterans without a medical record-based PTSD diagnosis, to also allow for case-control analyses. Data are collected from administrative databases, electronic medical records, a self-administered questionnaire, and a semi-structured diagnostic telephone interview. Project VALOR is a unique and timely registry study that will evaluate the clinical course of PTSD, psychosocial correlates, and health outcomes in a carefully selected cohort of returning OEF/OIF Veterans. Copyright (C) 2011 John Wiley & Sons, Ltd.	[Rosen, Raymond C.; Maserejian, Nancy N.; Gates, Margaret A.; Sleeper, Lynn A.] New England Res Inst Inc, Watertown, MA 02472 USA; [Marx, Brian P.; Holowka, Darren W.; Vasterling, Jennifer J.; Keane, Terence M.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA; [Marx, Brian P.; Holowka, Darren W.; Vasterling, Jennifer J.; Keane, Terence M.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA; [Kang, Han K.] Environm Epidemiol Serv, Dept Vet Affairs, Washington, DC USA	Rosen, RC (corresponding author), New England Res Inst Inc, 9 Galen St, Watertown, MA 02472 USA.	rrosen@neriscience.com	Marx, Brian/AAK-5072-2020; Keane, Terence/I-8253-2014	Keane, Terence/0000-0002-0482-3149; Gates Kuliszewski, Margaret/0000-0002-2111-6227	US Department of DefenseUnited States Department of Defense [W81XWH-08-2-0102, W81XWH-08-2-0100]	This work was funded by the US Department of Defense Awards W81XWH-08-2-0102 and W81XWH-08-2-0100.	Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Brown AW, 2005, J NEUROTRAUM, V22, P1040, DOI 10.1089/neu.2005.22.1040; Brown R L, 2001, J Am Board Fam Pract, V14, P95; Conway PH, 2009, NEW ENGL J MED, V361, P328, DOI 10.1056/NEJMp0905631; Dreyer NA, 2009, JAMA-J AM MED ASSOC, V302, P790, DOI 10.1001/jama.2009.1092; Forbes D, 2004, J TRAUMA STRESS, V17, P249, DOI 10.1023/B:JOTS.0000029268.22161.bd; Friedman MJ, 2007, J CLIN PSYCHIAT, V68, P711, DOI 10.4088/JCP.v68n0508; Gliklich RE, 2010, AHRQ PUBLICATION, V10-EHC049; Gray MJ, 2004, ASSESSMENT, V11, P330, DOI 10.1177/1073191104269954; Hawthorne G, 2006, SOC PSYCH PSYCH EPID, V41, P164, DOI 10.1007/s00127-005-0986-y; Hoge CW, 2007, AM J PSYCHIAT, V164, P150, DOI 10.1176/appi.ajp.164.1.150; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; JENKINS CD, 1988, J CLIN EPIDEMIOL, V41, P313, DOI 10.1016/0895-4356(88)90138-2; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kessler RC, 2003, J OCCUP ENVIRON MED, V45, P156, DOI 10.1097/01.jom.0000052967.43131.51; Kessler RC, 2008, INT J METH PSYCH RES, V17, pS6, DOI 10.1002/mpr.269; King LA, 1998, J PERS SOC PSYCHOL, V74, P420, DOI 10.1037/0022-3514.74.2.420; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Kubzansky LD, 2007, ARCH GEN PSYCHIAT, V64, P109, DOI 10.1001/archpsyc.64.1.109; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; Marx BP, 2009, S ANN M INT SOC TRAU; Marx BP, 2009, ARCH GEN PSYCHIAT, V66, P996, DOI 10.1001/archgenpsychiatry.2009.109; Monson CM, 2006, J CONSULT CLIN PSYCH, V74, P898, DOI 10.1037/0022-006X.74.5.898; Ozer EJ, 2003, PSYCHOL BULL, V129, P52, DOI 10.1037//0033-2909.129.1.52; Reid MC, 1999, ARCH INTERN MED, V159, P1681, DOI 10.1001/archinte.159.15.1681; Richardson LK, 2010, AUST NZ J PSYCHIAT, V44, P4, DOI 10.3109/00048670903393597; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schnurr P P, 1999, Semin Clin Neuropsychiatry, V4, P295; Schnurr PP, 2007, JAMA-J AM MED ASSOC, V297, P820, DOI 10.1001/jama.297.8.820; Schnurr PP, 2003, ARCH GEN PSYCHIAT, V60, P481, DOI 10.1001/archpsyc.60.5.481; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Scott CK, 2006, J TRAUMA STRESS, V19, P757, DOI 10.1002/jts.20186; Seal KH, 2009, AM J PUBLIC HEALTH, V99, P1651, DOI 10.2105/AJPH.2008.150284; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Sheehan DV, 1998, J CLIN PSYCHIAT S20, V59, P4; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Vasterling JJ, 2008, J REHABIL RES DEV, V45, P347, DOI 10.1682/JRRD.2007.05.0077; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; Wolfe J, 1999, J CONSULT CLIN PSYCH, V67, P520, DOI 10.1037/0022-006X.67.4.520	44	32	32	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1049-8931	1557-0657		INT J METH PSYCH RES	Int. J. Methods Psychiatr. Res.	MAR	2012	21	1					5	16		10.1002/mpr.355			12	Psychiatry	Psychiatry	907QI	WOS:000301432000004	22095917	Green Published			2021-06-18	
J	Zhu, F; Wagner, C; Leonardi, AD; Jin, X; VandeVord, P; Chou, C; Yang, KH; King, AI				Zhu, Feng; Wagner, Christina; Leonardi, Alessandra Dal Cengio; Jin, Xin; VandeVord, Pamela; Chou, Clifford; Yang, King H.; King, Albert I.			Using a gel/plastic surrogate to study the biomechanical response of the head under air shock loading: a combined experimental and numerical investigation	BIOMECHANICS AND MODELING IN MECHANOBIOLOGY			English	Article						Blast loading; Biomechanical response; Shock tube; Fluid/solid coupling; ALE method	TRAUMATIC BRAIN-INJURY; BLAST; PRESSURE; EXPOSURE; MODEL	A combined experimental and numerical study was conducted to determine a method to elucidate the biomechanical response of a head surrogate physical model under air shock loading. In the physical experiments, a gel-filled egg-shaped skull/brain surrogate was exposed to blast overpressure in a shock tube environment, and static pressures within the shock tube and the surrogate were recorded throughout the event. A numerical model of the shock tube was developed using the Eulerian approach and validated against experimental data. An arbitrary Lagrangian-Eulerian (ALE) fluid-structure coupling algorithm was then utilized to simulate the interaction of the shock wave and the head surrogate. After model validation, a comprehensive series of parametric studies was carried out on the egg-shaped surrogate FE model to assess the effect of several key factors, such as the elastic modulus of the shell, bulk modulus of the core, head orientation, and internal sensor location, on pressure and strain responses. Results indicate that increasing the elastic modulus of the shell within the range simulated in this study led to considerable rise of the overpressures. Varying the bulk modulus of the core from 0.5 to 2.0 GPa, the overpressure had an increase of 7.2%. The curvature of the surface facing the shock wave significantly affected both the peak positive and negative pressures. Simulations of the head surrogate with the blunt end facing the advancing shock front had a higher pressure compared to the simulations with the pointed end facing the shock front. The influence of an opening (possibly mimicking anatomical apertures) on the peak pressures was evaluated using a surrogate head with a hole on the shell of the blunt end. It was revealed that the presence of the opening had little influence on the positive pressures but could affect the negative pressure evidently.	[Zhu, Feng; Wagner, Christina; Leonardi, Alessandra Dal Cengio; Jin, Xin; VandeVord, Pamela; Chou, Clifford; Yang, King H.; King, Albert I.] Wayne State Univ, Ctr Bioengn, Detroit, MI 48201 USA	Zhu, F (corresponding author), Wayne State Univ, Ctr Bioengn, Detroit, MI 48201 USA.	fengzhume@gmail.com	Jin, Xin/J-6476-2015		Small Business Innovation Research (SBIR)United States Department of Agriculture (USDA) [W81XWH-09-C-0068]; Bioengineering Center, Wayne State University	This research was partially supported through Small Business Innovation Research (SBIR) Contract # W81XWH-09-C-0068, and partially supported by the Bioengineering Center, Wayne State University. The financial supports are gratefully acknowledged.	[Anonymous], 2007, LS DYNA KEYW US MAN; Anzelius A, 1943, ACTA PATHOL MICROB S, V48, P153; Bauman RA, 2009, J NEUROTRAUM, V26, P841, DOI 10.1089/neu.2009-0898; Bowen IG, 1968, 2133 LOV FDN DEF AT; Bradshaw DRS, 2001, P 17 INT TECHN C ENH; Brands DWA, 1999, 43 STAPP CAR CRASH C, P350; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chafi MS, 2008, PROCEEDINGS OF THE ASME INTERNATIONAL MECHANICAL ENGINEERING CONGRESS AND EXPOSITION 2007, VOL 2, P211; Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; ConWep, 1991, CONV WEAP EFF PROGR; Courtney AC, 2009, MED HYPOTHESES, V72, P76, DOI 10.1016/j.mehy.2008.08.015; Cullis I G, 2001, J R Army Med Corps, V147, P16; Dal Cengio Leonardi A, 2009, 2 JOINT S INT NATL N; DePalma RG, 2005, NEW ENGL J MED, V37, P664; Gaetani P, 2008, J FLUID MECH, V602, P267, DOI 10.1017/S0022112008000815; Hallquist J.O., 1998, LS DYNA THEORETICAL; Ivarsson J, 2002, J BIOMECH ENG-T ASME, V124, P422, DOI 10.1115/1.1485752; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Long JB, 2009, J NEUROTRAUM, V26, P1; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; Meyers MA., 1994, DYNAMIC BEHAV MAT; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Moss W.C., 2009, J ACOUST SOC AM, V125, P2650; Parnaik Yednesh, 2004, Stapp Car Crash J, V48, P259; RUAN JS, 1994, J BIOMECH ENG-T ASME, V116, P44, DOI 10.1115/1.2895703; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Saljo A, 2008, J NEUROTRAUM, V25, P1397, DOI 10.1089/neu.2008.0602; Sotudehchafi M, 2007, PROCEEDING OF THE ASME SUMMER BIOENGINEERING CONFERENCE - 2007, P349; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Teland, 2010, J ACOUST SOC AM, V127, P1790; Teland, 2010, POMA, V9; Wightman JM, 2001, ANN EMERG MED, V37, P664, DOI 10.1067/mem.2001.114906; Zhang JY, 2007, J BIOMECH, V40, P2341, DOI 10.1016/j.jbiomech.2006.10.021; Zhang Jiangyue, 2009, Biomed Sci Instrum, V45, P119; Zhang Jiangyue, 2008, Biomed Sci Instrum, V44, P129; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhu F, 2009, STRUCT ENG MECH, V32, P351, DOI 10.12989/sem.2009.32.2.351	40	32	32	0	15	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1617-7959	1617-7940		BIOMECH MODEL MECHAN	Biomech. Model. Mechanobiol.	MAR	2012	11	3-4					341	353		10.1007/s10237-011-0314-2			13	Biophysics; Engineering, Biomedical	Biophysics; Engineering	895SZ	WOS:000300518000005	21590345				2021-06-18	
J	Lyvers, M; Onuoha, R; Thorberg, FA; Samios, C				Lyvers, Michael; Onuoha, Roy; Thorberg, Fred Arne; Samios, Christina			Alexithymia in relation to parental alcoholism, everyday frontal lobe functioning and alcohol consumption in a non-clinical sample	ADDICTIVE BEHAVIORS			English	Article						Alcohol; Alexithymia; Frontal lobe	DISORDERS IDENTIFICATION TEST; TRAUMATIC BRAIN-INJURY; FACTORIAL VALIDITY; GENERAL-POPULATION; MAINTAINING ABSTINENCE; NEGATIVE FACTOR; DRUG-USE; SCALE; PSYCHOPATHOLOGY; RELIABILITY	Background: Recent studies have indicated that 45-67% of those in treatment for alcohol use disorders suffer from alexithymia, a multifaceted personality trait characterized by difficulties identifying and describing emotions and an externally oriented cognitive style. The high reported prevalence rates of alexithymia among those with alcohol dependence led to speculation that alexithymia is a personality dimension that may predispose to risky or problematic alcohol use. Methods: This notion was examined in 314 adult volunteers (54% female) aged 18-45 years (M = 27.6 years), all of whom reported at least occasional alcohol consumption, who completed online surveys assessing alexithymia (Toronto Alexithymia Scale, or TAS-20), parental alcoholism (Children of Alcoholics Screening Test, or CAST), everyday signs of frontal lobe dysfunction (Frontal Systems Behavior Scale, or FrSBe) and risky alcohol use (Alcohol Use Disorders Identification Test, or AUDIT). Results: TAS-20 scores were positively correlated with the index of parental alcoholism CAST, index of frontal lobe dysfunction FrSBe and measure of alcohol-related problems AUDIT. Chi-square test showed an association between TAS-20-defined alexithymia and being the offspring of an alcoholic parent as defined by CAST. Regression analysis showed that frontal lobe dysfunction (FrSBe) mediated the relationship between alexithymia (TAS-20 total score) and risky alcohol use (AUDIT). Conclusions: The findings suggest that alexithymia is related to deficiencies in frontal lobe functioning that may reflect a heritable predisposition to alcohol problems. (C) 2011 Elsevier Ltd. All rights reserved.	[Lyvers, Michael; Onuoha, Roy; Samios, Christina] Bond Univ, Dept Psychol, Gold Coast, Qld 4229, Australia; [Thorberg, Fred Arne] Queensland Univ Technol, Inst Hlth & Biomed Innovation, Brisbane, Qld 4059, Australia; [Thorberg, Fred Arne] Univ Queensland, Ctr Youth Substance Abuse Res, Fac Hlth, Brisbane, Qld 4072, Australia	Lyvers, M (corresponding author), Bond Univ, Dept Psychol, Gold Coast, Qld 4229, Australia.	mlyvers@bond.edu.au	Rodriguez, Lymarie/J-6382-2015; Samios, Christina/AAF-7603-2021	Samios, Christina/0000-0003-4661-8343; Thorberg, Fred Arne/0000-0002-8835-7631; Lyvers, Michael/0000-0002-8355-3182	internal Bond University Humanities & Social Sciences Research Grant	This study was funded by an internal Bond University Humanities & Social Sciences Research Grant. The funding sources had no further role in the study.	Australian Bureau of Statistics, 2006, APP CONS ALC AUSTR 2; Babor T.F., 1992, GUIDELINES USE PRIMA; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P33, DOI 10.1016/0022-3999(94)90006-X; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; Bar-On R., 2000, B ON EMOTIONAL QUOTI; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Becerra R, 2002, BRAIN INJURY, V16, P633, DOI 10.1080/02699050110119817; Bergman H, 2002, ALCOHOL ALCOHOLISM, V37, P245, DOI 10.1093/alcalc/37.3.245; Berthoz S, 2002, AM J PSYCHIAT, V159, P961, DOI 10.1176/appi.ajp.159.6.961; Chrikritzhs T., 1999, NATL ALCOHOL INDICAT; CLONINGER CR, 1987, SCIENCE, V236, P410, DOI 10.1126/science.2882604; Collins DJ, 2008, COSTS TOBACCO ALCOHO; FINN PR, 1987, PSYCHOTHER PSYCHOSOM, V47, P18, DOI 10.1159/000287993; Franz M, 2008, SOC PSYCH PSYCH EPID, V43, P54, DOI 10.1007/s00127-007-0265-1; Gawin F., 2005, J PSYCHOSOM RES, V59, P85; Grabe HJ, 2006, PSYCHOTHER PSYCHOSOM, V75, P312, DOI 10.1159/000093954; Gunzelmann T, 2002, COMPR PSYCHIAT, V43, P74, DOI 10.1053/comp.2002.29855; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P62, DOI 10.1016/j.neuropsychologia.2005.04.011; HILL SY, 1992, J AM ACAD CHILD PSY, V31, P1024, DOI 10.1097/00004583-199211000-00004; Honkalampi K, 2007, PSYCHOTHER PSYCHOSOM, V76, P312, DOI 10.1159/000104709; Iwamoto D.K., 2007, PSYCHOL MEN MASCULIN, V8, P25, DOI [10.1037/1524-9220.8.1.25, DOI 10.1037/1524-9220.8.1.25]; Jones JW., 1983, CHILDREN ALCOHOLICS; Jorgensen MM, 2007, PSYCHOTHER PSYCHOSOM, V76, P369, DOI 10.1159/000107565; Kane TA, 2004, PERS INDIV DIFFER, V36, P83, DOI 10.1016/S0191-8869(03)00070-9; Karlsson H, 2008, BRIT J PSYCHIAT, V192, P32, DOI 10.1192/bjp.bp.106.034728; KAUHANEN J, 1992, BEHAV MED, V18, P121, DOI 10.1080/08964289.1992.9936962; Koponen S, 2005, PSYCHOSOM MED, V67, P807, DOI 10.1097/01.psy.0000181278.92249.e5; Lane RD, 1998, COMPR PSYCHIAT, V39, P377, DOI 10.1016/S0010-440X(98)90051-7; Larson J. H., 1998, ALCOHOLISM TREATMENT, V16, P59; Loas G, 1997, COMPR PSYCHIAT, V38, P296, DOI 10.1016/S0010-440X(97)90063-8; Lowinson JH, 2005, SUBSTANCE ABUSE COMP; Lumley M. A., 2008, EMOTION REGULATION C, P43; Lumley MA, 2000, COMPR PSYCHIAT, V41, P352, DOI 10.1053/comp.2000.9014; Lyvers M, 2000, EXP CLIN PSYCHOPHARM, V8, P225, DOI 10.1037/1064-1297.8.2.225; Lyvers M, 2010, PERS INDIV DIFFER, V48, P332, DOI 10.1016/j.paid.2009.10.030; Lyvers M, 2009, ADDICT RES THEORY, V17, P668, DOI 10.3109/16066350802404158; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Masterman DL, 1997, J PSYCHOPHARMACOL, V11, P107, DOI 10.1177/026988119701100203; Mattila AK, 2006, J PSYCHOSOM RES, V61, P629, DOI 10.1016/j.jpsychores.2006.04.013; Moriguchi Y, 2009, HUM BRAIN MAPP, V30, P2063, DOI 10.1002/hbm.20653; Nemiah JC, 1976, MODERN TRENDS PSYCHO, Vthird, P430; Pal HR, 2004, J STUD ALCOHOL, V65, P794, DOI 10.15288/jsa.2004.65.794; Parker JDA, 2003, J PSYCHOSOM RES, V55, P269, DOI 10.1016/S0022-3999(02)00578-0; PARKER JDA, 1993, EUR J PERSONALITY, V7, P221, DOI 10.1002/per.2410070403; Passingham RE, 1993, FRONTAL LOBES VOLUNT; Petry NM, 1998, ADDICTION, V93, P729, DOI 10.1046/j.1360-0443.1998.9357298.x; Pilat J. M., 1985, ALCOHOL HEALTH RES W, V9, P27; Polce-Lynch M, 1998, SEX ROLES, V38, P1025, DOI 10.1023/A:1018830727244; REICH W, 1988, BRIT J ADDICT, V83, P831; Shields AL, 2004, SUBST USE MISUSE, V39, P1161, DOI 10.1081/JA-120038034; Spinella M, 2003, ADDICT BIOL, V8, P67, DOI 10.1080/1355621031000069909; Spinella M, 2007, J GEN PSYCHOL, V134, P101, DOI 10.3200/GENP.134.1.101-111; Steinhausen H. C., 1986, ADV CLIN CHILD PSYCH, P217; Stout JC, 2003, ASSESSMENT, V10, P79, DOI 10.1177/1073191102250339; STUSS DT, 1984, PSYCHOL BULL, V95, P3, DOI 10.1037/0033-2909.95.1.3; Tabachnick BG, 2007, USING MULTIVARIATE S; Taylor GJ, 2003, J PSYCHOSOM RES, V55, P277, DOI 10.1016/S0022-3999(02)00601-3; Thorberg FA, 2011, EUR PSYCHIAT, V26, P187, DOI 10.1016/j.eurpsy.2010.09.010; Thorberg FA, 2011, DRUG ALCOHOL DEPEN, V116, P238, DOI 10.1016/j.drugalcdep.2010.11.015; Thorberg FA, 2011, ADDICT BEHAV, V36, P427, DOI 10.1016/j.addbeh.2010.12.016; Thorberg FA, 2010, PERS INDIV DIFFER, V49, P119, DOI 10.1016/j.paid.2010.03.018; Thorberg FA, 2009, ADDICT BEHAV, V34, P237, DOI 10.1016/j.addbeh.2008.10.016; Verdejo-Garcia A, 2006, ADDICT BEHAV, V31, P1373, DOI 10.1016/j.addbeh.2005.11.003; Walter NT, 2011, PSYCHOSOM MED, V73, P23, DOI 10.1097/PSY.0b013e31820037c1; Wearden AJ, 2005, J PSYCHOSOM RES, V58, P279, DOI 10.1016/j.jpsychores.2004.09.010; Wester SR, 2002, COUNS PSYCHOL, V30, P630, DOI 10.1177/00100002030004008; Wilkinson D. A., 1991, SELF CONTROL ADDICTI, P107; Williams C, 2010, J CLIN EXP NEUROPSYC, V32, P259, DOI 10.1080/13803390902976940; Williams KR, 2001, BRAIN INJURY, V15, P349, DOI 10.1080/026990501750111319; ZIOLKOWSKI M, 1995, PSYCHOTHER PSYCHOSOM, V63, P169	70	32	32	1	22	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4603			ADDICT BEHAV	Addict. Behav.	FEB	2012	37	2					205	210		10.1016/j.addbeh.2011.10.012			6	Psychology, Clinical; Substance Abuse	Psychology; Substance Abuse	873VM	WOS:000298911100009	22075204				2021-06-18	
J	Lei, ZG; Deng, P; Li, JQ; Xu, ZC				Lei, Zhigang; Deng, Ping; Li, Jinqing; Xu, Zao C.			Alterations of A-Type Potassium Channels in Hippocampal Neurons after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						controlled cortical impact; hyperexcitability; I-A; Kv4.2; Kv4.3; post-traumatic epilepsy	TEMPORAL-LOBE EPILEPSY; CA1 PYRAMIDAL NEURONS; KV4.2 KNOCKOUT MICE; CLOSED-HEAD INJURY; K+ CHANNELS; POSTTRAUMATIC EPILEPSY; RAT-BRAIN; DIFFERENTIAL EXPRESSION; SUBTHRESHOLD POTENTIALS; HYPEREXCITABILITY	Traumatic brain injury (TBI) is associated with cognitive deficits, memory impairment, and epilepsy. Previous studies have reported neuronal loss and neuronal hyperexcitability in the post-traumatic hippocampus. A-type K+ currents (I-A) play a critical role in modulating the intrinsic membrane excitability of hippocampal neurons. The disruption of I-A is reportedly linked to hippocampal dysfunction. The present study investigates the changes of I-A in the hippocampus after TBI. TBI in rats was induced by controlled cortical impact. The impact induced a reproducible lesion in the cortex and an obvious neuronal death in the ipsilateral hippocampus CA3 region. At one week after TBI, immunohiistochemical staining and Western blotting showed that the expression of I-A channel subunit Kv4.2 was markedly decreased in the ipsilateral hippocampus, but remained unchanged in the contralateral hippocampus. Meanwhile, electrophysiological recording showed that I-A currents in ipsilateral CA1 pyramidal neurons were significantly reduced, which was associated with an increased neuronal excitability. Furthermore, there was an increased sensitivity to bicuculline-induced seizures in TBI rats. At 8 weeks after TBI, immunohistochemical staining and electrophysiological recording indicated that I-A returned to control levels. These findings suggest that TBI causes a transient downregulation of I-A in hippocampal CA1 neurons, which might be associated with the hyperexcitability in the post-traumatic hippocampus, and in turn leads to seizures and epilepsy.	[Lei, Zhigang; Deng, Ping; Li, Jinqing; Xu, Zao C.] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA	Xu, ZC (corresponding author), Indiana Univ Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS507, Indianapolis, IN 46202 USA.	zcxu@iupui.edu			National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS071238]; American Heart Association (AHA)American Heart Association [10GRNT4500000]; Indiana Spinal Cord and Brain Injury Research Fund [ISDH/A70-0-079212]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [U24NS050606]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U24NS050606, R21NS071238] Funding Source: NIH RePORTER	This work was supported by grants from National Institute of Neurological Disorders and Stroke (NINDS) NS071238, American Heart Association (AHA) 10GRNT4500000, and Indiana Spinal Cord and Brain Injury Research Fund ISDH/A70-0-079212.; The monoclonal antibody Kv4.3 was obtained from the University of California, Davis/National Institutes of Health (NTH) NeuroMab,Facility, supported by NIH grant U24NS050606 and maintained by the Department of Neurobiology, Physiology and Behavior, College of Biological Sciences, University of California, Davis, CA 95616.	Agrawal A, 2006, CLIN NEUROL NEUROSUR, V108, P433, DOI 10.1016/j.clineuro.2005.09.001; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Andrasfalvy BK, 2008, J PHYSIOL-LONDON, V586, P3881, DOI 10.1113/jphysiol.2008.154336; Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Barnwell LFS, 2009, EPILEPSIA, V50, P1741, DOI 10.1111/j.1528-1167.2009.02086.x; Bernard C, 2004, SCIENCE, V305, P532, DOI 10.1126/science.1097065; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Cai X, 2004, NEURON, V44, P351, DOI 10.1016/j.neuron.2004.09.026; Chen XX, 2006, J NEUROSCI, V26, P12143, DOI 10.1523/JNEUROSCI.2667-06.2006; D'Ambrosio R, 1999, J NEUROSCI, V19, P8152; D'Ambrosio R, 2004, CURR OPIN NEUROL, V17, P731, DOI 10.1097/00019052-200412000-00014; D'Ambrosio R, 2009, BRAIN, V132, P2805, DOI 10.1093/brain/awp217; Deng P, 2004, DEV BRAIN RES, V153, P97, DOI 10.1016/j.devbrainres.2004.08.001; Deng P, 2009, J NEUROPHYSIOL, V102, P2453, DOI 10.1152/jn.00325.2009; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Francis J, 1997, NEUROSCI LETT, V232, P91, DOI 10.1016/S0304-3940(97)00593-4; Frick A, 2004, NAT NEUROSCI, V7, P126, DOI 10.1038/nn1178; GANDOLFO G, 1989, BRAIN RES, V495, P189, DOI 10.1016/0006-8993(89)91236-5; Golarai G, 2001, J NEUROSCI, V21, P8523; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Griesemer D, 2007, J NEUROTRAUM, V24, P1823, DOI 10.1089/neu.2006.0237; Guo WN, 2005, CIRC RES, V97, P1342, DOI 10.1161/01.RES.0000196559.63223.aa; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hudak AM, 2004, J HEAD TRAUMA REHAB, V19, P290, DOI 10.1097/00001199-200407000-00003; Jerng HH, 2004, MOL CELL NEUROSCI, V27, P343, DOI 10.1016/j.mcn.2004.06.011; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; Kim J, 2005, J PHYSIOL-LONDON, V569, P41, DOI 10.1113/jphysiol.2005.095042; Lei Z, 2010, NEUROSCIENCE, V165, P350, DOI 10.1016/j.neuroscience.2009.10.041; Lei ZG, 2008, J NEUROCHEM, V106, P182, DOI 10.1111/j.1471-4159.2008.05356.x; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lugo JN, 2008, J NEUROCHEM, V106, P1929, DOI 10.1111/j.1471-4159.2008.05508.x; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Monaghan MM, 2008, NEUROSCIENCE, V156, P550, DOI 10.1016/j.neuroscience.2008.07.057; Nadal MS, 2003, NEURON, V37, P449, DOI 10.1016/S0896-6273(02)01185-6; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Santhakumar V, 2003, J NEUROSCI, V23, P5865; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Schindler CJ, 2004, PHARMACOL BIOCHEM BE, V77, P509, DOI 10.1016/j.pbb.2003.12.012; Serodio P, 1998, J NEUROPHYSIOL, V79, P1081; SERODIO P, 1994, J NEUROPHYSIOL, V72, P1516; Serodio P, 1996, J NEUROPHYSIOL, V75, P2174; Singh B, 2006, NEUROBIOL DIS, V24, P245, DOI 10.1016/j.nbd.2006.07.001; TSAUR ML, 1992, NEURON, V8, P1055, DOI 10.1016/0896-6273(92)90127-Y; vandenPol AN, 1996, J NEUROSCI, V16, P4283	51	32	32	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					235	245		10.1089/neu.2010.1537			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300004	21895522	Green Published			2021-06-18	
J	Thau-Zuchman, O; Shohami, E; Alexandrovich, AG; Trembovler, V; Leker, RR				Thau-Zuchman, Orli; Shohami, Esther; Alexandrovich, Alexander G.; Trembovler, Victoria; Leker, Ronen R.			The Anti-Inflammatory Drug Carprofen Improves Long-Term Outcome and Induces Gliogenesis after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						angiogenesis; neurogenesis; neuroprotection; vascular endothelial growth factor; traumatic brain injury	CLOSED-HEAD INJURY; ENDOTHELIAL GROWTH-FACTOR; NEUROTROPHIC FACTORS; CEREBRAL-ISCHEMIA; CELL-DEATH; STEM-CELLS; CYCLOOXYGENASE-2; MICE; NEUROGENESIS; ACTIVATION	Traumatic brain injury (TBI) initiates acute and chronic inflammatory processes involving cyclooxygenase-2 (COX-2), which may have detrimental effects on outcome and especially on brain regeneration. Therefore we aimed to study whether carprofen, a COX-2 inhibitor, would improve outcome and increase neurogenesis after TBI. TBI was induced in Sabra mice that were then treated with vehicle or carprofen for 7 days. Functional outcome was evaluated with the Neurological Severity Score (NSS).Cytokine levels were assessed 4 h post-TBI and water content was measured 24 h post TBI. Mice were given BrdU to label newborn cells for 10 days. The animals were killed 90 days post-TBI and the lesion size as well as newborn cell fate were assessed. Carprofen significantly reduced lesion size (p=0.002), decreased water content in the lesioned cortex (p=0.03), reduced the number of microglia in the lesioned cortex (p<0.0001), and lowered the levels of proinflammatory cytokines (IL-1 beta, p=0.03; IL-6, p=0.02). Carprofen led to significantly larger improvements in functional outcome (p <= 0.008) which were durable over 90 days. Carprofen also induced a threefold increase in the proliferation of new cells in the pen-lesion area ( p <= 0.002), but newborn cells differentiated mainly into glia in both groups. Carprofen is neuroprotective and induces cell proliferation and gliogenesis after TBI. Treatment with carprofen is consistently associated with better functional outcome. Our results imply that anti-inflammatory drugs may represent novel therapeutic options for TBI.	[Thau-Zuchman, Orli; Leker, Ronen R.] Hadassah Hebrew Univ, Med Ctr, Dept Neurol, Jerusalem, Israel; [Thau-Zuchman, Orli; Leker, Ronen R.] Hadassah Hebrew Univ, Med Ctr, Peritz & Chantal Scheinberg Cerebrovasc Res Lab, Jerusalem, Israel; [Thau-Zuchman, Orli; Shohami, Esther; Alexandrovich, Alexander G.; Trembovler, Victoria] Hebrew Univ Jerusalem, Sch Pharm, Inst Drug Res IDR, IL-91905 Jerusalem, Israel	Leker, RR (corresponding author), Hadassah Univ Hosp, Dept Neurol, POB 12000, IL-91120 Jerusalem, Israel.	leker@cc.huji.ac.il	Leker, Ronen/ABC-6096-2020	Leker, Ronen/0000-0003-4794-0334; Thau-Zuchman, Orli/0000-0003-0403-7962	Sol Irwin Juni Trust; Peritz and Chantal Scheinberg Cerebrovascular Research Fund; United States Agency for International DevelopmentUnited States Agency for International Development (USAID)	This study was supported by the Sol Irwin Juni Trust Fund and by the Peritz and Chantal Scheinberg Cerebrovascular Research Fund. E. Shohami is the incumbent of the Dr. Leon and Dr. Mina Deutsch Chair in Psychopharmacology at The Hebrew University, and a member of the Brettler Center for Research in Molecular Pharmacology and Therapeutics, The Hebrew University. This research was also supported in part by a grant from the United States Agency for International Development's American Schools and the Hospitals Abroad (ASHA) Program for the procurement of the confocal microscope.	Ben-Hur T, 2008, J NEUROL SCI, V265, P102, DOI 10.1016/j.jns.2007.05.007; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Brusselmans K, 2005, J BIOL CHEM, V280, P3493, DOI 10.1074/jbc.M406613200; Cacci E, 2008, GLIA, V56, P412, DOI 10.1002/glia.20616; Cernak I, 2001, CLIN EXP PHARMACOL P, V28, P922, DOI 10.1046/j.1440-1681.2001.03549.x; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Dash PK, 2000, J NEUROTRAUM, V17, P69, DOI 10.1089/neu.2000.17.69; Gopez JJ, 2005, NEUROSURGERY, V56, P590, DOI 10.1227/01.NEU.0000154060.14900.8F; Hakan T, 2010, NEUROL RES, V32, P629, DOI 10.1179/016164109X12464612122731; Hoehn BD, 2005, STROKE, V36, P2718, DOI 10.1161/01.STR.0000190020.30282.cc; Kelsen J, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-31; Kelso ML, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-108; Kluska MM, 2005, NEUROSCIENCE, V135, P723, DOI 10.1016/j.neuroscience.2005.06.082; Kunz T, 2002, J NEUROTRAUM, V19, P1051, DOI 10.1089/089771502760341965; Kunz T, 2006, RESTOR NEUROL NEUROS, V24, P55; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Morgan SC, 2004, J NEUROCHEM, V90, P89, DOI 10.1111/j.1471-4159.2004.02461.x; Sasaki T, 2003, J NEUROSCI RES, V72, P461, DOI 10.1002/jnr.10595; Schwartz M, 2000, ANN NY ACAD SCI, V917, P341; SHOHAMI E, 1987, J CEREBR BLOOD F MET, V7, P58, DOI 10.1038/jcbfm.1987.8; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stoll G, 2002, ADV EXP MED BIOL, V513, P87; Strauss KI, 2000, J NEUROTRAUM, V17, P695, DOI 10.1089/089771500415436; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Thau-Zuchman O, 2010, J CEREBR BLOOD F MET, V30, P1008, DOI 10.1038/jcbfm.2009.271; Tonchev AB, 2007, NEUROSCIENCE, V144, P1425, DOI 10.1016/j.neuroscience.2006.10.052; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Zhang Feng, 2009, P187, DOI 10.1007/978-1-60327-185-1_15	32	32	32	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 20	2012	29	2					375	384		10.1089/neu.2010.1673			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	885SO	WOS:000299801300016	21561314				2021-06-18	
J	Lopez, V; Galano, GJ; Black, CM; Gupta, AT; James, DE; Kelleher, KM; Allen, AA				Lopez, Victor, Jr.; Galano, Gregory J.; Black, Christopher M.; Gupta, Arun T.; James, Douglas E.; Kelleher, Kristen M.; Allen, Answorth A.			Profile of an American Amateur Rugby Union Sevens Series	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						rugby sevens; rugby union; sports injuries; epidemiology	DATA-COLLECTION PROCEDURES; CONSENSUS STATEMENT; INJURY DEFINITIONS; EPIDEMIOLOGY; PLAYERS; JUNIOR	Background: Rugby union will enter the Olympic arena as Rugby Sevens in 2016. Purpose: To investigate the injury rate, injury type, and nature of injuries sustained in an amateur American rugby union sevens tournament series. Study Design: Descriptive epidemiology study. Methods: The rate, demographics, and characteristics of injury were evaluated in 1536 rugby union sevens players, from 128 sides, competing in 4 amateur 1-day tournaments in a USA Rugby local area rugby union. Results: Forty-eight injuries occurred over 4 tournaments, for an injury rate of 55.4 injuries per 1000 playing hours. Head and neck injuries were most common (33.3% of injuries), followed by upper extremity (31.3%), trunk (18.8%), lower extremity (14.6%), and physiologic injuries (2.1%). The most common type of injury was ligament sprain (25.0%); followed by concussion (14.6%), hematoma/ contusion (12.5%), muscle strain (10.4%), and abrasion (8.3%). Tackling was the most common mechanism of injury (74.5%). Males were injured at a significantly higher rate than females (RR, 7.5, P < .01), but no significant difference was observed based on player position (P = .08). Conclusion: Injuries are common among American amateur rugby athletes, with a substantial proportion involving the head and neck region. Clinical Relevance: Understanding injury patterns in an American rugby union will be important for formulating future injury prevention, assessment, and treatment protocols.	[Lopez, Victor, Jr.; Galano, Gregory J.; Black, Christopher M.; Gupta, Arun T.; James, Douglas E.; Kelleher, Kristen M.; Allen, Answorth A.] Hosp Special Surg, New York, NY 10021 USA	Allen, AA (corresponding author), Hosp Special Surg, 535 E 70th St, New York, NY 10021 USA.	allena@hss.edu		Black, Christopher/0000-0003-2934-108X			Bathgate A, 2002, BRIT J SPORT MED, V36, P265, DOI 10.1136/bjsm.36.4.265; Bird YN, 1998, BRIT J SPORT MED, V32, P319, DOI 10.1136/bjsm.32.4.319; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Brooks JHM, 2005, BRIT J SPORT MED, V39, P767, DOI 10.1136/bjsm.2005.018408; Collins CL, 2008, ARCH PEDIAT ADOL MED, V162, P49, DOI 10.1001/archpediatrics.2007.1; Fuller CW, 2008, BRIT J SPORT MED, V42, P452, DOI 10.1136/bjsm.2008.047035; Fuller CW, 2007, CLIN J SPORT MED, V17, P177, DOI 10.1097/JSM.0b013e31803220b3; Fuller CW, 2007, BRIT J SPORT MED, V41, P328, DOI 10.1136/bjsm.2006.033282; Fuller CW, 2010, CLIN J SPORT MED, V20, P179, DOI 10.1097/JSM.0b013e3181df1eea; Fuller CW, 2010, J SCI MED SPORT, V13, P36, DOI 10.1016/j.jsams.2008.09.008; Gabbett TJ, 2008, J SCI MED SPORT, V11, P323, DOI 10.1016/j.jsams.2007.06.003; Gabbett TJ, 2004, SPORTS MED, V34, P849, DOI 10.2165/00007256-200434120-00004; Gabbett TJ, 2002, BRIT J SPORT MED, V36, P23, DOI 10.1136/bjsm.36.1.23; Gabbett TJ, 2003, BRIT J SPORT MED, V37, P36, DOI 10.1136/bjsm.37.1.36; Gabbett TJ, 2003, BRIT J SPORT MED, V37, P43; Haseler CM, 2010, BRIT J SPORT MED, V44, P1093, DOI 10.1136/bjsm.2010.074021; Headey J, 2007, AM J SPORT MED, V35, P1537, DOI 10.1177/0363546507300691; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; Kerr HA, 2008, BRIT J SPORT MED, V42, P595, DOI 10.1136/bjsm.2007.035881; Kjaer M., 2003, TXB SPORTS MED BASIC; Schick DM, 2008, BRIT J SPORT MED, V42, P447, DOI 10.1136/bjsm.2008.046672; Targett SGR, 1998, CLIN J SPORT MED, V8, P280, DOI 10.1097/00042752-199810000-00005	22	32	33	1	21	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JAN	2012	40	1					179	184		10.1177/0363546511427124			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	873CA	WOS:000298857200023	22102102				2021-06-18	
J	Togher, L; Power, E; Rietdijk, R; McDonald, S; Tate, R				Togher, Leanne; Power, Emma; Rietdijk, Rachael; McDonald, Skye; Tate, Robyn			An exploration of participant experience of a communication training program for people with traumatic brain injury and their communication partners	DISABILITY AND REHABILITATION			English	Article						Communication; communication partners; qualitative research; semi-structured interviews; training; traumatic brain injury	DISCOURSE; APHASIA; SKILLS; ADULTS; INTERVENTIONS; EFFICACY; TALK	Purpose: To investigate the experiences of participants who attended communication training programs for people with traumatic brain injury (TBI) and their everyday communication partners (CP) as part of a non-randomised controlled trial. Method: The participants were people with TBI and their CP, who were family members or carers of the people with TBI. Twenty-six participants (13 participants with TBI and 13 CP) completed the JOINT program, which involved participants with TBI and CP attending the program together. Fourteen participants with TBI completed the TBI SOLO training program, which did not involve the participation of a CP. Semi-structured videotaped interviews were completed by all participants at the end of the training. Using a six-step generic analysis procedure, data were categorised into topics and then subtopics to identify conceptually discrete units. Results: Participants described improvements in communication skills, the impact of improved communication skills, valuable components of the programs and components that needed changes. Conclusion: The accounts of participants provided additional evidence for the effectiveness of the training programs, assisted with identifying helpful components of the training and demonstrated the usefulness of a qualitative research methodology as part of evaluating the outcomes of the clinical trial.	[Tate, Robyn] Univ Sydney, Fac Hlth Sci, No Clin Sch, Rehabil Studies Unit, Sydney, NSW 2006, Australia; [McDonald, Skye] Univ New S Wales, Sch Psychol, Sydney, NSW, Australia; [Tate, Robyn] Royal Rehabil Ctr Sydney, Sydney, NSW, Australia	Togher, L (corresponding author), Univ Sydney, Fac Hlth Sci, POB 170, Lidcombe, NSW 1825, Australia.	leanne.togher@sydney.edu.au	Rietdijk, Rachael/J-6573-2012; Power, Emma/A-9263-2015; McDonald, Skye/G-4118-2014; Togher, Leanne/AAC-7083-2019	Rietdijk, Rachael/0000-0003-4343-4039; Power, Emma/0000-0002-2638-0406; McDonald, Skye/0000-0003-0723-6094; Togher, Leanne/0000-0002-4518-6748	National Health and Medical Research Council (NHMRC)National Health and Medical Research Council of Australia	This study was supported by a National Health and Medical Research Council (NH&MRC) project grant.	Bellon ML, 2006, BRAIN INJURY, V20, P1069, DOI 10.1080/02699050600909813; Blais MC, 2007, BRAIN INJURY, V21, P357, DOI 10.1080/02699050701311075; Braverman SE, 1999, BRAIN INJURY, V13, P405; Broom A, 2009, INT J SOC RES METHOD, V12, P51, DOI 10.1080/13645570701606028; Burgio LD, 2001, GERONTOLOGIST, V41, P449, DOI 10.1093/geront/41.4.449; Carlsson E, 2007, QUAL HEALTH RES, V17, P1361, DOI 10.1177/1049732307306926; Craig P, 2008, BRIT MED J, V337, DOI 10.1136/bmj.a1655; Creswell J., 2003, RES DESIGN QUALITATI, V2nd edn; Dahlberg CA, 2007, ARCH PHYS MED REHAB, V88, P1561, DOI 10.1016/j.apmr.2007.07.033; Elman RJ, 1999, J SPEECH LANG HEAR R, V42, P411, DOI 10.1044/jslhr.4202.411; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Glaser B. G., 1967, DISCOVERY GROUNDED T; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; GOLD RL, 1958, SOC FORCES, V36, P217, DOI 10.2307/2573808; Johnson JC, 2006, FIELD METHOD, V18, P111, DOI 10.1177/1525822X05285928; Kagan A, 2001, J SPEECH LANG HEAR R, V44, P624, DOI 10.1044/1092-4388(2001/051); Kovarsky D, 2008, INT J LANG COMM DIS, V43, P47, DOI 10.1080/13682820701698036; Kovarsky D, 2007, TOP LANG DISORD, V27, P50, DOI 10.1097/00011363-200701000-00006; Lampe LA, 2009, AUST NZ J PSYCHIAT, V43, P887, DOI 10.1080/00048670903179111; Lewin S, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b3496; *MAA, 1998, TRAIN NEEDS ATT CAR; Machamer J, 2002, J CLIN EXP NEUROPSYC, V24, P420, DOI 10.1076/jcen.24.4.420.1040; Marshall RS, 2009, J MED SPEECH-LANG PA, V17, P111; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; OFlaherty CA, 1997, APHASIOLOGY, V11, P889, DOI 10.1080/02687039708250463; Savage J, 2000, QUAL HEALTH RES, V10, P324, DOI 10.1177/104973200129118471; Shelton C, 2007, BRAIN INJURY, V21, P1259, DOI 10.1080/02699050701716935; Simmons-Mackie N, 2010, ARCH PHYS MED REHAB, V91, P1814, DOI 10.1016/j.apmr.2010.08.026; SNOW P, 1995, APHASIOLOGY, V9, P365, DOI 10.1080/02687039508248210; Snow PC, 1999, APHASIOLOGY, V13, P529, DOI 10.1080/026870399401993; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 2010, BRAIN INJURY, V24, P269; Togher L, 2009, BRAIN IMPAIR, V10, P188, DOI 10.1375/brim.10.2.188; Wade J, 2003, APHASIOLOGY, V17, P1031, DOI 10.1080/02687030344000373; Wedcliffe T, 2001, S Afr J Commun Disord, V48, P77; World Health Organization, 2001, INT CLASS FUNCT DIS; Worrall L, 2006, J COMMUN DISORD, V39, P320, DOI 10.1016/j.jcomdis.2006.02.007; Ylvisaker M, 2003, J HEAD TRAUMA REHAB, V18, P7, DOI 10.1097/00001199-200301000-00005	38	32	32	0	26	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2012	34	18					1562	1574		10.3109/09638288.2012.656788			13	Rehabilitation	Rehabilitation	974HR	WOS:000306424300009	22360709				2021-06-18	
J	Siman, R; Giovannone, N; Toraskar, N; Frangos, S; Stein, SC; Levine, JM; Kumar, MA				Siman, Robert; Giovannone, Nicholas; Toraskar, Nikhil; Frangos, Suzanne; Stein, Sherman C.; Levine, Joshua M.; Kumar, Monisha A.			Evidence that a Panel of Neurodegeneration Biomarkers Predicts Vasospasm, Infarction, and Outcome in Aneurysmal Subarachnoid Hemorrhage	PLOS ONE			English	Article							SPECTRIN BREAKDOWN PRODUCTS; TRAUMATIC BRAIN-INJURY; ALPHA-II-SPECTRIN; CEREBROSPINAL-FLUID; CEREBRAL VASOSPASM; SURROGATE MARKERS; CALPAIN-I; DAMAGE; ISCHEMIA; CASPASE	Biomarkers for neurodegeneration could be early prognostic measures of brain damage and dysfunction in aneurysmal subarachnoid hemorrhage (aSAH) with clinical and medical applications. Recently, we developed a new panel of neurodegeneration biomarkers, and report here on their relationships with pathophysiological complications and outcomes following severe aSAH. Fourteen patients provided serial cerebrospinal fluid samples for up to 10 days and were evaluated by ultrasonography, angiography, magnetic resonance imaging, and clinical examination. Functional outcomes were assessed at hospital discharge and 6-9 months thereafter. Eight biomarkers for acute brain damage were quantified: calpain-derived alpha-spectrin N- and C-terminal fragments (CCSntf and CCSctf), hypophosphorylated neurofilament H, 14-3-3 beta and zeta, ubiquitin C-terminal hydrolase L1, neuron-specific enolase, and S100 beta. All 8 biomarkers rose up to 100-fold in a subset of patients. Better than any single biomarker, a set of 6 correlated significantly with cerebral vasospasm, brain infarction, and poor outcome. Furthermore, CSF levels of 14-3-3 beta, CCSntf, and NSE were early predictors of subsequent moderate-to-severe vasospasm. These data provide evidence that a panel of neurodegeneration biomarkers may predict lasting brain dysfunction and the pathophysiological processes that lead to it following aSAH. The panel may be valuable as surrogate endpoints for controlled clinical evaluation of treatment interventions and for guiding aSAH patient care.	[Siman, Robert; Giovannone, Nicholas; Toraskar, Nikhil; Frangos, Suzanne; Stein, Sherman C.; Levine, Joshua M.; Kumar, Monisha A.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; [Levine, Joshua M.; Kumar, Monisha A.] Univ Penn, Sch Med, Dept Neurol, Philadelphia, PA 19104 USA	Siman, R (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA.	siman@mail.med.upenn.edu		Giovannone, Nicholas/0000-0001-5391-8729	National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS048234]; Groff Foundation; Sharps Foundation; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048234] Funding Source: NIH RePORTER	This work was supported by grants to RS from the National Institute of Health (NS048234) and to JML from the Groff Foundation and Sharps Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Chen HI, 2011, NEUROSURGERY, V69, P53, DOI 10.1227/NEU.0b013e3182191451; Frontera JA, 2006, NEUROSURGERY, V59, P21, DOI 10.1227/01.NEU.0000218821.34014.1B; Hoh BL, 2004, NEUROSURGERY, V55, P779, DOI 10.1227/01.NEU.0000137628.51839.D5; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; KASSELL NF, 1985, STROKE, V16, P562, DOI 10.1161/01.STR.16.4.562; Kramer A, 2009, STROKE, V40, P3403, DOI 10.1161/STROKEAHA.109.560243; LAD SP, 2011, J STROKE CE IN PRESS; Lewis SB, 2008, J CEREBR BLOOD F MET, V28, P1261, DOI 10.1038/jcbfm.2008.12; Lewis SB, 2007, J NEUROSURG, V107, P792, DOI 10.3171/JNS-07/10/0792; Lewis SB, 2010, J NEUROSCI RES, V88, P1475, DOI 10.1002/jnr.22323; Liu MC, 2010, EUR J NEUROSCI, V31, P722, DOI 10.1111/j.1460-9568.2010.07097.x; Nylen K, 2006, NEUROSCI LETT, V404, P132, DOI 10.1016/j.neulet.2006.05.029; Nylen K, 2007, STROKE, V38, P1489, DOI 10.1161/STROKEAHA.106.478362; Petzold A, 2006, J NEUROL NEUROSUR PS, V77, P753, DOI 10.1136/jnnp.2005.085175; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pineda JA, 2007, J NEUROTRAUM, V24, P354, DOI 10.1089/neu.2006.003789; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701; Sehba FA, 2011, MOL NEUROBIOL, V43, P27, DOI 10.1007/s12035-010-8155-z; Shirao S, 2010, CEREBROVASC DIS, V30, P105, DOI 10.1159/000314713; Siman R, 2005, J CEREBR BLOOD F MET, V25, P1433, DOI 10.1038/sj.jcbfm.9600138; SIMAN R, 1988, NEURON, V1, P279, DOI 10.1016/0896-6273(88)90076-1; Siman R, 2004, NEUROBIOL DIS, V16, P311, DOI 10.1016/j.nbd.2004.03.016; SIMAN R, 1989, J NEUROSCI, V9, P1579; Siman R, 2008, BRAIN RES, V1213, P1, DOI 10.1016/j.brainres.2008.03.034; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Smith ML, 2005, SURG NEUROL, V63, P229, DOI 10.1016/j.surneu.2004.06.017; Vergouwen MDI, 2011, J CEREBR BLOOD F MET, V31, P1545, DOI 10.1038/jcbfm.2011.56; Vergouwen MDI, 2010, STROKE, V41, P2391, DOI 10.1161/STROKEAHA.110.589275; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Yamashima T, 2004, CELL CALCIUM, V36, P285, DOI 10.1016/j.ceca.2004.03.001; Zhang C, 2002, NEUROBIOL DIS, V10, P289, DOI 10.1006/nbdi.2002.0526	35	32	35	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 9	2011	6	12							e28938	10.1371/journal.pone.0028938			9	Multidisciplinary Sciences	Science & Technology - Other Topics	866FK	WOS:000298365700084	22174930	DOAJ Gold, Green Published			2021-06-18	
J	Ho, KM; Honeybul, S; Litton, E				Ho, Kwok M.; Honeybul, Stephen; Litton, Edward			Delayed neurological recovery after decompressive craniectomy for severe nonpenetrating traumatic brain injury	CRITICAL CARE MEDICINE			English	Article						decompressive craniectomy; outcome; prediction; prognosis; traumatic brain injury	DISABILITY; MORTALITY	Objective: This study aimed to assess the incidence and factors associated with delayed neurologic recovery after decompressive craniectomy for severe nonpenetrating traumatic brain injury. Design: Retrospective cohort study. Setting: Two major neurotrauma centers in Western Australia. Patients: One hundred and four adult neurotrauma patients who had had a decompressive craniectomy and remained moderately disabled or worse at 6-month follow-up. Measurements and Main Results: Glasgow Outcome Scale scores at 6, 12, and 18 months were used to assess the neurologic recovery of the patients, and logistic regression was used to identify the factors associated with delayed neurologic recovery between 6 and 18 months after surgery. Among a total of 176 patients who required decompressive craniectomy between 2004 and 2010, 104 (59%) had moderate to severe disability 6 months after surgery. Fifty of these patients (48%, 95% confidence interval: 39-58) had >= 1 grade of improvement in Glasgow Outcome Scale score between 6 and 18 months after surgery. Of the 59 patients who had an unfavorable outcome (severe disability or vegetative state) 6 months after surgery, 15 patients (25%, 95% confidence interval: 16-38) improved and had attained a favorable outcome (moderate disability or near normal neurologic function) by the 18-month follow-up. An absence of nonevacuated intracerebral hematoma (> 1 cm in diameter) (odds ratio 6.67, 95% confidence interval: 1.12-33.3; p = .038) and a higher admission Glasgow Coma Scale (odds ratio per point increment 1.44, 95% confidence interval: 1.07-1.96; p = .018) were the only two factors significantly associated with a higher chance of delayed neurologic improvement from unfavorable to favorable neurologic outcome between 6 and 18 months after surgery. Conclusions: Delayed neurologic recovery after decompressive craniectomy for severe nonpenetrating traumatic brain injury was very common; absence of nonevacuated intracerebral hematoma and a high admission Glasgow Coma Scale were associated with a higher chance of delayed neurologic recovery after decompressive craniectomy. (Crit Care Med 2011; 39: 2495-2500)	[Ho, Kwok M.; Litton, Edward] Royal Perth Hosp, Dept Intens Care Med, Perth, WA, Australia; [Ho, Kwok M.] Univ Western Australia, Sch Populat Hlth, Nedlands, WA 6009, Australia; [Honeybul, Stephen] Sir Charles Gairdner Hosp, Dept Neurosurg, Perth, WA, Australia	Ho, KM (corresponding author), Royal Perth Hosp, Dept Intens Care Med, Perth, WA, Australia.	kwok.ho@health.wa.gov.au	Ho, Kwok M./E-3546-2010; litton, edward/C-5384-2017	Ho, Kwok M./0000-0002-6705-6004; litton, edward/0000-0002-5125-6829	Departments of Intensive Care Medicine and Neurosurgery, Royal Perth Hospital	Supported solely by the Departments of Intensive Care Medicine and Neurosurgery, Royal Perth Hospital.	Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Andelic N, 2009, ACTA NEUROL SCAND, V120, P16, DOI 10.1111/j.1600-0404.2008.01116.x; Bell RS, 2009, J TRAUMA, V66, pS104, DOI 10.1097/TA.0b013e31819d88c8; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; DuBose JJ, 2011, J TRAUMA, V70, P11, DOI 10.1097/TA.0b013e318207c563; Fins JJ, 2009, ANN NY ACAD SCI, V1157, P131, DOI 10.1111/j.1749-6632.2009.04473.x; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gillett GR, 2010, J MED ETHICS, V36, P727, DOI 10.1136/jme.2010.037424; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Ho KM, 2010, CRIT CARE MED, V38, P1562, DOI 10.1097/CCM.0b013e3181e2ccd8; Ho KM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003226; HONEYBUL S, 2010, J NEUROTRAUMA; Honeybul S, 2011, J NEUROTRAUM, V28, P13, DOI 10.1089/neu.2010.1584; Honeybul S, 2010, J NEUROTRAUM, V27, P1225, DOI 10.1089/neu.2010.1316; Honeybul S, 2009, J NEUROTRAUM, V26, P2179, DOI 10.1089/neu.2009.0989; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; Merino MA, 2010, NEUROCIRUGIA, V21, P289; Munch E, 2000, NEUROSURGERY, V47, P315; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; SBORDONE RJ, 1995, BRAIN INJURY, V9, P285, DOI 10.3109/02699059509008199; Schiff ND, 2005, NEUROLOGY, V64, P514, DOI 10.1212/01.WNL.0000150883.10285.44; Schiff ND, 2002, BRAIN, V125, P1210, DOI 10.1093/brain/awf131; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Servadei F, 2007, CURR OPIN CRIT CARE, V13, P163, DOI 10.1097/MCC.0b013e32807f2a94; THOMSEN IV, 1992, SCAND J REHABIL MED, P142; Voss HU, 2006, J CLIN INVEST, V116, P2005, DOI 10.1172/JCI27021	33	32	35	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2011	39	11					2495	2500		10.1097/CCM.0b013e318225764e			6	Critical Care Medicine	General & Internal Medicine	841JV	WOS:000296509500016	21705893				2021-06-18	
J	Lannsjo, M; Borg, J; Bjorklund, G; af Geijerstam, JL; Lundgren-Nilsson, A				Lannsjo, Marianne; Borg, Jorgen; Bjorklund, Gunilla; af Geijerstam, Jean-Luc; Lundgren-Nilsson, Asa			INTERNAL CONSTRUCT VALIDITY OF THE RIVERMEAD POST-CONCUSSION SYMPTOMS QUESTIONNAIRE	JOURNAL OF REHABILITATION MEDICINE			English	Article						mild traumatic brain injury; Rivermead Post-Concussion Symptoms Questionnaire; Rasch analysis	TRAUMATIC BRAIN-INJURY; MINOR HEAD-INJURIES; RASCH ANALYSIS; MILD; MODERATE; RELIABILITY; PREDICTION; SEQUELAE; COHORT; SCALE	Objective: To investigate the internal construct validity of the Rivermead Post-Concussion Symptoms Questionnaire (RPQ) by Rasch analysis of data from a national cohort of patients with mild traumatic brain injury. Methods: Data collected at 3 months after mild traumatic brain injury from 2,523 patients were analysed using the partial credit model, describing rating scale structure, local dependency, age and gender differential functioning, dimensionality and model fit. Results: Categories did not work in a consistent manner; however, collapsing of Categories 1 and 2 yielded ordered thresholds. Local dependency of items was present and 2 item pairs were combined. There was no differential item functioning by gender or age. The Rasch factor explained 47.7% of the variance and the first contrast explained 12.4% of the unexplained variance (eigenvalue 1.9). Further analysis indicated 3 or more dimensions. Person measure had a mean of -2.16, showing poor targeting of persons to items. Person reliability was 0.71 and person separation index was 1.56. Conclusion: According to this Rasch analysis of data from a representative sample of mild traumatic brain injury, the RPQ may not be optimal for this population. Even after reducing the number of categories and collapsing items with local dependency, unidimensionality was not reached, which argues against summation of a total score. However, the scale is unbiased for gender and age.	[Lannsjo, Marianne] Uppsala Univ, Dept Rehabil Med, Inst Neurosci, Uppsala, Sweden; [Borg, Jorgen] Karolinska Inst, Dept Rehabil Med, Inst Clin Sci, Stockholm, Sweden; [Bjorklund, Gunilla] Karolinska Inst, Dept Publ Hlth Sci, Div Publ Hlth Epidemiol, Stockholm, Sweden; [af Geijerstam, Jean-Luc] Karolinska Inst, Dept Med, Clin Epidemiol Unit, Stockholm, Sweden; [Lundgren-Nilsson, Asa] Univ Gothenburg, Dept Clin Neurosci & Rehabil, Inst Neurosci & Physiol, Gothenburg, Sweden	Lannsjo, M (corresponding author), Sandviken Hosp, SE-81189 Sandviken, Sweden.	marianne.lannsjo@lg.se		Lannsjo, Marianne/0000-0001-8792-3796; Borg, Jorgen/0000-0002-2372-7478	Swedish insurance company AFA; Centre for Research and Development, Uppsala University/County Council of Gavleborg	This study was supported by grants from the Swedish insurance company AFA and the Centre for Research and Development, Uppsala University/County Council of Gavleborg. Special thanks to Dr Mike Linacre for his kind support and statistical advice.	af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Angoff W. H., 1993, DIFFERENTIAL ITEM FU; Bazarian JJ, 1999, BRAIN INJURY, V13, P173, DOI 10.1080/026990599121692; BLAND JM, 1995, BRIT MED J, V310, P170, DOI 10.1136/bmj.310.6973.170; BOHNEN N, 1994, BRAIN INJURY, V8, P701, DOI 10.3109/02699059409151024; Bond T.G., 2007, APPL RASCH MODEL FUN; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Duncan PW, 2003, ARCH PHYS MED REHAB, V84, P950, DOI 10.1016/S0003-9993(03)00035-2; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Harrison D, 1986, MULTIVARIATE BEHAV R, V19, P49; Herrmann N, 2009, J NEUROPSYCH CLIN N, V21, P181, DOI 10.1176/appi.neuropsych.21.2.181; Holland P. W., 1993, DIFFERENTIAL ITEM FU; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Linacre J M, 1999, J Outcome Meas, V3, P103; Linacre JM, 2008, WINSTEPS VERSION 3 6; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; MASTERS GN, 1982, PSYCHOMETRIKA, V47, P149, DOI 10.1007/BF02296272; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Rasch G, 1960, POBABILISTIC MODELS; Reckase M.D., 1979, J EDUC STAT, V4, P207, DOI 10.3102/10769986004003207; Roe C, 2009, DISABIL REHABIL, V31, P1235, DOI 10.1080/09638280802532720; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; Smith Everett V Jr, 2002, J Appl Meas, V3, P205; Smith R M, 1998, J Outcome Meas, V2, P66; SMITH RM, 1994, OBJECTIVE MEASUREMEN, V2; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; TEASDALE G, 1974, LANCET, V2, P81; TEASDALE GM, 1995, J NEUROL NEUROSUR PS, V58, P526, DOI 10.1136/jnnp.58.5.526; Tennant A, 2006, RASCH MEASUREMENT T, V20, P1048; Tennant A, 2007, ARTHRIT RHEUM-ARTHR, V57, P1358, DOI 10.1002/art.23108; Tesio L, 2003, J REHABIL MED, V35, P105, DOI 10.1080/16501970310010448; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; World Health Organisation, 1993, ICD 10 CLASSIFICATIO; World Health Organization, 1992, ICD 10 CLASS MENT BE	45	32	33	0	9	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	NOV	2011	43	11					997	1002		10.2340/16501977-0875			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	856QN	WOS:000297658600006	22031345	DOAJ Gold			2021-06-18	
J	Selassie, AW; Fakhry, SM; Ford, DW				Selassie, Anbesaw Wolde; Fakhry, Samir M.; Ford, Dee W.			Population-Based Study of the Risk of In-Hospital Death After Traumatic Brain Injury: The Role of Sepsis	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Traumatic brain injury; Sepsis; Comorbidity; In-hospital death; Epidemiology	INSURANCE STATUS; UNITED-STATES; CARE; EPIDEMIOLOGY; MORTALITY; TRENDS; COMPLICATIONS; PREDICTORS; SURVIVAL; DISEASE	Background: Traumatic brain injury (TBI) accounts for the largest proportion of injury-related deaths and disability in the United States. The proportion of TBI-related deaths that occur after admission in a hospital remains high despite improvement in medical technology. We provide findings on the risk factors of in-hospital death and demonstrate the risk associated with sepsis occurring in the hospital environment. Methods: Population-based retrospective cohort study of 41,395 patients with TBI from all nonfederal hospitals in South Carolina, 1998 to 2009. TBI was ascertained by International Classification of Diseases-9th Rev.-Clinical Modification codes of 800 to 801, 803 to 804, 850 to 854, and 959.01. Observation was censored at the 120th day. Days elapsing from the date of injury to date of death established the survival time (T). Cox regression was used to examine the risk of death, whereas Kaplan-Meier survival curves compared survival probabilities across time. Results: Sepsis was independently associated with risk of in-hospital death with hazard ratio of 1.34 (p < 0.001). Severity of TBI was the strongest risk factor with hazard ratio of 4.97 (p < 0.001). Nearly 90% of patients with sepsis were identified with one of the nosocomial etiologies included in the analyses compared with 7% of patients without sepsis (p < 0.001). The survival probabilities were significantly lower for persons with sepsis compared with those without (log-rank test p < 0.001). Conclusion: Sepsis occurring in the hospital environment and associated with nosocomial etiologies is a strong risk factor for in-hospital death after TBI. Reducing the risk of infections and subsequent sepsis through adherence with infection control measures is a critical step to reduce in-hospital deaths among patients with TBI.	[Selassie, Anbesaw Wolde] Med Univ S Carolina, Div Epidemiol & Biostat, Charleston, SC 29425 USA; [Fakhry, Samir M.] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA; [Ford, Dee W.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA	Selassie, AW (corresponding author), Med Univ S Carolina, Div Epidemiol & Biostat, 135 Cannon St, Charleston, SC 29425 USA.	selassie@musc.edu			National Institute of Health, Center for Minority and Health DisparitiesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RC1MD004405-01]; NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD) [RC1MD004405] Funding Source: NIH RePORTER	This study is supported by a grant from the National Institute of Health, Center for Minority and Health Disparities, Grant No. RC1MD004405-01 to a project entitled CRitical Care Excellence in Sepsis and Trauma (CREST) Medical University of South Carolina (MUSC) (to D.W.F. and S.M.F.).	Allison PD, 1995, SURVIVAL ANAL USING, V1, P29; American Medical Association, 2009, INT CLASS DIS; Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI 10.1097/00003246-200107001-00035; BABA H, 1995, PARAPLEGIA, V33, P281, DOI 10.1038/sc.1995.64; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bansal V, 2009, J NEUROTRAUM, V26, P1353, DOI 10.1089/neu.2008-0858; Bateman BT, 2010, ANESTHESIOLOGY, V112, P917, DOI 10.1097/ALN.0b013e3181cea3d0; BOULANGER BR, 1994, CRIT CARE CLIN, V10, P537; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; *CDCP, 2006, TRAUM BRAIN INJ US C; Chotani R. A., 2007, Infectious disease epidemiology: theory and practice, P505; Colantonio A, 2008, J TRAUMA, V64, P876, DOI 10.1097/TA.0b013e31804d493e; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Ekshyyan O, 2004, FRONT BIOSCI-LANDMRK, V9, P1567, DOI 10.2741/1357; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Ferraris VA, 2010, J TRAUMA, V69, P645, DOI 10.1097/TA.0b013e3181d8941d; Georgiou C, 2009, WORLD J SURG, V33, P1087, DOI 10.1007/s00268-009-9923-7; HAAS JS, 1994, AM J PUBLIC HEALTH, V84, P1605, DOI 10.2105/AJPH.84.10.1605; Kao LS, 2006, AM J SURG, V192, P710, DOI 10.1016/j.amjsurg.2006.08.031; KLEINBAUM DG, 2010, EVALUATING PROPORTIO, P130; Lorelli DR, 2001, AM SURGEON, V67, P693; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Pfeifer R, 2009, INJURY, V40, P907, DOI 10.1016/j.injury.2009.05.006; Plurad DS, 2010, AM SURGEON, V76, P43; Romano PS, 2003, HEALTH AFFAIR, V22, P154, DOI 10.1377/hlthaff.22.2.154; *SAS I INC, 2010, STAT AN SOFTW VERS 9; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Selassie AW, 2005, J HEAD TRAUMA REHAB, V20, P257, DOI 10.1097/00001199-200505000-00008; Selassie AW, 2004, AM J EMERG MED, V22, P465, DOI 10.1016/j.ajem.2004.07.024; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 2007, BRAIN INJURY MED PRI, P45; Thurman DJ., 1995, GUIDELINES SURVEILLA; Upperman Jeffrey S, 2005, Pediatr Crit Care Med, V6, pS108, DOI 10.1097/01.PCC.0000161578.11270.39; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2; Wardle TD, 1999, BRIT MED BULL, V55, P744, DOI 10.1258/0007142991902754	38	32	33	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2011	71	5					1226	1234		10.1097/TA.0b013e318226ecfc			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	849IG	WOS:000297118600029	22071924				2021-06-18	
J	Snell, DL; Siegert, RJ; Hay-Smith, EJC; Surgenor, LJ				Snell, Deborah L.; Siegert, Richard J.; Hay-Smith, E. Jean C.; Surgenor, Lois J.			Factor Structure of the Brief COPE in People With Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						Brief COPE; coping; mild traumatic brain injury; MTBI; psychometrics	COPING STRATEGIES; HEAD-INJURY; STRESS; INVENTORY; APPRAISAL; RECOVERY; EMOTION; HEALTH; CANCER; SCALE	Objective: To investigate the factor structure and internal consistency of the Brief COPE, adapted for use with adults with mild traumatic brain injury (MTBI). Design: Prospective cohort study. Setting: Hospital based emergency department and concussion clinic. Participants: A total of 147 adults meeting diagnostic criteria for MTBI. Main Measure: Brief COPE. Analyses: The previously reported 9-factor structure of the Brief COPE was tested by using confirmatory factor analysis (CFA) and then exploratory factor analysis (EFA). The Cronbach alpha was computed for both the original subscales and those derived from EFA. Results: The CFA provided a less than satisfactory fit for the 9-factor model. While the EFA solution was very similar to that of the original scale, the reliability of some derived subscales was low. Further analyses identified improved internal consistency with a 3-factor model reflecting approach, avoidance, and help-seeking coping styles. Conclusions: The Brief COPE has satisfactory psychometric properties for use in MTBI but may be more reliably and meaningfully interpreted using 3 dimensions/subscales rather than 9.	[Snell, Deborah L.; Hay-Smith, E. Jean C.] Univ Otago, Rehabil Teaching & Res Unit, Wellington, New Zealand; [Siegert, Richard J.] Kings Coll London, Dept Palliat Care Policy & Rehabil, Cicely Saunders Inst, London WC2R 2LS, England; [Surgenor, Lois J.] Univ Otago, Dept Psychol Med, Christchurch, New Zealand	Snell, DL (corresponding author), Burwood Hosp, Brain Injury Rehabil Serv, Private Bag 4708, Christchurch, New Zealand.	deborah.snell@cdhb.govt.nz	Siegert, Richard J./K-2030-2019	Siegert, Richard/0000-0002-3074-0929			Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Carver CS, 1997, INT J BEHAV MED, V4, P92, DOI 10.1207/s15327558ijbm0401_6; CARVER CS, 1989, J PERS SOC PSYCHOL, V56, P267, DOI 10.1037/0022-3514.56.2.267; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Coolidge FL, 2000, J ANXIETY DISORD, V14, P157, DOI 10.1016/S0887-6185(99)00046-8; Cooper C, 2008, J NERV MENT DIS, V196, P838, DOI 10.1097/NMD.0b013e31818b504c; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Dias C, 2009, SPAN J PSYCHOL, V12, P338, DOI 10.1017/S1138741600001736; Fillion L, 2002, CURR PSYCHOL, V21, P17, DOI 10.1007/BF02903157; FOLKMAN S, 1985, J PERS SOC PSYCHOL, V48, P150, DOI 10.1037/0022-3514.48.1.150; Folkman S, 2004, ANNU REV PSYCHOL, V55, P745, DOI 10.1146/annurev.psych.55.090902.141456; FOLKMAN S, 1980, J HEALTH SOC BEHAV, V21, P219, DOI 10.2307/2136617; Franks HM, 2006, PSYCHO-ONCOL, V15, P1027, DOI 10.1002/pon.1043; Frydenberg E., 1996, COPING SCALE ADULTS; Godfrey HPD, 1996, J HEAD TRAUMA REHAB, V11, P29, DOI 10.1097/00001199-199612000-00006; HEPPNER PP, 1982, J COUNS PSYCHOL, V29, P66, DOI 10.1037/0022-0167.29.1.66; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Kay T., 1992, NEUROPSYCHOLOGY, V6, P371, DOI DOI 10.1037/0894-4105.6.4.371; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Lazarus R.S., 1984, STRESS APPRAISAL COP; Lowe R, 2000, BRIT J HEALTH PSYCH, V5, P337, DOI 10.1348/135910700168964; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; New Zealand Guidelines Group, 2006, TRAUM BRIAN INJ DIAG; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; Pett M., 2003, MAKING SENSE FACTOR; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Ponsford J, 2004, BRAIN INJURY, V18, P603, DOI 10.1080/02699050310001646152; Ptacek JT, 2008, ANXIETY STRESS COPIN, V21, P155, DOI 10.1080/10615800701466467; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Snell Deborah, 2006, N Z Med J, V119, pU1902; Snell D, 2009, J CLIN EXP NEUROPSYC, V31, P20, DOI 10.1080/13803390801978849; Streiner DL, 2003, J PERS ASSESS, V80, P217, DOI 10.1207/S15327752JPA8003_01; Strom TQ, 2007, BRAIN INJURY, V21, P1137, DOI 10.1080/02699050701687334; Taylor SE, 2007, ANNU REV CLIN PSYCHO, V3, P377, DOI 10.1146/annurev.clinpsy.3.022806.091520; TEASDALE G, 1974, LANCET, V2, P81; TOBIN DL, 1989, COGNITIVE THER RES, V13, P343, DOI 10.1007/BF01173478; Ullman J.B., 2001, USING MULTIVARIATE S; Watson R, 2006, J ADV NURS, V55, P330, DOI 10.1111/j.1365-2648.2006.03915.x; Wood RL, 2004, BRAIN INJURY, V18, P1135, DOI 10.1080/02699050410001675906	43	32	32	0	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2011	26	6					468	477		10.1097/HTR.0b013e3181fc5e1e			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	859AC	WOS:000297845000003	21245767				2021-06-18	
J	Ustinova, KI; Leonard, WA; Cassavaugh, ND; Ingersoll, CD				Ustinova, Ksenia I.; Leonard, Wesley A.; Cassavaugh, Nicholas D.; Ingersoll, Christopher D.			Development of a 3D immersive videogame to improve arm-postural coordination in patients with TBI	JOURNAL OF NEUROENGINEERING AND REHABILITATION			English	Article						virtual reality; motor rehabilitation; postural control; brain injury	VIRTUAL-REALITY; BRAIN-INJURY; BALANCE; TRUNK; REHABILITATION; SYNERGIES; EXERCISE; STROKE; ENVIRONMENTS; RELIABILITY	Background: Traumatic brain injury (TBI) disrupts the central and executive mechanisms of arm(s) and postural (trunk and legs) coordination. To address these issues, we developed a 3D immersive videogame- Octopus. The game was developed using the basic principles of videogame design and previous experience of using videogames for rehabilitation of patients with acquired brain injuries. Unlike many other custom-designed virtual environments, Octopus included an actual gaming component with a system of multiple rewards, making the game challenging, competitive, motivating and fun. Effect of a short-term practice with the Octopus game on arm-postural coordination in patients with TBI was tested. Methods: The game was developed using WorldViz Vizard software, integrated with the Qualysis system for motion analysis. Avatars of the participant's hands precisely reproducing the real-time kinematic patterns were synchronized with the simulated environment, presented in the first person 3D view on an 82-inch DLP screen. 13 individuals with mild-to-moderate manifestations of TBI participated in the study. While standing in front of the screen, the participants interacted with a computer-generated environment by popping bubbles blown by the Octopus. The bubbles followed a specific trajectory. Interception of the bubbles with the left or right hand avatar allowed flexible use of the postural segments for balance maintenance and arm transport. All participants practiced ten 90-s gaming trials during a single session, followed by a retention test. Arm-postural coordination was analysed using principal component analysis. Results: As a result of the short-term practice, the participants improved in game performance, arm movement time, and precision. Improvements were achieved mostly by adapting efficient arm-postural coordination strategies. Of the 13 participants, 10 showed an immediate increase in arm forward reach and single-leg stance time. Conclusion: These results support the feasibility of using the custom-made 3D game for retraining of arm-postural coordination disrupted as a result of TBI.	[Ustinova, Ksenia I.; Leonard, Wesley A.; Ingersoll, Christopher D.] Cent Michigan Univ, Herbert H & Grace A Dow Coll Hlth Profess, Mt Pleasant, MI 48859 USA; [Cassavaugh, Nicholas D.] Cent Michigan Univ, Dept Psychol, Mt Pleasant, MI USA; [Cassavaugh, Nicholas D.] Cent Michigan Univ, Ctr Driver Evaluat Educ & Res, Mt Pleasant, MI USA	Ustinova, KI (corresponding author), Cent Michigan Univ, Herbert H & Grace A Dow Coll Hlth Profess, Mt Pleasant, MI 48859 USA.	ustin1k@cmich.edu	Ustinova, Ksenia I/M-8250-2016; Ingersoll, Christopher/H-6474-2015	Ustinova, Ksenia I/0000-0002-1531-7591; Ingersoll, Christopher/0000-0001-9157-6846	US Department of DefenceUnited States Department of Defense	The authors acknowledge study participants, Lisette Tamkei for creating graphic design, Jessica Gardon-Rose and Christopher Hausbeck for patient recruitment and evaluation, and Amanda Schafer for help with data collection. The study was supported by the US Department of Defence.	Alexandrov A, 1998, EXP BRAIN RES, V118, P210, DOI 10.1007/s002210050274; Arce FI, 2004, HUM MOVEMENT SCI, V22, P749, DOI 10.1016/j.humov.2003.12.002; BERG K, 1989, Physiotherapy Canada, V41, P304; Bernstein N., 1967, COORDINATION REGULAT; Bryanton C, 2006, CYBERPSYCHOL BEHAV, V9, P123, DOI 10.1089/cpb.2006.9.123; Christiansen C, 1998, ARCH PHYS MED REHAB, V79, P888, DOI 10.1016/S0003-9993(98)90083-1; Cirstea AC, 2007, NEUROREHAB NEURAL RE, V21, P398, DOI 10.1177/1545968306298414; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Dault MC, 2002, BRAIN INJURY, V16, P231, DOI 10.1080/02699050110103300; Fitts P. M., 1967, HUMAN PERFORMANCE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fredericks CM, 1996, PATHOPHYSIOLOGY MOTO; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; Gentile A., 1987, SKILL ACQUISITION AC; Gonzalez-Fernandez M, 2010, STUD HEALTH TECHNOL, V154, P61, DOI 10.3233/978-1-60750-561-7-61; Grealy MA, 1999, ARCH PHYS MED REHAB, V80, P661, DOI 10.1016/S0003-9993(99)90169-7; HOLDEN MK, 2002, NEUROLOGY REPORT, V26, P62; Kaminski TR, 2007, GAIT POSTURE, V26, P256, DOI 10.1016/j.gaitpost.2006.09.006; KESHNER EA, 2004, J NEUROENG REHABIL, V3, P8; KLOCKGETHER T, 1990, J NEUROL NEUROSUR PS, V53, P297, DOI 10.1136/jnnp.53.4.297; Kuhtz-Buschbeck JP, 2003, ARCH PHYS MED REHAB, V84, P424, DOI 10.1053/apmr.2003.50017; Levin MF, 1996, BRAIN, V119, P281, DOI 10.1093/brain/119.1.281; Levin MF, 2002, EXP BRAIN RES, V143, P171, DOI 10.1007/s00221-001-0976-6; Levin MF, 2009, STUD HEALTH TECHNOL, V145, P94, DOI 10.3233/978-1-60750-018-6-94; MAGDALON EC, 2011, ACTA PSYCHOL AMST; MAH CD, 1994, J MOTOR BEHAV, V26, P83, DOI 10.1080/00222895.1994.9941664; Matheis RJ, 2007, CLIN NEUROPSYCHOL, V21, P146, DOI 10.1080/13854040601100668; Michaelsen SM, 2004, STROKE, V35, P1914, DOI 10.1161/01.STR.0000132569.33572.75; Mumford N, 2009, BRAIN INJURY, V23, P179, DOI 10.1080/02699050802695566; Newstead Ann H, 2005, J Neurol Phys Ther, V29, P18; Newton R., 2001, J GERONTOL A-BIOL, V56A, P248; Qin H, 2009, INT J HUM-COMPUT INT, V25, P107, DOI 10.1080/10447310802546732; Schultheis MT, 2001, PRESENCE-TELEOP VIRT, V10, P431, DOI 10.1162/1054746011470271; SKINNER BF, 1938, BEHAV ORGANISM EXPT; SMITHWHEELOCK M, 1991, AM J OTOL, V12, P218; SUBRAMANIAN SK, 2011, J NEUROENG REHABIL, V30, P8; Sveistrup H, 2003, CYBERPSYCHOL BEHAV, V6, P245, DOI 10.1089/109493103322011524; Thornton M, 2005, BRAIN INJURY, V19, P989, DOI 10.1080/02699050500109944; Tyson SF, 2004, CLIN REHABIL, V18, P916, DOI 10.1191/0269215504cr821oa; Ustinova KI, 2004, MOTOR CONTROL, V8, P139, DOI 10.1123/mcj.8.2.139; USTINOVA KI, 2011, P VIRT REH C ZUR SWI, P27; WEISS PI, 2004, J NEUROENG REHABIL, V20, P1; Wrisley DM, 2004, PHYS THER, V84, P906, DOI 10.1093/ptj/84.10.906; Yavuzer G, 2008, EUR J PHYS REHAB MED, V44, P237	44	32	34	0	30	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1743-0003		J NEUROENG REHABIL	J. NeuroEng. Rehabil.	OCT 31	2011	8								61	10.1186/1743-0003-8-61			11	Engineering, Biomedical; Neurosciences; Rehabilitation	Engineering; Neurosciences & Neurology; Rehabilitation	847NQ	WOS:000296980000001	22040301	DOAJ Gold, Green Published			2021-06-18	
J	Chelly, H; Chaari, A; Daoud, E; Dammak, H; Medhioub, F; Mnif, J; Ben Hamida, C; Bahloul, M; Bouaziz, M				Chelly, Hedi; Chaari, Anis; Daoud, Emna; Dammak, Hssan; Medhioub, Fatma; Mnif, Jameleddine; Ben Hamida, Chokri; Bahloul, Mabrouk; Bouaziz, Mounir			Diffuse Axonal Injury in Patients With Head Injuries: An Epidemiologic and Prognosis Study of 124 Cases	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Head trauma; Diffuse axonal injury; Brain magnetic resonance imaging; Cerebral computed tomography; Prognosis	TRAUMATIC BRAIN-INJURY; PRACTICAL SCALE; SEVERITY SCORE; COMA; CONSCIOUSNESS; TOMOGRAPHY; DIAGNOSIS; CT	Background: Diffuse axonal injury (DAI) is usually associated to severe trauma. Recent imaging advances made its diagnosis easier. Its prognosis impact is not yet well established. The aim of this article is to describe the epidemiologic, clinical, and radiologic features of posttraumatic DAI and to study its prognosis impact on mortality and outcome according to Glasgow Outcome Scale. Methods: This is a retrospective study over a 4-year period (2004-2007) of 124 patients admitted for head trauma. Demographic, clinical, biological, and radiologic findings were recorded at admission and during intensive care unit stay. Results: Mean age (+/- standard deviation) was 28 years +/- 15.8 years. Cranial computed tomography scan was sufficient enough to diagnose DAI in 31 patients. Magnetic resonance imaging was performed in 105 patients with a delay of 7.7 days +/- 8.6 days. Most patients were classified as stage II (49.5%) or stage III (44.8%) according to Gentry's classification. In a multivariate analysis, factors associated with higher mortality were dysautonomia (p = 0.018; odds ratio [OR] = 4.17), hyperglycemia >= 8 mmol/L (p = 0.001; OR = 3.84) on intensive care unit admission, and subdural hematoma (p = 0.031; OR = 3.99), whereas factors associated to poor outcome according to Glasgow Outcome Scale score were Glasgow Coma Scale score < 8 (p = 0.032, OR = 3.55), secondary systemic injuries score >= 3 (p = 0.034, OR = 2.83), hyperglycemia >= 8 mmol/L (p = 0.002, OR = 5.55), and DAI count >= 6 (p = 0.035, OR = 3.33). In patients with pure DAI, the absence of consciousness recovery was the unique independent factor of mortality (p < 0.001, OR = 116.4), whereas only transfusion need was an independent factor of poor outcome (p = 0.017, OR = 4.44). Conclusion: Dysautonomia, hyperglycemia, and subdural hematoma are the main factors associated to higher mortality when DAIs are diagnosed, whereas a DAI count >= 6 is associated to poor outcome. Magnetic resonance imaging classification did not have a prognosis value even in patients with pure DAI.	[Chelly, Hedi; Chaari, Anis; Dammak, Hssan; Medhioub, Fatma; Ben Hamida, Chokri; Bahloul, Mabrouk; Bouaziz, Mounir] CHU Habib Bourguiba, Serv Reanimat Med, Sfax, Tunisia; [Daoud, Emna] CHU Hedi Chaker, Serv Radiol, Sfax, Tunisia; [Mnif, Jameleddine] CHU Habib Bourguiba, Serv Radiol, Sfax, Tunisia	Chaari, A (corresponding author), CHU Habib Bourguiba, Serv Reanimat Med, Sfax, Tunisia.	anischaari2004@yahoo.fr		Bahloul, Mabrouk/0000-0002-6488-8294			ADAMS JH, 1984, LANCET, V2, P1420; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Ashikaga R, 1997, NEURORADIOLOGY, V39, P239, DOI 10.1007/s002340050401; Bahloul M, 2004, J TRAUMA, V57, P255, DOI 10.1097/01.TA.0000083004.35231.1E; Bardenheuer M, 2000, UNFALLCHIRURG, V103, P355, DOI 10.1007/s001130050550; DUROCHER A, 1988, INTENS CARE MED, V14, P39, DOI 10.1007/BF00254120; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Eum SW, 1998, J KOREAN NEUROSURG S, V27, P1668; Fiser SM, 1998, AM SURGEON, V64, P1088; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; GENTRY LR, 1994, RADIOLOGY, V191, P1; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; JENNETT B, 1975, LANCET, V1, P480; KALFF R, 1989, CHILD NERV SYST, V5, P156, DOI 10.1007/BF00272118; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Lagares A, 2009, ACTA NEUROCHIR, V151, P341, DOI 10.1007/s00701-009-0194-8; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Park SJ, 2009, J KOREAN NEUROSURG S, V46, P205, DOI 10.3340/jkns.2009.46.3.205; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; SAHUQUILLOBARRIS J, 1988, J NEUROSURG, V68, P894, DOI 10.3171/jns.1988.68.6.0894; SALAZAR AM, 1986, NEUROLOGY, V36, P178, DOI 10.1212/WNL.36.2.178; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; SKLAR EML, 1992, RADIOL CLIN N AM, V30, P353; TEASDALE G, 1974, LANCET, V2, P81; TEPAS JJ, 1987, J PEDIATR SURG, V22, P14, DOI 10.1016/S0022-3468(87)80006-4; Vyrostek Sara B., 2004, Morbidity and Mortality Weekly Report, V53, P1; Weiss N, 2007, CRIT CARE, V11, DOI 10.1186/cc6107; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; ZIMMERMAN RA, 1986, AM J ROENTGENOL, V147, P1215, DOI 10.2214/ajr.147.6.1215; TUNISIAN NATL GUARD	40	32	34	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5282			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2011	71	4					838	846		10.1097/TA.0b013e3182127baa			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	833ZT	WOS:000295925700018	21460740				2021-06-18	
J	Schneider, EB; Efron, DT; MacKenzie, EJ; Rivara, FP; Nathens, AB; Jurkovich, GJ				Schneider, Eric B.; Efron, David T.; MacKenzie, Ellen J.; Rivara, Frederick P.; Nathens, Avery B.; Jurkovich, Gregory J.			Premorbid Statin Use Is Associated With Improved Survival and Functional Outcomes in Older Head-Injured Individuals	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Statins; Head trauma; Survival; Functional outcomes	MORTALITY; TRAUMA; SEPSIS; SCALE; ONSET; BRAIN; RISK	Objective: To determine whether preinjury statin use is associated with survival and functional recovery in older adult victims of moderate/severe head trauma. Methods: Using the National Study of Costs and Outcomes of Trauma dataset compiled from 69 US hospitals, the effect of preinjury statin use was assessed for in-hospital mortality and functional outcome in patients aged >= 65 with head injury Abbreviated Injury Score (AIS) >= 3. Individuals dying within 24 hours of admission or presenting with fixed dilated pupils were excluded. The Extended Glasgow Outcome Scale, dichotomized at the ability to return to premorbid major activity, was used to measure functional outcome. Multivariate regression modeled statin use and outcomes controlling for demographic, comorbidity, and injury characteristics. Results: Of 523 eligible individuals, 117 (22%) used statins at the time of injury. Statin use was associated with a 76% lower adjusted risk of in-hospital death (relative risk[RR] = 0.24; 95% confidence interval [CI], 0.08-0.69). Of 395 individuals discharged alive, 303 survived 1 year and 264 had complete Extended Glasgow Outcome Scale scores. Statin users and nonusers demonstrated similar risk of good recovery at 3 months (RR = 0.83; 95% CI, 0.46-1.49). At 12 months postinjury, statin users had 13% higher likelihood of good recovery (RR = 1.13; 95% CI, 1.01-1.26). The presence of cardiovascular comorbidities abrogated this effect. Conclusion: Preinjury statin use in older adult traumatic brain injury victims is associated with reduced risk of death and improved functional recovery at 12 months postinjury. Individuals with cardiovascular comorbidities lose this benefit of premorbid statin use. Statins, as possible protective agents in head trauma, warrant further study.	[Schneider, Eric B.] Johns Hopkins Sch Med, Dept Surg, Ctr Surg Trials & Outcomes Res, Baltimore, MD 21218 USA; [MacKenzie, Ellen J.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; [Rivara, Frederick P.] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Jurkovich, Gregory J.] Univ Washington, Harborview Med Ctr, Sch Med, Seattle, WA 98104 USA; [Nathens, Avery B.] St Michaels Hosp, Dept Surg, Toronto, ON M5B 1W8, Canada; [Efron, David T.] Johns Hopkins Sch Med, Div Acute Care Surg & Adult Trauma Surg, Ctr Surg Trials & Outcomes Res, Baltimore, MD 21218 USA	Schneider, EB (corresponding author), Johns Hopkins Sch Med, Dept Surg, Ctr Surg Trials & Outcomes Res, 600 N Wolfe St,Harvey 611, Baltimore, MD 21218 USA.	eschnei1@jhmi.edu					Almog Y, 2004, CIRCULATION, V110, P880, DOI 10.1161/01.CIR.0000138932.17956.F1; *BRAIN INJ ASS, 2006, FACTS TRAUM BRAIN IN; Cheng Y, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-156; Cimino M, 2007, NEUROSCIENTIST, V13, P208, DOI 10.1177/1073858406297121; Dormuth CR, 2009, CIRCULATION, V119, P2051, DOI 10.1161/CIRCULATIONAHA.108.824151; Efron DT, 2008, J TRAUMA, V64, P66, DOI 10.1097/TA.0b013e31815b842a; Elkind MSV, 2005, NEUROLOGY, V65, P253, DOI 10.1212/01.WNL.0000171746.63844.6a; Galley HF, 1996, BRIT J ANAESTH, V77, P11; Hackam DG, 2006, LANCET, V367, P413, DOI 10.1016/S0140-6736(06)68041-0; Liao JK, 2005, ANNU REV PHARMACOL, V45, P89, DOI 10.1146/annurev.pharmtox.45.120403.095748; Liappis AP, 2001, CLIN INFECT DIS, V33, P1352, DOI 10.1086/323334; Lu DY, 2004, J NEUROSURG, V101, P813, DOI 10.3171/jns.2004.101.5.0813; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MACKENZIE EJ, 1986, AM ASS AUT MED P 30; MacKenzie EJ, 2007, J TRAUMA, V63, pS54, DOI 10.1097/TA.0b013e31815acb09; McGirt MJ, 2006, NEUROSURGERY, V58, P945, DOI 10.1227/01.NEU.0000210262.67628.7E; Neal MD, 2009, J TRAUMA, V67, P476, DOI 10.1097/TA.0b013e3181ad66bb; OSLER T, 1997, J TRAUMA, V43, P992; Pettigrew LEL, 1998, J NEUROSURG, V89, P939, DOI 10.3171/jns.1998.89.6.0939; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13	21	32	35	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	OCT	2011	71	4					815	819		10.1097/TA.0b013e3182319de5			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	833ZT	WOS:000295925700013	21986733				2021-06-18	
J	Scher, AI; Wu, H; Tsao, JW; Blom, HJ; Feit, P; Nevin, RL; Schwab, KA				Scher, Ann I.; Wu, Holly; Tsao, Jack W.; Blom, Henk J.; Feit, Preethy; Nevin, Remington L.; Schwab, Karen A.			MTHFR C677T Genotype As a Risk Factor for Epilepsy Including Post-Traumatic Epilepsy in a Representative Military Cohort	JOURNAL OF NEUROTRAUMA			English	Article						epidemiology; epilepsy; folate; head injury; homocysteine; migraine; MTHFR C677T; post-traumatic seizure; traumatic brain injury	METHYLENETETRAHYDROFOLATE REDUCTASE GENE; ANTIEPILEPTIC DRUGS; HOMOCYSTEINE; MUTATION; POLYMORPHISMS; ASSOCIATION; MIGRAINE; METAANALYSIS; SEIZURES; DISEASE	The well-studied C677T variant in the methylenetetrahydrofolate reductase (MTHFR) enzyme is a biologically plausible genetic risk factor for seizures or epilepsy. First, plasma/serum levels of homocysteine, a pro-convulsant, are moderately elevated in individuals with the homozygote TT genotype. Furthermore, the TT genotype has been previously linked with migraine with aura-a comorbid condition-and with alcohol withdrawal seizures. Finally, several small studies have suggested that the TT genotype may be overrepresented in epilepsy patients. In this study, we consider whether the MTHFR C677T or A1298C variants are associated with risk of epilepsy including post-traumatic epilepsy (PTE) in a representative military cohort. Study subjects were selected from the cohort of military personnel on active duty during the years 2003 through 2007 who had archived serum samples at the DoD Serum Repository, essentially all active duty personnel during this time frame. We randomly selected 800 epilepsy patients and 800 matched controls based on ICD-9-CM diagnostic codes. We were able to isolate sufficient genetic material from the archived sera to genotype approximately 85% of our study subjects. The odds of epilepsy were increased in subjects with the TT versus CC genotype (crude OR=1.52 [1.04-2.22], p=0.031; adjusted OR=1.57 [1.07-2.32], p=0.023). In our sensitivity analysis, risk was most evident for patients with repeated rather than single medical encounters for epilepsy (crude OR=1.85 [1.14-2.97], p=0.011, adjusted OR=1.95 [1.19-3.19], p=0.008), and particularly for PTE (crude OR=3.14 [1.41-6.99], p=0.005; adjusted OR=2.55 [1.12-5.80], p=0.026). Our early results suggest a role for the common MTHFR C677T variant as a predisposing factors for epilepsy including PTE. Further exploration of baseline homocysteine and folate levels as predictors of seizure risk following traumatic brain injury is warranted.	[Scher, Ann I.; Wu, Holly; Feit, Preethy] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA; [Tsao, Jack W.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [Blom, Henk J.] Vrije Univ Amsterdam Med Ctr, Inst Cardiovasc Res, Dept Clin Chem, Metab Unit, Amsterdam, Netherlands; [Nevin, Remington L.] Bayne Jones Army Community Hosp, Dept Prevent Med, Ft Polk, LA USA; [Schwab, Karen A.] Def & Vet Brain Injury Ctr, Washington, DC USA	Scher, AI (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biometr, Bethesda, MD 20814 USA.	ascher@usuhs.mil		Blom, Henk/0000-0001-5202-9241; Nevin, Remington/0000-0002-0534-1889; Scher, Ann/0000-0003-4599-9834	Henry Jackson Foundation for Military Medicine; Uniformed Services University	Funding for this study was provided by the Comprehensive Neuroscience Program of the Henry Jackson Foundation for Military Medicine, and the Intramural Research Program of the Uniformed Services University.	Apeland T, 2003, CLIN CHEM, V49, P1005, DOI 10.1373/49.6.1005; Bigal ME, 2003, EPILEPSY BEHAV, V4, pS13, DOI 10.1016/j.yebeh.2003.07.003; Bleich S, 2004, PROG NEURO-PSYCHOPH, V28, P453, DOI 10.1016/j.pnpbp.2003.11.019; Botto LD, 2000, AM J EPIDEMIOL, V151, P862; Caccamo D, 2004, NEUROMOL MED, V6, P117, DOI 10.1385/NMM:6:2-3:117; Cavalleri GL, 2007, LANCET NEUROL, V6, P970, DOI 10.1016/S1474-4422(07)70247-8; Cronin S, 2005, STROKE, V36, P1581, DOI 10.1161/01.STR.0000169946.31639.af; de Bree A, 2003, AM J CLIN NUTR, V77, P687; DEAN JC, 2007, SEIZURE, V17, P269; Dean JCS, 1999, CLIN GENET, V56, P216, DOI 10.1034/j.1399-0004.1999.560306.x; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1422, DOI 10.1001/archneur.57.10.1422; Esfahani ST, 2003, J AM DIET ASSOC, V103, P200, DOI 10.1053/jada.2003.50030; Greenberg DA, 2007, CURR NEUROL NEUROSCI, V7, P320, DOI 10.1007/s11910-007-0049-8; Helbig I, 2008, LANCET NEUROL, V7, P231, DOI 10.1016/S1474-4422(08)70039-5; Hillemacher T, 2007, J NEURAL TRANSM, V114, P151, DOI 10.1007/s00702-006-0541-3; Jette N, 2010, EPILEPSIA, V51, P62, DOI 10.1111/j.1528-1167.2009.02201.x; Kini U, 2007, EUR J MED GENET, V50, P411, DOI 10.1016/j.ejmg.2007.08.002; Kruman II, 2000, J NEUROSCI, V20, P6920, DOI 10.1523/JNEUROSCI.20-18-06920.2000; KUBOVA H, 1995, EPILEPSIA, V36, P750, DOI 10.1111/j.1528-1157.1995.tb01611.x; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lewis SJ, 2005, BMJ-BRIT MED J, V331, P1053, DOI 10.1136/bmj.38611.658947.55; Lievers KJA, 2003, ANN CLIN BIOCHEM, V40, P46, DOI 10.1258/000456303321016169; Ludvigsson P, 2006, ANN NEUROL, V59, P210, DOI 10.1002/ana.20745; Lutz UC, 2006, ALCOHOL CLIN EXP RES, V30, P1966, DOI 10.1111/j.1530-0277.2006.00242.x; Mares P, 2002, EPILEPSIA, V43, P61, DOI 10.1046/j.1528-1157.43.s.5.21.x; Mattson MP, 2003, TRENDS NEUROSCI, V26, P137, DOI 10.1016/S0166-2236(03)00032-8; Ono H, 2000, J INHERIT METAB DIS, V23, P525, DOI 10.1023/A:1005680701884; OTTMAN R, 1994, NEUROLOGY, V44, P2105, DOI 10.1212/WNL.44.11.2105; Rubertone MV, 2002, AM J PUBLIC HEALTH, V92, P1900, DOI 10.2105/AJPH.92.12.1900; Rubino E, 2007, CEPHALALGIA, V29, P807; Schneider JA, 1998, AM J HUM GENET, V62, P1258, DOI 10.1086/301836; Schurks M, 2010, HEADACHE, V50, P588, DOI 10.1111/j.1526-4610.2009.01570.x; Silverberg MJ, 2003, MIL MED, V168, P160; Sniezawska A, 2011, SEIZURE-EUR J EPILEP, V20, P533, DOI 10.1016/j.seizure.2011.04.001; Tan NCK, 2004, EPILEPSIA, V45, P1429, DOI 10.1111/j.0013-9580.2004.22904.x; Tan NCK, 2010, EPILEPSIA, V51, P686, DOI 10.1111/j.1528-1167.2009.02423.x; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Yoo JH, 1999, METABOLISM, V48, P1047, DOI 10.1016/S0026-0495(99)90204-4	38	32	35	0	5	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2011	28	9					1739	1745		10.1089/neu.2011.1982			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821AK	WOS:000294947000007	21787169				2021-06-18	
J	Minshall, CT; Eriksson, EA; Leon, SM; Doben, AR; McKinzie, BP; Fakhry, SM				Minshall, Christian T.; Eriksson, Evert A.; Leon, Stuart M.; Doben, Andrew R.; McKinzie, Brian P.; Fakhry, Samir M.			Safety and Efficacy of Heparin or Enoxaparin Prophylaxis in Blunt Trauma Patients With a Head Abbreviated Injury Severity Score > 2	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	69th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 22-25, 2010	Boston, MA	Amer Assoc Surg Trauma (AAST)		Trauma; Chemoprophylaxis; Intracranial hemorrhage	MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; BRAIN-INJURY; 1602 EPISODES; DATA-BANK	Background: Timing and type of chemoprophylaxis (CP) that should be used in patients with traumatic brain injury (TBI) remains unclear. We reviewed our institutions experience with low-molecular-weight heparin (LMWH) and unfractionated heparin (UFH) in TBI. Methods: The charts of all TBI patients with a head abbreviated injury severity score > 2 (HAIS) and an intensive care unit length of stay > 48 hours admitted during a 42-month period between 2006 and 2009 were reviewed. CP was initiated after intracranial hemorrhage was considered stable. We reviewed all operative notes and radiologic reports in these patients to analyze the rate of significant intracranial hemorrhagic complications, deep venous thrombosis, or pulmonary embolus. Results: A total of 386 patients with TBI were identified; 158 were treated with LMWH and 171 were treated with UFH. HAIS was significantly different between the LMWH (3.8 +/- 0.7) and UFH (4.1 +/- 0.7) groups; the time to initiation of CP was not. The UFH group had a significantly higher rate of deep venous thrombosis and pulmonary embolus. Progression of ICH that occurred after the initiation of CP was significantly higher in the UFH-treated patients (59%) when compared with those treated with LMWH (40%). Two patients in the UFH group required craniotomy after the initiation of CP. Conclusion: LMWH is an effective method of CP in patients with TBI, providing a lower rate of venous thromboembolic and hemorrhagic complications when compared with UFH. A large, prospective, randomized study would better evaluate the safety and efficacy of LMWH in patients suffering blunt traumatic brain injury.	[Minshall, Christian T.] Univ Texas SW, Parkland Mem Hosp, Burn Trauma Crit Care Div, Dept Surg, Dallas, TX 75390 USA; [Eriksson, Evert A.; Leon, Stuart M.; McKinzie, Brian P.; Fakhry, Samir M.] Med Univ S Carolina, Dept Surg, Charleston, SC 29425 USA; [Doben, Andrew R.] Baystate Med Ctr, Dept Surg, Springfield, MA 01107 USA	Minshall, CT (corresponding author), Univ Texas SW, Parkland Mem Hosp, Burn Trauma Crit Care Div, Dept Surg, 5323 Harry Hines Blvd,E5-508, Dallas, TX 75390 USA.	ctminshall@gmail.com		Eriksson, Evert/0000-0002-4099-325X			Arnold JD, 2010, AM SURGEON, V76, P563; Brandt MM, 2007, AM J SURG, V193, P383; Bratton SL, 2007, J NEUROTRAUMA S1, V24, pS32, DOI DOI 10.1089/NEU.2007.9991; Cothren CC, 2007, WORLD J SURG, V31, P98, DOI 10.1007/s00268-006-0304-1; Denson K, 2007, AM J SURG, V193, P380, DOI 10.1016/j.amjsurg.2006.12.004; Depew AJ, 2008, AM SURGEON, V74, P906; Ekeh AP, 2010, J TRAUMA, V68, P912, DOI 10.1097/TA.0b013e3181b21cad; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Kim J, 2002, J TRAUMA, V53, P38, DOI 10.1097/00005373-200207000-00008; Knudson MM, 2004, ANN SURG, V240, P490, DOI 10.1097/01.sla.0000137138.40116.6c; Kurtoglu M, 2004, WORLD J SURG, V28, P807, DOI 10.1007/s00268-004-7295-6; Nekludov M, 2007, J NEUROTRAUM, V24, P174, DOI 10.1089/neu.2006.0173; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; Norwood SH, 2002, ARCH SURG-CHICAGO, V137, P696, DOI 10.1001/archsurg.137.6.696; NORWOOD SH, 2002, ARCH SURG-CHICAGO, V137, P702; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Shackford SR, 2004, ANN SURG, V240, P496	18	32	33	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	AUG	2011	71	2					396	399		10.1097/TA.0b013e31822734c9			4	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	806XH	WOS:000293850200039	21825943				2021-06-18	
J	Kalayci, M; Unal, MM; Gul, S; Acikgoz, S; Kandemir, N; Hanci, V; Edebali, N; Acikgoz, B				Kalayci, Murat; Unal, Mufit M.; Gul, Sanser; Acikgoz, Serefden; Kandemir, Nilufer; Hanci, Volkan; Edebali, Nurullah; Acikgoz, Bektas			Effect of Coenzyme Q(10) on ischemia and neuronal damage in an experimental traumatic brain-injury model in rats	BMC NEUROSCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; LIPID-PEROXIDATION; SUPEROXIDE-PRODUCTION; CEREBRAL-ISCHEMIA; ANTIOXIDANT ROLE; FREE-RADICALS; PATHOPHYSIOLOGY; INVOLVEMENT; DECREASES; UBIQUINOL	Background: Head trauma is one of the most important clinical issues that not only can be fatal and disabling, requiring long-term treatment and care, but also can cause heavy financial burden. Formation or distribution of free oxygen radicals should be decreased to enable fixing of poor neurological outcomes and to prevent neuronal damage secondary to ischemia after trauma. Coenzyme Q(10) (CoQ(10)), a component of the mitochondrial electron transport chain, is a strong antioxidant that plays a role in membrane stabilization. In this study, the role of CoQ(10) in the treatment of head trauma is researched by analyzing the histopathological and biochemical effects of CoQ(10) administered after experimental traumatic brain injury in rats. A traumatic brain-injury model was created in all rats. Trauma was inflicted on rats by the free fall of an object of 450 g weight from a height of 70 cm on the frontoparietal midline onto a metal disc fixed between the coronal and the lambdoid sutures after a midline incision was carried out. Results: In the biochemical tests, tissue malondialdehyde (MDA) levels were significantly higher in the traumatic brain-injury group compared to the sham group (p < 0.05). Administration of CoQ(10) after trauma was shown to be protective because it significantly lowered the increased MDA levels (p < 0.05). Comparing the superoxide dismutase (SOD) levels of the four groups, trauma + CoQ(10) group had SOD levels ranging between those of sham group and traumatic brain-injury group, and no statistically significant increase was detected. Histopathological results showed a statistically significant difference between the CoQ(10) and the other trauma-subjected groups with reference to vascular congestion, neuronal loss, nuclear pyknosis, nuclear hyperchromasia, cytoplasmic eosinophilia, and axonal edema (p < 0.05). Conclusion: Neuronal degenerative findings and the secondary brain damage and ischemia caused by oxidative stress are decreased by CoQ(10) use in rats with traumatic brain injury.	[Kalayci, Murat; Unal, Mufit M.; Gul, Sanser; Edebali, Nurullah; Acikgoz, Bektas] Zonguldak Karaelmas Univ, Dept Neurosurg, Fac Med, TR-67600 Kozlu, Zonguldak, Turkey; [Acikgoz, Serefden] Zonguldak Karaelmas Univ, Dept Biochem, Fac Med, TR-67600 Kozlu, Zonguldak, Turkey; [Kandemir, Nilufer] Zonguldak Karaelmas Univ, Dept Pathol, Fac Med, TR-67600 Kozlu, Zonguldak, Turkey; [Hanci, Volkan] Zonguldak Karaelmas Univ, Dept Anesthesiol, Fac Med, TR-67600 Kozlu, Zonguldak, Turkey	Kalayci, M (corresponding author), Zonguldak Karaelmas Univ, Dept Neurosurg, Fac Med, TR-67600 Kozlu, Zonguldak, Turkey.	drkalayci@yahoo.com	Hanci, Volkan/Q-1573-2019	Hanci, Volkan/0000-0002-2227-194X			Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Bentinger M, 2007, MITOCHONDRION, V7, pS41, DOI 10.1016/j.mito.2007.02.006; ECKERSON HW, 1983, AM J HUM GENET, V35, P1126; Erol B, 2010, FERTIL STERIL, V93, P280, DOI 10.1016/j.fertnstert.2009.07.981; FOLKERS K, 1990, P NATL ACAD SCI USA, V87, P8931, DOI 10.1073/pnas.87.22.8931; HALL ED, 1989, FREE RADICAL BIO MED, V6, P303, DOI 10.1016/0891-5849(89)90057-9; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Kerimoglu A, 2007, ULUS TRAVMA ACIL CER, V13, P85; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; LEIBOVITZ BE, 1980, J GERONTOL, V35, P45, DOI 10.1093/geronj/35.1.45; LEMKE M, 1990, NEUROSCI LETT, V108, P201, DOI 10.1016/0304-3940(90)90731-N; Li H, 2000, BRAIN RES, V877, P7, DOI 10.1016/S0006-8993(00)02609-3; Littarru GP, 2005, CURR OPIN CLIN NUTR, V8, P641, DOI 10.1097/01.mco.0000171123.60665.16; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MASTERS SJ, 1980, AM J ROENTGENOL, V135, P539, DOI 10.2214/ajr.135.3.539; MELLORS A, 1966, J BIOL CHEM, V241, P4353; Nishio S, 1997, ACT NEUR S, V70, P84; Ostrowski RP, 2000, BRAIN RES BULL, V53, P399, DOI 10.1016/S0361-9230(00)00406-8; Ostrowski RP, 1999, FOLIA NEUROPATHOL, V37, P247; Piotrowski P, 1998, Neurol Neurochir Pol, V32, P1397; Portakal O, 1999, CLIN BIOCHEM, V32, P461, DOI 10.1016/S0009-9120(99)00041-7; Premkumar VG, 2008, VASC PHARMACOL, V48, P191, DOI 10.1016/j.vph.2008.02.003; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SOUTHORN PA, 1988, MAYO CLIN PROC, V63, P390, DOI 10.1016/S0025-6196(12)64862-9; SUN Y, 1988, CLIN CHEM, V34, P497; TAKAYANAGI R, 1980, BIOCHEM J, V192, P853, DOI 10.1042/bj1920853; Ucar T, 2006, J TRAUMA, V60, P558, DOI 10.1097/01.ta.0000209172.75637.db; Wang Zhipeng, 2007, Journal of Toxicological Sciences, V32, P505, DOI 10.2131/jts.32.505; Yokoyama K, 1999, SCAND J PLAST RECONS, V33, P1; YOKOYAMA K, 1992, PLAST RECONSTR SURG, V90, P890, DOI 10.1097/00006534-199211000-00026	33	32	33	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2202			BMC NEUROSCI	BMC Neurosci.	JUL 29	2011	12								75	10.1186/1471-2202-12-75			7	Neurosciences	Neurosciences & Neurology	811ND	WOS:000294217100001	21801363	DOAJ Gold, Green Published			2021-06-18	
J	Gould, KR; Ponsford, JL; Johnston, L; Schonberger, M				Gould, Kate Rachel; Ponsford, Jennie Louise; Johnston, Lisa; Schoenberger, Michael			Predictive and Associated Factors of Psychiatric Disorders after Traumatic Brain Injury: A Prospective Study	JOURNAL OF NEUROTRAUMA			English	Article						human studies; neuropsychology; psychiatric disorders; risk factors; TBI	POSTTRAUMATIC-STRESS-DISORDER; QUALITY-OF-LIFE; COPING STRATEGIES; FUNCTIONAL NEUROANATOMY; MAJOR DEPRESSION; ONSET DEPRESSION; HOSPITAL ANXIETY; NATURAL-HISTORY; SUBSTANCE-ABUSE; MOOD DISORDERS	Psychiatric disorders are common and often debilitating following traumatic brain injury (TBI). However, there is little consensus within the literature regarding the risk factors for post-injury psychiatric disorders. A 1-year prospective study was conducted to examine which pre-injury, injury-related, and concurrent factors were associated with experiencing a psychiatric disorder, diagnosed using the Structured Clinical Interview for DSM-IV-TR Axis I Disorders, at 1 year post-injury. Participants were 122 adults with TBI and 88 proxy informants. Psychiatric disorders were common both pre-injury (54.1%) and at 12 months post-injury (45.9%). Results of regression analyses indicated individuals without a pre-injury psychiatric disorder or psychiatric symptomatology in the acute post-injury period were less likely to have a psychiatric disorder at 12 months post-injury. These findings confirm the importance of pre-injury history for the prediction of post-injury psychiatric disorders. Limb injury also emerged as a useful early indicator of later psychiatric disorder. Post-injury psychiatric disorders were associated with concurrent unemployment, pain, poor quality of life, and use of unproductive coping skills. The clinical implications of these findings are discussed.	[Gould, Kate Rachel; Ponsford, Jennie Louise; Schoenberger, Michael] Monash Univ, Sch Psychol & Psychiat, Melbourne, Vic 3800, Australia; [Gould, Kate Rachel; Ponsford, Jennie Louise; Johnston, Lisa; Schoenberger, Michael] Epworth Med Fdn, Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [Schoenberger, Michael] Univ Freiburg, Inst Psychol, Dept Rehabil Psychol, Freiburg, Baden Wurttembe, Germany	Ponsford, JL (corresponding author), Monash Univ, Sch Psychol & Psychiat, Clayton Campus Wellington Rd, Melbourne, Vic 3800, Australia.	jennie.ponsford@monash.edu	Gould, Kate/AAA-5511-2020	Gould, Kate/0000-0002-3564-7408			Anson K, 2006, J HEAD TRAUMA REHAB, V21, P248, DOI 10.1097/00001199-200605000-00005; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Ashman TA, 2009, ARCH PHYS MED REHAB, V90, P733, DOI 10.1016/j.apmr.2008.11.005; Babor T., 2001, ALCOHOL USE DISORDER, V2nd ed.; Bay E, 2008, BRAIN INJURY, V22, P233, DOI 10.1080/02699050801953073; Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Bradbury CL, 2008, ARCH PHYS MED REHAB, V89, pS61, DOI 10.1016/j.apmr.2008.08.210; Branca B, 2004, J HEAD TRAUMA REHAB, V19, P40, DOI 10.1097/00001199-200401000-00005; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; Cleeland C. S., 1994, Annals Academy of Medicine Singapore, V23, P129; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; Deb S, 2007, BRAIN INJURY, V21, P301, DOI 10.1080/02699050701253137; Difede JA, 1997, PAIN, V72, P245, DOI 10.1016/S0304-3959(97)00045-6; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Draper K, 2007, J HEAD TRAUMA REHAB, V22, P278, DOI 10.1097/01.HTR.0000290972.63753.a7; Elliott R, 2000, CEREB CORTEX, V10, P308, DOI 10.1093/cercor/10.3.308; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; Feinstein A, 2002, J NEUROPSYCH CLIN N, V14, P25, DOI 10.1176/appi.neuropsych.14.1.25; Finset A, 2000, BRAIN INJURY, V14, P887; First MB., 2002, STRUCTURED CLIN INTE; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; FREDENBERG E, 1997, COPING SCALE ADULTS; Frisch M. B, 1994, QUALITY LIFE INVENTO; Frisch M.B., 1992, PSYCHOL ASSESSMENT, V4, P92, DOI [DOI 10.1037/1040-3590.4.1.92, 10.1037/1040-3590.4.1.92]; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; GomezHernandez R, 1997, ARCH PHYS MED REHAB, V78, P1321, DOI 10.1016/S0003-9993(97)90304-X; GOULD KR, 2011, PSYCHOL MED; Gracey F, 2009, NEUROPSYCHOL REHABIL, V19, P867, DOI 10.1080/09602010903027763; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hoffman JM, 2007, AM J PHYS MED REHAB, V86, P962, DOI 10.1097/PHM.0b013e31815b5ee5; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Horner MD, 2008, J HEAD TRAUMA REHAB, V23, P74, DOI 10.1097/01.HTR.0000314526.01006.c8; Huey ED, 2008, J NEUROPSYCH CLIN N, V20, P390, DOI 10.1176/appi.neuropsych.20.4.390; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Jorge RE, 2007, BIOL PSYCHIAT, V62, P332, DOI 10.1016/j.biopsych.2006.07.024; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Koponen S, 2006, PSYCHIAT RES-NEUROIM, V146, P263, DOI 10.1016/j.pscychresns.2005.05.015; Kortte KB, 2003, REHABIL PSYCHOL, V48, P131, DOI 10.1037/0090-5550.48.3.131; Krpan KM, 2007, J CLIN EXP NEUROPSYC, V29, P36, DOI 10.1080/13803390500376816; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Liberzon I, 2007, PROG BRAIN RES, V167, P151, DOI 10.1016/S0079-6123(07)67011-3; Lin MR, 2010, ARCH PHYS MED REHAB, V91, P474, DOI 10.1016/j.apmr.2009.10.031; Malhi GS, 2008, ACTA PSYCHIAT SCAND, V117, P100, DOI 10.1111/j.1600-0447.2007.01111.x; Mateer CA, 2006, NEUROREHABILITATION, V21, P315; Milad MR, 2002, NATURE, V420, P70, DOI 10.1038/nature01138; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087; Ponsford J, 2008, J TRAUMA, V64, P1001, DOI 10.1097/TA.0b013e31809fec16; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Rao V, 2010, J NEUROPSYCH CLIN N, V22, P100, DOI 10.1176/appi.neuropsych.22.1.100; Rapoport MJ, 2003, AM J GERIAT PSYCHIAT, V11, P365, DOI 10.1176/appi.ajgp.11.3.365; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Salmond CH, 2006, J NEUROTRAUM, V23, P1049, DOI 10.1089/neu.2006.23.1049; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Shalev AY, 2007, PROG BRAIN RES, V167, P187, DOI 10.1016/S0079-6123(07)67013-7; Shenal BV, 2003, NEUROPSYCHOL REV, V13, P33, DOI 10.1023/A:1022300622902; SKINNER HA, 1982, ADDICT BEHAV, V7, P363, DOI 10.1016/0306-4603(82)90005-3; Snaith R.P., 1994, HADS HOSP ANXIETY DE; Soo C., 2007, COCHRANE DB SYST REV, V3, P1; Stroud MW, 2000, PAIN, V84, P347, DOI 10.1016/S0304-3959(99)00226-2; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Tiersky LA, 2005, ARCH PHYS MED REHAB, V86, P1565, DOI 10.1016/j.apmr.2005.03.013; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; Turner-Stokes L, 2002, CLIN REHABIL, V16, P261, DOI 10.1191/0269215502cr489oa; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; Whelan-Goodinson R, 2010, J HEAD TRAUMA REHAB, V25, P320, DOI 10.1097/HTR.0b013e3181c8f8e7; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Wolters G, 2011, J HEAD TRAUMA REHAB, V26, P150, DOI 10.1097/HTR.0b013e3181e421dc; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	82	32	32	0	13	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2011	28	7					1155	1163		10.1089/neu.2010.1528			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	794BL	WOS:000292869600004	21476784				2021-06-18	
J	Patil, VK; St Andre, JR; Crisan, E; Smith, BM; Evans, CT; Steiner, ML; Pape, TL				Patil, Vijaya K.; St Andre, Justin R.; Crisan, Elena; Smith, Bridget M.; Evans, Charlesnika T.; Steiner, Monica L.; Pape, Theresa L.			Prevalence and Treatment of Headaches in Veterans With Mild Traumatic Brain Injury	HEADACHE			English	Article						headache; brain injury; veteran; blast injury	PERSISTENT POSTCONCUSSIVE SYMPTOMS; POSTTRAUMATIC-STRESS-DISORDER; POLYTRAUMA CLINICAL TRIAD; US SOLDIERS; CHRONIC PAIN; HEAD-INJURY; IRAQ; EPIDEMIOLOGY; AFGHANISTAN; WAR	Objectives.-To report the prevalence and characteristics of headaches in veterans with mild traumatic brain injury (TBI) and to describe most common treatment strategies after neurological evaluation. Methods.-We conducted a retrospective cohort study. The setting was a United States Veterans Healthcare Administration Polytrauma Network Site. The study participants consisted of 246 veterans with confirmed diagnosis of mild TBI. The main outcome measures were: Self-reported head pain occurring 30 days prior to initial mild TBI screening; headache severity measured by the Neurobehavioral Symptom Inventory; headache characteristics; and treatment prescribed by neurologists. Results.-The majority (74%) of veterans with a confirmed diagnosis of mild TBI (N = 246), due largely to blast exposure, reported headaches in the 30 days preceding the initial mild TBI evaluation. Thirty-three percent of these veterans (N = 81) were referred to neurology for persistent headaches. Of the 56 veterans attending the neurology evaluation, 45% were diagnosed with migraine headaches and 20% with chronic daily headaches. The most commonly used abortive agents were triptans (68%) and the most common preventive medications were anticonvulsants (55%) and tricyclics (40%). Conclusion.-There was an increased prevalence of headaches in veterans with mild TBI. Most of the TBI veterans in our study group were exposed to blast injury and findings indicate that the nature of head trauma may be contributing to headaches. Findings highlight the need for developing effective headache prevention and treatment strategies for all persons with mild TBI and in particular for veterans with blast-related mild TBI.	[St Andre, Justin R.; Smith, Bridget M.; Evans, Charlesnika T.; Pape, Theresa L.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Ctr Management Complex Chron Care, Hines, IL 60141 USA; [Patil, Vijaya K.; Crisan, Elena] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept Neurol, Hines, IL 60141 USA; [Steiner, Monica L.] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Dept Phys Med & Rehabil, Hines, IL 60141 USA; [Patil, Vijaya K.; Crisan, Elena; Smith, Bridget M.; Steiner, Monica L.] Loyola Univ, Med Ctr, Maywood, IL 60153 USA; [Evans, Charlesnika T.] Northwestern Univ, Inst Healthcare Studies, Feinberg Sch Med, Chicago, IL 60611 USA; [Pape, Theresa L.] Northwestern Univ, Dept Phys Med & Rehabil, Feinberg Sch Med, Chicago, IL 60611 USA	Patil, VK (corresponding author), Edward Hines Jr VA Hosp, Dept Neurol, Bldg 228,5th Floor,5000A,M-C 127,POB 5000, Hines, IL 60141 USA.	vijaya.patil2@va.gov		Bender Pape, Theresa/0000-0001-7738-5963	Department of Veterans AffairsUS Department of Veterans Affairs; Office of Research and Development, Health Services Research and Development ServiceUS Department of Veterans Affairs [IIR 07-188-3]; Locally-Initiated [42-533]; Edward Hines Jr. VA Hospital, Center for Management of Complex Chronic Care (CMC3)US Department of Veterans Affairs	This study was supported by the Department of Veterans Affairs, Office of Research and Development, Health Services Research and Development Service as grant IIR 07-188-3, Locally-Initiated Project 42-533 and the Edward Hines Jr. VA Hospital, Center for Management of Complex Chronic Care (CMC3). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.	Bernstein DM, 1999, BRAIN INJURY, V13, P151, DOI 10.1080/026990599121683; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Corby-Edwards A. K., 2009, TRAUMATIC BRAIN INJU; Defense and Veterans Brain Injury Center, 2006, DEF VET BRAIN INJ CT; Donnelly KT, 2011, J HEAD TRAUMA R 0307; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Formisano R, 2009, J HEADACHE PAIN, V10, P145, DOI 10.1007/s10194-009-0108-4; Hartlage LC, 2001, ARCH CLIN NEUROPSYCH, V16, P561, DOI 10.1016/S0887-6177(00)00067-6; Hayward P, 2008, LANCET NEUROL, V7, P200, DOI 10.1016/S1474-4422(08)70032-2; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lew HL, 2010, AM J PHYS MED REHAB, V89, P437, DOI 10.1097/PHM.0b013e3181ddd301; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Linder Steven L, 2007, Curr Pain Headache Rep, V11, P396, DOI 10.1007/s11916-007-0223-3; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Neely ET, 2009, HEADACHE, V49, P1089, DOI 10.1111/j.1526-4610.2009.001460.x; Okie S, 2006, NEW ENGL J MED, V355, P2609, DOI 10.1056/NEJMp068235; Olesen J, 2005, REV NEUROL-FRANCE, V161, P689; Packard RC, 1999, J HEAD TRAUMA REHAB, V14, P9, DOI 10.1097/00001199-199902000-00004; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Ruff RL, 2008, J REHABIL RES DEV, V45, P941, DOI 10.1682/JRRD.2008.02.0028; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; Stovner LJ, 2006, CURR OPIN NEUROL, V19, P281, DOI 10.1097/01.wco.0000227039.16071.92; Theeler BJ, 2008, HEADACHE, V48, P876, DOI 10.1111/j.1526-4610.2008.01159.x; Theeler BJ, 2010, HEADACHE, V50, P1262, DOI 10.1111/j.1526-4610.2010.01700.x; Theeler BJ, 2009, HEADACHE, V49, P529, DOI 10.1111/j.1526-4610.2009.01345.x; Uzzell BP, 1999, EVALUATION AND TREATMENT OF MILD TRAUMATIC BRAIN INJURY, P1; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Vasterling JJ, 2006, JAMA-J AM MED ASSOC, V296, P519, DOI 10.1001/jama.296.5.519; Warden DL, 2005, J NEUROTRAUM, V22, P1178	35	32	32	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	JUL-AUG	2011	51	7					1112	1121		10.1111/j.1526-4610.2011.01946.x			10	Clinical Neurology	Neurosciences & Neurology	793ZD	WOS:000292862100006	21762135				2021-06-18	
J	Abdel-Salam, OME				Abdel-Salam, Omar M. E.			Stem Cell Therapy for Alzheimer's Disease	CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS			English	Article						Alzheimer's disease; stem cells; neurogenesis; hippocampus	AMYLOID PRECURSOR PROTEIN; MARROW STROMAL CELLS; ADULT HIPPOCAMPAL NEUROGENESIS; TRANSGENIC MOUSE MODEL; MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; MICROTUBULE-ASSOCIATED PROTEIN; PROMOTES FUNCTIONAL RECOVERY; NEURONAL PROGENITOR CELLS; IN-VITRO DIFFERENTIATION	Alzheimer's disease (AD) is a progressive neurodegenerative disorder which impairs the memory and intellectual abilities of the affected individuals. Loss of episodic as well as semantic memory is an early and principal feature. The basal forebrain cholinergic system is the population of neurons most affected by the neurodegenerative process. Extracellular as well as intracellular deposition of beta-amyloid or Abeta (A beta) protein, intracellular formation of neurofibrillary tangles and neuronal loss are the neuropathological hallmarks of AD. In the last few years, hopes were raised that cell replacement therapy would provide cure by compensating the lost neuronal systems. Stem cells obtained from embryonic as well as adult tissue and grafted into the intact brain of mice or rats were mostly followed by their incorporation into the host parenchyma and differentiation into functional neural lineages. In the lesioned brain, stem cells exhibited targeted migration towards the damaged regions of the brain, where they engrafted, proliferated and matured into functional neurones. Neural precursor cells can be intravenously administered and yet migrate into brain damaged areas and induce functional recovery. Observations in animal models of AD have provided evidence that transplanted stem cells or neural precursor cells (NPCs) survive, migrate, and differentiate into cholinergic neurons, astrocytes, and oligodendrocytes with amelioration of the learning/memory deficits. Besides replacement of lost or damaged cells, stem cells stimulate endogenous neural precursors, enhance structural neuroplasticity, and down regulate proinflammatory cytokines and neuronal apoptotic death. Stem cells could also be genetically modified to express growth factors into the brain. In the last years, evidence indicated that the adult brain of mammals preserves the capacity to generate new neurons from neural stem/progenitor cells. Inefficient adult neurogenesis may contribute to the pathogenesis of AD and other neurodegenerative disorders. An attempt at mobilizing this endogenous pool of resident stem-like cells provides another attractive approach for the treatment of AD. Studies in patients with AD indicated decreased hippocampal volume derived by neurodegeneration. Intriguingly, many drugs including antidepressants, lithium, acetyl cholinesterase inhibitors, and ginkgo biloba, were able to enhance the impaired neurogenesis in this disease process. This paved the way towards exploring the possible pharmacological manipulation of neurogenesis which would offer an alternative approach for the treatment of AD.	[Abdel-Salam, Omar M. E.] Natl Res Ctr, Dept Pharmacol, Cairo, Egypt; [Abdel-Salam, Omar M. E.] Natl Res Ctr, Dept Toxicol & Narcot, Cairo, Egypt	Abdel-Salam, OME (corresponding author), Natl Res Ctr, Dept Pharmacol, Cairo, Egypt.	omasalam@hotmail.com	Abdel-Salam, Omar M.E./L-1296-2017	Abdel-Salam, Omar M.E./0000-0002-4450-1582			Abdipranoto A, 2008, CNS NEUROL DISORD-DR, V7, P187, DOI 10.2174/187152708784083858; Aggleton JP, 1999, BEHAV BRAIN SCI, V22, P425; Aizenstein HJ, 2008, ARCH NEUROL-CHICAGO, V65, P1509, DOI 10.1001/archneur.65.11.1509; ALEKSANDROVA MA, 2003, RUSS J DEV BIOL, V34, P131; Alexanian AR, 2008, STEM CELLS DEV, V17, P1123, DOI 10.1089/scd.2007.0212; Alley GM, 2010, J NEUROSCI RES, V88, P143, DOI 10.1002/jnr.22172; Alonso AD, 2001, P NATL ACAD SCI USA, V98, P6923, DOI 10.1073/pnas.121119298; Amaral DG, 1999, HIPPOCAMPUS, V9, P1; Amariglio N, 2009, PLOS MED, V6, P221, DOI 10.1371/journal.pmed.1000029; Ando K, 1999, J NEUROSCI, V19, P4421; Andrews EM, 2008, EXP NEUROL, V211, P588, DOI 10.1016/j.expneurol.2008.02.027; Arnhold S, 2004, INVEST OPHTH VIS SCI, V45, P4251, DOI 10.1167/iovs.03-1108; Ashford JW, 2002, J ALZHEIMERS DIS, V4, P169, DOI 10.3233/JAD-2002-4307; Bacigaluppi M, 2009, BRAIN, V132, P2239, DOI 10.1093/brain/awp174; Baddeley A, 2001, PHILOS T R SOC B, V356, P1345, DOI 10.1098/rstb.2001.0957; Baharvand H, 2007, INT J DEV BIOL, V51, P371, DOI 10.1387/ijdb.072280hb; BALIN B, 2006, ALZHEIMERS DEMENT, V2, pS431; BALL MJ, 1977, ACTA NEUROPATHOL, V37, P111, DOI 10.1007/BF00692056; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Baron R, 2008, FASEB J, V22, P2843, DOI 10.1096/fj.08-105866; Bartholomew A, 2002, EXP HEMATOL, V30, P42, DOI 10.1016/S0301-472X(01)00769-X; Becker M, 2007, P NATL ACAD SCI USA, V104, P1691, DOI 10.1073/pnas.0610180104; Bell-McGinty S, 2002, AM J PSYCHIAT, V159, P1424, DOI 10.1176/appi.ajp.159.8.1424; Bentz K, 2007, J NEUROSCI RES, V85, P1057, DOI 10.1002/jnr.21219; Bithell A, 2005, CLIN SCI, V108, P13, DOI 10.1042/CS20040276; Blau HM, 2001, CELL, V105, P829, DOI 10.1016/S0092-8674(01)00409-3; Blurton-Jones M, 2009, P NATL ACAD SCI USA, V106, P13594, DOI 10.1073/pnas.0901402106; Boekhoorn K, 2006, J NEUROSCI, V26, P3514, DOI 10.1523/JNEUROSCI.5425-05.2006; Boekhoorn K, 2006, NEUROBIOL DIS, V24, P1, DOI 10.1016/j.nbd.2006.04.017; Boldrini M, 2009, NEUROPSYCHOPHARMACOL, V34, P2376, DOI 10.1038/npp.2009.75; Bondolfi L, 2002, J NEUROSCI, V22, P515, DOI 10.1523/JNEUROSCI.22-02-00515.2002; Bonnet E, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003487; BRAMBLETT GT, 1993, NEURON, V10, P1089, DOI 10.1016/0896-6273(93)90057-X; Bremner JD, 2000, AM J PSYCHIAT, V157, P115, DOI 10.1176/ajp.157.1.115; Brera B, 2000, NEUROBIOL DIS, V7, P395, DOI 10.1006/nbdi.2000.0313; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Bueller JA, 2006, BIOL PSYCHIAT, V59, P812, DOI 10.1016/j.biopsych.2005.09.022; Bussiere T, 2004, AM J PATHOL, V165, P987, DOI 10.1016/S0002-9440(10)63360-3; Butterfield DA, 2002, FREE RADICAL RES, V36, P1307, DOI 10.1080/1071576021000049890; Calingasan NY, 2008, NEUROSCIENCE, V153, P986, DOI 10.1016/j.neuroscience.2008.02.071; Casalbore P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004434; Casserly I, 2004, LANCET, V363, P1139, DOI 10.1016/S0140-6736(04)15900-X; Celsi F, 2007, NEUROBIOL DIS, V26, P342, DOI 10.1016/j.nbd.2006.12.022; Chen HH, 2007, NEUROBIOL AGING, V28, P1148, DOI 10.1016/j.neurobiolaging.2006.05.036; Chen Q, 2008, NEUROBIOL DIS, V29, P316, DOI 10.1016/j.nbd.2007.09.005; Chen X, 2006, IUBMB LIFE, V58, P686, DOI 10.1080/15216540601047767; Chen Y, 2009, CELL DEATH DIFFER, V16, P386, DOI 10.1038/cdd.2008.94; Chevallier NL, 2005, AM J PATHOL, V167, P151, DOI 10.1016/S0002-9440(10)62962-8; Choi SH, 2008, NEURON, V59, P568, DOI 10.1016/j.neuron.2008.07.033; Chu K, 2004, NEUROSCI RES, V50, P459, DOI 10.1016/j.neures.2004.08.015; CLARE L, 2004, ESSENTIAL HDB MEMORY, P255; CLEVELAND DW, 1977, J MOL BIOL, V116, P207, DOI 10.1016/0022-2836(77)90213-3; Connor B, 1997, MOL BRAIN RES, V49, P71, DOI 10.1016/S0169-328X(97)00125-3; COOKE JA, 2007, CULTURE HUMAN STEM C, P23; Cotel MC, 2008, BRAIN RES, V1222, P207, DOI 10.1016/j.brainres.2008.05.052; Covacu R, 2006, STEM CELLS, V24, P2792, DOI 10.1634/stemcells.2005-0640; Coyne TM, 2006, STEM CELLS, V24, P2483, DOI 10.1634/stemcells.2006-0174; Cummings JL, 2002, AM FAM PHYSICIAN, V65, P2525; Czeh B, 2007, NEUROPSYCHOPHARMACOL, V32, P1490, DOI 10.1038/sj.npp.1301275; Davis DG, 1999, J NEUROPATH EXP NEUR, V58, P376, DOI 10.1097/00005072-199904000-00008; De Rosa R, 2005, P NATL ACAD SCI USA, V102, P3811, DOI 10.1073/pnas.0500195102; De Strooper B, 2000, J CELL SCI, V113, P1857; DeKosky ST, 1996, NEURODEGENERATION, V5, P417, DOI 10.1006/neur.1996.0056; DEMARS MP, 2008, ALZHEIMERS DEMENT S1, V4, pT633; Deng WW, 2001, BIOCHEM BIOPH RES CO, V282, P148, DOI 10.1006/bbrc.2001.4570; Di Nicola M, 2002, BLOOD, V99, P3838, DOI 10.1182/blood.V99.10.3838; Dodart JC, 2005, P NATL ACAD SCI USA, V102, P1211, DOI 10.1073/pnas.0409072102; Doetsch F, 2003, CURR OPIN GENET DEV, V13, P543, DOI 10.1016/j.gde.2003.08.012; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Dong H, 2004, NEUROSCIENCE, V127, P601, DOI 10.1016/j.neuroscience.2004.05.040; Donovan MH, 2006, J COMP NEUROL, V495, P70, DOI 10.1002/cne.20840; Doody RS, 2003, J CLIN PSYCHIAT, V64, P11; DOODY RS, 1995, J NEUROPSYCH CLIN N, V7, P54; Dorningues A, 2007, NEUROCHEM INT, V50, P872, DOI 10.1016/j.neuint.2007.03.001; Driscoll I, 2009, NEUROLOGY, V72, P1906, DOI 10.1212/WNL.0b013e3181a82634; DRUBIN DG, 1986, J CELL BIOL, V103, P2739, DOI 10.1083/jcb.103.6.2739; Du AT, 2007, BRAIN, V130, P1159, DOI 10.1093/brain/awm016; Du H, 2010, BBA-MOL BASIS DIS, V1802, P198, DOI 10.1016/j.bbadis.2009.07.005; Dupret D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001959; Duyckaerts C, 2009, ACTA NEUROPATHOL, V118, P5, DOI 10.1007/s00401-009-0532-1; Eckert A, 2008, NEURODEGENER DIS, V5, P157, DOI 10.1159/000113689; Eder-Colli L, 2009, BRAIN RES BULL, V80, P296, DOI 10.1016/j.brainresbull.2009.06.007; Egan MF, 2003, CELL, V112, P257, DOI 10.1016/S0092-8674(03)00035-7; Einstein O, 2007, ANN NEUROL, V61, P209, DOI 10.1002/ana.21033; El Seady R, 2008, BIOCHEM BIOPH RES CO, V376, P358, DOI 10.1016/j.bbrc.2008.08.166; Engler H, 2006, BRAIN, V129, P2856, DOI 10.1093/brain/awl178; Erceg S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002122; Ermini FV, 2008, AM J PATHOL, V172, P1520, DOI 10.2353/ajpath.2008.060520; Erten-Lyons D, 2009, NEUROLOGY, V72, P354, DOI 10.1212/01.wnl.0000341273.18141.64; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Eucher JN, 2007, EXP NEUROL, V203, P486, DOI 10.1016/j.expneurol.2006.09.021; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; Falke E, 2003, AM J PATHOL, V163, P1615, DOI 10.1016/S0002-9440(10)63518-3; Feng RB, 2001, NEURON, V32, P911, DOI 10.1016/S0896-6273(01)00523-2; Fleischman DA, 1999, CURR OPIN NEUROBIOL, V9, P240, DOI 10.1016/S0959-4388(99)80034-8; Fletcher PC, 1995, EXPERIENTIA, V51, P1197, DOI 10.1007/BF01944737; Folin M, 2003, INT J MOL MED, V11, P267; Francis PT, 1999, J NEUROL NEUROSUR PS, V67, P558; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; FRAUTSCHY SA, 1991, P NATL ACAD SCI USA, V88, P8362, DOI 10.1073/pnas.88.19.8362; Freed CR, 2001, NEW ENGL J MED, V344, P710, DOI 10.1056/NEJM200103083441002; Frodl T, 2008, J PSYCHIATR NEUROSCI, V33, P423; Galvan Veronica, 2007, CNS & Neurological Disorders-Drug Targets, V6, P303, DOI 10.2174/187152707783220938; Galvin KA, 2006, NEUROREHABILITATION, V21, P255; Gan L, 2008, NEUROBIOL DIS, V29, P71, DOI 10.1016/j.nbd.2007.08.002; Garbuzova-Davis S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002494; Garzon DJ, 2007, J NEUROSCI, V27, P2628, DOI 10.1523/JNEUROSCI.5053-06.2007; GELINAS D, 2006, ALZHEIMERS DEMENT S1, V2, pS476; Gerdoni E, 2007, ANN NEUROL, V61, P219, DOI 10.1002/ana.21076; GLOVER JC, 2008, STEM CELLS HUMAN EMB, P55; GomezIsla T, 1996, J NEUROSCI, V16, P4491; Gonul AS, 2005, EUR ARCH PSY CLIN N, V255, P381, DOI 10.1007/s00406-005-0578-6; Guerin D, 2009, NEUROBIOL AGING, V30, P272, DOI 10.1016/j.neurobiolaging.2007.05.020; Guzman R, 2007, P NATL ACAD SCI USA, V104, P10211, DOI 10.1073/pnas.0608519104; Habisch HJ, 2010, STEM CELLS DEV, V19, P629, DOI 10.1089/scd.2009.0045; Hagell P, 2002, NAT NEUROSCI, V5, P627, DOI 10.1038/nn863; Hao HN, 2003, J HEMATOTH STEM CELL, V12, P23, DOI 10.1089/152581603321210109; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; Hariri AR, 2003, J NEUROSCI, V23, P6690, DOI 10.1523/jneurosci.23-17-06690.2003; Hartl D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002759; Hattiangady B, 2008, NEUROBIOL AGING, V29, P129, DOI 10.1016/j.neurobiolaging.2006.09.015; Haughey NJ, 2002, J NEUROCHEM, V83, P1509, DOI 10.1046/j.1471-4159.2002.01267.x; He P, 2009, J NEUROSCI, V29, P6545, DOI 10.1523/JNEUROSCI.0421-09.2009; HEBERT LE, 1995, JAMA-J AM MED ASSOC, V273, P1354, DOI 10.1001/jama.273.17.1354; Heine VM, 2004, NEUROBIOL AGING, V25, P361, DOI 10.1016/S0197-4580(03)00090-3; Heng BC, 2004, CELL TISSUE RES, V315, P291, DOI 10.1007/s00441-003-0847-5; Henneman WJP, 2009, NEUROLOGY, V72, P999, DOI 10.1212/01.wnl.0000344568.09360.31; Heo C, 2007, J NEUROCHEM, V102, P493, DOI 10.1111/j.1471-4159.2007.04499.x; Herring A, 2009, EXP NEUROL, V216, P184, DOI 10.1016/j.expneurol.2008.11.027; Holmes C, 2008, LANCET, V372, P216, DOI 10.1016/S0140-6736(08)61075-2; Holsinger RMD, 2000, MOL BRAIN RES, V76, P347, DOI 10.1016/S0169-328X(00)00023-1; Honig LS, 2005, NEUROLOGY, V64, P494, DOI 10.1212/01.WNL.0000150886.50187.30; Hou JF, 2009, NEUROSCI LETT, V462, P294, DOI 10.1016/j.neulet.2009.07.031; Hu M, 2007, BRAIN RES, V1151, P227, DOI 10.1016/j.brainres.2007.03.051; Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3; Ikonomovic MD, 2003, J ALZHEIMERS DIS, V5, P39, DOI 10.3233/JAD-2003-5106; Ingelsson M, 2004, NEUROLOGY, V62, P925, DOI 10.1212/01.WNL.0000115115.98960.37; Iqbal K, 2005, BBA-MOL BASIS DIS, V1739, P198, DOI 10.1016/j.bbadis.2004.09.008; Irons H, 2004, CELL TRANSPLANT, V13, P283, DOI 10.3727/000000004783983990; Jack CR, 2009, BRAIN, V132, P1355, DOI 10.1093/brain/awp062; Janicki SM, 2000, NEUROBIOL AGING, V21, P829, DOI 10.1016/S0197-4580(00)00222-0; Jayatissa MN, 2008, NEUROPHARMACOLOGY, V54, P530, DOI 10.1016/j.neuropharm.2007.11.009; Jiang W, 2001, STROKE, V32, P1201, DOI 10.1161/01.STR.32.5.1201; Jin KL, 2004, P NATL ACAD SCI USA, V101, P13363, DOI 10.1073/pnas.0403678101; Jin KL, 2004, P NATL ACAD SCI USA, V101, P343, DOI 10.1073/pnas.2634794100; Jin K, 2006, BRAIN RES, V1085, P183, DOI 10.1016/j.brainres.2006.02.081; Kaneko N, 2006, GENES CELLS, V11, P1145, DOI 10.1111/j.1365-2443.2006.01010.x; Karbanova Jana, 2004, Biomedical Papers (Olomouc), V148, P217; Keller J, 2008, AM J PSYCHIAT, V165, P872, DOI 10.1176/appi.ajp.2008.07081257; Kelly S, 2004, P NATL ACAD SCI USA, V101, P11839, DOI 10.1073/pnas.0404474101; Kempermann G, 2003, BIOL PSYCHIAT, V54, P499, DOI 10.1016/S0006-3223(03)00319-6; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KIHLSTROM JF, 1987, SCIENCE, V237, P1445, DOI 10.1126/science.3629249; Kim DE, 2006, RADIOLOGY, V241, P822, DOI 10.1148/radiol.2413050466; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Kim JM, 2007, BRAIN RES, V1183, P43, DOI 10.1016/j.brainres.2007.09.005; Koh SH, 2008, BRAIN RES, V1229, P233, DOI 10.1016/j.brainres.2008.06.087; Koketsu D, 2006, EXP NEUROL, V199, P92, DOI 10.1016/j.expneurol.2006.03.012; Kokoeva MV, 2005, SCIENCE, V310, P679, DOI 10.1126/science.1115360; Kolecki R, 2008, ACTA NEUROPATHOL, V116, P419, DOI 10.1007/s00401-008-0380-4; KOPKE E, 1993, J BIOL CHEM, V268, P24374; Koshizuka S, 2004, J NEUROPATH EXP NEUR, V63, P64, DOI 10.1093/jnen/63.1.64; Kotani S, 2008, CHEM-BIOL INTERACT, V175, P227, DOI 10.1016/j.cbi.2008.04.004; Kronmuller KT, 2008, J AFFECT DISORDERS, V110, P241, DOI 10.1016/j.jad.2008.01.022; Kruman II, 2005, NEUROREPORT, V16, P1055, DOI 10.1097/00001756-200507130-00005; Kwak YD, 2006, STEM CELLS DEV, V15, P381, DOI 10.1089/scd.2006.15.381; Lacor PN, 2007, J NEUROSCI, V27, P796, DOI 10.1523/JNEUROSCI.3501-06.2007; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Laplagne DA, 2006, PLOS BIOL, V4, P2349, DOI 10.1371/journal.pbio.0040409; Laske C, 2008, J ALZHEIMERS DIS, V15, P451; Laske C, 2007, J PSYCHIATR RES, V41, P387, DOI 10.1016/j.jpsychires.2006.01.014; Laske C, 2009, J ALZHEIMERS DIS, V17, P115, DOI 10.3233/JAD-2009-1017; Le Blanc K, 2003, CYTOTHERAPY, V5, P485, DOI 10.1080/14653240310003611; Lee HJ, 2007, STEM CELLS, V25, P1204, DOI 10.1634/stemcells.2006-0409; Lee J, 2000, J MOL NEUROSCI, V15, P99, DOI 10.1385/JMN:15:2:99; Lee JK, 2010, STEM CELLS, V28, P329, DOI 10.1002/stem.277; Lee ST, 2008, BRAIN, V131, P616, DOI 10.1093/brain/awm306; Lee ST, 2005, NEUROSCI RES, V52, P243, DOI 10.1016/j.neures.2005.03.016; Lerch JP, 2005, CEREB CORTEX, V15, P995, DOI 10.1093/cercor/bhh200; Letenneur L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003637; Leuner B, 2007, P NATL ACAD SCI USA, V104, P17169, DOI 10.1073/pnas.0708228104; Leung E, 2011, NEUROBIOL AGING, V32, P387, DOI 10.1016/j.neurobiolaging.2009.02.025; Levesque MF, 2009, OPEN STEM CELL J, V1, P20, DOI DOI 10.2174/1876893800901010020; Leyhe T, 2008, EUR ARCH PSY CLIN N, V258, P124, DOI 10.1007/s00406-007-0764-9; LEYHE T, 2009, INT J NEUROPSYCHOPH, V7, P1; Li B, 2008, J NEUROPATH EXP NEUR, V67, P78, DOI 10.1097/nen.0b013e318160c5db; Li G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005424; Li LY, 2008, J MOL NEUROSCI, V34, P157, DOI 10.1007/s12031-007-9022-x; Lie DC, 2002, J NEUROSCI, V22, P6639; Liebau S, 2007, STEM CELLS, V25, P1720, DOI 10.1634/stemcells.2006-0823; Ling DJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004201; Little CS, 2004, NEUROBIOL AGING, V25, P419, DOI 10.1016/S0197-4580(03)00127-1; Liu Jinping, 2008, Neuroembryology and Aging, V5, P134, DOI 10.1159/000193851; Liu Y, 2008, J NEUROSCI, V28, P13805, DOI 10.1523/JNEUROSCI.4218-08.2008; Liu ZJ, 2009, J CELL BIOCHEM, V106, P984, DOI 10.1002/jcb.22091; Lopez-Toledano MA, 2004, J NEUROSCI, V24, P5439, DOI 10.1523/JNEUROSCI.0974-04.2004; Lopez-Toledano MA, 2007, J ALZHEIMERS DIS, V12, P229; Lovell MA, 2006, NEUROBIOL AGING, V27, P909, DOI 10.1016/j.neurobiolaging.2005.05.004; Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2; Luo XG, 2009, NEUROIMMUNOMODULAT, V16, P28, DOI 10.1159/000179664; Lyons A, 2007, J NEUROCHEM, V101, P771, DOI 10.1111/j.1471-4159.2006.04370.x; MacQueen GM, 2003, P NATL ACAD SCI USA, V100, P1387, DOI 10.1073/pnas.0337481100; Maekawa M, 2009, NEUROSCI RES, V63, P259, DOI 10.1016/j.neures.2008.12.006; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mann DMA, 2001, AM J PATHOL, V158, P2165, DOI 10.1016/S0002-9440(10)64688-3; Marchesi VT, 2005, P NATL ACAD SCI USA, V102, P9093, DOI 10.1073/pnas.0503181102; Marutle A, 2007, P NATL ACAD SCI USA, V104, P12506, DOI 10.1073/pnas.0705346104; MASAYUKI F, 2000, CEREBROVASC DIS, V10, P2; Mazur-Kolecka B, 2006, NEUROBIOL AGING, V27, P1181, DOI 10.1016/j.neurobiolaging.2005.07.006; McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030; Mega MS, 2002, PSYCHOSOM MED, V64, P487, DOI 10.1097/00006842-200205000-00013; Menendez M, 2005, BRAIN DEV-JPN, V27, P246, DOI 10.1016/j.braindev.2004.07.008; Michalski B, 2003, MOL BRAIN RES, V111, P148, DOI 10.1016/S0169-328X(03)00003-2; Miklossy J, 2006, NEUROBIOL AGING, V27, P228, DOI 10.1016/j.neurobiolaging.2005.01.018; Millet P, 2005, NEUROBIOL DIS, V19, P57, DOI 10.1016/j.nbd.2004.11.006; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; Mirochnic S, 2009, HIPPOCAMPUS, V19, P1008, DOI 10.1002/hipo.20560; Mishkin M, 1998, HIPPOCAMPUS, V8, P212; Miyajima F, 2008, GENES BRAIN BEHAV, V7, P411, DOI 10.1111/j.1601-183X.2007.00363.x; Mizoguchi H, 2009, J PHARMACOL EXP THER, V331, P14, DOI 10.1124/jpet.109.154724; Mizuno M, 2000, J NEUROSCI, V20, P7116, DOI 10.1523/JNEUROSCI.20-18-07116.2000; Mohapel P, 2004, NEUROBIOL DIS, V15, P196, DOI 10.1016/j.nbd.2003.11.010; Moreno H, 2009, P NATL ACAD SCI USA, V106, P5901, DOI 10.1073/pnas.0900944106; Morgan D, 2000, NATURE, V408, P982, DOI 10.1038/35050116; Morgan D, 2007, EXP NEUROL, V205, P330, DOI 10.1016/j.expneurol.2007.03.006; Morishima Y, 2001, J NEUROSCI, V21, P7551; Morizane A, 2008, CELL TISSUE RES, V331, P323, DOI 10.1007/s00441-007-0541-0; Mortimer JA, 1998, NEUROBIOL AGING, V19, P615; Mosconi L, 2006, J NUCL MED, V47, P1778; Mowla A, 2007, J CLIN PSYCHOPHARM, V27, P484, DOI 10.1097/jcp.0b013e31814b98c1; Munoz JR, 2005, P NATL ACAD SCI USA, V102, P18171, DOI 10.1073/pnas.0508945102; Muotri AR, 2005, P NATL ACAD SCI USA, V102, P18644, DOI 10.1073/pnas.0509315102; Murray IVJ, 2007, J BIOL CHEM, V282, P9335, DOI 10.1074/jbc.M608589200; Murrell W, 2005, DEV DYNAM, V233, P496, DOI 10.1002/dvdy.20360; Narr KL, 2004, NEUROIMAGE, V21, P1563, DOI 10.1016/j.neuroimage.2003.11.011; Naumann N, 2010, HIPPOCAMPUS, V20, P971, DOI 10.1002/hipo.20693; Niidome T, 2008, NEUROREPORT, V19, P1361, DOI 10.1097/WNR.0b013e32830e6dd6; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Pajak B, 2009, FOLIA NEUROPATHOL, V47, P252; Palop JJ, 2007, NEURON, V55, P697, DOI 10.1016/j.neuron.2007.07.025; Parodi J, 2010, J BIOL CHEM, V285, P2506, DOI 10.1074/jbc.M109.030023; Patterson D, 2009, HUM GENET, V126, P195, DOI 10.1007/s00439-009-0696-8; Pekcec A, 2008, AGING CELL, V7, P368, DOI 10.1111/j.1474-9726.2008.00392.x; Pencea V, 2001, J NEUROSCI, V21, P6706; Pereira AC, 2007, P NATL ACAD SCI USA, V104, P5638, DOI 10.1073/pnas.0611721104; Peters F, 2009, BRAIN, V132, P1833, DOI 10.1093/brain/awp075; Petersen RC, 2000, NEUROLOGY, V54, P581, DOI 10.1212/WNL.54.3.581; PETERSEN RC, 1994, NEUROLOGY, V44, P867, DOI 10.1212/WNL.44.5.867; Pham K, 2003, EUR J NEUROSCI, V17, P879, DOI 10.1046/j.1460-9568.2003.02513.x; Picone P, 2009, BIOPHYS J, V96, P4200, DOI 10.1016/j.bpj.2008.11.056; Pike KE, 2007, BRAIN, V130, P2837, DOI 10.1093/brain/awm238; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889; Pluchino S, 2003, NATURE, V422, P688, DOI 10.1038/nature01552; Pluchino S, 2008, BRAIN, V131, P2564, DOI 10.1093/brain/awn198; Politi LS, 2007, STEM CELLS, V25, P2583, DOI 10.1634/stemcells.2007-0037; Popa-Wagner A, 2006, CURR NEUROVASC RES, V3, P3, DOI 10.2174/156720206775541732; Porayette P, 2009, J BIOL CHEM, V284, P23806, DOI 10.1074/jbc.M109.026328; Probst A, 1991, BRAIN PATHOL, V1, P229, DOI 10.1111/j.1750-3639.1991.tb00666.x; Ramsay Michael A E, 2002, Proc (Bayl Univ Med Cent), V15, P135; Rao MS, 2006, AGING CELL, V5, P545, DOI 10.1111/j.1474-9726.2006.00243.x; Rapp MA, 2006, ARCH GEN PSYCHIAT, V63, P161, DOI 10.1001/archpsyc.63.2.161; Reddy PH, 2004, HUM MOL GENET, V13, P1225, DOI 10.1093/hmg/ddh140; Redwine JM, 2003, P NATL ACAD SCI USA, V100, P1381, DOI 10.1073/pnas.242746599; Rees Tina M., 2005, Current Alzheimer Research, V2, P291, DOI 10.2174/1567205054367847; Reif A, 2006, MOL PSYCHIATR, V11, P514, DOI 10.1038/sj.mp.4001791; Reiman EM, 2009, P NATL ACAD SCI USA, V106, P6820, DOI 10.1073/pnas.0900345106; Resende R, 2007, BRAIN RES, V1143, P11, DOI 10.1016/j.brainres.2007.01.071; Reubinoff BE, 2001, NAT BIOTECHNOL, V19, P1134, DOI 10.1038/nbt1201-1134; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399; Reyes M, 2001, ANN NY ACAD SCI, V938, P231; Rizk P, 2006, NEUROPSYCHOPHARMACOL, V31, P1146, DOI 10.1038/sj.npp.1300954; RIZOS EN, 2008, WORLD J BIOL PSYCHIA, V10, P1; Rockenstein E, 2007, ACTA NEUROPATHOL, V113, P265, DOI 10.1007/s00401-006-0166-5; Rodriguez JJ, 2009, NEUROREPORT, V20, P907, DOI 10.1097/WNR.0b013e32832be77d; Rodriguez JJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002935; Roisen FJ, 2001, BRAIN RES, V890, P11, DOI 10.1016/S0006-8993(00)03016-X; Roses AD, 1996, ANNU REV MED, V47, P387, DOI 10.1146/annurev.med.47.1.387; Rossato JI, 2007, LEARN MEMORY, V14, P36, DOI 10.1101/lm.422607; Rosser AE, 2007, CURR OPIN NEUROL, V20, P688, DOI 10.1097/WCO.0b013e3282f132fc; Salinero O, 2000, J NEUROSCI RES, V60, P87, DOI 10.1002/(SICI)1097-4547(20000401)60:1<87::AID-JNR9>3.0.CO;2-C; Sanchez-Ramos J, 2009, NEUROSCIENCE, V163, P55, DOI 10.1016/j.neuroscience.2009.05.071; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; SANDHUL JK, 2004, P INT SOC MAG RESON, P11; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schliebs R, 2006, J NEURAL TRANSM, V113, P1625, DOI 10.1007/s00702-006-0579-2; Schliebs R, 2005, NEUROCHEM RES, V30, P895, DOI 10.1007/s11064-005-6962-9; Schuff N, 2009, BRAIN, V132, P1067, DOI 10.1093/brain/awp007; Selkoe DJ, 2000, ANN NY ACAD SCI, V924, P17; Shah SB, 2009, NEUROBIOL DIS, V36, P11, DOI 10.1016/j.nbd.2009.05.016; Sheline YI, 2003, AM J PSYCHIAT, V160, P1516, DOI 10.1176/appi.ajp.160.8.1516; Sheline YI, 1999, J NEUROSCI, V19, P5034; Shen CY, 2008, J BIOL CHEM, V283, P17721, DOI 10.1074/jbc.M800013200; Shetty AK, 2008, J NEUROSCI RES, V86, P3062, DOI 10.1002/jnr.21764; Shi F, 2009, HIPPOCAMPUS, V19, P1055, DOI 10.1002/hipo.20573; Shiino A, 2006, NEUROIMAGE, V33, P17, DOI 10.1016/j.neuroimage.2006.06.010; Sigurdsson EM, 2001, AM J PATHOL, V159, P439, DOI 10.1016/S0002-9440(10)61715-4; Siman R, 2000, J NEUROSCI, V20, P8717; Siwak-Tapp CT, 2007, NEUROBIOL LEARN MEM, V88, P249, DOI 10.1016/j.nlm.2007.05.001; Sluimer JD, 2008, NEUROLOGY, V70, P1836, DOI 10.1212/01.wnl.0000311446.61861.e3; Small DH, 2009, J ALZHEIMERS DIS, V16, P225, DOI 10.3233/JAD-2009-0951; Small DH, 1999, J NEUROCHEM, V73, P443, DOI 10.1046/j.1471-4159.1999.0730443.x; Smith MM, 2009, CLIN HEMORHEOL MICRO, V41, P229, DOI 10.3233/CH-2009-1174; SQUIRE LR, 1993, ANNU REV PSYCHOL, V44, P453, DOI 10.1146/annurev.ps.44.020193.002321; Squire LR, 2004, ANNU REV NEUROSCI, V27, P279, DOI 10.1146/annurev.neuro.27.070203.144130; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; Srivastava AS, 2006, STEM CELLS, V24, P1689, DOI 10.1634/stemcells.2005-0531; St George-Hyslop PH, 2000, BIOL PSYCHIAT, V47, P183, DOI 10.1016/S0006-3223(99)00301-7; Stackman RW, 2003, EXP NEUROL, V184, P510, DOI 10.1016/S0014-4886(03)00399-6; Standridge John B., 2006, Current Alzheimer Research, V3, P95, DOI 10.2174/156720506776383068; STEELE C, 1990, AM J PSYCHIAT, V147, P1049; Stopford CL, 2007, CORTEX, V43, P846, DOI 10.1016/S0010-9452(08)70684-1; Sugaya K, 2006, PANMINERVA MED, V48, P87; Sugaya K, 2008, NEURODEGENER DIS, V5, P170, DOI 10.1159/000113693; Sugiura S, 2005, STROKE, V36, P859, DOI 10.1161/01.STR.0000158905.22871.95; SULLIVAN S, 2007, HUMAN EMBRYONIC STEM, P35; Suzuki H, 2004, BIOCHEM BIOPH RES CO, V322, P918, DOI 10.1016/j.bbrc.2004.07.201; Swijnenburg RJ, 2005, CIRCULATION, V112, pI166, DOI 10.1161/CIRCULATIONAHA.104.525824; Tackenberg C, 2009, J NEUROSCI, V29, P14439, DOI 10.1523/JNEUROSCI.3590-09.2009; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Takeuchi A, 2000, AM J PATHOL, V157, P331, DOI 10.1016/S0002-9440(10)64544-0; Takeuchi H, 2007, NEUROSCI LETT, V426, P69, DOI 10.1016/j.neulet.2007.08.048; Tang J, 2008, NEUROSCI RES, V62, P86, DOI 10.1016/j.neures.2008.06.005; Tang Jun, 2007, Neurosci Bull, V23, P263, DOI 10.1007/s12264-007-0039-5; Taniuchi N, 2007, NEUROREPORT, V18, P1801, DOI 10.1097/WNR.0b013e3282f1c9e9; Taupin P, 2002, J NEUROSCI RES, V69, P745, DOI 10.1002/jnr.10378; Taupin P, 2009, EXPERT OPIN THER PAT, V19, P373, DOI 10.1517/13543770802681649; Taupin P, 2009, EXPERT OPIN THER PAT, V19, P715, DOI 10.1517/13543770902721295; Tchantchou F, 2007, FASEB J, V21, P2400, DOI 10.1096/fj.06-7649com; Tchantchou F, 2009, J ALZHEIMERS DIS, V18, P787, DOI 10.3233/JAD-2009-1189; Terry AV, 2003, J PHARMACOL EXP THER, V306, P821, DOI 10.1124/jpet.102.041616; Thomas ED, 1999, BRIT J HAEMATOL, V105, P330, DOI 10.1111/j.1365-2141.1999.01337.x; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Thored P, 2006, STEM CELLS, V24, P739, DOI 10.1634/stemcells.2005-0281; Tomita M, 2002, STEM CELLS, V20, P279, DOI 10.1634/stemcells.20-4-279; Tomita T, 1997, P NATL ACAD SCI USA, V94, P2025, DOI 10.1073/pnas.94.5.2025; Tonchev AB, 2006, EXP NEUROL, V198, P101, DOI 10.1016/j.expneurol.2005.11.022; Tsai KJ, 2007, J EXP MED, V204, P1273, DOI 10.1084/jem.20062481; TULVING E, 1985, AM PSYCHOL, V40, P385, DOI 10.1037/0003-066x.40.4.385; Tulving E, 1998, HIPPOCAMPUS, V8, P198, DOI 10.1002/(SICI)1098-1063(1998)8:3<198::AID-HIPO2>3.0.CO;2-G; TULVING E, 1988, BRAIN COGNITION, V8, P3, DOI 10.1016/0278-2626(88)90035-8; Tulving E, 1983, ELEMENTS EPISODIC ME; Tulving Endel, 1995, P839; Tuszynski MH, 2005, NAT MED, V11, P551, DOI 10.1038/nm1239; Uylings H. B. M., 2000, NEURODEGENERATIVE DE, P61; Vakili K, 2000, BIOL PSYCHIAT, V47, P1087, DOI 10.1016/S0006-3223(99)00296-6; Valente T, 2009, J ALZHEIMERS DIS, V18, P849, DOI 10.3233/JAD-2009-1188; Van Vickle GD, 2008, MOL MED, V14, P184, DOI [10.2119/2007-00094.VanVickle, 10.2119/2007-00094.Van Vickle]; Veena J, 2009, J NEUROSCI RES, V87, P831, DOI 10.1002/jnr.21907; Verret L, 2007, J NEUROSCI, V27, P6771, DOI 10.1523/JNEUROSCI.5564-06.2007; Videbech P, 2004, AM J PSYCHIAT, V161, P1957, DOI 10.1176/appi.ajp.161.11.1957; Visser PJ, 2002, J NEUROL NEUROSUR PS, V72, P491; Vogel A, 2005, DEMENT GERIATR COGN, V19, P75, DOI 10.1159/000082352; Vogel A, 2004, DEMENT GERIATR COGN, V17, P181, DOI 10.1159/000076354; von Bohlen und Halbach O, 2007, CELL TISSUE RES, V329, P409, DOI 10.1007/s00441-007-0432-4; von Gunten A, 2006, BRAIN RES REV, V51, P176, DOI 10.1016/j.brainresrev.2005.11.003; Vythilingam M, 2004, BIOL PSYCHIAT, V56, P101, DOI 10.1016/j.biopsych.2004.04.002; Waldau B, 2008, CELL MOL LIFE SCI, V65, P2372, DOI 10.1007/s00018-008-8053-y; Walter J, 2001, CURR OPIN NEUROBIOL, V11, P585, DOI 10.1016/S0959-4388(00)00253-1; Wang PN, 2009, PSYCHIAT RES-NEUROIM, V171, P221, DOI 10.1016/j.pscychresns.2008.05.002; Wang QH, 2006, J MED INVESTIG, V53, P61, DOI 10.2152/jmi.53.61; Wang R, 2004, NEUROSCIENCE, V126, P305, DOI 10.1016/j.neuroscience.2004.03.048; Wang YM, 2007, J NEUROSCI RES, V85, P740, DOI 10.1002/jnr.21169; Watson DJ, 2006, HUM GENE THER, V17, P693, DOI 10.1089/hum.2006.17.693; Wegiel J, 2000, ACTA NEUROPATHOL, V100, P356, DOI 10.1007/s004010000199; Weiner HL, 2000, ANN NEUROL, V48, P567, DOI 10.1002/1531-8249(200010)48:4<567::AID-ANA3>3.3.CO;2-N; Wen PH, 2004, EXP NEUROL, V188, P224, DOI 10.1016/j.expneurol.2004.04.002; Wen PH, 2002, NEUROBIOL DIS, V10, P8, DOI 10.1006/nbdi.2002.0490; Wengenack TM, 2000, NAT BIOTECHNOL, V18, P868, DOI 10.1038/78482; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; Wianny F, 2008, STEM CELLS, V26, P1444, DOI 10.1634/stemcells.2007-0953; Winkler J, 1998, J MOL MED-JMM, V76, P555, DOI 10.1007/s001090050250; Winstead W, 2005, AM J RHINOL, V19, P83, DOI 10.1177/194589240501900115; Wisniewski HM, 1996, NEUROPATH APPL NEURO, V22, P3, DOI 10.1111/j.1365-2990.1996.tb00839.x; Wisniewski T, 1997, AM J PATHOL, V151, P601; Wolf SA, 2006, BIOL PSYCHIAT, V60, P1314, DOI 10.1016/j.biopsych.2006.04.004; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; WU EX, 2004, P INT SOC MAG RESON, V11, P1432; Wu L, 2008, J CELL MOL MED, V12, P1611, DOI 10.1111/j.1582-4934.2007.00203.x; Wu S, 2008, PATHOBIOLOGY, V75, P186, DOI 10.1159/000124979; Xiao M, 2005, EXP NEUROL, V194, P12, DOI 10.1016/j.expneurol.2005.01.021; Xiu MH, 2009, PROG NEURO-PSYCHOPH, V33, P1508, DOI 10.1016/j.pnpbp.2009.08.011; Xuan AG, 2008, NEUROSCI LETT, V440, P331, DOI 10.1016/j.neulet.2008.05.107; Xuan AG, 2009, NEUROSCI LETT, V450, P167, DOI 10.1016/j.neulet.2008.12.001; Yamasaki TR, 2007, J NEUROSCI, V27, P11925, DOI 10.1523/JNEUROSCI.1627-07.2007; Yasutake C, 2006, EUR ARCH PSY CLIN N, V256, P402, DOI 10.1007/s00406-006-0702-2; Young-Pearse TL, 2007, J NEUROSCI, V27, P14459, DOI 10.1523/JNEUROSCI.4701-07.2007; Yu TS, 2008, J NEUROSCI, V28, P12901, DOI 10.1523/JNEUROSCI.4629-08.2008; Yu YX, 2009, HIPPOCAMPUS, V19, P1247, DOI 10.1002/hipo.20587; Zhang C, 2007, EXP NEUROL, V204, P77, DOI 10.1016/j.expneurol.2006.09.018; Zhang SC, 2001, NAT BIOTECHNOL, V19, P1129, DOI 10.1038/nbt1201-1129; Zhang ZH, 2008, NEUROSCI LETT, V444, P227, DOI 10.1016/j.neulet.2008.08.049; Zhao GY, 2007, STEM CELLS DEV, V16, P429, DOI 10.1089/scd.2006.0092; Zheng XS, 2007, BRAIN INJURY, V21, P275, DOI 10.1080/02699050701225754; ZHIFEI W, 2006, PHARM BIOCH BEHAV, V83, P603; Zhu JH, 2006, NEW ENGL J MED, V355, P2376, DOI 10.1056/NEJMc055304; Ziabreva I, 2006, J PSYCHOSOM RES, V61, P311, DOI 10.1016/j.jpsychores.2006.07.017; Zuba-Surma EK, 2008, J MOL CELL CARDIOL, V44, P865, DOI 10.1016/j.yjmcc.2008.02.279; Zwart I, 2009, EXP NEUROL, V216, P439, DOI 10.1016/j.expneurol.2008.12.028	403	32	40	0	57	BENTHAM SCIENCE PUBL	BUSUM	PO BOX 294, BUSUM, 1400 AG, NETHERLANDS	1871-5273	1996-3181		CNS NEUROL DISORD-DR	CNS Neurol. Disord.-Drug Targets	JUN	2011	10	4					459	485					27	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	777PG	WOS:000291634700007	21495961				2021-06-18	
J	Prigatano, GP; Gale, SD				Prigatano, George P.; Gale, Shawn D.			The current status of postconcussion syndrome	CURRENT OPINION IN PSYCHIATRY			English	Article						assessment; concussion; management; postconcussion syndrome	TRAUMATIC BRAIN-INJURY; CONCUSSION SYMPTOMS QUESTIONNAIRE; DSM-IV CRITERIA; NATURAL-HISTORY; RECOVERY; RELIABILITY; MANAGEMENT; SPORTS; ICD-10; ABNORMALITIES	Purpose of review Concussion produces a brief disruption in mental status and is associated with a variety of physical and cognitive symptoms which typically diminish during the first several days to weeks posttrauma. This review highlights problems in defining and measuring concussion, the mildest form of traumatic brain injury (TBI). Furthermore, the 'natural' course of recovery correlates of postconcussion syndrome (PCS) and guidelines for clinical management are discussed. Recent findings Traditional measures of TBI severity (e.g. length of loss of consciousness or period of posttraumatic amnesia) do not correlate with persistent concussion symptoms. Abnormal eye movements, cerebrovascular disturbances, extra-axial injuries, alcohol intoxication at time of injury, and presence of an axis I disorder are associated with persistent symptoms. Early management of physical, cognitive, and emotional symptoms following concussion may reduce long-term morbidity. Techniques used to help concussed athletes return to play appear useful when evaluating and treating concussion in nonathletes. Summary The study of concussion and PCS has increased significantly over the past 10 years, with recent research supporting an underlying biological cause for initial symptomatology. Persistent symptoms may be associated with both neurological and non-neurological variables. Early and serial monitoring and treatment of symptoms appears to result in substantial improvement in the vast majority of concussed patients.	[Prigatano, George P.; Gale, Shawn D.] Barrow Neurol Inst, Dept Clin Neurophysiol, Phoenix, AZ 85013 USA	Prigatano, GP (corresponding author), Barrow Neurol Inst, Dept Clin Neurophysiol, 222 W Thomas Rd,315, Phoenix, AZ 85013 USA.	george.prigatano@chw.edu	Gale, Shawn/M-3144-2013	Gale, Shawn/0000-0002-8989-0964	Newsome Foundation	The senior author wishes to acknowledge the Newsome Foundation for providing economic support for the time necessary to help prepare this manuscript.	ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Andersson EE, 2006, J REHABIL MED, V38, P26, DOI 10.1080/16501970500310564; BENTON AL, 1989, MILD HEAD INJURY; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; Boake C, 2004, J NEUROPSYCH CLIN N, V16, P493, DOI 10.1176/appi.neuropsych.16.4.493; Echemendia RJ, 2006, SPORTS NEUROPSYCHOLO; Hammond-Tooke GD, 2010, J CLIN NEUROSCI, V17, P315, DOI 10.1016/j.jocn.2009.06.026; Heitger MH, 2009, BRAIN, V132, P2850, DOI 10.1093/brain/awp181; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jantzen KJ, 2010, J HEAD TRAUMA REHAB, V25, P256, DOI 10.1097/HTR.0b013e3181e5477c; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kirkwood MW, 2008, CLIN NEUROPSYCHOL, V22, P769, DOI 10.1080/13854040701543700; La Fountaine MF, 2009, AUTON NEUROSCI-BASIC, V148, P101, DOI 10.1016/j.autneu.2009.03.001; LEN TK, 2010, CLIN PHYSIOL FUNCT I, DOI DOI 10.1111/J.1475-097X.2010.00990.X; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; LEVIN HS, 1989, MILD HEAD INJURY, pR15; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; Maruta J, 2010, J HEAD TRAUMA REHAB, V25, P293, DOI 10.1097/HTR.0b013e3181e67936; McAllister TW, 2011, TXB TRAUMATIC BRAIN; McCauley SR, 2005, J NERV MENT DIS, V193, P540, DOI 10.1097/01.nmd.0000172592.05801.71; McCauley SR, 2008, J CLIN EXP NEUROPSYC, V30, P360, DOI 10.1080/13803390701416635; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2009, PM&R, V1, P406, DOI 10.1016/j.pmrj.2009.03.010; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Sroufe NS, 2010, PEDIATRICS, V125, pE1331, DOI 10.1542/peds.2008-2364; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587	37	32	32	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0951-7367	1473-6578		CURR OPIN PSYCHIATR	Curr. Opin. Psychiatr.	MAY	2011	24	3					243	250		10.1097/YCO.0b013e328344698b			8	Psychiatry	Psychiatry	744CA	WOS:000289069500011	21346569				2021-06-18	
J	Ning, RZ; Xiong, Y; Mahmood, A; Zhang, YL; Meng, YL; Qu, CS; Chopp, M				Ning, Ruizhuo; Xiong, Ye; Mahmood, Asim; Zhang, Yanlu; Meng, Yuling; Qu, Changsheng; Chopp, Michael			Erythropoietin promotes neurovascular remodeling and long-term functional recovery in rats following traumatic brain injury	BRAIN RESEARCH			English	Article						Angiogenesis; Cell proliferation; Erythropoietin; Neurogenesis; Functional recovery; Traumatic brain injury	CONTROLLED CORTICAL IMPACT; STROMAL CELL TRANSPLANTATION; ADULT RATS; ENHANCES NEUROGENESIS; SPATIAL MEMORY; STROKE; MICE; DAMAGE; NEUROPROTECTION; NEURONS	Erythropoietin (EPO) improves functional recovery after traumatic brain injury (TBI). This study was designed to investigate long-term (3 months) effects of EPO on brain remodeling and functional recovery in rats after TBI. Young male Wistar rats were subjected to unilateral controlled cortical impact injury. TBI rats were divided into the following groups: (1) saline group (n=7); (2) EPO-6 h group (n=8); and (3) EPO-24 h group (n=8). EPO (5000 U/kg in saline) was administered intraperitoneally at 6 h, and 1 and 2 days (EPO-6 h group) or at 1, 2, and 3 days (EPO-24 h group) postinjury. Neurological function was assessed using a modified neurological severity score, footfault and Morris water maze tests. Animals were sacrificed at 3 months after injury and brain sections were stained for immunohistochemical analyses. Compared to the saline, EPO-6 h treatment significantly reduced cortical lesion volume, while EPO-24 h therapy did not affect the lesion volume (P < 0.05). Both the EPO-6 h and EPO-24 h treatments significantly reduced hippocampal cell loss (P < 0.05), promoted angiogenesis (P < 0.05) and increased endogenous cellular proliferation (BrdU-positive cells) in the injury boundary zone and hippocampus (P < 0.05) compared to saline controls. Significantly enhanced neurogenesis (BrdU/NeuN-positive cells) was seen in the dentate gyrus of both EPO groups compared to the saline group. Both EPO treatments significantly improved long-term sensorimotor and cognitive functional recovery after TBI. In conclusion, the beneficial effects of posttraumatic EPO treatment on injured brain persisted for at least 3 months. The long-term improvement in functional outcome may in part be related to the neurovascular remodeling induced by EPO. (C) 2011 Elsevier B.V. All rights reserved.	[Ning, Ruizhuo; Xiong, Ye; Mahmood, Asim; Zhang, Yanlu; Meng, Yuling; Qu, Changsheng] Henry Ford Hlth Syst, Dept Neurosurg, Detroit, MI 48202 USA; [Chopp, Michael] Henry Ford Hlth Syst, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI 48309 USA	Xiong, Y (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, E&R Bldg,Room 3096,2799 W Grand Blvd, Detroit, MI 48202 USA.	nsxye@neuro.hfh.edu	Zhang, Yanlu/H-1275-2011; ning, ruizhuo/E-6401-2012	Xiong, Ye/0000-0001-9770-6031	NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1 NS62002, PO1 NS42345]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS042345, R01NS062002] Funding Source: NIH RePORTER	Sources of financial support: NINDS grants RO1 NS62002 (Ye Xiong) and PO1 NS42345 (Asim Mahmood, Michael Chopp).	BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Carmeliet P, 2003, NAT REV GENET, V4, P710, DOI 10.1038/nrg1158; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Cerami A, 2001, SEMIN HEMATOL, V38, P33, DOI 10.1053/shem.2001.27484; Chen JL, 2005, J CEREBR BLOOD F MET, V25, P281, DOI 10.1038/sj.jcbfm.9600034; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Cherian L, 2007, J PHARMACOL EXP THER, V322, P789, DOI 10.1124/jpet.107.119628; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Day LB, 1999, BEHAV NEUROSCI, V113, P914, DOI 10.1037/0735-7044.113.5.914; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Gonzalez FF, 2007, DEV NEUROSCI-BASEL, V29, P321, DOI 10.1159/000105473; Grasso G, 2006, J NEUROSURG-SPINE, V4, P310, DOI 10.3171/spi.2006.4.4.310; Grasso G, 2005, NEUROSURGERY, V56, P821, DOI 10.1227/01.NEU.0000156493.00904.7E; Grasso G, 2004, NEUROSCIENTIST, V10, P93, DOI 10.1177/1073858403259187; Grasso G, 2007, BRAIN RES, V1182, P99, DOI 10.1016/j.brainres.2007.08.078; Harris NG, 2010, J NEUROTRAUM, V27, P1971, DOI 10.1089/neu.2010.1470; Hartley CE, 2008, J NEUROSURG, V109, P708, DOI 10.3171/JNS/2008/109/10/0708; Liao ZB, 2008, EUR J NEUROL, V15, P140, DOI 10.1111/j.1468-1331.2007.02013.x; LIU Z, 2010, J CEREB BLOOD FLOW M; Liu ZW, 2008, STROKE, V39, P2571, DOI 10.1161/STROKEAHA.107.511659; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Lu DY, 2003, J NEUROSURG, V99, P351, DOI 10.3171/jns.2003.99.2.0351; Mahmood A, 2004, NEUROSURGERY, V55, P1185, DOI 10.1227/01.NEU.0000141042.14476.3C; Mahmood A, 2007, J NEUROSURG, V107, P392, DOI 10.3171/JNS-07/08/0392; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nudo RJ, 2006, CURR OPIN NEUROBIOL, V16, P638, DOI 10.1016/j.conb.2006.10.004; PAXINOS G, 1986, RAT BRAIN STEREOTAXI, pR8; Petraglia AL, 2010, NEUROSURGERY, V66, P165, DOI 10.1227/01.NEU.0000363148.49779.68; Popoli P, 2007, ANN NY ACAD SCI, V1112, P219, DOI 10.1196/annals.1415.033; Royo NC, 2003, J NEUROPATH EXP NEUR, V62, P801, DOI 10.1093/jnen/62.8.801; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Segura I, 2009, TRENDS MOL MED, V15, P439, DOI 10.1016/j.molmed.2009.08.005; Shen LH, 2010, GLIA, V58, P1074, DOI 10.1002/glia.20988; Sun D, 2007, EXP NEUROL, V204, P264, DOI 10.1016/j.expneurol.2006.11.005; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Takatsuru Y, 2009, J NEUROSCI, V29, P10081, DOI 10.1523/JNEUROSCI.1638-09.2009; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Xin HQ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009027; Xiong Y, 2008, BRAIN RES, V1230, P247, DOI 10.1016/j.brainres.2008.06.127; Xiong Y, 2008, J NEUROSURG, V109, P510, DOI 10.3171/JNS/2008/109/9/0510; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; Zhang RL, 2004, J NEUROSCI, V24, P5810, DOI 10.1523/JNEUROSCI.1109-04.2004; Zhang YL, 2010, BRAIN RES, V1353, P249, DOI 10.1016/j.brainres.2010.07.046; Zhang YL, 2009, BRAIN RES, V1294, P153, DOI 10.1016/j.brainres.2009.07.077; Zhang ZG, 2009, LANCET NEUROL, V8, P491, DOI 10.1016/S1474-4422(09)70061-4	56	32	35	0	13	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 12	2011	1384						140	150		10.1016/j.brainres.2011.01.099			11	Neurosciences	Neurosciences & Neurology	750JT	WOS:000289543100016	21295557	Green Accepted			2021-06-18	
J	Jiang, YF; Lv, HL; Huang, SS; Tan, HP; Zhang, YN; Li, H				Jiang, Yufeng; Lv, Hailong; Huang, Shanshan; Tan, Huiping; Zhang, Yinong; Li, He			Bone marrow mesenchymal stem cells can improve the motor function of a Huntington's disease rat model	NEUROLOGICAL RESEARCH			English	Article						Bone marrow mesenchymal stem cells; Huntington's disease; Quinolinic acid; Transplantation; Neurotrophic factor	TRAUMATIC BRAIN INJURY; STROMAL CELLS; RODENT MODEL; SPINAL-CORD; DIFFERENTIATE; DEFICITS; TRANSPLANTATION; RECOVERY; THERAPY; NEURONS	Objectives: The purpose of this study was to investigate the ability of bone marrow mesenchymal stem cells (BMSCs) to survive in the striatum and improve motor function in the quinolinic acid (QA) lesion rat model of Huntington's disease (HD). Methods: One week following QA lesioning of the striatum, rats were transplanted with BMSCs that had been expanded in culture and labeled with 4'-6-diamidino-2-phenylindole (DAPI) prior to transplantation. Results: BMSCs survived transplantation into the lesioned striatum and differentiated into both neurons. Moreover, transplantation of BMSCs significantly reduced motor dysfunction observed following striatal QA lesioning. Stereological striatal volume analyses performed on Nissl-stained sections revealed that rats transplanted with BMSCs had a greater striatal volume on the lesioned side compared with rats injected with vehicle. Cultured BMSCs expressed trophic factors, including nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF) and ciliary neurotrophic factor (CNTF). In the striatum of BMSC-treated group, the expression levels of these genes were significantly elevated when compared with those of the control group. Conclusion: Our data suggested that striatal transplants of BMSCs elicit behavioral and anatomical recovery in the QA lesion model of HD.	[Jiang, Yufeng; Huang, Shanshan; Tan, Huiping; Zhang, Yinong; Li, He] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Anat, Div Histol & Embryol, Wuhan 430030, Peoples R China; [Jiang, Yufeng] Shihezi Univ, Coll Med, Dept Histol & Embryol, Xinjiang, Peoples R China; [Lv, Hailong] Shihezi Univ, Affiliated Hosp 1, Sch Med, Dept Gen Surg, Xinjiang, Peoples R China	Li, H (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Anat, Div Histol & Embryol, Wuhan 430030, Peoples R China.	lihe7541@126.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30430260]	This work was supported by the National Natural Science Foundation of China (30430260).	Akiyama Y, 2002, J NEUROSCI, V22, P6623; Armstrong RJE, 2000, CELL TRANSPLANT, V9, P55, DOI 10.1177/096368970000900108; Azizi SA, 1998, P NATL ACAD SCI USA, V95, P3908, DOI 10.1073/pnas.95.7.3908; Black IB, 2001, BLOOD CELL MOL DIS, V27, P632, DOI 10.1006/bcmd.2001.0423; Chen GJ, 2002, J BIOMED SCI, V9, P303; Cuevas P, 2004, NEUROL RES, V26, P230, DOI 10.1179/016164104225013897; Emerich DF, 1996, J NEUROSCI, V16, P5168; Gaura V, 2004, BRAIN, V127, P65, DOI 10.1093/brain/awh003; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Humpel Christian, 1995, Journal of Neural Transplantation and Plasticity, V5, P257; Hurelbrink CB, 2000, CELL TRANSPLANT, V9, P743, DOI 10.1177/096368970000900601; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Li Y, 2002, NEUROLOGY, V59, P514, DOI 10.1212/WNL.59.4.514; Lindvall O, 2004, NAT MED, V10, pS42, DOI 10.1038/nm1064; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Ourednik J, 2002, NAT BIOTECHNOL, V20, P1103, DOI 10.1038/nbt750; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Song YN, 2006, NEUROSCIENCE, V140, P33, DOI 10.1016/j.neuroscience.2006.01.045; The Huntington's Disease Collaborative Research Group, 1993, CELL, V72, P971; Vazey EM, 2006, EXP NEUROL, V199, P384, DOI 10.1016/j.expneurol.2006.01.034; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	24	32	33	0	12	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	APR	2011	33	3					331	336		10.1179/016164110X12816242542571			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	751MW	WOS:000289623200016	21513650				2021-06-18	
J	Crompton, JG; Bone, C; Oyetunji, T; Pollack, KM; Bolorunduro, O; Villegas, C; Stevens, K; Cornwell, EE; Efron, DT; Haut, ER; Haider, AH				Crompton, Joseph G.; Bone, Curt; Oyetunji, Tolulope; Pollack, Keshia M.; Bolorunduro, Oluwaseyi; Villegas, Cassandra; Stevens, Kent; Cornwell, Edward E., III; Efron, David T.; Haut, Elliott R.; Haider, Adil H.			Motorcycle Helmets Associated with Lower Risk of Cervical Spine Injury: Debunking the Myth	JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS			English	Article							TRAUMA DATA-BANK; DEVELOPING-COUNTRY; HEAD-INJURIES; USE-LAW; MORTALITY; COMPLICATIONS; FATALITIES; SEVERITY; SAFETY; BURDEN	BACKGROUND: There has been a repeal of the universal helmet law in several states despite definitive evidence that helmets reduce mortality, traumatic brain injury, and hospital expenditures. Opponents of the universal helmet law have successfully claimed that helmets should not be required because of greater torque on the neck, which is thought to increase the likelihood of a cervical spine injury. There is currently insufficient evidence to counter claims that helmets do not increase the risk of cervical spine injury after a motorcycle collision. The objective of this study was to determine the impact of motorcycle helmets on the likelihood of developing a cervical spine injury after a motorcycle collision. STUDY DESIGN: We reviewed cases in the National Trauma Databank (NTDB) v7.0 involving motorcycle collisions. Multiple logistic regression was used to analyze the independent effect of helmets on cervical spine injury. Cases were adjusted for age, race, sex, insurance status, anatomic (Injury Severity Score) and physiologic injury severity (systolic blood pressure < 90 mmHg), and head injury (Abbreviated Injury Score > 3). RESULTS: Between 2002 and 2006, 62,840 cases of motorcycle collision were entered into the NTDB; 40,588 had complete data and were included in the adjusted analysis. Helmeted riders had a lower adjusted odds (0.80 [CI 0.72 to 0.90]) and a lower proportion of cervical spine injury (3.5% vs 4.4%, p < 0.05) compared with nonhelmeted riders. CONCLUSIONS: Helmeted motorcyclists are less likely to suffer a cervical spine injury after a motorcycle collision. This finding challenges a long-standing objection to mandatory helmet use that claims helmets are associated with cervical spine injury. Re-enactment of the universal helmet law should be considered in states where it has been repealed. (J Am Coll Surg 2011;212:295-300. (c) 2011 by the American College of Surgeons)	[Crompton, Joseph G.] Univ Calif Los Angeles, Sch Med, Dept Surg, Los Angeles, CA USA; [Bone, Curt; Villegas, Cassandra; Stevens, Kent; Efron, David T.; Haut, Elliott R.; Haider, Adil H.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Oyetunji, Tolulope; Bolorunduro, Oluwaseyi; Cornwell, Edward E., III] Howard Univ, Coll Med, Washington, DC USA; [Pollack, Keshia M.] Ctr Injury Res & Policy, Dept Hlth Policy & Management, Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA	Crompton, JG (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Surg, 75 Westwood Blvd, Los Angeles, CA USA.	jcrompton@mednet.ucla.edu	Oyetunji, Tolulope A/D-1447-2011; Haut, Elliott R./J-3948-2019	Haut, Elliott/0000-0001-7075-771X; Oyetunji, Tolulope/0000-0003-3039-7195			*AM COLL SURG COMM, 2008, NTDB VERS 7; BARANCIK JI, 1981, J TRAUMA, V21, P627, DOI 10.1097/00005373-198108000-00006; Chiu WT, 2000, AM J PUBLIC HEALTH, V90, P793, DOI 10.2105/AJPH.90.5.793; Croce MA, 2009, ANN SURG, V250, P390, DOI 10.1097/SLA.0b013e3181b365a2; Deitch EA, 2007, ANN SURG, V246, P447, DOI 10.1097/SLA.0b013e318148566; GOLDSTEIN JP, 1986, EVALUATION REV, V10, P355, DOI 10.1177/0193841X8601000306; Haider AH, 2008, ARCH SURG-CHICAGO, V143, P945, DOI 10.1001/archsurg.143.10.945; Haider AH, 2009, SURGERY, V146, P308, DOI 10.1016/j.surg.2009.05.006; Houston DJ, 2007, AM J PUBLIC HEALTH, V97, P2063, DOI 10.2105/AJPH.2006.094615; Jones MM, 2007, AM J PUBLIC HEALTH, V97, P208, DOI 10.2105/AJPH.2005.083204; Kardooni S, 2008, J TRAUMA, V64, P273, DOI 10.1097/TA.0b013e31816335ae; Keng SH, 2005, ACCIDENT ANAL PREV, V37, P349, DOI 10.1016/j.aap.2004.09.006; KRAUS JF, 1975, AM J EPIDEMIOL, V102, P99, DOI 10.1093/oxfordjournals.aje.a112137; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; LAWRENCE BA, COSTS INJURIES RESUL; Li LP, 2008, ACCIDENT ANAL PREV, V40, P1937, DOI 10.1016/j.aap.2008.06.019; LIU BC, 2009, COCHRANE LIB; LUNA GK, 1981, WESTERN J MED, V135, P89; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; *NAT HIGHW SAF ADM, 1996, CRASH OUTC DAT EV SY; *NAT HIGHW TRAFF S, 2006, REC TRENDS FAT MOT C; *NAT HIGHW TRAFF S, 2008, MOT HELM US LAWS; Norvell DC, 2002, AM J EPIDEMIOL, V156, P483, DOI 10.1093/aje/kwf081; O'Connor Peter J, 2005, Traffic Inj Prev, V6, P60, DOI 10.1080/15389580590903195; ORSAY E, 1996, ANN INJURY MED, V27, P389; Pervin A, 2009, B WORLD HEALTH ORGAN, V87, P369, DOI 10.2471/BLT.08.057109; Rubin DB., 1987, MULTIPLE IMPUTATION; SARKAR S, 1995, J TRAUMA, V38, P242, DOI 10.1097/00005373-199502000-00017; Solagberu BA, 2006, INJURY PREV, V12, P266, DOI 10.1136/ip.2005.011221; StataCorp, 2007, STAT STAT SOFTW REL; Vaca F, 2006, ANN EMERG MED, V47, P203, DOI 10.1016/j.annemergmed.2005.12.008; *WHO, WHO HELM IN US	32	32	34	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1072-7515			J AM COLL SURGEONS	J. Am. Coll. Surg.	MAR	2011	212	3					295	300		10.1016/j.jamcollsurg.2010.09.032			6	Surgery	Surgery	748XW	WOS:000289427400004	21227720				2021-06-18	
J	Kave, G; Heled, E; Vakil, E; Agranov, E				Kave, Gitit; Heled, Eyal; Vakil, Eli; Agranov, Eugenia			Which verbal fluency measure is most useful in demonstrating executive deficits after traumatic brain injury?	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Verbal fluency; Traumatic brain injury; Switching and clustering; Executive functions; Language testing; Hebrew	SEMANTIC FLUENCY; CATEGORY FLUENCY; NORMATIVE DATA; DISPROPORTIONATE IMPAIRMENT; ALZHEIMERS-DISEASE; PHONEMIC FLUENCY; PERFORMANCE; MEMORY; COMPONENTS; DEMENTIA	This paper examines switching and clustering in phonemic and semantic fluency tasks in individuals with traumatic brain injury (TBI). Fluency tasks were administered to 30 Hebrew-speaking patients with TBI and 30 age-matched control participants. Significant group differences were found in total output, number of switches, and number of clusters on both tasks, but not in mean cluster size. Unlike prediction, z scores of the number of semantic switches and clusters were lower than the equivalent z scores on the phonemic test. Results highlight the executive component of semantic fluency and the importance of using this task when assessing cognitive functioning after TBI.	[Kave, Gitit] Open Univ, Dept Educ & Psychol, IL-43107 Raanana, Israel; [Heled, Eyal] Hebrew Univ Jerusalem, Jerusalem, Israel; [Heled, Eyal; Agranov, Eugenia] Sheba Med Ctr, Ramat Gan, Israel; [Vakil, Eli] Bar Ilan Univ, Dept Psychol, Ramat Gan, Israel; [Vakil, Eli] Bar Ilan Univ, Leslie & Susan Gonda Goldschmied Multidisciplinar, Ramat Gan, Israel; [Agranov, Eugenia] Tel Aviv Univ, Fac Med, IL-69978 Tel Aviv, Israel	Kave, G (corresponding author), Open Univ, Dept Educ & Psychol, 1 Univ Rd,POB 808, IL-43107 Raanana, Israel.	gkave@012.net.il		Kave, Gitit/0000-0002-4950-5507	Rehabilitation Center for Veterans after traumatic brain injury (TBI) in Jaffa, Israel	This study was partially supported by a grant from the Rehabilitation Center for Veterans after traumatic brain injury (TBI) in Jaffa, Israel, given to the third author. We wish to thank Ayelet Avraham and Reut Lerer for their help in coding the data. There are no financial or other relationships that could be interpreted as a conflict of interests.	Alvarez JA, 2006, NEUROPSYCHOL REV, V16, P17, DOI 10.1007/s11065-006-9002-x; Axelrod B N, 2001, Appl Neuropsychol, V8, P248, DOI 10.1207/S15324826AN0804_8; Bittner RM, 2007, BRAIN INJURY, V21, P709, DOI 10.1080/02699050701468917; Bittner RM, 2006, BRAIN INJURY, V20, P971, DOI 10.1080/02699050600909763; Bokat CE, 2003, SCHIZOPHR RES, V64, P73, DOI 10.1016/S0920-9964(02)00282-7; Bozikas VP, 2005, SCHIZOPHR RES, V74, P51, DOI 10.1016/j.schres.2004.05.001; Busch RM, 2005, J CLIN EXP NEUROPSYC, V27, P1022, DOI 10.1080/13803390490919263; Capitani E, 2009, NEUROPSYCHOLOGIA, V47, P423, DOI 10.1016/j.neuropsychologia.2008.09.016; Curtis KL, 2008, CLIN NEUROPSYCHOL, V22, P930, DOI 10.1080/13854040701563591; Epker MO, 1999, J CLIN EXP NEUROPSYC, V21, P425, DOI 10.1076/jcen.21.4.425.890; Fagundo AB, 2008, INT J GERIATR PSYCH, V23, P1007, DOI 10.1002/gps.2025; Fossati P, 2003, PSYCHIAT RES, V117, P17, DOI 10.1016/S0165-1781(02)00300-1; Harrison JE, 2000, BRIT J CLIN PSYCHOL, V39, P181, DOI 10.1348/014466500163202; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P621, DOI 10.1037/0894-4105.18.4.621; Henry JD, 2004, NEUROPSYCHOLOGIA, V42, P1212, DOI 10.1016/j.neuropsychologia.2004.02.001; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Jurado MA, 2000, BRAIN INJURY, V14, P789; Kave G, 2005, J CLIN EXP NEUROPSYC, V27, P690, DOI 10.1080/13803390490918499; Kave G, 2008, J CLIN EXP NEUROPSYC, V30, P349, DOI 10.1080/13803390701416197; Kave G, 2007, J INT NEUROPSYCH SOC, V13, P424, DOI 10.1017/S1355617707070622; Koren R, 2005, ARCH CLIN NEUROPSYCH, V20, P1087, DOI 10.1016/j.acn.2005.06.012; Kosmidis MH, 2004, J INT NEUROPSYCH SOC, V10, P164, DOI 10.1017/S1355617704102014; Kremen WS, 2003, J INT NEUROPSYCH SOC, V9, P79, DOI 10.1017/S1355617703910095; Lanting S, 2009, J INT NEUROPSYCH SOC, V15, P196, DOI 10.1017/S1355617709090237; Rogers TT, 2006, NEUROPSYCHOLOGY, V20, P319, DOI 10.1037/0894-4105.20.3.319; Rosselli M, 2009, AGING NEUROPSYCHOL C, V16, P721, DOI 10.1080/13825580902912739; ROSSER A, 1994, J NEUROL NEUROSUR PS, V57, P1389, DOI 10.1136/jnnp.57.11.1389; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Troster AI, 1998, NEUROPSYCHOLOGIA, V36, P295, DOI 10.1016/S0028-3932(97)00153-X; Troyer AK, 1997, NEUROPSYCHOLOGY, V11, P138, DOI 10.1037/0894-4105.11.1.138; Troyer AK, 1998, NEUROPSYCHOLOGIA, V36, P499, DOI 10.1016/S0028-3932(97)00152-8; Troyer AK, 2000, J CLIN EXP NEUROPSYC, V22, P370, DOI 10.1076/1380-3395(200006)22:3;1-V;FT370; Tucha Oliver, 2005, Cogn Neuropsychiatry, V10, P231, DOI 10.1080/13546800444000047; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Vakil E, 2004, CHILD NEUROPSYCHOL, V10, P57, DOI 10.1080/09297040490911078; Woods SP, 2004, NEUROPSYCHOLOGIA, V42, P801, DOI 10.1016/j.neuropsychologia.2003.11.010	36	32	33	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2011	33	3					358	365	PII 929133278	10.1080/13803395.2010.518703			8	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	733LH	WOS:000288263700009	21058118				2021-06-18	
J	Kurczek, J; Duff, MC				Kurczek, Jake; Duff, Melissa C.			Cohesion, coherence, and declarative memory: Discourse patterns in individuals with hippocampal amnesia	APHASIOLOGY			English	Article; Proceedings Paper	40th Clinical Aphasiology Conference (CAC)	MAY 23-27, 2010	Isle of Palms, SC			Cohesion; Coherence; Declarative memory; Hippocampus; Discourse	CLOSED-HEAD INJURY; RELATIONAL MEMORY; ELICITATION TASK; WORKING-MEMORY; ADULTS; COMMUNICATION; NARRATIVES; DEMENTIA; LANGUAGE	Background: Discourse cohesion and coherence gives our communication continuity. Deficits in cohesion and coherence have been reported in patients with cognitive-communication disorders (e.g., TBI, dementia). However, the diffuse nature of pathology and widespread cognitive deficits of these disorders have made identification of specific neural substrates and cognitive systems critical for cohesion and coherence challenging. Aims: Taking advantage of a rare patient group with selective and severe declarative memory impairments, the current study attempts to isolate the contribution of declarative memory to the successful use of cohesion and coherence in discourse. Methods Procedures: Cohesion and coherence were examined in the discourse of six participants with hippocampal amnesia and six demographically matched comparison participants. Specifically, this study (1) documents the frequency, type, and completeness of cohesive ties; (2) evaluates discourse for local and global coherence; and (3) compares use of cohesive ties and coherence ratings in amnesia and healthy participants. Outcomes Results: Overall, amnesia participants produced fewer cohesive ties per T-unit, the adequacy of their ties were more often judged to be incomplete, and the ratings of their local coherence were consistently lower than comparison participants. Conclusions: These findings suggest that declarative memory may contribute to the discursive use of cohesion and coherence. Broader notions of cohesion, or interactional cohesion, i.e., cohesion across speakers (two or more people), time (days, weeks), and communicative resources (gesture), warrant further study as the experimental tasks used in the literature, and here, may actually underestimate or overestimate the extent of impairment.	[Duff, Melissa C.] Univ Iowa, Dept Commun Sci & Disorders, Iowa City, IA 52242 USA; [Kurczek, Jake; Duff, Melissa C.] Univ Iowa, Div Cognit Neurosci, Dept Neurol, Iowa City, IA USA; [Kurczek, Jake; Duff, Melissa C.] Univ Iowa, Neurosci Grad Programme, Iowa City, IA USA	Duff, MC (corresponding author), Univ Iowa, Dept Commun Sci & Disorders, 250 Hawkins Dr, Iowa City, IA 52242 USA.	melissa-duff@uiowa.edu	Kurczek, Jake/I-8619-2016	Kurczek, Jake/0000-0002-5965-2498	NIDCDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [1F32DC008825];  [NINDS NS 19632]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [F32DC008825] Funding Source: NIH RePORTER	We thank S. Shune for assistance in data coding and analysis and S. Shune, R. Gupta, and the Communication and Memory Laboratory for helpful comments on earlier versions of this manuscript. Funding from NIDCD grant 1F32DC008825, and Program Project Grant NINDS NS 19632 supported the study and manuscript preparation.	AGAR M, 1982, DISCOURSE PROCESS, V5, P1, DOI 10.1080/01638538209544529; ARBUCKLE TY, 1993, J GERONTOL, V48, pP225, DOI 10.1093/geronj/48.5.P225; Bourgeois M. S., 2009, DEMENTIA DIAGNOSIS M; COELHO CA, 1991, ARCH PHYS MED REHAB, V72, P465; Coelho CA, 2002, J SPEECH LANG HEAR R, V45, P1232, DOI 10.1044/1092-4388(2002/099); Cohen N.J., 2001, CONDITIONING CONSCIO; Cohen N. J., 2003, NEUROPSYCHOLOGY NEUR, P322; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; Davis GA, 2004, BRAIN LANG, V89, P508, DOI 10.1016/j.bandl.2004.01.003; Dijkstra K, 2004, J NEUROLINGUIST, V17, P263, DOI 10.1016/S0911-6044(03)00048-4; Dijkstra K, 2002, DISCOURSE PROCESS, V33, P53, DOI 10.1207/S15326950DP3301_03; Duff MC, 2006, NAT NEUROSCI, V9, P140, DOI 10.1038/nn1601; DUFF MC, 2005, LANGUAGE MEMORY ANAL; Duff MC, 2008, APHASIOLOGY, V22, P866, DOI 10.1080/02687030701844196; Duff MC, 2008, BRAIN LANG, V106, P41, DOI 10.1016/j.bandl.2007.10.004; Duff MC, 2007, APHASIOLOGY, V21, P702, DOI 10.1080/02687030701192265; Duff MC, 2009, APHASIOLOGY, V23, P926, DOI 10.1080/02687030802533748; GLOSSER G, 1991, BRAIN LANG, V40, P67, DOI 10.1016/0093-934X(91)90117-J; Glosser G., 1992, J CLIN EXPT NEUROPSY, V14, P40; Halliday Michael A. K., 1976, COHESION ENGLISH; Hannula DE, 2006, J NEUROSCI, V26, P8352, DOI 10.1523/JNEUROSCI.5222-05.2006; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; Hengst JA, 2007, TOP LANG DISORD, V27, P37, DOI 10.1097/00011363-200701000-00005; Hengst JA, 2010, APHASIOLOGY, V24, P887, DOI 10.1080/02687030903478330; Hunt K., 1970, MONOGRAPHS SOC RES C, V35; Konkel A, 2008, FRONT HUM NEUROSCI, V2, DOI 10.3389/neuro.09.015.2008; LILES BZ, 1989, J SPEECH HEAR DISORD, V54, P356, DOI 10.1044/jshd.5403.356; LILES BZ, 1985, J SPEECH HEAR RES, V28, P123, DOI 10.1044/jshr.2801.123; Liles BZ, 1998, ANAL DISCOURSE COMMU, P65; Louwerse M. M., 2005, ENCY LINGUISTICS, P216; Murray Laura L., 2001, Seminars in Speech and Language, V22, P127; Ogden J.A., 1991, MEMORY MECH TRIBUTE; Olson IR, 2006, J COGNITIVE NEUROSCI, V18, P1087, DOI 10.1162/jocn.2006.18.7.1087; RICHARDSON JTE, 2000, CLIN NEUROPSYCHOLOGI; Ripich DN, 2000, INT J LANG COMM DIS, V35, P49; Rogalski Y, 2010, J COMMUN DISORD, V43, P212, DOI 10.1016/j.jcomdis.2010.02.001; Ryan JD, 2004, J EXP PSYCHOL HUMAN, V30, P988, DOI 10.1037/0096-1523.30.5.988; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Shadden B.B., 1991, CLIN APHASIOLOGY, V20, P327; Tannen Deborah, 1989, TALKING VOICES REPET; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; Warren DE, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/fnhum.2010.00035; Winter P., 1976, BEAR FLY; Youse KM, 2005, BRAIN INJURY, V19, P1001, DOI 10.1080/02699050500109951	44	32	33	0	12	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology		2011	25	6-7					700	712	PII 931812299	10.1080/02687038.2010.537345			13	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	775XO	WOS:000291497000004	23136461	Green Accepted			2021-06-18	
J	Chisholm, KM; Harruff, RC				Chisholm, Karen M.; Harruff, Richard C.			Elderly Deaths Due to Ground-Level Falls	AMERICAN JOURNAL OF FORENSIC MEDICINE AND PATHOLOGY			English	Article						ground-level falls in the elderly; head injuries; warfarin anticoagulation	TRAUMATIC BRAIN-INJURY; PREINJURY WARFARIN USE; SEVERE HEAD-INJURIES; INTRACRANIAL HEMORRHAGE; OLDER-ADULTS; ATRIAL-FIBRILLATION; RISK-FACTORS; ADVANCED AGE; ANTICOAGULATION; COMPLICATIONS	This study analyzed 237 fatal ground-level falls occurring in decedents aged 65 years or older reported to the Seattle-King County Medical Examiner's Office during the year 2007. Head injuries accounted for 109 (46%) of the deaths, and nonhead injuries accounted for 128 (54%) of the deaths. Falls occurred in similar locations in both groups. Compared with those of nonhead injuries, decedents of head injuries were younger (82 vs 87.5 years), were more often male (58% vs 45%), died sooner after their injury (9 days vs 23 days), and were more likely treated with anticoagulants, especially warfarin (48% vs 16%). Subdural hematoma was the most common specific traumatic lesion, occurring in 86% of the decedents of head injury; skull fractures occurred in 13%. Decedents of head injury who were treated with anticoagulants, on average, sustained less severe head injury than those who were not treated with anticoagulants.	[Chisholm, Karen M.] Univ Washington, Dept Pathol, Div Med Genet, Seattle, WA 98195 USA; Univ Washington, Dept Med, Div Med Genet, Seattle, WA 98195 USA; [Harruff, Richard C.] King Cty Med Examiners Off, Seattle, WA USA	Harruff, RC (corresponding author), Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA.	richard.harruff@kingcounty.gov		Chisholm, Karen/0000-0002-1898-1252	National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, through the Division of Medical Genetics, Department of Medicine, University of WashingtonUniversity of WashingtonUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [F30 ES13069]; Department of Pathology, University of WashingtonUniversity of Washington [NIGMS GM07266]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [F30ES013069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM007266] Funding Source: NIH RePORTER	K.M.C. was supported by grant F30 ES13069 from the National Institute of Environmental Health Sciences, National Institutes of Health, Research Triangle Park, NC, through the Division of Medical Genetics, Department of Medicine, University of Washington. K.M.C. was also a recipient of the Medical Scientist Training Program grant NIGMS GM07266, through the Department of Pathology, University of Washington.	Close J, 1999, LANCET, V353, P93, DOI 10.1016/S0140-6736(98)06119-4; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Fang MC, 2004, ANN INTERN MED, V141, P745, DOI 10.7326/0003-4819-141-10-200411160-00005; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gage BF, 2005, AM J MED, V118, P612, DOI 10.1016/j.amjmed.2005.02.022; Hartshorne NJ, 1997, AM J FOREN MED PATH, V18, P258, DOI 10.1097/00000433-199709000-00006; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; Kannus P, 1999, JAMA-J AM MED ASSOC, V281, P1895, DOI 10.1001/jama.281.20.1895; Kannus P, 1999, AM J EPIDEMIOL, V149, P143; Kannus P, 2005, AM J PUBLIC HEALTH, V95, P422, DOI 10.2105/AJPH.2004.047779; Kannus P, 2007, INJURY, V38, P81, DOI 10.1016/j.injury.2006.08.027; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; MATHIESEN T, 1995, ACTA NEUROL SCAND, V91, P208; Mina AA, 2003, J TRAUMA, V54, P842, DOI 10.1097/01.TA.0000063271.05829.15; Mina AA, 2002, J TRAUMA, V53, P668, DOI 10.1097/00005373-200210000-00008; Oakley A, 1996, QUAL HEALTH CARE, V5, P243, DOI 10.1136/qshc.5.4.243; Pieracci FM, 2007, J TRAUMA, V63, P519, DOI 10.1097/TA.0b013e31812e519b; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Rivara FP, 1997, NEW ENGL J MED, V337, P613, DOI 10.1056/NEJM199708283370907; Rosand J, 2004, ARCH INTERN MED, V164, P880, DOI 10.1001/archinte.164.8.880; Saab M, 1996, J ACCID EMERG MED, V13, P208; Sterling DA, 2001, J TRAUMA, V50, P116, DOI 10.1097/00005373-200101000-00021; Stevens J. A., 2006, Morbidity and Mortality Weekly Report, V55, P1221; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TINETTI ME, 1989, NEW ENGL J MED, V320, P1055	26	32	32	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-7910	1533-404X		AM J FOREN MED PATH	Am. J. Forensic Med. Pathol.	DEC	2010	31	4					350	354		10.1097/PAF.0b013e3181f69c87			5	Medicine, Legal; Pathology	Legal Medicine; Pathology	688BQ	WOS:000284824700017	20938326				2021-06-18	
J	Meyer, KS; Marion, DW; Coronel, H; Jaffee, MS				Meyer, Kimberly S.; Marion, Donald W.; Coronel, Helen; Jaffee, Michael S.			Combat-Related Traumatic Brain Injury and Its Implications to Military Healthcare	PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article						TBI; PTSD; Screening; Management	POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSIVE SYMPTOMS; SERVICE MEMBERS; SLEEP DISORDERS; CHRONIC PAIN; VETERANS; ASSOCIATION; PREVALENCE; DEPLOYMENT; COMPLAINTS	Traumatic brain injury (TBI) is a known injury in today's combat arena Improved screening and surveillance methods have diagnosed TBI with increasing frequency Current treatment plans are based largely on information gleaned from sports injuries However these management paradigms fail to address the effect of physiologic stress (fatigue dehydration) and psychological stress at the time of injury as well as the number of previous concussions that may affect recovery from combat-related TBI This article presents current evaluation and management of combat-related injury and discusses other psychological conditions that may coexist with TBI	[Meyer, Kimberly S.; Marion, Donald W.; Coronel, Helen; Jaffee, Michael S.] Def & Vet Brain Injury Ctr, Washington, DC 20012 USA; [Meyer, Kimberly S.] Univ Louisville Hosp, Trauma Inst, Louisville, KY 40202 USA	Meyer, KS (corresponding author), Def & Vet Brain Injury Ctr, POB 59181, Washington, DC 20012 USA.		Marion, Donald/AAR-5749-2021; Meyer, Kimberly/L-5430-2019	Marion, Donald/0000-0003-4627-7702			Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Belanger HG, 2009, J INT NEUROPSYCH SOC, V15, P1, DOI 10.1017/S1355617708090036; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; *BRAIN TRAUM FDN A, 2001, J TRAUMA S2, V51, pS3; Brenner LA, 2008, J HEAD TRAUMA REHAB, V23, P401, DOI 10.1097/01.HTR.0000341436.59627.a5; Brenner LA, 2009, REHABIL PSYCHOL, V54, P390, DOI 10.1037/a0017802; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Dempsey Kenneth E, 2009, J Trauma Nurs, V16, P6, DOI 10.1097/01.JTN.0000348063.41099.a7; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; Gaylord KM, 2008, J TRAUMA, V64, pS200, DOI 10.1097/TA.0b013e318160ba42; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; Halbauer JD, 2009, J REHABIL RES DEV, V46, P757, DOI 10.1682/JRRD.2008.08.0119; Hill JJ, 2009, AM J PHYS MED REHAB, V88, P605, DOI 10.1097/PHM.0b013e3181ae0f83; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Ivins BJ, 2009, J HEAD TRAUMA REHAB, V24, P24, DOI 10.1097/HTR.0b013e3181957042; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Kraus J, 2009, J HEAD TRAUMA REHAB, V24, P344, DOI 10.1097/HTR.0b013e3181ae35fd; Lew HL, 2006, AM J PHYS MED REHAB, V85, P619, DOI 10.1097/01.phm.0000223235.09931.c0; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; McCrea M., 2000, STANDARDIZED ASSESSM; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Ponsford J, 2005, CURR OPIN NEUROL, V18, P692, DOI 10.1097/01.wco.0000186840.61431.44; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; THEELER BJ, 2010, HEADACHE; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Warden DL, 2009, NEUROIMAGE, V47, pT152, DOI 10.1016/j.neuroimage.2009.01.060; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f	47	32	32	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0193-953X	1558-3147		PSYCHIAT CLIN N AM	Psychiatr. Clin. North Amer.	DEC	2010	33	4					783	+		10.1016/j.psc.2010.08.007			15	Psychiatry	Psychiatry	694TA	WOS:000285320700004	21093678				2021-06-18	
J	Thompson, SN; Carrico, KM; Mustafa, AG; Bains, M; Hall, ED				Thompson, Stephanie N.; Carrico, Kimberly M.; Mustafa, Ayman G.; Bains, Mona; Hall, Edward D.			A Pharmacological Analysis of the Neuroprotective Efficacy of the Brain- and Cell-Permeable Calpain Inhibitor MDL-28170 in the Mouse Controlled Cortical Impact Traumatic Brain Injury Model	JOURNAL OF NEUROTRAUMA			English	Article						calpain; controlled cortical impact; cytoskeleton; neurodegeneration; traumatic brain injury	SPINAL-CORD-INJURY; INDUCED AXONAL INJURY; CYCLOSPORINE-A; HEAD-INJURY; SPECTRIN PROTEOLYSIS; CORPUS-CALLOSUM; DOSE-RESPONSE; RATS; NEURODEGENERATION; DEGRADATION	The cytoskeletal and neuronal protective effects of early treatment with the blood-brain barrier-and cell-permeable calpain inhibitor MDL-28170 was examined in the controlled cortical impact (CCI) traumatic brain injury (TBI) model in male CF-1 mice. This was preceded by a dose-response and pharmacodynamic evaluation of IV or IP doses of MDL-28170 with regard to ex vivo inhibition of calpain 2 activity in harvested brain homogenates. From these data, we tested the effects of an optimized MDL-28170 dosing regimen on calpain-mediated degradation of the neuronal cytoskeletal protein alpha-spectrin in cortical or hippocampal tissue of mice 24 h after CCI-TBI (1.0mm depth, 3.5 m/sec velocity). With treatment initiated at 15min post-TBI, alpha-spectrin degradation was significantly reduced by 40% in hippocampus and 44% in cortex. This effect was still observed with a 1-h but not a 3-h post-TBI delay. The cytoskeletal protection is most likely taking place in neurons surrounding the area of mainly necrotic degeneration, since MDL-28170 did not reduce hemispheric lesion volume as measured by the aminocupric silver staining method. This lack of effect on lesion volume has been seen with other calpain inhibitors, which suggests that pharmacological calpain inhibition by itself, while able to reduce axonal injury, may not be able to produce a measurable reduction in lesion volume. This is in contrast to certain other neuroprotective mechanistic approaches such as the mitochondrial protectant cyclosporine A, which produces at least a partial decrease in lesion volume in the same model. Accordingly, the combination of a calpain inhibitor with a compound such as cyclosporine A may be needed to achieve the optimal degree of post-TBI neuroprotection.	[Thompson, Stephanie N.; Carrico, Kimberly M.; Mustafa, Ayman G.; Bains, Mona; Hall, Edward D.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; [Mustafa, Ayman G.] Jordan Univ Sci & Technol, Coll Med, Dept Anat & Cell Biol, Irbid, Jordan	Hall, ED (corresponding author), Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, 741 S Limestone St,BBSRB Room 483, Lexington, KY 40536 USA.	edhall@uky.edu	Hall, Edward D/F-8930-2013		Kentucky Spinal Cord & Head Injury Research Trust;  [1P01 NS058484];  [5P30 NS051220]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, P01NS058484] Funding Source: NIH RePORTER	These studies were funded by grants 1P01 NS058484 and 5P30 NS051220 and the Kentucky Spinal Cord & Head Injury Research Trust.	Ai JL, 2007, J NEUROTRAUM, V24, P960, DOI 10.1089/neu.2006.0224; Arataki S, 2005, J NEUROTRAUM, V22, P398, DOI 10.1089/neu.2005.22.398; Ayala-Grosso C, 2004, NEUROSCIENCE, V126, P927, DOI 10.1016/j.neuroscience.2004.04.048; Bartus RT, 1997, NEUROSCIENTIST, V3, P314, DOI 10.1177/107385849700300513; Brophy GM, 2009, J NEUROTRAUM, V26, P471, DOI 10.1089/neu.2008.0657; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Czeiter E, 2009, MOLECULES, V14, P5115, DOI 10.3390/molecules14125115; Deng Y, 2007, EXP NEUROL, V205, P154, DOI 10.1016/j.expneurol.2007.01.023; Deng-Bryant Y, 2008, J CEREBR BLOOD F MET, V28, P1114, DOI 10.1038/jcbfm.2008.10; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; Goss CW, 2003, PHARMACOL BIOCHEM BE, V76, P231, DOI 10.1016/j.pbb.2003.07.003; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Kawamura M, 2005, BRAIN RES, V1037, P59, DOI 10.1016/j.brainres.2004.12.050; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Kupina NC, 2002, J CEREBR BLOOD F MET, V22, P1212; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; Mbye LH, 2009, J CEREBR BLOOD F MET, V29, P87, DOI 10.1038/jcbfm.2008.93; McCracken E, 1999, J NEUROTRAUM, V16, P749, DOI 10.1089/neu.1999.16.749; McGinn MJ, 2009, J NEUROPATH EXP NEUR, V68, P241, DOI 10.1097/NEN.0b013e3181996bfe; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; MEHDI S, 1988, BIOCHEM BIOPH RES CO, V157, P1117, DOI 10.1016/S0006-291X(88)80989-6; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Newcomb JK, 1997, J NEUROTRAUM, V14, P369, DOI 10.1089/neu.1997.14.369; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROPATH EXP NEUR, V55, P68, DOI 10.1097/00005072-199601000-00007; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Sullivan PG, 2000, NEUROSCIENCE, V101, P289, DOI 10.1016/S0306-4522(00)00380-8; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; Switzer RC, 2000, TOXICOL PATHOL, V28, P70, DOI 10.1177/019262330002800109; Thompson SN, 2006, EXP NEUROL, V201, P253, DOI 10.1016/j.expneurol.2006.04.013; Thompson VF, 2000, ANAL BIOCHEM, V279, P170, DOI 10.1006/abio.1999.4475; Wang KKW, 2000, TRENDS NEUROSCI, V23, P59, DOI 10.1016/S0166-2236(99)01536-2; Yu CG, 2008, J NEUROTRAUM, V25, P833, DOI 10.1089/neu.2007.0490; Yu CG, 2007, NEUROCHEM RES, V32, P2046, DOI 10.1007/s11064-007-9347-4; YUEN PW, 1996, EXPERT OPIN INV DRUG, V5, P1291	47	32	33	1	7	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2010	27	12					2233	2243		10.1089/neu.2010.1474			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	691PN	WOS:000285093400012	20874056	Green Published			2021-06-18	
J	Zink, BJ; Szmydynger-Chodobska, J; Chodobski, A				Zink, Brian J.; Szmydynger-Chodobska, Joanna; Chodobski, Adam			Emerging Concepts in the Pathophysiology of Traumatic Brain Injury	PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article						Pathophysiology; Traumatic brain injury; TBI; ICP; Blood-brain barrier	CEREBRAL-BLOOD-FLOW; INTRACRANIAL-PRESSURE; VASOPRESSIN V-1A; CHOROID-PLEXUS; IMPACT; BIOMARKERS; PROTEIN; MICROCIRCULATION; AUTOREGULATION; EPIDEMIOLOGY	A complex set of molecular and functional reactions is set into motion by traumatic brain injury (TBI) New research that extends beyond pathological effects on neurons suggests a key role for the blood-brain barrier neurovascular unit arginine vasopressin and neuroinflammation in the pathophysiology of TBI The prevalence of molecular derangements in TBI holds promise for the identification and use of biomarkers to assess severity of injury determine prognosis and perhaps direct therapy Hopefully, improved knowledge of these elements of pathophysiology will provide the mechanistic clues that lead to improved treatment of TBI	[Zink, Brian J.] Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Dept Emergency Med, Providence, RI 02903 USA; [Zink, Brian J.] Miriam Hosp, Providence, RI 02903 USA; [Szmydynger-Chodobska, Joanna; Chodobski, Adam] Brown Univ, Coro Ctr, Alpert Med Sch, Dept Emergency Med, Providence, RI 02903 USA	Zink, BJ (corresponding author), Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Dept Emergency Med, 593 Eddy St,Claverick 2, Providence, RI 02903 USA.						Abbott NJ, 2006, NAT REV NEUROSCI, V7, P41, DOI 10.1038/nrn1824; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; BUIJS RM, 1978, CELL TISSUE RES, V186, P423, DOI 10.1007/BF00224932; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Carter BG, 2008, CHILD NERV SYST, V24, P245, DOI 10.1007/s00381-007-0461-z; Chaiwat O, 2009, J NEUROTRAUM, V26, P657, DOI 10.1089/neu.2008.0770; Chen Y, 2003, J CEREBR BLOOD F MET, V23, P748, DOI 10.1097/01.WCB.0000071885.63724.20; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chodobski A, 1997, MOL BRAIN RES, V48, P67, DOI 10.1016/S0169-328X(97)00079-X; Chodobski A, 2003, NEUROSCIENCE, V122, P853, DOI 10.1016/j.neuroscience.2003.08.055; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; DELAOSSA NP, 2010, STROKE, P4; Dimitrijevic OB, 2007, STROKE, V38, P1345, DOI 10.1161/01.STR.0000259709.16654.8f; Figaji AA, 2009, J NEUROSURG-PEDIATR, V4, P420, DOI 10.3171/2009.6.PEDS096; Gennarelli T.A., 1990, 34 ANN P ASS ADV AUT; Haqqani AS, 2007, J NEUROTRAUM, V24, P54, DOI 10.1089/neu.2006.0079; Hergenroeder G, 2008, J NEUROTRAUM, V25, P79, DOI 10.1089/neu.2007.0386; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laterza OF, 2009, CLIN CHEM, V55, P1977, DOI 10.1373/clinchem.2009.131797; Lin JW, 2008, ACTA NEUROCHIR SUPPL, V101, P131; Liu DZ, 2010, J CEREBR BLOOD F MET, V30, P92, DOI 10.1038/jcbfm.2009.186; Lo EH, 2001, BRAIN RES REV, V38, P140, DOI 10.1016/S0165-0173(01)00083-2; Loscher W, 2005, PROG NEUROBIOL, V76, P22, DOI 10.1016/j.pneurobio.2005.04.006; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; Marmarou A, 2006, J NEUROSURG, V104, P720, DOI 10.3171/jns.2006.104.5.720; MCLEAN A, 1996, TRAUMATIC BRAIN INJU; Nakayama Y, 2000, BRAIN RES, V858, P416, DOI 10.1016/S0006-8993(00)01955-7; Neumann J, 2008, J NEUROSCI, V28, P5965, DOI 10.1523/JNEUROSCI.0060-08.2008; OBRIST WD, 1977, ACTA NEUROL SCAND, V56, P178; OBRIST WD, 1979, J NEUROSURG, V51, P292, DOI 10.3171/jns.1979.51.3.0292; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Puppo C, 2008, NEUROCRIT CARE, V8, P344, DOI 10.1007/s12028-008-9069-8; Rafols JA, 2007, NEUROL RES, V29, P339, DOI 10.1179/016164107X204648; RangeL-Castilla L, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E7; Regan RF, 1996, J NEUROTRAUM, V13, P223, DOI 10.1089/neu.1996.13.223; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Schmidt B, 2009, J NEUROTRAUM, V26, P651, DOI 10.1089/neu.2008.0784; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Schwarzmaier SM, 2010, J NEUROTRAUM, V27, P121, DOI 10.1089/neu.2009.1114; Scremin OU, 2007, BRAIN RES, V1141, P235, DOI 10.1016/j.brainres.2007.01.006; Shuaib A, 2002, STROKE, V33, P3033, DOI 10.1161/01.STR.0000039405.31526.06; Siman R, 2009, J NEUROTRAUM, V26, pA61; Smith M, 2008, ANESTH ANALG, V106, P240, DOI 10.1213/01.ane.0000297296.52006.8e; Soustiel JF, 2006, ACTA NEUROCHIR, V148, P845, DOI 10.1007/s00701-006-0792-7; Soustiel JF, 2005, J NEUROTRAUM, V22, P955, DOI 10.1089/neu.2005.22.955; Spudich A, 2006, NAT NEUROSCI, V9, P487, DOI 10.1038/nn1676; Stiell IG, 2008, CAN MED ASSOC J, V178, P1141, DOI 10.1503/cmaj.071154; STRBIAN D, 2009, ANN MED, V1, P1; Szmydynger-Chodobska J, 2004, J NEUROTRAUM, V21, P1090, DOI 10.1089/0897715041651033; Szmydynger-Chodobska J, 2009, J CEREBR BLOOD F MET, V29, P1503, DOI 10.1038/jcbfm.2009.71; TEASDALE G, 1996, NEUROLOGICAL SURG; Tisdall MM, 2007, BRIT J ANAESTH, V99, P61, DOI 10.1093/bja/aem143; Tolias Christos M, 2004, NeuroRx, V1, P71, DOI 10.1602/neurorx.1.1.71; Trabold R, 2008, J NEUROTRAUM, V25, P1459, DOI 10.1089/neu.2008.0597; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; WILLINGER R, 1996, TRAUMATIC BRAIN INJU; Yilmazlar S, 1997, J Neurosurg Sci, V41, P379	64	32	32	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0193-953X	1558-3147		PSYCHIAT CLIN N AM	Psychiatr. Clin. North Amer.	DEC	2010	33	4					741	+		10.1016/j.psc.2010.08.005			17	Psychiatry	Psychiatry	694TA	WOS:000285320700002	21093676				2021-06-18	
J	Hong, JH; Jang, SH				Hong, Ji Heon; Jang, Sung Ho			DEGENERATION OF CINGULUM AND FORNIX IN A PATIENT WITH TRAUMATIC BRAIN INJURY: DIFFUSE TENSOR TRACTOGRAPHY STUDY	JOURNAL OF REHABILITATION MEDICINE			English	Article						cingulum; fornix; trauma; brain injury; memory; diffusion tensor image	AXONAL INJURY; RECOVERY; TRACKING; DAMAGE	Objectives: The cingulum and fornix are important structures for memory function. Using follow-up diffusion tensor tractography in a patient with traumatic brain injury we found degeneration of the cingulum and fornix. Case report: An 18-year-old male who had had a traffic accident underwent conservative management for diffuse axonal injury. Brain magnetic resonance imaging showed an encephalomalactic lesion in the posterior portion of the corpus callosum. The patient had severe cognitive problems at 3 months after onset. However, while his intelligence had improved, his memory impairment had been aggravated at 14 months from onset. Results: On the first diffusion tensor tractographies, the integrity of both corticospinal tracts, right cingulum, and left fornix were preserved; however, compared with controls, there were disruptions in both ends of the left cingulum and right fornical crus. On the second diffusion tensor tractographies, both the cingulum and fornix showed severe degeneration, although the integrities of both corticospinal tracts were well preserved. Conclusion: We conclude that patients with memory impairment following traumatic brain injury should be evaluated using diffusion tensor imaging. In addition, follow-up diffusion tensor imaging may be necessary in patients with sustained memory impairment.	[Hong, Ji Heon; Jang, Sung Ho] Yeungnam Univ, Dept Phys Med & Rehabil, Coll Med, Taegu 705717, South Korea	Jang, SH (corresponding author), Yeungnam Univ, Dept Phys Med & Rehabil, Coll Med, 317-1 Daemyungdong, Taegu 705717, South Korea.	strokerehab@hanmail.net			Korean GovernmentKorean Government [KRF-2008-314-E00173]	This work was supported by National Research Foundation of Korea Grant funded by the Korean Government (KRF-2008-314-E00173)	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Ciccarelli O, 2003, NEUROIMAGE, V18, P348, DOI 10.1016/S1053-8119(02)00042-3; Concha L, 2005, AM J NEURORADIOL, V26, P2267; Danielian LE, 2010, NEUROIMAGE, V49, P1572, DOI 10.1016/j.neuroimage.2009.08.062; Jang SH, 2009, ARCH NEUROL-CHICAGO, V66, P1424, DOI 10.1001/archneurol.2009.242; Jang SH, 2009, NEUROREHABILITATION, V24, P349, DOI 10.3233/NRE-2009-0489; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Malykhin N, 2008, PSYCHIAT RES-NEUROIM, V164, P132, DOI 10.1016/j.pscychresns.2007.11.007; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Selden NR, 1998, BRAIN, V121, P2249, DOI 10.1093/brain/121.12.2249; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Spanos GK, 2007, AM J NEURORADIOL, V28, P537; Stieltjes B, 2001, NEUROIMAGE, V14, P723, DOI 10.1006/nimg.2001.0861; Sugiyama K, 2007, BRAIN INJURY, V21, P413, DOI 10.1080/02699050701311042; Sugiyama K, 2009, J NEUROTRAUM, V26, P1879, DOI [10.1089/neu.2008.0839, 10.1089/neu.2008-0839]; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; Wakana S, 2004, RADIOLOGY, V230, P77, DOI 10.1148/radiol.2301021640; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wechsler D., 1981, WAIS R MANUAL WECHSL; Williams JM, 1991, MAS MEMORY ASSESSMEN; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Zhang Y, 2009, BRAIN, V132, P2579, DOI 10.1093/brain/awp071	26	32	32	0	1	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977	1651-2081		J REHABIL MED	J. Rehabil. Med.	NOV	2010	42	10					979	981		10.2340/16501977-0603			3	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	687BK	WOS:000284748600014	21031297	DOAJ Gold			2021-06-18	
J	Klimek, M; Dammers, R				Klimek, Markus; Dammers, Ruben			Antiepileptic drug therapy in the perioperative course of neurosurgical patients	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						antiepileptic drugs; neurosurgery; perioperative; prophylaxis; side-effects	BRAIN-TUMORS; PHENYTOIN; LEVETIRACETAM; EPILEPSY; PROPHYLAXIS	Purpose of review Antiepileptic agents are widely used in the perioperative course of neurosurgical patients - for prophylactic and therapeutic reasons. However, the evidence supporting their use is extremely small and adverse events are common. This review highlights the current controversies. Recent findings Prophylactic use of antiepileptic agents is unfavorable for patients with subarachnoid hemorrhage. In patients with brain tumors, prophylactic use is not recommended. If the drugs are used nevertheless, stopping after the first postoperative week must be strongly recommended. After traumatic brain injury, early prophylactic use might prevent late post-traumatic seizures. The new antiepileptic drug levetiracetam seems to have a better safety profile, which makes it more suitable for prophylactic use. However, in all groups, evidence concerning the choice of drugs and duration of prophylaxis is lacking. Current research is focusing on prevention of epileptogenesis. Therapeutic use of antiepileptic drugs is supported by evidence. These drugs should be continued perioperatively. However, they might induce severe adverse events during adjuvant treatments like radiotherapy or chemotherapy in patients with brain tumors. Summary Despite lacking evidence, prophylactic antiepileptic drug use is common in the perioperative course of neurosurgical patients. More research is needed to deal better with epileptogenesis and to define the right drug for the right patient at the right time.	[Klimek, Markus] Erasmus MC, Univ Med Ctr, Dept Anesthesiol, Vice Head Residency Training Program, NL-3000 CA Rotterdam, Netherlands; [Dammers, Ruben] Erasmus MC, Univ Med Ctr, Dept Neurosurg, NL-3000 CA Rotterdam, Netherlands	Klimek, M (corresponding author), Erasmus MC, Univ Med Ctr, Dept Anesthesiol, Vice Head Residency Training Program, Off H-1279,POB 2040, NL-3000 CA Rotterdam, Netherlands.	m.klimek@erasmusmc.nl	Dammers, Ruben/AAL-8391-2021; Klimek, Markus/N-7047-2019; Dammers, Ruben/AAD-9095-2021; Klimek, Markus/I-6523-2013	Klimek, Markus/0000-0002-0122-9929; Dammers, Ruben/0000-0001-7033-0644			Benardo LS, 2003, EPILEPSIA, V44, P27, DOI 10.1046/j.1528-1157.44.s10.2.x; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS83; Chaichana KL, 2009, J NEUROSURG, V111, P282, DOI 10.3171/2009.2.JNS081132; Chang EF, 2008, J NEUROSURG, V108, P227, DOI 10.3171/JNS/2008/108/2/0227; Fountain NB, 2009, EPILEPSY CURR, V9, P71, DOI 10.1111/j.1535-7511.2009.01297.x; Glantz MJ, 2000, NEUROLOGY, V54, P1886, DOI 10.1212/WNL.54.10.1886; Heros RC, 2007, J NEUROSURG, V107, P251, DOI 10.3171/JNS-07/08/0251; Jensen FE, 2009, EPILEPSIA S2, V50, pS1; Kofke WA, 2010, CURR OPIN ANESTHESIO, V23, P391, DOI 10.1097/ACO.0b013e328339250b; Lim DA, 2009, J NEURO-ONCOL, V93, P349, DOI 10.1007/s11060-008-9781-4; LOWENSTEIN D, 2009, EPILEPSIA S2, V50, pS4; Milligan TA, 2008, NEUROLOGY, V71, P665, DOI 10.1212/01.wnl.0000324624.52935.46; Naidech AM, 2005, STROKE, V36, P583, DOI 10.1161/01.STR.0000141936.36596.1e; Naidech AM, 2009, STROKE, V40, P3810, DOI 10.1161/STROKEAHA.109.559948; Prince DA, 2009, EPILEPSIA, V50, P30, DOI 10.1111/j.1528-1167.2008.02008.x; Rosengart AJ, 2007, J NEUROSURG, V107, P253, DOI 10.3171/JNS-07/08/0253; Siomin V, 2005, J NEURO-ONCOL, V74, P211, DOI 10.1007/s11060-004-6912-4; Szaflarski JP, 2010, NEUROCRIT CARE, V12, P165, DOI 10.1007/s12028-009-9304-y; Tremont-Lukats IW, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004424.pub2; van Breemen MSM, 2007, LANCET NEUROL, V6, P421, DOI 10.1016/S1474-4422(07)70103-5	20	32	35	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	OCT	2010	23	5					564	567		10.1097/ACO.0b013e32833e14f2			4	Anesthesiology	Anesthesiology	646RR	WOS:000281560500005	20689411				2021-06-18	
J	Chen, LJ; Wang, YJ; Tseng, GF				Chen, Li-Jin; Wang, Yueh-Jan; Tseng, Guo-Fang			Compression Alters Kinase and Phosphatase Activity and Tau and MAP2 Phosphorylation Transiently while Inducing the Fast Adaptive Dendritic Remodeling of Underlying Cortical Neurons	JOURNAL OF NEUROTRAUMA			English	Article						in vivo studies; neuroplasticity; traumatic brain injury	MICROTUBULE-ASSOCIATED PROTEIN-2; ALZHEIMER NEUROFIBRILLARY DEGENERATION; GLYCOGEN-SYNTHASE KINASE-3; CYCLIN-DEPENDENT KINASE-5; COLD-WATER STRESS; CEREBRAL-CORTEX; BRAIN-INJURY; EPIDURAL COMPRESSION; HIPPOCAMPAL-NEURONS; HYPERPHOSPHORYLATED-TAU	In traumatic brain injury (TBI) there is often compression of the cerebral cortex. Using a rat epidural bead implantation model we found that mechanical compression distorted the dendrites of underlying cortical pyramidal neurons, and that the deformed dendrites regained straight morphology in 3 days. This was accompanied by a transient increase in the phosphorylation of microtubule-associated proteins (MAPs) at sites known to destabilize microtubules, including MAP2 from 30 min to 1 h, and tau from 10 min to 12 h following compression. Immunostaining confirmed that phosphorylated MAPs were concentrated at the somata and dendrites of compressed cortical pyramidal neurons. Enzymes regulating MAP phosphorylation were found to be simultaneously altered, including downregulation of protein phosphatase 2A, but not 2B, activity from 10 min to 1 day, and transient excitatory phosphorylation of extracellular signal-regulated protein kinase 1/2 and p38/mitogen-activated protein kinase. The temporal coincidence of these events suggests that alterations of phosphatase and kinase activity underlie MAP2 and tau phosphorylation, thus causing the compressed cortical neurons to remodel their dendrites, including the proximal segments. The rapid onset of these molecular changes demonstrates that compression causes cortical neurons to undergo active changes much early than expected. The large-scale structural changes that result can alter cortical function for an extended period of time.	[Wang, Yueh-Jan; Tseng, Guo-Fang] Tzu Chi Univ, Coll Med, Dept Anat, Hualien 970, Taiwan; [Chen, Li-Jin] Natl Taiwan Univ, Coll Med, Inst Anat & Cell Biol, Taipei 10764, Taiwan	Tseng, GF (corresponding author), Tzu Chi Univ, Coll Med, Dept Anat, 701,Sect 3,Jhongyang Rd, Hualien 970, Taiwan.	chris@mail.tcu.edu.tw; guofang@mail.tcu.edu.tw			National Science Council of TaiwanMinistry of Science and Technology, Taiwan [NSC97-2320-B-320-006, NSC97-2320-B-007]; Tzu-Chi University [TCIRP-95003, TCIRP-98006]	This work was supported by grants from the National Science Council of Taiwan to G.-F.T. (NSC97-2320-B-320-006), and Y.-J.W. (NSC97-2320-B-007), and from Tzu-Chi University to G.-F.T. and Y.-J.W. (TCIRP-95003 and TCIRP-98006).	ABE T, 1984, SURG NEUROL, V22, P477, DOI 10.1016/0090-3019(84)90306-9; Ahmad FJ, 1999, J CELL BIOL, V145, P305, DOI 10.1083/jcb.145.2.305; Alonso AD, 1997, P NATL ACAD SCI USA, V94, P298, DOI 10.1073/pnas.94.1.298; Alonso AD, 1996, NAT MED, V2, P783, DOI 10.1038/nm0796-783; Arendt T, 2003, J NEUROSCI, V23, P6972, DOI 10.1523/JNEUROSCI.23-18-06972.2003; Baas PW, 2005, TRENDS CELL BIOL, V15, P183, DOI 10.1016/j.tcb.2005.02.001; Baas PW, 2005, TRENDS CELL BIOL, V15, P518, DOI 10.1016/j.tcb.2005.08.004; Bennecib M, 2001, FEBS LETT, V490, P15, DOI 10.1016/S0014-5793(01)02127-5; Bennecib M, 2000, FEBS LETT, V485, P87, DOI 10.1016/S0014-5793(00)02203-1; Bjorkblom B, 2005, J NEUROSCI, V25, P6350, DOI 10.1523/JNEUROSCI.1517-05.2005; Braak E, 1997, ACTA NEUROPATHOL, V93, P323, DOI 10.1007/s004010050622; BRUGG B, 1991, J CELL BIOL, V114, P735, DOI 10.1083/jcb.114.4.735; CACERES A, 1986, J NEUROSCI, V6, P714; Caceres A., 1984, BRAIN RES, V315, P314; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Castejon O J, 1995, J Neurosurg Sci, V39, P47; Chen JR, 2010, NEUROSCIENCE, V167, P414, DOI 10.1016/j.neuroscience.2010.02.028; Chen JR, 2004, J NEUROTRAUM, V21, P1640, DOI 10.1089/0897715042441729; Chen JR, 2003, J NEUROTRAUM, V20, P767, DOI 10.1089/089771503767869999; Cohen P, 1999, PHILOS T ROY SOC B, V354, P485, DOI 10.1098/rstb.1999.0399; Collins VP, 2004, J NEUROL NEUROSUR PS, V75, P2, DOI 10.1136/jnnp.2004.040337; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; DIEZGUERRA FJ, 1993, NEUROREPORT, V4, P419, DOI 10.1097/00001756-199304000-00020; DIEZGUERRA FJ, 1995, EUR J BIOCHEM, V227, P68, DOI 10.1111/j.1432-1033.1995.tb20360.x; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Feng Q, 2005, NEUROSCI LETT, V388, P13, DOI 10.1016/j.neulet.2005.06.022; Fitzpatrick MO, 1998, BRIT J NEUROSURG, V12, P313; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Gomez-Ramos A, 2006, J NEUROSCI RES, V83, P264, DOI 10.1002/jnr.20726; Gong CX, 2000, BRAIN RES, V853, P299, DOI 10.1016/S0006-8993(99)02294-5; GOTO S, 1985, J NEUROCHEM, V45, P276, DOI 10.1111/j.1471-4159.1985.tb05504.x; Gotz J, 2001, NEUROREPORT, V12, P2007; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Hernandez F, 2007, CELL MOL LIFE SCI, V64, P2219, DOI 10.1007/s00018-007-7220-x; Imahori K, 1997, J BIOCHEM, V121, P179; Iqbal K, 2008, J ALZHEIMERS DIS, V14, P365; Itoh TJ, 1997, BIOCHEMISTRY-US, V36, P12574, DOI 10.1021/bi962606z; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; KHATOON S, 1994, FEBS LETT, V351, P80, DOI 10.1016/0014-5793(94)00829-9; KORNEYEV A, 1995, NEUROSCI LETT, V191, P19, DOI 10.1016/0304-3940(95)11546-3; Kundrotiene J, 2004, J NEUROTRAUM, V21, P83, DOI 10.1089/089771504772695977; Kundrotiene J, 2002, J NEUROTRAUM, V19, P69, DOI 10.1089/089771502753460259; Kusakawa G, 2000, J BIOL CHEM, V275, P17166, DOI 10.1074/jbc.M907757199; Lewthwaite JC, 2006, J BIOL CHEM, V281, P11011, DOI 10.1074/jbc.M510680200; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Lin JL, 2010, J CEREBR BLOOD F MET, V30, P1121, DOI 10.1038/jcbfm.2009.277; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; Liu F, 2006, PANMINERVA MED, V48, P97; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; Mandelkow EM, 1996, ANN NY ACAD SCI, V777, P96, DOI 10.1111/j.1749-6632.1996.tb34407.x; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; Papasozomenos SC, 1996, J NEUROCHEM, V66, P1140; Planel E, 2004, J NEUROSCI, V24, P2401, DOI 10.1523/JNEUROSCI.5561-03.2004; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Qiang L, 2006, J NEUROSCI, V26, P3120, DOI 10.1523/JNEUROSCI.5392-05.2006; Quinlan EM, 1996, NEURON, V16, P357, DOI 10.1016/S0896-6273(00)80053-7; Quinlan EM, 1996, J NEUROSCI, V16, P7627; Rauch C, 2008, CELL BIOCHEM FUNCT, V26, P866, DOI 10.1002/cbf.1518; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; Sanchez C, 2000, PROG NEUROBIOL, V61, P133, DOI 10.1016/S0301-0082(99)00046-5; Sanchez C, 1996, EUR J BIOCHEM, V241, P765, DOI 10.1111/j.1432-1033.1996.00765.x; Sengupta A, 1998, ARCH BIOCHEM BIOPHYS, V357, P299, DOI 10.1006/abbi.1998.0813; SPACEK J, 1987, ACTA NEUROPATHOL, V73, P77; SUTHERLAND C, 1994, FEBS LETT, V338, P37, DOI 10.1016/0014-5793(94)80112-6; Tashiro K, 1997, NEUROREPORT, V8, P2797, DOI 10.1097/00001756-199708180-00029; Toyota S, 2001, J NEUROTRAUM, V18, P1349, DOI 10.1089/08977150152725641; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; Wang JZ, 2008, PROG NEUROBIOL, V85, P148, DOI 10.1016/j.pneurobio.2008.03.002; Wang JZ, 2007, EUR J NEUROSCI, V25, P59, DOI 10.1111/j.1460-9568.2006.05226.x; Yanagisawa M, 1999, FEBS LETT, V461, P329, DOI 10.1016/S0014-5793(99)01480-5; Yang HY, 2006, J NEUROTRAUM, V23, P721, DOI 10.1089/neu.2006.23.721	74	32	33	1	9	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2010	27	9					1657	1669		10.1089/neu.2010.1308			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	649TJ	WOS:000281796500012	20568963				2021-06-18	
J	Monnerie, H; Tang-Schomer, MD; Iwata, A; Smith, DH; Kim, HA; Le Roux, PD				Monnerie, Hubert; Tang-Schomer, Min D.; Iwata, Akira; Smith, Douglas H.; Kim, Haesun A.; Le Roux, Peter D.			Dendritic alterations after dynamic axonal stretch injury in vitro	EXPERIMENTAL NEUROLOGY			English	Article						Dendrite; Traumatic brain injury; Diffuse axonal injury; Cerebral cortex; In vitro	TRAUMATIC BRAIN-INJURY; MICROTUBULE-ASSOCIATED PROTEIN-2; AMYLOID PRECURSOR PROTEIN; CORTICAL IMPACT INJURY; CYTOSKELETAL PROTEIN; COMPLEX ENVIRONMENT; CALPAIN ACTIVATION; ALZHEIMERS-DISEASE; COGNITIVE FUNCTION; MECHANICAL INJURY	Traumatic axonal injury (TAI) is the most common and important pathology of traumatic brain injury (TBI). However, little is known about potential indirect effects of TAI on dendrites. In this study, we used a well-established in vitro model of axonal stretch injury to investigate TAI-induced changes in dendrite morphology. Axons bridging two separated rat cortical neuron populations plated on a deformable substrate were used to create a zone of isolated stretch injury to axons. Following injury, we observed the formation of dendritic alterations or beading along the dendrite shaft. Dendritic beading formed within minutes after stretch then subsided over time. Pharmacological experiments revealed a sodium-dependent mechanism, while removing extracellular calcium exacerbated TAI's effect on dendrites. In addition, blocking ionotropic glutamate receptors with the N-methyl-D-aspartate (NMDA) receptor antagonist MK-801 prevented dendritic beading. These results demonstrate that axon mechanical injury directly affects dendrite morphology, highlighting an important bystander effect of TAL The data also imply that TAI may alter dendrite structure and plasticity in vivo. An understanding of TAI's effect on dendrites is important since proper dendrite function is crucial for normal brain function and recovery after injury. (C) 2010 Published by Elsevier Inc.	[Monnerie, Hubert; Tang-Schomer, Min D.; Smith, Douglas H.; Le Roux, Peter D.] Univ Penn, Dept Neurosurg, Philadelphia, PA 19107 USA; [Kim, Haesun A.] Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA; [Iwata, Akira] Nagakute Minami Clin, Aichi, Japan	Le Roux, PD (corresponding author), Univ Penn, Dept Neurosurg, 330 S 9th St,4th Floor, Philadelphia, PA 19107 USA.	lerouxp@uphs.upenn.edu	Tang-Schomer, Min/AAD-9501-2020; Tang-Schomer, Min/C-1967-2013; smith, douglas/A-1321-2007	Tang-Schomer, Min/0000-0001-7585-3890; 	New Jersey Commission on Brain Injury Research [021.BIR1]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS038104, NS048949, NS056202]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS038104, R01NS048949, P01NS056202] Funding Source: NIH RePORTER	This work was supported by a grant (021.BIR1) to H. A. K. and P. D. L from the New Jersey Commission on Brain Injury Research, and NIH grants NS038104, NS048949 and NS056202 to D. H. S.	Al-Noori S, 2000, NEUROSCIENCE, V101, P337, DOI 10.1016/S0306-4522(00)00384-5; Briones TL, 2006, BEHAV BRAIN RES, V168, P261, DOI 10.1016/j.bbr.2005.11.015; Castejon O. J., 2003, Journal of Submicroscopic Cytology and Pathology, V35, P395; Castejon OJ, 1997, BRAIN INJURY, V11, P363, DOI 10.1080/026990597123520; Castree N, 2004, ENVIRON PLANN A, V36, P191, DOI 10.1068/a36209; Cline HT, 2001, CURR OPIN NEUROBIOL, V11, P118, DOI 10.1016/S0959-4388(00)00182-3; Comery TA, 1996, NEUROBIOL LEARN MEM, V66, P93, DOI 10.1006/nlme.1996.0049; DEITCH JS, 1984, J COMP NEUROL, V229, P66, DOI 10.1002/cne.902290106; Denny-Brown D, 1940, J PHYSIOL-LONDON, V99, P153, DOI 10.1113/jphysiol.1940.sp003887; DeRidder MN, 2006, NEUROBIOL DIS, V22, P165, DOI 10.1016/j.nbd.2005.10.011; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; EMERY DG, 1995, BRAIN RES, V692, P161, DOI 10.1016/0006-8993(95)00726-7; Faddis BT, 1997, J NEUROSCI, V17, P951; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Fineman I, 2000, J NEUROTRAUM, V17, P739, DOI 10.1089/neu.2000.17.739; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Geddes-Klein DM, 2006, J NEUROCHEM, V97, P462, DOI 10.1111/j.1471-4159.2006.03761.x; Goldgerg M. P., 1993, Society for Neuroscience Abstracts, V19, P26; Greenwood SM, 2007, J BIOL CHEM, V282, P26235, DOI 10.1074/jbc.M704488200; Hasbani MJ, 1998, EXP NEUROL, V154, P241, DOI 10.1006/exnr.1998.6929; Hayes RL, 2008, J NEUROTRAUM, V25, P863; Hoskison MM, 2009, NEUROSCIENCE, V159, P483, DOI 10.1016/j.neuroscience.2008.12.050; Ip EYY, 2002, J NEUROTRAUM, V19, P573, DOI 10.1089/089771502753754055; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Jan YN, 2001, GENE DEV, V15, P2627, DOI 10.1101/gad.916501; Jones TA, 1996, BRAIN RES, V733, P142, DOI 10.1016/0006-8993(96)00792-5; Kanayama G, 1996, METHOD FIND EXP CLIN, V18, P105; Kao CQ, 2004, J NEUROTRAUM, V21, P259, DOI 10.1089/089771504322972059; Kozlowski DA, 2004, J NEUROTRAUM, V21, P513, DOI 10.1089/089771504774129856; Kozorovitskiy Y, 2005, P NATL ACAD SCI USA, V102, P17478, DOI 10.1073/pnas.0508817102; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Lamprecht R, 2004, NAT REV NEUROSCI, V5, P45, DOI 10.1038/nrn1301; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Lusardi TA, 2004, J NEUROTRAUM, V21, P61, DOI 10.1089/089771504772695959; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; Maxwell WL, 1997, J NEUROTRAUM, V14, P603, DOI 10.1089/neu.1997.14.603; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MEANEY DF, 1995, J NEUROTRAUM, V12, P689, DOI 10.1089/neu.1995.12.689; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; Mizrahi A, 2002, J COMP NEUROL, V452, P1, DOI 10.1002/cne.10275; Oliva AA, 2002, J NEUROSCI, V22, P8052; Park JS, 1996, NEUROBIOL DIS, V3, P215, DOI 10.1006/nbdi.1996.0022; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Posmantur RM, 2000, EXP NEUROL, V161, P15, DOI 10.1006/exnr.1999.7244; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Rowntree S, 1997, EUR J NEUROSCI, V9, P2432, DOI 10.1111/j.1460-9568.1997.tb01660.x; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 1996, J NEUROPATH EXP NEUR, V55, P850, DOI 10.1097/00005072-199607000-00010; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; Sjostrom PJ, 2008, PHYSIOL REV, V88, P769, DOI 10.1152/physrev.00016.2007; SLOVITER RS, 1985, BRAIN RES BULL, V15, P39, DOI 10.1016/0361-9230(85)90059-0; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1999, J NEUROSCI, V19, P4263; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; STEWART GR, 1991, ANN NEUROL, V30, P758, DOI 10.1002/ana.410300604; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Tang MD, 2003, J AM CHEM SOC, V125, P12988, DOI 10.1021/ja037677h; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Taylor AM, 2005, NAT METHODS, V2, P599, DOI 10.1038/NMETH777; VALVERDE F, 1968, EXP BRAIN RES, V5, P274; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; von Reyn CR, 2009, J NEUROSCI, V29, P10350, DOI 10.1523/JNEUROSCI.2339-09.2009; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; WINOCUR G, 1990, BEHAV BRAIN RES, V38, P145, DOI 10.1016/0166-4328(90)90012-4; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161; Zepeda A, 2004, J NEUROSCI, V24, P1812, DOI 10.1523/JNEUROSCI.3213-03.2004; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	77	32	32	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	AUG	2010	224	2					415	423		10.1016/j.expneurol.2010.05.001			9	Neurosciences	Neurosciences & Neurology	631II	WOS:000280339600011	20478308	Green Accepted			2021-06-18	
J	Carrera, E; Schmidt, JM; Fernandez, L; Kurtz, P; Merkow, M; Stuart, M; Lee, K; Claassen, J; Connolly, ES; Mayer, SA; Badjatia, N				Carrera, Emmanuel; Schmidt, J. Michael; Fernandez, Luis; Kurtz, Pedro; Merkow, Maxwell; Stuart, Morgan; Lee, Kiwon; Claassen, Jan; Connolly, E. Sander; Mayer, Stephan A.; Badjatia, Neeraj			Spontaneous hyperventilation and brain tissue hypoxia in patients with severe brain injury	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							CEREBRAL-BLOOD-FLOW; CENTRAL NEUROGENIC HYPERVENTILATION; CARBON-DIOXIDE; SUBARACHNOID HEMORRHAGE; VESSEL CALIBER; OXYGEN; PRESSURE; ARTERIAL; HYPERCAPNIA; REACTIVITY	Background Hyperventilation has been shown to be associated with cerebral vasoconstriction and increased risk of infarction. Our aim was to determine whether spontaneous reduction in end-tidal CO2 (EtCO2) was associated with an increased in brain tissue hypoxia (BTH). Method We studied 21 consecutive patients (mean age 50 +/- 16 years; 15 women) undergoing continuous monitoring for brain tissue oxygenation (PbtO(2)), intracranial pressure (ICP), cerebral perfusion pressure (CPP) and EtCO2; mean values were recorded hourly BTH was defined as brain tissue oxygen tension (PbtO(2)) <15 mm Hg. Results Diagnoses included subarachnoid haemorrhage (67%), intracranial haemorrhage (24%) and traumatic brain injury (10%). Overall, BTH occurred during 22.5% of the study period (490/2179 hourly data). The frequency of BTH increased progressively from 15.7% in patients with normal EtCO2 (35-44 mm Hg) to 33.9% in patients with EtCO2<25 mm Hg (p<0.001). The mean tidal volume and minute ventilation were 7 +/- 2 ml/kg and 9 +/- 2 1/min, respectively. Hypocapnia was associated with higher measured-than-set respiratory rates and maximal minute ventilation values, suggestive of spontaneous hyperventilation. Using a generalised estimated equation (GEE) and after adjustment for GCS, ICP and core temperature, the variables independently associated with BTH events were EtCO2 (OR: 0.94; 95% CI 0.90 to 0.97; p<0.001) and CPP (OR: 0.98; 95% CI 0.97 to 0.99; p=0.004). Conclusion The risk of brain tissue hypoxia in critically brain-injured patients increases when EtCO2 values are reduced. Unintentional spontaneous hyperventilation may be a common and under-recognised cause of brain tissue hypoxia after severe brain injury.	[Carrera, Emmanuel; Schmidt, J. Michael; Fernandez, Luis; Kurtz, Pedro; Lee, Kiwon; Claassen, Jan; Mayer, Stephan A.; Badjatia, Neeraj] Columbia Univ, Med Ctr, Dept Neurol, Div Neurocrit Care, New York, NY 10032 USA; [Merkow, Maxwell; Stuart, Morgan; Lee, Kiwon; Claassen, Jan; Connolly, E. Sander; Mayer, Stephan A.; Badjatia, Neeraj] Columbia Univ, Med Ctr, Dept Neurosurg, New York, NY 10032 USA	Badjatia, N (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, Div Neurocrit Care, 177 Ft Washington Ave,MHB 8-300, New York, NY 10032 USA.	nbadjatia@neuro.columbia.edu	Claassen, Jan/AAA-5451-2020	Carrera, Emmanuel/0000-0003-0045-5382; Schmidt, J. Michael/0000-0001-8141-2944	Swiss National Science Foundation, Bern, SwitzerlandSwiss National Science Foundation (SNSF) [PBLAB-119620]; SICPA Foundation, Lausanne, Switzerland; Charles A. Dana Foundation; National Center for Research Resources (NCRR), National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR024157]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024157] Funding Source: NIH RePORTER	This work was supported by research grants from the Swiss National Science Foundation (EC) (PBLAB-119620), Bern, Switzerland, the SICPA Foundation, Lausanne, Switzerland (EC) and the Charles A. Dana Foundation (SAM). NB received funding from a K 12 Career Development Award (RR024157; PI: H Ginsberg) from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH).	Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; BRATTON SL, 2007, J NEUROTRAUMA S1, V24, pS87; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Gaviani P, 2005, NEUROLOGY, V64, P166, DOI 10.1212/01.WNL.0000148579.80486.F1; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; HEFFNER JE, 1983, ARCH INTERN MED, V143, P765, DOI 10.1001/archinte.143.4.765; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; IADECOLA C, 1994, J CEREBR BLOOD F MET, V14, P175, DOI 10.1038/jcbfm.1994.25; JAECKLE KA, 1990, NEUROLOGY, V40, P1715, DOI 10.1212/WNL.40.11.1715; KETY SS, 1946, J CLIN INVEST, V25, P107, DOI 10.1172/JCI101680; KETY SS, 1948, J CLIN INVEST, V27, P484, DOI 10.1172/JCI101995; Manley GT, 2000, J TRAUMA, V48, P1025, DOI 10.1097/00005373-200006000-00005; Manley GT, 1999, J TRAUMA, V46, P261, DOI 10.1097/00005373-199902000-00011; Marion DW, 2000, J TRAUMA, V48, P1032; MAYBERG MR, 1994, CIRCULATION, V90, P2592, DOI 10.1161/01.CIR.90.5.2592; Neumann JO, 2008, INTENS CARE MED, V34, P1676, DOI 10.1007/s00134-008-1123-7; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; PETRUK KC, 1974, STROKE, V5, P230, DOI 10.1161/01.STR.5.2.230; REIVICH M, 1964, AM J PHYSIOL, V206, P25; Rosenthal G, 2008, J NEUROSURG, V108, P59, DOI 10.3171/JNS/2008/108/01/0059; RUSSELL GB, 1995, ANESTH ANALG, V81, P806, DOI 10.1097/00000539-199510000-00025; Scheufler KM, 2002, ANESTH ANALG, V95, P1042, DOI 10.1097/00000539-200210000-00046; Suazo JAC, 2000, CRIT CARE MED, V28, P3268, DOI 10.1097/00003246-200009000-00024; Tarulli AW, 2005, ARCH NEUROL-CHICAGO, V62, P1632, DOI 10.1001/archneur.62.10.1632; TUOR UI, 1984, AM J PHYSIOL, V247, pH40; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; WOLLMAN H, 1968, J APPL PHYSIOL, V24, P60; Zauner A, 1997, NEUROSURGERY, V41, P1082, DOI 10.1097/00006123-199711000-00011	32	32	34	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUL	2010	81	7					793	797		10.1136/jnnp.2009.174425			5	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	627LK	WOS:000280040800021	19965840				2021-06-18	
J	Jantzen, KJ				Jantzen, Kelly J.			Functional Magnetic Resonance Imaging of Mild Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						blood oxygen level-dependent; concussion; functional magnetic resonance imaging; literature review; mild brain injury; recovery of function; working memory	LONG-TERM POTENTIATION; VERBAL WORKING-MEMORY; HEAD-INJURY; PARAMETRIC MANIPULATION; POSTCONCUSSION SYNDROME; POSTURAL STABILITY; LONGITUDINAL FMRI; MOTOR RECOVERY; AXONAL INJURY; BOLD SIGNAL	Mild traumatic brain injury (MTBI) is a serious health problem that has been difficult to study because of the relative insensitivity of established anatomical imaging techniques for detecting the associated neural damage and dysfunction. Functional magnetic resonance imaging (fMRI) offers potential for understanding the neural and functional basis of MTBI and the relationship to behavioral and somatic symptoms. This article reviews the recent fMRI literature relevant to the study of MTBI. The pathophysiology of MTBI and the neural basis of the blood oxygen level-dependent fMRI response are also considered with particular focus on important issues for using fMRI to investigate MTBI.	Western Washington Univ, Bellingham, WA 98225 USA	Jantzen, KJ (corresponding author), Western Washington Univ, 516 High St, Bellingham, WA 98225 USA.	Kelly.jantzen@wwu.edu			National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS48229]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS048229] Funding Source: NIH RePORTER	Western Washington University, Bellingham. A portion of this work was supported by a grant from the National Institute of Neurological Disorders and Stroke (NS48229).	Aguirre GK, 1998, NEUROIMAGE, V8, P360, DOI 10.1006/nimg.1998.0369; Arthurs OJ, 2002, TRENDS NEUROSCI, V25, P27, DOI 10.1016/S0166-2236(00)01995-0; Attwell D, 2002, TRENDS NEUROSCI, V25, P621, DOI 10.1016/S0166-2236(02)02264-6; BANDETTINI PA, 2000, FUNCTIONAL MRI; Barth JT, 1989, MILD HEAD INJURY; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; Brookes MJ, 2005, NEUROIMAGE, V26, P302, DOI 10.1016/j.neuroimage.2005.01.050; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chun MM, 2007, CURR OPIN NEUROBIOL, V17, P177, DOI 10.1016/j.conb.2007.03.005; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Connor LT, 2004, BRAIN LANG, V91, P82, DOI 10.1016/j.bandl.2004.06.044; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; Davis GA, 2009, BRIT J SPORT MED, V43, pI36, DOI 10.1136/bjsm.2009.058123; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; de Fockert JW, 2001, SCIENCE, V291, P1803, DOI 10.1126/science.1056496; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Douglas EA, 2006, CURR MED IMAGING, V2, P105, DOI 10.2174/157340506775541712; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; Ekstrom A, 2009, J NEUROPHYSIOL, V101, P2668, DOI 10.1152/jn.91252.2008; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Feydy A, 2002, STROKE, V33, P1610, DOI 10.1161/01.STR.0000017100.68294.52; Fox MD, 2007, NEURON, V56, P171, DOI 10.1016/j.neuron.2007.08.023; FREEMAN JR, 2005, TXB TRAUMATIC BRAIN; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; Gaetz M, 2000, BRAIN INJURY, V14, P1077; GENNARELLI TA, 1993, HEAD INJURY, P127; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Giza CC, 2001, J ATHL TRAINING, V36, P228; Goense JBM, 2008, CURR BIOL, V18, P631, DOI 10.1016/j.cub.2008.03.054; Goldstein LB, 2003, BRAIN INJURY, V17, P685, DOI 10.1080/0269905031000107179; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; HAMM RJ, 1993, COGNITIVE BRAIN RES, V1, P223, DOI 10.1016/0926-6410(93)90006-Q; Heeger DJ, 2002, NAT REV NEUROSCI, V3, P142, DOI 10.1038/nrn730; Henninger N, 2007, CRIT CARE MED, V35, P2607, DOI 10.1097/01.CCM.0000286395.79654.8D; Hillary FG, 2008, J INT NEUROPSYCH SOC, V14, P526, DOI 10.1017/S1355617708080788; Hinton-Bayre AD, 1999, J CLIN EXP NEUROPSYC, V21, P70, DOI 10.1076/jcen.21.1.70.945; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; Huang MX, 2009, J NEUROTRAUM, V26, P1213, DOI 10.1089/neu.2008.0672; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Jantzen KJ, 2006, J HEAD TRAUMA REHAB, V21, P427, DOI 10.1097/00001199-200609000-00046; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Johnston KM, 2001, J AM COLL SURGEONS, V192, P515, DOI 10.1016/S1072-7515(01)00797-9; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kim DS, 2004, NEUROIMAGE, V21, P876, DOI 10.1016/j.neuroimage.2003.10.018; Kim SG, 2000, MED RAD DIA IMG, P195; Krakauer JW, 2007, EXP NEUROL, V204, P491, DOI 10.1016/j.expneurol.2006.12.026; Kraus JCL, 2005, TXB TRAUMATIC BRAIN; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; Mayer A, 2009, J NEUROTRAUM, V26, pA85; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MCALLISTER TW, 2005, TXB TRAUMATIC BRAIN; McCarthy, 2004, FUNCTIONAL MAGNETIC; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McGonigle DJ, 2000, NEUROIMAGE, V11, P708, DOI 10.1006/nimg.2000.0562; McKiernan KA, 2003, J COGNITIVE NEUROSCI, V15, P394, DOI 10.1162/089892903321593117; Mendez CV, 2005, J NEUROPSYCH CLIN N, V17, P297, DOI 10.1176/appi.neuropsych.17.3.297; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; MILLER LP, 1990, BRAIN RES, V526, P103, DOI 10.1016/0006-8993(90)90254-9; Moonen CTW, 2000, MED RAD DIA IMG, P161; Murphy K, 2004, NEUROIMAGE, V21, P219, DOI 10.1016/j.neuroimage.2003.09.016; Muthukumaraswamy SD, 2009, HUM BRAIN MAPP, V30, P2000, DOI 10.1002/hbm.20644; Nair DG, 2005, BRAIN RES REV, V50, P229, DOI 10.1016/j.brainresrev.2005.07.001; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Niessing J, 2005, SCIENCE, V309, P948, DOI 10.1126/science.1110948; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PARKINSON D, 1992, MED HYPOTHESES, V37, P37, DOI 10.1016/0306-9877(92)90010-A; Pearce JMS, 2008, EUR NEUROL, V59, P113, DOI 10.1159/000111872; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Peterson SE, 2009, ANN EMERG MED, V53, P796, DOI 10.1016/j.annemergmed.2008.10.015; PETRIDES M, 1993, P NATL ACAD SCI USA, V90, P878, DOI 10.1073/pnas.90.3.878; Phillips LL, 1998, HIPPOCAMPUS, V8, P390, DOI 10.1002/(SICI)1098-1063(1998)8:4<390::AID-HIPO7>3.0.CO;2-L; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; POVLISHOCK JT, 1989, MILD HEAD INJURY; Price CJ, 1999, HUM BRAIN MAPP, V8, P102, DOI 10.1002/(SICI)1097-0193(1999)8:2/3<102::AID-HBM6>3.0.CO;2-J; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.3.CO;2-2; Reeves TM, 1997, BRAIN RES, V757, P119, DOI 10.1016/S0006-8993(97)00170-4; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Singh KD, 2002, NEUROIMAGE, V16, P103, DOI 10.1006/nimg.2001.1050; Smith EE, 1996, CEREB CORTEX, V6, P11, DOI 10.1093/cercor/6.1.11; Smith SM, 2005, HUM BRAIN MAPP, V24, P248, DOI 10.1002/hbm.20080; Smits M, 2009, HUM BRAIN MAPP, V30, P2789, DOI 10.1002/hbm.20709; Sturm W, 2004, NEUROPSYCHOLOGIA, V42, P434, DOI 10.1016/j.neuropsychologia.2003.09.001; Tegeler C, 1999, HUM BRAIN MAPP, V7, P267, DOI 10.1002/(SICI)1097-0193(1999)7:4<267::AID-HBM5>3.0.CO;2-3; Thomason ME, 2005, NEUROIMAGE, V25, P824, DOI 10.1016/j.neuroimage.2004.12.026; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Tomasi D, 2006, HUM BRAIN MAPP, V27, P694, DOI 10.1002/hbm.20211; Tombari D, 2004, NEUROIMAGE, V23, P827, DOI 10.1016/j.neuroimage.2004.07.058; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Ward NS, 2003, BRAIN, V126, P2476, DOI 10.1093/brain/awg245; Wei XC, 2004, NEUROIMAGE, V21, P1000, DOI 10.1016/j.neuroimage.2003.10.039; Weissman DH, 2006, NAT NEUROSCI, V9, P971, DOI 10.1038/nn1727; Winterer G, 2007, HUM BRAIN MAPP, V28, P805, DOI 10.1002/hbm.20322; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161	118	32	32	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2010	25	4					256	266		10.1097/HTR.0b013e3181e5477c			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	622FO	WOS:000279646900004	20611044				2021-06-18	
J	Morad, Y; Wygnansky-Jaffe, T; Levin, AV				Morad, Yair; Wygnansky-Jaffe, Tamara; Levin, Alex V.			Retinal haemorrhage in abusive head trauma	CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY			English	Article						child abuse; head trauma; retinal haemorrhage; shaken baby syndrome	SHAKEN BABY SYNDROME; PERMANENT BRAIN-DAMAGE; GLUTARIC ACIDURIA; SUBDURAL-HEMATOMA; CHILD-ABUSE; INJURY; INFANTS; RETINOPATHY; SHAKING; UPDATE	P>Paediatric abusive head injury may have grave consequences, especially when characterized by repetitive acceleration-deceleration forces (shaken baby syndrome). Death occurs in approximately 30% and permanent neurologic damage in up to 80% of the victims. Retinal haemorrhages are a cardinal sign seen in approximately 85% of cases. In most cases haemorrhages are preretinal, intraretinal and subretinal, too numerous to count, and involving the entire retinal surface extending to the ora serrata. Traumatic macular retinoschisis is a lesion with important diagnostic significance. Vitreoretinal traction appears to be the mechanism of haemorrhage and schisis formation along with a possible role of orbital tissue trauma from repetitive acceleration-deceleration forces. Ophthalmologists must carefully document ocular findings. Appropriate autopsy examination should include ocular and orbital tissue removal. Although there is a wide differential diagnosis for retinal haemorrhages, clinical appearance, when considered in the context of systemic and laboratory findings, usually leads to the correct diagnosis.	[Levin, Alex V.] Wills Eye Inst, Philadelphia, PA 19107 USA; [Morad, Yair] Assaf Harofeh Med Ctr, Pediat Ophthalmol Serv, Zerifin, Israel; [Morad, Yair; Wygnansky-Jaffe, Tamara] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; [Wygnansky-Jaffe, Tamara] Chaim Sheba Med Ctr, Goldschleger Eye Inst, IL-52621 Tel Hashomer, Israel	Levin, AV (corresponding author), Wills Eye Inst, 840 Walnut St, Philadelphia, PA 19107 USA.	alevin@willseye.org					Adams G, 2004, EYE, V18, P795, DOI 10.1038/sj.eye.6701643; Aikman J, 1928, ARCH PEDIATR, V45, P56; Altman RL, 2007, EUR J OPHTHALMOL, V17, P648; Bandak FA, 2005, FORENSIC SCI INT, V151, P71, DOI 10.1016/j.forsciint.2005.02.033; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; Bhola RM, 2005, INVEST OPHTH VIS SCI, V46; Bullock DP, 2009, J PEDIATR ORTHOPED, V29, P231, DOI 10.1097/BPO.0b013e31819aad44; CAFFEY J, 1974, PEDIATRICS, V54, P396; CAFFEY J, 1946, AM J ROENTGENOL, V56, P163; CAFFEY J, 1972, AM J DIS CHILD, V124, P161, DOI 10.1001/archpedi.1972.02110140011001; Case ME, 2008, BRAIN PATHOL, V18, P571, DOI 10.1111/j.1750-3639.2008.00204.x; Chapman-Davies Anthony, 2002, Clin Exp Optom, V85, P42; COATS B, 2009, 2 INT C PED AB HEAD; COPPETO JR, 1985, J CLIN NEURO-OPHTHAL, V5, P45; Cory CZ, 2003, MED SCI LAW, V43, P317, DOI 10.1258/rsmmsl.43.4.317; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Emerson MV, 2007, OPHTHALMOLOGY, V114, P1384, DOI 10.1016/j.ophtha.2007.04.015; Emerson MV, 2001, OPHTHALMOLOGY, V108, P36, DOI 10.1016/S0161-6420(00)00474-7; Gago LC, 2003, RETINA-J RET VIT DIS, V23, P724, DOI 10.1097/00006982-200310000-00027; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GILKES UJ, 1967, FUNDI BATTERED BABIE, P468; GILLILAND MGF, 1993, AM J FOREN MED PATH, V14, P187, DOI 10.1097/00000433-199309000-00003; Gnanaraj L, 2007, EYE, V21, P5, DOI 10.1038/sj.eye.6702174; GOETTING MG, 1990, PEDIATRICS, V85, P585; Goldenberg-Cohen N, 2004, J AAPOS, V8, P20, DOI 10.1016/j.jaapos.2003.08.009; Goldman M, 2006, J PEDIATR-US, V148, P835, DOI 10.1016/j.jpeds.2005.12.052; GUTHKELCH AN, 1971, BMJ-BRIT MED J, V2, P430, DOI 10.1136/bmj.2.5759.430; Han D P, 1990, J Pediatr Ophthalmol Strabismus, V27, P299; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Herr S, 2004, PEDIATRICS, V113, P1658, DOI 10.1542/peds.113.6.1658; Hughes LA, 2006, J AAPOS, V10, P102, DOI 10.1016/j.jaapos.2005.12.005; KAUR B, 1992, SURV OPHTHALMOL, V37, P1, DOI 10.1016/0039-6257(92)90002-B; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; KEMPE CH, 1962, JAMA-J AM MED ASSOC, V181, P17, DOI 10.1001/jama.1962.03050270019004; King WJ, 2003, CAN MED ASSOC J, V168, P155; Kivlin JD, 2008, ARCH OPHTHALMOL-CHIC, V126, P800, DOI 10.1001/archopht.126.6.800; Kivlin JD, 2000, OPHTHALMOLOGY, V107, P1246, DOI 10.1016/S0161-6420(00)00161-5; KRISHNAN J, 1990, AUST NZ J SURG, V60, P447, DOI 10.1111/j.1445-2197.1990.tb07400.x; Lancon JA, 1998, ANAT REC, V253, P13, DOI 10.1002/(SICI)1097-0185(199802)253:1<13::AID-AR8>3.0.CO;2-F; Lantz PE, 2004, BRIT MED J, V328, P754, DOI 10.1136/bmj.328.7442.754; LESSELL S, 1989, ARCH OPHTHALMOL-CHIC, V107, P382, DOI 10.1001/archopht.1989.01070010392031; Levchakov A, 2006, J NEUROTRAUM, V23, P1570, DOI 10.1089/neu.2006.23.1570; Levin AV, 2000, RECENT ADV PAEDIAT, P151; Lueder GT, 2006, ARCH OPHTHALMOL-CHIC, V124, P1782, DOI 10.1001/archopht.124.12.1782; Mack J, 2009, PEDIATR RADIOL, V39, P200, DOI 10.1007/s00247-008-1084-6; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; McCabe CF, 2000, ARCH OPHTHALMOL-CHIC, V118, P373, DOI 10.1001/archopht.118.3.373; MERTEN DF, 1983, RADIOLOGY, V146, P377, DOI 10.1148/radiology.146.2.6849085; Morad Y, 2003, J PEDIATR-US, V142, P431, DOI 10.1067/mpd.2003.161; Morad Y, 2002, AM J OPHTHALMOL, V134, P354, DOI 10.1016/S0002-9394(02)01628-8; Mungan NK, 2007, CURR OPIN OPHTHALMOL, V18, P392, DOI 10.1097/ICU.0b013e3282a167f0; Newton AW, 2005, CURR OPIN PEDIATR, V17, P246, DOI 10.1097/01.mop.0000158730.56669.b1; Oral R, 2008, PEDIATR EMERG CARE, V24, P816, DOI 10.1097/PEC.0b013e31818e9f5d; Pierce MC, 2008, ANNU REV BIOMED ENG, V10, P85, DOI 10.1146/annurev.bioeng.9.060906.151907; Plunkett J, 2001, AM J FOREN MED PATH, V22, P1, DOI 10.1097/00000433-200103000-00001; PRANGE M, 2002, BIOMECHANICS TRAUMAT; Rangarajan N, 2009, J AAPOS, V13, P364, DOI 10.1016/j.jaapos.2008.11.006; Reddy SC, 2004, ACTA OPHTHALMOL SCAN, V82, P81, DOI 10.1046/j.1600-0420.2003.00197.x; Saleh M, 2009, BRIT J OPHTHALMOL, V93, P424, DOI 10.1136/bjo.2008.147561; Schloff S, 2002, OPHTHALMOLOGY, V109, P1472, DOI 10.1016/S0161-6420(02)01086-2; Scott AW, 2009, AM J OPHTHALMOL, V147, P364, DOI 10.1016/j.ajo.2008.08.010; SCOTT AW, 2009, AM J OPHTHALMOL, V147, pE2; Sherwood D, 1930, AM J DIS CHILD, V39, P980; Stoodley N, 2006, BRIT J RADIOL, V79, P550, DOI 10.1259/bjr/23921951; Strauss KA, 2003, AM J MED GENET C, V121C, P38, DOI 10.1002/ajmg.c.20007; Sturm V, 2008, AM J OPHTHALMOL, V146, P363, DOI 10.1016/j.ajo.2008.04.023; TARDIEU A, 1860, ANN HYGIENE PUBLIQUE, V13, P361; TOMASI LG, 1975, AM J DIS CHILD, V129, P1335, DOI 10.1001/archpedi.1975.02120480051012; Tyagi AK, 1997, LANCET, V349, P1224, DOI 10.1016/S0140-6736(05)62418-X; Vinchon M, 2005, J NEUROSURG, V102, P380, DOI 10.3171/ped.2005.102.4.0380; Watts P, 2008, EYE, V22, P1514, DOI 10.1038/eye.2008.224; Wolfson DR, 2005, P I MECH ENG H, V219, P63, DOI 10.1243/095441105X9237; Wygnanski-Jaffe T, 2007, EYE, V21, P83, DOI 10.1038/sj.eye.6702163; Wygnanski-Jaffe T, 2006, AM J OPHTHALMOL, V142, P233, DOI 10.1016/j.ajo.2006.03.038	76	32	34	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1442-6404	1442-9071		CLIN EXP OPHTHALMOL	Clin. Exp. Ophthalmol.	JUL	2010	38	5					514	520		10.1111/j.1442-9071.2010.02291.x			7	Ophthalmology	Ophthalmology	622HA	WOS:000279650800015	20584025	Bronze			2021-06-18	
J	Salgado, AJ; Fraga, JS; Mesquita, AR; Neves, NM; Reis, RL; Sousa, N				Salgado, Antonio J.; Fraga, Joana S.; Mesquita, Ana R.; Neves, Nuno M.; Reis, Rui L.; Sousa, Nuno			Role of Human Umbilical Cord Mesenchymal Progenitors Conditioned Media in Neuronal/Glial Cell Densities, Viability, and Proliferation	STEM CELLS AND DEVELOPMENT			English	Article							TRAUMATIC BRAIN-INJURY; STEM-CELLS; IN-VITRO; STROMAL CELLS; NEUROLOGICAL DEFICITS; MAMMALIAN FOREBRAIN; MATRIX CELLS; RAT-BRAIN; TRANSPLANTATION; DIFFERENTIATION	It has been recently reported that mesenchymal progenitor/stem cells isolated from the Wharton's Jelly (WJ) of umbilical cords (UC) ameliorate the condition of animals suffering from central nervous system (CNS)-related conditions. However, little is known on the mechanisms that regulate these actions. Therefore, the objective of the present work was to determine how the conditioned media (CM) of a population of mesenchymal progenitors present in the UC WJ, known as human umbilical cord perivascular cells (HUCPVCs), regulate processes such as cell viability, survival, and proliferation of postnatal hippocampal neurons and glial cells. For this purpose primary hippocampal and cortical cultures of neurons and glial cells, respectively, were incubated with CM from HUCPVCs. Results revealed that HUCPVCs CM increase glial cell viability and proliferation. Furthermore, it was observed that glial cell cultures exhibited higher numbers of GFAP-positive cells (astrocytes) and O4-positive cells (oligodendrocytes) when incubated with the CM. Additionally, it was also observed that the growth factors presents in the CM did not induce an increase on the microglial cells number. For hippocampal neurons similar results were obtained, as cultures exposed to HUCPVCs CM disclosed higher numbers of MAP-2-positive cells. Moreover it was also observed that the cell viability and proliferation in this primary hippocampal cell culture system was also higher, when compared to control cultures. From these results it was possible to conclude that HUCPVCs release neuroregulatory factors that have a direct impact on the densities, viability, and proliferation of glial cells and hippocampal primary cultures.	[Salgado, Antonio J.; Fraga, Joana S.; Mesquita, Ana R.; Sousa, Nuno] Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, P-4710057 Braga, Portugal; [Neves, Nuno M.; Reis, Rui L.] Univ Minho, Res Grp Biomat Biodegradables & Biomimet 3Bs, Headquarters European Inst Excellence Tissue Engn, Taipas, Guimaraes, Portugal; [Neves, Nuno M.; Reis, Rui L.] PT Govt Associated Lab, Inst Biotechnol & Bioengn, Guimaraes, Portugal	Sousa, N (corresponding author), Univ Minho, Sch Hlth Sci, Life & Hlth Sci Res Inst ICVS, Campus Gualtar, P-4710057 Braga, Portugal.	njcsousa@ecsaude.uminho.pt	Salgado, Antonio/J-4129-2013; Sousa, Nuno/C-2782-2009; Neves, Nuno M/B-4685-2008; Reis, Rui L./A-8938-2008; Sousa, Nuno JC/N-9137-2017; Fraga, Joana S. M./K-3509-2013; Salgado, Antonio J/T-6500-2018	Salgado, Antonio/0000-0003-3806-9823; Neves, Nuno M/0000-0003-3041-0687; Reis, Rui L./0000-0002-4295-6129; Sousa, Nuno JC/0000-0002-8755-5126; Fraga, Joana S. M./0000-0003-3234-0600; Salgado, Antonio J/0000-0003-3806-9823; Mesquita, Ana/0000-0002-9635-2355; UMinho, 3B's Research Group/0000-0002-5195-3456	Portuguese Foundation for Science and TechnologyPortuguese Foundation for Science and Technology [Salgado-SFRH/BPD/17595/2004]; Funda ao Calouste de Gulbenkian	Portuguese Foundation for Science and Technology through funds from POCTI and/or FEDER programs (funding to ICVS, 3B's Research Group and post doctoral fellowship to A.J. Salgado-SFRH/BPD/17595/2004); funding from Funda ao Calouste de Gulbenkian. The authors would also like to acknowledge Prof. J.E. Davies from the Institute of Biomaterials and Biomedical Engineering at the University of Toronto, Canada, for kindly providing some of the HUCPVCs lots used in the present work. This work was performed following the terms of the cooperation agreement signed between the 3B's Research Group of the University of Minho and the Hospital de Sao Marcos in Braga and approved by its ethical committee.	Akiyama Y, 2002, J NEUROSCI, V22, P6623; Baksh D, 2007, STEM CELLS, V25, P1384, DOI 10.1634/stemcells.2006-0709; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; COLLAZO D, 1992, NEURON, V9, P643, DOI 10.1016/0896-6273(92)90028-C; CORY AH, 1991, CANCER COMMUN, V3, P207; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Emsley JG, 2003, EXP NEUROL, V183, P298, DOI 10.1016/S0014-4886(03)00129-8; Ennis J, 2008, CYTOTHERAPY, V10, P174, DOI 10.1080/14653240801891667; Fiore M, 2002, PHYSIOL BEHAV, V77, P437, DOI 10.1016/S0031-9384(02)00875-2; Fu YS, 2006, STEM CELLS, V24, P115, DOI 10.1634/stemcells.2005-0053; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Hirko AC, 2008, STEM CELLS, V26, P2893, DOI 10.1634/stemcells.2008-0075; Kang SK, 2003, EXP NEUROL, V183, P355, DOI 10.1016/S0014-4886(03)00089-X; Kang SK, 2007, BRAIN PATHOL, V17, P263, DOI 10.1111/j.1750-3639.2007.00070.x; Kang SK, 2006, STEM CELLS DEV, V15, P583, DOI 10.1089/scd.2006.15.583; Karahuseyinoglu S, 2007, STEM CELLS, V25, P319, DOI 10.1634/stemcells.2006-0286; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu J, 2005, DEVELOPMENT, V132, P3231, DOI 10.1242/dev.01893; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Medicetty S, 2004, EXP NEUROL, V190, P32, DOI 10.1016/j.expneurol.2004.06.023; Mitchell KE, 2003, STEM CELLS, V21, P50, DOI 10.1634/stemcells.21-1-50; MORSHEAD CM, 1994, NEURON, V13, P1071, DOI 10.1016/0896-6273(94)90046-9; MUNOZ RM, 2005, PNAS, V37, P18171; PALMER TD, 1995, MOL CELL NEUROSCI, V6, P474, DOI 10.1006/mcne.1995.1035; Salih V, 2000, J MATER SCI-MATER M, V11, P615, DOI 10.1023/A:1008901612674; Sarugaser R, 2005, STEM CELLS, V23, P220, DOI 10.1634/stemcells.2004-0166; Scarisbrick IA, 2000, DEV BRAIN RES, V123, P87, DOI 10.1016/S0165-3806(00)00077-8; Scharfman H, 2005, EXP NEUROL, V192, P348, DOI 10.1016/j.expneurol.2004.11.016; Schneider A, 2005, J CLIN INVEST, V115, P2083, DOI 10.1172/JCI23559; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; Silva GA, 2003, J MATER SCI-MATER M, V14, P1055, DOI 10.1023/B:JMSM.0000004002.11278.30; Troyer DL, 2008, STEM CELLS, V26, P591, DOI 10.1634/stemcells.2007-0439; Weiss ML, 2006, STEM CELLS, V24, P781, DOI 10.1634/stemcells.2005-0330; Weiss ML, 2003, EXP NEUROL, V182, P288, DOI 10.1016/S0014-4886(03)00128-6; Wislet-Gendebien S, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-33; Zhao LR, 2002, EXP NEUROL, V174, P11, DOI 10.1006/exnr.2001.7853	37	32	35	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1547-3287	1557-8534		STEM CELLS DEV	Stem Cells Dev.	JUL	2010	19	7					1067	1074		10.1089/scd.2009.0279			8	Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation	Cell Biology; Hematology; Research & Experimental Medicine; Transplantation	626PC	WOS:000279976900012	19705968				2021-06-18	
J	Colantonio, A; Mar, W; Escobar, M; Yoshida, K; Velikonja, D; Rizoli, S; Cusimano, M; Cullen, N				Colantonio, Angela; Mar, Wanna; Escobar, Michael; Yoshida, Karen; Velikonja, Diana; Rizoli, Sandro; Cusimano, Michael; Cullen, Nora			Women's Health Outcomes After Traumatic Brain Injury	JOURNAL OF WOMENS HEALTH			English	Article							LONG-TERM; HYPOPITUITARISM; VALIDITY; RISK	Background: Traumatic brain injury (TBI) is a major public health problem, yet little is known about how this injury may affect long-term outcomes unique to women. This research examined the health outcomes relevant to premenopausal women 5-12 years after injury. Methods: This was a retrospective cohort study at eight participating acute care= rehabilitation facilities. Participants were consecutive eligible women with moderate to severe TBI. A follow-up interview assessed menstrual functioning, fertility, and pregnancy experiences before and after injury as well as cervical cancer screening. Demographic variables, self-rated general and mental health, and functional limitations were also collected. Injury-related information was abstracted from health records. Female control participants recruited were matched on age, education, and geographic location. Results: Of the 104 women with TBI (W-TBI), 46% experienced amenorrhea with duration of up to 60 months. Cycles became irregular for 68% of W-TBI after the injury. These findings were significantly different from those of controls. Among W-TBI, menstrual disturbances were associated with injury severity. No differences were shown between W-TBI and controls with respect to fertility, although significantly fewer W-TBI had one or more live births, and they reported more difficulties in the postpartum period than controls. W-TBI were less likely to have regular Pap smears and reported lower mental health, self-rated health, and function. Conclusions: These findings inform prognosis after TBI for women and provide evidence for long-term monitoring of health outcomes and increased support after childbirth. More research is needed in this area, particularly with respect to the neuroendocrine system.	[Colantonio, Angela] Univ Toronto, Toronto Rehabil Inst, Toronto, ON M5G 1V7, Canada; [Velikonja, Diana] McMaster Univ, Hamilton, ON, Canada; [Rizoli, Sandro] Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; [Cusimano, Michael] St Michaels Hosp, Toronto, ON M5B 1W8, Canada	Colantonio, A (corresponding author), Univ Toronto, Toronto Rehabil Inst, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca	Cusimano, Michael/X-4059-2019	Cullen, Nora/0000-0001-6359-9418; Cusimano, Michael/0000-0002-9989-0650; Colantonio, Angela/0000-0003-2094-4765; Escobar, Michael/0000-0001-9055-4709	Canadian Institutes for Health ResearchCanadian Institutes of Health Research (CIHR) [200903MOP]; The Toronto Rehabilitation Institute; Ministry of Health and Long Term CareMinistry of Health and Long-Term Care, Ontario	We thank our collaborators and the administrative staff who provided support at the participating sites. We also thank the Institute for Social Research at York University for their assistance with recruiting controls, the interviewers for their assistance with data collection, and Junlang Yin for performing the statistical analyses. The study received ethics approval from the University of Toronto and from the research ethics boards of the eight participating centers: Toronto Rehabilitation Institute, Sunnybrook Health Sciences Centre, St. Michael's Hospital, Bridgepoint Health, Hamilton General Hospital, Chedoke Hospital, Thunder Bay Regional Health Sciences Centre, Brain Injury Services of Northern Ontario. We also sincerely thank the participants in this research study and Alice Bellavance. Funding for the study was obtained from the Canadian Institutes for Health Research grant 200903MOP, The Toronto Rehabilitation Institute, and a grant from the Ministry of Health and Long Term Care to the Toronto Rehabilitation Institute. This report was presented at the American Congress of Rehabilitation Medicine Annual Meeting, October 2009, where it received a best paper award (first place).	Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Altman B, 2008, DISABILITY HLTH US 2; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bavisetty S, 2008, NEUROSURGERY, V62, P1080, DOI 10.1227/01.neu.0000325870.60129.6a; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; *CAN I HLTH INF, 2006, BRAIN INJ CAN DEC CH; *CAN PAR ASS, 2008, SCI FACTS; Canadian Institute for Health Information, 2007, BURD NEUR DIS DIS IN; Caplan LS, 2003, CANCER EPIDEM BIOMAR, V12, P1182; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Colantonio A, 2004, DISABIL REHABIL, V26, P253, DOI 10.1080/09638280310001639722; de Kruijk JR, 2001, BRAIN INJURY, V15, P99, DOI 10.1080/026990501458335; FILLENBAUM G, 1975, MULTIDIMENSIONAL FUN; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; GROSSMAN WF, 1994, J REPROD MED, V39, P738; Jackson AB, 1999, ARCH PHYS MED REHAB, V80, P1420, DOI 10.1016/S0003-9993(99)90253-8; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Mild Traumatic Brain Injury Committee of the Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHABI, V8, P86; Mukherjee D, 2003, WOMEN THER, V26, P3, DOI 10.1300/J015v26n01_01; *NAT I CAN CAN CAN, 2008, CAN CANC STAT 2008; Public Health Agency of Canada, 2007, HIV AIDS EP UPD NOV; RIDDELL L, 2003, WERE WOMEN TOO IDENT; Ripley DL, 2008, ARCH PHYS MED REHAB, V89, P1090, DOI 10.1016/j.apmr.2007.10.038; SANDER AM, 2006, BRAIN INJURY MED, P1117; SIPKSI ML, 1991, J AM PARAPLEGIC SOC, V14, P122; Sipski M L, 2001, Phys Med Rehabil Clin N Am, V12, P79; Smith PM, 1996, ARCH PHYS MED REHAB, V77, P431, DOI 10.1016/S0003-9993(96)90029-5; Solomon CG, 2002, J CLIN ENDOCR METAB, V87, P2013, DOI 10.1210/jc.87.5.2013; *STAT CAN, 2002, JOINT CAN US SURV HL; Stein K, 1999, BRIT MED J, V318, P641, DOI 10.1136/bmj.318.7184.641; TADMAN N, 2005, WOMEN TRAUMATIC BRAI; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Tomeo CA, 1999, EPIDEMIOLOGY, V10, P774, DOI 10.1097/00001648-199911000-00022; Uysal S, 1998, J HEAD TRAUMA REHAB, V13, P57, DOI 10.1097/00001199-199812000-00007; Ware JE., 1993, SF 36 HLTH SURVEY MA; World Health Organization, 2007, NEUR DIS PUBL HLTH C	39	32	32	0	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1540-9996	1931-843X		J WOMENS HEALTH	J. Womens Health	JUN	2010	19	6					1109	1116		10.1089/jwh.2009.1740			8	Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies	Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies	610YB	WOS:000278775400007	20469963				2021-06-18	
J	Figaji, AA; Zwane, E; Fieggen, AG; Argent, AC; Le Roux, PD; Peter, JC				Figaji, Anthony A.; Zwane, Eugene; Fieggen, A. Graham; Argent, Andrew C.; Le Roux, Peter D.; Peter, Jonathan C.			The Effect of Increased Inspired Fraction of Oxygen on Brain Tissue Oxygen Tension in Children with Severe Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Brain tissue oxygen tension; Arterial oxygen tension; Children; Traumatic brain injury; Outcome	SEVERE HEAD-INJURY; CEREBRAL-BLOOD-FLOW; POSITRON-EMISSION-TOMOGRAPHY; PERFUSION-PRESSURE; LUNG INJURY; HYPEROXIA; METABOLISM; ISCHEMIA; DELIVERY; AUTOREGULATION	This study examines the effect of an increase in the inspired fraction of oxygen (FiO(2)) on brain tissue oxygen (PbO2) in children with severe traumatic brain injury (TBI). A prospective observational study of patients who underwent PbO2 monitoring and an oxygen challenge test (temporary increase of FiO(2) for 15 min) was undertaken. Pre- and post-test values for arterial partial pressure of oxygen (PaO2), PbO2, and arterial oxygen content (CaO2) were examined while controlling for any changes in arterial carbon dioxide tension and cerebral perfusion pressure during the test. Baseline transcranial Doppler studies were done. Outcome was assessed at 6 months. A total of 43 tests were performed in 28 patients. In 35 tests in 24 patients, the PbO2 monitor was in normal-appearing white matter and in eight tests in four patients, the monitor was in a pericontusional location. When catheters were pericontusional or in normal white matter the baseline PbO2/PaO2 ratio was similar. PaO2 (P < 0.0001) and PbO2 (P < 0.0001) significantly increased when FiO(2) was increased. The magnitude of the PbO2 response (a dagger PbO2) was correlated with a dagger PaO2 (P < 0.0001, R (2) = 0.37) and a dagger CaO2 (P = 0.001, R (2) = 0.23). The a dagger PbO2/a dagger PaO2 ratio (oxygen reactivity) varied between patients, was related to the baseline PbO2 (P = 0.001, r = 0.54) and was inversely related to outcome (P = 0.02, confidence interval 0.03-0.78). Normobaric hyperoxia increases PbO2 in children with severe TBI, but the response is variable. The magnitude of this response is related to the change in PaO2 and the baseline PbO2. A greater response appears to be associated with worse outcome.	[Figaji, Anthony A.] Red Cross War Mem Childrens Hosp, Inst Child Hlth 617, ZA-7700 Cape Town, South Africa; [Zwane, Eugene] Univ Cape Town, Sch Publ Hlth & Family Med, Infect Dis Epidemiol Unit Biostat, ZA-7925 Cape Town, South Africa; [Le Roux, Peter D.] Hosp Univ Penn, Dept Neurosurg, Philadelphia, PA 19107 USA; [Figaji, Anthony A.; Fieggen, A. Graham; Peter, Jonathan C.] Univ Cape Town, Red Cross Childrens Hosp, Sch Child & Adolescent Hlth, Div Neurosurg, ZA-7925 Cape Town, South Africa	Figaji, AA (corresponding author), Red Cross War Mem Childrens Hosp, Inst Child Hlth 617, Klipfontein Rd, ZA-7700 Cape Town, South Africa.	Anthony.Figaji@uct.ac.za; gfieggen@gmail.com; Andrew.Argent@uct.ac.za; lerouxp@uphs.upenn.edu; Jonathan.Peter@uct.ac.za	Argent, Andrew/J-1605-2019	Argent, Andrew/0000-0001-9333-2036; Figaji, Anthony/0000-0002-3357-6490			Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS65; BISHOP CCR, 1986, STROKE, V17, P913, DOI 10.1161/01.STR.17.5.913; Bullock MR, 2003, J NEUROSURG, V98, P943, DOI 10.3171/jns.2003.98.5.0943; CLARK JM, 1971, PHARMACOL REV, V23, P37; Dings J, 1996, ACTA NEUROCHIR, V138, P425, DOI 10.1007/BF01420305; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Doppenberg EMR, 1998, J NEUROTRAUM, V15, P337, DOI 10.1089/neu.1998.15.337; Figaji AA, 2008, NEUROSURGERY, V63, P83, DOI 10.1227/01.NEU.0000335074.39728.00; Figaji AA, 2009, CHILD NERV SYST, V25, P1335, DOI 10.1007/s00381-009-0821-y; Figaji AA, 2009, CHILD NERV SYST, V25, P1325, DOI 10.1007/s00381-009-0822-x; Floyd TF, 2003, J APPL PHYSIOL, V95, P2453, DOI 10.1152/japplphysiol.00303.2003; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Gupta AK, 2002, J NEUROSURG, V96, P263, DOI 10.3171/jns.2002.96.2.0263; Habler OP, 1998, TRANSFUSION, V38, P135, DOI 10.1046/j.1537-2995.1998.38298193095.x; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; Hlatky R, 2008, J NEUROSURG, V108, P53, DOI 10.3171/JNS/2008/108/01/0053; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; Liu SM, 2006, J CEREBR BLOOD F MET, V26, P1274, DOI 10.1038/sj.jcbfm.9600277; Longhi L, 2002, ACT NEUR S, V81, P315; Magnoni S, 2003, J NEUROSURG, V98, P952, DOI 10.3171/jns.2003.98.5.0952; Maloney-Wilensky E, 2009, CRIT CARE MED, V37, P2057, DOI 10.1097/CCM.0b013e3181a009f8; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; NAKAJIMA S, 1983, ARCH NEUROL-CHICAGO, V40, P271, DOI 10.1001/archneur.1983.04050050039004; Nishimura N, 2007, AVIAT SPACE ENVIR MD, V78, P1121, DOI 10.3357/ASEM.2177.2007; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Pagano A, 2003, ANN NY ACAD SCI, V1010, P405, DOI 10.1196/annals.1299.074; PUCCIO AM, 2009, J NEUROTRAUM, DOI DOI 10.1089/NEU.2008-0624; Reinert M, 2004, J NEUROSURG, V101, P323, DOI 10.3171/jns.2004.101.2.0323; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Rosenthal G, 2008, J NEUROSURG, V108, P59, DOI 10.3171/JNS/2008/108/01/0059; Rossi S, 2001, J NEUROTRAUM, V18, P163, DOI 10.1089/08977150150502596; Scheufler KM, 2004, J NEUROSURG ANESTH, V16, P210, DOI 10.1097/00008506-200407000-00005; Scheufler KM, 2002, ANESTH ANALG, V95, P1042, DOI 10.1097/00000539-200210000-00046; Shah CV, 2008, CRIT CARE MED, V36, P2309, DOI 10.1097/CCM.0b013e318180dc74; Shin HK, 2007, BRAIN, V130, P1631, DOI 10.1093/brain/awm071; Steiner LA, 2003, STROKE, V34, P2404, DOI 10.1161/01.STR.0000089014.59668.04; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Suttner S, 2004, ANESTH ANALG, V99, P2, DOI 10.1213/01.ANE.0000120163.44315.47; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; van Santbrink H, 2003, ACTA NEUROCHIR, V145, P429, DOI 10.1007/s00701-003-0032-3; Vereczki V, 2006, J CEREBR BLOOD F MET, V26, P821, DOI 10.1038/sj.jcbfm.9600234; ZAUNER A, 1995, NEUROSURGERY, V37, P1168, DOI 10.1227/00006123-199512000-00017	50	32	32	0	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2010	12	3					430	437		10.1007/s12028-010-9344-3			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	590RJ	WOS:000277244700019	20232264				2021-06-18	
J	Israelsson, C; Bengtsson, H; Lobell, A; Nilsson, LNG; Kylberg, A; Isaksson, M; Wootz, H; Lannfelt, L; Kullander, K; Hillered, L; Ebendal, T				Israelsson, Charlotte; Bengtsson, Henrik; Lobell, Anna; Nilsson, Lars N. G.; Kylberg, Annika; Isaksson, Magnus; Wootz, Hanna; Lannfelt, Lars; Kullander, Klas; Hillered, Lars; Ebendal, Ted			Appearance of Cxcl10-expressing cell clusters is common for traumatic brain injury and neurodegenerative disorders	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						Alzheimer's disease; chemokines; dendritic cells; experimental autoimmune encephalomyelitis; inflammation; mouse	CENTRAL-NERVOUS-SYSTEM; CONTROLLED CORTICAL IMPACT; CHEMOKINE RECEPTORS; DENDRITIC CELLS; BLOOD MONOCYTES; CEREBRAL-CORTEX; T-CELLS; IN-VIVO; EXPRESSION; MODEL	Traumatic brain injury (TBI) in the mouse results in the rapid appearance of scattered clusters of cells expressing the chemokine Cxcl10 in cortical and subcortical areas. To extend the observation of this unique pattern, we used neuropathological mouse models using quantitative reverse transcriptase-polymerase chain reaction, gene array analysis, in-situ hybridization and flow cytometry. As for TBI, cell clusters of 150-200 mu m expressing Cxcl10 characterize the cerebral cortex of mice carrying a transgene encoding the Swedish mutation of amyloid precursor protein, a model of amyloid Alzheimer pathology. The same pattern was found in experimental autoimmune encephalomyelitis in mice modelling multiple sclerosis. In contrast, mice carrying a SOD1G93A mutant mimicking amyotrophic lateral sclerosis pathology lacked such cell clusters in the cerebral cortex, whereas clusters appeared in the brainstem and spinal cord. Mice homozygous for a null mutation of the Cxcl10 gene did not show detectable levels of Cxcl10 transcript after TBI, confirming the quantitative reverse transcriptase-polymerase chain reaction and in-situ hybridization signals. Moreover, unbiased microarray expression analysis showed that Cxcl10 was among 112 transcripts in the neocortex upregulated at least threefold in both TBI and ageing TgSwe mice, many of them involved in inflammation. The identity of the Cxcl10+ cells remains unclear but flow cytometry showed increased numbers of activated microglia/macrophages as well as myeloid dendritic cells in the TBI and experimental autoimmune encephalomyelitis models. It is concluded that the Cxcl10+ cells appear in the inflamed central nervous system and may represent a novel population of cells that it may be possible to target pharmacologically in a broad range of neurodegenerative conditions.	[Israelsson, Charlotte; Bengtsson, Henrik; Kylberg, Annika; Wootz, Hanna; Kullander, Klas; Ebendal, Ted] Uppsala Univ, Biomed Ctr, Dept Neurosci, SE-75124 Uppsala, Sweden; [Lobell, Anna; Isaksson, Magnus] Univ Uppsala Hosp, Dept Med Sci, Uppsala, Sweden; [Nilsson, Lars N. G.; Lannfelt, Lars] Uppsala Univ, Rudbeck Lab, Dept Publ Hlth & Caring Sci Mol Geriatr, SE-75124 Uppsala, Sweden; [Hillered, Lars] Univ Uppsala Hosp, Dept Neurosci, Uppsala, Sweden	Ebendal, T (corresponding author), Uppsala Univ, Biomed Ctr, Dept Neurosci, POB 593, SE-75124 Uppsala, Sweden.	ted.ebendal@neuro.uu.se		Hillered, Lars/0000-0002-2808-9292; Kullander, Klas/0000-0001-6418-5460; nilsson, lars/0000-0002-8362-1042	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Swedish Brain Research Foundation	This work was supported by the Swedish Research Council and the Swedish Brain Research Foundation. Hanna Goransson and Maria Rydaker carried out the GeneChip procedures.	Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Byrne FR, 2009, AUTOIMMUNITY, V42, P171, DOI 10.1080/08916930802629547; Carson MJ, 1999, J NEUROSCI RES, V55, P127, DOI 10.1002/(SICI)1097-4547(19990101)55:1<127::AID-JNR14>3.3.CO;2-U; Charo IF, 2006, NEW ENGL J MED, V354, P610, DOI 10.1056/NEJMra052723; Chiu IM, 2008, P NATL ACAD SCI USA, V105, P17913, DOI 10.1073/pnas.0804610105; Clausen F, 2007, J NEUROTRAUM, V24, P1295, DOI 10.1089/neu.2006.0258; Clausen F, 2009, EUR J NEUROSCI, V30, P385, DOI 10.1111/j.1460-9568.2009.06820.x; Dufour JH, 2002, J IMMUNOL, V168, P3195, DOI 10.4049/jimmunol.168.7.3195; Esche C, 2005, J INVEST DERMATOL, V125, P615, DOI 10.1111/j.0022-202X.2005.23841.x; Fife BT, 2001, J NEUROSCI RES, V66, P705, DOI 10.1002/jnr.10037; Furtado GC, 2006, J IMMUNOL, V177, P6871, DOI 10.4049/jimmunol.177.10.6871; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Greter M, 2005, NAT MED, V11, P328, DOI 10.1038/nm1197; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hausmann EHS, 1998, BRAIN RES, V788, P49, DOI 10.1016/S0006-8993(97)01160-8; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Israelsson C, 2006, J NEUROSCI RES, V84, P47, DOI 10.1002/jnr.20856; Karman J, 2006, J IMMUNOL, V177, P7750, DOI 10.4049/jimmunol.177.11.7750; Kieseier BC, 2002, BRAIN, V125, P823, DOI 10.1093/brain/awf070; Klein RS, 2004, J CELL BIOCHEM, V92, P213, DOI 10.1002/jcb.20052; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; Lord A, 2006, NEUROBIOL AGING, V27, P67, DOI 10.1016/j.neurobiolaging.2004.12.007; Marta M, 2008, EUR J IMMUNOL, V38, P565, DOI 10.1002/eji.200737187; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mildner A, 2007, NAT NEUROSCI, V10, P1544, DOI 10.1038/nn2015; Muller M, 2007, J IMMUNOL, V179, P2774, DOI 10.4049/jimmunol.179.5.2774; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Noshita N, 2002, NEUROBIOL DIS, V9, P294, DOI 10.1006/nbdi.2002.0482; Philipson O, 2009, NEUROBIOL AGING, V30, P1393, DOI 10.1016/j.neurobiolaging.2007.11.022; Potts Mathew B, 2006, NeuroRx, V3, P143; Reichmann G, 2002, J NEUROIMMUNOL, V129, P125, DOI 10.1016/S0165-5728(02)00184-4; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Sorensen TL, 1999, J CLIN INVEST, V103, P807, DOI 10.1172/JCI5150; Stalder AK, 2005, J NEUROSCI, V25, P11125, DOI 10.1523/JNEUROSCI.2545-05.2005; Swirski FK, 2007, J CLIN INVEST, V117, P195, DOI 10.1172/JCI29950; Trifilo MJ, 2004, VIROLOGY, V327, P8, DOI 10.1016/j.virol.2004.06.027; Trifilo MJ, 2003, J NEUROVIROL, V9, P315, DOI 10.1080/13550280390201029; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Xu HP, 2005, J IMMUNOL, V175, P6915, DOI 10.4049/jimmunol.175.10.6915	42	32	32	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	MAR	2010	31	5					852	863		10.1111/j.1460-9568.2010.07105.x			12	Neurosciences	Neurosciences & Neurology	563AC	WOS:000275096500008	20374285				2021-06-18	
J	Nishijima, DK; Dager, WE; Schrot, RJ; Holmes, JF				Nishijima, Daniel K.; Dager, William E.; Schrot, Rudolph J.; Holmes, James F.			The Efficacy of Factor VIIa in Emergency Department Patients With Warfarin Use and Traumatic Intracranial Hemorrhage	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	Scientific Assembly of the American-College-of-Emergency-Physicians	OCT 06, 2009	Boston, MA	Amer Coll Emergency Phys		factor VII; traumatic intracranial hemorrhage; warfarin	ACTIVATED FACTOR-VII; RECOMBINANT-FACTOR-VIIA; ACUTE INTRACEREBRAL HEMORRHAGE; INJURY SEVERITY SCORE; BRAIN-INJURY; DOUBLE-BLIND; ANTICOAGULANT-THERAPY; CLINICAL-TRIAL; HEAD-INJURIES; REVERSAL	Objectives: The objective was to compare outcomes in emergency department (ED) patients with preinjury warfarin use and traumatic intracranial hemorrhage (tICH) who did and did not receive recombinant activated factor VIIa (rFVIIa) for international normalized ratio (INR) reversal. Methods: This was a retrospective before-and-after study conducted at a Level 1 trauma center, with data from 1999 to 2009. Eligible patients had preinjury warfarin use and tICH on cranial computed tomography (CT) scan. Patients before (standard cohort) and after (rFVIIa cohort) implementation of a protocol for administering 1.2 mg of rFVIIa in the ED were reviewed. Glasgow Coma Scale (GCS) score, Revised Trauma Score (RTS), Injury Severity Score (ISS), INR, and Marshall score were collected. Outcome measures included mortality, thromboembolic complications, and INR normalization. Results: Forty patients (median age = 80.5 years, interquartile range [IQR] = 63.5-85) were included (20 in each cohort). Age, GCS score, ISS, RTS, initial INR, and Marshall score were similar (p > 0.05) between the two cohorts. Survival was identical between cohorts (13 of 20, or 65.0%, 95% confidence interval [CI] = 40.8% to 84.6%). There were no differences in rate of thromboembolic complications in the standard cohort (1 of 20, 5.0%, 95% CI = 0.1% to 24.9%) than the rFVIIa cohort (4 of 20, 20.0%, 95% CI = 5.7% to 43.7%; p = 0.34). Time to normal INR was earlier in the rFVIIa cohort (mean = 4.8 hours, 95% CI = 3.0 to 6.7 hours) than in the standard cohort (mean = 17.5 hours, 95% CI = 12.5 to 22.6; p < 0.001). Conclusions: In patients with preinjury warfarin and tICH, use of rFVIIa was associated with a decreased time to normal INR. However, no difference in mortality was identified. Use of rFVIIa in patients on warfarin and tICH requires further study to demonstrate important patient-oriented outcomes. ACADEMIC EMERGENCY MEDICINE 2010; 17:244-251 (C) 2010 by the Society for Academic Emergency Medicine.	[Nishijima, Daniel K.; Holmes, James F.] UC Davis, Sch Med, Dept Emergency Med, Davis, CA 95616 USA; [Dager, William E.] UC Davis, Sch Med, Dept Pharm, Davis, CA USA; [Schrot, Rudolph J.] UC Davis, Sch Med, Dept Neurosurg, Davis, CA USA	Nishijima, DK (corresponding author), UC Davis, Sch Med, Dept Emergency Med, Davis, CA 95616 USA.	daniel.nishijima@ucdmc.ucdavis.edu		Nishijima, Daniel/0000-0003-4952-8212			Baglin T, 1998, BLOOD REV, V12, P91, DOI 10.1016/S0268-960X(98)90020-0; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; Bosch J, 2004, GASTROENTEROLOGY, V127, P1123, DOI 10.1053/j.gastro.2004.07.015; Boulis NM, 1999, NEUROSURGERY, V45, P1113, DOI 10.1097/00006123-199911000-00020; Cohen DB, 2006, J TRAUMA, V60, P553, DOI 10.1097/01.ta.0000196542.54344.05; COPES WS, 1988, J TRAUMA, V28, P69, DOI 10.1097/00005373-198801000-00010; Dager WE, 2006, PHARMACOTHERAPY, V26, P1091, DOI 10.1592/phco.26.8.1091; Deveras RAE, 2002, ANN INTERN MED, V137, P884, DOI 10.7326/0003-4819-137-11-200212030-00009; Diprose P, 2005, BRIT J ANAESTH, V95, P596, DOI 10.1093/bja/aei244; Ferrera PC, 1999, AM J EMERG MED, V17, P154, DOI 10.1016/S0735-6757(99)90050-5; Fleming B, 2001, CAN FAM PHYSICIAN, V47, P727; Friederich PW, 2000, BLOOD COAGUL FIBRIN, V11, pS129, DOI 10.1097/00001721-200004001-00024; Hsia CC, 2008, ANN SURG, V248, P61, DOI 10.1097/SLA.0b013e318176c4ec; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Kalina M, 2008, AM SURGEON, V74, P858; Karni A, 2001, AM SURGEON, V67, P1098; Kawamata T, 1995, SURG NEUROL, V44, P438, DOI 10.1016/0090-3019(95)00249-9; Kennedy DM, 2000, J TRAUMA, V48, P451, DOI 10.1097/00005373-200003000-00012; KOCH GG, 1977, BIOMETRICS, V33, P133, DOI 10.2307/2529309; Lavoie A, 2004, J TRAUMA, V56, P802, DOI 10.1097/01.TA.0000066183.02177.AF; Lin J, 2003, J NEUROSURG, V98, P737, DOI 10.3171/jns.2003.98.4.0737; Lodge JPA, 2005, ANESTHESIOLOGY, V102, P269, DOI 10.1097/00000542-200502000-00006; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Makris M, 1997, THROMB HAEMOSTASIS, V77, P477; Mayer SA, 2005, NEW ENGL J MED, V352, P777, DOI 10.1056/NEJMoa042991; Mayer SA, 2008, NEW ENGL J MED, V358, P2127, DOI 10.1056/NEJMoa0707534; MEYER J, 2001, AGE 2000 CENSUS 2000; Narayan RK, 2008, NEUROSURGERY, V62, P776, DOI 10.1227/01.NEU.0000297095.04013.C4; Parmar K. A., 2006, SMJ Singapore Medical Journal, V47, P676; Pieracci FM, 2007, J TRAUMA, V63, P525, DOI 10.1097/TA.0b013e31812e5216; Raobaikady R, 2005, BRIT J ANAESTH, V94, P586, DOI 10.1093/bja/aei102; Schulman S, 2003, NEW ENGL J MED, V349, P675, DOI 10.1056/NEJMcp025373; SCHWAB CW, 2000, TRAUMA, P1099; Stanworth SJ, 2007, COCHRANE DB SYST REV, V2; Stein DM, 2008, J TRAUMA, V64, P620, DOI 10.1097/TA.0b013e3181650fc7; Stein DM, 2009, J TRAUMA, V66, P63, DOI 10.1097/TA.0b013e318191bc8a; Worster A, 2005, ANN EMERG MED, V45, P448, DOI 10.1016/j.annemergmed.2004.11.021; Yasuda CL, 2003, ARQ NEURO-PSIQUIAT, V61, P1011, DOI 10.1590/S0004-282X2003000600023	39	32	34	0	1	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	MAR	2010	17	3					244	251		10.1111/j.1553-2712.2010.00666.x			8	Emergency Medicine	Emergency Medicine	562YR	WOS:000275092500003	20370756	Bronze			2021-06-18	
J	Choi, SC; Park, JH; Pae, A; Kim, JR				Choi, Sung Chul; Park, Jae Hong; Pae, Ahran; Kim, Jong Ryul			Retrospective study on traumatic dental injuries in preschool children at Kyung Hee Dental Hospital, Seoul, South Korea	DENTAL TRAUMATOLOGY			English	Article							OF-THE-LITERATURE; PRIMARY TEETH; TOOTH INJURIES; PEDIATRIC DENTISTRY; PERMANENT TEETH; EPIDEMIOLOGY; COUNTY; MEXICO	The purpose of this study was to analyse the traumatic dental injuries (TDI) of Korean preschoolers by investigating the occurrence, type, area, cause, injured region, seasonal variation and the interval between injury and treatment. In this study, data from 1856 preschoolers aged 4 months to 6 years and 11 months (mean age : 3.6 +/- 1.6) were used, out of a total of 2761 patients who attended the Department of Pediatric Dentistry, Kyung Hee Dental Hospital for TDI between January 1998 and December 2007. All the data were statistically analysed using the anovaand chi-square statics. Most of the patients were 1-2, 2-3 years old (24.5%, 25.4%) and boys were 1.67 times more likely to have TDI. The most common cause, location and seasonal variation of the trauma, were respectively falling (50.8%), at home (48.8%) and late spring. The treatment intervals usually occurred within a day. Most of the injuries involved single (47%) or double (38%) tooth/teeth. However, car accidents or sports trauma often involved multiple teeth. In both primary and permanent dentition, the most common teeth injured were maxillary central incisors (72.6%), and periodontal injury was caused by subluxation or concussion. Among the various types of hard tissue injuries, enamel fracture in the primary dentition (35.0%) and enamel-dentin fracture in the permanent dentition (45.8%) were the most common types.	[Choi, Sung Chul; Park, Jae Hong] Kyung Hee Univ, Dept Pediat Dent, Sch Dent, Seoul 130702, South Korea; [Choi, Sung Chul; Park, Jae Hong] Kyung Hee Univ, Inst Oral Biol, Sch Dent, Seoul 130702, South Korea; [Pae, Ahran] Kyung Hee Univ, Dept Prosthodont Dent, Sch Dent, Seoul 130702, South Korea; [Kim, Jong Ryul] Kyung Hee Univ, Dept Conservat Dent, Sch Dent, Seoul 130702, South Korea	Park, JH (corresponding author), Kyung Hee Univ, Dept Pediat Dent, Sch Dent, Seoul 130702, South Korea.	pedopjh@khu.ac.kr	CHOI, SUNG CHUL/B-4574-2019	CHOI, SUNG CHUL/0000-0001-7221-2000	Kyung Hee University Research Fund in 2008 [KHU-20080548]	This research was supported by the Kyung Hee University Research Fund in 2008 (KHU-20080548).	ANDREASEN J O, 1985, Endodontics and Dental Traumatology, V1, P45; Andreasen JO, 2007, TXB COLOR ATLAS TRAU; Bastone EB, 2000, AUST DENT J, V45, P2, DOI 10.1111/j.1834-7819.2000.tb00234.x; DELROSARIO MEL, 1992, ENDOD DENT TRAUMATOL, V8, P213; Eyuboglu O, 2009, DENT TRAUMATOL, V25, P110, DOI 10.1111/j.1600-9657.2008.00668.x; Flores MT, 2007, DENT TRAUMATOL, V23, P196, DOI 10.1111/j.1600-9657.2007.00627.x; GARCIA-GODOY F, 1987, Endodontics and Dental Traumatology, V3, P126; Garcia-Godoy F, 2000, Dent Clin North Am, V44, P597; GARCIAGODOY F, 1983, COMMUNITY DENT ORAL, V11, P127, DOI 10.1111/j.1600-0528.1983.tb01370.x; Glendor U, 1996, SWED DENT J, V20, P15; Glendor U, 2008, DENT TRAUMATOL, V24, P603, DOI 10.1111/j.1600-9657.2008.00696.x; Hargreaves JA, 1999, ENDOD DENT TRAUMATOL, V15, P73; HARRINGTON MS, 1988, J DENT CHILD, V55, P334; Kramer PF, 2003, DENT TRAUMATOL, V19, P299, DOI 10.1046/j.1600-4469.2003.00203.x; OIKARINEN K, 1987, ENDOD DENT TRAUMATOL, V3, P172; Oliveira LB, 2007, DENT TRAUMATOL, V23, P76, DOI 10.1111/j.1600-9657.2005.00413.x; Otuyemi OD, 1996, E AFR MED J, V73, P604; Petersson EE, 1997, SWED DENT J, V21, P55; Rajab LD, 2003, DENT TRAUMATOL, V19, P6, DOI 10.1034/j.1600-9657.2003.00131.x; RAVN JJ, 1976, SCAND J DENT RES, V84, P137; Robson F, 2009, DENT TRAUMATOL, V25, P118, DOI 10.1111/j.1600-9657.2008.00725.x; Rocha MJD, 2001, DENT TRAUMATOL, V17, P245; Rodriguez JG, 2007, DENT TRAUMATOL, V23, P241, DOI 10.1111/j.1600-9657.2005.00428.x; SANCHEZ AV, 1990, ENDOD DENT TRAUMATOL, V6, P63; Skaare AB, 2005, DENT TRAUMATOL, V21, P315, DOI 10.1111/j.1600-9657.2005.00362.x; Soporowski Nancy Jo, 1994, Pediatric Dentistry, V16, P96; Zeng Yang, 1994, Pediatric Dentistry, V16, P419	27	32	32	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-4469	1600-9657		DENT TRAUMATOL	Dent. Traumatol.	FEB	2010	26	1					70	75		10.1111/j.1600-9657.2009.00840.x			6	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	541XE	WOS:000273453800013	20089062				2021-06-18	
J	Chun, KA; Manley, GT; Stiver, SI; Aiken, AH; Phan, N; Wang, V; Meeker, M; Cheng, SC; Gean, AD; Wintermark, M				Chun, Kimberly A.; Manley, Geoffrey T.; Stiver, Shirley I.; Aiken, Ashley H.; Phan, Nicholas; Wang, Vincent; Meeker, Michele; Cheng, Su-Chun; Gean, A. D.; Wintermark, Max			Interobserver Variability in the Assessment of CT Imaging Features of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						accuracy; computed tomography; imaging scores; interobserver agreement; traumatic brain injury	SEVERE HEAD-INJURY; SUBARACHNOID HEMORRHAGE; COMPUTERIZED-TOMOGRAPHY; OUTCOME PREDICTION; CLASSIFICATION; IMPACT; SCAN	The goal of our study was to determine the interobserver variability between observers with different backgrounds and experience when interpreting computed tomography (CT) imaging features of traumatic brain injury (TBI). We retrospectively identified a consecutive series of 50 adult patients admitted at our institution with a suspicion of TBI, and displaying a Glasgow Coma Scale score <= 12. Noncontrast CT (NCT) studies were anonymized and sent to five reviewers with different backgrounds and levels of experience, who independently reviewed each NCT scan. Each reviewer assessed multiple CT imaging features of TBI and assigned every NCT scan a Marshall and a Rotterdam grading score. The interobserver agreement and coefficient of variation were calculated for individual CT imaging features of TBI as well as for the two scores. Our results indicated that the imaging review by both neuroradiologists and neurosurgeons were consistent with each other. The kappa coefficient of agreement for all CT characteristics showed no significant difference in interpretation between the neurosurgeons and neuroradiologists. The average Bland and Altman coefficients of variation for the Marshall and Rotterdam classification systems were 12.7% and 21.9%, respectively, which indicates acceptable agreement among all five reviewers. In conclusion, there is good interobserver reproducibility between neuroradiologists and neurosurgeons in the interpretation of CT imaging features of TBI and calculation of Marshall and Rotterdam scores.	[Chun, Kimberly A.; Aiken, Ashley H.; Gean, A. D.; Wintermark, Max] Univ Calif San Francisco, Dept Radiol, Neuroradiol Sect, San Francisco, CA 94143 USA; [Manley, Geoffrey T.; Stiver, Shirley I.; Phan, Nicholas; Wang, Vincent; Meeker, Michele; Gean, A. D.] Univ Calif San Francisco, Brain & Spinal Injury Ctr, San Francisco, CA 94143 USA; [Cheng, Su-Chun] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; [Manley, Geoffrey T.; Stiver, Shirley I.; Phan, Nicholas; Wang, Vincent; Meeker, Michele] San Francisco Gen Hosp, San Francisco, CA 94110 USA; [Manley, Geoffrey T.; Stiver, Shirley I.; Phan, Nicholas; Wang, Vincent; Meeker, Michele] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA	Wintermark, M (corresponding author), Univ Calif San Francisco, Dept Radiol, Neuroradiol Sect, 505 Parnassus Ave,Box 0628, San Francisco, CA 94143 USA.	Max.Wintermark@radiology.ucsf.edu		Wintermark, Max/0000-0002-6726-3951	National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2 RR024130]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [KL2RR024130] Funding Source: NIH RePORTER	Max Wintermark receives funding from the National Center for Research Resources (grant KL2 RR024130). The content of the article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke, the National Center for Research Resources, the National Institutes of Health, or the other sponsors.	Altman D., 1991, PRACTICAL STAT MED R, P404; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; Doppenberg EMR, 1997, ANN NY ACAD SCI, V825, P305, DOI 10.1111/j.1749-6632.1997.tb48441.x; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Greene KA, 1996, J TRAUMA, V41, P964, DOI 10.1097/00005373-199612000-00004; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P327; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; SELLADURAI BM, 1992, BRIT J NEUROSURG, V6, P549, DOI 10.3109/02688699209002372; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Viera AJ, 2005, FAM MED, V37, P360	21	32	33	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	FEB	2010	27	2					325	330		10.1089/neu.2009.1115			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	557JG	WOS:000274664800005	19895192	Green Published			2021-06-18	
J	Flierl, MA; Stoneback, JW; Beauchamp, KM; Hak, DJ; Morgan, SJ; Smith, WR; Stahel, PF				Flierl, Michael A.; Stoneback, Jason W.; Beauchamp, Kathryn M.; Hak, David J.; Morgan, Steven J.; Smith, Wade R.; Stahel, Philip F.			Femur Shaft Fracture Fixation in Head-Injured Patients: When Is the Right Time?	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						Traumatic brain injury; femur fracture; intramedullary nail fixation; damage control; external fixation	TRAUMATIC BRAIN-INJURY; COMA SCALE SCORE; FEMORAL FRACTURES; MULTIPLE TRAUMA; EXTERNAL FIXATION; MAJOR FRACTURES; STABILIZATION; POLYTRAUMA; STRATEGIES; MANAGEMENT	The ideal timing and modality of femur shaft fracture fixation in head-injured patients remains a topic of debate. Several groups advocate the immediate definitive fixation Of femur fractures ("early total care"), whereas others support the concept of "damage control orthopaedics" with temporary fracture fixation by means of external fixation and staged, planned conversion to internal fixation. The present review was designed to address this unresolved controversy by outlining the underlying immunopathophysiology of traumatic brain injury and providing clinical recommendations on the timing of femur shaft fracture fixation in patients with severe head injuries.	[Flierl, Michael A.; Stoneback, Jason W.; Hak, David J.; Morgan, Steven J.; Smith, Wade R.; Stahel, Philip F.] Univ Colorado, Dept Orthopaed Surg, Denver Hlth Med Ctr, Sch Med, Denver, CO 80204 USA; [Beauchamp, Kathryn M.; Stahel, Philip F.] Univ Colorado, Dept Neurosurg, Denver Hlth Med Ctr, Sch Med, Denver, CO 80204 USA	Stahel, PF (corresponding author), Univ Colorado, Dept Orthopaed Surg, Denver Hlth Med Ctr, Sch Med, 777 Bannock St, Denver, CO 80204 USA.	philip.stahel@dhha.org					Anglen JO, 2003, J TRAUMA, V54, P1166, DOI 10.1097/01.TA.0000057232.66613.AC; Arand M, 2001, LANGENBECK ARCH SURG, V386, P241, DOI 10.1007/s004230100204; Bayir H, 2003, CRIT CARE MED, V31, pS112, DOI 10.1097/01.CCM.0000042464.46603.0E; Bhandari M, 2003, CLIN ORTHOP RELAT R, P187, DOI 10.1097/01.blo.0000043051.62337.bd; BONE LB, 1989, J BONE JOINT SURG AM, V71A, P336, DOI 10.2106/00004623-198971030-00004; Bose D, 2006, INJURY, V37, P20, DOI 10.1016/j.injury.2005.06.054; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Bratton SL, 2007, J NEUROTRAUMA, V24, pS7; Bratton SL, 2007, J NEUROTRAUMA S1, V24, pS45; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P555, DOI DOI 10.1089/NEU.2007.9988; Brundage SI, 2002, J TRAUMA, V52, P299, DOI 10.1097/00005373-200202000-00016; CHARASH WE, 1994, J TRAUMA, V37, P667, DOI 10.1097/00005373-199410000-00023; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; Davis DP, 2006, J TRAUMA, V60, P985, DOI 10.1097/01.ta.0000205860.96209.1c; Diaz-Parejo P, 2003, INTENS CARE MED, V29, P544, DOI 10.1007/s00134-003-1669-3; Edwards P, 2005, LANCET, V365, P1957; Elf K, 2003, EUR J TRAUMA, V29, P74; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Forteza AM, 1999, STROKE, V30, P2687, DOI 10.1161/01.STR.30.12.2687; Garg R, 2006, STROKE, V37, P267, DOI 10.1161/01.STR.0000195175.29487.30; Gebhard F, 2008, LANGENBECK ARCH SURG, V393, P825, DOI 10.1007/s00423-008-0334-2; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; Giannoudis PV, 1999, J BONE JOINT SURG BR, V81B, P356, DOI 10.1302/0301-620X.81B2.8988; Giannoudis PV, 2002, CLIN ORTHOP RELAT R, P378, DOI 10.1097/01.blo.00000236813.17269.24; Giannoudis PV, 2002, AM J SURG, V183, P261, DOI 10.1016/S0002-9610(02)00783-3; Glenn JN, 2004, CLIN ORTHOP RELAT R, P142, DOI 10.1097/01.blo.0000131644.61246.c4; Golding EM, 2002, BRAIN RES REV, V38, P377, DOI 10.1016/S0165-0173(02)00141-8; Gray AC, 2009, J ORTHOP TRAUMA, V23, P90, DOI 10.1097/BOT.0b013e31819194c6; Grotz MRW, 2004, INJURY, V35, P1077, DOI 10.1016/j.injury.2004.05.025; Harwood PJ, 2005, J TRAUMA, V58, P446, DOI 10.1097/01.TA.0000153942.28015.77; HOFMAN PAM, 1991, J TRAUMA, V31, P261, DOI 10.1097/00005373-199131020-00020; Holbein M, 2009, CRIT CARE, V13, DOI 10.1186/cc7711; Holcomb JB, 2007, J TRAUMA, V62, pS36, DOI 10.1097/TA.0b013e3180654134; Holcomb JB, 2007, J TRAUMA, V62, P307, DOI 10.1097/TA.0b013e3180324124; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jaicks RR, 1997, J TRAUMA, V42, P1, DOI 10.1097/00005373-199701000-00001; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; JOHNSON KD, 1985, J TRAUMA, V25, P375, DOI 10.1097/00005373-198505000-00001; Kalb DC, 1998, SURGERY, V124, P739, DOI 10.1067/msy.1998.91395; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; KOTWICA Z, 1990, ACTA NEUROCHIR, V102, P19, DOI 10.1007/BF01402180; Lehmann U, 2001, UNFALLCHIRURG, V104, P196, DOI 10.1007/s001130050715; LEHMANN U, 1995, UNFALLCHIRURG, V98, P437; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Masson F, 2001, J TRAUMA, V51, P481, DOI 10.1097/00005373-200109000-00010; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Morshed S, 2009, J BONE JOINT SURG AM, V91A, P3, DOI 10.2106/JBJS.H.00338; Mousavi M, 2001, INJURY, V32, P679, DOI 10.1016/S0020-1383(01)00048-1; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Nau T, 2003, ANZ J SURG, V73, P1018, DOI 10.1046/j.1445-2197.2003.t01-19-.x; Neugebauer E, 2000, UNFALLCHIRURG, V103, P122, DOI 10.1007/s001130050023; Nowotarski PJ, 2000, J BONE JOINT SURG AM, V82A, P781, DOI 10.2106/00004623-200006000-00004; Orliaguet GA, 2008, PEDIATR ANESTH, V18, P455, DOI 10.1111/j.1460-9592.2008.02507.x; Pape HC, 2008, J ORTHOP RES, V26, P1478, DOI 10.1002/jor.20697; Pape HC, 2007, ANN SURG, V246, P491, DOI 10.1097/SLA.0b013e3181485750; Pape Hans-Christoph, 2005, J Orthop Trauma, V19, P551, DOI 10.1097/01.bot.0000161712.87129.80; PELL ACH, 1993, J BONE JOINT SURG BR, V75, P921; POOLE GV, 1992, J TRAUMA, V32, P654, DOI 10.1097/00005373-199205000-00019; Ransohoff RM, 2002, ANN NY ACAD SCI, V961, P346, DOI 10.1111/j.1749-6632.2002.tb03120.x; Ransohoff RM, 2002, J INFECT DIS, V186, pS152, DOI 10.1086/344266; Reed AR, 2002, SAMJ S AFR MED J, V92, P221; REYNOLDS MA, 1995, ANN SURG, V222, P470; Rixen D, 2005, J TRAUMA, V59, P1375, DOI 10.1097/01.ta.0000198364.50334.39; Roberts Craig S, 2005, Instr Course Lect, V54, P447; Rose S, 1998, LANGENBECK ARCH SURG, V383, P199, DOI 10.1007/s004230050119; Sagraves Scott G, 2006, J Intensive Care Med, V21, P5, DOI 10.1177/0885066605282790; Scalea TM, 2008, J TRAUMA, V65, P253, DOI 10.1097/TA.0b013e31817fa475; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; SEIBEL R, 1985, ANN SURG, V202, P283, DOI 10.1097/00000658-198509000-00003; Spahn DR, 2007, CRIT CARE, V11, DOI 10.1186/cc5686; Spinella PC, 2007, J TRAUMA, V62, pS82, DOI 10.1097/TA.0b013e318065b21f; Stahel PF, 2005, ORTHOPADE, V34, P852, DOI 10.1007/s00132-005-0844-3; Stahel PF, 2005, ORTHOPADE, V34, P823, DOI 10.1007/s00132-005-0842-5; Stahel PF, 1998, BRAIN RES REV, V27, P243, DOI 10.1016/S0165-0173(98)00015-0; STAHEL PF, 2009, GEN SURG PRINCIPLES, P131; STAHEL PF, 2005, EUR J TRAUMA, V31, P200; Stahel PF, 2008, INTENS CARE MED, V34, P402, DOI 10.1007/s00134-007-0889-3; Stahel PF, 2007, INJURY, V38, P1409, DOI 10.1016/j.injury.2007.09.023; Stahel PF, 2009, CURR OPIN ANESTHESIO, V22, P289, DOI 10.1097/ACO.0b013e32832678ed; Starr AJ, 1998, J TRAUMA, V45, P980, DOI 10.1097/00005373-199811000-00026; Stiefel MF, 2006, J NEUROSURG, V105, P281, DOI 10.3171/ped.2006.105.4.281; Taeger G, 2005, J TRAUMA, V59, P408, DOI 10.1097/01.ta.0000175088.29170.3e; Townsend RN, 1998, J TRAUMA, V44, P977, DOI 10.1097/00005373-199806000-00008; Tracey KJ, 2001, FASEB J, V15, P1575, DOI 10.1096/fj.01-0148hyp; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; Velmahos GC, 1998, AM J SURG, V176, P324, DOI 10.1016/S0002-9610(98)00208-6; Wang MC, 2007, J TRAUMA, V62, P1250, DOI 10.1097/01.ta.0000215581.50234.56; WOOLF PD, 1992, CRIT CARE MED, V20, P216, DOI 10.1097/00003246-199202000-00011; Wu Xue-Hai, 2003, Chin J Traumatol, V6, P114; ZHUANG J, 1993, J TRAUMA, V35, P415, DOI 10.1097/00005373-199309000-00014	95	32	34	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0890-5339	1531-2291		J ORTHOP TRAUMA	J. Orthop. Trauma	FEB	2010	24	2					107	114		10.1097/BOT.0b013e3181b6bdfc			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	549RV	WOS:000274072700007	20101135				2021-06-18	
J	van der Eerden, AW; Twickler, MTB; Sweep, FCGJ; Beems, T; Hendricks, HT; Hermus, ARMM; Vos, PE				van der Eerden, Anke W.; Twickler, Marcel Th B.; Sweep, Fred C. G. J.; Beems, Tjemme; Hendricks, Henk T.; Hermus, Ad R. M. M.; Vos, Pieter E.			Should anterior pituitary function be tested during follow-up of all patients presenting at the emergency department because of traumatic brain injury?	EUROPEAN JOURNAL OF ENDOCRINOLOGY			English	Article							GROWTH-HORMONE DEFICIENCY; FREE TESTOSTERONE; HYPOPITUITARISM; DYSFUNCTION; PREVALENCE; WOMEN	Context: A wide range (15-56%) of prevalences of anterior pituitary insufficiency are reported in patients after traumatic brain injury (TBI). However, different study populations, study designs, and diagnostic procedures were used. No data are available on emergency-department-based cohorts of TBI patients. Objective: To assess the prevalence of pituitary dysfunction in an emergency-department-based cohort of TBI patients using strict endocrinological diagnostic criteria. Methods: Of all the patients presenting in the emergency department with TBI over a 2-year period, 516 matched the inclusion criteria. One hundred and seven patients (77 with mild TBI and 30 with moderate/severe TBI) agreed to participate. They were screened for anterior pituitary insufficiency by GHRH-arginine testing, evaluation of fasting morning hormone levels (cortisol, TSH, free thyroxine, FSH, LH, and 17 beta-estradiol or testosterone), and menstrual history 3-30 months after TBI. Abnormal screening results were defined as low peak GH to GHRH-arginine, or low levels of any of the end-organ hormones with low or normal pituitary hormone levels. Patients with abnormal screening results were extensively evaluated, including additional hormone provocation tests (insulin tolerance test, ACTH stimulation test, and repeated GHRH-arginine test) and assessment of free testosterone levels. Results: Screening results were abnormal in 15 of 107 patients. In a subsequent extensive endocrine evaluation, anterior pituitary dysfunction was diagnosed in only one patient (partial hypocortisolism). Conclusion: By applying strict diagnostic criteria to an emergency-department-based cohort of TBI patients, it was shown that anterior pituitary dysfunction is rare (< 1%). Routine pituitary screening in unselected patients after TBI is unlikely to be cost-effective.	[van der Eerden, Anke W.; Vos, Pieter E.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; [Twickler, Marcel Th B.; Hermus, Ad R. M. M.] Radboud Univ Nijmegen, Med Ctr, Dept Endocrinol, NL-6500 HB Nijmegen, Netherlands; [Sweep, Fred C. G. J.] Radboud Univ Nijmegen, Med Ctr, Dept Chem Endocrinol, NL-6500 HB Nijmegen, Netherlands; [Beems, Tjemme] Radboud Univ Nijmegen, Med Ctr, Dept Neurosurg, NL-6500 HB Nijmegen, Netherlands; [Hendricks, Henk T.] Radboud Univ Nijmegen, Med Ctr, Dept Rehabil Med, NL-6500 HB Nijmegen, Netherlands; [Twickler, Marcel Th B.] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands	Vos, PE (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Neurol, Internal Address 935,POB 9101, NL-6500 HB Nijmegen, Netherlands.	p.vos@neuro.umcn.nl	Hermus, A.R.M.M./H-8043-2014; Vos, Pieter/A-6043-2012; van der Eerden, Anke/H-9413-2017; Sweep, Fred/H-8096-2014	Hermus, A.R.M.M./0000-0003-1075-2655; van der Eerden, Anke/0000-0002-9182-9089; Sweep, Fred/0000-0003-1103-3070	NovoNordisk BVNovo Nordisk; Alphen aan de Rijn; Netherlands Organization of Research and Health (NWO-ZonMW)Netherlands Organization for Scientific Research (NWO)	This work was supported by NovoNordisk BV, Alphen aan de Rijn, The Netherlands, with an independent research grant. The funding source had no role in the study design, data collection, analyses, interpretation, or writing of this report. M Th B Twickler is supported by a grant of the Netherlands Organization of Research and Health (NWO-ZonMW).	Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; AGHA A, 2005, AM J MED, V118, pE4167; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Bouillon R, 2006, ENDOCRIN METAB CLIN, V35, P767, DOI 10.1016/j.ecl.2006.09.004; Deijen JB, 1998, PSYCHONEUROENDOCRINO, V23, P45, DOI 10.1016/S0306-4530(97)00092-9; EDWARDS OM, 1986, MEDICINE, V65, P281; Endert E, 2005, NETH J MED, V63, P435; Herrmann BL, 2006, EXP CLIN ENDOCR DIAB, V114, P316, DOI 10.1055/s-2006-924254; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; Mittenberg W, 2001, J CLIN EXP NEUROPSYC, V23, P829, DOI 10.1076/jcen.23.6.829.1022; Molitch ME, 2006, J CLIN ENDOCR METAB, V91, P1621, DOI 10.1210/jc.2005-2227; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Ross HA, 2008, CLIN CHEM LAB MED, V46, P1334, DOI 10.1515/CCLM.2008.261; Ross HA, 2005, CLIN CHEM LAB MED, V43, P613, DOI 10.1515/CCLM.2005.106; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2006, ACTA NEUROCHIR, V148, P449, DOI 10.1007/s00701-005-0724-y; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Sternbach H, 1998, AM J PSYCHIAT, V155, P1310, DOI 10.1176/ajp.155.10.1310; SWINKELS LMJW, 1991, CLIN CHEM, V37, P180; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; THOMAS CMG, 1977, ACTA ENDOCRINOL-COP, V86, P405, DOI 10.1530/acta.0.0860405; van Aken M O, 2005, Pituitary, V8, P183; Van Uytfanghe K, 2004, CLIN CHEM, V50, P2101, DOI 10.1373/clinchem.2004.037358; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yamamoto T, 1999, THYROID, V9, P1167, DOI 10.1089/thy.1999.9.1167	33	32	33	0	3	BIOSCIENTIFICA LTD	BRISTOL	STARLING HOUSE, 1600 BRISTOL PARKWAY N, BRISTOL, ENGLAND	0804-4643	1479-683X		EUR J ENDOCRINOL	Eur. J. Endocrinol.	JAN	2010	162	1					19	28		10.1530/EJE-09-0436			10	Endocrinology & Metabolism	Endocrinology & Metabolism	582QD	WOS:000276611800003	19783620	Bronze			2021-06-18	
J	Prigatano, GP				Prigatano, George P.			Anosognosia: clinical and ethical considerations	CURRENT OPINION IN NEUROLOGY			English	Article						anosognosia; causes; ethical issues; impaired self-awareness; treatment	TRAUMATIC BRAIN-INJURY; IMPAIRED AWARENESS; ANTONS-SYNDROME; FRONTOTEMPORAL DEMENTIA; COGNITIVE IMPAIRMENT; CORTICAL BLINDNESS; RIGHT-HEMISPHERE; HEMIPLEGIA; STROKE; DISEASE	Purpose of review This review considers recent findings on classical forms of anosognosia and less dramatic disturbances in self-awareness observed in various brain disorders. It also addresses issues of clinical management and ethical treatment. Recent findings The study of anosognosia for hemiplegia, Anton's syndrome, and less dramatic disturbances in self-awareness in conditions such as Alzheimer's disease, mild cognitive impairment, and severe traumatic brain injury suggests its 'multifactorial' nature. Lesions in various regions of the brain may contribute to different forms of anosognosia. Animal and human studies suggest that the insular cortex plays an important role in subjective awareness of feeling states, and may be implicated in various forms of anosognosia. Also, right frontal lobe lesions have been implicated, but typically in patients who have bilateral cerebral dysfunction. These patients require careful clinical management in light of their reduced awareness of their neurological and neuropsychological functions that impact daily activities. Summary The study of anosognosia and disorders of self-awareness has expanded greatly over the past 20 years. Various patient groups may show different levels of impaired awareness or anosognosia. Guidelines for the clinical management and ethical treatment of these patients are needed, but beginning efforts have been made.	[Prigatano, George P.] St Josephs Hosp, Barrow Neurol Inst, Div Neurol, Phoenix, AZ 85013 USA; [Prigatano, George P.] Maricopa Cty Gen Hosp, Phoenix, AZ USA	Prigatano, GP (corresponding author), St Josephs Hosp, Barrow Neurol Inst, Div Neurol, 222 W Thomas Rd,Suite 315, Phoenix, AZ 85013 USA.	george.prigatano@chw.edu			Newsome Foundation	The author thanks Jennifer Gray, PhD, and Bruce White, DO, for their help in reviewing earlier drafts of this manuscript and making helpful suggestions for improving it. The author also wishes to acknowledge the Newsome Foundation for providing economic support for the time to prepare this article. Special thanks to Mary Henry for her expert secretarial help.	Abutalebi J, 2007, BEHAV NEUROL, V18, P183, DOI 10.1155/2007/306075; Anderson MC, 2004, SCIENCE, V303, P232, DOI 10.1126/science.1089504; Anton G., 1898, WIEN KLIN WOCHENSCHR, V11, P227; Argenta PA, 1998, OBSTET GYNECOL, V91, P810, DOI 10.1016/S0029-7844(97)00718-7; Babinski J., 1914, REV NEUROL-FRANCE, V27, P845; Berti A, 2005, SCIENCE, V309, P488, DOI 10.1126/science.1110625; BISIACH E, 1986, NEUROPSYCHOLOGIA, V24, P471, DOI 10.1016/0028-3932(86)90092-8; BOTTINI G, STUDY ANOSO IN PRESS; BREIER JI, 1995, NEUROLOGY, V45, P65, DOI 10.1212/WNL.45.1.65; Cocchini G, 2002, NEUROPSYCHOLOGIA, V40, P2030, DOI 10.1016/S0028-3932(02)00054-4; CRAIG AD, STUDY ANOSO IN PRESS; Craig AD, 2008, HDB EMOTIONS; Cramer SC, 2008, CURR OPIN NEUROL, V21, P76, DOI 10.1097/WCO.0b013e3282f36cb6; Della Sala S, 1988, Schweiz Arch Neurol Psychiatr (1985), V139, P5; FORSTL H, 1993, NEUROPSY NEUROPSY BE, V6, P1; Fotopoulou A, 2009, NEUROPSYCHOLOGIA, V47, P1256, DOI 10.1016/j.neuropsychologia.2009.01.018; Gialanella B, 2005, STROKE, V36, P2687, DOI 10.1161/01.STR.0000189627.27562.c0; Hoth KF, 2007, J CLIN EXP NEUROPSYC, V29, P365, DOI 10.1080/13803390600718958; Jehkonen M, 2000, ACTA NEUROL SCAND, V102, P378, DOI 10.1034/j.1600-0404.2000.102006378.x; Jehkonen M, 2006, ACTA NEUROL SCAND, V114, P293, DOI 10.1111/j.1600-0404.2006.00723.x; Karnath HO, 2005, J NEUROSCI, V25, P7134, DOI 10.1523/JNEUROSCI.1590-05.2005; KARNATH HO, STUDY ANOSO IN PRESS; Kertesz A, 2000, J INT NEUROPSYCH SOC, V6, P460, DOI 10.1017/S1355617700644041; LEBRUN Y, 1987, CORTEX, V23, P251, DOI 10.1016/S0010-9452(87)80035-7; Misra M, 1989, Indian J Ophthalmol, V37, P196; O'Keeffe FM, 2007, BRAIN, V130, P753, DOI 10.1093/brain/awl367; Orfei MD, 2007, BRAIN, V130, P3075, DOI 10.1093/brain/awm106; Pedersen PM, 1996, J NEUROL REHABIL, V10, P243; Prigatano G., 2008, COGNITIVE NEUROREHAB, P218; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, AWARENESS DEFICIT BR, P111; PRIGATANO GP, STUDY ANOSOGNOSIA; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; PRIGATANO GP, STUDY ANOSO IN PRESS; RAMACHANDRAN VS, 1994, INT REV NEUROBIOL, V37, P291; Ries ML, 2007, J INT NEUROPSYCH SOC, V13, P450, DOI 10.1017/S1355617707070488; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; ROOS KL, 1990, CLIN ELECTROENCEPHAL, V21, P104, DOI 10.1177/155005949002100212; RUBENS AB, 1990, AWARENESS DEFICIT BR, P40; Salmon E, 2006, HUM BRAIN MAPP, V27, P588, DOI 10.1002/hbm.20203; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Schneider, 1998, PRACTICE AUTONOMY PA; Schonberger M, 2006, NEUROPSYCHOL REHABIL, V16, P298, DOI 10.1080/09602010500176476; Sherer M, 2003, ARCH PHYS MED REHAB, V84, P168, DOI 10.1053/apmr.2003.50045; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SIEGLER M, 2002, CLIN ETHICS; Snowden JS, 1998, ARCH NEUROL-CHICAGO, V55, P801, DOI 10.1001/archneur.55.6.801; STARKSTEIN SE, STUDY ANOSO IN PRESS; Trahan E, 2006, J HEAD TRAUMA REHAB, V21, P226, DOI 10.1097/00001199-200605000-00003; Trifiletti RR, 2007, EUR J NEUROL, V14, pE11, DOI 10.1111/j.1468-1331.2006.01581.x; VOCAT R, STUDY ANOSO IN PRESS; Vuilleumier P, 2001, BRAIN, V124, P1077, DOI 10.1093/brain/124.6.1077; Weinstein EA, 1955, DENIAL ILLNESS; White B., 2007, DRUGS ETHICS QUALITY; Yilmazlar S, 2003, PEDIATR NEUROSURG, V38, P156, DOI 10.1159/000068813	55	32	34	0	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1350-7540			CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	2009	22	6					606	611		10.1097/WCO.0b013e328332a1e7			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	529UK	WOS:000272544100008	19809315				2021-06-18	
J	Anderson, GD; Temkin, NR; Dikmen, SS; Diaz-Arrastia, R; Machamer, JE; Farhrenbruch, C; Miller, JW; Sadrzadeh, SMH				Anderson, Gail D.; Temkin, Nancy R.; Dikmen, Sureyya S.; Diaz-Arrastia, Ramon; Machamer, Joan E.; Farhrenbruch, Carol; Miller, John W.; Sadrzadeh, S. M. Hossein			Haptoglobin phenotype and apolipoprotein E polymorphism: Relationship to posttraumatic seizures and neuropsychological functioning after traumatic brain injury	EPILEPSY & BEHAVIOR			English	Article						Traumatic brain injury; Posttraumatic seizures; Haptoglobin; Apolipoprotein E	E GENOTYPE; ASSOCIATION; HYPOHAPTOGLOBINEMIA; PREVENTION; HEMOGLOBIN; VALPROATE; RECOVERY; EPILEPSY; CAT	The relationship of genetic predisposition to reduced iron capacity and apolipoprotein E (APOE) to posttraumatic seizures (PTSs) and neuropsychological outcomes was investigated in patients with traumatic brain injuries from a prior valproate clinical study. Haptoglobin concentration/phenotype and APOE genotype were determined in 25 patients with PTSs and 26 control (no PTSs) Subjects similar to 10 years after traumatic brain injury. Haptoglobin phenotype was also determined in previously collected frozen samples for 25 additional patients with PTSs and 32 no-PTS subjects. There was no relationship between haptoglobin phenotype or APOE genotype and occurrence of PTSs. APOE genotype was not related to neuropsychological outcome; however, when adjustments were made for differences in educational levels, APOE FA subjects did worse, especially on tests of verbal intellectual and verbal memory skills. In contrast to our hypothesis, those with haptoglobin 1-1 (high-affinity binder of hemoglobin) scored somewhat worse on Verbal IQ and Tapping D at I and 12 months after injury. (C) 2009 Elsevier Inc. All rights reserved.	[Anderson, Gail D.] Univ Washington, Dept Pharm, Seattle, WA 98195 USA; [Temkin, Nancy R.; Dikmen, Sureyya S.; Farhrenbruch, Carol] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Temkin, Nancy R.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Temkin, Nancy R.; Dikmen, Sureyya S.; Machamer, Joan E.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Miller, John W.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA; [Sadrzadeh, S. M. Hossein] Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; [Diaz-Arrastia, Ramon] Univ Texas SW Med Sch, Dept Neurol, Dallas, TX USA; [Sadrzadeh, S. M. Hossein] Univ Calgary, Dept Pathol & Lab Med, Calgary Lab Serv, Calgary, AB, Canada	Anderson, GD (corresponding author), Univ Washington, Dept Pharm, Box 357630, Seattle, WA 98195 USA.	gaila@u.washington.edu		Diaz-Arrastia, Ramon/0000-0001-6051-3594	American Epilepsy Society; NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS19643]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS019643] Funding Source: NIH RePORTER	Funding supported by a Research Initiative Award from the American Epilepsy Society. The valproate study data were collected under NIH/NINDS Grant R01NS19643.	BLACK JA, 1968, NATURE, V218, P736, DOI 10.1038/218736a0; BUSCHKE H, 1973, J VERB LEARN VERB BE, V12, P543, DOI 10.1016/S0022-5371(73)80034-9; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chapman J, 1996, NEUROLOGY, V46, P1484, DOI 10.1212/WNL.46.5.1484-a; Chesnut R M, 1995, New Horiz, V3, P366; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Diaz-Arrastia R, 2006, J HEAD TRAUMA REHAB, V21, P361, DOI 10.1097/00001199-200607000-00007; Dikmen SS, 2000, NEUROLOGY, V54, P895, DOI 10.1212/WNL.54.4.895; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; HALLIWELL B, 2000, FREE RADICAL BIO MED, P175; Javid J, 1978, Curr Top Hematol, V1, P151; KOEHLER J, 1994, BIOSTATISTICS; Langlois MR, 1996, CLIN CHEM, V42, P1589; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Melamed-Frank M, 2001, BLOOD, V98, P3693, DOI 10.1182/blood.V98.13.3693; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; PANTER SS, 1984, T ASSOC AM PHYSICIAN, V97, P56; PANTER SS, 1985, J EXP MED, V161, P748, DOI 10.1084/jem.161.4.748; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; REID SA, 1979, EXP NEUROL, V66, P205, DOI 10.1016/0014-4886(79)90075-X; REITAN R, 1993, H REITAN NEUROPSYCHO; Saccucci P, 2004, NEUROGENETICS, V5, P245, DOI 10.1007/s10048-004-0192-1; SADRZADEH SMH, 1987, J CLIN INVEST, V79, P662, DOI 10.1172/JCI112865; Sadrzadeh SMH, 2004, CLIN CHEM, V50, P1095, DOI 10.1373/clinchem.2003.028001; SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354; SMITHIES O, 1955, BIOCHEM J, V61, P629, DOI 10.1042/bj0610629; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Temkin NR, 1999, J NEUROSURG, V91, P593, DOI 10.3171/jns.1999.91.4.0593; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; VANLENTE F, 1979, CLIN CHEM, V25, P2007; Wechsler D., 1997, WAIS 3 ADM SCORING M; Wechsler D., 1955, MANUAL WECHSLER ADUL; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; WILLMORE LJ, 1978, SCIENCE, V200, P1501, DOI 10.1126/science.96527	36	32	32	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	NOV	2009	16	3					501	506		10.1016/j.yebeh.2009.08.025			6	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	521PY	WOS:000271935800025	19766540	Green Accepted			2021-06-18	
J	Hill, AJ; Theodoros, DG; Russell, TG; Ward, EC				Hill, Anne J.; Theodoros, Deborah G.; Russell, Trevor G.; Ward, Elizabeth C.			The Redesign and Re-evaluation of an Internet-Based Telerehabilitation System for the Assessment of Dysarthria in Adults	TELEMEDICINE JOURNAL AND E-HEALTH			English	Article						telehealth; Internet; telerehabilitation system; dysarthria	CLOSED-HEAD-INJURY; LANGUAGE DISORDERS; HIGH AGREEMENT; LOW KAPPA; SPEECH; HYPERNASALITY; RELIABILITY; RATINGS	A previous study revealed that reliable assessment of dysarthria was feasible. However, that study also revealed a number of system limitations and suggested that technological enhancements and improvements in study design and clinical assessment protocols were needed before validity and reliability of assessment of dysarthria via telerehabilitation could be confirmed. In the current study, improvements in technology, study design, and clinical assessment protocols were implemented in order to re-examine the validity and reliability of assessing and diagnosing dysarthria via the telerehabilitation medium. The aim of this study was to explore the validity and reliability of assessing dysarthria using both formal standardized and informal assessments via a purpose-built telerehabilitation system. Twenty-four participants with an acquired dysarthria were assessed simultaneously via telerehabilitation and face-to-face (FTF) on a battery of assessments. A custom-built telerehabilitation system enabled real-time telerehabilitation assessment over a 128 Kbps Internet connection. Data analysis included an analysis of strength of agreement between the two methods using percentage agreement and weighted. statistics. Inter-rater and intrarater reliability were also examined for both the FTF and telerehabilitation-led assessments. Good strength of agreement was found between the FTF and telerehabilitation assessment methods. High intrarater and inter-rater reliability within both the FTF and telerehabilitation assessment methods supported these findings. Participants reported high overall satisfaction in the telerehabilitation environment. This study describes the improvements made to the telerehabilitation system reported previously and confirms that valid and reliable assessment of dysarthria using both standardized and informal assessments over the Internet is possible using this system.	[Hill, Anne J.; Theodoros, Deborah G.; Ward, Elizabeth C.] Univ Queensland, Div Speech Pathol, Sch Hlth & Rehabil Sci, Brisbane, Qld, Australia; [Russell, Trevor G.] Univ Queensland, Div Physiotherapy, Sch Hlth & Rehabil Sci, Brisbane, Qld, Australia	Hill, AJ (corresponding author), Univ Queensland, Div Speech Pathol, Sch Hlth & Rehabil Sci, Brisbane, Qld, Australia.	annejhill@gmail.com	Russell, Trevor/F-6888-2010; Ward, Elizabeth/F-9652-2010; Theodoros, Deborah/F-1362-2010; Hill, Anne/F-4106-2010; Russell, Trevor/AAS-2590-2020	Russell, Trevor/0000-0002-9732-6167; Ward, Elizabeth/0000-0002-2680-8978; Hill, Anne/0000-0003-3907-8369; Russell, Trevor/0000-0002-9732-6167	National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [401604, 351649]	The authors gratefully acknowledge funding support for this study from the National Health and Medical Research Council of Australia Project Grant No. 401604 and the National Health and Medical Research Council of Australia Public Health Postgraduate Scholarship ID 351649. The authors also acknowledge the assistance of Roy Anderson for software development of the telerehabilitation application and Jasmin Cowles for data collection. We acknowledge the assistance of the Princess Alexandra Hospital, Queen Elizabeth II Jubilee Hospital, the Royal Brisbane and Women's Hospital, and The University of Queensland Health and Rehabilitation Clinics in the recruitment of participants for this study. Finally, the authors wish to acknowledge the participants of this study for the gift of their time.	Brennan DM, 2004, TELEMED J E-HEALTH, V10, P147, DOI 10.1089/1530562041641237; Chenery H., 1998, DYSARTHRIA PHYSL APP, P36; CICCHETTI DV, 1990, J CLIN EPIDEMIOL, V43, P551, DOI 10.1016/0895-4356(90)90159-M; Darley F., 1975, MOTOR SPEECH DISORDE; Duffy JR, 1997, MAYO CLIN PROC, V72, P1116, DOI 10.4065/72.12.1116; Duffy JR, 2019, MOTOR SPEECH DISORDE; ENDERBY PM, 1983, FRENCHAY DYSARTHRIA; FEINSTEIN AR, 1990, J CLIN EPIDEMIOL, V43, P543, DOI 10.1016/0895-4356(90)90158-L; FLEISS JL, 1973, EDUC PSYCHOL MEAS, V33, P613, DOI 10.1177/001316447303300309; Fleiss JL, 1981, STAT METHODS RATES P, V2nd; Georgeadis AC, 2004, APHASIOLOGY, V18, P639, DOI 10.1080/02687030444000075; Hill AJ, 2006, AM J SPEECH-LANG PAT, V15, P45, DOI 10.1044/1058-0360(2006/006); Hill AJ, 2009, APHASIOLOGY, V23, P627, DOI 10.1080/02687030801909659; KARNELL MP, 1995, CLEFT PALATE-CRAN J, V32, P145, DOI 10.1597/1545-1569(1995)032<0145:NDOHAT>2.3.CO;2; KEARNS KP, 1988, J SPEECH HEAR RES, V31, P131, DOI 10.1044/jshr.3101.131; KREIMAN J, 1993, J SPEECH HEAR RES, V36, P21, DOI 10.1044/jshr.3601.21; LANDIS JR, 1977, BIOMETRICS, V33, P174; Ludlow C. L., 1983, DYSARTHRIAS PHYSL AC, P163; McHenry MA, 1999, BRAIN INJURY, V13, P281, DOI 10.1080/026990599121656; SHEARD C, 1991, J SPEECH HEAR RES, V34, P285, DOI 10.1044/jshr.3402.285; THEODOROS D, 1993, BRAIN INJURY, V7, P59, DOI 10.3109/02699059309008157; Theodoros D, 2008, TELEMED J E-HEALTH, V14, P552, DOI 10.1089/tmj.2007.0091; THEODOROS DG, 1995, BRAIN INJURY, V9, P671, DOI 10.3109/02699059509008225; Yorkston K.M., 1981, ASSESSMENT INTELLIGI; Yorkston K. M., 1988, CLIN MANAGEMENT DYSA	25	32	34	1	17	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1530-5627	1556-3669		TELEMED J E-HEALTH	Telemed. J. e-Health	NOV	2009	15	9					840	850		10.1089/tmj.2009.0015			11	Health Care Sciences & Services	Health Care Sciences & Services	520UA	WOS:000271873100005	19919190				2021-06-18	
J	Missios, S; Harris, BT; Dodge, CP; Simoni, MK; Costine, BA; Lee, YL; Quebada, PB; Hillier, SC; Adams, LB; Duhaime, AC				Missios, Symeon; Harris, Brent T.; Dodge, Carter P.; Simoni, Michael K.; Costine, Beth A.; Lee, Ying-Lung; Quebada, Patricia B.; Hillier, Simon C.; Adams, Leslie B.; Duhaime, Ann-Christine			Scaled Cortical Impact in Immature Swine: Effect of Age and Gender on Lesion Volume	JOURNAL OF NEUROTRAUMA			English	Article						brain; contusion; development; gender; head injury; swine	TRAUMATIC BRAIN-INJURY; SERUM TESTOSTERONE CONCENTRATIONS; HEAD-INJURY; BODY TEMPERATURE; AXONAL INJURY; ESTROGEN; PIG; RATS; PROGESTERONE; HYPERTHERMIA	The piglet scaled cortical impact model creates a focal contusion using a skull-mounted, spring-loaded blunt indentation device scaled to achieve identical tissue strains in subjects with different brain sizes. Preliminary data showed that contusion size increased proportional to subject age. This study details the results from a new, larger series of subjects of three ages, and compares the effect of age and additional host and physiologic variables on injury response. Sixty-seven subjects, including infant (5- to 7-day-old), "toddler" (1-month-old), and early adolescent (4-month-old) swine underwent scaled cortical impact under strict anesthetic protocols. Serum glucose, testosterone, and 17 beta-estradiol levels were measured. Lesion size was measured at 1 week post injury, as the ratio of the lesion area over the area of the contralateral hemisphere. Adolescent subjects had lesions over eight times larger than infants (p < 0.0001). Lesion volumes were larger in toddlers than in infants, most significantly for males (p < 0.05). Adolescent subjects were warmer on average, but there was no correlation between temperature and lesion volume within any age group. Serum glucose did not differ among ages. Infant males had the highest levels of circulating sex steroids. In this model, age was the most robust predictor of lesion size. Temperature had an effect, but did not explain all the variability seen among age groups. There was an interaction among gender, hormone levels, and lesion size in younger subjects. Characterization of these variables allows use of this model for treatment trials for subjects at different stages of maturation.	[Missios, Symeon] Dartmouth Hitchcock Med Ctr, Neurosurg Sect, Div Neurosurg, Lebanon, NH 03756 USA; [Simoni, Michael K.; Costine, Beth A.; Lee, Ying-Lung; Adams, Leslie B.] Dartmouth Hitchcock Med Ctr, Dept Surg, Lebanon, NH 03756 USA; [Dodge, Carter P.; Hillier, Simon C.] Dartmouth Hitchcock Med Ctr, Dept Anesthesiol, Lebanon, NH 03756 USA; [Harris, Brent T.] Dartmouth Hitchcock Med Ctr, Dept Pathol, Lebanon, NH 03756 USA	Missios, S (corresponding author), Dartmouth Hitchcock Med Ctr, Neurosurg Sect, Div Neurosurg, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	symeon.missios@hitchcock.org	Adams, Leslie/AAZ-9323-2020	Adams, Leslie/0000-0003-4956-271X; Simoni, Michael/0000-0002-4514-4804; Costine-Bartell, Beth/0000-0001-7559-9378	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD045364]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD045364] Funding Source: NIH RePORTER	We would like to acknowledge Rachel Curtis for her assistance with this project. This work was supported by National Institute of Child Health and Human Development grant no. R01HD045364 to Ann-Christine Duhaime.	ALLRICH RD, 1982, J ANIM SCI, V55, P1139; Anderson RWG, 2003, J NEUROTRAUM, V20, P961, DOI 10.1089/089771503770195812; Bittigau P, 1998, RESTOR NEUROL NEUROS, V13, P11; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Castillo J, 1999, CEREBROVASC DIS, V9, P22, DOI 10.1159/000015891; COLENBRANDER B, 1978, J REPROD FERTIL, V53, P377, DOI 10.1530/jrf.0.0530377; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; Duhaime AC, 2003, J NEUROSURG, V99, P542, DOI 10.3171/jns.2003.99.3.0542; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; ENGLISH MJM, 1991, J TRAUMA, V31, P36, DOI 10.1097/00005373-199101000-00008; ESBENSHADE KL, 1982, J ANIM SCI, V54, P320; FLYNN TJ, 1984, NEUROCHEM RES, V9, P935, DOI 10.1007/BF00964525; Ford J J, 1990, J Reprod Fertil Suppl, V40, P311; FORD JJ, 1980, BIOL REPROD, V23, P583, DOI 10.1095/biolreprod23.3.583; FORD JJ, 1983, P SOC EXP BIOL MED, V174, P160, DOI 10.3181/00379727-174-41719; Grate LL, 2003, J NEUROSCI METH, V123, P201, DOI 10.1016/S0165-0270(02)00361-8; Hurn PD, 2005, STROKE, V36, P193, DOI 10.1161/01.STR.0000153064.41332.f6; Hurn PD, 2000, J CEREBR BLOOD F MET, V20, P631, DOI 10.1097/00004647-200004000-00001; INGRAM DL, 1970, J PHYSIOL-LONDON, V210, P989, DOI 10.1113/jphysiol.1970.sp009253; Kim Y, 1996, STROKE, V27, P2281; LUERSSEN TG, 1995, PEDIATR NEUROSURG, V23, P34, DOI 10.1159/000120933; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MILLER AT, 1958, J APPL PHYSIOL, V12, P17; Morrison B, 1998, J NEUROTRAUM, V15, P911, DOI 10.1089/neu.1998.15.911; MOUNT LE, 1960, J PHYSIOL-LONDON, V154, P408, DOI 10.1113/jphysiol.1960.sp006587; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; PAMPIGLIONE G, 1971, P ROY SOC MED, V64, P429, DOI 10.1177/003591577106400441; Pond WG, 2000, P SOC EXP BIOL MED, V223, P102, DOI 10.1046/j.1525-1373.2000.22314.x; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Roof RL, 2000, J NEUROTRAUM, V17, P1155, DOI 10.1089/neu.2000.17.1155; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Shaver EG, 1996, PEDIATR NEUROSURG, V25, P123, DOI 10.1159/000121109; Shear DA, 2002, EXP NEUROL, V178, P59, DOI 10.1006/exnr.2002.8020; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Stein DG, 2001, TRENDS NEUROSCI, V24, P386, DOI 10.1016/S0166-2236(00)01821-X	38	32	32	0	3	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	NOV	2009	26	11					1943	1951		10.1089/neu.2009.0956			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	523CO	WOS:000272049600010	19469691	Green Published			2021-06-18	
J	Richmond, TS; Amsterdam, JD; Guo, W; Ackerson, T; Gracias, V; Robinson, KM; Hollander, JE				Richmond, T. S.; Amsterdam, J. D.; Guo, W.; Ackerson, T.; Gracias, V.; Robinson, K. M.; Hollander, J. E.			The effect of post-injury depression on return to pre-injury function: a prospective cohort study	PSYCHOLOGICAL MEDICINE			English	Article						Depression; function; injury; psychiatric disorders; work	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; STATUS QUESTIONNAIRE; MULTIPLE INJURIES; SEVERITY SCORE; OLDER PERSONS; IMPACT; DISABILITY; SYMPTOMS	Background. Millions of people seek emergency department (ED) care for injuries each year, the majority for minor injuries. Little is known about the effect of psychiatric co-morbid disorders that emerge after minor injury on functional recovery. This Study examined the effect of post-injury depression on return to pre-injury levels of function. Method. This was a longitudinal cohort study with follow-up at 3, 6 and 12 months post-injury: 275 adult were randomly selected from those presenting to the ED with minor injury; 248 were retained over the post-injury year. Function was measured with the Functional Status Questionnaire (FSQ). Psychiatric disorders were diagnosed using the Structured Clinical Interview for DSM-IV-TR disorders (SCID). Results. During the post-injury year, 18.1 % [95% confidence interval (CI) 13.3-22.9] were diagnosed with depression. Adjusting for clinical and demographic covariates, the depressed group was less likely to return to pre-injury levels of activities of daily living [odds ratio (OR) 8.37, 95% CI 3.78-18.53] and instrumental activities of daily living (OR 3.25, 95%, CI 1.44-7.31), less likely to return to pre-injury work status (OR 2.37, 95% CI 1.04-5.38), and more likely to spend days in bed because of health (OR 2.41, 95% CI 1.15-5.07). Conclusions. Depression was the most frequent psychiatric diagnosis in the year after minor injury requiring emergency care. Individuals with depression did not return to pre-injury levels of function during the post-injury year.	[Richmond, T. S.] Univ Penn, Sch Nursing, Biobehav & Hlth Sci Div, Philadelphia, PA 19104 USA; [Amsterdam, J. D.] Univ Penn, Sch Med, Dept Psychiat, Depress Res Unit, Philadelphia, PA 19104 USA; [Guo, W.] Univ Penn, Sch Med, Dept Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Gracias, V.] Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA; [Robinson, K. M.] Univ Penn, Sch Med, Dept Phys Med & Rehabil, Philadelphia, PA 19104 USA; [Hollander, J. E.] Univ Penn, Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA	Richmond, TS (corresponding author), Univ Penn, Sch Nursing, Biobehav & Hlth Sci Div, Fagin Hall,418 Curie Blvd, Philadelphia, PA 19104 USA.	terryr@nursing.upenn.edu		Hollander, Judd/0000-0002-1318-2785	National Institute of Mental Health (NIMH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [ROIMH63818]; NIH/NCCAMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine; Lilly Research LaboratoriesEli Lilly; Novartis Inc.; Sanofi-Aventis Inc.Sanofi-Aventis; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH063818] Funding Source: NIH RePORTER	This study was funded by the National Institute of Mental Health (NIMH) grant ROIMH63818 (to T.S.R.).; J.D.A. is currently receiving research grant support from the NIMH, NIH/NCCAM, Lilly Research Laboratories, Novartis Inc., and Sanofi-Aventis Inc. He is on the speaker's bureau of Wyeth and Bristol-Myers-Squibb.	Akfaffiong M, 1999, INT J GERIATR PSYCH, V14, P845, DOI 10.1002/(SICI)1099-1166(199910)14:10<845::AID-GPS34>3.0.CO;2-H; Aklin WM, 2006, PSYCHOTHERAPY, V43, P50, DOI 10.1037/0033-3204.43.1.50; American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT, V4th; Arinzon Z, 2007, DISABIL REHABIL, V29, P651, DOI 10.1080/09638280600926470; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bisson JI, 2004, BRIT J PSYCHIAT, V184, P63, DOI 10.1192/bjp.184.1.63; Carty J, 2006, J AFFECT DISORDERS, V90, P257, DOI 10.1016/j.jad.2005.11.011; *CDC, 2005, CDC PROT HLTH LIF ST; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Cleary PD, 2000, QUAL LIFE RES, V9, P747, DOI 10.1023/A:1008977923785; Committee on the Future of Emergency Care in the United States Health System Institute of Medicine, 2007, HOSP BAS EM CAR BREA; Davis RG, 2008, J TRAUMA STRESS, V21, P218, DOI 10.1002/jts.20313; De Jonge P, 2006, PSYCHOSOMATICS, V47, P33, DOI 10.1176/appi.psy.47.1.33; ELASHOFF JD, 1999, NQUERY ADVISOR VERSI; Elklit A, 2002, J INTERPERS VIOLENCE, V17, P872, DOI 10.1177/0886260502017008005; First M., 1994, STRUCTURED CLIN INTE; Fishbain DA, 2003, PAIN MED, V4, P51, DOI 10.1046/j.1526-4637.2003.03008.x; FLASKERUD JH, 2001, ISSUES MENTAL HLTH N, V21, P5; Hepp U, 2005, PSYCHOTHER PSYCHOSOM, V74, P379, DOI 10.1159/000087786; Holbrook TL, 1999, J TRAUMA, V46, P765, DOI 10.1097/00005373-199905000-00003; Hollander JE, 2004, ACAD EMERG MED, V11, P200, DOI 10.1197/j.aem.2003.07.023; JETTE AM, 1987, PHYS THER, V67, P1854, DOI 10.1093/ptj/67.12.1854; JETTE AM, 1986, J GEN INTERN MED, V1, P143, DOI 10.1007/BF02602324; KELLER MB, 1987, ARCH GEN PSYCHIAT, V44, P540; Kempen GIJM, 2003, INT J GERIATR PSYCH, V18, P14, DOI 10.1002/gps.768; Kessing LV, 2007, ACTA PSYCHIAT SCAND, V115, P85, DOI 10.1111/j.1600-0447.2007.00966.x; Kilgo PD, 2006, J TRAUMA, V60, P1002, DOI 10.1097/01.ta.0000215827.54546.01; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; MACKENZIE EJ, 1987, AM J PUBLIC HEALTH, V77, P329, DOI 10.2105/AJPH.77.3.329; Mason S, 2002, EMERG MED J, V19, P400, DOI 10.1136/emj.19.5.400; Mooney G, 2005, BRAIN INJURY, V19, P975, DOI 10.1080/02699050500110264; Murphy N, 1998, J NEUROL NEUROSUR PS, V65, P460, DOI 10.1136/jnnp.65.4.460; O'Donnell ML, 2005, J TRAUMA, V59, P1328, DOI 10.1097/01.ta.0000197621.94561.4e; O'Donnell ML, 2005, J TRAUMA STRESS, V18, P557, DOI 10.1002/jts.20064; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; Rapoport MJ, 2006, J AFFECT DISORDERS, V92, P273, DOI 10.1016/j.jad.2005.05.022; Read KM, 2004, J TRAUMA, V57, P815, DOI 10.1097/01.TA.0000136289.15303.44; Richmond TS, 1997, NURS RES, V46, P262, DOI 10.1097/00006199-199709000-00004; Richmond TS, 2000, J TRAUMA STRESS, V13, P681, DOI 10.1023/A:1007866318207; Rosenthal DA, 1999, REHABIL COUNS BULL, V42, P243; SARASON IG, 1987, J SOC PERS RELAT, V4, P497, DOI 10.1177/0265407587044007; Scaf-Klomp W, 2003, AGE AGEING, V32, P88, DOI 10.1093/ageing/32.1.88; Shalev AY, 1998, AM J PSYCHIAT, V155, P630, DOI 10.1176/ajp.155.5.630; Soberg HL, 2007, J TRAUMA, V62, P461, DOI 10.1097/01.ta.0000222916.30253.ea; *STATACORP, 1999, STATA STAT SOFTW REL; Stein MB, 2006, PSYCHOL MED, V36, P587, DOI 10.1017/S0033291706007239; van Gool CH, 2005, SOC SCI MED, V60, P25, DOI 10.1016/j.socscimed.2004.04.021; World Health Organization, 2007, PREV INJ VIOL GUID M; Zatzick DF, 2001, GEN HOSP PSYCHIAT, V23, P114, DOI 10.1016/S0163-8343(01)00140-2; ZIMMERMAN M, 1986, ARCH GEN PSYCHIAT, V43, P234	51	32	32	0	11	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0033-2917	1469-8978		PSYCHOL MED	Psychol. Med.	OCT	2009	39	10					1709	1720		10.1017/S0033291709005376			12	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	499XQ	WOS:000270260500015	19250582	Green Accepted			2021-06-18	
J	Sykora, M; Diedler, J; Turcani, P; Rupp, A; Steiner, T				Sykora, Marek; Diedler, Jennifer; Turcani, Peter; Rupp, Andre; Steiner, Thorsten			Subacute perihematomal edema in intracerebral hemorrhage is associated with impaired blood pressure regulation	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						ICH; Intracranial hemorrhage; Sympathetic nervous system; Baroreflex sensitivity; Blood pressure variability; Edema; Dysautonomia; Deterioration	EARLY NEUROLOGIC DETERIORATION; ABC/2 ESTIMATION TECHNIQUE; TRAUMATIC BRAIN-INJURY; HEART-RATE-VARIABILITY; BETA-BLOCKER EXPOSURE; ISCHEMIC-STROKE; BODY-TEMPERATURE; BAROREFLEX SENSITIVITY; IMPROVED SURVIVAL; MORTALITY	Background: Perihematomal edema and secondary brain injury may influence the clinical course after intracerebral hemorrhage (ICH). The role of blood pressure (BP) in edema formation in ICH has not been studied sufficiently. We hypothesize that impaired blood pressure regulation (as measured by baroreflex sensitivity) leading to excessive BP fluctuations may enhance perilesional edema. The aims of our study were therefore to explore the effects of impaired baroreflex on edema in acute ICH and to evaluate the effects of perihematomal edema on early neurologic deterioration. Methods: In 38 patients with acute intracerebral hemorrhage we assessed baroreflex sensitivity (BRS) within the first 72 h using a time-domain cross-correlation method. Blood pressure was continuously monitored for 72 h after admission. Relative perihematomal edema was calculated from the follow-up scans at 48-72 h from ictus. Possible confounders such as body temperature, inflammation parameters, or glycemia were recorded. Early neurologic deterioration was defined as increase of 4 points at NIHSS within the first 72 h. Results: Decreased BRS correlated significantly with increased 72-hour MAP variability (r = -0.46, p = 0.004). In a stepwise multivariate linear regression model, decreased BRS was an independent predictor for relative edema (p = 0.005). Relative edema (p = 0.009, OR 22.6, CI 2.2-232.5) and body temperature at admission (p = 0.031, OR 0.17, CI 0.04-0.85) independently predicted early neurologic deterioration. Conclusions: We found an independent association between decreased baroreflex sensitivity with increased blood pressure fluctuations and relative perihematomal edema in ICH. Moreover, independent effects of relative edema on early neurologic deterioration have been observed. (C) 2009 Elsevier B. V. All rights reserved.	[Sykora, Marek; Diedler, Jennifer; Rupp, Andre; Steiner, Thorsten] Heidelberg Univ, Dept Neurol, D-69120 Heidelberg, Germany; [Sykora, Marek; Turcani, Peter] Comenius Univ, Dept Neurol, Bratislava 81369, Slovakia	Sykora, M (corresponding author), Heidelberg Univ, Dept Neurol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.	marek.sykora@med.uni-heidelberg.de	Steiner, Thorsten/A-7391-2014; Steiner, Thorsten/L-2868-2018	Steiner, Thorsten/0000-0002-5080-8222; Turcani, Peter/0000-0002-4868-6836			Brott T, 1997, STROKE, V28, P1, DOI 10.1161/01.STR.28.1.1; Castillo J, 2002, NEUROLOGY, V58, P624, DOI 10.1212/WNL.58.4.624; Castillo J, 2004, STROKE, V35, P520, DOI 10.1161/01.STR.0000109769.22917.B0; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Dawson SL, 2000, STROKE, V31, P463, DOI 10.1161/01.STR.31.2.463; Diedler J, 2009, STROKE, V40, P815, DOI 10.1161/STROKEAHA.108.531020; Elghozi JL, 2007, FUND CLIN PHARMACOL, V21, P337, DOI 10.1111/j.1472-8206.2007.00502.x; Enderson BL, 2007, J TRAUMA, V62, P33; Gebel JM, 1998, STROKE, V29, P1799, DOI 10.1161/01.STR.29.9.1799; Gebel JM, 2002, STROKE, V33, P2636, DOI 10.1161/01.STR.0000035283.34109.EA; Gebel JM, 2002, STROKE, V33, P2631, DOI 10.1161/01.STR.0000035284.12699.84; Godoy DA, 2005, NEUROLOGY, V64, P931, DOI 10.1212/WNL.64.5.931-a; GORDON CR, 1990, ACT NEUR S, V51, P268; Herweh C, 2007, STROKE, V38, P2941, DOI 10.1161/STROKEAHA.107.486977; Huttner HB, 2006, STROKE, V37, P404, DOI 10.1161/01.STR.0000198806.67472.5c; Immink RV, 2005, STROKE, V36, P2595, DOI 10.1161/01.STR.0000189624.06836.03; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Kidwell CS, 2001, NEUROLOGY, V57, P1611, DOI 10.1212/WNL.57.9.1611; Korpelainen JT, 1999, CLIN AUTON RES, V9, P325, DOI 10.1007/BF02318379; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Kuwata N, 1995, NEUROSURG REV, V18, P237, DOI 10.1007/BF00383874; Laowattana S, 2007, NEUROLOGY, V68, P509, DOI 10.1212/01.wnl.0000253186.23949.fd; Leira R, 2004, NEUROLOGY, V63, P461, DOI 10.1212/01.WNL.0000133204.81153.AC; LIU MY, 1995, J FORMOS MED ASSOC, V94, P386; Mayer SA, 1998, STROKE, V29, P1791, DOI 10.1161/01.STR.29.9.1791; MEGYERI P, 1992, NEUROSCI LETT, V148, P137, DOI 10.1016/0304-3940(92)90823-P; Mehdiratta M, 2008, STROKE, V39, P1165, DOI 10.1161/STROKEAHA.107.501213; Mortara A, 2000, J AM COLL CARDIOL, V36, P1612, DOI 10.1016/S0735-1097(00)00900-1; Pascual AM, 2007, CEREBROVASC DIS, V23, P6, DOI 10.1159/000095752; Qureshi AI, 1999, CRIT CARE MED, V27, P480, DOI 10.1097/00003246-199903000-00021; RAICHLE ME, 1975, P NATL ACAD SCI USA, V72, P3726, DOI 10.1073/pnas.72.9.3726; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; Robinson TG, 1997, STROKE, V28, P1671, DOI 10.1161/01.STR.28.9.1671; Savitz SI, 2000, J CEREBR BLOOD F MET, V20, P1197, DOI 10.1097/00004647-200008000-00005; Song EC, 2003, STROKE, V34, P2215, DOI 10.1161/01.STR.0000088060.83709.2C; Stead LG, 2006, NEUROLOGY, V66, P1878, DOI 10.1212/01.wnl.0000219628.78513.b5; Sykora M, 2008, CRIT CARE MED, V36, P3074, DOI 10.1097/CCM.0b013e31818b306d; Titova E, 2008, ACTA NEUROCHIR SUPPL, V105, P85; vanderPoll T, 1997, INFECT IMMUN, V65, P2378, DOI 10.1128/IAI.65.6.2378-2381.1997; Vemmos KN, 2003, J HYPERTENS, V21, P2167, DOI 10.1097/00004872-200311000-00027; Vemmos KN, 2004, J INTERN MED, V255, P257, DOI 10.1046/j.1365-2796.2003.01291.x; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404; Watanabe M, 2008, IMMUNOL LETT, V115, P43, DOI 10.1016/j.imlet.2007.09.010; Westerhof BE, 2004, J HYPERTENS, V22, P1371, DOI 10.1097/01.hjh.0000125439.28861.ed; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Yong M, 2008, STROKE, V39, P366, DOI 10.1161/STROKEAHA.107.492330; Zazulia AR, 1999, STROKE, V30, P1167, DOI 10.1161/01.STR.30.6.1167; Zazulia AR, 2001, J CEREBR BLOOD F MET, V21, P804, DOI 10.1097/00004647-200107000-00005	48	32	33	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	SEP 15	2009	284	1-2					108	112		10.1016/j.jns.2009.04.028			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	514YW	WOS:000271433900020	19428030				2021-06-18	
J	Vink, R; Cook, NL; van den Heuvel, C				Vink, Robert; Cook, Naomi L.; van den Heuvel, Corinna			Magnesium in acute and chronic brain injury: an update	MAGNESIUM RESEARCH			English	Article; Proceedings Paper	12th International Magnesium Symposium	SEP 22-25, 2009	Iasi, ROMANIA			magnesium; neurotrauma; ischemia; hypoxia; neurodegeneration; Parkinson's disease	INTRACELLULAR FREE MG; MILD HYPOTHERMIA; SULFATE; ISCHEMIA; THERAPY; STROKE; NEUROPROTECTION; MODEL; SUSCEPTIBILITY; EFFICACY	While brain free magnesium levels have been shown to decline in a number of acute and chronic brain pathologies, the mechanisms of such decline and the potential for magnesium administration as a therapeutic intervention are still unclear. In acute brain injury, magnesium therapy has failed in recent clinical trials of trauma, presumably because of an intact blood brain barrier at the time of administration reducing central penetration. Under such conditions, magnesium's peripheral effects on cardiovascular parameters may dominate over the central, and potentially neuroprotective, effects of the compound. In contrast, magnesium has been demonstrated to be beneficial in lacunar strokes, albeit that recent animal studies indicate that this effect is without any significant reduction of lesion size. Postnatal magnesium has also been shown to improve neurological outcome in term neonates with perinatal asphyxia, although this may be limited to cases of mild to moderate brain injury; no effect is observed following severe brain injury. Prenatal magnesium has been reported to be beneficial for outcome in very preterm infants, although this may only be at low doses. Combination therapies are also showing promise in experimental studies, with combined magnesium and mild hypothermia as well as magnesium and polyethylene glycol proving effective in ischemic stroke and in spinal cord injury, respectively. With respect to chronic brain injury, recent results indicate that magnesium deficient mice are susceptible to developing Parkinson's disease, which is consistent with earlier findings that magnesium deficiency over a number of generations is associated with the development of Parkinson's disease. The latter was associated with the appearance of variants of the TRPM channels. Our recent studies have shown that Parkinson's disease is associated with reduced TRPM2 and TRPM7 channel mRNA expression. Taken together, a more complete picture is emerging of the role of magnesium in brain injury, its therapeutic potential as well the mechanisms associated with its decline.	[Vink, Robert; Cook, Naomi L.; van den Heuvel, Corinna] Univ Adelaide, Sch Med Sci, Discipline Pathol, Adelaide, SA 5005, Australia	Vink, R (corresponding author), Univ Adelaide, Sch Med Sci, Discipline Pathol, Adelaide, SA 5005, Australia.	Robert.Vink@adelaide.edu.au	Cook, Naomi L/B-2536-2012; Vink, Robert/J-7351-2012; Cook, Naomi L/P-1223-2019; AM, Robert Vink/S-5616-2019	Cook, Naomi L/0000-0002-1830-2432; Vink, Robert/0000-0002-4885-0667; Cook, Naomi L/0000-0002-1830-2432; AM, Robert Vink/0000-0002-4885-0667			ALTURA BM, 1992, BIOCHIM BIOPHYS ACTA, V1111, P271, DOI 10.1016/0005-2736(92)90320-L; ALTURA BM, 1993, ALCOHOL, V10, P563, DOI 10.1016/0741-8329(93)90084-2; Andrasi E, 2000, MAGNESIUM RES, V13, P189; Aslanyan S, 2007, STROKE, V38, P1269, DOI 10.1161/01.STR.0000259628.94421.09; Barbre AB, 2006, BRAIN RES BULL, V69, P639, DOI 10.1016/j.brainresbull.2006.03.009; Bhat MA, 2009, PEDIATRICS, V123, pE764, DOI 10.1542/peds.2007-3642; Chassain C, 2003, EXP NEUROL, V182, P490, DOI 10.1016/S0014-4886(03)00125-0; Chung SY, 2004, MED SCI MONITOR, V10, pBR105; Doyle LW, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004661.pub3; Dribben WH, 2009, NEONATOLOGY, V96, P23, DOI 10.1159/000201327; Guluma KZ, 1999, J NEUROTRAUM, V16, P311, DOI 10.1089/neu.1999.16.311; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; Hashimoto Y, 2008, YONAGO ACTA MED, V51, P1; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Hermosura MC, 2007, BBA-MOL BASIS DIS, V1772, P822, DOI 10.1016/j.bbadis.2007.02.008; Ichiba H, 2006, PEDIATR INT, V48, P70, DOI 10.1111/j.1442-200X.2006.02167.x; IMER M, 2009, NEUROL RES, V11, P11; Iotti S, 2008, MAGNESIUM RES, V21, P157, DOI 10.1684/mrh.2008.0142; Jacka FN, 2009, AUST NZ J PSYCHIAT, V43, P45, DOI 10.1080/00048670802534408; KWON BK, 2009, J NEUROTRAUM, V24, P24; Lecrux C, 2008, STROKE, V39, P448, DOI 10.1161/STROKEAHA.107.492934; Lees KR, 2004, LANCET, V363, P439; Lin MC, 2004, J AM COLL NUTR, V23, p561S, DOI 10.1080/07315724.2004.10719404; McKee JA, 2005, CRIT CARE MED, V33, P661, DOI 10.1097/01.ccm.0000156293.35868.b2; Meloni BP, 2009, STROKE, V40, P2236, DOI 10.1161/STROKEAHA.108.542381; Miller John W, 2007, Epilepsy Curr, V7, P133, DOI 10.1111/j.1535-7511.2007.00201.x; Mittendorf R, 2006, J PERINATOL, V26, P57, DOI 10.1038/sj.jp.7211419; MULLINS PGM, 1995, NEUROREPORT, V6, P1633, DOI 10.1097/00001756-199508000-00011; Muroyama A, 2009, NEUROSCI RES, V63, P72, DOI 10.1016/j.neures.2008.09.009; Nechifor M, 2008, MAGNESIUM RES, V21, P97; Oyanagi K, 2006, NEUROPATHOLOGY, V26, P115, DOI 10.1111/j.1440-1789.2006.00672.x; Ozgurtas T, 2004, MAGNESIUM RES, V17, P327; RAMADAN NM, 1989, HEADACHE, V29, P416, DOI 10.1111/j.1526-4610.1989.hed2907416.x; Romani AMP, 2008, MAGNESIUM RES, V21, P197; Scholler K, 2004, BRAIN RES, V1023, P272, DOI 10.1016/j.brainres.2004.01.094; Spandou E, 2007, REPROD SCI, V14, P667, DOI 10.1177/1933719107305864; Starling AJ, 2005, J NEUROSCI RES, V82, P377, DOI 10.1002/jnr.20651; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Vink R, 2000, FRONT BIOSCI, V5, pD656, DOI 10.2741/Vink; VINK R, 1988, J BIOL CHEM, V263, P757; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Yang HP, 2008, CEREBROVASC DIS, V26, P223, DOI 10.1159/000147448	43	32	32	1	10	JOHN LIBBEY EUROTEXT LTD	ARCUEIL	30, RUE BERTHOLLET, BATIMENT A, 94110 ARCUEIL, FRANCE	0953-1424	1952-4021		MAGNESIUM RES	Magnes. Res.	SEP	2009	22	3					158S	162S					5	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	491CZ	WOS:000269556100005	19780402				2021-06-18	
J	Campbell, TA; Nelson, LA; Lumpkin, R; Yoash-Gantz, RE; Pickett, TC; McCormick, CL				Campbell, Thomas A.; Nelson, Lonnie A.; Lumpkin, Robin; Yoash-Gantz, Ruth E.; Pickett, Treven C.; McCormick, Cortney L.			Neuropsychological Measures of Processing Speed and Executive Functioning in Combat Veterans with PTSD, TBI, and Comorbid TBI/PTSD	PSYCHIATRIC ANNALS			English	Article							POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; COGNITIVE IMPAIRMENT; MILD; REHABILITATION; PERFORMANCE; VIOLENCE; VICTIMS; MEMORY		[Campbell, Thomas A.; Pickett, Treven C.] Vet Affairs Med Ctr, Hunter Holmes McGuire Dept, Mental Hlth Serv, Richmond, VA USA; [Nelson, Lonnie A.] Primary TBI Operat Component Def Ctr Psychol Hlth, Def & Vet Brain Injury Ctr, Rosslyn, VA USA; [Nelson, Lonnie A.] Primary TBI Operat Component Def Ctr Excellence T, Def & Vet Brain Injury Ctr, Rosslyn, VA USA; [Lumpkin, Robin; McCormick, Cortney L.] MIRECC, VISN6, Durham, NC USA; [Yoash-Gantz, Ruth E.] MIRECC, Salisbury, NC USA; [Yoash-Gantz, Ruth E.] Hefner Vet Affairs Med Ctr, Salisbury, NC USA; [Yoash-Gantz, Ruth E.] Wake Forest Univ, Bowman Gray Sch Med, Dept Psychiat & Behav Sci, Winston Salem, NC USA; [Pickett, Treven C.] MIRECC, Richmond, VA USA; [Pickett, Treven C.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Sch Med, Richmond, VA 23284 USA	Campbell, TA (corresponding author), McGuire VA Med Ctr, Psychol Sect 116B, 1201 Broad Rock Blvd, Richmond, VA 23249 USA.	Thomas.Campbell4@va.gov					American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Barrett DH, 1996, AM J PSYCHIAT, V153, P1492; Beckham JC, 1998, J TRAUMA STRESS, V11, P811, DOI 10.1023/A:1024409903617; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; Bremner J D, 1999, Semin Clin Neuropsychiatry, V4, P249; Bryant RA, 2001, J CLIN EXP NEUROPSYC, V23, P718, DOI 10.1076/jcen.23.6.718.1024; Buckley TC, 2000, CLIN PSYCHOL REV, V20, P1041, DOI 10.1016/S0272-7358(99)00030-6; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; Foa EB, 2004, J CONSULT CLIN PSYCH, V72, P879, DOI 10.1037/0022-006X.72.5.879; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Golden C., 1978, STROOP COLOR WORD TE; Green P., 1996, WORD MEMORY TEST USE; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Horner MD, 2002, NEUROPSYCHOL REV, V12, P15, DOI 10.1023/A:1015439106231; Kanagaratnam P, 2007, J ANXIETY DISORD, V21, P510, DOI 10.1016/j.janxdis.2006.06.008; Koso M, 2006, EUR PSYCHIAT, V21, P167, DOI 10.1016/j.eurpsy.2005.06.004; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lanius RA, 2001, AM J PSYCHIAT, V158, P1920, DOI 10.1176/appi.ajp.158.11.1920; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEZAK M, 2004, NEUROPSYCHOLOGICAL A; Nelson LA, 2009, J HEAD TRAUMA REHAB, V24, P32, DOI 10.1097/HTR.0b013e3181957016; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rassovsky Y, 2006, J CLIN EXP NEUROPSYC, V28, P581, DOI 10.1080/13803390500434474; REITAN RM, 1985, HALLSTEAD REITAN NEU; RESICK PA, 1992, J CONSULT CLIN PSYCH, V60, P748, DOI 10.1037/0022-006X.60.5.748; Samuelson KW, 2006, NEUROPSYCHOLOGY, V20, P716, DOI 10.1037/0894-4105.20.6.716; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Stein MB, 2002, BIOL PSYCHIAT, V52, P1079, DOI 10.1016/S0006-3223(02)01414-2; Tanielian T., 2008, INVISIBLE WOUNDS WAR, P3; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86	30	32	32	0	12	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086 USA	0048-5713			PSYCHIAT ANN	Psychiatr. Ann.	AUG	2009	39	8					796	803		10.3928/00485713-20090728-01			8	Psychiatry	Psychiatry	483EP	WOS:000268945500005					2021-06-18	
J	Cribier, A; Litzler, PY; Eltchaninoff, H; Godin, M; Tron, C; Bauer, F; Bessou, JP				Cribier, Alain; Litzler, Pierre-Yves; Eltchaninoff, Helene; Godin, Matthieu; Tron, Christophe; Bauer, Fabrice; Bessou, Jean-Paul			Technique of Transcatheter Aortic Valve Implantation with the Edwards-Sapien (R) Heart Valve Using the Transfemoral Approach	HERZ			English	Article						Aortic valve stenosis; Valve replacement; Valve implantation; Prosthetic valves	STENOSIS; REPLACEMENT; PROSTHESIS	Transcatheter aortic valve implantation (TAVI) using a balloon-expandable valve has been developed by the authors' group 7 years ago to offer a therapeutic solution to nonoperable or surgical high-risk patients with degenerative aortic stenosis. The technique and the devices used have rapidly evolved thereafter and TAVI has become a clinical reality with more than 3,500 patients implanted worldwide with this device. The currently used Edwards-Sapien (R) Transcatheter Heart Valve (THV) consists of a balloon-expandable stent with an integrated bovine pericardial valve. It can be implanted within the diseased native aortic valve using either the retrograde transfemoral or antegrade transapical routes. This article is aimed at describing the updated transfemoral technique. Appropriate patient selection is crucial for a successful procedure including close evaluation of the arterial characteristics. After predilatation of the native valve with a balloon catheter, the THV with its delivery system is introduced within the femoral artery, advanced to the native aortic valve under X-ray control, positioned across the aortic annulus, and delivered by balloon inflation under rapid heart pacing. The acute procedural success is 96% and the technique leads to an immediate and lasting improvement of hemodynamics and clinical status. Complications are rare and the mortality rate is 6.3% at 1 month in this cohort of very sick patients. Procedural complications are headed by vascular injury related to the large size of the arterial introducers. An upcoming lower-profile Edwards THV should improve this issue and increase the indication for this less invasive approach in the near future. At the present time, the indications should be restricted to nonoperable or surgical high-risk patients and the procedure performed by experienced and formally trained physicians working in an optimal multidisciplinary environment.	[Cribier, Alain; Eltchaninoff, Helene; Godin, Matthieu; Tron, Christophe; Bauer, Fabrice] Univ Rouen, Dept Cardiol, Hosp Charles Nicolle, F-76000 Rouen, France; [Cribier, Alain; Eltchaninoff, Helene; Godin, Matthieu; Tron, Christophe; Bauer, Fabrice] INSERM 144, F-76000 Rouen, France; [Litzler, Pierre-Yves; Bessou, Jean-Paul] INSERM 644, Paris, France; [Litzler, Pierre-Yves; Bessou, Jean-Paul] Univ Rouen, Dept Cardiothorac Surg, Hosp Charles Nicolle, F-76000 Rouen, France	Cribier, A (corresponding author), Univ Rouen, Dept Cardiol, 1 Rue Germont, F-76000 Rouen, France.	Alain.Cribier@chu-rouen.fr					Agatiello C, 2006, ARCH MAL COEUR VAISS, V99, P195; Chiam PTL, 2009, AM HEART J, V157, P229, DOI 10.1016/j.ahj.2008.10.003; Cribier A, 2004, J AM COLL CARDIOL, V43, P698, DOI 10.1016/j.jacc.2003.11.026; Cribier A, 2002, CIRCULATION, V106, P3006, DOI 10.1161/01.CIR.0000047200.36165.B8; Cribier A, 2006, J AM COLL CARDIOL, V47, P1214, DOI 10.1016/j.jacc.2006.01.049; Solomon L W, 2001, J Invasive Cardiol, V13, P592; *TASKF MAN VALV HE, 2007, EUR HEART J, V428, P1; Vahanian A, 2008, EUR J CARDIO-THORAC, V34, P1, DOI 10.1016/j.ejcts.2008.04.039; Walther T, 2007, CIRCULATION, V116, pI240, DOI 10.1161/CIRCULATIONAHA.106.677237; Walther T, 2009, ANN THORAC SURG, V87, P276, DOI 10.1016/j.athoracsur.2008.08.017; Webb JG, 2006, CIRCULATION, V113, P842, DOI 10.1161/CIRCULATIONAHA.105.582882; Webb JG, 2008, JACC-CARDIOVASC INTE, V1, P122, DOI 10.1016/j.jcin.2007.11.010; Webb JG, 2007, CIRCULATION, V116, P755, DOI 10.1161/CIRCULATIONAHA.107.698258; Webb JG, 2006, CATHETER CARDIO INTE, V68, P199, DOI 10.1002/ccd.20829	14	32	32	0	3	URBAN & VOGEL	MUNICH	NEUMARKTER STRASSE 43, D-81673 MUNICH, GERMANY	0340-9937	1615-6692		HERZ	Herz	AUG	2009	34	5					347	356		10.1007/s00059-009-3264-z			10	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	487XZ	WOS:000269313200003	19711030				2021-06-18	
J	Dausch, BM; Saliman, S				Dausch, Barbara M.; Saliman, Sheila			Use of Family Focused Therapy in Rehabilitation for Veterans With Traumatic Brain Injury	REHABILITATION PSYCHOLOGY			English	Article						family therapy; TBI; rehabilitation; veterans; Iraq	RANDOMIZED CONTROLLED-TRIAL; POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; SPINAL-CORD INJURIES; BIPOLAR DISORDER; EXPRESSED EMOTION; COMBAT DEPLOYMENT; IRAQ WAR; INTERVENTION; CAREGIVERS	Objective: Military personnel returning from Iraq and Afghanistan with traumatic brain injury (TBI) present with a complex array of stressors encountered during combat as well as upon re-entry, often with additional physical and mental health comorbidities. This requires an intensive approach to treatment that includes family intervention as a part of rehabilitation. There is a small but growing literature addressing the needs of families when a family member has sustained a TBI. An established treatment intervention for individuals with serious mental illness, such as family focused therapy (FFT), is uniquely suited to address the complexity of issues presented by returning military personnel, and may be adapted for moderate to severe TBI populations. In this article, we discuss the rationale for adapting this family intervention for this population and present a case vignette illustrating adaptations for TBI. Conclusions: The adaptation of an existing family intervention for a chronic condition that focuses on enhancing both individual and family functioning is a useful starting point. With further research to modify FFT for this unique population and establish feasibility, this approach may supplement existing models of family intervention.	[Dausch, Barbara M.; Saliman, Sheila] Denver Vet Affairs Med Ctr, Eastern Colorado Hlth Care Syst, Denver, CO 80220 USA; [Dausch, Barbara M.] Univ Colorado, Sch Med, Boulder, CO 80309 USA	Dausch, BM (corresponding author), Denver Vet Affairs Med Ctr, Eastern Colorado Hlth Care Syst, 1055 Clermont St,116 Denver, Denver, CO 80220 USA.	Barbara.Dausch@va.gov					ACORN S, 1995, J ADV NURS, V21, P872, DOI 10.1046/j.1365-2648.1995.21050872.x; Anthony W, 2003, PSYCHIATR REHABIL J, V27, P1, DOI 10.2975/27.2003.1.2; Anthony W. A., 1993, PSYCHOSC REHABIL J, V16, P11, DOI [10.1037/h0095655, DOI 10.1037/H0095655]; Boschen K, 2007, NEUROREHABILITATION, V22, P19; CAVALLO MM, 2005, TXB TRAUMATIC BRAIN, P533; Clark ME, 2009, PAIN MED, V10, P456, DOI 10.1111/j.1526-4637.2009.00589.x; Dausch BM, 2009, J TELEMED TELECARE, V15, P211, DOI 10.1258/jtt.2009.081216; DAUSCH BM, 2007, INT SOC TRAUM STRESS; Doyle ME, 2005, PSYCHIAT QUART, V76, P361, DOI 10.1007/s11126-005-4972-z; Elliott TR, 2008, BEHAV RES THER, V46, P1220, DOI 10.1016/j.brat.2008.08.004; Elliott TR, 2009, J CLIN PSYCHOL, V65, P406, DOI 10.1002/jclp.20527; Falloon IRH, 1985, FAMILY MANAGEMENT SC; French LM, 2008, J CLIN PSYCHOL, V64, P1004, DOI 10.1002/jclp.20514; Glynn SM, 2006, SCHIZOPHRENIA BULL, V32, P451, DOI 10.1093/schbul/sbj066; Grant JS, 2002, STROKE, V33, P2060, DOI 10.1161/01.STR.0000020711.38824.E3; Hoge CW, 2006, JAMA-J AM MED ASSOC, V295, P1023, DOI 10.1001/jama.295.9.1023; Jacobson IG, 2008, JAMA-J AM MED ASSOC, V300, P663, DOI 10.1001/jama.300.6.663; JOHNSON B, 2004, FAMILY J COUNSELING, V12, P178; La Bash HAJ, 2009, J INTERPERS VIOLENCE, V24, P231, DOI 10.1177/0886260508317177; LAROI F, 2000, J FAMILY PSYCHOTHERA, V11, P69; Lew HL, 2007, J REHABIL RES DEV, V44, pVII; McFarlane AC, 2009, CURR OPIN PSYCHIATR, V22, P369, DOI 10.1097/YCO.0b013e32832c9064; McFarlane WR, 2003, J MARITAL FAM THER, V29, P223, DOI 10.1111/j.1752-0606.2003.tb01202.x; McNulty PAF, 2005, MIL MED, V170, P530, DOI 10.7205/MILMED.170.6.530; Miklowitz D.J., 1997, BIPOLAR DISORDER FAM; Miklowitz DJ, 2007, AM J PSYCHIAT, V164, P1340, DOI 10.1176/appi.ajp.2007.07020311; Miklowitz DJ, 2006, DEV PSYCHOPATHOL, V18, P1247, DOI 10.1017/S0954579406060603; Miklowitz DJ, 2003, ARCH GEN PSYCHIAT, V60, P904, DOI 10.1001/archpsyc.60.9.904; Milliken CS, 2007, JAMA-J AM MED ASSOC, V298, P2141, DOI 10.1001/jama.298.18.2141; Murray-Swank AB, 2004, CNS SPECTRUMS, V9, P905, DOI 10.1017/S109285290000972X; NUECHTERLEIN KH, 1984, SCHIZOPHRENIA BULL, V10, P300, DOI 10.1093/schbul/10.2.300; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Perlick DA, 2007, BIPOLAR DISORD, V9, P262, DOI 10.1111/j.1399-5618.2007.00365.x; Pilling S, 2002, PSYCHOL MED, V32, P763, DOI 10.1017/S0033291702005895; Pitschel-Walz G, 2001, SCHIZOPHRENIA BULL, V27, P73, DOI 10.1093/oxfordjournals.schbul.a006861; Pledger C, 2003, AM PSYCHOL, V58, P279, DOI 10.1037/0003-066X.58.4.279; Polusny MA, 2009, MIL MED, V174, P353, DOI 10.7205/MILMED-D-01-1608; President's New Freedom Commission on Mental Health, 2003, ACH PROM TRANSF MENT; Rea MM, 2003, J CONSULT CLIN PSYCH, V71, P482, DOI 10.1037/0022-006X.71.3.482; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Rodgers ML, 2007, AM J PHYS MED REHAB, V86, P482, DOI 10.1097/PHM.0b013e31805c00a1; Sander AM, 2002, BRAIN INJURY, V16, P649, DOI 10.1080/02699050210128889; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Smith TC, 2008, EPIDEMIOLOGY, V19, P505, DOI 10.1097/EDE.0b013e31816a9dff; STEIN MB, 2009, AM J PSYCHIAT   0515; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Testa JA, 2006, J HEAD TRAUMA REHAB, V21, P236, DOI 10.1097/00001199-200605000-00004; Tyerman A, 2001, NEUROREHABILITATION, V16, P59; VAUGHN C, 1976, BRIT J SOC CLIN PSYC, V15, P157, DOI 10.1111/j.2044-8260.1976.tb00021.x; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wendel JS, 2000, J ABNORM PSYCHOL, V109, P792, DOI 10.1037/0021-843X.109.4.792; World Health Organization, 2001, INT CLASS FUNCT DIS	54	32	33	1	17	EDUCATIONAL PUBLISHING FOUNDATION	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2009	54	3					279	287		10.1037/a0016809			9	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	488SW	WOS:000269371100005	19702426				2021-06-18	
J	Hunt, TN; Ferrara, MS				Hunt, Tamerah N.; Ferrara, Michael S.			Age-Related Differences in Neuropsychological Testing Among High School Athletes	JOURNAL OF ATHLETIC TRAINING			English	Article						concussions; mild traumatic brain injuries; adolescents; cognitive maturity	FOOTBALL PLAYERS; NORMATIVE DATA; HEAD TRAUMA; CONCUSSION; COLLEGIATE; RECOVERY; STATEMENT; INJURY; SPORT	Context: Clinicians have questioned the need to obtain annual baseline neuropsychological tests in high school athletes. If no difference among academic grades exists, annual baseline testing may not be necessary. Objective: To examine differences at baseline testing on pencil-and-paper neuropsychological tests among grade levels in high school athletes. Design: Cross-sectional, between-groups design. Setting: Schools participating in a Georgia high school athletics association. Patients or Other Participants: High school football players (n = 198) in the 9th through 12th grades, with a mean age of 15.78 +/- 1.16 years. Main Outcome Measure(s): Participants were divided into 4 groups by grade and were administered a symptom checklist and brief neuropsychological test battery. Grade level served as the independent variable. Symptom and individual test scores within the neuropsychological test battery served as dependent variables. Results: Differences were noted among grades on the Trail Making Test A (F-3.194 = 3.23, P = .024, eta(2) = 0.048), Trail Making Test B (F-3,F-194 = 3.93, P = .009, eta(2) = 0.057), Symbol Digit Modalities Test (F-3,F-194 = 4.38, P = .005, eta(2) = 0.064), dominant tap (F-3,F-194 = 3.14, P = .026, eta(2) = 0.046), and nondominant tap (F-3,F-194 = 4.902, P = .003, eta(2) = 0.070). Using the Bonferroni correction (P <= .00625), we found differences between the 9th grade and 11th and 12th grades. Conclusions: Baseline neuropsychological test scores in high school athletes improved as a function of age, with differences between the 9th grade and 11th and 12th grades. Because the differences were driven by 9th-grade test scores, baseline testing should be completed, at minimum, upon entrance into 9th and 10th grades; however, annual testing is still recommended until additional research is conducted.	[Hunt, Tamerah N.] Ohio State Univ, Sports Med Ctr, Columbus, OH 43221 USA; [Ferrara, Michael S.] Univ Georgia, Athens, GA 30602 USA	Hunt, TN (corresponding author), Ohio State Univ, Sports Med Ctr, 2050 Kenny Rd,Suite 3100, Columbus, OH 43221 USA.	tamerah.hunt@osumc.edu	Hunt, Tamerah/E-3281-2011				Anderson V A, 1997, J Int Neuropsychol Soc, V3, P568; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; BAUMGARTNER TA, 2003, MEASUREMENT EVALUATI, P42; Benes FM, 2001, DEV COGN NEUROSCI, P79; BORNSTEIN RA, 1985, J CLIN PSYCHOL, V41, P651, DOI 10.1002/1097-4679(198509)41:5<651::AID-JCLP2270410511>3.0.CO;2-C; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; Donders J, 2000, J HEAD TRAUMA REHAB, V15, P792, DOI 10.1097/00001199-200004000-00004; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; FINLAYSON MAJ, 1976, PERCEPT MOTOR SKILL, V43, P475, DOI 10.2466/pms.1976.43.2.475; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; *IMPACT, NORM DAT HIGH SCH ST; KEPPEL G, 1991, DESIGN ANAL RES HDB, P62; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; LURIA AR, 1980, HIGHER CORTICAL FUNC, P42; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrea M, 2001, CLIN J SPORT MED, V11, P176, DOI 10.1097/00042752-200107000-00008; MCCREA M, 2001, JAMA-J AM MED ASSOC, V290, P2556; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; OBRZUT JE, 1986, CHILD NEUROPSYCHOL, P18; Passler MA, 1985, DEV NEUROPSYCHOL, V1, P349, DOI 10.1080/87565648509540320; Piland SG, 2003, J ATHL TRAINING, V38, P104; RASMUSSON DX, 1995, ARCH CLIN NEUROPSYCH, V10, P21, DOI 10.1016/0887-6177(94)E0001-6; RUFF RM, 1993, PERCEPT MOTOR SKILL, V76, P1219, DOI 10.2466/pms.1993.76.3c.1219; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; SMITH A, 1991, SEMINAR ON PUBLISHING FOR AN OPTIMAL PRODUCT : MEETING THE NEEDS OF READERS AND ADVERTISERS IN TODAYS MARKET, P1; SPREEN O, 1995, DEV NEUROPSYCHOL, P37; Theye Fred, 2004, Clin Med Res, V2, P165; Valovich TC, 2003, J ATHL TRAINING, V38, P51; YEUDALL LT, 1987, J CLIN PSYCHOL, V43, P346, DOI 10.1002/1097-4679(198705)43:3<346::AID-JCLP2270430308>3.0.CO;2-Q	36	32	32	2	12	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	JUL-AUG	2009	44	4					405	409		10.4085/1062-6050-44.4.405			5	Sport Sciences	Sport Sciences	474EZ	WOS:000268266600010	19593423	Green Published			2021-06-18	
J	Nowak, LA; Smith, GG; Reyes, PF				Nowak, L. A.; Smith, G. G.; Reyes, P. F.			Dementia in a retired world boxing champion: case report and literature review	CLINICAL NEUROPATHOLOGY			English	Article						dementia pugilistica; traumatic brain injury; Wernicke-Korsakoff syndrome	TRAUMATIC BRAIN-INJURY; NEUROFIBRILLARY TANGLES; ALZHEIMERS-DISEASE; CAROTID ARTERY; PUGILISTICA; BOXERS; DAMAGE; SPORT; RISK	Objective: Dementia in retired boxers, also referred to as "dementia pugilistica" (DP), is usually attributed to repeated concussive and subconcussive blows to the head. We report the case of a former world boxing champion whose progressive cognitive decline could be ascribed to DP, cerebral infarcts and Wernicke-Korsakoff syndrome. This case demonstrates that dementia in retired boxers may be caused and/or exacerbated by etiologic factors other than DP. Materials and methods: We correlated the clinical features with the histochemical and immunohistochemical changes observed on autopsy brain material from a retired boxer, reviewed the literature on boxing-related dementia, and compared Our findings with previous reports oil DP. Results: Neuropathologic examination revealed numerous neurofibrillary tangles (NFTs), rare neuritic plaques (NPs), multiple cerebral infarcts, fenestrated septum pellucidum, atrophic and gliotic mamillary bodies, and pale substantia nigra and locus ceruleus. Conclusions: Our neuropathologic data confirmed the notion that dementia in retired boxers Could be due to several factors Such as DP, Multiple cerebral infarcts and Wernicke-Korsakoff syndrome. Our findings illustrate the need to comprehensively examine former boxers with dementia as well as carefully evaluate the neuropathologic changes that may cause or contribute to the patient's cognitive and behavioral symptoms. Such an approach is crucial in order to provide prompt and more definitive therapies.	[Nowak, L. A.; Reyes, P. F.] St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ 85013 USA; [Smith, G. G.] Univ Penn, Philadelphia, PA 19104 USA; [Smith, G. G.] DVAMC, Coatesville, PA USA	Reyes, PF (corresponding author), St Josephs Hosp, Barrow Neurol Inst, NRC 4th Floor 428,350 W Thomas Rd, Phoenix, AZ 85013 USA.	Patricio.Reyes@chw.edu			St. Joseph's Hospital Medical Center	We would like to thank St. Joseph's Hospital & Medical Center, Barrow Neurological Institute and the Barrow Women's Board for their support in our work.	BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; Clausen H, 2005, BRIT J SPORT MED, V39, P661, DOI 10.1136/bjsm.2004.017046; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; DALE GE, 1991, J NEUROL NEUROSUR PS, V54, P116, DOI 10.1136/jnnp.54.2.116; Drachman DA, 1999, NEW ENGL J MED, V340, P1269, DOI 10.1056/NEJM199904223401609; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; GONZALES TA, 1951, JAMA-J AM MED ASSOC, V146, P1506, DOI 10.1001/jama.1951.03670160048012; GOREVIC PD, 1986, J NEUROPATH EXP NEUR, V45, P647, DOI 10.1097/00005072-198611000-00004; GURDJIAN ES, 1958, J NEUROSURG, V15, P125, DOI 10.3171/jns.1958.15.2.0125; GUTERMAN A, 1987, SPORTS MED, V4, P194, DOI 10.2165/00007256-198704030-00004; HARPER C, 1995, METAB BRAIN DIS, V10, P17, DOI 10.1007/BF01991779; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; HUGHES JT, 1968, J NEUROL NEUROSUR PS, V31, P307, DOI 10.1136/jnnp.31.4.307; ISHERWOOD I, 1966, ACTA RADIOL DIAGN, V5, P654, DOI 10.1177/02841851660050P203; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, pRC28, DOI 10.1007/BF03345299; Letenneur L, 2004, BIOL RES, V37, P189, DOI 10.4067/S0716-97602004000200003; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; MATTHEWS WB, 1972, BRIT MED J, V2, P326, DOI 10.1136/bmj.2.5809.326; McKenzie JE, 1996, NEURODEGENERATION, V5, P259, DOI 10.1006/neur.1996.0034; MENDEZ MF, 1995, INT J PSYCHIAT MED, V25, P249, DOI 10.2190/CUMK-THT1-X98M-WB4C; Mooijaart SP, 2007, ANN NY ACAD SCI, V1100, P148, DOI 10.1196/annals.1395.013; Ooi A, 2003, EUR J CARDIO-THORAC, V24, P1043, DOI 10.1016/S1010-7940(03)00579-7; REYES PF, 2006, BARROW Q, V22, P9; REYES PF, 1989, NEUROLOGY S1, V39; Richards R, 1995, Nurs Times, V91, P52; Roberts AH., 1969, BRAIN DAMAGE BOXERS; ROBERTS GW, 1988, LANCET, V2, P1456; RYAN AJ, 1987, CLIN SPORT MED, V6, P31; Schleimer Jonathan A, 2002, Curr Sports Med Rep, V1, P323; Sheedy D, 1999, ALCOHOL CLIN EXP RES, V23, P1624, DOI 10.1097/00000374-199910000-00009; Tanriverdi F, 2007, J ENDOCRINOL INVEST, V30, P150, DOI 10.1007/BF03347414; Tanriverdi F, 2007, CLIN ENDOCRINOL, V66, P360, DOI 10.1111/j.1365-2265.2006.02737.x; Unterharnscheidt F, 1995, Rev Neurol, V23, P1027; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	37	32	32	1	23	DUSTRI-VERLAG DR KARL FEISTLE	DEISENHOFEN-MUENCHEN	BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY	0722-5091			CLIN NEUROPATHOL	Clin. Neuropathol.	JUL-AUG	2009	28	4					275	280		10.2379/NPX0800			6	Clinical Neurology; Pathology	Neurosciences & Neurology; Pathology	469XE	WOS:000267933900003	19642506				2021-06-18	
J	Hamberger, A; Viano, DC; Saljo, A; Bolouri, H				Hamberger, Anders; Viano, David C.; Saljo, Annette; Bolouri, Hayde			CONCUSSION IN PROFESSIONAL FOOTBALL: MORPHOLOGY OF BRAIN INJURIES IN THE NFL CONCUSSION MODEL-PART 16	NEUROSURGERY			English	Article						Animal model; Brain edema; Brain injury; Diffuse axonal injury; Glial fibrillary acidic protein; Hemorrhage; NF-200	DIFFUSE AXONAL INJURY; CLOSED-HEAD INJURY; ROTATIONAL ACCELERATION; BLOOD-FLOW; RAT-BRAIN; SEQUELAE; REDISTRIBUTION; BIOMECHANICS; HIPPOCAMPUS; IMPACTS	OBJECTIVE: An animal model of concussions in National Football League players has been described in a previous study. It involves a freely moving 300-g Wistar rat impacted on the side of the head at velocities of 7.4 to 11.2 m/s with a 50-g impactor. The impact causes a 6% to 28% incidence of meningeal hemorrhages and 0.1- to 0.3-mm focal petechiae depending on the impact velocity. This study addresses the immunohistochemical responses of the brain. METHODS: Twenty-seven tests were conducted with a 50-g impactor and velocities of 7.4, 9.3, or 11.2 m/s. The left temporal region of the helmet-protected head was hit I or 3 times. Thirty-one additional tests were conducted with a 100-g impactor. Diffuse axonal injury in distant regions of the brain was assessed with immunohistochemistry for NF-200, the heaviest neurofilament subunit, and glial fibrillary acidic protein, an intermediate filament protein in astrocytes. Hemorrhages were analyzed by unspecific peroxidase. There were 10 controls. RESULTS: A single impact at 7.4 and 9.3 m/s velocity with the 50-g impactor causes minimal neuronal injury and astrocytosis. Repeat impacts with 11.2 m/s velocity and more than 9.3-m/s impacts with 100 g cause diffuse axonal injury and distant injury bilaterally in the cerebral cortex, the subcortical, the white matter, the hippocampus CA1, the corpus callosum, and the striatum, as indicated by NF-200 accumulation in neuronal perikarya 10 days after impact. It also causes reactive astrocytosis in the midline regions of the cerebral cortex and periventricularly. Regions with erythrocyte-loaded blood capillaries indicated brain edema in regions of the cerebral cortex, the brainstem, and the cerebellum. CONCLUSION: When the immunohistochemical results are extrapolated to professional football players, concussions result in no or minimal brain injury. Repeat impacts at higher velocity or with a heavier mass impactor cause extensive and distant diffuse axonal injury. Based on this model, the threshold for diffuse axonal injury is above even the most severe conditions for National Football League concussion.	[Saljo, Annette; Bolouri, Hayde] Univ Gothenburg, Sect Anat & Cell Biol, Inst Biomed, SE-40530 Gothenburg, Sweden; [Viano, David C.] Mild Traumat Brain Injury Comm, New York, NY USA; [Viano, David C.] ProBiomechanics LLC, Bloomfield Hills, MI USA	Hamberger, A (corresponding author), Univ Gothenburg, Sect Anat & Cell Biol, Inst Biomed, Box 440, SE-40530 Gothenburg, Sweden.	anders.hamberger@anatcell.gu.se					Adams JH, 1992, GREENFIELDS NEUROPAT, P106; AMADUCCI L, 1981, NEUROSCI LETT, V21, P27, DOI 10.1016/0304-3940(81)90052-5; Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Assaf Y, 1999, NMR BIOMED, V12, P335, DOI 10.1002/(SICI)1099-1492(199910)12:6<335::AID-NBM581>3.0.CO;2-A; Bodjarian N, 1997, NEUROREPORT, V8, P3951, DOI 10.1097/00001756-199712220-00020; BOLOURI H, NEUROSURGERY UNPUB; BULLOCK R, 2004, INT NEUR S AD S AUST; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; CROOKS DA, 1991, NEUROPATH APPL NEURO, V17, P407, DOI 10.1111/j.1365-2990.1991.tb00740.x; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Fork M, 2005, BRAIN INJURY, V19, P101, DOI 10.1080/02699050410001726086; Graham DI, 2000, ACTA NEUROPATHOL, V99, P117, DOI 10.1007/PL00007414; Gutierrez E, 2001, J NEUROTRAUM, V18, P247, DOI 10.1089/08977150151070874; Hamberger A, 2003, J NEUROTRAUM, V20, P169, DOI 10.1089/08977150360547080; Huh JW, 2002, EXP NEUROL, V175, P198, DOI 10.1006/exnr.2002.7880; Li R, 1998, AM J FOREN MED PATH, V19, P129, DOI 10.1097/00000433-199806000-00006; Lundblad C, 2004, J NEUROTRAUM, V21, P741, DOI 10.1089/0897715041269614; McGraw J, 2001, J NEUROSCI RES, V63, P109, DOI 10.1002/1097-4547(20010115)63:2<109::AID-JNR1002>3.0.CO;2-J; McIntosh TK, 1996, LAB INVEST, V74, P315; Mertz HJ, 1996, 960099 SAE; Paxinos G., 1982, RAT BRAIN STEREOTAXI; Pellman EJ, 2006, NEUROSURGERY, V58, P78, DOI 10.1227/01.NEU.0000196265.35238.7C; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; POVLISHOCK JT, 1995, J NEUROTRAUM, V12, P555, DOI 10.1089/neu.1995.12.555; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Saatman KE, 2006, J NEUROTRAUM, V23, P1241, DOI 10.1089/neu.2006.23.1241; Saljo A, 2000, J NEUROTRAUM, V17, P719, DOI 10.1089/089771500415454; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viano DC, 2005, NEUROSURGERY, V56, P266, DOI 10.1227/01.neu.0000150035.54230.3C; VIANO DC, NEUROSURGERY, V64, P1162; Vink R, 2003, ACT NEUR S, V86, P257; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YANG QN, 1995, BRAIN RES, V696, P49, DOI 10.1016/0006-8993(95)00755-F; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	41	32	32	0	28	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	JUN	2009	64	6					1174	1182		10.1227/01.NEU.0000316855.40986.2A			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	452YE	WOS:000266576300037	19487898				2021-06-18	
J	Peterson, SE; Stull, MJ; Collins, MW; Wang, HE				Peterson, Shane E.; Stull, Matthew J.; Collins, Michael W.; Wang, Henry E.			Neurocognitive Function of Emergency Department Patients With Mild Traumatic Brain Injury	ANNALS OF EMERGENCY MEDICINE			English	Article							HEAD-INJURY; GALVESTON ORIENTATION; EARLY INTERVENTION; AMNESIA TEST; FOLLOW-UP; CONCUSSION; IMPACT; MANAGEMENT; RECOVERY; SCALE	Study objective: We characterize the neurocognitive function of patients presenting to the emergency department (ED) with mild traumatic brain injury. Methods: This prospective study took place at an urban, academic ED and Level I trauma center. Case patients consisted of a convenience sample of ED patients aged 18 to 59 years, presenting to the ED with mild traumatic brain injury and having a head computed tomography scan without traumatic abnormalities. Controls consisted of patients aged 18 to 59 years, presenting to the ED with an isolated, nondominant hand extremity injury. We excluded patients with multiple injuries and recent alcohol consumption. Subjects completed a computerized neurocognitive test battery (Immediate Post-concussion Assessment and Cognitive Testing). The primary measures were verbal memory, visual memory, and visual motor and reaction speed. We compared raw and age-normalized neurocognitive performance between case patients and controls by using nonparametric statistics. Results: We included a total of 23 head-injured case patients and 31 non-head-injured controls. Case patients and controls exhibited similar raw (median 80.1 versus 85.0 points; difference in medians -4.9; P=.26) and age-normalized (31.9 versus 57.4 percentile; difference in medians -25.5; P=.12) verbal memory. Case patients and controls exhibited similar raw (64.6 versus 63.5; difference 1.1; P=.79) and age-normalized (20.8 versus 25.8 percentile; difference -5.0; P=.44) visual memory. Compared with controls, mild traumatic brain injury case patients demonstrated slower raw (31.6 versus 37.0 points; difference -5.4; P=.002) and age-normalized (17.1 versus 57.6 percentile; difference -40.5; P=.001) visual motor speed. Mild traumatic brain injury case patients exhibited slower raw (median 0.66 versus 0.60 seconds; difference 0.06; P=.01) and agenormalized (29.3 versus 42.8 percentile; difference -13.5; P-.009) reaction times. Conclusion: In conclusion, compared with the non-head-injured patients, ED mild traumatic brain injury patients demonstrated subtle but discernible neurocognitive deficits. [Ann Emerg Med. 2009;53:796-803.]	[Peterson, Shane E.; Stull, Matthew J.; Wang, Henry E.] Univ Pittsburgh, Sch Med, Dept Emergency Med, Pittsburgh, PA USA; [Collins, Michael W.] Univ Pittsburgh, Dept Orthoped Surg, Sports Concuss Program, Med Ctr,Ctr Sports Med, Pittsburgh, PA USA	Wang, HE (corresponding author), Univ Alabama Birmingham, Dept Emergency Med, 619 19th St S,JTN266, Birmingham, AL 35249 USA.	hwang@uabmc.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K08HS013628] Funding Source: NIH RePORTER; AHRQ HHSUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [K08 HS013628, K08-HS013628] Funding Source: Medline		Altman D. G., 1999, PRACTICAL STAT MED R; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bazarian J, 2000, BRAIN INJURY, V14, P285; Bazarian JJ, 2006, ACAD EMERG MED, V13, P199, DOI 10.1197/j.aem.2005.07.031; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; *CDCP, FACTS CONC BRAIN INJ; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; Cushman JG, 2001, J TRAUMA, V51, P1016, DOI 10.1097/00005373-200111000-00034; DAVIDOFF G, 1988, ARCH PHYS MED REHAB, V69, P432; Delaney JS, 2005, J EMERG MED, V29, P189, DOI 10.1016/j.jemermed.2005.01.020; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P567, DOI 10.1136/jnnp.2007.120162; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2001, CLIN J SPORT MED, V11, P166, DOI 10.1097/00042752-200107000-00007; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Lovell MR, IMPACT 2007 6 0 CLIN; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Sheedy J, 2006, J CLIN EXP NEUROPSYC, V28, P755, DOI 10.1080/13803390591000864; Shores EA, 2008, J NEUROL NEUROSUR PS, V79, P1100, DOI 10.1136/jnnp.2007.132571; Stewart DP, 1996, ACAD EMERG MED, V3, P21, DOI 10.1111/j.1553-2712.1996.tb03297.x; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	29	32	33	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644	1097-6760		ANN EMERG MED	Ann. Emerg. Med.	JUN	2009	53	6					796	803		10.1016/j.annemergmed.2008.10.015			8	Emergency Medicine	Emergency Medicine	455SY	WOS:000266787200021	19167782				2021-06-18	
J	Kharatishvili, I; Sierra, A; Immonen, RJ; Grohn, OHJ; Pitkanen, A				Kharatishvili, Irina; Sierra, Alejandra; Immonen, Riikka J.; Grohn, Olli H. J.; Pitkanen, Asla			Quantitative T2 mapping as a potential marker for the initial assessment of the severity of damage after traumatic brain injury in rat	EXPERIMENTAL NEUROLOGY			English	Article						Behavioral tests; Fluid percussion model; Histopathology; Lesion volume; Quantitative MRI; Traumatic brain injury	CLOSED-HEAD-INJURY; COMPUTERIZED-TOMOGRAPHY; POSTTRAUMATIC EPILEPSY; TIME-COURSE; SEIZURES; PREDICTION; DIFFUSION; MILD; MRI; CT	Severity of traumatic brain injury (TBI) positively correlates with the risk of post-traumatic epilepsy (PTE). Studies on post-traumatic epileptogenesis would greatly benefit from markers that at acute phase would reliably predict the extent and severity of histologic brain damage caused by TBI in individual subjects. Currently in experimental models, severity of TBI is determined by the pressure of applied load that does not directly reflect the extent of inflicted brain injury, mortality within experimental population, or impairment in behavioral tests that are laborious to perform. We aimed to compare MRI markers measured at acute post-injury phase to previously used indicators of injury severity in the ability to predict the extent of histologically determined post-traumatic tissue damage. We used lateral fluid-percussion injury model in rat that is a clinically relevant model of closed head injury in humans, and results in PTE in severe cases. Rats (48 injured, 12 controls) were divided into moderate (mTBI) and severe (sTBI) groups according to impact strength. MRI data (T2, T2*, lesion volume) were acquired 3 days post-injury. Motor deficits were analysed using neuroscore (NS) and beam balance (BB) tests 2 and 3 days post-injury, respectively. Histological evaluation of lesion volume (Fluoro-jade B) was used as the reference outcome measure, and was performed 2 weeks after TBI. From MRI parameters studied, quantitative T2 values of cortical lesion not only correlated with histologic lesion volume (P<0.001, r=0.6, N=34), as well as NS (P<0.01, r=-0.5, N=34) and BB (P<0.01, r=-0.5. N=34) results, but also successfully differentiated animals with mTBI from those with sTBI 70.6 +/- 6.2 6.2 ms vs. 75.9 +/- 2.6 ms, P<0.001). Quantitative T2 of the lesion early after TBI can serve as an indicator of the severity of post-traumatic cortical damage and neuro-motor impairment, and has a potential as a clinical marker for identification of individuals with elevated risk of PTE. (C) 2009 Elsevier Inc. All rights reserved.	[Kharatishvili, Irina; Pitkanen, Asla] Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, Epilepsy Res Lab, FIN-70211 Kuopio, Finland; [Sierra, Alejandra; Immonen, Riikka J.; Grohn, Olli H. J.] Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, Biomed NMR Res Grp,Biomed Imaging Unit, FIN-70211 Kuopio, Finland; [Pitkanen, Asla] Kuopio Univ Hosp, Dept Neurol, FIN-70211 Kuopio, Finland	Pitkanen, A (corresponding author), Univ Kuopio, AI Virtanen Inst Mol Sci, Dept Neurobiol, Epilepsy Res Lab, POB 1627, FIN-70211 Kuopio, Finland.	Asla.Pitkanen@uku.fi		Sierra Lopez, Alejandra/0000-0001-5399-2056	Academy of FinlandAcademy of FinlandEuropean Commission; Emil Aaltonen Foundation; Sigrid Juselius FoundationSigrid Juselius Foundation; Orion Pharma; Finnish Epilepsy Research Foundation; Finnish Cultural FoundationFinnish Cultural Foundation	This work was supported by the Academy of Finland, the Emil Aaltonen Foundation, the Sigrid Juselius Foundation, Orion Pharma, the Finnish Epilepsy Research Foundation, and the Finnish Cultural Foundation. We thank Mrs. Merja Lukkari, and Mr. Jarmo Hartikainen for their excellent technical assistance.	ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DALESSANDRO R, 1983, ARCH NEUROL-CHICAGO, V40, P831, DOI 10.1001/archneur.1983.04050120081022; DALESSANDRO R, 1982, J NEUROL NEUROSUR PS, V45, P1153, DOI 10.1136/jnnp.45.12.1153; De Santis A, 1992, Acta Neurochir Suppl (Wien), V55, P64; FRENCH BN, 1977, SURG NEUROL, V7, P171; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Golarai G, 2001, J NEUROSCI, V21, P8523; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; HAUSER WA, 1984, NEUROLOGY, V34, P746, DOI 10.1212/WNL.34.6.746; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hirtz D, 2007, NEUROLOGY, V68, P326, DOI 10.1212/01.wnl.0000252807.38124.a3; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 2005, HEAD INJURY PATHOPHY, P441; Jennett B, 1975, EPILEPSY NONMISSILE; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; KELLY AB, 1988, AM J NEURORADIOL, V9, P699; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; KURTZKE JF, 1987, CLIN NEUROLOGY, P1; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; PohlmannEden B, 1997, ACTA NEUROL SCAND, V95, P257, DOI 10.1111/j.1600-0404.1997.tb00206.x; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42	52	32	32	0	7	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	MAY	2009	217	1					154	164		10.1016/j.expneurol.2009.01.026			11	Neurosciences	Neurosciences & Neurology	442RT	WOS:000265859000018	19416663				2021-06-18	
J	Simon, CM; Sharif, S; Tan, RP; LaPlaca, MC				Simon, Crystal M.; Sharif, Shan; Tan, Richard P.; LaPlaca, Michelle C.			Spinal Cord Contusion Causes Acute Plasma Membrane Damage	JOURNAL OF NEUROTRAUMA			English	Article						bleb; mechanoporation; permeability; plasma membrane; spinal cord injury	TRAUMATIC BRAIN-INJURY; BLEB FORMATION; AXOLEMMAL PERMEABILITY; NEURONAL INJURY; CORTICAL ACTIN; CELL-SURFACE; REPAIR; DISRUPTION; AXONS; MECHANISMS	Spinal cord injury (SCI) launches a complex cascade of events that leads to progressive damage and loss of function. Compromise of plasma membrane integrity due to the mechanical impact is an acute event that may contribute to cellular dysfunction. Therefore, the objective of this study was to better understand the extent of acute plasma membrane damage associated with SCI as a function of injury severity and membrane defect size. Fluorescent cell-impermeant dyes were injected into the cerebrospinal fluid of adult male rats prior to contusion injury, and the anatomical location of cell bodies and axons taking up the dye within 10 min following SCI was quantified. Lucifer yellow uptake was assessed as a function of impact force (experimental groups: sham, 100 kdyn, 150 kdyn, and 200 kdyn force). In a separate group of animals, FITC-conjugated dextran molecules of various sizes (3 kDa and 10 kDa with a 1.6-nm and 2.7-nm radius, respectively) were used to approximate the size of membrane defects following moderate injury (150 kdyn force). Quantification revealed that cellular uptake of lucifer yellow was positively correlated with the force of the mechanical impact, indicating that the severity of injury is related to the degree of acute membrane failure. In addition, after moderate injury, cell bodies and axons (located up to 2 mm and 3 mm from the epicenter, respectively) took up significantly more of the 3-kDa and 10-kDa dextran permeability marker compared to sham controls. Permeable neuronal cell bodies exhibited a morphological appearance characterized by pericellular blebbing, suggesting that plasma membrane compromise is associated with pathophysiological cellular alterations. Collectively, these results enhance our understanding of acute SCI and provide targets for developing novel treatment strategies.	Georgia Inst Technol, Wallace H Coulter Dept Biomed Engn, Atlanta, GA 30332 USA; Emory Univ, Lab Neuroengn, Atlanta, GA 30322 USA; Georgia Inst Technol, Parker H Petit Inst Bioengn & Biosci, Atlanta, GA 30332 USA	LaPlaca, MC (corresponding author), Georgia Inst Technol, Emory Coulter Dept Biomed Engn, 313 Ferst Dr, Atlanta, GA 30332 USA.	michelle.laplaca@bme.gatech.edu			National Science FoundationNational Science Foundation (NSF) [EEC-9731643]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS061153] Funding Source: NIH RePORTER	The authors would like to acknowledge Sha'Aqua Asberry, Andres Garcia, Chris Lessing, Darren Miller, Gustavo Prado, Robyn Schlicher, and Akshay Shetty for their assistance with the technical aspects of experiments and data interpretation. Funding was provided by National Science Foundation grant EEC-9731643.	Baptiste DC, 2007, PROG BRAIN RES, V161, P217, DOI 10.1016/S0079-6123(06)61015-7; Barbee KA, 2005, ANN NY ACAD SCI, V1066, P67, DOI 10.1196/annals.1363.006; Barros LF, 2003, CELL DEATH DIFFER, V10, P687, DOI 10.1038/sj.cdd.4401236; Basso DM, 1996, EXP NEUROL, V139, P244, DOI 10.1006/exnr.1996.0098; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Charras GT, 2008, BIOPHYS J, V94, P1836, DOI 10.1529/biophysj.107.113605; Charras GT, 2006, J CELL BIOL, V175, P477, DOI 10.1083/jcb.200602085; Choo AM, 2007, J NEUROSURG-SPINE, V6, P255, DOI 10.3171/spi.2007.6.3.255; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; Detrait E, 2000, J NEUROBIOL, V44, P382, DOI 10.1002/1097-4695(20000915)44:4<382::AID-NEU2>3.0.CO;2-Q; Dumont RJ, 2001, CLIN NEUROPHARMACOL, V24, P254, DOI 10.1097/00002826-200109000-00002; Eddleman CS, 1997, P NATL ACAD SCI USA, V94, P4745, DOI 10.1073/pnas.94.9.4745; Farkas O, 2006, J NEUROSCI, V26, P3130, DOI 10.1523/JNEUROSCI.5119-05.2006; Farkas O, 2007, PROG BRAIN RES, V161, P43, DOI 10.1016/S0079-6123(06)61004-2; Geddes DM, 2003, J NEUROTRAUM, V20, P1039, DOI 10.1089/089771503770195885; Geddes-Klein DM, 2006, J NEUROTRAUM, V23, P193, DOI 10.1089/neu.2006.23.193; Guzman HR, 2001, J ACOUST SOC AM, V110, P588, DOI 10.1121/1.1376131; Hagg T, 2006, J NEUROTRAUM, V23, P264, DOI 10.1089/neu.2006.23.263; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hiruma H, 2007, J PHOTOCH PHOTOBIO B, V86, P1, DOI 10.1016/j.jphotobiol.2006.08.003; Howard MJ, 1999, NEUROSCIENCE, V93, P807, DOI 10.1016/S0306-4522(99)00195-5; Keller H, 1998, CELL MOTIL CYTOSKEL, V41, P181, DOI 10.1002/(SICI)1097-0169(1998)41:2<181::AID-CM8>3.0.CO;2-H; Keller H, 2002, EXP CELL RES, V277, P161, DOI 10.1006/excr.2002.5552; KILINC D, 2007, C P IEEE ENG MED BIO, V1, P5395; Kloos AD, 2005, EXP NEUROL, V191, P251, DOI 10.1016/j.expneurol.2004.09.016; Kwon Brian K, 2004, Spine J, V4, P451, DOI 10.1016/j.spinee.2003.07.007; LaPlaca MC, 2007, PROG BRAIN RES, V161, P13, DOI 10.1016/S0079-6123(06)61002-9; LaPlaca MC, 1997, J NEUROTRAUM, V14, P355, DOI 10.1089/neu.1997.14.355; Laster SM, 1996, MICROSC RES TECHNIQ, V34, P272, DOI 10.1002/(SICI)1097-0029(19960615)34:3<272::AID-JEMT10>3.0.CO;2-J; Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224; McNeil PL, 2000, J CELL SCI, V113, P1891; McNeil PL, 2002, J CELL SCI, V115, P873; McNeil PL, 2001, NAT CELL BIOL, V3, pE124, DOI 10.1038/35074652; Mills JC, 1998, J CELL BIOL, V140, P627, DOI 10.1083/jcb.140.3.627; Miyake K, 2001, J CELL SCI, V114, P3487; OLIVER JD, 1992, J AM SOC NEPHROL, V3, P214; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1996, ACT NEUR S, V66, P81; Prado GR, 2005, J NEURAL ENG, V2, P148, DOI 10.1088/1741-2560/2/4/011; Rentsch PS, 2000, EUR J CELL BIOL, V79, P975, DOI 10.1078/0171-9335-00124; Scheff SW, 2003, J NEUROTRAUM, V20, P179, DOI 10.1089/08977150360547099; SCHEIRER CJ, 1976, BIOMETRICS, V32, P429, DOI 10.2307/2529511; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 2006, J NEUROPHYSIOL, V95, P3384, DOI 10.1152/jn.00350.2005; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763; Shi RY, 2004, J NEUROCYTOL, V33, P203, DOI 10.1023/B:NEUR.0000030695.76840.19; Shi XR, 2005, AM J PHYSIOL-CELL PH, V288, pC1332, DOI 10.1152/ajpcell.00522.2004; Singleton RH, 2004, J NEUROSCI, V24, P3543, DOI 10.1523/JNEUROSCI.5048-03.2004; Sokal R.R., 1995, BIOMETRY PRINCIPLES, V3; Stone JR, 2004, EXP NEUROL, V190, P59, DOI 10.1016/j.expneurol.2004.05.022; Stroetz RW, 2001, J APPL PHYSIOL, V90, P2361; Terasaki M, 1997, J CELL BIOL, V139, P63, DOI 10.1083/jcb.139.1.63; Togo T, 1999, J CELL SCI, V112, P719; Tomiyoshi G, 2004, GENES CELLS, V9, P591, DOI 10.1111/j.1356-9597.2004.00745.x; Whalen MJ, 2008, J CEREBR BLOOD F MET, V28, P490, DOI 10.1038/sj.jcbfm.9600544; WRATHALL JR, 1985, EXP NEUROL, V88, P108, DOI 10.1016/0014-4886(85)90117-7; Yoo S, 2003, J NEUROSCI RES, V74, P541, DOI 10.1002/jnr.10771	58	32	33	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2009	26	4					563	574		10.1089/neu.2008.0523			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	430OV	WOS:000264999300008	19260780	Green Published			2021-06-18	
J	Kim, KH				Kim, Kyu-Hong			Predictors for Functional Recovery and Mortality of Surgically Treated Traumatic Acute Subdural Hematomas in 256 Patients	JOURNAL OF KOREAN NEUROSURGICAL SOCIETY			English	Article						Acute subdural hematoma; Functional recovery; Mortality	SEVERE HEAD-INJURY; PROGNOSTIC-FACTORS; MORBIDITY; COMA	Objective : The purpose of this study was to investigate the reliable factors influencing the surgical outcome of the patients with traumatic acute subdural hematoma (ASOH) and to improve the functional outcome of these patients. Methods : A total of 256 consecutive patients who underwent surgical intervention for traumatic ASDH between March 1998 and March 2008 were reviewed. We evaluated the influence of perioperative variables on functional recovery and mortality using multivariate logistic regression analysis. Results : Functional recovery was achieved in 42.2% of patients and the overall mortality was 39.8%. Age (OR=4.91, P=0.002), mechanism of injury (OR=3.66, p=0.003), pupillary abnormality (OR=3.73, p=0.003), GCS score on admission (OR=5.64, p=0.000), and intraoperative acute brain swelling (ABS) (OR=3.71, p=0.009) were independent predictors for functional recovery. And preoperative pupillary abnormality (OR=2.60, P=0.023), GCS score (OR=4.66, p=0.000), and intraoperative ABS (OR=4.16, p=0.001) were independent predictors for mortality. Midline shift, thickness and volume of hematoma, type of surgery, and time to surgery showed no independent association with functional recovery, although these variables were correlated with functional recovery in univariate analyses. Conclusion : Functional recovery was more likely to be achieved in patients who were under 40 years of age, victims of motor vehicle collision and having preoperative reactive pupils, higher GCS score and the absence of ABS during surgery. These results would be helpful for neurosurgeon to improve outcomes from traumatic acute subdural hematomas.	Sungkyunkwan Univ, Dept Neurosurg, Masan Samsung Hosp, Sch Med, Masan 630723, South Korea	Kim, KH (corresponding author), Sungkyunkwan Univ, Dept Neurosurg, Masan Samsung Hosp, Sch Med, 50 Hapseong 2 Dong, Masan 630723, South Korea.	unikkh@unitel.co.kr					BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Cooper P R, 1976, Surg Neurol, V5, P25; Cruz J, 2001, NEUROSURGERY, V49, P864; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; D'Amato L, 2007, J Neurosurg Sci, V51, P107; DENT DL, 1995, J TRAUMA, V39, P36, DOI 10.1097/00005373-199507000-00005; FELL DA, 1975, J NEUROSURG, V42, P37, DOI 10.3171/jns.1975.42.1.0037; HASELSBERGER K, 1988, ACTA NEUROCHIR, V90, P111, DOI 10.1007/BF01560563; Hatashita Shizuo, 1993, Neurologia Medico-Chirurgica, V33, P13, DOI 10.2176/nmc.33.13; HERNESNIEMI J, 1979, ACTA NEUROCHIR, V49, P67, DOI 10.1007/BF01809175; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; JANG HS, 1996, J KOREAN NEUROSURG S, V25, P111; JENNETT B, 1975, LANCET, V1, P480; KLUN B, 1984, ACTA NEUROCHIR, V71, P171, DOI 10.1007/BF01401312; Koc RK, 1997, NEUROSURG REV, V20, P239, DOI 10.1007/BF01105894; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; PHUENPATHOM N, 1993, SURG NEUROL, V40, P22, DOI 10.1016/0090-3019(93)90164-V; PIOTROWSKI WP, 1995, UNFALLCHIRURG, V98, P432; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; RICHARDS T, 1974, SURGERY, V75, P253; SAKAS DE, 1995, J NEUROSURG, V82, P961, DOI 10.3171/jns.1995.82.6.0961; SALVANT JB, 1993, NEUROSURGERY, V33, P387; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; Servadei F, 1997, ACTA NEUROCHIR, V139, P279, DOI 10.1007/BF01808822; SHIGEMORI M, 1980, ACTA NEUROCHIR, V54, P61, DOI 10.1007/BF01401944; STENING WA, 1986, AUST NZ J SURG, V56, P549, DOI 10.1111/j.1445-2197.1986.tb07098.x; STONE JL, 1983, SURG NEUROL, V19, P216, DOI 10.1016/S0090-3019(83)80005-6; TEASDALE G, 1974, LANCET, V2, P81; Tian HL, 2008, CHINESE MED J-PEKING, V121, P1080, DOI 10.1097/00029330-200806020-00007; TOKUTOMI T, 1992, RECENT ADV NEUROTRAU, P367; WILBERGER JE, 1990, J TRAUMA, V30, P733, DOI 10.1097/00005373-199006000-00014; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; WONG CW, 1995, ACTA NEUROCHIR, V135, P38, DOI 10.1007/BF02307412; Yanaka Kiyoyuki, 1993, Neurologia Medico-Chirurgica, V33, P552, DOI 10.2176/nmc.33.552	40	32	32	0	4	KOREAN NEUROSURGICAL SOC	SEOUL	BLDG B, #402, 27, CHILPAE-RO, JUNG-GU, SEOUL, 04511, SOUTH KOREA	2005-3711	1598-7876		J KOREAN NEUROSURG S	J. Korean. Neurosurg. Soc.	MAR	2009	45	3					143	150		10.3340/jkns.2009.45.3.143			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	430PD	WOS:000265000100002	19352475	DOAJ Gold, Green Published			2021-06-18	
J	Korenov, M; Zilk, N; Stozicka, Z; Bugos, O; Vanicky, I; Novak, M				Korenov, Miroslava; Zilk, Norbert; Stozicka, Zuzana; Bugos, Ondrej; Vanicky, Ivo; Novak, Michal			NeuroScale, the battery of behavioral tests with novel scoring system for phenotyping of transgenic rat model of tauopathy	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Neurobehavioural assessment; Sensorimotor impairment; Scoring system; Transgenic rat; Misfolded tau protein	CEREBRAL-ARTERY OCCLUSION; TRAUMATIC BRAIN-INJURY; MARROW STROMAL CELLS; TRUNCATED TAU; MOTOR; MICE; ISCHEMIA; RECOVERY; IMPAIRMENT; MOUSE	We have previously shown that transgenic rats expressing misfolded tau protein developed neurofibrillary tangles and axonal degeneration in the brain and spinal cord, which led to impairment of sensorimotor and neuromuscular functions. To quantify neurobehavioral phenotype of the transgenic rats we have designed a testing protocol and a novel scoring system - NeuroScale - that reliably reflects progression of functional impairment of transgenic rats. NeuroScale consists of three variants of beam walking test with different sensitivity and a rapid neuromuscular and neurological examination, where animal performance is evaluated and scored according to a pre-defined rating scale. The range of the rating scale was developed to increase homogeneity of the collected behavioral data without lowering sensitivity of the testing methods. Finally, all awarded points were summed up to obtain a complete quantitative behavioral readout, the NeuroScale score, from animals under investigation. Increase in the NeuroScale score faithfully mirrored disease progression and allowed statistically significant discrimination (p < 0.001) between behavioral responses of transgenic and control animals during the whole disease process. The method was suitable for a high-throughput test whereby an experienced operator can examine up to 60 rats per day. We show that this multi-test battery with novel sensitive scoring system - NeuroScale - represents a rapid, simple to perform, high throughput method for quantitative evaluation of behavioral phenotype of transgenic rats that could serve as a valuable primary read-out for in vivo validation of therapeutic agents. (C) 2008 Elsevier B.V. All rights reserved.	[Korenov, Miroslava; Zilk, Norbert; Stozicka, Zuzana; Bugos, Ondrej; Novak, Michal] Slovak Acad Sci, Inst Neuroimmunol, AD Ctr, Bratislava 84510, Slovakia; [Korenov, Miroslava; Zilk, Norbert; Novak, Michal] Axon Neurosci GmbH, A-1030 Vienna, Austria; [Vanicky, Ivo] Slovak Acad Sci, Inst Neurobiol, Kosice 04001, Slovakia	Novak, M (corresponding author), Slovak Acad Sci, Inst Neuroimmunol, AD Ctr, Dubravska 9, Bratislava 84510, Slovakia.	Michal.Novak@savba.sk		Stozicka, Zuzana/0000-0001-6888-9254	 [VEGA 210144/08];  [2/6183/26];  [2/5101/27];  [APVV 0603-06];  [APVV 0631-07];  [LPP-032606];  [LPP-0353-06];  [LPP-0354-06];  [LPP-0363-06]	This work was supported by research Grants VEGA 210144/08; 2/6183/26 and 2/5101/27, APVV 0603-06, APVV 0631-07, LPP-032606, LPP-0353-06, LPP-0354-06 and LPP-0363-06.	Abel A, 2001, HUM MOL GENET, V10, P107, DOI 10.1093/hmg/10.2.107; Alexis NE, 1996, BRAIN RES, V706, P273, DOI 10.1016/0006-8993(95)01180-3; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Biernaskie J, 2001, J NEUROSCI, V21, P5272, DOI 10.1523/JNEUROSCI.21-14-05272.2001; BURES J, 1983, TECHNIQUES BASIC EXP, P77; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Chen JL, 2001, J NEUROL SCI, V189, P49, DOI 10.1016/S0022-510X(01)00557-3; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; COMBS DJ, 1987, STROKE, V18, P503, DOI 10.1161/01.STR.18.2.503; Crawley JN, 1997, HORM BEHAV, V31, P197, DOI 10.1006/hbeh.1997.1382; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Goettl VM, 2001, BRAIN RES, V906, P92, DOI 10.1016/S0006-8993(01)02559-8; GOLDSTEIN LB, 1990, BEHAV NEUROSCI, V104, P320, DOI 10.1037/0735-7044.104.2.320; Hrnkova M, 2007, BRAIN RES, V1130, P206, DOI 10.1016/j.brainres.2006.10.085; Hunter AJ, 2000, NEUROPHARMACOLOGY, V39, P806, DOI 10.1016/S0028-3908(99)00262-2; IRWIN S, 1968, PSYCHOPHARMACOLOGIA, V13, P222, DOI 10.1007/BF00401402; Katsuoka F, 2003, MOL CELL BIOL, V23, P1163, DOI 10.1128/MCB.23.4.1163-1174.2003; KUNKELBAGDEN E, 1993, EXP NEUROL, V119, P153, DOI 10.1006/exnr.1993.1017; Lalonde R, 2004, BRAIN RES BULL, V64, P251, DOI 10.1016/j.brainresbull.2004.07.011; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lu DY, 2002, CELL TRANSPLANT, V11, P275; Mahmood A, 2006, J NEUROSURG, V104, P272, DOI 10.3171/jns.2006.104.2.272; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McManamny P, 2002, HUM MOL GENET, V11, P2103, DOI 10.1093/hmg/11.18.2103; Rogers DC, 1997, STROKE, V28, P2060, DOI 10.1161/01.STR.28.10.2060; Rogers DC, 1997, MAMM GENOME, V8, P711, DOI 10.1007/s003359900551; Ulrich PT, 1998, STROKE, V29, P2412, DOI 10.1161/01.STR.29.11.2412; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; WAHL F, 1992, STROKE, V23, P267, DOI 10.1161/01.STR.23.2.267; Zausinger S, 2000, BRAIN RES, V863, P94, DOI 10.1016/S0006-8993(00)02100-4; Zhang RL, 1997, BRAIN RES, V766, P83, DOI 10.1016/S0006-8993(97)00580-5; Zilka N, 2006, FEBS LETT, V580, P3582, DOI 10.1016/j.febslet.2006.05.029	34	32	32	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	FEB 15	2009	177	1					108	114		10.1016/j.jneumeth.2008.09.027			7	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	398BM	WOS:000262706300013	18977247				2021-06-18	
J	Yoganandan, N; Gennarelli, TA; Zhang, JY; Pintar, FA; Takhounts, E; Ridella, SA				Yoganandan, Narayan; Gennarelli, Thomas A.; Zhang, Jiangyue; Pintar, Frank A.; Takhounts, Erik; Ridella, Stephen A.			Association of Contact Loading in Diffuse Axonal Injuries From Motor Vehicle Crashes	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Brain trauma; Motor vehicle crash; Head contact; Mechanism of injury; Biomechanics	TRAUMATIC BRAIN-INJURY; ODONTOID FRACTURE; UNITED-STATES; HEAD-INJURY; IMPACT; MECHANISM; DAMAGE; NERVE	Background: Although studies have been conducted to analyze brain injuries from motor vehicle crashes, the association of head contact has not been fully established. This study examined ciation in occupants sustaining diffuse axonal injuries (DAIs). Methods: The 1997 to 2006 motor vehicle Crash Injury Research Engineering Network database was used. All crash modes and all changes in velocity were included; ejections and rollovers were excluded; injuries to front and rear seat occupants with and without restraint use were considered. DAI were coded in the database using Abbreviated Injury Scale 1990. Loss of consciousness was included and head contact was based on medical-and crash-related data. Results: Sixty-seven occupants with varying ages were coded with DAL Forty-one adult occupants (mean, 33 years of age, 171-cm tall, 71-kg weight; 30 drivers, 11 passengers) were analyzed. Mean change in velocity was 41.2 km/h and Glasgow Coma Scale score was 4. There were 33 lateral, 6 frontal, and 2 rear crashes with 32 survivors and 9 were fatalities. Two occupants in the same crash did not sustain DAL Although skull fractures and scalp injuries occurred in some impacts, head contact was identified in all frontal, rear, and far side, and all but one nearside crashes. Conclusions: Using a large sample size of occupants sustaining DAI in 1991 to 2006 model year vehicles, DAI occurred more frequently in side than frontal crashes, is most commonly associated with impact load transfer, and is not always accompanied by skull fractures. The association of head contact in >95% of cases underscores the importance of evaluating crash-related variables and medical information for trauma analysis. It would be prudent to include contact loading in addition to angular kinematics the analysis and characterization of DAL	[Yoganandan, Narayan; Gennarelli, Thomas A.; Zhang, Jiangyue; Pintar, Frank A.] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Yoganandan, Narayan; Gennarelli, Thomas A.; Zhang, Jiangyue] VA Med Ctr, Milwaukee, WI USA; [Takhounts, Erik; Ridella, Stephen A.] US Dept Transportat, Natl Highway Traff Safety Adm US, Human Injury Res Div, Washington, DC USA	Yoganandan, N (corresponding author), Med Coll Wisconsin, Dept Neurosurg, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.	yoga@mcw.edu					ABEL J, 1978, 22ND P STAPP CAR CRA, P33; Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; ADAMS JH, 1991, J NEUROL NEUROSUR PS, V54, P481, DOI 10.1136/jnnp.54.6.481; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1984, LANCET, V2, P1420; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; *AIS, 1990, ABBR INJ SCAL; Anderson RWG, 2003, J NEUROTRAUM, V20, P961, DOI 10.1089/089771503770195812; Augenstein J, 2000, Annu Proc Assoc Adv Automot Med, V44, P57; Augenstein J, 2005, Annu Proc Assoc Adv Automot Med, V49, P361; Augenstein J, 1999, P ANN C ASS, P139; Augenstein Jeffrey, 2003, Annu Proc Assoc Adv Automot Med, V47, P561; Augenstein Jeffrey, 2003, Annu Proc Assoc Adv Automot Med, V47, P99; Gennarelli T, 1996, NEUROSURGERY, V2, P2611; Gennarelli T.A., 1971, P 15 STAPP CAR CRASH, V39, P797; Gennarelli T. A., 1998, SEM CLIN NEUR, V3, P160; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENNARELLI TA, 1987, DIR DEP AX BRAIN INJ, P49; Gennarelli TA, 1972, P 16 STAPP CAR CRASH, P296; Graham D I, 1988, Prog Clin Biol Res, V264, P159; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; HODGSON VR, 1983, 27 STAPP CAR CRASH C, P225; IMAJO T, 1992, AM J FOREN MED PATH, V13, P169; Imajo T, 1996, AM J FOREN MED PATH, V17, P324, DOI 10.1097/00000433-199612000-00010; IMAJO T, 1984, AM J FOREN MED PATH, V5, P217, DOI 10.1097/00000433-198409000-00005; IMAJO T, 1987, AM J FOREN MED PATH, V8, P217, DOI 10.1097/00000433-198708030-00004; Kirkeby A., 2003, SOCIAL IMPACT TECHNO, P1; MARGULIES S S, 1989, Journal of Biomechanical Engineering, V111, P241; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MCLEAN AJ, 1995, J NEUROTRAUM, V12, P621, DOI 10.1089/neu.1995.12.621; MEANEY D, 1994, ROTATIONAL BRAIN INJ; MONCLUS J, ROAD ACCIDENT INVEST; Moran SG, 2002, J TRAUMA, V52, P1116, DOI 10.1097/00005373-200206000-00015; MOURADIAN WH, 1978, ORTHOP CLIN N AM, V9, P985; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pintar F A, 2000, Annu Proc Assoc Adv Automot Med, V44, P149; Pintar Frank A, 2008, Ann Adv Automot Med, V52, P185; Reiff DA, 2004, J TRAUMA, V57, P1324, DOI 10.1097/01.TA.0000141888.20402.2C; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; SANCES A, 1981, CRC CR REV BIOM ENG, V5, P79; Siegel JH, 2001, J TRAUMA, V51, P975, DOI 10.1097/00005373-200111000-00024; SINSON G, 2002, J NEUROTRAUM, V19, P1342; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Sosin DM, 1996, BRAIN INJURY, V10, P47; STRICH SJ, 1961, LANCET, V2, P443; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; USEPA, 1990, FED REG; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Yoganandan N, 2005, J NEUROSURG-SPINE, V2, P481, DOI 10.3171/spi.2005.2.4.0481; Yoganandan N, 2005, ACCIDENT ANAL PREV, V37, P505, DOI 10.1016/j.aap.2005.01.002; YOGANANDAN N, 2000, ACCIDENTAL INJURY BI, P550; ZAOUK A, 2001, SAE WORLD C DETR MI, P77; Zhang Jiangyue, 2006, Annu Proc Assoc Adv Automot Med, V50, P1	56	32	35	1	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	FEB	2009	66	2					309	315		10.1097/TA.0b013e3181692104			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	408NX	WOS:000263442800004	19204502				2021-06-18	
J	Cook, NL; Vink, R; Donkin, JJ; van den Heuvel, C				Cook, Naomi L.; Vink, Robert; Donkin, James J.; van den Heuvel, Corinna			Validation of Reference Genes for Normalization of Real-Time Quantitative RT-PCR Data in Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						real-time PCR; substance P; quantitation; rats; neurotrauma	POLYMERASE CHAIN-REACTION; MESSENGER-RNA; HOUSEKEEPING GENES; REVERSE TRANSCRIPTION; EDEMA FORMATION; RIBOSOMAL-RNA; BETA-ACTIN; INTERNAL CONTROL; SUBSTANCE-P; EXPRESSION	Careful validation of reference genes used for the normalization of real-time RT-PCR data is required to obtain accurate results regarding gene expression. We evaluated the stability of seven commonly used reference genes in the cerebral cortex and hippocampus of rats 3 days following traumatic brain injury (TBI). HPRT, SDHA, and GUSB were found to be the most stable reference genes in the cerebral cortex, whereas B2MG, TBP, and GAPDH were the most stable in the hippocampus. The use of three reference genes was determined to be the optimal number for accurate normalization of data. To illustrate this point, when our gene of interest, substance P (SP), was normalized against the three most stable reference genes in both brain areas, we found no significant difference between injured and uninjured rats at the 3-day time point. However, when our SP data were normalized to each reference gene individually, SP mRNA level was highly variable depending on the reference gene chosen. The results of the present study highlight the importance of validating reference genes to be used for real-time RT-PCR analysis. The use of the most stable reference genes presented here will allow more accurate normalization of gene expression data in TBI. (C) 2008 Wiley-Liss, Inc.	[van den Heuvel, Corinna] Univ Adelaide, Sch Med Sci, Discipline Pathol, Adelaide, SA 5005, Australia	van den Heuvel, C (corresponding author), Univ Adelaide, Sch Med Sci, Discipline Pathol, Adelaide, SA 5005, Australia.	corinna.vandenheuvel@adelaide.edu.au	Cook, Naomi L/B-2536-2012; Cook, Naomi L/P-1223-2019; Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019	Cook, Naomi L/0000-0002-1830-2432; Cook, Naomi L/0000-0002-1830-2432; Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667; , Corinna/0000-0003-0664-8935	Neurosurgical Research Foundation of Australia; NHMRC Dora Lush Biomedical Postgraduate ScholarshipNational Health and Medical Research Council of Australia	Neurosurgical Research Foundation of Australia; Contract grant sponsor: NHMRC Dora Lush Biomedical Postgraduate Scholarship (to N.L.C.).	Aerts JL, 2004, BIOTECHNIQUES, V36, P84, DOI 10.2144/04361ST04; Backman CM, 2006, MOL CELL ENDOCRINOL, V252, P160, DOI 10.1016/j.mce.2006.03.013; Bas A, 2004, SCAND J IMMUNOL, V59, P566, DOI 10.1111/j.0300-9475.2004.01440.x; Boutros PC, 2004, BIOINFORMATICS, V20, P2399, DOI 10.1093/bioinformatics/bth257; Brown R, 2008, NEUROSCI LETT, V432, P73, DOI 10.1016/j.neulet.2007.12.008; Bustin SA, 2005, J MOL ENDOCRINOL, V34, P597, DOI 10.1677/jme.1.01755; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; BUSTIN SA, 2005, ENCY DIAGNOSTIC GENO; Cormio M, 1997, J CLIN NEUROSCI, V4, P132, DOI 10.1016/S0967-5868(97)90062-X; Dheda K, 2004, BIOTECHNIQUES, V37, P112, DOI 10.2144/04371RR03; Dheda K, 2005, ANAL BIOCHEM, V344, P141, DOI 10.1016/j.ab.2005.05.022; Donkin JJ, 2007, PROG BRAIN RES, V161, P97, DOI 10.1016/S0079-6123(06)61007-8; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; Freeman WM, 1999, BIOTECHNIQUES, V26, P112, DOI 10.2144/99261rv01; Glare EM, 2002, THORAX, V57, P765, DOI 10.1136/thorax.57.9.765; Haller F, 2004, ANAL BIOCHEM, V335, P1, DOI 10.1016/j.ab.2004.08.024; Hellemans J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-2-r19; Heo JH, 2005, FREE RADICAL BIO MED, V39, P51, DOI 10.1016/j.freeradbiomed.2005.03.035; Huggett J, 2005, GENES IMMUN, V6, P279, DOI 10.1038/sj.gene.6364190; Jain M, 2006, BIOCHEM BIOPH RES CO, V345, P646, DOI 10.1016/j.bbrc.2006.04.140; Ke LD, 2000, MOL CELL PROBE, V14, P127, DOI 10.1006/mcpr.2000.0288; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; Klein D, 2002, TRENDS MOL MED, V8, P257, DOI 10.1016/S1471-4914(02)02355-9; Larner SF, 2005, J NEUROCHEM, V94, P97, DOI 10.1111/j.1471-4159.2005.03172.x; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Li Q, 2003, MOL BRAIN RES, V114, P46, DOI 10.1016/S0169-328X(03)00131-1; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Meldgaard M, 2006, J NEUROSCI METH, V156, P101, DOI 10.1016/j.jneumeth.2006.02.008; Moriya Y, 2006, BIOL PHARM BULL, V29, P535, DOI 10.1248/bpb.29.535; Nimmo AJ, 2004, NEUROPEPTIDES, V38, P40, DOI 10.1016/j.npep.2003.12.003; Nolan T, 2006, NAT PROTOC, V1, P1559, DOI 10.1038/nprot.2006.236; Pascale CL, 2006, J PHYSIOL PHARMACOL, V57, P161; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pohjanvirta R, 2006, CHEM-BIOL INTERACT, V160, P134, DOI 10.1016/j.cbi.2006.01.001; Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; Schroeder A, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-3; Shein NA, 2007, BRAIN RES, V1185, P313, DOI 10.1016/j.brainres.2007.09.024; Sifringer M, 2007, NEUROBIOL DIS, V25, P526, DOI 10.1016/j.nbd.2006.10.019; Smith RD, 2003, BIOTECHNIQUES, V34, P88, DOI 10.2144/03341st05; Sturzenbaum SR, 2001, COMP BIOCHEM PHYS B, V130, P281, DOI 10.1016/S1096-4959(01)00440-7; Tricarico C, 2002, ANAL BIOCHEM, V309, P293, DOI 10.1016/S0003-2697(02)00311-1; Turner RJ, 2006, ACTA NEUROCHIR SUPPL, V96, P263; Turner RJ, 2004, J AM COLL NUTR, V23, p534S, DOI 10.1080/07315724.2004.10719397; Ullmannova V, 2003, FOLIA BIOL-PRAGUE, V49, P211; UNTERGASSER A, 2007, NUCL ACIDS IN PRESS; van Wijngaarden P, 2007, MOL VIS, V13, P1508; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Vink R, 2003, ACT NEUR S, V86, P257; Wilhelm J, 2003, CHEMBIOCHEM, V4, P1120, DOI 10.1002/cbic.200300662; Wong ML, 2005, BIOTECHNIQUES, V39, P484, DOI 10.2144/000112064; Wong ML, 2005, BIOTECHNIQUES, V39, P75, DOI 10.2144/05391RV01; Yao XL, 2007, BRAIN RES, V1182, P116, DOI 10.1016/j.brainres.2007.08.076; Zhong H, 1999, BIOCHEM BIOPH RES CO, V259, P523, DOI 10.1006/bbrc.1999.0815; Zhu LJ, 2005, ANAL BIOCHEM, V345, P102, DOI 10.1016/j.ab.2005.07.028	56	32	32	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JAN	2009	87	1					34	41		10.1002/jnr.21846			8	Neurosciences	Neurosciences & Neurology	397QX	WOS:000262678300004	18711751				2021-06-18	
J	Crack, P; Gould, J; Bye, N; Ross, S; Ali, U; Habgood, M; Morganti-Kossman, C; Saunders, N; Hertzog, P				Crack, Peter J.; Gould, Jodee; Bye, Nicole; Ross, Shelley; Ali, Ugur; Habgood, Mark D.; Morganti-Kossman, Cristina; Saunders, Norman R.; Hertzog, Paul J.		Victorian Neurotrauma Research Grp	The genomic profile of the cerebral cortex after closed head injury in mice: effects of minocycline	JOURNAL OF NEURAL TRANSMISSION			English	Article						Traumatic brain injury; Microarray; Mouse; Minocycline	TRAUMATIC BRAIN-INJURY; DIFFERENTIAL REGULATION; MICROGLIAL ACTIVATION; NERVOUS-SYSTEM; NEUTROPHIL INFILTRATION; INFLAMMATORY RESPONSE; CEREBROSPINAL-FLUID; BARRIER FUNCTION; TRANSGENIC MICE; CELL-DEATH	Microarray analysis was used to delineate gene expression patterns and profile changes following traumatic brain injury (TBI) in mice. A parallel microarray analysis was carried out in mice with TBI that were subsequently treated with minocycline, a drug proposed as a neuroprotectant in other neurological disorders. The aim of this comparison was to identify pathways that may be involved in secondary injury processes following TBI and potential specific pathways that could be targeted with second generation therapeutics for the treatment of neurotrauma patients. Gene expression profiles were measured with the compugen long oligo chip and real-time PCR was used to validate microarray findings. A pilot study of effect of minocycline on gene expression following TBI was also carried out. Gene ontology comparison analysis of sham TBI and minocycline treated brains revealed biological pathways with more genes differentially expressed than predicted by chance. Among 495 gene ontology categories, the significantly different gene ontology groups included chemokines, genes involved in cell surface receptor-linked signal transduction and pro-inflammatory cytokines. Expression levels of some key genes were validated by real-time quantitative PCR. This study confirms that multiple regulatory pathways are affected following brain injury and demonstrates for the first time that specific genes and molecular networks are affected by minocycline following brain injury.	[Crack, Peter J.; Ali, Ugur; Habgood, Mark D.; Saunders, Norman R.] Univ Melbourne, Dept Pharmacol, Parkville, Vic 3010, Australia; [Gould, Jodee; Ross, Shelley; Hertzog, Paul J.] Monash Univ, Monash Inst Med Res, Clayton, Vic 3168, Australia; [Bye, Nicole; Morganti-Kossman, Cristina] Alfred Hosp, Natl Trauma Inst, Melbourne, Vic, Australia	Crack, P (corresponding author), Univ Melbourne, Dept Pharmacol, Parkville, Vic 3010, Australia.	pcrack@unimelb.edu.au	Crack, Peter J/A-1980-2011; Hertzog, Paul J/I-7053-2013; Hertzog, Paul J/G-6734-2013; Crack, Peter/ABE-2065-2020	Hertzog, Paul J/0000-0002-1373-8472; Hertzog, Paul J/0000-0002-1373-8472; Crack, Peter/0000-0002-5030-0330; Saunders, Norman/0000-0001-6660-7639; Morganti-Kossmann, Cristina/0000-0002-0807-2063			Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Bacon K, 2003, CYTOKINE, V21, P48, DOI 10.1016/S1043-4666(02)00493-3; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P627, DOI 10.1007/s004010000232; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Chen ZG, 2005, J NEUROBIOL, V62, P207, DOI 10.1002/neu.20099; Crack PJ, 2005, FREE RADICAL BIO MED, V38, P1433, DOI 10.1016/j.freeradbiomed.2005.01.019; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Fassbender K, 2000, NEUROSCI LETT, V284, P135, DOI 10.1016/S0304-3940(00)00977-0; Gebicke-Haerter PJ, 2005, J NEUROSCI RES, V81, P327, DOI 10.1002/jnr.20479; Gilchrist M, 2006, NATURE, V441, P173, DOI 10.1038/nature04768; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Hans VHJ, 1999, NEUROREPORT, V10, P409; Herrera DG, 1996, PROG NEUROBIOL, V50, P83, DOI 10.1016/S0301-0082(96)00021-4; Jiang SX, 2005, J BIOL CHEM, V280, P33811, DOI 10.1074/jbc.M503113200; Jo D, 2005, NAT MED, V11, P892, DOI 10.1038/nm1269; Kamm K, 2006, J TRAUMA, V60, P152, DOI 10.1097/01.ta.0000196345.81169.a1; Kandli M, 2000, GENOMICS, V68, P187, DOI 10.1006/geno.2000.6293; Kaplin AI, 2005, J CLIN INVEST, V115, P2731, DOI 10.1172/JCI25141; Kraus RL, 2005, J NEUROCHEM, V94, P819, DOI 10.1111/j.1471-4159.2005.03219.x; Leist M, 1998, EXP CELL RES, V239, P183, DOI 10.1006/excr.1997.4026; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; Loddick SA, 1996, NEUROREPORT, V7, P1465, DOI 10.1097/00001756-199606170-00004; Lund EG, 1998, J BIOL CHEM, V273, P34316, DOI 10.1074/jbc.273.51.34316; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Morganti-Kossmann MC, 1999, J NEUROTRAUM, V16, P617, DOI 10.1089/neu.1999.16.617; Ohba N, 2003, MOL BRAIN RES, V115, P147, DOI 10.1016/S0169-328X(03)00181-5; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Pi RB, 2004, J NEUROCHEM, V91, P1219, DOI 10.1111/j.1471-4159.2004.02796.x; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; SHOHAMI E, 1994, ACTA NEUROCHIR, P443; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Stirling DP, 2005, NEUROSCIENTIST, V11, P308, DOI 10.1177/1073858405275175; Tikka T, 2001, J NEUROSCI, V21, P2580, DOI 10.1523/JNEUROSCI.21-08-02580.2001; Truettner JS, 2005, MOL BRAIN RES, V138, P124, DOI 10.1016/j.molbrainres.2005.04.006; Valles A, 2006, NEUROBIOL DIS, V22, P312, DOI 10.1016/j.nbd.2005.11.015; Wang J, 2002, CURR TOP MICROBIOL, V265, P23; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Yrjanheikki J, 1998, P NATL ACAD SCI USA, V95, P15769, DOI 10.1073/pnas.95.26.15769; Zimmer DB, 2005, CELL MOL BIOL, V51, P201, DOI 10.1170/T620	45	32	34	0	8	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0300-9564	1435-1463		J NEURAL TRANSM	J. Neural Transm.	JAN	2009	116	1					1	12		10.1007/s00702-008-0145-1			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	387NB	WOS:000261957800001	19018450				2021-06-18	
J	Hiekkanen, H; Kurki, T; Brandstack, N; Kairisto, V; Tenovuo, O				Hiekkanen, Heli; Kurki, Timo; Brandstack, Nina; Kairisto, Veli; Tenovuo, Olli			Association of injury severity, MRI-results and ApoE genotype with 1-year outcome in mainly mild TBI: A preliminary study	BRAIN INJURY			English	Article						Traumatic brain injury; MRI; ApoE; GCS; PTA; outcome	TRAUMATIC BRAIN-INJURY; APOLIPOPROTEIN-E POLYMORPHISM; DIFFUSE AXONAL INJURY; CLOSED-HEAD INJURY; POSTTRAUMATIC AMNESIA; SCALE; RECOVERY; MODERATE; SEQUELAE; SUSCEPTIBILITY	Primary objective: To study the ability of MRI findings, apolipoprotein E (ApoE) genotype, the Glasgow Coma Score (GCS) and duration of post-traumatic amnesia (PTA) to predict the 1-year outcome in traumatic brain injury (TBI). Research design: A prospective study in unselected emergency room patients with an acute TBI, followed for 1 year. Methods and procedures: Thirty-three consecutive patients were studied. The TBI severity was assessed with GCS and duration of PTA. Brain MRI scans were obtained within 1 week post-injury. The ApoE genotypes were determined by standard methods. The outcome was evaluated with the Head Injury Symptom Checklist and the Glasgow Outcome Scale (extended) 1 year after the injury. The prognostic value of the explanatory variables was evaluated with multiple linear regression analysis. Main outcomes and results: The presence of traumatic axonal injury lesions or contusions in MRI and duration of PTA were independent predictors of poor outcome. The ApoE genotype and GCS were not associated with outcome. Conclusions: In multivariate models, the duration of PTA and acute MRI are the best predictors of 1-year outcome in TBI, whereas the prognostic values of GCS and ApoE are modest. The dominating role of GCS in assessing TBI severity should be questioned.	[Hiekkanen, Heli; Tenovuo, Olli] Turku Univ, Dept Neurol, Cent Hosp, Turku, Finland; [Kurki, Timo; Brandstack, Nina] Turku Univ, Cent Hosp, Dept Radiol, Turku, Finland; [Kairisto, Veli] Turku Univ, Cent Hosp, Dept Clin Chem, Turku, Finland	Tenovuo, O (corresponding author), Univ Turku, Dept Neurol, Kiinanmyllynkatu 4-8, FIN-20520 Turku, Finland.	olli.tenovuo@tyks.fi		Kurki, Timo/0000-0001-5532-3534			Alexander S, 2007, J NEUROTRAUM, V24, P790, DOI 10.1089/neu.2006.0133; ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Babikian T, 2005, PEDIATR NEUROL, V33, P184, DOI 10.1016/j.pediatrneurol.2005.03.015; Bazarian JJ, 2003, BRAIN INJURY, V17, P553, DOI 10.1080/0269905031000070260; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; Boake C, 1996, AM J PHYS MED REHAB, V75, P105, DOI 10.1097/00002060-199603000-00005; Brandstack N, 2006, BRAIN INJURY, V20, P409, DOI 10.1080/02699050500487951; Buechler CM, 1998, J TRAUMA, V45, P429, DOI 10.1097/00005373-199809000-00001; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; Donohoe GG, 2000, CLIN CHEM, V46, P1540; Donohoe GG, 1999, CLIN CHEM, V45, P143; EHNHOLM C, 1986, J LIPID RES, V27, P227; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Ezaki Y, 2006, ACTA RADIOL, V47, P733, DOI 10.1080/02841850600771486; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; GRONWALL D, 1975, LANCET, V2, P995; Horsburgh K, 2000, NEUROBIOL AGING, V21, P245, DOI 10.1016/S0197-4580(00)00097-X; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; JENNETT B, 1975, LANCET, V1, P480; King NS, 1996, J NEUROL NEUROSUR PS, V61, P75, DOI 10.1136/jnnp.61.1.75; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; McFarland K, 2001, CLIN NEUROPSYCHOL, V15, P59, DOI 10.1076/clin.15.1.59.1916; McIntosh TK, 1996, LAB INVEST, V74, P315; MCLEAN A, 1984, NEUROSURGERY, V14, P393, DOI 10.1227/00006123-198404000-00001; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; Nishimoto T, 1998, J BIOMECH ENG-T ASME, V120, P140, DOI 10.1115/1.2834294; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Paterakis K, 2000, J TRAUMA, V49, P1071, DOI 10.1097/00005373-200012000-00016; Ponsford J, 2007, NEUROLOGY, V68, P619, DOI 10.1212/01.wnl.0000254609.04330.9d; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; SCHELTENS P, 1993, J NEUROL SCI, V114, P7, DOI 10.1016/0022-510X(93)90041-V; Smith C, 2006, J NEUROL NEUROSUR PS, V77, P363, DOI 10.1136/jnnp.2005.074617; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; World Health Organization, 2006, NEUR DIS PUBL HLTH C; Zhang LY, 2001, NEUROL RES, V23, P144, DOI 10.1179/016164101101198488	52	32	33	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	5					396	402	PII 910860859	10.1080/02699050902926259			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	439NL	WOS:000265633700003	19408164				2021-06-18	
J	Jang, SH				Jang, Sung Ho			Review of motor recovery in patients with traumatic brain injury	NEUROREHABILITATION			English	Article						Brain injury; motor recovery; rehabilitation; hemiparesis	DIFFUSE AXONAL INJURY; CLOSED-HEAD TRAUMA; TRANSCRANIAL MAGNETIC STIMULATION; BASAL GANGLIA HEMORRHAGE; CORTICOSPINAL TRACT; FUNCTIONAL MRI; TRANSTENTORIAL HERNIATION; FOLLOW-UP; STROKE; CHILDREN	Detailed information about motor recovery is essential for brain rehabilitation because it enables us to establish scientific rehabilitative strategies and predict motor outcome. For this review, we summarized the literature on motor recovery of patients with traumatic brain injury (TBI) in relation to the following: epidemiology of motor weakness, mechanisms of injury that cause motor weakness, course of motor recovery, and mechanisms underlying motor recovery. The motor weakness in patients with TBI is characterized by a low incidence, decreased severity, long recovery time, and good motor outcome when comparing with cognitive or behavior problems following TBI or the motor weakness affecting stroke patients. However, there are few studies describing the course of motor recovery and the underlying mechanisms of motor recovery. Knowledge in the course of recovery and the mechanisms of recovery can alert clinicians to obtain the salient information about the critical period for rehabilitation and the rehabilitative strategies respectively. Therefore, we suggest that further research should focus on these topics.	Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, Taegu 705717, South Korea	Jang, SH (corresponding author), Yeungnam Univ, Coll Med, Dept Phys Med & Rehabil, 317-1 Daemyungdong, Taegu 705717, South Korea.	strokerehab@hanmail.net					ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Ahn YH, 2006, NEUROREHABILITATION, V21, P239; ANDREWS BT, 1991, NEUROSURGERY, V29, P227, DOI 10.1227/00006123-199108000-00010; Binder DK, 2004, NEUROSURGERY, V54, P999, DOI 10.1227/01.NEU.0000115674.15497.09; BOGOUSSLAVSKY J, 1988, STROKE, V19, P1083, DOI 10.1161/01.STR.19.9.1083; Boto GR, 2001, J NEUROSURG, V94, P224, DOI 10.3171/jns.2001.94.2.0224; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; BRUNNSTROM S, 1966, MOVEMENT THERAPY HEM, P34; DELISA JA, 1993, REHABILITATION MED P, P825; DUNCAN PW, 1992, STROKE, V23, P1084, DOI 10.1161/01.STR.23.8.1084; FAHY TJ, 1967, LANCET, V2, P475; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; Han BS, 2007, NEUROREHABILITATION, V22, P151; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P51; Jang SH, 2002, AM J PHYS MED REHAB, V81, P844, DOI 10.1097/00002060-200211000-00007; Jang SH, 2007, J COMPUT ASSIST TOMO, V31, P901, DOI 10.1097/rct.0b013e31804089a6; Jang SH, 2007, NEUROREHABILITATION, V22, P253; JAYAKUMAR PN, 1989, ACTA NEUROCHIR, V97, P114, DOI 10.1007/BF01772820; JENNETT B, 1975, LANCET, V7905, P480; Jorgensen H S, 1999, Phys Med Rehabil Clin N Am, V10, P887; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P406, DOI 10.1016/S0003-9993(95)80568-0; Katz DI, 1998, ARCH PHYS MED REHAB, V79, P488, DOI 10.1016/S0003-9993(98)90060-0; Katz DI, 2004, ARCH PHYS MED REHAB, V85, P865, DOI 10.1016/j.apmr.2003.11.020; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; KATZ DI, 1989, NEUROLOGY, V39, P897, DOI 10.1212/WNL.39.7.897; Kernohan JW, 1929, ARCH NEURO PSYCHIATR, V21, P274, DOI 10.1001/archneurpsyc.1929.02210200030004; Kim DG, 2007, NEUROREHABILITATION, V22, P273; KOTILA M, 1984, STROKE, V15, P1039, DOI 10.1161/01.STR.15.6.1039; LEE JP, 1991, J TRAUMA, V31, P376, DOI 10.1097/00005373-199103000-00011; Lee JW, 2006, J HEAD TRAUMA REHAB, V21, P272, DOI 10.1097/00001199-200605000-00007; MACPHERSON P, 1986, J NEUROL NEUROSUR PS, V49, P29, DOI 10.1136/jnnp.49.1.29; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Mori S, 1999, ANN NEUROL, V45, P265, DOI 10.1002/1531-8249(199902)45:2<265::AID-ANA21>3.0.CO;2-3; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Skoglund TS, 2008, ACTA RADIOL, V49, P98, DOI 10.1080/02841850701561372; Skoglund TS, 2005, ACTA ANAESTH SCAND, V49, P337, DOI 10.1111/j.1399-6576.2005.00624.x; Walker WC, 2007, J REHABIL RES DEV, V44, P975, DOI 10.1682/JRRD.2006.12.0158; Yasokawa YT, 2007, J NEUROTRAUM, V24, P163, DOI 10.1089/neu.2006.0073	43	32	37	0	17	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2009	24	4					349	353		10.3233/NRE-2009-0489			5	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	481VH	WOS:000268839800008	19597273				2021-06-18	
J	Lane-Brown, AT; Tate, RL				Lane-Brown, A. T.; Tate, R. L.			Apathy after acquired brain impairment: A systematic review of non-pharmacological interventions	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Apathy; Traumatic brain injury; Dementia; Cerebrovascular accident; Hydrocephalus	MULTISENSORY STIMULATION; DAY-CARE; DEMENTIA; PEOPLE; REHABILITATION; RELIABILITY; DEPRESSION; STRATEGIES; MANAGEMENT; DISORDERS	Apathy commonly occurs after acquired brain impairment. It is characterised by impaired initiative, diminished activity, and lack of concern; formally delineated as a decrease in cognitive, behavioural and emotional components of goal-directed activity. The impact is widespread, hampering rehabilitation and outcome. This systematic review identifies and assesses the efficacy of non-pharmacological treatments for apathy following four types of acquired brain impairment (traumatic brain injury, dementia, cerebrovascular accident, encephalitis). Nine databases were searched. Studies were reviewed according to the following criteria: age over 16 years, acquired brain impairment, non-pharmacological intervention for apathy, and data reported on treatment efficacy. The methodological quality of the studies was assessed. Searches yielded 1754 articles, with 28 meeting criteria. Methodological quality ranged greatly. The majority of trials involved the dementia population. Cognitive interventions were the most frequent mode of treatment. For those with severe impairments, the strongest evidence suggested music therapy and for milder impairment, the strongest evidence was for cognitive rehabilitation. This review reveals a need for more high quality, methodologically rigorous treatment studies for apathy, particularly within the milder ranges of impairment. Initially, however, a uniform operational definition needs to be utilised in all research studies to minimise variability. Additionally, employing a standardised outcome measure specific to apathy would greatly enhance comparison among treatments.	Univ Sydney, Rehabil Studies Unit, Sydney, NSW 2006, Australia; Royal Rehabil Ctr, Sydney, NSW, Australia	Lane-Brown, AT (corresponding author), Rehabil Studies Unit, POB 6, Ryde, NSW 1680, Australia.	amandal@med.usyd.edu.au			Rehabilitation Studies Unit, University of SydneyUniversity of Sydney; Northern Medical Research Foundation; Northern Clinical School, University of SydneyUniversity of Sydney; Australian Government through an Australian Postgraduate AwardAustralian Government	This study was supported by the University of Sydney and funding has been provided by the Rehabilitation Studies Unit, University of Sydney; the Northern Medical Research Foundation and the Northern Clinical School, University of Sydney; and the Australian Government through an Australian Postgraduate Award.	Adam S, 2000, NEUROPSYCHOL REHABIL, V10, P485, DOI 10.1080/09602010050143568; Altus Deborah E, 2002, J Gerontol Nurs, V28, P47; Baker R, 2003, J ADV NURS, V43, P465, DOI 10.1046/j.1365-2648.2003.02744.x; Baker R, 2001, BRIT J CLIN PSYCHOL, V40, P81, DOI 10.1348/014466501163508; Baker R, 1997, BR J OCCUP THER, V60, P213; Boyle PA, 2004, DEMENT GERIATR COGN, V17, P91, DOI 10.1159/000074280; BURKE W H, 1991, Brain Injury, V5, P241, DOI 10.3109/02699059109008095; Campbell JJ, 1997, PSYCHIAT ANN, V27, P44, DOI 10.3928/0048-5713-19970101-11; Chapman SB, 2004, J SPEECH LANG HEAR R, V47, P1149, DOI 10.1044/1092-4388(2004/085); Chatterjee A, 2002, J NEUROPSYCH CLIN N, V14, P461, DOI 10.1176/appi.neuropsych.14.4.461; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; DEPOY E, 1990, Occupational Therapy in Health Care, V7, P101, DOI 10.1080/J003v07n01_09; Droes RM, 2004, INT J GERIATR PSYCH, V19, P673, DOI 10.1002/gps.1142; DUFFY JD, 2006, GUIDE NEUROPSYCHIATR; Evans JJ, 1998, J INT NEUROPSYCH SOC, V4, P399, DOI 10.1017/S1355617798003993; Finnema E, 2005, INT J GERIATR PSYCH, V20, P330, DOI 10.1002/gps.1286; Finset A, 2000, BRAIN INJURY, V14, P887; Fitzpatrick K., 2003, CITY COMMUNITY, V2, P33, DOI DOI 10.1111/1540-6040.00037; GIACINO JT, 1995, ARCH PHYS MED REHAB, V76, P205; Gigliotti CM., 2004, DEMENTIA, V3, P161, DOI [10.1177/1471301204042335, DOI 10.1177/1471301204042335]; Glenn MB, 2002, BRAIN INJURY, V16, P509, DOI 10.1080/02699050110119132; GLISKY EL, 1988, NEUROPSYCHOLOGIA, V26, P173, DOI 10.1016/0028-3932(88)90041-3; Graff M.J., 2006, DEMENTIA, V5, P503, DOI [10.1177/1471301206069918, DOI 10.1177/1471301206069918]; Harvey Lisa, 2002, Physiother Res Int, V7, P1, DOI 10.1002/pri.236; Holmes C, 2006, INT PSYCHOGERIATR, V18, P623, DOI 10.1017/S1041610206003887; Hope K W, 1998, J Psychiatr Ment Health Nurs, V5, P377; Hozumi S, 1996, INT J NEUROSCI, V88, P1; Johnson JR, 1997, PHYS OCCUPATIONAL TH, V15, P15; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kirsch-Darrow L, 2006, NEUROLOGY, V67, P33, DOI 10.1212/01.wnl.0000230572.07791.22; Lane-Brown A, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006341.pub2; Macauley BL, 2006, J REHABIL RES DEV, V43, P357, DOI 10.1682/JRRD.2005.01.0027; Maher CG, 2003, PHYS THER, V83, P713, DOI 10.1093/ptj/83.8.713; Mai N, 1991, NEUROPSYCHOL REHABIL, V1, P45, DOI DOI 10.1080/09602019108401379; Marin RA, 2005, TXB TRAUMATIC BRAIN, P337; MARIN RS, 1991, PSYCHIAT RES, V38, P143, DOI 10.1016/0165-1781(91)90040-V; MARIN RS, 1991, J NEUROPSYCH CLIN N, V3, P243; MARIN RS, 1990, AM J PSYCHIAT, V147, P22; Marit RS, 2005, J HEAD TRAUMA REHAB, V20, P377, DOI 10.1097/00001199-200507000-00009; Mazaux JM, 1997, ARCH PHYS MED REHAB, V78, P1316, DOI 10.1016/S0003-9993(97)90303-8; McAllister T W, 2000, Semin Clin Neuropsychiatry, V5, P275, DOI 10.1053/scnp.2000.9557; Mickus MA., 2002, J MENTAL HLTH AGING, V8, P37; MILLARD KAO, 1989, J MUSIC THER, V26, P58; Newburn G, 2005, BRAIN INJURY, V19, P149, DOI 10.1080/02699050410001719989; PERDICES M, 2006, BRAIN IMPAIR, V7, P119, DOI DOI 10.1375/BRIM.7.2.119; PERDICES M, NEUROPSYCHO IN PRESS; Politis AM, 2004, INT J GERIATR PSYCH, V19, P1087, DOI 10.1002/gps.1215; Roth Robert M, 2007, Curr Treat Options Neurol, V9, P363, DOI 10.1007/s11940-007-0022-5; Rusted J., 2006, GROUP ANAL, V39, P517, DOI [10.1177/0533316406071447, DOI 10.1177/0533316406071447]; Sherratt K, 2004, AGING MENT HEALTH, V8, P233, DOI 10.1080/13607860410001669769; SMITH RB, 1994, BRAIN INJURY, V8, P357, DOI 10.3109/02699059409150986; SOHLBERG MM, 1988, COGNITIVE REHABILITA, V6, P36; Spaull D., 1998, BEHAV COGN PSYCHOTH, V26, P77, DOI DOI 10.1017/S1352465898000083; Stuss DT., 2000, DIFFERENTIATION STAT, P340; Tate R, 2004, NEUROPSYCHOL REHABIL, V14, P517, DOI 10.1080/09602010343000182; Tate RL, 2008, NEUROPSYCHOL REHABIL, V18, P385, DOI 10.1080/09602010802009201; Tenovuo O, 2005, PROG NEURO-PSYCHOPH, V29, P61, DOI 10.1016/j.pnpbp.2004.10.006; van Reekum R, 2005, J NEUROPSYCH CLIN N, V17, P7, DOI 10.1176/appi.neuropsych.17.1.7; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; WILSON B, 1987, J CLIN EXP NEUROPSYC, V9, P527, DOI 10.1080/01688638708410767; WONGPAKARAN N, 2007, DIRECTIONS PSYCHIAT, V27, P261	62	32	35	1	20	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2009	19	4					481	516		10.1080/09602010902949207			36	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	539EJ	WOS:000273236100001	19533496				2021-06-18	
J	Thomas, ML; Youngjohn, JR				Thomas, Michael L.; Youngjohn, James R.			Let's Not Get Hysterical: Comparing the MMPI-2 Validity, Clinical, and RC Scales in TBI Litigants Tested for Effort	CLINICAL NEUROPSYCHOLOGIST			English	Article						RC scale; Traumatic brain injury; Symptom validity test; MMPI-2; Litigation	FAKE-BAD-SCALE; MULTIPHASIC PERSONALITY-INVENTORY; TRAUMATIC BRAIN-INJURY; HEAD-INJURY; SYMPTOMATOLOGY; PROFILES; PATTERNS; IMPACT	The MMPI-2 restructured clinical (RC) scales replace the traditional clinical scales in the MMPI-2 restructured form (MMPI-2-RF). Few studies to date have examined the MMPI-2 RC scales in traumatic brain injury (TBI) litigants. We compared MMPI-2 validity, clinical, and RC scales profiles of 83 mild, complicated mild, and moderate/severe TBI litigants who were tested for effort. Past research shows that patients referred for neuropsychological evaluations with mild TBIs paradoxically have higher MMPI-2 clinical scale elevations than patients with moderate/severe TBIs. Failure on cognitive symptom validity tests (SVTs) has also been associated with elevated validity and clinical scales profiles. The oconversion Vo (elevated Hs and Hy, followed by D) is the most frequent elevated profile configuration in mild TBI and/or SVT failure. We sought to determine if these patterns of symptom reporting would replicate on the RC scales profile. Archival data from independent neuropsychological examinations were used to correlate TBI severity, cognitive test effort as indicated by SVTs, and MMPI-2 profiles. Results suggest that the validity, clinical, and RC scales profiles all correlate well with indices of cognitive test effort (namely that failure on SVTs is correlated with elevated symptom reporting). In addition, the validity scales profile, but not the clinical or RC scales profiles, was significantly inversely related to TBI severity. Discriminant function analyses suggest that the MMPI-2 RC scales can aid in the diagnosis of over-reported TBI symptomatology. However, RC3the RC equivalent of the Hy scaleno longer appears to serve as a marker of somatization and/or malingering.	[Thomas, Michael L.] Arizona State Univ, Scottsdale, AZ USA; [Youngjohn, James R.] Neuropsychol Clin, Scottsdale, AZ USA	Youngjohn, JR (corresponding author), 7533 E 1st St, Scottsdale, AZ 85251 USA.	drjyoungjohn@aol.com					Arbisi PA, 2008, J PERS ASSESS, V90, P122, DOI 10.1080/00223890701845146; BENPORATH YS, 2007, M NAT AC NEUR SCOTTS; Berry DTR, 1995, PSYCHOL ASSESSMENT, V7, P517; BINDER LM, 1993, PORTLAND DIGIT RECOG; Boone KB, 1999, CLIN NEUROPSYCHOL, V13, P414; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; BURKE J M, 1990, Brain Injury, V4, P223, DOI 10.3109/02699059009026171; Butcher JN, 2006, J PERS ASSESS, V87, P186, DOI 10.1207/s15327752jpa8702_08; Downing SK, 2008, CLIN NEUROPSYCHOL, V22, P680, DOI 10.1080/13854040701562825; Enders CK, 2003, MEAS EVAL COUNS DEV, V36, P40, DOI 10.1080/07481756.2003.12069079; Finn SE, 2006, J PERS ASSESS, V87, P202, DOI 10.1207/s15327752jpa8702_10; Forbey JD, 2008, J PERS ASSESS, V90, P136, DOI 10.1080/00223890701845161; GASS CS, 1991, J CLIN PSYCHOL, V47, P253, DOI 10.1002/1097-4679(199103)47:2<253::AID-JCLP2270470210>3.0.CO;2-A; Gough HG, 1946, J CLIN PSYCHOL, V2, P23, DOI 10.1002/1097-4679(194601)2:1<23::AID-JCLP2270020105>3.0.CO;2-Y; Graham JR, 1990, MMPI 2 ASSESSING PER; Green P., 1995, MANUAL ORAL WORD MEM; Greiffenstein M.F., 2007, ASSESSMENT FEIGNED C, P210; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; Greiffenstein MF, 2001, CLIN NEUROPSYCHOL, V15, P162, DOI 10.1076/clin.15.2.162.1895; Greve KW, 2006, CLIN NEUROPSYCHOL, V20, P816, DOI 10.1080/13854040500346610; Henry GK, 2008, CLIN NEUROPSYCHOL, V22, P919, DOI 10.1080/13854040701625853; Jackson D. N., 1970, CURRENT TOPICS CLIN, V2, P60; Kaemmer B, 2001, MMPI-2: Manual for Administration and Scoring; Kurtz JE, 2007, J PERS ASSESS, V88, P66, DOI 10.1207/s15327752jpa8801_09; Lanyon RI, 2002, J AM ACAD PSYCHIATRY, V30, P400; Lanyon RI., 1997, PERSONALITY ASSESSME; Larrabee GJ, 1998, CLIN NEUROPSYCHOL, V12, P179, DOI 10.1076/clin.12.2.179.2008; LeesHaley PR, 1997, J CLIN PSYCHOL, V53, P745, DOI 10.1002/(SICI)1097-4679(199711)53:7<745::AID-JCLP13>3.3.CO;2-7; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; LEININGER B E, 1991, Brain Injury, V5, P199, DOI 10.3109/02699059109008090; Maxwell S. E., 1992, ADV SOCIAL SCI METHO, V2, P137; McKinley JC, 1944, J APPL PSYCHOL, V28, P153, DOI 10.1037/h0059245; Miller LJ, 2001, BRAIN INJURY, V15, P297, DOI 10.1080/026990501750111238; Nelson NW, 2007, J INT NEUROPSYCH SOC, V13, P440, DOI 10.1017/S1355617707070373; Nelson NW, 2006, CLIN NEUROPSYCHOL, V20, P39, DOI 10.1080/13854040500459322; Nichols DS, 2006, J PERS ASSESS, V87, P121, DOI 10.1207/s15327752jpa8702_02; Nitch S. R., 2007, ASSESSMENT FEIGNED C, P78; NOVACK TA, 1984, INT J CLIN NEUROPSYC, V6, P139; Osberg TM, 2008, J PERS ASSESS, V90, P81, DOI 10.1080/00223890701693801; POPE KS, 1993, MMPI MMPI 2 MMPI A C; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Rogers R, 2006, J PERS ASSESS, V87, P139, DOI 10.1207/s15327752jpa8702_03; Sellbom M, 2008, J PERS ASSESS, V90, P129, DOI 10.1080/00223890701845153; Smart CM, 2008, J INT NEUROPSYCH SOC, V14, P842, DOI 10.1017/S1355617708081034; Smits M, 2008, AM J NEURORADIOL, V29, P506, DOI 10.3174/ajnr.A0852; Tellegen A., 2003, MMPI 2 RESTRUCTURED; Tellegen A., 2008, MMPI 2 RF TECHNICAL; Tellegen A, 2006, J PERS ASSESS, V87, P148, DOI 10.1207/s15327752jpa8702_04; Wallace A, 2005, ASSESSMENT, V12, P290, DOI 10.1177/1073191105276250; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593; Youngjohn JR, 1997, PSYCHOL ASSESSMENT, V9, P177, DOI 10.1037/1040-3590.9.3.177	51	32	32	0	12	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2009	23	6					1067	1084	PII 910192198	10.1080/13854040902795000			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	473BG	WOS:000268178000010	19343593				2021-06-18	
J	Warner, KJ; Cuschieri, J; Garland, B; Carlbom, D; Baker, D; Copass, MK; Jurkovich, GJ; Bidger, EM				Warner, Keir J.; Cuschieri, Joseph; Garland, Brandon; Carlbom, David; Baker, David; Copass, Michael K.; Jurkovich, Gregory J.; Bidger, Eileen M.			The Utility of Early End-Tidal Capnography in Monitoring Ventilation Status After Severe Injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						End-tidal capnography; Trauma; Ventilation; Prehospital; Emergency department; Intubation	TRAUMATIC BRAIN-INJURY; CARBON-DIOXIDE; TENSION DIFFERENCE; ARTERIAL PCO2; HYPERVENTILATION; ANESTHESIA; IMPACT	Background: An arterial CO2 (Paco(2)) of 30 mm Hg to 39 mm Fig has been shown to be the ideal target range for early ventilation in trauma patients; however, this requires serial arterial blood gases. The use of end-tidal capnography (Etco(2)) has been recommended as a surrogate measure of ventilation in the prehospital arena. This is based on the observation of close Etco(2) Paco(2) correlation in healthy patients, yet trauma patients frequently suffer from impaired pulmonary ventilation/perfusion. Thus, we hypothesize that Etco(2) will demonstrate a poor reflection of actual ventilation status after severe injury. Methods. Prospective observational study on consecutive intubated trauma patients treated in our emergency department (ED) during 9 months. Arterial blood gas values and concomitant Etco(2) levels were recorded. Regression was used to determine the strength of correlation among all trauma patients and subgroups based on injury severity (Abbreviated Injury Score and Injury Severity Score) and physiologic markers of perfusion status (lactate, shock index, and arterial base deficit). Results. During 9 months, 180 patients, were evaluated. The Etco(2) Paco(2) correlation was poor at R-2 = 0.277. Patients ventilated in the recommended Etco(2) (range, 35 to 40) were likely to be under ventilated (Paco(2) > 44) mm Hg) 80% of the time, and severely under ventilated (Paco(2) > 50 mm Hg) 30% of the time. Correlation was best for patients with isolated traumatic brain injury and worst for those with evidence of poor tissue perfusion. Conclusion: Etco(2) has low correlation with Paco(2), and therefore should not be used to guide ventilation in intubated trauma patients in the ED. Better strategies for guiding prehospital and ED ventilation are needed.	[Warner, Keir J.; Cuschieri, Joseph; Jurkovich, Gregory J.; Bidger, Eileen M.] Univ Washington, Harborview Med Ctr, Dept Trauma Surg, Seattle, WA 98104 USA; [Carlbom, David; Baker, David; Copass, Michael K.] Univ Washington, Harborview Med Ctr, Dept Emergency Med, Seattle, WA 98104 USA; [Garland, Brandon] Univ Washington, Sch Med, Seattle, WA 98104 USA	Warner, KJ (corresponding author), Univ Washington, Harborview Med Ctr, Dept Trauma Surg, 325 9Th Ave, Seattle, WA 98104 USA.	keirw@u.washington.edu					BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Belpomme V, 2005, AM J EMERG MED, V23, P852, DOI 10.1016/j.ajem.2005.04.011; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; *BRAIN TRAUM FDN, 2008, GUID PREH MAN TRAUM; *BRAIN TRAUM FDN, 2000, MAN PROGN SEV TRAUM; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Davis D, 2008, RESUSCITATION, V77, P418, DOI 10.1016/j.resuscitation.2008.01.014; Davis D, 2004, ARCHAEOLOGY, V57, P8; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Davis DP, 2004, J TRAUMA, V57, P1, DOI 10.1097/01.TA.0000135503.71684.C8; FLETCHER R, 1984, BRIT J ANAESTH, V56, P109, DOI 10.1093/bja/56.2.109; King RW, 1996, ACAD EMERG MED, V3, P1041, DOI 10.1111/j.1553-2712.1996.tb03351.x; *NAEMT, 2006, PHTLS PREH TRAUM LIF; No authors listed. Rating the severity of tissue damage, 1971, JAMA-J AM MED ASSOC, V215, P277; NUNN JF, 1960, J APPL PHYSIOL, V15, P383; Pepe Paul E, 2004, Crit Care Med, V32, pS414, DOI 10.1097/01.CCM.0000134264.88332.37; Prause G, 1997, RESUSCITATION, V35, P145, DOI 10.1016/S0300-9572(97)00043-9; SHANKAR KB, 1989, CAN J ANAESTH, V36, P124, DOI 10.1007/BF03011432; TEASDALE G, 1974, LANCET, V2, P81; Thomas SH, 2002, J TRAUMA, V52, P47, DOI 10.1097/00005373-200201000-00010; Warner KJ, 2008, J TRAUMA, V64, P341, DOI 10.1097/TA.0b013e318160dfb3; Warner KJ, 2007, J TRAUMA, V62, P1330, DOI 10.1097/TA.0b013e31804a8032; Yosefy C, 2004, EMERG MED J, V21, P557, DOI 10.1136/emj.2003.005819	23	32	35	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JAN	2009	66	1					26	31		10.1097/TA.0b013e3181957a25			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	395SJ	WOS:000262543500003	19131802				2021-06-18	
J	Hansen, TS; Larsen, K; Engberg, AW				Hansen, Trine S.; Larsen, Klaus; Engberg, Aase W.			The Association of Functional Oral Intake and Pneumonia in Patients With Severe Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Deglutition disorders; Pneumonia; Rehabilitation	INTENSIVE-CARE-UNIT; SEVERE HEAD-INJURY; FORMAL SWALLOWING EVALUATION; IMPROVES DYSPHAGIA OUTCOMES; ASPIRATION PNEUMONIA; RISK-FACTORS; GASTROESOPHAGEAL-REFLUX; NOSOCOMIAL PNEUMONIA; STROKE PATIENTS; REHABILITATION	Objectives: To investigate the incidence and onset time of pneumonia for patients with severe traumatic brain injury (TBI) in the early phase of rehabilitation and to identify parameters associated with the risk of pneumonia. Design: Observational retrospective cohort study. Setting: Subacute rehabilitation department in a university hospital in Denmark. Participants: Patients (N=173) aged 16 to 65 years with severe TBI who were admitted during a 5-year period. Patients are transferred to the brain injury unit as soon as they ventilate spontaneously. Interventions: Not applicable. Main Outcome Measure: Pneumonia. Results: Twenty-seven percent of the patients admitted to the brain injury unit were in treatment for pneumonia; pneumonia developed in 12% of the patients during rehabilitation; the condition occurred within 19 days of admission in all but I patient. Of these patients, 81% received nothing by mouth. Three factors identified patients at highest risk of pneumonia: Glasgow Coma Scale score less than 9 (1 day after cessation of sedation); Rancho Los Amigos Scale score less than 3 (on admission); and no oral intake on admission. Having a tracheotomy tube and/or feeding tube was also associated with a higher occurrence of pneumonia. Conclusions: Among patients with severe TBI, 27% had pneumonia at transfer from the intensive care unit. Pneumonia developed in only 12% of the participants during rehabilitation. Patients with a low level of consciousness and patients with a tracheotomy tube or feeding tube had a higher likelihood of pneumonia.	[Hansen, Trine S.; Engberg, Aase W.] Univ Copenhagen, Hvidovre Hosp, Dept Neurorehabil, Brain Injury Unit, DK-2650 Hvidovre, Denmark; [Hansen, Trine S.] Univ Copenhagen, Hvidovre Hosp, Dept Occupat Therapy, DK-2650 Hvidovre, Denmark; [Larsen, Klaus] Univ Copenhagen, Hvidovre Hosp, Clin Res Unit, DK-2650 Hvidovre, Denmark	Hansen, TS (corresponding author), Hvidovre Univ Hosp, Dept Neurorehabil 354, Kettegaard Alle 30, DK-2650 Hvidovre, Denmark.	trine.schow@gmail.com					AbeleHorn M, 1997, INTENS CARE MED, V23, P187, DOI 10.1007/s001340050314; AFFOLTER F, 1980, PERCEPTUAL PROCESSES; AHTARIDIS G, 1981, DIGEST DIS SCI, V26, P993, DOI 10.1007/BF01314761; Alp Emine, 2004, Ann Clin Microbiol Antimicrob, V3, P17, DOI 10.1186/1476-0711-3-17; Andermahr J, 2002, INFLAMM RES, V51, P265, DOI 10.1007/PL00000303; Artigas AT, 2001, CRIT CARE MED, V29, P304, DOI 10.1097/00003246-200102000-00015; AVERYSMITH W, 1994, AM J OCCUP THER, V48, P235, DOI 10.5014/ajot.48.3.235; BARTLETT JG, 1974, AM REV RESPIR DIS, V110, P56; BUCKWALTER JA, 1984, OTOLARYNG CLIN N AM, V17, P41; CHEVRET S, 1993, INTENS CARE MED, V19, P256, DOI 10.1007/BF01690545; COLE MJ, 1987, J CLIN GASTROENTEROL, V9, P90, DOI 10.1097/00004836-198702000-00023; Coombes K, 1996, WEGE ANFANG FRUHREHA, P137; COOMBES K, 2001, 1991 2001 JUBILAUMSS; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Crary MA, 2005, ARCH PHYS MED REHAB, V86, P1516, DOI 10.1016/j.apmr.2004.11.049; CROSS AS, 1981, AM J MED, V70, P681, DOI 10.1016/0002-9343(81)90596-9; DAVIES PM, 1994, STARTING AGAIN EARLY; Denes Z, 2004, DISABIL REHABIL, V26, P1163, DOI 10.1080/09638280412331270380; DENT J, 1980, J CLIN INVEST, V65, P256, DOI 10.1172/JCI109667; Deshpande AA, 1997, ARCH PHYS MED REHAB, V78, P350, DOI 10.1016/S0003-9993(97)90224-0; Engberg AW, 2006, ACTA NEUROL SCAND, V113, P178, DOI 10.1111/j.1600-0404.2005.00570.x; FINEGOLD SM, 1991, REV INFECT DIS, V13, pS737; Finucane TE, 1996, LANCET, V348, P1421, DOI 10.1016/S0140-6736(96)03369-7; Granger CV, 1998, ARCH PHYS MED REHAB, V79, P235, DOI 10.1016/S0003-9993(98)90000-4; Hansen TS, 2008, ARCH PHYS MED REHAB, V89, P1556, DOI 10.1016/j.apmr.2007.11.063; HASSETT JM, 1988, SURG GYNECOL OBSTET, V167, P383; Hind JA, 2001, ARCH PHYS MED REHAB, V82, P1661, DOI 10.1053/apmr.2001.28006; Holland A., 1984, LANGUAGE DISORDERS A; HSIEH AHH, 1992, AM REV RESPIR DIS, V146, P290, DOI 10.1164/ajrccm/146.2.290; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; JACOBS S, 1990, JPEN-PARENTER ENTER, V14, P353, DOI 10.1177/0148607190014004353; JENNETT B, 1976, LANCET, V1, P1031; JOHN S, 1994, DYSPHAGIA, V9, P7; Kofteridis DP, 2004, EUR J CLIN MICROBIOL, V23, P888, DOI 10.1007/s10096-004-1245-y; Langmore SE, 1996, SEMIN NEUROL, V16, P329, DOI 10.1055/s-2008-1040991; LAZARUS C, 1987, ARCH PHYS MED REHAB, V68, P79; Leder SB, 2002, DYSPHAGIA, V17, P214, DOI 10.1007/s00455-002-0054-7; Leibovitz A, 2005, ANTIMICROB AGENTS CH, V49, P3566, DOI 10.1128/AAC.49.8.3566-3568.2005; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Mackay LE, 1999, ARCH PHYS MED REHAB, V80, P365, DOI 10.1016/S0003-9993(99)90271-X; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; Magnotti Louis J, 2004, Surg Infect (Larchmt), V5, P237, DOI 10.1089/sur.2004.5.237; Martin Bonnie J. W., 1994, Dysphagia, V9, P1; Munro CL, 2004, AM J CRIT CARE, V13, P25, DOI 10.4037/ajcc2004.13.1.25; NERCELLES P, 2004, AM J INFECT CONTROL, V32, pE48; Niederman MS, 2001, AM J RESP CRIT CARE, V163, P1730, DOI 10.1164/ajrccm.163.7.at1010; Nishiwaki S, 2006, GASTROINTEST ENDOSC, V64, P890, DOI 10.1016/j.gie.2006.06.086; Ramsey DJC, 2003, STROKE, V34, P1252, DOI 10.1161/01.STR.0000066309.06490.B8; Rhoney DH, 2002, NEUROL RES, V24, P613, DOI 10.1179/016164102101200456; Richardson CJ, 2000, AM J SURG, V179, P8; RODRIGUEZ JL, 1991, J TRAUMA, V31, P907, DOI 10.1097/00005373-199107000-00005; SAXE JM, 1994, J TRAUMA, V37, P581, DOI 10.1097/00005373-199410000-00010; Schurr MJ, 1999, J TRAUMA, V46, P817, DOI 10.1097/00005373-199905000-00009; Seidl RO, 2005, OTOLARYNG HEAD NECK, V132, P484, DOI 10.1016/j.otohns.2004.09.047; SHAKER R, 1995, GASTROENTEROLOGY, V108, P1357, DOI 10.1016/0016-5085(95)90682-7; Shariatzadeh MR, 2006, J AM GERIATR SOC, V54, P296, DOI 10.1111/j.1532-5415.2005.00608.x; SPRAY SB, 1976, AM J SURG, V131, P701, DOI 10.1016/0002-9610(76)90181-1; Talbot Ana, 2005, Gerodontology, V22, P77, DOI 10.1111/j.1741-2358.2005.00049.x; Terpenning M, 2002, J AM GERIATR SOC, V50, P584, DOI 10.1046/j.1532-5415.2002.50131.x; Terpenning MS, 2001, J AM GERIATR SOC, V49, P557, DOI 10.1046/j.1532-5415.2001.49113.x; Varela JE, 2004, J AM COLL SURGEONS, V199, pS76; Warren J B, 1983, J Neurosurg Nurs, V15, P194; Woratyla S P, 1995, Conn Med, V59, P643; ZASLER ND, 1993, BRAIN INJURY, V7, P379, DOI 10.3109/02699059309029681	64	32	38	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2008	89	11					2114	2120		10.1016/j.apmr.2008.04.013			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	373PY	WOS:000260985600010	18996240				2021-06-18	
J	Fabbri, A; Servadei, F; Marchesini, G; Stein, SC; Vandelli, A				Fabbri, A.; Servadei, F.; Marchesini, G.; Stein, S. C.; Vandelli, A.			Observational approach to subjects with mild-to-moderate head injury and initial non-neurosurgical lesions	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; PROGNOSTIC-FACTORS; PROPENSITY SCORE; CARE; MANAGEMENT; PREDICTORS; DIAGNOSIS; PROPOSAL; ADULTS; SYSTEM	Background: The model of care for patients with mild-to-moderate head injury and CT-detected lesions that do not require an immediate intervention is a matter of debate. This study compared the effects on outcome of a model based either on observation in a neurosurgical unit (NSU) or in a peripheral hospital (PH), making use of neurosurgical expertise via a teleradiology system. Patients and methods: The investigation reviewed the data that was prospectively collected in 865 cases with mild-to-moderate head injury and positive CT scan, not needing immediate neurosurgical evacuation. Outcome was determined at 6 months. The predictive value of location of observation on outcome was evaluated by logistic regression, after adjustment for the propensity score to the type of observation (calculated on main entry variables). Findings: 700 subjects had a mild head injury, 105 had a moderate injury with GCS 13-11 and 60 with Glasgow Coma Scale (GCS) 10-9. Only 152/865 subjects (17.6%) were admitted to a NSU. During observation, neurosurgery was necessary in 117 cases (13.5%), 74/152 (48.7%) NSU-observed patients and 43/713 (6.0%; p, 0.001) PH-observed cases. The outcome was unfavourable in 18% of the NSU cases versus 10% of the PH cases (p=0.143). After correction for propensity, no significant differences were found between models of observation (NSU vs. PH; odds ratio, 0.92; 95% confidence interval, 0.49 to 1.75). Interpretation: A model of care based on observation in PH with neurosurgical consult by teleradiology system, repeat CT scanning and transfer time 30-60 min to a NSU is not detrimental for subjects with initial non-neurosurgical lesions after mild-to-moderate head injury.	[Fabbri, A.; Vandelli, A.] Azienda USL Forli, Presidio Osped Morgagni Pierantoni, Dipartimento Emergenza, I-47100 Forli, Italy; [Servadei, F.] Univ Parma, Azienda Osped, Unita Operat Neurochirurg, I-43100 Parma, Italy; [Marchesini, G.] Univ Bologna, I-40126 Bologna, Italy; [Stein, S. C.] Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	Fabbri, A (corresponding author), Azienda USL Forli, Presidio Osped Morgagni Pierantoni, Dipartimento Emergenza, Via Forlanini 34, I-47100 Forli, Italy.	dr.andrea.fabbri@gmail.com		Fabbri, Andrea/0000-0002-9837-4638; Marchesini, Giulio/0000-0003-2407-9860; Servadei, Franco/0000-0002-3595-3464	Emergency Medical System	We are grateful to the Emergency Medical System personnel for helpful support.	ASH AS, 1997, RISK ADJUSTMENT MEAS; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Cavuto S, 2006, DRUG DEVELOP RES, V67, P208, DOI 10.1002/ddr.20079; Chalrson ME, 1987, J CHRON DIS, V40, P373; Crimmins DW, 2000, J NEUROL NEUROSUR PS, V68, P8, DOI 10.1136/jnnp.68.1.8; D'Agostino RB, 2007, CIRCULATION, V115, P2340, DOI 10.1161/CIRCULATIONAHA.105.594952; DUBIN DB, 2007, STAT MED, V26, P20; Fabbri A, 2004, J NEUROL NEUROSUR PS, V75, P410, DOI 10.1136/jnnp.2003.016113; Fearnside M, 1998, AUST NZ J SURG, V68, P58, DOI 10.1111/j.1445-2197.1998.tb04638.x; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; MacKenzie EJ, 1999, J TRAUMA, V47, pS34, DOI 10.1097/00005373-199909001-00008; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; NORUSIS MJ, 2004, SPSS PC BASE SYSTEM; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; Servadei F, 2002, BRIT J NEUROSURG, V16, P36, DOI 10.1080/02688690120114255; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Servadei F, 2000, NEUROSURGERY, V46, P70; STEIN SC, 1996, NEUROTRAUMA, P755; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Visca A, 2006, BRIT J NEUROSURG, V20, P82, DOI 10.1080/02688690600682416	26	32	32	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050			J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	OCT	2008	79	10					1180	1185		10.1136/jnnp.2007.135178			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	348XG	WOS:000259242800021	18356255				2021-06-18	
J	Larsen, A; Kolind, K; Pedersen, DS; Doering, P; Pedersen, MO; Danscher, G; Penkowa, M; Stoltenberg, M				Larsen, Agnete; Kolind, Kristian; Pedersen, Dan Sonne; Doering, Peter; Pedersen, Mie Ostergaard; Danscher, Gorm; Penkowa, Milena; Stoltenberg, Meredin			Gold ions bio-released from metallic gold particles reduce inflammation and apoptosis and increase the regenerative responses in focal brain injury	HISTOCHEMISTRY AND CELL BIOLOGY			English	Article						apoptosis; autometallography (AMG); dissolucytosis; gold; immunosuppression; microglia; neuroregeneration; stem cells	NEURAL STEM-CELLS; OXIDATIVE STRESS; REACTIVE ASTROCYTES; INTERLEUKIN-6-DEFICIENT MICE; SODIUM THIOMALATE; TITANIUM IMPLANTS; TISSUE-RESPONSE; IFN-GAMMA; IN-VITRO; NEUROGENESIS	Traumatic brain injury results in loss of neurons caused as much by the resulting neuroinflammation as by the injury. Gold salts are known to be immunosuppressive, but their use are limited by nephrotoxicity. However, as we have proven that implants of pure metallic gold release gold ions which do not spread in the body, but are taken up by cells near the implant, we hypothesize that metallic gold could reduce local neuroinflammation in a safe way. Bio-liberation, or dissolucytosis, of gold ions from metallic gold surfaces requires the presence of disolycytes i.e. macrophages and the process is limited by their number and activity. We injected 20-45 mu m gold particles into the neocortex of mice before generating a cryo-injury. Comparing gold-treated and untreated cryolesions, the release of gold reduced microgliosis and neuronal apoptosis accompanied by a transient astrogliosis and an increased neural stem cell response. We conclude that bio-liberated gold ions possess pronounced anti-inflammatory and neuron-protective capacities in the brain and suggest that metallic gold has clinical potentials. Intra-cerebral application of metallic gold as a pharmaceutical source of gold ions represents a completely new medical concept that bypasses the blood-brain-barrier and allows direct drug delivery to inflamed brain tissue.	[Larsen, Agnete; Doering, Peter; Danscher, Gorm; Stoltenberg, Meredin] Univ Aarhus, Dept Neurobiol, Inst Anat, DK-8000 Aarhus C, Denmark; [Kolind, Kristian; Pedersen, Dan Sonne; Pedersen, Mie Ostergaard; Penkowa, Milena] Univ Copenhagen, Panum Inst, Sect Neuroprotect, DK-2200 Copenhagen, Denmark	Larsen, A (corresponding author), Univ Aarhus, Dept Neurobiol, Inst Anat, DK-8000 Aarhus C, Denmark.	al@neuro.au.dk		Larsen, Agnete/0000-0001-8765-8443			ACARIN L, 1994, J HISTOCHEM CYTOCHEM, V42, P1033, DOI 10.1177/42.8.8027523; Aktas O, 2007, ARCH NEUROL-CHICAGO, V64, P185, DOI 10.1001/archneur.64.2.185; Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; Aschner M, 2002, BRAIN PATHOL, V12, P475; Barker Roger A, 2004, NeuroRx, V1, P472, DOI 10.1007/BF03206631; Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Bondeson J, 1995, BIOCHEM PHARMACOL, V50, P1753, DOI 10.1016/0006-2952(95)02030-6; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Butovsky O, 2005, MOL CELL NEUROSCI, V29, P381, DOI 10.1016/j.mcn.2005.03.005; Cai JL, 2002, DEV BIOL, V251, P221, DOI 10.1006/dbio.2002.0828; CHANG DM, 1990, J RHEUMATOL, V17, P1148; Danscher G, 2002, HISTOCHEM CELL BIOL, V117, P447, DOI 10.1007/s00418-002-0400-8; DANSCHER G, 1981, HISTOCHEMISTRY, V71, P81, DOI 10.1007/BF00592572; Danscher G, 2006, PROG HISTOCHEM CYTO, V41, P57, DOI 10.1016/j.proghi.2006.06.001; Das S, 2008, J NEUROSCI RES, V86, P1199, DOI 10.1002/jnr.21585; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; FELSON DT, 1990, ARTHRITIS RHEUM, V34, P1342; Ferre N, 2006, MINI-REV MED CHEM, V6, P1321, DOI 10.2174/138955706778993049; Futami T, 2000, J PERIODONTOL, V71, P287, DOI 10.1902/jop.2000.71.2.287; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gilbertson RJ, 2007, NAT REV CANCER, V7, P733, DOI 10.1038/nrc2246; Ihrie RA, 2008, CELL TISSUE RES, V331, P179, DOI 10.1007/s00441-007-0461-z; Kang MK, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-15; KOIKE R, 1994, MOL PHARMACOL, V46, P599; Larsen A, 2007, HISTOCHEM CELL BIOL, V128, P1, DOI 10.1007/s00418-007-0295-5; Mhatre M, 2004, J ALZHEIMERS DIS, V6, P147; MOGILNICKA EM, 1982, CHEM-BIOL INTERACT, V40, P247, DOI 10.1016/0009-2797(82)90104-1; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Morshead CM, 2003, EUR J NEUROSCI, V18, P76, DOI 10.1046/j.1460-9568.2003.02727.x; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Okano H, 2007, J NEUROCHEM, V102, P1459, DOI 10.1111/j.1471-4159.2007.04674.x; Parent JM, 2003, NEUROSCIENTIST, V9, P261, DOI 10.1177/1073858403252680; Paxinos G., 1997, MOUSE BRAIN STEREOTA; Penkowa M, 2000, GLIA, V32, P271, DOI 10.1002/1098-1136(200012)32:3<271::AID-GLIA70>3.0.CO;2-5; PENKOWA M, 1995, GLIA, V13, P217, DOI 10.1002/glia.440130308; Penkowa M, 2006, J NEUROSCI RES, V83, P974, DOI 10.1002/jnr.20790; Penkowa M, 2004, J NEUROSCI RES, V77, P35, DOI 10.1002/jnr.20154; Penkowa M, 2003, EXP NEUROL, V181, P130, DOI 10.1016/S0014-4886(02)00051-1; Penkowa M, 1999, GLIA, V25, P343; PERSELLIN RH, 1966, ARTHRITIS RHEUM-US, V9, P57, DOI 10.1002/art.1780090107; Potashkin JA, 2006, ANTIOXID REDOX SIGN, V8, P144, DOI 10.1089/ars.2006.8.144; Roach P, 2007, J MATER SCI-MATER M, V18, P1263, DOI 10.1007/s10856-006-0064-3; Santos E, 2008, DEV NEUROBIOL, V68, P31, DOI 10.1002/dneu.20566; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; SENNERBY L, 1993, J MATER SCI-MATER M, V4, P494, DOI 10.1007/BF00120129; SHARMA RP, 1981, CLIN EXP PHARMACOL P, V8, P591, DOI 10.1111/j.1440-1681.1981.tb00771.x; Simard AR, 2004, NEUROREPORT, V15, P2305, DOI 10.1097/00001756-200410250-00001; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; TOZMAN ECS, 1987, MED TOXICOL ADV DRUG, V2, P177, DOI 10.1007/BF03259863; Turrin NP, 2006, MOL NEUROBIOL, V34, P221, DOI 10.1385/MN:34:3:221; Vaccarino FM, 2007, NEUROSCIENTIST, V13, P173, DOI 10.1177/1073858406298336; Van Raay TJ, 2001, DEV GENES EVOL, V211, P453, DOI 10.1007/s004270100174; Walton NM, 2006, GLIA, V54, P815, DOI 10.1002/glia.20419; YANNI G, 1994, ANN RHEUM DIS, V53, P315, DOI 10.1136/ard.53.5.315; Zhang RL, 2005, NEUROSCIENTIST, V11, P408, DOI 10.1177/1073858405278865	57	32	32	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0948-6143	1432-119X		HISTOCHEM CELL BIOL	Histochem. Cell Biol.	OCT	2008	130	4					681	692		10.1007/s00418-008-0448-1			12	Cell Biology; Microscopy	Cell Biology; Microscopy	344BT	WOS:000258901000006	18542984				2021-06-18	
J	Tallon, JM; Ackroyd-Stolarz, S; Karim, SA; Clarke, DB				Tallon, John M.; Ackroyd-Stolarz, Stacy; Karim, Saleema A.; Clarke, David B.			The epidemiology of surgically treated acute subdural and epidural hematomas in patients with head injuries: a population-based study	CANADIAN JOURNAL OF SURGERY			English	Article							TRAUMATIC BRAIN-INJURY; NONOPERATIVE MANAGEMENT; PREHOSPITAL CARE; LIFE-SUPPORT; MORTALITY; INTUBATION; TRANSPORT; SYSTEM; IMPACT	Background: The purpose of this paper is to review the population-based epidemiology of surgically treated post-traumatic epidural hematomas (EDHs) and/or subdural hematomas (SDHs) among patients who presented to the single neurosurgical centre in Nova Scotia. Methods: We included all patients aged 16 years or older who presented to the tertiary care hospital with acute post-traumatic EDHs and/or SDHs between May 23, 1996, and May 22, 2005, and who were surgically treated. We generated an initial cohort from the provincial trauma registry and reviewed a total of 152 charts for possible inclusion; 70 (46%) patients met the study criteria. We performed a blinded, explicit chart review using a standardized data collection form, and we generated descriptive statistics. Results: Of the patients who had surgery, 34 (49%) presented with SDHs, 23 (33%) presented with EDHs and 13 (19%) presented with both conditions. The median age was 45 years, and 80% of the cohort was male. The major mechanisms of injury were falls (11%), motor vehicle collisions ( 30%) and assault (11%). More than half (61%) of patients were transferred from referring hospitals while the remainder (39%) arrived directly without an intermediate facility. There were 18 postoperative deaths ( 26%). Forty-four of 70 patients (63%) had associated good outcomes at 6 months (Glasgow Outcome Scale). Conclusion: Acute post-traumatic EDHs and/or SDHs are relatively rare (0.83/100 000 population per annum) and are generally associated with good outcomes. Death was more likely among older, more severely injured patients and among those who required surgery for SDH rather than EDH.	[Tallon, John M.; Ackroyd-Stolarz, Stacy] Dalhousie Univ, Dept Emergency Med, Halifax, NS, Canada; [Karim, Saleema A.] Dalhousie Univ, Capital Dist Hlth Author, Nova Scotia Trauma Program, Halifax, NS, Canada; [Clarke, David B.] Dalhousie Univ, Dept Surg, Div Neurosurg, Halifax, NS B3H 4H2, Canada	Clarke, DB (corresponding author), Halifax Infirm, Div Neurosurg, 1796 Summer St,Rm 3807, Halifax, NS B3H 3A7, Canada.	d.clarke@dal.ca		Karim, Saleema/0000-0002-8946-9897			Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BIROS MH, 2002, ROSENS EMERGENCY MED, V1, P286; Brazier H, 1999, J ACCID EMERG MED, V16, P18; Callaham M, 1997, ANN EMERG MED, V30, P785, DOI 10.1016/S0196-0644(97)70049-0; Chesnut Randall M., 1997, Emergency Medicine Clinics of North America, V15, P581, DOI 10.1016/S0733-8627(05)70319-9; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Coats TJ, 1999, J ACCID EMERG MED, V16, P182; COLOHAN ART, 1989, J NEUROSURG, V71, P202, DOI 10.3171/jns.1989.71.2.0202; Davis DP, 2007, PREHOSP EMERG CARE, V11, P1, DOI 10.1080/10903120601021093; De Souza M, 2007, J TRAUMA, V63, P370, DOI 10.1097/TA.0b013e318124a95b; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Hebb MO, 2007, CAN J SURG, V50, P187; HEDGES JR, 1982, J TRAUMA, V22, P989, DOI 10.1097/00005373-198212000-00003; HUNT J, 1995, AUST NZ J SURG, V65, P83, DOI 10.1111/j.1445-2197.1995.tb07266.x; JACOBS LM, 1984, J TRAUMA, V24, P8, DOI 10.1097/00005373-198401000-00002; Jager TE, 2000, ACAD EMERG MED, V7, P134, DOI 10.1111/j.1553-2712.2000.tb00515.x; KLAUBER MR, 1985, J NEUROSURG, V62, P528, DOI 10.3171/jns.1985.62.4.0528; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liberman M, 2000, J TRAUMA, V49, P584, DOI 10.1097/00005373-200010000-00003; Lind CRP, 2005, ANZ J SURG, V75, P858, DOI 10.1111/j.1445-2197.2005.03574.x; LOKKEBERG AR, 1984, J NEUROSURG, V61, P254, DOI 10.3171/jns.1984.61.2.0254; MacKenzie EJ, 2000, EPIDEMIOL REV, V22, P112, DOI 10.1093/oxfordjournals.epirev.a018006; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; McKhann GM, 1996, NEUROTRAUMA, P103; Meyer SH, 1996, PRACTICE NEUROSURGER, V2, P1443; Mitchell AD, 2007, CAN J SURG, V50, P129; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; *NAT TRAUM REG, 2008, CIHI ICIS; Nathens AB, 2000, JAMA-J AM MED ASSOC, V283, P1990, DOI 10.1001/jama.283.15.1990; Offner PJ, 2006, AM J SURG, V192, P801, DOI 10.1016/j.amjsurg.2006.08.047; Pitts LH, 1998, J TRAUMA, V44, P989; Rinker CF, 1998, J TRAUMA, V44, P984, DOI 10.1097/00005373-199806000-00009; Sampalis JS, 1995, J TRAUMA, V39, P1029, DOI 10.1097/00005373-199512000-00002; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; STONE JL, 1986, J TRAUMA, V26, P445, DOI 10.1097/00005373-198605000-00006; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; Tallon JM, 2006, J TRAUMA, V60, P548, DOI 10.1097/01.ta.0000209336.66283.ea; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; VALADKA AB, 1996, TRAUMA, P267; WALD SL, 1995, SURG CLIN N AM, V75, P225, DOI 10.1016/S0039-6109(16)46585-0; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Ward J D, 1991, Neurosurg Clin N Am, V2, P251; Wester T, 1999, J TRAUMA, V46, P914, DOI 10.1097/00005373-199905000-00023; WHO, 2007, INT CLASS DIS ICD; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Wu JJ, 1999, J TRAUMA, V47, P39, DOI 10.1097/00005373-199907000-00009; Zink BJ, 2001, ANN EMERG MED, V37, P318, DOI 10.1067/mem.2001.113505; NOVA SCOTIA CANADA	56	32	33	0	4	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA	0008-428X	1488-2310		CAN J SURG	Can. J. Surg.	OCT	2008	51	5					339	345					7	Surgery	Surgery	353CM	WOS:000259543700011	18841222				2021-06-18	
J	French, LM; Parkinson, GW				French, Louis M.; Parkinson, Glenn W.			Assessing and treating veterans with traumatic brain injury	JOURNAL OF CLINICAL PSYCHOLOGY			English	Article						traumatic brain injury; posttraumatic stress disorder; explosive devices; psychotherapy; case example	POSTTRAUMATIC-STRESS-DISORDER; IRAQ; AFGHANISTAN; CARE; POLYTRAUMA; MILITARY; PATTERNS; SOLDIERS; BLAST	Conflicts in Iraq and Afghanistan have resulted in greater proportions of service members with traumatic brain injury than in prior conflicts. These brain injuries range from the mild (concussion) to severe, and have enormous implications for clinical practice with these soldiers. The highly stressful and dangerous context in which these injuries are sustained set them apart in significant ways from brain injuries seen in civilian settings. The associated emotional toll of the environment and comorbid injuries, often resulting from blast exposure, complicates the clinical picture. In this article, the authors describe the complex presentations in this population of traumatically brain injured combat veterans and illustrate with case vignettes. (c) 2008 Wiley Periodicals, Inc.	[French, Louis M.; Parkinson, Glenn W.] Walter Reed Army Med Ctr, Dept Orthopaed & Rehabil, Washington, DC 20307 USA; [French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	French, LM (corresponding author), Walter Reed Army Med Ctr, Dept Orthopaed & Rehabil, Bldg 2A,Room 203,6900 Georgia Avenue NW, Washington, DC 20307 USA.	louis.french@amedd.army.mil	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604			BERNSTEIN N R, 1992, Journal of Burn Care and Rehabilitation, V13, P4, DOI 10.1097/00004630-199201000-00004; *BROOK I, 2008, IR IND; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Frenisy MC, 2006, J TRAUMA, V60, P1018, DOI 10.1097/01-ta.0000215977.00034.c2; GLASSER R, 2007, WASHINGTON POST 0407; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Leskin GA, 2007, J REHABIL RES DEV, V44, pXXIII; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2007, J REHABIL RES DEV, V44, P1027, DOI 10.1682/JRRD.2007.05.0073; Lux WE, 2007, J REHABIL RES DEV, V44, P951, DOI 10.1682/JRRD.2007.01.0009; Murray CK, 2005, MIL MED, V170, P516, DOI 10.7205/MILMED.170.6.516; Peleg K, 2003, AM J EMERG MED, V21, P258, DOI 10.1016/S0735-6757(03)00043-3; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Rudy TE, 2003, CLIN J PAIN, V19, P18, DOI 10.1097/00002508-200301000-00003; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Silver JM, 2005, TXB TRAUMATIC BRAIN; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WARDEN DL, 2005, TXB TRAUMATIC BRAIN, P231; WEINSTEIN EA, 1961, PSYCHIATR, V24, P69; Xydakis MS, 2005, OTOLARYNG HEAD NECK, V133, P497, DOI 10.1016/j.otohns.2005.07.003	25	32	32	0	5	JOHN WILEY & SONS INC	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	0021-9762			J CLIN PSYCHOL	J. Clin. Psychol.	AUG	2008	64	8					1004	1013		10.1002/jclp.20514			10	Psychology, Clinical	Psychology	330ES	WOS:000257922900009	18561183				2021-06-18	
J	Duane, TM; Mayglothling, J; Grandhi, R; Warrier, N; Aboutanos, MB; Wolfe, LG; Malhotra, AK; Ivatury, RR				Duane, Therese M.; Mayglothling, Julie; Grandhi, Ramesh; Warrier, Nisha; Aboutanos, Michel B.; Wolfe, Luke G.; Malhotra, Ajai K.; Ivatury, Rao R.			The effect of anemia and blood transfusions on mortality in closed head injury patients	JOURNAL OF SURGICAL RESEARCH			English	Article						trauma; closed head injury; anemia; transfusion; outcome; mortality	POSTOPERATIVE BACTERIAL-INFECTION; INDEPENDENT RISK-FACTOR; TRAUMA PATIENTS; CRITICAL-CARE; REQUIREMENTS; INCREASES; STRATEGY	Background. The purpose of this study was to determine if anemia in isolated head trauma patients results in a higher mortality rate that would justify a more liberal use of blood transfusions. Methods. A retrospective review of isolated blunt head trauma patients was performed between January 2001 and December 2006. Comparisons were made between survivors and nonsurvivors regarding demographics, laboratory values, transfusions received, and lengths of stay. Results. There were 788 patients with 735 survivors who were significantly younger (46.3 y +/- 21.5 survivors versus 68.9 y +/- 18.8 nonsurvivors, P < 0.0001) and less injured [(ISS: 14.7 +/- 5.2 survivors versus 23.2 +/- 4.7 nonsurvivors, P < 0.0001), (head abbreviated injury severity: 3.7 +/- 0.7 survivors versus 4.7 +/- 0.5 nonsurvivors, P < 0.0001)] than those who died (n = 53). The survivors also had shorter lengths of stay (days) [(ICU: 2.4 +/- 4.2 versus 5.6 +/- 11.7, P = 0.03), (hospital: 6.3 +/- 9.8 versus 7.8 +/- 14.89 P = 0.02)]. Multivariate logistic regression showed age (OR 1.063, CI 1.042-1.084), ISS (OR 1.376, Cl 1.270-1.491), minimum hemoglobin (OR 0.855, Cl 0.732-1.000), and total blood products transfused (OR 1.073, Cl 1.008-1.142) to be independent predictors of mortality with an ROC of 0.942. Outcome was independent of the operative procedures, hematocrit and packed red blood cells transfused at 24, 48, and 72 h. Hemoglobin levels of <8 mg/dL were more predictive of death than >8 mg/dL (P = 0.01). Conclusions. This study supports the need to balance mild anemia with judicious blood product use in the head trauma patient. Given the risk with blood product use, each transfusion should be carefully considered and the patient re-evaluated regularly to determine the need for further intervention. (C) 2008 Elsevier Inc. All rights reserved.	[Duane, Therese M.; Mayglothling, Julie; Grandhi, Ramesh; Warrier, Nisha; Aboutanos, Michel B.; Wolfe, Luke G.; Malhotra, Ajai K.; Ivatury, Rao R.] Virginia Commonwealth Univ, Med Ctr, Div Trauma Crit Care & Emergency Gen Surg, Richmond, VA 23298 USA	Duane, TM (corresponding author), Virginia Commonwealth Univ, Med Ctr, W Hosp, 1200 E Broad St,15th Floor,POB 980454, Richmond, VA 23298 USA.	tmduane@vcu.edu	Ivatury, Rao R./H-2922-2019				Avall A, 1997, ANESTHESIOLOGY, V87, P511, DOI 10.1097/00000542-199709000-00009; Carlson AP, 2006, J TRAUMA, V61, P567, DOI 10.1097/01.ta.0000231768.44727.a2; Carson JL, 1999, TRANSFUSION, V39, P694, DOI 10.1046/j.1537-2995.1999.39070694.x; Chang H, 2000, VOX SANG, V78, P13, DOI 10.1046/j.1423-0410.2000.7810013.x; Claridge JA, 2002, AM SURGEON, V68, P566; Dunne James R, 2004, Surg Infect (Larchmt), V5, P395, DOI 10.1089/sur.2004.5.395; EDNA TH, 1992, J TRAUMA, V33, P659, DOI 10.1097/00005373-199211000-00010; Fransen E, 1999, CHEST, V116, P1233, DOI 10.1378/chest.116.5.1233; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; HEBERT PC, 1995, JAMA-J AM MED ASSOC, V273, P1439, DOI 10.1001/jama.273.18.1439; Hill GE, 2003, J TRAUMA, V54, P908, DOI 10.1097/01.TA.0000022460.21283.53; Malone DL, 2003, J TRAUMA, V54, P898, DOI 10.1097/01.TA.0000060261.10597.5C; May AK, 1997, AM SURGEON, V63, P233; McIntyre L, 2004, J TRAUMA, V57, P563, DOI 10.1097/01.TA.0000136158.93864.54; McIntyre LA, 2006, NEUROCRIT CARE, V5, P4, DOI 10.1385/NCC:5:1:4; Moore FA, 1997, ARCH SURG-CHICAGO, V132, P620; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49	17	32	33	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804			J SURG RES	J. Surg. Res.	JUN 15	2008	147	2					163	167		10.1016/j.jss.2008.02.044			5	Surgery	Surgery	306JP	WOS:000256244500001	18498864				2021-06-18	
J	Felker, GM; Anstrom, KJ; Rogers, JG				Felker, G. Michael; Anstrom, Kevin J.; Rogers, Joseph G.			A global ranking approach to end points in trials of mechanical circulatory support devices	JOURNAL OF CARDIAC FAILURE			English	Article						clinical trials; ventricular assist device; end points; heart failure	TRAUMATIC BRAIN-INJURY; HEART-FAILURE; CLINICAL-TRIALS; NEUROPROTECTION; MAGNESIUM; MORTALITY	Background: Although previous studies of mechanical circulatory support devices (MCSDs) have used all-cause mortality as a primary end point, trends in device technology and implementation will increasingly necessitate the use of composite end points for MCSD studies. The ideal composite end point for studies of MCSDs is uncertain. Methods and Results: We reviewed the advantages and disadvantages of traditional composite end points in MCSD studies from both a clinical and statistical perspective. Although composite end points may increase statistical power, they also introduce potential problems in interpretation of data, and in some situations may interpret a given clinical course in ways very different than it would be viewed by patients or providers. A global ranking end point, which ranks various aspects of the clinical course based on a prespecified hierarchical ranking system, may provide many of the advantages of composite end points while avoiding many of the pitfalls. One version of such an end point for use in MCSD studies is proposed. Conclusions: Use of a global ranking end point for incorporating various components of the clinical course into a single end point retains much of the benefit of composite end points while avoiding many of the limitations associated with the use of composites. Adoption of such end points may facilitate the development of MCSD therapy.	[Felker, G. Michael; Anstrom, Kevin J.; Rogers, Joseph G.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC 27705 USA; [Felker, G. Michael; Rogers, Joseph G.] Duke Univ, Sch Med, Div Cardiovasc Med, Durham, NC 27705 USA	Felker, GM (corresponding author), Duke Univ, Sch Med, Duke Clin Res Inst, 2400 Pratt St,Room 0311 Terrace Level, Durham, NC 27705 USA.			Felker, Gary/0000-0002-5931-1239	NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K23 HL072357] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K23HL072357] Funding Source: NIH RePORTER		Baughman KL, 2007, NEW ENGL J MED, V357, P846, DOI 10.1056/NEJMp078131; CALIFF RM, 1990, CIRCULATION, V82, P1847, DOI 10.1161/01.CIR.82.5.1847; Finkelstein DM, 1999, STAT MED, V18, P1341, DOI 10.1002/(SICI)1097-0258(19990615)18:11&lt;1341::AID-SIM129&gt;3.0.CO;2-7; Lachin JM, 1999, CONTROL CLIN TRIALS, V20, P408, DOI 10.1016/S0197-2456(99)00022-7; Maas AI, 2007, LANCET NEUROL, V6, P20, DOI 10.1016/S1474-4422(06)70668-8; McMahon RP, 2000, CONTROL CLIN TRIALS, V21, P305, DOI 10.1016/S0197-2456(00)00052-0; Miller LW, 2007, NEW ENGL J MED, V357, P885, DOI 10.1056/NEJMoa067758; MOYE LA, 1992, STAT MED, V11, P1705, DOI 10.1002/sim.4780111305; Neaton JD, 2007, J CARD FAIL, V13, P63, DOI 10.1016/j.cardfail.2006.12.003; Neaton JD, 2005, J CARD FAIL, V11, P567, DOI 10.1016/j.cardfail.2005.08.350; Normand SLT, 2005, J CARD FAIL, V11, P396, DOI 10.1016/j.cardfail.2005.04.002; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Rogers JG, 2007, J AM COLL CARDIOL, V50, P741, DOI 10.1016/j.jacc.2007.03.063; Rose EA, 2001, NEW ENGL J MED, V345, P1435, DOI 10.1056/NEJMoa012175; Stevenson LW, 2007, J AM COLL CARDIOL, V50, P748, DOI 10.1016/j.jacc.2007.04.071; Temkin NR, 2007, LANCET NEUROL, V6, P29, DOI 10.1016/S1474-4422(06)70630-5; Yusuf S, 2002, AM HEART J, V143, P22, DOI 10.1067/mhj.2002.119770	17	32	32	0	5	CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS	PHILADELPHIA	CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA	1071-9164			J CARD FAIL	J. Card. Fail.	JUN	2008	14	5					368	372		10.1016/j.cardfail.2008.01.009			5	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	313JN	WOS:000256737000002	18514927				2021-06-18	
J	Kirk, C; Nagiub, G; Abu-Arafeh, I				Kirk, Charlotte; Nagiub, George; Abu-Arafeh, Ishaq			Chronic post-traumatic headache after head injuryin children and adolescents	DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY			English	Article							PREVALENCE; MIGRAINE	This was a prospective, observational study of children aged 3 to 15 years admitted to hospital with head injury (HI). Demographic data and information on the nature of the HI, and history of premorbid headache were collected. A structured telephone questionnaire was used to interview parents and children 2 months after injury and at 4-monthly intervals for up to 3 years, if headache was reported. One hundred and ninety children were admitted with HI. Data were available on 117 children (81 males, 36 females; mean age 8y 5mo [SD 3y 1mo]). HI was minor in 93 patients and significant in the rest. Minor HI was defined as a closed injury, no loss of consciousness, and a Glasgow Coma Score (GCS) of 13 to 15. Significant HI was associated with loss of consciousness for > 30 minutes, GCS of < 13, and post-traumatic amnesia for > 48 hours. Eight children (five males, three females; mean age 10y 7mo [SD 2y]) reported chronic post-traumatic headache (CPTH). Five children had episodic tension-type headache and three had migraine with or without aura. Headache resolved over 3 to 27 months in all except one child who was lost to follow-up. Premorbid headache in three children transformed in frequency and type following HI. These patients were excluded from the study. CPTH is common after minor and significant HI. It has the clinical features of tension-type headache and migraine and has a good prognosis.	[Kirk, Charlotte; Nagiub, George; Abu-Arafeh, Ishaq] Stirling Royal Infirm, Dept Paediat, Stirling FK8 2AU, Scotland	Abu-Arafeh, I (corresponding author), Stirling Royal Infirm, Dept Paediat, Stirling FK8 2AU, Scotland.	ishaq.abu-arafeh@fvah.scot.nhs.uk	Abu-Arafeh, Ishaq/H-7417-2019	Abu-Arafeh, Ishaq/0000-0003-1252-0153			ABUAREFEH I, 1994, BRIT MED J, V309, P765, DOI 10.1136/bmj.309.6957.765; *BRIT PAED NEUR AS, 2000, AUD TOOLB HEAD DAT S; Callaghan M, 2001, DEV MED CHILD NEUROL, V43, P819, DOI 10.1017/S0012162201001487; Haas DC, 1996, CEPHALALGIA, V16, P486, DOI 10.1046/j.1468-2982.1996.1607486.x; Hawley CA, 2003, INJURY, V34, P256, DOI 10.1016/S0020-1383(02)00193-6; *INT HEAD SOC HEAD, 2004, CEPHALALGIA, V24, P56; KEIDEL M, 2006, ACUTE POST TRAUMATIC, P863; LANSER JBK, 1988, HEADACHE, V28, P176, DOI 10.1111/j.1526-4610.1988.hed2803176.x; LANZI G, 1985, CEPHALALGIA, V5, P211, DOI 10.1046/j.1468-2982.1985.0504211.x; Moscato Davide, 2005, J Headache Pain, V6, P284, DOI 10.1007/s10194-005-0208-8; *NHS FORTH VALL, 2004, 16 ANN REP DIR PUBL; Packard RC, 1997, HEADACHE, V37, P142, DOI 10.1046/j.1526-4610.1997.3703142.x; RAMADAN NM, 2006, CHRONIC POST TRAUMAT, P873; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x	14	32	32	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0012-1622	1469-8749		DEV MED CHILD NEUROL	Dev. Med. Child Neurol.	JUN	2008	50	6					422	425		10.1111/j.1469-8749.2008.02063.x			4	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	302AC	WOS:000255937200009	18422678	Bronze			2021-06-18	
J	Lu, J; Murray, GD; Steyerberg, EW; Butcher, I; Mchugh, GS; Lingsma, H; Mushkudiani, N; Choi, S; Maas, AIR; Marmarou, A				Lu, Juan; Murray, Gordon D.; Steyerberg, Ewout W.; Butcher, Isabella; Mchugh, Gillian S.; Lingsma, Hester; Mushkudiani, Nino; Choi, Sung; Maas, Andrew I. R.; Marmarou, Anthony			Effects of Glasgow Outcome Scale misclassification on traumatic brain injury clinical trials	JOURNAL OF NEUROTRAUMA			English	Article						clinical trial; Glasgow Outcome Scale; misclassifications; observer variation; power; traumatic brain injury	SEVERE HEAD-INJURY; STRUCTURED INTERVIEWS; RELIABILITY; EXPERIENCE; MULTICENTER; GUIDELINES; MANAGEMENT	The Glasgow Outcome Scale (GOS) is the primary endpoint for efficacy analysis of clinical trials in traumatic brain injury (TBI). Accurate and consistent assessment of outcome after TBI is essential to the evaluation of treatment results, particularly in the context of multicenter studies and trials. The inconsistent measurement or interobserver variation on GOS outcome, or for that matter, on any outcome scales, may adversely affect the sensitivity to detect treatment effects in clinical trial. The objective of this study is to examine effects of nondifferential misclassification of the widely used five-category GOS outcome scale and in particular to assess the impact of this misclassification on detecting a treatment effect and statistical power. We followed two approaches. First, outcome differences were analyzed before and after correction for misclassification using a dataset of 860 patients with severe brain injury randomly sampled from two TBI trials with known differences in outcome. Second, the effects of misclassification on outcome distribution and statistical power were analyzed in simulation studies on a hypothetical 800-patient dataset. Three potential patterns of nondifferential misclassification (random, upward and downward) on the dichotomous GOS outcome were analyzed, and the power of finding treatments differences was investigated in detail. All three patterns of misclassification reduce the power of detecting the true treatment effect and therefore lead to a reduced estimation of the true efficacy. The magnitude of such influence not only depends on the size of the misclassification, but also on the magnitude of the treatment effect. In conclusion, nondifferential misclassification directly reduces the power of finding the true treatment effect. An awareness of this procedural error and methods to reduce misclassification should be incorporated in TBI clinical trials.	[Lu, Juan; Marmarou, Anthony] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA 23298 USA; [Choi, Sung] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23298 USA; [Steyerberg, Ewout W.; Lingsma, Hester; Mushkudiani, Nino] Erasmus MC, Dept Publ Hlth, Ctr Med Decis Sci, Rotterdam, Netherlands; [Murray, Gordon D.; Butcher, Isabella; Mchugh, Gillian S.] Univ Edinburgh, Dept Community Hlth Sci, Edinburgh EH8 9YL, Midlothian, Scotland; [Maas, Andrew I. R.] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium	Marmarou, A (corresponding author), Virginia Commonwealth Univ, Dept Neurosurg, POB 980508, Richmond, VA 23298 USA.	marmarou@vcu.edu	Maas, Andrew IR/C-5584-2013; Steyerberg, Ewout/C-1509-2018	Maas, Andrew IR/0000-0003-1612-1264; Steyerberg, Ewout/0000-0002-7787-0122; Lu, Juan/0000-0002-5389-7603; Murray, Gordon/0000-0001-9866-4734	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R56NS019235, R01NS019235, R01NS042691] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 042691, NS 019235-21] Funding Source: Medline		Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; Bolland K, 1998, STAT MED, V17, P2835, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2835::AID-SIM933>3.3.CO;2-#; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; BULLOCK MR, 2002, FOCUS, V13, pECP1; Choi SC, 2002, J NEUROTRAUM, V19, P17, DOI 10.1089/089771502753460204; Choi SC, 1998, J NEUROTRAUM, V15, P771, DOI 10.1089/neu.1998.15.771; Fayol P., 2004, Annales de Readaptation et de Medecine Physique, V47, P142, DOI 10.1016/j.annrmp.2004.01.004; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; JENNETT B, 1975, LANCET, V1, P480; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MAAS AIR, 1983, J NEUROSURG, V58, P321, DOI 10.3171/jns.1983.58.3.0321; Marmarou A., 2001, HEAD TRAUMA BASIC PR; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; Scheibel RS, 1998, J NEUROTRAUM, V15, P685, DOI 10.1089/neu.1998.15.685; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Wilson JTL, 2007, NEUROSURGERY, V61, P123, DOI 10.1227/01.neu.0000279732.21145.9e; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910	20	32	32	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2008	25	6					641	651		10.1089/neu.2007.0510			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	326BW	WOS:000257633900007	18578634	Green Published			2021-06-18	
J	Mihalik, JP; Guskiewicz, KM; Jeffries, JA; Greenwald, RM; Marshall, SW				Mihalik, J. P.; Guskiewicz, K. M.; Jeffries, J. A.; Greenwald, R. M.; Marshall, S. W.			Characteristics of head impacts sustained by youth ice hockey players	PROCEEDINGS OF THE INSTITUTION OF MECHANICAL ENGINEERS PART P-JOURNAL OF SPORTS ENGINEERING AND TECHNOLOGY			English	Article						accelerometers; biomechanics; concussion; head impact; sports injury		This study aimed to measure the magnitude of head impacts sustained by 14 male, youth (13 years old) ice hockey players wearing instrumented helmets, and to compare impacts across event type (practice, game), player position, and location. Head impact magnitudes were captured during 58 games and 51 practices. Mixed linear models were utilized to analyze differences by event type, player position, and location of impact. Game impact magnitudes were significantly greater than practice impacts. Impacts sustained by forwards were similar in magnitude to those sustained by defensemen. Significant differences between head impact locations across all player positions were observed. Impacts to the top of the head were significantly greater than impacts to the back, front, left, and right sides. Youth ice hockey players sustain helmet impacts nearing 20 g on average, similar to measured values in collegiate American football players, and of potential concern because this sample involves younger athletes. Future biomechanical studies are needed to better interpret the finding that there is an increased likelihood of higher magnitude head impacts to the top of the head. The authors' long-term goal is to improve the understanding of impacts that may lead to concussions in young athletes.	[Mihalik, J. P.; Guskiewicz, K. M.; Jeffries, J. A.] Univ N Carolina, Dept Exercise & Sport Sci, Sports Med Res Lab, Chapel Hill, NC 27599 USA; [Mihalik, J. P.; Guskiewicz, K. M.] Univ N Carolina, Sch Med, Dept Allied Hlth Sci, Chapel Hill, NC 27599 USA; [Guskiewicz, K. M.; Marshall, S. W.] Univ N Carolina, Injury Prevent Res Ctr, Chapel Hill, NC 27599 USA; [Greenwald, R. M.] Simbex LLC, Lebanon, NH USA; [Greenwald, R. M.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA; [Marshall, S. W.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA	Guskiewicz, KM (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Sports Med Res Lab, 204 Fetzer Gymnasium,South Rd, Chapel Hill, NC 27599 USA.		Mihalik, Jason P/E-7059-2010		Ontario Neurotrauma Foundation (Toronto, ON, Canada) [2005-PREV-BANT-387]	This study was supported in part by a grant from the Ontario Neurotrauma Foundation (Toronto, ON, Canada) to the University of North Carolina at Chapel Hill Injury Prevention Research Center (grant number 2005-PREV-BANT-387). Additional thanks are offered to William Montelpare, Ph.D. (Lakehead University; Thunder Bay, Ontario, Canada), and his colleagues for their assistance with this project. We would also like to thank the engineering team at Simbex (Lebanon, New Hampshire, USA) for their continued support of this project.	ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; CHU JJ, 2006 WORLD C BIOM MU; Crisco JJ, 2004, J BIOMECH ENG-T ASME, V126, P849, DOI 10.1115/1.1824135; Duhaime AC, 2006, J NEUROSURG, V104, P259, DOI 10.3171/ped.2006.104.4.259; Duval J, 2002, BRAIN COGNITION, V48, P337, DOI 10.1006/brcg.2001.1373; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin HS, 2003, BRAIN INJURY, V17, P665, DOI 10.1080/0269905031000107151; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; Manoogian S, 2006, BIOMED SCI INSTRUM, V42, P383; Mihalik JP, 2007, NEUROSURGERY, V61, P1229, DOI 10.1227/01.neu.0000306101.83882.c8; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; PUDENZ RH, 1946, J NEUROSURG, V3, P487, DOI 10.3171/jns.1946.3.6.0487; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555	27	32	32	0	7	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1754-3371	1754-338X		P I MECH ENG P-J SPO	Proc. Inst. Mech. Eng. Part P-J. Sport. Eng. Technol.	JUN	2008	222	P1					45	52		10.1243/17543371JSET4			8	Engineering, Mechanical; Sport Sciences	Engineering; Sport Sciences	V13KB	WOS:000207664600006					2021-06-18	
J	Nenadovic, V; Hutchison, JS; Dominguez, LG; Otsubo, H; Gray, MP; Sharma, R; Belkas, J; Velazquez, JLP				Nenadovic, Vera; Hutchison, James S.; Dominguez, Luis Garcia; Otsubo, Hiroshi; Gray, Martin P.; Sharma, Rohit; Belkas, Jason; Velazquez, Jose Luis Perez			Fluctuations in cortical synchronization in pediatric traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						electroencephalography; pediatric TBI; synchrony	PHASE SYNCHRONIZATION; COMPUTED-TOMOGRAPHY; EEG; RADIATION; CHILDREN; PREDICTORS; CANCER; RISKS; TERM; ELECTRODE	Traumatic brain injury (TBI) is the leading cause of death and acquired disability in the pediatric population worldwide. We hypothesized that electroencephalography (EEG) synchrony and its temporal variability, analyzed during the acute phase following TBI, would be altered from that of normal children and as such would offer insights into TBI pathophysiology. Seventeen pediatric patients with mild to severe head injury admitted to a pediatric critical care unit were recruited along with 10 age- and gender-matched controls. Patients had two electroencephalographs performed 3 days apart. Outcome was measured at 1 year post- TBI utilizing the Pediatric Cerebral Performance Category score (PCPC). Maximal synchrony between EEG channels correlated to areas of primary injury as seen on computed tomography (CT) scan. The temporal variability of phase synchronization among EEG electrodes increased as patients recovered and emerged from coma (p < 0.001). This temporal variability correlated with outcome (Pearson coefficient of 0.74) better than the worst Glasgow Coma Scale score, length of coma, or extent of injury on CT scan. This represents a novel approach in the evaluation of TBI in children.	[Nenadovic, Vera; Hutchison, James S.; Dominguez, Luis Garcia; Gray, Martin P.; Belkas, Jason; Velazquez, Jose Luis Perez] Hosp Sick Children, Inst Res, Neurosci & Mental Hlth Program, Toronto, ON M5G 1X8, Canada; [Nenadovic, Vera; Velazquez, Jose Luis Perez] Univ Toronto, Dept Paediat, Toronto, ON M5S 1A1, Canada; [Nenadovic, Vera; Velazquez, Jose Luis Perez] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; [Nenadovic, Vera; Hutchison, James S.; Gray, Martin P.] Hosp Sick Children, Crit Care Med Program, Toronto, ON M5G 1X8, Canada; [Hutchison, James S.] Univ Toronto, Fac Med, Interdept Div Crit Care, Toronto, ON, Canada; [Otsubo, Hiroshi; Velazquez, Jose Luis Perez] Hosp Sick Children, Dept Paediat, Div Neurol, Toronto, ON M5G 1X8, Canada	Velazquez, JLP (corresponding author), Hosp Sick Children, Inst Res, Neurosci & Mental Hlth Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	jose-luis.perez-velazquez@sickkids.ca		Garcia Dominguez, Luis/0000-0002-2671-2845			Armenean C, 2004, MAGN RESON MED, V52, P1200, DOI 10.1002/mrm.20246; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; Bertell R, 2007, INT J HEALTH SERV, V37, P419, DOI 10.2190/7841-2700-348T-041X; Brenner DJ, 2001, MED PHYS, V28, P2387, DOI 10.1118/1.1415074; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Bricolo A, 1979, Acta Neurochir Suppl (Wien), V28, P35; Bricolo A, 1990, HDB CLIN NEUROLOGY, V13, P181; BUCHMAN T, 2006, CURR OPIN CRIT CARE, V10, P378; Bullock TH, 1997, P NATL ACAD SCI USA, V94, P1, DOI 10.1073/pnas.94.1.1; BURNS A, 2004, J NEUROSCI METH, V137, P321; Chodick G, 2007, ISR MED ASSOC J, V9, P584; Coles JP, 2003, ANAESTHESIA, V58, P143, DOI 10.1046/j.1365-2044.2003.02966.x; Dominguez LG, 2005, J NEUROSCI, V25, P8077, DOI 10.1523/JNEUROSCI.1046-05.2005; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Friston KJ, 2001, NEUROSCIENTIST, V7, P406, DOI 10.1177/107385840100700510; Giza CC, 2001, J ATHL TRAINING, V36, P228; Guevara R, 2005, NEUROINFORMATICS, V3, P301, DOI 10.1385/NI:3:4:301; Hagemann D, 2001, PSYCHOPHYSIOLOGY, V38, P847, DOI 10.1017/S0048577201001081; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Kinuya K, 2004, NUCL MED COMMUN, V25, P333, DOI 10.1097/00006231-200404000-00004; Lutz A, 2002, P NATL ACAD SCI USA, V99, P1586, DOI 10.1073/pnas.032658199; Max JE, 2006, J NEUROPSYCH CLIN N, V18, P21, DOI 10.1176/appi.neuropsych.18.1.21; Mormann F, 2000, PHYSICA D, V144, P358, DOI 10.1016/S0167-2789(00)00087-7; Norris PR, 2006, ANN SURG, V243, P804, DOI 10.1097/01.sla.0000219642.92637.fd; Nunez PL, 1997, ELECTROEN CLIN NEURO, V103, P499, DOI 10.1016/S0013-4694(97)00066-7; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; RASLAN A, 2007, FOCUS, V15, pE12; Rice HE, 2007, J PEDIATR SURG, V42, P603, DOI 10.1016/j.jpedsurg.2006.12.009; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Senouci K, 2004, INTENS CARE MED, V30, P38, DOI 10.1007/s00134-003-1923-8; Shaw NA, 2002, PROG NEUROBIOL, V67, P281, DOI 10.1016/S0301-0082(02)00018-7; Shields DC, 2007, SURG NEUROL, V67, P354, DOI 10.1016/j.surneu.2006.09.036; Spencer KM, 2003, J NEUROSCI, V23, P7407; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Thakker JC, 1997, CRIT CARE MED, V25, P1396, DOI 10.1097/00003246-199708000-00030; THATCHER RW, 1986, ELECTROEN CLIN NEURO, V64, P123, DOI 10.1016/0013-4694(86)90107-0; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Thomale UW, 2002, ACTA NEUROCHIR SUPPL, V81, P229; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; TUCKER DM, 1986, ELECTROEN CLIN NEURO, V63, P242, DOI 10.1016/0013-4694(86)90092-1; Van CA, 2003, CURRENT PRACTICE CLI, P463; Vanravenswaaijarts CMA, 1993, ANN INTERN MED, V118, P436, DOI 10.7326/0003-4819-118-6-199303150-00008; Varela F, 2001, NAT REV NEUROSCI, V2, P229, DOI 10.1038/35067550; Vos PE, 2001, J NEUROTRAUM, V18, P649, DOI 10.1089/089771501750357591; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011; WILDE EA, 2007, MAGN RESON MED, V58, P1028	50	32	34	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2008	25	6					615	627		10.1089/neu.2007.0474			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	326BW	WOS:000257633900005	18578633				2021-06-18	
J	Ripley, DL; Harrison-Felix, C; Sendroy-Terrill, M; Cusick, CP; Dannels-McClure, A; Morey, C				Ripley, David L.; Harrison-Felix, Cindy; Sendroy-Terrill, Melissa; Cusick, Christopher P.; Dannels-McClure, Amy; Morey, Clare			The impact of female reproductive function on outcomes after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	67th Annual Meeting of the American-Academy-of-Physical-Medicine-and-Rehabilitation	NOV 09-12, 2006	Honolulu, HI	Amer Acad Phys Med & Rehabil		amenorrhea; brain injuries; outcome assessment (health care); rehabilitation	HEAD-INJURY; NEUROENDOCRINE DYSFUNCTION; STRUCTURED INTERVIEWS; PRACTICAL SCALE; INDIVIDUALS; ABNORMALITIES; HYPOGONADISM; ORIENTATION; RELIABILITY; GENDER	Objectives: To determine the impact of traumatic brain injury (TBI) on female menstrual and reproductive functioning and to examine the relationships between severity of injury, duration of amenorrhea, and TBI outcomes. Design: Retrospective cohort survey. Setting: Telephone interview. Participants: Women (N=30; age range, 18-45y), between 1 and 3 years postinjury, who had completed inpatient rehabilitation for TBI. Interventions: Not applicable. Main Outcome Measures: Data collected included menstrual and reproductive functioning pre- and postinjury, demographic, and injury characteristics. Outcome measures included the Glasgow Outcome Scale-Extended (GOS-E), the Mayo-Portland Adaptability Inventory-4 (MPAI-4), and the Medical Outcome Study 12-Item Short-Form Health Survey, Version 2 (SF-12v2). Results: The median duration of amenorrhea was 61 days (range, 20-344d). Many subjects' menstrual function changed after TBI, reporting a significant increase in skipped menses postinjury (P<.001) and a trend toward more painful menses (P=.061). More severe TBI, as measured by the duration of posttraumatic amnesia, was significantly predictive of a longer duration of amenorrhea (P=.004). Subjects with a shorter duration of amenorrhea scored significantly better on the SF-12 physical component subscale (P=.004), the GOS-E (P=.05), and the MPAI-4 participation subscale (P=.05) after controlling for age, injury severity, and time postinjury. Conclusions: The severity of TBI was predictive of duration of amenorrhea and a shorter duration of amenorrhea was predictive of better ratings of global outcome, community participation, and health-related quality of life postinjury.	[Ripley, David L.] Craig Hosp, CNS Med Grp, Englewood, CO 80113 USA; [Ripley, David L.; Harrison-Felix, Cindy] Univ Colorado, Dept Phys Med & Rehabil, Denver, CO 80202 USA; [Ripley, David L.; Harrison-Felix, Cindy] Univ Colorado, Hlth Sci Ctr, Denver, CO USA	Ripley, DL (corresponding author), Craig Hosp, CNS Med Grp, 3425 S Clarkson, Englewood, CO 80113 USA.	dripley@craighospital.org		Ripley, David/0000-0002-5349-1830			Alaca R, 2002, AM J PHYS MED REHAB, V81, P788, DOI 10.1097/00002060-200210000-00013; Bell K R, 2001, Phys Med Rehabil Clin N Am, V12, P169; BINGYOU RG, 1992, J CLIN ENDOCR METAB, V75, P1054, DOI 10.1210/jc.75.4.1054; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BORN JD, 1985, SURG NEUROL, V23, P383, DOI 10.1016/0090-3019(85)90212-5; Burns A S, 2001, Phys Med Rehabil Clin N Am, V12, P183; Cernak I, 1999, BRAIN INJURY, V13, P1005; Childers MK, 1998, BRAIN INJURY, V12, P517, DOI 10.1080/026990598122476; Coimbra R, 2003, J TRAUMA, V54, P689, DOI 10.1097/01.TA.0000058314.31655.5F; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Ferin M, 1999, J CLIN ENDOCR METAB, V84, P1768, DOI 10.1210/jc.84.6.1768; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; GROSSMAN WF, 1994, J REPROD MED, V39, P738; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; Harrison-Felix C, 2004, NEUROREHABILITATION, V19, P45; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; LEE SC, 1994, BRAIN INJURY, V8, P571; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; MALEC J, 2003, MAYOPORTLAND ADAPTAB; MONGA TN, 1986, ARCH PHYS MED REHAB, V67, P19; Mount DL, 2002, BRAIN INJURY, V16, P1051, DOI 10.1080/02699050210154259; Pettigrew LEL, 2003, J HEAD TRAUMA REHAB, V18, P252, DOI 10.1097/00001199-200305000-00003; *QUALITYMETRIC INC, 2005, SF12V2 QUALITYMETRIC; Richard I., 2001, Annales de Readaptation et de Medecine Physique, V44, P19, DOI 10.1016/S0168-6054(00)00059-3; ROLIH CA, 1995, MED CLIN N AM, V79, P211, DOI 10.1016/S0025-7125(16)30093-1; Sherrill-Pattison S, 2000, CLIN NEUROPSYCHOL, V14, P496, DOI 10.1076/clin.14.4.496.7196; Sipski M L, 2001, Phys Med Rehabil Clin N Am, V12, P79; *SPSS, 2004, SPSS 13 0 WIND VERS; Stein DG, 2003, J HEAD TRAUMA REHAB, V18, P317, DOI 10.1097/00001199-200307000-00004; SUBRAMANIAN M, 1993, NEUROSCI LETT, V155, P151, DOI 10.1016/0304-3940(93)90695-H; Tate D G, 2001, Phys Med Rehabil Clin N Am, V12, P23; TEASDALE G, 1974, LANCET, V2, P81; Wagner AK, 2004, J NEUROTRAUM, V21, P125, DOI 10.1089/089771504322778596; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; Zafonte RD, 1997, AM J PHYS MED REHAB, V76, P246, DOI 10.1097/00002060-199705000-00018	41	32	33	0	4	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	2008	89	6					1090	1096		10.1016/j.apmr.2007.10.038			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	310TN	WOS:000256553400012	18503804				2021-06-18	
J	Curry, R; Hollingworth, W; Ellenbogen, RG; Vavilala, MS				Curry, Rebecca; Hollingworth, Will; Ellenbogen, Richard G.; Vavilala, Monica S.			Incidence of hypo- and hypercarbia in severe traumatic brain injury before and after 2003 pediatric guidelines	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						hyperventilation; traumatic brain injury; outcome; children; PaCO2; hypoventilation	CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; HYPERVENTILATION; CHILDREN; MANAGEMENT; METABOLISM; HYPOTENSION; PRESSURE	Objective: To examine the incidence of severe hypocarbia (PaCO2 < 30 mm Hg) in patients with severe pediatric traumatic brain injury before and after publication of the 2003 pediatric guidelines (PG). Design: Retrospective cohort analysis. Setting. Harborview Medical Center, Seattle, Washington (January 1, 1995, to December 31, 2005). Patients: Children < 15 yrs of age with severe pediatric traumatic brain injury. Interventions: None. Measurements and Main Results: The pre-PG group (before August 1, 2003) included 375 patients and the post-PG group included 89 patients. Post PG guidelines, there was a trend toward earlier (45 vs. 32 mins; p =.05) and more frequent (7.1 vs. 8.4 samples; p =.06) PaCO2 sampling within 48 hrs of admission. Children 0-2 yrs had a longer time (75.0 mins) between admission and first PaCO2 sample than older children (44.3 mins; p <.01). The youngest children also had the highest incidence of severe hypocarbia on the first PaCO2 sample (31% vs. 19%; p =.02). Incidence of severe hypocarbia was high and did not decline (60% vs. 52%; p =.2) after the PG guidelines. However, over the 11 yrs, the odds of severe hypocarbia decreased (adjusted odds ratio 0.9; 95% confidence interval 0.84-0.96). During both periods, the incidence of severe hypocarbia was highest during the first 2 hrs after hospital admission. Intracranial pressure monitors were used more frequently post-PG. In 62 of 82 (77%) patients with severe hypocarbia in whom an intracranial pressure monitor was in place, the preceding intracranial pressure was < 20 mm Hg. Severe hypocarbia independently predicted inpatient mortality (adjusted odds ratio 2.8; 95% confidence interval 1.3-5.9). Conclusions: Although PaCO2 sampling was more frequent during the post-PG period and severe hypocarbia decreased during successive study years, the incidence of severe hypocarbia remained high during the first 48 hrs after hospital admission during the post-PG period. Time to PaCO2 sampling was longer in young children and associated with more severe hypocarbia. The presence of severe hypocarbia predicted mortality.	[Curry, Rebecca] Univ Washington, Sch Med, Seattle, WA 98195 USA; [Hollingworth, Will] Univ Washington, Dept Radiol, Seattle, WA USA; [Hollingworth, Will] Univ Washington, Dept Pharm, Seattle, WA USA; [Ellenbogen, Richard G.; Vavilala, Monica S.] Univ Washington, Dept Neurol Surg, Seattle, WA USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol, Seattle, WA USA; [Hollingworth, Will; Ellenbogen, Richard G.; Vavilala, Monica S.] Harborview Injury Prevent & Res Ctr, Seattle, WA USA	Curry, R (corresponding author), Univ Washington, Sch Med, Seattle, WA 98195 USA.	vavilala@u.washington.edu		Hollingworth, William/0000-0002-0840-6254	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD044632] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23 HD044632-05] Funding Source: Medline		Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; *BRAIN TRAUM FDN, 2003, PEDIATR CRIT CARE ME, V4, P45; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Coates BM, 2005, CRIT CARE MED, V33, P2645, DOI 10.1097/01.CCM.0000186417.19199.9B; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Coles JP, 2002, CRIT CARE MED, V30, P1950, DOI 10.1097/00003246-200209000-00002; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Huizenga JE, 2002, ACAD EMERG MED, V9, P806, DOI 10.1197/aemj.9.8.806; Kokoska ER, 1998, J PEDIATR SURG, V33, P333, DOI 10.1016/S0022-3468(98)90457-2; Langlois JA., 2004, TRAUMATIC BRAIN INJU; McCulloch TJ, 2000, ANESTHESIOLOGY, V93, P1205, DOI 10.1097/00000542-200011000-00012; MUIZELAAR JP, 1989, J NEUROSURG, V71, P63, DOI 10.3171/jns.1989.71.1.0063; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P145, DOI 10.1136/jnnp.58.2.145; SHARPLES PM, 1995, J NEUROL NEUROSUR PS, V58, P153, DOI 10.1136/jnnp.58.2.153; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Vavilala MS, 2003, J TRAUMA, V55, P1039, DOI 10.1097/01.TA.0000101759.23607.57; Zwienenberg M, 1999, J NEUROTRAUM, V16, P937, DOI 10.1089/neu.1999.16.937	23	32	35	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAR	2008	9	2					141	146		10.1097/PCC.0B013e318166870e			6	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	274WP	WOS:000254033800001	18477926				2021-06-18	
J	Mckay, C; Wertheimer, JC; Fichtenberg, NL; Casey, JE				McKay, Cherisse; Wertheimer, Jeffrey C.; Fichtenberg, Norman L.; Casey, Joseph E.			The repeatable battery for the assessment of neuropsychological status (rbans): Clinical utility in a traumatic brain injury sample	CLINICAL NEUROPSYCHOLOGIST			English	Article						psychometrics; RBANS; TBI	IMPAIRMENT	The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS, Randolph, 1998), a neuropsychological screening measure initially designed to assess the cognitive deficits associated with dementia, has since been clinically implemented with other neurological populations including traumatic brain injury ( TBI). This study evaluated the clinical utility ofthe RBANS in a TBIpopulation by comparing the profiles of 51 TBI cases and 34 non-head-injured controls. A cross RBANS' Index Scores, the TBI group performed at a significantly lower level than the controls; sensitivity to TBI and likelihood ratios ranged from modest to strong; and specificity was high. Particularly efficacious was the clinical efficiency exhibited by the Total Scale Index (summary score) of the RBANS.	[McKay, Cherisse; Casey, Joseph E.] Univ Windsor, Windsor, ON N9B 3P4, Canada; [Wertheimer, Jeffrey C.; Fichtenberg, Norman L.] Wayne State Univ, Detroit, MI 48202 USA	Mckay, C (corresponding author), Univ Windsor, 401 Sunset Ave, Windsor, ON N9B 3P4, Canada.	cherissemckay@hotmail.com					Aupperle RL, 2002, MULT SCLER J, V8, P382, DOI 10.1191/1352458502ms832oa; Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Axelrod BN, 2006, CLIN NEUROPSYCHOL, V20, P513, DOI 10.1080/13854040590967117; Beatty WW, 2004, ARCH CLIN NEUROPSYCH, V19, P825, DOI 10.1016/j.acn.2003.12.001; Beatty WW, 2003, ARCH CLIN NEUROPSYCH, V18, P509, DOI 10.1016/S0887-6177(02)00148-8; Carone D.A., 2004, 32 M INT NEUR SOC BA; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Fuhrer MJ, 1987, REHABILITATION OUTCO, P137; JOHNSTONE B, 1995, BRAIN INJURY, V9, P377, DOI 10.3109/02699059509005777; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Larson EB, 2005, J CLIN EXP NEUROPSYC, V27, P16, DOI 10.1080/138033990513564; Larson Eric B, 2003, Top Stroke Rehabil, V9, P10; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; McKay C, 2007, ARCH CLIN NEUROPSYCH, V22, P91, DOI 10.1016/j.acn.2006.11.003; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Randolph C, 1998, J CLIN EXP NEUROPSYC, V20, P310, DOI 10.1076/jcen.20.3.310.823; Randolph C, 1998, REPEATABLE BATTERY A; Reitan RM, 1999, ARCH CLIN NEUROPSYCH, V14, P191, DOI 10.1016/S0887-6177(98)00012-2; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P531, DOI 10.1076/clin.17.4.531.27938; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; SILVERBERG N, 1974, IN PRESS CLIN NEUROP; TERRYBERRYSPOHR L, 2000, ANN M NAT AC NEUR OR; Tombaugh TN, 1996, TEST MEMORY MALINGER	25	32	33	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	MAR	2008	22	2					228	241		10.1080/13854040701260370			14	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	279ZA	WOS:000254393500004	17853143				2021-06-18	
J	Zanini, MA; Resende, LADL; Faleiros, ATDS; Gabarra, RC				Zanini, Marco Antonio; Resende, Luiz Antonio de Lima; Faleiros, Antonio Tadeu de Souza; Gabarra, Roberto Colichio			Traumatic subdural hygromas: Proposed pathogenesis based classification	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						subdural hygroma; pathogenesis; head injury; external hydrocephalus	EXTERNAL HYDROCEPHALUS; COMPUTED-TOMOGRAPHY; ARACHNOID CYST; EVOLUTION; EFFUSION; CSF; PRESSURE; RUPTURE; SURGERY; SPACE	Background: Traumatic subdural hygroma (TSHy) is an accumulation of cerebrospinal fluid (CSF) in the subdural space after head injury. It appears to be relatively common, but its onset time and natural history are not well defined. Considered a benign epiphenomenon of trauma, the pathogenesis of TSHy is still unclear and many questions remain unanswered. This study adds to the information on TSHy, and proposes a classification based on pathogenesis. Methods: Thirty-four consecutive adult patients with TSHy were analyzed for clinical evolution and serial CT scan, during a period of several months. TSHy diagnosis was based on published CT scan criteria of hypodense subdural collection after trauma, without enhancement and neomembrane, with a minimum distance of 3 mm between the skull and brain. Ventricle size was analyzed by calculating the bicaudate index (BCI). For comparison, the BCI was measured from CT scan at three moments: admission, at time of TSHy diagnosis, and from last CT scan. Results: There were 34 patients, aged between 16 and 85 years (mean 40), half of them were below 40 years. Road traffic crashes were the main cause of head injury. The mean time for hygroma diagnosis was 9 days. Twenty-one patients (61.8%) underwent conservative treatment for TSHy and 13 (38.2%), surgical treatment. TSHy are early lesions and can be detected in the first 24 hours after trauma, usually as small subdural effusion (SSEff). Based on clinical and CT scan findings, we divided the 34 patients into 3 groups, (Ia and Ib) without evident mass effect and (II) with evident mass effect. Group Ia includes patients without ventricle dilation; Ib, patients with associated ventricle dilations. Conclusions: SSEff detected in the first 24 hours posttrauma in our series evolved into TSHy suggesting that this is an early lesion; all THSy were divided in three groups according to the pathophysiologic mechanism. These three groups probably represent a continuum of CSF absorption impairment. Group la represents what most authors consider a simple hygroma, with no impairment on CSF absorption. Group Ib represent the external hydrocephalus form with various degrees of CSF imbalance, and group II were the cases presenting marked mass effect.	[Zanini, Marco Antonio; Resende, Luiz Antonio de Lima; Faleiros, Antonio Tadeu de Souza; Gabarra, Roberto Colichio] Sao Paulo State Univ, Sch Med, Dept Neurol & Psychiat, Botucatu, SP, Brazil	Zanini, MA (corresponding author), UNESP, Fac Med Botucatu, Dept Neurol & Psiquiatria, BR-18618970 Botucatu, SP, Brazil.	mzanini@fmb.unesp.br	Zanini, Marco Antonio/L-9691-2019; Zanini, Marco A/A-1413-2008; Zanini, Marco Antonio/M-4898-2019	Zanini, Marco Antonio/0000-0002-5712-9783; Zanini, Marco A/0000-0002-5712-9783; 			Albuquerque FC, 1997, NEUROSURGERY, V41, P951, DOI 10.1097/00006123-199710000-00036; ARNASON O, 1983, ACTA NEUROCHIR, V67, P231, DOI 10.1007/BF01401424; ASANO Y, 1992, NO SHINKEI, V42, P1127; Binder DK, 2002, NEUROSURGERY, V51, P830, DOI 10.1227/01.NEU.0000024286.95876.2F; Borzone M, 1983, J Neurosurg Sci, V27, P161; BRINKMAN SD, 1981, RADIOLOGY, V138, P89, DOI 10.1148/radiology.138.1.7455102; Caldarelli M, 2002, ACTA NEUROCHIR, V144, P581, DOI 10.1007/s00701-002-0947-0; Cardoso ER, 1996, J NEUROSURG, V85, P1143, DOI 10.3171/jns.1996.85.6.1143; Cayli SR, 2000, BRIT J NEUROSURG, V14, P568, DOI 10.1080/02688690050206738; Choong CT, 1998, BRAIN DEV-JPN, V20, P319, DOI 10.1016/S0387-7604(98)00039-4; DANDY WE, 1946, ARCH SURG-CHICAGO, V52, P421, DOI 10.1001/archsurg.1946.01230050428003; Donaldson JW, 2000, PEDIATR NEUROSURG, V32, P137, DOI 10.1159/000028918; ELKADI H, 1998, AM ASS NEUROLOGICAL, P157; ENDTZ LJ, 1978, SURG NEUROL, V10, P305; FRENCH BN, 1978, SURG NEUROL, V9, P145; GURDJIAN ES, 1978, ACTA NEUROCHIR WIE S, V25, P36; HAINES DE, 1993, NEUROSURGERY, V32, P111, DOI 10.1227/00006123-199301000-00017; HASEGAWA M, 1992, NEUROSURGERY, V31, P580, DOI 10.1227/00006123-199209000-00024; HOFF J, 1973, J TRAUMA, V13, P870, DOI 10.1097/00005373-197313100-00005; Huh PW, 2006, J NEUROSURG, V105, P65, DOI 10.3171/jns.2006.105.1.65; Ishibashi Akira, 1994, Kurume Medical Journal, V41, P81; JACCARD E, 1983, NEUROCHIRURGIE, V29, P333; Kalamangalam GP, 2002, ARCH NEUROL-CHICAGO, V59, P1027, DOI 10.1001/archneur.59.6.1027; KAUFMAN HH, 1984, ACTA NEUROCHIR, V72, P197, DOI 10.1007/BF01406870; Kawaguchi T, 1998, NEUROSURGERY, V43, P1033, DOI 10.1097/00006123-199811000-00017; KOIZUMI H, 1981, Neurologia Medico-Chirurgica, V21, P397; KOO AH, 1977, RADIOLOGY, V123, P345, DOI 10.1148/123.2.345; KULALI A, 1989, Neurosurgical Review, V12, P508, DOI 10.1007/BF01790696; Lang JK, 1999, SURG NEUROL, V52, P630, DOI 10.1016/S0090-3019(99)00144-5; Lee KS, 2000, J KOREAN MED SCI, V15, P560, DOI 10.3346/jkms.2000.15.5.560; LEE KS, 1994, BRIT J NEUROSURG, V8, P551, DOI 10.3109/02688699409002947; Lee KS, 1998, BRAIN INJURY, V12, P595, DOI 10.1080/026990598122359; Lee KS, 2000, BRAIN INJURY, V14, P355; LOEW F, 1982, ADV TECHNICAL STANDA, V9, P113; Marmarou A, 1996, J NEUROSURG, V85, P1026, DOI 10.3171/jns.1996.85.6.1026; MASUZAWA T, 1984, NEURORADIOLOGY, V26, P245, DOI 10.1007/BF00342423; MATSUMOTO S, 1986, ADV NEUROTRAUMATOLOG, V1, P157; Mitra S, 2001, NEUROL INDIA, V49, P178; MIZOI K, 1981, CHILD BRAIN, V8, P307; NAFFZIGER HC, 1924, JAMA-J AM MED ASSOC, V82, P1751; OHNO K, 2001, J NEUROL NEUROSUR PS, V32, P1694; OKA H, 1972, ACTA NEUROCHIR, V26, P265, DOI 10.1007/BF01407072; PARK CK, 1994, ACTA NEUROCHIR, V127, P41, DOI 10.1007/BF01808545; PIETILA TA, 1992, ACTA NEUROCHIR, V118, P103, DOI 10.1007/BF01401294; Raftopoulos C, 1996, NEUROSURGERY, V38, P51, DOI 10.1097/00006123-199601000-00014; RENGACHARY SS, 1994, J TRAUMA, V36, P890, DOI 10.1097/00005373-199406000-00025; SCHACHENMAYR W, 1978, AM J PATHOL, V92, P53; SO SK, 1976, J NUCL MED, V17, P119; STJOHN JN, 1981, NEUROSURGERY, V9, P621, DOI 10.1227/00006123-198112000-00002; STONE JL, 1981, NEUROSURGERY, V8, P542, DOI 10.1227/00006123-198105000-00005; TANAKA Y, 1987, SURG NEUROL, V27, P353, DOI 10.1016/0090-3019(87)90010-3; TODOROW S, 1981, NEUROCHIRURGIA, V24, P131; van den Berg JSP, 2002, ANESTH ANALG, V94, P1625, DOI 10.1097/00000539-200206000-00049; WEIR B, 1980, J NEUROSURG, V53, P512, DOI 10.3171/jns.1980.53.4.0512; WETTERLING T, 1986, ACTA NEUROCHIR, V83, P99, DOI 10.1007/BF01402385; WETTERLING T, 1988, ACTA NEUROCHIR, V91, P79, DOI 10.1007/BF01400533; Wippold FJ, 1996, AM J ROENTGENOL, V167, P1061, DOI 10.2214/ajr.167.4.8928696; WYCIS HT, 1945, J NEUROSURG, V2, P340, DOI 10.3171/jns.1945.2.4.0340; YAMADA H, 1980, SURG NEUROL, V13, P441; Yoshimoto Y, 1998, J NEUROSURG, V88, P485, DOI 10.3171/jns.1998.88.3.0485	60	32	39	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2008	64	3					705	713		10.1097/TA.0b013e3180485cfc			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	274JE	WOS:000253996800029	18332811				2021-06-18	
J	Moore, TM; Callaway, CW; Hostler, D				Moore, Tracy M.; Callaway, Clifton W.; Hostler, David			Core temperature cooling in healthy volunteers after rapid intravenous infusion of cold and room temperature saline solution	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	Scientific Assembly of the American-College-of-Emergency-Physicians	SEP 26-29, 2005	Washington, DC	Amer Coll Emergency Phys			CARDIAC-ARREST; HYPOTHERMIA; HUMANS; MEPERIDINE; INDUCTION; CLONIDINE; URAPIDIL; FLUID	Study objective: Studies have suggested that inducing mild hypothermia improves neurologic outcomes after traumatic brain injury, major stroke, traumatic hemorrhage, and cardiac arrest. Although infusion of cold normal saline solution is a simple and inexpensive method for initiating hypothermia, human cold-defense mechanisms potentially make this route stressful or ineffective. We hypothesize that rapid infusion of 30 mL/kg of cold (4 degrees C, 39.2 degrees F) 0.9% saline solution during 30 minutes to healthy subjects (aged 27 [standard deviation (SD) 4] years) will reduce core body temperature to the therapeutic range of 33 degrees C to 35 degrees C (91.4 degrees F to 95 degrees F). Methods: Sixteen subjects were randomly assigned to receive either cold (4 degrees C, 39.2 degrees F) or room temperature (23 degrees C, 73.4 degrees F) normal saline solution. Subjects were not informed of their assignment, but blinding was not possible after initiation of the infusion. Core temperature, skin temperature, and vital signs were recorded every 2 minutes. Subjects indicated global discomfort during the infusion on a 100-mm visual analog scale at 5-minute intervals. Results: Core temperature decreased in both the cold saline solution (1.0 degrees C [SD 0.4 degrees C]/1.8 degrees F [0.7 degrees F]) and room temperature saline solution (0.5 degrees C [SD 0.1 degrees C]/0.9 degrees F [0.2 degrees F]) groups, whereas skin temperature was unchanged. Slopes calculated from the core temperature cooling curves indicate that the majority of cooling occurred during the first half of the infusion. Examination of the core temperature cooling curves revealed a 2-phase temporal pattern in 30-minute cooling curves. The early phase, spanning 0 to 14 minutes, demonstrated rapid cooling in both groups, with a larger effect observed in subjects receiving cold saline solution. Conclusion: In this pilot study of healthy volunteers, rapid administration of cold saline solution to awake normothermic volunteers resulted in 1 degrees C (1.8 degrees F) cooling but did not induce a therapeutic plane of hypothermia. This change in core temperature was not accompanied by significant changes in skin temperature. These data suggest that a reduction in core temperature of about 1 degrees C (1.8 degrees F) can be achieved in healthy humans before a thermoregulatory response is triggered and that rapid infusion of cold intravenous fluids is insufficient by itself to overcome this response. The clinically relevant control arm of room temperature saline solution also resulted in mild core cooling.	[Moore, Tracy M.; Callaway, Clifton W.; Hostler, David] Univ Pittsburgh, Dept Emergency Med, Pittsburgh, PA 15213 USA; [Hostler, David] Univ Pittsburgh, Emergency Responder Human Performance Lab, Pittsburgh, PA 15213 USA	Hostler, D (corresponding author), Univ Pittsburgh, Dept Emergency Med, 230 McKee Pl,Suite 400, Pittsburgh, PA 15213 USA.	hostlerdp@upmc.edu		Callaway, Clifton/0000-0002-3309-1573; Hostler, David/0000-0002-7711-4001			Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; *CARD ARR STUD GRO, 2002, J AM COLL CARDIOL, V346, P549; Clifton GL, 2002, J NEUROTRAUM, V19, P293, DOI 10.1089/089771502753594864; De Georgia MA, 2004, NEUROLOGY, V63, P312, DOI 10.1212/01.WNL.0000129840.66938.75; Dixon SR, 2002, J AM COLL CARDIOL, V40, P1928, DOI 10.1016/S0735-1097(02)02567-6; Frank SM, 2000, AM J PHYSIOL-REG I, V279, pR349; Frank SM, 2003, CLIN SCI, V104, P503, DOI 10.1042/CS20020256; Frank SM, 1997, AM J PHYSIOL-REG I, V272, pR557; Giuliano K K, 2000, Am J Crit Care, V9, P254; Kliegel A, 2007, RESUSCITATION, V73, P46, DOI 10.1016/j.resuscitation.2006.08.023; Logue ES, 2007, ACAD EMERG MED, V14, P293, DOI 10.1197/j.aem.2006.10.097; O'Brien C, 1998, MED SCI SPORT EXER, V30, P468, DOI 10.1097/00005768-199803000-00020; Piper SN, 2000, ANESTH ANALG, V90, P954, DOI 10.1213/00000539-200004000-00033; Rajek A, 2000, ANESTHESIOLOGY, V93, P629, DOI 10.1097/00000542-200009000-00010; Schwarzkopf KRG, 2001, ANESTH ANALG, V92, P257; Silbergleit R, 1998, ANN EMERG MED, V31, P339, DOI 10.1016/S0196-0644(98)70344-0; Sramek P, 2000, EUR J APPL PHYSIOL, V81, P436, DOI 10.1007/s004210050065; Todd KH, 1996, ANN EMERG MED, V27, P485, DOI 10.1016/S0196-0644(96)70238-X	18	32	37	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	FEB	2008	51	2					153	159		10.1016/j.annemergmed.2007.07.012			7	Emergency Medicine	Emergency Medicine	256JO	WOS:000252725000007	18045737				2021-06-18	
J	Whyte, J; Vaccaro, M; Grieb-Neff, P; Hart, T; Polansky, M; Coslett, HB				Whyte, John; Vaccaro, Monica; Grieb-Neff, Patricia; Hart, Tessa; Polansky, Marcia; Coslett, H. Branch			The effects of bromocriptine on attention deficits after traumatic brain injury - A placebo-controlled pilot study	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						bromocriptine; attention deficit; traumatic brain injury	DOPAMINE-RECEPTOR AGONIST; WORKING-MEMORY; INATTENTIVE BEHAVIOR; FAILURES; TASK	Objective: To evaluate the effects of bromocriptine on a variety of aspects of attention, ranging from laboratory-based impairment measures to caregiver ratings and work productivity, in individuals after traumatic brain injury. Design: Twelve adults with moderate to severe traumatic brain injury and attention complaints in the postacute phase of recovery were enrolled in a 6-wk double-blind, placebo-controlled, crossover study of bromocriptine, titrated to a dose of 5 mg twice a day. A wide range of attentional measures was administered weekly, including computerized and paper-and-pencil tests of attention, videotaped records of individual work in a distracting environment, real-time observational scoring of attentiveness in a classroom environment, and caregiver and clinician ratings of attentiveness. Data from these 12 participants were used to identify attentional dimensions suggestive of a treatment effect for independent replication. Results: The effects of bromocriptine on 13 previously identified attentional factors and 13 individual performance scores were assessed via the Wilcoxon signed ranks test, using a relaxed probability cutoff of 0.20 to select those to be studied in a larger replication sample. Only two factor scores and one individual score met the cutoff, and all of these showed trends toward worse performance on bromocriptine than on placebo. A more detailed investigation of bromocriptine's effect on divided attention was also conducted, but the previously reported finding of a beneficial effect on this domain was not replicated. Blood pressure was marginally lower on bromocriptine than on placebo. In view of the lack of cognitive benefit and the fact that several participants experienced possible or probable drug side effects, we did not pursue a larger replication at this drug dose. Conclusions: Bromocriptine in a dose of 5 mg, given twice a day to individuals with attentional complaints after TBI, does not seem to enhance attentional skills, and it may be associated with an excess of adverse events. It is not clear whether intermittent dosing or lower doses might confer benefit.	[Whyte, John; Vaccaro, Monica; Grieb-Neff, Patricia; Hart, Tessa; Coslett, H. Branch] Moss Rehabil Res Inst, Albert Einstein Healthcare Network, Philadelphia, PA 19141 USA; [Whyte, John; Hart, Tessa] Thomas Jefferson Univ, Philadelphia, PA 19107 USA; [Polansky, Marcia] Drexel Univ, Philadelphia, PA 19104 USA; [Coslett, H. Branch] Univ Penn, Philadelphia, PA 19104 USA	Whyte, J (corresponding author), Moss Rehabil Res Inst, Albert Einstein Healthcare Network, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.			Whyte, John/0000-0002-4381-1474	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD039621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039163] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R24HD39621] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS39163] Funding Source: Medline		BARONA A, 1984, J CONSULT CLIN PSYCH, V52, P885, DOI 10.1037/0022-006X.52.5.885; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Deleu D, 2002, CLIN PHARMACOKINET, V41, P261, DOI 10.2165/00003088-200241040-00003; Efron D, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.6.e6; Hoffman BB, 2001, GOODMAN GILMANS PHAR, P215; Kim J, 2005, J INT NEUROPSYCH SOC, V11, P434, DOI 10.1017/S1355617705050563; Kimberg DY, 1997, NEUROREPORT, V8, P3581, DOI 10.1097/00001756-199711100-00032; Kimberg DY, 2001, HUM BRAIN MAPP, V12, P246, DOI 10.1002/1097-0193(200104)12:4<246::AID-HBM1019>3.0.CO;2-9; Kimberg DY, 2003, NEUROPSYCHOLOGIA, V41, P1020, DOI 10.1016/S0028-3932(02)00317-2; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; LUCIANA M, 1992, J COGNITIVE NEUROSCI, V4, P58, DOI 10.1162/jocn.1992.4.1.58; MARKEY SP, 1979, J PHARMACOL EXP THER, V211, P31; McAllister Thomas W., 1994, P357; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MELTZER HY, 1982, PHARMACOL BIOCHEM BE, V17, P1, DOI 10.1016/0091-3057(82)90504-4; Muller U, 1998, J NEUROSCI, V18, P2720; PICCIRILLI M, 1985, CLIN NEUROL, P167; PONSFORD J, 1991, NEUROPSYCHOL REHABIL, V1, P241, DOI DOI 10.1080/09602019108402257; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Robertson I H, 1996, J Int Neuropsychol Soc, V2, P525; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; VOLKOW ND, 2001, J NEUROSCI, V21, P1; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1996, J Int Neuropsychol Soc, V2, P274; Whyte J, 1998, J INT NEUROPSYCH SOC, V4, P127, DOI 10.1017/S1355617798001271; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Whyte J, 2000, J INT NEUROPSYCH SOC, V6, P1, DOI 10.1017/S1355617700611013; WHYTE J, 1998, INT PERSPECTIVES TRA, P154	30	32	34	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	FEB	2008	87	2					85	99		10.1097/PHM.0b013e3181619609			15	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	330PN	WOS:000257955400001	18209510				2021-06-18	
J	Brosseau-Lachaine, O; Gagnon, I; Forget, R; Faubert, J				Brosseau-Lachaine, Odile; Gagnon, Isabelle; Forget, Robert; Faubert, Jocelyn			Mild traumatic brain injury induces prolonged visual processing deficits in children	BRAIN INJURY			English	Article						visual perception; sensory integration; mild traumatic brain injury; paediatrics; second-order; optic flow	HEAD-INJURY; MOTION PERCEPTION; 2ND-ORDER MOTION; GLAUCOMA PATIENTS; OPTIC FLOW; STIMULI; CONCOMITANTS; PERFORMANCE; POTENTIALS; SYMPTOMS	Primary objective: To compare the sensitivity to simple and complex visual stimuli of children who have sustained a mild traumatic brain injury (mTBI) to that of matched non-injured children and to determine the evolution of visuo-perceptual performance over time. Research design: A prospective design was used to assess 18 children with mTBI and 18 matched healthy controls (8-16 years of age). Methods and procedures: Sensitivity to static and dynamic forms of simple (first-order) and complex (second-order) stimuli were assessed at 1, 4 and 12 weeks post-injury and at equivalent times for controls. Orientation and direction identification thresholds were measured for all participants for static and dynamic conditions, respectively. In addition, sensitivity to radial optic flow (inward vs outward), a complex motion stimulus, was assessed. Main outcomes and results: Thresholds measured from all complex stimuli were significantly affected for the mTBI children over time whereas no difference in threshold between groups across all testing conditions was found for simple, first-order information. Sensitivity to all complex stimuli was still affected 12 weeks after the injury. Conclusion: These findings suggest that injured children present selective processing deficits for higher-order information and that this deficit persists over relatively long periods. Such measures could be useful to assess children who have sustained mTBI and possibly contribute to identifying potential risks of returning these children to demanding physical activities.	[Faubert, Jocelyn] Univ Montreal, Ecole Optometrie, Visual Psychophys & Percept Lab, Montreal, PQ H3T 1P1, Canada; [Brosseau-Lachaine, Odile; Forget, Robert; Faubert, Jocelyn] Ctr Rech Interdisciplinaire Readaptat Montreal Me, Montreal, PQ, Canada; [Gagnon, Isabelle] McGill Univ, Montreal Childrens Hosp, Trauma Programs, Ctr Hlth, Montreal, PQ H3H 1P3, Canada; [Gagnon, Isabelle] McGill Univ, Sch Phys & Occupat Therapy, Montreal, PQ, Canada; [Forget, Robert] Univ Montreal, Ecole Readaptat, Fac Med, Montreal, PQ H3T 1P1, Canada	Faubert, J (corresponding author), Univ Montreal, Ecole Optometrie, Visual Psychophys & Percept Lab, 3744 Jean Brillant,Room 260-7, Montreal, PQ H3T 1P1, Canada.	jocelyn.faubert@umontreal.ca	Faubert, Jocelyn/E-2207-2011				Bertone A, 2005, BRAIN, V128, P2430, DOI 10.1093/brain/awh561; Bertone A, 2003, J COGNITIVE NEUROSCI, V15, P218, DOI 10.1162/089892903321208150; BERTONE A, 1999, INVEST OPHTHALMOL, V40, P2245; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BOHNEN NI, 1995, BRAIN INJURY, V9, P27, DOI 10.3109/02699059509004568; Bosworth CF, 1997, VISION RES, V37, P1989, DOI 10.1016/S0042-6989(96)00326-4; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; CAVANAGH P, 1989, Spatial Vision, V4, P103, DOI 10.1163/156856889X00077; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; CHUBB C, 1988, J OPT SOC AM A, V5, P1986, DOI 10.1364/JOSAA.5.001986; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Clifford CWG, 1999, VISION RES, V39, P113, DOI 10.1016/S0042-6989(98)00082-0; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Gagnon I, 2005, J HEAD TRAUMA REHAB, V20, P436, DOI 10.1097/00001199-200509000-00005; Gagnon I, 2004, J HEAD TRAUMA REHAB, V19, P391, DOI 10.1097/00001199-200409000-00004; Gagnon I, 2004, ARCH PHYS MED REHAB, V85, P444, DOI 10.1016/j.apmr.2003.06.014; Gagnon I, 1998, BRAIN INJURY, V12, P843, DOI 10.1080/026990598122070; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Giaschi DE, 1996, J OPT SOC AM A, V13, P707, DOI 10.1364/JOSAA.13.000707; Gibson JJ, 1950, PERCEPTION VISUAL WO, P235; GLOVINSKY Y, 1991, INVEST OPHTH VIS SCI, V32, P484; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Habak C, 2002, VISION RES, V42, P2843, DOI 10.1016/S0042-6989(02)00355-3; Habak C, 2000, VISION RES, V40, P943, DOI 10.1016/S0042-6989(99)00235-7; Heitger MH, 2004, BRAIN, V127, P575, DOI 10.1093/brain/awh066; Karwatsky P, 2006, OPTOMETRY VISION SCI, V83, P466, DOI 10.1097/01.opx.0000225107.38719.0d; Kay T., 1993, J HEAD TRAUMA REHABI, V8, P86, DOI [10.1097/00001199-199309000-00009, DOI 10.1097/00001199-199309000-00010]; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kogan CS, 2004, NEUROLOGY, V63, P1634, DOI 10.1212/01.WNL.0000142987.44035.3B; Lachapelle J, 2004, VISION RES, V44, P2835, DOI 10.1016/j.visres.2004.06.007; LACHAPELLE J, 2007, ELECTROPHYSIOL UNPUB; LEDGEWAY T, 1994, VISION RES, V34, P2879, DOI 10.1016/0042-6989(94)90056-6; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Nishida S, 1997, VISION RES, V37, P2685, DOI 10.1016/S0042-6989(97)00092-8; O'Brien HL, 2001, CEREB CORTEX, V11, P1083, DOI 10.1093/cercor/11.11.1083; PADULA WV, 2007, BRAIN INJURY MED; Potter DD, 2001, NEUROPSYCHOLOGIA, V39, P1464, DOI 10.1016/S0028-3932(01)00057-4; QUIGLEY HA, 1988, OPHTHALMOLOGY, V95, P357; SABATES NR, 1991, J CLIN NEURO-OPHTHAL, V11, P273; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Shabana N, 2003, SURV OPHTHALMOL, V48, P92, DOI 10.1016/S0039-6257(02)00401-0; Slobounov S, 2005, NEUROSCI LETT, V383, P251, DOI 10.1016/j.neulet.2005.04.039; Slobounov S, 2002, CLIN NEUROPHYSIOL, V113, P185, DOI 10.1016/S1388-2457(01)00737-4; Slobounov S, 2006, NEUROSURGERY, V59, P134, DOI 10.1227/01.NEU.0000219197.33182.3F; Smith AT, 1998, J NEUROSCI, V18, P3816; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; Suh M, 2006, NEUROSCI LETT, V401, P108, DOI 10.1016/j.neulet.2006.02.074; Swaine BR, 2001, J HEAD TRAUMA REHAB, V16, P292, DOI 10.1097/00001199-200106000-00008; Tetewsky SJ, 1999, NEUROLOGY, V52, P958, DOI 10.1212/WNL.52.5.958; WEIBULL W, 1951, J APPL MECH-T ASME, V18, P293; WILSON HR, 1992, VISUAL NEUROSCI, V9, P79, DOI 10.1017/S0952523800006386; WRIGHTSON P, 1995, J NEUROL NEUROSUR PS, V59, P375, DOI 10.1136/jnnp.59.4.375; Wurtz RH, 1998, CURR BIOL, V8, pR554, DOI 10.1016/S0960-9822(07)00359-4	57	32	32	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	9					657	668		10.1080/02699050802203353			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	336NS	WOS:000258371600003	18698516				2021-06-18	
J	Vickery, CD; Sherer, M; Nick, TG; Nakase-Richardson, R; Corrigan, JD; Hammond, F; Macciocchi, S; Ripley, DL; Sander, A				Vickery, Chad D.; Sherer, Mark; Nick, Todd G.; Nakase-Richardson, Risa; Corrigan, John D.; Hammond, Flora; Macciocchi, Stephen; Ripley, David L.; Sander, Angelle			Relationships among premorbid alcohol use, acute intoxication, and early functional status after traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						alcoholic intoxication; brain injuries; rehabilitation; treatment outcome	HEAD-INJURY; SUBSTANCE-ABUSE; LEVEL; INVOLVEMENT; SCALE; COMA	Objective: To investigate the relationships among intoxication at time of injury, preinjury history of problem drinking, and early functional status in patient's with traumatic brain injury (TBI). Design: Prospective cohort study. Setting: Acute inpatient TBI rehabilitation. Participants: Participants were 1748 persons with TBI. Interventions: Not applicable. Main Outcome Measures: Blood alcohol levels (BALs) were obtained at admission to the emergency department, and a history of problem drinking was obtained through interview. Study outcomes, Disability Rating Scale (DRS), and FIM instrument scores were gathered at admission to inpatient rehabilitation. Results: Multivariate regression analysis revealed that BAL and a history of binge drinking were predictive of DRS, but not FIM, scores. A higher BAL was associated with poorer functional status on the DRS. Paradoxically, a history of binge drinking was associated with more intact functional status on the DRS. Conclusions: The relationships among intoxication at time of injury, history of problem drinking, and early outcome after TBI were modest. Injury severity had a more significant association with TBI functional status.	[Vickery, Chad D.; Nakase-Richardson, Risa] Methodist Rehabil Ctr, Jackson, MS 39216 USA; [Vickery, Chad D.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA; [Sherer, Mark; Sander, Angelle] Mem Hermann TIRR, Houston, TX USA; [Nick, Todd G.] Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Med Ctr,Ctr Epidemiol & Biostat, Cincinnati, OH USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Macciocchi, Stephen] Shepherd Ctr, Atlanta, GA USA; [Ripley, David L.] Craig Hosp, Englewood, CO USA; [Sander, Angelle] Baylor Coll Med, Harris Cty Hosp Dist, Dept Phys Med & Rehabil, Houston, TX 77030 USA	Vickery, CD (corresponding author), Methodist Rehabil Ctr, 1350 E Woodrow Wilson, Jackson, MS 39216 USA.	cvickery@mmrcrehab.org	Corrigan, John D./E-2921-2011	Ripley, David/0000-0002-5349-1830			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BOMBARDIER CH, 1995, WESTERN J MED, V162, P150; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; Brooks N, 1989, Brain Inj, V3, P235, DOI 10.3109/02699058909029638; Bush BA, 2003, ARCH PHYS MED REHAB, V84, P1803, DOI 10.1016/S0003-9993(03)00367-8; Center for Disease Control & Prevention, ALC PUBL HLTH; Corrigan J, PROBLEMATIC SUBSTANC; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; DIKMEN SS, 1995, ANN EMERG MED, V26, P167, DOI 10.1016/S0196-0644(95)70147-8; Drubach D A, 1993, Md Med J, V42, P989; EDNA TH, 1982, ACTA CHIR SCAND, V148, P209; GRANT I, 1987, J CONSULT CLIN PSYCH, V55, P310, DOI 10.1037/0022-006X.55.3.310; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Harel O, 2007, STAT MED, V26, P3057, DOI 10.1002/sim.2787; HARRELL FE, HMISC DESIGN LIB; JURKOVICH GJ, 1992, ANN EMERG MED, V21, P704, DOI 10.1016/S0196-0644(05)82783-0; KAPLAN C P, 1992, Brain Injury, V6, P337, DOI 10.3109/02699059209034948; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; Kreutzer JS, 1996, J HEAD TRAUMA REHAB, V11, P58, DOI 10.1097/00001199-199610000-00006; KREUTZER JS, 1990, J HEAD TRAUMA REHAB, V5, P9, DOI DOI 10.1097/00001199-199009000-00005; Lehmkuhl L, 1993, J HEAD TRAUMA REHAB, V8, P88; LEONARD BE, 1995, NEUROCHEM INT, V26, P343, DOI 10.1016/0197-0186(94)00141-G; MARKWALDER TM, 1981, J NEUROSURG, V54, P637, DOI 10.3171/jns.1981.54.5.0637; Myers R., 1990, CLASSICAL MODERN REG; *NAT CTR HLTH STAT, 2006, HLTH US 2006 CHARTB; National Data and Statistical Center, TRAUM BRAIN INJ MOD; NEVO I, 1995, NEUROCHEM INT, V26, P305, DOI 10.1016/0197-0186(94)00139-L; PARSONS OA, 1993, NEUROL CLIN, V11, P205; PORIES SE, 1992, J TRAUMA, V32, P60, DOI 10.1097/00005373-199201000-00013; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; STEINBOK P, 1978, NEUROSURGERY, V3, P9, DOI 10.1227/00006123-197807000-00002; Tate PS, 1999, BRAIN INJURY, V13, P767; Turner AP, 2006, REHABIL PSYCHOL, V51, P78, DOI 10.1037/0090-5550.51.1.78; U.S. Department of Health and Human Services and U.S. Department of Agriculture, DIET GUID AM; WRIGHT J, 2002, FIM             0302; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P456, DOI 10.1097/00002060-199611000-00011	41	32	32	0	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2008	89	1					48	55		10.1016/j.apmr.2007.07.047			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	249LB	WOS:000252228600009	18164330				2021-06-18	
J	Yao, XL; Liu, J; McCabe, JT				Yao, Xianglan; Liu, Jiong; McCabe, Joseph T.			Alterations of cerebral cortex and hippocampal proteasome subunit expression and function in a traumatic brain injury rat model	JOURNAL OF NEUROCHEMISTRY			English	Article						brain injury; cerebral cortex; hippocampus; PA28 alpha; quantitative real-time PCR; beta-proteasome subunits	INTERFERON-GAMMA; GENE-EXPRESSION; OXIDATIVE STRESS; UBIQUITIN IMMUNOREACTIVITY; GENOMIC ORGANIZATION; ANTIGEN PRESENTATION; HYBRID PROTEASOMES; OXIDIZED PROTEINS; TISSUE EXPRESSION; 20S PROTEASOMES	Following cellular stress or tissue injury, the proteasome plays a critical role in protein degradation and signal transduction. The present study examined the beta-subunit expression of constitutive proteasomes (beta 1, beta 2, and beta 5), immunoproteasomes (beta 1i, beta 2i, and beta 5i) and the 11S proteasome activator, PA28 alpha, in the rat CNS after traumatic brain injury (TBI). Concomitant measures assessed changes in proteasome activities. Quantitative real time PCR results indicated that beta 1 and beta 2 mRNA levels were not changed, while beta 5 mRNA levels were significantly decreased in injured CNS following TBI. However, beta 1i, beta 2i, beta 5i, and PA28 alpha mRNA levels were significantly increased in the injured CNS. Western blotting studies found that beta 1, beta 2, beta 5, beta 2i, and beta 5i subunit protein levels remained unchanged in the injured CNS, but beta 1i and PA28 alpha protein levels were significantly elevated in ipsilateral cerebral cortex and hippocampus. Proteasome activity assays found that peptidyl glutamyl peptide hydrolase-like and chymotrypsin-like activity were significantly reduced in the CNS after TBI, and that trypsin-like proteasome activity was increased in the injured cerebral cortex. Our results demonstrated that both proteasome composition and function in the CNS were affected by trauma. Treatments that preserve proteasome function following CNS injury may be beneficial as an approach to cerebral neuroprotection.	[Yao, Xianglan; Liu, Jiong; McCabe, Joseph T.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA	Yao, XL (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	xyao@usuhs.mil					Adori C, 2006, J HISTOCHEM CYTOCHEM, V54, P263, DOI 10.1369/jhc.5B6752.2005; Adori C, 2005, NEUROBIOL DIS, V19, P427, DOI 10.1016/j.nbd.2005.01.015; Ahtoniemi T, 2007, MOL PHARMACOL, V71, P30, DOI 10.1124/mol.106.028415; Anselmi B, 1998, J GERONTOL A-BIOL, V53, pB173, DOI 10.1093/gerona/53A.3.B173; Arendt CS, 1999, EMBO J, V18, P3575, DOI 10.1093/emboj/18.13.3575; Bader N, 2006, BIOL CHEM, V387, P1351, DOI 10.1515/BC.2006.169; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Ceremuga TE, 2001, ENDOCR RES, V27, P433, DOI 10.1081/ERC-100107867; Conconi M, 1997, MOL BIOL REP, V24, P45, DOI 10.1023/A:1006852506884; Conconi M, 1996, ARCH BIOCHEM BIOPHYS, V331, P232, DOI 10.1006/abbi.1996.0303; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Diaz-Hernandez M, 2003, J NEUROSCI, V23, P11653; Ding QX, 2007, TRENDS NEUROSCI, V30, P31, DOI 10.1016/j.tins.2006.11.003; Eleuteri AM, 1997, J BIOL CHEM, V272, P11824, DOI 10.1074/jbc.272.18.11824; Farout L, 2000, ARCH BIOCHEM BIOPHYS, V374, P207, DOI 10.1006/abbi.1999.1585; Gaczynska M, 1996, J BIOL CHEM, V271, P17275, DOI 10.1074/jbc.271.29.17275; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gozal D, 2003, J NEUROCHEM, V86, P1545, DOI 10.1046/j.1471-4159.2003.01973.x; Griffin TA, 1998, J EXP MED, V187, P97, DOI 10.1084/jem.187.1.97; Groettrup M, 2001, BIOCHIMIE, V83, P367, DOI 10.1016/S0300-9084(01)01251-2; Groll M, 1999, P NATL ACAD SCI USA, V96, P10976, DOI 10.1073/pnas.96.20.10976; Grune T, 2005, FREE RADICAL BIO MED, V39, P1208, DOI 10.1016/j.freeradbiomed.2005.06.009; Halliwell B, 2002, ANN NY ACAD SCI, V962, P182, DOI 10.1111/j.1749-6632.2002.tb04067.x; HARRIS JR, 1968, BIOCHIM BIOPHYS ACTA, V150, P534, DOI 10.1016/0005-2736(68)90157-0; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Heink S, 2005, P NATL ACAD SCI USA, V102, P9241, DOI 10.1073/pnas.0501711102; Henninger N, 2006, NEUROSCI LETT, V398, P300, DOI 10.1016/j.neulet.2006.01.015; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ide T, 1999, J CEREBR BLOOD F MET, V19, P750, DOI 10.1097/00004647-199907000-00004; Jager S, 1999, J MOL BIOL, V291, P997, DOI 10.1006/jmbi.1999.2995; Keller JN, 2000, J CEREBR BLOOD F MET, V20, P1467, DOI 10.1097/00004647-200010000-00008; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Keller JN, 2004, INT J BIOCHEM CELL B, V36, P2376, DOI 10.1016/j.biocel.2004.05.003; Keller JN, 2002, AGEING RES REV, V1, P279, DOI 10.1016/S1568-1637(01)00006-X; Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572; Kopp F, 2001, J MOL BIOL, V313, P465, DOI 10.1006/jmbi.2001.5063; Lam YA, 2000, P NATL ACAD SCI USA, V97, P9902, DOI 10.1073/pnas.170173897; Lee CS, 2004, J NEUROCHEM, V91, P996, DOI 10.1111/j.1471-4159.2004.02813.x; Li J, 2001, BIOCHIMIE, V83, P373, DOI 10.1016/S0300-9084(01)01236-6; Li ZM, 2004, J NEUROCHEM, V90, P19, DOI 10.1111/j.1471-4159.2004.02456.x; Majetschak M, 2005, CRIT CARE MED, V33, P1589, DOI 10.1097/01.CCM.0000169883.41245.23; Martin S, 2004, NEUROSCI LETT, V357, P76, DOI 10.1016/j.neulet.2003.10.085; McNaught KS, 2003, EXP NEUROL, V179, P38, DOI 10.1006/exnr.2002.8050; Mendonca DMF, 2006, NEUROSCI LETT, V404, P315, DOI 10.1016/j.neulet.2006.06.009; Mengual E, 1996, J NEUROSCI, V16, P6331; Minami Y, 2000, J BIOL CHEM, V275, P9055, DOI 10.1074/jbc.275.12.9055; Mishto M, 2006, NEUROBIOL AGING, V27, P54, DOI 10.1016/j.neurobiolaging.2004.12.004; Mizukami K, 2002, ACTA NEUROPATHOL, V103, P453, DOI 10.1007/s00401-001-0489-1; MORI H, 1996, RECENT ADV GASTROENT, V1, P249; Murata S, 2001, EMBO J, V20, P5898, DOI 10.1093/emboj/20.21.5898; Nandi D, 1997, EMBO J, V16, P5363, DOI 10.1093/emboj/16.17.5363; NEUMANN H, 1995, SCIENCE, V269, P549, DOI 10.1126/science.7624779; Noda C, 2000, BIOCHEM BIOPH RES CO, V277, P348, DOI 10.1006/bbrc.2000.3676; Ordway GA, 2000, J APPL PHYSIOL, V88, P1134; Piccinini M, 2003, J NEUROIMMUNOL, V135, P135, DOI 10.1016/S0165-5728(02)00439-3; Preckel T, 1999, SCIENCE, V286, P2162, DOI 10.1126/science.286.5447.2162; Puttaparthi K, 2005, EXP NEUROL, V196, P441, DOI 10.1016/j.expneurol.2005.08.027; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schwarz K, 2000, EUR J IMMUNOL, V30, P3672, DOI 10.1002/1521-4141(200012)30:12<3672::AID-IMMU3672>3.0.CO;2-B; Tanahashi N, 2000, J BIOL CHEM, V275, P14336, DOI 10.1074/jbc.275.19.14336; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Weih M, 2001, J CEREBR BLOOD F MET, V21, P1090, DOI 10.1097/00004647-200109000-00006; Williams AJ, 2006, NEUROCHEM INT, V49, P106, DOI 10.1016/j.neuint.2006.03.018; Yamano T, 2002, J EXP MED, V196, P185, DOI 10.1084/jem.20011922; Yang Y, 2006, BRAIN RES, V1075, P1, DOI 10.1016/j.brainres.2005.12.060; YAO X, 2007, IN PRESS BRAIN RES; Yao XL, 2006, NEUROSCI LETT, V409, P65, DOI 10.1016/j.neulet.2006.09.015; Yao XL, 2005, J NEUROTRAUM, V22, P656, DOI 10.1089/neu.2005.22.656; Yewdell JW, 2005, P NATL ACAD SCI USA, V102, P9089, DOI 10.1073/pnas.0504018102; ZANELLI E, 1993, IMMUNOGENETICS, V38, P400, DOI 10.1007/BF00184520; Zhang L, 2006, THROMB HAEMOSTASIS, V95, P166, DOI 10.1160/TH05-07-0477; ZHOU P, 1993, GENOMICS, V16, P664, DOI 10.1006/geno.1993.1245	74	32	32	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	JAN	2008	104	2					353	363		10.1111/j.1471-4159.2007.04970.x			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	242ZX	WOS:000251765800007	17944870				2021-06-18	
J	Chen, M; Regan, RF				Chen, Mai; Regan, Raymond F.			Time course of increased heme oxygenase activity and expression after experimental intracerebral hemorrhage: correlation with oxidative injury	JOURNAL OF NEUROCHEMISTRY			English	Article						free radical; hemoglobin toxicity; iron; oxidative stress; stroke	VASCULAR ENDOTHELIAL-CELLS; TRAUMATIC BRAIN-INJURY; COMPLEMENT ACTIVATION; HEMOGLOBIN TOXICITY; CARBON-MONOXIDE; IN-VITRO; TIN-MESOPORPHYRIN; RAT-BRAIN; INDUCTION; PROTECTS	Heme oxygenase (HO) activity in tissue adjacent to an intracerebral hematoma may modulate cellular vulnerability to heme-mediated oxidative injury. Although HO-1 is induced after experimental intracerebral hemorrhage (ICH), the time course of this induction, its effect on tissue HO activity, and its association with oxidative injury markers has not been defined. We therefore quantified HO activity, HO-1 expression, tissue heme content, and protein carbonylation for 8 days after injection of autologous blood into the mouse striatum. Increased striatal HO-1 protein was observed within 24 h, peaked on day 5 at a level that was 10-fold greater than baseline, and returned to baseline by day 8; HO-2 expression was not altered. HO activity increased by only 1.6-fold at its peak on day 5, and had also returned to baseline by day 8. A significant increase in protein carbonylation was observed at 3-5 days, which also was markedly attenuated by 8 days, concomitant with a return of tissue heme to near-normal levels. These results suggest that the increase in HO activity in tissue surrounding an experimental ICH is considerably less than would be predicted based on an analysis of HO-1 expression per se. As HO-1 expression is temporally associated with increased tissue heme and increased protein carbonylation, it may be more useful as a marker of heme-mediated oxidative stress in ICH models, rather than as an index of HO activity.	Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA	Regan, RF (corresponding author), Thomas Jefferson Univ, Dept Emergency Med, 1020 Sansom St,Thompson Bldg Rm 239, Philadelphia, PA 19107 USA.	raymond.regan@jefferson.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS50662, NS42273] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042273, R01NS050662] Funding Source: NIH RePORTER		BALLA G, 1992, J BIOL CHEM, V267, P18148; Basuroy S, 2006, AM J PHYSIOL-CELL PH, V291, pC897, DOI 10.1152/ajpcell.00032.2006; Benvenisti-Zarom L, 2005, NEUROPHARMACOLOGY, V49, P687, DOI 10.1016/j.neuropharm.2005.04.023; Boehning D, 2003, NEURON, V40, P129, DOI 10.1016/S0896-6273(03)00596-8; Botros FT, 2005, KIDNEY INT, V68, P2745, DOI 10.1111/j.1523-1755.2005.00745.x; Chang EF, 2003, J NEUROSCI, V23, P3689; Chen JJ, 2005, CURR NEUROVASC RES, V2, P121, DOI 10.2174/1567202053586767; Cichon G, 2001, GENE THER, V8, P1794, DOI 10.1038/sj.gt.3301611; Dennery PA, 2003, FREE RADICAL BIO MED, V34, P124, DOI 10.1016/S0891-5849(02)01295-9; Dore S, 1999, MOL MED, V5, P656, DOI 10.1007/BF03401984; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; DWYER BE, 1992, GLIA, V5, P300, DOI 10.1002/glia.440050407; DWYER BE, 1995, MOL BRAIN RES, V30, P37, DOI 10.1016/0169-328X(94)00273-H; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Gong Y, 2006, ACTA NEUROCHIR SUPPL, V96, P232; HEINSEN H, 1994, ACTA NEUROPATHOL, V88, P320, DOI 10.1007/BF00310376; Hori R, 2002, J BIOL CHEM, V277, P10712, DOI 10.1074/jbc.M107749200; Hua Y, 2000, J NEUROSURG, V92, P1016, DOI 10.3171/jns.2000.92.6.1016; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; Hvidberg V, 2005, BLOOD, V106, P2572, DOI 10.1182/blood-2005-03-1185; Jing CR, 2005, J NEUROSCI RES, V82, P802, DOI 10.1002/jnr.20681; Koeppen AH, 2004, J NEUROPATH EXP NEUR, V63, P587, DOI 10.1093/jnen/63.6.587; Kreiser D, 2003, PEDIATR RES, V54, P172, DOI 10.1203/01.PDR.0000072516.83498.07; KUROSS SA, 1988, BLOOD, V71, P876; Lin Q, 2007, J BIOL CHEM, V282, P20621, DOI 10.1074/jbc.M607954200; Matz PG, 1997, NEUROSURGERY, V40, P152, DOI 10.1097/00006123-199701000-00034; Munoz AM, 2005, J CHEM NEUROANAT, V29, P113, DOI 10.1016/j.jchemneu.2004.10.001; Nakamura T, 2004, J NEUROSURG, V100, P672, DOI 10.3171/jns.2004.100.4.0672; Ono S, 2002, J NEUROSURG, V96, P1094, DOI 10.3171/jns.2002.96.6.1094; Opatrny K, 2007, ARTIF ORGANS, V31, P200, DOI 10.1111/j.1525-1594.2007.00365.x; Parfenova H, 2006, AM J PHYSIOL-CELL PH, V290, pC1399, DOI 10.1152/ajpcell.00386.2005; Qu Y, 2005, J CEREBR BLOOD F MET, V25, P1466, DOI 10.1038/sj.jcbfm.9600143; Qu Y, 2007, J NEUROSURG, V106, P428, DOI 10.3171/jns.2007.106.3.428; Quan S, 2004, KIDNEY INT, V65, P1628, DOI 10.1111/j.1523-1755.2004.00562.x; Quan S, 2002, J CELL BIOCHEM, V85, P410, DOI 10.1002/jcb.10147; Regan RF, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-34; Regan RF, 2000, NEUROSCI LETT, V282, P1, DOI 10.1016/S0304-3940(00)00817-X; Regan RF, 2003, J NEUROTRAUM, V20, P111, DOI 10.1089/08977150360517236; Ren H, 2007, J NEUROCHEM, V100, P532, DOI 10.1111/j.1471-4159.2006.04230.x; Rogers B, 2003, FREE RADICAL BIO MED, V35, P872, DOI 10.1016/S0891-5849(03)00431-3; Ryter SW, 2004, BIOESSAYS, V26, P270, DOI 10.1002/bies.20005; Salim M, 2001, J BIOL CHEM, V276, P10929, DOI 10.1074/jbc.M010753200; Salinas M, 2004, FEBS LETT, V578, P90, DOI 10.1016/j.febslet.2004.10.077; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; STURROCK RR, 1980, NEUROPATH APPL NEURO, V6, P51, DOI 10.1111/j.1365-2990.1980.tb00204.x; Teng ZP, 2004, NEUROBIOL DIS, V17, P179, DOI 10.1016/j.nbd.2004.07.009; Tolosano E, 2002, DNA CELL BIOL, V21, P297, DOI 10.1089/104454902753759717; TRAKSHEL GM, 1988, ARCH BIOCHEM BIOPHYS, V260, P732, DOI 10.1016/0003-9861(88)90503-6; TYRRELL RM, 1993, CARCINOGENESIS, V14, P761, DOI 10.1093/carcin/14.4.761; Vreman HJ, 2000, PLACENTA, V21, P337, DOI 10.1053/plac.1999.0495; VREMAN HJ, 1988, ANAL BIOCHEM, V168, P31, DOI 10.1016/0003-2697(88)90006-1; Wagner KR, 2000, CELL MOL BIOL, V46, P597; Wagner KR, 2004, ANN NY ACAD SCI, V1012, P237, DOI 10.1196/annals.1306.020; Wagner KR, 2002, DEV NEUROSCI-BASEL, V24, P154, DOI 10.1159/000065703; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Wang J, 2006, NEUROBIOL DIS, V22, P473, DOI 10.1016/j.nbd.2005.12.009; Weng YH, 2003, J BIOL CHEM, V278, P50999, DOI 10.1074/jbc.M307644200; Williams KR, 1998, NEUROBIOL DIS, V5, P271, DOI 10.1006/nbdi.1998.0198; Wu JM, 2003, STROKE, V34, P2964, DOI 10.1161/01.STR.0000103140.52838.45; Xi GH, 1998, J NEUROSURG, V89, P991, DOI 10.3171/jns.1998.89.6.0991; Xi GH, 1998, STROKE, V29, P2580, DOI 10.1161/01.STR.29.12.2580; Yang SX, 2006, J CEREBR BLOOD F MET, V26, P1490, DOI 10.1038/sj.jcbfm.9600305; Zakhary R, 1996, P NATL ACAD SCI USA, V93, P795, DOI 10.1073/pnas.93.2.795	63	32	35	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	DEC	2007	103	5					2015	2021		10.1111/j.1471-4159.2007.04885.x			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	231YN	WOS:000250985200029	17760860				2021-06-18	
J	Walker, R; Cole, JE; Logan, TK; Corrigan, JD				Walker, Robert; Cole, Jennifer E.; Logan, T. K.; Corrigan, John D.			Screening substance abuse treatment clients for traumatic brain injury: Prevalence and characteristics	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						traumatic brain injury; substance abuse; screening	DEPRESSION FOLLOWING MILD; MAJOR DEPRESSION; SPINAL-CORD; HEAD-INJURY; POPULATION	Objectives: To examine clinical characteristics of clients in state-funded substance abuse treatment who report traumatic brain injury with loss of consciousness (TBI-LOC). Participants: Adult clients (N = 7784) entering state-funded substance abuse treatment in a rural state during a 12-month period. Measurement tools: Substance use and mental health problems were measured using the federal Substance Abuse and Mental Health Services Administration (SAMHSA) adaptation of the Addiction Severity index (ASI). A brain injury screening question was used to determine the number of TBI-LOCs in a client's lifetime. Design: Cross-sectional study of intake characteristics as part of a state-mandated treatment outcome study. Results: Almost one-third (31.7%) of substance abuse treatment clients reported 1 or more TBI-LOCs. The clients reporting 2 or more TBI-LOCs were more likely than clients with none or 1 TBI-LOC to have serious mental health problems (ie, depression, anxiety, hallucinations, and suicidal thoughts and attempts), trouble controlling violent behavior, trouble concentrating or remembering, and more months of use of most substances. When depression and anxiety were held constant, and controlling for race and gender, clients with TBI-LOC had more months of marijuana and tranquilizer use. Conclusions: Findings suggest that treatment providers may need to be attentive to the complex conditions that co-occur with TBI-LOC. Future research should examine whether there are differences in treatment outcome for clients reporting TBI-LOC.	Univ Kentucky, Coll Med, Ctr Drug & Alcohol Res, Lexington, KY 40506 USA; Univ Kentucky, Coll Med, Dept Behav Sci, Lexington, KY 40506 USA; Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	Walker, R (corresponding author), Univ Kentucky, Coll Med, Ctr Drug & Alcohol Res, Lexington, KY 40506 USA.		Cole, Jennifer E/Y-6388-2019; Corrigan, John D./E-2921-2011; Logan, TK o/O-7061-2018				Bombardier CH, 2003, ARCH PHYS MED REHAB, V84, P185, DOI 10.1053/apmr.2003.50002; Chamelian L, 2006, J NEUROPSYCH CLIN N, V18, P33, DOI 10.1176/appi.neuropsych.18.1.33; CORRIGAN JD, 1995, J HEAD TRAUMA REHAB, V10, P29; CORRIGAN JD, 2005, REHABILITATION TRAUM, P133; Deb S, 1999, AM J PSYCHIAT, V156, P374; Dodge R, 2005, J SUBST ABUSE TREAT, V28, P189, DOI 10.1016/j.jsat.2004.12.005; EHRMAN RN, 1994, J CONSULT CLIN PSYCH, V62, P843, DOI 10.1037/0022-006X.62.4.843; Fals-Stewart W, 2000, J CONSULT CLIN PSYCH, V68, P134, DOI 10.1037/0022-006X.68.1.134; Holsinger T, 2002, ARCH GEN PSYCHIAT, V59, P17, DOI 10.1001/archpsyc.59.1.17; Horner MD, 2005, J INT NEUROPSYCH SOC, V11, P322, DOI 10.1017/S135561770505037X; Iverson GL, 2005, BRAIN INJURY, V19, P11, DOI 10.1080/02699050410001720068; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kelly MP, 1997, BRAIN INJURY, V11, P391, DOI 10.1080/026990597123386; Kolakowsky-Hayner S, 2002, BRAIN INJURY, V16, P583, DOI 10.1080/02699050110119475; Levin HS, 2005, ARCH GEN PSYCHIAT, V62, P523, DOI 10.1001/archpsyc.62.5.523; Levy DT, 2004, MED SCI MONITOR, V10, pCR17; MCLELLAN AT, 1992, J SUBST ABUSE TREAT, V9, P199, DOI 10.1016/0740-5472(92)90062-S; Mulvey KP, 2005, AM J EVAL, V26, P587, DOI 10.1177/1098214005281320; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P177, DOI 10.1053/apmr.2003.50106; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Walker R, 2003, J PSYCHOACTIVE DRUGS, V35, P343, DOI 10.1080/02791072.2003.10400017	23	32	32	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2007	22	6					360	367		10.1097/01.HTR.0000300231.90619.50			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	234RN	WOS:000251181500006	18025968				2021-06-18	
J	Itoh, T; Satou, T; Nishida, S; Hashimoto, S; Ito, H				Itoh, Tatsuki; Satou, Takao; Nishida, Shozo; Hashimoto, Shigeo; Ito, Hiroyuki			Immature and mature neurons coexist among glial scars after rat traumatic brain injury	NEUROLOGICAL RESEARCH			English	Article						doublecortin; glial scar; gliosis; neural stem cell; traumatic brain injury	NEURAL STEM-CELLS; CORTICAL IMPACT INJURY; DOUBLECORTIN EXPRESSION; INTERMEDIATE FILAMENT; ADULT; NEUROGENESIS; REORGANIZATION; PROLIFERATION; NESTIN; ASTROCYTES	Objectives: Glial scars around a damaged area after brain injury inhibit neurite elongation from surviving neurons and axonal plasticity, and thus prevent neural network regeneration. However, the generation, differentiation and maturation of neural stem cells (NSCs) among glial scars after brain injury have not yet been reported. Methods: In the present study, we investigated the chronological relationship between gliosis and maturation of new neurons around a damaged area using a rat traumatic brain injury (TBI) model. Results: Between 1 and 7 days after injury, many nestin-positive cells were observed around the damaged area. Three days after injury, many small nestin-positive cells showed an astrocytic morphology. Between 1 and 30 days after injury, doublecortin (DCX)-positive cells were present around the damaged area. Three and 7 days after injury, a small number of nestin-positive cells were immunopositive for glial fibrillary acidic protein (GFAP). Seven days after injury, there were DCX-positive cells in the gliosis occurring in the lesion. Thirty days after injury, DCX-positive cells were observed near and among the glial scars and a small number of these cells were immunopositive for NeuN. Discussion: These results suggest that DCX-positive cells were present near and among the glial scars after brain injury, and that these cells changed from immature to mature neurons. It is considered that promotion of the maturation and differentiation of newly formed immature neurons near and among glial scars after injury may improve the brain dysfunction induced by glial scars after brain injury.	Kinki Univ, Sch Med, Dept Pathol, Osaka 5898511, Japan; Kinki Univ Hosp, Sch Med, Div Hosp Pathol, Osaka 5898511, Japan; Kinki Univ, Inst Life Sci, Div Sports Med, Osaka, Japan; PL Hosp, Dept Pathol, Osaka, Japan; Kinki Univ, Sch Pharmaceut Sci, Osaka, Japan	Itoh, T (corresponding author), Kinki Univ, Sch Med, Dept Pathol, 377-2 Ohno-higashi, Osakasayama City, Osaka 5898511, Japan.	tatsuki@med.kindai		Itoh, Tatsuki/0000-0003-2015-7788			Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Bechmann I, 2000, ANN NY ACAD SCI, V911, P192; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Chirumamilla S, 2002, J NEUROTRAUM, V19, P693, DOI 10.1089/08977150260139084; Cooper-Kuhn CM, 2002, DEV BRAIN RES, V134, P13, DOI 10.1016/S0165-3806(01)00243-7; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Davies SJA, 1999, J NEUROSCI, V19, P5810, DOI 10.1523/JNEUROSCI.19-14-05810.1999; Deller T, 2000, ANN NY ACAD SCI, V911, P207; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Douen AG, 2004, BRAIN RES, V1008, P139, DOI 10.1016/j.brainres.2003.08.070; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gallo V, 2001, SCIENCE, V292, P872, DOI 10.1126/science.1060854; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Itoh T, 2005, NEUROL RES, V27, P429, DOI 10.1179/016164105X18476; Jurynec MJ, 2003, MOL CELL NEUROSCI, V23, P69, DOI 10.1016/S1044-7431(03)00019-8; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kaya SS, 1999, BRAIN RES, V840, P153, DOI 10.1016/S0006-8993(99)01757-6; Kernie SG, 2001, J NEUROSCI RES, V66, P317, DOI 10.1002/jnr.10013; Kuhn HG, 1996, J NEUROSCI, V16, P2027; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; McKay R, 1997, SCIENCE, V276, P66, DOI 10.1126/science.276.5309.66; MENEZES JRL, 1994, J NEUROSCI, V14, P5399; Moon C, 2004, BRAIN RES, V1028, P238, DOI 10.1016/j.brainres.2004.09.022; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; Nacher J, 2001, EUR J NEUROSCI, V14, P629, DOI 10.1046/j.0953-816x.2001.01683.x; Nakamura T, 2004, J NEUROTRAUM, V21, P1747, DOI 10.1089/0897715042664902; Palmer TD, 2002, NEURON, V34, P856, DOI 10.1016/S0896-6273(02)00738-9; Parent JM, 1997, J NEUROSCI, V17, P3727; Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207; Picard-Riera N, 2004, J NEUROSCI RES, V76, P223, DOI 10.1002/jnr.20040; Rao MS, 2004, EUR J NEUROSCI, V19, P234, DOI 10.1111/j.0953-816X.2003.03123.x; Rice AC, 2003, EXP NEUROL, V183, P406, DOI 10.1016/S0014-4886(03)00241-3; RUDGE JS, 1990, J NEUROSCI, V10, P3594; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Seri B, 2001, J NEUROSCI, V21, P7153, DOI 10.1523/JNEUROSCI.21-18-07153.2001; Shibuya S, 2002, NEUROSCIENCE, V114, P905, DOI 10.1016/S0306-4522(02)00323-8; Silver IA, 1997, NEUROSCIENCE, V78, P589, DOI 10.1016/S0306-4522(96)00600-8; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23	42	32	36	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	OCT	2007	29	7					734	742		10.1179/016164107X208086			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	234MJ	WOS:000251167900017	18183647				2021-06-18	
J	De Oliveira, CO; Reimer, AG; Da Rocha, AB; Grivicich, I; Schneider, RF; Roisenberg, I; Regner, A; Simon, D				De Oliveira, Clarissa Oliveira; Reimer, Alexandre Gard; Da Rocha, Adriana Brondani; Grivicich, Ivana; Schneider, Rogerio Fett; Roisenberg, Israel; Regner, Andrea; Simon, Daniel			Plasma von Willebrand factor levels correlate with clinical outcome of severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; biomarkers; outcome measures; traumatic brain injury; von Willebrand factor	SEVERE HEAD-INJURY; PROTEIN CONCENTRATIONS; EARLY PREDICTOR; SERUM S-100B; MARKER; S100B; HEMORRHAGE; CHILDREN; STROKE; DAMAGE	Biochemical markers of cellular stress/injury have been proposed to indicate outcome after head injury. The aim of the present study was to determine whether plasma von Willebrand factor (VWF) levels correlate with primary outcome and with clinical variables in severe traumatic brain injury (TBI). Forty-four male patients, victims of severe TBI, were analyzed. Clinical outcome variables of severe TBI comprised survival and neurological assessment using the Glasgow Outcome Scale (GOS) at intensive care unit (ICU) discharge. Computerized tomography (CT) scans were analyzed according to Marshall CT classification. Three consecutive venous blood samples were taken: first sample (11.4 +/- 5.2 h after trauma, mean +/- SD), and 24 h and 7 days later. The result of mean plasma VWF concentration was significantly higher in the TBI group (273 U/dL) than in the control group (107 U/dL; p < 0.001). Severe TBI was associated with a 50% mortality rate. Nonsurvivors presented significantly higher APACHE II scores than survivors (nonsurvivors mean, 18.8; survivors mean, 12.7; p < 0.001), and also presented higher scores in Marshall CT classification ( nonsurvivors mean, 4.6; survivors mean, 2.7; p < 0.05). There was a significant positive correlation between plasma levels at second plasma sampling and scores in Marshall CT classification (p < 0.05). The sensitivity of plasma VWF concentration in predicting mortality according to the cut-off of 234 U/dL was 64%, with a specificity of 68%. Therefore, VWF increases following severe TBI may be a marker of unfavorable outcome.	Univ Luterana Brasil, PPG Diagnost Genet & Mol, BR-92425900 Canoas, RS, Brazil; Univ Fed Rio Grande do Sul, PPG Genet & Biol Mol, Porto Alegre, RS, Brazil; Hosp Municipal Pronto Socorro, SAMU, Porto Alegre, RS, Brazil	Regner, A (corresponding author), Univ Luterana Brasil, PPG Diagnost Genet & Mol, Av Farroupilha 8001,Predio 22,5 Andar, BR-92425900 Canoas, RS, Brazil.	regner@uol.com.br	Simon, Daniel/A-9087-2011; Regner, Andrea/M-2596-2014; Grivicich, Ivana/A-6777-2013	Simon, Daniel/0000-0003-1122-8468; Regner, Andrea/0000-0002-6657-7991; Grivicich, Ivana/0000-0001-9820-5730			Becker S, 1999, EUR J PEDIATR, V158, pS197, DOI 10.1007/PL00014355; Berger RP, 2005, J NEUROSURG, V103, P61, DOI 10.3171/ped.2005.103.1.0061; BLANN AD, 1993, MED HYPOTHESES, V41, P419, DOI 10.1016/0306-9877(93)90118-A; Da Rocha AB, 2005, J NEUROTRAUM, V22, P966, DOI 10.1089/neu.2005.22.966; da Rocha AB, 2006, CLIN CHEM LAB MED, V44, P1234, DOI 10.1515/CCLM.2006.218; Finfer SR, 2001, RESUSCITATION, V48, P77, DOI 10.1016/S0300-9572(00)00321-X; Fischer RR, 1996, BRAZ J MED BIOL RES, V29, P1641; Garcia-Fernandez N, 2000, THROMB RES, V100, P19, DOI 10.1016/S0049-3848(00)00306-6; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Jarrar D, 2000, AM J PHYSIOL-HEART C, V279, pH1015; KESSLER CM, 2004, CECIL TXB MED, P1069; KRAUS JF, 1996, NEUROTRAUMA, P13; Lai Y. C., 1998, Annals Academy of Medicine Singapore, V27, P326; Leone M, 2003, CHEST, V124, P2261, DOI 10.1378/chest.124.6.2261; Lynch JR, 2004, STROKE, V35, P57, DOI 10.1161/01.STR.0000105927.62344.4C; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Masson F, 2003, BRAIN INJURY, V17, P279, DOI 10.1080/0269905021000030805; McGirt MJ, 2002, NEUROSURGERY, V51, P1128, DOI 10.1097/00006123-200211000-00005; MEISSNER RV, 1992, BRAZ J GENET, V15, P935; Mendolicchio GL, 2005, SEMIN HEMATOL, V42, P5, DOI 10.1053/j.seminhematol.2004.09.006; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Pelsers MMAL, 2005, CLIN CHEM LAB MED, V43, P802, DOI 10.1515/CCLM.2005.135; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; Pineda JA, 2004, BRAIN PATHOL, V14, P202, DOI 10.1111/j.1750-3639.2004.tb00054.x; Raabe A, 2003, RESTOR NEUROL NEUROS, V21, P159; Regner A, 2001, NEUROREPORT, V12, P691, DOI 10.1097/00001756-200103260-00015; Roof RL, 2000, J NEUROTRAUM, V17, P367, DOI 10.1089/neu.2000.17.367; Siemiatkowski A, 2000, HAEMOSTASIS, V30, P189; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Woertgen C, 1999, J TRAUMA, V47, P1126, DOI 10.1097/00005373-199912000-00026; Yokota H, 2002, J NEUROTRAUM, V19, P1007, DOI 10.1089/089771502760341929; ZAGARA G, 1992, J NEUROSURG SCI, V35, P77	32	32	33	0	2	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2007	24	8					1331	1338		10.1089/neu.2006.0159			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	202QQ	WOS:000248918500004	17711394				2021-06-18	
J	Boyd, LA; Vidoni, ED; Daly, JJ				Boyd, Lara A.; Vidoni, Eric D.; Daly, Janis J.			Answering the call: The influence of neuroimaging and electrophysiological evidence on rehabilitation	PHYSICAL THERAPY			English	Article; Proceedings Paper	Combined Sections Meeting of the American-Physical-Therapy-Association	FEB 01-05, 2006	San Diego, CA	Amer Phys Therapy Assoc			MOTOR CORTEX ACTIVATION; SOMATOSENSORY-EVOKED POTENTIALS; TRAUMATIC BRAIN-INJURY; WHITE-MATTER INJURY; DIFFUSION TENSOR; FUNCTIONAL MRI; PARKINSONS-DISEASE; BASAL GANGLIA; THERAPEUTIC FACILITATION; MOVEMENT REPRESENTATIONS	Functional recovery after brain damage or disease is dependent on the neuroplastic capability of the cortex and the nonaffected brain. Following cortical injury in the motor and sensory regions, the adjacent spared neural tissues and related areas undergo modifications that are required in order to drive more normal motor control. Current rehabilitation models seek to stimulate functional recovery by capitalizing on the inherent potential of the brain for positive reorganization after neurological injury or disease. This article discusses how neuroimaging and electrophysiological data can inform clinical practice; representative data from the modalities of functional magnetic resonance imaging, diffusion tensor imaging, magnetoencephalography, electroencephalography, and positron emission tomography are cited. Data from a variety of central nervous system disease and damage models are presented to illustrate how rehabilitation practices are beginning to be shaped and informed by neuroimaging and electrophysiological data.	Univ British Columbia, Sch Rehabil Sci, Vancouver, BC V6T 2B5, Canada; Univ Kansas, Med Ctr, Dept Phys Therapy & Rehabil Sci, Lawrence, KS 66045 USA; Case Western Reserve Univ, Sch Med, Dept Neurol, Cleveland, OH 44106 USA; Louis Stokes Cleveland Dept Vet Affairs Med Ctr, Stroke Control & Motor Learning Lab, Cleveland, OH USA	Boyd, LA (corresponding author), Univ British Columbia, Sch Rehabil Sci, T325-2211 Westbrook Mall, Vancouver, BC V6T 2B5, Canada.	Laraboyd@interchange.ubc.ca			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD36725, HD053163] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD053163, R01HD036725] Funding Source: NIH RePORTER		Ahn YH, 2006, NEUROREPORT, V17, P987, DOI 10.1097/01.wnr.0000220128.01597.e0; Bajo A, 2002, BRAIN INJURY, V16, P385, DOI 10.1080/02699050110119826; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Boecker H, 1998, J NEUROPHYSIOL, V79, P1070; Bondi MW, 1993, NEUROPSYCHOLOGY, V7, P89, DOI DOI 10.1037/0894-4105.7.1.89; Boyd LA, 2004, LEARN MEMORY, V11, P388, DOI 10.1101/lm.80104; Bruck W, 2003, NEUROL SCI, V24, pS265, DOI 10.1007/s10072-003-0170-7; Calautti C, 2003, STROKE, V34, P1553, DOI 10.1161/01.STR.0000071761.36075.A6; Cao Y, 1998, STROKE, V29, P112, DOI 10.1161/01.STR.29.1.112; Carey JR, 2004, EXP BRAIN RES, V154, P281, DOI 10.1007/s00221-003-1662-7; Carey JR, 2002, BRAIN, V125, P773, DOI 10.1093/brain/awf091; Carter BG, 1999, INTENS CARE MED, V25, P722, DOI 10.1007/s001340050936; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Cohen LG, 1998, J CLIN NEUROPHYSIOL, V15, P305, DOI 10.1097/00004691-199807000-00003; Cramer SC, 2004, STROKE, V35, P240; Cramer SC, 2003, NEUROL RES, V25, P811, DOI 10.1179/016164103771953899; Cramer SC, 2002, HUM BRAIN MAPP, V16, P197, DOI 10.1002/hbm.10040; Cramer SC, 2001, STROKE, V32, P334; Cramer SC, 2002, ANN NEUROL, V52, P607, DOI 10.1002/ana.10351; Cramer SC, 1997, STROKE, V28, P2518, DOI 10.1161/01.STR.28.12.2518; Cramer SC, 2000, NEUROPHARMACOLOGY, V39, P842, DOI 10.1016/S0028-3908(99)00258-0; Dagher A, 1999, BRAIN, V122, P1973, DOI 10.1093/brain/122.10.1973; Dagher A, 2001, BRAIN, V124, P1020, DOI 10.1093/brain/124.5.1020; Daly JJ, 2006, IEEE T NEUR SYS REH, V14, P168, DOI 10.1109/TNSRE.2006.875554; Dancause N, 2005, J NEUROSCI, V25, P10167, DOI 10.1523/JNEUROSCI.3256-05.2005; Dancause N, 2006, J COMP NEUROL, V495, P374, DOI 10.1002/cne.20875; DASILVA FL, 1999, ELECTROENCEPHALOGRAP, P43; Davies PM, 1985, STEPS FOLLOW GUIDE T; Dobkin BH, 2003, STROKE, V34, pE26, DOI 10.1161/01.STR.0000071140.00153.05; Dong Y, 2006, STROKE, V37, P1552, DOI 10.1161/01.STR.0000221281.69373.4e; Fang Y, 2004, BRAIN RES, V1023, P200, DOI 10.1016/j.brainres.2004.07.035; Fang Y, 2001, J NEUROPHYSIOL, V86, P1764; Feydy A, 2002, STROKE, V33, P1610, DOI 10.1161/01.STR.0000017100.68294.52; FISCH BJ, 1999, FISCH SPEBLMANNS EEG; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; Gerloff C, 2006, BRAIN, V129, P791, DOI 10.1093/brain/awh713; Gulani V, 2006, J NEURO-OPHTHALMOL, V26, P51, DOI 10.1097/01.wno.0000205978.86281.3e; Hallett M, 2005, J REHABIL RES DEV, V42, pXVII, DOI 10.1682/JRRD.2005.07.0126; HARRINGTON DL, 1990, J CLIN EXP NEUROPSYC, V12, P323, DOI 10.1080/01688639008400978; HARRINGTON DL, 1991, BRAIN, V114, P99; HARRINGTON DL, 1987, J MOTOR BEHAV, V19, P77, DOI 10.1080/00222895.1987.10735401; Herve D, 2005, J NEUROL NEUROSUR PS, V76, P200, DOI 10.1136/jnnp.2004.041012; Hesse S, 1998, ELECTROMYOGR MOTOR C, V109, P515, DOI 10.1016/S1388-2457(98)00033-9; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Jang SH, 2006, RESTOR NEUROL NEUROS, V24, P65; Johansen-Berg H, 2002, BRAIN, V125, P2731, DOI 10.1093/brain/awf282; Johansen-Berg H, 2002, P NATL ACAD SCI USA, V99, P14518, DOI 10.1073/pnas.222536799; Johansson BB, 2000, STROKE, V31, P223, DOI 10.1161/01.STR.31.1.223; Jonides J, 1998, J NEUROSCI, V18, P5026; JUEPTNER M, 1995, NEUROLOGY, V45, P1540, DOI 10.1212/WNL.45.8.1540; Kim YH, 2004, YONSEI MED J, V45, P241, DOI 10.3349/ymj.2004.45.2.241; Kleim JA, 2002, NEUROBIOL LEARN MEM, V77, P63, DOI 10.1006/nlme.2000.4004; Kleim JA, 1998, J NEUROPHYSIOL, V80, P3321; Knowlton BJ, 1996, SCIENCE, V273, P1399, DOI 10.1126/science.273.5280.1399; Kunimatsu A, 2003, NEURORADIOLOGY, V45, P532, DOI 10.1007/s00234-003-0974-4; Le Bihan D, 2001, J MAGN RESON IMAGING, V13, P534, DOI 10.1002/jmri.1076; Lee JS, 2005, NEUROIMAGE, V26, P771, DOI 10.1016/j.neuroimage.2005.02.036; Lee JW, 2006, J HEAD TRAUMA REHAB, V21, P272, DOI 10.1097/00001199-200605000-00007; Lew HL, 2003, AM J PHYS MED REHAB, V82, P53, DOI 10.1097/01.PHM.0000043771.90606.81; Lombardi WJ, 1999, J CLIN EXP NEUROPSYC, V21, P2, DOI 10.1076/jcen.21.1.2.940; Luft AR, 2002, STROKE, V33, P416; Lustig C, 2004, NEURON, V42, P865, DOI 10.1016/j.neuron.2004.04.002; Lustig C, 2003, P NATL ACAD SCI USA, V100, P14504, DOI 10.1073/pnas.2235925100; Marshall RS, 2000, STROKE, V31, P656, DOI 10.1161/01.STR.31.3.656; Mazzini L, 1999, ARCH PHYS MED REHAB, V80, P33, DOI 10.1016/S0003-9993(99)90304-0; Morgen K, 2004, BRAIN, V127, P2506, DOI 10.1093/brain/awh266; Morgen K, 2006, NEUROIMAGE, V30, P891, DOI 10.1016/j.neuroimage.2005.10.032; Mori S, 2002, NMR BIOMED, V15, P468, DOI 10.1002/nbm.781; Munoz-Cespedes JM, 2005, NEUROPSYCHOL REV, V15, P169, DOI 10.1007/s11065-005-9178-5; Munson S, 2006, PEDIATRICS, V117, P1372, DOI 10.1542/peds.2005-0826; Neuper C, 1996, NEUROSCI LETT, V216, P17; Nudo RJ, 1997, SEMIN NEUROSCI, V9, P13, DOI 10.1006/smns.1997.0102; Nudo RJ, 2001, MUSCLE NERVE, V24, P1000, DOI 10.1002/mus.1104; Nudo RJ, 1996, J NEUROSCI, V16, P785; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Owen AM, 1998, BRAIN, V121, P949, DOI 10.1093/brain/121.5.949; Owen AM, 1998, CURR BIOL, V8, pR850, DOI 10.1016/S0960-9822(07)00529-5; OWEN AM, 1992, BRAIN, V115, P1727, DOI 10.1093/brain/115.6.1727; Pendlebury ST, 1999, STROKE, V30, P956, DOI 10.1161/01.STR.30.5.956; Petrella JR, 2005, J NEUROPSYCH CLIN N, V17, P75, DOI 10.1176/appi.neuropsych.17.1.75; Pfurtscheller G., 1999, HANDB EL CL, V6, P245; Pierallini A, 2000, NEURORADIOLOGY, V42, P860, DOI 10.1007/s002340000447; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Pineiro R, 2002, STROKE, V33, P103, DOI 10.1161/hs0102.100482; Pineiro R, 2001, STROKE, V32, P1134, DOI 10.1161/01.STR.32.5.1134; Plautz EJ, 2003, NEUROL RES, V25, P801, DOI 10.1179/016164103771953880; Plautz EJ, 2000, NEUROBIOL LEARN MEM, V74, P27, DOI 10.1006/nlme.1999.3934; Rasova K, 2005, CLIN REHABIL, V19, P170, DOI 10.1191/0269215505cr831oa; Ricker JH, 2001, J CLIN EXP NEUROPSYC, V23, P196, DOI 10.1076/jcen.23.2.196.1204; Robinson LR, 2003, CRIT CARE MED, V31, P960, DOI 10.1097/01.CCM.0000053643.21751.3B; Romero SG, 2002, NEUROCASE, V8, P355, DOI 10.1093/neucas/8.5.355; SALMON DP, 1995, CURR OPIN NEUROBIOL, V5, P184, DOI 10.1016/0959-4388(95)80025-5; SALMONI AW, 1984, PSYCHOL BULL, V95, P355, DOI 10.1037/0033-2909.95.3.355; Schmidt R.A., 1999, MOTOR CONTROL LEARNI, V3rd ed; Seghier ML, 2005, BMC NEUROL, V5, DOI 10.1186/1471-2377-5-17; SHIBASAKI H, 1980, ELECTROEN CLIN NEURO, V50, P201, DOI 10.1016/0013-4694(80)90147-9; Shibasaki H, 1980, Prog Brain Res, V54, P237, DOI 10.1016/S0079-6123(08)61632-5; Slobounov S, 2004, CLIN NEUROPHYSIOL, V115, P2391, DOI 10.1016/j.clinph.2004.05.021; Small SL, 2002, BRAIN, V125, P1544, DOI 10.1093/brain/awf148; Sorensen AG, 1999, RADIOLOGY, V212, P785, DOI 10.1148/radiology.212.3.r99se24785; STANCAK A, 1999, HANDB EL CL, V6, P269; Strangman G, 2005, AM J PHYS MED REHAB, V84, P62, DOI 10.1097/01.PHM.0000150787.26860.12; Thomalla G, 2004, NEUROIMAGE, V22, P1767, DOI 10.1016/j.neuroimage.2004.03.041; Ukkonen M, 2003, EUR J NEUROL, V10, P663, DOI 10.1046/j.1468-1331.2003.00617.x; van Pul C, 2005, AM J NEURORADIOL, V26, P469; Vergara-Aragon P, 2003, J NEUROSCI, V23, P579; Wang L, 2006, NEUROIMAGE, V31, P496, DOI 10.1016/j.neuroimage.2005.12.033; WEILLER C, 1992, ANN NEUROL, V31, P463, DOI 10.1002/ana.410310502; WEILLER C, 1993, ANN NEUROL, V33, P181; Werring DJ, 1998, J NEUROL NEUROSUR PS, V65, P863, DOI 10.1136/jnnp.65.6.863; Wheaton LA, 2005, EXP BRAIN RES, V163, P535, DOI 10.1007/s00221-005-2314-x; Wheaton LA, 2005, CLIN NEUROPHYSIOL, V116, P1382, DOI 10.1016/j.clinph.2005.01.008; Wiese H, 2005, STROKE, V36, P1474, DOI 10.1161/01.STR.0000170639.26891.30; Winstein CJ, 2003, NEUROREHAB NEURAL RE, V17, P137, DOI 10.1177/0888439003255511; Yagura H, 2006, ARCH PHYS MED REHAB, V87, P529, DOI 10.1016/j.apmr.2005.11.035; You SH, 2005, STROKE, V36, P1166, DOI 10.1161/01.STR.0000162715.43417.91; Zemke AC, 2002, STROKE, V33, P351	118	32	34	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0031-9023	1538-6724		PHYS THER	Phys. Ther.	JUN	2007	87	6					684	703		10.2522/ptj.20060164			20	Orthopedics; Rehabilitation	Orthopedics; Rehabilitation	174ZU	WOS:000246982400007	17429001	Bronze			2021-06-18	
J	Lu, KT; Wu, CY; Yen, HH; Peng, JHF; Wang, CL; Yang, YL				Lu, Kwok-Tung; Wu, Chang-Yen; Yen, Hao-Han; Peng, Jeng-Hsiung F.; Wang, Chi-Ling; Yang, Yi-Ling			Bumetanide administration attenuated traumatic brain injury through IL-1 overexpression	NEUROLOGICAL RESEARCH			English	Article						traumatic brain injury; Na+-K+-2Cl(-) -cotransporter; IL-1	K-CL COTRANSPORTER; INTERLEUKIN-1 RECEPTOR ANTAGONIST; CEREBRAL-ISCHEMIA; NEURONAL DAMAGE; REACTIVE ASTROCYTES; EDEMA; EXPRESSION; RAT; INFLAMMATION; MODEL	Objective: To examine the effects of administration of bumetanide, a specific NKCC1 inhibitor, on traumatic brain injury (TBI)-induced interleukin-1 (IL-1) expression. Methods: TBI model was induced by the calibrated weight drop device (450 g in weight, 2.0 m in height) in adult rats based on procedures previously reported. One hundred and sixty Wistar rats were divided into sham-control group and experimental group for time course works of TBI. The expression of IL-1b brain edema and neuronal damage were determined in these animals after TBI. Results: We found that both mRNA and protein of IL-1b were up-regulated in the hippocampus 3-24 hours after TBI. Animals displayed severe brain edema and neuron damage after TBI. Bumetanide (15 mg/kg), a specific Na+- K+- 2Cl(-) cotransporter inhibitor, significantly attenuated the TBI-induced neuronal damage by IL-1b overexpression. The present study suggests that administration of bumetanide could significantly decreased TBI-induced inflammatory response and neuronal damage.	Natl Chiayi Univ, Inst Biotechnol, Dept Mol Biol & Biochem, Chiayi, Taiwan; Natl Chiayi Univ, Gen Educ Ctr, Chiayi, Taiwan; Natl Taiwan Normal Univ, Dept Life Sci, Taipei, Taiwan	Yang, YL (corresponding author), Natl Chiayi Univ, Inst Biotechnol, Dept Mol Biol & Biochem, Chiayi, Taiwan.	ylyang@mail.ncyu.edu.tw					Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Busse S, 2005, BRAIN RES, V1046, P116, DOI 10.1016/j.brainres.2005.03.055; Chen CA, 2002, MOL PHYLOGENET EVOL, V23, P137, DOI 10.1016/S1055-7903(02)00008-8; Chen H, 2005, NEUROL RES, V27, P280, DOI 10.1179/016164105X25243; Chen H, 2005, J CEREBR BLOOD F MET, V25, P54, DOI 10.1038/sj.jcbfm.9600006; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; GIULIAN D, 1989, J NEUROSCI, V9, P4416; GIULIAN D, 1985, SCIENCE, V228, P497, DOI 10.1126/science.3872478; Goss JR, 1998, EXP NEUROL, V149, P301, DOI 10.1006/exnr.1997.6712; GOSS JR, 1995, J NEUROCHEM, V64, P1351; Haas M, 2000, ANNU REV PHYSIOL, V62, P515, DOI 10.1146/annurev.physiol.62.1.515; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; JAVAHERI S, 1991, J APPL PHYSIOL, V71, P795; Lu KT, 2005, NEUROSCI LETT, V386, P40, DOI 10.1016/j.neulet.2005.05.057; Lu KT, 2005, J NEUROTRAUM, V22, P885, DOI 10.1089/neu.2005.22.885; Lu KT, 2006, EUR J PHARMACOL, V548, P99, DOI 10.1016/j.ejphar.2006.07.048; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; O'Donnell ME, 2004, J CEREBR BLOOD F MET, V24, P1046, DOI 10.1097/01.WCB.0000130867.32663.90; Obermuller N, 1996, J CLIN INVEST, V98, P635, DOI 10.1172/JCI118834; OBRENOVITCH TP, 1995, CEREBROVAS BRAIN MET, V7, P1; ODONNELL ME, 1995, AM J PHYSIOL-CELL PH, V268, pC747; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; PAYNE JA, 1995, CURR OPIN CELL BIOL, V7, P493, DOI 10.1016/0955-0674(95)80005-0; Plotkin MD, 1997, AM J PHYSIOL-CELL PH, V272, pC173; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; Ringel F, 2000, J NEUROCHEM, V75, P125, DOI 10.1046/j.1471-4159.2000.0750125.x; Rostworowski M, 1997, J NEUROSCI, V17, P3664; Stamatovic SM, 2006, ACTA NEUROCHIR SUPPL, V96, P444; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x	35	32	35	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUN	2007	29	4					404	409		10.1179/016164107X204738			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	192PM	WOS:000248214200011	17626737				2021-06-18	
J	Prilloff, S; Noblejas, MI; Chedhomme, V; Sabel, BA				Prilloff, S.; Noblejas, M. I.; Chedhomme, V.; Sabel, B. A.			Two faces of calcium activation after optic nerve trauma: life or death of retinal ganglion cells in vivo depends on calcium dynamics	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						calcium imaging; ICON-microscopy; light stimulation; optic nerve crush; Oregon Green BAPTA-dextran	VISUAL-CORTEX; NEURONAL-ACTIVITY; GRADED CRUSH; BRAIN INJURY; ADULT-RATS; VISION; RESTORATION; RECOVERY; GROWTH; PLASTICITY	Calcium elevations after neurotrauma are not only implicated in cell death but may contribute to adaptive plasticity. We now wished to resolve this contradiction by following calcium dynamics after optic nerve crush in vivo. Adult rats received no injury (n = 5), unilateral mild (n = 10) or moderate optic nerve crush (n = 10) (ONC), or axotomy (n = 5). Before surgery, retinal ganglion cells (RGCs) were retrogradely labelled with Oregon Green BAPTA-dextran, a fluorescent calcium marker. Calcium-related fluorescence intensity (FI) was repeatedly measured in individual RGCs in vivo using the in vivo confocal neuroimaging (ICON) method. Four different RGC types were found. Normal RGCs without FI change were found in sham rats and also in both ONC groups. RGCs with mild damage were seen only after mild ONC, showing an initial calcium depression of 26% at day 4 followed by a 169% increase 15 days after ONC. RGCs with moderate damage were found only after moderate ONC and showed calcium hypoactivation followed by a slower return toward baseline and a delayed calcium increase of 72% above baseline. Sixty to sixty-five per cent of the RGCs in both ONC groups and all RGCs in the axotomy group died within 6 days following a fast and massive calcium increase of 316% with a concomitant 156% soma size increase. In conclusion rapid calcium elevation leads to cell death, while an initial calcium depression followed by a delayed and moderate calcium hyperactivation is associated with cell survival. We propose that immediate, massive calcium activation is maladaptive whereas delayed and moderate hyperactivation of surviving cells is adaptive. Implications for pharmacotherapy are discussed.	Univ Magdeburg, Med Fac, Inst Med Psychol, D-39120 Magdeburg, Germany	Sabel, BA (corresponding author), Univ Magdeburg, Med Fac, Inst Med Psychol, Leipziger Str 44, D-39120 Magdeburg, Germany.	Bernhard.Sabel@medizin.uni-magdeburg.de	Sabel, Bernhard A./E-6579-2013	Sabel, Bernhard/0000-0002-4472-5543			Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Barmashenko G, 2001, NEUROREPORT, V12, P3023, DOI 10.1097/00001756-200110080-00009; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bootman MD, 2001, J CELL SCI, V114, P2213; Chino YM, 1999, RESTOR NEUROL NEUROS, V15, P165; CHOI DW, 1988, J NEUROSCI, V8, P185; COHAN CS, 1986, SCIENCE, V232, P1638, DOI 10.1126/science.3715470; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; DUVDEVANI R, 1990, RESTOR NEUROL NEUROS, V2, P31, DOI 10.3233/RNN-1990-2104; Eysel UT, 1999, RESTOR NEUROL NEUROS, V15, P153; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; Gomez TM, 1999, NATURE, V397, P350, DOI 10.1038/16927; Gomez TM, 2000, J NEUROBIOL, V44, P174, DOI 10.1002/1097-4695(200008)44:2<174::AID-NEU7>3.3.CO;2-I; Hanke J, 2004, ACT NEUR S, V89, P75; Hasbani MJ, 1998, EXP NEUROL, V154, P241, DOI 10.1006/exnr.1998.6929; Hatton J, 2001, CNS DRUGS, V15, P553, DOI 10.2165/00023210-200115070-00005; Hyrc K, 1997, J NEUROSCI, V17, P6669; Kasten E, 1998, NAT MED, V4, P1083, DOI 10.1038/2079; Kasten E, 1999, RESTOR NEUROL NEUROS, V15, P273; KATER SB, 1990, PROG BRAIN RES, V86, P117; KIMLEE MH, 1993, BRAIN RES, V613, P156, DOI 10.1016/0006-8993(93)90467-2; Konur S, 2005, NEURON, V46, P401, DOI 10.1016/j.neuron.2005.04.022; MATTSON MP, 1988, BRAIN RES REV, V13, P179, DOI 10.1016/0165-0173(88)90020-3; MCCAIG CD, 1991, EXP PHYSIOL, V76, P473, DOI 10.1113/expphysiol.1991.sp003514; MCCLELLAN AD, 1994, BRAIN RES, V663, P61, DOI 10.1016/0006-8993(94)90462-6; McPherson DR, 1997, BRAIN RES PROTOC, V1, P157, DOI 10.1016/S1385-299X(96)00024-4; Mittmann T, 2001, NEUROREPORT, V12, P3341, DOI 10.1097/00001756-200110290-00039; Mohr JP, 1998, CEREBROVASC DIS, V8, P17, DOI 10.1159/000047499; Nicotera P, 2003, TOXICOL SCI, V74, P4, DOI 10.1093/toxsci/kfg109; RASMUSSEN H, 1989, SCI AM, V261, P66, DOI 10.1038/scientificamerican1089-66; Rousseau V, 2001, RESTOR NEUROL NEUROS, V18, P177; Rousseau V, 1999, NEUROREPORT, V10, P3387, DOI 10.1097/00001756-199911080-00024; Sabel BA, 1999, RESTOR NEUROL NEUROS, V15, P177; Sabel BA, 1999, RESTOR NEUROL NEUROS, V15, P73; Sabel BA, 1997, NAT MED, V3, P244, DOI 10.1038/nm0297-244; SAUTTER J, 1993, EUR J NEUROSCI, V5, P680, DOI 10.1111/j.1460-9568.1993.tb00533.x; SAUTTER J, 1991, BRAIN RES, V565, P23, DOI 10.1016/0006-8993(91)91732-G; Schiefer U, 1999, RESTOR NEUROL NEUROS, V15, P201; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; SILVEIRA LCL, 1994, J NEUROCYTOL, V23, P75, DOI 10.1007/BF01183863; Spitzer NC, 2000, BIOESSAYS, V22, P811; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; VANHUIZEN F, 1987, DEV BRAIN RES, V31, P1, DOI 10.1016/0165-3806(87)90077-0; VANHUIZEN F, 1987, EXP NEUROL, V97, P280, DOI 10.1016/0014-4886(87)90089-6; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; Walker SA, 2003, FEBS LETT, V546, P6, DOI 10.1016/S0014-5793(03)00412-5; Werth R, 1999, RESTOR NEUROL NEUROS, V15, P229; Yoles E, 1998, ARCH OPHTHALMOL-CHIC, V116, P906, DOI 10.1001/archopht.116.7.906	48	32	32	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	JUN	2007	25	11					3339	3346		10.1111/j.1460-9568.2007.05550.x			8	Neurosciences	Neurosciences & Neurology	176WL	WOS:000247115500014	17553002				2021-06-18	
J	Hu, JN; Yang, SL; Xuan, Y; Jiang, Q; Yang, YH; Haacke, EM				Hu, Jiani; Yang, Shaolin; Xuan, Yang; Jiang, Quart; Yang, Yihong; Haacke, E. Mark			Simultaneous detection of resolved glutamate, glutamine, and gamma-aminobutyric acid at 4 T	JOURNAL OF MAGNETIC RESONANCE			English	Article						glutamate; glutamine; gamma-aminobutyric acid (GABA); H-1 MR spectroscopy; STEAM	MAGNETIC-RESONANCE SPECTROSCOPY; MULTIPLE-QUANTUM FILTER; HUMAN BRAIN; IN-VIVO; MR SPECTROSCOPY; COUPLED SPINS; 3 TESLA; GABA; PRESS; QUANTIFICATION	A new approach is introduced to simultaneously detect resolved glutamate (Gin), glutamine (Gin), and gamma-aminobutyric acid (GABA) using a standard STEAM localization pulse sequence with the optimized sequence timing parameters. This approach exploits the dependence of the STEAM spectra of the strongly coupled spin systems of Gin, Gin, and GABA on the echo time TE and the mixing time TM at 4 T to find an optimized sequence parameter set, i.e., {TE, TM}, where the outer-wings of the Gin C4 multiplet resonances around 2.35 ppm, the Gin C4 multiplet resonances around 2.45 ppm, and the GABA C2 multiplet resonance around 2.28 ppm are significantly suppressed and the three resonances become virtual singlets simultaneously and thus resolved. Spectral simulation and optimization were conducted to find the optimized sequence parameters, and phantom and in vivo experiments (on normal human brains, one patient with traumatic brain injury, and one patient with brain tumor) were carried out for verification. The results have demonstrated that the Gin, Glu, and GABA signals at 2.2-2.5 ppm can be well resolved using a standard STEAM sequence with the optimized sequence timing parameters around {82 ms, 48 ms} at 4 T, while the other main metabolites, such as N-acetyl aspartate (NAA), choline (Who), and creatine (tCr), are still preserved in the same spectrum. The technique can be easily implemented and should prove to be a useful tool for the basic and clinical studies associated with metabolism of Gin, Gin, and/or GABA. (C) 2006 Elsevier Inc. All rights reserved.	Wayne State Univ, Dept Radiol, Detroit, MI 48201 USA; Natl Inst Drug Abuse, Neuroimaging Res Branch, Baltimore, MD 21224 USA; Henry Ford Hosp, Dept Neurol, Detroit, MI 48201 USA	Hu, JN (corresponding author), Wayne State Univ, Dept Radiol, Detroit, MI 48201 USA.	jhu@med.wayne.edu			Intramural NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [Z01 DA000469-02] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [Z01DA000469] Funding Source: NIH RePORTER		Bartha R, 2000, MAGNET RESON MED, V44, P185; Chang WK, 1999, CLIN EXP IMMUNOL, V117, P482, DOI 10.1046/j.1365-2249.1999.01009.x; Choi C, 2006, MAGN RESON MED, V55, P997, DOI 10.1002/mrm.20875; CHOI C, 2006, P 14 SCI M INT SOC M, P3064; Choi CH, 2005, MAGN RESON MED, V54, P272, DOI 10.1002/mrm.20563; Clementi V, 2005, MAGN RESON MED, V54, P1333, DOI 10.1002/mrm.20703; de Graaf RA, 2001, J MAGN RESON, V152, P124, DOI 10.1006/jmre.2001.2371; ERNST T, 1993, J MAGN RESON SER B, V102, P1, DOI 10.1006/jmrb.1993.1055; Govindaraju V, 2000, NMR BIOMED, V13, P129, DOI 10.1002/1099-1492(200005)13:3<129::AID-NBM619>3.0.CO;2-V; Hanstock CC, 2002, MAGN RESON MED, V48, P617, DOI 10.1002/mrm.10265; Hetherington HP, 1998, MAGNET RESON MED, V39, P6, DOI 10.1002/mrm.1910390103; Hurd R, 2004, MAGNET RESON MED, V51, P435, DOI 10.1002/mrm.20007; Jensen JE, 2005, MAGNET RESON MED, V54, P783, DOI 10.1002/mrm.20644; Keltner JR, 1996, MAGNET RESON MED, V36, P458; Kim H, 2005, MAGNET RESON MED, V53, P760, DOI 10.1002/mrm.20434; LEE HK, 1995, MAGNET RESON MED, V34, P253, DOI 10.1002/mrm.1910340217; Mates JM, 2002, INT J BIOCHEM CELL B, V34, P439, DOI 10.1016/S1357-2725(01)00143-1; Maudsley AA, 2005, J MAGN RESON, V173, P54, DOI 10.1016/j.jmr.2004.11.018; Mayer D, 2005, MAGNET RESON MED, V54, P439, DOI 10.1002/mrm.20571; MOATS RA, 1994, MAGNET RESON MED, V32, P110, DOI 10.1002/mrm.1910320115; Oh J, 2005, J MAGN RESON IMAGING, V21, P701, DOI 10.1002/jmri.20335; Patel AB, 2005, P NATL ACAD SCI USA, V102, P5588, DOI 10.1073/pnas.0501703102; Petroff OAC, 1996, ANN NEUROL, V39, P95, DOI 10.1002/ana.410390114; Pioro EP, 1999, NEUROLOGY, V53, P71, DOI 10.1212/WNL.53.1.71; Pitt D, 2000, NAT MED, V6, P67, DOI 10.1038/71555; Ratiney H, 2005, NMR BIOMED, V18, P1, DOI 10.1002/nbm.895; Sanacora G, 1999, ARCH GEN PSYCHIAT, V56, P1043, DOI 10.1001/archpsyc.56.11.1043; SCHOUSBOE A, 1993, DEV NEUROSCI-BASEL, V15, P359, DOI 10.1159/000111356; Schubert F, 2004, NEUROIMAGE, V21, P1762, DOI 10.1016/j.neuroimage.2003.11.014; Seeger U, 2003, MAGNET RESON MED, V49, P19, DOI 10.1002/mrm.10332; Shen J, 2002, MAGNET RESON MED, V47, P447, DOI 10.1002/mrm.10104; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; SMITH SA, 1994, J MAGN RESON SER A, V106, P75, DOI 10.1006/jmra.1994.1008; Soher BJ, 2005, MAGNET RESON MED, V53, P1283, DOI 10.1002/mrm.20491; TaylorRobinson SD, 1996, MOVEMENT DISORD, V11, P167, DOI 10.1002/mds.870110209; Thompson RB, 1998, MAGNET RESON MED, V39, P762, DOI 10.1002/mrm.1910390514; Thompson RB, 1999, MAGNET RESON MED, V41, P1162, DOI 10.1002/(SICI)1522-2594(199906)41:6<1162::AID-MRM12>3.0.CO;2-N; Thompson RB, 2001, MAGNET RESON MED, V45, P955, DOI 10.1002/mrm.1128; Young K, 1999, J MAGN RESON, V140, P146, DOI 10.1006/jmre/1999.1809; Zipfel GJ, 2000, J NEUROTRAUM, V17, P857, DOI 10.1089/neu.2000.17.857	40	32	34	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1090-7807	1096-0856		J MAGN RESON	J. Magn. Reson.	APR	2007	185	2					204	213		10.1016/j.jmr.2006.12.010			10	Biochemical Research Methods; Physics, Atomic, Molecular & Chemical; Spectroscopy	Biochemistry & Molecular Biology; Physics; Spectroscopy	176HT	WOS:000247076200003	17223596	Green Accepted			2021-06-18	
J	Wagner, AK; Ren, DX; Conley, YP; Ma, XC; Kerr, ME; Zafonte, RD; Puccio, AM; Marion, DW; Dixon, CE				Wagner, Amy K.; Ren, Dianxu; Conley, Yvette P.; Ma, Xiecheng; Kerr, Mary E.; Zafonte, Ross D.; Puccio, Ava M.; Marion, Donald W.; Dixon, C. Edward			Sex and genetic associations with cerebrospinal fluid dopamine and metabolite production after severe traumatic brain injury	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; cerebrospinal fluid; dopamine; homovanillic acid; dihydroxyphenylacetic acid; sex-based difference; genetic polymorphism	WATER MAZE PERFORMANCE; GENDER-DIFFERENCES; METHYLPHENIDATE TREATMENT; TRANSPORTER AVAILABILITY; HOMOVANILLIC-ACID; DOWN-REGULATION; AMINO-ACIDS; IN-VIVO; ESTROGEN; HEALTHY	Object. Dopamine (DA) pathways have been implicated in cognitive deficits after traumatic brain injury (TBI). Both sex and the dopamine transporter (DAT) 3' variable number of tandem repeat polymorphism have been associated with differences in DAT protein density, and DAT protein affects both presynaptic DA release, through reverse transport, and DA reuptake. Catecholamines and associated metabolites are subject to autooxidation, resulting in the formation of reactive oxygen species that may contribute to subsequent oxidative injury. The purpose of this study was to determine associations between factors that affect DAT expression and cerebrospinal fluid (CSF) DA and metabolite levels after severe TBI. Methods. Sixty-three patients with severe TBI (Glasgow Coma Scale score : 8) were evaluated. The patients' genotypes were obtained using previously banked samples of CSF, and serial CSF samples (416 samples) were used to evaluate DA and metabolite levels. High-performance liquid chromatography was used to determine CSF levels of DA, 3,4-dihydroxyphenyl acetic acid (DOPAC), and homovanillic acid (HVA) during the first 5 days after injury. Mixed-effects multivariate regression modeling revealed that patients with the DAT 10/10 genotype had higher CSF DA levels than patients with either the DAT 9/9 or DAT 9/10 genotypes (p = 0.009). Females with the DAT 10/10 genotype had higher CSF DA levels than females with the DAT 9/9 or DAT 9/10 genotypes, and sex was associated with higher DOPAC levels (p = 0.004). Inotrope administration also contributed to higher DA levels (p = 0.002). Conclusions. In addition to systemic administration of DA, inherent factors such as sex and DAT genotype affect post-TBI CSF DA and DA metabolite levels, a phenomenon that may modulate susceptibility to DA-mediated oxidative injury.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15213 USA	Wagner, AK (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Suite 202, Pittsburgh, PA 15213 USA.	wagnerak@upmc.edu	Marion, Donald/AAR-5749-2021		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD040833] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030318] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K08HD40833] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS30318] Funding Source: Medline		AGNATI LF, 1995, MED RES REV, V15, P33, DOI 10.1002/med.2610150104; Beaumont A, 2001, J NEUROTRAUM, V18, P1359, DOI 10.1089/08977150152725650; Becker JB, 1999, PHARMACOL BIOCHEM BE, V64, P803, DOI 10.1016/S0091-3057(99)00168-9; Borland LM, 2004, J NEUROCHEM, V91, P220, DOI 10.1111/j.1471-4159.2004.02708.x; Bullock R, 1996, Eur J Emerg Med, V3, P109, DOI 10.1097/00063110-199606000-00010; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; COOK EH, 1995, AM J HUM GENET, V56, P993; Daws LC, 2002, BIOCHEM BIOPH RES CO, V290, P1545, DOI 10.1006/bbrc.2002.6384; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; Dluzen DE, 2000, J NEUROCYTOL, V29, P387, DOI 10.1023/A:1007117424491; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; DOUCETTESTAMM LA, 1995, GENET EPIDEMIOL, V12, P303, DOI 10.1002/gepi.1370120307; Engelborghs S, 2003, NEUROCHEM RES, V28, P1145, DOI 10.1023/A:1024255208563; Gardiner SA, 2004, AM J GERIAT PSYCHIAT, V12, P621, DOI 10.1176/appi.ajgp.12.6.621; GARRIS PA, 1994, J NEUROSCI, V14, P6084; Gerevich Z, 2001, NEUROSCIENCE, V104, P761, DOI 10.1016/S0306-4522(01)00102-6; Gerlach M, 2001, J NEURAL TRANSM, V108, P189, DOI 10.1007/s007020170087; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; Gulley JM, 2003, EUR J PHARMACOL, V479, P139, DOI 10.1016/j.ejphar.2003.08.064; Hastings TG, 1996, ADV EXP MED BIOL, V387, P97; Heinz A, 2000, NEUROPSYCHOPHARMACOL, V22, P133, DOI 10.1016/S0893-133X(99)00099-8; HORN AS, 1990, PROG NEUROBIOL, V34, P387, DOI 10.1016/0301-0082(90)90033-D; Jiang H, 2003, NEUROPHARMACOLOGY, V45, P1011, DOI 10.1016/S0028-3908(03)00286-7; Jones SR, 1998, P NATL ACAD SCI USA, V95, P4029, DOI 10.1073/pnas.95.7.4029; Jonsson EG, 2000, J PSYCHIAT RES, V34, P239, DOI 10.1016/S0022-3956(00)00013-3; Kelly SJ, 1999, PHARMACOL BIOCHEM BE, V64, P655, DOI 10.1016/S0091-3057(99)00167-7; Khoshbouei H, 2003, J BIOL CHEM, V278, P12070, DOI 10.1074/jbc.M212815200; Kline AE, 2000, NEUROSCI LETT, V280, P163, DOI 10.1016/S0304-3940(00)00797-7; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Krause KH, 2000, NEUROSCI LETT, V285, P107, DOI 10.1016/S0304-3940(00)01040-5; Kroppenstedt SN, 2000, CRIT CARE MED, V28, P3792, DOI 10.1097/00003246-200012000-00004; Lambert G, 2002, BRAIN RES BULL, V58, P77, DOI 10.1016/S0361-9230(02)00762-1; Laranjinha J, 2002, J NEUROCHEM, V81, P892, DOI 10.1046/j.1471-4159.2002.00900.x; Lavalaye J, 2000, EUR J NUCL MED, V27, P867, DOI 10.1007/s002590000279; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; McEwen B, 2002, RECENT PROG HORM RES, V57, P357, DOI 10.1210/rp.57.1.357; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Michelhaugh SK, 2001, J NEUROCHEM, V79, P1033, DOI 10.1046/j.1471-4159.2001.00647.x; MORISSETTE M, 1993, NEUROENDOCRINOLOGY, V58, P16, DOI 10.1159/000126507; Newcorn J H, 2001, Curr Psychiatry Rep, V3, P87, DOI 10.1007/s11920-001-0004-3; Nirenberg MJ, 1997, J NEUROSCI, V17, P6899; Oechsner M, 2002, J NEURAL TRANSM, V109, P69, DOI 10.1007/s702-002-8237-z; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; PORTA M, 1975, EUR NEUROL, V13, P545, DOI 10.1159/000114710; Ract C, 2001, J NEUROTRAUM, V18, P1247, DOI 10.1089/089771501317095287; Raiteri M, 1978, Ann Ist Super Sanita, V14, P97; RIVEST R, 1995, BRAIN RES, V692, P269, DOI 10.1016/0006-8993(95)00611-S; Sesack SR, 1998, J NEUROSCI, V18, P2697; SMITH TS, 1994, NEUROREPORT, V5, P1009, DOI 10.1097/00001756-199404000-00039; Swanson JM, 2000, NEUROSCI BIOBEHAV R, V24, P21, DOI 10.1016/S0149-7634(99)00062-7; VECHT CJ, 1975, ARCH NEUROL-CHICAGO, V32, P792, DOI 10.1001/archneur.1975.00490540036004; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Xie T, 1999, MOL PHARMACOL, V56, P31; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; YATES CM, 1979, J NEUROL NEUROSUR PS, V42, P887, DOI 10.1136/jnnp.42.10.887; Youdim MBH, 2004, NEUROLOGY, V63, pS32, DOI 10.1212/WNL.63.7_suppl_2.S32; Zhang H, 2003, J CHROMATOGR B, V784, P131, DOI 10.1016/S1570-0232(02)00788-2	59	32	32	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2007	106	4					538	547		10.3171/jns.2007.106.4.538			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	155OJ	WOS:000245586900005	17432702				2021-06-18	
J	Barber, RC; Aragaki, CC; Chang, LYE; Purdue, GF; Hunt, JL; Arnoldo, BD; Horton, JW				Barber, Robert C.; Aragaki, Corinne C.; Chang, Ling-Yu E.; Purdue, Gary F.; Hunt, John L.; Arnoldo, Brett D.; Horton, Jureta W.			CD14-159 C allele is associated with increased risk of mortality after burn injury	SHOCK			English	Article						mortality; burn injury; innate immunity; polymorphism; SNP; CD14	TOLL-LIKE RECEPTOR-4; INTERLEUKIN-6 PROMOTER POLYMORPHISM; LIPOPOLYSACCHARIDE-BINDING PROTEIN; SINGLE NUCLEOTIDE POLYMORPHISM; ACUTE MYOCARDIAL-INFARCTION; GRAM-NEGATIVE BACTERIA; SEVERE SEPSIS; SIGNAL-TRANSDUCTION; SOLUBLE CD14; MYCOBACTERIUM-TUBERCULOSIS	Although comprehension of postburn pathophysiology has grown in recent years, we are still unable to accurately identify burn patients who are at an increased risk of infectious complications and death. This unexplained variation is likely influenced by heritable factors; the genetic predisposition for death from infection has been estimated as greater than that for cardiovascular disease or cancer. Identify genetic variants associated with increased mortality after burn injury. A total of 233 patients with burns of 15% of total body surface area or greater or smoke inhalation injury who survived more than 48 h after admission and were without significant nonburn-related trauma (injury severity score >= 16), traumatic or anoxic brain injury, or spinal cord injury. We examined the influence of genotype at five candidate loci (interleukin [IL]-1 beta, IL-6, tumor necrosis factor-a, toll-like receptor 4, CD14) on mortality risk after burn injury. DNA was isolated from residual blood from laboratory draws and candidate genotypes were determined by real-time polymerase chain reaction using TaqMan probes. Clinical data were prospectively collected into a local, curated database. Allelic associations were analyzed by multivariate logistic regression. After adjustment for age, full-thickness burn size, inhalation injury, ethnicity, and sex, carriage of the CD14-159 C allele imparted at least a 1.3-fold increased risk for death after burn injury, relative to TT homozygotes (adjusted odds ratio, 2.9; 95% confidence interval, 1.3 - 6.8; P= 0.01). This association was stronger (adjusted odds ratio, 3.3; 95% confidence interval, 1.3 - 8.4; P = 0.01) when the analysis was conducted only on deaths accompanied by severe sepsis. In addition, a gene dosage effect for increased mortality was apparent for carriage of the CD14-159 C allele (P = 0.006). The gene dosage effect remained when white, Hispanic, or African American patients were analyzed independently, although statistical significance was not achieved in the subgroup analysis. None of the other single nucleotide polymorphisms examined were significantly associated with mortality. These data provide strong evidence that a CD14 promoter allele that is known to impart lower baseline and induced CD14 transcription also affects mortality risk after burn injury. A potential (although untested) mechanism for our observation is that reduced signaling through CD14/toll-like receptor 4 in response to challenge by gram-negative bacteria after burns results in a blunted innate immune response and subsequent increased likelihood for systemic infection and death.	Univ Texas, SW Med Ctr, Dept Surg, Dallas, TX 75390 USA; Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Div Epidemiol, Houston, TX USA; Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Div Biostat, Houston, TX USA	Barber, RC (corresponding author), Univ Texas, SW Med Ctr, Dept Surg, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	robert.barber@utsouthwesternm.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P50GM021681] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [5P50GM021681-40] Funding Source: Medline		Abel B, 2002, J IMMUNOL, V169, P3155, DOI 10.4049/jimmunol.169.6.3155; Abraham LJ, 1999, J LEUKOCYTE BIOL, V66, P562; Agnese DM, 2002, J INFECT DIS, V186, P1522, DOI 10.1086/344893; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; An HZ, 2002, IMMUNOLOGY, V106, P38, DOI 10.1046/j.1365-2567.2002.01401.x; Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI 10.1097/00003246-200107001-00035; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Arnalich F, 2002, CLIN EXP IMMUNOL, V127, P331, DOI 10.1046/j.1365-2249.2002.01743.x; Barber RC, 2003, CRIT CARE MED, V31, pA50; Barber RC, 2004, J MED GENET, V41, P808, DOI 10.1136/jmg.2004.021600; Barber RC, 2006, CLIN MED RES, V4, P250, DOI 10.3121/cmr.4.4.250; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Brull DJ, 2001, ARTERIOSCL THROM VAS, V21, P1458, DOI 10.1161/hq0901.094280; Burgmann H, 1996, CLIN IMMUNOL IMMUNOP, V80, P307, DOI 10.1006/clin.1996.0128; Carrillo EH, 2001, J TRAUMA, V50, P810, DOI 10.1097/00005373-200105000-00006; Comstock KL, 1998, J MOL CELL CARDIOL, V30, P2761, DOI 10.1006/jmcc.1998.0851; Diks SH, 2004, CURR TOP MED CHEM, V4, P1115, DOI 10.2174/1568026043388141; Ebong SJ, 2001, INFECT IMMUN, V69, P2099, DOI 10.1128/IAI.69.4.2099-2106.2001; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Fang CWH, 2002, J TRAUMA, V53, P957, DOI 10.1097/00005373-200211000-00024; Fishman D, 1998, EUR CYTOKINE NETW, V9, P364; Gibot S, 2002, CRIT CARE MED, V30, P969, DOI 10.1097/00003246-200205000-00003; Haynes LM, 2001, J VIROL, V75, P10730, DOI 10.1128/JVI.75.22.10730-10737.2001; Henneke P, 2001, J IMMUNOL, V167, P7069, DOI 10.4049/jimmunol.167.12.7069; Heumann D, 2002, CLIN CHIM ACTA, V323, P59, DOI 10.1016/S0009-8981(02)00180-8; Hubacek JA, 1999, CIRCULATION, V99, P3218, DOI 10.1161/01.CIR.99.25.3218; Hubacek JA, 2000, GENES IMMUN, V1, P405, DOI 10.1038/sj.gene.6363691; Kitchens RL, 2001, J CLIN INVEST, V108, P485, DOI 10.1172/JCI200113139; Koch W, 2002, AM HEART J, V143, P971, DOI 10.1067/mhj.2002.122512; Kondo T, 2003, HEART, V89, P931, DOI 10.1136/heart.89.8.931; Kroeger KM, 2000, CYTOKINE, V12, P110, DOI 10.1006/cyto.1999.0529; LANDMANN R, 1995, J INFECT DIS, V171, P639, DOI 10.1093/infdis/171.3.639; Le Roy D, 2001, J IMMUNOL, V167, P2759, DOI 10.4049/jimmunol.167.5.2759; LeVan TD, 2001, J IMMUNOL, V167, P5838, DOI 10.4049/jimmunol.167.10.5838; Lin Jing, 2004, Zhongguo Wei Zhong Bing Ji Jiu Yi Xue, V16, P271; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Nwariaku F, 1996, J TRAUMA, V40, P564, DOI 10.1097/00005373-199604000-00007; O'Keefe GE, 2002, J TRAUMA, V52, P817, DOI 10.1097/00005373-200205000-00001; O'Neill LAJ, 2002, CURR TOP MICROBIOL, V270, P47; Power CP, 2004, J IMMUNOL, V173, P5229, DOI 10.4049/jimmunol.173.8.5229; PUGIN J, 1993, J EXP MED, V178, P2193, DOI 10.1084/jem.178.6.2193; Pugin J, 1995, Prog Clin Biol Res, V392, P369; Reiling N, 2002, J IMMUNOL, V169, P3480, DOI 10.4049/jimmunol.169.7.3480; Schimke J, 1998, P NATL ACAD SCI USA, V95, P13875, DOI 10.1073/pnas.95.23.13875; Schluter B, 2002, CRIT CARE MED, V30, P32, DOI 10.1097/00003246-200201000-00005; Schwartz DA, 2002, INT J HYG ENVIR HEAL, V205, P221, DOI 10.1078/1438-4639-00117; Shimada K, 2000, AM J CARDIOL, V86, P682, DOI 10.1016/S0002-9149(00)01054-7; SORENSEN TIA, 1988, NEW ENGL J MED, V318, P727, DOI 10.1056/NEJM198803243181202; STEINEMANN S, 1994, ARTERIOSCLER THROMB, V14, P1202, DOI 10.1161/01.ATV.14.7.1202; Ulevitch RJ, 2001, CRIT CARE MED, V29, pS8, DOI 10.1097/00003246-200107001-00004; ULEVITCH RJ, 1990, J TRAUMA, V30, pS189; Wang Y, 2003, HEPATOLOGY, V37, P65, DOI 10.1053/jhep.2003.50017	52	32	33	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	MAR	2007	27	3					232	237		10.1097/01.shk.0000239770.10528.9a			6	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	140AV	WOS:000244475300003	17304102				2021-06-18	
J	Qu, Y; Chen-Roetling, J; Benvenisti-Zarom, L; Regan, RF				Qu, Yan; Chen-Roetling, Jing; Benvenisti-Zarom, Luna; Regan, Raymond F.			Attenuation of oxidative injury after induction of experimental intracerebral hemorrhage in heme oxygenase-2 knockout mice	JOURNAL OF NEUROSURGERY			English	Article						stroke; intracerebral hemorrhage; free radical; hemoglobin; iron; lipid peroxidation; mouse	TRAUMATIC BRAIN-INJURY; HEME OXYGENASE-1 HO-1; RAT-BRAIN; SUBARACHNOID HEMORRHAGE; HEMOGLOBIN TOXICITY; LIPID-PEROXIDATION; TIN-MESOPORPHYRIN; CARBON-MONOXIDE; CELL INJURY; NEURONS	Object. Experimental evidence suggests that hemoglobin degradation products contribute to cellular injury after intracerebal hemorrhage (ICH). Hemoglobin breakdown is catalyzed in part by the heme oxygenase (HO) enzymes. In the present study, the authors tested the hypothesis that HO-2 gene deletion is cytoprotective in an experimental ICH model. Methods. After anesthesia was induced with isoflurane, 3- to 6-month-old HO-2 knockout and wild-type mice were stereotactically injected with 15 mu l autologous blood and a group of control mice were injected with an equal volume of sterile saline. Striatal protein and lipid oxidation were quantified 72 hours later using carbonyl and malondialdehyde assays. Cell viability was determined by performing a 3(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) assay. Following blood injection, the investigators found a 3.4-fold increase in protein carbortylation compared with that in the contralateral striatum in wild-type mice; in knockout mice, the investigators found a twofold increase. The mean malondialdehyde concentration in injected striata was increased twofold in wild-type mice at this time, compared with 1.5-fold in knockout mice. Cell viability, as determined by NITT reduction, was reduced in injected striata to 38 +/- 4% of that in the contralateral striata in wild-type mice, compared with 66 +/- 5% in HO-2 knockout mice. Baseline striatal HO-1 protein expression was similar in wild-type and HO-2 knockout mice, but was induced more rapidly in the former after blood injection. Conclusions. Deletion of HO-2 attenuates oxidative cell injury after whole-blood injection into the mouse striatum. Therapies that specifically target HO-2 may improve outcome after ICH.	Thomas Jefferson Univ, Dept Emergency Med, Philadelphia, PA 19107 USA	Regan, RF (corresponding author), Thomas Jefferson Univ, Dept Emergency Med, 1020 Sansom St,Thompson Bldg,Room 329, Philadelphia, PA 19107 USA.	Raymond.Regan@jefferson.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS042273] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042273] Funding Source: NIH RePORTER		Arthur AS, 1997, NEUROSURGERY, V41, P1385, DOI 10.1097/00006123-199712000-00028; Balla J, 2005, MOL NUTR FOOD RES, V49, P1030, DOI 10.1002/mnfr.200500076; Blumenthal SB, 2005, FASEB J, V19, P1272, DOI 10.1096/fj.04-3259com; Chang EF, 2003, J NEUROSCI, V23, P3689; Dennery PA, 1998, J CLIN INVEST, V101, P1001, DOI 10.1172/JCI448; Dore S, 1999, MOL MED, V5, P656, DOI 10.1007/BF03401984; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Fukuda K, 1996, BRAIN RES, V736, P68, DOI 10.1016/0006-8993(96)00680-4; Grundemar L, 1997, TRENDS PHARMACOL SCI, V18, P193, DOI 10.1016/S0165-6147(97)01065-1; GUTTERIDGE JMC, 1986, FEBS LETT, V201, P291, DOI 10.1016/0014-5793(86)80626-3; HEINSEN H, 1994, ACTA NEUROPATHOL, V88, P320, DOI 10.1007/BF00310376; Huang FP, 2002, J NEUROSURG, V96, P287, DOI 10.3171/jns.2002.96.2.0287; Jing CR, 2005, J NEUROSCI RES, V82, P802, DOI 10.1002/jnr.20681; Koeppen AH, 2004, J NEUROPATH EXP NEUR, V63, P587, DOI 10.1093/jnen/63.6.587; Kress GJ, 2002, J NEUROSCI, V22, P5848; Matz P, 1996, BRAIN RES, V713, P211, DOI 10.1016/0006-8993(95)01511-6; Matz PG, 1997, NEUROSURGERY, V40, P152, DOI 10.1097/00006123-199701000-00034; Munoz AM, 2005, J CHEM NEUROANAT, V29, P113, DOI 10.1016/j.jchemneu.2004.10.001; Murrell M. T., 1997, Society for Neuroscience Abstracts, V23, P849; Nakamura T, 2004, J NEUROSURG, V100, P672, DOI 10.3171/jns.2004.100.4.0672; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; Nimura T, 1996, MOL BRAIN RES, V37, P201, DOI 10.1016/0169-328X(95)00315-J; Ono S, 2001, ACT NEUR S, V77, P93; POSS KD, 1995, NEURON, V15, P867, DOI 10.1016/0896-6273(95)90177-9; Qu Y, 2005, J CEREBR BLOOD F MET, V25, P1466, DOI 10.1038/sj.jcbfm.9600143; Regan RF, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-34; Regan RF, 2003, J NEUROTRAUM, V20, P111, DOI 10.1089/08977150360517236; Rogers B, 2003, FREE RADICAL BIO MED, V35, P872, DOI 10.1016/S0891-5849(03)00431-3; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Ryter SW, 2004, BIOESSAYS, V26, P270, DOI 10.1002/bies.20005; SADRZADEH SMH, 1987, J CLIN INVEST, V79, P662, DOI 10.1172/JCI112865; SADRZADEH SMH, 1984, J BIOL CHEM, V259, P4354; STURROCK RR, 1980, NEUROPATH APPL NEURO, V6, P51, DOI 10.1111/j.1365-2990.1980.tb00204.x; Wagner KR, 2000, CELL MOL BIOL, V46, P597; Wang J, 2006, NEUROBIOL DIS, V22, P473, DOI 10.1016/j.nbd.2005.12.009; WEBER CM, 1994, J NEUROCHEM, V63, P953; Wu JM, 2003, STROKE, V34, P2964, DOI 10.1161/01.STR.0000103140.52838.45; Xi GH, 1998, STROKE, V29, P2580, DOI 10.1161/01.STR.29.12.2580; Yamauchi T, 2004, J NEUROTRAUM, V21, P1017, DOI 10.1089/0897715041651042	39	32	33	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2007	106	3					428	435		10.3171/jns.2007.106.3.428			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	145KV	WOS:000244864700010	17367065				2021-06-18	
J	Sherman, TE; Rapport, LJ; Hanks, RA; Ryan, KA; Keenan, PA; Khan, O; Lisak, RP				Sherman, T. E.; Rapport, L. J.; Hanks, R. A.; Ryan, K. A.; Keenan, P. A.; Khan, O.; Lisak, R. P.			Predictors of well-being among significant others of persons with multiple sclerosis	MULTIPLE SCLEROSIS			English	Article						anosognosia; awareness of deficit; caregiver; multiple sclerosis; neurobehavioral; significant other; social support; subjective well-being	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; SOCIAL SUPPORT; SHORT-FORM; CAREGIVERS; AWARENESS; IMPAIRMENT; SYMPTOMS; INDIVIDUALS; DYSFUNCTION	Objective To examine patient and significant other characteristics as predictors of significant other well-being. Methods A total of 74 persons with multiple sclerosis (MS) and their significant others participated. Executive functioning was measured using neuropsychological tests. Awareness of cognitive deficit was measured as the discrepancy between the patient's reports of their abilities and objective test results. Awareness of functional deficit was measured as the discrepancy between the patient's and significant other's reports of the patient's functional abilities. Patient neurobehavioral disturbance was measured using a significant-other rated questionnaire. Significant other perceived social support and well-being (ie, psychological distress, life satisfaction, and general health status) were assessed using questionnaires filled out by the significant other. Results Executive dysfunction, neurobehavioral disturbance, and lack of awareness of functional deficits in patients were associated with poor well-being outcomes; whereas, lack of awareness of cognitive deficits was only weakly related to well-being. Social support was associated with positive well-being outcomes. Conclusions Diminished insight regarding functional limitations may increase significant others' supervisory burden as patients attempt activities independently, whereas lack of awareness of cognitive deficits may not be directly associated with behavior-relevant impairments that significant others find distressing. Social support appears to be a powerful aid in diffusing the distress among significant others of MS patients.	Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Detroit, MI 48201 USA; Wayne State Univ, Dept Psychol, Detroit, MI 48202 USA; Sci Oriented Solut, Kennesaw, GA 30144 USA; Wayne State Univ, Sch Med, Dept Neurol, Detroit, MI 48201 USA	Sherman, TE (corresponding author), Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Detroit, MI 48201 USA.	tsherman@dmc.org					Anderson S. W., 1989, CLIN NEUROPSYCHOL, V3, P327, DOI DOI 10.1080/13854048908401482; Aronson KJ, 1997, NEUROLOGY, V48, P74, DOI 10.1212/WNL.48.1.74; BEATTY WW, 1988, ARCH NEUROL-CHICAGO, V45, P611, DOI 10.1001/archneur.1988.00520300029013; BEATTY WW, 1991, J CLIN EXP NEUROPSYC, V13, P309, DOI 10.1080/01688639108401046; BENTON A L, 1978, Archives of Neurology, V35, P364; BOYLE EA, 1991, ARCH NEUROL-CHICAGO, V48, P1150, DOI 10.1001/archneur.1991.00530230058022; Carone DA, 2005, J INT NEUROPSYCH SOC, V11, P574, DOI 10.1017/S135561770505068X; Chiaravalloti ND, 2003, COGN BEHAV NEUROL, V16, P54, DOI 10.1097/00146965-200303000-00007; Cottrell SS, 1926, J NEUROL PSYCHOPATHO, V7, P1; Cutrona CE., 1987, ADV PERSONAL RELATIO, V1, P37; DEBETTIGNIES BH, 1990, J CLIN EXP NEUROPSYC, V12, P355, DOI 10.1080/01688639008400980; Delis D. C., 2000, CVLT 2 CALIFORNIA VE; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595, DOI 10.1017/S0033291700048017; Derogatis LR., 1993, NATL COMPUTER SYSTEM; DEsposito M, 1996, NEUROPSYCHOLOGY, V10, P51, DOI 10.1037/0894-4105.10.1.51; DesRosier M B, 1992, Rehabil Nurs, V17, P87; DIENER E, 1984, J PERS SOC PSYCHOL, V47, P1105, DOI 10.1037/0022-3514.47.5.1105; Diener E., 2002, HDB POSITIVE PSYCHOL, P63, DOI DOI 10.1093/OXFORDHB/9780195187243.013.0017; ELSASS P, 1983, ACTA NEUROL SCAND, V68, P257, DOI 10.1111/j.1600-0404.1983.tb04835.x; ERGH T, 2004, P 32 ANN M INT NEUR; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Feinstein A, 1997, ARCH NEUROL-CHICAGO, V54, P1116, DOI 10.1001/archneur.1997.00550210050012; Good D M, 1995, J Neurosci Nurs, V27, P305; Goverover Y, 2005, MULT SCLER J, V11, P203, DOI 10.1191/1352458505ms1153oa; GRANT I, 1989, CURR PROB N, V10, P17; Hart T, 2004, ARCH PHYS MED REHAB, V85, P1450, DOI 10.1016/j.apmr.2004.01.030; HEATON RK, 1993, WISCONSIN CORD SORTI; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Hobart J, 2001, BRAIN, V124, P962, DOI 10.1093/brain/124.5.962; Hoogervorst ELJ, 2001, NEUROLOGY, V56, P934, DOI 10.1212/WNL.56.7.934; JUDGE T, 1990, THESIS U ILLINOIS; Knight RG, 1997, J CLIN EXP NEUROPSYC, V19, P7, DOI 10.1080/01688639708403832; KNIGHT RG, 1992, NEUROPSYCHOLOGY DEGE; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; McKeown LP, 2003, CLIN REHABIL, V17, P234, DOI 10.1191/0269215503cr618oa; Mohr DC, 2001, J CLIN PSYCHOL, V57, P479, DOI 10.1002/jclp.1042; MOHR DC, 1998, CLIN HDB HLTH PSYCHO, P313; NELSON L, 1994, NEUROPSYCHOLOGY BEHA; O'Brien M T, 1993, J Community Health Nurs, V10, P123, DOI 10.1207/s15327655jchn1003_1; O'Brien R A, 1995, Sch Inq Nurs Pract, V9, P323; Pakenham K. I., 2001, PSYCHOL HEALTH MED, V6, P13, DOI [DOI 10.1080/13548500125141, 10.1080/13548500125141]; Paul RH, 1998, MULT SCLER, V4, P433, DOI 10.1177/135245859800400506; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; PEARLIN LI, 1990, GERONTOLOGIST, V30, P583, DOI 10.1093/geront/30.5.583; Pozzilli C, 2004, MULT SCLER, V10, P442, DOI 10.1191/1352458504ms1046oa; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P96; Provinciali L, 1999, ACTA NEUROL SCAND, V100, P156; Psychological Corporation, 1997, WAIS 3 WMS 3 TECHN M; RABINS PV, 1986, BRAIN, V109, P585, DOI 10.1093/brain/109.4.585; Randolph JJ, 2001, CLIN NEUROPSYCHOL, V15, P357, DOI 10.1076/clin.15.3.357.10278; RAO SM, 1991, NEUROLOGY, V41, P685, DOI 10.1212/WNL.41.5.685; RAO SM, 1984, BRAIN COGNITION, V3, P94, DOI 10.1016/0278-2626(84)90010-1; SARASON IG, 1985, PSYCHOSOM MED, V47, P156, DOI 10.1097/00006842-198503000-00007; Schretlen D, 1996, CLIN NEUROPSYCHOL, V10, P80, DOI 10.1080/13854049608406666; SCHULZ R, 1991, PSYCHOL AGING, V6, P569, DOI 10.1037/0882-7974.6.4.569; Seltzer B, 1997, GERONTOLOGIST, V37, P20, DOI 10.1093/geront/37.1.20; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; SMTIH A, 1973, SYMBOL DIGIT MODALIT; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stuss D.T., 1986, FRONTAL LOBES; Sugar C, 1943, J NERV MENT DIS, V98, P267, DOI 10.1097/00005053-194309000-00004; SURRIDGE D, 1969, BRIT J PSYCHIAT, V115, P749, DOI 10.1192/bjp.115.524.749; Tabachnick B.G., 2000, USING MULTIVARIATE S, V4th; Thornton AE, 2002, J INT NEUROPSYCH SOC, V8, P395, DOI 10.1017/S1355617702813200; Ware DL, 1996, QUALITY LIFE PHARMAC, P337; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Weinert C., 1993, FAM COMMUNITY HEALTH, V16, P46; Winegarden BJ, 1998, CLIN NEUROPSYCHOL, V12, P311, DOI 10.1076/clin.12.3.311.1992; Zakzanis KK, 2000, ARCH CLIN NEUROPSYCH, V15, P115, DOI 10.1016/S0887-6177(98)00157-7; Zivadinov R, 1999, J NEUROL SCI, V168, P127, DOI 10.1016/S0022-510X(99)00189-6	76	32	32	0	5	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	1352-4585			MULT SCLER	Mult. Scler.	MAR	2007	13	2					238	249		10.1177/1352458506070754			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	158LK	WOS:000245792800014	17439890				2021-06-18	
J	Redell, JB; Dash, PK				Redell, John B.; Dash, Pramod K.			Traumatic brain injury stimulates hippocampal catechol-O-methyl transferase expression in microglia	NEUROSCIENCE LETTERS			English	Article						protein array; microarray; proteomics; dopamine; COMT; TBI	RAT FRONTAL-CORTEX; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CONTROLLED CORTICAL IMPACT; DOPAMINE TRANSPORTER; PROTEIN EXPRESSION; PREFRONTAL CORTEX; WORKING-MEMORY; METHYLTRANSFERASE; TECHNOLOGY; GENOTYPE	Outcome following traumatic brain injury (TBI) is in large part determined by the combined action of multiple processes. In order to better understand the response of the central nervous system to injury, we utilized an antibody array to simultaneously screen 507 proteins for altered expression in the injured hippocampus, a structure critical for memory formation. Array analysis indicated 41 candidate proteins have altered expression levels 24h after TBI. Of particular interest was catechol-O-methyl transferase (COMT), an enzyme involved in metabolizing catecholamines released following neuronal activity. Altered catecholamine signaling has been observed after brain injury, and may contribute to the cognitive dysfunctions and behavioral deficits often experienced after TBI. Our data shows that COMT expression in the injured ipsilateral hippocampus was elevated for at least 14 d after controlled cortical impact injury. We found strong co-localization of COMT immunoreactivity with the microglia marker lbal near the injury site. Since dopamine transporter expression has been reported to be down-regulated after brain injury, COMT-mediated catecholamine metabolism may play a more prominent role in terminating catecholamine signaling in injured areas. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Univ Texas, Sch Med, Dept Neurobiol, Houston, TX 77030 USA; Univ Texas, Sch Med, Dept Anat, Houston, TX 77030 USA; Univ Texas, Sch Med, Vivian L Smith Ctr Neurol Res, Houston, TX 77030 USA	Dash, PK (corresponding author), Univ Texas, Sch Med, Dept Neurobiol & Anat, POB 20708, Houston, TX 77225 USA.	p.dash@uth.tmc.edu			NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH072933, R01 MH072933] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS035457, R01 NS049160, NS35457, NS049160] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH072933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS049160, R01NS035457] Funding Source: NIH RePORTER		Akil M, 2003, J NEUROSCI, V23, P2008; Anderson K, 2003, BRAIN, V126, P2052, DOI 10.1093/brain/awg208; Breitling R, 2004, FEBS LETT, V573, P83, DOI 10.1016/j.febslet.2004.07.055; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; Dash PK, 2004, NEUROCHEM RES, V29, P1275, DOI 10.1023/B:NERE.0000023614.30084.eb; Denslow N, 2003, J NEUROTRAUM, V20, P401, DOI 10.1089/089771503765355487; Egan MF, 2001, P NATL ACAD SCI USA, V98, P6917, DOI 10.1073/pnas.111134598; Farber K, 2005, MOL CELL NEUROSCI, V29, P128, DOI 10.1016/j.mcn.2005.01.003; Gao WM, 2006, BRAIN RES, V1070, P31, DOI 10.1016/j.brainres.2005.11.038; Gogos JA, 1998, P NATL ACAD SCI USA, V95, P9991, DOI 10.1073/pnas.95.17.9991; Haskins WE, 2005, J NEUROTRAUM, V22, P629, DOI 10.1089/neu.2005.22.629; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jiang YJ, 2002, J CEREBR BLOOD F MET, V22, P689, DOI 10.1097/00004647-200206000-00007; KAROUM F, 1994, J NEUROCHEM, V63, P972, DOI 10.1046/j.1471-4159.1994.63030972.x; Kline AE, 2002, J NEUROTRAUM, V19, P415, DOI 10.1089/08977150252932370; Kobori N, 2006, J NEUROSCI, V26, P4236, DOI 10.1523/JNEUROSCI.4687-05.2006; Kobori N, 2006, J NEUROTRAUM, V23, P1094, DOI 10.1089/neu.2006.23.1094; Lipsky RH, 2005, J NEUROPSYCH CLIN N, V17, P465, DOI 10.1176/appi.neuropsych.17.4.465; LUNDSTROM K, 1995, BBA-PROTEIN STRUCT M, V1251, P1, DOI 10.1016/0167-4838(95)00071-2; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Mu DZ, 2003, NEUROBIOL DIS, V14, P524, DOI 10.1016/j.nbd.2003.08.020; Privalsky ML, 2004, ANNU REV PHYSIOL, V66, P315, DOI 10.1146/annurev.physiol.66.032802.155556; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Redell JB, 2003, EXP BIOL MED, V228, P261; Sesack SR, 1998, J NEUROSCI, V18, P2697; Srivastava M, 2006, MOL GENET METAB, V87, P303, DOI 10.1016/j.ymgme.2005.10.021; Yan HQ, 2002, NEUROREPORT, V13, P1899, DOI 10.1097/00001756-200210280-00013; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009; Zhu J, 2000, EXP NEUROL, V166, P136, DOI 10.1006/exnr.2000.7484	30	32	35	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940			NEUROSCI LETT	Neurosci. Lett.	FEB 8	2007	413	1					36	41		10.1016/j.neulet.2006.11.060			6	Neurosciences	Neurosciences & Neurology	141JO	WOS:000244574800008	17240060	Green Accepted			2021-06-18	
J	Agha, A; Phillips, J; Thompson, CJ				Agha, Amar; Phillips, Jack; Thompson, C. J.			Hypopituitarism following traumatic brain injury (TBI)	BRITISH JOURNAL OF NEUROSURGERY			English	Article						hypopituitarism; pituitary; traumatic brain injury	GROWTH-HORMONE DEFICIENCY; ANTERIOR-PITUITARY INSUFFICIENCY; ANTI-DIURETIC HORMONE; SEVERE HEAD-INJURY; POSTTRAUMATIC HYPOPITUITARISM; INAPPROPRIATE SECRETION; BODY-COMPOSITION; HYPOGONADOTROPIC HYPOGONADISM; NEUROENDOCRINE DYSFUNCTION; SUBARACHNOID HEMORRHAGE	Traumatic brain injury ( TBI) is the commonest cause of death and disability in young adults living in industrialised countries. Recently, several studies have shown that hypopituitarism is a common complication of head trauma, with a prevalence of at least 25% among patients who were studied months or years following injury. This remarkably high frequency has changed the traditional concept of hypopituitarism being a rare complication of TBI, and suggests that most cases of posttraumatic hypopituitarism remain undiagnosed and untreated in clinical practice. It is therefore reasonable to infer that posttraumatic hypopituitarism may have an important contribution to the high physical and neuropsychiatric morbidity seen in patients with head injury. This article discusses the published reports on neuroendocrine dysfunction in TBI patients and the natural history of this disorder. The potential impact of posttraumatic hypopituitarism on recovery and rehabilitation after injury will also be examined, as well as the need for the identification, and appropriate and timely management of hormone deficiencies in order to reduce morbidity, aid recovery, and avoid the long-term complications of pituitary failure.	Beaumont Hosp, Div Endocrinol, Dublin 9, Ireland; Beaumont Hosp, Div Neurosurg, Dublin 9, Ireland; RCSI Med Sch, Dublin, Ireland	Agha, A (corresponding author), Beaumont Hosp, Dept Endocrinol, Beaumont Rd, Dublin 9, Ireland.	amaragha@beaumont.ie					Agha A, 2006, CLIN ENDOCRINOL, V64, P481, DOI 10.1111/j.1365-2265.2006.02517.x; Agha A, 2005, QJM-INT J MED, V98, P463, DOI 10.1093/qjmed/hci075; Agha A, 2005, AM J PHYS MED REHAB, V84, P381, DOI 10.1097/01.PHM.0000156898.47097.93; Agha A, 2005, EUR J ENDOCRINOL, V152, P371, DOI 10.1530/eje.1.01861; Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; BARTON RN, 1987, J TRAUMA, V27, P384, DOI 10.1097/00005373-198704000-00007; BECKER RM, 1973, J TRAUMA, V13, P112, DOI 10.1097/00005373-197302000-00003; Benvenga S, 1997, J ENDOCRINOL INVEST, V20, P675, DOI 10.1007/BF03348031; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; BESHYAH SA, 1995, CLIN ENDOCRINOL, V42, P179, DOI 10.1111/j.1365-2265.1995.tb01860.x; BINNERTS A, 1992, AM J CLIN NUTR, V55, P918; BJORK S, 1989, ACTA PAEDIATR SCAND, P55; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; BORN JD, 1985, SURG NEUROL, V23, P383, DOI 10.1016/0090-3019(85)90212-5; Boughey JC, 2004, AM SURGEON, V70, P500; Ceballos R, 1966, Ala J Med Sci, V3, P185; Cernak I, 1999, BRAIN INJURY, V13, P1005; CHIOLERO R, 1988, J TRAUMA, V28, P1368, DOI 10.1097/00005373-198809000-00011; CITTADINI A, 1994, AM J PHYSIOL, V267, pE219; Cohan P, 2005, CRIT CARE MED, V33, P2358, DOI 10.1097/01.CCM.0000181735.51183.A7; Colao A, 1999, J CLIN ENDOCR METAB, V84, P1919, DOI 10.1210/jc.84.6.1919; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; CUNEO RC, 1991, J APPL PHYSIOL, V70, P695; Cyran E, 1918, DEUT MED WOCHENSCHR, V44, P1261; DANIEL PM, 1959, LANCET, V2, P927; DEBOER H, 1992, J CLIN ENDOCR METAB, V75, P833, DOI 10.1210/jc.75.3.833; Della Corte F, 1998, CRIT CARE MED, V26, P1419; DOCZI T, 1982, NEUROSURGERY, V10, P685, DOI 10.1227/00006123-198206010-00001; EDWARDS OM, 1986, MEDICINE, V65, P281; EIHOLZER U, 1986, EUR J PEDIATR, V145, P128, DOI 10.1007/BF00441873; Escamilla RF, 1942, J CLIN ENDOCRINOL, V2, P65, DOI 10.1210/jcem-2-2-65; FLEISCHER AS, 1978, J NEUROSURG, V49, P650, DOI 10.3171/jns.1978.49.5.0650; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; HOLMES SJ, 1994, J CLIN ENDOCR METAB, V78, P669, DOI 10.1210/jc.78.3.669; Iglesias P, 1996, J ENDOCRINOL INVEST, V19, P320, DOI 10.1007/BF03347870; Kelly DF, 2006, J NEUROTRAUM, V23, P928, DOI 10.1089/neu.2006.23.928; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; KING LR, 1981, NEUROSURGERY, V9, P229, DOI 10.1227/00006123-198109000-00002; KLASBEEK WD, 1980, J NEUROSURG, V53, P519; Koiv L, 1997, ACTA NEUROL SCAND, V96, P52; KORNBLUM RN, 1969, ARCH PATHOL, V88, P242; Leal-Cerro A, 2005, CLIN ENDOCRINOL, V62, P525, DOI 10.1111/j.1365-2265.2005.02250.x; LEE SC, 1994, BRAIN INJURY, V8, P571; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Masel BE, 2004, GROWTH HORM IGF RES, V14, pS108, DOI 10.1016/j.ghir.2004.03.024; MATSUURA H, 1985, NEUROSURGERY, V16, P791, DOI 10.1227/00006123-198506000-00009; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; MCGAULEY GA, 1989, ACTA PAEDIATR SCAND, P70; MEROLA B, 1993, J CLIN ENDOCR METAB, V77, P1658, DOI 10.1210/jc.77.6.1658; Monson JP, 2003, EUR J ENDOCRINOL, V148, pS9, DOI 10.1530/eje.0.148S009; PIERUCCI G, 1971, Pathologica (Genoa), V63, P71; Popovic V, 2004, J ENDOCRINOL INVEST, V27, P1048, DOI 10.1007/BF03345308; RUDMAN D, 1977, J CLIN ENDOCR METAB, V45, P747, DOI 10.1210/jcem-45-4-747; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; TEASDALE G, 1974, LANCET, V2, P81; TWIJNSTRA A, 1980, CLIN NEUROL NEUROSUR, V82, P263, DOI 10.1016/0303-8467(80)90018-9; Van Baalen B, 2003, DISABIL REHABIL, V25, P9, DOI 10.1080/713813430; VIGERHOETS F, 1988, ACTA NEUROCHIR, V91, P50; Wong M. F. M., 1998, Annals Academy of Medicine Singapore, V27, P340; WOOLF PD, 1986, CLIN ENDOCRINOL, V25, P265, DOI 10.1111/j.1365-2265.1986.tb01691.x; WOOLF PD, 1988, AM J MED, V84, P201, DOI 10.1016/0002-9343(88)90414-7; World Health Organization, 1980, INT CLASS IMP DIS HA; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209; 1998, NIH             1026, P1	70	32	35	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.		2007	21	2					210	216		10.1080/02688690701253331			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	167UC	WOS:000246476900009	17453791				2021-06-18	
J	Goddeau, RP; Silverman, SB; Sims, JR				Goddeau, Richard P., Jr.; Silverman, Scott B.; Sims, John R.			Dexmedetomidine for the treatment of paroxysmal autonomic instability with dystonia	NEUROCRITICAL CARE			English	Article						dexmedetomidine; sympathetic storming; paroxysmal autonomic instability with dystonia; diencephalic seizure; dysautonomia; traumatic brain injury	TRAUMATIC BRAIN-INJURY; DIENCEPHALIC SEIZURES; SYMPATHETIC STORM; DYSAUTONOMIA; STIMULATION; LABETALOL; INFUSION	Introduction A 38-year-old man with severe head trauma complicated by paroxysmal severe intracranial pressure elevation associated with tachypnea, tachycardia, diaphoresis, and extensor posturing was diagnosed as suffering from paroxysmal autonomic instability with dystonia (PAID). These events were unresponsive to standard medical therapy, which included morphine, fentanyl, labetalol, lorazepam, metoprolol, and clonidine. Methods A trial treatment with dexmedetomidine dine, a central acting alpha2-agonist, to control symptoms of PAID was initiated 12 days after injury. PAID-related events subsided during the 72-h infusion protocol of 0.2-0.7 mcg/kg/h. No further events were noted after termination of the 72-h infusion. Conclusions Dexmedetomidine may be a novel pharmacologic agent to aid in abrogating PAID.	Massachusetts Gen Hosp East, Dept Neurol & Radiol, Div Neurocrit Care & Stroke, Boston, MA 02129 USA; Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA USA; Massachusetts Gen Hosp, Harvard Med Sch, Dept Neurol, Div Neucrit Care & Stroke, Boston, MA USA	Sims, JR (corresponding author), Massachusetts Gen Hosp East, Dept Neurol & Radiol, Div Neurocrit Care & Stroke, CNY149 Rm6403, Boston, MA 02129 USA.	jsims@partners.org					Baguley IJ, 2006, BRAIN INJURY, V20, P437, DOI 10.1080/02699050600664715; Becker R, 2000, J CLIN NEUROSCI, V7, P316, DOI 10.1054/jocn.1999.0227; Bernath O, 2001, J NEUROL NEUROSUR PS, V70, P818, DOI 10.1136/jnnp.70.6.818; Bicer C, 2006, EUR J ANAESTH, V23, P149, DOI 10.1017/S0265021505002061; Blackman JA, 2004, ARCH NEUROL-CHICAGO, V61, P321, DOI 10.1001/archneur.61.3.321; Boeve BF, 1998, MAYO CLIN PROC, V73, P148; BULLARD DE, 1987, ANN NEUROL, V21, P609, DOI 10.1002/ana.410210617; Cuny E, 2001, BRAIN INJURY, V15, P917, DOI 10.1080/02699050110065277; Diamond AL, 2005, NEUROCRIT CARE, V2, P288, DOI 10.1385/NCC:2:3:288; Do D, 2000, J NEUROL NEUROSUR PS, V69, P832, DOI 10.1136/jnnp.69.6.832; Eltorai I M, 1997, J Spinal Cord Med, V20, P361; Feld J, 2007, J CLIN ANESTH, V19, P30, DOI 10.1016/j.jclinane.2006.05.019; Fernandez-Ortega JF, 2006, J TRAUMA, V61, P1129, DOI 10.1097/01.ta.0000197634.83217.80; Goh KYC, 1999, PEDIATR NEUROL, V21, P742, DOI 10.1016/S0887-8994(99)00069-7; Gurbet A, 2006, CAN J ANAESTH, V53, P646, DOI 10.1007/BF03021622; Hogue CW, 2002, ANESTHESIOLOGY, V97, P592, DOI 10.1097/00000542-200209000-00012; Keren O, 2005, BRAIN INJURY, V19, P605, DOI 10.1080/02699050400024946; Oppenheimer SM, 1996, CLIN AUTON RES, V6, P131, DOI 10.1007/BF02281899; OPPENHEIMER SM, 1992, NEUROLOGY, V42, P1727, DOI 10.1212/WNL.42.9.1727; Swissa M, 2004, J AM COLL CARDIOL, V43, P858, DOI 10.1016/j.jacc.2003.07.053; TALMAN WT, 1988, ARCH NEUROL-CHICAGO, V45, P1037, DOI 10.1001/archneur.1988.00520330129022; Watt JA, 1999, J NEUROSCI, V19, P1586; Zhou SM, 2004, J CARDIOVASC ELECTR, V15, P430, DOI 10.1046/j.1540-8167.2004.03517.x	23	32	33	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care		2007	7	3					217	220		10.1007/s12028-007-0066-0			4	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	237SO	WOS:000251396900006	17603760				2021-06-18	
J	Moyle, JJ; Fox, AM; Bynevelt, M; Arthur, M; Burnett, JR				Moyle, J. J.; Fox, A. M.; Bynevelt, M.; Arthur, M.; Burnett, J. R.			A neuropsychological profile of off-diet adults with phenylketonuria	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; TREATED PHENYLKETONURIA; SUSTAINED ATTENTION; MULTIPLE-SCLEROSIS; TYROSINE DEPLETION; DOPAMINE SYNTHESIS; PHENYLALANINE; TRAIL; PKU; PERFORMANCE	The metabolic disorder phenylketonuria (PKU) is treated early by a low-phenylalanine diet. While this prevents global cognitive impairment, some patients still experience cognitive and neurophysiological abnormalities. Neuropsychological testing of early treated, currently off-diet, PKU patients attending an adult PKU clinic showed a reduction in the Perceptual Organization Index (POI), Processing Speed Index ( PSI) from the Wechsler Adult Intelligence Scale Third Edition (WAIS-III), and Part A of the Trail Making Test for the PKU group relative to controls. Taken together, these results supported a profile of reduced information-processing speed.	Univ Western Australia, Sch Psychol, Crawley, WA 6009, Australia; Royal Perth Hosp, Dept Radiol, Perth, WA, Australia; Royal Perth Hosp, Dept Nutr & Dietet, Perth, WA, Australia; Royal Perth Hosp, PathWest Lab Med WA, Dept Core Clin Pathol & Biochem, Perth, WA, Australia; Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia	Moyle, JJ (corresponding author), Univ Western Australia, Sch Psychol M304, 35 Stirling Highway, Crawley, WA 6009, Australia.	jmoyle@student.uwa.edu.au; afox@psy.uwa.edu.au	Fox, Allison M/H-9218-2014	Fox, Allison M/0000-0001-5189-6271			Arbuthnott K, 2000, J CLIN EXP NEUROPSYC, V22, P518, DOI 10.1076/1380-3395(200008)22:4;1-0;FT518; Brassington JC, 1998, NEUROPSYCHOL REV, V8, P43, DOI 10.1023/A:1025621700003; Brumm VL, 2004, J INHERIT METAB DIS, V27, P549, DOI 10.1023/B:BOLI.0000042985.02049.ff; Burgard P, 1997, PEDIATR RES, V41, P368, DOI 10.1203/00006450-199703000-00011; Channon S, 2005, NEUROPSYCHOLOGY, V19, P679, DOI 10.1037/0894-4105.19.5.679; Channon S, 2004, NEUROPSYCHOLOGY, V18, P613, DOI 10.1037/0894-4105.18.4.613; CHOI TB, 1986, J BIOL CHEM, V261, P6536; CLARKE JTR, 1987, AM J MENT RETARD, V92, P255; De Sonneville LMJ, 2002, NEUROPSYCHOLOGIA, V40, P1751, DOI 10.1016/S0028-3932(02)00041-6; DIAMOND A, 1987, MONOGRAPHS SOC RES C, V62, P1; Donders J, 2001, J INT NEUROPSYCH SOC, V7, P892, DOI 10.1017/S1355617701777132; Grevet EH, 2002, J PSYCHOPHARMACOL, V16, P51, DOI 10.1177/026988110201600103; Harmer CJ, 2001, PSYCHOPHARMACOLOGY, V154, P105, DOI 10.1007/s002130000613; Hedges L.V., 1985, STAT METHODS META AN; Henry JD, 2004, NEUROPSYCHOLOGY, V18, P284, DOI 10.1037/0894-4105.18.2.284; Huijbregts SCJ, 2002, NEUROPSYCHOLOGIA, V40, P7, DOI 10.1016/S0028-3932(01)00078-1; Huijbregts SCJ, 2003, NEUROPSYCHOLOGY, V17, P369, DOI 10.1037/0894-4105.17.3.369; Huttenlocher PR, 2000, EUR J PEDIATR, V159, pS102, DOI 10.1007/PL00014371; Joseph B, 2003, J NEUROCHEM, V86, P615, DOI 10.1046/j.1471-4159.2003.01887.x; Koch R, 2002, J INHERIT METAB DIS, V25, P333, DOI 10.1023/A:1020158631102; Lange RT, 2005, J CLIN EXP NEUROPSYC, V27, P897, DOI 10.1080/1380339049091290; Langeluddecke PM, 2003, CLIN NEUROPSYCHOL, V17, P273, DOI 10.1076/clin.17.2.273.16499; Luciana M, 2004, PSYCHOPHARMACOLOGY, V175, P18, DOI 10.1007/s00213-004-1775-0; Martin TA, 2003, APPL NEUROPSYCHOL, V10, P163, DOI 10.1207/S15324826AN1003_05; Miner T, 1998, BRAIN COGNITION, V38, P246, DOI 10.1006/brcg.1998.1034; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; PIETZ J, 1993, DEV MED CHILD NEUROL, V35, P54; Pietz J, 1998, EUR J PEDIATR, V157, P824, DOI 10.1007/s004310050945; *PSYCH CORP, 1997, WECHSL AD INT SCAL 3; *PSYCH CORP, 1997, WECHSL MEM SCAL 3 ED; Robertson I. H., 1994, TEST EVERYDAY ATTENT; SCHMIDT E, 1994, J CLIN EXP NEUROPSYC, V16, P681, DOI 10.1080/01688639408402681; Scriber C.R., 2001, METABOLIC MOL BASES, P1667, DOI [https://doi.org/10.1036/ommbid.97, DOI 10.1036/OMMBID.97]; Sumerall SW, 1997, J CLIN PSYCHOL, V53, P517, DOI 10.1002/(SICI)1097-4679(199708)53:5<517::AID-JCLP14>3.0.CO;2-H; TAM SY, 1990, J NEURAL TRANSM-GEN, V81, P97, DOI 10.1007/BF01245830	35	32	34	1	9	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2007	29	4					436	441		10.1080/13803390600745829			6	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	177EP	WOS:000247136700010	17497567				2021-06-18	
J	Sundstrom, A; Nilsson, LG; Cruts, M; Adolfsson, R; Van Broeckhoven, C; Nyberg, L				Sundstroem, A.; Nilsson, L.-G.; Cruts, M.; Adolfsson, R.; Van Broeckhoven, C.; Nyberg, L.			Fatigue before and after mild traumatic brain injury: Pre-post-injury comparisons in relation to Apolipoprotein E	BRAIN INJURY			English	Article						mild head injury; fatigue; Apolipoprotein E; pre-injury	HEAD-INJURY; PATIENT COMPLAINTS; PROSPECTIVE COHORT; FOOTBALL PLAYERS; E POLYMORPHISM; APOE GENOTYPE; E EPSILON-4; RECOVERY; CONCUSSION; ASSOCIATION	Primary objective: To assess the incidence of fatigue for persons following a mild traumatic brain injury (MTBI) and to evaluate the relationship between fatigue and APOE genotype. As fatigue is often found to be influenced by anxiety, depression and sleep disturbance, these factors were also measured. Methods and procedures: Thirty-one persons who sustained a MTBI were drawn from a population-based longitudinal study. Each person who sustained a MTBI was matched by age, gender, education and APOE genotype with two non-head injury controls. Self-reported pre- and post-injury incidence of fatigue, anxiety, depression and sleep disturbance was compared within-group and between groups. Results: For the MTBI group, incidence of fatigue was almost twice as common post- than pre-injury, whereas there was no corresponding change in a non-injured control group. Within the MTBI-group, post-injury fatigue was particularly common for carriers of the APOE epsilon 4 allele. Conclusions: Fatigue is common sequela after a MTBI and especially pronounced for carriers of the APOE epsilon 4 allele.	Umea Univ, Dept Psychol, S-90187 Umea, Sweden; Stockholm Univ, Dept Psychol, Stockholm, Sweden; Univ Antwerp VIB, Dept Mol Genet, B-2610 Antwerp, Belgium; Umea Univ, Dept Radiat Sci Diagnost Radiol, S-90187 Umea, Sweden; Umea Univ, Physiol Sect, S-90187 Umea, Sweden	Sundstrom, A (corresponding author), Umea Univ, Dept Psychol, S-90187 Umea, Sweden.	anna.sundstrom@psy.umu.se	Van Broeckhoven, Christine/G-8362-2017; Nyberg, Lars/C-2514-2009; Nyberg, Lars/M-5986-2019; Cruts, Marc/J-6161-2013; Van Broeckhoven, Christine/M-7853-2019	Van Broeckhoven, Christine/0000-0003-0183-7665; Nyberg, Lars/0000-0002-3367-1746; Nyberg, Lars/0000-0002-3367-1746; Cruts, Marc/0000-0002-1338-992X; Van Broeckhoven, Christine/0000-0003-0183-7665; Adolfsson, Rolf/0000-0001-9785-8473			Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Borgaro SR, 2005, J HEAD TRAUMA REHAB, V20, P416, DOI 10.1097/00001199-200509000-00003; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Corwin Elizabeth J, 2002, Biol Res Nurs, V3, P222, DOI 10.1177/10900402003004007; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; EVENS RW, 1992, NEUROL CLIN, V10, P815; FOLSTEIN MF, 1975, J PSYCHIATR RES, V12, P198; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Gerberding JL, 2003, C MILD TRAUM BRAIN I; GROOT MH, 2003, ARCH PHYS MED REHAB, V84, P1714; Haboubi NHJ, 2001, DISABIL REHABIL, V23, P635; Ingles JL, 1999, ARCH PHYS MED REHAB, V80, P173, DOI 10.1016/S0003-9993(99)90116-8; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kashluba S, 2004, ARCH CLIN NEUROPSYCH, V19, P805, DOI 10.1016/j.acn.2003.09.005; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; LaChapelle DL, 1998, BRAIN INJURY, V12, P649, DOI 10.1080/026990598122214; Liberman JN, 2002, NEUROLOGY, V58, P1038, DOI 10.1212/WNL.58.7.1038; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Loge JH, 1998, J PSYCHOSOM RES, V45, P53, DOI 10.1016/S0022-3999(97)00291-2; LOGE JH, 2003, EUROPEAN J PALLI S14, V10; Masson F, 1996, BRAIN INJURY, V10, P487, DOI 10.1080/026990596124205; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCullagh S, 2001, BRAIN INJURY, V15, P489, DOI 10.1080/02699050010007353; Millar K, 2003, J NEUROL NEUROSUR PS, V74, P1047, DOI 10.1136/jnnp.74.8.1047; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V412, P611; Nathoo N, 2003, J NEUROSURG, V98, P302, DOI 10.3171/jns.2003.98.2.0302; Nilsson LG, 1997, AGING NEUROPSYCHOL C, V4, P1, DOI 10.1080/13825589708256633; Nilsson LG, 2004, AGING NEUROPSYCHOL C, V11, P134, DOI 10.1080/13825580490511026; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Stulemeijer M, 2006, J NEUROL, V253, P1041, DOI 10.1007/s00415-006-0156-5; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Sundstrom A, 2007, INT PSYCHOGERIATR, V19, P159, DOI 10.1017/S1041610206003498; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Teasdale GM, 1997, LANCET, V350, P1069, DOI 10.1016/S0140-6736(97)04318-3; The Mild Traumatic Brain Injury Committee of the Head Injury Interdisciplinary Special Interest Group of the American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86; van der Linden G, 1999, PSYCHOL MED, V29, P863, DOI 10.1017/S0033291799008697; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Werf SP, 2001, EUR NEUROL, V45, P28, DOI 10.1159/000052085; WENHAM PR, 1991, CLIN CHEM, V37, P241; Ziino C, 2005, J INT NEUROPSYCH SOC, V11, P416, DOI 10.1017/S1355617705050472; Ziino C, 2006, NEUROPSYCHOLOGY, V20, P383, DOI 10.1037/0894-4105.20.3.383	45	32	33	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	10					1049	1054		10.1080/02699050701630367			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	222WU	WOS:000250329600007	17891567				2021-06-18	
J	Tombaugh, TN; Rees, L; Stormer, P; Harrison, AG; Smith, A				Tombaugh, Tom N.; Rees, Laura; Stormer, Peter; Harrison, Allyson G.; Smith, Andra			The effects of mild and severe traumatic brain injury on speed of information processing as measured by the computerized tests of information processing (CTIP)	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						computerized tests of information processing; CTIP; TBI	CLOSED-HEAD-INJURY; VISUAL REACTION-TIME; NEUROPSYCHOLOGICAL ASSESSMENT; ATTENTION DEFICITS; DIVIDED ATTENTION; CONCUSSION; MEMORY; PERFORMANCE; RECOVERY; CONSISTENCY	In spite of the fact that reaction time (RT) measures are sensitive to the effects of traumatic brain injury (TBI), few RT procedures have been developed for use in standard clinical evaluations. The computerized test of information processing (CTIP) [Tombaugh, T.N., & Rees, L. (2000). Manual for the computerized tests of information processing (CTIP). Ottawa, Ont.: Carleton University] was designed to measure the degree to which TBI decreases the speed at which information is processed. The CTIP consists of three computerized programs that progressively increase the amount of information that is processed. Results of the current study demonstrated that RT increased as the difficulty of the CTIP tests increased (known as the complexity effect), and as severity of injury increased (from mild to severe TBI). The current study also demonstrated the importance of selecting a non-biased measure of variability. Overall, findings suggest that the CTIP is an easy to administer and sensitive measure of information processing speed. (c) 2006 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Carleton Univ, Dept Psychol, Ottawa, ON K1S 5B6, Canada; Rehabil Ctr, Ottawa, ON, Canada; Queens Univ, Dept Psychol, Kingston, ON K7L 3N6, Canada; Hawkes Bay Dist Hlth Board, Rehabil Unit, Hastings, New Zealand; Univ Ottawa, Ottawa, ON K1N 6N5, Canada	Tombaugh, TN (corresponding author), Carleton Univ, Dept Psychol, 1125 Colonel By Dr, Ottawa, ON K1S 5B6, Canada.	tom_tombaugh@carleton.ca					BAIRD B, IN PRESS J APPL NEUR; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 1997, NEUROPSY NEUROPSY BE, V10, P247; BRAUN CMJ, 1989, INT J CLIN NEUROPSYC, V11, P167; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; BRUHN P, 1971, CORTEX, V7, P279; CHANG TM, 1986, PSYCHOL BULL, V99, P199, DOI 10.1037/0033-2909.99.2.199; Collins LF, 1996, ARCH CLIN NEUROPSYCH, V11, P613, DOI 10.1016/0887-6177(97)81255-3; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; ELSASS P, 1985, ACTA NEUROL SCAND, V71, P11; Erlanger DM, 1999, CLIN NEUROPSYCHOL, V13, P193, DOI 10.1076/clin.13.2.193.1963; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Ferraro FR, 1996, BRAIN COGNITION, V32, P429, DOI 10.1006/brcg.1996.0075; GODEFROY O, 1994, J NEUROL SCI, V126, P168, DOI 10.1016/0022-510X(94)90268-2; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; Halstead WC, 1985, HALSTEAD REITAN NEUR; Haut M W, 1990, Arch Clin Neuropsychol, V5, P299, DOI 10.1016/0887-6177(90)90028-N; Hetherington CR, 1996, BRAIN INJURY, V10, P473, DOI 10.1080/026990596124197; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; IVERSON GL, 1991, LAW HUMAN BEHAV, V15, P667, DOI 10.1007/BF01065859; LEVIN HS, 1986, J CLIN EXP NEUROPSYC, V8, P643, DOI 10.1080/01688638608405185; LOFTUS EF, 1973, J EXP PSYCHOL, V97, P70, DOI 10.1037/h0033782; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MARING W, 1984, INS B, V24; Miller E, 1970, Cortex, V6, P121; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; RABBITT P, 1989, J EXP PSYCHOL GEN, V118, P338; REEVES D, 1989, 891 US NAV AER MED R; Roman DD, 1991, CLIN NEUROPSYCHOL, V5, P33; Sarno S, 2003, BRAIN INJURY, V17, P413, DOI 10.1080/0269905031000070161; Schmidt J. P., 1995, LEARNING MEMORY BATT; Smith A., 1982, SYMBOL DIGIT MODALIT; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1994, NEUROPSYCHOLOGY, V8, P316, DOI DOI 10.1037/0894-4105.8.3.316; Timmerman ME, 1999, NEUROPSYCHOLOGIA, V37, P467, DOI 10.1016/S0028-3932(98)00085-2; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 2000, MANUAL COMPUTERIZED; Van Zomeren A. H., 1981, REACTION TIME ATTENT; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VANZOMEREN AH, 1978, J NEUROL NEUROSUR PS, V41, P452, DOI 10.1136/jnnp.41.5.452; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Willison J, 2006, ARCH CLIN NEUROPSYCH, V21, P41, DOI 10.1016/j.acn.2005.07.005; Wilson BA, 1999, BRAIN INJURY, V13, P505, DOI 10.1080/026990599121412; Zahn TP, 1999, J CLIN EXP NEUROPSYC, V21, P352, DOI 10.1076/jcen.21.3.352.924; Zwaagstra R, 1996, J CLIN EXP NEUROPSYC, V18, P383, DOI 10.1080/01688639608408995	53	32	33	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2007	22	1					25	36		10.1016/j.acn.2006.06.013			12	Psychology, Clinical; Psychology	Psychology	144RV	WOS:000244814700003	17071052				2021-06-18	
J	Turner-Stokes, L				Turner-Stokes, Lynne			Cost-efficiency of longer-stay rehabilitation programmes: Can they provide value for money?	BRAIN INJURY			English	Article						rehabilitation; outcome measurement; dependency; cost-efficiency; brain injury	TRAUMATIC BRAIN-INJURY; NEEDS-ASSESSMENT NPCNA; INPATIENT REHABILITATION; CARE NEEDS; PREDICTION; DEPENDENCY; OUTCOMES; STROKE; SCORE	Purpose: To examine the cost-efficiency of longer stay rehabilitation in patients with complex neurological disabilities. Methods: Longitudinal cohort analysis of consecutive admissions to a specialized in-patient rehabilitation unit. Selection criteria: patients who were highly dependent on admission (NPDS >= 25) and had a length of stay> 125 days. Serial changes in dependency and care costs were measured by the Northwick Park Dependency and Care Needs Assessment (NPDS/ NPCNA), which provides a generic estimation of dependency, care hours and weekly cost of continuing care in the community. Results: Of 410 admissions over 5 years, 51 met the case-selection criteria - mean age 39 +/- 17 years, male: female ratio 2:1. The mean length of stay (LOS) was 184 +/- 56 days (max 312). Between 4 months and discharge ( mean 58 +/- 56 days later) significant changes were seen in dependency ( t = 4.8, p< 0.0001) and care costs ( t = 2.0, p< 0.05). The mean additional cost of rehabilitation beyond 4 months ( pound 16 766 +/- 17 334) would be offset by the mean weekly savings in cost of care within 36 months. The two cases who stayed> 300 days are presented in more detail. Conclusions: The additional investment in longer-stay rehabilitation in this group of complex patients was offset relatively quickly by long-term savings in the cost of care.	Northwick Pk Hosp & Clin Res Ctr, Reg Rehabil Unit, Harrow HA1 3UJ, Middx, England; Kings Coll London, Sch Med, Dept Palliat Care Policy & Rehabil, London WC2R 2LS, England	Turner-Stokes, L (corresponding author), Northwick Pk Hosp & Clin Res Ctr, Reg Rehabil Unit, Watford Rd, Harrow HA1 3UJ, Middx, England.	lynne.turner-stokes@dial.pipex.com	Turner-Stokes, Lynne/F-4418-2012	Turner-Stokes, Lynne/0000-0002-3302-9462			Gray DS, 2000, ARCH PHYS MED REHAB, V81, P1447, DOI 10.1053/apmr.2000.16343; Gray DS, 2000, BRAIN INJURY, V14, P1003, DOI 10.1080/02699050050191940; HEDRICK WP, 1995, BRAIN INJURY, V9, P563, DOI 10.3109/02699059509008215; HEINEMANN AW, 1994, ARCH PHYS MED REHAB, V75, P133; Hoffman JM, 2003, ARCH PHYS MED REHAB, V84, P1165, DOI 10.1016/S0003-9993(03)00232-6; Kwakkel G, 1997, STROKE, V28, P1550, DOI 10.1161/01.STR.28.8.1550; Nyein K, 1999, CLIN REHABIL, V13, P482, DOI 10.1191/026921599674590637; Nyein K, 1999, CLIN REHABIL, V13, P56, DOI 10.1191/026921599701532135; Rusconi S, 2003, DISABIL REHABIL, V25, P1281, DOI 10.1080/09638280310001608582; SLADE A, 1999, CLIN REHABIL, V13, P80; Stineman MG, 1997, STROKE, V28, P550, DOI 10.1161/01.STR.28.3.550; Turner-Stokes L, 2006, J NEUROL NEUROSUR PS, V77, P634, DOI 10.1136/jnnp.2005.073411; Turner-Stokes L, 1999, CLIN REHABIL, V13, P277, DOI 10.1191/026921599676896799; Turner-Stokes L, 1999, CLIN REHABIL, V13, P253, DOI 10.1191/026921599677787870; Turner-Stokes L, 1998, CLIN REHABIL, V12, P304, DOI 10.1191/026921598669173600; TURNERSTOKES L, 2007, IN PRESS CLIN MED; TURNERSTOKES L, 2005, COCHRANE DATABASE SY; TURNERSTOKES L, 1999, CLIN REHABILITATIO S, V13	18	32	35	0	0	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2007	21	10					1015	1021		10.1080/02699050701591445			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	222WU	WOS:000250329600003	17891563				2021-06-18	
J	Dohi, K; Satoh, K; Mihara, Y; Nakamura, S; Miyake, Y; Ohtaki, H; Nakamachi, T; Yoshikawa, T; Shioda, S; Arugai, T				Dohi, Kenji; Satoh, Kazue; Mihara, Yuko; Nakamura, Shunsuke; Miyake, Yasuhumi; Ohtaki, Hirokazu; Nakamachi, Tomoya; Yoshikawa, Toshikazu; Shioda, Seiji; Arugai, Tohru			Alkoxyl radical-scavenging activity of edaravone in patients with traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						free radical; free-radical scavenger; reactive oxygen species; electron spin resonance; alkoxyl radical; traumatic brain injury; human; edaravone	MCI-186	Lipid peroxidation is caused by reactive oxygen species (ROS) and is involved in traumatic brain injury (TBI). Consequently, a therapeutic strategy for TBI may be to control lipid peroxidation. The only drug approved to date for blocking lipid peroxidation is edaravone (MCI-186), a novel free-radical scavenger shown to exert neuroprotective effects in acute ischemic stroke. Although edaravone scavenges hydroxyl and nitric oxide radicals, its effect on alkoxyl radicals (OR-), which also contribute to lipid peroxidation, is unknown. To date, the study of free radicals in blood has been severely hampered by technical difficulties in their detection. We used an in vitro and ex vivo electron spin resonance (ESR) method employing 5,5-dimethyl-l-pyrroline-N-oxide as a spin trap to investigate whether edaravone can scavenge OR-. By mixing either methemoglobin or human blood with tert-butyl hydroperoxide, we found that this technique can detect OR- generated in vitro. We also found that generated OR- can be completely absorbed by administration of edaravone in vitro (400 mu M). Analysis of jugular venous blood collected from 17 TBI patients immediately before and 20 minutes after the administration of edaravone (30 mg, i.v.) revealed higher OR- levels in the untreated patients blood than in normal control blood samples. However, treatment with edaravone suppressed these OR- levels by 24.6% (radical intensity = 71.1 +/- 5.2-53.6 +/- 5.2; p < 0.01). Thus, edaravone can scavenge OR- and significantly reduce levels of these radicals in TBI patients. The novel ex vivo ESR method described here provides a valuable clinical measure of oxidative stress.	Showa Univ, Sch Med, Dept Emergency & Crit Care Med, Shinagawa Ku, Tokyo 1428555, Japan; Showa Univ, Sch Med, Dept Anat, Tokyo 142, Japan; Kyoto Prefectural Univ, Dept Med 1, Kyoto 606, Japan	Dohi, K (corresponding author), Showa Univ, Sch Med, Dept Emergency & Crit Care Med, Shinagawa Ku, Tokyo 1428555, Japan.	kdop@med.showa-u.ac.jp		dohi, kenji/0000-0002-4451-0382	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [18591989] Funding Source: KAKEN		Blair IA, 2001, EXP GERONTOL, V36, P1473, DOI 10.1016/S0531-5565(01)00133-4; HOUKIN K, 2003, CEREBROVASC DIS, V15, P222; IKEDA Y, 1990, NEUROSURGERY, V27, P1; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P344, DOI 10.1097/00004647-200104000-00003; Mihara Y, 2004, HYPOTHERMIA FOR ACUTE BRAIN DAMAGE: PATHOMECHANISM AND PRACTICAL ASPECTS, P94; Nakamura H, 2003, ACT NEUR S, V86, P309; OCHI H, 1992, BIOCHIM BIOPHYS ACTA, V1136, P247, DOI 10.1016/0167-4889(92)90113-P; PRYOR WA, 1990, FREE RADICAL BIO MED, V8, P541, DOI 10.1016/0891-5849(90)90153-A; Satoh K, 2002, REDOX REP, V7, P219, DOI 10.1179/135100002125000587; Shibata H, 1998, JPN J CLIN PHARM THE, V29, P863; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Watanabe K, 2003, REDOX REP, V8, P151, DOI 10.1179/135100003225001520; WATANABE T, 1988, PROSTAG LEUKOTR ESS, V33, P81, DOI 10.1016/0952-3278(88)90127-5; WATANABE T, 1994, J PHARMACOL EXP THER, V268, P1597; WATANABE T, 1994, J PHARMACOL EXP THER, V271, P1624; Yamato M, 2003, FREE RADICAL BIO MED, V35, P1619, DOI 10.1016/j.freeradbiomed.2003.09.013	19	32	32	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2006	23	11					1591	1599		10.1089/neu.2006.23.1591			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	106RK	WOS:000242118200002	17115906				2021-06-18	
J	Sury, MD; Frese-Schaper, M; Muhlemann, MK; Schulthess, FT; Blasig, IE; Tauber, MG; Shaw, SG; Christen, S				Sury, Matthias D.; Frese-Schaper, Manuela; Muhlemann, Miranda K.; Schulthess, Fabienne T.; Blasig, Ingolf E.; Tauber, Martin G.; Shaw, Sidney G.; Christen, Stephan			Evidence that N-acetylcysteine inhibits TNF-alpha-induced cerebrovascular endothelin-1 upregulation via inhibition of mitogen- and stress-activated protein kinase	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						nuclear factor kappa B; reactive oxygen species; cerebral blood flow; nitric oxide	FACTOR-KAPPA-B; NITRIC-OXIDE SYNTHASE; EXPERIMENTAL PNEUMOCOCCAL MENINGITIS; TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; BACTERIAL-MENINGITIS; TRANSCRIPTIONAL ACTIVITY; INDUCED PHOSPHORYLATION; CEREBROSPINAL-FLUID; OXIDATIVE STRESS	N-Acetylcysteine (NAC) is neuroprotective in animal models of acute brain injury such as caused by bacterial meningitis. However, the mechanism(s) by which NAC exerts neuroprotection is unclear. Gene expression of endothelia-1 (ET-1), which contributes to cerebral blood flow decline in acute brain injury, is partially regulated by reactive oxygen species, and thus a potential target of NAC. We therefore examined the effect of NAC on tumor necrosis factor (TNF)-alpha-induced ET-1 production in cerebrovascular endothelial cells. NAC dose dependently inhibited TNF-alpha-induced preproET-1 mRNA upregulation and ET-1 protein secretion, while upregulation of inducible nitric oxide synthase (iNOS) was unaffected. Intriguingly, NAC had no effect on the initial activation (i.e., 11513 degradation, nuclear p65 translocation, and Ser536 phosphorylation) of NF-kappa B by TNF-alpha. However, transient inhibition of NF-kappa B DNA binding suggested that NAC may inhibit ET-1 upregulation by inhibiting (a) parallel pathway(s) necessary for full transcriptional activation of NF-kappa B-mediated ET-1 gene expression. Similar to NAC, the MEK1/2 inhibitor U0126, the p38 inhibitor SB203580, and the protein kinase inhibitor H-89 selectively inhibited ET-1 upregulation without affecting nuclear p65 translocation, suggesting that NAC inhibits ET-1 upregulation via inhibition of mitogen- and stress-activated protein kinase (MSK). Supporting this notion, cotreatment with NAC inhibited the TNF-alpha-induced rise in MSK1 and MSK2 kinase activity, while siRNA knock-down experiments showed that MSK2 is the predominant isoform involved in TNF-alpha-induced ET-1 upregulation. (c) 2006 Elsevier Inc. All rights reserved.	Univ Bern, Inst Infect Dis, CH-3010 Bern, Switzerland; Inst Mol Pharmacol, Berlin, Germany; Univ Bern, Dept Clin Res, CH-3012 Bern, Switzerland	Christen, S (corresponding author), Univ Bern, Inst Infect Dis, Friedbuehlstr 51, CH-3010 Bern, Switzerland.	stephan.christen@ifik.unibe.ch	Christen, Stephan/B-8602-2009; Kummer, Juerg/B-3322-2011		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS033997] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS33997] Funding Source: Medline		Anrather J, 2005, J BIOL CHEM, V280, P244, DOI 10.1074/jbc.M409344200; Arthur JSC, 2004, J NEUROSCI, V24, P4324, DOI 10.1523/JNEUROSCI.5227-03.2004; Auer M, 2000, J INFECT DIS, V182, P347, DOI 10.1086/315658; Bedford H, 2001, BRIT MED J, V323, P533, DOI 10.1136/bmj.323.7312.533; Blasig IE, 2001, MICROVASC RES, V62, P114, DOI 10.1006/mvre.2001.2318; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Christen S, 2001, FREE RADICAL BIO MED, V31, P754, DOI 10.1016/S0891-5849(01)00642-6; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Faraci FM, 1998, PHYSIOL REV, V78, P53; Grimwood K, 2000, ARCH DIS CHILD, V83, P111, DOI 10.1136/adc.83.2.111; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; Kishore N, 2003, J BIOL CHEM, V278, P32861, DOI 10.1074/jbc.M211439200; Koedel U, 1997, NEUROSCI LETT, V225, P33, DOI 10.1016/S0304-3940(97)00177-8; Lahiri DK, 2000, BRAIN RES PROTOC, V5, P257, DOI 10.1016/S1385-299X(00)00021-0; Leib SL, 1998, J INFECT DIS, V177, P692, DOI 10.1086/514226; Leib SL, 1996, J CLIN INVEST, V98, P2632, DOI 10.1172/JCI119084; MARSDEN PA, 1992, AM J PHYSIOL, V262, pC854; McCoy CE, 2005, BIOCHEM J, V387, P507, DOI 10.1042/BJ20041501; MCLELLAN LI, 1995, CARCINOGENESIS, V16, P2099, DOI 10.1093/carcin/16.9.2099; Merkelbach S, 2000, ACTA NEUROL SCAND, V102, P118, DOI 10.1034/j.1600-0404.2000.102002118.x; Miyauchi T, 1999, ANNU REV PHYSIOL, V61, P391, DOI 10.1146/annurev.physiol.61.1.391; Modanlou HD, 1996, CAN J PHYSIOL PHARM, V74, P368, DOI 10.1139/cjpp-74-4-368; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Ohkita M, 2002, JPN J PHARMACOL, V88, P197, DOI 10.1254/jjp.88.197; Ohkita M, 2002, JPN J PHARMACOL, V89, P81, DOI 10.1254/jjp.89.81; Oka S, 2000, FEBS LETT, V472, P196, DOI 10.1016/S0014-5793(00)01464-2; Pahan K, 1998, FREE RADICAL BIO MED, V24, P39, DOI 10.1016/S0891-5849(97)00137-8; PFISTER HW, 1992, STROKE, V23, P1798, DOI 10.1161/01.STR.23.12.1798; Pfister LA, 2000, ANN NEUROL, V47, P329, DOI 10.1002/1531-8249(200003)47:3<329::AID-ANA8>3.3.CO;2-I; Quehenberger P, 2000, DIABETES, V49, P1561, DOI 10.2337/diabetes.49.9.1561; Rossi GP, 2001, INT REV CYTOL, V209, P241; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sato M, 1998, BRAIN RES, V809, P39, DOI 10.1016/S0006-8993(98)00817-8; Schaper M, 2002, J NEUROPATH EXP NEUR, V61, P605, DOI 10.1093/jnen/61.7.605; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; Schubert SY, 2002, FASEB J, V16, P1931, DOI 10.1096/fj.02-0147fje; Shaw SG, 2000, ANAL BIOCHEM, V278, P143, DOI 10.1006/abio.1999.4451; Sibson NR, 2002, BRAIN, V125, P2446, DOI 10.1093/brain/awf256; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Soloaga A, 2003, EMBO J, V22, P2788, DOI 10.1093/emboj/cdg273; Sporbert A, 1999, MOL BRAIN RES, V67, P258, DOI 10.1016/S0169-328X(99)00067-4; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; TUREEN J, 1995, J CLIN INVEST, V95, P1086, DOI 10.1172/JCI117755; VERDON CP, 1995, ANAL BIOCHEM, V224, P502, DOI 10.1006/abio.1995.1079; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Woods M, 2003, MOL PHARMACOL, V64, P923, DOI 10.1124/mol.64.4.923; Xu J, 1997, BIOCHEM BIOPH RES CO, V235, P394, DOI 10.1006/bbrc.1997.6800; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	57	32	33	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	NOV 1	2006	41	9					1372	1383		10.1016/j.freeradbiomed.2006.07.016			12	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	097CM	WOS:000241424000003	17023264				2021-06-18	
J	Mauri, M; Sinforiani, E; Bono, G; Cittadella, R; Quattrone, A; Boller, F; Nappi, G				Mauri, Marco; Sinforiani, Elena; Bono, Giorgio; Cittadella, Rita; Quattrone, Aldo; Boller, Francois; Nappi, Giuseppe			Interaction between apolipoprotein epsilon 4 and traumatic brain injury in patients with Alzheimer's disease and mild cognitive impairment	FUNCTIONAL NEUROLOGY			English	Article						Alzheimer's disease; apolipoproteins; mild cognitive impairment; traumatic brain injury	AMYLOID BETA-PROTEIN; HEAD-INJURY; RISK-FACTORS; DEMENTIA; DEPOSITION; GENOTYPE; ALLELE; SUSCEPTIBILITY; POPULATION; SCALE	Several pathogenetic factors seem to contribute to the development of Alzheimer's disease (AD). Some data point to a role for traumatic brain injury (TBI), but this suggestion is not universally supported. Mayeux et al. have shown that TBI increases the risk of AD, but only through a synergistic relationship with apolipoprotein epsilon (Apo E) 4. We present the results of a cross-sectional and longitudinal study of the relationship between these factors, conducted in northern and southern Italy. We studied 337 consecutive patients with probable AD and 63 subjects with mild cognitive impairment (MCI). Information concerning head injuries was collected by interview of informants and review of medical records. Twenty-one patients with AD and 9 with MCI were found to have a history of TBI with loss of consciousness. AD and MCI patients with a history of TBI, compared with control groups matched for age, sex, education and degree of mental impairment, showed more marked depressive and behavioural disturbances (Global Deterioration Scale and Neuropsychiatric Inventory, p<0.05). Six- and 12-month follow up of both groups did not show significant differences in the rate of progression of cognitive changes. A high frequency of Apo E 4 was detected in the patients with TBI and cognitive impairment (40.5% in the AD and 11% in the MCI subgroups). The distribution of the epsilon 4 allele in our control group was 4%, comparable to that found in the Italian population. Distribution of the above parameters was similar in patients from northern and southern Italy. The higher frequency of TBI and Apo E 4 genotype among AD and MCI patients confirms the synergistic interaction of environmental and genetic factors in the development of dementia. Our data do not suggest that the presence of these two factors influences the clinical presentation or the course of the disease.	Univ Insubria, Dept clin Med, Sect Neurol, Varese, Italy; IRCSS, C Mondino Inst Neurol Fdn, Pavia, Italy; CNR, Inst Neurol Sci, Cosenza, Italy; Magna Graecia Univ Catanzaro, Inst Neurol, Dept Med Sci, Catanzaro, Italy; INSERM, U549, F-75005 Paris, France; Univ Roma La Sapienza, Dept Neurol & Otorhinolaringol, I-00161 Rome, Italy	Boller, F (corresponding author), 5500 Friendship Blvd, Chevy Chase, MD 20815 USA.	bollerf@csr.nih.gov	QUATTRONE, Aldo/A-6734-2016; Sinforiani, Elena/AAB-6052-2020	QUATTRONE, Aldo/0000-0003-2001-957X; Nappi, Giuseppe/0000-0003-4274-5281			AMADUCCI LA, 1986, NEUROLOGY, V36, P922, DOI 10.1212/WNL.36.7.922; BEVILACQUA L, 1996, QA, V7, P97; Blass JP, 1996, CLIN DIAGNOSIS MANAG, P17; BROE GA, 1990, NEUROLOGY, V40, P1698, DOI 10.1212/WNL.40.11.1698; Carlesimo GA, 1996, EUR NEUROL, V36, P378, DOI 10.1159/000117297; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; CHANDRA V, 1989, NEUROLOGY, V39, P1576, DOI 10.1212/WNL.39.12.1576; CORBO RM, 1995, ANN HUM GENET, V59, P197, DOI 10.1111/j.1469-1809.1995.tb00741.x; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; Friedman G, 1999, NEUROLOGY, V52, P244, DOI 10.1212/WNL.52.2.244; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Katzman R, 1996, NEUROLOGY, V46, P889; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; NICOLL JAR, 1995, NAT MED, V1, P135, DOI 10.1038/nm0295-135; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; RYAN DH, 1994, DEMENTIA, V5, P339, DOI 10.1159/000106744; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; Spinnler H., 1987, ITAL J NEUROL SCI, V8, P6; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; YESAVAGE JA, 1983, J PSYCHIATR RES, V17, P37, DOI 10.1016/0022-3956(82)90033-4	35	32	33	0	7	C I C-EDIZIONI INT SRL	ROME	CORSO TRIESTE, 42, 00198 ROME, ITALY	0393-5264	1971-3274		FUNCT NEUROL	Funct. Neurol.	OCT-DEC	2006	21	4					223	228					6	Clinical Neurology	Neurosciences & Neurology	162HQ	WOS:000246078000009	17367583				2021-06-18	
J	Thelandersson, A; Cider, A; Nellgard, B				Thelandersson, A.; Cider, A.; Nellgard, B.			Prone position in mechanically ventilated patients with reduced intracranial compliance	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article						prone position; neurosurgery; intracranial pressure; cerebral perfusion pressure; acute lung insufficiency	RESPIRATORY-DISTRESS-SYNDROME; INTENSIVE-CARE-UNIT; OXYGENATION; MANAGEMENT; PRESSURE; INJURY; LUNG	Background: Prone position has been used for several years to treat acute lung insufficiency, but in previous studies patients with unstable intracranial pressure (ICP) are mostly excluded. The aim of this study was to investigate if prone position is a safe and useful treatment in patients with reduced intracranial compliance. Methods: A consecutive, prospective pilot study of 11 patients admitted to the neuro intensive care unit (NICU) due to traumatic brain injury or intracerebral haemorrhage. ICP, cerebral perfusion pressure (CPP), heart rate (HR), mean arterial blood pressure (MABP), arterial partial pressure of oxygen (PaO2), arterial partial pressure of carbon dioxide (PaCO2), arterial oxygen saturation (SaO(2)) and respiratory system compliance were measured before, three times during and two times after the patients were placed in the prone position. Results: No significant changes were demonstrated in ICP, CPP or MABP. PaO2 and SaO(2) were significantly increased in the prone position. HR was significantly increased in the prone position and after 10 min in the supine post-prone position and the respiratory system compliance was increased after 1 h in the supine post-prone position. Conclusion: Turning NICU patients from the supine to the prone position did not influence ICP, CPP or MABP, but significantly improved patient PaO2, SaO(2) and respiratory system compliance.	Sahlgrens Univ Hosp, Dept Phys Therapy, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Anesthesiol & Intens Care Med, S-41345 Gothenburg, Sweden	Thelandersson, A (corresponding author), Sahlgrens Univ Hosp, Dept Phys Therapy, S-41345 Gothenburg, Sweden.	anneli.thelandersson@vgregion.se		Cider, Asa/0000-0003-2140-8569			Blanch L, 1997, INTENS CARE MED, V23, P1033, DOI 10.1007/s001340050453; Dettenkofer M, 2001, J NEUROL, V248, P959, DOI 10.1007/s004150170048; Fletcher SJ, 2003, BRIT J ANAESTH, V90, P238, DOI 10.1093/bja/aeg026; HEDENSTIERNA G, 1986, ACTA ANAESTH SCAND, V30, P183, DOI 10.1111/j.1399-6576.1986.tb02393.x; Johannigman JA, 2000, SURGERY, V128, P708, DOI 10.1067/msy.2000.108225; Mure M, 1997, CRIT CARE MED, V25, P1539, DOI 10.1097/00003246-199709000-00022; Ng I, 2004, NEUROSURGERY, V54, P593, DOI 10.1227/01.NEU.0000108639.16783.39; Reinprecht A, 2003, CRIT CARE MED, V31, P1831, DOI 10.1097/01.CCM.0000063453.93855.0A; Sofianou DC, 2000, EUR J CLIN MICROBIOL, V19, P460, DOI 10.1007/s100960000236; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Takahashi N, 2004, CHEST, V125, P935, DOI 10.1378/chest.125.3.935; Williams A, 1993, Am J Crit Care, V2, P68	13	32	33	0	5	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0001-5172			ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	SEP	2006	50	8					937	941		10.1111/j.1399-6576.2006.01037.x			5	Anesthesiology	Anesthesiology	076EF	WOS:000239939100005	16923087				2021-06-18	
J	Oda, J; Sakamoto, J; Sakano, K				Oda, Juhachi; Sakamoto, Jiro; Sakano, Kenichi			Mechanical evaluation of the skeletal structure and tissue of the woodpecker and its shock absorbing system	JSME INTERNATIONAL JOURNAL SERIES A-SOLID MECHANICS AND MATERIAL ENGINEERING			English	Article						impact strength; framed structure; biomechanics; woodpecker		A woodpecker strikes its beak toward a tree repeatedly. But, the damage of brain or the brain concussion doesn't occur by this action. Human cannot strike strongly the head without the damage of a brain. Therefore, it is predicted that the brain of a woodpecker is protected from the shock by some methods and that the woodpecker has the original mechanism to absorb a shock. In this study, the endoskeltal structure, especially head part structure of woodpecker is dissected and the impact-proof system is analyzed by FEM and model experiment. From the results, it is obvious that the woodpecker has the original impact-proof system as the unique states of hyoid bone, skull, tissue and brain. Moreover it is considered that woodpecker has the advanced impact-proof system relating with not only the head part but also with the whole body.	Kanazawa Univ, Dept Human & Mech Syst Engn, Bion Design Lab, Kanazawa, Ishikawa 9201192, Japan; Toyota Motor Co Ltd, Chassis Prod Engn Div, FR Chassis Planning & Engn Dept, Toyota, Aichi 4718572, Japan	Oda, J (corresponding author), Kanazawa Univ, Dept Human & Mech Syst Engn, Bion Design Lab, Kanazawa, Ishikawa 9201192, Japan.	oda18@t.kanazawa-u.ac.jp	SAKAMOTO, Jiro/E-7095-2015	SAKAMOTO, Jiro/0000-0002-1511-9958			AIDA T, 2000, STUDY HUMAN HEAD IMP, P12; MAY PRA, 1976, LANCET, P454; NISHIMOTO T, 1996, T JAPAN SOC MECH E A, V62, P2109; OGASAWARA K, 1998, WORLD BLACK WOODPECK; ZHANG L, 2001, P BIOENG C, P831	5	32	36	1	48	JAPAN SOC MECHANICAL ENGINEERS	TOKYO	SHINANOMACHI-RENGAKAN BLDG, SHINANOMACHI 35, SHINJUKU-KU, TOKYO, 160-0016, JAPAN	1344-7912			JSME INT J A-SOLID M	JSME Int. J. Ser. A-Solid Mech. Mat. Eng.	JUL	2006	49	3					390	396		10.1299/jsmea.49.390			7	Engineering, Mechanical; Materials Science, Multidisciplinary	Engineering; Materials Science	080RK	WOS:000240265500015		DOAJ Gold			2021-06-18	
J	Tasker, RC; Morris, KP; Forsyth, RJ; Hawley, CA; Parslow, RC				Tasker, RC; Morris, KP; Forsyth, RJ; Hawley, CA; Parslow, RC		UK Paediat Brain Injury Study G; Paediat Intens Care Soc Grp	Severe head injury in children: emergency access to neurosurgery in the United Kingdom	EMERGENCY MEDICINE JOURNAL			English	Article							INTENSIVE-CARE; UK	Objective: To determine the scale of acute neurosurgery for severe traumatic brain injury (TBI) in childhood, and whether surgical evacuation for haematoma is achieved within four hours of presentation to an emergency department. Methods: A 12 month audit of emergency access to all specialist neurosurgical and intensive care services in the UK. Severe TBI in a child was defined as that necessitating admission to intensive care. Results: Of 448 children with severe head injuries, 91 (20.3%) underwent emergency neurosurgery, and 37% of these surgical patients had at least one non-reactive and dilated pupil. An acute subdural or epidural haematoma was present in 143/448 (31.9%) children, of whom 66 (46.2%) underwent surgery. Children needing surgical evacuation of haematoma were at a median distance of 29 km (interquartile range (IQR) 11.8-45.7) from their neurosurgical centre. One in four children took longer than one hour to reach hospital after injury. Once in an accident and emergency department, 41% took longer than fours hours to arrive at the regional centre. The median interval between time of accident and arrival at the surgical centre was 4.5 hours ( IQR 2.23-7.73), and 79% of inter-hospital transfers were undertaken by the referring hospital rather than the regional centre. In cases where the regional centre undertook the transfer, none were completed within four hours of presentation-the median interval was 6.3 hours (IQR 5.1-8.12). Conclusions: The system of care for severely head injured children in the UK does not achieve surgical evacuation of a significant haematoma within four hours. The recommendation to use specialist regional paediatric transfer teams delays rather than expedites the emergency service.	Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Cambridge CB2 2QQ, England; Diana Princess Wales Childrens Hosp, Birmingham, W Midlands, England; Royal Victoria Infirm, Sir James Spence Inst Child Hlth, Sch Clin Med Sci Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Univ Warwick, Warwick Med Sch, Div Hlth Community, Coventry CV4 7AL, W Midlands, England; Univ Leeds, Leeds Inst Genet Hlth & Therapeut, Ctr Biostat & Epidemiol, Paediat Epidemiol Grp, Leeds, W Yorkshire, England	Tasker, RC (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Hills Rd, Cambridge CB2 2QQ, England.	rct31@cam.ac.uk	Forsyth, Rob J/I-9226-2012; Hawley, Carol/AAG-3830-2019; Tasker, Robert C/R-5837-2019; Parslow, Roger/AAV-1477-2020; Forsyth, Rob/H-9193-2019	Forsyth, Rob J/0000-0002-5657-4180; Forsyth, Rob/0000-0002-5657-4180; Parslow, Roger/0000-0002-3945-5294; Tasker, Robert/0000-0003-3647-8113			Abdalla IM, 1997, ACCIDENT ANAL PREV, V29, P583, DOI 10.1016/S0001-4575(97)00011-0; Atkins DJ, 1995, STUDIES MED POPULATI, V58; *DEP HLTH, 1977, PAED INT CAR FRAM FU; *GEN REG OFF SCOTL, 2001 CENS STAND AR S; Hewson P, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-15; *NAT COLL CTR AC C, 2003, HEAD INJ TRIAG ASS I, P74; *OFF NAT STAT, 2001, CENS STAND AR STAT E; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; *ROYAL COLL PAED C, 2001, CLIN APPR SIGN HEAD; *ROYAL COLL SURG E, 1999, REP WORK PART MAN PA; Royal College of Surgeons of England and the British Orthopaedic Society, 2000, BETT CAR SEV INJ; *SCOTT INT GUID NE, 2000, EARL MAN PAT HEAD IN, P36; Seeley HM, 2001, EMERG MED J, V18, P358, DOI 10.1136/emj.18.5.358; SHANN F, 1993, LANCET, V342, P68, DOI 10.1016/0140-6736(93)91282-Q; *SOC BRIT NEUR SUR, 1999, SAF NEUR 2000; Tasker RC, 2004, EMERG MED J, V21, P433, DOI 10.1136/emj.2002.004069	16	32	32	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205			EMERG MED J	Emerg. Med. J.	JUL	2006	23	7					519	522		10.1136/emj.2005.028779			4	Emergency Medicine	Emergency Medicine	055UV	WOS:000238477000006	16794092	Green Published			2021-06-18	
J	Kesting, MR; Holzle, F; Pox, C; Thurmuller, P; Wolff, KD				Kesting, Marco Rainer; Hoelzle, Frank; Pox, Christian; Thurmueller, Petra; Wolff, Klaus-Dietrich			Animal bite injuries to the head: 132 cases	BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY			English	Article						animal bites; primary wound closure; wound infection; antibiotic prophylaxis	DOG BITES; WOUNDS; FACE; RECONSTRUCTION; ANTIBIOTICS; CHILDREN; NECK	We made a retrospective study of the casenotes of 132 patients with bite injuries who were treated in the departments of craniomaxillofacial surgery in Berlin and Bochum university hospitals. Dogs caused most of the injuries (n = 121, 92%) and the lips were most commonly involved. Nearly half the patients had superficial injuries. More than 70% of the patients presented to the clinic within 6 h after the bite, and developed fewer wound infections than the patients who presented late. A total of 71 patients were given antibiotics for prophylaxis. Patients who were given amoxycillin with clavulanic acid developed no Wound infections. Surgical management included cleansing and primary Closure of the wound. Infected wounds were closed primarily after insertion of a drain. Wound cultures showed mainly streptococcus. We Concluded that antibiotic prophylaxis is essential for several indications and the antibiotic of first choice is amoxycillin-clavulanic acid. Primary wound closure is an approved principle even in infected wounds. (C) 2005 The British Association of Oral and Maxillofacial surgeons. Published by Elsevier Ltd. All rights reserved.	Ruhr Univ Bochum, Knappschaftskrankenhaus Bochum Langendreer, Dept Oral & Maxillofacial Plast Surg, D-44892 Bochum, Germany; Ruhr Univ Bochum, Knappschaftskrankenhaus Bochum Langendreer, Dept Med, D-44892 Bochum, Germany	Kesting, MR (corresponding author), Ruhr Univ Bochum, Knappschaftskrankenhaus Bochum Langendreer, Dept Oral & Maxillofacial Plast Surg, Schornau 23-25, D-44892 Bochum, Germany.	marco.kesting@ruhr-uni-bochum.de					Burt JD, 2000, PLAST RECONSTR SURG, V105, P2440, DOI 10.1097/00006534-200006000-00021; CALLAHAM M, 1980, ANN EMERG MED, V9, P410, DOI 10.1016/S0196-0644(80)80153-3; Correira Kristine, 2003, JAAPA, V16, P28; DIRE DJ, 1992, PEDIATR EMERG CARE, V8, P194, DOI 10.1097/00006565-199208000-00005; DIRE DJ, 1992, ANN EMERG MED, V21, P1008; Ebinger T, 2002, CHIRURG, V73, P601, DOI 10.1007/s00104-002-0430-8; GILBERT DN, 2002, SANFORD GUIDE ANTIMI; GOLDSTEIN EJC, 1992, CLIN INFECT DIS, V14, P633, DOI 10.1093/clinids/14.3.633; Goldstein EJC, 1999, CURR CLIN TOPICS INF, V19, P99; Holm M, 2000, SCAND J INFECT DIS, V32, P181, DOI 10.1080/003655400750045303; Javaid M, 1998, J ROY SOC MED, V91, P414, DOI 10.1177/014107689809100804; Kountakis S E, 1998, Ear Nose Throat J, V77, P216; LACKMANN GM, 1992, J CRANIO MAXILL SURG, V20, P81, DOI 10.1016/S1010-5182(05)80472-X; Lengele BG, 2004, INT J ORAL MAX SURG, V33, P396, DOI 10.1016/j.ijom.2003.11.004; LIEBANA J, 2004, MED ORAL PATOL ORA S, V9, P75; Liebana Jose, 2004, Med Oral Patol Oral Cir Bucal, V9 Suppl, P82; Matter HC, 1998, EUR J EPIDEMIOL, V14, P483, DOI 10.1023/A:1007460213308; Metzger R, 2002, MMW Fortschr Med, V144, P46; Mitchell RB, 2003, LARYNGOSCOPE, V113, P492, DOI 10.1097/00005537-200303000-00018; Scheithauer MO, 1997, HNO, V45, P891, DOI 10.1007/s001060050170; Smith PF, 2000, J CLIN PHARM THER, V25, P85; Talan DA, 1999, NEW ENGL J MED, V340, P85, DOI 10.1056/NEJM199901143400202; Tu AH, 2002, PLAST RECONSTR SURG, V109, P1259, DOI 10.1097/00006534-200204010-00008; Wolff KD, 1998, J ORAL MAXIL SURG, V56, P838, DOI 10.1016/S0278-2391(98)90009-X	24	32	33	0	7	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0266-4356	1532-1940		BRIT J ORAL MAX SURG	Br. J. Oral Maxillofac. Surg.	JUN	2006	44	3					235	239		10.1016/j.bjoms.2005.06.015			5	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	050CE	WOS:000238064300018	16055237				2021-06-18	
J	Christofides, J; Bridel, M; Egerton, M; Mackay, GM; Forrest, CM; Stoy, N; Darlington, LG; Stone, TW				Christofides, J; Bridel, M; Egerton, M; Mackay, GM; Forrest, CM; Stoy, N; Darlington, LG; Stone, TW			Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington's disease or chronic brain injury	JOURNAL OF NEUROCHEMISTRY			English	Article						Huntington's disease; 5-hydroxyindoleacetic acid (5-HIAA); 5-hydroxytryptamine (5-HT); oxidative stress; peroxidation; tryptophan	CEREBROSPINAL-FLUID CONCENTRATIONS; TRYPTOPHAN-HYDROXYLASE; OXIDATIVE STRESS; RECEPTOR-BINDING; NEURODEGENERATIVE DISORDERS; SEROTONERGIC MEASURES; PLASMA TRYPTOPHAN; RAT; METABOLISM; DEPLETION	Following a study of oxidative tryptophan metabolism to kynurenines, we have now analysed the blood of patients with either Huntington's disease or traumatic brain injury for levels of 5-hydroxytryptamine (5-HT), 5-hydroxyindoleacetic acid (5-HIAA) and melatonin. There were no differences in the baseline levels of these compounds between patients and healthy controls. Tryptophan depletion did not reduce 5-HT levels in either the controls or in the patients with Huntington's disease, but it increased 5-HT levels in patients with brain injury and lowered 5-HIAA in the control and Huntington's disease groups. An oral tryptophan load did not modify 5-HT levels in the patients but increased 5-HT in control subjects. The tryptophan load restored 5-HIAA to baseline levels in controls and patients with brain injury, but not in those with Huntington's disease, in whom 5-HIAA remained significantly depressed. Melatonin levels increased on tryptophan loading in all subjects, with levels in patients with brain injury increasing significantly more than in controls. Baseline levels of neopterin and lipid peroxidation products were higher in patients than in controls. It is concluded that both groups of patients exhibit abnormalities in tryptophan metabolism, which may be related to increased inflammatory status and oxidative stress. Interactions between the kynurenine, 5-HT and melatonin pathways should be considered when interpreting changes of tryptophan metabolism.	Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Epsom Gen Hosp, W Pk Biochem Labs, Epsom, Surrey, England; Royal Hosp Neurodisabil, London, England	Stone, TW (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, W Med Bldg, Glasgow G12 8QQ, Lanark, Scotland.	t.w.stone@bio.gla.ac.uk	Stone, Trevor/M-7904-2015	Stone, Trevor/0000-0002-5532-0031			BADAWY AAB, 1991, BRIT J PHARMACOL, V102, P429, DOI 10.1111/j.1476-5381.1991.tb12190.x; Barriga C, 2001, J PINEAL RES, V30, P180, DOI 10.1034/j.1600-079X.2001.300307.x; Bates G, 2003, LANCET, V361, P1642, DOI 10.1016/S0140-6736(03)13304-1; BEAL MF, 1992, J NEUROL SCI, V108, P80; BIGGIO G, 1974, LIFE SCI, V14, P1321, DOI 10.1016/0024-3205(74)90440-8; Castro ME, 1998, BRAIN RES, V790, P323, DOI 10.1016/S0006-8993(97)01566-7; CELADA P, 1993, J NEUROCHEM, V61, P2191, DOI 10.1111/j.1471-4159.1993.tb07459.x; COWEN PJ, 1994, HUM PSYCHOPHARM CLIN, V9, P371, DOI 10.1002/hup.470090509; Cummings TJ, 1996, BRAIN RES, V743, P240, DOI 10.1016/S0006-8993(96)01053-0; De Marchi N, 2001, PSYCHOPHARMACOLOGY, V153, P264, DOI 10.1007/s002130000575; Degg TJ, 2000, ANN CLIN BIOCHEM, V37, P724, DOI 10.1258/0004563001899780; DEGRELL I, 1990, BIOL PSYCHIAT, V27, P1179, DOI 10.1016/0006-3223(90)90055-7; Duan WZ, 2004, ANN NEUROL, V55, P590, DOI 10.1002/ana.20075; Esteban S, 2004, MOL CELL BIOCHEM, V267, P39, DOI 10.1023/B:MCBI.0000049363.97713.74; FERNSTROM JD, 1971, SCIENCE, V173, P149, DOI 10.1126/science.173.3992.149; FORREST CM, 2005, IN PRESS KYNURENINES; FRASER S, 1983, CLIN CHEM, V29, P396; Grimes MA, 2000, NEUROCHEM RES, V25, P413, DOI 10.1023/A:1007557524370; Guevara BH, 2002, CELL MOL NEUROBIOL, V22, P835, DOI 10.1023/A:1021829629357; HUETHER G, 1992, PSYCHOPHARMACOLOGY, V109, P422, DOI 10.1007/BF02247718; Kubera M, 2005, PSYCHIAT RES, V134, P251, DOI 10.1016/j.psychres.2004.01.014; Kuemmerle S, 1999, ANN NEUROL, V46, P842; Kuhn DM, 1996, J NEUROCHEM, V67, P1072; Mackay GM, 2006, EUR J NEUROL, V13, P30, DOI 10.1111/j.1468-1331.2006.01220.x; Mattson MP, 2004, TRENDS NEUROSCI, V27, P589, DOI 10.1016/j.tins.2004.08.001; MOJA EA, 1991, LIFE SCI, V49, P1121, DOI 10.1016/0024-3205(91)90600-G; Nishizawa S, 1997, P NATL ACAD SCI USA, V94, P5308, DOI 10.1073/pnas.94.10.5308; PIETRASZEK MH, 1992, LIFE SCI, V51, P75, DOI 10.1016/0024-3205(92)90221-A; Pussard E, 1996, CLIN CHEM, V42, P1086; Reiter RJ, 2000, J BIOMED SCI, V7, P444, DOI 10.1159/000025480; REYNOLDS GP, 1995, BRIT J PHARMACOL, V114, P993, DOI 10.1111/j.1476-5381.1995.tb13303.x; REYNOLDS GP, 1987, NEUROSCI LETT, V78, P233, DOI 10.1016/0304-3940(87)90639-2; Roseboom PH, 1996, ENDOCRINOLOGY, V137, P3033, DOI 10.1210/en.137.7.3033; Rousseau A, 1999, J NEURAL TRANSM, V106, P883, DOI 10.1007/s007020050208; RUIZ PJG, 1995, CLIN NEUROPHARMACOL, V18, P58, DOI 10.1097/00002826-199502000-00007; SHARP T, 1992, LIFE SCI, V50, P1215, DOI 10.1016/0024-3205(92)90321-F; Stone TW, 2003, CLIN CHEM LAB MED, V41, P852, DOI 10.1515/CCLM.2003.129; Stoy N, 2005, J NEUROCHEM, V93, P611, DOI 10.1111/j.1471-4159.2005.03070.x; Strawn JR, 2002, LIFE SCI, V71, P1219, DOI 10.1016/S0024-3205(02)01828-3; Takada Akikazu, 1996, Polish Journal of Pharmacology, V48, P173; van der Stelt HM, 2004, PSYCHOPHARMACOLOGY, V172, P137, DOI 10.1007/s00213-003-1632-6; Vanhatalo S, 1999, EXP NEUROL, V157, P305, DOI 10.1006/exnr.1999.7053; WAEBER C, 1989, NEUROSCIENCE, V32, P337, DOI 10.1016/0306-4522(89)90082-1; Williams WA, 1999, J NEUROCHEM, V72, P1641, DOI 10.1046/j.1471-4159.1999.721641.x; Wong EHF, 1996, BEHAV BRAIN RES, V73, P249; Wu C, 1999, EXP NEUROL, V158, P529, DOI 10.1006/exnr.1999.7105; YAN D, 1993, LIFE SCI, V52, P745, DOI 10.1016/0024-3205(93)90237-W; Yohrling GJ, 2002, J NEUROCHEM, V82, P1416, DOI 10.1046/j.1471-4159.2002.01084.x; YOUNG SN, 1988, PHARMACOL BIOCHEM BE, V31, P149, DOI 10.1016/0091-3057(88)90326-7; YU AQ, 1995, BRAIN RES, V688, P209, DOI 10.1016/0006-8993(95)00539-3	50	32	32	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0022-3042	1471-4159		J NEUROCHEM	J. Neurochem.	MAY	2006	97	4					1078	1088		10.1111/j.1471-4159.2006.03807.x			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	036HW	WOS:000237063200017	16573644	Bronze			2021-06-18	
J	Tamas, A; Zsombok, A; Farkas, O; Reglodi, D; Pal, J; Buki, A; Lengvari, I; Povlishock, JT; Doczi, T				Tamas, Andrea; Zsombok, Andrea; Farkas, Orsolya; Reglodi, Dora; Pal, Jozsef; Buki, Andras; Lengvari, Istvan; Povlishock, John T.; Doczi, Tamas			Postinjury administration of pituitary adenylate cyclase activating polypeptide (PACAP) attenuates traumatically induced axonal injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						beta-amyloid precursor protein; corticospinal tract; neuroprotection; PACAP; traumatic brain injury	VASOACTIVE-INTESTINAL-PEPTIDE; PERCUSSION BRAIN-INJURY; CEREBELLAR GRANULE NEURONS; FOCAL CEREBRAL-ISCHEMIA; FREE-RADICAL PRODUCTION; CYCLOSPORINE-A; HIPPOCAMPAL-NEURONS; MILD HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; NEUROTROPHIC FACTOR	Pituitary adenylate cyclase activating polypeptide (PACAP) has several different actions in the nervous system. Numerous studies have shown its neuroprotective effects both in vitro and in vivo. Previously,, it has been demonstrated that PACAP reduces brain damage in rat models of global and focal cerebral ischemia. Based on the protective effects of PACAP in cerebral ischemia and the presence of common pathogenic mechanisms in cerebral ischemia and traumatic brain injury (TBI), the aim of the present study was to investigate the possible protective effect of PACAP administered 30 min or 1 h postinjury in a rat model of diffuse axonal injury. Adult Wistar male rats were subjected to impact acceleration, and PACAP was administered intracerebroventricularly 30 min (n = 4), and 1 h after the injury (n = 5). Control animals received the same volume of vehicle at both time-points (n = 5). Two hours after the injury, brains were processed for immunohistochemical localization of damaged axonal profiles displaying either beta-amyloid precursor protein (beta-APP) or RMO-14 immunoreactivity, both considered markers of specific features of traumatic axonal injury. Our results show that treatment with PACAP (100 mu g) 30 min or 1 h after the induction of TBI resulted in a significant reduction of the density of beta-APP-immunopositive axon profiles in the corticospinal tract (CSpT). There was no significant difference between the density of beta-APP-immunopositive axons in the medial longitudinal fascicle (MLF). PACAP treatment did not result in significantly different number of RMO-14-immunopositive axonal profiles in either brain areas 2 hours post-injury compared to normal animals. While the results of this study highlighted the complexity of the pathogenesis and manifestation of diffuse axonal injury, they also indicate that PACAP should be considered a potential therapeutic agent in TBI.	Univ Pecs, Dept Anat, Fac Med, Hungarian Acad Sci,Neurohumoral Regulat Res Grp, Pecs, Hungary; Univ Pecs, Dept Neurosurg, Fac Med, Pecs, Hungary; Univ Pecs, Cent Lab Anim Res, Fac Med, Pecs, Hungary; Virginia Commonwealth Univ, Dept Anat & Neurobiol, Richmond, VA USA; Univ Pecs, Dept Neurosurg, Fac Med, Hungarian Acad Sci,Clin Neurosci Res Grp, Pecs, Hungary	Tamas, A (corresponding author), Univ Pecs, Dept Anat, Fac Med, Hungarian Acad Sci,Neurohumoral Regulat Res Grp, Pecs, Hungary.	andrea.tamas@aok.pte.hu	Doczi, Tamas/C-5750-2009; Pal, Jozsef/I-3416-2013; Pal, Jozsef/C-4073-2009; Buki, Andras/B-1960-2010	Pal, Jozsef/0000-0001-6468-6409	FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [R03TW001313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER; FIC NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [1-R03-TW0131302A1] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193] Funding Source: Medline		Arimura A, 1998, JPN J PHYSIOL, V48, P301, DOI 10.2170/jjphysiol.48.301; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Buki A, 2003, J NEUROTRAUM, V20, P261, DOI 10.1089/089771503321532842; Buki A, 1999, EXP NEUROL, V159, P319, DOI 10.1006/exnr.1999.7139; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Buki A, 2000, J NEUROSCI, V20, P2825; Bullock J.A., 1993, AMATEUR ENTOMOLOGI A, V11a, P1; Canonico PL, 1996, ANN NY ACAD SCI, V805, P470; Cernak I, 2002, EXP BRAIN RES, V147, P193, DOI 10.1007/s00221-002-1245-z; Delgado M, 1999, J IMMUNOL, V162, P2358; Delgado M, 2003, J LEUKOCYTE BIOL, V73, P155, DOI 10.1189/jlb.0702372; Delgado M, 2002, GLIA, V39, P148, DOI 10.1002/glia.10098; Deng H, 2003, STROKE, V34, P2495, DOI 10.1161/01.STR.0000091269.67384.E7; Dietrich WD, 1996, J NEUROTRAUM, V13, P309, DOI 10.1089/neu.1996.13.309; DIRNAGL U, 1990, BRAIN RES, V527, P62, DOI 10.1016/0006-8993(90)91060-T; Farkas O, 2004, REGUL PEPTIDES, V123, P69, DOI 10.1016/j.regpep.2004.05.014; Figiel M, 2000, J NEUROSCI, V20, P3596; Fink KB, 1999, NEUROSCIENCE, V94, P1213, DOI 10.1016/S0306-4522(99)00345-0; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Frechilla D, 2001, NEUROREPORT, V12, P919, DOI 10.1097/00001756-200104170-00011; Ganea D, 2002, CRIT REV ORAL BIOL M, V13, P229, DOI 10.1177/154411130201300303; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Goda M, 2002, J NEUROTRAUM, V19, P1445, DOI 10.1089/089771502320914679; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; KADOYA C, 1995, STROKE, V26, P1035, DOI 10.1161/01.STR.26.6.1035; Katahira M., 2003, Regulatory Peptides, V115, P49; Kawamata T, 1997, P NATL ACAD SCI USA, V94, P8179, DOI 10.1073/pnas.94.15.8179; Kim WK, 2000, J NEUROSCI, V20, P3622; Kimura H, 2003, LARYNGOSCOPE, V113, P1000, DOI 10.1097/00005537-200306000-00016; Kinhult J, 2001, PEPTIDES, V22, P2151, DOI 10.1016/S0196-9781(01)00568-X; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; LEE VMY, 1987, J NEUROSCI, V7, P3474; Leker RR, 2002, BRAIN RES REV, V39, P55, DOI 10.1016/S0165-0173(02)00157-1; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; LYETH BG, 1993, J NEUROTRAUM, V10, P57, DOI 10.1089/neu.1993.10.57; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MITANI A, 1991, BRAIN RES, V562, P159, DOI 10.1016/0006-8993(91)91201-B; Morio H, 1996, BRAIN RES, V741, P82, DOI 10.1016/S0006-8993(96)00920-1; Nakayama M, 1998, P NATL ACAD SCI USA, V95, P10954, DOI 10.1073/pnas.95.18.10954; OHTAKI H, 2003, REGUL PEPTIDES, V15, P53; Okonkwo DO, 1998, BRAIN RES, V784, P1, DOI 10.1016/S0006-8993(97)01075-5; Okonkwo DO, 1999, NEUROREPORT, V10, P353, DOI 10.1097/00001756-199902050-00026; Okonkwo DO, 1999, J CEREBR BLOOD F MET, V19, P443, DOI 10.1097/00004647-199904000-00010; Otani N, 2002, J NEUROTRAUM, V19, P1587, DOI 10.1089/089771502762300247; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 2001, HEAD TRAUMA BASIC PR; Reglodi D, 2000, STROKE, V31, P1411, DOI 10.1161/01.STR.31.6.1411; Reglodi D, 2004, BEHAV BRAIN RES, V151, P303, DOI 10.1016/j.bbr.2003.09.007; Reglodi D, 2002, PEPTIDES, V23, P2227, DOI 10.1016/S0196-9781(02)00262-0; Sakamoto KI, 1997, J NEUROTRAUM, V14, P349, DOI 10.1089/neu.1997.14.349; Sanderson KL, 1999, J CEREBR BLOOD F MET, V19, P1118, DOI 10.1097/00004647-199910000-00008; SEKI T, 2003, REGUL PEPTIDES, V115, P55; Shioda S, 1998, ANN NY ACAD SCI, V865, P111, DOI 10.1111/j.1749-6632.1998.tb11169.x; Shoge K, 1999, BRAIN RES, V839, P66, DOI 10.1016/S0006-8993(99)01690-X; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; Somogyvari-Vigh A, 2004, CURR PHARM DESIGN, V10, P2861, DOI 10.2174/1381612043383548; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Suehiro E, 2001, EXP NEUROL, V172, P199, DOI 10.1006/exnr.2001.7765; Tabuchi A, 2003, J NEUROSCI RES, V71, P504, DOI 10.1002/jnr.10505; Tanaka J, 1997, REGUL PEPTIDES, V72, P1, DOI 10.1016/S0167-0115(97)01038-0; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; TSUDA T, 1991, NEUROSCIENCE, V44, P335, DOI 10.1016/0306-4522(91)90058-V; Uchida D, 1996, BRAIN RES, V736, P280, DOI 10.1016/S0006-8993(96)00716-0; Vaudry D, 2000, P NATL ACAD SCI USA, V97, P13390, DOI 10.1073/pnas.97.24.13390; Vaudry D, 2000, PHARMACOL REV, V52, P269; Vaudry D, 2002, J NEUROCHEM, V83, P1272, DOI 10.1046/j.1471-4159.2002.01242.x; Vaudry D, 2002, P NATL ACAD SCI USA, V99, P6398, DOI 10.1073/pnas.082112699; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; ZAMBONI L, 1967, J CELL BIOL, V35, pA148	79	32	33	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2006	23	5					686	695		10.1089/neu.2006.23.686			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	042LJ	WOS:000237529200007	16689670				2021-06-18	
J	Avesani, R; Gambini, MG; Albertini, G				Avesani, R; Gambini, MG; Albertini, G			The vegetative state: A report of two cases with a long-term follow-up	BRAIN INJURY			English	Article						persistent vegetative state; outcome; follow-up; traumatic brain injury	TRAUMATIC BRAIN-INJURY; DISABILITY RATING-SCALE; GLASGOW OUTCOME SCALE; RECOVERY; PROGNOSIS	Objectives: To demonstrate that patients with Prolonged Vegetative State (PVS) can show signs of improvements and important changes and, consequently, to strengthen the necessity to evaluate them with long-term serial follow-ups. Setting: Rehabilitation of patients with severe traumatic brain injury (TBI). Participants: Two people with severe TBI discharged after a long period of inpatient rehabilitation in a condition of PVS. Results: After 5 years some important changes happened and the initial prognosis was proved to be wrong. Conclusion: Sometimes patients declared to be in PVS have the possibility to recover, especially when initial clinical conditions are particularly severe and do not allow the emergence of the state of consciousness. It is important to conduct regular follow-ups to better evaluate changes and, if it is necessary, to re-adjust the rehabilitation accordingly.	Rehabil Dept Sacro Cuore Don Calabria, Verona, Italy	Avesani, R (corresponding author), Osped Sacro Cuore Don Calabria, I-37024 Verona, Italy.	renato.avesani@sacrocuore.it		Gambini, Maria Grazia/0000-0002-6211-2169			Andrews K, 1996, BRIT MED J, V313, P13, DOI 10.1136/bmj.313.7048.13; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; Avesani R, 2002, ACT NEUR S, V79, P45; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; BROOKS DN, 1995, DOCUMENT EUROPEENNE; Childs NL, 1996, BRIT MED J, V313, P944; Giacino JT, 1997, J HEAD TRAUMA REHAB, V12, P36, DOI 10.1097/00001199-199708000-00005; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Gostin L, 1989, Law Med Health Care, V17, P295; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hammond FM, 2001, J HEAD TRAUMA REHAB, V16, P318, DOI 10.1097/00001199-200108000-00003; *I SUP SAN PROGR L, 2000, C NAZ CONS MOD TRATT; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; Jennett B, 2002, J NEUROL NEUROSUR PS, V73, P355, DOI 10.1136/jnnp.73.4.355; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; SAZBON L, 1990, J NEUROSURG, V72, P75, DOI 10.3171/jns.1990.72.1.0075; Struchen MA, 2001, J NEUROTRAUM, V18, P115, DOI 10.1089/08977150150502569; Wade DT, 1999, BMJ-BRIT MED J, V319, P841, DOI 10.1136/bmj.319.7213.841; Whyte J, 2001, ARCH PHYS MED REHAB, V82, P1355, DOI 10.1053/apmr.2001.26091	21	32	32	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2006	20	3					333	338		10.1080/02699050500487605			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	021GT	WOS:000235972400013	16537275				2021-06-18	
J	Prayer, D; Brugger, PC; Kasprian, G; Witzani, L; Helmer, H; Dietrich, W; Eppel, W; Langer, M				Prayer, D; Brugger, PC; Kasprian, G; Witzani, L; Helmer, H; Dietrich, W; Eppel, W; Langer, M			MRI of fetal acquired brain lesions	EUROPEAN JOURNAL OF RADIOLOGY			English	Article						fetal magnetic resonance imaging; acquired fetal brain injury; diffusion-weighted sequences	WHITE-MATTER DEVELOPMENT; PRENATAL-DIAGNOSIS; IN-UTERO; SUBEPENDYMAL GERMINOLYSIS; INTRACRANIAL HEMORRHAGE; PULMONARY HYPOPLASIA; CLINICAL-FEATURES; PREMATURE RUPTURE; ISCHEMIC LESIONS; SUBPLATE NEURONS	Acquired fetal brain damage is suspected in cases of destruction of previously normally formed tissue, the primary cause of which is hypoxia. Fetal brain damage may occur as a consequence of acute or chronic maternal diseases, with acute diseases causing impairment of oxygen delivery to the fetal brain, and chronic diseases interfering with normal, placental development. Infections, metabolic diseases, feto-fetal transfusion syndrome, toxic agents, mechanical traumatic events, iatrogenic accidents, and space-occupying lesions may also qualify as pathologic conditions that initiate intrauterine brain damage. MR manifestations of acute fetal brain injury (such as hemorrhage or acute ischemic lesions) can easily be recognized, as they are hardly different from postnatal lesions. The availability of diffusion-weighted sequences enhances the sensitivity in recognizing acute ischemic lesions. Recent hemorrhages are usually readily depicted on T2 (*) sequences, where they display hypointense signals. Chronic fetal brain injury may be characterized by nonspecific changes that must be attributable to the presence of an acquired cerebral pathology. The workup in suspected acquired fetal brain injury also includes the assessment of extra-CNS organs that may be affected by an underlying pathology. Finally, the placenta, as the organ that mediates oxygen delivery from the maternal circulation to the fetus, must be examined on MR images. (C) 2005 Elsevier Ireland Ltd. All rights reserved.	Med Univ Vienna, Dept Radiodiagnost, A-1090 Vienna, Austria; Med Univ Vienna, Ctr Anat & Cell Biol, A-1090 Vienna, Austria; Med Univ Vienna, Dept Obstet & Gynecol, A-1090 Vienna, Austria; Med Univ Vienna, Dept Neurosurg, A-1090 Vienna, Austria	Prayer, D (corresponding author), Med Univ Vienna, Dept Radiodiagnost, Waehringerguertel 18-20, A-1090 Vienna, Austria.	daniela.prayer@meduniwien.ac.at	Kasprian, Gregor/AAJ-5052-2020	Kasprian, Gregor/0000-0003-3858-3347; Helmer, Hanns/0000-0003-3623-2180			Adegbite AL, 2005, EUR J OBSTET GYN R B, V119, P47, DOI 10.1016/j.ejogrb.2004.06.016; Baldoli C, 2002, ANN NEUROL, V52, P243, DOI 10.1002/ana.10255; Barkovich AJ, 1998, AM J NEURORADIOL, V19, P1389; Barkovich AJ, 2003, CHILD NERV SYST, V19, P501, DOI 10.1007/s00381-003-0763-8; Baschat AA, 2004, BJOG-INT J OBSTET GY, V111, P1031, DOI 10.1111/j.1471-0528.2004.00273.x; Baschat AA, 2001, CURR OPIN OBSTET GYN, V13, P161, DOI 10.1097/00001703-200104000-00011; Bats AS, 2002, ULTRASOUND OBST GYN, V20, P502, DOI 10.1046/j.1469-0705.2002.00848.x; Bettendorf M, 2002, EUR J NUCL MED MOL I, V29, pS439, DOI 10.1007/s00259-002-0905-3; BEYDOUN SN, 1986, AM J OBSTET GYNECOL, V155, P471, DOI 10.1016/0002-9378(86)90257-7; Bookstein Fred L., 2002, Anatomical Record, V269, P162, DOI 10.1002/ar.10110; Brewerton L, 2005, RADIOLOGY, V235, P1005, DOI 10.1148/radiol.2353040280; BRUGGER PC, EUR J RADIOL; Brunelle F, 2003, CHILD NERV SYST, V19, P524, DOI 10.1007/s00381-003-0791-4; Campbell K, 2005, NEURON, V46, P373, DOI 10.1016/j.neuron.2005.04.014; Castillo M, 1996, RADIOGRAPHICS, V16, P241, DOI 10.1148/radiographics.16.2.8966284; Cavalheiro S, 2003, CHILD NERV SYST, V19, P529, DOI 10.1007/s00381-003-0770-9; Chan KY, 2003, PEDIATR PATHOL MOL M, V22, P277, DOI 10.1080/15227950307712; Cherian S, 2004, BRAIN PATHOL, V14, P305; de Laveaucoupet J, 2005, PRENATAL DIAG, V25, P307, DOI 10.1002/pd.1128; de Laveaucoupet J, 2001, PRENATAL DIAG, V21, P729, DOI 10.1002/pd.135; Drobyshevsky A, 2005, J NEUROSCI, V25, P5988, DOI 10.1523/JNEUROSCI.4983-04.2005; Elchalal U, 2005, ULTRASOUND OBST GYN, V26, P233, DOI 10.1002/uog.1969; Ernest JM, 1998, CLIN OBSTET GYNECOL, V41, P827, DOI 10.1097/00003081-199812000-00006; Ferriero D M, 1999, Curr Opin Neurol, V12, P161, DOI 10.1097/00019052-199904000-00006; Galarza M, 2002, NEUROSURG REV, V25, P205, DOI 10.1007/s10143-002-0208-y; Garel C, 2004, AM J NEURORADIOL, V25, P1563; Garnier Y, 2003, J SOC GYNECOL INVEST, V10, P450, DOI 10.1016/S1071-5576(03)00150-3; Gicquel JM, 2000, PRENATAL DIAG, V20, P824; Gilles FH, 2005, EARLY HUM DEV, V81, P245, DOI 10.1016/j.earlhumdev.2005.01.005; Girard N, 2003, CHILD NERV SYST, V19, P490, DOI 10.1007/s00381-003-0761-x; Guibaud L, 2004, PRENATAL DIAG, V24, P727, DOI 10.1002/pd.914; Hahn JS, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.5.e95; Haverkamp F, 1999, EUR J PEDIATR, V158, P474, DOI 10.1007/s004310051123; Herini E, 2003, PEDIATR INT, V45, P692, DOI 10.1111/j.1442-200X.2003.t01-1-01814.x; Huleihel Mahmoud, 2004, Reprod Biol Endocrinol, V2, P17, DOI 10.1186/1477-7827-2-17; HUSAIN AN, 1993, PEDIATR PATHOL, V13, P475, DOI 10.3109/15513819309048237; Inder TE, 1999, ANN NEUROL, V45, P798, DOI 10.1002/1531-8249(199906)45:6<798::AID-ANA16>3.0.CO;2-U; Kammoun F, 2004, AM J MED GENET A, V126A, P191, DOI 10.1002/ajmg.a.20562; Kopelman A E, 1998, J Perinatol, V18, P74; Kostovic I, 2002, CEREB CORTEX, V12, P536, DOI 10.1093/cercor/12.5.536; Lee HC, 2003, J KOREAN MED SCI, V18, P764, DOI 10.3346/jkms.2003.18.5.764; Levine D, 2003, RADIOLOGY, V229, P51, DOI 10.1148/radiol.2291020770; Levine D, 2002, RADIOLOGY, V223, P652, DOI 10.1148/radiol.2233011336; Lidow MS, 2003, DEV BRAIN RES, V147, P23, DOI 10.1016/j.devbrainres.2003.09.001; Lopriore E, 2003, AM J OBSTET GYNECOL, V189, P1314, DOI 10.1067/S0002-9378(03)00760-9; Malinger G, 2003, AM J NEURORADIOL, V24, P28; Manning FA, 2002, CLIN OBSTET GYNECOL, V45, P975, DOI 10.1097/00003081-200212000-00004; McKinney AM, 2004, AM J NEURORADIOL, V25, P1659; McQuillen PS, 2003, J NEUROSCI, V23, P3308; Meroni PL, 2004, LUPUS, V13, P649, DOI 10.1191/0961203304lu2001oa; Moore RJ, 2000, PLACENTA, V21, P726, DOI 10.1053/plac.2000.0567; MORGANE PJ, 1993, NEUROSCI BIOBEHAV R, V17, P91, DOI 10.1016/S0149-7634(05)80234-9; Pang Y, 2000, J NEUROSCI RES, V62, P510, DOI 10.1002/1097-4547(20001115)62:4<510::AID-JNR5>3.0.CO;2-F; Pang Y, 2005, DEV BRAIN RES, V157, P141, DOI 10.1016/j.devbrainres.2005.03.015; Paupe A, 2002, ULTRASOUND OBST GYN, V20, P616, DOI 10.1046/j.1469-0705.2002.00869.x; Prayer D, 2004, PEDIATR RADIOL, V34, P685, DOI 10.1007/s00247-004-1246-0; Prayer D, 2003, EUR J RADIOL, V45, P235, DOI 10.1016/S0720-048X(02)00312-1; Prayer D, 2001, AM J NEURORADIOL, V22, P1572; RAMENGHI L, 2005, PEDIAT NEURORADIOLOG; Riley EP, 2005, EXP BIOL MED, V230, P357, DOI 10.1177/15353702-0323006-03; Roland EP, 1998, ANN NEUROL, V44, P161, DOI 10.1002/ana.410440205; Sanchis A, 2005, J PEDIATR-US, V146, P701, DOI 10.1016/j.jpeds.2005.01.033; SHAW CM, 1974, ARCH NEUROL-CHICAGO, V31, P374, DOI 10.1001/archneur.1974.00490420040003; Smith AS, 2004, AM J NEURORADIOL, V25, P1037; Syridou Garyfallia, 2005, Expert Rev Anti Infect Ther, V3, P651, DOI 10.1586/14787210.3.4.651; Tan TYT, 2005, CURR OPIN OBSTET GYN, V17, P135, DOI 10.1097/01.gco.0000162181.61102.d7; Tews G, 2004, WIEN KLIN WOCHENSCHR, V116, P692, DOI 10.1007/s00508-004-0246-2; van Straaten HLM, 2005, NEUROPEDIATRICS, V36, P193, DOI 10.1055/s-2005-865713; Viscardi RM, 2001, EARLY HUM DEV, V62, P1, DOI 10.1016/S0378-3782(01)00114-1; Volpe JJ, 1996, PEDIATRICS, V97, P112; von Mandach U, 2005, Ther Umsch, V62, P29, DOI 10.1024/0040-5930.62.1.29; Williams G, 2004, RADIOLOGY, V233, P457, DOI 10.1148/radiol.2332031566; WIMBERGER DM, 1995, J COMPUT ASSIST TOMO, V19, P28, DOI 10.1097/00004728-199501000-00005; Yanney Michael, 2004, Semin Fetal Neonatal Med, V9, P411, DOI 10.1016/j.siny.2004.03.005	74	32	36	0	7	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0720-048X			EUR J RADIOL	Eur. J. Radiol.	FEB	2006	57	2					233	249		10.1016/j.ejrad.2005.11.023			17	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	016PV	WOS:000235633300008	16413156				2021-06-18	
J	Thiessen, ML; Woolridge, DP				Thiessen, ML; Woolridge, DP			Pediatric minor closed head injury	PEDIATRIC CLINICS OF NORTH AMERICA			English	Article							TRAUMATIC BRAIN-INJURY; INTRACRANIAL INJURY; POSTTRAUMATIC SEIZURES; COMPUTED-TOMOGRAPHY; CHILDREN YOUNGER; CLINICAL PREDICTORS; SKULL FRACTURE; HELICAL CT; 2ND IMPACT; CONCUSSION	Many Studies have found conflicting evidence over the use of clinical indicators to predict intracranial injury in pediatric mild head injury. Although altered mental status, loss of consciousness, and abnormal neurologic examination have all been found to be more prevalent among head-injured children, studies have observed inconsistent results over their specificity and predictive value. Children older than 2 years have been evaluated, managed, and studied differently than those less than 2 years old. Evidence strongly supports a lower threshold to perform a CT scan in younger children because they have a higher risk of significant brain injury after blunt head trauma.	Univ Arizona, Dept Emergency Med, Tucson, AZ 85724 USA	Woolridge, DP (corresponding author), Univ Arizona, Dept Emergency Med, 1515 N Campbell Ave, Tucson, AZ 85724 USA.	dale@aemrc.arizona.edu					Adams J, 2001, J PEDIATR SURG, V36, P119, DOI 10.1053/jpsu.2001.20026; American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson VA, 2005, J NEUROL NEUROSUR PS, V76, P401, DOI 10.1136/jnnp.2003.019174; Bazarian Jeffrey J, 2003, Ann Emerg Med, V41, P738, DOI 10.1067/mem.2003.142; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bergman DA, 1999, PEDIATRICS, V104, P1407; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289, DOI 10.2214/ajr.176.2.1760289; Brown L, 2003, AM J EMERG MED, V21, P467, DOI 10.1016/S0735-6757(03)00174-8; Bull MJ, 2001, PEDIATRICS, V108, P790; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CANTU RC, 1988, SPORTS MED DIGEST, V10, P1; Chung S, 2004, ANN EMERG MED, V43, P718, DOI 10.1016/j.annemergmed.2003.09.020; *COL MED SOC, 1991, REP SPORTS MED COMM; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P2283, DOI 10.1001/jama.282.24.2283; DAVIES RL, 1995, PEDIATRICS, V95, P345; DAVIS RL, 1994, ANN EMERG MED, V24, P640, DOI 10.1016/S0196-0644(94)70273-X; Dias MS, 1999, PEDIATR NEUROSURG, V30, P232, DOI 10.1159/000028803; DIETRICH AM, 1993, ANN EMERG MED, V22, P1535, DOI 10.1016/S0196-0644(05)81254-5; Donnelly LF, 2001, AM J ROENTGENOL, V176, P303, DOI 10.2214/ajr.176.2.1760303; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Frush DP, 2003, PEDIATRICS, V112, P951, DOI 10.1542/peds.112.4.951; GHAJAR J, 1992, PEDIATR CLIN N AM, V39, P1093; Greenes DS, 1997, ANN EMERG MED, V30, P253, DOI 10.1016/S0196-0644(97)70158-6; Greenes DS, 1998, ANN EMERG MED, V32, P680, DOI 10.1016/S0196-0644(98)70067-8; Greenes DS, 2001, PEDIATR EMERG CARE, V17, P88, DOI 10.1097/00006565-200104000-00002; Greenes DS, 1999, PEDIATRICS, V104, P861, DOI 10.1542/peds.104.4.861; Gruskin KD, 1999, ARCH PEDIAT ADOL MED, V153, P15; HAHN YS, 1993, PEDIATR NEUROSURG, V19, P135, DOI 10.1159/000120718; Halley Michelle K, 2004, Pediatr Crit Care Med, V5, P230, DOI 10.1097/01.PCC.0000123543.40224.73; Hawley CA, 2004, J NEUROL NEUROSUR PS, V75, P737, DOI 10.1136/jnnp.2003.020651; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; Hinton-Bayre AD, 2002, NEUROLOGY, V59, P1068, DOI 10.1212/WNL.59.7.1068; Holmes JF, 2004, ANN EMERG MED, V43, P706, DOI 10.1016/j.annemergmed.2003.11.008; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Klassen TP, 2000, ACAD EMERG MED, V7, P739, DOI 10.1111/j.1553-2712.2000.tb02260.x; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; Lloyd DA, 1997, LANCET, V349, P821, DOI 10.1016/S0140-6736(96)09356-7; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Macpherson AK, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e60; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; MASTERS SJ, 1987, NEW ENGL J MED, V316, P84, DOI 10.1056/NEJM198701083160205; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrory P, 2005, PHYSICIAN SPORTSMED, V33, P29, DOI 10.3810/psm.2005.04.76; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; McKinlay A, 2002, J NEUROL NEUROSUR PS, V73, P281, DOI 10.1136/jnnp.73.3.281; MITCHELL KA, 1994, J PEDIATR SURG, V29, P851, DOI 10.1016/0022-3468(94)90001-9; PALCHAK MH, 2003, ACAD EMERG MED, V10, P497; Palchak MJ, 2004, PEDIATRICS, V113, pE507, DOI 10.1542/peds.113.6.e507; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; PARTINGTON MD, 1991, ANN EMERG MED, V20, P652, DOI 10.1016/S0196-0644(05)82386-8; Paterson A, 2001, AM J ROENTGENOL, V176, P297, DOI 10.2214/ajr.176.2.1760297; PAVLOVITCH C, 2003, ACAD EMERG MED, V10, P495; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Ponsford J, 2001, PEDIATRICS, V108, P1297, DOI 10.1542/peds.108.6.1297; QUAYLE KS, 1998, PEDIATRICS, V99, P1; RAMUNDO ML, 1995, PEDIATR EMERG CARE, V11, P1, DOI 10.1097/00006565-199502000-00001; Roddy SP, 1998, PEDIATRICS, V101, P575, DOI 10.1542/peds.101.4.575; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Savitsky EA, 2000, AM J EMERG MED, V18, P96, DOI 10.1016/S0735-6757(00)90060-3; Schunk JE, 1996, PEDIATR EMERG CARE, V12, P160, DOI 10.1097/00006565-199606000-00004; Schutzman SA, 2001, PEDIATRICS, V107, P983, DOI 10.1542/peds.107.5.983; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; Shafi S, 1998, J PEDIATR SURG, V33, P317, DOI 10.1016/S0022-3468(98)90454-7; Shane SA, 1997, PEDIATR EMERG CARE, V13, P198, DOI 10.1097/00006565-199706000-00006; Simon B, 2001, J TRAUMA, V51, P231, DOI 10.1097/00005373-200108000-00004; Spencer MT, 2003, AM J EMERG MED, V21, P111, DOI 10.1053/ajem.2003.50031; Thompson Matthew D, 2003, Semin Pediatr Neurol, V10, P130, DOI 10.1016/S1071-9091(03)00021-4; Wang MY, 2001, J PEDIATR SURG, V36, P1528, DOI 10.1053/jpsu.2001.27037; Wang MY, 2000, NEUROSURGERY, V46, P1093, DOI 10.1097/00006123-200005000-00014; WOESTMAN R, 1999, INT J TRAUMA NURS, V5, P49; World Health Organization, 1992, ICD 10 INT STAT CLAS; Young KD, 2004, ANN EMERG MED, V43, P435, DOI 10.1016/j.annemergmed.2003.09.016	78	32	33	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0031-3955	1557-8240		PEDIATR CLIN N AM	Pediatr. Clin. N. Am.	FEB	2006	53	1					1	+		10.1016/j.pcl.2005.09.004			27	Pediatrics	Pediatrics	022SY	WOS:000236077300002	16487782				2021-06-18	
B	White, HS; Smith-Yockman, M; Srivastava, A; Wilcox, KS		Pitkanen, A; Schwartzkroin, PA; Moshe, SL		White, H. Steve; Smith-Yockman, Misty; Srivastava, Ajay; Wilcox, Karen S.			Therapeutic Assays for the Identification and Characterization of Antiepileptic and Antiepileptogenic Drugs	MODELS OF SEIZURES AND EPILEPSY			English	Article; Book Chapter							TEMPORAL-LOBE EPILEPSY; SPONTANEOUS RECURRENT SEIZURES; SPONTANEOUS MOTOR SEIZURES; KAINATE-INDUCED EPILEPSY; TRAUMATIC BRAIN-INJURY; IMMATURE RAT MODEL; STATUS EPILEPTICUS; ANIMAL-MODELS; ANTICONVULSANT EFFICACY; HIPPOCAMPAL DAMAGE		[White, H. Steve; Smith-Yockman, Misty; Srivastava, Ajay; Wilcox, Karen S.] Univ Utah, Dept Pharmacol & Toxicol, Anticonvulsant Drug Dev Program, Salt Lake City, UT 84112 USA	White, HS (corresponding author), Univ Utah, Dept Pharmacol & Toxicol, Anticonvulsant Drug Dev Program, 112 Skaggs Hall, Salt Lake City, UT 84112 USA.						Andre V, 2001, EPILEPSY RES, V47, P99, DOI 10.1016/S0920-1211(01)00299-6; Andre V, 2000, NEUROSCIENCE, V99, P469, DOI 10.1016/S0306-4522(00)00209-8; Armand V, 2000, EPILEPSIA, V41, P28, DOI 10.1111/j.1528-1157.2000.tb01501.x; Barton ME, 2003, EPILEPSY RES, V56, P17, DOI 10.1016/j.eplepsyres.2003.08.001; Barton ME, 2001, EPILEPSY RES, V47, P217, DOI 10.1016/S0920-1211(01)00302-3; Brandt C, 2004, EPILEPSIA, V45, P1488, DOI 10.1111/j.0013-9580.2004.16904.x; BROWN WC, 1953, J PHARMACOL EXP THER, V107, P273; Dalby NO, 2001, CURR OPIN NEUROL, V14, P187, DOI 10.1097/00019052-200104000-00009; Dube C, 2000, ANN NEUROL, V47, P336, DOI 10.1002/1531-8249(200003)47:3<336::AID-ANA9>3.0.CO;2-W; ECHLIN FA, 1963, ARCH NEUROL-CHICAGO, V9, P154, DOI 10.1001/archneur.1963.00460080064009; Engstrom ER, 2001, EPILEPSY RES, V43, P135, DOI 10.1016/S0920-1211(00)00191-1; Everett GM, 1944, J PHARMACOL EXP THER, V81, P402; Glien M, 2002, EPILEPSIA, V43, P350, DOI 10.1046/j.1528-1157.2002.18101.x; Golarai G, 2001, J NEUROSCI, V21, P8523; GOWER AJ, 1992, EUR J PHARMACOL, V222, P193, DOI 10.1016/0014-2999(92)90855-X; Gower AJ, 1995, EPILEPSY RES, V22, P207, DOI 10.1016/0920-1211(95)00077-1; Grabenstatter HL, 2004, EPILEPSIA, V45, P197; Grabenstatter HL, 2005, EPILEPSIA, V46, P8, DOI 10.1111/j.0013-9580.2005.13404.x; Hosford DA, 1997, EPILEPSIA, V38, P408, DOI 10.1111/j.1528-1157.1997.tb01729.x; HOSFORD DA, 1992, SCIENCE, V257, P398, DOI 10.1126/science.1321503; Jacobs MP, 2001, NEUROLOGY, V57, P1536, DOI 10.1212/WNL.57.9.1536; JENSEN FE, 1995, EPILEPSIA, V36, P966, DOI 10.1111/j.1528-1157.1995.tb00954.x; Kharatishvili I, 2004, EPILEPSIA, V45, P45; Klitgaard H, 1998, EUR J PHARMACOL, V353, P191, DOI 10.1016/S0014-2999(98)00410-5; Kupferberg H, 2001, EPILEPSIA, V42, P7, DOI 10.1046/j.1528-1157.2001.0420s4007.x; Lado FA, 2001, EPILEPSIA, V42, P458, DOI 10.1046/j.1528-1157.2001.30900.x; Lado FA, 2000, MENT RETARD DEV D R, V6, P242, DOI 10.1002/1098-2779(2000)6:4<242::AID-MRDD3>3.3.CO;2-N; Laurer HL, 1999, CURR OPIN NEUROL, V12, P715, DOI 10.1097/00019052-199912000-00010; LEITE JP, 1995, EPILEPSY RES, V20, P93, DOI 10.1016/0920-1211(94)00070-D; LENNOX WG, 1945, JAMA-J AM MED ASSOC, V129, P1069, DOI 10.1001/jama.1945.02860500001001; Liptakova S, 2000, EPILEPSIA, V41, P788, DOI 10.1111/j.1528-1157.2000.tb00244.x; Loscher W, 1998, J PHARMACOL EXP THER, V284, P474; Loscher W, 2000, EPILEPSY RES, V40, P63, DOI 10.1016/S0920-1211(00)00108-X; Loscher W, 1997, PROG NEUROBIOL, V53, P239, DOI 10.1016/S0301-0082(97)00035-X; LOSCHER W, 1993, EUR J PHARMACOL, V232, P147, DOI 10.1016/0014-2999(93)90768-D; Loscher W, 2002, EPILEPSY RES, V50, P105, DOI 10.1016/S0920-1211(02)00073-6; Loscher W, 2002, TRENDS PHARMACOL SCI, V23, P113, DOI 10.1016/S0165-6147(00)01974-X; LOSCHER W, 1991, TRENDS PHARMACOL SCI, V12, P52, DOI 10.1016/0165-6147(91)90496-F; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MARESCAUX C, 1995, ITAL J NEUROL SCI, V16, P113, DOI 10.1007/BF02229083; MCNAMARA JO, 1995, PSYCHIAT CLIN NEUROS, V49, pS175, DOI 10.1111/j.1440-1819.1995.tb02167.x; Nissinen J, 2000, EPILEPSY RES, V38, P177, DOI 10.1016/S0920-1211(99)00088-1; Pitkanen A, 2004, IDRUGS, V7, P471; Pitkanen A, 2002, LANCET NEUROL, V1, P173, DOI 10.1016/S1474-4422(02)00073-X; Putnam TJ, 1937, SCIENCE, V85, P525, DOI 10.1126/science.85.2213.525; ROGAWSKI MA, 1990, PHARMACOL REV, V42, P223; Sankar R, 2000, ANN NEUROL, V48, P580, DOI 10.1002/1531-8249(200010)48:4<580::AID-ANA4>3.3.CO;2-2; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; SHARPLESS SK, 1962, ELECTROEN CLIN NEURO, V14, P244, DOI 10.1016/0013-4694(62)90034-2; Sloviter R S, 1991, Hippocampus, V1, P41, DOI 10.1002/hipo.450010106; SNEAD OC, 1992, J NEURAL TRANSM-GEN, P7; Stables James P., 2003, Epilepsia, V44, P1472, DOI 10.1111/j.0013-9580.2003.32803.x; SUZDAK PD, 1995, EPILEPSIA, V36, P612, DOI 10.1111/j.1528-1157.1995.tb02576.x; Temkin NR, 2001, EPILEPSIA, V42, P515, DOI 10.1046/j.1528-1157.2001.28900.x; Toth Z, 1998, J NEUROSCI, V18, P4285; VELISEK L, 1995, EPILEPSIA, V36, P179, DOI 10.1111/j.1528-1157.1995.tb00978.x; VELISEK L, 1995, ITAL J NEUROL SCI, V16, P127, DOI 10.1007/BF02229085; Walker MC, 2002, BRAIN, V125, P1937, DOI 10.1093/brain/awf203; White H S, 1998, Adv Neurol, V76, P29; White H.S., 2004, TREATMENT EPILEPSY, P89; White H. Steve, 1995, P99; White S.H., 2002, ANTIEPILEPTIC DRUGS, V5th, P36; WILLMORE LJ, 1978, SCIENCE, V200, P1501, DOI 10.1126/science.96527	63	32	32	0	1	ELSEVIER ACADEMIC PRESS INC	SAN DIEGO	525 B STREET, SUITE 1900, SAN DIEGO, CA 92101-4495 USA			978-0-08-045702-4; 978-0-12-088554-1				2006							539	549		10.1016/B978-012088554-1/50046-3			11	Neurosciences	Neurosciences & Neurology	BCT46	WOS:000311355400046					2021-06-18	
J	Zhang, ZR; Artelt, M; Bernet, M; Trautmann, K; Schluesener, HJ				Zhang, ZR; Artelt, M; Bernet, M; Trautmann, K; Schluesener, HJ			Lesional accumulation of P2X(4) receptor(+) monocytes following experimental traumatic brain injury	EXPERIMENTAL NEUROLOGY			English	Article						P2X(4) receptor; traumatic brain injury; microglia/macrophages	SPINAL MICROGLIA; UP-REGULATION; CELL-DEATH; ATP; ACTIVATION; MACROPHAGES; MECHANISMS; EXPRESSION; STRIATUM; RELEASE	P2X(4) receptor (P2X(4)R) is an ATP-gated ion channel. ATP is an important messenger in traumatic brain injury. Here, we report expression of P2X(4)R in rat traumatic brain injury with focus on the early phase, most amenable to therapy. Accumulation of P2X(4)R(+) cells was observed as early as 6 h after injury and continued to increase 4 days post-injury at the lesion and remote areas. Double staining revealed that most P2X(4)R(+) cells coexpressed ED-1, a marker for reactive microglia/macrophages, but not nestin or W3/13. Our data suggest that P2X(4)R expression defines a Subtype of activated microglia/macrophages involved in the early processes following traumatic brain injury. (c) 2005 Elsevier Inc. All rights reserved.	Univ Tubingen, Inst Brain Res, D-72076 Tubingen, Germany; Synovo GmbH, D-72076 Tubingen, Germany	Zhang, ZR (corresponding author), Univ Tubingen, Inst Brain Res, Calwer Str 3, D-72076 Tubingen, Germany.	zhangzhiren@yahoo.com	Zhang, Zhiren/O-1012-2019; zhang, zhiren/I-1046-2014	Zhang, Zhiren/0000-0002-5238-2835; zhang, zhiren/0000-0002-5238-2835			BO XN, 1995, FEBS LETT, V375, P129, DOI 10.1016/0014-5793(95)01203-Q; Braun N, 1998, J NEUROSCI, V18, P4891; Brough D, 2002, MOL CELL NEUROSCI, V19, P272, DOI 10.1006/mcne.2001.1054; Burnstock G, 2004, CURR TOP MED CHEM, V4, P793, DOI 10.2174/1568026043451014; Burnstock G, 2003, CURR TOP MEMBR, V54, P307, DOI 10.1016/S1063-5823(03)01010-X; BURNSTOCK G, 2004, INT REV CYTOL, V240, P304; Cavaliere F, 2003, NEUROSCIENCE, V120, P85, DOI 10.1016/S0306-4522(03)00228-8; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577; EDWARDS FA, 1993, FEBS LETT, V325, P86, DOI 10.1016/0014-5793(93)81419-Z; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Ferrari D, 1997, J EXP MED, V185, P579, DOI 10.1084/jem.185.3.579; Gendron FP, 2003, J NEUROCHEM, V87, P344, DOI 10.1046/j.1471-4159.2003.01995.x; Golarai G, 2001, J NEUROSCI, V21, P8523; GREGERSEN R, 2002, J CEREB BLOOD FLOW M, V20, P53; Guo LH, 2005, NEUROSCIENCE, V134, P199, DOI 10.1016/j.neuroscience.2005.04.026; Guo LH, 2005, J NEUROIMMUNOL, V163, P120, DOI 10.1016/j.jneuroim.2005.03.007; Guo LH, 2004, J NEUROIMMUNOL, V152, P67, DOI 10.1016/j.jneuroim.2004.04.005; Kennedy C, 2000, J AUTONOM NERV SYST, V81, P158, DOI 10.1016/S0165-1838(00)00133-8; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Ladeby R, 2005, BRAIN RES REV, V48, P196, DOI 10.1016/j.brainresrev.2004.12.009; Ladeby R, 2005, GLIA, V50, P121, DOI 10.1002/glia.20159; Lehrmann E, 1997, J COMP NEUROL, V386, P461; McIntosh TK, 1996, LAB INVEST, V74, P315; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Nieber K, 1999, PROG BRAIN RES, V120, P287; Norenberg W, 1999, PROG BRAIN RES, V120, P209; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; Robson SC, 1997, J EXP MED, V185, P153, DOI 10.1084/jem.185.1.153; Rothermel Annette L., 2004, BMC Immunology, V5, P1; Ryu JK, 2002, NEUROREPORT, V13, P1611, DOI 10.1097/00001756-200209160-00008; Schwab JM, 2005, J NEUROIMMUNOL, V163, P185, DOI 10.1016/j.jneuroim.2005.02.016; Soto F, 1996, P NATL ACAD SCI USA, V93, P3684, DOI 10.1073/pnas.93.8.3684; Tsuda M, 2003, NATURE, V424, P778, DOI 10.1038/nature01786; Tsuda M, 2005, TRENDS NEUROSCI, V28, P101, DOI 10.1016/j.tins.2004.12.002; WIERASZKO A, 1989, BRAIN RES, V485, P244, DOI 10.1016/0006-8993(89)90567-2; Yamamoto K, 2000, AM J PHYSIOL-HEART C, V279, pH285; Zimmermann H, 1996, PROG NEUROBIOL, V49, P589, DOI 10.1016/0301-0082(96)00026-3	38	32	34	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JAN	2006	197	1					252	257		10.1016/j.expneurol.2005.09.015			6	Neurosciences	Neurosciences & Neurology	001LI	WOS:000234534200026	16259982				2021-06-18	
J	Zhang, C; Saatman, KE; Royo, NC; Soltesz, KM; Millard, M; Schouten, JW; Motta, M; Hoover, RC; McMillan, A; Watson, DJ; Lee, VMY; Trojanowski, JQ; McIntosh, TK				Zhang, C; Saatman, KE; Royo, NC; Soltesz, KM; Millard, M; Schouten, JW; Motta, M; Hoover, RC; McMillan, A; Watson, DJ; Lee, VMY; Trojanowski, JQ; McIntosh, TK			Delayed transplantation of human neurons following brain injury in rats: A long-term graft survival and behavior study	JOURNAL OF NEUROTRAUMA			English	Article						fluid percussion; head injury; neuronal grafts; NT2N	NERVE GROWTH-FACTOR; PROMOTES FUNCTIONAL RECOVERY; POSTMITOTIC HUMAN NEURONS; NEURAL STEM-CELLS; HNT NEURONS; HEAD-INJURY; COGNITIVE DEFICITS; CHOLINERGIC NEURONS; FACTOR INFUSION; ISCHEMIC RATS	The NTera2 (NT2) cell line is a homogeneous population of cells, which, when treated in vitro with retinoic acid, terminally differentiate into postmitotic neuronal NT2N cells. Although NT2N neurons transplanted in the acute (24 h postinjury) period survive for up to 1 month following experimental traumatic brain injury (TBI), nothing is known of their ability to survive for longer periods or of their effects when engrafted during the chronic postinjury period. Adult male Sprague-Dawley rats (n = 348; 360-400 g) were initially anesthetized, and subjected to severe lateral fluid-percussion (FP) brain injury or sham injury. At 1 month postinjury, only brain-injured animals showing severe neurobehavioral deficits received cryopreserved NT2N neurons stereotaxically transplanted into three sites in the peri-injured cortex (n = 18). Separate groups of similarly brain-injured rats received human fibroblast cells (n = 13) or cell suspension vehicle (n = 14). Sham-injured animals (no brain injury) served as controls and received NT2N transplants (n = 24). All animals received daily immunosuppression for three months. Behavioral testing was performed at 1, 4, 8, and 12 weeks post-transplantation, after which animals were sacrificed for histological analysis. Nissl staining and anti-human neuronal specific enolase (NSE) immunostaining revealed that NT2N neurons transplanted in the chronic post-injury period survived up to 12 weeks post-transplantation, extended processes into the host cortex and immunolabeled positively for synaptophysin. There were no statistical differences in cognitive or motor function among the transplanted brain-injured groups. Long-term graft survival suggests that NT2N neurons may be a viable source of neural cells for transplantation after TBI and also that these grafts can survive for a prolonged time and extend processes into the host cortex when transplanted in the chronic post-injury period following TBI.	Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA; Univ Penn, Dept Pathol & Lab Med, Traumat Brain Injury Lab, Philadelphia, PA 19104 USA; Vet Adm Med Ctr, Philadelphia, PA 19104 USA; Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA; IRCCS, Osped Maggiore Policlin, Dept Anesthesia & Crit Care Med, Milan, Italy	Zhang, C (corresponding author), Univ Penn, Dept Neurosurg, Traumat Brain Injury Lab, 105 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.	chzhang@mail.med.upenn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS040978] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01 GM 34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50 NS 08803, R01 NS 40978] Funding Source: Medline		Adelson PD, 2000, J NEUROTRAUM, V17, P273, DOI 10.1089/neu.2000.17.273; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Alessandri B, 2002, J NEUROTRAUM, V19, P829, DOI 10.1089/08977150260190429; Baker KA, 2000, EXP NEUROL, V162, P350, DOI 10.1006/exnr.1999.7337; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Borlongan CV, 1998, EXP NEUROL, V149, P310, DOI 10.1006/exnr.1997.6730; Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Buki A, 1999, J NEUROTRAUM, V16, P511, DOI 10.1089/neu.1999.16.511; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Emerich DF, 1996, BRAIN RES, V736, P99, DOI 10.1016/S0006-8993(96)00683-X; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Garbuzova-Davis S, 2002, EXP NEUROL, V174, P169, DOI 10.1006/exnr.2002.7860; HAGG T, 1990, J NEUROSCI, V10, P3087; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; Hartley RS, 1999, J COMP NEUROL, V415, P404, DOI 10.1002/(SICI)1096-9861(19991220)415:3<404::AID-CNE6>3.0.CO;2-R; HEFTI F, 1986, J NEUROSCI, V6, P2155; HERNANDEZ TD, 1988, EXP NEUROL, V102, P318, DOI 10.1016/0014-4886(88)90226-9; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hurlbert MS, 1999, CELL TRANSPLANT, V8, P143, DOI 10.1177/096368979900800106; Jeong SW, 2003, STROKE, V34, P2258, DOI 10.1161/01.STR.0000083698.20199.1F; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KLEPPNER SR, 1995, J COMP NEUROL, V357, P618, DOI 10.1002/cne.903570410; Kondziolka D, 2000, NEUROLOGY, V55, P565, DOI 10.1212/WNL.55.4.565; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Levin HS, 1998, CURR OPIN NEUROL, V11, P643, DOI 10.1097/00019052-199812000-00006; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; Longhi L, 2004, J NEUROTRAUM, V21, P1723, DOI 10.1089/0897715042664876; Lu DY, 2002, CELL TRANSPLANT, V11, P275; MartinezSerrano A, 1996, J NEUROSCI, V16, P4604; MARTINEZSERRANO A, 1995, J NEUROSCI, V15, P5668; Mattiasson GJ, 2000, J NEUROSCI METH, V95, P75, DOI 10.1016/S0165-0270(99)00162-4; McDermott KL, 1997, J NEUROTRAUM, V14, P191, DOI 10.1089/neu.1997.14.191; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meltzer CC, 2001, NEUROSURGERY, V49, P586, DOI 10.1097/00006123-200109000-00011; MIYAZONO M, 1996, J COMP NEUROL, V376, P1; Muir JK, 1999, J NEUROTRAUM, V16, P403, DOI 10.1089/neu.1999.16.403; Nelson PT, 2002, AM J PATHOL, V160, P1201, DOI 10.1016/S0002-9440(10)62546-1; NIIJIMA K, 1995, J NEUROSCI, V15, P1180; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; PAXINOS G, 1994, RAT BRAIN STEREOTAXI; Philips MF, 1999, J NEUROSURG, V90, P116, DOI 10.3171/jns.1999.90.1.0116; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; Riess P, 2001, RESTOR NEUROL NEUROS, V18, P1; Rossi F, 2002, NAT REV NEUROSCI, V3, P401, DOI 10.1038/nrn809; Saporta S, 1999, NEUROSCIENCE, V91, P519, DOI 10.1016/S0306-4522(98)00610-1; Savitz SI, 2002, ANN NEUROL, V52, P266, DOI 10.1002/ana.60000; SCHALLERT T, 1982, PHARMACOL BIOCHEM BE, V16, P455, DOI 10.1016/0091-3057(82)90452-X; Sinson G, 1996, J NEUROSURG, V84, P655, DOI 10.3171/jns.1996.84.4.0655; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES H, 1991, Journal of Neural Transplantation and Plasticity, V2, P207; Soares HD, 1995, J NEUROSCI, V15, P8223; Sullivan PG, 2000, EXP NEUROL, V161, P631, DOI 10.1006/exnr.1999.7282; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; TROJANOWSKI JQ, 1993, EXP NEUROL, V122, P283, DOI 10.1006/exnr.1993.1128; Trojanowski JQ, 1997, EXP NEUROL, V144, P92, DOI 10.1006/exnr.1996.6393; TUSZYNSKI MH, 1994, EXP NEUROL, V126, P1, DOI 10.1006/exnr.1994.1037; Watson DJ, 2003, J NEUROPATH EXP NEUR, V62, P368, DOI 10.1093/jnen/62.4.368; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	70	32	33	0	4	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2005	22	12					1456	1474		10.1089/neu.2005.22.1456			19	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	000EA	WOS:000234442500008	16379583				2021-06-18	
J	Hayashi, Y; Shumsky, JS; Connors, T; Otsuka, T; Fischer, I; Tessler, A; Murray, M				Hayashi, Y; Shumsky, JS; Connors, T; Otsuka, T; Fischer, I; Tessler, A; Murray, M			Immunosuppression with either cyclosporine A or FK506 supports survival of transplanted fibroblasts and promotes growth of host axons into the transplant after spinal cord injury	JOURNAL OF NEUROTRAUMA			English	Article						allograft survival; axonal growth; cyclosporine A; FK506; immunophilin ligands; spinal cord injury; transplantation	TRAUMATIC BRAIN-INJURY; BDNF-PRODUCING FIBROBLASTS; IMMUNOPHILIN LIGAND FK506; RAT SCIATIC-NERVE; ADULT RATS; FUNCTIONAL RECOVERY; LIPID-PEROXIDATION; IMMUNE SUPPRESSION; SCHWANN-CELLS; IN-VIVO	Fibroblasts that have been genetically modified to secrete neurotrophins can stimulate axonal regeneration, rescue injured neurons, and improve function when grafted into a spinal cord injury site. These grafts are usually allografts that require immunosuppression to prevent rejection. In this study, we compared the effects of two immunophilin-ligands (cyclosporine A [CsA] and FK506) that are used clinically to prevent transplant rejection on protection of grafted fibroblasts. As there are risks associated with prolonged immunosuppression, we compared the effects of 2 or 8 weeks of administration of these drugs, in combination with our standard methylprednisolone protocol, in animals that survived for 8 weeks, to determine whether a shorter course of immunosuppression would be effective. Outcome measures included fibroblast survival, infiltration of activated macrophages and microglia into the graft, final lesion size, and growth of host axons into the graft. The graft consisted of a Vitrogen matrix into which fibroblasts were suspended; the graft was placed into a C3/C4 lateral funiculus lesion. The fibroblasts were isolated from a transgenic strain of Fischer rats that produce the marker alkaline phosphatase (Fb/AP). This enabled us to track the grafted fibroblasts and to evaluate the extent of their survival. The grafted matrix filled the lesion cavity. The density of fibroblasts within the matrix differed according to treatment. Fibroblast survival was most robust in animals that received 8 weeks of immunophilin-ligand treatment. FK506 supported greater Fb/AP survival than CsA. ED-1 immunostaining for activated microglia and macrophages showed an inverse correlation between AP immunoreactivity and the density of immune cells within the graft. Thus, prolonged administration of either FK506 or CsA was necessary for maximal fibroblast survival and for limiting the macrophage invasion of the graft. None of the FK506 or CsA protocols modified the size of the lesion, indicating that these immunophilin-ligands had little effect on secondary enlargement of the lesion and therefore little neuroprotective effect. Because immunophilin-ligands have been shown to be neurotrophic, we used RT-97 immunostaining for neurofilaments and calcitonin gene related protein (CGRP) staining for dorsal root axons to visualize axons that grew into the graft. Some axons grew into the matrix even in the absence of immunophilin-ligand treatment, suggesting that the Vitrogen matrix itself is permissive, but all of the immunophilin-ligand protocols were much more effective in eliciting axonal growth. Growth of axons into the transplants was equally increased by drug treatment for 2 or 8 weeks. Thus, both treatments improved fibroblast survival, diminished immune cell invasion, and promoted axonal growth, and a 2-week course of treatment with either immunophilin-ligand was as effective as 8 weeks in stimulating axonal growth.	Drexel Univ, Coll Med, Dept Neurobiol & Anat, Philadelphia, PA 19129 USA; Nagoya City Univ, Sch Med, Dept Orthoped Surg, Nagoya, Aichi 467, Japan; Dept Vet Affairs Med Ctr, Philadelphia, PA 19104 USA	Murray, M (corresponding author), Drexel Univ, Coll Med, Dept Neurobiol & Anat, 299 Queen Lane, Philadelphia, PA 19129 USA.	mm72@drexel.edu	Fischer, Itzhak/D-1080-2012	Fischer, Itzhak/0000-0003-3187-8740	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS24707] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS024707, P50NS024707] Funding Source: NIH RePORTER		ANDERSON DK, 1988, J NEUROSURG, V69, P562, DOI 10.3171/jns.1988.69.4.0562; BARTHOLDI D, 1995, BRAIN RES, V672, P177, DOI 10.1016/0006-8993(94)01410-J; Bavetta S, 1999, EXP NEUROL, V158, P382, DOI 10.1006/exnr.1999.7119; Borlongan CV, 2005, LIFE SCI, V76, P1503, DOI 10.1016/j.lfs.2004.09.022; Chow SY, 2000, BRAIN RES, V874, P87, DOI 10.1016/S0006-8993(00)02443-4; Diaz-Ruiz A, 2000, NEUROREPORT, V11, P1765, DOI 10.1097/00001756-200006050-00033; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; FINBERG R, 2004, INFECT TRANSPLANT RE; Gold BG, 2000, EXPERT OPIN INV DRUG, V9, P2331, DOI 10.1517/13543784.9.10.2331; Gold BG, 1997, EXP NEUROL, V147, P269, DOI 10.1006/exnr.1997.6630; Hadley MN, 2002, NEUROSURGERY, V50, pS63; Han SSW, 2002, EXP NEUROL, V177, P360, DOI 10.1006/exnr.2002.7995; Ibarra A, 2003, BRAIN RES, V979, P165, DOI 10.1016/S0006-8993(03)02898-1; Ibarra A, 1996, J NEUROTRAUM, V13, P569, DOI 10.1089/neu.1996.13.569; Jost SC, 2000, RESTOR NEUROL NEUROS, V17, P39; Katsube K, 1998, TRANSPLANTATION, V66, P772, DOI 10.1097/00007890-199809270-00012; Kaymaz M, 2005, SPINAL CORD, V43, P22, DOI 10.1038/sj.sc.3101621; Kim D, 2001, NEUROREHAB NEURAL RE, V15, P141, DOI 10.1177/154596830101500207; Kisseberth WC, 1999, DEV BIOL, V214, P128, DOI 10.1006/dbio.1999.9417; Lee M, 2000, MUSCLE NERVE, V23, P633, DOI 10.1002/(SICI)1097-4598(200004)23:4<633::AID-MUS24>3.0.CO;2-Q; Liu Y, 1999, J NEUROSCI, V19, P4370; Liu Y, 2002, EXP NEUROL, V178, P150, DOI 10.1006/exnr.2002.7977; Mabon PJ, 1999, J NEUROVIROL, V5, P268, DOI 10.3109/13550289909015813; Madsen JR, 1998, EXP NEUROL, V154, P673, DOI 10.1006/exnr.1998.6974; MCCARTHY PW, 1990, NEUROSCIENCE, V34, P623, DOI 10.1016/0306-4522(90)90169-5; OCHIAI T, 1989, TRANSPLANT P, V21, P829; Pan YA, 2003, J NEUROSCI, V23, P11479; Pearse DD, 2004, J NEUROTRAUM, V21, P1223, DOI 10.1089/0897715041953876; Rabchevsky AG, 2001, J NEUROTRAUM, V18, P513, DOI 10.1089/089771501300227314; Rosenstiel P, 2003, J NEUROTRAUM, V20, P297, DOI 10.1089/089771503321532888; Scheff SW, 1999, J NEUROTRAUM, V16, P783, DOI 10.1089/neu.1999.16.783; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; Schwab ME, 1996, PHYSIOL REV, V76, P319; SEWELL TJ, 1994, J BIOL CHEM, V269, P21094; Singleton RH, 2001, J NEUROTRAUM, V18, P607, DOI 10.1089/089771501750291846; Springer JE, 2000, J NEUROSCI, V20, P7246; Steiner JP, 1997, P NATL ACAD SCI USA, V94, P2019, DOI 10.1073/pnas.94.5.2019; Steiner JP, 1997, NAT MED, V3, P421, DOI 10.1038/nm0497-421; Sugawara T, 1999, NEUROREPORT, V10, P3949, DOI 10.1097/00001756-199912160-00041; Sullivan PG, 2004, J COMP NEUROL, V474, P524, DOI 10.1002/cne.20130; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Takami T, 2002, J NEUROTRAUM, V19, P653, DOI 10.1089/089771502753754118; Tanaka KI, 2003, BRAIN RES, V970, P250, DOI 10.1016/S0006-8993(03)02434-X; TATOR CH, 1995, BRAIN PATHOL, V5, P407, DOI 10.1111/j.1750-3639.1995.tb00619.x; Teichner A, 1993, J Hirnforsch, V34, P343; Tobias CA, 2001, J NEUROTRAUM, V18, P287, DOI 10.1089/08977150151070937; Tobias CA, 2005, J NEUROTRAUM, V22, P138, DOI 10.1089/neu.2005.22.138; Tobias CA, 2003, EXP NEUROL, V184, P97, DOI 10.1016/S0014-4886(03)00394-7; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Udina E, 2004, GLIA, V47, P120, DOI 10.1002/glia.20025; Udina E, 2004, MUSCLE NERVE, V29, P812, DOI 10.1002/mus.20029; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang M S, 1999, J Spinal Cord Med, V22, P287; Wang MS, 1997, J PHARMACOL EXP THER, V282, P1084; Winter C, 2000, NEUROSCIENCE, V95, P753	55	32	38	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2005	22	11					1267	1281		10.1089/neu.2005.22.1267			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	989OI	WOS:000233683000001	16305315				2021-06-18	
J	Horneman, G; Folkesson, P; Sintonen, H; von Wendt, L; Emanuelson, I				Horneman, G; Folkesson, P; Sintonen, H; von Wendt, L; Emanuelson, I			Health-related quality of life of adolescents and young adults 10 years after serious traumatic brain injury	INTERNATIONAL JOURNAL OF REHABILITATION RESEARCH			English	Article						health-related quality of life; traumatic brain injury; children	CHILDREN; PREVALENCE; RECOVERY; TERM	The aim of this study was to investigate health-related quality of life (HRQoL) in a population-based group of young adults with serious traumatic brain injury (TBI) acquired 10 years earlier. In the time period 1987-1991, all 165 residents (< 18 years of age) in the south-western health care region of Sweden who had suffered a serious TBI were followed up. Of these, 109 (67%) participated in this follow-up study, which was conducted using the 15-dimension (15D) HRQoL instrument. Their H RQoL was compared with that of 1039 individuals drawn randomly from the National Population Register for the Finnish Health Care Survey 1995/1996 and matched for age and sex. Nine (mobility, vision, hearing, eating, speech, mental status, depression, distress and usual activities) of the 15 dimensions were significantly aberrant in the TBI group. This TBI group differed markedly from children with organ transplantation, as the transplantation children did not differ from a control group in terms of HRQoL. Compared with other groups of children with congenital or longlasting conditions, the TBI group had more medical and mental problems.	Gothenburg Univ, Dept Psychol, S-41124 Gothenburg, Sweden; Local Habilitat Ctr, Vanersborg, Sweden; Univ Helsinki, Dept Child Neurol, FIN-00014 Helsinki, Finland; Karolinska Inst, Dept Woman & Child Hlth, S-10401 Stockholm, Sweden; Gothenburg Univ, Dept Hlth Women & Children, S-41124 Gothenburg, Sweden	Horneman, G (corresponding author), Skeppspromenaden 5, SE-41763 Gothenburg, Sweden.	g.horneman@telia.com	Emanuelson, Ulf/AAC-7809-2020	Emanuelson, Ulf/0000-0001-7889-417X			Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; ANDRICH R, 1996, COST OUTCOME ANAL AS; Apajasalo M, 1998, EUR J PEDIATR, V157, P114, DOI 10.1007/s004310050781; Apajasalo M, 1997, Pediatr Transplant, V1, P130; ARINEN S, 1998, HLTH USE HLTH SERVIC; ARNARSON EO, 1995, ACTA PAEDIATR, V84, P96, DOI 10.1111/j.1651-2227.1995.tb13496.x; Bjork S, 1999, HEALTH ECON, V8, P117; Emanuelson I, 1998, Pediatr Rehabil, V2, P65; Emanuelson I, 1997, ACTA PAEDIATR, V86, P730, DOI 10.1111/j.1651-2227.1997.tb08576.x; Hawley CA, 2003, BRAIN INJURY, V17, P105, DOI 10.1080/0269905021000010131; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; Kuhtz-Buschbeck JP, 2003, DEV MED CHILD NEUROL, V45, P821, DOI 10.1017/S001216220300152X; Lubinski R, 1997, BRAIN INJURY, V11, P103, DOI 10.1080/026990597123692; Morgan A, 2004, BRAIN INJURY, V18, P359, DOI 10.1080/02699050310001617424; Ohinmaa A, 1996, EUROQOL PLEN M BARC, P67; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; PERSSON J, 1995, PROTOTYPE TOOL ASSIS; Poggi G, 2000, BRAIN INJURY, V14, P833, DOI 10.1080/026990500421930; Salo J, 2002, J NEUROL NEUROSUR PS, V72, P373, DOI 10.1136/jnnp.72.3.373; Sintonen H, 2001, ANN MED, V33, P328, DOI 10.3109/07853890109002086; Sintonen H., 1994, 41 NAT CTR HLTH PROG; Sintonen H, 1995, 42 NAT CTR HLTH PROG; Sintonen H, 1994, PHARMACOECONOMICS S3, V5, P17, DOI DOI 10.2165/00019053-199400053-00005; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Sturms LM, 2003, ARCH PHYS MED REHAB, V84, P431, DOI 10.1053/apmr.2003.50015; Tate R, 1997, J HEAD TRAUMA REHAB, V12, P16, DOI 10.1097/00001199-199712000-00003; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	28	32	32	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0342-5282	1473-5660		INT J REHABIL RES	Int. J. Rehabil. Res.	SEP	2005	28	3					245	249		10.1097/00004356-200509000-00007			5	Rehabilitation	Rehabilitation	959PT	WOS:000231530900007	16046918				2021-06-18	
J	Koponen, S; Taiminen, T; Honkalampi, K; Joukamaa, M; Vinamaki, H; Kurki, T; Portin, P; Himanen, L; Isoniemi, H; Hinkka, S; Tenovuo, O				Koponen, S; Taiminen, T; Honkalampi, K; Joukamaa, M; Vinamaki, H; Kurki, T; Portin, P; Himanen, L; Isoniemi, H; Hinkka, S; Tenovuo, O			Alexithymia after traumatic brain injury: Its relation to magnetic resonance imaging findings and psychiatric disorders	PSYCHOSOMATIC MEDICINE			English	Article						alexithymia; traumatic brain injury; magnetic resonance imaging; psychiatric disorders	MAJOR DEPRESSIVE DISORDER; GENERAL-POPULATION; PANIC DISORDER; PERSONALITY-DISORDERS; ANTERIOR CINGULATE; FACTORIAL VALIDITY; FAMILY-PRACTICE; HEAD-INJURY; SCALE; PREVALENCE	Objective: People with traumatic brain injury (TBI) were studied to assess the prevalence of alexithymia and its relationship to magnetic resonance imaging (MRI) findings and psychiatric disorders. Methods: Fifty-four participants, 67% men, were evaluated after a median of 30 years since TBI. A control group was matched for age, gender, and severity of depression. Alexithymia was measured with the 20-item Toronto Alexithymia Scale (TAS-20). In patients with TBI, axis I psychiatric disorders were assessed with the Schedules for Clinical Assessment in Neuropsychiatry (SCAN, version 2.1), and axis 11 disorders with the Structured Clinical Interview for DSM-III-R Personality Disorders (SCID-II). MRI examinations were carried out with a 1.5 T MRI scanner. Results: Alexithymia was significantly more common in patients with TBI than in controls (31.5% versus 14.8%; odds ratio 2.64, 95% confidence interval 1.03-6.80). None of the variables representing TBI, ie, severity of TBI or the presence, laterality, or location of contusions on MRI was associated with the TAS-20 total scores. Several current axis I and II psychiatric disorders, particularly organic personality syndrome, were connected to higher TAS-20 scores. Conclusion: Alexithymia is common, along with psychiatric disorders, in patients with TBI. Both of them may reflect dysfunction of the injured brain. In clinical practice, alexithymic features should be taken into consideration in psychosocial rehabilitation after TBI.	Turku Univ Hosp, Dept Psychiat, FI-20521 Turku, Finland; Turku Univ Hosp, Dept Radiol, FI-20521 Turku, Finland; Turku Univ Hosp, Dept Neurol, FI-20521 Turku, Finland; Univ Turku, Dept Biostat, SF-20500 Turku, Finland; Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Dept Psychiat, Tampere, Finland	Koponen, S (corresponding author), Turku Univ Hosp, Dept Psychiat, Pl 52, FI-20521 Turku, Finland.	salla.koponen@utu.fi		Himanen, Leena/0000-0001-7261-8027; Kurki, Timo/0000-0001-5532-3534			BACH M, 1994, COMPR PSYCHIAT, V35, P239, DOI 10.1016/0010-440X(94)90197-X; Bagby R.M., 1997, DISORDERS AFFECT REG, P46; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P33, DOI 10.1016/0022-3999(94)90006-X; BAGBY RM, 1994, J PSYCHOSOM RES, V38, P23, DOI 10.1016/0022-3999(94)90005-1; Bagby RM, 1997, DISORDERS AFFECT REG, P26, DOI DOI 10.1017/CBO9780511526831.005; Becerra R, 2002, BRAIN INJURY, V16, P633, DOI 10.1080/02699050110119817; BECK AT, 1972, POSTGRAD MED, V52, P81, DOI 10.1080/00325481.1972.11713319; Berthoz S, 2002, AM J PSYCHIAT, V159, P961, DOI 10.1176/appi.ajp.159.6.961; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; Fukunishi I, 1997, COMPR PSYCHIAT, V38, P166, DOI 10.1016/S0010-440X(97)90070-5; Gundel H, 2004, PSYCHOSOM MED, V66, P132, DOI 10.1097/01.PSY.0000097348.45087.96; Hintikka J, 2001, COMPR PSYCHIAT, V42, P234, DOI 10.1053/comp.2001.23147; Honkalampi K, 2000, J PSYCHOSOM RES, V48, P99, DOI 10.1016/S0022-3999(99)00083-5; Honkalampi K, 2001, PSYCHOSOMATICS, V42, P229, DOI 10.1176/appi.psy.42.3.229; Honkalampi K, 2001, J PERS DISORD, V15, P245, DOI 10.1521/pedi.15.3.245.19211; HOPPE KD, 1977, PSYCHOTHER PSYCHOSOM, V28, P148, DOI 10.1159/000287057; Joukamaa M, 1996, COMPR PSYCHIAT, V37, P144, DOI 10.1016/S0010-440X(96)90576-3; Joukamaa M, 2001, NORD J PSYCHIAT, V55, P123, DOI 10.1080/08039480151108561; Kano M, 2003, BRAIN, V126, P1474, DOI 10.1093/brain/awg131; Kokkonen P, 2001, COMPR PSYCHIAT, V42, P471, DOI 10.1053/comp.2001.27892; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Lane RD, 1998, COMPR PSYCHIAT, V39, P377, DOI 10.1016/S0010-440X(98)90051-7; Lane RD, 1997, BIOL PSYCHIAT, V42, P834, DOI 10.1016/S0006-3223(97)00050-4; Luminet O, 2001, PSYCHOTHER PSYCHOSOM, V70, P254, DOI 10.1159/000056263; Marchesi C, 2000, J PSYCHOSOM RES, V49, P43, DOI 10.1016/S0022-3999(00)00084-2; Marchesi C, 2005, PSYCHOTHER PSYCHOSOM, V74, P56, DOI 10.1159/000082028; PARKER J, 1997, DISORDERS AFFECT REG, P93; PARKER JDA, 1993, AM J PSYCHIAT, V150, P1105; Parker JDA, 2003, J PSYCHOSOM RES, V55, P269, DOI 10.1016/S0022-3999(02)00578-0; PASINI A, 1992, COMPR PSYCHIAT, V33, P42, DOI 10.1016/0010-440X(92)90078-5; Porcelli P, 1996, J PSYCHOSOM RES, V41, P569, DOI 10.1016/S0022-3999(96)00221-8; Saarijorvi S, 2001, J PSYCHOSOM RES, V51, P729, DOI 10.1016/S0022-3999(01)00257-4; Salminen JK, 1999, J PSYCHOSOM RES, V46, P75, DOI 10.1016/S0022-3999(98)00053-1; SALMINEN JK, 1994, J PSYCHOSOM RES, V38, P681, DOI 10.1016/0022-3999(94)90020-5; SIFNEOS PE, 1973, PSYCHOTHER PSYCHOSOM, V22, P255, DOI 10.1159/000286529; Spalletta G, 2001, PSYCHOSOM MED, V63, P944, DOI 10.1097/00006842-200111000-00013; Spitzer R.L., 1989, STRUCTURED CLIN INTE; Taylor GJ, 2003, J PSYCHOSOM RES, V55, P277, DOI 10.1016/S0022-3999(02)00601-3; Taylor GJ, 2000, CAN J PSYCHIAT, V45, P134, DOI 10.1177/070674370004500203; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Williams KR, 2001, BRAIN INJURY, V15, P349, DOI 10.1080/026990501750111319; WING JK, 1990, ARCH GEN PSYCHIAT, V47, P589; Yount R, 2002, J NEUROPSYCH CLIN N, V14, P416, DOI 10.1176/appi.neuropsych.14.4.416	44	32	33	1	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	0033-3174			PSYCHOSOM MED	Psychosom. Med.	SEP-OCT	2005	67	5					807	812		10.1097/01.psy.0000181278.92249.e5			6	Psychiatry; Psychology; Psychology, Multidisciplinary	Psychiatry; Psychology	970GT	WOS:000232294000020	16204442				2021-06-18	
J	Messori, A; Polonara, G; Carle, F; Gesuita, R; Salvolini, U				Messori, A; Polonara, G; Carle, F; Gesuita, R; Salvolini, U			Predicting posttraumatic epilepsy with MRI: Prospective longitudinal morphologic study in adults	EPILEPSIA			English	Article						posttraumatic epilepsy; brain MRI; hemosiderin; gliosis	TRAUMATIC BRAIN-INJURY; RISK-FACTORS; HEAD-INJURY; SEIZURES; FEATURES; MODEL	Purpose: Evaluation of morphologic risk factors for posttraumatic epilepsy (PTE) by using brain magnetic resonance imaging (MRI) in serial assessments <= 2 years after traumatic brain injury (TBI). Methods: Brain MRI hyperintense (gliosis) or hypointense (hemosiderin) areas or both were assessed in the images of 135 adult TBI inpatients who completed a 2-year clinical, EEG, and MRI study protocol. Overall clinical follow-up for the development of PTE was 5-10 years (median, 102 months). Morphologic risk factors for PTE were evaluated by using Kaplan-Meier curves and Cox regression analysis. Results: In 20 patients, PTE developed. Kaplan-Meier curves showed that gliomesenchymal sequelae of focal brain lesions (subdural hematomas/contusions) that required surgical treatment (sSDH-C) were a PTE risk factor (p < 0.001), as were sequelae of nonsurgical hemorrhagic contusions with gliosis wall incompletely surrounding hemosiderin dregs (IW) (p = 0.039) and mainly those with time-related changes from incomplete to complete gliosis wall around hemosiderin (I/CW) (p = 0.005); those with early hemosiderin completely surrounded by gliosis (CW) were not (p = 0.821). Cox regression analysis showed that for patients with sequelae of sSDH-C, the PTE risk was 4.38 (p = 0.023) times higher than for those who did not require surgical treatment or underwent surgery because of purely extradural hematoma; for those with IW and I/CW lesions, considered pooled, it was 6.61 times higher (p = 0.014) than for those with CW lesions. Conclusions: MRI follow-up examination in the early chronic stage can differentiate among low-, intermediate-, and high-risk sequelae of TBI. These findings yield new evidence for, but do not resolve, the debate on posttraumatic epileptogenesis.	Univ Hosp Umberto 1, Dept Neuroradiol, I-60020 Ancona, Italy; Univ Ancona, Dept Epidemiol & Biostat, Ancona, Italy	Salvolini, U (corresponding author), Univ Hosp Umberto 1, Dept Neuroradiol, Via Conca Torrette, I-60020 Ancona, Italy.	u.salvolini@univpm.it	Gesuita, Rosaria/AAU-8863-2020; Messori, Andrea/U-6903-2019	POLONARA, GABRIELE/0000-0002-2866-2749			Adams JH, 2001, J NEUROL NEUROSUR PS, V71, P521, DOI 10.1136/jnnp.71.4.521; Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; Annegers JF, 2000, SEIZURE-EUR J EPILEP, V9, P453, DOI 10.1053/seiz.2000.0458; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; Appleton RE, 2002, J NEUROL NEUROSUR PS, V72, P669, DOI 10.1136/jnnp.72.5.669; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; ATLAS SW, 1988, RADIOLOGY, V168, P803, DOI 10.1148/radiology.168.3.3406410; CAVENESS WF, 1979, J NEUROSURG, V50, P545, DOI 10.3171/jns.1979.50.5.0545; COX DR, 1972, J R STAT SOC B, V34, P187; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; DALESSANDRO R, 1983, ARCH NEUROL-CHICAGO, V40, P831, DOI 10.1001/archneur.1983.04050120081022; DALESSANDRO R, 1982, J NEUROL NEUROSUR PS, V45, P1153, DOI 10.1136/jnnp.45.12.1153; DALESSANDRO R, 1988, ARCH NEUROL-CHICAGO, V45, P42, DOI 10.1001/archneur.1988.00520250048019; De Santis A, 1992, Acta Neurochir Suppl (Wien), V55, P64; Diaz-Arrastia R, 2003, ARCH NEUROL-CHICAGO, V60, P818, DOI 10.1001/archneur.60.6.818; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Englander J, 2003, ARCH PHYS MED REHAB, V84, P365, DOI 10.1053/apmr.2003.50022; FOULKES MA, 1991, J NEUROSURG, V75, pS8, DOI 10.3171/sup.1991.75.1s.00s8; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; HAUSER WA, 1984, NEUROLOGY, V34, P746, DOI 10.1212/WNL.34.6.746; Herman ST, 2002, NEUROLOGY, V59, pS21, DOI 10.1212/WNL.59.9_suppl_5.S21; JACKSON GD, 1993, AM J NEURORADIOL, V14, P753; Jacobs KM, 2000, EPILEPSIA, V41, pS153, DOI 10.1111/j.1528-1157.2000.tb01574.x; Jennett B, 1975, EPILEPSY NONMISSILE; JENNETT WB, 1960, J NEUROL NEUROSUR PS, V23, P295, DOI 10.1136/jnnp.23.4.295; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kumar R, 2003, AM J NEURORADIOL, V24, P218; KUZNIECKI RI, 1995, MAGNETIC RESONANCE E; LEE TE, 1990, STAT METHODS SURVIVA; Leone M, 2002, NEUROL SCI, V23, P99, DOI 10.1007/s100720200034; Lowenstein D, 2001, ANN NEUROL, V50, P696, DOI 10.1002/ana.10090; Mazzini L, 2003, EPILEPSIA, V44, P569, DOI 10.1046/j.1528-1157.2003.34902.x; Messori A, 2003, NEURORADIOLOGY, V45, P881, DOI 10.1007/s00234-003-1048-3; PAGNI CA, 1990, ACT NEUR S, V50, P38; PohlmannEden B, 1997, ACTA NEUROL SCAND, V95, P257, DOI 10.1111/j.1600-0404.1997.tb00206.x; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Samuelsson C, 2003, EPILEPSY RES, V56, P165, DOI 10.1016/j.eplepsyres.2003.09.004; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Temkin NR, 2003, EPILEPSIA, V44, P18, DOI 10.1046/j.1528-1157.44.s10.6.x; WILLMORE LJ, 1990, EPILEPSIA, V31, pS67, DOI 10.1111/j.1528-1157.1990.tb05861.x; WILLMORE LJ, 1978, ANN NEUROL, V4, P329, DOI 10.1002/ana.410040408	42	32	32	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0013-9580	1528-1167		EPILEPSIA	Epilepsia	SEP	2005	46	9					1472	1481		10.1111/j.1528-1167.2005.34004.x			10	Clinical Neurology	Neurosciences & Neurology	959GV	WOS:000231507100015	16146443	Bronze			2021-06-18	
J	Tweedy, SM; Trost, SG				Tweedy, SM; Trost, SG			Validity of accelerometry for measurement of activity in people with brain injury	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						activity monitors; health promotion; physical activity; rehabilitation; stroke; traumatic brain injury	COMPUTER-SCIENCE; VALIDATION; INC.	Purpose: To evaluate the validity of a uniaxial accelerometer (MTI Actigraph) for measuring physical activity in people with acquired brain injury (ABI) using portable indirect calorimetry (Cosmed K4b(2)) as a criterion measure. Methods: Fourteen people with ABI and related gait pattern impairment (age 32 +/- 8 yr) wore an MTI Actigraph that measured activity (counts(.)min-(1)) and a Cosmed K4b(2) that measured oxygen consumption (mL(.)kg(-1.)min(-1)) during four activities: quiet sitting (QS) and comfortable paced (CP), brisk paced (BP), and fast paced (FP) walking. MET levels were predicted from Actigraph counts using a published equation and compared with Cosmed measures. Predicted METs for each of the 56 activity bouts (14 participants X 4 bouts) were classified (light, moderate, vigorous, or very vigorous intensity) and compared with Cosmed-based classifications. Results: Repeated-measures ANOVA indicated that walking condition intensities were significantly different (P < 0.05) and the Actigraph detected the differences. Overall correlation between measured and predicted METs was positive, moderate, and significant (r = 0.74). Mean predicted METs were not significantly different from measured for CP and BP, but for FP walking, predicted METs were significantly less than measured (P < 0.05). The Actigraph correctly classified intensity for 76.8% of all activity bouts and 91.5% of light- and moderate-intensity bouts. Conclusions: Actigraph counts provide a valid index of activity across the intensities investigated in this study. For light to moderate activity, Actigraph-based estimates of METs are acceptable for group-level analysis and are a valid means of classifying activity intensity. The Actigraph significantly underestimated higher intensity activity, although, in practice, this limitation will have minimal impact on activity measurement of most community-dwelling people with ABI.	Univ Queensland, Sch Human Movement Studies, Brisbane, Qld 4072, Australia; Kansas State Univ, Dept Kinesiol, Manhattan, KS 66506 USA; Kansas State Univ, Commun Hlth Inst, Manhattan, KS 66506 USA	Tweedy, SM (corresponding author), Univ Queensland, Sch Human Movement Studies, Brisbane, Qld 4072, Australia.	seant@hms.uq.edu.au	Tweedy, Sean M/E-8448-2011; Trost, Stewart G/B-5948-2012	Tweedy, Sean M/0000-0002-2011-3382; Trost, Stewart G/0000-0001-9587-3944			*AM COLL SPORTS ME, 2000, ACSMS GUID EX TEST P, P22; Bauman A, 1999, J Sci Med Sport, V2, P30, DOI 10.1016/S1440-2440(99)80182-0; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; Boyd R, 1999, DEV MED CHILD NEUROL, V41, P676, DOI 10.1017/S0012162299001395; *DEP HLTH FAM SERV, 1998, DEV ACT AUSTR FRAM A, P1; *EUR HEART NETW, 1999, PHYS ACT CARD DIS PR, P21; Fortune N, 1999, DEFINITION INCIDENCE; Freedson PS, 1998, MED SCI SPORT EXER, V30, P777, DOI 10.1097/00005768-199805000-00021; Gonzalez EG, 2001, DOWNEY DARLINGS PHYS, P417; Gordon WA, 1998, J HEAD TRAUMA REHAB, V13, P58, DOI 10.1097/00001199-199808000-00006; HASKELL WL, 1998, EXERCISE HLTH CONNEC, P301; HOFFER MM, 1973, J BONE JOINT SURG AM, VA 55, P137, DOI 10.2106/00004623-197355010-00014; LUCIA A, 1993, INT J SPORTS MED, V14, P380, DOI 10.1055/s-2007-1021196; McLaughlin JE, 2001, INT J SPORTS MED, V22, P280, DOI 10.1055/s-2001-13816; MELANSON EL, 1995, MED SCI SPORT EXER, V27, P934; Nichols JF, 2000, RES Q EXERCISE SPORT, V71, P36, DOI 10.1080/02701367.2000.10608878; SALLIS JF, 1999, PHYSICAL ACTIVITY BE, P5; Trost SG, 1998, MED SCI SPORT EXER, V30, P629, DOI 10.1097/00005768-199804000-00023; US Department of Health and Human Services, 2000, HLTH PEOPL 2010 UND; US Department of Health and Human Services, 2002, PROGR BRIEF E BYRN M, P2; Vinet A, 1996, SPINAL CORD, V34, P288, DOI 10.1038/sc.1996.52; Welk GJ, 2000, MED SCI SPORT EXER, V32, pS489, DOI 10.1097/00005768-200009001-00008; *WHO, 2004, FOOD NUTR BULL, V25, P292	23	32	32	0	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	SEP	2005	37	9					1474	1480		10.1249/01.mss.0000177584.43330.ae			7	Sport Sciences	Sport Sciences	967FY	WOS:000232078100004	16177597				2021-06-18	
J	Hong, G; Luo, CF; Zhang, CQ; Shi, HP; Fan, CY; Zen, BF				Hong, G; Luo, CF; Zhang, CQ; Shi, HP; Fan, CY; Zen, BF			Internal fixation of diaphyseal fractures of the forearm by interlocking intramedullary nail - Short-term results in eighteen patients	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						forearm; fracture; interlocking; internal fixation; intramenullary nail; shaft	COMPRESSION-PLATE FIXATION; MEDULLARY FIXATION; BONES; RADIUS; ULNA	Objective: This study was designed to evaluate the efficacy of the treatment of diaphyseal fractures of the forearm using the ForeSight (R) forearm interlocking intramedullary nail. Design: Retrospective study. Setting: University-affiliated teaching hospital. Patients: Eighteen patients with 32 displaced diaphyseal forearm fractures were identified. Intervention: All fractures were treated with the ForeSight' forearm interlocking intramedullary nail. Eighteen fractures were stabilized with static interlocking technique. Main Outcome Measures: The assessment of patients was based on the time to union, the functional recovery, and the incidence of complications. Physical capability was evaluated by using the rating system of Grace and Eversmann. Patient-rated outcome was assessed by completion of the Disability of Arm Shoulder Hand questionnaire (DASH). Results: All fractures healed with the index procedure. The average time to union for fractures utilizing a closed technique was 10 weeks(7-12); for fractures using an open reduction technique, 15 weeks(10-21) The mean pronation was 62 (range, 0-96) degrees, and the mean supination was 80 (range, 0-105) degrees. Compared with the normal arm, the mean loss of rotation of the forearm was 32 (range, 5-162) degrees. Using the rating system of Grace and Eversmann, 13 patients had an excellent or good result, 3 had an acceptable result, and 2 had an unacceptable result. Using the patientrated functional questionnaire, the mean DASH of 19 (range, 4-72) points at the time of the most recent follow-up indicated a mild-tomoderate impairment. There were 7 postoperative complications. The incidence of complications was 22% (7/32). One cross-union between forearm bones occurred in a patient with a closed head injury and high-energy trauma. Two nondriving end screws of the ulna nail backed out causing wrist pain and had to be removed. There were 4 superficial infections occurring all in the fractures that necessitated an open reduction technique. The overall rate of infection was 12.5% (4/32). Three patients who presented with an open fracture needed a skin graft to cover the open wound. Conclusions: Forearm interlocking intramedullary nailing is an acceptable method to stabilize displaced diaphyseal forearm fractures in adult.	Jiao Tong Univ, Affiliated Shanghai Peoples Hosp 6, Dept Orthopaed, Shanghai 200233, Peoples R China	Hong, G (corresponding author), Jiao Tong Univ, Shanghai Peoples Hosp 6, Dept Orthopaed Surg, 600 Yishan Rd,Post Code 200233, Shanghai 200233, Peoples R China.	honggao630@yahoo.com.cn	fan, cunyi/ABI-7199-2020	fan, cunyi/0000-0002-7854-5233			ANDERSON LD, 1975, J BONE JOINT SURG AM, VA 57, P287, DOI 10.2106/00004623-197557030-00001; BOLTON H, 1952, LANCET, V263, P700; CHAPMAN MW, 1989, J BONE JOINT SURG AM, V71A, P159, DOI 10.2106/00004623-198971020-00001; COTLER JM, 1971, J BONE JOINT SURG AM, VA 53, P1228; Crenshaw AH, 1997, SURG TECHNIQUE FORES; Crenshaw Andrew H, 2002, Instr Course Lect, V51, P279; Crenshaw Jr AH, 2003, CAMPBELLS OPERATIVE, P3049; DEPEDRO JA, 1992, CLIN ORTHOP RELAT R, V283, P81; EKELAND A, 1988, CLIN ORTHOP RELAT R, P205; GOULET JA, 1997, CLIN ORTHOP RELAT R, V339, P76, DOI DOI 10.1097/00003086-199706000-00011; GRACE TG, 1980, J BONE JOINT SURG AM, V62, P433, DOI 10.2106/00004623-198062030-00013; GUSTILO RB, 1976, J BONE JOINT SURG AM, V58, P453, DOI 10.2106/00004623-197658040-00004; HASTY CC, 1999, 66 ANN M P ROS IL AM, P312; HIDAKA S, 1984, J BONE JOINT SURG AM, V66A, P1241, DOI 10.2106/00004623-198466080-00012; Hudak PL, 1996, AM J IND MED, V29, P602, DOI 10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO;2-L; INGMAN AM, 1994, J BONE JOINT SURG BR, V76B, P23; JONES DJ, 1995, J ORTHOP TRAUMA, V9, P198, DOI 10.1097/00005131-199506000-00004; KLEMM KW, 1986, CLIN ORTHOP RELAT R, V212, P89; KNIGHT RA, 1949, J BONE JOINT SURG AM, V31-A, P755, DOI 10.2106/00004623-194931040-00006; LANGKAMER VG, 1991, INJURY, V22, P97, DOI 10.1016/0020-1383(91)90063-K; MAREK FM, 1961, J BONE JOINT SURG AM, V43, P1099, DOI 10.2106/00004623-196143080-00003; Markolf KL, 1998, J BONE JOINT SURG AM, V80A, P879, DOI 10.2106/00004623-199806000-00012; MATTHEWS LS, 1982, J BONE JOINT SURG AM, V64, P14, DOI 10.2106/00004623-198264010-00003; MIH AD, 1994, CLIN ORTHOP RELAT R, P256; MOED BR, 1986, J BONE JOINT SURG AM, V68A, P1008, DOI 10.2106/00004623-198668070-00007; Moerman J, 1996, Acta Orthop Belg, V62, P34; Muller ME, 1990, COMPREHENSIVE CLASSI; RAND JA, 1981, J BONE JOINT SURG AM, V63, P427, DOI 10.2106/00004623-198163030-00018; SAGE FP, 1959, J BONE JOINT SURG AM, V41, P1489, DOI 10.2106/00004623-195941080-00010; SCHEMITSCH EH, 1992, J BONE JOINT SURG AM, V74A, P1068, DOI 10.2106/00004623-199274070-00014; SCHEMITSCH EH, 1995, J ORTHOP TRAUMA, V9, P8, DOI 10.1097/00005131-199502000-00002; SMITH H, 1957, J BONE JOINT SURG AM, V39, P91, DOI 10.2106/00004623-195739010-00010; STREET DM, 1986, CLIN ORTHOP RELAT R, P219; STREET DM, 1957, J BONE JOINT SURG AM, V39, P223; TABOR OB, 1995, J ORTHOP TRAUMA, V9, P427, DOI 10.1097/00005131-199505000-00011; TARR RR, 1984, J BONE JOINT SURG AM, V66A, P65, DOI 10.2106/00004623-198466010-00010; Turchin DC, 1998, J BONE JOINT SURG AM, V80A, P154, DOI 10.2106/00004623-199802000-00002; Zinar DM, 1996, SCI PRACTICE INTRAME, P265	38	32	39	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0890-5339	1531-2291		J ORTHOP TRAUMA	J. Orthop. Trauma	JUL	2005	19	6					384	391		10.1097/01.bot.0000157911.76433.db			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	950OC	WOS:000230865700005	16003197				2021-06-18	
J	Salmond, CH; Menon, DK; Chatfield, DA; Pickard, JD; Sahakian, BJ				Salmond, CH; Menon, DK; Chatfield, DA; Pickard, JD; Sahakian, BJ			Deficits in decision-making in head injury survivors	JOURNAL OF NEUROTRAUMA			English	Article						decision making; head injury; impulsivity; personality change	TRAUMATIC BRAIN-INJURY; PREFRONTAL CORTEX; PERSONALITY-CHANGE; SOCIAL-ADJUSTMENT; NORMAL VOLUNTEERS; BASAL FOREBRAIN; FOLLOW-UP; COGNITION; DAMAGE; DEPRESSION	Many survivors of head injury suffer chronic personality changes, such as increased impulsivity and a lack of insight and poor judgment. These changes are well recognized and likely to affect the ability to make decisions. However, systematic investigations into their nature have been limited. This study aims to explore the nature of decision making in head injury survivors using a computerized task. Forty-three head injury survivors and a group of 29 matched controls completed the computerized task. The task required participants to make a probability-based choice and to further qualify this choice with an associated "bet." This betting component allows an assessment of the participant's level of confidence in the decision, via the affective evaluation of its possible consequences in terms of points won or lost. The survivors were found to be slow at making the probability-based choice. Whilst at highly favorable odds, the survivors chose the most likely option in a similar manner to the controls, they chose the most likely option less often than the controls at less favorable odds. Examination of the survivors' betting behavior revealed that they responded impulsively compared to controls. This pattern of prolonged decision making and poor quality of decisions is similar to that found in patients with orbitofrontal cortex lesions, whilst impulsive betting has been associated with abnormalities of the dopamine system. These complex deficits in decision making may contribute to difficulties with poor judgment and inhibition in head injury survivors.	Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Wolfson Brain Imaging Ctr,Dept Anaesthet, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Wolfson Brain Imaging Ctr,Dept Neurosurg, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Wolfson Brain Imaging Ctr,Dept Psychiat, Cambridge CB2 2QQ, England	Salmond, CH (corresponding author), Univ Cambridge, Addenbrookes Hosp, Sch Clin Med, Wolfson Brain Imaging Ctr,Dept Anaesthet, Box 65, Cambridge CB2 2QQ, England.	chs20@wbic.cam.ac.uk	Sahakian, Barbara/AAW-1198-2020	Sahakian, Barbara/0000-0001-7352-1745	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ARCIA E, 1994, BRAIN INJURY, V8, P395, DOI 10.3109/02699059409150991; Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; Bazanis E, 2002, PSYCHOL MED, V32, P1395, DOI 10.1017/S0033291702006657; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Beck AT., 1970, DEPRESSION CAUSES TR; Chan RCK, 2000, BRAIN INJURY, V14, P227, DOI 10.1080/026990500120709; Cools R, 2003, NEUROPSYCHOLOGIA, V41, P1431, DOI 10.1016/S0028-3932(03)00117-9; Damasio A. R., 1994, DESCARTESERROR; Deakin J, 2004, J INT NEUROPSYCH SOC, V10, P590, DOI 10.1017/S1355617704104104; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Holbourn AHS, 1943, LANCET, V2, P438; Howell D. C., 2002, STAT METHODS PSYCHOL; Johansson AK, 1999, BEHAV BRAIN RES, V102, P17, DOI 10.1016/S0166-4328(98)00159-4; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kolitz BP, 2003, ARCH PHYS MED REHAB, V84, P277, DOI 10.1053/apmr.2003.50100; Manes F, 2002, BRAIN, V125, P624, DOI 10.1093/brain/awf049; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mayou R, 2001, BRIT J PSYCHIAT, V179, P528, DOI 10.1192/bjp.179.6.528; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; Murphy FC, 2001, PSYCHOL MED, V31, P679, DOI 10.1017/S0033291701003804; NELSON HE, 1982, NATL ADULT READING; Nelson LD, 1998, ARCH CLIN NEUROPSYCH, V13, P549, DOI 10.1016/S0887-6177(97)00052-8; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Polo MD, 2002, NEUROPSYCHOLOGIA, V40, P2350, DOI 10.1016/S0028-3932(02)00127-6; Rahman S, 1999, BRAIN, V122, P1469, DOI 10.1093/brain/122.8.1469; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Rogers RD, 1999, NEUROPSYCHOPHARMACOL, V20, P322, DOI 10.1016/S0893-133X(98)00091-8; Rogers RD, 1999, J NEUROSCI, V19, P9029, DOI 10.1523/JNEUROSCI.19-20-09029.1999; Rubinsztein JS, 2001, BRAIN, V124, P2550, DOI 10.1093/brain/124.12.2550; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; SANTORO J, 1994, BRAIN INJURY, V8, P265, DOI 10.3109/02699059409150978; Swainson R, 2001, DEMENT GERIATR COGN, V12, P265, DOI 10.1159/000051269; Sweeney JA, 2000, BIOL PSYCHIAT, V48, P674, DOI 10.1016/S0006-3223(00)00910-0; Tavares JVT, 2003, PSYCHOL MED, V33, P959, DOI 10.1017/S0033291703008432; TUOKKO H, 1991, Brain Injury, V5, P287, DOI 10.3109/02699059109008098; Wade TR, 2000, PSYCHOPHARMACOLOGY, V150, P90; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WHYTE J, 1995, NEUROPSYCHOLOGIA, V33, P797, DOI 10.1016/0028-3932(95)00029-3; Yody BB, 2000, J HEAD TRAUMA REHAB, V15, P1041, DOI 10.1097/00001199-200008000-00006	44	32	32	0	7	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUN	2005	22	6					613	622		10.1089/neu.2005.22.613			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	936EN	WOS:000229838400001	15941371				2021-06-18	
J	Rutland-Brown, W; Wallace, LJD; Faul, MD; Langlois, JA				Rutland-Brown, W; Wallace, LJD; Faul, MD; Langlois, JA			Traumatic brain injury hospitalizations among American Indians/Alaska natives	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						accidents; alcohol drinking; craniocerebral trauma; hospitalization; North American Indians; seat belts; traumatic brain injury; wounds and injury	DRINKING DRIVERS; BELT USE; ALCOHOL; PATTERNS; CHILDREN; CRASHES; LAWS	Objectives: To compare the incidence of nonfatal traumatic brain injury (TBI) hospitalization among American Indians/Alaska Natives (AI/AN) with that of other race groups and to assess alcohol and protective equipment (PE) use among those who sustained TBI related to a motor vehicle (MV) incident. Methods: Data were obtained from 13 states funded by the Centers for Disease Control and Prevention to conduct TBI surveillance from 1997 to 1999. Rates by race and by cause were calculated for the 13 states combined. Blood alcohol concentration (BAC) levels and PE use were compared between AI/AN and "other" races in a subgroup of these states. Results: Although not significantly different, AI/AN had the highest overall age-adjusted TBI hospitalization rate (71.5 per 100,000). Rates were significantly higher among AI/AN than among whites for ages 20 to 44 years (78.5 per 100,000 vs 54.7 per 100,000, P < .0001). MV incidents were the leading cause of TBI (40.1% of cases) among AI/AN, and AI/AN injured in MV incidents had higher BAC levels (65.7% >= 0.08 g/dL vs 31.6% >= 0.08 g/dL, P < .0001) and lower PE use (22.0% vs 40.4%, P < .0001) than the "other" race group. Conclusion: AI/AN have high rates of TBI hospitalization compared with other races. High BAC levels and low use of PE in MV incidents appear to be associated with the higher rates in this population.	Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA	Rutland-Brown, W (corresponding author), 4770 Buford Highway,NE,MS F-41, Atlanta, GA 30341 USA.	wfr7@cdc.gov		Faul, Mark/0000-0002-7683-0348			Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; Blackmer J, 1999, BRAIN INJURY, V13, P627; Campos-Outcalt D, 2003, INJURY PREV, V9, P251, DOI 10.1136/ip.9.3.251; *CDCP NAT CTR HLTH, 1999, TRAUM BRAIN INJ US; Centers for Disease Control and Prevention (CDC), 2002, MMWR Morb Mortal Wkly Rep, V51, P303; Cunningham RM, 2002, ALCOHOL ALCOHOLISM, V37, P236, DOI 10.1093/alcalc/37.3.236; Dee TS, 1998, ACCIDENT ANAL PREV, V30, P1, DOI 10.1016/S0001-4575(97)00056-0; FOSS RD, 1994, AM J PUBLIC HEALTH, V84, P1732, DOI 10.2105/AJPH.84.11.1732; Lange JE, 1998, AM J PUBLIC HEALTH, V88, P1718, DOI 10.2105/AJPH.88.11.1718; Langlois Jean A, 2003, MMWR Surveill Summ, V52, P1; Levy DT, 2004, MED SCI MONITOR, V10, pCR17; MAY PA, 1992, AM INDIAN ALASKA NAT, V4, P5; MAY PA, 1995, IHS PRIM CARE PROVID, V20, P37; McDonald AJ, 2004, ARCH INTERN MED, V164, P531, DOI 10.1001/archinte.164.5.531; Phelan KJ, 2002, INJURY PREV, V8, P216, DOI 10.1136/ip.8.3.216; Quinlan K P, 1998, Inj Prev, V4, P276; Quinlan KP, 2000, JAMA-J AM MED ASSOC, V283, P2249, DOI 10.1001/jama.283.17.2249; Sallee D, 2000, Alaska Med, V42, P37; Siegel JH, 2001, J TRAUMA, V51, P975, DOI 10.1097/00005373-200111000-00024; Valent F, 2002, J TRAUMA, V52, P745, DOI 10.1097/00005373-200204000-00023; VOAS R, 1999, ETHNICITY ALCOHOL RE; Voas RB, 2002, ADDICTION, V97, P1439, DOI 10.1046/j.1360-0443.2002.t01-2-00267.x	22	32	33	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAY-JUN	2005	20	3					205	214		10.1097/00001199-200505000-00004			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	926ZZ	WOS:000229163500004	15908821				2021-06-18	
J	Wagner, KR; Dean, C; Beiler, S; Bryan, DW; Packard, BA; Smulian, AG; Linke, MJ; de Courten-Myers, GM				Wagner, KR; Dean, C; Beiler, S; Bryan, DW; Packard, BA; Smulian, AG; Linke, MJ; de Courten-Myers, GM			Plasma infusions into porcine cerebral white matter induce early edema, oxidative stress, pro-inflammatory cytokine gene expression and DNA fragmentation: Implications for white matter injury with increased blood-brain-barrier permeability	CURRENT NEUROVASCULAR RESEARCH			English	Article						edema; plasma proteins; cytokines; DNA damage; blood-brain-barrier	EXPERIMENTAL INTRACEREBRAL HEMORRHAGE; CENTRAL-NERVOUS-SYSTEM; FACTOR-KAPPA-B; SERUM-PROTEIN; VASOGENIC EDEMA; THROMBIN; DAMAGE; RAT; EXTRAVASATION; ASTROCYTES	Plasma infused into porcine cerebral white matter induces both acute interstitial and delayed vasogenic edema. Edematous white matter contains extracellular plasma proteins and rapidly induces oxidative stress as evidenced by increased protein carbonyl formation and heme oxygenase-1 induction. We tested the hypothesis that edematous white matter would also upregulate pro-inflammatory cytokine gene expression and develop DNA damage. We infused autologous plasma into the frontal hemispheric white matter of pentobarbital-anesthetized pigs. We monitored and controlled physiological variables and froze brains in situ at 1, 4 or 24 hrs. We determined edema volumes by computer-assisted morphometry. We measured white matter protein carbonyl formation by immunoblotting, cytokine gene expression by standard RT-PCR methods and DNA fragmentation by agarose gel electrophoresis. White matter edema developed acutely (1 hr) after plasma infusion and increased significantly in volume between 4 and 24 hrs. Protein carbonyl formation also occurred rapidly in edematous white matter with significant elevations (3 to 4-fold) already present at I hr. This increase remained through 24 hrs. Pro-inflammatory cytokine gene expression was also rapidly increased at I hr post-infusion. Evidence for DNA fragmentation began at 2 to 4 hrs, and a pattern indicative of both ongoing necrosis and apoptosis was robust by 24 hrs. Plasma protein accumulation in white matter induces acute edema development and a cascade of pathochemical events including oxidative stress, pro-inflammatory cytokine gene expression and DNA damage. These results suggest that in diseases with increased blood-brain barrier (BBB) permeability or following intracerebral hemorrhage or traumatic brain injury, interstitial plasma can rapidly damage white matter.	Dept Vet Affairs Med Ctr, Res Serv 151, Med Res Serv, Cincinnati, OH 45220 USA; Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH 45267 USA	Wagner, KR (corresponding author), Dept Vet Affairs Med Ctr, Res Serv 151, Med Res Serv, 3200 Vine St, Cincinnati, OH 45220 USA.	wagnerkr@email.uc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS-30652] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS030652] Funding Source: NIH RePORTER		Bethea JR, 2000, PROG BRAIN RES, V128, P33; BETZ A L, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P133; Brown M S, 1995, J Neuroimaging, V5, P23; Budka H, 1991, BRAIN PATHOL, V1, P163, DOI 10.1111/j.1750-3639.1991.tb00656.x; DelBigio MR, 1996, STROKE, V27, P2312, DOI 10.1161/01.STR.27.12.2312; DELBIGIO MR, 1993, ACTA NEUROPATHOL, V85, P573, DOI 10.1007/BF00334666; DOLINSKAS CA, 1977, AM J ROENTGENOL, V129, P681, DOI 10.2214/ajr.129.4.681; Dozois CM, 1997, VET IMMUNOL IMMUNOP, V58, P287, DOI 10.1016/S0165-2427(97)00039-1; Dul K, 1994, INTRACEREBRAL HEMORR, P73; DVORAK HF, 1992, ANN NY ACAD SCI, V667, P101, DOI 10.1111/j.1749-6632.1992.tb51603.x; EDDLESTON M, 1993, J CLIN INVEST, V92, P349, DOI 10.1172/JCI116573; GAY D, 1991, BRAIN, V114, P557, DOI 10.1093/brain/114.1.557; Gebel JM, 1998, STROKE, V29, P563, DOI 10.1161/01.STR.29.3.563; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Grilli M, 1999, CELL DEATH DIFFER, V6, P22, DOI 10.1038/sj.cdd.4400463; Hall NC, 2000, CELL MOL BIOL, V46, P673; Hickenbottom SL, 1999, STROKE, V30, P2472, DOI 10.1161/01.STR.30.11.2472; Holmin S, 2000, J NEUROSURG, V92, P108, DOI 10.3171/jns.2000.92.1.0108; JENKINS A, 1989, NEUROPATH APPL NEURO, V15, P477, DOI 10.1111/j.1365-2990.1989.tb01247.x; KALIMO H, 1994, ACTA NEUROL SCAND, V89, P353; Koeppen AH, 1995, J NEUROL SCI, V134, P102, DOI 10.1016/0022-510X(95)00215-N; KONAT G, 1986, EXPERIENTIA, V42, P37, DOI 10.1007/BF01975883; Kuroiwa T, 1990, Adv Neurol, V52, P11; Lee KR, 1997, J NEUROSURG, V86, P272, DOI 10.3171/jns.1997.86.2.0272; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; Masada T, 2001, J NEUROSURG, V95, P680, DOI 10.3171/jns.2001.95.4.0680; Matz PG, 2001, J CEREBR BLOOD F MET, V21, P921, DOI 10.1097/00004647-200108000-00004; Mayne M, 2001, STROKE, V32, P240, DOI 10.1161/01.STR.32.1.240; MCLEAN BN, 1995, J NEUROL NEUROSUR PS, V58, P548, DOI 10.1136/jnnp.58.5.548; Murakami K, 1998, J NEUROTRAUM, V15, P825, DOI 10.1089/neu.1998.15.825; NISHINO A, 1993, J NEUROTRAUM, V10, P167, DOI 10.1089/neu.1993.10.167; OHATA K, 1990, ACTA NEUROPATHOL, V81, P162, DOI 10.1007/BF00334505; RHODES RH, 1991, J NEUROPATH EXP NEUR, V50, P171, DOI 10.1097/00005072-199103000-00008; Rothwell N, 1997, J CLIN INVEST, V100, P2648, DOI 10.1172/JCI119808; Rothwell NJ, 1999, J PHYSIOL-LONDON, V514, P3, DOI 10.1111/j.1469-7793.1999.003af.x; SCHMIDTKASTNER R, 1990, NEUROSCIENCE, V38, P527, DOI 10.1016/0306-4522(90)90048-9; SELMAJ KW, 1988, ANN NEUROL, V23, P339, DOI 10.1002/ana.410230405; Si QS, 1997, GLIA, V21, P413, DOI 10.1002/(SICI)1098-1136(199712)21:4<413::AID-GLIA9>3.0.CO;2-3; SZYMAS J, 1984, ACTA NEUROCHIR, V71, P229, DOI 10.1007/BF01401318; Tang Y, 2002, EUR J NEUROSCI, V15, P1937, DOI 10.1046/j.1460-9568.2002.02030.x; Van Wagoner NJ, 1999, J NEUROSCI, V19, P5236; WAGNER KR, 1985, EXP NEUROL, V89, P146, DOI 10.1016/0014-4886(85)90272-9; Wagner KR, 2002, DEV NEUROSCI-BASEL, V24, P154, DOI 10.1159/000065703; Wagner KR, 2001, STROKE, V32, P327; Wagner KR, 1998, J NEUROSURG, V88, P1058, DOI 10.3171/jns.1998.88.6.1058; Wagner KR, 1996, STROKE, V27, P490, DOI 10.1161/01.STR.27.3.490; Wagner KR, 2003, J CEREBR BLOOD F MET, V23, P629, DOI 10.1097/01.WCB.0000073905.87928.6D; Wagner KR, 1999, J NEUROSURG, V90, P491, DOI 10.3171/jns.1999.90.3.0491; WAGNER KR, 2001, NEUROPROTECTION, P471; WAGNER KR, 1995, J CEREB BLOOD FLO S1, V15, pS28; WAGNER KR, 2003, J CEREB BLOOD FLO S1, V23, P277; Wang H, 2003, BIOL CHEM, V384, P193, DOI 10.1515/BC.2003.021; Wardlaw JM, 2003, STROKE, V34, P806, DOI 10.1161/01.STR.0000058480.77236.B3; Xi GH, 2002, NEUROSURG CLIN N AM, V13, P371, DOI 10.1016/S1042-3680(02)00007-4; Xi GH, 1998, STROKE, V29, P2580, DOI 10.1161/01.STR.29.12.2580; Xue MZ, 2001, STROKE, V32, P2164, DOI 10.1161/hs0901.095408; YAMANOUCHI H, 1991, ACTA NEUROL SCAND, V83, P301, DOI 10.1111/j.1600-0404.1991.tb04706.x	58	32	32	0	2	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1567-2026			CURR NEUROVASC RES	Curr. Neurovasc. Res.	APR	2005	2	2					149	155		10.2174/1567202053586785			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	946ZX	WOS:000230612900007	16181107				2021-06-18	
J	Barton, CW; Hemphill, JC; Morabito, D; Manley, G				Barton, CW; Hemphill, JC; Morabito, D; Manley, G			A novel method of evaluating the impact of secondary brain insults on functional outcomes in traumatic brain-injured patients	ACADEMIC EMERGENCY MEDICINE			English	Article; Proceedings Paper	SAEM Annual Meeting 2004	MAY, 2004	Orlando, FL	SAEM		secondary brain insults; hypotension; hypoxia; traumatic brain injury; head trauma	SEVERE HEAD-INJURY; HYPOTENSION; HYPOXIA; SCALE; REGION; SYSTEM	Objectives: Prior studies suggest that the emergency department (ED) occurrence of secondary brain insults (SBIs), such as systemic hypotension and hypoxia, worsens outcome in patients with traumatic brain injury. However, previous methods of assessing SBIs have been relatively crude, generally only determining the incidence and duration of events. The authors hypothesized that a new method that accounts for the cumulative depth and duration of SBIs would provide a more informative measure that better correlates with outcome. Methods: The authors developed a computer algorithm to calculate the total "dose" of an SBI (in this case, hypotension and hypoxia) as the area under the curve between a cut-point value and a measured vital sign over time. To test this method, the authors used an existing data set of head trauma patients for whom occurrence in the ED of any hypotension had been shown to be associated with in-hospital mortality. The authors applied the algorithm using the cut-point values from the prior study (systolic blood pressure less than or equal to 90 mm Hg and oxygen saturation less than or equal to 92%). The effects of SBIs on in-hospital mortality and three-month Glasgow Outcome Scale score were evaluated. Results: Of 107 patients overall, 26 had hypotension (dose range 0.2-898 mm Hg . min) and 40 had hypoxia (dose range 0.005-6.7% . min). Moderate and high doses of hypotension were more strongly associated with outcome than the measures from the initial study (any hypotension and number of hypotensive episodes). Hypoxia had no effect. Conclusions: New methods of measuring SBIs that take into account depth and duration of episodes may more accurately reflect the influence of these events on outcome after head trauma.	Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94143 USA	Barton, CW (corresponding author), San Francisco Gen Hosp, Emergency Serv, Room 1E21,1001 Potrero Ave, San Francisco, CA 94110 USA.	cbarton@itsa.ucsf.edu	Demchuk, Andrew M/E-1103-2012	Demchuk, Andrew M/0000-0002-4930-7789; Hemphill, Claude/0000-0003-4019-7525	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS41420] Funding Source: Medline; ODCDC CDC HHS [R49CCR903697] Funding Source: Medline		Biros M H, 2001, Curr Opin Crit Care, V7, P444, DOI 10.1097/00075198-200112000-00012; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Diringer MN, 2004, CRIT CARE MED, V32, P559, DOI 10.1097/01.CCM.0000108868.97433.3F; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; JEFFREYS RV, 1981, LANCET, V2, P459; JENNETT B, 1975, LANCET, V1, P480; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Manley G, 2001, ARCH SURG-CHICAGO, V136, P1118, DOI 10.1001/archsurg.136.10.1118; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; PIGULA FA, 1993, J PEDIATR SURG, V28, P310, DOI 10.1016/0022-3468(93)90223-8; Schmutzhard E, 2002, CRIT CARE MED, V30, P2481, DOI 10.1097/00003246-200211000-00013; WALD SL, 1993, J TRAUMA, V34, P377, DOI 10.1097/00005373-199303000-00012; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, STROKE, V33, P2243, DOI 10.1161/01.STR.0000027437.22450.BD; Winchell RJ, 1996, ARCH SURG-CHICAGO, V131, P533	17	32	35	0	5	HANLEY & BELFUS INC	PHILADELPHIA	210 S 13TH ST, PHILADELPHIA, PA 19107 USA	1069-6563			ACAD EMERG MED	Acad. Emerg. Med.	JAN	2005	12	1					1	6		10.1197/j.aem.2004.08.043			6	Emergency Medicine	Emergency Medicine	885XI	WOS:000226190200001	15635130				2021-06-18	
J	Bergemalm, PO; Lyxell, B				Bergemalm, PO; Lyxell, B			Appearances are deceptive? - Long-term cognitive and central auditory sequelae from closed head injury	INTERNATIONAL JOURNAL OF AUDIOLOGY			English	Article						audiometry; closed head injury; central auditory processing; APD; cognitive; sequelae; TIPS	SELF-RATING SCALE; EVALUATING MEMORY; EVERYDAY LIFE; HEARING-LOSS; BRAIN-STEM; SPEECH; ADULTS	The purpose of the present study was to examine possible signs of long-term cognitive and/or central auditory sequelae seven to eleven years after a closed head injury (CHI) of sufficient severity to cause scull fracture and/or brain contusion. Another purpose was that this investigation should be carried out in a group of recovered trauma victims with, to the individual, no known or minimal sequelae. A computer-based set of five cognitive tests and three central auditory tests were used in a group of formerly brain-injured patients who considered themselves as well recovered. Most of the participants did not report any signs of cognitive or auditory impairment. Tests of working memory capacity, verbal information processing speed, phonological processing and verbal inference-making ability were used. Auditory brain response (ABR), distorted speech audiometry (interrupted speech), and phase audiometry were used to test central auditory function. The initial severity of brain damage, i.e. status when the patient arrived at the emergency ward, was estimated with Swedish Reaction Level Scale (RLS). Cognitive shortcomings after CHI were demonstrated in a high percentage (59%, 13/22) of the cases seven to eleven years after the injury. Central auditory processing disorders (APD) were also demonstrated in a fairly high percentage (58%, 11/19) of the subjects. None of the correlations between RLS and the results on cognitive and central auditory tests reached statistical significance. However, there was a correlation between cognitive performance and the results on the central auditory tests used in this investigation. Eighty percent (8/10) of those participants with pathologies on ABR and/or phase audiometry and/or IS also failed on one or more of the cognitive tasks, compared to 44% (4/9) among those with no signs of APD. It is possible, many years after CHI, to observe cognitive shortcomings and APD in a relatively high percentage of CHI cases that are subjectively considered to be fairly well recovered. The cognitive tasks used in the study have proved to be a sensitive method to discover cognitive impairments. Long-term cognitive sequelae and APD could not be predicted from RLS scores.	Orebro Univ Hosp, Ahlsen Res Inst, S-70185 Orebro, Sweden; Lindesberg Cty Hosp, ENT Dept, Lindesberg, Sweden; Linkoping Univ, Dept Behav Sci, S-58183 Linkoping, Sweden	Bergemalm, PO (corresponding author), Orebro Univ Hosp, Ahlsen Res Inst, S-70185 Orebro, Sweden.	per-olof.bergemalm@orebroll.se					ALLEN S, 1970, FREQUENCY DICT PRESE; Andersson U, 2002, EUR J COGN PSYCHOL, V14, P335, DOI 10.1080/09541440143000096; BADDELEY A, 1985, J MEM LANG, V24, P119, DOI 10.1016/0749-596X(85)90019-1; BADDELEY A, 1985, J MEM LANG, V24, P490, DOI 10.1016/0749-596X(85)90041-5; Baddeley AD., 1990, HUMAN MEMORY; BERGEMALM PO, ACTA OTOLARYNGOL, V121, P724; BIGLE ED, 1990, TRAUMATIC BRAIN INJU, P1; BROOKS N, 1984, CLOSED HEAD INJURY P, P44; BROUWER WH, 1985, CORTEX, V21, P111, DOI 10.1016/S0010-9452(85)80019-8; BROUWER WH, 1985, LIMITATIONS ATTENTIO; Chiappa KH, 1989, EVOKED POTENTIALS CL, P173; Conrad R., 1979, DEAF SCHOOLCHILD; CROOK TH, 1990, PSYCHOL AGING, V5, P48, DOI 10.1037/0882-7974.5.1.48; CROOK TH, 1992, ARCH CLIN NEUROPSYCH, V7, P41, DOI 10.1016/0887-6177(92)90017-H; ELWANY S, 1988, J LARYNGOL OTOL, V102, P755, DOI 10.1017/S0022215100106383; GRIFFITH MV, 1979, J LARYNGOL OTOL, V93, P252; HAGOBOAM TW, 1978, MEM COGNITION, V2, P189; HERMANN DJ, 1982, PSYCHOL BULL, V92, P434; HUNT E, 1985, HUMAN ABILITIES; JENNET B, 1979, NEUROSURGERY, V5, P283; KARLSSON AK, 1995, SCAND AUDIOL, V24, P155, DOI 10.3109/01050399509047529; Korsan-Bengtsen M, 1973, Acta Otolaryngol Suppl, V310, P1; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P176; LYXELL B, 1994, SCAND AUDIOL, V23, P179, DOI 10.3109/01050399409047505; Lyxell B, 1996, J Deaf Stud Deaf Educ, V1, P190; Lyxell B, 1998, SCAND J PSYCHOL, V39, P175, DOI 10.1111/1467-9450.393075; LYXELL B, 1989, British Journal of Audiology, V23, P339, DOI 10.3109/03005368909076523; LYXELL B, 1992, SCAND AUDIOL, V21, P67, DOI 10.3109/01050399209045984; LYXELL B, 1989, THESIS U UMEA DEP PS; MACFLYNN G, 1984, J NEUROL NEUROSUR PS, V47, P1326, DOI 10.1136/jnnp.47.12.1326; Musiek FE, 1995, EAR HEARING, V16, P631, DOI 10.1097/00003446-199512000-00009; Ronnberg J, 1998, J Deaf Stud Deaf Educ, V3, P143; Ronnberg J., 1990, EUROPEAN J COGNITIVE, V2, P253, DOI [10.1080/09541449008406207, DOI 10.1080/09541449008406207]; ROSENHALL U, 1985, SCAND AUDIOL, V14, P187, DOI 10.3109/01050398509045940; STARMARK JE, 1988, ACTA NEUROCHIR, V91, P12, DOI 10.1007/BF01400521; TROMP E, 1991, J CLIN EXP NEUROPSYC, V13, P821, DOI 10.1080/01688639108405100; VANGORP WG, 1991, J CLIN EXP NEUROPSYC, V13, P812, DOI 10.1080/01688639108401091; Wennmo C, 1989, Acta Otolaryngol Suppl, V468, P379	38	32	38	1	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1499-2027			INT J AUDIOL	Int. J. Audiol.	JAN	2005	44	1					39	49		10.1080/14992020400022546			11	Audiology & Speech-Language Pathology; Otorhinolaryngology	Audiology & Speech-Language Pathology; Otorhinolaryngology	909AA	WOS:000227830100006	15796101				2021-06-18	
J	Wang, YT; Kent, RD; Duffy, JR; Thomas, JE				Wang, YT; Kent, RD; Duffy, JR; Thomas, JE			Dysarthria in traumatic brain injury: A breath group and intonational analysis	FOLIA PHONIATRICA ET LOGOPAEDICA			English	Article						traumatic brain injury; dysarthria; dysprosody; intonation; breath groups	CLOSED-HEAD-INJURY; NATIONAL HOUSEHOLD SURVEY; VERBAL IMPAIRMENT; VOWEL DISTORTION; UNITED-STATES; SPEECH; DISCOURSE; DISABILITIES; PREVALENCE; SPEAKING	Prosodic abnormality is a common feature in the dysarthrias associated with traumatic brain injury (TBI), but very few analytic studies have been reported on the nature of the prosodic disturbances. This study, based on analyses of conversational and sentence speech samples, reports on breath group structure and its temporal and intonational components for 12 subjects with TBI and 8 healthy controls. It introduces the method of f(0) close-copy stylization to the study of intonational patterns in dysarthria. The subjects with TBI had reduced mean length and variation of breath groups along with frequent inappropriate locations of breath pause and lengthy and variable breath pauses. Prosodic features that were preserved in the subjects with TBI were phrase final lengthening, f(0) downtrend and a relatively normal f(0) distribution. However, these subjects had reduced speaking and articulation rates, reduced f(0) movement and reduced f(0) slope. The phrase final lengthening and f(0) downtrend phenomena, which can serve as prosodic cues of syntactic boundary, appear to be robust features of speech production, but the dynamic features of f(0) control were more vulnerable to the neurological damage. This study indicates the importance of breath group management in TBI-induced dysarthria and the need to use methods such as those used in this study for large-scale investigations that examine cognitive, linguistic and motoric factors that conspire to reduce communicative efficiency. Copyright (c) 2005 S. Karger AG, Basel.	Univ Wisconsin, Waisman Ctr, Madison, WI 53705 USA; Natl Yang Ming Univ, Sch Dent, Taipei 112, Taiwan; Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	Kent, RD (corresponding author), Univ Wisconsin, Waisman Ctr, Room 435,1500 Highland Ave, Madison, WI 53705 USA.	kentray@waisman.wisc.edu	Kent, Raymond D/AAI-1928-2020		NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [5 R01 DC 00319] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC000319] Funding Source: NIH RePORTER		BAER T, 1979, J ACOUST SOC AM, V65, P1271, DOI 10.1121/1.382795; BLUMBERGER J, 1995, BRAIN INJURY, V9, P797, DOI 10.3109/02699059509008235; Bunton K, 2000, CLIN LINGUIST PHONET, V14, P13, DOI 10.1080/026992000298922; CAMPBELL TF, 1995, J SPEECH HEAR RES, V38, P864, DOI 10.1044/jshr.3804.864; Cohen H, 2001, BRAIN COGNITION, V46, P73, DOI 10.1016/S0278-2626(01)80038-5; Galski T, 1998, BRAIN INJURY, V12, P769, DOI 10.1080/026990598122160; GENTRY LR, 1988, AM J NEURORADIOL, V9, P101, DOI 10.2214/ajr.150.3.663; HARMANN E, 1984, BR J DISORD COMMUN, V19, P253; HENDERSON A, 1966, LANG SPEECH, V9, P207, DOI 10.1177/002383096600900402; Kent RD, 2002, ACOUSTIC ANAL SPEECH; LEFKOWITZ D, 1994, J MED SPEECH-LANG PA, V2, P1; Lieberman P., 1967, INTONATION PERCEPTIO; Lubinski R, 1997, BRAIN INJURY, V11, P103, DOI 10.1080/026990597123692; McHenry M, 1998, BRAIN INJURY, V12, P495, DOI 10.1080/026990598122458; McHenry M, 2000, LARYNGOSCOPE, V110, P1157, DOI 10.1097/00005537-200007000-00017; McHenry MA, 2001, BRAIN INJURY, V15, P741, DOI 10.1080/02699050117120; MENNEL HD, 1997, SEVERE HEAD INJURIES, P19; MILENKOVIC P, 2001, TIME FREQUENCY ANAL; MOSCATO BS, 1994, J NEUROPSYCH CLIN N, V6, P134; Nathani S, 2001, BEHAV RES METH INS C, V33, P321, DOI 10.3758/BF03195385; NETSELL R, 1983, CLIN DYSARTHRIA, P1; Nooteboom S., 1997, HDB PHONETIC SCI, P640; OLLER DK, 1977, J ACOUST SOC AM, V62, P994, DOI 10.1121/1.381594; Oller DK, 1992, PHONOLOGICAL DEV MOD, P509; PONSFORD JL, 1995, BRAIN INJURY, V9, P1, DOI 10.3109/02699059509004565; RIETVELD ACM, 1985, J PHONETICS, V13, P299, DOI 10.1016/S0095-4470(19)30761-2; Samuel C, 1998, J NEUROL NEUROSUR PS, V64, P482, DOI 10.1136/jnnp.64.4.482; SARNO MT, 1986, ARCH PHYS MED REHAB, V67, P400; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SARNO MT, 1984, J NERV MENT DIS, V172, P475, DOI 10.1097/00005053-198408000-00006; SCHLENCK KJ, 1993, CLIN LINGUIST PHONET, V7, P119, DOI 10.3109/02699209308985549; SNOW D, 1994, J SPEECH HEAR RES, V37, P831, DOI 10.1044/jshr.3704.831; Snow D, 1998, J SPEECH LANG HEAR R, V41, P1158, DOI 10.1044/jslhr.4105.1158; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stierwalt JAG, 1996, DISORDERS MOTOR SPEE, P241; STRIK H, 1995, J PHONETICS, V23, P203, DOI 10.1016/S0095-4470(95)80043-3; Swerts M, 1996, ICSLP 96 - FOURTH INTERNATIONAL CONFERENCE ON SPOKEN LANGUAGE PROCESSING, PROCEEDINGS, VOLS 1-4, P1501, DOI 10.1109/ICSLP.1996.607901; THEODOROS DG, 1994, BRAIN INJURY, V8, P101, DOI 10.3109/02699059409150963; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Togher L, 2001, J COMMUN DISORD, V34, P131, DOI 10.1016/S0021-9924(00)00045-9; WANG YT, IN PRESS SYLLABLE AL; WILSON J T L, 1990, Brain Injury, V4, P349; Wozniak RJ, 1999, BRAIN INJURY, V13, P191, DOI 10.1080/026990599121700; Yorkston KM., 1999, MANAGEMENT MOTOR SPE; Yorkston KM, 1989, J HEAD TRAUMA REHAB, V4, P1; Zebenholzer K, 1998, WIEN KLIN WOCHENSCHR, V110, P253; ZIEGLER W, 1986, BRIT J DISORD COMMUN, V21, P173; ZIEGLER W, 1988, BRIT J DISORD COMMUN, V23, P215; ZIEGLER W, 1983, PHONETICA, V40, P63; ZIEGLER W, 1993, J SPEECH HEAR RES, V36, P683, DOI 10.1044/jshr.3604.683; ZIEGLER W, 1983, PHONETICA, V40, P312, DOI 10.1159/000261698	51	32	38	0	10	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1021-7762	1421-9972		FOLIA PHONIATR LOGO	Folia Phoniatr. Logop.		2005	57	2					59	89		10.1159/000083569			31	Audiology & Speech-Language Pathology; Otorhinolaryngology; Rehabilitation	Audiology & Speech-Language Pathology; Otorhinolaryngology; Rehabilitation	930QR	WOS:000229431700001	15914992				2021-06-18	
J	Dow, C; Seidenberg, M; Hermann, B				Dow, C; Seidenberg, M; Hermann, B			Relationship between information processing speed in temporal lobe epilepsy and white matter volume	EPILEPSY & BEHAVIOR			English	Article						temporal lobe epilepsy; magnetic resonance volumetrics; white matter; Sternberg task	WORKING-MEMORY; ABNORMALITIES; MRI	Abnormalities in white matter have been linked to processing speed impairment in clinical populations (e.g., multiple sclerosis, closed head injury). Recent studies indicate the presence of significant reduction in cerebral white matter volume in some patients with chronic temporal lobe epilepsy (TLE). The objective of this study was to examine the relationship between white matter volume and processing speed and performance efficiency on the Sternberg Memory Scanning Test (SMST). The study groups included TLE subjects with white matter volume reduction (n = 13), TLE subjects with normal white matter volume (n = 14), and healthy controls (n = 18). The groups did not differ in total cerebral gray matter volume. Compared with the controls, the reduced white matter volume TLE group exhibited a significantly steeper slope on the SMST. This was characterized by a disproportionate increase in reaction time with increased processing demands (set size), particularly for negative probe trials. In contrast, no significant differences on the SMST were evident between controls and the normal white matter volume TLE group. These findings suggest the presence of information processing speed and efficiency impairment in TLE and its relationship with white matter volume integrity. (C) 2004 Elsevier Inc. All rights reserved.	Rosalind Franklin Univ Sci & Med, Dept Psychol, N Chicago, IL 60064 USA; Univ Wisconsin, Dept Neurol, Madison, WI 53706 USA	Seidenberg, M (corresponding author), Rosalind Franklin Univ Sci & Med, Dept Psychol, 3333 Green Bay Rd, N Chicago, IL 60064 USA.	michael.seidenberg@rosalindfranklin.edu			NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [MO1 RR03186] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [2R01-37738] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR003186] Funding Source: NIH RePORTER		ANDREASEN NC, 1992, J NEUROPSYCH CLIN N, V4, P125; ANDREASEN NC, 1993, J NEUROPSYCH CLIN N, V5, P121; Archibald CJ, 2000, J CLIN EXP NEUROPSYC, V22, P686, DOI 10.1076/1380-3395(200010)22:5;1-9;FT686; Awh E, 1996, PSYCHOL SCI, V7, P25, DOI 10.1111/j.1467-9280.1996.tb00662.x; Becker J T, 1995, J Int Neuropsychol Soc, V1, P3; FILLEY CM, 2001, BEHAV NEUROLOGY WHIT; Fletcher PC, 2001, BRAIN, V124, P849, DOI 10.1093/brain/124.5.849; GRIPPO A, 1994, BEHAV NEUROL, V7, P143, DOI 10.3233/BEN-1994-73-406; Gron G, 1996, J CLIN EXP NEUROPSYC, V18, P406, DOI 10.1080/01688639608408997; Gunning-Dixon FM, 2000, NEUROPSYCHOLOGY, V14, P224, DOI 10.1037//0894-4105.14.2.224; Harris G, 1999, J COMPUT ASSIST TOMO, V23, P144, DOI 10.1097/00004728-199901000-00030; Hermann B, 2003, J INT NEUROPSYCH SOC, V9, P353, DOI 10.1017/S1355617703930013; Hermann BP, 1997, ARCH NEUROL-CHICAGO, V54, P369, DOI 10.1001/archneur.1997.00550160019010; Hermann BP, 2002, PROG BRAIN RES, V135, P429; Kail R, 1998, J CLIN EXP NEUROPSYC, V20, P98, DOI 10.1076/jcen.20.1.98.1483; Magnotta VA, 1999, RADIOLOGY, V211, P781, DOI 10.1148/radiology.211.3.r99ma07781; Marsh L, 1997, EPILEPSIA, V38, P576, DOI 10.1111/j.1528-1157.1997.tb01143.x; PAULESU E, 1993, NATURE, V331, P68; Pelosi L, 2000, CLIN NEUROPHYSIOL, V111, P1531, DOI 10.1016/S1388-2457(00)00354-0; RAO SM, 1989, J CLIN EXP NEUROPSYC, V11, P471, DOI 10.1080/01688638908400907; SININGER YS, 1989, J SPEECH HEAR RES, V32, P289, DOI 10.1044/jshr.3202.289; Sperling RA, 2001, ARCH NEUROL-CHICAGO, V58, P115, DOI 10.1001/archneur.58.1.115; STERNBERG S, 1969, AM SCI, V57, P421; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; STUSS DT, 1987, J CLIN EXP NEUROPSYC, V9, P131, DOI 10.1080/01688638708405353; SWIRSKYSACCHETTI T, 1992, NEUROLOGY, V42, P1291, DOI 10.1212/WNL.42.7.1291; Verger K, 2001, BRAIN INJURY, V15, P211; WARD LC, 1990, J CLIN PSYCHOL, V46, P436, DOI 10.1002/1097-4679(199007)46:4<436::AID-JCLP2270460411>3.0.CO;2-M	28	32	32	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1525-5050	1525-5069		EPILEPSY BEHAV	Epilepsy Behav.	DEC	2004	5	6					919	925		10.1016/j.yebeh.2004.08.007			7	Behavioral Sciences; Clinical Neurology; Psychiatry	Behavioral Sciences; Neurosciences & Neurology; Psychiatry	881NL	WOS:000225874100018	15582841				2021-06-18	
J	Gerber, DJ; Weintraub, AH; Cusick, CP; Ricci, PE; Whiteneck, GG				Gerber, DJ; Weintraub, AH; Cusick, CP; Ricci, PE; Whiteneck, GG			Magnetic resonance imaging of traumatic brain injury: relationship of T2 SE and T2*GE to clinical severity and outcome	BRAIN INJURY			English	Article							CLOSED-HEAD-INJURY; COMPUTED-TOMOGRAPHY; PRACTICAL SCALE; AXONAL INJURY; CT; COMA; MRI; REHABILITATION; CONSCIOUSNESS; HEMORRHAGE	Primary objectives: To evaluate (1) the sensitivity of magnetic resonance imaging (MRI) T2* weighted gradient echo (GE) vs T2 weighted spin echo (SE) technology for lesion detection in traumatic brain injury (TBI) and (2) the relationship of lesion patterns to acute clinical severity and I year post-injury outcome measures. Research design: Comparative analysis. Methods and procedures: Forty-three acute rehabilitation patients with TBI were imaged utilizing T2 SE and T2* GE techniques an average of 26 days post-injury. Acute clinical severity measures, including Glasgow Coma Scale (GCS), time to follow commands (TFC) and post-traumatic amnesia (PTA) were abstracted from medical records. One-year post-injury outcome measures including Glasgow Outcome Scale (GOS), Disability Rating Scale (DRS) and the Craig Handicap Assessment and Reporting Technique-Short Form (CHART-SF) were collected as part of a comprehensive annual follow-up. Main outcomes and results: In comparison to T2 SE, T2* GE more frequently detected lesions in each of the cortical (p < 0.0001), white matter (p < 0.001), central grey (p < 0.001) and brainstem (p < 0.01) regions and in each of the frontal (p < 0.0001), temporal (p < 0.0001), parietal (p <.0.001) and occipital (p < 0.0001) lobes. With regards to acute clinical severity measures, T2* GE findings were the best predictors of GCS and the only significant predictors of PTA, while T2 SE findings were better predictors of TFC. For I year post-injury outcome measures, multivariate regression models utilizing T2 SE and T2* GE findings in combination were the best predictors of DRS and GOS and T2 SE findings alone were the best predictors of CHART-SF. Conclusions: This study demonstrates the enhanced sensitivity of T2* GE for detecting haemorrhagic lesions associated with TBI and Supports a complimentary role for both T2 SE and T2* GE weighted imaging in characterizing injury severity and predicting longer-term outcomes.	Craig Hosp, Englewood, CO 80113 USA; Swedish Med Ctr, Englewood, CO 80110 USA	Gerber, DJ (corresponding author), Craig Hosp, 3425 S Clarkson St, Englewood, CO 80113 USA.	dgerber@craighospital.org					ATLAS SW, 1988, RADIOLOGY, V168, P803, DOI 10.1148/radiology.168.3.3406410; COURVILLE CB, 1945, PATHOLOGY CENTRAL NE; Damasio H., 1989, LESION ANAL NEUROPSY; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; EDELMAN RR, 1986, AM J NEURORADIOL, V7, P751; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1994, RADIOLOGY, V19, P1; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661, DOI 10.1001/archneur.1994.00540190041013; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1988, J NEUROSURG, V69, P861, DOI 10.3171/jns.1988.69.6.0861; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MacNamara AF, 1995, INJURY, V26, P667, DOI 10.1016/0020-1383(95)00147-6; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCLEAN A, 1993, ARCH PHYS MED REHAB, V74, P1041, DOI 10.1016/0003-9993(93)90059-J; Mitchener A, 1997, J NEUROL NEUROSUR PS, V62, P633, DOI 10.1136/jnnp.62.6.633; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SALCMAN M, 1992, NEUROCHIRURGIE, V38, P329; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; VANWOERKOM TCAM, 1977, LANCET, V1, P812; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391; Yanagawa Y, 2000, J TRAUMA, V49, P272, DOI 10.1097/00005373-200008000-00013; ZAFONTE RD, 1996, NEUROIMAGING TRAUMAT, P251; 1996, J HEAD TRAUMA REHABI, V11, P1	32	32	33	0	0	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	NOV	2004	18	11					1083	1097		10.1080/02699050410001672341			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	863JW	WOS:000224558900002	15545206				2021-06-18	
J	Krimchansky, BZ; Keren, O; Sazbon, L; Groswasser, Z				Krimchansky, BZ; Keren, O; Sazbon, L; Groswasser, Z			Differential time and related appearance of signs, indicating improvement in the state of consciousness in vegetative state traumatic brain injury (VS-TBI) patients after initiation of dopamine treatment	BRAIN INJURY			English	Article							CONNECTIVITY; AMANTADINE; RECOVERY; SCAN	Objective: The goal of the study was to look for the response of treatment with increasing doses of dopaminergic medication on the recovery of vegetative state patients post-TBI. Design: A prospective study of eight patients aged 25-50 years in vegetative state (VS) of mean duration of 104 days following traumatic brain injury (TBI) was performed by investigating changes of their state of consciousness while they were treated with levodopa/carbidopa. Results: Initial improvement was observed in all patients within a mean of 13 days after onset of treatment. Seven patients recovered consciousness after a mean time of 31 days of treatment. The remaining patient showed only slight improvement to minimally conscious state. The sequence of symptoms leading to recovery was the same in all patients; the first to appear was moving a limb on a request, which appeared at a mean time of 13 days. Gradual increase of dose leads to the appearance of better-organized responses like reacting to more than one command, than opening the mouth and appearance of a reciprocal contact. The orgy side effect was visual hallucinations in one patient, which disappeared after decreasing the dosage. Conclusions: Clinical awareness to the structured order of responses and to the effect of dosage can help clinicians in early assessment of response to dopaminergic treatment in VS patients.	Loewenstein Hosp & Rehabil Ctr, Rehabil Intens Care Unit Comatose Patients, IL-43100 Raanana, Israel; Loewenstein Hosp & Rehabil Ctr, Dept TBI Rehabil, IL-43100 Raanana, Israel; Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel	Groswasser, Z (corresponding author), Loewenstein Hosp & Rehabil Ctr, Rehabil Intens Care Unit Comatose Patients, 278 Achuza St,POB 3, IL-43100 Raanana, Israel.	zeevgros@post.tau.ac.il					Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Forsyth R., 2003, COCHRANE DB SYST REV, V1; GOMORI JM, 1984, NEURORADIOLOGY, V26, P21, DOI 10.1007/BF00328197; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; Lal S, 1988, Brain Inj, V2, P225, DOI 10.3109/02699058809150946; Laureys S, 1999, NEUROIMAGE, V9, P377, DOI 10.1006/nimg.1998.0414; Laureys S, 2000, LANCET, V355, P1790, DOI 10.1016/S0140-6736(00)02271-6; Meythaler JM, 2002, J HEAD TRAUMA REHAB, V17, P300, DOI 10.1097/00001199-200208000-00004; NOLTE J, 1998, HUMAN BRAIN INTRO IT, P171; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; Rall JM, 2003, NEUROPATH APPL NEURO, V29, P118, DOI 10.1046/j.1365-2990.2003.00439.x; Rapp B, 2002, NEUROREPORT, V13, P207, DOI 10.1097/00001756-200202110-00007; ReiderGroswasser I, 1997, BRAIN INJURY, V11, P865, DOI 10.1080/026990597122936; STAFFORD JL, 1988, ARCH NEUROL-CHICAGO, V45, P409, DOI 10.1001/archneur.1988.00520280055016; VANWOERKOM TCAM, 1982, EUR NEUROL, V21, P227, DOI 10.1159/000115485; Zafonte RD, 1998, BRAIN INJURY, V12, P617	16	32	36	0	5	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV	2004	18	11					1099	1105		10.1080/02699050310001646206			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	863JW	WOS:000224558900003	15545207				2021-06-18	
J	Dunlop, SA; Tee, LBG; Stirling, RV; Taylor, AL; Runham, PB; Barber, AB; Kuchling, G; Rodger, J; Roberts, JD; Harvey, AR; Beazley, LD				Dunlop, SA; Tee, LBG; Stirling, RV; Taylor, AL; Runham, PB; Barber, AB; Kuchling, G; Rodger, J; Roberts, JD; Harvey, AR; Beazley, LD			Failure to restore vision after optic nerve regeneration in reptiles: Interspecies variation in response to axotomy	JOURNAL OF COMPARATIVE NEUROLOGY			English	Article						visual system; evolution; neurotrauma; repair	RETINAL GANGLION-CELLS; LIZARD GALLOTIA-GALLOTI; RETINOTECTAL PROJECTION; AXONAL REGENERATION; SUPERIOR COLLICULUS; WALLERIAN DEGENERATION; SUBSTRATE PROPERTIES; NEURITE GROWTH; TIME-COURSE; CNS MYELIN	Optic nerve regeneration within the reptiles is variable. In a snake, Viper aspis, and the lizard Gallotia galloti, regeneration is slow, although some retinal ganglion cell (RGC) axons eventually reach the visual centers (Rio et al. [1989] Brain Res 479:151-156; Lang et al. [1998] Glia 23:61-74). By contrast, in a lizard, Ctenophorus ornatus, numerous RGC axons regenerate rapidly to the visual centers, but unless animals are stimulated visually, the regenerated projection lacks topography and animals remain blind via the experimental eye (Beazley et al. [2003] J. Neurotrauma 20:1263-1269). V. aspis, G. galloti, and C. ornatus belong respectively to the Serpentes, Lacertidae, and Agamidae within the Eureptilia, the major modem group of living reptiles comprising the Squamata (snakes, lizards, and geckos) and the Crocodyllia. Here we have extended the findings on Eureptilia to include two geckos (Gekkonidae), Cehyra variegata and Nephrurus stellatus. We also examined a turtle, Chelodina oblonga, the Testudines being the sole surviving representatives of the Parareptilia, the more ancient reptilian group. In all three species, visually elicited behavioral responses were absent throughout regeneration, a result supported electrophysiologically; axonal tracing revealed that only a small proportion of RGC axons crossed the lesion and none entered the contralateral optic tract. RGC axons failed to reach the chiasm in C. oblonga, and in G. variegata, and N. stellatus RGC axons entered the opposite optic nerve; a limited ipsilateral projection was seen in G. variegata. Our results support a heterogeneous response to axotomy within the reptiles, each, of which is nevertheless dysfunctional. (C) 2004 Wiley-Liss, Inc.	Univ Western Australia, Sch Anim Biol, Crawley, WA 6009, Australia; Univ Western Australia, Western Australian Inst Med Res, Crawley, WA 6009, Australia; Univ Western Australia, Sch Anat & Human Biol, Crawley, WA 6009, Australia	Dunlop, SA (corresponding author), Univ Western Australia, Sch Anim Biol, Nedlands, WA 6009, Australia.	sarah@cyllene.uwa.edu.au	Dunlop, Sarah A/G-9357-2013; Harvey, Alan/A-4911-2008; Rodger, Jennifer/H-5735-2014	Rodger, Jennifer/0000-0003-3413-4229; , Alan/0000-0002-2590-831X; Dunlop, Sarah/0000-0002-1306-3962			ALLCUTT D, 1984, DEV BRAIN RES, V16, P219, DOI 10.1016/0165-3806(84)90027-0; Asher R A, 2001, Prog Brain Res, V132, P611; Barbieri AM, 2002, DEVELOPMENT, V129, P805; Beaver RS, 2001, VISION RES, V41, P1765, DOI 10.1016/S0042-6989(01)00053-0; Beazley LD, 1998, VISION RES, V38, P789, DOI 10.1016/S0042-6989(97)00212-5; Beazley LD, 2003, J NEUROTRAUM, V20, P1263, DOI 10.1089/089771503770802925; Beazley LD, 1997, J COMP NEUROL, V377, P105, DOI 10.1002/(SICI)1096-9861(19970106)377:1<105::AID-CNE10>3.0.CO;2-P; BEAZLEY LD, 1986, VISION RES, V26, P543, DOI 10.1016/0042-6989(86)90003-9; BEAZLEY LD, 2000, AXONAL REGENERATION; Beazley LD, 2000, DEGENERATION REGENER, P119; BOHN RC, 1981, J COMP NEUROL, V196, P621, DOI 10.1002/cne.901960408; BUNT SM, 1981, BRAIN RES, V211, P399, DOI 10.1016/0006-8993(81)90712-5; Campbell G, 1999, NEUROREPORT, V10, P3955, DOI 10.1097/00001756-199912160-00042; CARONI P, 1988, NEURON, V1, P85, DOI 10.1016/0896-6273(88)90212-7; CARONI P, 1988, J CELL BIOL, V106, P1281, DOI 10.1083/jcb.106.4.1281; Chierzi S, 2001, RESTOR NEUROL NEUROS, V19, P109; COGGER H, 1992, REPTILES AMPHIBIANS, P192; COOK RD, 1987, ACTA NEUROPATHOL, V72, P261, DOI 10.1007/BF00691099; Cui Q, 2000, NEUROREPORT, V11, P3999, DOI 10.1097/00001756-200012180-00019; Cui Q, 1999, INVEST OPHTH VIS SCI, V40, P760; Dunlop SA, 2003, EXP NEUROL, V184, P805, DOI 10.1016/j.expneurol.2003.08.013; Dunlop SA, 2003, J COMP NEUROL, V465, P319, DOI 10.1002/cne.10782; Dunlop SA, 2002, J COMP NEUROL, V453, P71, DOI 10.1002/cne.10394; Dunlop SA, 1997, BEHAV BRAIN RES, V84, P195, DOI 10.1016/S0166-4328(96)00150-7; Dunlop SA, 2002, J COMP NEUROL, V446, P276, DOI 10.1002/cne.10213; Dunlop SA, 2000, J COMP NEUROL, V416, P188; FAN TX, 1995, J NEUROPHYSIOL, V73, P2507; Fischer D, 2001, EXP NEUROL, V172, P257, DOI 10.1006/exnr.2001.7822; FITE KV, 1985, BRAIN BEHAV EVOLUT, V26, P71, DOI 10.1159/000118769; FITE KV, 1973, BEHAV BIOL, V9, P707, DOI 10.1016/S0091-6773(73)80131-2; FUJISAWA H, 1981, BRAIN RES, V206, P27, DOI 10.1016/0006-8993(81)90098-6; Fukuda Y, 1998, VISION RES, V38, P1545, DOI 10.1016/S0042-6989(98)00005-4; GODEMENT P, 1987, DEVELOPMENT, V101, P697; GRAFSTEIN B, 1982, EXP NEUROL, V76, P318, DOI 10.1016/0014-4886(82)90212-6; GROBSTEIN P, 1980, J COMP NEUROL, V190, P175, DOI 10.1002/cne.901900112; HARTLIEB E, 1989, J COMP NEUROL, V284, P148, DOI 10.1002/cne.902840111; HARVEY AR, 1992, NEUROREPORT, V3, P239, DOI 10.1097/00001756-199203000-00005; HARVEY AR, 1992, J COMP NEUROL, V325, P83, DOI 10.1002/cne.903250108; HEDGES SB, 1990, MOL BIOL EVOL, V7, P607; Herrera E, 2003, CELL, V114, P545, DOI 10.1016/S0092-8674(03)00684-6; HOLDER N, 1988, TRENDS NEUROSCI, V11, P94, DOI 10.1016/0166-2236(88)90151-8; HUMPHREY MF, 1992, EXP BRAIN RES, V90, P630; HUMPHREY MF, 1982, BRAIN RES, V239, P595, DOI 10.1016/0006-8993(82)90534-0; HUMPHREY MF, 1985, J COMP NEUROL, V236, P382, DOI 10.1002/cne.902360307; HUTCHINSON MN, 1993, FAUNA AUSTR A, V2, P210; Kardong KV, 2002, VERTEBRATES COMP ANA; KEIRSTEAD SA, 1985, BRAIN RES, V359, P402, DOI 10.1016/0006-8993(85)91461-1; KIERNAN JA, 1985, J ANAT, V141, P139; Kolls BJ, 2000, J NEUROSCI, V20, P338, DOI 10.1523/JNEUROSCI.20-01-00338.2000; KRUGER L, 1969, AM J ANAT, V125, P247, DOI 10.1002/aja.1001250302; Lang DM, 1998, GLIA, V23, P61, DOI 10.1002/(SICI)1098-1136(199805)23:1<61::AID-GLIA6>3.0.CO;2-7; Lang DM, 2002, J NEUROBIOL, V52, P322, DOI 10.1002/neu.10099; Lang DM, 1996, GLIA, V18, P92, DOI 10.1002/(SICI)1098-1136(199610)18:2<92::AID-GLIA2>3.0.CO;2-E; LANG DM, 1995, J NEUROSCI, V15, P99; LAZAR G, 1972, BRAIN BEHAV EVOLUT, V5, P443, DOI 10.1159/000123761; LAZAR G, 1983, ACTA BIOL HUNG, V34, P371; Logan A, 2002, ADV EXP MED BIOL, V513, P115; Lu Q, 2003, INVEST OPHTH VIS SCI, V44, P5342, DOI 10.1167/iovs.03-0444; LUDWIN SK, 1990, ACTA NEUROPATHOL, V80, P266, DOI 10.1007/BF00294644; MEYER RL, 1985, J COMP NEUROL, V239, P27, DOI 10.1002/cne.902390103; MISANTONE LJ, 1984, J NEUROCYTOL, V13, P449, DOI 10.1007/BF01148334; Miyoshi T, 1999, EXP BRAIN RES, V124, P383, DOI 10.1007/s002210050635; MUCHNICK N, 1980, EXP NEUROL, V68, P205, DOI 10.1016/0014-4886(80)90079-5; MULLER M, 1988, EXP BRAIN RES, V71, P611, DOI 10.1007/BF00248754; MURRAY M, 1982, J COMP NEUROL, V209, P352, DOI 10.1002/cne.902090405; MURRAY M, 1982, J COMP NEUROL, V209, P374, DOI 10.1002/cne.902090407; PARE M, 1982, BRAIN RES, V243, P360, DOI 10.1016/0006-8993(82)90261-X; Quan MZ, 1999, INVEST OPHTH VIS SCI, V40, P2360; Rasband K, 2003, NEURON, V39, P885, DOI 10.1016/S0896-6273(03)00563-4; RIO JP, 1989, BRAIN RES, V479, P151, DOI 10.1016/0006-8993(89)91345-0; Rodger J, 1998, VISUAL NEUROSCI, V15, P677, DOI 10.1017/S095252389815407X; RusselakisCarneiro M, 1996, J NEUROCYTOL, V25, P393, DOI 10.1007/BF02284810; SASAKI H, 1993, VISION RES, V33, P877, DOI 10.1016/0042-6989(93)90070-D; Sauve Y, 2001, J NEUROSCI, V21, P951; SCALIA F, 1985, BRAIN RES, V344, P267, DOI 10.1016/0006-8993(85)90804-2; SCHMIDT JT, 1983, BRAIN RES, V269, P29, DOI 10.1016/0006-8993(83)90959-9; SCHMIDT JT, 1983, BRAIN RES, V269, P15, DOI 10.1016/0006-8993(83)90958-7; SIVRON T, 1994, J COMP NEUROL, V343, P237, DOI 10.1002/cne.903430205; SPRINGER AD, 1980, BRAIN RES, V199, P214, DOI 10.1016/0006-8993(80)90242-5; STELZNER DJ, 1986, J COMP NEUROL, V245, P83, DOI 10.1002/cne.902450107; STELZNER DJ, 1981, J COMP NEUROL, V201, P299, DOI 10.1002/cne.902010212; Stichel CC, 1999, RESTOR NEUROL NEUROS, V15, P1; Stirling RV, 1998, J NEUROSCI METH, V81, P85, DOI 10.1016/S0165-0270(98)00020-X; Stirling RV, 1999, VISUAL NEUROSCI, V16, P681, DOI 10.1017/S0952523899164083; TAYLOR JSH, 1989, EUR J NEUROSCI, V1, P626, DOI 10.1111/j.1460-9568.1989.tb00368.x; TENNANT M, 1993, VISUAL NEUROSCI, V10, P681, DOI 10.1017/S095252380000537X; Thanos S, 1997, EXP BRAIN RES, V114, P483, DOI 10.1007/PL00005657; THANOS S, 1992, EUR J NEUROSCI, V4, P691, DOI 10.1111/j.1460-9568.1992.tb00178.x; VANCREVEL H, 1963, J ANAT, V97, P451; VIDALSANZ M, 1987, J NEUROSCI, V7, P2894; WANNER M, 1995, J NEUROSCI, V15, P7500; YCAJAL SR, 1928, DEGENERATION REGENER; Yin YQ, 2003, J NEUROSCI, V23, P2284	93	32	33	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0021-9967	1096-9861		J COMP NEUROL	J. Comp. Neurol.	OCT 18	2004	478	3					292	305		10.1002/cne.20299			14	Neurosciences; Zoology	Neurosciences & Neurology; Zoology	859HX	WOS:000224255100007	15368531				2021-06-18	
J	Bittigau, P; Sifringer, M; Felderhoff-Mueser, U; Ikonomidou, C				Bittigau, P; Sifringer, M; Felderhoff-Mueser, U; Ikonomidou, C			Apoptotic neurodegeneration in the context of traumatic injury to the developing brain	EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY			English	Article; Proceedings Paper	4th International Congress of Pathophysiology	JUN 29-JUL 05, 2002	BUDAPEST, HUNGARY			apoptosis; excitotoxicity; neuroprotection; immature brain; caspases	DEVELOPING RAT-BRAIN; METHYL-D-ASPARTATE; CELL-DEATH; SIGNALING COMPLEX; NEURONAL DEATH; IMMATURE RAT; HEAD TRAUMA; MODEL; DAMAGE; NEUROTOXICITY	Head trauma is the leading cause of death and disability in the pediatric population. Some recent studies on neuropathological and biochemical features of traumatic injury to the developing brain revealed interesting aspects and potential targets for future research. Trauma triggers both excitotoxic and apoptotic neurodegeneration in the developing rat brain. Apoptotic neurodegeneration occurs in a delayed fashion over several days and contributes in an age-dependent fashion to neuropathologic outcome following head trauma, with the immature brain being exceedingly sensitive. Biochemical studies indicate that both the extrinsic and the intrinsic apoptotic pathways are involved in pathogenesis of apoptotic cell death following trauma in the developing brain and that caspase inhibition ameliorates apoptotic neurodegeneration in an infant head trauma model. Given the major contribution of apoptotic neurodegeneration to neuropathologic outcome following trauma to the developing brain, interference with apoptotic pathways may comprise a potential therapeutic target in pediatric traumatic brain injury. (C) 2004 Elsevier GmbH. All rights reserved.	Humboldt Univ, Childrens Hosp, Dept Pediat Neurol, Charite, D-13353 Berlin, Germany	Ikonomidou, C (corresponding author), Humboldt Univ, Childrens Hosp, Dept Pediat Neurol, Charite, Virchow Campus,Augustenburger Pl 1, D-13353 Berlin, Germany.	hrissanthi.ikonomidou@charite.de	Felderhoff-Muser, Ursula/AAU-9682-2020				Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Adelson PD, 1998, J CHILD NEUROL, V13, P2, DOI 10.1177/088307389801300102; Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Beer R, 2000, J CEREBR BLOOD F MET, V20, P669, DOI 10.1097/00004647-200004000-00004; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Cheng Y, 1998, J CLIN INVEST, V101, P1992, DOI 10.1172/JCI2169; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; DEOLMOS JS, 1971, BRAIN RES, V33, P523, DOI 10.1016/0006-8993(71)90130-2; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Endres H, 1998, J CEREBR BLOOD F MET, V18, P238, DOI 10.1097/00004647-199803000-00002; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Felderhoff-Mueser U, 2002, NEUROBIOL DIS, V11, P231, DOI 10.1006/nbdi.2002.0521; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Ferrer I, 1996, EUR J NEUROSCI, V8, P1286, DOI 10.1111/j.1460-9568.1996.tb01297.x; Fink K, 1998, J CEREBR BLOOD F MET, V18, P1071, DOI 10.1097/00004647-199810000-00003; Hara H, 1997, P NATL ACAD SCI USA, V94, P2007, DOI 10.1073/pnas.94.5.2007; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Himi T, 1998, EUR J NEUROSCI, V10, P777, DOI 10.1046/j.1460-9568.1998.00073.x; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; Ikonomidou C, 1996, PEDIATR RES, V39, P1020, DOI 10.1203/00006450-199606000-00015; Ishimaru MJ, 1999, J COMP NEUROL, V408, P461; KOSKINIEMI M, 1995, ARCH PEDIAT ADOL MED, V149, P249, DOI 10.1001/archpedi.1995.02170150029004; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MCDONALD JW, 1988, BRAIN RES, V459, P200, DOI 10.1016/0006-8993(88)90306-X; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakashima K, 1999, J NEUROTRAUM, V16, P143, DOI 10.1089/neu.1999.16.143; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Pohl D, 1999, P NATL ACAD SCI USA, V96, P2508, DOI 10.1073/pnas.96.5.2508; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Prins ML, 1996, DEV BRAIN RES, V95, P272, DOI 10.1016/0165-3806(96)00098-3; Rich T, 2000, NATURE, V407, P777, DOI 10.1038/35037717; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	43	32	32	0	6	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0940-2993	1618-1433		EXP TOXICOL PATHOL	Exp. Toxicol. Pathol.	OCT	2004	56	1-2					83	89		10.1016/j.etp.2004.04.006			7	Pathology; Toxicology	Pathology; Toxicology	872QF	WOS:000225221900011	15581279				2021-06-18	
J	Oppermann, JD				Oppermann, JD			Interpreting the meaning individuals ascribe to returning to work after traumatic brain injury: a qualitative approach	BRAIN INJURY			English	Article							COMMUNITY INTEGRATION; OF-LIFE; EMPLOYMENT; REHABILITATION; PREDICTION; OUTCOMES; TBI	Objective: The purpose of this study was to describe, qualitatively, the meaning individuals ascribe to returning to work after traumatic injury to the brain. Design: A qualitative multiple-case study design was used for this study to allow for flexibility during data collection and to support naturalistic generalizations. Methods: A random sample of two participants was included in the study using snowball sampling. Semi-structured interviews and written documentation was used to collect data. Cross-case analysis was used to identify phenomenological themes. Results: While defining the meaning of work, thematic analysis revealed three themes: (a) experience of finding work after injury, (b) experience of maintaining work and (c) independence related to work. Conclusion: The several important points that were identified throughout semi-structured interviews were how individuals subjectively and objectively define work, important points about personal experiences finding and maintaining work and the societal value individuals relate to work. Important themes found in this study could be addressed by intermittent long-term interventions following traumatic brain injury (TBI).	Creighton Univ, Sch Med, Omaha, NE 68178 USA	Oppermann, JD (corresponding author), Creighton Univ, Sch Med, 2500 Calf Plaza, Omaha, NE 68178 USA.						Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Creswell J., 2003, RES DESIGN QUALITATI, V2nd edn; Creswell J.W., 2013, QUAL INQ; DePoy E., 1998, INTRO RES UNDERSTAND, V2nd ed.; DREW P, TURN YOUR GUIDE FEDE, pCH11; Fleming J, 1999, BRAIN INJURY, V13, P417; Hirsh A, 1996, J VOCAT REHABIL, V7, P217; Hoofien D, 2001, BRAIN INJURY, V15, P189; Johnstone B, 1999, J HEAD TRAUMA REHAB, V14, P220, DOI 10.1097/00001199-199906000-00003; Kowalske K, 2000, J HEAD TRAUMA REHAB, V15, P989, DOI 10.1097/00001199-200008000-00003; KREFTING L, 1991, AM J OCCUP THER, V45, P214, DOI 10.5014/ajot.45.3.214; Lincoln Y.S., 1985, NATURALISTIC INQUIRY, V75; Malec JF, 2000, ARCH PHYS MED REHAB, V81, P1007, DOI 10.1053/apmr.2000.6980; NAGELE DA, 1999, PHYS MED REHABILITAT, V13, P161; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; ROCCHIO C, 1998, FAMILY NEWS VIEWS MO, V5; Ruffolo CF, 1999, ARCH PHYS MED REHAB, V80, P392, DOI 10.1016/S0003-9993(99)90275-7; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; Sherer M, 1999, BRAIN INJURY, V13, P973; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; Stake R.E., 1995, ART CASE STUDY RES; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; Wolcott H. F., 1994, TRANSFORMING QUALITA; Yasuda S, 2001, AM J PHYS MED REHAB, V80, P852, DOI 10.1097/00002060-200111000-00011	27	32	32	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	SEP	2004	18	9					941	955		10.1080/02699050410001671919			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	831FG	WOS:000222178700009	15223746				2021-06-18	
J	Walker, W; Seel, R; Gibellato, M; Lew, H; Cornis-Pop, M; Jena, T; Silver, T				Walker, W; Seel, R; Gibellato, M; Lew, H; Cornis-Pop, M; Jena, T; Silver, T			The effects of Donepezil on traumatic brain injury acute rehabilitation outcomes	BRAIN INJURY			English	Article							FUNCTIONAL INDEPENDENCE MEASURE; PLACEBO-CONTROLLED TRIAL; ALZHEIMERS-DISEASE; DOUBLE-BLIND; HEAD-INJURY; MEMORY; DYSFUNCTION; HYPOTHESIS; IMPAIRMENT; COGNITION	Primary objective: To evaluate the effects of administering Donepezil during inpatient rehabilitation for individuals with TBI. Research design: Retrospective, age and injury severity matched, mixed between-within subjects analysis. Methods and procedures: Thirty-six patients with moderate-to-severe TBI admitted to acute rehabilitation within 90 days of injury. Main outcome measures included FIM cognitive total scores and rehabilitation lengths of stay. Intervention: Initiation of Donepezil administration beginning at 5 mg daily. Dose titration and continuation based on perceived clinical response. Main outcomes and results: No differences in cognitive improvement were observed between the Donepezil treatment group and the matched control group. Sub-set analyses suggested that administration of Donepezil early in the rehabilitation stay was significantly related to higher rates of cognitive improvement. Conclusions: Preliminary evidence suggests that Donepezil administration early in the rehabilitation stay may have advantageous treatment effects. A prospective, randomized, placebo-controlled clinical trial with standard timing, dosage and treatment duration is recommended to further evaluate treatment efficacy.	McGuire VAMC, DVBIC, Dept Phys Med & Rehabil 117, Richmond, VA 23249 USA; Vet Affairs Palo Alto Hlth Care Syst, Def & Vet Brain Injury Ctr, Palo Alto, CA USA	Seel, R (corresponding author), McGuire VAMC, DVBIC, Dept Phys Med & Rehabil 117, 1201 Broad Rock Blvd, Richmond, VA 23249 USA.	RONALD.SEEL@med.va.gov					Arciniegas D, 1999, BRAIN INJURY, V13, P1, DOI 10.1080/026990599121827; Blount PJ, 2002, J HEAD TRAUMA REHAB, V17, P314, DOI 10.1097/00001199-200208000-00005; CARDENAS DD, 1994, BRAIN INJURY, V8, P579, DOI 10.3109/02699059409151010; *CARF, 2002, STAND MAN INT GUID M; Cummings JL, 2000, AM J PSYCHIAT, V157, P4, DOI 10.1176/ajp.157.1.4; Cummings JL, 1996, NEUROLOGY, V47, P876, DOI 10.1212/WNL.47.4.876; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Dixon CE, 1997, BRAIN RES, V749, P127, DOI 10.1016/S0006-8993(96)01310-8; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; Hays WL, 1994, STATISTICS; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Levin H S, 1986, Cent Nerv Syst Trauma, V3, P333; LINACRE JM, 1994, ARCH PHYS MED REHAB, V75, P127; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; Masanic CA, 2001, ARCH PHYS MED REHAB, V82, P896, DOI 10.1053/apmr.2001.23833; McLean A Jr, 1987, Brain Inj, V1, P145, DOI 10.3109/02699058709034453; Murdoch I, 1998, J NEUROTRAUM, V15, P295, DOI 10.1089/neu.1998.15.295; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Rogers SL, 1998, ARCH INTERN MED, V158, P1021, DOI 10.1001/archinte.158.9.1021; Rogers SL, 1996, DEMENTIA, V7, P293, DOI 10.1159/000106895; Salazar AM, 2000, J HEAD TRAUMA REHAB, V15, P1081, DOI 10.1097/00001199-200010000-00002; SALAZAR AM, 1999, BRAIN INJ SOURCE, V3, P8; Tabachnick B.G., 1989, USING MULTIVARIATE S; Taverni JP, 1998, BRAIN INJURY, V12, P77; vanReekum R, 1997, CAN J PSYCHIAT, V42, pS35; Whelan F J, 2000, Ann Clin Psychiatry, V12, P131; Whitlock JA, 1999, J HEAD TRAUMA REHAB, V14, P424, DOI 10.1097/00001199-199908000-00010; Wirkowski E, 1991, J Neuropsychiatry Clin Neurosci, V3, P73	30	32	33	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	AUG	2004	18	8					739	750		10.1080/02699050310001646224			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	826AN	WOS:000221801300001	15204315				2021-06-18	
J	Grande, LA; Loeser, JD; Ozuna, J; Ashleigh, A; Samii, A				Grande, LA; Loeser, JD; Ozuna, J; Ashleigh, A; Samii, A			Complex regional pain syndrome as a stress response	PAIN			English	Article						complex regional pain syndrome; reflex sympathetic dystrophy; conversion disorder; post-traumatic stress disorder; encephalomalacia; traumatic brain injury	REFLEX SYMPATHETIC DYSTROPHY; DISORDER	A man in his 50's with a prior traumatic brain injury and multiple psychiatric disorders developed acute pain and swelling in his left leg distal to the mid shin. These symptoms arose during an exacerbation of his post-traumatic stress disorder (PTSD). Among his traumatic memories, he reported having witnessed the combat injury and death of a friend who had lost his left leg distal to the mid shin. A diagnosis of conversion disorder was technically excluded because the findings met criteria for Complex Regional Pain Syndrome (CRPS) type 1. Based on recent research into the neurobiology of CRPS, PTSD and conversion disorder, we propose a supraspinal mechanism which could explain how emotional stress can produce both symptoms and signs. (C) 2004 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.	Vet Affairs Puget Sound Hlth Care Syst, Dept Neurol, Seattle, WA 98108 USA; Vet Affairs Puget Sound Hlth Care Syst, Dept Psychiat, Seattle, WA 98108 USA; Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA	Samii, A (corresponding author), Vet Affairs Puget Sound Hlth Care Syst, Dept Neurol, Mailstop 127,1660 S Columbian Way, Seattle, WA 98108 USA.	asamii@u.washington.edu					Andreski P, 1998, PSYCHIAT RES, V79, P131, DOI 10.1016/S0165-1781(98)00026-2; Bajic D, 1999, J COMP NEUROL, V405, P359; BANDLER R, 1982, NEUROSCI LETT, V30, P183, DOI 10.1016/0304-3940(82)90294-4; Bandler R, 2000, BRAIN RES BULL, V53, P95, DOI 10.1016/S0361-9230(00)00313-0; Bantick SJ, 2002, BRAIN, V125, P310, DOI 10.1093/brain/awf022; Bremner JD, 1999, BIOL PSYCHIAT, V45, P806, DOI 10.1016/S0006-3223(98)00297-2; BREUHL S, 2001, PROGR PAIN RES MANAG, V22; Cameron JS, 1999, J AM SOC NEPHROL, V10, P413; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Drevets WC, 1998, COGNITION EMOTION, V12, P353, DOI 10.1080/026999398379646; Driessens M, 2002, Acta Orthop Belg, V68, P330; Drummond PD, 2001, LANCET, V358, P168, DOI 10.1016/S0140-6736(01)05400-9; Ettinger AB, 1999, EPILEPSIA, V40, P1292, DOI 10.1111/j.1528-1157.1999.tb00860.x; Geertzen JHB, 1998, CLIN J PAIN, V14, P143, DOI 10.1097/00002508-199806000-00009; GELLMAN H, 1992, PAIN, V51, P307, DOI 10.1016/0304-3959(92)90214-V; LEE GW, 1995, J HAND SURG-AM, V20A, P458, DOI 10.1016/S0363-5023(05)80107-8; Mailis-Gagnon A, 2003, NEUROLOGY, V60, P1501, DOI 10.1212/WNL.60.9.1501; Maleki J, 2000, PAIN, V88, P259, DOI 10.1016/S0304-3959(00)00332-8; Marshall JC, 1997, COGNITION, V64, pB1, DOI 10.1016/S0010-0277(97)00020-6; MELZAK R, 1999, PSYCYHOSOCIAL FACTOR; Merskey H, 1994, CLASSIFICATION CHRON; Monti DA, 1998, CLIN J PAIN, V14, P295, DOI 10.1097/00002508-199812000-00005; Ochoa JL, 1999, J NEUROL, V246, P875, DOI 10.1007/s004150050476; Petchkrua W, 2000, NEUROREHAB NEURAL RE, V14, P59, DOI 10.1177/154596830001400107; Sewards TV, 2002, BRAIN RES BULL, V59, P163, DOI 10.1016/S0361-9230(02)00864-X; Wasner G, 2003, SPINAL CORD, V41, P61, DOI 10.1038/sj.sc.3101404	26	32	33	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0304-3959	1872-6623		PAIN	Pain	JUL	2004	110	1-2					495	498		10.1016/j.pain.2004.03.032			4	Anesthesiology; Clinical Neurology; Neurosciences	Anesthesiology; Neurosciences & Neurology	845HL	WOS:000223232800059	15275803				2021-06-18	
J	DeKosky, ST; Taffe, KM; Abrahamson, EE; Dixon, CE; Kochanek, PM; Ikonomovic, MD				DeKosky, ST; Taffe, KM; Abrahamson, EE; Dixon, CE; Kochanek, PM; Ikonomovic, MD			Time course analysis of hippocampal nerve growth factor and antioxidant enzyme activity following lateral controlled cortical impact brain injury in the rat	JOURNAL OF NEUROTRAUMA			English	Article						catalase; free radical; glutathione peroxidase; hippocampus; nerve growth factor; reactive oxygen species; superoxide dismutase; traumatic brain injury	GLUTATHIONE-PEROXIDASE ACTIVITY; NGF RESTORES DECREASE; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; RADICAL GENERATION; CEREBRAL-ISCHEMIA; TEMPORAL PROFILES; OXIDATIVE DAMAGE; HEAD-INJURY; CATALASE	Gradual secondary injury processes, including the release of toxic reactive oxygen species, are important components of the pathogenesis of traumatic brain injury (TBI). The extent of oxidative stress is determined in part by the effectiveness of the antioxidant response, involving the enzymes glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD). Since nerve growth factor (NGF) may be involved in the initiation of antioxidant activity, we employed a controlled cortical impact injury model in rats to produce secondary hippocampal damage and determined the subsequent time course of changes in NGF production and GPx, CAT, and SOD activity in this brain region. Hippocampal NGF production showed a rapid increase with a biphasic response after TBI. NGF protein was increased at 6 h, plateaued at 12 h, declined by 7 days, and exhibited a second rise at 14 days after injury. Similar to NGF, hippocampal GPx activity also showed a biphasic response, increasing by 12 h, declining at 24 h, and exhibiting a second peak at 7 days. In contrast, increased CAT activity occured steadily from 1 day through 7 days after injury. SOD activity was decreased at 6 h after injury, and continued to decline through 14 days. The initial rise in NGF preceded that of CAT, and coincided with an increase in GPX and a drop in SOD activity. These data demonstrate a complex temporal spectrum of antioxidant enzyme activation following secondary brain injury in the hippocampus, and suggest a selective regulatory role for NGF in this response.	Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Brain Trauma Res Ctr, Pittsburgh, PA 15213 USA	DeKosky, ST (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol, 3471 5th Ave,Ste 811, Pittsburgh, PA 15213 USA.	DekoskyST@upmc.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; DeKosky, Steven/0000-0003-3743-2758	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS030318, P50NS030318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG005133] Funding Source: NIH RePORTER; NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG05133] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS07391, NS30318] Funding Source: Medline		AEBI H, 1984, METHOD ENZYMOL, V105, P121; ASHTON D, 1989, BRAIN RES, V487, P368, DOI 10.1016/0006-8993(89)90842-1; Awasthi D, 1997, SURG NEUROL, V47, P575, DOI 10.1016/S0090-3019(96)00461-2; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; BENZI G, 1995, NEUROBIOL AGING, V16, P661, DOI 10.1016/0197-4580(95)00066-N; BLUM J, 1985, ARCH BIOCHEM BIOPHYS, V240, P500, DOI 10.1016/0003-9861(85)90056-6; BRAY RC, 1974, BIOCHEM J, V139, P43, DOI 10.1042/bj1390043; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; CHAN PH, 1992, J NEUROTRAUM, V9, pS417; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; CRISTIANO F, 1995, MECH AGEING DEV, V80, P93, DOI 10.1016/0047-6374(94)01561-Y; DEKOSKY ST, 1994, EXP NEUROL, V130, P173, DOI 10.1006/exnr.1994.1196; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; FRIM DM, 1994, EXP NEUROL, V128, P172, DOI 10.1006/exnr.1994.1125; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Goss JR, 1997, EXP NEUROL, V146, P291, DOI 10.1006/exnr.1997.6515; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Inci S, 1998, NEUROSURGERY, V43, P330, DOI 10.1097/00006123-199808000-00095; Islekel S, 1999, RES EXP MED, V199, P167, DOI 10.1007/s004330050121; JACKSON GR, 1990, J NEUROSCI RES, V25, P360, DOI 10.1002/jnr.490250313; JENNER P, 1992, ANN NEUROL, V32, pS82, DOI 10.1002/ana.410320714; Jorgensen OS, 1997, EXP NEUROL, V144, P326, DOI 10.1006/exnr.1996.6372; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KIM YS, 1991, J NEUROSCI RES, V29, P100, DOI 10.1002/jnr.490290111; KITAGAWA K, 1990, NEUROSCIENCE, V35, P551, DOI 10.1016/0306-4522(90)90328-2; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; MATSUYAMA T, 1993, J CEREBR BLOOD F MET, V13, P135, DOI 10.1038/jcbfm.1993.16; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; MATTSON MP, 1995, J NEUROCHEM, V65, P1740; Mayo JC, 2003, FREE RADICAL RES, V37, P543, DOI 10.1080/1071576031000083206; MICHOWIZ SD, 1990, STROKE, V21, P1613, DOI 10.1161/01.STR.21.11.1613; Namba K, 2001, J NEUROSURG ANESTH, V13, P131, DOI 10.1097/00008506-200104000-00010; NISTICO G, 1991, NEUROSCI LETT, V130, P117, DOI 10.1016/0304-3940(91)90241-K; NISTICO G, 1992, FREE RADICAL BIO MED, V12, P177, DOI 10.1016/0891-5849(92)90024-B; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PAN ZH, 1993, J NEUROCHEM, V61, P1713, DOI 10.1111/j.1471-4159.1993.tb09808.x; Paolin A, 2002, NEUROSURGERY, V51, P949, DOI 10.1227/01.NEU.0000027881.33381.3F; PIGEOLET E, 1990, MECH AGEING DEV, V51, P283, DOI 10.1016/0047-6374(90)90078-T; POSMANTUR R, 1994, J NEUROTRAUM, V11, P533, DOI 10.1089/neu.1994.11.533; Povlishock J T, 1992, Hum Cell, V5, P345; POVLISHOCK JT, 1995, BRAIN PATHOL, V5, P415, DOI 10.1111/j.1750-3639.1995.tb00620.x; RICEEVANS C, 1993, PROG LIPID RES, V32, P71, DOI 10.1016/0163-7827(93)90006-I; Salvemini D, 2003, CRIT CARE MED, V31, pS29, DOI 10.1097/00003246-200301001-00005; Sampath D, 1997, NEUROCHEM RES, V22, P351, DOI 10.1023/A:1027387105882; SAMPATH D, 1994, J NEUROCHEM, V62, P2476; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Takeuchi A, 2000, J NEUROBIOL, V45, P39, DOI 10.1002/1097-4695(200010)45:1<39::AID-NEU4>3.0.CO;2-A; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; YANG K, 1995, J NEUROSCI RES, V42, P571, DOI 10.1002/jnr.490420415; Yunoki M, 1997, J NEUROTRAUM, V14, P739, DOI 10.1089/neu.1997.14.739	50	32	32	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2004	21	5					491	500		10.1089/089771504774129838			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821LK	WOS:000221461900001	15165358				2021-06-18	
J	Breed, ST; Flanagan, SR; Watson, KR				Breed, ST; Flanagan, SR; Watson, KR			The relationship between age and the self-report of health symptoms in persons with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	State of the Science Conference	APR, 2002	Geroge Washington Univ, Washington, DC	Rehabilitat Res & Training Ctr, NIDRR	Geroge Washington Univ	age of onset; brain injuries; health status; rehabilitation	HEAD-INJURY; CONSEQUENCES; INDIVIDUALS; COMMUNITY	Objective: To examine the impact of age on health problems related to traumatic brain injury (TBI). Design: Case-control study using a survey instrument. Setting: Outpatient setting of a large urban tertiary care hospital. Participants: Young and old community dwellers with histories of TBI and control subjects matched for age. Intervention: Structured interview using the Living Life After TBI assessment tool. Main Outcome Measure: Symptom reporting on 52 potential health problems. Results: Individuals with TBI reported significantly more overall health problems than those without TBI. Younger subjects with TBI reported more problems than their nondisabled, age-matched peers with their patterns of sleep as well as with their metabolic/endocrine, neurologic, and musculoskeletal systems. Conclusions: Older people with TBI were more likely than nondisabled, age-matched peers to report problems with their metabolic/endocrine and neurologic systems. Younger people with TBI were more likely than older people with TBI to report difficulty falling asleep.	Mt Sinai Sch Med, Dept Rehabil Med, New York, NY 10029 USA	Breed, ST (corresponding author), Mt Sinai Sch Med, Dept Rehabil Med, 1 Gustave Levy Pl, New York, NY 10029 USA.	Sabrina.Breed@msnyuhealth.org		Flanagan, Steven/0000-0001-9005-5897			AMACHER AL, 1987, NEUROSURGERY, V20, P954; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Brown M, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199808000-00002; CHAMPION HR, 1989, AM J PUBLIC HEALTH, V79, P1278, DOI 10.2105/AJPH.79.9.1278; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; FIELDS RB, 1994, TXB GERIATRIC NEUROP, P479; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; GOODMAN H, 1992, PHYS MED REH CLIN N, V3, P441; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; HOWARD MA, 1989, J NEUROSURG, V71, P858, DOI 10.3171/jns.1989.71.6.0858; Lehmkuhl D, 1988, TIRR SYMPTOM CHECKLI; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; *MED COLL VIRG DEP, TBI SYMPT CHECKL; *MED OUTC TRUST, 1992, MED OUTC TRUST SF 36; *MOUNT SIN SCH MED, 1998, BRAIN INJ SCREEN QUE; *MOUNT SIN SCH MED, 1995, QUAL LIF INT HLTH IN; *MOUNT SIN SCH MED, 1998, LIV LIF TBI LLATBI; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; PENTLAND B, 1986, AGE AGEING, V15, P193, DOI 10.1093/ageing/15.4.193; Picard M., 1991, HELPS; Ross A M, 1992, J Neurosci Nurs, V24, P88; ROY CW, 1986, INJURY, V17, P220, DOI 10.1016/0020-1383(86)90222-6; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; THURMAN DJ, 1999, J HEAD TRAUMA REHAB, V46, P8; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	25	32	32	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	APR	2004	85	4		2			S61	S67		10.1016/j.apmr.2003.08.115			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	812FL	WOS:000220825300008	15083423				2021-06-18	
J	Shanmuganathan, K; Gullapalli, RP; Mirvis, SE; Roys, S; Murthy, P				Shanmuganathan, K; Gullapalli, RP; Mirvis, SE; Roys, S; Murthy, P			Whole-brain apparent diffusion coefficient in traumatic brain injury: Correlation with Glasgow coma scale score	AMERICAN JOURNAL OF NEURORADIOLOGY			English	Article							WEIGHTED MR; AXONAL INJURY; ACUTE STROKE; HEAD-INJURY; EDEMA	BACKGROUND AND PURPOSE: Patients with traumatic brain injury (TBI) and low Glasgow coma scale (GCS) scores may have severe injury associated with cellular disruption that can be studied with whole-brain apparent diffusion coefficient (ADC) histograms. We retrospectively studied this hypothesis and correlated ADC with GCS. METHODS: Twenty-one patients (37.81 +/- 41.3 years) with TBI were enrolled: Group A had normal MR imaging findings but low GCS scores (n = 6). Group B had brain stem injury with low GCS scores (n = 6). Group C had cortical lesions with normal GCS scores (n = 5), and group D had cortical lesions with low GCS scores (n = 4). Eleven control subjects were enrolled (32.7 +/- 19.2 years). Whole-brain ADC maps and histograms were generated and normalized for each subject. Mean and peak ADCs were determined. A one-sided t test was performed for each parameter. Average GCS scores and corresponding peak and mean ADCs were correlated. RESULTS: Peak histogram values significantly differed between controls and groups A, B, and D (P < .0019, P < .00129, and P < .0148, respectively). In groups A and D, values were significantly skewed compared with control values. Mean ADC was significantly different between the control ADC and group A (P < .013) but not group C. In each group, peak ADC and GCS score were strongly correlated (R-2 = 0.67). CONCLUSION. Whole-brain peak ADCs and GCS scores are significantly correlated in patients with TBI. Although conventional MR images were normal, ADC independently indicated TBI and better represents the degree of neurologic dysfunction.	Univ Maryland, Ctr Med, Dept Diagnost Radiol, Baltimore, MD 21201 USA; Univ Maryland, Ctr Med, Maryland Shock Trauma Ctr, Baltimore, MD 21201 USA	Shanmuganathan, K (corresponding author), Univ Maryland, Ctr Med, Dept Radiol, 22 S Greene St, Baltimore, MD 21201 USA.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Alsop DC, 1996, J NEUROTRAUM, V13, P515, DOI 10.1089/neu.1996.13.515; Assaf Y, 1997, MAGN RESON IMAGING, V15, P77, DOI 10.1016/S0730-725X(96)00246-9; Bartnik BL, 2001, BRAIN RES, V915, P133, DOI 10.1016/S0006-8993(01)02805-0; Carhuapoma JR, 2002, AM J NEURORADIOL, V23, P1322; CHIEN D, 1992, AM J NEURORADIOL, V13, P1097; ENGELTER ST, 2000, AM J ROENTGENOL, V175, P2; FISHER M, 1995, SURG NEUROL, V43, P606, DOI 10.1016/0090-3019(95)00015-1; GEAN DA, 1994, IMAGING HEAD TRAUMA, P1; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Hergan K, 2002, EUR RADIOL, V12, P2536, DOI 10.1007/s00330-002-1333-2; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; JENNETT B, 1976, LANCET, V1, P1031; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; MOSELEY ME, 1990, AM J NEURORADIOL, V11, P423; Nakahara M, 2001, ACTA RADIOL, V42, P365, DOI 10.1034/j.1600-0455.2001.420404.x; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Sunshine JL, 1999, RADIOLOGY, V212, P325, DOI 10.1148/radiology.212.2.r99au52325; TEASDALE G, 1974, LANCET, V2, P81; Vorisek I, 2002, MAGNET RESON MED, V48, P994, DOI 10.1002/mrm.10305; Wittsack HJ, 2002, RADIOLOGY, V222, P397, DOI 10.1148/radiol.2222001731; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	24	32	34	0	0	AMER SOC NEURORADIOLOGY	DENVILLE	PO BOX 3000, DENVILLE, NJ 07834-9349 USA	0195-6108	1936-959X		AM J NEURORADIOL	Am. J. Neuroradiol.	APR	2004	25	4					539	544					6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	815LD	WOS:000221042900005	15090338				2021-06-18	
J	Kuipers, P; Kendall, M; Fleming, J; Tate, R				Kuipers, P; Kendall, M; Fleming, J; Tate, R			Comparison of the Sydney Psychosocial Reintegration Scale (SPRS) with the Community Integration Questionnaire (CIQ): psychometric properties	BRAIN INJURY			English	Article							TRAUMATIC BRAIN-INJURY; REHABILITATION; OUTCOMES; RELATIVES; VALIDITY; NEEDS	Primary objective: This study compared the psychometric properties of two community integration measures used with people with acquired brain injury (ABI) in the community. Research design: Questionnaires were mailed-out to people with ABI and nominated proxies. Methods and procedures: Responses were obtained from 96 people with ABI and 121 proxies on the Community Integration Questionnaire (CIQ) and the Sydney Psychosocial Reintegration Scale ( SPRS). Main outcomes and results: Matched client-proxy scores were not significantly different. The SPRS had greater internal consistency and more normal distributions than the CIQ. Correlations between the three pairs of theoretically parallel sub-scales were modest (0.41 - 0.60). Multi-dimensional scaling did not support the theoretical structure of the sub-scales, but found two dimensions underpinning the measurement of community integration. Conclusions: Mail-out administration is associated with poor completion rates. The SPRS has sound psychometric properties when compared to the CIQ. Further research investigating the theoretical structure of community integration in ABI is recommended.	Univ Queensland, CONROD, Herston, Qld 4006, Australia; Princess Alexandra Hosp, Woolloongabba, Qld 4102, Australia; Univ Queensland, St Lucia, Qld 4072, Australia; Univ Sydney, Sydney, NSW 2006, Australia; Royal Rehabil Ctr Sydney, Ryde, NSW 1680, Australia	Kuipers, P (corresponding author), Univ Queensland, CONROD, Herston, Qld 4006, Australia.		Fleming, Jennifer M/B-4436-2011	Kuipers, Pim/0000-0003-0340-2286			BERKOWITZ S, 1996, NEEDS ASSESSMENT CRE, P33; Coakes S., 1999, SPSS ANAL ANGUISH; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P1, DOI 10.1097/00001199-200102000-00004; *CTR OUTC MEAS BRA, 2001, COMBI; Dijkers M, 1997, J HEAD TRAUMA REHAB, V12, P74, DOI 10.1097/00001199-199712000-00007; Dijkers Marcel., 1998, TOP SPINAL CORD INJ, V4, P1, DOI [10.1310/BJJA-2018-45KL-0VTL, DOI 10.1310/BJJA-2018-45KL-0VTL]; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; Hellawell DJ, 2000, DISABIL REHABIL, V22, P446, DOI 10.1080/09638280050045910; Kaplan CP, 2001, BRAIN INJURY, V15, P725, DOI 10.1080/02699050010005913; Kruskal Joseph B, 1978, MULTIDIMENSIONAL SCA, V11; Malec JF, 2001, ARCH PHYS MED REHAB, V82, P885, DOI 10.1053/apmr.2001.23895; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; McColl MA, 1998, BRAIN INJURY, V12, P15, DOI 10.1080/026990598122827; Powell JH, 1998, ARCH PHYS MED REHAB, V79, P1213, DOI 10.1016/S0003-9993(98)90265-9; Ricker JH, 2002, J HEAD TRAUMA REHAB, V17, P242, DOI 10.1097/00001199-200206000-00005; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Tate R, 1999, J HEAD TRAUMA REHAB, V14, P543, DOI 10.1097/00001199-199912000-00003; TATE RL, 1989, J NEUROL NEUROSUR PS, V52, P1128, DOI 10.1136/jnnp.52.10.1128; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; *WHO, 2001, ICF INT CLASS FUNCT; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; Willer B, 1993, J HEAD TRAUMA REHAB, V3, P75, DOI DOI 10.1097/00001199-199308020-00009; World Health Organization, 1980, ICIDH INT CLASS IMP	26	32	32	0	8	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	FEB	2004	18	2					161	177		10.1080/0269905031000149524			17	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	751DR	WOS:000187038000005	14660228				2021-06-18	
J	Funk, M; Endler, G; Schillinger, M; Mustafa, S; Hsieh, K; Exner, M; Lalouschek, W; Mannhalter, C; Wagner, O				Funk, M; Endler, G; Schillinger, M; Mustafa, S; Hsieh, K; Exner, M; Lalouschek, W; Mannhalter, C; Wagner, O			The effect of a promoter polymorphism in the heme oxygenase-1 gene on the risk of ischaemic cerebrovascular events - The influence of other vascular risk factors	THROMBOSIS RESEARCH			English	Article						heme oxygenase 1; GT dinucleotide repeats; ischaemic stroke; cerebrovascular disease	CORONARY-ARTERY-DISEASE; TRAUMATIC BRAIN-INJURY; MICROSATELLITE POLYMORPHISM; OXIDATIVE STRESS; RAT-BRAIN; CEREBRAL-ISCHEMIA; FOCAL ISCHEMIA; PROTEIN; EXPRESSION; BILIRUBIN	Heme oxygenase-1 (HO-1) has been demonstrated to exert potent anti-oxidant and anti-inflammatory effects in the context of atherosclerotic vascular disease, and therefore was referred to as a potential vascular protective factor. A (GT)n dinucteotide repeat polymorphism in the HO-1 promoter has been shown to modulate HO-1 gene expression. Short (< 25) GT repeats were associated with HO1 up-regulation, and therefore may influence susceptibility to ischaemic vascular events. We investigated the association of HO-1 repeat length with the risk of cerebrovascular events in a case control study and assessed possible interrelations with vascular risk factors. We determined the number of GT repeats in the HO-1 promoter in 399 patients with ischaemic cerebrovascular events and 398 healthy controls and compared the frequencies of short (<25) repeat (class S) and long (greater than or equal to 25) repeat (class L) alleles after adjustment for potentially confounding factors. Genotype distributions of S/S, S/L and L/L in patients were 9.8% (n = 39), 45.1% (n = 180) and 45.1% (n = 180), which was similar to the distribution in controls with 11.5% (n = 46), 44.5% (n = 177) and 44.0% (n = 175). In the presence of vascular risk factors, the HO-1 genotype became functionally relevant: in patients without hyperlipidemia the S/S genotype exerted a protective effect on the development of ischaemic cerebrovascular events (OR 0.2; 95% CI 0.1-0.6), while this effect was no longer present in hyperlipidemic patients. Short (<25 GT) repeats in the HO-1 gene promoter confer a reduced risk for cerebrovascular events in individuals with normal plasma lipid levels. This may explain controversial findings in different populations. (C) 2004 Elsevier Ltd. All rights reserved.	Med Univ Vienna, Klin Inst Med & Chem Labordiagnost, A-1090 Vienna, Austria; Med Univ Vienna, Div Angiol, Dept Internal Med 2, A-1090 Vienna, Austria; Med Univ Vienna, Dept Neurol, A-1090 Vienna, Austria	Mannhalter, C (corresponding author), Med Univ Vienna, Klin Inst Med & Chem Labordiagnost, Waehringerguertel 18-20, A-1090 Vienna, Austria.	Christine.Mannhalter@univie.ac.at; Oswald.Wagner@univie.ac.at		Mannhalter, Christine/0000-0001-7667-8078			Alf C, 2001, WIEN KLIN WOCHENSCHR, V113, P141; Bergeron M, 1997, J CEREBR BLOOD F MET, V17, P647; Beschorner R, 2000, ACTA NEUROPATHOL, V100, P377, DOI 10.1007/s004010000202; Chen K, 2000, J NEUROCHEM, V75, P304, DOI 10.1046/j.1471-4159.2000.0750304.x; Chen YH, 2002, HUM GENET, V111, P1, DOI 10.1007/s00439-002-0769-4; Dwyer BE, 1998, J NEUROCHEM, V71, P2497; Endler G, 2004, THROMB HAEMOSTASIS, V91, P155, DOI 10.1160/TH03-05-0291; Exner M, 2001, J ENDOVASC THER, V8, P433, DOI 10.1583/1545-1550(2001)008<0433:HOGPMP>2.0.CO;2; FUKUDA K, 1995, NEUROSCI LETT, V199, P127, DOI 10.1016/0304-3940(95)12042-3; Geddes JW, 1996, NEUROSCI LETT, V210, P205, DOI 10.1016/0304-3940(96)12703-8; Hu FB, 2000, AM J CLIN NUTR, V72, P912; KADOYA C, 1995, STROKE, V26, P1035, DOI 10.1161/01.STR.26.6.1035; Kaneda H, 2002, ARTERIOSCL THROM VAS, V22, P1680, DOI 10.1161/01.ATV.0000033515.96747.6F; Kitamura Y, 2003, J NEUROSCI RES, V71, P544, DOI 10.1002/jnr.10514; Le W, 1999, J NEUROSCI RES, V56, P652; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1988, FASEB J, V2, P2557; MARKS GS, 1991, TRENDS PHARMACOL SCI, V12, P185, DOI 10.1016/0165-6147(91)90544-3; NEUZIL J, 1994, J BIOL CHEM, V269, P16712; Nimura T, 1996, MOL BRAIN RES, V37, P201, DOI 10.1016/0169-328X(95)00315-J; Panahian N, 1999, J NEUROCHEM, V72, P1187; Satoh T, 2003, EUR J NEUROSCI, V17, P2249, DOI 10.1046/j.1460-9568.2003.02688.x; Schillinger M, 2002, THROMB RES, V106, P131, DOI 10.1016/S0049-3848(02)00100-7; Schillinger M, 2002, J ENDOVASC THER, V9, P385, DOI 10.1583/1545-1550(2002)009<0385:HOGIAV>2.0.CO;2; Schipper HM, 2000, EXP GERONTOL, V35, P821, DOI 10.1016/S0531-5565(00)00148-0; SCHMIDT HHHW, 1993, BIOCHIM BIOPHYS ACTA, V1178, P153, DOI 10.1016/0167-4889(93)90006-B; Takizawa S, 1998, J CEREBR BLOOD F MET, V18, P559, DOI 10.1097/00004647-199805000-00011; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; Yamada N, 2000, AM J HUM GENET, V66, P187, DOI 10.1086/302729; YAMAGUCHI T, 1995, BIOCHEM BIOPH RES CO, V214, P11, DOI 10.1006/bbrc.1995.2250	30	32	38	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0049-3848			THROMB RES	Thromb. Res.		2004	113	3-4					217	223		10.1016/j.thromres.2004.03.003			7	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	824ME	WOS:000221689900006	15140586				2021-06-18	
J	Harker, KT; Whishaw, IQ				Harker, KT; Whishaw, IQ			Impaired place navigation in place and matching-to-place swimming pool tasks follows both retrosplenial cortex lesions and cingulum bundle lesions in rats	HIPPOCAMPUS			English	Article						learning and memory; posterior cingulate; place learning; spatial behavior; hippocampal formation	HEAD-DIRECTION CELLS; SPATIAL MEMORY; HIPPOCAMPAL-FORMATION; BEHAVIORAL-ANALYSIS; POSTERIOR CORTEX; PERFORMANCE; DEFICITS; CONNECTIONS; TESTS; DARK	The retrosplenial (RS) cortex (area 29) and the adjacent cingulum bundle (CG) are components of neural circuits that include the hippocampus. Given the evidence suggesting that the hippocampus plays a central role in spatial navigation, several lines of investigation have examined the possible contributions of these structures to spatial navigation. The combined and/or separate contributions of these structures have been difficult to establish because their close proximity usually results in combined injury after lesions and because there have been conflicting results related to lesion type and the strain of rat subjects. The purpose of the present study was to compare the effects of selective CG damage with selective RS damage in Long-Evans rats, a domestic rat strain that displays superior spatial skills, and by using spatial behavior assessment procedures that are sensitive to CC damage. Rats with cytotoxic N-methyl-D-aspartate (NMDA) RS lesions or surgical CG transection were tested on two spatial tasks in the Morris water task; a place learning task, sensitive to nonspatial and spatial behavior, and a matching-to-place task, sensitive to spatial behavior. Both the RS and CG groups were impaired on most measures relative to the control group on both the place task and the matching-to-place task. The results are discussed in relation to the anatomical organization of CG and RG projections to the hippocampus and with respect to their possible separate/conjoint contributions to spatial behavior. (C) 2004 Wiley-Liss, Inc.	Univ Lethbridge, Canadian Ctr Behav Neurosci, Lethbridge, AB T1K 3M4, Canada	Harker, KT (corresponding author), Dalhousie Univ, Dept Psychol & Neurosci, 1355 Oxford St, Halifax, NS B3J 4J1, Canada.	kharker@dal.ca					AGGLETON JP, 1995, J NEUROSCI, V15, P7270; Brown RW, 2000, BEHAV BRAIN RES, V114, P135, DOI 10.1016/S0166-4328(00)00225-4; CHEN LL, 1994, EXP BRAIN RES, V101, P8, DOI 10.1007/BF00243212; CHEN LL, 1994, EXP BRAIN RES, V101, P24, DOI 10.1007/BF00243213; Cho JW, 2001, BEHAV NEUROSCI, V115, P3, DOI 10.1037//0735-7044.115.1.3; Cooper BG, 2001, J NEUROSCI, V21, P3986, DOI 10.1523/JNEUROSCI.21-11-03986.2001; Cooper BG, 2001, BEHAV NEUROSCI, V115, P1012, DOI 10.1037//0735-7044.115.5.1012; DOMESICK VB, 1969, BRAIN RES, V12, P296, DOI 10.1016/0006-8993(69)90002-X; Harker KT, 2002, J NEUROSCI, V22, P1155, DOI 10.1523/JNEUROSCI.22-03-01155.2002; Harker KT, 2002, BEHAV BRAIN RES, V134, P467; JELTSCH H, 1994, BEHAV NEURAL BIOL, V62, P121, DOI 10.1016/S0163-1047(05)80033-0; KOLB B, 1991, Brain Dysfunction, V4, P75; MORRIS RGM, 1990, EUR J NEUROSCI, V2, P1016, DOI 10.1111/j.1460-9568.1990.tb00014.x; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MUFSON EJ, 1984, J COMP NEUROL, V225, P31, DOI 10.1002/cne.902250105; NEAVE N, 1994, BEHAV BRAIN RES, V65, P89, DOI 10.1016/0166-4328(94)90077-9; O'Keefe J., 1978, HIPPOCAMPUS COGNITIV; PAKHOMOVA A S, 1985, Neirofiziologiya, V17, P102; Papez JW, 1937, ARCH NEURO PSYCHIATR, V38, P725, DOI 10.1001/archneurpsyc.1937.02260220069003; Prusky GT, 2002, BEHAV BRAIN RES, V136, P339, DOI 10.1016/S0166-4328(02)00126-2; Saucier D, 1996, BEHAV NEUROSCI, V110, P103, DOI 10.1037/0735-7044.110.1.103; SUTHERLAND RJ, 1983, BEHAV BRAIN RES, V7, P133, DOI 10.1016/0166-4328(83)90188-2; SUTHERLAND RJ, 1989, BEHAV BRAIN RES, V32, P265, DOI 10.1016/S0166-4328(89)80059-2; SUTHERLAND RJ, 1988, J NEUROSCI, V8, P1863; SUTHERLAND RJ, 1993, NEUROBIOLOGY CINGULA, P461; VANDERWOLF CH, 1985, ELECTRICAL ACTIVITY, P47; Vann SD, 2002, BEHAV NEUROSCI, V116, P85, DOI 10.1037//0735-7044.116.1.85; VOGT BA, 1983, J COMP NEUROL, V216, P192, DOI 10.1002/cne.902160207; Warburton EC, 1998, EUR J NEUROSCI, V10, P622, DOI 10.1046/j.1460-9568.1998.00074.x; Whishaw IQ, 1997, CURR OPIN NEUROBIOL, V7, P228, DOI 10.1016/S0959-4388(97)80011-6; WHISHAW IQ, 1985, BEHAV NEUROSCI, V99, P979, DOI 10.1037/0735-7044.99.5.979; WHISHAW IQ, 1985, PHYSIOL BEHAV, V35, P139, DOI 10.1016/0031-9384(85)90186-6; Whishaw IQ, 2001, BEHAV BRAIN RES, V118, P67, DOI 10.1016/S0166-4328(00)00312-0; Winer B.J., 1962, STAT PRINCIPLES EXPT; WYSS JM, 1992, HIPPOCAMPUS, V2, P1	35	32	33	0	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	1050-9631			HIPPOCAMPUS	Hippocampus		2004	14	2					224	231		10.1002/hipo.10159			8	Neurosciences	Neurosciences & Neurology	805TF	WOS:000220387900010	15098727				2021-06-18	
J	Nicholson, K; Martelli, MF				Nicholson, K; Martelli, MF			The problem of pain	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						chronic pain; posttraumatic pain; traumatic brain injury	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; AFFECTIVE DIMENSION; SYSTEM; MODEL; REORGANIZATION; COMPENSATION; HEADACHE	Pain problems, especially posttraumatic headache, are very common following head trauma. Pain may be the most significant problem, more disabling than any brain or other injuries, and interfering with aspects of cognition or other function. However, posttraumatic headache and most other chronic posttraumatic pain problems remain poorly understood. This article reviews fundamental issues that should be considered in understanding the nature of chronic pain including the distinction between acute and chronic pain; neurobiological distinctions between the lateral and medial pain system; nociceptive versus neuropathic or other central pain; sensitization effects; the widely accepted view of chronic pain as a multidimensional subjective experience involving sensory, motivational-affective and cognitive-behavioral components; the problem of mind-body dualism; the role of psychosocial factors in the onset, maintenance, exacerbation or severity of pain; plus issues of response bias and malingering.	Toronto Western Hosp, Comprehens Pain Program, Toronto, ON M5T 2S8, Canada; Concuss Care Ctr Virginia Ltd, Glen Allen, VA USA; Tree Life, LLC, Glen Allen, VA USA; Virginia Commonwealth Univ, Hlth Syst, Richmond, VA USA; Univ Virginia, Charlottesville, VA USA	Nicholson, K (corresponding author), Toronto Western Hosp, Comprehens Pain Program, Fell Pavill,Room 4F-811,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	keith@uhnres.utoronto.ca					American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ANDERSSON HI, 1994, QUAL LIFE RES, V3, pS19, DOI 10.1007/BF00433371; ARBISI PA, IN PRESS CLIN J PAIN; BIRBAUMER N, 1995, ADV PAIN RES THER, V22, P331; BLANCHARD EB, 1999, PSYCHOSOCIAL FACTORS, P270; BLOCK A, 1999, HDB PAIN SYNDROMES; BRATTBERG G, 1989, PAIN, V37, P215, DOI 10.1016/0304-3959(89)90133-4; BROMM B, 1995, PAIN BRAIN NOCICEPTI; Bryant RA, 1999, J HEAD TRAUMA REHAB, V14, P588, DOI 10.1097/00001199-199912000-00007; BURCHER JN, IN PRESS ARCH CLIN N; BURTON AK, 1995, SPINE, V20, P722, DOI 10.1097/00007632-199503150-00014; Cassidy JD, 2000, NEW ENGL J MED, V342, P1179, DOI 10.1056/NEJM200004203421606; CHAPMAN CR, 1995, ADV PAIN RES THER, V22, P283; De Benedittis G, 1983, J Neurosurg Sci, V27, P177; Dionne CE, 1997, J CLIN EPIDEMIOL, V50, P31, DOI 10.1016/S0895-4356(96)00313-7; DWORKIN RH, 1999, PSYCHOSOCIAL FACTORS, P247; FISHBAIN DA, 1995, CLIN J PAIN, V11, P6, DOI 10.1097/00002508-199503000-00003; FISHBAIN DA, 1999, INT ASS PAIN 9 WORLD; Flor H, 1997, NEUROSCI LETT, V224, P5, DOI 10.1016/S0304-3940(97)13441-3; FLOR H, 1992, PAIN, V49, P221, DOI 10.1016/0304-3959(92)90145-2; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; FORDYCE WE, 1988, AM PSYCHOL, V43, P276, DOI 10.1037/0003-066X.43.4.276; Gabriel M., 1993, NEUROBIOLOGY CINGULA, P478; GABRIEL M, 1990, PROG BRAIN RES, V85, P467; Gatchel R. J., 1999, PSYCHOSOCIAL FACTORS, P412; GRACELY RH, 1996, PROG PAIN RES MANAG, V6, P151; GRZESIAK RC, 1994, PSYCHOL VULNERABILIT; Hart Robert P, 2003, Curr Pain Headache Rep, V7, P116, DOI 10.1007/s11916-003-0021-5; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; HINNANT DW, 1994, HDB CHRONIC PAIN MAN, P18; HOLROYD KA, 1999, PSYCHOSOCIAL FACTORS, P193; Keidel M, 1997, NERVENARZT, V68, P769, DOI 10.1007/s001150050193; Khostanteen I, 2000, J RHEUMATOL, V27, P2671; LEESHALEY PR, 1991, PSYCHOL REP, V68, P203, DOI 10.2466/PR0.68.1.203-210; Lenz FA, 1997, PAIN FORUM, V6, P22; Linton SJ., 1999, PSYCHOSOCIAL FACTORS; LORISH CD, 1991, J RHEUMATOL, V18, P1150; Mailis A, 1997, PAIN, V70, P69, DOI 10.1016/S0304-3959(96)03300-3; MAILIS A, 2002, FUNCTIONAL MED DISOR, P131; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; MARTELLI MF, 2001, J CONTROVERSIAL MED, V8, P13; MARTELLI MF, 2001, PAIN MANAGEMENT PRAC; MELZACK R, 1966, SKIN SENSES, P423; MERSKERY H, 1994, CLASSIFICATION CHRON; Miller L, 2000, NEUROREHABILITATION, V14, P25; Morley S, 1999, PAIN, V80, P1, DOI 10.1016/S0304-3959(98)00255-3; Nicholson K, 2000, NEUROREHABILITATION, V14, P57; Nicholson K, 2000, NEUROREHABILITATION, V14, P3; Nicholson K, 2000, NEUROREHABILITATION, V14, P95; NICHOLSON K, 2001, PAIN MANAGEMENT GUID; Okifuji A, 1999, HDB PAIN SYNDROMES B, P77; Rogers R, 1997, CLIN ASSESSMENT MALI, P1; ROHLING ML, 1995, HEALTH PSYCHOL, V14, P537, DOI 10.1037/0278-6133.14.6.537; ROLLMAN GB, 1977, PAIN, V3, P187, DOI 10.1016/0304-3959(77)90002-1; SCHREIBER S, 1993, PAIN, V54, P107, DOI 10.1016/0304-3959(93)90105-X; Sharp TJ, 2001, CLIN PSYCHOL REV, V21, P857, DOI 10.1016/S0272-7358(00)00071-4; TUEK DC, 1986, PAIN MANAGEMENT HDB, P1; Vogt B.A., 1993, NEUROBIOLOGY CINGULA; *WHO, 2001, ICIDH2 WHO; Willis WD, 1997, J CLIN NEUROPHYSIOL, V14, P2, DOI 10.1097/00004691-199701000-00002	60	32	34	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2004	19	1					2	9		10.1097/00001199-200401000-00002			8	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	768UT	WOS:000188554000002	14732827				2021-06-18	
J	Messori, A; Polonara, G; Mabiglia, C; Salvolini, U				Messori, A; Polonara, G; Mabiglia, C; Salvolini, U			Is haemosiderin visible indefinitely on gradient-echo MRI following traumatic intracerebral haemorrhage?	NEURORADIOLOGY			English	Article						head injury; cerebral haemorrhage; haemosiderin; magnetic resonance imaging	DIFFUSE AXONAL INJURY; HIGH-FIELD MR; HEAD-INJURY; MAGNETIC-RESONANCE; CEREBRAL MICROBLEEDS; BRAIN; FERRITIN; HEMATOMAS; IRON; CT	Gradient-echo (GE) MRI has been demonstrated to be the most sensitive current technique for detection of intracerebral haemosiderin, especially in the chronic stage of haemorrhage. Our purpose was to see whether GE MRI shows old haemorrhage indefinitely. We reviewed serial GE images of 105 adults with imaging features consistent with post-traumatic intracerebral haemorrhage, who had serial MRI at 1, 4-6, 12, and 24 months after trauma. Of 1235 scattered low-signal foci consistent with isolated intracerebral haemosiderin deposits on images at 4-6 months, 248 (20.1%) were not seen at 24-month assessment. Reviewing individual patients, we saw that in 71.8% of those with scattered haemosiderin deposits and 46.4% of those with haemosiderin surrounded by gliosis, the low-signal foci appeared less conspicuous with time. Even given certain limitations to the interpretation of these findings, it would appear that, even with the use of GE MRI, time affects the visibility of haemorrhagic intracerebral lesions. We therefore conclude that a time of 4-6 months to 1 year or slightly more should be recommended for most precise detection of haemosiderin deposits on MRI of head-injured patients, should this be thought desirable. Normal GE images may not exclude old haemorrhage.	Umberto I Hosp & Univ Ancona, Dept Neuroradiol, I-60020 Ancona, Italy	Salvolini, U (corresponding author), Umberto I Hosp & Univ Ancona, Dept Neuroradiol, Via Conca, I-60020 Ancona, Italy.		Messori, Andrea/U-6903-2019	POLONARA, GABRIELE/0000-0002-2866-2749			Angeleri F, 1999, EPILEPSIA, V40, P1222, DOI 10.1111/j.1528-1157.1999.tb00850.x; ATLAS SW, 1988, RADIOLOGY, V168, P803, DOI 10.1148/radiology.168.3.3406410; Besenski N, 2002, EUR RADIOL, V12, P1237, DOI 10.1007/s00330-002-1355-9; BRADLEY WG, 1993, RADIOLOGY, V189, P15, DOI 10.1148/radiology.189.1.8372185; CAMPEAU NG, 2001, NEURORADIOLOGY, V43, pS89; Chan S, 1996, AM J NEURORADIOL, V17, P1821; CHEN JC, 1989, RADIOLOGY, V173, P521, DOI 10.1148/radiology.173.2.2798884; CHEN JC, 1993, AM J NEURORADIOL, V14, P275; DARROW VC, 1988, AM J PATHOL, V130, P44; Fazekas F, 1999, AM J NEURORADIOL, V20, P637; FOBBEN ES, 1989, AM J NEURORADIOL, V10, P687; GENTRY LR, 1994, RADIOLOGY, V191, P1; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; Greenberg SM, 1999, NEUROLOGY, V53, P1135, DOI 10.1212/WNL.53.5.1135; Greenberg SM, 1996, NEUROLOGY, V46, P1751, DOI 10.1212/WNL.46.6.1751; Grossman R I, 1988, Radiographics, V8, P441; HESSELINK JR, 1988, AM J NEURORADIOL, V9, P269; Kuzma BB, 2000, SURG NEUROL, V53, P400; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Offenbacher H, 1996, AM J NEURORADIOL, V17, P573; Parizel PM, 1998, EUR RADIOL, V8, P960, DOI 10.1007/s003300050496; Patel MR, 1996, STROKE, V27, P2321, DOI 10.1161/01.STR.27.12.2321; PELLICANO G, 1997, NEURORADIOLOGY, V39, pS82; Roob G, 1999, NEUROLOGY, V52, P991, DOI 10.1212/WNL.52.5.991; Roob G, 2000, CURR OPIN NEUROL, V13, P69, DOI 10.1097/00019052-200002000-00013; SCHARF J, 1994, NEURORADIOLOGY, V36, P504, DOI 10.1007/BF00593508; THULBORN KR, 1990, AM J NEURORADIOL, V11, P291; Tsushima Y, 2002, NEURORADIOLOGY, V44, P31, DOI 10.1007/s002340100649; Tsushima Y, 2000, NEURORADIOLOGY, V42, P499, DOI 10.1007/s002340000326; UNGER EC, 1989, MAGN RESON IMAGING, V7, P163, DOI 10.1016/0730-725X(89)90700-5; Vymazal J, 2000, CELL MOL BIOL, V46, P835; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; ZIMMERMAN RA, 1986, AM J NEURORADIOL, V7, P757; ZYED A, 1991, AM J NEURORADIOL, V12, P469	34	32	32	0	1	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0028-3940			NEURORADIOLOGY	Neuroradiology	DEC	2003	45	12					881	886		10.1007/s00234-003-1048-3			6	Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging	Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging	749XY	WOS:000186956400007	14579110				2021-06-18	
J	Zygun, DA; Doig, CJ; Gupta, AK; Whiting, G; Nicholas, C; Shepherd, E; Conway-Smith, C; Menon, DK				Zygun, DA; Doig, CJ; Gupta, AK; Whiting, G; Nicholas, C; Shepherd, E; Conway-Smith, C; Menon, DK			Non-neurological organ dysfunction in neurocritical care	JOURNAL OF CRITICAL CARE			English	Article							CEREBRAL-BLOOD-FLOW; SOFA SCORE; BRAIN-INJURY; METABOLISM; CIRCULATION	Purpose: To determine the incidence of non-neurological organ dysfunction in patients with severe neurological injury. Materials and Methods: Modified daily SOFA (mSOFA) scores were retrospectively calculated for 55 consecutive patients with severe head injury or subarachnoid hemorrhage. mSOFA was defined as the sum of the 5 non-neurological component SOFA scores, maximum mSOFA as the sum of the most abnormal non-neurological SOFA component scores and delta mSOFA as the difference between maximum mSOFA and admission mSOFA. Organ failure was defined as a SOFA component score greater than or equal to3. Results: Median (IQR) admission, maximum and delta mSOFA scores were 4 (3-6),8 (6-9), and 2 (1-5), respectively. Respiratory and cardiac failure developed in 80% and 82% of patients, respectively. No patient developed renal or hepatic failure. Three patients developed hematological failure. There was no difference between survivors and nonsurvivors with respect to admission mSOFA (P = .45), maximum mSOFA (P = .54), or delta mSOFA (P = .19). There was no difference between those patients with favorable or unfavorable neurological outcome with respect to admission mSOFA (P = .24), maximum mSOFA (P = .84), or delta mSOFA (P = .20). Conclusions: Cardiopulmonary failure, as defined by SOFA, is common in intensive care unit patients with severe head injury and subarachnoid hemorrhage. In contrast to other intensive care unit patient populations, the mortality of patients with closed head injury or subarachnoid hemorrhage was not related to the severity of organ dysfunction on admission or its development during the intensive care unit stay. (C) 2003 Elsevier Inc. All rights reserved.	Univ Cambridge, Addenbrookes Hosp, Dept Anaesthesia, Neurosci Crit Care Unit, Cambridge CB2 2QQ, England; Univ Cambridge, Dept Anesthesia, Cambridge, England; Addenbrookes Hosp, Cambridge, England; Univ Calgary, Dept Crit Care Med, Calgary, AB T2N 1N4, Canada	Menon, DK (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Anaesthesia, Neurosci Crit Care Unit, Box 93,Hills Rd, Cambridge CB2 2QQ, England.	dkm13@wbic.cam.ac.uk	Doig, Christopher/AAC-7949-2020	Doig, Christopher/0000-0002-8576-9139			Antonelli M, 1999, INTENS CARE MED, V25, P389, DOI 10.1007/s001340050863; Ben-Eliyahu S, 1999, ANESTHESIOLOGY, V91, P732, DOI 10.1097/00000542-199909000-00026; Bota DP, 2002, INTENS CARE MED, V28, P1619, DOI 10.1007/s00134-002-1491-3; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; DEVLIN EG, 1994, BRIT J ANAESTH, V73, P315, DOI 10.1093/bja/73.3.315; Dujardin KS, 2001, J HEART LUNG TRANSPL, V20, P350, DOI 10.1016/S1053-2498(00)00193-5; GADKARY CS, 2002, COCHRANE DATABASE SY; Gruber A, 1999, CRIT CARE MED, V27, P505, DOI 10.1097/00003246-199903000-00026; Hayashi T, 2000, J NEUROSURG, V93, P1014, DOI 10.3171/jns.2000.93.6.1014; Ishikawa K, 2000, J TRAUMA, V49, P912, DOI 10.1097/00005373-200011000-00020; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Loop T, 2002, ANESTHESIOLOGY, V96, P1202, DOI 10.1097/00000542-200205000-00025; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; Mayer SA, 1999, STROKE, V30, P780, DOI 10.1161/01.STR.30.4.780; Menon DK, 1999, BRIT MED BULL, V55, P226, DOI 10.1258/0007142991902231; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Stover JF, 1998, EUR J CLIN PHARMACOL, V54, P529, DOI 10.1007/s002280050508; Vincent JL, 1998, CRIT CARE MED, V26, P1793, DOI 10.1097/00003246-199811000-00016; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751	21	32	34	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	DEC	2003	18	4					238	244		10.1016/j.jcrc.2003.10.007			7	Critical Care Medicine	General & Internal Medicine	759BG	WOS:000187717500006	14691897				2021-06-18	
J	Borgaro, SR; Prigatano, GP				Borgaro, SR; Prigatano, GP			Modification of the Patient Competency Rating Scale for use on an acute neurorehabilitation unit: the PCRS-NR	BRAIN INJURY			English	Article							AWARENESS; DEFICITS; INJURY	Objective: The Patient Competency Rating Scale (PCRS) is a 30-item self-report questionnaire that was developed to assess awareness of deficits in post-acute patients following traumatic brain injury (TBI). The purpose of this study was to develop a modified and psychometrically sound version of the PCRS for use on an acute, inpatient neurorehabilitation unit. Research design: Prospective cohort of patients seen for inpatient rehabilitation following brain injury. Procedures: Nineteen items from the original PCRS were retained for their applicability to an inpatient neurorehabilitation unit and administered to 108 acute neurological inpatients. Results: Principle components factor analyses with varimax rotation yielded a three factor solution. Acceptable internal consistencies were calculated for each factor and the total PCRS score. Conclusions: These findings document the psychometric properties of a briefer version of the PCRS for use on an inpatient rehabilitation unit. This modified version has been labelled the PCRS for neurorehabilitation (i.e. PCRS-NR).	St Josephs Hosp, Barrow Neurol Inst, Phoenix, AZ USA	Borgaro, SR (corresponding author), Barrow Neurol Inst, Dept Clin Neuropsychol, 350 W Thomas Rd, Phoenix, AZ 85013 USA.	sborgar@chw.edu					BAER DM, 1983, NEUROLOGICAL REV, V40, P195; BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; DILLER L, 1981, J CONSULT CLIN PSYCH, V49, P822, DOI 10.1037/0022-006X.49.6.822; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; HEILBRONNER RL, 1993, J CLIN EXP NEUROPSYC, V15, P67; Heilman K. M., 1979, CLIN NEUROPSYCHOLOGY, P268, DOI DOI 10.1055/S-2008-1041551; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; PRIGATANO GP, 1975, AWARENESS DEFICIT BR; PRIGATANO GP, 1983, REHABIL PSYCHOL, V34, P135; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; SHERER M, IN PRESS ARCH PHYSIC; STARKSTEIN SE, 1992, STROKE, V23, P1446, DOI 10.1161/01.STR.23.10.1446; STARKSTEIN SE, 1993, NEUROPSY NEUROPSY BE, V6, P43	22	32	35	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2003	17	10					847	853		10.1080/0269905031000089350			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	719CR	WOS:000185186500003	12963551				2021-06-18	
J	Huh, JW; Raghupathi, R; Laurer, HL; Helfaer, MA; Saatman, KE				Huh, JW; Raghupathi, R; Laurer, HL; Helfaer, MA; Saatman, KE			Transient loss of microtubule-associated protein 2 immunoreactivity after moderate brain injury in mice	JOURNAL OF NEUROTRAUMA			English	Article						cytoskeleton; head injury; immunohistochemistry; microtubule-associated protein 2 (MAP2); plasticity; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; CORTICAL IMPACT; CYTOSKELETAL ALTERATIONS; MAP2 IMMUNOREACTIVITY; MOLECULAR MECHANISMS; RAT; CALPAIN; PROTEOLYSIS; DEGRADATION; HIPPOCAMPUS	Microtubule-associated protein 2 (MAP2) is important for microtubule stability and neural plasticity and appears to be among the most vulnerable of the cytoskeletal proteins under conditions of neuronal injury. To evaluate the acute effects of moderate severity traumatic brain injury on MAP2, anesthetized, adult male C57BL/6 mice were subjected to controlled cortical impact brain injury. At 5 min, 15 min, 90 min, 4 h, and 24 h following brain injury (n = 4 injured and n = 1 sham-injured per time point), mice were sacrificed and immunohistochemistry was performed on coronal brain sections. Profound decreases in MAP2 immunolabeling were observed in the ipsilateral cortex and hippocampal dentate hilus at 5 min postinjury and in the ipsilateral hippocampal CA3 area by 4 h postinjury. Decreases in MAP2 labeling occurred prior to notable neuronal cell loss. Interestingly, cortical MAP2 immunoreactivity returned by 90 min postinjury, but the recovery was short-lived within the core in comparison to the periphery of the impact site. Partial restoration of MAP2 immunoreactivity was also observed in the ipsilateral CA3 and dentate hilus by 24 h postinjury. Our data corroborate that MAP2 is an early and sensitive marker for neuronal damage following traumatic brain injury. Acute MAP2 loss, however, may not necessarily presage neuronal death, even following moderate severity traumatic brain injury. Rather, to the best of our knowledge, our data are the first to suggest an intrinsic ability of the traumatized brain for MAP2 recovery after injury of moderate severity.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Anesthesia & Crit Care, Philadelphia, PA USA; Drexel Univ, Dept Neurobiol & Anat, Philadelphia, PA 19104 USA	Saatman, KE (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, 113 Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041561, P50NS008803] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS41561, P50-NS08803] Funding Source: Medline		Alessandri B, 1998, PROG BRAIN RES, V116, P303, DOI 10.1016/S0079-6123(08)60445-8; AVILA J, 1992, LIFE SCI, V50, P327, DOI 10.1016/0024-3205(92)90433-P; BRADY ST, 1985, CELL MOTIL CYTOSKEL, V5, P81, DOI 10.1002/cm.970050203; CHAPIN SJ, 1992, CELL MOTIL CYTOSKEL, V23, P236, DOI 10.1002/cm.970230403; CHEN J, 1992, NATURE, V360, P674, DOI 10.1038/360674a0; Dawson DA, 1996, J CEREBR BLOOD F MET, V16, P170, DOI 10.1097/00004647-199601000-00020; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; Hasbani MJ, 1998, EXP NEUROL, V154, P241, DOI 10.1006/exnr.1998.6929; Hicks RR, 1997, MOL CHEM NEUROPATHOL, V32, P1, DOI 10.1007/BF02815164; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; Huh JW, 2002, EXP NEUROL, V175, P198, DOI 10.1006/exnr.2002.7880; JOHNSON GVW, 1991, J NEUROCHEM, V56, P1630, DOI 10.1111/j.1471-4159.1991.tb02061.x; JOHNSON GVW, 1992, J NEUROSCI RES, V33, P505, DOI 10.1002/jnr.490330402; JOHNSTON HM, 1994, J NEUROCHEM, V63, P379; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KITAGAWA K, 1989, NEUROSCIENCE, V2, P401; KWAK S, 1988, J NEUROCYTOL, V17, P189, DOI 10.1007/BF01674206; Lewen A, 1996, BRAIN RES, V719, P161, DOI 10.1016/0006-8993(96)00081-9; Li Y, 1998, STROKE, V29, P1972, DOI 10.1161/01.STR.29.9.1972; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; MATUS A, 1988, ANNU REV NEUROSCI, V11, P29, DOI 10.1146/annurev.neuro.11.1.29; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; Minger SL, 1998, BRAIN RES, V810, P181, DOI 10.1016/S0006-8993(98)00921-4; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; *NAT RES COUNC, 1996, GUID CAR US LAB; Pettigrew LC, 1996, J CEREBR BLOOD F MET, V16, P1189, DOI 10.1097/00004647-199611000-00013; Pettus EH, 1996, BRAIN RES, V722, P1, DOI 10.1016/0006-8993(96)00113-8; Popa-Wagner A, 1999, J CEREBR BLOOD F MET, V19, P425, DOI 10.1097/00004647-199904000-00008; Posmantur RM, 1996, J NEUROTRAUM, V13, P125, DOI 10.1089/neu.1996.13.125; Saatman KE, 1998, J NEUROTRAUM, V15, P1047, DOI 10.1089/neu.1998.15.1047; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; SAATMAN KE, 1999, J NEUROTRAUM, V16, P1002; Schwab M, 1998, J NEURAL TRANSM-SUPP, P299; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281	37	32	36	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	2003	20	10					975	984		10.1089/089771503770195821			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	734RX	WOS:000186072300006	14588114				2021-06-18	
J	von Gertten, C; Holmin, S; Mathiesen, T; Nordqvist, ACS				von Gertten, C; Holmin, S; Mathiesen, T; Nordqvist, ACS			Increases in matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 mRNA after cerebral contusion and depolarisation	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						rat; traumatic brain injury (TBI); in situ hybridisation; RT-PCR	TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; CORTICAL SPREADING DEPRESSION; GENE KNOCK-OUT; RAT-BRAIN; C-FOS; CYTOKINE EXPRESSION; FOCAL ISCHEMIA; GELATINASE-B; BARRIER	Matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) play major roles in physiological extracellular matrix turnover during normal development and in pathological processes. In brain, increases in MMP activity occur, for example, in multiple sclerosis, Alzheimer's disease, and after head trauma. We examined MMP-9 and TIMP-1, -2, and -3 in events after head trauma. A time-course study was carried out using two different rat injury models, cerebral contusion and depolarisation. Brains were analysed by RT-PCR and in situ hybridisation. We observed a distinct and time-dependent upregulation of MMP-9 and TIMP-1 mRNA in ipsilateral cortical areas. MMP-9 mRNA levels were upregulated 1 day after cerebral contusion with a peak at Day 4. Depolarisation per se, which also occurs after traumatic brain injury, lead to delayed increase of MMP-9 mRNA, 4 days post application. At Day 14, MMP-9 mRNA levels were indistinguishable from controls in both models. TIMP-1 mRNA increases were observed in both models 4 hr after injury, and increased further at Days 1 and 4. At Day 14, mRNA levels declined and were no higher than control levels. No alterations in mRNA levels were noted for TIMP-2 or -3. Our results support earlier reports on MMP-9 involvement in brain injury. It also shows a role for TIMP-1 in the mechanisms of trauma, where depolarisation could be the mechanism responsible for this upregulation. (C) 2003 Wiley-Liss, Inc.	Karolinska Inst, Karolinska Hosp, Dept Clin Neurosci, Neurosurg Sect, S-17176 Stockholm, Sweden	Nordqvist, ACS (corresponding author), Karolinska Inst, Karolinska Hosp, Dept Clin Neurosci, Neurosurg Sect, S-17176 Stockholm, Sweden.			Holmin, Staffan/0000-0002-1628-1615; Mathiesen, Tiit/0000-0001-9463-1919			Asahi M, 2001, J NEUROSCI, V21, P7724; Bahr MJ, 1999, HEPATOLOGY, V29, P839, DOI 10.1002/hep.510290333; Bode W, 2001, Methods Mol Biol, V151, P45; Bugno M, 1999, FEBS LETT, V448, P9, DOI 10.1016/S0014-5793(99)00323-3; Castellanos M, 2003, STROKE, V34, P40, DOI 10.1161/01.STR.0000046764.57344.31; Clark AW, 1997, NEUROSCI LETT, V238, P53, DOI 10.1016/S0304-3940(97)00859-8; COUSSENS LM, 2001, METHOD MOL BIOL, V151, P149; DRAGUNOW M, 1990, EXP NEUROL, V107, P236, DOI 10.1016/0014-4886(90)90141-E; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Gasche Y, 2001, J CEREBR BLOOD F MET, V21, P1393, DOI 10.1097/00004647-200112000-00003; HAYAKAWA T, 1994, J CELL SCI, V107, P2373; HAYAKAWA T, 1992, FED EUR BIOCH SOC, V1, P29; Hermann DM, 1999, NEUROSCIENCE, V88, P599, DOI 10.1016/S0306-4522(98)00249-8; Hermann DM, 1999, RESTOR NEUROL NEUROS, V14, P103; HOLMIN S, 1995, NEUROSCI LETT, V194, P97, DOI 10.1016/0304-3940(95)11737-H; Holmin S, 1997, J NEUROSURG, V86, P493, DOI 10.3171/jns.1997.86.3.0493; Jaworski DM, 2000, GLIA, V30, P199, DOI 10.1002/(SICI)1098-1136(200004)30:2<199::AID-GLIA9>3.0.CO;2-#; Jaworski DM, 2000, J NEUROSCI RES, V61, P396, DOI 10.1002/1097-4547(20000815)61:4<396::AID-JNR6>3.0.CO;2-S; Jaworski J, 1999, J BIOL CHEM, V274, P28106, DOI 10.1074/jbc.274.40.28106; Kaczmarek L, 2002, EMBO J, V21, P6643, DOI 10.1093/emboj/cdf676; Kariko K, 1998, J CEREBR BLOOD F MET, V18, P1308, DOI 10.1097/00004647-199812000-00005; Kawahara N, 1999, EXP NEUROL, V158, P27, DOI 10.1006/exnr.1999.7091; Khuth ST, 2001, J VIROL, V75, P8268, DOI 10.1128/JVI.75.17.8268-8282.2001; KOBAYASHI S, 1995, J CEREBR BLOOD F MET, V15, P721, DOI 10.1038/jcbfm.1995.92; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; Lukes A, 1999, MOL NEUROBIOL, V19, P267, DOI 10.1007/BF02821717; Montaner J, 2003, CIRCULATION, V107, P598, DOI 10.1161/01.CIR.0000046451.38849.90; Mori T, 2002, J NEUROTRAUM, V19, P1411, DOI 10.1089/089771502320914642; Morita-Fujimura Y, 2000, J CEREBR BLOOD F MET, V20, P130, DOI 10.1097/00004647-200001000-00017; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; NEDIVI E, 1993, NATURE, V363, P718, DOI 10.1038/363718a0; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; Pagenstecher A, 1998, AM J PATHOL, V152, P729; Parsons AA, 1998, CURR OPIN NEUROL, V11, P227, DOI 10.1097/00019052-199806000-00006; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Rangel YM, 2001, MOL BRAIN RES, V88, P103, DOI 10.1016/S0169-328X(01)00037-7; Rathke-Hartlieb S, 2000, FEBS LETT, V481, P227, DOI 10.1016/S0014-5793(00)02011-1; Rivera S, 1997, J NEUROSCI, V17, P4223; Rivera S, 2002, EUR J NEUROSCI, V15, P19, DOI 10.1046/j.0953-816x.2001.01838.x; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; Rosenberg GA, 1996, J CEREBR BLOOD F MET, V16, P360, DOI 10.1097/00004647-199605000-00002; Rosenberg GA, 1997, NEUROLOGY, V48, P921, DOI 10.1212/WNL.48.4.921; Rosenberg GA, 1996, NEUROLOGY, V46, P1626, DOI 10.1212/WNL.46.6.1626; ROSENBERG GA, 1992, BRAIN RES, V576, P203, DOI 10.1016/0006-8993(92)90681-X; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; Szklarczyk A, 2002, J NEUROSCI, V22, P920, DOI 10.1523/JNEUROSCI.22-03-00920.2002; Trim JE, 2000, J BIOL CHEM, V275, P6657, DOI 10.1074/jbc.275.9.6657; Vecil GG, 2000, J NEUROSCI RES, V61, P212, DOI 10.1002/1097-4547(20000715)61:2<212::AID-JNR12>3.0.CO;2-9; Vincenti M P, 2001, Methods Mol Biol, V151, P121; Wang XK, 1998, J CEREBR BLOOD F MET, V18, P1173, DOI 10.1097/00004647-199811000-00002; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Yong VW, 1998, TRENDS NEUROSCI, V21, P75	52	32	32	0	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0360-4012			J NEUROSCI RES	J. Neurosci. Res.	SEP 15	2003	73	6					803	810		10.1002/jnr.10729			8	Neurosciences	Neurosciences & Neurology	718MK	WOS:000185150400007	12949906				2021-06-18	
J	Alvarez, XA; Sampedro, C; Perez, P; Laredo, M; Couceiro, V; Hernandez, A; Figueroa, J; Varela, M; Arias, D; Corzo, L; Zas, R; Lombardi, V; Fernandez-Novoa, L; Pichel, V; Cacabelos, R; Windisch, M; Aleixandre, M; Moessler, H				Alvarez, XA; Sampedro, C; Perez, P; Laredo, M; Couceiro, V; Hernandez, A; Figueroa, J; Varela, M; Arias, D; Corzo, L; Zas, R; Lombardi, V; Fernandez-Novoa, L; Pichel, V; Cacabelos, R; Windisch, M; Aleixandre, M; Moessler, H			Positive effects of cerebrolysin on electroencephalogram slowing, cognition and clinical outcome in patients with postacute traumatic brain injury: An exploratory study	INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY			English	Article						cerebrolysin; clinical outcome; cognition; quantitative EEG; traumatic brain injury	DOUBLE-BLIND; ALZHEIMERS-DISEASE; PERFORMANCE; SEVERITY; DAMAGE	The potential effects of Cerebrolysin (EBEWE Pharma, Unterach, Austria), a peptide preparation with neurotrophic activity, on brain bioelectrical activity, cognitive performance and clinical outcome in postacute traumatic brain injury (TBI) patients, were investigated in an exploratory study. A decrease in slow electroencephalogram (EEG) activity and an increase in fast frequencies were observed after the administration of Cerebrolysin. This EEG-activating effect was not influenced by TBI time course or severity, nor by the chronic treatment with nootropic compounds. Cognitive performance, evaluated with the Syndrome Kurztest test, improved in TBI patients after Cerebrolysin treatment, independent of disease severity, time course or disability. A significant improvement in the patients' clinical outcome, only evident during the first year after brain trauma, was also found following Cerebrolysin infusions. No relevant changes in biological parameters nor drug-related adverse events were observed. These promising preliminary results suggest that Cerebrolysin might be a useful treatment to improve the recovery of patients with traumatic brain damage, and encourage the conduction of confirmatory clinical trials. (C) 2003 Lippincott Williams Wilkins.	EuroEspes Biomed Res Ctr, Dept Neuropharmacol, La Coruna 15166, Spain; JSW Res Inc, Graz, Austria; Univ Granada, Fac Psicol, Granada, Spain; EBEWE Pharma, Unterach, Austria	Alvarez, XA (corresponding author), EuroEspes Biomed Res Ctr, Dept Neuropharmacol, La Coruna 15166, Spain.	me-direccion@euroespes.com					AKAI F, 1992, HISTOL HISTOPATHOL, V7, P213; ALBRECHT E, 1993, ADV BIOSCI, V87, P341; Alvarez XA, 2000, J NEURAL TRANSM-SUPP, P281; Alvarez XA, 1999, METHOD FIND EXP CLIN, V21, P633; Alvarez XA, 1999, 1ST INTERNATIONAL CONGRESS ON VASCULAR DEMENTIA, P233; Alvarez XA, 2000, J NEURAL TRANSM-SUPP, P315; ALVAREZ XA, 2001, RES PRACTICE ALZHEIM, V5, P179; Arciniegas D, 2000, J NEUROPSYCH CLIN N, V12, P77, DOI 10.1176/jnp.12.1.77; Axelrod BN, 2001, CLIN NEUROPSYCHOL, V15, P516, DOI 10.1076/clin.15.4.516.1884; Bae CY, 2000, J AM GERIATR SOC, V48, P1566, DOI 10.1111/j.1532-5415.2000.tb03865.x; Cacabelos R, 1996, ANN NY ACAD SCI, V777, P399, DOI 10.1111/j.1749-6632.1996.tb34452.x; CACABELOS R, 1996, ALZHEIMER DIS MOL BI, P469; Csuka E, 1999, J NEUROIMMUNOL, V101, P211, DOI 10.1016/S0165-5728(99)00148-4; Emmerling MR, 2000, ANN NY ACAD SCI, V903, P118, DOI 10.1111/j.1749-6632.2000.tb06357.x; FrancisTurner L, 1996, NEUROSCI LETT, V202, P193, DOI 10.1016/0304-3940(95)12240-0; Funke M, 1998, J NEURAL TRANSM-SUPP, P385; Gennarelli TA, 1997, NEUROSCIENTIST, V3, P73, DOI 10.1177/107385849700300117; Hutter-Paier B, 1998, J NEURAL TRANSM-SUPP, P351; HutterPaier B, 1996, J NEURAL TRANSM-SUPP, P267; Jellinger KA, 2001, EUR J NEUROL, V8, P707, DOI 10.1046/j.1468-1331.2001.00322.x; JENNETT B, 1975, LANCET, V1, P480; Kane NM, 1998, ELECTROEN CLIN NEURO, V106, P244, DOI 10.1016/S0013-4694(97)00141-7; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; Leclercq PD, 2001, J NEUROTRAUM, V18, P1, DOI 10.1089/089771501750055721; Lombardi VRM, 1999, METHOD FIND EXP CLIN, V21, P331, DOI 10.1358/mf.1999.21.5.541910; Masliah E, 1999, PHARMACOL BIOCHEM BE, V62, P239, DOI 10.1016/S0091-3057(98)00144-0; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Muller SV, 2002, ARCH PHYS MED REHAB, V83, P115, DOI 10.1053/apmr.2002.27472; Overall J E, 1992, J Geriatr Psychiatry Neurol, V5, P220; Panisset M, 2002, J NEURAL TRANSM, V109, P1089, DOI 10.1007/s007020200092; PEREZ P, 1999, ANN PSYCHIAT, V7, P77; RAINER M, 2002, RES PRACTICE ALZHEIM, V6, P244; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rockenstein E, 2002, J NEURAL TRANSM-SUPP, P327; Ruether E, 2002, J NEURAL TRANSM-SUPP, P265; Ruether E, 2001, INT CLIN PSYCHOPHARM, V16, P253, DOI 10.1097/00004850-200109000-00002; RUTHER E, 1994, PHARMACOPSYCHIATRY, V27, P32, DOI 10.1055/s-2007-1014271; SALETU B, 1995, INT J CLIN PHARM TH, V33, P249; Satou T., 1994, JPN PHARMACOL THER, V22, P205; Schwab M, 1998, J NEURAL TRANSM-SUPP, P299; Silvestrini MC, 1997, NAT MED, V3, P521, DOI 10.1038/nm0597-521; Tatebayashi Y, 2003, ACTA NEUROPATHOL, V105, P225, DOI 10.1007/s00401-002-0636-3; TEASDALE G, 1974, LANCET, V2, P81; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; Wallace BE, 2001, J HEAD TRAUMA REHAB, V16, P165, DOI 10.1097/00001199-200104000-00006; Windisch M, 1998, J NEURAL TRANSM-SUPP, P289	47	32	35	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0268-1315	1473-5857		INT CLIN PSYCHOPHARM	Int. Clin. Psychopharmacol.	SEP	2003	18	5					271	278		10.1097/07.yic.0000085765.24936.9a			8	Pharmacology & Pharmacy; Psychiatry	Pharmacology & Pharmacy; Psychiatry	715WA	WOS:000184994700003	12920387				2021-06-18	
J	Ropacki, MT; Elias, JW				Ropacki, MT; Elias, JW			Preliminary examination of cognitive reserve theory in closed head injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	20th Annual Meeting of the National-Academy-of-Neuropsychology	NOV 14-18, 2000	ORLANDO, FLORIDA	Natl Acad Neuropsychol		closed head injury; cognitive reserve; Oklahoma premorbid intelligence estimate; post-traumatic amnesia; severity of head injury; premorbid history	ALZHEIMERS-DISEASE; PREMORBID INTELLIGENCE; EDUCATION; OCCUPATION; DEMENTIA	This investigation was designed to provide preliminary support for cognitive reserve theory in closed head injury (CHI), and demonstrate the effectiveness of using the Oklahoma premorbid intelligence estimate (OPIE) in research and clinical activities. Out of a possible 124 consecutive referrals, 26 patients (N = 26) who underwent neuropsychological assessment following brain injury met study inclusion/exclusion criteria. Participants were included if they had exited post-traumatic amnesia (PTA), demonstrated uncompromised upper extremity use, displayed adequate verbal communication, and were judged capable of completing a full neuropsychological evaluation. Participants were divided into a closed head injury-negative premorbid history (CHI-) or closed head injury-positive premorbid history (CIH+) group based upon premorbid variables (e.g., history of alcoholism). Groups did not differ in terms of demographic variables or premorbid IQ. Despite having less severe head injuries, the CHI+ group had a greater pre-post difference for PIQ, and a significantly larger VIQ/PIQ discrepancy than the CHI-group. In conclusion, these findings suggest that the CHI+ group had diminished cognitive reserve secondary to the aggregate effects of premorbid insult, which resulted in greater cognitive decline following an additional stressor (i.e., CFH) than what might otherwise be expected from the head injury alone. (C) 2002 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA; Univ Nevada, Sanford Ctr Aging, Reno, NV 89557 USA	Ropacki, MT (corresponding author), Univ Calif Los Angeles, Sch Med, Inst Neuropsychiat, 760 Westwood Plaza,Room C8-747, Los Angeles, CA 90024 USA.						Alexander GE, 1997, AM J PSYCHIAT, V154, P165; Basso MR, 2000, J CLIN EXP NEUROPSYC, V22, P208, DOI 10.1076/1380-3395(200004)22:2;1-1;FT208; Basso MR, 2000, CLIN NEUROPSYCHOL, V14, P325, DOI 10.1076/1385-4046(200008)14:3;1-P;FT325; Dwork AJ, 1998, AM J PSYCHIAT, V155, P1536, DOI 10.1176/ajp.155.11.1536; Glatt SL, 1996, NEUROEPIDEMIOLOGY, V15, P20, DOI 10.1159/000109885; Huck S., 1975, PSYCHOL BULL, V82, P311; KATZMAN R, 1988, ANN NEUROL, V23, P138, DOI 10.1002/ana.410230206; Kaufman A. S., 1990, ASSESSING ADOLESCENT; KRULL KR, 1995, CLIN NEUROPSYCHOL, V9, P83, DOI 10.1080/13854049508402063; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MITTENBERG W, 1995, PROF PSYCHOL-RES PR, V26, P491, DOI 10.1037/0735-7028.26.5.491; Mortimer JA, 1997, GERIATRICS, V52, pS50; Ropacki MT, 1999, ARCH CLIN NEUROPSYCH, V14, P788; RUDELLI R, 1982, ARCH NEUROL-CHICAGO, V39, P570, DOI 10.1001/archneur.1982.00510210040009; Satz P., 1993, NEUROPSYCHOLOGY, V7, P273, DOI DOI 10.1037/0894-4105.7.3.273; Scott JG, 1997, CLIN NEUROPSYCHOL, V11, P146, DOI 10.1080/13854049708407043; Spreen O., 1998, COMPENDIUM NEUROPSYC; Stern RA, 1996, ARCH NEUROL-CHICAGO, V53, P148, DOI 10.1001/archneur.1996.00550020052015; STERN Y, 1995, NEUROLOGY, V45, P55, DOI 10.1212/WNL.45.1.55; STERN Y, 1992, ANN NEUROL, V32, P371, DOI 10.1002/ana.410320311; Stern Y, 1999, NEUROLOGY, V53, P1942, DOI 10.1212/WNL.53.9.1942; STERN Y, 1994, JAMA-J AM MED ASSOC, V271, P1004, DOI 10.1001/jama.271.13.1004	24	32	35	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2003	18	6					643	654	PII S0887-6177(02)00153-1	10.1016/S0887-6177(02)00153-1			12	Psychology, Clinical; Psychology	Psychology	715FU	WOS:000184961000008	14591438				2021-06-18	
J	Bigler, ED; Lowry, CM; Kerr, B; Tate, DF; Hessel, CD; Earl, HD; Miller, MJ; Rice, SA; Smith, KH; Tschanz, JT				Bigler, ED; Lowry, CM; Kerr, B; Tate, DF; Hessel, CD; Earl, HD; Miller, MJ; Rice, SA; Smith, KH; Tschanz, JT			Role of white matter lesions, cerebral atrophy, and APOE on cognition in older persons with and without dementia: The Cache County, Utah, Study of Memory and Aging	NEUROPSYCHOLOGY			English	Article							APOLIPOPROTEIN-E GENOTYPE; E EPSILON-4 ALLELE; TRAUMATIC BRAIN INJURY; TEMPORAL-LOBE ATROPHY; MINI-MENTAL STATE; ALZHEIMERS-DISEASE; NEUROPSYCHOLOGICAL BATTERY; CEREBROVASCULAR-DISEASE; CARDIOVASCULAR HEALTH; HIPPOCAMPAL VOLUME	Neuropsychological, qualitative, and quantitative magnetic resonance imaging findings were examined in subjects with Alzheimer's disease (AD), non-AD dementia or mixed neuropsychiatric disorder, subjects characterized as mild/ambiguous, and controls, all with known apolipoprotein E (APOE) genotype. Neuropsychological tasks included an expanded Consortium to Establish a Registery for Alzheimer's Disease (J. T. Tschanz et al., 2000; K. A. Welsh, J. M. Hoffman, N. L. Earl, & M. W. Hanson 1994) battery and the Mini-Mental Status Examination (M. F. Folstein, S. E. Folstein, & P. R. McHugh, 1975). Periventricular white matter lesions were the most clinically salient, and generalized measures of cerebral atrophy were the most significant quantitative indicators. APOE genotype was unrelated to imaging or neuropsychological performance. Neuropsychological relationships with neuroimaging findings depend on the qualitative or quantitative method used.	Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; Univ Utah, Dept Radiol, Salt Lake City, UT 84132 USA; Univ Utah, Dept Psychiat, Salt Lake City, UT 84132 USA; Brigham Young Univ, Dept Psychol, Provo, UT USA; Utah State Univ, Dept Psychol, Logan, UT 84322 USA; Duke Univ, Ctr Med, Dept Psychiat & Behav Sci, Durham, NC 27706 USA; Univ So Calif, Dept Neurol, Los Angeles, CA 90089 USA	Bigler, ED (corresponding author), Brigham Young Univ, Dept Psychol, 1001 Spencer W Kimball Tower, Provo, UT 84602 USA.		Tschanz, JoAnn T./E-5986-2010; Tate, David/G-5166-2011	Tate, David/0000-0003-0213-1920	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG-11380] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH-14592] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH014592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG011380] Funding Source: NIH RePORTER		American Psychiatric Association, 1987, DIAGN STAT MAN MENT; ARVANITAKIS Z, 1999, ALZHEIMER DIS, P147; Barber R, 1999, ARCH NEUROL-CHICAGO, V56, P961, DOI 10.1001/archneur.56.8.961; Barboriak DP, 2000, NEUROLOGY, V54, P2150, DOI 10.1212/WNL.54.11.2150; Benson RR, 2002, NEUROLOGY, V58, P48, DOI 10.1212/WNL.58.1.48; Benton A., 1994, MULTILINGUAL APHASIA; Benton A. L., 1992, BENTON VISUAL RETENT; Berg L, 1998, ARCH NEUROL-CHICAGO, V55, P326, DOI 10.1001/archneur.55.3.326; Bezeau S, 2001, J CLIN EXP NEUROPSYC, V23, P399, DOI 10.1076/jcen.23.3.399.1181; Bigler E, 1997, DIAGNOSTIC CLIN NEUR; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 2002, ALZ DIS ASSOC DIS, V16, P161, DOI 10.1097/00002093-200207000-00006; Bigler ED, 2001, INVEST RADIOL, V36, P539, DOI 10.1097/00004424-200109000-00006; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Bigler ED, 2000, AM J NEURORADIOL, V21, P1857; Bookheimer SY, 2000, NEW ENGL J MED, V343, P450, DOI 10.1056/NEJM200008173430701; BREITNER JCS, 1995, ARCH NEUROL-CHICAGO, V52, P763, DOI 10.1001/archneur.1995.00540320035011; Breitner JCS, 1999, NEUROLOGY, V53, P321, DOI 10.1212/WNL.53.2.321; Carmelli D, 1998, NEUROLOGY, V50, P1580, DOI 10.1212/WNL.50.6.1580; Caselli RJ, 1999, NEUROLOGY, V53, P201, DOI 10.1212/WNL.53.1.201; Chen PJ, 2001, ARCH GEN PSYCHIAT, V58, P853, DOI 10.1001/archpsyc.58.9.853; Clark CM, 1996, ALZ DIS ASSOC DIS, V10, P31, DOI 10.1097/00002093-199601010-00006; COFFEY CE, 2000, TXB GERIATRIC NEUROP, P181; Cohen RA, 2001, J NEUROIMAGING, V11, P253, DOI 10.1111/j.1552-6569.2001.tb00043.x; Daly E, 2000, ARCH NEUROL-CHICAGO, V57, P675, DOI 10.1001/archneur.57.5.675; de Groot JC, 2000, ANN NEUROL, V47, P145; de Groot JC, 2001, NEUROLOGY, V56, P1539, DOI 10.1212/WNL.56.11.1539; de Leeuw FE, 2000, NEUROLOGY, V54, P1795, DOI 10.1212/WNL.54.9.1795; DECARLI C, 1995, NEUROLOGY, V45, P2077, DOI 10.1212/WNL.45.11.2077; DECARLI C, 2000, NEURODEGENERATIVE DE, P33; Elias MF, 2000, ARCH NEUROL-CHICAGO, V57, P808, DOI 10.1001/archneur.57.6.808; Fama R, 2000, NEUROPSYCHOLOGY, V14, P29, DOI 10.1037/0894-4105.14.1.29; Filley CM, 1998, NEUROLOGY, V50, P1535, DOI 10.1212/WNL.50.6.1535; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Forstl H, 1995, BRIT J PSYCHIAT, V167, P739, DOI 10.1192/bjp.167.6.739; Forstl H, 1996, BRIT J PSYCHIAT, V168, P280, DOI 10.1192/bjp.168.3.280; FOSTER NL, 1999, ALZHEIMER DIS, P67; Ganguli M, 2000, ARCH NEUROL-CHICAGO, V57, P824, DOI 10.1001/archneur.57.6.824; Geroldi C, 1999, NEUROLOGY, V53, P1825, DOI 10.1212/WNL.53.8.1825; Geroldi C, 2000, J NEUROL NEUROSUR PS, V68, P93, DOI 10.1136/jnnp.68.1.93; Gunning-Dixon FM, 2000, NEUROPSYCHOLOGY, V14, P224, DOI 10.1037//0894-4105.14.2.224; Guttmann CRG, 2000, NEUROLOGY, V54, P1277, DOI 10.1212/WNL.54.6.1277; Haan MN, 1999, JAMA-J AM MED ASSOC, V282, P40, DOI 10.1001/jama.282.1.40; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; Hashimoto M, 2001, NEUROLOGY, V57, P1461, DOI 10.1212/WNL.57.8.1461; Hirono N, 1998, ALZ DIS ASSOC DIS, V12, P362, DOI 10.1097/00002093-199812000-00018; Holtzman DM, 2000, ANN NEUROL, V47, P739, DOI 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; Inzitari D, 2000, ANN NEUROL, V47, P141; Itoh Y, 1999, NEUROLOGY, V53, P236, DOI 10.1212/WNL.53.1.236; Jack CR, 1998, ANN NEUROL, V43, P303, DOI 10.1002/ana.410430307; Jack CR, 1999, NEUROLOGY, V52, P1397, DOI 10.1212/WNL.52.7.1397; Kaplan E., 1983, BOSTON NAMING TEST; Killiany RJ, 2000, ANN NEUROL, V47, P430, DOI 10.1002/1531-8249(200004)47:4<430::AID-ANA5>3.3.CO;2-9; Kramer-Ginsberg E, 1999, AM J PSYCHIAT, V156, P438; Kuller LH, 1998, STROKE, V29, P388, DOI 10.1161/01.STR.29.2.388; Lehtovirta M, 1996, J NEUROL NEUROSUR PS, V60, P644, DOI 10.1136/jnnp.60.6.644; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Longstreth WT, 1996, STROKE, V27, P1274, DOI 10.1161/01.STR.27.8.1274; Lopez OL, 2000, NEUROLOGY, V54, P1780, DOI 10.1212/WNL.54.9.1780; McCarron MO, 1999, NEUROLOGY, V53, P1308, DOI 10.1212/WNL.53.6.1308; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Meiners LC, 1999, INVEST RADIOL, V34, P38, DOI 10.1097/00004424-199901000-00006; Moroney JT, 1999, JAMA-J AM MED ASSOC, V282, P254, DOI 10.1001/jama.282.3.254; Moser DJ, 2000, ARCH NEUROL-CHICAGO, V57, P707, DOI 10.1001/archneur.57.5.707; Moser DJ, 2001, NEUROPSY NEUROPSY BE, V14, P89; Nebes RD, 2001, AM J PSYCHIAT, V158, P878, DOI 10.1176/appi.ajp.158.6.878; ORRISON WW, 2000, NEUROIMAGING, P800; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; PETERSEN RC, 1999, ARCH NEUROL-CHICAGO, V50, P1563; Prince M, 2000, NEUROLOGY, V54, P397, DOI 10.1212/WNL.54.2.397; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; SALTHOUSE TA, 1978, J GERONTOL, V33, P232, DOI 10.1093/geronj/33.2.232; Schmidt R, 1999, NEUROLOGY, V53, P132, DOI 10.1212/WNL.53.1.132; SHEAR PK, 1995, ARCH NEUROL-CHICAGO, V52, P392, DOI 10.1001/archneur.1995.00540280078021; SHIPLEY WC, 1967, SHIPLEY I LIVING SCA; Skoog I, 1998, J NEUROL NEUROSUR PS, V64, P37, DOI 10.1136/jnnp.64.1.37; Small BJ, 2000, ARCH NEUROL-CHICAGO, V57, P839, DOI 10.1001/archneur.57.6.839; Smith A., 1973, SYMBOL DIGIT MODALIT; Smith CD, 2000, NEUROLOGY, V54, P838, DOI 10.1212/WNL.54.4.838; Smith CD, 2000, J NEUROIMAGING, V10, P13, DOI 10.1111/jon200010113; Snowdon DA, 1996, JAMA-J AM MED ASSOC, V275, P528, DOI 10.1001/jama.275.7.528; Steffens DC, 2000, ARCH GEN PSYCHIAT, V57, P601, DOI 10.1001/archpsyc.57.6.601; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Swan GE, 2000, NEUROLOGY, V54, P2108, DOI 10.1212/WNL.54.11.2108; Tanabe JL, 1997, AM J NEURORADIOL, V18, P115; TENG EL, 1987, J CLIN PSYCHIAT, V48, P314; Tschanz JT, 2000, NEUROLOGY, V54, P1290, DOI 10.1212/WNL.54.6.1290; VICTOROFF J, 1994, NEUROLOGY, V44, P2267, DOI 10.1212/WNL.44.12.2267; Wechsler D., 1987, WECHSLER MEMORY SCAL; WELSH KA, 1994, ARCH CLIN NEUROPSYCH, V9, P395, DOI 10.1016/0887-6177(94)90003-5; WELSH KA, 1994, NEUROLOGY, V44, P609, DOI 10.1212/WNL.44.4.609; Wilson RS, 1996, NEUROPSYCHOLOGY, V10, P459; Yaffe K, 2000, NEUROLOGY, V54, P1949, DOI 10.1212/WNL.54.10.1949	94	32	32	0	2	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	JUL	2003	17	3					339	352		10.1037/0894-4105.17.3.339			14	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	713BY	WOS:000184836600001	12959500				2021-06-18	
J	Foster, M; Tilse, C				Foster, M; Tilse, C			Referral to rehabilitation following traumatic brain injury: a model for understanding inequities in access	SOCIAL SCIENCE & MEDICINE			English	Article						brain injury; social problems theory; rehabilitation	HEALTH-CARE; HEAD-INJURY; CHILDREN; SERVICES; STROKE; DISABILITY; CENTERS; PEOPLE	Identifying inequities in access to health care requires critical scrutiny of the patterns and processes of care decisions. This paper describes a conceptual model. derived from social problems theory. which is proposed as a useful framework for explaining patterns of post-acute care referral and in particular, individual variations in referral to rehabilitation after traumatic brain injury (TBI). The model is based on three main components: (1) characteristics of the individual with TBI, (2) activities of health care professionals and the processes of referral. and (3) the contexts of care. The central argument is that access to rehabilitation following TBI is a dynamic phenomenon concerning the interpretations and negotiations of health care professionals. which in turn are shaped by the organisational and broader health care contexts. The model developed in this paper provides opportunity to develop a complex analysis of post-acute care referral based on patient factors, contextual factors and decision-making processes. It is anticipated that this framework will have utility in other areas examining and understanding patterns of access to health care. (C) 2002 Elsevier Science Ltd. All rights reserved.	Univ Queensland, CONROD, Ctr Natl Res Disabil & Rehabil Med, Herston, Qld 4006, Australia; Univ Queensland, Sch Social Work & Social Policy, Brisbane, Qld 4072, Australia	Foster, M (corresponding author), Univ Queensland, CONROD, Ctr Natl Res Disabil & Rehabil Med, Herston, Qld 4006, Australia.		Tilse, Cheryl/AAH-2155-2019; Tilse, Cheryl/A-1266-2008	Tilse, Cheryl/0000-0001-5596-9132			Banja J, 1999, BRAIN INJURY, V13, P745, DOI 10.1080/026990599121142; BARTON L, 1996, DISABILITY SOC EMERG, P3; BATAVIA AI, 1993, HEALTH AFFAIR, V12, P40, DOI 10.1377/hlthaff.12.1.40; BENTOVIN D, 1994, AUSTR CASEMIX B, V6, P11; BEST J, 1987, SOC PROBL, V34, P101, DOI 10.1525/sp.1987.34.2.03a00010; Best J., 1993, RECONSIDERING SOCIAL, P129; BEST J, 1995, IMAGES ISSUES TYPIFY, P3; BONITA R, 1987, AGE AGEING, V16, P29; CAPLAN AL, 1987, ETHICAL POLICY ISSUE, P1; Cavestri R, 1997, ITAL J NEUROL SCI, V18, P9, DOI 10.1007/BF02106224; CLARK JA, 1991, SOC SCI MED, V32, P853, DOI 10.1016/0277-9536(91)90241-4; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; DiScala C, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199704000-00002; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; Duckett S, 1995, J Qual Clin Pract, V15, P133; Foster M, 2000, BRAIN INJURY, V14, P1035; FOSTER M, 2001, THESIS U QUEENSLAND; GILES GM, 1994, AM J OCCUP THER, V48, P199, DOI 10.5014/ajot.48.3.199; GREENWALD CG, 1993, FRONT FOOD FOOD INGR, V1, P7; GRIFFIN D, 1993, ARCH PHYSICAL MED RE, V74, P1087; GRIFFITHS L, 1993, SOCIOL REV, V41, P415, DOI 10.1111/j.1467-954X.1993.tb00072.x; Griffiths L., 1994, QUALITATIVE HLTH RES, V4, P385; GRIMMER K, 1996, J QUALITY CLIN PRACT, V16, P4; HAAS JF, 1988, ARCH PHYS MED REHAB, V69, P329; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; HARRISON S, 1995, BRIT MED BULL, V51, P885, DOI 10.1093/oxfordjournals.bmb.a073003; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; Holstein JA, 1993, RECONSIDERING SOCIAL, P151; Hughes D, 1997, SOC SCI MED, V44, P589, DOI 10.1016/S0277-9536(96)00207-9; HUNTER DJ, 1995, BRIT MED BULL, V51, P876, DOI 10.1093/oxfordjournals.bmb.a073002; Ibarra P. R., 1993, RECONSIDERING SOCIAL, P25; Jamrozik A., 1998, SOCIOLOGY SOCIAL PRO; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; MANNING N, 1985, SOCIAL PROBLEMS WELF, P1; Marks D, 1997, DISABIL REHABIL, V19, P85, DOI 10.3109/09638289709166831; MECHANIC D, 1992, U PENN LAW REV, V140, P1713, DOI 10.2307/3312429; Mechanic David, 1989, PAINFUL CHOICES RES; MELVIN JL, 1988, ARCH PHYS MED REHAB, V69, P163; Miller G, 1993, RECONSIDERING SOCIAL, P5; MUNFORD R, 1997, HUMAN SERVICES PARTN, P17; OSBERG JS, 1990, AM J PHYS MED REHAB, V69, P67, DOI 10.1097/00002060-199004000-00004; Pain K, 1998, J REHABIL, V64, P5; Patford J., 1999, AUSTR SOCIAL WORK, V52, P3, DOI 10.1080/03124079908414103; POPE C, 1995, BRIT MED J, V311, P42, DOI 10.1136/bmj.311.6996.42; Reitan TC, 1998, SOC SERV REV, V72, P285, DOI 10.1086/515760; Rubington E., 1995, STUDY SOCIAL PROBLEM; SAX S, 1990, HEALTH CARE CHOICES; SCHNEIDER JW, 1985, ANNU REV SOCIOL, V11, P209; Spector M., 1987, CONSTRUCTING SOCIAL; SUSMAN J, 1994, SOC SCI MED, V38, P15, DOI 10.1016/0277-9536(94)90295-X; Unsworth C A, 1997, Pediatr Rehabil, V1, P207; UNSWORTH CA, 1995, ARCH PHYS MED REHAB, V76, P331, DOI 10.1016/S0003-9993(95)80658-X; WILLIAMS S, 1995, AUSTR OCCUPATIONAL T, V42, P143; WRIGLEY JM, 1994, ARCH PHYS MED REHAB, V75, P149; Ylvisaker Mark, 1995, Seminars in Speech and Language, V16, P32, DOI 10.1055/s-2008-1064109	55	32	32	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0277-9536			SOC SCI MED	Soc. Sci. Med.	MAY	2003	56	10					2201	2210	PII S0277-9536(02)00236-8	10.1016/S0277-9536(02)00236-8			10	Public, Environmental & Occupational Health; Social Sciences, Biomedical	Public, Environmental & Occupational Health; Biomedical Social Sciences	668VF	WOS:000182313300016	12697208				2021-06-18	
J	Grate, LL; Golden, JA; Hoopes, PJ; Hunter, JV; Duhaime, AC				Grate, LL; Golden, JA; Hoopes, PJ; Hunter, JV; Duhaime, AC			Traumatic brain injury in piglets of different ages: techniques for lesion analysis using histology and magnetic resonance imaging	JOURNAL OF NEUROSCIENCE METHODS			English	Article						brain; swine; immature; trauma; injury; histology; immunohistochemistry; magnetic resonance imaging	DOMESTIC PIG; NEWBORN	Quantitation of lesions in large gyrencephalic brains presents a variety of technical challenges. Specific techniques are required when comparing lesions in subjects of different ages in order to assess maturational effects. We have modified existing techniques to attain reliable, consistent and reproducible paraffin-embedded histological sections for volumetric lesion analysis and correlation with magnetic resonance imaging (MRI) in piglets of different ages following focal traumatic brain injury. Twenty-four Yorkshire domestic piglets at three different ages (5 days, 1 month, and 4 months old) underwent scaled cortical impact injury to the frontoparietal cortex. This contusion model utilizes a rapid volume of indentation scaled proportionally to the growth of the brain, allowing for examination of maturational influences on the brain's response to focal mechanical trauma. To overcome problems with differential processing and embedding of brains ranging from 43 to 107 g, we developed a piglet parallel brain slicing apparatus. Along with specific methods for processing, embedding, mounting, and slide preparation, these techniques enabled excellent quality 10-mum serial coronal sections to be obtained for histology and immunohistochemical analysis. Accurate co-registration of histologic, immunohistochemical and radiologic images at different,ages was possible, which may enhance understanding of developmental aspects of brain injury pathophysiology. (C) 2003 Elsevier Science B.V. All rights reserved.	Dartmouth Hitchcock Med Ctr, Dept Surg, Neurosurg Sect, Lebanon, NH 03756 USA; Childrens Hosp Philadelphia, Philadelphia, PA 17104 USA; Texas Childrens Hosp, Dept Radiol, Houston, TX 77030 USA	Grate, LL (corresponding author), Dartmouth Hitchcock Med Ctr, Dept Surg, Neurosurg Sect, Hinman Box 7850,1 Med Ctr Dr, Lebanon, NH 03756 USA.		Dilger, Ryan N./E-7031-2010	Dilger, Ryan N./0000-0003-2538-2845	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS037132] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS37132-02] Funding Source: Medline		ARMSTEAD WM, 1994, BRAIN RES, V660, P19, DOI 10.1016/0006-8993(94)90834-6; ARMSTEAD WM, 1994, J NEUROTRAUM, V11, P487, DOI 10.1089/neu.1994.11.487; Bauer R, 1999, PEDIATR NEUROSURG, V30, P62, DOI 10.1159/000028765; DICKERSON JW, 1967, PROC R SOC SER B-BIO, V166, P384, DOI 10.1098/rspb.1967.0002; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; DUHAIME AC, 2002, ANN M NEV; DUHAIME AC, 2002, UNPUB J NEUROSURG; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; FLYNN TJ, 1984, NEUROCHEM RES, V9, P935, DOI 10.1007/BF00964525; MADSEN FF, 1990, ACTA NEUROCHIR, V106, P24, DOI 10.1007/BF01809329; MADSEN FF, 1987, ACTA NEUROCHIR, V88, P65, DOI 10.1007/BF01400517; MCGOWAN JE, 1995, BRAIN RES, V670, P283, DOI 10.1016/0006-8993(94)01289-T; Pond WG, 2000, P SOC EXP BIOL MED, V223, P102, DOI 10.1046/j.1525-1373.2000.22314.x; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Shaver EG, 1996, PEDIATR NEUROSURG, V25, P123, DOI 10.1159/000121109; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Sorensen JC, 2000, J NEUROSCI METH, V104, P93, DOI 10.1016/S0165-0270(00)00330-7; THOMAS JM, 1971, GROWTH, V35, P259; Yue X, 1997, NEUROPATH APPL NEURO, V23, P16	19	32	32	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270			J NEUROSCI METH	J. Neurosci. Methods	MAR 15	2003	123	2					201	206		10.1016/S0165-0270(02)00361-8			6	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	652ZF	WOS:000181410200008	12606068				2021-06-18	
J	Faden, AI; Fox, GB; Di, X; Knoblach, SM; Cernak, I; Mullins, P; Nikolaeva, M; Kozikowski, AP				Faden, AI; Fox, GB; Di, X; Knoblach, SM; Cernak, I; Mullins, P; Nikolaeva, M; Kozikowski, AP			Neuroprotective and nootropic actions of a novel cyclized dipeptide after controlled cortical impact injury in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						TRH analogs; traumatic brain injury; neuroprotection; behavior; diketopiperazine	TRAUMATIC BRAIN INJURY; THYROTROPIN-RELEASING-HORMONE; SPINAL-CORD INJURY; HEAD-INJURY; TRH; RECOVERY; DIFFUSION; RATS; METHYLPREDNISOLONE; STRATEGIES	1-ARA-35b (35b) is a cyclized dipeptide that shows considerable neuroprotective activity in vitro and improves neurologic recovery after fluid percussion-induced traumatic brain injury in rats. The authors evaluated the effects of treatment with 35b in mice subjected to controlled cortical impact brain injury. Animals treated with intravenous 35b after traumatic injury showed significantly enhanced recovery of beam walking and place learning functions compared with vehicle-treated controls, in addition to reduced lesion volumes. Beneficial effects were dose related and showed an inverted U-shaped dose-response curve between 0.1 and 10 mg/kg. Protective actions were found when the drug was administered initially at 30 minutes or 1, 4, or 8 hours, but not at 24 hours, after trauma. In separate experiments, rats treated with 35b on days 7 through 10 after injury showed remarkably improved place learning in comparison with injured controls. These studies confirm and extend the neuroprotective effects of this diketopiperazine in traumatic brain injury. In addition, they show that 35b has a relatively wide therapeutic window and improves cognitive function after both acute and chronic injury.	Georgetown Univ, Med Ctr, Dept Neurosci, Washington, DC 20057 USA; Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20057 USA	Faden, AI (corresponding author), Georgetown Univ, Med Ctr, Dept Neurosci, 3970 Reservoir Rd NW,Room EP-12, Washington, DC 20057 USA.		Cernak, Ibolja/A-6399-2008	Mullins, Paul/0000-0002-1339-6361; Ibolja, Cernak/0000-0003-3214-698X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS041119] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS 41119] Funding Source: Medline		AKDEMIR H, 1993, RES EXP MED, V193, P297, DOI 10.1007/BF02576237; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; ARIAS MJ, 1987, SURG NEUROL, V28, P335, DOI 10.1016/0090-3019(87)90054-1; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; BEHRMANN DL, 1994, EXP NEUROL, V126, P61, DOI 10.1006/exnr.1994.1042; BRACKEN MB, 1993, J NEUROSURG, V79, P500, DOI 10.3171/jns.1993.79.4.0500; CEYLAN S, 1992, RES EXP MED, V192, P23, DOI 10.1007/BF02576254; CEYLAN S, 1990, RES EXP MED, V190, P111, DOI 10.1007/PL00020013; Faden AI, 1999, AM J PHYSIOL-REG I, V277, pR1196; FADEN AI, 1981, NEW ENGL J MED, V305, P1063, DOI 10.1056/NEJM198110293051806; FADEN AI, 1990, J PHARMACOL EXP THER, V255, P608; Faden AI, 2001, ARCH NEUROL-CHICAGO, V58, P1553, DOI 10.1001/archneur.58.10.1553; FADEN AI, 1993, J NEUROTRAUM, V10, P91, DOI 10.1089/neu.1993.10.91; Faden AI, 2001, EXP NEUROL, V167, P435, DOI 10.1006/exnr.2000.7577; FADEN AI, 1989, BRAIN RES, V486, P228, DOI 10.1016/0006-8993(89)90509-X; Faden AI, 1999, ANN NY ACAD SCI, V890, P120, DOI 10.1111/j.1749-6632.1999.tb07987.x; FADEN AI, 1996, NEUROTRAUMA, P1479; FADEN AI, 2003, J CEREB BLOOD FLOW M, P23; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; FUKUDA N, 1979, FOLIA PHARMACOL JPN, V75, P321, DOI 10.1254/fpj.75.321; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; HOCKINGS PD, 1995, JMRI-J MAGN RESON IM, V5, P437, DOI 10.1002/jmri.1880050412; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; LOUBINOUX I, 1997, STROKE, V28, P426; Maas AIR, 2001, EXPERT OPIN INV DRUG, V10, P753, DOI 10.1517/13543784.10.4.753; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PITTS LH, 1995, J NEUROTRAUM, V12, P235, DOI 10.1089/neu.1995.12.235; PRASAD C, 1995, PEPTIDES, V16, P151, DOI 10.1016/0196-9781(94)00017-Z; Puniak MA, 1991, J NEUROTRAUM, V8, P193, DOI 10.1089/neu.1991.8.193; TAKAMI K, 1991, JPN J PHARMACOL, V57, P405, DOI 10.1254/jjp.57.405; WANG GL, 1991, CHINESE MED J-PEKING, V104, P939; YARBROUGH GG, 1979, PROG NEUROBIOL, V12, P291, DOI 10.1016/0301-0082(79)90012-1	34	32	37	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0271-678X			J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2003	23	3					355	363		10.1097/01.WCB.0000046144.31247.33			9	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	652VH	WOS:000181401200010	12621310	Bronze			2021-06-18	
J	Stendel, R; Heidenreich, J; Schilling, A; Akhavan-Sigari, R; Kurth, R; Picht, T; Pietila, T; Suess, O; Kern, C; Meisel, J; Brock, M				Stendel, R; Heidenreich, J; Schilling, A; Akhavan-Sigari, R; Kurth, R; Picht, T; Pietila, T; Suess, O; Kern, C; Meisel, J; Brock, M			Clinical evaluation of a new intracranial pressure monitoring device	ACTA NEUROCHIRURGICA			English	Article							FIBEROPTIC DEVICE; COMPLICATIONS; INFECTIONS; PROBES; RISK	Background. Continuous monitoring of intracranial pressure (ICP) still plays a key role in the management of patients at risk from intracranial hypertension. Numerous ICP-measuring devices are available. The aim of the present study was to investigate the clinical characteristics and the magnetic resonance imaging (MRI) compatibility of the recently developed Neurovent-P(R) (REHAU AG+CO, REHAU, Germany) ICP monitoring device. Method. In a prospective two-center study, a total of 98 patients with severe head injury, subarachnoid haemorrhage, intracerebral haemorrhage, and non-traumatic brain edema underwent intraparenchymal monitoring of ICP using the Neurovent-P(R). A control group comprising 50 patients underwent implantation of the Camino(R)-OLM-110-4B ICP monitor. The zero drift of the probes was determined before and after the ICP recording period. Technical and medical complications were documented. The MRI compatibility of the Neurovent-P(R) ICP probe was investigated by evaluating artifacts caused by the probe, probe function and temperature changes during MRI, and probe movement caused by the magnetic field. Findings. The mean zero drift was 0.2 +/- 0.41 mmHg (maximum 3 rnmHg) for the Neurovent-P(R) ICP probes and 0.4 +/- 0.57 mmHg (maximum 12 mmHg) for the Caminol(R)-OLM-110-4B ICP probes. No significant correlation was identified between the extent of zero drift following the removal of the probes and the length of monitoring. Intraparenchymal haemorrhage spatially related to the probe occurred in 1 out of 50 (2%) patients with a Camino(R)-OLM-110-4B probe and in 1 out of 98 (1%) with a Neurovent-P(R). Damage of the probe due to kinking or overextension of the cable or glass fiber occurred in 4 of the 50 (8%) Camino(R)-OLM-110-4B ICP probes and in 5 of the 98 (5%) Neurovent-P(R) probes. On T2-weighted MR images, the Neurovent-P(R) ICP probe induced only small artifacts with very good discrimination of the surrounding tissue. On T1-weighted MR images, there was a good imaging quality but artifact-related local disturbances in signal occurred. There was no temperature change in the Neurovent-P(R) probe and in the surrounding brain tissue during MR imaging. Interpretation. The Neurovent-P(R) ICP measuring system is a safe and reliable tool for ICP monitoring. Handling of the Neurovent-P(R) system is safe when performed properly.	Free Univ Berlin, Dept Neurosurg, Benjamin Franklin Med Ctr, D-12203 Berlin, Germany; Free Univ Berlin, Dept Radiol & Nucl Med, Benjamin Franklin Med Ctr, D-12203 Berlin, Germany; BG Hosp Bergmannstrost, Dept Neurosurg, Halle Saale, Germany	Stendel, R (corresponding author), Free Univ Berlin, Dept Neurosurg, Benjamin Franklin Med Ctr, Hindenburgdamm 30, D-12203 Berlin, Germany.			Picht, Thomas/0000-0002-8630-1466			AUCOIN PJ, 1986, AM J MED, V80, P369, DOI 10.1016/0002-9343(86)90708-4; Bavetta S, 1997, J NEUROSURG, V86, P927, DOI 10.3171/jns.1997.86.6.0927; Bullock Ross, 1996, Journal of Neurotrauma, V13, P639; CHAMBERS IR, 1993, NEUROSURGERY, V33, P866; GAMBARDELLA G, 1992, NEUROSURGERY, V31, P918, DOI 10.1227/00006123-199211000-00014; Ghajar J, 1995, New Horiz, V3, P395; Holzschuh M, 1998, BRAIN INJURY, V12, P191, DOI 10.1080/026990598122665; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; Miller JD, 1989, INTRACRANIAL PRESSUR, P5; MOLLMAN HD, 1988, J NEUROSURG, V68, P737, DOI 10.3171/jns.1988.68.5.0737; Munch E, 1998, ACTA NEUROCHIR, V140, P1113, DOI 10.1007/s007010050224; PIPER IR, 1999, BRIT J NEUROSURG, V13, P114; Sahuquillo J, 1999, J NEUROSURG, V90, P16, DOI 10.3171/jns.1999.90.1.0016; Schurer L, 1997, ACT NEUR S, V70, P296; SYMON L, 1974, J NEUROL NEUROSUR PS, V37, P617, DOI 10.1136/jnnp.37.6.617; TASKER RC, 1991, NEUROPEDIATRICS, V22, P47, DOI 10.1055/s-2008-1071416; WEINSTABL C, 1992, J CLIN MONITOR, V8, P116, DOI 10.1007/BF01617429; WILKINSON HA, 1989, NEUROSURGERY, V24, P348, DOI 10.1227/00006123-198903000-00007; Williams EJ, 1999, J NEUROSURG, V91, P706, DOI 10.3171/jns.1999.91.4.0706; WINFIELD JA, 1993, NEUROSURGERY, V33, P424; YABLON JS, 1993, J CLIN MONITOR, V9, P171, DOI 10.1007/BF01617024; YAU YH, 2000, NEUROSURG FOCUS, V9, P1	22	32	35	0	2	SPRINGER WIEN	VIENNA	SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	MAR	2003	145	3					185	193		10.1007/s00701-002-1052-0			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	658GZ	WOS:000181714400005	12632114				2021-06-18	
J	Kolitz, BP; Vanderploeg, RD; Curtiss, G				Kolitz, BP; Vanderploeg, RD; Curtiss, G			Development of the key behaviors change inventory: A traumatic brain injury behavioral outcome assessment instrument	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Meeting of the American-Association-of-Spinal-Cord-Injury-Psychologists-and-Social-Workers	SEP, 2001	LAS VEGAS, NEVADA	American Assoc Spinal Cord Injury Psychologists Social Workers		brain injuries; multiple sclerosis; Neurobehavioral manifestations; rehabilitation; treatment outcome	NEUROPSYCHOLOGY BEHAVIOR; AFFECT PROFILE; REHABILITATION; REPLICATION; VALIDITY; SCALES	Objective: To describe the development and initial validation of a neurobehavioral outcome measure, the Key Behaviors Change Inventory (KBCI), for individuals with traumatic brain injury (TBI). Design: Scale construction and development, and validity study. Setting: Large state university and postal survey. Participants: Seventy-five volunteer undergraduate students and 25 volunteer collateral informants of individuals with TBI participated in the item-analysis phase. Thirty members of the Brain Injury Association and 20 members of the National Multiple Sclerosis Society rated both an identified patient and an age- and gender-equated control in the validation phase. Interventions: Not applicable. Main Outcome Measure: Content validity was examined through expert panel item sorts. Scale internal consistencies were examined with the Cronbach a. Construct validity was examined by comparing scale elevations between controls and 2 neurologic groups. Results: Item-analysis procedures resulted in 8 scales of 8 items each: inattention, impulsivity, unawareness of problems, apathy, interpersonal difficulties, communication problems, somatic difficulties, and emotional adjustment. Internal consistency reliability coefficients ranged from .82 to .91. Multivariate analysis of variance revealed significant (P<.001) differences in scale elevations among TBI, multiple sclerosis (MS), and control groups. The TBI and MS groups scored significantly higher than the control group on all scales; a subset of KBCI scales discriminated between the 2 neurologic groups. Conclusions: The KBCI was both sensitive and specific to typical behavioral changes after TBI, thus supporting its usefulness in rehabilitation settings. Cross-validation and development of a normative database are future steps necessary in its development.	Univ S Florida, Dept Psychol, Tampa, FL 33620 USA; Univ S Florida, Dept Psychiat, Tampa, FL 33620 USA; James A Haley Vet Affairs Med Ctr, Tampa, FL USA; Def & Vet Head Injury Program, Tampa, FL USA	Kolitz, BP (corresponding author), Off Russell & Kolitz, Financial Ctr 9350, 9350 S Dixie Hwy,Penthouse 3, Miami, FL 33156 USA.		Curtiss, Glenn/ABB-5566-2020				Antonak R. F., 1993, J HEAD TRAUMA REHAB, V8, P87, DOI DOI 10.1097/00001199-199312000-00009; Beatty WW, 1996, NEUROPSYCHOLOGY CLIN, P225; BENYISHAY Y, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P194; BURGESS PW, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P110; BURISCH M, 1984, AM PSYCHOL, V39, P214, DOI 10.1037/0003-066X.39.3.214; CAMPBELL JJ, 1994, J NEUROPSYCH CLIN N, V6, P411; Cope D., 1993, J HEAD TRAUMA REHAB, V8, P1; CROSSON B, 1987, CLIN NEUROPSYCHOL, V1, P335, DOI DOI 10.1080/13854048708520069; Dywan J, 1996, J HEAD TRAUMA REHAB, V11, P79, DOI 10.1097/00001199-199604000-00008; Forer S., 1987, FUNCTIONAL INDEPENDE; GILES GM, 1994, AM J OCCUP THER, V48, P199, DOI 10.5014/ajot.48.3.199; Grace J, 1999, ASSESSMENT, V6, P269, DOI 10.1177/107319119900600307; HIGH WM, 1995, J HEAD TRAUMA REHAB, V10, P14, DOI 10.1097/00001199-199502000-00004; Ho MR, 1997, ARCH CLIN NEUROPSYCH, V12, P1; Holden R.R., 1990, PSYCHOL ASSESSMENT J, V2, P35, DOI https://doi.org/10.1037/1040-3590.2.1.35; HOLDEN RR, 1989, J CLIN PSYCHOL, V45, P583, DOI 10.1002/1097-4679(198907)45:4<583::AID-JCLP2270450413>3.0.CO;2-H; JACKSON DN, 1970, CURRENT TOPICS CLIN, V2, P62; JOHNSTON MV, 1995, J HEAD TRAUMA REHAB, V10, pR7, DOI 10.1097/00001199-199502000-00002; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KNIGHT RG, 1992, NEUROPSYCHOLOGY DEGE; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; LEVIN HS, 1991, FRONTAL LOBE FUNCTION AND DYSFUNCTION, P318; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LEZAK MD, 1989, FRONTIERS CLIN NEURO, V7, P113; LEZAK MD, 1990, TRAUMATIC BRAIN INJU, P365; MARSHALL RC, 1989, FRONTIERS CLIN NEURO, V7, P87; MAYER NH, 1993, J HEAD TRAUMA REHAB, V8, pR5; MENDE JM, 1998, DISS ABSTR INT SCI E, V59, P2476; Morey L. C., 1991, PERSONALITY ASSESSME; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; NELSON L, 1994, NEUROPSYCHOLOGY BEHA; Nelson LD, 1998, ARCH CLIN NEUROPSYCH, V13, P549, DOI 10.1016/S0887-6177(97)00052-8; NELSON LD, 1989, J CONSULT CLIN PSYCH, V1, P266; NELSON LD, 1993, PSYCHOL ASSESSMENT, V5, P374; PAUL RH, 1997, DISS ABSTR INT SCI E, V58, P2173; Paulsen JS, 1996, ASSESSMENT, V3, P327; PETERSON GW, 1989, J CLIN PSYCHOL, V45, P575, DOI 10.1002/1097-4679(198907)45:4<575::AID-JCLP2270450412>3.0.CO;2-F; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P29; RAO SM, 1990, SUBCORTICAL DEMENTIA, P164; ROSENTHAL M, 1987, J HEAD TRAUMA REHAB, V2, pR7; Satz P, 1996, PSYCHOL ASSESSMENT, V8, P115; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; THOMSEN IV, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P52; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; Wishart H, 1997, J CLIN EXP NEUROPSYC, V19, P810, DOI 10.1080/01688639708403762; WOOD RLL, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P3	48	32	32	0	5	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2003	84	2					277	284		10.1053/apmr.2003.50100			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	643QV	WOS:000180872700019	12601661				2021-06-18	
J	Catroppa, C; Anderson, V				Catroppa, C; Anderson, V			Children's attentional skills 2 years post-traumatic brain injury	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							PEDIATRIC HEAD-INJURY; DEFICITS	This study examined sustained attention abilities 24 months postinjury, in 3 groups of children who had suffered a traumatic brain injury (TBI): (a) mild TBI (n = 24), (b) moderate TBI (n = 3 1), and (c) severe TBI (n = 14). Three manipulations of the traditional Continuous Performance Test paradigm (CPT) were employed in the study, to delineate factors that might influence CPT performance, including speed of processing, attentional lapses, and stimulus complexity. No significant differences were evident among the TBI groups on a measure of simple reaction time, nor on a CPT version where the interstimulus interval was lengthened. However, there was a significant difference between the mild and severe TBI groups on the most complex task, which required speed, accuracy, and decision making, suggesting that these factors underlie impaired performances previously identified on the CPT in children with severe TBI. These findings have implications for the development of intervention programs for these children.	Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic 3052, Australia	Catroppa, C (corresponding author), Royal Childrens Hosp, Dept Psychol, Flemington Rd, Parkville, Vic 3052, Australia.						Anderson V, 1998, NEUROPSYCHOL REHABIL, V8, P283; ANDERSON V, UNPUB NEUROPSYCHOLOG; Catroppa C, 1999, J INT NEUROPSYCH SOC, V5, P48, DOI 10.1017/S1355617799511077; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; COOLEY EL, 1990, DEV NEUROPSYCHOL, V6, P239, DOI 10.1080/87565649009540465; Daniel A. E., 1983, POWER PRIVILEGE PRES; Dennis M, 1995, TRAUMATIC HEAD INJUR; Fenwick T, 1999, CHILD NEUROPSYCHOL, V5, P213, DOI 10.1076/0929-7049(199912)05:04;1-R;FT213; HALPERIN JM, 1991, INT J NEUROSCI, V58, P171, DOI 10.3109/00207459108985433; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Maule AJ, 2000, ACTA PSYCHOL, V104, P283, DOI 10.1016/S0001-6918(00)00033-0; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; MIRSKY AF, 1996, ATTENTION MEMORY EXE; MURRAY R, 1992, BRAIN COGNITION, V18, P99, DOI 10.1016/0278-2626(92)90072-T; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Posner M.I., 1994, IMAGES MIND; Posner MI., 1978, CHRONOMETRIC EXPLORA; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; Sparrow S., 1984, VINELAND ADAPTIVE BE; Stuss DT, 1995, ANN NY ACAD SCI, V769, P191, DOI 10.1111/j.1749-6632.1995.tb38140.x; TEASDALE G, 1974, LANCET, V2, P81; Timmermans SR, 1991, COGNITIVE REHABILITA, V9, P26; van Zomeren A. H., 1994, CLIN NEUROSPYCHOLOGY; WALSH K, 1978, NEUROPSYCHOLOGY CLIN; Wechsler D., 1991, MANUAL WECHSLER INTE; Willmott C, 2000, DEV NEUROPSYCHOL, V17, P361, DOI 10.1207/S15326942DN1703_5	27	32	32	0	1	LAWRENCE ERLBAUM ASSOC INC	MAHWAH	10 INDUSTRIAL AVE, MAHWAH, NJ 07430-2262 USA	8756-5641			DEV NEUROPSYCHOL	Dev. Neuropsychol.		2003	23	3					359	373		10.1207/S15326942DN2303_3			15	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	684XM	WOS:000183231800003	12740190				2021-06-18	
S	Gilchrist, MD		DulieuBarton, JM; Brennan, MJ; Holford, KM; Worden, K		Gilchrist, MD			Modelling and accident reconstruction of head impact injuries	DAMAGE ASSESSMENT OF STRUCTURES, PROCEEDINGS	Key Engineering Materials		English	Article; Proceedings Paper	5th International Conference on Damage Assessment of Structures	JUL 01-03, 2003	SOUTHAMPTON, ENGLAND			accident reconstruction; head injury; impact; neurotrauma	BIOMECHANICS; EPIDEMIOLOGY; PRESSURE	This paper describes a computational mechanics framework within which the physiological consequences of an accidental head impact injury can be. simulated. This method relies on a combined use of multibody dynamics and finite element analyses. Such a procedure could ultimately be used to assist in the clinical diagnosis of neurotrauma and in the design of optimised safety helmets.	Univ Coll Dublin, Dept Mech Engn, Dublin 4, Ireland	Gilchrist, MD (corresponding author), Univ Coll Dublin, Dept Mech Engn, Dublin 4, Ireland.	Michael.Gilchrist@ucd.ie	Gilchrist, Michael D/B-6100-2017	Gilchrist, Michael D/0000-0003-1765-429X			Allsop D, 1991, P 35 STAPP CAR CRASH, V35, P269; AUER C, 2001, P INT SOC BIOM 18 C; Claessans M., 1997, P 41 STAPP CAR CRASH, P315, DOI DOI 10.4271/973338; Dassios G, 1998, COMPUT MECH, V21, P382, DOI 10.1007/s004660050315; DIMASI F, 1991, P 13 INT TECHN C EXP; EDBERG S, 1963, LAB INVEST, V12, P1305; *EEVC WORK GROUP, 1994, 10 EEVC WORK GROUP; Gilchrist MD, 2000, COMPUT MECH, V26, P229, DOI 10.1007/s004660000179; Gilchrist MD, 2001, INT J CRASHWORTHINES, V6, P253, DOI 10.1533/cras.2001.0176; GOLDSMITH W, 1972, BIOMECHANICS HEAD IN; Gurdjian E S, 1972, Clin Neurosurg, V19, P1; Holbourn AHS, 1943, LANCET, V2, P438; HORGAN TJ, 2003, IN PRESS INT J CRASH; HOSEY RR, 1982, HOMEOMORPHIC FINITE, P379; HU H, 1998, P 5 INT LS DYNA US C; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; Jones SE, 1998, COMPUT MECH, V22, P413, DOI 10.1007/s004660050373; Kang HS, 1997, P 41 STAPP CAR CRASH, P329; Kleiven S, 2002, J BIOMECH, V35, P153, DOI 10.1016/S0021-9290(01)00202-0; LEE ES, 1990, THESIS GEORGIA I TEC; LJUNG C, 1978, SCALING HEAD INJURY; LORENSON B, VTK OPEN SOURCE SOFT; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Meerhoff S R, 2000, Ned Tijdschr Geneeskd, V144, P1915; MENDIS KK, 1995, ASME, V117, P279; MISRA JC, 1984, J BIOMECH, V17, P459, DOI 10.1016/0021-9290(84)90014-9; MOHAN D, 1979, ASME, V101, P250; Mortensen K., 1999, Tidsskrift for den Norske Laegeforening, V119, P1870; Nahum A. M., 1977, P 21 STAPP CAR CRASH; *NIH, VIS HUM DAT; Nisitani H, 1997, COMPUT MECH, V19, P470, DOI 10.1007/s004660050195; North JB, 1991, P INT RES COUNC BIOK, P77; O'Donoghue D, 1998, IRISH J MED SCI, V167, P263; ODONOGHUE D, 1999, THESIS U COLL DUBLIN; OMMAYA AK, 1994, INT J IMPACT ENG, V15, P535, DOI 10.1016/0734-743X(94)80033-6; ONO K, 1980, P 24 STAPP CAR CRASH, P101; ORIORDAIN K, 2003, IN PRESS CLIN BIOMEC; ORIORDAIN K, 2002, THESIS U COLL DUBLIN; RUAN JS, 1994, THESIS WAYNE STATE U; Sauren A. A. H. J., 1993, P INT IRCOBI C BIOM, P241; SCALLAN E, 2001, INJURY IRELAND; SHUGAR TA, 1975, ASCE J ENG MECH, V173, P223; SMYTH A, 2002, P IR NEUR GROUP ANN; SPEYER H, 1997, 970088 SAE; TURQUIER F, 1996, P 40 STAPP CAR CRASH; VAZQUEZBARQUERO A, 1992, EUR J EPIDEMIOL, V8, P832, DOI 10.1007/BF00145328; VIANO DC, 1989, J BIOMECH, V22, P403, DOI 10.1016/0021-9290(89)90201-7; Ward C, 1975, P 19 STAPP CAR CRASH; Watson WL, 2000, ACCIDENT ANAL PREV, V32, P277, DOI 10.1016/S0001-4575(99)00121-9; WILLINGER R, 1995, J NEUROTRAUM, V12, P743, DOI 10.1089/neu.1995.12.743; Willinger R., 1992, P INT RES COUNC BIOK, P283; Willinger R., 1992, P INT IRCOBI C BIOM, P179; YANAGIDA Y, 1989, FORENSIC SCI INT, V41, P135, DOI 10.1016/0379-0738(89)90245-4; YOGANANDAN N, 1995, J NEUROTRAUM, V12, P659, DOI 10.1089/neu.1995.12.659; ZHOU C, 1996, P 1996 INT IRCOBI C, P35; 2000, ABAQUS STANDARD USER; 1999, MADYMO VERSION 5 4 1; 2002, MSC PATRAN USERS MAN	58	32	32	0	6	TRANS TECH PUBLICATIONS LTD	DURNTEN-ZURICH	KREUZSTRASSE 10, 8635 DURNTEN-ZURICH, SWITZERLAND	1013-9826		0-87849-922-9	KEY ENG MATER			2003	245-2						417	429		10.4028/www.scientific.net/KEM.245-246.417			13	Materials Science, Ceramics; Materials Science, Composites	Materials Science	BW97Q	WOS:000183830800047					2021-06-18	
J	Lippert-Gruner, M; Wedekind, C; Klug, N				Lippert-Gruner, M; Wedekind, C; Klug, N			Outcome of prolonged coma following severe traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; REHABILITATION	Primary objective : To assess the outcome of severe traumatic brain injury 1 year after trauma. Research design : Prospective study conducted at the neurosurgical department of a university hospital. Methods and procedures : A total of 24 patients were included. Outcome was assessed by means of Glasgow outcome scale, Barthel index, Functional independence measure (FIM) and Disability rating scale (DRS). Need of care and job ability were also evaluated. Experimental interventions : Patients received multimodal early-onset stimulation and continuous inpatient and outpatient rehabilitation therapy. Main outcomes and results : Six patients died, three remained in a vegetative state, six were severely disabled, six were moderately disabled and three achieved a good recovery 1 year after injury. Mean Barthel index was 68.9, mean FIM was 88.3 and mean DRS 27.7. The majority of patients still were at least intermittently dependent on care. Most of the trauma survivors were unable to work. Conclusions : Despite intensive rehabilitation treatment, severe traumatic brain injury is still burdened with significant mortality and morbidity.	Univ Cologne, Dept Neurosurg, D-50924 Cologne, Germany	Lippert-Gruner, M (corresponding author), Univ Cologne, Dept Neurosurg, D-50924 Cologne, Germany.	drchrwedekind@web.de					Anderson SI, 1996, BRAIN INJURY, V10, P115, DOI 10.1080/026990596124601; Bouillon B, 1999, RESTOR NEUROL NEUROS, V14, P85; Chua KSG, 1999, INT J REHABIL RES, V22, P189, DOI 10.1097/00004356-199909000-00005; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; DAVIS CHH, 1997, AM J PHYSICAL MED RE, V76, P20; DODDS TA, 1993, ARCH PHYS MED REHAB, V74, P531, DOI 10.1016/0003-9993(93)90119-U; Grossman P, 1996, DISABIL REHABIL, V18, P57, DOI 10.3109/09638289609166019; Gruner ML, 2000, BRAIN INJURY, V14, P585; Hawkins ML, 1996, J TRAUMA, V41, P257, DOI 10.1097/00005373-199608000-00010; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1976, LANCET, V1, P1031; KATZ DI, 1994, ARCH NEUROL-CHICAGO, V41, P661; MAHONEY F I, 1965, Md State Med J, V14, P61; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; MITCHELL S, 1990, Brain Injury, V4, P273, DOI 10.3109/02699059009026177; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; RHODES M, 1988, J TRAUMA, V28, P931, DOI 10.1097/00005373-198807000-00005; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; TALBOT LR, 1994, BRAIN INJURY, V8, P689, DOI 10.3109/02699059409151023; TEASDALE G, 1974, LANCET, V2, P81	20	32	34	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2003	17	1					49	54		10.1080/0269905021000010230			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	633LK	WOS:000180284600004	12519647				2021-06-18	
J	Taylor, AN; Romeo, HE; Beylin, AV; Tio, DL; Rahman, SU; Hovda, DA				Taylor, AN; Romeo, HE; Beylin, AV; Tio, DL; Rahman, SU; Hovda, DA			Alcohol consumption in traumatic brain injury: Attenuation of TBI-induced hyperthermia and neurocognitive deficits	JOURNAL OF NEUROTRAUMA			English	Article						alcohol; brain temperature; core body temperature; hyperthermia; neuroprotection; spatial learning; traumatic brain injury	CONTROLLED CORTICAL IMPACT; ACUTE-PHASE RESPONSE; ETHANOL; HYPOTHERMIA; RATS; INTERLEUKIN-6; TEMPERATURE; PROTECTION; CONTUSION; FEVER	Clinical and animal studies indicate that hyperthermia during or after traumatic brain injury (TBI) is associated with poor outcome. Alcohol intoxication, a complicating risk factor in many cases of head injury, has been found to both worsen or attenuate posttraumatic neural damage and outcome. The purpose of the present study was to determine whether chronic ethanol consumption would affect TBI-induced hyperthermia and deficits in spatial learning. TBI was produced by cortical contusion injury in adult male rats. We first characterized the TBI-induced febrile response using probes implanted intraperitoneally (ip) or intracerebroventricularly for continuous biotelemetric recording of core body and brain temperatures and locomotor activity. In another experiment, rats, implanted with ip probes, were fed a liquid diet containing ethanol (5% w/v, 35% ethano/derived calories); control rats were pair-fed the isocaloric liquid diet (P-P). At 14 days after commencement of diet feeding, TBI or sham surgery was performed, and the ethanol-fed rats were divided into two groups: half were transferred to the isocaloric diet (E-P) and the other half remained on the ethanol-containing diet (E-E). TBI produced a significant febrile response in all rats, that persisted for at least 6 days in the E-P and P-P groups but lasted for only 2 days in the E-E group. When tested at 3-4 weeks after TBI, E-E rats required significantly fewer trials than E-P rats to reach criterion in the Morris water maze. In sum, continuous consumption of ethanol before and after TBI attenuated TBI-induced hyperthermia and deficits in spatial learning. Whereas the results suggest that this ethanol regimen may be neuroprotective, a causal relationship between the two outcomes remains to be determined.	Univ Calif Los Angeles, Sch Med, Dept Neurobiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Brain Res, Los Angeles, CA 90095 USA; VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA	Taylor, AN (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Neurobiol, 10833 Le Conte Ave,Box 951763, Los Angeles, CA 90095 USA.	ataylor@mednet.ucla.edu			NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA009850] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA09850] Funding Source: Medline		ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; ALKANA RL, 1996, PHARM EFFECTS ETHANO, P251; Barone FC, 1997, NEUROSCI BIOBEHAV R, V21, P31, DOI 10.1016/0149-7634(95)00080-1; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; BRAMLETT HM, 1995, J NEUROTRAUM, V12, P289, DOI 10.1089/neu.1995.12.289; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1995, J NEUROTRAUM, V12, P923, DOI 10.1089/neu.1995.12.923; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; COEHLO MM, 1995, AM J PHYSIOL, V269, pR527; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; Folkerts MM, 1998, J NEUROTRAUM, V15, P349, DOI 10.1089/neu.1998.15.349; GIBERTINI M, 1995, BRAIN BEHAV IMMUN, V9, P113, DOI 10.1006/brbi.1995.1012; Ginsberg MD, 1998, STROKE, V29, P529, DOI 10.1161/01.STR.29.2.529; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; HOFFMAN SW, 1994, J NEUROTRAUM, V11, P417, DOI 10.1089/neu.1994.11.417; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; KELLY DF, 1995, J NEUROTRAUM, V12, P883, DOI 10.1089/neu.1995.12.883; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; KLUGER MJ, 1991, PHYSIOL REV, V71, P93; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; Lin HZ, 1998, ALCOHOL CLIN EXP RES, V22, p231S, DOI 10.1111/j.1530-0277.1998.tb04008.x; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; Masse J, 2000, J NEUROTRAUM, V17, P421, DOI 10.1089/neu.2000.17.421; MCCLAIN C, 1991, J LAB CLIN MED, V118, P225; MCCLAIN CJ, 1987, J LAB CLIN MED, V110, P48; OITZL MS, 1993, BRAIN RES, V613, P160, DOI 10.1016/0006-8993(93)90468-3; PERSSON L, 1977, ACTA NEUROL SCAND, V56, P7; Prasad RM, 2001, J NEUROTRAUM, V18, P1019, DOI 10.1089/08977150152693719; Prins ML, 1998, J NEUROTRAUM, V15, P799, DOI 10.1089/neu.1998.15.799; Rasmussen DD, 2000, ALCOHOL CLIN EXP RES, V24, P1836, DOI 10.1097/00000374-200012000-00013; Roe SY, 1997, J NEUROTRAUM, V14, P399, DOI 10.1089/neu.1997.14.399; Shapira Y, 1997, J NEUROSURG ANESTH, V9, P118, DOI 10.1097/00008506-199704000-00003; Sundgren-Andersson AK, 1998, NEUROIMMUNOMODULAT, V5, P241, DOI 10.1159/000026344; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Taylor AN, 2002, ALCOHOL CLIN EXP RES, V26, P44; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; YAMAKAMI I, 1995, J NEUROSURG, V82, P813, DOI 10.3171/jns.1995.82.5.0813; YOUNG AB, 1988, J NEUROSURG, V69, P375, DOI 10.3171/jns.1988.69.3.0375; Zhang LX, 1999, J NEUROTRAUM, V16, P243, DOI 10.1089/neu.1999.16.243; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; Zink BJ, 1999, BRAIN RES, V837, P1, DOI 10.1016/S0006-8993(99)01646-7	50	32	33	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2002	19	12					1597	1608		10.1089/089771502762300256			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	629UY	WOS:000180070700007	12542860				2021-06-18	
J	Kentner, R; Rollwagen, FM; Prueckner, S; Behringer, W; Wu, XR; Stezoski, J; Safar, P; Tisherman, SA				Kentner, R; Rollwagen, FM; Prueckner, S; Behringer, W; Wu, XR; Stezoski, J; Safar, P; Tisherman, SA			Effects of mild hypothermia on survival and serum cytokines in uncontrolled hemorrhagic shock in rats	SHOCK			English	Article						hemorrhage; fluid resuscitation; outcome; inflammatory response	TRAUMATIC BRAIN INJURY; TUMOR-NECROSIS-FACTOR; MODERATE HYPOTHERMIA; RESUSCITATION; SUPPRESSION; DYSFUNCTION; TEMPERATURE; IMPROVES; IL-10	Previous studies have suggested benefit of mild hypothermia during hemorrhagic shock (HS). This finding needs additional confirmation and investigation into possible mechanisms. Proinflammatory cytokines are mediators of multiple organ failure following traumatic hemorrhagic shock and resuscitation. We hypothesized that mild hypothermia would improve survival from HIS and may affect the pro- and anti-inflammatory cytokine response in a rat model of uncontrolled HS. Under light halothane anesthesia, uncontrolled HS was induced by blood withdrawal of 3 mL/1 00 g over 15 min followed by tail amputation. Hypotensive (limited) fluid resuscitation (to prevent mean arterial pressure [MAP] from decreasing below 40 mmHg) with blood was started at 30 min and continued to 90 min. After hemostasis and resuscitation with initially shed blood and Ringer's solution, the rats were observed for 72 h. The animals were randomized into two HS groups (n = 10 each): normothermia (38degreesC 0.5degreesC) and mild hypothermia (34degreesC 0.5degreesC) from HS 30 min until resuscitation time (RT) 60 min; and a sham group (n = 3). Venous blood samples were taken at baseline, RT 60 min, and days 1, 2, and 3. Serum interleukin (IL)-1beta, IL-6, IL-10, and tumor necrosis factor (TNF)-alpha concentrations were quantified by ELISA. Values are expressed as median and interquartile range. Survival time by life table analysis was greater in the hypothermia group (P = 0.04). Survival rates to 72 h were 1 of 10 vs. 6 of 10 in the normothermia vs. hypothermia groups, respectively (P = 0.057). All cytokine concentrations were significantly increased from baseline at RT 60 min in both HS groups, but not in the shams. At RT 60 min, in the normothermia vs. hypothermia groups, respectively, IL-1beta levels were 185 (119-252) vs. 96 (57-135) pg/mL (P = 0.15); IL-6 levels were 2242 (1903-3777) vs. 1746 (585-2480) pg/mL (P = 0.20); TNF-alpha levels were 97 (81-156) vs. 394 (280-406) pg/mL (P = 0.02); and IL-10 levels were 1.7 (0-13.3) vs. 15.8 (1.9-23.0) pg/mL (P = 0.09). IL-10 remained increased until day 3 in the hypothermia group. High IL-1 p levels (>100 pg/mL) at RT 60 min were associated with death before 72 h (odds ratio 66, C.I. 3.5-1255). We conclude that mild hypothermia improves survival time after uncontrolled HS. Uncontrolled HS induces a robust proinflammatory cytokine response. The unexpected increase in TNF-a with hypothermia deserves further investigation.	Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Anesthesiol, CCM, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA; Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD 20814 USA	Tisherman, SA (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.		Tisherman, Samuel A./AAK-9377-2020	Tisherman, Samuel A./0000-0003-3810-3729; Behringer, Wilhelm/0000-0003-2261-3193			Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; BarrosoAranda J, 1995, J CARDIOVASC PHARM, V25, pS23, DOI 10.1097/00005344-199500252-00006; Beilin B, 1998, ANESTHESIOLOGY, V89, P1133, DOI 10.1097/00000542-199811000-00013; BELLAMY RF, 1984, MIL MED, V149, P55; Bull DA, 2000, J THORAC CARDIOV SUR, V119, P242, DOI 10.1016/S0022-5223(00)70179-6; DEMPSEY RJ, 1987, NEUROSURGERY, V21, P177, DOI 10.1227/00006123-198708000-00007; Dietrich WD, 1999, EXP NEUROL, V158, P444, DOI 10.1006/exnr.1999.7115; Foex BA, 1997, SHOCK, V8, P276, DOI 10.1097/00024382-199710000-00007; Gentilello LM, 1997, ANN SURG, V226, P439, DOI 10.1097/00000658-199710000-00005; GIROIR BP, 1994, AM J PHYSIOL, V267, pH118; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Hasko G, 1998, EUR J IMMUNOL, V28, P1417, DOI 10.1002/(SICI)1521-4141(199804)28:04<1417::AID-IMMU1417>3.0.CO;2-L; HEGNAUER AH, 1954, AM J PHYSIOL, V178, P138; HOOPARIS R, 1991, AM J PHYSIOL, V260, pR480; Jarrar D, 1999, INT J MOL MED, V4, P575; JURKOVICH GJ, 1987, J TRAUMA, V27, P1019, DOI 10.1097/00005373-198709000-00011; Kim SH, 1997, J TRAUMA, V42, P213, DOI 10.1097/00005373-199702000-00006; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; LEI BP, 1994, STROKE, V25, P147, DOI 10.1161/01.STR.25.1.147; LUNA GK, 1987, J TRAUMA, V27, P1014, DOI 10.1097/00005373-198709000-00010; Mizushima Y, 2000, ARCH SURG-CHICAGO, V135, P175, DOI 10.1001/archsurg.135.2.175; Palo M, 2000, EUR J APPL PHYSIOL, V81, P391, DOI 10.1007/s004210050059; Pasquale MD, 1996, CRIT CARE MED, V24, P1238, DOI 10.1097/00003246-199607000-00029; Prueckner S, 2001, J TRAUMA, V50, P253, DOI 10.1097/00005373-200102000-00010; RHEE P, 1993, RESUSCITATION, V25, P249, DOI 10.1016/0300-9572(93)90122-7; ROUMEN RMH, 1993, ANN SURG, V218, P769, DOI 10.1097/00000658-199312000-00011; Rozenfeld RA, 1996, J APPL PHYSIOL, V81, P1834; SAFAR P, 1997, TXB NEUROANESTHESIA, P557; Seekamp A, 1999, J TRAUMA, V47, P673, DOI 10.1097/00005373-199910000-00011; STEINEMANN S, 1990, J TRAUMA, V30, P200, DOI 10.1097/00005373-199002000-00011; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Takasu A, 2000, CRIT CARE MED, V28, P2465, DOI 10.1097/00003246-200007000-00047; Tisherman SA, 1999, SURG CLIN N AM, V79, P1269, DOI 10.1016/S0039-6109(05)70077-3; Whalen MJ, 1997, J NEUROTRAUM, V14, P561, DOI 10.1089/neu.1997.14.561; ZAGER RA, 1991, CIRC RES, V68, P185, DOI 10.1161/01.RES.68.1.185	35	32	38	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	JUN	2002	17	6					521	526		10.1097/00024382-200206000-00014			6	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	626MT	WOS:000179877200014	12069191				2021-06-18	
J	Wells, RG; Vetter, C; Laud, P				Wells, RG; Vetter, C; Laud, P			Intracranial Hemorrhage in children younger than 3 years - Prediction of intent	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							TRAUMATIC BRAIN INJURY; SHAKEN-BABY SYNDROME; HEAD-INJURY; SUBDURAL-HEMATOMA; INFANTS; ABUSE	Objective: To determine whether certain computed tomographic imaging patterns in infants and young children with intracranial hemorrhage help predict intentional compared with unintentional injuries. Design: Retrospective consecutive case series over a 10-year period. Patients: Two hundred ninety-three children younger than 3 years with intracranial hemorrhage. Main Outcome Measures: The sensitivity and specificity of computed tomographic imaging patterns for intentional head injury. Setting: Regional pediatric medical center. Results: Four variables used in the multiple logistic regression analysis for predicting intentional head injury were statistically significant (P<.05): subdural hematoma located over the cerebral convexities, hematoma within the interhemispheric subdural space, hygroma (nonhemic subdural fluid) with intracranial hemorrhage, and absence of a skull fracture with intracranial hemorrhage. The prediction model for the diagnosis of intentional head trauma using combinations of these 4 variables and a 45 probability cutoff point indicated a sensitivity of 84% (95% confidence interval, 78%-90%) and a specificity of 83% (95% confidence interval, 74%-89%). Conclusion: Computed tomographic imaging patterns of intracranial hemorrhage in children younger than 3 years help predict whether the injury was intentional.	Childrens Hosp Wisconsin, Dept Radiol, Milwaukee, WI 53201 USA; Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA	Wells, RG (corresponding author), Childrens Hosp Wisconsin, Dept Radiol, MS 721,9000 W Wisconsin Ave,POB 1997, Milwaukee, WI 53201 USA.	rwells@chw.org					AOKI N, 1990, J NEUROSURG, V73, P201, DOI 10.3171/jns.1990.73.2.0201; BILLMIRE ME, 1985, PEDIATRICS, V75, P340; DiScala C, 2000, ARCH PEDIAT ADOL MED, V154, P16; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; GENNARELLI TA, 1982, J TRAUMA, V22, P680, DOI 10.1097/00005373-198208000-00005; Hymel KP, 1997, PEDIATR RADIOL, V27, P743, DOI 10.1007/s002470050215; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; MERTEN DF, 1984, PEDIATR RADIOL, V14, P272, DOI 10.1007/BF01601874; *NAT CTR CHILD AB, 1988, STUD NAT INC PREV CH; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; TSAI FY, 1980, CT-J COMPUT TOMOGR, V4, P277; Zimmerman R A, 1994, Neuroimaging Clin N Am, V4, P349; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687	17	32	32	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	1072-4710	1538-3628		ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	MAR	2002	156	3					252	257		10.1001/archpedi.156.3.252			6	Pediatrics	Pediatrics	528XK	WOS:000174270000009	11876669	Bronze			2021-06-18	
J	Dario, A; Di Stefano, MG; Grossi, A; Casagrande, F; Bono, G				Dario, A; Di Stefano, MG; Grossi, A; Casagrande, F; Bono, G			Long-term intrathecal Baclofen infusion in supraspinal spasticity of adulthood	ACTA NEUROLOGICA SCANDINAVICA			English	Article						Baclofen; brain injury; cerebral spasticity; intrathecal infusion	INTRACTABLE SPASTICITY; ADMINISTERED BACLOFEN; CEREBRAL ORIGIN; BRAIN INJURY; FOLLOW-UP; CHILDREN; PALSY	Objectives - To evaluate long-term results or chronic intrathecal Baclofen infusion on the spasticity, on the spasms and to evaluate the side-effects of the intrathecal Bacloren in patients with supraspinal spasticity. Clinical materials and methods - Fourteen patients with severe progressive refractory to medical therapy spasticity were evaluated after chronic intrathecal Baclofen infusion performed by implantation of subcutaneous pump. The patients had suffered traumatic or anoxic acquired brain injuries. The clinical evaluation was made using Ashworth Scale (AS) and the Spasm Frequency Scale (SFS). Results - The intrathecal therapy showed a statistically significant improvement of the tone and of the spasms. Conclusions - The intrathecal infusion of Baclofen seems to be an effective treatment in patients with supraspinal spasticity.	Univ Insubria, Dept Neurosurg, Varese, Italy; Univ Insubria, Dept Neurol, Varese, Italy; Varese Reg Hosp, Rehabil Unit, Varese, Italy; Macchi Fdn, Varese, Italy	Dario, A (corresponding author), Macchi Fdn, Via Torriani 32, I-22100 Como, Italy.		Dario, Alessandro/U-4426-2017				Armstrong RW, 1997, J NEUROSURG, V87, P409, DOI 10.3171/jns.1997.87.3.0409; Azouvi P, 1996, ARCH PHYS MED REHAB, V77, P35, DOI 10.1016/S0003-9993(96)90217-8; Becker R, 1997, J NEUROL, V244, P160, DOI 10.1007/s004150050067; Berg-Johnsen Jon, 1998, Tidsskrift for den Norske Laegeforening, V118, P3256; CAMPBELL SK, 1995, PHYS THER, V75, P352, DOI 10.1093/ptj/75.5.352; COFFEY RJ, 1993, J NEUROSURG, V78, P226, DOI 10.3171/jns.1993.78.2.0226; CONCALVES J, 1994, STEREOT FUNCT NEUROS, V62, P108, DOI 10.1159/000098605; Gerszten PC, 1998, J NEUROSURG, V88, P1009, DOI 10.3171/jns.1998.88.6.1009; Grabb PA, 1999, NEUROSURGERY, V45, P833, DOI 10.1097/00006123-199910000-00020; JENNETT B, 1975, LANCET, V1, P480; Lazorthes Y, 1998, NEUROCHIRURGIE, V44, P201; Meythaler JM, 1999, ARCH PHYS MED REHAB, V80, P13, DOI 10.1016/S0003-9993(99)90301-5; Meythaler JM, 1997, J NEUROSURG, V87, P415, DOI 10.3171/jns.1997.87.3.0415; MULLER H, 1992, PARENTERAL DRUG THER, P103; PIROTHE B, 1997, STEREOT FUNCT NEUROS, V67, P107; Rawicki B, 1999, J NEUROSURG, V91, P733, DOI 10.3171/jns.1999.91.5.0733; RIECI C, 1994, FUNCT NEUROL, V19, P29; Rodriguez M J, 1992, Rev Esp Anestesiol Reanim, V39, P289; STEINBOK P, 1995, PEDIATR NEUROSURG, V22, P255, DOI 10.1159/000120911; Van Schaeybroeck P, 2000, NEUROSURGERY, V46, P603, DOI 10.1097/00006123-200003000-00017	20	32	33	0	0	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	FEB	2002	105	2					83	87		10.1034/j.1600-0404.2002.1o042.x			5	Clinical Neurology	Neurosciences & Neurology	525UU	WOS:000174093100002	11903116				2021-06-18	
J	Fragala, MA; Haley, SM; Dumas, HM; Rabin, JP				Fragala, MA; Haley, SM; Dumas, HM; Rabin, JP			Classifying mobility recovery in children and youth with brain injury during hospital-based rehabilitation	BRAIN INJURY			English	Article							HEAD-INJURY; CHILDHOOD; SEVERITY; STROKE; PERFORMANCE; OUTCOMES; SYSTEM; COHORT	Primary objective: This article describes mobility recovery for children and youth with traumatic and non-traumatic brain injury during hospital-based rehabilitation. Research design: A retrospective, descriptive pre-test/post-test design was used. Methods and procedures: One hundred and fifty-seven individuals with brain injury who were admitted for rehabilitation over a 5-year period were enrolled in this study. The Paediatric Evaluation of Disability Inventory (PEDI) was used to document functional mobility at admission and discharge from the rehabilitation programme. The PEDI mobility classification system consisting of seven discrete levels of mobility was developed to provide clinically relevant and succinct outcome information. Main outcomes and results: The majority of children with brain injury (69%) improved one or more mobility classification levels. Children in the traumatic brain injury group made greater changes (p = 0.001) in mobility recovery than children in the non-traumatic group. Conclusions: Information about recovery using a well-defined functional classification system may assist with programme evaluation and facilitate optimal service delivery.	Franciscan Childrens Hosp & Rehabil Ctr, Res Ctr Children Special Hlth Care Needs, Boston, MA 02135 USA; Boston Univ, Sargent Coll Hlth & Rehabil Sci, Ctr Rehabil Effectiveness, Boston, MA 02215 USA; Franciscan Childrens Hosp & Rehabil Ctr, Inpatient Rehabil Program, Boston, MA USA	Fragala, MA (corresponding author), Franciscan Childrens Hosp & Rehabil Ctr, Res Ctr Children Special Hlth Care Needs, 30 Warren St, Boston, MA 02135 USA.	mfragala@tiac.net					Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Bowen JM, 1997, DEV MED CHILD NEUROL, V39, P17; BOYER MG, 1991, INJURY, V22, P315, DOI 10.1016/0020-1383(91)90014-6; CAMPBELL NN, 1994, J ROY SOC MED, V87, P73; CARNEY N, 1999, AHCPR PUBLICATION; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; COSTER WJ, 1994, AM J OCCUP THER, V48, P211, DOI 10.5014/ajot.48.3.211; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; EWINGCOBBS I, 1997, J INT NEUROPSYCHOLOG, V3; Ganesan V, 2000, DEV MED CHILD NEUROL, V42, P455, DOI 10.1017/S0012162200000852; GROSWASSER Z, 1989, ARCH PHYS MED REHAB, V70, P186; HALEY S, 1992, PEDIAT EVALUATION IN; HALEY SM, 1997, J REHABILITATION OUT, V1, P61; HAMILITON BB, 1994, PHYS THER, V74, P494, DOI 10.1093/ptj/74.5.494; Hurvitz E A, 1999, Pediatr Rehabil, V3, P43; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; LANSKA MJ, 1991, PEDIATR NEUROL, V7, P333, DOI 10.1016/0887-8994(91)90062-P; MASSAGLI TL, 1994, PEDIATR ANN, V23, P29, DOI 10.3928/0090-4481-19940101-08; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; Montgomery PC, 1998, PEDIAT PHYSICAL THER, V10, P148; Moorthi S, 1999, BRAIN INJURY, V13, P139, DOI 10.1080/026990599121809; Nichols D.S., 1996, PEDIATR PHYS THER, V8, DOI [https://doi.org/10.1097/00001577-199600810-00004, DOI 10.1097/00001577-199600810-00004]; Palisano R, 1997, DEV MED CHILD NEUROL, V39, P214, DOI 10.1111/j.1469-8749.1997.tb07414.x; Peacock WJ, 1996, CHILD NERV SYST, V12, P376, DOI 10.1007/BF00395089; PHILIP PA, 1994, ARCH PHYS MED REHAB, V75, P36; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; VanderSchaaf PJ, 1997, PEDIATR NEUROL, V16, P306, DOI 10.1016/S0887-8994(97)00025-8; *WHO, 2000, ICIDH2 INT CLASS FUN; WOLFEN W, 1998, DEV MED CHILD NEUROL, V40, P667; Wright FV, 1993, CAN J REHABIL, V7, P41	33	32	32	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	FEB	2002	16	2					149	160		10.1080/02699050110103328			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	518TG	WOS:000173683500004	11839109				2021-06-18	
J	Slobounov, S; Sebastianelli, W; Simon, R				Slobounov, S; Sebastianelli, W; Simon, R			Neurophysiological and behavioral concomitants of mild brain injury in collegiate athletes	CLINICAL NEUROPHYSIOLOGY			English	Article						post-concussion; electroencephalography; isometric force production	MOVEMENT-RELATED POTENTIALS; MINOR HEAD-INJURY; FINGER MOVEMENTS; RESPONSES; DISCRETE; LESIONS; TASK	Objectives: There is still limited understanding regarding the effect of mild brain injury (MBI) on normal functioning of the human brain with respect to motor control and coordination. To our knowledge, no research exists on how both the accuracy of force production and underlying neurophysiological concomitants are interactively affected by MBI. The aim of this study is to provide empirical evidence that there are at least transient functional changes in the brain associated with motor control and coordination in collegiate athletes suffering from MBI as reflected in alterations of force trajectory patterns and electroencephalogram (EEG) potentials both in time and frequency domains. Methods: Comparisons of the performance and concomitant EEG waveforms both in time and frequency domains of 6 collegiate athletes with MBI and 6 normal subjects in a series of isometric force production tasks were made. The traditional averaging techniques to obtain the slow-wave movement-related potentials (MRP) and Morlet wavelet transform to obtain EEG time-frequency (TF) profiles associated with task performance were used. Subjects performed isometric force production tasks when the level of nominal force was experimentally manipulated. EEG recordings from the frontal-central areas were analyzed with respect to the accuracy of force production during the ramp phase. Results: Behaviorally. the accuracy of force trajectory performance was considerably impaired in MBI subjects even when the amount of task force was only increased from 25 to 50% maximum voluntary contraction (MVC) within a given subject. Electro-cortically, impaired performance in MBI subjects was associated with alterations in EEG waveforms, amplitude of MRP and TF profiles of EEG. Conclusions: Both behavioral and electro-cortical data of control subjects generally were comparable with those from subjects with MBI when small amounts of force were regulated. However, differences become apparent as the amount of task force production was increased. Overall our findings identify the presence of transient functional changes in the brain associated with motor control and coordination in subjects suffering from MBI. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.	Penn State Univ, Dept Kinesiol, University Pk, PA 16802 USA; Ctr Community Hosp, Ctr Sport Med, State Coll, PA 16801 USA	Slobounov, S (corresponding author), Penn State Univ, Dept Kinesiol, 19 Recreat Hall, University Pk, PA 16802 USA.	sms18@psu.edu					BasarEroglu C, 1996, INT J PSYCHOPHYSIOL, V24, P101, DOI 10.1016/S0167-8760(96)00051-7; BOITEN F, 1992, ELECTROEN CLIN NEURO, V82, P302, DOI 10.1016/0013-4694(92)90110-4; BOUYER JJ, 1987, NEUROSCIENCE, V22, P863, DOI 10.1016/0306-4522(87)92965-4; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; CARLTON LG, 1988, J EXP PSYCHOL HUMAN, V14, P24; Gabor D., 1946, Journal of the Institution of Electrical Engineers. III. Radio and Communication Engineering, V93, P429; Gerloff C, 1996, ELECTROEN CLIN NEURO, V98, P59, DOI 10.1016/0013-4694(95)00204-9; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; GEVINS AS, 1987, SCIENCE, V235, P580, DOI 10.1126/science.3810158; Goldberg G, 1998, POSTGRAD MED, V104, P91, DOI 10.3810/pgm.1998.08.553; GRUNEWALD G, 1983, TUTORIALS EVENT RELA, P311; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Ikeda A, 1997, ELECTROEN CLIN NEURO, V102, P142, DOI 10.1016/S0921-884X(96)95067-5; INGERSOLL CD, 1992, MED SCI SPORT EXER, V24, P739; JENKINS A, 1986, LANCET, V2, P445; Johnson KA, 2001, EXP BRAIN RES, V138, P492, DOI 10.1007/s002210100733; KEELE SW, 1968, PSYCHOL BULL, V70, P387, DOI 10.1037/h0026739; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; KORNHUBE.HH, 1965, PFLUG ARCH GES PHYS, V284, P1, DOI 10.1007/BF00412364; KRISTEVA R, 1990, ELECTROEN CLIN NEURO, V75, P410, DOI 10.1016/0013-4694(90)90086-Y; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; Maddocks D, 1996, BRAIN INJURY, V10, P99, DOI 10.1080/026990596124584; MCCLELLAND RJ, 1994, J ROY SOC MED, V87, P508; MISITY M, 1996, TOOLBOX USERS GUIDE; MONTGOMERY EA, 1991, PSYCHOL MED, V21, P375, DOI 10.1017/S0033291700020481; Newell KM, 2001, PSYCHOL REV, V108, P57, DOI 10.1037//0033-295X.108.1.57; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PFURTSCHELLER G, 1992, NEUROREPORT, V3, P1057, DOI 10.1097/00001756-199212000-00006; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; RICHARDS P, 1992, PERCEPT MOTOR SKILL, V74, P1027, DOI 10.2466/PMS.74.4.1027-1030; Salenius S, 1996, NEUROSCI LETT, V213, P75, DOI 10.1016/0304-3940(96)12796-8; SCHIFF SJ, 1994, ELECTROEN CLIN NEURO, V91, P442, DOI 10.1016/0013-4694(94)90165-1; SCHMIDT RA, 1975, PSYCHOL REV, V82, P225, DOI 10.1037/h0076770; SHEER D, 1976, NEUROPSYCHOLOGY LEAR, P71; Simon R, 1999, J STRENGTH COND RES, V13, P139; Slobounov S, 2000, COGNITIVE BRAIN RES, V9, P177, DOI 10.1016/S0926-6410(99)00055-5; Slobounov S, 2000, MOTOR CONTROL, V4, P350, DOI 10.1123/mcj.4.3.350; Slobounov S, 2000, CLIN NEUROPHYSIOL, V111, P1997, DOI 10.1016/S1388-2457(00)00432-6; Slobounov SM, 1998, PSYCHOPHYSIOLOGY, V35, P537, DOI 10.1017/S0048577298970342; Slobounov SM, 1998, EXP BRAIN RES, V123, P461, DOI 10.1007/s002210050590; Slobounov SM, 2000, COGNITIVE BRAIN RES, V9, P287, DOI 10.1016/S0926-6410(00)00009-4; TallonBaudry C, 1996, J NEUROSCI, V16, P4240; TallonBaudry C, 1997, J NEUROSCI, V17, P722; TAYLOR AR, 1966, LANCET, V2, P178; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Thornton KE, 1999, BRAIN INJURY, V13, P477, DOI 10.1080/026990599121395; TIITINEN H, 1993, NATURE, V364, P59, DOI 10.1038/364059a0; WALKER AE, 1994, J NEUROSURG, V81, P493, DOI 10.3171/jns.1994.81.3.0493; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514; WOBER C, 1993, ARCH PHYS MED REHAB, V74, P1151; Wright SC, 1998, AVIAT SPACE ENVIR MD, V69, P999; Yazawa S, 2000, EXP BRAIN RES, V131, P165, DOI 10.1007/s002219900311	60	32	32	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	1388-2457	1872-8952		CLIN NEUROPHYSIOL	Clin. Neurophysiol.	FEB	2002	113	2					185	193	PII S1388-2457(01)00737-4	10.1016/S1388-2457(01)00737-4			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	536FF	WOS:000174689500002	11856624				2021-06-18	
J	Duerstock, BS; Borgens, RB				Duerstock, BS; Borgens, RB			Three-dimensional morphometry of spinal cord injury following polyethylene glycol treatment	JOURNAL OF EXPERIMENTAL BIOLOGY			English	Article						three-dimensional reconstruction; computer visualization; morphometry; spinal cord injury; neurotrauma; cavitation	3-DIMENSIONAL RECONSTRUCTION; RAT; REPAIR; MACROPHAGES; CONTUSION; NUCLEUS; FUSION; MODEL; CELLS; AXONS	We are developing a novel means of restoring function after severe acute spinal cord injury. This involves a brief application of polyethylene glycol (PEG) to the site of injury. In the companion paper, we have shown that a delayed application of PEG can produce strikingly significant physiological and behavioral recovery in 90-100 % of spinal-cord-injured guinea pigs. In the present paper, we used three-dimensional computer reconstructions of PEG-treated and sham-treated spinal cords to determine whether the pathological character of a 1-month-old injury is ameliorated by application of PEG. Using a novel isocontouring algorithm, we show that immediate PEG treatment and treatment delayed by up to 7 h post-injury statistically increased the volume of intact spinal parenchyma and reduced the amount of cystic cavitation. Furthermore, in PEG-treated animals, the lesion was more focal and less diffuse throughout the damaged segment of the spinal cord, so that control cords showed a significantly extended lesion surface area. This three-dimensional computer evaluation showed that the functional recovery produced by topical application of a hydrophilic polymer is accompanied by a reduction in spinal cord damage.	Purdue Univ, Sch Vet Med, Dept Basic Med Sci, Inst Appl Neurol,Ctr Paralysis Res, W Lafayette, IN 47907 USA	Duerstock, BS (corresponding author), Purdue Univ, Sch Vet Med, Dept Basic Med Sci, Inst Appl Neurol,Ctr Paralysis Res, W Lafayette, IN 47907 USA.	cpr@vet.purdue.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039288] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS39288-01] Funding Source: Medline		Allen A.R., 1911, JAMA-J AM MED ASSOC, V57, P878, DOI DOI 10.1001/JAMA.1911.04260090100008; Arndt S, 1994, Neuroimage, V1, P191, DOI 10.1006/nimg.1994.1004; Bajaj CL, 1997, VISUALIZATION '97 - PROCEEDINGS, P167, DOI 10.1109/VISUAL.1997.663875; Beattie MS, 1997, EXP NEUROL, V148, P453, DOI 10.1006/exnr.1997.6695; Blight A R, 1985, Cent Nerv Syst Trauma, V2, P299; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; BLIGHT AR, 1993, ADV NEUROL, V59, P91; BLIGHT AR, 1992, J NEUROTRAUMA, V9, P83; Borgens RB, 2000, FASEB J, V14, P27; Borgens RB, 2002, J EXP BIOL, V205, P1; Bresnahan JC, 1991, J NEUROTRAUM, V8, P91, DOI 10.1089/neu.1991.8.91; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; Duerstock BS, 2000, COMPUT MED IMAG GRAP, V24, P389, DOI 10.1016/S0895-6111(00)00034-3; HALLIDAY GM, 1993, SYNAPSE, V15, P1, DOI 10.1002/syn.890150102; HARRIS KM, 1988, J NEUROSCI, V8, P4455; HASHIMOTO S, 1988, ACTA OTO-LARYNGOL, V105, P64, DOI 10.3109/00016488809119447; Honmou Osamu, 1995, P480; KRAUSE TL, 1990, P NATL ACAD SCI USA, V87, P1471, DOI 10.1073/pnas.87.4.1471; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; Leskovar A, 2000, J EXP BIOL, V203, P1783; LISS AG, 1995, J MICROSC-OXFORD, V178, P160, DOI 10.1111/j.1365-2818.1995.tb03592.x; MARKS JD, 2001, IN PRESS FASEB J; MARTONE ME, 1993, J NEUROSCI, V13, P4636; Moriarty LJ, 1998, J NEUROL SCI, V155, P121, DOI 10.1016/S0022-510X(97)00203-7; NAKAJIMA N, 1994, J BIOMAT SCI-POLYM E, V6, P751, DOI 10.1163/156856295X00139; NAVARRO A, 1994, ANAT RECORD, V240, P572, DOI 10.1002/ar.1092400414; NOBLE LJ, 1985, EXP NEUROL, V88, P135, DOI 10.1016/0014-4886(85)90119-0; OLAGUE PH, 1980, P NATL ACAD SCI-BIOL, V77, P1701, DOI 10.1073/pnas.77.3.1701; PERRY VH, 1987, J EXP MED, V165, P1218, DOI 10.1084/jem.165.4.1218; PERRY VH, 1993, TRENDS NEUROSCI, V16, P268, DOI 10.1016/0166-2236(93)90180-T; SALISBURY JR, 1994, HISTOL HISTOPATHOL, V9, P773; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi RY, 1999, J NEUROTRAUM, V16, P727, DOI 10.1089/neu.1999.16.727	33	32	32	0	7	COMPANY BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING, STATION RD, HISTON, CAMBRIDGE CB24 9LF, ENGLAND	0022-0949	1477-9145		J EXP BIOL	J. Exp. Biol.	JAN	2002	205	1					13	24					12	Biology	Life Sciences & Biomedicine - Other Topics	516DH	WOS:000173536200002	11818408				2021-06-18	
J	Jorge, R; Robinson, RG				Jorge, R; Robinson, RG			Mood disorders following traumatic brain injury	NEUROREHABILITATION			English	Article							HEAD-INJURY; SECONDARY MANIA; MAJOR DEPRESSION; SYMPTOMS; IMPROVEMENT; POPULATION; SEQUELAE; LESIONS; STROKE; DEATH		Univ Iowa, Coll Med, Dept Psychiat, Iowa City, IA 52242 USA	Jorge, R (corresponding author), Univ Iowa, Coll Med, Dept Psychiat, 200 Hawkins Dr 2887 JPP, Iowa City, IA 52242 USA.		Robinson, Robert/AAF-6191-2021				Ashton D, 1997, BRAIN RES, V745, P210, DOI 10.1016/S0006-8993(96)01094-3; BAKCHINE S, 1989, NEUROLOGY, V39, P778; BAMRAH JS, 1980, BRIT J PSYCHIAT, V258, P117; Bareyre FM, 2000, J NEUROTRAUM, V17, P1029, DOI 10.1089/neu.2000.17.1029; BOUVY PF, 1988, ACTA PSYCHIAT SCAND, V77, P361, DOI 10.1111/j.1600-0447.1988.tb05136.x; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; CORN TH, 1983, BRIT J PSYCHIAT, V143, P74, DOI 10.1192/bjp.143.1.74; CUMMINGS JL, 1984, AM J PSYCHIAT, V141, P1084; CUMMINGS JL, 1996, NEUROLOGY, V47; DAVIDSON J, 1986, BRIT J PSYCHIAT, V148, P442, DOI 10.1192/bjp.148.4.442; Dixon CE, 1996, PHARMACOL BIOCHEM BE, V53, P679, DOI 10.1016/0091-3057(95)02069-1; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Fann JR, 2000, J NEUROPSYCH CLIN N, V12, P226, DOI 10.1176/appi.neuropsych.12.2.226; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gillen R, 2001, ARCH PHYS MED REHAB, V82, P1645, DOI 10.1053/apmr.2001.26249; GOGGANS FC, 1984, AM J PSYCHIAT, V141, P300; GRAFMAN J, 1986, BRAIN, V109, P1127, DOI 10.1093/brain/109.6.1127; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Gualtari CT, 1991, BRAIN INJURY, V5, P219; Gualtieri CT, 1991, J HEAD TRAUMA REHAB, V6, P90; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; HOLSINGER T, 2001, IN PRESS ARCH GEN PS; Hornstein A, 1989, J Neuropsychiatry Clin Neurosci, V1, P446; ISLES LJ, 1991, BRIT J PSYCHIAT, V159, P280, DOI 10.1192/bjp.159.2.280; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; JORGE RE, 1993, AM J PSYCHIAT, V150, P916; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Leonard JR, 1997, EXP NEUROL, V143, P177, DOI 10.1006/exnr.1996.6366; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; Luukinen H, 1999, NEUROLOGY, V52, P557, DOI 10.1212/WNL.52.3.557; LYETH BG, 1992, J NEUROTRAUMA S2, V9, P463; MARIN RS, 1995, J NEUROPSYCH CLIN N, V7, P23; MARKIANOS M, 1992, ACTA NEUROL SCAND, V86, P190, DOI 10.1111/j.1600-0404.1992.tb05064.x; McHugh PR, 1998, PERSPECTIVES PSYCHIA; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Oyesiku NM, 1999, BRAIN RES, V833, P161, DOI 10.1016/S0006-8993(99)01501-2; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; Philips MF, 2001, J NEUROSURG, V94, P765, DOI 10.3171/jns.2001.94.5.0765; POPE HG, 1988, COMPR PSYCHIAT, V29, P34, DOI 10.1016/0010-440X(88)90035-1; Prigatano G.P., 1991, J HEAD TRAUMA REHAB, V6, P1; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; ROBINSON RG, 1988, AM J PSYCHIAT, V145, P172; ROBINSON RG, 1993, AM J PSYCHIAT, V150, P286; ROBINSON RG, 1998, CLIN NEUROPSYCHIATRY, P186; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; RUTHERFORD WH, 1977, LANCET, V1, P1; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SBORDONE RJ, 1990, COMMUNITY INTEGRATIO; SCHIFFER RB, 1985, NEW ENGL J MED, V312, P1480, DOI 10.1056/NEJM198506063122303; SCHMIDT RH, 1995, J NEUROSURG, V83; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; SELIGER G M, 1992, Brain Injury, V6, P267, DOI 10.3109/02699059209029668; SHUKLA S, 1987, AM J PSYCHIAT, V144, P93; Silver J. M., 1991, NEUROPSY NEUROPSY BE, V4, P12; SILVER JM, 1990, J CLIN PSYCHIAT, V51, P33; Sinson G, 1997, J NEUROSURG, V86, P511, DOI 10.3171/jns.1997.86.3.0511; STARKSTEIN SE, 1987, ARCH NEUROL-CHICAGO, V44, P1069, DOI 10.1001/archneur.1987.00520220065019; Starr L B, 1982, Soc Work Res Abstr, V18, P28; STUTZMANN JM, 1995, NEURODEGENERATIVE DI, P205; THIENHAUS OJ, 1984, AM J PSYCHIAT, V141, P1459; THOMAS CS, 1991, BRIT J PSYCHIAT, V158, P119, DOI 10.1192/bjp.158.1.119; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; Wroblewski BA, 1996, J CLIN PSYCHIAT, V57, P582, DOI 10.4088/JCP.v57n1206; YOUNG RC, 1978, BRIT J PSYCHIAT, V133, P429, DOI 10.1192/bjp.133.5.429; ZASLER N D, 1992, Brain Injury, V6, P1, DOI 10.3109/02699059209008117	77	32	36	0	3	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135			NEUROREHABILITATION	Neurorehabilitation		2002	17	4					311	324					14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	636GA	WOS:000180445200005	12547979				2021-06-18	
J	Rieger, M; Gauggel, S				Rieger, M; Gauggel, S			Inhibition of ongoing responses in patients with traumatic brain injury	NEUROPSYCHOLOGIA			English	Article						traumatic brain injury; response inhibition; stop signal task; stop signal reaction time; executive function	CLOSED-HEAD-INJURY; CARD SORTING TEST; FRONTAL-LOBE; REACTION-TIME; DIVIDED ATTENTION; DEFICITS; PERFORMANCE; DYSFUNCTION; DISORDER; TASK	In addition to slowness of information processing, it is often assumed that executive functions are deficient in patients with traumatic brain injuries (TBI). The aim of this study was to investigate a specific executive function, the inhibition of ongoing responses in TBI. Twenty-seven patients with TBI and 27 orthopedic patients (OC) performed the stop signal task, which allows the estimation of the time it takes to inhibit an ongoing response. Contrary to expectations, patients with TBI did not perform worse than the OC in the inhibition of ongoing responses. Furthermore, subgroups of the TBI, with frontal and nonfrontal lesions, and with focal versus diffuse damage, did not show any differences in performance. None of the clinical, demographic or neuropsychological data had a significant relationship to inhibition time, apart from age, which showed a significant relationship only in the TBI. It seems likely that deficits in the inhibition of ongoing responses are not very common after TBI. (C) 2001 Elsevier Science Ltd. All rights reserved.	Max Planck Inst Psychol Res, D-80799 Munich, Germany; Univ Technol Chemnitz, Dept Psychol, Chemnitz, Germany	Rieger, M (corresponding author), Max Planck Inst Psychol Res, Amalienstr 33, D-80799 Munich, Germany.			Gauggel, Siegfried/0000-0002-2742-4917			ARBUTHNOTT KD, 1995, CAH PSYCHOL COGN, V14, P3; AXELROD BN, 1994, NEUROPSY NEUROPSY BE, V7, P20; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; BAND GPH, 1997, THESIS U AMSTERDAM; Bigler E D, 1987, Arch Clin Neuropsychol, V2, P293, DOI 10.1016/0887-6177(87)90017-5; BRAUN CMJ, 1989, INT J CLIN NEUROPSYC, V11, P167; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Cockburn J, 1995, J Int Neuropsychol Soc, V1, P537; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Collins LF, 1996, ARCH CLIN NEUROPSYCH, V11, P613, DOI 10.1016/0887-6177(97)81255-3; CREMONAMETEYARD SL, 1994, BRAIN INJURY, V8, P541, DOI 10.3109/02699059409151006; Damasio H., 1989, LESION ANAL NEUROPSY; DELANGEN EG, 1995, REHABILITATION, V34, P4; deZubicaray G, 1996, CLIN NEUROPSYCHOL, V10, P245, DOI 10.1080/13854049608406687; Duncan J, 1997, COGNITIVE NEUROPSYCH, V14, P713, DOI 10.1080/026432997381420; FROMMELT P, 1995, HDB KLASSIFIKATION, P125; FUSTER JM, 1985, HUM NEUROBIOL, V4, P169; Fuster JM, 1999, ACTA PSYCHIAT SCAND, V99, P51, DOI 10.1111/j.1600-0447.1999.tb05983.x; Gansler DA, 1996, BRAIN COGNITION, V30, P194, DOI 10.1006/brcg.1996.0012; GREVE KW, 1991, GERONTOLOGY GERIATRI, V11, P57, DOI DOI 10.1300/J021v11n04_05; Heubrock D, 1992, Z DIFFERENTIELLE DIA, V3, P161; Horn W, 1983, LEISTUNGSPRUFSYSTEM; Houghton G, 1996, VIS COGN, V3, P119, DOI 10.1080/713756733; KAERNBACH C, 1991, PERCEPT PSYCHOPHYS, V49, P227, DOI 10.3758/BF03214307; KEITH RA, 1987, ADV CLIN REHABILITAT, P6; Kiefer M, 1998, NEUROREPORT, V9, P765, DOI 10.1097/00001756-199803090-00037; Konrad KN, 2000, BRAIN INJURY, V14, P859; Leon-Carrion J, 1998, INT J NEUROSCI, V94, P75, DOI 10.3109/00207459808986440; LEVIN H, 1994, J NEUROPSYCH CLIN N, V6, P443; LEVITT H, 1971, J ACOUST SOC AM, V49, P467, DOI 10.1121/1.1912375; LEZAK MD, 1982, INT J PSYCHOL, V17, P281, DOI 10.1080/00207598208247445; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LOGAN GD, 1984, PSYCHOL REV, V91, P295, DOI 10.1037/0033-295X.91.3.295; LOGAN GD, 1981, ATTENTION PERFORM, P208; Logan Gordon D., 1994, P189; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; McGarry T, 1997, J EXP PSYCHOL HUMAN, V23, P1533, DOI 10.1037//0096-1523.23.5.1533; Milner B, 1964, FRONTAL GRANULAR COR, P313; MOUNTAIN MA, 1993, CLIN NEUROPSYCHOL, V7, P108, DOI 10.1080/13854049308401893; Neill W. Trammell, 1995, P207, DOI 10.1016/B978-012208930-5/50008-8; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Park NW, 1999, NEUROPSYCHOLOGIA, V37, P1119, DOI 10.1016/S0028-3932(99)00034-2; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; *SAS I INC, 1988, SAS SYST WIND VERS 6; SCHACHAR R, 1990, DEV PSYCHOL, V26, P710, DOI 10.1037/0012-1649.26.5.710; SCHACHAR RJ, 1993, CLIN PSYCHOL REV, V13, P721, DOI 10.1016/S0272-7358(05)80003-0; Schmidt I W, 1996, Appl Neuropsychol, V3, P155, DOI 10.1207/s15324826an0303&4_8; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Stewart JAL, 1999, BRAIN COGNITION, V41, P411, DOI 10.1006/brcg.1999.1141; Sturm W, 1983, DIAGNOSTICA, V29, P346; STURM W, 1995, LEISTUNGSPRUFSYSTEM; Stuss D.T., 1986, FRONTAL LOBES; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Tabachnick BG, 2013, USING MULTIVARIATE S; TROUNG MK, 1993, SHORT WISCONSIN CARD; Umilta C, 1998, METACOGNITION AND COGNITIVE NEUROPSYCHOLOGY, P37; vanGorp WG, 1997, CLIN NEUROPSYCHOL, V11, P155, DOI 10.1080/13854049708407044; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Wechsler D., 1987, WMS R WECHSLER MEMOR; Whyte J, 1997, NEUROPSYCHOLOGIA, V35, P313, DOI 10.1016/S0028-3932(96)00092-9; Williams BR, 1999, DEV PSYCHOL, V35, P205, DOI 10.1037/0012-1649.35.1.205	66	32	32	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia		2002	40	1					76	85		10.1016/S0028-3932(01)00068-9			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	487WN	WOS:000171902200007	11595263				2021-06-18	
J	Forsman, L; Eriksson, A				Forsman, L; Eriksson, A			Skateboarding injuries of today	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						skateboard; injury; prevention	CHILDREN	Background-Skateboarding injuries have increased with the rise in popularity of the sport, and the injury pattern can be expected to have changed with the development of both skateboard tricks and the materials used for skateboard construction. Objective-To describe the injury pattern of today. Methods-The pattern of injuries, circumstances, and severity were investigated in a study of all 139 people injured in skateboarding accidents during the period 1995-1998 inclusive and admitted to the University Hospital of Umea. This is the only hospital in the area, serving a population of 135 000. Results-Three of the 139 injured were pedestrians hit by a skateboard rider; the rest were riders. The age range was 7-47 years (mean 16). The severity of the injuries was minor (AIS 1) to moderate (AIS 2); fractures were classified as moderate. The annual number of injuries increased during the study period. Fractures were found in 29% of the casualties, and four children had concussion. The most common fractures were of the ankle and wrist. Older patients had less severe injuries, mainly sprains and soft tissue injuries. Most children were injured while skateboarding on ramps and at arenas; only 12 (9%) were injured while skateboarding on roads. Some 37% of the injuries occurred because of a loss of balance, and 26% because of a failed trick attempt. Falls caused by surface irregularities resulted in the highest proportion of the moderate injuries. Conclusions-Skateboarding should be restricted to supervised skateboard parks, and skateboarders should be required to wear protective gear. These measures would reduce the number of skateboarders injured in motor vehicle collisions, reduce the personal injuries among skateboarders, and reduce the number of pedestrians injured in collisions with skateboarders.	Umea Univ, Sect Forens Med, Dept Community Hlth & Rehabil, SE-90712 Umea, Sweden	Forsman, L (corresponding author), Umea Univ, Sect Forens Med, Dept Community Hlth & Rehabil, POB 7642, SE-90712 Umea, Sweden.						ADAMS ID, 1979, NURS TIMES, V26, P707; ALLUM RL, 1978, INJURY, V10, P152; *ASS ADV AUT MED, ABBR INJ SCAL 1990 R; ATIENZA F, 1976, PEDIATRICS, V57, P793; Banas M P, 1992, J Orthop Trauma, V6, P301, DOI 10.1097/00005131-199209000-00006; BOYLE WE, 1995, PEDIATRICS, V95, P611; Brudvik C, 2001, Tidsskr Nor Laegeforen, V121, P19; CARRAGHER A M, 1990, Journal of Emergency Medicine, V8, P419, DOI 10.1016/0736-4679(90)90168-U; CASS DT, 1990, MED J AUSTRALIA, V153, P140, DOI 10.5694/j.1326-5377.1990.tb136832.x; CASSORLA A, 1988, ULTIMATE SKATEBOARD, P17; Christian M S, 1980, Br J Sports Med, V14, P102; *COMM ACC POIS PRE, 1979, PEDIATRICS, V63, P924; Fountain JL, 1996, SPORTS MED, V22, P360, DOI 10.2165/00007256-199622060-00004; FYFE IS, 1979, J SPORT MED PHYS FIT, V19, P265; FYFE IS, 1978, INJURY, V10, P149; HAWKINS RW, 1981, AM J SPORT MED, V9, P99, DOI 10.1177/036354658100900205; HAWKINS RW, 1978, AM J DIS CHILD, V132, P751, DOI 10.1001/archpedi.1978.02120330023004; ILLINGWORTH CM, 1978, CLIN PEDIATR, V17, P781, DOI 10.1177/000992287801701012; JAKOBS RA, 1977, PEDIATRICS, V59, P939; KEMM I, 1978, BRIT MED J, V1, P894, DOI 10.1136/bmj.1.6117.894; Maddox D, 1976, PHYSICIAN SPORTSMED, V4, P24; MAITRA AK, 1979, BRIT J CLIN PRACT, V33, P281; MAITRA AK, 1979, BR J CLIN PRACT, V33, P288; MORGAN WJ, 1980, SCOT MED J, V25, P39, DOI 10.1177/003693308002500109; PENDERGRAST RA, 1990, J ADOLESCENT HEALTH, V11, P408, DOI 10.1016/0197-0070(90)90087-I; RETSKY J, 1991, AM J DIS CHILD, V145, P188, DOI 10.1001/archpedi.1991.02160020080022; SCHIEBER RA, 1994, JAMA-J AM MED ASSOC, V271, P1856, DOI 10.1001/jama.271.23.1856; SMITH RG, 1979, CAN MED ASSOC J, V121, P510; Tordai P, 1979, Lakartidningen, V76, P2781; WIDOME MD, 1989, PEDIATRICS, V83, P1070	30	32	33	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	OCT	2001	35	5					325	328		10.1136/bjsm.35.5.325			4	Sport Sciences	Sport Sciences	479FR	WOS:000171394800013	11579065	Green Published, Bronze			2021-06-18	
J	Matuja, WBP; Kilonzo, G; Mbena, P; Mwango'mbola, RL; Wong, P; Goodfellow, P; Jilek-Aall, L				Matuja, WBP; Kilonzo, G; Mbena, P; Mwango'mbola, RL; Wong, P; Goodfellow, P; Jilek-Aall, L			Risk factors for epilepsy in a rural area in Tanzania - A community-based case-control study	NEUROEPIDEMIOLOGY			English	Article						epilepsy; risk factors; electroencephalography; Tanzania; Africa	FEBRILE CONVULSIONS; UNPROVOKED SEIZURES; CLASSIFICATION; EPIDEMIOLOGY; POPULATION; ROCHESTER; MINNESOTA	Background and Methods: The high prevalence of epilepsy detected in rural Tanzania by Dr. Jilek-Aall since 1960, was verified by the World Health Organization (WHO) survey on neurological and seizure disorders. Neurologists and psychiatrists further interviewed both patients and controls using standard methods. The presence of possible risk factors was complemented by corroborative evidence through interviewing close relatives and scrutinizing medical records. Seizures were classified based on clinical symptoms and the use of EEG. Results: A family history of epilepsy in first-degree relatives was found in 46.6% of patients, but in only 19.6% of controls. The odds ratio for family history with epilepsy was 3.52 (95% confidence interval, CI 2.4-5.74, p < 0.001). A past history of febrile convulsion was found in 44% of patients in comparison to 23% of the control group which was significant (odds ratio 2.4, 95% CI 1.5-3.8; p < 0.001). A history of intrapartum complications was found in 12.1% of patients and 1.8% of controls (odds ratio 7.3, 95% CI 2.5-25.2; p < 0.002). Head injury was not a significant risk factor for epilepsy in this rural community. Conclusion: The results indicated a strongly independent association between four factors and the risk of developing epilepsy. It would seem more likely that previous brain insults/diseases play a significant major role in the cause of epilepsy in the Mahenge area. However, a genetic predisposition to low threshold for convulsions cannot be excluded. Copyright (C) 2001 S. Karger AG, Basel.	Muhimbili Univ, Coll Hlth Sci, Dept Med, Neurol Unit, Dar Es Salaam, Tanzania; Muhimbili Univ, Coll Hlth Sci, Dept Psychiat, Neurol Unit, Dar Es Salaam, Tanzania; Mahenge Dist Hosp, Morogoro, Tanzania; Morogoro Reg Hosp, Morogoro, Tanzania; Univ British Columbia, Neuroelectrophysiol Dept, Vancouver, BC, Canada; Univ British Columbia, Dept Genet, Vancouver, BC, Canada; Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada	Matuja, WBP (corresponding author), Muhimbili Univ, Coll Hlth Sci, Dept Med, Neurol Unit, POB 65001, Dar Es Salaam, Tanzania.						ANNEGERS JF, 1987, NEW ENGL J MED, V316, P493, DOI 10.1056/NEJM198702263160901; ANNEGERS JF, 1979, NEUROLOGY, V29, P297, DOI 10.1212/WNL.29.3.297; BANCAUD J, 1981, EPILEPSIA, V22, P489, DOI 10.1111/j.1528-1157.1981.tb06159.x; CAMPBELL CD, 1987, S AFR MED J, V72, P885; DANESI MA, 1985, EPILEPSIA, V26, P131, DOI 10.1111/j.1528-1157.1985.tb05396.x; GERRITS C, 1983, LANCET, V1, P358; GOODRIDGE DMG, 1983, BMJ-BRIT MED J, V287, P641, DOI 10.1136/bmj.287.6393.641; GOODSMIT J, 1983, NEUROEPIDEMIOLOGY, V2, P24; HAUSER WA, 1984, NEUROLOGY, V34, P746, DOI 10.1212/WNL.34.6.746; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; HAUSER WA, 1975, EPILEPSIA, V16, P1, DOI 10.1111/j.1528-1157.1975.tb04721.x; JILEK W G, 1970, African Journal of Medical Sciences, V1, P305; JILEKAALL L, 1994, 12 INT C TROP NEUR S; JILEKAALL L, 1979, EPILEPSIA, V20, P612; KIPP W, 1992, LANCET, V340, P789, DOI 10.1016/0140-6736(92)92329-E; KIPP W, 1994, LANCET, V343, P183, DOI 10.1016/S0140-6736(94)90980-6; LEVITON A, 1982, Neuroepidemiology, V1, P40, DOI 10.1159/000110688; LI SC, 1985, EPILEPSIA, V26, P391, DOI 10.1111/j.1528-1157.1985.tb05669.x; MATUJA W B P, 1990, African Journal of Medicine and Medical Sciences, V19, P89; MATUJA WBP, 1994, E AFR MED J, V71, P236; MATUJA WBP, 1989, E AFR MED J, V66, P343; OGUNNIYI A, 1987, EPILEPSIA, V28, P280, DOI 10.1111/j.1528-1157.1987.tb04219.x; OSUNTOKUN BO, 1974, DEV MED CHILD NEUROL, V16, P659; OSUNTONKUN BO, 1982, NEUROEPIDEMIOLOGY, V1, P145; OTTMAN R, 1995, NEUROLOGY, V39, P442; ROCCA WA, 1987, ANN NEUROL, V21, P22, DOI 10.1002/ana.410210106; RWIZA HT, 1992, EPILEPSIA, V33, P1051, DOI 10.1111/j.1528-1157.1992.tb01758.x; SANDER JW, 1990, LANCET, V335, P267; SHORVON SD, 1988, EPILEPSIA, V29, pS36, DOI 10.1111/j.1528-1157.1988.tb05790.x; SRIDHARAN R, 1986, EPILEPSIA, V27, P60, DOI 10.1111/j.1528-1157.1986.tb03502.x; TAYLOR J, 1978, PRELIMINARY REPORT C; TECKLEHAIMANOT R, 1990, EPILEPSY RES, V7, P230; WEGESA P, 1970, TROP GEOGR MED, V22, P345; World Health Organization, 1981, RES PROT MEAS PREV N	34	32	33	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0251-5350			NEUROEPIDEMIOLOGY	Neuroepidemiology	OCT	2001	20	4					242	247		10.1159/000054797			6	Public, Environmental & Occupational Health; Clinical Neurology	Public, Environmental & Occupational Health; Neurosciences & Neurology	491UN	WOS:000172128600005	11684900				2021-06-18	
J	Klocker, N; Zerfowski, M; Gellrich, NC; Bahr, M				Klocker, N; Zerfowski, M; Gellrich, NC; Bahr, M			Morphological and functional analysis of an incomplete CNS fiber tract lesion: Graded crush of the rat optic nerve	JOURNAL OF NEUROSCIENCE METHODS			English	Article						retinal ganglion cell; optic nerve; graded crush; neurodegeneration; VEP	RETINAL GANGLION-CELLS; IN-VIVO; CONTRAST SENSITIVITY; NEUROTROPHIC FACTOR; PIGMENTED RAT; ADULT-RATS; AXOTOMY; SURVIVAL; DEATH; LAYER	Fiber tract lesions in the central nervous system (CNS) often induce delayed retrograde neuronal degeneration, a phenomenon that represents an important therapeutic challenge in clinical neurotraumatology. In the present study, we report an in vivo trauma model of graded axonal lesion of CNS neurons. Controlled by a newtonmeter device, we induced retrograde degeneration of adult rat retinal ganglion cells (RGCs) by graded crush of the optic nerve. The extent of secondary RGC death increased linearly with the applied crush force. Moreover, visually evoked potentials were used to characterize the consequences of controlled optic nerve lesion on the functional integrity of the visual projection. The presented model of faber tract lesion closely resembles the clinical conditions of traumatic brain injury and could prove useful to screen for neuroprotective drugs based on both a morphological and functional read-out. (C) 2001 Elsevier Science B.V. All rights reserved.	Univ Tubingen, Dept Neurol, D-72076 Tubingen, Germany; Univ Tubingen, Dept Physiol 2, D-72074 Tubingen, Germany; Univ Tubingen, Dept Oral & Maxillofacial Surg, D-72076 Tubingen, Germany; Univ Freiburg, Dept Oral & Maxillofacial Surg, D-79106 Freiburg, Germany	Klocker, N (corresponding author), Univ Tubingen, Dept Neurol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	nikolaj.kloecker@uni-tuebingen.de	Baehr, Mathias/K-2188-2014				Bien A, 1999, J NEUROTRAUM, V16, P153, DOI 10.1089/neu.1999.16.153; BIRCH D, 1979, VISION RES, V19, P933, DOI 10.1016/0042-6989(79)90029-4; FRIEDMAN LJ, 1982, VISION RES, V22, P441, DOI 10.1016/0042-6989(82)90191-2; GARCIAVALENZUELA E, 1994, J NEUROBIOL, V25, P431, DOI 10.1002/neu.480250408; Gellrich NC, 1997, OPHTHALMOLOGE, V94, P807, DOI 10.1007/s003470050208; Giehl KM, 1996, EUR J NEUROSCI, V8, P1167, DOI 10.1111/j.1460-9568.1996.tb01284.x; Kermer P, 1999, FEBS LETT, V453, P361, DOI 10.1016/S0014-5793(99)00747-4; Kermer P, 2000, J NEUROSCI, V20, P722, DOI 10.1523/JNEUROSCI.20-02-00722.2000; Klocker N, 1997, NEUROREPORT, V8, P3439; Klocker N, 1998, J NEUROSCI, V18, P1038; NI SYK, 1981, P AUST PHYSL PHARM S, V12, pP97; PeinadoRamon P, 1996, INVEST OPHTH VIS SCI, V37, P489; PERRY VH, 1981, NEUROSCIENCE, V6, P931, DOI 10.1016/0306-4522(81)90174-3; PERRY VH, 1979, PROC R SOC SER B-BIO, V204, P363, DOI 10.1098/rspb.1979.0033; Pizzorusso T, 1997, VISION RES, V37, P389, DOI 10.1016/S0042-6989(96)00172-1; Porciatti V, 1999, VISION RES, V39, P3071, DOI 10.1016/S0042-6989(99)00022-X; SAUTTER J, 1993, EUR J NEUROSCI, V5, P680, DOI 10.1111/j.1460-9568.1993.tb00533.x; Schmitt U, 1996, J NEUROTRAUM, V13, P791, DOI 10.1089/neu.1996.13.791; SCHNELL L, 1993, EUR J NEUROSCI, V5, P1156, DOI 10.1111/j.1460-9568.1993.tb00970.x; SILVEIRA LCL, 1987, VISION RES, V27, P1719, DOI 10.1016/0042-6989(87)90101-5; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103	21	32	34	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	SEP 30	2001	110	1-2					147	153		10.1016/S0165-0270(01)00435-6			7	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	482VM	WOS:000171598000018	11564535				2021-06-18	
J	Randolph, C				Randolph, C			Implementation of neuropsychological testing models for the high school, collegiate, and professional sport settings	JOURNAL OF ATHLETIC TRAINING			English	Article						concussion; sports; brain injury	TRAUMATIC BRAIN INJURY; STANDARDIZED ASSESSMENT; ALZHEIMERS-DISEASE; CONCUSSION; FOOTBALL; HEAD; RISK	Objective: To review models for the use of neuropsychological testing in the management of sport-related concussion at various levels of competition. Background: As we come to understand the natural history of sport-related concussive brain injury, it is increasingly evident that significant neurologic risks are associated with this type of injury. These risks include (1) acute intracranial pathology, (2) catastrophic brain swelling from second-impact syndrome, and (3) the potential risk for markedly prolonged recovery or permanent cognitive dysfunction associated with multiple concussions. Description: Neuropsychological testing has proved to be a useful tool in the medical management of sport-related concussion. In this paper, I describe a systematic model for the implementation of neuropsychological assessment of athletes at various levels of competition. Clinical Advantages: The systematic model was designed to incorporate state-of-the-art techniques for the detection and tracking of neurocognitive deficits associated with concussion into recently formulated guidelines for the medical management of sport-related concussion. Current applications of the model are discussed, as well as ongoing studies designed to elaborate the empirical underpinnings of the model and refine clinical decision making in this area.	Chicago Neurol Inst, Chicago, IL 60611 USA; Loyola Univ, Med Ctr, Maywood, IL 60153 USA	Randolph, C (corresponding author), Chicago Neurol Inst, 233 E Erie St,Suite 704, Chicago, IL 60611 USA.						ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; Bailes JE, 2001, J ATHL TRAINING, V36, P236; Barr WB, 2001, J ATHL TRAINING, V36, P297; Bream H., 1996, ATHLETIC THERAPY TOD, V1, P7; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; *COL MED SOC, 1991, GUID MAN CONS SPORTS; Daniel JC, 1999, NEUROPSY NEUROPSY BE, V12, P167; DICK RW, 1994, HEAD NECK INJURIES S; FEKETE JF, 1968, CAN MED ASSOC J, V99, P1234; GRONWALL D, 1975, LANCET, V2, P995; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P581; LINDENBERG R, 1970, ARCH PATHOL, V90, P509; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; MAYEUX R, 1993, ANN NEUROL, V33, P494, DOI 10.1002/ana.410330513; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2001, J ATHL TRAINING, V36, P274; McCrory PR, 1998, NEUROLOGY, V50, P677, DOI 10.1212/WNL.50.3.677; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; Mueller FO, 2001, J ATHL TRAINING, V36, P312; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; STERN M, 1991, ARCH NEUROL-CHICAGO, V48, P903, DOI 10.1001/archneur.1991.00530210029018	28	32	32	0	3	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050			J ATHL TRAINING	J. Athl. Train.	JUL-SEP	2001	36	3					288	296					9	Sport Sciences	Sport Sciences	557NC	WOS:000175913800012	12937498				2021-06-18	
J	Lavie, G; Teichner, A; Shohami, E; Ovadia, H; Leker, RR				Lavie, G; Teichner, A; Shohami, E; Ovadia, H; Leker, RR			Long term cerebroprotective effects of dexanabinol in a model of focal cerebral ischemia	BRAIN RESEARCH			English	Article						cerebral ischemia; dexanabinol; HU-211; NMDA; cytokines; free radical	CLOSED-HEAD INJURY; NONCOMPETITIVE NMDA ANTAGONIST; INFARCT VOLUME; BRAIN INJURY; HU-211; RAT; NEUROPROTECTANT; APOPTOSIS; NECROSIS; ALPHA	In order to test the long-term cerebroprotective effects of dexanabinol, a synthetic non-competitive NMDA antagonist that also has anti-TNF alpha effects, spontaneously hypertensive rats underwent permanent middle cerebral artery occlusion (PMCAO). Rats were given vehicle or dexanabinol (3.5 mg/kg) 1. 3 or 6 h after PMCAO. The research consisted of 2 stages. In the short-term set of experiments animals (n=5/group). were tested with a motor disability scale 24 h post PMCAO, then sacrificed and the infarct volume was measured using 2,3.5-Triphenylterrazolium chloride (TTC) staining. In the long-term set of experiments the rats (n=7/group) were examined daily with a motor disability scale up to 30 days after PMCAO and then sacrificed and infarct volumes were determined using TTC staining. Motor scores were significantly improved in the dexanabinol treated rats (P<0.05 for all groups) at all the time points examined. Infarct volumes were significantly reduced 24 h after PMCAO in the groups treated 1 or 3 h, but not 6 h after PMCAO compared with vehicle (Mean<plus/minus>S.D., 11.5 +/-2.02, 12 +/-3.2 and 14.4 +/-2.4% vs. 20.8 +/-1.3% hemispheric volume respectively). The lesions remained significantly smaller in the dexanabinol groups 30 days after PMCAO (Mean +/-S.D., 24.39 +/-1.9% vs. 8.1 +/-0.6, 11.1 +/-2.3 and 13.8 +/-2.5% hemispheric volume in animals treated with vehicle vs. dexanabinol 1, 3 or 6 h after PMCAO respectively: P<0.05 for all). In conclusion, the extended therapeutic window and the multi-mechanistic durable neuroprotective effects of dexanabinol make it a promising candidate for Future stroke therapy. (C) 2001 Elsevier Science B.V. All rights reserved.	Hebrew Univ Jerusalem, Hadassah Univ Hosp, Hadassah Med Sch, Agnes Ginges Ctr Human Neurogenet,Dept Neurol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Univ Hosp, Hadassah Med Sch, Dept Pharmacol, IL-91120 Jerusalem, Israel; Univ Rome, Dept Neurol Sci, Rome, Italy	Leker, RR (corresponding author), Hebrew Univ Jerusalem, Hadassah Univ Hosp, Hadassah Med Sch, Agnes Ginges Ctr Human Neurogenet,Dept Neurol, Ein Karem,POB 12000, IL-91120 Jerusalem, Israel.		Leker, Ronen/ABC-6096-2020	Leker, Ronen/0000-0003-4794-0334			ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; BARJOSEPH A, 1994, MOL CHEM NEUROPATHOL, V23, P125, DOI 10.1007/BF02815406; Barone FC, 1997, STROKE, V28, P1233, DOI 10.1161/01.STR.28.6.1233; BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; BELAYEV L, 1995, BRAIN RES, V702, P266, DOI 10.1016/0006-8993(95)01127-9; BELAYEV L, 1995, STROKE, V26, P2313, DOI 10.1161/01.STR.26.12.2313; BELAYEV L, 1995, STROKE, V26, P2319; BIEGON A, 1995, NEUROL RES, V17, P275, DOI 10.1080/01616412.1995.11740326; Biegon A, 1995, Ann N Y Acad Sci, V765, P314, DOI 10.1111/j.1749-6632.1995.tb16597.x; Brewster ME, 1997, INT J CLIN PHARM TH, V35, P361; Choi DW, 1996, CURR OPIN NEUROBIOL, V6, P667, DOI 10.1016/S0959-4388(96)80101-2; DelZoppo GJ, 1997, ANN NY ACAD SCI, V823, P132; ESHHAR N, 1995, EUR J PHARMACOL, V283, P19, DOI 10.1016/0014-2999(95)00271-L; ESHHAR N, 1993, NEUROREPORT, V5, P237, DOI 10.1097/00001756-199312000-00013; FEIGENBAUM JJ, 1989, P NATL ACAD SCI USA, V86, P9584, DOI 10.1073/pnas.86.23.9584; Kogure T, 1997, CLIN NEUROSCI, V4, P179; Leker RR, 1999, J NEUROL SCI, V162, P114, DOI 10.1016/S0022-510X(98)00301-3; Li Y, 1997, BRAIN RES, V765, P301, DOI 10.1016/S0006-8993(97)00524-6; LIN TN, 1993, STROKE, V24, P117, DOI 10.1161/01.STR.24.1.117; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6	24	32	32	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAY 18	2001	901	1-2					195	201		10.1016/S0006-8993(01)02356-3			7	Neurosciences	Neurosciences & Neurology	433PK	WOS:000168768800024	11368967				2021-06-18	
J	Piepgras, A; Elste, V; Frietsch, T; Schmiedek, P; Reith, W; Schilling, L				Piepgras, A; Elste, V; Frietsch, T; Schmiedek, P; Reith, W; Schilling, L			Effect of moderate hypothermia on experimental severe subarachnoid hemorrhage, as evaluated by apparent diffusion coefficient changes	NEUROSURGERY			English	Article; Proceedings Paper	24th American-Heart-Association International Conference on Stroke and Cerebral Circulation	FEB 04-06, 1999	NASHVILLE, TN	Amer Heart Assoc		apparent diffusion coefficient mapping; brain edema; ischemia; magnetic resonance imaging; moderate hypothermia; subarachnoid hemorrhage	CEREBRAL BLOOD-FLOW; TRAUMATIC BRAIN INJURY; COMPLETE COMPRESSION ISCHEMIA; ENERGY-STATE; RAT-BRAIN; POSTISCHEMIC HYPOTHERMIA; GLYCOLYTIC METABOLITES; BARRIER DISRUPTION; NEURONAL DAMAGE; AMINO-ACIDS	OBJECTIVE: The aims of this study were to investigate the early changes in the mean apparent diffusion coefficient (ADC) after severe subarachnoid hemorrhage (SAH), as a marker of ischemic damage, and to examine the effects of moderate hypothermia, induced at various time points, on ADC changes. METHODS: ADC maps were calculated from diffusion-weighted, blipped-epi, spin echo, magnetic resonance imaging sequences (2.35-T BIOSPEC 24/40 scanner; Bruker Medizin Technik GmbH, Karlsruhe, Germany) for 21 anesthetized (0.45-1% halothane, temperature-adjusted/30% oxygen/69% nitrogen) and ventilated Wistar rats. After baseline scanning, bolus injection of 0.5 mi of autologous arterial blood or artificial cerebrospinal fluid (control group), into the cisterna magna, was performed. Serial scanning was performed for 3 hours after injection, using normothermic or hypothermic (32 degreesC) rats. In an additional series of experiments, hypothermia was initiated either immediately or 60 minutes after normothermic SAH. The water contents of the removed brains were calculated using the wet/dry weight method. RESULTS: The ADC values did not change in the control group but decreased to 88.6 +/- 5.2% (P < 0.05 versus baseline) after SAH and remained significantly decreased throughout the experiment in normothermia. An injection of blood during hypothermia caused an initial decrease in ADC to 96.1 <plus/minus> 5.6% (P < 0.05 versus baseline); values continuously increased and reached normal levels within 60 minutes. Delayed hypothermia also normalized ADC values within the observation period. The brain water content in the control group was 80.3 <plus/minus> 0.1%, that after SAH in normothermia was 81.1 +/- 0.7%, and that after SAH in hypothermia was 79.3 +/- 0.5%. CONCLUSION: This model of severe SAH in rats causes significant ADC changes, which are reversible by application of moderate hypothermia even when it is induced after a 60-minute delay. These findings support the concept of moderate hypothermia exerting a neuroprotective effect in severe SAH.	Heidelberg Univ, Dept Neurosurg, Fac Clin Med Mannheim, Heidelberg, Germany; Heidelberg Univ, Dept Neuroradiol, Heidelberg, Germany	Piepgras, A (corresponding author), Klinikum Hannover Nordstadt, Neurochirurg Klin, Halthoffstr 41, D-30167 Hannover, Germany.	neuro@piepgras.de					BAETHMANN A, 1989, J NEUROSURG, V70, P578, DOI 10.3171/jns.1989.70.4.0578; BAKER AJ, 1991, STROKE, V22, P666, DOI 10.1161/01.STR.22.5.666; BAKER CJ, 1992, J NEUROSURG, V77, P438, DOI 10.3171/jns.1992.77.3.0438; BRINKER T, 1992, ACTA NEUROCHIR, V115, P47, DOI 10.1007/BF01400590; BRODERICK JP, 1994, STROKE, V25, P1342, DOI 10.1161/01.STR.25.7.1342; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; BUSTO R, 1989, NEUROSCI LETT, V101, P299, DOI 10.1016/0304-3940(89)90549-1; CARROLL M, 1992, METAB BRAIN DIS, V7, P45, DOI 10.1007/BF01000440; COIMBRA C, 1994, ACTA NEUROPATHOL, V87, P325, DOI 10.1007/bf00313599; COLBOURNE F, 1995, J NEUROSCI, V15, P7250; DELGADO TJ, 1986, J CEREBR BLOOD F MET, V6, P600, DOI 10.1038/jcbfm.1986.107; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; DOCZI T, 1986, NEUROSURGERY, V18, P733, DOI 10.1227/00006123-198606000-00010; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122; GROTE E, 1988, NEUROSURGERY, V22, P654, DOI 10.1227/00006123-198804000-00006; HASEGAWA Y, 1994, J CEREBR BLOOD F MET, V14, P383, DOI 10.1038/jcbfm.1994.49; HIRSCH H, 1957, PFLUG ARCH GES PHYS, V265, P328, DOI 10.1007/BF00364182; HOEHNBERLAGE M, 1995, J CEREBR BLOOD F MET, V15, P1002, DOI 10.1038/jcbfm.1995.126; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; Ito J, 1996, J NEUROSURG, V84, P97, DOI 10.3171/jns.1996.84.1.0097; JACKOWSKI A, 1990, J CEREBR BLOOD F MET, V10, P835, DOI 10.1038/jcbfm.1990.140; JAKOBSEN J, 1992, ACTA NEUROL SCAND, V86, P1, DOI 10.1111/j.1600-0404.1992.tb08044.x; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; KAMIYA K, 1983, J NEUROSURG, V59, P917, DOI 10.3171/jns.1983.59.6.0917; KARIBE H, 1994, J CEREBR BLOOD F MET, V14, P620, DOI 10.1038/jcbfm.1994.77; KOCH KA, 1984, J CEREBR BLOOD F MET, V4, P343, DOI 10.1038/jcbfm.1984.51; Krafft P, 2000, STROKE, V31, P1393, DOI 10.1161/01.STR.31.6.1393; LEBIHAN D, 1988, RADIOLOGY, V168, P497, DOI 10.1148/radiology.168.2.3393671; LJUNGGREN B, 1974, BRAIN RES, V73, P291, DOI 10.1016/0006-8993(74)91050-6; LJUNGGREN B, 1974, BRAIN RES, V73, P277, DOI 10.1016/0006-8993(74)91049-X; MINTOROVITCH J, 1991, MAGNET RESON MED, V18, P39, DOI 10.1002/mrm.1910180106; Nakashima K, 1996, STROKE, V27, P913, DOI 10.1161/01.STR.27.5.913; NAKASHIMA K, 1995, ANESTHESIOLOGY, V82, P1199, DOI 10.1097/00000542-199505000-00015; NORDSTROM CH, 1978, J NEUROCHEM, V30, P479, DOI 10.1111/j.1471-4159.1978.tb06553.x; NORDSTROM CH, 1978, STROKE, V9, P335, DOI 10.1161/01.STR.9.4.335; PIEPGRAS A, 1995, STROKE, V26, P2347, DOI 10.1161/01.STR.26.12.2347; Pierpaoli C, 1996, J CEREBR BLOOD F MET, V16, P892, DOI 10.1097/00004647-199609000-00013; PRUSINER S, 1968, ARCH NEUROL-CHICAGO, V19, P623, DOI 10.1001/archneur.1968.00480060093013; RAM Z, 1991, ACTA NEUROCHIR WIEN, V110, P3; Reith W, 1997, ROFO-FORTSCHR RONTG, V166, P133, DOI 10.1055/s-2007-1015395; RONG H, 1993, BRAIN RES, V618, P346, DOI 10.1016/0006-8993(93)91289-5; Rother J, 1996, J CEREBR BLOOD F MET, V16, P214; Rother J, 1996, STROKE, V27, P980, DOI 10.1161/01.STR.27.5.980; SCHWAB S, 1994, NERVENARZT, V65, P828; SHIGENO T, 1982, STROKE, V13, P368, DOI 10.1161/01.STR.13.3.368; STEJSKAL EO, 1965, J CHEM PHYS, V42, P288, DOI 10.1063/1.1695690; VERHEUL B, 1994, NMR BIOMED, V7, P96, DOI 10.1002/nbm.1940070115; VITEZ TS, 1974, ANESTHESIOLOGY, V41, P80, DOI 10.1097/00000542-197407000-00020; VOLDBY B, 1985, J NEUROSURG, V62, P48, DOI 10.3171/jns.1985.62.1.0048	50	32	32	0	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAY	2001	48	5					1128	1134		10.1097/00006123-200105000-00033			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	424GB	WOS:000168223000083	11334280				2021-06-18	
J	Reverter, D; Strobl, S; Fernandez-Catalan, C; Sorimachi, H; Suzuki, K; Bode, W				Reverter, D; Strobl, S; Fernandez-Catalan, C; Sorimachi, H; Suzuki, K; Bode, W			Structural basis for possible calcium-induced activation mechanisms of calpains	BIOLOGICAL CHEMISTRY			English	Article						C2 domain; calcium activation; calmodulin; calpain; cysteine proteinase	MUSCLE-SPECIFIC CALPAIN; CA-2+-ACTIVATED NEUTRAL PROTEASE; SMALL-SUBUNIT GENE; CRYSTAL-STRUCTURE; CA2+-BINDING DOMAIN; MESSENGER-RNA; EF-HAND; PHYSIOLOGICAL-FUNCTION; DEPENDENT PROTEASE; MOLECULAR-CLONING	The calpains form a growing family of structurally related intracellular multidomainal cysteine proteinases, which exhibit a catalytic domain distantly related to papain, In contrast to papain, however, their activity in most cases depends on calcium. The calpains are believed to play important roles in cytoskeletal remodeling processes, cell differentiation, apoptosis and signal transduction, but have also been implicated in muscular dystrophy, ischemia, traumatic brain injury, neurodegenerative diseases, rheumatoid arthritis and cataract formation. The best characterized calpains are the ubiquitously expressed mu- and m-calpains, consisting of a common 30 kDa small S-subunit (domains V and VI) and slightly differing 80 kDa large L-subunits (domains I to IV). We have recently determined the 2.3 Angstrom structure of recombinant full-length human m-calpain in the absence of calcium, which reveals that the catalytic domain and the two calmodulin-like domains, previously believed to represent the unique calcium switch, are not positioned adjacent to each other, but are separated by the P-sandwich domain III, which distantly resembles C2 domains. Although the catalytic domain of apocalpain is strongly disrupted compared to papain (which explains its inactivity in the absence of calcium), the crystal structure reveals several sites where calcium could bind, thereby causing a subdomain fusion to form a papain-like catalytic center. All current evidence points to the cooperative interaction of several calcium binding sites. Sites identified include the three EF-hand binding sites in each calmodulin-like domain, the negatively charged segments arranged around the active-site cleft (provided by both catalytic subdomains), as well as an exposed acidic loop of domain Ill, whose charge compensation could allow the adjacent barrel-like subdomain IIb to move toward the helical subdomain IIa, The Gly-rich S-chain N-terminus and the calcium-loaded acidic loop could target the conventional calpains to cellular/nuclear membranes, thereby explaining their strongly reduced calcium requirement in vivo and in vitro in the presence of acidic phospholipids.	Max Planck Inst Biochem, D-82152 Planegg Martinsried, Germany; Univ Tokyo, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan; Tokyo Metropolitan Inst Gerontol, Itabashi Ku, Tokyo 1720015, Japan	Bode, W (corresponding author), Max Planck Inst Biochem, Klopferspitz 18A, D-82152 Planegg Martinsried, Germany.		Reverter, David/H-5360-2015; Sorimachi, Hiroyuki/C-6448-2009	Reverter, David/0000-0002-5347-0992; Sorimachi, Hiroyuki/0000-0001-9509-6727			ANDRESEN K, 1991, J BIOL CHEM, V266, P15085; AOKI K, 1986, FEBS LETT, V205, P313, DOI 10.1016/0014-5793(86)80919-X; Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Blanchard H, 1997, NAT STRUCT BIOL, V4, P532, DOI 10.1038/nsb0797-532; BODE W, 1979, J MOL BIOL, V127, P357, DOI 10.1016/0022-2836(79)90227-4; BOGARDUS C, 2000, NAT GENET, V26, P163; Carafoli E, 1998, BIOCHEM BIOPH RES CO, V247, P193, DOI 10.1006/bbrc.1998.8378; CHAHINIAN H, 2000, SCIENCE, V1, P91; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; Dear N, 1997, GENOMICS, V45, P175, DOI 10.1006/geno.1997.4870; Dear TN, 1999, MECH DEVELOP, V89, P201, DOI 10.1016/S0925-4773(99)00214-2; Dutt P, 2000, BIOCHEM J, V348, P37, DOI 10.1042/0264-6021:3480037; ETO A, 1995, J BIOL CHEM, V270, P25115, DOI 10.1074/jbc.270.42.25115; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Garcia RA, 2000, P NATL ACAD SCI USA, V97, P5883, DOI 10.1073/pnas.100127197; GOLL DE, 1992, BIOESSAYS, V14, P549, DOI 10.1002/bies.950140810; Gonen H, 1997, FEBS LETT, V406, P17, DOI 10.1016/S0014-5793(97)00225-1; Herasse M, 1999, MOL CELL BIOL, V19, P4047; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Hosfield CM, 2001, J BIOL CHEM, V276, P7404, DOI 10.1074/jbc.M007352200; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/S0968-0004(06)80021-6; IMAJOH S, 1988, BIOCHEMISTRY-US, V27, P8122, DOI 10.1021/bi00421a022; IMAJOH S, 1986, J BIOCHEM-TOKYO, V99, P1281, DOI 10.1093/oxfordjournals.jbchem.a135593; Jekely G, 2000, METH MOL B, V144, P67; Johnson GVW, 1997, BIOESSAYS, V19, P1011, DOI 10.1002/bies.950191111; KAMPHUIS IG, 1984, J MOL BIOL, V179, P233, DOI 10.1016/0022-2836(84)90467-4; Kinbara K, 1998, BIOCHEM J, V335, P589, DOI 10.1042/bj3350589; Kitagaki H, 2000, BIOSCI BIOTECH BIOCH, V64, P689, DOI 10.1271/bbb.64.689; Kretsinger RH, 1996, NAT STRUCT BIOL, V3, P12, DOI 10.1038/nsb0196-12; Lee HJ, 1999, ARCH BIOCHEM BIOPHYS, V362, P22, DOI 10.1006/abbi.1998.1021; Lin GD, 1997, NAT STRUCT BIOL, V4, P539, DOI 10.1038/nsb0797-539; Ma H, 1998, INVEST OPHTH VIS SCI, V39, P454; Maki M, 1997, BIOCHEM J, V328, P718; MAKI M, 1988, J BIOL CHEM, V263, P10254; Masumoto H, 1998, J BIOCHEM, V124, P957, DOI 10.1093/oxfordjournals.jbchem.a022213; Masumoto J, 2000, ACTA CRYSTALLOGR D, V56, P73, DOI 10.1107/S0907444999013748; Melloni E, 1998, BIOCHEM BIOPH RES CO, V249, P583, DOI 10.1006/bbrc.1998.9200; Michetti M, 1997, BIOCHEM J, V325, P721, DOI 10.1042/bj3250721; Mugita N, 1997, BIOCHEM BIOPH RES CO, V239, P845, DOI 10.1006/bbrc.1997.7571; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NICHOLLS A, 1993, GRASP GRAPHICAL REPR; OHNO S, 1986, NUCLEIC ACIDS RES, V14, P5559; OHNO S, 1990, J BIOL CHEM, V265, P6296; Ono Y, 1998, BIOCHEM BIOPH RES CO, V245, P289, DOI 10.1006/bbrc.1998.8085; Ono Y, 1998, J BIOL CHEM, V273, P17073, DOI 10.1074/jbc.273.27.17073; Richard I, 1999, AM J HUM GENET, V64, P1524, DOI 10.1086/302426; Rizo J, 1998, J BIOL CHEM, V273, P15879, DOI 10.1074/jbc.273.26.15879; SAIDO TC, 1992, J BIOL CHEM, V267, P24585; SALAMINO F, 1994, CELL CALCIUM, V15, P28, DOI 10.1016/0143-4160(94)90101-5; SALVESEN G, 1986, BIOCHEM J, V234, P429, DOI 10.1042/bj2340429; Shao XG, 1998, BIOCHEMISTRY-US, V37, P16106, DOI 10.1021/bi981789h; SORIMACHI H, 1989, J BIOL CHEM, V264, P20106; Sorimachi H, 1996, BBA-GENE STRUCT EXPR, V1309, P37, DOI 10.1016/S0167-4781(96)00135-2; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; SORIMACHI H, 1993, J BIOL CHEM, V268, P19476; SORIMACHI H, 1992, BIOCHIM BIOPHYS ACTA, V1160, P55, DOI 10.1016/0167-4838(92)90037-E; Strobl S, 2000, P NATL ACAD SCI USA, V97, P588, DOI 10.1073/pnas.97.2.588; Sutton RB, 1999, J CELL BIOL, V147, P589, DOI 10.1083/jcb.147.3.589; SUZUKI K, 1995, BIOL CHEM H-S, V376, P523; Suzuki K, 1998, FEBS LETT, V433, P1, DOI 10.1016/S0014-5793(98)00856-4; TAKANO E, 1995, FEBS LETT, V362, P93, DOI 10.1016/0014-5793(95)00219-Y; TURK D, 1995, BIOCHEMISTRY-US, V34, P4791, DOI 10.1021/bi00014a037; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; Vilei EM, 1997, J BIOL CHEM, V272, P25802, DOI 10.1074/jbc.272.41.25802; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; YOSHIZAWA T, 1995, BIOCHEM BIOPH RES CO, V208, P376, DOI 10.1006/bbrc.1995.1348; Zimmerman UJP, 2000, IUBMB LIFE, V50, P63	69	32	34	0	7	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	1431-6730	1437-4315		BIOL CHEM	Biol. Chem.	MAY	2001	382	5					753	766		10.1515/BC.2001.091			14	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	453AR	WOS:000169893300006	11517928				2021-06-18	
J	Shaw, K; MacKinnon, MA; Raghupathi, R; Saatman, KE; McIntosh, TK; Graham, DI				Shaw, K; MacKinnon, MA; Raghupathi, R; Saatman, KE; McIntosh, TK; Graham, DI			TUNEL-positive staining in white and grey matter after fatal head injury in man	CLINICAL NEUROPATHOLOGY			English	Article						human traumatic brain injury; hippocampus; cingulate gyrus; insula; TUNEL staining; necrosis; apoptosis	TRAUMATIC BRAIN INJURY; SPINAL-CORD INJURY; CONTROLLED CORTICAL IMPACT; SELECTIVE NEURONAL DEATH; CELL-DEATH; APOPTOSIS; RATS; BCL-2; NEUROPATHOLOGY; EXPRESSION	Paraffin sections from the hippocampus, the cingulate gyrus and the insula of 18 head-injured patients who survived between 5 hours and 10 days, and 18 age-matched controls, were stained by the terminal deoxynucleotidyl transferase mediated biotinylated deoxyuridine triphosphate nick end labelling (TUNEL) technique for evidence of in situ DNA fragmentation. Additional staining techniques (HE, combined LFB/CV and immunohistochemistry for GFAP and CD68) were used to characterize any lesions and their time course. Only the occasional TUNEL+ cell per area was seen in the control brains. TUNEL+ cells were identified in both grey and white matter of the head-injured material and their numbers peaked between 24 and 48 hours and were still present at 10 days. Within the hippocampus, fewer TUNEL+ cells were seen in grey (between 3 - 5 per area) than In the white mat ter, (up to 51+ per area) whereas in the cingulate gyrus and in the insula, the number of TUNEL+ cells was always greater in the cortex (between 11 - 20 per area) than in white matter (6 - 10 per area). In the grey matter. most TUNEL+ cells had the morphology of necrosis. However, the histological appearances of some of the neurons (2 - 3%), and of oligodendroglia and macrophages in white matter (about 5%) were those of apoptosis.	Univ Glasgow, So Gen Hosp, Inst Neurol Sci, Dept Neuropathol,So Glasgow Univ Hosp NHS Trust, Glasgow G51 4TF, Lanark, Scotland; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	Graham, DI (corresponding author), Univ Glasgow, So Gen Hosp, Inst Neurol Sci, Dept Neuropathol,So Glasgow Univ Hosp NHS Trust, 1345 Govan Rd, Glasgow G51 4TF, Lanark, Scotland.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS026818] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50-NS08803, R01-NS26818] Funding Source: Medline		ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1985, NEUROPATH APPL NEURO, V11, P299, DOI 10.1111/j.1365-2990.1985.tb00027.x; AUER RN, 1997, GREENFIELDS NEUROPAT, P263; Beattie MS, 1998, NEUROSCIENTIST, V4, P163, DOI 10.1177/107385849800400312; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bien A, 1999, J NEUROTRAUM, V16, P153, DOI 10.1089/neu.1999.16.153; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BURKE MJ, 1996, BRAIN PATHOL, V6, P427; CharriautMarlangue C, 1996, TRENDS NEUROSCI, V19, P109, DOI 10.1016/S0166-2236(96)80039-7; Clark RSB, 1997, J NEUROSCI, V17, P9172; Clark RSB, 1999, FASEB J, V13, P813; Colicos MA, 1996, BRAIN RES, V739, P111, DOI 10.1016/S0006-8993(96)00819-0; Conti AC, 1998, J NEUROSCI, V18, P5663; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; Emery E, 1998, J NEUROSURG, V89, P911, DOI 10.3171/jns.1998.89.6.0911; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; Graham DI, 2000, J NEUROPATH EXP NEUR, V59, P641, DOI 10.1093/jnen/59.8.641; Johnson EM, 1996, BRAIN PATHOL, V6, P397, DOI 10.1111/j.1750-3639.1996.tb00872.x; Li GL, 1996, J NEUROPATH EXP NEUR, V55, P280, DOI 10.1097/00005072-199603000-00003; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; NAMASHIMA K, 1999, J NEUROTRAUM, V16, P143; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; RINK A, 1995, AM J PATHOL, V147, P1575; Sheng JG, 1998, J NEUROPATH EXP NEUR, V57, P714, DOI 10.1097/00005072-199807000-00008; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Taniike M, 1999, J NEUROPATH EXP NEUR, V58, P644, DOI 10.1097/00005072-199906000-00009; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Yong C, 1998, J NEUROTRAUM, V15, P459, DOI 10.1089/neu.1998.15.459	33	32	39	0	0	DUSTRI-VERLAG DR KARL FEISTLE	MUNCHEN-DEISENHOFEN	BAHNHOFSTRABE 9 POSTFACH 49, W-8024 MUNCHEN-DEISENHOFEN, GERMANY	0722-5091			CLIN NEUROPATHOL	Clin. Neuropathol.	MAY-JUN	2001	20	3					106	112					7	Clinical Neurology; Pathology	Neurosciences & Neurology; Pathology	439AR	WOS:000169089100003	11430493				2021-06-18	
J	Nicholson, K; Martelli, MF; Zasler, ND				Nicholson, K; Martelli, MF; Zasler, ND			Does pain confound interpretation of neuropsychological test results?	NEUROREHABILITATION			English	Article							TRAUMATIC BRAIN INJURY; POSTTRAUMATIC HEADACHE; COGNITIVE PERFORMANCE; ANXIETY DISORDERS; RISK-FACTORS; MEMORY; DEFICITS; METAANALYSIS; ATTENTION; MORPHINE	There is increasing evidence that pain and related problems (e.g., affective distress, sleep disturbance, medication use) can interfere with cognitive performance and confound the interpretation of neuropsychological test results. This maybe of particular concern incases of the persistent post-concussive syndrome where headache is the primary problem. Such effects can be pronounced, obscuring the effects associated with mild or even much more significant brain injury. However, it remains unclear what specific chronic or acute pain experiences, in what individuals, with or without which associated problems, will actually result in particular performance deficits. Whereas pain may disrupt brain function, this is likely to be temporary and not indicative of permanent impairment of neuropsychological function. Further study of this important topic is warranted.	Toronto Western Hosp, Comprehens Pain Program, Toronto, ON M5T 2S8, Canada; Pinnacle Rehabil & Tree Life, Concuss Care Ctr Virginia, Glen Allen, VA USA; Virginia Commonwealth Univ, Richmond, VA 23298 USA; Virginia Commonwealth Univ Med Coll Virginia, Richmond, VA USA	Nicholson, K (corresponding author), Toronto Western Hosp, Comprehens Pain Program, 4BFell-150,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	keith@uhnres.utoronto.ca					Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; BOROD JC, 2000, NEUROPSYCHOL EMOTION; Branca B, 1996, HEADACHE, V36, P300, DOI 10.1046/j.1526-4610.1996.3605300.x; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; BURT DB, 1995, PSYCHOL BULL, V117, P285, DOI 10.1037/0033-2909.117.2.285; Cleeland CS, 1996, NEUROPSYCHOPHARMACOL, V15, P252, DOI 10.1016/0893-133X(95)00205-R; Crombez G, 1997, PAIN, V70, P149, DOI 10.1016/S0304-3959(96)03304-0; Crombez G, 1996, BEHAV RES THER, V34, P911, DOI 10.1016/S0005-7967(96)00058-7; CROMBEZ G, 1994, BEHAV RES THER, V32, P611, DOI 10.1016/0005-7967(94)90015-9; DANDREA G, 1989, CEPHALALGIA, V9, P25, DOI 10.1046/j.1468-2982.1989.0901025.x; Davidson RJ, 1999, CURR OPIN NEUROBIOL, V9, P228, DOI 10.1016/S0959-4388(99)80032-4; Davis PJ, 2000, PAIN MED, V1, P238, DOI 10.1046/j.1526-4637.2000.00032.x; DUFTON BD, 1989, INT J PSYCHIAT MED, V19, P291, DOI 10.2190/JDJK-0795-5BFL-5N6K; ECCLESTON C, 1994, BRIT J CLIN PSYCHOL, V33, P535, DOI 10.1111/j.2044-8260.1994.tb01150.x; ECCLESTON C, 1995, BEHAV RES THER, V33, P391, DOI 10.1016/0005-7967(94)00057-Q; Eccleston C, 1997, PAIN, V72, P209, DOI 10.1016/S0304-3959(97)00030-4; EDNA TH, 1987, ACTA NEUROCHIR, V86, P12, DOI 10.1007/BF01419498; Fishbain DA, 1997, CLIN J PAIN, V13, P116, DOI 10.1097/00002508-199706000-00006; FISHBAIN DA, 1999, INT ASS PAIN 9 WORLD; Francis Se, 2000, DISS ABSTR INT B, V60, P3562; GFELLER JD, 1994, HEADACHE, V34, P503, DOI 10.1111/j.1526-4610.1994.hed3409503.x; Gonzales VA, 2000, NEUROREHABILITATION, V14, P69; GRIGSBY J, 1995, PERCEPT MOTOR SKILL, V81, P403, DOI 10.2466/pms.1995.81.2.403; Hart RP, 2000, NEUROPSYCHOL REV, V10, P131, DOI 10.1023/A:1009020914358; Iezzi T, 1999, J BEHAV MED, V22, P205, DOI 10.1023/A:1018791622441; JAKOBSEN J, 1987, ACTA NEUROL SCAND, V75, P341, DOI 10.1111/j.1600-0404.1987.tb05456.x; JAMISON RN, 1988, INT J PSYCHIAT MED, V18, P183; Jorge RE, 1999, NEUROLOGY, V53, P543, DOI 10.1212/WNL.53.3.543; KAY T, 1992, PHYSICAL MED REHABIL, V6, P109; Kessels RPC, 2000, J INT NEUROPSYCH SOC, V6, P271, DOI 10.1017/S1355617700633027; KEWMAN DG, 1989, ARCH PHYSL MED REHAB; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lorenz J, 1997, PAIN, V73, P369, DOI 10.1016/S0304-3959(97)00123-1; Lorenz J, 1997, PSYCHOPHYSIOLOGY, V34, P436, DOI 10.1111/j.1469-8986.1997.tb02387.x; Martelli MF, 1999, J HEAD TRAUMA REHAB, V14, P49, DOI 10.1097/00001199-199902000-00007; MARTELLI MF, IN PRESS PAIN MANAGE; Menefee LA, 2000, PAIN MED, V1, P156, DOI 10.1046/j.1526-4637.2000.00022.x; MIDDELBOE T, 1992, J PERS DISORD, V6, P246, DOI 10.1521/pedi.1992.6.3.246; Nicholson K, 2000, NEUROREHABILITATION, V14, P57; Nicholson K, 2000, NEUROREHABILITATION, V14, P95; PACKARD RC, 1993, HEADACHE, V33, P365, DOI 10.1111/j.1526-4610.1993.hed3307365.x; PATIL PG, 1995, PHYSIOL BEHAV, V58, P1281, DOI 10.1016/0031-9384(95)02071-3; Pilcher JJ, 1996, SLEEP, V19, P318, DOI 10.1093/sleep/19.4.318; Pita G, 1998, HUM PSYCHOPHARM CLIN, V13, P315, DOI 10.1002/(SICI)1099-1077(199807)13:5<315::AID-HUP2>3.0.CO;2-B; Post RM, 2000, PSYCHIAT ANN, V30, P485, DOI 10.3928/0048-5713-20000701-09; Robinson ME, 1999, PSYCHOSOCIAL FACTORS, P74; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; RUTHERFORD WH, 1979, MILD HEAD INJURY, P217; RUTTAN LA, 1998, SCI ENG 5B, V59, P2432; SCHNURR RF, 1995, CLIN J PAIN, V11, P103, DOI 10.1097/00002508-199506000-00004; SCHWARTZ DP, 1987, CLIN J PAIN, V3, P94; SELTZER SF, 1991, PAIN, V47, P47, DOI 10.1016/0304-3959(91)90010-U; SHAPIRO AP, 1993, SPINE STATE ART REV, V7, P455; Sjogren P, 2000, PAIN, V86, P237, DOI 10.1016/S0304-3959(00)00248-7; Taylor AE, 1996, ARCH PHYS MED REHAB, V77, P529, DOI 10.1016/S0003-9993(96)90290-7; Toren P, 2000, J ANXIETY DISORD, V14, P239, DOI 10.1016/S0887-6185(99)00036-5; VERNONWILKINSON R, 1993 NAT AC NEUR ANN; YOUNGJOHN JR, 1995, CLIN NEUROPSYCHOL, V9, P112, DOI 10.1080/13854049508401593; Zacny JP, 1995, EXP CLIN PSYCHOPHARM, V3, P432, DOI 10.1037/1064-1297.3.4.432; ZEITLIN C, 1984, BRIT J CLIN PSYCHOL, V23, P27, DOI 10.1111/j.2044-8260.1984.tb00623.x	62	32	32	0	3	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2001	16	4					225	230					6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	521VC	WOS:000173861200006	11790908				2021-06-18	
J	Erlich, S; Shohami, E; Pinkas-Kramarski, R				Erlich, S; Shohami, E; Pinkas-Kramarski, R			Closed head injury induces up-regulation of ErbB-4 receptor at the site of injury	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						tyrosine kinase; ErbB-4; brain; closed head injury; microglia/macrophages	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; NECROSIS-FACTOR-ALPHA; RAT-BRAIN; NERVOUS-SYSTEM; EXPRESSION; MICROGLIA; CELLS; MEMBER; FAMILY	ErbB-4 receptor tyrosine kinase and its ligand neu differentiation factor (NDF/neuregulin) are widely expressed in the brain. The closed head injury model was used to investigate the possible role of ErbB-4 receptor in neurodegeneration. It is demonstrated that levels of ErbB-4 are dramatically increased at the site of injury. Activated microglia/macrophages constitute the major population of cells with the highest receptor levels at the site of injury. In addition ErbB-4 expression after injury is elevated also in neurons but not in astrocytes. Confocal microscopy analysis suggests that the high level of ErbB-4 protein in activated microglia/macrophages is probably due to phagocytosis of neuronal cells. These findings show for the first time that ErbB-4 receptors play a role in brain responses to head trauma. Overexpression of ErbB-4 receptors may be important for directing activated microglia/macrophages to the lesion site.	Tel Aviv Univ, Dept Neurobiochem, IL-69978 Ramat Aviv, Israel; Hebrew Univ Jerusalem, Dept Pharmacol, IL-91120 Jerusalem, Israel	Pinkas-Kramarski, R (corresponding author), Tel Aviv Univ, Dept Neurobiochem, IL-69978 Ramat Aviv, Israel.	lironit@post.tau.ac.il		Pinkas-Kramarski, Ronit/0000-0002-1000-369X			AKIYAMA H, 1994, BRAIN RES, V635, P257, DOI 10.1016/0006-8993(94)91447-8; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Beerli RR, 1996, J BIOL CHEM, V271, P6071, DOI 10.1074/jbc.271.11.6071; CARPENTER G, 1991, PEPTIDE GROWTH FACTO; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; CORFAS G, 1993, J NEUROSCI, V13, P2118; CORFAS G, 1993, P NATL ACAD SCI USA, V90, P1624, DOI 10.1073/pnas.90.4.1624; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DERYNCK R, 1985, CANCER CELL, V3, P79; Eilam R, 1998, P NATL ACAD SCI USA, V95, P1888, DOI 10.1073/pnas.95.4.1888; FADEN AI, 1993, CRIT REV NEUROBIOL, V7, P175; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; KRISTT DA, 1993, NEUROSURGERY, V33, P106; LOTAN M, 1994, FASEB J, V8, P1026; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; Mograbi B, 1997, EUR CYTOKINE NETW, V8, P73; NAKAJIMA K, 1993, NEUROSCI RES, V17, P187, DOI 10.1016/0168-0102(93)90047-T; NIETOSAMPEDRO M, 1988, NEUROSCI LETT, V91, P276, DOI 10.1016/0304-3940(88)90693-3; Opanashuk LA, 1999, J NEUROSCI, V19, P133; ORRURTREGER A, 1993, P NATL ACAD SCI USA, V90, P1867, DOI 10.1073/pnas.90.5.1867; Pinkas-Kramarski R, 1997, J MAMMARY GLAND BIOL, V2, P97, DOI 10.1023/A:1026343528967; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PinkasKramarski R, 1997, ONCOGENE, V15, P2803, DOI 10.1038/sj.onc.1201466; PINKASKRAMARSKI R, 1995, ENTRY HUMAN CYTOKINE, V2, P340; Planas AM, 1998, GLIA, V23, P120, DOI 10.1002/(SICI)1098-1136(199806)23:2<120::AID-GLIA3>3.0.CO;2-A; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; Rabchevsky AG, 1998, J NEUROSCI, V18, P10541, DOI 10.1523/jneurosci.18-24-10541.1998; RAFF MC, 1978, CELL, V15, P813, DOI 10.1016/0092-8674(78)90266-0; Riese DJ, 1996, ONCOGENE, V12, P345; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; SASADA R, 1993, BIOCHEM BIOPH RES CO, V190, P1173, DOI 10.1006/bbrc.1993.1173; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Shohami E, 1996, J CEREBR BLOOD F MET, V16, P378, DOI 10.1097/00004647-199605000-00004; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; SIESJO BK, 1988, ANN NY ACAD SCI, V522, P638; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Tanaka N, 1999, BRAIN RES, V827, P130, DOI 10.1016/S0006-8993(99)01319-0; TOYODA H, 1995, J BIOL CHEM, V270, P7495, DOI 10.1074/jbc.270.13.7495; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; VARTANIAN T, 1994, P NATL ACAD SCI USA, V91, P11626, DOI 10.1073/pnas.91.24.11626; Verdi JM, 1996, NEURON, V16, P515, DOI 10.1016/S0896-6273(00)80071-9; Yamamoto T, 1986, Horiz Biochem Biophys, V8, P571	53	32	34	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	NOV	2000	16	5					597	608		10.1006/mcne.2000.0894			12	Neurosciences	Neurosciences & Neurology	378XT	WOS:000165611200006	11083921				2021-06-18	
J	Carrasco, J; Giralt, M; Penkowa, M; Stalder, AK; Campbell, IL; Hidalgo, J				Carrasco, J; Giralt, M; Penkowa, M; Stalder, AK; Campbell, IL; Hidalgo, J			Metallothioneins are upregulated in symptomatic mice with astrocyte-targeted expression of tumor necrosis factor-alpha	EXPERIMENTAL NEUROLOGY			English	Article							CENTRAL-NERVOUS-SYSTEM; TRAUMATIC BRAIN INJURY; GROWTH-INHIBITORY FACTOR; II-DEFICIENT MICE; TRANSGENIC MICE; OXIDATIVE STRESS; RAT HEPATOCYTES; CEREBRAL OVEREXPRESSION; INDUCED HEPATOTOXICITY; INFLAMMATORY RESPONSE	Transgenic mice expressing TNF-alpha under the regulatory control of the GFAP gene promoter (GFAP-TNF alpha mice) exhibit a unique, late-onset chronic-progressive neurological disorder with meningoencephalomyelitis, neurodegeneration, and demyelination with paralysis. Here we show that the metallothionein-I + II (MT-I + II) isoforms were dramatically upregulated in the brain of symptomatic but not presymptomatic GFAP-TNF alpha mice despite TNF-alpha expression being present in both cases. lit situ hybridization analysis for MT-I RNA and radioimmunoassay results for MT-I + II protein revealed that the induction was observed in the cerebellum but not in other brain areas. Increased MT-I RNA levels occurred in the Purkinje and granular neuronal layers of the cerebellum but also in the molecular layer. Reactive astrocytes, activated rod-like microglia, and macrophages, but not the infiltrating lymphocytes, were identified as the cellular sources of the MT-I + II proteins. in situ hybridization for MT-III RNA revealed a modest increase in the white matter of the cerebellum, which was confirmed by immunocytochemistry. MT-III immunoreactivity was present in cells which were mainly round or amoeboid monocytes/macrophages. The pattern of expression of the different MT isoforms in the GFAP-TNF alpha mice differed substantially from that described previously in GFAP-IL6 mice, demonstrating unique effects associated with the expression of each cytokine. The results suggest that the MT expression in the CNS reflects the inflammatory response and associated damage rather than a direct role of the TNF-alpha in their regulation and support a major role of these proteins during CNS injury. (C) 2000 Academic Press.	Univ Autonoma Barcelona, Fac Ciencias, Unidad Fisiol Anim, Dept Biol Celular Fisiol & Inmunol, Barcelona 08193, Spain; Univ Copenhagen, Panum Inst, Dept Med Anat, Sect C, DK-2200 Copenhagen, Denmark; Scripps Res Inst, Dept Neuropharmacol, La Jolla, CA 92037 USA	Hidalgo, J (corresponding author), Univ Autonoma Barcelona, Fac Ciencias, Unidad Fisiol Anim, Dept Biol Celular Fisiol & Inmunol, Barcelona 08193, Spain.		Giralt, Mercedes/K-1626-2014; Carrasco, Javier/C-9732-2011; Hidalgo, Juan/C-9082-2011	Giralt, Mercedes/0000-0002-1806-1528; Carrasco, Javier/0000-0001-6436-0863; Hidalgo, Juan/0000-0003-0921-1122	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH050426] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [MH50426] Funding Source: Medline		Akwa Y, 1998, J IMMUNOL, V161, P5016; Amoureux MC, 1997, MOL CHEM NEUROPATHOL, V32, P101, DOI 10.1007/BF02815170; Aschner M, 1996, FASEB J, V10, P1129; Aschner M, 1997, TOXICOL APPL PHARM, V142, P229, DOI 10.1006/taap.1996.8054; Barnum SR, 1996, GLIA, V18, P107, DOI 10.1002/(SICI)1098-1136(199610)18:2<107::AID-GLIA3>3.0.CO;2-Y; BRETT FM, 1995, J NEUROPATH EXP NEUR, V54, P766, DOI 10.1097/00005072-199511000-00003; Campbell IL, 1998, BRAIN RES REV, V26, P327, DOI 10.1016/S0165-0173(97)00038-6; CAMPBELL IL, 1993, P NATL ACAD SCI USA, V90, P10061, DOI 10.1073/pnas.90.21.10061; Carrasco J, 1998, EXP NEUROL, V153, P184, DOI 10.1006/exnr.1998.6861; Carrasco J, 1998, MOL BRAIN RES, V57, P221, DOI 10.1016/S0169-328X(98)00087-4; Carrasco J, 1999, J NEUROTRAUM, V16, P1115, DOI 10.1089/neu.1999.16.1115; Castelnau PA, 1998, J NEUROPATH EXP NEUR, V57, P268, DOI 10.1097/00005072-199803000-00008; CHIANG CS, 1994, DEV NEUROSCI-BASEL, V16, P212, DOI 10.1159/000112109; Chiang CS, 1996, J CLIN INVEST, V97, P1512, DOI 10.1172/JCI118574; COYLE P, 1993, BIOL TRACE ELEM RES, V36, P35, DOI 10.1007/BF02783778; COYLE P, 1995, INFLAMM RES, V44, P475, DOI 10.1007/BF01837913; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; Dalton TP, 1996, J BIOL CHEM, V271, P26233, DOI 10.1074/jbc.271.42.26233; DE SK, 1990, J BIOL CHEM, V265, P15267; ERICKSON JC, 1994, BRAIN RES, V649, P297, DOI 10.1016/0006-8993(94)91076-6; Erickson JC, 1997, J NEUROSCI, V17, P1271; Fu K, 1998, PANCREAS, V17, P238, DOI 10.1097/00006676-199810000-00003; GASULL T, 1993, J IMMUNOASSAY, V14, P209, DOI 10.1080/15321819308019851; GASULL T, 1994, AM J PHYSIOL, V266, pE760; Ghirnikar RS, 1998, NEUROCHEM RES, V23, P329, DOI 10.1023/A:1022453332560; GRIMBLE RF, 1989, P NUTR SOC, V48, pA64; HALLIWELL B, 1992, J NEUROCHEM, V59, P1609, DOI 10.1111/j.1471-4159.1992.tb10990.x; Hanada K, 1998, J INVEST DERMATOL, V111, P582, DOI 10.1046/j.1523-1747.1998.00342.x; Hernandez J, 1996, CHEM-BIOL INTERACT, V100, P27, DOI 10.1016/0009-2797(95)03683-0; Hernandez J, 1997, MOL BRAIN RES, V48, P125, DOI 10.1016/S0169-328X(97)00087-9; Heyser CJ, 1997, P NATL ACAD SCI USA, V94, P1500, DOI 10.1073/pnas.94.4.1500; HIDALGO J, 1997, CURR TOPICS NEUROCHE, V1, P1; Hidalgo J, 1989, AM J PHYSIOL, V255, P518; Hoey JG, 1997, TOXICOL LETT, V92, P149, DOI 10.1016/S0378-4274(97)00049-0; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; Hozumi I, 1998, NEUROCHEM RES, V23, P319, DOI 10.1023/A:1022401315721; Kang YJ, 1997, J CLIN INVEST, V100, P1501, DOI 10.1172/JCI119672; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Kondo Y, 1997, MOL PHARMACOL, V52, P195; LAZO JS, 1995, J BIOL CHEM, V270, P5506, DOI 10.1074/jbc.270.10.5506; Liang LC, 1996, MOL REPROD DEV, V43, P25, DOI 10.1002/(SICI)1098-2795(199601)43:1&lt;25::AID-MRD4&gt;3.0.CO;2-W; LIU J, 1991, TOXICOL APPL PHARM, V109, P235, DOI 10.1016/0041-008X(91)90171-A; Liu J, 1998, TOXICOL APPL PHARM, V149, P24, DOI 10.1006/taap.1997.8325; Liu J, 1999, J PHARMACOL EXP THER, V289, P580; Martiney JA, 1998, NEUROCHEM RES, V23, P349, DOI 10.1023/A:1022457500700; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; Moffatt P, 1998, DNA CELL BIOL, V17, P501, DOI 10.1089/dna.1998.17.501; PALMITER RD, 1992, P NATL ACAD SCI USA, V89, P6333, DOI 10.1073/pnas.89.14.6333; Penkowa M, 1999, GLIA, V25, P343; Penkowa M, 1999, EXP NEUROL, V156, P149, DOI 10.1006/exnr.1998.7009; Penkowa M, 1999, J NEUROSCI, V19, P2535; POWELL HC, 1994, BRAIN PATHOL, V4, P278; QUAIFE CJ, 1994, BIOCHEMISTRY-US, V33, P7250, DOI 10.1021/bi00189a029; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; SATO M, 1995, ARCH BIOCHEM BIOPHYS, V316, P738, DOI 10.1006/abbi.1995.1098; SATO M, 1994, INT J IMMUNOPHARMACO, V16, P187; SATO M, 1992, RES COMMUN CHEM PATH, V75, P159; SATO M, 1993, FREE RADICAL BIO MED, V14, P325, DOI 10.1016/0891-5849(93)90029-T; Stalder AK, 1998, AM J PATHOL, V153, P767, DOI 10.1016/S0002-9440(10)65620-9; STEFFENSEN SC, 1994, BRAIN RES, V652, P149, DOI 10.1016/0006-8993(94)90329-8; Stichel CC, 1998, PROG NEUROBIOL, V56, P119, DOI 10.1016/S0301-0082(98)00033-1; TAUBENECK MW, 1995, J NUTR, V125, P908; THORNALLEY PJ, 1985, BIOCHIM BIOPHYS ACTA, V827, P36, DOI 10.1016/0167-4838(85)90098-6; UCHIDA Y, 1991, NEURON, V7, P337, DOI 10.1016/0896-6273(91)90272-2; Unsicker K, 1992, Curr Opin Neurobiol, V2, P671, DOI 10.1016/0959-4388(92)90037-L; YAGLE MK, 1985, MOL CELL BIOL, V5, P291, DOI 10.1128/MCB.5.2.291	66	32	33	0	1	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886			EXP NEUROL	Exp. Neurol.	MAY	2000	163	1					46	54		10.1006/exnr.1999.7335			9	Neurosciences	Neurosciences & Neurology	313NV	WOS:000087006500006	10785443	Green Published			2021-06-18	
J	Jiang, QB; Stys, PK				Jiang, QB; Stys, PK			Calpain inhibitors confer biochemical, but not electrophysiological, protection against anoxia in rat optic nerves	JOURNAL OF NEUROCHEMISTRY			English	Article						axon; calcium; sodium channel; spectrin; anoxia; white matter	CALCIUM-ACTIVATED PROTEASE; CNS WHITE-MATTER; IN-VITRO; ELEMENTAL COMPOSITION; MYELINATED AXONS; WATER-CONTENT; BRAIN; NEURONS; INJURY; DEGRADATION	Calpains are ubiquitous Ca2+-activated neutral proteases that have been implicated in ischemic and traumatic CNS injury. Ischemia and trauma of central white matter are dependent on Ca2+ accumulation, and calpain overactivation likely plays a significant role in the pathogenesis. Adult rat optic nerves, representative central white matter tracts, were studied in an in vitro anoxic model. Functional recovery following 60 min of anoxia and reoxygenation was measured electrophysiologically. Calpain activation was assessed using western blots with antibodies against calpain-cleaved spectrin breakdown products. Sixty minutes of in vitro anoxia increased the amount of spectrin breakdown approximate to 20-fold over control, with a further increase after reoxygenation to >70 times control, almost as much as 2 h of continuous anoxia. Blocking voltage-gated Na+ channels with tetrodotoxin or removing bath Ca2+ was highly neuroprotective electrophysiologically and resulted in a marked reduction of spectrin degradation. The membrane-permeable calpain inhibitors MDL 28,170 and calpain inhibitor-1 (10-100 mu M) were effective at reducing spectrin breakdown in anoxic and reoxygenated optic nerves, but no electrophysiological improvement was observed. We conclude that calpain activation is an important step in anoxic white matter injury, but inhibition of this Ca2+-dependent process in isolation does not improve functional outcome, probably because other deleterious Ca2+-activated pathways proceed unchecked.	Ottawa Hosp, Leob Hlth Res Inst, Div Neurosci, Ottawa, ON K1Y 4K9, Canada	Stys, PK (corresponding author), Ottawa Hosp, Leob Hlth Res Inst, Div Neurosci, Civic Campus,725 Parkdale Ave, Ottawa, ON K1Y 4K9, Canada.						ARAI A, 1990, BRAIN RES, V532, P63, DOI 10.1016/0006-8993(90)91742-Y; BRORSON JR, 1995, STROKE, V26, P1259, DOI 10.1161/01.STR.26.7.1259; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; CANER H, 1993, BRAIN RES, V607, P354, DOI 10.1016/0006-8993(93)91531-V; Chen ZF, 1997, BRAIN RES, V769, P188, DOI 10.1016/S0006-8993(97)00848-2; CROALL DE, 1991, PHYSIOL REV, V71, P813; DELCERRO S, 1990, BRAIN RES, V530, P91; DESHPANDE RV, 1995, J NEUROSCI RES, V42, P259, DOI 10.1002/jnr.490420214; Faddis BT, 1997, J NEUROSCI, V17, P951; FERN R, 1993, J PHARMACOL EXP THER, V266, P1549; GIANCOTTI FG, 1992, J CELL BIOL, V118, P951, DOI 10.1083/jcb.118.4.951; HAMAKUBO T, 1986, J NEUROSCI, V6, P3103, DOI 10.1523/jneurosci.06-11-03103.1986; Hewitt KE, 1998, J NEUROSCI RES, V54, P223, DOI 10.1002/(SICI)1097-4547(19981015)54:2<223::AID-JNR10>3.0.CO;2-5; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; James T, 1998, J NEUROSCI RES, V51, P218, DOI 10.1002/(SICI)1097-4547(19980115)51:2<218::AID-JNR10>3.3.CO;2-#; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; LEE KS, 1991, P NATL ACAD SCI USA, V88, P7233, DOI 10.1073/pnas.88.16.7233; LI ZH, 1995, BRAIN RES, V697, P112; LoPachin RM, 1999, J NEUROPHYSIOL, V82, P2143; LOPACHIN RM, 1995, J NEUROSCI, V15, P6735; MANEV H, 1991, J NEUROCHEM, V57, P1288, DOI 10.1111/j.1471-4159.1991.tb08292.x; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; MouattPrigent A, 1996, NEUROSCIENCE, V73, P979, DOI 10.1016/0306-4522(96)00100-5; Neumar RW, 1996, J NEUROCHEM, V66, P421; NIXON RA, 1986, J NEUROSCI, V6, P1252; ORRENIUS S, 1996, CELLULAR MOL MECH IS, P137; PERLMUTTER LS, 1990, J COMP NEUROL, V296, P269, DOI 10.1002/cne.902960207; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; Rami A, 1997, NEUROSCI RES, V27, P93, DOI 10.1016/S0168-0102(96)01123-6; ROBERTSLEWIS JM, 1994, J NEUROSCI, V14, P3934; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; SALAMINO F, 1994, CELL CALCIUM, V15, P28, DOI 10.1016/0143-4160(94)90101-5; Schumacher PA, 1999, NEUROSCIENCE, V91, P733, DOI 10.1016/S0306-4522(98)00552-1; Shields DC, 1999, P NATL ACAD SCI USA, V96, P11486, DOI 10.1073/pnas.96.20.11486; SIMAN R, 1989, J NEUROSCI, V9, P1579; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; Stys PK, 1996, NEUROSCIENCE, V73, P1081, DOI 10.1016/0306-4522(96)00114-5; STYS PK, 1990, P NATL ACAD SCI USA, V87, P4212, DOI 10.1073/pnas.87.11.4212; STYS PK, 1992, J NEUROSCI, V12, P430; Stys PK, 1998, NEUROSCIENCE, V82, P21; STYS PK, 1991, BRAIN RES, V546, P18, DOI 10.1016/0006-8993(91)91154-S; WANG KKW, 1990, TRENDS PHARMACOL SCI, V11, P139, DOI 10.1016/0165-6147(90)90060-L; WANG KKW, 1994, TRENDS PHARMACOL SCI, V15, P412, DOI 10.1016/0165-6147(94)90090-6	45	32	34	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3042			J NEUROCHEM	J. Neurochem.	MAY	2000	74	5					2101	2107		10.1046/j.1471-4159.2000.0742101.x			7	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	304CY	WOS:000086466200036	10800955				2021-06-18	
J	Rao, AM; Hatcher, JF; Dogan, A; Dempsey, RJ				Rao, AM; Hatcher, JF; Dogan, A; Dempsey, RJ			Elevated N-1-acetylspermidine levels in gerbil and rat brains after CNS injury	JOURNAL OF NEUROCHEMISTRY			English	Article						cerebral ischemia; spermidine/spermine-N-1-acetyltransferase; polyamine oxidase; MDL 72527; putrescine; traumatic brain injury; polyamine interconversion pathway; polyamines; ornithine decarboxylase	FOCAL CEREBRAL-ISCHEMIA; SPERMIDINE-SPERMINE N1-ACETYLTRANSFERASE; POLYAMINE INTERCONVERSION PATHWAY; ORNITHINE DECARBOXYLASE ACTIVITY; INDUCED SEIZURE ACTIVITY; BARRIER BREAKDOWN; EDEMA FORMATION; MESSENGER-RNA; TRANSGENIC RATS; METABOLISM	The polyamine system is very sensitive to different pathological stales of the brain and is perturbed after CNS injury. The main modifications are significant increases in ornithine decarboxylase activity and an increase in tissue putrescine levels. Previously we have shown that the specific polyamine oxidase (PAO) inhibitor N-1,N-4-bis(2,3-butadienyl)-1,4-butanediamine (MDL 72527) reduced the tissue putrescine levels, edema, and infarct volume after transient focal cerebral ischemia in spontaneously hypertensive rats and traumatic brain injury of Sprague-Dawley rats. In the present study, N-1-acetylspermidine accumulation was greater in injured brain regions compared with sham or contralateral regions following inhibition of PAO by MDL 72527. This indicates spermidine/spermine-N-1-acetyltransferase (SSAT) activation after CNS injury. The observed increase in N-1-acetylspermidine levels at I day after CNS trauma paralleled the decrease in putrescine levels after treatment with MDL 72527, This suggests that the increased putrescine formation at I day after CNS injury is mediated by the SSAT/PAO pathway, consistent with increased SSAT mRNA after transient ischemia.	Univ Wisconsin, Dept Neurol Surg, Ctr Clin Sci, Madison, WI 53792 USA; Vet Adm Hosp, Madison, WI USA	Dempsey, RJ (corresponding author), Univ Wisconsin, Dept Neurol Surg, Ctr Clin Sci, H4-336,600 Highland Ave, Madison, WI 53792 USA.		Dogan, Aclan/AAF-8305-2019		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS031220, R01NS028000] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01 NS31220, R01 NS 28000] Funding Source: Medline		Baskaya MFK, 1996, NEUROSURGERY, V38, P140; Baskaya MK, 1996, J NEUROTRAUM, V13, P85, DOI 10.1089/neu.1996.13.85; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Baskaya MK, 1997, BRAIN RES, V744, P302; Baskaya MK, 1997, NEUROSURGERY, V40, P364; BAUDRY M, 1994, NEUROSCI LETT, V171, P151, DOI 10.1016/0304-3940(94)90627-0; CASERO RA, 1993, FASEB J, V7, P653; DEMPSEY RJ, 1991, J CEREBR BLOOD F MET, V11, P979, DOI 10.1038/jcbfm.1991.164; deVera N, 1997, AMINO ACIDS, V12, P1; Dogan A, 1998, NEUROL RES, V20, P265; Dogan A, 1999, J NEUROSURG, V90, P1078, DOI 10.3171/jns.1999.90.6.1078; Dogan A, 1999, J NEUROCHEM, V72, P765, DOI 10.1046/j.1471-4159.1999.0720765.x; GERNER EW, 1993, BIOCHEM J, V294, P491, DOI 10.1042/bj2940491; HAYASHI Y, 1995, DEV BRAIN RES, V87, P96, DOI 10.1016/0165-3806(95)00053-G; Henley CM, 1997, J NEUROCHEM, V69, P259; Henley CM, 1996, J NEUROTRAUM, V13, P487, DOI 10.1089/neu.1996.13.487; Ivanova S, 1998, J EXP MED, V188, P327, DOI 10.1084/jem.188.2.327; Johnson TD, 1998, PROG DRUG RES, V50, P193; KABRA PM, 1986, J CHROMATOGR, V380, P19, DOI 10.1016/S0378-4347(00)83621-X; Keinanen R, 1997, NEUROSCI LETT, V239, P69, DOI 10.1016/S0304-3940(97)00890-2; KINDY MS, 1994, J CEREBR BLOOD F MET, V14, P1040, DOI 10.1038/jcbfm.1994.136; KOENIG H, 1983, BIOCHEM BIOPH RES CO, V116, P1039, DOI 10.1016/S0006-291X(83)80247-2; Lukkarinen J, 1997, STROKE, V28, P639, DOI 10.1161/01.STR.28.3.639; Lukkarinen JA, 1998, EUR J NEUROSCI, V10, P2046, DOI 10.1046/j.1460-9568.1998.00216.x; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; Morgan DML, 1998, BIOCHEM SOC T, V26, P586, DOI 10.1042/bst0260586; MORGAN DML, 1987, ESSAYS BIOCHEM, V23, P82; PASCHEN W, 1988, BRAIN RES, V453, P9, DOI 10.1016/0006-8993(88)90138-2; PASCHEN W, 1992, MOL CHEM NEUROPATHOL, V16, P241, DOI 10.1007/BF03159973; PASCHEN W, 1993, PROG BRAIN RES, V96, P147; PASCHEN W, 1992, CEREBROVAS BRAIN MET, V4, P59; PEGG AE, 1982, AM J PHYSIOL, V243, pC212; PERSSON L, 1984, J BIOL CHEM, V259, P2364; Rao AM, 1999, NEUROCHEM RES, V24, P1225, DOI 10.1023/A:1020916905312; Rao AM, 1999, J NEUROSCI RES, V58, P697, DOI 10.1002/(SICI)1097-4547(19991201)58:5<697::AID-JNR11>3.3.CO;2-2; Rao AM, 1998, NEUROSCI LETT, V256, P65, DOI 10.1016/S0304-3940(98)00780-0; Rao AM, 1997, MOL BRAIN RES, V44, P134, DOI 10.1016/S0169-328X(96)00245-8; RAO AM, 1995, J NEUROCHEM, V65, P2639; SCHMITZ MP, 1993, NEUROSURGERY, V33, P882; SEILER N, 1985, NEUROCHEM RES, V10, P529, DOI 10.1007/BF00964656; Seiler N, 1995, PROG BRAIN RES, V106, P333; Suppola S, 1999, BIOCHEM J, V338, P311, DOI 10.1042/0264-6021:3380311; WOSTER PM, 1995, POLYAMINES REGULATIO, P171; Zoli M, 1996, MOL BRAIN RES, V38, P122, DOI 10.1016/0169-328X(95)00339-T	44	32	34	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-3042			J NEUROCHEM	J. Neurochem.	MAR	2000	74	3					1106	1111					6	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	284ME	WOS:000085335500024	10693942				2021-06-18	
J	Oehmichen, M; Meissner, C; Konig, HG				Oehmichen, M; Meissner, C; Konig, HG			Brain injury after gunshot wounding: Morphometric analysis of cell destruction caused by temporary cavitation	JOURNAL OF NEUROTRAUMA			English	Article						astrocyte; axonal injury; neuronal injury; permanent track; temporary cavitation	BALLISTICS; MECHANISMS; PROTEIN; HEAD	In addition to the primary destruction of brain tissue readily visible at autopsy (permanent track), gunshot wounding to the brain creates a pulsating temporary cavity due to radial expansion along the bullet's track. To determine the maximum extent of this temporary cavitation in brains of victims of gunshots from weapons with low muzzle velocity, we carried out morphometric studies on 20 cases of death from gunshot wounding to the head from bullets with a muzzle energy <500 J and a survival time of <90 min. The brains were fixed in formalin, examine macroscopically and microscopically, and subjected to morphometric analyses. Surrounding the permanent track, a narrow mantle-like zone of astrocyte destruction was found within an area of hemorrhagic extravasation, Axons near the permanent track had been broken into tiny fragments. The axonal damage lessened with increasing distance from the permanent track, although axons continued to be fragmented and to exhibit varicose changes and clumping until assuming their normal structure beyond 18 mm, Nerve cells were extremely shrunken close to the permanent track but gradually took on their normal shape with increasing distance. We also assessed the loss of glial fibrillary acid protein expression by astrocytes in the white matter, the extent of traumatic bleeding, and damage to axons and neurons as measured radially from the permanent track. Axonal and neuronal damage were found to extend about 18 mm radially from the permanent track, tapering gradually along the track from entry point to exit point. The destruction was probably produced by the temporary cavitation and accords with theoretical considerations and experimental observations.	Univ Lubeck, Inst Legal Med, D-23562 Lubeck, Germany; Univ Tubingen, Inst Legal Med, Tubingen, Germany	Oehmichen, M (corresponding author), Univ Lubeck, Inst Legal Med, Kahlhorststr 31-35, D-23562 Lubeck, Germany.						Baker J.R., 1958, PRINCIPLES BIOL MICR; Bowen TE, 1988, EMERGENCY WAR SURG 2; BUTLER FG, 1945, J NEUROSURG, V2, P238; Callender GR, 1935, MIL SURG, V77, P177; CAMPBELL E, 1950, J NEUROPATH EXP NEUR, V9, P139, DOI 10.1097/00005072-195004000-00002; CAMPBELL E, 1958, SURG WORLD WAR 2 NEU, V1, P335; DEMUTH WE, 1966, J TRAUM, V6, P222, DOI 10.1097/00005373-196606020-00008; ENG LF, 1983, PROG NEUROPATH, V5, P19; Fackler M. L., 1991, WOUND BALLISTICS REV, V1, P38; FACKLER ML, 1985, J TRAUMA, V25, P522, DOI 10.1097/00005373-198506000-00009; FACKLER ML, 1988, J TRAUMA, V28, pS21, DOI 10.1097/00005373-198801001-00007; FACKLER ML, 1991, WOUND BALLISTICS REV, V1, P41; HARVEY EN, 1947, SURGERY, V21, P218; Harvey EN, 1945, WAR MED, V8, P91; HOLLERMAN JJ, 1990, AM J ROENTGENOL, V155, P685, DOI 10.2214/ajr.155.4.2119095; KARGER B, 1995, INT J LEGAL MED, V108, P53, DOI 10.1007/BF01369905; KARGER B, 1988, INT J LEGAL MED, V111, P314; KARGER B, 1996, INT LEG MED, V108, P117; KIRKPATRICK JB, 1988, FORENSIC NEUROPATHOL, P276; Koszyca B, 1998, J NEUROTRAUM, V15, P675, DOI 10.1089/neu.1998.15.675; NAOUMENKO JULIA, 1963, ACTA NEUROPATHOL, V2, P402; Oehmichen M, 1985, Beitr Gerichtl Med, V43, P55; OEHMICHEN M, 2000, UNPUB BRAIN INJURY S; OEHMICHEN M, 1992, KOPFSCHUSS SPANNUNGS, P37; OTTOSON R, 1964, MIL MED, V129, P1017; Parkinson J, 1982, J Neurosurg Nurs, V14, P232; Ramon YCajalS, 1928, DEGENERATION REGENER; Rand CW, 1934, ARCH NEURO PSYCHIATR, V31, P527, DOI 10.1001/archneurpsyc.1934.02250030067004; Sellier K, 1969, SCHUSSWAFFEN SCHUSSW; Sellier KG., 1994, WOUND BALLISTICS SCI; UNTERHARNSCHEID.F, 1993, PATHOLOGIE NERVENS A, V6	31	32	35	1	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	FEB	2000	17	2					155	162		10.1089/neu.2000.17.155			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	286MB	WOS:000085448800005	10709873				2021-06-18	
J	Stevens, H; Jansen, HML; De Reuck, J; Lemmerling, M; Strijckmans, K; Goethals, P; Lemahieu, I; de Jong, BM; Willemsen, ATM; Korf, J				Stevens, H; Jansen, HML; De Reuck, J; Lemmerling, M; Strijckmans, K; Goethals, P; Lemahieu, I; de Jong, BM; Willemsen, ATM; Korf, J			(55)Cobalt (Co) as a PET-tracer in stroke, compared with blood flow, oxygen metabolism, blood volume and gadolinium-MRI	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						cerebral ischemia; cobalt; cerebral blood flow; cerebral oxygen metabolic rate; tomography; emission-computed	POSITRON-EMISSION-TOMOGRAPHY; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; COBALT-55; PATHOPHYSIOLOGY; NEURONS; DAMAGE; CO-57; VISUALIZATION; ACCUMULATION	Several studies have shown the feasibility of divalent cobalt (Co)-isotopes (Co-55 and Co-57) in imaging of neuronal damage in stroke, multiple sclerosis, cerebral tumors and traumatic brain injury. Little is known how regional Co uptake relates to other pathophysiological changes after stroke. Therefore, we compared Co-55-PET with functional parameters such as regional cerebral blood dow (rCBF) using (CO2)-O-15, regional oxygen metabolism (rCMRO(2)) using O-15(2), regional cerebral bloodvolume (rCBV) and post-gadolinium (Gd) T(1)w-MRI to assess the permeability of the blood-brain-barrier (BBB). Sixteen patients (10 female; six male) aged 43 to 84 (mean 69) years with first ever stroke, as shown by CT or MRI, were examined with Co-55-PET and (CO2)-O-15-, O-15(2)- and (CO)-O-15-PET in one single session, in a period varying from 0 to 30 days after stroke-onset. Regions of infarction on (CO2)-O-15- and O-15(2)-PET (defined by rCMRO(2) <65% or rCBF<45% of the contralateral value) were subsequently superimposed on the Co-55-PET scan. Clinical status was established using the Orgogozo stroke scale, which was assessed both at day 1 and at discharge (at least 6 weeks after day 1). Accumulation of Co-55 was Seen in eight out of 16 patients, occurring in areas showing a diminished oxygen metabolism, was only partially related to blood flow, and was located mainly outside the extent of the infarction or luxury perfusion as seen on post-Gd T(1)w-MRI. Statistical analysis showed a negative correlation between the Orgogozo score at discharge and the uptake of radioactive cobalt. (C) 1999 Elsevier Science B.V. All rights reserved.	Univ Groningen Hosp, Dept Biol Psychiat, Groningen, Netherlands; State Univ Ghent Hosp, PET Ctr, B-9000 Ghent, Belgium; State Univ Ghent, Dept Neurol, B-9000 Ghent, Belgium; State Univ Ghent, Dept Radiol, B-9000 Ghent, Belgium; State Univ Ghent, Inst Sci Nucl, Dept Analyt Chem, B-9000 Ghent, Belgium; State Univ Ghent, Dept Elect & Informat Sci, B-9000 Ghent, Belgium; Univ Groningen Hosp, Dept Neurol, Groningen, Netherlands; Univ Groningen Hosp, Natl PET Ctr, Groningen, Netherlands	Korf, J (corresponding author), Univ Groningen Hosp, Dept Biol Psychiat, Groningen, Netherlands.		Lemahieu, Ignace/G-8625-2012	Lemahieu, Ignace/0000-0002-0894-9988			BARON JC, 1987, CLIN EFFICACY POSITR, P15; DEREUCK J, 1993, J NEUROL, V3, P416; FREI K, 1987, EUR J IMMUNOL, V17, P1271, DOI 10.1002/eji.1830170909; FRISTON KJ, 1995, HUM BRAIN MAPP, V0003, P00165, DOI DOI 10.1002/HBM.460030303; Furlan M, 1996, ANN NEUROL, V40, P216, DOI 10.1002/ana.410400213; GRAMSBERGEN JBP, 1988, J NEUROCHEM, V50, P1798, DOI 10.1111/j.1471-4159.1988.tb02481.x; HEISS WD, 1992, J CEREBR BLOOD F MET, V12, P193, DOI 10.1038/jcbfm.1992.29; HEISS WD, 1994, EUR J NUCL MED, V21, P455; HEISS WD, 1993, STROKE, V24, P1784, DOI 10.1161/01.STR.24.12.1784; HEISS WD, 1993, STROKE S1, V24, P50; Jansen HM, 1997, NUCL MED COMMUN, V18, P734, DOI 10.1097/00006231-199708000-00007; Jansen HML, 1996, J NEUROL NEUROSUR PS, V60, P221, DOI 10.1136/jnnp.60.2.221; Jansen HML, 1996, J NUCL MED, V37, P2082; JANSEN HML, 1995, J NEUROL SCI, V132, P139, DOI 10.1016/0022-510X(95)00139-S; Jansen HML, 1997, CLIN NEUROL NEUROSUR, V99, P6, DOI 10.1016/S0303-8467(96)00558-6; KOCHANEK PM, 1992, STROKE, V23, P1367, DOI 10.1161/01.STR.23.9.1367; Korf J, 1998, J NUCL MED, V39, P836; Linde R, 1996, ACT NEUR S, V66, P15; MARCHAL G, 1993, LANCET, V341, P925, DOI 10.1016/0140-6736(93)91214-7; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; ORGOGOZO JM, 1991, CEREBROVASC DIS, V1, P100, DOI 10.1159/000108904; Pagani M, 1997, EUR J NUCL MED, V24, P1301, DOI 10.1007/s002590050156; PRUSS RM, 1991, NEURON, V7, P509, DOI 10.1016/0896-6273(91)90302-G; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; Stevens H, 1998, NEUROSCI LETT, V258, P183, DOI 10.1016/S0304-3940(98)00883-0; Stevens H, 1998, NUCL MED COMMUN, V19, P573, DOI 10.1097/00006231-199806000-00010; Stevens H, 1998, J NUCL MED, V39, P495; WANG PY, 1993, STROKE, V24, P236, DOI 10.1161/01.STR.24.2.236; WILLIAMS LR, 1992, BRAIN RES, V581, P181, DOI 10.1016/0006-8993(92)90707-G	31	32	34	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0022-510X			J NEUROL SCI	J. Neurol. Sci.	DEC 1	1999	171	1					11	18		10.1016/S0022-510X(99)00229-4			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	269PX	WOS:000084487700004	10567044				2021-06-18	
J	Wilkinson, R; Meythaler, JM; Guin-Renfroe, S				Wilkinson, R; Meythaler, JM; Guin-Renfroe, S			Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY; AMANTADINE; DAMAGE; RECOVERY	The use of neuroleptics in the acute management of traumatic brain injury (TBI) is controversial and may be detrimental to recovery. The following case report describes a patient developing neuroleptic malignant syndrome (NMS) secondary to the use of haloperidol given to control the patient's agitation. The patient began to exhibit symptoms consistent with NMS (high fever, dystonia, diaphoresis, tachycardia, and decerebrate posturing) shortly after administration of the haloperidol. Upon transfer to a rehabilitation hospital, the symptoms persisted. When NMS is suspected, the first intervention is to remove the offending agent; thus, the administration of haloperidol was suspended, and the patient was placed on Amantadine and propranolol. Amantadine was used to increase the availability of dopamine to the mid-brain region, and the propranolol was used to control the fever, which was believed to be central in origin. The patient was able to complete his rehabilitation with no further incidence of fever or agitation. The patient met or exceeded all short-term physical therapy goals and was able to complete most of the neuropsychological tasks presented. The patient returned home 38 days after admission to the rehabilitation hospital and was able to perform most activities of daily Living. At the 6-months follow-up visit, the patient was considering entrance into an adult vocational school.	Univ Alabama, Sch Med, Dept Phys Med & Rehabil, Spain Rehabil Ctr R157, Birmingham, AL 35233 USA	Meythaler, JM (corresponding author), Univ Alabama, Sch Med, Dept Phys Med & Rehabil, Spain Rehabil Ctr R157, 1717 6th Ave S, Birmingham, AL 35233 USA.						ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P459; ADAMS RD, 1993, PRINCIPLES NEUROLOGY, P934; ADELOYE A, 1971, PRACTITIONER, V206, P517; AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; BAREGGI SR, 1975, EUR NEUROL, V13, P528, DOI 10.1159/000114709; Bourgeois M, 1971, Bord Med, V4, P1115; BRISTOW MF, 1993, BRIT MED J, V307, P1223, DOI 10.1136/bmj.307.6914.1223; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P917; CARDENAS DD, 1992, PHYS MED REH CLIN N, V3, P273; CAROFF SN, 1993, MED CLIN N AM, V77, P185, DOI 10.1016/S0025-7125(16)30278-4; DELAY J, 1960, Ann Med Psychol (Paris), V118(1), P145; Evans R. W., 1987, J HEAD TRAUMA REHAB, V2, P29; FEENEY DM, 1982, SCIENCE, V217, P855, DOI 10.1126/science.7100929; GELENBERG AJ, 1988, AM J PSYCHIAT, V145, P517; HENDERSON VW, 1981, NEUROLOGY, V1331, P1495; *INT HEAD INJ TASK, 1989, NAT I NEUR DIS STROK; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; KAPLAN HI, 1993, POCKET HDB PSYCHIAT, P104; KECK PE, 1991, AM J PSYCHIAT, V148, P880; KECK PE, 1989, ARCH GEN PSYCHIAT, V46, P914; KELLAM AMP, 1987, BRIT J PSYCHIAT, V150, P752, DOI 10.1192/bjp.150.6.752; KELLAM AMP, 1990, BRIT J PSYCHIAT, V157, P16; Kraus MF, 1997, BRAIN INJURY, V11, P455, DOI 10.1080/026990597123430; LINDSAY KW, 1991, NEUROLOGY NEUROSURGE, P141; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MCLELLAN DR, 1990, PHYSICAL MED REHABIL, V4, P389; MEYTHALER JM, 1994, ARCH PHYS MED REHAB, V75, P816; Mooney R P, 1990, W V Med J, V86, P95; MYERS FH, 1989, LANCET, V1, P50; NICKELS J, 1994, BRAIN INJURY, V8, P809; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Reinhard DL, 1996, ARCH PHYS MED REHAB, V77, P80, DOI 10.1016/S0003-9993(96)90225-7; ROSEBUSH P, 1989, AM J PSYCHIAT, V146, P717; ROSS ED, 1981, NEUROLOGY, V31, P1435, DOI 10.1212/WNL.31.11.1435; SAKKAS P, 1991, PSYCHIAT ANN, V21, P157, DOI 10.3928/0048-5713-19910301-08; SHALEV A, 1986, ACTA PSYCHIAT SCAND, V73, P337, DOI 10.1111/j.1600-0447.1986.tb02694.x; SNYDER S, 1974, ARCH GEN PSYCHIAT, V31, P58; VANHASSELT P, 1973, NEUROPHARMACOLOGY, V12, P245, DOI 10.1016/0028-3908(73)90109-3; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; VANWOERKOM M, 1990, PM R REV, V4, P447; VANWOERKOM TCAM, 1977, LANCET, V1, P812; Vasconcellos J, 1978, JAMA-J AM MED ASSOC, V240, P380; Whyte J, 1993, REHABILITATION MED P, P825; Zafonte RD, 1998, BRAIN INJURY, V12, P617; 1994, DIAGN STAT MAN MENT, P739	47	32	33	0	0	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	1999	13	12					1025	1031					7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	264UJ	WOS:000084200600008	10628507				2021-06-18	
J	Lang, EW; Diehl, RR; Timmermann, L; Baron, R; Deuschl, G; Mehdorn, HM; Zunker, P				Lang, EW; Diehl, RR; Timmermann, L; Baron, R; Deuschl, G; Mehdorn, HM; Zunker, P			Spontaneous oscillations of arterial blood pressure, cerebral and peripheral blood flow in healthy and comatose subjects	NEUROLOGICAL RESEARCH			English	Article						cerebral autoregulation; peripheral autoregulation; coma; transcranial Doppler ultrasound; cerebral circulation; covariance analysis	TRANSCRANIAL DOPPLER RECORDINGS; ROSTRAL VENTROLATERAL MEDULLA; SEROTONERGIC INNERVATION; INTRACRANIAL-PRESSURE; RHYTHMIC OSCILLATIONS; AUTOREGULATION; HUMANS; STIMULATION; NEURONS; MUSCLE	Slow and rhythmic spontaneous oscillations of cerebral and peripheral blood flow occur within frequencies of 0.5-3 min(-1) (0.008-0.05 Hz, B-waves) and 3-9 min(-1) (0.05-0.15 Hz, M-waves). The generators and pathways of such oscillations are not fully understood. We compared the coefficient of variance (CoV), which serves as an indicator for the amplitude of oscillations and is calculated as the percent standard deviation of oscillations within a particular frequency band from the mean, to study the impairment of generators or pathways of such oscillations in normal subjects and comatose patients in a controlled fashion. With local ethic committee approval, data were collected from 19 healthy volunteers and nine comatose patients suffering from severe traumatic brain injury (n = 3), severe subarachnoid hemorrhage (n = 3), and intracerebral hemorrhage (n = 3). Cerebral blood flow velocities were measured by transcranial Doppler ultrasound (TCD), peripheral vasomotion by finger tip laser Doppler flowmetry (LDF), and ABP by either non-invasive continuous blood pressure recordings (Finapres method) in control subjects, or by direct radial artery recordings in comatose patients. Each recording session lasted similar to 20-30 min. Data were stored in the TCD device for offline analysis of CoV. For CoV in the cerebral B-wave frequency range there was no difference between coma patients and controls, however there was a highly significant reduction in the amplitude of peripheral B-wave LDF and ABP vasomotion (3.8 +/- 2.1 vs. 28.2 +/- 16.1 for LDF, p < 0.001; and 1.2 +/- 0.7 vs. 4.6 +/- 2.8 for ABP, p < 0.007) This observation was confirmed for spontaneous cerebral and peripheral oscillations in the M-wave frequency range. The CoV reduction in peripheral LDF and ABP oscillations suggest a severe impairment of the proposed sympathetic pathway in comatose patients. The preservation of central TCD oscillations argues in favor of different pathways and/or generators of cerebral and peripheral B- and M-waves.	Univ Kiel, Dept Neurosurg, D-24106 Kiel, Germany; Univ Kiel, Dept Neurol, D-2300 Kiel, Germany; Alfried Krupp Hosp, Dept Neurol, Essen, Germany	Lang, EW (corresponding author), Univ Kiel, Dept Neurosurg, Weimarer Str 8, D-24106 Kiel, Germany.		Baron, Ralf/E-4298-2010; Deuschl, Guenther/A-7986-2010; Mehdorn, Maximilian/D-2495-2010	Deuschl, Guenther/0000-0002-4176-9196; 			AASLID R, 1991, STROKE, V22, P1148, DOI 10.1161/01.STR.22.9.1148; AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; ANDERSON EA, 1987, HYPERTENSION, V9, P114, DOI 10.1161/01.HYP.9.6_Pt_2.III114; ARBAB MAR, 1988, J CEREBR BLOOD F MET, V8, P54, DOI 10.1038/jcbfm.1988.8; AUER LM, 1983, ACTA NEUROCHIR, V68, P93, DOI 10.1007/BF01406205; BAKER CH, 1990, CIRC SHOCK, V32, P101; BIRCH AA, 1995, STROKE, V26, P834, DOI 10.1161/01.STR.26.5.834; Blessing WW, 1997, LOWER BRAINSTEM BODI, P165; BONVENTO G, 1991, J NEUROCHEM, V56, P681, DOI 10.1111/j.1471-4159.1991.tb08203.x; BONVENTO G, 1991, BRAIN RES REV, V16, P257, DOI 10.1016/0165-0173(91)90009-W; Czosnyka M, 1996, CEREBROVAS BRAIN MET, V8, P273; Czosnyka M, 1996, STROKE, V27, P1829, DOI 10.1161/01.STR.27.10.1829; DAMPNEY RAL, 1988, J PHYSIOL-LONDON, V395, P41, DOI 10.1113/jphysiol.1988.sp016907; Diehl B, 1997, STROKE, V28, P2457, DOI 10.1161/01.STR.28.12.2457; Diehl RR, 1998, CLIN AUTON RES, V8, P7, DOI 10.1007/BF02267598; DROSTE DW, 1994, ACTA NEUROL SCAND, V90, P99; EINHAUPL KM, 1986, INTRACRANIAL PRESSUR, V6, P290; GOADSBY PJ, 1985, AM J PHYSIOL, V248, pR257; GOADSBY PJ, 1986, BRAIN RES, V381, P63, DOI 10.1016/0006-8993(86)90690-6; GUYENET PG, 1990, AM J PHYSIOL, V259, pR1063; JANIG W, 1988, ANNU REV PHYSIOL, V50, P525, DOI 10.1146/annurev.ph.50.030188.002521; KANO T, 1993, J AUTONOM NERV SYST, V45, P191, DOI 10.1016/0165-1838(93)90051-U; LAL SKL, 1995, HYPERTENSION, V26, P307, DOI 10.1161/01.HYP.26.2.307; LIANG CS, 1987, CIRCULATION, V75, P443, DOI 10.1161/01.CIR.75.2.443; LUNDBERG N, 1960, ACTA PSYCHIATRICA  S, V149, P1; MAEDA M, 1986, INTRACRANIAL PRESSUR, V6, P151; Mayer S., 1876, SITZ KAISER AKAD WIS, V74, P281; MCALLEN RM, 1994, AM J PHYSIOL-REG I, V267, pR935; Michaloudis D, 1998, ANAESTHESIA, V53, P446, DOI 10.1046/j.1365-2044.1998.00323.x; MORITATSUZUKI Y, 1992, ACTA PHYSIOL SCAND, V146, P431, DOI 10.1111/j.1748-1716.1992.tb09444.x; Steinmeier R, 1996, STROKE, V27, P2236, DOI 10.1161/01.STR.27.12.2236; SUN MK, 1988, BRAIN RES, V442, P229, DOI 10.1016/0006-8993(88)91508-9; TSAI SH, 1985, NEUROSURGERY, V16, P463, DOI 10.1227/00006123-198504000-00005; vandenBerg F, 1996, PSYCHOPHARMACOLOGY, V128, P21, DOI 10.1007/s002130050105; WALLIN BG, 1975, PFLUG ARCH EUR J PHY, V358, P101, DOI 10.1007/BF00583921; WALLIN BG, 1994, NEWS PHYSIOL SCI, V9, P203; Yu YH, 1997, AM J PHYSIOL-REG I, V272, pR208; Zunker P., 1997, NEW TRENDS CEREBRAL, P718	38	32	32	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	OCT	1999	21	7					665	669		10.1080/01616412.1999.11740995			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	246XT	WOS:000083190700010	10555189				2021-06-18	
J	Muir, JK; Raghupathi, R; Emery, DL; Bareyre, FM; McIntosh, TK				Muir, JK; Raghupathi, R; Emery, DL; Bareyre, FM; McIntosh, TK			Postinjury magnesium treatment attenuates traumatic brain injury-induced cortical induction of p53 mRNA in rats	EXPERIMENTAL NEUROLOGY			English	Article						magnesium; in situ hybridization; cell death; apoptosis; p53; traumatic brain injury	NUCLEOTIDE EXCISION-REPAIR; TUMOR-SUPPRESSOR P53; SPINAL-CORD INJURY; CLOSED-HEAD INJURY; DNA FRAGMENTATION; CELL-DEATH; MESSENGER-RNA; BAX GENE; APOPTOSIS; EXPRESSION	Administration of magnesium has been shown to be neuroprotective in experimental models of traumatic brain injury (TBI). The present study examined the effect of magnesium on posttraumatic regional induction of p53, a gene associated with induction of cell death. Male Sprague-Dawley rats (350-400 g, n = 26) were anesthetized with sodium pentobarbital and subjected to either lateral fluid percussion brain injury of moderate severity (2.4-2.6 atm; n = 22) or sham surgery (n = 4). At 15 min postinjury, animals randomly received an intravenous bolus of either 125 mu mol magnesium chloride (n = 12) or saline vehicle (n = 10). Expression of p53 mRNA was not observed in any uninjured animal. By 6 h postinjury in vehicle-treated, brain-injured animals, p53 mRNA was induced in the cortex, dentate hilus, and CA3 regions of the hippocampus and geniculate nuclei of the thalamus, ipsilateral to the impact site. Posttraumatic magnesium treatment significantly reduced the number of labeled cells in the injured cortex (P < 0.05), but not in the hippocampus or thalamus. p53 mRNA expression returned to near baseline in all animals by 24 h postinjury. These data suggest that the neuroprotective effects of magnesium treatment may be related, in part, to a downregulation in expression of a gene associated with induction of cell death and further support the utility of magnesium as a pharmacotherapy for TBI. (C) 1999 Academic Press.	Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA	Muir, JK (corresponding author), Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA.				NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS08803, R01-NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS008803, R01NS026818] Funding Source: NIH RePORTER		Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; BAREYRE FM, 1998, J NEUROTRAUM, V15, P857; Beattie MS, 1998, NEUROSCIENTIST, V4, P163, DOI 10.1177/107385849800400312; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; CHESSELET MF, 1996, IN SITU HYBRIDIZATIO, P79; CHOPP M, 1995, BIOCHEM BIOPH RES CO, V182, P1201; Clark RSB, 1997, J NEUROSCI, V17, P9172; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; delaMonte SM, 1997, J NEUROL SCI, V152, P73, DOI 10.1016/S0022-510X(97)00131-7; Didier M, 1996, J NEUROSCI, V16, P2238; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; GARFINKEL L, 1985, Magnesium, V4, P60; GRUBBS RD, 1987, MAGNESIUM, V6, P113; Hartmann M, 1998, CARCINOGENESIS, V19, P617, DOI 10.1093/carcin/19.4.617; HARTWIG A, 1994, CANCER RES, V54, P4045; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Heath DL, 1998, SCAND J CLIN LAB INV, V58, P161, DOI 10.1080/00365519850186751; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1998, J NEUROTRAUM, V15, P183, DOI 10.1089/neu.1998.15.183; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hughes PE, 1996, NEUROSCIENCE, V74, P1143, DOI 10.1016/S0306-4522(96)00174-1; Jordan J, 1997, J NEUROSCI, V17, P1397; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kasten U, 1997, MUTAT RES-DNA REPAIR, V383, P81, DOI 10.1016/S0921-8777(96)00052-3; Kawabata H, 1997, BIOCHEM BIOPH RES CO, V233, P133, DOI 10.1006/bbrc.1997.6362; LAPLACA MC, 1998, J NEUROTRAUM, V15, P878; LI Y, 1994, STROKE, V25, P849, DOI 10.1161/01.STR.25.4.849; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LI Y, 1996, J NEUROPATHOL EXP NE, V55, P280; LITTEFIELD NA, 1994, CELL BIOL TOXICOL, V10, P127, DOI 10.1007/BF00756493; Lynn S, 1997, BIOL TRACE ELEM RES, V59, P1, DOI 10.1007/BF02783224; MACMANUS JP, 1995, J CEREBR BLOOD F MET, V15, P728, DOI 10.1038/jcbfm.1995.93; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; McIntosh TK, 1998, J NEUROTRAUM, V15, P731, DOI 10.1089/neu.1998.15.731; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Memon ZI, 1995, SCAND J CLIN LAB INV, V55, P671, DOI 10.3109/00365519509075397; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Morrison RS, 1996, J NEUROSCI, V16, P1337; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; NITATORI T, 1995, J NEUROSCI, V15, P1001; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; Raghupathi R, 1998, J NEUROTRAUM, V15, P555, DOI 10.1089/neu.1998.15.555; RAGHUPATHI R, 1997, J CEREB BLOOD FLOW M, V17, pS494; RINK A, 1995, AM J PATHOL, V147, P1575; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Smith DH, 1998, J NEUROTRAUM, V15, P665, DOI 10.1089/neu.1998.15.665; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; TERASAKI M, 1985, P NATL ACAD SCI USA, V82, P7324, DOI 10.1073/pnas.82.21.7324; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1988, J BIOL CHEM, V263, P757; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Xiang H, 1996, J NEUROSCI, V16, P6753; Xiang H, 1998, J NEUROSCI, V18, P1363; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	70	32	35	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	OCT	1999	159	2					584	593		10.1006/exnr.1999.7187			10	Neurosciences	Neurosciences & Neurology	246ED	WOS:000083150700026	10506531				2021-06-18	
J	Samii, A; Badie, H; Fu, K; Luther, RR; Hovda, DA				Samii, A; Badie, H; Fu, K; Luther, RR; Hovda, DA			Effects of an N-type calcium channel antagonist (SNX 111; ziconotide) on calcium-45 accumulation following fluid-percussion injury	JOURNAL OF NEUROTRAUMA			English	Article						calcium; calcium-45 autoradiography; concussion; fluid percussion; omega conopeptide	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; METHYL-D-ASPARTATE; OMEGA-CONOTOXIN; SPINAL-CORD; CELL-DEATH; RAT-BRAIN; NEUROCHEMICAL SEQUELAE; GLUCOSE-UTILIZATION; CA-45 ACCUMULATION	Accumulation of calcium following experimental traumatic brain injury (TBI) has been demonstrated to be a prominent pathophysiological component that can compromise mitochondrial functioning and threaten cell survival. The omega-conopeptide SNX-111, also known as Ziconotide, is a potent antagonist of the voltage-gated N-type calcium channel and has demonstrated significant neuroprotective effects against ischemia-induced neuronal injury. To determine whether this compound would be effective in reducing calcium accumulation associated with TBI, SNX-111 was administered intravenously to rats 1 hour following a moderate (2.2 to 2.75 atm) lateral fluid-percussion injury (or sham) at doses of 1 (n = 30), 3 (n = 31), or 5 (n = 30) mg/kg; another group received 0.9% saline solution (n = 35). Brains were processed for calcium 45 (Ca-45) autoradiography at 6, 12, 24, 48, and 96 hours following insult. Optical density measurements of 20 cortical and subcortical regions were analyzed. Injured animals administered saline solution exhibited a significant increase in Ca-45 uptake within 12 regions ipsilateral to the site of injury. The most prominent increases were evident throughout the ipsilateral cerebral cortex. SNX-111 reduced the injury-induced calcium accumulation within the ipsilateral cortex in a dose-response fashion when measured at 6, 12, and 48 hours after insult. These drug-induced reductions in calcium accumulation were as high as 75% in the ipsilateral cerebral cortex, and up to 50% in other ipsilateral regions (including thalamus and hippocampus). Consequently, the results suggest that posttraumatic blocking of the voltage-gated N-type calcium channel after injury reduces prolonged, trauma-induced calcium accumulation.	Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Brain Res Inst, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA USA	Hovda, DA (corresponding author), Univ Calif Los Angeles, Sch Med, Div Neurosurg, Los Angeles, CA 90095 USA.	hovda@mednet.ucla.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27544, NS30308] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS030308, R01NS027544] Funding Source: NIH RePORTER		ARAKI T, 1990, BRAIN RES, V528, P114, DOI 10.1016/0006-8993(90)90202-M; BELAYEV L, 1995, STROKE, V26, P2313, DOI 10.1161/01.STR.26.12.2313; BETZ AL, 1989, BASIC NEUROCHEMISTRY, P591; BIGNAMI A, 1987, BRAIN RES, V409, P143, DOI 10.1016/0006-8993(87)90750-5; Bowersox S, 1997, DRUG METAB DISPOS, V25, P379; BOWERSOX SS, 1992, J CARDIOVASC PHARM, V20, P756, DOI 10.1097/00005344-199211000-00011; Bowersox SS, 1997, BRAIN RES, V747, P343; BUCHAN AM, 1994, J CEREBR BLOOD F MET, V14, P903, DOI 10.1038/jcbfm.1994.121; CARTER CJ, 1987, J NEUROCHEM, V49, P195, DOI 10.1111/j.1471-4159.1987.tb03414.x; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DIENEL GA, 1984, J NEUROCHEM, V43, P913, DOI 10.1111/j.1471-4159.1984.tb12825.x; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; DOOLEY DJ, 1987, N-S ARCH PHARMACOL, V336, P467, DOI 10.1007/BF00164885; FARBER JL, 1981, LIFE SCI, V29, P1289, DOI 10.1016/0024-3205(81)90670-6; FARBER JL, 1981, AM J PATHOL, V102, P271; FAROOQUI AA, 1991, BRAIN RES REV, V16, P171, DOI 10.1016/0165-0173(91)90004-R; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Ghosh S, 1997, NEUROL RES, V19, P403, DOI 10.1080/01616412.1997.11740833; GRAMSBERGEN JBP, 1988, J NEUROCHEM, V50, P1798, DOI 10.1111/j.1471-4159.1988.tb02481.x; HOVDA DA, 1991, BRAIN RES, V567, P1, DOI 10.1016/0006-8993(91)91429-5; HOVDA DA, 1994, ACTA NEUROCHIR, P521; IWASAKI Y, 1987, BRAIN RES, V406, P99, DOI 10.1016/0006-8993(87)90773-6; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; JENKINS LW, 1986, MECHANISMS SECONDARY, P273; Kampfl A, 1997, J NEUROTRAUM, V14, P121, DOI 10.1089/neu.1997.14.121; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KATO H, 1989, BRAIN RES, V479, P366, DOI 10.1016/0006-8993(89)91642-9; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MEYER FB, 1989, BRAIN RES REV, V14, P227, DOI 10.1016/0165-0173(89)90002-7; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; MORIYA T, 1994, J NEUROTRAUM, V11, P255, DOI 10.1089/neu.1994.11.255; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; Nilsson P, 1996, J CEREBR BLOOD F MET, V16, P262, DOI 10.1097/00004647-199603000-00011; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; OYAMA Y, 1987, BRAIN RES, V424, P58, DOI 10.1016/0006-8993(87)91192-9; POVLISHOCK JT, 1989, SOC NEUROSCI, V15; ROBERTSLEWIS JM, 1993, ANN NY ACAD SCI, V679, P78; ROSENBERG C, 1984, ARCH NEUROL-CHICAGO, V41, P835, DOI 10.1001/archneur.1984.04050190041012; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SCHETTINI A, 1989, J NEUROSURG, V71, P578, DOI 10.3171/jns.1989.71.4.0578; SCHMIDLEY JW, 1990, STROKE, V21, P1086, DOI 10.1161/01.STR.21.7.1086; SIESJO BK, 1988, ANN NY ACAD SCI, V522, P638; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJO BK, 1989, MAGNESIUM, V8, P223; STEIN DT, 1988, J CEREBR BLOOD F MET, V8, P834, DOI 10.1038/jcbfm.1988.140; STOEHR SJ, 1993, NEUROSCI LETT, V161, P113, DOI 10.1016/0304-3940(93)90153-C; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; TAKIZAWA S, 1995, J CEREBR BLOOD F MET, V15, P611, DOI 10.1038/jcbfm.1995.75; THOMAS S, 1991, Society for Neuroscience Abstracts, V17, P166; Tymianski M, 1996, NEUROSURGERY, V38, P1176; VALENTINO K, 1993, P NATL ACAD SCI USA, V90, P7894, DOI 10.1073/pnas.90.16.7894; VERITY MA, 1992, NEUROTOXICOLOGY, V13, P139; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Watanabe H, 1998, J CEREBR BLOOD F MET, V18, P686, DOI 10.1097/00004647-199806000-00011; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; YAMAUCHI Y, 1990, J CEREBR BLOOD F MET, V10, P207, DOI 10.1038/jcbfm.1990.36; Yenari MA, 1996, BRAIN RES, V739, P36, DOI 10.1016/S0006-8993(96)00808-6; YOSHINO A, 1992, J CEREBR BLOOD F MET, V12, P996, DOI 10.1038/jcbfm.1992.137; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1; YOUNG W, 1992, J NEUROTRAUM, V9, pS9; YOUNG W, 1996, NEUROTRAUMA, P1421; ZHAO Q, 1994, ACTA PHYSIOL SCAND, V150, P459, DOI 10.1111/j.1748-1716.1994.tb09713.x	70	32	33	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	1999	16	10					879	892		10.1089/neu.1999.16.879			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	246JD	WOS:000083159900003	10547097				2021-06-18	
J	Perez-Pinzon, MA; Alonso, O; Kraydieh, S; Dietrich, WD				Perez-Pinzon, MA; Alonso, O; Kraydieh, S; Dietrich, WD			Induction of tolerance against traumatic brain injury by ischemic preconditioning	NEUROREPORT			English	Article						global ischemia; neuropathology; tolerance; trauma	HEAD-INJURY; SUPEROXIDE-DISMUTASE; CEREBRAL-ISCHEMIA; PATHO-PHYSIOLOGY; DAMAGE; GERBIL; RATS; HYPOTHERMIA; GLUTAMATE; NEURONS	WE tested the hypothesis that a transient non-lethal ischemic insult lasting 2 min would protect against subsequent moderate traumatic brain injury. Sprague-Dawley rats were randomized into three experimental groups, including sham ischemia procedures and ischemic preconditioning (IPC) followed 48 h later by moderate traumatic brain injury (TBI) provoked by parasagittal fluid percussion injury (1.8-2.1 atm) and IPC followed by 48h sham TBI. Seven days after the secondary insult, animals were perfusion-fixed for quantitative histopathological analysis. The CA3 necrotic;cell count was decreased by 63% in TBI animals that-had undergone IPC as compared to TBI animals that:underwent sham IPC. TBI animals that had undergone IPC demonstrated significantly smaller contusion:volumes than the TBI alone group (6.44 +/- 1.51 vs 1.37 +/- 0.63 mm(3), mean +/- s.e.m.) These data indicate that IPC applied 2 days before moderate fluid percussion brain injury increases the brain resistance to traumatic brain: damage. (C) 1999 Lippincott Williams & Wilkins.	Univ Miami, Sch Med, Dept Neurol, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Neurol Surg, Miami, FL 33101 USA	Perez-Pinzon, MA (corresponding author), Univ Miami, Sch Med, Dept Neurol, D4-5,POB 016960, Miami, FL 33101 USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30291, NS 34773] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R29NS034773, P50NS030291, R55NS034773, R01NS034773] Funding Source: NIH RePORTER		BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BULLOCK R, 1992, J NEUROTRAUM, V9, pS443; BULLOCK R, 1992, BRIT J CLIN PHARMACO, V34, P396, DOI 10.1111/j.1365-2125.1992.tb05648.x; CHAN PH, 1987, ANN NEUROL, V21, P540, DOI 10.1002/ana.410210604; Das Dipak K., 1992, Cellular and Molecular Biology (Noisy-Le-Grand), V38, P739; Dietrich WD, 1996, J CEREBR BLOOD F MET, V16, P481, DOI 10.1097/00004647-199605000-00015; Dietrich WD, 1998, NEUROSURGERY, V43, P585, DOI 10.1097/00006123-199809000-00105; DIETRICH WD, 1993, J CEREBR BLOOD F MET, V13, P541, DOI 10.1038/jcbfm.1993.71; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; GRAHAM DI, 1978, J NEUROL SCI, V39, P213, DOI 10.1016/0022-510X(78)90124-7; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; HOSHIDA S, 1993, HEART VESSELS, V8, P115, DOI 10.1007/BF01744795; KATO H, 1995, J CEREBR BLOOD F MET, V15, P60, DOI 10.1038/jcbfm.1995.7; Kawai K, 1998, J CEREBR BLOOD F MET, V18, P288, DOI 10.1097/00004647-199803000-00007; KITAGAWA K, 1990, BRAIN RES, V528, P21, DOI 10.1016/0006-8993(90)90189-I; LIPTON SA, 1993, CURR OPIN NEUROL NEU, V6, P588; OHTSUKI T, 1992, BRAIN RES, V599, P246, DOI 10.1016/0006-8993(92)90398-S; PerezPinzon MA, 1997, J CEREBR BLOOD F MET, V17, P175, DOI 10.1097/00004647-199702000-00007; PFENNINGER EG, 1989, J NEUROSURG, V70, P774, DOI 10.3171/jns.1989.70.5.0774; ROBERTSON CS, 1992, J NEUROTRAUM, V9, pS349; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; ROTHMAN SM, 1987, TRENDS NEUROSCI, V10, P299, DOI 10.1016/0166-2236(87)90177-9; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; TOSAKI A, 1994, J CARDIOVASC PHARM, V23, P365, DOI 10.1097/00005344-199423030-00002	25	32	33	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0959-4965			NEUROREPORT	Neuroreport	SEP 29	1999	10	14					2951	2954		10.1097/00001756-199909290-00014			4	Neurosciences	Neurosciences & Neurology	241CV	WOS:000082865500017	10549803				2021-06-18	
J	Zink, BJ; Schultz, CH; Wang, X; Mertz, M; Stern, SA; Betz, AL				Zink, BJ; Schultz, CH; Wang, X; Mertz, M; Stern, SA; Betz, AL			Effects of ethanol on brain lactate in experimental traumatic brain injury with hemorrhagic shock	BRAIN RESEARCH			English	Article						ethanol; brain injury; lactate; shock	SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; LACTIC-ACIDOSIS; ALCOHOL-INTOXICATION; AMINO-ACIDS; ACCUMULATION; RATS; METABOLITES; PRESSURE; VOLUME	Objective: Previous studies of traumatic brain injury (TBI) and hemorrhagic shock (HS) models, have shown cardiorespiratory depression in ethanol-treated animals. This study investigated the effects of ethanol (ET) on brain lactate concentrations and acidosis in a TBI/HS model. Methods: Anesthetized swine were instrumented and subjected to injury (INJ) consisting of fluid percussion TBI of 3 atm with concurrent 30 ml/kg graded hemorrhage over 30 min. Three groups were studied: Sham, INJ and INJ/ET. ET was given preinjury as a 2-g/kg i.v. bolus over 30 min, and an infusion of 0.4 g kg(-1) h(-1). Cardiorespiratory and cerebral physiologic data were monitored continuously for 150 min postinjury. Cerebral and renal blood flow was measured with colored microspheres. Brains were frozen in situ with liquid nitrogen. Lactate was measured with an enzymatic method. Results: ET levels at injury were 219 +/- 24 mg/dl. The INJ/ET group had increased mortality, impaired ventilation, and reduced renal blood flow. Brain (cortical) lactate levels were significantly higher and cerebral venous lactate concentrations were increased in the INJ/ET group during the postinjury period. Cerebral venous glucose was significantly higher in the INJ/ET group, and cerebral venous pH was significantly lower. Conclusion: In this TBI/HS model, ethanol-induced increases in lactate concentrations in brain tissue and cerebral venous blood are associated with respiratory depression and reduced organ blood flow. (C) 1999 Published by Elsevier Science B.V. All rights reserved.	Univ Michigan, Sect Emergency Med, Ann Arbor, MI 48109 USA; Univ Michigan, Emergency Med Res Lab, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Surg, Neurosurg Sect, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pediat, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Neurol, Ann Arbor, MI 48109 USA	Zink, BJ (corresponding author), Univ Michigan, Sect Emergency Med, TC B1354,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [K08AA000184] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [5 K08-AA00184-02A2] Funding Source: Medline		ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; COLD GE, 1981, ACTA ANAESTH SCAND, V25, P332, DOI 10.1111/j.1399-6576.1981.tb01662.x; CROCKARD HA, 1972, EUR NEUROL, V8, P151, DOI 10.1159/000114569; DESALLES AAF, 1986, J NEUROSURG, V65, P615, DOI 10.3171/jns.1986.65.5.0615; DEWITT DS, 1992, J NEUROSURG, V76, P812, DOI 10.3171/jns.1992.76.5.0812; EDNA TH, 1982, ACTA CHIR SCAND, V148, P209; ENEVOLDSEN EM, 1976, J NEUROSURG, V44, P191, DOI 10.3171/jns.1976.44.2.0191; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FRANCO CD, 1988, J NATL MED ASSOC, V80, P63; GARDINER M, 1982, J CEREBR BLOOD F MET, V2, P429, DOI 10.1038/jcbfm.1982.49; GARRISON HG, 1984, ANN EMERG MED, V13, P26, DOI 10.1016/S0196-0644(84)80379-0; GETTLER DT, 1963, ANN SURG, V158, P151, DOI 10.1097/00000658-196308000-00001; GURDJIAN ES, 1994, SURG GYNECOL OBSTET, V7, P618; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; HARIRI RJ, 1993, J NEUROSURG, V79, P421, DOI 10.3171/jns.1993.79.3.0421; HAWKINS RD, 1972, PHARMACOL REV, V24, P103; HORTON JW, 1986, SURGERY, V100, P520; HOVDA DA, 1992, J NEUROTRAUMA S1, V9, P47; INAO S, 1988, J NEUROSURG, V69, P736, DOI 10.3171/jns.1988.69.5.0736; JAGGER J, 1984, NEUROSURGERY, V15, P303, DOI 10.1227/00006123-198409000-00002; JUHLINDANNFELT A, 1977, SCAND J CLIN LAB INV, V37, P443; KAWAMATA T, 1995, BRAIN RES, V674, P196, DOI 10.1016/0006-8993(94)01444-M; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; KIM HJ, 1989, J NEUROSURG, V71, P565, DOI 10.3171/jns.1989.71.4.0565; KING LR, 1974, J NEUROSURG, V40, P617, DOI 10.3171/jns.1974.40.5.0617; KRAUS JF, 1989, AM J PUBLIC HEALTH, V79, P294, DOI 10.2105/AJPH.79.3.294; MARMAROU A, 1992, J NEUROTRAUM, V9, pS551; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; MOHANACHARI V, 1983, NEUROCHEM RES, V8, P575, DOI 10.1007/BF00964698; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; PETERS TJ, 1982, BRIT MED BULL, V38, P17, DOI 10.1093/oxfordjournals.bmb.a071726; Prasad RM, 1997, J NEUROTRAUM, V14, P919, DOI 10.1089/neu.1997.14.919; RABOW L, 1986, J NEUROSURG, V65, P625, DOI 10.3171/jns.1986.65.5.0625; REHNCRONA S, 1981, J CEREBR BLOOD F MET, V1, P297, DOI 10.1038/jcbfm.1981.34; REVES JG, 1972, Q J STUD ALCOHOL, V3, P464; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RONTY H, 1993, EUR J CLIN INVEST, V23, P182, DOI 10.1111/j.1365-2362.1993.tb00759.x; Shapira Y, 1997, J NEUROSURG ANESTH, V9, P118, DOI 10.1097/00008506-199704000-00003; SIEGEL JH, 1991, CRIT CARE MED, V19, P1252, DOI 10.1097/00003246-199110000-00007; WAGNER KR, 1985, EXP NEUROL, V89, P146, DOI 10.1016/0014-4886(85)90272-9; YANG MS, 1985, J NEUROSURG, V63, P617, DOI 10.3171/jns.1985.63.4.0617; ZINK BJ, 1995, J NEUROSURG, V82, P822, DOI 10.3171/jns.1995.82.5.0822; ZINK BJ, 1993, J NEUROTRAUM, V10, P275, DOI 10.1089/neu.1993.10.275; Zink BJ, 1996, ALCOHOL CLIN EXP RES, V20, P1518, DOI 10.1111/j.1530-0277.1996.tb01693.x; ZINK BJ, 1988, CIRC SHOCK, V24, P19; Zink BJ, 1998, J NEUROSURG, V89, P983, DOI 10.3171/jns.1998.89.6.0983; Zink BJ, 1998, ACAD EMERG MED, V5, P9, DOI 10.1111/j.1553-2712.1998.tb02568.x	51	32	35	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	AUG 7	1999	837	1-2					1	7		10.1016/S0006-8993(99)01646-7			7	Neurosciences	Neurosciences & Neurology	226FK	WOS:000082009500001	10433981				2021-06-18	
J	Woodward, H; Winterhalther, K; Donders, J; Hackbarth, R; Kuldanek, A; Sanfilippo, D				Woodward, H; Winterhalther, K; Donders, J; Hackbarth, R; Kuldanek, A; Sanfilippo, D			Prediction of neurobehavioral outcome 1-5 years post pediatric traumatic head injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cerebral perfusion pressure; neurobehavioral outcome; traumatic head injury	BRAIN INJURY; CHILDREN; ADOLESCENTS; SEQUELAE; CHILDHOOD; SEVERITY; COHORT; SCALE; COMA	Objective: To examine the neurobehavioral status of children with traumatic head injury (THI) and to identify variables that predict outcome. Design: Retrospective chart review, with follow-up 1-5 years after injury. Outcome predictor variables were identified through stepwise regression analysis. Setting: Level one trauma center and pediatric rehabilitation program. Patients: 71 Children with THI, selected from a four-year series of consecutive admissions. Measure: Vineland Adaptive Behavior Scales-Survey Edition. Results: Significant predictors of better neurobehavioral status at follow-up included absence of a premorbid learning problem (p < .01), older age at injury (P < .01), and normal pupillary response (P < .001) and higher cerebral perfusion pressure (P < .0001) during critical care management. Conclusions: Neurobehavioral outcome after THI is influenced by premorbid psychosocial variables as well as by critical care management.	Mary Free Bed Hosp, Psychol Serv, Grand Rapids, MI 49503 USA; DeVos Childrens Hosp, Div Pediat Crit Care, Grand Rapids, MI USA; Mary Free Bed Hosp, Pediat Rehabil Program, Grand Rapids, MI USA	Donders, J (corresponding author), Mary Free Bed Hosp, Psychol Serv, 235 Wealthy SE, Grand Rapids, MI 49503 USA.	jdonders@mfbrc.com					ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; ASARNOW RF, 1995, TRAUMATIC HEAD INJUR; BRUCE DA, 1995, TRAUMATIC HEAD INJUR; Butler K, 1997, CHILD NEUROPSYCHOL, V3, P98, DOI 10.1080/09297049708401371; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; CHESNUT RM, 1993, ACTA NEUROCHIR, P121; CHOI SC, 1991, J NEUROSURG, V75, P251, DOI 10.3171/jns.1991.75.2.0251; DALBY PR, 1991, DEV NEUROPSYCHOL, V7, P35, DOI 10.1080/87565649109540476; DENCKLA MB, 1995, TRAUMATIC HEAD INJUR; DEWEY D, 1998, ANN M INT NEUR SOC H; Donders J, 1997, CHILD NEUROPSYCHOL, V3, P71, DOI 10.1080/09297049708401369; DONDERS J, 1994, J SCHOOL PSYCHOL, V32, P53, DOI 10.1016/0022-4405(94)90028-0; Donders J, 1997, Pediatr Rehabil, V1, P179; Donders J, 1996, J HEAD TRAUMA REHAB, V11, P67, DOI 10.1097/00001199-199606000-00010; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FRANCIS DJ, 1991, J CONSULT CLIN PSYCH, V59, P27, DOI 10.1037/0022-006X.59.1.27; HACKBARTH R, 1998, ED SCI S SOC CRIT CA; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JENNETT B, 1975, LANCET, V1, P480; KINSELLA G, 1995, J PEDIATR PSYCHOL, V20, P753, DOI 10.1093/jpepsy/20.6.753; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; LIEHLAI MW, 1992, J PEDIATR-US, V120, P195, DOI 10.1016/S0022-3476(05)80426-3; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; Papero PH, 1997, J HEAD TRAUMA REHAB, V12, P51, DOI 10.1097/00001199-199706000-00006; PRIGATANO GP, 1993, NEUROPSYCHOL REHABIL, V3, P411, DOI 10.1080/09602019308401449; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; RIVARA JB, 1993, ARCH PHYS MED REHAB, V74, P1047, DOI 10.1016/0003-9993(93)90060-N; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SPARROW SS, 1984, VINELAND ADAPTIVE BH; TEASDALE G, 1974, LANCET, V2, P81; *UB FDN ACT UN DAT, 1993, GUID UN DAT SET MED; WADE S, 1995, J PEDIATR PSYCHOL, V20, P737, DOI 10.1093/jpepsy/20.6.737; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; YLVISAKER M, 1993, NEUROPSYCHOL REHABIL, V3, P367, DOI 10.1080/09602019308401447	38	32	32	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	AUG	1999	14	4					351	359		10.1097/00001199-199908000-00004			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	224LW	WOS:000081901400005	10407208				2021-06-18	
J	Finset, A; Anke, AW; Hofft, E; Roaldsen, KS; Pillgram-Larsen, J; Stanghelle, JK				Finset, A; Anke, AW; Hofft, E; Roaldsen, KS; Pillgram-Larsen, J; Stanghelle, JK			Cognitive performance in multiple trauma patients 3 years after injury	PSYCHOSOMATIC MEDICINE			English	Article						multiple trauma; neuropsychological tests; cognitive impairment; psychological distress; brain injuries	MINOR HEAD-INJURY; CHRONIC FATIGUE SYNDROME; MAJOR DEPRESSION; SYMPTOMS; VALIDITY; RECOVERY; CARE; IMPAIRMENTS; SEVERITY; SEQUELAE	Objectives: Patients with sequelae from multiple trauma commonly display cognitive disturbances, specifically in the areas of attention and memory. This study was designed to assess cognitive functioning 3 years after severe multiple trauma and to investigate how cognitive performance is related to head injury severity and psychological distress respectively. Methods: Sixty-eight multiple trauma patients were tested with a screening battery consisting of six neuropsychological tasks 3 years after injury. A measure of psychological distress (20-item General Health Questionnaire, or GHQ-PO) was also administered. Results: Patients who neither showed signs of reduced consciousness on admission to the hospital nor reported significant psychological distress at follow-up tended to have normal test performance. In five of the six tasks, cognitive impairment was related to the severity of the traumatic brain injury as measured by the Glasgow Coma Scale (GCS). In both attention span tasks, patients designated as cases by the GHQ had significantly lower scores than noncase patients. These bivariate relationships were upheld in multiple regression analyses, in which age, sex, and GCS and GHQ scores were entered as independent variables. When patients with severe head injuries were excluded from the analyses, GCS scores still contributed to the variance in tests of verbal attention span and delayed recall, but performance on attentional tasks was more strongly related to psychological distress than to GCS scores. Conclusions: Cognitive deficits in multiple trauma patients were related both to the severity of the traumatic brain injury and to the degree of psychological distress. The strength of the association between brain injury as indicated by GCS scores and cognitive performance differed between different tasks. Neuropsychological testing may assist in differentiating primary organic from secondary psychogenic impairments.	Univ Oslo, Dept Behav Sci Med, Fac Med, N-0317 Oslo, Norway; Univ Tromso Hosp, Dept Phys Med & Rehabil, Tromso, Norway; Univ Oslo, Sunnaas Rehabil Hosp, Nesoddtangen, Norway; Ctr Physiotherapy Res & Dev, Oslo, Norway; Univ Oslo, Ullevaal Hosp, Dept Surg, N-0407 Oslo, Norway	Finset, A (corresponding author), Univ Oslo, Dept Behav Sci Med, Fac Med, POB 1111 Blindern, N-0317 Oslo, Norway.		Roaldsen, Kirsti Skavberg/D-6306-2016	Roaldsen, Kirsti Skavberg/0000-0003-0933-3875; Anke, Audny/0000-0002-2491-2560			Anke AGW, 1997, J TRAUMA, V42, P54, DOI 10.1097/00005373-199701000-00010; ARCIA E, 1993, BRAIN INJURY, V7, P481, DOI 10.3109/02699059309008175; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BLANCHARD EB, 1995, BEHAV RES THER, V33, P529, DOI 10.1016/0005-7967(94)00079-Y; BOHNEN N, 1992, J NERV MENT DIS, V180, P683, DOI 10.1097/00005053-199211000-00002; BORKOWSKI JG, 1967, NEUROPSYCHOLOGIA, V5, P135, DOI 10.1016/0028-3932(67)90015-2; BORNSTEIN RA, 1983, J CLIN NEUROPSYCHOL, V5, P105, DOI 10.1080/01688638308401158; Christensen AL., 1975, LURIAS NEUROPSYCHOLO; COLBY CA, 1988, COGNITIVE THER RES, V12, P611, DOI 10.1007/BF01205013; *COMM INJ SCAL, 1990, ABB INJ SCAL 1990 RE; Dahlmann W, 1993, Fortschr Med, V111, P234; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; Goldberg DP, 1998, PSYCHOL MED, V28, P915, DOI 10.1017/S0033291798006874; Goldberg DP, 1997, PSYCHOL MED, V27, P191, DOI 10.1017/S0033291796004242; GRONWALL D, 1974, LANCET, V2, P605; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Lehmann U, 1997, UNFALLCHIRURG, V100, P552, DOI 10.1007/s001130050157; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MALT U, 1988, BRIT J PSYCHIAT, V153, P810, DOI 10.1192/bjp.153.6.810; Malt U F, 1992, Psychiatr Med, V10, P135; Malt U F, 1992, Psychiatr Med, V10, P117; MALT UF, 1989, ACTA PSYCHIAT SCAND, V80, P103, DOI 10.1111/j.1600-0447.1989.tb05260.x; Malt Ulrik Fredrik, 1994, P103, DOI 10.1017/CBO9780511570162.007; Marshall PS, 1997, PSYCHOSOM MED, V59, P58, DOI 10.1097/00006842-199701000-00008; MILZMAN DP, 1993, CRIT CARE CLIN, V9, P633; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Prasad K, 1996, J CLIN EPIDEMIOL, V49, P755, DOI 10.1016/0895-4356(96)00013-3; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; SCHMALING KB, 1994, PSYCHOSOM MED, V56, P383, DOI 10.1097/00006842-199409000-00001; SLETVOLD H, 1995, J RHEUMATOL, V22, P137; Smed A, 1997, ACTA NEUROL SCAND, V95, P73, DOI 10.1111/j.1600-0404.1997.tb00072.x; SMITS J, 1992, PHYS WORLD, V5, P48, DOI 10.1088/2058-7058/5/11/31; Strohmyer L L, 1993, J Neurosci Nurs, V25, P30; TANCER ME, 1990, PSYCHIAT RES, V31, P161, DOI 10.1016/0165-1781(90)90118-O; TATE RL, 1991, J NERV MENT DIS, V179, P117, DOI 10.1097/00005053-199103000-00001; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; THIAGARAJAN J, 1994, ANAESTHESIA, V49, P211; Veiel HOF, 1997, J CLIN EXP NEUROPSYC, V19, P587, DOI 10.1080/01688639708403745; Wechsler D., 2008, WECHSLER ADULT INTEL; WEINGARTNER H, 1984, PSYCHIAT RES, V11, P223, DOI 10.1016/0165-1781(84)90071-4	44	32	32	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0033-3174			PSYCHOSOM MED	Psychosom. Med.	JUL-AUG	1999	61	4					576	583		10.1097/00006842-199907000-00024			8	Psychiatry; Psychology; Psychology, Multidisciplinary	Psychiatry; Psychology	221PC	WOS:000081734600021	10443768				2021-06-18	
J	Thatcher, RW; Moore, N; John, ER; Duffy, F; Hughes, JR; Krieger, M				Thatcher, RW; Moore, N; John, ER; Duffy, F; Hughes, JR; Krieger, M			QEEG and traumatic brain injury: Rebuttal of the American Academy of Neurology 1997 report by the EEG and Clinical Neuroscience Society	CLINICAL ELECTROENCEPHALOGRAPHY			English	Article						quantitative EEG; traumatic brain injury	TEST-RETEST RELIABILITY; CLOSED-HEAD INJURY; QUANTITATIVE EEG; SPECTRAL PARAMETERS; BIOPHYSICAL LINKAGE; AMPLITUDE; MRI; COHERENCE; LESIONS; MILD		Vet Adm Med Ctr, Res & Dev Serv 151, Bay Pines, FL 33504 USA	Thatcher, RW (corresponding author), Vet Adm Med Ctr, Res & Dev Serv 151, Bay Pines, FL 33504 USA.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Arruda JE, 1996, INT J PSYCHOPHYSIOL, V23, P63, DOI 10.1016/0167-8760(96)00032-3; BURGESS A, 1993, ELECTROEN CLIN NEURO, V86, P219, DOI 10.1016/0013-4694(93)90101-Z; CAVENESS W, TRAUMA, V18, P61; CorsiCabrera M, 1997, ELECTROEN CLIN NEURO, V102, P248, DOI 10.1016/S0013-4694(96)95179-6; DUFFY FH, 1994, CLIN ELECTROENCEPHAL, V25, pR6, DOI 10.1177/155005949402500403; GASSER T, 1985, ELECTROEN CLIN NEURO, V60, P312, DOI 10.1016/0013-4694(85)90005-7; Gentry L.R., 1990, MAGNETIC RESONANCE I, P439; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; Hamilton-Bruce M A, 1991, Clin Exp Neurol, V28, P219; Harmony T, 1993, Int J Neurosci, V68, P263, DOI 10.3109/00207459308994281; Hoffman D. A., 1995, J NEUROTHERAPY, V1, P14, DOI [10.1300/ J184v01n01_03, DOI 10.1300/J184V01N01_03]; HOFFMAN DA, 1996, CLIN ELECTROENCEPHAL, V27, P6; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; LUND TR, 1995, PSYCHOPHYSIOLOGY, V32, P66, DOI 10.1111/j.1469-8986.1995.tb03407.x; MacKenzie E., 1991, J HEAD TRAUMA REHAB, V6, P76, DOI [10.1097/00001199-199106000-00010, DOI 10.1097/00001199-199106000-00010]; MAS F, 1993, CLIN ELECTROENCEPHAL, V24, P118, DOI 10.1177/155005949302400309; *NIH, 1998, NIH CONS DEV C STAT; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; NUWER M R, 1992, Brain Topography, V4, P243, DOI 10.1007/BF01135561; Nuwer MR, 1996, BRAIN TOPOGR, V8, P201, DOI 10.1007/BF01184770; POLLOCK VE, 1991, ELECTROEN CLIN NEURO, V79, P20, DOI 10.1016/0013-4694(91)90152-T; RUIJS MBM, 1994, NEUROPEDIATRICS, V25, P73, DOI 10.1055/s-2008-1071589; SALINSKY MC, 1991, ELECTROEN CLIN NEURO, V79, P382, DOI 10.1016/0013-4694(91)90203-G; Sullivan T E, 1994, J Neurosci Nurs, V26, P24; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; Thatcher R W, 1991, Ann N Y Acad Sci, V620, P82, DOI 10.1111/j.1749-6632.1991.tb51576.x; Thatcher R. W., 1989, ELECTROENCEPHALOGR C, V73, DOI [10.1016/0013-4694(89)90188-0, DOI 10.1016/0013-4694(89)90188-0, https://doi.org/10.1016/0013-4694(89)90188-0]; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; Thatcher RW, 1997, J NEUROTRAUM, V14, P1, DOI 10.1089/neu.1997.14.1; Thatcher RW, 1998, NEUROIMAGE, V8, P307, DOI 10.1006/nimg.1998.0365; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; Van Egren L., 1996, CLIN ELECTROENCEPHAL, V27, P164; VONBIERBRAUER A, 1992, EEG-EMG-Z ELEK ELEKT, V23, P151; WILDER CS, 1998, HLTH INTERVIEW SURVE; WIRSEN A, 1992, ELECTROEN CLIN NEURO, V84, P127, DOI 10.1016/0168-5597(92)90017-6	38	32	32	0	3	EEG & CLINICAL NEUROSCIENCE SOC (E C N S)	WHEATON	805 W LIBERTY DR, PO BOX 725, WHEATON, IL 60187 USA	0009-9155			CLIN ELECTROENCEPHAL	Clin. Electroencephalogr.	JUL	1999	30	3					94	98		10.1177/155005949903000304			5	Engineering, Biomedical; Clinical Neurology	Engineering; Neurosciences & Neurology	220ZC	WOS:000081698900002	10578471				2021-06-18	
J	Frieboes, RM; Muller, U; Murck, H; von Cramon, DY; Holsboer, F; Steiger, A				Frieboes, RM; Muller, U; Murck, H; von Cramon, DY; Holsboer, F; Steiger, A			Nocturnal hormone secretion and the sleep EEG in patients several months after traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							CLOSED HEAD-INJURY; GROWTH-HORMONE; PSYCHIATRIC-DISORDERS; ENDOGENOUS-DEPRESSION; CORTISOL; MEN; ABNORMALITIES; PROLACTIN; RECOVERY; ILLNESS	After severe traumatic brain injury (TBI), sleep disturbances and changes in hormone secretion are frequently observed. Similarly, in depression, abnormalities of sleep and neuroendocrine regulation are common. To test the hypothesis that the changes in brain-injured patients several months after injury are similar to those seen in patients with depression, the authors investigated simultaneously the sleep EEG and nocturnal hormone secretion in 13 young male nondepressed patients after TBI and 13 age-matched control subjects. The resulting data show a pattern of sleep-ednocrine changes in patients after TBI, which has some similarities to that of patients with remitted depression.	Max Planck Inst Psychiat, Dept Psychiat, D-80804 Munich, Germany; Max Planck Inst Cognit Neurosci, Dept Neurol, Leipzig, Germany	Frieboes, RM (corresponding author), Max Planck Inst Psychiat, Dept Psychiat, Kraepelinstr 10, D-80804 Munich, Germany.		Murck, Harald/AAZ-1897-2020; Sanguansri, Luz/B-6630-2011	Murck, Harald/0000-0003-4827-1945; Sanguansri, Luz/0000-0003-1908-7604			BENCA RM, 1992, ARCH GEN PSYCHIAT, V49, P651; CARROLL BJ, 1982, BRIT J PSYCHIAT, V140, P292, DOI 10.1192/bjp.140.3.292; CARTWRIGHT RD, 1983, ARCH GEN PSYCHIAT, V40, P197; Cheeta S, 1997, BIOL PSYCHIAT, V41, P419, DOI 10.1016/S0006-3223(96)00058-3; COHEN M, 1992, J NEUROL NEUROSUR PS, V55, P313, DOI 10.1136/jnnp.55.4.313; CROMPTON MR, 1971, BRAIN, V94, P165, DOI 10.1093/brain/94.1.165; EHLERS CL, 1986, NEUROENDOCRINOLOGY, V42, P467, DOI 10.1159/000124489; EHLERS CL, 1987, BIOL PSYCHIAT, V22, P513, DOI 10.1016/0006-3223(87)90173-9; FEDOROFF JP, 1992, AM J PSYCHIAT, V149, P918; FRIESS E, 1994, J SLEEP RES, V3, P73, DOI 10.1111/j.1365-2869.1994.tb00110.x; HACKL JM, 1991, INTENS CARE MED, V17, P25, DOI 10.1007/BF01708405; HALBREICH U, 1985, ARCH GEN PSYCHIAT, V42, P904; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HOLSBOER F, 1988, NEUROENDOCRINOLOGY, V48, P32, DOI 10.1159/000124986; Holsboer F, 1995, NEUROPSYCHOPHARMACOL, P957; JACKSON RD, 1989, AM J PHYS MED REHAB, V68, P18, DOI 10.1097/00002060-198902000-00006; Jarrett D B, 1985, Acta Psychiatr Belg, V85, P603; JARRETT DB, 1990, ARCH GEN PSYCHIAT, V47, P113; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; KING LR, 1981, NEUROSURGERY, V9, P229, DOI 10.1227/00006123-198109000-00002; KING LR, 1970, ANN SURG, V172, P975, DOI 10.1097/00000658-197012000-00008; KUPFER DJ, 1993, PSYCHIAT RES, V49, P121, DOI 10.1016/0165-1781(93)90100-U; LAUER CJ, 1995, ARCH GEN PSYCHIAT, V52, P145; LINKOWSKI P, 1989, ARCH GEN PSYCHIAT, V46, P813; LINKOWSKI P, 1987, J CLIN ENDOCR METAB, V65, P141, DOI 10.1210/jcem-65-1-141; MENDLEWICZ J, 1985, J CLIN ENDOCR METAB, V60, P505, DOI 10.1210/jcem-60-3-505; MOLITCH ME, 1992, ENDOCRIN METAB CLIN, V21, P877, DOI 10.1016/S0889-8529(18)30193-2; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; PRIGATANO GP, 1982, J NEUROL NEUROSUR PS, V45, P78, DOI 10.1136/jnnp.45.1.78; Rechtschaffen A, 1968, MANUAL STANDARDIZED; ROKY R, 1995, SLEEP, V18, P536; RON S, 1980, ELECTROEN CLIN NEURO, V48, P432, DOI 10.1016/0013-4694(80)90135-2; RUSH AJ, 1986, ARCH GEN PSYCHIAT, V43, P878; SHIPLEY JE, 1992, BIOL PSYCHIAT, V32, P146, DOI 10.1016/0006-3223(92)90017-T; STEIGER A, 1989, J AFFECT DISORDERS, V16, P189, DOI 10.1016/0165-0327(89)90073-6; STEIGER A, 1992, NEUROENDOCRINOLOGY, V56, P566, DOI 10.1159/000126275; STEIGER A, 1994, J PSYCHIAT RES, V28, P225, DOI 10.1016/0022-3956(94)90008-6; TEASDALE G, 1974, LANCET, V2, P81; THASE ME, 1994, AM J PSYCHIAT, V151, P1615; VALENTA LJ, 1980, AM J MED, V68, P614, DOI 10.1016/0002-9343(80)90314-9; WEITZMAN ED, 1976, ANNU REV MED, V27, P225, DOI 10.1146/annurev.me.27.020176.001301; YUAN XQ, 1991, FRONT NEUROENDOCRIN, V12, P209	42	32	35	0	3	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	1999	11	3					354	360		10.1176/jnp.11.3.354			7	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	222CG	WOS:000081765400009	10440012				2021-06-18	
J	Timmerman, ME; Brouwer, WH				Timmerman, ME; Brouwer, WH			Slow information processing after very severe closed head injury: impaired access to declarative knowledge and intact application and acquisition of procedural knowledge	NEUROPSYCHOLOGIA			English	Article						traumatic brain injury; memory access; speed of information processing; attention; mental rotation; mirror reading	MEMORY PERFORMANCE; DIVIDED ATTENTION; SURVIVORS; AMNESIA	As an explanation of the pattern of slow information processing after closed head injury (CHI), hypotheses of impaired access to declarative memory and intact application and acquisition of procedural memory after CHI are presented. These two hypotheses were tested by means of four cognitive reaction-time tasks, a semantic memory task, a memory comparison task, a mental rotation task and a mirror reading task. These tasks were administered on two different days to 12 survivors of a CHI tested more than 5 years after injury and a healthy control group of comparable age and education. In three tasks the difficulty of access to declarative knowledge was varied and it was expected that this would slow the CHI group more than the controls. In two tasks opportunities for procedural learning were provided by repeatedly presenting the same cognitive tasks and in one task, the difficulty of access to procedural memory was varied. It was expected that the CHI group would profit as much from this as would the control group. Both hypotheses were supported. (C) 1999 Elsevier Science Ltd. All rights reserved.	Univ Groningen, Dept Psychol, NL-9712 TS Groningen, Netherlands	Timmerman, ME (corresponding author), Univ Groningen, Dept Psychol, Grote Kruisstr 2-1, NL-9712 TS Groningen, Netherlands.	m.e.timmerman@ppsw.rug.nl					ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Anderson John R., 1976, LANGUAGE MEMORY THOU; Anderson John Robert, 1993, RULES MIND; Brouwer W.H., 1985, THESIS U GRONINGEN N; COHEN NJ, 1980, SCIENCE, V210, P207, DOI 10.1126/science.7414331; COOPER LA, 1973, VISUAL INFORMATION P; Deelman B, 1980, NEUROPSYCHOLOGIE NED; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; GOLDSTEIN FC, 1990, J CLIN EXP NEUROPSYC, V12, P286, DOI 10.1080/01688639008400975; HAUT MW, 1991, BRAIN COGNITION, V17, P31, DOI 10.1016/0278-2626(91)90064-F; Luteijn F., 1983, Handleiding Groninger Intelligentie Test [Manual Groningen Intelligence Test]; *M PLANCK I PSYCH, 1992, CELEX LEX DAT CD ROM; MARING W, 1984, INS B, P24; MARING W, 1989, GRIJZE CELLEN WIJZE; PARKMAN JM, 1971, J EXP PSYCHOL, V89, P335, DOI 10.1037/h0031198; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; Schmitter-Edgecombe M., 1993, NEUROPSYCHOLOGY, V7, P136, DOI DOI 10.1037/0894-4105.7.2.136; SchmitterEdgecombe M, 1996, NEUROPSYCHOLOGY, V10, P155; SchmitterEdgecombe M, 1997, NEUROPSYCHOLOGY, V11, P296, DOI 10.1037/0894-4105.11.2.296; SCHNEIDER W, 1990, MEL USERS GUIDE COMP; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; TRONRP E, 1991, J CLIN EXPT NEUROPSY, V13, P1; Van Zomeren AH., 1994, CLIN NEUROPSYCHOLOGY; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357	27	32	32	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia	APR	1999	37	4					467	478		10.1016/S0028-3932(98)00085-2			12	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	180NF	WOS:000079391500008	10215093				2021-06-18	
J	Hanten, G; Levin, HS; Song, JX				Hanten, G; Levin, HS; Song, JX			Working memory and metacognition in sentence comprehension by severely head-injured children: A preliminary study	DEVELOPMENTAL NEUROPSYCHOLOGY			English	Article							SHORT-TERM-MEMORY; LANGUAGE COMPREHENSION; ALZHEIMERS-DISEASE; RECOVERY; AGE; ADOLESCENTS; DISABILITY; CHILDHOOD; CAPACITY; SEVERITY	We studied the effects of working memory (WM) load on a sentence anomaly task in 12 children (mean age at study = 10.3 years) who had sustained a severe closed-head injury (CHI) at least 10 months previously and 12 healthy children (mean age = 8.92 years). Children were asked to judge whether each sentence (32 anomalous and 32 correct under high and low WM load conditions) was "good" or "not good," and to identify and repair the anomaly. Group and age effects were significant, and both variables interacted with sentence type, reflecting greater sensitivity of anomalous than sensible sentences to CHI and age. A Group x WM load interaction was found. WM deficit contributes to impaired language processing after severe CHI and a metacognitive problem is dissociable from generalized cognitive dysfunction. Traumatic brain injury is one of the leading causes of morbidity in children, with an estimated incidence of 200/100,000 (17,000) children annually (Kraus, 1995). Among the most disabling sequelae of pediatric traumatic brain injury is cognitive impairment, including disabilities in executive functioning (e.g., planning, flexibility in problem solving allocation of resources, inhibitory control), attention, and working memory (WM; Mateer, Kerns, & Eso, 1996). Children who sustain severe closed-head injuries (CHIs) are likely to display impairments in both verbal and nonverbal WM Levin et al. 1988) as well as in semantic memory (Levin, Fletcher, Kufera, et al., 1996; (Levin, Fletcher, Kusnerik, et al., 1996). Recent research has also linked deficits in executive control functions as a consequence of head injury to impairment in metacognitive abilities (Dennis, Barnes, Donnelley, Wilkinson, & Humphreys, 1996).	Baylor Coll Med, PM&R Res Off, Dept Phys Med & Rehabil, Cognit Neurosci Lab, Houston, TX 77030 USA; Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Levin, HS (corresponding author), Baylor Coll Med, PM&R Res Off, Dept Phys Med & Rehabil, Cognit Neurosci Lab, 1333 Moursund Ave,Rm A205, Houston, TX 77030 USA.	hlevin@bcm.tmc.edu					Baddeley A, 1993, Memory, V1, P65, DOI 10.1080/09658219308258225; Baddeley A., 1974, PSYCHOL LEARN MOTIV, P47, DOI [10.1016/s0079-7421(08)60452-1, DOI 10.1016/S0079-7421(08)60452-1]; Barnes MA, 1999, DEV NEUROPSYCHOL, V15, P1, DOI 10.1080/87565649909540737; BATES E, 1984, CHILD DEV, V55, P341; Brown A. L., 1978, ADV INSTRUCTIONAL PS, V1, P77; *CARN MELL U, 1994, PSYSC 1 1 COMP SOFTW; CARPENTER PA, 1981, J VERB LEARN VERB BE, V20, P137, DOI 10.1016/S0022-5371(81)90357-1; Chapman S. B., 1997, AM J SPEECH-LANG PAT, V6, P66; CHAPMAN SB, 1997, AM J SPEECH-LANG PAT, V6, P50, DOI DOI 10.1044/1058-0360.0602.50; Condray R, 1996, SCHIZOPHR RES, V20, P1, DOI 10.1016/0920-9964(95)00061-5; Dennis M, 1996, DEV NEUROPSYCHOL, V12, P77, DOI 10.1080/87565649609540641; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; Flavell J H, 1970, Adv Child Dev Behav, V5, P181, DOI 10.1016/S0065-2407(08)60467-X; FLAVELL JH, 1971, HUM DEV, V14, P272, DOI 10.1159/000271221; Flavell JH., 1981, COGNITIVE MONITORING, P35; FLAVELL JH, 1985, DEV PSYCHOL, V30, P663; GATHERCOLE SE, 1990, BRIT J PSYCHOL, V81, P439, DOI 10.1111/j.2044-8295.1990.tb02371.x; GATHERCOLE SE, 1994, MEMORY, V2, P83; GAULIN CA, 1994, PERCEPT MOTOR SKILL, V79, P55, DOI 10.2466/pms.1994.79.1.55; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; Kabrich M, 1996, AM J MENT RETARD, V100, P510; Kraus JF, 1995, TRAUMATIC HEAD INJUR, P22; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; Levin HS, 1996, CORTEX, V32, P461, DOI 10.1016/S0010-9452(96)80004-9; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; Levin HS, 1997, NEUROSURGERY, V40, P432, DOI 10.1097/00006123-199703000-00002; LEVIN HS, 1986, CHILD DEV LEARNING B, P317; *MACR, 1994, SOUND PRO COMP SOFTW; MANN VA, 1989, J LEARN DISABIL, V22, P76, DOI 10.1177/002221948902200202; Martin R.C., 1994, NEUROPSYCHOLOGY, V8, P506, DOI [10.1037/0894-4105.8.4.506, DOI 10.1037/0894-4105.8.4.506]; MARTIN RC, 1987, BRAIN LANG, V32, P159, DOI 10.1016/0093-934X(87)90122-2; MARTIN RC, 1990, BRAIN LANG, V38, P1, DOI 10.1016/0093-934X(90)90099-3; Mateer CA, 1996, J LEARN DISABIL, V29, P618, DOI 10.1177/002221949602900606; MONTGOMERY JW, 1995, J SPEECH HEAR RES, V38, P187, DOI 10.1044/jshr.3801.187; SATTERTHWAITE FE, 1946, BIOMETRICS BULL, V2, P110, DOI 10.2307/3002019; SHAFFER D, 1980, J AM ACAD CHILD PSY, V19, P592, DOI 10.1016/S0002-7138(09)60964-X; Siegler R. S., 1978, CHILDRENS THINKING W, P3; Small JA, 1997, PSYCHOL AGING, V12, P3, DOI 10.1037/0882-7974.12.1.3; Small JA, 1997, AGING NEUROPSYCHOL C, V4, P126, DOI 10.1080/13825589708256641; SUTTER JC, 1990, J SPEECH HEAR RES, V33, P84, DOI 10.1044/jshr.3301.84; Swanson HL, 1996, BRIT J EDUC PSYCHOL, V66, P333, DOI 10.1111/j.2044-8279.1996.tb01201.x; SWANSON HL, 1993, J EXP CHILD PSYCHOL, V56, P87, DOI 10.1006/jecp.1993.1027; TEASDALE G, 1974, LANCET, V2, P81; TUNNER WE, 1984, METALINGUISTIC AWARE; VILLIERS PA, 1972, J PSYCHOLINGUIST RES, V1, P299, DOI 10.1007/BF01067785; WALCZYK JJ, 1991, CONTEMP EDUC PSYCHOL, V16, P2, DOI 10.1016/0361-476X(91)90002-3; WATERS G, 1991, COGNITIVE NEUROPSYCH, V8, P81, DOI 10.1080/02643299108253368; Waters GS, 1997, J PSYCHOLINGUIST RES, V26, P377, DOI 10.1023/A:1025073902269; WILSON BA, 1993, CORTEX, V29, P153, DOI 10.1016/S0010-9452(13)80220-1	50	32	32	0	12	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	8756-5641	1532-6942		DEV NEUROPSYCHOL	Dev. Neuropsychol.		1999	16	3					393	414		10.1207/S15326942DN1603_23			22	Psychology, Developmental; Psychology; Psychology, Experimental	Psychology	275DB	WOS:000084803200025					2021-06-18	
J	Ribotta, MGY; Privat, A				Ribotta, MGY; Privat, A			Biological interventions for spinal cord injury	CURRENT OPINION IN NEUROLOGY			English	Article							TRAUMATIC NEURONAL INJURY; CENTRAL-NERVOUS-SYSTEM; CORTICAL CELL-CULTURE; D-ASPARTATE RECEPTORS; ADULT-RATS; GLUTAMATE NEUROTOXICITY; LOCOMOTOR RECOVERY; BRAIN INJURY; ANTAGONISTS; GENE	Spinal cord injury is frequently followed by the loss of supraspinal control of sensory, autonomus and motor functions at sublesional level. To enhance recovery in patients with spinal cord injuries, three fundamental strategies have been developed in experimental models. These strategies involve three different time points for postlesional intervention in the spinal cord. Neuroprotection soon after injury uses pharmacological tools to reduce the progressive secondary injury processes that follow during the first week after the initial lesion occurs, in order to limit tissue damage. A second strategy, which is initiated shortly after the lesion occurs, aims at promoting axonal regeneration by acting pharmacologically on inhibitors or barriers of regeneration, or by the application of cell or gene therapy as a source of neurotrophic factors or as a bridge or support to enhance the regeneration of lesioned axons. Finally, a mid-term substitutive strategy is the management of the sublesional spinal cord by sensorimotor stimulation or the supply of missing key afferents, such as monoaminergic systems. These three strategies are reviewed. Only a combination of these different approaches can provide an optimal basis for potential therapeutic interventions aimed at functional recovery after spinal cord injury. Curr Opin Neurol 11:647-654 (C) 1998 Lippincott Williams & Wilkins.	Univ Montpellier 2, INSERM, U336, F-34095 Montpellier, France	Ribotta, MGY (corresponding author), Univ Montpellier 2, INSERM, U336, Pl E Bataillon,BP 106, F-34095 Montpellier, France.	u336@univ-montp2.ir					Akesson E, 1998, EXP NEUROL, V149, P262, DOI 10.1006/exnr.1997.6668; Alonso G, 1997, J COMP NEUROL, V384, P181; BARBEAU H, 1994, CURR OPIN NEUROL, V7, P517, DOI 10.1097/00019052-199412000-00008; Baumgartner BJ, 1997, J NEUROSCI, V17, P6504; Bjugn R, 1997, EXP NEUROL, V148, P179, DOI 10.1006/exnr.1997.6610; BRACKEN MB, 1990, NEW ENGL J MED, V322, P1405, DOI 10.1056/NEJM199005173222001; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Bregman BS, 1998, EXP NEUROL, V149, P13, DOI 10.1006/exnr.1997.6669; Bregman BS, 1997, EXP NEUROL, V148, P475, DOI 10.1006/exnr.1997.6705; Brook GA, 1998, ACTA NEUROPATHOL, V95, P378, DOI 10.1007/s004010050814; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; Chau C, 1998, J NEUROPHYSIOL, V79, P392; Chauvet N, 1998, EXP NEUROL, V151, P1, DOI 10.1006/exnr.1998.6784; Cheng HR, 1997, EXP NEUROL, V148, P544, DOI 10.1006/exnr.1997.6708; CHOI DW, 1987, J NEUROSCI, V7, P357; Cot C, 1998, INT J DEV NEUROSCI, V16, P9, DOI 10.1016/S0736-5748(97)00048-8; DAVID S, 1981, SCIENCE, V214, P931, DOI 10.1126/science.6171034; Davies SJA, 1997, NATURE, V390, P680; Diener PS, 1998, J NEUROSCI, V18, P779; DiProspero NA, 1997, EXP NEUROL, V148, P628, DOI 10.1006/exnr.1997.6700; EIDELBERG E, 1989, BRAIN RES BULL, V22, P39, DOI 10.1016/0361-9230(89)90125-1; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; Farooque M, 1996, J NEUROTRAUM, V13, P537, DOI 10.1089/neu.1996.13.537; Felici F, 1997, SPINAL CORD, V35, P383, DOI 10.1038/sj.sc.3100403; FeraboliLohnherr D, 1997, EXP BRAIN RES, V113, P443, DOI 10.1007/PL00005597; FERNAUDESPINOSA I, 1993, GLIA, V8, P277, DOI 10.1002/glia.440080408; Finiels F, 1995, NEUROREPORT, V7, P373, DOI 10.1097/00001756-199512290-00088; Franzen R, 1998, J NEUROSCI RES, V51, P316, DOI 10.1002/(SICI)1097-4547(19980201)51:3<316::AID-JNR5>3.0.CO;2-J; Gerin C, 1998, BRAIN RES, V794, P169, DOI 10.1016/S0006-8993(98)00278-9; Grill R, 1997, J NEUROSCI, V17, P5560; Grill RJ, 1997, EXP NEUROL, V148, P444, DOI 10.1006/exnr.1997.6704; Guest JD, 1997, EXP NEUROL, V148, P502, DOI 10.1006/exnr.1997.6693; Holtmaat AJGD, 1998, BRAIN RES REV, V26, P43, DOI 10.1016/S0165-0173(97)00044-1; Hughes S, 1997, DEV BRAIN RES, V102, P13, DOI 10.1016/S0165-3806(97)00072-2; Iadecola C, 1997, J NEUROSCI, V17, P9157; Kanellopoulos GK, 1997, ANN THORAC SURG, V64, P1279, DOI 10.1016/S0003-4975(97)00903-X; Keirstead HS, 1998, EXP NEUROL, V151, P303, DOI 10.1006/exnr.1998.6806; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; LEVALLOIS C, 1994, INT J DEV NEUROSCI, V12, P547, DOI 10.1016/0736-5748(94)90062-0; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; Li Y, 1997, EXP NEUROL, V145, P397, DOI 10.1006/exnr.1997.6502; Liu S, 1997, J NEUROSCI RES, V49, P425, DOI 10.1002/(SICI)1097-4547(19970815)49:4<425::AID-JNR4>3.0.CO;2-A; Lu YM, 1996, J NEUROSCI, V16, P5457; LUNDBERG A, 1966, MUSCULAR AFFERENTS M, P275; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; Morin-Richaud C, 1998, BRAIN RES, V783, P85, DOI 10.1016/S0006-8993(97)01282-1; Muir GD, 1997, TRENDS NEUROSCI, V20, P72, DOI 10.1016/S0166-2236(96)10068-0; Mukhin AG, 1997, J NEUROTRAUM, V14, P651, DOI 10.1089/neu.1997.14.651; Olney J. W., 1978, NEUROTOXICITY EXCITA, P95; PENCALET P, 1993, J NEUROSURG, V78, P603, DOI 10.3171/jns.1993.78.4.0603; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; PRIVAT A, 1988, PROG BRAIN RES, V78, P155; Privat A, 1997, REV NEUROL-FRANCE, V153, P515; Ramon-Cueto A, 1998, J NEUROSCI, V18, P3803; Ramon-Cueto A, 1998, BRAIN RES BULL, V46, P175, DOI 10.1016/S0361-9230(97)00463-2; REGAN RF, 1995, BRAIN RES, V682, P144, DOI 10.1016/0006-8993(95)00330-S; RIBOTTA MGY, 1995, J NEUROSCI RES, V41, P79, DOI 10.1002/jnr.490410110; Ribotta MGY, 1997, J NEUROSCI RES, V48, P281; Ribotta MGY, 1997, ADV EXP MED BIOL, V429, P121; RIBOTTA MGY, 1998, IN PRESS ANN NY ACAD; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; RONDOUIN G, 1988, NEUROSCI LETT, V91, P199, DOI 10.1016/0304-3940(88)90768-9; ROSSIGNOL S, 1966, HDB PHYSL 12, P173; Rossignol Serge, 1994, Current Opinion in Neurobiology, V4, P894, DOI 10.1016/0959-4388(94)90139-2; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; ROTHSTEIN JD, 1995, J NEUROCHEM, V65, P643; Steward O, 1997, EXP NEUROL, V148, P100, DOI 10.1006/exnr.1997.6613; Sundstrom E, 1997, EXP NEUROL, V148, P407, DOI 10.1006/exnr.1997.6691; Taoka Y, 1998, J NEUROSCI, V18, P1393; Tello JF, 1911, TRAB LAB INVEST BIOL, V9, P123; Teng YD, 1998, EUR J NEUROSCI, V10, P798, DOI 10.1046/j.1460-9568.1998.00100.x; Thallmair M, 1998, NAT NEUROSCI, V1, P124, DOI 10.1038/373; Tuszynski MH, 1998, CELL TRANSPLANT, V7, P187, DOI 10.1016/S0963-6897(97)00166-8; Vanek P, 1998, EUR J NEUROSCI, V10, P45, DOI 10.1046/j.1460-9568.1998.00018.x; Watanabe M, 1998, J NEUROTRAUM, V15, P285, DOI 10.1089/neu.1998.15.285; Wickelgren I, 1998, SCIENCE, V279, P319, DOI 10.1126/science.279.5349.319; WICTORIN K, 1992, NEUROREPORT, V3, P1045, DOI 10.1097/00001756-199212000-00003; Wrathall JR, 1997, EXP NEUROL, V145, P565, DOI 10.1006/exnr.1997.6506; YAKOVLEFF A, 1995, EXP BRAIN RES, V106, P69; Zompa EA, 1997, J NEUROTRAUM, V14, P479, DOI 10.1089/neu.1997.14.479	80	32	33	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1350-7540	1473-6551		CURR OPIN NEUROL	Curr. Opin. Neurol.	DEC	1998	11	6					647	654		10.1097/00019052-199812000-00007			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	148EC	WOS:000077490900007	9870132				2021-06-18	
J	Hogg, S; Moser, PC; Sanger, DJ				Hogg, S; Moser, PC; Sanger, DJ			Mild traumatic lesion of the right parietal cortex of the rat: Selective behavioural deficits in the absence of neurological impairment	BEHAVIOURAL BRAIN RESEARCH			English	Article						cerebral trauma; neurologic function; motor activity; paw reaching; water maze; passive avoidance; active avoidance; plus-maze; holeboard	PERCUSSION BRAIN INJURY; WATER-MAZE PROCEDURE; HOODED RATS; HIPPOCAMPAL; DAMAGE; DYSFUNCTION	Fluid impact models are widely used to study the histological and neurochemical consequences of traumatic brain injury and although behavioural consequences have also been studied, behavioural changes are often confounded by non-specific neurological deficits. In the present study we investigated behavioural effects of a unilateral mild traumatic lesion of the right lateral parietal cortex. This region is implicated in a number of basic and complex behaviors, and we therefore analyzed the performance of rats in a diverse range of behavioural procedures. The lesion had no effects on general neurological function, motor activity (activity boxes, rota-rod and paw reaching tests), habituation to a novel environment (holeboard), spatial learning ability (Morris water maze) or anxiety (elevated plus-maze). However, the lesioned animals demonstrated lower levels of exploration than the control group when novel objects were placed beneath some of the holes in the holeboard. Lesioned animals also differed from controls in their performance in passive and active avoidance procedures. In a step-through passive avoidance test the lesioned rats performed worse than the sham-operated controls, i.e. they had significantly lower entry latencies on the 2nd day. In contrast, in the active avoidance task the lesioned animals performed better than sham-operated rats, demonstrating a better ability to learn to avoid and escape from the shock. These diverse results in different tests of learning and memory, in particular the impairment in passive avoidance and the improvement in active avoidance behavior, are difficult to reconcile with a simple effect of the lesion on cognitive performance per se. The complete absence of general neurological deficits following the mild traumatic injury rules out the possibility that the observed behavioural changes reflect a non-specific impairment. These results demonstrate that mild traumatic lesion of the right parietal cortex can induce relatively selective behavioural changes that may serve to study functional recovery after trauma. However further work is required to establish the underlying deficit(s) that has led to the behavioural effects described here. (C) 1998 Elsevier Science B.V. All rights reserved.	Synthelabo Rech, F-92500 Rueil Malmaison, France; Synthelabo Rech, F-92220 Bagneux, France	Moser, PC (corresponding author), Synthelabo Rech, 10 Rue Carrieres, F-92500 Rueil Malmaison, France.			Moser, Paul/0000-0002-6887-3508			ADAMEC R E, 1991, Journal of Psychopharmacology, V5, P175, DOI 10.1177/026988119100500301; ANDERSEN RA, 1987, HDB PHYSL 1, P483; CAHN J, 1988, CURR PROB N, V7, P27; CROWNE DP, 1992, BEHAV NEUROSCI, V106, P808, DOI 10.1037/0735-7044.106.5.808; FERNANDEZTERUEL A, 1991, BRAIN RES BULL, V26, P173, DOI 10.1016/0361-9230(91)90205-X; FILE SE, 1994, PHARMACOL BIOCHEM BE, V49, P449, DOI 10.1016/0091-3057(94)90054-X; FOREMAN N, 1992, BEHAV NEUROSCI, V106, P529, DOI 10.1037/0735-7044.106.3.529; HAMM RJ, 1993, BEHAV BRAIN RES, V59, P169, DOI 10.1016/0166-4328(93)90164-L; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HOGG S, 1997, IN PRESS BEHAV BRAIN; Holm Soren, 1993, Acta Neurobiologiae Experimentalis (Warsaw), V53, P569; KOLB B, 1987, BEHAV BRAIN RES, V23, P127, DOI 10.1016/0166-4328(87)90050-7; Kraemer PJ, 1996, BRAIN RES BULL, V39, P17, DOI 10.1016/0361-9230(95)02028-4; LEVI L, 1990, NEUROSURGERY, V27, P429, DOI 10.1227/00006123-199009000-00015; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYNCH JC, 1980, BEHAV BRAIN SCI, V3, P485, DOI 10.1017/S0140525X00006324; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MONTOYA CP, 1991, J NEUROSCI METH, V36, P219, DOI 10.1016/0165-0270(91)90048-5; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; MUIR JK, 1995, J NEUROTRAUM, V12, P87, DOI 10.1089/neu.1995.12.87; Paxinos G., 1982, RAT BRAIN STEREOTAXI; SAVE E, 1992, BEHAV BRAIN RES, V47, P113, DOI 10.1016/S0166-4328(05)80118-4; SAVE E, 1992, BEHAV NEUROSCI, V106, P447, DOI 10.1037/0735-7044.106.3.447; SINSON G, 1995, J NEUROCHEM, V65, P2209; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1993, J NEUROSCI, V13, P5383; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; TEMKIN NR, 1995, J NEUROSURG, V82, P764, DOI 10.3171/jns.1995.82.5.0764; ThinusBlanc C, 1996, BEHAV BRAIN RES, V80, P33, DOI 10.1016/0166-4328(96)00016-2; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; TOULMOND S, 1995, BRAIN RES, V671, P261, DOI 10.1016/0006-8993(94)01343-G; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; Yamaguchi T, 1996, NEUROPHARMACOLOGY, V35, P329, DOI 10.1016/0028-3908(95)00171-9	35	32	32	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328			BEHAV BRAIN RES	Behav. Brain Res.	JUN	1998	93	1-2					143	155		10.1016/S0166-4328(97)00146-0			13	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	ZX806	WOS:000074557300016	9659996				2021-06-18	
J	Macciocchi, SN; Barth, JT; Littlefield, LM				Macciocchi, SN; Barth, JT; Littlefield, LM			Outcome after mild head injury	CLINICS IN SPORTS MEDICINE			English	Article							ICE HOCKEY; CONCUSSION; PLAYERS; BRAIN; SEQUELAE; LONG; FOOTBALLERS; MANAGEMENT; PREVENTION; SPORTS	Mild sports head injury is common, but few studies have been completed. A number of factors, including injury biomechanics, severity, frequency, and complications are important in understanding morbidity associated with mild head injury. At present, empirical studies are required to address many complex questions regarding outcome.	Univ Virginia, Sch Med, Dept Psychiat Med, Charlottesville, VA 22901 USA; Univ Virginia, Sch Med, Dept Phys Med & Rehabil, Charlottesville, VA 22901 USA	Macciocchi, SN (corresponding author), Univ Virginia, Sch Med, Dept Med Phys, Charlottesville, VA 22901 USA.						ALVES WA, 1993, J HEAD TRAUMA REHAB, V3, P48; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Barth JT., 1989, MILD HEAD INJURY, P257; Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; BOHENEN N, 1992, NEUROSURGERY, V30, P692; BOHENEN N, 1992, J NEUROL NEUROSUR PS, V55, P222; BRUNO LA, 1987, CLIN SPORT MED, V6, P17; CANTU RC, 1992, SPORTS MED, V14, P64, DOI 10.2165/00007256-199214010-00005; CANTU RC, 1995, CLIN SPORT MED, V14, P517; COONLEYHOGANSON R, 1984, NEUROSURGERY, V14, P315, DOI 10.1227/00006123-198403000-00009; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V6, P649; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P227; DIKMEN SS, 1993, J HEAD TRAUMA REHAB, V3, P30; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; GRONWALL D, 1975, LANCET, V2, P995; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; INGERSOLL CD, 1993, SPORTS MED, V16, P342, DOI 10.2165/00007256-199316050-00005; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Macciocchi SN, 1996, NEUROSURGERY, V39, P510, DOI 10.1097/00006123-199609000-00014; MACCIOCCHI SN, UNPUB NEUROSURGERY; MADDOCKS DL, 1995, AUST PSYCHOL, V30, P125, DOI 10.1080/00050069508258916; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; MORTIMER JA, 1985, NEUROLOGY, V35, P264, DOI 10.1212/WNL.35.2.264; OMMAYA AK, 1995, J NEUROTRAUM, V12, P527, DOI 10.1089/neu.1995.12.527; POLIN RS, 1996, NEUROLOGY TRAUMA; Putukian M, 1996, PHYSICIAN SPORTSMED, V24, P25, DOI 10.3810/psm.1996.11.1283; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROSS RJ, 1987, CLIN SPORT MED, V6, P41; RUFF RM, 1994, BRAIN INJURY, V8, P297, DOI 10.3109/02699059409150981; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Spear J, 1995, INT J GERIATR PSYCH, V10, P1011, DOI 10.1002/gps.930101203; STILLER JW, 1985, PSYCHIAT CLIN N AM, V8, P339; STUART MJ, 1995, AM J SPORT MED, V23, P458, DOI 10.1177/036354659502300415; Tegner Y, 1996, BRIT J SPORT MED, V30, P251, DOI 10.1136/bjsm.30.3.251; TORG JS, 1989, PHYSICIAN SPORTSMED, V17, P573; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	45	32	32	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0278-5919			CLIN SPORT MED	Clin. Sports Med.	JAN	1998	17	1					27	+		10.1016/S0278-5919(05)70058-2			12	Sport Sciences	Sport Sciences	YU153	WOS:000071687600004	9475968				2021-06-18	
J	Nochi, M				Nochi, M			Dealing with the 'Void': traumatic brain injury as a story	DISABILITY & SOCIETY			English	Article							HEAD-INJURY; NEUROPSYCHOLOGY; REHABILITATION; DISABILITY; RECOVERY; ILLNESS	Traumatic brain injury (TBI) is considered to drastically affect the individual's sense of self To discover how people with TBI understand themselves, in-depth interviews with four individuals with TBI were conducted. Their narratives suggest that they feel they are carrying a 'void' in their understandings of their past and present. individuals tend to fill the 'void' in their long-term memory with stories about the accident and recovery. The concept of 'void' is also useful in understanding how TBI survivors view the causal relationship between the accident, the brain injury and their present difficulties. This relationship can be another 'void' that threatens their sense of agency. The findings suggest that the experience of TBI appears as meanings in their self-narratives rather than as objective truth. Rehabilitation professionals should consider how their client interprets his or her TBI and self in everyday life when they work with this population.		Nochi, M (corresponding author), SYRACUSE UNIV,DEPT COUNSELING & HUMAN SERV,259 HUNTINGTON HALL,SYRACUSE,NY 13244, USA.						BARCLAY CR, 1994, ENCY HUMAN BEHAV, V1; BERGLAND MM, 1991, REHABIL COUNS BULL, V35, P5; BOGDAN R, 1989, SOC PROBL, V36, P135, DOI 10.1525/sp.1989.36.2.03a00030; Bogdan R., 1984, INTRO QUALITATIVE RE; Bogdan R., 1992, QUALITATIVE RES ED I; BOND MR, 1976, SCAND J REHABIL MED, V8, P127; BOND MR, 1990, REHABILITATION ADULT; Bruner J., 1986, ACTUAL MINDS POSSIBL; Bruner Jerome, 1994, REMEMBERING SELF CON; CAPLAN B, 1987, REHABILITATION COUNS; CICERONE KD, 1989, REHABIL PSYCHOL, V34, P105, DOI 10.1037//0090-5550.34.2.105; Conrad P., 1992, DEVIANCE MED BADNESS, VExpanded ed; CORNWAY MA, 1992, THEORETICAL PERSPECT; Crisp R., 1994, J APPL REHABILITATIO, V25, P16; CROVITZ HF, 1986, AUTOBIOGRAPHICAL MEM; DANN MD, 1984, COGNITIVE REHABILITA, V2, P11; FALVO DR, MED PSYCHOSOCIAL ASP; FAUST P, 1987, ARCH CLIN NEUROPSYCH, V3, P145; FORSTERLING F, 1988, ATTRIBUTION THEORY C; FRASER RT, 1988, CONT CHALLENGES REHA; GAMA EMP, 1992, COUNSELING HUMAN DEV, V25, P1; Gergen Kenneth J., 1988, ADV EXPT SOCIAL PSYC, V21; GERGEN KJ, 1982, EXPLAINING SOCIAL BE; GERHARDT U, 1990, SOC SCI MED, V30, P1149, DOI 10.1016/0277-9536(90)90255-Q; Glaser B. G., 1967, DISCOVERY GROUNDED T; GOLDEN CJ, 1983, CLIN NEUROPSYCHOLOGY; Goldstein K., 1939, ORGANISM HOLISTIC AP; HAGNER DC, 1994, REHABIL COUNS BULL, V37, P290; HARRELL M, 1992, COGNITIVE REHABILITA; Heilman K.M.V.E., 1993, CLIN NEUROPSYCHOLOGY; HEWITT JP, 1975, AM SOCIOL REV, V40, P1, DOI 10.2307/2094442; JOHNSON CN, 1990, CHILD DEV, V61, P962, DOI 10.1111/j.1467-8624.1990.tb02834.x; JOHNSON CN, 1982, CHILD DEV, V53, P222, DOI 10.2307/1129656; KARPMAN T, 1985, J APPL REHABILITATIO, V17, P28; KEMP AD, 1992, COUNS PSYCHOL, V20, P571, DOI 10.1177/0011000092204003; KREFTING L, 1990, SOC SCI MED, V30, P859, DOI 10.1016/0277-9536(90)90213-C; Kreutzer JS, 1990, COMMUNITY INTEGRATIO; Lefcourt H.M., 1983, RES LOCUS CONTROL CO, V. 2; Lincoln Y.S., 1985, NATURALISTIC INQUIRY, V75; LINGE FR, 1990, CAN J PSYCHOL, V44, P116, DOI 10.1037/h0084383; LUTFIYYA ZM, 1991, DISABILITY HANDICAP, V6, P233, DOI DOI 10.1080/02674649166780271; MALEC JF, 1992, COUNS PSYCHOL, V20, P620, DOI 10.1177/0011000092204005; MCCARTHY RA, 1990, COGNITIVE NEUROPSYCH; Meier M. J., 1987, NEUROPSYCHOLOGICAL R; MELTZER ML, 1983, J CLIN PSYCHOL, V39, P3, DOI 10.1002/1097-4679(198301)39:1<3::AID-JCLP2270390102>3.0.CO;2-F; MILLER E, 1980, MODELS MAN; Miller L., 1993, PSYCHOTHERAPY BRAIN; Neisser U., 1988, PHILOS PSYCHOL, V1, P35, DOI [10.1080/09515088808572924, DOI 10.1080/09515088808572924]; Neisser U, 1994, REMEMBERING SELF CON; PHILLIPS MJ, 1990, SOC SCI MED, V30, P849, DOI 10.1016/0277-9536(90)90212-B; Polkinghorne D.E., 1988, NARRATIVE KNOWING HU; POLLACK IW, 1994, NEUROPSYCHIATRY TRAU; PRIGATANO GP, 1987, NEUROPSYCHOLOGICAL R; RIESSMAN CK, 1990, SOC SCI MED, V30, P1195, DOI 10.1016/0277-9536(90)90259-U; RIMEL RW, 1990, REHABILIATION ADULT; Roth Julius., 1963, TIMETABLES STRUCTURI; Rubin D. C., 1986, AUTOBIOGRAPHICAL MEM; SARBIN TR, 1988, NARRATIVE PSYCHOL ST; SBORDONE RJ, 1988, J HEAD TRAUMA REHAB, V3, P55; Schwarzer R.E., 1992, SELF EFFICACY THOUGH; SCOTT MB, 1968, AM SOCIOL REV, V33, P46, DOI 10.2307/2092239; Shotter J., 1984, SOCIAL ACCOUNTABILIT; Strauss A., 1987, QUALITATIVE ANAL SOC; TAYLOR SJ, 1995, VARIETY COMMUNITY EX; THOMAS KR, 1986, APPL REHABILITATION; WILSON B, 1988, REHABILITATION MEMOR	66	32	33	0	5	CARFAX PUBL CO	ABINGDON	PO BOX 25, ABINGDON, OXFORDSHIRE, ENGLAND OX14 3UE	0968-7599			DISABIL SOC	Disabil. Soc.	SEP	1997	12	4					533	555		10.1080/09687599727119			23	Rehabilitation; Social Sciences, Interdisciplinary	Rehabilitation; Social Sciences - Other Topics	XX066	WOS:A1997XX06600003					2021-06-18	
J	Cantu, RC				Cantu, RC			Athletic head injuries	CLINICS IN SPORTS MEDICINE			English	Article							SPORTS	This article describes head and neck injuries and their hazardous results to the athlete. The causes and types of brain and spinal cord injury are reviewed, including concussion, second impact syndrome, postconcussion syndrome, and intracranial hemorrhage.	EMERSON HOSP,NEUROSURG SERV,CONCORD,MA; EMERSON HOSP,SERV SPORTS MED,CONCORD,MA							CANTU RC, 1987, EXERCISING ADULT; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P76; Committee on Head Injury Nomenclature of Congress of Neurological Surgeons, 1966, CLIN NEUROSURG, V12, P386; FEKETE JF, 1968, CAN MED ASSOC J, V99, P1234; GRUBER R, 1985, Z KINDERCHIR, V40, P199; GUTHKELCH AN, 1980, EUR NEUROL, V19, P91, DOI 10.1159/000115133; HUGENHOLTZ H, 1982, CAN MED ASSOC J, V127, P827; JENNET B, 1971, SCI FDN NEUROLOGY, P441; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; Maroon J C, 1980, Clin Neurosurg, V27, P414; MCQUILLEN JB, 1988, AM J FOREN MED PATH, V9, P12, DOI 10.1097/00000433-198803000-00004; Meggyesy Dave, 1970, OUT THEIR LEAGUE, P125; MUELLER F, 1996, ANN SURVEY FOOTBALL; MURPHEY F, 1959, AM J SURG, V98, P379, DOI 10.1016/0002-9610(59)90530-6; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; SCHNEIDER RC, 1983, HEAD NECK INJURIES F; YARNELL PR, 1983, NEUROLOGY, V23, P196	18	32	33	0	0	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0278-5919			CLIN SPORT MED	Clin. Sports Med.	JUL	1997	16	3					531	&		10.1016/S0278-5919(05)70038-7			13	Sport Sciences	Sport Sciences	XJ010	WOS:A1997XJ01000010	9209824				2021-06-18	
J	Hillier, SL; Metzer, J				Hillier, SL; Metzer, J			Awareness and perceptions of outcomes after traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURY	Awareness or insight has been identified as a major factor in successful rehabilitation after traumatic brain injury (TBI). Anecdotal evidence suggests people with TBI are more Likely to be aware of residual physical disabilities, perhaps focusing on these to the exclusion of other issues in the psychosocial and cognitive domains, for example. To investigate this more accurately, recovery and outcome questionnaires were administered to people with TBI and their nominated significant others, and, as appropriate, an assessment of their level of functioning was also recorded. Two- and three-way analyses (t-tests, Kendall's and Wilcoxon's) comparing these perceptions were then conducted. The results indicated a high level of agreement for basic demographic data and broad outcomes. it was found the subjects reported a lower rate of physical impairment and disability than the significant other or the author, suggesting that, as a group, they do not fixate on physical issues. Other areas of difference were found, such as a tendency for the significant other to perceive the subject as being more dependent in mobility and self-care tasks, possibly because of their close involvement. Also the author reported more impairments, using clinical language and assessment that did not necessarily have meaning or significance for the other groups. There was also evidence to support the notion that there is an inherent hierarchy of needs ranging from the lower-order, physiological or survival skills through to higher-order, self-actualizing areas. Because of the differing awareness and perceptions, care must be taken in service provision to identify the personal needs and values of each individual involved.	UNIV S AUSTRALIA,SCH PSYCHOL,ADELAIDE,SA 5001,AUSTRALIA; UNIV S AUSTRALIA,SCH PHYSIOTHERAPY,ADELAIDE,SA 5001,AUSTRALIA			Hillier, Susan/Q-7713-2019; Hillier, Susan/D-4590-2009	Hillier, Susan/0000-0002-6071-6137; Hillier, Susan/0000-0002-6071-6137			ALLEN C C, 1990, Brain Injury, V4, P7, DOI 10.3109/02699059009026143; Antonak R. F., 1993, J HEAD TRAUMA REHAB, V8, P87, DOI DOI 10.1097/00001199-199312000-00009; Bond M R, 1975, Ciba Found Symp, P141; BROOKS DN, 1983, J NEUROL NEUROSUR PS, V46, P336, DOI 10.1136/jnnp.46.4.336; BROOKS N, 1991, Brain Injury, V5, P103, DOI 10.3109/02699059109008082; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; CHIOU IIL, 1985, PHYS THER, V65, P901, DOI 10.1093/ptj/65.6.901; DOLLARD J, 1950, PERS PSYCHOTHER, P30; ELLIOTT J, 1982, AUSTR REHABILITATION, V6, P50; Farmer J E, 1988, Brain Inj, V2, P323, DOI 10.3109/02699058809150903; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Heilbronner R L, 1989, Brain Inj, V3, P387, DOI 10.3109/02699058909004562; Heilman K., 1991, AWARENESS DEFICIT BR, P53; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; JACKSON H F, 1992, Brain Injury, V6, P109, DOI 10.3109/02699059209029650; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JELLINEK HM, 1982, ARCH PHYS MED REHAB, V63, P160; MASLOW AH, 1954, MOTIV PERS, P80; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MELAMED S, 1992, Brain Injury, V6, P233, DOI 10.3109/02699059209029665; MILLER E, 1979, BRIT J SOC CLIN PSYC, V18, P87, DOI 10.1111/j.2044-8260.1979.tb00310.x; MOSEY AC, 1973, ACTIVITIES THERAPY, P12; OHARA C, 1988, COGNITIVE REHABILITA, V6, P26; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; TATE RL, 1989, ACTA NEUROL SCAND, V79, P97, DOI 10.1111/j.1600-0404.1989.tb03719.x	25	32	32	0	2	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JUL	1997	11	7					525	536		10.1080/713802189			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	XF661	WOS:A1997XF66100005	9210988				2021-06-18	
J	Williams, IM; Ponsford, JL; Gibson, KL; Mulhall, LE; Curran, CA; Abel, LA				Williams, IM; Ponsford, JL; Gibson, KL; Mulhall, LE; Curran, CA; Abel, LA			Cerebral control of saccades and neuropsychological test results after head injury	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						brain injury; saccades; neuropsychology	CORTICAL CONTROL; SUPERIOR COLLICULUS; DIRECTED SACCADES; GUIDED SACCADES; EYE-MOVEMENTS; DISEASE	Abnormalities in the control of saccades have been described in patients with cerebral pathology(1,2). We assessed control of visually guided, reflexive and volitional saccades in 16 patients suffering severe traumatic brain injury and 12 controls and related the results to deficits on neuropsychological tests of speed of information processing and goal directed behaviour. All saccadic latencies were prolonged, Suppression of inappropriate saccades nas impaired on volitional saccade tests which proved to be more sensitive in identifying impairment of goal directed behaviour than the neuropsychological test results. Patients' self-paced saccade rate was lower than controls' and correlated with performance on several visually mediated neuropsychological test results. Patients' visually guided, reflexive saccades were hypometric; this hypometria correlated with both visual and non-visual neuropsychological test results and with post-traumatic amnesia duration. Hypometria in reflexive saccades may reflect diffuse brain injury. Re-examination after 12 months revealed that the control of volitional saccades improved but there was no improvement in the visually guided reflexive saccade measures. The volitional saccade tests may be useful in documenting both impairment and subsequent recovery.	MONASH UNIV, ALFRED HOSP, DEPT MED, NEUROOPHTHALMOL LAB, MELBOURNE, VIC 3181, AUSTRALIA; BETHESDA HOSP, MELBOURNE, VIC, AUSTRALIA; INDIANA UNIV, DEPT OPHTHALMOL, INDIANAPOLIS, IN 46204 USA			Abel, Larry/D-9915-2012	Abel, Larry/0000-0002-2393-0644			ABEL LA, 1984, NEURO-OPHTHALMOLOGY, V4, P21, DOI 10.3109/01658108409019492; ADAMS JH, 1990, HDB CLIN NEUROLOGY, V57, P43; Benton A., 1976, MULTILINGUAL APHASIA; BROWN JW, 1985, HDB CLIN NEUROLOGY, V1, P23; Christensen AL, 1979, LURIAS NEUROPSYCHOLO; DEJONG JD, 1971, EXP NEUROL, V32, P58, DOI 10.1016/0014-4886(71)90165-8; Deng S.-Y., 1986, ADAPTIVE PROCESSES V, P201; FLETCHER WA, 1986, ANN NEUROL, V20, P464, DOI 10.1002/ana.410200405; GENTRY LR, 1991, MAGNETIC RESONANCE I, P439; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; GUITTON D, 1985, EXP BRAIN RES, V58, P455; HEYWOOD S, 1975, BASIC MECHANISMS OCU, P561; HOTSON JR, 1982, NEUROLOGY, V32, P31, DOI 10.1212/WNL.32.1.31; KEATING EG, 1986, BEHAV BRAIN RES, V22, P191, DOI 10.1016/0166-4328(86)90064-1; LASKER AG, 1987, NEUROLOGY, V37, P364, DOI 10.1212/WNL.37.3.364; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Milner B., 1964, FRONTAL GRANULAR COR; OHTSUKA K, 1991, NEUROSCI RES, V10, P290, DOI 10.1016/0168-0102(91)90086-E; PIERROTDESEILLIGNY C, 1991, BRAIN, V114, P1473, DOI 10.1093/brain/114.3.1473; PIERROTDESEILLIGNY C, 1991, EXP BRAIN RES, V83, P607; PIERROTDESEILLIGNY C, 1991, NEURO-OPHTHALMOLOGY, V11, P63, DOI 10.3109/01658109108997298; PIERROTDESEILLIGNY C, 1991, J NEUROL NEUROSUR PS, V54, P1106, DOI 10.1136/jnnp.54.12.1106; POSNER MI, 1984, J NEUROSCI, V4, P1863; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SHARPE JA, 1982, NEUROLOGY, V32, P57, DOI 10.1212/WNL.32.1.57; SHARPE JA, 1986, ADAPTIVE PROCESSES V, P239; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith A., 1973, SYMBOL DIGIT MODALIT; TEDESCHI G, 1983, PSYCHOPHARMACOLOGY, V79, P190, DOI 10.1007/BF00427810; TEDESCHI G, 1989, EUR J CLIN PHARMACOL, V37, P513, DOI 10.1007/BF00558133; Tusa R J, 1989, Bull Soc Belge Ophtalmol, V237, P67; WURTZ RH, 1986, PROGR BRAIN RES OCUL, V64, P190	33	32	32	0	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	APR	1997	4	2					186	196		10.1016/S0967-5868(97)90072-2			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	WQ637	WOS:A1997WQ63700015	18638954				2021-06-18	
J	Quintana, DA; Jordan, FB; Tuggle, DW; Mantor, PC; Tunell, WP				Quintana, DA; Jordan, FB; Tuggle, DW; Mantor, PC; Tunell, WP			The spectrum of pediatric injuries after a bomb blast	JOURNAL OF PEDIATRIC SURGERY			English	Article; Proceedings Paper	27th Annual Meeting of the American-Pediatric-Surgical-Association	MAY 19-22, 1996	SAN DIEGO, CA	Amer Pediat Surg Assoc		blast injuries; pediatric trauma; Oklahoma bombing; terrorism; triage	BEIRUT	The spectrum of pediatric injuries seen after a bomb blast is poorly documented. The pathophysiology of blast injuries differ significantly from other forms of trauma and typically result in large numbers of distinctly patterned injuries. On April 19, 1995, a truck bomb was detonated directly adjacent to the Alfred P. Murrah Federal Building in Oklahoma City, Oklahoma. A total of 816 adults and children were injured or killed as a direct result of the blast. Twenty infants and children were seated by the window of the second floor day care center at the time of the explosion. The injuries incurred by all children involved in the blast were studied. Nineteen children, 16 of whom were in the day care center, died as a direct result of the blast. The injury patterns among the 19 dead children included a 90% (17 of 19) incidence of skull fractures, 19 df those with cerebral evisceration (skull capping); 37% with abdominal or thoracic injuries; 31% amputations; 47% arm fractures, 26% leg fractures; 21% burns; and 100% with extensive; cutaneous contusions, avulsions, ana lacerations. Forty-seven children sustained nonfatal injuries with only seven children requiring hospitalization. The injuries sustained by the seven hospitalized children included two open, depressed skull fractures, with partially extruded brain, two closed head injuries, three arm fractures, one leg fracture, one arterial injury, one splenic injury, five tympanic membrane perforations, three corneal abrasions, and four burn cases (1 > 40% body surface area [BSA]). After a bomb blast, pediatric patients sustain a high incidence of cranial injuries. Fractures and traumatic amputations are common. Intraabdominal and thoracic injuries occur frequently in the deceased but infrequently in survivors. Copyright (C) 1997 by W.B. Saunders Company.	UNIV OKLAHOMA,COLL MED,DEPT PATHOL,OFF CHIEF MED EXAMINER,OKLAHOMA CITY,OK; UNIV OKLAHOMA,COLL MED,PEDIAT SURG SECT,OKLAHOMA CITY,OK; CHILDRENS HOSP OKLAHOMA,OKLAHOMA CITY,OK							ADLER OB, 1988, ACTA RADIOL, V29, P1; Boffard K D, 1993, Surg Annu, V25 Pt 1, P29; FRYKBERG ER, 1988, ANN SURG, V208, P569, DOI 10.1097/00000658-198811000-00005; HULLER T, 1970, ARCH SURG-CHICAGO, V100, P24; Mellor S G, 1988, Br J Hosp Med, V39, P536; *OKL STAT DEP HLTH, 1996, INV PHYS INJ PREV SE; PHILLIPS YY, 1986, ANN EMERG MED, V15, P1446, DOI 10.1016/S0196-0644(86)80940-4; RIGNAULT DP, 1989, ANN SURG, V209, P368, DOI 10.1097/00000658-198903000-00019; SCOTT BA, 1986, NEUROSURGERY, V18, P107, DOI 10.1227/00006123-198601000-00020; STAPCZYNSKI JS, 1982, ANN EMERG MED, V11, P687, DOI 10.1016/S0196-0644(82)80268-0; WATERWORTH TA, 1975, BRIT MED J, V2, P25, DOI 10.1136/bmj.2.5961.25	11	32	32	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0022-3468			J PEDIATR SURG	J. Pediatr. Surg.	FEB	1997	32	2					307	311		10.1016/S0022-3468(97)90199-8			5	Pediatrics; Surgery	Pediatrics; Surgery	WH207	WOS:A1997WH20700031	9044142				2021-06-18	
J	Gracies, JM; Elovic, E; McGuire, J; Simpson, D				Gracies, JM; Elovic, E; McGuire, J; Simpson, D			Traditional pharmacological treatments for spasticity - Part 1: Local treatments	MUSCLE & NERVE			English	Article							PHENOL INJECTION; SYSTEMIC LIDOCAINE; STEROID INJECTION; ETHANOL INJECTION; MUSCLE ATROPHY; SOLEUS MUSCLE; BLOCK; NERVE; SINGLE; MICE	Spasticity is a velocity-dependent increase in stretch reflex activity. It is one of the forms of muscle overactivity that may affect patients with damage to the central nervous system. Spasticity monitoring is relevant to function because the degree of spasticity may reflect the intensity of other disabling types of muscle overactivity such as unwanted antagonistic co-contractions, permanent muscle activity in the absence of any stretch or volitional command (spastic dystonia), or inappropriate responses to cutaneous or vegetative inputs. In addition, spasticity like other muscle overactivity can cause muscle shortening, which is another significant source of disability. Finally, spasticity is the only form of muscle overactivity easily quantifiable at the bedside. Under the name pharmacological treatments of spasticity, we understand the use of agents designed to reduce all types of muscle overactivity, by reducing excitability of motor pathways, at the level of the central nervous system, the neuromuscular junctions, or the muscle. Pharmacologic treatment should be an adjunct to muscle lengthening and training of antagonists. Localized muscle overactivity of specific muscle groups is often seen in a number of common pathologies, including stroke and traumatic brain injury. In these cases, we favor the use of local treatments in those muscles where overactivity is most disabling, by injection into muscle (neuromuscular block) or close to the nerve supplying the muscle (perineural block). Two types of local agents have been used in addition to the newly emerged botulinum toxin: local anesthetics (lidocaine and congeners), with a fully reversible action of short duration, and alcohols (ethanol and phenol), with a longer duration of action. Local anesthetics block both afferent and efferent messages. The onset of action is within minutes and duration of action varies between one and several hours according to the agent used. Their use requires resuscitation equipment available close by. When a long-lasting blocking agent is being considered, we favor the use of transient blocks with local anesthetics for therapeutic tests or diagnostic procedures to answer the following questions: Can function be improved by the block? What are the roles played by overactivity and contracture in the impairment of function! Which muscle is contributing to pathologic posturing? What is the true level of performance of antagonistic muscles! A short-acting anesthetic can also serve as preparation to casting or as an analgesic for intramuscular injections of other antispastic treatment. Alcohol and phenol provide long-term chemical neurolysis through destruction of peripheral nerve. Experience with ethanol is more developed in children using intramuscular injection, while experience with phenol is greater in adults with perineural injection. In both cases, there are anecdotal reports of efficacy but studies have rarely been controlled. Side effects are numerous and include pain during injection, chronic dysesthesia and chronic pain, and episodes of local or regional vascular complications by vessel toxicity. In the absence of controlled studies, a theoretical comparison of neurolytic agents with botulinum toxin is proposed. Neurolytic agents may be preferred to botulinum toxin on a number of grounds, including earlier onset, potentially longer duration of effect, lower cost, and easier storage. Conversely, pain during injection, tissue destruction with chronic sensory side effects, and lack of selectivity on motor function with neurolytic agents may favor the use of botulinum toxin. Neurolytic agents and botulinum toxin may be used in combination, the former for larger proximal muscles and the latter for selective injection into distal muscles. In the future, neurolytic agents may prove more appropriate in very severely affected patients for whom the purposes of the block are comfort and hygiene. Conversely, botulinum toxin may be better indicated in patients for whom there is hope for functional improvement in the affected limb, since the integrity of sensory afferents is indispensable. Controlled comparative studies between neurolytic agents and botulinum toxin are needed in specific patient populations to help determine the most appropriate applications of each. (C) 1997 John Wiley & Sons, Inc.	Mt Sinai Med Ctr, Dept Neurol, New York, NY 10029 USA; JFK Johnson Rehabil Inst, Ctr Head Injuries, Edison, NJ USA; Rehabil Inst Chicago, Chicago, IL 60611 USA; Mt Sinai Med Ctr, Dept Clin Neurophysiol, New York, NY 10029 USA	Gracies, JM (corresponding author), Mt Sinai Med Ctr, Dept Neurol, 1 Gustave L Levy Pl, New York, NY 10029 USA.						ADA L, KEY ISSUES NEUROLOGI; AQUILONIUS SM, 1984, MUSCLE NERVE, V7, P287, DOI 10.1002/mus.880070406; ASHWORTH B, 1964, PRACTITIONER, V192, P540; AWAD EA, 1972, MINN MED, V8, P711; BENNANI S, 1994, ANN UROL, V28, P13; BERNTSEN RF, 1992, AM HEART J, V124, P1478, DOI 10.1016/0002-8703(92)90060-9; BIRCH M, 1993, ANN OPHTHALMOL, V25, P267; BodineFowler SC, 1996, MUSCLE NERVE, V19, P497, DOI 10.1002/mus.880190404; Bohbot V, 1996, P NATL ACAD SCI USA, V93, P4016, DOI 10.1073/pnas.93.9.4016; BRAUN RM, 1973, J BONE JOINT SURG AM, VA 55, P580, DOI 10.2106/00004623-197355030-00015; BRAZEAU GA, 1989, PHARM RES-DORDR, V6, P766, DOI 10.1023/A:1015971429942; BRAZEAU GA, 1990, J PHARM SCI-US, V79, P393, DOI 10.1002/jps.2600790506; BROMAGE PR, 1974, CAN ANAESTH SOC J, V21, P535, DOI 10.1007/BF03006015; BUCHTHAL F, 1966, ELECTROEN CLIN NEURO, V20, P321, DOI 10.1016/0013-4694(66)90001-0; BURGENER FA, 1987, INVEST RADIOL, V22, P472, DOI 10.1097/00004424-198706000-00005; Burke D., 1973, NEW DEV ELECTROMYOGR, V3, P475; BURKEL W E, 1970, Archives of Physical Medicine and Rehabilitation, V51, P391; Burman MS, 1939, ARCH NEURO PSYCHIATR, V41, P307, DOI 10.1001/archneurpsyc.1939.02270140093008; CARPENTER EB, 1980, DEV MED CHILD NEUROL, V22, P497; CARPENTER EB, 1983, FOOT ANKLE, V4, P164, DOI 10.1177/107110078300400309; CARR JH, 1990, PHYSIOTHERAPY FDN PR; CHEN HW, 1995, CARCINOGENESIS, V16, P1963, DOI 10.1093/carcin/16.8.1963; Chiba K, 1993, Nihon Seikeigeka Gakkai Zasshi, V67, P1055; Cockin J, 1971, Br J Clin Pract, V25, P73; CRESWELL LL, 1994, ANN THORAC SURG, V57, P203, DOI 10.1016/0003-4975(94)90397-2; de Micheli A, 1992, Arch Inst Cardiol Mex, V62, P11; DEJONG RH, 1977, LOCAL ANESTHETICS; DELATEUR BJ, 1972, ARCH PHYS MED REHAB, V53, P179; DELATOUR EH, 1979, J NEUROL SCI, V40, P123; DELORIMIER AA, 1995, J PEDIATR SURG, V30, P188, DOI 10.1016/0022-3468(95)90558-8; Denny-Brown D., 1966, CEREBRAL CONTROL MOV; EASTON JKM, 1979, ARCH PHYS MED REHAB, V60, P155; EKEN T, 1989, PROG BRAIN RES, V80, P257; EMRE M, 1993, SPASTICITY MECH MANA; ERIKSSON M, 1995, ACTA ANAESTH SCAND, V39, P210, DOI 10.1111/j.1399-6576.1995.tb04045.x; Feldman PA, 1990, PRACTICAL MANAGEMENT; FELSENTH.G, 1974, ARCH PHYS MED REHAB, V55, P504; FELSENTHAL G, 1974, ARCH PHYS MED REHAB, V55, P13; FISHER E, 1970, AM J PHYS MED, V49, P333; FISHER E, 1971, AM J PHYS MED, V50, P230; FRANZ DN, 1974, J PHYSIOL-LONDON, V236, P193, DOI 10.1113/jphysiol.1974.sp010430; FUSFELD ROBERT D., 1968, ARCH PHYS MED REHABIL, V49, P217; GARLAND DE, 1982, CLIN ORTHOP RELAT R, P217; GARLAND DE, 1984, ARCH PHYS MED REHAB, V65, P243; Gasser HS, 1929, AM J PHYSIOL, V88, P581; GIOUX M, 1993, J APPL PHYSIOL, V75, P2629; GLASS A, 1968, Archives of Physical Medicine and Rehabilitation, V49, P455; GLENN MB, 1990, PRACTICAL MANAGEMENT, P227; Gordon A, 1914, J NERV MENT DIS, V41, P81, DOI 10.1097/00005053-191402000-00003; Gracies JM, 1997, ARCH PHYS MED REHAB, V78, P1066, DOI 10.1016/S0003-9993(97)90129-5; GRACIES JM, 1997, IN PRESS ARCH PHYS M; GRACIES JM, UNPUB QUANTITATIVE A; GRACIES JM, 1997, 122 ANN M AM NEUR AS; GREENSTEIN D, 1994, INT J CLIN MONIT COM, V11, P31, DOI 10.1007/BF01132841; GRIFFITH ER, 1977, ARCH PHYS MED REHAB, V58, P154; HALPERN D, 1977, ARCH PHYS MED REHAB, V58, P438; HALPERN DANIEL, 1966, ARCH PHYS MED REHABIL, V47, P659; HARIGA J., 1964, REV NEUROL [PARIS], V111, P472; HARIGA J, 1966, ACTA NEUROL BELG, V66, P607; Harvey AM, 1939, B JOHNS HOPKINS HOSP, V65, P223; Hasegawa O, 1990, Rinsho Shinkeigaku, V30, P718; Held J. P., 1969, REEDUCATION MOTRICE, P31; HELWEGLARSEN J, 1969, DAN MED BULL, V16, P20; Hesse S, 1995, NEUROSCI LETT, V201, P37, DOI 10.1016/0304-3940(94)12124-9; HOGAN QH, 1993, ANESTHESIOLOGY, V79, P1250, DOI 10.1097/00000542-199312000-00016; HOLLAND AJC, 1978, ANAESTHESIA, V34, P260; Hong CZ, 1996, ARCH PHYS MED REHAB, V77, P573, DOI 10.1016/S0003-9993(96)90297-X; ITOH M, 1995, ARCH ORAL BIOL, V40, P365, DOI 10.1016/0003-9969(94)00191-D; JONES R V Jr, 1955, Arch Phys Med Rehabil, V36, P301; KAJI R, 1995, ANN NEUROL, V38, P155, DOI 10.1002/ana.410380206; KALICHMAN MW, 1992, ANESTHESIOLOGY, V77, P941, DOI 10.1097/00000542-199211000-00017; KALICHMAN MW, 1993, J NEUROPATH EXP NEUR, V52, P234, DOI 10.1097/00005072-199305000-00007; KARATASSAS A, 1993, AUST NZ J SURG, V63, P766, DOI 10.1111/j.1445-2197.1993.tb00338.x; KATZ JA, 1995, REGION ANESTH, V20, P283; KATZ JORDAN, 1967, ARCH PHYS MED REHABIL, V48, P97; KELLY RE, 1959, LANCET, V2, P1102; KENYON EM, 1995, J TOXICOL ENV HEALTH, V44, P219, DOI 10.1080/15287399509531956; KHALILI AA, 1984, CURRENT THERAPY PHYS; KHALILI ALI A., 1964, ARCH PHYS MED REHABIL, V45, P513; KHALILI ALIA, 1966, CLIN ORTHOP RELAT RES, V47, P97; KHAO SV, 1990, GRUDSERDECHNOSOSUDIS, V4, P63; KIERNAN MC, 1997, IN PRESS J PHYSL LON; KITAOKA M, 1994, KIDNEY INT, V46, P1110, DOI 10.1038/ki.1994.373; KIZELSHTEYN G, 1992, ANESTH ANALG, V74, P499; KJELLBERG R. N., 1961, TRANS AMER NEUROL ASSOC, V86, P126; Koman LA, 1996, J CHILD NEUROL, V11, pS23, DOI 10.1177/0883073896011001S04; KUFFLER SW, 1951, J NEUROPHYSIOL, V14, P29; LABAT G, 1933, ANESTH ANALG, V12, P190; LABIB KB, 1984, CHEM NEUROLYSIS TECH; Lance J. W., 1980, SPASTICITY DISORDERE, P485; LANDAU WM, 1974, ARCH NEUROL-CHICAGO, V31, P217; Lapicque L, 1931, J PHYSIOL-LONDON, V73, P189, DOI 10.1113/jphysiol.1931.sp002806; Liddell EGT, 1924, P R SOC LOND B-CONTA, V96, P212, DOI 10.1098/rspb.1924.0023; Liljestrand G, 1919, PFLUG ARCH GES PHYS, V176, P168, DOI 10.1007/BF01722339; LUND S, 1965, ACTA PHYSIOL SCAND, V64, P345, DOI 10.1111/j.1748-1716.1965.tb04189.x; MACEK K, 1983, JAMA-J AM MED ASSOC, V249, P1807; MAIER A, 1972, EXP NEUROL, V37, P100, DOI 10.1016/0014-4886(72)90229-4; MARTIN C, 1994, CLIN PHARMACOKINET, V26, P248, DOI 10.2165/00003088-199426040-00002; MASSEY JM, 1995, J NEUROL NEUROSUR PS, V58, P258, DOI 10.1136/jnnp.58.2.258; MATTHEWS PBC, 1957, J PHYSIOL-LONDON, V135, P263, DOI 10.1113/jphysiol.1957.sp005708; MAY O, 1912, BRIT MED J, V31, P465; MEELHUYSEN FE, 1968, ARCH PHYS MED REHAB, V49, P36; MOONEY V, 1969, CLIN ORTHOP RELAT R, P122; MOORE TJ, 1991, FOOT ANKLE, V11, P219, DOI 10.1177/107110079101100406; MORGAN RJ, 1994, ANAESTHESIA, V49, P142, DOI 10.1111/j.1365-2044.1994.tb03372.x; Nathan P W, 1965, J Neurol Sci, V2, P7, DOI 10.1016/0022-510X(65)90060-2; NATHAN PW, 1959, LANCET, V2, P1099; NEUBERGER TJ, 1994, GASTROINTEST ENDOSC, V40, P316, DOI 10.1016/S0016-5107(94)70063-X; O'Hanlan J T, 1969, Va Med Mon (1918), V96, P429; O'Rahilly R, 1986, ANATOMY REGIONAL STU; ODwyer NJ, 1996, BRAIN, V119, P1737, DOI 10.1093/brain/119.5.1737; Okazaki A, 1993, Masui, V42, P819; Okazaki A, 1993, Masui, V42, P726; PAPINI E, 1995, THYROID, V5, P147, DOI 10.1089/thy.1995.5.147; Pelissier J, 1993, Cah Anesthesiol, V41, P139; PETRILLO CR, 1980, ORTHOPEDICS, V3, P871, DOI 10.3928/0147-7447-19800901-10; POLLOCK LJ, 1930, AM J PHYSIOL, V98, P47; RITCHIE JM, 1980, GOODMAN GILMANS PHAR, P376; RITCHIE JM, 1980, PHARMACOL BASIS THER, P300; RUFF RL, 1977, J PHYSIOL-LONDON, V264, P89, DOI 10.1113/jphysiol.1977.sp011659; SAHRMANN SA, 1977, ANN NEUROL, V2, P460, DOI 10.1002/ana.410020604; SANTOS G, 1993, DIS COLON RECTUM, V36, P958, DOI 10.1007/BF02050633; SCHICHOR A, 1994, ARCH PEDIAT ADOL MED, V148, P72, DOI 10.1001/archpedi.1994.02170010074017; SOMMAMAUVAIS H, 1992, REV NEUROL-FRANCE, V148, P708; SOTGIU ML, 1992, SOMATOSENS MOT RES, V9, P227, DOI 10.3109/08990229209144773; SPIRA R, 1971, DEV MED CHILD NEUROL, V13, P164; STAV A, 1993, ACTA ANAESTH SCAND, V37, P562, DOI 10.1111/j.1399-6576.1993.tb03765.x; Sun C F, 1987, Proc Chin Acad Med Sci Peking Union Med Coll, V2, P165; SUN X, 1990, CHUNG HUA LIU HSING, V11, P291; Supe A N, 1994, Indian J Gastroenterol, V13, P1; TABARY JC, 1972, J PHYSIOL-LONDON, V224, P231, DOI 10.1113/jphysiol.1972.sp009891; TARDIEU C, 1979, Journal of the Neurological Sciences, V42, P357, DOI 10.1016/0022-510X(79)90169-2; TARDIEU C, 1988, DEV MED CHILD NEUROL, V30, P3, DOI 10.1111/j.1469-8749.1988.tb04720.x; TARDIEU CATHERINE, 1964, ARCH FRANC PEDIAT, V21, P5; TARDIEU G, 1968, DEV MED CHILD NEUROL, V10, P555; TARDIEU G, 1954, REV NEUROL, V91, P143; TARDIEU G, 1962, B MEM SOC MED HOP P, V113, P7; TARDIEU G, 1964, REV NEUROL, V110, P563; Tekkok IH, 1996, CAN J ANAESTH, V43, P306, DOI 10.1007/BF03011749; TRIGAUX JP, 1992, CARDIOVASC INTER RAD, V15, P180, DOI 10.1007/BF02735584; TRUSCELLI J, COMMUNICATION; VALLBO AB, 1974, ACTA PHYSIOL SCAND, V90, P303, DOI 10.1111/j.1748-1716.1974.tb05593.x; Walthard KM, 1971, ELECTRODIAGNOSIS ELE; WIDERHOLT WC, 1970, NEUROLOGY, V20, P214; WILLIAMS RG, 1980, J PHYSIOL-LONDON, V306, pP26; WILSON LR, 1997, 33 INT C PHYS SCI IU; WONG GY, 1995, REGION ANESTH, V20, P352; WOOD KM, 1978, PAIN, V5, P205, DOI 10.1016/0304-3959(78)90009-X; Yadav S. L., 1994, Indian Journal of Pediatrics, V61, P249, DOI 10.1007/BF02752218; Yamauchi Y, 1993, Masui, V42, P606; Zack SI, 1971, MOTOR ENDPLATE	151	32	33	0	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0148-639X	1097-4598		MUSCLE NERVE	Muscle Nerve		1997				6			S61	S91					31	Clinical Neurology; Neurosciences	Neurosciences & Neurology	YQ157	WOS:000071354200006	9826983				2021-06-18	
J	Witol, AD; Sander, AM; Kreutzer, JS				Witol, AD; Sander, AM; Kreutzer, JS			A longitudinal analysis of family needs following traumatic brain injury	NEUROREHABILITATION			English	Article						family needs; traumatic brain injury	CRITICALLY ILL PATIENTS; HEAD-INJURY; RELATIVES	The present investigation assessed 38 family members' perceptions of unmet, partly met and met needs following the brain injury of a relative. Follow-up data was collected at two time intervals averaging 6 and 24 months post-injury. There was no significant difference between the proportion of needs rated as important or very important at time I or II. Highly ranked needs included requests for information, clear and honest explanations from professionals, reassurance, respite care, educational and social activities for the patient, emotional support, financial counseling, and advice about community resources. Relatives rated nearly half of the 40 needs as not met at either time. A significant difference was noted in the proportion of unmet/partly met needs within each factor scale at time I and II. A larger number of Emotional Support and Involvement with Care needs were reported as not met at time II. Needs for Professional Support were more frequently reported as met at time II. For both time periods, Health information needs were generally perceived as met while needs relating to Instrumental Support were largely unmet. The findings are discussed in light of implications for treatment and long term adjustment to injury related changes.	VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,DIV NEUROL SURG,RICHMOND,VA	Witol, AD (corresponding author), VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA,DEPT PHYS MED & REHABIL,MCV BOX 980542,RICHMOND,VA 23298, USA.						BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Campbell C H, 1988, Rehabil Nurs, V13, P320; CASSEL J, 1974, INT J HEALTH SERV, V4, P471, DOI 10.2190/WF7X-Y1L0-BFKH-9QU2; Engli M, 1993, J Neurosci Nurs, V25, P78; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; Kozloff R, 1987, J HEAD TRAUMA REHAB, V2, P14, DOI DOI 10.1097/00001199-198709000-00004; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; LESKE JS, 1986, HEART LUNG, V15, P189; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; Mathis M, 1984, J Neurosurg Nurs, V16, P36; Mauss-Clum N, 1981, J Neurosurg Nurs, V13, P165; MCCAFFREY RJ, 1987, INT J CLIN NEUROPSYC, V9, P177; MOLTER NC, 1979, HEART LUNG, V8, P332; NORRIS LO, 1986, HEART LUNG, V15, P194; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; SANDER AM, 1996, J INT NEUROPSYCHOL S, V2, P47; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; SERIO CD, 1996, IN PRESS BRAIN INJ; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460	22	32	32	0	3	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	1053-8135			NEUROREHABILITATION	Neurorehabilitation	NOV	1996	7	3					175	187		10.1016/1053-8135(96)00190-4			13	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	VQ826	WOS:A1996VQ82600003	24525887				2021-06-18	
J	Rossi, C; Sullivan, SJ				Rossi, C; Sullivan, SJ			Motor fitness in children and adolescents with traumatic brain injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article							CLOSED HEAD-INJURY; RECOVERY; RELIABILITY	Objective: This study examined the test-retest reliability of selected motor fitness test items among children with severe traumatic brain injury. Design: A cohort study consisting of two testing session, one week apart. Setting: All subjects were recruited from among the former clients of a pediatric rehabilitation center. Subjects: A convenience sample of 19 subjects, 13 boys and 6 girls aged 8 to 17 years, volunteered to participate, All participants had a diagnosis of a severe traumatic brain injury ((X) over bar +/- SD = 5.88 +/- 1.71 on the Glascow Coma Scale), had completed a program of physical rehabilitation. and were evaluated at 4.16 +/- 2.61 years after their injury. Main Outcome Measures: Performance on twelve motor fitness test items (including flexibility, agility, muscular strength. cardiorespiratory endurance, power, muscular endurance. and coordination) was measured at each of two structured evaluation sessions. Results: No differences (t tests, p less than or equal to.05) were found between the performances on the two testing sessions for any of the variables. The test-retest reliability was established via the intraclass correlation (ICC) and ranged from .84 to .98, indicating ''almost perfect'' agreement. Conclusion: The data indicate that these motor fitness testing protocols are reliable and applicable to traumatic brain injured children in a clinical setting and can thus be used by therapists to plan future interventions to improve the fitness of this clientele. (C) 1996 by the American Congress of Rehabilitation Medicine and the American Academy of Physical Medicine and Rehabilitation	CONCORDIA UNIV,DEPT EXERCISE SCI,MONTREAL,PQ,CANADA; UNIV MONTREAL,FAC MED,ECOLE READAPTAT,MONTREAL,PQ H3C 3J7,CANADA; INST READAPTAT MONTREAL,CTR RECH,MONTREAL,PQ,CANADA							*AM ALL HLTH PHYS, 1980, TECHNICAL MANUAL HLT; AYRES AJ, 1976, INTERPRETING SO CALI; BARROW HM, 1989, PRACTICAL MEASUREMEN, P99; BLASKEY J, 1984, PEDIAT NEUROLOGIC PH, P213; Bosco J. S., 1983, MEASUREMENT EVALUATI; BRINK JD, 1970, DEV MED CHILD NEUROL, V12, P565; BRINK JD, 1980, J PEDIATR-US, V97, P721, DOI 10.1016/S0022-3476(80)80253-8; Bruininks R. H., 1978, BRUININKS OSERETSKY; CASEY R, 1986, PEDIATRICS, V78, P497; CHAPLIN D, 1993, ARCH PHYS MED REHAB, V74, P161; Costeff H, 1985, Scand J Rehabil Med Suppl, V12, P10; CURETON TK, 1964, CHILD DEV PUBLICATIO; EIBEN CF, 1984, ARCH PHYS MED REHAB, V65, P168; FLEISHMAN EA, 1964, STRUCTURE MEASUREMEN, P58; GLENCROSS DJ, 1966, RES QUART, V37, P353, DOI 10.1080/10671188.1966.10614761; GRUBER JJ, 1964, TESTS MEASUREMENTS L; HALEY S M, 1991, Physical and Occupational Therapy in Pediatrics, V11, P1; HALEY SM, 1990, J HEAD TRAUMA REHAB, V5, P77; JACKSON AS, 1967, RES QUART, V40, P708; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JAFFE MB, 1985, HEAD INJURY REHABILI, P167; Jennett B, 1981, MANAGEMENT HEAD INJU; JOHNSTON RB, 1980, DEV MED CHILD NEUROL, V22, P3; Kirkendall D., 1987, MEASUREMENT EVALUATI; KRAUS JF, 1987, PEDIATRICS, V79, P501; KRIEL RL, 1988, ARCH PHYS MED REHAB, V69, P678; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LEGER L, 1992, CAN J APPL SPT SCI, V9, P64; LEHMANN JF, 1990, ARCH PHYS MED REHAB, V71, P955; LIU NYS, 1992, RES Q EXERCISE SPORT, V63, P360, DOI 10.1080/02701367.1992.10608757; PATE RR, 1991, J SCHOOL HEALTH, V61, P231, DOI 10.1111/j.1746-1561.1991.tb06021.x; Pate RR, 1983, PHYSICIAN SPORTSMED, V11, P77, DOI DOI 10.1080/00913847.1983.11708509; PERRIN JC, 1985, PEDIAT REHABILITATIO, P254; RUIJS MBM, 1990, CLIN NEUROL NEUROSUR, V92, P323, DOI 10.1016/0303-8467(90)90058-D; SAFRIT MJ, 1981, EVALUATION PHYSICAL; SHICK J, 1970, RES QUART, V41, P88, DOI 10.1080/10671188.1970.10614951; SHROUT PE, 1979, PSYCHOL BULL, V86, P420, DOI 10.1037/0033-2909.86.2.420; SHUMWAYCOOK A, 1992, PHYS MED REHABIL CLI, V3, P355; VITALE AE, IN PRESS BRAIN INJ; WINNICK JP, 1985, PHYSICAL FITNESS TES	41	32	32	0	4	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	OCT	1996	77	10					1062	1065		10.1016/S0003-9993(96)90069-6			4	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	VL132	WOS:A1996VL13200012	8857887				2021-06-18	
J	Swaine, BR; Sullivan, SJ				Swaine, BR; Sullivan, SJ			Longitudinal profile of early motor recovery following severe traumatic brain injury	BRAIN INJURY			English	Article							SEVERE HEAD-INJURY; REHABILITATION; STROKE	A prospective longitudinal design was employed to describe early (first 6 weeks post-injury) motor function recovery in 16 individuals with severe traumatic brain injury (TBI). Reliable, standardized testing and scoring protocols were used by a physical therapist to evaluate subjects on several different aspects of motor function, including primitive reflexes, equilibrium/protective reactions, and a wide range of motor skills. The findings revealed that subjects demonstrated significant changes (chi(2), P less than or equal to 0.05) between 1 and 6 weeks for the following variables: equilibrium reactions in sitting, rolling prone to side-lying, sitting (supported and unsupported), kneeling, standing (assisted and independently), walking (assisted and independently), stair climbing with the use of the handrail and walking 25 m on even ground. A significant change in ability to sit supported between 1 and 3 weeks post-injury was also observed. In addition, recovery was found to be a heterogeneous process, in that different patterns of recovery were evident for the 26 variables and among individual subjects. The clinical implications for physical therapists involved in the rehabilitation of adults with a severe TBI are discussed.	INST READAPTAT MONTREAL, CTR RECH, MONTREAL, PQ H3S 2J4, CANADA; UNIV MONTREAL, FAC MED, ECOLE READAPTAT, MONTREAL, PQ, CANADA; CONCORDIA UNIV, DEPT EXERCISE SCI, MONTREAL, PQ, CANADA							Bayley N., 1969, MANUAL BAYLEY SCALES; Bond M R, 1979, Int Rehabil Med, V1, P155; BOND MR, 1976, SCAND J REHABIL MED, V8, P127; BORN JD, 1985, NEUROSURGERY, V16, P595, DOI 10.1227/00006123-198505000-00002; Braakman R, 1986, Acta Neurochir Suppl (Wien), V36, P112; Brooks V. B., 1986, NEURAL BASIS MOTOR C; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; CARR JH, 1980, PHYSIOTHERAPY DISORD; CASTONGUAY S, 1991, PHYSIOTHERAPY CANA S, V43, P5; COHADON F, 1988, SCAND J REHABIL MED, P75; COHADON F, 1983, NEUROCHIRURGIE, V29, P303; Conover W.J., 1980, PRACTICAL NONPARAMET; DAVIES PM, 1994, STARTING AGAIN; Dombovy M L, 1988, Adv Neurol, V47, P265; FAHY TJ, 1967, LANCET, V2, P475; FINGER S, 1982, BRAIN DAMAGE RECOVER; Fiorentino M, 1973, REFLEX TESTING METHO; Fletcher JM, 1987, NEUROBEHAVIORAL RECO, P279; GOWLAND C, 1982, Physiotherapy Canada, V34, P77; GROSWASSER Z, 1977, SCAND J REHABIL MED, V9, P147; HALEY SM, 1992, PEDIAT PHYS THERAPY, V4, P24; HALL KM, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199502000-00003; Horak FB., 1991, CONT MANAGEMENT MOTO, P11, DOI DOI 10.1016/J.NEUROSCIENCE.2015.04.009; ILLINGWORTH RS, 1975, DEV INFANT YONG CHIL; JACKSON JH, 1932, SELECTED WRITINGS JB, V2; JACKSON JH, 1932, SELECTED WRITINGS JB, V1; JENNETT B, 1976, LANCET, V1, P1031; JENNETT B, 1984, CLOSED HEAD INJURY, P38; Knobloch H, 1974, GESELL AMATRUDAS DEV; KOTTKE FJ, 1990, KRUSENS HDB PHYSICAL, P234; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MACKAY LE, 1992, ARCH PHYS MED REHAB, V73, P635; MacPherson Valerie, 1992, Brain Injury, V6, P489, DOI 10.3109/02699059209008146; MCCARTHY GT, 1986, CASHS TXB NEUROLOGY, P39; MILLS VM, 1988, PHYSICAL REHABILITAT, P495; MINDERHOUD JM, 1982, CLIN NEUROL NEUROSUR, V84, P15, DOI 10.1016/0303-8467(82)90106-8; MOORE J, 1980, RECOVERY FUNCTION TH, P9; NAJENSON T, 1975, SCAND J REHABIL MED, V7, P101; NAJENSON T, 1974, SCAND J REHABIL MED, V6, P5; PANIKOFF LB, 1983, AM J OCCUP THER, V37, P735, DOI 10.5014/ajot.37.11.735; Partridge C J, 1992, Int J Technol Assess Health Care, V8, P55; PARTRIDGE CJ, 1987, LANCET, V1, P373; Povlishock John T., 1993, P185; POWELL GE, 1994, CLIN REHABIL, V8, P54; Sherrington C, 1906, INTEGRATIVE ACTION N; SMITH LM, 1985, NEURAL GRAFTING MAMM, P249; SULLIVAN S J, 1991, Society for Neuroscience Abstracts, V17, P167; SULLIVAN SJ, 1990, BILAN EVOLUTION MOTR; SWAINE BR, 1994, BRAIN INJURY, V8, P323, DOI 10.3109/02699059409150983; Swaine BR, 1996, BRAIN INJURY, V10, P263, DOI 10.1080/026990596124449; TALMAGE EW, 1983, PHYS THER, V63, P2010, DOI 10.1093/ptj/63.12.2010; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TOBIS JS, 1982, SCAND J REHABIL MED, V14, P83; TROMBLY CS, 1989, OCCUPATIONAL THERAPY, P55; TUEL S M, 1992, Brain Injury, V6, P363, DOI 10.3109/02699059209034951; WADE DT, 1987, SCAND J REHABIL MED, V19, P25; WADE DT, 1987, J NEUROL NEUROSUR PS, V50, P177, DOI 10.1136/jnnp.50.2.177; WEINTRAUB AH, 1989, PHYSICAL MED REHABIL, V3, P59; WONG PP, 1994, BRAIN INJURY, V8, P509, DOI 10.3109/02699059409151003	59	32	32	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAY	1996	10	5					347	366		10.1080/026990596124368			20	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UL742	WOS:A1996UL74200003	8735665				2021-06-18	
J	Kant, R; SmithSeemiller, L; Duffy, JD				Kant, R; SmithSeemiller, L; Duffy, JD			Obsessive-compulsive disorder after closed head injury: Review of literature and report of four cases	BRAIN INJURY			English	Article							BEHAVIOR; SYMPTOMS	An increasing number of recent reports has pointed to the underlying neuropathological substrate for obsessive-compulsive disorder (OCD). Neuropsychological testing may suggest underlying organicity even though the neuroimaging studies and the neurological examination may be normal. Earlier reports are not in agreement about the laterality of deficits. Abnormalities in frontal regions, limbic areas and basal ganglia are noted in functional neuroimaging and neuropsychological studies. In closed head injury the damage tends to be diffuse, and it is not easy to clearly localize deficits or to determine their laterality. In this paper we review the various theories and literature on OCD and organicity, and report on four individuals who developed OCD symptoms after closed head injury. We also discuss their neuroimaging and neuropsychological testing results.	HAHNEMANN UNIV,ALLEGHENY GEN HOSP,PITTSBURGH,PA	Kant, R (corresponding author), MED COLL PENN,DEPT PSYCHIAT,ALLEGHENY CAMPUS,320 E NORTH AVE,PITTSBURGH,PA 15212, USA.		Kant, Ravi/F-7025-2013	Kant, Ravi/0000-0003-3878-9775			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BAXTER LR, 1992, ARCH GEN PSYCHIAT, V49, P681; BAXTER LR, 1987, ARCH GEN PSYCHIAT, V44, P211; BEHAR D, 1984, AM J PSYCHIAT, V141, P363; BOONE KB, 1991, NEUROPSY NEUROPSY BE, V4, P96; Brickner RM, 1940, PSYCHOSOM MED, V2, P369, DOI 10.1097/00006842-194010000-00002; CAMBIER J, 1988, REV NEUROL, V144, P158; DRUMMOND LM, 1988, BRIT J PSYCHIAT, V153, P839, DOI 10.1192/bjp.153.6.839; Epstein Richard S., 1994, P285; FLORHENRY P, 1979, BIOL PSYCHIAT, V14, P119; Freud Sigmund, 1959, COLLECTED PAPERS; GEORGE MS, 1989, J NERV MENT DIS, V177, P304, DOI 10.1097/00005053-198905000-00010; Hamilton M, 1989, COMPREHENSIVE TXB PS, P892; HILLBOM E, 1960, Acta Psychiatr Scand Suppl, V35, P1; HOLLANDER E, 1989, PSYCHIATRIC DEV, V4, P267; INSEL TR, 1992, INT CLIN PSYCHOPHARM, V7, P31, DOI 10.1097/00004850-199206001-00008; INSEL TR, 1983, BIOL PSYCHIAT, V18, P741; Jelliffe SE, 1929, ARCH NEURO PSYCHIATR, V21, P491, DOI 10.1001/archneurpsyc.1929.02210210017002; JENIKE MA, 1986, OBSESSIVE COMPULSIVE, P171; Khanna S, 1985, Indian J Psychiatry, V27, P337; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MALLOY P, FRONTAL LOBE REVISIT, P207; MATTSON AJ, 1990, J NERV MENT DIS, V178, P282, DOI 10.1097/00005053-199005000-00002; MCKEON J, 1984, BRIT J PSYCHIAT, V144, P190, DOI 10.1192/bjp.144.2.190; MONTGOMERY S A, 1991, Journal of Psychiatry and Neuroscience, V16, P30; NEMIAH JC, 1989, COMPREHENSIVE TXB PS, P984; PRITCHARD PB, 1983, NEUROPSYCHOLOGY HUMA, P165; RASMUSSEN SA, 1984, J CLIN PSYCHIAT, V45, P450; ROBINS LN, 1984, ARCH GEN PSYCHIAT, V41, P949; Schilder P, 1938, AM J PSYCHIAT, V94, P1397, DOI 10.1176/ajp.94.6.1397; SCHNEIDER JS, 1984, BIOL PSYCHIAT, V19, P1693; SCHWAB RS, 1951, AM J PSYCHIAT, V107, P901, DOI 10.1176/ajp.107.12.901; SEIBYL JP, 1989, NEUROPSY NEUROPSY BE, V1, P295; SWEDO SE, 1989, ARCH GEN PSYCHIAT, V46, P518; SWEDO SE, 1989, AM J PSYCHIAT, V146, P246; TURNER SM, 1985, PSYCHOL BULL, V97, P430, DOI 10.1037/0033-2909.97.3.430; Zielinski CM, 1991, **DROPPED REF**, V4, P110	37	32	33	0	6	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	JAN	1996	10	1					55	63					9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	TY049	WOS:A1996TY04900006	8680393				2021-06-18	
J	Reiter, F; Danni, M; Ceravolo, MG; Provinciali, L				Reiter, F; Danni, M; Ceravolo, MG; Provinciali, L			Disability changes after treatment of upper limb spasticity with botulinum toxin	JOURNAL OF NEUROLOGIC REHABILITATION			English	Article						spasticity; botulinum toxin; assessment; disability	RELIABILITY; STROKE	We performed an open label single blind trial with seventeen patients with moderate to severe upper limb spasticity following stroke or traumatic brain injury, treated with an average dose of 165 MU (mouse units) botulinum toxin (range: 100 MU to 210 MU). Evaluation of outcome was carried out analyzing the changes in standard measures of impairment, disability, and quality of life. Spasticity reduction, with increased range of motion (ROM), was observed in all patients, independent of the duration of spasticity. Changes either in ''focal'' or in ''global'' disability scores occurred in two subgroups of subjects showing, respectively, residual motor function of the extensor muscles or severe spasticity-related disability. Patients with no residual motricity of the antagonist muscles at the spastic limb, with moderate spasticity, scoring high values on the Functional Independence Measure (FIM) assessment, did not show any disability decrease after treatment. These findings stress the need for an accurate assessment of the patient's impairment and disability to optimize the cost/benefit ratio of BTX application.	UNIV ANCONA,DEPT NEUROREHABIL,ANCONA,ITALY							Benecke R, 1994, THERAPY BOTULINUM TO, P557; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; COLLIN C, 1990, J NEUROL NEUROSUR PS, V53, P576, DOI 10.1136/jnnp.53.7.576; Daniels L, 1986, MUSCLE TESTING TECHN; DAS TK, 1989, BRIT J CLIN PRACT, V43, P401; DENGLER R, 1992, J NEUROL, V239, P375; DUNNE JW, 1995, J NEUROL NEUROSUR PS, V58, P232, DOI 10.1136/jnnp.58.2.232; EBRAHIM S, 1985, J EPIDEMIOL COMMUN H, V39, P86, DOI 10.1136/jech.39.1.86; Granger CV, 1986, GUIDE USE UNIFORM DA; GRAZKO MA, 1995, NEUROLOGY, V45, P712, DOI 10.1212/WNL.45.4.712; HESSE S, 1994, J NEUROL NEUROSUR PS, V57, P1321, DOI 10.1136/jnnp.57.11.1321; Hesse S, 1992, J REHABIL SCI, V5, P98; HUNT SM, 1980, J EPIDEMIOL COMMUN H, V34, P281, DOI 10.1136/jech.34.4.281; SNOW BJ, 1990, ANN NEUROL, V28, P512, DOI 10.1002/ana.410280407; TSUI JKC, 1994, THERAPY BOTULINUM TO, P523; WADE DT, 1983, J NEUROL NEUROSUR PS, V46, P521, DOI 10.1136/jnnp.46.6.521; Wade DT, 1992, MEASUREMENT NEUROLOG; World Health Organization, INT CLASS IMP DIS HA	18	32	32	0	0	DEMOS PUBLICATIONS	NEW YORK	386 PARK AVE S STE 201, NEW YORK, NY 10016-8804	0888-4390			J NEUROL REHABIL	J. Neurol. Rehabil.		1996	10	1					47	52					6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	WQ023	WOS:A1996WQ02300008					2021-06-18	
J	Delahunty, TM; Jiang, JY; Gong, QZ; Black, RT; Lyeth, BG				Delahunty, TM; Jiang, JY; Gong, QZ; Black, RT; Lyeth, BG			Differential consequences of lateral and central fluid percussion brain injury on receptor coupling in rat hippocampus	JOURNAL OF NEUROTRAUMA			English	Article						brain trauma; fluid percussion; hippocampus; muscarinic receptor; metabotropic	PROTEIN-KINASE-C; LONG-TERM POTENTIATION; EXCITATORY AMINO-ACIDS; METABOTROPIC GLUTAMATE RECEPTORS; INOSITOL PHOSPHOLIPID HYDROLYSIS; VASCULAR DISRUPTION; FOREBRAIN ISCHEMIA; MEMORY IMPAIRMENT; KINDLED RATS; HEAD-INJURY	We have identified alterations in the responses of muscarinic and metabotropic receptors in rat hippocampus that persist for at least 15 days after central fluid percussion injury, This study compares the effect of lateral fluid percussion and central fluid percussion on these responses, Moderate injury was obtained by displacement and deformation of the brain within the closed cranial cavity using a fluid percussion device positioned either centrally or laterally, Carbachol and (+/-)-1-aminocyclopentane-trans-1,3-dicarboxylic acid (trans-ACPD)-stimulated polyphosphoinositide (PPI) hydrolysis was assayed in hippocampus from injured and sham-injured controls at 15 days following injury, At 15 days after central fluid percussion traumatic brain injury (TBI), the response to carbachol was enhanced by 30% and the response to trans-ACPD was enhanced by 75% compared to sham-injured animals, At 15 days after lateral fluid percussion TBI the response to trans-ACPD was enhanced by 40% both ipsilateral and contralateral to the side of injury, In contrast, the response to carbachol was enhanced by 29% contralateral to the side of injury but was diminished by 12% ipsilateral to the side of injury, Cresyl violet staining shows no hippocampal cell death after central fluid percussion injury or on the side contralateral to lateral fluid percussion injury but on the ipsilateral side cell death was identified in hippocampal area CA3, Thus, abnormal hippocampal cell signaling through the phosphoinositide pathway occurs in the absence of cell death and may contribute to cognitive impairment.		Delahunty, TM (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,BOX 980693,MCV STN,RICHMOND,VA 23298, USA.			Lyeth, Bruce/0000-0003-4811-1474	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS012587, P50NS012587, R01NS029995] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 12587, NS 29995, NS 07288] Funding Source: Medline		AKIYAMA K, 1992, BRAIN RES, V569, P71, DOI 10.1016/0006-8993(92)90370-O; ARONICA E, 1991, J NEUROCHEM, V57, P376, DOI 10.1111/j.1471-4159.1991.tb03763.x; AUER RN, 1988, ANN NEUROL, V24, P699, DOI 10.1002/ana.410240602; BAUER A, 1992, NEUROSCIENCE, V47, P95, DOI 10.1016/0306-4522(92)90124-K; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BEVILACQUA JA, 1994, NEUROSCIENCE, V60, P945, DOI 10.1016/0306-4522(94)90274-7; Bruton CJ, 1988, NEUROPATHOLOGY TEMPO; BULLOCK MR, 1992, J NEUROTRAUM, V9, pS443; CHEN CK, 1988, J NEUROCHEM, V51, P353, DOI 10.1111/j.1471-4159.1988.tb01046.x; CHEN L, 1992, NATURE, V356, P521, DOI 10.1038/356521a0; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; DELACALLE S, 1994, J COMP NEUROL, V345, P321, DOI 10.1002/cne.903450302; DELAHUNTY TM, 1988, BIOCHEM J, V255, P69, DOI 10.1042/bj2550069; DELAHUNTY TM, 1992, BRAIN RES, V594, P307, DOI 10.1016/0006-8993(92)91140-A; DELAHUNTY TM, 1995, NEUROCHEM RES, V20, P335; DIAMANT S, 1990, NEUROSCI LETT, V109, P140, DOI 10.1016/0304-3940(90)90552-K; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; DISON CE, 1993, J NEUROTRAUM, V10, pS209; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1992, ROLE OF NEUROTRANSMITTERS IN BRAIN INJURY, P213; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAROOQUI AA, 1991, BRAIN RES REV, V16, P171, DOI 10.1016/0165-0173(91)90004-R; FISHER SK, 1992, J NEUROCHEM, V58, P18, DOI 10.1111/j.1471-4159.1992.tb09273.x; FOTUHI M, 1993, J NEUROSCI, V13, P2001; GENARELLI TA, 1994, J NEUROTRAUM, V11, P357; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; GORMAN LK, 1994, SOC NEUR ABSTR, P195; HAMM RJ, 1992, NEUROSURGERY, V31, P1072, DOI 10.1227/00006123-199212000-00013; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; Jenkins LW, 1988, J NEUROTRAUM, V5, P275, DOI 10.1089/neu.1988.5.275; JIANG JY, 1994, BRAIN RES, V651, P123, DOI 10.1016/0006-8993(94)90687-4; JIANG JY, 1992, ACTA NEUROPATHOL, V84, P495, DOI 10.1007/BF00304468; JOPE RS, 1986, EXP NEUROL, V91, P471, DOI 10.1016/0014-4886(86)90045-2; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KELSO SR, 1992, J PHYSIOL-LONDON, V449, P705, DOI 10.1113/jphysiol.1992.sp019110; Kotapka MJ, 1991, J NEUROTRAUM, V8, P247, DOI 10.1089/neu.1991.8.247; LEONARD JR, 1994, J NEUROTRAUM, V11, P379, DOI 10.1089/neu.1994.11.379; LIPARTITI M, 1993, LIFE SCI, V52, P85; LITTMAN L, 1993, J NEUROCHEM, V61, P586; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; LYETH BG, 1994, BRAIN RES, V640, P240, DOI 10.1016/0006-8993(94)91879-1; LYETH BG, 1993, MOL CHEM NEUROPATHOL, V18, P247, DOI 10.1007/BF03160117; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; LYETH BG, 1992, J NEUROTRAUMA S2, V9, P463; MARKRAM H, 1992, J PHYSIOL-LONDON, V457, P491, DOI 10.1113/jphysiol.1992.sp019389; MARTIN D, 1992, J NEUROSCI, V12, P1928; MCDONALD JW, 1992, EUR J PHARMACOL, V215, P353, DOI 10.1016/0014-2999(92)90058-C; MCINTOSH TK, 1993, J NEUROTRAUM, V10, P215, DOI 10.1089/neu.1993.10.215; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Meldrum B S, 1986, Adv Neurol, V44, P849; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; NICOLETTI F, 1988, J NEUROCHEM, V51, P725, DOI 10.1111/j.1471-4159.1988.tb01804.x; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; PALMER AM, 1994, NEUROREPORT, V6, P153, DOI 10.1097/00001756-199412300-00039; PIREDDA S, 1985, NATURE, V317, P623, DOI 10.1038/317623a0; POVLISHOCK JT, 1979, ACTA NEUROPATHOL, V47, P1, DOI 10.1007/BF00698266; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; PRASAD MR, 1994, J NEUROCHEM, V63, P773; PULSINELLI WA, 1982, ANN NEUROL, V11, P491, DOI 10.1002/ana.410110509; REEVES TM, 1995, EXP BRAIN RES, V106, P248; ROBINSON SE, 1990, BRAIN RES, V509, P41, DOI 10.1016/0006-8993(90)90306-V; SASS KJ, 1990, NEUROLOGY, V40, P1694, DOI 10.1212/WNL.40.11.1694; SAVOLAINEN K, 1994, NEUROTOXICOLOGY, V15, P493; SCHMIDT RH, 1993, J NEUROTRAUM, V10, P415, DOI 10.1089/neu.1993.10.415; SEREN MS, 1989, J NEUROCHEM, V53, P1700, DOI 10.1111/j.1471-4159.1989.tb09233.x; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; SHIMA K, 1991, J NEUROSURG, V74, P270, DOI 10.3171/jns.1991.74.2.0270; SLOVITER RS, 1992, NEUROSCI LETT, V137, P91, DOI 10.1016/0304-3940(92)90306-R; SMITH DH, 1993, J NEUROSCI, V13, P5383; SMITH ML, 1984, ACTA NEUROPATHOL, V64, P319, DOI 10.1007/BF00690397; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; TIGER G, 1990, NEUROSCI LETT, V115, P243, DOI 10.1016/0304-3940(90)90462-I; VILARO MT, 1993, HIPPOCAMPUS, V3, P149; YANG KY, 1994, J NEUROTRAUM, V11, P523, DOI 10.1089/neu.1994.11.523; YANG KY, 1993, J NEUROTRAUM, V10, P287, DOI 10.1089/neu.1993.10.287; ZHANG WQ, 1990, NEUROSCI LETT, V118, P57, DOI 10.1016/0304-3940(90)90248-8	82	32	32	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	1995	12	6					1045	1057		10.1089/neu.1995.12.1045			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	TU518	WOS:A1995TU51800005	8742133				2021-06-18	
J	CAMPBELL, TF; DOLLAGHAN, CA				CAMPBELL, TF; DOLLAGHAN, CA			SPEAKING RATE, ARTICULATORY SPEED, AND LINGUISTIC PROCESSING IN CHILDREN AND ADOLESCENTS WITH SEVERE TRAUMATIC BRAIN INJURY	JOURNAL OF SPEECH AND HEARING RESEARCH			English	Article						TRAUMATIC BRAIN INJURY; SPEAKING RATE; ARTICULATORY SPEED; LINGUISTIC PROCESSING; CHILDREN AND ADOLESCENTS	CLOSED-HEAD-INJURY; PERFORMANCE; CHILDHOOD; DISCOURSE	Two studies were conducted to examine speaking rate following traumatic brain injury (TBI) in childhood and adolescence. Study 1 focused on longitudinal changes in speaking rate in 9 subjects with severe TBI and their age-matched control subjects. Physical measurements of speaking rate (in syllables/sec) were made from spontaneous speech samples obtained from each subject during three sampling sessions over a 13-month period. Although the average speaking rate of the group with TBI was slower than that of the control group at all three sampling sessions, an examination of the data from individual subject pairs revealed markedly slower speaking rates in only 5 of the 9 subjects with TBI at the final sampling session. The perceptual significance of slowed speaking rates in these 5 subjects was confirmed through subjective ratings by naive listeners. In Study 2, the contributions of two potential causes of slowed speaking rats were explored: reduced-articulatory speed, and increased pausing believed to be associated With linguistic. processing difficulties. It is hypothesized that articulatory speed and linguistic processing speed may contribute independently to slowed	UNIV PITTSBURGH,PITTSBURGH,PA	CAMPBELL, TF (corresponding author), CHILDRENS HOSP PITTSBURGH,DEPT AUDIOL & COMMUN DISORDERS,3705 5TH AVE,PITTSBURGH,PA 15213, USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R03DC001328] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [DC 01328] Funding Source: Medline		Bagnato SJ, 1986, DEV NEUROPSYCHOL, V2, P213, DOI 10.1080/87565648609540343; BAWDEN HN, 1985, J CLIN EXP NEUROPSYC, V7, P39, DOI 10.1080/01688638508401241; Bernthal J., 1994, CHILD PHONOLOGY CHAR, P140; CAMPBELL TF, 1990, J SPEECH HEAR DISORD, V55, P567, DOI 10.1044/jshd.5503.567; CHADWICK O, 1981, J CHILD PSYCHOL PSYC, V22, P117, DOI 10.1111/j.1469-7610.1981.tb00538.x; CHAPMAN SB, 1992, BRAIN LANG, V43, P42, DOI 10.1016/0093-934X(92)90020-F; COOK M, 1974, LANG SPEECH, V17, P11, DOI 10.1177/002383097401700102; Crystal D, 1982, PROFILING LINGUISTIC; Darley F., 1975, MOTOR SPEECH DISORDE; DENNIS M, 1990, BRAIN LANG, V39, P428, DOI 10.1016/0093-934X(90)90149-B; DOLLAGHAN CA, 1990, J SPEECH HEAR DISORD, V55, P582, DOI 10.1044/jshd.5503.582; DOLLAGHAN CA, 1992, TOP LANG DISORD, V12, P56, DOI 10.1097/00011363-199202000-00007; Dunn L., 1981, PEABODY PICTURE VOCA; Ewing-Cobbs L, 1990, TRAUMATIC BRAIN INJU, P107; EWINGCOBBS L, 1987, J CLIN EXP NEUROPSYC, V9, P575, DOI 10.1080/01688638708410770; Goldman-Eisler F, 1954, BRIT J PSYCHOL, V45, P94, DOI 10.1111/j.2044-8295.1954.tb01232.x; Jordan F M, 1988, Brain Inj, V2, P179, DOI 10.3109/02699058809150943; JORDAN FM, 1991, J SPEECH HEAR RES, V34, P572, DOI 10.1044/jshr.3403.572; Kent R.D., 1987, PHONETIC APPROACHES, P181; KENT RD, 1980, J PHONETICS, V8, P157, DOI 10.1016/S0095-4470(19)31460-3; LOBAN W, 1976, LANGUAGE DEV; Marascuilo LA., 1977, NONPARAMETRIC DISTRI; Milenkovic P., 1988, CSPEECH; Miller J. F., 1981, ASSESSING LANGUAGE P; Rutter M, 1983, DEV NEUROPSYCHIATRY, P83; SCHIAVETTI N, 1981, J SPEECH HEAR RES, V24, P441, DOI 10.1044/jshr.2403.441; Shriberg L, 1990, PROSODY VOICE SCREEN; SHRIBERG LD, 1982, J SPEECH HEAR DISORD, V47, P256, DOI 10.1044/jshd.4703.256; SMITH BL, 1983, J ACOUST SOC AM, V74, P744, DOI 10.1121/1.389860; Stevens S. S., 1975, PSYCHOPHYSICS; TEASDALE G, 1974, LANCET, V2, P81; TURNER GS, 1993, J SPEECH HEAR RES, V36, P1134, DOI 10.1044/jshr.3606.1134; WALKER JF, 1992, J SPEECH HEAR RES, V35, P4, DOI 10.1044/jshr.3501.04; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; 1975, ASHA, V17, P94	35	32	32	0	9	AMER SPEECH-LANG-HEARING ASSN	ROCKVILLE	10801 ROCKVILLE PIKE RD, ROCKVILLE, MD 20852-3279	0022-4685			J SPEECH HEAR RES	J. Speech Hear. Res.	AUG	1995	38	4					864	875		10.1044/jshr.3804.864			12	Language & Linguistics; Rehabilitation	Linguistics; Rehabilitation	RM866	WOS:A1995RM86600012	7474979				2021-06-18	
J	YAMAKAMI, I; VINK, R; FADEN, AI; GENNARELLI, TA; LENKINSKI, R; MCINTOSH, TK				YAMAKAMI, I; VINK, R; FADEN, AI; GENNARELLI, TA; LENKINSKI, R; MCINTOSH, TK			EFFECTS OF ACUTE ETHANOL INTOXICATION ON EXPERIMENTAL BRAIN INJURY IN THE RAT - NEUROBEHAVIORAL AND P-31 NUCLEAR-MAGNETIC-RESONANCE SPECTROSCOPY STUDIES	JOURNAL OF NEUROSURGERY			English	Article						BRAIN INJURY; ETHANOL; ACUTE ETHANOL INTOXICATION; BIOENERGETICS; RAT	FLUID-PERCUSSION MODEL; D-ASPARTATE RECEPTORS; MISSILE HEAD-INJURY; CEREBRAL BLOOD-FLOW; ENDOGENOUS OPIOIDS; INTRACELLULAR PH; AMINO-ACIDS; P-31 NMR; DAMAGE; TRAUMA	Using the lateral fluid-percussion model of experimental brain injury in the rat, the authors investigated the effect of acute ethanol (EtOH) intoxication on cardiovascular changes, neurological motor deficits, brain bioenergetics, and mortality associated with traumatic brain injury. Two hours after gastric administration of EtOH (low dose in 20 animals, 1.5 g/kg; high dose in 28, 3.0 g/kg) or saline (equal volume), animals were subjected to a fluid-percussion brain injury centered over the left parietal cortex. These injuries were of either moderate (X = 2.2 atm; 10 animals/treatment) or high severity (($) over bar X = 3.0 arm; 18 animals/saline, 10 animals/low-dose EtOH, and 18 animals/high-dose EtOH). Neurological motor function was evaluated daily over a 1-week period, while a subset of eight animals receiving high-dose EtOH and subjected to brain injury of high severity were monitored for 4 hours using phosphorus-31 nuclear magnetic resonance spectroscopy to determine intracellular pH, free magnesium, and brain cytosolic phosphorylation potential. A significant (p < 0.05) and prolonged (up to 1 hour) hypotension was observed in animals pretreated with either low- or high-dose EtOH. Neither low-dose (blood-EtOH concentration = 110 +/- 40 mg/dl) nor high-dose (blood-EtOH = 340 +/- 70 mg/dl) EtOH had any effect on survival or neurological motor function after moderate brain injury. Following severe brain injury, animals pretreated with high-dose (blood-EtOH concentration = 352 +/- 65 mg/dl) EtOH showed a significantly increased mortality and markedly worsened neurological deficits at 24 hours postinjury. Following injury, free magnesium and cytosolic phosphorylation potential declined in both groups by approximately 50% to 60%, with no significant differences between groups with respect to these variables. In contrast, brain intracellular pH in the EtOH-treated animals was consistently higher than in the control group after injury. These data suggest that prior exposure to EtOH, particularly at high concentrations, may have detrimental effects on neurobehavioral function and survival in the acute period (up to 24 hours) after severe brain injury, and may be associated with posttraumatic cerebral alkalosis.	UNIV PENN,DEPT NEUROSURG,DIV NEUROSURG,PHILADELPHIA,PA 19104; UNIV PENN,DEPT RADIOL,PHILADELPHIA,PA 19104; CHIBA UNIV,DEPT NEUROSURG,CHIBA,JAPAN; JAMES COOK UNIV N QUEENSLAND,DEPT CHEM & BIOCHEM,TOWNSVILLE,QLD 4811,AUSTRALIA; GEORGETOWN UNIV,SCH MED,WASHINGTON,DC			Lenkinski, Robert/F-9045-2014; Vink, Robert/J-7351-2012; AM, Robert Vink/S-5616-2019	Vink, Robert/0000-0002-4885-0667; AM, Robert Vink/0000-0002-4885-0667; Lenkinski, Robert/0000-0001-7371-5048	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS26818] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818, R55NS026818] Funding Source: NIH RePORTER		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; ALBIN MS, 1986, CRIT CARE MED, V14, P841, DOI 10.1097/00003246-198610000-00001; ALTURA BM, 1983, SCIENCE, V220, P331, DOI 10.1126/science.6836278; ALTURA BM, 1987, ALCOHOL CLIN EXP RES, V11, P99, DOI 10.1111/j.1530-0277.1987.tb01272.x; BLACHLEY JD, 1985, AM J MED SCI, V289, P22, DOI 10.1097/00000441-198501000-00004; BOCK JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P8, DOI 10.1016/0167-4889(87)90079-6; BONNICHSEN RK, 1951, SCAND J CLIN LAB INV, V3, P58, DOI 10.3109/00365515109060572; BRODNER RA, 1981, J TRAUMA, V21, P124, DOI 10.1097/00005373-198102000-00005; CHANDLER LJ, 1993, ALCOHOL CLIN EXP RES, V17, P54, DOI 10.1111/j.1530-0277.1993.tb00726.x; DeCrescito V, 1974, Surg Forum, V25, P438; DIETRICH RA, 1989, PHARMACOL REV, V41, P489; DILDY JE, 1989, BRAIN RES, V499, P383, DOI 10.1016/0006-8993(89)90789-0; DIXON CE, 1987, J NEUROSURG, V6, P110; FADEN AI, 1981, ANN NEUROL, V10, P326, DOI 10.1002/ana.410100403; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FADEN AI, 1986, ARCH NEUROL-CHICAGO, V43, P501, DOI 10.1001/archneur.1986.00520050073026; FLAMM ES, 1977, J NEUROSURG, V46, P328, DOI 10.3171/jns.1977.46.3.0328; FLINK EB, 1953, J CLIN INVEST, V32, P568; GARFINKEL L, 1984, BIOCHEMISTRY-US, V23, P3547, DOI 10.1021/bi00310a025; GONZALEZMENDEZ R, 1984, J MAGN RESON, V57, P526, DOI 10.1016/0022-2364(84)90270-1; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; GUPTA RK, 1983, BIOCHEM BIOPH RES CO, V117, P210, DOI 10.1016/0006-291X(83)91562-0; HADFIELD JM, 1983, J TRAUMA, V23, P518, DOI 10.1097/00005373-198306000-00013; HAUT MJ, 1974, AM J MED, V56, P22, DOI 10.1016/0002-9343(74)90747-5; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HAYES RL, 1983, J NEUROSURG, V58, P720, DOI 10.3171/jns.1983.58.5.0720; HOFFMAN PL, 1989, J NEUROCHEM, V52, P1937, DOI 10.1111/j.1471-4159.1989.tb07280.x; HUBSCHMANN OR, 1985, J NEUROSURG, V62, P698, DOI 10.3171/jns.1985.62.5.0698; HUTH JF, 1983, J TRAUMA, V23, P494, DOI 10.1097/00005373-198306000-00009; IKEDA Y, 1990, NEUROSURGERY, V27, P1; JENKINS LW, 1988, J NEUROTRAUM, V5, P303; JOHNSON DA, 1979, MOL PHARMACOL, V15, P739; JORGENSEN MB, 1982, ACTA NEUROL SCAND, V66, P536; KALBFLEISCH JM, 1963, J CLIN INVEST, V42, P1471, DOI 10.1172/JCI104831; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; LANGFITT TW, 1982, CLIN NEUR, V29, P353; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; LUCCHI L, 1984, BRAIN RES, V293, P368, DOI 10.1016/0006-8993(84)91245-9; LUNA GK, 1984, J TRAUMA, V24, P695, DOI 10.1097/00005373-198408000-00001; MCCOLLISTER R, 1958, J LAB CLIN MED, V52, P928; MCINTOSH TK, 1987, AM J PHYSIOL, V253, pE565; MCINTOSH TK, 1987, BRAIN RES, V425, P225, DOI 10.1016/0006-8993(87)90505-1; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; MENDELSON JH, 1969, ANN NY ACAD SCI, V162, P918, DOI 10.1111/j.1749-6632.1969.tb13021.x; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; MOORE JW, 1964, J GEN PHYSIOL, V48, P279, DOI 10.1085/jgp.48.2.279; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; PERSSON L, 1977, ACTA NEUROL SCAND, V56, P7; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; RAO PA, 1985, NEUROCHEM RES, V10, P1577, DOI 10.1007/BF00988600; Ridella S A, 1986, Cent Nerv Syst Trauma, V3, P195; RITCHIE JM, 1985, GOODMAN GILMANS PHAR, P372; RIX KJB, 1977, ALCOHOL ALCOHOLISM; ROOS A, 1981, PHYSIOL REV, V61, P296; ROSNER MJ, 1984, J NEUROSURG, V60, P961, DOI 10.3171/jns.1984.60.5.0961; ROSSNER W, 1971, Zentralblatt fuer Veterinaermedizin Reihe A, V18, P139; ROTHMAN SM, 1983, SCIENCE, V220, P536, DOI 10.1126/science.6836300; RUBIN E, 1983, PHARMACOL BIOCHEM BE, V18, P7, DOI 10.1016/0091-3057(83)90139-9; SIESJO BK, 1981, J CEREBR BLOOD F MET, V1, P155, DOI 10.1038/jcbfm.1981.18; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; STEWART PA, 1988, BRAIN RES, V443, P12, DOI 10.1016/0006-8993(88)91593-4; STRANDGAARD S, 1984, STROKE, V15, P413, DOI 10.1161/01.STR.15.3.413; STRUBELT O, 1974, ARCH TOXICOL, V32, P83, DOI 10.1007/BF00316229; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1988, MAGNET RESON MED, V6, P37, DOI 10.1002/mrm.1910060105; VINK R, 1990, MAGNESIUM EXCITABLE, P125; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; WARD RE, 1982, AM J SURG, V144, P153, DOI 10.1016/0002-9610(82)90617-1; WOODWARD JJ, 1990, J NEUROCHEM, V54, P712, DOI 10.1111/j.1471-4159.1990.tb01931.x; YAMAKAMI I, 1991, J CEREBR BLOOD F MET, V11, P655, DOI 10.1038/jcbfm.1991.117; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16	76	32	35	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	1995	82	5					813	821		10.3171/jns.1995.82.5.0813			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	QU325	WOS:A1995QU32500015	7714607				2021-06-18	
J	SHAPIRA, Y; ARTRU, AA; QASSAM, N; NAVOT, N; VALD, U				SHAPIRA, Y; ARTRU, AA; QASSAM, N; NAVOT, N; VALD, U			BRAIN EDEMA AND NEUROLOGIC STATUS WITH RAPID INFUSION OF 0.9-PERCENT SALINE OR 5-PERCENT DEXTROSE AFTER HEAD TRAUMA	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						BLOOD, GLUCOSE; BRAIN, EDEMA, HEAD INJURY; FLUID BALANCE, CRYSTALLOID, OSMOLALITY	CEREBRAL-ISCHEMIA; PLASMA OSMOLALITY; HEMORRHAGIC-SHOCK; COLLOID SOLUTIONS; ONCOTIC PRESSURE; CARDIAC-ARREST; WATER-CONTENT; INJURY; RATS; RESUSCITATION	We previously reported that intravenous (i.v.) administration of large volumes (0.2 ml/g) of either an isotonic dextrose-free solution or 5% dextrose solution given over 18 h after closed head trauma (CHT) in rats did not significantly affect neurological severity score or brain tissue specific gravity. However, it is possible that with more rapid administration, isotonic or 5% dextrose i.v. solutions may alter neurological outcome after CHT. Our study examined whether neurological severity score, brain tissue specific gravity and water content, and blood composition were significantly altered when 0.25 ml/g of either 0.9% saline or 5% dextrose was given i.v. over 0.5 h (rather than over 18 h) after CHT. Eighty-four rats that survived ether anesthesia and CHT were randomly assigned to one of 11 experimental groups. Saline- and dextrose-treated rats were evaluated at 4 and 48 h after CHT and were compared to rats without CHT and to untreated rats at 4 and 48 h after CHT. There were no statistically significant differences in neurologic outcome and brain edema between the untreated and the saline-treated groups. However, 5% dextrose i.v. increased mortality (group 6 and 11, 50 and 0% survivors, respectively), decreased specific gravity in the noncontused hemisphere, and worsened neurologic outcome with and without CHT. Blood osmolality remained stable in comparison to the baseline value of 291.9 +/- 7.4 mOsm/kg (mean +/- SD). Sodium and glucose levels, initially 139.2 +/- 2.6 mEq/L and 168 +/- 61.9 g%, remained stable in the saline-treated animals at 138 +/- 2.1 mEq/L and 162.7 +/- 18.5 g%, but after 5% dextrose i.v. administration, values decreased to 86.3 +/- 9.7 mEq/L and increased to >450 mg/dl, respectively. We conclude that in our model of CHT, giving large boluses of 0.9% saline i.v. does not affect electrolyte balance, neurologic outcome, or formation of brain edema in rats with or without CHT. However, the same volume of 5% dextrose i.v. decreased serum sodium, increased brain edema in the noncontused hemisphere (in rats with CHT) and in intact brains (in rats without CHT), and decreased neurological outcome with and without CHT.	UNIV WASHINGTON,SCH MED,DEPT ANESTHESIOL,RN-10,SEATTLE,WA 98195; HADASSA MED CTR,DEPT EXPTL SURG,JERUSALEM,ISRAEL; ASUTA MED CTR,TEL AVIV,ISRAEL; SOROKA MED CTR,IL-84101 BEER SHEVA,ISRAEL							DALECY LG, 1986, SURGERY, V100, P505; DRUMMOND JC, 1989, ANESTHESIOLOGY, V70, P64, DOI 10.1097/00000542-198901000-00014; DRUMMOND JC, 1989, STROKE, V20, P1538, DOI 10.1161/01.STR.20.11.1538; KAIEDA R, 1989, NEUROSURGERY, V24, P671, DOI 10.1227/00006123-198905000-00003; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; LANIER WL, 1987, ANESTHESIOLOGY, V66, P39, DOI 10.1097/00000542-198701000-00008; LEMAY DR, 1988, STROKE, V19, P1411, DOI 10.1161/01.STR.19.11.1411; LONGSTRETH WT, 1984, ANN NEUROL, V15, P59, DOI 10.1002/ana.410150111; MARMAROU A, 1978, J NEUROSURG, V49, P503; NEDERGAARD M, 1987, BRAIN RES, V408, P79, DOI 10.1016/0006-8993(87)90360-X; POOLE GV, 1987, J TRAUMA, V27, P18, DOI 10.1097/00005373-198701000-00004; POOLE GV, 1986, CRIT CARE MED, V14, P629, DOI 10.1097/00003246-198607000-00009; PULSINELLI WA, 1983, AM J MED, V74, P540, DOI 10.1016/0002-9343(83)91007-0; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; SCHMIDT GA, 1992, PRINCIPLES CRITICAL, P52; SHAPIRA Y, 1992, ANESTHESIOLOGY, V77, P79, DOI 10.1097/00000542-199207000-00012; SHAPIRA Y, 1993, J CEREBR BLOOD F MET, V13, P962, DOI 10.1038/jcbfm.1993.120; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHAPIRA Y, 1992, ANESTH ANALG, V75, P238; TOMMASINO C, 1988, CRIT CARE MED, V16, P862, DOI 10.1097/00003246-198809000-00009; VENABLES GS, 1985, J NEUROL NEUROSUR PS, V48, P663, DOI 10.1136/jnnp.48.7.663; VOLL CL, 1988, ANN NEUROL, V24, P638, DOI 10.1002/ana.410240508; WARNER DS, 1988, ANESTHESIOLOGY, V68, P86, DOI 10.1097/00000542-198801000-00014; WISNER D, 1989, J SURG RES, V46, P49, DOI 10.1016/0022-4804(89)90181-9; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011; ZORNOW MH, 1988, ANESTHESIOLOGY, V69, P180, DOI 10.1097/00000542-198808000-00005; ZORNOW MH, 1987, ANESTHESIOLOGY, V67, P936, DOI 10.1097/00000542-198712000-00010	27	32	34	0	1	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	1995	7	1					17	25		10.1097/00008506-199501000-00004			9	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	PX798	WOS:A1995PX79800004	7881236				2021-06-18	
J	GIBBS, N				GIBBS, N			COMMON RUGBY LEAGUE INJURIES - RECOMMENDATIONS FOR TREATMENT AND PREVENTATIVE MEASURES	SPORTS MEDICINE			English	Article								Rugby league is the main professional team sport played in Eastern Australia. It is also very popular at a junior and amateur level. However, injuries are common because of the amount of body contact that occurs and the amount of running that is required to participate in the game. Injuries to the lower limbs account for over 50% of all injuries. The most common specific injuries are ankle lateral ligament tears, knee medial collateral and anterior cruciate ligament tears, groin musculotendinous tears, hamstring and calf muscle tears, and quadriceps muscle contusions. Head injuries are common and consist of varying degrees of concussion as well as lacerations and facial fractures. Serious head injury is rare. Some of the more common upper limb injuries are to the actomioclavicular and gleholaxineral joints. Accurate diagnosis of these common injuries using appropriate history, examination and investigations is critical in organising a treatment and rehabilitation plan that will return the player to competition as soon as possible. An understanding of the mechanism of injury is also important in order to develop preventative strategies.		GIBBS, N (corresponding author), S SYDNEY ORTHOPAED & SPORTS MED CTR,315 BUNNERONG RD,MAROUBRA,NSW 2035,AUSTRALIA.							0	32	32	0	16	ADIS INTERNATIONAL LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW ZEALAND	0112-1642			SPORTS MED	Sports Med.	DEC	1994	18	6					438	450		10.2165/00007256-199418060-00007			13	Sport Sciences	Sport Sciences	PZ776	WOS:A1994PZ77600006	7886357				2021-06-18	
J	HASLAM, C; BATCHELOR, J; FEARNSIDE, MR; HASLAM, SA; HAWKINS, S; KENWAY, E				HASLAM, C; BATCHELOR, J; FEARNSIDE, MR; HASLAM, SA; HAWKINS, S; KENWAY, E			POST-COMA DISTURBANCE AND POSTTRAUMATIC AMNESIA AS NONLINEAR PREDICTORS OF COGNITIVE OUTCOME FOLLOWING SEVERE CLOSED-HEAD INJURY - FINDINGS FROM THE WESTMEAD-HEAD-INJURY-PROJECT	BRAIN INJURY			English	Article							EARLY INDEXES; SCALE; SEQUELAE	This study sought to identify combinations of early neurological variables which best predict cognitive outcome 12 months after severe head injury. At the time of admission patients were assessed on seven neurological indices. Twelve months later a battery of neuropsychological tests examining recent memory functioning and speed of information processing was administered. Recent memory functioning was best predicted by a combination of post-coma disturbance (PCD; i.e. the duration of post-traumatic amnesia, PTA, minus the duration of coma) and presence of subarachnoid haemorrhage (multiple r = 0.54, p<0.001). Speed of information processing was best predicted by the duration of PTA (r=0.35, p<0.01). However, these conclusions were based on square root transformation of PCD and PTA variables. The success of this transformation in assisting prediction confirms suggestions that the relationship between PTA and cognitive outcome is nonlinear.	WESTMEAD HOSP,DEPT CLIN PSYCHOL,WESTMEAD,AUSTRALIA; WESTMEAD HOSP,DEPT NEUROSURG,WESTMEAD,AUSTRALIA; AUSTRALIAN NATL UNIV,DEPT PSYCHOL,CANBERRA,ACT 2600,AUSTRALIA	HASLAM, C (corresponding author), WODEN VALLEY HOSP,RACS,NEUROPSYCHOL SECT,POB 35,GARRAN,ACT 2605,AUSTRALIA.		Haslam, Catherine/Y-5763-2018; Haslam, Alex/AAA-2512-2019	Haslam, Catherine/0000-0003-0124-9601; Haslam, Alex/0000-0001-9523-7921; Batchelor, Jennifer/0000-0003-4438-4993			ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; Brooks D. N, 1990, REHABILITATION ADULT, P163; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BROOKS DN, 1986, J NEUROL NEUROSUR PS, V49, P549, DOI 10.1136/jnnp.49.5.549; BROOKS DN, 1984, J CLIN NEUROPSYCHOL, V6, P71, DOI 10.1080/01688638408401198; BROOKS DN, 1989, BRAIN INJURY, V3, P325; BROOKS DN, 1984, CLOSED HEAD PSYCHOL; CULLUM M, 1985, INT J NEUROSCI, V28, P299; DYE OA, 1979, ACTA NEUROL SCAND, V59, P10; GRONWALL D, 1981, J NEUROL NEUROSUR PS, V44, P889, DOI 10.1136/jnnp.44.10.889; GRONWALL D, 1976, Proceedings of the Australian Association of Neurologists, V13, P143; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; JENNETT B, 1975, LANCET, V1, P480; Jennett B, 1981, MANAGEMENT HEAD INJU; KLOVE H, 1972, SCANDINAVIAN J REHAB, V4, P155; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1982, NEUROBEHAVIORAL CONS; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; LINDBERG M, 1991, SEP S BRAIN INJ REH; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MANDLEBERG IA, 1975, J NEUROL NEUROSUR PS, V38, P1121, DOI 10.1136/jnnp.38.11.1121; NORUSIS MJ, 1985, SPSSX ADV STATISTICS; SHORES EA, 1989, J NEUROL NEUROSUR PS, V52, P126, DOI 10.1136/jnnp.52.1.126-a; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Smith A., 1982, SYMBOL DIGIT MODALIT; TEASDALE G, 1974, LANCET, V2, P81; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WILLIAMS JM, 1984, J NEUROSURG, V61, P581, DOI 10.3171/jns.1984.61.3.0581; WILSON B, 1991, Brain Injury, V5, P189, DOI 10.3109/02699059109008089	29	32	34	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNDPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	AUG-SEP	1994	8	6					519	528		10.3109/02699059409151004			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	PE682	WOS:A1994PE68200004	7987288				2021-06-18	
J	KITA, H; MARMAROU, A				KITA, H; MARMAROU, A			THE CAUSE OF ACUTE BRAIN-SWELLING AFTER THE CLOSED-HEAD INJURY IN RATS	ACTA NEUROCHIRURGICA			English	Article						BRAIN SWELLING; HEAD INJURY; BRAIN EDEMA; CEREBRAL BLOOD VOLUME	COMA DATA-BANK; COMPUTED-TOMOGRAPHY; BLOOD-VOLUME; EDEMA	The major component of acute brain swelling was determined using a new closed head injury (CHI) model in rats. Twenty seven Sprague-Dawley rats were separated into four groups (Sham, CHI, CHI combined with hypotension and CHI combined with hypoxia and hypotension). Hypoxia (pO2 of 40 mmHg) and hypotension (mean arterial blood pressure of 30 to 40 mmHg) were induced immediately after head injury and were maintained for 30 minutes. These experiments were terminated at two hours after CHI by transcalvarial freezing with liquid nitrogen. Blood pressure, intracranial pressure (ICP) and physiological parameters were monitored. Regional cerebral blood volume and water content were measured quantitatively. Rats with CHI, and with CHI and hypotension, had mild increase in ICP. Otherwise, rats with CHI, hypoxia and hypotension showed a significant increase in ICP (36.2 +/- 5.6 mmHg). Water content showed an increase of 1.6% in the estimated total brain and 2.4% in the cerebral cortex in those rats. Cerebral blood volume decreased by 61.4% in the total brain and 57.3% in the cortex. There was a reduction in the cerebral hematocrit of 2.4% in the total brain and 4.7% in the cortex. The main component of brain swelling in this head injury model was brain edema. Cerebral blood volume and hematocrit were reduced in the remarkable edematous brain.	VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV NEUROSURG, MCV STN, POB 508, RICHMOND, VA 23298 USA							ALDRICH EF, 1992, J NEUROSURG, V76, P450, DOI 10.3171/jns.1992.76.3.0450; CREMER JE, 1983, J CEREBR BLOOD F MET, V3, P254, DOI 10.1038/jcbfm.1983.35; CRUMRINE RC, 1991, J CEREBR BLOOD F MET, V11, P272, DOI 10.1038/jcbfm.1991.59; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Fahraeus R, 1931, AM J PHYSIOL, V96, P562; GROEGER U, 1989, ACTA NEUROCHIR, V101, P134, DOI 10.1007/BF01410529; ISHIGE N, 1988, J NEUROSURG, V68, P129, DOI 10.3171/jns.1988.68.1.0129; ISHIGE N, 1987, J CEREBR BLOOD F MET, V7, P759, DOI 10.1038/jcbfm.1987.131; Krogh A, 1921, J PHYSIOL-LONDON, V55, P412, DOI 10.1113/jphysiol.1921.sp001985; KUHL DE, 1980, J NEUROSURG, V52, P309, DOI 10.3171/jns.1980.52.3.0309; PONTEN U, 1973, J NEUROCHEM, V21, P1127, DOI 10.1111/j.1471-4159.1973.tb07567.x; SVANES K, 1968, Microvascular Research, V1, P210, DOI 10.1016/0026-2862(68)90019-8; VANDENBRINK WA, 1990, ACT NEUR S, V51, P261; YAMAGUCHI M, 1976, STROKE, V7, P77, DOI 10.1161/01.STR.7.1.77; ZIMMERMAN RA, 1978, RADIOLOGY, V126, P403, DOI 10.1148/126.2.403	15	32	32	0	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.		1994				60			452	455					4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	NX226	WOS:A1994NX22600124	7976618				2021-06-18	
J	WILBERGER, JE				WILBERGER, JE			MINOR HEAD-INJURIES IN AMERICAN FOOTBALL - PREVENTION OF LONG-TERM SEQUELAE	SPORTS MEDICINE			English	Article								The most common head injury in sports is the minor head injury or concussion - estimated to occur at a rate of 250 000 per year in contact sports. The risks of serious immediate consequences from a minor head injury can be obviated by careful attention to the athlete's post-traumatic complaints. No athlete who is still symptomatic from a head injury - regardless of how minor the injury originally appeared - should be allowed to compete until the symptoms resolve. If the complaints do not resolve rapidly, then more complete evaluation by a neurosurgeon or a neurologist is recommended. The potential long term consequences of minor head injuries in athletes remain to be elucidated. The available information appears to show definite, but probably reversible, neuropsychological impairment after a single minor head injury. However, much more data must be collected before any reasonable statement can be made about the potential cumulative effects of these injuries.		WILBERGER, JE (corresponding author), MED COLL PENN,DEPT NEUROSURG,420 E NORTH AVE,SUITE 302,PITTSBURGH,PA 15212, USA.							0	32	33	0	11	ADIS INTERNATIONAL LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW ZEALAND	0112-1642			SPORTS MED	Sports Med.	MAY	1993	15	5					338	343		10.2165/00007256-199315050-00005			6	Sport Sciences	Sport Sciences	LA770	WOS:A1993LA77000005	8321947				2021-06-18	
J	SHAPIRA, Y; ARTRU, AA; COTEV, S; MUGGIASULAM, M; FREUND, HR				SHAPIRA, Y; ARTRU, AA; COTEV, S; MUGGIASULAM, M; FREUND, HR			BRAIN EDEMA AND NEUROLOGIC STATUS FOLLOWING HEAD TRAUMA IN THE RAT - NO EFFECT FROM LARGE VOLUMES OF ISOTONIC OR HYPERTONIC INTRAVENOUS FLUIDS, WITH OR WITHOUT GLUCOSE	ANESTHESIOLOGY			English	Article						BLOOD, GLUCOSE; BRAIN, EDEMA; HEAD INJURY; FLUID BALANCE, CRYSTALLOID; HAEMACCEL; OSMOLARITY; NUTRITION, PARENTERAL	CEREBRAL-ISCHEMIA; HEMORRHAGIC-SHOCK; COLLOID SOLUTIONS; CARDIAC-ARREST; WATER-CONTENT; HYPERGLYCEMIA; RESUSCITATION; DEXTROSE; INJURY; DAMAGE	Disagreement exists regarding the need to restrict the administration of fluid and glucose following head injury to prevent cerebral edema and neurologic deterioration. We examined whether blood osmolality and glucose, neurologic outcome, and the development of brain edema following head trauma were altered by intravenous infusion of large volumes of isotonic or hypertonic fluids that contained or did not contain glucose. Fifty-five rats that survived ether anesthesia and closed head trauma (delivered using a weight drop device) were assigned to one of five groups. In the first group no fluid was infused. In the second group minimal volumes of saline were infused during placement of a jugular vein catheter. In the three remaining groups 10 ml.kg-1.h-1 of either total parenteral nutrition (TPN) (glucose 25%, amino acids 4.25%, 40 mEq/1 sodium and 40 mEq/1 potassium, 1935 mOsm/kg), dextrose 5% in 0.45% saline (495 mOsm/kg), or Haemaccel (isotonic plasma expander, 298 mOsm/kg) was infused via the jugular vein. Following head trauma and cannula placement, ether was discontinued. Neurologic severity score at 1 and 18 h after head tr,una was used to assess neurologic outcome. A score between 0 and 6 was assigned by an observer who was blinded as to the experimental groups, with 0 representing no neurologic damage and 6 representing severe damage. Specific gravity of brain tissue samples containing gray matter and subcortical white matter from the traumatized and contralateral hemispheres was measured at 18 h after head trauma to determine the development of brain edema. There were no statistically significant differences in neurologic outcome and brain edema between the groups. Blood osmolality (318 +/- 8 mOsm/kg, mean +/- SD) and glucose (17.5 +/- 4.2 mM) were increased in the group receiving total parenteral nutrition but not in the groups receiving dextrose 5% in 0.45% saline or Haemaccel. It is concluded that giving large volumes of isotonic or hypertonic intravenous solutions, with or without glucose, for 18 h after head trauma does not significantly alter neurologic outcome or formation of brain edema in rats.	UNIV WASHINGTON,SCH MED,DEPT ANESTHESIOL,RN-10,SEATTLE,WA 98195; EIN KAREM MED CTR,DEPT ANESTHESIOL,JERUSALEM,ISRAEL; EIN KAREM MED CTR,DEPT SURG,JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,HADASSAH MED SCH,MT SCOUPS MED CTR,DEPT SURG,IL-91010 JERUSALEM,ISRAEL							BECKER PD, 1985, INTENSIVE MANAGEMENT, P1593; COLLINS WF, 1974, NEUROLOGIC SURGERY P, P1631; DALECY LG, 1986, SURGERY, V100, P505; DRUMMOND JC, 1989, ANESTHESIOLOGY, V70, P64, DOI 10.1097/00000542-198901000-00014; FOXWORTHY JC, 1990, J NEUROSURG ANESTH, V2, P256, DOI 10.1097/00008506-199012000-00002; GINSBERG MD, 1987, STROKE, V18, P570, DOI 10.1161/01.STR.18.3.570; LANIER WL, 1987, ANESTHESIOLOGY, V66, P39, DOI 10.1097/00000542-198701000-00008; LEMAY DR, 1988, STROKE, V19, P1411, DOI 10.1161/01.STR.19.11.1411; LONGSTRETH WT, 1984, ANN NEUROL, V15, P59, DOI 10.1002/ana.410150111; MARMAROU A, 1978, J NEUROSURG, V49, P530, DOI 10.3171/jns.1978.49.4.0530; MCCOMIST PB, 1971, HEAD INJURY ANESTHET, P304; MCNAMARA JJ, 1971, AM J SURG, V122, P70; NEDERGAARD M, 1987, BRAIN RES, V408, P79, DOI 10.1016/0006-8993(87)90360-X; NEDERGAARD M, 1987, ACTA NEUROPATHOL BER, V73, P121; POOLE GV, 1987, J TRAUMA, V27, P18, DOI 10.1097/00005373-198701000-00004; POOLE GV, 1986, CRIT CARE MED, V14, P629, DOI 10.1097/00003246-198607000-00009; PULSINELLI WA, 1983, AM J MED, V74, P540, DOI 10.1016/0002-9343(83)91007-0; PULSINELLI WA, 1982, NEUROLOGY, V32, P1239, DOI 10.1212/WNL.32.11.1239; RAPP RP, 1983, J NEUROSURG, V58, P906, DOI 10.3171/jns.1983.58.6.0906; SAFAR P, 1988, CARDIOPULMONARY CERE, P248; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHENKIN HA, 1976, J NEUROSURG, V45, P432, DOI 10.3171/jns.1976.45.4.0432; THOMAS LM, 1973, NEUROLOGICAL SURGERY, P956; TOMMASINO C, 1988, CRIT CARE MED, V16, P862, DOI 10.1097/00003246-198809000-00009; VENABLES GS, 1985, J NEUROL NEUROSUR PS, V48, P663, DOI 10.1136/jnnp.48.7.663; VOLL CL, 1988, ANN NEUROL, V24, P638, DOI 10.1002/ana.410240508; WARNER DS, 1988, ANESTHESIOLOGY, V68, P86, DOI 10.1097/00000542-198801000-00014; WISNER D, 1989, J SURG RES, V46, P49, DOI 10.1016/0022-4804(89)90181-9; ZASSLOW MA, 1989, STROKE, V20, P519, DOI 10.1161/01.STR.20.4.519; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011; ZORNOW MH, 1988, ANESTHESIOLOGY, V69, P180, DOI 10.1097/00000542-198808000-00005; ZORNOW MH, 1987, ANESTHESIOLOGY, V67, P936, DOI 10.1097/00000542-198712000-00010	32	32	32	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0003-3022			ANESTHESIOLOGY	Anesthesiology	JUL	1992	77	1					79	85		10.1097/00000542-199207000-00012			7	Anesthesiology	Anesthesiology	JB534	WOS:A1992JB53400012	1610013				2021-06-18	
J	GOLDSTEIN, LH; POLKEY, CE				GOLDSTEIN, LH; POLKEY, CE			EVERYDAY MEMORY AFTER UNILATERAL TEMPORAL LOBECTOMY OR AMYGDALO-HIPPOCAMPECTOMY	CORTEX			English	Article							SEVERE HEAD-INJURY; QUESTIONNAIRE SMQ; SKILLS	Patients who had undergone unilateral temporal lobe surgery (right or left temporal lobectomy or amygdalo-hippocampectomy) for intractable temporal lobe epilepsy, and normal control subjects, completed two questionnaires about everyday memory, the Subjective Memory Questionnaire (SMQ) and the Everyday Memory Questionnaire (EMQ). Relatives/close friends completed suitably adapted versions of these questionnaires about the patient. Patients who had undergone right and left temporal lobectomy rated themselves, and were rated by relatives/friends as having worse memories than controls on both the SMQ and EMQ. Individual items on both questionnaires differentiated between the memory abilities of the five groups. Age at surgery was correlated with one measure of everyday memory for the right temporal lobectomy group, and seizure frequency was correlated with memory performance for the amygdalo-hippocampectomy groups. Issues concerning validity and accuracy of rating memory lapses are discussed.	MAUDSLEY HOSP & INST PSYCHIAT,LONDON SE5 8AZ,ENGLAND	GOLDSTEIN, LH (corresponding author), INST PSYCHIAT,DEPT PSYCHOL,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND.		Goldstein, Laura/E-7817-2010	Goldstein, Laura/0000-0001-9387-3035			BENNETTLEVY J, 1980, BRIT J SOC CLIN PSYC, V19, P177, DOI 10.1111/j.2044-8260.1980.tb00946.x; BENNETTLEVY J, 1980, CORTEX, V16, P543, DOI 10.1016/S0010-9452(80)80002-5; CROVITZ HF, 1984, CORTEX, V20, P349, DOI 10.1016/S0010-9452(84)80003-9; GOLDSTEIN LH, 1992, BRIT J CLIN PSYCHOL, V31, P75, DOI 10.1111/j.2044-8260.1992.tb00969.x; LINCOLN NB, 1989, BRIT J CLIN PSYCHOL, V28, P61, DOI 10.1111/j.2044-8260.1989.tb00812.x; MCGLONE J, 1991, CORTEX, V27, P19, DOI 10.1016/S0010-9452(13)80265-1; MCMILLAN TM, 1984, CORTEX, V20, P333, DOI 10.1016/S0010-9452(84)80002-7; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; POLKEY CE, 1987, SURGICAL TREATMENT E, P641; SCHWARTZ AF, 1989, CORTEX, V25, P665, DOI 10.1016/S0010-9452(89)80026-7; SUNDERLAND A, 1983, J VERB LEARN VERB BE, V22, P341, DOI 10.1016/S0022-5371(83)90229-3; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; WIESER HG, 1982, SURG NEUROL, V17, P445, DOI 10.1016/S0090-3019(82)80016-5; WILSON BA, 1985, RIVERMEAD BEHAVIOUR	14	32	32	0	2	MASSON DIVISIONE PERIODICI	MILAN	VIA FRATELLI BRESSAN 2, 20126 MILAN, ITALY	0010-9452			CORTEX	Cortex	JUN	1992	28	2					189	201		10.1016/S0010-9452(13)80047-0			13	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	JB361	WOS:A1992JB36100003	1499305				2021-06-18	
J	KIDO, DK; COX, C; HAMILL, RW; ROTHENBERG, BM; WOOLF, PD				KIDO, DK; COX, C; HAMILL, RW; ROTHENBERG, BM; WOOLF, PD			TRAUMATIC BRAIN INJURIES - PREDICTIVE USEFULNESS OF CT	RADIOLOGY			English	Article						BRAIN, CT; BRAIN, HEMORRHAGE; BRAIN, INJURIES; TRAUMA, 10.434	SEVERE HEAD-INJURY; COMPUTERIZED-TOMOGRAPHY; CATECHOLAMINES; CONSCIOUSNESS; DISPLACEMENT; MANAGEMENT; LESION; LEVEL; MR	The computed tomographic (CT) scans from 72 patients with traumatic brain injury were reviewed to determine whether a specific type, location, or size of lesion correlated with changes in neurologic function (assessed with the Glasgow Coma Scale [GCS]), patient outcome (assessed with the Glasgow Outcome Scale [GOS]), or catecholamine levels. The lesions were classified as focal or diffuse. GOS changed as a function of lesion size (P = .00004) in the 48 patients with focal hemorrhages, regardless of whether the lesions were intra- or extraaxial, and in the 19 patients with normal CT scans. Patients with lesions larger than 4,100 mm3 had a twofold greater risk of a poor outcome than patients with smaller lesions (100% vs 50%). Patients with normal CT scans were significantly more likely to have mild neurological dysfunction or none than patients with abnormal CT scans (P = .03), but lesion location, skull fracture, and pineal shift were not significant predictors of GCS or GOS scores. A positive relationship existed between lesion size and both plasma norepinephrine and epinephrine levels (P < .02); a significant relationship existed between lesion size and GCS score (P = .02).	UNIV ROCHESTER,MED CTR,DEPT RADIOL,ROCHESTER,NY 14642; UNIV ROCHESTER,MED CTR,DEPT NEUROL,ROCHESTER,NY 14642; UNIV ROCHESTER,MED CTR,DEPT MED,ROCHESTER,NY 14642; UNIV ROCHESTER,MED CTR,DIV BIOSTAT,ROCHESTER,NY 14642					NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01-AA-07066] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA007066] Funding Source: NIH RePORTER		ABDELDAYEM HM, 1987, RADIOLOGY, V165, P221, DOI 10.1148/radiology.165.1.3498184; CLIFTON GL, 1980, J NEUROSURG, V52, P611, DOI 10.3171/jns.1980.52.5.0611; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; FRENCH BN, 1977, SURG NEUROL, V7, P171; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; HESSELINK JR, 1988, AM J NEURORADIOL, V9, P269; JENNETT B, 1975, LANCET, V1, P480; LANGFITT TW, 1986, J NEUROSURG, V64, P760, DOI 10.3171/jns.1986.64.5.0760; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LOBATO RD, 1986, J NEUROSURG, V65, P784, DOI 10.3171/jns.1986.65.6.0784; MCCULLAGH P, 1983, GEN LINEAR MODELS, P127; MERINODEVILLASANTE J, 1976, AM J ROENTGENOL, V126, P765, DOI 10.2214/ajr.126.4.765; ROPPER AH, 1989, NEUROLOGY, V39, P622, DOI 10.1212/WNL.39.5.622; ROPPER AH, 1986, NEW ENGL J MED, V314, P953, DOI 10.1056/NEJM198604103141504; SNOW RB, 1986, NEUROSURGERY, V18, P45, DOI 10.1227/00006123-198601000-00008; STOVRING J, 1977, NEURORADIOLOGY, V14, P101, DOI 10.1007/BF00333050; TEASDALE G, 1974, LANCET, V2, P81; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; ZIMMERMAN RA, 1986, AM J NEURORADIOL, V7, P757	23	32	34	0	0	RADIOLOGICAL SOC NORTH AMER	EASTON	20TH AND NORTHAMPTON STS, EASTON, PA 18042	0033-8419			RADIOLOGY	Radiology	MAR	1992	182	3					777	781		10.1148/radiology.182.3.1535893			5	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	HE860	WOS:A1992HE86000030	1535893				2021-06-18	
J	LEE, RB; STAHLMAN, GC; SHARP, KW				LEE, RB; STAHLMAN, GC; SHARP, KW			TREATMENT PRIORITIES IN PATIENTS WITH TRAUMATIC RUPTURE OF THE THORACIC AORTA	AMERICAN SURGEON			English	Article; Proceedings Paper	59TH ANNUAL ASSEMBLY AND POST GRADUATE COURSE PROGRAM OF THE SOUTHEASTERN SURGICAL CONGRESS	APR 14-17, 1991	NEW ORLEANS, LA	SE SURG CONGRESS			TRANSECTION	Autopsy studies reveal that 90 per cent of patients with traumatic rupture of the thoracic aorta (TRTA) die at the scene of the accident and 25 per cent of those reaching the hospital do not survive their injuries. Treatment priorities in patients with TRTA and associated life-threatening head and intra-abdominal injuries have not been adequately studied. The authors reviewed their experience with 57 consecutive patients sustaining TRTA to establish treatment priorities in these multiply injured patients. The mean age of the population was 35 years (43 men, 14 women). Hospital mortality was 24 per cent; the most common cause of death was hemorrhage. Fully 95 per cent of the patients had associated injuries requiring operative intervention. Abdominal injuries requiring laparotomy were present in 20 patients (35%): 14 splenic injuries, 8 liver injuries, 3 pancreatic injuries, and 3 mesenteric lacerations. Twenty-eight patients (49%) had orthopaedic injuries requiring operative fixation. Maxillofacial injuries requiring surgical repair occurred in 20 patients (35%). Fifteen patients (26%) sustained significant closed head injuries, but only 1 required craniotomy for hemorrhage. Nine hemodynamically unstable patients with intra-abdominal hemorrhage underwent immediate laparotomy for control of bleeding followed by aortography and aortic repair (2 deaths, 22%). Seven hemodynamically stable patients had aortography followed by laparotomy for control of intra-abdominal hemorrhage with subsequent thoractomy (1 death, 14%). Thirty stable patients underwent aortography followed by immediate thoracotomy; 22 required no further procedures, while 8 required an additional operation (7 deaths, 23%). Based on this review, the authors have developed a treatment algorithm for patients with suspected TRTA incorporating hemodynamic stability, diagnostic peritoneal lavage, and aortography as the major determinants for treatment priorities in patients with TRTA. Patients with intra-abdominal hemorrhage should undergo laparotomy before the other procedures.	VANDERBILT UNIV,DEPT SURG,NASHVILLE,TN 37232							BORMAN KR, 1982, AM J SURG, V144, P728, DOI 10.1016/0002-9610(82)90559-1; Greendyke R.M., 1996, JAMA-J AM MED ASSOC, V195, P119, DOI 10.1001/jama.1966.03100070071021; HANSCHEN S, 1982, SOUTHERN MED J, V75, P653, DOI 10.1097/00007611-198206000-00005; HARTFORD JM, 1986, AM J SURG, V151, P224, DOI 10.1016/0002-9610(86)90075-9; HOOD RM, 1977, THORACIC TRAUMA, P224; KIRSH MM, 1976, ANN SURG, V184, P308, DOI 10.1097/00000658-197609000-00008; KLASSIN KP, 1959, SURGERY, V46, P787; MATTOX KL, 1989, ANN THORAC SURG, V48, P1, DOI 10.1016/0003-4975(89)90164-1; MERRILL WH, 1988, ANN SURG, V207, P699, DOI 10.1097/00000658-198806000-00009; PATE JW, 1985, ANN THORAC SURG, V39, P531, DOI 10.1016/S0003-4975(10)61993-5; RICHARDSON JD, 1990, ANN SURG, V211, P731, DOI 10.1097/00000658-199006000-00012; SHORR RM, 1987, ANN SURG, V206, P200, DOI 10.1097/00000658-198708000-00013; SYMBAS PN, 1973, ANN SURG, V178, P6, DOI 10.1097/00000658-197307000-00002; 1983, ACCIDENT FACTS PRELI	14	32	32	0	0	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	1776 PEACHTREE RD, NW., SUITE 410N, ATLANTA, GA 30309-2352	0003-1348			AM SURGEON	Am. Surg.	JAN	1992	58	1					37	43					7	Surgery	Surgery	GY748	WOS:A1992GY74800006	1739228				2021-06-18	
J	PATTEN, SB; LAUDERDALE, WM				PATTEN, SB; LAUDERDALE, WM			DELAYED SLEEP PHASE DISORDER AFTER TRAUMATIC BRAIN INJURY	JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY			English	Article						SLEEP DISORDER; SLEEP; ADOLESCENCE; SCHOOL PHOBIA; HEAD INJURIES	MINOR HEAD-INJURY; CONCUSSION	Sleep-wake schedule disorder is defined by DSM-III-R as a mismatch between the normal sleep-wake wake schedule for a person's environment and his or her circadian sleep-wake pattern. The authors report a case in which a sleep-wake schedule disorder arose after a closed head injury. Sleep-wake schedule disorder has not been described as an outcome of closed head injury. As patients with sleep-wake schedule disorders may present with insomnia, this case suggests the possibility that some of the insomnia that frequently follows closed head injury may represent sleep-wake schedule disorders.	UNIV CALGARY,DEPT PSYCHIAT,CALGARY T2N 1N4,ALBERTA,CANADA; UNIV CALGARY,ALBERTA HERITAGE FDN MED RES,CALGARY T2N 1N4,ALBERTA,CANADA			Patten, Scott/B-4434-2011; Sanguansri, Luz/B-6630-2011	Patten, Scott/0000-0001-9871-4041; Sanguansri, Luz/0000-0003-1908-7604			American Psychiatric Association, 1987, DIAGN STAT MAN MENT; CARSKADON MA, 1983, SLEEP WAKE DISORDERS, P201; CZEISLER CA, 1981, SLEEP, V4, P1; DILLON H, 1961, JAMA-J AM MED ASSOC, V175, P110; DRAKE ME, 1986, NEUROLOGY, V36, P867, DOI 10.1212/WNL.36.6.867; FERBER R, 1987, SLEEP ITS DISORDERS, P165; FERBER R, 1983, SLEEP RES, V12, P239; Gerring J P, 1986, Pediatr Rev, V8, P115, DOI 10.1542/pir.8-4-115; GITTELMANKLEIN R, 1975, RECENT ADV CHILD PSY, P257; Guilleminault C, 1982, SLEEPING WAKING DISO, P155; HALL CW, 1975, ARCH NEUROL-CHICAGO, V32, P57, DOI 10.1001/archneur.1975.00490430079016; JAKOBSEN J, 1987, ACTA NEUROL SCAND, V75, P341, DOI 10.1111/j.1600-0404.1987.tb05456.x; KAY DWK, 1971, LANCET, V2, P1052; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; NYLANDER I, 1988, ACTA PAEDIATR SCAND, V77, P475, DOI 10.1111/j.1651-2227.1988.tb10685.x; POGACNIK T, 1989, PSYCHIAT RES, V29, P313, DOI 10.1016/0165-1781(89)90075-9; ROBERTSON A, 1988, AUST NZ J PSYCHIAT, V22, P396, DOI 10.3109/00048678809161348; SCHOENHUBER R, 1986, NEUROSURGERY, V19, P532, DOI 10.1227/00006123-198610000-00006; Silverman J J, 1986, Adv Psychosom Med, V16, P115; STEPHAN FK, 1972, P NATL ACAD SCI USA, V69, P1583, DOI 10.1073/pnas.69.6.1583; TAYLOR AR, 1967, BRIT MED J, V3, P67, DOI 10.1136/bmj.3.5557.67	21	32	32	0	1	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0890-8567			J AM ACAD CHILD PSY	J. Am. Acad. Child Adolesc. Psychiatr.	JAN	1992	31	1					100	102		10.1097/00004583-199201000-00015			3	Psychology, Developmental; Pediatrics; Psychiatry	Psychology; Pediatrics; Psychiatry	GZ437	WOS:A1992GZ43700015	1537759				2021-06-18	
J	Marsh, NV; Knight, RG				Marsh, Nigel; Knight, Robert			Relationship Between Cognitive Deficits and Social Skill After Head Injury	NEUROPSYCHOLOGY			English	Article						closed head injury; cognitive deficits; social skills		The relationship between impaired neuropsychological functioning and level of skill during social interaction was examined in a group of 12 male patients who had experienced a very severe closed head injury (CHI) at least 36 months previously. The patients were community based but still required contact with rehabilitation services. The patients' performance on neuropsychological tasks was compared with the results obtained by a group of 6 normal control subjects. CHI patients exhibited deficits on memory and verbal fluency tasks. The CHI patients' memory deficits were not related to their level of skill during social interaction. There was a significant relationship between patients' performance on the verbal fluency task and their level of social skill, suggesting that patients' inflexibility in processing contributed to their impaired performance during social interaction.	[Marsh, Nigel] Univ Waikato, Hamilton, New Zealand; [Knight, Robert] Univ Otago, Dunedin, New Zealand	Marsh, NV (corresponding author), Univ Waikato, Dept Psychol, Private Bag 3105, Hamilton, New Zealand.		Marsh, Nigel V./F-5433-2019	Marsh, Nigel V./0000-0002-4060-6432			ACKER MB, 1986, CLIN NEUROPSYCHOL IN, P85; Becker R.E., 1988, BEHAV ASSESSMENT PRA, P365; BELLACK AS, 1983, BEHAV RES THER, V21, P29, DOI 10.1016/0005-7967(83)90123-7; BELLACK AS, 1979, BEHAVIORAL ASSESSMEN, V1, P157; Benton A., 1976, MULTILINGUAL APHASIA; Blair C D, 1987, Arch Clin Neuropsychol, V2, P33; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Cronbach L. J., 1972, DEPENDABILITY BEHAV; Cushman LA, 1989, NEUROPSYCHOLOGY, V3, P103; DODWELL D, 1988, J NEUROL NEUROSUR PS, V51, P833, DOI 10.1136/jnnp.51.6.833; Dull-Baird A., 1988, J CONSULT CLIN PSYCH, V56, P148; DULLBAIRD A, 1987, J CLIN EXP NEUROPSYC, V9, P407; Dunn E J, 1990, Arch Clin Neuropsychol, V5, P103, DOI 10.1016/0887-6177(90)90032-K; GLOSSER G, 1990, J CLIN EXP NEUROPSYC, V12, P485, DOI 10.1080/01688639008400995; Heaton R., 1981, MANUAL WISCONSIN CAR; HEATON RK, 1981, J CONSULT CLIN PSYCH, V49, P807, DOI 10.1037/0022-006X.49.6.807; HOLM S, 1979, SCAND J STAT, V6, P65; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Little M M, 1986, Arch Clin Neuropsychol, V1, P323, DOI 10.1016/0887-6177(86)90136-8; Marsh N. V., J CLIN EXPT IN PRESS; Marsh NV, 1990, NEUROPSYCHOLOGY, V4, P13, DOI 10.1037/0894-4105.4.1.13; MARSHALL JC, 1984, J CLIN NEUROPSYCHOL, V6, P65, DOI 10.1080/01688638408401197; MCSWEENY AJ, 1985, J CLIN EXP NEUROPSYC, V7, P281, DOI 10.1080/01688638508401260; Nelson HE, 1982, NATL ADULT READING T; NEWTON A, 1985, BRIT J CLIN PSYCHOL, V24, P225, DOI 10.1111/j.2044-8260.1985.tb00655.x; ODDY M, 1980, J NEUROL NEUROSUR PS, V43, P798, DOI 10.1136/jnnp.43.9.798; POWELL GE, 1980, BRIT J SOC CLIN PSYC, V19, P189, DOI 10.1111/j.2044-8260.1980.tb00947.x; PRIGATANO GP, 1984, J NEUROL NEUROSUR PS, V47, P505, DOI 10.1136/jnnp.47.5.505; Ruff R M, 1986, Arch Clin Neuropsychol, V1, P87, DOI 10.1016/0887-6177(86)90009-0; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; Searight HR, 1989, NEUROPSYCHOLOGY, V3, P135; Snedecor G.W., 1980, STAT METHODS, V7th; Stroop JR, 1935, J EXP PSYCHOL, V18, P643, DOI 10.1037/h0054651; Sunderland A., 1990, CLIN REHABIL, V4, P181, DOI DOI 10.1177/026921559000400301; SUNDET K, 1988, J CLIN EXP NEUROPSYC, V10, P363, DOI 10.1080/01688638808408245; TAYLOR R, 1990, BRIT J CLIN PSYCHOL, V29, P251, DOI 10.1111/j.2044-8260.1990.tb00882.x; Wechsler D., 1955, MANUAL WECHSLER ADUL; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WILSON B, 1987, J CLIN EXP NEUROPSYC, V9, P527, DOI 10.1080/01688638708410767	40	32	32	0	2	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	APR	1991	5	2					107	117		10.1037/0894-4105.5.2.107			11	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	V74CV	WOS:000211756000004					2021-06-18	
J	FEE, CRA; RUTHERFORD, WH				FEE, CRA; RUTHERFORD, WH			A STUDY OF THE EFFECT OF LEGAL SETTLEMENT ON POST-CONCUSSION SYMPTOMS	ARCHIVES OF EMERGENCY MEDICINE			English	Article										FEE, CRA (corresponding author), CRAIGAVON AREA HOSP,DEPT ACCIDENT & EMERGENCY,CRAIGAVON BT63 5QQ,ARMAGH,NORTH IRELAND.							0	32	32	0	1	BLACKWELL SCIENCE LTD	OXFORD	OSNEY MEAD, OXFORD, OXON, ENGLAND OX2 0EL	0264-4924			ARCH EMERG MED		MAR	1988	5	1					12	17					6	Emergency Medicine	Emergency Medicine	N4399	WOS:A1988N439900003	3408521				2021-06-18	
J	Cheng, CLY; Povlishock, JT				Cheng, Charles L. Y.; Povlishock, John T.			The Effect of Traumatic Brain Injury on the Visual System: A Morphologic Characterization of Reactive Axonal Change	JOURNAL OF NEUROTRAUMA			English	Article							MINOR HEAD-INJURY; LATERAL GENICULATE-NUCLEUS; HORSERADISH-PEROXIDASE; CAT; DEGENERATION	Reactive axonal changes following fluid-percussion brain injury were studied in the highly organized afferent pathways of the cat visual system. The visual system offers several features advantageous to the study of traumatic brain injury. Specifically, as the retinal cells of origin of the optic nerve and tract are isolated from the employed fluid-percussion injury, concomitant traumatically induced somatic change is not a confounding variable. Additionally, the existence of axons of varying diameters and topographic localization within the visual pathways allows the relationship between both fiber size and distribution and their predilection for traumatically induced change to be considered. Since the visual pathway is a highly organized sensory pathway, data obtained in this system can be compared with similar studies previously conducted in motor systems. In these experiments, 20 adult cats were subjected to brain injury and killed at posttraumatic survival periods ranging from 2 to 60 days. Six cats received intravitreous injections of horseradish peroxidase (HRP) to aid in the recognition of axonal change. At the designated survival time, all animals were perfused with aldehydes. The visual system from optic chiasm to lateral geniculate was sectioned and prepared for routine light (LM) and electron microscopic (TEM) study. Animals injected with HRP were processed for the LM and TEM visualization of HRP reaction products. By the second posttraumatic day, reactive axonal swellings were observed in the optic tracts as they entered the medial intralaminar nuclei of the lateral geniculate bodies. Proximal segments of the reactive axons showed enlargement and lobulation, whereas the distal segments underwent wallerian degeneration. Over a 2 week posttraumatic course, some axonal swellings persisted unchanged, some degenerated, and others initiated regenerative sprouting. With continued survival, however, all the reactive swellings manifested only progressive degenerative change. These reactive axonal changes appeared to constitute a primary response to the traumatic episode and occurred without concomitant damage to either the related brain parenchyma or its intrinsic vasculature. Although these findings replicate many of those previously described in motor pathways, new conceptual information has been provided. These studies preclude concomitant somal damage as a confounding variable and suggest that large-caliber axons are susceptible to the shear and tensile forces of traumatic brain injury.	[Povlishock, John T.] Virginia Commonwealth Univ, Med Coll Virginia, MCV Stn, Dept Anat, Richmond, VA 23298 USA	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, MCV Stn, Dept Anat, Box 709, Richmond, VA 23298 USA.				NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 20193]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS020193] Funding Source: NIH RePORTER	This work was supported by NIH Grant NS 20193.	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; GENNARELLI JA, 1982, ANN NEUROL, V12, P564; GUILLERY RW, 1980, J COMP NEUROL, V194, P117, DOI 10.1002/cne.901940107; GUILLERY RW, 1970, J COMP NEUROL, V138, P339, DOI 10.1002/cne.901380307; GUILLERY RW, 1982, J NEUROSCI, V2, P714; ITAYA SK, 1982, BRAIN RES, V236, P199, DOI 10.1016/0006-8993(82)90046-4; ITOH K, 1979, BRAIN RES, V175, P341, DOI 10.1016/0006-8993(79)91013-8; JANE JA, 1985, J NEUROSURG, V62, P96, DOI 10.3171/jns.1985.62.1.0096; LAEMLE LK, 1975, BRAIN RES, V100, P650, DOI 10.1016/0006-8993(75)90164-X; LASEK RJ, 1981, POSTTRAUMATIC PERIPH; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MESULAM MM, 1980, NEUROSCIENCE, V5, P1277, DOI 10.1016/0306-4522(80)90200-6; MESULAM MM, 1978, J HISTOCHEM CYTOCHEM, V26, P206; OPPENHEI.DR, 1968, J NEUROL NEUROSUR PS, V31, P299, DOI 10.1136/jnnp.31.4.299; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Povlishock J T, 1985, Cent Nerv Syst Trauma, V2, P285; POVLISHOCK JT, 1985, LAB INVEST, V52, P540; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; ROBSON JA, 1983, J COMP NEUROL, V216, P89, DOI 10.1002/cne.902160108; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; STRICH SJ, 1961, LANCET, V2, P443; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Tomlinson B, 1970, J CLIN PATHOL S4, V23, P154	25	32	32	0	1	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma		1988	5	1					47	60		10.1089/neu.1988.5.47			14	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	V22HC	WOS:000208265300004	3193463				2021-06-18	
J	OVERGAARD, J; TWEED, WA				OVERGAARD, J; TWEED, WA			CEREBRAL-CIRCULATION AFTER HEAD-INJURY .2. EFFECTS OF TRAUMATIC BRAIN EDEMA	JOURNAL OF NEUROSURGERY			English	Article									ODENSE UNIV HOSP,DEPT NEUROSURG,DK-5000 ODENSE,DENMARK							BEKS JWF, 1972, INTRACRANIAL PRESSUR, P119; BROCK M, 1975, INTRACRANIAL PRESSUR, V2, P215; BRUCE DA, 1973, J NEUROSURG, V38, P131, DOI 10.3171/jns.1973.38.2.0131; BUSCH EAV, 1961, CLIN NEUROSURG, V9, P18; FEIGIN I, 1962, ARCH NEUROL-CHICAGO, V6, P151, DOI 10.1001/archneur.1962.00450200065006; FREI HJ, 1973, ACTA NEUROCHIR, V29, P15, DOI 10.1007/BF01414613; GO KG, 1974, EXP NEUROL, V42, P332, DOI 10.1016/0014-4886(74)90030-2; HOHORST H, 1962, METHODEN ENZYMATISCH, V1, P266; JENNETT B, 1973, 8TH CER VASC DIS C, P163; JENNETT WB, 1972, PERSISTENT VEGETA, P737; JOHANSSON B, 1970, ACTA NEUROPATHOL, V16, P117, DOI 10.1007/BF00687666; JOHNSTON I H, 1970, Lancet, V2, P433; KALIN EM, 1975, NEW ENGL J MED, V293, P1013, DOI 10.1056/NEJM197511132932003; Klatzo I, 1973, ADV NEUROSURG, V1, P1; KLATZO I, 1974, EXCERPTA MEDICA  320, P310; KLATZO I, 1972, STEROIDS BRAIN EDEMA, P1; LASSEN NA, 1966, LANCET, V2, P1113, DOI 10.1016/S0140-6736(66)92199-4; LUNDBERG NA, 1974, ADV TECHNICAL STANDA, V1, P6; MARSHALL WJ, 1969, ARCH NEUROL-CHICAGO, V21, P545, DOI 10.1001/archneur.1969.00480170117012; MEINIG G, 1972, EUR NEUROL, V8, P97, DOI 10.1159/000114558; NAKATANI S, 1972, INTRACRANIAL PRESSUR, P144; NORTHFIELD PWG, 1973, SURGERY CENTRAL NERV, P38; Olesen J, 1971, STROKE, V2, P519, DOI 10.1161/01.STR.2.6.519; OMMAYA AK, 1974, EXCERPTA MEDICA  320, P275; OVERGAARD J, 1973, LANCET, V2, P631; OVERGAARD J, 1974, J NEUROSURG, V41, P531, DOI 10.3171/jns.1974.41.5.0531; PAPPIUS HM, 1967, BRAIN EDEMA; Reivich M, 1969, CEREBRAL BLOOD FLOW, P205; REULEN HJ, 1975, INTRACRANIAL PRESSUR, V2, P233; SCHUTTA HS, 1968, BRAIN, V91, P281, DOI 10.1093/brain/91.2.281; TROUPP H, 1971, ACTA NEUROCHIR, V25, P189, DOI 10.1007/BF01809100; Tweed W A, 1976, Can J Neurol Sci, V3, P35; TWEED WA, 1973, STROKE, V4, P348	33	32	32	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1976	45	3					292	300		10.3171/jns.1976.45.3.0292			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CC173	WOS:A1976CC17300005	948015				2021-06-18	
J	Nicholson, SE; Watts, LT; Burmeister, DM; Merrill, D; Scroggins, S; Zou, Y; Lai, Z; Grandhi, R; Lewis, AM; Newton, LM; Eastridge, BJ; Schwacha, MG				Nicholson, Susannah E.; Watts, Lora T.; Burmeister, David M.; Merrill, Daniel; Scroggins, Shannon; Zou, Yi; Lai, Zhao; Grandhi, Ramesh; Lewis, Aaron M.; Newton, Larry M.; Eastridge, Brian J.; Schwacha, Martin G.			MODERATE TRAUMATIC BRAIN INJURY ALTERS THE GASTROINTESTINAL MICROBIOME IN A TIME-DEPENDENT MANNER	SHOCK			English	Article						Brain-gut axis; gastrointestinal (GI); gut; commensals; microbiome; traumatic brain injury (TBI)	GUT MICROBIOTA; BIOMARKERS; PERFUSION; AXIS	The microbiome is defined as the collective genomes of the microbes (composed of bacteria, bacteriophage, fungi, protozoa, and viruses) that colonize the human body, and alterations have been associated with a number of disease states. Changes in gut commensals can influence the neurologic system via the brain-gut axis, and systemic insults such as trauma or traumatic brain injury (TBI) may alter the gut microbiome. The objective of this study was to evaluate the gut microbiome in a preclinical TBI cortical impact model. Male rats underwent craniotomy and randomized to a sham group (n = 4), or a moderate TBI (n = 10) using a pneumatic impactor. MRI and behavioral assessments were performed pre-TBI and on days 2, 7, and 14 days thereafter. Microbiome composition was determined with 16s rRNA sequencing from fecal sample DNA pre-TBI and 2 hrs, 1, 3, and 7 days afterward. Alpha- and beta-bacterial diversity, as well as organizational taxonomic units (OTUs), were determined. Significant changes in the gut microbiome were evident as early as 2 h after TBI as compared with pre-injured samples and sham rats. While there were varying trends among the phylogenetic families across time, some changes persisted through 7 days in the absence of therapeutic intervention. While large structural lesions and behavioral deficits were apparent post-TBI, there were modest but significant decreases in alpha-diversity. Moreover, both changes in representative phyla and alpha-diversity measures were significantly correlated with MRI-determined lesion volume. These results suggest that changes in the microbiome may represent a novel biomarker to stage TBI severity and predict functional outcome.	[Nicholson, Susannah E.; Merrill, Daniel; Scroggins, Shannon; Grandhi, Ramesh; Lewis, Aaron M.; Newton, Larry M.; Eastridge, Brian J.; Schwacha, Martin G.] Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA; [Watts, Lora T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA; [Burmeister, David M.; Schwacha, Martin G.] US Army, Inst Surg Res, Ft Sam Houston, TX 78234 USA; [Zou, Yi; Lai, Zhao] Univ Texas Hlth Sci Ctr San Antonio, Greehey Childrens Canc Res Inst, San Antonio, TX 78229 USA	Nicholson, SE (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Surg, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	Nicholson@uthscsa.edu	Nicholson, Susannah/AAI-2757-2021; Scroggins, Shannon/AAY-5909-2020	Sayyadioskoie (Scroggins), Shannon/0000-0002-2542-8877	National Center for Advancing Translational Sciences, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2 TR001118]; University of Texas Health Science Center at San Antonio Military Health Institute; Bob Kelso Endowment; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR001118] Funding Source: NIH RePORTER	The project described was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant KL2 TR001118. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the Department of the Army and the Department of Defense. Support was also received by the University of Texas Health Science Center at San Antonio Military Health Institute, the Bob Kelso Endowment awarded to the UTHSCSA Department of Surgery and The Greehey Children's Cancer Research Institute Genome Sequencing Facility's Illumina MiSeq Pilot Grant.	Adelson PD, 1998, ACT NEUR S, V71, P104; Ahluwalia V, 2016, SCI REP-UK, V6, DOI 10.1038/srep26800; Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Braniste V, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009759; Caricilli Andrea Moro, 2014, World J Gastrointest Pathophysiol, V5, P18, DOI 10.4291/wjgp.v5.i1.18; Carlucci C, 2016, EBIOMEDICINE, V13, P37, DOI 10.1016/j.ebiom.2016.09.029; Centers for Disease Control and Prevention, 2015, REP C TRAUM BRAIN IN; Cho I, 2012, NAT REV GENET, V13, P260, DOI 10.1038/nrg3182; Earley ZM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129996; Faith DP, 2006, EVOL BIOINFORM, V2, P121; Garrett WS, 2010, CELL HOST MICROBE, V8, P292, DOI 10.1016/j.chom.2010.08.004; Grenham S, 2011, FRONT PHYSIOL, V2, DOI 10.3389/fphys.2011.00094; Houlden A, 2016, BRAIN BEHAV IMMUN, V57, P10, DOI 10.1016/j.bbi.2016.04.003; Ivanov II, 2012, CELL HOST MICROBE, V12, P496, DOI 10.1016/j.chom.2012.09.009; Keenan JI, 2016, ANAEROBE, V40, P50, DOI 10.1016/j.anaerobe.2016.05.004; Korley FK, 2019, J NEUROTRAUM, V36, P182, DOI 10.1089/neu.2017.5623; Korley FK, 2016, J NEUROTRAUM, V33, P215, DOI 10.1089/neu.2015.3949; Krezalek MA, 2016, SHOCK, V45, P475, DOI 10.1097/SHK.0000000000000534; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/4441022a; Liu ZHM, 2004, MAGN RESON MED, V52, P277, DOI 10.1002/mrm.20148; Lloyd-Price J, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0307-y; Mayer EA, 2015, J CLIN INVEST, V125, P926, DOI 10.1172/JCI76304; Paziana K, 2015, FUTUR NEUROL, V10, P281, DOI 10.2217/FNL.15.13; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Scheperjans F, 2015, MOVEMENT DISORD, V30, P350, DOI 10.1002/mds.26069; Shen Q, 2005, J CEREBR BLOOD F MET, V25, P1265, DOI 10.1038/sj.jcbfm.9600132; Shen Q, 2003, J CEREBR BLOOD F MET, V23, P1479, DOI 10.1097/01.WCB.0000100064.36077.03; Singh V, 2016, J NEUROSCI, V36, P7428, DOI 10.1523/JNEUROSCI.1114-16.2016; Solomon S, 2003, AM J INFECT CONTROL, V31, P481; Travagli RA, 2006, ANNU REV PHYSIOL, V68, P279, DOI 10.1146/annurev.physiol.68.040504.094635; Turnbaugh PJ, 2007, NATURE, V449, P804, DOI 10.1038/nature06244; Watts LT, 2014, J NEUROTRAUM, V31, P1063, DOI 10.1089/neu.2013.3193; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhang XY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071108	35	31	32	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	AUG	2019	52	2					240	248		10.1097/SHK.0000000000001211			9	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	IQ5NG	WOS:000480798900014	29953417	Bronze			2021-06-18	
J	Clark, DPQ; Perreau, VM; Shultz, SR; Brady, RD; Lei, E; Dixit, S; Taylor, JM; Beart, PM; Boon, WC				Clark, David P. Q.; Perreau, Victoria M.; Shultz, Sandy R.; Brady, Rhys D.; Lei, Enie; Dixit, Shilpi; Taylor, Juliet M.; Beart, Philip M.; Boon, Wah Chin			Inflammation in Traumatic Brain Injury: Roles for Toxic A1 Astrocytes and Microglial-Astrocytic Crosstalk	NEUROCHEMICAL RESEARCH			English	Article						Traumatic brain injury; Inflammation; Astrocyte; Toxic phenotype; Glial crosstalk	REACTIVE ASTROCYTES; SCAR FORMATION; CELLS; NEUROINFLAMMATION; SENSOR; MODEL; STEREOLOGY; MECHANISMS; RESPONSES; OUTCOMES	Traumatic brain injury triggers neuroinflammation that may contribute to progressive neurodegeneration. We investigated patterns of recruitment of astrocytes and microglia to inflammation after brain trauma by firstly characterising expression profiles over time of marker genes following TBI, and secondly by monitoring glial morphologies reflecting inflammatory responses in a rat model of traumatic brain injury (i.e. the lateral fluid percussion injury). Gene expression profiles revealed early elevation of expression of astrocytic marker glial fibrillary acidic protein relative to microglial marker allograft inflammatory factor 1 (also known as ionized calcium-binding adapter molecule 1). Adult rat brains collected at day 7 after injury were processed for immunohistochemistry with allograft inflammatory factor 1, glial fibrillary acidic protein and complement C3 (marker of bad/disruptive astrocytic A1 phenotype). Astrocytes positive for glial fibrillary acidic protein and complement C3 were significant increased in the injured cortex and displayed more complex patterns of arbourisation with significantly increased bifurcations. Our observations suggested that traumatic brain injury changed the phenotype of microglia from a ramified appearance with long, thin, highly branched processes to a swollen amoeboid shape in the injured cortex. These findings suggest differential glial activation with astrocytes likely undergoing strategic changes in morphology and function. Whilst a detailed analysis is needed of temporal patterns of glial activation, ours is the first evidence of a role for the bad/disruptive astrocytic A1 phenotype in an open head model of traumatic brain injury.	[Clark, David P. Q.; Perreau, Victoria M.; Lei, Enie; Dixit, Shilpi; Beart, Philip M.; Boon, Wah Chin] Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3051, Australia; [Shultz, Sandy R.; Brady, Rhys D.] Monash Univ, Dept Neurosci, Cent Clin Sch, Melbourne, Vic 3004, Australia; [Shultz, Sandy R.; Brady, Rhys D.] Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3052, Australia; [Taylor, Juliet M.; Beart, Philip M.] Univ Melbourne, Dept Pharmacol & Therapeut, Parkville, Vic 3010, Australia	Beart, PM (corresponding author), Florey Inst Neurosci & Mental Hlth, Parkville, Vic 3051, Australia.; Beart, PM (corresponding author), Univ Melbourne, Dept Pharmacol & Therapeut, Parkville, Vic 3010, Australia.	philip.beart@florey.edu.au		Dixit, Shilpi/0000-0003-4837-0548	J and M Nolan Family Trust; Victorian Government through the Operational Infrastructure Scheme	PMB is pleased to contribute a paper to this Special Issue honouring Tony Turner who has been a colleague furthering the neurochemical cause via the Journal of Neurochemistry and internationally (ISN) and in Europe (ESN) for some 20 years. This work is partly funded by the J and M Nolan Family Trust. This work was supported by the Victorian Government through the Operational Infrastructure Scheme.	Abeysinghe HCS, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17030288; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; [Anonymous], 2015, RSTUDIO INT DEV R; Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Barres BA, 2008, NEURON, V60, P430, DOI 10.1016/j.neuron.2008.10.013; Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193; Beart PM, 2007, BRIT J PHARMACOL, V150, P5, DOI 10.1038/sj.bjp.0706949; Boisvert MM, 2018, CELL REP, V22, P269, DOI 10.1016/j.celrep.2017.12.039; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bouvier DS, 2015, J ALZHEIMERS DIS, V45, P1001, DOI 10.3233/JAD-143156; Burda JE, 2017, CELL RES, V27, P726, DOI 10.1038/cr.2017.37; Cafferty WBJ, 2007, J NEUROSCI, V27, P2176, DOI 10.1523/JNEUROSCI.5176-06.2007; Chiu CC, 2016, J NEUROSCI METH, V272, P38, DOI 10.1016/j.jneumeth.2016.06.018; Clarke LE, 2018, P NATL ACAD SCI USA, V115, pE1896, DOI 10.1073/pnas.1800165115; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; Deczkowska A, 2018, CELL, V173, P1073, DOI 10.1016/j.cell.2018.05.003; Donat CK, 2017, FRONT AGING NEUROSCI, V9, DOI 10.3389/fnagi.2017.00208; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Fehily B, 2017, CELL TRANSPLANT, V26, P1131, DOI 10.1177/0963689717714092; Fourgeaud L, 2016, NATURE, V532, P240, DOI 10.1038/nature17630; Grabert K, 2016, NAT NEUROSCI, V19, P504, DOI 10.1038/nn.4222; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008; Hickman SE, 2013, NAT NEUROSCI, V16, P1896, DOI 10.1038/nn.3554; Huber BR, 2016, NEUROSCIENCE, V319, P206, DOI 10.1016/j.neuroscience.2016.01.022; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Johnson VE, 2017, ADV NEUROBIOL, V15, P383, DOI 10.1007/978-3-319-57193-5_15; Johnstone VPA, 2015, J NEUROTRAUM, V32, P1333, DOI 10.1089/neu.2014.3785; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Kelso ML, 2014, CURR PHARM DESIGN, V20, P4284; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Keren-Shaul H, 2017, CELL, V169, P1276, DOI 10.1016/j.cell.2017.05.018; Kim JV, 2006, J IMMUNOL, V177, P5269, DOI 10.4049/jimmunol.177.8.5269; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; Lau CL, 2012, J CELL PHYSIOL, V227, P1199, DOI 10.1002/jcp.22838; Lenz KM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00698; Li LZ, 2008, J CEREBR BLOOD F MET, V28, P468, DOI 10.1038/sj.jcbfm.9600546; Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029; Loane David J, 2015, Handb Clin Neurol, V127, P343, DOI 10.1016/B978-0-444-52892-6.00022-2; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Martinez-Lozada Z, 2016, ADV PHARMACOL, V76, P103, DOI 10.1016/bs.apha.2016.01.004; Meng QY, 2017, EBIOMEDICINE, V16, P184, DOI 10.1016/j.ebiom.2017.01.046; Namihira M, 2013, CURR OPIN NEUROBIOL, V23, P921, DOI 10.1016/j.conb.2013.06.002; Natale JE, 2003, J NEUROTRAUM, V20, P907, DOI 10.1089/089771503770195777; Norden DM, 2014, GLIA, V62, P881, DOI 10.1002/glia.22647; Panickar KS, 2005, GLIA, V50, P287, DOI 10.1002/glia.20181; Paxinos G., 2007, RAT BRAIN STEREOTAXI, V6th ed.; Ramlackhansingh AF, 2011, ANN NEUROL, V70, P374, DOI 10.1002/ana.22455; Ransohoff RM, 2016, NAT NEUROSCI, V19, P987, DOI 10.1038/nn.4338; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Sarlus H, 2017, J CLIN INVEST, V127, P3240, DOI 10.1172/JCI90606; Schipke CG, 2001, FASEB J, V15, P255, DOI 10.1096/fj.01-0514fje; Schmitz C, 2005, NEUROSCIENCE, V130, P813, DOI 10.1016/j.neuroscience.2004.08.050; Sewell DL, 2004, J NEUROIMMUNOL, V155, P55, DOI 10.1016/j.jneuroim.2004.06.003; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shultz SR, 2015, J CEREBR BLOOD F MET, V35, P1339, DOI 10.1038/jcbfm.2015.56; Shultz SR, 2013, EPILEPSIA, V54, P1240, DOI 10.1111/epi.12223; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sun MJ, 2018, BRAIN BEHAV IMMUN, V69, P618, DOI 10.1016/j.bbi.2018.01.007; Verderio C, 2001, J IMMUNOL, V166, P6383, DOI 10.4049/jimmunol.166.10.6383; Verkhratsky A, 2017, ADV NEUROBIOL, V15, P427, DOI 10.1007/978-3-319-57193-5_17; Webster KM, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-016-0786-1; Webster KM, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0457-7; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wright DK, 2017, CEREB CORTEX, V27, P4503, DOI 10.1093/cercor/bhw254; Yun SP, 2018, NAT MED, V24, P931, DOI 10.1038/s41591-018-0051-5; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Ziebell JM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-247; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	81	31	32	2	14	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	JUN	2019	44	6			SI		1410	1424		10.1007/s11064-019-02721-8			15	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	HY8CL	WOS:000468364900015	30661228				2021-06-18	
J	Gall, LS; Vulliamy, P; Gillespie, S; Jones, TE; Pierre, RSJ; Breukers, SE; Gaarder, C; Juffermans, NP; Maegele, M; Stensballe, J; Johansson, PI; Davenport, RA; Brohi, K; Kolstadbraaten, KM; Baksaas-Aasen, K; Naess, PA; Ostrowski, SR; Vrangbaek, K; Bergmann, R; Hansen, SK; Rourke, C; Goerlinger, K; Hochleitner, M; Dias, J; Stanworth, SJ; Curry, N; Sturmer, EK; Schafer, N; Driessen, A; Balvers, K; van Dieren, S; Harrison, M; Soyel, H				Gall, Lewis S.; Vulliamy, Paul; Gillespie, Scarlett; Jones, Timothy E.; Pierre, Rochelle S. J.; Breukers, Sabine E.; Gaarder, Christine; Juffermans, Nicole P.; Maegele, Marc; Stensballe, Jakob; Johansson, Par, I; Davenport, Ross A.; Brohi, Karim; Kolstadbraaten, K. M.; Baksaas-Aasen, K.; Naess, P. A.; Ostrowski, S. R.; Vrangbaek, K.; Bergmann, R.; Hansen, S. K.; Rourke, C.; Goerlinger, K.; Hochleitner, M.; Dias, J.; Stanworth, S. J.; Curry, N.; Stuermer, E. K.; Schaefer, N.; Driessen, A.; Balvers, K.; van Dieren, S.; Harrison, M.; Soyel, H.		Targeted Action Curing Trauma-Indu	The S100A10 Pathway Mediates an Occult Hyperfibrinolytic Subtype in Trauma Patients	ANNALS OF SURGERY			English	Article						coagulopathy; fibrinolysis; S100A10; trauma	ANNEXIN II TETRAMER; TRANEXAMIC ACID; FIBRINOLYSIS SHUTDOWN; EARLY COAGULOPATHY; PLASMINOGEN; INJURY; HETEROTETRAMER; ACTIVATION; RECEPTORS; MORTALITY	Objective: To determine the characteristics of trauma patients with low levels of fibrinolysis as detected by viscoelastic hemostatic assay (VHA) and explore the underlying mechanisms of this subtype. Background: Hyperfibrinolysis is a central component of acute traumatic coagulopathy but a group of patients present with low levels of VHA-detected fibrinolysis. There is concern that these patients may be at risk of thrombosis if empirically administered an antifibrinolytic agent. Methods: A prospective multicenter observational cohort study was conducted at 5 European major trauma centers. Blood was drawn on arrival, within 2 hours of injury, for VHA (rotation thromboelastometry [ROTEM]) and fibrinolysis plasma protein analysis including the fibrinolytic mediator S100A10. An outcomes-based threshold for ROTEM hypofibrinolysis was determined and patients grouped by this and by D-dimer (DD) levels. Results: Nine hundred fourteen patients were included in the study. The VHA maximum lysis (ML) lower threshold was determined to be <5%. Heterogeneity existed among patients with low ML, with survivors sharing similar clinical and injury characteristics to patients with normal ML values (5-15%). Those who died were critically injured with a preponderance of traumatic brain injury and had a 7-fold higher DD level (died vs. survived: 103,170 vs. 13,672 ng/mL, P < 0.001). Patients with low ML and high DD demonstrated a hyperfibrinolytic biomarker profile, low tissue plasminogen activator levels but high plasma levels of S100A10. S100A10 was negatively correlated with % ML (r = -0.26, P < 0.001) and caused a significant reduction in % ML when added to whole blood ex-vivo. Conclusions: Patients presenting with low ML and low DD levels have low injury severity and normal outcomes. Conversely, patients with low ML but high DD levels are severely injured, functionally coagulopathic and have poor clinical outcomes. These patients have low tissue plasminogen activator levels and are not detectable by ROTEM. S100A10 is a cell surface plasminogen receptor which may drive the hyperfibrinolysis in these patients and which when shed artificially lowers % ML ex-vivo.	[Gall, Lewis S.; Vulliamy, Paul; Gillespie, Scarlett; Jones, Timothy E.; Pierre, Rochelle S. J.; Breukers, Sabine E.; Davenport, Ross A.; Brohi, Karim; Rourke, C.] Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Trauma Sci, Blizard Inst, London E1 2AT, England; [Gaarder, Christine; Kolstadbraaten, K. M.; Baksaas-Aasen, K.; Naess, P. A.; Ostrowski, S. R.; Vrangbaek, K.; Bergmann, R.; Hansen, S. K.] Oslo Univ Hosp, Dept Traumatol, Oslo, Norway; [Juffermans, Nicole P.] Acad Med Ctr, Dept Intens Care Med, Amsterdam, Netherlands; [Maegele, Marc; Stuermer, E. K.; Schaefer, N.; Driessen, A.] Univ Witten Herdecke, Cologne Merhe Med Ctr, Dept Traumatol & Orthopaed Surg, Cologne, Germany; [Stensballe, Jakob; Johansson, Par, I] Univ Copenhagen, Dept Anaesthesia, Ctr Head & Orthopaed, Rigshosp, Copenhagen, Denmark; [Stensballe, Jakob; Johansson, Par, I] Copenhagen Univ Hosp, Capital Reg Blood Bank, Rigshosp, Dept Anaesthesia,Ctr Head & Orthopaed, Copenhagen, Denmark; [Stensballe, Jakob; Johansson, Par, I] Univ Copenhagen, Rigshosp, Trauma Ctr, Ctr Head & Orthopaed, Copenhagen, Denmark; [Goerlinger, K.] Univ Duisburg Essen, Univ Hosp Essen, Dept Anaesthesiol & Intens Care Med, Duisburg, Germany; [Goerlinger, K.; Hochleitner, M.] Tem Int, Munich, Germany; [Dias, J.] Haemonet SA, Dept Clin Mkt, Signy, Switzerland; [Stanworth, S. J.; Curry, N.] Oxford Univ Hosp NHS Fdn Trust, Dept Haematol, Oxford, England; [Stanworth, S. J.] NHS Blood & Transplant, Oxford, England; [Curry, N.] NIHR BRC Oxford Haematol Theme, Oxford, England; [Balvers, K.; van Dieren, S.; Harrison, M.; Soyel, H.] Queen Mary Univ London, Sch Elect Engn & Comp Sci, London, England; [Harrison, M.] Newcastle Univ, Sch Comp, Newcastle, NSW, Australia	Brohi, K (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Trauma Sci, Blizard Inst, London E1 2AT, England.	k.brohi@qmul.ac.uk	Baksaas-Aasen, Kjersti/AAP-4957-2021; Ostrowski, Sisse R/E-7423-2011	Baksaas-Aasen, Kjersti/0000-0002-1140-8939; Ostrowski, Sisse R/0000-0001-5288-3851	European Commission under the FP7 HEALTH-Contract [F3-2013-602771]; Royal College of Surgeons of England; Barts Charity (UK)	The research leading to these results has received funding from the European Commission under the FP7 HEALTH-Contract No. F3-2013-602771. PVis the recipient of a research fellowship from the Royal College of Surgeons of England. Additional financial support was provided by Barts Charity (UK). Reagents and materials were provided on an unrestricted basis by Haemonetics (USA) and TEM international (Germany).	[Anonymous], 2013, PREHOSPITAL TRANEXAM; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brohi K, 2008, J TRAUMA, V64, P1211, DOI 10.1097/TA.0b013e318169cd3c; Choi KS, 2001, J BIOL CHEM, V276, P25212, DOI 10.1074/jbc.M101426200; Cole E, 2015, ANN SURG, V261, P390, DOI 10.1097/SLA.0000000000000717; Davenport RA, 2017, ANESTHESIOLOGY, V126, P115, DOI 10.1097/ALN.0000000000001428; Dewan Y, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-87; Egeland M, 2011, NEUROPHARMACOLOGY, V61, P442, DOI 10.1016/j.neuropharm.2011.01.046; Gall LS, 2017, SEMIN THROMB HEMOST, V43, P224, DOI 10.1055/s-0036-1598001; Ganter MT, 2008, ANESTH ANALG, V106, P1366, DOI 10.1213/ane.0b013e318168b367; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Kassam G, 1998, J BIOL CHEM, V273, P4790, DOI 10.1074/jbc.273.8.4790; Kwaan HC, 2004, J THROMB HAEMOST, V2, P306, DOI 10.1111/j.1538-7933.2004.00593.x; Luo M, 2013, SEMIN THROMB HEMOST, V39, P338, DOI 10.1055/s-0033-1334143; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; MacLeod TJ, 2003, J BIOL CHEM, V278, P25577, DOI 10.1074/jbc.M301017200; Madureira PA, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/353687; Madureira PA, 2011, BLOOD, V118, P4789, DOI 10.1182/blood-2011-06-334672; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; Moore EE, 2016, TRANSFUSION, V56, pS110, DOI 10.1111/trf.13486; Moore HB, 2016, J AM COLL SURGEONS, V222, P347, DOI 10.1016/j.jamcollsurg.2016.01.006; Moore HB, 2014, J TRAUMA ACUTE CARE, V77, P811, DOI 10.1097/TA.0000000000000341; Morrison JJ, 2013, JAMA SURG, V148, P218, DOI 10.1001/jamasurg.2013.764; Morrison JJ, 2012, ARCH SURG-CHICAGO, V147, P113, DOI 10.1001/archsurg.2011.287; O'Connell PA, 2011, BLOOD, V117, P4095, DOI 10.1182/blood-2010-07-298851; Raza I, 2013, J THROMB HAEMOST, V11, P307, DOI 10.1111/jth.12078; Roberts I, 2016, TRANSFUSION, V56, pS115, DOI 10.1111/trf.13490; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5	28	31	32	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	JUN	2019	269	6					1184	1191		10.1097/SLA.0000000000002733			8	Surgery	Surgery	IQ4OM	WOS:000480730100035	31082919	Green Accepted			2021-06-18	
J	Hill, CE; Blank, LJ; Thibault, D; Davis, KA; Dahodwala, N; Litt, B; Willis, AW				Hill, Chloe E.; Blank, Leah J.; Thibault, Dylan; Davis, Kathryn A.; Dahodwala, Nabila; Litt, Brian; Willis, Allison W.			Continuous EEG is associated with favorable hospitalization outcomes for critically ill patients	NEUROLOGY			English	Article							TRAUMATIC BRAIN-INJURY; STATUS EPILEPTICUS; ELECTROGRAPHIC SEIZURES; VALIDATION; CHILDREN	Objective To characterize continuous EEG (cEEG) use patterns in the critically ill and to determine the association with hospitalization outcomes for specific diagnoses. Methods We performed a retrospective cross-sectional study with National Inpatient Sample data from 2004 to 2013. We sampled hospitalized adult patients who received intensive care and then compared patients who underwent cEEG to those who did not. We considered diagnostic subgroups of seizure/status epilepticus, subarachnoid or intracerebral hemorrhage, and altered consciousness. Outcomes were in-hospital mortality, hospitalization cost, and length of stay. Results In total, 7,102,399 critically ill patients were identified, of whom 22,728 received cEEG. From 2004 to 2013, the proportion of patients who received cEEG increased from 0.06% (95% confidence interval [CI] 0.03%-0.09%) to 0.80% (95% CI 0.62%-0.98%). While the cEEG cohort appeared more ill, cEEG use was associated with reduced in-hospital mortality after adjustment for patient and hospital characteristics (odds ratio [OR] 0.83, 95% CI 0.75-0.93, p < 0.001). This finding held for the diagnoses of subarachnoid or intracerebral hemorrhage and for altered consciousness but not for the seizure/status epilepticus subgroup. Cost and length of hospitalization were increased for the cEEG cohort (OR 1.17 and OR 1.11, respectively, p < 0.001). Conclusions There was a >10-fold increase in cEEG use from 2004 to 2013. However, this procedure may still be underused; cEEG was associated with lower in-hospital mortality but used for only 0.3% of the critically ill population. While administrative claims analysis supports the utility of cEEG for critically ill patients, our findings suggest variable benefit by diagnosis, and investigation with greater clinical detail is warranted.	[Hill, Chloe E.; Blank, Leah J.; Thibault, Dylan; Davis, Kathryn A.; Dahodwala, Nabila; Litt, Brian; Willis, Allison W.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA; [Hill, Chloe E.; Dahodwala, Nabila; Willis, Allison W.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; [Thibault, Dylan; Willis, Allison W.] Univ Penn, Dept Neurol, Translat Ctr Excellence Neurol Outcomes Res, Philadelphia, PA 19104 USA; [Willis, Allison W.] Univ Penn, Dept Biostat Epidemiol & Informat, Philadelphia, PA 19104 USA	Hill, CE (corresponding author), Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.; Hill, CE (corresponding author), Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA.	chloehi@med.umich.edu	Willis, Allison/ABC-9010-2020	Willis, Allison/0000-0001-5724-7192; Blank, Leah J/0000-0001-8719-6752; Dahodwala, Nabila/0000-0003-3659-0244	Mirowski Family Fund; Family of Johnathan Rothberg; American Epilepsy Society/Epilepsy Foundation Research and Training Fellowship for Clinicians; Neurologic Clinical Epidemiology Training Grant [T32-NS-061779]; University of Pennsylvania Department of Neurology; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS092973, T32NS061779] Funding Source: NIH RePORTER	The first authors were supported by the Mirowski Family Fund and the Family of Johnathan Rothberg (C.H.) and by the American Epilepsy Society/Epilepsy Foundation Research and Training Fellowship for Clinicians, as well as the Neurologic Clinical Epidemiology Training Grant (T32-NS-061779) (L.B.). Additional funding for this study came from the University of Pennsylvania Department of Neurology.	Abend NS, 2015, J CLIN NEUROPHYSIOL, V32, P257, DOI 10.1097/WNP.0000000000000170; Abend NS, 2011, NEUROCRIT CARE, V15, P70, DOI 10.1007/s12028-010-9380-z; Abend NS, 2010, NEUROCRIT CARE, V12, P382, DOI 10.1007/s12028-010-9337-2; Alvarez V, 2017, CLIN NEUROPHYSIOL, V128, P570, DOI 10.1016/j.clinph.2017.01.001; Betjemann JP, 2015, LANCET NEUROL, V14, P615, DOI 10.1016/S1474-4422(15)00042-3; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Claassen J, 2004, NEUROLOGY, V62, P1743, DOI 10.1212/01.WNL.0000125184.88797.62; Committee on the Learning Health Care System in America Institute of Medicine, 2013, BEST CARE LOWER COST; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Friedman D, 2009, ANESTH ANALG, V109, P506, DOI 10.1213/ane.0b013e3181a9d8b5; Gavvala J, 2014, EPILEPSIA, V55, P1864, DOI 10.1111/epi.12809; Gorelick PB, 2016, LANCET NEUROL, V15, P444, DOI 10.1016/S1474-4422(16)00020-X; Gutierrez-Colina AM, 2012, PEDIATR NEUROL, V46, P158, DOI 10.1016/j.pediatrneurol.2011.12.009; Herman ST, 2015, J CLIN NEUROPHYSIOL, V32, P87, DOI 10.1097/WNP.0000000000000166; Hirsch LJ, 2015, EPILEPSY CURR, V15, P313, DOI 10.5698/1535-7511-15.6.313; Kerlin MP, 2016, AM J RESP CRIT CARE, V194, P1548; Khawaja AM, 2017, MED SCI MONITOR, V23, P649, DOI 10.12659/MSM.900826; Kilbride RD, 2009, ARCH NEUROL-CHICAGO, V66, P723, DOI 10.1001/archneurol.2009.100; Litt B, 1998, EPILEPSIA, V39, P1194, DOI 10.1111/j.1528-1157.1998.tb01311.x; McCormick N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135834; Ney JP, 2013, NEUROLOGY, V81, P2002, DOI 10.1212/01.wnl.0000436948.93399.2a; Payne ET, 2014, BRAIN, V137, P1429, DOI 10.1093/brain/awu042; Reid AY, 2012, EPILEPSY RES, V102, P173, DOI 10.1016/j.eplepsyres.2012.05.009; Scheuer ML, 2002, EPILEPSIA, V43, P114, DOI 10.1046/j.1528-1157.43.s.3.7.x; Schmitt SE, 2017, J CLIN NEUROPHYSIOL, V34, P158, DOI 10.1097/WNP.0000000000000335; Sutter R, 2013, NAT REV NEUROL, V9, P525, DOI 10.1038/nrneurol.2013.154; Topjian AA, 2013, CRIT CARE MED, V41, P215, DOI 10.1097/CCM.0b013e3182668035; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J CLIN NEUROPHYSIOL, V16, P1, DOI 10.1097/00004691-199901000-00001	30	31	33	1	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0028-3878	1526-632X		NEUROLOGY	Neurology	JAN 1	2019	92	1					E9	E18		10.1212/WNL.0000000000006689			10	Clinical Neurology	Neurosciences & Neurology	HQ3TZ	WOS:000462334700002	30504428	Green Published			2021-06-18	
J	Brossart, DF; Laird, VC; Armstrong, TW				Brossart, Daniel F.; Laird, Vanessa C.; Armstrong, Trey W.			Interpreting Kendall's Tau and Tau-U for single-case experimental designs	COGENT PSYCHOLOGY			English	Article						effect size; single-case; single-subject; Tau; time series	TRAUMATIC BRAIN-INJURY; VISUAL ANALYSIS; TIME-SERIES; EFFECT SIZES; QUANTITATIVE SYNTHESIS; INTRASUBJECT DATA; SUBJECT RESEARCH; SELF-TALK; INTERVENTION; PERFORMANCE	Tau (tau), a nonparametric rank order correlation statistic, has been applied to single-case experimental designs with promising results. Tau-U, a family of related coefficients, partitions variance associated with changes in trend and level. By examining within-phase trend and across-phase differences separately with Tau-U, single-case investigators may gain useful descriptive and inferential insights about their data. Heuristic data sets were used to explore Tau-U's conceptual foundation, and 115 published single-case data sets were analyzed to demonstrate that Tau-U coefficients perform predictably when they are well understood. An understanding of Tau-U's theoretical basis and unique limitations will help investigators select the appropriate statistical method to test their hypotheses and interpret their results appropriately. Limitations of Tau-U include as follows: vague or inconsistent Tau-U terminology in published single-case research; arithmetic problems that lead to unexpected and difficult-to-interpret results, especially when controlling for baseline trend; Tau-U methods are difficult to graph visually, and a comparison with visual raters found that several Tau-U effect size statistics are weakly correlated with visual analysis.	[Brossart, Daniel F.; Laird, Vanessa C.; Armstrong, Trey W.] Texas A&M Univ, Dept Educ Psychol, College Stn, TX 77843 USA	Brossart, DF (corresponding author), Texas A&M Univ, Educ Psychol, College Stn, TX 77843 USA.	brossart@tamu.edu; vanessaclaird@gmail.com; treywarmstrong@gmail.com	Brossart, Daniel/B-9770-2015	Brossart, Daniel/0000-0003-2619-1450	University Libraries; Office of the Vice President for Research	The authors received no direct funding for this research. The open access publishing fees for this article have been covered by the Texas A&M University Open Access to Knowledge Fund (OAKFund), supported by the University Libraries and the Office of the Vice President for Research.	ALLISON DB, 1993, BEHAV RES THER, V31, P621, DOI 10.1016/0005-7967(93)90115-B; Atkins DC, 2005, J CONSULT CLIN PSYCH, V73, P982, DOI 10.1037/0022-006X.73.5.982; BAER DM, 1977, J APPL BEHAV ANAL, V10, P167, DOI 10.1901/jaba.1977.10-167; Barlow D.H., 1984, SINGLE CASE EXPT DES; Barnett SD, 2012, J REHABIL RES DEV, V49, P175, DOI 10.1682/JRRD.2010.12.0242; Borckardt JJ, 2008, AM PSYCHOL, V63, P77, DOI 10.1037/0003-066X.63.2.77; Brossart DF, 2008, REHABIL PSYCHOL, V53, P357, DOI 10.1037/a0012973; Brossart DF, 2006, BEHAV MODIF, V30, P531, DOI 10.1177/0145445503261167; Brossart DF, 2014, NEUROPSYCHOL REHABIL, V24, P464, DOI 10.1080/09602011.2013.868361; Brossart DF, 2011, BEHAV RES METHODS, V43, P710, DOI 10.3758/s13428-011-0079-7; Byiers BJ, 2012, AM J SPEECH-LANG PAT, V21, P397, DOI 10.1044/1058-0360(2012/11-0036); Campbell JM, 2004, BEHAV MODIF, V28, P234, DOI 10.1177/0145445503259264; Cole K, 2005, BEHAV COGN PSYCHOTH, V33, P89, DOI 10.1017/S1352465804001791; Cook T. D., 2002, EXPT QUASIEXPERIMENT; Cory L, 2006, THER RECREAT J, V40, P144; DEPROSPERO A, 1979, J APPL BEHAV ANAL, V12, P573, DOI 10.1901/jaba.1979.12-573; Faith M. S., 1996, DESIGN ANAL SINGLE C, P245, DOI DOI 10.4324/9781315806402; Fisher W. W., 2003, J APPL BEHAV ANAL, V36, P406; *Geremia G. M., 1997, THESIS; GetData Graph Digitizer, 2013, GETDATA GRAPH DIG 2; Hagopian LP, 1997, J APPL BEHAV ANAL, V30, P313, DOI 10.1901/jaba.1997.30-313; Hamilton RA, 2007, J APPL SPORT PSYCHOL, V19, P226, DOI 10.1080/10413200701230613; HARBST KB, 1991, PHYS THER, V71, P107, DOI 10.1093/ptj/71.2.107; Heard K, 1997, THESIS; Hedges, 2008, EVIDENCE BASED COMMU, V2, P188, DOI [10.1080/17489530802581603, DOI 10.1080/17489530802581603]; Hillis AE, 1998, J INT NEUROPSYCH SOC, V4, P648, DOI 10.1017/S135561779846613X; Hopper T, 1998, APHASIOLOGY, V12, P933, DOI 10.1080/02687039808249461; Huitema BE, 2000, EDUC PSYCHOL MEAS, V60, P38, DOI 10.1177/00131640021970358; HUITEMA BE, 1986, RES METHODS APPL BEH; Huitema BE, 2007, J MOD APPL STAT METH, V6, P367; Johnson JJM, 2004, SPORT PSYCHOL, V18, P44, DOI 10.1123/tsp.18.1.44; Jonsdottir J, 2007, NEUROREHAB NEURAL RE, V21, P190, DOI 10.1177/1545968306290823; Kahng S, 2010, J APPL BEHAV ANAL, V43, P35, DOI 10.1901/jaba.2010.43-35; KAZDIN AE, 1978, J CONSULT CLIN PSYCH, V46, P629, DOI 10.1037/0022-006X.46.4.629; Kendall M.G., 1976, RANK CORRELATION MET, V4th; Kendall MG, 1938, BIOMETRIKA, V30, P81, DOI 10.1093/biomet/30.1-2.81; Kevan IM, 2007, CLIN PSYCHOL PSYCHOT, V14, P229, DOI 10.1002/cpp.534; *Khawaja N. G., 1998, BEHAV COGNITIVE PSYC, V26, P271, DOI 10.1017/S1352465898000289; Kinugasa T, 2004, SPORTS MED, V34, P1035, DOI 10.2165/00007256-200434150-00003; Koul R., 1998, AUGMENT ALTERN COMM, V14, P11, DOI [10.1080/07434619812331278166, DOI 10.1080/07434619812331278166]; Kratochwill T., 2010, SINGLE CASE DESIGN T; Kratochwill TR, 2013, REM SPEC EDUC, V34, P26, DOI 10.1177/0741932512452794; Krippendorff K., 2013, CONTENT ANAL INTRO I, V3rd; Lerner BS, 1996, SPORT PSYCHOL, V10, P382, DOI 10.1123/tsp.10.4.382; Levesque M, 2004, J BEHAV THER EXP PSY, V35, P287, DOI 10.1016/j.jbtep.2004.05.002; *Lewin L. M., 1997, J CLIN GEROPSYCHOLOG, V3, P245; Ma HH, 2006, BEHAV MODIF, V30, P598, DOI 10.1177/0145445504272974; Manolov R, 2008, BEHAV MODIF, V32, P860, DOI 10.1177/0145445508318866; MATSON JL, 1993, J APPL BEHAV ANAL, V26, P389, DOI 10.1901/jaba.1993.26-389; Matson JL, 2012, RES AUTISM SPECT DIS, V6, P931, DOI 10.1016/j.rasd.2011.12.008; MATYAS TA, 1990, J APPL BEHAV ANAL, V23, P341, DOI 10.1901/jaba.1990.23-341; McDonnell A. A., 1998, BEHAV COGN PSYCHOTH, V26, P163, DOI DOI 10.1017/S1352465898000174; McKelvey ML, 2007, J MED SPEECH-LANG PA, V15, P305; Nott MT, 2008, BRAIN INJURY, V22, P669, DOI 10.1080/02699050802227170; Palmisano B, 2007, BEHAV CHANGE, V24, P36, DOI 10.1375/bech.24.1.36; PARK HS, 1990, J EXP EDUC, V58, P311, DOI 10.1080/00220973.1990.10806545; Parker RI, 2006, SCHOOL PSYCHOL QUART, V21, P46, DOI 10.1521/scpq.2006.21.1.46; Parker RI, 2003, BEHAV THER, V34, P189, DOI 10.1016/S0005-7894(03)80013-8; Parker RI, 2007, BEHAV THER, V38, P95, DOI 10.1016/j.beth.2006.05.002; Parker RI, 2007, BEHAV MODIF, V31, P919, DOI 10.1177/0145445507303452; Parker RI, 2007, J SPEC EDUC, V40, P194, DOI 10.1177/00224669070400040101; Parker RI, 2011, BEHAV MODIF, V35, P303, DOI 10.1177/0145445511399147; Parker RI, 2009, BEHAV THER, V40, P357, DOI 10.1016/j.beth.2008.10.006; Parsonson B. S., 1986, RES METHODS APPL BEH, P157, DOI DOI 10.1007/978-1-4684-8786-2_8; Peach RK, 2004, APHASIOLOGY, V18, P429, DOI 10.1080/02687030444000147; R Core Team, 2013, R LANG ENV STAT COMP; RASING EJ, 1993, J APPL BEHAV ANAL, V26, P405, DOI 10.1901/jaba.1993.26-405; Raymer AM, 2007, NEUROPSYCHOL REHABIL, V17, P244, DOI 10.1080/09602010600814661; REID DH, 1993, J APPL BEHAV ANAL, V26, P139, DOI 10.1901/jaba.1993.26-139; Renvall K, 2007, APHASIOLOGY, V21, P499, DOI 10.1080/02687030701254248; Rizvi SL, 2008, SUICIDE LIFE-THREAT, V38, P498, DOI 10.1521/suli.2008.38.5.498; Rose M, 2006, APHASIOLOGY, V20, P1186, DOI 10.1080/02687030600757325; SCRUGGS TE, 1987, REM SPEC EDUC, V8, P24, DOI 10.1177/074193258700800206; SEN PK, 1968, J AM STAT ASSOC, V63, P1379; Shadish W. R., 2015, ROLE BETWEEN CASE EF; Shadish WR, 2014, J SCHOOL PSYCHOL, V52, P149, DOI 10.1016/j.jsp.2013.11.004; Singh NN, 2006, BEHAV MODIF, V30, P423, DOI 10.1177/0145445504272971; Smith JD, 2012, PSYCHOL METHODS, V17, P510, DOI 10.1037/a0029312; Solomon BG, 2014, BEHAV MODIF, V38, P477, DOI 10.1177/0145445513510931; Stapleton S, 2007, BRAIN INJURY, V21, P401, DOI 10.1080/02699050701252030; Stewart KK, 2007, J APPL BEHAV ANAL, V40, P713, DOI 10.1901/jaba.2007.713-718; Suzman KB, 1997, J BEHAV THER EXP PSY, V28, P203, DOI 10.1016/S0005-7916(97)00023-2; Tarlow K.R., 2016, BASELINE CORRECTED T; Tarlow K. R., 2014, KENDALLS TAU TAU U S; Tarlow KR, 2017, BEHAV MODIF, V41, P427, DOI 10.1177/0145445516676750; Tate RL, 2008, NEUROPSYCHOL REHABIL, V18, P385, DOI 10.1080/09602010802009201; Theil H., 1950, NETH AK VAN WETT P, V53, P1397; Thompson CD, 1999, BEHAV INTERVENT, V14, P171, DOI 10.1002/(SICI)1099-078X(199907/09)14:3<171::AID-BIN33>3.0.CO;2-B; Thompson CK, 2006, APHASIOLOGY, V20, P1226, DOI 10.1080/02687030600875655; Tloczynski J, 1997, PSYCHOLOGIA, V40, P14; Vannest K. J., 2011, SINGLE CASE RES WEB; Wanlin CM, 1997, J APPL SPORT PSYCHOL, V9, P212, DOI 10.1080/10413209708406483; *Warren J. O., 1998, THESIS; Weems CF, 1998, J BEHAV THER EXP PSY, V29, P157, DOI 10.1016/S0005-7916(98)00005-6; WERLE MA, 1993, J APPL BEHAV ANAL, V26, P421, DOI 10.1901/jaba.1993.26-421; White O. R., 1980, EXCEPTIONAL TEACHING; Whitfield GW, 1999, RES SOCIAL WORK PRAC, V9, P399, DOI 10.1177/104973159900900402; Wilkinson LA, 2005, EDUC PSYCHOL PRACT, V21, P307, DOI 10.1080/02667360500344914; Wolery M, 2010, J SPEC EDUC, V44, P18, DOI 10.1177/0022466908328009; Wolfe K, 2015, J APPL BEHAV ANAL, V48, P472, DOI 10.1002/jaba.212; Ximenes VM, 2009, SPAN J PSYCHOL, V12, P823, DOI 10.1017/S1138741600002195	101	31	32	1	2	TAYLOR & FRANCIS AS	OSLO	KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY	2331-1908			COGENT PSYCHOL	Cogent Psychol.	OCT 21	2018	5	1							1518687	10.1080/23311908.2018.1518687			26	Psychology, Multidisciplinary	Psychology	GX7LA	WOS:000447951400001		DOAJ Gold			2021-06-18	
J	Marion, CM; Radomski, KL; Cramer, NP; Galdzicki, Z; Armstrong, RC				Marion, Christina M.; Radomski, Kryslaine L.; Cramer, Nathan P.; Galdzicki, Zygmunt; Armstrong, Regina C.			Experimental Traumatic Brain Injury Identifies Distinct Early and Late Phase Axonal Conduction Deficits of White Matter Pathophysiology, and Reveals Intervening Recovery	JOURNAL OF NEUROSCIENCE			English	Article						axon damage; CLARITY; myelin; nerve conduction; node of Ranvier; paranode	CORPUS-CALLOSUM; UNMYELINATED AXONS; MYELINATED NERVES; MILD; SPEED; NODES; HEAD; PATHOLOGY; RANVIER; DEMYELINATION	Traumatic brain injury (TBI) patients often exhibit slowed information processing speed that can underlie diverse symptoms. Processing speed depends on neural circuit function at synapses, in the soma, and along axons. Long axons in white matter (WM) tracts are particularly vulnerable to TBI. We hypothesized that disrupted axon-myelin interactions that slow or block action potential conduction in WM tracts may contribute to slowed processing speed after TBI. Concussive TBI in male/female mice was used to produce traumatic axonal injury in the corpus callosum (CC), similar to WM pathology in human TBI cases. Compound action potential velocity was slowed along myelinated axons at 3 d after TBI with partial recovery by 2 weeks, suggesting early demyelination followed by remyelination. Ultrastructurally, dispersed demyelinated axons and disorganized myelin attachment to axons at paranodes were apparent within CC regions exhibiting traumatic axonal injury. Action potential conduction is exquisitely sensitive to paranode abnormalities. Molecular identification of paranodes and nodes of Ranvier detected asymmetrical paranode pairs and abnormal heminodes after TBI. Fluorescent labeling of oligodendrocyte progenitors in NG2CreER;mTmG mice showed increased synthesis of new membranes extended along axons to paranodes, indicating remyelination after TBI. At later times after TBI, an overall loss of conducting axons was observed at 6 weeks followed by CC atrophy at 8 weeks. These studies identify a progression of both myelinated axon conduction deficits and axon-myelin pathology in the CC, implicating WM injury in impaired information processing at early and late phases after TBI. Furthermore, the intervening recovery reveals a potential therapeutic window.	[Marion, Christina M.; Radomski, Kryslaine L.; Cramer, Nathan P.; Galdzicki, Zygmunt; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Radomski, Kryslaine L.; Cramer, Nathan P.; Galdzicki, Zygmunt; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Anat Physiol & Genet, Bethesda, MD 20814 USA; [Marion, Christina M.; Galdzicki, Zygmunt; Armstrong, Regina C.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Program Neurosci, Bethesda, MD 20814 USA	Armstrong, RC (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Ctr Neurosci & Regenerat Med, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	regina.armstrong@usuhs.edu	Marion, Christina M/B-8120-2015	Marion, Christina M/0000-0003-0381-4109; Armstrong, Regina/0000-0001-7296-6750; Cramer, Nathan/0000-0001-6146-3664	U.S. Department of Defense in the Center for Neuroscience and Regenerative Medicine [CNRM703386, CNRM702720, CNRM702577]; Uniformed Services University of the Health Sciences Program [308430]; Congressionally Directed Medical Research ProgramUnited States Department of Defense [SC160213]; Center for Neuroscience and Regenerative Medicine Preclinical Models Core and Microscopy Core	This work was supported by the U.S. Department of Defense in the Center for Neuroscience and Regenerative Medicine (CNRM703386 to R.C.A.; CNRM702720 to R.C.A.; CNRM702577 to Z.G.), Uniformed Services University of the Health Sciences Program Project 308430 to Z.G., and the Congressionally Directed Medical Research Program SC160213 to R.C.A. We thank Dr. Fengshan Yu, Dr. Genevieve Sullivan, and Xiaomei Zi for technical assistance; Dr. Cara Olsen for advice with statistical analysis; Center for Neuroscience and Regenerative Medicine Preclinical Models Core and Microscopy Core for support, particularly Dr. Fritz Lishka; and Dr. Amanda Mierzwa for initial development of the myelin remodeling experiments.	Almeida RG, 2017, J NEUROSCI, V37, P10023, DOI 10.1523/JNEUROSCI.3185-16.2017; Amor V, 2017, ELIFE, V6, DOI 10.7554/eLife.21392; Arancibia-Carcamo IL, 2017, ELIFE, V6, DOI 10.7554/eLife.23329; Arancibia-Carcamo IL, 2014, ACTA NEUROPATHOL, V128, P161, DOI 10.1007/s00401-014-1305-z; Armstrong RC, 2002, J NEUROSCI, V22, P8574; Armstrong RC, 2006, J NEUROPATH EXP NEUR, V65, P245, DOI 10.1097/01.jnen.0000205142.08716.7e; Armstrong RC, 2016, NEUROPHARMACOLOGY, V110, P654, DOI 10.1016/j.neuropharm.2015.04.029; Armstrong RC, 2016, EXP NEUROL, V275, P328, DOI 10.1016/j.expneurol.2015.02.011; Babbs CF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067767; Baker AJ, 2002, J NEUROTRAUM, V19, P587, DOI 10.1089/089771502753754064; Benjamini D, 2016, NEUROIMAGE, V135, P333, DOI 10.1016/j.neuroimage.2016.04.052; BLUMBERGS PC, 1995, J NEUROTRAUM, V12, P565, DOI 10.1089/neu.1995.12.565; Brivio V, 2017, CURR BIOL, V27, P1068, DOI 10.1016/j.cub.2017.01.025; Budd JML, 2012, FRONT NEUROANAT, V6, DOI 10.3389/fnana.2012.00042; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Chung K, 2013, NATURE, V497, P332, DOI 10.1038/nature12107; Chung S, 2018, J NEUROTRAUM, V35, P1015, DOI 10.1089/neu.2017.5320; Coman I, 2006, BRAIN, V129, P3186, DOI 10.1093/brain/awl144; Donders J, 2015, ASSESSMENT, V22, P17, DOI 10.1177/1073191114530776; Dymowski AR, 2015, J CLIN EXP NEUROPSYC, V37, P1024, DOI 10.1080/13803395.2015.1074663; Felmingham KL, 2004, NEUROPSYCHOLOGY, V18, P564, DOI 10.1037/0894-4105.18.3.564; Freeman SA, 2016, CELL MOL LIFE SCI, V73, P723, DOI 10.1007/s00018-015-2081-1; Greer JE, 2013, ACTA NEUROPATHOL, V126, P59, DOI 10.1007/s00401-013-1119-4; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Griggs RB, 2017, NEUROSCI RES, V116, P77, DOI 10.1016/j.neures.2016.09.010; Gu YZ, 2017, J CELL BIOL, V216, P2179, DOI 10.1083/jcb.201606065; Hamada MS, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00045; Hartline DK, 2007, CURR BIOL, V17, pR29, DOI 10.1016/j.cub.2006.11.042; Hayes JP, 2016, J INT NEUROPSYCH SOC, V22, P120, DOI 10.1017/S1355617715000740; Huang CYM, 2017, J NEUROSCI, V37, P11323, DOI 10.1523/JNEUROSCI.2113-17.2017; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kohan ED, 2018, MED BIOL ENG COMPUT, V56, P395, DOI 10.1007/s11517-017-1691-1; Kourtidou P, 2013, J HEAD TRAUMA REHAB, V28, P433, DOI 10.1097/HTR.0b013e3182585d06; Lee YJ, 2012, NATURE, V487, P443, DOI 10.1038/nature11314; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Maxwell WL, 1996, MICROSC RES TECHNIQ, V34, P522, DOI 10.1002/(SICI)1097-0029(19960815)34:6<522::AID-JEMT4>3.0.CO;2-L; MAXWELL WL, 1993, ACTA NEUROPATHOL, V86, P136, DOI 10.1007/BF00334880; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Mierzwa AJ, 2015, J NEUROPATH EXP NEUR, V74, P218, DOI 10.1097/NEN.0000000000000165; Mierzwa AJ, 2014, ASN NEURO, V6, DOI 10.1177/1759091414551782; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; O'Jile JR, 2006, ARCH CLIN NEUROPSYCH, V21, P293, DOI 10.1016/j.acn.2006.03.003; Poliak S, 2003, NAT REV NEUROSCI, V4, P968, DOI 10.1038/nrn1253; Powers BE, 2013, P NATL ACAD SCI USA, V110, P4075, DOI 10.1073/pnas.1210293110; Reeves TM, 2012, J NEUROPATH EXP NEUR, V71, P198, DOI 10.1097/NEN.0b013e3182482590; Reeves TM, 2010, BRAIN PATHOL, V20, P1055, DOI 10.1111/j.1750-3639.2010.00412.x; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Saporta MA, 2009, BRAIN, V132, P3263, DOI 10.1093/brain/awp274; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Spitz G, 2013, J HEAD TRAUMA REHAB, V28, P116, DOI 10.1097/HTR.0b013e3182452f4f; Stone JR, 2001, EXP NEUROL, V172, P320, DOI 10.1006/exnr.2001.7818; STURROCK RR, 1980, NEUROPATH APPL NEURO, V6, P415, DOI 10.1111/j.1365-2990.1980.tb00219.x; Sullivan GM, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/9342534; Sullivan GM, 2013, J NEUROPATH EXP NEUR, V72, P1106, DOI 10.1097/NEN.0000000000000009; Susuki K, 2013, ASN NEURO, V5, DOI 10.1042/AN20130025; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; Takagishi Y, 2016, NEUROBIOL AGING, V43, P34, DOI 10.1016/j.neurobiolaging.2016.03.020; Takano M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052904; Tomer R, 2014, NAT PROTOC, V9, P1682, DOI 10.1038/nprot.2014.123; Volman V, 2014, J COMPUT NEUROSCI, V37, P439, DOI 10.1007/s10827-014-0515-7; Waxman SG, 2006, NAT REV NEUROSCI, V7, P932, DOI 10.1038/nrn2023; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Xie MQ, 2010, J NEUROPATH EXP NEUR, V69, P704, DOI 10.1097/NEN.0b013e3181e3de90; Yu FS, 2017, J NEUROTRAUM, V34, P1364, DOI 10.1089/neu.2016.4569; Zhu XQ, 2011, DEVELOPMENT, V138, P745, DOI 10.1242/dev.047951; Ziogas NK, 2018, J NEUROSCI, V38, P4031, DOI 10.1523/JNEUROSCI.2343-17.2018	70	31	31	0	2	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	OCT 10	2018	38	41					8723	8736		10.1523/JNEUROSCI.0819-18.2018			14	Neurosciences	Neurosciences & Neurology	GW3XH	WOS:000446842200001	30143572	Other Gold, Green Published			2021-06-18	
J	Arneson, D; Zhang, GL; Ying, Z; Zhuang, YM; Byun, HR; Ahn, IS; Gomez-Pinilla, F; Yang, X				Arneson, Douglas; Zhang, Guanglin; Ying, Zhe; Zhuang, Yumei; Byun, Hyae Ran; Ahn, In Sook; Gomez-Pinilla, Fernando; Yang, Xia			Single cell molecular alterations reveal target cells and pathways of concussive brain injury	NATURE COMMUNICATIONS			English	Article							NUCLEUS RNA-SEQ; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; EPENDYMAL CELLS; EXPRESSION; TRANSTHYRETIN; CONNECTIVITY; SIGNATURE; CADHERIN; CORTEX	The complex neuropathology of traumatic brain injury (TBI) is difficult to dissect, given the convoluted cytoarchitecture of affected brain regions such as the hippocampus. Hippocampal dysfunction during TBI results in cognitive decline that may escalate to other neurological disorders, the molecular basis of which is hidden in the genomic programs of individual cells. Using the unbiased single cell sequencing method Drop-seq, we report that concussive TBI affects previously undefined cell populations, in addition to classical hippocampal cell types. TBI also impacts cell type-specific genes and pathways and alters gene co-expression across cell types, suggesting hidden pathogenic mechanisms and therapeutic target pathways. Modulating the thyroid hormone pathway as informed by the T4 transporter transthyretin Ttr mitigates TBI-associated genomic and behavioral abnormalities. Thus, single cell genomics provides unique information about how TBI impacts diverse hippocampal cell types, adding new insights into the pathogenic pathways amenable to therapeutics in TBI and related disorders.	[Arneson, Douglas; Zhang, Guanglin; Ying, Zhe; Zhuang, Yumei; Byun, Hyae Ran; Ahn, In Sook; Gomez-Pinilla, Fernando; Yang, Xia] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA 90095 USA; [Arneson, Douglas; Yang, Xia] Univ Calif Los Angeles, Bioinformat Interdept Program, Los Angeles, CA 90095 USA; [Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA; [Gomez-Pinilla, Fernando] Univ Calif Los Angeles, Brain Injury Res Ctr, Los Angeles, CA 90095 USA; [Yang, Xia] Univ Calif Los Angeles, Inst Quantitat & Computat Biosci, Los Angeles, CA 90095 USA; [Yang, Xia] Univ Calif Los Angeles, Mol Biol Inst, Los Angeles, CA 90095 USA	Gomez-Pinilla, F; Yang, X (corresponding author), Univ Calif Los Angeles, Dept Integrat Biol & Physiol, Los Angeles, CA 90095 USA.; Yang, X (corresponding author), Univ Calif Los Angeles, Bioinformat Interdept Program, Los Angeles, CA 90095 USA.; Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Dept Neurosurg, Los Angeles, CA 90095 USA.; Gomez-Pinilla, F (corresponding author), Univ Calif Los Angeles, Brain Injury Res Ctr, Los Angeles, CA 90095 USA.; Yang, X (corresponding author), Univ Calif Los Angeles, Inst Quantitat & Computat Biosci, Los Angeles, CA 90095 USA.; Yang, X (corresponding author), Univ Calif Los Angeles, Mol Biol Inst, Los Angeles, CA 90095 USA.	fgomezpi@ucla.edu; xyang123@ucla.edu		Arneson, Douglas/0000-0002-9464-2586	UCLA BIRC; Hyde Fellowship; NIH-NCI National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [T32CA201160];  [R01 DK104363];  [R21 NS103088];  [R01 NS50465]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [T32CA201160] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK104363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050465, R21NS103088] Funding Source: NIH RePORTER	We thank Dr. Weizhe Hong for advice on neuronal subpopulation analysis and helpful discussions. X.Y. and F.G-P. are funded by R01 DK104363 and R21 NS103088. F.GP. is funded by R01 NS50465 and UCLA BIRC. D.A. is funded by Hyde Fellowship and NIH-NCI National Cancer Institute T32CA201160.	BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; Bassett DS, 2017, NAT NEUROSCI, V20, P353, DOI 10.1038/nn.4502; Blake JA, 2015, NUCLEIC ACIDS RES, V43, pD1049, DOI 10.1093/nar/gku1179; Blennow K, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.84; Bodzioch M, 2009, GENOMICS, V94, P247, DOI 10.1016/j.ygeno.2009.05.006; Brewer GJ, 2007, NAT PROTOC, V2, P1490, DOI 10.1038/nprot.2007.207; Butler CR, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00163; Butovsky O, 2014, NAT NEUROSCI, V17, P131, DOI 10.1038/nn.3599; Cai H, 2012, CURR ALZHEIMER RES, V9, P5, DOI 10.2174/156720512799015064; Carlen M, 2009, NAT NEUROSCI, V12, P259, DOI 10.1038/nn.2268; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Croft D, 2014, NUCLEIC ACIDS RES, V42, pD472, DOI 10.1093/nar/gkt1102; Di YM, 2011, STAT APPL GENET MOL, V10, DOI 10.2202/1544-6115.1637; Elliott RC, 2001, NEUROSCIENCE, V106, P79, DOI 10.1016/S0306-4522(01)00198-1; Fulcher BD, 2016, P NATL ACAD SCI USA, V113, P1435, DOI 10.1073/pnas.1513302113; Giddaluru S, 2016, BRAIN STRUCT FUNCT, V221, P4643, DOI 10.1007/s00429-016-1194-0; Girgis F, 2016, FRONT SYST NEUROSCI, V10, DOI 10.3389/fnsys.2016.00008; Habib N, 2017, NAT METHODS, V14, P955, DOI [10.1038/NMETH.4407, 10.1038/nmeth.4407]; Habib N, 2016, SCIENCE, V353, P925, DOI 10.1126/science.aad7038; Hayes JP, 2016, J INT NEUROPSYCH SOC, V22, P120, DOI 10.1017/S1355617715000740; Ino Y, 2002, P NATL ACAD SCI USA, V99, P365, DOI 10.1073/pnas.012425299; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kim JS, 2008, J NEUROSCI, V28, P6030, DOI 10.1523/JNEUROSCI.0891-08.2008; Lein ES, 2007, NATURE, V445, P168, DOI 10.1038/nature05453; Li JR, 2017, MOL CELL ENDOCRINOL, V452, P120, DOI 10.1016/j.mce.2017.05.023; Liang KS, 2017, EXP THER MED, V13, P576, DOI 10.3892/etm.2016.4006; Lim DA, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a018820; Lipponen A, 2016, SCI REP-UK, V6, DOI 10.1038/srep31570; Lu LY, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/470676; Lyeth BG, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00217; Macosko EZ, 2015, CELL, V161, P1202, DOI 10.1016/j.cell.2015.05.002; Madura SA, 2016, BRAIN INJURY, V30, P908, DOI 10.3109/02699052.2016.1146958; Matsuda S, 2005, J BIOL CHEM, V280, P28912, DOI 10.1074/jbc.C500217200; McDavid A, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003696; McLoughlin DM, 1999, EUR J NEUROSCI, V11, P1988, DOI 10.1046/j.1460-9568.1999.00610.x; Mendez MF, 2013, BRAIN INJURY, V27, P10, DOI 10.3109/02699052.2012.722252; Meng QY, 2017, EBIOMEDICINE, V16, P184, DOI 10.1016/j.ebiom.2017.01.046; Mondello S, 2011, EXPERT REV MOL DIAGN, V11, P65, DOI 10.1586/ERM.10.104; Mueller F, 2013, NAT METHODS, V10, P277, DOI 10.1038/nmeth.2406; Nathoo N, 2003, J CLIN PATHOL-MOL PA, V56, P132, DOI 10.1136/mp.56.3.132; Okabe T, 2003, J BIOL CHEM, V278, P9920, DOI 10.1074/jbc.M208872200; Oliveira SM, 2011, J ALZHEIMERS DIS, V27, P429, DOI 10.3233/JAD-2011-110488; Raz E, 2011, AM J NEURORADIOL, V32, P1851, DOI 10.3174/ajnr.A2637; Redell JB, 2013, J NEUROTRAUM, V30, P752, DOI 10.1089/neu.2012.2437; Richardson SJ, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00066; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Salehi A, 2017, J CEREBR BLOOD F MET, V37, P2320, DOI 10.1177/0271678X17701460; Samal BB, 2015, J MOL NEUROSCI, V57, P282, DOI 10.1007/s12031-015-0626-2; Sanders MJ, 2000, BRAIN RES, V861, P69, DOI 10.1016/S0006-8993(00)01986-7; Shively S, 2012, ARCH NEUROL-CHICAGO, V69, P1245, DOI 10.1001/archneurol.2011.3747; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Smith DJ, 2016, MOL PSYCHIATR, V21, P749, DOI 10.1038/mp.2016.49; Soltysik-Espanola M, 1999, MOL BIOL CELL, V10, P2361, DOI 10.1091/mbc.10.7.2361; Szabolcsi V, 2015, GLIA, V63, P567, DOI 10.1002/glia.22768; Takamori S, 2000, NATURE, V407, P189, DOI 10.1038/35025070; van der Maaten L, 2008, J MACH LEARN RES, V9, P2579; Van Horn JD, 2017, TRENDS NEUROSCI, V40, P39, DOI 10.1016/j.tins.2016.10.007; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; von Gertten C, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-69; Wu A, 2003, NEUROSCIENCE, V119, P365, DOI 10.1016/S0306-4522(03)00154-4; Zeisel A, 2015, SCIENCE, V347, P1138, DOI 10.1126/science.aaa1934	61	31	32	1	7	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	2041-1723			NAT COMMUN	Nat. Commun.	SEP 25	2018	9								3894	10.1038/s41467-018-06222-0			18	Multidisciplinary Sciences	Science & Technology - Other Topics	GU8CI	WOS:000445560800002	30254269	DOAJ Gold, Green Published			2021-06-18	
J	Alosco, ML; Tripodis, Y; Fritts, NG; Heslegrave, A; Baugh, CM; Conneely, S; Mariani, M; Martin, BM; Frank, S; Mez, J; Stein, TD; Cantu, RC; Mckee, AC; Shaw, LM; Trojanowski, JQ; Blennow, K; Zetterberg, H; Stern, RA				Alosco, Michael L.; Tripodis, Yorghos; Fritts, Nathan G.; Heslegrave, Amanda; Baugh, Christine M.; Conneely, Shannon; Mariani, Megan; Martin, Brett M.; Frank, Samuel; Mez, Jesse; Stein, Thor D.; Cantu, Robert C.; Mckee, Ann C.; Shaw, Leslie M.; Trojanowski, John Q.; Blennow, Kaj; Zetterberg, Henrik; Stern, Robert A.			Cerebrospinal fluid tau, A beta, and sTREM2 in Former National Football League Players: Modeling the relationship between repetitive head impacts, microglial activation, and neurodegeneration	ALZHEIMERS & DEMENTIA			English	Article						Cerebrospinal fluid; A beta; sTREM2; Chronic traumatic encephalopathy; Microglial activation; Alzheimer's disease; Repetitive head impacts; Concussion; Subconcussive	CHRONIC TRAUMATIC ENCEPHALOPATHY; ALZHEIMERS-DISEASE; BRAIN-INJURY; SOLUBLE TREM2; COGNITIVE IMPAIRMENT; POTENTIAL BIOMARKER; MULTIPLE-SCLEROSIS; PHOSPHORYLATED TAU; AMYLOID-BETA; MOUSE MODEL	Introduction: Cerebrospinal fluid (CSF) protein analysis may facilitate detection and elucidate mechanisms of neurological consequences from repetitive head impacts (RHI), such as chronic traumatic encephalopathy. We examined CSF concentrations of total tau (t-tau), phosphorylated tau, and amyloid beta(1-42) and their association with RHI in former National Football League (NFL) players. The role of microglial activation (using sTREM2) was examined as a pathogenic mechanism of chronic traumatic encephalopathy. Methods: Sixty-eight former NFL players and 21 controls underwent lumbar puncture to quantify t-tau, p-tau(181), amyloid beta(1-)(42), and sTREM2 in the CSF using immunoassays. The cumulative head impact index estimated RHI. Results: No between-group differences for CSF analytes emerged. In the former NFL players, the cumulative head impact index predicted higher t-tau concentrations (P = .041), and higher sTREM2 levels were associated with higher t-tau concentrations (P = .009). Discussion: In this sample of former NFL players, greater RHI and increased microglial activation were associated with higher CSF t-tau concentrations. (C) 2018 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.	[Alosco, Michael L.; Tripodis, Yorghos; Fritts, Nathan G.; Conneely, Shannon; Mariani, Megan; Martin, Brett M.; Mez, Jesse; Stein, Thor D.; Cantu, Robert C.; Mckee, Ann C.; Stern, Robert A.] Boston Univ, Alzheimers Dis Ctr, Boston, MA 02215 USA; [Alosco, Michael L.; Tripodis, Yorghos; Fritts, Nathan G.; Conneely, Shannon; Mariani, Megan; Martin, Brett M.; Mez, Jesse; Stein, Thor D.; Cantu, Robert C.; Mckee, Ann C.; Stern, Robert A.] Boston Univ, Sch Med, CTE Ctr, Boston, MA 02118 USA; [Alosco, Michael L.; Mez, Jesse; Cantu, Robert C.; Mckee, Ann C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Tripodis, Yorghos] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA; [Heslegrave, Amanda; Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, Queen Sq, London, England; [Heslegrave, Amanda; Zetterberg, Henrik] UCL, UK Dementia Res Inst, London, England; [Baugh, Christine M.] Harvard Univ, Interfac Initiat Hlth Policy, Boston, MA 02115 USA; [Martin, Brett M.] Boston Univ, Sch Publ Hlth, Data Coordinating Ctr, Boston, MA 02215 USA; [Frank, Samuel] Harvard Med Sch, Dept Neurol, Boston, MA USA; [Stein, Thor D.; Mckee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [Stein, Thor D.; Mckee, Ann C.] Boston Univ, Sch Med, Dept Lab Med, Boston, MA 02118 USA; [Stein, Thor D.; Mckee, Ann C.] US Dept Vet Affairs, VA Boston Healthcare Syst, Jamaica Plain, MA USA; [Stein, Thor D.; Mckee, Ann C.] Dept Vet Affairs Med Ctr, Bedford, MA USA; [Cantu, Robert C.] Concuss Legacy Fdn, Boston, MA USA; [Cantu, Robert C.; Stern, Robert A.] Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA; [Cantu, Robert C.] Emerson Hosp, Dept Neurosurg, Concord, MA USA; [Shaw, Leslie M.; Trojanowski, John Q.] Univ Penn, Perelman Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; [Blennow, Kaj] Sahlgrens Univ Hosp, Clin Neurochem Lab, Molndal, Sweden; [Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Dept Psychiat & Neurochem, Gothenburg, Sweden; [Stern, Robert A.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA	Stern, RA (corresponding author), Boston Univ, Alzheimers Dis Ctr, Boston, MA 02215 USA.; Stern, RA (corresponding author), Boston Univ, Sch Med, CTE Ctr, Boston, MA 02118 USA.; Stern, RA (corresponding author), Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.; Stern, RA (corresponding author), Boston Univ, Sch Med, Dept Neurosurg, Boston, MA 02118 USA.; Stern, RA (corresponding author), Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA.	bobstern@bu.edu	, Bob/ABA-8507-2020; Baugh, Christine/AAG-2324-2020; Lang, Steven/AAE-8102-2021	Baugh, Christine/0000-0002-9340-6338; Lang, Steven/0000-0003-1669-9146; Heslegrave, Amanda/0000-0002-7290-6405; Tripodis, Yorghos/0000-0003-2190-7608	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30 AG13846, R01 NS078337, R56 9500304025, U01 NS093334, U01NS086659-01, 1F32NS096803-01, K23AG046377, RF1AG05416, RF1AG054156-01, P30AG10124]; Department of Veterans AffairsUS Department of Veterans Affairs [I01-CX001038]; National Center for Advancing Translational Sciences, National Institutes of Health, through BU-CTSI [1UL1TR001430]; Royal Swedish Academy of Sciences; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001430] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F32NS096803, U01NS086659, K23NS102399, U01NS093334, R01NS078337, R56NS078337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG013846, P30AG010124, K23AG046377, RF1AG054156] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01CX001038] Funding Source: NIH RePORTER	This work was supported by grants from the NIH (P30 AG13846; R01 NS078337; R56 9500304025; U01 NS093334, U01NS086659-01; 1F32NS096803-01; K23AG046377; RF1AG05416; RF1AG054156-01; P30AG10124) and Department of Veterans Affairs (I01-CX001038). This publication was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through BU-CTSI Grant Number 1UL1TR001430. KB holds the Torsten Soderberg professorship at the Royal Swedish Academy of Sciences. The sTREM2 measurements were supported by the Leonard Wolfson Experimental Neurology Centre at UCL. The content is solely the responsibility of the authors. There is no sponsor.	Alosco Michael L, 2018, Alzheimers Dement (Amst), V10, P56, DOI 10.1016/j.dadm.2017.10.003; Alosco Michael L, 2017, Alzheimers Dement (Amst), V7, P33, DOI 10.1016/j.dadm.2016.11.003; Alosco ML, 2017, J NEUROTRAUM, V34, P772, DOI 10.1089/neu.2016.4536; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Blaylock Russell L, 2011, Surg Neurol Int, V2, P107, DOI 10.4103/2152-7806.83391; Blennow K, 2010, NAT REV NEUROL, V6, P131, DOI 10.1038/nrneurol.2010.4; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Cherry JD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185541; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; Coughlin JM, 2017, JAMA NEUROL, V74, P67, DOI 10.1001/jamaneurol.2016.3764; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Deters KD, 2017, J ALZHEIMERS DIS, V58, P1245, DOI 10.3233/JAD-161114; Gispert JD, 2016, ALZHEIMERS DEMENT, V12, P1259, DOI 10.1016/j.jalz.2016.06.005; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Grossman M, 2014, JAMA NEUROL, V71, P442, DOI 10.1001/jamaneurol.2013.6064; Guerreiro R, 2013, NEW ENGL J MED, V368, P117, DOI 10.1056/NEJMoa1211851; Hampel H, 2004, ARCH GEN PSYCHIAT, V61, P95, DOI 10.1001/archpsyc.61.1.95; Hausman J.A., 1983, HDB EC, V1, P391, DOI [10.1016/S1573-4412(83)01011-9, DOI 10.1016/S1573-4412(83)01011-9]; Henjum K, 2016, ALZHEIMERS RES THER, V8, DOI 10.1186/s13195-016-0182-1; Heslegrave A, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0071-x; Hesse C, 2001, NEUROSCI LETT, V297, P187, DOI 10.1016/S0304-3940(00)01697-9; Houck Z, 2018, J INT NEUROPSYCH SOC, V24, P1, DOI 10.1017/S1355617717000716; Hu WT, 2013, NEUROLOGY, V81, P1945, DOI 10.1212/01.wnl.0000436625.63650.27; Jack CR, 2016, NEUROLOGY, V87, P539, DOI 10.1212/WNL.0000000000002923; Jay TR, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0197-5; Jin SC, 2015, MOL NEURODEGENER, V10, DOI 10.1186/s13024-015-0016-9; Jonsson T, 2013, NEW ENGL J MED, V368, P107, DOI 10.1056/NEJMoa1211103; Kang JH, 2015, ALZHEIMERS DEMENT, V11, P772, DOI 10.1016/j.jalz.2015.05.003; Kitazawa M, 2005, J NEUROSCI, V25, P8843, DOI 10.1523/JNEUROSCI.2868-05.2005; Kleinberger G, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3009093; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Lee CYD, 2018, NEURON, V97, P1032, DOI 10.1016/j.neuron.2018.02.002; Lee DC, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-56; Li YK, 2003, J NEUROSCI, V23, P1605; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Metcalfe MJ, 2010, MT SINAI J MED, V77, P50, DOI 10.1002/msj.20163; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; Montenigro PH, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/s13195-014-0068-z; Nakagawa Y, 1999, J COMP NEUROL, V411, P390; Nakagawa Y, 2000, EXP NEUROL, V163, P244, DOI 10.1006/exnr.2000.7375; Neselius S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033606; Ohrfelt A, 2016, MULT SCLER J, V22, P1587, DOI 10.1177/1352458515624558; Olsson B, 2016, LANCET NEUROL, V15, P673, DOI [10.1016/s1474-4422(16)00070-3, 10.1016/S1474-4422(16)00070-3]; Petraglia Anthony L, 2014, Surg Neurol Int, V5, P184, DOI 10.4103/2152-7806.147566; Piccio L, 2008, BRAIN, V131, P3081, DOI 10.1093/brain/awn217; Piccio L, 2016, ACTA NEUROPATHOL, V131, P925, DOI 10.1007/s00401-016-1533-5; Piccio L, 2016, MULT SCLER J, V22, P54; Rosso SM, 2003, ARCH NEUROL-CHICAGO, V60, P1209, DOI 10.1001/archneur.60.9.1209; Shaw LM, 2009, ANN NEUROL, V65, P403, DOI 10.1002/ana.21610; Smith DH, 1998, AM J PATHOL, V153, P1005, DOI 10.1016/S0002-9440(10)65643-X; Spiegel J, 2016, J ALZHEIMERS DIS, V49, P93, DOI 10.3233/JAD-150167; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stern RA, 2016, J ALZHEIMERS DIS, V51, P1099, DOI 10.3233/JAD-151028; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Suarez-Calvet M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1767; Suarez-Calvet M, 2016, EMBO MOL MED, V8, P466, DOI 10.15252/emmm.201506123; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; Teunissen CE, 2018, ALZHEIMERS RES THER, V10, DOI 10.1186/s13195-018-0359-x; Udeochu J, 2018, NEURON, V97, P991, DOI 10.1016/j.neuron.2018.02.018; Ulland TK, 2017, CELL, V170, P649, DOI 10.1016/j.cell.2017.07.023; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Zetterberg H, 2006, ARCH NEUROL-CHICAGO, V63, P1277, DOI 10.1001/archneur.63.9.1277; Zetterberg H, 2016, NAT REV NEUROL, V12, P563, DOI 10.1038/nrneurol.2016.127; Zetterberg H, 2015, MOL CELL NEUROSCI, V66, P99, DOI 10.1016/j.mcn.2015.02.003; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; Zhao Y., 2018, NEURON, V97	68	31	31	3	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1552-5260	1552-5279		ALZHEIMERS DEMENT	Alzheimers. Dement.	SEP	2018	14	9					1159	1170		10.1016/j.jalz.2018.05.004			12	Clinical Neurology	Neurosciences & Neurology	GS9AZ	WOS:000444008800007	30049650	Green Accepted			2021-06-18	
J	Chen, J; Hu, J; Liu, H; Xiong, Y; Zou, YC; Huang, WT; Shao, MJ; Wu, JM; Yu, L; Wang, XJ; Wang, X; Lin, L				Chen, Jun; Hu, Jian; Liu, Huan; Xiong, Ye; Zou, Yuchi; Huang, Wenting; Shao, Mingjie; Wu, Jiamin; Yu, Li; Wang, Xiaojie; Wang, Xue; Lin, Li			FGF21 Protects the Blood-Brain Barrier by Upregulating PPAR gamma via FGFR1/beta-klotho after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						BBB; FGF21; FGF21; FGFR1; beta-klotho complex; PPAR gamma; traumatic brain injury	GROWTH-FACTOR 21; TIGHT JUNCTIONS; DAMAGE; DYSFUNCTION; BREAKDOWN; THERAPY; PATHWAY; FGF-21; TARGET; ALPHA	Blood-brain barrier (BBB) disruption and dysfunction result in brain edema, which is responsible for more than half of all deaths after severe traumatic brain injury (TBI). Fibroblast growth factor 21 (FGF21) has a potential neuroprotective function in the brain. However, the effects and underlying possible mechanism of action on BBB integrity following TBI remain unknown. The purpose of the current study was to determine the effects of FGF21 on BBB protection and TBI treatment. The effects of recombinant human FGF21 (rhFGF21) on BBB integrity and on tight junction (TJ) and adhesion junction (AJ) proteins were investigated both in a TBI mouse model and an in vitro BBB disruption model established with tumor necrosis factor alpha (TNF-alpha)-induced human brain microvascular endothelial cells (HBMECs). The ability of rhFGF21 to form an FGF21/FGFR1/beta-klotho complex was confirmed by in vitro beta-klotho small interfering RNA (siRNA) transfection and FGFR1 co-immunoprecipitation. In addition, the specific FGFR1 and peroxisome proliferator-activated receptor gamma (PPAR gamma) inhibitors PD173074 and GW9662, respectively, were applied to further explore the possible mechanism of rhFGF21 in BBB maintenance after TBI. rhFGF21 markedly reduced neurofunctional behavior deficits and cerebral edema degree, preserved BBB integrity, and recued brain tissue loss and neuron apoptosis in the mouse model after TBI. Both in vivo and in vitro, rhFGF21 upregulated TJ and AJ proteins, thereby preserving the BBB. Moreover, rhFGF21 activated PPAR gamma in TNF-alpha-induced HBMECs through formation of an FGF21/FGFR1/beta-klotho complex. rhFGF21 protected the BBB through FGF21/FGFR1/beta-klotho complex formation and PPAR gamma activation, which upregulated TJ and AJ proteins.	[Chen, Jun; Hu, Jian; Liu, Huan; Wu, Jiamin; Wang, Xiaojie; Wang, Xue; Lin, Li] Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou 325035, Zhejiang, Peoples R China; [Huang, Wenting; Shao, Mingjie] Wenzhou Med Univ, Sch Clin Med Sci 1, Wenzhou, Zhejiang, Peoples R China; [Xiong, Ye; Zou, Yuchi] Wenzhou Med Univ, Affiliated Hosp 1, Wenzhou, Zhejiang, Peoples R China; [Yu, Li] Ningbo Univ, Med Sch, Affiliated Hosp, Ningbo, Zhejiang, Peoples R China	Wang, X; Lin, L (corresponding author), Wenzhou Med Univ, Sch Pharmaceut Sci, Wenzhou 325035, Zhejiang, Peoples R China.	xinyuw001@163.com; linliwz@163.com			Public Welfare Technology Application Research Foundation of Zhejiang Province [2017C33080]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81771284]; Opening Project of Zhejiang Provincial Top Key Discipline of Pharmaceutical Sciences	This study was supported by research grants from the Public Welfare Technology Application Research Foundation of Zhejiang Province (No. 2017C33080), National Natural Science Foundation of China (Grant No. 81771284), and the Opening Project of Zhejiang Provincial Top Key Discipline of Pharmaceutical Sciences.	Abbasloo E, 2016, SCI REP-UK, V6, DOI 10.1038/srep31866; Banks WA, 2015, BRAIN BEHAV IMMUN, V44, P1, DOI 10.1016/j.bbi.2014.08.007; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Chow BW, 2015, TRENDS NEUROSCI, V38, P598, DOI 10.1016/j.tins.2015.08.003; Dutchak PA, 2012, CELL, V148, P556, DOI 10.1016/j.cell.2011.11.062; Foltz IN, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004690; Fukuda AM, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-279; GARCIA JH, 1995, STROKE, V26, P627, DOI 10.1161/01.STR.26.4.627; Glushakova OY, 2018, J NEUROTRAUM, V35, P157, DOI 10.1089/neu.2017.4999; Gupte J, 2011, J MOL BIOL, V408, P491, DOI 10.1016/j.jmb.2011.03.003; Hotta Y, 2009, ENDOCRINOLOGY, V150, P4625, DOI 10.1210/en.2009-0119; Hsuchou H, 2007, PEPTIDES, V28, P2382, DOI 10.1016/j.peptides.2007.10.007; Hu YY, 2017, ONCOTARGET, V8, P31638, DOI 10.18632/oncotarget.15780; Kharitonenkov A, 2005, J CLIN INVEST, V115, P1627, DOI 10.1172/JCI23606; Kharitonenkov A, 2007, ENDOCRINOLOGY, V148, P774, DOI 10.1210/en.2006-1168; Kimbler DE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041229; Kniesel U, 1996, DEV BRAIN RES, V96, P229, DOI 10.1016/S0165-3806(96)00117-4; Lin L, 2018, MOL NEUROBIOL, V55, P3131, DOI 10.1007/s12035-017-0544-0; [刘银华 Liu Yinhua], 2016, [中国临床药理学与治疗学, Chinese Journal of Clinical Pharmacology and Therapeutics], V21, P6; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Maas AIR, 2010, NEUROTHERAPEUTICS, V7, P115, DOI 10.1016/j.nurt.2009.10.022; Malkesman O, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00157; McTigue DM, 2007, EXP NEUROL, V205, P396, DOI 10.1016/j.expneurol.2007.02.009; Miller F, 2005, EUR J NEUROSCI, V22, P835, DOI 10.1111/j.1460-9568.2005.04273.x; Mohammadi M, 1998, EMBO J, V17, P5896, DOI 10.1093/emboj/17.20.5896; Nag S, 2011, NEUROPATH APPL NEURO, V37, P3, DOI 10.1111/j.1365-2990.2010.01138.x; Nishimura T, 2000, BBA-GENE STRUCT EXPR, V1492, P203, DOI 10.1016/S0167-4781(00)00067-1; Ouk T, 2013, CURR DRUG TARGETS, V14, P752, DOI 10.2174/1389450111314070005; Potts Mathew B, 2006, NeuroRx, V3, P143; Pulicherla KK, 2015, AAPS PHARMSCITECH, V16, P223, DOI 10.1208/s12249-015-0287-z; Rochfort KD, 2015, MICROVASC RES, V100, P48, DOI 10.1016/j.mvr.2015.04.010; Sa-nguanmoo P, 2016, METAB BRAIN DIS, V31, P239, DOI 10.1007/s11011-015-9789-3; Sabirzhanov B, 2016, CELL DEATH DIFFER, V23, P654, DOI 10.1038/cdd.2015.132; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Staiger H, 2017, ENDOCR REV, V38, P468, DOI 10.1210/er.2017-00016; Su EJ, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00385; Tanajak P, 2016, ACTA PHYSIOL, V217, P287, DOI 10.1111/apha.12698; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Thal SC, 2011, J NEUROTRAUM, V28, P983, DOI 10.1089/neu.2010.1685; Verkman AS, 2011, ACTA PHARMACOL SIN, V32, P702, DOI 10.1038/aps.2011.27; Wang F, 2017, J MOL NEUROSCI, V62, P123, DOI 10.1007/s12031-017-0917-x; Wang QZ, 2018, MOL NEUROBIOL, V55, P4702, DOI 10.1007/s12035-017-0663-7; Wang XM, 2014, CELL PHYSIOL BIOCHEM, V34, P658, DOI 10.1159/000363031; Wang Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep37098; Wang ZX, 2016, MOL NEUROBIOL, V53, P1905, DOI 10.1007/s12035-015-9143-0; Wheaton P, 2011, J PSYCHOPHARMACOL, V25, P1581, DOI 10.1177/0269881110388331; Wolburg H, 2002, VASC PHARMACOL, V38, P323, DOI 10.1016/S1537-1891(02)00200-8; Wu JS, 2016, MOL NEUROBIOL, V53, P3626, DOI 10.1007/s12035-015-9294-z; Xu ZM, 2017, J NEUROTRAUM, V34, P925, DOI 10.1089/neu.2016.4491; Yang WQ, 2017, MOL NUTR FOOD RES, V61, DOI 10.1002/mnfr.201601075; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Zhao J, 2007, J NEUROSCI, V27, P10240, DOI 10.1523/JNEUROSCI.1683-07.2007; Zhao LW, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-017-0368-z; Zheng YG, 2015, J CARDIOVASC PHARM, V66, P504, DOI 10.1097/FJC.0000000000000302	57	31	32	0	15	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2018	35	17					2091	2103		10.1089/neu.2017.5271			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GQ7LU	WOS:000441923700009	29648978				2021-06-18	
J	Sreedharan, NPN; Ganesan, B; Raveendran, R; Sarala, P; Dennis, B; Boothalingam, RR				Sreedharan, Ninu Preetha Nirmala; Ganesan, Brammya; Raveendran, Ramya; Sarala, Praveena; Dennis, Binu; Boothalingam, Rajakumar R.			Grey Wolf optimisation-based feature selection and classification for facial emotion recognition	IET BIOMETRICS			English	Article						face recognition; gradient methods; feature extraction; evolutionary computation; particle swarm optimisation; neural nets; optimisation; emotion recognition; Grey Wolf optimisation; feature selection; facial emotion recognition; human emotions; facial emotions; elemental facial expressions; fear; recognition process; FER system; pre-processing; scale invariant feature; feature extraction method; facial point; optimal features; NN-particle swarm optimisation	TRAUMATIC BRAIN-INJURY; EXPRESSION RECOGNITION; NEURAL-NETWORKS; INDIVIDUAL-DIFFERENCES; ALGORITHM; SCHIZOPHRENIA; SIFT; ASSOCIATION; CHILDHOOD; DEFICITS	The channels used to convey the human emotions consider actions, behaviours, poses, facial expressions, and speech. An immense research has been carried out to analyse the relationship between the facial emotions and these channels. The goal of this study is to develop a system for Facial Emotion Recognition (FER) that can analyse the elemental facial expressions of human, such as normal, smile, sad, surprise, anger, fear, and disgust. The recognition process of the proposed FER system is categorised into four processes, namely pre-processing, feature extraction, feature selection, and classification. After preprocessing, scale invariant feature transform -based feature extraction method is used to extract the features from the facial point. Further, a meta-heuristic algorithm called Grey Wolf optimisation (GWO) is used to select the optimal features. Subsequently, GWO-based neural network (NN) is used to classify the emotions from the selected features. Moreover, an effective performance analysis of the proposed as well as the conventional methods such as convolutional neural network, NN-Levenberg-Marquardt, NN-Gradient Descent, NN-Evolutionary Algorithm, NN-firefly, and NN-Particle Swarm Optimisation is provided by evaluating few performance measures and thereby, the effectiveness of the proposed strategy over the conventional methods is validated.	[Sreedharan, Ninu Preetha Nirmala; Ganesan, Brammya; Raveendran, Ramya; Sarala, Praveena; Dennis, Binu; Boothalingam, Rajakumar R.] Resbee Info Technol Private Ltd, Thuckalay 629175, India	Sreedharan, NPN (corresponding author), Resbee Info Technol Private Ltd, Thuckalay 629175, India.	research@resbee.org	R, Rajakumar B/AAJ-6031-2020	R, Rajakumar B/0000-0002-4720-8875			Ahmed F, 2012, ELECTRON LETT, V48, P1203, DOI 10.1049/el.2012.1841; Alqahtani MMJ, 2015, POSTEP PSYCHIATR NEU, V24, P217, DOI 10.1016/j.pin.2015.11.003; Azeem A., 2015, J. appl. res. technol, V13, P402; Balas B, 2015, J EXP CHILD PSYCHOL, V140, P171, DOI 10.1016/j.jecp.2015.07.006; Barnard-Brak L, 2017, PSYCHIAT RES, V249, P109, DOI 10.1016/j.psychres.2016.12.049; Boutorh A, 2016, ENG APPL ARTIF INTEL, V51, P58, DOI 10.1016/j.engappai.2016.01.004; Celik O, 2016, J CLEAN PROD, V116, P1, DOI 10.1016/j.jclepro.2015.12.082; Cruz AC, 2014, IEEE T AFFECT COMPUT, V5, P418, DOI 10.1109/TAFFC.2014.2316151; Fan XJ, 2017, PATTERN RECOGN, V64, P399, DOI 10.1016/j.patcog.2016.12.002; Fasel B, 2002, INT C PATT RECOG, P40, DOI 10.1109/ICPR.2002.1048231; Gaidhane VH, 2016, SADHANA-ACAD P ENG S, V41, P415, DOI 10.1007/s12046-016-0479-6; Gola KA, 2017, NEUROIMAGE-CLIN, V14, P672, DOI 10.1016/j.nicl.2017.01.016; Hargreaves A, 2016, NEUROSCI LETT, V633, P47, DOI 10.1016/j.neulet.2016.09.017; Hernandez-Matamoros A, 2016, KNOWL-BASED SYST, V110, P1, DOI 10.1016/j.knosys.2016.07.011; Jiana J., 2011, PROCEDIA ENG, V15, P5126, DOI 10.1016/j.proeng.2011.08.951; Kobayashi M, 2017, NEUROCOMPUTING, V260, P174, DOI 10.1016/j.neucom.2017.04.025; Komaki GM, 2015, J COMPUT SCI-NETH, V8, P109, DOI 10.1016/j.jocs.2015.03.011; Lee SY, 2015, SCHIZOPHR RES, V165, P60, DOI 10.1016/j.schres.2015.03.026; Lenc L, 2015, COMPUT ELECTR ENG, V46, P256, DOI 10.1016/j.compeleceng.2015.01.014; Lin CH, 2016, ISA T, V64, P405, DOI 10.1016/j.isatra.2016.05.013; Lopes AT, 2017, PATTERN RECOGN, V61, P610, DOI 10.1016/j.patcog.2016.07.026; Meng HY, 2016, IEEE T CYBERNETICS, V46, P916, DOI 10.1109/TCYB.2015.2418092; Mirjalili S, 2016, EXPERT SYST APPL, V47, P106, DOI 10.1016/j.eswa.2015.10.039; Mirjalili S, 2014, ADV ENG SOFTW, V69, P46, DOI 10.1016/j.advengsoft.2013.12.007; Moeini A, 2017, J VIS COMMUN IMAGE R, V45, P20, DOI 10.1016/j.jvcir.2017.02.007; Moeini A, 2016, J VIS COMMUN IMAGE R, V35, P1, DOI 10.1016/j.jvcir.2015.11.006; Neoh SC, 2015, APPL SOFT COMPUT, V34, P72, DOI 10.1016/j.asoc.2015.05.006; Ozturk S., 2017, ELECT PALANGA, V2014, P1; Prado CE, 2015, PERS INDIV DIFFER, V80, P22, DOI 10.1016/j.paid.2015.02.013; Pu XR, 2015, NEUROCOMPUTING, V168, P1173, DOI 10.1016/j.neucom.2015.05.005; Rigon A, 2017, NEUROIMAGE-CLIN, V13, P370, DOI 10.1016/j.nicl.2016.12.010; Russo M, 2015, PSYCHIAT RES, V229, P771, DOI 10.1016/j.psychres.2015.08.004; Sanchez D, 2017, ENG APPL ARTIF INTEL, V64, P172, DOI 10.1016/j.engappai.2017.06.007; Song XH, 2015, SOIL DYN EARTHQ ENG, V75, P147, DOI 10.1016/j.soildyn.2015.04.004; Sonmez EB, 2013, IET COMPUT VIS, V7, P500, DOI 10.1049/iet-cvi.2012.0127; Sun Y, 2014, ELECTRON LETT, V50, P671, DOI 10.1049/el.2014.0441; Tang XW, 2016, PSYCHIAT RES, V246, P353, DOI 10.1016/j.psychres.2016.09.055; Theurel A, 2016, J EXP CHILD PSYCHOL, V150, P252, DOI 10.1016/j.jecp.2016.06.004; Vinay A, 2016, PROCEDIA COMPUT SCI, V79, P543, DOI 10.1016/j.procs.2016.03.069; Wang SF, 2014, IMAGE VISION COMPUT, V32, P682, DOI 10.1016/j.imavis.2014.04.013; Yang ML, 2017, NEUROCOMPUTING, V267, P195, DOI 10.1016/j.neucom.2017.06.007; Yi JZ, 2014, IET COMPUT VIS, V8, P429, DOI 10.1049/iet-cvi.2013.0171; Yu KM, 2013, PATTERN RECOGN, V46, P2144, DOI 10.1016/j.patcog.2013.01.032; Zhang L, 2016, KNOWL-BASED SYST, V111, P248, DOI 10.1016/j.knosys.2016.08.018; Zhang T, 2016, IEEE T MULTIMEDIA, V18, P2528, DOI 10.1109/TMM.2016.2598092; Zhou Q, 2016, CHINESE J ELECTRON, V25, P1034, DOI 10.1049/cje.2016.10.001; Zwick JC, 2017, J AFFECT DISORDERS, V210, P90, DOI 10.1016/j.jad.2016.12.022	47	31	31	3	27	INST ENGINEERING TECHNOLOGY-IET	HERTFORD	MICHAEL FARADAY HOUSE SIX HILLS WAY STEVENAGE, HERTFORD SG1 2AY, ENGLAND	2047-4938	2047-4946		IET BIOMETRICS	IET Biom.	SEP	2018	7	5					490	499		10.1049/iet-bmt.2017.0160			10	Computer Science, Artificial Intelligence	Computer Science	GR0UL	WOS:000442238900013					2021-06-18	
J	Wen, L; You, WD; Wang, H; Meng, YY; Feng, JF; Yang, XF				Wen, Liang; You, Wendong; Wang, Hao; Meng, Yuanyuan; Feng, Junfeng; Yang, Xiaofeng			Polarization of Microglia to the M2 Phenotype in a Peroxisome Proliferator-Activated Receptor Gamma-Dependent Manner Attenuates Axonal Injury Induced by Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						axonal injury; microglia; neuroinflammation; peroxisome proliferator-activated receptor gamma (PPAR-gamma); polarization	PPAR-GAMMA; MACROPHAGE ACTIVATION; TNF-ALPHA; INFLAMMATION; ROSIGLITAZONE; AGONIST; DISEASE; DAMAGE; MODEL; NEURODEGENERATION	Increasing evidence indicates that activated microglia play an important role in the inflammatory response following traumatic brain injury (TBI). Inhibiting M1 and stimulating M2 activated microglia have demonstrated protective effects in several animal models of central nervous system diseases. However, it is not clear whether the polarization of microglia to M2 attenuates axonal injury following TBI. In this study, we used a lateral fluid percussion injury device to induce axonal injury in mice. Mice were randomly assigned to the sham, TBI, TBI + rosiglitazone (peroxisome proliferator-activated receptor gamma [PPAR-gamma] agonist), and TBI + GW9662 (PPAR-gamma antagonist) groups. Axonal injury was assessed using immunohistochemical staining for beta amyloid precursor protein. The inflammatory response was assessed by enzyme-linked immunosorbent assay, microglia polarization was assessed using specific markers of M1 and M2 microglia, and neurological function was assessed using the neurological severity score. Following TBI, microglia of the M1 phenotype increased significantly, while those of the M2 phenotype decreased. Rosiglitazone-induced PPAR-gamma activation promoted microglia polarization to the M2 phenotype, which reduced the inflammatory response, attenuated axonal injury in the cerebral cortex, and improved neurological function. Conversely, GW9662 inhibited the polarization of microglia to M2 and aggravated inflammation and axonal injury. Our in vitro findings in lipopolysaccharide-induced microglia were consistent with those of our in vivo experiments. In conclusion, the polarization of microglia to the M2 phenotype via PPAR-gamma activation attenuated axonal injury following TBI in mice, which may be a potential therapeutic approach for TBI-induced axonal injury.	[Wen, Liang; You, Wendong; Wang, Hao; Meng, Yuanyuan; Yang, Xiaofeng] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Neurosurg, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China; [Feng, Junfeng] Shanghai Jiao Tong Univ, Ren Ji Hosp, Sch Med, Dept Neurosurg, Shanghai, Peoples R China	Yang, XF (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Neurosurg, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.	zjcswk@zju.edu.cn			Natural Science Foundation of Zhejiang ProvinceNatural Science Foundation of Zhejiang Province [LY15H090005]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81200955, 31371406, 81771317]; SMC-Star Award for Young Scholars	The authors sincerely thank the laboratory staff of the First Affiliated Hospital College of Medicine at Zhejiang University for their technical assistance. Our study was supported by the Natural Science Foundation of Zhejiang Province (No. LY15H090005) and the National Natural Science Foundation of China (No. 81200955, No. 31371406 and No. 81771317). JFF is also supported by SMC-Star Award for Young Scholars (B).	Alder J, 2011, JOVE-J VIS EXP, DOI 10.3791/3063; Vieira RDA, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00178; Ansari MA, 2015, J NEUROL SCI, V357, P41, DOI 10.1016/j.jns.2015.06.062; BAZAN NG, 1995, J NEUROTRAUM, V12, P791, DOI 10.1089/neu.1995.12.791; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Bernardo A, 2000, EUR J NEUROSCI, V12, P2215, DOI 10.1046/j.1460-9568.2000.00110.x; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; Byrav DSP, 2013, PHARMACOL REP, V65, P951; Carta AR, 2011, NEUROSCIENCE, V194, P250, DOI 10.1016/j.neuroscience.2011.07.046; Colton CA, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-27; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Daynes RA, 2002, NAT REV IMMUNOL, V2, P748, DOI 10.1038/nri912; Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Gensel JC, 2015, BRAIN RES, V1619, P1, DOI 10.1016/j.brainres.2014.12.045; Hyong A, 2008, BRAIN RES, V1215, P218, DOI 10.1016/j.brainres.2008.04.025; Jassam YN, 2017, NEURON, V95, P1246, DOI 10.1016/j.neuron.2017.07.010; Jiang CY, 1998, NATURE, V391, P82; Jimenez S, 2008, J NEUROSCI, V28, P11650, DOI 10.1523/JNEUROSCI.3024-08.2008; Kettenmann H, 2011, PHYSIOL REV, V91, P461, DOI 10.1152/physrev.00011.2010; Kita T, 2000, INT J LEGAL MED, V113, P221, DOI 10.1007/s004149900095; Kumar A, 2016, J NEUROTRAUM, V33, P1732, DOI 10.1089/neu.2015.4268; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; Liu H, 2016, BIOCHEM BIOPH RES CO, V472, P648, DOI 10.1016/j.bbrc.2016.03.003; Liu M, 2017, J NEUROTRAUM, V34, P414, DOI 10.1089/neu.2015.4361; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Mandrekar-Colucci S, 2013, ASN NEURO, V5, DOI 10.1042/AN20130030; Mandrekar-Colucci S, 2012, J NEUROSCI, V32, P10117, DOI 10.1523/JNEUROSCI.5268-11.2012; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Moein P, 2013, BRAIN INJURY, V27, P1454, DOI 10.3109/02699052.2013.825009; Pan J, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0270-3; Park SW, 2007, J PHARMACOL EXP THER, V320, P1002, DOI 10.1124/jpet.106.113472; Pilipovic K, 2015, PROG NEURO-PSYCHOPH, V59, P8, DOI 10.1016/j.pnpbp.2015.01.003; Ramanan S, 2009, INT J RADIAT ONCOL, V75, P870, DOI 10.1016/j.ijrobp.2009.06.059; Ranganathan PV, 2013, AM J PHYSIOL-RENAL, V304, pF948, DOI 10.1152/ajprenal.00580.2012; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; Varnum MM, 2012, ARCH IMMUNOL THER EX, V60, P251, DOI 10.1007/s00005-012-0181-2; Walker DG, 2015, ALZHEIMERS RES THER, V7, DOI 10.1186/s13195-015-0139-9; Wang B, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4479; Wang GH, 2013, J CEREBR BLOOD F MET, V33, P1864, DOI 10.1038/jcbfm.2013.146; Xiao YC, 2010, GLIA, V58, P932, DOI 10.1002/glia.20975; Ya JC, 2015, MOL MED REP, V12, P6591, DOI 10.3892/mmr.2015.4292; Yenari MA, 2010, NEUROTHERAPEUTICS, V7, P378, DOI 10.1016/j.nurt.2010.07.005; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Zhang B, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0440-3	51	31	31	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	OCT	2018	35	19					2330	2340		10.1089/neu.2017.5540		JUN 2018	11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GV3OA	WOS:000434867400001	29649924				2021-06-18	
J	Zhao, RT; Zhou, J; Dong, XL; Bi, CW; Jiang, RC; Dong, JF; Tian, Y; Yuan, HJ; Zhang, JN				Zhao, Rui-ting; Zhou, Ju; Dong, Xin-long; Bi, Chong-wen; Jiang, Rong-cai; Dong, Jing-fei; Tian, Ye; Yuan, Heng-jie; Zhang, Jian-ning			Circular Ribonucleic Acid Expression Alteration in Exosomes from the Brain Extracellular Space after Traumatic Brain Injury in Mice	JOURNAL OF NEUROTRAUMA			English	Article						circular RNA; exosomes; microRNA; traumatic brain injury	RNAS; CELLS; MICRORNAS; RECOGNITION; MATURATION; REVEALS; PATHWAY; DEATH	Traumatic brain injury (TBI) has high morbidity and mortality rates. The mechanisms underlying TBI are unclear and may include the change in biological material in exosomes. Circular ribonucleic acids (circRNAs) are enriched and stable in exosomes, which can function as microRNA (miRNA) sponges to regulate gene expression levels. Therefore, we speculated that circRNAs in exosomes might play an important role in regulating gene expression after TBI and then regulate specific signaling pathways, which may protect the brain. We first isolated exosomes from the brain extracellular space in mice with TBI by digestion. We then investigated the alterations in circRNA expression in exosomes by high-throughput whole transcriptome sequencing, analyzed the data by gene ontology (GO) and pathway analysis, and constructed the circRNA-miRNA network. In this study, we identified 231 significantly and differentially expressed circRNAs, including 155 that were upregulated and 76 that were downregulated. GO analysis showed that these differentially expressed circRNAs might be related to the growth and repair of neurons, the development of the nervous system, and the transmission of nerve signals. The most highly correlated pathways that we identified were involved primarily with glutamatergic synapse and the cyclic guanosine monophosphate-protein kinase G signaling pathway. The circRNA-miRNA network predicted the potential roles of these differentially expressed circRNAs and the interaction of circRNAs with miRNAs. Our study broadens the horizon of research on gene regulation in exosomes from the brain extracellular space after TBI and provides novel targets for further research on both the molecular mechanisms of TBI and the potential intervention therapy targets.	[Zhao, Rui-ting; Zhou, Ju; Bi, Chong-wen; Yuan, Heng-jie] Tianjin Med Univ, Gen Hosp, Dept Pharm, Tianjin, Peoples R China; [Dong, Xin-long; Jiang, Rong-cai; Tian, Ye; Yuan, Heng-jie; Zhang, Jian-ning] Tianjin Med Univ, Tianjin Neurol Inst, Gen Hosp, Dept Neurosurg, Tianjin, Peoples R China; [Dong, Jing-fei] Bloodworks Northwest, Bloodworks Res Inst, Seattle, WA USA; [Dong, Jing-fei] Univ Washington, Dept Med, Div Hematol, Sch Med, Seattle, WA 98195 USA	Tian, Y; Yuan, HJ; Zhang, JN (corresponding author), Tianjin Med Univ, Gen Hosp, 154 Anshan Rd, Tianjin 300052, Peoples R China.	tianye030710@163.com; hengjieyuan@163.com; jianningzhang@hotmail.com			National Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81501057]; Tianjin Research Program of Application Foundation and Advanced Technology [16JCQNJC10600, 15JCQNJC11300]	This study was supported by the National Science Foundation of China (81501057) and the Tianjin Research Program of Application Foundation and Advanced Technology (grants 16JCQNJC10600 and 15JCQNJC11300).	Alder J, 2011, JOVE-J VIS EXP, DOI 10.3791/3063; Bachmayr-Heyda A, 2015, SCI REP-UK, V5, DOI 10.1038/srep08057; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Cheng J, 2016, BIOINFORMATICS, V32, P1094, DOI 10.1093/bioinformatics/btv656; Cocucci E, 2009, TRENDS CELL BIOL, V19, P43, DOI 10.1016/j.tcb.2008.11.003; Conde-Vancells J, 2008, J PROTEOME RES, V7, P5157, DOI 10.1021/pr8004887; Eken C, 2008, J IMMUNOL, V180, P817, DOI 10.4049/jimmunol.180.2.817; Enright AJ, 2004, GENOME BIOL, V5; Ge XT, 2015, BRAIN RES, V1603, P150, DOI 10.1016/j.brainres.2015.01.009; Geddes JF, 2004, FORENSIC SCI INT, V146, P83, DOI 10.1016/S0379-0738(03)00283-4; Han ZL, 2014, BRAIN RES, V1582, P12, DOI 10.1016/j.brainres.2014.07.045; Hansen TB, 2013, NATURE, V495, P384, DOI 10.1038/nature11993; Hansen TB, 2011, EMBO J, V30, P4414, DOI 10.1038/emboj.2011.359; Hetman M, 1999, J BIOL CHEM, V274, P22569, DOI 10.1074/jbc.274.32.22569; Huang TT, 2009, J NEUROTRAUM, V26, P1535, DOI [10.1089/neu.2008.0743, 10.1089/neu.2008-0743]; Huntley RP, 2015, NUCLEIC ACIDS RES, V43, pD1057, DOI 10.1093/nar/gku1113; Jayakumar AR, 2014, J NEUROTRAUM, V31, P1249, DOI 10.1089/neu.2013.3169; Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112; Jin W, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/725174; JOHNSTONE RM, 1987, J BIOL CHEM, V262, P9412; Junker K, 2016, EUR UROL, V70, P323, DOI 10.1016/j.eururo.2016.02.046; Katoh M, 2013, INT J MOL MED, V32, P763, DOI 10.3892/ijmm.2013.1444; Khan S, 2011, APOPTOSIS, V16, P1, DOI 10.1007/s10495-010-0534-4; Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82; Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959; Lin SP, 2016, BIOCHEM BIOPH RES CO, V471, P52, DOI 10.1016/j.bbrc.2016.01.183; Longhi L, 2007, INTENS CARE MED, V33, P2136, DOI 10.1007/s00134-007-0845-2; Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928; Michaelidis TM, 2008, CELL TISSUE RES, V331, P193, DOI 10.1007/s00441-007-0476-5; Naghavi M, 2015, LANCET, V385, P117, DOI 10.1016/S0140-6736(14)61682-2; Niedzwecki CM, 2008, J HEAD TRAUMA REHAB, V23, P209, DOI 10.1097/01.HTR.0000327253.61751.29; Numakawa T, 2010, HISTOL HISTOPATHOL, V25, P237, DOI 10.14670/HH-25.237; Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162; Pierfelice T, 2011, NEURON, V69, P840, DOI 10.1016/j.neuron.2011.02.031; Salzman J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003777; Simpson RJ, 2009, EXPERT REV PROTEOMIC, V6, P267, DOI 10.1586/EPR.09.17; Sobrino Justin, 2013, Proc (Bayl Univ Med Cent), V26, P120; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Subra C, 2010, J LIPID RES, V51, P2105, DOI 10.1194/jlr.M003657; Suzuki H, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl151; Talhouarne GJS, 2014, RNA, V20, P1476, DOI 10.1261/rna.045781.114; Thomas S, 2000, ACT NEUR S, V76, P397; Tojima T, 2011, NAT REV NEUROSCI, V12, P191, DOI 10.1038/nrn2996; TRAMS EG, 1981, BIOCHIM BIOPHYS ACTA, V645, P63, DOI 10.1016/0005-2736(81)90512-5; Uhlen P, 2015, DEV NEUROBIOL, V75, P360, DOI 10.1002/dneu.22273; Valdmanis PN, 2013, MOL THER, V21, P1112, DOI 10.1038/mt.2013.101; van Niel G, 2001, GASTROENTEROLOGY, V121, P337, DOI 10.1053/gast.2001.26263; Vicens Q, 2014, CELL, V159, P13, DOI 10.1016/j.cell.2014.09.005; Vlassov AV, 2012, BBA-GEN SUBJECTS, V1820, P940, DOI 10.1016/j.bbagen.2012.03.017; Weissman TA, 2004, NEURON, V43, P647, DOI 10.1016/j.neuron.2004.08.015; Wilusz JE, 2013, SCIENCE, V340, P440, DOI 10.1126/science.1238522; Yang CJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022517; Yang J, 2015, CELL, V160, P161, DOI 10.1016/j.cell.2014.11.053; Ye SB, 2014, ONCOTARGET, V5, P5439, DOI 10.18632/oncotarget.2118; Zhang XO, 2014, CELL, V159, P134, DOI 10.1016/j.cell.2014.09.001; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhong ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep30919	57	31	35	3	12	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2018	35	17					2056	2066		10.1089/neu.2017.5502		MAY 2018	11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GQ7LU	WOS:000434702400001	29409384				2021-06-18	
J	Howell, DR; Buckley, TA; Lynall, RC; Meehan, WP				Howell, David R.; Buckley, Thomas A.; Lynall, Robert C.; Meehan, William P., III			Worsening Dual-Task Gait Costs after Concussion and their Association with Subsequent Sport-Related Injury	JOURNAL OF NEUROTRAUMA			English	Article						head injury; injury risk; mild traumatic brain injury; pediatric sports medicine	EXTREMITY MUSCULOSKELETAL INJURY; 4TH INTERNATIONAL-CONFERENCE; TRAUMATIC BRAIN-INJURY; CONSENSUS STATEMENT; BALANCE CONTROL; ADOLESCENTS; RISK; PERFORMANCE; RECOVERY; INCREASE	Prior studies suggest that concussion may lead to an increased risk of a subsequent time-loss sport-related injury, but the mechanisms responsible are unknown. We measured the symptom and dual-task gait outcomes for athletes initially post-concussion and after clinical recovery. Participants then self-reported any additional injuries incurred in the year after their concussion. Forty-two athletes (52% female, mean age=16.8 +/- 3.2 years) completed the study. They underwent a dual-task gait evaluation and symptom inventory within 21 days post-concussion, and again after they were deemed clinically recovered. Approximately one year later, participants documented if they had sustained any subsequent sport-related injuries. The repeated measures analysis of variance (ANOVA) was used to evaluate changes in dual-task gait and symptoms across time and between groups. A significant group*time interaction (p=0.02) indicated that the group that went on to sustain a subsequent time-loss injury after returning to sports (n=15) demonstrated significant average walking speed dual-task cost worsening across time (-17.9 +/- 9.1% vs. -25.1 +/- 12.5%; p=0.007). In contrast, the group that did not sustain an additional injury walked with consistent dual-task cost values across time (-25.2 +/- 9.2% vs. -24.6 +/- 8.4%; p=0.76). Symptoms improved for all participants (main effect of time, p<0.001; Post-Concussion Symptom Scale [PCSS]=25.0 +/- 16.9 vs. 2.8 +/- 7.5; p<0.001), but did not differ between groups (p=0.77). Significant dual-task gait cost worsening throughout concussion recovery was associated with time-loss injuries during sports in the year after a concussion. These findings indicate that worsening ability to execute a concurrent gait and cognitive task may relate to the risk of incurring an injury during sports after clinical concussion recovery.	[Howell, David R.] Childrens Hosp Colorado, Sports Med Ctr, 13123 East 16th Ave,B060, Aurora, CO 80045 USA; [Howell, David R.] Univ Colorado, Sch Med, Dept Orthoped, Aurora, CO USA; [Howell, David R.; Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Buckley, Thomas A.] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE USA; [Buckley, Thomas A.] Univ Delaware, Interdisciplinary Program Biomech & Movement Sc, Newark, DE USA; [Lynall, Robert C.] Univ Georgia, Dept Kinesiol, UGA Concuss Res Lab, Athens, GA 30602 USA; [Meehan, William P., III] Boston Childrens Hosp, Dept Orthopaed, Div Sports Med, Boston, MA USA; [Meehan, William P., III] Harvard Med Sch, Dept Orthopaed Surg & Pediat, Boston, MA USA	Howell, DR (corresponding author), Childrens Hosp Colorado, Sports Med Ctr, 13123 East 16th Ave,B060, Aurora, CO 80045 USA.	David.Howell@ucdenver.edu	Buckley, Thomas A/B-7525-2016; Lynall, Robert/M-2888-2014	Buckley, Thomas A/0000-0002-0515-0150; Lynall, Robert/0000-0002-0785-6640			Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Baugh CM, 2016, AM J SPORT MED, V44, P1391, DOI 10.1177/0363546516635639; Brooks MA, 2016, AM J SPORT MED, V44, P742, DOI 10.1177/0363546515622387; Burman E., 2016, BMJ OPEN SPORT EXERC, V2; Cossette I, 2016, BRAIN INJURY, V30, P1648, DOI 10.1080/02699052.2016.1200143; Cross M, 2016, BRIT J SPORT MED, V50, P926, DOI 10.1136/bjsports-2015-094982; De Beaumont L, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12278; Fino P.C., 2017, CLIN J SPORT MED; Fino PC, 2016, J NEUROENG REHABIL, V13, DOI 10.1186/s12984-016-0177-y; Gilbert FC, 2016, SPORTS HEALTH, V8, P661, DOI 10.1177/1941738116666509; Guy J.A., 2016, PRIM CARE COMPANION, P18; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Herman DC, 2017, SPORTS MED, V47, P1003, DOI 10.1007/s40279-016-0607-9; Herman DC, 2015, CURR SPORT MED REP, V14, P194, DOI 10.1249/JSR.0000000000000157; Howell D R, 2017, CLIN J SPORT MED; Howell DR, 2018, J SCI MED SPORT, V21, P358, DOI 10.1016/j.jsams.2017.08.004; Howell DR, 2017, J NEUROTRAUM, V34, P3288, DOI 10.1089/neu.2017.5191; Howell DR, 2017, J SCI MED SPORT, V20, P622, DOI 10.1016/j.jsams.2016.11.020; Howell DR, 2017, GAIT POSTURE, V54, P284, DOI 10.1016/j.gaitpost.2017.03.034; Howell DR, 2017, J NEUROTRAUM, V34, P838, DOI 10.1089/neu.2016.4609; Howell DR, 2016, GAIT POSTURE, V49, P176, DOI 10.1016/j.gaitpost.2016.07.008; Howell DR, 2016, ACTA PAEDIATR, V105, pE426, DOI 10.1111/apa.13486; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Mancini Martina, 2011, J Bioeng Biomed Sci, VSuppl 1, P007; McCrea M, 2005, J INT NEUROPSYCH SOC, V11, P58, DOI 10.1017/S1355617705050083; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Plummer P, 2015, FRONT HUM NEUROSCI, V9, DOI 10.3389/fnhum.2015.00225; Read PJ, 2016, SPORTS MED, V46, P1059, DOI 10.1007/s40279-016-0479-z; Stache S, 2016, CLIN J SPORT MED, V26, P381, DOI 10.1097/JSM.0000000000000270; Wilkerson GB, 2012, INT J ATHL THER TRAI, V17, P4, DOI 10.1123/ijatt.17.6.4; Zazulak BT, 2007, AM J SPORT MED, V35, P1123, DOI 10.1177/0363546507301585	36	31	31	1	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2018	35	14					1630	1636		10.1089/neu.2017.5570		MAY 2018	7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GK9FP	WOS:000431462900001	29490564				2021-06-18	
J	Zhang, JN; Zhang, FY; Dong, JF				Zhang, Jianning; Zhang, Fangyi; Dong, Jing-fei			Coagulopathy induced by traumatic brain injury: systemic manifestation of a localized injury	BLOOD			English	Article							PLATELET-ACTIVATING-FACTOR; PLASMINOGEN-BINDING SITES; ADENOSINE-DIPHOSPHATE; INTRAVASCULAR COAGULATION; ENDOTHELIAL JUNCTIONS; PROCOAGULANT ACTIVITY; TIME-COURSE; MORTALITY; DYSFUNCTION; BLOOD	Traumatic brain injury (TBI)-induced coagulopathy is a common and well-recognized risk for poor clinical outcomes, but its pathogenesis remains poorly understood, and treatment options are limited and ineffective. We discuss the recent progress and knowledge gaps in understanding this lethal complication of TBI. We focus on (1) the disruption of the brain-blood barrier to disseminate brain injury systemically by releasing brain-derived molecules into the circulation and (2) TBI-induced hypercoagulable and hyperfibrinolytic states that result in persistent and delayed intracranial hemorrhage and systemic bleeding.	[Zhang, Jianning] Tianjin Med Univ, Dept Neurosurg, Gen Hosp, Tianjin 300052, Peoples R China; [Zhang, Jianning] Tianjin Inst Neurol, Tianjin, Peoples R China; [Zhang, Fangyi] Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; [Dong, Jing-fei] Bloodworks Res Inst, 1551 Eastlake Ave East, Seattle, WA 98102 USA; [Dong, Jing-fei] Univ Washington, Sch Med, Dept Med, Div Hematol, Seattle, WA 98195 USA	Zhang, JN (corresponding author), Tianjin Med Univ, Dept Neurosurg, Gen Hosp, Tianjin 300052, Peoples R China.; Dong, JF (corresponding author), Bloodworks Res Inst, 1551 Eastlake Ave East, Seattle, WA 98102 USA.	jianningzhang@hotmail.com; jfdong@psbc.org			National Institutes of Health, National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS087296]; National Heart, Lung, and Blood InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL119391]; Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81330029];  [81271361];  [81271359]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087296] Funding Source: NIH RePORTER	This study is supported by National Institutes of Health, National Institute of Neurological Disorders and Stroke grant NS087296 and National Heart, Lung, and Blood Institute grant HL119391 (J.-f.D.), Natural Science Foundation of China State Key Program Grant 81330029, and Research grants 81271361 and 81271359 (J.Z.).	Abdelmalik PA, 2016, NEUROCRIT CARE, V24, P361, DOI 10.1007/s12028-015-0191-0; Anglin CO, 2013, J NEUROSURG, V118, P676, DOI 10.3171/2012.11.JNS12622; Aurrand-Lions M, 2001, BLOOD, V98, P3699, DOI 10.1182/blood.V98.13.3699; Bartels AN, 2016, SURGERY, V160, P954, DOI 10.1016/j.surg.2016.07.012; Batchelor JS, 2013, BRIT J NEUROSURG, V27, P12, DOI 10.3109/02688697.2012.705361; Batchelor JS, 2012, BRIT J NEUROSURG, V26, P525, DOI 10.3109/02688697.2011.650736; BROMMER EJP, 1984, THROMB RES, V34, P109, DOI 10.1016/0049-3848(84)90067-7; Brown SB, 2000, J BIOL CHEM, V275, P5987, DOI 10.1074/jbc.275.8.5987; Cardenas JC, 2014, SHOCK, V41, P514, DOI 10.1097/SHK.0000000000000161; Castellino FJ, 2014, J TRAUMA ACUTE CARE, V76, P1169, DOI 10.1097/TA.0000000000000216; Chang R, 2016, BLOOD, V128, P1043, DOI 10.1182/blood-2016-01-636423; CHAO W, 1993, BIOCHEM J, V292, P617, DOI 10.1042/bj2920617; Chapman MP, 2016, J TRAUMA ACUTE CARE, V80, P16, DOI 10.1097/TA.0000000000000885; Cristante E, 2013, P NATL ACAD SCI USA, V110, P832, DOI 10.1073/pnas.1209362110; Daley MJ, 2017, EUR J TRAUMA EMERG S, V43, P105, DOI 10.1007/s00068-016-0643-z; Davis PK, 2013, NEUROCRIT CARE, V18, P201, DOI 10.1007/s12028-012-9745-6; Donahue DL, 2014, J NEUROTRAUM, V31, P404, DOI 10.1089/neu.2013.3089; EDDLESTON M, 1993, J CLIN INVEST, V92, P349, DOI 10.1172/JCI116573; EMEIS JJ, 1992, ANN NY ACAD SCI, V667, P249, DOI 10.1111/j.1749-6632.1992.tb51622.x; Fabbri A, 2013, CRIT CARE, V17, DOI 10.1186/cc12575; FLECK RA, 1990, THROMB RES, V59, P421, DOI 10.1016/0049-3848(90)90148-6; Folkerson LE, 2018, AM J EMERG MED, V36, P38, DOI 10.1016/j.ajem.2017.06.057; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Grandhi R, 2015, J TRAUMA ACUTE CARE, V78, P614, DOI 10.1097/TA.0000000000000542; Haltmeier T, 2018, INJURY, V49, P62, DOI 10.1016/j.injury.2017.07.035; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Haseloff RF, 2015, SEMIN CELL DEV BIOL, V38, P16, DOI 10.1016/j.semcdb.2014.11.004; Heemskerk JWM, 1997, BLOOD, V90, P2615, DOI 10.1182/blood.V90.7.2615.2615_2615_2625; Hijazi N, 2015, BLOOD, V125, P2558, DOI 10.1182/blood-2014-08-588442; Horng S, 2017, J CLIN INVEST, V127, P3136, DOI 10.1172/JCI91301; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; Joseph B, 2014, J TRAUMA ACUTE CARE, V76, P817, DOI 10.1097/TA.0b013e3182aafcf0; Karri J, 2017, SHOCK, V48, P644, DOI 10.1097/SHK.0000000000000912; Kim DY, 2015, J NEUROTRAUM, V32, P1815, DOI 10.1089/neu.2014.3728; Komarova YA, 2017, CIRC RES, V120, P179, DOI 10.1161/CIRCRESAHA.116.306534; KUMAR R, 1988, BIOCHIM BIOPHYS ACTA, V963, P375, DOI 10.1016/0005-2760(88)90304-9; Lu DY, 2004, J NEUROTRAUM, V21, P1756, DOI 10.1089/0897715042664885; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; Maani CV, 2009, CURR OPIN ANESTHESIO, V22, P255, DOI 10.1097/ACO.0b013e32832922be; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; Maeda T, 1997, ACT NEUR S, V70, P102; Maegele M, 2013, TRANSFUSION, V53, p28S, DOI 10.1111/trf.12033; Medved L, 2003, THROMB HAEMOSTASIS, V89, P409; Mitra B, 2012, INJURY, V43, P22, DOI 10.1016/j.injury.2010.10.015; Morel N, 2008, J TRAUMA, V64, P698, DOI 10.1097/TA.0b013e31816493ad; Nakae R, 2016, J NEUROTRAUM, V33, P688, DOI 10.1089/neu.2015.4039; Niles SE, 2008, J TRAUMA, V64, P1459, DOI 10.1097/TA.0b013e318174e8bc; Palmeri D, 2000, J BIOL CHEM, V275, P19139, DOI 10.1074/jbc.M003189200; Ploplis VA, 2014, J NEUROTRAUM, V31, P1672, DOI 10.1089/neu.2013.3302; Prodan CI, 2016, J NEUROTRAUM, V33, P818, DOI 10.1089/neu.2014.3846; Reddy GD, 2015, CURR TREAT OPTION NE, V17, DOI 10.1007/s11940-015-0379-9; Roberts I, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI [10.3310/HTA17100, 10.3310/hta17100]; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; SATOH K, 1992, ACTA NEUROL SCAND, V85, P122, DOI 10.1111/j.1600-0404.1992.tb04010.x; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Shcherbina A, 1999, BLOOD, V93, P4222, DOI 10.1182/blood.V93.12.4222.412k34_4222_4231; Siljander P, 2001, ARTERIOSCL THROM VAS, V21, P618, DOI 10.1161/01.ATV.21.4.618; Sillesen M, 2013, J TRAUMA ACUTE CARE, V74, P1252, DOI 10.1097/TA.0b013e31828c7a6b; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; Stein SC, 2002, J NEUROSURG, V97, P1373, DOI 10.3171/jns.2002.97.6.1373; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Tian Y, 2015, BLOOD, V125, P2151, DOI 10.1182/blood-2014-09-598805; Tsukita S, 2000, ANN NY ACAD SCI, V915, P129, DOI 10.1111/j.1749-6632.2000.tb05235.x; Tsurupa G, 2001, BIOCHEMISTRY-US, V40, P801, DOI 10.1021/bi001789t; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021; VARADI A, 1983, BIOCHEMISTRY-US, V22, P2440, DOI 10.1021/bi00279a021; Wafaisade A, 2010, EMERG MED J, V27, P934, DOI 10.1136/emj.2009.088484; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Wohlauer MV, 2012, J AM COLL SURGEONS, V214, P739, DOI 10.1016/j.jamcollsurg.2012.01.050; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Wu XW, 2016, AM J PHYSIOL-REG I, V310, pR323, DOI 10.1152/ajpregu.00401.2015; Wutzler S, 2009, J AM COLL SURGEONS, V209, P75, DOI 10.1016/j.jamcollsurg.2009.03.015; Xiong Y, 2017, NEURAL REGEN RES, V12, P19, DOI 10.4103/1673-5374.198966; Zhao ZL, 2016, BLOOD, V127, P2763, DOI [10.1182/blood-2015-12688838, 10.1182/blood-2015-12-688838]; Zhou Y, 2018, BLOOD, V131, P563, DOI 10.1182/blood-2017-08-801738	76	31	33	1	6	AMER SOC HEMATOLOGY	WASHINGTON	2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA	0006-4971	1528-0020		BLOOD	Blood	MAY 3	2018	131	18					2001	2006		10.1182/blood-2017-11-784108			6	Hematology	Hematology	GE6ZC	WOS:000431378700004	29507078	Bronze, Green Published			2021-06-18	
J	Oravec, CS; Motiwala, M; Reed, K; Kondziolka, D; Barker, FG; Michael, LM; Klimo, P				Oravec, Chesney S.; Motiwala, Mustafa; Reed, Kevin; Kondziolka, Douglas; Barker, Fred G., II; Michael, L. Madison, II; Klimo, Paul, Jr.			Big Data Research in Neurosurgery: A Critical Look at this Popular New Study Design	NEUROSURGERY			English	Article						Administrative databases; Databases; Data; Outcomes; Cost; Complications	NATIONWIDE INPATIENT SAMPLE; TRAUMATIC BRAIN-INJURY; ANEURYSMAL SUBARACHNOID HEMORRHAGE; UNRUPTURED INTRACRANIAL ANEURYSMS; STANDARD PERFORMANCE-MEASURES; HOSPITAL-ACQUIRED CONDITIONS; CERVICAL SPONDYLOTIC MYELOPATHY; ENDOSCOPIC 3RD VENTRICULOSTOMY; PATIENT SAFETY INDICATORS; SURGICAL SITE INFECTION	The use of"big data" in neurosurgical research has become increasingly popular. However, using this type of data comes with limitations. This study aimed to shed light on this new approach to clinical research. We compiled a list of commonly used databases that were not specifically created to study neurosurgical procedures, conditions, or diseases. Three North American journalsweremanually searched for articles published since 2000 utilizing these and other non-neurosurgery-specific databases. A number of data points per article were collected, tallied, and analyzed. A total of 324 articles were identified since 2000 with an exponential increase since 2011 (257/324, 79%). The Journal of Neurosurgery Publishing Group published the greatest total number (n =200). The National Inpatient Sample was themost commonly used database (n =136). The average study size was 114 841 subjects (range, 30-4 146 777). The most prevalent topics were vascular (n =77) and neuro-oncology (n =66). When categorizing study objective (recognizing that many papers reported more than 1 type of study objective),"Outcomes" was themost common (n=154). The top 10 institutions by primary or senior author accounted for 45%-50% of all publications. Harvard Medical School was the top institution, using this research technique with 59 representations (31 by primary author and 28 by senior). The increasing use of data from non-neurosurgery-specific databases presents a unique challenge to the interpretation and application of the study conclusions. The limitations of these studies must be more strongly considered in designing and interpreting these studies.	[Oravec, Chesney S.; Motiwala, Mustafa; Reed, Kevin] Univ Tennessee, Hlth Sci Ctr, Coll Med, Memphis, TN USA; [Kondziolka, Douglas] NYU, Dept Neurosurg, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA; [Barker, Fred G., II] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA; [Michael, L. Madison, II; Klimo, Paul, Jr.] Univ Tennessee, Dept Neurosurg, Hlth Sci Ctr, Memphis, TN USA; [Michael, L. Madison, II; Klimo, Paul, Jr.] Semmes Murphey Clin, Memphis, TN USA; [Klimo, Paul, Jr.] Le Bonheur Childrens Hosp, Dept Neurosurg, Memphis, TN USA	Klimo, P (corresponding author), Semmes Murphey Neurol & Spine Inst, 6325 Humphreys Blvd, Memphis, TN 38120 USA.	pklimo@semmes-murphey.com		Kondziolka, Douglas/0000-0001-8925-7344			Ackerman SJ, 2014, J NEUROSURG-SPINE, V20, P354, DOI 10.3171/2014.1.SPINE13188; Adams H, 2013, WORLD NEUROSURG, V80, pE237, DOI 10.1016/j.wneu.2013.02.010; Ahmed KA, 2014, WORLD NEUROSURG, V82, pE291, DOI 10.1016/j.wneu.2013.10.035; Alali AS, 2015, J NEUROSURG-PEDIATR, V16, P523, DOI 10.3171/2015.3.PEDS14507; Alan N, 2014, J NEUROSURG, V120, P811, DOI 10.3171/2014.1.JNS131852; Alan N, 2014, J NEUROSURG, V120, P764, DOI 10.3171/2013.10.JNS131028; Alawi A, 2014, J NEUROSURG-PEDIATR, V14, P23, DOI 10.3171/2014.4.PEDS13464; Algattas H, 2016, WORLD NEUROSURG, V87, P531, DOI 10.1016/j.wneu.2015.09.020; Algattas H, 2015, WORLD NEUROSURG, V84, P1372, DOI 10.1016/j.wneu.2015.06.033; Ali R, 2016, J NEUROSURG-SPINE, V25, P537, DOI 10.3171/2015.10.SPINE14582; Amin BY, 2013, J NEUROSURG-SPINE, V18, P134, DOI 10.3171/2012.10.SPINE12559; Amin-Hanjani S, 2005, J NEUROSURG, V103, P794, DOI 10.3171/jns.2005.103.5.0794; Andaluz N, 2008, J NEUROSURG, V108, P1163, DOI 10.3171/JNS/2008/108/6/1163; Andaluz N, 2009, J NEUROSURG, V110, P403, DOI 10.3171/2008.5.17559; Anumula N, 2011, AM J NEURORADIOL, V32, P2000, DOI 10.3174/ajnr.A2912; Arrigo RT, 2011, NEUROSURGERY, V68, P1520, DOI 10.1227/NEU.0b013e31820cd426; Attenello FJ, 2015, J NEUROSURG PEDIAT, V17, P156; Attenello FJ, 2015, J NEUROSURG-PEDIATR, V15, P560, DOI 10.3171/2014.11.PEDS14451; Attenello FJ, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.08.053; Austin MT, 2016, J NEUROSURG-PEDIATR, V18, P585, DOI 10.3171/2016.5.PEDS15704; Baaj AA, 2011, J NEUROSURG-SPINE, V15, P367, DOI 10.3171/2011.5.SPINE10934; Baaj AA, 2010, J NEUROSURG-SPINE, V13, P61, DOI 10.3171/2010.3.SPINE09530; Baaj AA, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC/2008/25/9/E10; Babu MA, 2011, NEUROSURGERY, V69, P659, DOI 10.1227/NEU.0b013e31821bc667; Babu R, 2014, J NEUROSURG-SPINE, V21, P502, DOI 10.3171/2014.5.SPINE13283; Babu R, 2014, J NEUROSURG, V121, P262, DOI 10.3171/2014.5.JNS1314; Babu R, 2013, J NEUROSURG, V119, P434, DOI 10.3171/2013.4.JNS122329; Babu R, 2013, J NEUROSURG, V119, P121, DOI 10.3171/2013.1.JNS121370; Backes D, 2016, J NEUROSURG, V125, P737, DOI 10.3171/2015.8.JNS151473; Bagley JH, 2013, NEUROSURG FOCUS, V34, DOI 10.3171/2012.12.FOCUS12343; Bakhsheshian J, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.8.FOCUS16268; Barker FG, 2004, NEUROSURGERY, V55, P506, DOI 10.1227/01.NEU.0000134284.47965.71; Barker FG, 2004, NEUROSURGERY, V54, P18, DOI 10.1227/01.NEU.0000097195.48840.C4; Barker FG, 2003, NEUROSURGERY, V52, P995, DOI 10.1227/01.NEU.0000057743.56678.5F; Barnholtz-Sloan JS, 2008, J NEUROSURG, V108, P642, DOI 10.3171/JNS/2008/108/4/0642; Barnholtz-Sloan JS, 2003, J NEUROSURG, V99, P458, DOI 10.3171/jns.2003.99.3.0458; Barton SE, 2013, J NEUROSURG-PEDIATR, V11, P392, DOI 10.3171/2013.1.PEDS12362; Bateman BT, 2005, NEUROSURGERY, V57, P866, DOI 10.1227/01.NEU.0000179923.66729.87; Bekelis K, 2017, J NEUROSURG, V126, P805, DOI 10.3171/2016.2.JNS152994; Bekelis K, 2017, J NEUROSURG, V126, P811, DOI 10.3171/2016.1.JNS152028; Bekelis K, 2016, WORLD NEUROSURG, V95, P542, DOI 10.1016/j.wneu.2016.08.042; Bekelis K, 2016, J NEUROSURG, V125, P1390, DOI 10.3171/2015.11.JNS151841; Bekelis K, 2017, J NEUROSURG, V126, P29, DOI 10.3171/2015.11.JNS151725; Bekelis K, 2016, J NEUROSURG-PEDIATR, V18, P623, DOI 10.3171/2016.5.PEDS16137; Bekelis K, 2016, WORLD NEUROSURG, V94, P551, DOI 10.1016/j.wneu.2016.07.077; Bekelis K, 2015, J NEUROSURG, V123, P1223, DOI 10.3171/2014.11.JNS142111; Bekelis K, 2015, WORLD NEUROSURG, V84, P82, DOI 10.1016/j.wneu.2015.02.032; Bekelis K, 2014, J NEUROSURG, V120, P591, DOI 10.3171/2013.8.JNS13228; Benchimol EI, 2011, J CLIN EPIDEMIOL, V64, P821, DOI 10.1016/j.jclinepi.2010.10.006; Bernstein DN, 2016, WORLD NEUROSURG, V96, P538, DOI 10.1016/j.wneu.2016.09.058; Berry JG, 2008, NEUROSURGERY, V62, P445, DOI 10.1227/01.neu.0000316012.20797.04; Boakye M, 2008, NEUROSURGERY, V63, P295, DOI 10.1227/01.NEU.0000327028.45886.2E; Boakye M, 2008, NEUROSURGERY, V62, P455, DOI 10.1227/01.neu.0000316013.97926.4c; Bohman LE, 2014, WORLD NEUROSURG, V82, P806, DOI 10.1016/j.wneu.2014.07.005; Borgstedt-Bakke JH, 2017, J NEUROSURG-PEDIATR, V19, P227, DOI 10.3171/2016.8.PEDS1654; Bowers C, 2015, WORLD NEUROSURG, V84, P202, DOI 10.1016/j.wneu.2015.06.035; Brockmeyer D, 2016, J NEUROSURG-PEDIATR, V18, P413, DOI 10.3171/2016.2.PEDS1639; Busl KM, 2013, J NEUROSURG, V119, P1296, DOI 10.3171/2013.4.JNS122236; Bydon M, 2015, NEUROSURGERY, V77, P347, DOI 10.1227/NEU.0000000000000852; Bydon M, 2015, J NEUROSURG, V122, P955, DOI 10.3171/2014.11.JNS14890; Cahill KS, 2015, J NEUROSURG-SPINE, V23, P86, DOI 10.3171/2014.10.SPINE14338; Cahill KS, 2011, J NEUROSURG, V115, P259, DOI 10.3171/2011.3.JNS101748; Cahill KS, 2011, NEUROSURGERY, V68, P705, DOI 10.1227/NEU.0b013e31820773b2; Carlson ML, 2016, J NEUROSURG, V125, P1120, DOI 10.3171/2015.7.JNS151056; Chan AK, 2016, J NEUROSURG-SPINE, V25, P31, DOI 10.3171/2015.10.SPINE15670; Chan AK, 2013, NEUROSURGERY, V73, P951, DOI 10.1227/NEU.0000000000000129; Charland Kim, 2007, Healthc Financ Manage, V61, P60; Cherian J, 2016, J NEUROSURG-PEDIATR, V18, P416, DOI 10.3171/2016.1.PEDS15674; Chi JH, 2005, J NEUROSURG, V103, P113, DOI 10.3171/ped.2005.103.2.0113; Christian EA, 2016, J NEUROSURG-PEDIATR, V17, P260, DOI 10.3171/2015.7.PEDS15140; Claassen J, 2007, NEUROSURGERY, V61, P60, DOI 10.1227/01.neu.0000279724.05898.e7; Claassen J, 2007, NEUROSURGERY, V61, P64, DOI 10.1227/01.NEU.0000255504.51096.DE; Claus EB, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2014.10.FOCUS12367; Claus EB, 2013, J NEUROSURG, V118, P649, DOI 10.3171/2012.9.JNS12811; Clement RC, 2013, J NEUROSURG, V118, P687, DOI 10.3171/2012.10.JNS12682; Cohen HW, 2011, AM J HYPERTENS, V24, P18, DOI 10.1038/ajh.2010.205; Connolly ID, 2015, WORLD NEUROSURG, V84, P1864, DOI 10.1016/j.wneu.2015.08.018; Corliss BM, 2015, NEUROSURGERY, V77, P44, DOI 10.1227/NEU.0000000000000734; Couldwell WT, 2014, J NEUROSURG, V121, P1474, DOI 10.3171/2014.8.JNS132139; Cowan JA, 2003, J NEUROSURG, V99, P947, DOI 10.3171/jns.2003.99.6.0947; Cowan JA, 2003, NEUROSURGERY, V52, P48, DOI 10.1097/00006123-200301000-00005; Cowan JA, 2007, J NEUROSURG, V107, P530, DOI 10.3171/JNS-07/09/0530; Cowan JA, 2006, NEUROSURGERY, V59, P15, DOI 10.1227/01.NEU.0000219836.54861.CD; Cross DT, 2003, J NEUROSURG, V99, P810, DOI 10.3171/jns.2003.99.5.0810; Crowley RW, 2009, J NEUROSURG, V111, P60, DOI 10.3171/2008.11.JNS081038; Curry WT, 2010, NEUROSURGERY, V66, P427, DOI 10.1227/01.NEU.0000365265.10141.8E; Curry WT, 2005, J NEUROSURG, V102, P977, DOI 10.3171/jns.2005.102.6.0977; Curry WT, 2005, NEUROSURGERY, V57, P97, DOI 10.1227/01.NEU.0000163094.23923.E5; D'Oro A, 2016, J NEUROSURG-SPINE, V24, P476, DOI 10.3171/2015.7.SPINE15442; Daniels AH, 2016, J NEUROSURG-SPINE, V25, P165, DOI 10.3171/2015.11.SPINE15776; Dasenbrock HH, 2012, NEUROSURGERY, V70, P1353; Dasenbrock HH, 2017, J NEUROSURG, V127, P36, DOI 10.3171/2016.4.JNS152562; Dasenbrock HH, 2017, J NEUROSURG, V126, P677, DOI 10.3171/2016.2.JNS152345; Dasenbrock HH, 2017, J NEUROSURG, V126, P537, DOI 10.3171/2015.12.JNS151107; Dasenbrock HH, 2016, WORLD NEUROSURG, V88, P459, DOI 10.1016/j.wneu.2015.10.054; Dasenbrock HH, 2016, NEUROSURGERY, V78, P412, DOI 10.1227/NEU.0000000000001065; Dasenbrock HH, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.10.FOCUS15386; Dasenbrock HH, 2012, NEUROSURGERY, V70, P1346, DOI 10.1227/NEU.0b013e318251791a; Dasenbrock HH, 2012, NEUROSURGERY, V70, P586, DOI 10.1227/NEU.0b013e318232d1ee; Davies JM, 2017, J NEUROSURG, V127, P69, DOI 10.3171/2016.7.JNS15925; Davies JM, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.5.FOCUS12107; De la Garza Ramos R, 2016, WORLD NEUROSURG, V95; Ramos RD, 2016, WORLD NEUROSURG, V95, P480, DOI 10.1016/j.wneu.2016.06.096; De la Garza-Ramos R, 2016, J NEUROSURG-SPINE, V25, P15, DOI 10.3171/2015.11.SPINE151021; Deorah Sundeep, 2006, Neurosurg Focus, V20, pE1, DOI 10.3171/foc.2006.20.4.E1; Dorsi MJ, 2010, J NEUROSURG-PEDIATR, V5, P573, DOI 10.3171/2010.3.PEDS09538; Drazin D, 2016, J NEUROSURG-SPINE, V24, P686, DOI 10.3171/2015.7.SPINE14133; Dudley RWR, 2015, NEUROSURGERY, V76, P313, DOI 10.1227/NEU.0000000000000619; Duhaime AC, 2012, J NEUROSURG-PEDIATR, V10, P255, DOI 10.3171/2012.4.PEDS12143; Dumont TM, 2012, NEUROSURGERY, V71, P1041, DOI 10.1227/NEU.0b013e31826cdd73; Dumont TM, 2012, J NEUROSURG, V116, P1251, DOI 10.3171/2012.3.JNS111320; Englot DJ, 2013, J NEUROSURG, V118, P169, DOI 10.3171/2012.9.JNS12776; Eskandar EN, 2003, J NEUROSURG, V99, P863, DOI 10.3171/jns.2003.99.5.0863; Fargen KM, 2015, J NEUROSURG, V122, P870, DOI 10.3171/2014.12.JNS14646; Fargen KM, 2013, J NEUROSURG, V119, P1633, DOI 10.3171/2013.7.JNS13595; Fargen KM, 2013, J NEUROSURG, V119, P966, DOI 10.3171/2013.5.JNS122378; Fennell VS, 2016, J NEUROSURG, V124, P13, DOI 10.3171/2014.11.JNS141030; Finn MA, 2010, NEUROSURGERY, V67, P993, DOI 10.1227/NEU.0b013e3181f209db; Flynn-O'Brien KT, 2015, NEUROSURGERY, V76, P451, DOI 10.1227/NEU.0000000000000693; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Garcia RM, 2016, WORLD NEUROSURG, V96, P230, DOI 10.1016/j.wneu.2016.08.114; Gephart MGH, 2012, J NEUROSURG-PEDIATR, V10, P555, DOI 10.3171/2012.9.PEDS1272; Gephart MGH, 2012, WORLD NEUROSURG, V78, P545, DOI 10.1016/j.wneu.2011.12.089; Ghia AJ, 2013, NEUROSURGERY, V72, P203, DOI 10.1227/NEU.0b013e31827b9e68; Gittleman H, 2014, J NEUROSURG, V121, P527, DOI 10.3171/2014.5.JNS131819; Golinvaux NS, 2014, SPINE J, V14, P2923, DOI 10.1016/j.spinee.2014.04.025; Gologorsky Y, 2014, J NEUROSURG-SPINE, V21, P984, DOI 10.3171/2014.8.SPINE131113; Gonda DD, 2014, J NEUROSURG, V120, P1349, DOI 10.3171/2014.3.JNS131159; Goodman S, 2008, SEMIN HEMATOL, V45, P135, DOI 10.1053/j.seminhematol.2008.04.003; Greenberg JK, 2016, J NEUROSURG-PEDIATR, V17, P525, DOI 10.3171/2015.10.PEDS15369; Greenberg JK, 2015, NEUROSURGERY, V77, P261, DOI 10.1227/NEU.0000000000000777; Grimes DA, 2015, HUM REPROD, V30, P1749, DOI 10.1093/humrep/dev151; Grimes DA, 2010, OBSTET GYNECOL, V116, P1018, DOI 10.1097/AOG.0b013e3181f98300; Grossman R, 2011, WORLD NEUROSURG, V75, P279, DOI 10.1016/j.wneu.2010.09.003; Hammers R, 2010, J NEUROSURG, V112, P257, DOI 10.3171/2009.6.JNS081235; Hankinson TC, 2016, J NEUROSURG-PEDIATR, V17, P289, DOI 10.3171/2015.7.PEDS15224; Harris DA, 2014, J NEUROSURG-PEDIATR, V13, P448, DOI 10.3171/2014.1.PEDS13479; Hassan AE, 2017, J NEUROSURG, V127, P270, DOI 10.3171/2016.6.JNS152476; Haut ER, 2012, JAMA-J AM MED ASSOC, V307, P2589, DOI 10.1001/jama.2012.6626; Hirshman BR, 2016, WORLD NEUROSURG, V96, P237, DOI 10.1016/j.wneu.2016.07.105; Hoh BL, 2012, NEUROSURGERY, V70, P1369, DOI 10.1227/NEU.0b013e3182486a75; Hoh BL, 2011, WORLD NEUROSURG, V76, P548, DOI 10.1016/j.wneu.2011.05.054; Hoh BL, 2011, NEUROSURGERY, V69, P644, DOI 10.1227/NEU.0b013e31821bc46d; Holland CM, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.9.FOCUS15497; Hooten KG, 2015, NEUROSURGERY, V76, P239, DOI 10.1227/NEU.0000000000000594; Hsu S, 2011, J NEUROSURG-SPINE, V14, P742, DOI 10.3171/2011.1.SPINE10351; Hu KJ, 2016, WORLD NEUROSURG, V94, P409, DOI 10.1016/j.wneu.2016.07.023; Hubbard ME, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.8.FOCUS11179; Jacob RL, 2016, J NEUROSURG, V124, P1517, DOI 10.3171/2015.5.JNS15433; Jaja BNR, 2013, J NEUROSURG, V119, P1627, DOI 10.3171/2013.7.JNS13544; James WS, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.8.FOCUS14449; Jernigan SC, 2014, J NEUROSURG-PEDIATR, V13, P295, DOI 10.3171/2013.11.PEDS13138; Jeswani S, 2013, NEUROSURGERY, V73, P240, DOI 10.1227/01.neu.0000430288.85680.37; Jin DL, 2016, WORLD NEUROSURG, V88, P399, DOI 10.1016/j.wneu.2015.12.046; Johnson DR, 2013, WORLD NEUROSURG, V79, P110, DOI 10.1016/j.wneu.2012.03.033; Joseph JR, 2016, WORLD NEUROSURG, V92, P366, DOI 10.1016/j.wneu.2016.05.033; Kainth DS, 2013, NEUROSURGERY, V72, P210, DOI 10.1227/NEU.0b013e31827b9beb; KALAKOTI P, 2015, NEUROSURG FOCUS, V39; KALAKOTI P, 2015, NEUROSURG FOCUS, V38; Kalakoti P, 2016, WORLD NEUROSURG, V85, P114, DOI 10.1016/j.wneu.2015.08.020; Kalanithi P, 2011, J NEUROSURG, V115, P1013, DOI 10.3171/2011.6.JNS101989; Kalkanis SN, 2003, NEUROSURGERY, V52, P1251, DOI 10.1227/01.NEU.0000065129.25359.EE; Karhade AV, 2016, NEUROSURG FOCUS, V41, DOI 10.3171/2016.5.FOCUS16168; Kesler H, 2008, J NEUROSURG-PEDIATR, V1, P351, DOI 10.3171/PED/2008/1/5/351; Kestle JRW, 2015, J NEUROSURG, V122, P441, DOI 10.3171/2014.4.JNS14689; Khuri SF, 1998, ANN SURG, V228, P491, DOI 10.1097/00000658-199810000-00006; Kim BD, 2014, J NEUROSURG-SPINE, V20, P606, DOI 10.3171/2014.3.SPINE13699; Kim YW, 2013, NEUROSURGERY, V73, P450, DOI 10.1227/NEU.0000000000000001; Kim YW, 2013, NEUROSURGERY, V72, P143, DOI 10.1227/NEU.0b013e3182796af9; Kimmell KT, 2015, J NEUROSURG, V122, P1004, DOI 10.3171/2014.10.JNS14632; King JT, 2009, NEUROSURGERY, V65, P1011, DOI 10.1227/01.NEU.0000360347.10596.BD; Klimo P, 2015, NEUROSURGERY, V77, P1, DOI 10.1227/NEU.0000000000000743; Kondziolka D, 2015, BIG DATA-US, V3, P80, DOI 10.1089/big.2014.0069; Kshettry VR, 2014, J NEUROSURG-PEDIATR, V13, P666, DOI 10.3171/2014.3.PEDS13597; Kukreja S, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2015.1.FOCUS14825; Kurtz SM, 2012, J NEUROSURG-SPINE, V17, P342, DOI 10.3171/2012.7.SPINE12203; Kwon JW, 2013, WORLD NEUROSURG, V79, P499, DOI 10.1016/j.wneu.2012.07.032; Lad SP, 2007, J NEUROSURG-SPINE, V7, P305, DOI 10.3171/SPI-07/09/305; Lad SP, 2013, NEUROSURGERY, V73, P440, DOI 10.1227/NEU.0000000000000018; Lad SP, 2013, NEUROSURGERY, V72, P1000, DOI 10.1227/01.neu.0000429284.91142.56; Lad Shivanand P, 2007, Neurosurg Focus, V23, pE3; Lad Shivanand P, 2009, Neurosurg Focus, V26, P1, DOI 10.3171/FOC.2009.26.1.E10; Lad SP, 2010, NEUROSURGERY, V66, P953, DOI 10.1227/01.NEU.0000368545.83463.91; Lai PMR, 2014, WORLD NEUROSURG, V82, P380, DOI 10.1016/j.wneu.2013.07.015; Lam S, 2016, J NEUROSURG-PEDIATR, V17, P763, DOI 10.3171/2015.8.PEDS15481; Lam S, 2014, J NEUROSURG-PEDIATR, V14, P455, DOI 10.3171/2014.8.PEDS13680; Lam SK, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.8.FOCUS14454; Lam SK, 2014, J NEUROSURG-PEDIATR, V14, P476, DOI 10.3171/2014.7.PEDS1499; Larsen AMG, 2016, WORLD NEUROSURG, V93, P299, DOI 10.1016/j.wneu.2016.06.020; Larson AN, 2016, J NEUROSURG-SPINE, V24, P116, DOI 10.3171/2015.4.SPINE131119; Lau T, 2012, J NEUROSURG, V117, P514, DOI 10.3171/2012.5.JNS111858; Lawson EH, 2015, ANN SURG, V261, P290, DOI 10.1097/SLA.0000000000000707; Lawson EH, 2012, ANN SURG, V256, P973, DOI 10.1097/SLA.0b013e31826b4c4f; Lawson MF, 2013, WORLD NEUROSURG, V79, P472, DOI 10.1016/j.wneu.2012.01.038; Leake CB, 2011, J NEUROSURG, V115, P1179, DOI 10.3171/2011.7.JNS11590; Lee EJ, 2012, J NEUROSURG, V117, P53, DOI 10.3171/2012.3.JNS111221; Lieber B, 2016, WORLD NEUROSURG, V89, P517, DOI 10.1016/j.wneu.2015.12.085; Lieber BA, 2016, WORLD NEUROSURG, V91, P149, DOI 10.1016/j.wneu.2016.03.052; Lieber BA, 2016, J NEUROSURG, V125, P187, DOI 10.3171/2015.4.JNS142719; Lieber BA, 2016, J NEUROSURG, V125, P213, DOI 10.3171/2015.4.JNS142149; Lieber BA, 2016, WORLD NEUROSURG, V89, P126, DOI 10.1016/j.wneu.2016.01.033; Lim S, 2015, J NEUROSURG, V122, P962, DOI 10.3171/2014.11.JNS1494; Lin YM, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.9.FOCUS15383; Lin YM, 2015, J NEUROSURG-PEDIATR, V15, P243, DOI 10.3171/2014.9.PEDS1473; Lindekleiv H, 2015, J NEUROSURG, V123, P631, DOI 10.3171/2014.12.JNS142106; Little AS, 2013, J NEUROSURG, V119, P504, DOI 10.3171/2013.1.JNS121375; Lukasiewicz AM, 2016, J NEUROSURG, V124, P760, DOI 10.3171/2015.2.JNS142721; Majercik S, 2015, NEUROSURGERY, V77, P927, DOI 10.1227/NEU.0000000000000957; Malone H, 2015, WORLD NEUROSURG, V84, P1084, DOI 10.1016/j.wneu.2015.05.025; Mannix R, 2013, NEUROSURGERY, V73, P129, DOI 10.1227/01.neu.0000429846.14579.41; Marcus LP, 2014, J NEUROSURG, V120, P1201, DOI 10.3171/2014.1.JNS131264; Marguerie M, 2016, J NEUROSURG-PEDIATR, V18, P509, DOI 10.3171/2016.4.PEDS16222; Maud A, 2009, J NEUROSURG, V110, P880, DOI 10.3171/2008.8.JNS0858; Mcclelland S, 2007, J NEUROSURG, V107, P469, DOI 10.3171/PED-07/12/469; McCutcheon BA, 2016, WORLD NEUROSURG, V91, P272, DOI [10.1016/j.wneu.2016.04.039, 10.1016/J.WNEU.2016.04.039]; McCutcheon BA, 2016, WORLD NEUROSURG, V89, P101, DOI 10.1016/j.wneu.2016.01.089; McCutcheon BA, 2016, WORLD NEUROSURG, V88, P350, DOI 10.1016/j.wneu.2015.12.068; McCutcheon BA, 2015, J NEUROSURG, V123, P406, DOI 10.3171/2015.3.JNS131356; McDonald JS, 2013, J NEUROSURG-SPINE, V18, P280, DOI 10.3171/2012.12.SPINE12300; McDonald RJ, 2012, J NEUROSURG, V116, P157, DOI 10.3171/2011.8.JNS11324; McGirt MJ, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.9.FOCUS15335; McGirt MJ, 2011, J NEUROSURG-SPINE, V14, P771, DOI 10.3171/2011.1.SPINE10571; McGovern RA, 2013, J NEUROSURG, V119, P1546, DOI 10.3171/2013.8.JNS13475; McGuire CS, 2009, J NEUROSURG, V110, P725, DOI 10.3171/2008.9.JNS08117; McKinley BP, 2000, J NEUROSURG, V93, P932, DOI 10.3171/jns.2000.93.6.0932; Meagher AD, 2015, J NEUROSURG, V122, P595, DOI 10.3171/2014.10.JNS14187; Menger RP, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.8.FOCUS14436; Michalak SM, 2016, NEUROSURGERY, V79, P182, DOI 10.1227/NEU.0000000000001251; Missios S, 2016, J NEUROSURG-SPINE, V25, P264, DOI 10.3171/2016.1.SPINE151155; Missios S, 2015, WORLD NEUROSURG, V83, P957, DOI 10.1016/j.wneu.2015.04.052; Missios S, 2014, J NEUROSURG-PEDIATR, V14, P688, DOI 10.3171/2014.8.PEDS14112; Moghavem N, 2015, J NEUROSURG, V123, P189, DOI 10.3171/2014.12.JNS14447; Mukherjee D, 2011, WORLD NEUROSURG, V76, P580, DOI 10.1016/j.wneu.2011.05.016; Mukherjee D, 2011, J NEUROSURG-SPINE, V14, P143, DOI 10.3171/2010.10.SPINE10189; Mukhtar TK, 2016, J NEUROSURG, V125, P698, DOI 10.3171/2015.5.JNS142115; Murphy ME, 2017, J NEUROSURG-SPINE, V26, P353, DOI 10.3171/2016.8.SPINE16616; Muszynski CA, 2005, J NEUROSURG, V102, P374, DOI 10.3171/ped.2005.102.4.0374; Newman WC, 2016, J NEUROSURG, V125, P713, DOI 10.3171/2015.8.JNS14553; Noonan VK, 2013, J NEUROTRAUM, V30, P173, DOI 10.1089/neu.2012.2441; Noorbakhsh A, 2014, J NEUROSURG, V120, P31, DOI 10.3171/2013.9.JNS13877; Norby K, 2014, J NEUROSURG, V121, P247, DOI 10.3171/2014.4.JNS131191; Nuno M, 2015, J NEUROSURG, V123, P1247, DOI 10.3171/2014.10.JNS141516; Nuno M, 2015, J NEUROSURG-PEDIATR, V16, P515, DOI 10.3171/2015.3.PEDS14544; Nuno M, 2014, NEUROSURGERY, V74, P196, DOI 10.1227/NEU.0000000000000243; Nuno M, 2013, NEUROSURGERY, V73, P458, DOI 10.1227/01.neu.0000431477.02408.5e; Nuzzo R, 2014, NATURE, V506, P150, DOI 10.1038/506150a; O'Kane R, 2013, J NEUROSURG-PEDIATR, V12, P227, DOI 10.3171/2013.5.PEDS12514; O'Kelly CJ, 2010, J NEUROSURG, V113, P795, DOI 10.3171/2009.9.JNS081645; O'Kelly CJ, 2009, J NEUROSURG, V111, P1029, DOI 10.3171/2008.9.JNS08881; Ohya J, 2015, WORLD NEUROSURG, V83, P603, DOI 10.1016/j.wneu.2014.12.019; Ong KL, 2014, NEUROSURG FOCUS, V36, DOI 10.3171/2014.4.FOCUS1440; Padwal JA, 2016, WORLD NEUROSURG, V90, P186, DOI 10.1016/j.wneu.2016.02.078; PAN IW, 2015, NEUROSURG FOCUS, V39; Pandey AS, 2015, NEUROSURGERY, V77, P462, DOI 10.1227/NEU.0000000000000850; Park HS, 2016, J NEUROSURG, V124, P1018, DOI 10.3171/2015.4.JNS1573; Parker SL, 2015, WORLD NEUROSURG, V83, P382, DOI 10.1016/j.wneu.2014.06.010; Parker SL, 2015, J NEUROSURG, V122, P443, DOI 10.3171/2014.10.JNS13395; Patel S, 2013, WORLD NEUROSURG, V80, P142, DOI 10.1016/j.wneu.2012.06.029; Patil Chirag G, 2007, Neurosurg Focus, V23, pE7; Patil CG, 2012, WORLD NEUROSURG, V78, P640, DOI 10.1016/j.wneu.2011.10.042; Patil PG, 2005, NEUROSURGERY, V57, P753, DOI 10.1227/01.NEU.0000175729.79119.1d; Patwardhan RV, 2005, NEUROSURGERY, V56, P139, DOI 10.1227/01.NEU.0000146206.40375.41; Piatt JH, 2016, J NEUROSURG-SPINE, V25, P69, DOI 10.3171/2015.9.SPINE15771; Piatt JH, 2015, J NEUROSURG-PEDIATR, V16, P463, DOI 10.3171/2015.2.PEDS1515; Piatt JH, 2014, J NEUROSURG-PEDIATR, V14, P179, DOI 10.3171/2014.5.PEDS1421; Piatt JH, 2014, J NEUROSURG-PEDIATR, V14, P48, DOI 10.3171/2014.3.PEDS13618; Piatt JH, 2012, J NEUROSURG-PEDIATR, V10, P257, DOI 10.3171/2012.7.PEDS11532; Piatt Joseph H Jr, 2011, J Neurosurg Pediatr, V7, P567, DOI 10.3171/2011.3.PEDS10504; Piatt Joseph H Jr, 2005, Neurosurg Focus, V19, pE6; Piper K, 2017, J NEUROSURG-SPINE, V26, P90, DOI 10.3171/2016.6.SPINE1656; Puvanesarajah V, 2016, WORLD NEUROSURG, V96, P267, DOI 10.1016/j.wneu.2016.09.014; Puvanesarajah V, 2016, J NEUROSURG-SPINE, V25, P486, DOI 10.3171/2016.2.SPINE151345; Qureshi AI, 2015, NEUROSURGERY, V76, P34, DOI 10.1227/NEU.0000000000000551; Qureshi AI, 2014, NEUROSURGERY, V75, P380, DOI 10.1227/NEU.0000000000000450; Qureshi AI, 2013, J NEUROSURG-PEDIATR, V12, P49, DOI 10.3171/2013.4.PEDS12568; Qureshi AI, 2011, J NEUROSURG, V114, P834, DOI 10.3171/2010.6.JNS091486; Qureshi AI, 2005, NEUROSURGERY, V57, P1, DOI 10.1227/01.NEU.0000163081.55025.CD; Qureshi AI, 2005, NEUROSURGERY, V57, P647, DOI 10.1227/01.NEU.0000175546.62088.D6; Qureshi SA, 2013, J NEUROSURG-SPINE, V19, P546, DOI 10.3171/2013.8.SPINE12623; Rahman M, 2013, WORLD NEUROSURG, V80, P699, DOI 10.1016/j.wneu.2013.08.024; Rambachan A, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2013.08.020; Ramos RD, 2016, J NEUROSURG-PEDIATR, V18, P730, DOI 10.3171/2016.6.PEDS16200; Rao G, 2009, NEUROSURGERY, V65, P483, DOI 10.1227/01.NEU.0000350876.91495.E0; Rincon F, 2014, J NEUROSURG, V121, P950, DOI 10.3171/2014.7.JNS132470; Rincon F, 2013, NEUROSURGERY, V73, P217, DOI 10.1227/01.neu.0000430290.93304.33; Rincon F, 2012, NEUROSURGERY, V71, P795, DOI 10.1227/NEU.0b013e3182672ae5; Rocque BG, 2014, J NEUROSURG-PEDIATR, V14, P635, DOI 10.3171/2014.8.PEDS13665; Rolston JD, 2014, J NEUROSURG, V121, P908, DOI 10.3171/2014.6.JNS131419; Rolston JD, 2014, J NEUROSURG, V120, P736, DOI 10.3171/2013.10.JNS122419; Romano PS, 2002, MED CARE, V40, P856, DOI 10.1097/00005650-200210000-00004; Ronning PA, 2016, J NEUROSURG, V125, P393, DOI 10.3171/2015.6.JNS15985; Rughani AI, 2010, J NEUROSURG, V113, P585, DOI 10.3171/2009.11.JNS09857; Rughani AI, 2011, J NEUROSURG, V115, P202, DOI 10.3171/2011.4.JNS101924; Rumalla K, 2016, J NEUROSURG-SPINE, V25, P500, DOI 10.3171/2016.2.SPINE151377; Rumalla K, 2016, WORLD NEUROSURG, V91, P542, DOI 10.1016/j.wneu.2016.03.003; Rush B, 2016, WORLD NEUROSURG, V88, P25, DOI 10.1016/j.wneu.2015.12.034; Sampson JH, 2014, J NEUROSURG, V120, P297, DOI 10.3171/2013.6.JNS13993; Sarda S, 2015, J NEUROSURG-PEDIATR, V15, P544, DOI 10.3171/2014.9.PEDS14459; Sarrazin MSV, 2012, JAMA-J AM MED ASSOC, V307, P2589, DOI 10.1001/jama.2012.6636; Sarrazin MSV, 2012, JAMA-J AM MED ASSOC, V307, P1433, DOI 10.1001/jama.2012.404; Savage JW, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15240; Seicean A, 2015, J NEUROSURG, V123, P91, DOI 10.3171/2014.10.JNS14551; Seicean A, 2012, J NEUROSURG, V116, P1097, DOI 10.3171/2012.1.JNS111760; Semrad TJ, 2007, J NEUROSURG, V106, P601, DOI 10.3171/jns.2007.106.4.601; Shah SS, 2008, NEUROSURGERY, V62, P1095, DOI 10.1227/01.neu.0000325871.60129.23; Shamji MF, 2008, J NEUROSURG-SPINE, V9, P10, DOI 10.3171/SPI/2008/9/7/010; Shamji MF, 2009, NEUROSURGERY, V65, P490, DOI 10.1227/01.NEU.0000350863.69524.8E; Sharma M, 2014, J NEUROSURG-SPINE, V20, P125, DOI 10.3171/2013.9.SPINE13274; Sharma M, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.8.FOCUS13295; Shea AM, 2007, NEUROSURGERY, V61, P1131, DOI 10.1227/01.neu.0000306090.30517.ae; Sherrod BA, 2016, J NEUROSURG-PEDIATR, V18, P350, DOI 10.3171/2016.2.PEDS15604; Shi HY, 2014, J NEUROSURG, V121, P1323, DOI 10.3171/2014.8.JNS131526; Shi HY, 2013, J NEUROSURG, V118, P732, DOI 10.3171/2012.12.JNS12693; Shi HY, 2013, J NEUROSURG, V118, P746, DOI 10.3171/2013.1.JNS121130; Shweikeh F, 2016, J NEUROSURG-PEDIATR, V17, P27, DOI 10.3171/2015.4.PEDS14342; Shweikeh F, 2015, J NEUROSURG-PEDIATR, V15, P427, DOI 10.3171/2014.9.PEDS14241; Siddiq F, 2015, NEUROSURGERY, V77, P726, DOI 10.1227/NEU.0000000000000905; Siddiq F, 2014, WORLD NEUROSURG, V82, P678, DOI 10.1016/j.wneu.2013.07.079; Siddiq F, 2012, NEUROSURGERY, V71, P670, DOI 10.1227/NEU.0b013e318261749b; Simon SD, 2015, WORLD NEUROSURG, V83, P431, DOI 10.1016/j.wneu.2015.01.011; Simon TD, 2008, J NEUROS-PEDIATR, V1, P131, DOI 10.3171/PED/2008/1/2/131; Simon TD, 2010, J NEUROSURG-PEDIATR, V6, P277, DOI 10.3171/2010.5.PEDS09457; Simon TD, 2009, J NEUROS-PEDIATR, V4, P156, DOI 10.3171/2009.3.PEDS08215; Smith ER, 2006, J NEUROSURG, V105, P169, DOI 10.3171/ped.2006.105.3.169; Smith ER, 2004, NEUROSURGERY, V54, P553, DOI 10.1227/01.NEU.0000108421.69822.67; Smith ER, 2004, J NEUROSURG, V100, P90, DOI 10.3171/ped.2004.100.2.0090; Smith GA, 2011, J NEUROSURG, V114, P1768, DOI 10.3171/2011.1.JNS101528; So L, 2010, HEALTH INFORM J, V16, P101, DOI 10.1177/1460458210364784; Solheim O, 2014, J NEUROSURG, V120, P827, DOI 10.3171/2013.12.JNS131312; Solheim O, 2012, J NEUROSURG, V116, P825, DOI 10.3171/2011.12.JNS11339; Sonabend AM, 2014, J NEUROSURG, V120, P300, DOI 10.3171/2013.10.JNS13113; Sonig A, 2012, NEUROSURG FOCUS, V33, pE3, DOI DOI 10.3171/2012.7.F0CUS12193; Sonig A, 2016, J NEUROSURG, V124, P1228, DOI 10.3171/2015.4.JNS141631; Sonig A, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.5.FOCUS1269; Starke RM, 2012, NEUROSURGERY, V71, P93, DOI 10.1227/NEU.0b013e318253ab8e; Stessin AM, 2012, J NEUROSURG, V117, P669, DOI 10.3171/2012.7.JNS111439; Taylor BES, 2016, NEUROSURGERY, V79, P356, DOI 10.1227/NEU.0000000000001110; Taylor CL, 2014, NEUROSURGERY, V75, P609, DOI 10.1227/NEU.0000000000000543; Thomas AJ, 2000, J NEUROSURG, V93, P927, DOI 10.3171/jns.2000.93.6.0927; Trinh VT, 2015, J NEUROSURG, V122, P280, DOI 10.3171/2014.9.JNS131648; Tseng CH, 2015, J NEUROSURG, V123, P1528, DOI 10.3171/2014.11.JNS141269; Vadera S, 2015, NEUROSURGERY, V77, P185, DOI 10.1227/NEU.0000000000000815; Van Cleve W, 2013, NEUROSURGERY, V73, P746, DOI 10.1227/NEU.0000000000000097; van Walraven C, 2012, J CLIN EPIDEMIOL, V65, P126, DOI 10.1016/j.jclinepi.2011.08.002; Varelas PN, 2006, J NEUROSURG, V104, P713, DOI 10.3171/jns.2006.104.5.713; Veeravagu A, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.3.FOCUS1669; Veeravagu A, 2015, J NEUROSURG-SPINE, V23, P374, DOI 10.3171/2014.12.SPINE14659; Veeravagu A, 2014, WORLD NEUROSURG, V82, pE235, DOI 10.1016/j.wneu.2014.02.030; Verla T, 2016, WORLD NEUROSURG, V87, P591, DOI 10.1016/j.wneu.2015.10.061; Vigneswaran HT, 2015, J NEUROSURG-PEDIATR, V16, P322, DOI 10.3171/2015.3.PEDS14649; Villelli NW, 2017, J NEUROSURG, V126, P167, DOI 10.3171/2015.7.JNS15786; Vivas AC, 2012, NEUROSURG FOCUS, V32, DOI 10.3171/2012.1.FOCUS11322; Washington CW, 2014, J NEUROSURG, V121, P482, DOI 10.3171/2014.4.JNS131100; Weaver KJ, 2012, NEUROSURGERY, V71, P562, DOI 10.1227/NEU.0b013e31825ea51b; Wen T, 2015, WORLD NEUROSURG, V84, P58, DOI 10.1016/j.wneu.2015.02.028; Wen T, 2014, J NEUROSURG, V121, P580, DOI 10.3171/2014.4.JNS131253; Wen T, 2014, NEUROSURGERY, V75, P43, DOI 10.1227/NEU.0000000000000352; Westwick HJ, 2015, J NEUROSURG-SPINE, V23, P368, DOI 10.3171/2014.12.SPINE14974; Wilkinson DA, 2017, J NEUROSURG-PEDIATR, V19, P208, DOI 10.3171/2016.8.PEDS16273; Williams C, 2012, J NEUROSURG-PEDIATR, V9, P524, DOI 10.3171/2012.1.PEDS11465; Williams MA, 2007, J NEUROSURG, V107, P21, DOI 10.3171/JNS-07/07/0021; Wilson D, 2015, NEUROSURG FOCUS, V38, DOI 10.3171/2014.11.FOCUS14694; Wilson TA, 2016, WORLD NEUROSURG, V91, P97, DOI 10.1016/j.wneu.2016.03.043; Winkler EA, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15613; Winkler EA, 2015, NEUROSURG FOCUS, V39, DOI 10.3171/2015.7.FOCUS15270; Woodworth GF, 2009, NEUROSURGERY, V65, P251, DOI 10.1227/01.NEU.0000347003.35690.7A; Wu JC, 2013, NEUROSURG FOCUS, V35, DOI 10.3171/2013.4.FOCUS13122; Wu JC, 2011, NEUROSURG FOCUS, V30, DOI 10.3171/2010.12.FOCUS10268; Wu Y, 2007, NEUROSURGERY, V61, P557, DOI 10.1227/01.NEU.0000290903.07943.AF; Yen YS, 2014, J NEUROSURG, V120, P655, DOI 10.3171/2013.10.JNS131357; Youngerman BE, 2016, J NEUROSURG, V125, P461, DOI 10.3171/2015.7.JNS142599; Yue JK, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15612; Zacharia BE, 2017, NEUROSURGERY, V80, P73, DOI 10.1227/NEU.0000000000001270; Zacharia BE, 2014, NEUROSURGERY, V74, P638, DOI 10.1227/NEU.0000000000000342; Zada G, 2012, WORLD NEUROSURG, V77, P518, DOI 10.1016/j.wneu.2011.05.051; Zaidi HA, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.8.FOCUS14366	376	31	31	1	5	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	MAY	2018	82	5					728	745		10.1093/neuros/nyx328			18	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	GO1FE	WOS:000439693800047	28973512	Bronze			2021-06-18	
J	Beker, MC; Caglayan, B; Yalcin, E; Caglayan, AB; Turkseven, S; Gurel, B; Kelestemur, T; Sertel, E; Sahin, Z; Kutlu, S; Kilic, U; Baykal, AT; Kilic, E				Beker, Mustafa Caglar; Caglayan, Berrak; Yalcin, Esra; Caglayan, Ahmet Burak; Turkseven, Seyma; Gurel, Busra; Kelestemur, Taha; Sertel, Elif; Sahin, Zafer; Kutlu, Selim; Kilic, Ulkan; Baykal, Ahmet Tarik; Kilic, Ertugrul			Time-of-Day Dependent Neuronal Injury After Ischemic Stroke: Implication of Circadian Clock Transcriptional Factor Bmal1 and Survival Kinase AKT	MOLECULAR NEUROBIOLOGY			English	Article						Circadian rhythm; Cerebral ischemia; Proteomics; Akt signaling; PI3K; Bmal1	FOCAL CEREBRAL-ISCHEMIA; HYPOXIA-INDUCIBLE FACTOR; TRAUMATIC BRAIN-INJURY; PROTEIN BMAL1; MECHANISMS; EXPRESSION; PATHWAY; GROWTH; RAT; METABOLISM	Occurrence of stroke cases displays a time-of-day variation in human. However, the mechanism linking circadian rhythm to the internal response mechanisms against pathophysiological events after ischemic stroke remained largely unknown. To this end, temporal changes in the susceptibility to ischemia/reperfusion (I/R) injury were investigated in mice in which the ischemic stroke induced at four different Zeitgeber time points with 6-h intervals (ZT0, ZT6, ZT12, and ZT18). Besides infarct volume and brain swelling, neuronal survival, apoptosis, ischemia, and circadian rhythm related proteins were examined using immunohistochemistry, Western blot, planar surface immune assay, and liquid chromatography-mass spectrometry tools. Here, we present evidence that midnight (ZT18; 24:00) I/R injury in mice resulted in significantly improved infarct volume, brain swelling, neurological deficit score, neuronal survival, and decreased apoptotic cell death compared with ischemia induced at other time points, which were associated with increased expressions of circadian proteins Bmal1, PerI, and Clock proteins and survival kinases AKT and Erk-1/2. Moreover, ribosomal protein S6, mTOR, and Bad were also significantly increased, while the levels of PRAS40, negative regulator of AKT and mTOR, and phosphorylated p53 were decreased at this time point compared to ZT0 (06:00). Furthermore, detailed proteomic analysis revealed significantly decreased CSKP, HBB-1/2, and HBA levels, while increased GNAZ, NEGR1, IMPCT, and PDE1B at midnight as compared with early morning. Our results indicate that nighttime I/R injury results in less severe neuronal damage, with increased neuronal survival, increased levels of survival kinases and circadian clock proteins, and also alters the circadian-related proteins.	[Beker, Mustafa Caglar; Caglayan, Berrak; Yalcin, Esra; Caglayan, Ahmet Burak; Turkseven, Seyma; Gurel, Busra; Kelestemur, Taha; Sertel, Elif; Kilic, Ulkan; Kilic, Ertugrul] Istanbul Medipol Univ, Regenerat & Restorat Med Res Ctr, Ekinciler Cad 19, TR-34810 Istanbul, Turkey; [Beker, Mustafa Caglar; Caglayan, Berrak; Yalcin, Esra; Caglayan, Ahmet Burak; Kelestemur, Taha; Sertel, Elif; Kilic, Ertugrul] Istanbul Medipol Univ, Dept Physiol, TR-34810 Istanbul, Turkey; [Beker, Mustafa Caglar; Caglayan, Ahmet Burak; Kelestemur, Taha; Kutlu, Selim] Necmettin Erbakan Univ, Dept Physiol, TR-42060 Konya, Turkey; [Gurel, Busra; Baykal, Ahmet Tarik] Acibadem Univ, Sch Med, Dept Med Biochem, TR-34752 Istanbul, Turkey; [Sahin, Zafer] Necmettin Erbakan Univ, Dept Physiotherapy & Rehabil, TR-42060 Konya, Turkey	Kilic, E (corresponding author), Istanbul Medipol Univ, Regenerat & Restorat Med Res Ctr, Ekinciler Cad 19, TR-34810 Istanbul, Turkey.; Kilic, E (corresponding author), Istanbul Medipol Univ, Dept Physiol, TR-34810 Istanbul, Turkey.	ekilic@medipol.edu.tr	Gurel, Busra/AAD-6244-2020; Kutlu, Selim/AAQ-5501-2021; Baykal, Ahmet T/C-3948-2013; Kilic, Ertugrul/W-4563-2018; Beker, Mustafa Caglar/ABH-2222-2020; Sahin, Zafer/ABD-5367-2020	Kutlu, Selim/0000-0001-9257-4797; Baykal, Ahmet T/0000-0002-8814-7351; Kilic, Ertugrul/0000-0001-6494-8923; Sahin, Zafer/0000-0001-7982-7155; Kelestemur, Taha/0000-0003-3616-1204; Yalcin, Esra/0000-0002-1064-7989; caglayan, ahmet burak/0000-0002-6242-3709; Beker, Mustafa/0000-0002-9476-8488; Caglayan, Berrak/0000-0002-5072-132X; Gurel, Busra/0000-0001-9779-1467	Necmettin Erbakan UniversityNecmettin Erbakan University [161330001]; Turkish Academy of Sciences (TUBA)Turkish Academy of Sciences	This study was supported by The Turkish Academy of Sciences (TUBA) and Necmettin Erbakan University (Scientific Research Project: 161330001).	Abe M, 2002, J NEUROSCI, V22, P350, DOI 10.1523/JNEUROSCI.22-01-00350.2002; Acioglu C, 2016, BRAIN BEHAV IMMUN, V56, P310, DOI 10.1016/j.bbi.2016.03.027; Bacigaluppi M, 2009, BRAIN, V132, P2239, DOI 10.1093/brain/awp174; Beker MC, 2015, ONCOTARGET, V6, P30604, DOI 10.18632/oncotarget.5773; Bele T, 2016, J NEUROCHEM, V138, P587, DOI 10.1111/jnc.13680; Boone DR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046204; Chang AM, 2012, J PHYSIOL-LONDON, V590, P3103, DOI 10.1113/jphysiol.2011.226555; Dlaboga D, 2008, NEUROPHARMACOLOGY, V54, P745, DOI 10.1016/j.neuropharm.2007.12.002; Elliott WJ, 1998, STROKE, V29, P992, DOI 10.1161/01.STR.29.5.992; Fahrenkrug J, 2008, J NEUROENDOCRINOL, V20, P323, DOI 10.1111/j.1365-2826.2008.01651.x; Fodor Dana Marieta, 2014, Clujul Med, V87, P242, DOI 10.15386/cjmed-328; Hacariz O, 2014, PROTEOMICS, V14, P1519, DOI 10.1002/pmic.201400012; Hata Y, 1996, J NEUROSCI, V16, P2488; He YD, 2010, TRANSL STROKE RES, V1, P48, DOI 10.1007/s12975-009-0004-x; Hermann DM, 2001, NEUROSCIENCE, V104, P947, DOI 10.1016/S0306-4522(01)00125-7; Ho MKC, 2001, ONCOGENE, V20, P1615, DOI 10.1038/sj.onc.1204190; Hultman R, 2014, MOL CELL NEUROSCI, V58, P53, DOI 10.1016/j.mcn.2013.12.004; Karatsoreos IN, 2011, P NATL ACAD SCI USA, V108, P1657, DOI 10.1073/pnas.1018375108; Khapre RV, 2011, CELL CYCLE, V10, P4162, DOI 10.4161/cc.10.23.18381; Kilic E, 2006, FASEB J, V20, P1185, DOI 10.1096/fj.05-4829fje; Kilic E, 2010, J CEREBR BLOOD F MET, V30, P969, DOI 10.1038/jcbfm.2009.268; Kim H, 2017, BIOCHEM BIOPH RES CO, V482, P1367, DOI 10.1016/j.bbrc.2016.12.043; Ko ML, 2009, J NEUROCHEM, V108, P1607, DOI 10.1111/j.1471-4159.2009.05931.x; Koh PO, 2012, NEUROSCI LETT, V507, P156, DOI 10.1016/j.neulet.2011.12.012; Kohsaka A, 2007, TRENDS ENDOCRIN MET, V18, P4, DOI 10.1016/j.tem.2006.11.005; Kondratov RV, 2009, AGING-US, V1, P979, DOI 10.18632/aging.100113; KUBOTA K, 1987, STROKE, V18, P812, DOI 10.1161/str.18.4.812b; Kunz A, 2010, BEST PRACT RES-CLIN, V24, P495, DOI 10.1016/j.bpa.2010.10.001; Mander BA, 2015, NAT NEUROSCI, V18, P1051, DOI 10.1038/nn.4035; Manev H, 1998, J Stroke Cerebrovasc Dis, V7, P165, DOI 10.1016/S1052-3057(98)80002-5; Meng He, 2008, J Circadian Rhythms, V6, P9, DOI 10.1186/1740-3391-6-9; Nafzger S, 2017, CELL CALCIUM, V61, P10, DOI 10.1016/j.ceca.2016.10.001; Okamura H, 2002, CELL TISSUE RES, V309, P47, DOI 10.1007/s00441-002-0572-5; Paranjpe Dhanashree A, 2005, J Circadian Rhythms, V3, P7, DOI 10.1186/1740-3391-3-7; Pardiwalla F K, 1993, J Assoc Physicians India, V41, P203; Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234; Razorenova OV, 2012, CELL CYCLE, V11, P213, DOI 10.4161/cc.11.2.18786; Roenneberg T, 2002, CELL TISSUE RES, V309, P3, DOI 10.1007/s00441-002-0568-1; Roffe M, 2013, J BIOL CHEM, V288, P10860, DOI 10.1074/jbc.M113.461970; Sattlegger E, 2011, J BIOL CHEM, V286, P10341, DOI 10.1074/jbc.M110.171587; Serhatli M, 2014, J PROTEOME RES, V13, P5071, DOI 10.1021/pr5006586; Sharp FR, 2001, ADV EXP MED BIOL, V502, P273; Soddu A, 2017, NEUROLOGY, V88, P226, DOI 10.1212/WNL.0000000000003529; Spudich A, 2006, NAT NEUROSCI, V9, P487, DOI 10.1038/nn1676; Srivastava S, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0295-6; Tischkau SA, 2007, EXP NEUROL, V208, P314, DOI 10.1016/j.expneurol.2007.09.003; Turin TC, 2012, ACTA NEUROL SCAND, V125, P206, DOI 10.1111/j.1600-0404.2011.01522.x; Vinall PE, 2000, J NEUROSURG, V93, P82, DOI 10.3171/jns.2000.93.1.0082; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Yamamoto T, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-18; Yan J, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000193; Zheng XZ, 2010, CURR BIOL, V20, P1203, DOI 10.1016/j.cub.2010.05.027; Zunzunegui C, 2011, SLEEP, V34, P1261, DOI 10.5665/SLEEP.1252	55	31	31	0	11	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	MAR	2018	55	3					2565	2576		10.1007/s12035-017-0524-4			12	Neurosciences	Neurosciences & Neurology	FY5TG	WOS:000426897800060	28421530				2021-06-18	
J	Keenan, HT; Clark, AE; Holubkov, R; Cox, CS; Ewing-Cobbs, L				Keenan, Heather T.; Clark, Amy E.; Holubkov, Richard; Cox, Charles S.; Ewing-Cobbs, Linda			Psychosocial and Executive Function Recovery Trajectories One Year after Pediatric Traumatic Brain Injury: The Influence of Age and Injury Severity	JOURNAL OF NEUROTRAUMA			English	Article						cohort; pediatrics; trauma; traumatic brain injury	BEHAVIOR PROBLEMS; SOCIAL OUTCOMES; TERM; DISORDERS; CHILDREN	Time since traumatic brain injury (TBI) and developmental stage at injury may affect the trajectory of outcomes associated with adjustment and school success. We prospectively enrolled a cohort of 519 children with either TBI or orthopedic injury (OI) age 2.5-15 years to examine children's psychosocial and executive function outcomes at 3- and 12-months post-injury. Outcome measures included the Child Behavior Checklist (CBCL), Strengths and Difficulties Questionnaire (SDQ), and Behavior Rating Inventory of Executive Function (BRIEF) ratings. Controlling for pre-injury ratings and using the OI group as the reference, children with TBI, regardless of age or injury severity, had affective, anxiety, and attention-deficit/hyperactivity disorder (ADHD) problems on the CBCL. Symptom trajectories differed both by injury severity and age at injury. Children with mild and complicated mild TBI had a decreasing anxiety trajectory, whereas children with severe TBI had increasing symptoms. Children 6-11 years of age had high ADHD and affective scores; however, the youngest children had increasing symptoms over time. On the SDQ, peer relationships and prosocial behaviors were not significantly affected by TBI but were associated with family environment. Children with severe TBI had the worst executive function scores; however, mild and complicated mild/moderate TBI groups had clinically important working memory deficits. Hispanic ethnicity and strong social capital were positively associated with multiple outcomes. Children's recovery trajectories differed by injury severity, time since injury, and developmental stage when injured. Schools need to reassess children's skills over time as new problems in behavior and learning may emerge.	[Keenan, Heather T.; Clark, Amy E.; Holubkov, Richard] Univ Utah, Dept Pediat, 295 Chipeta Way,POB 581289, Salt Lake City, UT 84158 USA; [Cox, Charles S.] Univ Texas Houston, Med Sch Houston, Dept Pediat Surg, Houston, TX USA; [Ewing-Cobbs, Linda] Univ Texas Hlth Sci Ctr Houston, Dept Pediat, Houston, TX 77030 USA; [Ewing-Cobbs, Linda] Univ Texas Hlth Sci Ctr Houston, Childrens Learning Inst, Houston, TX 77030 USA	Keenan, HT (corresponding author), Univ Utah, Dept Pediat, 295 Chipeta Way,POB 581289, Salt Lake City, UT 84158 USA.	heather.keenan@hsc.utah.edu			Centers for Disease ControlUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U01/CE002188]; National Institute of Health/Eunice Kennedy Shriver National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24HD072984]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K24HD072984] Funding Source: NIH RePORTER; NATIONAL CENTER FOR INJURY PREVENTION AND CONTROLUnited States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U01CE002188] Funding Source: NIH RePORTER	This study was supported by The Centers for Disease Control under Cooperative Agreement U01/CE002188. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention. This study was supported also by the National Institute of Health/Eunice Kennedy Shriver National Institute of Child Health and Human Development K24HD072984. Neither the NICHD or the CDC played a role in the design or conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.	Achenbach T M, 2000, Pediatr Rev, V21, P265, DOI 10.1542/pir.21-8-265; Arnett AB, 2013, J INT NEUROPSYCH SOC, V19, P881, DOI 10.1017/S1355617713000635; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Dennis M, 2014, NEUROPSYCHOL REV, V24, P389, DOI 10.1007/s11065-014-9261-x; Ewing-Cobbs L, 2004, DEV NEUROPSYCHOL, V25, P107, DOI 10.1207/s15326942dn2501&2_7; Gallo LC, 2009, J PERS, V77, P1707, DOI 10.1111/j.1467-6494.2009.00598.x; Ganesalingam K, 2007, J INT NEUROPSYCH SOC, V13, P298, DOI 10.1017/S1355617707070324; Gennarelli T.A., 2008, ABBREVIATED INJURY S; Gioa GA., 2000, BEHAV RATING INVENTO; Giza CC, 2009, DEV NEUROREHABIL, V12, P255, DOI 10.3109/17518420903087558; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Karver CL, 2012, REHABIL PSYCHOL, V57, P256, DOI 10.1037/a0029522; Kurowski BG, 2011, PM&R, V3, P836, DOI 10.1016/j.pmrj.2011.05.016; Levin HS, 2008, J NEUROSURG-PEDIATR, V1, P461, DOI 10.3171/PED/2008/1/6/461; Marr AL., 2004, CENTRAL NERVOUS SYST; Max JE, 2012, J NEUROPSYCH CLIN N, V24, P427, DOI 10.1176/appi.neuropsych.12060149; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; National Center for Injury Prevention and Control Report to Congress on Mild Traumatic Brain Injury in the United States, 2003, REP C MILD TRAUM BRA; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Prasad MR, 2017, J HEAD TRAUMA REHAB, V32, pE24, DOI 10.1097/HTR.0000000000000218; Raj SP, 2014, J PEDIATR PSYCHOL, V39, P84, DOI 10.1093/jpepsy/jst075; Rivara FP, 2011, HEALTH SERV RES, V46, P964, DOI 10.1111/j.1475-6773.2010.01236.x; Runyan DK, 1998, PEDIATRICS, V101, P12, DOI 10.1542/peds.101.1.12; Ryan NP, 2016, INT J DEV NEUROSCI, V49, P23, DOI 10.1016/j.ijdevneu.2015.12.004; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Stone LL, 2010, CLIN CHILD FAM PSYCH, V13, P254, DOI 10.1007/s10567-010-0071-2; TEASDALE G, 1974, LANCET, V2, P81; Wade SL, 2016, JAMA PEDIATR, V170, P343, DOI 10.1001/jamapediatrics.2015.4485; Yeates KO, 2007, PSYCHOL BULL, V133, P535, DOI 10.1037/0033-2909.133.3.535; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	31	31	31	2	28	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2018	35	2					286	296		10.1089/neu.2017.5265			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FT1TA	WOS:000422918000009	28854841	Green Published			2021-06-18	
J	Kenney, K; Iacono, D; Edlow, BL; Katz, DI; Diaz-Arrastia, R; Dams-O'Connor, K; Daneshvar, DH; Stevens, A; Moreau, AL; Tirrell, LS; Varjabedian, A; Yendiki, A; van der Kouwe, A; Mareyam, A; McNab, JA; Gordon, WA; Fischl, B; McKee, AC; Perl, DP				Kenney, Kimbra; Iacono, Diego; Edlow, Brian L.; Katz, Douglas I.; Diaz-Arrastia, Ramon; Dams-O'Connor, Kristen; Daneshvar, Daniel H.; Stevens, Allison; Moreau, Allison L.; Tirrell, Lee S.; Varjabedian, Ani; Yendiki, Anastasia; van der Kouwe, Andre; Mareyam, Azma; McNab, Jennifer A.; Gordon, Wayne A.; Fischl, Bruce; McKee, Ann C.; Perl, Daniel P.			Dementia After Moderate-Severe Traumatic Brain Injury: Coexistence of Multiple Proteinopathies	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						alpha-Synuclein; beta-Amyloid; Hyperphosphorylated tau; Neurodegeneration; Neurofibrillary tangle; Proteinopathy; Traumatic brain injury	AMYOTROPHIC-LATERAL-SCLEROSIS; ONSET ALZHEIMERS-DISEASE; HEAD-INJURY; RISK; ENCEPHALOPATHY; PATHOLOGY; TDP-43; DEGENERATION; INDIVIDUALS; PERSIST	We report the clinical, neuroimaging, and neuropathologic characteristics of 2 patients who developed early onset dementia after a moderate-severe traumatic brain injury (TBI). Neuropathological evaluation revealed abundant beta-amyloid neuritic and cored plaques, diffuse beta-amyloid plaques, and frequent hyperphosphorylated-tau neurofibrillary tangles (NFT) involving much of the cortex, including insula and mammillary bodies in both cases. Case 1 additionally showed NFTs in both the superficial and deep cortical layers, occasional perivascular and depth-of-sulci NFTs, and parietal white matter rarefaction, which corresponded with decreased parietal fiber tracts observed on ex vivo MRI. Case 2 additionally showed NFT predominance in the superficial layers of the cortex, hypothalamus and brainstem, diffuse Lewy bodies in the cortex, amygdala and brainstem, and intraneuronal TDP-43 inclusions. The neuropathologic diagnoses were atypical Alzheimer disease (AD) with features of chronic traumatic encephalopathy and white matter loss (Case 1), and atypical AD, dementia with Lewy bodies and coexistent TDP-43 pathology (Case 2). These findings support an epidemiological association between TBI and dementia and further characterize the variety of misfolded proteins that may accumulate after TBI. Analyses with comprehensive clinical, imaging, genetic, and neuropathological data are required to characterize the full clinicopathological spectrum associated with dementias occurring aftermoderate-severe TBI.	[Kenney, Kimbra; Iacono, Diego] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bldg 51,Room 2306,4860 South Palmer Rd, Bethesda, MD 20889 USA; [Iacono, Diego; Perl, Daniel P.] Uniformed Serv Univ Hlth Sci, F Edward Hebert Sch Med, Dept Pathol, Bethesda, MD 20814 USA; [Iacono, Diego; Perl, Daniel P.] Uniformed Serv Univ Hlth Sci, CNRM, Bethesda, MD 20814 USA; [Iacono, Diego] Henry M Jackson Fdn Adv Mil Res HJF, Boston, MA USA; [Edlow, Brian L.] Massachusetts Gen Hosp, Dept Neurol, Ctr Neurotechnol & Neurorecovery, Boston, MA 02114 USA; [Edlow, Brian L.; Stevens, Allison; Moreau, Allison L.; Tirrell, Lee S.; Varjabedian, Ani; Yendiki, Anastasia; van der Kouwe, Andre; Mareyam, Azma; Fischl, Bruce] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA USA; [Edlow, Brian L.; Stevens, Allison; Moreau, Allison L.; Tirrell, Lee S.; Varjabedian, Ani; Yendiki, Anastasia; van der Kouwe, Andre; Mareyam, Azma; Fischl, Bruce] Harvard Med Sch, Charlestown, MA USA; [Katz, Douglas I.; Daneshvar, Daniel H.; McKee, Ann C.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [Katz, Douglas I.; Daneshvar, Daniel H.] Boston Univ, Sch Med, Alzheimers Dis Ctr, Boston, MA 02118 USA; [Katz, Douglas I.; Daneshvar, Daniel H.] Boston Univ, Sch Med, CTE Program, Boston, MA 02118 USA; [Diaz-Arrastia, Ramon] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA; [Dams-O'Connor, Kristen; Gordon, Wayne A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA; [Dams-O'Connor, Kristen] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA; [McNab, Jennifer A.] Stanford Univ, Dept Radiol, Radiol Sci Lab, Stanford, CA 94305 USA; [Fischl, Bruce] MIT, Comp Sci & Artificial Intelligence Lab, Boston, MA USA; [McKee, Ann C.] VA Boston Healthcare Syst, Boston, MA USA; [McKee, Ann C.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA	Kenney, K (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Neurol, Bldg 51,Room 2306,4860 South Palmer Rd, Bethesda, MD 20889 USA.	kimbra.kenney@usuhs.edu	Moreau, Allison L./T-2625-2019; Iacono, Diego/K-8203-2016	Moreau, Allison L./0000-0002-8758-8622; Iacono, Diego/0000-0001-5511-0950; MICHAUD, ANI/0000-0001-9039-3212; Daneshvar, Daniel/0000-0003-3691-9513	Chronic Effects of Neurotrauma Consortium (DoD VA) [W81XWH-13-2-0095]; Brain Tissue Repository (BTR) and Neuropathology Core, CNRM, USUHS [308049-4.01-60855]; Boston University Alzheimer's disease Center [NIA P30 AG13846, 0572063345-5]; Department of Veterans AffairsUS Department of Veterans Affairs; Worldwide Wrestling Foundation; Andlinger Foundation; American Academy of Neurology/American Brain Foundation; James S. McDonnell Foundation; National Center for Research ResourcesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR014075, U24 RR021382]; National Institute for Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB015896, R01EB006758, R01EB019956, R21EB018907]; National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [AG022381, 5R01AG008122, R01 AG016495]; National Center for Alternative Medicine [RC1 AT005728-01]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS052585-01, 1R21NS072652-01, 1R01NS070963, R01NS083534, 5U01NS086625, U01NS086625, K23NS094538]; National Institute of Child Health and DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01 HD074651-01A1]; Shared Instrumentation Grants [1S10RR023401, 1S10RR019307, 1S10RR023043]; NIH Blueprint for Neuroscience ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [5U01-MH093765]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1S10RR023401, 1S10RR019307, 1S10RR023043]; VA award [IO1RX 002170]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS094538, U01NS086659] Funding Source: NIH RePORTER	Supported by Chronic Effects of Neurotrauma Consortium (DoD & VA), Award Number W81XWH-13-2-0095 and VA award IO1RX 002170; The Brain Tissue Repository (BTR) and Neuropathology Core, CNRM, USUHS, CNRM Award Number 308049-4.01-60855; Boston University Alzheimer's disease Center NIA P30 AG13846, supplement 0572063345-5; Department of Veterans Affairs; Worldwide Wrestling Foundation and the Andlinger Foundation; American Academy of Neurology/American Brain Foundation; the James S. McDonnell Foundation; the National Center for Research Resources (P41RR014075, U24 RR021382); the National Institute for Biomedical Imaging and Bioengineering (P41EB015896, R01EB006758, R21EB018907, R01EB019956, R21EB018907); the National Institute on Aging (AG022381, 5R01AG008122, R01 AG016495); the National Center for Alternative Medicine (RC1 AT005728-01); the National Institute of Neurological Disorders and Stroke (R01NS052585-01, 1R21NS072652-01, 1R01NS070963, R01NS083534, 5U01NS086625, U01NS086625, K23NS094538); National Institute of Child Health and Development (K01 HD074651-01A1) and was made possible by the resources provided by Shared Instrumentation Grants 1S10RR023401, 1S10RR019307, and 1S10RR023043. NIH Blueprint for Neuroscience Research (5U01-MH093765), part of the multiinstitutional Human Connectome Project also provided support. This research also utilized resources provided by National Institutes of Health shared instrumentation grants 1S10RR023401, 1S10RR019307, and 1S10RR023043.	Augustinack JC, 2005, ANN NEUROL, V57, P489, DOI 10.1002/ana.20426; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Braak H, 2006, ACTA NEUROPATHOL, V112, P389, DOI 10.1007/s00401-006-0127-z; Chen HL, 2007, AM J EPIDEMIOL, V166, P810, DOI 10.1093/aje/kwm153; Corrigan F, 2011, BRAIN RES, V1378, P137, DOI 10.1016/j.brainres.2010.12.077; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Dams-O'Connor K, 2013, NEUROREHABILITATION, V32, P199, DOI 10.3233/NRE-130838; Dams-O'Connor K, 2013, J NEUROL NEUROSUR PS, V84, P177, DOI 10.1136/jnnp-2012-303938; Daneshvar DH, 2013, 2014 ALZH ASS INT C; Edlow BL, 2013, J NEUROPATH EXP NEUR, V72, P505, DOI 10.1097/NEN.0b013e3182945bf6; Elobeid A, 2016, J NEUROPATH EXP NEUR, V75, P316, DOI 10.1093/jnen/nlw002; Fischl B, 2004, NEUROIMAGE, V23, pS69, DOI 10.1016/j.neuroimage.2004.07.016; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; FRATIGLIONI L, 1993, ANN NEUROL, V33, P258, DOI 10.1002/ana.410330306; Gardner RC, 2014, JAMA NEUROL, V71, P1490, DOI 10.1001/jamaneurol.2014.2668; Goldman SM, 2006, ANN NEUROL, V60, P65, DOI 10.1002/ana.20882; Hartman RE, 2002, J NEUROSCI, V22, P10083; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; Hill CS, 2016, TRENDS NEUROSCI, V39, P311, DOI 10.1016/j.tins.2016.03.002; Himanen L, 2006, NEUROLOGY, V66, P187, DOI 10.1212/01.wnl.0000194264.60150.d3; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Ikonomovic MD, 2004, EXP NEUROL, V190, P192, DOI 10.1016/j.expneurol.2004.06.011; Jellinger K A, 2001, BMC Neurol, V1, P3, DOI 10.1186/1471-2377-1-3; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2011, ACTA NEUROPATHOL, V122, P715, DOI 10.1007/s00401-011-0909-9; Johnson VE, 2012, BRAIN PATHOL, V22, P142, DOI 10.1111/j.1750-3639.2011.00513.x; Josephs KA, 2015, ANN NEUROL, V78, P697, DOI 10.1002/ana.24493; Katzman R, 1996, NEUROLOGY, V46, P889; KATZMAN R, 1989, ANN NEUROL, V25, P317, DOI 10.1002/ana.410250402; Kenney K, 2014, 2014 ALZH ASS INT C; LoBue C, 2016, J NEUROL NEUROSUR PS, V87, P817, DOI 10.1136/jnnp-2015-311438; Management of Major Depressive Disorder Working Group, 2016, VA DOD CLIN PRACT GU; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; McKee AC, 2010, J NEUROPATH EXP NEUR, V92, P608; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mehta KM, 1999, NEUROLOGY, V53, P1959, DOI 10.1212/WNL.53.9.1959; Mendez MF, 2015, J ALZHEIMERS DIS, V47, P985, DOI 10.3233/JAD-143207; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Moisse K, 2009, BRAIN RES, V1296, P176, DOI 10.1016/j.brainres.2009.07.023; Mortimer JA, 1991, INT J EPIDEMIOL; Neumann M, 2006, SCIENCE, V314, P130, DOI 10.1126/science.1134108; OMeara ES, 1997, AM J EPIDEMIOL, V146, P373, DOI 10.1093/oxfordjournals.aje.a009290; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Sayed N, 2013, J NEUROTRAUM, V30, P1117, DOI 10.1089/neu.2012.2638; Scott G, 2016, NEUROLOGY, V86, P821, DOI 10.1212/WNL.0000000000002413; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Tateno A, 2015, GEN HOSP PSYCHIAT, V37, DOI 10.1016/j.genhosppsych.2014.09.016; Tolppanen A-M, 2017, ALZHEIMERS DEMENT; Tsolaki M, 1997, Int Psychogeriatr, V9, P327, DOI 10.1017/S104161029700447X; Tsuang D, 2013, JAMA NEUROL, V70, P223, DOI 10.1001/jamaneurol.2013.600; Vossel KA, 2013, NEUROCASE, V19, P295, DOI 10.1080/13554794.2012.667124; Washington PM, 2016, EXP NEUROL, V275, P381, DOI 10.1016/j.expneurol.2015.06.015	54	31	32	1	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	JAN	2018	77	1					50	63		10.1093/jnen/nlx101			14	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	GB3IB	WOS:000428948900004	29155947	Green Published, Bronze			2021-06-18	
J	Kim, JY; Han, Y; Lee, JE; Yenari, MA				Kim, Jong Youl; Han, Yeonseung; Lee, Jong Eun; Yenari, Midori A.			The 70-kDa heat shock protein (Hsp70) as a therapeutic target for stroke	EXPERT OPINION ON THERAPEUTIC TARGETS			English	Article						70-kDa heat shock protein (Hsp70); chaperon; ischemic stroke; apoptosis; inflammation; neuroprotection	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; KAPPA-B ACTIVATION; INTRACEREBRAL HEMORRHAGE; INDUCIBLE HEAT-SHOCK-PROTEIN-70; PHARMACOLOGICAL INDUCTION; GLUCOSE DEPRIVATION; INHIBITS APOPTOSIS; SIGNALING PATHWAY; CELL-DEATH	Introduction: The 70-kDa heat shock protein (Hsp70) is a cytosolic chaperone which facilitates protein folding, degradation, complex assembly, and translocation. Following stroke, these functions have the potential to lead to cytoprotection, and this has been demonstrated using genetic mutant models, direct gene transfer or the induction of Hsp70 via heat stress, approaches which limit its translational utility. Recently, the investigation of Hsp70-inducing pharmacological compounds, which, through their ability to inhibit Hsp90, has obvious clinical implications in terms of potential therapies to mitigate cell death and inflammation, and lead to neuroprotection from brain injury. Areas covered: In this review, we will focus on the role of Hsp70 in cell death and inflammation, and the current literature surrounding the pharmacological induction in acute ischemic stroke models with comments on potential applications at the clinical level. Expert opinion: Such neuroprotectants could be used to synergistically improve neurological outcome or to extend the time window of existing interventions, thus increasing the numbers of stroke victims eligible for treatment.	[Kim, Jong Youl; Han, Yeonseung; Lee, Jong Eun] Yonsei Univ, Coll Med, Dept Anat, Seoul, South Korea; [Lee, Jong Eun] Yonsei Univ, Coll Med, Plus Project Med Sci BK21, Seoul, South Korea; [Lee, Jong Eun] Yonsei Univ, Coll Med, Brain Res Inst, Seoul, South Korea; [Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, Neurology 127 VAMC 4150 Clement St, San Francisco, CA 94143 USA; [Yenari, Midori A.] San Francisco VA Med Ctr, San Francisco, CA USA	Yenari, MA (corresponding author), Univ Calif San Francisco, Dept Neurol, Neurology 127 VAMC 4150 Clement St, San Francisco, CA 94143 USA.; Lee, JE (corresponding author), Yonsei Univ, Coll Med, Brain Res Inst, Dept Anat,Brain Korea Plus Project Med Sci 21, 50-1 Yonsei Ro, Seoul 03722, South Korea.; Yenari, MA (corresponding author), SF VAMC, Neurology 127 VAMC 4150 Clement St, San Francisco, CA 94121 USA.	jelee@yuhs.ac; yenari@alum.mit.edu		Lee, Jong Eun/0000-0001-6203-7413; Kim, Jong Youl/0000-0002-8340-2894	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03NS101246, R01NS040516] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX000589] Funding Source: NIH RePORTER; VAUS Department of Veterans Affairs [2I01BX000589-05A1] Funding Source: Federal RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R03 NS101246, R01 NS040516] Funding Source: Medline; BLRD VA [I01 BX000589] Funding Source: Medline		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Alberti S, 2002, J BIOL CHEM, V277, P45920, DOI 10.1074/jbc.M204196200; Aschkenasy G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026956; Asea Alexzander, 2008, V183, P111; Banecka-Majkutewicz Z, 2012, ACTA BIOCHIM POL, V59, P495; Beere HM, 2000, NAT CELL BIOL, V2, P469; Chen HW, 2003, SHOCK, V20, P274, DOI 10.1097/00024382-200309000-00013; Davies CA, 1998, EXP NEUROL, V154, P199, DOI 10.1006/exnr.1998.6891; de Jong PR, 2009, CELL STRESS CHAPERON, V14, P117, DOI 10.1007/s12192-008-0066-9; De Maio A, 2014, CURR PROTEIN PEPT SC, V15, P225, DOI 10.2174/1389203715666140331113057; Deane CAS, 2016, CELL STRESS CHAPERON, V21, P837, DOI 10.1007/s12192-016-0708-2; del Zoppo GJ, 2003, J CEREBR BLOOD F MET, V23, P879, DOI 10.1097/01.WCB.0000078322.96027.78; del Zoppo GJ, 2011, J CEREBR BLOOD F MET, V31, P1836, DOI 10.1038/jcbfm.2011.93; Ding XZ, 2001, CYTOKINE, V16, P210, DOI 10.1006/cyto.2001.0959; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; Fischer N, 2010, EUR J IMMUNOL, V40, P986, DOI 10.1002/eji.200939738; Frebel K, 2006, BIOCHEM SOC T, V34, P1287, DOI 10.1042/BST0341287; Gabai VL, 2002, MOL CELL BIOL, V22, P3415, DOI 10.1128/MCB.22.10.3415-3424.2002; Gaston JSH, 2002, CLIN EXP IMMUNOL, V127, P1, DOI 10.1046/j.1365-2249.2002.01759.x; Geissler A, 2000, MOL BIOL CELL, V11, P3977, DOI 10.1091/mbc.11.11.3977; Giffard RG, 2004, J NEUROSURG ANESTH, V16, P53, DOI 10.1097/00008506-200401000-00010; Guo F, 2005, BLOOD, V105, P1246, DOI 10.1182/blood-2004-05-2041; Guzhova IV, 1997, CELL STRESS CHAPERON, V2, P132, DOI 10.1379/1466-1268(1997)002<0132:MSPHIW>2.3.CO;2; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Heneka MT, 2000, J CEREBR BLOOD F MET, V20, P800, DOI 10.1097/00004647-200005000-00006; Hoehn B, 2001, J CEREBR BLOOD F MET, V21, P1303, DOI 10.1097/00004647-200111000-00006; Howard M, 2010, THORAX, V65, P346, DOI 10.1136/thx.2008.101139; Ivanov VN, 2006, J BIOL CHEM, V281, P1840, DOI 10.1074/jbc.M509866200; Jiang BM, 2005, CELL STRESS CHAPERON, V10, P252, DOI 10.1379/CSC-124R.1; Jin KL, 2001, J CEREBR BLOOD F MET, V21, P1411, DOI 10.1097/00004647-200112000-00005; Jo SK, 2006, J AM SOC NEPHROL, V17, P3082, DOI 10.1681/ASN.2005101077; Johnston JB, 2000, J VIROL, V74, P7211, DOI 10.1128/JVI.74.16.7211-7220.2000; Kacimi R, 2015, GLIA, V63, P1200, DOI 10.1002/glia.22811; Kelly Stephen, 2002, Curr Med Res Opin, V18 Suppl 2, ps55, DOI 10.1185/030079902125000732; Kim JY, 2015, NEUROSCIENCE, V286, P272, DOI 10.1016/j.neuroscience.2014.11.057; Kim JY, 2016, STROKE, V47, P2103, DOI 10.1161/STROKEAHA.116.012763; Kim JY, 2013, ANAT CELL BIOL, V46, P1, DOI 10.5115/acb.2013.46.1.1; Kim JY, 2013, NEUROBIOL DIS, V58, P289, DOI 10.1016/j.nbd.2013.06.012; Kim N, 2015, NEUROSCIENCE, V284, P912, DOI 10.1016/j.neuroscience.2014.11.010; Kim Nuri, 2012, Inflammopharmacology, V20, P177, DOI 10.1007/s10787-011-0115-3; Kriz J, 2009, ACTA NEUROPATHOL, V117, P497, DOI 10.1007/s00401-009-0496-1; Lai Y, 2005, J NEUROCHEM, V94, P360, DOI 10.1111/j.1471-4159.2005.03212.x; Lakhan SE, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-97; Lanneau D, 2010, THESCIENTIFICWORLDJO, V10, P1543, DOI 10.1100/tsw.2010.152; Lee JE, 2004, NEUROREPORT, V15, P499, DOI 10.1097/00001756-200403010-00023; Lee SH, 2004, STROKE, V35, P2195, DOI 10.1161/01.STR.0000136150.73891.14; Love S, 2003, PROG NEURO-PSYCHOPH, V27, P267, DOI 10.1016/S0278-5846(03)00022-8; Manaenko A, 2010, NEUROCHEM INT, V57, P844, DOI 10.1016/j.neuint.2010.09.001; Matsumori Y, 2005, J CEREBR BLOOD F MET, V25, P899, DOI 10.1038/sj.jcbfm.9600080; Mehta SL, 2007, BRAIN RES REV, V54, P34, DOI 10.1016/j.brainresrev.2006.11.003; Namura S, 1998, J NEUROSCI, V18, P3659; O'Sullivan JC, 2007, J NEUROTRAUM, V24, P532, DOI 10.1089/neu.2006.0128; Okuno S, 2004, J NEUROSCI, V24, P7879, DOI 10.1523/JNEUROSCI.1745-04.2004; Ouyang YB, 2006, CELL STRESS CHAPERON, V11, P180, DOI 10.1379/CSC-182R.1; Ouyang YB, 2013, TRANSL STROKE RES, V4, P693, DOI 10.1007/s12975-013-0280-3; Parsons MJ, 2010, ESSAYS BIOCHEM, V47, P99, DOI [10.1042/BSE0470099, 10.1042/bse0470099]; POLLA BS, 1995, INFLAMMATION, V19, P363, DOI 10.1007/BF01534393; Porter JR, 2010, CURR OPIN CHEM BIOL, V14, P412, DOI 10.1016/j.cbpa.2010.03.019; Rabinstein Alejandro A, 2017, Continuum (Minneap Minn), V23, P62, DOI 10.1212/CON.0000000000000420; Ran RQ, 2004, CELL STRESS CHAPERON, V9, P229, DOI 10.1379/CSC-19R.1; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; Saibil H, 2013, NAT REV MOL CELL BIO, V14, P630, DOI 10.1038/nrm3658; Sharp FR, 2000, J CEREBR BLOOD F MET, V20, P1011, DOI 10.1097/00004647-200007000-00001; Singh-Jasuja H, 2000, J EXP MED, V191, P1965, DOI 10.1084/jem.191.11.1965; Sinn DI, 2007, NEUROBIOL DIS, V26, P464, DOI 10.1016/j.nbd.2007.02.006; Sinn DI, 2007, BRAIN RES, V1135, P167, DOI 10.1016/j.brainres.2006.11.098; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; Stankiewicz AR, 2005, J BIOL CHEM, V280, P38729, DOI 10.1074/jbc.M509497200; Steel R, 2004, J BIOL CHEM, V279, P51490, DOI 10.1074/jbc.M401314200; Strong K, 2007, LANCET NEUROL, V6, P182, DOI 10.1016/S1474-4422(07)70031-5; SUPKO JG, 1995, CANCER CHEMOTH PHARM, V36, P305, DOI 10.1007/BF00689048; Suzuki K, 2002, CIRCULATION, V106, pI270, DOI 10.1161/01.cir.0000032880.55215.92; Tsuchiya D, 2003, NEUROSURGERY, V53, P1179, DOI 10.1227/01.NEU.0000090341.38659.CF; Uchida S, 2006, NEUROSCI LETT, V396, P220, DOI 10.1016/j.neulet.2005.11.065; Van Molle W, 2002, IMMUNITY, V16, P685, DOI 10.1016/S1074-7613(02)00310-2; Vogelgesang A, 2014, ACTA NEUROL SCAND, V129, P1, DOI 10.1111/ane.12165; Voloboueva LA, 2008, J CEREBR BLOOD F MET, V28, P1009, DOI 10.1038/sj.jcbfm.9600600; Wang JA, 2007, BRAIN, V130, P1643, DOI 10.1093/brain/awm095; Xu LJ, 2001, EXP NEUROL, V169, P416, DOI 10.1006/exnr.2001.7678; Yasuda H, 2005, BRAIN RES, V1032, P176, DOI 10.1016/j.brainres.2004.11.009; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhan XH, 2010, STROKE, V41, P538, DOI 10.1161/STROKEAHA.109.572537; Zhao HP, 2012, ADV PHARMACOL, V64, P1, DOI 10.1016/B978-0-12-394816-8.00001-5; Zhao ZR, 2013, J CEREBR BLOOD F MET, V33, P1897, DOI 10.1038/jcbfm.2013.144; Zheng Z, 2004, NEUROL RES, V26, P884, DOI 10.1179/016164104X2357; Zheng Z, 2008, J CEREBR BLOOD F MET, V28, P53, DOI 10.1038/sj.jcbfm.9600502	86	31	37	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1472-8222	1744-7631		EXPERT OPIN THER TAR	Expert Opin. Ther. Targets		2018	22	3					191	199		10.1080/14728222.2018.1439477			9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	GA4KF	WOS:000428297900001	29421932	Green Accepted, Green Published			2021-06-18	
J	Alali, AS; Mukherjee, K; McCredie, VA; Golan, E; Shah, PS; Bardes, JM; Hamblin, SE; Haut, ER; Jackson, JC; Khwaja, K; Patel, NJ; Raj, SR; Wilson, LD; Nathens, AB; Patel, MB				Alali, Aziz S.; Mukherjee, Kaushik; McCredie, Victoria A.; Golan, Eyal; Shah, Prakesh S.; Bardes, James M.; Hamblin, Susan E.; Haut, Elliott R.; Jackson, James C.; Khwaja, Kosar; Patel, Nimitt J.; Raj, Satish R.; Wilson, Laura D.; Nathens, Avery B.; Patel, Mayur B.			Beta-blockers and Traumatic Brain Injury A Systematic Review, Meta-analysis, and Eastern Association for the Surgery of Trauma Guideline	ANNALS OF SURGERY			English	Article; Proceedings Paper	29th Annual Scientific Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 09-16, 2016	San Antonio, TX	Eastern Assoc Surg Trauma		beta-blocker; cardiovascular; Eastern Association for the Surgery of Trauma; mortality; traumatic brain injury	HEAD-INJURY; CRASH TRIAL; DECOMPRESSIVE CRANIECTOMY; CEREBRAL PERFUSION; IMPROVED SURVIVAL; EARLY PROPRANOLOL; IMPROVE SURVIVAL; BLOCKADE; OUTCOMES; METOPROLOL	Objective: To determine if beta-(beta)-blockers improve outcomes after acute traumatic brain injury (TBI). Background: There have been no new inpatient pharmacologic therapies to improve TBI outcomes in a half-century. Treatment of TBI patients with beta-blockers offers a potentially beneficial approach. Methods: Using MEDLINE, EMBASE, and CENTRAL databases, eligible articles for our systematic review and meta-analysis (PROSPERO CRD42016048547) included adult (age >= 16 years) blunt trauma patients admitted with TBI. The exposure of interest was beta-blocker administration initiated during the hospitalization. Outcomes were mortality, functional measures, quality of life, cardiopulmonary morbidity (e.g., hypotension, bradycardia, bronchospasm, and/or congestive heart failure). Data were analyzed using a random-effects model, and represented by pooled odds ratio (OR) with 95% confidence intervals (CI) and statistical heterogeneity (I-2). Results: Data were extracted from 9 included studies encompassing 2005 unique TBI patients with beta-blocker treatment and 6240 unique controls. Exposure to beta-blockers after TBI was associated with a reduction of inhospital mortality (pooled OR 0.39, 95% CI: 0.27-0.56; I-2 = 65%, P < 0.00001). None of the included studies examined functional outcome or quality of life measures, and cardiopulmonary adverse events were rarely reported. No clear evidence of reporting bias was identified. Conclusions: In adults with acute TBI, observational studies reveal a significant mortality advantage with beta-blockers; however, quality of evidence is very low. We conditionally recommend the use of in-hospital beta-blockers. However, we recommend further high-quality trials to answer questions about the mechanisms of action, effectiveness on subgroups, dose-response, length of therapy, functional outcome, and quality of life after beta-blocker use for TBI.	[Alali, Aziz S.; McCredie, Victoria A.; Golan, Eyal] Univ Toronto, Interdept Div Crit Care, Toronto, ON, Canada; [Mukherjee, Kaushik] Loma Linda Univ, Med Ctr, Dept Surg, Div Acute Care Surg, Loma Linda, CA 92350 USA; [Mukherjee, Kaushik; Bardes, James M.; Haut, Elliott R.; Khwaja, Kosar; Patel, Nimitt J.; Patel, Mayur B.] Eastern Assoc Surg Trauma, Chicago, IL USA; [McCredie, Victoria A.; Golan, Eyal] Univ Hlth Network, Dept Crit Care, Toronto, ON, Canada; [Golan, Eyal] Mackenzie Hlth, Div Crit Care, Toronto, ON, Canada; [Golan, Eyal] Mackenzie Hlth, Dept Med, Toronto, ON, Canada; [Shah, Prakesh S.] Univ Toronto, Dept Pediat, Toronto, ON, Canada; [Bardes, James M.] West Virginia Univ, Dept Surg, Morgantown, WV 26506 USA; [Bardes, James M.] USC LAC, Dept Surg, Los Angeles, CA USA; [Hamblin, Susan E.] Vanderbilt Univ, Med Ctr, Dept Pharmaceut Serv, 221 Kirkland Hall, Nashville, TN 37235 USA; [Haut, Elliott R.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA; [Haut, Elliott R.] Johns Hopkins Univ, Sch Med, Dept Anesthesiol Crit Care Med, Baltimore, MD 21205 USA; [Haut, Elliott R.] Johns Hopkins Univ, Sch Med, Dept Emergency Med, Baltimore, MD USA; [Jackson, James C.] Vanderbilt Univ, Med Ctr, Div Pulm & Crit Care Med, 221 Kirkland Hall, Nashville, TN 37235 USA; [Jackson, James C.] Vanderbilt Univ, Med Ctr, Dept Med, Ctr Hlth Serv Res, 221 Kirkland Hall, Nashville, TN 37235 USA; [Jackson, James C.] Tennessee Valley Healthcare Syst, Nashville Vet Affairs Med Ctr, Res Serv, Nashville, TN USA; [Khwaja, Kosar] McGill Univ, Hlth Ctr, Dept Surg, Montreal, PQ, Canada; [Khwaja, Kosar] McGill Univ, Hlth Ctr, Dept Crit Care Med, Montreal, PQ, Canada; [Patel, Nimitt J.] Metrohlth Med Ctr, Dept Surg, Div Trauma Crit Care & Burns, Cleveland, OH 44109 USA; [Raj, Satish R.] Univ Calgary, Libin Cardiovasc Inst, Dept Cardiac Sci, Calgary, AB, Canada; [Wilson, Laura D.] Univ Tulsa, Oxley Coll Hlth Sci, Dept Commun Sci & Disorders, Tulsa, OK 74104 USA; [Wilson, Laura D.] Vanderbilt Univ, Sch Med, Dept Hearing & Speech Sci, Nashville, TN 37212 USA; [Nathens, Avery B.] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Nathens, Avery B.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Toronto, ON, Canada; [Patel, Mayur B.] Vanderbilt Univ, Vanderbilt Brain Inst,Dept Surg, Vanderbilt Ctr Hlth Serv Res,Sect Surg Sci, Med Ctr,Div Trauma Emergency Gen Surg & Crit Care, 221 Kirkland Hall, Nashville, TN 37235 USA; [Patel, Mayur B.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Hlth Serv Res, Vanderbilt Brain Inst,Sect Surg Sci,Dept Neurosur, 221 Kirkland Hall, Nashville, TN 37235 USA; [Patel, Mayur B.] Vanderbilt Univ, Vanderbilt Brain Inst,Sect Surg Sci, Vanderbilt Ctr Hlth Serv Res, Med Ctr,Dept Hearing & Speech Sci, 221 Kirkland Hall, Nashville, TN 37235 USA; [Patel, Mayur B.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville VA Med Ctr, Gen Surg Sect,Surg Serv, Nashville, TN USA	Patel, MB (corresponding author), 1211 21st Ave South,404 Med Arts Bldg, Nashville, TN 37212 USA.	mayur.b.patel@vanderbilt.edu	Shah, Prakesh S/I-8098-2013; Haut, Elliott R./J-3948-2019; Shah, Prakesh/AAA-9884-2020	Bardes, James/0000-0002-9361-6263	Vanderbilt Institute for Clinical and Translational Research via CTSA grant [VR1584, VR5351, VR9276, VR12073, UL1TR000011]; EAST Trauma Foundation Research Scholarship; PfizerPfizer; AHRQ grant of a PCORI contractPatient-Centered Outcomes Research Institute - PCORI [R01HS024547, CE-12-11-4489]; VHA/Vizient IMPERATIV Advantage Performance Improvement Collaborative; Illinois Surgical Quality Improvement Collaborative; National Academies of Medicine; AGENCY FOR HEALTHCARE RESEARCH AND QUALITYUnited States Department of Health & Human ServicesAgency for Healthcare Research & Quality [R01HS024547] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR002243, UL1TR000445] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL111111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM120484] Funding Source: NIH RePORTER	Dr MBP has been or is supported by the Vanderbilt Institute for Clinical and Translational Research awards (VR1584, VR5351, VR9276, VR12073) via CTSA grant UL1TR000011 (NCRR/NCATS/NIH), a 2013 EAST Trauma Foundation Research Scholarship, and speaker fees from Pfizer. Drs ERH and MBP have served on the EAST Guidelines Section and Board of Directors. Dr ERH is the primary investigator of a AHRQ grant (R01HS024547) of a PCORI contract (CE-12-11-4489). Dr ERH receives book royalties from Lippincott, Williams, Wilkins ("Avoiding Common ICU Errors''), consultant and speaker fees from VHA/Vizient IMPERATIV Advantage Performance Improvement Collaborative, and consultant and speaker fees for the Illinois Surgical Quality Improvement Collaborative. Dr ERH was the paid author of a paper commissioned by the National Academies of Medicine.	Alali AS, 2014, NEUROCRIT CARE, V20, P514, DOI 10.1007/s12028-013-9903-5; Alderson P, 1997, BRIT MED J, V314, P1855, DOI 10.1136/bmj.314.7098.1855; Alderson P, 1999, BRIT MED J, V319, P1068, DOI 10.1136/bmj.319.7216.1068a; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, 2009, J Am Coll Cardiol, V54, P2102, DOI 10.1016/j.jacc.2009.07.004; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P347, DOI 10.1111/j.1399-6576.1995.tb04075.x; Berry C, 2012, INJURY, V43, P1833, DOI 10.1016/j.injury.2011.08.014; Bukur M, 2012, AM J SURG, V204, P697, DOI 10.1016/j.amjsurg.2012.02.007; Bukur M, 2012, J TRAUMA ACUTE CARE, V72, P1013, DOI 10.1097/TA.0b013e318241bc5b; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Coppola S, 2015, ANN UPDATE INTENSIVE, P139; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; CRUICKSHANK JM, 1987, LANCET, V2, P585, DOI 10.1016/s0140-6736(87)92984-9; Devereaux PJ, 2008, LANCET, V371, P1839, DOI 10.1016/S0140-6736(08)60601-7; Do D, 2000, J NEUROL NEUROSUR PS, V69, P832, DOI 10.1136/jnnp.69.6.832; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Evans David C, 2014, J Emerg Trauma Shock, V7, P305, DOI 10.4103/0974-2700.142766; Friedman A, 2014, EXPERT REV NEUROTHER, V14, P1365, DOI 10.1586/14737175.2014.972945; FUCHS HJ, 1980, DEUT MED WOCHENSCHR, V105, P1531, DOI 10.1055/s-2008-1070906; Grande P O, 1994, Nord Med, V109, P157; Gregson B, 1999, BRIT MED J, V319, P578, DOI 10.1136/bmj.319.7209.578; Griffin GD, 2015, MED HYPOTHESES, V85, P224, DOI 10.1016/j.mehy.2015.05.005; Guyatt GH, 2008, BMJ-BRIT MED J, V336, P1049, DOI 10.1136/bmj.39493.646875.AE; Guyatt GH, 2008, BRIT MED J, V336, P924, DOI 10.1136/bmj.39489.470347.AD; Hadjizacharia P, 2011, AM SURGEON, V77, P634; Heffernan DS, 2010, J TRAUMA, V69, P1602, DOI 10.1097/TA.0b013e3181f2d3e8; Henden PL, 2014, J NEUROSURG ANESTH, V26, P50, DOI 10.1097/ANA.0b013e3182a47b62; Hendrick LE, 2016, AM SURGEON, V82, P575; Higgins JPT, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d5928; Hutchinson PJ, 2016, NEW ENGL J MED, V375, P1119, DOI 10.1056/NEJMoa1605215; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Kerwin AJ, 2012, J TRAUMA ACUTE CARE, V73, pS283, DOI 10.1097/TA.0b013e31827013e9; Ko A, 2016, J TRAUMA ACUTE CARE, V80, P637, DOI 10.1097/TA.0000000000000959; Kochanek PM, 2016, J NEUROTRAUM, V33, P513, DOI 10.1089/neu.2015.4113; Koskinen LOD, 2014, NEUROSCIENCE, V283, P245, DOI 10.1016/j.neuroscience.2014.06.039; Lewis PR, 2016, J TRAUMA ACUTE CARE, V80, P643, DOI 10.1097/TA.0000000000000957; Ley EJ, 2010, J SURG RES, V163, P142, DOI 10.1016/j.jss.2010.04.046; Ley EJ, 2010, J TRAUMA, V68, P353, DOI 10.1097/TA.0b013e3181c8269a; Ley EJ, 2009, J TRAUMA, V66, P154, DOI 10.1097/TA.0b013e31819388be; Menon DK, 2009, CURR OPIN CRIT CARE, V15, P437, DOI 10.1097/MCC.0b013e3283307a26; Mohseni S, 2015, WORLD J SURG, V39, P2076, DOI 10.1007/s00268-015-3039-z; Mohseni S, 2014, J TRAUMA ACUTE CARE, V76, P804, DOI 10.1097/TA.0000000000000139; Morelli A, 2013, JAMA-J AM MED ASSOC, V310, P1683, DOI 10.1001/jama.2013.278477; Murry JS, 2016, J SURG RES, V200, P221, DOI 10.1016/j.jss.2015.06.045; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/s0140-6736(04)17188-2; Naredi S, 2001, ACTA ANAESTH SCAND, V45, P402, DOI 10.1034/j.1399-6576.2001.045004402.x; Naredi S, 2014, INTENS CARE MED, V24, P446; Neideen T, 2008, J TRAUMA, V65, P1016, DOI 10.1097/TA.0b013e3181897eac; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Panczykowski DM, 2012, J NEUROTRAUM, V29, P47, DOI 10.1089/neu.2010.1482; Patel MB, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-177; Radosevich JJ, 2013, BRAIN INJURY, V27, P1492, DOI 10.3109/02699052.2013.823658; Riordan WP, 2007, J TRAUMA, V63, P503, DOI 10.1097/TA.0b013e3181271c34; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROBERTSON CS, 1983, J NEUROSURG, V59, P455, DOI 10.3171/jns.1983.59.3.0455; Salim A, 2008, J TRAUMA, V64, P46, DOI 10.1097/TA.0b013e31815eb15a; Schneider EB, 2011, J TRAUMA, V71, P815, DOI 10.1097/TA.0b013e3182319de5; Schroeppel TJ, 2014, J TRAUMA ACUTE CARE, V76, P504, DOI 10.1097/TA.0000000000000104; Schroeppel TJ, 2010, J TRAUMA, V69, P776, DOI 10.1097/TA.0b013e3181e981b8; Shoup JP, 2014, J NEUROL SCI, V336, P127, DOI 10.1016/j.jns.2013.10.022; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Song D, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/873590; Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z; Stein D., 2016, OPINION WHY MOST TBI; Tran TY, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E8; van den Bergh WM, 2016, NETH J CRIT CARE, V24, P6; Velayutham PK, 2013, J SURG RES, V179, P125, DOI 10.1016/j.jss.2012.09.005; Webb A, GREATER TRANSMISSION; Wright DW, 2014, NEW ENGL J MED, V371, P2457, DOI 10.1056/NEJMoa1404304; Xiong Y, 2015, EXPERT OPIN INV DRUG, V24, P743, DOI 10.1517/13543784.2015.1021919; Zangbar B, 2016, J SURG RES, V200, P586, DOI 10.1016/j.jss.2015.08.020	73	31	31	2	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	DEC	2017	266	6					952	961		10.1097/SLA.0000000000002286			10	Surgery	Surgery	FR4FZ	WOS:000419022400108	28525411	Green Accepted			2021-06-18	
J	Valera, E; Kucyi, A				Valera, Eve; Kucyi, Aaron			Brain injury in women experiencing intimate partner-violence: neural mechanistic evidence of an "invisible" trauma	BRAIN IMAGING AND BEHAVIOR			English	Article						Intimate-partner violence; Traumatic brain injury; Functional connectivity; Default mode network; Salience network; Domestic violence	DEFAULT MODE NETWORK; INTRINSIC FUNCTIONAL CONNECTIVITY; CONCUSSION SYMPTOMS QUESTIONNAIRE; RANDOMIZED CLINICAL-TRIAL; SALIENCE NETWORK; EXECUTIVE CONTROL; FMRI; DISEASE; CORTEX; COGNITION	Traumatic brain injury (TBI) in women experiencing intimate-partner violence (IPV) is common, and IPV afflicts 30 % of women worldwide. However, the neurobiology and related sequelae of these TBIs have never been systematically examined. Consequently, TBI treatments are typically absent and IPV interventions are inadequate. There has been a call for a comprehensive assessment of IPV-related TBIs and their relationship to aspects of women's cognitive and neural functioning. In response, we examined brain-network organization associated with TBI and its cognitive effects using clinical interviews and neuropsychological measures as well as structural and functional Magnetic Resonance Imaging (fMRI) in women experiencing IPV-related TBI. We hypothesized that TBI severity would be related to poorer cognitive performance and be associated with structural and functional connectivity between cognitive networks previously implicated in other TBI populations. As predicted, severity of TBI was negatively associated with inter-network intrinsic functional connectivity indicative of TBI, between the right anterior insula and posterior cingulate cortex/precuneus (FLAME1 + 2; family-wise error-corrected Z > 2.3, cluster- based p < 0.05). This association remained significant when controlling for partner-abuse severity, age, head motion, childhood trauma and psychopathology. Additionally, intrinsic functional connectivity between the same regions correlated positively with cognitive performance on indices of memory and learning. These data provide the first mechanistic evidence of TBI and its association with cognitive functioning in women sustaining IPV-related TBI. These data underscore the need to address and consider the role TBI may be playing in the efficacy of IPV interventions ranging from emergency first responder interactions to specific treatment plans.	[Valera, Eve; Kucyi, Aaron] Massachusetts Gen Hosp, Dept Psychiat, 149 Thirteenth St,Room 2660, Charlestown, MA 02129 USA; [Valera, Eve; Kucyi, Aaron] Harvard Med Sch, Dept Psychiat, Boston, MA USA	Valera, E (corresponding author), Massachusetts Gen Hosp, Dept Psychiat, 149 Thirteenth St,Room 2660, Charlestown, MA 02129 USA.; Valera, E (corresponding author), Harvard Med Sch, Dept Psychiat, Boston, MA USA.	eve_valera@hms.harvard.edu; akucyi@mgh.harvard.edu			Harvard Medical School Center of Excellence grant from the HMS Fund for Women's Health; Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); NCRRUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR14075, P41 EB015896]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1S10RR023043, 1S10RR023401]	EMV and AK had full access to all of the data in the study and take responsibility for the integrity of the data and accuracy of the data analysis. We thank all of the women who participated in this study. We thank Brittany LeBlanc for data management assistance, Drs. Michael Alexander, Margaret O'Connor and Gregory Sorensen for helpful advice in developing this project, Dr. Steven Stufflebeam for performing the clinical reads of the imaging scans, Drs. Randy Buckner, Kevin Spencer, Martha Shenton and Michael Hove for helpful feedback in preparing the manuscript. This work was supported by a Harvard Medical School Center of Excellence grant from the HMS Fund for Women's Health (EMV), the Canadian Institutes of Health Research (AK), and grants provided to the Athinoula A. Martinos Center for Biomedical Imaging, NCRR P41RR14075 and P41 EB015896. This work also involved the use of instrumentation supported by the NIH Shared Instrumentation Grant Program and/or High-End Instrumentation Grant Program; specifically, grant numbers 1S10RR023043 and 1S10RR023401.	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anticevic A, 2012, TRENDS COGN SCI, V16, P584, DOI 10.1016/j.tics.2012.10.008; Banks M. E., 2013, HLTH HEALING TRAUMAT, P153; Banks ME, 2007, TRAUMA VIOLENCE ABUS, V8, P290, DOI 10.1177/1524838007303503; Behzadi Y, 2007, NEUROIMAGE, V37, P90, DOI 10.1016/j.neuroimage.2007.04.042; Benson RR, 2012, NEUROREHABILITATION, V31, P261, DOI 10.3233/NRE-2012-0795; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; Cai W, 2015, CAUSAL INTERACTIONS; Carroll Linda J., 2004, Journal of Rehabilitation Medicine Supplement, P113; Chai XQJ, 2012, NEUROIMAGE, V59, P1420, DOI 10.1016/j.neuroimage.2011.08.048; Committee on Mild Traumatic Brain Injury and American Congress of Rehabilitation Medicine, 1993, J HEAD TRAUMA REHAB, V8, P48; Demirtas-Tatlidede A, 2012, J HEAD TRAUMA REHAB, V27, P274, DOI 10.1097/HTR.0b013e318217df55; Devries KM, 2013, SCIENCE, V340, P1527, DOI 10.1126/science.1240937; Eisenstat SA, 1999, NEW ENGL J MED, V341, P886, DOI 10.1056/NEJM199909163411206; Eklund A, 2016, P NATL ACAD SCI USA, V113, P7900, DOI 10.1073/pnas.1602413113; Fox MD, 2007, NAT REV NEUROSCI, V8, P700, DOI 10.1038/nrn2201; Goulden N, 2014, NEUROIMAGE, V99, P180, DOI 10.1016/j.neuroimage.2014.05.052; Hammoud DA, 2002, NEUROIMAG CLIN N AM, V12, P205, DOI 10.1016/S1052-5149(02)00011-4; Jenkinson M, 2012, NEUROIMAGE, V62, P782, DOI 10.1016/j.neuroimage.2011.09.015; Jilka SR, 2014, J NEUROSCI, V34, P10798, DOI 10.1523/JNEUROSCI.0518-14.2014; Kasahara M, 2011, BRAIN INJURY, V25, P1170, DOI 10.3109/02699052.2011.608210; Kelly AMC, 2008, NEUROIMAGE, V39, P527, DOI 10.1016/j.neuroimage.2007.08.008; Kim YH, 2009, NEUROREHAB NEURAL RE, V23, P468, DOI 10.1177/1545968308328728; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Klevens J, 2015, JAMA-J AM MED ASSOC, V314, P515, DOI 10.1001/jama.2015.6755; Kondo A, 2015, NATURE, V523, P431, DOI 10.1038/nature14658; Kucyi A, 2015, HUM BRAIN MAPP, V36, P3373, DOI 10.1002/hbm.22850; Kucyi A, 2013, P NATL ACAD SCI USA, V110, P18692, DOI 10.1073/pnas.1312902110; Kucyi A, 2012, J NEUROPHYSIOL, V108, P3382, DOI 10.1152/jn.00674.2012; Kwako LE, 2011, TRAUMA VIOLENCE ABUS, V12, P115, DOI 10.1177/1524838011404251; Leech R, 2014, BRAIN, V137, P12, DOI 10.1093/brain/awt162; Levin HS, 2015, LANCET NEUROL, V14, P506, DOI 10.1016/S1474-4422(15)00002-2; Liebschutz JM, 2012, NEW ENGL J MED, V367, P2071, DOI 10.1056/NEJMp1204278; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Menon V, 2010, BRAIN STRUCT FUNCT, V214, P655, DOI 10.1007/s00429-010-0262-0; Murray CE, 2016, TRAUMA VIOLENCE ABUS, V17, P298, DOI 10.1177/1524838015584364; Nathan DE, 2015, BRAIN CONNECT, V5, P102, DOI 10.1089/brain.2014.0273; Palacios EM, 2013, JAMA NEUROL, V70, P845, DOI 10.1001/jamaneurol.2013.38; Potter S, 2006, J NEUROL, V253, P1603, DOI 10.1007/s00415-006-0275-z; Power JD, 2015, NEUROIMAGE, V105, P536, DOI 10.1016/j.neuroimage.2014.10.044; Power JD, 2013, NEURON, V79, P798, DOI 10.1016/j.neuron.2013.07.035; Rhodes KV, 2015, JAMA-J AM MED ASSOC, V314, P466, DOI 10.1001/jama.2015.8369; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Seeley WW, 2007, J NEUROSCI, V27, P2349, DOI 10.1523/JNEUROSCI.5587-06.2007; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shumskaya E, 2012, NEUROLOGY, V79, P175, DOI 10.1212/WNL.0b013e31825f04fb; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Sridharan D, 2008, P NATL ACAD SCI USA, V105, P12569, DOI 10.1073/pnas.0800005105; Stevens MC, 2012, BRAIN IMAGING BEHAV, V6, P293, DOI 10.1007/s11682-012-9157-4; Turner GR, 2008, NEUROLOGY, V71, P812, DOI 10.1212/01.wnl.0000325640.18235.1c; Uddin LQ, 2015, NAT REV NEUROSCI, V16, P55, DOI 10.1038/nrn3857; Uddin LQ, 2011, J NEUROSCI, V31, P18578, DOI 10.1523/JNEUROSCI.4465-11.2011; Valera EM, 2003, J CONSULT CLIN PSYCH, V71, P797, DOI 10.1037/0022-006X.71.4.797; Venkatesan UM, 2015, J NEUROTRAUM, V32, P252, DOI 10.1089/neu.2013.3318; Whitfield-Gabrieli S, 2012, ANNU REV CLIN PSYCHO, V8, P49, DOI 10.1146/annurev-clinpsy-032511-143049; World Health Organization, 1992, ICD 10 CLASS MENT BE; Worsley KJ, 2002, NEUROIMAGE, V15, P1, DOI 10.1006/nimg.2001.0933; Yarkoni T, 2009, PERSPECT PSYCHOL SCI, V4, P294, DOI 10.1111/j.1745-6924.2009.01127.x; Yeo BTT, 2011, J NEUROPHYSIOL, V106, P1125, DOI 10.1152/jn.00338.2011	64	31	31	4	25	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1931-7557	1931-7565		BRAIN IMAGING BEHAV	Brain Imaging Behav.	DEC	2017	11	6					1664	1677		10.1007/s11682-016-9643-1			14	Neuroimaging	Neurosciences & Neurology	FO1VO	WOS:000416555800010	27766587				2021-06-18	
J	Zhao, YY; Lee, JH; Chen, DD; Gu, XH; Caslin, A; Li, JM; Yu, SP; Wei, L				Zhao, Yingying; Lee, Jin Hwan; Chen, Dongdong; Gu, Xiaohuan; Caslin, Asha; Li, Jimei; Yu, Shan Ping; Wei, Ling			DL-3-n-butylphthalide induced neuroprotection, regenerative repair, functional recovery and psychological benefits following traumatic brain injury in mice	NEUROCHEMISTRY INTERNATIONAL			English	Article						NBP; Traumatic brain injury; Regeneration; Inflammation; Depression	FOCAL CEREBRAL-ISCHEMIA; PHARMACOLOGICALLY INDUCED HYPOTHERMIA; ADULT-RAT HIPPOCAMPUS; NEURAL STEM; CHIRAL 3-N-BUTYLPHTHALIDE; PARKINSONS-DISEASE; PROGENITOR CELLS; DENTATE GYRUS; NITRIC-OXIDE; HEAD-INJURY	Previous investigations suggest that DL-3-n-butylphthalide (NBP) is a promising multifaceted drug for the treatment of stroke. It is not clear whether NBP can treat traumatic brain injury (TBI) and what could be the mechanisms of therapeutic benefits. To address these issues, TBI was induced by a controlled cortical impact in adult male mice. NBP (100 mg/kg) or saline was intraperitoneally administered within 5 min after TBI. One day after TBI, apoptotic events including caspase-3/9 activation, cytochrome c release from the mitochondria, and apoptosis-inducing factor (AIF) translocation into the nucleus in the pericontusion region were attenuated in NBP-treated mice compared to TBI-saline controls. In the assessment of the nuclear factor kappa-light-chain-enhancer of activated B (NF-kappa B) pathway, NBP ameliorated the p65 expression and the p-I kappa B-alpha/I kappa B-alpha ratio, indicating reduced NF-kappa B activation. Consistently, NBP reduced the upregulation of proinflammatory cytokines such as tumor necrotizing factor-alpha (TNF-alpha) and interleukin-1beta (IL-1 beta) after TBI. In sub-acute treatment experiments, NBP was intranasally delivered once daily for 3 days. At 3 days after TBI, this repeated NBP treatment significantly reduced the contusion volume and cell death in the pericontusion region. In chronic experiments up to 21 days after TBI, continues daily intranasal NBP treatment increased neurogenesis, angiogenesis, and arteriogenesis in the post-TBI brain, accompanied with up regulations of regenerative genes including brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), endothelial-derived nitric oxide synthase (eNOS), and matrix metallopeptidase 9 (MMP-9). The NBP treatment significantly improved sensorimotor functional recovery and reduced post-TBP depressive behavior. These new findings demonstrate that NBP shows multiple therapeutic benefits after TBI. (C) 2017 Elsevier Ltd. All rights reserved.	[Zhao, Yingying; Li, Jimei; Yu, Shan Ping] Capital Med Univ, Beijing Friendship Hosp, Dept Neurol, Lab Stem Cell Biol & Neural Regenerat & Funct Reco, Beijing 100050, Peoples R China; [Zhao, Yingying; Lee, Jin Hwan; Chen, Dongdong; Gu, Xiaohuan; Caslin, Asha; Yu, Shan Ping; Wei, Ling] Emory Univ, Dept Anesthesiol, Sch Med, Atlanta, GA 30322 USA; [Wei, Ling] Emory Univ, Dept Neurol, Sch Med, Atlanta, GA 30322 USA; [Lee, Jin Hwan; Chen, Dongdong; Gu, Xiaohuan; Yu, Shan Ping] VA Med Ctr, Ctr Visual & Neurocognit Rehabil Atlanta, Decatur, GA 30033 USA	Wei, L (corresponding author), Emory Univ, Sch Med, 101 Woodruff Circle,Woodruff Mem Res Bldg, Atlanta, GA 30322 USA.; Yu, SP (corresponding author), Emory Univ, Sch Med, 101 Woodruff Circle, Atlanta, GA 30322 USA.	lwei7@emory.edu		Yu, Shan Ping/0000-0003-1335-1398	VA Merit grant [RX000666]; AHA Postdoctoral FellowshipAmerican Heart Association [15POST25680013];  [NS075338];  [NS085568];  [NS091585]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS075338, R01NS091585, R01NS085568] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000666] Funding Source: NIH RePORTER	This study was supported by NS075338 (LW), NS085568 (LW/SPY), NS091585 (LW), AHA Postdoctoral Fellowship 15POST25680013 (JHL), and a VA Merit grant RX000666 (SPY).	Anderson VA, 2004, BRAIN, V127, P2608, DOI 10.1093/brain/awh320; Barker-Collo S, 2013, BRAIN INJURY, V27, P1124, DOI 10.3109/02699052.2013.801513; Ben-Hur T, 2003, MOL CELL NEUROSCI, V24, P623, DOI 10.1016/S1044-7431(03)00218-5; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Castren E, 2007, CURR OPIN PHARMACOL, V7, P18, DOI 10.1016/j.coph.2006.08.009; Chang Q, 2003, ACTA PHARMACOL SIN, V24, P796; Choi KE, 2012, FASEB J, V26, P2799, DOI 10.1096/fj.11-201822; Chong ZZ, 2000, CHINESE MED J-PEKING, V113, P613; Chong ZZ, 1999, ACTA PHARMACOL SIN, V20, P696; Christoforidis GA, 2005, AM J NEURORADIOL, V26, P1789; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Collen A, 2003, BLOOD, V101, P1810, DOI 10.1182/blood-2002-05-1593; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Cryan JF, 2005, PSYCHOPHARMACOLOGY, V182, P335, DOI 10.1007/s00213-005-0093-5; Curtis MA, 2007, SCIENCE, V315, P1243, DOI 10.1126/science.1136281; Deng W, 1997, Chin Med Sci J, V12, P102; Djupesland P. G., THER DEILY, V5, P709; Dong Gao-xiang, 2002, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V24, P93; Ekdahl CT, 2003, P NATL ACAD SCI USA, V100, P13632, DOI 10.1073/pnas.2234031100; Erdo Franciska, 2007, Orv Hetil, V148, P633, DOI 10.1556/OH.2007.27916; Fann JR, 2001, PSYCHOSOMATICS, V42, P48, DOI 10.1176/appi.psy.42.1.48; Feng Y. P., 1995, Yaoxue Xuebao, V30, P741; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Gertz K, 2006, CIRC RES, V99, P1132, DOI 10.1161/01.RES.0000250175.14861.77; Greenberg DA, 2013, CELL MOL LIFE SCI, V70, P1753, DOI 10.1007/s00018-013-1282-8; Guo WX, 2012, NAT PROTOC, V7, P2005, DOI 10.1038/nprot.2012.123; Huang JZ, 2010, NEUROSCI LETT, V475, P89, DOI 10.1016/j.neulet.2010.03.053; Jakubs K, 2008, J NEUROSCI, V28, P12477, DOI 10.1523/JNEUROSCI.3240-08.2008; Johnson C, 2004, CIRC RES, V94, P262, DOI 10.1161/01.RES.0000111527.42357.62; Kobeissy F.H, 2015, BRAIN NEUROTRAUMA MO; Lee JH, 2016, BRAIN STRUCT FUNCT, V221, P3259, DOI 10.1007/s00429-015-1099-3; Lee JH, 2014, J NEUROTRAUM, V31, P1417, DOI 10.1089/neu.2013.3251; Li JM, 2010, BRAIN RES, V1359, P216, DOI 10.1016/j.brainres.2010.08.061; Liao SJ, 2009, BRAIN RES, V1289, P69, DOI 10.1016/j.brainres.2009.06.018; Lin J. F., 1996, Yaoxue Xuebao, V31, P166; Liou AKF, 2003, PROG NEUROBIOL, V69, P103, DOI 10.1016/S0301-0082(03)00005-4; Liu X. G., 1995, Yaoxue Xuebao, V30, P896; Liu XB, 2008, CNS NEUROL DISORD-DR, V7, P227, DOI 10.2174/187152708784936617; Contreras DL, 2006, PHARMACOL THERAPEUT, V112, P553, DOI 10.1016/j.pharmthera.2006.05.003; Ma SP, 2009, N-S ARCH PHARMACOL, V379, P565, DOI 10.1007/s00210-009-0398-8; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Mohamad O, 2013, J PHYSIOL-LONDON, V591, P149, DOI 10.1113/jphysiol.2012.239251; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; NIBUYA M, 1995, J NEUROSCI, V15, P7539; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Peng Y, 2007, J PHARMACOL EXP THER, V321, P902, DOI 10.1124/jpet.106.118760; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; PORSOLT RD, 1977, NATURE, V266, P730, DOI 10.1038/266730a0; Rosenberg H, 2015, NEUROPSYCHOLOGY, V29, P509, DOI 10.1037/neu0000171; Runyan DK, 2008, AM J PREV MED, V34, pS112, DOI 10.1016/j.amepre.2008.01.011; Scheff SW, 2013, EXP NEUROL, V239, P183, DOI 10.1016/j.expneurol.2012.09.019; Semenza GL, 2007, J CELL BIOCHEM, V102, P840, DOI 10.1002/jcb.21523; Silver JM., 2011, TXB TRAUMATIC BRAIN, V2nd ed.; Simard JM, 2010, J NEUROSURG, V113, P622, DOI 10.3171/2009.11.JNS081052; Stutzmann JM, 2002, CNS DRUG REV, V8, P1; Takahashi J, 1999, J NEUROBIOL, V38, P65, DOI 10.1002/(SICI)1097-4695(199901)38:1<65::AID-NEU5>3.3.CO;2-H; Tobin MK, 2014, J CEREBR BLOOD F MET, V34, P1573, DOI 10.1038/jcbfm.2014.130; Wei L, 2001, STROKE, V32, P2179, DOI 10.1161/hs0901.094282; Williams WH, 2003, NEUROPSYCHOL REHABIL, V13, P1, DOI [10.1080/09602010244000444, 10.1016/S0960-9822(02)01374-X]; Xiong NA, 2012, NEUROBIOL AGING, V33, P1777, DOI 10.1016/j.neurobiolaging.2011.03.007; Xu HL, 2000, ACTA PHARMACOL SIN, V21, P433; Yan CH, 1998, ACTA PHARMACOL SIN, V19, P117; Yokota T, 2006, STEM CELLS, V24, P13, DOI 10.1634/stemcells.2004-0346; Zhang L. Y., 1996, Yaoxue Xuebao, V31, P18; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zhao YN, 2013, NEURAL REGEN RES, V8, P2615, DOI 10.3969/j.issn.1673-5374.2013.28.003	69	31	34	2	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0197-0186	1872-9754		NEUROCHEM INT	Neurochem. Int.	DEC	2017	111				SI		82	92		10.1016/j.neuint.2017.03.017			11	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	FR3OS	WOS:000418976600009	28359729	Green Accepted			2021-06-18	
J	Godin, JA; Chahla, J; Moatshe, G; Kruckeberg, BM; Muckenhirn, KJ; Vap, AR; Geeslin, AG; LaPrade, RF				Godin, Jonathan A.; Chahla, Jorge; Moatshe, Gilbert; Kruckeberg, Bradley M.; Muckenhirn, Kyle J.; Vap, Alexander R.; Geeslin, Andrew G.; LaPrade, Robert F.			A Comprehensive Reanalysis of the Distal Iliotibial Band Quantitative Anatomy, Radiographic Markers, and Biomechanical Properties	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						knee; iliotibial band; Kaplan fibers; quantitative anatomy	ANTEROLATERAL LIGAMENT; SEGOND FRACTURE; POSTEROLATERAL KNEE; TRACT; RECONSTRUCTION; IDENTIFICATION; LANDMARKS; INJURIES; PATTERNS; TRAUMA	Background: The qualitative anatomy of the distal iliotibial band (ITB) has previously been described. However, a comprehensive characterization of the quantitative anatomic, radiographic, and biomechanical properties of the Kaplan fibers of the deep distal ITB has not yet been established. It is paramount to delineate these characteristics to fully understand the distal ITB's contribution to rotational knee stability. Purpose/Hypothesis: There were 2 distinct purposes for this study: (1) to perform a quantitative anatomic and radiographic evaluation of the distal ITB's attachment sites and their relationships to pertinent osseous and soft tissue landmarks, and (2) to quantify the biomechanical properties of the deep (Kaplan) fibers of the distal ITB. It was hypothesized that the distal ITB has definable parameters concerning its anatomic attachments and consistent relationships to surgically pertinent landmarks with correlating plain radiographic findings. In addition, it was hypothesized that the biomechanical properties of the Kaplan fibers would support their role as important restraints against internal rotation. Study Design: Descriptive laboratory study. Methods: Ten nonpaired, fresh-frozen human cadaveric knees (mean age, 61.1 years; range, 54-65 years) were dissected for anatomic and radiographic purposes. A coordinate measuring device quantified the attachment areas of the distal ITB to the distal femur, patella, and proximal tibia and their relationships to pertinent bony landmarks. A radiographic analysis was performed by inserting pins into the attachment sites of relevant anatomic structures to assess their location relative to pertinent bony landmarks with fluoroscopic guidance. A further biomechanical assessment of 10 cadaveric knees quantified the load to failure and stiffness of the Kaplan fibers' insertion on the distal femur after a preconditioning protocol. Results: Two separate deep (Kaplan) fiber bundles were identified with attachments to 2 newly identified femoral bony prominences (ridges). The proximal and distal bundles inserted on the distal femur 53.6 mm (95% CI, 50.7-56.6 mm) and 31.4 mm (95% CI, 27.3-35.5 mm) proximal to the lateral epicondyle, respectively. The centers of the bundle insertions were 22.5 mm (95% CI, 19.1-25.9 mm) apart. The total insertion area of the distal ITB on the proximal tibia was 429.1 mm(2) (95% CI, 349.2-509.1 mm(2)). A distinct capsulo-osseous layer of the distal ITB was also identified that was intimately related to the lateral knee capsule. Its origin was in close proximity to the lateral gastrocnemius tubercle, and it inserted on the proximal tibia at the lateral tibial tubercle between the fibular head and the Gerdy tubercle. Radiographic analysis supported the quantitative anatomic findings. The mean maximum load during pull-to-failure testing was 71.3 N (95% CI, 41.2-101.4 N) and 170.2 N (95% CI, 123.6-216.8 N) for the proximal and distal Kaplan bundles, respectively. Conclusion: The most important finding of this study was that 2 distinct deep bundles (Kaplan fibers) of the distal ITB were identified. Each bundle of the deep layer of the ITB was associated with a newly identified distinct bony ridge. Radiographic analysis confirmed the measurements previously recorded and established reproducible landmarks for the newly described structures. Biomechanical testing revealed that the Kaplan fibers had a strong attachment to the distal femur, thereby supporting a role in rotational knee stability.	[Godin, Jonathan A.; Chahla, Jorge; Moatshe, Gilbert; Kruckeberg, Bradley M.; Muckenhirn, Kyle J.; Vap, Alexander R.; Geeslin, Andrew G.; LaPrade, Robert F.] Steadman Philippon Res Inst, Dept Biomed Engn, Vail, CO USA; [Godin, Jonathan A.; Chahla, Jorge; Moatshe, Gilbert; Vap, Alexander R.; Geeslin, Andrew G.; LaPrade, Robert F.] Steadman Clin, 181 West Meadow Dr,Suite 400, Vail, CO 81657 USA; [Godin, Jonathan A.; Kruckeberg, Bradley M.; Muckenhirn, Kyle J.; Vap, Alexander R.; Geeslin, Andrew G.; LaPrade, Robert F.] Steadman Philippon Res Inst, Vail, CO USA; [Moatshe, Gilbert] Oslo Univ Hosp, Oslo, Norway; [Moatshe, Gilbert] Univ Oslo, Oslo, Norway; [Moatshe, Gilbert; LaPrade, Robert F.] Norwegian Sch Sport Sci, Oslo Sports Trauma Res Ctr, Oslo, Norway	LaPrade, RF (corresponding author), Steadman Clin, 181 West Meadow Dr,Suite 400, Vail, CO 81657 USA.	drlaprade@sprivail.org	Geeslin, Andrew/AAL-8969-2020		Arthrex; Ossur; Smith Nephew; Linvatec; South-Eastern Norway Regional Health Authorities	One or more of the authors has declared the following potential conflict of interest or source of funding: R.F.L. receives royalties from Arthrex and Smith & Nephew; is a paid consultant for Arthrex, Ossur, and Smith & Nephew; and receives research support from Arthrex, Smith & Nephew, Ossur, and Linvatec. G.M. receives research support from South-Eastern Norway Regional Health Authorities and Arthrex.	Cerminara AJ, 2014, AM J SPORT MED, V42, P2988, DOI 10.1177/0363546514549447; Claes S, 2013, J ANAT, V223, P321, DOI 10.1111/joa.12087; Vieira ELC, 2007, ARTHROSCOPY, V23, P269, DOI 10.1016/j.arthro.2006.11.019; De Maeseneer M, 2015, SKELETAL RADIOL, V44, P413, DOI 10.1007/s00256-014-2044-x; Dodds AL, 2014, BONE JOINT J, V96B, P325, DOI [10.1302/0301-620X.96B3.33033, 10.1302/0301620X.96B3.33033]; Flores DV, 2016, SKELETAL RADIOL, V45, P1635, DOI 10.1007/s00256-016-2479-3; GROOD ES, 1983, J BIOMECH ENG-T ASME, V105, P136, DOI 10.1115/1.3138397; Helito CP, 2014, AM J SPORT MED, V42, P2356, DOI 10.1177/0363546514543770; KAPLAN EB, 1958, J BONE JOINT SURG AM, V40, P817, DOI 10.2106/00004623-195840040-00006; Kennedy MI, 2015, AM J SPORT MED, V43, P1606, DOI 10.1177/0363546515578253; KITTL C, 2016, AM J SPORT MED, V44; Kittl C, 2015, AM J SPORT MED, V43, P354, DOI 10.1177/0363546514560993; LaPrade RF, 2000, AM J SPORT MED, V28, P191, DOI 10.1177/03635465000280020901; LaPrade RE, 2007, J BONE JOINT SURG AM, V89A, P2000, DOI 10.2106/JBJS.F.01176; LOBENHOFFER P, 1987, ARCH ORTHOP TRAUM SU, V106, P285, DOI 10.1007/BF00454335; Mansour R, 2014, SKELETAL RADIOL, V43, P1369, DOI 10.1007/s00256-014-1918-2; Mazzuca SA, 2001, ARTHRITIS RHEUM, V44, P1786, DOI 10.1002/1529-0131(200108)44:8<1786::AID-ART315>3.0.CO;2-L; Parsons EM, 2015, AM J SPORT MED, V43, pNP22, DOI 10.1177/0363546515597218; Pietrini SD, 2009, AM J SPORT MED, V37, P542, DOI 10.1177/0363546508328117; Rahnemai-Azar AA, 2016, AM J SPORT MED, V44, P892, DOI 10.1177/0363546515623500; Schottle PB, 2007, AM J SPORT MED, V35, P801, DOI 10.1177/0363546506296415; Sonnery-Cottet B, 2016, AM J SPORT MED, V44, P1209, DOI 10.1177/0363546515625282; Spencer L, 2015, AM J SPORT MED, V43, P2189, DOI 10.1177/0363546515589166; TERRY GC, 1993, AM J SPORT MED, V21, P55, DOI 10.1177/036354659302100110; TERRY GC, 1986, AM J SPORT MED, V14, P39, DOI 10.1177/036354658601400108; Terry GC, 1996, AM J SPORT MED, V24, P732, DOI 10.1177/036354659602400606; Wijdicks CA, 2009, J BONE JOINT SURG AM, V91A, P521, DOI 10.2106/JBJS.H.00909; WU G, 1995, J BIOMECH, V28, P1257, DOI 10.1016/0021-9290(95)00017-C; Wytrykowski K, 2016, ARTHROSCOPY, V16, P241	29	31	31	1	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	SEP	2017	45	11					2595	2603		10.1177/0363546517707961			9	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	FF3NP	WOS:000408809800019	28609131				2021-06-18	
J	Mao, AH; Ma, XD; He, YN; Luo, J				Mao, Aihua; Ma, Xuedong; He, Yinan; Luo, Jie			Highly Portable, Sensor-Based System for Human Fall Monitoring	SENSORS			English	Article						fall detection; sensors; easy portability; body segment	ALGORITHM	Falls are a very dangerous situation especially among elderly people, because they may lead to fractures, concussion, and other injuries. Without timely rescue, falls may even endanger their lives. The existing optical sensor-based fall monitoring systems have some disadvantages, such as limited monitoring range and inconvenience to carry for users. Furthermore, the fall detection system based only on an accelerometer often mistakenly determines some activities of daily living (ADL) as falls, leading to low accuracy in fall detection. We propose a human fall monitoring system consisting of a highly portable sensor unit including a triaxis accelerometer, a triaxis gyroscope, and a triaxis magnetometer, and a mobile phone. With the data from these sensors, we obtain the acceleration and Euler angle (yaw, pitch, and roll), which represents the orientation of the user's body. Then, a proposed fall detection algorithm was used to detect falls based on the acceleration and Euler angle. With this monitoring system, we design a series of simulated falls and ADL and conduct the experiment by placing the sensors on the shoulder, waist, and foot of the subjects. Through the experiment, we re-identify the threshold of acceleration for accurate fall detection and verify the best body location to place the sensors by comparing the detection performance on different body segments. We also compared this monitoring system with other similar works and found that better fall detection accuracy and portability can be achieved by our system.	[Mao, Aihua; He, Yinan] South China Univ Technol, Sch Comp Sci & Engn, Guangzhou 510006, Guangdong, Peoples R China; [Ma, Xuedong] South China Univ Technol, Sch Elect & Informat Engn, Guangzhou 510006, Guangdong, Peoples R China; [Luo, Jie] Guangzhou Univ, Sch Fine Art & Artist Design, Guangzhou 510006, Guangdong, Peoples R China	Mao, AH (corresponding author), South China Univ Technol, Sch Comp Sci & Engn, Guangzhou 510006, Guangdong, Peoples R China.; Luo, J (corresponding author), Guangzhou Univ, Sch Fine Art & Artist Design, Guangzhou 510006, Guangdong, Peoples R China.	ahmao@scut.edu.cn; eemaxuedong@mail.scut.edu.cn; heyinanscut@outlook.com; jieluo@gzhu.edu.cn			National Natural Science Foundations of ChinaNational Natural Science Foundation of China (NSFC) [61502112]; NSF of Guangdong ProvinceNational Natural Science Foundation of Guangdong Province [2016A030313499]; Science and Technology Planning Project of Guangdong Province [2015A030401030, 2015A020219014]; Guangzhou Municipal University Research Projects [1201630279]; Fundamental Research Funds for the Central UniversitiesFundamental Research Funds for the Central Universities [2017ZD054]; Guangdong Province Universities and Colleges Excellent Youth Teacher Training Program; Student Research Project (SRP) of South China University of Technology	The work of this paper is financially supported by The National Natural Science Foundations of China (No. 61502112), NSF of Guangdong Province (No. 2016A030313499), The Science and Technology Planning Project of Guangdong Province (No. 2015A030401030, No. 2015A020219014), Guangzhou Municipal University Research Projects (No. 1201630279), and the Fundamental Research Funds for the Central Universities (No. 2017ZD054), The Guangdong Province Universities and Colleges Excellent Youth Teacher Training Program and the Student Research Project (SRP) of South China University of Technology.	Albert MV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036556; Anderson Derek, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P6388; Ando B, 2016, IEEE T INSTRUM MEAS, V65, P1960, DOI 10.1109/TIM.2016.2552678; Bian ZP, 2015, IEEE J BIOMED HEALTH, V19, P430, DOI 10.1109/JBHI.2014.2319372; Erdogan SZ, 2012, IET COMMUN, V6, P3281, DOI 10.1049/iet-com.2011.0228; Gasparrini S, 2014, SENSORS-BASEL, V14, P2756, DOI 10.3390/s140202756; He J, 2017, SENSORS-BASEL, V17, DOI 10.3390/s17061393; Heinrich S, 2010, OSTEOPOROSIS INT, V21, P891, DOI 10.1007/s00198-009-1100-1; Hsieh CY, 2017, SENSORS-BASEL, V17, DOI 10.3390/s17020307; Kangas M, 2007, P ANN INT IEEE EMBS, P1367, DOI 10.1109/IEMBS.2007.4352552; Kangas M, 2008, GAIT POSTURE, V28, P285, DOI 10.1016/j.gaitpost.2008.01.003; Karantonis DM, 2006, IEEE T INF TECHNOL B, V10, P156, DOI 10.1109/TITB.2005.856864; Kurniawan A, 2016, 2016 INTERNATIONAL SEMINAR ON INTELLIGENT TECHNOLOGY AND ITS APPLICATIONS (ISITIA): RECENT TRENDS IN INTELLIGENT COMPUTATIONAL TECHNOLOGIES FOR SUSTAINABLE ENERGY, P671, DOI 10.1109/ISITIA.2016.7828740; Lai CF, 2011, IEEE SENS J, V11, P763, DOI 10.1109/JSEN.2010.2062501; Lee YS, 2012, SENSORS-BASEL, V12, P573, DOI 10.3390/s120100573; Li Q, 2009, SIXTH INTERNATIONAL WORKSHOP ON WEARABLE AND IMPLANTABLE BODY SENSOR NETWORKS, PROCEEDINGS, P138, DOI [10.1109/P3644.45, 10.1109/BSN.2009.46]; Liu SH, 2012, SENSORS-BASEL, V12, P12301, DOI 10.3390/s120912301; Luque R, 2014, SENSORS-BASEL, V14, P18543, DOI 10.3390/s141018543; Munoz-Organero M, 2016, SENSORS-BASEL, V16, DOI 10.3390/s16091464; Nari MI, 2016, 2016 INTERNATIONAL SYMPOSIUM ON ELECTRONICS AND SMART DEVICES (ISESD), P88, DOI 10.1109/ISESD.2016.7886698; Ntalampiras S., 2016, P IEEE S SER COMP IN, P1; Ojetola O., 2011, 2011 7th International Conference on Intelligent Environments, P318, DOI 10.1109/IE.2011.38; Pierleoni P, 2015, IEEE SENS J, V15, P4544, DOI 10.1109/JSEN.2015.2423562; Rougier Caroline, 2006, Conf Proc IEEE Eng Med Biol Soc, V2006, P6384; Sorvala A., 2012, P 6 INT S MED INF CO, P1; Stone EE, 2015, IEEE J BIOMED HEALTH, V19, P290, DOI 10.1109/JBHI.2014.2312180; Tao S, 2012, SENSORS-BASEL, V12, P16920, DOI 10.3390/s121216920; Tran TH, 2017, COMPUT METH PROG BIO, V146, P151, DOI 10.1016/j.cmpb.2017.05.007; Wibisono W, 2013, CONF TECHNOL APPL, P382, DOI 10.1109/TAAI.2013.82; Yang L, 2015, SENSORS-BASEL, V15, P23004, DOI 10.3390/s150923004; Yean S., 2016, P 2016 IEEE 7 ANN IN, P1, DOI DOI 10.1109/IEMCON.2016.7746263; Yu M, 2012, IEEE T INF TECHNOL B, V16, P1274, DOI 10.1109/TITB.2012.2214786	32	31	32	0	6	MDPI	BASEL	ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND		1424-8220		SENSORS-BASEL	Sensors	SEP	2017	17	9							2096	10.3390/s17092096			15	Chemistry, Analytical; Engineering, Electrical & Electronic; Instruments & Instrumentation	Chemistry; Engineering; Instruments & Instrumentation	FH8WD	WOS:000411484700166	28902149	DOAJ Gold, Green Published			2021-06-18	
J	Di Pietro, V; Lazzarino, G; Amorini, AM; Signoretti, S; Hill, LJ; Porto, E; Tavazzi, B; Lazzarino, G; Belli, A				Di Pietro, Valentina; Lazzarino, Giacomo; Amorini, Angela Maria; Signoretti, Stefano; Hill, Lisa J.; Porto, Edoardo; Tavazzi, Barbara; Lazzarino, Giuseppe; Belli, Antonio			Fusion or Fission: The Destiny of Mitochondria In Traumatic Brain Injury of Different Severities	SCIENTIFIC REPORTS			English	Article							PROTEOLYTIC CLEAVAGE; GENE-EXPRESSION; QUALITY-CONTROL; IN-VITRO; OPA1; MODEL; MORPHOLOGY; NEUROPROTECTION; DEATH; DYSFUNCTION	Mitochondrial dynamics are regulated by a complex system of proteins representing the mitochondrial quality control (MQC). MQC balances antagonistic forces of fusion and fission determining mitochondrial and cell fates. In several neurological disorders, dysfunctional mitochondria show significant changes in gene and protein expression of the MQC and contribute to the pathophysiological mechanisms of cell damage. In this study, we evaluated the main gene and protein expression involved in the MQC in rats receiving traumatic brain injury (TBI) of different severities. At 6, 24, 48 and 120 hours after mild TBI (mTBI) or severe TBI (sTBI), gene and protein expressions of fusion and fission were measured in brain tissue homogenates. Compared to intact brain controls, results showed that genes and proteins inducing fusion or fission were upregulated and downregulated, respectively, in mTBI, but downregulated and upregulated, respectively, in sTBI. In particular, OPA1, regulating inner membrane dynamics, cristae remodelling, oxidative phosphorylation, was post-translationally cleaved generating differential amounts of long and short OPA1 in mTBI and sTBI. Corroborated by data referring to citrate synthase, these results confirm the transitory (mTBI) or permanent (sTBI) mitochondrial dysfunction, enhancing MQC importance to maintain cell functions and indicating in OPA1 an attractive potential therapeutic target for TBI.	[Di Pietro, Valentina; Hill, Lisa J.; Porto, Edoardo; Belli, Antonio] Univ Birmingham, Neurosci & Ophthalmol Res Grp, Inst Inflammat & Ageing, Sch Clin & Expt Med,Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England; [Di Pietro, Valentina; Hill, Lisa J.; Belli, Antonio] Queen Elizabeth Hosp, Natl Inst Hlth Res, Surg Reconstruct & Microbiol Res Ctr, Birmingham B15 2TH, W Midlands, England; [Lazzarino, Giacomo; Amorini, Angela Maria; Tavazzi, Barbara] Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Largo F Vito 1, I-00168 Rome, Italy; [Signoretti, Stefano] San Camillo Hosp, Dept Neurosci Head & Neck Surg, Div Neurosurg, Circonvallaz Gianicolense 87, I-00152 Rome, Italy; [Lazzarino, Giuseppe] Univ Catania, Div Med Biochem, Dept Biomed & Biotechnol Sci, Viale A Doria 6, I-95125 Catania, Italy	Tavazzi, B (corresponding author), Univ Cattolica Sacro Cuore, Inst Biochem & Clin Biochem, Largo F Vito 1, I-00168 Rome, Italy.; Lazzarino, G (corresponding author), Univ Catania, Div Med Biochem, Dept Biomed & Biotechnol Sci, Viale A Doria 6, I-95125 Catania, Italy.	barbara.tavazzi@unicatt.it; lazzarig@unict.it	Hill, Lisa J/AAO-1560-2021; TAVAZZI, BARBARA/AAB-9830-2019; Belli, Antonio/I-3799-2015; Signoretti, stefano/AAL-5631-2020; lazzarino, giuseppe/K-2277-2015	Hill, Lisa J/0000-0001-8431-7029; TAVAZZI, BARBARA/0000-0001-8743-0895; Belli, Antonio/0000-0002-3211-9933; Signoretti, stefano/0000-0002-8086-1622; Lazzarino, Giacomo/0000-0003-1639-0966; lazzarino, giuseppe/0000-0002-5917-7279; Porto, Edoardo/0000-0002-1442-9137	research funds of Catholic University of Rome; University of Catania; University of Birmingham	This work has been funded in part by research funds of the Catholic University of Rome (BT) the University of Catania (Giuseppe L) and the University of Birmingham (AB).	Alavi MV, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-32; Amorini AM, 2017, J CELL MOL MED, V21, P530, DOI 10.1111/jcmm.12998; Amorini AM, 2016, BBA-MOL BASIS DIS, V1862, P679, DOI 10.1016/j.bbadis.2016.01.023; Ashrafi G, 2015, AUTOPHAGY, V11, P187, DOI 10.1080/15548627.2014.996021; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Bohovych I, 2015, ANTIOXID REDOX SIGN, V22, P977, DOI 10.1089/ars.2014.6199; Borgia D, 2017, HUM MOL GENET, V26, P1087, DOI 10.1093/hmg/ddx019; Bracko O, 2014, J CEREBR BLOOD F MET, V34, P1522, DOI 10.1038/jcbfm.2014.112; Bulstrode H, 2014, ANN NEUROL, V75, P186, DOI 10.1002/ana.24116; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Delettre C, 2001, HUM GENET, V109, P584, DOI 10.1007/s00439-001-0633-y; Di Pietro V, 2014, MOL MED, V20, P147, DOI 10.2119/molmed.2013.00153; Di Pietro V, 2014, FREE RADICAL BIO MED, V69, P258, DOI 10.1016/j.freeradbiomed.2014.01.032; Di Pietro V, 2013, MOL CELL BIOCHEM, V375, P185, DOI 10.1007/s11010-012-1541-2; Di Pietro V, 2010, J NEUROTRAUM, V27, P349, DOI 10.1089/neu.2009.1095; Duvezin-Caubet S, 2006, J BIOL CHEM, V281, P37972, DOI 10.1074/jbc.M606059200; Ehses S, 2009, J CELL BIOL, V187, P1023, DOI 10.1083/jcb.200906084; Exner N, 2012, EMBO J, V31, P3038, DOI 10.1038/emboj.2012.170; Fischer TD, 2016, FRONT SYST NEUROSCI, V10, DOI [10.3389/fnsys.2016.00029, 10.3389/fnsys.2010.00020]; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Frezza C, 2006, CELL, V126, P177, DOI 10.1016/j.cell.2006.06.025; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Grohm J, 2012, CELL DEATH DIFFER, V19, P1446, DOI 10.1038/cdd.2012.18; Guskiewicz Kevin M, 2015, Handb Clin Neurol, V127, P157, DOI 10.1016/B978-0-444-52892-6.00010-6; Hobbs JG, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15617; Ishihara N, 2006, EMBO J, V25, P2966, DOI 10.1038/sj.emboj.7601184; Jahani-Asl A, 2011, J BIOL CHEM, V286, P4772, DOI 10.1074/jbc.M110.167155; Jiang X, 2014, P NATL ACAD SCI USA, V111, P14782, DOI 10.1073/pnas.1417253111; Kaminskyy VO, 2014, ANTIOXID REDOX SIGN, V21, P86, DOI 10.1089/ars.2013.5746; Kannurpatti SS, 2017, J CEREBR BLOOD F MET, V37, P381, DOI 10.1177/0271678X16680637; Kao SH, 2015, INVEST OPHTH VIS SCI, V56, P2269, DOI 10.1167/iovs.14-16288; Kumar R, 2016, MOL CELL NEUROSCI, V76, P68, DOI 10.1016/j.mcn.2016.08.010; Lehmann S, 2013, J MOL MED, V91, P665, DOI 10.1007/s00109-013-1044-y; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loson OC, 2013, MOL BIOL CELL, V24, P659, DOI 10.1091/mbc.E12-10-0721; Mahad D, 2008, NEUROPATH APPL NEURO, V34, P577, DOI 10.1111/j.1365-2990.2008.00987.x; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Mead B, 2016, CYTOTHERAPY, V18, P487, DOI 10.1016/j.jcyt.2015.12.002; Mishra P, 2014, CELL METAB, V19, P630, DOI 10.1016/j.cmet.2014.03.011; Moreira PI, 2010, BBA-MOL BASIS DIS, V1802, P2, DOI 10.1016/j.bbadis.2009.10.006; O'Brien LC, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13080; Omalu B, 2014, PROG NEUROL SURG, V28, P38, DOI 10.1159/000358761; Pellegrini L, 2007, CELL DEATH DIFFER, V14, P1275, DOI 10.1038/sj.cdd.4402145; Ramonet D, 2013, CELL DEATH DIFFER, V20, P77, DOI 10.1038/cdd.2012.95; Rappold PM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6244; Rugarli EI, 2012, EMBO J, V31, P1336, DOI 10.1038/emboj.2012.38; Ruszkiewicz J, 2015, NEUROCHEM INT, V88, P66, DOI 10.1016/j.neuint.2014.12.012; Shi P, 2010, BBA-MOL BASIS DIS, V1802, P45, DOI 10.1016/j.bbadis.2009.08.012; Signoretti S., 2014, CONCUSSIONS ATHLETIC, P89; Signoretti S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10183; Song ZY, 2007, J CELL BIOL, V178, P749, DOI 10.1083/jcb.200704110; Song ZY, 2009, MOL BIOL CELL, V20, P3525, DOI 10.1091/mbc.E09-03-0252; Szklarz LKS, 2012, BBA-BIOENERGETICS, V1817, P1886, DOI 10.1016/j.bbabio.2012.05.001; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; Tondera D, 2009, EMBO J, V28, P1589, DOI 10.1038/emboj.2009.89; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Vagnozzi R, 2007, NEUROSURGERY, V61, P379, DOI 10.1227/01.NEU.0000280002.41696.D8; van der Bliek AM, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011072; Varanita T, 2015, CELL METAB, V21, P834, DOI 10.1016/j.cmet.2015.05.007; Voigt A, 2016, J NEUROCHEM, V139, P232, DOI 10.1111/jnc.13655; Wang X, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.473; Wu Q, 2016, BRAIN RES, V1630, P134, DOI 10.1016/j.brainres.2015.11.016; Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855; Youle RJ, 2005, NAT REV MOL CELL BIO, V6, P657, DOI 10.1038/nrm1697; Zhao YX, 2014, CNS NEUROSCI THER, V20, P528, DOI 10.1111/cns.12266	67	31	31	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	AUG 23	2017	7								9189	10.1038/s41598-017-09587-2			13	Multidisciplinary Sciences	Science & Technology - Other Topics	FE8AC	WOS:000408427000007	28835707	DOAJ Gold, Green Published			2021-06-18	
J	Thelin, EP; Nelson, DW; Vehvilainen, J; Nystrom, H; Kivisaari, R; Siironen, J; Svensson, M; Skrifvars, MB; Bellander, BM; Raj, R				Thelin, Eric Peter; Nelson, David W.; Vehvilainen, Juho; Nystrom, Harriet; Kivisaari, Riku; Siironen, Jari; Svensson, Mikael; Skrifvars, Markus B.; Bellander, Bo-Michael; Raj, Rahul			Evaluation of novel computerized tomography scoring systems in human traumatic brain injury: An observational, multicenter study	PLOS MEDICINE			English	Article							GLASGOW COMA SCALE; HEAD-INJURY; SUBARACHNOID HEMORRHAGE; CLINICAL-PRACTICE; PREDICTIVE-VALUE; IMPACT; EPIDEMIOLOGY; CLASSIFICATION; MANAGEMENT; STATEMENT	Background Traumatic brain injury (TBI) is a major contributor to morbidity and mortality. Computerized tomography (CT) scanning of the brain is essential for diagnostic screening of intracranial injuries in need of neurosurgical intervention, but may also provide information concerning patient prognosis and enable baseline risk stratification in clinical trials. Novel CT scoring systems have been developed to improve current prognostic models, including the Stockholm and Helsinki CT scores, but so far have not been extensively validated. The primary aim of this study was to evaluate the Stockholm and Helsinki CT scores for predicting functional outcome, in comparison with the Rotterdam CT score and Marshall CT classification. The secondary aims were to assess which individual components of the CT scores best predict outcome and what additional prognostic value the CT scoring systems contribute to a clinical prognostic model. Methods and findings TBI patients requiring neuro-intensive care and not included in the initial creation of the Stockholm and Helsinki CT scoring systems were retrospectively included from prospectively collected data at the Karolinska University Hospital (n = 720 from 1 January 2005 to 31 December 2014) and Helsinki University Hospital (n = 395 from 1 January 2013 to 31 December 2014), totaling 1,115 patients. The Marshall CT classification and the Rotterdam, Stockholm, and Helsinki CT scores were assessed using the admission CT scans. Known outcome predictors at admission were acquired (age, pupil responsiveness, admission Glasgow Coma Scale, glucose level, and hemoglobin level) and used in univariate, and multivariable, regression models to predict long-term functional outcome (dichotomizations of the Glasgow Outcome Scale [GOS]). In total, 478 patients (43%) had an unfavorable outcome (GOS 1-3). In the combined cohort, overall prognostic performance was more accurate for the Stockholm CT score (Nagelkerke's pseudo-R-2 range 0.24-0.28) and the Helsinki CT score (0.18-0.22) than for the Rotterdam CT score (0.13-0.15) and Marshall CT classification (0.03-0.05). Moreover, the Stockholm and Helsinki CT scores added the most independent prognostic value in the presence of other known clinical outcome predictors in TBI (6% and 4%, respectively). The aggregate traumatic subarachnoid hemorrhage (tSAH) component of the Stockholm CT score was the strongest predictor of unfavorable outcome. The main limitations were the retrospective nature of the study, missing patient information, and the varying follow-up time between the centers. Conclusions The Stockholm and Helsinki CT scores provide more information on the damage sustained, and give a more accurate outcome prediction, than earlier classification systems. The strong independent predictive value of tSAH may reflect an underrated component of TBI pathophysiology. A change to these newer CT scoring systems may be warranted.	[Thelin, Eric Peter; Nystrom, Harriet; Svensson, Mikael; Bellander, Bo-Michael] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Thelin, Eric Peter] Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Biomed Campus, Cambridge, England; [Nelson, David W.] Karolinska Inst, Sect Perioperat Med & Intens Care, Dept Physiol & Pharmacol, Stockholm, Sweden; [Vehvilainen, Juho; Kivisaari, Riku; Siironen, Jari; Raj, Rahul] Univ Helsinki, Dept Neurosurg, Helsinki, Finland; [Vehvilainen, Juho; Kivisaari, Riku; Siironen, Jari; Skrifvars, Markus B.; Raj, Rahul] Helsinki Univ Hosp, Helsinki, Finland; [Svensson, Mikael; Bellander, Bo-Michael] Karolinska Univ Hosp, Dept Neurosurg, Stockholm, Sweden; [Skrifvars, Markus B.] Univ Helsinki, Dept Anaesthesiol Intens Care & Pain Med, Helsinki, Finland; [Skrifvars, Markus B.] Monash Univ, Sch Publ Hlth & Prevent Med, Australian & New Zealand Intens Care Res Ctr, Melbourne, Vic, Australia	Thelin, EP (corresponding author), Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden.; Thelin, EP (corresponding author), Univ Cambridge, Div Neurosurg, Dept Clin Neurosci, Biomed Campus, Cambridge, England.	eric.thelin@ki.se	Raj, Rahul/K-7693-2012; Svensson, Mikael/F-8662-2012; Viani, Rafael/V-1196-2018; Thelin, Eric Peter/K-2144-2012	Raj, Rahul/0000-0003-4243-9591; Svensson, Mikael/0000-0003-1179-7003; Thelin, Eric Peter/0000-0002-2338-4364; Nelson, David/0000-0003-2530-8207; Bellander, Bo-Michael/0000-0002-0648-2501	Swedish Society of Medicine [SLS-587221]; Maire Taponen's Foundation; Medical Association Life & Health (Liv och Halsa); Swedish Medical Society in Finland; Swedish Cultural Foundation in Finland; Maud Kuistila Memorial Foundation; Eemil Aaltonen Foundation; Ella and Georg Ehrnrooth Foundation; Finnish-Norwegian Medical Foundation; Finnish Medical Foundation; Maire Taponen Foundation	EPT has received funding from the Swedish Society of Medicine (Grant no. SLS-587221, http://www.sls.se/). JV has received funding from Maire Taponen's Foundation (http://www.mairetaposensaatio.fi/). RR is funded by personal grants from the Medical Association Life & Health (Liv och Halsa, http://www.livochhalsa.fi/), the Swedish Medical Society in Finland (http://www.fls.fi/), the Swedish Cultural Foundation in Finland (http:// www.kulturfonden.fi/), the Maud Kuistila Memorial Foundation (http://www. maudkuistilanmuistosaatio.fi/), the Eemil Aaltonen Foundation (http://www.emilaaltonen.fi/ ), The Ella and Georg Ehrnrooth Foundation (http://www.ellageorg.fi/), the Finnish-Norwegian Medical Foundation (http://www.hanaholmen.fi/ en/foundations/finnish-norwegian), the Finnish Medical Foundation (http://www. laaketieteensaatio.fi/) and the Maire Taponen Foundation (http://www.mairetaposensaatio.fi/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Armin SS, 2006, NEUROL RES, V28, P445, DOI 10.1179/016164106X115053; Balestreri M, 2004, J NEUROL NEUROSUR PS, V75, P161; Bledsoe BE, 2015, PREHOSP DISASTER MED, V30, P46, DOI 10.1017/S1049023X14001289; *BRAIN TRAUM FDN, 2000, MAN PROGN SEV TRAUM; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Corral L, 2007, BRAIN INJURY, V21, P1225, DOI 10.1080/02699050701727460; Flynn-O'Brien KT, 2015, NEUROSURGERY, V76, P451, DOI 10.1227/NEU.0000000000000693; GREENE KA, 1995, J NEUROSURG, V83, P445, DOI 10.3171/jns.1995.83.3.0445; Hellewell S, 2016, BRAIN RES, V1640, P36, DOI 10.1016/j.brainres.2015.12.024; Hoogmartens O, 2014, PREHOSP EMERG CARE, V18, P265, DOI 10.3109/10903127.2013.856506; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Hutchinson PJ, 2015, INTENS CARE MED, V41, P1517, DOI 10.1007/s00134-015-3930-y; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jennett B, 1996, J NEUROL NEUROSUR PS, V60, P362, DOI 10.1136/jnnp.60.4.362; JENNETT B, 1975, LANCET, V1, P480; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; Kakarieka A, 1997, NEUROL RES, V19, P230, DOI 10.1080/01616412.1997.11740804; Kim YJ, 2014, INT EMERG NURS, V22, P214, DOI 10.1016/j.ienj.2014.02.005; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; Maas AIR, 2013, LANCET NEUROL, V12, P1200, DOI 10.1016/S1474-4422(13)70234-5; Marshall A, 2010, BMC MED RES METHODOL, V10, DOI 10.1186/1471-2288-10-7; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Miller KJ, 2005, J NEUROSURG, V103, P239, DOI 10.3171/jns.2005.103.2.0239; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Olivecrona M, 2016, J NEUROTRAUM, V33, pA34; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; R Core Team, 2017, R LANG ENV STAT COMP; Raj R, 2015, J NEUROTRAUM, V32, P95, DOI 10.1089/neu.2014.3488; Raj R, 2014, NEUROSURGERY, V75, P632, DOI 10.1227/NEU.0000000000000533; Reilly BM, 2006, ANN INTERN MED, V144, P201, DOI 10.7326/0003-4819-144-3-200602070-00009; Ringdal KG, 2008, SCAND J TRAUMA RESUS, V16, DOI 10.1186/1757-7241-16-7; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Servadei F, 1997, ACTA NEUROCHIR, V139, P279, DOI 10.1007/BF01808822; Servadei F, 2000, NEUROSURGERY, V46, P70; Steyerberg EW, 2001, J CLIN EPIDEMIOL, V54, P774, DOI 10.1016/S0895-4356(01)00341-9; Steyerberg EW., 2009, CLIN PREDICTION MODE; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stocchetti N, 2004, J NEUROTRAUM, V21, P1131, DOI 10.1089/neu.2004.21.1131; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; TEASDALE G, 1974, LANCET, V2, P81; The PLoS Medicine Editors, 2014, PLOS MED, V11; Velmahos GC, 2006, J TRAUMA, V60, P494, DOI 10.1097/01.ta.0000203546.14824.0d; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.1016/j.jclinepi.2007.11.008; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Zuercher M, 2009, BRAIN INJURY, V23, P371, DOI 10.1080/02699050902926267	49	31	33	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1277	1549-1676		PLOS MED	PLos Med.	AUG	2017	14	8							e1002368	10.1371/journal.pmed.1002368			19	Medicine, General & Internal	General & Internal Medicine	FF2ZW	WOS:000408766300005	28771476	DOAJ Gold, Green Published			2021-06-18	
J	Ge, RM; Tornero, D; Hirota, M; Monni, E; Laterza, C; Lindvall, O; Kokaia, Z				Ge, Ruimin; Tornero, Daniel; Hirota, Masao; Monni, Emanuela; Laterza, Cecilia; Lindvall, Olle; Kokaia, Zaal			Choroid plexus-cerebrospinal fluid route for monocyte-derived macrophages after stroke	JOURNAL OF NEUROINFLAMMATION			English	Article						Stroke; Inflammation; Choroid plexus; Transplantation; Functional recovery	REGULATORY T-CELLS; CHEMOATTRACTANT PROTEIN-1; M2 MACROPHAGES; MOUSE MODEL; DISEASE; CNS; POLARIZATION; RECRUITMENT; DYNAMICS; EFFECTOR	Background: Choroid plexus (CP) supports the entry of monocyte-derived macrophages (MDMs) to the central nervous system in animal models of traumatic brain injury, spinal cord injury, and Alzheimer's disease. Whether the CP is involved in the recruitment of MDMs to the injured brain after ischemic stroke is unknown. Methods: Adult male C57BL/6 mice were subjected to focal cortical ischemia by permanent occlusion of the distal branch of the right middle cerebral artery. Choroid plexus tissues were collected and analyzed for Vcam1, Madcam1, Cx(3)cl1, Ccl2, Nt5e, and Ifn gamma expression at different timepoints after stroke using qPCR. Changes of MDMs in CP and cerebrospinal fluid (CSF) at 1 day and 3 days after stroke were analyzed using flow cytometry. Infiltration of MDMs into CP and CSF were validated using beta-actin-GFP chimeric mice and Fgd5-CreERT2 x Lox-stop-lox-Tomato mice. CD115+ monocytes were isolated using a magnetic cell separation system from bone marrow of Cx(3)cr1-GFP or wild-type C57BL/6 donor mice. The freshly isolated monocytes or M2-like MDMs primed in vitro with IL4 and IL13 were stereotaxically injected into the lateral ventricle of stroke-affected mice to trace for their migration into ischemic hemisphere or to assess their effect on post-stroke recovery using open field, corridor, and active avoidance behavioral tests. Results: We found that CP responded to cortical stroke by upregulation of gene expression for several possible mediators of MDM trafficking and, concomitantly, MDMs increased in CP and cerebrospinal fluid (CSF). We then confirmed that MDMs infiltrated from blood into CP and CSF after the insult using beta-actinGFP chimeric mice and Fgd5-CreERT2 x Lox-stop-lox-Tomato mice. When MDMs were directly administered into CSF following stroke, they homed to the ischemic hemisphere. If they had been primed in vitro prior to their administration to become M2-like macrophages, they promoted post-stroke recovery of motor and cognitive function without influencing infarct volume. Conclusions: Our findings suggest the possibility that autologous transplantation of M2-like MDMs into CSF might be developed into a new strategy for promoting recovery also in patients with stroke.	[Ge, Ruimin; Tornero, Daniel; Hirota, Masao; Monni, Emanuela; Laterza, Cecilia; Lindvall, Olle; Kokaia, Zaal] Univ Hosp, Lund Stem Cell Ctr, Lab Stem Cells & Restorat Neurol, SE-22184 Lund, Sweden	Kokaia, Z (corresponding author), Univ Hosp, Lund Stem Cell Ctr, Lab Stem Cells & Restorat Neurol, SE-22184 Lund, Sweden.	zaal.kokaia@med.lu.se	Laterza, Cecilia/AAP-7932-2020; Tornero, Daniel/N-2049-2014; Kokaia, Zaal/AAL-6009-2020	Tornero, Daniel/0000-0002-4812-4091; Kokaia, Zaal/0000-0003-2296-2449	Swedish Research CouncilSwedish Research CouncilEuropean Commission; European Union project TargetBraIn [279017]; AFA Foundation; Swedish Brain Foundation; Torsten Soderberg Foundation; Region Skane; Sparbanksstiftelsen Fars Frosta; Swedish Government Initiative for Strategic Research Areas (StemTherapy)	This work was supported by the Swedish Research Council, European Union project TargetBraIn (279017), AFA Foundation, Swedish Brain Foundation, Torsten Soderberg Foundation, Region Skane, Sparbanksstiftelsen Fars & Frosta, and Swedish Government Initiative for Strategic Research Areas (StemTherapy).	Baruch K, 2016, NAT MED, V22, P135, DOI 10.1038/nm.4022; Baruch K, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8967; Chernykh ER, 2016, CELL TRANSPLANT, V25, P1461, DOI 10.3727/096368915X690279; Desestret V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067063; Desland FA, 2014, J CENT NERV SYST DIS, V6, P7, DOI [10.4137/JCNSNSD.S13194, 10.4137/JCNSD.S13194]; Dowd E, 2005, BRAIN RES BULL, V68, P24, DOI 10.1016/j.brainresbull.2005.08.009; Gazit R, 2014, J EXP MED, V211, P1314, DOI 10.1084/jem.20130428; Gelderblom M, 2009, STROKE, V40, P1849, DOI 10.1161/STROKEAHA.108.534503; Gevrey JC, 2005, J IMMUNOL, V175, P3737, DOI 10.4049/jimmunol.175.6.3737; Gillardon F, 1996, NEUROSCI LETT, V207, P113, DOI 10.1016/0304-3940(96)12508-8; Gordon S, 2005, NAT REV IMMUNOL, V5, P953, DOI 10.1038/nri1733; Grealish S, 2010, EUR J NEUROSCI, V31, P2266, DOI 10.1111/j.1460-9568.2010.07265.x; Hu XM, 2012, STROKE, V43, P3063, DOI 10.1161/STROKEAHA.112.659656; Korf-Klingebiel M, 2015, NAT MED, V21, P140, DOI 10.1038/nm.3778; Kunis G, 2015, J NEUROSCI, V35, P6381, DOI 10.1523/JNEUROSCI.3644-14.2015; Kunis G, 2013, BRAIN, V136, P3427, DOI 10.1093/brain/awt259; Liu Li, 2008, J Vis Exp, DOI 10.3791/960; Losy J, 2001, STROKE, V32, P2695, DOI 10.1161/hs1101.097380; Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133; Miro-Mur F, 2016, BRAIN BEHAV IMMUN, V53, P18, DOI 10.1016/j.bbi.2015.08.010; Moskowitz MA, 2010, NEURON, V67, P181, DOI 10.1016/j.neuron.2010.07.002; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI [10.1161/01.cir.0000441139.02102.80, 10.1161/CIR.0000000000000152, 10.1161/CIR.0b013e31828124ad]; Nahrendorf M, 2007, J EXP MED, V204, P3037, DOI 10.1084/jem.20070885; Ozdinler PH, 2006, NAT NEUROSCI, V9, P1371, DOI 10.1038/nn1789; Perez-de Puig I, 2013, J CEREBR BLOOD F MET, V33, P1955, DOI 10.1038/jcbfm.2013.155; Raposo C, 2014, J NEUROSCI, V34, P10141, DOI 10.1523/JNEUROSCI.0076-14.2014; SANSONE M, 1993, PHARMACOL BIOCHEM BE, V44, P451, DOI 10.1016/0091-3057(93)90490-K; Schlager C, 2016, NATURE, V530, P349, DOI 10.1038/nature16939; Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012; Strazielle N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0150945; Szmydynger-Chodobska J, 2012, J CEREBR BLOOD F MET, V32, P93, DOI 10.1038/jcbfm.2011.111; Szmydynger-Chodobska J, 2009, J CEREBR BLOOD F MET, V29, P1503, DOI 10.1038/jcbfm.2009.71; TAKEYA M, 1991, EXP MOL PATHOL, V54, P61, DOI 10.1016/0014-4800(91)90044-X; Urra X, 2009, J CEREBR BLOOD F MET, V29, P994, DOI 10.1038/jcbfm.2009.25; Wattananit S, 2016, J NEUROSCI, V36, P4182, DOI 10.1523/JNEUROSCI.4317-15.2016	35	31	31	0	11	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	JUL 28	2017	14								153	10.1186/s12974-017-0909-3			15	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	FC0LF	WOS:000406529000004	28754163	DOAJ Gold, Green Published			2021-06-18	
J	Esopenko, C; Chow, TW; Tartaglia, MC; Bacopulos, A; Kumar, P; Binns, MA; Kennedy, JL; Muller, DJ; Levine, B				Esopenko, Carrie; Chow, Tiffany W.; Tartaglia, Maria Carmela; Bacopulos, Agnes; Kumar, Priya; Binns, Malcolm A.; Kennedy, James L.; Muller, Daniel J.; Levine, Brian			Cognitive and psychosocial function in retired professional hockey players	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; FOOTBALL LEAGUE PLAYERS; APOLIPOPROTEIN-E; HEAD-INJURY; ALZHEIMERS-DISEASE; RECURRENT CONCUSSION; EARLY ADULTHOOD; APOE GENOTYPE; NFL PLAYERS; ENCEPHALOPATHY	Background and Objective The relationship between repeated concussions and neurodegenerative disease has received significant attention, particularly research in postmortem samples. Our objective was to characterise retired professional ice hockey players' cognitive and psychosocial functioning in relation to concussion exposure and apolipoprotein epsilon 4 status. Methods Alumni athletes (N=33, aged 34-71 years) and an age-matched sample of comparison participants (N=18) were administered measures of cognitive function and questionnaires concerning psychosocial and psychiatric functioning. Results No significant group differences were found on neuropsychological measures of speeded attention, verbal memory or visuospatial functions, nor were significant differences observed on computerised measures of response speed, inhibitory control and visuospatial problem solving. Reliable group differences in cognitive performance were observed on tests of executive and intellectual function; performance on these measures was associated with concussion exposure. Group differences were observed for cognitive, affective and behavioural impairment on psychosocial questionnaires and psychiatric diagnoses. There was no evidence of differential effects associated with age in the alumni athletes. Possession of an apolipoprotein e4 allele was associated with increased endorsement of psychiatric complaints, but not with objective cognitive performance. Conclusions We found only subtle objective cognitive impairment in alumni athletes in the context of high subjective complaints and psychiatric impairment. Apolipoprotein e4 status related to psychiatric, but not cognitive status. These findings provide benchmarks for the degree of cognitive and behavioural impairment in retired professional athletes and a point of comparison for future neuroimaging and longitudinal studies.	[Esopenko, Carrie; Bacopulos, Agnes; Kumar, Priya; Binns, Malcolm A.; Levine, Brian] Baycrest Hlth Sci, Rotman Res Inst, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada; [Esopenko, Carrie] Rutgers State Univ, Dept Rehabil & Movement Sci, 65 Bergen St, Newark, NJ 07107 USA; [Chow, Tiffany W.] Univ Southern Calif, Los Angeles, CA USA; [Tartaglia, Maria Carmela] Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON, Canada; [Tartaglia, Maria Carmela] Krembil Neurosci Ctr, Div Neurol, Toronto, ON, Canada; [Kumar, Priya] CAMH, Toronto, ON, Canada; [Binns, Malcolm A.; Levine, Brian] Univ Toronto, Toronto, ON, Canada; [Kennedy, James L.; Muller, Daniel J.] Ctr Addict & Mental Hlth, Campbell Family Mental Hlth Res Inst, Toronto, ON, Canada; [Kennedy, James L.; Muller, Daniel J.] Univ Toronto, Dept Psychiat, Toronto, ON, Canada	Esopenko, C; Levine, B (corresponding author), Baycrest Hlth Sci, Rotman Res Inst, 3560 Bathurst St, Toronto, ON M6A 2E1, Canada.; Esopenko, C (corresponding author), Rutgers State Univ, Dept Rehabil & Movement Sci, 65 Bergen St, Newark, NJ 07107 USA.	carrie.esopenko@rutgers.edu	Muller, Daniel J./L-4159-2016; Levine, Brian/O-2725-2019; Binns, Malcolm/AAQ-9195-2020; Kennedy, James Lowery/AAZ-6947-2020; Levine, Brian/G-4328-2010	Muller, Daniel J./0000-0003-4978-4400; Levine, Brian/0000-0003-4343-811X; Binns, Malcolm/0000-0001-9998-6612; Kennedy, James Lowery/0000-0002-8733-3806; Levine, Brian/0000-0003-4343-811X; Esopenko, Carrie/0000-0001-8607-5633	Canadian Institutes of Health Research Catalyst (CIHR) [CBT 127060]; Ontario Neurotrauma Foundation [2012-ABI-CAT3-973]; CIHR Operating GrantCanadian Institutes of Health Research (CIHR) [MOP133728]; Alzheimer's Society of Canada's Research Program Post Doctoral Fellowship	Canadian Institutes of Health Research Catalyst (CIHR; Grant # CBT 127060) Ontario Neurotrauma Foundation (Grant # 2012-ABI-CAT3-973) CIHR Operating Grant (Grant # MOP133728) Alzheimer's Society of Canada's Research Program Post Doctoral Fellowship awarded to CE.	Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Asken BM, 2016, NEUROPSYCHOL REV, V26, P340, DOI 10.1007/s11065-016-9327-z; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Casson IR, 2014, SPORTS HEALTH, V6, P384, DOI 10.1177/1941738114540270; Chio A, 2005, BRAIN, V128, P472, DOI 10.1093/brain/awh373; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Cottler LB, 2011, DRUG ALCOHOL DEPEN, V116, P188, DOI 10.1016/j.drugalcdep.2010.12.003; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Dikmen S S, 1995, J Int Neuropsychol Soc, V1, P67; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Esopenko C, 2015, J NEUROTRAUM, V32, P209, DOI 10.1089/neu.2014.3506; Evans S, 2014, NEUROBIOL AGING, V35, P1615, DOI 10.1016/j.neurobiolaging.2014.01.145; First M.B., 1996, STRUCTURED CLIN INTE; Fleminger S, 2003, J NEUROL NEUROSUR PS, V74, P857, DOI 10.1136/jnnp.74.7.857; Goswami R, 2016, BRAIN STRUCT FUNCT, V221, P1911, DOI 10.1007/s00429-015-1012-0; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hampshire A, 2012, NEURON, V76, P1225, DOI 10.1016/j.neuron.2012.06.022; Hart J, 2013, JAMA NEUROL, V70, P326, DOI 10.1001/2013.jamaneurol.340; Hay J, 2016, ANNU REV PATHOL-MECH, V11, P21, DOI 10.1146/annurev-pathol-012615-044116; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Ihle A, 2012, NEUROPSYCHOLOGY, V26, P267, DOI 10.1037/a0026769; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Jordan BD, 1997, JAMA-J AM MED ASSOC, V278, P136, DOI 10.1001/jama.278.2.136; Kutner KC, 2000, NEUROSURGERY, V47, P651, DOI 10.1097/00006123-200009000-00026; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Lichtman SW, 2000, NEUROLOGY, V55, P1536, DOI 10.1212/WNL.55.10.1536; Lineweaver TT, 2014, AM J PSYCHIAT, V171, P201, DOI 10.1176/appi.ajp.2013.12121590; Maroon JC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117338; Martens MP, 2006, J SUBST ABUSE TREAT, V31, P305, DOI 10.1016/j.jsat.2006.05.004; Maruff P, 2009, ARCH CLIN NEUROPSYCH, V24, P165, DOI 10.1093/arclin/acp010; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Montenigro PH, 2015, ANNU REV CLIN PSYCHO, V11, P309, DOI 10.1146/annurev-clinpsy-032814-112814; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Ponsford J, 2011, J NEUROTRAUM, V28, P1683, DOI 10.1089/neu.2010.1623; Raber J, 2004, NEUROBIOL AGING, V25, P641, DOI 10.1016/j.neurobiolaging.2003.12.023; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Stern RA, 2013, NEUROLOGY, V81, P1122, DOI 10.1212/WNL.0b013e3182a55f7f; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Tomaszczyk JC, 2014, NEUROPSYCHOL REV, V24, P409, DOI 10.1007/s11065-014-9273-6; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Weintraub S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006171; Williams JMG, 2007, PSYCHOL BULL, V133, P122, DOI 10.1037/0033-2909.133.1.122	49	31	32	0	24	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	JUN	2017	88	6					512	519		10.1136/jnnp-2016-315260			8	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	EX0JI	WOS:000402906000010	28396361				2021-06-18	
J	Finan, JD; Sundaresh, SN; Elkin, BS; McKhann, GM; Morrison, B				Finan, John D.; Sundaresh, Sowmya N.; Elkin, Benjamin S.; McKhann, Guy M., II; Morrison, Barclay, III			Regional mechanical properties of human brain tissue for computational models of traumatic brain injury	ACTA BIOMATERIALIA			English	Article						Human brain; Material properties; Viscoelasticity; Hippocampus; Cortex	VISCOELASTIC PROPERTIES; DISEASE	To determine viscoelastic shear moduli, stress relaxation indentation tests were performed on samples of human brain tissue resected in the course of epilepsy surgery. Through the use of a 500 mm diameter indenter, regional mechanical properties were measured in cortical grey and white matter and subregions of the hippocampus. All regions were highly viscoelastic. Cortical grey matter was significantly more compliant than the white matter or hippocampus which were similar in modulus. Although shear modulus was not correlated with the age of the donor, cortex from male donors was significantly stiffer than from female donors. The presented material properties will help to populate finite element models of the brain as they become more anatomically detailed. Statement of Significance We present the first mechanical characterization of fresh, post-operative human brain tissue using an indentation loading mode. Indentation generates highly localized data, allowing structure-specific mechanical properties to be determined from small tissue samples resected during surgery. It also avoids pitfalls of cadaveric tissue and allows data to be collected before degenerative processes alter mechanical properties. To correctly predict traumatic brain injury, finite element models must calculate intracranial deformation during head impact. The functional consequences of injury depend on the anatomical structures injured. Therefore, morbidity depends on the distribution of deformation across structures. Accurate prediction of structure-specific deformation requires structure-specific mechanical properties. This data will facilitate deeper understanding of the physical mechanisms that lead to traumatic brain injury. (C) 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Finan, John D.] NorthShore Univ Hlth Syst, Dept Neurosurg, 1001 Univ Pl, Evanston, IL 60201 USA; [Sundaresh, Sowmya N.; Morrison, Barclay, III] Columbia Univ, Dept Biomed Engn, 351 Engn Terrace,MC 8904,1210 Amsterdam Ave, New York, NY 10027 USA; [Elkin, Benjamin S.] MEA Forens Engineers & Scientists, 22 Voyager Court South, Toronto, ON M9W 5M7, Canada; [McKhann, Guy M., II] Columbia Univ, Med Ctr, Dept Neurol Surg, New York Presbyterian Hosp, 710 West 168th St, New York, NY 10032 USA	Morrison, B (corresponding author), Columbia Univ, Dept Biomed Engn, 351 Engn Terrace,MC 8904,1210 Amsterdam Ave, New York, NY 10027 USA.	Bm2119@columbia.edu	Morrison, Barclay/B-7132-2008	Morrison, Barclay/0000-0001-7676-0864; Finan, John/0000-0003-4626-9702	National Highway Traffic Safety Administration [DTNH22-08-C-00088]	The authors gratefully acknowledge Dr. A.A. Sosunov at the Columbia University Medical Center and the patients who provided samples of brain tissue. This work was funded in part by the National Highway Traffic Safety Administration, project No. DTNH22-08-C-00088.	ARMSTRONG E, 1995, CEREB CORTEX, V5, P56, DOI 10.1093/cercor/5.1.56; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Bilston LE, 1997, BIORHEOLOGY, V34, P377, DOI 10.1016/S0006-355X(98)00022-5; Chatelin S., 2015, J CEREB BLOOD FLOW M; Chen FQ, 2015, ANN BIOMED ENG, V43, P2903, DOI 10.1007/s10439-015-1350-3; Darvish KK, 2001, MED ENG PHYS, V23, P633, DOI 10.1016/S1350-4533(01)00101-1; Elkin BS, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025386; Elkin BS, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4004494; Elkin BS, 2011, J NEUROTRAUM, V28, P2235, DOI 10.1089/neu.2010.1604; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Finan J. D, 2012, IRCOBI C DUBL IREL, V40, P474; Finan JD, 2014, BIOMECH MODEL MECHAN, V13, P573, DOI 10.1007/s10237-013-0519-7; Finan JD, 2012, ANN BIOMED ENG, V40, P70, DOI 10.1007/s10439-011-0394-2; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Garo A, 2007, BIORHEOLOGY, V44, P51; HAYES WC, 1972, J BIOMECH, V5, P541, DOI 10.1016/0021-9290(72)90010-3; Hrapko M, 2008, J BIOMECH ENG-T ASME, V130, DOI 10.1115/1.2907746; Jin X, 2013, J BIOMECH, V46, P2795, DOI 10.1016/j.jbiomech.2013.09.001; Kruse SA, 2008, NEUROIMAGE, V39, P231, DOI 10.1016/j.neuroimage.2007.08.030; Laksari K, 2012, J BIOMECH, V45, P642, DOI 10.1016/j.jbiomech.2011.12.023; Mao H., 2013, J NEUROTRAUMA; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McKee AC, 2015, ACTA NEUROPATHOL; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Moran R, 2014, J BIOMECH, V47, P3762, DOI 10.1016/j.jbiomech.2014.09.030; MORTIMER JA, 1991, INT J EPIDEMIOL, V20, pS28, DOI 10.1093/ije/20.Supplement_2.S28; Ono K. E, 2015, AM J SPORTS MED; Prange MT, 2002, J BIOMECH ENG-T ASME, V124, P244, DOI 10.1115/1.1449907	28	31	31	0	30	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1742-7061	1878-7568		ACTA BIOMATER	Acta Biomater.	JUN	2017	55						333	339		10.1016/j.actbio.2017.03.037			7	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	EX7FU	WOS:000403414500025	28351681				2021-06-18	
J	Swan, AA; Nelson, JT; Swiger, B; Jaramillo, CA; Eapen, BC; Packer, M; Pugh, MJ				Swan, A. A.; Nelson, J. T.; Swiger, B.; Jaramillo, C. A.; Eapen, B. C.; Packer, M.; Pugh, M. J.			Prevalence of hearing loss and tinnitus in Iraq and Afghanistan Veterans: A Chronic Effects of Neurotrauma Consortium study	HEARING RESEARCH			English	Article						Head injury; Hearing loss; Tinnitus; Prevalence; Comorbidities; Veterans	TRAUMATIC BRAIN-INJURY; POLYTRAUMA-CLINICAL-TRIAD; UNITED-STATES; IMPAIRMENT; BLAST; DEPRESSION; ASSOCIATION; HEALTH; COHORT; ADULTS	The purpose of this study was to describe the prevalence of hearing loss and tinnitus in a cohort of Iraq and Afghanistan Veterans (IAV) with common post-deployment conditions, including traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), and other typical post-concussive conditions such as headaches and vertigo/dizziness. This retrospective observational study used data from the national Veterans Health Administration (VA) data repository from fiscal years 2001-2014. Veteran data was included if there were at least three years of VA care, with one or more years of care in 2007 or after. We identified comorbidities that may be associated with post-deployment hearing loss or tinnitus including TBI, PTSD, depression, and common post-concussive symptoms using International Classification of Diseases, 9th Revision, Clinical Modification codes. A multinomial logistic regression analysis was used to examine conditions associated with hearing loss or tinnitus. Among IAV, 570,332 were included in the final analysis. Of these, 7.78% of these were diagnosed with hearing loss alone, 6.54% with tinnitus alone, and 6.24% with both hearing loss and tinnitus. Comorbid TBI, PTSD, and depression were significantly associated with increased rates of hearing loss, tinnitus, or both conditions together. Older individuals, males, and those with TBI, PTSD, or vertigo/dizziness were significantly more likely to have hearing loss, tinnitus, or both. In order to provide more holistic post-deployment support, this myriad of conditions should be carefully considered in the planning of clinical care and beyond. (C) 2017 Elsevier B.V. All rights reserved.	[Swan, A. A.; Jaramillo, C. A.; Eapen, B. C.; Pugh, M. J.] South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA; [Swan, A. A.; Nelson, J. T.; Pugh, M. J.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA; [Nelson, J. T.; Packer, M.] Dept Def Hearing Ctr Excellence, Washington, DC USA; [Swiger, B.] Brooke Army Med Ctr, Ctr Nursing Sci & Clin Inquiry, Ft Sam Houston, TX 78234 USA	Swan, AA (corresponding author), South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.	swana3@uthscsa.edu	Swan, Alicia A/O-3536-2018; Pugh, Mary Jo/K-5336-2019	Swan, Alicia A/0000-0003-2412-0499; Pugh, Mary Jo/0000-0003-4196-7763; Nelson, Jeremy/0000-0003-4428-8694			Abrams TE, 2006, J AM GERIATR SOC, V54, P1475, DOI 10.1111/j.1532-5415.2006.00875.x; Armed Forces Health Surveillance Branch, 2015, SURV CAS DEF 13 0 NE; AXELSSON A, 1985, ACTA OTO-LARYNGOL, V100, P379, DOI 10.3109/00016488509126561; Bartels H, 2008, EAR HEARING, V29, P947, DOI 10.1097/AUD.0b013e3181888f83; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; BRUINS WR, 1991, J LARYNGOL OTOL, V105, P890, DOI 10.1017/S002221510011775X; Burch RC, 2015, HEADACHE, V55, P21, DOI 10.1111/head.12482; Casale M, 2012, SLEEP BREATH, V16, P413, DOI 10.1007/s11325-011-0517-x; Chandler D W, 1997, J Am Acad Audiol, V8, P81; Collett GA., 2016, DRUGS REAL WORLD OUT, V3, P45, DOI [10.1007/s40801-015-0055-0, DOI 10.1007/S40801-015-0055-0]; Cruickshanks KJ, 2015, J AM GERIATR SOC, V63, P918, DOI 10.1111/jgs.13401; Cruickshanks KJ, 2010, HEARING RES, V264, P3, DOI 10.1016/j.heares.2009.10.008; de Graaf R, 2002, PSYCHOSOM MED, V64, P61, DOI 10.1097/00006842-200201000-00009; Fausti SA, 2005, J REHABIL RES DEV, V42, P45, DOI 10.1682/JRRD.2005.02.0039; Figueiredo RR, 2015, EUR ARCH OTO-RHINO-L, V272, P3089, DOI 10.1007/s00405-014-3277-y; Finley EP, 2015, AM J PUBLIC HEALTH, V105, P380, DOI 10.2105/AJPH.2014.301957; Frayne SM, 2011, J GEN INTERN MED, V26, P33, DOI 10.1007/s11606-010-1497-4; Geocze L, 2013, BRAZ J OTORHINOLAR, V79, P106, DOI 10.5935/1808-8694.20130018; Hebert P L, 1999, Am J Med Qual, V14, P270, DOI 10.1177/106286069901400607; Helfer Thomas M, 2005, Am J Audiol, V14, P161, DOI 10.1044/1059-0889(2005/018); Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Jaramillo CA, 2016, HEADACHE, V56, P528, DOI 10.1111/head.12726; KERR AG, 1975, J LARYNGOL OTOL, V89, P131, DOI 10.1017/S002221510008018X; Knol MJ, 2011, EUR J EPIDEMIOL, V26, P253, DOI 10.1007/s10654-011-9563-8; Langguth B, 2011, OTOLARYNG HEAD NECK, V145, P519, DOI 10.1177/0194599811411851; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Lew HL, 2011, J HEAD TRAUMA REHAB, V26, P489, DOI 10.1097/HTR.0b013e318204e54b; Lew HL, 2009, J REHABIL RES DEV, V46, P819, DOI 10.1682/JRRD.2008.09.0129; Lin FR, 2011, ARCH INTERN MED, V171, P1851, DOI 10.1001/archinternmed.2011.506; Office of Public Health, 2015, AN VA HLTH CAR UT OP; Office of the Deputy Assistant Secretary of Defense, 2015, 2014 DEM REP PROF MI; Oleksiak M, 2012, J REHABIL RES DEV, V49, P995, DOI 10.1682/JRRD.2011.01.0001; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Pogoda TK, 2012, J REHABIL RES DEV, V49, P971, DOI 10.1682/JRRD.2011.06.0099; Pugh MJ, 2016, BRAIN INJURY, V30, P1481, DOI 10.1080/02699052.2016.1219055; Pugh MJV, 2014, MED CARE, V52, P172, DOI 10.1097/MLR.0000000000000059; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Selim Alfredo J, 2004, J Ambul Care Manage, V27, P281; Shargorodsky J, 2010, AM J MED, V123, P711, DOI 10.1016/j.amjmed.2010.02.015; Sindhusake Doungkamol, 2004, J Am Acad Audiol, V15, P269; Snell FI, 2010, J PSYCHOSOC NURS MEN, V48, P22, DOI [10.3928/02793695-20100108-02, 10.3928/02793695-20100107-01]; Theodoroff SM, 2015, EPIDEMIOL REV, V37, P71, DOI 10.1093/epirev/mxu005; TYLER RS, 1983, J SPEECH HEAR DISORD, V48, P150, DOI 10.1044/jshd.4802.150; Udupi Venkataraja Aithal, 2013, Int Tinnitus J, V18, P29, DOI 10.5935/0946-5448.20130005; Veterans Benefits Administration, 2016, COMP SERV CONN DIS D; WICKENS T. D., 1989, MULTIWAY CONTINGENCY; Wilk JE, 2010, J HEAD TRAUMA REHAB, V25, P9, DOI 10.1097/HTR.0b013e3181bd090f; YETISER S, 1993, MIL MED, V158, P803	48	31	31	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0378-5955	1878-5891		HEARING RES	Hear. Res.	JUN	2017	349				SI		4	12		10.1016/j.heares.2017.01.013			9	Audiology & Speech-Language Pathology; Neurosciences; Otorhinolaryngology	Audiology & Speech-Language Pathology; Neurosciences & Neurology; Otorhinolaryngology	EW2SB	WOS:000402345200002	28153668	Other Gold			2021-06-18	
J	Dobson, JL; Yarbrough, MB; Perez, J; Evans, K; Buckley, T				Dobson, John L.; Yarbrough, Mary Beth; Perez, Jose; Evans, Kelsey; Buckley, Thomas			Sport-related concussion induces transient cardiovascular autonomic dysfunction	AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY			English	Article						concussion; brain injury; cardiovascular; autonomic	TRAUMATIC BRAIN-INJURY; HEART-RATE-VARIABILITY; PROFESSIONAL FOOTBALL PLAYERS; MANAGEMENT PRACTICE PATTERNS; LOW-FREQUENCY POWER; POSTCONCUSSION SYNDROME; RECURRENT CONCUSSION; ATHLETIC TRAINERS; EXERCISE; ASSOCIATION	Recent evidence suggests that concussions may disrupt autonomic cardiovascular control. This study investigated the initial effects of concussion on cardiovascular function using three autonomic reflex tests. Twenty-three recreational athletes (12 women, 11 men) were divided into concussed (n = 12) and control (n = 11) groups. Concussed participants performed forced breathing, standing, and Valsalva autonomic tests four times: 1) within 48 h of injury; 2) 24 h later; 3) 1 wk after injury; and 4) 2 wk after injury. The controls performed the same tests on the same schedule. Differences in heart rate (HR), systolic blood pressure (SBP), and diastolic blood pressure (DBP) responses to the tests were continuously measured using finger photoplethysmography and were analyzed using repeated-measures multivariate ANOVAs and ANOVAs. Within 48 h of injury, the concussed group had significantly greater resting SBP (t(21) = 2.44, P = 0.02, d = 1.03), HR (t(21) = 2.33, P = 0.03, d = 1.01), and SBP responses to standing (t(21) = 2.98, P = 0.01, d = 1.24), and 90% SBP normalization times (t(21) = 2.64, P = 0.02, d = 1.10) after the Valsalva, but those group differences subsided 24 h later. There was also a significant interaction with the HR responses to forced breathing (F-3,F-60 = 4.13, P = 0.01, eta p(2) = 0.17), indicating the concussed responses declined relative to the control's over time. The results demonstrate that concussion disrupted autonomic cardiovascular control, and that autonomic reflex tests are practical means by which to evaluate that dysfunction.	[Dobson, John L.; Yarbrough, Mary Beth; Perez, Jose; Evans, Kelsey] Georgia Southern Univ, Sch Hlth & Kinesiol, Statesboro, GA 30460 USA; [Buckley, Thomas] Univ Delaware, Dept Kinesiol & Appl Physiol, Newark, DE USA; [Buckley, Thomas] Univ Delaware, Interdisciplinary Program Biomech & Movement Sci, Newark, DE USA	Dobson, JL (corresponding author), POB 8076, Statesboro, GA 30458 USA.	jdobson@georgiasouthern.edu	Buckley, Thomas A/B-7525-2016	Buckley, Thomas A/0000-0002-0515-0150			Abaji JP, 2016, J NEUROTRAUM, V33, P811, DOI 10.1089/neu.2015.3989; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Aminoff M, 1996, NEUROLOGY, V46, P873; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blake TA, 2016, BRAIN INJURY, V30, P132, DOI 10.3109/02699052.2015.1093659; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Buckley TA, 2015, J ATHL TRAINING, V50, P879, DOI 10.4085/1062-6050-50.7.04; Capo-Aponte JE., 2013, J SPINE S, V4, P1; Clausen M, 2016, J HEAD TRAUMA REHAB, V31, P215, DOI 10.1097/HTR.0000000000000145; Conder RL, 2014, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.00890; EWING DJ, 1985, DIABETES CARE, V8, P491, DOI 10.2337/diacare.8.5.491; Gall B, 2004, BRIT J SPORT MED, V38, P773, DOI 10.1136/bjsm.2003.009530; Gall B, 2004, MED SCI SPORT EXER, V36, P1269, DOI 10.1249/01.MSS.0000135787.73757.4D; Giza CC, 2001, J ATHL TRAINING, V36, P228; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Goldstein B, 1998, AM J PHYSIOL-REG I, V275, pR1287; Goldstein B, 1996, CRIT CARE MED, V24, P234, DOI 10.1097/00003246-199602000-00009; Goldstein DS, 2011, EXP PHYSIOL, V96, P1255, DOI 10.1113/expphysiol.2010.056259; Goodman B, 2013, NEUROLOGY, V80, P265; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Heyer GL, 2016, CLIN J SPORT MED, V26, P40, DOI 10.1097/JSM.0000000000000183; Hilz MJ, 2016, BMC NEUROL, V16, DOI 10.1186/s12883-016-0584-5; Hilz MJ, 2011, J NEUROTRAUM, V28, P1727, DOI 10.1089/neu.2010.1497; Kanjwal K, 2010, CARDIOL J, V17, P482; Kelly KC, 2014, J ATHL TRAINING, V49, P665, DOI 10.4085/1062-6050-49.3.25; King ML, 1997, BRAIN INJURY, V11, P445; Kozlowski KF, 2013, J ATHL TRAINING, V48, P627, DOI 10.4085/1062-6050-48.5.02; La Fountaine MF, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00013; La Fountaine MF, 2011, J ATHL TRAINING, V46, P230; La Fountaine MF, 2009, AUTON NEUROSCI-BASIC, V148, P101, DOI 10.1016/j.autneu.2009.03.001; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Len TK, 2011, MED SCI SPORT EXER, V43, P2241, DOI 10.1249/MSS.0b013e3182249539; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Ling H, 2015, MOL CELL NEUROSCI, V66, P114, DOI 10.1016/j.mcn.2015.03.012; Llewellyn T, 2014, CLIN J SPORT MED, V24, P76, DOI 10.1097/01.jsm.0000432853.77520.3d; Low P.A., 2008, CLIN AUTONOMIC DISOR, P130; Makdissi M, 2010, AM J SPORT MED, V38, P464, DOI 10.1177/0363546509349491; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Moak JP, 2007, HEART RHYTHM, V4, P1523, DOI 10.1016/j.hrthm.2007.07.019; Moreau M. S., 2014, INT J EXERCISE SCI, V7, P62; Nacajauskaite O, 2006, BRAIN DEV-JPN, V28, P507, DOI 10.1016/j.braindev.2006.02.010; Papaioannou BP, 2006, COMPUT CARDIOL, V33, P853; Papaioannou V, 2008, J CRIT CARE, V23, P380, DOI 10.1016/j.jcrc.2007.04.006; Parashar R, 2016, J CLIN DIAGN RES, V10, pCC11, DOI 10.7860/JCDR/2016/16889.7497; Rahman F, 2011, CLIN AUTON RES, V21, P133, DOI 10.1007/s10286-010-0098-y; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sung CW, 2016, CLIN NEUROPHYSIOL, V127, P1629, DOI 10.1016/j.clinph.2015.08.006; Tabachnick BG, 2013, USING MULTIVARIATE S; Wieling W, 2013, AUTONOMIC FAILURE TX, P290, DOI DOI 10.1093/MED/9780198566342.003.0025	56	31	31	0	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6119	1522-1490		AM J PHYSIOL-REG I	Am. J. Physiol.-Regul. Integr. Comp. Physiol.	APR	2017	312	4					R575	R584		10.1152/ajpregu.00499.2016			10	Physiology	Physiology	HB1XG	WOS:000450822100004	28148495	Bronze			2021-06-18	
J	Eskreis-Winkler, S; Zhang, Y; Zhang, JW; Liu, Z; Dimov, A; Gupta, A; Wang, Y				Eskreis-Winkler, Sarah; Zhang, Yan; Zhang, Jingwei; Liu, Zhe; Dimov, Alexey; Gupta, Ajay; Wang, Yi			The clinical utility of QSM: disease diagnosis, medical management, and surgical planning	NMR IN BIOMEDICINE			English	Article; Proceedings Paper	4th International Workshop on MRI Phase Contrast and Quantitative Susceptibility Mapping (QSM)	SEP 26-28, 2016	Univ Graz, Graz, AUSTRIA		Univ Graz	QSM; quantitative susceptibility mapping; susceptibility-weighted imaging; iron; neurological; neurodegenerative diseases	SUSCEPTIBILITY MAPPING QSM; MULTIPLE-SCLEROSIS LESIONS; BACKGROUND FIELD REMOVAL; OXYGEN EXTRACTION FRACTION; ENABLED DIPOLE INVERSION; IMAGING FILTERED PHASE; GRADIENT-ECHO MRI; MAGNETIC-SUSCEPTIBILITY; PARKINSONS-DISEASE; SUBSTANTIA-NIGRA	Quantitative susceptibility mapping (QSM) is an MR technique that depicts and quantifies magnetic susceptibility sources. Mapping iron, the dominant susceptibility source in the brain, has many important clinical applications. Herein, we review QSM applications in the diagnosis, medical management, and surgical treatment of disease. To assist in early disease diagnosis, QSM can identify elevated iron levels in the motor cortex of amyotrophic lateral sclerosis patients, in the substantia nigra of Parkinson's disease (PD) patients, in the globus pallidus, putamen, and caudate of Huntington's disease patients, and in the basal ganglia of Wilson's disease patients. Additionally, QSM can distinguish between hemorrhage and calcification, which could prove useful in tumor subclassification, and can measure microbleeds in traumatic brain injury patients. In guiding medical management, QSM can be used to monitor iron chelation therapy in PD patients, to monitor smoldering inflammation of multiple sclerosis (MS) lesions after the blood-brain barrier (BBB) seals, to monitor active inflammation of MS lesions before the BBB seals without using gadolinium, and to monitor hematoma volume in intracerebral hemorrhage. QSM can also guide neurosurgical treatment. Neurosurgeons require accurate depiction of the subthalamic nucleus, a tiny deep gray matter nucleus, prior to inserting deep brain stimulation electrodes into the brains of PD patients. QSM is arguably the best imaging tool for depiction of the subthalamic nucleus. Finally, we discuss future directions, including bone QSM, cardiac QSM, and using QSM to map cerebral metabolic rate of oxygen. Copyright (C) 2016 John Wiley & Sons, Ltd.	[Eskreis-Winkler, Sarah; Zhang, Yan; Zhang, Jingwei; Liu, Zhe; Dimov, Alexey; Gupta, Ajay; Wang, Yi] Weill Cornell Med, Dept Radiol, New York, NY 10065 USA	Wang, Y (corresponding author), Weill Cornell Med, Dept Radiol, New York, NY 10065 USA.	yiwang@med.cornell.edu	Dimov, Alexey V./AAC-4157-2019		National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA178007]; National Institute of Biomedical Imaging and EngineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01 EB013443]; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS095562, R01 NS090464, R01 NS072370]	Sponsors: National Cancer Institute, R01 CA178007; National Institute of Biomedical Imaging and Engineering, R01 EB013443; National Institute of Neurological Disorders and Stroke, R01 NS095562, R01 NS090464, R01 NS072370.	Acosta-Cabronero J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081093; Atasoy HT, 2004, NEUROL INDIA, V52, P332; Ayton S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7760; Azuma M, 2016, AM J NEURORADIOL, V37, P782, DOI 10.3174/ajnr.A4645; Beard JL, 2003, ANNU REV NUTR, V23, P41, DOI 10.1146/annurev.nutr.23.020102.075739; Bian W, 2016, AM J NEURORADIOL, V37, P1808, DOI 10.3174/ajnr.A4830; Bilgic B, 2014, MAGN RESON MED, V72, P1444, DOI 10.1002/mrm.25029; Blazejewska AI, 2015, J MAGN RESON IMAGING, V41, P1065, DOI 10.1002/jmri.24644; Blystad I, 2016, AM J NEURORADIOL, V37, P94, DOI 10.3174/ajnr.A4501; Brar S, 2009, ARCH NEUROL-CHICAGO, V66, P371, DOI 10.1001/archneurol.2008.586; BRODERICK JP, 1993, STROKE, V24, P987, DOI 10.1161/01.STR.24.7.987; Bulte DP, 2012, NEUROIMAGE, V60, P582, DOI 10.1016/j.neuroimage.2011.12.017; Cellura E, 2012, CLIN NEUROL NEUROSUR, V114, P550, DOI 10.1016/j.clineuro.2011.11.026; Chandran AS, 2016, J NEUROSURG, V124, P96, DOI 10.3171/2015.1.JNS142066; Chawla S, 2016, AM J NEURORADIOL, V37, P1223, DOI 10.3174/ajnr.A4729; Chen WW, 2014, RADIOLOGY, V271, P183, DOI 10.1148/radiol.13130353; Chen WW, 2014, RADIOLOGY, V270, P496, DOI 10.1148/radiol.13122640; Crichton RR, 2011, J NEURAL TRANSM, V118, P301, DOI 10.1007/s00702-010-0470-z; de Hollander G, 2014, HUM BRAIN MAPP, V35, P4440, DOI 10.1002/hbm.22485; de Rochefort L, 2008, MAGN RESON MED, V60, P1003, DOI 10.1002/mrm.21710; de Rochefort L, 2010, MAGN RESON MED, V63, P194, DOI 10.1002/mrm.22187; Deh K, 2015, J MAGN RESON IMAGING, V42, P1592, DOI 10.1002/jmri.24943; Deistung A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057924; Devos D, 2014, ANTIOXID REDOX SIGN, V21, P195, DOI 10.1089/ars.2013.5593; DEXTER DT, 1987, LANCET, V2, P1219; DEXTER DT, 1992, ANN NEUROL, V32, pS94, DOI 10.1002/ana.410320716; DEXTER DT, 1991, BRAIN, V114, P1953, DOI 10.1093/brain/114.4.1953; Dominguez DJ, 2015, J NEUROL NEUROSURG P; Du GW, 2016, MOVEMENT DISORD, V31, P317, DOI 10.1002/mds.26417; Du GW, 2011, MOVEMENT DISORD, V26, P1627, DOI 10.1002/mds.23643; Dwyer MG, 2015, J NEUROIMMUNOL, V281, P44, DOI 10.1016/j.jneuroim.2015.03.002; Eskreis-Winkler S, 2015, J MAGN RESON IMAGING, V42, P224, DOI 10.1002/jmri.24745; Fan AP, 2015, NEUROIMAGE, V104, P146, DOI 10.1016/j.neuroimage.2014.09.068; Fan AP, 2014, MAGN RESON MED, V72, P149, DOI 10.1002/mrm.24918; Fine JM, 2015, NEUROSCI LETT, V584, P362, DOI 10.1016/j.neulet.2014.11.013; Fritzsch D, 2014, INVEST RADIOL, V49, P299, DOI 10.1097/RLI.0000000000000010; Gauthier CJ, 2012, NEUROIMAGE, V60, P1212, DOI 10.1016/j.neuroimage.2011.12.056; Gross RE, 2006, MOVEMENT DISORD, V21, pS259, DOI 10.1002/mds.20960; Guan XJ, 2017, NMR BIOMED, V30, DOI 10.1002/nbm.3489; Guo C, 2013, NEUROBIOL AGING, V34, P562, DOI 10.1016/j.neurobiolaging.2012.05.009; Gupta A, 2014, AM J NEURORADIOL, V35, P250, DOI 10.3174/ajnr.A3668; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P663, DOI 10.1002/jmri.22276; Haacke EM, 2015, MAGN RESON IMAGING, V33, P1, DOI 10.1016/j.mri.2014.09.004; Haacke EM, 2009, J MAGN RESON IMAGING, V29, P537, DOI 10.1002/jmri.21676; HALLGREN B, 1958, J NEUROCHEM, V3, P41, DOI 10.1111/j.1471-4159.1958.tb12607.x; Hametner S, 2013, ANN NEUROL, V74, P848, DOI 10.1002/ana.23974; Harrison DM, 2016, AM J NEURORADIOL, V37, P1447, DOI 10.3174/ajnr.A4726; Harrison TR, 2010, HARRISONS NEUROLOGY; Hinoda T, 2015, INVEST RADIOL, V50, P522, DOI 10.1097/RLI.0000000000000159; Ide S, 2015, EUR RADIOL, V25, P710, DOI 10.1007/s00330-014-3472-7; Kanda T, 2015, RADIOLOGY, V275, P803, DOI 10.1148/radiol.14140364; Khabipova D, 2015, NEUROIMAGE, V107, P163, DOI 10.1016/j.neuroimage.2014.11.038; Klohs J, 2011, J CEREBR BLOOD F MET, V31, P2282, DOI 10.1038/jcbfm.2011.118; Kressler B, 2010, IEEE T MED IMAGING, V29, P273, DOI 10.1109/TMI.2009.2023787; Kudo K, 2016, J CEREBR BLOOD F MET, V36, P1424, DOI 10.1177/0271678X15606713; Kutzelnigg A, 2014, HAND CLINIC, V122, P15, DOI 10.1016/B978-0-444-52001-2.00002-9; Kwan JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035241; Langkammer C, 2015, NEUROIMAGE, V111, P622, DOI 10.1016/j.neuroimage.2015.02.041; Langkammer C, 2013, RADIOLOGY, V267, P551, DOI 10.1148/radiol.12120707; Langkammer C, 2012, NEUROIMAGE, V62, P1593, DOI 10.1016/j.neuroimage.2012.05.049; Lassmann H, 2011, J NEUROL SCI, V306, P167, DOI 10.1016/j.jns.2010.07.023; Li JQ, 2012, MAGN RESON MED, V68, P1563, DOI 10.1002/mrm.24135; Li W, 2016, NMR BIOMED; Li W, 2015, NEUROIMAGE, V108, P111, DOI 10.1016/j.neuroimage.2014.12.043; Li W, 2014, NMR BIOMED, V27, P219, DOI 10.1002/nbm.3056; Li W, 2011, NEUROIMAGE, V55, P1645, DOI 10.1016/j.neuroimage.2010.11.088; Li X, 2016, J MAGN RESON IMAGING, V43, P463, DOI 10.1002/jmri.24976; Li X, 2012, NEUROIMAGE, V62, P314, DOI 10.1016/j.neuroimage.2012.04.042; Lin PY, 2015, AM J NEURORADIOL, V36, P467, DOI 10.3174/ajnr.A4137; Liu CL, 2011, NEUROIMAGE, V56, P930, DOI 10.1016/j.neuroimage.2011.02.024; Liu CL, 2010, MAGN RESON MED, V63, P1471, DOI 10.1002/mrm.22482; Liu J, 2012, NEUROIMAGE, V59, P2560, DOI 10.1016/j.neuroimage.2011.08.082; Liu T, 2013, RADIOLOGY, V269, P216, DOI 10.1148/radiol.13121991; Liu T, 2013, MAGN RESON MED, V69, P467, DOI 10.1002/mrm.24272; Liu T, 2012, IEEE T MED IMAGING, V31, P816, DOI 10.1109/TMI.2011.2182523; Liu T, 2012, RADIOLOGY, V262, P269, DOI 10.1148/radiol.11110251; Liu T, 2011, MAGN RESON MED, V66, P777, DOI 10.1002/mrm.22816; Liu TA, 2010, MAGN RESON IMAGING, V28, P1383, DOI 10.1016/j.mri.2010.06.011; Liu T, 2009, MAGN RESON MED, V61, P196, DOI 10.1002/mrm.21828; Liu W, 2016, RADIOLOGY, V278, P536, DOI 10.1148/radiol.2015150160; Lo CP, 2014, BMC NEUROL, V14, DOI 10.1186/1471-2377-14-100; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Macellari F, 2014, STROKE, V45, P903, DOI 10.1161/STROKEAHA.113.003701; Makdissi M, 2014, AUST FAM PHYSICIAN, V43, P94; Mehta V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057573; Mikati AG, 2014, STROKE, V45, P598, DOI 10.1161/STROKEAHA.113.003548; Moon Y, 2016, J ALZHEIMERS DIS, V51, P737, DOI 10.3233/JAD-151037; Murakami Y, 2015, AM J NEURORADIOL, V36, P1102, DOI 10.3174/ajnr.A4260; Nijeholt GJLA, 1998, BRAIN, V121, P687, DOI 10.1093/brain/121.4.687; O'Neil M.E., 2013, COMPLICATIONS MILD T; Ogasawara A, 2015, EUR RADIOL; Barbosa JHO, 2015, MAGN RESON IMAGING, V33, P559, DOI 10.1016/j.mri.2015.02.021; Planting BR, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00876; Press D, 2016, CHOLINESTERASE INHIB; Radbruch A, 2015, RADIOLOGY, V275, P783, DOI 10.1148/radiol.2015150337; Raven EP, 2013, J ALZHEIMERS DIS, V37, P127, DOI 10.3233/JAD-130209; Richter EO, 2004, J NEUROSURG, V100, P541, DOI 10.3171/jns.2004.100.3.0541; Roccatagliata L, 2009, RADIOLOGY, V251, P503, DOI 10.1148/radiol.2511081269; Rouault TA, 2013, NAT REV NEUROSCI, V14, P551, DOI 10.1038/nrn3453; Rudko DA, 2014, RADIOLOGY, V272, P851, DOI 10.1148/radiol.14132475; Santin MD, 2017, NMR BIOMED, V30, DOI 10.1002/nbm.3491; Schafer A, 2012, HUM BRAIN MAPP, V33, P2831, DOI 10.1002/hbm.21404; Schenck J, 2015, ISMRM 23 ANN M EXH C; Schenck John F, 2006, Top Magn Reson Imaging, V17, P41, DOI 10.1097/01.rmr.0000245455.59912.40; Schmalbrock P, 2016, AM J NEURORADIOL, V37, P439, DOI 10.3174/ajnr.A4599; Schweitzer AD, 2015, AM J ROENTGENOL, V204, P1086, DOI 10.2214/AJR.14.13459; Schweser F, 2011, NEUROIMAGE, V54, P2789, DOI 10.1016/j.neuroimage.2010.10.070; Schweser F, 2010, MED PHYS, V37, P5165, DOI 10.1118/1.3481505; Shinohara RT, 2012, AM J NEURORADIOL, V33, P1586, DOI 10.3174/ajnr.A2997; Shmueli K, 2009, MAGN RESON MED, V62, P1510, DOI 10.1002/mrm.22135; Stuber C, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010100; Sun HF, 2015, NEUROIMAGE, V105, P486, DOI 10.1016/j.neuroimage.2014.11.010; Sun HF, 2014, MAGN RESON MED, V71, P1151, DOI 10.1002/mrm.24765; Tan H, 2016, AM J NEURORADIOL, V37, P1209, DOI 10.3174/ajnr.A4724; Tan H, 2014, INVEST RADIOL, V49, P498, DOI 10.1097/RLI.0000000000000043; Tang J, 2013, MAGN RESON MED, V69, P1396, DOI 10.1002/mrm.24384; Treaba CA, 2014, DIAGN INTERV RADIOL, V20, P178, DOI 10.5152/dir.2013.13313; van Bergen JMG, 2016, AM J NEURORADIOL, V37, P789, DOI 10.3174/ajnr.A4617; Vega RA, 2014, NEUROSURG CLIN N AM, V25, P159, DOI 10.1016/j.nec.2013.08.008; WALSHE JM, 1993, Q J MED, V86, P197; Wang S, 2013, IEEE T BIO-MED ENG, V60, P3441, DOI 10.1109/TBME.2013.2266795; Wang S, 2013, STROKE, V44, P2315, DOI 10.1161/STROKEAHA.113.001638; Wang Y, 2015, MAGN RESON MED, V73, P82, DOI 10.1002/mrm.25358; Wang Y, 2009, IEEE ENG MED BIO, P53, DOI 10.1109/IEMBS.2009.5335128; Ward R, 2014, LANCET NEUROL, V13, P1045, DOI 10.1016/S1474-4422(14)70117-6; Wehrli FW, 2016, AM J NEURORADIOL; Wen Y, 2016, MAGN RESON MED, V75, P823, DOI 10.1002/mrm.25652; Wen Y, 2014, MAGN RESON MED, V72, P1065, DOI 10.1002/mrm.24998; Wharton S, 2010, MAGN RESON MED, V63, P1292, DOI 10.1002/mrm.22334; Wisnieff C, 2014, ANN M INT SOC MAGN R, P3403; Wisnieff C, 2016, MAGN RESON IMAGING, V34, P682, DOI 10.1016/j.mri.2015.12.003; Wisnieff C, 2015, MAGN RESON MED, V74, P564, DOI 10.1002/mrm.25420; Wisnieff C, 2013, NEUROIMAGE, V70, P363, DOI 10.1016/j.neuroimage.2012.12.050; Xie LK, 2016, AM J PHYSIOL-RENAL, V310, pF174, DOI 10.1152/ajprenal.00351.2015; Xu B, 2014, MAGN RESON MED, V72, P438, DOI 10.1002/mrm.24937; Zecca L, 2004, NAT REV NEUROSCI, V5, P863, DOI 10.1038/nrn1537; Zhang JW, 2015, MAGN RESON MED, V74, P945, DOI 10.1002/mrm.25463; Zhang Y, 2016, AM J NEURORADIOL, V37, P1794, DOI 10.3174/ajnr.A4856; Zhang Y, 2016, AM J NEURORADIOL, V37, P1629, DOI 10.3174/ajnr.A4825; Zhang Y, 2015, 31 C ECTRIMS BARC SP, P986; Zhang Y, 2016, J MAGN RESON IMAGING, V44, P426, DOI 10.1002/jmri.25144; Zhou D, 2014, NMR BIOMED, V27, P312, DOI 10.1002/nbm.3064; Zivadinov R, 2012, NEUROIMAGE, V59, P331, DOI 10.1016/j.neuroimage.2011.07.045	143	31	33	2	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0952-3480	1099-1492		NMR BIOMED	NMR Biomed.	APR	2017	30	4			SI				e3668	10.1002/nbm.3668			11	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy	EQ5CY	WOS:000398100400008	27906525				2021-06-18	
J	Iverson, KM; Dardis, CM; Pogoda, TK				Iverson, Katherine M.; Dardis, Christina M.; Pogoda, Terri K.			Traumatic brain injury and PTSD symptoms as a consequence of intimate partner violence	COMPREHENSIVE PSYCHIATRY			English	Article							POSTTRAUMATIC-STRESS-DISORDER; WOMEN VETERANS; RISK-FACTOR; INTERPERSONAL VIOLENCE; MENTAL-HEALTH; PRIMARY-CARE; STRANGULATION; HOMICIDE; STATE; IRAQ	Objective: To effectively diagnose and treat women who have experienced intimate partner violence (IPV), it is important to identify the full range of physical and mental health consequences, including hidden wounds such as traumatic brain injury (TBI) and posttraumatic stress disorder (PTSD). We aimed to identify the occurrence of IPV-related TBI and associated PTSD symptoms among women veterans who experienced IPV. Methods: A web-based survey was administered in 2014 to a national sample of U.S. women veterans. Among 411 respondents (75% participation rate), 55% reported IPV during their lives. These participants (N = 224) completed screening measures of IPV-related TBI, PTSD, and past-year IPV and comprised the current sample. Results: A total of 28.1% (n = 63) met criteria for IPV-related TBI history, and 12.5% (n = 28) met criteria for IPV-related TBI with current symptoms. When adjusting for race, income, and past-year IPV, women with IPV-related TBI with current symptoms were 5.9 times more likely to have probable IPV-related PTSD than those with no IPV-related TBI history. Despite symptom overlap between TBI and PTSD, women with IPV-related TBI with current symptoms were significantly more likely to meet criteria for all four DSM-5 PTSD symptom clusters compared to women with an IPV-related TBI history without current symptoms (Cramer's V's =.34.42). Conclusion: Findings suggest there may be clinical utility in screening women who experience lifetime IPV for both TBI and PTSD symptoms in order to help clinicians better target their examinations, treatment, and referrals. Published by Elsevier Inc.	[Iverson, Katherine M.; Dardis, Christina M.] Womens Hlth Sci Div, Natl Ctr PTSD, VA Boston Hlthcare Syst, 150 South Huntington Ave 116B-3, Boston, MA 02130 USA; [Iverson, Katherine M.; Dardis, Christina M.] Boston Univ, Sch Med, Dept Psychiat, 72 East Concord St, Boston, MA 02118 USA; [Pogoda, Terri K.] Ctr Hlthcare Org & Implement Res, VA Boston Hlthcare Syst, 150 S Huntington Ave Bldg 9, Boston, MA 02130 USA; [Pogoda, Terri K.] Boston Univ, Sch Publ Hlth, Dept Hlth Law Policy & Management, 715 Albany St, Boston, MA 02118 USA	Iverson, KM (corresponding author), Womens Hlth Sci Div, Natl Ctr PTSD, VA Boston Hlthcare Syst, 150 South Huntington Ave 116B-3, Boston, MA 02130 USA.	katherine.iverson@va.gov	Pogoda, Terri/F-6243-2012	Pogoda, Terri/0000-0003-1397-8780	Department of Veterans Affairs (VA), Veterans Health Administration, Health Services Research and Development (HSRD); Dr. Iverson's HSR&D Career Development Award [CDA 10-029]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [5R25MH08091607]; VA HSRD Services; Quality Enhancement Research Initiative; VA HSR&D Investigator Initiated Research [11-078, 11-358]; Presidential Early Career Award for Scientists and EngineersUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [USA 14-275]	This work was supported by the Department of Veterans Affairs (VA), Veterans Health Administration, Health Services Research and Development (HSR&D) Services as part of Dr. Iverson's HSR&D Career Development Award (CDA 10-029) and her Presidential Early Career Award for Scientists and Engineers (USA 14-275). Dr. Iverson is an investigator with the Implementation Research Institute, at the George Warren Brown School of Social Work, Washington University in St. Louis; through an award from the National Institute of Mental Health (5R25MH08091607) and the VA HSR&D Services, Quality Enhancement Research Initiative. This material is also based upon work supported in part by VA HSR&D Investigator Initiated Research Award #11-078 and #11-358. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the VA or United States government. The authors have no conflicts of interest to report.	Amoroso T., J NERVOUS M IN PRESS; Arciniegas David B, 2005, Neuropsychiatr Dis Treat, V1, P311; Association AP, 2013, DIAGN STAT MAN MENT; Banks ME, 2007, TRAUMA VIOLENCE ABUS, V8, P290, DOI 10.1177/1524838007303503; Bovin M.J, 2015, PSYCHOL ASSESS, V27; Brenner LA, 2010, J HEAD TRAUMA REHAB, V25, P307, DOI 10.1097/HTR.0b013e3181cada03; Bryant RA, 2008, NEW ENGL J MED, V358, P525, DOI 10.1056/NEJMe078235; Campbell JC, 2007, TRAUMA VIOLENCE ABUS, V8, P246, DOI 10.1177/1524838007303505; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Department of Veterans Affairs, 2016, DOD CLIN PRACT GUID; Dichter ME, PAST YEAR I IN PRESS; Dichter ME, 2015, MIL MED, V180, P1124, DOI 10.7205/MILMED-D-14-00582; Dichter ME, 2011, WOMEN HEALTH ISS, V21, pS190, DOI 10.1016/j.whi.2011.04.008; Donnelly KT, 2011, J HEAD TRAUMA REHAB, V26, P439, DOI 10.1097/HTR.0b013e3182005de3; Dutton MA, 2009, TRAUMA VIOLENCE ABUS, V10, P211, DOI 10.1177/1524838009334451; Ellsberg M, 2008, LANCET, V371, P1165, DOI 10.1016/S0140-6736(08)60522-X; Gardner RC, 2015, MOL CELL NEUROSCI, V66, P75, DOI 10.1016/j.mcn.2015.03.001; Gerber MR, 2014, J WOMENS HEALTH, V23, P302, DOI 10.1089/jwh.2013.4513; Glass N, 2008, J EMERG MED, V35, P329, DOI 10.1016/j.jemermed.2007.02.065; Goldin Y, 2016, SCREENING HIST TRAUM; Golding JM, 1999, J FAM VIOLENCE, V14, P99, DOI 10.1023/A:1022079418229; GRISSO JA, 1991, AM J EPIDEMIOL, V134, P59, DOI 10.1093/oxfordjournals.aje.a115993; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; IBM, 2013, INV IBM SPSS STAT WI; IOM (Institute of Medicine), 2011, CLIN PREV SERV WOM C; Iverson KM, 2016, GEN HOSP PSYCHIAT, V40, P33, DOI 10.1016/j.genhosppsych.2016.03.001; Iverson KM, 2015, MED CARE, V53, pS112, DOI 10.1097/MLR.0000000000000263; Iverson KM, 2013, J TRAUMA STRESS, V26, P767, DOI 10.1002/jts.21867; Iverson KM, 2013, PSYCHOL VIOLENCE, V3, P273, DOI 10.1037/a0030956; Iverson KM, 2011, WOMEN HEALTH ISS, V21, pS210, DOI 10.1016/j.whi.2011.04.019; Iverson KM, 2011, J CONSULT CLIN PSYCH, V79, P193, DOI 10.1037/a0022512; Jackson H, 2002, PROF PSYCHOL-RES PR, V33, P39, DOI 10.1037//0735-7028.33.1.39; Johnson DM, 2011, J CONSULT CLIN PSYCH, V79, P542, DOI 10.1037/a0023822; Kimerling R, 2016, J GEN INTERN MED, V31, P888, DOI 10.1007/s11606-016-3701-7; Kimerling R, 2015, MED CARE, V53, pS97, DOI 10.1097/MLR.0000000000000272; Kochanek PM, 2016, LANCET NEUROL, V15, P13, DOI 10.1016/S1474-4422(15)00339-7; Kwako LE, 2011, TRAUMA VIOLENCE ABUS, V12, P115, DOI 10.1177/1524838011404251; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; National Center for Veterans Analysis and Statistics, 2014, VET POP LIV VET AG G; Sayer NA, 2009, J REHABIL RES DEV, V46, P703, DOI 10.1682/JRRD.2009.01.0008; Smith DJ, 2001, J EMERG MED, V21, P323, DOI 10.1016/S0736-4679(01)00402-4; Sohal H, 2007, BMC FAM PRACT, V8, DOI 10.1186/1471-2296-8-49; St Ivany A, 2016, FAM COMMUNITY HEALTH, V39, P129, DOI 10.1097/FCH.0000000000000094; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Sweeney AC, 2013, WOMEN HEALTH ISS, V23, pE73, DOI 10.1016/j.whi.2012.12.004; Tjaden P., 1998, **DROPPED REF**; U.S. Preventive Services Task Force, 2013, SCREEN INT PARTN VIO; Veterans Health Administration Domestic Violence Task Force, 2013, PLAN IMPL DOM VIOL I; Warshaw C., 2013, SYSTEMATIC REV TRAUM; Weathers F. W., 2013, PTSD CHECKLIST DSM 5; World Health Organization DoRHaR, 2013, GLOB REG EST VIOL WO	51	31	31	0	17	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0010-440X	1532-8384		COMPR PSYCHIAT	Compr. Psychiat.	APR	2017	74						80	87		10.1016/j.comppsych.2017.01.007			8	Psychiatry	Psychiatry	EP9MI	WOS:000397697300012	28126481				2021-06-18	
J	Zhong, JJ; Cheng, CJ; Liu, H; Huang, ZJ; Wu, Y; Teng, ZP; He, JC; Zhang, HR; Wu, JC; Cao, F; Jiang, L; Sun, XC				Zhong, Jianjun; Cheng, Chongjie; Liu, Han; Huang, Zhijian; Wu, Yue; Teng, Zhipeng; He, Junchi; Zhang, Hongrong; Wu, Jinchuan; Cao, Fang; Jiang, Li; Sun, Xiaochuan			BEXAROTENE PROTECTS AGAINST TRAUMATIC BRAIN INJURY IN MICE PARTIALLY THROUGH APOLIPOPROTEIN E	NEUROSCIENCE			English	Article						traumatic brain injury; bexarotene; apolipoprotein E; inflammation; apoptosis	CLOSED-HEAD INJURY; E-DEFICIENT MICE; PPAR-GAMMA AGONIST; AD MOUSE MODELS; INFLAMMATORY RESPONSES; ALZHEIMERS-DISEASE; REVERSE DEFICITS; MOTOR DEFICITS; X-RECEPTORS; NEUROPROTECTION	Bexarotene has been proved to have neuroprotective effects in many animal models of neurological diseases. However, its neuroprotection in traumatic brain injury (TBI) is still unknown. This study aims to explore the neuroprotective effects of bexarotene on TBI and its possible mechanism. Controlled cortical impact (CCI) model was used to simulate TBI in C57BL/6 mice as well as APOE gene knockout (APOE-KO) mice. After CCI, mice were daily dosed with bexarotene or vehicle solution intraperitoneally. The motor function, learning and memory, inflammatory factors, microglia amount, apoptosis condition around injury site and main side-effects were all measured. The results showed that, after CCI, bexarotene treatment markedly improved the motor function and spatial memory in C57BL/6 compare to APOE-KO mice which showed no improvement. The inflammatory cytokines, microglia amount, cell apoptosis rate, and protein of cleaved caspase-3 around the injury site were markedly upregulated after TBI in both C57BL/6 and APOE-KO mice, and all these upregulation were significantly mitigated by bexarotene treatment in C57BL/6 mice, but not in APOE-KO mice. No side-effects were detected after consecutive administration. Taken together, bexarotene inhibits the inflammatory response as well as cell apoptosis and improves the neurological function of mice after TBI partially through apolipoprotein E. This may make it a promising candidate for the therapeutic treatment after TBI. (C) 2016 Published by Elsevier Ltd on behalf of IBRO.	[Zhong, Jianjun; Cheng, Chongjie; Liu, Han; Huang, Zhijian; Wu, Yue; Teng, Zhipeng; He, Junchi; Zhang, Hongrong; Wu, Jinchuan; Jiang, Li; Sun, Xiaochuan] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China; [Cao, Fang] Zunyi Med Coll, Affiliated Hosp 1, Dept Cerebrovasc, Zunyi 653000, Guizhou, Peoples R China	Jiang, L; Sun, XC (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China.		He, Junchi/AAD-8482-2019	sun, xiao chuan/0000-0001-6992-332X; Huang, Zhijian/0000-0002-8241-0761	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571159, 81371319]; Chongqing Graduate Innovation Project [40010200100417]	This work was supported by grants from the National Natural Science Foundation of China (grant No.: 81571159, 81371319) and the Chongqing Graduate Innovation Project (grant No.: 40010200100417). We express special acknowledgement to "Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology" for providing experimental platform. We also appreciate Yong Jiang from Southwest Medical University, Jie Ma, Xiaocui Tian and Mei Yang from Chongqing Medical University for their technical support, Rami Darwazeh from the first affiliated hospital of Chongqing Medical University for language modification.	Aicardi G, 2013, REJUV RES, V16, P524, DOI 10.1089/rej.2013.1497; Bachmeier C, 2013, J MOL NEUROSCI, V49, P270, DOI 10.1007/s12031-012-9866-6; Baitsch D, 2011, ARTERIOSCL THROM VAS, V31, P1160, DOI 10.1161/ATVBAHA.111.222745; Bennett RE, 2014, J NEUROTRAUM, V31, P1647, DOI 10.1089/neu.2013.3320; Bomben V, 2014, NEUROBIOL AGING, V35, P2091, DOI 10.1016/j.neurobiolaging.2014.03.029; Cederberg D, 2010, CHILD NERV SYST, V26, P221, DOI 10.1007/s00381-009-1029-x; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Christensen DJ, 2011, J IMMUNOL, V186, P2535, DOI 10.4049/jimmunol.1002847; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Cramer PE, 2012, SCIENCE, V335, P1503, DOI 10.1126/science.1217697; Fang Cao YJ, 2015, APOLIPOPROTEIN E MIM; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Han SH, 2000, ANN NY ACAD SCI, V903, P357, DOI 10.1111/j.1749-6632.2000.tb06387.x; James ML, 2009, STROKE, V40, P632, DOI 10.1161/STROKEAHA.108.530402; Jiang L, 2015, NEUROSCIENCE, V301, P375, DOI 10.1016/j.neuroscience.2015.06.005; Jiang L, 2011, NEUROSCI LETT, V505, P160, DOI 10.1016/j.neulet.2011.10.011; Jiang Y, 2008, ACTA NEUROCHIR SUPPL, V105, P233; Jiang Y, 2012, J NEUROTRAUM, V29, P2332, DOI 10.1089/neu.2012.2362; Joseph SB, 2003, NAT MED, V9, P213, DOI 10.1038/nm820; Laskowitz DT, 2010, J NEUROTRAUM, V27, P1983, DOI 10.1089/neu.2010.1396; Lefebvre P, 2010, TRENDS ENDOCRIN MET, V21, P676, DOI 10.1016/j.tem.2010.06.009; Lerner V, 2013, J CLIN PSYCHIAT, V74, P1224, DOI 10.4088/JCP.12m08160; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Lomnitski L, 1999, BBA-MOL BASIS DIS, V1453, P359, DOI 10.1016/S0925-4439(99)00010-1; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; Margulies S, 2009, J NEUROTRAUM, V26, P925, DOI [10.1089/neu.2008.0794, 10.1089/neu.2008-0794]; McFarland K, 2013, ACS CHEM NEUROSCI, V4, P1430, DOI 10.1021/cn400100f; Namjoshi DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053529; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; O'Connor WT, 2011, PHARMACOL THERAPEUT, V130, P106, DOI 10.1016/j.pharmthera.2011.01.001; Price AR, 2013, SCIENCE, V340, DOI 10.1126/science.1234089; Riancho J, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00250; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Siopi E, 2013, NEUROPHARMACOLOGY, V67, P183, DOI 10.1016/j.neuropharm.2012.11.009; Tanaka Y, 2013, NEUROSCIENCE, V231, P49, DOI 10.1016/j.neuroscience.2012.11.032; Villapol S, 2012, NEUROPSYCHOPHARMACOL, V37, P2817, DOI 10.1038/npp.2012.152; Wang GH, 2013, NEUROTHERAPEUTICS, V10, P124, DOI 10.1007/s13311-012-0157-2; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wong J, 2005, NEUROCRIT CARE, V3, P177, DOI 10.1385/NCC:3:2:177; Xu L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122744; Yi JH, 2008, BRAIN RES, V1244, P164, DOI 10.1016/j.brainres.2008.09.074; Zhai PP, 2015, NEUROPHARMACOLOGY, V95, P1, DOI 10.1016/j.neuropharm.2015.02.026; Zhang CL, 2006, DERMATOL THER, V19, P264, DOI 10.1111/j.1529-8019.2006.00083.x; Zhou S, 2013, FEBS LETT, V587, P254, DOI 10.1016/j.febslet.2012.12.003	45	31	34	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	FEB 20	2017	343						434	448		10.1016/j.neuroscience.2016.05.033			15	Neurosciences	Neurosciences & Neurology	EJ5PB	WOS:000393269100041	27235741				2021-06-18	
J	Semple, BD; Dixit, S; Shultz, SR; Boon, WC; O'Brien, TJ				Semple, Bridgette D.; Dixit, Shilpi; Shultz, Sandy R.; Boon, Wah Chin; O'Brien, Terence J.			Sex-dependent changes in neuronal morphology and psychosocial behaviors after pediatric brain injury	BEHAVIOURAL BRAIN RESEARCH			English	Article						Social behavior; Brain development; Golgi staining; Mouse model; Traumatic brain injury; Sex	MEDIAL PREFRONTAL CORTEX; DEFICIT HYPERACTIVITY DISORDER; NEONATAL EXCITOTOXIC LESIONS; CORTICAL IMPACT INJURY; TRAUMATIC BRAIN; SOCIAL-BEHAVIOR; DENDRITIC MORPHOLOGY; MOUSE MODEL; VENTRAL HIPPOCAMPUS; PYRAMIDAL NEURONS	Chronic social behavior problems after pediatric traumatic brain injury (TBI) significantly contribute to poor quality of life for survivors. Using a well-characterized mouse model of early childhood TBI, we have previously demonstrated that young brain-injured mice develop social deficits by adulthood. As biological sex may influence both normal and aberrant social development, we here evaluated potential sex differences in post-TBI psychosocial deficits by comparing the behavior of male and female mice at adulthood (8 weeks post-injury). Secondly, we hypothesized that pediatric TBI would influence neuronal morphology identified by Golgi-Cox staining in the hippocampus and prefrontal cortex, regions involved in social cognition and behavior, before the onset of social problems (3 weeks post-injury). Morphological analysis of pyramidal neurons in the ipsilateral prefrontal cortex and granule cells of the hippocampal dentate gyrus revealed a reduction in dendritic complexity after pediatric TBI. This was most apparent in TBI males, whereas neurons from females were less affected. At adulthood, consistent with previous studies, TBI males showed deficits in sociability and social recognition. TBI females also showed a reduction in sociability, but intact social recognition and increased sociosexual avoidance. Together, these findings indicate that sex is a determinant of regional neuroplasticity and social outcomes after pediatric TBI. Reduced neuronal complexity in the prefrontal cortex and hippocampus, several weeks after injury in male mice, appears to precede the subsequent emergence of social deficits. Sex-specific alterations in the social brain network are thus implicated as an underlying mechanism of social dysfunction after pediatric TBI. (C) 2016 Elsevier B.V. All rights reserved.	[Semple, Bridgette D.; Shultz, Sandy R.; O'Brien, Terence J.] Univ Melbourne, Melbourne Brain Ctr, Royal Melbourne Hosp, Dept Med, Kenneth Myer Bldg, Parkville, Vic, Australia; [Dixit, Shilpi; Boon, Wah Chin] Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia	Semple, BD (corresponding author), Univ Melbourne, Melbourne Brain Ctr, Royal Melbourne Hosp, Dept Med, Kenneth Myer Bldg, Parkville, Vic, Australia.	Bridgette.Semple@unimelb.edu.au		Dixit, Shilpi/0000-0003-4837-0548; O'Brien, Terence/0000-0002-7198-8621	CJ Martin Overseas Early Career Fellowship from National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of Australia [1052505]; Early Career Researcher Grant from the University of Melbourne	BDS was supported by a CJ Martin Overseas Early Career Fellowship (#1052505) from the National Health and Medical Research Council of Australia, and an Early Career Researcher Grant from the University of Melbourne. The authors thank A/Prof. Ann Turnley for providing access to the controlled cortical impactor device, and Victorian State Government Infrastructure Support.	Anderson KJ, 2005, EXP NEUROL, V193, P125, DOI 10.1016/j.expneurol.2004.11.025; Antshel KM, 2011, BMC MED, V9, DOI 10.1186/1741-7015-9-72; Bachevalier J, 1999, BIOL PSYCHIAT, V46, P329, DOI 10.1016/S0006-3223(99)00123-7; Bajwa NM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146886; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Beauregard M, 1995, NEUROREPORT, V6, P2521, DOI 10.1097/00001756-199512150-00018; Bicks LK, 2015, FRONT PSYCHOL, V6, DOI 10.3389/fpsyg.2015.01805; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Breau LM, 2015, J CHILD NEUROL, V30, P588, DOI 10.1177/0883073814528282; Bruce-Keller AJ, 2007, J NEUROTRAUM, V24, P203, DOI 10.1089/neu.2006.0163; Brydges NM, 2014, HIPPOCAMPUS, V24, P684, DOI 10.1002/hipo.22259; Byers SL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035538; Camacho-Abrego I, 2014, SYNAPSE, V68, P114, DOI 10.1002/syn.21722; Casella EM, 2014, CHILD NERV SYST, V30, P1333, DOI 10.1007/s00381-014-2446-z; Castagne Vincent, 2011, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0810as55; Catroppa C, 2008, J PEDIATR PSYCHOL, V33, P707, DOI 10.1093/jpepsy/jsn006; Catroppa C, 2015, J NEUROTRAUM, V32, P109, DOI 10.1089/neu.2013.3276; Choleris E, 2009, FRONT NEUROENDOCRIN, V30, P442, DOI 10.1016/j.yfrne.2009.05.003; Collins NC, 2013, EMERG MED J, V30, P675, DOI 10.1136/emermed-2011-200496; Crews F, 2007, PHARMACOL BIOCHEM BE, V86, P189, DOI 10.1016/j.pbb.2006.12.001; De Bellis MD, 2001, CEREB CORTEX, V11, P552, DOI 10.1093/cercor/11.6.552; Dennis M, 2013, DEV COGN NEUROS-NETH, V5, P25, DOI 10.1016/j.dcn.2012.11.006; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P34, DOI 10.1017/S1355617712000884; Despins E. H., 2015, ARCH PHYS MED REHABI; Di Battista A, 2012, J NEUROTRAUM, V29, P1717, DOI 10.1089/neu.2011.2157; Drzewiecki CM, 2016, SYNAPSE, V70, P361, DOI 10.1002/syn.21909; Dumais KM, 2013, HORM BEHAV, V64, P693, DOI 10.1016/j.yhbeh.2013.08.012; ELY DL, 1977, PHYSIOL BEHAV, V18, P1075, DOI 10.1016/0031-9384(77)90014-2; Ewing-Cobbs L, 1997, J Int Neuropsychol Soc, V3, P581; Ewing-Cobbs L, 2013, J INT NEUROPSYCH SOC, V19, P497, DOI 10.1017/S1355617713000210; Faden AI, 2016, BRIT J PHARMACOL, V173, P681, DOI 10.1111/bph.13179; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fenn A. M., 2013, BIOL PSYCHIAT, V25; Fernandes C, 1999, PHARMACOL BIOCHEM BE, V64, P731, DOI 10.1016/S0091-3057(99)00139-2; Flores G, 2005, NEUROSCIENCE, V133, P463, DOI 10.1016/j.neuroscience.2005.02.021; Flores G, 2005, SYNAPSE, V56, P147, DOI 10.1002/syn.20140; Forgie ML, 2003, BEHAV NEUROSCI, V117, P257, DOI 10.1037/0735-7044.117.2.257; Gao X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024566; Garrett JE, 2009, NEUROSCIENCE, V162, P195, DOI 10.1016/j.neuroscience.2009.04.057; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Gibb R, 1998, J NEUROSCI METH, V79, P1, DOI 10.1016/S0165-0270(97)00163-5; Giedd JN, 1997, PROG NEURO-PSYCHOPH, V21, P1185, DOI 10.1016/S0278-5846(97)00158-9; Giza CC, 2006, DEV NEUROSCI-BASEL, V28, P364, DOI 10.1159/000094163; Gonzalez CLR, 2003, EUR J NEUROSCI, V18, P1950, DOI 10.1046/j.1460-9568.2003.02928.x; Greco T, 2015, DEV NEUROBIOL, V75, P193, DOI 10.1002/dneu.22218; Greco T, 2013, J NEUROTRAUM, V30, P1983, DOI 10.1089/neu.2013.2990; Gregoire CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086237; Hall ED, 2005, J NEUROTRAUM, V22, P669, DOI 10.1089/neu.2005.22.669; Hehar H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139842; Hsieh CL, 2014, J NEUROTRAUM, V31, P1677, DOI 10.1089/neu.2013.3252; Humphreys KL, 2016, J ABNORM CHILD PSYCH, V44, P1023, DOI 10.1007/s10802-015-0095-7; Insel TR, 2004, ANNU REV NEUROSCI, V27, P697, DOI 10.1146/annurev.neuro.27.070203.144148; JOHNSTON AL, 1991, PHYSIOL BEHAV, V49, P245, DOI 10.1016/0031-9384(91)90039-Q; JURASKA JM, 1990, DEV BRAIN RES, V53, P291, DOI 10.1016/0165-3806(90)90021-P; Kaldoja ML, 2015, J CHILD NEUROL, V30, P860, DOI 10.1177/0883073814544705; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; KARLSSON SA, 2015, BMC NEUROSCI, V16, DOI DOI 10.1186/S12868-12015-10221-Z; Karlsson SA, 2016, FRONT BEHAV NEUROSCI, V10, DOI 10.3389/fnbeh.2016.00041; Kim Y, 2015, CELL REP, V10, P292, DOI 10.1016/j.celrep.2014.12.014; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Kogan JH, 2000, HIPPOCAMPUS, V10, P47, DOI 10.1002/(SICI)1098-1063(2000)10:1<47::AID-HIPO5>3.0.CO;2-6; KOLB B, 1974, PHYSIOL BEHAV, V13, P637, DOI 10.1016/0031-9384(74)90234-0; Kolb B, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00015; Kolb B, 2012, P NATL ACAD SCI USA, V109, P17186, DOI 10.1073/pnas.1121251109; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Landis SC, 2012, NATURE, V490, P187, DOI 10.1038/nature11556; Langlois JA, 2000, TRAUMATIC BRAIN INJU; Li L, 2013, DEV MED CHILD NEUROL, V55, P37, DOI 10.1111/j.1469-8749.2012.04414.x; Lipska BK, 1998, NEUROPSYCHOPHARMACOL, V19, P451, DOI 10.1016/S0893-133X(98)00045-1; Lipska BK, 2000, NEUROPSYCHOPHARMACOL, V23, P223, DOI 10.1016/S0893-133X(00)00137-8; Llorente R, 2009, INT J DEV NEUROSCI, V27, P233, DOI 10.1016/j.ijdevneu.2009.01.002; Maaswinkel H, 1996, PHYSIOL BEHAV, V60, P55, DOI 10.1016/0031-9384(95)02233-3; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; Maxwell WL, 2013, BRAIN SCI, V3, P1374, DOI 10.3390/brainsci3031374; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P22, DOI 10.1111/j.1365-2214.2009.00947.x; Meyer-Lindenberg A, 2011, NAT REV NEUROSCI, V12, P524, DOI 10.1038/nrn3044; Meziane H, 2007, GENES BRAIN BEHAV, V6, P192, DOI 10.1111/j.1601-183X.2006.00249.x; Misra V, 2014, ANN NEUROSCI, V21, P69, DOI 10.5214/ans.0972.7531.210208; Moadab G, 2015, BEHAV NEUROSCI, V129, P339, DOI 10.1037/bne0000062; Mogil JS, 2005, PAIN, V117, P1, DOI 10.1016/j.pain.2005.06.020; Monaco CM, 2013, EXP NEUROL, V247, P410, DOI 10.1016/j.expneurol.2013.01.007; Moreno JA, 2015, BEHAV NEUROL, V2015, DOI 10.1155/2015/914134; Mychasiuk R, 2015, NEUROSCIENCE, V288, P145, DOI 10.1016/j.neuroscience.2014.12.034; Mychasiuk R, 2015, BEHAV BRAIN RES, V286, P285, DOI 10.1016/j.bbr.2015.03.010; Neumann ID, 2012, TRENDS NEUROSCI, V35, P649, DOI 10.1016/j.tins.2012.08.004; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Paxinos G., 1997, MOUSE BRAIN STEREOTA; Pellis SM, 2006, BEHAV NEUROSCI, V120, P72, DOI 10.1037/0735-7044.120.1.72; Prendergast BJ, 2014, NEUROSCI BIOBEHAV R, V40, P1, DOI 10.1016/j.neubiorev.2014.01.001; Pullela R, 2006, DEV NEUROSCI-BASEL, V28, P396, DOI 10.1159/000094166; Radley JJ, 2004, NEUROSCIENCE, V125, P1, DOI 10.1016/j.neuroscience.2004.01.006; Ramon-Moliner E., 1970, CONT RES METHODS NEU, P32, DOI [10.1007/978-3-642-85986-1_3, DOI 10.1007/978-3-642-85986-1_3]; Rosema S, 2012, J NEUROTRAUM, V29, P1277, DOI 10.1089/neu.2011.2144; Rudebeck PH, 2007, EUR J NEUROSCI, V26, P2315, DOI 10.1111/j.1460-9568.2007.05844.x; Ryan N. P., 2016, NEUROSCI BIOBEHAV RE; Ryan NP, 2016, NEUROSCI BIOBEHAV R, V64, P196, DOI 10.1016/j.neubiorev.2016.02.020; SamsDodd F, 1997, PSYCHOPHARMACOLOGY, V132, P303, DOI 10.1007/s002130050349; Schmidt AT, 2012, INT J DEV NEUROSCI, V30, P225, DOI 10.1016/j.ijdevneu.2011.11.003; Schwarzbold ML, 2010, J NEUROTRAUM, V27, P1883, DOI 10.1089/neu.2010.1318; Scott C, 2015, NEUROPSYCHOLOGY, V29, P501, DOI 10.1037/neu0000074; Semple B. D., 2014, NEUROBIOL DIS, V74; Semple BD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143386; Semple BD, 2015, NEUROBIOL DIS, V74, P263, DOI 10.1016/j.nbd.2014.12.003; Semple BD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103386; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Semple BD, 2012, J NEUROTRAUM, V29, P2672, DOI 10.1089/neu.2012.2595; SERESS L, 1992, HIPPOCAMPUS, V2, P127, DOI 10.1002/hipo.450020205; Shah NM, 2004, NEURON, V43, P313, DOI 10.1016/j.neuron.2004.07.008; Sharp DJ, 2014, NAT REV NEUROL, V10, P156, DOI 10.1038/nrneurol.2014.15; SHOLL DA, 1953, J ANAT, V87, P387; Shultz SR, 2015, J CEREBR BLOOD F MET, V35, P1339, DOI 10.1038/jcbfm.2015.56; Shultz SR, 2014, J NEUROTRAUM, V31, P976, DOI 10.1089/neu.2013.3106; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Shultz SR, 2011, BEHAV BRAIN RES, V224, P326, DOI 10.1016/j.bbr.2011.06.012; Sigurdsson T, 2016, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00190; Silva-Gomez AB, 2003, BRAIN RES, V983, P128, DOI 10.1016/S0006-8993(03)03042-7; Soztutar E, 2016, EXP NEUROL, V275, P274, DOI 10.1016/j.expneurol.2015.06.005; Spring S, 2007, NEUROIMAGE, V35, P1424, DOI 10.1016/j.neuroimage.2007.02.023; Stevenson EL, 2014, EUR J NEUROSCI, V40, P3294, DOI 10.1111/ejn.12689; Thurman DJ, 2016, J CHILD NEUROL, V31, P20, DOI 10.1177/0883073814544363; Tong W, 2002, EXP NEUROL, V176, P105, DOI 10.1006/exnr.2002.7941; Tucker LB, 2016, J NEUROTRAUM, V33, P880, DOI 10.1089/neu.2015.3977; Uekita T, 2011, BEHAV BRAIN RES, V219, P302, DOI 10.1016/j.bbr.2011.01.042; Uylings HBM, 2003, BEHAV BRAIN RES, V146, P3, DOI 10.1016/j.bbr.2003.09.028; UYLINGS HBM, 1990, PROG BRAIN RES, V85, P31; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Wells R, 2009, DEV NEUROREHABIL, V12, P12, DOI 10.1080/17518420902773109; Williams MW, 2014, REHABIL PSYCHOL, V59, P298, DOI 10.1037/a0037164; Yang LY, 2016, PEDIATR RES, V80, P356, DOI 10.1038/pr.2016.85; Yang M., 2011, CURR PROTOC NEUROSCI, V56; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093; Zitman FMP, 2013, NEUROSCIENCE, V249, P21, DOI 10.1016/j.neuroscience.2013.05.030	132	31	31	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0166-4328	1872-7549		BEHAV BRAIN RES	Behav. Brain Res.	FEB 15	2017	319						48	62		10.1016/j.bbr.2016.10.045			15	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	EI5TS	WOS:000392558300007	27829127				2021-06-18	
J	Abu Hamdeh, S; Marklund, N; Lannsjo, M; Howells, T; Raininko, R; Wikstrom, J; Enblad, P				Abu Hamdeh, Sami; Marklund, Niklas; Lannsjo, Marianne; Howells, Tim; Raininko, Raili; Wikstrom, Johan; Enblad, Per			Extended Anatomical Grading in Diffuse Axonal Injury Using MRI: Hemorrhagic Lesions in the Substantia Nigra and Mesencephalic Tegmentum Indicate Poor Long-Term Outcome	JOURNAL OF NEUROTRAUMA			English	Article						adult brain injury; axonal injury; head trauma; MRI; susceptibility weighted imaging	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD INJURY; VEGETATIVE STATE; PROGNOSTIC VALUE; STEM LESIONS; INTRACEREBRAL HEMORRHAGE; WHITE-MATTER; CLASSIFICATION; NEUROPATHOLOGY; EPIDEMIOLOGY	Clinical outcome after traumatic diffuse axonal injury (DAI) is difficult to predict. In this study, three magnetic resonance imaging (MRI) sequences were used to quantify the anatomical distribution of lesions, to grade DAI according to the Adams grading system, and to evaluate the value of lesion localization in combination with clinical prognostic factors to improve outcome prediction. Thirty patients (mean 31.2 years +/- 14.3 standard deviation) with severe DAI (Glasgow Motor Score [GMS] < 6) examined with MRI within 1 week post-injury were included. Diffusion-weighted (DW), T2*-weighted gradient echo and susceptibility-weighted (SWI) sequences were used. Extended Glasgow outcome score was assessed after 6 months. Number of DW lesions in the thalamus, basal ganglia, and internal capsule and number of SWI lesions in the mesencephalon correlated significantly with outcome in univariate analysis. Age, GMS at admission, GMS at discharge, and low proportion of good monitoring time with cerebral perfusion pressure < 60mm Hg correlated significantly with outcome in univariate analysis. Multivariate analysis revealed an independent relation with poor outcome for age (p = 0.005) and lesions in the mesencephalic region corresponding to substantia nigra and tegmentum on SWI (p = 0.008). We conclude that higher age and lesions in substantia nigra and mesencephalic tegmentum indicate poor long-term outcome in DAI. We propose an extended MRI classification system based on four stages (stage I-hemispheric lesions, stage II-corpus callosum lesions, stage III-brainstem lesions, and stage IV-substantia nigra or mesencephalic tegmentum lesions); all are subdivided by age (>=/<= 30 years).	[Abu Hamdeh, Sami; Marklund, Niklas; Howells, Tim; Enblad, Per] Uppsala Univ, Neurosurg, Dept Neurosci, Uppsala, Sweden; [Lannsjo, Marianne] Uppsala Univ, Rehabil Med, Dept Neurosci, Uppsala, Sweden; [Lannsjo, Marianne] Uppsala Univ, Cty Council Gavleborg, Gavle Hosp, Ctr Res & Dev, Gavle, Sweden; [Raininko, Raili; Wikstrom, Johan] Uppsala Univ, Dept Radiol, Uppsala, Sweden	Abu Hamdeh, S (corresponding author), Univ Uppsala Hosp, Neurosurg, Dept Neurosci, S-75185 Uppsala, Sweden.	sami.abu.hamdeh@neuro.uu.se		Wikstrom, Johan/0000-0002-9481-6857; Marklund, Niklas/0000-0002-9797-5626			Adams JH, 2011, J NEUROTRAUM, V28, P701, DOI 10.1089/neu.2010.1733; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Andriessen TMJC, 2011, J NEUROTRAUM, V28, P2019, DOI 10.1089/neu.2011.2034; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P573; Chastain CA, 2009, J NEUROTRAUM, V26, P1183, DOI 10.1089/neu.2008.0650; Chelly H, 2011, J TRAUMA, V71, P838, DOI 10.1097/TA.0b013e3182127baa; Chew BG, 2012, J NEUROSURG, V117, P722, DOI 10.3171/2012.6.JNS111736; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Dinkel J, 2014, AM J NEURORADIOL, V35, P23, DOI 10.3174/ajnr.A3616; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Firsching R, 2002, NEUROL RES, V24, P145, DOI 10.1179/016164102101199684; Firsching R, 2001, ACTA NEUROCHIR, V143, P263; Firsching R, 1998, J NEUROSURG, V89, P707, DOI 10.3171/jns.1998.89.5.0707; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1994, RADIOLOGY, V191, P1; Graham DI, 2005, NEUROPSYCHOL REHABIL, V15, P198, DOI 10.1080/09602010443000452; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Hilario A, 2012, AM J NEURORADIOL, V33, P1925, DOI 10.3174/ajnr.A3092; Howells T. P., 1995, Journal of Neurotrauma, V12, P471; Howells T, 2012, INTENS CARE MED, V38, P1061, DOI 10.1007/s00134-012-2571-7; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kampfl A, 1998, J NEUROSURG, V88, P809, DOI 10.3171/jns.1998.88.5.0809; Lansberg MG, 2001, AM J NEURORADIOL, V22, P637; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Mannion RJ, 2007, J NEUROTRAUM, V24, P128, DOI 10.1089/neu.2006.0127; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Messori A, 2003, NEURORADIOLOGY, V45, P881, DOI 10.1007/s00234-003-1048-3; Mittal S, 2009, AM J NEURORADIOL, V30, P232, DOI 10.3174/ajnr.A1461; Moen KG, 2014, J NEUROTRAUM, V31, P1486, DOI 10.1089/neu.2013.3258; Moen KG, 2016, J NEUROSCI RES, V94, P623, DOI 10.1002/jnr.23728; Moen KG, 2012, J NEUROL NEUROSUR PS, V83, P1193, DOI 10.1136/jnnp-2012-302644; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Ripoll MA, 2003, ACTA RADIOL, V44, P199, DOI 10.1034/j.1600-0455.2003.00038.x; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Rusnak M, 2007, WIEN KLIN WOCHENSCHR, V119, P23, DOI 10.1007/s00508-006-0760-5; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Shibata Y, 2000, CLIN NEUROL NEUROSUR, V102, P124, DOI 10.1016/S0303-8467(00)00095-0; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Skoglund K, 2012, CRIT CARE MED, V40, P216, DOI 10.1097/CCM.0b013e31822d7dbd; Stocchetti N, 2012, J NEUROTRAUM, V29, P1119, DOI 10.1089/neu.2011.1995; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wardlaw JM, 2000, NEURORADIOLOGY, V42, P81, DOI 10.1007/s002340050019; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208; Yanagawa Y, 2009, J TRAUMA, V66, P162, DOI 10.1097/TA.0b013e3181469857	50	31	33	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2017	34	2					341	352		10.1089/neu.2016.4426			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EH4QD	WOS:000391754800009	27356857	Green Published, Bronze			2021-06-18	
J	Akin, FW; Murnane, OD; Hall, CD; Riska, KM				Akin, Faith W.; Murnane, Owen D.; Hall, Courtney D.; Riska, Kristal M.			Vestibular consequences of mild traumatic brain injury and blast exposure: a review	BRAIN INJURY			English	Article						Mild brain injury; concussion; balance	PAROXYSMAL POSITIONAL VERTIGO; HEAD-INJURY; POSTCONCUSSION SYMPTOMS; POSTURAL STABILITY; BALANCE DISORDERS; NOISE EXPOSURE; REHABILITATION; DIZZINESS; DYSFUNCTION; IMPAIRMENT	The purpose of this article is to review relevant literature on the effect of mild traumatic brain injury (mTBI) and blast injury on the vestibular system. Dizziness and imbalance are common sequelpe associated with mTBI; and in some individuals, these symptoms may last for six months or longer. In war-related injuries, mTBI is often associated with blast exposure. The causes of dizziness Or imbalance following mTBI and blast injuries have been linked to white matter abnormalities, diffuse axonal injury in the brain, and central and peripheral vestibular system damage. There is some evidence that the otolith organs may be more vulnerable to damage from blast exposure or mTBI than the horizontal semicircular canal's. In addition benign paroxysmal positional vertigo (BPPV) is a common vestibular disorder following head injury that is treated effectively with canalith repositioning therapy. Treatment for (non-BPPV) mTBI-related vestibular dysfunction has focused on the use of vestibular, rehabilitation (VR) augmented with additional rehabilitation methods and Medication: New treatment approaches may be necessary for effective otolith organ pathway recovery in addition to traditional VR for horizontal semicircular canal (vestibulo-ocular reflex) recovery.	[Akin, Faith W.; Murnane, Owen D.; Riska, Kristal M.] James H Quillen VA Med Ctr Mt Home, Vestibular Lab, Mountain Home, TN USA; [Akin, Faith W.; Murnane, Owen D.; Riska, Kristal M.] East Tennessee State Univ, Dept Audiol & Speech Language Pathol, Johnson City, TN 37614 USA; [Hall, Courtney D.] James H Quillen VA Med Ctr, Gait & Balance Lab, Mountain Home, TN USA; [Hall, Courtney D.] East Tennessee State Univ, Dept Phys Therapy, Johnson City, TN 37614 USA	Akin, FW (corresponding author), James H Quillen VA Med Ctr, Vestibular & Balance Lab, Mountain Home, TN 37684 USA.	Faith.Akin@va.gov					Ahn SK, 2011, J TRAUMA, V70, P442, DOI 10.1097/TA.0b013e3181d0c3d9; Akin FW, 2012, EAR HEARING, V33, P458, DOI 10.1097/AUD.0b013e3182498c5f; Akin FW, 2011, OTOLARYNG CLIN N AM, V44, P323, DOI 10.1016/j.otc.2011.01.005; Alhilali LM, 2014, RADIOLOGY, V272, P224, DOI 10.1148/radiol.14132670; Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; [Anonymous], 2016, VADOD CLIN PRACT GUI; Balaban C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162168; Baldassarre M, 2015, PM&R, V7, P845, DOI 10.1016/j.pmrj.2015.03.003; BARBER H O, 1964, Laryngoscope, V74, P891; Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Basta D, 2005, HUM MOVEMENT SCI, V24, P268, DOI 10.1016/j.humov.2005.04.002; Basta D, 2008, GAIT POSTURE, V28, P397, DOI 10.1016/j.gaitpost.2008.01.006; BERMAN JM, 1978, J OTOLARYNGOL, V7, P237; Bhattacharyya N, 2008, OTOLARYNG HEAD NECK, V139, pS47, DOI 10.1016/j.otohns.2008.08.022; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Chandrasekhar SS, 2013, NEUROREHABILITATION, V32, P445, DOI 10.3233/NRE-130867; Cohen JT, 2002, ISRAEL MED ASSOC J, V4, P559; Curthoys IS, 2007, VESTIBULAR REHABILIT; DAVIES RA, 1995, J NEUROL, V242, P222, DOI 10.1007/BF00919595; DIFABIO RP, 1995, PHYS THER, V75, P290, DOI 10.1093/ptj/75.4.290; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; EPLEY JM, 1992, OTOLARYNG HEAD NECK, V107, P399, DOI 10.1177/019459989210700310; Ernst A, 2005, OTOLARYNG HEAD NECK, V132, P554, DOI 10.1016/j.otohns.2004.09.034; Ettenhofer ML, 2016, J NEUROPSYCH CLIN N, V28, P223, DOI 10.1176/appi.neuropsych.15100243; Farrell L, 2014, ISRN REHABIL, P1; Fife TD, 2008, NEUROLOGY, V70, P2067, DOI 10.1212/01.wnl.0000313378.77444.ac; Fife TD, 2000, NEUROLOGY, V55, P1431, DOI 10.1212/WNL.55.10.1431; GANNON RP, 1978, ARCH OTOLARYNGOL, V104, P404; Gattu R, BRAIN INJ IN PRESS; Geurts ACH, 1996, ARCH PHYS MED REHAB, V77, P639, DOI 10.1016/S0003-9993(96)90001-5; Gordon CR, 2004, ARCH NEUROL-CHICAGO, V61, P1590, DOI 10.1001/archneur.61.10.1590; Gottshall K, 2003, LARYNGOSCOPE, V113, P1746, DOI 10.1097/00005537-200310000-00016; Gurr B, 2001, BRAIN INJURY, V15, P387, DOI 10.1080/02699050010005904; Guskiewicz KM, 1996, J ATHL TRAINING, V31, P300; Hall CD, 2016, J NEUROL PHYS THER, V40, P124, DOI 10.1097/NPT.0000000000000120; HALL SF, 1979, J OTOLARYNGOL, V8, P151; Hayes JP, 2015, NEUROIMAGE-CLIN, V8, P148, DOI 10.1016/j.nicl.2015.04.001; Hoffer ME, 2004, OTOL NEUROTOL, V25, P135, DOI 10.1097/00129492-200403000-00009; Hoffer ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054163; Hsu WC, 2008, ARCH OTOLARYNGOL, V134, P1099, DOI 10.1001/archotol.134.10.1099; KERR AG, 1975, J LARYNGOL OTOL, V89, P131, DOI 10.1017/S002221510008018X; KERR AG, 1980, J LARYNGOL OTOL, V94, P107, DOI 10.1017/S0022215100088538; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Laborey M, 2014, J HEAD TRAUMA REHAB, V29, pE28, DOI 10.1097/HTR.0b013e318280f896; Lachman J, 1955, ACTA MED ORIENT, V14, P44; Lee JD, 2011, EUR ARCH OTO-RHINO-L, V268, P1427, DOI 10.1007/s00405-010-1426-5; Leigh RJ, 2001, NEUROLOGY EYE MOVEME; Lynn S, 1995, OTOLARYNG HEAD NECK, V113, P712, DOI 10.1016/S0194-5998(95)70010-2; Marshall S, 2015, BRAIN INJURY, P1; McDonnell MN, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005397.pub4; Murray KJ, 2010, J NEUROL PHYS THER, V34, P70, DOI 10.1097/NPT.0b013e3181dde5dd; Naguib MB, 2014, J CHIROPR MED, V13, P14, DOI 10.1016/j.jcm.2014.01.011; PAHOR AL, 1981, J LARYNGOL OTOL, V95, P399, DOI 10.1017/S0022215100090873; Patterson JH, 1997, TOXICOLOGY, V121, P29, DOI 10.1016/S0300-483X(97)03653-6; Perez R, 2002, LARYNGOSCOPE, V112, P1110, DOI 10.1097/00005537-200206000-00032; Picciotti PM, 2016, INT J AUDIOL, V55, P279, DOI 10.3109/14992027.2016.1143981; PROCTOR B, 1956, Laryngoscope, V66, P16; RUBIN AM, 1995, AM J OTOL, V16, P216; Scherer MR, 2011, OTOL NEUROTOL, V32, P571, DOI 10.1097/MAO.0b013e318210b8fa; Schneider KJ, 2014, BRIT J SPORT MED, P1; Schultz BA, 2011, NEUROREHABILITATION, V28, P309, DOI 10.3233/NRE-2011-0659; Semont A, 1988, Adv Otorhinolaryngol, V42, P290; Serrador JM, 2012, P 35 ANN ASS RES OT; Serrador JM, 2009, NEUROSCI LETT, V465, P10, DOI 10.1016/j.neulet.2009.08.057; Sessoms PH, 2015, MIL MED, V180, P143, DOI 10.7205/MILMED-D-14-00385; SHEPARD NT, 1993, ANN OTO RHINOL LARYN, V102, P198, DOI 10.1177/000348949310200306; SHUPAK A, 1993, ARCH OTOLARYNGOL, V119, P1362; Tuohimaa P, 1978, Acta Otolaryngol Suppl, V359, P3; Van Campen L E, 1999, J Am Acad Audiol, V10, P467; Wang YP, 2006, OTOL NEUROTOL, V27, P956, DOI 10.1097/01.mao.0000231590.57348.4b; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Weightman MM, 2010, J HEAD TRAUMA REHAB, V25, P206, DOI 10.1097/HTR.0b013e3181dc82d3; Wu CC, 2009, INT J AUDIOL, V48, P655, DOI 10.1080/14992020903012481; Yang CC, 2007, J TRAUMA, V62, P657, DOI 10.1097/01.ta.0000203577.68764.b8	75	31	32	0	7	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2017	31	9			SI		1188	1194		10.1080/02699052.2017.1288928			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FK0NN	WOS:000413176600005	28981340	Other Gold			2021-06-18	
J	Chen, T; Dai, SH; Jiang, ZQ; Luo, P; Jiang, XF; Fei, Z; Gui, SB; Qi, YL				Chen, Tao; Dai, Shu-Hui; Jiang, Zhi-Quan; Luo, Peng; Jiang, Xiao-Fan; Fei, Zhou; Gui, Song-Bai; Qi, Yi-Long			The AMPAR Antagonist Perampanel Attenuates Traumatic Brain Injury Through Anti-Oxidative and Anti-Inflammatory Activity	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						AMPA receptor; Perampanel; TBI; Oxidative stress; Inflammation	GLUTAMATE RECEPTORS; DOUBLE-BLIND; ISCHEMIA; MICE; RAT; INFLAMMATION; EXPRESSION; MODEL; PHOSPHORYLATION; NEUROPROTECTION	Perampanel is a novel alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor (AMPAR) antagonist, approved in over 35 countries as an adjunctive therapy for the treatment of seizures. Recently, it was found to exert protective effects against ischemic neuronal injury in vitro. In the present study, we investigated the potential protective effects of perampanel in a traumatic brain injury (TBI) model in rats. Oral administration with perampanel at a dose of 5 mg/kg exerted no major organ-related toxicities. We found that perampanel significantly attenuated TBI-induced brain edema, brain contusion volume, and gross motor dysfunction. The results of Morris water maze test demonstrated that perampanel treatment also improved cognitive function after TBI. These neuroprotective effects were accompanied by reduced neuronal apoptosis, as evidenced by decreased TUNEL-positive cells in brain sections. Moreover, perampanel markedly inhibited lipid peroxidation and obviously preserved the endogenous antioxidant system after TBI. In addition, enzyme-linked immunosorbent assay (ELISA) was performed at 4 and 24 h after TBI to evaluate the expression of inflammatory cytokines. The results showed that perampanel suppressed the expression of pro-inflammatory cytokines TNF-alpha and IL-1 beta, whereas increased the levels of anti-inflammatory cytokines IL-10 and TGF-beta 1. These data show that the orally active AMPAR antagonist perampanel affords protection against TBI-induced neuronal damage and neurological dysfunction through anti-oxidative and anti-inflammatory activity.	[Chen, Tao; Qi, Yi-Long] PLA, Dept Neurosurg, Hosp 123, Bengbu 233010, Anhui, Peoples R China; [Gui, Song-Bai] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China; [Chen, Tao; Dai, Shu-Hui; Luo, Peng; Jiang, Xiao-Fan; Fei, Zhou] Fourth Mil Med Univ, Xijing Inst Clin Neurosci, Xijing Hosp, Dept Neurosurg, Xian 710032, Shaanxi, Peoples R China; [Jiang, Zhi-Quan] Bengbu Med Coll, Dept Neurosurg, Affiliated Hosp 1, Bengbu 233004, Anhui, Peoples R China	Qi, YL (corresponding author), PLA, Dept Neurosurg, Hosp 123, Bengbu 233010, Anhui, Peoples R China.; Gui, SB (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China.	guisb_tiantan@126.com; qiyl_PLA123@126.com		Luo, Peng/0000-0003-0746-939X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371447, 81301037]	This work was supported by the National Natural Science Foundation of China (Nos. 81371447 and 81301037).	Arundine M, 2004, CELL MOL LIFE SCI, V61, P657, DOI 10.1007/s00018-003-3319-x; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Bolton C, 2006, MEDIAT INFLAMM, V2006, DOI 10.1155/mi/2006/93684; Calabresi P, 2003, NEUROBIOL DIS, V12, P82, DOI 10.1016/S0969-9961(02)00016-5; Ceolin L, 2012, NEUROCHEM INT, V61, P517, DOI 10.1016/j.neuint.2012.02.035; Cernak Ibolja, 2005, NeuroRx, V2, P410, DOI 10.1602/neurorx.2.3.410; Chang J, 2015, EXP NEUROL, V273, P225, DOI 10.1016/j.expneurol.2015.08.020; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Chen T, 2011, BRAIN RES BULL, V84, P163, DOI 10.1016/j.brainresbull.2010.11.015; Chua KSG, 2007, ANN ACAD MED SINGAP, V36, P31; Correale J, 2004, J NEUROL, V251, P1304, DOI 10.1007/s00415-004-0649-z; Davis A E, 2000, Crit Care Nurs Clin North Am, V12, P447; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Durand D, 2008, NEUROPHARMACOLOGY, V55, P577, DOI 10.1016/j.neuropharm.2008.06.022; Frenkel D, 2003, J IMMUNOL, V171, P6549, DOI 10.4049/jimmunol.171.12.6549; Grossman SA, 2009, J CLIN ONCOL, V27, P4155, DOI 10.1200/JCO.2008.21.6895; Hanada T, 2011, EPILEPSIA, V52, P1331, DOI 10.1111/j.1528-1167.2011.03109.x; Henley Jeremy M, 2013, Dialogues Clin Neurosci, V15, P11; Hibi S, 2012, J MED CHEM, V55, P10584, DOI 10.1021/jm301268u; Hwabejire JO, 2013, SURGERY, V154, P234, DOI 10.1016/j.surg.2013.04.008; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Jiang XF, 2013, J SURG RES, V184, pE27, DOI 10.1016/j.jss.2013.03.067; Koeglsperger T, 2013, GLIA, V61, P985, DOI 10.1002/glia.22490; Lea PM, 2001, MENT RETARD DEV D R, V7, P235, DOI 10.1002/mrdd.1033; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Mao Haojie, 2006, Stapp Car Crash J, V50, P583; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nichol A, 2015, LANCET, V386, P2499, DOI 10.1016/S0140-6736(15)00386-4; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; Ooboshi H, 2005, CIRCULATION, V111, P913, DOI 10.1161/01.CIR.0000155622.68580.DC; Pang L, 2001, STROKE, V32, P544, DOI 10.1161/01.STR.32.2.544; Schumann J, 2008, J NEUROTRAUM, V25, P945, DOI 10.1089/neu.2008.0521; Seeburg PH, 2001, BRAIN RES, V907, P233, DOI 10.1016/S0006-8993(01)02445-3; SHEARDOWN MJ, 1990, SCIENCE, V247, P571, DOI 10.1126/science.2154034; Simma N, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/s12964-014-0075-5; Smith S E, 1993, Funct Neurol, V8, P43; Spaethling J, 2012, NEUROBIOL DIS, V46, P646, DOI 10.1016/j.nbd.2012.03.003; Stone TW, 2002, EUR J PHARMACOL, V447, P285, DOI 10.1016/S0014-2999(02)01851-4; Turetsky D, 2005, J NEUROSCI, V25, P7438, DOI 10.1523/JNEUROSCI.1108-05.2005; Walters MR, 2005, CEREBROVASC DIS, V20, P304, DOI 10.1159/000087929; Weiser T, 2005, CNS NEUROL DISORD-DR, V4, P153, DOI 10.2174/1568007053544129; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	46	31	31	1	9	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	JAN	2017	37	1					43	52		10.1007/s10571-016-0341-8			10	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	EI3QU	WOS:000392407200006	26883519				2021-06-18	
J	Gallaway, M; Scheiman, M; Mitchell, GL				Gallaway, Michael; Scheiman, Mitchell; Mitchell, G. Lynn			Vision Therapy for Post-Concussion Vision Disorders	OPTOMETRY AND VISION SCIENCE			English	Article						vision therapy; vision rehabilitation; concussion; convergence insufficiency; accommodative insufficiency; near point of convergence	TRAUMATIC BRAIN-INJURY; RANDOMIZED CLINICAL-TRIAL; INSUFFICIENCY SYMPTOM SURVEY; CONVERGENCE INSUFFICIENCY; OCULOMOTOR REHABILITATION; VISUAL FUNCTION; DYSFUNCTIONS; CHILDREN; RESPONSIVITY; STATEMENT	Purpose. To determine the frequency and types of vision disorders associated with concussion, and to determine the success rate of vision therapy for these conditions in two private practice settings. Methods. All records over an 18-month period of patients referred for post-concussion vision problems were reviewed from two private practices. Diagnoses of vergence, accommodative, or eye movement disorders were based on pre-established, clinical criteria. Vision therapy was recommended based on clinical findings and symptoms. Results. Two hundred eighteen patient records were found with a diagnosis of concussion. Fifty-six percent of the concussions were related to sports, 20% to automobile accidents, and 24% to school, work, or home-related incidents. The mean age was 20.5 years and 58% were female. Eighty-two percent of the patients had a diagnosis of an oculomotor problem [binocular problems (62%), accommodative problems (54%), eye movement problems (21%)]. The most prevalent diagnoses were convergence insufficiency (CI, 47%) and accommodative insufficiency (AI, 42%). Vision therapy was recommended for 80% of the patients. Forty-six per cent (80/175) either did not pursue treatment or did not complete treatment. Of the 54% (95/175) who completed therapy, 85% of patients with CI were successful and 15% were improved, and with AI, 33% were successful and 67% improved. Clinically and statistically significant changes were measured in symptoms, near point of convergence, positive fusional vergence, and accommodative amplitude. Conclusions. In this case series, post-concussion vision problems were prevalent and CI and AI were the most common diagnoses. Vision therapy had a successful or improved outcome in the vast majority of cases that completed treatment. Evaluation of patients with a history of concussion should include testing of vergence, accommodative, and eye movement function. Prospective clinical trials are necessary to assess the natural history of concussion-related vision disorders and treatment effectiveness.	[Gallaway, Michael; Scheiman, Mitchell] Salus Univ, Penn Coll Optometry, 1200 W Godfrey Ave, Philadelphia, PA 19141 USA; [Mitchell, G. Lynn] Ohio State Univ, Coll Optometry, 338 W 10th Ave, Columbus, OH 43210 USA	Gallaway, M (corresponding author), Salus Univ, Penn Coll Optometry, 1200 W Godfrey Ave, Philadelphia, PA 19141 USA.	mgallaway@salus.edu	Mitchell, Gladys/E-7973-2012	Scheiman, Mitchell/0000-0002-9274-5696			Alvarez TL, 2012, OPTOMETRY VISION SCI, V89, P1740, DOI 10.1097/OPX.0b013e3182772dce; Borsting EJ, 2003, OPTOMETRY VISION SCI, V80, P832, DOI 10.1097/00006324-200312000-00014; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Broglio SP, 2015, CLIN SPORT MED, V34, P213, DOI 10.1016/j.csm.2014.12.005; Capo-Aponte JE, 2012, MIL MED, V177, P804, DOI 10.7205/MILMED-D-12-00061; Ciuffreda Kenneth J, 2007, Optometry, V78, P155, DOI 10.1016/j.optm.2006.11.011; Cockerham GC, 2009, J REHABIL RES DEV, V46, P811, DOI 10.1682/JRRD.2008.08.0109; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Goodrich GL, 2013, OPTOMETRY VISION SCI, V90, P105, DOI 10.1097/OPX.0b013e31827f15a1; Grady MF, 2012, PEDIATR ANN, V41, P377, DOI 10.3928/00904481-20120827-12; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Hunt AW, 2016, J HEAD TRAUMA REHAB, V31, P252, DOI 10.1097/HTR.0000000000000174; Kapoor N, 2004, ARCH PHYS MED REHAB, V85, P1667, DOI 10.1016/j.apmr.2003.12.044; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Porcar E, 1997, OPTOMETRY VISION SCI, V74, P111, DOI 10.1097/00006324-199702000-00023; Rouse M, 2009, OPTOMETRY VISION SCI, V86, P357, DOI 10.1097/OPX.0b013e3181989252; Scheiman M, 2005, OPTOMETRY VISION SCI, V82, P583, DOI 10.1097/01.opx.0000171331.36871.2f; Scheiman M, 1996, J Am Optom Assoc, V67, P193; Scheiman M, 2005, ARCH OPHTHALMOL-CHIC, V123, P14, DOI 10.1001/archopht.123.1.14; Scheiman M., 2014, CLIN MANAGEMENT BINO, V4th; Scheiman M, 2011, COCHRANE DATABASE SY, V16; Scheiman M, 2008, ARCH OPHTHALMOL-CHIC, V126, P1336, DOI 10.1001/archopht.126.10.1336; Scheiman M, 2011, OPTOMETRY VISION SCI, V88, P1343, DOI 10.1097/OPX.0b013e31822f4d7c; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; Tannen B, 2015, VIS DEV REHAB, V1, P206; Thiagarajan P, 2014, OPTOM VIS PERF, V2, P539; Thiagarajan P, 2014, J REHABIL RES DEV, V51, P175, DOI 10.1682/JRRD.2013.01.0027; Thiagarajan P, 2013, J REHABIL RES DEV, V50, P1223, DOI 10.1682/JRRD.2012.12.0235; Ventura RE, 2014, LANCET NEUROL, V13, P1006, DOI 10.1016/S1474-4422(14)70111-5; Youngstrom EA, 2014, J PEDIATR PSYCHOL, V39, P204, DOI 10.1093/jpepsy/jst062	34	31	31	1	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1040-5488	1538-9235		OPTOMETRY VISION SCI	Optom. Vis. Sci.	JAN	2017	94	1					68	73		10.1097/OPX.0000000000000935			6	Ophthalmology	Ophthalmology	EM5ZZ	WOS:000395393900010	27505624				2021-06-18	
J	Hwang, S; Ma, L; Kawata, K; Tierney, R; Jeka, JJ				Hwang, Sungjae; Ma, Lei; Kawata, Keisuke; Tierney, Ryan; Jeka, John J.			Vestibular Dysfunction after Subconcussive Head Impact	JOURNAL OF NEUROTRAUMA			English	Article						behavioral assessments; head trauma; human studies; outcome measures; sensory function	POSTURAL CONTROL; SOCCER; CONCUSSION; BALANCE; STABILITY; COLLEGIATE; INJURY; FOOTBALL; POSITION; UPRIGHT	Current thinking views mild head impact (i.e., subconcussion) as an underrecognized phenomenon that has the ability to cause significant current and future detrimental neurological effects. Repeated mild impacts to the head, however, often display no observable behavioral deficits based on standard clinical tests, which may lack sensitivity. The current study investigates the effects of subconcussive impacts from soccer heading with innovative measures of vestibular function and walking stability in a pre-0-2 h, post-24 h post-heading repeated measures design. The heading group (n = 10) executed 10 headers with soccer balls projected at a velocity of 25 mph (11.2 m/sec) over 10 min. Subjects were evaluated 24 h before, immediately after, and 24 h after soccer heading with: the modified Balance Error Scoring System (mBESS); a walking stability task with visual feedback of trunk movement; and galvanic vestibular stimulation (GVS) while standing with eyes closed on foam. A control group (n = 10) followed the same protocol with no heading. The results showed significant decrease in trunk angle, leg angle gain, and center of mass gain relative to GVS for the heading group compared with controls. Medial-lateral trunk orientation displacement and velocity during treadmill walking increased immediately after mild head impact for the heading group compared with controls. Controls showed an improvement in mBESS scores over time, indicating a learning effect, which was not observed with the heading group. These results suggest that mild head impact leads to a transient dysfunction in vestibular processing, which deters walking stability during task performance.	[Hwang, Sungjae; Ma, Lei; Kawata, Keisuke; Tierney, Ryan; Jeka, John J.] Temple Univ, Dept Kinesiol, 1800 N Broad St, Philadelphia, PA 19122 USA	Hwang, S (corresponding author), Temple Univ, Dept Kinesiol, 1800 N Broad St, Philadelphia, PA 19122 USA.	sungjae.hwang@temple.edu		Ma, Lei/0000-0002-0050-6461; Jeka, John/0000-0001-5942-3209	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R21 AG041714-01A1]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG041714] Funding Source: NIH RePORTER	This study was partially supported by NIH grant R21 AG041714-01A1, J. Jeka, PI. The authors thank Eric Anson, PhD and Peter Agada, MS for their input and assistance.	Anson E, 2014, EXP BRAIN RES, V232, P1941, DOI 10.1007/s00221-014-3885-1; Bailes JE, 2013, J NEUROSURG, V119, P1235, DOI 10.3171/2013.7.JNS121822; Bauer JA, 2001, J SPORT SCI, V19, P171, DOI 10.1080/026404101750095312; Bendat J.S., 2000, RANDOM DATA ANAL MEA, V3rd ed.; Bouguet J.Y., 2013, CAMERA CALIBRATION T; Broglio SP, 2004, BRIT J SPORT MED, V38, P561, DOI 10.1136/bjsm.2003.004887; Clark D, 2012, NEUROLOGY, V78, pE140, DOI 10.1212/WNL.0b013e31825bc685; Dashnaw ML, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.10.FOCUS12284; Day BL, 2010, J PHYSIOL-LONDON, V588, P671, DOI 10.1113/jphysiol.2009.181768; Donelan JM, 2004, J BIOMECH, V37, P827, DOI 10.1016/j.jbiomech.2003.06.002; Franke LM, 2012, J REHABIL RES DEV, V49, P985, DOI 10.1682/JRRD.2011.12.0250; Gard SA, 2004, HUM MOVEMENT SCI, V22, P597, DOI 10.1016/j.humov.2003.11.002; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Haran FJ, 2013, INT J SPORTS MED, V34, P350, DOI 10.1055/s-0032-1304647; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Hurt CP, 2010, GAIT POSTURE, V31, P461, DOI 10.1016/j.gaitpost.2010.02.001; Hwang S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088132; Ijmker T, 2013, J BIOMECH, V46, P2109, DOI 10.1016/j.jbiomech.2013.07.005; Jeka J, 2004, J NEUROPHYSIOL, V92, P2368, DOI 10.1152/jn.00983.2003; Kaminski TW, 2008, RES Q EXERCISE SPORT, V79, P235; Logan D, 2010, EXP BRAIN RES, V206, P337, DOI 10.1007/s00221-010-2414-0; MACKINNON CD, 1993, J BIOMECH, V26, P633, DOI 10.1016/0021-9290(93)90027-C; Mangus Brent C, 2004, Sports Biomech, V3, P209, DOI 10.1080/14763140408522841; McCrory P, 2013, PM&R, V5, P255, DOI 10.1016/j.pmrj.2013.02.012; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; O'Connor SM, 2009, J NEUROPHYSIOL, V102, P1411, DOI 10.1152/jn.00131.2009; Parker TM, 2005, CLIN BIOMECH, V20, P389, DOI 10.1016/j.clinbiomech.2004.12.004; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Peterka RJ, 2004, J NEUROPHYSIOL, V91, P410, DOI 10.1152/jn.00516.2003; PETERKA RJ, 1995, EXP BRAIN RES, V105, P101; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Schmid-Priscoveanu A, 2000, EXP BRAIN RES, V134, P212; Schmitt DM, 2004, INT J SPORTS MED, V25, P326, DOI 10.1055/s-2004-819941; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; Winter D., 1995, GAIT POSTURE, V3, P193, DOI 10.1016/0966-6362(96)82849-9; Winter D. A., 2009, BIOMECHANICS MOTOR C, V4th	42	31	31	0	53	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2017	34	1					8	15		10.1089/neu.2015.4238			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EF6DE	WOS:000390420100002	26885560	Green Published			2021-06-18	
J	Rodriguez Cruz, Y; Strehaiano, M; Obaya, TR; Rodriguez, JCG; Maurice, T				Rodriguez Cruz, Yamila; Strehaiano, Manon; Rodriguez Obaya, Teresita; Garcia Rodriguez, Julio Cesar; Maurice, Tangui			An Intranasal Formulation of Erythropoietin (Neuro-EPO) Prevents Memory Deficits and Amyloid Toxicity in the APP(Swe) Transgenic Mouse Model of Alzheimer's Disease	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Alzheimer's disease; erythropoietin; intranasal formulation; learning and memory; Neuro-EPO; neuroprotection	COGNITIVE IMPAIRMENT; SYNAPTIC PLASTICITY; BRAIN; MICE; RECEPTOR; IMPROVES; HIPPOCAMPAL; MODULATION; EXPRESSION; INJURY	Erythropoietin (EPO) is a cytokine known to have effective cytoprotective action in the brain, particularly in ischemic, traumatic, inflammatory, and neurodegenerative conditions. We previously reported the neuroprotective effect of a low sialic form of EPO, Neuro-EPO, applied intranasally in rodent models of stroke or cerebellar ataxia and in a non-transgenic mouse model of Alzheimer's disease (AD). Here we analyzed the protective effect of Neuro-EPO in APP(Swe) mice, a reference transgenic mouse model of AD. Mice were administered 3 times a day, 3 days in the week with Neuro-EPO (125, 250 mu g/kg) intranasally, between 12 and 14 months of age. Motor responses, general activity, and memory responses were analyzed during and after treatment. The deficits in spontaneous alternation, place learning in the water-maze, and novel object recognition observed in APP(Swe) mice were alleviated by the low dose of Neuro-EPO. Oxidative stress, neuroinflammation, trophic factor levels, and a synaptic marker were analyzed in the hippocampus or cortex of the animals. The increases in lipid peroxidation or in GFAP and Iba-1 contents in APP(Swe) mice were significantly reduced after Neuro-EPO. Activation of intrinsic and extrinsic apoptotic pathways was analyzed. The increases in Bax/Bcl-2 ratio, TNF alpha, or Fas ligand levels observed in APP(Swe) mice were reduced by Neuro-EPO. Finally, immunohistochemical and ELISA analyses of A beta(1-42) levels in the APP(Swe) mouse cortex and hippocampus showed a marked reduction in A beta deposits and in soluble and insoluble A beta(1-42) forms. This study therefore confirmed the neuroprotective activity of EPO, particularly for an intranasally deliverable formulation, devoid of erythropoietic side effects, in a transgenic mouse model of AD. Neuro-EPO alleviated memory alterations, oxidative stress, neuroinflammation, apoptosis induction, and amyloid load in 14-month-old APP(Swe) mice.	[Rodriguez Cruz, Yamila; Garcia Rodriguez, Julio Cesar] Univ Med Sci, Inst Preclin & Basic Sci, Dept Histol, Havana, Cuba; [Rodriguez Cruz, Yamila; Rodriguez Obaya, Teresita] Ctr Mol Immunol CIM, Havana, Cuba; [Strehaiano, Manon; Maurice, Tangui] INSERM, U1198, Montpellier, France; [Strehaiano, Manon; Maurice, Tangui] Univ Montpellier, Montpellier, France; [Strehaiano, Manon; Maurice, Tangui] EPHE, Paris, France	Maurice, T (corresponding author), Univ Montpellier, INSERM, U1198, CC105, Pl Eugene Bataillon, F-34095 Montpellier 5, France.	tangui.maurice@umontpellier.fr	Rodriguez, Julio Cesar Garcia/V-7643-2019; Maurice, Tangui/AAP-2499-2020	Maurice, Tangui/0000-0002-4074-6793	program FSP Cuba (Havana, Cuba) [2011-16, 29967RG]; University of Montpellier; Franco-Cuban scientific	We thank Drs. Gaelle Naert and Catherine Desrumaux (INSERM U1198, Montpellier, France) for helpful advices and CIMAB (Habana, Cuba) for providing Neuro-EPO. This work is a scientific collaboration between the University of Montpellier and the University of Medical Sciences of Havana, Institute of Basic and Preclinical Sciences "Victoria de Giron". It was funded by a Franco-Cuban scientific cooperation between the French Embassy in Cuba and the Cuban Ministry of Foreign Trade and Foreign Investment (MINCEX), program FSP Cuba 2011-16, 29967RG (Havana, Cuba) and external resources from Inserm (Paris, France) and the University of Montpellier (Montpellier, France). JCGR acknowledges a visiting professor fellowship from the University of Montpellier.	Adamcio B, 2008, BMC BIOL, V6, DOI 10.1186/1741-7007-6-37; Alcala-Barraza SR, 2010, J DRUG TARGET, V18, P179, DOI 10.3109/10611860903318134; Almaguer-Melian W, 2016, SYNAPSE, V70, P240, DOI 10.1002/syn.21895; Arabpoor Zohreh, 2012, Adv Biomed Res, V1, P50, DOI 10.4103/2277-9175.100157; Armand-Ugon M, 2015, J ALZHEIMERS DIS, V45, P407, DOI [10.3233/JAD-141389, 10.3233/JAD-150002]; Assaraf MI, 2007, J NEUROPATH EXP NEUR, V66, P389, DOI 10.1097/nen.0b013e3180517b28; Bailey DM, 2014, ACTA PHYSIOL, V212, P175, DOI 10.1111/apha.12313; Barichello T, 2014, TRANSL RES, V163, P503, DOI 10.1016/j.trsl.2013.12.008; Bartesaghi S, 2005, NEUROTOXICOLOGY, V26, P923, DOI 10.1016/j.neuro.2005.01.016; Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Bond WS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00523; Brettschneider J, 2006, NEUROSCI LETT, V404, P347, DOI 10.1016/j.neulet.2006.06.011; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Brureau A, 2013, NEUROBIOL AGING, V34, P1426, DOI 10.1016/j.neurobiolaging.2012.11.015; Castatneda-Arellano R, 2014, NEUROSCI LETT, V583, P16, DOI 10.1016/j.neulet.2014.09.013; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chapman PF, 1999, NAT NEUROSCI, V2, P271; Chateauvieux S, 2011, BIOCHEM PHARMACOL, V82, P1291, DOI 10.1016/j.bcp.2011.06.045; Chong ZZ, 2005, CURR NEUROVASC RES, V2, P387, DOI 10.2174/156720205774962683; Chong ZZ, 2003, J NEUROSCI RES, V71, P659, DOI 10.1002/jnr.10528; Craft S, 2012, ARCH NEUROL-CHICAGO, V69, P29, DOI 10.1001/archneurol.2011.233; Dey S, 2015, BRAIN RES, V1608, P14, DOI 10.1016/j.brainres.2015.02.052; DIGICAYLIOGLU M, 1995, P NATL ACAD SCI USA, V92, P3717, DOI 10.1073/pnas.92.9.3717; Dong H, 2004, NEUROSCIENCE, V127, P601, DOI 10.1016/j.neuroscience.2004.05.040; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; El-Kordi A, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-37; Frautschy SA, 1998, AM J PATHOL, V152, P307; Rodriguez JCG, 2009, THESCIENTIFICWORLDJO, V9, P970, DOI 10.1100/tsw.2009.103; Garcia-Rodriguez JC, 2012, CURR PSYCHOPHARMACOL, V1, P228, DOI DOI 10.2174/2211556011201030228]; Genc S, 2011, EXPERT OPIN DRUG DEL, V8, P19, DOI 10.1517/17425247.2011.540236; Goodnough LT, 2007, EXP HEMATOL, V35, P167, DOI 10.1016/j.exphem.2007.01.026; Hassouna I, 2016, MOL PSYCHIATR, V21, P1752, DOI 10.1038/mp.2015.212; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Jacobsen JS, 2006, P NATL ACAD SCI USA, V103, P5161, DOI 10.1073/pnas.0600948103; Jubinsky PT, 1997, BLOOD, V90, P1867, DOI 10.1182/blood.V90.5.1867; Jung JH, 2011, MOL CELLS, V32, P197, DOI 10.1007/s10059-011-0077-8; Kumral A, 2005, BIOL NEONATE, V87, P15, DOI 10.1159/000080490; Kumral A, 2004, BIOL NEONATE, V85, P51, DOI 10.1159/000074958; Lahmy V, 2013, NEUROPSYCHOPHARMACOL, V38, P1706, DOI 10.1038/npp.2013.70; Lanz TA, 2003, NEUROBIOL DIS, V13, P246, DOI 10.1016/S0969-9961(03)00079-2; Lee ST, 2012, J NEUROCHEM, V120, P115, DOI 10.1111/j.1471-4159.2011.07534.x; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Li F, 2006, CURR NEUROVASC RES, V3, P187, DOI 10.2174/156720206778018758; Li G, 2008, NEUROSCI LETT, V442, P143, DOI 10.1016/j.neulet.2008.07.007; Li WP, 2004, ANN NEUROL, V56, P767, DOI 10.1002/ana.20274; Ma R, 2009, NEUROPHARMACOLOGY, V56, P1027, DOI 10.1016/j.neuropharm.2009.02.006; Maiese K, 2004, TRENDS PHARMACOL SCI, V25, P577, DOI 10.1016/j.tips.2004.09.006; Maiese K, 2009, THESCIENTIFICWORLDJO, V9, P1072, DOI 10.1100/tsw.2009.121; Maurice T, 1996, BRAIN RES, V706, P181, DOI 10.1016/0006-8993(95)01032-7; Maurice T, 2013, J PSYCHOPHARMACOL, V27, P1044, DOI 10.1177/0269881113494939; McGeer Edith G., 2005, Current Drug Targets - CNS and Neurological Disorders, V4, P569, DOI 10.2174/156800705774322067; McGowan E, 2005, NEURON, V47, P191, DOI 10.1016/j.neuron.2005.06.030; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; Nadam J, 2007, NEUROBIOL DIS, V25, P412, DOI 10.1016/j.nbd.2006.10.009; Naert G, 2011, MOL CELL NEUROSCI, V46, P55, DOI 10.1016/j.mcn.2010.08.006; Nagai A, 2001, J NEUROPATH EXP NEUR, V60, P386, DOI 10.1093/jnen/60.4.386; Ott C, 2015, MOL MED, V21, P803, DOI 10.2119/molmed.2015.00192; Paxinos G., 2004, MOUSE BRAIN STEREOTA; Rabie T, 2008, PHYSIOLOGY, V23, P263, DOI 10.1152/physiol.00016.2008; Cruz YR, 2010, THESCIENTIFICWORLDJO, V10, P2288, DOI 10.1100/tsw.2010.215; Rothman SM, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.07.005; Sanchez PE, 2009, P NATL ACAD SCI USA, V106, P9848, DOI 10.1073/pnas.0901840106; Shang YC, 2012, AGING-US, V4, P187, DOI 10.18632/aging.100440; Sosa T. I., 2006, PHARM ONLINE, V1, P100; Stewart S, 2011, J ALZHEIMERS DIS, V26, P105, DOI 10.3233/JAD-2011-101827; Sun ZK, 2008, J NEUROSCI RES, V86, P3018, DOI 10.1002/jnr.21745; Tringali G, 2007, ENDOCRINOLOGY, V148, P4711, DOI 10.1210/en.2007-0431; van Woensel Matthias, 2013, Cancers (Basel), V5, P1020, DOI 10.3390/cancers5031020; VANPAPENDRECHT MAH, 1992, EUR J SURG, V158, P83; Wang L, 2004, STROKE, V35, P1732, DOI 10.1161/01.STR.0000132196.49028.a4; Webster SJ, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00088; Yazihan N, 2008, INJURY, V39, P1408, DOI 10.1016/j.injury.2008.03.010; Zussy C, 2011, AM J PATHOL, V179, P315, DOI 10.1016/j.ajpath.2011.03.021	74	31	31	0	16	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2017	55	1					231	248		10.3233/JAD-160500			18	Neurosciences	Neurosciences & Neurology	EB8WI	WOS:000387671600019	27662300				2021-06-18	
J	Wong, D; Sinclair, K; Seabrook, E; McKay, A; Ponsford, J				Wong, Dana; Sinclair, Kelly; Seabrook, Elizabeth; McKay, Adam; Ponsford, Jennie			Smartphones as assistive technology following traumatic brain injury: a preliminary study of what helps and what hinders	DISABILITY AND REHABILITATION			English	Article						Cognitive rehabilitation; smartphones; traumatic brain injury; memory aids; apps	ANXIETY STRESS SCALES; MEMORY IMPAIRMENTS; REHABILITATION; INDIVIDUALS; PEOPLE; TRIAL; AIDS; DEPRESSION; RECALL; TBI	Purpose: Smartphones have great potential as a convenient, multifunction tool to support cognition and independence following traumatic brain injury (TBI). However, there has been limited investigation of their helpful and less helpful aspects for people with TBI. We aimed to investigate patterns of smartphone use amongst individuals with TBI, identify potential barriers to use, and examine the relationships between smartphone use and daily functioning. Method: Twenty-nine participants with TBI and 33 non-injured participants completed the Smartphone Survey, and measures of subjective and objective cognitive functioning, mood, and community integration. Results: Smartphone use was equally common in both groups, and patterns of app use were similar. More participants with TBI than the comparison group listed using their smartphone as a memory aid as its main benefit. Difficulty in learning how to use the smartphone was identified by participants with TBI, however only 10% had been shown how to use it by a clinician. Those with poorer subjective cognitive function used memory/organisational apps more frequently; and higher communication app use with better social integration, in participants with TBI. Conclusions: These findings suggest that smartphones have potential in improving independence following TBI, but receiving support in using them is vital. Implications for Rehabilitation Smartphones are accessible, acceptable, convenient devices for most individuals with traumatic brain injury (TBI), and are perceived as a useful memory and organizational aid as well as having multiple other helpful functions. Use of communication apps such as text messages and social media is associated with better social and community integration in people with TBI. Direct instruction on how to use smartphone apps is more important for people with TBI than for non-injured individuals. Developers of apps designed for this population should prioritize ease of app use, large displays, and availability of technical support, while maintaining an engaging design and interface.	[Wong, Dana; Seabrook, Elizabeth; McKay, Adam; Ponsford, Jennie] Monash Univ, Sch Psychol Sci, 18 Innovat Walk, Clayton, Vic 3800, Australia; [Wong, Dana; Seabrook, Elizabeth; McKay, Adam; Ponsford, Jennie] Monash Univ, Monash Inst Cognit & Clin Neurosci, Melbourne, Vic, Australia; [Wong, Dana; Sinclair, Kelly; McKay, Adam; Ponsford, Jennie] Monash Epworth Rehabil Res Ctr, Melbourne, Vic, Australia; [McKay, Adam] Epworth Med Fdn, Melbourne, Vic, Australia	Wong, D (corresponding author), Monash Univ, Sch Psychol Sci, 18 Innovat Walk, Clayton, Vic 3800, Australia.	dana.wong@monash.edu	; McKay, Adam/M-6003-2017	Seabrook, Elizabeth/0000-0003-1844-127X; Wong, Dana/0000-0001-9619-1929; McKay, Adam/0000-0002-0479-7681	Centre of Excellence in Traumatic Brain Injury Research, National Trauma Research Institute, Alfred Hospital, Melbourne	This work was partly supported by the Centre of Excellence in Traumatic Brain Injury Research, National Trauma Research Institute, Alfred Hospital, Melbourne [N/A].	BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; CALLAHAN CD, 1994, J CLIN PSYCHOL MED S, V1, P261, DOI 10.1007/BF01989627; Chu Y, 2014, DISABIL REHABIL-ASSI, V9, P279, DOI 10.3109/17483107.2013.823631; Culley C, 2010, NEUROPSYCHOL REHABIL, V20, P103, DOI 10.1080/09602010902906926; Dahm J, 2013, J AFFECT DISORDERS, V151, P392, DOI 10.1016/j.jad.2013.06.011; De Joode EA, 2013, NEUROPSYCHOL REHABIL, V23, P133, DOI 10.1080/09602011.2012.726632; de Joode EA, 2012, BRAIN INJURY, V26, P1257, DOI 10.3109/02699052.2012.667590; Dowds MM, 2011, J HEAD TRAUMA REHAB, V26, P339, DOI 10.1097/HTR.0b013e3181f2bf1d; Evald L, 2015, NEUROPSYCHOL REHABIL, V25, P283, DOI 10.1080/09602011.2014.970557; Evans JJ, 2003, J INT NEUROPSYCH SOC, V9, P925, DOI 10.1017/S1355617703960127; Ferguson S, 2015, BRAIN INJURY, V29, P583, DOI 10.3109/02699052.2014.1002109; Fish J, 2007, NEUROPSYCHOLOGIA, V45, P1318, DOI 10.1016/j.neuropsychologia.2006.09.015; Gavett BE, 2012, ARCH CLIN NEUROPSYCH, V27, P125, DOI 10.1093/arclin/acr104; Gentry T, 2008, BRAIN INJURY, V22, P19, DOI 10.1080/02699050701810688; Gillespie A, 2012, J INT NEUROPSYCH SOC, V18, P1, DOI 10.1017/S1355617711001548; Hart T, 2004, J HEAD TRAUMA REHAB, V19, P351, DOI 10.1097/00001199-200409000-00001; Jamieson M, 2017, NEUROPSYCHOL REHABIL, V27, P919, DOI 10.1080/09602011.2015.1103760; Jamieson M, 2014, NEUROPSYCHOL REHABIL, V24, P419, DOI 10.1080/09602011.2013.825632; Lannin N, 2014, CLIN REHABIL, V28, P470, DOI 10.1177/0269215513512216; Lovibond SH., 2004, MANUAL DEPRESSION AN, V4th; Lund ML, 2011, DISABIL REHABIL-ASSI, V6, P402, DOI 10.3109/17483107.2011.574309; McDonald A, 2011, NEUROPSYCHOL REHABIL, V21, P784, DOI 10.1080/09602011.2011.598405; Rey A, 1964, EXAMEN CLIN PSYCHOL; Svoboda E, 2012, NEUROPSYCHOL REHABIL, V22, P408, DOI 10.1080/09602011.2011.652498; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Wilson BA, 2009, NEUROPSYCHOLOGICAL REHABILITATION: THEORY, MODELS, THERAPY AND OUTCOME, P1, DOI 10.1017/CBO9780511581083; Wilson BA, 1997, J NEUROL NEUROSUR PS, V63, P113, DOI 10.1136/jnnp.63.1.113; Wong D, 2013, BRAIN INJURY, V27, P1377, DOI 10.3109/02699052.2013.823662	28	31	31	1	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.		2017	39	23					2387	2394		10.1080/09638288.2016.1226434			8	Rehabilitation	Rehabilitation	FF8IJ	WOS:000409260200003	27748145				2021-06-18	
J	Simpson, S; Tan, H; Otahal, P; Taylor, B; Ponsonby, AL; Lucas, RM; Blizzard, L; Valery, PC; Lechner-Scott, J; Shaw, C; Williams, D; van der Mei, I				Simpson, S., Jr.; Tan, H.; Otahal, P.; Taylor, B.; Ponsonby, A. -L.; Lucas, R. M.; Blizzard, L.; Valery, P. C.; Lechner-Scott, J.; Shaw, C.; Williams, D.; van der Mei, I.		Ausimmune AusLong Investigators	Anxiety, depression and fatigue at 5-year review following CNS demyelination	ACTA NEUROLOGICA SCANDINAVICA			English	Article						multiple sclerosis; prevalence; anxiety; depression; fatigue; first demyelinating event	QUALITY-OF-LIFE; MULTIPLE-SCLEROSIS; PREVALENCE; DIAGNOSIS; DISTRESS; DISABILITY; SEVERITY; IMPACT; SCALE; TIME	BackgroundAnxiety and depression are common in multiple sclerosis (MS). We evaluated the prevalence and factors associated with anxiety, depression and fatigue at the 5-year review of a longitudinal cohort study following a first clinical diagnosis of CNS demyelination (FCD). MethodsCases with a FCD were recruited soon after diagnosis and followed annually thereafter. A variety of environmental, behavioural and clinical covariates were measured at five-year review. Anxiety and depression were measured using the Hospital Anxiety & Depression Scale (HADS), and fatigue by the Fatigue Severity Scale (FSS). ResultsOf the 236 cases, 40.2% had clinical anxiety (median HADS-A: 6.0), 16.0% had clinical depression (median HADS-D: 3.0), and 41.3% had clinical fatigue (median FSS: 4.56). The co-occurrence of all three symptoms was 3.76 times greater than expectation. Younger age, higher disability, concussion or other disease diagnosis were independently associated with a higher anxiety score; male sex, higher disability, being unemployed, less physical activity, and antidepressant and/or anxiolytic-sedative medication use were independently associated with a higher depression score. Higher disability, immunomodulatory medication use, other disease diagnosis and anxiolytic-sedative medication use were independently associated with having fatigue, while female sex, higher BMI, having had a concussion, being unemployed and higher disability were associated with a higher fatigue score. ConclusionThese results support previous findings of the commonality of anxiety, depression and fatigue in established MS and extend this to post-FCD and early MS cases. The clustering of the three symptoms indicates that they may share common antecedents.	[Simpson, S., Jr.; Taylor, B.; Blizzard, L.; van der Mei, I.] Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia; [Tan, H.; Otahal, P.] Univ Tasmania, Sch Med, Hobart, Tas, Australia; [Ponsonby, A. -L.] Univ Melbourne, Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Lucas, R. M.] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia; [Valery, P. C.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia; [Lechner-Scott, J.; Williams, D.] John Hunter Hosp, Dept Neurol, New Lambton, NSW, Australia; [Lechner-Scott, J.; Williams, D.] Univ Newcastle, Callaghan, NSW, Australia; [Shaw, C.] Deakin Univ, Sch Med, Fac Hlth, Geelong, Vic, Australia	van der Mei, I (corresponding author), Univ Tasmania, Menzies Inst Med Res, Hobart, Tas, Australia.	ingrid.vandermei@utas.edu.au	Valery, Patricia/AAV-5448-2020; Simpson, Steve Jr/J-2454-2013; Ponsonby, Anne-Louise/AAE-4351-2019	Valery, Patricia/0000-0002-8823-3006; Simpson, Steve Jr/0000-0001-6521-3056; Dear, Keith/0000-0002-0788-7404; Ponsonby, Anne-Louise/0000-0002-6581-3657; Otahal, Petr/0000-0003-4042-1769; Lucas, Robyn/0000-0003-2736-3541	National Multiple Sclerosis Society of the United States of AmericaNational Multiple Sclerosis Society [RG3364A1/2]; National Health and Medical Research Council of AustraliaNational Health and Medical Research Council of AustraliaUK Research & Innovation (UKRI)Medical Research Council UK (MRC) [APP316901, 224215]; MS Research Australia Postdoctoral Research Fellowship; Australian National Health and Medical Research Council (Career Development Fellowship)National Health and Medical Research Council of Australia [1083090]; Australian Research CouncilAustralian Research Council	The Ausimmune and AusLong Studies were funded by the National Multiple Sclerosis Society of the United States of America (award RG3364A1/2) and the National Health and Medical Research Council of Australia (APP316901 and 224215).; SSJ is supported by an MS Research Australia Postdoctoral Research Fellowship.; PCV was supported by the Australian National Health and Medical Research Council (Career Development Fellowship #1083090).; IvdM is supported by an Australian Research Council Future Fellowship.	Aronson KJ, 1997, NEUROLOGY, V48, P74, DOI 10.1212/WNL.48.1.74; Auty A, 1998, CAN J NEUROL SCI, V25, P31; Bakshi R, 2000, MULT SCLER, V6, P181, DOI 10.1191/135245800701566052; Black LJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135478; Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7; Dahl OP, 2009, MULT SCLER J, V15, P1495, DOI 10.1177/1352458509351542; Di Legge S, 2003, MULT SCLER J, V9, P302, DOI 10.1191/1352458503ms921oa; Giordano A, 2011, J NEUROL SCI, V307, P86, DOI 10.1016/j.jns.2011.05.008; Hakim EA, 2000, DISABIL REHABIL, V22, P288; Janssens ACJW, 2006, MULT SCLER J, V12, P794, DOI 10.1177/1352458506070935; Janssens ACJW, 2003, ACTA NEUROL SCAND, V108, P389, DOI 10.1034/j.1600-0404.2003.00166.x; Johansson S, 2008, J NEUROL NEUROSUR PS, V79, P454, DOI 10.1136/jnnp.2007.121129; Johnston SC, 2001, AM J EPIDEMIOL, V154, P276, DOI 10.1093/aje/154.3.276; Jones KH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041910; Kilkkinen A, 2007, AUST J RURAL HEALTH, V15, P114, DOI 10.1111/j.1440-1584.2007.00863.x; Knippenberg S, 2011, ACTA NEUROL SCAND, V124, P171, DOI 10.1111/j.1600-0404.2010.01447.x; Kroencke DC, 2001, MULT SCLER, V7, P237, DOI 10.1177/135245850100700405; KRUPP LB, 1989, ARCH NEUROL-CHICAGO, V46, P1121, DOI 10.1001/archneur.1989.00520460115022; Lucas RM, 2009, CANCER EPIDEM BIOMAR, V18, P2887, DOI 10.1158/1055-9965.EPI-09-0191; Mattarozzi K, 2012, INT J CLIN PRACT, V66, P504, DOI 10.1111/j.1742-1241.2012.02912.x; Moore P, 2012, J PSYCHOSOM RES, V73, P272, DOI 10.1016/j.jpsychores.2012.08.004; Neuberger G.B., 2003, ARTHRITIS RHEUM, V49, pS175, DOI [DOI 10.1002/art.11405, 10.1002/art.11405, DOI 10.1002/ART.11405]; Nortvedt MW, 1999, NEUROLOGY, V53, P1098, DOI 10.1212/WNL.53.5.1098; Polman CH, 2005, ANN NEUROL, V58, P840, DOI 10.1002/ana.20703; Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366; Putzki N, 2008, EUR NEUROL, V59, P136, DOI 10.1159/000111876; Shnek ZM, 1997, ANN BEHAV MED, V19, P287, DOI 10.1007/BF02892293; Simioni S, 2007, SWISS MED WKLY, V137, P496; SKEGG K, 1988, PSYCHOL MED, V18, P733, DOI 10.1017/S0033291700008436; Smith SJ, 2000, CLIN REHABIL, V14, P50, DOI 10.1191/026921500676724210; Solari A, 2001, NEUROL SCI, V22, P307, DOI 10.1007/s10072-001-8173-8; SULLIVAN MJL, 1995, CAN J NEUROL SCI, V22, P228, DOI 10.1017/S0317167100039895; Tellez N, 2006, J NEUROL, V253, P1466, DOI 10.1007/s00415-006-0247-3; Wood B, 2013, MULT SCLER J, V19, P217, DOI 10.1177/1352458512450351; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	35	31	31	0	22	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	DEC	2016	134	6					403	413		10.1111/ane.12554			11	Clinical Neurology	Neurosciences & Neurology	EA6QT	WOS:000386754600002	26756925	Bronze			2021-06-18	
J	Feather-Schussler, DN; Ferguson, TS				Feather-Schussler, Danielle N.; Ferguson, Tanya S.			A Battery of Motor Tests in a Neonatal Mouse Model of Cerebral Palsy	JOVE-JOURNAL OF VISUALIZED EXPERIMENTS			English	Article						Medicine; Issue 117; Behavior; neonatal mouse; motor deficits; cerebral palsy; hypoxia; ischemia; inflammation; neonatal motor tests	SPINAL-CORD; ADULT; INJURY; BEHAVIOR; BRAIN; RATS	As the sheer number of transgenic mice strains grow and rodent models of pediatric disease increase, there is an expanding need for a comprehensive, standardized battery of neonatal mouse motor tests. These tests can validate injury or disease models, determine treatment efficacy and/or assess motor behaviors in new transgenic strains. This paper presents a series of neonatal motor tests to evaluate general motor function, including ambulation, hindlimb foot angle, surface righting, negative geotaxis, front-and hindlimb suspension, grasping reflex, four limb grip strength and cliff aversion. Mice between the ages of post-natal day 2 to 14 can be used. In addition, these tests can be used for a wide range of neurological and neuromuscular pathologies, including cerebral palsy, hypoxic-ischemic encephalopathy, traumatic brain injury, spinal cord injury, neurodegenerative diseases, and neuromuscular disorders. These tests can also be used to determine the effects of pharmacological agents, as well as other types of therapeutic interventions. In this paper, motor deficits were evaluated in a novel neonatal mouse model of cerebral palsy that combines hypoxia, ischemia and inflammation. Forty-eight hours after injury, five tests out of the nine showed significant motor deficits: ambulation, hindlimb angle, hindlimb suspension, four limb grip strength, and grasping reflex. These tests revealed weakness in the hindlimbs, as well as fine motor skills such as grasping, which are similar to the motor deficits seen in human cerebral palsy patients.	[Feather-Schussler, Danielle N.; Ferguson, Tanya S.] Temple Univ, Lewiz Katz Sch Med, Dept Med Genet & Mol Biochem, Philadelphia, PA 19122 USA; [Feather-Schussler, Danielle N.; Ferguson, Tanya S.] Shriners Hosp Pediat Res Ctr, Philadelphia, PA 19140 USA	Ferguson, TS (corresponding author), Temple Univ, Lewiz Katz Sch Med, Dept Med Genet & Mol Biochem, Philadelphia, PA 19122 USA.; Ferguson, TS (corresponding author), Shriners Hosp Pediat Res Ctr, Philadelphia, PA 19140 USA.	tanyaf@temple.edu			Shriners Hospitals	We would like to thank everyone at Shriners Hospital Pediatric Research Center, in particular Dr. Mickey Seltzer, of whom without his support, this work would not have been funded. In addition, we would like to thank Isha Srivastava, who contributed to early data collection and Amy He, who helped with the figures. This study was funded by Shriners Hospitals for Children. No funding source played a role in experimental design or decision to submit the paper for publication.	Balasubramaniam J., 2005, J CEREBR BLOOD F MET; BARRETT CP, 1984, EXP NEUROL, V84, P374, DOI 10.1016/0014-4886(84)90234-6; Carlson G., 2011, EXPT PROTOCOLS SMA A; Corti S., 2014, TREAT NMD EXPT PROTO; Corti S, 2008, J CLIN INVEST, V118, P3316, DOI 10.1172/JCI35432; Craig A, 2003, EXP NEUROL, V181, P231, DOI 10.1016/S0014-4886(03)00032-3; Cusick CG, 1996, PROG BRAIN RES, V108, P379, DOI 10.1016/S0079-6123(08)62553-4; El-Khodor B. F., 2011, EXPT PROTOCOLS SMA A; El-Khodor BF, 2008, EXP NEUROL, V212, P29, DOI 10.1016/j.expneurol.2008.02.025; Fernandez-Lopez D, 2012, J NEUROSCI, V32, P9588, DOI 10.1523/JNEUROSCI.5977-11.2012; FOX WM, 1965, ANIM BEHAV, V13, P234, DOI 10.1016/0003-3472(65)90041-2; Futagi Y, 2012, INT J PEDIAT, V2012, DOI 10.1155/2012/191562; Gordon AM, 1999, DEV MED CHILD NEUROL, V41, P586, DOI 10.1017/S0012162299001231; Grondard C, 2005, J NEUROSCI, V25, P7615, DOI 10.1523/JNEUROSCI.1245-05.2005; Heyser Charles J, 2004, Curr Protoc Neurosci, VChapter 8, DOI 10.1002/0471142301.ns0818s25; Hill JM, 2008, PROCEEDINGS OF THE 3RD FRONTIERS IN BIOMEDICAL DEVICES CONFERENCE - 2008, P39; Nakamura M, 2001, EXP NEUROL, V169, P407, DOI 10.1006/exnr.2001.7670; Shen Y., 2010, J VIS EXP; Shen Y, 2012, J NEUROSCI RES, V90, P105, DOI 10.1002/jnr.22722; Tremml P, 1998, BEHAV BRAIN RES, V95, P65, DOI 10.1016/S0166-4328(97)00211-8; Venerosi A, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-12; Villapol S, 2008, NEUROSCIENTIST, V14, P339, DOI 10.1177/1073858408316003; WAHLSTEN D, 1974, BRAIN RES, V72, P251, DOI 10.1016/0006-8993(74)90863-4; Widenfalk J, 2001, J NEUROSCI, V21, P3457, DOI 10.1523/JNEUROSCI.21-10-03457.2001; WILLIAMS E, 1953, BEHAVIOUR, V6, P35, DOI 10.1163/156853954X00031; Yu Y., 2016, COMB SECT M IN PRESS	26	31	31	0	4	JOURNAL OF VISUALIZED EXPERIMENTS	CAMBRIDGE	1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA	1940-087X			JOVE-J VIS EXP	J. Vis. Exp.	NOV	2016		117							e53569	10.3791/53569			12	Multidisciplinary Sciences	Science & Technology - Other Topics	EQ1QX	WOS:000397845800005	27842358	Bronze, Green Published			2021-06-18	
J	Calcagnile, O; Anell, A; Unden, J				Calcagnile, Olga; Anell, Anders; Unden, Johan			The addition of S100B to guidelines for management of mild head injury is potentially cost saving	BMC NEUROLOGY			English	Article							COMPUTED-TOMOGRAPHY; BRAIN-INJURY; SERUM-LEVELS; ADULTS; TRAUMA; STRATEGIES; PROTEIN; S-100B; RULE	Background: Mild traumatic brain injury (TBI) is associated with substantial costs due to over-triage of patients to computed tomography (CT) scanning, despite validated decision rules. Serum biomarker S100B has shown promise for safely omitting CT scans but the economic impact from clinical use has never been reported. In 2007, S100B was adapted into the existing Scandinavian management guidelines in Halmstad, Sweden, in an attempt to reduce CT scans and save costs. Methods: Consecutive adult patients with mild TBI (GCS 14-15, loss of consciousness and/or amnesia), managed with the aid of S100B, were prospectively included in this study. Patients were followed up after 3 months with a standardized questionnaire. Theoretical and actual cost differences were calculated. Results: Seven hundred twenty-six patients were included and 29 (4.7 %) showed traumatic abnormalities on CT. No further significant intracranial complications were discovered on follow-up. Two hundred twenty-nine patients (27 %) had normal S100B levels and 497 patients (73 %) showed elevated S100B levels. Over-triage occurred in 73 patients (32 %) and under-triage occurred in 39 patients (7 %). No significant intracranial complications were missed. The introduction of S100B could save 71 (sic) per patient if guidelines were strictly followed. As compliance to the guidelines was not perfect, the actual cost saving was 39 (sic) per patient. Conclusion: Adding S100B to existing guidelines for mild TBI seems to reduce CT usage and costs, especially if guideline compliance could be increased.	[Calcagnile, Olga] Halmstad Reg Hosp, Dept Paediat Med, Halmstad, Sweden; [Calcagnile, Olga] Hallandssjukhus Halmstad, Barnkliniken, S-30185 Halmstad, Sweden; [Anell, Anders] Lund Univ, Inst Econ Res, Sch Econ & Management, Lund, Sweden; [Unden, Johan] Skane Univ Hosp, Dept Anaesthesiol & Intens Care, Malmo, Sweden	Calcagnile, O (corresponding author), Halmstad Reg Hosp, Dept Paediat Med, Halmstad, Sweden.; Calcagnile, O (corresponding author), Hallandssjukhus Halmstad, Barnkliniken, S-30185 Halmstad, Sweden.	olga.calcagnile@regionhalland.se					Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Bouvier D, 2009, ANN BIOL CLIN-PARIS, V67, P425, DOI 10.1684/abc.2009.0347; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; Morton MJ, 2012, ANN EMERG MED; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; Norlund A, 2006, BMJ-BRIT MED J, V333, P469, DOI 10.1136/bmj.38918.659120.4F; Pandor A, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15270; Ruan S, 2009, J NEUROTRAUM, V26, P1655, DOI [10.1089/neu.2009.0928, 10.1089/neu.2009-0928]; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Smits M, 2010, RADIOLOGY, V254, P532, DOI 10.1148/radiol.2541081672; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Stein SC, 2009, ANN EMERG MED, V53, P180, DOI 10.1016/j.annemergmed.2008.01.002; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Yates DW, 2003, EMERG MED J, V20, P117, DOI 10.1136/emj.20.2.117; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	22	31	31	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2377			BMC NEUROL	BMC Neurol.	OCT 20	2016	16								200	10.1186/s12883-016-0723-z			7	Clinical Neurology	Neurosciences & Neurology	DZ7ZK	WOS:000386087300002	27765016	DOAJ Gold, Green Published			2021-06-18	
J	Bu, W; Ren, HL; Deng, YP; Del Mar, N; Guley, NM; Moore, BM; Honig, MG; Reiner, A				Bu, Wei; Ren, Huiling; Deng, Yunping; Del Mar, Nobel; Guley, Natalie M.; Moore, Bob M.; Honig, Marcia G.; Reiner, Anton			Mild Traumatic Brain Injury Produces Neuron Loss That Can Be Rescued by Modulating Microglial Activation Using a CB2 Receptor Inverse Agonist	FRONTIERS IN NEUROSCIENCE			English	Article						traumatic brain injury; neuron loss; neuron rescue; cerebral cortex; striatum; basolateral amygdala; cannabinoid type-2 receptor inverse agonist	RAT BASOLATERAL AMYGDALA; CONDITIONED FEAR; BASAL GANGLIA; AXONAL INJURY; CELL-DEATH; CONTAINING INTERNEURONS; GABAERGIC INTERNEURONS; INHIBITORY CIRCUITS; GLUTAMATE-RECEPTOR; CORPUS-CALLOSUM	We have previously reported that mild TBI created by focal left-side cranial blast in mice produces widespread axonal injury, microglial activation, and a variety of functional deficits. We have also shown that these functional deficits are reduced by targeting microglia through their cannabinoid type-2 (CB2) receptors using 2-week daily administration of the CB2 inverse agonist SMM-189. CB2 inverse agonists stabilize the G-protein coupled CB2 receptor in an inactive conformation, leading to increased phosphorylation and nuclear translocation of the cAMP response element binding protein (CREB), and thus bias activated microglia from a pro-inflammatory M1 to a pro-healing M2 state. In the present study, we showed that SMM-189 boosts nuclear pCREB levels in microglia in several brain regions by 3 days after TBI, by using pCREB/CD68 double immunofluorescent labeling. Next, to better understand the basis of motor deficits and increased fearfulness after TBI, we used unbiased stereological methods to characterize neuronal loss in cortex, striatum, and basolateral amygdala (BLA) and assessed how neuronal loss was affected by SMM-189 treatment. Our stereological neuron counts revealed a 20% reduction in cortical and 30% reduction in striatal neurons bilaterally at 2-3 months post blast, with SMM-189 yielding about 50% rescue. Loss of BLA neurons was restricted to the blast side, with 33% of Thy1+ fear-suppressing pyramidal neurons and 47% of fear-suppressing parvalbuminergic (PARV) interneurons lost, and Thy1-negative fear-promoting pyramidal neurons not significantly affected. SMM-189 yielded 50-60% rescue of Thy1+ and PARV neuron loss in BLA. Thus, fearfulness after mild TBI may result from the loss of fear-suppressing neuron types in BLA, and SMM-189 may reduce fearfulness by their rescue. Overall, our findings indicate that SMM-189 rescues damaged neurons and thereby alleviates functional deficits resulting from TBI, apparently by selectively modulating microglia to the beneficial M2 state. CB2 inverse agonists thus represent a promising therapeutic approach for mitigating neuroinflammation and neurodegeneration.	[Bu, Wei; Ren, Huiling; Deng, Yunping; Del Mar, Nobel; Guley, Natalie M.; Honig, Marcia G.; Reiner, Anton] Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA; [Moore, Bob M.] Univ Tennessee, Ctr Hlth Sci, Dept Pharmaceut Sci, Memphis, TN 38163 USA; [Reiner, Anton] Univ Tennessee, Ctr Hlth Sci, Dept Ophthalmol, Memphis, TN 38163 USA	Reiner, A (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Anat & Neurobiol, Memphis, TN 38163 USA.; Reiner, A (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Ophthalmol, Memphis, TN 38163 USA.	areiner@uthsc.edu	Reiner, Anton/AAG-8860-2020	Reiner, Anton/0000-0002-2146-5232	Neuroscience Institute at UTHSC; Methodist Hospitals Endowed Professorship in Neuroscience; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-081370]; College of Pharmacy at UTHSC; Office of the Dean of the College of Medicine at UTHSC	Supported by the Neuroscience Institute and the Office of the Dean of the College of Medicine, both at UTHSC, The Methodist Hospitals Endowed Professorship in Neuroscience (AR), NIH grant NS-081370 (AR), and the College of Pharmacy at UTHSC (BM).	Almeida-Suhett CP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102627; Amenta PS, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0191-6; Amenta PS, 2012, J NEUROSCI RES, V90, P2293, DOI 10.1002/jnr.23114; Ashton JC, 2007, CURR NEUROPHARMACOL, V5, P73, DOI 10.2174/157015907780866884; Atwood BK, 2012, PROG NEURO-PSYCHOPH, V38, P16, DOI 10.1016/j.pnpbp.2011.12.001; Avramescu S, 2009, J NEUROTRAUM, V26, P799, DOI 10.1089/neu.2008.0739; Baek JH, 2013, J NEUROSCI METH, V216, P87, DOI 10.1016/j.jneumeth.2013.03.021; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bales JW, 2011, EXP NEUROL, V229, P300, DOI 10.1016/j.expneurol.2011.02.013; Bareyre FM, 2005, NAT MED, V11, P1355, DOI 10.1038/nm1331; Bartolini G, 2013, NEURON, V79, P849, DOI 10.1016/j.neuron.2013.08.014; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Benito C, 2003, J NEUROSCI, V23, P11136; Brown GC, 2015, BRAIN RES, V1628, P288, DOI 10.1016/j.brainres.2015.08.031; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Ciocchi S, 2010, NATURE, V468, P277, DOI 10.1038/nature09559; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; DeFelipe J, 2013, NAT REV NEUROSCI, V14, P202, DOI 10.1038/nrn3444; Deng YP, 2007, J CHEM NEUROANAT, V33, P167, DOI 10.1016/j.jchemneu.2007.02.008; Deng YP, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00198; Deng YP, 2015, FRONT SYST NEUROSCI, V9, DOI 10.3389/fnsys.2015.00051; Donat CK, 2014, ACTA NEUROBIOL EXP, V74, P197; Ehrlich I, 2009, NEURON, V62, P757, DOI 10.1016/j.neuron.2009.05.026; Elliott MB, 2011, J NEUROTRAUM, V28, P973, DOI 10.1089/neu.2010.1672; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Firsching R, 2012, J NEUROL SURG PART A, V73, P204, DOI 10.1055/s-0032-1304815; Fujinaga M, 2010, BIOORG MED CHEM LETT, V20, P1565, DOI 10.1016/j.bmcl.2010.01.074; Gelderblom H, 2001, EUR J CANCER, V37, P1590, DOI 10.1016/S0959-8049(01)00171-X; Godavarthi SK, 2014, J NEUROCHEM, V130, P444, DOI 10.1111/jnc.12726; Goddeyne C, 2015, J NEUROPHYSIOL, V113, P3268, DOI 10.1152/jn.00970.2014; Gorski JA, 2002, J NEUROSCI, V22, P6309; Guley NH, 2016, J NEUROTRAUM, V33, P403, DOI 10.1089/neu.2015.3886; Gupta RK, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00059; Hattox AM, 2007, J NEUROPHYSIOL, V98, P3330, DOI 10.1152/jn.00397.2007; Haubensak W, 2010, NATURE, V468, P270, DOI 10.1038/nature09553; Heck D. H., 2015, SOC NEUR ABST, V589, P13; Heldt SA, 2012, TRANSL PSYCHIAT, V2, DOI 10.1038/tp.2012.101; Heldt SA, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00002; Herry C, 2008, NATURE, V454, P600, DOI 10.1038/nature07166; Herry C, 2014, NAT NEUROSCI, V17, P1644, DOI 10.1038/nn.3869; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Janak PH, 2015, NATURE, V517, P284, DOI 10.1038/nature14188; Jasnow AM, 2013, J NEUROSCI, V33, P10396, DOI 10.1523/JNEUROSCI.5539-12.2013; Jayakumar AR, 2016, NEUROCHEM RES, V41, P307, DOI 10.1007/s11064-015-1801-0; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Kallakuri S, 2012, BRAIN RES, V1452, P29, DOI 10.1016/j.brainres.2012.02.065; Kelley BJ, 2007, J NEUROPATH EXP NEUR, V66, P989, DOI 10.1097/NEN.0b013e3181588245; Koliatsos VE, 2011, J NEUROPATH EXP NEUR, V70, P399, DOI 10.1097/NEN.0b013e3182189f06; Kordower JH, 2001, ANN NEUROL, V49, P202, DOI 10.1002/1531-8249(20010201)49:2<202::AID-ANA40>3.3.CO;2-V; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Laksari K, 2014, J MECH BEHAV BIOMED, V32, P132, DOI 10.1016/j.jmbbm.2013.12.021; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Leunissen I, 2014, CORTEX, V51, P67, DOI 10.1016/j.cortex.2013.10.009; Liu Y., 2016, SOC NEUR ABST, V607, P14; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Luthi A, 2014, NAT NEUROSCI, V17, P1635, DOI 10.1038/nn.3849; Lunn CA, 2008, BRIT J PHARMACOL, V153, P226, DOI 10.1038/sj.bjp.0707480; Lunn CA, 2006, J PHARMACOL EXP THER, V316, P780, DOI 10.1124/JPET.105.093500; Mac Donald CL, 2011, NEW ENGL J MED, V364, P2091, DOI 10.1056/NEJMoa1008069; Mascagni F, 2003, BRAIN RES, V976, P171, DOI 10.1016/S0006-8993(03)02625-8; Maxwell WL, 2010, BRAIN, V133, P139, DOI 10.1093/brain/awp264; McGinn Melissa J, 2015, Handb Clin Neurol, V127, P67, DOI 10.1016/B978-0-444-52892-6.00005-2; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Mechoulam R, 2002, Sci STKE, V2002, pre5, DOI 10.1126/stke.2002.129.re5; Meyer MJ, 2010, BRAIN INJURY, V24, P706, DOI 10.3109/02699051003692126; Morey RA, 2013, HUM BRAIN MAPP, V34, P2986, DOI 10.1002/hbm.22117; Morozov A, 2011, J NEUROSCI, V31, P339, DOI 10.1523/JNEUROSCI.5537-10.2011; Muller JF, 2007, J COMP NEUROL, V500, P513, DOI 10.1002/cne.21185; Muller JF, 2003, J COMP NEUROL, V456, P217, DOI 10.1002/cne.10435; Muller JF, 2006, J COMP NEUROL, V494, P635, DOI 10.1002/cne.20832; Myers KM, 2006, LEARN MEMORY, V13, P216, DOI 10.1101/lm.119806; Namjoshi DR, 2013, DIS MODEL MECH, V6, P1325, DOI 10.1242/dmm.011320; Neervannan S, 2006, EXPERT OPIN DRUG MET, V2, P715, DOI 10.1517/17425255.2.5.715; Ozdinler PH, 2011, J NEUROSCI, V31, P4166, DOI 10.1523/JNEUROSCI.4184-10.2011; Pare D, 2004, J NEUROPHYSIOL, V92, P1, DOI 10.1152/jn.00153.2004; Patterson ZR, 2012, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00058; Perez-Polo JR, 2013, J NEUROTRAUM, V30, P727, DOI 10.1089/neu.2012.2650; PETERS A, 1985, J COMP NEUROL, V238, P263, DOI 10.1002/cne.902380303; Petras JM, 1997, TOXICOLOGY, V121, P41, DOI 10.1016/S0300-483X(97)03654-8; Presley C, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.159; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Rainnie DG, 2006, J COMP NEUROL, V498, P142, DOI 10.1002/cne.21049; Redell JB, 2007, NEUROSCI LETT, V413, P36, DOI 10.1016/j.neulet.2006.11.060; Reiner A, 1998, BRAIN RES REV, V28, P235, DOI 10.1016/S0165-0173(98)00016-2; Reiner A, 2012, NEUROBIOL DIS, V47, P75, DOI 10.1016/j.nbd.2012.03.025; Reiner A, 2015, INT J MOL SCI, V16, P758, DOI 10.3390/ijms16010758; Risdall JE, 2011, PHILOS T R SOC B, V366, P241, DOI 10.1098/rstb.2010.0230; Rosenkranz JA, 2001, J NEUROSCI, V21, P4090, DOI 10.1523/JNEUROSCI.21-11-04090.2001; Sajja VSSS, 2015, SCI REP-UK, V5, DOI 10.1038/srep15075; Sajja VSSS, 2013, J NEUROSCI RES, V91, P593, DOI 10.1002/jnr.23179; Schomberg D, 2012, EXP NEUROL, V234, P262, DOI 10.1016/j.expneurol.2011.12.021; Shi L, 2004, J COMP NEUROL, V478, P282, DOI 10.1002/cne.20303; Shitaka Y., 2001, J NEUROPATHOL EXP NE, V70, P551, DOI DOI 10.1097/NEN.0B013E31821F891F; Smith C, 2013, NEUROPATH APPL NEURO, V39, P654, DOI 10.1111/nan.12008; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Stella N, 2010, GLIA, V58, P1017, DOI 10.1002/glia.20983; Tam WY, 2014, SCI REP-UK, V4, DOI 10.1038/srep07279; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Tovar-y-Romo LB, 2016, J NEUROCHEM, V136, P13, DOI 10.1111/jnc.13362; Truitt WA, 2009, NEUROSCIENCE, V160, P284, DOI 10.1016/j.neuroscience.2009.01.083; Tsuda S, 2016, NEUROREPORT, V27, P724, DOI 10.1097/WNR.0000000000000598; Tzekov R, 2014, J NEUROPATH EXP NEUR, V73, P345, DOI 10.1097/NEN.0000000000000059; Unal-Cevik I, 2004, BRAIN RES, V1015, P169, DOI 10.1016/j.brainres.2004.04.032; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wolff SBE, 2014, NATURE, V509, P453, DOI 10.1038/nature13258; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xu LY, 2016, EXP NEUROL, V275, P436, DOI 10.1016/j.expneurol.2014.11.004; Yttri EA, 2016, NATURE, V533, P402, DOI 10.1038/nature17639; Zakaria N, 2012, BRAIN RES, V1467, P81, DOI 10.1016/j.brainres.2012.05.046; Zhang L, 2015, INT J MED SCI, V12, P288, DOI 10.7150/ijms.10527	116	31	32	0	12	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	OCT 6	2016	10								449	10.3389/fnins.2016.00449			17	Neurosciences	Neurosciences & Neurology	DY7FI	WOS:000385294600001	27766068	DOAJ Gold, Green Published			2021-06-18	
J	Makdissi, M; Davis, G				Makdissi, Michael; Davis, Gavin			The reliability and validity of video analysis for the assessment of the clinical signs of concussion in Australian football	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Brain concussion; Football; Diagnosis; Sensitivity and specificity; Video analysis	HOCKEY LEAGUE NHL	Objectives: The objective of this study was to determine the reliability and validity of identifying clinical signs of concussion using video analysis in Australian football. Design: Prospective cohort study. Methods: All impacts and collisions potentially resulting in a concussion were identified during 2012 and 2013 Australian Football League seasons. Consensus definitions were developed for clinical signs associated with concussion. For intra- and inter-rater reliability analysis, two experienced clinicians independently assessed 102 randomly selected videos on two occasions. Sensitivity, specificity, positive and negative predictive values were calculated based on the diagnosis provided by team medical staff. Results: 212 incidents resulting in possible concussion were identified in 414 Australian Football League games. The intra-rater reliability of the video-based identification of signs associated with concussion was good to excellent. Inter-rater reliability was good to excellent for impact seizure, slow to get up, motor incoordination, ragdoll appearance (2 of 4 analyses), clutching at head and facial injury. Inter-rater reliability for loss of responsiveness and blank and vacant look was only fair and did not reach statistical significance. The feature with the highest sensitivity was slow to get up (87%), but this sign had a low specificity (19%). Other video signs had a high specificity but low sensitivity. Blank and vacant look (100%) and motor incoordination (81%) had the highest positive predictive value. Conclusions: Video analysis may be a useful adjunct to the side-line assessment of a possible concussion. Video analysis however should not replace the need for a thorough multimodal clinical assessment. (C) 2016 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Makdissi, Michael; Davis, Gavin] Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Austin Campus, Melbourne, Vic, Australia; [Makdissi, Michael] Federat Univ, ACRISP, Mt Helen, Australia; [Makdissi, Michael] La Trobe Univ, Sch Allied Hlth, Bundoora, Vic 3086, Australia; [Davis, Gavin] Austin Hosp, Dept Neurosurg, Heidelberg, Vic, Australia; [Davis, Gavin] Cabrini Hlth, Dept Neurosurg, Malvern, Australia	Makdissi, M (corresponding author), Melbourne Brain Ctr, Florey Inst Neurosci & Mental Hlth, Austin Campus, Melbourne, Vic, Australia.; Makdissi, M (corresponding author), Federat Univ, ACRISP, Mt Helen, Australia.; Makdissi, M (corresponding author), La Trobe Univ, Sch Allied Hlth, Bundoora, Vic 3086, Australia.	makdissi@unimelb.edu.au					Davis GA, 2015, NEUROSURGERY, V76, P643, DOI 10.1227/NEU.0000000000000722; Gardner AJ, 2015, BRAIN INJURY, V17, P1; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Hutchison MG, 2015, BRIT J SPORT MED, V49, P547, DOI 10.1136/bjsports-2013-092234; Hutchison MG, 2014, BRIT J SPORT MED, V48, P125, DOI 10.1136/bjsports-2012-092059; Makdissi M, 2016, J SCI MED SPORT, V19, P859, DOI 10.1016/j.jsams.2016.02.015; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; Makdissi M, 2009, AM J SPORT MED, V37, P877, DOI 10.1177/0363546508328118; McCrea M, 2013, BRIT J SPORT MED, V47, P272, DOI 10.1136/bjsports-2013-092145; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory PR, 2000, NEUROLOGY, V54, P1488, DOI 10.1212/WNL.54.7.1488; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Putukian M, 2013, BRIT J SPORT MED, V47, P285, DOI 10.1136/bjsports-2013-092158	14	31	31	1	10	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	OCT	2016	19	10					859	863		10.1016/j.jsams.2016.02.015			5	Sport Sciences	Sport Sciences	DY2SZ	WOS:000384943600017	27009774				2021-06-18	
J	Maung, AA; Bhattacharya, B; Schuster, KM; Davis, KA				Maung, Adrian A.; Bhattacharya, Bishwajit; Schuster, Kevin M.; Davis, Kimberly A.			Trauma patients on new oral anticoagulation agents have lower mortality than those on warfarin	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	29th Annual Scientific Meeting of the Eastern-Association-for-the-Surgery-of-Trauma	JAN 09-16, 2016	San Antonio, TX	Eastern Assoc Surg Trauma		Warfarin; trauma; dabigatran; apixaban; rivaroxaban; outcomes; mortality	PREINJURY WARFARIN; ATRIAL-FIBRILLATION; RISK; DABIGATRAN; REVERSAL; OUTCOMES	BACKGROUND Although anticoagulation with warfarin has been associated with increased risk of adverse outcomes after trauma, the effects of the new oral agents (NOA) such as dabigatran, apixaban, rivaroxaban are not yet well characterized. METHODS A retrospective review of a level 1 trauma center database identified all patients aged 50 admitted after trauma during a 24 month period starting September 2013. Demographics, including preadmission anticoagulation agents, injuries, hospital course and outcomes were abstracted from the electronic medical record. RESULT Over the 24-month period, 3,392 patients were admitted; 112 (3.3%) were anticoagulated with NOA and 373 (11.0%) with warfarin with a trend toward increasing utilization of the new agents compared with warfarin over that period. Although comparable in age, injury severity scores, and mechanism of injury, patients anticoagulated with warfarin had both a higher overall mortality (10.9%) compared with the NOA (6.25%) and the non-anticoagulated control (5.5%) groups (p < 0.001) as well as a higher trauma-related mortality (9.0%) versus NOA (2.8%) and control (3.7%) groups (p < 0.001). Patients on warfarin or NOA were admitted to intensive care unit or step down unit more frequently than control patients. (45.0% and 41.9% vs. 35.7% respectively; p < 0.001). The incidence of traumatic brain injury was similar among the three groups. Although it did not reach statistical significance, trauma-specific mortality in the traumatic brain injury subset was higher in the warfarin group (19.3%) than the NOA (16.7%) or control (10.9%) groups (p = 0.08). In a multivariable logistic regression, warfarin (odds ratio, 2.215; 95% confidence interval, 1.365-3.596; p = 0.001), but not the NOA (odds ratio, 0.871; 95% confidence interval, 0.258-2.939; p = 0.823), was an independent predictor for mortality. CONCLUSIONS Although the experience with the new oral anticoagulation agents is still limited, patients on these agents appear to have lower mortality after traumatic injury than patients on warfarin. LEVEL OF EVIDENCE Epidemiologic study, level III.	[Maung, Adrian A.; Bhattacharya, Bishwajit; Schuster, Kevin M.; Davis, Kimberly A.] Yale Sch Med, New Haven, CT USA	Maung, AA (corresponding author), Dept Surg, Sect Gen Surg Trauma & Surg Crit Care, 330 Cedar St BB310, New Haven, CT 06520 USA.	adrian.maung@yale.edu		Bhattacharya, Bishwajit/0000-0002-7118-7621			Collins CE, 2014, AM J SURG, V208, P544, DOI 10.1016/j.amjsurg.2014.05.019; Eikelboom JW, 2011, CIRCULATION, V123, P2363, DOI 10.1161/CIRCULATIONAHA.110.004747; Falzon CM, 2013, EMERG MED J, V30, P809, DOI 10.1136/emermed-2012-201687; Franko J, 2006, J TRAUMA, V61, P107, DOI 10.1097/01.ta.0000224220.89528.fc; Gallego P, 2012, CIRCULATION, V126, P1573, DOI 10.1161/CIRCULATIONAHA.112.135681; Granger CB, 2011, NEW ENGL J MED, V365, P981, DOI 10.1056/NEJMoa1107039; Greinacher A, 2015, THROMB HAEMOSTASIS, V113, P931, DOI 10.1160/TH14-11-0982; Hernandez I, 2015, JAMA INTERN MED, V175, P18, DOI 10.1001/jamainternmed.2014.5398; Howard JL, 2009, J TRAUMA, V66, P1518, DOI 10.1097/TA.0b013e3181a59728; Mookadam M, 2015, J AM BOARD FAM MED, V28, P510, DOI 10.3122/jabfm.2015.04.140297; Mountain D, 2010, MED J AUSTRALIA, V193, P202, DOI 10.5694/j.1326-5377.2010.tb03868.x; Pakraftar S, 2014, WORLD J CLIN CASES, V2, P362, DOI 10.12998/wjcc.v2.i8.362; Parra MW, 2013, J NEUROSURG, V119, P760, DOI 10.3171/2013.3.JNS12503; Patel MR, 2011, NEW ENGL J MED, V365, P883, DOI 10.1056/NEJMoa1009638; Siegal DM, 2015, NEW ENGL J MED, V373, P2413, DOI 10.1056/NEJMoa1510991; Wojcik R, 2001, J TRAUMA, V51, P1147, DOI 10.1097/00005373-200112000-00021	16	31	31	2	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	OCT	2016	81	4					652	657		10.1097/TA.0000000000001189			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	DZ2FX	WOS:000385658800005	27438683				2021-06-18	
J	Balaban, C; Hoffer, ME; Szczupak, M; Snapp, H; Crawford, J; Murphy, S; Marshall, K; Pelusso, C; Knowles, S; Kiderman, A				Balaban, Carey; Hoffer, Michael E.; Szczupak, Mikhaylo; Snapp, Hillary; Crawford, James; Murphy, Sara; Marshall, Kathryn; Pelusso, Constanza; Knowles, Sean; Kiderman, Alex			Oculomotor, Vestibular, and Reaction Time Tests in Mild Traumatic Brain Injury	PLOS ONE			English	Article							ERROR SCORING SYSTEM; COGNITIVE RESERVE; BALANCE; CONCUSSION; DIZZINESS; NEURITIS; STROKE; GAIN; TBI	Objective Mild traumatic brain injury is a major public health issue and is a particular concern in sports. One of the most difficult issues with respect to mild traumatic brain injury involves the diagnosis of the disorder. Typically, diagnosis is made by a constellation of physical exam findings. However, in order to best manage mild traumatic brain injury, it is critically important to develop objective tests that substantiate the diagnosis. With objective tests the disorder can be better characterized, more accurately diagnosed, and studied more effectively. In addition, prevention and treatments can be applied where necessary. Methods Two cohorts each of fifty subjects with mild traumatic brain injury and one hundred controls were evaluated with a battery of oculomotor, vestibular and reaction time related tests applied to a population of individuals with mild traumatic brain injury as compared to controls. Results We demonstrated pattern differences between the two groups and showed how three of these tests yield an 89% sensitivity and 95% specificity for confirming a current diagnosis of mild traumatic brain injury. Interpretation These results help better characterize the oculomotor, vestibular, and reaction time differences between those the mild traumatic brain injury and non-affected individuals. This characterization will allow for the development of more effective point of care neurologic diagnostic techniques and allow for more targeted treatment which may allow for quicker return to normal activity.	[Balaban, Carey] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA; [Hoffer, Michael E.; Szczupak, Mikhaylo; Murphy, Sara; Knowles, Sean] Univ Miami, Miller Sch Med, Dept Otolaryngol, Miami, FL 33136 USA; [Hoffer, Michael E.] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA; [Hoffer, Michael E.; Szczupak, Mikhaylo; Pelusso, Constanza] Univ Miami, Sports Performance & Wellness Inst, Miami, FL USA; [Crawford, James; Marshall, Kathryn] Madigan Army Med Ctr, Dept Otolaryngol, Tacoma, WA 98431 USA; [Murphy, Sara] Naval Med Ctr, San Diego, CA USA; [Kiderman, Alex] Neurokinet Inc, Pittsburgh, PA USA	Hoffer, ME (corresponding author), Univ Miami, Miller Sch Med, Dept Otolaryngol, Miami, FL 33136 USA.; Hoffer, ME (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA.; Hoffer, ME (corresponding author), Univ Miami, Sports Performance & Wellness Inst, Miami, FL USA.	michael.hoffer@miami.edu	Balaban, Carey/O-6586-2019; Balaban, Carey/I-3467-2017	Balaban, Carey/0000-0002-3570-3844; Balaban, Carey/0000-0002-3570-3844; Szczupak, Mikhaylo/0000-0002-2569-2184	Head Health Challenge II grant (National Football League, Underarmor, General Electric); Department of DefenseUnited States Department of Defense [W81XWH-12-C-0205]; Neuro-Kinetics, Inc.	This work was supported by Head Health Challenge II grant (National Football League, Underarmor, General Electric) and Department of Defense grant W81XWH-12-C-0205. These sponsors provided funding to conduct the study, only. The funder provided support in the form of salaries for authors (MEH, MS, CB) but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Author Alex Kiderman is employed by Neuro-Kinetics, Inc. Neuro-Kinetics, Inc. provided support in the form of salaries for author AK, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section.; This work was supported by Head Health Challenge II grant (National Football League, Underarmor, General Electric) and Department of Defense grant W81XWH-12-C-0205. These sponsors provided funding to conduct the study, only. The funder provided support in the form of salaries for authors (MEH, MS, CB) but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. Author Alex Kiderman is employed by Neuro-Kinetics, Inc. Neuro-Kinetics, Inc. provided support in the form of salaries for author AK, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific role of this author is articulated in the 'author contributions' section. The specific roles of these authors are articulated in the 'author contributions' section.	[Anonymous], 2015, PREVENTION INJURY CO; Barulli D, 2013, TRENDS COGN SCI, V17, P502, DOI 10.1016/j.tics.2013.08.012; Chandrasekhar SS, 2013, NEUROREHABILITATION, V32, P445, DOI 10.3233/NRE-130867; Chang JO, 2014, CLIN J SPORT MED, V24, P256, DOI 10.1097/JSM.0000000000000016; Chen L, 2014, NEUROLOGY, V83, P1513, DOI 10.1212/WNL.0000000000000906; Guerrero JL, 2000, BRAIN INJURY, V14, P181, DOI 10.1080/026990500120827; Guskiewicz Kevin M, 2015, Handb Clin Neurol, V127, P157, DOI 10.1016/B978-0-444-52892-6.00010-6; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hosek J., 2011, IS DEPLOYMENT IRAQ A; King LA, 2014, ARCH PHYS MED REHAB, V95, P353, DOI 10.1016/j.apmr.2013.10.015; Lei-Rivera L, 2013, NEUROREHABILITATION, V32, P463, DOI 10.3233/NRE-130869; Mantokoudis G, 2015, OTOL NEUROTOL, V36, P457, DOI 10.1097/MAO.0000000000000638; Munoz DP, 2004, NAT REV NEUROSCI, V5, P218, DOI 10.1038/nrn1345; Plog BA, 2015, EXPERT REV NEUROTHER, V15, P465, DOI 10.1586/14737175.2015.1031112; Poltavski DV, 2014, BRAIN INJURY, V28, P475, DOI 10.3109/02699052.2014.888771; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Rakyan VK, 2011, NAT REV GENET, V12, P529, DOI 10.1038/nrg3000; Scherer MR, 2011, OTOL NEUROTOL, V32, P571, DOI 10.1097/MAO.0b013e318210b8fa; Snyder AR, 2014, CLIN NEUROPSYCHOL, V28, P1091, DOI 10.1080/13854046.2014.952667; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8	22	31	31	0	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	SEP 21	2016	11	9							e0162168	10.1371/journal.pone.0162168			11	Multidisciplinary Sciences	Science & Technology - Other Topics	DW8GK	WOS:000383892700017	27654131	DOAJ Gold, Green Published			2021-06-18	
J	Wu, LC; Laksari, K; Kuo, C; Luck, JF; Kleiven, S; Bass, CR; Camarillo, DB				Wu, Lyndia C.; Laksari, Kaveh; Kuo, Calvin; Luck, Jason F.; Kleiven, Svein; Bass, Cameron R. 'Dale'; Camarillo, David B.			Bandwidth and sample rate requirements for wearable head impact sensors	JOURNAL OF BIOMECHANICS			English	Article						Traumatic brain injury; Head impact biomechanics; Wearable sensors; Bandwidth; Sample rate; Head injury criteria	BRAIN-INJURY; ACCELERATION MEASUREMENT; AMERICAN FOOTBALL; CONCUSSION; FREQUENCY; EXPOSURE; PLAYERS; MODEL	Wearable inertial sensors measure human head impact kinematics important to the on-going development and validation of head injury criteria. However, sensor specifications have not been scientifically justified in the context of the anticipated field impact dynamics. The objective of our study is to determine the minimum bandwidth and sample rate required to capture the impact frequency response relevant to injury. We used high-bandwidth head impact data as ground-truth measurements, and investigated the attenuation of various injury criteria at lower bandwidths. Given a 10% attenuation threshold, we determined the minimum bandwidths required to study injury criteria based on skull kinematics and brain deformation in three different model systems: helmeted cadaver (no neck), unhelmeted cadaver (no neck), and helmeted dummy impacts (with neck). We found that higher bandwidths are required for unhelmeted impacts in general and for studying strain rate injury criteria. Minimum gyroscope bandwidths of 300 Hz in helmeted sports and 500 Hz in unhelmeted sports are necessary to study strain rate based injury criteria. A minimum accelerometer bandwidth of 500 Hz in unhelmeted sports is necessary to study most injury criteria. Current devices typically sample at 1000 Hz, with gyroscope bandwidths below 200 Hz, which are not always sufficient according to these requirements. With hard contact test conditions, the identified requirements may be higher than most soft contacts on the field, but should be satisfied to capture the worst contact, and often higher risk, scenarios relative to the specific sport or activity. Our findings will help establish standard guidelines for sensor choice and design in traumatic brain injury research. (C) 2016 Elsevier Ltd. All rights reserved.	[Wu, Lyndia C.; Laksari, Kaveh; Camarillo, David B.] Stanford Univ, Dept Bioengn, Stanford, CA 94305 USA; [Kuo, Calvin; Camarillo, David B.] Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA; [Luck, Jason F.; Bass, Cameron R. 'Dale'] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA; [Kleiven, Svein] KM Royal Inst Technol, Dept Neuron Engn, Stockholm, Sweden	Wu, LC (corresponding author), 443 Via Ortega, Stanford, CA 94305 USA.	lyndiacw@stanford.edu	Kuo, Calvin/AAH-1933-2019; Wu, Lyndia/AAQ-1106-2020	Kuo, Calvin/0000-0001-8401-9136; Wu, Lyndia/0000-0002-8236-032X	National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [3R21EB01761101S1]; Stanford Child Health Research Institute Transdisciplinary Initiatives Programs; Stanford Bio-X Graduate Research Fellowship Program; Natural Sciences and Engineering Research Council of Canada Postgraduate ScholarshipNatural Sciences and Engineering Research Council of Canada (NSERC); University of Pennsylvania Prime; US Army Research Office [W911NF-10-1-0526]; Duke University Pratt School of Engineering	We would like to thank Dr. Jason Mihalik's team at University of North Carolina at Chapel Hill for their involvement in the collaborative effort to collect cadaver drop test data. This work was mainly supported by the National Institutes of Health (NIH) National Institute of Biomedical Imaging and Bioengineering (NIBIB) 3R21EB01761101S1, the Stanford Child Health Research Institute Transdisciplinary Initiatives Programs, the Stanford Bio-X Graduate Research Fellowship Program, and the Natural Sciences and Engineering Research Council of Canada Postgraduate Scholarship. We appreciate additional funding from the University of Pennsylvania Prime, US Army Research Office W911NF-10-1-0526 and the Duke University Pratt School of Engineering.	[Anonymous], 2007, J2111 SAE, P4970; ANTONSSON EK, 1985, J BIOMECH, V18, P39, DOI 10.1016/0021-9290(85)90043-0; Bartsch Adam, 2014, Stapp Car Crash J, V58, P1; Camarillo DB, 2013, ANN BIOMED ENG, V41, P1939, DOI 10.1007/s10439-013-0801-y; Campbell KR, 2016, ANN BIOMED ENG, V44, P1246, DOI 10.1007/s10439-015-1391-7; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Fijalkowski RJ, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3078182; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Hanlon EM, 2012, MED SCI SPORT EXER, V44, P1102, DOI 10.1249/MSS.0b013e3182444d7d; Hernandez F, 2015, ANN BIOMED ENG, V43, P1918, DOI 10.1007/s10439-014-1212-4; Ji SB, 2014, BIOMECH MODEL MECHAN, V13, P1121, DOI 10.1007/s10237-014-0562-z; Kang YS, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4005427; King D, 2015, AM J SPORT MED, V43, P614, DOI 10.1177/0363546514560876; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Laituri T. R., 2015, 2015011437 SAE; Laksari K, 2015, J R SOC INTERFACE, V12, DOI 10.1098/rsif.2015.0331; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; PELLMAN EJ, 2003, NEUROSURGERY, V53, P796; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Sullivan S, 2015, BIOMECH MODEL MECHAN, V14, P877, DOI 10.1007/s10237-014-0643-z; Takhounts EG, 2008, STAPP CAR C, V52, P1; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Versace J, 1971, P 15 STAPP CAR CRASH, DOI [DOI 10.4271/710881, 10.4271/710881]; Wilcox BJ, 2014, J BIOMECH, V47, P109, DOI 10.1016/j.jbiomech.2013.10.004; Wong RH, 2014, CLIN NEUROL NEUROSUR, V118, P1, DOI 10.1016/j.clineuro.2013.11.036; Wu LC, 2014, IEEE T BIO-MED ENG, V61, P2659, DOI 10.1109/TBME.2014.2320153	30	31	32	1	17	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	SEP 6	2016	49	13					2918	2924		10.1016/j.jbiomech.2016.07.004			7	Biophysics; Engineering, Biomedical	Biophysics; Engineering	DY9RH	WOS:000385472300047	27497499				2021-06-18	
J	Houck, Z; Asken, B; Bauer, R; Pothast, J; Michaudet, C; Clugston, J				Houck, Zachary; Asken, Breton; Bauer, Russell; Pothast, Jason; Michaudet, Charlie; Clugston, James			Epidemiology of Sport-Related Concussion in an NCAA Division I Football Bowl Subdivision Sample	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						concussion; football; incidence rate; epidemiology	STATES HIGH-SCHOOL; COLLEGIATE FOOTBALL; PLAYERS; ASSOCIATION; INJURIES	Background: Concussions are common in football, and knowledge of their incidence rates across settings is needed to develop strategies to decrease occurrence. Purpose: To examine sports-related concussion rates in a National Collegiate Athletic Association (NCAA) Division I Football Bowl Subdivision sample based on the activity setting where injuries occurred, during which type of play, and when relative to the 2010 NCAA concussion management policy. Study Design: Descriptive epidemiology study. Methods: Medical records from January 2006 to January 2015 for an NCAA Division I Football Bowl Subdivision program were analyzed. Concussion rates (per 1000 athlete-exposures [AEs]) were compared among the following settings: spring practice, preseason training camp, regular season high-contact practice, regular season low-contact practice, bowl game practice, and game competition. Play-type analyses examined incidence rates during offensive, defensive, and special teams plays. Changes in concussion rate coinciding with the 2010 NCAA concussion management policy were also studied. Results: Of the 452 unique players on the roster during the 9-year study period, 118 (26.1%) were diagnosed with a concussion. The concussion rate during games was significantly higher than all practices combined (P < .001). However, when game rate (4.46 per 1000 AEs) was compared with preseason training camp alone (3.81 per 1000 AEs), there was no significant difference (P = .433). The concussion rate during special teams plays was significantly higher than that during offensive (P < .001) or defensive plays (P < .001). The concussion rate in the 4 seasons (2010-2014) after the 2010 NCAA concussion management policy was initiated was significantly higher than the 4 seasons (2006-2009) preceding the policy (P = .036). Conclusion: Study results show that (1) based on activity type, games and preseason training camp present the greatest risk of sustaining a concussion; (2) based on play type, special teams plays pose the greatest risk of sustaining a concussion; and (3) the 2010 NCAA concussion management policy coincided with a significant increase in recognition of concussion.	[Houck, Zachary; Asken, Breton; Bauer, Russell; Pothast, Jason; Michaudet, Charlie; Clugston, James] Univ Florida, Yon Hall East Stadium,2nd Floor,Room 226, Gainesville, FL 32608 USA	Houck, Z (corresponding author), Univ Florida, Yon Hall East Stadium,2nd Floor,Room 226, Gainesville, FL 32608 USA.	zhouck@phhp.ufl.edu		Clugston, James/0000-0002-2103-1039; Asken, Breton/0000-0001-8419-142X			[Anonymous], CONC MAN PLAN; Barth JT., 1989, MILD HEAD INJURY, P257; Booher MA, 2003, CLIN J SPORT MED, V13, P93, DOI 10.1097/00042752-200303000-00005; BUCKLEY WE, 1988, AM J SPORT MED, V16, P51, DOI 10.1177/036354658801600109; Casson IR, 2010, SPORTS HEALTH, V2, P471, DOI 10.1177/1941738110383963; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Dick R, 2002, 2001 2002 NCAA INJUR; Dick R, 2007, J ATHL TRAINING, V42, P221; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Kerr ZY, 2015, AM J SPORT MED, V43, P1134, DOI 10.1177/0363546515570622; Kilcoyne KG, 2014, SPORTS HEALTH, V6, P402, DOI 10.1177/1941738113491545; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Mueller FO, ANN SURVEY FOOTBALL; National Collegiate Athletic Association Sport Science Institute, CONC SAF PROT CHECKL; Ocwieja KE, 2012, ANN BIOMED ENG, V40, P90, DOI 10.1007/s10439-011-0401-7; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; WILBERGER JE, 1993, SPORTS MED, V15, P338, DOI 10.2165/00007256-199315050-00005	21	31	31	0	7	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	SEP	2016	44	9					2269	2275		10.1177/0363546516645070			7	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	DV6CU	WOS:000383019300015	27159307				2021-06-18	
J	Manocha, GD; Floden, AM; Rausch, K; Kulas, JA; McGregor, BA; Rojanathammanee, L; Puig, KR; Puig, KL; Karki, S; Nichols, MR; Darland, DC; Porter, JE; Combs, CK				Manocha, Gunjan D.; Floden, Angela M.; Rausch, Keiko; Kulas, Joshua A.; McGregor, Brett A.; Rojanathammanee, Lalida; Puig, Kelley R.; Puig, Kendra L.; Karki, Sanjib; Nichols, Michael R.; Darland, Diane C.; Porter, James E.; Combs, Colin K.			APP Regulates Microglial Phenotype in a Mouse Model of Alzheimer's Disease	JOURNAL OF NEUROSCIENCE			English	Article						Alzheimer's disease; amyloid beta oligomers; amyloid precursor protein; microglia; neuroinflammation	AMYLOID PRECURSOR PROTEIN; STIMULATED PROINFLAMMATORY RESPONSES; MULTIPLE-SCLEROSIS LESIONS; TRAUMATIC BRAIN-INJURY; LONG-TERM POTENTIATION; NECROSIS-FACTOR-ALPHA; BETA-PROTEIN; MESSENGER-RNA; ENDOTHELIAL-CELLS; TRANSGENIC MICE	Prior work suggests that amyloid precursor protein (APP) can function as a proinflammatory receptor on immune cells, such as monocytes and microglia. Therefore, we hypothesized that APP serves this function in microglia during Alzheimer's disease. Although fibrillar amyloid beta (A beta)-stimulated cytokine secretion from both wild-type and APP knock-out (mAPP(-/-)) microglial cultures, oligomeric A beta was unable to stimulate increased secretion from mAPP(-/-) cells. This was consistent with an ability of oligomeric A beta to bind APP. Similarly, intracerebroventricular infusions of oligomeric A beta produced less microgliosis in mAPP(-/-) mice compared with wild-type mice. The mAPP(-/-) mice crossed to an APP/PS1 transgenic mouse line demonstrated reduced microgliosis and cytokine levels and improved memory compared with wild-type mice despite robust fibrillar A beta plaque deposition. These data define a novel function for microglial APP in regulating their ability to acquire a proinflammatory phenotype during disease.	[Manocha, Gunjan D.; Floden, Angela M.; Rausch, Keiko; Kulas, Joshua A.; McGregor, Brett A.; Puig, Kelley R.; Puig, Kendra L.; Porter, James E.; Combs, Colin K.] Univ North Dakota, Sch Med & Hlth Sci, Dept Biomed Sci, 504 Hamline St,Room 118, Grand Forks, ND 58203 USA; [Rojanathammanee, Lalida] Suranaree Univ Technol, Inst Sci, Nakhon Ratchasima 30000, Thailand; [Karki, Sanjib; Nichols, Michael R.] Univ Missouri, Dept Chem & Biochem, St Louis, MO 63121 USA; [Darland, Diane C.] Univ North Dakota, Dept Biol, Grand Forks, ND 58202 USA	Combs, CK (corresponding author), Univ North Dakota, Sch Med & Hlth Sci, Dept Biomed Sci, 504 Hamline St,Room 118, Grand Forks, ND 58203 USA.	colin.combs@med.und.edu	Manocha, Gunjan/AAF-2471-2020	Manocha, Gunjan/0000-0003-4488-6627; Kulas, Joshua/0000-0002-8055-1894	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NIH 1R01AG026330, NIH 1R01AG042819]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R01AG026330, R01AG042819] Funding Source: NIH RePORTER	This work was supported in part by National Institutes of Health Grants NIH 1R01AG026330 and NIH 1R01AG042819 (to C.K.C.).	Akaaboune M, 2000, MOL CELL NEUROSCI, V15, P355, DOI 10.1006/mcne.2000.0834; Austin SA, 2010, NEUROBIOL AGING, V31, P1854, DOI 10.1016/j.neurobiolaging.2008.10.013; Austin SA, 2009, J NEUROSCI, V29, P14451, DOI 10.1523/JNEUROSCI.3107-09.2009; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; BANATI RB, 1993, GLIA, V9, P199, DOI 10.1002/glia.440090305; BAUER J, 1991, FEBS LETT, V282, P335, DOI 10.1016/0014-5793(91)80508-Z; Beher D, 1996, J BIOL CHEM, V271, P1613, DOI 10.1074/jbc.271.3.1613; Bitsch A, 2000, BRAIN, V123, P1174, DOI 10.1093/brain/123.6.1174; Borg JP, 1996, MOL CELL BIOL, V16, P6229; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; Bullido MJ, 1996, BBA-MOL CELL RES, V1313, P54, DOI 10.1016/0167-4889(96)00015-8; BUSCIGLIO J, 1993, P NATL ACAD SCI USA, V90, P2092, DOI 10.1073/pnas.90.5.2092; Cain JT, 2014, DEV NEUROBIOL, V74, P63, DOI 10.1002/dneu.22130; Carrano A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140210; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Chromy BA, 2003, BIOCHEMISTRY-US, V42, P12749, DOI 10.1021/bi030029q; Chung HY, 1999, J BIOL CHEM, V274, P32301, DOI 10.1074/jbc.274.45.32301; Cleary JP, 2005, NAT NEUROSCI, V8, P79, DOI 10.1038/nn1372; Combs CK, 2000, J NEUROSCI, V20, P558, DOI 10.1523/JNEUROSCI.20-02-00558.2000; Combs CK, 2001, NEUROCHEM INT, V39, P449, DOI 10.1016/S0197-0186(01)00052-3; Combs CK, 2001, J NEUROSCI, V21, P1179; Combs CK, 1999, J NEUROSCI, V19, P928; Combs CK, 2009, J NEUROIMMUNE PHARM, V4, P380, DOI 10.1007/s11481-009-9165-3; Corrigan F, 2011, BRAIN RES, V1378, P137, DOI 10.1016/j.brainres.2010.12.077; DELBO R, 1995, NEUROSCI LETT, V188, P70, DOI 10.1016/0304-3940(95)11384-9; Dhawan G, 2012, NEUROBIOL AGING, V33, P2247, DOI 10.1016/j.neurobiolaging.2011.10.027; Dhawan G, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-117; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Farkas IG, 2003, ACTA HISTOCHEM, V105, P115, DOI 10.1078/0065-1281-00696; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Floden AM, 2005, J NEUROSCI, V25, P2566, DOI 10.1523/JNEUROSCI.4998-04.2005; Galloway S, 2007, J NUTR BIOCHEM, V18, P279, DOI 10.1016/j.jnutbio.2006.07.003; GEHRMANN J, 1995, GLIA, V15, P141, DOI 10.1002/glia.440150206; GIULIAN D, 1995, NEUROCHEM INT, V27, P119, DOI 10.1016/0197-0186(95)00067-I; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; Grant JL, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004145; HAASS C, 1993, ANN NY ACAD SCI, V695, P109, DOI 10.1111/j.1749-6632.1993.tb23037.x; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1991, J NEUROSCI, V11, P3783; Herzog V, 2004, EUR J CELL BIOL, V83, P613, DOI 10.1078/0171-9335-00401; Jankowsky JL, 2007, J BIOL CHEM, V282, P22707, DOI 10.1074/jbc.M611050200; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; Klegeris A, 1997, BRAIN RES, V747, P114, DOI 10.1016/S0006-8993(96)01229-2; Klyubin I, 2005, NAT MED, V11, P556, DOI 10.1038/nm1234; Kurnellas MP, 2015, CURR TOP BEHAV NEURO, V26, P221, DOI 10.1007/7854_2015_377; Kurnellas MP, 2014, J EXP MED, V211, P1847, DOI 10.1084/jem.20140107; Lee YH, 2008, OBESITY, V16, P1493, DOI 10.1038/oby.2008.267; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Lorenzo A, 2000, NAT NEUROSCI, V3, P460; Lu DC, 2003, ANN NEUROL, V54, P781, DOI 10.1002/ana.10761; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; MONNING U, 1992, J BIOL CHEM, V267, P23950; PERLMUTTER LS, 1990, NEUROSCI LETT, V119, P32, DOI 10.1016/0304-3940(90)90748-X; Puig KL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030378; Radde R, 2006, EMBO REP, V7, P940, DOI 10.1038/sj.embor.7400784; Roher AE, 1996, J BIOL CHEM, V271, P20631, DOI 10.1074/jbc.271.34.20631; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; SANDBRINK R, 1994, J BIOL CHEM, V269, P1510; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; Sharma S, 2012, AGE, V34, P609, DOI 10.1007/s11357-011-9253-1; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHOJI M, 1992, SCIENCE, V258, P126, DOI 10.1126/science.1439760; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SMALL DH, 1992, J NEUROSCI, V12, P4143; Soba P, 2005, EMBO J, V24, P3624, DOI 10.1038/sj.emboj.7600824; Sondag CM, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-22; Sondag CM, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-1; Sondag CM, 2004, J BIOL CHEM, V279, P14456, DOI 10.1074/jbc.M313747200; Steinman L, 2014, J CLIN IMMUNOL, V34, pS61, DOI 10.1007/s10875-014-0034-3; Takahashi RH, 2004, J NEUROSCI, V24, P3592, DOI 10.1523/JNEUROSCI.5167-03.2004; Thornton E, 2006, BRAIN RES, V1094, P38, DOI 10.1016/j.brainres.2006.03.107; Van Nostrand WE, 2002, J BIOL CHEM, V277, P36392, DOI 10.1074/jbc.M204676200; Vehmas A, 2004, J NEUROIMMUNOL, V157, P99, DOI 10.1016/j.jneuroim.2004.08.035; Wagner MR, 2000, BIOCHEMISTRY-US, V39, P7420, DOI 10.1021/bi0002840; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; Wenk G.L., 2001, CURR PROTOC NEUROSCI, V4, DOI [10.1002/0471142301.ns0805bs04, DOI 10.1002/0471142301.NS0805BS04]; WEST MJ, 1990, J COMP NEUROL, V296, P1, DOI 10.1002/cne.902960102; WISNIEWSKI HM, 1992, ACTA NEUROPATHOL, V84, P117, DOI 10.1007/BF00311383; YAMADA T, 1989, BIOCHEM BIOPH RES CO, V158, P906, DOI 10.1016/0006-291X(89)92808-8; Young-Pearse TL, 2007, J NEUROSCI, V27, P14459, DOI 10.1523/JNEUROSCI.4701-07.2007	86	31	33	0	3	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	AUG 10	2016	36	32					8471	8486		10.1523/JNEUROSCI.4654-15.2016			16	Neurosciences	Neurosciences & Neurology	DU6GQ	WOS:000382312700017	27511018	Green Published, Bronze			2021-06-18	
J	Parola, A; Gabbatore, I; Bosco, FM; Bara, BG; Cossa, FM; Gindri, P; Sacco, K				Parola, Alberto; Gabbatore, Ilaria; Bosco, Francesca M.; Bara, Bruno G.; Cossa, Federico M.; Gindri, Patrizia; Sacco, Katiuscia			Assessment of pragmatic impairment in right hemisphere damage	JOURNAL OF NEUROLINGUISTICS			English	Article						Communication; Assessment; Right hemisphere damage; Non-verbal; ABaCo; Pragmatic	TRAUMATIC BRAIN-INJURY; RIGHT CEREBRAL HEMISPHERE; EXECUTIVE FUNCTIONS; EMOTIONAL PROSODY; COMMUNICATION; DISCOURSE; MIND; LANGUAGE; NEUROPRAGMATICS; COMPREHENSION	Aim of the present study is to provide a multifocal assessment of pragmatic abilities in patients with right hemisphere damage (RHD). Pragmatics refers to the ability to use language and non-verbal expressive means (e.g., gestures) to convey meaning in a given context, and it also involves the appropriate use of connotative elements such as rhythm and prosody. Patients with RHD frequently report a wide range of pragmatic disorders: despite the heterogeneity of their clinical profiles, these difficulties can seriously undermine their ability to effectively communicate in everyday situations. We analysed the performance of 17 patients with RHD and 17 healthy controls using the Assessment Battery for Communication, a clinical tool for assessing a wide range of pragmatic phenomena both in comprehension and production- and considering different expressive means. The results suggest patients have difficulties both in comprehending and producing pragmatic phenomena of differing complexity; in particular, patients seem to be significantly impaired when dealing with non-verbal modality, i.e., gestures and facial expressions. Moreover a hierarchical cluster analysis revealed the presence of a number of clusters corresponding to different outcomes of pragmatic performance, in line with the heterogeneity of communicative profiles following RHD frequently reported in the literature. (C) 2015 Elsevier Ltd. All rights reserved.	[Parola, Alberto; Gabbatore, Ilaria; Bosco, Francesca M.; Bara, Bruno G.; Sacco, Katiuscia] Univ Turin, Dept Psychol, Ctr Cognit Sci, I-10124 Turin, Italy; [Bosco, Francesca M.; Bara, Bruno G.; Sacco, Katiuscia] Neurosci Inst Turin, Turin, Italy; [Cossa, Federico M.] Fdn Salvatore Maugeri, Dipartimento Riabilitaz Neurol, Turin, Italy; [Gindri, Patrizia] Presidio Sanit San Camillo, Turin, Italy; [Sacco, Katiuscia] Brain Imaging Grp, Turin, Italy; [Gabbatore, Ilaria] Univ Oulu, Fac Humanities, Child Language Res Ctr, POB 1000, Oulu 90014, Finland	Gabbatore, I (corresponding author), Univ Oulu, Fac Humanities, Child Language Res Ctr, POB 1000, Oulu 90014, Finland.	ilaria.gabbatore@oulu.fi	Gabbatore, Ilaria/AAC-1925-2019; Parola, alberto/AAK-3748-2020; bosco, francesca marina/B-6746-2013	Gabbatore, Ilaria/0000-0002-9724-8066; bosco, francesca marina/0000-0001-6101-8587; PAROLA, ALBERTO/0000-0002-6039-0907			AIRENTI G, 1993, COGNITIVE SCI, V17, P197, DOI 10.1016/0364-0213(93)90011-V; ALBERT ML, 1973, NEUROLOGY, V23, P658, DOI 10.1212/WNL.23.6.658; Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Angeleri R., 2015, BATTERIA ASSESSMENT; Angeleri R, 2012, BEHAV RES METHODS, V44, P845, DOI 10.3758/s13428-011-0174-9; Bambini V, 2011, BRAIN RES BULL, V86, P203, DOI 10.1016/j.brainresbull.2011.07.015; Bara B. G., 2011, EUROPEAN PERSPECTIVE, P1; Bara BG, 2000, BRAIN LANG, V71, P10, DOI 10.1006/brln.1999.2198; Bara BG., 2010, COGNITIVE PRAGMATICS; Bartels-Tobin LR, 2005, J NEUROLINGUIST, V18, P461, DOI 10.1016/j.jneuroling.2005.04.001; Beeman MJ, 2000, BRAIN LANG, V71, P310, DOI 10.1006/brln.1999.2268; Blake ML, 2007, AM J SPEECH-LANG PAT, V16, P331, DOI 10.1044/1058-0360(2007/037); Blake ML, 2006, AM J SPEECH-LANG PAT, V15, P255; Blake ML, 2009, J SPEECH LANG HEAR R, V52, P359, DOI 10.1044/1092-4388(2009/07-0012); BOSCO FM, 2006, ENCY LANGUAGE LINGUI, P546; Bosco FM, 2008, J PRAGMATICS, V40, P583, DOI 10.1016/j.pragma.2007.05.004; Bosco FM, 2015, INT J LANG COMM DIS, V50, P63, DOI 10.1111/1460-6984.12114; Bosco FM, 2013, J CHILD LANG, V40, P741, DOI 10.1017/S0305000913000081; Bosco FM, 2012, J COGN PSYCHOL, V24, P525, DOI 10.1080/20445911.2012.658156; Bosco FM, 2009, J COGN SCI, V10, P245; Bosco FM, 2012, J COMMUN DISORD, V45, P290, DOI 10.1016/j.jcomdis.2012.03.002; BROWNELL HH, 1992, BRAIN LANG, V43, P121, DOI 10.1016/0093-934X(92)90025-A; BRUNDAGE S, 1996, CLIN APHASIOLOGY, V24, P215; Bryan KL., 1995, RIGHT HEMISPHERE LAN; Bucciarelli M, 2003, J PRAGMATICS, V35, P207, DOI 10.1016/S0378-2166(02)00099-1; Champagne-Lavau M, 2009, J NEUROLINGUIST, V22, P413, DOI 10.1016/j.jneuroling.2009.02.002; Chantraine Y, 1998, J NEUROLINGUIST, V11, P21, DOI 10.1016/S0911-6044(98)00003-7; Cheang HS, 2006, CLIN LINGUIST PHONET, V20, P447, DOI 10.1080/02699200500135684; Cocks N, 2007, APHASIOLOGY, V21, P299, DOI 10.1080/02687030600911393; Colle L, 2013, J COMMUN DISORD, V46, P294, DOI 10.1016/j.jcomdis.2013.01.003; Cote H, 2007, APHASIOLOGY, V21, P739, DOI 10.1080/02687030701192331; Cummings L., 2014, PRAGMATIC DISORDERS; Cutica I, 2006, BRAIN LANG, V98, P12, DOI 10.1016/j.bandl.2006.01.001; DERENZI E, 1962, BRAIN, V85, P665, DOI 10.1093/brain/85.4.665; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gabbatore I, 2015, J HEAD TRAUMA REHAB, V30, pE14, DOI 10.1097/HTR.0000000000000087; Gabbatore L, 2014, MINERVA PSICHIATR, V55, P45; GARDNER H, 1986, RIGHT HEMISPHERE COM; GARDNER H, 1983, COGNITIVE PROCESSING, P37; Goodglass H., 1983, ASSESSMENT APHASIA R; Griffin R, 2006, LATERALITY, V11, P195, DOI 10.1080/13576500500450552; Hird K, 2003, CLIN LINGUIST PHONET, V17, P309, DOI 10.1080/0269920031000080037; Joanette Y, 1990, RIGHT HEMISPHERE VER; KAPLAN JA, 1990, BRAIN LANG, V38, P315, DOI 10.1016/0093-934X(90)90117-Y; Kasher Asa, 1991, CHOMSKYAN TURN, P122; KRAUSS RM, 1991, J PERS SOC PSYCHOL, V61, P743, DOI 10.1037/0022-3514.61.5.743; Krauss RM, 1998, CURR DIR PSYCHOL SCI, V7, P54, DOI 10.1111/1467-8721.ep13175642; Kucharska-Pietura K, 2003, NEUROPSYCHOLOGIA, V41, P1082, DOI 10.1016/S0028-3932(02)00294-4; Levinson S. C, 1983, PRAGMATICS CAMBRIDGE; MACKENZIE C, 2001, ADV SPEECH LANGUAGE, V3, P81, DOI DOI 10.3109/14417040109003716; MacSweeney M, 2008, TRENDS COGN SCI, V12, P432, DOI 10.1016/j.tics.2008.07.010; Marini A, 2005, BRAIN LANG, V93, P46, DOI 10.1016/j.bandl.2004.08.002; Marini A, 2012, SEMIN SPEECH LANG, V33, P68, DOI 10.1055/s-0031-1301164; Mason R.A., 2006, HDB PSYCHOLINGUISTIC, P765, DOI [10.1016/B978-012369374-7/50020-1, DOI 10.1016/B978-012369374-7/50020-1]; McDonald S, 2000, BRAIN LANG, V75, P82, DOI 10.1006/brln.2000.2342; Myers PS, 2001, APHASIOLOGY, V15, P913, DOI 10.1080/02687040143000285; MYERS PS, 1999, RIGHT HEMISPHERE DIS; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Papagno C, 2006, NEUROPSYCHOLOGY, V20, P598, DOI 10.1037/0894-4105.20.5.598; Pell MD, 1998, NEUROPSYCHOLOGIA, V36, P701, DOI 10.1016/S0028-3932(98)00008-6; Pell MD, 2006, BRAIN LANG, V96, P221, DOI 10.1016/j.bandl.2005.04.007; Pell MD, 1999, BRAIN LANG, V69, P161, DOI 10.1006/brln.1999.2065; Rainville C, 2003, NEUROCASE, V9, P356, DOI 10.1076/neur.9.4.356.15548; Rinaldi M. C., 2004, BLED SANTALUCIA BATT; Sabbagh MA, 1999, BRAIN LANG, V70, P29, DOI 10.1006/brln.1999.2139; Sacco K, 2008, J COGN SCI, V9, P111; Shamay-Tsoory SG, 2005, COGN BEHAV NEUROL, V18, P55, DOI 10.1097/01.wnn.0000152228.90129.99; Sherratt S, 2012, J NEUROLINGUIST, V25, P213, DOI 10.1016/j.jneuroling.2012.01.001; Spinnler H., 1987, ITALIAN J NEUROLOGIC, V6, P20; Tompkins C.A., 1995, RIGHT HEMISPHERE COM; TOMPKINS CA, 1985, BRAIN LANG, V24, P185, DOI 10.1016/0093-934X(85)90130-0; Tompkins CA, 1999, APHASIOLOGY, V13, P725, DOI 10.1080/026870399401830; TOMPKINS CA, 2002, HDB ADULT LANGUAGE D, P429; Tompkins CA, 2012, ARCH PHYS MED REHAB, V93, pS61, DOI 10.1016/j.apmr.2011.10.015; Vaissiere J, 2005, BLACKW HBK LINGUIST, P236, DOI 10.1002/9780470757024.ch10; WEYLMAN ST, 1989, BRAIN LANG, V36, P580, DOI 10.1016/0093-934X(89)90087-4; Winner E, 1998, BRAIN LANG, V62, P89, DOI 10.1006/brln.1997.1889; Xu J, 2009, P NATL ACAD SCI USA, V106, P20664, DOI 10.1073/pnas.0909197106; Zaidel E, 2002, BRAIN LANG, V80, P510, DOI 10.1006/brln.2001.2612	79	31	31	0	26	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0911-6044			J NEUROLINGUIST	J. Neurolinguist.	AUG	2016	39						10	25		10.1016/j.jneuroling.2015.12.003			16	Linguistics; Neurosciences; Psychology, Experimental	Linguistics; Neurosciences & Neurology; Psychology	DO5NL	WOS:000377829700002					2021-06-18	
J	Kehoe, A; Smith, JE; Bouamra, O; Edwards, A; Yates, D; Lecky, F				Kehoe, A.; Smith, J. E.; Bouamra, O.; Edwards, A.; Yates, D.; Lecky, F.			Older patients with traumatic brain injury present with a higher GCS score than younger patients for a given severity of injury	EMERGENCY MEDICINE JOURNAL			English	Article							GLASGOW COMA SCALE; SEVERE HEAD-INJURY; MAJOR TRAUMA; AGE; EVACUATION; MORTALITY; CRITERIA; TRIAGE; NEED	Introduction Recent evidence suggests that presenting GCS may be higher in older rather than younger patients for an equivalent anatomical severity of traumatic brain injury (TBI). The aim of this study was to confirm these observations using a national trauma database and to test explanatory hypotheses. Methods The Trauma Audit Research Network database was interrogated to identify all adult cases of severe isolated TBI from 1988 to 2013. Cases were categorised by age into those under 65 years and those 65 years and older. Median presenting GCS was compared between the groups at abbreviated injury score (AIS) level (3, 4 and 5). Comparisons were repeated for subgroups defined by mechanism of injury and type of isolated intracranial injury. Results 25 082 patients with isolated TBI met the inclusion criteria, 10 936 in the older group and 14 146 in the younger group. Median or distribution of presenting GCS differed between groups at each AIS level. AIS 3: 14 (11-15) vs 15 (13-15), AIS 4: 14 (9-15) vs 14 (13-15), AIS 5: 9 (4-14) vs 14 (5-15) all p < 0.001. Similar differences between the groups were observed across all mechanisms of injury and types of isolated intracranial injury. We detected no influence of gender on results. Conclusions For an equivalent severity of intracranial injury, presenting GCS is higher in older patients than in the young. This observation is unlikely to be explained by differences in mechanism of injury or types of intracranial injury between the two groups.	[Kehoe, A.; Smith, J. E.] Derriford Hosp, Emergency Dept, Plymouth PL6 8DH, Devon, England; [Kehoe, A.; Smith, J. E.] Univ Plymouth, Peninsula Sch Med, Ctr Clin Trials & Populat Studies, Plymouth PL4 8AA, Devon, England; [Kehoe, A.; Smith, J. E.] Univ Plymouth, Peninsula Sch Dent, Ctr Clin Trials & Populat Studies, Plymouth PL4 8AA, Devon, England; [Smith, J. E.] Royal Ctr Def Med Res & Acad, Acad Dept Mil Emergency Med, Med Directorate, Birmingham, W Midlands, England; [Bouamra, O.; Edwards, A.; Yates, D.; Lecky, F.] Univ Manchester, Hope Hosp, TARN, Salford M6 8HD, Lancs, England; [Lecky, F.] Univ Sheffield, Sch Hlth & Related Res, Hlth Serv, EMRiS Grp,Res Sect, Sheffield, S Yorkshire, England	Kehoe, A (corresponding author), Derriford Hosp, Emergency Dept, Plymouth PL6 8DH, Devon, England.	tony.kehoe@nhs.net	Smith, Jason Edward/H-9380-2013	Smith, Jason Edward/0000-0002-6143-0421; bouamra, omar/0000-0002-3155-4634			Bouras T, 2007, J NEUROTRAUM, V24, P1355, DOI 10.1089/neu.2005.370; Caterino JM, 2011, ACAD EMERG MED, V18, P1014, DOI 10.1111/j.1553-2712.2011.01164.x; CONOVER WJ, 1981, AM STAT, V35, P124, DOI 10.2307/2683975; Farace E, 2000, J NEUROSURG, V93, P539, DOI 10.3171/jns.2000.93.4.0539; Hart A, 2001, BRIT MED J, V323, P391, DOI 10.1136/bmj.323.7309.391; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Ichwan B, 2015, ANN EMERG MED, V65, P92, DOI 10.1016/j.annemergmed.2014.04.019; JENNETT B, 1976, LANCET, V1, P1031; Kehoe A, 2015, EMERG MED J, V32, P911, DOI 10.1136/emermed-2015-205265; Kehoe A, 2015, EMERG MED J, V32, P613, DOI 10.1136/emermed-2013-203488; Lau D, 2012, J NEUROSURG, V116, P234, DOI 10.3171/2011.7.JNS11396; Mak CHK, 2012, CURR GERIATR REP, V1, P171, DOI 10.1007/s13670-012-0017-2; Nakamura Y, 2012, ANN EMERG MED, V60, P335, DOI 10.1016/j.annemergmed.2012.04.006; Pascual JL, 2013, AM J SURG, V206, P5; Pascual JL, 2013, AM J SURG, V206, P840, DOI 10.1016/j.amjsurg.2013.07.016; Patel HC, 2010, ACTA NEUROCHIR, V152, P1353, DOI 10.1007/s00701-010-0666-x; Patel HC, 2010, ACTA NEUROCHIR WIEN, V152, P7; Potter D, 2013, J R Nav Med Serv, V99, P16; Ramanathan DM, 2012, J NEUROTRAUM, V29, P1371, DOI 10.1089/neu.2011.2197; Salottolo K, 2014, JAMA SURG, V149, P727, DOI 10.1001/jamasurg.2014.13; Sasser Scott M, 2012, MMWR Recomm Rep, V61, P1; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; Wong George K C, 2011, J Emerg Trauma Shock, V4, P346, DOI 10.4103/0974-2700.83861; Xiang HY, 2014, AM J EMERG MED, V32, P997, DOI 10.1016/j.ajem.2014.05.038; Yates DW, 2003, EMERG MED J, V20, P117, DOI 10.1136/emj.20.2.117	26	31	31	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1472-0205	1472-0213		EMERG MED J	Emerg. Med. J.	JUN	2016	33	6					381	+		10.1136/emermed-2015-205180			5	Emergency Medicine	Emergency Medicine	DN2UZ	WOS:000376919800003	26825613	Green Accepted, Green Published, Bronze			2021-06-18	
J	Wolf, JA; Koch, PF				Wolf, John A.; Koch, Paul F.			Disruption of Network Synchrony and Cognitive Dysfunction After Traumatic Brain Injury	FRONTIERS IN SYSTEMS NEUROSCIENCE			English	Article						TBI; concussion; axonal injury; synchrony; ensemble coding; oscillations; limbic system; hippocampus	DIFFUSE AXONAL INJURY; HIGH-FREQUENCY OSCILLATIONS; SHARP-WAVE RIPPLES; THETA-OSCILLATIONS; WORKING-MEMORY; SYNAPTIC-TRANSMISSION; GAMMA OSCILLATIONS; NEURONAL ENSEMBLES; PATH-INTEGRATION; STRIATAL NEURONS	Traumatic brain injury (TBI) is a heterogeneous disorder with many factors contributing to a spectrum of severity, leading to cognitive dysfunction that may last for many years after injury. Injury to axons in the white matter, which are preferentially vulnerable to biomechanical forces, is prevalent in many TBIs. Unlike focal injury to a discrete brain region, axonal injury is fundamentally an injury to the substrate by which networks of the brain communicate with one another. The brain is envisioned as a series of dynamic, interconnected networks that communicate via long axonal conduits termed the "connectome". Ensembles of neurons communicate via these pathways and encode information within and between brain regions in ways that are timing dependent. Our central hypothesis is that traumatic injury to axons may disrupt the exquisite timing of neuronal communication within and between brain networks, and that this may underlie aspects of post-TBI cognitive dysfunction. With a better understanding of how highly interconnected networks of neurons communicate with one another in important cognitive regions such as the limbic system, and how disruption of this communication occurs during injury, we can identify new therapeutic targets to restore lost function. This requires the tools of systems neuroscience, including electrophysiological analysis of ensemble neuronal activity and circuitry changes in awake animals after TBI, as well as computational modeling of the effects of TBI on these networks. As more is revealed about how inter-regional neuronal interactions are disrupted, treatments directly targeting these dysfunctional pathways using neuromodulation can be developed.	[Wolf, John A.; Koch, Paul F.] Univ Penn, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA; [Wolf, John A.] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA	Wolf, JA (corresponding author), Univ Penn, Dept Neurosurg, Ctr Brain Injury & Repair, Philadelphia, PA 19104 USA.; Wolf, JA (corresponding author), Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA.	wolfjo@upenn.edu	Wolf, John A/A-1034-2007	Wolf, John A/0000-0002-6950-2303	Department of Veterans Affairs Rehabilitation Research and DevelopmentUS Department of Veterans Affairs [B1097-I, IK2-RX001479]; CURE Taking Flight Award; Codman Neurotrauma Award; Veterans AffairsUS Department of Veterans Affairs [IK2RX001479] Funding Source: NIH RePORTER	This work was made possible due to financial support provided by the Department of Veterans Affairs Rehabilitation Research and Development (Merit Review Award #B1097-I, Career Development Award #IK2-RX001479), the CURE Taking Flight Award, and the Codman Neurotrauma Award.	ABELES M, 1993, J NEUROPHYSIOL, V70, P1629; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Aertsen A, 1996, J PHYSIOLOGY-PARIS, V90, P243, DOI 10.1016/S0928-4257(97)81432-5; Alivisatos AP, 2012, NEURON, V74, P970, DOI 10.1016/j.neuron.2012.06.006; Almeida-Suhett CP, 2015, EXP NEUROL, V273, P11, DOI 10.1016/j.expneurol.2015.07.028; Backus AR, 2016, CURR BIOL, V26, P450, DOI 10.1016/j.cub.2015.12.048; Barnes TD, 2005, NATURE, V437, P1158, DOI 10.1038/nature04053; Benchenane K, 2010, NEURON, V66, P921, DOI 10.1016/j.neuron.2010.05.013; Berke JD, 2004, NEURON, V43, P883, DOI 10.1016/j.neuron.2004.08.035; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Bonnelle V, 2012, P NATL ACAD SCI USA, V109, P4690, DOI 10.1073/pnas.1113455109; Bonnelle V, 2011, J NEUROSCI, V31, P13442, DOI 10.1523/JNEUROSCI.1163-11.2011; Bragin A, 2010, CURR OPIN NEUROL, V23, P151, DOI 10.1097/WCO.0b013e3283373ac8; Browne KD, 2011, J NEUROTRAUM, V28, P1747, DOI 10.1089/neu.2011.1913; Buckner RL, 2008, ANN NY ACAD SCI, V1124, P1, DOI 10.1196/annals.1440.011; BUZSAKI G, 1987, BRAIN RES, V400, P321, DOI 10.1016/0006-8993(87)90631-7; Buzsaki G, 2005, HIPPOCAMPUS, V15, P827, DOI 10.1002/hipo.20113; BUZSAKI G, 1995, CURR OPIN NEUROBIOL, V5, P504, DOI 10.1016/0959-4388(95)80012-3; Buzsaki G, 2004, NAT NEUROSCI, V7, P446, DOI 10.1038/nn1233; BUZSAKI G, 1986, BRAIN RES, V398, P242, DOI 10.1016/0006-8993(86)91483-6; BUZSAKI G, 1987, NEUROSCIENCE, V22, P871, DOI 10.1016/0306-4522(87)92966-6; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; Buzsaki G, 2002, NEURON, V33, P325, DOI 10.1016/S0896-6273(02)00586-X; Buzsaki G, 2015, HIPPOCAMPUS, V25, P1073, DOI 10.1002/hipo.22488; Buzsaki G, 2013, NAT NEUROSCI, V16, P130, DOI 10.1038/nn.3304; Buzsaki G, 2012, NAT REV NEUROSCI, V13, P407, DOI 10.1038/nrn3241; Buzsaki Gyorgy, 2012, Dialogues Clin Neurosci, V14, P345; Canolty RT, 2006, SCIENCE, V313, P1626, DOI 10.1126/science.1128115; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Carr MF, 2011, NAT NEUROSCI, V14, P147, DOI 10.1038/nn.2732; Christidi F, 2011, J NEUROTRAUM, V28, P711, DOI 10.1089/neu.2010.1644; Cole JT, 2010, P NATL ACAD SCI USA, V107, P366, DOI 10.1073/pnas.0910280107; Colley BS, 2010, EXP NEUROL, V224, P241, DOI 10.1016/j.expneurol.2010.03.026; De Monte VE, 2006, BRAIN INJURY, V20, P1345, DOI 10.1080/02699050601082073; Diba K, 2007, NAT NEUROSCI, V10, P1241, DOI 10.1038/nn1961; Diesmann M, 1999, NATURE, V402, P529, DOI 10.1038/990101; Dragoi G, 1999, J NEUROSCI, V19, P6191, DOI 10.1523/JNEUROSCI.19-14-06191.1999; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Eichenbaum H, 2000, NAT REV NEUROSCI, V1, P41, DOI 10.1038/35036213; Fedor M, 2010, J NEUROTRAUM, V27, P1605, DOI 10.1089/neu.2010.1370; Fisher D C, 2000, Appl Neuropsychol, V7, P126, DOI 10.1207/S15324826AN0703_2; Foffani G, 2007, NEURON, V55, P930, DOI 10.1016/j.neuron.2007.07.040; Foster DJ, 2006, NATURE, V440, P680, DOI 10.1038/nature04587; FREUND TF, 1988, NATURE, V336, P170, DOI 10.1038/336170a0; Friese U, 2013, NEUROIMAGE, V66, P642, DOI 10.1016/j.neuroimage.2012.11.002; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Girardeau G, 2009, NAT NEUROSCI, V12, P1222, DOI 10.1038/nn.2384; Goforth PB, 2011, J NEUROPHYSIOL, V105, P2350, DOI 10.1152/jn.00467.2010; Graham D I, 1988, Prog Clin Biol Res, V264, P159; Ham TE, 2012, CURR OPIN NEUROL, V25, P662, DOI 10.1097/WCO.0b013e328359488f; Hebb DO., 1949, ORG BEHAV NEUROPSYCH; Hoffman KL, 2002, SCIENCE, V297, P2070, DOI 10.1126/science.1073538; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Hyafil A, 2015, TRENDS NEUROSCI, V38, P725, DOI 10.1016/j.tins.2015.09.001; Ibarz JM, 2010, J NEUROSCI, V30, P16249, DOI 10.1523/JNEUROSCI.3357-10.2010; Iwata A, 2004, J NEUROSCI, V24, P4605, DOI 10.1523/JNEUROSCI.0515-03.2004; Johnson VE, 2016, ACTA NEUROPATHOL, V131, P115, DOI 10.1007/s00401-015-1506-0; Johnson Victoria E, 2015, Handb Clin Neurol, V127, P115, DOI 10.1016/B978-0-444-52892-6.00008-8; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Johnson VE, 2013, EXP NEUROL, V246, P35, DOI 10.1016/j.expneurol.2012.01.013; Jones MW, 2005, PLOS BIOL, V3, P2187, DOI 10.1371/journal.pbio.0030402; Jones MW, 2005, HIPPOCAMPUS, V15, P867, DOI 10.1002/hipo.20119; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Josselyn SA, 2015, NAT REV NEUROSCI, V16, P521, DOI 10.1038/nrn4000; JURKO MF, 1974, BEHAV BIOL, V10, P377, DOI 10.1016/S0091-6773(74)91964-6; Kaplan R, 2016, CURR BIOL, V26, P686, DOI 10.1016/j.cub.2016.01.017; KEREN O, 1991, Brain Injury, V5, P233, DOI 10.3109/02699059109008094; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Lashley K.S., 1950, SOC EXPT BIOL S, V4, P2; Laubach M, 2000, NATURE, V405, P567, DOI 10.1038/35014604; Lee AK, 2002, NEURON, V36, P1183, DOI 10.1016/S0896-6273(02)01096-6; Lee DJ, 2015, J NEUROTRAUM, V32, P1822, DOI 10.1089/neu.2014.3744; Lee DJ, 2013, J NEUROTRAUM, V30, P131, DOI 10.1089/neu.2012.2646; Lew HL, 2004, AM J PHYS MED REHAB, V83, P428, DOI 10.1097/00002060-200406000-00004; Likhtik E, 2014, NAT NEUROSCI, V17, P106, DOI 10.1038/nn.3582; Lim MM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007092; Lisman J, 2008, SCHIZOPHRENIA BULL, V34, P974, DOI 10.1093/schbul/sbn060; Lisman JE, 2013, NEURON, V77, P1002, DOI 10.1016/j.neuron.2013.03.007; Liu X, 2012, NATURE, V484, P381, DOI 10.1038/nature11028; Logothetis NK, 2012, NATURE, V491, P547, DOI 10.1038/nature11618; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; Lozano AM, 2013, NEURON, V77, P406, DOI 10.1016/j.neuron.2013.01.020; MacDonald CL, 2008, NEUROLOGY, V71, P1199, DOI 10.1212/01.wnl.0000327521.69520.7f; Maren S, 2001, ANNU REV NEUROSCI, V24, P897, DOI 10.1146/annurev.neuro.24.1.897; MARGULIES SS, 1990, J BIOMECH, V23, P823, DOI 10.1016/0021-9290(90)90029-3; Maris E, 2011, NEUROIMAGE, V54, P836, DOI 10.1016/j.neuroimage.2010.09.029; Mathias JL, 2004, J INT NEUROPSYCH SOC, V10, P286, DOI 10.1017/S1355617704102117; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McNaughton BL, 2006, NAT REV NEUROSCI, V7, P663, DOI 10.1038/nrn1932; McNaughton N, 2006, HIPPOCAMPUS, V16, P1102, DOI 10.1002/hipo.20235; Melzer S, 2012, SCIENCE, V335, P1506, DOI 10.1126/science.1217139; Merkow MB, 2014, HIPPOCAMPUS, V24, P1562, DOI 10.1002/hipo.22335; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Monti JM, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00041; Morgalla M H, 2014, Neurodiagn J, V54, P338; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; OKEEFE J, 1971, BRAIN RES, V34, P171, DOI 10.1016/0006-8993(71)90358-1; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; Ortiz F, 2015, EXP NEUROL, V271, P319, DOI 10.1016/j.expneurol.2015.06.009; Pajevic S, 2014, NEUROSCIENCE, V276, P135, DOI 10.1016/j.neuroscience.2013.11.007; Palacios EM, 2012, NEUROLOGY, V78, P852, DOI 10.1212/WNL.0b013e31824c465a; Paterno R, 2016, J NEUROTRAUM, V33, P1645, DOI 10.1089/neu.2015.4107; PENNARTZ CMA, 1994, PROG NEUROBIOL, V42, P719, DOI 10.1016/0301-0082(94)90025-6; Peredeny JV, 2013, FRONT NEURAL CIRCUIT, V7, DOI 10.3389/fncir.2013.00017; PETSCHE H, 1962, ELECTROEN CLIN NEURO, V14, P202, DOI 10.1016/0013-4694(62)90030-5; Popa D, 2010, P NATL ACAD SCI USA, V107, P6516, DOI 10.1073/pnas.0913016107; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Rajji TK, 2017, CEREB CORTEX, V27, P1482, DOI 10.1093/cercor/bhv326; RAPPAPORT M, 1991, CLIN ELECTROENCEPHAL, V22, P199, DOI 10.1177/155005949102200407; Reeves TM, 2005, EXP NEUROL, V196, P126, DOI 10.1016/j.expneurol.2005.07.014; Reeves TM, 2000, J NEUROSCI RES, V60, P370, DOI 10.1002/(SICI)1097-4547(20000501)60:3<370::AID-JNR12>3.3.CO;2-2; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Seager MA, 2002, P NATL ACAD SCI USA, V99, P1616, DOI 10.1073/pnas.032662099; Sederberg PB, 2003, J NEUROSCI, V23, P10809; Seidenbecher T, 2003, SCIENCE, V301, P846, DOI 10.1126/science.1085818; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Sharp DJ, 2011, BRAIN, V134, P2233, DOI 10.1093/brain/awr175; Siman R, 2015, J NEUROTRAUM, V32, P1294, DOI 10.1089/neu.2014.3698; Siman R, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00190; Skelton RW, 1998, BEHAV BRAIN RES, V96, P13, DOI 10.1016/S0166-4328(97)00199-X; Smith DH, 2000, NEUROSCIENTIST, V6, P483, DOI 10.1177/107385840000600611; Smith DH, 1997, J NEUROPATH EXP NEUR, V56, P822; Smith DH, 2013, J NEUROTRAUM, V30, P307, DOI 10.1089/neu.2012.2825; Spellman T, 2015, NATURE, V522, P309, DOI 10.1038/nature14445; Spitz G, 2013, BRAIN TOPOGR, V26, P648, DOI 10.1007/s10548-013-0283-0; Sporns O, 2005, PLOS COMPUT BIOL, V1, P245, DOI 10.1371/journal.pcbi.0010042; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Strich S., 1961, SHEARING NERVE FIBRE, V278, P443, DOI [10.1016/S0140-6736(61)92426-6, DOI 10.1016/S0140-6736(61)92426-6]; Stujenske JM, 2014, NEURON, V83, P919, DOI 10.1016/j.neuron.2014.07.026; STUMPF C, 1962, ELECTROEN CLIN NEURO, V14, P212, DOI 10.1016/0013-4694(62)90031-7; Sutherland GR, 2000, CURR OPIN NEUROBIOL, V10, P180, DOI 10.1016/S0959-4388(00)00079-9; Tang CY, 2012, TRANSL NEUROSCI, V3, P9, DOI 10.2478/s13380-012-0003-3; Tonegawa S, 2008, NEURON, V57, P175, DOI 10.1016/j.neuron.2008.01.005; Tonegawa S, 2015, CURR OPIN NEUROBIOL, V35, P101, DOI 10.1016/j.conb.2015.07.009; Tort ABL, 2009, P NATL ACAD SCI USA, V106, P20942, DOI 10.1073/pnas.0911331106; TOTH K, 1993, J NEUROSCI, V13, P3712; Tritsch NX, 2012, NEURON, V76, P33, DOI 10.1016/j.neuron.2012.09.023; van den Heuvel MP, 2011, J NEUROSCI, V31, P15775, DOI 10.1523/JNEUROSCI.3539-11.2011; Vandecasteele M, 2014, P NATL ACAD SCI USA, V111, P13535, DOI 10.1073/pnas.1411233111; Wierzynski CM, 2009, NEURON, V61, P587, DOI 10.1016/j.neuron.2009.01.011; Wolf JA, 2001, J NEUROSCI, V21, P1923, DOI 10.1523/JNEUROSCI.21-06-01923.2001; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Xiao H, 2015, NEURAL REGEN RES, V10, P2062, DOI 10.4103/1673-5374.172328; Yallampalli R, 2013, J NEUROIMAGING, V23, P224, DOI 10.1111/j.1552-6569.2010.00537.x; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161	153	31	32	0	10	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND		1662-5137		FRONT SYST NEUROSCI	Front. Syst. Neurosci.	MAY 17	2016	10								43	10.3389/fnsys.2016.00043			14	Neurosciences	Neurosciences & Neurology	DM0OD	WOS:000376044400001	27242454	DOAJ Gold, Green Published			2021-06-18	
J	Weil, ZM; Karelina, K; Gaier, KR; Corrigan, TED; Corrigan, JD				Weil, Zachary M.; Karelina, Kate; Gaier, Kristopher R.; Corrigan, Timothy E. D.; Corrigan, John D.			Juvenile Traumatic Brain Injury Increases Alcohol Consumption and Reward in Female Mice	JOURNAL OF NEUROTRAUMA			English	Article						alcohol; BDNF; development; environmental enrichment; sex differences; traumatic brain injury	SEX-DIFFERENCES; ETHANOL-CONSUMPTION; NUCLEUS-ACCUMBENS; SUBSTANCE-ABUSE; NEUROTROPHIC FACTOR; DOPAMINE RELEASE; CONTROLLED-TRIAL; USE DISORDERS; RATS; DRINKING	Traumatic brain injury (TBI) is closely and bi-directionally linked with alcohol use, as by some estimates intoxication is the direct or indirect cause of one-third to one-half of all TBI cases. Alcohol use following injury can reduce the efficacy of rehabilitation and increase the chances for additional injury. Finally, TBI itself may be a risk factor for the development of alcohol use disorders. Children who suffer TBIs have poorer life outcomes and more risk of substance abuse. We used a standardized closed-head injury to model mild traumatic brain injuries. We found that mice injured as juveniles but not during adulthood exhibited much greater alcohol self-administration in adulthood. Further, this phenomenon was limited to female mice. Using behavioral testing, including conditioned place preference assays, we showed that early injuries increase the rewarding properties of alcohol. Environmental enrichment administered after injury reduced axonal degeneration and prevented the increase in drinking behavior. Additionally, brain-derived neurotrophic factor gene expression, which was reduced by TBI, was normalized by environmental enrichment. Together, these results suggest a novel model of alterations in reward circuitry following trauma during development.	[Weil, Zachary M.; Karelina, Kate; Gaier, Kristopher R.; Corrigan, Timothy E. D.] Ohio State Univ, Dept Neurosci, Wexner Med Ctr, Columbus, OH 43210 USA; [Weil, Zachary M.; Karelina, Kate; Gaier, Kristopher R.; Corrigan, Timothy E. D.] Ohio State Univ, Grp Behav Neuroendocrinol, Wexner Med Ctr, Columbus, OH 43210 USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Wexner Med Ctr, Columbus, OH 43210 USA	Weil, ZM (corresponding author), Biomedical Res Tower 618,460 West 12th Ave, Columbus, OH 43210 USA.	Zachary.weil@osumc.edu	Weil, Zachary M/A-2439-2008; Weil, Zachary M/B-5003-2008; Corrigan, John D./E-2921-2011	Weil, Zachary M/0000-0003-3758-1809; Weil, Zachary M/0000-0003-3758-1809; Karelina Weil, Kate/0000-0002-6628-0768			Adams RS, 2012, J HEAD TRAUMA REHAB, V27, P349, DOI 10.1097/HTR.0b013e318268db94; Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Barker J. M., 2014, BRAIN RES; Barker JM, 2010, J NEUROSCI, V30, P9140, DOI 10.1523/JNEUROSCI.0548-10.2010; Bjork JM, 2009, J NEUROTRAUM, V26, P1077, DOI 10.1089/neu.2008-0849; BLANCHARD BA, 1993, ALCOHOL CLIN EXP RES, V17, P968, DOI 10.1111/j.1530-0277.1993.tb05650.x; Cailhol S, 2001, ALCOHOL CLIN EXP RES, V25, P594, DOI 10.1097/00000374-200104000-00017; Ceylan-Isik AF, 2010, LIFE SCI, V87, P133, DOI 10.1016/j.lfs.2010.06.002; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2014, J HEAD TRAUMA REHAB, V29, pE1, DOI 10.1097/HTR.0000000000000020; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1940, DOI 10.1016/j.apmr.2013.05.018; Corrigan JD, 2012, BRAIN INJURY, V26, P139, DOI 10.3109/02699052.2011.648705; CRABBE JC, 1981, BEHAV NEURAL BIOL, V33, P188, DOI 10.1016/S0163-1047(81)91625-3; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Epstein EE, 2007, J WOMEN AGING, V19, P31, DOI 10.1300/J074v19n01_03; FARACE E, 2000, NEUROSURG FOCUS, V8, P1, DOI DOI 10.3171/F0C.2000.8.1.152; Faul M.D., 2010, TRAUMATIC BRAIN INJU; GEORGE SR, 1995, J PHARMACOL EXP THER, V273, P373; Gerber P, 2007, CHILD NERV SYST, V23, P499, DOI 10.1007/s00381-006-0267-4; Goldstein LB, 2003, BRAIN INJURY, V17, P685, DOI 10.1080/0269905031000107179; Huang MC, 2011, ALCOHOL CLIN EXP RES, V35, P126, DOI 10.1111/j.1530-0277.2010.01329.x; HUGER F, 1979, J NEUROCHEM, V33, P89, DOI 10.1111/j.1471-4159.1979.tb11710.x; Karver CL, 2012, REHABIL PSYCHOL, V57, P256, DOI 10.1037/a0029522; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; Kramer ME, 2008, J INT NEUROPSYCH SOC, V14, P424, DOI 10.1017/S1355617708080545; KREUTZER J S, 1991, Brain Injury, V5, P177, DOI 10.3109/02699059109008088; Kreutzer JS, 1996, J LEARN DISABIL, V29, P643, DOI 10.1177/002221949602900608; Lancaster FE, 1996, ALCOHOL CLIN EXP RES, V20, P1043, DOI 10.1111/j.1530-0277.1996.tb01945.x; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lowing JL, 2014, J NEUROTRAUM, V31, P1700, DOI 10.1089/neu.2013.3286; Machens HG, 2006, SURGERY, V139, P550, DOI 10.1016/j.surg.2005.09.001; Massucci JL, 2004, NEUROSCI LETT, V372, P127, DOI 10.1016/j.neulet.2004.09.026; McBride WJ, 1998, CRIT REV NEUROBIOL, V12, P339, DOI 10.1615/CritRevNeurobiol.v12.i4.40; McGough NNH, 2004, J NEUROSCI, V24, P10542, DOI 10.1523/JNEUROSCI.3714-04.2004; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; McKinlay A, 2014, J HEAD TRAUMA REHAB, V29, P498, DOI 10.1097/HTR.0000000000000001; Middaugh LD, 1999, ALCOHOL, V17, P175, DOI 10.1016/S0741-8329(98)00055-X; Navarro RR, 2011, CURR SPORT MED REP, V10, P27, DOI 10.1249/JSR.0b013e318205e072; Pascual M, 2009, J NEUROCHEM, V108, P920, DOI 10.1111/j.1471-4159.2008.05835.x; Patton GC, 2004, PEDIATRICS, V114, pE300, DOI 10.1542/peds.2003-0626-F; Philpot RM, 2009, INT J DEV NEUROSCI, V27, P805, DOI 10.1016/j.ijdevneu.2009.08.009; REID LD, 1985, PHARMACOL BIOCHEM BE, V22, P483, DOI 10.1016/0091-3057(85)90051-6; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Ruff R. M., 1990, J HEAD TRAUMA REHAB, V5, P21, DOI DOI 10.1097/00001199-199009000-00006; Torres OV, 2014, ALCOHOL CLIN EXP RES, V38, P108, DOI 10.1111/acer.12213; Wagner AK, 2005, EXP NEUROL, V195, P475, DOI 10.1016/j.expneurol.2005.06.009; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Weil ZM, 2014, NEUROBIOL DIS, V70, P108, DOI 10.1016/j.nbd.2014.06.016; Whyte J, 2004, AM J PHYS MED REHAB, V83, P401, DOI 10.1097/01.PHM.0000128789.75375.D3; Whyte J, 1997, AM J PHYS MED REHAB, V76, P440, DOI 10.1097/00002060-199711000-00002; Witt ED, 2007, NEUROTOXICOL TERATOL, V29, P81, DOI 10.1016/j.ntt.2006.10.013; Zanardini R, 2011, ALCOHOL CLIN EXP RES, V35, P1529, DOI 10.1111/j.1530-0277.2011.01489.x; Zandy SL, 2015, PSYCHOPHARMACOLOGY, V232, P777, DOI 10.1007/s00213-014-3712-1	53	31	32	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY 1	2016	33	9					895	903		10.1089/neu.2015.3953			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DK7SA	WOS:000375124800011	26153729	Green Published			2021-06-18	
J	Tian, RF; Hou, ZG; Hao, SY; Wu, WC; Mao, X; Tao, XG; Lu, T; Liu, BY				Tian, Runfa; Hou, Zonggang; Hao, Shuyu; Wu, Weichuan; Mao, Xiang; Tao, Xiaogang; Lu, Te; Liu, Baiyun			Hydrogen-rich water attenuates brain damage and inflammation after traumatic brain injury in rats	BRAIN RESEARCH			English	Article						Anti-inflammatory; Controlled cortical impact; Hydrogen-rich water; Neuroprotective effect; Traumatic brain injury	MAGNETIC-RESONANCE SPECTROSCOPY; REDUCING OXIDATIVE STRESS; FOCAL CEREBRAL-ISCHEMIA; CORTICAL IMPACT INJURY; PROINFLAMMATORY CYTOKINE; MICROGLIAL ACTIVATION; SEPTIC ENCEPHALOPATHY; PARKINSONS-DISEASE; REPERFUSION INJURY; MODEL	Inflammation and oxidative stress are the two major causes of apoptosis after traumatic brain injury (TBI). Most previous studies of the neuroprotective effects of hydrogen-rich water on TBI primarily focused on antioxidant effects. The present study investigated whether hydrogen-rich water (HRW) could attenuate brain damage and inflammation after traumatic brain injury in rats. A TBI model was induced using a controlled cortical impact injury. HRW or distilled water was injected intraperitoneally daily following surgery. We measured survival rate, brain edema, blood-brain barrier (BBB) breakdown and neurological dysfunction in all animals. Changes in inflammatory cytokines, inflammatory cells and Cho/Cr metabolites in brain tissues were also detected. Our results demonstrated that TBI-challenged rats exhibited significant brain injuries that were characterized by decreased survival rate and increased BBB permeability, brain edema, and neurological dysfunction, while HRW treatment ameliorated the consequences of TBI. HRW treatment also decreased the levels of pro-inflammatory cytokines (TNF-alpha, IL-1 beta and HMGB1), inflammatory cell number (Iba1) and inflammatory metabolites (Cho) and increased the levels of an anti-inflammatory cytokine (IL-10) in the brain tissues of TBI-challenged rats. In conclusion, HRW could exert a neuroprotective effect against TBI and attenuate inflammation, which suggests HRW as an effective therapeutic strategy for TBI patients. (C) 2016 Published by Elsevier B.V.	[Tian, Runfa; Hou, Zonggang; Hao, Shuyu; Tao, Xiaogang; Lu, Te; Liu, Baiyun] Capital Med Univ, Beijing Tian Tan Hosp, Dept Neurosurg, Beijing 100050, Peoples R China; [Tian, Runfa; Hou, Zonggang; Hao, Shuyu; Tao, Xiaogang; Lu, Te; Liu, Baiyun] China Natl Clin Res Ctr Neurol Dis, Beijing 100050, Peoples R China; [Tian, Runfa; Hou, Zonggang; Hao, Shuyu; Tao, Xiaogang; Lu, Te; Liu, Baiyun] Beijing Key Lab Cent Nervous Syst Injury, Beijing 100050, Peoples R China; [Wu, Weichuan] Baoan Cent Hosp, Dept Neurosurg, Shenzhen 518102, Peoples R China; [Mao, Xiang] Anhui Med Univ, Dept Neurosurg, Affiliated Hosp 1, Hefei 230000, Peoples R China; [Liu, Baiyun] Capital Med Univ, Beijing Neurosurg Inst, Neurotrauma Lab, Beijing 100050, Peoples R China; [Liu, Baiyun] Beijing Inst Brain Disorders, Nerve Injury & Repair Ctr, Beijing 100050, Peoples R China; [Liu, Baiyun] Gen Hosp Armed Police Forces, Dept Neurotrauma, Beijing 100039, Peoples R China	Liu, BY (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Tiantan Xili 6, Beijing 100050, Peoples R China.	liubaiyun1212@163.com			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81171144, 81471238]; Beijing Nova programBeijing Municipal Science & Technology Commission [XX2012033]; National Key Technology Research and Development Program of the Ministry of Science and Technology of ChinaNational Key Technology R&D Program [2013BAI09B03]; Beijing Institute for Brain Disorders [BIBD-PXM2013_014226_07_000084]	We would like to acknowledge the assistance of Feifan Xu and Xuetao Chen for their support of this study. This study was supported by National Natural Science Foundation of China (No. 81171144 and No. 81471238), Beijing Nova program (No. XX2012033), National Key Technology Research and Development Program of the Ministry of Science and Technology of China (2013BAI09B03) and Beijing Institute for Brain Disorders (BIBD-PXM2013_014226_07_000084). We also thank Beijing Huoli Qingyuan Co, Ltd. (China) for their assistance in providing the hydrogen-rich water.	Alexander JJ, 2008, NEUROCHEM INT, V52, P447, DOI 10.1016/j.neuint.2007.08.006; Andersson U, 2000, J EXP MED, V192, P565, DOI 10.1084/jem.192.4.565; Brooks WM, 2001, J HEAD TRAUMA REHAB, V16, P149, DOI 10.1097/00001199-200104000-00005; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; Cai JM, 2009, BRAIN RES, V1256, P129, DOI 10.1016/j.brainres.2008.11.048; Calabresi P, 2013, LANCET NEUROL, V12, P811, DOI 10.1016/S1474-4422(13)70118-2; Chavan SS, 2012, MOL MED, V18, P930, DOI 10.2119/molmed.2012.00195; Davis A E, 2000, Crit Care Nurs Clin North Am, V12, P447; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dogan A, 1997, J NEUROSURG, V87, P921, DOI 10.3171/jns.1997.87.6.0921; Elkind MSV, 2010, STROKE, V41, pS3, DOI 10.1161/STROKEAHA.110.594945; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Fu Y, 2009, NEUROSCI LETT, V453, P81, DOI 10.1016/j.neulet.2009.02.016; Fukuda KI, 2007, BIOCHEM BIOPH RES CO, V361, P670, DOI 10.1016/j.bbrc.2007.07.088; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; George JF, 2010, KIDNEY INT, V77, P85, DOI 10.1038/ki.2009.432; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Han L, 2015, BRAIN RES, V1615, P129, DOI 10.1016/j.brainres.2015.04.038; Harris JL, 2012, J CEREBR BLOOD F MET, V32, P2122, DOI 10.1038/jcbfm.2012.114; Hayashida K, 2014, CIRCULATION, V130, P2173, DOI 10.1161/CIRCULATIONAHA.114.011848; Hou ZG, 2012, BRAIN RES BULL, V88, P560, DOI 10.1016/j.brainresbull.2012.06.006; Hu N, 2014, BRAIN RES, V1551, P13, DOI 10.1016/j.brainres.2014.01.015; Huang WC, 2010, CYTOKINE, V51, P119, DOI 10.1016/j.cyto.2010.02.021; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Ji XT, 2012, J SURG RES, V178, pE9, DOI 10.1016/j.jss.2011.12.038; Kadowaki T, 2007, NEUROSCI LETT, V411, P26, DOI 10.1016/j.neulet.2006.07.079; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; Kumar A., 2015, J NEUROTRAUMA; Kumar A, 2012, BRAIN BEHAV IMMUN, V26, P1191, DOI 10.1016/j.bbi.2012.06.008; Lee HF, 2012, RESP PHYSIOL NEUROBI, V182, P1, DOI 10.1016/j.resp.2012.01.016; Lescot T, 2010, J NEUROTRAUM, V27, P85, DOI 10.1089/neu.2009.0982; Lozano D, 2015, NEUROPSYCH DIS TREAT, V11, P97, DOI 10.2147/NDT.S65815; Marino S, 2011, NEUROCRIT CARE, V14, P127, DOI 10.1007/s12028-010-9406-6; Molteni R, 2004, NEUROSCIENCE, V123, P429, DOI 10.1016/j.neuroscience.2003.09.020; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Nishioku T, 2009, CELL MOL NEUROBIOL, V29, P309, DOI 10.1007/s10571-008-9322-x; Ohsawa I, 2007, NAT MED, V13, P688, DOI 10.1038/nm1577; Price WS, 1996, J MAGN RESON SER B, V112, P190, DOI 10.1006/jmrb.1996.0129; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; Pytel P, 2009, CURR OPIN NEUROL, V22, P283, DOI 10.1097/WCO.0b013e32832b3101; Saghaei E, 2013, NEUROSCI RES, V75, P316, DOI 10.1016/j.neures.2013.01.010; Schuhmann MU, 2003, J NEUROTRAUM, V20, P725, DOI 10.1089/089771503767869962; Sha YG, 2008, J IMMUNOL, V180, P2531, DOI 10.4049/jimmunol.180.4.2531; SHARIEF MK, 1992, J NEUROIMMUNOL, V38, P27, DOI 10.1016/0165-5728(92)90087-2; Sheu JN, 2013, COMP IMMUNOL MICROB, V36, P137, DOI 10.1016/j.cimid.2012.11.002; Shimoda K, 2014, WORLD NEUROSURG, V82, DOI 10.1016/j.wneu.2014.08.014; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Su Y, 2014, NEUROSCIENCE, V266, P56, DOI 10.1016/j.neuroscience.2014.02.006; Suda S, 2013, EUR J PHARMACOL, V707, P26, DOI 10.1016/j.ejphar.2013.03.020; Sun QA, 2011, CRIT CARE MED, V39, P765, DOI 10.1097/CCM.0b013e318206bf44; Tian RF, 2015, BRAIN RES, V1622, P339, DOI 10.1016/j.brainres.2015.06.039; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wei XE, 2012, J NEUROTRAUM, V29, P2413, DOI 10.1089/neu.2010.1510; Zhang JY, 2011, STROKE, V42, P1420, DOI 10.1161/STROKEAHA.110.598334; Zweckberger K, 2011, NEUROL RES, V33, P875, DOI 10.1179/1743132811Y.0000000017	55	31	36	2	32	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	APR 15	2016	1637						1	13		10.1016/j.brainres.2016.01.029			13	Neurosciences	Neurosciences & Neurology	DK0NY	WOS:000374610700001	26826009				2021-06-18	
J	El Idrissi, NB; Bosch, S; Ramaglia, V; Aronica, E; Baas, F; Troost, D				El Idrissi, Nawal Bahia; Bosch, Sanne; Ramaglia, Valeria; Aronica, Eleonora; Baas, Frank; Troost, Dirk			Complement activation at the motor end-plates in amyotrophic lateral sclerosis	JOURNAL OF NEUROINFLAMMATION			English	Article						Amyotrophic lateral sclerosis; Motor end-plates; Complement; C1q; MAC; CD55; CD59	TRAUMATIC BRAIN-INJURY; G93A MOUSE MODEL; NEUROMUSCULAR-JUNCTION; TRANSMITTER RELEASE; PATHWAY ACTIVATION; ANIMAL-MODELS; ALS; DISEASE; SYSTEM; NERVE	Background: Amyotrophic lateral sclerosis (ALS) is a fatal progressive neurodegenerative disease with no available therapy. Components of the innate immune system are activated in the spinal cord and central nervous system of ALS patients. Studies in the SOD1(G93A) mouse show deposition of C1q and C3/C3b at the motor end-plate before neurological symptoms are apparent, suggesting that complement activation precedes neurodegeneration in this model. To obtain a better understanding of the role of complement at the motor end-plates in human ALS pathology, we analyzed post-mortem tissue of ALS donors for complement activation and its regulators. Methods: Post-mortem intercostal muscle biopsies were collected at autopsy from ALS (n = 11) and control (n = 6) donors. The samples were analyzed for C1q, membrane attack complex (MAC), CD55, and CD59 on the motor end-plates, using immunofluorescence or immunohistochemistry. Results: Here, we show that complement activation products and regulators are deposited on the motor end-plates of ALS patients. C1q co-localized with neurofilament in the intercostal muscle of ALS donors and was absent in controls (P = 0.001). In addition, C1q was found deposited on the motor end-plates in the intercostal muscle. MAC was also found deposited on motor end-plates that were innervated by nerves in the intercostal muscle of ALS donors but not in controls (P = 0.001). High levels of the regulators CD55 and CD59 were detected at the motor end-plates of ALS donors but not in controls, suggesting an attempt to counteract complement activation and prevent MAC deposition on the end-plates before they are lost. Conclusions: This study provides evidence that complement activation products are deposited on innervated motor end-plates in the intercostal muscle of ALS donors, indicating that complement activation may precede end-plate denervation in human ALS. This study adds to the understanding of ALS pathology in man and identifies complement as a potential modifier of the disease process.	[El Idrissi, Nawal Bahia; Bosch, Sanne; Ramaglia, Valeria; Baas, Frank] Univ Amsterdam, Acad Med Ctr, Dept Genome Anal, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands; [Aronica, Eleonora; Troost, Dirk] Univ Amsterdam, Acad Med Ctr, Dept Neuropathol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands	Baas, F (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Genome Anal, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	f.baas@amc.nl	Baas, Frank/F-9574-2010	Baas, Frank/0000-0003-3912-5428; Aronica, Eleonora/0000-0002-3542-3770			Anderson AJ, 2004, J NEUROTRAUM, V21, P1831, DOI 10.1089/0897715042664894; APPEL SH, 1991, ADV NEUROL, V56, P405; Boillee S, 2006, SCIENCE, V312, P1389, DOI 10.1126/science.1123511; Bonifati DM, 2007, MOL IMMUNOL, V44, P999, DOI 10.1016/j.molimm.2006.03.007; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Cozzolino M, 2008, ANTIOXID REDOX SIGN, V10, P405, DOI 10.1089/ars.2007.1760; Di Giorgio FP, 2007, NAT NEUROSCI, V10, P608, DOI 10.1038/nn1885; Dupuis L, 2009, CURR OPIN PHARMACOL, V9, P341, DOI 10.1016/j.coph.2009.03.007; Dupuis L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005390; Eisen A, 2001, MUSCLE NERVE, V24, P564, DOI 10.1002/mus.1042; El Idrissi NB, 2015, ACTA NEUROPATHOL, V129, P653, DOI 10.1007/s00401-015-1404-5; Ferraiuolo L, 2007, J NEUROSCI, V27, P9201, DOI 10.1523/JNEUROSCI.1470-07.2007; Fischer LR, 2004, EXP NEUROL, V185, P232, DOI 10.1016/j.expneurol.2003.10.004; Fluiter K, 2014, J IMMUNOL, V192, P2339, DOI 10.4049/jimmunol.1302793; Heurich B, 2011, J NEUROIMMUNOL, V235, P104, DOI 10.1016/j.jneuroim.2011.03.011; Huber-Lang M, 2006, NAT MED, V12, P682, DOI 10.1038/nm1419; Humayun S, 2009, J NEUROIMMUNOL, V210, P52, DOI 10.1016/j.jneuroim.2009.01.028; Karlsborg M, 2004, AMYOTROPH LATERAL SC, V5, P136, DOI 10.1080/14660820410018982; Lee JD, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-119; LEHRER GM, 1959, J BIOPHYS BIOCHEM CY, V6, P399, DOI 10.1083/jcb.6.3.399; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Leslie M, 2012, SCIENCE, V337, P1034, DOI 10.1126/science.337.6098.1034; Lin F, 2001, IMMUNOLOGY, V104, P215, DOI 10.1046/j.1365-2567.2001.01287.x; Liszewski MK, 1996, ADV IMMUNOL, V61, P201; Lobsiger CS, 2007, P NATL ACAD SCI USA, V104, P7319, DOI 10.1073/pnas.0702230104; Lobsiger CS, 2014, P NATL ACAD SCI USA, V111, pE5, DOI 10.1073/pnas.1321606111; Lobsiger CS, 2013, P NATL ACAD SCI USA, V110, pE4385, DOI 10.1073/pnas.1318309110; Mantovani S, 2014, J NEUROIMMUNOL, V276, P213, DOI 10.1016/j.jneuroim.2014.09.005; Mitchell JD, 2007, LANCET, V369, P2031, DOI 10.1016/S0140-6736(07)60944-1; Mohamed HA, 2002, J NEUROSCI RES, V69, P110, DOI 10.1002/jnr.10271; Muchnik S, 2002, CLIN NEUROPHYSIOL, V113, P1066, DOI 10.1016/S1388-2457(02)00108-6; O'Shaughnessy TJ, 1998, MUSCLE NERVE, V21, P81, DOI 10.1002/(SICI)1097-4598(199801)21:1<81::AID-MUS11>3.0.CO;2-3; Pagani MR, 2006, J NEUROSCI, V26, P2661, DOI 10.1523/JNEUROSCI.4394-05.2006; Pasinelli P, 2006, NAT REV NEUROSCI, V7, P710, DOI 10.1038/nrn1971; Ramaglia V, 2008, AM J PATHOL, V172, P1043, DOI 10.2353/ajpath.2008.070660; Ramaglia V, 2009, MOL IMMUNOL, V47, P302, DOI 10.1016/j.molimm.2009.09.019; Rancan M, 2003, J CEREBR BLOOD F MET, V23, P1070, DOI 10.1097/01.WCB.0000084250.20114.2C; Raoul C, 2002, NEURON, V35, P1067, DOI 10.1016/S0896-6273(02)00905-4; Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923; de Cordoba SR, 2012, IMMUNOBIOLOGY, V217, P1034, DOI 10.1016/j.imbio.2012.07.021; Soltys J, 2012, J NEUROIMMUNOL, V244, P63, DOI 10.1016/j.jneuroim.2012.01.003; Sta M, 2011, NEUROBIOL DIS, V42, P211, DOI 10.1016/j.nbd.2011.01.002; Stahel PF, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-2; UCHITEL OD, 1988, P NATL ACAD SCI USA, V85, P7371, DOI 10.1073/pnas.85.19.7371; UCHITEL OD, 1992, NEUROLOGY, V42, P2175, DOI 10.1212/WNL.42.11.2175; Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406; Walport MJ, 2001, NEW ENGL J MED, V344, P1140, DOI 10.1056/NEJM200104123441506; Woodruff TM, 2014, P NATL ACAD SCI USA, V111, pE3, DOI 10.1073/pnas.1321248111; Woodruff TM, 2008, J IMMUNOL, V181, P8727, DOI 10.4049/jimmunol.181.12.8727; Woodruff TM, 2008, ADV EXP MED BIOL, V632, P143, DOI 10.1007/978-0-387-78952-1_11	50	31	31	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	APR 7	2016	13								72	10.1186/s12974-016-0538-2			12	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	DI6EQ	WOS:000373592400001	27056040	DOAJ Gold, Green Published			2021-06-18	
J	Gelonch, O; Garolera, M; Valls, J; Rossello, L; Pifarre, J				Gelonch, Olga; Garolera, Maite; Valls, Joan; Rossello, Lluis; Pifarre, Josep			Executive function in fibromyalgia: Comparing subjective and objective measures	COMPREHENSIVE PSYCHIATRY			English	Article							BEHAVIOR RATING INVENTORY; SELF-REPORTED DIFFERENCES; TRAUMATIC BRAIN-INJURY; ECOLOGICAL VALIDITY; WORKING-MEMORY; MAJOR DEPRESSION; HEALTHY CONTROLS; NEUROPSYCHOLOGICAL ASSESSMENT; COGNITIVE COMPLAINTS; DECISION-MAKING	Background: There is evidence to suggest the existence of an executive dysfunction in people diagnosed with fibromyalgia, although there are certain inconsistencies between studies. Here, we aim to compare executive performance between patients with fibromyalgia and a control group by using subjective and objective cognitive tests, analyzing the influence of patient mood on the results obtained, and studying associations between the two measures. Method: 82 patients diagnosed with fibromyalgia and 42 healthy controls, matched by age and years of education, were assessed using the Behavioral Rating Inventory of Executive Function Adult Version (BRIEF-A) as a subjective measure of executive functioning. A selection of objective cognitive tests were also used to measure a series of executive functions and to identify symptoms of depression and anxiety. Results: Patients with fibromyalgia perceived greater difficulties than the control group on all of the BRIEF-A scales. However, after adjustments were made for depression and anxiety the only differences that remained were those associated with the working memory scale and the Metacognition and Global Executive Composite index. In the case of the objective cognitive tests, a significantly worse overall performance was evidenced for the fibromyalgia patients. However, this also disappeared when adjustments were made for depression and anxiety. After this adjustment, fibromyalgia patients only performed significantly worse for the interference effect in the Stroop Test. Although there were no significant associations between most of the objective cognitive tests and the BRIEF-A scales, depression and anxiety exhibited strong associations with almost all of the BRIEF-A scales and with several of the objective cognitive tests. Conclusions: Patients with fibromyalgia showed executive dysfunction in subjective and objective measures, although most of this impairment was associated with mood disturbances. Exceptions to this general rule were observed in the impairment of working memory evidenced on the BRIEF-A scale and the inhibition impairment exhibited by the interference effect from the Stroop Test. The two types of measurement provide different yet complementary information. (C) 2016 Elsevier Inc. All rights reserved.	[Gelonch, Olga; Garolera, Maite] Consorci Sanitari Terrassa, Clin Res Grp Brain Cognit & Behav, Terrassa, Spain; [Gelonch, Olga; Pifarre, Josep] Univ Lleida, C Montserrat Roig 2, Lleida 25008, Spain; [Garolera, Maite] Hosp Terrassa, Consorci Sanitari Terrassa, Neuropsychol Unit, Terrassa, Spain; [Valls, Joan; Pifarre, Josep] IRB Lleida, Inst Biomed Res Lleida, Lleida, Spain; [Rossello, Lluis] Hosp Univ Santa Maria, Fibromyalgia & Chron Fatigue Syndrome Unit, Rheumatol Sect, Lleida, Spain	Pifarre, J (corresponding author), Univ Lleida, C Montserrat Roig 2, Lleida 25008, Spain.	pifarre1@comll.cat	Garolera, Maite/D-7811-2012; Garolera, Maite/A-3109-2015; GELONCH, OLGA/P-6406-2018; Pifarre, Josep/B-5884-2009	Garolera, Maite/0000-0001-7443-8249; Garolera, Maite/0000-0001-7443-8249; GELONCH, OLGA/0000-0002-0788-2486; Pifarre, Josep/0000-0001-6284-4709; Valls, Joan/0000-0002-4806-7568; Rossello, Lluis/0000-0001-6752-4851			Amutio A, 2015, FRONT PSYCHOL, V5, DOI 10.3389/fpsyg.2014.01572; Arnold LM, 2008, PATIENT EDUC COUNS, V73, P114, DOI 10.1016/j.pec.2008.06.005; Artiola L, 1999, MANUAL NORMAS PROCED; Balash Y, 2013, ACTA NEUROL SCAND, V127, P344, DOI 10.1111/ane.12038; Barkley RA, 2011, DEV NEUROPSYCHOL, V36, P137, DOI 10.1080/87565641.2010.549877; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; Berryman C, 2014, CLIN PSYCHOL REV, V34, P563, DOI 10.1016/j.cpr.2014.08.003; Bombin-Gonzalez I, 2014, REV NEUROLOGIA, V59, P77, DOI 10.33588/rn.5902.2013578; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Chaytor N, 2007, J INT NEUROPSYCH SOC, V13, P377, DOI 10.1017/S1355617707070592; Cherry BJ, 2014, J GERONTOL B-PSYCHOL, V69, P199, DOI 10.1093/geronb/gbs122; Ciszewski S, 2014, EAT BEHAV, V15, P175, DOI 10.1016/j.eatbeh.2014.01.004; Moreno MIC, 2012, PSICOTHEMA, V24, P668; Crombez G, 2005, PAIN, V116, P4, DOI 10.1016/j.pain.2005.03.035; Fietta Pierluigi, 2007, Acta Biomed, V78, P88; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Ganguli M, 2009, INT J GERIATR PSYCH, V24, P1277, DOI 10.1002/gps.2257; Garcia-Molina A, 2012, BRAIN INJURY, V26, P864, DOI 10.3109/02699052.2012.655362; Glass JM, 2011, J PAIN, V12, P1219, DOI 10.1016/j.jpain.2011.06.007; Glass JM, 2009, RHEUM DIS CLIN N AM, V35, P299, DOI 10.1016/j.rdc.2009.06.002; Goldberg E, 2000, J CLIN EXP NEUROPSYC, V22, P56, DOI 10.1076/1380-3395(200002)22:1;1-8;FT056; Golden C, STROOP COLOR WORD TE; Gracely RH, 2002, ARTHRITIS RHEUM-US, V46, P1333, DOI 10.1002/art.10225; Greve KW, 2001, CLIN NEUROPSYCHOL, V15, P228, DOI 10.1076/clin.15.2.228.1901; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Hadjiefthyvoulou F, 2012, COGN BEHAV NEUROL, V25, P128, DOI 10.1097/WNN.0b013e318261459c; Hanssen KT, 2014, ACTA NEUROL SCAND, V129, P234, DOI 10.1111/ane.12177; Harvey PO, 2005, NEUROIMAGE, V26, P860, DOI 10.1016/j.neuroimage.2005.02.048; Heaton R. K, 1981, WISCONSIN CARD SORTI; Landro NI, 1997, J PSYCHOSOM RES, V42, P297, DOI 10.1016/S0022-3999(96)00301-7; Leeuw M, 2007, J BEHAV MED, V30, P77, DOI 10.1007/s10865-006-9085-0; Lewis MW, 2011, NEUROPSYCHOL REHABIL, V21, P145, DOI 10.1080/09602011.2010.543867; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Li Y, 2013, SCAND J PSYCHOL, V54, P485, DOI 10.1111/sjop.12083; Liik M, 2009, EPILEPSY RES, V84, P194, DOI 10.1016/j.eplepsyres.2009.02.006; Lovstad M, 2012, BRAIN INJURY, V26, P1586, DOI 10.3109/02699052.2012.698787; Luerding R, 2008, BRAIN, V131, P3222, DOI 10.1093/brain/awn229; Magan I, 2008, SPAN J PSYCHOL, V11, P626, DOI 10.1017/S1138741600004637; Martyr A, 2012, DEMENT GERIATR COGN, V33, P189, DOI 10.1159/000338233; McAuley T, 2010, J INT NEUROPSYCH SOC, V16, P495, DOI 10.1017/S1355617710000093; Mercado F, 2013, INT J PSYCHOPHYSIOL, V88, P182, DOI 10.1016/j.ijpsycho.2013.03.017; Miro E, 2011, PSYCHOL HEALTH, V26, P765, DOI 10.1080/08870446.2010.493611; Moore DJ, 2007, J PSYCHIATR RES, V41, P97, DOI 10.1016/j.jpsychires.2005.10.008; Munguia-Izquierdo D, 2008, PSICOTHEMA, V20, P427; Owen AM, 2005, HUM BRAIN MAPP, V25, P46, DOI 10.1002/hbm.20131; Park DC, 2001, ARTHRITIS RHEUM, V44, P2125, DOI 10.1002/1529-0131(200109)44:9<2125::AID-ART365>3.0.CO;2-1; Peters AT, 2014, J PSYCHIATR RES, V53, P87, DOI 10.1016/j.jpsychires.2014.02.018; Power BD, 2012, J NEUROPSYCH CLIN N, V24, P215, DOI 10.1176/appi.neuropsych.11060145; Rabin LA, 2006, ARCH CLIN NEUROPSYCH, V21, P721, DOI 10.1016/j.acn.2006.08.004; Reid RC, 2012, INT J NEUROSCI, V122, P500, DOI 10.3109/00207454.2012.673516; Reid RC, 2010, INT J NEUROSCI, V120, P120, DOI 10.3109/00207450903165577; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Roth R.M., 2005, BEHAV RATING INVENTO; Roth RM, 2004, PSYCHIAT CLIN N AM, V27, P83, DOI 10.1016/S0193-953X(03)00112-6; Schmidt-Wilcke T, 2010, SCHMERZ, V24, P46, DOI 10.1007/s00482-009-0872-8; Seo J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037808; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Shmygalev S, 2014, PAIN THER; SLETVOLD H, 1995, J RHEUMATOL, V22, P137; Spielberger C. D., 2008, CUESTIONARIO ANSIEDA; Spielberger C.D., 1970, STATE TRAIT ANXIETY; Suhr JA, 2003, J PSYCHOSOM RES, V55, P321, DOI 10.1016/S0022-3999(02)00628-1; Tesio V, 2014, ARTHRITIS CARE RES H; Torta R, 2014, REUMATISMO, V66, P92, DOI 10.4081/reumatismo.2014.769; van Beilen M, 2005, J PSYCHIATR RES, V39, P585, DOI 10.1016/j.jpsychires.2005.02.001; Verdejo-Garcia A, 2009, ARCH CLIN NEUROPSYCH, V24, P113, DOI 10.1093/arclin/acp014; Vogel A, 2011, LUPUS, V20, P35, DOI 10.1177/0961203310382430; Walitt B, 2008, RHEUMATOL INT, V28, P561, DOI 10.1007/s00296-007-0487-2; Wechsler D, 1999, WAIS 3 WCALA INTELIG; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; Wolfe F, 2010, ARTHRIT CARE RES, V62, P600, DOI 10.1002/acr.20140; Zimmer HD, 2008, NEUROSCI BIOBEHAV R, V32, P1373, DOI 10.1016/j.neubiorev.2008.05.016	72	31	31	1	21	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0010-440X	1532-8384		COMPR PSYCHIAT	Compr. Psychiat.	APR	2016	66						113	122		10.1016/j.comppsych.2016.01.002			10	Psychiatry	Psychiatry	DH4ML	WOS:000372760000016	26995244	Green Accepted			2021-06-18	
J	Park, S; Theodoros, D; Finch, E; Cardell, E				Park, Stacie; Theodoros, Deborah; Finch, Emma; Cardell, Elizabeth			Be Clear: A New Intensive Speech Treatment for Adults With Nonprogressive Dysarthria	AMERICAN JOURNAL OF SPEECH-LANGUAGE PATHOLOGY			English	Article							SILVERMAN-VOICE-TREATMENT; NEURAL PLASTICITY; ACOUSTIC CHARACTERISTICS; CONTEXTUAL INTERFERENCE; CONVERSATIONAL SPEECH; PRINCIPLED APPROACH; PARKINSONS-DISEASE; TREATMENT LSVT; INDIVIDUALS; INTELLIGIBILITY	Purpose: This article describes the effects of a new intensive dysarthria treatment program (Be Clear) on speech intelligibility in adults with dysarthria secondary to stroke and traumatic brain injury. Method: A small group-repeated measures research design was used to examine the effects of treatment on the speech of 8 participants with nonprogressive dysarthria. Treatment consisted of a 1-hr prepractice session followed by 1-hr therapy sessions, 4 times per week, for 4 weeks (16 sessions). Paired-comparison ratings of speech intelligibility served as the primary outcome measure for the study. Perceptual data, quality of life, and communication partner opinion were obtained at 3 time intervals: (a) prior to treatment, (b) immediately posttreatment, and (c) 1-3 months posttreatment. Results: Following treatment, group data demonstrated substantial improvements in speech intelligibility as perceived by naive listeners on a paired-comparison rating task. Word intelligibility was clinically significantly improved posttreatment and sentence intelligibility demonstrated statistically significant improvement. Communication partner ratings of speech intelligibility and overall communicative function were statistically significantly improved posttreatment. Conclusions: The results of this study suggest that this new intensive treatment may have potential as an effective intervention for nonprogressive dysarthria. However, controlled studies are required to establish treatment efficacy.	[Park, Stacie; Theodoros, Deborah; Finch, Emma] Univ Queensland, St Lucia, Qld, Australia; [Finch, Emma] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia; [Finch, Emma] Metro South Hlth, Ctr Functioning & Hlth Res, Brisbane, Qld, Australia; [Cardell, Elizabeth] Griffith Univ, Griffith Hlth Inst, Gold Coast, Australia	Park, S (corresponding author), Univ Queensland, St Lucia, Qld, Australia.	s.park3@uq.edu.au	Finch, Emma/B-3067-2011; Cardell, Elizabeth/AAV-8394-2020	Finch, Emma/0000-0002-9690-8165; Cardell, Elizabeth/0000-0002-8327-1003			Albaret JM, 1998, ACTA PSYCHOL, V100, P9, DOI 10.1016/S0001-6918(98)00022-5; Ballard KJ, 2007, APHASIOLOGY, V21, P1195, DOI 10.1080/02687030601047858; Ballard KJ, 2012, MOTOR CONTROL, V16, P106, DOI 10.1123/mcj.16.1.106; Beukelman DR, 2002, J MED SPEECH-LANG PA, V10, P237; Bhogal SK, 2003, STROKE, V34, P987, DOI 10.1161/01.STR.0000062343.64383.D0; Blanchet P., 2014, J COMMUN DISORD, V2, P106; Blanchet PG, 2010, PERCEPT MOTOR SKILL, V110, P965, DOI 10.2466/PMS.110.3.965-982; Blanchet PG, 2009, J MED SPEECH-LANG PA, V17, P1; Bradlow AR, 2003, J SPEECH LANG HEAR R, V46, P80, DOI 10.1044/1092-4388(2003/007); Brady MC, 2011, CLIN REHABIL, V25, P935, DOI 10.1177/0269215511405079; Bunton Kate, 2008, Seminars in Speech and Language, V29, P267, DOI 10.1055/s-0028-1103390; Clark HM, 2003, AM J SPEECH-LANG PAT, V12, P400, DOI 10.1044/1058-0360(2003/086); Dickson S, 2008, INT J LANG COMM DIS, V43, P135, DOI 10.1080/13682820701862228; Duffy JR, 2013, MOTOR SPEECH DISORDE; Dykstra Allyson D., 2007, Seminars in Speech and Language, V28, P301, DOI 10.1055/s-2007-986527; Feigin VL, 2003, LANCET NEUROL, V2, P43, DOI 10.1016/S1474-4422(03)00266-7; Ferguson SH, 2007, J SPEECH LANG HEAR R, V50, P1241, DOI 10.1044/1092-4388(2007/087); Fox CM, 2002, AM J SPEECH-LANG PAT, V11, P111, DOI 10.1044/1058-0360(2002/012); Fox Cynthia M., 2006, Seminars in Speech and Language, V27, P283, DOI 10.1055/s-2006-955118; Goberman AM, 2005, J COMMUN DISORD, V38, P215, DOI 10.1016/j.jcomdis.2004.10.001; HOGAN EA, 1987, ACAD MANAGE J, V30, P354, DOI 10.2307/256279; INCE LP, 1973, ARCH PHYS MED REHAB, V54, P233; Kleim JA, 2008, J SPEECH LANG HEAR R, V51, pS225, DOI 10.1044/1092-4388(2008/018); Knock TR, 2000, APHASIOLOGY, V14, P653, DOI 10.1080/026870300401379; Krause JC, 2004, J ACOUST SOC AM, V115, P362, DOI 10.1121/1.1635842; Landin D, 1997, RES Q EXERCISE SPORT, V68, P357, DOI 10.1080/02701367.1997.10608017; Lawrence ES, 2001, STROKE, V32, P1279, DOI 10.1161/01.STR.32.6.1279; LEE TD, 1983, J EXP PSYCHOL LEARN, V9, P730, DOI 10.1037/0278-7393.9.4.730; Ludlow CL, 2008, J SPEECH LANG HEAR R, V51, pS240, DOI 10.1044/1092-4388(2008/019); Maas E, 2008, AM J SPEECH-LANG PAT, V17, P277, DOI 10.1044/1058-0360(2008/025); Mackenzie C, 2007, INT J LANG COMM DIS, V42, P131, DOI 10.1080/13682820600861776; Mackenzie C, 2010, INT J LANG COMM DIS, V45, P617, DOI 10.3109/13682820903470577; Merbah S, 2011, PSYCHOL BELG, V51, P15, DOI 10.5334/pb-51-1-15; Myburgh JA, 2008, J TRAUMA, V64, P854, DOI 10.1097/TA.0b013e3180340e77; PAYTON KL, 1994, J ACOUST SOC AM, V95, P1581, DOI 10.1121/1.408545; PICHENY MA, 1986, J SPEECH HEAR RES, V29, P434, DOI 10.1044/jshr.2904.434; Ramig LO, 2001, MOVEMENT DISORD, V16, P79, DOI 10.1002/1531-8257(200101)16:1<79::AID-MDS1013>3.0.CO;2-H; Robertson S, 2001, INT J LANG COMM DIS, V36, P292, DOI 10.3109/13682820109177900; Robey RR, 2004, J COMMUN DISORD, V37, P401, DOI 10.1016/j.jcomdis.2004.04.003; Sapir S, 2003, AM J SPEECH-LANG PAT, V12, P387, DOI 10.1044/1058-0360(2003/085); Schmidt R. A., 2011, MOTOR CONTROL LEARNI; Sellars C, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002088.pub2; Shea J.B., 1983, MEM CONTROL ACTION, V12, P345; Shepperd JA, 2002, PSYCHOL SCI, V13, P85, DOI 10.1111/1467-9280.00416; Spielman J, 2007, AM J SPEECH-LANG PAT, V16, P95, DOI 10.1044/1058-0360(2007/014); Walshe M, 2009, INT J LANG COMM DIS, V44, P693, DOI 10.1080/13682820802317536; Wenke RJ, 2011, J MED SPEECH-LANG PA, V19, P1; Wulf G., 2007, E J BEWEGUNG TRAININ, V1, P1, DOI DOI 10.1016/J.PSYCHSP0RT.2017.02.007; Yorkston K. M., 1984, ASSESSMENT INTELLIGI; Yorkston KM, 2007, J MED SPEECH-LANG PA, V15, pXI; Yorkston KM, 1996, J SPEECH HEAR RES, V39, pS46, DOI 10.1044/jshr.3905.s46; Yorkston KM, 1989, J HEAD TRAUMA REHAB, V4, P1	52	31	32	1	38	AMER SPEECH-LANGUAGE-HEARING ASSOC	ROCKVILLE	2200 RESEARCH BLVD, #271, ROCKVILLE, MD 20850-3289 USA	1058-0360	1558-9110		AM J SPEECH-LANG PAT	Am. J. Speech-Lang. Pathol.	FEB	2016	25	1					97	110		10.1044/2015_AJSLP-14-0113			14	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Rehabilitation	DI3XO	WOS:000373433900007	26882004				2021-06-18	
J	Bajwa, NM; Halavi, S; Hamer, M; Semple, BD; Noble-Haeusslein, LJ; Baghchechi, M; Hiroto, A; Hartman, RE; Obenaus, A				Bajwa, Nikita M.; Halavi, Shina; Hamer, Mary; Semple, Bridgette D.; Noble-Haeusslein, Linda J.; Baghchechi, Mohsen; Hiroto, Alex; Hartman, Richard E.; Obenaus, Andre			Mild Concussion, but Not Moderate Traumatic Brain Injury, Is Associated with Long-Term Depression-Like Phenotype in Mice	PLOS ONE			English	Article							MOUSE MODEL; BEHAVIORAL DEFICITS; MOOD DISORDERS; ANIMAL-MODEL; IMPACT; IMPAIRMENTS; BLAST; MOTOR; MAZE; RATS	Mild traumatic brain injuries can lead to long-lasting cognitive and motor deficits, increasing the risk of future behavioral, neurological, and affective disorders. Our study focused on long-term behavioral deficits after repeated injury in which mice received either a single mild CHI (mCHI), a repeated mild CHI (rmCHI) consisting of one impact to each hemisphere separated by 3 days, or a moderate controlled cortical impact injury (CCI). Shams received only anesthesia. Behavioral tests were administered at 1, 3, 5, 7, and 90 days post-injury (dpi). CCI animals showed significant motor and sensory deficits in the early (1-7 dpi) and long-term (90 dpi) stages of testing. Interestingly, sensory and subtle motor deficits in rmCHI animals were found at 90 dpi. Most importantly, depression-like behaviors and social passiveness were observed in rmCHI animals at 90 dpi. These data suggest that mild concussive injuries lead to motor and sensory deficits and affective disorders that are not observed after moderate TBI.	[Bajwa, Nikita M.; Halavi, Shina; Hartman, Richard E.] Loma Linda Univ, Sch Behav Hlth, Dept Psychol, Loma Linda, CA 92350 USA; [Hamer, Mary; Baghchechi, Mohsen; Hiroto, Alex; Obenaus, Andre] Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92350 USA; [Semple, Bridgette D.] Univ Melbourne, Melbourne Brain Ctr, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3052, Australia; [Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Sch Med, Dept Neurol Surg, San Francisco, CA USA; [Noble-Haeusslein, Linda J.] Univ Calif San Francisco, Sch Med, Dept Phys Therapy & Rehabil Sci, San Francisco, CA USA; [Obenaus, Andre] Univ Calif Riverside, Cell Mol & Dev Biol Program, Riverside, CA 92521 USA; [Obenaus, Andre] Loma Linda Univ, Sch Behav Hlth, Div Interdisciplinary Studies, Loma Linda, CA 92350 USA	Hartman, RE (corresponding author), Loma Linda Univ, Sch Behav Hlth, Dept Psychol, Loma Linda, CA 92350 USA.; Obenaus, A (corresponding author), Loma Linda Univ, Sch Med, Dept Pediat, Loma Linda, CA 92350 USA.; Obenaus, A (corresponding author), Univ Calif Riverside, Cell Mol & Dev Biol Program, Riverside, CA 92521 USA.; Obenaus, A (corresponding author), Loma Linda Univ, Sch Behav Hlth, Div Interdisciplinary Studies, Loma Linda, CA 92350 USA.	behavioralneuroscience@gmail.com; aobenaus@llu.edu			School of Behavioral Health seed grant at Loma Linda University; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS077767] Funding Source: NIH RePORTER	Funding for this study was provided by the School of Behavioral Health seed grant at Loma Linda University.; This work was supported by School of Behavioral Health seed grant at Loma Linda University. We are thankful to Chris Nishioka for his assistance in behavioral testing and CHI surgeries. Lastly, we would like to thank the Biomedical Undergraduate Research Program at University of California, Riverside for providing research students to assist in MRI analysis.	Ajao DO, 2012, J NEUROTRAUM, V29, P2060, DOI 10.1089/neu.2011.1883; Arakawa H, 2008, NEUROSCI BIOBEHAV R, V32, P1236, DOI 10.1016/j.neubiorev.2008.05.012; Arakawa H, 2009, BEHAV BRAIN RES, V205, P138, DOI 10.1016/j.bbr.2009.07.007; Awwad HO, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00132; Baratz R, 2011, J NEUROCHEM, V118, P1032, DOI 10.1111/j.1471-4159.2011.07377.x; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bowen A, 1998, BRAIN INJURY, V12, P177, DOI 10.1080/026990598122656; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Budde MD, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00154; Budinich CS, 2013, PHARMACOL BIOCHEM BE, V108, P66, DOI 10.1016/j.pbb.2013.04.001; Chauhan NB, 2010, J NEUROSCI METH, V190, P1, DOI 10.1016/j.jneumeth.2010.04.004; Chun IY, 2015, DEV NEUROPSYCHOL, V40, P92, DOI 10.1080/87565641.2015.1020945; Costa TL, 2015, NEUROPSYCHOLOGIA, V78, P142, DOI 10.1016/j.neuropsychologia.2015.10.008; Craft TKS, 2006, BIOL PSYCHIAT, V60, P812, DOI 10.1016/j.biopsych.2006.03.011; Creeley CE, 2004, ACAD EMERG MED, V11, P809, DOI 10.1197/j.aem.2004.03.006; Dantzer R, 2006, NEUROL CLIN, V24, P441, DOI 10.1016/j.ncl.2006.03.003; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Di Battista A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101842; Dompier TP, 2015, JAMA PEDIATR, V169, P659, DOI 10.1001/jamapediatrics.2015.0210; Donovan V, 2014, J CEREBR BLOOD F MET, V34, P715, DOI 10.1038/jcbfm.2014.6; Donovan V, 2012, NEUROIMAGE-CLIN, V1, P18, DOI 10.1016/j.nicl.2012.08.001; Dowlati Y, 2010, BIOL PSYCHIAT, V67, P446, DOI 10.1016/j.biopsych.2009.09.033; Dulcich MS, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/940830; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fenn AM, 2013, BIOL PSYCHIAT, P1; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gerberding JL, 2003, REPORT TO CONGRESS O; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Guley NH, 2015, J NEUROTRAUM, P1; Hall CS, 1932, U CALIFORNIA PUBLICA, V6, P1; Hartman RE, 2006, NEUROBIOL DIS, V24, P506, DOI 10.1016/j.nbd.2006.08.006; Helmick KM, 2015, BRAIN IMAGING BEHAV, V9, P358, DOI 10.1007/s11682-015-9399-z; Hua Y, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/272976; Huang L, 2013, BRAIN RES, V1499, P109, DOI 10.1016/j.brainres.2012.12.038; JONES BJ, 1968, N-S ARCH PHARMAKOL, V259, P211, DOI 10.1007/BF00537801; Jorge RE, 2014, PSYCHIAT CLIN N AM, V37, P13, DOI 10.1016/j.psc.2013.11.005; Kamper JE, 2013, EXP NEUROL, V250, P8, DOI 10.1016/j.expneurol.2013.09.016; Kane MJ, 2012, J NEUROSCI METH, V203, P41, DOI 10.1016/j.jneumeth.2011.09.003; Kim J, 2014, J INT NEUROPSYCH SOC, V20, P887, DOI 10.1017/S1355617714000812; Klemenhagen KC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074510; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Laskowski R.A., 2015, BRAIN NEUROTRAUMA MO, DOI [10.1201/b18126-6, DOI 10.1201/B18126-6]; Lekic T, 2011, EXP NEUROL, V227, P96, DOI 10.1016/j.expneurol.2010.09.017; Luo J, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00012; Mac Donald CL, 2014, JAMA NEUROL, V71, P994, DOI 10.1001/jamaneurol.2014.1114; Mannix R, 2014, J NEUROSURG, V121, P1342, DOI 10.3171/2014.7.JNS14272; McDonald BC, 2012, BRAIN IMAGING BEHAV, V6, P193, DOI 10.1007/s11682-012-9173-4; Milman A, 2008, EUR NEUROPSYCHOPHARM, V18, P181, DOI 10.1016/j.euroneuro.2007.05.007; Milman A, 2005, J NEUROTRAUM, V22, P1003, DOI 10.1089/neu.2005.22.1003; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Namjoshi DR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053529; Nauman EA, 2015, DEV NEUROPSYCHOL, V40, P85, DOI 10.1080/87565641.2015.1016161; Obenaus A., 2012, MILD TRAUMATIC BRAIN, P53; Obenaus A, 2015, ENCYCLOPEDIA OF MENT; Obenaus A, 2007, J NEUROTRAUM, V24, P1147, DOI 10.1089/neu.2006.0211; Pandey DK, 2009, BEHAV BRAIN RES, V205, P436, DOI 10.1016/j.bbr.2009.07.027; Petraglia AL, 2014, J NEUROTRAUM, V31, P1211, DOI 10.1089/neu.2013.3255; PORSOLT RD, 1977, ARCH INT PHARMACOD T, V229, P327; Roth TL, 2014, NATURE, V505, P223, DOI 10.1038/nature12808; Scheff SW, 1997, J NEUROTRAUM, V14, P615, DOI 10.1089/neu.1997.14.615; Schmanke TD, 1996, J NEUROTRAUM, V13, P293, DOI 10.1089/neu.1996.13.293; Semple BD, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00069; Semple BD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103386; Semple BD, 2012, J NEUROTRAUM, V29, P2672, DOI 10.1089/neu.2012.2595; SHEPHERD JK, 1994, PSYCHOPHARMACOLOGY, V116, P56, DOI 10.1007/BF02244871; Shultz SR, 2012, BEHAV BRAIN RES, V229, P145, DOI 10.1016/j.bbr.2011.12.015; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Strain JF, 2015, JAMA NEUROL, V72, P773, DOI 10.1001/jamaneurol.2015.0206; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Trotter BB, 2015, BRAIN, V138, P2278, DOI 10.1093/brain/awv139; Yang ZH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11178; Yu HR, 2014, BRAIN INJURY, V28, P244, DOI 10.3109/02699052.2013.859735; Yu SJ, 2009, BRAIN RES, V1287, P157, DOI 10.1016/j.brainres.2009.06.067	76	31	31	1	22	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	JAN 21	2016	11	1							e0146886	10.1371/journal.pone.0146886			19	Multidisciplinary Sciences	Science & Technology - Other Topics	DB5CE	WOS:000368530300014	26796696	DOAJ Gold, Green Published			2021-06-18	
J	Cao, F; Jiang, Y; Wu, Y; Zhong, JJ; Liu, JS; Qin, XH; Chen, LG; Vitek, MP; Li, FQ; Xu, L; Sun, XC				Cao, Fang; Jiang, Yong; Wu, Yue; Zhong, Jianjun; Liu, Jieshi; Qin, Xinghu; Chen, Ligang; Vitek, Michael P.; Li, Fengqiao; Xu, Lu; Sun, Xiaochuan			Apolipoprotein E-Mimetic COG1410 Reduces Acute Vasogenic Edema following Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						apolipoprotein E; blood-brain barrier; COG1410; controlled cortical impact injury; traumatic brain injury; vasogenic edema	CLOSED-HEAD INJURY; E-BASED PEPTIDE; IMPROVES COGNITIVE PERFORMANCE; SYSTEM INFLAMMATORY RESPONSE; E-DEFICIENT MICE; SUBARACHNOID HEMORRHAGE; MICROGLIAL ACTIVATION; BARRIER PERMEABILITY; CEREBRAL EDEMA; MURINE MODEL	The degree of post-traumatic brain edema and dysfunction of the blood-brain barrier (BBB) influences the neurofunctional outcome after a traumatic brain injury (TBI). Previous studies have demonstrated that the administration of apolipoprotein E-mimetic peptide COG1410 reduces the brain water content after subarachnoid hemorrhage, intra-cerebral hemorrhage, and focal brain ischemia. However, the effects of COG1410 on vasogenic edema following TBI are not known. The current study evaluated the effects of 1mg/kg daily COG1410 versus saline administered intravenously after a controlled cortical impact (CCI) injury on BBB dysfunction and vasogenic edema at an acute stage in mice. The results demonstrated that treatment with COG1410 suppressed the activity of matrix metalloproteinase-9, reduced the disruption of the BBB and Evans Blue dye extravasation, reduced the TBI lesion volume and vasogenic edema, and decreased the functional deficits compared with mice treated with vehicle, at an acute stage after CCI. These findings suggest that COG1410 is a promising preclinical therapeutic agent for the treatment of traumatic brain injury.	[Cao, Fang; Wu, Yue; Zhong, Jianjun; Sun, Xiaochuan] Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China; [Jiang, Yong; Liu, Jieshi; Qin, Xinghu; Chen, Ligang] Luzhou Med Coll, Affiliated Hosp, Dept Neurosurg, Luzhou, Peoples R China; [Vitek, Michael P.] Duke Univ, Med Ctr, Dept Med Neurol, Durham, NC 27710 USA; [Li, Fengqiao] Cognosci Inc, Res Triangle Pk, NC USA; [Xu, Lu] Chongqing Med Univ, Chongqing Key Lab Biochem & Mol Pharmacol, Chongqing 400016, Peoples R China	Sun, XC (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Chongqing 400016, Peoples R China.	jiangy0122@qq.com; sunxch1445@qq.com		Vitek, Michael/0000-0001-8140-8048; Wu, Yue/0000-0002-9073-5988; sun, xiao chuan/0000-0001-6992-332X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81371319, 81371378, 81000528]; Program for New Century Excellent Talents in UniversityProgram for New Century Excellent Talents in University (NCET) [NCET-12-1057]; Foundation for outstanding youth academic technology leaders of Sichuan province [2014JQ0022]	This work was supported by the National Natural Science Foundation of China (81371319, 81371378 & 81000528), the Program for New Century Excellent Talents in University (NCET-12-1057), and the Foundation for outstanding youth academic technology leaders of Sichuan province (2014JQ0022). We thank Cognosci Inc. for providing COG1410.	Alves JL, 2014, J NEUROSCI RES, V92, P141, DOI 10.1002/jnr.23300; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Cao F, 2012, NEURAL REGEN RES, V7, P119, DOI 10.3969/j.issn.1673-5374.2012.02.007; Chen Y, 1997, NEUROSCIENCE, V80, P1255, DOI 10.1016/S0306-4522(97)00007-9; Donkin JJ, 2010, CURR OPIN NEUROL, V23, P293, DOI 10.1097/WCO.0b013e328337f451; Fullerton SM, 2001, EXP NEUROL, V169, P13, DOI 10.1006/exnr.2001.7631; Gao J, 2006, NEUROCRIT CARE, V4, P25, DOI 10.1385/NCC:4:1:025; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Guo ZD, 2011, ACTA NEUROCHIR SUPPL, V110, P71, DOI 10.1007/978-3-7091-0353-1_13; Hadass O, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076904; Hafezi-Moghadam A, 2007, AM J PHYSIOL-CELL PH, V292, pC1256, DOI 10.1152/ajpcell.00563.2005; HAMM RJ, 1994, J NEUROTRAUM, V11, P187, DOI 10.1089/neu.1994.11.187; Hoane MR, 2007, J NEUROTRAUM, V24, P1108, DOI 10.1089/neu.2006.0254; Hoane MR, 2009, J NEUROTRAUM, V26, P121, DOI 10.1089/neu.2008.0565; James ML, 2009, STROKE, V40, P632, DOI 10.1161/STROKEAHA.108.530402; Jiang Y, 2012, J NEUROTRAUM, V29, P2332, DOI 10.1089/neu.2012.2362; Kaufman NA, 2010, BEHAV BRAIN RES, V214, P395, DOI 10.1016/j.bbr.2010.06.017; Kaya M, 2011, METHODS MOL BIOL, V763, P369, DOI 10.1007/978-1-61779-191-8_25; Kim GW, 2003, J NEUROSCI, V23, P8733; Laskowitz DT, 2006, ACTA NEUROL SCAND, V114, P15, DOI 10.1111/j.1600-0404.2006.00680.x; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Laskowitz DT, 2012, NEUROCRIT CARE, V16, P316, DOI 10.1007/s12028-011-9641-5; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Lomnitski L, 1999, BBA-MOL BASIS DIS, V1453, P359, DOI 10.1016/S0925-4439(99)00010-1; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Lynch JR, 2002, ANN NEUROL, V51, P113, DOI 10.1002/ana.10098; Lynch JR, 2001, J NEUROIMMUNOL, V114, P107, DOI 10.1016/S0165-5728(00)00459-8; Mace BE, 2007, NEUROL RES, V29, P243, DOI 10.1179/016164107X158974; Marmarou A, 2003, ACT NEUR S, V86, P7; Methia N, 2001, MOL MED, V7, P810, DOI 10.1007/BF03401973; Nishitsuji K, 2011, J BIOL CHEM, V286, P17536, DOI 10.1074/jbc.M111.225532; Norris CM, 2009, J NEUROTRAUM, V26, P2269, DOI 10.1089/neu.2009.1029; POIRIER J, 1994, TRENDS NEUROSCI, V17, P525, DOI 10.1016/0166-2236(94)90156-2; Qiao M, 2001, STROKE, V32, P958, DOI 10.1161/01.STR.32.4.958; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; Simard JM, 2007, LANCET NEUROL, V6, P258, DOI 10.1016/S1474-4422(07)70055-8; Thal SC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050752; Truettner JS, 2005, J CEREBR BLOOD F MET, V25, P1505, DOI 10.1038/sj.jcbfm.9600150; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Wang H, 2013, EXP NEUROL, V241, P67, DOI 10.1016/j.expneurol.2012.11.027; Watts LT, 2014, J NEUROTRAUM, V31, P1063, DOI 10.1089/neu.2013.3193; Wei XE, 2011, J TRAUMA, V71, P1645, DOI 10.1097/TA.0b013e31823498eb; Zhou S, 2013, FEBS LETT, V587, P254, DOI 10.1016/j.febslet.2012.12.003	46	31	35	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2016	33	2					175	182		10.1089/neu.2015.3887			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DA7PH	WOS:000367995800003	26192010	Green Published			2021-06-18	
J	Ownsworth, T; Haslam, C				Ownsworth, Tamara; Haslam, Catherine			Impact of rehabilitation on self-concept following traumatic brain injury: An exploratory systematic review of intervention methodology and efficacy	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Traumatic brain injury; Rehabilitation; Self-concept; Systematic review; Self-identity	RANDOMIZED CONTROLLED-TRIAL; HEAD-INJURY; GROUP MEMBERSHIPS; THERAPY; PROGRAM; ADJUSTMENT; COMMUNITY; ESTEEM; HEALTH; QUESTIONNAIRE	To date, reviews of rehabilitation efficacy after traumatic brain injury (TBI) have overlooked the impact on sense of self, focusing instead on functional impairment and psychological distress. The present review sought to address this gap by critically appraising the methodology and efficacy of intervention studies that assess changes in self-concept. A systematic search of PsycINFO, Medline, CINAHL and PubMed was conducted from inception to September 2013 to identify studies reporting pre- and post-intervention changes on validated measures of self-esteem or self-concept in adults with TBI. Methodological quality of randomised controlled trials (RCTs) was examined using the Physiotherapy Evidence Database (PEDro) scale. A total of 17 studies (10 RCTs, 4 non-RCT group studies, 3 case studies) was identified, which examined the impact of psychotherapy, family-based support, cognitive rehabilitation or activity-based interventions on self-concept. The findings on the efficacy of these interventions were mixed, with only 10 studies showing some evidence of improvement in self-concept based on within-group or pre-post comparisons. Such findings highlight the need for greater focus on the impact of rehabilitation on self-understanding with improved assessment and intervention methodology. We draw upon theories of identity reconstruction and highlight implications for the design and evaluation of identity-oriented interventions that can supplement existing rehabilitation programmes for people with TBI.	[Ownsworth, Tamara] Griffith Univ, Sch Appl Psychol, Mt Gravatt, Qld 4122, Australia; [Ownsworth, Tamara] Griffith Univ, Griffith Hlth Inst, Mt Gravatt, Qld 4122, Australia; [Haslam, Catherine] Univ Queensland, Sch Psychol, St Lucia, Qld, Australia	Ownsworth, T (corresponding author), Griffith Univ, Sch Appl Psychol, Mt Gravatt, Qld 4122, Australia.	t.ownsworth@griffith.edu.au	Haslam, Catherine/Y-5763-2018	Haslam, Catherine/0000-0003-0124-9601; Ownsworth, Tamara/0000-0003-1835-7094			Allport G. W., 1961, PATTERN GROWTH PERSO; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Ashworth F, 2011, BRAIN IMPAIR, V12, P128, DOI 10.1375/brim.12.2.128; Backhaus SL, 2010, ARCH PHYS MED REHAB, V91, P840, DOI 10.1016/j.apmr.2010.03.015; Ben-Yishay Y., 2011, HDB HOLISTIC NEUROPS; Berry E, 2009, J NEUROL NEUROSUR PS, V80, P1202, DOI 10.1136/jnnp.2008.164251; Best D, 2014, THER COMMUNITIES, V35, P10, DOI 10.1108/TC-04-2013-0007; Blake H, 2009, CLIN REHABIL, V23, P589, DOI 10.1177/0269215508101736; Bowen C., 2010, RELATIONAL APPROACH; Brenner LA, 2012, J HEAD TRAUMA REHAB, V27, pE57, DOI 10.1097/HTR.0b013e318273414c; Brindley R, 2011, MEMORY, V19, P745, DOI 10.1080/09658211.2010.493893; Bryan-Hancock C, 2010, INJURY PREV, V16, pA99, DOI 10.1136/ip.2010.029215.356; Carroll E, 2011, NEUROPSYCHOL REHABIL, V21, P289, DOI 10.1080/09602011.2011.555972; Cattelani R, 2010, NEUROPSYCHOL REV, V20, P52, DOI 10.1007/s11065-009-9125-y; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cicerone KD, 2008, ARCH PHYS MED REHAB, V89, P2239, DOI 10.1016/j.apmr.2008.06.017; Cooper-Evans S, 2008, NEUROPSYCHOL REHABIL, V18, P607, DOI 10.1080/09602010801948516; Coopersmith S., 1989, SELF ESTEEM INVENTOR; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Culley C, 2010, NEUROPSYCHOL REHABIL, V20, P103, DOI 10.1080/09602010902906926; D'Argembeau A, 2008, SOC COGN AFFECT NEUR, V3, P244, DOI 10.1093/scan/nsn020; Dirette D, 2002, BRAIN INJURY, V16, P861, DOI 10.1080/02699050210131902; Doering BK, 2011, NEUROPSYCHOL REHABIL, V21, P42, DOI 10.1080/09602011.2010.525947; Douglas JM, 2013, BRAIN INJURY, V27, P60, DOI 10.3109/02699052.2012.722254; Driver S, 2006, BRAIN INJURY, V20, P133, DOI 10.1080/02699050500443822; Driver S, 2003, J COGNITIVE REHABILI, V21, P22; Evans JJ, 2011, BRAIN IMPAIR, V12, P117, DOI 10.1375/brim.12.2.117; Feeney T. J., 2010, J BEHAV NEUROSCIENCE, V8, P70; Feinberg TE, 2011, CONSCIOUS COGN, V20, P75, DOI 10.1016/j.concog.2010.09.017; Fines L., 1994, J COGNITIVE REHABILI, V12, P10; Fitts W.H., 1996, TENNESSEE SELF CONCE, V2nd ed; Gelech JM, 2011, QUAL HEALTH RES, V21, P62, DOI 10.1177/1049732310377454; Gracey F., 2012, SOCIAL CURE IDENTITY, P273, DOI DOI 10.4324/9780203813195; Gracey F, 2008, NEUROPSYCHOL REHABIL, V18, P627, DOI 10.1080/09602010802041238; Gracey F, 2009, NEUROPSYCHOL REHABIL, V19, P867, DOI 10.1080/09602010903027763; Harter S., 2012, CONSTRUCTION SELF, V2nd ed; Haslam C., 2012, SOCIAL CURE IDENTITY, P319; Haslam C, 2008, NEUROPSYCHOL REHABIL, V18, P671, DOI 10.1080/09602010701643449; Hawley CA, 2012, NEUROREHABILITATION, V30, P173, DOI 10.3233/NRE-2012-0742; HELFFENSTEIN DA, 1982, INT J CLIN NEUROPSYC, V4, P139; Hodgson J, 2005, BRAIN IMPAIR, V6, P169, DOI DOI 10.1375/BRIM.2005.6.3.169; Howes H, 2005, BRAIN INJURY, V19, P135, DOI 10.1080/02699050410001720077; Hsieh MY, 2012, NEUROPSYCHOL REHABIL, V22, P585, DOI 10.1080/09602011.2012.678860; Iyer A, 2009, BRIT J SOC PSYCHOL, V48, P707, DOI 10.1348/014466608X397628; Jetten J., 2012, SOCIAL CURE IDENTITY, P97; Jetten J, 2014, SOC ISS POLICY REV, V8, P103, DOI 10.1111/sipr.12003; Jones J. M., 2012, SOCIAL CURE IDENTITY, P255; Jones JM, 2011, PSYCHOL HEALTH, V26, P353, DOI 10.1080/08870440903440699; Jumisko Eija, 2005, J Neurosci Nurs, V37, P42; Kangas M, 2011, NEUROPSYCHOL REHABIL, V21, P250, DOI 10.1080/09602011.2010.540920; Kelly A, 2013, NEUROPSYCHOL REHABIL, V23, P563, DOI 10.1080/09602011.2013.795903; Klonoff P. S., 2010, PSYCHOTHERAPY BRIAN; KREFTING L, 1989, OCCUP THER J RES, V9, P67, DOI 10.1177/153944928900900201; Kreutzer JS, 2010, NEUROREHABILITATION, V27, P19, DOI 10.3233/NRE-2010-0578; Kristensen OS, 2004, BRAIN INJURY, V18, P1049, DOI 10.1080/02699050410001672279; Lemmon J., 1996, J COGNITIVE REHABILI, V14, P18; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.7326/0003-4819-151-4-200908180-00136]; Maher CG, 2003, PHYS THER, V83, P713, DOI 10.1093/ptj/83.8.713; Manchester D, 2007, NEUROPSYCHOL REHABIL, V17, P206, DOI 10.1080/09602010600696472; Marsh H.W., 1992, SELF DEFINITIONAL ME, P44; Marsh HW, 1996, RES Q EXERCISE SPORT, V67, P249, DOI 10.1080/02701367.1996.10607952; MCGUIRE BE, 1990, CLIN REHABIL, V4, P319, DOI DOI 10.1177/026921559000400412; McPherson KM, 2009, CLIN REHABIL, V23, P296, DOI 10.1177/0269215509102980; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Muenchberger H, 2008, BRAIN INJURY, V22, P979, DOI 10.1080/02699050802530532; Nochi M, 1997, DISABIL SOC, V12, P533, DOI 10.1080/09687599727119; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; OCEBM, 2011, OXFORD 2011 LEVELS E; Ownsworth T., 2014, SELF IDENTITY BRAIN; Ownsworth TL, 2008, NEUROPSYCHOL REHABIL, V18, P692, DOI 10.1080/09602010701595136; Ponsford J, 2014, BRAIN INJURY, V28, P146, DOI 10.3109/02699052.2013.859733; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Riley GA, 2010, NEUROPSYCHOL REHABIL, V20, P869, DOI 10.1080/09602011.2010.503041; ROBSON P, 1989, PSYCHOL MED, V19, P513, DOI 10.1017/S003329170001254X; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI 10.1126/science.148.3671.804; Schwandt M, 2012, J HEAD TRAUMA REHAB, V27, P99, DOI 10.1097/HTR.0b013e31820e6858; Simpson GK, 2011, J HEAD TRAUMA REHAB, V26, P290, DOI 10.1097/HTR.0b013e3182225250; Sinnakaruppan I, 2005, BRAIN INJURY, V19, P283, DOI 10.1080/02699050400003924; Snyder M, 2009, PSYCHOL PROSOCIAL BE, P139; Tajfel H., 1979, SOCIAL PSYCHOL INTER, P33, DOI DOI 10.1016/S0065-2601(05)37005-5; Tate RL, 1999, PSYCHOL MED, V29, P713, DOI 10.1017/S0033291799008466; TREXLER LE, 2000, INT HDB NEUROPSYCHOL, P137; Turner B, 2009, AM J OCCUP THER, V63, P609, DOI 10.5014/ajot.63.5.609; Turner J.C., 1982, SOCIAL IDENTITY INTE, P15; Turner-Stokes L, 2008, J REHABIL MED, V40, P691, DOI 10.2340/16501977-0265; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; Tyerman A., 1997, HEAD INJURY SEMANTIC; Vickery CD, 2006, REHABIL PSYCHOL, V51, P30, DOI 10.1037/0090-5550.51.1.30; Vickery CD, 2005, BRAIN INJURY, V19, P657, DOI 10.1080/02699050400005218; Walsh RS, 2014, HEALTH PSYCHOL REV, V8, P458, DOI 10.1080/17437199.2012.733914; Wilcock A., 1999, AUST OCCUP THER J, V46, P1, DOI [10.1046/j.1440-1630.1999.00174.x, DOI 10.1046/J.1440-1630.1999.00174.X, DOI 10.1177/000841749806500501]; Wilson BA, 2009, NEUROPSYCHOLOGICAL REHABILITATION: THEORY, MODELS, THERAPY AND OUTCOME, P1, DOI 10.1017/CBO9780511581083; Wright JC, 1996, BRIT J CLIN PSYCHOL, V35, P399, DOI 10.1111/j.2044-8260.1996.tb01194.x; Ylvisaker M, 2008, NEUROPSYCHOL REHABIL, V18, P713, DOI 10.1080/09602010802201832	97	31	31	0	33	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JAN 2	2016	26	1					1	35		10.1080/09602011.2014.977924			35	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	CU7EM	WOS:000363699300001	25384260	Green Accepted			2021-06-18	
J	Amen, DG; Willeumier, K; Omalu, B; Newberg, A; Raghavendra, C; Raji, CA				Amen, Daniel G.; Willeumier, Kristen; Omalu, Bennet; Newberg, Andrew; Raghavendra, Cauligi; Raji, Cyrus A.			Perfusion Neuroimaging Abnormalities Alone Distinguish National Football League Players from a Healthy Population	JOURNAL OF ALZHEIMERS DISEASE			English	Article						Brain imaging; cognition; concussion; football; NFL; SPECT; traumatic brain injury	CHRONIC TRAUMATIC ENCEPHALOPATHY; RETIRED NFL PLAYERS; PROFESSIONAL FOOTBALL; DEPRESSIVE SYMPTOMS; CONCUSSION HISTORY; BRAIN; PATTERNS; ATROPHY	Background: National Football League (NFL) players are exposed to multiple head collisions during their careers. Increasing awareness of the adverse long-term effects of repetitive head trauma has raised substantial concern among players, medical professionals, and the general public. Objective: To determine whether low perfusion in specific brain regions on neuroimaging can accurately separate professional football players from healthy controls. Method: A cohort of retired and current NFL players (n = 161) were recruited in a longitudinal study starting in 2009 with ongoing interval follow up. A healthy control group (n = 124) was separately recruited for comparison. Assessments included medical examinations, neuropsychological tests, and perfusion neuroimaging with single photon emission computed tomography (SPECT). Perfusion estimates of each scan were quantified using a standard atlas. We hypothesized that hypoperfusion particularly in the orbital frontal, anterior cingulate, anterior temporal, hippocampal, amygdala, insular, caudate, superior/mid occipital, and cerebellar sub-regions alone would reliably separate controls from NFL players. Cerebral perfusion differences were calculated using a one-way ANOVA and diagnostic separation was determined with discriminant and automatic linear regression predictive models. Results: NFL players showed lower cerebral perfusion on average (p < 0.01) in 36 brain regions. The discriminant analysis subsequently distinguished NFL players from controls with 90% sensitivity, 86% specificity, and 94% accuracy (95% CI 95-99). Automatic linear modeling achieved similar results. Inclusion of age and clinical co-morbidities did not improve diagnostic classification. Conclusion: Specific brain regions commonly damaged in traumatic brain injury show abnormally low perfusion on SPECT in professional NFL players. These same regions alone can distinguish this group from healthy subjects with high diagnostic accuracy. This study carries implications for the neurological safety of NFL players.	[Amen, Daniel G.; Willeumier, Kristen] Amen Clin Inc, Costa Mesa, CA USA; [Omalu, Bennet] Univ Calif Davis, Dept Pathol, Davis, CA 95616 USA; [Newberg, Andrew] Thomas Jefferson Univ, Myrna Brind Ctr Integrat Med, Philadelphia, PA 19107 USA; [Raghavendra, Cauligi] Univ Southern Calif, Dept Comp Sci, Los Angeles, CA USA; [Raji, Cyrus A.] Univ Calif Los Angeles, Med Ctr, Dept Radiol, Los Angeles, CA USA	Raji, CA (corresponding author), Univ Calif Los Angeles, Med Ctr, Los Angeles, CA USA.	cyrusraji@gmail.com					Alhilali LM, 2015, RADIOLOGY, V277, P793, DOI 10.1148/radiol.2015142974; Amen DG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129659; Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Barrio JR, 2015, P NATL ACAD SCI USA, V112, pE2039, DOI 10.1073/pnas.1409952112; Centers for Disease Control and Prevention, SPORTS REL REC BRAIN; Conners K, CONNERS CPT 2 V 5; Coughlin JM, 2015, NEUROBIOL DIS, V74, P58, DOI 10.1016/j.nbd.2014.10.019; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; Grothe MJ, 2016, HUM BRAIN MAPP, V37, P35, DOI 10.1002/hbm.23018; Hampshire A, 2013, SCI REP-UK, V3, DOI 10.1038/srep02972; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Koerte IK, 2016, J NEUROTRAUM, V33, P346, DOI 10.1089/neu.2015.3880; Moller C, 2016, RADIOLOGY, V279, P838, DOI 10.1148/radiol.2015150220; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Power JD, 2011, NEURON, V72, P665, DOI 10.1016/j.neuron.2011.09.006; Raji CA, 2015, BRAIN IMAGING BEHAV, V9, P527, DOI 10.1007/s11682-015-9385-5; Raji CA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091088; Raymond PD, 2006, CLIN NEUROPSYCHOL, V20, P261, DOI 10.1080/13854040590947416; Richieri R, 2015, PSYCHIAT RES-NEUROIM, V231, P134, DOI 10.1016/j.pscychresns.2014.11.013; Robbins L, 2013, HEADACHE, V53, P817, DOI 10.1111/head.12104; Selverstein SM, 2007, BEHAV RES METHODS, V39, P940, DOI 10.3758/BF03192989; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Strain J, 2013, NEUROLOGY, V81, P25, DOI 10.1212/WNL.0b013e318299ccf8; Strain JF, 2015, JAMA NEUROL, V72, P773, DOI 10.1001/jamaneurol.2015.0206; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Yang H, 2013, MULT LINEAR REGRESSI, V92, P27	27	31	31	0	17	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1387-2877	1875-8908		J ALZHEIMERS DIS	J. Alzheimers Dis.		2016	53	1					237	241		10.3233/JAD-160207			5	Neurosciences	Neurosciences & Neurology	DR2NW	WOS:000379742200021	27128374	Green Published			2021-06-18	
J	Carlozzi, NE; Brickell, TA; French, LM; Sander, A; Kratz, AL; Tulsky, DS; Chiaravalloti, ND; Hahn, EA; Kallen, M; Austin, AM; Miner, JA; Lange, RT				Carlozzi, Noelle E.; Brickell, Tracey A.; French, Louis M.; Sander, Angelle; Kratz, Anna L.; Tulsky, David S.; Chiaravalloti, Nancy D.; Hahn, Elizabeth A.; Kallen, Michael; Austin, Amy M.; Miner, Jennifer A.; Lange, Rael T.			Caring for our wounded warriors: A qualitative examination of health-related quality of life in caregivers of individuals with military-related traumatic brain injury	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						caregiver; health-related quality of life; outcome assessment (health care); quality of life; rehabilitation; service-members; traumatic brain injury; underserved populations; Veterans; wounded warriors	POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH; FAMILY ADJUSTMENT; ISSUES RELEVANT; DEPLOYMENT; VETERANS; SYMPTOMS; IRAQ; IDENTIFICATION; AFGHANISTAN	The purpose of this study was to develop a conceptual framework that captures aspects of health-related quality of life (HRQOL) for caregivers of individuals with military-related traumatic brain injury (TBI). We analyzed qualitative data from nine focus groups composed of caregivers of wounded warriors with a medically documented TBI. Focus group participants were recruited through hospital-based and/or community outreach efforts at the Walter Reed National Military Medical Center, the University of Michigan, and Hearts of Valor support groups (Tennessee and Washington). Participants were the caregivers (n = 45) of wounded warriors who had sustained a mild, moderate, severe, or penetrating TBI. Qualitative frequency analysis indicated that caregivers most frequently discussed social health (44% of comments), followed by emotional (40%) and physical health (12%). Areas of discussion that were specific to this population included anger regarding barriers to health services (for caregivers and servicemembers), emotional suppression (putting on a brave face for others even when things are not going well), and hypervigilance (controlling one's behavior/environment to prevent upsetting the servicemember). Caring for wounded warriors with TBI is a complex experience that positively and negatively affects HRQOL. While some aspects of HRQOL can be evaluated with existing measures, evaluation tools for other important components do not exist. The development of military-specific measures would help facilitate better care for these individuals.	[Carlozzi, Noelle E.; Kratz, Anna L.; Austin, Amy M.; Miner, Jennifer A.] Univ Michigan, Sch Med, Dept Phys Med & Rehabil, North Campus Res Complex,Bldg 14,G216, Ann Arbor, MI 48109 USA; [Brickell, Tracey A.; French, Louis M.; Lange, Rael T.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Brickell, Tracey A.; French, Louis M.; Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [Brickell, Tracey A.; French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA; [Brickell, Tracey A.; French, Louis M.] Ctr Neurosci & Regenerat Med, Bethesda, MD USA; [Sander, Angelle] Baylor Coll Med, TIRR Mem Hermann, Brain Injury Res Ctr, Houston, TX 77030 USA; [Sander, Angelle] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Sander, Angelle] Harris Hlth Syst, Houston, TX USA; [Tulsky, David S.] Univ Delaware, Dept Phys Therapy, Newark, DE USA; [Chiaravalloti, Nancy D.] Kessler Fdn Res Ctr, Traumatic Brain Injury Lab, Neuropsychol & Neurosci Lab, W Orange, NJ USA; [Hahn, Elizabeth A.; Kallen, Michael] Northwestern Univ, Dept Med Social Sci, Chicago, IL 60611 USA; [Lange, Rael T.] Univ British Columbia, Vancouver, BC, Canada	Carlozzi, NE (corresponding author), Univ Michigan, Sch Med, Dept Phys Med & Rehabil, North Campus Res Complex,Bldg 14,G216, Ann Arbor, MI 48109 USA.	carlozzi@med.umich.edu	french, louis/AAB-2083-2020	Chiaravalloti, Nancy/0000-0003-2943-7567; Tulsky, David/0000-0002-4335-4509; french, louis/0000-0002-9451-0604	National Institutes of Health, National Institute of Nursing ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01-NR013658]; Defense and Veterans Brain Injury Center, U.S. Army Medical Research and Materiel Command; National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [K01AR064275]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [K01AR064275] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR013658] Funding Source: NIH RePORTER	This material was based on work supported by the National Institutes of Health, National Institute of Nursing Research (grant R01-NR013658). This material is also based upon work supported in part by the Defense and Veterans Brain Injury Center, U.S. Army Medical Research and Materiel Command. Dr. Kratz's contribution to this manuscript was supported, in part, by the National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant K01AR064275).	Bagalman E, 2013, R40941 C RES SERV US; BASCH CE, 1987, HEALTH EDUC QUART, V14, P411, DOI 10.1177/109019818701400404; BASCH CE, 1989, HEALTH EDUC QUART, V16, P389, DOI 10.1177/109019818901600307; Campbell A., 1976, QUALITY AM LIFE PERC; Carlozzi NE, 2015, ARCH PHYS MED REHAB, V96, P105, DOI 10.1016/j.apmr.2014.08.021; Carlozzi NE, 2013, ARCH PHYS MED REHAB, V94, P1721, DOI 10.1016/j.apmr.2013.02.024; Carlozzi NE, 2013, J HEALTH PSYCHOL, V18, P212, DOI 10.1177/1359105312438109; Carlozzi NE, 2011, ARCH PHYS MED REHAB, V92, pS52, DOI 10.1016/j.apmr.2010.12.046; CELLA DF, 1995, SEMIN ONCOL, V22, P73; Coll JE, 2011, SOC WORK HEALTH CARE, V50, P487, DOI 10.1080/00981389.2010.528727; Dausch BM, 2009, REHABIL PSYCHOL, V54, P279, DOI 10.1037/a0016809; Defense and Veterans Brain Injury Center (DVBIC), DOD WORLDW NUMB TBI; Fischer H, 2015, RS22452 C RES SERV U; Frappell-Cooke W, 2010, OCCUP MED-OXFORD, V60, P645, DOI 10.1093/occmed/kqq149; Griffin JM, 2012, J HEAD TRAUMA REHAB, V27, P3, DOI 10.1097/HTR.0b013e3182274260; Hall LK, 2011, SOC WORK HEALTH CARE, V50, P4, DOI 10.1080/00981389.2010.513914; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Howe LLS, 2009, CLIN NEUROPSYCHOL, V23, P1315, DOI 10.1080/13854040903266928; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Kisala Pamela A, 2010, J Appl Meas, V11, P315; Kratz AL, 2015, NEUROPSYCHOL REHABIL, P1; Lapierre CB, 2007, J TRAUMA STRESS, V20, P933, DOI 10.1002/jts.20278; Lester P, 2010, J AM ACAD CHILD PSY, V49, P310, DOI 10.1016/j.jaac.2010.01.003; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; Mansfield AJ, 2010, NEW ENGL J MED, V362, P101, DOI 10.1056/NEJMoa0900177; McFarlane AC, 2009, CURR OPIN PSYCHIATR, V22, P369, DOI 10.1097/YCO.0b013e32832c9064; Melcer T, 2013, J TRAUMA ACUTE CARE, V75, pS247, DOI 10.1097/TA.0b013e318299d95e; Meyer EG, 2015, ACAD PSYCHIATR, V39, P416, DOI 10.1007/s40596-015-0285-1; National Alliance for Caregiving & United Health Foundation, 2010, CAR VET SERV HOM; Patrick DL, 1988, CLIN NUTR, V7, P53; Phelan SM, 2011, DISABIL HEALTH J, V4, P177, DOI 10.1016/j.dhjo.2011.03.003; Pietrzak RH, 2009, J NERV MENT DIS, V197, P748, DOI 10.1097/NMD.0b013e3181b97a75; Riviere LA, 2012, MIL MED, V177, P1169, DOI 10.7205/MILMED-D-12-00164; Ruff RL, 2009, J REHABIL RES DEV, V46, P1071, DOI 10.1682/JRRD.2009.05.0062; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Stein MB, 2009, AM J PSYCHIAT, V166, P768, DOI 10.1176/appi.ajp.2009.08101604; Taft CT, 2008, J CONSULT CLIN PSYCH, V76, P648, DOI 10.1037/a0012576; Traumatic Brain Injury Model Systems National Data Center, 2006, TRAUM BRAIN INJ MOD; Wilkinson Charles W, 2012, Front Neurol, V3, P11, DOI 10.3389/fneur.2012.00011; Zemke R., 1985, FIGURING THINGS OUT	40	31	31	0	1	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2016	53	6					669	679		10.1682/JRRD.2015.07.0136			11	Rehabilitation	Rehabilitation	EK5SC	WOS:000393985100003	27997672	Green Accepted, Bronze			2021-06-18	
J	Hesdorffer, DC; Ishihara, L; Webb, DJ; Mynepalli, L; Galwey, N; Hauser, WA				Hesdorffer, Dale C.; Ishihara, Lianna; Webb, David J.; Mynepalli, Lakshmi; Galwey, NicholasW.; Hauser, W. Allen			Occurrence and Recurrence of Attempted Suicide Among People With Epilepsy	JAMA PSYCHIATRY			English	Article							TRAUMATIC BRAIN-INJURY; PSYCHIATRIC-DISORDERS; RISK-FACTORS; ANTIEPILEPTIC DRUGS; MULTIPLE-SCLEROSIS; PREMATURE MORTALITY; UNPROVOKED SEIZURES; ALZHEIMERS-DISEASE; MAJOR DEPRESSION; POPULATION	IMPORTANCE People with epilepsy have a 5-fold increased risk of suicide. Less is known about attempted suicide and whether psychiatric disorders and antiepileptic drugs modify the risk of attempted suicide. OBJECTIVES To estimate the magnitude of the association between attempted suicide and epilepsy by comparing a first suicide attempt and a second suicide attempt (hereafter referred to as a recurrent suicide attempt) among people before they received a diagnosis of epilepsy (case patients) with a first suicide attempt and a recurrent suicide attempt among people without epilepsy (control patients), and to evaluate the effect of comorbid psychiatric disorders and the exclusion of antiepileptic drug prescriptions on this association. DESIGN, SETTING, AND PARTICIPANTS Population-based retrospective cohort study in the United Kingdom of case patients with incident epilepsy and control patients without a history of epilepsy in a general practice setting using Clinical Practice Research Datalink. The case patients with incident epilepsy were identified between 1987 and 2013 and were 10 to 60 years of age. The control patients for each case patient were 4 randomly selected people who did not receive a diagnosis of epilepsy before the case patient's epilepsy was diagnosed (the index date), matched by year of birth, sex, and general practice for a control to case ratio of 4 to 1. MAIN OUTCOMES AND MEASURES Hazard ratio for incident and recurrent suicide attempts among case patients with epilepsy compared with control patients without. RESULTS For 14 059 case patients (median age, 36 years [range, 10-60 years]) who later had an onset of epilepsy vs 56 184 control patients (median age, 36 years [range, 10-60 years]), the risk was increased 2.9-fold (95% CI, 2.5-to 3.4-fold) for a first suicide attempt during the time period before the case patients received a diagnosis of epilepsy. For 278 case patients (median age, 37 years [range, 10-61 years]) who later had an onset of epilepsy vs 434 control patients (median age, 35 years [range, 11-61 years]), the risk was increased 1.8-fold (95% CI, 1.3-to 2.5-fold) for a recurrent suicide attempt up to and including the day that epilepsy was diagnosed. Exclusion of antiepileptic drugs prescribed before the index date did not meaningfully alter the findings, nor did separate analyses of patients with and patients without diagnosed psychiatric disorders. CONCLUSIONS AND RELEVANCE Suicide attempts and recurrent suicide attempts are associated with epilepsy even before epilepsy manifests, suggesting a common underlying biology. Our findings indicate that both incident and recurrent suicide attempts are associated with incident epilepsy in the absence of antiepileptic drugs and in the absence of diagnosed psychiatric disorders, further strengthening the evidence for a common underlying etiology with an as-yet-unknown mechanism.	[Hesdorffer, Dale C.; Hauser, W. Allen] Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10032 USA; [Hesdorffer, Dale C.; Hauser, W. Allen] Columbia Univ, Dept Epidemiol, New York, NY 10032 USA; [Ishihara, Lianna] GlaxoSmithKline GSK, Worldwide Epidemiol, London, England; [Ishihara, Lianna] Lundbeck SAS, Paris, France; [Webb, David J.] GSK, Observat Data Analyt, London, England; [Mynepalli, Lakshmi] GSK Pharmaceut Ltd, Stat & Programming, Quantitat Sci India, Bangalore, Karnataka, India; [Galwey, NicholasW.] GSK, London, England; [Hauser, W. Allen] Columbia Univ, Dept Neurol, New York, NY 10032 USA	Hesdorffer, DC (corresponding author), Columbia Univ, Gertrude H Sergievsky Ctr, 630 W 168th St,P&S Unit 16, New York, NY 10032 USA.	dch5@columbia.edu	Hauser, W Allen/AAB-5277-2020		GlaxoSmithKlineGlaxoSmithKline	GlaxoSmithKline provided funding for their employees who were involved in this study.	Adelow C, 2012, NEUROLOGY, V78, P396, DOI 10.1212/WNL.0b013e318245f461; Alper K, 2007, BIOL PSYCHIAT, V62, P345, DOI 10.1016/j.biopsych.2006.09.023; Andersohn F, 2010, NEUROLOGY, V75, P335, DOI 10.1212/WNL.0b013e3181ea157e; Arana A, 2010, NEW ENGL J MED, V363, P542, DOI 10.1056/NEJMoa0909801; Barak Y, 2002, DEMENT GERIATR COGN, V14, P101, DOI 10.1159/000064931; Baram TZ, 1998, TRENDS NEUROSCI, V21, P471, DOI 10.1016/S0166-2236(98)01275-2; BARRACLOUGH BM, 1987, ACTA PSYCHIAT SCAND, V76, P339, DOI 10.1111/j.1600-0447.1987.tb05616.x; BRESLAU N, 1991, PSYCHIAT RES, V37, P11, DOI 10.1016/0165-1781(91)90102-U; Christensen J, 2007, EPILEPSY BEHAV, V11, P324, DOI 10.1016/j.yebeh.2007.06.003; Christensen J, 2007, LANCET NEUROL, V6, P693, DOI 10.1016/S1474-4422(07)70175-8; Christiansen E, 2007, AUST NZ J PSYCHIAT, V41, P257, DOI 10.1080/00048670601172749; Chronis-Tuscano A, 2010, ARCH GEN PSYCHIAT, V67, P1044, DOI 10.1001/archgenpsychiatry.2010.127; Coulter DA, 2012, GLIA, V60, P1215, DOI 10.1002/glia.22341; Dong JY, 2012, STROKE, V43, P32, DOI 10.1161/STROKEAHA.111.630871; Ernst C, 2009, PROG NEUROBIOL, V89, P315, DOI 10.1016/j.pneurobio.2009.09.001; Fazel S, 2014, JAMA PSYCHIAT, V71, P326, DOI 10.1001/jamapsychiatry.2013.3935; Fazel S, 2013, LANCET, V382, P1646, DOI 10.1016/S0140-6736(13)60899-5; Fazel S, 2013, BIPOLAR DISORD, V15, P491, DOI 10.1111/bdi.12053; Fergusson DM, 2000, PSYCHOL MED, V30, P23, DOI 10.1017/S003329179900135X; Geerlings MI, 2000, BRIT J PSYCHIAT, V176, P568, DOI 10.1192/bjp.176.6.568; Gilboa T, 2012, EPILEPSIA, V53, pe29, DOI 10.1111/j.1528-1167.2011.03342.x; Hackett ML, 2005, STROKE, V36, P2296, DOI 10.1161/01.STR.0000183622.75135.a4; Harris EC, 1998, BRIT J PSYCHIAT, V173, P11, DOI 10.1192/bjp.173.1.11; Hauser WA, 1998, NEW ENGL J MED, V338, P429, DOI 10.1056/NEJM199802123380704; Heaney DC, 2002, BMJ-BRIT MED J, V325, P1013, DOI 10.1136/bmj.325.7371.1013; Herrett E, 2010, BRIT J CLIN PHARMACO, V69, P4, DOI 10.1111/j.1365-2125.2009.03537.x; Hesdorffer DC, 2012, ANN NEUROL, V72, P184, DOI 10.1002/ana.23601; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Hesdorffer DC, 2006, ANN NEUROL, V59, P35, DOI 10.1002/ana.20685; Hesdorffer DC, 2005, EPILEPSIA, V46, P1297, DOI 10.1111/j.1528-1167.2005.10705.x; Hesdorffer DC, 2004, ARCH GEN PSYCHIAT, V61, P731, DOI 10.1001/archpsyc.61.7.731; Hesdorffer DC, 2000, ANN NEUROL, V47, P246, DOI 10.1002/1531-8249(200002)47:2<246::AID-ANA17>3.0.CO;2-E; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick SS, 2003, PHARMACOTHERAPY, V23, P686, DOI 10.1592/phco.23.5.686.32205; Jones JE, 2003, EPILEPSY BEHAV, V4, pS31, DOI 10.1016/j.yebeh.2003.08.019; Kanner AM, 2003, EPILEPSY BEHAV, V4, P597, DOI 10.1016/j.yebeh.2003.09.013; Kotsopoulos IAW, 2002, EPILEPSIA, V43, P1402, DOI 10.1046/j.1528-1157.2002.t01-1-26901.x; Ludvigsson P, 2006, ANN NEUROL, V59, P210, DOI 10.1002/ana.20745; Mann JJ, 2010, EUR PSYCHIAT, V25, P268, DOI 10.1016/j.eurpsy.2010.01.009; Meeraus WH, 2013, ARCH DIS CHILD, V98, P195, DOI 10.1136/archdischild-2012-302237; Murray PS, 2014, BIOL PSYCHIAT, V75, P542, DOI 10.1016/j.biopsych.2013.08.020; NAZARETH I, 1993, BRIT MED J, V307, P32, DOI 10.1136/bmj.307.6895.32; Nicoletti A, 2003, EPILEPSIA, V44, P1445, DOI 10.1046/j.1528-1157.2003.09203.x; Olesen JB, 2010, PHARMACOEPIDEM DR S, V19, P518, DOI 10.1002/pds.1932; Patorno E, 2010, JAMA-J AM MED ASSOC, V303, P1401, DOI 10.1001/jama.2010.410; Patten SB, 2003, NEUROLOGY, V61, P1524, DOI 10.1212/01.WNL.0000095964.34294.B4; PETRONIS KR, 1990, SOC PSYCH PSYCH EPID, V25, P193; Prudhomme C, 1941, J NERV MENT DIS, V94, P722, DOI 10.1097/00005053-194112000-00006; Pugh MJV, 2013, NEUROLOGY, V81, P1900, DOI 10.1212/01.wnl.0000436614.51081.2e; Richard YF, 2015, AM J EPIDEMIOL, V182, P177, DOI 10.1093/aje/kwv014; Scharfman HE, 2014, ADV EXP MED BIOL, V813, P133, DOI 10.1007/978-94-017-8914-1_11; Seifert G, 2013, EXP NEUROL, V244, P4, DOI 10.1016/j.expneurol.2011.08.024; Seo JH, 2007, EPILEPSIA, V48, P801, DOI 10.1111/j.1528-1167.2007.01025.x; Shneker BF, 2009, NEUROLOGY, V72, P987, DOI 10.1212/01.wnl.0000344403.13815.8d; Sigurdardottir KR, 1998, EPILEPSIA, V39, P749, DOI 10.1111/j.1528-1157.1998.tb01161.x; STENAGER EN, 1992, J NEUROL NEUROSUR PS, V55, P542, DOI 10.1136/jnnp.55.7.542; Teasdale TW, 2001, J EPIDEMIOL COMMUN H, V55, P863, DOI 10.1136/jech.55.12.863; Thurman DJ, 2011, EPILEPSIA, V52, P2, DOI 10.1111/j.1528-1167.2011.03121.x; VanCott AC, 2010, BMC MED, V8, DOI 10.1186/1741-7015-8-4	59	31	32	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-622X	2168-6238		JAMA PSYCHIAT	JAMA Psychiatry	JAN	2016	73	1					80	86		10.1001/jamapsychiatry.2015.2516			7	Psychiatry	Psychiatry	DA5CP	WOS:000367820000013	26650853	Bronze			2021-06-18	
J	Merritt, VC; Arnett, PA				Merritt, Victoria C.; Arnett, Peter A.			Apolipoprotein E (APOE) epsilon 4 Allele Is Associated with Increased Symptom Reporting Following Sports Concussion	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						APOE gene; Genetics; Mild traumatic brain injury; Post-concussion symptoms; Sports injuries; Collegiate athletes	TRAUMATIC BRAIN-INJURY; HEAD-INJURY; E GENOTYPE; PREDICTORS; MODERATE	Exploring the relationship between genetic factors and outcome following brain injury has received increased attention in recent years. However, few studies have evaluated the influence of genes on specific sequelae of concussion. The purpose of this study was to determine how the E4 allele of the apolipoprotein E (APOE) gene influences symptom expression following sports-related concussion. Participants included 42 collegiate athletes who underwent neuropsychological testing, including completion of the Post-Concussion Symptom Scale (PCSS), within 3 months after sustaining a concussion (73.8% were evaluated within 1 week). Athletes provided buccal samples that were analyzed to determine the make-up of their APOE genotype. Dependent variables included a total symptom score and four symptom clusters derived from the PCSS. Mann-Whitney U tests showed higher scores reported by athletes with the E4 allele compared to those without it on the total symptom score and the physical and cognitive symptom clusters. Furthermore, logistic regression showed that the E4 allele independently predicted those athletes who reported physical and cognitive symptoms following concussion. These findings illustrate that E4+ athletes report greater symptomatology post-concussion than E4- athletes, suggesting that the E4 genotype may confer risk for poorer post-concussion outcome. (JINS, 2016, 22, 89-94)	[Merritt, Victoria C.; Arnett, Peter A.] Penn State Univ, University Pk, PA 16802 USA	Merritt, VC (corresponding author), Penn State Univ, Dept Psychol, 372 Moore Bldg, University Pk, PA 16802 USA.	vca106@psu.edu		Merritt, Victoria/0000-0001-5683-4168	American Psychological Foundation	We thank Dr. Deborah Grove, PhD, Director of the Genomics Core Facility at Penn State, who was instrumental in processing the genetic data for this study. She also was involved in writing the description of the laboratory procedures (under the Method section). We also thank Dr. Wayne Sebastianelli, MD, Director of Athletic Medicine at Penn State, and Penn State Sports Medicine, for their ongoing support of our research. Ms. Merritt has no conflicts of interest to report. Dr. Arnett has served as part of a paid speaker series sponsored by EMD Serono. He has also served as a consultant for Biogen IDEC. Finally, the research described in this manuscript was supported by a grant to the first author from the American Psychological Foundation.	Ariza M, 2006, J NEUROL NEUROSUR PS, V77, P1191, DOI 10.1136/jnnp.2005.085167; Bazarian JJ, 2006, BRAIN INJURY, V20, P759, DOI 10.1080/02699050500488207; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Chamelian L, 2004, BRAIN, V127, P2621, DOI 10.1093/brain/awh296; Chiang MF, 2003, ACTA NEUROCHIR, V145, P649, DOI 10.1007/s00701-003-0069-3; Christensen Helen, 2008, BMC Geriatr, V8, P14, DOI 10.1186/1471-2318-8-14; Dardiotis E, 2010, NEUROSURG FOCUS, V28, DOI 10.3171/2009.10.FOCUS09215; Eisenberg DTA, 2010, AM J PHYS ANTHROPOL, V143, P100, DOI 10.1002/ajpa.21298; Freeman B, 2003, BEHAV GENET, V33, P67, DOI 10.1023/A:1021055617738; Ingelsson M, 2003, CURRENT PROTOCOLS HU, DOI DOI 10.1002/0471142905.HG0914S38.; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Lange RT, 2013, J NEUROTRAUM, V30, P237, DOI 10.1089/neu.2012.2685; Liaquat I, 2002, J NEUROSURG, V96, P90, DOI 10.3171/jns.2002.96.1.0090; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Merritt VC, 2014, J CLIN EXP NEUROPSYC, V36, P1098, DOI 10.1080/13803395.2014.983463; Moran LM, 2009, J NEUROTRAUM, V26, P1489, DOI 10.1089/neu.2008.0767; Ruff RM, 2009, ARCH CLIN NEUROPSYCH, V24, P3, DOI 10.1093/arclin/acp006; Silver JM, 2009, AM J PSYCHIAT, V166, P653, DOI 10.1176/appi.ajp.2009.08111676; Sundstrom A, 2004, NEUROLOGY, V62, P1963, DOI 10.1212/01.WNL.0000129268.83927.A8; Teasdale GM, 2005, BRAIN, V128, P2556, DOI 10.1093/brain/awh595	20	31	31	0	9	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JAN	2016	22	1					89	94		10.1017/S1355617715001022			6	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	DA1XW	WOS:000367590300010	26483005				2021-06-18	
J	Zhao, H; Cheng, L; Du, XW; Hou, Y; Liu, Y; Cui, ZQ; Nie, L				Zhao, Hua; Cheng, Lei; Du, Xinwen; Hou, Yong; Liu, Yi; Cui, Zhaoqiang; Nie, Lin			Transplantation of Cerebral Dopamine Neurotrophic Factor Transducted BMSCs in Contusion Spinal Cord Injury of Rats: Promotion of Nerve Regeneration by Alleviating Neuroinflammation	MOLECULAR NEUROBIOLOGY			English	Article						Spinal cord injury; Cell therapy; Bone marrow-derived mesenchymal stem cells; Cerebral dopamine neurotrophic factor; Nerve regeneration; Neuroinflammation	OLFACTORY ENSHEATHING GLIA; ENDOPLASMIC-RETICULUM STRESS; TRAUMATIC BRAIN-INJURY; MESENCHYMAL STEM-CELLS; FUNCTIONAL RECOVERY; STROMAL CELLS; BONE-MARROW; ADULT RATS; AXONAL REGENERATION; BEHAVIORAL RECOVERY	Traumatic spinal cord injury (SCI) causes neuron death and axonal damage resulting in functional motor and sensory loss, showing limited regeneration because of adverse microenvironment such as neuroinflammation and glial scarring. Currently, there is no effective therapy to treat SCI in clinical practice. Bone marrow-derived mesenchymal stem cells (BMSCs) are candidates for cell therapies but its effect is limited by neuroinflammation and adverse microenvironment in the injured spinal cord. In this study, we developed transgenic BMSCs overexpressing cerebral dopamine neurotrophic factor (CDNF), a secretory neurotrophic factor that showed potent effects on neuron protection, anti-inflammation, and sciatic nerve regeneration in previous studies. Our results showed that the transplantation of CDNF-BMSCs suppressed neuroinflammation and decreased the production of proinflammatory cytokines after SCI, resulting in the promotion of locomotor function and nerve regeneration of the injured spinal cord. This study presents a novel promising strategy for the treatment of spinal cord injury.	[Zhao, Hua; Cheng, Lei; Hou, Yong; Liu, Yi; Nie, Lin] Shandong Univ, Qilu Hosp, Dept Spine Surg, Jinan 250012, Peoples R China; [Zhao, Hua; Liu, Yi; Cui, Zhaoqiang] Shandong Univ, Qilu Hosp, Res Ctr Cell Therapy, Key Lab Cardiovasc Remodeling & Funct Res, Jinan 250012, Peoples R China; [Du, Xinwen] Laizhou Peoples Hosp, Dept Pediat Surg, Laizhou, Peoples R China	Nie, L (corresponding author), Shandong Univ, Qilu Hosp, Dept Spine Surg, Jinan 250012, Peoples R China.	niemedmail@126.com			Ph.D. Programs Foundation of Ministry of Education of ChinaMinistry of Education, China [20110131120079]; Natural Science Foundation of Shandong Province, ChinaNatural Science Foundation of Shandong Province [ZR2013HM095]	The authors are grateful to Prof. Tang DQ, Wang XL, Research Center for Cell Therapy, Qilu Hospital of Shandong University, and Prof. Chen ZY, Department of Neurobiology, Shandong University, for their kind advice and help with this research. The study was supported by the grant from Ph.D. Programs Foundation of Ministry of Education of China (20110131120079) and Natural Science Foundation of Shandong Province, China (ZR2013HM095).	Airavaara M, 2009, J COMP NEUROL, V515, P116, DOI 10.1002/cne.22039; Bernardo ME, 2012, BONE MARROW TRANSPL, V47, P164, DOI 10.1038/bmt.2011.81; Bolton DAE, 2006, BEHAV BRAIN RES, V168, P272, DOI 10.1016/j.bbr.2005.11.017; Bradbury EJ, 2006, NAT REV NEUROSCI, V7, P644, DOI 10.1038/nrn1964; Bruhn H, 2005, BIOCHEM J, V389, P249, DOI 10.1042/BJ20050051; Bydon M, 2014, WORLD NEUROSURG, V82, P848, DOI 10.1016/j.wneu.2013.02.062; Caplan A, 2009, J PATHOL, V217, P318, DOI 10.1002/path.2469; Caplan AI, 2007, J CELL PHYSIOL, V213, P341, DOI 10.1002/jcp.21200; Cheng L, 2013, BIOCHEM BIOPH RES CO, V440, P330, DOI 10.1016/j.bbrc.2013.09.084; Cheng L, 2013, BIOCHEM BIOPH RES CO, V435, P34, DOI 10.1016/j.bbrc.2013.04.029; Cho JS, 2009, NEUROSCI LETT, V454, P43, DOI 10.1016/j.neulet.2009.02.024; Cho SR, 2009, CELL TRANSPLANT, V18, P1359, DOI 10.3727/096368909X475329; Deumens R, 2006, NEUROSCI LETT, V400, P208, DOI 10.1016/j.neulet.2006.02.050; Donnelly DJ, 2008, EXP NEUROL, V209, P378, DOI 10.1016/j.expneurol.2007.06.009; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Forraz N, 2013, J TISSUE ENG REGEN M, V7, P523, DOI 10.1002/term.552; Guest JD, 2008, EXP NEUROL, V212, P261, DOI 10.1016/j.expneurol.2008.03.010; Hall Edward D, 2004, NeuroRx, V1, P80, DOI 10.1602/neurorx.1.1.80; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; Hawryluk GWJ, 2012, STEM CELLS DEV, V21, P2222, DOI 10.1089/scd.2011.0596; Hellman M, 2011, J BIOL CHEM, V286, P2675, DOI 10.1074/jbc.M110.146738; Himes BT, 2006, NEUROREHAB NEURAL RE, V20, P278, DOI 10.1177/1545968306286976; Hofstetter CP, 2002, P NATL ACAD SCI USA, V99, P2199, DOI 10.1073/pnas.042678299; Johnston H, 2011, BIOCHEM SOC T, V39, P886, DOI 10.1042/BST0390886; Karimi-Abdolrezaee S, 2012, MOL NEUROBIOL, V46, P251, DOI 10.1007/s12035-012-8287-4; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Kubasak MD, 2008, BRAIN, V131, P264, DOI 10.1093/brain/awm267; Kwiatkoski M, 2013, EXP NEUROL, V240, P88, DOI 10.1016/j.expneurol.2012.11.008; Li Wei, 2006, Neurosci Bull, V22, P34; Lindholm P, 2007, NATURE, V448, P73, DOI 10.1038/nature05957; Lindstrom R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073928; Lu J, 2001, BRAIN RES, V889, P344, DOI 10.1016/S0006-8993(00)03235-2; Mahmood A, 2004, J NEUROTRAUM, V21, P33, DOI 10.1089/089771504772695922; Mahmood A, 2002, J NEUROTRAUM, V19, P1609, DOI 10.1089/089771502762300265; Markandaya M, 2012, CURR TREAT OPTION NE, V14, P175, DOI 10.1007/s11940-011-0162-5; Martin D, 1996, J NEUROSCI RES, V45, P588; Mei JM, 2014, NEUROL SCI, V35, P1275, DOI 10.1007/s10072-014-1700-1; Messmer K, 2005, NEUROSCI LETT, V388, P39, DOI 10.1016/j.neulet.2005.06.047; Miller SM, 2008, J NEUROSURG ANESTH, V20, P140, DOI 10.1097/01.ana.0000314442.40952.0d; Nashmi R, 2001, BRAIN RES REV, V38, P165, DOI 10.1016/S0165-0173(01)00134-5; Nauta AJ, 2007, BLOOD, V110, P3499, DOI 10.1182/blood-2007-02-069716; Okano H, 2013, CIRC RES, V112, P523, DOI 10.1161/CIRCRESAHA.111.256149; Parr AM, 2008, NEUROSCIENCE, V155, P760, DOI 10.1016/j.neuroscience.2008.05.042; Pearse DD, 2007, GLIA, V55, P976, DOI 10.1002/glia.20490; Ramer LM, 2005, SPINAL CORD, V43, P134, DOI 10.1038/sj.sc.3101715; Ritfeld GJ, 2014, BIOMATERIALS, V35, P1924, DOI 10.1016/j.biomaterials.2013.11.062; Ritfeld GJ, 2012, CELL TRANSPLANT, V21, P1561, DOI 10.3727/096368912X640484; Ruff CA, 2010, PANMINERVA MED, V52, P125; Schiwy N, 2009, EUR J NEUROSCI, V30, P1544, DOI 10.1111/j.1460-9568.2009.06929.x; Silva NA, 2014, PROG NEUROBIOL, V114, P25, DOI 10.1016/j.pneurobio.2013.11.002; Sun ZP, 2011, J NEUROCHEM, V117, P121, DOI 10.1111/j.1471-4159.2011.07179.x; TAKAKUWA T, 1994, RES COMMUN CHEM PATH, V84, P283; Takami T, 2002, J NEUROSCI, V22, P6670; Takami T, 2002, J NEUROTRAUM, V19, P653, DOI 10.1089/089771502753754118; Thuret S, 2006, NAT REV NEUROSCI, V7, P628, DOI 10.1038/nrn1955; van den Berg MEL, 2010, J NEUROTRAUM, V27, P1517, DOI 10.1089/neu.2009.1138; Voutilainen MH, 2009, J NEUROSCI, V29, P9651, DOI 10.1523/JNEUROSCI.0833-09.2009; Wright KT, 2011, STEM CELLS, V29, P169, DOI 10.1002/stem.570; Wu W, 2014, BIOMATERIALS, V35, P2355, DOI 10.1016/j.biomaterials.2013.11.074; Wu WL, 2011, NEUROSCI LETT, V491, P73, DOI 10.1016/j.neulet.2011.01.009; Yoon SH, 2007, STEM CELLS, V25, P2066, DOI 10.1634/stemcells.2006-0807; Zhang N, 2012, INDIAN J MED RES, V135, P287; Zhao H, 2014, J MOL NEUROSCI, V52, P186, DOI 10.1007/s12031-013-0120-7; Zhao H, 2013, J MOL NEUROSCI, V51, P671, DOI 10.1007/s12031-013-0042-4; Zindler E, 2010, BEST PRACT RES-CLIN, V24, P551, DOI 10.1016/j.bpa.2010.11.001	66	31	32	1	11	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	JAN	2016	53	1					187	199		10.1007/s12035-014-9000-6			13	Neurosciences	Neurosciences & Neurology	DB0CN	WOS:000368176300017	25421210				2021-06-18	
J	Addington, CP; Heffernan, JM; Millar-Haskell, CS; Tucker, EW; Sirianni, RW; Stabenfeldt, SE				Addington, C. P.; Heffernan, J. M.; Millar-Haskell, C. S.; Tucker, E. W.; Sirianni, R. W.; Stabenfeldt, S. E.			Enhancing neural stem cell response to SDF-1 alpha gradients through hyaluronic acid-laminin hydrogels	BIOMATERIALS			English	Article						Chemotaxis; SDF-1 alpha-CXCR4 axis; Tissue engineering; Brain injury; Regenerative medicine	TRAUMATIC BRAIN-INJURY; FOCAL ADHESION; STEM/PROGENITOR CELLS; EXTRACELLULAR-MATRIX; COLLAGEN SCAFFOLDS; VASCULAR NICHE; RAT MODEL; MIGRATION; EXPRESSION; CD44	Traumatic brain injury (TBI) initiates an expansive biochemical insult that is largely responsible for the long-term dysfunction associated with TBI; however, current clinical treatments fall short of addressing these underlying sequelae. Pre-clinical investigations have used stem cell transplantation with moderate success, but are plagued by staggeringly low survival and engraftment rates (2-4%). As such, providing cell transplants with the means to better dynamically respond to injury-related signals within the transplant microenvironment may afford improved transplantation survival and engraftment rates. The chemokine stromal cell-derived factor-1 alpha (SDF-1 alpha) is a potent chemotactic signal that is readily present after TBI. In this study, we sought to develop a transplantation vehicle to ultimately enhance the responsiveness of neural transplants to injury-induced SDF-1 alpha. Specifically, we hypothesize that a hyaluronic acid (HA) and laminin (Lm) hydrogel would promote 1. upregulated expression of the SDF-1 alpha receptor OCCR4 in neural progenitor/stem cells (NPSCs) and 2. enhanced NPSC migration in response to SDF-1 alpha gradients. We demonstrated successful development of a HA-Lm hydrogel and utilized standard protein and cellular assays to probe NPSC CXCR4 expression and NPSC chemotactic migration. The findings demonstrated that NPSCs significantly increased CXCR4 expression after 48 h of culture on the HA-Lm gel in a manner critically dependent on both HA and laminin. Moreover, the HA-Lm hydrogel significantly increased NPSC chemotactic migration in response to SDF-1 alpha at 48 h, an effect that was critically dependent on HA, laminin and the SDF-1 alpha gradient. Therefore, this hydrogel serves to 1. prime NPSCs for the injury microenvironment and 2. provide the appropriate infrastructure to support migration into the surrounding tissue, equipping cells with the tools to more effectively respond to the injury microenvironment. (C) 2015 Elsevier Ltd. All rights reserved.	[Addington, C. P.; Heffernan, J. M.; Millar-Haskell, C. S.; Tucker, E. W.; Sirianni, R. W.; Stabenfeldt, S. E.] Arizona State Univ, Sch Biol & Hlth Syst Engn, Tempe, AZ 85287 USA; [Heffernan, J. M.; Sirianni, R. W.] Barrow Neurol Inst, Barrow Brain Tumor Res Ctr, Phoenix, AZ 85013 USA	Stabenfeldt, SE (corresponding author), Arizona State Univ, Sch Biol & Hlth Syst Engn, POB 879709, Tempe, AZ 85287 USA.	sarah.stabenfeldt@asu.edu		Addington, Caroline/0000-0003-4534-8222	ASU startup funds; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1DP2HD084067]; ARCS, Inc.; Barrow Neurological Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [DP2HD084067] Funding Source: NIH RePORTER	The authors acknowledge David Lowry and the College of Liberal Arts and Sciences Bioimaging Facility for assistance with electron microscopy, Sanjay Srinivasan for assistance with monomer preparation and the following funding sources: ASU startup funds (SES), NIH 1DP2HD084067 (SES), and ARCS, Inc. Fellowship (CPA), the Barrow Neurological Foundation (JMH, RWS).	Addington CP, 2014, BIOMATERIALS, V35, P3263, DOI 10.1016/j.biomaterials.2013.12.102; Arbour RB, 2013, CRIT CARE NURS CLIN, V25, P297, DOI 10.1016/j.ccell.2013.02.010; Avigdor A, 2004, BLOOD, V103, P2981, DOI 10.1182/blood-2003-10-3611; Azari H, 2011, JOVE-J VIS EXP, DOI 10.3791/2457; BIGNAMI A, 1993, ANAT EMBRYOL, V188, P419; Bonneh-Barkay D, 2009, BRAIN PATHOL, V19, P573, DOI 10.1111/j.1750-3639.2008.00195.x; Brannvall K, 2007, J NEUROSCI RES, V85, P2138, DOI 10.1002/jnr.21358; Cohen M, 2006, EMBO J, V25, P302, DOI 10.1038/sj.emboj.7600960; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; Deboux C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057430; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Fraley SI, 2010, NAT CELL BIOL, V12, P598, DOI 10.1038/ncb2062; Friedl P, 2000, CELL MOL LIFE SCI, V57, P41, DOI 10.1007/s000180050498; Friedl P, 2010, J CELL BIOL, V188, P11, DOI 10.1083/jcb.200909003; Guan J, 2013, BIOMATERIALS, V34, P5937, DOI 10.1016/j.biomaterials.2013.04.047; Harting MT, 2008, NEUROSURG FOCUS, V24, DOI 10.3171/FOC/2008/24/3-4/E17; Harting MT, 2009, J SURG RES, V153, P188, DOI 10.1016/j.jss.2008.03.037; Heffernan JM, 2015, ANN BIOMED ENG, V43, P1965, DOI 10.1007/s10439-014-1223-1; Hicks RR, 1999, EXP NEUROL, V160, P469, DOI 10.1006/exnr.1999.7216; Huang YS, 2012, BRAIN DEV-JPN, V34, P674, DOI 10.1016/j.braindev.2011.10.011; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Itoh T, 2009, NEUROL RES, V31, P90, DOI 10.1179/174313208X332995; Jacques TS, 1998, DEVELOPMENT, V125, P3167; Jensen JB, 2006, MOL NEUROBIOL, V34, P153, DOI 10.1385/MN:34:3:153; Kim MS, 2005, CANCER RES, V65, P686; Kokovay E, 2010, CELL STEM CELL, V7, P163, DOI 10.1016/j.stem.2010.05.019; Lee JL, 2008, MOL CELL BIOL, V28, P5710, DOI 10.1128/MCB.00186-08; Lindwall C, 2013, BRAIN RES, V1503, P62, DOI 10.1016/j.brainres.2013.01.045; Lisignoli G, 2006, J CELL PHYSIOL, V207, P364, DOI 10.1002/jcp.20572; Liu Y, 2004, DEV BIOL, V276, P31, DOI 10.1016/j.ydbio.2004.08.018; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Lu YB, 2006, P NATL ACAD SCI USA, V103, P17759, DOI 10.1073/pnas.0606150103; Martino G, 2006, NAT REV NEUROSCI, V7, P395, DOI 10.1038/nrn1908; McAllister Thomas W, 2011, Dialogues Clin Neurosci, V13, P287; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Naruse M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053109; Nolan S, 2005, CRIT CARE NURS Q, V28, P188, DOI 10.1097/00002727-200504000-00010; Preston M., 2012, FRONT BIOSCI, V3, P1165; PRICE J, 1985, J NEUROSCI, V5, P2205; Purcell BP, 2012, BIOMATERIALS, V33, P7849, DOI 10.1016/j.biomaterials.2012.07.005; Qu CS, 2011, BRAIN RES, V1371, P129, DOI 10.1016/j.brainres.2010.10.088; Riess P, 2002, NEUROSURGERY, V51, P1043, DOI 10.1097/00006123-200210000-00035; ROONEY P, 1993, J CELL SCI, V105, P213; Shear DA, 2004, BRAIN RES, V1026, P11, DOI 10.1016/j.brainres.2004.07.087; Shear DA, 2011, RESTOR NEUROL NEUROS, V29, P215, DOI 10.3233/RNN-2011-0593; Shu XZ, 2006, J BIOMED MATER RES A, V79A, P902, DOI 10.1002/jbm.a.30831; Shu XZ, 2004, J BIOMED MATER RES A, V68A, P365, DOI 10.1002/jbm.a.20002; Shu XZ, 2003, BIOMATERIALS, V24, P3825, DOI 10.1016/S0142-9612(03)00267-9; Suri S, 2010, TISSUE ENG PT A, V16, P1703, DOI 10.1089/ten.tea.2009.0381; Suslov ON, 2002, P NATL ACAD SCI USA, V99, P14506, DOI 10.1073/pnas.212525299; Tate CC, 2009, J TISSUE ENG REGEN M, V3, P208, DOI 10.1002/term.154; Tavazoie M, 2008, CELL STEM CELL, V3, P279, DOI 10.1016/j.stem.2008.07.025; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tian WM, 2005, TISSUE ENG, V11, P513, DOI 10.1089/ten.2005.11.513; Tran PB, 2007, J COMP NEUROL, V500, P1007, DOI 10.1002/cne.21229; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Vercruysse KP, 1997, BIOCONJUGATE CHEM, V8, P686, DOI 10.1021/bc9701095; Wang TY, 2012, BIOMATERIALS, V33, P9188, DOI 10.1016/j.biomaterials.2012.09.013; Wang Y, 2011, PHARM RES-DORDR, V28, P1406, DOI 10.1007/s11095-011-0452-3; Wang ZF, 2014, MATER RES-IBERO-AM J, V17, P33, DOI [10.1590/S1516-14392014000100005, 10.1590/S1516-14392013005000155]; Wei YT, 2007, BIOMED MATER, V2, pS142, DOI 10.1088/1748-6041/2/3/S11; Wennersten A, 2004, J NEUROSURG, V100, P88, DOI 10.3171/jns.2004.100.1.0088; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; Wu PH, 2014, P NATL ACAD SCI USA, V111, P3949, DOI 10.1073/pnas.1318967111; Yu XL, 2012, J NEUROL SCI, V316, P141, DOI 10.1016/j.jns.2012.01.001; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	67	31	33	2	92	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0142-9612	1878-5905		BIOMATERIALS	Biomaterials	DEC	2015	72						11	19		10.1016/j.biomaterials.2015.08.041			9	Engineering, Biomedical; Materials Science, Biomaterials	Engineering; Materials Science	CT6MH	WOS:000362926600002	26340314	Green Accepted			2021-06-18	
J	Zgaljardic, DJ; Seale, GS; Schaefer, LA; Temple, RO; Foreman, J; Elliott, TR				Zgaljardic, Dennis J.; Seale, Gary S.; Schaefer, Lynn A.; Temple, Richard O.; Foreman, Jack; Elliott, Timothy R.			Psychiatric Disease and Post-Acute Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						caregiver distress; maladaptive behaviors; mood disorder; TBI	POSTTRAUMATIC-STRESS-DISORDER; RANDOMIZED CONTROLLED-TRIAL; MAJOR DEPRESSIVE DISORDER; OF-THE-LITERATURE; COGNITIVE-BEHAVIORAL THERAPY; ANTERIOR CINGULATE CORTEX; HEAD-INJURY; POSTCONCUSSION SYNDROME; FRONTAL-LOBE; FAMILY CAREGIVERS	Psychiatric disorders are common following traumatic brain injury (TBI) and can include depression, anxiety, and psychosis, as well as other maladaptive behaviors and personality changes. The epidemiologic data of psychiatric disorders post-TBI vary widely, although the incidence and prevalence rates typically are higher than in the general population. Although the experience of psychiatric symptoms may be temporary and may resolve in the acute period, many patients with TBI can experience psychopathology that is persistent or that develops in the post-acute period. Long-term psychiatric disorder, along with cognitive and physical sequelae and greater risk for substance use disorders, can pose a number of life-long challenges for patients and their caregivers, as they can interfere with participation in rehabilitation as well as limit functional independence in the community. The current review of the literature considers the common psychiatric problems affecting individuals with TBI in the post-acute period, including personality changes, psychosis, executive dysfunction, depression, anxiety, and substance misuse. Although treatment considerations (pharmacological and nonpharmacological) are referred to, an extensive description of such protocols is beyond the scope of the current review. The impact of persistent psychiatric symptoms on perceived caregiver burden and distress is also discussed.	[Zgaljardic, Dennis J.; Seale, Gary S.; Foreman, Jack] Transit Learning Ctr, Galveston, TX 77550 USA; [Zgaljardic, Dennis J.] Univ Texas Med Branch, Galveston, TX 77555 USA; [Schaefer, Lynn A.] Nassau Univ Med Ctr, E Meadow, NY USA; [Elliott, Timothy R.] Texas A&M Univ, College Stn, TX USA	Zgaljardic, DJ (corresponding author), Transit Learning Ctr, Dept Neuropsychol, 1528 PO St, Galveston, TX 77550 USA.	dzgaljardic@tlc-galveston.org	Elliott, Timothy R./I-5301-2012	Elliott, Timothy R./0000-0002-6608-7714	Moody Endowment	This work was funded by the generous support of the Moody Endowment.	Abreau B. C., 2009, LIFE BALANCE MULTIDI, P223; Ahmed A, 2013, THER CLIN RISK MANAG, V9, P483, DOI 10.2147/TCRM.S53906; Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; ANDERSEN G, 1993, LANCET, V342, P837, DOI 10.1016/0140-6736(93)92696-Q; Anderson K., 1998, SEMIN CLIN NEUROPSYC, V3, P232; Ashman TA, 2004, ARCH PHYS MED REHAB, V85, pS36, DOI 10.1016/j.apmr.2003.08.117; Ashman T, 2014, J HEAD TRAUMA REHAB, V29, P467, DOI 10.1097/HTR.0000000000000098; Bay Esther, 2006, Care Manag J, V7, P3, DOI 10.1891/cmaj.7.1.3; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; Bedard M, 2014, J HEAD TRAUMA REHAB, V29, pE13, DOI 10.1097/HTR.0b013e3182a615a0; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Belmaker RH, 2008, NEW ENGL J MED, V358, P55, DOI 10.1056/NEJMra073096; Belmont A., 2006, Annales de Readaptation et de Medecine Physique, V49, P370, DOI 10.1016/j.annrmp.2006.04.018; BERGLAND MM, 1991, REHABIL COUNS BULL, V35, P5; Berry JW, 2012, REHABIL PSYCHOL, V57, P98, DOI 10.1037/a0028229; Bigler ED, 1996, BRAIN INJURY, V10, P197, DOI 10.1080/026990596124511; Binder S, 2005, J HEAD TRAUMA REHAB, V20, P189, DOI 10.1097/00001199-200505000-00002; Blackerby W.F., 1990, J HEAD TRAUMA REHAB, V5, P47; Bogner J, 2013, BRAIN IMPAIR, V14, P77, DOI 10.1017/BrImp.2013.5; Bombardier CH, 1999, REHABIL PSYCHOL, V44, P52, DOI 10.1037/0090-5550.44.1.52; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Bombardier CH, 2009, J HEAD TRAUMA REHAB, V24, P230, DOI 10.1097/HTR.0b013e3181ad65f0; Bremner JD, 2002, BIOL PSYCHIAT, V51, P273, DOI 10.1016/S0006-3223(01)01336-1; Brossart DF, 2008, REHABIL PSYCHOL, V53, P357, DOI 10.1037/a0012973; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Campbell LC, 2003, BIOL PSYCHIAT, V54, P399, DOI 10.1016/S0006-3223(03)00545-6; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; Cheng SKW, 2006, BRAIN INJURY, V20, P621, DOI 10.1080/02699050600677196; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Cimino C.R., 1994, CLIN GUIDE NEUROPSYC, P69; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; CORRIGAN JD, 1995, ARCH PHYS MED REHAB, V76, P302, DOI 10.1016/S0003-9993(95)80654-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Corrigan JD, 2007, BRAIN INJURY, V21, P343, DOI 10.1080/02699050701253103; Corrigan JD, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P1315; Cox WM, 2003, J ADDICT DIS, V22, P93, DOI 10.1300/J069v22n01_07; Cuijpers P, 2007, CLIN PSYCHOL REV, V27, P318, DOI 10.1016/j.cpr.2006.11.001; CUMMINGS JL, 1993, ARCH NEUROL-CHICAGO, V50, P873, DOI 10.1001/archneur.1993.00540080076020; Damasio A., 1994, DESCARTESERROR EMOTI; David AS, 2005, J NEUROL NEUROSUR PS, V76, pI53, DOI 10.1136/jnnp.2004.060475; DAVIDSON DLW, 1983, SCOT MED J, V28, P325, DOI 10.1177/003693308302800402; De Reuck J, 2011, CLIN NEUROL NEUROSUR, V113, P469, DOI 10.1016/j.clineuro.2011.02.004; Deb S, 2004, BRAIN INJURY, V18, P1, DOI 10.1080/0269905031000110463; Deb S, 1999, AM J PSYCHIAT, V156, P374; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Dyer KFW, 2006, BRAIN INJURY, V20, P1163, DOI 10.1080/02699050601049312; Dzurilla T.J., 2004, SOCIAL PROBLEM SOLVI, P11, DOI DOI 10.1037/10805-001; Elliott TR, 2008, BEHAV RES THER, V46, P1220, DOI 10.1016/j.brat.2008.08.004; Elliott TR, 2001, J COUNS PSYCHOL, V48, P223, DOI 10.1037//0022-0167.48.2.223; Ettenhofer ML, 2012, J INT NEUROPSYCH SOC, V18, P451, DOI 10.1017/S1355617711001895; Fann JR, 2015, J NEUROTRAUM, V32, P45, DOI 10.1089/neu.2014.3423; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Farrer TJ, 2012, TRAUMA VIOLENCE ABUS, V13, P77, DOI 10.1177/1524838012440338; Fazel S, 2009, J NEUROL, V256, P1591, DOI 10.1007/s00415-009-5134-2; Feinstein A, 2000, BRAIN COGNITION, V44, P78; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; FOLKMAN S, 1986, J PERS SOC PSYCHOL, V50, P571, DOI 10.1037/0022-3514.50.3.571; FRITH CD, 1991, P ROY SOC B-BIOL SCI, V244, P241, DOI 10.1098/rspb.1991.0077; Fujii D, 2002, J NEUROPSYCH CLIN N, V14, P130, DOI 10.1176/appi.neuropsych.14.2.130; Fujii D., 1996, J NEUROPSYCHIATRY CL, V24, P278; Fujii D, 2012, J NEUROPSYCH CLIN N, V24, P278, DOI 10.1176/appi.neuropsych.11070176; Fujii DE, 2014, PSYCHIAT CLIN N AM, V37, P113, DOI 10.1016/j.psc.2013.11.006; Fujii DE, 2001, J NEUROPSYCH CLIN N, V13, P61, DOI 10.1176/appi.neuropsych.13.1.61; George MS, 1994, DEPRESSION, V2, P59, DOI 10.1002/depr.3050020202.; GLENN MB, 1989, AM J PHYS MED REHAB, V68, P221, DOI 10.1097/00002060-198910000-00004; Gould KR, 2011, PSYCHOL MED, V41, P2099, DOI 10.1017/S003329171100033X; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Graham DP, 2008, ANN NY ACAD SCI, V1141, P148, DOI 10.1196/annals.1441.029; Gray J A, 1996, Nebr Symp Motiv, V43, P61; Greve KW, 2001, BRAIN INJURY, V15, P255; Guerreiro DF, 2009, BRAIN INJURY, V23, P358, DOI 10.1080/02699050902800918; GURNEY JG, 1992, J TRAUMA, V33, P709, DOI 10.1097/00005373-199211000-00020; Hammond FM, 2014, J HEAD TRAUMA REHAB, V29, P391, DOI 10.1097/01.HTR.0000438116.56228.de; Handel SF, 2007, PSYCHOSOMATICS, V48, P67, DOI 10.1176/appi.psy.48.1.67; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Hart T, 2011, ARCH PHYS MED REHAB, V92, P1211, DOI 10.1016/j.apmr.2011.03.005; Hashimoto K, 2009, BRAIN RES REV, V61, P105, DOI 10.1016/j.brainresrev.2009.05.005; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; Heilman K., 1991, AWARENESS DEFICIT BR, P53; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Hibbard MR, 2004, ARCH PHYS MED REHAB, V85, pS43, DOI 10.1016/j.apmr.2003.08.116; Hoffman JM, 2012, ARCH PHYS MED REHAB, V93, P287, DOI 10.1016/j.apmr.2011.08.041; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hou RH, 2012, J NEUROL NEUROSUR PS, V83, P217, DOI 10.1136/jnnp-2011-300767; Isaac F, 2011, NEUROPSYCH DIS TREAT, V7, P57, DOI 10.2147/NDT.S16267; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Jha A, 2008, J HEAD TRAUMA REHAB, V23, P52, DOI 10.1097/01.HTR.0000308721.77911.ea; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Johnson CL, 2010, REHABIL PSYCHOL, V55, P180, DOI 10.1037/a0019480; Jones G.A., 1992, NEUROREHABILITATION, V2, P27; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Jorge RE, 2005, ARCH GEN PSYCHIAT, V62, P742, DOI 10.1001/archpsyc.62.7.742; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P369; Kalpinski RJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/102570; Kerr K, 2011, BRAIN INJURY, V25, P729, DOI 10.3109/02699052.2011.580315; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; King NS, 1997, J NEUROL NEUROSUR PS, V62, P82, DOI 10.1136/jnnp.62.1.82; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Koponen S, 2002, AM J PSYCHIAT, V159, P1315, DOI 10.1176/appi.ajp.159.8.1315; Kosch Y, 2010, BRAIN INJURY, V24, P479, DOI 10.3109/02699051003610417; Koskinen S, 1998, BRAIN INJURY, V12, P631, DOI 10.1080/026990598122205; KREUTZER JS, 1991, J HEAD TRAUMA REHAB, V6, P12; Krpan KM, 2011, J INT NEUROPSYCH SOC, V17, P248, DOI 10.1017/S1355617710001499; Leavitt VM, 2010, PM&R, V2, P332, DOI 10.1016/j.pmrj.2010.03.027; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MacDonald AW, 2000, SCIENCE, V288, P1835, DOI 10.1126/science.288.5472.1835; Malec JF, 2010, ARCH PHYS MED REHAB, V91, P1087, DOI 10.1016/j.apmr.2010.04.002; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; MAYBERG HS, 1994, J NUCL MED, V35, P929; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCALLISTER TW, 1985, J CLIN PSYCHIAT, V46, P393; McCabe P, 2007, BRAIN INJURY, V21, P231, DOI 10.1080/02699050701201631; McDonald BC, 2002, NEUROREHABILITATION, V17, P333; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P139, DOI 10.1016/0887-6177(95)00006-2; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Moore EL, 2006, BRAIN INJURY, V20, P117, DOI 10.1080/02699050500443558; MORAWETZ D, 2003, SLEEP RES ONLINE, V5, P77; Morris PLP, 1996, J NEUROPSYCH CLIN N, V8, P399; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nicholl J, 2009, SEMIN NEUROL, V29, P247, DOI 10.1055/s-0029-1223878; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; Paradiso S, 1999, J NEUROL NEUROSUR PS, V67, P664, DOI 10.1136/jnnp.67.5.664; PARDO JV, 1990, P NATL ACAD SCI USA, V87, P256, DOI 10.1073/pnas.87.1.256; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; PASSINGHAM RE, 1972, NEUROPSYCHOLOGIA, V10, P41, DOI 10.1016/0028-3932(72)90041-3; Pentland B, 2005, J NEUROL NEUROSUR PS, V76, P395, DOI 10.1136/jnnp.2004.037861; Pfeiffer K, 2014, J CONSULT CLIN PSYCH, V82, P628, DOI 10.1037/a0036987; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Ponsford J, 2007, BRAIN INJURY, V21, P1385, DOI 10.1080/02699050701796960; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Ponsford J, 2010, J INT NEUROPSYCH SOC, V16, P306, DOI 10.1017/S1355617709991342; Ponsford JL, 2012, J HEAD TRAUMA REHAB, V27, P224, DOI 10.1097/HTR.0b013e31824ee1a8; Rajkowska G, 1999, BIOL PSYCHIAT, V45, P1085, DOI 10.1016/S0006-3223(99)00041-4; Ramkumar NA, 2010, NEUROREHABILITATION, V27, P105, DOI 10.3233/NRE-2010-0585; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Rao V, 2009, J NEUROPSYCH CLIN N, V21, P420, DOI 10.1176/appi.neuropsych.21.4.420; Rapoport M, 2002, NEUROPSY NEUROPSY BE, V15, P123, DOI 10.1097/01.WNN.0000016801.80266.36; Rapoport MJ, 2005, J NEUROPSYCH CLIN N, V17, P61, DOI 10.1176/appi.neuropsych.17.1.61; Rapoport MJ, 2003, PSYCHOSOMATICS, V44, P31, DOI 10.1176/appi.psy.44.1.31; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; Reeves RR, 2011, J PSYCHOSOC NURS MEN, V49, P42, DOI 10.3928/02793695-20110201-03; Reger ML, 2012, BIOL PSYCHIAT, V71, P335, DOI 10.1016/j.biopsych.2011.11.007; Reid-Arndt SA, 2007, BRAIN INJURY, V21, P1361, DOI 10.1080/02699050701785062; Reischies FM, 1999, ANN NY ACAD SCI, V877, P775, DOI 10.1111/j.1749-6632.1999.tb09321.x; Riemann D, 2003, J AFFECT DISORDERS, V76, P255, DOI 10.1016/S0165-0327(02)00072-1; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; ROSENBAUM A, 1994, J CONSULT CLIN PSYCH, V62, P1187, DOI 10.1037/0022-006X.62.6.1187; ROSENBAUM A, 1989, AM J PSYCHIAT, V146, P1048; Rothman MS, 2007, J NEUROPSYCH CLIN N, V19, P363, DOI 10.1176/appi.neuropsych.19.4.363; Sachdev P, 2001, PSYCHOL MED, V31, P231, DOI 10.1017/S0033291701003336; Sander AM, 2012, J HEAD TRAUMA REHAB, V27, P319, DOI 10.1097/HTR.0b013e318269838c; Sander AM, 2009, J HEAD TRAUMA REHAB, V24, P248, DOI 10.1097/HTR.0b013e3181ad593a; Schonberger M, 2011, J INT NEUROPSYCH SOC, V17, P781, DOI 10.1017/S1355617711000701; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Seel RT, 2003, ARCH PHYS MED REHAB, V84, P1621, DOI 10.1053/S0003-9993(03)00270-3; Seton J.D., 1990, J HEAD TRAUMA REHAB, V5, P41; Sheline YI, 1999, J NEUROSCI, V19, P5034; Sherer M, 1999, BRAIN INJURY, V13, P973; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; Smith L.M., 1995, FAMILY SUPPORT PROGR; Sparadeo F. R., 1989, J HEAD TRAUMA REHAB, V4, P75, DOI DOI 10.1097/00001199-198903000-00010; STEBBINS P, 1997, AUSTR J REHABILITATI, V3, P30; Stein S., 1996, CLASSIFICATION HEAD; Stern Judith M, 2004, Curr Neurol Neurosci Rep, V4, P179, DOI 10.1007/s11910-004-0034-4; Stuss DT, 1998, J INT NEUROPSYCH SOC, V4, P265, DOI 10.1017/S1355617798002653; Stuss DT, 2001, NEUROPSYCHOLOGIA, V39, P771, DOI 10.1016/S0028-3932(01)00013-6; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; Tateno A, 2004, J NEUROPSYCH CLIN N, V16, P426, DOI 10.1176/appi.neuropsych.16.4.426; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Tsaousides T, 2011, J HEAD TRAUMA REHAB, V26, P265, DOI 10.1097/HTR.0b013e3182225271; Tweedly L, 2012, J HEAD TRAUMA REHAB, V27, P331, DOI 10.1097/HTR.0b013e318262200a; Tyerman A, 2008, PSYCHOL APPROACHES R; Upton D, 1999, ARCH CLIN NEUROPSYCH, V14, P203, DOI 10.1016/S0887-6177(98)00013-4; van Reekum R, 2000, J NEUROPSYCH CLIN N, V12, P316, DOI 10.1176/appi.neuropsych.12.3.316; VANREEKUM R, 1995, BRAIN INJURY, V9, P49, DOI 10.3109/02699059509004571; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; VILKKI J, 1994, J CLIN EXP NEUROPSYC, V16, P325, DOI 10.1080/01688639408402643; Vungkhanching M, 2007, J HEAD TRAUMA REHAB, V22, P167, DOI 10.1097/01.HTR.0000271117.19652.98; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Walling SM, 2012, J MARITAL FAM THER, V38, P471, DOI 10.1111/j.1752-0606.2011.00226.x; Warden DL, 2006, J NEUROTRAUM, V23, P1468, DOI 10.1089/neu.2006.23.1468; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; West SL, 2011, NEUROREHABILITATION, V29, P1, DOI 10.3233/NRE-2011-0671; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; WILSON J T L, 1990, Brain Injury, V4, P349; Wood RLL, 2013, BRAIN INJURY, V27, P253, DOI 10.3109/02699052.2012.743181; Work SS, 2011, ADV THER, V28, P586, DOI 10.1007/s12325-011-0031-3; World Health Organization, 2001, INT CLASS FUNCT DIS; Zaloshnja E, 2005, AM J PREV MED, V28, P88, DOI 10.1016/j.amepre.2004.09.016; Zeitzer JM, 2009, J REHABIL RES DEV, V46, P827, DOI 10.1682/JRRD.2008.08.0099; Zgaljardic DJ, 2010, ENCYCLOPEDIA OF MOVEMENT DISORDERS, VOL 1: A-G, P458; Zgaljardic DJ, 2014, BRAIN INJURY, V28, P389, DOI 10.3109/02699052.2014.884242	211	31	31	0	23	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC 1	2015	32	23			SI		1911	1925		10.1089/neu.2014.3569			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CX4TW	WOS:000365694200008	25629222				2021-06-18	
J	Sajja, VSSS; Hubbard, WB; Hall, CS; Ghoddoussi, F; Galloway, MP; VandeVord, PJ				Sajja, Venkata Siva Sai Sujith; Hubbard, W. Brad; Hall, Christina S.; Ghoddoussi, Farhad; Galloway, Matthew P.; VandeVord, Pamela J.			Enduring deficits in memory and neuronal pathology after blast-induced traumatic brain injury	SCIENTIFIC REPORTS			English	Article							INDUCED NEUROTRAUMA; OXIDATIVE STRESS; BARRIER DYSFUNCTION; AMYLOID LOAD; US VETERANS; GLUTAMATE; ANXIETY; NEUROTRANSMITTERS; PATHOPHYSIOLOGY; MYOINOSITOL	Few preclinical studies have assessed the long-term neuropathology and behavioral deficits after sustaining blast-induced neurotrauma (BINT). Previous studies have shown extensive astrogliosis and cell death at acute stages (<7 days) but the temporal response at a chronic stage has yet to be ascertained. Here, we used behavioral assays, immmunohistochemistry and neurochemistry in limbic areas such as the amygdala (Amy), Hippocampus (Hipp), nucleus accumbens (Nac), and prefrontal cortex (PFC), to determine the long-term effects of a single blast exposure. Behavioral results identified elevated avoidance behavior and decreased short-term memory at either one or three months after a single blast event. At three months after BINT, markers for neurodegeneration (FJB) and microglia activation (Iba-1) increased while index of mature neurons (NeuN) significantly decreased in all brain regions examined. Gliosis (GFAP) increased in all regions except the Nac but only PFC was positive for apoptosis (caspase-3). At three months, tau was selectively elevated in the PFC and Hipp whereas a-synuclein transiently increased in the Hipp at one month after blast exposure. The composite neurochemical measure, myo-inositol+glycine/creatine, was consistently increased in each brain region three months following blast. Overall, a single blast event resulted in enduring long-term effects on behavior and neuropathological sequelae.	[Sajja, Venkata Siva Sai Sujith; Hubbard, W. Brad; Hall, Christina S.; VandeVord, Pamela J.] Virginia Polytech & State Univ, Sch Biomed Engn & Sci, Blacksburg, VA 24061 USA; [Ghoddoussi, Farhad; Galloway, Matthew P.] Wayne State Univ, Sch Med, Dept Anesthesiol, Detroit, MI USA; [Galloway, Matthew P.] Wayne State Univ, Sch Med, Dept Psychiat, Detroit, MI USA; [VandeVord, Pamela J.] Salem VA Med Ctr, Res & Dev Serv, Salem, VA USA	VandeVord, PJ (corresponding author), Virginia Polytech & State Univ, Sch Biomed Engn & Sci, Blacksburg, VA 24061 USA.	pvord@vt.edu	Sajja, Sujith/I-5289-2019	Sajja, Sujith/0000-0002-1992-9501			Arun P, 2013, J NEUROTRAUM, V30, P1645, DOI 10.1089/neu.2012.2834; Bolanos JP, 2010, TRENDS BIOCHEM SCI, V35, P145, DOI 10.1016/j.tibs.2009.10.006; Bowery NG, 2006, BRIT J PHARMACOL, V147, pS109, DOI 10.1038/sj.bjp.0706443; Candiota AP, 2011, JBR-BTR, V94, P319, DOI 10.5334/jbr-btr.698; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cheng LL, 1997, P NATL ACAD SCI USA, V94, P6408, DOI 10.1073/pnas.94.12.6408; Cho HJ, 2013, NEUROSCIENCE, V253, P9, DOI 10.1016/j.neuroscience.2013.08.037; Cirstea CM, 2011, STROKE, V42, P1004, DOI 10.1161/STROKEAHA.110.601047; Edison P, 2008, J NEUROL NEUROSUR PS, V79, P1331, DOI 10.1136/jnnp.2007.127878; Elder GA, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00048; Fernandez-Lopez B, 2014, GLIA, V62, P1254, DOI 10.1002/glia.22678; Gecz J, 2010, NAT GENET, V42, P925, DOI 10.1038/ng1110-925; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hertz L, 2004, TRENDS NEUROSCI, V27, P735, DOI 10.1016/j.tins.2004.10.008; Huber BR, 2013, J ALZHEIMERS DIS, V37, P309, DOI 10.3233/JAD-130182; Hue CD, 2013, J NEUROTRAUM, V30, P1652, DOI 10.1089/neu.2012.2773; Jett S, 2010, NURS FORUM, V45, P237, DOI 10.1111/j.1744-6198.2010.00195.x; Kamnaksh A, 2014, SCI REP-UK, V4, DOI 10.1038/srep04809; Kamnaksh A, 2011, J NEUROTRAUM, V28, P2145, DOI 10.1089/neu.2011.1983; Kantarci K, 2011, NEUROLOGY, V77, P951, DOI 10.1212/WNL.0b013e31822dc7e1; Kobeissy F, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00186; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Matthews SC, 2011, NEUROIMAGE, V54, pS69, DOI 10.1016/j.neuroimage.2010.04.269; Mendez MF, 2013, NEUROREHABILITATION, V32, P397, DOI 10.3233/NRE-130861; Miller SM, 2011, PHARMACOL BIOCHEM BE, V100, P130, DOI 10.1016/j.pbb.2011.08.002; Nelson NW, 2012, J INT NEUROPSYCH SOC, V18, P845, DOI 10.1017/S1355617712000616; Pederzolli CD, 2009, METAB BRAIN DIS, V24, P283, DOI 10.1007/s11011-009-9137-6; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; PROVENCHER SW, 1993, MAGNET RESON MED, V30, P672, DOI 10.1002/mrm.1910300604; Pugh KR, 2014, J NEUROSCI, V34, P4082, DOI 10.1523/JNEUROSCI.3907-13.2014; Ramos A, 2008, TRENDS PHARMACOL SCI, V29, P493, DOI 10.1016/j.tips.2008.07.005; Sajja VSSS, 2015, SHOCK, V44, P71, DOI 10.1097/SHK.0000000000000311; Sajja VSSS, 2014, NEUROSCI LETT, V570, P33, DOI 10.1016/j.neulet.2014.03.072; Sajja VSSS, 2014, MOL CELL NEUROSCI, V59, P119, DOI 10.1016/j.mcn.2014.02.004; Sajja VSSS, 2013, J NEUROSCI RES, V91, P593, DOI 10.1002/jnr.23179; Sajja VSSS, 2012, NMR BIOMED, V25, P1331, DOI 10.1002/nbm.2805; Shetty AK, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00232; Svetlov SI, 2010, J TRAUMA, V69, P795, DOI 10.1097/TA.0b013e3181bbd885; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Tumer N, 2013, NEUROSCI LETT, V544, P62, DOI 10.1016/j.neulet.2013.03.042; VandeVord PJ, 2016, J NEUROTRAUM, V33, P82, DOI 10.1089/neu.2014.3786; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wilcox CS, 2010, PHARMACOL THERAPEUT, V126, P119, DOI 10.1016/j.pharmthera.2010.01.003; Xie K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064907; Yeoh S, 2013, ANN BIOMED ENG, V41, P2206, DOI 10.1007/s10439-013-0805-7	46	31	31	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	NOV 5	2015	5								15075	10.1038/srep15075			10	Multidisciplinary Sciences	Science & Technology - Other Topics	CV3HY	WOS:000364151100001	26537106	DOAJ Gold, Green Published			2021-06-18	
J	Bajsarowicz, P; Prakash, I; Lamoureux, J; Saluja, RS; Feyz, M; Maleki, M; Marcoux, J				Bajsarowicz, Paul; Prakash, Ipshita; Lamoureux, Julie; Saluja, Rajeet Singh; Feyz, Mitra; Maleki, Mohammad; Marcoux, Judith			Nonsurgical acute traumatic subdural hematoma: what is the risk?	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; subdural hematoma; acute subdural hematoma; nonsurgical subdural hematoma; trauma	CEREBRAL ATROPHY; PRACTICAL SCALE; INJURY; BICAUDATE; SCORE; COMA	OBJECT The Brain Trauma Foundation has published guidelines on the surgical management of traumatic subdural hematoma (SDH). However, no data exist on the proportion of patients with SDH that can be selected for conservative management and what is the outcome of these patients. The goals of this study were as follows: 1) to establish what proportion of patients are initially treated conservatively; 2) to determine what proportion of patients will deteriorate and require surgical evacuation; and 3) to identify risk factors associated with deterioration and delayed surgery. METHODS All cases of acute traumatic SDH (869 when inclusion criteria were met) presenting over a 4-year period were reviewed. For all conservatively treated SDH, the proportion of delayed surgical intervention and the Glasgow Outcome Scale score were taken as outcome measures. Multiple factors were compared between patients who required delayed surgery and patients without surgery. RESULTS Of the 869 patients with acute traumatic SDH, 646 (74.3%) were initially treated conservatively. A good outcome was achieved in 76.7% of the patients. Only 6.5% eventually required delayed surgery, and the median delay for surgery was 9.5 days. Factors associated with deterioration were as follows: 1) thicker SDH (p < 0.001); 2) greater midline shift (p < 0.001); 3) location at the convexity (p = 0.001); 4) alcohol abuse (p = 0.0260); and 5) history of falls (p = 0.018). There was no significant difference in regard to age, sex, Glasgow Coma Scale score, Injury Severity Score, abnormal coagulation, use of blood thinners, and presence of cerebral atrophy or white matter disease. CONCLUSIONS The majority of patients with SDH are treated conservatively. Of those, only 6.5% later required surgery, for raised intracranial pressure or SDH progression. Patients at risk can be identified and followed more carefully.	[Bajsarowicz, Paul] McGill Univ, Dept Radiol, Montreal, PQ H3A 2T5, Canada; [Prakash, Ipshita] McGill Univ, Dept Surg, Montreal, PQ H3A 2T5, Canada; [Saluja, Rajeet Singh; Maleki, Mohammad; Marcoux, Judith] McGill Univ, Dept Neurol & Neurosurg, Montreal, PQ H3A 2T5, Canada; [Feyz, Mitra] McGill Univ, Dept Surg, Ctr Hlth, Montreal, PQ H3A 2T5, Canada; [Maleki, Mohammad; Marcoux, Judith] McGill Univ, Ctr Hlth, Dept Neurosurg, Montreal, PQ H3G 1A4, Canada; [Lamoureux, Julie] Baptist Hlth South Florida, Miami, FL USA	Marcoux, J (corresponding author), McGill Univ, Ctr Hlth, Montreal Gen Hosp, Dept Neurosurg, 1650 Cedar Ave,Rm L7-516, Montreal, PQ H3G 1A4, Canada.	judith.marcoux@mcgill.ca					BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS37; Bullock MR, 2006, NEUROSURGERY S, V58, pSi; Doraiswamy P M, 1994, J Geriatr Psychiatry Neurol, V7, P13; Dudley RR, 2010, J NEUROTRAUM, V27, P2165, DOI 10.1089/neu.2010.1366; Institut de la Statistique du Quebec, 2006, PROJ POP QUEB SEL TE; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Lee KS, 1998, BRAIN INJURY, V12, P901; Marion DW, 2006, NEUROSURGERY, V58, P655; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; MATHEW P, 1993, ACTA NEUROCHIR, V121, P100, DOI 10.1007/BF01809258; Servadei F, 1998, J TRAUMA, V44, P868, DOI 10.1097/00005373-199805000-00021; TEASDALE G, 1974, LANCET, V2, P81; Tokmak M, 2007, J NEUROSURG, V107, P290, DOI 10.3171/JNS-07/08/0290; van Zagten M, 1999, NEURORADIOLOGY, V41, P261, DOI 10.1007/s002340050743; WONG CW, 1995, ACTA NEUROCHIR, V135, P38, DOI 10.1007/BF02307412; Yang AIL, 2012, BRAIN INJURY, V26, P1731, DOI 10.3109/02699052.2012.698364	18	31	32	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2015	123	5					1176	1183		10.3171/2014.10.JNS141728			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CU3QL	WOS:000363439800010	25955872	Bronze			2021-06-18	
J	Biederman, J; Feinberg, L; Chan, J; Adeyemo, BO; Woodworth, KY; Panis, W; McGrath, N; Bhatnagar, S; Spencer, TJ; Uchida, M; Kenworthy, T; Grossman, R; Zafonte, R; Faraone, SV				Biederman, Joseph; Feinberg, Leah; Chan, James; Adeyemo, Bamidele O.; Woodworth, K. Yvonne; Panis, Walter; McGrath, Neal; Bhatnagar, Saurabha; Spencer, Thomas J.; Uchida, Mai; Kenworthy, Tara; Grossman, Rebecca; Zafonte, Ross; Faraone, Stephen V.			Mild Traumatic Brain Injury and Attention-Deficit Hyperactivity Disorder in Young Student Athletes	JOURNAL OF NERVOUS AND MENTAL DISEASE			English	Article						Traumatic brain injury; mild; attention-deficit hyperactivity disorder; student athlete	PROFESSIONAL FOOTBALL PLAYERS; DEFICIT/HYPERACTIVITY DISORDER; RECURRENT CONCUSSION; LEAGUE PLAYER; HEAD-INJURY; ADOLESCENTS; CHILDREN; IMPACT; ENCEPHALOPATHY; RECOVERY	A recent meta-analysis documented a significant statistical association between mild traumatic brain injury (mTBI) and attention deficit hyperactivity disorder (ADHD) (Adeyemo et al., 2014), but the direction of this effect was unclear. In this study, we hypothesized that ADHD would be an antecedent risk factor for mTBI. Participants were student athletes ages 12 to 25 who had sustained a mTBI and Controls of similar age and sex selected from studies of youth with and without ADHD. Subjects were assessed for symptoms of ADHD, concussion severity, and cognitive function. mTBI subjects had a significantly higher rate of ADHD than Controls, and in all cases the age of onset of ADHD was before mTBI onset. mTBI+ADHD subjects also had more severe concussion symptoms (fatigue and poor concentration) than mTBI-ADHD subjects. These results support ADHD as an antecedent risk factor for mTBI in student athletes and that its presence complicates the course of mTBI.	[Biederman, Joseph; Feinberg, Leah; Chan, James; Woodworth, K. Yvonne; Spencer, Thomas J.; Uchida, Mai; Kenworthy, Tara; Grossman, Rebecca] Massachusetts Gen Hosp, Clin & Res Programs Pediat Psychopharmacol & Adul, Boston, MA 02114 USA; [Biederman, Joseph; Adeyemo, Bamidele O.; Bhatnagar, Saurabha; Spencer, Thomas J.; Uchida, Mai; Zafonte, Ross] Harvard Univ, Sch Med, Boston, MA USA; [Adeyemo, Bamidele O.] Emory Univ, Sch Med, Dept Phys Med & Rehabil, Atlanta, GA USA; [Panis, Walter; Bhatnagar, Saurabha; Zafonte, Ross] Massachusetts Gen Hosp, Spaulding Rehabil Hospital, Dept Phys Med & Rehabil, Charlestown, MA USA; [McGrath, Neal] Sports Concuss New England, Brookline, MA USA; [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Neurosci, Syracuse, NY 13210 USA; [Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Physiol, Syracuse, NY 13210 USA; [Faraone, Stephen V.] Univ Bergen, KG Jebsen Ctr Res Neuropsychiat Disorders, Bergen, Norway	Biederman, J (corresponding author), Massachusetts Gen Hosp, 55 Fruit St,YAW 6A, Boston, MA 02114 USA.	jbiederman@partners.org	Meijer, Anna/K-5118-2016; Kenworthy, Tara/M-8712-2019; Faraone, Stephen V/O-7239-2018; Faraone, Stephen/AAE-7334-2019	Faraone, Stephen V/0000-0002-9217-3982; Faraone, Stephen/0000-0002-9217-3982	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01MH050657, R01HD036317]; Pediatric Psychopharmacology Research Council Fund; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD036317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH050657] Funding Source: NIH RePORTER	This work was supported by NIH grants (J.B., grant numbers R01MH050657, R01HD036317) and by the Pediatric Psychopharmacology Research Council Fund. The authors thank Elana Kagan for her contributions to the early stages of coordinating this study.	Adeyemo BO, 2014, J ATTEN DISORD, V18, P576, DOI 10.1177/1087054714543371; American Psychiatric Association, 1987, DIAGN STAT MAN MENT, VThird, P567; American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 2000, DIAGN STAT MAN MENT, V4th, P1; Antshel KM, 2009, PSYCHOL MED, V39, P1325, DOI 10.1017/S0033291708004959; BARKLEY RA, 1993, PEDIATRICS, V92, P212; Barkley RA., 2010, ADHD ADULTS WHAT SCI; Biederman J, 2006, PSYCHOL MED, V36, P167, DOI 10.1017/S0033291705006410; Biederman J, 1996, ARCH GEN PSYCHIAT, V53, P437; Biederman J, 1999, J AM ACAD CHILD PSY, V38, P966, DOI 10.1097/00004583-199908000-00012; Biederman J, 2005, LANCET, V366, P237, DOI 10.1016/S0140-6736(05)66915-2; Biederman J, 2006, BIOL PSYCHIAT, V60, P1098, DOI 10.1016/j.biopsych.2006.02.031; Biederman J, 2006, AM J PSYCHIAT, V163, P1730, DOI 10.1176/appi.ajp.163.10.1730; Bonfield CM, 2013, J NEUROSURG-PEDIATR, V12, P97, DOI 10.3171/2013.5.PEDS12424; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Fann JR, 2004, ARCH GEN PSYCHIAT, V61, P53, DOI 10.1001/archpsyc.61.1.53; Faraone Stephen V, 2003, World Psychiatry, V2, P104; Gerring J, 2000, BRAIN INJURY, V14, P205; Gioia G. A., 2000, BRIEF BEHAV RATING I; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Iverson GL, 2006, BRAIN INJURY MED PRI, P373; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Keenan HT, 2008, BMJ-BRIT MED J, V337, DOI 10.1136/bmj.a1984; LAHEY BB, 1994, AM J PSYCHIAT, V151, P1673; Lam L T, 2002, J Atten Disord, V6, P77, DOI 10.1177/108705470200600204; Lambert NM, 1995, ANAL DRIVING HISTORI, P1; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lovell MR., 2000, IMPACT IMMEDIATE POS; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Orvaschel H, 1994, SCHEDULE AFFECTIVE D; Orvaschel H., 1987, SCHEDULE AFFECTIVE D, V4th Version; Pastor PN, 2006, AMBUL PEDIATR, V6, P38, DOI 10.1016/j.ambp.2005.07.002; R Core Team, 2014, R LANG ENV STAT COMP; Roth R.M., 2005, BRIEF BEHAV RATING I; Ruff RM, 2011, NEUROREHABILITATION, V28, P167, DOI 10.3233/NRE-2011-0646; Swensen, 2004, J ADOLESCENT HEALTH, V35, DOI [DOI 10.1016/J.JAD0HEALTH.2003.12.003, 10.1016/j.jadohealth.2003.12.003]; Wechsler D., 1974, MANUAL WECHSLER INTE; Wechsler D., 2011, WECHSLER ABBREVIATED	44	31	31	1	21	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-3018	1539-736X		J NERV MENT DIS	J. Nerv. Ment. Dis.	NOV	2015	203	11					813	819		10.1097/NMD.0000000000000375			7	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	CV7UW	WOS:000364482100001	26461480	Green Accepted			2021-06-18	
J	Ruozi, B; Belletti, D; Sharma, HS; Sharma, A; Muresanu, DF; Mossler, H; Forni, F; Vandelli, MA; Tosi, G				Ruozi, Barbara; Belletti, Daniela; Sharma, Hari S.; Sharma, Aruna; Muresanu, Dafin F.; Moessler, Herbert; Forni, Flavio; Vandelli, Maria Angela; Tosi, Giovanni			PLGA Nanoparticles Loaded Cerebrolysin: Studies on Their Preparation and Investigation of the Effect of Storage and Serum Stability with Reference to Traumatic Brain Injury	MOLECULAR NEUROBIOLOGY			English	Article						Nanoparticles (NPs); Polylactic-co-glycolide (PLGA); Cerebrolysin; Long-termstability; Serumstability; Traumatic brain injury; Neuroprotection	WHOLE-BODY HYPERTHERMIA; CEREBRAL BLOOD-FLOW; NORMOTENSIVE YOUNG-RATS; SPINAL-CORD-INJURY; BARRIER PERMEABILITY; NEUROTROPHIC FACTORS; SOLVENT EVAPORATION; EDEMA FORMATION; DRUG-DELIVERY; 5-HT LEVEL	Cerebrolysin is a peptide mixture able to ameliorate symptomatology and delay progression of neurological disorders such as Alzheimer's disease and dementia. The administration of this drug in humans presents several criticisms due to its short half-life, poor stability, and high doses needed to achieve the effect. This paper investigates the potential of polylactic-co-glycolide (PLGA) nanoparticles (NPs) as sustained release systems for iv administration of cerebrolysin in normal and brain injured rats. NPs were prepared by water-in-oil-in-water (w/o/w) double emulsion technique and characterized by light scattering for mean size and zeta potential and by scanning electron microscopy (SEM) for surface morphology. The NPs produced by double sonication under cooling at 60 W for 45 s, 12 mL of 1 % w:v of PVA, and 1:0.6 w:w drug/PLGA ratio (C-NPs4) displayed an adequate loading of drug (24 +/- 1 mg/100 mg of NPs), zeta potential value (-13 mV), and average diameters (ranged from 250 to 330 nm) suitable to iv administration. SEM images suggested that cerebrolysin was molecularly dispersed into matricial systems and partially adhered to the NP surface. A biphasic release with an initial burst effect followed by sustained release over 24 h was observed. Long-term stability both at room and at low temperature of freeze-dried NPs was investigated. To gain deeper insight into NP stability after in vivo administration, the stability of the best NP formulation was also tested in serum. These PLGA NPs loaded with cerebrolysin were able to reduce brain pathology following traumatic brain injury. However, the size, the polydispersivity, and the surface properties of sample were significantly affected by the incubation time and the serum concentration.	[Ruozi, Barbara; Belletti, Daniela; Forni, Flavio; Vandelli, Maria Angela; Tosi, Giovanni] Univ Modena & Reggio Emilia, Dept Life Sci, Lab Pharmaceut Technol, I-41125 Modena, Italy; [Sharma, Hari S.; Sharma, Aruna] Uppsala Univ, Univ Uppsala Hosp, Dept Surg Sci Anaesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75185 Uppsala, Sweden; [Muresanu, Dafin F.] Univ Med & Pharm, Univ Hosp, Dept Clin Neurosci, Cluj Napoca, Romania; [Moessler, Herbert] Ever Neuro Pharma, Oberburgau, Austria; [Sharma, Hari S.] Univ Uppsala Hosp, IECNSIR, SE-75421 Uppsala, Sweden	Sharma, HS (corresponding author), Uppsala Univ, Univ Uppsala Hosp, Dept Surg Sci Anaesthesiol & Intens Care Med, Lab Cerebrovasc Res, SE-75185 Uppsala, Sweden.	Sharma@surgsci.uu.se	Muresanu, Fior-Dafin/AAI-8120-2021; Tosi, Giovanni/D-4547-2011; Belletti, Daniela/L-5288-2016	Tosi, Giovanni/0000-0001-8318-667X; Belletti, Daniela/0000-0003-2872-445X	Air Force Office of Scientific Research (EOARD, London, UK)United States Department of DefenseAir Force Office of Scientific Research (AFOSR); Air Force Material Command, USAF [FA8655-05-1-3065]; Swedish Medical Research CouncilSwedish Medical Research Council (SMRC)European Commission [Nr 2710-HSS]; Swedish Strategic Research Foundation, Stockholm, Sweden; Goran Gustafsson Foundation, Stockholm, Sweden; Astra Zeneca, Molndal, SwedenAstraZeneca; University Grants Commission, New Delhi, IndiaUniversity Grants Commission, India; Ministry of Science and Technology, Govt. of India and Govt. of Sweden; Indian Medical Research Council, New Delhi, India; India-EU Research Co-operation Program	This investigation is supported in part by grants from the Air Force Office of Scientific Research (EOARD, London, UK), and Air Force Material Command, USAF, under grant number FA8655-05-1-3065; Swedish Medical Research Council (Nr 2710-HSS), Swedish Strategic Research Foundation, Stockholm, Sweden; Goran Gustafsson Foundation, Stockholm, Sweden (HSS), Astra Zeneca, Molndal, Sweden (HSS/AS), The University Grants Commission, New Delhi, India (HSS/AS), Ministry of Science and Technology, Govt. of India and Govt. of Sweden (HSS/AS), Indian Medical Research Council, New Delhi, India (HSS/AS); and India-EU Research Co-operation Program (AS/HSS).	Abdelwahed W, 2006, ADV DRUG DELIVER REV, V58, P1688, DOI 10.1016/j.addr.2006.09.017; Belletti D, 2012, INT J PHARMACEUT, V436, P753, DOI 10.1016/j.ijpharm.2012.07.070; Biswal I., 2011, INT J PHARM PHARM SC, V3, P256; BODMEIER R, 1987, PHARMACEUT RES, V4, P465, DOI 10.1023/A:1016419303727; Costantino L, 2005, J CONTROL RELEASE, V108, P84, DOI 10.1016/j.jconrel.2005.07.013; DEY PK, 1983, INDIAN J MED RES, V77, P554; Dobson J, 2006, GENE THER, V13, P283, DOI 10.1038/sj.gt.3302720; ELLIOTT KAC, 1949, AM J PHYSIOL, V157, P122; Feczko T, 2011, CHEM ENG PROCESS, V50, P757, DOI 10.1016/j.cep.2011.06.008; Gromova OA, 2003, ZH NEVROPATOL PSIKH, V103, P59; Hartbauer M, 2001, J NEURAL TRANSM, V108, P459, DOI 10.1007/s007020170067; Heurtault B, 2003, BIOMATERIALS, V24, P4283, DOI 10.1016/S0142-9612(03)00331-4; JOSHI DP, 1979, ANAL CHIM ACTA, V104, P153, DOI 10.1016/S0003-2670(01)83825-3; Katas H, 2013, J NANOMATER, V2013, DOI 10.1155/2013/536291; Liu WM, 2001, SPECTROSC SPECT ANAL, V21, P397; Menon JU, 2012, J BIOMED MATER RES A, V100A, P1998, DOI 10.1002/jbm.a.34040; MOHANTY S, 1989, J NEUROL SCI, V90, P87, DOI 10.1016/0022-510X(89)90048-8; Naahidi S, 2013, J CONTROL RELEASE, V166, P182, DOI 10.1016/j.jconrel.2012.12.013; Rosca ID, 2004, J CONTROL RELEASE, V99, P271, DOI 10.1016/j.jconrel.2004.07.007; Ruozi B, 2012, INT REV NEUROBIOL, V102, P207, DOI 10.1016/B978-0-12-386986-9.00009-0; Ruozi B, 2014, CNS NEUROL DISORD-DR, V13, P1475, DOI 10.2174/1871527313666140806145540; Sharma A, 2012, CNS NEUROL DISORD-DR, V11, P7, DOI 10.2174/187152712799960790; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P288; Sharma HS, 2007, ANN NY ACAD SCI, V1122, P112, DOI 10.1196/annals.1403.008; Sharma HS, 2007, PROG BRAIN RES, V162, P173, DOI 10.1016/S0079-6123(06)62010-4; Sharma HS, 2014, J NANOSCI NANOTECHNO, V14, P577, DOI 10.1166/jnn.2014.9213; Sharma HS, 2012, INT REV NEUROBIOL, V102, P249, DOI 10.1016/B978-0-12-386986-9.00010-7; Sharma HS, 2010, ANN NY ACAD SCI, V1199, P125, DOI 10.1111/j.1749-6632.2009.05329.x; Sharma HS, 2010, ACTA NEUROCHIR SUPPL, V106, P321, DOI 10.1007/978-3-211-98811-4_60; Sharma HS, 2010, ACTA NEUROCHIR SUPPL, V106, P295, DOI 10.1007/978-3-211-98811-4_55; SHARMA HS, 1986, NEUROPHARMACOLOGY, V25, P161, DOI 10.1016/0028-3908(86)90037-7; SHARMA HS, 1987, NEUROPHARMACOLOGY, V26, P85, DOI 10.1016/0028-3908(87)90049-9; SHARMA HS, 1995, RESTOR NEUROL NEUROS, V7, P207, DOI 10.3233/RNN-1994-7403; SHARMA HS, 1986, J NEUROL SCI, V72, P61, DOI 10.1016/0022-510X(86)90036-5; SHARMA HS, 1987, BRAIN RES, V424, P153, DOI 10.1016/0006-8993(87)91205-4; SHARMA HS, 1990, ACTA NEUROPATHOL, V79, P604, DOI 10.1007/BF00294237; Sharma HS, 2004, BLOOD SPINAL CORD BR, P117; Tosi G, 2010, J CONTROL RELEASE, V145, P49, DOI 10.1016/j.jconrel.2010.03.008; Tosi G, 2012, NANOMEDICINE-UK, V7, P365, DOI [10.2217/NNM.11.98, 10.2217/nnm.11.98]; Zhang Y, 2013, ADV DRUG DELIVER REV, V65, P104, DOI 10.1016/j.addr.2012.10.003	40	31	31	0	25	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	OCT	2015	52	2			SI		899	912		10.1007/s12035-015-9235-x			14	Neurosciences	Neurosciences & Neurology	CQ6AQ	WOS:000360687200009	26108180				2021-06-18	
J	Dean, PJA; Sato, JR; Vieira, G; McNamara, A; Sterr, A				Dean, Philip J. A.; Sato, Joao Ricardo; Vieira, Gilson; McNamara, Adam; Sterr, Annette			Long-term structural changes after mTBI and their relation to post-concussion symptoms	BRAIN INJURY			English	Article						Magnetic resonance imaging; diffusion tensor imaging; cortical thickness; mild traumatic brain injury; persistent post-concussion syndrome	TRAUMATIC BRAIN-INJURY; WHITE-MATTER ABNORMALITIES; VOXEL-BASED MORPHOMETRY; SURFACE-BASED ANALYSIS; DIFFUSE AXONAL INJURY; HUMAN CEREBRAL-CORTEX; HEAD-INJURY; NEUROPSYCHOLOGICAL PERFORMANCE; UNITED-STATES; MILD	Primary objective: To investigate sustained structural changes in the long-term (>1 year) after mild traumatic brain injury (mTBI) and their relationship to ongoing post-concussion syndrome (PCS). Research design: Morphological and structural connectivity magnetic resonance imaging (MRI) data were acquired from 16 participants with mTBI and nine participants without previous head injury. Main outcomes and results: Participants with mTBI had less prefrontal grey matter and lower fractional anisotropy (FA) in the anterior corona radiata and internal capsule. Furthermore, PCS severity was associated with less parietal lobe grey matter and lower FA in the corpus callosum. Conclusions: There is evidence for both white and grey matter damage in participants with mTBI over 1 year after injury. Furthermore, these structural changes are greater in those that report more PCS symptoms, suggesting a neurophysiological basis for these persistent symptoms.	[Dean, Philip J. A.; McNamara, Adam; Sterr, Annette] Univ Surrey, Dept Psychol, Guildford GU2 7XH, Surrey, England; [Sato, Joao Ricardo] Univ Fed ABC, Ctr Math Computat & Cognit, Sao Paulo, Brazil; [Sato, Joao Ricardo; Vieira, Gilson] Univ Sao Paulo, Fac Med, Dept Radiol, NIF LIM44, Sao Paulo, Brazil	Dean, PJA (corresponding author), Univ Surrey, Dept Psychol, Guildford GU2 7XH, Surrey, England.	p.dean@surrey.ac.uk		Sterr, Annette/0000-0003-4490-985X; Dean, Philip/0000-0002-2362-513X	Wingate Foundation Scholarship, UK; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0200128] Funding Source: researchfish	This research was supported by a Wingate Foundation Scholarship, UK.	Bailey CM, 2006, J INT NEUROPSYCH SOC, V12, P475, DOI 10.1017/S1355617706060619; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P262, DOI 10.1017/S1355617709991287; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; Cubon VA, 2011, J NEUROTRAUM, V28, P189, DOI 10.1089/neu.2010.1430; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Davenport ND, 2012, NEUROIMAGE, V59, P2017, DOI 10.1016/j.neuroimage.2011.10.050; Dean PJA, 2013, NEUROREPORT, V24, P677, DOI 10.1097/WNR.0b013e3283637aa4; Dean PJA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00030; Dean PJA, 2012, BRAIN INJURY, V26, P14, DOI 10.3109/02699052.2011.635354; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2000, P NATL ACAD SCI USA, V97, P11050, DOI 10.1073/pnas.200033797; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gonzalez PG, 2011, PM&R, V3, pS413, DOI 10.1016/j.pmrj.2011.08.536; Goodacre S, 2008, EMERG MED J, V25, P556, DOI 10.1136/emj.2007.055723; Hessen E, 2008, BRAIN INJURY, V22, P39, DOI 10.1080/02699050701846179; Holli KK, 2010, ACAD RADIOL, V17, P1096, DOI 10.1016/j.acra.2010.04.009; Hunter JV, 2012, J NEUROTRAUM, V29, P654, DOI 10.1089/neu.2011.1906; Irimia Andrei, 2012, Front Neurol, V3, P10, DOI 10.3389/fneur.2012.00010; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jorge RE, 2012, AM J PSYCHIAT, V169, P1284, DOI 10.1176/appi.ajp.2012.12050600; Kasahara K, 2012, MAGN RESON IMAGING, V30, P496, DOI 10.1016/j.mri.2011.12.018; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee H, 2008, J NEUROTRAUM, V25, P1049, DOI 10.1089/neu.2008.0566; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Ling JM, 2012, BRAIN, V135, P1281, DOI 10.1093/brain/aws073; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Mayer AR, 2011, HUM BRAIN MAPP, V32, P1825, DOI 10.1002/hbm.21151; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Mulhern S, 2006, J PSYCHOSOM RES, V61, P439, DOI 10.1016/j.jpsychores.2006.03.004; NCIPC, 2003, REP C MILD TRAUM BRA; Newcombe V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019214; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Rosenbaum SB, 2012, BRAIN IMAGING BEHAV, V6, P255, DOI 10.1007/s11682-012-9162-7; Ross DE, 2011, BRAIN INJURY, V25, P1271, DOI 10.3109/02699052.2011.624568; Rutgers DR, 2008, AM J NEURORADIOL, V29, P514, DOI 10.3174/ajnr.A0856; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Shen S, 2013, J MAGN RESON IMAGING, V37, P1468, DOI 10.1002/jmri.23927; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Singh M, 2010, MAGN RESON IMAGING, V28, P22, DOI 10.1016/j.mri.2009.05.049; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sosin DM, 1996, BRAIN INJURY, V10, P47; Sterr A, 2006, BMC NEUROL, V6, DOI 10.1186/1471-2377-6-7; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Topal NB, 2008, NEUROL RES, V30, P974, DOI 10.1179/016164108X323799; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Weiss D. S, 2007, CROSS CULTURAL ASSES, P218; World Health Organization, 1992, ICD 10 INT STAT CLAS; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Yurgelun-Todd DA, 2011, J HEAD TRAUMA REHAB, V26, P276, DOI 10.1097/HTR.0b013e31822251dc; Zhang K, 2012, J NEUROTRAUM, V29, P756, DOI 10.1089/neu.2011.2125; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	65	31	32	1	18	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	SEP	2015	29	10					1211	1218		10.3109/02699052.2015.1035334			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	CR3UK	WOS:000361258400010	26067623	Green Accepted			2021-06-18	
J	Kennis, M; van Rooij, SJH; Tromp, DPM; Fox, AS; Rademaker, AR; Kahn, RS; Kalin, NH; Geuze, E				Kennis, Mitzy; van Rooij, Sanne J. H.; Tromp, Do P. M.; Fox, Andrew S.; Rademaker, Arthur R.; Kahn, Rene S.; Kalin, Ned H.; Geuze, Elbert			Treatment Outcome-Related White Matter Differences in Veterans with Posttraumatic Stress Disorder	NEUROPSYCHOPHARMACOLOGY			English	Article							DEFAULT NETWORK CONNECTIVITY; PREDICTS TREATMENT RESPONSE; TRAUMATIC BRAIN-INJURY; ANTERIOR CINGULATE; INTEGRITY; THERAPY; NEUROCIRCUITRY; PSYCHOTHERAPY; AFGHANISTAN; SYMPTOMS	Posttraumatic stress disorder (PTSD) is a debilitating disorder that has been associated with brain abnormalities, including white matter alterations. However, little is known about the effect of treatment on these brain alterations. To investigate the course of white matter alterations in PTSD, we used a longitudinal design investigating treatment effects on white matter integrity using diffusion tensor imaging (DTI). Diffusion tensor and magnetization transfer images were obtained pre- and posttreatment from veterans with (n=39) and without PTSD (n=22). After treatment, 16 PTSD patients were remitted, and 23 had persistent PTSD based on PTSD diagnosis. The dorsal and hippocampal cingulum bundle, stria terminalis, and fornix were investigated as regions of interest. Exploratory whole-brain analyses were also performed. Groups were compared with repeated-measures ANOVA for fractional anisotropy (FA), and magnetization transfer ratio. Persistently symptomatic PTSD patients had increasing FA of the dorsal cingulum over time, and at reassessment these FA values were higher than both combat controls and the remitted PTSD group. Group-by-time interactions for FA were found in the hippocampal cingulum, fornix, and stria terminalis, posterior corona radiata, and superior longitudinal fasciculus. Our results indicate that higher FA of the dorsal cingulum bundle may be an acquired feature of persistent PTSD that develops over time. Furthermore, treatment might have differential effects on the hippocampal cingulum, fornix, stria terminalis, posterior corona radiata, and superior longitudinal fasciculus in remitted vs persistent PTSD patients. This study contributes to a better understanding of the neural underpinnings of PTSD treatment outcome.	[Kennis, Mitzy; van Rooij, Sanne J. H.; Rademaker, Arthur R.; Kahn, Rene S.; Geuze, Elbert] Univ Med Ctr Utrecht, Dept Psychiat, Brain Ctr Rudolf Magnus, NL-3584 CX Utrecht, Netherlands; [Kennis, Mitzy; van Rooij, Sanne J. H.; Rademaker, Arthur R.; Geuze, Elbert] Minist Def, Res Ctr Mil Mental Healthcare, Utrecht, Netherlands; [Tromp, Do P. M.; Fox, Andrew S.; Kalin, Ned H.] Univ Wisconsin, Dept Psychiat, Madison, WI 53706 USA	Kennis, M (corresponding author), Univ Med Ctr Utrecht, Dept Psychiat, Brain Ctr Rudolf Magnus, 100 HPN A01-1-46, NL-3584 CX Utrecht, Netherlands.	M.Kennis@umcutrecht.nl		van Rooij, Sanne/0000-0002-0160-7248	Dutch Ministry of Defence	This research was funded by the Dutch Ministry of Defence. Dr Kalin has served on scientific advisory boards for Corcept Therapeutics, Neuronetics, CeNeRx BioPharma, and Skyland Trail; is a stockholder with equity options in Corcept Therapeutics and CeNeRx BioPharma; owned Promoter Neurosciences; and holds patents for promoter sequences for corticotropin-releasing factor CRF2 alpha and a method of identifying agents that alter the activity of the promoter sequences, promoter sequences for urocortin II and the use thereof, and promoter sequences for corticotropin-releasing factor binding protein and the use thereof. The authors declare no conflict of interest.	Abe O, 2006, PSYCHIAT RES-NEUROIM, V146, P231, DOI 10.1016/j.pscychresns.2006.01.004; Alexander AL, 2011, BRAIN CONNECT, V1, P423, DOI 10.1089/brain.2011.0071; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Aupperle RL, 2013, PSYCHIAT RES-NEUROIM, V214, P48, DOI 10.1016/j.pscychresns.2013.05.001; Avery SN, 2014, NEUROIMAGE, V91, P311, DOI 10.1016/j.neuroimage.2014.01.017; Balkom AV, 2013, RICHTLIJN DIAGNOSTIE; Bazarian JJ, 2013, J HEAD TRAUMA REHAB, V28, P1, DOI 10.1097/HTR.0b013e318256d3d3; Beaulieu C, 2009, DIFFUSION MRI: FROM QUANTITATIVE MEASUREMENT TO IN VIVO NEUROANATOMY, P105, DOI 10.1016/B978-0-12-374709-9.00006-7; Bisson JI, 2007, BRIT J PSYCHIAT, V190, P97, DOI 10.1192/bjp.bp.106.021402; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Bluhm RL, 2009, J PSYCHIATR NEUROSCI, V34, P187; Brady K, 2000, JAMA-J AM MED ASSOC, V283, P1837, DOI 10.1001/jama.283.14.1837; Bryant RA, 2008, PSYCHOL MED, V38, P555, DOI 10.1017/S0033291707002231; Bryant RA, 2008, J PSYCHIATR NEUROSCI, V33, P142; Concha L, 2014, NEUROSCIENCE, V276, P14, DOI 10.1016/j.neuroscience.2013.09.004; Costanzo ME, 2014, NEUROSCI LETT, V577, P11, DOI 10.1016/j.neulet.2014.05.054; Daniels JK, 2013, DEPRESS ANXIETY, V30, P207, DOI 10.1002/da.22044; Daniels JK, 2010, J PSYCHIATR NEUROSCI, V35, P258, DOI 10.1503/jpn.090010; Dickie EW, 2013, PSYCHOL MED, V43, P645, DOI 10.1017/S0033291712001328; Ding AY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0051704; Fani N, 2012, NEUROPSYCHOPHARMACOL, V37, P2740, DOI 10.1038/npp.2012.146; Fani N, 2011, NEUROSCI LETT, V491, P196, DOI 10.1016/j.neulet.2011.01.037; First MB., 1997, STRUCTURED CLIN INTE; Foa EB, 1997, ANNU REV PSYCHOL, V48, P449, DOI 10.1146/annurev.psych.48.1.449; FOA EB, 1986, PSYCHOL BULL, V99, P20, DOI 10.1037/0033-2909.99.1.20; Gray J. A., 1982, NEUROPSYCHOL ANXIETY; Hayes JP, 2012, BIOL MOOD ANXIETY DI, V2, DOI 10.1186/2045-5380-2-9; Henkelman RM, 2001, NMR BIOMED, V14, P57, DOI 10.1002/nbm.683; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kennis M, 2015, HUM BRAIN MAPP, V36, P99, DOI 10.1002/hbm.22615; Kim MJ, 2005, NEUROREPORT, V16, P1049, DOI 10.1097/00001756-200507130-00004; Lanius RA, 2003, BIOL PSYCHIAT, V53, P204, DOI 10.1016/S0006-3223(02)01466-X; Lindauer RJL, 2005, PSYCHOL MED, V35, P1421, DOI 10.1017/S0033291705005246; Linden DEJ, 2006, MOL PSYCHIATR, V11, P528, DOI 10.1038/sj.mp.4001816; Mori S., 2005, MRI ATLAS HUMAN WHIT; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Morina N, 2013, J CLIN PSYCHIAT, V74, pE212, DOI 10.4088/JCP.12m07844; Philip NS, 2013, EUR NEUROPSYCHOPHARM, V23, P24, DOI 10.1016/j.euroneuro.2012.10.008; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Reijnen A, 2015, EUR PSYCHIAT, V30, DOI 10.1016/j.eurpsy.2014.05.003; Rothbaum BO, 2003, ANN NY ACAD SCI, V1008, P112, DOI 10.1196/annals.1301.012; Roy MJ, 2010, ANN NY ACAD SCI, V1208, P142, DOI 10.1111/j.1749-6632.2010.05689.x; Sanjuan PM, 2013, PSYCHIAT RES-NEUROIM, V214, P260, DOI 10.1016/j.pscychresns.2013.09.002; Schuff N, 2011, NEUROIMAGE, V54, pS62, DOI 10.1016/j.neuroimage.2010.05.024; Sekiguchi A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0083967; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; van Rooij SJH, 2015, NEUROPSYCHOPHARMACOL, V40, P667, DOI 10.1038/npp.2014.220; van Rooij SJH, 2015, PREDICTING PER UNPUB; van Wingen GA, 2012, P NATL ACAD SCI USA, V109, P15508, DOI 10.1073/pnas.1206330109; Wang S, 2014, NEUROSCIENCE, V276, P148, DOI 10.1016/j.neuroscience.2013.10.018; World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053; Zhang L, 2012, ACTA NEUROPSYCHIATR, V24, P34, DOI 10.1111/j.1601-5215.2011.00580.x; Zhang L, 2011, J AFFECT DISORDERS, V133, P294, DOI 10.1016/j.jad.2011.03.040	53	31	31	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0893-133X	1740-634X		NEUROPSYCHOPHARMACOL	Neuropsychopharmacology	SEP	2015	40	10					2434	2442		10.1038/npp.2015.94			9	Neurosciences; Pharmacology & Pharmacy; Psychiatry	Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry	CO9KE	WOS:000359493700016	25837284	Green Published, Bronze			2021-06-18	
J	Fuhrmann, T; Obermeyer, J; Tator, CH; Shoichet, MS				Fuehrmann, T.; Obermeyer, J.; Tator, C. H.; Shoichet, M. S.			Click-crosslinked injectable hyaluronic acid hydrogel is safe and biocompatible in the intrathecal space for ultimate use in regenerative strategies of the injured spinal cord	METHODS			English	Article						Hydrogel; Spinal cord injury; Drug delivery	DELIVERY-SYSTEM; BRAIN; EXPRESSION; PROTEIN; DIFFERENTIATION; MACROPHAGES; SURVIVAL; MATTER; IBA1; BDNF	Traumatic spinal cord injury (SCI) causes damage and degeneration at and around the lesion site resulting in a loss of function. SCI presents a complex regenerative problem due to the multiple aspects of growth inhibition and the heterogeneity in size, shape and extent of injury. Currently, there is no widely accepted treatment strategy available and delivering biomolecules to the central nervous system remains a challenge. With a view towards achieving local release, we designed a hydrogel that can be injected into the intrathecal space. Here we describe the synthesis and characterization of a click-crosslinked hyaluronic acid hydrogel and demonstrate controlled in vitro release of bioactive brain derived neurotrophic factor. Importantly, we demonstrate that this new hydrogel is both biocompatible in the intrathecal space based on immunohistochemistry of the host tissue response and safe based on behavioral analysis of locomotor function. (C) 2015 Elsevier Inc. All rights reserved.	[Fuehrmann, T.; Obermeyer, J.; Shoichet, M. S.] Univ Toronto, Dept Chem Engn & Appl Chem, Toronto, ON M5S 3E5, Canada; [Fuehrmann, T.; Obermeyer, J.; Shoichet, M. S.] Inst Biomat & Biomed Engn, Toronto, ON M5S 3E1, Canada; [Tator, C. H.] Univ Toronto, Toronto Western Res Inst, Krembil Neurosci Ctr, Toronto, ON M5T 2S8, Canada; [Tator, C. H.] Univ Toronto, Dept Surg, Toronto, ON M5T 2S8, Canada	Shoichet, MS (corresponding author), Univ Toronto, Dept Chem Engn & Appl Chem, 200 Coll St, Toronto, ON M5S 3E5, Canada.	molly.shoichet@utoronto.ca	Fuhrmann, Tobias/D-3880-2014	Fuhrmann, Tobias/0000-0003-1857-4806	Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR); CIHR TPRM training grantCanadian Institutes of Health Research (CIHR); Natural Sciences and Engineering Research Council (NSERC) graduate student scholarshipNatural Sciences and Engineering Research Council of Canada (NSERC)	We are grateful to Mrs. Rita van Bendegem for tissue processing. We thank Peter Poon for animal surgery, Jennifer Chan for the assistance with immunohistochemistry and fluorescence imaging, Shawn Owen for discussions regarding xHA chemistry and the Fehlings lab for help with animal care. We thank the Canadian Institutes of Health Research (CIHR) for operating funding (to M.S.S.), the CIHR TPRM training grant (to T.F.) and the Natural Sciences and Engineering Research Council (NSERC) graduate student scholarship (to J.O.).	Abbott NJ, 1996, MOL MED TODAY, V2, P106, DOI 10.1016/1357-4310(96)88720-X; AHMED S, 1995, J NEUROSCI, V15, P5765; [Anonymous], ANIMAL MODELS ACUTE, V2; BARRETT CP, 1981, EXP NEUROL, V73, P365, DOI 10.1016/0014-4886(81)90272-7; BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; Baumann MD, 2010, BIOMATERIALS, V31, P7631, DOI 10.1016/j.biomaterials.2010.07.004; Buchwalow I, 2011, SCI REP-UK, V1, DOI 10.1038/srep00028; Caicco MJ, 2013, J CONTROL RELEASE, V166, P197, DOI 10.1016/j.jconrel.2013.01.002; Chen WYJ, 1999, WOUND REPAIR REGEN, V7, P79, DOI 10.1046/j.1524-475X.1999.00079.x; Consortium for Spinal Cord Medicine, 2008, J SPINAL CORD MED, V31, P408; ENG LF, 1985, J NEUROIMMUNOL, V8, P203, DOI 10.1016/S0165-5728(85)80063-1; Fehlings MG, 2005, INJURY, V36, P13, DOI 10.1016/j.injury.2005.06.011; Guo J, 2007, NANOMED-NANOTECHNOL, V3, P311, DOI 10.1016/j.nano.2007.09.003; Gupta D, 2006, BIOMATERIALS, V27, P2370, DOI 10.1016/j.biomaterials.2005.11.015; Hamann MCJ, 2005, EXP NEUROL, V194, P106, DOI 10.1016/j.expneurol.2005.01.030; Hamann MCJ, 2003, EXP NEUROL, V182, P300, DOI 10.1016/S0014-4886(03)00040-2; Hoare TR, 2008, POLYMER, V49, P1993, DOI 10.1016/j.polymer.2008.01.027; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Jakeman L.B., 2012, ANIMAL MODELS ACUTE, VII, P417, DOI DOI 10.1007/978-1-61779-782-8_37; Johnson PJ, 2010, J BIOMED MATER RES A, V92A, P152, DOI 10.1002/jbm.a.32343; Jones LL, 2001, MICROSC RES TECHNIQ, V54, P317, DOI 10.1002/jemt.1144; Kolb HC, 2001, ANGEW CHEM INT EDIT, V40, P2004, DOI 10.1002/1521-3773(20010601)40:11<2004::AID-ANIE2004>3.0.CO;2-5; Kwon BK, 2007, SPINE, V32, P1164, DOI 10.1097/BRS.0b013e318053ec35; Macaya D, 2012, BIOMED MATER, V7, DOI 10.1088/1748-6041/7/1/012001; MILLIGAN CE, 1991, J COMP NEUROL, V314, P125, DOI 10.1002/cne.903140112; Mueller CA, 2006, J NEUROSURG-SPINE, V4, P233, DOI 10.3171/spi.2006.4.3.233; Nimmo CM, 2011, BIOMACROMOLECULES, V12, P824, DOI 10.1021/bm101446k; Otto S, 2003, ORG BIOMOL CHEM, V1, P2809, DOI 10.1039/b305672d; Pardridge WM, 2005, MOL BIOTECHNOL, V30, P57, DOI 10.1385/MB:30:1:057; Pawar R, 2004, EXPERT OPIN BIOL TH, V4, P1203, DOI 10.1517/14712598.4.8.1203; Poon PC, 2007, SPINE, V32, P2853, DOI 10.1097/BRS.0b013e31815b7e6b; RIDEOUT DC, 1980, J AM CHEM SOC, V102, P7816, DOI 10.1021/ja00546a048; RIVLIN AS, 1978, SURG NEUROL, V10, P39; Roth A, 2005, ARTHRITIS RES THER, V7, pR677, DOI 10.1186/ar1725; Sasaki Y, 2001, BIOCHEM BIOPH RES CO, V286, P292, DOI 10.1006/bbrc.2001.5388; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schwab ME, 1996, PHYSIOL REV, V76, P319; Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P329; Shechter R, 2013, IMMUNITY, V38, P555, DOI 10.1016/j.immuni.2013.02.012; Sheehan KM, 2003, J ORTHOP RES, V21, P744, DOI 10.1016/S0736-0266(03)00007-X; Shetty AK, 1998, J NEUROBIOL, V35, P395, DOI 10.1002/(SICI)1097-4695(19980615)35:4<395::AID-NEU7>3.0.CO;2-U; Shu XZ, 2002, BIOMACROMOLECULES, V3, P1304, DOI 10.1021/bm025603c; Stanwick JC, 2012, J CONTROL RELEASE, V160, P666, DOI 10.1016/j.jconrel.2012.03.024; Streit WJ, 2009, J NEUROIMMUNE PHARM, V4, P371, DOI 10.1007/s11481-009-9163-5; Terada H, 2001, J THORAC CARDIOV SUR, V122, P979, DOI 10.1067/mtc.2001.117278; Turner PV, 2011, J AM ASSOC LAB ANIM, V50, P600; Volpato F.Z., 2013, BIOMATERIALS; Wang YF, 2013, J CONTROL RELEASE, V172, P1, DOI 10.1016/j.jconrel.2013.07.032; Ward RE, 2014, NEUROSCIENCE, V260, P227, DOI 10.1016/j.neuroscience.2013.12.024; Weishaupt N, 2012, EXP NEUROL, V238, P254, DOI 10.1016/j.expneurol.2012.09.001; WINTER HH, 1986, J RHEOL, V30, P367, DOI 10.1122/1.549853; Yaksh TL, 2004, TOXICOL SCI, V80, P322, DOI 10.1093/toxsci/kfh168; Yung SS, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/180594	53	31	31	3	45	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1046-2023	1095-9130		METHODS	Methods	AUG	2015	84						60	69		10.1016/j.ymeth.2015.03.023			10	Biochemical Research Methods; Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	CO5DP	WOS:000359180100008	25846399				2021-06-18	
J	O'Neill, BR; Handler, MH; Tong, SH; Chapman, KE				O'Neill, Brent R.; Handler, Michael H.; Tong, Suhong; Chapman, Kevin E.			Incidence of seizures on continuous EEG monitoring following traumatic brain injury in children	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						continuous EEG; traumatic brain injury; abusive head trauma; subclinical seizure; early posttraumatic seizure	ABUSIVE HEAD TRAUMA; EARLY POSTTRAUMATIC SEIZURES; NONCONVULSIVE ELECTROGRAPHIC SEIZURES; RADIOLOGICAL ASPECTS; NEUROPATHOLOGY; EPILEPSY; SCALE; COMA	OBJECT Seizures may cause diagnostic confusion and be a source of metabolic stress after traumatic brain injury (TBI) in children. The incidence of electroencephalography (EEG)-confirmed seizures and of subclinical seizures in the pediatric population with TBI is not well known. METHODS A routine protocol for continuous EEG (cEEG) monitoring was initiated for all patients with moderate or severe TBI at a Level 1 pediatric trauma center. Over a 3.5-year period, all patients with TBI who underwent cEEG monitoring, both according to protocol and those with mild head injuries who underwent cEEG monitoring at the discretion of the treating team, were identified prospectively. Clinical data were collected and analyzed. RESULTS Over the study period, 594 children were admitted with TBI, and 144 of these children underwent cEEG monitoring. One hundred two (71%) of these 144 children had moderate or severe TBI. Abusive head trauma (AHT) was the most common mechanism of injury (65 patients, 45%) in children with cEEG monitoring. Seizures were identified on cEEG in 43 patients (30%). Forty (93%) of these 43 patients had subclinical seizures, including 17 (40%) with only subclinical seizures and 23 (53%) with both clinical and subclinical seizures. Fifty-three percent of patients with seizures experienced status epilepticus. Age less than 2.4 years and AHT mechanism were strongly correlated with presence of seizures (odds ratios 8.7 and 6.0, respectively). Those patients with only subclinical seizures had the same risk factors as the other groups. The presence of seizures did not correlate with discharge disposition but was correlated with longer hospital stay and intensive care unit stay. CONCLUSIONS Continuous EEG monitoring identifies a significant number of subclinical seizures acutely after TBI. Children younger than 2.4 years of age and victims of AHT are particularly vulnerable to subclinical seizures, and Seizures in general. Continuous EEG monitoring allows for accurate diagnosis and timely treatment of posttraumatic seizures, and may mitigate secondary injury to the traumatized brain.	[O'Neill, Brent R.; Handler, Michael H.] Univ Colorado, Childrens Hosp Colorado, Dept Neurosurg, Aurora, CO 80045 USA; [Chapman, Kevin E.] Univ Colorado, Childrens Hosp Colorado, Dept Neurol, Aurora, CO 80045 USA; [Tong, Suhong; Chapman, Kevin E.] Univ Colorado, Childrens Hosp Colorado, Dept Pediat, Aurora, CO 80045 USA	O'Neill, BR (corresponding author), Univ Colorado, Childrens Hosp Colorado, Dept Neurosurg, 13123 E 16th Ave,B-330, Aurora, CO 80045 USA.	brent.oneill@childrenscolorado.org					Arango JI, 2012, CHILD NERV SYST, V28, P1925, DOI 10.1007/s00381-012-1863-0; Arndt DH, 2013, EPILEPSIA, V54, P1780, DOI 10.1111/epi.12369; Babikian T, 2009, PEDIATR NEUROL, V41, P406, DOI 10.1016/j.pediatrneurol.2009.06.002; Barlow KM, 2000, DEV MED CHILD NEUROL, V42, P591, DOI 10.1017/S0012162200001110; Bourgeois M, 2008, CHILD NERV SYST, V24, P169, DOI 10.1007/s00381-007-0493-4; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Galloway NR, 2008, J NEUROTRAUM, V25, P1153, DOI 10.1089/neu.2007.0494; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Goldstein JL, 2011, NEUROCRIT CARE, V15, P63, DOI 10.1007/s12028-010-9468-5; Hasbani DM, 2013, PEDIATR CRIT CARE ME, V14, P709, DOI 10.1097/PCC.0b013e3182917b83; HENDRICK EB, 1968, J TRAUM, V8, P547; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; Maguire S, 2009, ARCH DIS CHILD, V94, P860, DOI 10.1136/adc.2008.150110; Ong LC, 1996, J PAEDIATR CHILD H, V32, P173, DOI 10.1111/j.1440-1754.1996.tb00917.x; Rakhade SN, 2009, NAT REV NEUROL, V5, P380, DOI 10.1038/nrneurol.2009.80; Ratan SK, 1999, PEDIATR NEUROSURG, V30, P127, DOI 10.1159/000028779; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; Schreiber JM, 2012, NEUROCRIT CARE, V17, P31, DOI 10.1007/s12028-012-9715-z; Sieswerda-Hoogendoorn T, 2012, EUR J PEDIATR, V171, P617, DOI 10.1007/s00431-011-1611-6; Sieswerda-Hoogendoorn T, 2012, EUR J PEDIATR, V171, P415, DOI 10.1007/s00431-011-1598-z; TEASDALE G, 1974, LANCET, V2, P81; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Vespa PM, 2007, CRIT CARE MED, V35, P2830, DOI 10.1097/01.CCM.0000295667.66853.BC; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Welker KM, 2012, SEMIN NEUROL, V32, P15, DOI 10.1055/s-0032-1306382; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983	30	31	31	0	5	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	AUG	2015	16	2					167	176		10.3171/2014.12.PEDS14263			10	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	CN8PB	WOS:000358702000009	25955809	Bronze			2021-06-18	
J	Ahadi, R; Khodagholi, F; Daneshi, A; Vafaei, A; Mafi, AA; Jorjani, M				Ahadi, Reza; Khodagholi, Fariba; Daneshi, Abdolhadi; Vafaei, Ali; Mafi, Amir Ali; Jorjani, Masoumeh			Diagnostic Value of Serum Levels of GFAP, pNF-H, and NSE Compared With Clinical Findings in Severity Assessment of Human Traumatic Spinal Cord Injury	SPINE			English	Article							FIBRILLARY ACIDIC PROTEIN; NEURON-SPECIFIC ENOLASE; NEUROFILAMENT HEAVY-CHAIN; CERVICAL-SPINE; CEREBROSPINAL-FLUID; INFLAMMATORY CYTOKINES; IMAGING EVALUATION; AXONAL INJURY; BRAIN-INJURY; BIOMARKERS	Study Design. An analytical cohort study. Objective. This study aimed to evaluate severity of traumatic spinal cord injury (SCI) based on the serum levels of phosphorylated form of heavy subunit of neurofilament (pNF-H), neuron-specific enolase (NSE), and glial fibrillary acidic protein (GFAP), which are axonal, neural cell body, and glial cell injury markers, respectively. Summary of Background Data. Prior studies have reported elevated serum levels of pNF-H, NSE, and GFAP as biomarkers for the detection of traumatic SCI in animals. However, in this study, these biomarkers were studied in humans and with an extended level of timing. Methods. The study included 35 patients with SCI with a mean age of 36.5 years. All patients were evaluated using the American Spinal Injury Association Impairment Scale, followed by examinations including radiography and spinal computed tomography for determining the injury level. Serum levels of NSE, pNF-H, and GFAP were determined using enzyme-linked immunosorbent assay. Results. The mean serum level of GFAP was significantly higher in patients with SCI than in the control group. Mean serum levels of pNF-H and NSE were significantly higher during 24 and 48 hours after injury in patients with SCI than in the control group. The serum level of GFAP was appropriate for estimating the severity of SCI in the first 24 hours after injury. Conclusion. Our findings suggest that increased serum levels of GFAP, NSE, and pNF-H can be used for the diagnosis and degree of SCI severity in trauma patients. During 48 hours after injury, estimation of serum levels of pNF-H, NSE, and GFAP, combined with neurological testing, could predict the presence of SCI and severity prior to spinal computed tomography and surgical or conservative interventions. Level of Evidence: 2	[Ahadi, Reza] Shahid Beheshti Univ Med Sci, Neurosci Res Ctr, Tehran, Iran; [Khodagholi, Fariba; Jorjani, Masoumeh] Shahid Beheshti Univ Med Sci, Neurobiol Res Ctr, Tehran, Iran; [Daneshi, Abdolhadi; Vafaei, Ali] Shohadye Haftom Tir Hosp, Dept Emergency Med, Tehran, Iran; [Mafi, Amir Ali] Shahid Beheshti Univ Med Sci, Tehran, Iran; [Jorjani, Masoumeh] Shahid Beheshti Univ Med Sci, Fac Med, Dept Pharmacol, Tehran, Iran	Jorjani, M (corresponding author), Shahid Beheshti Univ Med Sci, Fac Med, Dept Pharmacol, Tehran, Iran.	msjorjani@sbmu.ac.ir	Khodagholi, Fariba/AAZ-4436-2020; Mafi, Amir/ABH-7659-2020; ahadi, reza/AAN-1578-2021	Khodagholi, Fariba/0000-0002-4911-4530; Mafi, Amir Ali/0000-0002-4917-7312; Daneshi, Abdolhadi/0000-0001-7255-4692	Shahid Beheshti University Medical Science funds	Shahid Beheshti University Medical Science funds were received in support of this work.	Al-Chalabi A, 2003, BIOESSAYS, V25, P346, DOI 10.1002/bies.10251; Benzel EC, 1996, J NEUROSURG, V85, P824, DOI 10.3171/jns.1996.85.5.0824; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BIGNAMI A, 1974, J COMP NEUROL, V153, P27, DOI 10.1002/cne.901530104; Brisby H, 1999, SPINE, V24, P742, DOI 10.1097/00007632-199904150-00003; BURGHUBER OC, 1990, CANCER, V65, P1386, DOI 10.1002/1097-0142(19900315)65:6<1386::AID-CNCR2820650623>3.0.CO;2-9; D'Alise MD, 1999, J NEUROSURG, V91, P54, DOI 10.3171/spi.1999.91.1.0054; Daffner RH, 2006, INJURY, V37, P652, DOI 10.1016/j.injury.2006.01.018; Foerch C, 2009, NEUROLOGY, V73, P393, DOI 10.1212/WNL.0b013e3181b05ef9; Ghanta MK, 2002, AM SURGEON, V68, P563; Guez M, 2003, J NEUROTRAUM, V20, P853, DOI 10.1089/089771503322385782; HASHIMOTO T, 1988, SPINE, V13, P1268, DOI 10.1097/00007632-198811000-00011; Holmes JF, 2002, J TRAUMA, V53, P524, DOI 10.1097/00005373-200209000-00021; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Hu YY, 2002, NEUROSCI LETT, V320, P156, DOI 10.1016/S0304-3940(02)00047-2; Kwon BK, 2011, CLIN CHEM LAB MED, V49, P425, DOI 10.1515/CCLM.2011.068; Kwon BK, 2010, J NEUROTRAUM, V27, P669, DOI 10.1089/neu.2009.1080; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Lima JE, 2004, BRAZ J MED BIOL RES, V37, P19, DOI 10.1590/S0100-879X2004000100003; Liu Q, 2004, CELL MOL LIFE SCI, V61, P3057, DOI 10.1007/s00018-004-4268-8; Loy DN, 2005, NEUROSURGERY, V56, P391, DOI 10.1227/01.NEU.0000148906.83616.D2; Loy DN, 2006, NEUROSURGERY, V58, pE590; Missler U, 1999, CLIN CHEM, V45, P138; Munera F, 2012, RADIOLOGY, V263, P645, DOI 10.1148/radiol.12110526; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Pelinka LE, 2004, J TRAUMA, V57, P1006, DOI 10.1097/01.TA.0000108998.48026.C3; Petzold A, 2005, J NEUROL SCI, V233, P183, DOI 10.1016/j.jns.2005.03.015; Petzold A, 2004, J NEUROL NEUROSUR PS, V75, P1178, DOI 10.1136/jnnp.2003.017236; Petzold A, 2003, J IMMUNOL METHODS, V278, P179, DOI 10.1016/S0022-1759(03)00189-3; Petzold A, 2007, J IMMUNOL METHODS, V319, P34, DOI 10.1016/j.jim.2006.09.021; Saltzherr TP, 2009, INJURY, V40, P795, DOI 10.1016/j.injury.2009.01.015; Shaw G, 2005, BIOCHEM BIOPH RES CO, V336, P1268, DOI 10.1016/j.bbrc.2005.08.252; Siman R, 2009, J NEUROTRAUM, V26, P1867, DOI 10.1089/neu.2009.0882; Stammers AT, 2012, J NEUROSCI RES, V90, P782, DOI 10.1002/jnr.22820; Tator CH, 2012, J NEUROSURG-SPINE, V17, P157, DOI 10.3171/2012.5.AOSPINE12116; Yokobori S, 2015, WORLD NEUROSURG, V83, P867, DOI 10.1016/j.wneu.2013.03.012; Zhang B, 2011, J TRAUMA, V71, P1680, DOI 10.1097/TA.0b013e318231bce7; Ziemann U, 2011, PROG NEUROBIOL, V95, P670, DOI 10.1016/j.pneurobio.2011.04.007	38	31	35	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0362-2436	1528-1159		SPINE	SPINE	JUL 15	2015	40	14					E823	E830		10.1097/BRS.0000000000000654			8	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	CM8JF	WOS:000357945400004	25341992				2021-06-18	
J	Frank, BS; Register-Mihalik, J; Padua, DA				Frank, Barnett S.; Register-Mihalik, Johna; Padua, Darin A.			High levels of coach intent to integrate a ACL injury prevention program into training does not translate to effective implementation	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Athletic injuries; Anterior cruciate ligament; Primary prevention; Physical education and training; Compliance	FOOTBALL PLAYERS; KNEE INJURIES; WARM-UP; FEMALE; SPORTS; SOCCER; RISK; RECOMMENDATIONS; EPIDEMIOLOGY; CONCUSSION	Objectives: Evaluate the effect of a anterior cruciate ligament injury prevention program coaching workshop on elite-level youth soccer coaches' behavioral determinants to implement a injury prevention program and describe coaches' subsequent injury prevention program implementation compliance. Design: Descriptive study. Methods: We evaluated a soccer club's coaches' behavioral determinants regarding injury prevention programming implementation before and after a coaching workshop using pre- and post-workshop surveys. We then described the club's coaches' subsequent adoption of and implementation compliance with the injury prevention programming during the following season. Results: The injury prevention workshop increased coaches' attitudes toward conducting a program at the beginning of practice (p < 0.05), substituting the program for a warm-up prior to practice (p < 0.05), and improving player cutting and landing technique by implementing the program (p < 0.05). The injury prevention program workshop increased coaches' perceived behavioral control; feeling more comfortable in their ability to teach their team a program (p < 0.05), and more confident leading a program if given instructions (p < 0.05). The injury prevention program workshop increased coaches' intent to implement a program the next season (p < 0.05), to implement a program for 15 min (p < 0.05), and 20 min (p < 0.05) prior to the start of a training session. Only 53% of the club's teams implemented the injury prevention program, with implementers demonstrating high variability in program fidelity. Conclusions: Coaching workshops can effectively increase coach attitudes, perceived behavioral control, and intent to implement a injury prevention program. However, high levels of behavioral determinants do not appear to translate to high levels of implementation compliance. (C) 2014 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Frank, Barnett S.; Register-Mihalik, Johna; Padua, Darin A.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27515 USA	Frank, BS (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27515 USA.	bsfrank@unc.edu	Mista, Wlodzimierz/K-3369-2017	Mista, Wlodzimierz/0000-0003-1298-2198; Register-Mihalik, Johna/0000-0002-4229-4743; Padua, Darin/0000-0002-9383-4236	North Carolina Injury Prevention Research Center	The researchers would like to thank the research assistants who contributed to the data collection and implementation facilitation during the study. This study was financially supported by The North Carolina Injury Prevention Research Center.	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; DiStefano LJ, 2010, J STRENGTH COND RES, V24, P332, DOI 10.1519/JSC.0b013e3181cc2225; Donaldson A, 2012, BRIT J SPORT MED, V46, P306, DOI 10.1136/bjsports-2011-090461; Donaldson A, 2013, BRIT J SPORT MED, V47, P473, DOI 10.1136/bjsports-2013-092323; Ferguson R, 2013, GAME CHANGERS STATS; Finch CF, 2010, BRIT J SPORT MED, V44, P973, DOI 10.1136/bjsm.2008.056069; Finch CF, 2013, BRIT J SPORT MED, V47, P12, DOI 10.1136/bjsports-2012-091796; Fixsen D, 2005, IMPLEMENTATION RES S, P1; Gianotti S, 2010, J SCI MED SPORT, V13, P32, DOI 10.1016/j.jsams.2008.07.010; Hagglund M, 2013, BRIT J SPORT MED, V47, P974, DOI 10.1136/bjsports-2013-092644; Hagglund M, 2013, BRIT J SPORT MED, V47, P738, DOI 10.1136/bjsports-2013-092215; Hootman JM, 2007, J ATHL TRAINING, V42, P311; Joy EA, 2013, J STRENGTH COND RES, V27, P2263, DOI 10.1519/JSC.0b013e31827ef12e; Junge A, 2011, AM J SPORT MED, V39, P57, DOI 10.1177/0363546510377424; Keats MR, 2012, SPORTS MED, V42, P175, DOI 10.2165/11597050-000000000-00000; LaBella CR, 2011, ARCH PEDIAT ADOL MED, V165, P1033, DOI 10.1001/archpediatrics.2011.168; McGlashan AJ, 2010, SPORTS MED, V40, P841, DOI 10.2165/11534960-000000000-00000; Myklebust G, 2003, CLIN J SPORT MED, V13, P71, DOI 10.1097/00042752-200303000-00002; Myklebust G, 2013, BRIT J SPORT MED, V47, P476, DOI 10.1136/bjsports-2012-091862; Renstrom PA, 2013, BRIT J SPORT MED, V47, P367, DOI 10.1136/bjsports-2012-091623; Sadoghi P, 2012, J BONE JOINT SURG AM, V94A, P769, DOI 10.2106/JBJS.K.00467; Saunders N, 2010, BRIT J SPORT MED, V44, P1128, DOI 10.1136/bjsm.2009.069039; Shultz SJ, 2012, J ATHL TRAINING, V47, P591, DOI 10.4085/1062-6050-47.5.13; Soligard T, 2010, BRIT J SPORT MED, V44, P787, DOI 10.1136/bjsm.2009.070672; Steffen K, 2013, BRIT J SPORT MED, V47, P794, DOI 10.1136/bjsports-2012-091886; Sugimoto D, 2012, J ATHL TRAINING, V47, P714, DOI 10.4085/1062-6050-47.6.10; Swenson DM, 2013, MED SCI SPORT EXER, V45, P462, DOI 10.1249/MSS.0b013e318277acca; Viljoen W, 2012, BRIT J SPORT MED, V46, P692, DOI 10.1136/bjsports-2012-091278; White PE, 2014, BRIT J SPORT MED, V48, DOI 10.1136/bjsports-2012-091987; White PE, 2014, BRIT J SPORT MED, V48, P119, DOI 10.1136/bjsports-2013-092785	30	31	31	0	32	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1440-2440	1878-1861		J SCI MED SPORT	J. Sci. Med. Sport	JUL	2015	18	4					400	406		10.1016/j.jsams.2014.06.008			7	Sport Sciences	Sport Sciences	CL3HL	WOS:000356840900008	25086795				2021-06-18	
J	Liao, KM; Ho, CH; Ko, SC; Li, CY				Liao, Kuang-Ming; Ho, Chung-Han; Ko, Shian-Chin; Li, Chung-Yi			Increased Risk of Dementia in Patients With Chronic Obstructive Pulmonary Disease	MEDICINE			English	Article							MILD COGNITIVE IMPAIRMENT; TRAUMATIC BRAIN-INJURY; ALZHEIMER-DISEASE; PARKINSONS-DISEASE; DIABETES-MELLITUS; ASSOCIATION; DECLINE	Neurodegenerative disease in patients with chronic obstructive pulmonary disease (COPD) was observed. We aim to clarify the risk of dementia in patients with COPD.The study used claims data from Taiwan's National Health Insurance Research Database. Subjects were those who received a discharge diagnosis of COPD between January 1, 2002 and December 31, 2011. Only the first hospitalization was enrolled, and the index date was the first day of admission. Patients younger than 40 years or those with a history of Alzheimer disease (AD) or Parkinson disease (PD) before the index date were excluded. The patients with COPD were then followed until receiving a diagnosis of AD or PD, death, or the end of the study. Control subjects were selected from hospitalized patients without a history of COPD, AD, or PD and were matched according to age (3 years), gender, and the year of admission at a 2:1 ratio. The comorbidities were measured from 1 year before the index date based on the ICD-9-CM codes. The study included 8640 patients with COPD and a mean age of 68.76 (+/- 10.74) years. The adjusted hazard ratio of developing dementia (AD or PD) was 1.74 (95% confidence interval=1.55-1.96) in patients with COPD compared with patients without COPD after adjusting for age, gender, and comorbidities.This nationwide cohort study demonstrates that the risk of dementia, including AD and PD, is significantly increased in patients with COPD compared with individuals in the general population.	[Liao, Kuang-Ming] Chi Mei Med Ctr, Dept Internal Med, Chiali, Taiwan; [Liao, Kuang-Ming] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Tainan 70101, Taiwan; [Ho, Chung-Han] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan; [Ho, Chung-Han] Chia Nan Univ Pharm & Sci, Dept Hosp & Hlth Care Adm, Tainan, Taiwan; [Ko, Shian-Chin] Chi Mei Med Ctr, Dept Chest Med, Tainan, Taiwan; [Li, Chung-Yi] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan 704, Taiwan; [Li, Chung-Yi] China Med Univ, Coll Publ Hlth, Dept Publ Hlth, Taichung, Taiwan	Li, CY (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, 138 Shengli Rd, Tainan 704, Taiwan.	cyli99@mail.ncku.edu.tw	LI, CHUNG-YI/ABI-1419-2020; Liao, Kuang-Ming/AAF-4994-2020	LI, CHUNG-YI/0000-0002-0321-8908; Ho, Chung-Han/0000-0001-5925-8477; Liao, Kuang Ming/0000-0003-4364-8248			Akomolafe A, 2006, ARCH NEUROL-CHICAGO, V63, P1551, DOI 10.1001/archneur.63.11.1551; Arvanitakis Z, 2004, ARCH NEUROL-CHICAGO, V61, P661, DOI 10.1001/archneur.61.5.661; Bednarek M, 2008, THORAX, V63, P402, DOI 10.1136/thx.2007.085456; Centurion VP, 2012, BMC PULM MED, V12, DOI 10.1186/1471-2466-12-73; Chi NF, 2013, NEUROLOGY, V80, P705, DOI 10.1212/WNL.0b013e31828250af; de la Torre JC, 1999, ACTA NEUROPATHOL, V98, P1, DOI 10.1007/s004010051044; Dodd JW, 2010, EUR RESPIR J, V35, P913, DOI 10.1183/09031936.00125109; GRANT I, 1982, ARCH INTERN MED, V142, P1470, DOI 10.1001/archinte.142.8.1470; Greig NH, 2004, ANN NY ACAD SCI, V1035, P290, DOI 10.1196/annals.1332.018; Hnizdo Eva, 2006, COPD, V3, P95, DOI 10.1080/15412550600651552; Jafari S, 2013, MOVEMENT DISORD, V28, P1222, DOI 10.1002/mds.25458; Johnson VE, 2010, NAT REV NEUROSCI, V11, P361, DOI 10.1038/nrn2808; Li CH, 2015, QJM-INT J MED, V108, P39, DOI 10.1093/qjmed/hcu136; Nussbaum RL, 2003, NEW ENGL J MED, V348, P1356, DOI 10.1056/NEJM2003ra020003; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Roberts RO, 2010, ALZ DIS ASSOC DIS, V24, P11, DOI 10.1097/WAD.0b013e3181a4485c; Roberts RO, 2009, ALZHEIMERS DEMENT, V5, P398, DOI 10.1016/j.jalz.2009.01.025; Rusanen M, 2013, CURR ALZHEIMER RES, V10, P549, DOI 10.2174/1567205011310050011; Schernhammer E, 2011, DIABETES CARE, V34, P1102, DOI 10.2337/dc10-1333; Singh B, 2014, JAMA NEUROL, V71, P581, DOI 10.1001/jamaneurol.2014.94; Sivanandam TM, 2012, NEUROSCI BIOBEHAV R, V36, P1376, DOI 10.1016/j.neubiorev.2012.02.013; Tajiri N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078851; Wysocki M, 2012, AM J GERIAT PSYCHIAT, V20, P179, DOI 10.1097/JGP.0b013e31820ee833	23	31	31	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	JUN	2015	94	23							e930	10.1097/MD.0000000000000930			5	Medicine, General & Internal	General & Internal Medicine	CQ6LD	WOS:000360715000001	26061317	DOAJ Gold, Green Published			2021-06-18	
J	Wu, LM; Walas, S; Leung, W; Sykes, DB; Wu, J; Lo, EH; Lok, J				Wu, Limin; Walas, Samantha; Leung, Wendy; Sykes, David B.; Wu, Jiang; Lo, Eng H.; Lok, Josephine			Neuregulin1-beta Decreases IL-1 beta-Induced Neutrophil Adhesion to Human Brain Microvascular Endothelial Cells	TRANSLATIONAL STROKE RESEARCH			English	Article						Neuroinflammation; IL-1 beta; NRG1-beta; Neutrophil; VCAM-1; E-selectin	RECEPTOR SUBUNIT; ERBB RECEPTORS; INJURY; SCHIZOPHRENIA; INFLAMMATION; PROMOTES; LEADS; INTERLEUKIN-1-BETA; MICRODIALYSIS; ANGIOGENESIS	Neuroinflammation contributes to the pathophysiology of diverse diseases including stroke, traumatic brain injury, Alzheimer's disease, Parkinson's disease, and multiple sclerosis, resulting in neurodegeneration and loss of neurological function. The response of the microvascular endothelium often contributes to neuroinflammation. One such response is the upregulation of endothelial adhesion molecules which facilitate neutrophil adhesion to the endothelium and their migration from blood to tissue. Neuregulin-1 (NRG1) is an endogenous growth factor which has been reported to have anti-inflammatory effects in experimental stroke models. We hypothesized that NRG1 would decrease the endothelial response to inflammation and result in a decrease in neutrophil adhesion to endothelial cells. We tested this hypothesis in an in vitro model of cytokine-induced endothelial injury, in which human brain microvascular endothelial cells (BMECs) were treated with IL-1 beta, along with co-incubation with vehicle or NRG1-beta. Outcome measures included protein levels of endothelial ICAM-1, VCAM-1, and E-selectin, as well as the number of neutrophils that adhere to the endothelial monolayer. Our data show that NRG1-beta decreased the levels of VCAM-1, E-selectin, and neutrophil adhesion to brain microvascular endothelial cells activated by IL1-beta. These findings open new possibilities for investigating NRG1 in neuroprotective strategies in brain injury.	[Wu, Limin; Walas, Samantha; Leung, Wendy; Lo, Eng H.; Lok, Josephine] Harvard Univ, Sch Med, Neuroprotect Res Lab, Massachusetts Gen Hosp, Charlestown, MA 02129 USA; [Wu, Limin; Wu, Jiang] Jilin Univ, Hosp 1, Dept Neurol, Changchun 130021, Jilin, Peoples R China; [Lok, Josephine] Harvard Univ, Sch Med, Dept Pediat, Div Pediat Crit Care,Massachusetts Gen Hosp, Boston, MA 02115 USA; [Sykes, David B.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Div Hematol Oncol, Boston, MA 02115 USA; [Sykes, David B.] Broad Inst Massachusetts Inst Technol & Harvard U, Cambridge, MA USA	Lok, J (corresponding author), Harvard Univ, Sch Med, Neuroprotect Res Lab, Massachusetts Gen Hosp, Charlestown, MA 02129 USA.	jlok1@mgh.harvard.edu			China Scholarship CouncilChina Scholarship Council [201206170107];  [R37NS037074-13];  [R01NS076694-02];  [P01NS055104-05];  [K08N5057339-04]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS055104, K08NS057339, R01NS076694, R37NS037074] Funding Source: NIH RePORTER	This work is supported by the following grants:; R37NS037074-13 (EHL); R01NS076694-02(EHL); P01NS055104-05 (EHL); K08N5057339-04 (JL); China Scholarship Council (#201206170107; LW)	Acosta SA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053376; Asp L, 2009, BRAIN BEHAV IMMUN, V23, P733, DOI 10.1016/j.bbi.2009.04.004; BEVILACQUA MP, 1987, SEMIN THROMB HEMOST, V13, P425, DOI 10.1055/s-2007-1003519; Boato F, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-6; Borlongan CV, 2011, PROG NEUROBIOL, V95, P213, DOI 10.1016/j.pneurobio.2011.08.005; Brooks TA, 2005, AM J PHYSIOL-HEART C, V289, pH738, DOI 10.1152/ajpheart.01288.2004; Brothers Holly M, 2013, J Alzheimers Dis Parkinsonism, V3, P110; Calvo M, 2010, J NEUROSCI, V30, P5437, DOI 10.1523/JNEUROSCI.5169-09.2010; Dimayuga FO, 2003, J NEUROIMMUNOL, V136, P67, DOI 10.1016/S0165-5728(03)00003-1; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Finigan JH, 2013, EUR RESPIR J, V41, P396, DOI 10.1183/09031936.00004912; Finnie JW, 2013, INFLAMMOPHARMACOLOGY, V21, P309, DOI 10.1007/s10787-012-0164-2; Fisahn A, 2009, CEREB CORTEX, V19, P612, DOI 10.1093/cercor/bhn107; Ghosh S, 2013, J NEUROSCI, V33, P5053, DOI 10.1523/JNEUROSCI.4361-12.2013; Hedhli N, 2012, CARDIOVASC RES, V93, P516, DOI 10.1093/cvr/cvr352; Hutchinson PJ, 2007, J NEUROTRAUM, V24, P1545, DOI 10.1089/neu.2007.0295; Iivanainen E, 2007, EXP CELL RES, V313, P2896, DOI 10.1016/j.yexcr.2007.03.042; Kalinowski A, 2010, FASEB J, V24, P2567, DOI 10.1096/fj.08-129072; Kanakry CG, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001369; Kwon OB, 2005, J NEUROSCI, V25, P9378, DOI 10.1523/JNEUROSCI.2100-05.2005; Lok J, 2007, J NEUROTRAUM, V24, P1817, DOI 10.1089/neu.2007.0372; Lok J, 2012, TRANSL STROKE RES, V3, pS119, DOI 10.1007/s12975-012-0157-x; Lyman M, 2014, NEUROSCI RES, V79, P1, DOI 10.1016/j.neures.2013.10.004; Maki T, 2013, CNS NEUROL DISORD-DR, V12, P302, DOI 10.2174/1871527311312030004; Makinodan M, 2012, SCIENCE, V337, P1357, DOI 10.1126/science.1220845; Mako V, 2010, CYTOM PART A, V77A, P962, DOI 10.1002/cyto.a.20952; Marballi K, 2010, J MOL MED, V88, P1133, DOI 10.1007/s00109-010-0653-y; Mellergard P, 2011, NEUROSURGERY, V68, P12, DOI 10.1227/NEU.0b013e3181ef2a40; Mencel M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070338; Norton N, 2006, AM J MED GENET B, V141B, P96, DOI 10.1002/ajmg.b.30236; Ozaki M, 1997, NATURE, V390, P691; Ridder DA, 2011, J EXP MED, V208, P2615, DOI 10.1084/jem.20110398; Rieff HI, 1999, J NEUROSCI, V19, P10757; Rigor RR, 2012, AM J PHYSIOL-CELL PH, V302, pC1513, DOI 10.1152/ajpcell.00371.2011; Rio C, 1997, NEURON, V19, P39, DOI 10.1016/S0896-6273(00)80346-3; Russell KS, 1999, AM J PHYSIOL-HEART C, V277, pH2205; Safa RN, 2011, AM J PHYSIOL-HEART C, V300, pH1311, DOI 10.1152/ajpheart.01104.2009; Schaff U, 2008, J LEUKOCYTE BIOL, V83, P99, DOI 10.1189/jlb.0507304; Tan GH, 2012, NAT NEUROSCI, V15, P258, DOI 10.1038/nn.3005; Ting AK, 2011, J NEUROSCI, V31, P15, DOI 10.1523/JNEUROSCI.2538-10.2011; Wen Y, 2008, J NEUROSCI, V28, P2624, DOI 10.1523/JNEUROSCI.5245-07.2008; Winter CD, 2002, J NEUROSCI METH, V119, P45, DOI 10.1016/S0165-0270(02)00153-X; WOODROOFE MN, 1991, J NEUROIMMUNOL, V33, P227, DOI 10.1016/0165-5728(91)90110-S; Xu ZF, 2004, BIOCHEM BIOPH RES CO, V322, P440, DOI 10.1016/j.bbrc.2004.07.149	44	31	36	0	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1868-4483	1868-601X		TRANSL STROKE RES	Transl. Stroke Res.	APR	2015	6	2					116	124		10.1007/s12975-014-0347-9			9	Clinical Neurology; Neurosciences	Neurosciences & Neurology	CD8AH	WOS:000351317000004	24863743	Green Accepted			2021-06-18	
J	Purushothurnan, S; Johnstone, DM; Nandasena, C; van Eersel, J; Ittner, LM; Mitrofanis, J; Stone, J				Purushothurnan, Sivaraman; Johnstone, Daniel M.; Nandasena, Charith; van Eersel, Janet; Ittner, Lars M.; Mitrofanis, John; Stone, Jonathan			Near infrared light mitigates cerebellar pathology in transgenic mouse models of dementia	NEUROSCIENCE LETTERS			English	Article							LEVEL LASER THERAPY; MIDBRAIN DOPAMINERGIC CELLS; TERM NEUROLOGICAL DEFICITS; TRAUMATIC BRAIN-INJURY; MPTP-TREATED MICE; ALZHEIMERS-DISEASE; PHOTOBIOMODULATION; DEPOSITION; SURVIVAL; NEUROPROTECTION		[Purushothurnan, Sivaraman; Johnstone, Daniel M.; Nandasena, Charith; Mitrofanis, John; Stone, Jonathan] Univ Sydney, Bosch Inst, Sydney, NSW 2006, Australia; [Purushothurnan, Sivaraman; Johnstone, Daniel M.; Nandasena, Charith; Stone, Jonathan] Univ Sydney, Discipline Physiol, Sydney, NSW 2006, Australia; [Purushothurnan, Sivaraman; Johnstone, Daniel M.; Nandasena, Charith; Stone, Jonathan] Univ Sydney, Save Sight Inst, Sydney, NSW 2000, Australia; [Purushothurnan, Sivaraman; Johnstone, Daniel M.; Nandasena, Charith; Stone, Jonathan] Univ Sydney, Clin Ophthalmol, Sydney, NSW 2000, Australia; [Purushothurnan, Sivaraman; Johnstone, Daniel M.; Nandasena, Charith; Stone, Jonathan] Sydney Eye Hosp, Sydney, NSW 2000, Australia; [van Eersel, Janet; Ittner, Lars M.] Univ New S Wales, Sch Med Sci, Dementia Res Unit, Sydney, NSW 2052, Australia; [Ittner, Lars M.] Neurosci Res Australia, Sydney, NSW 2031, Australia; [Mitrofanis, John] Univ Sydney, Discipline Anat & Histol, Sydney, NSW 2006, Australia	Johnstone, DM (corresponding author), Univ Sydney, Discipline Physiol, Anderson Stuart Bldg F13, Sydney, NSW 2006, Australia.	Daniel.Johnstone@sydney.edu.au	van Eersel, Janet/AAZ-4197-2020; Johnstone, Daniel/E-9929-2013	van Eersel, Janet/0000-0002-1354-6171; Ittner, Lars/0000-0001-6738-3825; Johnstone, Daniel/0000-0003-2876-3299; Purushothuman, Sivaraman/0000-0002-0880-5060			Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; BRAAK H, 1989, J NEUROL SCI, V93, P277, DOI 10.1016/0022-510X(89)90197-4; Bruck W, 1997, ANN NEUROL, V42, P783, DOI 10.1002/ana.410420515; De Taboada L, 2011, J ALZHEIMERS DIS, V23, P521, DOI 10.3233/JAD-2010-100894; Eells JT, 2003, P NATL ACAD SCI USA, V100, P3439, DOI 10.1073/pnas.0534746100; Franklin KBJ, 2007, MOUSE BRAIN STEREOTA; Grillo SL, 2013, J PHOTOCH PHOTOBIO B, V123, P13, DOI 10.1016/j.jphotobiol.2013.02.015; Ittner LM, 2008, P NATL ACAD SCI USA, V105, P15997, DOI 10.1073/pnas.0808084105; Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132; JOACHIM CL, 1989, AM J PATHOL, V135, P309; Johnstone DM, 2014, NEUROSCIENCE, V274, P93, DOI 10.1016/j.neuroscience.2014.05.023; Lampl Y, 2007, STROKE, V38, P1843, DOI 10.1161/STROKEAHA.106.478230; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Moro C, 2014, J NEUROSURG, V120, P670, DOI 10.3171/2013.9.JNS13423; Moro C, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-40; Natoli R, 2010, MOL VIS, V16, P1801; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Oron A, 2007, J NEUROTRAUM, V24, P651, DOI 10.1089/neu.2006.0198; Oron A, 2006, STROKE, V37, P2620, DOI 10.1161/01.STR.0000242775.14642.b8; Peoples C, 2012, PARKINSONISM RELAT D, V18, P469, DOI 10.1016/j.parkreldis.2012.01.005; Purushothuman S, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt232; Rojas JC, 2011, EYE BRAIN, V3, P49, DOI 10.2147/EB.S21391; Shaw VE, 2012, PARKINSONS DIS-US, V2012, DOI 10.1155/2012/296875; Shaw VE, 2010, J COMP NEUROL, V518, P25, DOI 10.1002/cne.22207; Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791; Trinchese F, 2004, ANN NEUROL, V55, P801, DOI 10.1002/ana.20101; Tuby H, 2013, PHOTOMED LASER SURG, V31, P269, DOI 10.1089/pho.2012.3395; van Eersel J, 2010, P NATL ACAD SCI USA, V107, P13888, DOI 10.1073/pnas.1009038107; Wallace BA, 2007, BRAIN, V130, P2129, DOI 10.1093/brain/awm137; Wu QH, 2012, LASER SURG MED, V44, P218, DOI 10.1002/lsm.22003; Xuan WJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053454; Yan Q, 2003, J NEUROSCI, V23, P7504	32	31	32	0	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	MAR 30	2015	591						155	159		10.1016/j.neulet.2015.02.037			5	Neurosciences	Neurosciences & Neurology	CE4FO	WOS:000351786700029	25703226				2021-06-18	
J	Bekelis, K; Missios, S; Mackenzie, TA				Bekelis, Kimon; Missios, Symeon; Mackenzie, Todd A.			Prehospital Helicopter Transport and Survival of Patients With Traumatic Brain Injury	ANNALS OF SURGERY			English	Article						ground emergency medical services; helicopter; traumatic brain injury; mortality; NTDB	EMERGENCY MEDICAL-SERVICES; IN-HOSPITAL MORTALITY; GROUND TRANSPORT; SCENE TRANSPORT; DATA-BANK; ASSOCIATION; PATTERNS; OUTCOMES; ADULTS; IMPACT	Objective: To investigate the association of helicopter transport with survival of patients with traumatic brain injury (TBI), in comparison with ground emergency medical services (EMS). Background: Helicopter utilization and its effect on the outcomes of TBI remain controversial. Methods: We performed a retrospective cohort study involving patients with TBI who were registered in the National Trauma Data Bank between 2009 and 2011. Regression techniques with propensity score matching were used to investigate the association of helicopter transport with survival of patients with TBI, in comparison with ground EMS. Results: During the study period, there were 209,529 patients with TBI who were registered in the National Trauma Data Bank and met the inclusion criteria. Of these patients, 35,334 were transported via helicopters and 174,195 via ground EMS. For patients transported to level I trauma centers, 2797 deaths (12%) were recorded after helicopter transport and 8161 (7.8%) after ground EMS. Multivariable logistic regression analysis demonstrated an association of helicopter transport with increased survival [OR (odds ratio), 1.95; 95% confidence interval (CI), 1.81-2.10; absolute risk reduction (ARR), 6.37%]. This persisted after propensity score matching (OR, 1.88; 95% CI, 1.74-2.03; ARR, 5.93%). For patients transported to level II trauma centers, 1282 deaths (10.6%) were recorded after helicopter transport and 5097 (7.3%) after ground EMS. Multivariable logistic regression analysis demonstrated an association of helicopter transport with increased survival (OR, 1.81; 95% CI, 1.64-2.00; ARR 5.17%). This again persisted after propensity score matching (OR, 1.73; 95% CI, 1.55-1.94; ARR, 4.69). Conclusions: Helicopter transport of patients with TBI to level I and II trauma centers was associated with improved survival, in comparison with ground EMS.	[Bekelis, Kimon] Dartmouth Hitchcock Med Ctr, Neurosurg Sect, Lebanon, NH 03756 USA; [Missios, Symeon] Cleveland Clin, Dept Neurosurg, Cleveland, OH 44106 USA; [Mackenzie, Todd A.] Dartmouth Hitchcock Med Ctr, Dept Med, Lebanon, NH 03756 USA; [Mackenzie, Todd A.] Dartmouth Hitchcock Med Ctr, Dept Community & Family Med, Lebanon, NH 03756 USA; [Mackenzie, Todd A.] Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA	Bekelis, K (corresponding author), Dartmouth Hitchcock Med Ctr, Neurosurg Sect, One Med Ctr Dr, Lebanon, NH 03756 USA.	kbekelis@gmail.com	Bekelis, Kimon/Y-3402-2019		National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [PO1-AG19783]; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG019783] Funding Source: NIH RePORTER	Supported by grant from the National Institute on Aging (PO1-AG19783). The authors declare no conflicts of interest.	American College of Surgeons, 2011, ANN REPORT; [Anonymous], 2010, TRAUMATIC BRAIN INJU; BAXT WG, 1987, J TRAUMA, V27, P365, DOI 10.1097/00005373-198704000-00004; Berlot G, 2009, EUR J EMERG MED, V16, P312, DOI 10.1097/MEJ.0b013e32832d3aa1; Bledsoe BE, 2006, J TRAUMA, V60, P1257, DOI 10.1097/01.ta.0000196489.19928.c0; Bledsoe Bryan E, 2003, Emerg Med Serv, V32, P88; Brown JB, 2010, J TRAUMA, V69, P1030, DOI 10.1097/TA.0b013e3181f6f450; Davis DP, 2005, ANN EMERG MED, V46, P115, DOI 10.1016/j.annemergmed.2005.01.024; Delgado MK, 2014, ANN EMERG MED, V63, P411; Delgado MK, 2013, ANN EMERG MED, V62, P351, DOI 10.1016/j.annemergmed.2013.02.025; Di Bartolomeo S, 2001, ARCH SURG-CHICAGO, V136, P1293, DOI 10.1001/archsurg.136.11.1293; Frankema SPG, 2004, BRIT J SURG, V91, P1520, DOI 10.1002/bjs.4756; Galvagno SM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009228.pub2; Galvagno SM, 2012, JAMA-J AM MED ASSOC, V307, P1602, DOI 10.1001/jama.2012.467; Haider AH, 2012, J AM COLL SURGEONS, V214, P756, DOI 10.1016/j.jamcollsurg.2011.12.013; Hirano K., 2001, HLTH SERVICE OUTCOME, V2, P259, DOI [10.1023/A:1020371312283, DOI 10.1023/A:1020371312283]; Ho D., 2007, MATCHIT NONPARAMETRI; HONAKER J, 2009, AMELIA 2 PROGRAM MIS; Imai K., 2009, ZELIG EVERYONES STAT; Imai K, 2008, J COMPUT GRAPH STAT, V17, P892, DOI 10.1198/106186008X384898; Lindenauer PK, 2004, JAMA-J AM MED ASSOC, V291, P2092, DOI 10.1001/jama.291.17.2092; Mitchell AD, 2007, CAN J SURG, V50, P129; Oyetunji TA, 2011, J SURG RES, V165, pE37, DOI 10.1016/j.jss.2010.09.025; Ringburg Akkie N, 2009, Air Med J, V28, P298, DOI 10.1016/j.amj.2009.03.007; Roudsari B, 2008, INJURY PREV, V14, P96, DOI 10.1136/ip.2007.017129; Rubin DB, 1997, ANN INTERN MED, V127, P757, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00064; Rubin DB, 2007, STAT MED, V26, P20, DOI 10.1002/sim.2739; SCHILLER WR, 1988, J TRAUMA, V28, P1127, DOI 10.1097/00005373-198808000-00004; Stewart KE, 2011, ACAD EMERG MED, V18, P1208, DOI 10.1111/j.1553-2712.2011.01207.x; Sullivent EE, 2011, PREHOSP EMERG CARE, V15, P295, DOI 10.3109/10903127.2011.569849; Taylor CB, 2010, INJURY, V41, P10, DOI 10.1016/j.injury.2009.09.030; Thomas SH, 2002, J TRAUMA, V52, P136, DOI 10.1097/00005373-200201000-00023; Thomas Stephen H, 2003, Curr Opin Anaesthesiol, V16, P153, DOI 10.1097/00001503-200304000-00008; Thomas Stephen H, 2002, Prehosp Emerg Care, V6, P359, DOI 10.1080/10903120290938508	34	31	32	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0003-4932	1528-1140		ANN SURG	Ann. Surg.	MAR	2015	261	3					579	585		10.1097/SLA.0000000000000672			7	Surgery	Surgery	CB3WK	WOS:000349559900057	24743624	Green Accepted			2021-06-18	
J	Sessoms, PH; Gottshall, KR; Collins, JD; Markham, AE; Service, KA; Reini, SA				Sessoms, Pinata H.; Gottshall, Kim R.; Collins, John-David; Markham, Amanda E.; Service, Kathrine A.; Reini, Seth A.			Improvements in Gait Speed and Weight Shift of Persons With Traumatic Brain Injury and Vestibular Dysfunction Using a Virtual Reality Computer-Assisted Rehabilitation Environment	MILITARY MEDICINE			English	Article; Proceedings Paper	Military Health Systems Research Symposium (MHSRS)	AUG 13-16, 2012	Fort Lauderdale, FL				DISORDERS; BALANCE; HEAD	Many people sustaining a traumatic brain injury experience vestibular pathology requiring physical therapy for treatment. This study measured improvements in gait speed and weight shift for subjects receiving vestibular physical therapy using a Computer-Assisted Rehabilitation Environment (CAREN). A 6-session CAREN, 6-session traditional vestibular therapy group was compared with a 12-session CAREN only (0 traditional sessions) therapy group. These two groups were compared to each other and with data from healthy controls performing similar tasks on the CAREN. Those participating in 12 CAREN sessions had greater improvements in gait speed (p = 0.014) and weight shift scores (p < 0.001) and demonstrated similar values achieved by a healthy control population.	[Sessoms, Pinata H.; Collins, John-David; Markham, Amanda E.; Service, Kathrine A.; Reini, Seth A.] Naval Hlth Res Ctr, Warfighter Performance Dept, San Diego, CA 92106 USA; [Gottshall, Kim R.] Naval Med Ctr San Diego, Phys Therapy Dept, San Diego, CA 92134 USA	Sessoms, PH (corresponding author), Naval Hlth Res Ctr, Warfighter Performance Dept, 140 Sylvester Rd, San Diego, CA 92106 USA.			Collins, John-David/0000-0002-9867-5465; Sessoms, Pinata/0000-0002-6960-0659	Bureau of Medicine and Surgery Wounded, Ill, and Injured grant R116 [60818]	We thank Sarah E. Kruger from Walter Reed National Military Medical Center National Intrepid Center of Excellence for her initial work on establishing a scoring system for the boat-steering application, from which our scoring system is based. This work was supported by the Bureau of Medicine and Surgery Wounded, Ill, and Injured grant R116 under work unit no. 60818.	Alsalaheen BA, 2010, J NEUROL PHYS THER, V34, P87, DOI 10.1097/NPT.0b013e3181dde568; Collins JD, 2015, WORK, V50, P121, DOI 10.3233/WOR-141927; Gottshall Kim, 2005, Work, V24, P381; Gottshall K, 2011, NEUROREHABILITATION, V29, P167, DOI 10.3233/NRE-2011-0691; Gottshall KR, 2012, IEEE ENG MED BIO, P6141, DOI 10.1109/EMBC.2012.6347395; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; Johnson CM, 2014, OTOLARYNG HEAD NECK, V150, P437, DOI 10.1177/0194599813515184; Marchetti GF, 2008, PHYS THER, V88, P640, DOI 10.2522/ptj.20070130; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; Rabago CA, 2011, J NEUROL PHYS THER, V35, P185, DOI 10.1097/NPT.0b013e318235d7e6; Rustemeyer J, 2007, BRIT J ORAL MAX SURG, V45, P556, DOI 10.1016/j.bjoms.2007.01.003; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85	12	31	34	1	16	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075	1930-613X		MIL MED	Milit. Med.	MAR	2015	180	3		S			143	149		10.7205/MILMED-D-14-00385			7	Medicine, General & Internal	General & Internal Medicine	CD3OQ	WOS:000350988500026	25747645	Bronze			2021-06-18	
J	Howells, T; Johnson, U; McKelvey, T; Enblad, P				Howells, Tim; Johnson, Ulf; McKelvey, Tomas; Enblad, Per			An optimal frequency range for assessing the pressure reactivity index in patients with traumatic brain injury	JOURNAL OF CLINICAL MONITORING AND COMPUTING			English	Article						Cerebral pressure autoregulation; Intracranial pressure; Cerebral perfusion pressure; Clinical monitoring; Optimization	CEREBRAL PERFUSION-PRESSURE; HEAD-INJURY; NEUROINTENSIVE CARE; SPECTRAL-ANALYSIS; BLOOD-PRESSURE; AUTOREGULATION; FLUCTUATIONS; VARIABILITY; FACTS; WAVES	The objective of this study was to identify the optimal frequency range for computing the pressure reactivity index (PRx). PRx is a clinical method for assessing cerebral pressure autoregulation based on the correlation of spontaneous variations of arterial blood pressure (ABP) and intracranial pressure (ICP). Our hypothesis was that optimizing the methodology for computing PRx in this way could produce a more stable, reliable and clinically useful index of autoregulation status. The patients studied were a series of 131 traumatic brain injury patients. Pressure reactivity indices were computed in various frequency bands during the first 4 days following injury using bandpass filtering of the input ABP and ICP signals. Patient outcome was assessed using the extended Glasgow Outcome Scale (GOSe). The optimization criterion was the strength of the correlation with GOSe of the mean index value over the first 4 days following injury. Stability of the indices was measured as the mean absolute deviation of the minute by minute index value from 30-min moving averages. The optimal index frequency range for prediction of outcome was identified as 0.018-0.067 Hz (oscillations with periods from 55 to 15 s). The index based on this frequency range correlated with GOSe with rho = -0.46 compared to -0.41 for standard PRx, and reduced the 30-min variation by 23 %.	[Howells, Tim; Johnson, Ulf; Enblad, Per] Univ Uppsala Hosp, Dept Neurosci, Sect Neurosurg, S-75185 Uppsala, Sweden; [McKelvey, Tomas] Chalmers, Dept Signals & Syst, S-41296 Gothenburg, Sweden	Howells, T (corresponding author), Univ Uppsala Hosp, Dept Neurosci, Sect Neurosurg, S-75185 Uppsala, Sweden.	timothy.howells@lul.se	McKelvey, Tomas/R-7193-2019; McKelvey, Tomas/B-6801-2016	McKelvey, Tomas/0000-0003-2982-5535; McKelvey, Tomas/0000-0003-2982-5535; Johnson, Ulf/0000-0002-3879-6476			Andrews PJD, 2008, INTENS CARE MED, V34, P1362, DOI 10.1007/s00134-008-1103-y; Aries MJH, 2012, CRIT CARE MED, V40, P2456, DOI 10.1097/CCM.0b013e3182514eb6; Brady KM, 2012, J APPL PHYSIOL, V113, P1362, DOI 10.1152/japplphysiol.00853.2012; Brady KM, 2009, PEDIATRICS, V124, pE1205, DOI 10.1542/peds.2009-0550; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Caricato A, 2012, CRIT CARE MED, V40, P2526, DOI 10.1097/CCM.0b013e318256b9af; Consonni F, 2009, NEUROCRIT CARE, V10, P232, DOI 10.1007/s12028-008-9151-2; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Frigo M, 2005, P IEEE, V93, P216, DOI 10.1109/JPROC.2004.840301; Goldman D, 2001, J THEOR BIOL, V209, P189, DOI 10.1006/jtbi.2000.2254; Greensted AJ, 2010, FINITE IMPULSE RESPO; Guiza F, 2013, CRIT CARE S2, V17, P327; Howells T, 2005, J NEUROSURG, V102, P311, DOI 10.3171/jns.2005.102.2.0311; Jaeger M, 2010, CRIT CARE MED, V38, P1343, DOI 10.1097/CCM.0b013e3181d45530; Joseph VR, 2008, J QUAL TECHNOL, V40, P282; Julien C, 2006, CARDIOVASC RES, V70, P12, DOI 10.1016/j.cardiores.2005.11.008; Kirkness C J, 2001, Biol Res Nurs, V2, P175, DOI 10.1177/109980040100200303; Lescot T, 2005, ACTA NEUROCHIR, V147, P125, DOI 10.1007/s00701-004-0355-8; Maas AIR, 2012, J NEUROTRAUM, V29, P32, DOI 10.1089/neu.2010.1599; Malpas SC, 2002, AM J PHYSIOL-HEART C, V282, pH6; Nilsson Holger, 2003, Mol Interv, V3, P79, DOI 10.1124/mi.3.2.79; O'Leary DD, 2004, AM J PHYSIOL-REG I, V287, pR670, DOI 10.1152/ajpregu.00408.2003; PARATI G, 1995, HYPERTENSION, V25, P1276, DOI 10.1161/01.HYP.25.6.1276; Press W.H., 1992, NUMERICAL RECIPES C, VSecond; Santos E, 2011, ACTA NEUROCHIR, V153, P2189, DOI 10.1007/s00701-011-1148-5; Smielewski PC, 2010, P 14 INT C INTR PRES, P48; Stauss HM, 2007, CLIN EXP PHARMACOL P, V34, P362, DOI 10.1111/j.1440-1681.2007.04588.x; Steiner LA, 2003, J NEUROL NEUROSUR PS, V74, P765, DOI 10.1136/jnnp.74.6.765; TEASDALE G, 1974, LANCET, V2, P81; Turalska M, 2008, ACTA NEUROCHIR SUPPL, V102, P43, DOI 10.1007/978-3-211-85578-2_9; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Zhang R, 2002, CIRCULATION, V106, P1814, DOI 10.1161/01.CIR.0000031798.07790.FE; Zweifel C, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E2	35	31	31	0	3	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1387-1307	1573-2614		J CLIN MONIT COMPUT	J. Clin. Monitor. Comp.	FEB	2015	29	1					97	105		10.1007/s10877-014-9573-7			9	Anesthesiology	Anesthesiology	CA5ID	WOS:000348941200015	24664812				2021-06-18	
J	Lange, RT; Panenka, WJ; Shewchuk, JR; Heran, MKS; Brubacher, JR; Bioux, S; Eckbo, R; Shenton, ME; Iverson, GL				Lange, Rael T.; Panenka, William J.; Shewchuk, Jason R.; Heran, Manraj K. S.; Brubacher, Jeffrey R.; Bioux, Sylvain; Eckbo, Ryan; Shenton, Martha E.; Iverson, Grant L.			Diffusion Tensor Imaging Findings and Postconcussion Symptom Reporting Six Weeks Following Mild Traumatic Brain Injury	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Mild traumatic brain injury; Diffusion tensor imaging; Postconcussion symptoms; Neurocognitive; Biomarkers	POST-CONCUSSION SYNDROME; POSTTRAUMATIC-STRESS-DISORDER; GOOD OLD DAYS; WHITE-MATTER; AXONAL INJURY; CORPUS-CALLOSUM; HEAD-INJURY; BASE RATES; MODERATE; DTI	The purpose of this study is to examine the relation between the microstructural architecture of white matter, as measured by diffusion tensor imaging (DTI), and postconcussion symptom reporting 6-8 weeks following mild traumatic brain injury (MTBI). Participants were 108 patients prospectively recruited from a Level 1 Trauma Center (Vancouver, BC, Canada) following an orthopedic injury [i.e., 36 trauma controls (TCs)] or MTBI (n = 72). DTI of the whole brain was undertaken using a Phillips 3T scanner at 6-8 weeks postinjury. Participants also completed a 5 h neurocognitive test battery and a brief battery of self-report measures (e.g., depression, anxiety, and postconcussion symptoms). The MTBI sample was divided into two groups based on ICD-10 criteria for postconcussional syndrome (PCS): first, PCS-present (n = 20) and second, PCS-absent (n = 52). There were no significant differences across the three groups (i.e., TC, PCS-present, and PCS-absent) for any of the neurocognitive measures (p = .138-.810). For the self-report measures, the PCS-present group reported significantly more anxiety and depression symptoms compared with the PCS-absent and TC groups (p < .001, d = 1.63-1.89, very large effect sizes). For the DTI measures, there were no significant differences in fractional anisotropy, axial diffusivity, radial diffusivity, or mean diffusivity when comparing the PCS-present and PCS-absent groups. However, there were significant differences (p < .05) in MD and RD when comparing the PCS-present and TC groups. There were significant differences in white matter between TC subjects and the PCS-present MTBI group, but not the PCS-absent MTBI group. Within the MTBI group, white-matter changes were not a significant predictor of ICD-10 PCS.	[Lange, Rael T.; Iverson, Grant L.] Def & Vet Brain Injury Ctr, Bethesda, MD USA; [Lange, Rael T.] Walter Reed Natl Mil Med Ctr, Bethesda, MD 20814 USA; [Lange, Rael T.; Panenka, William J.; Shewchuk, Jason R.; Heran, Manraj K. S.; Brubacher, Jeffrey R.; Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Shewchuk, Jason R.; Heran, Manraj K. S.; Brubacher, Jeffrey R.] Vancouver Gen Hosp, Vancouver, BC, Canada; [Bioux, Sylvain; Eckbo, Ryan; Shenton, Martha E.] Brigham Womens Hosp, Boston, MA USA; [Bioux, Sylvain; Eckbo, Ryan; Shenton, Martha E.; Iverson, Grant L.] Harvard Univ, Sch Med, Boston, MA USA; [Shenton, Martha E.] VA Boston Healthcare Syst, Brockton, MA USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Charlestown, MA USA; [Iverson, Grant L.] Red Sox Fdn, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Home Base Program, Boston, MA 02114 USA	Lange, RT (corresponding author), Walter Reed Natl Mil Med Ctr, Def & Vet Brain Injury Ctr, Bldg 8,Room 2264,8901 Wisconsin Ave, Bethesda, MD 20814 USA.	rael.lange@gmail.com	Shenton, Martha/V-8780-2019	Panenka, William/0000-0001-7143-6512; Brubacher, Jeffrey/0000-0002-4866-4231; Iverson, Grant/0000-0001-7348-9570	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [200903MOP-200377-BSB-CAAA-161276] Funding Source: Medline		American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bazarian JJ, 2012, MAGN RESON IMAGING, V30, P171, DOI 10.1016/j.mri.2011.10.001; Beck A.T., 1993; Beck AT., 1996, BECK DEPRESSION INVE, V2; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bruns JJ, 2009, MT SINAI J MED, V76, P129, DOI 10.1002/msj.20101; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; de Guise E, 2010, CLIN NEUROPSYCHOL, V24, P1113, DOI 10.1080/13854046.2010.506199; Deepika A, 2013, J HEAD TRAUMA REHAB, V28, P442, DOI 10.1097/HTR.0b013e31825e19e5; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; Gaetz M, 2000, BRAIN INJURY, V14, P815; Garden N, 2010, APPL NEUROPSYCHOL, V17, P1, DOI 10.1080/09084280903297495; GENTILINI M, 1985, J NEUROL NEUROSUR PS, V48, P137, DOI 10.1136/jnnp.48.2.137; Gering DT, 2001, J MAGN RESON IMAGING, V13, P967, DOI 10.1002/jmri.1139; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Hahn RA, 1997, PREV MED, V26, P607, DOI 10.1006/pmed.1996.0124; Hartikainen KM, 2010, J CLIN EXP NEUROPSYC, V32, P767, DOI 10.1080/13803390903521000; Hibbard MR, 2000, BRAIN INJURY, V14, P45, DOI 10.1080/026990500120925; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Hua K, 2008, NEUROIMAGE, V39, P336, DOI 10.1016/j.neuroimage.2007.07.053; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Inglese M, 2005, AM J NEURORADIOL, V26, P719; Iverson G.L., 2007, BRAIN INJURY MED PRI, P373; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P470; Iverson GL, 2011, BRAIN INJURY, V25, P1325, DOI 10.3109/02699052.2011.608409; Iverson GL, 2010, J HEAD TRAUMA REHAB, V25, P23, DOI 10.1097/HTR.0b013e3181b4b6ab; Iverson GL, 2010, CLIN NEUROPSYCHOL, V24, P17, DOI 10.1080/13854040903190797; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Landman BA, 2007, NEUROIMAGE, V36, P1123, DOI 10.1016/j.neuroimage.2007.02.056; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lange RT, 2014, ARCH CLIN NEUROPSYCH, V29, P329, DOI 10.1093/arclin/acu013; Lange RT, 2014, J NEUROTRAUM, V31, P198, DOI 10.1089/neu.2013.2866; Lange RT, 2013, J NEUROTRAUM, V30, P237, DOI 10.1089/neu.2012.2685; Lange RT, 2012, J HEAD TRAUMA REHAB, V27, P188, DOI 10.1097/HTR.0b013e318217f0ad; Lannsjo M, 2013, EUR J NEUROL, V20, P124, DOI 10.1111/j.1468-1331.2012.03813.x; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; McCrea M, 2009, CLIN NEUROPSYCHOL, V23, P1368, DOI 10.1080/13854040903074652; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Messe A, 2012, BRAIN IMAGING BEHAV, V6, P283, DOI 10.1007/s11682-012-9159-2; Messe A, 2011, HUM BRAIN MAPP, V32, P999, DOI 10.1002/hbm.21092; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mori A., 2005, MRI ATLAS HUMAN WHIT; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ponsford J, 2000, J INT NEUROPSYCH SOC, V6, P568, DOI 10.1017/S1355617700655066; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Pruessmann KP, 1999, MAGNET RESON MED, V42, P952, DOI 10.1002/(SICI)1522-2594(199911)42:5<952::AID-MRM16>3.0.CO;2-S; Psychological Corporation, 2001, WECHSL TEST AD READ; Reynolds C. R., 2003, REYNOLDS INTELLECTUA; Rohling ML, 2012, CLIN NEUROPSYCHOL, V26, P197, DOI 10.1080/13854046.2011.647085; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Sexton CE, 2009, BIOL PSYCHIAT, V66, P814, DOI 10.1016/j.biopsych.2009.05.024; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; Sosin DM, 1996, BRAIN INJURY, V10, P47; Stern RA, 2003, NEUROPSYCHOLOGICAL A; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P981, DOI 10.1076/jcen.24.8.981.8372; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Sullivan Michael J L, 2002, Pain Res Manag, V7, P120; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; Tombaugh TN, 1996, TEST MEMORY MALINGER; Waljas M, 2014, J NEUROTRAUM, V31, P108, DOI 10.1089/neu.2013.2941; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Winkler AM, 2014, NEUROIMAGE, V92, P381, DOI 10.1016/j.neuroimage.2014.01.060; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	85	31	31	0	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2015	30	1					7	25		10.1093/arclin/acu060			19	Psychology, Clinical; Psychology	Psychology	CE6BA	WOS:000351919400002	25416729	Bronze			2021-06-18	
J	Newell, EA; Exo, JL; Verrier, JD; Jackson, TC; Gillespie, DG; Janesko-Feldman, K; Kochanek, PM; Jackson, EK				Newell, Elizabeth A.; Exo, Jennifer L.; Verrier, Jonathan D.; Jackson, Travis C.; Gillespie, Delbert G.; Janesko-Feldman, Keri; Kochanek, Patrick M.; Jackson, Edwin K.			2 ',3 '-cAMPI, 3 '-AMP, 2 '-AMP and adenosine inhibit TNF-alpha and CXCL10 production from activated primary murine microglia via A(2A) receptors	BRAIN RESEARCH			English	Article						Primary microglia; CXCL10; TNF; 2',3'-cAMP; 2'-AMP; 3'-AMP; Adenosine; Adenosine receptors; A(2A) receptors	TUMOR-NECROSIS-FACTOR; TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; SMOOTH-MUSCLE-CELL; BONE-MARROW-CELLS; CYCLIC-AMP; DIFFERENTIAL EXPRESSION; A2A RECEPTORS; PATHWAY; RAT	Background: Some cells, tissues and organs release 2',3'-cAMP (a positional isomer of 3',5'-cAMP) and convert extracellular 2',3'-cAMP to 2'-AMP plus 3'-AMP and convert these AMPs to adenosine (called the extracellular 2',3'-cAMP-adenosine pathway). Recent studies show that microglia have an extracellular 2',3'-cAMP-adenosine pathway. The goal of the present study was to investigate whether the extracellular 2',3'-cAMP-adenosine pathway could have functional consequences on the production of cytokines/chemokines by activated microglia. Methods: Experiments were conducted in cultures of primary murine microglia. In the first experiment, the effect of 2',3'-cAMP, 3'-AMP, 2'-AMP and adenosine on LPS-induced TNF-alpha and CXCL10 production was determined. In the next experiment, the first protocol was replicated but with the addition of 1,3-dipropyl-8-p-sulfophenylxanthine (DPSPX) (0.1 mu M; antagonist of adenosine receptors). The last experiment compared the ability of 2-chloro-N-6-cyclopentyladenosine (CCPA) (10 mu M; selective A(1) agonist), 5'-N-ethylcarboxamide adenosine (NECA) (10 mu M; agonist for all adenosine receptor subtypes) and CGS21680 (10 mu M; selective A(2A) agonist) to inhibit LPS-induced TNF-alpha and CXCL10 production. Results: (1) 2',3'-cAMP, 3'-AMP, 2'-AMP and adenosine similarly inhibited LPS-induced TNF-alpha and CXCL10 production; (2) DPSPX nearly eliminated the inhibitory effects of 2',3'-cAMP, 3'-AMP, 2'-AMP and adenosine on LPS-induced TNF-alpha and CXCL10 production; (3) CCPA did not affect LPS-induced TNF-alpha and CXCL10; (4) NECA and CGS21680 similarly inhibited LPS-induced TNF-alpha and CXCL10 production. Conclusions: 2',3'-cAMP and its metabolites (3'-AMP, 2'-AMP and adenosine) inhibit LPS-induced TNF-alpha and CXCL10 production via A(2A)-receptor activation. Adenosine and its precursors, via A(2A) receptors, likely suppress TNF-alpha and CXCL10 production by activated microglia in brain diseases. (C) 2014 Elsevier B.V. All rights reserved.	[Newell, Elizabeth A.; Exo, Jennifer L.; Jackson, Travis C.; Janesko-Feldman, Keri; Kochanek, Patrick M.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Safar Ctr Resuscitat Res,Dept Crit Care Med, Pittsburgh, PA USA; [Verrier, Jonathan D.; Gillespie, Delbert G.; Jackson, Edwin K.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA	Jackson, EK (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15260 USA.	elizabeth-newell@uiowa.edu; jnnfrx0@gmail.com; jdv17@pitt.edu; tcj10@pitt.edu; dgg3@pitt.edu; JaneskoKL@anes.upmc.edu; kochanekpm@ccm.upmc.edu; edj@pitt.edu	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X; Newell, Elizabeth/0000-0002-1476-033X; Jackson, Edwin/0000-0002-8101-6009	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS087978, HD040686, HL109002, DK091190, HL069846, DK068575, DK079307]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL109002, R01HL069846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [R01DK068575, R01DK091190, P30DK079307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS087978] Funding Source: NIH RePORTER	Supported by grants from the National Institutes of Health [NS087978 (PMK/EKJ); HD040686 (JLE); HL109002, DK091190, HL069846, DK068575 and DK079307 (EKJ)].	Aden U, 2003, STROKE, V34, P739, DOI 10.1161/01.STR.0000060204.67672.8B; Bermpohl D, 2007, J CEREBR BLOOD F MET, V27, P1806, DOI 10.1038/sj.jcbfm.9600487; Biber K, 2002, NEUROSCIENCE, V112, P487, DOI 10.1016/S0306-4522(02)00114-8; Block ML, 2007, NAT REV NEUROSCI, V8, P57, DOI 10.1038/nrn2038; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Chen JF, 1999, J NEUROSCI, V19, P9192, DOI 10.1523/jneurosci.19-21-09192.1999; Cheong CU, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/620837; Chio CC, 2013, BMC NEUROSCI, V14, DOI 10.1186/1471-2202-14-33; Dai SS, 2011, REV NEUROSCIENCE, V22, P231, DOI 10.1515/RNS.2011.020; Dai SS, 2010, J NEUROCHEM, V113, P1536, DOI 10.1111/j.1471-4159.2010.06716.x; Dai SS, 2010, J NEUROSCI, V30, P5802, DOI 10.1523/JNEUROSCI.0268-10.2010; Dare E, 2007, PHYSIOL BEHAV, V92, P15, DOI 10.1016/j.physbeh.2007.05.031; Duan RS, 2008, NEUROCHEM RES, V33, P1085, DOI 10.1007/s11064-007-9554-z; Dubey RK, 2001, HYPERTENSION, V37, P1095, DOI 10.1161/01.HYP.37.4.1095; Dubey RK, 1998, HYPERTENSION, V31, P296, DOI 10.1161/01.HYP.31.1.296; Dubey RK, 1996, HYPERTENSION, V28, P765, DOI 10.1161/01.HYP.28.5.765; Dubey RK, 2000, HYPERTENSION, V36, P337, DOI 10.1161/01.HYP.36.3.337; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Eltzschig HK, 2009, ANESTHESIOLOGY, V111, P904, DOI 10.1097/ALN.0b013e3181b060f2; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; Frugier T, 2010, J NEUROTRAUM, V27, P497, DOI 10.1089/neu.2009.1120; Galimberti D, 2006, ARCH NEUROL-CHICAGO, V63, P538, DOI 10.1001/archneur.63.4.538; Giunti D, 2003, J LEUKOCYTE BIOL, V73, P584, DOI 10.1189/jlb.1202598; Grip O, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005263; Haselkorn ML, 2010, J NEUROTRAUM, V27, P901, DOI 10.1089/neu.2009.1075; Hasko G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99-0508com; Helmy A, 2011, J CEREBR BLOOD F MET, V31, P658, DOI 10.1038/jcbfm.2010.142; Jackson EK, 2012, AM J PHYSIOL-RENAL, V303, pF954, DOI 10.1152/ajprenal.00335.2012; Jackson EK, 2011, J PHARMACOL EXP THER, V337, P444, DOI 10.1124/jpet.110.178137; Jackson EK, 2010, HYPERTENSION, V56, P151, DOI 10.1161/HYPERTENSIONAHA.110.152454; Jackson EK, 2009, J BIOL CHEM, V284, P33097, DOI 10.1074/jbc.M109.053876; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kochanek PM, 2005, J CEREBR BLOOD F MET, V25, P1596, DOI 10.1038/sj.jcbfm.9600154; Kolb SA, 1999, J NEUROIMMUNOL, V93, P172, DOI 10.1016/S0165-5728(98)00223-9; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Latini S, 2001, J NEUROCHEM, V79, P463, DOI 10.1046/j.1471-4159.2001.00607.x; Lee JY, 2006, NEUROSCI LETT, V396, P1, DOI 10.1016/j.neulet.2005.11.004; Link AA, 2000, J IMMUNOL, V164, P436, DOI 10.4049/jimmunol.164.1.436; Lu DY, 2007, J NEUROTRAUM, V24, P1132, DOI 10.1089/neu.2007.0288; MI ZC, 1994, LIFE SCI, V54, pPL277, DOI 10.1016/0024-3205(94)00846-9; Mi ZC, 1998, J PHARMACOL EXP THER, V287, P926; MI ZC, 1995, J PHARMACOL EXP THER, V273, P728; Muller M, 2010, NEUROPATH APPL NEURO, V36, P368, DOI 10.1111/j.1365-2990.2010.01089.x; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Rappert A, 2004, J NEUROSCI, V24, P8500, DOI 10.1523/JNEUROSCI.2451-04.2004; ROSS SA, 1994, BRIT J NEUROSURG, V8, P419, DOI 10.3109/02688699408995109; Saura J, 2003, GLIA, V44, P183, DOI 10.1002/glia.10274; Scherbel U, 1999, P NATL ACAD SCI USA, V96, P8721, DOI 10.1073/pnas.96.15.8721; Shohami E, 1999, CYTOKINE GROWTH F R, V10, P119, DOI 10.1016/S1359-6101(99)00008-8; Tsutsui S, 2004, J NEUROSCI, V24, P1521, DOI 10.1523/JNEUROSCI.4271-03.2004; van der Putten C, 2009, J IMMUNOL, V182, P7603, DOI 10.4049/jimmunol.0803383; van Weering HRJ, 2011, HIPPOCAMPUS, V21, P220, DOI 10.1002/hipo.20742; Verrier JD, 2012, J NEUROCHEM, V122, P115, DOI 10.1111/j.1471-4159.2012.07705.x; Verrier JD, 2011, J NEUROCHEM, V118, P979, DOI 10.1111/j.1471-4159.2011.07392.x; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Waters RJ, 2013, J NEUROTRAUM, V30, P1710, DOI 10.1089/neu.2012.2792; Wilson NO, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060898; Wilson NO, 2011, DIS MARKERS, V30, P39, DOI [10.1155/2011/828256, 10.3233/DMA-2011-0763]; Yu LQ, 2004, NAT MED, V10, P1081, DOI 10.1038/nm1103	59	31	31	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JAN 12	2015	1594						27	35		10.1016/j.brainres.2014.10.059			9	Neurosciences	Neurosciences & Neurology	AY5CE	WOS:000347590100003	25451117	Green Accepted			2021-06-18	
J	DeRight, J; Jorgensen, RS				DeRight, Jonathan; Jorgensen, Randall S.			I Just Want My Research Credit: Frequency of Suboptimal Effort in a Non-Clinical Healthy Undergraduate Sample	CLINICAL NEUROPSYCHOLOGIST			English	Article						Performance validity testing; Effort testing.; College students	SYMPTOM VALIDITY TEST; CNS VITAL SIGNS; TEST-PERFORMANCE; BRAIN-DAMAGE; TEST BATTERY; IMPACT; TESTS; PARTICIPANTS; CONCUSSION; CHILDREN	Although performance validity testing is becoming fairly routine in clinical settings, research protocols involving neuropsychological tests infrequently include assessments of performance validity. The current study utilized an embedded measure of effort over two administrations of CNS Vital Signs to determine the frequency of poor effort in non-clinical healthy undergraduate students participating in a research study for course credit. Results indicate that more than 1 in 10 college students participating in a cognitive test battery for research showed test scores consistent with inadequate effort, which was associated with poor performance on testing across many domains. This conclusion was supported by poor performance on many other subtests. Healthy college students with suboptimal effort (n = 11) had an overall score in the 15th percentile on average compared to the 48th percentile in the rest of the students (n = 66). Those who failed validity indicators on the baseline administration were more likely to fail validity indicators on the repeat administration. Those who were tested in the morning were also more likely to fail validity indicators. The current study provides evidence for the potential limitations of conducting research using neuropsychological tests with healthy college student volunteers in the absence of performance validity testing. Revised college-level cutoffs are proposed.	[DeRight, Jonathan; Jorgensen, Randall S.] Syracuse Univ, Dept Psychol, Syracuse, NY USA	DeRight, J (corresponding author), 600 N Wolfe St,Meyer 218, Baltimore, MD 21287 USA.	jderight@gmail.com			CNS Vital Signs	We would like to thank CNS Vital Signs for allowing us to use their program for research. There were no conditions attached to the use of their program and we do not receive any financial compensation from CNS Vital Signs. We would also like to thank Paul Hoskinson for his work in adapting the Brain Workshop program to the specifications of our study.	An KY, 2012, ARCH CLIN NEUROPSYCH, V27, P849, DOI 10.1093/arclin/acs085; Armistead-Jehle P, 2011, ARCH CLIN NEUROPSYCH, V26, P592, DOI 10.1093/arclin/acr049; Barr WB, 2003, ARCH CLIN NEUROPSYCH, V18, P91, DOI 10.1016/S0887-6177(01)00185-8; Bauer L, 2005, APPL NEUROPSYCHOL, V12, P202, DOI 10.1207/s15324826an1204_3; Boone K. B., 2002, DOT COUNTING TEST MA; Brooks BL, 2014, ARCH CLIN NEUROPSYCH, V29, P422, DOI 10.1093/arclin/acu029; Brooks BL, 2012, ARCH CLIN NEUROPSYCH, V27, P858, DOI 10.1093/arclin/acs087; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Carone DA, 2008, BRAIN INJURY, V22, P960, DOI 10.1080/02699050802491297; Delis DC, 2000, CALIFORNIA VERBAL LE; DeRight J, 2015, CHILD NEUROPSYCHOL, V21, P1, DOI 10.1080/09297049.2013.864383; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; Forbey JD, 2013, ASSESSMENT, V20, P448, DOI 10.1177/1073191113478154; Forbey JD, 2011, J PERS ASSESS, V93, P556, DOI 10.1080/00223891.2011.608757; Green, 2004, GREENS MED SYMPTOM V; Green P., 2013, MILD TRAUMATIC BRAIN, P73; Green P., 2005, WORD MEMORY TEST WIN; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Gualtieri C. T., 2008, INT C ALZH DIS CHIC; Gualtieri CT, 2006, ARCH CLIN NEUROPSYCH, V21, P623, DOI 10.1016/j.acn.2006.05.007; Halstead WC, 1947, BRAIN INTELLIGENCE; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hoskinson P, 2009, BRAIN WORKSHOP DUAL; Kirkwood MW, 2010, CHILD NEUROPSYCHOL, V16, P604, DOI 10.1080/09297049.2010.495059; Letz R, 2003, NEUROTOXICOLOGY, V24, P479, DOI 10.1016/S0161-813X(03)00047-0; Lovell M., 2004, IMPACT VERSION 2 0 C; O'Bryant SE, 2006, CLIN NEUROPSYCHOL, V20, P533, DOI 10.1080/13854040590967568; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Santos OA, 2014, ARCH CLIN NEUROPSYCH, V29, P609, DOI 10.1093/arclin/acu039; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2013, ARCH CLIN NEUROPSYCH, V28, P236, DOI 10.1093/arclin/act009; Silk-Eglit GM, 2014, ARCH CLIN NEUROPSYCH, V29, P415, DOI 10.1093/arclin/acu028; Slick D., 1997, VICTORIA SYMPTOM VAL; Stanczak EM, 2000, ARCH CLIN NEUROPSYCH, V15, P587; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Willison J, 2006, ARCH CLIN NEUROPSYCH, V21, P41, DOI 10.1016/j.acn.2005.07.005; Wintre MG, 2001, CAN PSYCHOL, V42, P216; Wolfson D., 1993, HALSTEAD REITAN NEUR	38	31	31	1	13	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	JAN 2	2015	29	1					101	117		10.1080/13854046.2014.989267			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	CC4CS	WOS:000350299000008	25494327				2021-06-18	
J	Moser, RS; Schatz, P; Lichtenstein, JD				Moser, Rosemarie Scolaro; Schatz, Philip; Lichtenstein, Jonathan D.			The Importance of Proper Administration and Interpretation of Neuropsychological Baseline and Postconcussion Computerized Testing	APPLIED NEUROPSYCHOLOGY-CHILD			English	Article						sports-related concussion; concussion assessment and management; mild traumatic brain injury	SPORTS-RELATED CONCUSSION; INTERNATIONAL-CONFERENCE; MEDICINE PROFESSIONALS; MANAGEMENT; STATEMENT; PERFORMANCE; KNOWLEDGE; IMPACT	Media coverage, litigation, and new legislation have resulted in a heightened awareness of the prevalence of sports concussion in both adult and youth athletes. Baseline and postconcussion testing is now commonly used for the assessment and management of sports-related concussion in schools and in youth sports leagues. With increased use of computerized neurocognitive sports concussion testing, there is a need for standards for proper administration and interpretation. To date, there has been a lack of standardized procedures by which assessments are administered. More specifically, individuals who are not properly trained often interpret test results, and their methods of interpretation vary considerably. The purpose of this article is to outline factors affecting the validity of test results, to provide examples of misuse and misinterpretation of test results, and to communicate the need to administer testing in the most effective and useful manner. An increase in the quality of test administration and application may serve to decrease the prevalence of invalid test results and increase the accuracy and utility of baseline test results if an athlete sustains a concussion. Standards for test use should model the American Psychological Association and Centers for Disease Control and Prevention guidelines, as well as the recent findings of the joint position paper on computerized neuropsychological assessment devices.	[Moser, Rosemarie Scolaro; Schatz, Philip; Lichtenstein, Jonathan D.] Sports Concuss Ctr New Jersey, Lawrenceville, NJ 08648 USA; [Moser, Rosemarie Scolaro] Int Brain Res Fdn, Flanders, NY USA; [Schatz, Philip] St Josephs Univ, Dept Psychol, Philadelphia, PA 19131 USA	Moser, RS (corresponding author), Sports Concuss Ctr New Jersey, 3131 Princeton Pike,Bldg 5,Suite 110, Lawrenceville, NJ 08648 USA.	Rmoser@SportsConcussionNJ.com					American Psychological Association, 1999, AM PSYCH ASS AM ED R; American Psychological Association, 2010, ETH PRINC PSYCH COD; [Anonymous], 2012, CONC VIT SIGNS; Aubry Mark, 2002, Phys Sportsmed, V30, P57, DOI 10.3810/psm.2002.02.176; Barth JT., 1989, MILD HEAD INJURY, P257; Bauer RM, 2012, ARCH CLIN NEUROPSYCH, V27, P362, DOI 10.1093/arclin/acs027; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Boggild M, 2012, CAN J NEUROL SCI, V39, P361, DOI 10.1017/S0317167100013524; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Centers for Disease Control and Prevention, 2012, FAQS BAS TEST YOUNG; Centers for Disease Control & Prevention, 2010, CONC SPORTS; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Covassin T, 2009, J ATHL TRAINING, V44, P639, DOI 10.4085/1062-6050-44.6.639; Covassin T, 2009, J ATHL TRAINING, V44, P400, DOI 10.4085/1062-6050-44.4.400; Echemendia RJ, 2009, BRIT J SPORT MED, V43, pI32, DOI 10.1136/bjsm.2009.058164; Erlanger DM, 1999, CONCUSSION RESOLUTIO; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; ImPACT, 2012, IMPACT TEST ADM; Jotwani V, 2010, CURR SPORT MED REP, V9, P21, DOI 10.1249/JSR.0b013e3181ccb55e; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Lovell M. R., 2007, IMPACT VERS 6 0 CLIN; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Mayo Clinic, 2012, 40 000 AR STUD ATHL; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Moser R. S., 2012, AHEAD GAME PARENTS G; Moser RS, 2007, PROF PSYCHOL-RES PR, V38, P699, DOI 10.1037/0735-7028.38.6.699; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Moser RS, 2011, AM J SPORT MED, V39, P2325, DOI 10.1177/0363546511417114; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; National Athletic Trainers' Association, 2012, ATHL TRAIN FILL NEC; Putukian M, 2009, BRIT J SPORT MED, V43, pI28, DOI 10.1136/bjsm.2009.058230; Schatz P, 2003, APPL NEUROPSYCHOL, V10, P42, DOI 10.1207/S15324826AN1001_6; Simovska A., 2012, MANDATORY TEST TRACK; U. S. Food & Drug Administration., 2012, REG INF; Udall T., 2012, CNN; Van Kampen DA, 2006, AM J SPORT MED, V34, P1630, DOI 10.1177/0363546506288677; Webbe F. M., 2010, HDB SPORT NEUROPSYCH, P1630; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	43	31	31	0	17	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXFORDSHIRE, ENGLAND	2162-2965	2162-2973		APPL NEUROPSYCH-CHIL	Appl. Neuropsychol.-Child	JAN 2	2015	4	1					41	48		10.1080/21622965.2013.791825			8	Clinical Neurology; Psychology	Neurosciences & Neurology; Psychology	AY0KW	WOS:000347286400005	24236894				2021-06-18	
J	Glang, AE; Koester, MC; Chesnutt, JC; Gioia, GA; McAvoy, K; Marshall, S; Gau, JM				Glang, Ann E.; Koester, Michael C.; Chesnutt, James C.; Gioia, Gerard A.; McAvoy, Karen; Marshall, Sondra; Gau, Jeff M.			The Effectiveness of a Web-Based Resource in Improving Postconcussion Management in High Schools	JOURNAL OF ADOLESCENT HEALTH			English	Article						Concussion; High school; Web-based training; School-based health care	POSITIVE BEHAVIOR SUPPORT; CONCUSSION EDUCATION; SPORT; KNOWLEDGE; MISCONCEPTIONS; COACHES; INJURY; HEADS	Purpose: Because many sports concussions happen during school-sponsored sports events, most state concussion laws specifically hold schools accountable for coach training and effective concussion management practices. Brain 101: The Concussion Playbook is a Web-based intervention that includes training in sports concussion for each member of the school community, presents guidelines on creating a concussion management team, and includes strategies for supporting students in the classroom. Methods: The group randomized controlled trial examined the efficacy of Brain 101 in managing sports concussion. Participating high schools (N = 25) were randomly assigned to the Brain 101 intervention or control. Fall athletes and their parents completed online training, and Brain 101 school administrators were directed to create concussion management policy and procedures. Results: Student athletes and parents at Brain 101 schools significantly outperformed those at control schools on sports concussion knowledge, knowledge application, and behavioral intention to implement effective concussion management practices. Students who had concussions in Brain 101 schools received more varied academic accommodations than students in control schools. Conclusions: Brain 101 can help schools create a comprehensive schoolwide concussion management program. It requires minimal expenditures and offers engaging and effective education for teachers, coaches, parents, and students. (C) 2015 Society for Adolescent Health and Medicine. All rights reserved.	[Glang, Ann E.] Univ Oregon, Ctr Brain Injury Res & Training, Eugene, OR 97401 USA; [Glang, Ann E.] ORCAS, Eugene, OR USA; [Koester, Michael C.] Slocum Ctr Orthoped & Sports Med, Sports Concuss Program, Eugene, OR USA; [Chesnutt, James C.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [Gioia, Gerard A.] Childrens Natl Med Ctr, Rockville, MD USA; [McAvoy, Karen] Rocky Mt Hosp Children, Centennial, CO USA; [Marshall, Sondra] St Charles Hlth Syst, Bend, OR USA; [Gau, Jeff M.] Oregon Res Inst, Eugene, OR 97403 USA	Glang, AE (corresponding author), Univ Oregon, Ctr Brain Injury Res & Training, 99 W 10th St,Suite 370, Eugene, OR 97401 USA.	aglang@uoregon.edu			National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD056610]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R44HD056610, R43HD056610] Funding Source: NIH RePORTER	This project was completed with funding from the National Institute of Child Health and Human Development (grant number HD056610).	AJZEN I, 1991, ORGAN BEHAV HUM DEC, V50, P179, DOI 10.1016/0749-5978(91)90020-T; Ajzen I, 2011, BASIC APPL SOC PSYCH, V33, P101, DOI 10.1080/01973533.2011.568834; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; BECKER MH, 1974, HLTH ED MONOGR, V2, P342; *CDCP, 1996, TEENS HAZ WE FAC WOR; *CDCP, 2013, HEADS ONL TRAIN COUR; Centers for Disease Control and Prevention, 2010, PAR AR KEY SAF TEEN; *CHILDR SAF NETW, 2012, IMPLEMENTATION OF ST; Cohen R, 2007, J POSIT BEHAV INTERV, V9, P203, DOI 10.1177/10983007070090040301; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; Glang A, 2010, INT J SPORTS SCI COA, V5, P1, DOI 10.1260/1747-9541.5.1.1; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P331; Guilmette TJ, 2007, BRAIN INJURY, V21, P1039, DOI 10.1080/02699050701633080; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Handler MW, 2007, PSYCHOL SCHOOLS, V44, P29, DOI 10.1002/pits.20203; Institute of Medicine (IOM) and National Research Council (NRC), 2014, SPORTS REL CONC YOUT; Kroshus E, 2014, J ADOLESCENT HEALTH, V54, P269, DOI 10.1016/j.jadohealth.2013.11.011; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McGlashan AJ, 2010, SPORTS MED, V40, P841, DOI 10.2165/11534960-000000000-00000; McLeod TCV, 2007, CLIN J SPORT MED, V17, P140; McLeod TCV, 2013, J ATHL TRAINING, V48, P483, DOI 10.4085/1062-6050-48.4.04; Meehan WP, 2011, AM J SPORT MED, V39, P2304, DOI 10.1177/0363546511423503; Miyashita TL, 2013, CLIN J SPORT MED, V23, P349, DOI 10.1097/JSM.0b013e318289c321; Murray, 1998, DESIGN ANAL GROUP RA; *NAT FED STAT HIGH, 2010, CONC SPORTS ONL COUR; *NAT FOOTB LEAG, 2014, ZACK LYST LAW; National Athletic Trainers' Association, 2009, ATHL TRAIN FILL NEC; Provvidenza CF, 2009, BRIT J SPORT MED, V43, pI68, DOI 10.1136/bjsm.2009.058180; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; ROSENSTOCK IM, 1988, HEALTH EDUC QUART, V15, P175, DOI 10.1177/109019818801500203; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Sarmiento K, 2010, J SCHOOL HEALTH, V80, P112, DOI 10.1111/j.1746-1561.2010.00491.x; Singer J.D., 2003, APPL LONGITUDINAL DA; Tomei KL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12280; Torres Daniel M, 2013, Neurol Clin Pract, V3, P279; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P	39	31	31	0	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1054-139X	1879-1972		J ADOLESCENT HEALTH	J. Adolesc. Health	JAN	2015	56	1					91	97		10.1016/j.jadohealth.2014.08.011			7	Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics	Psychology; Public, Environmental & Occupational Health; Pediatrics	AW9OM	WOS:000346586900016	25438964	Green Accepted			2021-06-18	
J	McCulloch, KL; Goldman, S; Lowe, L; Radomski, MV; Reynolds, J; Shapiro, R; West, TA				McCulloch, Karen L.; Goldman, Sarah; Lowe, Lynn; Radomski, Mary Vining; Reynolds, John; Shapiro, Rita; West, Therese A.			Development of Clinical Recommendations for Progressive Return to Activity After Military Mild Traumatic Brain Injury: Guidance for Rehabilitation Providers	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						balance; cognition; concussion; exertional progression; mild traumatic brain injury; military mild traumatic brain injury; progressive return to activity; vestibular	CONCUSSION; EXERCISE; PLAY; SYMPTOMS; SPORT; MANAGEMENT; STATEMENT; SCALE	Objective: Previously published mild traumatic brain injury (mTBI) management guidelines provide very general recommendations to return individuals with mTBI to activity. This lack of specific guidance creates variation in military rehabilitation. The Office of the Army Surgeon General in collaboration with the Defense and Veterans Brain Injury Center, a component center of the Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury, convened an expert working group to review the existing literature and propose clinical recommendations that standardize rehabilitation activity progression following mTBI. Participants: A Progressive Activity Working Group consisted of 11 Department of Defense representatives across all service branches, 7 Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury representatives, and 8 academic/research/civilian experts with experience assessing and treating individuals with mTBI for return to activity. An expert working group meeting included the Progressive Activity Working Group and 15 additional subject matter experts. Methods: In February 2012, the Progressive Activity Working Group was established to determine the need and purpose of the rehabilitation recommendations. Following literature review, a table was created on the basis of the progression from the Zurich consensus statement on concussion in sport. Issues were identified for discussion with a meeting of the larger expert group during a July 2012 conference. Following development of rehabilitation guidance, the Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury coordinated a similar process for military primary care providers. Results: End products for rehabilitation and primary care providers include specific recommendations for return to activity after concussion. A 6-stage progression specifies activities in physical, cognitive, and balance/vestibular domains and allows for resumption of activity for those with low-level or preinjury symptom complaints. Conclusions: The clinical recommendations for progressive return to activity represent an important effort to standardize activity progression across functional domains and offer providers duty-specific activities to incorporate into intervention. Recommendations were released in January 2014.	[McCulloch, Karen L.] Univ N Carolina, Sch Med, Dept Allied Hlth Sci, Div Phys Therapy, Chapel Hill, NC 27599 USA; [Goldman, Sarah; Lowe, Lynn] Def Hlth Headquarters, Off Surgeon Gen, Rehabil & Reintegrat Div, Falls Church, VA USA; [Radomski, Mary Vining] Sister Kenny Res Ctr, Minneapolis, MN USA; [Reynolds, John] Fairfax Cty Publ Sch, George C Marshall High Sch, Fairfax, VA USA; [Shapiro, Rita] Def Ctr Excellence Psychol Hlth, Silver Spring, MD USA; [Shapiro, Rita] Def Ctr Traumat Brain Injury, Silver Spring, MD USA; [West, Therese A.] Def Ctr Excellence Psychol Hlth, Def & Vet Brain Injury Ctr Clin Affairs, Silver Spring, MD USA; [West, Therese A.] Def Ctr Traumat Brain Injury, Silver Spring, MD USA	McCulloch, KL (corresponding author), Univ N Carolina, Allied Hlth Sci, 321 S Columbia St,Bondurant Hall Suite 3024, Chapel Hill, NC 27599 USA.	kmac@med.unc.edu					Alla S, 2012, BRIT J SPORT MED, V46, P562, DOI 10.1136/bjsm.2010.081299; Alla S, 2010, J SCI MED SPORT, V13, P24, DOI 10.1016/j.jsams.2008.12.629; [Anonymous], 2011, MED SCI SPORT EXER, V43, P2412, DOI 10.1249/MSS.0b013e3182342e64; Baker JG, 2012, REHABIL RES PRACT, V2012, DOI 10.1155/2012/705309; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; CDC, 2012, PHYSICAL ACTIVITY FO; Centers for Disease Control and Prevention, PERCEIVED EXERTION B; Chamelian L, 2004, ARCH PHYS MED REHAB, V85, P1662, DOI 10.1016/j.apmr.2004.02.012; Chen MJ, 2002, J SPORT SCI, V20, P873, DOI 10.1080/026404102320761787; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Defense and Veterans Brain Injury Center, 2008, JOINT THEATER TRAUMA, P7; Defense and Veterans Brain Injury Center, 2014, PROGRESSIVE RETURN T; Defense and Veterans Brain Injury Center, 2014, DOD WORLDW NUMB TBI; Defense Centers of Excellence for Psychological Health and Traumatic Brain Injury, 2012, CONC MAN DEPL SETT V; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Echlin PS, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.9.FOCUS10210; Fait P, 2009, BRAIN INJURY, V23, P362, DOI 10.1080/02699050902788485; GAESSER GA, 1984, MED SCI SPORT EXER, V16, P29; Gaetz MB, 2009, BRIT J SPORT MED, V43, P508, DOI 10.1136/bjsm.2008.051748; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6; JETTE M, 1990, CLIN CARDIOL, V13, P555, DOI 10.1002/clc.4960130809; Johnston Karen M, 2004, Curr Sports Med Rep, V3, P316; KARLSSON J, 1971, ACTA PHYSIOL SCAND, V82, P115, DOI 10.1111/j.1748-1716.1971.tb04948.x; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2011, CLIN J SPORT MED, V21, P89, DOI 10.1097/JSM.0b013e3181fdc721; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lutz Robert H, 2010, J Spec Oper Med, V10, P23; Management of Concussion/mTBI Working Group, 2009, J Rehabil Res Dev, V46, pCP1; McCardle WD, 1996, EXERCISE PHYSIOLOGY; McCrea M, 2008, MILD TRAUMATIC BRAIN; McCrory P, 2009, J ATHL TRAINING, P36; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Randolph C, 2009, ARCH CLIN NEUROPSYCH, V24, P219, DOI 10.1093/arclin/acp025; Sabini RC, 2011, PHYSICIAN SPORTSMED, V39, P23, DOI 10.3810/psm.2011.09.1917; Scherr J, 2013, EUR J APPL PHYSIOL, V113, P147, DOI 10.1007/s00421-012-2421-x; Silverberg ND, 2013, J HEAD TRAUMA REHAB, V28, P250, DOI 10.1097/HTR.0b013e31825ad658; University of North Carolina at Chapel Hill, 2010, THE UNIVERSITY OF NO	42	31	31	0	24	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2015	30	1					56	67		10.1097/HTR.0000000000000104			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AY8BW	WOS:000347780400015	25563414				2021-06-18	
